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Critical Care Nursing of Infants and Children
Abstract
This publication of the second edition of Critical Care Nursing of Infants and Children is another
important milestone in the evolving development of pediatric critical care nursing. It often surprises
students and colleagues when I discuss my experiences in the days "before pediatric intensive care units."
They cannot conceive of a time when these specialized units, along with their highly technologic
treatments, were not available to facilitate the care of critically ill children. During this "before" period,
seriously ill children were cared for on regular hospital units with minimal technology. Staff nurses were
often assigned to "special" the child, unless the family provided a private duty nurse. Sometimes a
separate room was set aside for care of several seriously ill children so that one nurse could care for
several children. The level of expertise of these staff and private duty nurses, however, was not adequate
for the intensive care needs of critically ill children. Obviously children with serious health problems or
children recovering from major surgery were at high risk of dying because adequate treatments and
monitoring measures were not available.
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To the patients and families
we've had the privilege to come to know.

To my nursing colleagues:

It's NOT Invisible
Today, I saw you . ..
Make room for more than 20 family members at the bedside all at once,
so that everyone could be together with Billy one last time.
Ask Billy:~ grandfather to plug the extension cord in; you knew he
needed to do something-anything.
Give options to Billy:~ parents about "being there" during resuscitation attempts and help
them choose words to talk with him, considering he was only 8 years old.
Speak very softly to Stephen while removing the tape from his eyelids
only to find his pupils blown and unequal . ... you didn't even change
your facial expression-you didn't want to upset mom . .. , not any more
... not just then.
Ask Stephen '.I mom what she was thinking as she stood near his bed
looking out the window just before support was withdrawn. ... "He was
always very quiet, but I knew something was wrong; I should have taken him to the hospitalbut, he didn't want to go". .. , wipe your tears as you listened and convincingly say that she
did the best that she could.
Take a deep breath before you spoke up at team conference . .. "We ought to be more vigilant
aboUl the conversations we hold at the bedside-we don't know what Stephen s level of
consciousness is under the sedation and chemical paralyzing agents". .. , whisper in Stephen:~
ear that the new ventilator might be scary because of the noise it made, then dly his tears.
Take the time to sit with Rachel's mom while others resuscitated her
daughtel; your patient, because you knew she was alone~her husband was on his way in.
Resuscitate Rachel because you knew that Rachel's mom needed your
colleague right then.
Care enough to take the time to "orchestrate" death
worst-thing-in-the-world-anyone-could-ever-experience

to make the
, a little more tolerable.

It may be very hard for others to hear what we do . .. it can just be so sad. We eventually stop
telling them. Eventually, we might think that our caring becomes invisible. But, it is not invisiblenot to Billy, not to Stephen, not to Rachel, or their parents, or to one anothet:
MARTHA A.Q. CURLEY, RN, PhD, CCNS, FAAN
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FOREWORD
This publication of the second edition of Critical Care
Nursing of Infants and Children is another important milestone in the evolving development of pediatric critical care
nursing. It often surprises students and colleagues when I
discuss my experiences in the days "before pediatric intensive care units." They cannot conceive of a time when
these specialized units, along with their highly technologic
treatments, were not available to facilitate the care of critically ill children. During this "before" period, seriously ill
children were cared for on regular hospital units with minimal technology. Staff nurses were often assigned to "special" the child, unless the family provided a private duty
nurse. Sometimes a separate room was set aside for care of
several seriously ill children so that one nurse could care
for several children. The level of expertise of these staff
and private duty nurses, however, was not adequate for the
intensive care needs of critically ill children. Obviously
children with serious health problems or children recovering from major surgery were at high risk of dying because
adequate treatments and monitoring measures were not
available.
The development of pediatric critical care units alongside
the development of more-sophisticated treatments and
related technology was highly effective in reducing the
mortality of acutely ill children. As these units developed, it
soon became obvious that the nurses working in these units
needed advanced training to adequately monitor and care for
these seriously ill children. It was essential that nurses have
access to the developing knowledge about critical care and
develop the skills to apply that knowledge. Staff education,
advanced critical care modules, and graduate education
were some of the approaches used to prepare nurses for roles
in pediatric critical care. In addition, nurses themselves
began to become involved in the development of knowledge
about critical care nursing through the conduct of nursing
research and the synthesis and application of knowledge
through the publication of clinical articles and textbooks.
The publication of Critical Care Nursing of Infants and
Children was another important step in the evolution of
nursing knowledge related to pediatric critical care. This
state-of-the-art textbook was unique in its strong nursing
perspective, and the organization of the textbook was highly
innovative. The first two sections provide a comprehensive
background for the book, including a focus on historical,
developmental, and family issues, as well as issues related to
the practice environment. This section has been improved

with a greater depth of information about development.
Given the current complexities of treatment options in the
PICU, the ethics section also has been expanded. The next
section, on phenomena of concern, thoroughly covers the
major phenomena that pediatric critical care nurses must
deal with on a daily basis. This content is then pulled
together by focusing in depth on problems involving the
major body systems as well as multisystem problems. All of
these sections have been updated to reflect current knowledge and practice.
The end result is a reference and teaching textbook that
provides comprehensive and holistic content related to pediatric critical care nursing. Furthermore, the book has very
high standards for scholarship. Content is well validated
through reference to research and the latest clinical and
theoretical knowledge in the field. Putting this material together in an organized, cohesive, reader-friendly manner
was truly a challenging and exciting endeavor.
Having watched and participated in the evolution of pediatric critical care nursing over the past 35 years, I am astounded at the knowledge explosion in the field and at the
comprehensive and complex scope of this specialty area of
nursing. To be a pediatric critical care nurse takes knowledge and skills in both the art and the science of nursing. All
nurses who take the step toward becoming pediatric critical
care nurses should have a copy of this book to guide their
development as professionals in this exciting and everchallenging field. Nurses who are already experienced pediatric critical care nurses can gain new ways of conceptualizing their practice and will find the book extremely valuable
as a resource in caring for challenging patients on their
units. The text will also be invaluable for students enrolled
in advanced practice pediatric graduate programs. One
would hope that every pediatric intensive care unit in the
country will have copies available for staff reference.
Critical Care Nursing of Infants and Children continues
to be a milestone in nursing textbooks because of its
excellence and creativity. It serves as a model for future
approaches in knowledge synthesis for practice. It certainly
can serve to strengthen the specialty of pediatric critical care
nursing by providing a strong framework and background
for practice.
MARGARET SHANDOR MILES, PhD, RN, FAAN
Professor, School of Nursing
The University of North Carolina at Chapel Hill
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PREFACE
of pediatric critical care nursing as a specialty is presented. Discussion of the impact of critical illness on
children and families provides nurses with an appreciation
of the magnitude of this experience and guides interventions
aimed at mitigating stress and promoting individual and
family growth.
Section II: The Practice Environment focuses on the
milieu affecting nursing care delivery. The broadening professional responsibilities of the nurse as leader, teacher,
and mentor are acknowledged and supported. Ethical issues are illuminated from a pediatric critical care nursing
perspective.
Section III: Phenomena of Concern focuses on the
unique care needs of all pediatric patients regardless of their
primary problem. Nurses playa major role in optimizing the
patient's potential outcome through a deliberative proactive
process that integrates skilled clinical knowledge about
tissue perfusion, oxygenation and ventilation, acid-base
balance, intracranial dynamics, fluid and electrolyte regulation, nutrition, clinical pharmacology, thermal regulation,
host defenses, skin integrity, and comfort. Within each
phenomenon of concern, essential embryology, maturational
anatomy and physiology, and instrumentation are discussed.
Section IV: Final Common Pathways presents stateof-the-art nursing care for patient problems within each
body system. A focus on the final common pathways of
many disease states is presented so that system dysfunction
is viewed broadly and addressed within a nursing framework. For example, the numerous pathophysiologic states
that result in increased intracranial pressure become similar
to the nurse who is responsible for managing moment-tomoment changes in cerebral compliance in an effort to
prevent secondary brain injury. The etiology, incidence, and
pathogenesis of specific disorders that lead to development
of a final common pathway are also presented when appropriate. Critical care management is focused on the final
common pathways of system dysfunction and specifically
on patient care unique to a particular disorder.
Section V: Multisystem Problems addresses the
needs of patients experiencing multiple system dysfunction
and their complicated demands and unique needs. Because
these patients' illnesses involve more than a single body
system, they present a distinctive challenge to the care team.
Critical care nursing of infants and children is a dynamic
specialty necessitating nurses to ensure their practice is
evidenced-based. Our goal in writing this text will be
realized if readers are provided the knowledge they need to
ensure excellent care to critically ill children and their
families. The goal of excellence in the critical care nursing
of infants and children is based on commitment to children
as our most precious resource and to families as the agents
of developing human potential. Also necessary is genuine
respect for the unique contributions of each member of the
multidisciplinary team and for our nursing colleagues as
sources of immeasurable humanity and healing.

Critical Care Nursing of Infants and Children is a state-ofthe-art textbook, written to provide a comprehensive reference for experienced nurses caring for critically ill pediatric
patients and their families. It is based on the broad clinical
experiences of its contributors in the care of seriously ill or
injured children and in nursing research aimed at improving
and perfecting care. The strong nursing focus of this book is
apparent in its structural approach-phenomena of concern
andjinal common pathways. Phenomena of concern address
nursing care issues common to all critically ill pediatric
patients regardless of their primary problem. Final common
pathways cluster patient problems in such a way that allows
them to be reframed from a perspective that guides nursing
care.
Pediatric critical care nursing has experienced extraordinary development since the advent of intensive care units
designed specifically for the care of critically ill children.
Nurses who care for critically ill infants and children are
continuously challenged by diversity in patient age and
diagnosis. Skilled clinical practice requires knowledge
about a wide variety of illnesses and injuries integrated with
an awareness of the continuums of growth and development.
Pediatric critical care nurses also require comprehensive
information about maturational anatomy and physiology,
physical and psychosocial development, pathophysiology
and disease, critical instrumentation and patient management, and the most current pediatric critical care research
findings.
The foundation for the text is provided in the chapters
that detail children's and families' responses to the experiences of critical illness and intensive care, because this
aspect of pediatric critical care nursing is inherent to the
practice. Practical information supporting the evolving role
of the nurse as tender of the care milieu is unique. Chapters
on nutrition, clinical pharmacology, thermal regulation, host
defenses, skin integrity, and comfort management provide
hard-to-find, clinically relevant information specific for the
critically ill pediatric patient. A comprehensive review of
physiology, with emphasis on the impact of maturation on
system structure and function, is provided for each body
system. The pathophysiologic mechanisms, clinical manifestations' and diagnosis of disease in infants and children
are presented in detail. Multisystem problems, including
oncology, organ transplantation, shock, trauma, thermal
injury, toxic ingestions, and resuscitation and transport, are
presented separately. Instrumentation appropriate to caring
for critically ill children and critical care management
of infants and children is discussed from a collaborative
framework. Appendixes are provided as a clinically useful
reference. A complete reference list is found at the end of
each chapter, and tables and figures provide support to the
entire text.
Critical Care Nursing of Infants and Children is divided
into six sections that encompass all aspects of pediatric
critical care nursing.
Section I: Holistic Pediatric Critical Care Nursing
presents essential concepts that provide a foundation for the
practice of pediatric critical care nursing. The evolution
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This section presents essential concepts that provide a foundation for the
practice of pediatric critical care nursing. The evolution of pediatric critical
care nursing as a specialty is presented. Discussion of the impact of critical
illness on children and families provides nurses with an appreciation of the
magnitude of this experience and guides interventions aimed at mitigating
stress and promoting individual growth.
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Critical Care Nursing
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ICUs. 3 In the late nineteenth century, Louisa May Alcott
wrote:

EVOLUTION OF THE DISCIPLINE

First Units
Patient Population
Levels of PICU Care
Literature
Professional Organizations
Certification in Pediatric Critical Care Nursing

My ward was divided into three rooms.... I had managed to
sort out the patients in such a way that I had what I called "my
duty room, my pleasure room, and my pathetic room," and
worked for each in a different way. One, I visited, armed with
a dressing tray, full of rollers, plasters, and pins; another, with
books, flowers, games, and gossip; a third, with teapots,
lullabies, consolation, and, sometimes, a shroud.... wherever
the sickest or most helpless man chanced to be, there r held my
watch."

DESCRIBING WHAT NURSES Do: THE SYNERGY MODEL

Patient Characteristics of Concern to Nurses
Nurse Competencies Important to the Patient
Optimal Patient Outcomes

First Units

CURRENT ENVIRONMENT

North Carolina Memorial Hospital opened the first "special
care unit" for acutely ill patients in 1953. 5 This unit was
created to meet the challenge of improving patient care
while simultaneously saving time for nursing personnel.
Before creating the special care unit, patients were assigned
beds by virtue of their financial status. Nurses would care
for patients with varying levels of acuity on the same unit;
the almost constant attention requiTed of acutely ill patients
prevented nurses from adequately caring for less acute
patients. 5 Of interest to pediatrics, the idea of putting all
critically ill patients in one room with everything available
in case of an emergency was generated by an assistant
director of nursing, chief of anesthesia, medical director of
the hospital, and otolaryngologist after a near-miss Iifethreatening respiratory event involving a 4-year-old patient. 6 This young patient survived only by chance; a nurse
passed her door (a private room at the end of a hallway),
noted her distress, and gave her emergency treatment.
The first pediatric-specific ICUs opened after improved
patient outcomes were realized when specialized care was
provided to critically ill neonates and adults. From the 1920s
to early I950s, epidemics of acute poliomyelitis necessitated
the use of assisted ventilation for polio victims (Fig. 1-2).
First described was negative pressure ventilation by Drinker
and Shaw 7 in Boston, followed by tracheal intubation and
positive pressure ventilation by Lassen 8 in Copenhagen.

Nurses are privy, like almost no one else, to the body's secret
bruises and disfigurements, the mind's unuttered worries, the
heart's sweetest emotions, and the spirit's last glimmer.
Allgeia McBride'

P

ediatric critical care nurses create an environment in
which critically unstable, highly vulnerable infants and
children benefit from the vigilant care and the coordinated
efforts of a team of highly skilled pediatric healthcare
professionals. Indeed, the art and science of pediatric critical
care have matured tremendously over the past three decades.
Still vivid are memories of small rooms, minimum technology, changing boundaries of professional practice, and little
clinical expertise. As noted by Diers,2 nursing is what is
intense about intensive care unit (ICU) care; the constant
within the pediatric critical care environment is the pediatric
critical care nurse. This chapter introduces the reader to both
the genesis and essence of the practice of pediatric critical
care nursing.

EVOLUTION OF THE DISCIPLINE
Nursing's historical practice of watchful vigilance and triage
provided the model for the care of critically ill patients in

3
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Fig. 1-1 Sun room where babies in sun bonnets received the benefit of natural lighting through large
windows. 1930. (Courtesy Children's Hospital. Boston.)

Fig. 1-2

Infant in respirator, 1934. Infant's Hospital, Boston. (Courtesy Children's Hospital, Boston.)
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Box 1·1

Early PICUPrograms
Abroad
1955 Children's Hospital of Goteburg, Sweden
1961 Stockholm, Sweden
1963 Hospital St. Vincent de Paul. Paris
1963 Royal Children's Hospital, Melbourne
1964 Alder Hey Children's Hospital, Liverpool
United States
1967 Children's Hospital of Philadelphia
1969 Children's Hospital of Pittsburgh
1969 Yale-New Haven Medical Center
1971 Massachusetts General Hospital, Boston
From Downes JJ: The historical evolution, current status. and prospective
development of pediatric critical care, eric Care Clin North Am 8: 1-22,
1992.

Fig. 1-3 Nurses reading to children in a four-unit respirator, c.
1955. (Courtesy Children's Hospital, Boston.)

James Wilson, a pediatrician at the Children's Hospital of
Boston, designed the four-bed negative pressure ventilator
in 1952 (Fig. 1_3).9 As noted by Downes,lO this was
"probably the first unit in the world to cohort and support
pediatric patients with vital organ failure." Later in Scandinavia, it was recognized that children had higher mortality
rates than adults in these special poliomyelitis respiratory
units. Responding to this, separate pediatric respiratory units
were developed to specifically care for children in Uppsala
and Stockholm. II
In January 1967, John J. Downes lO and his colleagues
from Children's Hospital of Philadelphia opened the first
multidisciplinary pediatric intensive care unit (PICU) in the
United States (Box 1-1). This unit consisted of six fully
monitored beds with an adjacent procedure room and
intensive care chemistry laboratory (Fig. 1-4). As recalled
by Downes, Erna Goulding, then director of nursing,
became convinced that opening the ICU would be the right
decision. Willing to err on the side of what was best for
patients, Ms. Goulding recruited a number of high-caliber
nursing staff for the unit. The unit's first nurse manager was
Janet Johnson, followed by Joan Alessio. According to
Downes, Johnson's tenure was short. Alessio contributed
creativity, drive, and spark to build a self-directed cohesive
team that adapted well to the new PICU environment. 12
By the end of the 1970s, medical training programs for
pediatric intensivists developed. In 1985, the American
Board of Pediatrics recognized the subspecialty of Pediatric
Critical Care Medicine and set criteria for subspecialty

certification. The American Boards of Medicine, Surgery,
and Anesthesiology gave similar recognition to the subspecialty. By the mid-1980s, advanced practice nursing programs in acute care pediatrics were established at Yale
University, the University of Pennsylvania, and the University of California at San Francisco. Currently, PICUs are
found in every major center that provides care to seriously
ill pediatric patients. In 1992 the American Hospital
Association listed 328 PICUs,13 and in 1998, this number
increased to 411 PICUS. 14

Patient Population
Although many PICUs care for critically ill surgical
neonates and maturing young adults with a congenital or
childhood disease, the pediatric critical care population
traditionally consists of patients who range in age from
full-term neonates to adolescents and their families. Unlike
system-specific adult critical care units, a wide spectrum of
illnesses are found in most PICUs. Extremes in age and
illness require pediatric critical care nurses to function as
generalists within a subspeciality area.

Levels of PICU Care
Although patients with a wide variety of illness can be
found in most PICUs, Guidelines and Levels of Care
for Pediatric Intensive Care Units have been promulgated by the Pediatric Section of the Society of Critical
Care Medicine, the American Academy of Pediatrics
Section on Critical Care Medicine, and the Committee on
Hospital Care. 15 • 16 The guidelines recommend that level I
PICUs provide multidisciplinary definitive care for a wide
range of complex, progressive, rapidly changing, medical,
surgical, and traumatic disorders, occurring in pediatric
patients of all ages, excluding premature newborns. The
guidelines also recommend that level II PICUs provide
stabilization of critically ill children before transfer to
another center or, to avoid long-distance transfers, provide
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Fig. 1-4 Patient in the first pediatric intensive
care unit in the United States (Children's Hospital of Philadelphia, 1970.) Note Emerson
PV-l ventilator, Gomlan-Rupp water mattress,
Stratham monitoring system, and strain-gauge
transducers. (From Downes JJ: The historical
evolution, current status, and prospective development of pediatric critical care, Crit Care
Cli" North Am 8:1-22, 1992,)

care for disorders of less complexity or lower acuity,
Although the same standards of quality are applied to
patients managed in both level I and level II PICUs,
requirements for level II PICUs differ from those for level
I PICUs in respect to the type and immediacy of physician
presence and hospital resources, Cooperation between
hospitals and professionals within a given region is essential
to ensure that an appropriate number of level I and II units
are designated. Duplication of services leads to underuse of
resources and inadequate development of skills by clinical
personnel and are costly. 17

Literature
The rapid evolution of pediatric critical care required nurses
to be self-motivated learners accountable for their own
education. Before the early 1980s, educational materials
specific to pediatric critical care nursing were nonexistent.
Pediatric critical care nurses wou Id occasionally find an
additional chapter on pediatrics or an appendix on normal
pediatric vital signs placed at the end of a critical care
nursing text. In 1981, the first pediatric critical care nursing
texts were published: Pediatric Critical Care Nursing,
edited by Katherine W. Vestal, and Critical Care Nursing of
Children and Adolescents, edited by Annalee R. Oakes and
sponsored by the American Association of Critical-Care
Nurses (AACN).18,19 These were followed by Janis Bloedel
Smith's Pediatric Critical Care and then Mary Fran
Hazinski's AACN-endorsed first edition of Nursing Care of
the Critically III Child,z°·21 Journal articles about pediatric
critical care nursing are sporadically found in both pediatric
and critical care journals.
As we enter a new millennium, pediatric critical care
nurses have many options. In addition to a selection of
nursing and medical pediatric critical care textbooks, the
Society of Critical Care Medicine and the World Federation
of Pediatric Intensive and Critical Care Societies released its
inaugural journal Pediatric Critical Care Medicine at the

Third World Congress in Pediatric Critical Care. In addition
to print media, pediatric clinicians now have the World Wide
Web. PCCMeds (http://PedsCCM.wustl.edu/) provides a
multidisciplinary educational and practical resource for the
subspecialty. The web site contains original peer-reviewed
content and is linked to numerous associated sites on the
Internet.

Professional Organizations
The AACN, first organized in 1969 as the American
Association of Cardiovascular Nurses, has a long history of
supporting critical care nursing across the lifespan?2 The
mission of AACN is to provide and inspire leadership to
establish work and care environments that are respectful,
healing, and humane. AACN is committed to providing
the highest quality resources to maximize nurses' contribution to caring and improving the healthcare of critically
ill patients and their families. AACN's vision is to create
a healthcare system driven by the needs of patients
and families whereby critical care nurses make their
optimal contribution (see http://www.aacn.org for more
information).
In 1982 the AACN introduced Special Interest Groups
(SIGs) to respond to members' expressed needs for specialized information, networking, and education. 23 The pediatric SIG, later known as the Neonatal and Pediatric Special
Interest Group (NAP SIG), provided the first opportunities
for pediatric critical care nurses to collectively gather and
share their expertise. The first members of this group
included Mary Fran Hazinski (coordinator), Nan SmithBlair, Margaret Slota, Karen Killian, Holly Weeks-Webster,
Janet Wintle, Linda Miers (AACN board liaison), and James
Niebuhr (AACN staff liaison).
Priorities for the NAP SIG included the provision of
high-level programming to meet the specific educational
needs of its members. Before this initiative, pediatric critical
care nurses attended adult or neonatal programs and
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extrapolated perceived relevant information when caring for
the pediatric patient population. Other priorities of the NAP
SIG included developing a resource file of consultants,
audiovisual programs, policies and procedures, care plans,
and teaching programs and support of separate critical care
certification examinations for neonatal and pediatric critical
care nurses 24 .25
In 1989 AACN restructured all SIGs into a national
network of Special Interest Consultants (SICs). Acknowledging the unique and separate needs of neonatal and
pediatric nurses, distinct neonatal and pediatric SIC positions were established. Pediatric SICs specifically focused
on issues related to pediatric critical care nursing and were
readily available to AACN as regional experts on issues
related to pediatric critical care nursing practice. The
pediatric SICs have now been phased out and replaced the
pediatric Board Advisory Team (BAT), who communicate
electronically using e-mail.
Other organizations of interest to pediatric critical care
nurses include the Society of Pediatric Nurses (SPN) and the
Society of Critical Care Medicine (SCCM). Established in
1990, the mission of the SPN is to promote the optimal
health of children and excellence in nursing care of children
and their families (see http://www.pednurse.org for more
information). Established in 1970, the SCCM is a multidisciplinary multispecialty, international organization whose
mission is to secure the highest quality care for all critically
ill patients by promoting the superiority of a multidisciplinary, ICU-based, intensivist-directed team for delivery of
the highest quality, cost-efficient critical care (see http://
www.sccm.org for more information).

Certification in Pediatric Critical
Care Nursing
In 1975 the AACN Certification Corporation was established to formally recognize the professional competence of
critical care nurses. The mission of the AACN Certification
Corporation is to certify and promote critical care nursing
practice that optimally contributes to desired patient outcomes. The program establishes the body of knowledge
necessary for CCRN certification, tests the conunon body of
knowledge needed to function effectively within the critical
care setting, recognizes professional competence by granting CCRN status to successful certification candidates, and
assists and promotes the continual professional development
of critical care nurses.
Certification is attractive to both the critical care nurse
and the consumer of critical care nursing services. State
licensure signifies that an individual has the basic knowledge needed for the general practice of nursing, whereas
certification provides a means of recognizing professionals
who have specialized knowledge and experience and
assures the public that they are receiving care from
practitioners who meet a defined level of competence. 26
Because critical care nursing practice is constantly
changing, a Role Delineation Study (ROS) is conducted
every 3 to 5 years to define the dimensions of current critical
care nursing practice and to identify the actual tasks required
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TABLE 1-1 Percentage of Time Caring
for Patients With Alterations
in Body Systems

":0
~ystem
lPY5function

Pediatric
Practice

Neonatal
Practice

Adult
Practice

28%
24%
15%
12%

39%
15%
6%
22%

22%
39%
8%
10%

of a competent critical care nurse. The tasks serve as a
framework for the CCRN examination blueprint. Examination questions are linked to the study data and evaluate the
knowledge and skills required of a nurse to perform the
tasks at a competent level of critical care nursing practice.
Before 1992 content and construct validity of the CCRN
examination was established for critical care nurses who
primarily cared for adult patients. Pediatric critical care
nurses who sat for the CCRN examination were tested on
content that did not reflect their practice. For example, the
cardiovascular system, which reflected 19% of the CCRN
examination, contained questions on myocardial infarctions
and angina/atherosclerosis, a rare phenomenon in pediatric
critical care. For years, pediatric critical care nurses
recognized both the similarities and differences between
their practice and that of neonatal and adult critical care but
found them difficult to articulate.
In 1989 AACN Certification Corporation began a new
RDS. The purpose of the 1989-1990 study was to refine the
existing adult CCRN examination and define the tasks,
knowledge, and skills fundamental to neonatal and pediatric
critical care nursing. Major differences among neonatal,
pediatric, and adult critical care nursing practice were
identified in the types of patient care problems for which
direct bedside care is provided and in the amount of time
spent caring for the patients with specific problems (Table
I-I). The results, for the first time, described the practice of
pediatric critical care nursing and justified the need for
separate pediatric, neonatal, and adult CCRN examinations.
The 1989-1990 RDS described the diverse practice of
pediatric critical care nursing and communicated it in terms
that could be equated with neonatal and adult critical care
nursing practice. The first CCRN examination, specific for
pediatric critical care nursing, was administered in July
1992. Almost 75% of the first 848 pediatric critical care
nurses who sat for the examination passed it. 27
In 1997 the unique competencies of pediatric, neonatal,
and adult critical care nurses were rearticulated using the
Synergy Model as a conceptual framework. 28 Again, dif-
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ferences across the lifespan were described, and the
separate CCRN programs still exist (Table 1-2). To date,
over 1200 pediatric critical care nurses hold CCRNPediatric certification.
In 1999 AACN also initiated a certification program for
clinical nurse specialists in pediatric critical care (CCNSPediatric). The CCNS program validates an advanced
practice nurse's qualifications and knowledge for practice as
a clinical nurse specialist. The examination also uses the
Synergy Model as a conceptual framework and consists of
questions designed to reflect general knowledge needed in
the CNS role and questions covering age-specific content
(Table 1-3). To date, 14 pediatric clinical nurse specialists
hold CCNS-Pediatric certification. It is anticipated that a
TABLE 1-2
CCRN Blueprints Using
the Synergy Model as a Conceptual
Framework

Pediatric
Practice·
!H1iY

~i,~linical

Judgment
)f}iulmonary
~ardiovascular

'" . eurologic
~Ultisystem

80%

80%

24%

31%

17%

19%

13%

29%

10%
11%

4%

7%

17%
3%
3%

10%
3%
5%

6%

6%

IHematology/immunology

4%

~Renal

3%
5%

IGastrointestinal

~ijEndocrine

~"

Neonatal Adult
Practice· Practice·
80%

4%

3%

3%

20%

20%

20%

4%
4%
4%
2%
2%
2%

4%
4%
4%
2%

4%
4%
4%
2%

2%
2%
2%

2%
2%

.

f,Ca.·
••. ring Practices

!!l'

mtAdvocacy/Moral agency
ilit aring practices
~ollaboration

:;: ystems thinking
p.:
.... esponse to diversity
~Clinical inquiry
I~facilitation of learning

2%

2%

!1!'W

il!p'ata from Certification Corporation. American Association of Critical!!tl:::are Nurses: Role delineorion study 1997. Aliso Viejo, Calif, 2000.

~iJ:Percenl of examination questions.
lli'.c

[tI

TABLE

1·3

Pediatric ceNS Exam Blueprint

~[

~pimension

Percent of
Examination Questions

lB-

!J,Clinical judgment .
~faClh[alton of learnmg
~.:Collaboration

1~linical inquiry

li;;(Janng practlces
~~ystems thinking
1"'Advocacy/agency
~iResponse to diversity
ij11

25%

18%
14%

13%
10%
8%

7%

5%

~~pata from Certification Corporation. American Association of Critical·
lfare Nurse" CCNS Exam Blueprill/. Aliso Viejo. Calif. 2000.

Pediatric Acute Care Nurse Practitioner certification program will soon be initiated.

DESCRIBING WHAT NURSES
DO: THE SYNERGY MODEL
Given the current demands of the healthcare environment, a
clear sense of the unique contributions of nursing to patient
outcomes is critical. The synergy model describes nursing
g
practice based on the needs and characteristics of patients.z
The fundamental premise of this model is that patient
characteristics drive nurse competencies. When patient
characteristics and nurse competencies match and synergize,
optimal patient outcomes result.
Synergy is an evolving phenomenon that occurs when
individuals work together in mutually enhancing ways
toward a common goal. The Synergy Model recognizes the
combined actions of both patient and nurse. Within this
model the patient and family are active participants in the
patient-nurse interaction. Patient-nurse synergy results in a
better outcome than what could be achieved independently.
The following presents the major tenets of the Synergy
Model: patient characteristics of concern to nurses, nurse
competencies important to the patient, and patient outcomes
that result when patient characteristics and nurse competencies are mutually enhancing.

Patient Characteristics of Concern to Nurses
Contextually, each patient and family is unique with varying
capacities for health and vulnerability to illness. Each
individual possesses a singular genetic and biologic makeup
that establishes a capacity for health. Each individual
practices various degrees of healthy behaviors, for example,
diet, exercise, and stress reduction. Each lives within a
community with different institutions, economic structures,
government, social organization, and community perceptions. All exist within a macrosocial structure consisting of
societal infrastructure, the physical environment, cultural
characteristics, and population perceptions. All of these
factors place the patient within the context of an individual,
unique environment and impact the nursing care required
for a particular patient and family.
Each person brings a unique cl uster of personal characteristics to a healthcare situation. These characteristicsstability, complexity, predictability, resiliency, vulnerability,
participation in decision making, participation in care, and
resource availability-span the continuum of health and
illness. Stability refers to the person's ability to maintain a
steady-state equilibrium. Complexity is the intricate entanglement of two or more systems (e.g., body, family
therapies). Predictability is a sumrnative patient characteristic that allows the nurse to expect a certain trajectory of
illness. Resiliency is the patient's capacity to return to a
restorative level of functioning using compensatory and
coping mechanisms. Vulnerability refers to an individual's
susceptibility to actual or potential stressors that may
adversely affect outcomes. Participation in decision making
and in care is the extent to which the patient and family
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engage in decision making and in aspects of care. Resource
availability refers to resources the patient, family, or
community bring to a care situation; resources include
personal, psychologic, social, technical, and fiscal.
These eight continua are applicable to patients in all
practice settings. which is important for nurse-to-nurse
communication of patient characteristics across traditional
unit and system boundaries. For example. a healthy
uninsured 4-year-old girl undergoing a preschool physical
examination could be described as an individual who is
(a) stable, (b) not complex, (c) very predic\able, (d) resilient,
(e) not vulnerable, (f) parent able to participate in decision
making and care, but (g) has inadequate resource availability; whereas a critically ill infant in multisystem organ
failure can be described on the other end of the continuum
in some areas but very similar in others, for example, as an
individual who is (a) unstable, (b) higWy complex. (c) unpredictable. (d) highly resilient, (e) vulnerable, (f) unable to
become involved in decision making and care. but (g) has
adequate resource availability.
Individuals vacillate at different points along these eight
continua. For example, in the case of the critically ill infant
in multisystem organ failure, stability can range from a high
to low risk of death; complexity, from atypical to typical;
predictability, from uncertain to certain; resiliency, from
minimal to strong reserves; vulnerability, from susceptible
to safe; family participation in decision making and care,
from no capacity to full capacity; and resource availability,
from minimal to extensive. At any point in time, various
combinations of these eight continua paint a different
picture of the patient. From a clinical perspective, this
makes sense. Patient characteristics evolve over time; what
might seem very important one day may be less important
the next. Compared with traditional patient classification
systems that count nursing tasks, for example, partial or
complete bath. frequency of vital signs, and so on, these
eight dimensions better describe the needs of patients.

Nurse Competencies Important
to the Patient
Nursing competencies, derived from the needs of patients,
are also described in terms of essential continua: clinical
judgment, advocacy/moral agency, caring practices, facilitation of learning, collaboration, systems thinking, response
to diversity, and clinical inquiry. Clinical judgment is
clinical reasoning that includes clinical decision making,
critical thinking, and a global grasp of the situation, coupled
with nursing skills acquired through a process of integrating
formal and experiential knowledge. Advocacy/moral agency
is defined as working on another's behalf and representing
the concerns of the patient, family, or community. The nurse
serves as a moral agent when assuming a leadership role in
identifying and helping to resolve ethical and clinical
concerns within the clinical setting. Caring practices are a
constellation of nursing activities that are responsive to the
uniqueness of the patient and family and create a compassionate and therapeutic environment with the aim of
promoting comfort and preventing suffering. Caring behav-
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iors include but are not limited to vigilance, engagement,
and responsiveness. Facilitator of learning is the ability to
use one's self to facilitate patient learning. Collaboration is
working with others (patients, families, healthcare providers) in a way that promotes and encourages each person's
contributions toward achieving optimal, realistic patient
goals. Collaboration involves intradisciplinary and interdisciplinary work with colleagues. Systems thinking is appreciating the care environment from a perspective that
recognizes the holistic interrelationships that exist within
and across healthcare systems. Response to diversity is the
sensitivity to recognize. appreciate, and incorporate differences into the provision of care. Differences may include but
are not limited to individuality, cultural practices, spiritual
beliefs, gender, race, ethnicity, disability, family configuration, lifestyle, socioeconomic status, age, values, and
alternative care practices involving patients and families and
members of the healthcare team. Clinical inquiry is the
ongoing process of questioning and evaluating practice,
providing informed practice based on available data, and
innovating through research and experiential learning. The
nurse engages in clinical knowledge development to promote the best patient outcomes.
These competencies reflect a dynamic integration of
knowledge, skills, experience, and attitudes necessary to
meet patients' needs and optimize patient outcomes. Nurses
become competent within each continuum at a level that
best meets the fluctuating needs of their patient population.
Logically, more compromised patients have more severe
or complex needs; this in tum requires the nurse to possess
a higher level of knowledge and skill in an associated
continuum. For example, if the gestalt of a patient were
stable but unpredictable, minimally resilient, and vulnerable, primary competencies of the nurse would be centered
on clinical judgment and caring practices (which includes
vigilance). If the gestalt of a patient were vulnerable,
unable to participate in decision making and care, and
inadequate resource availability, the primary competencies
of the nurse would focus on advocacy/moral agency,
collaboration, and systems thinking. Although all eight
competencies are essential for contemporary nursing practice, each assumes more or less importance depending on
a patient's characteristics. Synergy results when there is
a match between patient's needs/characteristics and nurse
competencies.
Clinical Judgment. Pediatric critical care nursing
practice is based on a unique body of knowledge that
integrates the individual effects of system maturation on
physiology, pathophysiology, sociology, psychology, and
human development. Clinical expertise-that is, skilled
clinical knowledge, use of discretionary judgment, the
ability to integrate complex multisystem effects and understand the expected trajectory of illness and human response
to critical illness-embellishes competent practice. In critical care, Funk notes that the clinician first masters then
transcends the technology and uses it as a means to an end
in providing holistic care. With experience, personal mastery develops, enabling the competent nurse to balance the
art and science of care. The expert nurse anticipates the
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needs of patients, predicts the patient's trajectory of illness,
and envisions the patient's level of recovery.
Aiken, Smith, and Lake29 note that the current expectations for professional nursing practice are high: "Care has
become increasingly complex; the exercise of professional
judgment by nurses is ever more important in preventing
adverse and sometimes catastrophic events." Clinical expertise creates safe passage for patients. In fact, excellent
nursing care is often invisible, and from a perspective of
preventing untoward effects and complications, it should be.
Nursing's unique contribution to patients within the healthcare environment, the one that encompasses all nursing's
competencies, is that nurses create safe passage for patients
and families. Safe passage may include helping the patient
and family move toward greater self-awareness, selfunderstanding, competence, and health and through transitions and stressful events or a peaceful death.
Safe passage requires that the nurse "know the patient."
Tanner and colleagues 30 described "knowing the patient" as
a primary caring practice that includes knowing the patient
as a person and having in-depth knowledge of that
individual's typical responses. Knowing the patient refers to
how a nurse understands a patient, grasps the meaning of a
situation for a patient, or recognizes the need for a particular
intervention. Knowing the patient requires clinical judgment
and creates the possibility for advocacy, which limits patient
vulnerability.
Advocacy/Moral Agency. "Agency"-an expression of responsibility for a patient's outcome-includes
reading the situation based on expected changing relevance,
including action based on the significance inherent in the
situation, and a practical grasp of other clinicians' perception of the situation? 1 Moral agency is a competency that
acknowledges the unique trust inherent within nurse-patient
relationships, a trust gained from nursing's long history of
speaking on the patient's behalf in an effort to preserve a
patient's "lifeworld.,,32
Each discipline offers a unique and necessary perspective
in advocating for patients. Visintainer33 applied an analogy
of maps to contrast each discipline's unique approach to
clinical problem solving. Various maps exist to describe a
geographic location, for example, road maps, air traffic
maps, weather maps, and mineral distribution maps. Although all of these maps represent the same geographic area,
they differ in what they represent as relevant. A traveler
would find a mineral distribution map completely irrelevant,
as would an air traffic controller when using a road map.
Similar to geographic maps, maps of a discipline provide a
framework for selecting and organizing information. In
determining what is relevant and what is not relevant for that
specific discipline, the nursing map reflects an illness
perspective-to care, helping patients and families. The
medical map reflects a disease perspecti ve-to cure.
In the PICV, it is especially challenging to balance
technology with values that emphasize the quality of life,
consumer choice, risk-benefit decisions, access, and integrity of human life. 34 Nursing's moral sensitivity reflects a
holistic view of the patient. Nursing practice values and
empowers the patient's and families' right to make informed

choices consistent with autonomy, personal values, lifestyles, plans, or self-determination.
When cure becomes futile, nurses assume a leadership
role in focusing care to ensure death with dignity and
comfort. When parents must make difficult decisions about
their child's life, what they require from nursing is a real
presence that will support them, empower them, and give
them the courage to decide. 35 Through experience, we know
which activities might be helpful to families, and we provide
options when death is imminent. Nurses "orchestrate"
death, supporting parents and family members through the
worst thing in the world anyone could ever experience, the
death of a loved one.
II is extremely difficult to "orchestrate death" and then
continue on with the day as if nothing happened. Often
nurses are not able to share their day (like the rest of the
world) with non nurse friends because of the difficulty in
talking about and listening to the topic. As one continues to
experience the death of patients, one personally recovers
much more quickly-<ieath may become too routine,
although it shouldn't be. It is emotionally exhausting to
orchestrate death, and traditionally, nurses learn how to do
so by watching their colleagues. This almost never-talkedabout intimate aspect of care, which is learned through role
modeling--<;olleague to colleague-is nursing's most profound contribution to humankind.
Caring Practices. Caring practices optimize and
make clinical competence and expertise more visible. As a
basic value, caring embodies a spiritual and metaphysical
dimension concerned with preserving, protecting, and enhancing human dignity?6.37 Caring practices include not
only what nurses do but also how they do it. From the
patient's perspective, caring practices are expressive activities that help the patients and families feel cared for. 38
Essential to the process of caring is nurse recognition and
appreciation of the patient's and parent's worth and competency to know and attend to self and congruence of the
nursing action with the patient's or parent's perception of
need. 39. 41
Demonstration of professional knowledge and skill,
surveillance, and reassuring presence have been identified as
important caring practices when there is perceived threat to
an individual's physical well-being. 38 Extremely vulnerable
patients require a high level of nursing vigilance. From a
patient's perspective, vigilance is a highly valued caring
practice unique to critical care. In critical care, caring is
vigilant behavior that embodies nurturance and highly
skilled and technical practices. 42 Vigilance preserves, protects, and enhances human dignity. Alert and constant
watchfulness, attenti veness, and reassuring presence are
necessary to limit potential problems and complications.
The unique significance of nursing is in making a
difference for patients; understanding the impact of critical
illness on the infant's or child's person, development, and
entire family; and helping so that patients and their families
can tolerate the experience. This aspect of practice, our
presence with patients, is unique to nursing.
Nurses coordinate the patient's and family's experiences
by continuousIy focusing on the person beneath all the high
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technology. Nursing's concept of vigilance includes the
"illness perspective," or the patient's experience of being
ill. It takes courage to acknowledge the person of someone
critically ill-those patients, surrounded by technology,
therapists, physicians, and nurses, chemically paralyzed,
narcotized, and apparently lifeless except for the rhythm
of monitors, ventilators, and occasional alarms. We acknowledge their person by surrounding them with their
possessions-for example, family pictures, cards from
friends, their music. We make them human by talking with
them, orientating them, and telling them what's going on.
Occasionally the communication is not only one way. The
person responds by increasing heart rate or blood pressure or
dropping intracranial pressure or sometimes by just shedding a tear. Not only are nurses sensitive to this level of
communication, but also they take it one step further by
teaching this level of communication to family members so
that they too can interact with their critically ill loved one.
Through our vigilance, we coordinate the indi vidual
experience of illness and create the environment, making it
bearable. Not only do we make it bearable, but also in some
cases, we make it growth provoking. Numerous nursing
research studies now exist to help guide nursing practice in
the neonatal ICU to support the development of preterm
infants. Nursing research has changed the environment from
one that was provider suited to one that is patient driven.
The bright, noisy, and sterile neonatal ICUs of long ago now
facilitate "kangaroo care"-the practice of giving preterm
infants skin-to-skin contact with their parents, enabling
them to share warmth and natural closeness. In addition to
easing the pain associated with parent-infant separation,
kangaroo care helps premature infants grow; leave their
isolettes sooner; and achieve a deeper, more peaceful
sleep.43 Lights are dimmed, isolettes are covered with
blankets to decrease both light and noise, and blankets
provide appropriate boundaries. Patient survival mandates
that neonatal critical care nurses be responsive to the
behavioral clues of newborns and assist parents in interpreting and responding to their baby's behavior. Care is focused
at supporting the entire family unit, not just a piece of it that
can be biologically but never emotionally separated from
the rest.
Critical care nurses have always prided themselves on
having empathetic practices that value the family and
provide close, attentive care to the patient. 44 More than any
other subspeciality, pediatric critical care nurses have made
significant progress in role modeling family-centered care in
critical care. An abundance of nursing research describes
family stress associated with critical illness. Regardless of
the population, the themes are similar: the need for hope,
information, proximity; to believe that their loved one is
receiving the best care possible; to be helpful; to be
recognized as important; and to talk with others with similar
issues.
Pediatric critical care nurses have moved beyond just
describing what is upsetting to families to describing
interventions that the recipients of our care, themselves, find
helpful. 2 8.40.45 We have improved our dialogue with families
so that we provide families what they need to make
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responsible care decisions-to be educated consumers of
critical care. Parents note that the most significant contribution pediatric critical care nurses make in their care is to
serve as "interpreter" of their critically ill child's responses
and of the PICU environment. 45
When nurses develop mutually respectful trusting relationships with parents, families become empowered to
choose and to take responsibility for their choices. Creating
a humanistic, empowered environment that recognizes
parents as unique autonomous individuals who, when
supported, are capable of providing vital elements of care to
their children forms the foundation for family-centered care.
Different for each individual, humane care incorporates the
hopes, dreams, values, cultural preferences, and concerns of
patients and their families into the daily practice of critical
care. 46 The only time parents should ever have to be placed
in a situation in which they must ask permission to see their
children is when the pri vacy of other patients must be
protected. However, ICUs should be designed to provide all
patients with privacy. Parents are not visitors to their
children. 4o Family-centered care implies more than just that
open visiting hours exist.39
Facilitator of Learning. Providing patients and families the opportunity, accountability, and responsibility to
make their needs explicit requires consumer education.
Nurses facilitate patient learning so that patients can
understand the healthcare system and make informed
choices. Pediatric critical care nurses infuse teaching into
each and every patient encounter. Learning helps alley
patient and family fear and helps indi viduals accommodate
to and transition from the PICU environment.
Collaboration. Jacques,47 an organization theorist
who studied the structural dimensions of nurses' work,
noted: "The nurse is the one person on the unit whose job
is to care about anything that might happen in the universe
of the patient and to connect any parties who need to be
connected in order to assure a successful outcome for the
patient." Although it is critically important for the novice
nurse to learn, come to know, then articulate nursing's
independent contributions, only through the work of the
entire team will patient outcomes be optimized.
Optimal collaboration requires multidisciplinary socialization. Interpersonal team skills include conflict resolution
and consensus building. Senge 48 notes that team learning
begins with dialogue, in which members suspend assumptions and think together to solve problems or chart the
future.
Knaus and associates 49 found an inverse relationship
between actual and predicted patient mortality and the
degree of interaction and coordination of multidisciplinary
intensive care teams. Hospitals with good collaboration and
communication and a lower mortality had a comprehensive
nursing educational support program that included a clinical
nurse specialist and specific educational programming to
support the use of clinical protocols in which staff nurses
were independently responsible. AACN's demonstration
project also documented a low mortality ratio, low complication rate, and high patient satisfaction in a unit that had a
high perceived level of nurse-physician collaboration,
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higWy rated objective nursing performance, positive organizational climate, and job satisfaction and morale.so
Systems Thinking. Nurses are leaders in creating and
managing systems. Back in the 1960s, only nurses who gave
direct patient care were considered "real" nurses. Today, as
Angela McBride notes, real nurses also design, implement,
and evaluate whole programs of caregiving; manage units in
which care is provided; monitor whether the healthcare
system as a whole is sensitive to patient needs; and playa
role in ethical decision making around caregiving. 1
Current expectations for professional nursing practice are
high. Although professional skill and technologic capability
are vital, these essential traits must exist in a patientcentered culture that emphasizes strong leadership, coordination of activities, continuous multidisciplinary communication, open collaborative problem solving, and conflict
management. Sl Nurses have learned to manipulate the
system to work for the patients, systems thinking,48 whereas
the ability to understand the interrelationships and patterns
involved in complex problem solving is a new but required
skill in assuming overall responsibility for the environment
in which care is provided.
Managing multidisciplinary high-performance teams focused on outcomes requires systems savvy. Nurses are
comfortable as team leaders, team members, and colleagues
while providing supervision of unlicensed employees.
Delegation is a new activity for those with singular
experience within a primary nursing model.
The role of case/care manager "ups the ante" on
professional practice by ensuring a level of professional
accountability not always apparent within the actual, not
intended, primary nursing model. s2 The case management
model outlines and activates strategic management of
quality patient outcomes and costs. Transforming primary
nurses into case managers moves the focus of practice from
the nursing process to multidisciplinary outcomes.
Creating a safe environment includes managing complex
systems. Schumacher and Meleis s3 gave evidence to support
"transitions" as a central concept in nursing. Nurses-patient
relationships generally occur around transitional periods of
instability brought on by the demands of developmental,
situational, or health-illness changes. Facilitating transitions
across traditional healthcare system boundaries, for example, into and out of the community, requires systems savvy
and intradisciplinary collaboration.
Response to Diversity. Response to diversity celebrates the individual differences that exists in everyday
life. At a minimum, care is delivered in a nonjudgmental,
nondiscriminatory manner. This approach requires effective
communication with patients and families at their level of
understanding and, perhaps, tailoring the healthcare culture
to meet the diverse needs and strengths of families. At a
higher level, the expert clinician anticipates differences and
beliefs within the team and negotiates consensus in the best
interest of the patient and family.
Clinical Inquiry. Clinical inquiry helps push the limits
of current practice so that patients receive evidence-based
care. Studying the clinical effectiveness of care and how it

impacts patients will provide information that helps determine where to draw the line between cost and quality.
Quality improvement methods continue to progress from
single-department joint commission mandates to multidisciplinary teams working together to integrate systems in the
best interests of patient care. Parallel processes working
with outdated management tools (e.g., nursing care plans)
continue to give way to collaborative practice groups
working with clinical practice guidelines.
Clinical practice guidelines (CPGs)-patient-centered,
multidisciplinary, multidimensional plans of care-help the
team move toward evidence-based practice and improve the
process of how care is delivered. CPGs encourage practitioner accountability, encourage highly coordinated care,
decrease unnecessary variation in practice patterns, increase
high-quality cost-effective services, and provide a mechanism to systematically evaluate the quality and effectiveness
of practice in moving patients toward desired outcomes.
Effective CPGs are driven by the patient's needs and the
evidence that the intervention truly does make a difference
in patient outcomes. CPGs guide the appropriate use of
resources in that, if any intervention does not directly benefit
the patient, it's probably not worth doing.
Nursing's primary model for knowledge generation has
been the empirical/analytic model of the traditional sciences. 54 When instituting new therapies, the nursing focus is
on the illness aspect of care-the human response to disease
and therapy. For example, although our medical colleagues
may design a randomized study to investigate the effects of
high-frequency oscillatory ventilation in pediatric patients
with diffuse alveolar disease and air-leak syndrome, nursing
may focus on what bed to nurse the patient on (the chest
shakes differently on an air than on a conventional
mattress); the noise level, which is still quite high with this
mode of ventilation; how to maintain skin integrity, which is
challenging with the rigid arm of the ventilator; and how to
suction the patient without compromising lung volume.
Numerous caring behaviors that create safe passage for
patients, especially those behaviors mentored by peers, for
example, clinical leadership, creating trust, comforting
behaviors, and orchestrating death, are best investigated
using qualitative methodologies. Yet, although qualitative
methods more accurately describe the essence of nursing,
they lack a causal, predictive requirement. This limits their
use as a sole strategy of inquiry for nursing.

Optimal Patient Outcomes
According to the Synergy Model, when patient characteristics and nurse competencies match and synergize, optimal
patient outcomes result. Many outcome measures have been
proposed including: physiologic status, psychologic outcomes. functional measures, behavior, knowledge, symptom
control, quality of life, home functioning, family strain, goal
attainment, utilization of services, safety, problem resolution, and patient satisfaction. 55
Making pediatric critical acute care nursing visible by
delineating "nurse-sensitive" outcomes is challenging.

Chapter 1

Nurse-sensitive outcomes, a tenn first coined by Johnson
and McCloskey,56 define a dynamic patient or family caregiver state, condition, or perception that is responsive to
nursing interventions. Quite recently, Mitchell, Ferketich,
and Jennings 57 described a quality health outcomes model
that aligns more closely the dynamic processes of patient
care and outcomes. To best capture the unique contribution
of nursing and care delivery models to patient and family
well-being, Mitchell and co-workers 58 proposed that outcome measures should integrate the functional, social, psychologic, physical, and the physiologic aspects of patients'
experiences in health and illness. Outcome measures were
further proposed to be operationized in five categories:
(I) achievement of appropriate self-care, (2) demonstration
of health-promoting behaviors, (3) health-related quality of
life, (4) patient perception of being cared for well, and
(5) symptom management.
Numerous mediating factors impact nurse-sensitive outcomes. First, optimal patient outcomes require both the
unique and collective contributions of the patient and family, the nurse, the entire multidisciplinary team, the healthcare system, and the community. According to Mitchell,59
outcomes should be "relevant to the individual's goals in
seeking care, the institution's social contract in providing
care, and the society's value and understanding of elements
relevant to public as well as private health." The Synergy
Model views patients in the context of their environments
and as active participants in the care process. Thus the responsibility and accountability for optimal patient outcomes
are shared.
Isolating nursing from the unique contributions of the
patient and family and other practitioners is problematic.
Brooten and Naylor60 note: "The current search for
'nurse-sensitive patient outcomes' should be tempered in the
reality that nurses do not care for patients in isolation and
patients do not exist in isolation." What might be infl uenced
by nursing care in one context may be influenced by another
discipline or family in another.
Fearing that changes in both the structure and composition of the nursing workforce would jeopardize patient
safety, the American Nurses Association published Nursing
Report Card for Acute Care Settings. 61 The purpose of this
report was to begin to explore the nature and strength of
linkages between nursing care and patient outcomes. From
an initial pool of 21, six major nursing quality indicators
were identified; they include patient and family satisfaction,
adverse incident rate, complication rate, patient adherence
to discharge plan, mortality rate, and patient length of stay.
Adverse incident rates include medication errors and patient
injuries not directly related to their primary healthcare
problem. Total complication rates include additional healthcare problems, for example, pressure ulcers and nosocomial
infections that are unrelated to the patient's primary
healthcare problem. Both these factors alter safe passage
and increase patient suffering, risk of mortality, length of
~tay, and healthcare spending.
The Synergy Model is congruent with the Nursing Report
Card for Acute Care Settings and provides a framework for
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outcome analysis. Three levels of outcomes are delineated:
patient level outcomes, patient-nurse level outcomes, and
patient-system level outcomes. Keeping the patient in a
primary position, "optimal patient outcomes" are what
patients (or the people of significance to the patient),
themselves, define as important. Safe passage is reflected in
a number of these outcome variables.
Patient Level Outcomes. From the patient's or
family's perspective, illness is associated with perceived
vulnerability and powerlessness, which stimulates the need
for both competence and caring that could inspire immediate and unqualified truSt. 62 In part, trust results from the
nurse knowing the patient and patient knowing the nurse.
Trust is a product of the nurse's clinical competency and
moral agency. Patients and families will be vigilant if
concerned about caregiver competence or agency. Fidelity
to patient concerns, family empowennent, and coaching
honors the outcomes of moral agency.
Caregiver trust is a prerequisite for the dispensing and the
receiving of infonnation. Knowledge in and of itself is not
an outcome, whereas the associated change in patient health
behavior related to the knowledge is. Patients and families
have grown in their knowledge about health and its
promotion and have gradually assumed a greater responsibility for their own health. 63
From the patient's perspective, care that comforts them,
especially when they are acutely ill, is one of the most basic
services that caregivers can provide. 62 Caring practices
create a compassionate and therapeutic environment with
the aim of promoting comfort and preventing unnecessary
suffering. The patient's experience of comfort is a qualityof-care outcome. 64 Patient and family satisfaction and
ratings are subjective measures of individual health or
quality of health services. Although patient and family
satisfaction measures query individuals about their expectations and the extent to which they were attained, ratings
include individual assessment of fact, for example, level of
overall health or time one waited for services. Patient
satisfaction measures involving nursing typically include
technical-professional factors, trusting relationships, and
education experiences. 65
Patient-perceived functional change and quality of life
are multidisciplinary outcome measures. Nurses uniquely
help patients manage through transitions of functional
health and quality of life. Both of these generic outcome
measures can be used across all patient populations, but
when analyzed separately, they provide infonnation specific
to a patient population. Precise longitudinal measures, for
example, use of the Child Health Questionnaire,66 is
important so that real change in status can be detected over
time. Measuring functional status at intennediate steps will
map the trajectory of a patient's recovery. Linking patient
satisfaction, functional status, and quality of life is important because the three are often related.
Patient-Nurse Level Outcomes. Patient-nurse level
outcomes include physiologic changes, the presence or
absence of complications, and the extent to which care or
treatment objectives are attained. Monitoring and managing
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instantaneous therapies by trending physiologic changes are
a specific phenomenon of critical care nursing. For example,
when weaning a patient from mechanical ventilation, the
nurse expects to find a gradual transference of the work of
breathing from the ventilator to the patient. A certain
trajectory of physiologic changes, for example, arterial
blood gases and the percent of minute ventilation assumed
by the patient can be predicted, monitored, and then
evaluated.
Outcomes related to limiting iatrogenic injury and
complications to therapy acknowledge the potential hazards
inherent in illness and the healthcare environment. Again,
nurses through their vigilance and clinical judgment create
healing environments that provide safe passage for vulnerable individuals. Safe passage mandates preventive care, for
example, the prevention of iatrogenic injury, infection, and
hazards of immobility (e.g., pressure ulcers).
The extent to which care or treatment objectives are
attained within the predicted period also serve as outcome
variables. Nurses coordinate the day-to-day efforts of the
entire multidisciplinary team. The nurse's role as the
integrator of numerous services is critical for optimal patient
outcomes and abbreviated lengths of stay. As discussed,
nurse-physician collaboration and positive interaction are
associated with lower mortality rates, high patient satisfaction with care, and low nosocomial complications. 48 ,49
Patient-System Level Outcomes. To economically
survive, healthcare systems must tighten resources arul
maintain quality that is collaboratively defined by both users
and providers in the system. The goal is high-quality care at
moderate cost for the greatest number of people. Important
patient-system outcome data include recidivism and costs/
resource use.
Recidivism, that is, rehospitalization and readmission, is
rework that adds to the personal and financial burden of
providing care. In addition to patient and system factors,
nurses can decrease tbe patient's length of stay through
coordination of care, prevention of complications, timely
discharge planning, and appropriate referral to community
resources. Reducing length of stay and tracking rehospitalization and acute care visits ensure that cost shifting is not
occurring.
Payers are not interested in spending more for similar
clinical outcomes. They are also not interested is assessing
the unique contributions of a specific discipline but, rather,
the entire outcome from an episode of care. Clinical
effecti veness questions are answered by linking patient
outcomes to cost data. Strong data serve as the safety net to
protect against too little care. Benner3 ! notes, that costeffective care will only exist in situations in which the
patient is known and continuity of care is provided by expert
caregivers. Continuity in care and clinical judgment stabilize care within chaotic environments.

CURRENT ENVIRONMENT
Acuity within intensive and acute care units continues to
rise. Care, traditionally provided in inpatient settings, is
being transferred to tbe outpatient setting. Much of the

technology used in the ICU has been adapted for use in the
home. All this challenges our traditional understanding of
intensive care; describing critical care nursing practice by
location or by its technology seems passe. In a patientdriven system, nursing practice is described from a patientneeds perspecti ve. Critically ill patients are characterized by
the presence of, or being at high risk for developing,
life-threatening problems. 67 Benner3 ! notes that critically ill
patients need astute clinical judgment applied to problems
that have very little margin for error. Redefining critical
care of nursing from a concept of vigilance allows us to
maintain our focus on the patient's needs and not on
geography and tecbnology.
Critical illness is just one point on the health-illness
continuum. Caring for patients in isolation from where they
came or where they are going will interrupt the fluidity of
care. Desperately needed is a balanced healthcare system
that equally values prevention; health maintenance and
education; and primary, chronic, and acute care. Pediatric
critical care practitioners have long supported the value of
primary prevention (e.g., pool and bicycle safety and helmet
legislation). Caring for chronically ill infants and children
during acute episodes of their illness, pediatric critical care
practitioners appreciate the continuum of care.
Ensuring continued competence of healthcare professionals is critical to consumer protection. 68 Across the
country, hospitals are experiencing a sbortage of nurses.
Many units, in dire distress, are offering new incentives,
such as sign-on bonuses for experienced nurses and new
graduates or critical care internship programs for new or
inexperienced nurses. What started out as a scattered regional issue is rapidly becoming a widespread phenomenon.
The AACN's Registered Nurse Statistics Fact Sheet
demonstrates that this trend has been building since the
mid-1990s. 69 For example, almost 2 million registered
nurses (RNs) were employed in 1996; the prediction is that
there will be 2.3 million RN jobs in 2006 (21 % increase).
In 1996, 1.2 million RNs were employed in hospitals; the
prediction is that there will be 1.3 million RN hospital jobs
in 2006 (7.4% increase). The most critical shortages and
thus the highest needs are for those critical care nurses
in the most specialized areas; for example, requests to
fi II open pediatric ICU positions increased 50% from 1997
to 1995 7o
The bottom line is that our patient population is sicker
and we have fewer nurses entering and staying within
nursing. Creative strategies to recruit and retain experienced
critical care nurses are a priority for tbe profession.
Workplace redesign requires innovation, an imagination
to see what is possible, and a willingness to try something
new. When creating new realities, everyone is accountable
for innovation and change. This is begun by challenging the
givens, which are fundamentally unsupportive to a patientdriven system and unsupported by clinical research. The
"givens" are similar to what Senge51 describes as mental
models-notions or assumptions that have the power to
move us forward or hold us back. Stellar changes have
occurred when the status quo or basic "givens" were
challenged.
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Innovation requires both risk taking and collegial support. Nursing and risk taking appear to be dichotomous
terms. 7t The American Nurses Association Code for Nurses
states that the nurse acts to "safeguard the client," which
may be perceived as limiting opportunities in taking risks. 72
However, the code also challenges us to participate in the
development of new knowledge and in improving our
standards of care. This aspect of practice definitely involves
risk taking in identifying innovations or changes in the care
we deliver to groups of patients.
Change-any change--ean be risky. Advocating for
change, especially when it may appear to buck the system or
be unpopular with colleagues, is risky. However, in taking
risks, having the courage to move out of a "comfort zone"
to value diversity in thought is the essential element for both
personal growth and innovations in care. Defeo 73 notes that
personal and professional growth requires courage to move
ahead despite doubts or opposition. Three types of courage
have been described: (1) social courage, to invest in open
relationships; (2) creative courage, the willingness to
instigate change and allow innovation; and (3) moral
courage, the courage to care enough to become involved,
that is, the courage to take a risk for a matter of principle 74
Many nurses have never learned how or when to take
risks. Critically important is timing-being strategic in
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taking risks for what is really important to the profession. Again, what is right for patients and their families
is right for the profession. Ask, then really listen to the
consumers of care-they know their needs. Be a leader.
True nursing leaders support a learning environment
because, as Burns 75 points out, successful leaders are
comfortable enough with their own fallibility in that they
allow themselves to be vulnerable and are willing to take
risks. Giving oneself permission to make mistakes empowers one to take risks.
By continuing the historic tradition of creating safe
passage for patients, nurses make a significant contribution
to the quality of patient care services, containment of costs,
and patient outcomes. By reducing mortality rates, length of
stay, costs, and complications and by increasing family
satisfaction and readiness and ability to function upon
discharge, nurses make significant contributions to both the
quality of hospital services and the containment of hospital
costS. 76
In conclusion, as Donna Diers 77 pointed out in 1984:
Believe in nursing, in the wildest possible expanse of role and
function, and believe so strongly that your beliefs can sustain
you through the battles with the unknowing, unthinking,
deluded, and barefoot pragmatists who wish to restrain the
ideas and talents of nurses.
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Caring Practice: Providing
Developmentally
Supportive Care
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DEATH IN THE PEDIATRIC INTENSIVE CARE UNIT

CONCEPTUAL FOUNDATION FOR CARING PRACTICE

Development of Concepts About Death
Talking to Children About Death
Application in the PICD
Helping After a Child's Death

Stress
Coping
Adaptation and Mastery
Stressors During Hospitalization
THE INFANT

(O TO 12 MONTHs)

Developmental Characteristics of the First
Year of Life
Impact of Hospitalization
Developmental Care
THE TODDLER

(1

TO

CONCEPTUAL FOUNDATION
FOR CARING PRACTICE
Hospitalization during childhood is a situational crisis for
children and their families. Illness, disability, disfiguring
treatment, disrupted family relationships, and unsupportive
environments threaten development. Behavioral disturbances after brief, scheduled hospital admissions are not
uncommon and include regression in achievement of
developmental milestones, feeding difficulties, and altered
sleep and rest cycles. Nurses have been actively involved in
identifying aspects of hospitalization that are difficult for
children and their families and in implementing developmental practices aimed at mitigating stress during the
experience. In fact, managing the emotional aspects of
critical illness and intensive care is a unique aspect of the
nurse's role. A foundation for effective intervention to meet
the developmental needs of children in the pediatric
intensive care unit (PICD) is an appreciation of the impact
of critical illness on the individual child's experience. This
chapter discusses the concepts of stress, coping, and
adaptation related to critical care hospitalization. Stresses of
a PICO hospitalization are reviewed, and the developmental
significance for children from infancy through adolescence
is discussed. Interventions to assist children in the PICO to
manage stress, cope with illness, and achieve mastery are
presented.

3 YEARS)

Developmental Characteristics of Toddlers
Impact of Hospitalization
Developmental Care

(3 TO 5 YEARS)
Developmental Characteristics of Preschoolers
Impact of Hospitalization
Developmental Care

THE PRESCHOOLER

THE SCHOOL-AGE CHILD

(6 TO 11

YEARS)

Developmental Characteristics of School-Age
Children
Impact of Hospitalization
Developmental Care
THE ADOLESCENT

(12

TO

21

YEARS)

Developmental Characteristics of Adolescents
Impact of Hospitalization
Developmental Care
THE CHRONICALLY CRITICAllY ILL CHILD

Impact of Chronic U1ness on the Child
Impact of Chronic U1ness on the Family
Impact of Critical Care
Developmental Care
Family Care

Stress
Stress is the result of a problem or an especially demanding
situation that cannot be easily solved, that taxes or exceeds
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an individual's resources, and endangers personal wellbeing. Selye I and Lazarus 2 have provided the foundation for
understanding the human stress response from both physiologic and psychologic perspectives.
Stress results in a complex physiologic response. Selye I
described the physiologic response as mediated by the
action of a stressor on the anterior pituitary, which
stimulates production of somatotropin and adrenocorticotropic hormone (ACTH). Somatotropin augments the inflammatory response and combats the pathogen; ACTH
stimulates the adrenal cortex to produce both mineralocorticoids and glucocorticoids. Catecholamine production by
the adrenal medulla is also increased. Epinephrine and
norepinephrine production increases in stressful experiences, increasing metabolic rate and influencing a wide
range of physiologic functions. The autonomic nervous
system also influences production of the catecholamines by
the adrenal medulla in the stress response. Designed to
regulate physiologic defense mechanisms, the stress response is a multifactorial hormonal and nervous system
protective reaction.
Psychologic stresses activate this same pituitary-adrenal
response. Increased stress hormone production occurs in
response to failing ego defenses, punishment, sleep deprivation, noxious stimulation, and general anxiety. However,
psychologic sources of stress and the individual's psychologic responses are not as uniform and predictable as
physiologic stresses and responses. Consequently, psychologic stress cannot be defined in completely objective terms.
A unique relationship exists between the individual and the
stressful experience, mediated by cognitive appraisal. Cognitive appraisal determines the meaning of an event for
individuals and shapes their emotional and behavioral
response to it. Through cognitive appraisal, individuals
evaluate the significance of what is happening in terms of
their own well-being. Cognitive appraisal is not always a
conscious, obvious mental operation. Defense mechanisms
or routine problem-solving processes may operate unpercei ved on a conscious level.
Stress appraisal is influenced by factors related to the
indi vidual experiencing the stressful event and by characteristics of the event. The most important personal factors
are commitments and beliefs. The more meaningful and
important a commitment, the greater the threat and challenge in a stressful situation that menaces that commitment.
Greater threat also can motivate the person to action and
help sustain hope. Beliefs, particularly those about selfcontrol and control over the stressful event, affect emotion
and coping. Existential beliefs enable individuals to find
meaning and maintain hope in difficult situations.
Interdependently influencing the cognitive appraisal are
characteristics of the stressful situation. Situations that are
uncertain or ambiguous are threatening. Individual tolerance
of ambiguity or uncertainty varies between persons. Ambiguity can intensify threat because it limits the individual's
sense of control over the situation and increases feelings of
helplessness. On the other hand, ambiguity can reduce threat
because it permits individuals to consider alternative interpretations of a situation and maintain hope.

The timing of a stressful event influences its appraisal.
Generally, imminent events are more urgent. Delay before a
stressful event can heighten anxiety, but delay also provides
opportunity to marshal coping efforts and reduce stress. A
lengthy event may lead to exhaustion but also permits
emotional habituation through coping.
The timing of events over the life cycle can affect
cognitive appraisal. Normal life events may be stressful
crises if they occur "off time" or out of sequence. When
events occur off time, they are often unexpected, and
individuals do not have the opportunity to prepare. In
addition, they may not have the support of compatible peers.
The timing of a stressful event in relation to other events
may magnify the cumulative stress experienced. Accumulated stressful events can increase distress because of the
added weight of additional events or because of links
between events.
An individual's perception of stress is influenced by past
experience in coping, both with a particular stress and by
general coping ability. Stress-resistant people have a certain
"hardiness"-a set of attitudes that leaves them open to
change, feeling involved, and in control of events. These
characteristics, even under very stressful circumstances, are
linked to positive coping ability.
The perceived magnitude of a stress also influences
coping ability. Perception of stress as minimal, requiring
only a simple response, is likely to result in effective coping
behaviors. When stress is perceived as complex and large,
the coping response must be similarly complex. The
individual's coping abilities may be overwhelmed, unless
the stress can be divided into manageable pieces.
For children, the ability to appraise a stressful situation is
linked to cognitive development. In addition, each developmental phase is characterized by concerns unique to that
stage. Appraisal of a situation is determined by both
cognitive maturity and developmental age. Each child's
view of a stressful situation or event is most meaningful
from the vantage point of individual development.

Coping
Coping involves cognitive and behavioral efforts to minimize, tolerate, or manage external or internal stresses that
tax or exceed the individual's resources. Automatic thoughts
and behaviors that do not require effort are useful in
situations that do not burden an individual's resources.
Coping is process oriented, and effort is required to manage
stressful demands regardless of the outcome. Consequently,
no coping strategy can be considered inherently better or
worse than another. Some situations cannot be mastered and
require that the individual minimize, avoid, deny, tolerate,
and accept the stressful conditions.
Coping during childhood is influenced by a variety of
factors. Most significant is the individual child's developmental stage, which largely determines the range of
responses available to the child. As young children come to
understand the world, they learn complex ways of coping.
However, despite changes in the details of coping that are
related to maturation and development, evidence shows that
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patterns in coping responses are apparent early in life and
remain constant across life. Likewise, sources of stress
change with age, but it is doubtful that coping changes in
basic ways across the lifespan.
Resources. Resources determine, in part, individual
coping. Resources include health, energy, problem-solving
skills, social skills, social support, commitments, beliefs,
and material resources. Effective use of resources may be
constrained by a variety of factors. Personal constraints are
internalized cultural values that define acceptable ways of
behaving. Environmental constraints include institutions
that thwart coping efforts. In addition, when a high level of
threat is present, as in the PICU, individuals may be unable
to use coping resources effectively. This is of particular
concern because the critically ill patient obviously lacks
fundamental coping resources: health and energy. Box 2-1
illustrates resources found to contribute to positive coping in
children.
Parental Coping. The level of parental coping during
the stress of a child's illness and hospitalization affects how
children cope. Because of the close relationship between
parents and their children and the dependence normally
experienced during childhood, children tend to accept what
their parents accept. Parental anxiety, despite attempts to
conceal it, is often transmitted to children. Termed "emotional contagion," the transmission of parental anxiety to
children has been identified and effectively treated by
providing parents information about what will occur and
how they can assist their child 3 ,4 These interventions not
only are effective in reducing the child's distress but also
increase parents' feelings of comfort and competence.
Because parents are the most important individuals in a
child's support system, characteristics of the parent-child
relationship are correlated with the child's coping abilities.
When the relationship is characterized by a high degree of
compatibility, parents are able to provide their children with
a great deal of emotional support. Conversely, parent-child
relationships that are unreliable and tenuous may result in
children receiving limited support from their parents. There
is no substitute for parental love, encouragement, and
support.
Coping Experiences. Cognitive maturation permits
children to recall previous experiences with stressful or
challenging situations. A child who has coped successfully
with a demanding situation in the past is able to recall the
experience with pride and self-confidence. However, the
child who has had little opportunity or has been unsuccessful in attempts to master new experiences may lack the
confidence necessary to succeed when challenged. Doubtful
about their personal abilities, these children are likely to
react negatively to new or challenging situations.
Temperament. Innate qualities that determine individual temperament can be identified during infancy and are
characteristics remarkably stable across the lifespan. Regularity of body functions and daily schedule, confident
responses to new stimuli, pleasant mood, and persistence in
challenging activities characterize children who cope well
with new situations. A positive, outgoing attitude toward life
is evident in children likely to have a broad range of positive
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Fadors That Contribute to. Positive
Coping in Children
.

..

Individual Child Factors
Positive temperament
Above-average intelligence
Good academic achievement
Ability to relate well to others
Participation in activities

Family Factors
Supportive parents
Family closeness
Adequate rule setting

Community Factors
Availability of friends
Availability of extended family
Good schools
From Byrne C, Hunsberger M: Stress, crises, and coping. In Betz el,
Hunsberger M, Wright S, eds: Fanll'ly·centered nursing care of children,
ed 2, Philadelphia. 1994, WB Saunders, p 635.

coping resources and the pride, courage, and resilience to
mobilize resources despite disappointment and frustration.
Children who feel secure about themselves and confident
about the adults around them are tolerant of retreat and
regression, which may be necessary in very stressful
situations.
Defense Mechanisms. Defense mechanisms are intrapsychic ways of thinking or behaving unconsciously
employed in coping with stress. Because the range of
defense mechanisms increases with cognitive development
(Table 2-1), young children have a limited repertoire of
mechanisms available for coping. Some are considered
undesirable or even pathologic in older children, adolescents, and adults; however, the stress of critical illness
justifies, at least for limited periods, the use of any
mechanism that assists with coping.
For example, regression is a defense mechanism often
identified in children that may be difficult for others to
accept. Regression is a temporary retreat or reversion to an
earlier stage of behavior to retain or regain mastery of a
stressful, anxiety-producing, or frustrating situation, thus
achieving self-gratification and protection. Regression allows the child to conserve energy and strength for recuperation and accept caring provided by others. The child who
regresses during a period of stress usually gives up the most
recently acquired skill. For example, toilet training may be
"forgotten" or the child may revert to thumb sucking or
drinking from a bottle. The regressed child may also cry a
great deal, especially when parents are present. Rather than
constituting a negative behavior, crying with parents permits
the child to release tension and demonstrates a feeling of
safety in relating strong emotions. Lost skills are generally
rapidly relearned as recuperation and recovery restore
available energy. Regression is an unhealthy response to a
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2-1 Defense Mechanisms Available
by Developmental Age

TABLE

G·!

f~tage

Defense Mechanism

! ..-

'!Infants

':1--'
iji

.!~oddlers

"!r'i;

n[

and
preschoolers

.

Discrete defense mechanisms not
identifiable
Regression: Return to an earlier stage of
development in thought, feeling, or
behavior
Denial: Mental refusal to acknowledge a
stressful reality
Repression: Unpleasant experiences or
thoughts are barred from conscious
awareness

Displacement: Transfer of emotionally
charged thoughts or feelings to a
more acceptable substitute object
Preceding mechanisms, plus the
following:
Projection: Attribution of unacceptable
thoughts or impulses to another
person or out into the environment
Reaction formation: Expression of an
unacceptable impulse or feeling by
transforming it into the polar opposite
Sublimation: Transformation of unpleasant, blocked, or unacceptable
thoughts or wishes into socially
acceptable pursuits
Preceding mechanisms, plus the
following:
Rationalization: Application of logical,
socially acceptable reasons for behavior or events that do not reflect the
real reasons behind the action
Intellectualization: Excessive reasoning
is applied to allay disturbing feelings
or thoughts and to permit isolation

stressful situation only if the child is unable to remaster
previously learned skills.
Denial is another defense mechanism often regarded as
pathologic. However, when stress is acute, denial is
necessary for at least short periods. Denial allows the child
to ward off threatening aspects of the environment and to
maintain hope. For example, the child who closes or covers
the eyes during a stressful procedure, such as suctioning the
endotracheal tube, or one who indicates dismissal, turning
the head away when a parent must leave, uses denial in a
protective way. Like regression, denial is an unhealthy
defense only if it persists unreasonably and interferes with a
child accepting a permanent aspect of reality.

Adaptation and Mastery
Adaptation implies that an individual experiencing stress
undergoes change that facilitates interaction with the envi-

ronment. Assimilating aspects of the environment that are
new, different, or challenging into previously learned behaviors and accommodating or modifying behavior in response
to new or different demands are essential aspects of adaptation. In fact, Piaget5 viewed the ability to adapt as key to the
survival and subsequent development of the human infant.
Adaptation is based on accommodation (modification to
conform to environmental demands) and assimilation (incorporation of previously learned activities in current behavior). The two processes together comprise the key techniques that children and adults use to interact successfully
with the world. Adaptation is a key process in maintaining
health. The concepts of development, stress, and adaptation
emphasize change as the constant feature of life.
Mastery is possession or development of the skills
needed to overcome and defeat a specific challenge. For
critically ill children, the challenge is the experience of the
illness or injury and the subsequent intensive care hospitalization, with all its inherent stresses. Adaptation may well be
required in this circumstance. Mastery is the outcome when
caring interventions identify and supply the tools necessary
for each child to experience a level of success that surpasses
adaptation; that is, the child has the feelings of pride,
self-esteem, and self-reliance associated with sure success in
a challenging encounter.

Stressors During Hospitalization
Despite the indi vidual nature of stress, events characteristic
of critical illness and intensive care are predictable stresses.
The PICU environment itself, separation from family and
significant others, pain, intrusive procedures, and developmental disruption necessitate caring intervention to mitigate
stress and promote coping.
The PICU Environment. Little in the intensive care
environment bears resemblance to the everyday world
of infants and children. The environment is one of high
activity around the clock and is crowded with equipment
and people. The noise level is often excessive, as equipment
alarms sound, telephones ring, and voices of caregiverssometimes raised in anxiety-contribute to a technologic
symphony. The mean noise level recorded in a busy PICU
was measured at 55.1 decibels, with sudden, sharp increases
to 90 decibels 6 ; these levels are significantly in excess of the
35 decibels considered necessary for adequate rest. 7 Noise
was the most significant cause of sleep deprivation in one
study on sleep disturbance in intensive care units. 8 Unlike
the critical care nurse, who knows the significance of each
beep and buzz, children in a PICU can make no sense of
these sounds.
Visual stimulation is also excessive because of continuous overhead lighting. Lights can create sensory confusion,
cause patients to lose day-night orientation, and interrupt
sleep. Sleep-wake cycles are disturbed by environmental
stimulation, by pain and discomfort, and also by caregi ving interventions. Sleep deprivation is a common problem
for children in the PlCU. Children in the prcu sleep far
less than is normal and have seriously disturbed sleep
pattems. 6 .7 .9 - 10 In the recent Cureton-Lane and Fontaine
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study, 6 children slept a mean total of 4.7 hours, in intervals
that averaged only 28 minutes. Their sleep was interrupted
nearly IO times during a IO-hour night by noise, light, and
contact with caregivers.
Unfamiliar sights and people characterize the PICU.
Children as young as those beginning their school years are
aware of other patients and are concerned for their
welfare. II Unable to understand the meaning of what they
observe. children may become anxious for another child and
concerned that they too may undergo a painful or distressing
procedure.
The "Intensive Care Unit syndrome" (also called ICU
psychoses) has been described in adult patients. Contributing factors include sensory overload or monotony, sleep
deprivation, and use of medications. Manifestations include
fear, anxiety, depression, hallucinations, and delirium. In the
PICU environment, children have been subjectively described as withdrawn, passive, anxious, egocentric, negative, and demanding. 12 . 13 Objectively measurable behavioral expression of anxiety, depression, agitation, and
withdrawal occurs in children in the PICD. 14 PICU patients
in the study exhibited apprehension about routine nonpainful procedures, anxiety and worry, detachment with staff,
sadness and weeping, and tremulousness and shakiness.
Positively correlated with the presence of these behaviors
were the duration of the intensive care hospitalization, the
number of previous hospitalizations, increasing severity of
illness, and preexisting psychiatric disorders. Critically ill
children are at high risk for the development of stressrelated behavioral disturbances.
Separation. Nurses are instrumental in ensuring liberal visiting policies for parents of children who are
hospitalized. However, children in the PICU often experience periods of separation from those who are their most
important source of emotional support. As recently as 1994,
a survey of 125 hospitals in ten southeastern states found
that 57% restricted visits to pediatric patients in intensive
care units. J 5 Parents may be asked to leave the unit when
procedures are performed on their child or others and are
often excluded during resuscitative efforts.
Separation is a painful experience at any age. The normal
passages of life include leaving familiar and comforting
people and surroundings as individuals move through
school, career, intimate relationships, and the eventual death
of parents and other older relatives and friends.
The significance of parents for children has been
demonstrated in both animal and human studies. Although
hospitalization at the start of the twenty-first century will not
likely include extremes of separation of children from their
parents, historical studies illustrate the importance of that
close and continuing relationship.
Harlow and Zirnmerman l6 showed that newborn monkeys provided adequate nutrition from a cloth and wiremesh "mother" became antisocially aggressive and unable
to interact within a clan. Spitz 17 observed children separated
from their mothers for both short and long periods in penal
nurseries and orphanages. After 6 months of separation, the
children had fixed changes: they were silent, their measured
intelligence fell, previously acquired motor skills were lost,
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2-2 Phases of Separation Anxiety
in Infants and Young Children

TABLE

Behavioral Responses
Loud, vigorous protest at the absence
of parents
Restlessness: expectant watching for
the parents' return
Refuses care or attention from others
Loud crying ceases
Less activity, withdrawn, disinterested
in play or food
Apathetic and isolated appearance
Hopeless and grieving
Resigned to loss and appears to have
adjusted
Shows some interest in surroundings,
begins new relationships but is
detached

and their faces were rigid and expressionless. Although
these children were fed and kept clean, by age 4 years, of the
21 children still in the institutions, only I could talk in
sentences, 6 could not talk at all, 5 could not walk, and 16
walked only by holding onto furniture.
In his study of hospitalized children, Robertson 18 provided the labels for the stages of separation that Spitz 17 had
observed. Young children in the hospital demonstrated three
stages of "separation anxiety," characterized by protest,
despair, and resignation (Table 2-2). Bowlby 19 studied
children who had been separated from their London families
during World War II and placed in physically safe English
countryside homes when nightly bombing raids threatened.
These children, although physically safe, suffered deprivation and were characterized as emotionally flat and expressionless. Children deprived of parental contact demonstrate
persistent long-term manifestations of their deprivation:
impaired trust, diminished intellectual and motor functioning, and disturbed behavior. Children are dependent on the
close and reliable presence of their parents under normal
circumstances; their need for parental closeness when they
are ill is still greater. Maintaining the parent-child relationship and preventing stress related to separation is the
standard of care in the PICU.
Fagin 20 noted that the quality of the parent-child
relationship influenced children's responses to separation.
Assured of the fact that parents return after they have
"disappeared," through the development of object pernlanence (the knowledge that the object or person has an
independent, individual, and permanent existence), older
infants and toddlers learn to tolerate periods of separation
when well as their parents reliably return after a period of
absence. When parents have an inconsistent relationship
with their child and are unable to provide consistent
substitute caregivers, the child may have difficulty learning
to tolerate periods of separation. Consequently, separation
may affect the child who has an insecure relationship with
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parents to a greater extent than those children with a secure
and confident relationship with their parents.
Pain and Intrusive Procedures. Pain and painful
or invasive procedures are potentially destabilizing and
demoralizing experiences for critically ill patients (see
Chapter 17). Pain induces fear because it evokes unpleasant
physical sensations and because of the emotional responses
common to the experience of pain. Critically ill children
may not be able to articulate their experiences or their fears
of pain but are afraid of both physical sensations and threats
to self-integrity and self-esteem.
Fear of body intrusion and mutilation is a stress related to
pain and common to the experience of critical illness and
intensi ve care. Like pain, intrusive procedures threaten
self-esteem and self-integrity. Consequently, children respond similarly to both. They fear that body injury and
mutilation may result from invasive procedures and
equipment.
Developmental Disruption. Social and emotional
development provides children with increasing ability for
self-control-an essential part of ego integrity. Emotional
self-control is a marker of self-confidence and self-esteem.
Children who feel confident and proud of themselves and
their abilities are more likely to be self-controlled. New
situations challenge an individual's ability to maintain
self-control, particularly when the situation is threatening.
The experiences of critical illness and intensive care disrupt
familiar routines and the opportunities for physical activity,
independence, and productivity that children need to maintain developmental progress toward self-control.
AU individuals establish routines that provide a sense of
order in their daily lives. The need to maintain an orderly,
predictable environment safe from threat is ageless and
universal. The need for a safe, stable environment is ranked
just above the need for food, winer, shelter, and other
physiologic needs. Young children are dependent on routines and rituals to view the world as safe, predictable, and
subject to their control. Serious illness and intensive care
dramatically alter daily routines. The ability of children to
maintain self-control despite the loss of trusted people,
objects, and routines relied on for stability is tenuous.
Children who are hospitalized experience fear and
anxiety about the unknown. Children actively engage their
world by learning about it and mastering its sometimes complex, challenging parts. When understanding is
achieved, control follows. Young children in the hospital
often have vague, generalized fears related to their stage of
development, whereas older children tend to have more
specific fears related to events or procedures for which they
are unprepared. An event or procedure does not need to be
potentially or actually painful to induce stress; unfamiliar
settings, equipment, and machines may be threatening and
challenge children's ability to maintain self-control.
Coping during childhood is aided by the discharge of
anxious energy in physical activity. Illness necessitates
some restriction of activity to conserve energy for recuperation, whereas a variety of procedures required by a
critically ill child may necessitate actual physical restraint
and immobility. Physical restrictions limit sensory stimula-

tion and threaten self-control. Physical restraints to prevent
the child from dislodging needed critical care paraphernalia
and immobilization techniques used by healthcare providers
during a procedure have the potential to produce high
anxiety and near panic.
Infants and young children are accustomed to depending
on others for care. Consequently, the enforced dependency
of hospitalization, particularly if familiar caregivers playa
substantial role in providing aspects of care, may not
threaten the self-esteem and self-control of these youngsters.
On the other hand, even toddlers assert their independence
when they are well, as their sense of autonomy develops.
Older children and adolescents, accustomed to independence in self-care activities, have increased stress by the
necessary dependence of the sick role. By the school-age
years, these characteristics are often an internal source of
self-control and may lead to feelings of inadequacy,
powerlessness, and anxiety when illness requires dependency on others. Illness must not only require that sick
children be dependent. The environment must permit and
provide recovery opportunities to regain independence. 21
Children also experience feelings of loss of self-control
and powerlessness because they are unable to enact the
social roles that provided them status in their families, their
school settings, and peer groups. Sick children fear that their
status and position within the family may be preempted by
a sibling if they are not present to perform certain tasks.
Loss of status with schoolmates and peers is feared by
children absent from these social groups.
Critical illness and intensive care are stressful for infants
and children. Mitigating the effects of the stress imposed
by the PICU environment, separation from family and
significant others, pain and intrusive procedures, and developmental disruption define caring critical care nursing
practice. Pain and illness are not simply physiologic
phenomena, leaving the mind and the spirit unaffected. The
total patient-physiologic. psychologic, sociocultural, and
developmental-is the concern of nursing.

THE INFANT (0 TO 12 MONTHS)
Developmental Characteristics
of the First Year of Life
The rapid development and magnitude of change across the
first year of life warrant considering this stage in two phases:
the neonatal period (the first month of life) and infancy. The
following section and Table 2-3 describe the most significant aspects of development for the infant.
Parent-Infant Attachment. During the neonatal period, the foundation for parent-infant attachment established
during the prenatal period is solidified and strengthened.
Parent-infant attachment is a reciprocal process in which the
parents and their infant become acquainted and bond with
one another. Attachment is a process, not a spontaneous
occurrence, in that it does not occur instinctively but is the
result of the unique relationship that develops between
parents and infants. From the infant's perspective, the
process of attachment permits a view of the world as reliable

TABLE

2-3

Infant Development
0-3 Months

3-6 Months

6-9 Months

9-12 Months

Sensorimotor
Stage I (birth- I month)
• Continued practice with reflex
activities leads to a sense of
order
Understands through direct
sensations and motor actions

Sensorimotor
Stage 2 (1-4 months)
Primary circular reactions
stimulate effort to repeat a
behavior
Able to fixate, conjugate, differentiate size and shape, can
see clearly at a distance

Sensori motor
Stage 3 (4-8 months)
• Secondary circular reactions
stimulate effort to re-create
an interesting effect in the

Sensorimotor
Stage 4 (8- I2 months)
Coordination of secondary
circular reactions to intentionally form new, more complex
behaviors

environment

• The basis for play is established

ial-emotioDal
.~~, Erikson 22 --developmental

t progression through mastery
. of tasks and subtasks and
negative component
.Fears/death
According to Johnson,23 the
concept of death (not
returning) can develop without mastering the cognitive
tasks of object/person permanence and separation anxiety. Separation anxiety and
person permanence provide
the foundation for the concepts of fear and death.

Sense of tTust (vs. mistrust)
is gained with consistent,
quality care

Has definite likes and dislikes

Fears: Separation anxiety
develops at 8-9 months
Greatest fear is separation from
parents
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Good head control (2-3 months)

"Dada" and "mama" (8-9
months)
Responds to own name

Two words other than "dada"
and "mama"
Understands simple commands

Rolls front to back (4-5 months)
Rolls back (0 front (5-6 months)

Sits alone (6 months)
Crawls
Pulls self to stand

Stands alone
Toddling

Reaches for objects or persons
(3-4 months)
Hand-to-hand transfer of objects
(5-6 months)

Raking grasp (6-7 months)
Pincer grasp (7-9 months)

Holds a spoon
Makes marks on paper with
pencil or crayon (I 0-}2
months)

Smiles and coos
Babbles (5-6 months)
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Grasp and shake raule (2-3
months)
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Fears: Stranger anxiety develops at 6-7 months and peaks
at 18 months

Responds to sound (birth)

'll~ross motor

Shows emotions: anger, fear,
and affection
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0-3 Months

3-6 Months

6-9 Months

9-12 Months
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.rowth

r~rAverage u.s.

newborn weighs
3.1 kg (7 pounds). is 51 cm
Iii' (20-21 inches) in length,
and head circumference is
!liit;.
33-35.6 cm (14 Inches)
!~i; Growth spurts at 6 weeks and
3 months
~.':.:.

I.

Newborn loses 10% of birth
weight during the first 3 days
of life; weight regained by
14 days
Gains J 80-240 grams (6-8
ounces) per week
Head circumference increases
1.27 cm ('/2 inch) per month
for the first 6 months

!Pentition
!, Eruption timing can vary, but
sequence is generally
consistent
To estimate expected number
of teeth during the first 2
'C"
years (age of child in
'f_ .
[
months - 6 = expected
~j" number of teeth)

Gains 180-240 grams (6-8
ounces) per week
Birth weight doubles by 4
months

Gains 90-120 grams (3-4
ounces) per week
Head circumference increases
0.64 cm ('I, inch) per month
through 12 months

Triples birth weight by I year
Length increases 50% from birth
by 1 year

ii!m Breast-feed or fornlUla for the
""1
first 4 to 6 months
i', All prepared formulas should
.j,
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contaIn Ifon

if . No
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milk before I year, as
contributes to allergies and
iron deficiency

c.' •·. : No honey before 2 years
'C
because of the risk of
:~
botulism

·~f

m!2!.·.:.
~;;:

If
l[,
"'"

Breast-feeding intake, feeding
times vary; breast milk is
preferred and should be used
if available (encourage
pumping during periods of
critical illness and administer
by gavage); breast-feeding
is contraindicated only in
HIY-positive mothers
Parents instructed to hold the
infant for feeding; avoid
bottles in bed or propping the
bottle
Intake variable: 0-1 month: 60120 ml every 3-4 hours; 2-4
months: 150-210 ml every 4-5
hours
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Mandibular central incisors (5-7
months)

Maxillary central incisors (6-8
months), mandibular lateral
incisors (7-10 months)
Initiate brushing teeth

Maxillary lateral incisors (8-11
months)
Mandibular and maxillary first
molars (10-16 months)

Introduce rice cereal at 4-6
months (mix cereal with
breast milk or formula and
feed wi th a spoon)
Introduce pureed fruits or
vegetables next (one new
food every 3-5 days)
Avoid common allergenic foods
(cow's milk, egg whites,
wheat, and citrus)

Initiate drinking from a cup at 6
months with water or juice
«120 ml/day)

Finger foods, mashed table
foods begun at 9 months
Avoid "choke foods": peanuts,
popcorn, carrot stickS, whole
grapes, hot dogs. raisins, and
hard candy

i\![)iet

1::1. Require 100-120
lib calories/kg/day
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Neonates sleep an average of 18
hours/day
2-4 months: 8-12 hours at night;
2 or 3 daytime naps

At 4 months, start bed routine,
put infant to sleep awake

11-12 hours at night; 2-3 naps
(6-12 months)

At I year, sleep approximately
12-14 hours/day

First month:
Breast-feeding, bottle feeding
Crib and bath safety
Position on back to sleep
Car seat use
Smoke-free environment
2-4 Months:
Introduction of solids
Anticipation of rolling

4-6 Months:
Discourage walkers
Reaching for objects begins
Keep hot liquids, cigarettes
away

Introduction of table foods
Use of cup
Teething
Crawling, reaching
Childproofing
Syrup of Ipecac available for
emergency use

Progression of table foods
Use of cup
Self-feeding
Increased mobility-hazards
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Birth: hepatitis B (#1)
I month: hepatitis B (#2)
2 months: DTaP (#1), HiB (#1),
fPV (#1)
!lJi~lm,rrlach to
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Physical Examination and Interventions
Strive to provide continuity
with caregivers to support
a consistent care routine

4 months: DTaP (#2), HiB (#2),
IPV (#2)

6 months: DTaP (#3), HiS (#3)

9 months: hepatitis (#3)
12 months: IPV (#3), varicella
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Conduct from noninvasive to
invasive (auscultate first)
Approach slowly
Use distraction and engaging
facial expression
Ask parents to provide a transitional object

Restraints are stressful because
the infant cannot explore and
play
Liberal visitation

Keep parents within visual field
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11!:[?TaP, Dipbtheria, tetanus, pertussis; HiB, Haemophilus ilif[uenzae type B; IPV, polio vaccioe.
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and trustworthy. When parents reliably respond to their
infant's needs, the baby learns trust. Mistrust is the negative
counterpart of the task of infancy.
The innate, awakening senses of infants equip them for
interaction with their parents and their environment. Tactile
sensation is obvious at birth, as demonstrated by the rooting
reflex and sensitivity to pain and temperature extremes.
Affectionate and comforting touch from parents confirms
feelings of reassurance and builds trust. At birth, infants
demonstrate a preference for staring into a human face
rather than at an inanimate object. In addition, the senses of
taste, smell, and hearing are present within hours of birth.
The infant sucks when a pleasant taste is introduced. Babies
can differentiate between the smell of their mothers and
others and prefer the familiar maternal scent. Hearing is
present even before birth. The healthy infant is equipped
from the moment of birth to engage in the processes that
promote attachment and the development of trust.
The Neonatal Period. In the first month, infants
spend as much as 80% of the time sleeping. Their waking
hours are spent exercising the activities with which they are
born: sucking, looking, grasping, and crying. Through
repeating and perfecting these activities, the infant gains
control over small aspects of the environment and becomes
expert at a limited repertoire of activities by the end of the
first month. Coordination between activities is undeveloped;
neonates can look at a visually appealing object but are
unable to reach out for it.
Infancy. Infants are engaged in establishing the differences between themselves and the rest of their world. By the
middle of the first year, infants recognize themselves as
separate from their parents. Simultaneously, parents become
the strongly preferred caregivers. By 4 to 6 months of age,
the attachment of infants for their parents has grown beyond
the assurance that needs for food and comfort will be met.
Infants begin to prefer their parents for the sake of their
company alone, apart from the satisfaction of physical
needs. The responsive smile that greets fanliliar caregivers
signals infants' preference for these individuals.
Their developing physical abilities permit infants to have
greater interaction with the world that surrounds them.
Infants learn new behaviors as the result of accidental
responses. For example, the baby accidentally gets a hand,
finger, or thumb into the mouth, triggering the sucking
response and the sensation of the thumb in the mouth. The
response and the sensation lead to repetition of the behavior
until it is intentional, rather than accidental. Similarly,
infants learn that kicking makes a mobile sway and move.
Tremendous learning takes place in the second half of the
first year of life. Infants learn to use signs to anticipate
events. For example, putting on an infant's jacket signals
that the family is going out. Rituals at bedtime-a bath.
putting on pajamas, stories in the rocking chair-become
increasingly important as the infant learns to view the world
as reliable and predictable.
Infants in the second 6 months of life are able to
coordinate their activities to bring about a desired end. They
can now look at an object, reach for it, grasp it, and bring it
to the mouth. An important consequence is the development
of the realization that objects exist separately and apart from

the actions of the baby. Piaget 5 referred to this development
as the acquisition of the object concept.
The beginnings of the cognitive knowledge of object
permanence follow. Object permanence refers to the ability
of infants to separate objects from their perception of them
and realize that an object continues to exist even when it is
out of sight. The delight that infants in the first year
demonstrate at peek-a-boo games provides evidence of their
progress at mastering this concept. However, infants have
not sufficiently mastered the concept of object permanence
to face separation from their parents with relaxed ease.
Stranger anxiety is often evident in infants between 6 and 9
months of age. The anxiety displayed by infants toward
strangers is related to anxiety regarding separation from
parents who are not established as having a permanent
existence when out of sight. Under usual circumstances,
infants in the last part of the first year of life awaken at night
and cry for the comfort and reassurance of their parents.
The primary mode of activity during infancy is sensorimotor. Motor control is developed through nearly constant muscle activity during an infant's waking hours. Motor
activity is also the primary mechanism by which the
infant learns to distinguish between self, others, and the
environment.

Impact of Hospitalization
Research with neonates has demonstrated the impact of the
stressful, hectic PICU environment on newborns. 26 -29 Stress
during intensive care hospitalization affects neurobehavioral
organization, physiologic stability, and both short-term and
long-term outcomes. Bright lighting, noise, and caregi ving
activities have been linked to stress in the newborn intensive
care patient. Strategies to mitigate stressful aspects of the
PICU environment by structuring caregiving and modifying
the environment have been associated with improved
outcomes for neonates26.27.30
Signs of distress in the infant resulting from environmental overstimulation are nonspecific, requiring that the critical
care nurse be alert to their presence because early intervention can prevent physiologic and behavioral decompensation. Distressed newborns may be jittery, frequently agitated, and unable to quiet themselves. Vital signs are altered;
heart rate, blood pressure, and respiratory rate are elevated.
Breathing may be irregular, and oxygenation and skin color
may be altered. Digestion is affected, and hiccuping,
gagging, and feeding intolerance may develop. Level of
consciousness may change, with some infants demonstrating "shut down," that is, becoming unreactive to the
environment. Consistency in the assignment of caregivers to
critically ill infants assists each to know individual patients
on a more sophisticated level and enables the accurate
identification of subtle, nonspecific behavioral and physical
signs of distress.
As the infant proceeds from the newborn period across
the first year of life, recognition of signs that the baby is
distressed becomes steadily clearer. Often parents recognize
distinguishable differences in how the baby cries when
hungry, tired, fearful, in pain, or when needing comfort and
support for some other reason. Critical care nurses receive
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valuable input from parents to assist them in recognizing
these signs. In addition, infants experience tremendous
refinement of fine and gross motor skills throughout the first
year, enabling them to express distress and displeasure far
more articulately than earlier.
Turning away from an unpleasant stimulus is a simple
coping tool. Older infants even attempt to remove a noxious
stimulus. Autonomic nervous system stability develops
steadily in the first months of life. Characteristic changes in
vital signs persist in the face of overstimulation and distress,
but changes in oxygenation and skin color are not anticipated beyond the newborn period, unless the infant is
premature or gravely ill.
Illness and hospitalization disrupt the infant's usual
existence. Regularity and reliability in the environment and
freedom to explore the environment are important requirements for the development of trust in themselves and others
that engages infants across the first year. Predictable daily
routines provide infants the stability necessary for them to
view their environment as safe and reliable. Immobilization
and restraint limit motor activity and alter the amount and
the variety of environmental stimuli the infant receives.
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Developmental Care
Modifying the PICD environment is a necessary first step to
prevent neurobehavioral disorganization. Overhead lighting
is dimmed and augmented with individually controlled
bedside lighting. When procedures necessitate bright lighting, a light blanket shielding the infant's eyes mitigates
distress. Staff awareness of the auditory impact of loud
conversation, telephones, stereo equipment, overhead intercom announcements, and mechanical equipment and alarms
is crucial. Monitor and equipment alarms are kept at a safe
minimum volume, which ensures that they are heard but do
not startle infants when they sound. Reduction of the overall
noise level effectively minimizes stress for infants. An
environmental assessment by each nurse at the start of each
shift ensures that the environment is appropriately modified
for infants in the PICD.
The isolette or infant bed requires modification to avoid
overstimulation and promote neurobehavioral organization.
Isolettes shield infants from the environment, especially if
partially covered to decrease both light and noise stimulation. Parents can assist the critical care staff to create a bed
space that is personalized and soothing for their infant. The
goal is to enhance the infant's ability to rest and sleep between caregiving episodes. A calm, relaxing environment is
the ideal. Selected toys, music, and pictures are to comfort,
not overstimulate. Any combination of containment, swaddling, and supportive positioning promotes neurobehavioral
organization (Figure 2-1). Containment can be provided
during routine handling, as well as during stressful procedures. "Containing" the infant's extremities close to the
trunk with the caregiver's or parent's hands or with swaddling diminishes extraneous, disorganized motor activity.
Light swaddling of the infant with hands free to reach the
face enables hand-to-mouth maneuvers. Successfully bringing the hands to the mouth assists in the development of
motor organization and the ability to self-comfort. Support-

Fig. 2-1 Containment. A, Infant's mother is providing physical
and emotional support by placement of her hand on the infant's
head. The mother applies gentle firm pressure while the infant's
grandmother uses both hands to gatber tbe lower extremities and
hold them in a supported position close to the body. B, Infant's
lower extremities are being contained by the mother, while bedding
and blanket rolls around the infant provide containing support to
the infant's upper extremities and trunk. Containment can be
offered during stressful procedures or as a method of comforting
and calming the infant.

ive positioning promotes comfort and rest in a firm nest,
maintains a balance of muscular flexion and extension, and
prevents abnorn1al posturing or malformation. The infant is
positioned with neck, trunk, and extremities flexed and in
the midline position. Positioning is maintained with rolls,
swaddling, foam supports, or commercially available positioning devices. Inappropriate arousal and exaggerated motor responses to stimuli are minimized. 30
Direct caregiving activities are best begun slowly and
very gently, maintaining containment and flexion and
allowing the infant to grasp or suck during care. Startling the
infant is avoided by close attention to the infant's state as
care is initiated and by gentle arousal. Swaddling during
stressful procedures helps to prevent disorganization and
maintains physiologic stability. A period of rest and
recovery is provided after stressful procedures, such as
blood san1pling or endotracheal tube retaping, before
another intervention is carried out. Rest and sleep facilitate
organization. Sleep is promoted hy providing supportive
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positioning, ending interaction with the infant, and modifying the environment to ensure quiet and dim lighting.
Involving parents in their baby's care is the foundation to
alleviating environmental stress for the older infant in the
PICU. Infants require the close and reliable presence of their
primary caregivers to relax, rest, and recuperate. Ensuring
that the environment is warm, quiet, and dimly lit also
minimizes environmental stress for infants beyond the
newborn period. Comforting and familiar objects from
home may support an infant's coping abilities during
distressing procedures, as does distraction with a rattle or
small toy and use of a pacifier or the fingers or thumb for
sucking, rocking, and swaddling.
Very young, very ill infants cannot demonstrate distinct
behavioral responses to separation from their parents. Nonspecific changes in behavior, such as increased gross motor
activity, frequent crying, poor feeding, insomnia, emotional
withdrawal, and self-stimulating behaviors may indicate
distress. Older infants, if well enough, are likely to demonstrate the phases of separation anxiety (see Table 2-2).
Parents can provide data regarding how their infant has
responded in the past to strangers and new situations. With
that information in mind, the critical care nurse develops an
approach to the individual baby and assesses responses to
separation from parents and to substitute caregivers. Subtle
cues indicating distress are evaluated, as the baby may well
be too young or too ill to protest at separation or stranger.
Critical care nurses demonstrate that they recognize parental
presence is crucial by welcoming parents in the PICU and
including them in both the planning and implementation of
the care required by their infant.
Infants are assisted to cope with temporary separation
from their parents, when unavoidable, by assignment of
consistent substitute caregivers. In addition, a quiet, gentle
approach to the sick infant helps to establish trust, as does
the prompt and consistent response of caregivers to signs
that the infant is distressed. Trust develops with a combination of consistency, continuity, and sameness 31 Transitional or security objects can ease periods of separation for
the infant, as can familiar musical or story tape recordings.
Very ill or very young infants respond to immobilization
and restraint with little physical resistance. However, infants
recovering from critical illness and those who are older may
protest vigorously when restrained. Nurses assess the
amount of physical restriction required by an individual
infant to maintain safety and perform procedures effectively.
Not only is motor activity limited by physical restraint, but
the infant is unable to move away from sources of
environmental sensory overload or appreciate fully a range
of sensory experiences. Assessing the PICU environment for
factors that contribute to sensory overstimulation or deprivation is a first step in the process of evaluating the infant
for distress related to physical restriction. When restraints
are necessary for safety, they are regularly removed to
permit the infant to move freely while supervised. Restraints
are applied in a manner that permits the infant to selfcomfort (e.g., to get the thumb to mouth) whenever feasible.
Infants who are ill require frequent position changes within
their bed.

Ensuring appropriate infant stimulation is an important
corollary to the physical care ofthe baby in the PICU. While
the infant is ill, stimulation must be gently planned to
protect the baby from environmental overstimulation. As the
infant recovers, social stimulation is of particular importance because it encourages relationship formation and trust
in others. All stimulation is designed to mitigate sensory
deprivation with sights, sounds, or activities that appeal to
infants.

THE TODDLER (1 TO 3 YEARS)
Developmental Characteristics of Toddlers
Toddlers are among the most challenging children cared for
in the critical care setting. The toddler period represents only
about 3% of the average human lifespan but encompasses
more physical, intellectual, and emotional change than any
other period. Table 2-4 summarizes development during the
toddler period.
The beginning of toddlerhood is marked by the development of object permanence, an elementary concept of cause
and effect, and actions that demonstrate deliberate intention.
Through assimilation, tactile stimulation, manipulation, and
interaction with the environment, toddlers are intent on
figuring out how things work. Toddlers are driven by a
nearly insatiable curiosity. Nonetheless, verbal ability is
limited, and toddlers tend to act out much of what they feel.
Their thinking is egocentric, and their world view is
absolute and animistic.
The social and emotional task of individuating and
separating from parents, with the ultimate goal of autonomy,
evolves over the 2 years of the toddler period. The struggles
for independence characteristic of toddlers are evidenced in
battles over holding their own spoon and squirming against
a restraining parent's hand. The inevitable passage through
a "no" stage also marks the quest for autonomy. The
successful establishment of toddlers' sense of autonomy
opposes feelings of shame and doubt that are the negative
counterpart of development at this stage.
These social developmental tasks require tremendous
emotional growth and change, which often produce ambivalence and aggression in toddlers. Change is managed
by dependence on aspects of daily life that are stable
and consistent. The sense of security deri ved from
the sameness of certain routine aspects of living is so
important to toddlers that routines become rituals. Repetition and mimicking are commonplace in both language
and action.

Impact of Hospitalization
Hospitalization is likely to be particularly threatening in
the evolution of autonomous toddlers. Their limited intellectual ability renders preparatory explanations of upcoming
events ineffective. Logical explanations likewise prove
ineffective because toddlers are not logical. Because newly
acquired independence is founded on the security of a
trusting relationship with their parents, this relationship is
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Toddler Development

lWPevelopmental
W'~haracteristic
jilCognitivelLanguage
~,~ Piaget's stages'

:Social-Emotional
',. Erikson 22

;.• Fears/death

Attributes
Sensorimotor: 0-2 years
Stage 5 (12-18 months):
Tertiary circular reactions to attain a goal
Rudimentary trial-and-error behavior with active experimentation
Object permanence achieved
Stage 6 (18-24 months):
Can remember, plan, imitate, and imagine
Use mental symbols
See themselves as separate from others
Onset of magical thinking
Preoperational: 2-7 years
Stage I (2-4 years):
Preconceptual stage; reason dominated by perception and linkage to events
Play is symbolic and imitative
Egocentrism influences perception of objects, events, and language
Use two-word phrases, 10 or more words in vocabulary (18 months)
900-word vocabulary (3 years)
Autonomy vs. shame and doubt
A sense of autonomy and realization of will develop, giving opportunities to gain some
self-control
Acceptance of reality develops
Striving for independence
Negativism and temper tantrums are common
Awareness of ownership/"mine" (18 months)
Fears: separation from parents/abandonment, intrusion of body orifices, bodily injury, loss of
control, and pain; stranger anxiety
Death: Unable to comprehend the concept of death; may show fear or sadness as displayed by
parents

~:Motor

Uses a cup well (15 months)
Kneels without support (15 months)
Runs (3 years)
Most children are psychologically and physically ready to begin toilet training between 18-30
months
Reduced rate of growth
Gains approximately 1.8-2.7 kg (4-6 pounds)/year
Grows approximately 7.5 cm (3 inches)/year
Head circumference 2.5 cm (I inch)/year up to 3 years (measure head circumference until
2 years)
First molars 10-16 months, second molars 20-30 months; has approximately 20 teeth by 3 years

:iDiet
Nutritional requirements
100 cal/kg/day

fl~pata from

"Anorexia" and food jags are common
Provide foods from the five major food groups: one fourth to one third of adult portions or
I tablespoon for each year
Whole milk until 2 years of age (potential for iron deficiency anemia if drinks more than
24 ounces of milk/day)
Self-feed, bottle to cup transition at about 1 year
Start using utensils (18 months)
Eat meals as a family

the American Academy of Pediatrics. In Shelov SP, Hannemann RE, eds: Caring for your baby and young child: birth to age 5, New York.

rt~'11998, Bantam Books; Green M, ed: Bright futures: guidelines for health supervision of infants, children, and adolescents pocket guide. rev ed, Arlington,

I'ra, 1998,ed 3,National
Center for Education in Maternal and Child Health; Millonig VL, Baroni MA, eds: Pediatric nurse practitioner certification review
Potomac, Md. 1999, Health Leadership Associates.
Continued
r~~uide.
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TABLE

2-4 Toddler. Development-4:ont'd

iltl)evelopmental
iiliCharacteristic
~;

~i~pproach to Physical Examiii. . nation 25 and Interventions

Attributes
Immunizations: HiB (#4), MMR (#1) (15 months); DTaP (#4) (18 months)
Sleep 10 to 12 hours at night; take 1-2 naps
Safety: check for hazards at toddler walking level, keep medications and poisons out of reach (highest poisoning incidence at 2 years), parents should have syrup of Ipecac, emphasize street safety
Develop strategies to deal with nightmares (2-3 years)
First dental examination by 3 years
Noninvasive to invasive sequence
Use a slow gradual approach
Talk quietly and calmly about what will occur just before the event
Allow child to touch and hold equipment
Give choices when possible; reinforce limits
Praise the toddler often; need to be told they are "good"
Distraction is helpful
Limit number of caregi vers, if possible
Allow to sit up when possible (allows them to gain familiarity with caregivers and environment)
Familiar toys and family photos can serve as transitional or security objects

a from the American Academy of Pediatrics, In Shelov SP. Hannemann RE, eds: Caring for your baby and young child: birth to age 5, New York.
8. Bantam Books: Green M. ed: Bright futures: guidelines for health supervision of infants. children, and adolescents pocket guide, rev ed. Arlington,
1998, National Center for Education in Maternal and Chlld Health; Millonig VL, Baronl MA, eds: Pediatric nurse practitioner certification review
e, ed 3. Potomac. Md, 1999. Health Leadership Associates,
Ta?, Diphtheria, tetanus, pertussis; HiB, H. influenzae type B; MMR, measles, mumps, rubella.

key to managing the stress inherent in a critical care
hospitalization,
In the PICD, a cold chrome crib replaces the familiar
warmth of a wooden crib filled with comforting toys. The
environment is intimidating with bright lighting, strange
noise (often loud and offensive), and unknown equipment
and people around the bed, Toddlers, who adventure out into
the unknown on short excursions from the safely known, are
thrust into a completely foreign environment.
If able, toddlers may cry fearfully, Some may react to the
unfamiliarity of the environment with increased vigilance,
rarely closing their eyes even when exhausted. Sicker
toddlers are likely to withdraw from the environment. Their
withdrawal is essential to coping because it allows them to
take in the environment a little at a time,
Toddlers require the close and consistent presence of
their parents to manage distress. The security of their
relationship with trusted parents permits them to rest and
recuperate. Separation from parents is a major source of
stress for toddlers who are hospitalized. When separation is
unexpected and enforced, toddlers fear abandonment. Egocentric thinking may lead toddlers to conclude that some
misdeed of theirs is the cause of their parents' absence.
Toddlers react to impending separation from their parents
with vigorous verbal protest and clinging. The seriously ill
toddler lacks the ability to protest but may cry inconsolably
when left alone. When a behavioral response is impossible
for the toddler, separation is no less frightening. Toddlers
who are denied the dependable and consistent presence of
their parents for an extended period may demonstrate the
behaviors associated with separation anxiety: protest, de-

spair, and resignation. Even when parents are reliably
present, toddlers are not relieved of all distress. Parents may
be subjected to avoidance behaviors, aggression, and
ambivalence,
Denial and regression are the primary defense mechanisms available to toddlers. Denial is evidenced in avoidance of the parents when they are present. Behaviors
including gaze aversion and refusal to seek physical comfort
or initiate contact with their parents may be observed,
particularly as critically ill toddlers recover. Regression is
necessitated by the stress of critical illness and high anxiety.

Developmental Care
The ability of the hospitalized toddler to maintain selfcontrol is threatened by altered routines and physical
restriction. The development of an autonomous toddler who
is able to separate from parents is dependent on the toddler's
ability to move away from them physically. As the growing
toddler's world widens, self-control is maintained chiefly
through routine and ritual, which permit these youngsters to
view their expanding world as reliable and subject to
control. The usual routines toddlers rely on to maintain
self-control separate from their parents are likely disrupted
by hospitalization. The world is no longer reliable. Fear of
the unknown and enforced dependency may affect the older
toddler.
Nurses learn of the individual child's routines and habits,
particularly those related to eating, sleeping, bathing, and
toileting, from the toddler's parents. Disruption in all of
these areas is likely during a PICU admission. Bedtime is an
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especially vulnerable time for the toddler, with difficulty
settling for sleep and sleep disturbances common among
these young children. Regression is a common response to
altered routines. Negativism may also be evidenced as
toddlers protest disruption. Incorporating as many of the
toddler's routines and habits into the hospital schedule as
possible provides the foundation for individualized care.
Parents playa key role in maintaining routine and are the
greatest source of stability for their child. When parents
cannot be present, transitional objects and tape recordings,
particularly of bedtime stories or songs. assist toddlers to
relax and maintain self-control.
Toddlers lack the cognitive development necessary for
specific fears of the unknown aspects of hospitalization.
However, the unfamiliarity of the entire environment is
likely to intimidate even the bravest toddler. Toddlers can
recall past experiences that were painful or frightening, and
fearful anticipation often precedes a procedure or event. In
fact, fearfulness may prevent the toddler's maintaining
much, if any, self-control.
Transitional or security objects also provide a measure of
reassurance in the unfamiliar PICo environment or when
new and unknown procedures or events occur. Preparation
of toddlers for events is best provided only shortly before
the experience and, because of the egocentric nature of
toddlers' thought processes, is depersonalized. Parents are
thoroughly prepared for the events their child will experience to facilitate their support and comfort of the child.
Illness slows the typical active pace of the toddler's life,
but immobilization and restraint result in protest if physical
energy is available. Sensory deprivation and immobilization
are likely to result in regression and aggression in toddlers.
Aggression may be evidenced by general restlessness,
physical resistance, or struggling. Aggression, which permits the release of tension and energy, may be impossible
until the toddler is less ill. Limiting immobilization and
restraint whenever possible diminishes their impact on the
recuperating toddler in the PICo. Parents can provide
watchful eyes and ensure that their child is safe. Recuperation can also provide outlets for aggression if the toddler is
permitted activities such as throwing soft balls, exploring,
manipulating toys, and the like. Enforced dependency can
be mitigated by providing toddlers with choices when there
is an option they can safely choose. Choices are not offered
when none exist. Recuperation also permits the toddler to
accomplish some aspects of care independently, such as
self-feeding. Liberal praise is in order when toddlers
complete tasks.

THE PRESCHOOLER (3 TO 5 YEARS)
Developmental.Characteristics
of Preschoolers
Preschool children, through the development of initiative,
become active members of their world. Successful transition
through the toddler years produces a self-confident and
separate person who has overcome fears of abandonment.
Rapid progress in cognitive function, language develop-
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ment, and motor abilities leads to the acquisition of a
distinctive, individual personality. Each preschooler develops a "self." Table 2-5 provides a summary of preschool
development.
Cognitive development is reflected in increasing awareness of themselves and others. Preschoolers are aware of
their own sex and that of others, understand kinship, and
become aware of cultural differences at 5 years. However,
preschool logic is preoperational. Preschoolers are unable to
apply the principle of conservation and cannot classify
objects. They focus attention on the most obvious, immediate single aspect or characteristic of a situation. For
example, healthcare providers may be classified together as
individuals who wear white coats and give shots. Egocentrism, animism, magical thinking. and fantasy characterize
the preschooler's view of the world. They are unable to
separate fantasy from reality and may fear ghosts, monsters,
supernatural forces, robbers, kidnappers, and people in
white coats. Consequently, preschoolers are most often not
as mature as might be thought from their verbal ability.
Conscience begins developing during the preschool years
and is tied to identification of what behaviors are acceptable
to parents. Behavior is refined in taking turns, sharing, and
following the rules to games. Rules are absolute during the
preschool years, determined by parents who are always
right. Preschoolers strive to be similar to their parents,
particularly the parent of the same sex. Sexual curiosity is
characteristic of the preschool years. The development of
longing for the opposite-sex parent and its resolution in
identification with the same-sex parent occurs.
Emotional and social development is characterized by
egocentrism and is related to the preschooler's developing
sense of self. Preschoolers are unable to see the viewpoint of
others and unable to understand another's inability to see
their own point of view. Their sense of self provides security
and competence, which motivates them to accomplish the
tasks and activities that lead to the development of initiative.
Initiative is the boldness or courage to take on great projects.
If initiative does not develop and the preschooler Lacks the
self-confidence to tackle new opportunities, guilty feelings
are the negative counterpart of preschool developmental
tasks.

Impact of Hospitalization
Hospitalization interrupts the preschooler's efforts to master
control of the enviromnent and develop initiative through
mastery of physical and social skills. The restrictive hospital
environment causes considerable distress for preschoolers
who experience guilt when their accomplishments are
obstructed. Guilty feelings may also be related to egocentric
thinking, which leads to the conclusion that "wrong" or
"bad" thoughts or actions have caused their illness.
Treatment and hospitalization are seen as punishment.
Preconceptual and magical thinking create exaggerated
fears. Despite resolution of fears of abandonment, preschool
children fear being left alone. Separation anxiety is expressed more subtly, and protest when parents must leave is
less aggressive. Distress may be evidenced in sleep distur-
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2·5 Preschooler Development

velopmental Characteristic

Attributes
Preoperational stage
Stage 2 (4-7 years): .
Intuitive stage. reason is not governed by logic
Reasorting is transductive, from one particular to the next
Able to focus on one aspect of an object or event only
"Magical thinking" places at risk for accidental injury and increase in fears
May see illness as retribution for "bad" thoughts
Continually questions "why?" (4 years)
Can count, identify colors and geometric shapes, and memorize nursery rhymes
Speech is intelligible (4 years)
2100-word vocabulary used in meartingful sentences (5 years)
Initiative vs. guilt
A sense of initiative and the realization of purpose develop given opportunity to do for self
A period of questioning and exploring the environment and own body
Sexual differences noted
Feels guilty for negative events
Mood swings and verbal tantrums (4 years)
Conscience develops and is tied to the identification of what behaviors are acceptable to parents
• Follows "the rules" (5 years)
Multiple fears as have active imaginations (bodily injury, the dark, monsters, robbers,
kidnappers, and being left alone)
Fears: the unknown related to inability to maintain self-control when distressed
Death": Between the ages of 3-6 years, reality and magic are mixed when thinking about the
causes of death; believe that death is reversible
Skips, hops on one foot (4 years)
Skips. hops on alternate feet (5 years)
Usually daytime toilet trained (3 years)
Usually nighttime toilet trained (3-5 years)
Gains approximately 2.3 kg (5 pounds)/year
Grows approximately 7.5 em (2 to 31/2 inches)/year
May begin to lose primary teeth

iet
Requirements: 90 cal/kg/day

ticipatory Guidance
ealth Maintenance

pproach to Physical Exami.nation" and Interventions

Strong food preferences
Provide food from the five food groups in realistic amounts and nutritious snacks
Low-fat milk recommended; may use whole milk
Immunizations: DTaP (#5), IPY (#4), MMR (#2) at 4-6 years
Sleeps 8-12 hours/night, gradually eliminates nap
Sleep disturbances persist as these children are sensitive to sensory input and dependent on
bedtime routines
May have dreams and nightmares
Safety: stranger danger, use bike helmet, reinforce pedestrian safety, and use seat belt
Annual dental appointment
Brush teeth after each meal and at bedtime
Needs feedback during assessments
Provide concrete, truthful information; emphasize events to be expected, regardless of the child's
clinical condition (unclear neurologic status, chemical sedation, neuromuscular blockade, etc.)
Provide consistent caregivers
Play therapy may be therapeutic

lPata from the American Academy of Pediatrics. In Shelov SP. Hannemann RE, eds: Caring Jor YOllr baby and yOllng child: birth 10 age 5. New York.
~1998, Balllam Books: Green M, ed: BrightJlltllres: gllidelinesJor health .",perv;sion oJinJallts. children. and ada/escerllS pocket gllide. rev ed. Arlington,
IfLa, 1998. National Center for Education in Maternal and Child Health; Millonig VL, Baroni MA. eds: Pediatric nurse practitioner cerrification review
~uide, ed 3, Potomac. Md, 1999, Health Leadership Associates.
!l'!'pTaP. Diphtheria. tetanus. pertussis: /pv, polio vaccine: MMR. measles, mumps, rubella.
r~.!.-.
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bances, eating difficulties, quiet crying, and withdrawal
from others. Without parental presence, preschoolers may
be unable to cooperate with healthcare personnel during
procedures. They may not cooperate with their parents,
either, if they leave for a period. Aggression is usually not
experienced with this age group, although younger preschoolers may still have temper tantrums.
Regression is the most common coping response for
preschoolers dealing with separation. Thumb sucking may
be resumed, or baby talk may replace the typical language
of the preschooler. Self-care skills and control of body
functions, often recently acquired, may be threatened.
The critical care environment remains a source of distress
for hospitalized preschoolers. Egocentricity, magical thinking, and preconceptual logic may lead to exaggerated fears
of equipment, procedures, and personnel. Older preschoolers are often aware of others and may, as a consequence,
have fears from information they overhear and do not
understand or for other patients around them. Sleep disturbances persist among these young children who are exquisitely sensitive to sensory input (sights, sounds, odors) and
still reasonably dependent on bedtime routines.
Fearful behaviors may not be detected in those preschoolers who are very ill. During recuperation, some
exhibit fearfulness related to the PICO environment, procedures, or personnel by tense behaviors such as nail biting or
whining. Others exhibit distress in regressed behavior, such
as clinging to their parents or a security object, dependency,
and withdrawal. Concrete evidence of the fears that some
preschool children experience is sometimes obtained from
their drawings or by requesting that they tell a "story" about
hospital procedures or experiences. Nightmares occurring
after recovery and hospital discharge are sometimes related
to lingering fears and are reported by many parents after
young children are hospitalized. Sleep or night terrors in
preschoolers following hospitalization occur when usual
sleep patterns have been disorganized. 7 . 32

Developmental Care
Preschoolers can be protected from at least some of the fears
associated with the critical care unit. All procedures are
explained in concrete, understandable terms, with emphasis
on events to be expected. This practice is ensured even when
a child's condition is critical, neurologic status unclear, and
responses prohibited by chemical sedation or paralysis.
When preschoolers are less ill, they benefit from therapeutic
play and education.
Shielding preschoolers from disturbing sights and sounds
offers protection from the PICO environment and from other
patients around them. Conversations about the child between caregivers or with parents are not held within earshot
of the preschooler unless the child is included. Not only may
unintentionally overheard conversations be frightening to
preschoolers who are unable to completely understand the
content, but they may also inadvertently induce guilty
feelings. The preschooler may feel guilty and responsible
based on comments such as "she failed to wean," in
reference to a patient's inability to tolerate a decrease in
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mechanical ventilation, or "he's certainly not doing any
better," to describe a patient's condition. It is crucial to
remember that the preschooler understands concretely and
literally.
Preschoolers require the close and consistent presence of
their parents when ill. Because they have learned to extend
trust to other adults, providing consistent caregivers is
especially advantageous for this age group, particularly
when parents must leave. Transitional or security objects are
valuable to ease distress when separation from parents
occurs. Parental participation in caretaking is comforting for
these young children. Parents can also assist their preschooler to maintain contact with siblings and peers through
audiotape or videotape recordings. Even the sickest child
can benefit from the comforting voices or images of family
members and friends.
Because of the tremendous cognitive development that
occurs during the preschool years, children of this age group
who are successfully gaining initiative feel extremely
powerful. These feelings are instrumental in the preschooler's ability to maintain self-control despite serious illness
and hospitalization in an unfamiliar and threatening environment. Loss of self-control may result when preschoolers'
omnipotent feelings are confronted by fears of the unknown
and enforced dependency. Physical restriction and altered
routines continue to contribute to distress for preschoolers in
the PICV.
Dependency on routines diminishes across the preschool
years, but bedtime remains a vulnerable time. All preschoolers relate their sense of time to routine daily activities and
may feel disruption of their sense of time and need routine
and ritual more when ill. Regression also increases dependence on rituals. Fears are vague and generalized and may
be exaggerated by the thought processes characteristic of the
age group (magical thinking, animism, etc.).
Preschoolers require explanation of the equipment
around them and of all procedures just before they are done.
Information about what they are experiencing and who the
people are around them orients them to reality and helps to
avoid or correct fantasy and rnisperception. Preschoolers
who are well enough to interact verbally are encouraged to
ask questions. They can be questioned to elicit fears or
misconceptions about illness and its treatment. Restraint
during procedures may be minimized if the preschooler is
adequately prepared. Preschoolers can cooperate if they are
calm, have had adequate explanation, and are permitted to
participate.
Restraint may be perceived as punishment. Both limited
mobility and restraint in the critical care environment result
in altered sensory stimulation. The impact of physical
restriction and restraint may not be significant if only briefly
necessary. Longer periods of immobilization may result in
quiet, passive submission or active protest and aggressi ve
behavior. Enforced dependency also often results in extremes of behavior if illness and critical care are lengthy.
Preschoolers may become overly dependent as a consequence of regression or may actively protest and aggressively act out their frustration with lost independence.
Limiting physical restriction and restraint, while maintain-
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ing a safe environment, encourages cooperation and selfcontrol. When restraint is necessary, its need is simply stated
and the child reassured that immobilization is not a
punishment. Child participation in self-care or hygiene and
participation in treatments encourages maintenance of
self-control and mastery of the environment while it limits
dependency. With the exception of the most seriously ill
children, all children most likely can participate in some
aspect of their care.

THE SCHOOL-AGE CHILD
Developmental Characteristics
of School-Age Children
Although physical growth and neuromuscular development
are fairly slow and steady during the school years, cognitive
and social skills explode (Table 2-6). The school-age period
is a time of mastering an ever-expanding world as the
foundation for adult roles is established. Cognitive development is characterized by dramatic shifts. The young
school-age child uses intuiti ve thought based on immediate,
unanalyzed relationships between particular elements of the
environment and the child. Reasoning is not logical.
Thought processes become concrete at 7 or 8 years of age,
and by the end of the school-age years, cognitive operations
have moved toward formal operations.
Concrete operations strongly influence knowledge acquisition. School-age children work hard to discover how the
world around them functions. Conservation of matter,
weight, and volume are achieved. The various parts of a
whole can be considered while the concept of the whole is
maintained. Classification, seriation, and numerical concepts are mastered. Concrete and personal observation are
the foundation for learning. Abstract or hypothetical thinking is not yet possible.
Concrete operations also profoundly influence emotional
and social development as children's experiences broaden
and their intellectual capacity increases. During this stage,
children emerge from their egocentric view of the world and
realize that their way of thinking is not the only way. They
can mentally retrace the steps they took to reach a
conclusion and realize that there may be more than one way
of reaching the same end point. They also recognize the role
of chance in the occurrence of events as egocentricity
diminishes. They are no longer the cause of every action and
reaction around them. Cooperation with others in a group
effort leads to an appreciation of the democratic principles
of mutual consent and consensus, as well as respect for
others and for self. Rules are more flexible; reasoning and
discussion can lead to their being reconsidered and
reworked.
The major challenge of Erikson's fourth stage of
development is the establishment of a sense of industry-a
sense of being useful and able to make and do things well.
The negative counterpart of this stage is a sense of
inadequacy or inferiority, rather than competence, which
may develop if children view their physical and intellectual
skills as deficient. School-age children learn to recognize

their limitations and accept them, as they also recognize and
capitalize on their abilities to develop a sense of competence
and self-esteem.
The peer group, especially same-sex peers, increases in
importance across the school-age years. Interest in the
opposite sex begins at the end of the school-age period, but
a best friend is more important at this stage. Clubs, teams,
camp, and group projects are enjoyed. Team loyalty is
intense at the end of the school years. The competent and
industrious school-age child becomes productive within a
social group of peers in preparation for being a productive
member of society as an adult. Cooperation and collaboration based on mutual respect are evidenced in the pride
school-age children feel for each other's accomplishments,
as well as those of the group. Group activities teach children
that individual strengths and weaknesses are balanced in a
group.
The absolute rules that guide action for the preschooler
become tempered by the realization that the same act can be
viewed differently by different individuals. Intentions
prompting an act are taken into consideration. Through
cooperative and competitive interaction with peers, schoolage children develop rules by consensus and mutual
consent. Rules are no longer unbendable but can be changed
in a democratic process or by extenuating circumstances.
Moral judgment becomes increasingly independent of adults
as peer groups grow in solidarity. Morality is based on
cooperation, developed in discussion with peers.
Increasing independence from adults peaks at age II or
12, with the child wanting unreasonable independence and
demanding privacy. Relationships with parents and family
are ambivalent; children are often self-conscious about their
parents. Unruliness, sloppiness, and secretive behavior may
impede reasonable increases in the independence permitted
children in the transitional period that concludes the
school-age years.

Impact of Hospitalization
School-age children are better equipped, from a developmental perspective, to cope with hospitalization. Short-term
hospital admissions are associated with less distress for
children older than 5 years of age. Although intellectually
more mature and capable of sophisticated language and
communication, school-age children focus on reality and are
unlikely to have had specific experiences that will mitigate
all the stress of hospitalization. Their abilities to solve
problems and learn are likely to be thwarted when they are
seriously ill. Illness restricts opportunities for individual
achievement, as well as group accomplishments.
School-age children have low rates of mortality and
serious morbidity when compared with other age groups.
Chronic illness, which may be a factor in a school-age
child's admission to the PICU, places concomitant demands
on the child and family and may influence the coping
responses of both when critical care is necessitated.
Generally, for school-age children, the unfamiliar PICU
environment is less intimidating than it is for those who are
younger. During the school years, unreasonable fears and
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TABLE

2-6 School-Age Development

)evelopmental Characteristic
Cognitive
Piaget's stage'

ociallEmotional
Erikson 22

Fears/death

:
..

Attributes
Concrete operations (7-11 years)
Reasons with inductive logic; comprehends conservation and reversibility
Able to classify and order; comprehends multiple aspects of object, event, or situation
Problem-solving requires that the problem involve identifiable (concrete) objects
The future and the abstract are still beyond comprehension
Can consider various parts of the whole, while retaining the concept of the whole
• Achieves understanding of conservation of matter, weight, and volume
Defines common objects in terms of their use (6 years)
• Tells time (7 years)
School performance great indicator of development (9-10 years)
May view illness as a fornl of punishment
Vocabulary of 2500 words, learns to read, learns correct grammar, and uses language as a tool
in riddles, jokes, chants, and word games
Steady increase in vocabulary, with words used in complex sentences
Industry vs. inferiority
A sense of industry is gained given opportunities to achieve success and recognition, which
fosters self-esteem
Competence, responsibility, social and work skills, cooperation, and fair play is learned
Relates closely with same-sex peers
Can share and cooperate (6 years)
6-7 years: egocentric thinking, nervous mannerisms, restless activity
8-10 years: takes on idols and heroes; friends serve as allies against adults
10-12 years: increased self awareness and self-consciousness, body image concerns, mood
swings, need for independence
Lying and cheating common
Fears: bodily injury, loss of control, failure to attain expectations, and death
May have specific fears related to unfanJiliar aspects of hospitalization
Death (7-11 years)
Aware that death is irreversible, permanent, and universal; able to state examples of causes of
death, express logical thoughts about death
Linked to external forces (e.g., iUness, violence, and old age)
Recognized as a source of sadness; characterized as dangerous, scary, and mean

rowth
Gain approximately 1.4-2.2 kg (3-5 pounds)/year; at 10 years, may gain 10 pounds/year
Grow approximately 4-6 cm (I ~h-2V2inches)/year
Deciduous teeth are lost. and most permanent teeth erupt during these years
iet
Requirements are
___ 80 cal/kg/day
liIotor
ealth Maintenance
nticipatory Guidance

-,
,

i'"

'.

"'pproach to Physical Examination and Interventions

Teach how to choose healthy foods, including fruits and vegetables
Eat some meals as a fanJily
Refinement of dexterity (6 years)
Good eye-hand coordination (9 years)
Growth rate has slowed, and sleep needs decrease to 8-11 hours
Reinforce seat belt use
Encourage discussions about drugs, smoking, and alcohol
Sex education: anatomy and physiology, sexual activity, contraception, prevention of sexually
transmitted diseases and acquired immunodeficiency syndrome
Annual dental appointment
Brush teeth after every meal and before bedtime
Likes to help and have choices
Respects the need for pri vacy
Provides clear and factual information
Provides positive feedback as builds evolving self-esteem and encourages self-esteem
About one half of school-age children have a special attachment object
During recovery, play therapy may be therapeutic
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fantasies lessen, and these children actively master that
which is unknown or unfamiliar through concrete cognition.
However, school-age children do fear bodily injury, loss of
self-control, and death, and they may be intimidated by the
critical care environment. In addition, school-age children in
the PICU have demonstrated worry for other patients.
Anxiety, depression, agitation, and withdrawal have been
reported among school-age children requiring intensive
care. These occur with greater frequency in the PICU
environment than in other hospital settings. 14
Little overt fearfulness is demonstrated by children past
the earliest school-age years (6 or 7 years of age).
Maintenance of self-control is of vital importance, but
anxiety may lead to nail biting or hair twirling in children
who are well enough. Behavioral expression of anxiety may
be exhibited in apprehension with routine nonpainful
procedures, worried detachment with staff, sadness, and
weeping. Some patients demonstrate tremulousness, shakiness, and motor agitation. The length of hospital stay
correlates positively with these findings. Increasing severity
of illness is positively correlated with the presence of
confusion and disorientation and apprehension or fearfulness about staff and routine procedures. 14 Serious illness
may necessitate regression, with behaviors and fears similar
to those of preschoolers. Crying, excessive fearfulness, or
difficulty separating are examples of regressive behaviors.
A concrete concept of time develops across the school
years, permitting more accurate appraisal of time spent
alone. Despite this developmental progress toward independence, school-age children continue to need close, reliable
contact with parents. Familiar articles from home remain
important, particularly during the early school years. About
one half of school-age children continue to have a special
object to which an attachment was formed during early
childhood.
Young school-age children may have lingering fears of
being left alone and demonstrate fearfulness when their
parents leave them, clinging to a transitional object, if
available, or crying. By the middle school years, such
fearfulness is less common, but when alone, older schoolage children may feel threatened, rejected, isolated, depressed, lonely, and bored. Their tolerance of the PICU
environment and necessary procedures diminishes without
the supportive presence of their parents. Anxiety or
hostility may be evidenced in irritability or verbal aggression. Some children withdraw from contact with others,
longing to ask their parents to stay but afraid of appearing
to be "a baby."
Separation from siblings, friends, and schoolmates,
which includes the concomitant loss of their productive
roles in the family, neighborhood, and classroom, affects
hospitalized school-age children. These children value the
roles they play within their families, peer groups, and
schools. Actual or perceived changes in the roles they play
threaten self-esteem and self-control. Fear of being displaced from their usual position within their families and
among friends provokes stress and anxiety. Fear of falling
behind at school is the consequence of the student role being
disrupted during hospitalization. Being displaced from
productive roles at home and school results in feelings of

sadness and fearfulness about school failure. Withdrawal
and depression are common responses.
School-age children are actively engaged in their world.
Self-control is normal for them. New experiences carry
a high sense of adventure for school-age children when
they are well. Industrious school-age children thrive on
their steadily increasing ability to be independent. However, independence is limited by hospitalization. Feelings
of loss are experienced when they are placed in the
dependent role of a hospitalized patient for a period beyond
a day or two. Self-control is diminished by limited
opportunities for independence in self-care and the pursuit
of industry and its associated feelings of worthiness and
importance.
Immobility or physical restraint limits the discharge of
energy and anxiety in physical activi ty. The sensory burden
of the PICU may be overwhelming to immobilized children
who are unable to turn away from it. Immobilization or
physical restraint may result in depression, frustration, or
hostility among school-age children. If physical restraint is
viewed as a significant threat, anger, hostility, and aggression are common responses. Regression is likely if physical
restriction is prolonged or permanent. When dependency is
prolonged, regression and overdependency are common
responses. Serious illness may limit displays of hostility and
aggression but not the angry, hostile feelings. Their release
in agitated behavior or their sublimation in regressed
behavior may be detected.
School-age children usually have very specific fears
related to the unfamiliar aspects of hospitalization and are
anxious about matters that they do not know or understand.
Enhancing their sense of personal control through cognitive
mastery of the unknown is an essential component of caring
for them.

Developmental Care
The nursing history provides data regarding routines to
which a school-age child is accustomed. Their incorporation
into the hospital routine, whenever possible, assists the
youngest school-age children in maintaining self-control
and normalizes the PICU environment to an extent. Bedtime
routines are often most important for young school-age
children and warrant special effort. Recuperation provides
increased opportunity to incorporate the child in developing
comfortable daily patterns like those followed at home. The
provision of consistent caregivers helps school-age children
to maintain self-control. Support of their close bonds to
parents is key to managing distress during hospitalization.
The family also serves as a conduit for information about
friends and classmates, easing school-age children's sense
of absence from important social groups. Letters and cards
from classmates or videotapes of family and school activities assure school-age children that they have not been
forgotten if hospitalization is lengthy.
School-age children are information seekers. The ability
of children to understand their illness, treatment, and
procedures increases steadily across the school years. The
youngest children may still relate illness to bad behavior, a
misunderstanding that requires correction. The information
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that school-age children have received in preparation for
hospitalization is assessed to develop an effective teaching
plan. The child's perception of events to come is elicited, if
possible, and verbalization of fears and questions is
encouraged. Fears of unknown aspects of illness and critical
care are addressed by providing accurate, concrete, and
scientific descriptions of the illness and its treatment.
Because school-age children may be disturbed by unfamiliar
body responses, these too are explained in scientific terms.
An explanation and a rationale for procedures assist
school-age children to maintain self-control and are important even when verbal or physical interaction is prevented by
illness or its treatment. School-age patients in the PICU are
likely to hear and appreciate explanation of what they are
experiencing, even if unable to participate in discussion. As
recovery occurs, children are encouraged to verbalize
concerns and ask questions. Misinformation or misunderstanding is corrected with complete, truthful information
provided in a caring and supportive manner.
School-age children are accustomed to external appraisal
of their accomplishments and are supported in coping with
the PICU environment when they receive praise. Positive
feedback is a primary intervention with school-age children
in the PICU; it builds self-esteem and encourages selfcontrol. Praise is offered for efforts at cooperation, self-care,
and participation in procedures or treatments. Providing
opportunities for success several times daily gives the child
a sense of accomplishment. Regression is tolerated without
negative comment or criticism, and the child is reassured
that crying or fearfulness is not unusual when someone is
very ill.
Physical restrictions are limited to those imposed by
illness, as well as those necessary for safety, because
school-age children usually cooperate. Thorough preparation for procedures and treatments may limit the amount of
restraint necessary. When actively held down for a procedure, the school-age child may abandon all attempts at
self-control and cooperation. During recovery, quiet activities are enjoyed, but creative outlets for frustration normally
discharged in physical activity are also needed.
School-aged children can direct procedures, participate
in self-care, and make decisions regarding their care to
mitigate the negative aspects of enforced dependence as
soon as they are physically able. Children age 7 years or
older, in the stage of concrete operations, are able to assent
(agree or concur with a decision made by others). Maturation through the school years increases knowledge, understanding, and competence, preparing children by about age
10 to dissent (disagree and withhold assent). Dissent should
be taken seriously when the child displays sufficient
knowledge and understanding of the illness and its treatment. Additional discussion, at a minimum, is necessary
when school-age children indicate disagreement with their
treatment plan. Involving children in healthcare decisions is
not without practical problems, including determining
competence and cognitive development, legal ramifications,
and potential conflict with parental rights 33 .34
If hospitalization is lengthy, peer relationships within the
hospital setting are fostered. Provision for continuing
schoolwork is also important during lengthy hospitalization.
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THE ADOLESCENT (12 TO 21 YEARS)
Developmental Characteristics
of Adolescents
Adolescence begins at approximately 12 years of age and
ends when the child is independent of the family. Physical
growth, which once marked the end of adolescence, is
complete at about 18 years of age. Cognitive, emotional, and
social development are considered to extend the period of
adolescent Iife until the emancipation of an independent
young adult. Table 2-7 provides a summary of adolescent
development.
Physical growth increases significantly during adolescence. Around puberty, both boys and girls attain the final
20% of their mature height. At 18 years, nearly all growth is
complete. Growth is typically uneven, with the legs
lengthening first, followed by broadening of the thighs and
then the shoulders, and trunk growth occurring last. Lack of
coordination is often evident, resulting from uneven growth.
Sexual maturation is generally not completed until 20 or 21
years of age. The hormones produced by the ovary and
testes are the consequence of hypothalamic and pituitary
secretion and are responsible for the development of the
secondary sexual characteristics. Tanner36 described and
labeled these stages as guidelines to the progression of
normal development.
Piaget 5 describes the cognitive development of the
adolescent years as a progression and reconstruction of concrete operations to a new level called formal operations.
With formal operations, adolescents can imagine possibilities, form and test a hypothesis, and interpret the results.
Unexpected results are not as confusing as they are to
school-age children because the adolescent has considered
several possibilities. Adolescents are able to mentally
reverse a sequence of events to understand why something
has happened. Piaget 37 notes that in addition to the ability
to form hypotheses and the capacity for deductive reasoning, adolescents' thought processes become more flexible, and new problems stimulate the use of previous
learning.
As adolescents contemplate the future, they construct
ideals, sometimes leading to a critical view of the adults
around them. Their ability to think about thinking leads
to introspection, accompanied by a resurgence of egocentricity and preoccupation with self. Adolescents believe that everyone is observing their appearance and
behavior, noting their flaws, and taking measure of their
assets. Teenage egocentricity also leads adolescents to
consider their experience as unique. They accuse adults
of lack of understanding, believing that no one has ever
been through what they are experiencing. Egocentricity
diminishes by late adolescence as young adults discover
that although they are individuals, their experiences and
emotions are not unique. The audience teens once believed
was watching fades, enabling them to act and react
genuinely.
Erikson 22 described the central task of adolescence as the
development of identity, with role confusion the possible
negative outcome of unsuccessful teen social and emotional
development. Formal operations permit the internalization
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Early Adolescence
(11-14 Years)

Middle Adolescence
(15-17 Years)

Early adolescence: a period of transition from
concrete to formal operations

• Formal operations (II years on)
Logical reasoning based on deductive logic
Able to consider the hypothetical and abstract;
understand symbolism
Problem analysis is systematic
• Can think about past, present, and future
Pure thought independent of action
Develops strong idealism

Late Adolescence
(18-21 Years)
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Identity vs. role diffusion
Sense of identity is established through
experiences that build self-esteem and
foster independence
Fidelity is realized
Moves toward heterosexuality, selects
vocation, begins separation from family
Emergence of independence from family; peer
group provides important social support
Interest in sexuality
Fears: Adopt an "it can't happen to me" attitude
Death 23 : Differences between the adolescent and
adult reaction to death
Death viewed only as a remote possibility
Period of rapid change; varies regarding timing
and between sexes
Girls gain 7-25 kg (15-55 pounds)
Girls grow 5-20 cm (2-8 inches)
Boys gain 7-30 kg (15-65 pounds)
Boys grow 10-30 cm (4-12 inches)
Puberty onset for girls between 8-10 years and
for boys usually 10-12 years
Menarche at 10,5-15 years, with ovulation
occurring 6-12 months later

Major task is achievement of sexual identity
Preoccupation with self
Increased interest in member of the
opposite sex
Engages in some sort of sexual
experimentation

• Fears/death: potential for loss of control is
predominant
Fears death

Consolidation of formal operations, which
allow planning for the future
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Intimacy vs, isolation
Intimacy and solidarity are established in
close, shared relationships
Love is realized with individuals of the same
and the opposite sex
Creativity and productivity are achieved
Major task is identification of an occupational
identity

Fears/death: understands death as a final and
universal experience that is intensely personal
Capacity to think about the future allows
consideration of impending death
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Immunizations: dT booster (12-14 years, at
least 5 years after last DTaP); dT booster
recommended every 10 years
Review immunization status: hepatitis B required
after 1992; many adolescents are not
immunized
Adolescents are the highest-risk group for nearly
all sexually transmitted diseases (STDs)"
Sex education: anatomy and physiology, sexual
activity, contraception, prevention of
STDs and acquired immunodeficiency
syndrome
Encourage discussions about drugs, smoking,
and al,cohol
Provide feedback and reassurance about assessment findings; emphasize normalcy
Ensure privacy during examinations and
procedures

Sex education should include discussion about
sexual intercourse and contraception
Discuss substance abuse because often increased
exposure with dating
Discuss use of seat belt because many are
driving

Provide specific, detailed, accurate, and scientific
information about events and procedures
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of self-image, self-concept, or identity. Potential sources of
confusion are the rapid body changes that the adolescent
undergoes and the reality of the future and adulthood, with
the accompanying loss of the comfortable familiarity of
childhood.
Peer alliances formed in early adolescence ease the way
toward comfort with their own bodies for young teens.
Joking and teasing about voice changes or discussing
menstrual cramps assure most adolescents that their experiences are normal. However, the invariable comparisons
with those around them may produce anxiety in those who
develop slightly earlier or later than the majority of the peer
group.
Peer relationships help the adolescent avoid role confusion. Peer alliances are firmly established in middle
adolescence, but early in the adolescent years, changes in
groups of friends, as well as the accepted style of dress and
manner of speech, are common. Once established, the peer
group provides a sort of safety net for teens trying out social
roles and behaviors. In fact, isolated or disconnected teens
may appear self-reliant but are likely feeling that they have
no one to depend on or trust and must insulate themselves
because their emotional pain is too much to bear.3 8 The
sometimes violent and traumatic world may be a personal
reality for some teens, whereas it is an existential truth for
others. Strategies to deal with its reality in either circumstance are a necessity for effective intervention with
adolescents. By late adolescence, the peer group naturally
diminishes in importance, and roles and behavior are
individually determined.
Independence from parents and family assists adolescents to develop their individuality and identity. Early
adolescents have incorporated the values and standards of
their parents, usually viewing them as role models and
accepting their authority. However, adolescence is a progressive test of parental limit setting as more and more
independence is demanded. Some adolescents engage in
rebellious behavior. Middle adolescents also often confide in
an adult other than one of their parents, limiting the
influence parents exert as their adolescent progresses.
Consistent and trustworthy adults who value adolescents
and what they have to say may help them to establish
connections and trust. 38 Older adolescents may return to
parents for consultation, once they are secure outside the
home when parents are no longer seen as a threat to
independence or autonomy. Parents and their children
ideally develop an adult relationship across the years of
adolescence.

Impact of Hospitalization
Critical illness during adolescence is a potentially serious threat to the successful transition from childhood
to adulthood. Young adolescents are less troubled by
enforced dependency and better able to permit their parents
and others to care for them. Middle adolescents (15 to 17
years of age) tolerate illness the least well because
their drive for independence is at its peak. Young and

middle adolescents experience anxiety related to physical
appearance, function, and mobility when ill. Older adolescents have often achieved sufficient maturity to tolerate
some temporary dependence and are individually secure
enough to use their families for support. Older adolescents
fear that illness will disrupt their career and other future
goals. All are distressed by disruption of their usual
lifestyle. Fear of death is perva~ive across the adolescent
years.
Like adult patients, an adolescent ill enough to require admission to a PICD will manifest an emotional
response. Anxiety and fear are usual emotional responses
to critical illness and intensive care. Adolescents realize
there is a danger of death. Anxiety may be evidenced by
agitation, excessive verbosity, or complete withdrawal.
High anxiety is not tolerable, usually resulting in some
degree of denial, which is indicated by withdrawal or
regression. When illness and intensive care are prolonged,
anxiety is often followed by despondency and depression.
Some adolescent patients deal with stress and depression
by constant talk, whereas others withdraw. Serious illness
requiring lengthy critical care is also associated with
disorientation.
Withdrawing from contact with others may also indicate
feelings of depersonalization. Adolescents in the PICD are
isolated from their important peer associations and activities
and are at high risk for such feelings. Staff communication
about personal topics within earshot of the adolescent is
particularly distressing because it also depersonalizes the
individual. Individual identity is threatened, particularly if
the adolescent needs to communicate with staff. Adolescents
may be embarrassed by overhearing details of the personal
lives of staff who are caring for them.
Separation from home and family is usually tolerated
without distress by adolescents who require hospitalization.
Separation from the peer group, however, causes significant
anxiety. Illness and hospitalization are clear deviations
from the accepted group norm. Adolescents feel deprived
when separated from their peers and are threatened by
potential loss of status within their social groups, particularly if they have achieved leadership status and must
relinquish that position. The absence of peer acceptance
and approval may threaten emerging individual identity.
Separation anxiety may be evidenced by withdrawal,
uncooperativeness, and ambivalence about visitors, especially family members. Defense mechanisms may mask the
verbal acknowledgment of the importance of peers or
family because the adolescent is adept at intellectualization
and rationalization.
Chronic illness ties adolescents to their familiesphysically, emotionally, and financially. Some respond with
active rebellion, whereas others are passive and overdependent. The chronically ill adolescent in the PICD may react
to separation from the family more intensely than others.
The stress of critical illness may delay progress at leaming
to manage a chronic illness independently, a vital transition
for the chronically ill teenager. Regressed behavior is not
uncommon among chronically ill adolescents who may, for
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example, want their parents to stay with them until they fall
asleep. Critical illness may exacerbate overdependency, but
when survival itself is questioned, independence is a lower
priority.
Adolescents generally adapt to brief interruption of their
typical routines without difficulty but are threatened by the
possibility that their lifestyle may be permanently altered.
Anxiety results from the fact that seriously ill adolescents
can do little to exert control over the events happening
around and to them. Routines for every aspect of life are
altered and controlled. Loss of control of daily routines
forces dependency on an age group struggling for independence. Fear of unknown events and procedures in the critical
care environment is stressful. For some, the uncertainty of
treatment efficacy and eventual recovery is even more
significant, heightening anxiety. Serious illness forces adolescents to reexamine their present and future lifestyle, as
well as their potential for adult fulfillrnent.
Adolescents are unlikely to be unduly anxious about brief
periods of immobility or limited physical restrictions. Most
procedures do not require restraint if the adolescent is aware
of events that will occur and is sufficiently cognizant to
cooperate. Immobility that persists beyond a brief period or
repetitive procedures may cause distress for even the most
resilient adolescent. Adolescents facing lengthy immobilization often are angry and aggressive during the early stages
of dealing with their illness or injury. Withdrawal and
depression often follow, particularly when dependence on
others is necessary. Enforced dependence, and the concomitant depersonalization experienced by adolescents, may
result in episodes of resentment, anger, and acting out from
an otherwise withdrawn teenager. Loss of productive roles
contributes to feelings of depersonalization and may exacerbate depression or anxiety.
Critical illness or injury permits adolescents to temporarily release self-control to others. However, if recovery
does not provide opportunity for reexerting control, most
adolescents demonstrate distress. For example, overly rigid
hospital routines or regulations are likely to result in
resentment, anger, and hostility as adolescent patients
protest the alterations in their usual lifestyle.

Developmental Care
Like adult patients, adolescents require orientation to their
environment, as well as to date and time. Some relief of
anxiety and distress is provided by verbal explanation of
what is happening, how it is anticipated to feel, what it will
accomplish, and how long it will last. Even when patients
cannot communicate, explanation is reliably provided.
When adolescent patients are able to communicate, they are
encouraged to verbalize questions and concerns. Some may
need their caregivers to broach the topics of anxiety, fear, or
feelings of sadness to begin to express their own concerns.
Positive reassurance can be therapeutic. Pharmacologic
management of anxiety and psychiatric consultation may be
indicated for adolescents who have marked emotional
reactions in the PICU.
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Assignment of consistent caregivers for adolescent patients in the PICU can mitigate some of the depersonalization and dependence experienced by teenage patients. Trust
is established, and a personal, but respectful, relationship
develops, providing an atmosphere for optimal recognition
of individual identity. Most adolescents strive to regain
self-control and independence after serious illness.
Mitigating the stress associated with separation from
peers and family members is accomplished by ensuring
contact with parents and liberal visits from siblings and
friends, particularly if an adolescent has a prolonged PICU
stay. Peer visitation is a significant event for these patients.
As progress occurs throughout adolescence, teenagers
develop the cognitive skills necessary for informed consent
for treatment and procedures. The stage of formal operations
encourages a sense of internal control and recognition that
decision-making authority about events in an individual's
life should lie with the individual. Informed consent requires
that adolescents receive sufficient information, comprehend
it, and voluntarily consent. Adolescents are assured opportunities to exert control over decisions regarding their
treatment regimen.
Adolescents need to express frustration via physical
activity. Innovation is necessary to develop ways for
adolescents to move out of bed and around the unit as they
recover from serious illness. Physical and occupational
therapy are encouraged to build independence, strength, and
mobility during recuperation. When serious or chronic
illness prolongs limited mobility and dependency, some
adolescents regress because the need to be cared for
outweighs the need to be independent. When immobilization is the permanent consequence of illness or injury,
significant adaptation is required. Long-term rehabilitation
deals with the emotional aspects of this life change, as well
as its physical consequences.
Setting flexible limits and encouraging participation in
self-care as adolescents recover restore a measure of control
over daily routines. Adolescents are also provided opportunities to participate in setting goals, planning their care, and
choosing options to promote self-control and independence.
Feelings of depersonalization are avoided when the staff
attends to the emotional needs of patients with the same
energy and commitment demonstrated in the intense care of
physical needs. Willingness to talk and listen to patients and
know them as individuals is essential.

THE CHRONICALLY CRITICALLY ILL CHILD
Advances in pediatric critical care continue to result in
decreased mortality and increased survival of infants and
children who require repeated, sometimes prolonged, PICU
admission and depend on technology for survival. Children
who are ventilator dependent, have significant neurologic
impairment or neuromuscular disease with respiratory
complications, and are seriously, but chronically, ill are
often transitioned from hospital to home or long-term care
setting after a prolonged PICU hospitalization. Improved
management of resuscitation, acute injury, and rehabilitation
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technology and the development of improved technologies
have resulted in a rise in the number of chronically ill
children at home and in school requiring technology. The
Presidential Task Force on Technology Dependent Children 39 reported in 1988 that some 2300 to 17,000 children
in the United States were dependent on ventilators, parenteral nutrition, intravenous medications, or other respiratory
or nutritional support.
Children who require lengthy PICU admission are often
the sickest and youngest patients. Feldman and coworkers4() examined the incidence and cause of hospital stays longer than 30 days among children less than
3 years of age. They reported that although only 2% of
the inpatient population required such lengthy hospitalization, their hospital stays represented 23% of the
patient days for children from newborn to 3 years and
II % of the total patient days for children of all ages.
Chronically ill children and their families present special
issues for the PICD care team. The social and emotional
needs of these children and their families are complex, as
their life experiences are distorted by prolonged
hospitalizations.

Impact of Chronic Illness on the Family
Chronic illness affects many aspects of family life: cognitive, social, emotional, behavioral, and financial. Chronic
illness increases obligations, tasks, commitments, and expenses for the family. Chronically ill children may cause
anxiety and confusion in social situations when others are
uncertain how to interact with the child or family. Families
with a chronically ill child strive to lead a "normal" family
life. They must actively reconstruct family life following the
diagnosis of a child's chronic illness, engage in parenting
activities and family routines, and interact with others from
a perspective that permits normalization. 42 Normalization is
complex as it changes and evolves with family situations,
processes, and developmental transitions. Parents may have
feelings of guilt, blame, and personal grief because of their
child's illness. The grieving process may be exacerbated or
reactivated by new medical issues or developmental transitions, such as starting school. Hospitalization often brings
renewed or additional sadness. Mastering guilt and grief is
necessary for each parent's emotional well-being, influences
the self-esteem and emotional development of the chronically ill child and siblings, and affects the normalization of
the family.

Impact of Chronic Illness on the Child
Chronic illness influences the cognitive, social, emotional,
and physical development of children. The diagnosis,
symptoms, treatment, and prognosis are factors influencing
the impact of a specific illness on an individual child. All
face separation from their families, home, school, and other
familiar environments when hospitalized. The critical care
experience is unlikely to provide a developmentally nurturing environment. Although all critically ill children adopt
the "sick role" and display illness behaviors; children with
chronic illness are unable to fully recover and discard the
sick role.
Chronic illness shapes a child's foundation and limits
developmental opportunities at every age. During infancy,
repeated hospitalizations may interfere with the parentinfant attachment and acquisition of trust. For chronically ill
toddlers and preschoolers, acquiring autonomy and initiative is difficult as illness erects barriers to independence.
Preschoolers who are chronically ill are aware that they are
different from their peers. By school age, parents describe
chronically ill children as lacking skills for social interaction, self-care, and compliance, often exhibiting aggressive
and self-destructive behaviors. 41 School is often a source of
stress for these children rather than an environment in which
they thrive because academic and social progress is interrupted by their illness. Peers are often unsupportive, if not
unkind. Chronically ill adolescents may react to separation
from the family more intensely and experience an increased
dependency on their families as their peers are achieving
independence. The stress of critical illness may delay
progress at leaming to manage their illness, which is a vital
transition for the chronically ill teenager. Adolescents may
be blocked from establishing independence and forced to
consider limitations on social, educational, and vocational
plans.

Impact of Critical Care
The potential for distress is high when an acute illness
necessitates intensive care for the chronically ill child.
Critical illness may negate family efforts at normalization.
Managing uncertainty and stress is the new priority.
Chronically ill children in the PICD require a supportive
environment that will protect the family and child's growth
and development. For the technologically dependent child,
prolonged hospitalization requires multidisciplinary team
intervention. An identified primary physician and nurse
coordinate the efforts of the multidisciplinary care team and
facilitate communication. These individuals are primarily
responsible for identifying specific family and patient needs
and formulating comprehensive plans to facilitate achieving
desired outcomes.

Developmental Care
Environmental factors in the PICD affect care of long-term
or chronically ill patients. Ongoing evaluation of the need
for critical care for the chronically ill child is crucial because
the care of these children should be deescalated as soon as
possible. Jansen and associates 43 contend that a change in
the philosophy of care for chronically ill patients who are
medically stable is necessary to optimize psychosocial
and cognitive development of both the patient and the
family. Many PICU staffs face caring for alert, active
children with normal intelligence in the midst of the hectic
critical care setting because the PICD may be the only unit
equipped to care for ventilator-dependent children. To
minimize the exposure to the harshness of the environment,
the child may be located in a corner, by a window, and
away from heavily traveled areas. Plugging electrical
outlets, removing sharp objects and possible hazardous
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equipment, and devising play areas in the child's bed space
or room provide safety and may enhance cognitive
development as these children have greater freedom to
interact with their environment. 43
Regression to an earlier and safer period of development or lack of developmental progress are common
responses to the demands of a chronic illness. Critical
illness further necessitates some degree of regression,
but motivation for developmental progress may be nearl y
nonexistent for chronically ill children even during
recovery. Exclusion from activity, learned inferiority,
and nonacceptance take a toll on the emotional well-being
of children who are chronically il1. 44 Table 2-8 lists
responses commonly identified among chronically ill children and the needs that typically underlie each response.
Critical care staffs who consistently meet those needs offer
an opportunity for chronically ill children to adapt and
progress.
As the number of advanced practice nurses (APNs)
practicing in the PICD continues to increase, assignment of
chronically ill children to their caseload ensures continuity
of care. Developmentally supportive care is enhanced
through multidisciplinary involvement coordinated by the
APN. Patient care conferences with involved disciplines
permit planning a daily schedule and supporting routines.
Needed changes in the schedule are accommodated, as
occurs in the outpatient or home setting.
Federal law (PL 99-457) and state regulations provide
infants and children requiring prolonged hospitalization
with eligibility for early intervention programs that may
commence during hospitalization and for schooling. Consultation with child life specialists, social workers, and
psychologists may lead to services that benefit chronically
ill or disabled children and their families as they transition
to home and the community.
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2·8 Responses to Chronic Illness .
From Children
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TABLE

Child's Needs

ar
rightened of everything
xaggerated normal fears
J~W friends
'ves up easily

ntasy
reates imaginary world
scapes undesired
, thoughts
eglects real needs
elpless, dependent
one
visibility
nobtrusive
. different, passive
ithdrawn
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ppears happy
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others

Self-confidence
Independence

Reality
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Security
Structure
Encouragement
Express anger, sadness
Closeness
Independence

verinvolvement in Medical Care
loaf, rigidly
Express anger, depression
independent
Normal peer relationships
ept at medical jargon
erbally assertive
leases others
.endships with healthcare personnel

Family Care
Families are an asset and source of support for chronically
ill children in the PICD. However, parents of chronically ill
children often experience conflict with staff members during
their child's hospitalization. According to Anderson,45 70%
to 90% of illness episodes in chronically ill children are
managed at home, outside the formal healthcare system.
Parents are knowledgeable and skilled in providing their
child's care, sometimes providing care more often within the
scope of professional healthcare practice. Clearly, these
parents are capable of assessing and making some management decisions for their children. PICD staff may feel
threatened by such parental knowledge and parents' expectations for complete and accurate information about their
child. Parents of chronically ill children are often viewed as
excessively demanding by the staff in a busy PICD. Their
insistence on care performed in a manner they designate
may be viewed as inappropriate or even uncooperative.
Their emphasis on normal routines for their child may be
seen as unrealistic.
Modification of usual PICD routines, such as decreasing
the frequency of vital sign measurement and suctioning, can
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~pata from Siemon M: Patterns of impairment: cognitive/emotional. In
mll~.ose MH. Thomas RB, eds: Children with chronic conditions: nursing
~u!it a family alld cammullity COil/ext. Orlando, Fla, 1987. Grune &
~tratton; Stevens M: Adolescents' perceptions of stressful events during
IosPi,aliza,ion, J Pediatr Nurs 1:303-313, 1986.

44

Part I

TABLE

Holistic Pediatric Critical Care Nursing

2-9

Family Power Resources Model
Interventions
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~--
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t.,tiF.. amily physical functioning, strength of the marriage. strength
~. of slbhng support, health of the family system
~tJ:>sychologic Stamina
t.psychologic strength and resiliency of individual family
~.I-: members and the family system

Recognize coping skills
Support maintenance of "normalcy"
Promote family involvement in child's care
Promote parent/child control
Encourage family sharing of the child's illness
Divide and share family tasks

~i1L

~lSupport Networks
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)It,;:,;,,

•

lfT. services
[!

Identify sources of strength
Maximize support systems

y~nergy

-~~ apacity to do work
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realistic view of the child's situation
Il\,

ur:

Ensure adequate nutrition, rest, equitable distribution of labor
Provide detailed, up-to-date information
Provide question-and-answer sessions

,jl

J

otivation

.1· ·.
f

~. piritual or philosophical orientation that overcomes inevitable

~.· l osses, maximizes potential, and develops positive self-esteem
F

Provide support
Recognize achievements
Focus on the present
Support family decisions

;!Adapted from Ferraro AR, Longo DC: Nursing care of the family with a chronically ill, hospitalized child: an alternative approach, Image J MlTs Sell
-7:77-81, 1985.
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be negotiated with families and home routines incorporated
in the plan of care for chronically ill children. Daily
communication with the families by a hospital staff member
is essential. Ferraro and Long046 described a model of
family power that increased coping and adaptation with
chronic, disabling illness in a child. Table 2-9 summarizes
components of the model and suggest~ interventions with
families while their chronically ill child is hospitalized.
Nurses who must balance the demands of physiologically
unstable patients and the expectations of parents of chronically ill children may need an opportunity to participate in
patient rounds and care conferences to optimize the plan of
care for long-term patients.

DEATH IN THE PEDIATRIC INTENSIVE
CARE UNIT
The death of a child is not an uncommon experience in
pediatric critical care. Knowledge of the experiences of
tenninally ill children, the responses of parents and siblings
to the death of a child, and the process of bereavement guide
practices in the PICU.

Development of Concepts About Death
Children learn about death through the course of regular
life events. Children younger than 2 years of age have little

awareness of death. Between the ages of 3 and 5 years,
death is usually thought of as temporary and reversible,
like sleep. Although death is seen as departure, those who
have died are thought of existing in some other place, most
often in heaven, and are attributed with life processes,
actions, and thoughts. There is lack of realization of its
finality. Often these young children associate death with
old age.
School-age children gradually move toward the concept of death as pennanent and irreversible when they
gain firsthand experience and exposure to death. Death
is most often identified with the dead object; the process
of dying remains elusive. Death is linked to external
forces and violence or associated with illness and old
age. Because death is recognized as a source of sadness,
it is also considered dangerous, scary, or mean. Near
the end of the school years, children who are 10 to
12 years old recognize that death is universal and final
and that death happens to all living things. The process
of dying is identified and associated with pain and
suffering. Death is fearful and brings feelings of sadness
and loneliness.
Adolescents develop an understanding of death similar to
adults. Death is the final and universal experience of all
living things but is also an intensely personal experience.
The capacity of adolescents to think about the future allows
them to consider impending death, thereby increasing its
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impact. Periods of rapid physical and emotional change
during adolescence are often periods of vulnerability to
fears about loss. Adolescents are especially fearful about
death.

Talking to Children About Death
Terminally ill children come to know that they are dying,
although no one may directly inform them. Often they
conceal this information from their families and from
healthcare personnel. Because children do not often tell
what they know or ask questions about what will happen to
them, some adults believe that children do not know that
they are gravely ill. If they do, adults believe that children
do not want to talk about it or that they are silent because
they sense the reluctance of the adults around them to
discuss the situation. Children interpret the behavior of
others, especially those they trust, in their view of themselves. They are adept at identifying inconsistencies between verbal and nonverbal messages. Tearful, anxious
parents and staff members who speak in hushed voices come
to have meaning across time and with experiences in
healthcare settings.
Evidence that children are knowledgeable about death
does not ease the task of talking with them about their
own impending death. Few guidelines are available.
Children who are dying need to share their knowledge, and
they need to have their parents with them. Terminally ill
children conceal their knowledge of their prognosis from
their parents, leading to the conclusion that their need for
parental closeness is greater than their need to talk about
dying. However, their preoccupation with death is evidenced in their play and art, in avoidance of conversation
about the future and concern that things be done immediately, in anxiety, and in acting ont or withdrawing from
others to establish emotional distance. Children do share
their knowledge if given the opportunity. They talk with
those adults who listen to them carefully, taking cues from
the child and answering only what is asked on the child's
terms. Parents and healthcare professionals are guided by
this principle.

Application in the PICU
Some patients in the PICO may be physically and neurologically able to talk with parents and caregivers. Discussion
with them is particularly important if, for example, an
aggressive treatment plan is considered. However, many
children in the critical care unit are too ill to participate in
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discussion. Death most often occurs only after aggressive,
lifesaving interventions have been attempted and ultimately
are deemed futile. Death is unavoidable and imminent,
expected within moments or days, and aggressive interventions no longer appropriate.
Families and caregivers may not know what to say to
these children. They have no way of knowing with certainty
whether terminally ill children can hear or understand. Some
parents continue to talk with their unconscious children,
often acknowledging that the child is dying and that they are
saying good-bye. Caregivers can follow the parents' lead in
talking with children who are dying in the PICU. Caregivers
may also show an example of such behavior to parents who
may need unspoken permission to continue to interact with
their dying child.
When aggressive intensive care is discontinued, care is
directed toward maintaining the child's comfort and dignity.
Many tools among the personal and caring resources of
professional caregi vers can ensure humane care to dying
children and to their families. Ensuring cleanliness and
comfort, providing pri vacy, and speaking with the child are
only a few examples. Dying children, if they are able,
maintain some sense of control by choosing care or
therapies that enable them to make each day as comfortable
as possible. Pain control is a priority because fear of pain
with death is common among children and is a worry for
parents of dying children. Parents are logically the individuals who also benefit from participating with or for their child
in care that ensures comfort. Parents may perform caregiving tasks if they wish for this sort of physical closeness to
their child.

Helping After a Child's Death
Parents may need practical assistance with making funeral arrangements and contacting their extended families. They also face the sizable task of talking with their
other children. Siblings are best told about the death as
soon as possible in clear and truthful terms. A parent or
another trusted adult share information, as well as their
feelings of sadness, in a controlled manner. Some parents
find books that describe talking to children about death
helpful or are assisted by books written for children. Others
may find community support groups, such as Compassionate Friends or the Candlelighters, beneficial in the
bereavement process. Programs established in the PICU for
families who lost a child in death, institutional memorial
services, and the like are beneficial for families and
caregivers.
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Caring Practices: The
Impact of the Critical Care
Experience on the Family
Martha A.Q. Curley
Elaine C. Meyer

apeutic to them and their critically ill children. Factors
compromising the care of families include gaps in nurses'
knowledge and skill in working with families, unclear lines
of responsibility for various aspects of family care, and
insufficient support or mentoring for the difficult emotional
work inherent in caring for families. 2•3 This chapter reviews
the evolution of family interactions in pediatric settings and
the rationale for psychosocial intervention in the intensive
care setting. We then review the research on pediatric
intensive care unit (PICU)-related parental stress, the
trajectory of parental stress, and parental needs during the
pediatric critical care hospitalization. The unique role of
nursing in helping families to cope and alleviate stress is
emphasized. The nursing mutual participation model of
care is presented, which provides a framework for supportive psychosocial interventions for parents of critically
ill children. This is followed by a review of issues of
particular concern to nursing staff, including the support
of other family members, transition from the PlCU,
bereavement in the context of the intensive care setting,
and referral and collaboration with ancillary psychosocial
support personnel.

EVOLUTION OF FAMILY-CENTERED CARE PRACTICES
CHANGING AMERICAN FAMILY DEMOGRAPHICS
BASIS FOR INTERVENTION
SOURCES OF PARENTAL STRESS

Crisis Theory
Stress Unique to the PICU
Trajectory of Parental Stress
IDENTIFIED PARENTAL NEEDS AND COPING STRATEGIES
INTERVENTION STRATEGIES
NURSING MUTUAL PARTICIPATION MODEL OF CARE

Initial contact
Daily Bedside Contact
FAMILY CONTEXT OF CHILDHOOD CRITICAL IUNESS

Supporting the Siblings of a Critically III Child
Professional Relationships
Collaborative Relationships With Psychosocial
Support Staff
PREPARING FOR PAnENT TRANSFER

EVOLUTION OF FAMILY-CENTERED
CARE PRACTICES

BEREAVEMENT

The parental role in the care of hospitalized infants and
children has evolved over time. Not too long ago, parents
were neither welcomed nor allowed in pediatric inpatient
units primarily because of concerns about infection control.
Bowlby's and Robertson's classic work 1,4.5 describing the
stages of separation trauma experienced by young children
in hospitals-protest, despair, then detachment-supported
the hypothesis that parent-child separation is detrimental to
the child and to the parent-child relationship. We now
acknowledge that parents are crucial to a child's healthy
psychosocial and physical well-being and that parental
support during a stressful event, such as critical care
hospitalization, is essential for the child's continued socioemotional growth and development.

SUMMARY
It is a good professional rule to let a mother work at her own

level, supporting ber in her skills and understanding and
bolstering her confidence in herself, quietly supplementing her
effort instead of giving detailed directions and cautions which
may undermine her confidence.
James Robertson'

I

nherent in the practice of pediatric critical care nursing is
helping families to endure the stressful and unspeakable
experience of an infant's or child's critical illness. This
humanistic aspect of practice is essential so that families can
continue to function in vitally important roles that are ther-
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Family-centered care is currently considered "best practice" in pediatric healthcare settings. The central tenet of
family-centered care is that the family is the constant in the
child's life and, ultimately, holds the responsibility for
ensuring that the child's physical, social, and emotional
needs are met. 6 Thus parents are now encouraged to
continue parenting during the entire period of their infant or
child's hospitalization.
The basic tenets of family-centered care are outlined in
Box 3-1. Family-centered care is a philosophy of care that
recognizes, respects, and supports the essential role of the
family in the lives of children. It is a philosophy that
acknowledges and supports diversity among familiesdiversity that encompasses varied family structures and
sociocultural backgrounds; family goals and priorities;
strategies and actions; as well as diversity in family support,
service, and informational needs.? Family-centered care

.

Box 3-1

Key Elements of Family-Centered Care

.

Incorporating into policy and practice the recognition that
the family is the constant in a child's life, while the service
systems and support personnel within those systems
fluctuate
• Facilitating family-professional collaboration at all levels
of hospital, home, and community care:
-Care of an individual child
-Program development, implementation, evaluation, and
evolution
-Policy formation
Exchanging complete and unbiased information between
families and professionals in a supportive manner at all
times
Incorporating into policy and practice the recognition and
honoring of cultural diversity, strengths, and individuality
within and across all families, including ethnic, racial,
spiritual, social, economic, educational, and geographic
diversity
Recognizing and respecting different methods of coping
and implementing comprehensive policies and programs
that provide developmental, educational, emotional,
environmental, and financial supports to meet the diverse
needs of families
Encouraging and facilitating family-to-family support and
networking
Ensuring that hospital, home, and community service and
suppon systems for children needing specialized health
and developmental care and their families are flexible,
accessible. and comprehensive in responding to diverse
family-identified needs
Appreciating families as families and children as children,
recognizing that they possess a wide range of strengths,
concerns, emotions, and aspirations beyond their need for
specialized health and developmental services and support
From Shelton TL. Stepanek 1S: Family·centered care for children needing
spl'L'ialized health and developmenlal servin's. 1994. Association for the

Care of Children's Health. 7910 Woodman' Avenue, Suite 300, Bethesda,
MD 20814, 301/654-6549.

stri ves to support families in their natural caregiving roles
by building on their unique strengths as indi viduals and
families, It is a philosophy that views parents and professionals as equals in a partnership committed to excellence at
all levels of healthcare. 6 Shelton 8 notes that the key to
family-centered care is a fundamental commitment to a
helping style that truly embodies partnerships. Box 3-2
reviews the values and beliefs identified as critical for
developing positive parent-professional partnerships.
Although pediatric nurses have long recognized the
fundamental importance of caring for infants and children
within a family context, the operationalization or "how to"
of family-centered care in the clinical setting is less clear
and is often based on intuition and untested assumptions
with few empirical guidelines. 9 . lo At times, particularly in
intensive care settings, parents may be only marginally
involved in the decision-making process and care of their
children. Parents may be considered as "visitors," thus
forcing a temporary or perhaps permanent disruption in the
parent-child relationship. Rushton lo has identified several
barriers to family-centered care in pediatric critical care
settings, including the highly technologic environment,
ethical dilemmas, range in patient population, staff shortages, professional attitudes, the intensive care organizational culture, and economic trends.
Despite the greater expectations that parents participate
as partners in their child's care to the extent that they wish,
paternalistic attitudes and behaviors can be prevalent within
the PICU as a result of underlying assumptions that parents
are incapable of complex decision making under the
circumstances. There may be the tendency to "protect"
parents and to present a "consistent picture," which,
although well-intended, limits parents from fully participating as equal-status partners in the decision-making process
and care of their child. 9 ,11 Information that is incomplete,
biased, or otherwise not understandable can diminish the
parents' status relative to professionals and cripples full
participation in healthcare decision making, Bogdan,
Brown, and Fosterl 2 address the complexities of parenlprofessional communication within the intensive care setting and advise that professionals be "honest but not cruel."
..

~

Box 3-2 .
Beliefs and Behaviors Critical for
Parent-Professional Partnerships

A presumption of and respect for the inherent capabilities
and strengths of families
• A commitment to and valuing of diversity
• An ability to communicate and share information in ways
that are affirming and useful
An ability to treat others with dignity and respect
An ability to build on family strengths to enhance feelings
of control and independence
An ability to provide assistance in ways that match family
priorities
From Shelton TL: Family-centered care in pediatric practice: when and how?
J Dev Behav Pediatr 20:117-118, 1999.

Chapter 3

Caring Practices: The Impact of the Critical Care Experience on the Family

Parental needs, parental roles within the PICU, and the
establishment of therapeutic nurse-parent relationships are
aspects of family-centered care that continue to present
challenges to pediatric critical care nurses. Fundamentally,
family members are not visitors but part of nursing's sphere
of concern-the people nurses take care of. Specifically,
pediatric nurses participate in therapeutic relationships with
individual patients and their families. The concept of
"mutuality" articulates the nurse-parent relationship that
embodies the philosophy of family-centered-care. 13
Mutuality is defined as a synchronous, co-constituting
parent-nurse relationship that stimulates the process of
personal growth. Two attributes characterize mutuality: (I) a
synchronous co-constituted relationship and (2) evolution of
both individuals toward personal growth. The synchronous
co-constituted relationship speaks to the responsive interdependence, intersubjectivity, shared commonality, and equity
within the relationship. The feelings engendered by mutual
respect belong to each respectively. Movement toward
personal growth speaks to the goal of the interaction-to
benefit each participant in the relationship. Through the
relationship, participants develop greater self-awareness and
self-understanding, which contribute to their personal
growth.
Nurse-family mutuality may help contribute to optimal
family outcomes. Outcomes of concern include the perception of being well cared for, achievement of appropriate
self-care, demonstration of health-promoting behaviors,
improved symptom management, and quality of life. 14

CHANGING AMERICAN
FAMILY DEMOGRAPHICS
Any discussion of family-centered care would be incomplete without recognizing the great variability among
families with respect to family structure, function, and role
responsibilities. The "traditional" two-parent family is no
longer the norm, in which mother serves as child caregiver,
nurturer, and homemaker and father serves as economic
breadwinner, protector, and disciplinarian. Indeed, many of
our assumptions about family membership and organization
are no longer applicable and must be adjusted to effectively
serve and support children and their families. It is recommended that in psychosocial assessments, nurses inquire
directly about family member composition, parental role
assignments, employment, and child-care arrangements
rather than inaccurately assuming traditional family structure and function.
Family members include anyone who is important in the
life of the child. Consider the following facts as evidence of
changing American family demographic characteristics. 15 It
is estimated that only 22% of American families are
structured in which the father is employed outside of the
home and the mother stays at home full time. As further
evidence of the changing parental role responsibilities
within families, approximately 73% of all mothers with
children between the ages of 6 and 13 years are employed
outside of the home. One in five families currently has a
female head of household. Twenty-five percent of all infants
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are born to unwed mothers. Approximately 500,000 infants
each year are born to teenage mothers. Twenty-one percent
of our nation's children are being reared amid poverty
conditions. Chronic, persistent poverty is overrepresented
among minority children and families in the United States. 16
From conception, minority children are directly or indirectly
exposed to a host of problems associated with socioeconomic disadvantage, including differential access to heaIthcare, residential segregation, unsafe neighborhoods and
violence, substandard housing, and parental unemployment
or underemployment. 17
The projections of population growth for the twenty-first
century emphasize the need for healthcare providers to
understand the parenting processes and family characteristics among ethnic and minority families. Demographers
project that the proportion of minority children and families
will continue to increase over the next 20 years, as the result
of immigration and higher fertility rates in those groups,
among other factors. 18.19 African Americans currently make
up approximately 12% of the population and constitute the
largest ethnic minority group in the country. Hispanic
Americans now constitute approximately 8% of the population but are projected to become the largest minority group
in the country.
The values, attitudes, and parenting behaviors of ethnic
and minority parents vary widely and influence their
experience and coping with childhood critical illness and
intensive care hospitalization. Factors that are important to
consider include the family's cultural heritage and ancestral
world views, language preference, degree of acculturation,
access to societal institutions, socioeconomic status, exposure to poverty, and other life stressors in the context of
racism, prejudice, and discrimination. 17

BASIS FOR INTERVENTION
lt is simply impossible to care for infants and children
without caring for them in the context of their families.
From a family systems perspective, family members are
interconnected, and consequently, events that befall a single
member affect all family members. 2 O-24 Although infants
and children can be physically separated from their parents,
they cannot be separated emotionally or legally. Mahler,
Pine, and Bergman 25 proposed that mothers and infants
are psychologically inseparable until completion of the
separation-individuation process, which occurs at about
3 years of age. They note that "the biological birth of the
human infant and the psychological birth of the individual
are not coincident in time. The former is a dramatic,
observable, and well-circumscribed event; the latter a
slowly unfolding intrapsychic process." Mahler and colleagues 25 note that developmental readiness for independent
functioning is the driving force behind this normal process.
Historically, parents have served as the primary decision
makers for their infants and children. II From a legal
perspective, parents who have custody must provide consent
for their child's procedures. For parents to provide informed
consent, they must understand their child's condition and the
proposed treatment plan and procedures, and they must have
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the opportunity to ask questions. Consent forms should be
available in the parent's primary language.
In general, critical illness is extremely stress provoking
for infants, children, and their families. Parents are confronted with the possible or actual mortality of their
offspring, which represents a great violation of the natural
order, whereby children are expected to outlive their
parents. Intensive care hospitalization violates the parents'
usual role in caring for and protecting their child, which may
be experienced by parents as displacement, enforced passivity, and profound helplessness. Circumstances surrounding the child's admission (e.g., accident, planned surgery,
new diagnosis) and the family's previous experience with
illness and hospitalization influence the parental experience
of stress and coping responses 26 The most prominent
sources of parental stress include the fear of death, brain
damage, and physical handicapY·28 Specific fears depend
on the characteristics of the child's illness, including acuity,
condition, and prognosis. Uncertainty, that is, ambiguity,
lack of clarity, conflicting information, and unpredictability
over various aspects of the illness or outcome, can also be
extremely stress provoking for parents.29.30.31
Anxiety and stress may be transferred from the parent to
the infant or child through what Skipper and Leonard 32 first
described as the "emotional contagion" hypothesis. Infants
and children can be exquisitely sensitive to the emotions and
moods of their parents. Children's moods often reflect their
own internal states, as well as the feelings of their parents.
Nursing care that facilitates adaptive functioning in the
parents will, theoretically, decrease both parent and child
emotional disequilibrium and stress.
The crisis inherent in hospitalization can severely impair
parental sense of confidence and control, thereby compromising parental coping and performance. Hebb 33 described
the relationship between stress and behavioral functioning
as an inverted U -shaped curve; that is, moderate degrees of
stress are related to optimal behavioral functioning and performance, and very low and very high degrees of stress are
related to poor functioning and performance. Thus helping
parents to reduce their own levels of stress into the moderate
range enables parents to better fulfill their natural parenting
roles, which can be therapeutically useful at the bedside.3 4
Effective parental functioning can be both supportive and

Fig. 3-1

ABCX model of crisis.

stabilizing to critically ill children. Some preliminary
evidence now supports the therapeutic value of parental
involvement in the PICU environment. For example,
Mitchell and colleagues 35 noted that parental stroking
reduced children's intracranial pressure (lCP). Compared
with an investigator's touch, the researchers noted an
occasional, rather profound decrease in the ICP with
apparent stabilization following parental touch. Similarly,
increased parental caregiving and visitation with preterm
infants in the neonatal intensive care unit have been found
to improve weight gain and reduce the length of hospitalization 36 Nursing research has also documented the positive
effects on neonatal growth and development of "kangaroo"
care, in which mothers have early and regular skin-to-skin
contact with their preterm infants. 3?

SOURCES OF PARENTAL STRESS
The critical illness of an infant or child is clearly recognized
as stressful to parents. Understanding the basis and progression of that stress is necessary so that care can be focused to
help parents modulate PICU-related stress. The nature of the
nurse-family relationship can be instrumental in reducing
the stress experienced by parents of critically ill children,
enabling parents to function effectively in their supportive
and therapeutic roles with their children.

Crisis Theory
Hill's ABCX model of crisis 38 provides a basis for
understanding the individual responses and needs of parents
of critically ill infants and children (Fig. 3-1). Hill described
family crises as those situations that create a sense of
sharpened insecurity or that block the usual patterns of
action or call for new ones. Three interacting variables
determine whether and to what degree an event becomes a
crisis (X) for a family. The variables include the hardship of
the situation or the event itself (A); the family's crisismeeting resources, such as role structure, flexibility, and
previous history with crises (B); and the meaning the family
ascribes to the event according to their goals, sociocultural
background, and religious affiliation (C).
Thus the ABCX model of crisis can help to explain
individual differences among family members and why
family members have different perceptions, needs, and
coping styles when confronting similar illnesses in their
children. It is important to note that parental responses to the
PICU admission of their child are not well predicted by
objective measures of the child's severity of illness 39
Rather, parental perceptions of the child's illness and
hospitalization appear to have greater use in understanding
and predicting parental responses and coping. Hospitalization often precipitates changes in a family's social support
network and view of themsel ves as protectors and nurturers
and can disrupt the balance between available resources and
presenting demands 40
Expanding on Hill's work, the double ABCX model
proposed by McCubbin and Patterson 41 incorporates postcrises events that may affect family stress and coping over
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time (Fig. 3-2). The double ABCX model provides a useful
conceptual model for families of chronically critically ill
children who require ongoing treatment and periodic
hospitalization. This model includes the cumulative nature,
or pileup, of demands for change within a family as the
crisis extends over time (aA); family system resources
that may include family members, the family unit, and
the community (bB); and the family's perception of the
illness-related experience, which includes the family's
definition of the major stressor event, the meaning of the
resulting hardships, and the family's effort to redefine the
event (cC). The resultant crisis (X) may be perceived
differently by family members as an opportunity, challenge,
or an overwhelming burden. Coping strategies, which are
defined as the cognitive, behavioral, or emotional processes
that individuals use to adapt to the demands of stressful and
associated events, result from interactions between aA, bB,
and cc.
Through cognitive appraisal of the perceived meaning of
the event, a crisis sets forth basic adaptive tasks to which
varied coping skills can be applied. 42 Five major adaptive
tasks to be confronted in managing crises have been
identified (Box 3-3). Coping skills focus on the meaning of
the crisis, the reality of the crisis, or the emotions associated
with the crisis. Parents of critically ill children typically use
both problem-focused and emotion-focused forms of coping
almost equally.43-45 Problem-focused coping behaviors include attempting to modify or eliminate the source of stress,
to deal with the tangible changes, to actively change oneself,
and to develop a more satisfying situation. Emotion-focused
coping behaviors include managing the emotions aroused by
the stressors. The constellation of coping strategies used by
parents varies according to parental age, perception of the
illness, locus of control, anxiety level, and parental involve-

ment in caregiving activities. 46 Philichi 47 noted that an
important role for nurses is the identification and facilitation
of the various coping strategies used by families.

Stress Unique to the PICU
Rothstein 26 noted that the family's stress level is increased
when the child's illness is severe, when little or no
preparation for hospitalization has occurred, when the cause
is unclear, and when the outcome is uncertain. Miles and
Carter48 were the first to empirically describe parental stress
in the PICD setting. They identified three major sources of
stress specifically experienced by parents of children in the
PICD, including situational variables, personal characteristics, and the PICU environment. The first two sources of
stress identified by Miles and Carter are congruent with
Hill's ABCX model of crises. Situational variables corre-
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5. Preserve a positive self-image and maintain a sense of
competence and mastery
3.
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York, 1986, Plenum Medical Books, pp 3-28.
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spond to Hill's "A" component of the model, for example,
the child's critical illness and hospitalization. Personal
characteristics correspond with Hill's "8" and "C" components of the model, for example, the family's existing
resources and individual perceptions of what is occurring.
The third factor, environmental sources of stress, is unique
to the PICU setting and potentially within nursing's role to
manipulate.
Miles and Carter48 delineated seven dimensions of the
PICU experience that parents find stressful (Table 3-1).
These dimensions, derived from observational data, parent
and staff nurse interviews, and the literature, form the basis
of the Parental Stressor Scale: Pediatric Intensive Care Unit
(PSS:PICU). These dimensions may be conceptually divided into two major categories of stress including (I) the
physical aspects of the intensive care environment and
(2) the psychosocial aspects, which include parent-staff
relationships and the parent-child relationship. Alterations
in parental role, and the subsequent disruption in the
parent-child relationship, have consistently been identified
as the most stressful aspect of the PICU environment.49.54.60
Changes in the child's behavioral and emotional reactions,
which can challenge the parents' ability to know and care for
their child, are ranked second in degree of stressful ness
following parental role alteration. Rennick 55 noted that
when the parental role is threatened, the parent as a whole
person is at risk.
Under usual circumstances, parents provide a safe and
constructive environment for their child, which fosters their
growth and development. Traditionally, parents nurture,
protect, educate, and advocate for their children. Parents are
usually considered to be the "expert" on their child, in that
they know their child better than anyone else. Although
parents take for granted their usual control over their
children's lives, critical illness and hospitalization often
threaten that sense of control, competence, and stabili ty56
Parents can find themselves displaced from their familiar
roles and, in many cases, dependent on healthcare providers
for the very survival of their child. It is not uncommon, over
the course of a PICU hospitalization, for parents to lose
confidence in their ability to know or to comfort their child
in meaningful ways.

TABlE]-1

Environmental Sources of PleU-Related Stress

l~imension
!Sights and sounds
gChild's appearance
~;'Child's behaviors and emotional responses

I~(

~Child's procedures
If)'Staff communication

ir"
l\rStaff behavior

Irarental role revision

~'

~~pata

Parent-child interactions are often compromised as a
result of barriers created by life support equipment, sedating
medications, precaution policies designed to reduce the risk
of infection (e.g., surgical masks), prolonged hospitalization, and visitation restrictions (e.g., during change of
shift).57.58 The critically ill child does not look or act the
same to the parent when, for example, paralyzing agents
distort the child's facial features. A child might respond to
the parent with an increased heart rate, causing monitoring
alarms to sound-this can be not only unnerving but also
serve to squelch future attempts to interact with the child. It
can be discouraging and frustrating to parents that the
familiar methods of comforting their child are not feasible or
effecti ve. Parents may become unsure of themselves during
caregiving activities and tasks that they had previously
completed hundreds of times. Not only must parents face the
uncertainty of their child's critical illness, but also they may
feel helpless and ineffectual because they believe that they
can do little or nothing to improve the situation.
Susan Jai 9 first identified role revision, the process of
giving up the familiar role of "parent-to-a-well-child" and
taking on a new role as "parent-to-an-acutely-ill-child," as
a stressor to parents of critically ill children. Jay noted that
during the crisis of a sudden acute illness, parents first
grieve for their previous role and "need time to resolve the
fact that others have their child's life in their hands, that they
are no longer in control, and that they may no longer know
what is best for their own child." Transition to their new role
occurs by first imitating the caretaking responses of others
available to them. They watch parents of other children in
the PICU and also watch nurses caring for their own infant
or child. Parents slowly assume their revised identity as
parent-to-an-acutely-ill-child. Variability in parental role
attainment will normally occur. The spectrum is wide and
ranges from abandonment, keeping a distance, passive
involvement, and active involvement to hypervigilance.
Rennick 55 has questioned whether role revision would occur
in parents who spent only brief periods in the PICU before
transfer of the infant or child to another unit.
Mothers generally report higher levels of stress than
fathers in the PICU. Miles and colleagues 53 concluded that
stress is associated with alterations in parental role and is the

Items

Monitors, alarms, other sick children
Puffiness, color changes, appearing cold
Confusion, uncooperative, crying, demanding, pain, restless, inability to talk,
frightened, angry, sad
Injections, tubes, suctioning, IV, pulmonary care, ventilator, incisions
Explaining too fast, using words that are not understood, inconsistent information, not saying what is wrong, not talking enough
Not introducing themselves. laughing, joking, too many people
Not seeing, not holding, not taking care of the child themselves. not visiting, not
with crying child, not knowing how to help child

from Carter Me, Miles MS: Parental stressor scale: pediatric intensive care unit, Kansas City. KS, 1983, School of Nursing, University of Kansas.
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result of changes in the child's behavior and emotional
reactions. Parents who experience an unexpected admission
of their child are usually more stressed than parents who are
prepared for their child's admission.50.51.6O Similarly, parents who are unprepared for the admission are more
stressed than parents who had formal preparation before the
experience. 49
Advanced preparation for parents whose children will be
hospitalized typically includes providing parents with information about (1) a child's anticipated response to the illness
or procedure based on their developmental stage; (2) a
preadmission tour, informal interview, or information session; (3) preadmission parent-child interaction guidelines;
and (4) printed resources for the child and parent. 61 Miles
and Mathes62 noted that parents of critically ill children
were seldom prepared for the perceived alterations in the
parent-child relationship, which is the most stressful aspect
of the PICU hospitalization.

Trajectory of Parental Stress
Research to date has delineated phases and characteristics of
the trajectory of parental stress in the PICU. Awareness of
the normal trajectory of PICU-related parental stress enables
nurses to focus intervention strategies and to identify
extreme parental behavior. Parents who experience stress
responses that are outside the expected range or extreme
may benefit from early consultation or referral for more
imensive intervention with psychosocial support staff.
Rothstein26 studied parents of children admitted to the
PICU after catastrophic illnesses and described a pattern of
parental reactions. Within the first 12 hours of admission,
parents often exhibit overwhelming shock associated with
feelings of helplessness. Within 24 hours, this period is
followed by a phase in which parents grapple for explanations. This behavior supports the parent's search for
explanations to ascribe meaning to the illness. 29 .31 Rothstein 26 noted that parents are "responsible" for their
children and thus may experience real or imagined guilt or
blame themselves for their child's critical illness.
Rothstein 26 next described an anticipatory waiting phase,
lasting hours to days, which coincides with the child's
medical stabilization. During this phase, parents frequently
express concerns about the long-term effects of the illness;
focus on seemingly insignificant changes, hoping to see
improvement; and become more demanding of and perhaps
angry at the staff. Specific uncertainties during this time
include the child's likelihood of survival, future appearance,
anticipated level of functioning, and duration of illness and
hospitalization. Parental helplessness continues during this
period of waiting. Anticipatory waiting is then followed by
either the elation of discharge or the bereavement process if
the outcome is death.
Lewandowski 63 was the first to describe the initial
responses and coping strategies of parents of children
undergoing open-hean surgery. Lewandowski reported that
despite preoperative teaching and a preadmission tour of the
PICU, parents often express shock and feel unprepared for
their first postoperative visit at the bedside. Parents may
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experience helplessness and powerlessness because they are
unable to function in their familiar role of protector.
Lewandowski described several parental coping strategies,
which are presented in Table 3-2. Restructuring, sometimes
referred to as a time to focus on little things, allows the
parent to focus on one thing at a time, which prevents
parents from becoming overwhelmed by the overall condition of the child.
Curl ey 51.60 found that changes in a child's appearance
and PICU-related procedures were more stressful to parents
during the first few days of hospitalization than later in the
course of hospitalization. As the hospitalization progresses,
issues related to staff communication and behavior become
greater contributors to the parental experience of stress.
Supporting Rothstein's notion of the anticipatory waiting
phase, Curley documented an overall increase in parental
stress after the first few days of PICU hospitalization.26.51.6O
Most importantly, parental stress related to role alterations
was significant throughout the entire PICU hospitalization.
Parents, accustomed to their protector role, report helplessness in protecting their child from pain and in knowing how
best to help their child. Curley and Wallace 52 noted that the
trajectory of child illness and concomitant trajectory of
parental stress vary across different patient populations. The
"typical" trajectory of parental stress differs significantly
between parents of surgical patients and medical patients.
The trajectory for surgical patients often begins with a
hyperacute phase that predictably improves over time,
whereas the trajectory for medical patients is often more
variable and can be just the opposite of the surgical patients.
As the child's condition stabilizes and the parents
gradually adjust to the role of parent-to-a-critically-ill-child,
parents frequently express the need to become personally
involved in their child's care. Although parents may initially
have been relieved that they were not solely responsible for
the care of the child, they wish to playa more active role as
their child improves 27 or as they gain self-confidence within
the PICU setting. 51 ,6O Curleil. 60 has postulated that increases in perceived parental stress relate specifically to
nursing communication and nursing behavior and, in
general, may reflect parents' unmet needs to participate in
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Initial Coping Strategies
Delay in parental approach
to the bedside
Visually scanning the environment and
orienting self before attending to
verbal explanations
Nonresponsive passive behaviors or
actual physical withdrawal from the
bed space
Focusing on one physical detail or on
the care provided
Dealing with the child's illness on an
intellectual level

~.:IData from Lewandowski LA: StressoTS and coping styles of parents of
i!j;hildren undergoing open heart surgery, Crit Care Q 3:75-84, 1980.
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caregiving and to fulfill meaningful roles. Parents may
experience displacement by staff and usurpation of their
traditional parental caregiving role. Similarly, Rothstein 26
noted that the helplessness experienced by parents is
heightened when parents are discouraged or excluded from
taking an active role in the care of their child. Despite the
high levels of technology in the PICU environment and the
seriousness of the child's illness, most parents wish to be
informed, to have input into the plan of care, to help with
their child's physical care, and to be recognized as important
in their child's recovery.64.65

IDENTIFIED PARENTAL NEEDS
AND COPING STRATEGIES
Numerous researchers have described the perceived needs
of parents during the course of PICU hospitalization.
Perceived needs support parents' individual coping efforts
and, ultimately, the ways in which they are able to manage
the threat of their infant's or child's illness. Psychosocial
intervention that addresses the parents' identified needs
serves to support their individual coping. Commonly cited
parental needs are summarized in Box 3-4.
Even when parents are stressed within the PICU setting,
Kirschbaum64 ,65 found that they are still readily able to
identify their own needs when asked. Needs that are most
important to parents included believing that there is hope,
knowing that the child is receiving the best care possible,
and believing that they are getting as much information as
possible. One half of the 10 most important needs identified
by parents are informational in nature. Thus excellence in
clinical care and provision of information are major factors
that support families. Accurate information is necessary for
parents to cognitively appraise the situation, to construct
meaning of the illness, to make informed decisions, and to
help their children understand events. Rothstein 26 noted that
parental trust develops when information is honest, consistent, and anticipatory in nature.
Melnyk and colleagues 66 .67 designed Creating Opportunities for Parent Empowerment (COPE), a two-part intervention that provides parents with (I) information about
their child's behavior during recovery from critical illness
and how parents could help facilitate their child's adjustment and (2) a parent-child workbook containing three
parent-child activities designed to assist parents in enhancing their children's coping during and after the hospital
experience. They found that mothers who received the
COPE program provided more support to their children
during intrusive procedures; provided more emotional
support to their children; reported less negative mood states
and less parental stress related to their children's emotions
and behaviors; and reported fewer posttraumatic stress
symptoms and less parental role changes for weeks following hospitalization.
Compared to relatives of acutely ill adult patients,
parents of acutely ill children report a greater need to be
recognized as vital to their ill child's recovery, to visit
anytime, and to help with the child's physical care. 64 ,65,68
These findings make intuitive sense because parents nor-
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Box 3-4

-

Identified Parental Need5

• Gelling as mucb infonnation as possible
• Assurance tbat tbeir cbild is receiving the best possible
care
• Feeling that there is hope
• Vigilance
• Being near their child as much as possible
• Help witb pbysical care
• Being recognized as important to child's recovery
• Talking witb otber parents
• Prayer
• Instrumental resources (e.g., transportation, meals)

mally "take care of" their children. Parents need to feel
important to their children regardless of how sick they are.
For example, parents generally tend to put their child's
needs above their own needs. Parents consistently rate their
own personal needs (e.g., "having someone concerned
about my health") as less important than any child or
parent-child need. 65 Some parents, however, do acknowledge a physiologic and psychologic need to curtail the
amount of time they spend with their child in the PICU. 69
Miles and Carter44 identified fi ve coping strategies
perceived as most helpful to parents of critically ill children.
Coping strategies included (I) seeking help or comfort from
others, (2) believing that the child is getting the best possible
care, (3) seeking as much information as possible, (4) having hope, and (5) being near the child as much as possible.
The use of prayer, asking questions of the staff, and talking
with other parents were also cited as important. Similarly,
Kasper and Nyamathi 69 identified the most common parental needs as proximity to the child; frequent, accurate, and
truthful information about the child's condition; participation in the child's caregiving; sleeping accommodations
near the PICU; and reassurance that the child is receiving
needed care and treatment.
In addition, parents need to know that their child is being
treated as a person. 70 Parents assessed this parameter by
noting whether staff called their child by name or talked to
their child at an appropriate developmental level, even if
their child was comatose or heavily medicated. Verbally
preparing even an unresponsi ve child for procedures conveyed the message to parents that the nurse cared about. not
just for, their child. Parents perceived staff efforts to treat
their children with such dignity as the "best possible care."
Although parents have consistently identified proximity
to their infants and children as a very important need, some
PICUs limit parental access to children several times during
the day. Notwithstanding 24-hours-a-day visitation policies,
nurses and other staff often excuse parents from the bed
space during activities such as nursing reports, medical
rounds, and procedures 7 ! This exclusion is inconsistent
with family-centered, humane care in the PICU. Furthermore, mothers who have the benefit of individualized
visitation have significantly lower anxiety scores and
perceive their child's illness as less severe than mothers who
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experience structured visitation 72 Carnevale 73 notes that
even the word visitation marginalizes the significance of
family presence. The most salient component of family
visiting guidelines is flexibility. An individual approach that
enables the family's informal social support system to be
involved during the hospitalization is also recommended. 74
This not only includes parents, but also siblings, grandparents, and child-care workers, among others, whom the
family identifies as important.
The coping strategy of vigilance serves to reduce the
parental sense of helplessness and to maintain the parental
role of protector75 The vigilant parent of a critically ill
infant or child is one who stays with the child as much as
possible but who is also able to leave to meet the needs of
self and family. The vigilant parent asks questions to keep
informed, checks to ensure that the child is receiving proper
care, and may request to remain with the child during procedures for the purpose of supporting the child. Vigilant parental behavior increases when the child and parents are exposed to many different caregivers. 51 One could hypothesize
that parents will remain vigilant until they feel confident that
their assigned nurse "knows" them and their child.
In some cases, parents may manifest hypervigilance, in
which the positive aspects of vigilance are outweighed by
the negative or even the well-being of the child is
jeopardized. 75 Several factors have been associated with
hypervigilance (Table 3-3). The hypervigilant parent overuses or exaggerates the use of vigilance. Parents never or
rarely leave the bedside. They may demand detailed
information before agreeing to even minor changes in the
child's treatment plan, sometimes delaying or denying
medications or treatments. Hypervigilant parents may continually monitor staff, attempt to control how care is
provided, or assume total care of the child. These parents
may trust only a few staff and wish to select the nurses
assigned to care for their child. They might examine the
medical record to identify problems or discrepancies and
then record them in a logbook.
Our society generally values and rewards the vigilant
parent but not necessarily in the PICD setting. Hypervigilant
parents can be unnerving or even threatening to nursing
staff. Nursing interventions should be focused to decrease
the parent's sense of helplessness and provide the parent
with some degree of control. Positive nursing interventions
include welcoming parents and their assistance at the
bedside, reinforcing parental questioning, providing information on a consistent basis, reinforcing the parental role,
and being receptive to their telephone calls. Nurses need to
support each other when providing care for hypervigilant
parents and to remember that, although it may be difficult,
the parents are doing the best that they can under the
circumstances. Negati ve staff behavior that can further fuel
parental hypervigilance includes acting defensi vely, withholding information, maintaining power and control, failing
to include parents in the decision-making process, avoiding
the parents, and resenting their questions.
Parents have also identified the importance of parent-toparent support as a means of coping in the PICD. Parents
can offer perspectives and support to each other that
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Parent's personality
Family relationships
Cultural/parental role
Child's meaning to parent
Parent's perception of the
infant's or child's
vulnerability
Parent's usual level of responsibility for the child's care
at home
Parent's understanding about the
illness
Acuity of the illness
Illness trajectory
Pain; painful or invasive
procedures
Parent-staff communications
Level of trust
Quality of communication
Quality of care
History of misdiagnosis,
improper care or treatment
Continuity of nurses and
physicians
Response of the staff to vigilant
behaviors
from Miles MS: Vigilance as a parental coping strategy when a
is seriously ill. Abstract for poster presentation. Biennial meeting

Society for Research in Child Development. Baltimore, Md.

professionals are not able to provide. 15 Although parents
spontaneously interact in waiting rooms, Halm 76 studied the
effect of formal support groups on the anxiety levels of
family members during critical illness. Family members
perceived many benefits of the group milieu, such as sharing
with other people in similar situations, instilling hope,
reducing anxiety, and learning new coping strategies.
Nursing staff can be instrumental in facilitating parent-toparent support. lO
Parent-professional trust is the necessary foundation
from which all supportive care can build. Trust develops in
the context of the parents' perception that their child is
receiving excellent care, from the nurses' reassuring presence, and through recognition of parents as unique autonomous individuals who have important contributions to make
toward the child's care. Continuity of nursing and medical
care allows strong alliances to form with parents, which
further contribute to the development of truSt. 55
Although competence is the most highly valued quality
of nursing care, parents also prefer nurses who are sensitive
and caring. 77 For example, nurses are considered caring
when they talk with parents, provide information without
asking, do not make parents feel intrusive, help parents feel
that they are part of the team, enable parents to feel
comfortable in leaving, and reassure them that everything
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will be taken care of and communicated. 51 In general,
parents can more willingly relinquish their child's care to
someone they trust.

INTERVENTION STRATEGIES
Most of the nursing research generated on parental stress has
been descriptive in nature. Many consistent recommendations for interventions intended to minimize parental stress
in the PICU setting have been offered. Interventions may be
divided into three major categories: (I) those that nurture a
trusting environment, in parents themselves, their children,
and PICU staff; (2) those that establish effective communication patterns and provide information and anticipatory
guidance; and (3) those that limit parental powerlessness by
reestablishing a parental relationship through visitation and
participation in caregiving activities. Such interventions are
consonant with the Parents' Bill of Rights (Box 3-5).
Nurses tend to intervene in a similar manner with all
families whose needs are perceived to be essentially the
same. 7S This approach is problematic because there is
significant variability in parental perceptions and experiences, stress levels, and needs among individuals that
require individualized nursing interventions. Interventions
that may be helpful to one parent may not be helpful or even
useful to another parent, even within the same family.
Nursing perceptions and interventions may be well
intended but may not be accurate. Researchers have noted
differences between what nurses perceive parental needs to
be and what parents perceive as their own needs within the
PICU setting. 79 Indeed, additional parental stress may result
from mismatches between nurses' understanding of parental
needs and parents' own understanding. so Generalized or
generic family supportive intervention strategies intended to
meet nonexistent needs or needs already met by others often
lead to much wasted time and energy.SI

NURSING MUTUAL PARTICIPATION
MODEL OF CARE
Models that emphasize an individual approach to nursing
interventions are preferred, given the individualized nature
of PICU-related parental stress and findings that generic
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Box 3·5

A Pediatric Bill of Rights

In this hospital you and your child have the right to:
• Respect and personal dignity
• Care that supports you as a family
• Infonnation you can understand
• Quality healthcare
• Emotional support
• Care that respects your child's growth and development
• Make decisions about your child's care
Data from Association for Ihe Care of Children's Heallh: Bill of rights for
parents: a pediatric bil! of rights. Bethesda, Md. 1991, Association for the
Care of Children's Health.

family support models are not adequate and may even
exacerbate parental stress. The nursing mutual participation
model of care (NMPMC) represents such an example (Box
3-6). Szasz and Hollenders2 first described a "mutual
participation" model for use with chronically ill adults. The
model, fundamentally different from others practiced at the
time, was based on the premise that the healthcare provider
could not profess to know what is best for an individual. The
search for that which may be considered individually
helpful was the essence of the therapeutic interaction. The
individual was assisted to help himself or herself as his or
her own experiences and beliefs provided reliable and
important clues to therapy. In 1980, Brod ys3 further
elaborated the model as a four-step process for use with
adults in outpatient settings. The foundation of the intervention process was conceptualized as agenda seeking; the
patient was enlisted and invited into the healthcare decisionmaking process by asking, "How can I help you today~"
Curlei 1.60 adapted the model for nursing care of
critically ill children and their parents because it provided
the philosophical foundation to incorporate many of the
therapeutic interventions recommended from descriptive
research. The model supports the view that the nature of
PICU-related stress requires individualized nursing interventions. The model is based on the premise that nurses
have something of value to offer parents and acknowledges

~

Box 3·6

Nursing Mutual Participation Model of Care

Admission

Extend our care to include parents
Acknowledge their importance
Daily Bedside Contact

Enabling strategies that provide parents with system savvy
• Infonnation-teach and clarify
• Anticipatory guidance-illness trajectory
• Provide instrumental resources
Facilitate transition to "parent-to-a-critically-ill-child"
• Enhance parent--child unique connectedness
Role model interactions
• Invite participation in nurturant activity
• Provide options during procedures
Communication pallem
• Establish a caring relationship with the parent
How are you doing today?

• Assess parental perception of the child's illness
How does slhe look to you today?

Detennine parental goals. objectives, and expectations
What troubles you most?

Seek infonned suggestions and preferences, and invite parlicipation in care
How can I help you today?
Data from Curley MAQ: Effects of the nursing mutual participation model of
care and parental stress in the pediatric intensive l,;are unit, Hearl Lung 17:
682-688, 1988; Curley MAQ. Wallace J: Effects of the nursing mutual
participation model of care on parental stress in the pediatric intensive care
unil-A replication. J Pedia'r Nurs 7:377-385. 1992.
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that parents also have something of value to contribute to the
caregi ving process of their children. Nurses have some
expertise in knowing what might generally be helpful to
parents who are experiencing the critical illness of a child,
but nurses do not specifically know what might be best for
an individual parent. Parents, on the other hand, know what
may be helpful to them and their infant or child, but they do
not know what is unique about the PICU or what strategies
have helped other parents in similar situations.
The NMPMC provides a framework for individualized
nursing interactions in the PICU. It clarifies the parental
role, supports active parental involvement with their critically ill child, and fosters parental confidence in performing
their role in a foreign selling. The process is individually
determined and evol ves to meet the expressed needs of each
parent. Nurse-parent relationships are characterized by a high
degree of empathy and partnership, and expert knowledge is
imparted to limit perceived helplessness and passivity. Critical features of the model include the equal status of parent
and professional in the relationship, mutual interdependency, and mutual satisfaction between nurses and parents.
The effects of the NMPMC on helping parents to
alleviate their stress have been supported in two separate
nursing research studies. In the first study, the principal
investigator, functioning in the role of a clinical nurse
specialist, implemented the modeI. 51 .60 Parents reported
significantly less overall stress in the areas of child's
behavior and emotions, parental role revision, child's
procedures, and nursing communication and behavior. In the
second study,52 primary nurses implemented the model.
Parents who had the benefit of NMPMC intervention
reported significantly less stress associated with the hospitalization, particularly in the area of parental role alteration.
The NMPMC is consistent with Greeneich and Long's
nursing taxonomy of family satisfaction (NTFS).84 Within
the NTFS, family satisfaction results from an interaction
between the family, nurse, and healthcare system. Nurses
can influence family satisfaction by (I) optimizing critical
juncture incidents, (2) accommodating parental personality
styles, (3) determining family expectations, and (4) adapting
the environment to the family's needs. Critical juncture
incidents are episodes in which a nurse's behavior and
intervention significantly affect the patient at a time when
the family perceives the patient to be most vulnerable. Nurse
personality attributes include social courtesy, acceptance,
kindness, helpfulness, empathy, and advocacy. The ability of
the nurse to develop a trusting relationship with the family
is also considered to be an element of personality fit. Trust
is inherently linked to effective communication (matched to
the family's style) and nursing proficiency. Nurses create a
milieu to adapt to the family's expectations and needs.
Family satisfaction results when the parent's expectations of
care match with the reality of care.

Initial Contact
For parents, admission is a very stressful period, during
which they experience a significant loss of control. 32,34
Acknowledging the parent's valuable and irreplaceable role
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in actions and words during this critical period helps to set
the tone for the entire PICU hospitalization. Also important
is an acknowledgment of the individuality of a family's
experience as its relates to their present and past experiences
of illness. The nurse should state the obvious, for example,
"Here at Children's Hospital we believe parents to be very
important to their children, especially when they're sick. We
would like to work with you to help you find ways that you
can continue to be important to your child while she or he
is in the ICU." These words broaden the perspective of care
to include parents. Right from the start, parents are invited
as partners into the caregiving process, thus establishing an
atmosphere in which parents feel that their contributions are
valued, expected, and essential. Parents feel less anxious
when they sense that their role is valued, that their child still
belongs to them, and that someone will help them to get
through the experience with their child as a welcomed
participant.
As soon as information is available, the nurse and the
physician should provide it. This demonstrates multidisciplinary collaboration and communication to the family.
After any period of separation or change in their infant's or
child's appearance or behavior, parents require preparation
for what they will see or hear before reuniting them.
Information may need to be repeated several times because
high levels of parental stress can interfere with the parent's
ability to process, understand, and remember information.
If parent-child separation is necessary, parents are
provided with privacy and a telephone so that they may
contact extended family members. During this period of
separation, it is imperative that nursing staff maintain
contact with the parents. Right from the beginning, staff
should seek the parent's preference about the level of
infornlation and frequency of contact. Parents usually
request information about stabilizing methods, and they
wish to be reunited with their infant or child as soon as
possible. If prolonged periods of separation are unavoidable,
opportunities are sought to provide parents with brief
updates or visits between procedures.

Daily Bedside Contact
After openly acknowledging the importance of the parental
role, the model provides a framework for daily interventions
that are supportive to and guided by the unique perceived
needs of each parent. The model (I) incorporates enabling
and empowering strategies to equip the parent with healthcare system savvy, (2) facilitates the parent's transition to
parent-to-a-critically-ill-child, and (3) delineates a consistent nurse-parent communication pattern. An accurate family assessment, such as that suggested by Miles,27 helps to
guide effective intervention strategies (Box 3-7). Family
characteristics such as the degree of adaptability (rigid,
structured, flexible, chaotic) and cohesion (disengaged,
separated, connected, enmeshed) are important considerations in psychosocial intervention planning 47

Enabling Strategies That Provide Parents
With System Savvy. It has been said that parents do not
need to be empowered within the clinical selling; they just
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Box 3-7

.

Parameters of a Family Assessment

I. History of child's illness: when and how diagnoses were
made; previous hospitalizations and treatments
2. Parental perception and understanding of illness
3. Feelings engendered by the child's illness: fear, guilt,
remorse, helplessness, hopelessness, anger
4. Family history and significant events: past experiences
with illness, divorce, death
5. Current family functioning: family membership, structure,
and roles, current marital relationship, communication
patterns within family, patterns of expressing feelings,
siblings and their relationship within the family,
religious background, cultural values, financial problems
6. Parental roles and relationships with child: identification
of the child as "special" as a result of having been the
only child, only daughter, only son, youngest, eldest, most
vulnerable
7. Un met parental needs: lack of sleep, lack of privacy, poor
nutrition, untreated health problems, poor hygiene, lack of
opportunity for sexual expression
Data from Miles MS: Impact of the intensive care unit on parents, Issues Compr
Pediatr Nit'S 3:72-90, 1979.

need their inherent power recognized. Socializing parents to
the PICU and hospital system serves to empower them,
especially those skills that improve their access to information and resources.
Provide Information That Instructs and Clarifies.
In addition to information about the infant's or child's
illness and the standard PICU equipment (monitors,
catheters, endotracheal tubes, etc.), specific information is
vital about the changes in the child's appearance, behavior,
and emotional reactions and in the parental role. When
discussing the technologic devices surrounding the patient,
including a discussion about alarm systems is important.
Although nurses know that there is a hierarchy of alarm
systems about which to be concerned and how quickly to
respond, parents do not n'ecessarily' understand these
distinctions. Unfamiliar alarms are feared equally by
parents, such as those that signal hypotension to those that
signal the end of an antibiotic infusion or artifact on a
cardiac monitor.
After addressing these immediate needs, parents require
an understanding of the PICU and hospital environment.
Written materials, such as orientation booklets, are effective
in assisting families to remember discrete pieces of information. 85 The process of how parents gain access to their
infants and children is critically important. It should be
stressed that the only reason parents are asked to request
permission to see their child in the PICU is for the protection
and privacy of other patients.
Information including the routines of the unit, who is in
charge of their child's medical and nursing care, and when
and where parents get information enables them to effectively function within the system's hierarchy. Parents of
children who require multiple services and parents of

chronically critically ill children are at high risk for
communication problems related to insufficient, incorrect,
or contradictory information about their child's care and
management. It is essential that the nurse coordinate the
informational needs of parents by delineating, together with
the attending physician and parents, a daily communication
plan. Routinely scheduled weekly multidisciplinary team
meetings can be very helpful to the entire team and to
parents of chronically critically ill children.
Only after (I) sharing information about their infant or
child, (2) providing information about the hospital environment, and (3) answering questions that the parents have
should dialogue progress to the perceived alterations in
parental role and responsibility.
Provide Anticipatory Guidance About the Illness
Trajectory. Information about what parents will see or
experience should be shared before it happens, if at all
possible. If feasible, nurses should meet with parents and
patients before a planned admission to the PICU. Describing
the illness trajectory, as far as it can be reasonably predicted,
is extremely helpful in allowing parents to understand and
distinguish what is "normal and expected" from what is
"life threatening." Although videotapes may be helpful,
tours (except to empty bed spaces) should be avoided
because they violate the privacy of existing patients and may
frighten the future patient.
Provide Instrumental Resources, Provision of adequate instrumental resources is also necessary so that
families are able to maintain both physical and emotional
accessibility to their critically ill child 24 hours a day.
Necessary resources include sleep facilities, showers, telephones, data ports, nutritious food, transportation, and
parking.86.87.88 Providing beepers to parents can help to ease
their separation anxiety and conveys a message about the
importance of communication and access to staff. Physical
barriers to the welcoming process, including activities that
make parents feel like visitors to their own infants and
children, should be eliminated.
Facilitate Transition to Parent-to-a-Critically-IIIChild. Alterations in parental role and the subsequent
disruption in the parent-child relationship are the most
stressful aspects of the PICU environment. Assisting parents
to formulate a role with which they are personally comfortable and supporting them in their decision-making capacity
help parents in a successful transition to parent-to-acritically-ill-child,
Enhance Parent-Child Unique Connectedness.
Because of changes in their child's appearance and behavior,
parents may need help reconnecting to a child who appears
to be so much different. Strategies include finding some
characteristic of the child that has not changed (that is, some
enduring feature) and emphasizing it to the parents.
Examples may include hair or eye color or evidence of the
child's increased heart rate in response to the parent's voice.
Creativity is sometimes needed to help reestablish the
unique parent-child connection when significant disfigurement is present. Parents may need "permission'· and
demonstrations of how to touch and interact with their
critically ill infant or child. Rubin's maternal touch progres-
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sion,89 for example, can be demonstrated in the PICU
regardless of the age of the infant or child.
Parents can also be encouraged to bring in the child's
favorite blanket, toy, doll, or family pictures to comfort
the child and to individualize the bed space. All of these
reminders of life at home provide nonverbal cues of
the valued nature of the family, and they are as important as direct verbal communication. Macnab and colleagues 90 noted that displaying pictures might open an
avenue for communication, allow parents to express unspoken concerns, and give parents comfort or a goal to strive
for, thus alleviating some stress associated with having a
child in the ICU.
Role Model Interactions. Parents have reported that
their initial fears are lessened by observing and imitating
nursing care activities. Parents notice and sort observed
nursing activities into two categories: those that are familiar
activity (bathing, diaper changing, holding, etc.) and those
that are different activity (dressing changes, endotracheal
suctioning, etc.).59 Parents watch what nurses do to learn,
not to make judgments on the correctness of how care is
done, because the majority of parents are not healthcare
professionals. Acknowledging that one's nursing care activity is being observed provides an opportunity for the nurse
to role model care through nonverbal communication. For
example, knowing that their actions are being observed,
nurses can role model where parents can safely touch their
instrumented child during a bedside conversation with
parents. Typically, parents can be observed following the
nurses lead in safe touch after the conversation is over.
Invite Participation. After the initial period of
shock and disbelief, parents are usually able to identify
those activities in which they wish to participate. When offered caregi ving options and opportunity, parents typically
wish to participate. Such participation can renew their
sense of self-esteem and help them to feel instrumental
in their child's recovery. Suggesting ways in which parents
can assist their child in coping helps to reduce parental
anxiety.91 Ideally, special aspects of parental care and comforting can be distinguished from things that others
can do for the child (e.g., provide breast milk, voice, touch).
Nursing staff should help parents to identify the range of
options by suggesting appropriate diversional, nurturing,
comforting, caregiving, and monitoring activities.
The social and emotional needs of infants, in particular,
are met in close association with their bodily needs.
With a new caregiver, the infant loses much of what is familiar. Physical care constitutes an essential element
of the very intimate relationship between parents and infants. Usurping this role from parents is generally not welcomed by the infant, nor is it helpful, especially when the infant is stressed. Nursing practice that directly involves
the primary caregiver is more therapeutic than care that
replaces the primary caregiver. Efforts should be extended
to welcome parents; they should never'be made to feel out
of place or in competition for their infant or child. 92
Parents generally enjoy helping with activities that
they find personally rewarding and participating in new activities with nursing guidance. A developmental approach
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is a starting point, for example, consideration of what parents normally do for their baby, toddler, child, or adolescent.52 Reading, massages, bathing, and hairbrushing are familiar and comforting activities for both parents and child.
Sociocultural influences will likely affect the parent's
selection of activities. Communication, teaching, anticipatory guidance, and mutual trust and support are essential
during this process. Parents frequently feel uncomfortable
performing tasks that they had previously mastered as a parent of a well child. Clearly, bathing an infant at home is
different than bathing an infant who is attached to numerous
pieces of equipment. Once the child's condition is stabilized, it is important to incorporate parent-child "private
time" in the management plan to sustain the parent-child
relationship.
With time, some parents may ask to participate in daily
bedside rounds. In practice, most parents can be observed
listening in (at a distance) whenever any team rounds
on their child. If the system can support the parent's request, nursing can support the parent's success by reviewing
the structure of rounds (who presents what information)
and, in teaching institutions, the educational mission
of the hospital as healthy debate often permeates rounds.
As with any new experience, the nurse should mentor
the parent and provide feedback and debriefing as necessary.
Provide Options During Procedures. Traditionally,
parents have been asked to step out of the PICU during their
or another child's procedures or treatments. Enforced
separations, sometimes lasting hours, and related conflicts in
values about the approaches used to obtain the child's
cooperation are significant sources of stress for parents. 45
Currently, great variability is seen among institutions
regarding parental presence during special procedures.
Inconsistency among staff and unclear policies about
visitation and parental presence during procedures can
provoke further anxiety for parents, as well as the staff. lO
Parents may be dismissed from treatments because of
staff fear and apprehension that they may interfere with the
procedure or make their child more upset. Sevedra93 studied
60 children, ages 2 weeks to 6 years, who had blood drawn
in the presence of their parents. The study suggested that
even when the procedure was difficult and stressful, parents
were not disruptive but instead were supportive of their
child as directed by personnel. A variety of verbal and
nonverbal strategies were used by parents to help the child
to better cope. Similarly, Shaw and Routh 94 compared
l8-month-old and 5-year-old children's reactions to immunizations in the presence and absence of mothers. They
found more upset behavior when mothers were present, but
the researchers hypothesized that the children's increase in
negative responses reflected a disinhibitory response. That
is, the mother's presence allowed the child greater expression of his or her feelings in an unfamiliar and threatening
environment. Behavioral difficulties including crying, terror, uncooperation, or violent protest can be expected when
the infant or toddler is stressed by the parent's absence,
Jet alone by a painful procedure. Lack of expected distress
responses may reflect deterioration in the child's level of
functioning, detachment, or severe emotional withdrawal.
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Expecting cooperative behavior or a diminished negative
response when parents are present is probably unrealistic.
Parental presence can potentially support the child's
coping efforts and provide the child with a familiar source
of comfort. The recommendation is that parents be offered
a choice regarding their presence or participation, as well as
support for their decision. In fact, Robinson and colleagues95 found little evidence to support the exclusion of
relatives who wish to be present during resuscitation.
Meyers and co-workers 96 supported these findings in their
study of family presence during invasive procedures and
resuscitation. Families described their presence as helpful
and noted that they would do it again. Instead of functioning
as passive observers, families perceived themselves as
active participants, caring for the patient with staff. Flexible
policies based on the needs and preferences of individual
patients and their parents are ideal.
Developmentally appropriate, honest preparation should
precede all procedures. It is important to remember that
young children's receptive language generally exceeds their
expressive language abilities. Simple explanations that can
be easily understood are always offered. For parents to be
supportive during a procedure, they need to know the
importance of the procedure, what to expect during the
procedure, normal age-related reactions that may occur, and
how they can best help. Parents should not be placed in a
position of restraining their child during any procedure.
Parent support is also important when parents choose to
excuse themselves during a procedure. It is likely that
parents can anticipate the ways that they and their child can
best be helped through a given procedure. Parents may need
help to articulate the fears that may block their ability to
believe that they are the best possible parent under the
circumstances. Parents may find it especially difficult to be
present during painful procedures because this seems in
conflict with their protective and nurturant roles. Parents
may benefit from information about their child's developmental level, efforts to prepare the child, and means of pain
control, should that be necessary.
Parents also serve as their child's teachers. Using parents
as the primary source of information for their children may
enhance communication and may also limit misconceptions
and misinterpretation. Gutstein and Tamow 97 found that
children's active involvement in preparatory play was
significantly related to lower levels of distress after elective
surgery. They also found that the child's active involvement
in preparatory play with stress-related objects was significantly related to parent helping behaviors. For example, a
child may try on several types of oxygen masks if their
parent participates in the activity.
When parents must wait during procedures, they often
make assumptions that the longer the wait, the more difficult
the procedure or that something is wrong. Parents of sick
children spend much time waiting together. This can be a
source of either comfort or additional stress. Comfort can be
had when another parent is one step ahead and can share in
the experience "with someone who really understands."
Stress can be exacerbated when another family's child is not
doing well. Upset and grieving parents require privacy for
themselves and for other parents.

Communication. The NMPMC delineates a fourstep communication process that is helpful and demonstrates caring toward the parent, assesses parental perceptions, determines the parental agenda, and invites
participation in care. This communication process is congruent with the ABCX model of crisis in that nursing
interventions should depend on the family's perception of
the stressful event. This communication strategy is helpful
in the PICU because interventions can be specifically
focused when time is limited. In addition, Scott98 found
significant differences in what parents identify as impOltant
and what nurses identify as important. When help is
rationally directed to what parents identify as important and
purposefully focused at the right time, it is perceived as
more effective than more help given at a period of less
emotional accessibility.
Establish a Caring Relationship. This first aspect
adds a humanistic touch by extending the focus of our care
to include parents. Asking the parents, for example, "How
are you doing? Were you able to sleep?" helps to convey the
message that parents, too, are important. An interesting note
is that parents often answer queries based on their child's
state, for example, "I feel better today. Paul was able to get
off his blood pressure medication." Unless assessed and
validated, parental affect or behaviors may be misinterpreted in the intensive care setting. For example, a father's
body language may be misinterpreted as anger, but when
queried, he may remark how scared and upset he feels.
Interventions for angry parents versus scared parents are
quite different.
Assess Family's Perceptions of the Child's JIIness.
To assess the parental perception of illness severity, ask,
"How does your child look to you today? How serious do
you think his illness is? How are other family members
dealing with everything?" Here, the nurse builds trust by
providing accurate, concise, and complete information and
by clarifying any misconceptions. In addition, nurses often
make assessments and judgments about a child's pain,
activity, and behavior based on PICU experience but
without familiarity with an individual child. Parents are
often well aware of their child's subtle behavioral and
communicative cues that can be helpful in individualizing
care. Nurses and parents working together can better
understand and address an individual child's needs.
Help Families Participate. The third step helps
parents to rank their concerns. It also sanctions the expression of feelings that parents may otherwise consider
inappropriate to express. Here, the nurse may ask, "What
troubles you most? Do you have any questions? Is this
what you expected? Do you have any suggestions or
preferences concerning the care your child is receiving?
Is there anything that you personally want to do for your
child?"
Seek Informed Suggestions and Preferences and
Invite Participation in Care. The last step invites
parental participation in determining how nursing interventions can be provided. Here, the nurse may ask, "How can
I help you? How can we do this together?" Interventions are
then focused on parent-specific issues rather than nursespeculated problems. Note that failure to address a parent's
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agenda, especially after it has been elicited, may often lead
to an increase in stress and parental dissatisfaction.
Providing a humanistic PICU environment that recognizes parents as unique autonomous individuals who, when
supported, are capable of providing vital elements of care to
their critically ill child helps to alleviate parental stress. The
NMPMC is effective in helping to decrease parental stress
by assisting parents to formulate a role that is individually
comfortable and supportive of them in their decisionmaking capacity. Not all parents have the desire or
capability to actively participate in the care of their child;
however, the NMPMC provides a means to assess and
individualize psychosocial interventions.

FAMILY CONTEXT OF CHILDHOOD
CRITICAL ILLNESS
Traditionally, hospitals have had an approach that emphasizes the treatment of individuals in isolation from their
broader family and sociocultural context. 99 By contrast,
family-centered care embraces a systems approach in which
the child's illness is viewed in context. Family-centered care
advocates for the child and family as the appropriate focus
of healthcare intervention, thus necessarily broadening the
care perspective and traditional interventions.
Entire families are affected when an infant or child is
critically ill. Parents find themselves thrust into unfamiliar
roles, including negotiating an often overwhelming healthcare setting, integrating information about the child's
illness, and participating in emotionally laden decision
making. 48 .56 Family routines are suddenly disrupted, and
traditional roles are altered. In addition, parents must
balance multiple demands, including traveling to the hospital or temporarily residing at the hospital, maintaining a
home, caring for other children, meeting financial obligations, and negotiating employment circumstances, among
others. Parents may feel tom between the needs of children
at home and their critically ill child's immediate needs. As
described earlier, parents often experience diminished
competence and helplessness relative to their critically ill
child, and their inability to adequately meet the needs of
their healthy children may compound these self-deprecating
feelings. This sense of conflict may be long-standing and
particularly difficult for parents when their child is chronically critically ill.
To a great extent, families adjust their priorities and
family life when a child requires hospitalization. Hospital
staff members tend to view parents primarily as parents of
a hospitalized child, however, with less than adequate
recognition of the parents' broader family, employment, and
community responsibilities (see Box 3_7).9.99 Problems
arise, for example, when staff members assume that parents
can be available at any time for meetings and care
conferences. Similarly, convenient visiting times for parents
may conflict with unit rounds or nursing report. Thus
flexibility and mutual respect are necessary on the part of
both staff and family members to facilitate a collaborative
parent-professional partnership.
For the majority of parents, the most important potentially supportive relationship during this time is with their
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spouse 56 •ilK) The crisis of critical illness and hospitalization
is emotionally charged and represents fertile ground for
conflict that may strain even strong spousal relationships.
For example, parents may need to come to consensus on
issues such as how far to pursue treatment or whether the
child's organs may be donated. Aspects of successful
adaptation include how parents develop and negotiate their
new roles amid the challenges of the PICU and how they
manage to support each other. Parents need to communicate
with many healthcare providers and with each other, to
grapple with potentially difficult ethical decisions, to
negotiate being parents with little privacy, and to keep
family and friends informed of the child's condition. lUI The
unanticipated and fearsome financial burdens inherent in
PICU hospitalization may represent an additional, although
often unspoken, stressor for parents. Preexisting vulnerabilities in the couple's relationship may be seriously challenged
by the child's illness. Spousal conflicts that were present but
compensated for before the child's critical illness may now
resurface and threaten to disrupt the couple's equilibrium.

Supporting the Siblings
of a Critically III Child
Siblings of hospitalized infants and children often have
concerns and questions regarding the well-being of their
brother or sister and their parents.l02.10J Multiple factors
influence a sibling's responses and adjustment to critical
illness, including the sibling's developmental stage, nature
of illness, the sibling's perception of the illness, number and
type of other operative stressors, and available situational
supportS. I04 Children may experience disruption in usual
family routines, separation from parents, and changes in
caregi ving arrangements, all of which may contribute to
their degree of stress. Siblings may experience feelings of
helplessness, fear, guilt, and anger that they mayor may not
be able to communicate to parents. lOS
It is not uncommon for parents to request help for
siblings who are perceived to be having difficulty coping
with the illness. Parents may also wish guidance about how
and how much to explain to their children about the illness,
visitation in the PICU, ways to meaningfully involve their
other children in the hospitalization, and, in some cases,
preparation for the child's death. It may be that enlisting
supportive services for their other children is more acceptable to parents than the alternative of direct psychologic
service for themselves. At the same time, it may also serve
to bolster parents in their familiar roles of protector and
provider for their children.
In a study investigating the impact of critical care
hospitalization on the perceptions of adult patients, spouses,
children, and nurses, Titler, Craft, and Cohen 106 noted that
parents frequently shielded their children from anxietyprovoking information. Parents perceived that their children, ranging in age from 5 to 18 years of age, did not
comprehend much about the parental illness or hospitalization. However, children provided accurate descriptions of
the hospitalized parent and of both parents' feelings. These
findings suggest that children are keenly aware of illnessrelated experiences and, to the extent possible, construct
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their own meanings despite limited access to information
and healthcare providers.
Formal sibling programs can be facilitated through
collaborative efforts between nurses, child life specialists,
and volunteers. Developmentally appropriate interventions
are recommended that prepare siblings for what they might
see and hear. 107 Educational, supportive visitation programs
may include preparation of siblings for visitation, follow-up
contact, individual or group activities in the waiting area,
and a sibling library.74.102.108 Children who had the benefit
of Facilitated Child Visitation Intervention (FCV!), which
includes educational and supportive components, experienced fewer parent-reported behavioral and emotional
problems after visitation. 109 Before visitation, children need
to be carefully screened for signs of illness and exposure to
communicable diseases. Sibling visitation enables children
to experience the reality of the situation firsthand and to
participate in family problem solving and support of their ill
brother or sister?4.105.107 Overall, sibling visitation can
contribute to greater family cohesion, adaptation, and
satisfaction.

Professional Relationships
Intervening with families while maintaining appropriate
professional nursing boundaries has been addressed by
Barnsteiner and Gillis-Donovan. I 10 The goal of a professional relationship is to have caring, well-defined boundaries between a nurse and the patient and family, that is,
boundaries that are positive and therapeutic and that
promote the family's control over the child's healthcare. 11I
Professional nursing is emotionally complicated, requiring
the ability to stay meaningfully concerned about a patient
and family but, at the same time, separate enough to
distinguish one's own feelings and needs. Extremes in
inappropriate professional relationships include overinvolvement or underinvolvement with individual patients and
their families. ll2
Relatively inexperienced nurses and those who are new
to the intensive care unit necessarily tend to concentrate on
technical skill attainment and mastery rather than psychosocial aspects of care. Within the highly technical and
demanding PICU setting, nurses may have little time to
devote to psychosocial aspects of care. Moreover, nurses
may feel ill-prepared to address the often highly charged
emotional aspects of PICU hospitalization. In general, as
professionals gain clinical experience, they become increasingly willing and comfortable to formulate collaborative
relationships with parents that are consistent with the model
of family-centered care. I 13
In a study investigating critical care nurses' perceptions
of their role with families, in which 20% were pediatric
critical care nurses, Hickey and Lewandowski 114 found that
most critical care nurses believed it was emotionally
exhausting to repeatedly become involved with families in
need of support. Despite this, nurses report becoming
involved with families regardless of their ambivalence and
the possible emotional costs to themselves. More than one
third of the nurses believed that they did not have the
requisite knowledge to meet the emotional and psychosocial

needs of families. This underscores the need for ongoing
nursing education and collaboration with psychosocial
support staff, including advanced practice nurses, social
work, pediatric psychology, psychiatry, and child life
specialists. Among the factors that most influenced nurses'
involvement with families were situations relating to the
child's death and subjective feelings and responses toward
the patient and fami Iy.

Collaborative Relationships
With Psychosocial Support Staff
Nursing staff who care directly for the child and family
generally have the greatest degree of familiarity and regular
contact with families. The role of staff nurses in acknowledging and systematically integrating psychosocial aspects
of care, as in the NMPMC, usefully broadens the focus of
intervention from the child alone to the child-in-family.
Thus nurses playa pivotal role in expanding the traditional
medical-technologic orientation and language of the intensive care unit to include psychosocial aspects of care. I 15
Through inquiry and attention to parental perceptions and
experiences, the nurse emphasizes that these are legitimate
aspects of clinical concern and conveys the message that
family members, too, are important.
In addition to the nurse's role in psychosocial assessment and intervention, several psychosocial support staff
members are available within the intensive care setting who
may play a role in psychosocial service delivery to the
family (Box 3-8). Social workers are assigned to each
family in the ICU and fulfill a varied role, including
psychosocial assessment, family support and advocacy,
instrumental support, and accessing legal and protective
services, if required. Although considerable variability
exists among PIC Us, other professionals who are available
to meet the family's psychosocial needs may include
pediatric psychologists, psychiatrists, child life specialists,
discharge planners, ethicists, chaplains, child-abuse specialists, and parent volunteers. Appleyard and colleagues116
described using a nurse-coached volunteer program to help
support families of critically ill patients. After implementation of the program, families believed that nurses
were more willing to accept families as members of the
care team.
In many cases, the nursing staff and unit-based social
worker can adequately address the family's psychosocial
needs. However, when the child's or family's needs demand
additional services or consultation, support staff should be
readily incorporated in the psychosocial planning and
intervention efforts. Introducing support staff to parents and
letting them know that support staff have something
valuable to offer for many hospitalized children help to
facilitate the consultation process.
The nurse plays a pivotal role in contacting and
mobilizing these additional services or consultations when
needed on behalf of families. It is important that the nurse
have a good working knowledge about the various roles of
these disciplines, including what they have to offer families
and how they may be consulted. 1I7 To facilitate psychosocial service delivery and referral, the unit can establish
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Box 3·8

Psychosocial Support Staff
Advanced practice nurse/clinical nurse specialist
• Assesses family coping capacities
• Provides short-term family support
• Consults with staff regarding expected trajectory of parental stress and coping and interventions with families in
crisis related to the critical illness of their child
Social worker
• Performs psychosocial family assessments
• Provides family support and advocacy
• Promotes client access to financial and community services
• Serves as liaison with child protection team
Child life specialist
• Provides developmental and therapeutic play acti vities
• Supports patient and sibling coping
• Consults with parents regarding normal child development
and adjustment
• Initiates tutoring referrals
Patient care coordinator
Facilitates comprehensive discharge plan
Serves as liaison for family with third-party payers
Performs utilization review
Accesses community support services for family
Psychologist, psychiatrist
• Performs diagnostic assessments of children and families
• Facilitates management and discharge planning of suicidal
patients
• Provides short-term family counseling
• Provides crisis intervention
• Facilitates psychopharmacology referrals
Parent volunteer
Welcomes family to the PICU
Orients parents to the family area
Assures family comfort in the waiting area
Provides information about hospital resources (meals,
telephone, sleep facilities, etc.)
Chaplain
• Provides spiritual support
• Performs sacraments as requested by family (e.g., baptism)
Ethics committee
• Consults with families and staff on ethical issues
• Educates staff about ethical and legal issues

regular psychosocial rounds in which representatives from
these disciplines are present. Note that ancillary personnel
may provide direct service to children and families or may
merely consult with nursing and social work staff in the
context of psychosocial rounds. An organizational chart that
delineates the various roles and collaborative relationships
of psychosocial support staff and details regarding contact
and referral information can be helpful.

PREPARING FOR PATIENT TRANSFER
Transition from the intensive care setting to a general
hospital unit or to home can be fraught with apprehension.
On one hand, parents may derive comfort from the fact that
their child has achieved another step toward recovery5t.52.60
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On the other hand, the transfer requires adjustment to new
staff members who do not yet know their child and to a new
environment. Parents may be concerned about their child's
readiness for transfer or the lower staff-to-patient ratio
on the prospective unit. Parents who have come to trust
the PICU staff members may be reluctant to reinitiate
the process with yet another set of healthcare providers.
Anticipatory guidance to assist parents in the transition from
the PICU to the general inpatient unit may help to alleviate
parental stress related to PICU discharge. Bouve, Rozmus,
and Giordano 118 demonstrated that a straightforward preparatory letter explaining the impending transfer from the
PICU to a general pediatric floor significantly lowered
parental anxiety. Parents need to know that the staff of the
receiving unit will be fully informed about the child's
history and progress, preferably by the primary nurse or
another staff member who knows the child well. This not
only ensures optimal clinical care but also reduces parental
anxiety about the transfer.
Formal care conferences that involve the PICU primary
nurse, family members, and a nurse from the receiving unit
have also been demonstrated to significantly reduce the
transfer-related anxiety of families. 119 In this particular
study, the care conference lasted 15 to 30 minutes and
consisted of three phases. First, there were introductions and
a discussion about the purpose of the meeting. Second, the
group discussed the physical environment of the new unit
and the child's degree of recovery and progress and
addressed mutual goals and expectations. The third phase
provided an opportunity for the group to establish childcentered goals. Conferences such as these serve to mark the
transfer from the PICU as a significant event and have the
advantage of focused communication, mutual goal setting,
and parent participation.

BEREAVEMENT
The death of a child is one of the most stressful and
traumatic events that a family may ever experience and
endure. 120- 122 The death of a young child is generally
percei ved in our society as unnatural, untimely, and
particularly tragic. Compared with other deaths, the grief of
parents can be particularly severe, complicated, and long
lasting as a result of the nature of the parent-child
relationship, the circumstances of the death, and societal
expectations.122.123 Parents typically remember the events
surrounding the child's death, including the responses
of healthcare providers, with great clarity, detail, and
emotion.120.124-126 The immediate responses and subsequent
adjustment of bereaved parents are significantly influenced
by the attitudes, psychosocial interventions, and bereavement support offered by healthcare professionals.l2l·127.128
Thus positive experiences in the intensive care setting have
the potential to facilitate parental bereavement and adjustment, whereas negative experiences may compromise or
even derail the parental bereavement and coping process.
Stage models of grief and bereavement have been
proposed,I29·130 including an adaptation specifically for
parents who have suffered the loss of a child. t21.131-133
Expanding on Parkes' original model, Miles131.132 has
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usefully described three broad phases of parental grief,
including numbness and shock, intense grief, and reorganization. Although stage models offer a "blueprint" with
which to understand the bereavement process, it is important
to recognize the inherent limitations of linear models to fully
explain such complex processes. 1OO How intense and
enduring the pain of bereavement is for any given parent is
more a function of idiopathic factors rather than the mere
passage of time.
In the intensive care setting, parents may experience
emotional turmoil and anticipatory grief before the child's
death and a combination of disbelief, shock, and intense
grief responses upon the death of the child. In retrospective
semistructured interviews conducted I to 3 years after their
children's deaths, parents frequently reported "numbness,"
accompanied by difficulty integrating information, listening
to healthcare providers, and making decisions during the
time at the hospital. 125 Initial emotional and behavioral
responses vary greatly among parents, depending on personality style, sociocultural background, social support, and
circumstances of the death.122.131.132 Emotionally, parents
may experience sadness, despair, anger, rage, regret, frustration, guilt, resentment, or relief, among others. Behavioral responses may include crying, withdrawal, hysteria, or
physical acting out, such as clinging to the child's dead body
or aggression toward objects or people. 133 During the
subsequent phase of intense grief, parents may experience
intense loneliness and yearning for the child, helplessness,
guilt, anger, fearfulness for the safety and well-being of
other children, depressive symptoms such as sleep and
appetite changes, and disorganization. 121 During the reorganization phase, bereaved parents gradually begin to
remember the child with less emotional pain, commemorate
the child and focus on happier memories, reinvest in new
relationships, and return to their usual life activities and
responsibilities. Some bereaved parents report that they
never truly recover from the death of their child, but rather
that they learn to go on and, as a result of the loss, they can
never truly be the same persons again. 120
When the decision has been made to discontinue
intensive treatment efforts and the child's death has been
declared imminent, the burden of comfort care rests with the
nursing staff. 134 During this time, the priorities for nursing
intervention include comfort and dignity for the dying infant
or child and his or her family. 135 The most important aspects
of care for families during this time is to demonstrate a
caring and genuine attitude, to extend kindness and understanding, and to be present with the family.I2I·122.125.136
Although nurses sometimes worry about what to say and
specifically how to say it to families, a caring and genuine
approach is most important and more likely to be remembered by families than any particular thing that might
be said. Johnson and Mattson 137 have addressed the issue
of communication with families before and after the
child's death, including suggestions for open-ended questions and responses that may be helpful to families and
anxiety containing for nurses. 137 Key elements of parentprofessional communication at the end of life include
validation of feelings, empathy, and support.

Nurses do indeed help to "orchestrate" the death and
early bereavement process for families in the context of the
hospital setting. When curative interventions become futile,
care shifts to ensure death with dignity and comfort.
Suggestions for intervention include providing accurate and
ongoing information to parents, preparing parents for what
to expect relative to the child's bodily functions and the
dying process, and listening to and honoring parental stories
about the child and parental expressions of grief. 121.125
Parents often need and seek reassurance from nursing staff
that everything possible has been done for the child and that
the child will not experience pain. Parents remember and
acknowledge the importance of caring for the child with
respect, addressing the child by name, attending to the
"little kindnesses" (e.g., combing the child's hair), welcoming family members and friends, and individualizing aspects
of care according to the family's wishes (e.g., child wearing
own pajamas, favorite sleeping positions). Nurses may
facilitate referrals for hospital chaplains; however, parents
emphasize that it is important to be given a choice about this
beforehand. 125
Choices about whether and how to hold and view the
body during discontinuation of life support equipment and
following death are highly individual decisions for parents
that are remembered long after the death. Parents should be
offered an explanation of how life support is discontinued
(e.g., child will be extubated), including what they can
expect and who, if anyone, may be in attendance, according
to their wishes. Parents report that viewing the child's dead
body serves as a means of closure. 125 Parents may also like
the infant's footprints, lock of hair, or hospital identification
band as keepsakes. The parents' final good-bye to staff and
exit from the unit, with its symbolic finality, may be eased
with the escort of a familiar nurse.
Some units have developed standardized care plans for
terminally ill patients that may be modified according to the
child's circumstances and family wishes. 136 Care plans such
as these serve to assist nursing staff in delivering comprehensive care, facilitate the psychosocial aspects of care, coordinate communication and referrals, and ensure individualized aspects of care. Guidelines such as these help the staff
to orchestrate the many aspects of providing care to a dying
child and also ease the burden on individual nurses. In addition, in an effort to provide the best practice and to support
families during the early bereavement process, many hospitals have implemented bereavement support and follow-up
programs. 138-140 In general, families and staff alike note the
benefits of bereavement support programs as a means to
cope with childhood death. Educational and support programs, designed specifically to address the needs of staff
nurses, have also been developed with the goals of better
preparing nurses for caring for dying children and their
families and preventing "bereavement overload,"141-143

SUMMARY
Continued nursing research is needed to describe the
possible differences in perceived parental stress in relation
to the age of the parent and in relation to a constant primary
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nurse provider and the trajectory of parental involvement in
relation to the child's clinical status. Studies investigating
the relationship between nursing staff attitudes toward
parental involvement on parental stress and participation in
care are also needed. Studies that illuminate how specific
parental involvement can be therapeutic in the PICD setting
can guide clinical practice. Few studies describe the
long-term effects of PICU hospitalization on parents and
children.
Pediatric critical care nurses must continue to challenge
and improve traditional practice. Nurses traditionally serve
as the gatekeepers, that is, the people who directly control
parental access and involvement with their children. Parents
are the ultimate consumers of pediatric healthcare. It is
imperative that parental- and consumer-driven satisfaction

6S

be accomplished to economically survive in a highly competitive healthcare delivery system. Care must be inherently
supportive to parents. Parental involvement must be encouraged and welcomed because family-centered care implies an
ongoing parent-professional partnership, not merely that
24-hour visitation is allowed. 51 ,6o Nurses must continue to
accept the challenge of developing strategies that assess
parental needs, establish therapeutic nurse-parent relationships, provide care that is flexible and individualized, and
support the parents' role in the care of their critically ill
child. Nurses can make a significant positive difference for
parents of critically ill children. By providing care that is
inherently supportive to parents, we help to make the experience of parent-to-a-critically-ill-child as positive as
possible.

REFERENCES
1. Robertson J: Young children in hospitals,
Great Britain, 1958, Tavistock Publications.
2. Bruce B, Ritchie J: Nurses' practices and
perceptions of family-centered care, J Pediarr Nurs 12:214-222. 1997.
3. Chesla CA, Stannard D: Breakdown in the
nursing care of families in the leU, Am
J Crit Care 6:64-71, 1997.
4. Bowlby J: Marernal care and mental health,
Geneva, 1952, World Health Organization.
5. Bowlby J: Attachment and loss, vol 2,
separation, New York, 1973, Basic Books.
6. Shelton TL, Stepanek JS: Family-centered

care for children needing speciaUzed health
and developmental services, ed 3. Bethesda,
Md, 1994, Association for the Care of
Children's Health.
7. Ahmann E: Family-centered care: the time
has come, Pediatr Nurs 20:52-53, 1994.
8. Shelton TL: Family-centered care in pediatric practice: when and how? J Dev Behav
Pediatr 20:117-118,1999.
9. Meyer EC, Bailey DB: Family-centered care
in early intervention: community and hospital settings. In Paul JL, Simeonsson RJ, eds:

Children with special needs: family, culture,
and society. New York, 1993, Harcourt
Brace Jovanovich College Publishers.
] O. Rushton CH: Family-centered care in the
critical care setting: myth or reality? ChUd
Health Care 19:68-78. 1990.
11. Zaner RM, Bliton MJ: Decisions in the
N1CU: the moral authority of parents, Child
Health Care 20: 19-25, 1991.
12. Bogdan R, Brown MA, Foster SB: Be
honest but not cruel: staff/parent communication on a neonatal unit, Human Organ
41:6-16, 1982.
13. Curley MAQ: Mutuality: an expression of
nursing presence. J Pediatr NuTS ] 2: 1-6,
1997.
14. Mitchell PH, Ferketich S, Jennings BM:
American Academy of Nursing Expert Panel
on Quality Health Care, Image J Nurs Sch
30:43-46, 1997.
IS. Shelton TL, Jeppson ES, Johnson BH:

Family centered care for children J,vith
!o,pecial health care needs, ed 2, Washington,
DC, 1987. Association for the Care of
Children's Health.

16. Current population reports, Washington,
DC, 1991, Department of Commerce, Economics and Statistics.
17. Garcia Coli CT, Meyer EC, Brillon L:
Ethnic and minority parenting. In Bornstein
MH, ed: Handbook of parenting, vol II,
Mahwah, NJ, 1995, Lawrence Erlbaum
Associates.
18. United States Bureau of Census: US children and their families: current conditions
and recent trends. Projections: 1988-20RO.
Washington. DC, 1989, Government Printing Office.
19. United States Bureau of Census: US population estimates by age, sex, race and Hispanic
origin, 1980-1988, Current Population Reports, Series P-25, No 1045. Washington,
DC, 1990, US Government Printing Office.
20. Berger MM, ed: Beyond the double bind:
communication and family systems, theories, and techniques with schizophrenics,
New York, 1978, BrunnerfMazel.
21. von Bertalanffy L: General systems theory,
New York, 1968, George Braziller.
22. Bowen M: Family therapy in clinical practice, New York, 1978, Jason Aronson.
23. Minuchin S: Families and family therapy,
Cambridge, Mass, 1974, Harvard University
Press.
24. Watzlawick P. Beavin JH, Jackson DD:
Pragmatics of human communication, New
York, 1967, WW Norton & Company.
25. Mahler MS, Pine F, Bergman A: The psychological birth of the human infant, New
York, 1975, Basic Books.
26. Rothstein P: Psychological stress in families
of children in the pediatric intensive care
unit, Pediatr Clin North Am 27:613-620,
1980.
27. Miles MS: Impact of the intensive care unit
on parents, Issues Compr Pediatr Nurs
3:72-90, 1979.
28. Youngblut JM, Jay SS: Emergent admission
to the pediatric intensive care unit: parental
concerns, AACN Clin Issues Crit Care Nurs
2:329-337, 1991.
29. Comoroff J, Maguire P: Ambiguity and the
search for meaning: childhood leukaemia in
the modern clinical context, Soc Sci Med
15B:115-123,1981.

30. Mishel MH: Parent's perception of uncertainty concerning their hospitalized child,
Nurs Res 32:324-330, 1983.
31. Turner MA, Tomlinson PS, Harbaugh BL:
Parental uncertainty in critical care hospitalization of children, MCN Am J Matern Child
Nurs 19:45-62, 1990.
32. Skipper JK, Leonard RC: Children, stress,
and hospitalization, J Health Soc Behav
9:275-287, 1968.
33. Hebb DO: Textbook of psychology. ed 3.
Philadelphia, 1972, WB Saunders.
34. Wolfer JA, Visintainer MA: Pediatric surgical patients' and parents' stress responses
and adjustment, Nurs Res 24:244-255, 1975.
35. Mitchell PH, Johnson FB, Habermann Little
B: Promoting physiologic stability: touch
and ICP, Communicat Nurs Res 18:93,1985.
36. Zeskind PS, lacino R: Effects of maternal
visitation to preterm infants in the neonatal
intensive care unit, Child Develop 55:18871893, 1984.
37. Anderson GC: Current knowledge aboul
skin-to-skin (kangaroo) care for preterm
infants, J Perinatol II :216-226, 1991.
38. Hill R: Families under stress. New York,
1949, Harper & Row.
39. Youngblut JM, Shiao SYP: Characteristics
of a child's critical illness and parents'
reactions: preliminary report of a pilot study,
Am J Crit Care 1:80-84, 1992.
40. Broome ME: Working with the family of a
critically ill child, Heart Lung 14:368-372,
1985.
41. McCubbin HI, Patterson JM: Family transitions: adaptation to stress. In McCubbin Hl,
Figley CR, eds: Stress and the family:
coping with normative transitions, vol I,
New Yurk, 1983, BrunnerfMazel.
42. Moos RH: Coping with life crises: an integrated appmach, 1986, New York, 1986,
Plenum Medical Books.
43. Lazarus RS, Folkman S: Stress, appraisal,
and coping, New York, 1984. Springer.
44. Miles MS, Carter MC: Coping strategies
used by parents during their child's hospitalization in an intensive care unit, Child
Health Care 14:14-21, 1985.

66

Part I

Holistic Pediatric Critical Care Nursing

45. LaMontagne LL, Pawlak R: Stress and
coping of parents of children in a pediatric
intensive care unit, Heart Lang 19:416-421,
1990.
46. LaMontagne LL, Hepworth n, Pawlak R
et al: Parental coping and activities during
pediatric critical care, Am J eric Care

1:76-80, 1992.
47. Philichi LM: Fanlily adaptation during a
pediatric

intensive

care

hospitalization.

J Pediatr Nurs 4:268-276, 1989.
48. Miles MS, Carter MC: Sources of parental
stress in pediatric intensive care units. Child
Health Care 11:65-69, 1982.
49. Carter MC, Miles MS, Buford TH el al:
Parental environmental stress in pediatric
intensive care units, Dimens Cr;l Care NUTS

64. Kirschbaum MS: Needs af parents of critically ill childrel!. unpublished master's thesis, 1983. University of Illinois.
65. Kirschbaum MS: Needs of parents of critically ill children. Dimens Crit Care Nurs
9:344-352, 1990.
66. Melnyk BM, Alpert-Gillis L, Hensel PB
et al: Helping mothets cope with a critically
ill child: a pilot test of the COPE intervention, Res Nurs HeaLth 20:3-14, 1997.
67. Melnyk BM, Alpert-Gillis LJ: The COPE

86.

87.

parents' perceptions. Intens Crit Care Nun

Parental stress after the unexpected admission of a child to the intensive care unit. Crit

in the pediatric intensive care unit: what

Conn, 1987, Yale University School of
Nursing.
52. Cutley MAQ, Wallace J: Effects of the
nursing mutual participation model of care
on parental stress in the pediatric intensive
care unit: a replication. J Pediatr Nurs

7:377-385, 1992.
53. Miles MS, Carter MC, Spicher C et al:
Maternal and paternal stress reactions when
a child is hospitalized in a pediatric intensive
care unit, Issues Campr Pediatr Nurs 7:333-

342, 1984.
54. Seideman RY, Watson MA, Corff KE et al:
Parent stress and coping in NICU and PICU,
J Pediatr Nurs 12:169-177, 1997.
55. Rennick J: Reestablishing the parental role
in a pediatric intensive care unit, J Pediatr
Nurs 1:40-44, 1986.
56. Harrison H: The premature baby book: a
parent's guide to coping and caring in the
first years, New York, 1983, St Martin's
Press.
57. Minde KK: The impact of prematurity on
the later behavior of children and their
families, Clil! Perinatol 11:227-244, 1984.
58. Resnick MB. Eyler FD, Nelson RM et al:
Developmental outcome for low birthweight
infants: improved early developmental outcome, Pediatrics 80:68-74, 1987.
59. Jay SS: Pediatric intensive care involving
parents in the care of their child, MCN Am J
Matern Child Nars 6:195-204, 1977.
60. Curley MAQ: Effects of the nursing mutual
participation model of care and paremal
stress in the pediatric intensive care unit.

Heart Lung 17:682-688, 1988.
61. Pa,s MD, Pass CM: Anticipatory guidance
for parents of hospitalized children, J Pediatr Nars 2:250-258, 1987.
62. Miles MS, Mathes M: Preparation of parents
for the

leu experience:

what are we miss-

ing, Child Health Care 20:132-137, 1991.
63. Lewandowski LA: Stressors and coping
styles of parents of children undergoing
open heart surgery, Crit Care Q 3:75-84.
1980.

et al: An evaluation of interventions for
meeting the informational needs of families

program: a strategy to improve outcomes of

8:1-10,1993.
69. Kasper J, Nyanlathi A: Parents of children

stress in the pediatric intensive care unit,
unpublished master's thesis, New Haven.

assess family satisfaction. Dimens Cric Care

Nurs 12:272-278, 1993.
85. Henneman EA, McKenzie JB, Dewa JB

critically ill young children and their parents, Pediatr Nllrs 24:521-527. 1998.
68. Farrel MJ, Frost C: The most important
needs of parents of critically ill children:

4:180-188.1985.
50. Eberly TW, Miles MS, Carter MC et al:

Care Q 8:57-65, 1985.
51. Curley MAQ: Effects of the nursing murual
participation model of care and parental

83. Brody OS: The patient's role in cunical
decision making, Alln Internal Med 93:718722, 1980.
84. Greeneich DS, Long CO: Using a model to

88.

are their needs? Heart Lung 17, 574-581,
1988.
70. Jay SS, Youngblut JM: Parent stress as-

89.

sociated with pediatric critical care nursing:

90.

linking research with practice, AACN Clill
Issues Crit Care Nurs 2:276-284, 1991.
71. Tughan L:Visiting in the PICU: a study
of the perceptions of patients, parents, and
staff members, Crit Care N Q 15:57-68,
1992.
72. Proctor DL: Relationship between visitation

9 I.

policy in a pediatric intensive unit and

parental anxiety, ChiLd Health Care 16:1317, 1987.
73. Carnevale FA: Striving to recaprure our
previous life: the experience of families with

critically ill children, Off J Can Assoc Crit
Care Nurs 10: 16-22. 1999.
74. Wincek 1M: Promoting family-centered visitation makes a difference. AAeN Clill

Issues Crit Care Nurs 2:293-298, 1991.
75. Miles MS: Vigilance as a parental coping
strategy when a child is seriously ill. Abstract for poster presentation. Biennial meet-

ing of the Society for Research in Child
Development, Baltimore, Md, 1987.
76. Halrn M: Effects of support groups on
anxiety of family members during critical
illness, Heart LUllg 19:62-71, 1990.
77. Beckham JD: Andrew's not-so-excellent
adventure, HeaLthcare Forum J 36:90-98,
1993.
78. Jacono J, Hicks G, Antonioni C et al:
Comparison of perceived needs of family
members between registered nurses and

family members of critically ill patients in
intensive care and neonatal intensive care

unit, Heart Lung 19:72-78, 1990.
79. Johnson PA, Nelson GL. Brunnquell DJ:
Parent and nurse perceptions of parental
stress in the pediatric intensive care unit,

of chronically ill patients, Am J Crit Care
1:85-93, 1992.
Fisher DH, Stanford G, Dorman DJ: Services for parental stress reduction in a
pediatric ICU, Crit Care Med 12:504-507,
1984.
Hamilton OK: Design for flexibility in
critical care, New Horiz 7:205-217, 1999.
McNamara ST, Meyer EC, Fraser KA et al:
In the middle of the night: a psychosocial
resource book for after hours, J Emerg Nurs
23:68-69, 1997.
Rubin R: Attainment of the maternal role.
Nllrs Res 16:83-91, 16:324-346, 1967.
Macnab AJ, Emerton-Downey J, Phillips N
et al: Purpose of family photographs displayed in the pediatric intensive care unit.
Heart LUllg 26:68-75, 1997.
Vulcan BM, Nikulich-Barrett M: The effect
of selected information on mothers' anxiety

levels during their children's hospitalization,
J Pediatr Nurs 3:97-102, 1988.

92. Rowe J: Making oneself at home? Examining the nurse-parent relationship, Contemp

Nars 5:101-106, 1996.
93. Sevedra M: Parental responses to a painful
procedure performed on their child. In
Azarnoff P, Hardgrove C, eds: The family ill
child health care. New York, 1981, John
Wiley & Sons.
94. Shaw EG, Routh DK: Effect of mother's
presence on children's reactions to aversive
procedures, J Pediatr PsychoL 7:33-42,

1982.
95. Robinson SM, Mackenzie-Ross S, Campbell
Hewson GL et al: Psychological effect of
witnessed resuscitation on bereaved rela-

tives, Lancet 352:614-617, 1998.
96. Meyers TA, Erichhorn DJ, Guzzetta CE
et aT: Family presence during invasive procedures and resuscitation, Am J Nars 100:

32-42, 2000.
97. Gutstein SE, Tarnow JO: Parental facilitation of children's preparatory play behavior
in a stressful situation. J Abnormal Psychol

11:l81-191. 1983.
98. Scott LD: Perceived needs of parents of
critically ill children. J Soc Pediatr Nurs
3:4-12, 1998.
99. Gilkerson L: Understanding institutional
functioning style: a resource for hospital

Child Health Care 17:98-105, 1988.
80. Hayes YE, Knox JE: The experience of
stress in parents of children hospitalized
with long-term disabilities, J Adv Nurs
9:333·341, 1984.
81. Molter NC: Needs of relatives of critically
ill patients: a descriptive study, Heart Lung
8:332-339, 1979.
82. Szasz TS, Hollender MH: A contribution to

and early intervention collaboration, Infants
Young Childrell 2:22-30, 1990.
100. Featherstone H: A differellce ill the family:
Living with a disabled child, New York.
1980, Basic Books.
101. Meyer EC, Zeanah CH, Boukydis CFZ et al:
A clinical interview for parents of high-risk
infants: concept and applications. Infom
Mental Health J 14:192-207,1993.
102. Doll-Speck L, Miller B, Rohrs K: Sibling

the philosophy of medicine. Arch Imem

education: implementing a program in the

Med 97:585-592, 1956.

NICU, NeonataL Nerw 12:49-52, 1993.

Chapter 3 Caring Practices: The Impact of the Critical Care Experience on the Family
103. Maloney MJ, Ballard JL, Hollister L et al: A
prospective, controlled study of scheduled
sibling visits to a newborn intensive care
unit, J Am Acad Child Psychiatry 22:565-

570, 1983.
104. Lewandowski LA: Needs of children during the critkaJ illness of a parent or sibling, Crit Care Clin North Am 4:573-585,
1992.
105. Newman CB, McSweeney M: A descriptive
study of sibling visitation in the N1CU,
Neonatal Nnw 9:27-31. 1990.
106. Tiller M, Craft M, Cohen M: Impact of

115. Als H: Individualized, family focused developmental care for the very low binhweight
preterm infant in the NICU. In Friedman SL,
Sigman M, eds: Advallces ill applied developmelltal psychology: The psychological
development of low binhweight children,
Norwood, NJ, 1992, Ablex.
116. Appleyard ME, Gavaghan SR, Gonzalez C
et al: Nurse-coached intervention for the
families of patients in critical care unit'), Crit
Care Nurs 20:40-48, 2000.
117. Harvey MA, Ninos NP, Adler D et al:
Results of the consensus conference on
fostering more humane critical care: creating

a critical care hospitalization: perceptions

107.

108.

109.

110.

111.

112.

of patients. spouses. children. and nurses,
Heart Lullg 17:314-315, 1988.
Craft MT, Wyau N: Effect of visitation
upon siblings of hospitalized children,
MCN Am J Matern Child Nurs 15:47-59,
1986.
Rushton CH, Booth P: The role of siblings
during pediatric hospitalization. Presented at
the 21 st Annual Association for the Care of
Childten's Health Conference, San Francisco, Calif. 1986.
Nicholson AC, Titler MG, Montgomery LA
et al: Effects of child visitation in adult
critical care units: a pilot study, Heart Lung
22:36-45, 1993.
Barnsteiner J, Gillis-Donovan J: Being related and separate: a standard for therapeutic
relationships, MCN Am J Matern Child Nurs
15:223-228, 1990.
McKlindon D, Bamsteiner JH: Therapeutic
relationships: evolution of the Children's
Hospital of Philadelphia model, MCN Am
J Matern Child Nurs 24:237-243, 1999.
Bamsteiner JH. Gillis-Donovan J, KnoxFischer C et al: Defining and implementing
a standard for therapeutic relationships,
J Holistic Nurs 12:35-49, 1994.

113. Gill KM: Health professionals' attitudes
toward parent panicipation in hospitalized
children's care, Child Health Care 22:257271, 1993.
114. Hickey M, Lewandowski L: Critical care
nurses' role with families: a descriptive
study, Heart Lung 17:670-676, 1988.

118.

119.

120.
121.

122.
123.

124.
125.

126.
127.

128.

129.

a healing environment, AACN Clin Issues
Cri/ Care Nurs 4:484-507, 1993.
Bouve LR, Rozmus CL, Giordano P: Preparing parents for their child's transfer from
the PICU to the pediatric floor, Appl Nurs
Res 12: 114-120, 1999.
Bokinskie JC: Family conferences: a method
to diminish transfer anx.iety, J Neurosci Nurs
24: 129-133, 1992.
Schiff HS: The bereaved parelll, New York,
1977, Crown.
Miles MS, Perry K: Parental responses to
sudden accidental death of a child, CriT Care
Q 8:73-82, 1985.
Rando TA: Parelltal loss of a child, Champaign, III, 1986, Research Press Company.
Sanders CM: A comparison of adult bereavement in the death of a spouse. child,
and parent, Omega 10:303-322, 1978-1980.
Fischoff 1. O'Brien N: After the child dies,
J Pediatr 88:140-146,1976.
Jost KE, Haase JE: At the time of death: help
for the child's parents, Child HealTh Care
18:146-152, 1989.
Strom-Paikin J: Our son is dead, Nurs Life
4: 18-20, 1984.
Cauthorne CV: Coping with death in the
emergency depanment, J Emerg Nurs I :2426, 1975.
Wonman CB, Silver RC: The myths of
coping with loss. J COlISulr Clin Psychol
57:349-357, 1989.
Kuhler-Ro" E: all deaTh alld dying, New
York. 1969, Macmillan.

130. Parkes

CM:

Bereavement

and

67
mental

iHness: a classification for bereavement
reactions, Br J Med Psychol 38: 13-26,

1965.
131. Miles MS: The griefofparellts when a child
dies, Oak Brook, Ill. 1980, Compassionate
Friends.
132. Miles MS: Helping adulls mourn the death
of a child. In Wass H, Corr C, eds: Children
and death, New York, 1984. Hemisphere.
133. Miles MS: Emotional symptoms and physical health in bereaved parents, Nurs Res
34:76-81, 1985.
134. Davies B, Eng B: Factors influencing nursing care of children who are terminally ill: a
selective review, Pediatr Nurs 19:9-14.
1993.
135. Henneman E: Multidisciplinary care plan
for the dying patient: a strategy to promote
humane caring in ICU, AACN Clill Issues
Crit Care Nurs 4:527, 1993.
136. Mendyka BE: The dying patient in the
intensive care unit: assisting the family in
crisis, AAeN Clin Issues Crit Care NUTS
4:550-557, 1993.
137. Johnson L, Mattson S: Communication: the
key to crisis intervention in pediatric death,

Crit Care Nurse 12:23-27. 1992.
138. Johnson LC, Rincon B, Gober C et al: The
development of a comprehensive bereavement program to assist families experiencing pediatric loss, J Pediarr Nurs 8: 142-146,

1993.
139. McClelland ML: Our unit has a bereavement program, Am J Nurs 93:62-68, 1993.
140. Murphy SA: Preventive intervention following the accidental death of a child, Image
J Nurs Sch 22: 174-179, 1990.
141. pazola K: Rememhrance: a strategy to
prevent bereavement overload, Caring 4,
Winter 1988.
142. Richmond T, Craig M: Timeout: facing
death in the ICU, Dimens Critl Care Nurs
4:41-45. 1985.
143. Vachon MLS: Occupational stress in the
care oj the critically ill. the dying, and the
bereaved, New York, 1987, Hemisphere
Publishing.

The Practice
Environment

This section focuses on the milieu affecting nursing care delivery. The
broadening professional responsibilities of the pediatric critical care nurse as
leader, teacher, mentor, and advocate are acknowledged and supported.

Leadership in Pediatric
Critical Care
Mary J. Fagan

The I990s presented an era of healthcare cost cutting to
survive in the world of managed care. Organizations were
forced to merge or reorganize and reengineer to drive out
cost in the face of declining reimbursement. Turnaround
efforts, largely led by outside consultants, engineered
average cuts in clinical staff expenses by more than 60% and
nursing department cuts by as much as 25% in an attempt to
mend the bottom line. I
In the wake of these cutbacks, serious questions about
quality of care in hospitals have been being raised. A New
York State Nurses Association study found that 52% of the
nurses responding believed that patient care was either
minimally safe or not safe at all. 1 Responding to these
concerns, many states passed legislation or were considering
legislation creating mandatory nursing staff ratios. Nursing
unionization activity was at an all-time high.
Nurses, physicians, and consumers all described inadequacies in care, while hospital administrators remained
concerned with worsening margins. This left nurses feeling "beat up" by dissatisfied families and physicians
and by the hospital's need to cut costs. Overall, stress
levels were high, and morale was low. In fact, one
study ranked posttraumatic stress disorder (PTSD) symptoms across disciplines and found intensive care unit
(ICU) nurses to have the highest rate of all groups
studied, ahead of Israeli soldiers and Vietnam veterans
with PTSD?
Lastly, a major nursing shortage looms. Nursing vacancy
and turnover rates are on the rise, and open positions are
being filled at alarming rates by inexperienced staff or new
graduates. Vacancies are especially evident in areas that are
highly specialized, such as Pediatric Critical Care. With the
national average age of a registered nurse (RN) at 44.3 and
rising, an even larger number of RNs will be leaving the
profession in the coming years. This, coupled with the fact
that nursing school enrollments in bachelor of science in
nursing (BSN) programs are on the decline, has a lot of
people worried.
Massive efforts have been instituted to recruit experienced nurses from one hospital to another. Sign-on bonuses
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Time Management
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SUMMARY

world-class pediatric intensive care unit-what does
this mean and how is it achieved? Is it the technical
skill of the staff? Is it the amount of research that is being
done? Is it the physician talent? The answer is that none of
these attributes, if taken in isolation, will create a worldclass organization. Excellence is achieved through a combination of many factors, and it is highly dependent on
effective leadership. The quality of the leadership is the
most important component in detertnining whether a pediatric critical care unit (PICU) will stand out as being one of
the best in the world, especially in this era of incredible
change.

A

CURRENT CHALLENGES
The twenty-first century finds healthcare and nursing in
a tumultuous state. Times have been tough, and they
appear to be getting tougher. Never has the need for
effective front-line leadership been more dramatic than it
is today.

71

72

Part II

The Practice Environment

and pay incentives have led to full-scale bidding wars for
some positions.
Studies have demonstrated that improving manager
leadership behaviors is more likely than any other intervention to improve retention of hospital nurses. 3 However, the
dilemma is that most nurses who are promoted to leadership
positions have exceptionally strong clinical skills. Their
success at the bedside has led to promotion to a position of
authority. Unfortunately, the skills that are required to be a
great leader are not necessarily clinical in nature. This
chapter describes some of the attributes and methods for
developing strong leadership skills.

EFFECTIVE LEADERSHIP
Leadership is defined as "a relational process of bringing
people together attempting to accomplish change or make a
difference to benefit the common good."4 It encompasses a
broad spectrum of attributes, including those discussed next.

Vision and Values
The type of leadership necessary to support a world-class
critical care department begins with a positive vision of the
future. A vision is a clear mental picture of a desired future
outcome. To emphasize the importance of a clear vision,
Flaherty and StarkS describe the process of putting together
a WOO-piece jigsaw puzzle. The picture on the top of the
box is the end result or the vision of what is to be accomplished. It is much more difficult, if not impossible, to put a
jigsaw puzzle together without ever looking at the picture.
Trying to lead a group without a vision is like trying to
put together a jigsaw puzzle without ever looking at the
picture.
A good vision is clear and compelling. It works like a
magnet, pulling people toward it. As the vision provides a
clear picture of where to go, values provide the how. They
provide the road map of how to achieve the vision. For
example, the critical care unit at Children's Hospital in
San Diego has articulated the following vision and values:
We envision a critical care unit which is acknowledged as one
of the world's premiere providers of pediatric critical care.
COlllillliOUS learning and teamwork are the foundation upon
which we develop Olir expertise. Ollr success is a result of the
dedication alld commitment of each member of Olir leam to the
work we do, the people we serve. and each olher.

If an entire department shares the same vision and makes
decisions on how to operationalize the vision based on the
same set of consistent values, success will follow.
So how do leaders facilitate the process of establishing a
shared vision? According to Senge,6 shared visions emanate
from personal visions. He encourages leaders to give up the
traditional notion that visions must corne from the top of an
organization or that it is appropriate for the leaders to go off
and write a "vision statement" that will then be shared with
and adopted by others. Although shared visions may come
from the top of an organization, Senge suggests visions that
are truly shared take time to emerge and are most often the

result of ongoing conversations, wherein people feel free to
discuss their dreams and are inspired to truly listen to the
dreams of others. People need not give up their personal
visions; instead, over time and work, multiple visions begin
to coexist, and shared visions are the result.
Senge6 sees the development of a shared vision as one
piece of a set of "governing ideas" that are necessary for
organizations. These include the organization's vision,
purpose or mission, and core values. A vision that is not
consistent with the values people live from day to day will
not be successful. The governing ideas are simply the
answers to three basic questions: "What?" "Why?" and
"How?" The vision is the "what," the purpose or mission is
the "why," and the core values are the "how."

Teamwork
Aligning people into high-performing teams is an imperative to be a world-class department or organization.
Common characteristics define these groups and set them
apart from others. They demonstrate a participative leadership style that empowers members, a shared responsibility
for group acti vities and their outcomes, an alignment of
purpose with clearly delineated group goals, high levels
of communication characterized by mutual trust and respect,
a future focus, a task focus, encouragement and support of
creative talents, and a penchant for rapid responses.
The landmark APACHE study demonstrated just how
important teamwork is in overall critical care unit performance. 7 It studied adult critical care units that were stratified
on the basis of severity-based outcomes. Significant variations in actual versus predicted mortality rates were
apparent between the highest-performing units and the
underachievers. Researchers evaluated many factors, including presence or absence of a board-certified attending
physician, fellowship programs, size of departments, university affiliations, and percentage of RNs with CCRN
status and found none to be significantly correlated with the
results. The differences were largely explainable, however,
by the level of teamwork between caregivers, especially
nurses and physicians. The APACHE study demonstrated
that effective teamwork saves lives and distinguishes those
organizations that truly excel from the rest.
Perhaps the biggest barrier to teamwork is the absence of
trust. Work groups in which little trust exists between
members may go through the motions of teamwork but will
not be effective. In The 7 Habits of Highly Effective People.
Covel describes the natural process of growth and development that groups must go through to establish trust and
become high functioning. The process involves developing
such principles as fairness, integrity, honesty, human dignity, service, excellence, potential, growth, patience, nurturance, and encouragement. Attempting to shortcut the
process will result in disappointment and frustration. As a
group leader, Covey states, "If you want to be trusted, be
trustworthy." This process takes time and patience. Heider9
has similar beliefs about the role of group leaders (Box 4-1).
Leaders can foster teamwork through systems that
support collaboration and teamwork among all members.

Chapter 4
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Box 4-1

Doing Less and Being More

• Run an honest, open group.
Your job is to facilitate and illuminate what is happening.
Interfere as little as possible. Interference, however brilliant, creates dependency on the leader.
• The fewer the rules. the better. Rules reduce freedom and responsibility. Enforcement of rules is coercive and manipulative. which diminishes spontaneity and absorbs group energy.
• The more coercive you are, the more resistant the group will
become. Your manipulations will only breed evasions. Every
law creates an outlaw. This is no way to run a group.
• The wise leader establishes a wholesome climate in the
group room. In the light of awareness, the group naturally acts in a wholesome manner.
• When the leader practices silence, the group remains
focused. When the leader does not impose rules, the group
discovers its own goodness. When the leader acts unselfishly, the group simply does what is to be done.
• Good leadership consists of doing less and being more.
From Heider J: The Tao of leadership, Atlanta, 1985: Humanics Publishing
Group.

Sometimes, in organizations that have reputations for being
world-class, a misconception is that success is a result of the
skills of one superstar or perhaps a few individuals who
really stand out. In fact, as demonstrated in the APACHE
study, the level of collaboration among all team members,
not just the skill of a superstar, makes an organization stand
out. This phenomenon has been illustrated in the book
Sacred Hoops, by previous Chicago Bulls coach, Phil
Jackson. lo In his book, Jackson describes his experience
coaching a team that included the superstar Michael Jordan.
In his early years with the team, even though Jordan was a
clear superstar and crowd pleaser, the Bulls were not
winning championships.
Then Jackson worked with Jordan and coached him to
become more than an individual superstar. He learned to be
a team leader, whose role was to elevate the level of play of
all the Chicago Bulls players and to focus on the work of the
team, not just his individual performance. This change in
strategy is thought to be the number-one factor that led the
Bulls to becoming more than "Michael Jordan's team."
Instead, they became the most successful basketball team in
history.
The Phil Jackson story has a lot of applicability to
pediatric critical care units that are seeking to be the best.
First, it outlines the importance of focusing on teamwork, as
well as individual performance. Then, it emphasizes the role
that the team's superstars should have in elevating the level
of performance of every team member to be the best. An
example of a situation in which this opportunity may arise
is a change of shift in the PICU when a more experienced
staff member takes over for a junior member. The more
experienced individual may have some ideas about improvements in the plan of care. Here are some possible
options: The senior staff member could wait until the junior
member leaves, talk about how inexperienced the junior
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staff member was, and change the plan. Or, the senior staff
member could discuss the possible care plan changes with
the junior staff member, agree on any changes, and support
the junior staff member in communicating the changes to the
rest of the team. The second scenario is the one that will
produce the winning team.

Conflict Resolution
Often, people will not take the approach outlined previously
because they are afraid of conflict. A common problem for
nurses in developing their leadership skills is dealing with
difficult people and resolving conflict. Perhaps because of a
desire to make things run smoothly or keep everyone happy,
many nurses avoid dealing with these issues. There are
several types of difficult people: the hostile aggressive, the
complainer, the silent and unresponsive, the super agreeable, the negativist, the know-it-all expert, and the indecisive. To effectively deal with these types of people,
Bramson II offers the following suggestions: (I) do not
simply wish that the person were different, (2) consider
reasons for the difficult person's behavior, (3) achieve
distance from the difficult person, (4) develop a plan to cope
with the individual, (5) implement the plan using support
from others and principles from behavior modification, and
(6) evaluate and update the plan as necessary. These
suggestions are also valuable for management teams or
groups of nursing staff. If an entire group sees a particular
person as difficult, developing a plan to cope with the person
that is implemented consistently with group support can be
very powerful. Especially if the plan incorporates principles
of behavior modification and is evaluated and updated
regularly, positive results can be achieved.
Conflict is inevitable in organizations and in life.
Certainly, in the emotionally charged atmosphere of the
PICU, conflict is a daily occurrence. Conflict can be seen as
a negative occurrence, or it can be seen as an opportunity for
learning and growth. When conflict is resolved successfully,
positive change has occurred. Five possible responses to
conflict are competition, accommodation, avoidance, compromise, and collaboration. Competition is an aggressive
and uncooperative approach to conflict. It creates a win-lose
situation in which the loser is left feeling angry and
antagonistic. Accommodation is cooperative but unassertive,
and it creates a lose-win situation, leaving the accommodator feeling resentful and angry. Avoidance is unassertive and
uncooperative, and it creates a lose-lose situation. Pretending that a conflict does not exist when it has surfaced serves
no one well. Compromise has some aspects of cooperation
and some of assertion. Each side makes concessions in a
win-lose situation in which both sides win a little and lose
a little. Compromise is preferable to competition, accommodation, and avoidance, but it is a weak conflict-resolution
technique. Compromise results in decisions that both sides
can live with but not necessarily the best solution that could
have come from the interaction. Collaboration is both
assertive and cooperative, creating a win-win situation. Tn
this method, both sides work together to find the best
solution to a problem. 12
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Empowerment and Accountability
Empowerment, a tenn that became an overused buzzword in
the 1990s, still has applicability at the individual and
organization level in the 2000s. When viewed from an
individual perspective, empowennent means the ability to
make a decision and take action responsibly. From an
organizational position, empowennent is the process of
increasing the power of others by allowing them to make
decisions and take responsible actions. 5 Leaders support
staff members by fostering empowennent on both an
individual and an organizational level.
In the realm of individual empowennent, a model that
illustrates 5 C's has been has been described by Flaherty and
Stark. 5 The first C. and the foundation, is choice-the belief
that everyone has choice in everything they do; next is
confidence-believing that a positive outcome is possible;
the third C is courage-the power to take action; the fourth
is to communicate intentions; lastly, and at the top of the
pyramid, is to commit to make it happen. Sharing these
fundamentals with others can help to develop their personal
sense of empowennent.
One cannot talk about empowennent without a clear
definition and commitment to accountability. At risk of
becoming the buzzword of the 2000s, accountability means
accepting responsibility for one's actions and following
through on commitments. Leaders can foster accountability
by consistently maintaining and expecting high standards.
This sounds simple, but in fact, it is an area in which many
leaders struggle. The Five Temptations of a CEO. describes
a "temptation" that many leaders have-to choose popularity over accountability.13 It involves being more concerned with being popular with direct reports than in holding
them accountable.
Organizational empowennent is based on trust and
respect. Giving employees the power to make decisions and
to take actions demonstrates trust in a dramatic way.
Organizational systems such as Shared Governance are

rooted in the belief that people, given the right information,
will do the right thing. Again, it essential to build accountability measures into any system at the level in which decision making is done.
The first published reports of Shared Governance in
hospital nursing departments came from Rose Medical
Center in Denver and St. Joseph's Hospital in Atlanta in the
early 1980s. These organizations described their experience
with a model that employed a councilor structure, wherein
responsibility and accountability rested with the same
individuals or groups (Fig. 4-1). Their model included a
council on practice, a council on management, a council on
quality improvement, and a council on education. A
coordinating council integrated and coordinated the governance structure. 14
The major role of the council on nursing practice was the
establishment of professional nursing practice standards.
The council was composed of clinical specialists, educators,
managers. and front-line staff, who represented the majority.
The council on quality assurance also had a staff nurse
majority and included other nursing practitioners. This
council's function was to review all nursing practices in the
institution to ensure that the standards identified by the
council on nursing practice were being carried out and to
ensure their appropriateness.
The council on education had responsibility for ensuring
that the educational needs of the staff are met and that the
mechanisms to maintain high levels of competence are in
place. This council has accountability at both the unit and
the corporate level, and membership is broad, including all
unit-level services.
Membership in the council on management consisted of
the traditional management representatives, but the scope of
responsibility changes dramatically from a traditional management role. This council is responsible for giving support
to the nursing staff and allowing them to make decisions.
Often, the role of the management council is to institute
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measures to ensure that the decisions of the councils are
carried out.
The coordinating council consists of chairpersons of each
of the governance councils and the nursing administrator.
This council focuses on all nursing activities, ensuring their
congruence with the nursing department's philosophy,
goals, and objectives.
In addition to the councils, Porter-O'Grady and Finnigan 14 describe a unit-based component to their model, the
unit-level practice committees. These committees are subsets of the council on nursing practice and work under the
leadership of the council. They are responsible for developing quality working relationships between physicians and
nurses. These committees focus on the collaborative development of practice parameters, care plans, and intervention
strategies.
Another form of shared governance, called collaborative
governance, has been described by Jacoby and Terpstra. 15
This is a unit-based structure that has its roots in the
12 shared beliefs of the nursing department (Box 4-2).
These values provide the basis for consensual decision
making in this structure and make bylaws unnecessary. The
unit is the heart of collaborative governance, and a central
structure ensures that unit activities are coordinated with
departmental and hospital activities and goals.
Based on the philosophy that true professionalism means
control over one's hours, as well as one's work, many
hospitals have converted from hourly pay practices to
salaried status. Most of the programs have been successful,
with nurses reporting increases in professionalism, selfconcept, and self-esteem. 16. 18

Box 4-2

Twelve Shared Beliefs of Collaborative
Governance
I. Knowledge is power.
2. Given adequate information, people will make appropriate decisions.
3. Individuals are unique in their contributions.
4. A sense of purpose results when organization and
personal values are congruent.
5. Maximum productivity results when organizational and
personal goals are congruent.
6. Risk taking, with or without success, is growth.
7. People are honest and trustworthy and will work hard
to achieve their full potential.
8. Individuals are accountable and responsible for their
practice.
9. All problems identified are mutually owned, and responsibility for resolution begins with problem identification.
10. Weaknesses and strengths are the same characteristics
used differently. (Weaknesses are strengths in excess.)
II. Our decisions will acknowledge federal and state
regulations and reasonable economic restraints.
12. Full cooperation with other divisions must be maintained
to fulfill the hospital's mission.

..
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The pediatric critical care unit at University Children's
Hospital in Hermann, Texas, devised a salaried status
program that met the needs of the nursing staff and the
hospital. 19 The plan, professional reimbursement for nurses
(PRN), allowed each nursing staff member to be available
for six 12-hour shifts with two on-call shifts in a 2-week
period. The nurse's compensation was based on 84 hours of
work and included usual shift differentials and overtime
observed for the hours over 80. The nurse's salary, as a
result, was based on 86 hours of work every 2 weeks. This
schedule allowed the nurse to work a minimum of 72 hours
per pay period or as many as 96 hours while receiving a
salary based on 86.
Evaluation of the PRN program by staff and management
was favorable. Ninety-one percent of the staff wanted to
continue the plan. The staff cited reasons such as relief from
floating, provision of reliable unit coverage with trained
staff, more time off (actual hours worked often less than
number paid), improved unit teamwork and professionalism, more suggestions from staff with regard to scheduling,
and consistent quality care.
Management evaluation revealed many advantages:
(I) unit coverage was more consistent for a variable census;
(2) cost per patient day remained within the targeted goal
(the salaried plan did not increase labor costs, a major
concern of hospital administration); (3) individual nurses
became more accountable for unit coverage, independently
solving scheduling problems; and (4) staff participated more
broadly in unit activities.
Turnover rate in the unit dropped 14% after initiation of
the program, and as a result, orientation hours decreased.
Overtime use decreased significantly, and sick leave use was
reduced by 19 sick hours per employee per year. Overall, the
plan was budget neutral, and patient care quality and unit
morale were reported to be significantly improved. In
becoming salaried employees, nurses must have the benefits
and responsibilities attendant with being exempt employees.
These include discussions on decision-making processes
and scheduling practices.

Coaching
Being a good coach means seeing talent and potential in
people that they may not presently see for themselves,
providing honest feedback on performance, and presenting
opportunities to learn and grow.
Feedback should be provided on an ongoing basis and
also formally through the performance evaluation process.
According to Covey, 8 the most successfuI method for
evaluating performance is to have people evaluate themselves. If they participate in establishing the criteria by
which they are evaluated, this method of evaluation can
eliminate awkward and emotionally exhausting traditional
methods. He conveyed experiences in self-evaluation with
college students described as his best: He starts with a
shared understanding of the goal up front: "This is what we
are trying to accomplish. Here are the requirements for an A,
B, or C grade. My goal is to help every one of you get an A.
Now you take what we've talked about and analyze it and

76

Part II

The Practice Environment

come up with your own understanding of what you want to
accomplish that is unique to you. Then let's get together and
agree on the grade you want and what you plan to do to get
it." This type of evaluation is possible in nursing units.
Specific criteria-based evaluation tools can be created in
collaboration with those being evaluated and can still be
tailored to meet the needs of each person. In addition, if
leaders are committed to help each person achieve their
agreed-on individual objectives, the evaluation process can
be a very positi ve experience.
Feedback from others provides a powerful learning
opportunity that may be incorporated into the evaluation
process. Many institutions use peer review as a component
of each team member's performance appraisal. Feedback of
any type is most helpful if it is provided continuously,
however, rather than only at the time of one's annual
appraisal. Although most commonly referred to as either
positive feedback or negative feedback, it is also most
effective when it is not simply one way but circular and is
incorporated into a "feedback loop" in which change and
growth take place.
When leadership supports people to grow, learn, and be
self-managing, the entire organization wins. The ultimate
test for a leader is not whether he or she can make smart
decisions and take decisive action, but whether he or she can
teach others to be leaders and build an organization that
remains successful even when he or she is not around,z° It
is this type of teaching and coaching that truly sets
organizations apart from others.

Assertive Communication
An area in which many people in the healthcare field could

benefit from coaching is in communicating assertively.
Assertiveness is another learned skill that must be practiced.
To be assertive is to be positive or confident in a persistent
way. It is based on self-esteem and respect for self and
others. Assertive behavior is standing up for one's rights to
express one's feelings, reactions, or expectations without
alienating the other person. Assertive communication is
honest, direct, and appropriate. It is behavior-focused rather
than personal criticism.
Assertion needs to be discussed in relation to its contrast
to both passivity and aggression. Passive communicators do
not stand up for themselves. They allow others to speak up
for them or to push them around, and because of this, they
may harbor resentment and anger. Aggressive people stand
up for their individual rights but in a manner that infringes
on the rights of others. Aggression allows a person to obtain
what they desire but often alienates others in the process.
Baillie and co-workers 21 offer the following suggestions
to assist in cultivating assertiveness skills.
Practice Positive Self-Communication. Expressions of positive regard such as "I am confident," "I am an
effective nurse and leader," and "I can do this" help us
better deal with conflict and stressful situations that affect
our self-worth.
Learn to Deal With Criticism. People who have
difficulty dealing with criticism are those who feel that it is

essential to be liked and approved of by everyone or that
they must never make a mistake. Many see criticism as a
rejection of self instead of a rejection of an action. It is
essential to separate the problem from one's integrity and
then to respond to the criticism. Negative ways of responding to criticism include (1) apologizing more than is
necessary, (2) becoming defensive, (3) attacking the critic,
and (4) internalizing the stress and saying nothing. By
contrast, one may deal with criticism in a productive and
assertive manner. Options include (1) accepting it, (2) disagreeing with it, (3) setting limits for the critic, (4) fogging,
and (5) delaying.
Accepting justified criticism from a respected individual is assertive as long as it is accepted without being
considered an insult. Disagreeing with the critic is appropriate when the criticism is unjustified. It is important to
back up a disagreement with a statement of self-affirmation.
Setting limits with the critic is appropriate when the critic
is behaving in an inappropriate manner, such as using
foul language or yelling. In this situation, it is fitting to
tell the individual to stop, to wait until a more suitable
time for the interaction, or to leave the area. Fogging is
a technique in which the individual acknowledges the
critic but then immediately changes the subject. Delaying is
simply responding to criticism with a statement that the
person needs more time to gather information before
responding.
Setting Limits and Saying "No." In being assertive,
it is important to set limits and say "no" when it is meant.
Expectations must be made clear. Saying "no" and setting
limits require allowing negative feelings to be expressed.
With practice, one can learn to set limits and say "no"
because it fits with one's values, and in this way people
teach others how to treat them.
Making Requests and Expressing Initiative.
Knowing what is wanted and asking for it are hallmarks of
this strategy. It requires risk taking, a knowledge of self, and
the ability to take "no" for an answer. Taking initiative
and asking for what is wanted improves self-esteem and
self-actualization, but it does not mean always getting what
is asked.
Expressing Anger. Expressing anger in an assertive
manner requires being in touch with the feelings associated
with anger and expressing them in a manner that allows
further communication to occur. Using "I" instead of "you"
statements allows the expression of anger without closing
communication pathways.

Systems Thinking
One of the most important roles that leaders play is that of
problem solver. Good problem solvers are typically people
who approach issues with a can-do attitude and a willingness to make necessary changes. Often, leaders have been
promoted within their institutions because they are good
problem solvers. In a system such as a pediatric critical care
unit within a healthcare organization, the best problem
solvers are also systems thinkers. They understand that their
area of focus is simply a piece of a larger puzzle, and they
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approach problem solving from the perspective of trying to
understand the big picture.
All organizations are systems. Systems can be defined as
a set of interdependent components that work together to
achieve a common goal. Systems thinking describes a way
of thinking about and a language for describing and
understanding the forces and interrelationships that shape
the behavior of systems. 6 It encompasses a large body of
methods, tools, and principles all oriented at looking at the
interrelatedness of forces-seeing them as a part of a
common process. In pediatric critical care, this emphasizes
the importance of seeing the work done in the lCU as part
of the bigger picture of the organization.
Three main components of systems thinking are
(l) studying and understanding processes that contribute to
care, (2) measuring performance of processes and their
outcomes using valid statistical methods, and (3) taking
action to improve the way processes are designed and
carried out.
An example of the use of systems thinking as a
problem-solving tool in pediatric critical care follows: The
problem was an increasing incidence of diverting trauma
patients to other hospitals because of the unavailability of
ICU beds or staff. Using a systems thinking approach to this
problem, the first step was to study and understand the
processes that contribute to care. Contributions were
gathered from nursing staff, managers, staffing coordinators,
physicians, and the trauma program manager, and a new
data collection tool aimed at gathering information about
why the hospital was refusing trauma admissions was
devised and implemented. Next, performance was measured
using valid statistical method. Concurrent data from the new
tool were collected and presented using the actual numbers
of trauma patients turned away (numerators) and the actual
number of all trauma calls (denominators). Lastly, the group
took action to improve the way processes were carried out.
Based on the new data, it was evident that nursing staff
members and bed availability were not the only reasons the
hospital was referring trauma patients elsewhere. Other
reasons included evaluating the appropriateness of the
patients that were in the PlCU, establishing systems to speed
up the discharge process on the floors to open beds, and the
inadequacy of the present per diem float pool. By improving
the way these processes were carried out, more global
improvements were possible.
Tools can be used in systems thinking to help understand
the processes that are being studied and to clearly present
the data that have been collected. Reliable data are essential
to all systems improvement activities. Useful tools in
understanding processes include brainstorming, the "fishbone" technique, and flowcharts. Brainstorming is a technique for generating ideas about an issue from a group. It
involves defining the subject of the brainstorming session,
allowing time for everyone to think about the issues, and
setting a time limit. One way to implement brainstorming is
for each group member to callout ideas with someone
noting each idea. During this time, no one may comment or
react to an idea. After all ideas have been shared, the group
clarifies the ideas that were presented.
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The fishbone technique is also known as a cause-andeffect diagram. This is a diagram showing a large number of
possible causes for a problem, which, when constructed,
looks something like a fishbone (Fig. 4-2). To construct a
cause-and-effect diagram, a problem statement is placed to
the right of a horizontal line with an arrow pointing to the
problem. Major categories that contribute to the problem are
then written on diagonal lines that point at the original
horizontal line. If applicable, subcategories (or causes) may
be listed that affect the main categories. The intent is to
begin to understand the root causes of problems, and, once
they are listed, the diagram can be used to determine
obvious areas for improvement.
Flowcharts are graphic representations of the sequence of
steps that are performed in a specific work process. They can
be used to identify an actual path that a service follows to
see if there are any redundancies, inefficiencies, or misunderstandings; to identify an ideal path for a product or
service; or to create a common understanding of how a work
process should be done. To implement a flowchart, it is
necessary to decide on a starting and ending point for the
process. Next, activities and decision points are arranged in
the order of occurrence, and analysis of the flowchart serves
to determine areas for improvement or explain the steps of
a newly created process.
Tools that can be used to present data in an easily
understandable fashion include histograms and run charts.
Histograms are graphic representations of the frequency
with which something occurs. They involve listing possible
scores on one axis of a graph and the actual count for each
category on the other axis (Fig. 4-3).
A run chart is a collection of points plotted on a graph in
the order in which they became available over time. A graph
is established with the horizontal axis representing time or
seq uence of the data and the vertical axis indicating
increments of measure. Points are then plotted on the graph
and connected with a line. The chart can be evaluated to
identify meaningful trends or shifts in the average (Fig. 4-4).
These statistical tools are all incorporated to accomplish
the goal of presenting accurate, understandable data. Without the use of statistical control measures, unsystematic data
collection and subjective evaluation of care can render
improvement activities futile.
Collaboration by departments and groups on problemsolving and systems improvement activities is crucial. For
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Fig. 4-2 Fishbone diagram. (Used with permission from The
memory jogger: a pocket guide of tools for continuous improvement. Copyright 1988 by GOALlQPC, 13 Branch Street, Methuen,
MA 01844-1953. Tel: 508-685-3900.)
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example, if a problem is identified that involves patient
medications, it is essential that the pharmacy and nursing
cooperate with other departments involved to study the
processes that lead to medication administration and discover ways to improve current processes. A single department cannot conduct meaningful systems improvement
activities in a vacuum.
Systems improvement must also be undertaken in a spirit
of respect and support. This approach requires the belief
that all people in the organization are committed to doing
their best.

Listening to People
Visibility and a willingness to really listen are hallmarks of
an excellent leader. The problem that many leaders face is
how to find the time for these activities. The answer is very

simple-it just has to become an absolute priority. Leaders
who could potentially be some of the busiest people in the
world, such as Jack Welch, CEO of the General Electric, the
world's largest corporation, and Roger Enrico, CEO of
PepsiCo, say that they spend as much as 30% of their time
interacting with and teaching others? I Being visible is
essential to being an effective leader.
Listening may be the chief distinguisher between leaders
who succeed and those who fail. Active, engaged listening
is the goal. This kind of listening demonstrates respect for an
individual, exhibits genuine concern, and encourages people
to express their views in return. Developing active listening
skills requires that one internalize what a speaker has said.
This means that the time the person is speaking is not spent
formulating a response. An excellent method to use in
improving listening skills is to practice hearing what others
mean to be saying. Repeating or validating a message is a
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useful tool. For those who are experiencing difficulty with
listening skills, a helpful exercise is to have the listener
repeat exactly what the speaker has said before responding.
This is a time-consuming operation, but it serves to ensure
active listening and can lead to the development of this
important skill.

Building Morale
Leaders are never energy neutral. They either create positive
energy by paying attention to spreading ideas and teaching
values, or they sap energy by ignoring it. Positive energy
creates positive morale. The most pivotal position in
affecting the morale of a department is that of the front-line
leader or manager. According to Taunton and colleagues, 3
improving managers' leadership behaviors will be more
likely than any other intervention to improve retention of
hospital nurses. Supportive management has been proven
effective in the management of nursing professionals.
Studies have demonstrated that supportive supervision has
many positive effects, including decreasing job stress and
burnout and increasing job satisfaction.12-25
A prime example of the effect of front-line management
on morale is the landmark magnet hospital study originally
conducted in 1982.16 This study identified 41 hospitals
across the United States that were known for their excellent
nursing care, for being places where nurses wanted to work,
and for having low turnover and vacancy rates.
In 1986, Kramer and Schmallenberg 27 .28 conducted a
follow-up study on a representative sample of 16 hospitals
from this group. The results indicated that these hospitals
were not experiencing problems from the nursing shortage
that was occurring at that time and that they had remained
institutions of excellence in the delivery of healthcare. A
common thread was identified among the institutions-the
hospitals and their nursing staffs were value driven. The
values are highlighted in Box 4-3.
In 1989, Kramer29 revisited the magnet hospitals and
learned that they were still centers of nursing excellence.
She found that these institutions had remained value driven
and identi fled seven other common threads among these
institutions.
Staff Mix: Still Moving Toward More RNs. These
hospitals were increasing the percentage of RNs by decreasing the use of licensed vocational nurses (LVNs). They
were also increasing the use of nursing assistants under
various titles. The important component of the nursing
assistant's role was that they were not assigned to patients;
instead, they were assigned to a registered nurse. Their
duties involved nonnursing patient care and environmental
activities.
Organizational Structure: Middle Managers Had
Been Removed From Clinical Decision Making. At
these hospitals, the staff RNs were respected for their
education, clinical competence, autonomy, and decisionmaking abilities. With a competent, autonomous RN staff,
less supervision was needed, and the nurse manager role
was redesigned. The role of the nurse manager was changed
from that of controller to leader. The span of leadership
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Box 4-3

Magnet Hospital Values

Quality care
Nurse autonomy
Informal, nonrigid communication
Innovation
Bringing out the best in each individual
Valuing education
Respect and caring for the individual
Striving for excellence
Data from Kramer M, Schmallenberg C: Magnel hospitals: institutions of
excellence. J Nurs Admin 18:13·24. 1988.

responsibility was increased so that one person often had
more than one unit to manage.
Salaried Status: Treating Nurses as Professionals.
The trend toward having nurses become salaried employees
was increasing. In 1986, nurses in 5 of the 16 magnet
hospitals studied were on salaried status. In 1989, nurses in
9 hospitals were either salaried or moving toward salaried
status.
Self-Governance: Minding Their Own Stores, but
Participating in Department-Wide Issues. The trend
toward self-governance in 1986 was continuing. The change
noted was that at this time, many of the chief nurse
executi ves were distinguishing between the concepts of
shared and self-governance. Most of the magnet hospitals
had a system of autonomous self-governed operation at the
unit level and participative, representative involvement in
department-wide issues.
Nursing Care Delivery Systems: More Flexibility
According to Patient Needs. Probably the biggest
difference seen in the years from 1982 until 1989 was in the
delivery systems used. In 1982, almost all of the magnet
hospitals were using the primary nursing model, but in 1986
the shift moved toward total patient care. As the patients'
length of stay was decreasing and flexible scheduling (with
10- and 12-hour shifts) found nurses working fewer days,
there was a push to individualize the delivery system to meet
the needs of the patient population and the unit. Case
management was gaining popularity as a delivery system,
and primary nursing, for the most part, was on its way out.
One chief nurse executive was quoted as saying, "Primary
nursing has taken a real beating...29 The hospitals were
committed to the philosophy of primary nursing and wanted
to continue to achieve the positive results that primary
nursing brought about, but changes in the care delivery
structure were needed.
Maximizing the Practice of Available Nurses. In
the magnet hospitals, more than 50% of the RNs were BSN
prepared. This mix provided the opportunity for nurses to
work with other nurses who were clinically competent,
experienced. and educated.
In addition, 12 of the 16 hospitals had a "no floating
policy," which represents an increase from 10 of 16 in 1986.
The hospitals were trying to stop or limit the use of agency
nurses. There was a slight increase in the use of agency
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nurses in the magnet hospitals from 1986, but II used either
none or fewer than four full-time equivalents (FTEs) per
month.
The hospitals used RNs predominantly; they were
committed to holding to selective hiring values and practices in the face of the nursing shortage. New graduate
employment was also being limited. In nine hospitals, only
25% or less of the new hires were new graduates. Units were
being self-managed. Nine of the 16 hospitals reported
self-managed units.
Innovative New Programs. The hospitals were
seeking to redesign or further develop new nursing care
delivery systems. They were differentiating nurses' roles
and setting up programs and activities to enable or empower
staff. These institutions were focusing on strengthening
nurse-physician practice relationships, flattening the organizational structure, and expanding computerization programs, particularly for documentation.

Stress Management
In the introduction, a study was referenced that described
intensive care nurses as having higher levels of stress than
even Vietnam war veterans with PTSD. Clearly, stress
management is an area is which leaders of critical care
should focus to support staff. Steinmetz and co-workers 30
describe a conceptual model that addresses the stressors that
occur in the ICU. It includes three components: external
stressors, internal stressors, and conflict avoidance. External
stressors are those occurring as a result of crowded workplaces or confusing organizational policies. Internal stressors are created by role ambiguity, professional bureaucratic
conflict, and situations such as dealing with angry people or
believing that perfection is necessary. Conflict avoidance is
a stressor brought on by failing to deal directly with conflicts
or problematic situations.
In a study focusing on PICU nurses, Gilmer31 identified
the death of a child as the most stress-producing event.
Other situations that were highly stressful to PICU nurses
included dealing with families who were attempting to cope,
problems involving interpersonal relationships, inefficient
unit design, and the absence of necessary equipment.
Oehler and Davidson 32 measured the predictors and
incidence of job stress and burnout in PICU and nonacute
unit nurses and found that although burnout was more of a
problem in critical care nurses, 22% of all pediatric nurses
reported symptoms associated with burnout. Particularly
troublesome was the high incidence of burnout associated
with personal accomplishment. Thirty-nine percent of nonacute unit nurses and 59% of acute care nurses reported a
low sense of personal accomplishment.
In relation to the contributors to burnout, results indicated that job stress makes the most significant contribution
to feelings of burnout. The death of a child was the highest
source of job stress, followed by workload. Conflict with
physicians and uncertainty regarding treatment were the
third and fourth factors. Oehler and Davidson 32 also found
that state anxiety (the level of anxiety a person is experiencing at the present time) and trait anxiety (the amount of
anxiety they usually experience) are powerful indicators of

burnout. Co-worker support was also a predictor of burnout,
with groups perceiving low co-worker support demonstrating higher levels of burnout. In this study the amount of
experience that the nurse had was the weakest predictor of
burnout, with less experience being associated with higher
rates of burnout.
To reduce stress and burnout, Oehler and Davidson 32
recommend programs to help all personnel cope with death,
creative solutions to managing patient assignments and
monitoring of individual workload, and work on strategies
for improving nurse-physician communication (particularly
on the issues of patient management). With respect to
anxiety levels, they suggest referrals to personal assistance
programs if available. In the area of co-worker support,
work to develop a supportive work environment with group
cohesiveness is recommended. They also suggest that less
experienced nurses, because of their increased incidence of
burnout, be targeted for special attention.
These findings were confirmed in a recent nationwide
study that included over 1000 PICU RNs.3 3 The report cited
issues concerning families as the most frequently perceived
stressor for PICU RNs, with staffing issues and concerns
about death and dying completing the top three. Also
reported was the finding that the amount of job stress
perceived by PICU nurses was the most important predictor
of both job satisfaction and organizational work satisfaction.
The next most important predictor of job satisfaction was
the quality of nursing leadership. The study concluded that
retention efforts for PICU nurses should focus on management strategies that empower staff to provide quality care
with specific interventions aimed at reducing the stress
caused by nurse-family interactions.
Fein34 has recommended strategies categorized as stress
reducing, altering the perception of stress, managing physical well-being, and enhancing coping skills. Strategies to
reduce stress include learning to say "no," distinguishing
work from home activities, spending time efficiently, and
developing friendship networks outside of work. In altering
the perception of stress, Fein 34 recommends increasing
self-awareness through introspection, reevaluating personal
and professional goals, determining what is important, and
accepting that which cannot be changed. Managing physical
well-being includes taking time out, treating oneself with
love and respect, learning to relax without drugs or alcohol,
exercising regularly, and eating for health. In addition,
organizational strategies aimed at managing stress and
preventing burnout are described in Box 4-4.

Time Management
One of today's major stressors is the perception that there is
not enough time to do everything that needs to get done. If
there is one thing most people would say that they would
like more of, it would probably be time. How do people find
time? The answer is that they don't. Time management is
really self-management. The challenge is not to manage
time but to manage oneself. CoveyS has identified four ways
that time is spent involving the concepts of urgent and
important. He has described a matrix with four quadrants in
which urgent and not urgent are on the horizontal axis and
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Organizational Strategies to Manage Stress
and Prevent Burnout

Provide adequate staffing.
Institute staff psychosocial rounds.
Allow participatory decision making.
Periodically review all policies, procedures, and guidelines.
Experiment with flexible scheduling.
Support and encourage creativity.
Increase personal accountability.
Recognize performance.
Establish professional support groups.
Encourage staff to express feelings.
Establish a nurses' journal club.
Promote personal growth by encouraging reading, writing,
teaching, and research.
Adequately orient new staff.
Teach stress management as part of orientation.
Encourage continuing education at all levels.

important and not important are on the vertical axis.
"Urgent" means that something requires immediate attention, and "importance" has to do with results-something
that will contribute to accomplishing high-priority goals.
Urgent matters are something to which people react, and
important matters are those in which is it necessary to
consciously act, to make things happen.
Activities that are both urgent and important are commonly referred to as "crises" or "problems." Everyone has
some critical activities in their lives, but others seem to
spend all of their time thrown from one crisis to another.
They are often referred to as "crisis managers." As a relief
from the stress of constantly solving crises, they sometimes
seek relief in activities that are neither urgent nor important.
They can thus run the risk of neglecting important yet not
urgent activities, as well as those that are urgent but not
important.
CoveyS also describes people who spend much of
their time dealing with urgent unimportant tasks. Although
they may think they are dealing with the highest priority
items, they are in fact reacting to the priorities of others, not
their own.
People who deal primarily with unimportant issues,
whether "urgent" or not, never address the highest priorities
and basically lead irresponsible lives. Effective people avoid
dealing with unimportant issues and spend most of their
time on the important priorities.
Effecti ve people spend most of their time dealing with
issues that are important but not urgent. This is how they can
reduce the amount of time spent with important-urgent
issues ("crises" )-by dealing with important issues before
they become matters of critical urgency. Important, nonurgent concerns include such things as vision, building
relationships, long-range planning, and exercising-things
people know they need but often cannot seem to find the
time to do.
To spend more time on the important nonurgent issues, it
is necessary to spend less time on all the unimportant ones.
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This will involve learning to say "no" to some activities,
some of which may appear urgent. This means deciding
what one's priorities are and sticking to them. It may then
be necessary to kindly and courteously say "no" to some
other things.
In organizing to spend as much time as possible dealing
with important nonurgent issues, Covel has found that four
key activities are involved: identifying roles, selecting
goals, scheduling, and daily adapting. As a method to
understand his principles, he recommends that people try
this experience by organizing I week.
Identifying roles is simply the practice of listing key
roles. These include the role of being an individual
and may include being a parent or a spouse, son or
daughter, professional, manager, committee member, volunteer, neighbor, or church member, among others. After
the roles have been identified, the next step is to think
of two or three important results that should be accomplished during the next 7 days in each of the roles. These
are listed as goals and should contain some quadrant II
activities. For scheduling, the recommended process is to
look ahead at the week and schedule time to achieve each
of the listed goals. Previous commitments that are in line
with established goals should then be added to the
schedule, and those that are not in line should be
rescheduled or canceled. Daily adapting is then the process
of prioritizing activities and responding to unanticipated
events in a meaningful way.
CoveyS believes that this type of organizing allows
people the freedom and flexibility to handle unanticipated
events, to shift appointments if necessary, and to enjoy
relationships and interactions with others while still knowing that their week has been organized to accomplish key
goals in every area of their life.
One method to accomplish more in less time is to be an
effective delegator. Delegation is used to get work done
efficiently and with optimal use of human resources (Fig.
4-5). Effective delegation requires knowledge and skill. It is
often said that it is easier to do a task oneself than to
delegate, which may be true for those who have not acquired
the knowledge and skill necessary to delegate effectively.
Initially, the work to be done must be identified and defined.
The individual to whom the work is being delegated must be
aware of the definition and description of the work and the
time frame in which it is to be accomplished. Helpful
methods establish controls and checkpoints so that the work
can be evaluated and maintain open lines of communication
and mutually agreed-on goals. 35
Stewardship delegation, as described by Covey, 8 is
focused on results instead of methods. This type of
delegation involves clear, direct mutual understanding and
commitment regarding expectations in five areas. It takes
more time in the beginning, but the time is well spent.
The five areas Covey is referring to are desired results,
guidelines, resources, accountability, and consequences.
With desired results, a clear, mutual understanding of what
needs to be accomplished is important. This is not telling the
person how to do the project, but rather stating what needs
to be accomplished and the time frame thaI is involved.
Guidelines refer to parameters within which the individual
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What tools are available to measure the success of
leadership? They are the same tools that measure the success
of the product being delivered-patient outcomes, customer
satisfaction, physician satisfaction, and staff satisfaction
plus the measure offered by Tichy and Cohen 2o-how well
the staff you lead are doing.

SUMMARY
In conclusion, this chapter has discussed the "essential-

Fig. 4-5 Leadership role of the nurse is significant during
multidisciplinary rounds.

should operate. These should not be overly restrictive but
should provide assistance so that the person does not violate
long-standing values or practices or have to re-create the
wheel. Be honest-let the individual learn from previous
mistakes and experiences. Do not tell people how to
accomplish their objective, just give them a start. In the area
of resources, Covey is referring to the human, financial,
technical, or organizational resources people can use to
accomplish their goals. Accountability means that specific
standards of performance and time frames for evaluation
should be determined in advance. Consequences are the
specific things that will happen, good and bad, as a result of
the evaluation. This could mean financial rewards, psychic
rewards, promotions, or other consequences.
With a stewardship type of delegation, even when it takes
more time initially, both parties benefit, and ultimately more
work is done in less time. Stewards becomes their own boss,
governed by agreed-on results, and they have the potential
to use their own creati ve energies to achieve the desired
results. In the words of Covey, 8 "Effective delegation is
perhaps the best indicator of effective management because
it is so basic to both personal and organizational growth."

Measuring Success
In The Leadership Engine: How Winning Companies Build
Leaders at Every Level, Tichy and Cohen 2o offer the
following question and answer: "How are you doing as a
leader? The answer is, how are the people you lead doing?
Do they visit customers? Do they manage conflict? Do they
learn? Do they initiate change? Are they growing and
getting promoted? When you retire, you won't remember
what you did the in the first quarter or the third. What you'll
remember is how many people you developed-how many
people you helped have a better career because of your
interest and dedication to their development. When confused about how you are doing as a leader, find out how the
people you lead are doing. You'll know the answer."

ness" of leadership in creating a world-class pediatric
critical care unit. Attributes and values such as teamwork
and building morale have been addressed; however, perhaps
the most essential ingredient to becoming a successful
leader is having a solid sense of self-esteem. Self-esteem
allows the leader to take risks and adapt to challenges and
avoid the pitfalls that cause many leaders to fail. These
pitfalls are so prevalent that they are the basis of the book
The Five Temptations of a CEO (l998)l3 It depicts five
behaviors that are essential for success in leadership and that
if not adhered to will cause the leader to fail. The behaviors
are described as temptations that must be rejected to
succeed. All of the temptations are rooted in a need for a
solid sense of self-esteem.
The first temptation is to focus on status rather than
results. This occurs when the leader is more concerned with
protecting career status and ego than in achieving results.
The second was described as choosing popularity over
accountability. This was discussed previously and is related
to being more concerned with being popular with direct
reports than with holding them accountable. The third
temptation is to choose certainty over clarity. It is the
temptation to ensure that all decisions are absolutely correct
before proceeding and stems from a fear of being wrong.
The fourth temptation is to choose harmony over conflict. In this scenario, the leader avoids heated discussions, disagreement, and conflict within the department
for fear that someone will get hurt. The result is making
decisions without the full benefit of everyone's ideas.
Lastly, the fifth temptation is to choose invulnerability
over trust. In this temptation, the leader is afraid to trust
others, to be vulnerable, and to create an environment in
which others trust him or her. It requires opening oneself
to being burned.
The one area singled out as that which will make or break
leaders in a changing environment is the establishment of
trust. Trust is defined as the "firm belief or confidence in the
honesty, integrity, reliability, and justice of another person." 36 Most of the struggles people encounter in providing
effective leadership have to do with a lack of trust. This
concept can be especially difficult for new nurse managers
or those who have been recently promoted because the need
to move forward at a rapid pace and make necessary
changes is countered by the necessity to move slowly in
establishing trust. A delicate balance must be achieved
between spending time developing trusting relationships
and spending time planning and acting on future goals. Most
importantly, as Covel has stated, "If you want to be
trusted, be trustworthy."
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Facilitation of Learning
Sandra Czerwinski
Eugene D. Martin

designed to support and enhance a well-defined clinical
advancement program.
A successful critical care unit-based professional advancement program recognizes varying cognitive levels
and staff nurses' knowledge and expertise and fosters
advancement through a wide range of clinical learning and
professional development experiences. Essential components of this program include an orientation program, a
continuing education plan, an in-service education schedule,
and an array of other opportunities for clinical and professional development. Unit-based advancement programs
are most effective when they are linked to the nursing
department's professional advancement program. In departments without central professional advancement programs,
the philosophy and goals of a unit-based program should be
congruent with the nursing department's stated philosophy
and goals and mission of the organization.
This chapter describes how professional development in
critical care nursing is facilitated through a staff development plan that supports a professional advancement model.
Based on the understanding that novices in practice focus,
interpret, and apply information differently than experts, a
unit-based plan that recognizes developmental levels of
practice best facilitates the professional advancement of all
staff members.
A professional advancement program for the development, recognition, and reward of expertise contains elements of both clinical and professional development strategies. The Synergy Model, developed by the American
Association of Critical-Care Nurses (AACN) Certification
Corporation, reflects the values and philosophy of professional advancement. 1.2 The model's ability to describe a
patient-nurse relationship that optimizes patient and family
outcomes helps to clarify the various contributions of
critical care nursing practice. The impact of these contributions can be measured based on the nurse's level of
expertise, and professional development strategies can be
focllsed to achieve the greatest influence on patient care.
Therefore critical care education should include multiple
opportunities for the promotion of both clinical and

RECOGNIZING CLINICAL DEVELOPMENT

Skill Acquisition Model
Synergy Model
RN I Practice
RN II Practice
RN III Practice
RN IV Practice
Clinical Advancement Process
Facilitating Clinical Learning
DESIGNING STAFF DEVELOPMENT PROGRAMS
FOR PROFESSIONAL ADVANCEMENT

Developing a Program Philosophy
Adult Learning Theory
Organizing Framework for Staff Development
Steps in Program Development
COMPONENTS OF STAFF DEVELOPMENT

Orientation
Designing a Competency-Based Orientation
Program
Preceptor Programs
Critical Care Nursing In-service Education
Continuing Education
Fostering Professional Advancement
SUMMARY

T

he activity and process of staff development are a shared
responsibility of the staff nurse, nurse manager, clinical
nurse specialist, unit educator, and staff development
department. Even though professional growth and development are facilitated by those in leadership positions, the
ultimate responsibility is assumed by the individual staff
nurse. Opportunities for professional development are best
supported when the staff development plan for a unit is
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professional growth. Although many of these opportunities
are ultimately interrelated for the advanced practitioner,
planning a comprehensive unit-based program that fosters
advancement necessitates separate consideration of these
two areas.
To best accomplish this objective, levels of practice
defined by Benner and supported within the framework of
the Synergy Model 2 •3 are used to illustrate aspects of clinical
development. Implications for planning and implementing a
program of professional advancement based on these levels
are then discussed, and broad performance characteristics
are described for each level. In addition, specific examples
are given to illustrate critical care behaviors typical of each
performance level.

RECOGNIZING CLINICAL DEVELOPMENT
Skill Acquisition Model
Dr. Patricia Benner applied a model of skill acqUlslllon
identified by Dreyfuss to nursing. 3 This model of skill
acquisition serves as a useful framework for understanding
how nurses integrate knowledge and skill over time and,
with repeated experience, progress from a novice to an
expert practitioner. Benner describes five levels of professional development: novice beginner, advanced beginner,
competent, proficient, and expert practitioner.
Benner describes lhe novice and advanced beginner as a
nurse who possesses little or no experience of situations in
which they are expected to perform? Behavior at these
levels is governed by rules, and these practitioners are
somewhat inflexible. The competent nurse has at least 2 to
3 years of experience in the same or similar clinical practice
environment. This nurse is beginning to set long-term goals
based on conscious, abstract, and analytical problem solving 3 The proficient nurse conceptualizes more of the whole
rather than individual parts. This practitioner learns from
experience and demonstrates more sophisticated decisionmaking skills. The expert nurse has enormous breadth of
experience and an intuitive grasp of each situation.
For each level of practice, Benner identifies clinical practice behaviors and teaching and learning needs 3
Benner's work is particularly important in the design and
implementalion of a clinical practice program that differentiates practice, as well as specialized continuing education,
because she connects specific aspects of clinical experience
with the nurse's level of practice.
Thus clinical knowledge development can be enhanced
by assisting the nurse at any particular level of practice to
focus on the knowledge and experience associated with that
level. Specific practice indicators for meeting advancement
criteria can be developed to help staff identify examples of
expected behaviors. It is important that staff understand
these examples as one way, rather than the only way, to meet
advancement criteria.

Synergy Model
Many problems are associated with recognizing and rewarding progressive clinical practice. 4 Historically, the most

skilled nurses moved away from the bedside into management and educational roles to pursue professional
advancement; expertise at the bedside failed to receive
recognition and reward. In the current healthcare environment, nursing leadership is challenged to find innovative solutions that define, recognize, and reward expertise
at the bedside. The Synergy Model achieves this by
describing nurses' unique contributions to patients' outcomes and defining nursing's best practice and value-added
services 2
The Synergy Model describes nursing practice based on
the needs and characteristics of patients and the demands of
the healthcare environment predicted for the future? The
model describes patients' characteristics that are of concern
to nursing, nurse's competencies that are important to
patients, and the outcomes that result when characteristics
and competencies are mutually enhancing . The model is
adaptable to all areas of nursing practice and is able to
capture neonatal, pediatric, and adult patient care experiences. The patient exists within a variety of continua, not
only reflecting the holistic and dynamic nature of the patient
in a time of physiologic instability but also recognizing the
family and community as essential components in determining a patient's outcome 5
Each patient and family possess unique personal characteristics that span the continuum of health and illness and
affect essential nursing care. The Synergy Model describes
eight patient characteristics that influence nursing care
needs. These characteristics evolve over time and present a
different picture as the individual's healthcare situation
changes. 6
The Synergy Model also defines nursing competencies?
The model articulates the wide variety of activities in which
nurses are involved every day and reflects the behaviors that
nurses often characterize as valuable to nursing practice.
These competencies describe the unique contributions that
nurses make. The competencies are clinical judgment,
advocacy, moral agency, caring practices, facilitation of
learning, collaboration, system thinking, response to diversity, and clinical inquiry. All of the competencies demonstrate the active combination of knowledge, skills, experience, and attitudes necessary to meet patients' needs and to
optimize outcomes. 2 Nurses develop competency within
each continuum so that they are able to meet the changing
needs of their particular patient population. Each of these
competencies is an essential part of nursing practice, but the
degree of importance is determined by the patient's
characteristics.
By combining the nurse competencies identified in the
Synergy Model and the behaviors identified in Benner's
levels of practice, a continuum of expertise can be developed that matches behavior with practice levels. It focuses
recognition and reward on clinical practice. The impact of
expert nurses on patient outcomes is presented in quantitative and financial parameters that can be understood
throughout the healthcare system. The model provides the
needed links between clinical competencies and patient
outcomes.
The levels of clinical nursing practice can be used as the
foundation for a clinical advancement program. As iIlus-
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trated in Table 5-1, four levels of nursing practice are
described using broad performance standards and specific
behavioral characteristics associated with a selected competency of the Synergy Model.

RN I Practice
RN I practice is based on Benner's description of the novice
and advanced beginners, those with little or no experience in
the clinical area. The rule-governed behavior that is typical
of this level practitioner is strict and limited. RN I staff
nurses tend to apply rules equally to all situations with little
or no ability to consider the context in which they are
applied? These factors significantly affect their ability to
perform the competencies outlined in the Synergy Model. 2
RN Is make clinical judgments based on policies,
procedures, and textbook knowledge. At this level, they
focus on one aspect of a situation and tend to weigh all
assessment data equally because they lack prior experience.
RN Is do not have a global perspective and will not be able
to predict the patient's clinical course if it deviates from the
norm. Collaboration is basic, which can be evidenced by
their limited participation in multidisciplinary teams and
their need to be coached through a situation. RN Is facilitate
learning by knowing what resources are available and using
them. They function as advocates simply by recognizing the
need and securing help to meet the need. They demonstrate
a basic awareness of the complex systems within the
healthcare system but need assistance to integrate this
knowledge into a meaningful plan of care. Clinical inquiry
behaviors are evidenced through the RN I's use of unit
resources and clinical experts. These nurses demonstrate
empathetic, compassionate, and helpful hands-on caring
practices.
New or relatively new graduates, nurses who have never
practiced in critical care, and experienced critical care
nurses new to pediatrics are considered RN I level
practitioners. Orientation expectations are consistent for all
new staff; though the rate at which orientation competencies
are demonstrated varies between individuals, depending on
past experience.
As RN Is complete orientation, learning experiences
from actual situations that illustrate one aspect of care can
be examined. These practitioners begin to see how the rules
are influenced by the situation but require help to integrate
the parts into the whole. RN Is benefit from repeated
experiences with similar aspects of patient care and from
mentors who can point out salient aspects of a patient's
response to care. These beginners, although competent to
provide safe care, benefit from assistance in interpreting
assessments and in setting priorities. They require support in
the clinical area so that important patient needs will not go
unmet. If they are to care for complex unstable patients,
close supervision and guidance are required.
As previously mentioned, RN Is respond to the situation
according to rules, focus on only one aspect of the situation,
and need help in setting priorities if the patient's response is
not the one that is anticipated. For example, an RN I caring
for a patient who requires emergency intubation can focus
only on the airway during the crisis. This nurse performs
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bag-valve-mask ventilation with 100% oxygen, has suction
available, and has the appropriate endotracheal tube and
laryngoscope blade ready. The nurse requires additional
support in this situation if the equipment malfunctions, if the
patient's vital signs become unstable, or if the intubation is
technically difficult. The RN I may be unable to recognize
the need for additional resources or be unable to secure
those that are obviously needed.
Educational opportunities, teaching methods, information, and content are provided in various forms to meet the
needs of the individual learners at this level. Formalized
lectures and presentations, unit in-services, self-study modules, computer-based learning modules, and bedside teaching are examples of learning activities that support the RN
I. Historically, these skill-based, technical offerings have
been the strength of unit- and hospital-based nursing
education programs. Access to these programs is readily
available through sources such as the Internet, professional
organizations, medical libraries, texts, and professional
literature. Costs for offering these basic classes to the RN I
are predictable because many of these programs already
exist. Evaluation of the effectiveness of these skill-based
programs is measured by behavioral changes in the practice
of the RN I. Successful integration of knowledge and skill
will enable this nurse to care for increasingly complex
critical care patients.
Support for this nurse is typically provided by the RN II,
who functions in the preceptor role. Overall guidance for the
development of the RN I is monitored by the clinical nurse
specialist, unit educator, or nurse manager. Peer review
processes, quality improvement activities, and exemplar
writing are introduced to the RN I.
The overall expectations of RN Is are that they identify
obvious patient care needs, provide safe care, and recognize
the need for more experienced assistance. The RN I benefits
from discussing the situation after the fact. Senior staff can
identify areas for improvement, provide positive feedback,
and allow RN Is to ask questions and practice skills.

RN II Practice
RN lIs, modeled after Benner's definition of competent
nurses, are characterized by their organizational abilities in
coping with the competing demands and shifting priorities
of clinical practice. 3 These nurses gain efficiency and the
ability to understand and react to a situation as a whole
rather than in parts. RN lIs have developed the ability to
recognize the unexpected turn of events and identify which
aspects of a situation are more important than others. This
increased knowledge and experience base enables them to
demonstrate a higher level of competence within the
synergy framework and have a greater impact on patient
outcome than RN Is.
RN lIs use more sophisticated critical thinking skills as
part of their clinical judgments. They question clinical
practices, compare and contrast alternatives, and recognize
that outcomes may vary. They collaborate more acti vely
within the multidisciplinary team and recognize the need for
patient and family participation in care decisions. These
nurses assess the patient and family's readiness to learn and
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!terformance Competency Document
!J>osition Title: RN I Entry Level

',6sition Swnmary: The RN I constantly demonstrates current, comprehensive, professional knowledge and skill in accordance with nursing standards and department policies
~!i'when caring for patients and their families. The RN I develops individualized and collaborative plans of care using appropriate standards of care and practice and demonstrates
~i'. effective communication to promote and maintain a professional environment.
IQllnical Judgment: Clinical decision making, critical thinking, and global grasp of the situation coupled with nursing skills acquired by integrating formal and experiential
~!' knowledge
'~"i!l

Behavioral Characteristics

Performance Outcome Level

Outcome Measurement Tools

',ecOgniZes the value of the nursing process.

Demonstrates application of the nursing
process. Assesses, plans, implements,
and evaluates patient care.

Patient/family/nurse interactions

Patient/family satisfaction
Self-evaluation
Director evaluation
Peer review
Clinical exemplar module
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iferforms physical, psychosocial, and devel-

f;: opmental assessment of the patient and
~k family. Identifies and documents deviations

~i( from the norm.

~~valuates, documents, and communicates
(',';' patient response to interventions and
" revises plan of care as indicated.
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Demonstrates clinical thinking skills through
early cognition of changing patient conditions, appropriately asking for assistance
and timely follow-up with prioritized
interventions.
References unit-based resource materials.
Documentation meets hospital standards.
Assesses and anticipates patient needs from
previous experiences.
Identi fies, establishes, documents, and
communicates plan of care based on
assessed patient characteristics. Patient
characteristics are:
Resiliency: capacity to return to or
achieve a restorative or optimal level
of functioning
Vulnerability: susceptibility to stressors,
which may impact the outcome
Stability: risks associated with overall
patient condition
Complexity: interaction of multiple
systems creating the patient's condition
Resource availability: access to social,
technical, emotional, or financial resources
Participation in decision making and care;
the patient/family's ability to collaborate
in care
Predictability: certainty of projected
outcome
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1~tervenes
~~,:

with safe, appropriate, and scientifically based nursing care.

tRemonstrates the knowledge and skills neces~~. sary to assess and lJ1tervene appropnately
~~. based on developmental age of patients
R:' and families served on the assigned unit.

Recognizes disease processes and surgical
procedures and their effects.
Completes and uses age-specific assessment
tools and individualizes to meet patient
needs.
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J'erformancc Competency Document
!fosition Title: RN II Competent Level
Position Summary: The RN II consistently applies specialized knowledge and skills in the management of nursing care for specific types of patient populations and their families .
.,,' The RN II recognizes the need for ongoing evaluation and inquiry to improve patient outcomes. The RN II develops patient-specific long-range goals and plans that are
Ii:. managed through organizing, prioritizing, and coping with multiple patient needs and skill requirements. At this level, expected performance outcomes are based on patient/
~'i: family/nurse interactions.
j:;linicaJ Judgment: Clinical decision making, critical thinking, and global grasp of the situation, coupled with nursing skills acquired by integrating formal and experiential
.:if..knowledge
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Standard

Behavioral Characteristics

Performance Outcome Level

Outcome Measurement Tools

Demonstrates application of the nursing
process. Assesses, plans, implements,
and evaluates patient care.
Questions situations and recognizes variances
in clinical outcomes.
Demonstrates critical thinking skills through
early recognition of changing patient conditions, appropriately asking for assistance
and timely follOW-Up with prioritized
interventions.
Documentation meets hospital standards.
Considers algorithms for treatment.
Identifies, establishes, documents, and communicates plan of care based on assessed
patient characteristics.
Patient characteristics defined as:
Resiliency: capacity to return to or achieve a
restorative or optimal level of functioning
Vulnerability: susceptibility to stressors,
which may affect outcome
Stability: risks associated with overall
patient condition
Complexity: interaction of multiple systems
creating the patient's condition
Resource availability: access to social, tech·
nical, emotional, or financial resources
Participation in decision making and care:
patient/family's ability to collaborate

Patient/family/nurse interactions

Patient/family satisfaction
Self-evaluation
Director evaluation
Peer review
Clinical exemplar
Action plan
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~~l1tegrates the nursing process into the

'i.e provision of safe patient care. Collects

~';: and interprets patient data.
!i!valuates, documents, and communicates
~in patient response to interventions and
~l'revises plan of care as indicated.
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rforms physical, psychosocial, and
.. developmental assessment of the
1[( patient and family.
Identifies, documents, and reports deviations
!iii!; from the norm.

i'"

;!Wtervenes with safe, appropriate, and sci en•
•
ufically based nursing care, Possesses

'il"·
•"1i,i:..1.•

I.

mastery of technical skills that enable a
. ",; response to the unique needs of the patient
and family.
.,!Pemonstrates competence in performaning
"Iifl: nursing skills in stressful, complex, or
.,it;! unusual circumstances

i;

J~eCognizes limitations of own experience and
~'. knowledge.
~:~

~

=

Completes and uses age-specific assessment
tools and individualizes to meet patient
needs.
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II)

...,"tl
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II)
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Anticipates and acts to prevent potential or
preventable problems.
Provides basic care for complex patients.
Participates in unit-based quality assurance or
quality improvement (QAlQI) activities.
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:>

Develops self-assessment skills to improve care
delivery.
Seeks new knowledge,

I

llPerformance Competency Document
iositioll 7Itle: RN III Proficient Level
l!\~osition Summary: The RN III demonstrates advanced knowledge and skills in the management of nursing care for specific types of patient populations and their families. The

~m~ RN III holistically views patient situations, anticipates exceptions, and implements a disease and treatment pathway in the planning of care and prevention of complications.
i i. The RN III leads to development and implementation of a interdisciplinary outcomes-oriented plan of care. The RN III collaborati vely develops strategies to manage the care
~i.: environment and negotiate the patient through the care experience. The RN III demonstrates commitment to nursing practice through unit-based leadership, educational
~k interventions with outcomes analysis, and quality improvement activities to enhance the provision of optimal practice outcomes.
lPinical Judgment: Clinical decision making, critical thinking. and global grasp of the situation, coupled with nursing skills acquired by integrating formal and experiential
ii: knowledge

l!J:ierformance Standard
"',,:

\W:f'
~onsiders patient as a whole person and
::1'_"

1::;' anticipates exceptions in care. Anticipates
r." a disease and treatment pathway in the
[,j'
l!f;: planning of immediate care and in the
'iii-' prevention of complications. Recognizes
i!z' subtle changes In patIent assessments and
iH: intervenes with considerations toward
~~,: multisystem interrelationships.
~~eadj)y identifies the rapid state in which a
WI patient's condition can change. Evaluates,
lit· documents, and communicates patient
i.!!,' responses to interventions and revises
"~: plan of care as indicated.

I

Behavioral Characteristics

Performance Outcome Level

Outcome Measurement Tools

Demonstrates and models application of the
nursing process. Assesses, plans, implements, and evaluates patient care.
Identifies, establishes. documents, and communicates plan of care based on assessed
patient characteristics.
Patient characteristics defined as:
Resiliency: capacity to return to or achieve a
restorative or optimal level of functioning
Vulnerability: susceptibility to stressors,
which may affect outcome
Stability: risks associated with overall
patient condition

Patient/family/nurse interactions
Unit-based impact
Outcome report to nursing division

Patient/family satisfaction
Self-evaluation
Director evaluation
Peer review
Clinical exemplar
Action plan
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r~j,

~~I .

Iii'
'Jntervenes with safe, appropriate, well[" planned, and scientifically based
~~, nursing care.
r,Demonstrates proficiency in performing
~; nursing skills in stressful, complex, or
unusual circumstances with minimal
assistance in assessment of patient needs.
'emonstrates advanced k.nolwedge of
,ilt emergency care practices and intervenes
th, appropriately.

Complexity: interaction of multiple systems
creating the patient's condition
Resource availability: access to social, technical, emotional, or financial resources
Participation in decision making and care:
patient/family's ability to collaborate
in care
Predictability: certainty of projected outcome
Initiates, uses, and updates standards of care to
support assessments and individualizes plan
of care.
Documentation meets hospital standards.
Identifies problems and uses QA/QI projects to
solve problems.
Anticipates and acts to prevent potential or
preventable problems.
Demonstrates speed and flexibility in prioritizing, recognizing, and intervening in all
aspects of care.
Maintains calm, professional demeanor during
crisis situations.
Directs the care of multiple complex patients
(charge nurse role).

'Iti

i~¢rforms comprehensive physical, psycho,li,;,
.

'i';,' socIal, and developmental assessment

Completes, revises, and individualizes agespecific assessment tools.

~1! of the patient and family.
J)emonstrates the knowledge and skills neces~!' sary to assess and intervene appropriately
f.: 'based on the developmental age of the
~:; patients served on the assigned unit.
1;~ Identifies, documents, and reports
if deviations from the noml.
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~sition Summary: The RN IV demonstrates a deep understanding of the unique meaning and imact of health and illness issues for the patient and family. Possessing a vast
~l\ background of experience. the RN IV recognizes and responds to the dynamic situation by using past experiences to synthesize and interpret multiple. sometimes conflicting,
~!i, sources of data. The RN IV models collaborative practice behaviors, provides mentorship, coaches. consults. and demonstrates professional commitment to the healthcare
';:'system. The RN IV cngages in the development and implementation of research. quality improvement, leadership, publication, and community education programs for the
~'advancement of clinical practice. The RN IV further performs analysis to demonstrate and support synergized. optimal patient. system, and professional outcomes.
~linical Judgment: Clinical decision making. critical thinking, and global grasp of the situation, coupled with nursing skills acquired by integrating formal and experiential
~' knowledge
lerformance Standard

Behavioral Characteristics

Performance Outcome Level

Outcome Measurement Tools

~ses independent nursing action to meet
mir unusual or stressful cIrcumstances.
!ecognizes and responds to the dynamic
~j;situation, using past experiences to
~\.;anticipate problems.
J1ashions judgments based on an immediate
~i,.grasp of the whole picture.
§ynthesizes and interpretes multiple.
~:; sometimes conflicting sources
~!l of data.

Demonstrates and supports peers in the
application of the nursing process.
Assesses, plans, implements, and evaluates
patient care.
Incorporates long-range planning at onset
of care.
Helps the family see the "big picture."
Collaborates as clinical consultant.
Identifies. establishes. documents, and
communicates plan of care based on
assessed patient characteristics.
Patient characteristics defined as:
Resiliency: capacity to return to or achieve a
restorative or optimal level of functioning
Vulnerability: susceptibility to stressors,
which may affect the outcome
Stability: risks associated with overall
patient condition

PatienUfamily/nurse interactions
Unit-based impact
Healthcare system impact
Outcome report to nursing division

PatienUfamily satisfaction
Self-evaluation
Director evaluation
Peer review
Clinical exemplar
Action plan
QAlQl activities

~1

"1, .
~1~
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,I'

~.

;;,i

1

Complexity: interaction of multiple systems
creating the patient's condition
Resource availability: assess to social, technical, emotional, or financial resources
Participation in decision making and care:
patient/family's ability to collaborate
in care
Predictability: certainty of projected outcome
'Jecognizes subtle changes in patient assess~" ments and intervenes with consideration
i~,!, toward multisystem interrelationships.
j·il:. Readily identifies the rapid state in which a
:!ii" child's or adult's condition can change.

Demonstrates critical thinking skills through
early recognition of changing patient conditions, appropriately providing assistance
and timely follow-up with prioritized
interventions.
Recognizes subtle trends and intervenes before
explicit diagnostic signs are evident.

.~valuates,

Completes and revises age-specific assessment
tools. Individualizes to meet patient needs.
Models hospital standards for documentation.

documents, and communicates
patient response to interventions and
revises plan of care as indicated. Performs
comprehensive physical, psychosocial, and
" developmental assessment of the patient
~!' and family. Identifies, documents, and
:i' communicates deviations from the norm.
#1>:

'~ecognizes

limitations of own experience and

,lii~ know ledge base.
lossesses mastery of technical skills that
~ii. 'enable a response to the unique needs of
mi:' patient and family.
[ilDemonstrates expert skills in performing
., nursing care in stressful, complex, or
unusual circumstances.

iii!',

lf~Adapted
tiih:

Develops and teaches peers sel f-assessment
skills to improve care delivery.
Interacts with community through inservices,
presentations, and/or publication.
Serves as a role model for the standard and
demonstrates professional practice based on
academic or clinical experiences. Demonstrates independence by taking initiative,
makes changes when appropriate, is selfdirected and creative, and requires lillie or
no supervision concerning standard.

from Clinical Practice Program, All Children's Hospital, 51. Petersburg. Fla.

n

::r

.....
III

~
~

U'I

.,.,
llJ

!:l.
;::;:
llJ
....

O·
OJ

o-h
r

I1l
llJ

:;

S'

lC

ID
W

94

Part II

The Practice Environment

can adapt available resources for learning. Many RN lIs are
assuming mentor and preceptor roles for newer staff and are
consulted about more complex patient care issues by
inexperienced staff. RN II staff nurses recognize situations
that may produce conflict and are active participants in the
resolution of ethical dilemmas. Care is planned with input
from the family, and decisions are based on this input when
possible. RN lIs have a deeper understanding of the health
system's effect on the patient and family and can anticipate
the impact of the system on patient outcomes. They recognize resources and seek help when these resources are not
available. Additional experience and knowledge allow the
competent nurse to function more effectively and have a
greater influence on the patient's safe passage through the
healthcare system. These skills engender patient trust and
improve satisfaction.
In the situation of the patient who requires emergency
intubation mentioned earlier, the RN II responds in a more
organized and proactive manner than the RN 1. The RN II
assists in airway management and has the appropriate
equipment and drugs ready. The patient's response to
therapy is anticipated, and the family is supported. This
nurse demonstrates some mastery to cope with the potential
emergency events that may be encountered. The RN II
closely monitors for hemodynamic instability as an anticipated complication during intubation. The nurse recognizes
the need to interrupt the intubation procedure if the patient
requires bag-valve-mask ventilation.
RN lIs learn best from simulations that allow them to
practice prioritizing, delegating, decision making, negotiating for resources, and problem solving in complex situations. They need to be challenged with increasing complex
problems to maintain interest and identify areas for learning.
Interactive case studies, journal clubs, and patient scenario
simulations conducted at the unit level offer an excellent
opportunity to challenge the critical thinking skills of this
nurse. Integrating nursing research into practice is encouraged at this level. Learning activities offered through
nursing education or staff development departments that
support collaboration, diversity training, preceptorships,
negotiation, self-assessment, and basic quality improvement
skills are important to the maturation of this nurse. Cost
management for these programs remains primarily at the
unit level and can be incorporated in time allotted for staff
meetings and unit-based in-service education. Personal
responsibility for lifelong learning is an emphasis at this
level and reflects the institutional culture as a learning
organization. Networking with professional peers for improved practice options is encouraged. Evaluation of the
effectiveness of these learning activities is measured in the
ability to care for complex patients, effectively act in a
preceptor role, participate in quality improvement activities,
and safely manage care in a rapidly changing patient care
environment.
Unit guidance for the RN II is provided by the RN III and
RN IV. Clinical nurse specialists, unit educators, hospital
educators, and nurse managers act in supportive coaching
roles. The RN II participates in peer review activities that

support practice improvements for colleagues. The RN II
demonstrates individual nursing competency through written exemplars and a self-evaluation process. Goals and
objectives developed by this nurse include plans for future
learning activities, which have an affect on patient
outcomes.

RN III Practice
RN Ills practice at a level that Benner defines as proficient. 3
These nurses visualize the clinical situation as a whole.
Judgment and decisions are based on experience and recent
assessments. These nurses achieve an even greater degree of
competency and can have a measurable impact on patient
outcomes.
RN Ills, who possess a minimum of 3 years of clinical
nursing experience, demonstrate the ability to assess and
evaluate the current clinical picture from a more global
perspective. 3 Nursing practice reflects judgments and decisions based on accumulated knowledge and experience. RN
Ills sort out the nonessential aspects of a case, recognize
subtleties, and intervene before they become a larger
problem. Provision of care reflects an understanding of
patients' needs as they progress across the healthcare
continuum. RN Ills are regarded as resources for specific
care issues and use data to assist in decision making.
Proficient nurses know what to expect in a given situation
and adjust plans in response to these changes. Because they
recognize the difference between essential and nonessential,
decision making is more efficient. Prioritization skills are
well developed, and these nurses recognize subtle aspects of
a situation that can significantly change the patient's
outcome. RN Ills function as clinical resources and preceptors, mentor new staff, and network throughout the healthcare system. They consistently integrate and formally and
informally evaluate knowledge retention of their patients
and fellow staff. Advocacy is highly visible in this level of
practice. RN IIIs anticipate areas of potential conflict and
work quickly to resolve issues. Cultural diversity issues are
routinely integrated into an inclusive and holistic plan of
care. RN Ills' knowledge of the healthcare system enables
patients to negotiate through the system more successfully.
Their practice can have a significant impact on patient,
family, and collegial relationships.
In the emergency intubation situation, the RN III
responds in a controlled and organized manner and may be
able to prevent the situation altogether. All resources are
available, and less experienced staff are encouraged to learn
from the experience. Communication with the family is a
priority, and questions are anticipated. The situation is understood as a whole, and the response is accurate, influenced by past experience and recent changes. This situation
is used as a learning opportunity for RN Is and RN lIs who
are nearby.
RN Ills learn best from case presentations and interactive
situations that focus on realistic clinical events. These
educational scenarios should have the same level of
complexity and ambiguity as real clinical situations to

Chapter 5 Facilitation of Learning

stimulate thought and promote critical thinking. Encouraging this level of practitioner to learn in a way that makes
sense is the best approach and encourages the advancement
of the current practice level.
Educational experiences for RN Ills are developed to
reflect the assessed learning needs of the individual practitioner. Nursing competencies emphasized at this level
include collaboration, systems thinking, clinical judgment,
facilitation of learning, clinical inquiry, and advocacy and
moral agency. Examples of learning activities that support
this level of practice include development programs for
presentation and communication skills, team-building acti vities, review and development of outcomes measurement
tools, and unit-based leadership development, such as
coaching and mentoring. RN Ills are involved in teaching,
coaching, and facilitating unit-based in-services, journal
clubs, and case study discussions. They facilitate unit-based
peer review processes and mentor RN Is and RN lis in their
practice. Accessing information from resources outside of
the system and professional networking activities that
improve patient care practices are expectations at this level.

RN IV Practice
RN IV staff or expert performers have broad experiences
and do not rely solely on rules, guidelines, or other dogma
to make decisions. The expert nurse focuses on the real
issues without consideration of numerous unfruitful alternative diagnoses and solutions. 3 The expert takes the entire
situation and past experience into account when responding
to patient situations. This response is often characterized as
intuitive and is an example of mastery: the ability to
recognize a wide range of subtle cues, extract maximum
information from those cues, and intervene decisively.3.7
RN IVs are able to demonstrate the competencies of synergy
most completely, and their practice has a significant impact on patients and implementation of cost-effective
interventions. 8
Staff at the RN IV level recognize subtle trends in their
patients and can often intervene before the patient's
decompensation. Itan09 found evidence that highly skilled
nurses make accurate judgments after only a few minutes of
patient contact. They are adept at managing complex
situations, and they manage intricate tasks considering the
concerns of the family and other healthcare providers. These
nurses are recognized as experts by physicians, and they can
often impact medical decisions because of the level of
respect that past performance has bestowed on them.
Expertise at this level results from repeated similar experiences that prompt the nurse to begin to make predictions
based on the patient's response.
These clinicians incorporate long-range planning at the
onset of care and help the family understand the broader
picture. They use creative approaches to empower patients
and families. Knowledge of current clinical practice is based
on both research and experience. Other clinical statI
consults these nurses; they set the standard for the unit and
practice specialty. They promote collaboration among cli-
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nicians and seek opportunities to teach, coach, and mentor
other staff. As expert clinicians, they educate less experienced staff. Facilitation of learning is a priority, and they
anticipate the need to learn. These nurses are willing to share
knowledge, and they often develop creative teaching
methods. Leadership and role modeling are an expectation
at this level. These nurses exhibit behaviors that are clearly
recognized as expert practice, so other staff use them to
guide and measure their own professional development.
When the situation is stable, RN IVs are in familiar
territory. When they are not knowledgeable about a situation, RN IVs will do whatever is necessary to understand the
situation. lo These nurses care for patients holistically and
incorporate cultural needs into the plan of care. RN lVs have
a much broader understanding of the healthcare system and
are able to procure necessary resources. Critical thinking
skills are well developed, and the art of negotiation is
practiced skillfully. Active participation in research and
quality activities is an important component of the role. RN
IVs encourage staff to question practice and use research
and quality initiatives to evaluate effectiveness. They
participate in professional activities, such as publishing and
speaking. They maximize patient outcomes because they
employ sophisticated assessment expertise, develop comprehensive plans of care, implement coordinated processes
to accomplish the goals of the plan, and influence the
success of the outcome.
In the emergency intubation situation, the RN IV may
first recognize the need to electively intubate early and enlist
a physician or colleague's assistance before the patient's
condition further deteriorates. The RN IV is able to
recognize a cluster of subtle cues as predictive and
meaningful. Holden and Klinger!1 studied ways that expert
nurses use critical thinking skills to differentiate cries in
infants. These researchers support Benner's findings that
expert nurses demonstrate increased problem-solving skills.
Even if unsuccessful in convincing the physician to act, the
RN IV is able to anticipate the patient's needs and responses.
Examples of learning activities for this level include
opportunities to strengthen teaching skills, participation in
quality improvement processes, and case management
practices. Specific types of educational programs offered
may include topics on research utilization, outcomes measurement tools and reporting, case management processes,
legislative issues, and leadership and negotiation skills.
The clinical nurse specialist serves as the resource for
nurses at all levels but provides important advanced practice
learning opportunities for RN IVs. Educational opportunities that enable dialogue with other clinicians and pertain to
realistic clinical situations are beneficial for nurses at this
level. This is especially true if these case studies contain the
many factors, subtle cues, and contextual meanings that
nurses consider in their daily clinical decision making.
Dealy and Bass 12 determined that expert nurses find it
harder to leave the bedside to pursue professional development opportunities. These nurses typically choose to develop themselves by interacting with professional colleagues. As an important resource person, the clinical nurse
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specialist further pinpoints the subtle warning cues with
which expert nurses identify and respond. Discussion of
these cues is instructive for staff at many levels and may
provide rich material for nursing research. RN IVs can
participate in and offer unique contributions to clinical
research.

Clinical Advancement Process
Clinical advancement programs were first developed in
1972 to recognize and reward increasingly effective nursing
practice. 4 These programs continued to evolve and began to
focus on recruitment and retention issues. 13- IS Although
these programs had a solid theoretical foundation and
acknowledged salary compensation issues, they did not
clearly identify nursing behaviors that contribute to improved patient's outcome. They also did not adequately
represent nursing satisfaction or fiscal responsibility.1O
Clinical advancement programs became increasingly difficult to defend in relation to return on investment to the
healthcare system as a whole.
Financial resources to support clinical education and
clinical advancement programs have been greatly reduced, yet these programs and services are directly linked
to the retention of experienced expert nursing staff. 16
Nurses who possess certain expert skills are highly
desirable and beneficial to the patient and organization.
Researchers have quantified the financial impact of expert nurses in decreased medication costs, decreased patient
falls, and increased quality of care. 10 A clinical advancement program that provides encouragement and guidance
for the development of nurses and nursing practice can
become an important tool in supporting organizational
fiscal and quality objectives.
A structured, well-defined clinical advancement process
can facilitate professional growth and personal feelings of
value and worth in the staff nurse. The key to accomplishing
these goals is implementing a model that links clinical
competence with patient outcomes. The impact of practice
evolution can only be recognized if clinical behaviors are
identified within levels and core characteristics of the most
expert clinicians are documented. s This process presents
comprehensive methods to specify essential competencies
and related skills that demonstrate advancement in diverse
clinical settings. The process enables the recognition of the
contributions of nursing to the patient and system. It
encourages staff to see that what they value about nursing
practice is reflected in the advancement process. They
become capable of defining themselves within the concepts
of nursing competence, patient characteristics, and outcome
measures. The process assists in the articulation of the worth
of clinical advancement from the perspective of patient and
family satisfaction, market share, recruitment and retention
cost offsets, cost benefit analysis or productivity, turnover,
and unexpected time off.
Advancement of staff from one level to another is based
on a variety of factors, including competent performance of
characteristic behaviors that represent current level of
practice, accomplishment of measurable outcomes, nurse

manager support, peer review, self-evaluation, budgetary
constraints, years of experience, and certification or academic qualifications at the expert level. This process should
be clear and consistently applied to all applicants. A written
guide to promotion at each level facilitates advancement and
enhances understanding of the program as a whole. Table
5-2 outlines an example of advancement criteria.
The clinical advancement process can be completely
centralized, completely unit based, or a combination of
both. For example, the process may be unit based for
advancement from RN I through RN III but centralized
for RN IV so that a consistent description of expert practice
throughout the nursing department exists and practice
outcomes remain focused on system-wide issues. Clinical
advancement can also be a centralized program built
around core competencies that have distinct behavioral
characteristics. These characteristics reflect the practice
specialty and have outcome measures defined within the
framework of that specialty practice. The competencies
define discrete practice skills that can be adapted to fit a
specific practice setting. Table 5-3 provides an overview
of specific outcome examples developed for a pediatric
intensive care unit.

Facilitating Clinical Learning
In the current healthcare environment, nurses are required to
possess an extensive body of knowledge and meet the needs
of the consumer and the organization. This responsibility
requires a lifelong process of professional development
targeted to specific levels of clinical practice. Professional
development staff apply knowledge of instructional strategies appropriate to each practice level to facilitate clinical
learning and promote job satisfaction. Benner3 suggests that
the way in which nurses approach problems is similar within
each level of skill acquisition. She proposes that learning
situations that pair a learner of one level with a preceptor
closest to the learner's own skill level are the most
successfuL 3 Adult learning theoryl7.18 supports this position because it involves the teacher's awareness of the
learner's readiness to learn the information or skill being
taught. Nurses can choose from many learning options,
such as academic education, continuing education, participation in research, collaborative learning, case studies, and
simulations.
Facilitation of professional advancement in a pediatric
critical care setting can be realized through a well-designed,
unit-based staff development program. This program is a
key element in the advancement process and promotes the
knowledge and skills necessary for continued professional
development. Dealy and Bass 12 identified numerous factors
that motivated nurses to seek professional development.
Their work illustrated clinical advancement programs as
strategies that promote professional growth.
A staff development program that reflects professional
advancement criteria offers nurses the means to achieve
professional advancement objectives. Furthermore, when
these two important programs complement each other,
nursing practice as a whole is strengthened.

,Practice Differentiation Program Guidelines
Practice Level Requirements
RN II: Competent Nurse

RN III: Proficient Nurse

RN IV: Expert Nurse

level
standards as described in
I performance competency
document (PCD)
~Qmpletes the exemplar learning module
first year evaluation

Maintenance of RN II
Maintains standards as described in
RN II PCD
Submits a clinical exemplar with annual
self-evaluation
Develops a plan with potential outcomes
defined for patient/family/nurse
Participates in peer review process
Receives yearly merit increase as
detennined by performance

Maintenance of RN III
Maintains standards as described in
RN III PCD
Submits clinical exemplar with annual
self-evaluation
Participates in peer review process
Develops plan with potential defined outcomes for the patient/family/nurse/unit
Receives yearly merit increase as
detennined by performance
Reports goals and outcomes to the
CAP Committee

Maintenance of RN IV
Maintains standards as described in
RN IV PCD
Submits clinical exemplar with annual
self-evaluation
Participates in peer review process
Develops a plan with potential outcomes
for patient/family/nurse/hospital
Maintains national certification, if
applicable
Receives yearly merit increase as
determined by performance
Reports goals and outcomes to the
CAP Committee

I~dvancement

Advancement to RN III
Has a minimum of 3 years of experience

Advancement to RN IV
Has a minimum of 5 years of experience

I~amlains

to RN II
year of RN experience
RN I performance competencies
lII!articipates in peer review process
IjDevelops a plan with potential outcomes
for the patient/family/nurse
IlAdvances to RN II with title change,
Advancement Program (CAP)
mcenllve, and yearly merit increase as
'determined by performance

in nursing

Meets RN II performance competencies
RN III position vacant and posted
Completes a request for transfer, if
appropriate
Interviews with respective department
director to discuss possible
advancement
Develops plan or enhances RN II plan
with potential defined outcomes for
patient/family/nurse/unit
Advances to RN III with title change,
CAP incentive, and yearly merit
increase as determined by
performance, if applicable

in nursing

Must possess specialty national certification or bachelor's degree
Meets RN III performance competencies
RN IV position vacant and posted
Completes a request for transfer, if
appropriate
Interviews with respective department
director to discuss possible
advancement
Develops plan or enhances RN III plan
with potential outcomes defined for
patient/family/nurse/system
Advances to RN IV with title change,
CAP incentive, and yearly merit
increase as determined by performance, if applicable

n
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Outcome Examples: Clinical Judgment-Infant Instability Assessment

f!lRN I

RN II

RN III

RNIV

(Recognizes child with signs

Identifies early signs of respiratory distress
Performs initial interventions
(e.g., bag-valve-mask
and cardiopulmonary
resuscitation)
Identifies respiratory distress
a~ a frequent situation on
the unit
Designs poster board and
"pocket pal" for staff with
references
Patient/family outcomes: lifethreatening situation
receives immediate
intervention
Nurse outcomes: demonstrates
ability to act effectively in
an emergency situation

Functions as a preceptor for
new staff; teaches assessment and communication
skills
Serves as a peer consultant on
the unit
Participates in hospital-wide
mock codes
Active member of the hospital Code Committee
Develops unit-specific protocol with respiratory therapy
personnel
Patient/family outcomes: lifethreatening situation
recei ves immediate

Functions as preceptor for
new staff; tracks retention
of staff
Participates in the development of outcomes for the
hospital Code Committee
Develops an interdisciplinary
protocol for the treatment
of respiratory distress,
tracks length of stay
(LOS), or functional status
on discharge
Develops algorithm according
to national standard and
presents at conference
Patient/family outcomes: lifethreatening sirnation
receives immediate
intervention
Nurse outcomes: demonstrates
ability to lead others in
effectively intervening in
an emergency situation
Unit outcomes: demonstrates
changes in system practices
that affect improvements in
service. cost, or outcomes

~.

1Jk of respiratory distress

i~otifies charge nurse and
~:i'" physician

~atientlfarnily/nurse out-

&t"
WL
~~

~1".
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i~~~
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m~:;
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t~

comes: practice demonstrates ability to assess
changes in patient condition and communicate
needs for assistance

I~[:l
~jr

liu,

ilf

11:'

intervention

Nurse outcomes: demonstrates
ability to act and support
others in effectively intervening in an emergency
situation
Unit outcomes: demonstrates
changes in unit practices
that affect improvements in
service. cost, or outcomes

iii'"
'2',-

b.

~Adapled from Clinical Practice Program, All Children's Hospital, St. Petersburg, Fla.
~

DESIGNING STAFF DEVELOPMENT
PROGRAMS FOR PROFESSIONAL
ADVANCEMENT
Multiple educational support components must be explored to support the development and maintenance of
a clinical advancement program within the critical care
setting, Learning activities, evaluation processes, and outcome measurement systems are aligned to meet the needs
of the program. Learning activities become directly linked
to improving patient outcomes, affecting system efficiencies, and influencing caregivers' satisfaction. A basic premise for staff development programs is that they support
learning and nurture individuals to engage in lifelong learning activities. 19
The fundamental aim of staff development programs for
critical care nurses is safe, competent practice. Comprehensive programs for staff development provide the essential resources to support and promote this goal. Similarly,
healthcare laws, regulations, and accreditation requirements
focus on the basic importance of safe, competent patient
care in an effort to protect the healthcare consumer. Professional nursing standards of practice likewise serve as guides
for ensuring safe practice and consumer protection. To en-

sure that the institution meets all current standards, those
responsible for designing critical care education programs
must be familiar with all of these prerequisites. The establishment of a staff development program that is linked to
clinical practice is key to the success of a professional advancement program.
The first step in establishing a staff development program
is the acquisition of finn support from both nursing and
hospital administration. This support requires a commitment
to provide the human, financial, material, and environmental
resources necessary to implement the program. Once this
commitment is secured, the nurse educator may begin to
structure the program.
Hospital-based critical care staff development programs
may be centralized or decentralized. Centralized programs
offer the advantage of maximizing resources within the
entire nursing department and standardizing programs
across units; whereas unit-based, or decentralized, programs
maintain separate budgets to specifically respond to the
needs of a particular unit.
Regardless of which option is chosen, the reporting
relationship between the critical care nurse educator
and nursing administration requires clarity. Once the administrati ve structure is in place, the program philos-
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ophy, goals, policies, and organizing framework may be
developed.

enhances the decision-making process, and encourages
continued learning. 24

Developing a Program Philosophy

Organizing Framework
for Staff Development

A philosophy statement consists of a set of beliefs related
to a specific issue. A comprehensive critical care staff
development philosophy reflects the beliefs and values of
the critical care area, the department of nursing, and the
hospital. This consistency reinforces the program's integration within overall hospital and nursing programs and
verifies a commitment to common goals. In addition, an
essential component of the critical care staff development
philosophy is a clearly stated philosophy of adult education
that defines learning and the factors that distinguish both
the role of the educator and the role of the learner. It is
important that underlying beliefs about learning are clearly
communicated.

Adult Learning Theory
Developing a philosophy statement that reflects adult
educational principles requires a working knowledge of
adult learning theory and the specific characteristics of adult
learners. Fox 2o asserts that the purpose of adult learning is
to enhance proficiency and improve performance. Pike 21
describes adults as "babies in big bodies," which implies
that they expect much and like to play while they learn. As
adult learners, nurses seek out learning experiences that
meet personal needs or are interesting to them relative to
their practice; they typically prefer to learn by doing rather
than by observation.
Knowles 18 and other theorists of adult learning describe
common characteristics of adult learners. They are selfdirected, problem-oriented learners who are guided by their
own values and come from a heterogeneous experience.
Unlike children, adult learners hold an independent selfconcept and value their personal time?2 Principles of adult
learning are derived from these characteristics.
The four principles of adult learning that are most
applicable to critical care nurses are those concerning
reinforcement, readiness to learn, goals, and the learning
environment.23 Reinforcement in the learning process may
be positive or negative. If a newly learned behavior
stimulates a positive response, the chances of the behavior
recurring are increased. Likewise, if a behavior leads to the
elimination of an undesirable response, that behavior will
most likely be repeated. For example, an RN I who correctly
manages a patient's slow cardiac rhythm by implementing a
newly learned treatment protocol is likely to follow that
protocol again.
Adults learn better if they perceive that an educational
program meets their personal goals. If program content
relates to their current concerns, they are more motivated to
learn. For example, nurses interested in working with
patients with a congenital diaphragmatic hernia will be more
motivated to learn about extracorporeal membrane oxygenation (ECMO) than nurses with other interests. Self-directed
learning promotes efficient self-management of learning,

Nurses are part of a large group of "knowledge workers"
currently in the workforce. Although nurses possess many
technical ski lis, the real talent that each nurse demonstrates
is the ability to assess and evaluate based on knowledge of
various healthcare processes. The work is accomplished by
making judgments based on the ability to gather information, identify problems, decide on an action, and accept
accountability for the outcomes.
Critical care staff development programs can be designed
to educate staff nurses within the competencies of the
Synergy Model 2 Each of these competencies comprises a
tract in the overall staff development program design and
serves as the link that connects the staff development
program to the professional advancement program. The
program is designed to build on the nurse's prior education
and professional nursing experience, which facilitates attainment and maintenance of competence. Concepts inherent to the educational process and to critical care nursing are
used as a framework around which educational programs
and professional development opportunities are organized.
Once defined, the organizing framework serves as the
structure within which all development programs for critical
care nursing staff are designed.
Skill education alone is no longer sufficient to meet the
care delivery needs of the nurse in the critical care
environment. Educational strategies that promote learning
in the clinical unit and use experiential methods are
incorporated into the educational plan. Critical care nurses
require extensive knowledge and proficiency in areas such
as communication, critical thinking, and collaboration. 25
They must acquire the diverse skills necessary to meet the
complex needs of their patients and families.
Clinical narratives are used to teach the competencies of
the Synergy Model. 2 Novice nurses learn and gain confidence by telling their stories and focusing on excellent
practices identified in the narrati ves of expert staff. Focused
group discussion and examination of the clinical stories add
to each participant's knowledge base, can clarify issues, and
redirect practice. For example, caring practices are taught
and reinforced by using stories that highlight relationship
building and the development of trust and support. According to Benner, Hooper-Kyriokidis, and Stannard,26 critical
care nurses disclose emotional responses in their clinical
narratives. These emotional concerns and relationships
direct clinical understanding and actions. 26 Much is learned
about critical care nursing, the art of paying attention, and
responding compassionately from reading these stories.
The theory and science of content necessary to meet the
synergy competencies include topics such as disease processes, nursing procedures, cultural differences, moral and
ethical principles and reasoning, research principles, and
educational learning theories. This information is presented
by lecture, written information, posters, self-studies, or
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computer-based technology. However, it is crucial that the
information is related to realistic clinical situations. Clinical
scenarios, case studies, and simulations representing the
dynamic and ambiguous clinical situations that nurses
encounter daily are most effective. These educational tools
are focused to define behaviors associated with specific
competencies.
Bedside teaching is particularly helpful in the development of clinical judgment and caring practice skills. Expert
nurses, however, serve as tremendous role models for any of
the competencies delineated by the Synergy Model. Novice
nurses learn by observing these expert nurses and emulating
behaviors. Clinical teaching also enables the novice practitioner to gain experience with unfamiliar interventions in a
safe and protected environment. Open discussion and
opportunities for questions about certain interventions
impact learning for all staff. Communication and validation
of clinical knowledge focus learning, positively affect
patient outcomes, and add to the total body of nursing
knowledge.
Information about research and research use builds
clinical inquiry and system thinking skills. Demystifying the
research, outcome, and quality processes significantly enhances these skills. Use of journal club formats and
supporting staff involvement in research assist in developing
clinical inquiry. Building knowledge in the areas of healthcare trends and political action assists nurses to expand their
systems thinking skills. Attention to the development of
critical thinking skills and problem-solving skills also
assists with development of systems thinking.
Facilitation of learning skills are acquired by incorporating communication development into the professional
development plan. Presenting clinical teaching strategies,
assisting staff to determine learner readiness, and assessing
understanding is also included. The importance of developing patience, flexibili ty, and a nonconfrontational styIe is
reinforced.
Collaboration skills are developed by focusing on content
such as negotiation, conflict resolution, time management,
communication, and team building. Role-playing, role
modeling, and clinical narratives are methods that have been
used successfully. Expert nurses teach less experienced staff
about the available resources that are helpful and how to
access these resources.
Nurses learn technical skills and scientific knowledge in
many ways, but the essential aspects of self-assurance,
caring practices, and advocacy are only developed through
relationships that evolve over time. 27 Nurturing, professional relationships with experienced staff are needed to
facilitate the novice's integration into practice 28 Experienced nurses who share their clinical knowledge and coach
other nurses have a tremendous impact on collective
learning. 29 Staff nurses who function as coaches are in their
roles because they are able to clinically influence and guide
situations. They demonstrate expert clinical and leadership
skills and facilitate the ongoing clinical development of
others.
Effective coaches are characterized by their ability to
(I) acknowledge and reward individual strengths and

accomplishments; (2) offer constructive, focused feedback;
(3) support further growth; and (4) challenge people's
proficiency with assignments that foster the individual's
skills. 3o Coaching of individual staff is an evolving process
that includes appraisal of current performance, mutual goal
setting, development of a feedback mechanism, and implementation of an improvement plan 31 The use of preceptors
and mentors as teachers and coaches is linked to providing
learning opportunities reflective of each level of practice.

Steps in Program Development
The steps in the process of program development for all
types of nursing education programs are assessment, planning, implementation, and evaluation. Following these steps
in an organized manner with specific time lines for each
ensures quality programming.
Assessment. The first step in developing an educational program is conducting an assessment to identify staff
nurses' educational needs, as well as those of the unit or
institution as a whole. The method used may be simple or
sophisticated, depending on the resources available. Five
methods commonly used are (I) interviews with the
leadership group, (2) nursing care audits, (3) quality
improvement/risk management feedback, (4) Joint Commission on Accreditation of Healthcare Organizations (JCAHO)
recommendations, and (5) staff surveys and interviews.
Drawing the information from more than one source
provides a broader perspective of needs and strengthens the
validity of the data obtained. Key elements to consider when
developing a needs assessment include patient population
and nursing population characteristics. Knowledge and
skills necessary to provide care to the patient population are
identified to ensure that the specific needs of the units and
nurse are addressed. Data are analyzed, and identified needs
are ranked. Once the priorities are established, the appropriate educational delivery method, costs, and objectives are
developed.
The needs assessment process is continuous to meet the
changing needs of staff and the institution. This may be
accomplished in part by incorporating needs assessment
questions into individual program evaluation tools.
Planning. Once the data from the needs assessment
are analyzed, program planning may begin. Overall goals
for each program are established first, and outcome statements emerge from these. They serve as a framework for
program design and guide the educator in selecting appropriate instructional methods. Outcome statements also
provide a means for evaluating whether competencies were
achieved and learning took place.
Outcome statements differ from traditional behavioral
objectives because they require learners to become competent in skills used in practice. 32 Behavioral objectives
typically focus on ways of learning and directions for
learning content. Writing outcome statements involves the
techniques of concisely stating what performance competence is expected, the extent to which it is expected, and how
it will be demonstrated. The use of subjective terms such as
understand or know should be avoided because it is unclear
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how to measure those behaviors. The use of action words
such as conduct, plan, integrate, provide, and engage reflect
practice-related abilities for which the content is learned.
Box 5-1 provides some basic criteria for writing competency outcome statements.
Outcome statements provide the nurse educator with the
basis for program format and design. The program content
and time frame are related directly to the competency
statements.
Implementation. Program implementation varies according to the teaching methods selected to meet program
outcomes. The leamers are encouraged to select the type of
teaching methods that best match their learning style. A
critical aspect of the educator's role is to ensure that the
environment is conducive to learning both physically and
psychologically.
Evaluation. Nursing education programs are evaluated in relation to the program goals, desired outcomes, and
other predetermined criteria. All those involved in the
program participate in the program evaluation. Nurse
educators and managers evaluate the relevance of each
offering to overall program goals, desired outcomes, and the
current scope of practice. Learners evaluate the program
content and teaching strategies relative to both the overall
program and indi vidual learner outcomes.
Abruzzese 33 developed a simple evaluation model that
describes various levels of evaluation from simple to
complex and is based on frequency of implementation and
cost factors. The Roberta Straessle Abruzzese (RSA) model
defines the first level as process evaluations. These evaluations are used for all educational programs and target the
learner's general satisfaction with the program. If adult
learners are not satisfied at this level, learning will be less
effective. An evaluation form using a 3- to 5-point scale with
qualitative descriptors such as agree/disagree or excellent!
poor is often used for this level of evaluation. Questions
focused on satisfaction with faculty, objectives, content,
teaching methods, physical setting, and overall program
management are often used.
The second level is content evaluation that occurs
immediately after the learning experience. This level of
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evaluation targets a change in knowledge, affect, skill, or a
combination of these. Content evaluation can be assessed by
using self-rating scales, pretests and posttests, simulations
or case studies, return demonstration, or multiple-choice
examinations. These criterion-referenced tools relate to the
expected outcomes and are compared with preset criteria.
The third level is outcome evaluation, which is used to
measure changes in clinical practice after a learning experience. These changes can be evidenced by integration of
a new value or skill or creation of a new product or process.
Outcome evaluation is generally performed 3 to 6 months
after an extensive learning experience. The evaluation takes
place on the clinical unit and can take the form of a
questionnaire, observation of practice, audits of changes, or
a system of self-report.
The fourth level is impact evaluation, which represents
an institutional operational result such as a positive impact
on quality, cost-benefit, cost effectiveness, decreased staff
turnover, improved staff retention, or decreased risk management issues. These evaluations are developed for programs that can possibly influence changes at the unit,
department, or institutional level. These tools are complex
and resemble a formal research measurement process.
Every program does not need all four levels of evaluation. The third and fourth levels are reserved for more
extensive and complex undertakings. The overall program
evaluation focuses on the congruence of goals and accomplishments for the educational offerings. Measurement is
accomplished through quarterly reports to administration,
cost-benefit analysis, cost-effectiveness reports, and updates
to a clinical advisory committee.
Developing valid and reliable evaluation tools is a
difficult and time-consuming process. The type of tool used
depends on the purpose and level of the evaluation;
therefore an existing tool with established validity is often
more desirable. Once the validity of the tool is established,
the results may be considered with confidence.

COMPONENTS OF STAFF DEVELOPMENT
Staff development programs can be divided into three major
categories: orientation, in-service, and continuing education
programs. Each of these programs has its own scope,
purpose, goals, and objectives. It is important that those
responsible for nursing education programs distinguish and
understand the difference between each category.

.

1. Use leamer-oriented wording.
2. Describe the essential competency (psychomotor, cognitive, or affective) to be achieved.
3. Use clear, specific, and concise language.
4. Write measurable statements.
5. Use action-oriented words.
6. Be consistent with standards, practice, and real-world
expectations for performance.
Adapted from Lenberg C: The framework, concepts, and methods of the
competency. outcomes, and performance assessment (COPA), 1999, in
Online Journal of Issues in Nursing, at hnp:/lwwwnursingworld.org/ojinJ
lopicI 0-2.hlm.

Orientation
The American Nurses Association (ANA) describes orientation as "the means by which new staff members are introduced to the philosophy, goals, policies, procedures,
role expectations, physical facilities, and special services
in a specific work setting. ,,34 This description implies
that all nurses who begin employment in a critical care
setting need to participate in some aspects of orientation regardless of their level of experience. For example,
a nurse who transfers into a critical care area from another area in the same hospital needs to be oriented to the
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critical care nursing role expectations, special procedures,
and services of the critical care unit. A nurse hired from
outside the institution with previous experience in critical
care also needs to be oriented to the new working
environment. The challenge for the critical care educator
is to design an orientation program that meets both
the individual needs of nurses from a variety of backgrounds
and unit-specific needs.
One way to accomplish this goal is to design a competency-based orientation program. "Competency-based education can be percei ved as a very broad concept that is used
as the conceptual framework for a total curriculum, or it can
be interpreted in a very narrow way, as a framework
for an individual unit of instruction such as a self-learning
module.,,35
A competency-based orientation model has six characteristics: (I) an empha~is on outcomes, (2) use of selfdirected learning activities, (3) flexibility and time allowed
for achievement of outcomes, (4) use of the teacher as
facilitator, (5) assessment of previous learning, and (6) assessment of learning styles. 36 A competency-based approach
to orientation facilitates a more positive experience for the
orientee through recognition of previously acquired knowledge and skills. For example, an experienced critical care
nurse would be frustrated to participate in electrocardiogram
recognition classes if that concept had been mastered. A
competency-based program enables orientees to select those
learning activities that meet their individual learning needs
and demonstrate mastery of those required competencies.
As some of these needs are satisfied or reprioritized
as a lesser need, others needs will be met in a "Maslowian"
sequence. 3? A new nurse orientee first seeks safety in the environment and then progresses through stages to attain
membership in the work tearn. At the end of a well-designed
orientation, orientees should feel comfortable in the environment and integrated into the staff.
Critical care internship programs have been extensively
used as a mechanism to recruit and train entry-level nurses.
These programs are specifically designed to introduce
nurses with little or no nursing experience into the complex
critical care environment. They provide extended clinical
support for novice nurses and introduce new knowledge
more deliberately than traditional orientation programs.
They focus on basic information and skill acquisition.
This focus builds on the knowledge and skills that these
nurses have previously acquired in their nursing school
programs. Program development can be supported through
the use of content outlines developed by AACN and can be
individualized to address specific needs of staff, patients,
and the institution. Teaching is characteristically under the
direction of a clinical nurse specialist or hospital educator
and usually involves the most senior staff as preceptors.
Typically, competency development is focused on the
delivery of safe care to the least complex patients. The
program is designed to establish a foundation on which
the novice can develop into a competent clinician. Critical
care internship programs are developed to meet the needs of
individual hospitals or health systems, so very little research

is available to measure the overall etfectiveness of these
programs. Internship programs can be costly, and outcomes
require careful monitoring to ensure effectiveness.

Designing a Competency-Based
Orientation Program
The steps to follow in designing a competency-based
orientation are the same as those discussed earlier for
program development, with emphasis on details specific to
orientation.
Assessment. During the needs assessment phase, the
competencies expected of an orientee in critical care are
identified. "The competencies identified should represent
realistic expectations of general categories of performance
for a beginning level staff nurse on that unit. ,,38 The orientee
should not be expected to function at the same level as
senior staff by the end of the orientation period.
The process of identifying required competencies necessitates a comprehensive exploration of the specific field of
practice. Resources to assist in identifying entry level
competencies include (I) staff nurse position descriptions,
(2) JCAHO requirements, (3) professional standards of
practice (e.g., ANA and AACN), (4) review of the literature,
(5) needs of the patient population on the specific unit, and
(6) consensus of expert practitioners. Analysis of the
information compiled from these resources provides the
nurse educator with a foundation for formulating orientation
competency statements. The greatest challenge in this
process is to gain consensus from preceptors, staff, and
managers regarding levels of competence to expect from
orientees. Once this is achieved, the nurse educator ensures
that these competencies are clearly stated and attainable by
all orientees.
A competency statement is a broad sample of behavior
that integrates knowledge, psychomotor skills, and attitudes.
These broad competency statements are then separated into
specific tenninal performance criteria that are observable

~
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Box 5-2
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Sample Competency Statement .
With Related Performance Criteria

Competency
I. Provides safe nursing care for the patient who requires

temporary cardiac pacing
Performance Criteria

I.
2.
3.
4.
5.
6.

Identifies clinical indications for temporary pacing
Labels wires A and V
Dresses insertion sites with occlusive dressing
Secures wires with 2-inch piece of tourniquet
Changes battery
Documents pacemaker function, settings, and patient
response
7. Supports patient and family throughout the period of
temporary cardiac pacing
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and measurable examples of expected behaviors for demonstration of competency.
Competency statements and performance criteria are
developed collaboratively with all those involved in orienting and evaluating new staff. This approach strengthens the
validity of the competencies identified. Box 5-2 illustrates
an example of a competency statement with its related
performance criteria.
Planning. The next step in the orientation process is to
consider which methods of evaluation are appropriate for
determining attainment of performance criteria. The educator may choose among a written test, a skills laboratory
inventory, a performance checklist, or a case study, depending on the nature of the criteria; sometimes a combination of
two or more methods is preferable.
Prerequisites may exist for certain competencies before
they can be achieved (e.g., knowledge of institutional
policies or basic knowledge in critical care nursing). These
prerequisites, along with the identified competencies, dictate
the core content for critical care orientation.
The content outline for orientation is structured in an
orderly manner that reflects the organizing framework of the
staff development program. Performance criteria may be
arranged according to knowledge, competence, and role and
is integrated into the core content outline. The instructional
methods for teaching this core content are then delineated.
Whenever possible, more than one instructional design is
provided to enable orientees to select their own learning
methods. Table 5-4 lists appropriate instructional techniques
according to the type of behavioral outcome expected. The
time frame for achievement of orientation competencies is
also negotiated. Depending on the orientee's level of
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competence and the complexity of the unit, this may range
from 6 weeks to 6 months. All these negotiated conditions
may be written into a learning contract to serve as a guide
for implementation and ongoing evaluation.
Implementation. A competency-based orientation
program may be implemented using a variety of formats.
The role of the nurse educator is to facilitate the acquisition
of required competencies. This may involve some formal
classes or skills-building workshops, depending on the
orientee's needs and learning styles. A novice critical care
nurse requires close supervision and continuous instruction. 3 An expert critical care nurse may demonstrate
knowledge on written tests and validate current competence
in performance of identified skills but may need instruction
on role expectations specific to the institution. In each case,
goals may be set for every day or week of orientation, which
serve as guidelines for ongoing feedback for the orientee.
During the implementation phase of orientation, the
expected level of competence must be clear to the orientee
and educator. For example, competence in hemodynamic
monitoring involves setting up equipment, assisting with
insertion, identifying waveforms, troubleshooting, interpreting data, and analyzing the data concurrently with the
clinical assessment of a specific patient. These tasks can be
overwhelming to an orientee. A well-designed orientation
program will allay some of a new orientee's anxiety by
making specific expectations clear. Specific behaviors expected of an orientee relative to all competencies are stated
explicitly.
Evaluation. Program elements (the program itself, the
educator, and the orientee) are evaluated at the end of
the orientation period, The orientee may be evaluated using

lfI'AIlLE5-4 .·Behavior~1 Outcome~
I~e of Behavioral Outcome

Most Appropriate Technique

Ijnowledge
ill1~neralizations about

experience; internalization of information

m~c
I~~j,nderstanding
fj~pplication of information and generalization
rug;

liN' .

?1::I~kills

,"I::'

Lecture, videotape, debate, dialogue, interview, symposium,
panel, group discussion, book-based discussion, reading
Audience participation, demonstration, dramatization, problemsolving, discussion, case study, games

Ij::l.llcorporation of new ways of performing through practice

Role-playing, games, participative cases, skill labs

i~doption of new feelings through experiencing greater success

Experience-sharing discussion, group-centered discussion, roleplaying, critical incident process, case method, games

I~ttitudes

lil.With them than with old
dJd'Values
I~doption and priority arrangement of beliefs
.•:
ll'
@lEi': '.

I,

Videotape, lecture, debate, dialogue, symposium, dramatization,
guided discussion, experience-sharing discussion, role-playing,
critical incident process, games

~lJtterests

JS,atisfying exposure to new activities

1m::'
ill1"

Videotape, demonstration, dramatization, experience-sharing
discussion, exhibits
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the methods outlined in the planning phase of the program.
An evaluation of overall job performance may also be
included.
Orientees also evaluate how well the orientation program
met their individual needs. The quality and appropriateness
of instruction are part of that evaluation.
All those involved in the orientation process evaluate the
program as a whole related to outcomes. This process
should occur formally each year. The relationship of the
orientation program outcomes to expected outcomes for
the unit or the nursing department should be evident. Based
on the evaluation data, recommendations for revisions may
be made.

Preceptor Programs
For several years, preceptorship has been a popular approach to unit-based clinical orientation of critical care
nurses. This person oversees the new staff nurse's orientation process in conjunction with the nurse manager, clinical
nurse specialist, or nurse educator for the unit. The preceptor
negotiates a learning contract with the orientee based on
identified learning needs. During this process, the preceptor
introduces the orientee to both written and unwritten
policies and practices of the unit.
Preceptors act as role models, socializers, and educators. 39.40 They introduce the orientee to staff nurse role
expectations by demonstrating clinical competence, good
communication skills, and strong organizational skills. The
preceptor socializes the new staff member into the work
group through introductions to other nurses and by providing formal and informal opportunities for interactions with
several members of the healthcare team during the orientation period.
The chief component of the preceptor role is that of
educator. The preceptor assesses, plans, implements, and
evaluates an individualized orientation plan with the orientee. The plan includes consideration of the orientee's
previous experience and identified learning needs. At this
point, the preceptor may clarify the expectation that the
responsibility for meeting orientation requirements rests
with the orientee. The preceptor acts as a resource and
facilitates the orientee's accomplishment of program requirements. Clinical teachers consider the leamer's level of
practice and present information based on the individual's
cognitive style. Selection criteria for preceptors are clearly
defined before embarking on such a program. Common
criteria include (I) clinical competence, (2) exemplary
interpersonal skills, (3) teaching ability, (4) leadership
ability, (5) conflict-resolution ability, (6) commitment to the
program, and (7) a positive attitude. 41 . 43
The role of the clinical nurse specialist or the nurse
educator during the unit-based orientation is to establish
ongoing communication and facilitate a trusting preceptororientee relationship. This goal may be achieved through
weekly meetings with the preceptor and orientee to review
accomplishments, set goals for the following week, and give
feedback to the orientee. It also is an opportunity for the
nurse educator to assess the preceptor-orientee relationship.

Many institutions require preceptor experience as
one criterion for clinical advancement. Others consider it
as professional recognition and responsibility without related promotional or financial reward. Whatever the institution's philosophy, some mechanism of positive reinforcement of the preceptor role must exist to avoid burnout.
Alspach 44 proposed a preceptor's bill of rights, which
includes the right to role preparation. 44 This is best
accomplished by providing a preceptor development workshop. Workshop content includes (I) a description of the
preceptor role, (2) an overview of adult learning principles,
(3) steps in orientation needs assessment, (4) communication skills, (5) conflict-resolution strategies, and (6) evaluation strategies.
The workshop design should be highly interactive and
provide participants opportunities in role-playing and clarifying expectations. A review of both central and unit-based
orientation programs at the workshop is also essential.
Preceptors need a clear understanding of the orientation
program's goals and desired outcomes to maintain program
consistency. This preceptor development workshop serves
as a prerequisite to each preceptor's role in program
evaluation and revision.
Follow-up sessions or "advanced" preceptor workshops
are recommended to continue to support the development of
expert preceptors. These sessions provide experienced
preceptors with an opportunity to clarify issues and meet the
changing needs of orientees, as well as recognize the
preceptors' commitment to the program. Nurse managers
and nurse recruiters may be invited to participate at these
meetings to offer feedback to the preceptor group. These
sessions should be continuous and responsive to the needs of
preceptors if they are to support them in fulfilling role
expectations. Moreover. this kind of support from the
leadership group enhances retention of these vital staff
members and promotes collaboration between educators and
managers.

Critical Care Nursing In-service Education
In-service education programs, the most common type of
staff development activity, involves learning experiences
provided in the workplace to assist staff in the performance
of assigned functions and maintenance of competency.45
These programs are usually informal and narrow in scope.
They are often unplanned, spontaneous sessions that arise
from new situations on the unit in settings such as patient
rounds or staff meetings. Examples of planned in-services
are demonstrations of new equipment, procedure reviews.
and patient care conferences.
These activities are the most unrecognized types of
educational programs, and subsequently they often are not
well documented. The astute nurse educator develops a
mechanism for documenting these learning activities as part
of the unit-based education program. The documentation
substantiates ongoing efforts to ensure competence and
compliance with JCAHO and other regulatory requirements.
In-service education, however, does not meet the criteria
for continuing education credit in nursing. The scope of
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these programs is limited to the specific work setting and
not necessarily to overall professional development of
individual nurses. This distinction should be clarified with
nursing staff who may be expecting continuing education
credit from fire safety classes or other institution-specific
in-services.

Continuing Education
The category of staff development activity that is in highest
demand is continuing education. This need has been fueled
by legislation, regulations, professional standards, and
expectations of healthcare consumers. Continuing nursing
education is an ongoing process that includes planned,
organized learning experiences designed to expand knowledge and skills beyond the level of basic education. 46 The
focus is on knowledge and skills that are not specific to one
institution and build on previously acquired knowledge and
skills. Examples of continuing education programs include
formal conferences, seminars, workshops, and courses.
Limited financial and human resources, as well as evol ving technologies, have encouraged the use of more creative
educational strategies. Self-study, interactive computerbased programs, Internet options, case studies available on
compact disk, and various distance learning opportunities
have decreased classroom time and made education programs more accessible.
Accreditation of continuing education programs is the
process by which an approving body recognizes that a
program meets its required standards. The accreditation
process in nursing is accomplished primarily through the
ANA. The ANA Board on Accreditation has specific criteria
that must be met for approval of continuing education credit.
The ANA also has a mechanism for nursing associations
to become accredited as approvers of continuing education
so that an organization can approve the programs of its
constituents. The AACN is one such accredited approver.
The measure by which continuing education credit is
awarded is the 50-minute contact hour. For every 50 minutes
of a planned, organized learning activity, I contact hour may
be awarded. Partial credit may also be awarded. Three
categories of continuing education may be approved for
continuing education credit: an offering, program, or
independent study. A summary of definitions and examples
of each one is provided in Table 5-5.
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The educational design criteria for all three categories of
continuing education are similar. All of the defined criteria
must be met to obtain continuing education credit. Each
criterion is listed on the application for approval for
continuing education credit.
The institution's provision of ongoing continuing education rellects two commitments to the nursing staff and to the
public they serve. The first is to ensure that patients are
cared for by nurses who are current in their practice. The
second is a commitment to meet the changing learning needs
of the nursing staff so that they are able to maintain
competence.
The establishment of a comprehensive staff development program sustains varying levels of knowledge and
skill in the educational preparation of nursing staff. It
provides a climate that supports career development and
fosters excellence in clinical practice. Nurses who practice
in this type of environment are encouraged to accept new
challenges in clinical and professional arenas and are
supported through the growth process on the road to
advancement.

Fostering Professional Advancement
Fostering professional advancement includes stimulating
growth in clinical knowledge and skills, as well as promoting development of the nurse as an active participant
in the profession of nursing. Supporting this type of growth
and professional involvement requires that the educator be
in touch with a variety of professional activities, opportunities, and resources appropriate for staff at all levels. These
opportunities can and should be identified at the unit and
institutional level (e.g., unit or interdepartmental councils,
committees, or task forces), at the state level (e.g., state
nurses associations, state political movements or organizations related to healthcare policy, healthcare program grants
administered at the state level), and nationally (e.g., national
nursing organizations, federal grants, and national policy
agendas related to healthcare).
Formal and informal opportunities exist for staff to
participate in professional development activities at the unit,
institutional, local, state, or national level. These may
include activities such as clinical role modeling, formal
education, development of areas of expertise, certification,
leadership role development, peer review, professional

5·5 Categories of Continuing Education
Definition

Examples

~Pffering

A single educational activity that may be presented
once or repeated

ECG Workshop
Nursing Grand Rounds

'·fProgram

A series of offerings that have a common theme
and common overall goal.

National Teaching Institute
CCRN Core Review Program

Self-paced learning activity developed for use by
an indi vidual learner

Professional journal CEU articles
Computer-assisted learning modules

iii?'

I:'
..r~.;'-

~dependent

I,·

study module
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presentations, writing for publication, and participation in
nursing research related to critical care.

SUMMARY
Professional development activities are numerous in pediatric critical care and can serve to enhance and enrich
clinical practice. They are supported at various levels of
the organization and are direct!y linked to a professional advancement program that focuses on clinical

support and educational development at the clinician's level
of nursing practice. The concept of professional advancement reflects the institution's commitment to quality
healthcare for consumers and to the protection of critically
ill pediatric patients who are cared for by highly skilled
and knowledgeable staff. A program that combines opportunities for professional growth and development with
a professional advancement program that recognizes and
supports nursing staff at all levels of practice can best meet
these goals.
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Advocacy and Moral
Agency: A Road Map for
Navigating Ethical Issues
in Pediatric Critical Care
Cynda Hylton Rushton
triumphs more rewarding than in almost any other kind of job.
The Slakes are so high: whole lifetimes.

WHAT Is ETHICS'?
ETHICAL PRINCIPLES FOR DECISION MAKING

Peggy Anderson'

Balancing Benefit and Harm
Respect for Persons and the Role of Children
in Decision Making
Autonomy and Informed Consent
Truth Telling: The Ethical Principle of Veracity
Justice
An Ethic of Care

N

urses accompany pediatric patients and their families
on an uncertain journey from aggressive treatment
aimed at cure, recovery, palliation, or-when cure is no
longer possible-toward a peaceful death. Nurses assist
patients and families in finding safe passage through the
complex maze of decisions and treatment options. The
situations that arise within pediatric critical care raise ethical
questions concerning the rights of children to make their
own treatment decisions, the status of parental rights, the
obligations of nurses and other healthcare professionals to
prevent and relieve suffering, and society's beliefs about
how children should live and how they should die.
These questions arise in a context of increasingl y scarce
human and economic resources, health systems in disarray,
and healthcare providers who are grieving the loss of their
previous professional roles and relationships. These issues
are often surrounded by confusion, ambi valence, and
tension on the part of healthcare professionals, patients, and
families. The emotional intensity that surrounds the care of
critically ill children can magnify the ethical concerns.
The myriad ethical questions that surround the provision
of pediatric critical care often arise from specific treatment
choices such as do-not-attempt-resuscitation (DNAR) decisions, abatement of life-sustaining therapies including
medically provided hydration and nutrition, use of innovati ve therapies, or pain management. Individuals may wonder, for example, whether it is morally justified under any
circumstances to forgo life-sustaining therapy provided to a
young child who has significant morbidity and a small
chance of survival.
Ethical questions may also arise because there are
genuine value conflicts about the right thing to do and the
proper outcomes to pursue. For example, parents and
professionals may disagree about which values ought to
guide the treatment of a child with a life-threatening disease
such as cancer or congenital heart disease. Evaluating the

ETHICAL ISSUES IN PEDIATRIC CRITICAL CARE

Forgoing Life-Sustaining Treatment
Cardiopulmonary Resuscitation
Medically Provided Hydration and Nutrition
Pain Management
Euthanasia
DECISION-MAKING MODELS

Shared Decision Making
Synergy Model
Partners on the Journey: Critical Care Nurse
Advocacy
PARENTS' AND CHILDREN'S RIGHTS

Limits to Parental Authority
The Courts
NAVAGATING THROUGH ETHICAL ISSUES

Addressing Conflict
Environments That Support Ethical Practice
SUMMARY

Being a very ill child or the parent of a very ill child must test
the outermost limits of human tolerance ... being involved in
the care of very ill children must be one of the most demanding
responsibilities in the world, the failures more awful, the
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possible goals for the child involves important values about
what makes life meaningful and what sorts of burdens are
acceptable in order to achieve those goals. The parents may
value the possibility, however small, to promote survival
and therefore have a high threshold for the burdens they will
tolerate in order to give the child a chance for life. The
treatment team, in contrast, also values gi ving the child a
chance for life but their threshold for reasonable burdens
may instead be based on the possibility that survival may
commit the child to a life of burden they believe is
disproportionate in relation to the chance for survival now
and into adulthood.
Nurses working in pediatric critical care may experience
frustration and anguish as they watch children struggle
against formidable odds and observe parents grapple with
some of the most difficult decisions a family can ever
confront. Nurses watch children bear the consequences of
disease, injury, and technology. A nurse's perceived inability
to minimize or eliminate tragic outcomes brings on feelings
of powerlessness and helplessness. The demands of the
critical care unit are hectic and at times unrelenting. Tasks
are accomplished under high personal and professional
tension. Ethical dilemmas grow as some children's lives end
before potential is reached and other children's lives hang on
too long. It is within this complex environment that nurses
experience moral uncertainty, moral dilemmas, and moral
distress.
Andrew Jameton sorts the mora) problem nurses face into
three categories 2 :
1. Moral uncertainty-When one is unsure of which
principles or values apply, or even what the moral
problem is.
2. Moral dilemmas-When two or more clear moral
principles apply. but they support mutually inconsistent courses of action.
3. Moral distress-When one knows the right thing to
do but is prevented by institutional or other constraints from pursuing the right course of action.
Moral uncertainty and moral dilemmas produce discomfort because of the nurse's inability to decide what is the
right thing to do or the proper outcome to pursue. Moral
distress, on the other hand, produces negative feelings
because of the nurse's inability to maneuver through the
environment, to do what he or she believes is right.
This chapter describes the specific moral issues that arise
in the care of sick children and discusses the ethical
principles of beneficence, nonmaleficence, autonomy, and
veracity as they relate to pediatric critical care. The
discussion of these principles along with a model for
decision making will provide the nurse with practical
assistance in sorting through the ethical dilemmas typically
present in the pediatric critical care unit.

WHAT IS ETHICS?
Ethics is concerned with the behavior, choices, and character of individuals and groups. More specifically, ethics is the
study of the process for deternlining the best course of

action in the face of conflicting choices. Most people have
a sense of what is right and what is wrong. These values
are developed while growing up within a society that
teaches specific social rules, expectations, and prohibitions.
"Morality tells us not to harm others, not to kill, to be good
persons, to keep promises, and to tell the truth.,,3 Morality
provides us with general rules of conduct; it tells us whether
the consequences of actions are good or bad. Thus people
form opinions about how one ought to act and what one
ought to believe in certain situations.
Ethics, however, refers to the systematic study of
principles and values. It is a discipline that looks at the way
people act and asks whether their actions are good or
harmful. The study of ethics goes beyond what is and asks
what ought 10 be. In asking these questions, ethical inquiry
helps form and change moral conduct. Ethical questions
arise alongside, but differ from, fundamental social, legal,
political, professional, and scientific questions. For example, public policies and laws surrounding end-of-life care set
boundaries for human behavior but do not necessarily
correspond to an individual's sense of what might to be.
Practically, ethical issues in the clinical arena primarily
involve problem solving using a systematic process. 4
Ethical deliberation involves a process of discernment,
analysis, and articulation of ethically defensible positions.
and then acting upon them. Ethical thinking helps give a
reasoned account of an ethical position and move beyond
intuition or emotions. The goal of ethical deliberations is not
to achieve absolute certainty about what is right, but rather
to achieve reliability and coherence in behavior, choices,
character, process, and outcomes. This requires that participants make reasoned judgments about the justifications that
are offered to support a particular course of action.
Judgments should be grounded by ethical theories and
principles to avoid making decisions based solely on
individual opinions 4

ETHICAL PRINCIPLES
FOR DECISION MAKING
Balancing Benefit and Harm
Based on the principles of beneficence and nonmaleficence,
healthcare professionals seek to promote the well-being of
their patients and to reduce or alleviate harm. The Code for
Nurses of the American Nurses Association (ANA) stresses
the alleviation of suffering as a nursing duty over saving life.
The ANA Code for Nurses states: "Nursing encompasses
the promotion and restoration of health, the prevention of
illness and the alleviation of suffering.,,5 When promoting
"good" such as health. relief from pain and suffering, and
the prevention of illness, nurses may seek answers to these
difficult questions: How do you know what is good in a
specific situation? Can circumstances alter the perception of
what is good? When does doing good become harm? Who
decides what is good? Is one doing good when one
continues to treat a critically ill child for whom there is no
hope? Is one doing good when a child in a persistent
vegetative state continues to receive antibiotics, food, and
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fluids? Is one doing good when a 15-year-old child is forced
to continue chemotherapy against his or her wishes?
Choices among treatments should benefit the infant or
child, and clearly outweigh the associated burdens and
harms. This "best interest" principle relies on subjective
and objective weighing of the benefits and burdens of each
therapy. 6 Weighing of benefits and burdens occurs within a
framework of patient/family goals and preferences, treatment goals, and possible outcomes. The interests of infants
and children are not limited to biologic interests and include
developmental, emotional, social, spiritual, and other interests. A "best interest" standard recognizes the possibility
that medically indicated treatment may result in a profoundly burdensome life for the child and that death may not
be the "greatest evil to befall a person.,,7 Thus, it presumes
that prolongation of life may not always be in the child's
best interest. Focusing on what is best for the child avoids
morally dubious justification based preferentially on the
interests of other involved parties such as the parents,
siblings, healthcare professionals, or the institution.
When the best interest principle is applied to children, a
"reasonable person" standard is generally used to evaluate
benefits and burdens because children have frequently not
expressed autonomous values or choices about treatment. A
reasonable person standard relies on what most informed
and reasonable persons would view as in the child's best
interest. It is meant to reflect a social consensus about what
would be the appropriate response for someone in a similar
situation. However, in many instances a clear social
consensus is lacking. 608
A variety of criteria have been suggested to assess
whether a treatment is in a child's best interest (Box 6-1).
Benefits and burdens may be understood based on the
child's and/or parent's values and preferences for what
constitutes a meaningful life and death. The following are
commonly viewed as benefits to the critically ill child:
(a) comfort or relief from suffering; (b) alertness; (c) unconsciousness of severe pain or anxiety; (d) awareness of
one's condition, prognosis, or impending death (if cognitively able); (e) relating to friends and loved ones; (f) exercising authority over or participation in decisions; or
(g) completing life tasks. These benefits must be weighed
against the burdens associated with certain treatments such
as: (a) repeated pain and suffering associated with invasive
procedures and the underlying disease; (b) new, unrelieved,
or exacerbated symptoms; (c) physical and emotional
isolation; (d) anxiety; (e) lack of human contact; (f) loss of
hope; (g) despair; (h) meaningless existence; (i) immobilization; (j) noninvolvement in decisions; (k) prolonged
hospitalization; (I) developmental deprivation; or (m) lack
of continuity by a consistent person of special significance.
Most medical interventions are not benign and are accompanied by some degree of pain, bodily inva~ion, and
physical, psychologic, or spiritual burden. Hence the
process of weighing benefits and burdens is ongoing and
evolving over time. The threshold for tolerating the burdens
of certain therapies may change as goals change in light of
patient responses. For example, parents, children, and
healthcare professionals may be willing to tolerate the side
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Assessment Criteria to Determine Whether
Treatment Is in the Child's Best Interest

1. The degree of pain and psychologic and spiritual suffering

and the potential for relief.
2. The severity of the patient's medical condition. This may
be assessed by: (a) verifying the diagnosis, (b) detennining the accuracy of predicting prognosis, (c) detennining the degree of certainty needed for diagnosis and
prognosis, (d) detennining the degree of major organ
systems affected by the disease, and (e) the presence
of severe neurologic impainnent.
3. The potential for developing a capacity for selfdetennination.
4. The potential for personal satisfaction and enjoyment
of life.
5. The potential for restoration of function, improvement
in symptoms, or cure. Consider questions sucb as: Is
this condition reversible? Will this treatment extend a
meaningful life or prolong dying? Will the treatment
change the disease trajectory or outcome? Will the
therapy be effective in achieving an important goal? Is
the treatment beneficial from the patient's perspective?
6. The goals that are possible for the patient and those
desired by the patient, if competent, or by the surrogate.
These goals may include restoration and cure, stabilization
of functioning, or preparation for death.
7. The proportionality of treatment-related benefits and
burdens.
Data from President's Commission for the Study of Ethics Problems in Medicine
and Biomedical and Behavioral Research. Deciding 10 forego life-sustaining
trearment. Washington, DC. 1983. US Government Priming Office; and
Weil R, Bale J: Selective nontreatment of neurologically impaired neonales.

Neurol C/in North Am 7:807-822. 1989.

effects of chemotherapy when cure is possible. However,
after repeated relapses those same burdens may be viewed
as unjustified.
Decision making is more complicated when the prospect
of successful outcome is less certain, the outcome of
the treatment is expected to be of marginal usefulness, or the
degree of burden is high. This is most common during the
terminal phases of many diseases. In these cases, the agony
of certain treatments may be viewed as disproportionate in
relation to the small statistical chance for survival, especially if the course of therapy is prolonged. 9
Decisions regarding the treatment of critically ill children
always occur under conditions of uncertainty. Determining
the child's best interests can be particularly difficult when
the precise diagnosis and/or prognosis is unclear or it is
difficult to accurately predict the disease trajectory. As a
consequence, it is more difficult to understand the benefits
or burdens that will result from treatment or nontreatment.
The unpredictability of a child's response to treatment may
motivate caregivers or parents to try to reduce the uncertainty by pursuing additional diagnostic studies and innovative therapies. This creates ambiguity and controversy
about whether the child's condition is reversible or whether
it represents the terminal phase of the disease. Depending on
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how the uncertainty is viewed, either as threat or opportunity, caregi vers or parents may be willing in some instances
to accept a greater degree of burden in order to give the child
an opportunity for a longer life and the possibility of future
beneficial treatments. 10
At times, however, the quest for absolute certainty may
result in disproportionate burden by the patient. As uncertainry and the burdens associated with treatment escalate,
other important moral considerations must be brought to
bear on the decision. The prolongation of life cannot be
considered exclusively. Prioriry must also be given to the
comfort or ease with which a life is lived. Hence, as the
benefits of medical interventions diminish, the focus of care
necessarily shifts to relieving pain and promoting comfort,
rather than on therapies to prolong life.
Assessing benefits and burdens in permanently unconscious children is particularly problematic. Presumably, a
permanently unconscious child is not capable of experiencing benefits or burdens. In such instances, it has been argued
that the child's interests are limited to the maintenance of
biologic functions without an awareness of benefit or
burden. For example, children who are permanently unconscious cannot interact with their environment or family nor
can they derive satisfaction or pleasures associated with
living. Similarly, these children cannot perceive the potential burdens associated with treatment. In such a state the
child lacks the neurologic function to perceive pain. In this
special circumstance, the best interest principle does not
apply since it appears that the child's interests cannot be
changed by enhancing benefits or reducing burdens. A
vitalist argument based on sanctiry of life may be used as
justification for continuing treatment but does not rely on a
benefit or burden for it's justification. Opponents may argue
otherwise. Miller-Thiel and colleagues have suggested that
consideration be given to whether the prolongation of the
unconscious life of a child is an act of caring.! [ The Baby
Doe regulations,12 for example, regard permanent unconsciousness as a condition that does not require lifesustaining treatment; yet there are a wide range of views on
the degree of neurologic impairment that justifies limiting or
forgoing treatment.

Respect for Persons and the Role
of Children in Decision Making
A second principle involved in decision making is respect
for persons. In its broadest interpretation, respect for
persons means recognizing another human being as sharing
a common human destiny.13 Each life, regardless of how
diminished it may be, must be regarded with fundamental
reverence and respect. There are opposing views about
whether such respect for human life mandates that life must
be sustained unconditionally. Despite this, the principle of
respect for persons invites thoughtful consideration of the
child's uniqueness and inherent worth.
Respect for persons requires that children be recognized
as individuals whose thoughts, experiences, and opinions
malter, despite their developmental immaturity and legal
status as minors. 14 Even though children are not autono-

mous or self-determining, an element of respect is required
because the lives of children have unique meaning. To treat
children with respect is to acknowledge and value who they
are outside of a medical context.'s Even though a child may
not be fully able to direct his or her own treatment, it is
possible and desirable to involve even young children in
decisions about their treatment. Many children with lifelimiting conditions have an accelerated understanding of
their condition and an intimate knowledge of the consequences of certain treatments. This profound personal
knowledge should be given appropriate moral status in the
decision-making process.
The degree of involvement of children and adolescents
in treatment decisions varies depending upon their capaciry
and desire for involvement. The capacity to consent to
medical treatment requires a person's ability to understand the treatment options and consequences, reason about
them, and freely choose from various alternatives. Two
factors that influence a child's level of participation in
healthcare decisions are cognition and competence. As
these aptitudes develop, a child is able to take on increased
responsibility for treatment decisions. Children do not
suddenly develop decision-making capacity when they
reach 18 years of age. Children's ability to recognize their
own best interest and to choose or refuse treatment follows
a developmental process like any other normal path of
growth and development. This ability develops gradually
throughout childhood, at a pace that varies from one child
to another.
How, then, does one weigh the child's ability to choose
or refuse treatment? The normal childhood developmental processes have been fully explored by Erikson and
Piaget. 16• 17 They describe milestones or points at which a
child masters certain tasks or processes. Although most
children pass through these milestones at a steady pace,
some children advance, stop, or even fall back as environmental conditions, such as their home life, limits in mental
intelligence, and illness, interfere with normal progress. In
particular, chronic or terminal illness often influences a
child's developmental progress. Capacity for healthcare
decision making is not an all-or-none concept and may be
situational. For example, an individual child may be able to
decide to discontinue chemotherapy but not have the
capacity to decide to go home and die. Thus each child must
be viewed individually, taking into account developmental,
as well as chronologic, age and the particular characteristics
of the situation.
Before the age of 11 or 12, children believe illness is
caused by something external to their bodies or something
they ingest. 18 Very young children who are sick are principally concerned with separation from their parents and the
unpleasantness of the procedures that they must undergo. At
about age 6 or 7 the child often believes that illness is
retribution for bad thoughts or actions. By 12 years of age
children develop the capacity to think abstractly. At this
stage of development a child is able to consider multiple
factors, hypothesize, and predict future consequences. The
child is able to understand illness as a process caused by a
malfunctioning of an internal organ system and is therefore
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able to understand the long-term risks of chronic disease,
instead of just focusing on whether the disease will interfere
with their immediate routine. By the time adolescents reach
the age of 15, they are less likely to acquiesce to their
parents' wishes. Thus the ability to freely assent to treatment or nontreatment has developed.
As children attain greater capacities to participate in
decision making, they should be involved more fully in
decisions about their care. McCabe and colleagues offer
guidelines for determining the level of involvement of
minors in treatment decisions. Involvement includes preparation of procedures and assent, shared decision making
with parents, and autonomous decision making. 19 Generally,
children who are not fully autonomous are asked to assent
to treatment rather than consent, which requires decisionmaking capacity and autonomous decision making. Assent
to treatment means that the child has agreed to proceed
with a specific course of treatment or has decided to
withhold or limit certain treatments, with the approval of
the parent or surrogate. The process of obtaining assent
confers respect for a child by encouraging involvement and
understanding. Although it is important not to accept
uncritically a child's reluctance to undergo painful and
distressing interventions, it is essential to respect the wishes
and self-defined goals of mature children, particularly when
parents support making comfort the primary goal of
management at the end of life.
When a child is incapable of forming and stating his or
her own goals, respect is still required, but it is more difficult
to determine the proper balance of benefits and harms. The
nature of the consequences of the decision may be useful in
determining the decision-making role of minors. Clearly,
special caution should be exercised when death is a likely
outcome of a decision. Confidence in assessing the child's
decision-making capacity and the process for making
decisions will be crucial for justified deference to his or her
preferences and choices. 4
At a minimum children should be granted the following:
(a) informed in developmentally appropriate terms about the
nature of their condition, proposed treatment, and expected
outcomes; (b) informed about who is caring for them and
performing procedures; (c) prepared for medications and
treatments; (d) their views and preferences listened to
and taken account of in decision making. Children with
life-limiting conditions should, for instance, be involved in
determining the how much, when, and to what extent they
prefer to have information provided. Regardless of the
child's level of participation in care planning, he or she
should be given as much control over the treatment plan as
possible.1 9
Children should not be deceived or misled about the
scope of their authority in decisions. 9 If the child's
preferences are not determinative of treatment, this should
be openly acknowledged. For example, when decisions are
made to forgo life-sustaining treatment, it is desirable to
acknowledge how the child's preferences will be incorporated into the decision-making process and to determine
whether or the extent to which the child's views will
determine treatment.
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Autonomy and Informed Consent
The ethical principle of autonomy, which is derived from
respect for persons, refers to individual self-determination
and freedom of choice. "It requires that we respect the rights
of others to make autonomous decisions. To violate a
person's autonomy is to treat that person merely as a means
to an end that is in accordance with one's own beliefs and
values. ,,20 An extension of the principle of respect for
persons is the ethical standard for informed consent
Informed consent is also the legal standard by which
permission is sought for medical treatment of an individual.
The only acceptable legal exception to this law is that in
which the need for medical treatment constitutes an
emergency, that is, when the patient would suffer irreversible harm if not treated. Thus, when consent cannot be
obtained because the patient is not competent and a
surrogate decision maker is not immediately available, the
treatment can proceed. However, in all other instances, the
patient or the patient's surrogate must consent to or refuse
treatment.
The Role of Minors. In caring for children, special
ethical issues arise because children are not consenting
adults. Since young children do not have the cognitive
ability to provide informed consent or refusal, parents or
legal guardians are usually responsible for treatment decisions for their children. As a child nears adolescence,
parents' rights to make healthcare decisions may be limited
by both the increase in the minor's cognitive ability and
precepts of law.
The concept of "mature minor" has received increasing
judicial approval. A mature minor statute recognizes that a
young person (14 or 15 years of age or older) can understand
the nature and consequences of certain proposed treatments.
The treatment must not involve very serious risks and the
physician must believe that the minor could give the same
degree of informed consent as an adult. 21 Treatment for
venereal disease, drug and alcohol abuse, pregnancy, and
communicable diseases may fall into this area. In fact,
California state law recommends that it may be appropriate
to seek legal advice if a minor aged 14 or older objects when
parental consent is given for a procedure that involves a
significant risk of severe adverse consequences. 22
Specific state statutory provisions "emancipate" minors
for the purpose of making their own healthcare decisions.
Generally, an emancipated minor is someone younger than
18 years of age who is not living at home and/or is
self-supporting, married, in the military, or an unmarried
mother. An emancipated minor statute reflects the judgment
of a particular state that, when certain conditions are met,
these minors are capable of consenting to their own
healthcare. In particular, provisions that grant adult status to
minor parents consenting to treatment for their own child
have significant implications in the care and treatment of
children.
State laws may need to be clarified in situations such as
when a minor is in the custody of juvenile court or foster
parents and when minors are suspected victims of child
abuse. Legally, some minors have been given the authority
to give consent for medical treatment in specific situations.
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Although the federal Patient Self Determination Act of 1990
(PSDA) endorses adults making decisions for themselves
and documents their choices, the spirit of the law reinforces
the involvement of minors, especially adolescents, in their
own treatment decisions and encourages the creation of an
atmosphere in which children, with their parents, can make
informed decisions.2 3 .24
Ensuring Informed ness. Although full informed
consent has been said to be a theoretic ideal, reality must
come as close as is possible to that ideal for parents to make
decisions in the best interests of their child. Informed
decisions are made with full knowledge of that which needs
to be done and why. An atmosphere of open discussion must
exist, free from fear of reprisal. Informing patients and their
families is a dialogue, not a lecture, wherein the provision of
information helps to clarify understanding.
To make a decision about medical treatment requires that
the same information be provided to either an adult or a
child. The physician must provide all the information
necessary for the patient or the surrogate to make a
reasoned, free choice about treatment. The risks of doing or
not doing a procedure must be explained, as well as any
alternative choices that are available. The information given
should focus on the child and what life will be like with and
without treatment. Parents should be asked questions about
their goals and desires for the child; their values regarding
disease, disability, and death; and their desire to be involved
in healthcare decision making. It is within this fuller context
of communication that informedness can be assured.
Information must be conveyed in a quiet atmosphere in
which optimal communication can occur. The critical care
unit can be a frightening place for parents and children alike.
Constant artificial light, ceaseless activity, frequent emergencies, and the ever-present threat of death unnerves the
sturdiest of families. Information should be provided in the
language of the decision maker, minimizing the use of
medical terminology. For example, "unconsciousness,"
"mental retardation," and "life support" are words that
must be explained. Parents must be helped to understand
that what they see as movement, for example, is actually
involuntary motion indicating the child's level of neurologic
damage. Whether a child has an 80% chance of survival or
a 20% chance of dying has little meaning for many parents.
Healthcare professionals must explain these serious discussion points in clear language and avoid using them to sway
the parent's decision. Written materials should be offered to
further clarify the circumstances whenever possible.
Obviously, no single information session ensures informedness, especially when decisions about life and death
are involved. The nurse plays a vital role in ensuring informedness through ongoing discussion of the situation with
the child and family, arranging to have medical specialists
and social work professionals available for discussion, and
by providing support, clarification, and understanding as
decisions are reached. Davis 25 defined the role of nurses in
the informed consent process as including: (I) monitoring
informed consent, (2) advocating for patients to the physician, (3) providing patients with explanations and informa-

tion about alternatives, (4) coordinating consent processes
with families and patients, and (5) negotiating between involved parties when there are differences of opinions.
Clearly, the involvement of nurses is critical as parents and
their children grapple with serious issues.

Truth Telling: The Ethical Principle
of Veracity
Veracity, being truthful, is also derived from the principle of
respect for persons. Whether to inform children about the
seriousness of their illness and encourage their participation
in treatment decisions is an issue with which both parents
and healthcare professionals wrestle. The idea of having
children actively participate in health-related decisions can
be intimidating. Yet, when the child is able to reason and
understand the consequences of actions, withholding information or lying is an act of paternalism and requires
justification.
Parents and healthcare professionals who practice such
deception do so because they believe that they are allaying
fear and anxiety on the part of the child. "An overwhelming
wish to protect the sick child from disturbing information,
guilt feelings, or the emotional threat posed by the imminent
death of their child may overshadow parental recognition or
acceptance of the juveniles' autonomy or even his or her
welfare. ,,26
There is no certainty, however, that being honest, even
when the situation is a difficult one, will cause a significant
negative reaction. Knowing the full extent of tbe illness is
often less anxiety provoking to tbe minor than receiving no
or false information??
Furthermore, withholding from children accurate and
appropriate information denies them the opportunity to
discuss their feelings and come to terms with what is
happening to their bodies and minds. Family relationships
may become strained at a time when both the child and the
parents need each other. Talking and explaining helps
children to see the reasons for medical treatment and
understand the various treatment or nontreatment alternatives. In fact, researchers have demonstrated that children
older than 5 years of age have an understanding of the
finality of death and should be openly provided information
and be involved in treatment decisions 28
Trust is at the foundation of the ethical principle of
veracity. Veracity teaches us that truthfulness is fundamental
to establishing trust between individuals. Sick children
depend upon the trusting relationship they have with their
parents and their healthcare providers, especially at a time
when dependency needs are at their highest. Withholding
information or lying threatens the trusting relationship and,
consequently, children's ability to rely on the adults on
whom they depend. As with adults, children may not want
to hear certain information and may want their parents to
make decisions. Such requests should be respected. However, it is necessary for ongoing dialogue to occur so that the
children are certain that any information they request will be
provided truthfully.
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Justice
Justice pertains to fairness and equity in the treatment of
others. It refers to an individual's access to an adequate level
of healthcare and to the distribution of available healthcare
resources. Justice demands that individual patients are
treated fairly and decisions are not made based on criteria
such as race, age, sex, diagnosis, religious beliefs, or
socioeconomic status. Children, regardless of their life
circumstances, should be availed of the same treatments and
advantages as other children in a similar situation. Children
with life-limiting conditions, for example, may be denied
certain therapies or services because their life expectancy is
shortened. Questions of justice arise when the reasons for
denying such care is based on questionable criteria or
criteria that is inherently discriminatory, such as ability to
pay, social status, race, or age. In other instances, children
who become wards of the state because their parents are
unable or unwilling to act as their surrogate decision maker
are at greater risk for discrimination, which could result in
undertreatment or overtreatment. 4
Questions of resource allocation and the proper limits of
treatment often arise when the utilization and consumption
of resources is high. An appeal to fairness compels healthcare professionals to create equitable systems for the distribution of scarce healthcare resources. Dying children, for
example, may face unique threats to access to and reimbursement for end-of-life care. Regulatory criteria for access
to hospice, for example, currently limit access to children
because the criteria are based on an adult model of hospice
that does not reflect the unique needs or trajectory of illness
of children. Moreover, insurance criteria may create unjustified barriers to providing necessary services at the end oflife
based on inflexible interpretation of guidelines 4
Healthcare professionals have dual obligations for allocating resources at the individual and societal levels. Often
these obligations create intense conflicts of interest and
responsibility. The conventional wisdom is that decisions
about what will benefit individual patients should generally
be separated from decisions about how society will allocate
its healthcare resources. Such decisions are not suited for the
bedside, but belong within the context of a larger societal
debate. Yet when marginally beneficial treatments or other
scarce resources are considered, healthcare providers have a
responsibility to allocate resources in a fair, fiscally responsible manner. A societal consensus about how to resolve
these competing obligations is currently lacking, creating
conflict for patients, families, providers, and other members
of society.

An Ethic of Care
Traditional ethical reasoning requires providers to ascertain
the rights of indi viduals and weigh the ethical principles in
order to resolve conflicting obligations. Applying ethical
principles alone cannot resolve the clinical quandaries that
arise while caring for critically ill or dying children. When
the rights of children are held in opposition to the rights of
their parents, for example, an adversarial tension can be
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established that may polarize discussion. This method of
moral reasoning focuses on an ethic of rights that is achieved
through a process of separation and individuation of the
child from others including their family. In contrast,
considering other aspects of the moral life, such as care,
harmony, compassion, and responsibility for self and
others, may reduce adversarial tensions between the rights
of children and their parents. Such an approach allows for
a more comprehensive appreciation of the attitudes, values,
and moral commitments of decision makers within the
context of their family and other significant relationships. This perspective is often referred to as an "ethic
of care." 29
From a care perspective, the resolution of ethical
quandaries is focused on the child's needs in the context of
the family, and the provider's corresponding responsibilities
within the context of the professional-patient relationship.
The professional is guided to focus on the special circumstances and context of the specific situation in which moral
action occurs instead of merely considering the child's
interests and preferences in isolation. In other words, the
uniqueness of a child and the particular dynamics of his or
her relationships are endorsed as essential components of
moral decision making.29 Such a model supports efforts to
assist children and their families in finding unique meaning
or purpose in their living or their dying and to assist them
to realize goals that promote a meaningful life or death.
AACN's Syngergy Model also supports attentiveness to
these concerns. 30
The values and expectations involved in certain roles and
relationships are seen as primary from this vantage point.
Therefore, being an advocate for a child with a critical
illness or life-limiting condition involves appreciating the
relationships significant to the child and understanding how
those relationships affect care and decision making. Children develop an intricate web of relationships that support
and sustain them throughout their lives. In keeping with a
family-centered phi losophy of care, families are viewed as
essential partners in children's treatment and care. Professionals must recognize and respect these interconnections as
central to the well-being of the child. 4
A care perspective also emphasizes the interrelationships
of the members of the healthcare team. It recognizes that
nurses, physicians, and other caregivers work collaboratively to advance the interests and goals of children with
life-limiting conditions. Threats to harmony and relationships are viewed as the essential nature of moral dilemmas
from a care perspective. Therefore, when there is conflict or
disharmony among caregivers or among caregivers and
family members, relationships are threatened and the moral
endeavor is undermined. The goal is to create connection,
promote openness and dialogue, and engage in activities to
promote healing of the fractured relationship.4
A care perspective also invites attention to the narrative
dimensions of the case. The diagnosis and treatment of a
child's disease evolves over time. The story of the process is
an essential element of the context of ethical decision
making. Focusing on the narrative dimensions of the process
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enables parents and professionals to negotiate meaning and
to make sense of an often foreign and incomprehensible
situation. The meaning that each person assigns to a
particular situation is unique and is derived from his or her
own social, cultural, familial, religious, political, and other
influences. Understanding this context gives insight into
how meaning is derived. The search for meaning often leads
to understanding. Understanding adheres to meaning ascribed to a situation or set of values or behaviors, but it does
not simply mean "knowing" certain facts or concepts. It
requires an integration of the information into one's values,
and requires cognitive activities that are not exclusively an
act of reason. Within a care perspective, meaning and
understanding are accessible and relevant to the decisionmaking process.

ETHICAL ISSUES IN PEDIATRIC
CRITICAL CARE
Technologic achievements in critical care created unanticipated dilemmas as powerful diagnostic techniques, sophisticated surgical procedures, effective drugs, and expedient
therapeutic interventions interrupted the usual course of
illness and disability. Problems became magnified because
life could be sustained for a significant period if the patient
accepted dependence on a specific procedure or machine.
Medical technology can be a double-edged sword. It is
usually beneficial in the care of sick or injured persons,
sometimes dramatically so. However; since it is often
intrusive, occasionally cruel. sometimes of little value, and
almost always expensive. its use must be assessed critically,
particularly in ICUs. 3J
The uncertainties and ambiguities that result from
disease, injury, and the use of technology often force
healthcare professionals to demand cure in the absence of
otherwise compelling evidence to choose a different course.
The inevitable conflicts that arise produce questions such as
these: Can treatment be stopped once initiated? Who gives
consent for medical treatment? Can patients be forced to go
along with a recommended treatment plan? Do all patients
have to be resuscitated? Who judges the quality of
someone's life? When is a patient considered dead? The
indecision that occurs reflects a growing uneasiness with the
consequences of scientific advances, especially when death
is not imminent but the quality of life is greatly impaired. In
pediatric critical care, the problems are complicated further
by the child's developmental stage, chronologic age, and
family situation.
The ethical quandaries that arise in healthcare are not
new. They have always been a part of clinical practice.
Ethical considerations lie on or just below the surface of
many clinical activities, yet are rarely noticed. It is only
when decisions feel uncomfortable or when alternatives
seem equally unsatisfactory that the finer issues of moral
decision making are considered. Increasingly, a proactive
process for addressing these issues using clinical guidelines has been advocated?2 In the next section, prominent
ethical issues that arise in pediatric critical care will be
emphasized.

Forgoing Life-Sustaining Treatment
Numerous quandaries arise when treatment choices such as
do-not-resuscitate (DNR) decisions, abatement of lifesustaining therapies including medically provided hydration
and nutrition, and pain management are considered. There
are many myths about forgoing life-sustaining treatment
(Box 6-2) and tenninology is often used inconsistently,
leading to confusion about the justification and ethical
propriety of certain acts that influence the timing and
circumstances of death.
Forgoing life-sustaining treatment refers to discontinuing
a therapy already begun or not starting a treatment. The
reasons for forgoing life-sustaining treatment include:
(l) cure is no longer possible, (2) the burdens of treatment
outweigh the benefits, or (3) the quality of life is undesirable. In such instances questions may arise about whether
current therapies ought to be continued or whether additional therapies should be added. Although it may be
psychologically easier to withhold than to withdraw treatment, there is no ethical distinction between the reasons for
stopping a therapy or not starting a therapy. Fear about
stopping a treatment once started may lead clinicians to
avoid a treatment with potential benefit. For example,
parents or professionals may fear that trying mechanical
ventilation in a child with pneumonia and multiple relapses
of leukemia may result in chronic ventilator dependence.
The American Academy of Pediatrics (AAP) recommends
initiating potentially beneficial interventions and discontinuing them after a trial of therapy proves their ineffectiveness 33 In this case it may be appropriate to institute a trial
of mechanical ventilation to determine whether the pulmonary process is reversible. In the AAP's view, continuing
Ilonbeneficial treatment causes children great burden and
obviates professional responsibility.33
Resuscitation, mechanical ventilation, blood products,
medications, medically provided hydration and nutrition,
dialysis, and other therapies must be considered individually
based on the goals for the patient. Clarifying goals of
treatment is essential for determining an ethically justifiable
course of treatment. It is unjustified, for instance, to assume

~

Box 6-2

Myths About Forgoing
Life-Sustaining Treatment

• Anything that is not specifically permitted by law is
prohibited.
• Termination of life support is murder or suicide.
• A patient must be tenninally ill for life support to be
stopped.
• It is pennissible to terminate extraordinary treatments,
not ordinary ones.
• Terminating tube feedings is legally different from
stopping other treatments.
• Termination of life support requires going to court.
Data from Meisel A: Legal myths about terminating life support, Arch Intern
Med 151:1497-1501.
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that a decision not to resuscitate a dying child automatically
means that all other aggressive measures will also be
foregone. Cardiopulmonary resuscitation, for example, may
not be desirable for a child dying with cancer but his or her
parents may still desire that antibiotics, blood products, and
other palliative interventions be continued.
Determining whether it is morally justifiable to forgo
certain therapies depends upon the child's and the family's
goals and preferences for certain therapies, weighing the
benefits and burdens of each therapy in light of the goals,
and the moral analysis. When a child is dying, for example,
focusing on the comfort associated with dying rather than on
therapies to prolong life may be justifiable.
Although it is difficult to determine what may count in
determining a child's best interest, forgoing life-sustaining
treatment is justifiable when a child experiences substantial
and unrelievable suffering and when the child has suffered
irreversible brain injury that precludes human or environmental interaction. When life is judged worse than death for
a child, it is justified to choose death over continued
suffering. The more severely burdened or damaged the
child's condition and the greater the certainty of the nature,
degree, and irreversibility of the child's condition, the
greater the justification for not prolonging the dying
process. When in good faith it is not possible to determine
which is worse, the presumption for treatment that allows
for a chance for life and greater certainty may be warranted. Those with decision-making authority must accept the responsibility of choosing the conditions that
they believe be so dehumanized or dehumanizing as to
justify terminating life-extending treatment. Based on the
Baby Doe Regulations,12 there appears to be consensus
about terminal illness, permanent unconscious, medically
futility, and disproportionate burdens of treatment over
benefits as justifiable reasons to forgo life sustaining
therapies.
In some cases, disagreement may arise about whether a
particular intervention constitutes life prolonging treatment
or comfort care. For example, when does suctioning of the
pharynx merely prolong the dying process by preventing the
patient from aspirating his secretions, and when is it an
appropriate intervention that enhances the patient's comfort? A similar question may be asked about the use of
antibiotics or supplemental oxygen. Again, each intervention must be assessed based on the goal of treatment and
whether it contributes to the attainment of that goal.
Establishing strict criteria for distinguishing life-prolonging
interventions from those that are palliative and promote
comfort are unlikely to resolve the controversy or ambiguity. Rather, clinicians and parents should openly discuss the
use of interventions in the "gray zone" within the context of
the child's condition, goals, and preferences.
Within this process, professionals should examine their
own responses and reasoning in light of professional codes
and guidelines and personal morality. Professionals may
benefit from examining the extent to which the following
factors may be influencing their view about forgoing lifesustaining treatment: (1) their own frustration of caring for
an infant on a long-term basis, (2) the appearance of the
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infant, (3) lack of family involvement, (4) a biased
impression of prognosis,34 (5) their own threshold for
balancing benefit and burden, and (6) the influence of
personal social, economic, cultural, or religious values. The
extent to which these factors can be illuminated will assist
in clarifying the professional's moral obligations and
defining ethically defensible boundaries for providing care.

Cardiopulmonary Resuscitation
Often the discussion about forgoing life sustaining treatments begins with a discussion about cardiopulmonary
resuscitation (CPR). Valid and reliable data are essential to
good decision making. When discussing resuscitation, it is
essential that professionals accurately convey the likely
outcomes of attempting CPR including the likelihood that
the child will be restored to his or her current condition or
sustain complications that may significantly alter their
quality of life. When a child is dying, cardiac or respiratory
arrest marks the terminal phase of the process. In this case,
CPR disrupts the body's natural progression to death and
may only prolong the dying process. When resuscitation
will not change the course of the disease and will prolong
dying, a DNAR order should be documented. 4
Based on practice standards and ethical guidelines, slow
codes are not ethically justifiable. If a patient does not have
a DNAR documented, healthcare professional are obliged to
resuscitate. This reality does not mean, however, that healthcare professionals are obliged to continue resuscitation beyond its usefulness. Like other interventions the application of CPR requires clinical judgment and knowledge of
patient/family goals. DNAR orders do not imply that routine
care, attention, and human presence are abandoned. Moreover, it does not necessarily mean that all other lifesustaining therapies should also be foregone. Each therapy
must be evaluated individually to determine whether the
initiation, continuation, or limitation is warranted.

Medically Provided Hydration and Nutrition
One of the most controversial areas of forgoing Ii fesustaining treatment involves medically provided hydration
and nutrition (MPH&N). MPH&N includes the provision of
fluids andlor nutrients via medical devices inserted into the
gastrointestinal tract such as gastrostomy or nasogastric
tubes or into blood vessels such as central venous lines
and portable infusion devices. 35 Forgoing MPH&N in
any circumstance remains controversial despite widespread
consensus among professional groups, ethicists, and the
courts that it is justifiable in some instances. 35-38 For a
variety of psychologic, cultural, and societal reasons, the
controversy intensifies when it is considered in children.
These reasons may include the following: (1) the powerful
symbolic significance of the act of feeding dependent
children; (2) the view that providing hydration and nutrition
is a basic care requirement to sustain life; (3) a child's
incapacity for independent decision making, which creates a
high threshold for continuing treatments until death is
imminent; (4) diagnostic and prognostic uncertainty about
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detennining a tenninal condition; (5) the injustice of young
children dying; and (6) fear of legal reprisal. Despite these
reasons, Nelson and colleagues argue that decisions about
forgoing medically provided hydration and nutrition should
be guided by the presumption that it is medically and
ethically appropriate in the majority of pediatric cases, and
nutrition and fluids should always be offered by mouth,
except in the unusual case when, for example, oral feedings
unavoidably lead to recurrent direct aspiration. 35 They
further argued that it is ethically permissible to forgo
MPH&N in certain cases. These include neurologic devastation, irreversible total intestinal failure, and proximate
death from any pathologic cause. 35
When death is imminent, within days or weeks, it is
ethically justified to stop those interventions that prolong
the dying process. lI The continuation of MPH&N can
significantly lengthen the dying process by interfering
with the natural dying process. In some instances, the
provision of MPH&N can impose unnecessary burdens
for the child and family. These include increased oral
and pulmonary secretions, diarrhea, edema, increased urine
output, abdominal distention, and discomfort. 11 A dying
child is likely to have anorexia and decreased desire for
eating or drinking. Forcing intake, either parenterally or
enterally, may not promote the child's best interests at the
end of life.
When MPH&N is considered as an option for forgoing life-sustaining treatment, it will be essential that the
decision-making process allow for divergent views to be
appreciated. Although many professionals and parents are
comfortable with discontinuing mechanical ventilation, the
issue of forgoing MPH&N may instigate intense emotional
responses that will require vigilant attention and a fair and
open process.

Pain Management
The ethical mandate to treat a child's pain is based on the
principles of beneficence and nonmaleficence. Healthcare
providers have an obligation to reduce or eliminate pain and
suffering by assessing and managing it using their clinical
knowledge and skill. Relieving the distress caused by pain
is an inherently humanitarian act, embodying the ethical
principle of beneficence-doing good for others. The
American Nurses Association, the World Health Organization, and other organizations unequivocally endorse the
professional's responsibility to assess and manage pain in
children. 39 ,4o It is now indisputable that infants and children
experience pain, and professionals have an unequivocal
responsibility to assess and manage pain in children. Yet
many infants and children continue to be undermedicated
for pain despite efforts to enhance professional awareness of
their needs. This is explained in part by philosophic and
clinical barriers to providing analgesia that is commensurate
with the intensity of the pain experienced by infants and
children.
When the burdens of treatment outweigh the benefits of
continued existence, the priority of care becomes the relief
of pain and suffering. Making comfort the primary goal of

management may involve maximizing analgesic interventions despite hazards such as sedation and respiratory
depression, or it may mean withdrawing or forgoing painful
or invasive treatments such as CPR, ventilator, or diagnostic
blood work. The benefits of the relief of pain and suffering
include the following: (1) the child may feel more comfortable during the dying process; (2) the child may be more
available for interaction with others, allowing the child and
family to connect with each other and/or complete their life
work together, thereby decreasing isolation and loneliness;
(3) the child may experience an increased sense of control
over his or her environment and treatment; (4) increased
activity may allow the child and significant others to share
important experiences together; and (5) the child's and famiIy's perception of the treatment or the final stages of the
child's life. These benefits must be weighed against the
physical, psychologic, and spiritual burdens of unmanaged
pain that include: (a) decreased interaction, isolation, or
immobility, (b) real or perceived sense of abandonment,
(c) anxiety and fear about being in pain without relief,
(d) loss of trust in and fear of healthcare professionals,
(e) irritability, (f) nightmares, and (g) decreased resources
for coping and living. When pain occurs at the end of life,
additional burdens include avoidance of the reality of death
and decreased opportunities for child and family to complete their life work together.
Throughout treatment, healthcare professionals may need
to discuss with the child and parents the plan for managing
pain during treatment and, when appropriate, at the end of
life. It is essential to note that intractable pain is uncommon
in children because most diseases produce pain that is
treatable with medications, For example, unlike adults,
children with cancer overwhelmingly experience pain that is
treatment related. 41 ,42 Clarification about the trade-offs that
may be necessary to manage pain will be necessary. For
example, some children may prefer to endure some pain in
order to remain interactive and not be sedated. Others may
prefer not to feel any pain and be drowsy and less
responsive. Being clear about the goals of management and
anticipating the various outcomes to different treatments
may help to avoid conflicts. Moreover, in the spirit of full
disclosure, a variety of pharmacologic and anesthetic
options that are available to manage pain at the end of life
that do not produce diminished awareness should also be
explored. 32 ,43
When children are dying, nurses and other healthcare
providers often struggle to balance their obligation to relieve
pain against the concern that their actions may cause the
child's death. Although some philosophers have argued that
there are no important differences between withdrawal of
treatment and active euthanasia, many clinicians and
ethicists have stressed the importance of maintaining a
distinction between active killing and efforts to promote
comfort at the end of life. Aggressive pain management at
the end of life can be ethically justified based on several
arguments. First, when a patient is dying, one may reason
that the obligation to relieve pain and suffering overrides
concerns about hastening death. In assessing risks and
burdens, common side effects of analgesia such as sedation,
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nausea, and respiratory depression should be distinguished
from rarer events such as the possibility of addiction. 40
Concerns about respiratory depression, addiction, or tolerance are insufficient reasons for inadequate pain management in the care of the dying. 4o Second, the intent of
providing sufficient analgesia to the dying person is to
relieve pain in order to enhance living until death occurs. In
contrast, the intent of active euthanasia, which is the
deliberate killing of the patient by lethal injections of toxic
agents or overdoses of analgesics or sedatives, is to
precipitate death. 41
The means to achieving pain relief in the dying person
are distinct from the means to achieving active euthanasia. 44
Generally analgesics are titrated in small increments with
constant assessment and monitoring of the patient's response in an attempt to maximize comfort while minimizing
undesirable side effects. Although death may occur secondary to the administration of the medication, it is in service to
the goal of pain relief. In active euthanasia, large, sometimes
massi ve doses that exceed the customary dosing parameters
and intensity of the patient's pain are given with the intent
of preventing any possibility that the person would survive
the administration of the agent. In this instance the goal is
irreversible cessation of heart rate and respiration. The
difference in intent carries with it a corresponding difference
in meaning for the patient, family, and caregivers.
Administering enough analgesia to relieve pain, even if
death occurs secondarily, is morally permissible as long as
the intent is to relieve suffering. Such an approach is
consistent with American Nurses Association (ANA) "Code
for Nurses. ,,45 The Code instructs nurses to promote health,
relieve pain and suffering, or promote a peaceful death. An
ANA position statement on pain relief at the end of life
encourages nurses to aggressively advocate for and provide
adequate pain relief in the dying patient even if it
secondarily foreshortens life. 39 The pursuit of adequate pain
relief is fully protected by laws and regulations governing
the practice of medicine; however, active euthanasia is
currently illegal in all 50 states. (One state [Oregon] has
legalized assisted suicide but this deals exclusively with
competent adults and therefore does not apply to children.)
To address concerns about pain management at the of
life, it is prudent to use end-of-Iife pain management
protocols that include a variety of safeguards, including
incremental titration of medications, ongoing assessment,
dosage parameters, and process guidelines. Careful attention
and monitoring should be employed to minimize the risks
associated with analgesia and to continually monitor the
balance of benefits and burdens associated with various
treatment regimens 32

Euthanasia
Strictly speaking, euthanasia means "good death." Although there is significant controversy about whether bright
lines can be maintained between different categories of acts
that lead to death, consensus among clinicians and some
ethicists supports distinctions between killing and allowing
to die. Many clinicians use the term euthanasia to refer to
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acts that intentionally and deliberately cause a person's
immediate death. 46 In this sense, euthanasia means killing
the patient. Allowing to die is a term used to refer to the
intentional avoidance of interventions that interfere with the
natural progression of a disease or injury to death. Yet there
is often confusion at the bedside on whether appropriate
management of pain at the end of life (see previous
discussion) or the forgoing of life-sustaining therapies
constitutes active euthanasia. This is particularly problematic in intensive care settings where the availability and
widespread use of complex technology blurs the distinctions
between acts that are forestalling an inevitable death and
those that are intended to end the patient's life. Moreover,
there is considerable debate about the ethical justification of
using pharmacologic paralytic agents during withdrawal of
mechanical ventilation. 47 .48
As a practical matter, parents rarely request that professionals actively end their child's life. Yet parents may beg
professionals to "do something" when their anguish at
watching their child suffer becomes unbearable. Such requests do not necessarily imply that parent's are asking for
euthanasia. Rather, such requests should invite further exploration of the feelings and the motivation behind such
pleas. The request to intervene is insufficient justification for
professionals to engage in acts that are outside their usual
protocols for caring for dying children such as giving lethal
injections in an effort to assuage parental and professional
anguish.
Despite the confusion in terminology, it is clear that
physicians and nurses have an obligation to respect life and
not to kill patients. Decisions to forgo or limit life-sustaining
treatment should always be subject to review and systematic
scrutiny. Ethically justifiable end-of-life care can be enhanced when the process of decision making includes
appropriate safeguards and clinical gUidelines. 32

DECISION-MAKING MODELS
In addition to an analysis of the ethical principles that apply
to issues in pediatric critical care, elements of an ethical
decision-making process should be taken into account. A
shared decision-making model and AACN's Synergy Model
are described below. Although not mutually exclusive, each
offers a unique perspective on the ideal manner in which
ethical issues may be resolved. In addition, the role of the
critical care nurse in decision making is addressed.

Shared Decision Making
Historically, healthcare professionals did not consider a
patient's or family's wishes, beliefs, and values. Wanting to
protect patients from their own lack of knowledge and
subsequent bad judgment, healthcare professionals did not
involve patients or families in heaIthcare decisions. The
norm that functioned promoted the belief that healthcare
professionals knew what was best for patients. Patients were
not to know too much about their diagnosis or prognosis and
were not to interfere with treatment plans. This paternalistic
attitude was often justified on the basis of doing no harm.
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Duff called this attitude "ethical elitism" and noted that
when paternalism thrives, the dictum of "do no harm" may
be violated?! Caring for others requires consideration of
their values and contributions. 49 Healthcare professionals
who believe that they know best foster family dependency
and increase feelings of loss of control. Healthcare professionals must remember that parental acceptance or rejection
of recommended medical treatment is a moral decision and
is not the healthcare professional's responsibility.
Despite our history, a moral framework based on a
model of shared decision making has been endorsed as
ideal. 15.33.50.51 The desired outcomes of shared decision
making are summarized in Box 6-3. Shared decision making
relies on establishing and nurturing a relationship that is
synergistic and reciprocal among the child, family, and
healthcare professionals. The relationship flourishes when
honesty, openness, and trustworthy interactions prevail.
Endorsement of a model of shared decision making
means that the outcome of the process of informed consent
is evaluated based on the quality of the relationship rather
than the amount or type of information shared. To accomplish this goal, parents must be respected and supported to
engage fully in the process, be enabled to fully understand
the range of possibilities for treatment and their consequences, and to share in meaningful ways in the dialogue
about their goals, values, and aspirations for their child's
life. Such a model goes beyond the legal requirements for
disclosure, comprehension, and voluntary consent,52 Although in theory professionals embrace the ideal of shared
decision making as the desired model of parent-professional
decision making, it is rarely accomplished in practice. 52
One possible reason for the lack of success in achieving
shared decision making is that professionals have focused
primarily on the decision itself, rather than the process
necessary to engage parents in a shared journey to realize
their child's interests. A revised model of shared decision
making would therefore focus more on the context of the
situation, especially the relational dimensions, the parent's
unique conception of good parenting, and the factors that
mediate decision making, rather than the decision itself.
A broader conception of the process of shared decision
making is necessary to account for the differences between
approaches of parents and professionals. Professionals, for
instance, must begin to appreciate the parental perspective

~
•
•
•
•
•
•

Box 6·3
.
Desired Outcomes of Shared
Decision Making

Mutual respect
Preserved integrity
Mutual participation, authority
Understanding
Shared meaning
Hope balanced with honesty and realistic expectations
Mutual satisfaction with the process regardless of the
outcome

in decision making and not attempt to force parents to
conform to the professional decision-making framework.
Unlike the rational, scientific approach of professionals, the
context for parents' attitudes and behaviors is derived from
their unique conception of good parenting of which
commitment to their child is a central feature. 53 Instead of
asking parents whether they want their child to be resuscitated, professionals may find that focusing on the parent's
commitments to their child's life and connecting with parents as human beings may be a more fruitful approach.
Professionals should carefully assess each parent's appraisals of their situation and their coping strategies in order
to respect the myriad factors that may account for their
diversity in their patterns of adjustment,54 Box 6-4 describes
some key questions to promote understanding and dialogue
with parents. It must be acknowledged, however, that the
way parents choose to participate in decisions and their need
for control is varied. Some parents are accepting of and/or
desire professional dominance 55 ; others covet autonomous
decision making on behalf of their child. Although many
parents do not wish to abdicate their decision making
authority to others, they struggle with their own ambivalence about what role they could play in a situation they
view as largely out of their control.53.56 Professionals may
base their assessments of parental understanding on their
own values about what is important and meaningful to the
decision. Understanding each parent's conception of good
parenting involves assessing and fostering decisional involvement for parents based on their particular style of
decision making, coping strategies, and need for control. A
supportive approach is to ask parents what role they desire
regarding decisions for their child and what information is
meaningful to their decision making.
The process of shared decision making is thwarted when
parents and professionals fail to connect and achieve a
shared meaning of values and value labels that guide decision making. This process can be undermined when professionals fail to understand the richness of the patient/family's
life story and context, draw premature conclusions, or label
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Box 6·4

.

Key Questions To Promote Understanding
and Dialogue With Parents
.

• What is your understanding of your child's condition?
Is there anything about your child's care that is
worrying you"
Do you feel you are being guided too much or too little"
• What would you find to be most helpful right now?
• Have you been able to consider that your child is in danger
of not getting better or dying?
• What are you hoping for?
• What do you fear the most right now?
• What will this decision mean for your child's life?
• What will this decision mean for your family?
Adapted from Jellineck M. Catlin E, Todres D et al: Facing tragic decisions with
parents in the neonatal intensive care unit: clinical perspectives. Pediatrics
89: I19-122. 1992.
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a parent or their behavior or actions without validating their
interpretation of the action, behavior, or situation. For example, professionals may conclude that parents are denying the
severity of their child's condition when they repeatedly ask
when the child will go home. With clarification, professionals may learn that they parents understand their child's prognosis and their statement may be an expression of a deeply
held desire to spend time with their child outside of the
hospital, particularly if death is likely.
Increasingly a model of shared decision making has
been challenged, particularly when parents request treatments that healthcare professionals perceive to be inappropriate or futile. 57 .58 Unilateral decision making in
certain situations has been suggested as a means for
resolving conflicts. Such claims are based on the ethical
integrity of the professionals and support the claim that
professionals are not obligated to provide futile treatments.
Unilateral decisions represent a significant departure from
the usual model of shared decision making and should be
subject to careful examination.
Parents may request treatments that are of questionable benefit for a variety of reasons. These include:
(I) faulty reasoning about the efficacy or benefit of a
therapy; (2) psychologic factors such as fear, anxiety, stress,
or depression; (3) unrealistic expectations about the outcomes of certain treatments; (4) inability of the family to
trust professionals to act in the child's best interest;
(5) religious conviction that life must be preserved at all
costs; and (6) an attitude that getting "everything" is an
entitlement 59 Understanding some of the reasons that may
influence parental requests offers professionals avenues to
explore as they work with parents to develop a mutually
agreeable plan of care.
For shared decision making to be authentic, the parental
perspective must be appreciated as legitimate and meaningful. Efforts should be undertaken to begin to bridge the gaps
between the professional and parental perspectives. This
means that the goals of the parent-professional relationship,
the outcomes of the process, and the process itself must be
closely scrutinized and evaluated.

Synergy Model
AACN's Synergy Model offers an additional framework for
applying ethical principles to the care of critically ill children and their families and contributes to a process of ethical
decision making. 30 Synergy, individuals working together in
mutually enhancing ways toward a common goal, is one of
the goals of the ethical decision-making process. Synergy
derives from responsive interdependence, shared commonality, and equity within relationships congruent with an ethic
of care (described previously). In the Synergy Model, the
child's needs are considered within the individual family
context, the community environment, and the child's unique
personal characteristics. These factors can be incorporated
into the assessment phase of the ethical decision-making
process (see later section). By achieving the desired patient
outcomes, integrity is promoted for the patient, family,
healthcare professional, and broader community.J°
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Partners on the Journey: Critical Care
Nurse Advocacy
Pediatric critical care nurses have a moral mandate to be
involved in resolving the ethical issues that arise in the care
of critically ill children and their families. Nurses bring a
unique perspective to decision making for critically ill
children because of their close proximity to patients and
families and their professional orientation, knowledge,
and skill. Their involvement is essential for the child and
family's safe passage through the often tumultuous experience of critical illness. Simultaneously, they struggle to
balance competing obligations to the patient, family, physician, institution, profession, colleagues, and society. It is
within this context that their advocacy occurs.
Advocacy, acting to safeguard and advance the interests
of another, is an essential dimension of critical care nursing practice 5 .30.60 The critical competencies described in
AACN's Synergy Model are consistent with the moral
obligations of nurses to advocate for the best interests of the
child in the context ofthe family.3o Nurses demonstrate their
moral agency when they assume a leadership role in
identifying and helping resolve ethical and clinical concerns. Effective advocacy requires clinical judgment, caring
practices, collaboration, systems thinking, and a commitment to clinical inquiry. Clinical judgment, for example, is
essential for understanding the child's disease trajectory and
prognosis, assessing benefits and burdens, and participating
in the development of goals and treatment plans, and
responding to the unique needs of the child and family.
Caring practices are how nurses express their moral
commitments of compassion, beneficence, and nonmaleficence in promoting the child's best interests and well-being.
Collaboration with the patient, family, and interdisciplinary
team is the means for understanding the values and goals of
the patient and family, communicating with others, and
engaging members of the interdisciplinary team in achieving mutually determined goals. Systems thinking focuses on
holistic interrelationships and the broader needs of the child
and family in addition to an awareness of how to navigate
effectively in the institution, healthcare system, and community. Such an orientation enables the nurse to nurture the
child and family's inherent capacities and the resources of
the healthcare system to promote the child's interests.
Finally, a commitment to clinical inquiry involves an ongoing process of questioning and evaluating practice and providing practice based on available data. These key elements
are essential for nurses to discharge their moral responsibilities on behalf of children and families.

PARENTS' AND CHILDREN'S RIGHTS
Based on the moral framework of shared decision making,
it is necessary for someone to represent the interests of the
child. In the United States there is presumption of parental
moral and legal authority in matters of concern for their
minor children. This is based on a belief that parents
generally have a sincere concern to protect their child's life.
Parents are obligated to protect their children from harm and
to do as much good for them as possible. Parents are in the
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best position to know their child's wants and desires. They
have a tendency to place their child's interests ahead of their
own. As a result of a long-tenn specific relationship with
their child, parents have a commitment to ongoing care. To
respect a child is to respect the relationships that are central
to the child's life. Thus, parents should have responsibility
for their children's healthcare decisions. After all, they bear
the financial, emotional, and medical consequences for
those decisions. Long after well-meaning healthcare professionals have gone home, "the family will be remembering
and incorporating this momentous decision into the fabric of
their lives.,,15
Generally parents are considered to be competent decision makers when they put their child's interest as primary,
appear to understand the essential components of their
child's illness and prognosis, and demonstrate rational
thinking processes. 61 This "reasonable parent standard" is
consistent with the elements of adult decision making
capacity. However, healthcare team members may question
parental competency, particularly when their decisions are
not congruent with professional recommendations. At times,
assessment of parental competency is clouded by the
parent's response to the crisis situation and grief. Under
these circumstances, professionals often assume that parents
are unable to participate in decision making because of lack
of understanding emotional upheaval or because professionals believe they must protect the parent from future
guilt. Professionals may also judge parental involvement,
behavior, and visiting patterns without adequate infonnation
or verification of their perceptions.
Despite professional assumptions to the contrary, most
parents in crisis are able to make sense out of the unexpected
and uncertain situation they are thrust into by their child's
illness. Their search for infonnation, support, and meaning
in the experience demonstrated their commitment to the life
of their child. They demonstrated their commitment to their
child's welfare by placing their own sense of self-worth and
their emotional needs in abeyance. Parents make significant
psychologic adjustments and major adjustments in interpersonal, family, financial, social, community, spiritual, and
moral contexts. Rather than being incapacitated, parents
demonstrate their advocacy by searching for acceptable
resolutions to the issues and problems that they face. 53 .54.62
In practice, the issue of who decides is not usually raised
to the surface. Only when disagreement arises over what
measures will serve the child best does the question of
who decides become a thorny one. For example, during the
past two decades, the question of parents' rights to make
medical decisions for their children has gained national
attention. It began in 1975 with the case of Karen Ann
Quinlan,53 whose parents had to go to the New Jersey
Supreme Court to be allowed to remove their comatose
daughter from a ventilator. The Baby Doe cases in 1982
prompted an attempt by the federal government to take
decision-making power away from parents who refused any
medical intervention for seriously handicapped newborns. 12
Then in 1989 a father in a Chicago pediatric intensive care
unit held hospital staff at bay with a shotgun while he

unplugged the respirator from his son, who was diagnosed
to be in a persistent vegetative state. 64

Limits to Parental Authority
The social policy of the United States gives a great deal of
discretion to parents and pennits supplanting their authority
only when the child's interests are clearly and severely
threatened by parental action. Children exist and develop
within the context of their families. As long as parents do not
neglect those people under their care, society should not
intervene. However, society has a responsibility to intervene
when parents refuse to give care to children that would
clearly benefit them or when parents subject children to
clear harm. For example, parental rights do not include the
right to abandon or endanger a child. However, when
parents insist on undertreatment or overtreatment in situations in which the healthcare team is in disagreement, the
responsibility for decision making is less certain.
Healthcare team members should use their knowledge of
the child's health status to attempt to resolve disagreement
with the family rather than supplant the family's decisionmaking authority. The physician and other team members
must be certain that to withhold a specific treatment or a
specific procedure would result in serious harm that would
threaten the child's life. The process of informing parents
often causes pain and anguish for them. Yet to avoid gi ving
parents all the infonnation available about their child's
diagnosis and prognosis does not show respect for their right
to make infonned healthcare decisions and provide their
child with needed support. Informed consent demands being
given the infonnation and then being allowed to make
a choice.
The interests of parents and the family must take a high
priority but do not override the fundamental respect for the
best interest of the child. Accepting parental perceptions and
actions does not imply that they must be blindly accepted or
acted upon. Each person's conclusions are open to examination, reflection, and comparison to socially and politically
detennined norms of behavior. Parental decision must be
assessed in light of the child's diagnosis, expected outcome
with and without treatment, degree of uncertainty about the
outcome, quality of the child's life, probability of benefits
from treatment, and presumed burdens if treatment occurs or
does not occur. However, parents' unique interpretations of
their child's interests must be taken seriously. Based on an
understanding of the parental perspective, it is, as Rhoden
suggests, justified to begin the assessment with the assumption that parents are the best decision makers for their
children and that their child's interests are primary in their
decision making. 55 It is incumbent upon others who would
challenge the parents' motives and commitments to prove
that they should be disqualified as decision makers instead
of parents having to prove their motives and commitments
are authentic. Unless a child is in imminent danger of dying,
the healthcare team has a duty to both the child and family
to take the time and effort necessary to reach consensus on
treatment decisions.
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When assessing parents as decision makers, several key
questions are recommended: (I) Do the parents meet the
"reasonable parent" standard? (2) Is the parent's request
within a morally acceptable range of options? (3) What
evidence is there that the parents should be disqualified as
the decision maker? (4) Are there actions that could be taken
to enhance the parent's ability to act as their child's
surrogate such as support and empathic listening, provisions
for nourishment and sleep, transportation, counseling, child
care, housing, or other resources?
Despite efforts to enable their participation. some parents
may be unable or unwilling to function in their proper role
as surrogate. In these relatively rare instances, healthcare
professionals must seek an alternative surrogate decision
maker who can represent the interests of the child. The issue
of who will speak for a dying child is particularly poignant
when an infant is unable to speak for himself or herself and
does not have a parent advocate. Without a parent or
surrogate to give meaning to the child's interests, to create
opportunities to question, explore, accept, or reject the
recommendations of caregivers, the child becomes voiceless. The balance of sharing in decision making can be
tipped in favor of the interests of the healthcare providers or
the bureaucracy of an overburdened state welfare system
may jeopardize decision making. When morally appropriate
surrogates are not present, caregivers must be more vigilant
in adhering to and having in place stringent safeguards to
protect the interest of the infant or child. When a parent
surrogate is absent, additional safeguards are necessary to
monitor how the balance of benefit and burden are
interpreted to avoid using technology inappropriately or
allowing treatment to continue beyond its usefulness.
Clearly there will always be cases in which assumptions
about parental authority will be appropriately challenged;
however, these will likely be few in number if a process of
shared decision making is made a reality. Cases of abuse or
neglect of the child (when a serious conflict of interest
exists), or instances in which the parental decision maker
lacks decision making capacity or refuses to serve as the
decision maker are examples of the types of situations in
which parental authority may be challenged. Safeguards to
protect the interests of children, families, and healthcare
providers will continue to be necessary and prudent.

The Courts
Although there is wide latitude given to families to practice
various religions and lifestyles, courts have intervened to
protect children and have not permitted refusal of standard
medical treatment in life-threatening situations, for example, by parents who are Jehovah's Witnesses or Christian
Scientists. The courts justify this interference by invoking
the "parens patriae" doctrine; that is, the state's legitimate
interest in the welfare of children and its right and duty
to protect vulnerable people from harm. The "parens
patriae" doctrine is often used in legislation and authorizes
the state to intervene when parents fail to provide necessary
medical care. 66

121

Ultimately, a court must decide when parents will be
disqualified as decision makers and another person designated to act in their stead. It is incumbent upon the
healthcare team to show the court convincing evidence of
why the parents should be removed as the child's decision
maker. It has been argued that when parents appear unable
to make decisions in the best interest of their child, a
healthcare professional-usually the physician-ought to
make the healthcare decisions. However, healthcare professionals are not necessarily unbiased participants. Personal
feelings of defeat and helplessness become interwoven with
their own individual beliefs about life and death. Conflicts
among the various agendas of research, education, and
treatment may slant their perspective.
A court may appoint a surrogate decision maker, who can
be another family member or a person who is not a member
of the healthcare team. The surrogate decision maker should
have knowledge of the facts of the child's case and should
be free of serious conflicts of interest. It is important that the
healthcare team understand the circumstances under which
the surrogate was appointed, which decisions the surrogate
can make, and what other judicial action may be occurring.
If the state removed itself completely from such situations, the consequences could be devastating for many
children. Yet, because of a primary belief that parents
want to and do act in their child's best interest, the healthcare team should guard against reaching premature conclusions about parental intentions.

NAVAGATING THROUGH ETHICAL ISSUES
There are many ways of discerning the ethical dimensions of
a situation or issue. The process of discernment is complex
and is influenced by emotions, scientific facts, values,
interpersonal relationships, culture, religion, the essence of
who we are, and myriad situational factors. All of these
elements converge to shape the way ethical questions are
framed. The discernment process involves clarifying factual, conceptual, and ethical issues. For example, when a
child is dying it is important to understand the diagnosis and
prognosis and to clarify any factual issues related to medical
care. Additionally, conceptual issues such as the meaning or
quality of life or what constitutes a life worth living may
also need clarification and discussion. Ethical issues such as
the reasons for forgoing certain life-sustaining therapies will
also require rigorous analysis and discernment.
When situations arise that precipitate feelings of ambiguity, conflict, or confusion, there is an occasion for reflection, analysis, and critique. A systematic process applying a
moral framework for pediatric decision making can help to
clarify and resolve the ethical tension. The first step is to
assess and clarify what is at stake in the situation and the
nature of the ambiguity, confusion, or conflict. Often important values of patients, families, and professionals such as
patient self-determination, prevention of harm, or relief of
pain and suffering may be in conflict. Responding to such
conflicts involves clarifying and verifying the medical, psychosocial, and spiritual facts of the case. This includes as-
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certaining: (a) who is involved in the case; (b) who has
decision-making authority-legally and morally-and the
role of the child in decisions; (c) the patient's diagnosis,
prognosis, and therapeutic options for treatment; (d) the
context for the decision including a chronology of events
and any factors that are influencing the decision making and
implementation of actions; (e) goals of treatment and reasons to support various viewpoints; (f) application of clinical and moral criteria used in reaching a decision with particular attention to the degree of certainty needed or desired
for decision making; and (g) determination of the healthcare
professional's moral and professional obligations. 67
Based on the Synergy Model, personal characteristics of
the patient-stability, complexity, predictability, resiliency,
vulnerability, participation in decision making and care and
resource availability---{)ffer a useful framework for illuminating the unique context for decision making. 3o For
example, stability, complexity, predictability, resiliency, and
vulnerability are key factors in assessing the child's clinical
condition, prognosis, or morbidity associated with illness or
injury. Assessing the child's and family's participation in
decision making and care and the personal, psychologic,
social, technical, and fiscal resources that the patient, the
patient's family, and the community bring to the situation
are essential for creating a comprehensive picture of the
situation. Based on the model, patient characteristics must
be evaluated on an ongoing basis as the situation evolves.
This process invites healthcare professionals and parents to
review these data regularly and continually assess goals,
treatment plans, and prognosis.
Following the assessment and analysis stage, it is
necessary to identify a range of reasonable options and the
reasons to support each. This involves clarifying the above
inforn1ation, determining the effectiveness of the proposed
treatments using a benefit-burden analysis for available
treatment options, evaluating the relevance of factors such
as age, quality of life, legal considerations, economics,
cultural, and other patient/family factors, and examining the
strengths and weaknesses of the moral arguments that
support each option. 67 Again, the Synergy Model offers a
useful framework for assessing these concerns.
The following questions may be helpful in this process67 :
• Is the decision within a morally acceptable range of
options?
• Does pursing a particular course of action violate other
highly valued moral principles such as avoiding harm
or self-determination?
• What competing personal or professional values
might affect your willingness to take moral action in
this case?
• What kinds of objections might be raised about the
proposed decision? How can you explain your decision
in a way that addresses those objections?
Once the analysis is complete the decision maker must
choose the option that advances the child's interests
best. The final step in the process is to implement the
decision, evaluate the process and outcomes, and detern1ine
what you have leamed that will be helpful in similar future

situations. Participants (parents and professionals) must
engage in a disciplined decision-making process that
includes procedural safeguards. Cassidy suggests a set of
procedural checks to evaluate the quality of the ethical
analysis (Box 6_5)68

Addressing Conflict
Providing care for critically children may result in controversy or conflict among patients, families, and healthcare
professionals. When healthcare professionals, older children, and families disagree about the treatment plan or
goals, a method for conflict resolution is necessary. During
moments of conflict or confusion, individuals may experience vague feelings of unrest or a generalized feeling of
distress or anxiety. At this stage such feelings may not be
fully comprehensible and only partially articulated. Emotions are often heightened as participants attempt to interpret
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Box 6·5
.
Procedural Check fQrEvaluating
the Ethical Analysis
.

.

.....

...

Clarity
Have participants been open and seen each factor as it is and
incorporated it into the system without distortions? Have
individuals projected their own views or values onto the
meanings of others statements? Have assumptions been made
or conclusions drawn without sufficient information or validation? Has a particular action or reason been labeled in a way
that short-circuits the initiation or continuation of the moral
work that is necessary to resolve quandaries and conflicts?

Consistency
Have key concepts such as quality of life, eurhallosia, etc., been
used consistently? Have terms or values been respected not
only when they would serve individual purposes or interests.
but also when they would inhibit them? Have the participants
clarified the meanings of terms and concepts?

Coherence
Do all of the clear and consistent parts of a judgment truly lit
together without contradictions or gaps? Are judgments sufliciently grounded in ethical theory, principles, and/or methodologies and lead to a rationally connected conclusion?

Comprehensiveness
Have all relevant views and factors been taken into account? Or, have the preferred elements such as facts, values,
etc., been included while confounding views and factors been
disregarded?

Conclusiveness
Have all countervailing views and arguments been openly
recognized and honestly refuted? Have I fairly won tI1e right to
claim that my conclusion is conclusive?
Adapted from Cassidy R: From principles to practice. In Cassidy R. Fleishman
A, eds: Pediatric l'thics-from principle." to practice. United Kingdom.
1996. Harwood Academic Publishers.
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their "gut feeling" that something is amiss. Individuals
often translate their intuitive and visceral signals into questions of "why are we doing this?" In response, individuals
may either become quite determined in attempts to have
their concerns acknowledged and discussed or become apathetic and retreat from the situation. Paying attention to
one's intuitive signals can create an opportunity for further
reflection and inquiry to identify and name the cause of the
anxiety and moral distress. During this period there may be
heightened levels of personal and professional hesitancy to
act according to the proposed plan of care. Questions of
"why are we doing this?" may become more intense. It is
prudent that individuals share their concerns with colleagues
and supervisors to avoid acting in isolation or implementing
risky, unreflective, unethical, or illegal plans. 67
For example, Sarah is a critical care nurse caring for
Joshua, a 4-year-old with end-stage neuroblastoma. Joshua
was transferred to the PICU 48 hours ago following a rapid
deterioration in his condition in response to gram-negative
sepsis. After initial stabilization with vasopressors, mechanical ventilation, neuromuscular blockade, antibiotics, and
narcotics, Joshua's condition has steadily declined. Although Joshua's parents have been aware of the possibility
of his death, they are clinging to the hope that he will be able
to recover from the sepsis. The team caring for Joshua
believes that it is unlikely that he will survive this episode
of sepsis and that death in imminent.
A family meeting has been arranged to discuss the
treatment plan. The physicians and nurses caring for Joshua
convey their concern about his condition and prepare the
family for the inevitability of his death. After appropriate
grieving, the family states that they "do not want Joshua to
suffer" and they agree that life-sustaining therapies should
be discontinued. The team agrees to do everything possible
to eliminate any distress during the process of treatment
withdrawal.
An order is written to administer a combination of
morphine sulfate at 10 times the current dose and a
neuromuscular blocking agent. Following medication administration, vasopressors and mechanical ventilation are to
be withdrawn. CPR is not to be initiated. Sarah calls the
physician covering the case and questions the infusion
regimen because it exceeds the unit standards for delivering
analgesia at the end of life and violates standards governing
the use of neuromuscular blockade. When Sarah questions
the order, the physician becomes defensive, stating, "Just
give the dose-he's dying anyway." When she returns to the
bedside, his mother begs her to "do something to end this."
In this example, Sarah is experiencing conflicting obligations: first, to advance Joshua's well-being by promoting
a humane death; to his mother who is begging her to end
Joshua's suffering (and hers); to the physician who has
ordered an inappropriate dose of medication; and to the
employing institution to practice within institutional, professional, regulatory, and legal boundaries. Without systematic reflecting, Sarah could become confused about the
moral justification for her actions.
First, Sarah must use her intuitive wisdom and her
clinical expertise to identify what is at stake in this situation.
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Second, it is useful to articulate and name the conflict using
ethical terms and concepts. In this instance, she may reason
that her primary goal is to relieve Joshua's pain and
suffering. Administering a dose of narcotic that exceeds her
assessment of his pain intensity combined with a neuromuscular blocking agent may threaten a moral boundary to
avoid intentionally ending a patient's life. Third, it would be
prudent to review the goals of treatment, the assessment data
regarding Joshua's pain, his responses to dosage changes in
the past, and to clarify the justification for using neuromuscular blocking agents with ventilator withdrawal, and to
reiterate the moral foundation of pain relief at the end of life
with the physician. Such clarification would also apply in
response to the mother's request within a context of
acknowledging and clarifying her fears and reassuring her
about the nurse's continued presence and support throughout the process. Fourth, Sarah must use the chain of command to clarify issues and address concerns in a constructive
manner. Nurses have an obligation to exercise their moral
agency in situations that are illegal or unethical. Fifth, it
would be helpful for Sarah to disclose the boundaries of
ethical practice to both the physician and mother. Based on
the ANA Code and End-of-Life Position Statements, she
must convey to the physician and Joshua's mother whether
she is willing to undertake any actions to intentionally end
the life of any person. At the same time, it is important to
reaffirm her commitment to providing humane care including aggressive treatment of pain, nonabandonment, continuing support, and presence. Sixth, Sarah may involve others
in helping to resolve the issue (e.g., ethics consultants, palliative care specialists, or other advisors). Finally, Sarah must
decide whether this situation warrants her conscientious refusal to participate in implementing the orders written for
the patient. If she reasons that she cannot, she must ensure
that the patient is not abandoned or compromised as a result
of her refusal. In this case, following the institutional process for conscientious refusal, mandated by JCABO, is
essential.69
When approaching a questionable or controversial act or
decision, special caution is advised as a response is
formulated. Before acting upon the physician's order and the
mother's request, further deliberation is warranted. The
following questions can assist in clarifying issues and
describing the nature of the ethical quandary67:
• Is the situation emotionally charged? Has the emotional nature of the situation changed over time? What
is the emotional tenor of those involved in the case?
Patient? Family? Healthcare professionals? Have relationships and interaction patterns changed?
• Has the patent's condition significantly changed? Is
there confusion about the facts or values that surround
the case? Is there explicit or overt conflict, disagreement, or questioning about the course of care? Is there
some patient circumstance or characteristic (social,
religious, economic, cultural, clinical, psychologic)
that is unduly influencing decisions?
• Is there evidence of increased hesitancy about the right
course of action? Is there increased resistance to
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implementing the proposed plan of action? Is there
evidence of intimidation, manipulation, coercion, or
threats being leveraged by healthcare professionals,
families, patients, or others?
• Is the proposed action a deviation from usual or
customary practice? Does this action violate a practice
standard or professional code of ethics?
• Is there a perceived need for secrecy around this
action? Could a disinterested party interpret this action
differently? Could you openly disclose the proposed
action to the patient, family, colleagues, or the public?
Would those involved be willing to be challenged,
sanctioned, or punished for their actions by licensing
boards, legal decision, professional organizations, or
the public?
Answers to these questions may be helpful in articulating
the nature of the ethical conflict, ambiguity, or confusion.
Initiating this process of assessment and discernment may
resolve the conflict. General strategies for resolving ethical
conflicts are included in Box 6-6. In other instances, this
process will be the beginning of a longer process that may
involve ethics consultants or committees.

Environments That Support Ethical Practice
Critical care environments may be conducive and supportive of ethical thinking and decision making or may erect
numerous formal or informal barriers to the process. Formal
barriers may result, for example, from the development of
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Box 6-6

.

.

Strategies for Addressing Conflicts

• Anticipate and address ethical concerns in a proactive
manner.

•
•
•
•
•
•
•
•

•

•

Be accessible and fully present in each encounter.
Create an atmosphere of open communication
Listen without problem solving.
Engage in nonjudgmental listening.
Acknowledge a common commitment to the child's
well-being.
Admit areas of uncertainty and the limits of
prognostication.
Communicate decisions and plan of care honestly and
openly.
Provide a forum for staff to discuss and understand the
decision and the decision-making process that is not
focused on convincing those who share different views.
Develop policies regarding end-of-life care and decision
making including do-not-resuscitate orders, forgoing
life-sustaining treatment including medically provided
hydration and nutrition, pain management, and terminal
sedation.
Honor healthcare providers' requests not to participate in
morally objectionable situations based on hospital policy.
When standard methods fail, involve outside parties such
as ethics committees or ethics consultants.

end-of-life care institutional policies that are ambiguous,
controversial, or ignored. Additionally the traditional hierarchy within medical institutions may effectively silence
those who challenge the authority of physicians or administrators, or question the intent or substance of institutional
policies. 7o
An ideal environment would bring into harmony ethical
standards, the scientific basis for care, a holistic approach,
and a family-centered focus. Pluralistic values and beliefs
would not have to clash, but could be openly acknowledged
and truthfully communicated in order for harmony to exist
and for honorable decision making to occur. The following
strategies may promote better care through the development
of an environment that promotes ethical practice.
Clarify Personal and Professional Values. Selfreflection and a process for clarifying personal and professional values that influence the provision of pediatric
critical care is an essential first step in creating an ethical
practice environment. Within this process, healthcare professionals must explore within themselves the boundaries
of their commitment to accommodate values and commitments that are different from their own. For example,
professionals who hold a strict sanctity of life view may
find a request to forgo life-sustaining treatment morally
objectionable. In such instances the person must ask what
it would take to be able to accommodate and respect the
conscience and integrity of another while preserving one's
own. In the end, the person must determine whether
integrity-preserving compromise is possible or whether the
threat to one's deeply held values requires conscientious
refusal to participate.
Specify Norms of Professional Behavior and
Clinical Practice. A key element in developing an ethical
practice environment is to engage in a process of defining
norms of professional behavior and clinical practice.
Ideally, members of the community would be involved in
developing the norms for end-of-Iife care, care of children
with disabling or life-threatening conditions, etc., through
participation in focus groups or institutional committees.
Norms may include, for example, expectations about
the process for decision making, advance care planning, pain and symptom management, end-of-life care,
conflict resolution, professional communication, and collaboration. These norms become the "benchmarks" for
evaluating quality of care and are the basis for professional
accountability.70
Develop Processes to Monitor and Evaluate
Ethical Performance. Once norms are developed, it is
essential that individuals are held accountable for upholding
the norms of behavior and ethical performance. One
mechanism for monitoring adherence to agreed-upon norms
for clinical care is through quality improvement mechanisms. Through these mechanisms variances can be documented and strategies for recognizing excellence and
addressing deficiencies developed.
Standards for ethical performance for the entire organization help to uphold the ethical values and behaviors.
Structures to monitor ethical performance may include
integration of ethical performance into quality improvement
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activities, and mechanisms for identifying and dealing
with ethical violations, conscientious objection, and public
accountability.
Develop a Culture of Integrity. The goal of monitoring and evaluating performance is not merely to
detennine whether compliance standards are met. Rather,
the goal is toward a commitment to integrity in relationships, services, and decisions. If an institution is not clear
about what it values, then decisions are likely to be guided
by individual values and may result in incongruencies in
clinical care or between the employees and the institution's
leaders. Attitudes and actions of individuals at all levels of
the organization are a tangible sign of their commitment to
the values they espouse 70
Integrity is essential for maintaining a coherent professional identity that is based on compassion, caring, and trust
and for preserving self-esteem. For professionals to see
themselves as being trustworthy, they must believe that what
they are doing is consistent with their personal or professional standards and moral guides. If professionals perceive
that their personal or professional standards are being
undennined or that there is inconsistency between what they
believe and how they behave, their integrity is compromised. When integrity is threatened, professionals may be
unable to convey confidence in their clinical practice to
patients or others, their communication may be thwarted,
their ability to respond compassionately to the needs of
others may be eroded, and ultimately, the quality of patient
care will be undennined.
Create or Refine Structures That Support Ethical
Inquiry and Action. An ethical practice environment
demands systems that support proactive identification and
addressing of ethical issues. Participating in institutional
ethics committees, creating and offering a curriculum for
ethics education, developing forums such as ethics rounds
for interdisciplinary discussion of ethical issues, and organizing ethics councils or interest groups are essential
strategies to promote ethical inquiry and action. Each is
described below.
Institutional Ethics Committees. Institutional
ethics committees are an important tool for promoting
individual and institutional sensitivity to the ethical issues
faced at the bedside. When healthcare professionals, older
children, and/or families disagree about the treatment plan
or goals, a method for conflict resolution is necessary. Since
the 1980s ethics committees have become a common
institutional mechanism for clarifying, analyzing, and resolving difficult ethical issues. The Joint Commission on
Accreditation of Healthcare Organizations (JCHAO) now
requires healthcare institutions to have a mechanism for
addressing ethical issues. In many cases, this involves a
multidisciplinary ethics committee.? I Most often ethics
committees are used when standard approaches to decision
making through collaboration are insufficient or are not
successful in resolving the ethical tensions. Generally ethics
committees function in an advisory capacity and in many
cases provide education, mediation, support, and external
review. Standards for ethics consultation have contributed to
greater awareness of the need for consistency in approach,
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specialized knowledge and skill, a systematic process. and
ongoing education and evaluation. 72
Ethics committees can assist parents and caregivers to
reflect upon, analyze, and develop ethically sound responses
to the ethical issues that may arise, particularly at the end of
life. Ethics committees can provide a forum of impartiality
to assist parents and healthcare professionals in the process
of ethical decision making. Complex issues coupled with
obvious disagreement about what the treatment should be or
who should decide invite ethics committee consultation.
Most ethics committees provide (I) education about ethical
principles that guide decision making; (2) a forum for airing
feelings and conflicts about dilemmas; (3) a system for
emotional support for healthcare professionals and families;
and (4) an interdisciplinary group to fonnulate policies that
guide decision making. Generally, the actions of the
committee are purely consultative and are not binding on
any professional. However, submitting ethical dilemmas to
uninvolved parties for consideration allows for objective
discussion of various viewpoints.
The generic makeup of an ethics committee is not
uni versally agreed upon. The consultation process is enhanced when committees include diverse representation
including physician, nurses, social workers, chaplains,
administrators, parents, and community members. A broad
perspective enhances contributions on issues that may
require knowledge about organizational systems and external resources that may aid decision making. Other committee members may include ethicists and/or attorneys, ideally
ones without an institutional conflict of interest. It is most
important that all committee members are willing to look
beyond their own values and preferences and view issues
from the patient's perspective. The members should have a
desire to be informed about ethical theory and principles, as
well as current issues. The members must be willing to listen
to each other; accept ambiguity; and be reflective, critical
thinkers 20
Access to ethics committees should be available to all
members of the healthcare team, patients, and families. The
committee should develop procedures to ensure timely and
effective consultation. Written information that outlines the
committee's roles should be provided to staff and families.
Ideally parents and professionals are proactive in addressing
ethical concerns. Professionals should anticipate decision
points and potential sources of disagreement and conflict
and regularly review and revise treatment goals based on
patient/family preferences.
The involvement of the courts in resolving conflict
should be reserved for cases of intractable conflict and only
as a last resort. Professionals and parents must consider the
limitations of the courts in resolving value conflicts and
what the appropriate role the courts can play in resolving
disputes. Pursuing court intervention necessarily alters the
nature of the relationships and may serve to create or
exacerbate adversarial tensions. It is prudent for ethics
committees and attorneys to work collaboratively to appreciate both the ethical and legal context of troubling cases.
The legal response may not necessarily be the best moral
response. Therefore, the process of working through diffi-
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cult cases must first focus on what is justifiable from an
ethical perspective and how to address the legal concerns
that accompany the best decision.
Ethics Education. Healthcare professionals who
work in critical care units have been expected to be experts
in the moral issues that surround life and death. Unfortunately, most have received little education in ethics. Many
professionals still practice with the belief that one's desire to
do good is directly proportional to how much good is
actually done. Thus, when called upon to buffer the
powerful reality of disease and disability and to make sense
out of alternative courses of action, healthcare professionals
may not be successful.
Nurses can enhance their decision-making ability by
taking advantage of educational opportunities that focus on
ethical analysis and the specific moral issues faced by
critical care nurses. Ethics education helps practitioners
make moral choices based upon reason rather than intuition.
Hospitals can provide a variety of educational opportunities
for both nurses and physicians that enhance their knowledge
of ethics and their collaboration. Grand rounds, unit-based
rounds, and journal clubs are excellent additions to formal
educational seminars.
Ethics Rounds. Ethics rounds are similar to other
formal case discussions. However, in ethics rounds the
clinical aspects of the case become the backdrop for an
organized discussion of the ethical dilemma and possible
solutions. Ethics rounds can be multidisciplinary or confined
to a homogeneous group such as nurses in the pediatric
critical care unit. To be helpful, these rounds must be
regularly scheduled and conducted by a skilled leader with
knowledge in bioethics. It is helpful if this individual is also
a nurse or is a person experienced in working with nurses on

resolving ethical issues so that nursing concerns are raised
and discussed. Ethics rounds can be a discussion of
retrospective or concurrenl cases. They offer an opportunily
to consider ethical concerns prospectively, rather than
operaling from a crisis position. The goal of these rounds is
not to make clinical decisions, but to discuss moral
problems confronting caregivers.
A commitment to ethical practice will incorporate a
variety of these mechanisms, depending on the resources,
priorities, and culture of the institution. Awareness of ethical
principles and theories, a methodology for ethical analysis.
and institutional support are key ingredients to support
quality care and the integrity of parents and healthcare
providers.

SUMMARY
Ethical reasoning and deliberation are essential for optimal
care of critically ill children and their families. Understanding current ethical issues and a process for ethical
decision making allows nurses to participate fully as a team
member and patient advocate. Creating an ethical practice
environment for professional practice and patient care
involves establishing an environment in which communication and coordination of care are optimized, the focus
is on the best interests of the child, and there are continual
efforts to encourage the child's participation in decision
making. Providing ongoing education through ethics
rounds and participation in ethics committees will immeasurably enhance the ability of the healthcare team to
support patients and families, as well as one another, when
addressing the ethical issues that arise in pediatric critical
care.
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Phenomena
of Concern

Critical care nurses are concerned with tissue perfusion, oxygenation and
ventilation, acid-base balance, intracranial dynamics, fluid and electrolyte
regulation, nutrition, clinical pharmacology, thermal regulation, host defenses, skin integrity, and comfort in each critically ill infant and child for
whom they provide care. These phenomena are the focus of the chapters in
this section. Universal care needs, rather than specific primary problems, are
examined where nurses play a major role in optimizing patient outcomes
through a deliberate proactive process that integrates clinical knowledge and
skillful assessment and intervention. Within each phenomenon of concern
for critical care nurses, essential embryology, maturational anatomy and
physiology, and instrumentation are discussed.
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S

urvival of cells, organ systems, and the individual
depends on the maintenance of adequate tissue perfusion. The production of energy for the multitude of functions
required for homeostasis is dependent on the delivery of
sufficient oxygen and nutrients to cells throughout the body.
Although cells in the human body vary widely in structure
and function, mitochondria in all cells are responsible for
the production of energy. In the presence of oxygen, the
mitochondria synthesize significant quantities of adenosine
triphosphate (ATP) from glucose. ATP forms adenosine
diphosphate (ADP), releasing cellular energy in the process.
Constant energy is available because ADP can recombine
with a phosphate group to form another ATP. Without
oxygen (that is, under anaerobic conditions) only a fraction
of ATP nonnally synthesized from glucose is produced. All
the processes that require energy can be disrupted if a
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pathophysiologic process interferes with the delivery of
oxygen to cells.
The cardiovascular system is responsible for the delivery
of oxygen and nutrients to tissues. Not only does the heart
pump continuously to ensure that the billions of cells within
the body are adequately perfused, but the cardiovascular
system is responsive to demands for more or less blood to
tissues.
This chapter provides a foundation for understanding the
complex physiology of the cardiovascular system in infants
and children. Fetal development of the heart is presented as
a basis for understanding the structural abnormalities seen in
congenital heart disease. Essential anatomy of the cardiovascular system is reviewed, and the physiology of cardiovascular performance is developed in greater detail, with
attention to the maturational changes that are characteristic
of infancy and childhood. Assessment of the cardiovascular
system is related to the care of infants and children who are
seriously ill and require intensive care. Pharmacologic
support of cardiovascular function, pacemaker therapy, and
mechanical support of circulation are discussed. Cardiovascular dysfunction is detailed in Chapter 18.

ESSENTIAL EMBRYOLOGY
Cardiac embryologic development begins just before the
third week of gestation and is normally completed by the
seventh week. The cardiovascular system is the first system

to function in the embryo; its early development is most
likely a response to the high metabolic demands of the
rapidly developing fetus.

Development of the Heart
The origin of cardiac tissue is the mesoderm of the embryo.
At day 18, during the third gestational week, a crescent, or
arch, of mesoderm is formed from a pair of endothelial
tubes. The endothelial tubes fuse and grow, establishing a
single, straight "heart tube" at about day 20. A rhythmic ebb
and flow of blood that precedes heartbeating characterize
the primitive heart.
Continued cellular development around the cardiac tube
results in the formation of distinct myocardium and
endocardium. By day 22, contractile activity of the heart is
evident, and forward blood flow is achieved. Between days
24 and 26, heartbeating is evident, as is the regulation of
heart rate, vascular tone, and cardiac output through cardiac
sympathetic nervous system innervation and action of
circulating catecholamines.
Bulbus Cordis. Because the anterior (arterial) and
posterior (venous) ends of the cardiac tube are fixed in
place, growth of cardiac tissue occurs in a confined space,
causing torsion and flexion of the cardiac tube. At approximately 25 days' gestation, the straight tube has flexed into
a loop with the rightward expansion forming the bulboventricular mass-the future right ventricle (Figure 7-1, A).

Aortic sac

Right --i--:HJ.Jj
ventricle

Fig. 7-1 A and B, Early embryonic heart. Straight
tube has looped; ventricle is left and posterior; and
bulbus cordis is right and anterior. Delinitive right
ventricle is noted to bud out of the bulbus cordis.
Earliest connection between the primitive (left) ventricle and evolving right ventricle is the primary
interventricular foramen (bulboventricular foramen).
(From Holbrook PRo Textbook of pediatric critical
care, Philadelphia, 1993, WB Saunders, p 243.)
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Looping to the right is referred to as dextro- or D-Iooping
and results in the right ventricle lying to the right of the
primitive left ventricle. (Looping to the left is called levo- or
L-Iooping, which results in ventricular inversion.)
Differentiation of the ventricles begins as continued hyperplasia of the cardiac tube (see Figure7-1, B). Growth of
the proximal bulbus cordis gives rise to the right ventricle.
The midportion of the bulbus cordis, called the conus cordis,
gives rise to the outflow portions of both ventricles. The
distal portion of the bulbus cordis, the truncus arteriosus,
di vides into the aortic and pulmonary roots.
Septation of the Heart. The primitive ventricles are
connected by the primary interventricular foramen, which is
the only route for blood flow into the developing right
ventricle because the atrioventricular (AY) canal is associated only with the left ventricle. As the ventricles enlarge,
the muscular septum develops from the floor of the ventricles. The endocardial cushions, which initially appear as
heaped up masses of endocardium, develop from the walls
of the AY canal. The cushions grow toward each other,
eventually fusing in a process that results in the origin of
two AV valve orifices, each aligned with one ventricle. The
tricuspid and mitral valves evolve from the processes, which
divide and align the AV canal. A communication between
the two ventricles, referred to as the secondary interventricular foramen, persists until the sixth week of gestation
(Figure 7-2). The secondary interventricular foramen closes
through contributions from the muscular septum, endocardial cushion tissue, and conus cordis.
The atria are separated by a series of partitions (Figure
7-3). The first to form is the septum primum, which grows
toward the endocardial cushions. Communication between
the atria persists through the ostium prirnum. As septum
primum joins the AV septal portion of the AY canal,
perforations of the septum primum join to give rise to the
septum secundum. Growth of the septum secundum leads to
the obliteration of any communication between the atria
except for the foramen ovale. This flaplike valve is covered

3~~,L---1H---AV canal

Fig. 7-2 Septation of the ventricles. Two ventricles are well
formed and are connected by the secondary interventricular
foramen. Outflow region of the heart is defined by the conus.
(From Holbrook PR: Textbook of pediatric critical care. Philadelphia, 1993, WB Saunders, p 243.)
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by a portion of septum primum and permits right-to-Ieft
blood flow across the atrial septum throughout gestation.
Conotruncal Development. The truncus arteriosus
is the common outlet for blood flow from the heart. Ultimately it separates into an aortic and a pulmonary trunk.
Ridges from the bulbus cordis form proximally as truncal
ridges form distally. The ridges grow and fuse into the aorticopulmonary septum. Under the influence of streaming
blood flow, the common truncus arteriosus spirals and divides into the great arteries around day 34 of gestation.
Spiraling results in a right-to-left reversal of the aorta from
above the right ventricle to the left ventricle. If the aorticopulmonary septum fails to align with the interventricular
septum, a ventricular septal defect results. In addition, unequal partitioning or alignment can result in an undersized
aorta or pulmonary artery. Persistence of the truncus arteriosus can also result, if aorticopulmonary septation fails, associated with ventricular septal defect, because the bulbar
ridges contribute to ventricular septation as well.
The conus cordis, the midportion of the developing
bulbus cordis, is important in right ventricular development,
particularly in the development of the right ventricular
outflow tract. The distal tissues of the conus also participate
in septation of the truncus arteriosus. Development of the
midportion of the conus results in the establishment of
definitive continuity between the left ventricle and the aorta.
The right side of the conus establishes the outflow tract or
infundibulum of the right ventricle associated with the
pulmonary trunk. If the conus is inverted, transposition of
the great arteries results. Double-outlet right ventricle or
Taussig-Bing malformation can result when the subaortic
conus is not absorbed.
Pulmonary and Systemic Veins. The common pulmonary vein grows from the posterior atrial wall as atrial
septation is developing (Figure 7-4). It forms connections
with the splanchnic plexus, which is associated with both
the developing lungs and the cardinal venous system, which
in turn drains into the umbilical vein. Growth and expansion
of the common pulmonary vein establishes four drainage
channels from the lungs. As the four individual pulmonary
veins enlarge, the left atrium enlarges as well, incorporating
the pulmonary veins directly into its posterior wall. Connections of the systemic veins into the splanchnic plexus
separate as the individual pulmonary veins develop. Subsequently, all pulmonary venous drainage from the splanchnic
plexus flows to the left atrium via the pulmonary veins.
Persistence of connections between the cardinal venous and
pulmonary venous systems results in partial or total
anomalous pulmonary venous connection or drainage.
The sinus venosus is the proximal end of the cardiac tube,
the inlet chamber ofthe primitive heart. The right sinus horn
ultimately forms the superior vena cava (SYC). The
coronary sinus forms from the proximal left sinus hom and
the connection of the two sinus horns. Development of the
SVC and of pulmonary drainage of the splanchnic plexus
results in involution of the left common cardinal vein and
the distal portion of the left sinus horn by the end of the sixth
week of gestation. The left innominate vein develops from
the left common cardinal system. The right common
cardinal system may persist as the azygous vein.
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Fig. 7-3 Drawings of the developing heart, showing partitioning of the atrioventricular canal, primitive
atrium, and ventricle. A, Sketch showing the plane of the coronal sections. B, During the fourth week
(about 28 days), showing the early appearance of the septum primum, interventricular septum, and dorsal
endocardial cushion. C, Section of the heart (about 32 days), showing perforations in the dorsal part of the
septum. D, Section of the heart (about 35 days), showing the foramen secundum. E, About 8 weeks,
showing the heart after it is partitioned into four chambers. (From Moore KL, Persaud TVN, Shiota K:
Color atlas of clinical embryology, Philadelphia, 1994, WB Saunders, p 185.)

Atrioventricular Valves. The mitral and tricuspid
valves develop primarily from the ventricles, with contributions to the anterior leaflets of both derived from the
tissue that surrounds the developing AV valve orifices.
Sheets of tissue form along ventricular trabeculations that
subsequently create definitive valve leaflets with supporting
tendons and muscles. The anterior leaflet of the mitral valve
recei ves an important contribution from the superior endocardial cushion. The tricuspid valve develops almost exclusively from the right ventricle. Mitral valve development is
complete before development of the tricuspid valve, which
continues to 12 weeks of gestation.

Semilunar Valves. Partitioning of the truncus arteriosus into the aorta and pulmonary trunk has occurred by
33 days of gestation. Paired swellings of truncus cushion
tissue form the primitive aortic and pulmonic valves. Blood
flow through the valves results in evacuation and migration
of the valves through 6 weeks of gestation.
Aortic Arch. Six pairs of aortic arches develop from
the truncus arteriosus, giving rise to major arteries and the
aortic arch itself. Head and neck arteries develop from the
third and fourth pairs of arches. The fourth arch also
develops into the aortic isthmus or the definitive aortic arch.
The right and left sixth arches form the right and left
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Fig.7-4 A, Development of the common pulmonary vein (CPV). As the individual pulmonary veins (PV)
are defined, connections to the systemic veins are losl. During this time, ventricular and atrial septation are
proceeding. B, Connection of the pulmonary veins. The common pulmonary vein becomes incorporated
into the back of the left atrium, allowing connection of four individual veins. Septation is complete,
and the cardinal system has atrophied. SVC. Superior vena cava; IVC. inferior vena cava.
(From Holbrook PR: TeXlbook of pedialric crilical care, Philadelphia, 1993, WB Saunders, p 244.)

pulmonary arteries. The distal portion of the left sixth arch
persists as the ductus arteriosus. Incomplete involution of
the aortic arch vessels can result in coarctation of the aorta,
interrupted aortic arch, and other defects.

Congenital Cardiac Defects
No single classification system adequately organizes congenital cardiac malformations into major etiologic groups.
One system divides congenital heart defects (CHDs) into
four groups (Box 7-1): (I) anomalies of the three major
cardiac segme~ts, (2) defects of cardiac septation, (3) congenital defects of the arterial wall and intracardiac connective tissue, and (4) congenital abnormalities of the endomyocardium.' This system remains the most universally
accepted.
Defects of Cardiac 5egmentation. Van Praagh and
Vlad 2 described the heart as consisting of three major
segments: the visceroatrial situs, the ventricular loop, and
the conotruncus. Variations of the visceroatrial situs include
situs solitus (normal location of organs and vessels), situs
inversus (mirror image of the normal location of organs and
vessels) and heterotaxy (ambiguous location of organs).
Heterotaxy infers an abnormal arrangement of body organs
(situs ambiguous) with either duplication or absence of
normally unilateral organs (spleen), hence the associated
asplenia or polysplenia.
Ventricular looping refers to the position of the heart
within the thorax. Dextrocardia denotes the heart is in the

right chest. In dextrocardia the heart may be structurally
normal, or it may have structural defects. Levocardia
denotes the heart is in the left chest. When levocardia occurs
with situs inversus, it is almost always associated with
complex structural heart disease. 3 Abnormal ventricular
looping can also result in CHD such as corrected transposition of the great arteries, which is associated with defects
in cardiac septation and abnormalities of the AV valves.
Many of the major cyanotic CHDs are most likely the
result of anomalies of the developing conotruncus. Abnormal development of this vital area of the fetal heart may
result in tetralogy of Fallot or transposition of the great
arteries, the two most common cyanotic heart defects.
Abnormal development of the conus almost invariably leads
to secondary defects, including defects of the ventricular
septum.
Defects of Cardiac Septation. Defects of the atrial
septum are among the most common forms of structural
heart disease. Most are compatible with multifactorial
inheritance. Defects of the ventricular septum are even more
common, probably because the ventricular septum closes
over a longer period (as compared with other developmental
occurrences in the fetal heart), leaving it susceptible to
adverse environmental conditions.
The endocardial cushions playa role in both atrial and
ventricular septation, as well as in the formation of the AV
valves. Defects in their development result in severe CHD,
including ostium primum atrial septal defect and complete
AV canal defect. Infants with trisomy 21 have about a 40%
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Box 7-1

~ Etiologic Classification of Congenital
Heart Diseases

Defects of the Major Cardiac Segments
Dextrocardia
Levocardia with situs inversus
Corrected transposition
Tetralogy of Fallot
Transposition of the great arteries
Defects of Cardiac Septation
Atrial septal defect
Ventricular septal defect
Endocardial cushion defect
Aortic stenosis (valvar and subvalvar)
Pulmonic valve stenosis
Defects of the Arterial Wall and Cardiac
Connective Tissue
Persistent ductus arteriosus
Coarctation of the aorta
Interrupted aortic arch
Peripheral pulmonary stenosis
Supravalvar aortic stenosis
Aortic, pulmonary, or mitral insufficiency
Defects of the Endomyocardium
Endocardial fibroelastosis
Glycogen storage disease
Hypertrophic obstructive cardiomyopathy
Cardiac conduction disorders

incidence of CHD; almost all are. defects of atrial or
ventricular septation and maldevelopment of the endocardial cushions. The precise reason for this association is
unknown; the other major autosomal trisomies (15 and 18)
also can have endocardial cushion anomalies or ventricular
septal defects.
Defects of the Arterial Wall and Intracardiac
Connective Tissue. Patency of the ductus arteriosus is
likely the result of both prenatal and perinatal influences.
Premature infants and those infants with congenital rubella
syndrome have a higher incidence of patent ductus arteriosus. Perinatal hypoxia plays a role in persistent patency of
the ductus, although the exact mechanism is unclear. An
increased incidence of persistent patent ductus arteriosus is
found among infants born at high altitude, and the ductus
remains patent somewhat longer in infants with cyanotic
heart disease than in the normal infant.
Coarctation of the aorta and interrupted aortic arch may
be the result of reduced flow across the left ventricular
outflow tract. Patients with interrupted aortic arch can also
have an associated ventricular septal defect, transposition of
the great arteries, or double-outlet right ventricle. These
cases reflect complex events during cardiogenesis related to
abnormal migration of neural crest cells, which contribute to

the development of the aortic arch and the conotruncal
region of the heart. Neural crest cells are also important in
the development of the thymus. The association of
conotruncal abnormalities (interrupted aortic arch, truncus
arteriosus) and DiGeorge syndrome (hypoplasia to aplasia
of thymus and parathyroids) may be related to neural crest
abnormalities.
Coarctation of the aorta may occur as an isolated defect,
suggesting that the events contributing to its development
occur after development of the heart is complete. Coarctation usually involves a shelf of tissue that extends in the
aortic wall around its circumference. The shelf may develop
at the orifice of the left subclavian artery or the insertion of
the ductus arteriosus.
Congenital rubella syndrome is associated with generalized hypoplasia of the pulmonary artery branches, which
results in peripheral pulmonic stenosis. Supravalvular aortic
stenosis is often a familial problem.
Abnormalities of intracardiac connective tissue may lead
to aortic, pulmonary, or mitral valve insufficiency. Patients
with Marfan's syndrome may have myxomatous degeneration of valve leaflets that most often affects the aortic and
mitral valves.
Congenital Anomalies of the Myocardium, Endocardium, and Conducting System. Endocardial fibroelastosis (EFE) often is a sequela to perinatal viral infection.
Glycogen storage disease is a metabolic disorder in which
glycogen infiltrates the myocardium. An abnormal recessive
gene results in the characteristic enzymatic abnormality.
Prenatal diagnosis is possible. Hypertrophic obstructive
cardiomyopathy (HOCM) is a progressive cardiomyopathy
usually manifested in early adult life and is associated with
left ventricular hypertrophy, left ventricular outflow tract
obstruction, and rhythm disturbances. Multiple gene abnormalities have been identified as the cause, and at least 50%
of affected individuals acquire this disease through an
autosomal dominant trait. 4
Several disorders of cardiac conduction, including WolffParkinson-White (WPW) syndrome, are reported in families; however, the mode of inheritance of WPW syndrome is
unclear. The congenital long QT syndrome is an inherited
cardiac ion channel disorder in which five gene defects have
been identified as the causative abnormality. This disorder is
associated with syncope and torsade de pointes-a polymorphic form of ventricular tachycardia.

Fetal Circulation
Structure and function of the fetal cardiovascular system not
only support fetal life and development but also permit
nearly instantaneous transition to extrauterine life at birth.
During fetal life, the placenta is the source of oxygenated
blood, which flows from the placenta via the umbilical vein
to the fetal liver (Figure 7-5). Here, flow divides. Some
blood flows to the developing liver and abdominal viscera,
while most is shunted through the ductus venosus to the fetal
inferior vena cava (lVC). The most oxygen-rich blood
passes up the lYC, where it preferentially streams across the
foramen ovale to the left atrium and left ventricle, the aortic

Chapter 7 Tissue Perfusion

Fig. 7-5 Fetal circulation. Flow from the placenta is directed
into the umbilical vein, through tbe liver via the ductus venosus,
and into the right atrium. Streaming, aided by venous valves,
carries the oxygenated blood through the foramen ovale to
the systemic circulation. Smaller flows proceed through the
right heart and ductus arteriosus to the descending aorta. (From
Holbrook PR: Textbook of pediatric critical care, Philadelphia,
1993, WB Saunders, p 246.)

arch, and the developing heart (via the coronary circulation)
and brain.
Blood from the coronary circulation, brain, and upper
body ofthe fetus returns to the fetal heart via the SVC. Flow
from the SVC, which has less oxygen than IVC blood,
drains into the right ventricle and is ejected into the
pulmonary artery. Flow here again divides. The majority
flows across the ductus arteriosus to the descending aorta.
All but 7% to 8% shunts away from the fetal lungs. SVC
blood mixes with a smaller volume of blood descending
from the aortic arch, supplies the lower body of the fetus,
and returns to the placenta via the umbilical arteries.
Fetal oxygenation is unique. Blood from the placenta is
70% to 80% saturated with oxygen (P0 2 , 32 to 35 mmHg).
Blood ejected from the left ventricle, perfusing the heart,
head, and brain, is 65% to 70% oxygenated (POz, 28 to
30 mmHg). Oxygen saturation in the descending aorta is
60% to 65% (P02 , 20 to 22 mmHg). Blood returning to the
placenta in the umbilical arteries is less than 60% saturated
(P0 2 , 14 to 21 mmHg). Polycythemia and fetal hemoglobin,
which has an increased affinity for oxygen, permit compensation for the relative hypoxia of the fetal environment.
The largest volume of flow to the fetal heart is through
the IVe. Therefore the hepatic circulation and the ductus
venosus are significant regulators of the total venous return
and ventricular preload. During periods of fetal stress or
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hypoxia, the ductus venosus dilates to preserve delivery of
oxygenated blood to the heart. Consequently, less blood
flows through the hepatic veins. In addition, a larger
percentage of SVC blood flows across the foramen ovale
rather than streaming almost exclusively into the right
ventricle. Both factors allow more efficient delivery of
oxygen and nutrients to vital organs. 5
Fetal Cardiac Output. During fetal life, mechanisms
that are similar to those that function in the mature cardiovascular system regulate cardiac output. However, fetal response to regulatory mechanisms is different. As is true of
the infant after birth, the capacity for change of stroke volume is limited. Thus the heart rate response to demands for
increased cardiac output is especially important. Similarly,
although the relationship between end-diastolic volume
and stroke volume holds, the fetal heart, like that of the
infant, functions near the top of the Frank-Starling curve.
Because of fetal myocardial noncompliance, changes in filling volume often result in little change in cardiac output.
Finally, as is also true in the infant, afterJoad is the primary
regulator of cardiac output. When afterJoad is increased,
cardiac output falls because of the limited capacity for increased contractility related to limited numbers of myofibrils and less efficient calcium exchange across the myocardial cell membrane.
Fetal Stress Response. Hypoxia is the major stress
to the fetal heart. The mature cardiovascular system responds to hypoxia via neurohormonal and local vascular
pathways, which result in tachycardia, vasoconstriction, increased cardiac output, and redistribution of blood flow to
the brain and myocardium. However, in the fetus, hypoxia
leads to bradycardia rather than tachycardia. Bradycardia
results from both vagal action and decreased myocardial
oxygenation. In addition, because hypoxia stimulates vasoconstriction in the fetus, afterload is increased, and both
right and left ventricular output falls.

Circulatory Changes at Birth
At birth, as the neonate takes a first breath and the umbilical
cord is clamped, rapid adaptation to extrauterine life occurs.
The establishment of respiration is associated with increased
P02 . In addition, the onset of breathing stimulates synthesis
of pulmonary vascular prostacyclin, which is undetectable
in fetal life. Both prostacyclin and increased P02 have
pulmonary vasodilatory effects. Consequently, pulmonary
vascular resistance (PVR) falls acutely within 15 minutes,
and pulmonary blood flow (PBF) increases. Pulmonary
venous return to the left atrium is increased, raising left
atrial pressure and forcing closure of the foramen ovale.
Only functionally closed, the foramen ovale may open and
permit right-to-left blood flow if PVR increases abruptly, as
occurs with crying.
The ductus arteriosus, which diverts blood away from the
pulmonary circuit during fetal life, may permit a persistent
right-to-left shunt for up to 3 days in the normal newborn
because of nearly equal pulmonary artery and aortic
pressures. More commonly, PVR decreases rapidly, such
that mean pulmonary artery pressure decreases from 60 to
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30 mmHg during the first 10 hours of life. Right-to-left
shunting is normal for about 6 hours after birth. Thereafter,
flow across the ductus arteriosus reverses because systemic
vascular resistance (SVR) and pressure are greater than that
in the pulmonary circuit. Left-to-right shunting persists for
an additional 9 hours. At about 15 hours, the ductus
demonstrates physiologic (functional) closure. Ductal closure is partially a response to increased P02 , which induces
constriction of the duct. In addition, prostacyclin synthesis,
responsible for pulmonary vasodilation, decreases significantly by 5 hours of life. Thrombosis and fibrosis of the
ductus, which result in anatomic closure into the ligamentum arteriosum, take several more days and may extend into
the first few weeks of life. During this time, the ductus may
open and close physiologically.
Intravenous infusion of the potent vasodilator prostaglandin E) can reestablish or maintain ductal patency. Conversely, agents such as indomethacin inhibit prostacyclin
and stimulate ductal closure.
Cardiac output increases steadily following birth as the
right and left ventricles begin functioning in circular series
and because of increased left ventricular end-diastolic volume. The increase in left ventricular volume is the result
of several factors: decreased PVR and right ventricular
afterload and increased PBF with subsequently increased
pulmonary venous return to the left ventricle. The drop
in PVR over time is exponential. By 6 weeks of age, resistance in the pulmonary circuit falls to levels near the normal
adult range.
The normal adaptation of the cardiovascular system that
occurs after birth may be delayed in sick newborns. Infants
with hypoxemia, hypercarbia and acidosis, hypothermia,
sepsis, low gestational age, hematologic abnormalities, and
left-to-right cardiac shunting are at risk for delayed adaptation of the cardiovascular system to extrauterine life.
Persistence of fetal circulation (i.e., the right-to-left shunt at
the ductus arteriosus and foramen ovale) is related to
continued elevated PVR.

ESSENTIAL ANATOMY AND PHYSIOLOGY
Structure and function of the cardiovascular system serve to
deliver metabolic nutrients to cells and remove the end
products of metabolism. The system is composed of the
heart, divided into two coordinated pumps (the right
ventricle and the left ventricle) and two circulations. The
pulmonary circulation is between the right and left sides of
the heart, and the systemic circulation is between the left
and right sides of the heart.
The interatrial and interventricular septa divide the heart
longitudinally. The right and left atria are thin-walled
chambers that function primarily as reservoirs for blood
returning to the heart. Atrial contraction at the end of
ventricular diastole propels a small percentage of the
end-diastolic volume into the ventricles. The AV valves
separate the atria from the ventricles: the tricuspid valve on
the right and the mitral valve on the left. During ventricular
diastole, the AV valves are open, and blood flows through
each into the relaxed muscular ventricles. During ventricular

systole, the ventricular muscle contracts and propels blood
through the semilunar valves (the pulmonary valve on the
right and the aortic valve on the left) into the pulmonary
artery and the aorta.
Because the pulmonary circulation is short and broad,
resistance to flow through it is low. In contrast, the systemic
circulation is longer and has higher resistance to flow.
Consequently, right heart and pulmonary pressures are low
compared with left heart and systemic pressures. However,
it is important to note that these characteristics are present in
the mature cardiovascular system. The transition from fetal
circulation to neonatal circulation includes changes in the
resistance and pressure in the pulmonary circulation and the
right side of the heart.
Ventricular contraction produces a pressure pulse that
propels blood through the arteries. The arteries branch into
arterioles and capillaries, which distribute blood to the
microcirculation, deliver oxygen and nutrients to tissues,
and remove metabolic waste products. The venules and
veins coalesce as they return blood to the heart. The
arterioles are the primary regulators of vascular resistance.
The total cross-sectional area of the circulatory system
increases as the arterioles branch, decreasing flow. The veins
are capacitance vessels that serve as reservoirs for blood.
The veins contain nearly two thirds of the total blood
volume at any given time. As they coalesce, the crosssectional area of circulation decreases, and flow increases as
blood returns to the heart.
Blood moves from the arterial to the venous side of the
circulation along a pressure gradient. Pressure steadily
declines along the circulatory pathway. Mean arterial
pressure in children is approximately 60 mmHg; central
venous pressure, about 6 mmHg; and right ventricular
end-diastolic pressure, 0 to 2 mmHg. The pulmonary system
has similar arterial venous pressure differences, although the
magnitude of the difference is less (Figure 7-6).
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Fig. 7-6 Resistance and resulting loss of pressure within the
circulation. Arterial pressure diminishes very rapidly in the small
resistance vessels of the circulation. In the venous vessels the
pressure gradient is very low. (Redrawn from Kinney MR et al:
AACN's clinical reference for critical care nllrsing, ed 4, St Louis,
1998, Mosby.)
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The Heart
The heart is located within the thoracic cavity in the mediastinal space, covered by the loosely fitting fibrous pericardium. The pericardium provides the heart with physical protection and a barrier to infection. It limits, somewhat,
overdistension of the heart chambers. The pericardium consists of an inner serous layer and an outer fibrous layer.
Between the layers is the pericardial space, a potential space
that normally contains a small volume of serous fluid that
acts as a lubricant during cardiac contraction and relaxation.
The heart, suspended by the great vessels, is positioned
obliquely so that the right atrium and ventricle are almost
fully anterior to the left. Only a small portion of the lateral
left ventricle is on the frontal plane of the heart.
Fibrous Skeleton. The cardiac skeleton consists of
four interconnecting valve rings and surrounding connective
tissues. It forms a rigid support for attachment of the heart
valves and for insertion of cardiac muscle and separates the
atria from the ventricles.
Cardiac Musculature. The walls of the heart are
composed of two layers in the atria and three in the
ventricles. Atrial muscle fibers originate in and insert on the
fibrous cardiac skeleton. Deep muscle fibers within each
atria propel blood through the AV valves with atrial
contraction. Superficial muscle fibers pass through both atria
and produce lateral constriction of the chambers and
coordinated contraction between them.
The walls of the ventricle consist of three layers. The
endocardium lines the ventricular chambers and is contin- .
uous with the lining of the blood vessels that leave the heart
and with the myocardium. The myocardium is the middle
layer, and the epicardium is the outermost layer. The muscle
fibers of the ventricle arise from the fibrous skeleton and the
roots of the aorta and pulmonary artery. The muscle fibers in
each ventricle interlock and change orientation as they pass
from the epicardium, through the myocardium, and to the
endocardium. The interlocking arrangement of the fibers
produces both circumferential and longitudinal compression
of the ventricular chamber during cardiac contraction, which
propels blood into the great arteries.
The Heart Valves. The heart valves provide unidirectional flow of blood through the heart and into the great
arteries. The opening and closing motion of the valves is
most likely the passive result of pressure changes between
the heart chambers and between the ventricles and great
arteries. During ventricular systole, the valve leaflets, valve
annulus, papillary muscles, chordae tendineae, and atrial
wall all function to ensure closure and competency of the
AV valves. The valve leaflets begin to close when pressure
in the ventricle exceeds atrial pressure. The valve annulus
narrows as the ventricular chamber becomes smaller with
contraction. Contraction of the papillary muscles exerts
tension on the chordae tendineae to prevent eversion of the
val ve leaflets.
The aortic and pulmonic valves have three cusps,
permitting them to open widely with ventricular ejection.
During ventricular diastole, the cusps collect the retrograde
flow of blood in the great arteries, ensuring complete closure
of the valve.
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There are no valves where blood enters the heart from the
systemic and pulmonary veins. Venous congestion develops
when outflow from either atrium is impeded.
The Coronary Circulation. The coronary arteries,
which arise in the aortic root just above the aortic valve and
traverse the heart's surface in the epicardium, provide the
blood supply for the heart. The major epicardial vessels are
the right coronary artery and the left main coronary artery,
which divides near its origin to form the left anterior
descending branch and the circumflex branch. The epicardial coronary arteries give otf penetrating branches that
perfuse the myocardium. Although the usual origin and
course of the coronary arteries are well described, a number
of variations are recognized to occur commonly. Figure 7-7
illustrates the usual route of the coronary arteries.
The right coronary artery runs laterally and posteriorly
from its origin in the AV sulcus between the right atrium and
right ventricle. The acute marginal branches perfuse the
right ventricular free wall. The right coronary artery turns
downward in the posterior right ventricular epicardium in
the posterior interventricular sulcus and becomes the
posterior descending coronary artery. The posterior descending artery perfuses the posterior aspect of the interventricular septum and a portion of the posterior left
ventricle.
The left main coronary artery is very short and branches
into the left anterior descending and the circumflex arteries.
The left anterior descending artery runs in the anterior
interventricular sulcus in an inferior direction, branching
into septal perforates that perfuse most of both the
interventricular septum and the conduction system. The
diagonal branches perfuse the anterior and lateral walls of
the left ventricle. The circumflex artery runs posterior in the
AV sulcus and, with its major branches, perfuses the
posterior wall of the left ventricle.
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Fig. 7-7

Descending Bronch

Diagram showing location of major coronary arteries
and veins on anterior (top) and posterior (bottom) surfaces of the
heart. (From Little R, Little W: Physiology of the heart and
circulation, St Louis, 1985, Mosby.)
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After passing through the arteries and capillary beds,
venous blood from the myocardium drains through the
cardiac and coronary veins and the coronary sinus into the
right atri urn.
The metabolic needs of the myocardium regulate coronary artery blood flow. When cardiac work is increased,
generalized coronary artery vasodilation occurs. The precise
mediators of the vasodilation have not yet been fully
determined; however, carbon dioxide, reduced oxygen
tension, lactic acid, hydrogen ions, and other metabolites are
suggested. The sympathetic nervous system (SNS) also
plays a role in regulating coronary blood flow. Both lX- and
p-receptors are known to exist in the coronary arteries.
Cardiac contraction affects blood flow through the
coronary arteries. Unlike flow in other arteries, coronary
blood flow occurs during ventricular diastole rather than
during systole. During systole, the muscular contraction
compresses the coronary arteries and reduces flow.
Metabolic Needs of the Myocardium. Under normal conditions the heart extracts and consumes 60% to 80%
of the oxygen delivered by the coronary arteries, compared
with the approximately 25% consumed by skeletal muscle.
Consequently, there is little oxygen reserve in coronary
venous blood. Increased coronary flow is necessary to meet
demands for increased oxygen. During strenuous exercise,
coronary blood flow increases 4 to 5 times to meet the
energy requirements of the heart.
The oxygen demands of the heart are a function of the
ventricular wall tension generated to pump blood, stroke
volume, the contractile state of the myocardium, and heart
rate. When wall tension is greater, as occurs with ventricular
dilation, the heart expends more energy to overcome the
tension and decrease its size in contraction. Stroke work is
the effort the heart expends to pump blood. The volume of
blood ejected with each heartbeat and the pressure the
ventricle must develop to eject blood against the resistances
to flow determine stroke work. The contractile state of the
myocardium refers to the heart's inherent ability to modulate its force of contraCtion without a change in end-diastolic
volume, heart rate, or arterial pressure. Heart rate reflects
the frequency with which the heart repeats the energyconsuming process of contraction. A higher heart rate
increases oxygen demand.
The Conduction System. A unique rhythmic property of the heart allows it to beat independently of nervous
system stimulation. Unlike skeletal muscle, the heart
generates and conducts its own electrical impulses (action
potentials). The conduction system of the heart is composed
of modified myocardial tissue that forms the following:
I.
2.
3.
4.
5.
6.

Sinus (sinoatrial [SA]) node
Atrial internodal tracts
AV node
The His (common) bundle
Right and left bundle branches
Purkinje fibers (Figure 7-8)

These specialized tissues both generate and transmit
electrical impulses more rapidly than other cardiac tissue,
allowing control of heart rate and rhythm.
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Fig. 7·8 Conduction system and corresponding normal waveforms using lead II. (From Curley MAQ: Pediatric cardiac
dysrhythmias, Bowie, Md, 1985. Brady Communications, p 43.)

Nornlally, cells in the SA node initiate an electrical impulse that spreads to other cells via low-resistance pathways
in the specialized conduction tissues throughout the atria to
the AV node. Transmission of the impulse is slowed through
the junctional fibers of the AV node to approximately one
twenty-fifth the speed of conduction in other cardiac tissues.
The delay in the transmission of electrical impulses at the
AV node permits atrial contraction to occur before ventric·
ular contraction begins. The impulse then spreads to the His
bundle, bundle branches, Purkinje fibers, and, finally, from
cell to cell in the ventricles. Transmission of the action
potential in the ventricle is very rapid, allowing for nearly
simultaneous excitation of the right and left ventricle and
rapid ejection of blood from the heart.
Mechanisms of Contraction. A number of independent cylindrical elements called myofibrils compose cardiac
muscle fibers. Each myofibril consists of smaller units that
contain thin actin and thick myosin filaments. Each unit is a
sarcomere, the functional unit of the contractile system in
muscle. The actin and myosin filaments are embedded in the
sarcoplasmic reticulum, an intracellular system of longitudinal tubules (T tubules) that conduct action potentials
across the myofibrils and lateral sacs, which store calcium
for release during muscle contraction.
When cardiac myofibrils are relaxed, regulatory proteins
inhibit the active binding sites for myosin on actin. An
action potential, propagated along the T tubule, triggers the
release of calcium from the lateral sacs of the sarcoplasmic
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relaxation. In addition, heart failure or intravascular volume
overload with excessive myofibril stretch decreases crossbridge formation. Chronic heart failure results in depletion
of endogenous catecholamine stores, which decreases calcium transport, further impairing contractile performance.
Digitalis drugs, which block the sodium channels, increase
the amount of calcium available and improve contractility.
Myocardial ischemia and hypoxemia impair calcium transport out of the cytosol, diminishing ventricular relaxation
and decreasing compliance.

The Heart's Electrical Activity
Na+

Intracellular
fluid space
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Fig. 7·9 Transmembrane potential in the resting, depolarized,
and repoJarized states. (Redrawn from Lipman BS, Dunn M,
Massie E: Clinical electrocardiography, ed 7, St Louis, 1984,
Mosby, p 35.)

reticulum and increases calcium diffusion from the interstitial fluid into the cytosol, the area of the actin and myosin
filaments. The calcium ions bind with regulatory proteins in
the myofibril, exposing the binding sites for myosin on
actin. The myosin attaches to the actin, using energy from
ATP. The binding, or crossbridging, of actin and myosin
pulls the actin fiber past the myosin fiber toward the center
of the sarcomere and results in fiber shortening. This process
repeats many times during a single contraction, as long as
calcium and ATP are available.
During muscle relaxation, calcium influx ceases, and
active calcium pumps in the sarcoplasmic reticulum and
T tubule remove calcium from the cytosol. The active
binding sites on the actin filaments are again inhibited.
Calcium is removed by means of the non-energy-dependent
sodium-calcium exchange, in which two internal calcium
ions are exchanged for one external sodium ion.
The strength and rate of contraction and the rate and
degree of relaxation are all determined by intracellular
calcium concentration, the rate of calcium exchange, and the
resting myofibril length. Each of these factors influences the
number of actin and myosin crossbridges that form. At rest,
maximal crossbridge formation does not occur, and there is
considerable systolic or contractile reserve. When SNS
stimulation occurs, however, the amount of calcium that
enters the cell and the rate of calcium exchange through
energy-dependent channels are both increased. The strength
of contraction and the rate of contraction and relaxation are
greater. Medications that block calcium exchange channels
decrease contractility and slow the rate of contraction and

The electrical activity of myocardial cells depends primarily
on changes in cell membrane permeability to the cations
sodium. potassium, and calcium. Membrane permeability to
these and other ions is dependent on the electrochemical
gradient of the ions on each side of the membrane and the
function of ionic pumps in the cell membrane. Movement of
ions across the cell membrane occurs both passively along
the electrochemical gradient and via energy-dependent ion
pumps in the cell membrane, which actively transport ions
against their electrochemical gradient.
Electrical activity or action potential in cardiac cells is
divided into five phases, which are illustrated in Figure 7-9
and are summarized as follows:
Phase 0: depolarization, characterized by the rapid
upstroke of the action potential
Phase I: the brief period of repolarization
Phase 2: the plateau, which causes the action potential of
cardiac muscle to persist far longer than in other
muscle, resulting in a correspondingly increased
period of contraction
Phase 3: the period of repolarization
Phase 4: the resting membrane potential
The cardiac cell membrane in a resting state is permeable
to potassium and slightly permeable to sodium and calcium.
Potassium slowly diffuses out of the intracellular compartment along its electrochemical concentration gradient,
leaving the inside of the cell increasingly negative in charge.
The resting membrane potential of the cell is -90 mV, whieh
is established by the passive movement of potassium out of
the cell and minimal influx of sodium and calcium ions.
With electrical excitation of the membrane during phase 0,
the cell membrane permeability to sodium increases rapidly
as the voltage-regulated fast sodium channels open. There is
rapid influx of sodium into the cell, as well as slowing of
the efflux of potassium, so the membrane potential rises to
+30 mY. In phase I, the fast sodium channels close abruptly,
decreasing membrane permeability to sodium. Slow efflux
of potassium continues, bringing the membrane potential to
near 0 mY.
Partial depolarization of the cell membrane results in the
opening of the slow sodium and calcium channels in phase
2. The infl ux of calcium and sodium matches the efflux
of potassium, and the cell membrane remains depolarized.
The influx of calcium stimulates actin and myosin crossbridge formation, and mechanical contraction results. In the
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Fig. 7-10 Action potential of SA nodal fiber and ventricular
muscle fiber. (Redrawn from Guyton AC: Texrbook of medical
physiology. ed 8, Philadelphia, 1991, WB Saunders, p 112.)

phase 3 repolarization period, the influx of sodium and
calcium ceases as the slow channels close and membrane
permeability to potassium rises sharply. The efflux of
potassium from the cell restores the resting membrane
potential at phase 4, which corresponds mechanically with
ventricular diastole.
After an action potential there is a period during which
the cell membrane is not polarized and cannot accept another electrical stimul us. During phases 0, I, and 2, the cell
is absolutely refractory or completely insensitive to stimulation. As the cell membrane potential is reestablished during
phase 3, the cell is relatively refractory; that is, a more
intense stimulus is required to initiate an action potential. At
the end of phase 3, a supemormal period permits stimulation
of an action potential by a weak stimulus. In cardiac muscle,
the absolute refractory period is prolonged. Because this
period is nearly as long as the heart's contraction, a second
contraction cannot be stimulated until the first is over. The
length of the absolute refractory period permits the altemating contraction and relaxation of cardiac muscle essential
for its pumping action.
Sinus Node Action Potential. Electrical activity in
the sinus node differs from that described earlier (which is
characteristic of the cells of the atria, ventricles, interatrial
conducting fibers, and Purkinje fibers) in several important
ways (Figure 7-lO). [n the sinus node, the resting membrane
potential is -55 to -60 m V. The fast sodium channels are
inactive at this membrane charge. During phase 0 of the
sinus action potential, the rise is relatively slow because it is
the result of opening of the slow calcium and sodium
channels. There is no plateau phase (phase 2). Instead, when
the slow calcium and sodium channels are inactivated and
potassium efflux occurs, repolarization is permitted.
The third difference between the two cardiac action potentials is the spontaneous rise of phase 4 in the action
potential of the sinus node. This rise is the basis of automaticity in the pacemaker cells of the heart, which produces an
action potential without an outside stimulus such a~ that

required for skeletal muscle. During phase 4 in pacemaker
cells, there is a slow decrease in the efflux of potassium
(which limits the negativity of the cell's interior) or an increase in influx of sodium and calcium (which exerts the
same effect) or both. Consequently, the cells automatically
(or spontaneously) reach the threshold for depolarization
and initiate depolarization of the entire heart.
The autonomic nervous system influences the slope of
the rise in phase 4 of the pacemaker cells. Epinephrine and
norepinephrine, released when the SNS is stimulated, increase the slope of phase 4 to firing threshold by increasing
cell membrane permeability to calcium. Sinus node firing is
increased. These neurotransmitters act along the entire
length of the conduction system, increasing conduction velocity. Contractile cardiac cells are affected, as well.
Conversely, acetylcholine (which is released with parasympathetic nervous system stimulation) causes the resting
membrane potential to be more negative and slows the rate
of spontaneous depolarization in the SA node and the rate of
conduction in the AV node. The increased negativity of the
action potential is the result of slowed sodium influx in the
face of persistent potassium efflux. Consequently, it takes
longer for the cell membrane to reach firing threshold and
longer for the electrical stimulus to be conducted through
the AV node. Extreme vagal stimulation of the parasympathetic nervous system can produce complete conduction
block at the AV node. Carotid massage may evoke such an
extreme stimulus.
The action potentials of cardiac cells outside the SA and
AV nodes can be converted to those of the specialized
conduction nodes under certain abnormal circumstances.
For example, myocardial ischemia and electrolyte imbalances predispose to premature ectopic beats and cardiac
rhythm disturbances.

The Cardiac Cycle
The cardiac cycle is the relationship between the electrical
events, mechanical events, and blood flow that occurs with
each heartbeat (Figure 7-11). The electrocardiogram (ECG)
records and permits evaluation of the electrical events of the
heart. Measurement of atrial, ventricular, and aortic pressure
and volume requires cardiac catheterization or echocardiography. However, atrial and arterial pressure can be monitored at the bedside and provide data that can be used in
clinical evaluation of critically ill patients. The phonocardiogram records the heart sounds.
The cardiac cycle is divided into two parts: ventricular
systole, the period during which the ventricles are contracting and blood is ejected from the heart, and ventricular
dia~tole, the period when the ventricles are relaxed and are
filled with blood. Atrial systole occurs late in ventricular
diastole. During the cardiac cycle, electrical events precede
mechanical events, and the mechanical events produce the
heart sounds.
Ventricular Systole. As a wave of depolarization
passes through the ventricle, the ECG records the QRS
complex. Mechanical contraction is stimulated and begins in
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Fig. 7-11 Diagram of the cardiac cycle, showing the pressure curves of the great vessels and cardiac
chambers, valvular events and heart sounds, left ventricular volume curve, jugular pulse wave, apex
cardiogram (Sanborn piezo crystal), and the electrocardiogram. For illustrative purposes, the time intervals
between the valvular events have been modified and the z point has been prolonged. Valve motion:
MC. mitral component of the first heart sound; MO. mitral valve opening; TC, tricuspid component of
the first heart sound; TO, tricuspid valve opening; AC, aortic component of the second heart sound;
AD. aortic valve opening; pc, pulmonic valve component of the second heart sound; PO, pulmonic
valve opening; OS. opening snap of atrioventricular valves. Apex cardiogram: fC, isovolumic or
isovolumetric (isochoric) contraction wave; JR, isovolumic or isovolumetric (isochoric) relaxation wave;
0, opening of mitral valve; RFW, rapid-filling wave; SFW, slow-filling wave. (From Hurst J et al, eds: The
heart, arteries and veins. ed 7. Copyright 1978 by McGraw-Hili. Used by pernlission of McGraw-Hili
Book Company.)
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the middle of the QRS complex. As the ventricles begin to
contract, ventricular pressure exceeds atrial pressure almost
immediately, and the AV valves close, producing the first
heart sound (S 1)' The aortic and pulmonic valves remain
closed because pressure in the ventricles is less than
pressure in the aorta and pulmonary artery. The ventricles
continue to contract, increasing the intraventricular pressure. Because all of the heart valves are closed, no change
occurs in ventricular volume during this period-a condition called isovolumetric contraction. Ninety percent of
myocardial oxygen consumption occurs during this phase of
systole. The ventricle shortens from base to apex and becomes more spherical. The AV valves bulge into the atria,
producing the c wave on the atrial pressure waveform.
Continuing increases in ventricular tension pull the floor of
each atrium downward, increasing their size and decreasing
their pressure, as evidenced on the atrial waveform as the x
descent.
When ventricular pressure exceeds pressure in the aorta
and pulmonary artery, the semilunar valves open, and blood
ejects rapidly from the heart. Ventricular contraction continues during ejection. The myofibrils shorten circumferentially and longitudinally, ventricular wall thickness increases, and chamber size decreases. Peak ejection produces
systolic pressure in the aorta and pulmonary artery. More
than 50% of the stroke volume is ejected in the first quarter
of systole. The atria continue to fill with blood during
ventricular systole. The subsequent increase in atrial pressure produces the v wave on the atrial pressure waveform.
As each ventricle empties, the volume of blood ejected
decreases, and pressure in the ventricular chambers, aorta,
and pulmonary artery falls. At the end of systole, intraventricular pressure falls suddenly as the ventricles relax.
Retrograde flow in the aorta and pulmonary artery results,
catching the cusps of the semilunar valves and closing them.
Mechanical closure of the valves produces the second heart
sound (S2) and the dicrotic notch (or incisura) in the arterial
pressure waveforms. Arterial pressure continues to decline
to the diastolic level as blood runs off toward the periphery.
The ventricle does not empty completely with any
contraction. Blood left in the heart at the end of systole is the
residual or end-systolic volume (ESV). Stroke volume, the
amount of blood ejected per beat, is the difference between
end-diastolic volume (EDV) and ESY. The ejection fraction
is the measure of the stroke volume as a percentage of the
EDY. Normal ejection fraction is 65% to 70%. In the healthy
heart, the ESV provides a reserve that can increase stroke
volume and cardiac output with more vigorous contraction.
In the failing myocardium, the ESV is typically elevated
because of the poor contractile performance of the heart.
Ventricular Diastole. After closure of the aortic and
pulmonic valves, the heart continues to relax with all the
valves closed. Intraventricular volume does not change
during this period of isovolumetric relaxation, and ventricular pressure falls below atrial pressure. The AV valves
open, and blood that has filled the atria during systole pours
into the ventricles, resulting in the y descent on the atrial
pressure waveform. Ventricular relaxation continues; consequently, ventricular pressure continues to fall despite the

rapid filling of the chambers. A third heart sound (53) may
be auscultated during the period of rapid ventricular filling
if the ventricles are noncompliant or distended. In children
an S3 is not always indicative of a cardiac pathologic
condition and can be a normal finding. Slow filling of the
ventricle continues through the middle third of the diastolic
period. The ventricular chambers do not relax further, but as
the AV valves remain open, the ventricles continue to
distend with blood that returns to the heart. The ventricular
pressure waveform shows an increase in ventricular
pressure.
The P wave on the ECG indicates atrial depolarization,
which is followed by atrial contraction at end diastole. The
final component of the ventricular EDV is delivered to the
ventricles, marked by the a wave on the atrial pressure
waveforms. In the normal, mature individual, atrial contraction contributes up to 20% of the EDY. The contribution is
less in pediatric patients, who are less dependent on "atrial
kick." However, in patients of any age with ventricular
failure or excessively rapid heart rate, which limits the
diastolic filling time, the atrial contribution to EDV is more
significant. The propulsion of blood into the ventricle with
atrial contraction may produce a fourth heart sound (S4) if
ventricular compliance is poor.

Regulation of Cardiac Performance
Cardiac output (CO) measures the efficiency or performance
of the heart. CO is the volume of blood ejected from the
heart in I minute. It is the product of heart rate (HR) and
stroke volume (SV), the amount of blood pumped from the
heart with each beat:
CO=HRxSV

CO varies with body size; it is indexed to reflect that
variation by dividing CO by body surface area (BSA). BSA
is determined on a nomogram or calculated from the
following equation:
0.007184 x weight (kg) x height (em)
Normal cardiac index is 3.5 ± 0.7 L/min/m 2

Cardiac output varies with the physiologic demands of
metabolizing tissues. The determinants of CO, HR, and SV
are sensitive to a number of physiologic influences. In
addition, maturation in growing infants and young children
affects both. The sections that follow detail the impact of
HR, heart rhythm, and the factors that control SV (i.e.,
preload, ventricular compliance, afterload, and ventricular
contractility) on CO and describe the maturational factors
that influence cardiac performance.

Determinants of Cardiac Output
Heart Rate. The expression "children are heart rate
dependent" is often heard in pediatric critical care. In fact,
HR is one half of the CO equation and is crucial to cardiac
performance in all individuals. However, infants and young
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children are less able to vary SV when demand for CO is
increased because myocardial performance in the young is
near maximal under basal conditions. As a consequence, SV
is less dynamic, and HR influences CO to a greater extent
than in mature individuals.
When HR is nomlal for age, the systolic component of
the cardiac cycle occupies about 30% of the time that
elapses in the cycle, and the diastolic component occupies
about 70%. When HR increases, the systolic component
remains constant because ventricular contraction is an efficient process. However, the diastolic period of the cycle
becomes progressively shorter. Figure 7-12 illustrates the
shortening of the diastolic component of the cardiac cycle
with elevation of HR to one and one-half and twice the
nOm1al.
The potential pathophysiologic consequences of the
shortened diastolic period are twofold. First, the period
during which the ventricles fill with blood is shorter.
Ultimately, excessively rapid HR will diminish CO because
preload is inadequate. Second, myocardial oxygen supply
decreases during tachycardia because the coronary arteries
fill and perfuse the myocardium during diastole. This
decrease in supply occurs in the face of increased demand
because a higher HR increases myocardial oxygen consumption. The consequences of prolonged tachyarrhythmias
are myocardial failure and inadequate tissue perfusion.
Slow HR easily diminishes CO in infants and young
children because SV is relatively fixed. In fact, clinically
significant bradycardia necessitates active resuscitation in
the infant. Infants are at risk for bradycardia because
sympathetic innervation of the SA node and myocardium is
incomplete at birth, whereas parasympathetic innervation is
complete well before term. Consequently, vagal stimulation
can result in bradycardia mediated by parasympathetic
stimulation of the SA node, which is inadequately balanced
by sympathetic impulses that would increase the HR.
Heart Rhythm. The sequential relationship between
the electrical and the mechanical events of the cardiac cycle
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result from orderly electrical stimulation of the heart, which
is followed by mechanical contraction and ejection of blood
into the systemic and pulmonary circulations.
Whenever the electrical wave of depolarization that
produces the mechanical contraction (excitation-contraction
coupling) is disturbed, mechanical performance is influenced. When ventricular ejection occurs early (as with a
premarure ventricular contraction) or if it occurs without the
preceding atrial contraction (as in a junctional rhythm), SV
is diminished. Figure 7-13 demonstrates the altered SV as
reflected in the arterial pressure waveform as a narrow pulse
pressure that is the consequence of abnormal electrical
stimulation of ventricular contraction.
Preload. Preload is the distending force or the stretch
on myocardial muscle fibers just before electrical stimulation and ventricular contraction. As with skeletal muscle
fibers, the force of myocardial muscle contraction is a
function of the initial length of the muscle fibers. The
well-known Frank-Starling law of the heart was defined at
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Fig. 7-13 Premature ventricular contractions producing altered
stroke volume as reflected in the arterial pressure waveform. (From
Daily, EK, Schroeder JS: Techniques in bedside hemodynamic
monitoring, St Louis, 1989, Mosby.)
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the end of the nineteenth century, when the length-tension
relationship was first demonstrated by Frank and confirmed
in later work by Starling. The law states that the more the
diastolic volume or fiber stretch at end diastole, the greater
the force of the next contraction during systole.
Preload determines the force and efficiency of ventricular
contraction because it regulates the resting sarcomere's
length, determining the number of actin and myosin
crossbridges formed during systole. Most alterations in CO
in the patient with a normal heart relate to the volume of
venous return to the heart. Optimal stretch on the sarcomere
facilitates crossbridge formation. The number of crossbridges formed directly relates to the muscular tension
generated in the myocardium and therefore to the force of
ventricular contraction. Modifications of venous return
through volume administration contribute to relatively large
changes in CO. Patients with heart failure have higher
ventricular EOV and pressure for measured ventricular
performance (Figure 7-14). Administration of additional
volume in the face of myocardial failure is far less
efficacious and may worsen the patient's clinical status.
Venous tone has a significant effect on venous return to
the heart and therefore on CO. Vascular tone on the venous
side of the circulation is dependent on a number of nervous
system and hormonal factors. Venoconstriction results from
SNS stimulation, muscular exercise, anxiety, and marked
hypotension, as well as from medications, including the
cardiac glycosides and sympathomimetic agents. Venous
constriction has a profound effect on improving venous
return and CO. However, even marked venous constriction

does not adversely increase SVR because the venous system
is normally highly compliant. Venous dilation can cause
pooling of blood in the venous system outside the thorax.
Generally, venodilation is the consequence of medications
such as nitrates, ~-blockers, or calcium channel blockers.
Total blood volume and blood distribution in the
intravascular compartment affect ventricular EOY. Acute or
massive reduction of the total blood volume causes SV to
fall. However, gradual reduction or loss of less than 10% to
15% of the total blood volume does not result in perceptible
decreases in CO.
Body position affects blood distribution. Blood pools in
the lower extremities in the supine position. Trendelenburg
position increases venous return and CO. Military antishock
trousers (MAST) and intermittent liver compression improve CO by the same mechanism.
Normal respiration results in negative intrathoracic pressure during inspiration. This negative pressure pulls blood
into the intrathoracic cavity, augmenting venous return. In
addition, pulmonary artery pressure is lower during inspiration, enhancing PBF and left ventricular EOY. Positive pressure ventilation reverses both these phenomena, especially
in combination with positive end-expiratory pressure.
Compliance. Compliance is the ability of the ventricle to relax and distend, that is, to fill, during diastole. The
relationship between end-diastolic pressure and EOV defines compliance (Figure 7-15). The normal, mature ventricle is highly compliant, allowing it to accept large increases
in EOV without a significant increase in pressure. However,
as ventricular EOV increases, additions of more volume
result in larger changes in end-diastolic pressure. In addition, if the ventricle is stiffer or less distensible (i.e., compliance is low), the pressure change is greater for any change in
intracardiac volume.
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Fig. 7-14 Frank-Starling ventricular perfornlance curves. In the
nonnal ventricle when end-diastolic volume is increased, there is
a concomitant increase in ventricular perfonnance until a plateau is
reached. Patients with myocardial dysfunction and heart failure
demonstrate a shift of this curve downward and to the right. In
heart failure. an increase in end-diastolic volume produces less of
an increase in ventricular perfonnance, and a "plateau" is reached
at a much lower level of ventricular perfonnance. (From Chernow
B: Phnnnacologic approach to the critically ill patient, Baltimore,
1988, Williams & Wilk.ins, p 347.)
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Fig. 7-15 Diastolic pressure-volume relationship of the left
ventricle. At low ventricular volumes, substantial changes in
volume produce little change in ventricular pressure. At higher
ventricular volumes, small changes produce exponentially greater
increases in pressure. Increasing ventricular compliance with
vasodilator therapy shifts the curve to the right, allowing a greater
end-diastolic volume at a lower pressure. (From Chernow B:
Pharmacologic approach to the critically ill patient. Baltimore,
1988, Williams & Wilkins, p 347.)
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At birth, infants have a greater proportion of noncontractile myocardial tibers than contractile elements. Consequently, the ventricle is relatively less compliant than is the
case within several months. Reduced diastolic compliance limits diastolic reserve. In clinical practice, volume
loading in the very young patient may achieve little
improvement in cardiac pelformance, unless the patient is
clearly hypovolemic. Instead, volume administration may
produce an acute rise in ventricular end-diastolic pressure,
resulting in possible myocardial failure. Ventricular interdependence also affects diastolic tilling and subsequent CO. In
the scenario of right ventricular volume overload, the ventricular septum will be displaced toward the left ventricle
(LV). These phenomena will limit LV filling and obstruct the
left ventricular outflow tract, subsequently decreasing LV
output.
A number of clinical problems reduce ventricular compliance. Most common are myocardial hypoxemia and
acidosis, which may be the consequence of a variety of
pathophysiologic processes. Congestive heart failure (CHF),
ventricular hypertrophy, and pericardial tamponade can all
diminish compliance.
Unavoidable decreases in ventricular compliance are
evidenced in patients who require the administration of
positive inotropic agents or the application of high levels of
positive end-expiratory pressure (PEEP). Conversely, ensuring adequate myocardial oxygenation and normal acid-base
balance or administering afterload-reducing agents enhance
compliance. Compliance is abnormally high in individuals
with dilated cardiomyopathy.
Afterload. Afterload is the amount of resistance or
impedance to ventricular ejection. The forces opposing ventricular tiber shortening include ventricular size and shape
(the law of Laplace), aortic and pulmonary artery impedance, and systemic and pulmonary vascular resistance. SV is
inversely proportional to afterload, whereas ventricular
work and oxygen consumption are directly proportional to
afterload.
EDV and the radius of the ventricle are the forces that
oppose ventricular fiber shortening. When EDV is high, as
it is in CHF or volume overload, tiber shortening must
overcome a greater intraventricular pressure. The period of
isovolumetric contraction is longer, and oxygen consumption is increased. Thus preload contributes to the force of
ventricular afterload.
Before ejection of blood from the ventricles can occur,
aortic and pulmonary artery impedance (the stiffness of the
great arteries) and the inertia of the column of blood in each
must be overcome. The more distensible the great arteries,
the less the force that must be generated by the ventricles to
eject their stroke volumes.
Vascular resistance is the major determinant of afterload
and is a measure of the degree of constriction in the
arterioles of either the systemic or the pulmonary circulation. SVR varies with tissue metabolic demands, the degree
of autonomic nervous system stimulation, and the level of
circulating catecholamines. In the mature cardiovascular
system, SVR is the major determinant of afterload; however, in some pathophysiologic states and with some CHDs,
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the PVR may be the factor that limits cardiovascular
performance.
The pulmonary vascular bed is in a vasoconstricted state
in the fetus by a mechanism or mechanisms that remain
unknown despite many years of investigation. At birth, both
oxygenation and expansion of the lungs are independently
effective in decreasing PVR. Recruitment of peripheral
arteries, which were closed in fetal life, for PBF, dilation of
the normally muscular proximal arteries, and growth of
peripheral vessels all contribute to decreased PVR from the
first moments through several months of life.
PVR will not fall at birth, and persistent pulmonary artery
hypertension will result as the consequence of several problems. 6 Maladaptation of the pulmonary vascular bed results
if physiologic maturation has not occurred or the arteries are
unresponsive to the mediators that decrease PVR at birth. A
perinatal insult such as hypoxia may sustain the vasoconstricted state of the fetus, as does acute or chronic hypoxia in
utero. Finally, structural maldevelopment of the pulmonary
vascular bed and conditions that result in pulmonary hypoplasia, such as congenital diaphragmatic hernia, may also
result in persistent pulmonary hypertension.
Pulmonary hypertension can also be induced by a number of factors. 6 High oxygen concentration used in the treatment of neonatal lung disease is associated with abnormal
muscularization of the pulmonary arteries and hypertrophy
of the medial layer of the proximal pulmonary arteries.
Heart defects such as ventricular or AV septal defects,
which cause a left-to-right shunt as PVR begins to fall in the
postnatal period, result in high pulmonary blood flow and
pressure. If left unrepaired, subsequent structural changes in
the pulmonary vascular bed result. These changes can be
progressive and are associated with pulmonary hypertension
and decreased reactivity of the pulmonary vascular bed to
pulmonary vasodilators (i.e., nitric oxide or oxygen).
Pulmonary embolism, acute respiratory distress syndrome, upper airway obstruction, or chronic lung disease
(bronchopulmonary dysplasia, cystic fibrosis) can lead to
respiratory insufticiency and hypoxemia. 7 During these
acute illnesses, PVR can increase sharply, resulting in rightsided heart failure and hemodynamic instability. Chronic
conditions will result in pulmonary hypertension that can
take months to years to develop.
If EDV (preload), contractility, and HR are held constant,
an acute increase in pulmonary or systemic afterload
decreases SV and CO or results in increased myocardial
work to maintain sv. With normal cardiac function, the
acute increase in aflerload decreases SV, which increases
ESV and thus the preload for the next cardiac contraction.
Contractility increases for subsequent contractions and
maintains CO, although at the expense of increased work.
Gradual increases in SVR or PVR, as occurs with chronic
systemic or pulmonary hypertension, do not decrease SV or
CO acutely (Figure 7-16). An increase in contractility
maintains CO, overcoming the increased vascular resistance. However, malignant hypertension leads to heart
failure.
When ventricular function is impaired and myocardial
contractility is diminished, afterload is the most influential
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Fig. 7-16 Relationship of systemic vascular resistance to stroke
volume in a normal and dysfunctional ventricle. Increases in
afterload do not cause a decrease in stroke volume in a normal
ventricle (upper curve) except at very high levels of afterload when
severe hypertension caused ventricular decompensation. In a
failing ventricle (lower curve), however, an increase in afterload
causes a progressive depression of stroke volume and cardiac
output. Thus vasodilator-induced reductions in afterload enhance
stroke volume in patients with severe ventricular dysfunction.
(From Chernow B: Pharmacologic approach to the critically ill
patient. Baltimore, 1988, Williams & Wilkins, p 348.)

factor affecting SV and CO. Similarly, infants are exquisitely sensitive to increases in afterload because myocardial
immaturity limits the ability of the heart to enhance
contractile performance.
Contractility. The inotropic capacity of the heart refers to the inherent capacity to modulate contractile performance (the rate and force of fiber shortening) independent of
fiber length. Increased contractility results in increased CO
independent of preload and afterload, although inverse
changes in afterload produce very important clinical effects
(Figure 7-17). SNS activity, circulating catecholamines,
metabolic imbalances, exogenous pharmacologic agents,
loss of contractile mass, and maturity influence contractility.
Sympathetic stimulation increases cardiac contractility
because of direct release of norepinephrine in cardiac tissue.
The adrenal medulla and extracardiac sympathetic ganglia
also release catecholamines that circulate in the blood.
Circulating catecholamines enhance contractility but do so
more slowly than cardiac norepinephrine. However, depletion of the cardiac stores of catecholamine, as is the case
with chronic severe CHF, increases the importance of
circulating catecholarnines. Catecholamines increase the
rate of both calcium influx during stimulation and efflux
during repolarization, increasing both the force and the rate
of contraction and relaxation.
The physiologic milieu of the myocardium influences
contractile performance. Hyponatremia slows depolarization and decreases contractility. Hyperkalemia decreases
contractility, as does acidosis, hypoxia, and ischemia.
Pharmacologic agents can either augment or depress
cardiac contractility. The cardiac glycosides, sympathomimetic agents, caffeine, and theophylline all have positive
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Fig. 7-17 Ventricular function curves demonstrating the effects
of changes in contractility or afterload. If afterload is held constant,
an increase in contractility of the ventricle will shift the functional
curve upward and to the left, demonstrating improved ventricular
performance at any given level of end-diastolic volume. If ventricle contractility is left unchanged, a decrease in afterload will
produce a similar shift in the ventricular function curve. (From
Chernow B: Pharmacologic approach to the critically ill patienl.
Baltimore, 1988, Williams & Wilkins, p 349.)

inotropic effects. Conversely, J3-adrenergic and calcium
channel blockers, anesthetic agents, and barbiturates depress
cardiac contractility.
Loss of functional cardiac muscle, as occurs with
myocardial infarction, results in loss of contractile mass
necessary for ventricular contraction. Myocardial infarction, although unusual in infants and children, does occur. This is most often secondary to abnormalities of
coronary artery anatomy, Kawasaki disease, or familial
hypercholesterolemia.
Relative immaturity is characteristic of the infant heart.
Compared with that of the adult, the infant's heart differs in
its mechanical properties, autonomic nervous system innervation, and, the appearance of its ultrastructure. Myocardial
cells in the very young are smaller in diameter and contain
fewer contractile elements than later in life. Consequently,
the force generated and the degree and velocity of fiber
shortening are diminished. In conditions in which resistance
to ventricular emptying (afterload) is increased, the functional capacity (systolic reserve) of the immature heart is
limited. In addition, the newborn myocardium lacks complete development of sympathetic (adrenergic) innervation,
whereas parasympathetic (cholinergic) innervation is complete at birth. Releasable stores of norepinephrine in
ventricular myocardium are fewer, also decreasing the
inotropic response that increases contractility in the mature
heart. The infant heart may be functioning near capacity,
limiting its ability to increase contractility.

Regulation of Tissue Perfusion
The volume of blood circulated to the various tissues of the
body is dependent on the metabolic needs of each tissue.
The cardiovascular system responds to differences among
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tissues and to changes in metabolic demand. Autoregulation,
humoral factors, and the autonomic nervous system permit
acute control of the circulation.
Autoregulation of Blood Flow. Factors not yet
completely or precisely understood govern the autoregulation of tissue perfusion. Local metabolic needs control blood
flow. When metabolic needs in a tissue are increased,
vasodilation occurs and blood flow increases. The reverse is
the case when metabolic needs are low. Decreased demand
results in vasoconstriction and reduced flow.
Increased metabolic activity causes formation of substances including carbon dioxide, lactic acid, hydrogen ions,
adenosine, and bradykinin, which are all vasodilators.
Tissue hypoxia is responsible for the local release of these
substances. Their release stimulates localized vasodilation
and increased blood flow. Tissue oxygen deficiency may
directly cause vasodilation. Oxygen is necessary to maintain
normal vascular tone; thus hypoxia allows vascular smooth
muscle to dilate.
Active hyperemia is the term that describes the increase
in blood flow to an area at a time of increased demand.
When flow to an abruptly obstructed area is reestablished,
the surplus blood flow is reactive hyperemia. Reactive
hyperemia may continue for minutes to hours after release
of the obstruction. Hyperemia in both cases illustrates the
relationship between metabolic demand and blood flow.
Changes in vascular tone may result from changes in
arterial tone caused by increases or decreases in mean
arterial pressure. When mean arterial pressure falls, arteriolar tone decreases and the vessel dilates, allowing increased flow to the area. Autoregulation may well be the
result of a combination of all these factors.
Autonomic Nervous System Regulation of Blood
Flow. The autonomic nervous system operates both
globally and locally to regulate blood flow through sympathetic and parasympathetic functions. Sympathetic innervation of the heart and blood vessels arises from neurons
located in the reticular formation of the brainstem. The
axons of these neurons descend in the spinal cord. Cell
bodies in the paravertebral ganglia and their postganglionic
axons transmit impulses from the SNS to the cardiovascular
system. The catecholamines released from the sympathetic
nerve terminus (norepinephrine) and the adrenal medulla
(epinephrine) mediate sympathetic control of cardiovascular function. Thus the catecholamines exert their effects
locally at the receptor site and globally as a circulating
hormone. 8
Fibers of the SNS are widely distributed throughout the
myocardium, the SA and AV nodes, and both arterial and
venous smooth muscle. Their origin in the vasomotor center
of the medulla is composed of three major areas: the
vasoconstrictor area, the vasodilator area, and the cardioaccelerator area. The primary role of the vasodilator area is to
inhibit vasoconstriction.
Stimulation of the cardioaccelerator and vasoconstrictor
areas of the vasomotor system elicits SNS response. The
results are increased cardiac inotropy and chronotropy, increased venous return by venous vasoconstriction, and increased SVR and blood pressure by generalized arteriolar
constriction.
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TABLE

~\Vasodilators

Vasoconstrictors

ISystemic

Systemic

iCarbon dioxide
~iactic acid
!r:,;,_
~[fiydrogen ions
tAdenosine
~~radykini n

Epinephrine
Norepinephrine
Angiotensin II
Vasopressin (antidiuretic hormone)

iife:

~t1istamine

~Serotonin

r~:Prostaglandins
I';"

~Pulmonary
~:j[Nitric oxide
it"

~j~)xygen

!i!!'.-'

.

~[Prostagland,"s

s-

Pulmonary
Carbon dioxide
Hypoxia
Hydrogen ions

Baroreceptors in the aortic arch, atria, large arteries, and
veins stimulate the vasomotor centers of the medulla.
Baroreceptors respond to decreased mean pressure or pulse
pressure, which decreases their stretch by decreasing their
rate of firing. The vasomotor center responds by increasing
SNS output and decreasing the output from the parasympathetic nervous system (PNS). CO increases through the
Starling mechanism as venoconstriction augments venous
return to the heart, increasing EDY. Increased arteriolar tone
maintains central blood pressure and diverts flow from
the peripheral vascular beds to essential organs. Increased
HR and force of contraction maintain CO despite the
increase in SVR.
Parasympathetic innervation of the heart originates in the
vagal nucleus in the medulla. The cardiac branches of the
vagal nerve transmit impulses from the medulla to the heart
itself. Parasympathetic stimulation inhibits SA node firing,
slows conduction through the AV node, and decreases
myocardial contractility. Normally, the PNS is tonically
active and has a constraining effect on HR. Strong vagal
stimulation can stop impulse formation at the SA node or
block impulse transmission at the AV node. PNS effects on
the vascular system are negligible.
Humoral Regulation of Blood Flow. The catecholarnines and other substances described earlier, which
influence local blood flow (carbon dioxide, hydrogen ions,
lactic acid, etc.), are humoral factors that regulate blood
flow. In addition, other hormones and vasoactive substances
regulate blood flow and tissue perfusion (Table 7-1). It is
important to note that some biologic modifiers that augment
systemic vasodilation can have the reverse effect on the
pulmonary vasculature. This circumstance has clear clinical
implications in the management of patients with some forms
of complex congenital heart disease. For example, acidosis
and hypercarbia produce pulmonary vasoconstriction, but
they vasodilate the systemic vascular bed.
Angiotensin II is a potent vasoconstricting substance that
increases SVR and blood pressure. Decreased renal blood
flow results in angiotensin II synthesis via the reninangiotensin system (Figure 7-18). Decreased renal blood
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Fig. 7-18 Renin-angiotensin constrictor mechanisms for arterial
pressure control. (From Guyton AC: Textbook of medical physiology, ed 8, Philadelphia, 1991, WB Saunders.)

flow, an early consequence of inadequate tissue perfusion,
stimulates the release of renin from the juxtaglomerular
cells of the kidney, where it is produced and stored. Renin
acts on angiotensinogen to release angiotensin I, which, in
the presence of a converting enzyme in the lung, results in
the formation of angiotensin II. Angiotensin II has two
major effects on blood flow and pressure. The first is a rapid
and generalized arteriolar vasoconstriction; the second is a
decrease in sodium and water excretion by the kidney. Water
and sodium retention increases the blood volume, thereby
increasing blood pressure as well. The renal effects of
angiotensin II are not immediate but persist far longer than
its vasoconstricting effects.
Vasopressin or antidiuretic hormone (ADH) is an even
more potent vasoconstrictor than angiotensin n. However,
the posterior pituitary gland releases it in such small
quantities that it has little short-term impact on blood flow
or blood pressure.

PHYSICAL EXAMINATION OF
THE CARDIOVASCULAR SYSTEM
The stress of critical illness can impose significant physiologic demands on the cardiovascular system. In some cases,
normal compensatory mechanisms may prevent the clinical
recognition of the cardiovascular sequela of critical illness.
In other cases, cardiac disease will be clearly evident. In
either situation, expertise in pediatric cardiovascular assessment is necessary to ensure the timely recognition of
aberrations in cardiac function.

General Health and Appearance
A child's general health and appearance often reflects
cardiovascular status. However, any number of pathologic

conditions can present with cardiac symptoms, For example,
a child with growth retardation, poor appetite, frequent
upper respiratory infections, and lillie energy may have a
serious disorder that is not cardiac in etiology. On the other
hand, poor weight gain in a child with known heart disease
is a sign of concern, requiring intervention.
Accurate assessment of cardiovascular status cannot be
established on the basis of general health and appearance
alone. Careful review of past medical history and family
history, as well as physical examination, may elicit information that leads to further investigation and determination
of cardiac disease. Refer to Box 7-2 for review of areas
of assessmelll that are closely related to cardiovascular
function.

Vital Signs
Heart Rate. Heart rates in infants and children can be
quite variable and are age dependent. Fever, dehydration,
CHF, and sepsis can increase HR significantly. Cold, stress,
sinus node disease, and heart block can lead to clinically
significant bradycardia. A fixed HR, regardless of activity
(asleep or awake), is cause for concern because this may
represent atrial reentrant tachycardia or atrial fluller,
Blood Pressure. Indirect blood pressure (BP) measurement is best achieved by auscultation or through the use
of noninvasive automatic equipment. These two techniques
provide measurement of both systolic and diastolic pressures, allowing calculation of pulse pressure and mean
arterial pressure. Palpation of the radial pulse while an arm
BP cuff is deflated approximates only the systolic' pressure.
Although a common maneuver for all nurses to perform, auscultation of BP can be fraught with error.
Selection of an appropriately sized BP cuff is of critical
importance. The cuff bladder width should be approximately 40% of the circumference of the arm, and when on,
the cuff bladder must cover 80% to 100% of the circumference of the arm, 12 A cuff that is too narrow results in a
falsely elevated measurement, and a large cuff may yield
low measurements. 13
Ideally, BP is measured in the right upper extremity.
Although use of this site may not always be possible, it is
preferred because arterial flow to the right arm is derived
from the first vessels that branch from the aortic arch. In
certain CHDs, such as interrupted aortic arch and coarctation of the aorta, it may be the only pressure that
approximates proximal aortic pressure. Measurement of BP
in all four extremities is indicated if hypertension is detected
in the right arm measurement and in some children with
CHD (i.e., those with an anatomic obstruction of the aorta).
The systolic pressure in the thigh is equal to arm pressure in
infants and young children. After the first year of life, the
systolic pressure in the leg is 10 to 20 mmHg higher than the
arm. Diastolic pressure in the upper and lower extremities is
nearly equal.
Four factors are important in accurate and reproducible
auscultation of indirect BP. They are (I) cuff placement,
(2) rate of cuff deflation, (3) identification of systolic and
diastolic pressure points, and (4) function of the auscultatory
equipment.
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Box 7-2

General.Health Assessment

Physical growth: Height and weight are measured serially
and plotted on a standard growth chart. Inadequate cardiac output
and chronic cyanosis can impair growth.'·
Nutritional status: Intake of food, caloric density of formula,
dietary iron, and fluid are assessed. Infants should have caloric
intake calculated as calories/kg/day. Anemia can contribute to
exercise intolerance, limitations in oxygen delivery, hyperdynamic cardiac function, increased cardiac output, and worsening
of ventricular outflow tract obstruction.
Activity: Feeding is the exercise of the infant. Therefore
feeding difficulties. diaphoresis, or shortness of brearh with
feeding should be assessed. Squatting after exertion is a classic
symptom of tetralogy of Fallot in children who arc old enough to
walk; however because of early surgical intervention, this
phenomenon is rarely observed. School-age children and adolescents should be queried regarding exercise tolerance (both
the child and parents should be questioned because perceptions can be quite dichotomousf Chest pain is a common
complaint in children and adolescents; however, if it is associated with exercise, further investigation is required. Chest
pain may be related to left ventricular outflow tract obstruction
or myocardial ischemia. III Estimation of functional limitation

Cuff Placement. The inflatable bladder within the
cuff is to be centered over the artery to be compressed. The
measured pressure can be erroneous when the cuff is
misplaced.
Deflation Rate. The cuff is to be deflated at a rate of
2 to 3 mmHg per heartbeat or per second. In patients with
a slow HR, rapid cuff deflation can result in significant
measurement error. The systol ic pressure may be underestimated simply because the sounds are not heard at their true
pressure reading but at a lower pressure because of rapid
cuff deflation. Accurate assessment of diastolic BP is
difficult if the cuff is deflated too rapidly.
. Systolic and Diastolic Measurement Points. In BP
auscultation the measurement points correlate with a series
of sounds known as the Korotkoff sounds. Systolic pressure
is determined by the onset of the audible tapping sound that
occurs with cuff deflation. Measurement of diastolic pressure is more controversial. Previously it was thought that
diastolic pressure in children should be recorded when a
muffling of the Korotkoff sounds (rather than disappearance) occurred. However, in 1996 the Task Force on High
Blood Pressure in Children and Adolescents reanalyzed the
normative data on BP in pediatrics. Their findings determined that disappearance of the Korotkoff sound was a
reliable measure of diastolic pressure and should now be the
uniform designation for diastolic BP. '2
Oscillometric Blood Pressure Monitoring. Oscillometric BP monitoring is a form of automated indirect BP
monitoring often used in the critically ill child. It provides
measurement of systolic, diastolic, and mean arterial pressure as long as the extremity is receiving adequate pulsatile
flow. Units use two air bladders, one of which occludes

using the New York Heart Association (NYHA) grading system
is helpful:
• Class I: Patients with heart disease who have no symptoms
of any kind. Ordinary physical activity does not cause
fatigue, palpitation, dyspnea, or anginal pain.
Class 1/: Patients who are comfortable at rest but have
symptoms with ordinary physical activity.
Class Ill: Patients who are comfortable at rest but who have
symptoms with less than ordinary effort.
Class IV: Patients who have symptoms at rest.
Medications: Information regarding prescriplion and nonprescription medications should be obtained, as well as drug allergies.
Medical history: Prenatal, birth, and history of significant
illness or hospitalizations may prove to be relevant. Frequent
respiratory infections may be related to lesions with increased
pulmonary blood flow.
Family history: Family history of congenital heart disease,
sudden unexpected death in children or young adults, arrhythmias, or genetic diseases should be inquired about. The incidence
of congenital heart disease in the general population is about 1%;
this increases to 3% to 4% when a first-degree relative is
affected. II

blood flow and the other measures arterial wall oscillations.
The cuff deflates in a stepwise manner, measuring the
amplitude of pulse oscillations. The first small, rhythmic
oscillations correspond with systolic pressure. Maximal
oscillations correspond with the mean arterial pressure.
Subsequent recurrence of small oscillations generally corresponds with diastolic pressure. Stepwise deflation also
allows time for the microprocessor in the unit to reject
artifact, enhancing measurement accuracy.
In clinical practice, auscultatory systolic BP has been
found to be less than and diastolic BP is greater than
corresponding oscillometric measurements. 14 However, systolic BP obtained by auscultation is generally lower than the
true physiologic systolic pressure. Generally, good correlation is found between direct and oscillometric measurement
of BP in normotensive infants and children.
Reliability and accuracy can be questionable in hypotensive, vasoconstricted, or hemodynamically compromised
critically ill children. 15 .'6 Clinical problems that can interfere with accurate measurement include muscular activity
and patient movement. Some children find the tourniquet
effect of the cuff uncomfortable. Frequent cuff inflation can
contribute to skin breakdown with possible pressure necrosis; therefore frequent skin inspection is necessary. Ideally
the cuff is not used on an extremity with an intravenous
infusion distal to the cuff because frequent inflations may
contribute to extravasation or clotting of the intravenous
(IV) tubi ng.
Respiratory Assessment. The cardiovascular and
respiratory systems are closely linked; therefore both must
be assessed in the critically ill child. Cardiovascular
pathologic conditions may be evidenced by respiratory
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symptoms, including retractions, increased work of breathing, and nasal flaring.

Physical Assessment
Inspection. Inspection is the first step in any physical
examination and can be accomplished without disrupting
the child. Initially the child is simply observed, preferably in
a relaxed state or while being held by the parent. General
appearance, body habitus, and level of comfort are evaluated. Physical abnormalities, such as dysmorphic features,
skin color, edema, and chest wall deformities, are noted.
Color. Color is best assessed in natural lighting and at a
comfortable temperature. Artificial lighting may create a
blue or yellow cast to the skin. Environmental factors (temperature) can produce peripheral vasoconstriction with subsequent peripheral cyanosis, pallor, or mottling. However,
vasoconstriction can also occur with low CO. In this situation, tachycardia, tachypnea, and cool extremities, along
with other signs of physiologic distress, will be observed.
Color is best assessed in the highly vascularized areas of
the head and neck, the earlobes, and the mucous membranes. Visual inspection is an indirect means of judging
arterial oxygen saturation. Trends or acute changes alert
caregivers to alterations in physical state when based on
careful and continuous observation of the critically ill child.
Continuous noninvasive pulse oximetry (Spoz) provides
more accurate evaluation of arterial desaturation.
Peripheral cyanosis is often observed in healthy children
and is generally caused by environmental influences such as
temperature. Central cyanosis is evident when 5 g/dl of
hemoglobin is reduced, resulting in blueness of the tongue,
mucous membranes, and nail beds. Visible cyanosis is dependent on arterial saturation and total hemoglobin. Therefore cyanosis may not be appreciated in anemic children
(although they can be quite hypoxemic), and polycythemic
patients can be cyanotic at a higher level of oxygen saturation. l7 Central cyanosis (and associated arterial desaturation) is secondary to intracardiac or intrapulmonary right-toleft shunt. 18 Cyanosis is difficult to detect in deeply
pigmented skin. Chronic cyanosis results in other abnormalities, such as clubbing of the digits, dry skin, and
polycythemia.
Clubbing. In the presence of chronic hypoxemia,
proliferation and engorgement of the capillary bed occur at
the base of the nail. This is a soft tissue deformity resulting
in the loss of the normal angle between the nail and the nail
bed. In severe cases the fingers and toes become broad and
round. Clubbing from cyanotic heart disease rarely occurs
before 3 months of age. Corrective surgery and removal of
the chronic hypoxic stimulus can reverse this deformity. 18.19
Edema. Generalized edema is rare in children, except
in nephrotic syndrome. Periorbital edema and, more rarely,
ankle, tibial, and sacral edema are detected in infants and
children with CHF.
Visible Pulsations. The jugular veins are inspected
for distension and abnormal pulsations. This maneuver is
helpful in the child and adolescent, but the short neck of
infants makes it difficult to assess the jugular veins.

When the child is supine, the jugular veins are normally
distended and visible. When the head is elevated 35 to
45 degrees, the veins should no longer be visible. Neck vein
distension indicates either elevated right atrial pressure or
right ventricular volume overload. The typically rapid HR of
infants and children often prevents visualization of the
double pulsation in the jugular veins that are detected in the
adult and correspond to the a and v waves. Carotid
pulsations are normally visible in children in the supine
position. They too are not visually detectable when the head
is elevated. Visible, bounding carotid pulsations may occur
with hypertension, hypoxia, anemia, or anxiety.
Chest Inspection. The chest is observed for symmetry, shape, contour, and pulsations. Obvious bulging over the
precordium is caused by chronic cardiac enlargement. In
young or thin children the apical pulse may be visible as a
precordial impulse. This visible pulsation normally corresponds to the point of maximal impulse (PMI) and is usually
the apex of the heart. An active precordium can be a normal
finding; however, a heave is abnormal. A heave, or thrust,
over the precordium will be noted in cardiac lesions that
produce volume overload.
Palpation. Precordial palpation is performed to confirm and qualify visible findings and to detect normal and
abnormal pulsations and thrills. A thrill indicates a loud
murmur (at least grade 4) and is associated with turbulent
blood flow. Use the palm of the hand to palpate in the areas
outlined on Figure 7-19. Table 7-2 outlines cardiac defects
associated with thrills. The PMI is normally located at the
fourth left intercostal space in children less than 7 years old

Fig. 7-19 Areas for auscultation and palpation of the heart.
A, Mitral or apical area, where the first heart sound is loudest and
where the third and fourth heart sounds may be heard. E, Tricuspid
area, where a split in the first heart sound may be heard. C, Aortic
area where the second heart sound is heard well. D, Pulmonic area,
where a split in the second heart sound may be heard.
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and moves to the fifth left intercostal space medial to the
midclavicular line after 7 years. Lateral displacement of the
PMI occurs with left ventricular hypertrophy (LVH). Medial
displacement occurs with right ventricular hypertrophy.
Moving to the base of the heart, the aortic area is palpated
for pulsations, thrills, or heaves. Palpation of the aortic area
is enhanced when the patient sits up or leans forward.
Pulsations in this area are not normal. A thrill in this area
may indicate aortic stenosis.
In the pulmonic area, a single, slight, brief pulsation may
be palpated simultaneously in timing with the PM!. This is
a normal finding in the child with a thin chest wall, and it
may be evident in children with fever or anemia or following exertion. A slow, sustained, forceful pulsation in this area
may indicate pulmonary hypertension or mitral stenosis.
Palpation is continued over the parasternal area until the
tricuspid or right ventricular area is reached. Pulsation in the
tricuspid area may indicate right ventricle (RV) enlargement. A significant heave in this location indicates increased
RV pressure or enlargement.
A pericardial friction rub may be palpated as a scratchy
or grating sensation over the precordium. Unlike a pleural
friction rub, it does not vary with respiration. It is always an
abnormal finding. Subcutaneous air may be noted in
postoperative patients, indicating a possible air leak.
Abdominal Palpation. Palpation of the abdomen is
included in the cardiovascular exarnination because CHF in
infants and young children is associated with hepatomegaly.
The liver cannot usually be palpated in adolescents or adults
because it is located well above the right costal margin.
However, in the infant the liver edge is normally as much as
2 cm below the costal margin. The size of the liver relative
to the child's size decreases with age: at age I year, the liver
edge is palpable 2 cm below the costal margin, and by 4 or
5 years of age, it is located I cm below the costal margin.
Palpation of a normal liver reveals a sharp edge, in
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TABLE

7-2

Palpable Cardiac Thrill

i;;J>efect

i~{i:>uctus arteriosus
~:
':'!

ITi.Ventricular septal defect
'f!

"

';'

~iAortic stenosis

BPulmonic stenosis
;/

Description of
Associated Thrill

Palpable throughout the cardiac
cycle at the LSB; second and
third ICS
Palpable during systole at the
LSB; fourth, fifth, and sixth
ICS; may radiate to axillary
line
Palpable during systole at RSB;
second rcs and suprasternal
notch; may radiate to right
neck
Palpable during systole at the
LSB; second ICS; may
radiate to lerr neck

,t.-

(!f.iSR, Left sternal border; ICS. intercostal space; RSR. right sternal

!f.border.
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contrast with the blunted edge of the liver distended in
patients with CHF. In addition, the distended liver is usnally
tender. (Note that in abdominal situs inversus, the liver
would be on the left.)
The epigastric area is palpated to detect pulsations
present in that area. Pulsation of the aorta in children
can often easily be detected and is not abnormal. Pulsation
of the liver may be detected in the epigastric location,
indicating CHF.
Pulses. Central and peripheral pulses are evaluated for
their intensity and compared with one another in both timing
and intensity. Intensity is graded on a scale from 0 to +4
(Box 7-3). The brachial and femoral pulses should be equal
in intensity without pulse delay. Simultaneous palpation of
upper and lower extremities pulses helps to evaluate for
coarctation of the aorta.
Characteristics of the pulses provide important clinical
data. Strong, bounding pulses are found in aortic regurgitation and patent ductus arteriosus. Weak, thready pulses are
found in shock, severe aortic stenosis, and cardiac tamponade. Pulsus paradoxus is an exaggeration of the variation of
arterial pulsation and BP with respiration. Normally, during
inspiration the reduction in systolic BP is only a few
millimeters of mercury, If the reduction is greater than 10
mmHg, then pulsus paradoxes exists. These phenomena can
be appreciated on palpation of the pulses but are more
accurately assessed with BP monitoring. Pulsus paradoxus
occurs with pericardial effusion and cardiac tamponade.
Skin Temperature. Skin temperature assists in the
assessment of peripheral perfusion. Normally the skin is
warm and dry. In the presence of decreased perfusion
temperature, demarcation assists in the determination of
severity (i.e., cool to the knees, cool to the groin).
Capillary Refill Time. Capillary refill time is determined by compressing the skin on an extremity until it
blanches and noting the time it takes to reperfuse the
blanched area. Normal capillary refill is less than 3 seconds;
prolonged capillary refill is associated with decreased CO.
Percussion. Percussion can be used to estimate heart
and liver size and location. Chest radiograph and echocardiogram provide definitive data on cardiac size, shape, and
position. Therefore percussion is generally reserved for
evaluation of the liver.
Auscultation. The deceleration of blood flow and
vibration of the valves produce normal heart sounds. The
first heart sound (51) is produced by AV valve closure at the
beginning of systole. Closure of the semilunar valves
produces the second heart sound (52) at the beginning of
diastole.

~

Box 7·3
Pulse Intensity Scale

0= absent
+ I = weak, easily obliterated
+2 = normal. easily palpated, cannol be obliterated
+3 = full
+4 = full, bounding
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Auscultation of the chest requires a systematic approach
that should be followed with each patient evaluation. The
following is a recommendation; the most important caveat is
that the examination is always consistent so that physical
findings are not missed. Begin at the apex to best evaluate
S I' Then move the stethoscope to the left lower sternal
border and move up the chest to the pulmonic region to best
evaluate S2' Systematically compare murmurs and heart
sounds in the right and left sides of the chest, axilla, and
posterior chest. Start with the diaphragm of the stethoscope
for best auscultation of high-frequency sounds. Repeat the
sequence with the bell to best evaluate low-frequency
sounds. Refer to Figure 7-19 for areas of auscultation.
Split Heart Sounds. SI is usually heard as a single
sound. In children, normal splining of SI may be audible
over the tricuspid area. It is not uncommon for systolic
ejection clicks to be misinterpreted as splitting of SI.13
Normal physiologic splitting of S2 occurs with inspiration and is easily audible in children. A split S2 is best heard
at the second or third left intercostal space. S2 is split on
inspiration because of increased venous return that occurs
during inspiration, resulting in delayed closure of the
pulmonary valve. S2 should become single with expiration.
Normally the aortic valve (A 2) closes just before the
pulmonary valve (P2)n.2o
Careful attention should be paid to physiologic splitting
of the second heart sound because this can be quite
diagnostic. If the second heart sound never becomes single
with expiration (a "fixed" split), is always single (often
difficult to determine in infants) or is wider on exhalation
than on inspiration (a "paradoxical" split), the finding is
considered pathologic and warrants further evaluation. 18 For
example, a fixed split of S2 occurs with atrial septal defect
(ASD) and right bundle branch block (both of these
phenomena delay pulmonary valve closure). A single S2 is
associated with pulmonary hypertension, pulmonary or
aortic atresia, and dextro-transposition of the great arteries
(D-TGA). Paradoxical splitting may occur when LV contraction is delayed because of a left bundle branch block,
and the aortic valve closes after the pulmonic valve during
exhalation.
Accentuated Heart Sounds. Each component of the
second heart sound is also assessed for its intensity. An
accentuated pulmonic (P2) component of S2 is a marker of
pulmonary hypertension. P2 may also be accentuated in
heart failure and with an ASD. A 2 is accentuated with
systemic hypertension. The aortic component of S2 may be
diminished when arterial pressure is low, as in hypovolemia
or shock.
Extra Heart Sounds. Extra heart sounds include
ejection clicks. S3, and S4' Ejection clicks can be heard in
early, middle, or late systole and are associated with
abnormalities of the cardiac valves. These crisp sounds are
well localized to the valve areas. Pulmonic and aortic
ejection clicks are heard in early systole just after S I' A
pulmonary ejection click may diminish in intensity during
inspiration and is associated with pulmonary stenosis. An
aortic ejection click does not vary with respiration and is
associated with aortic valve stenosis or bicuspid aortic
valve. Mitral valve prolapse produces a midsystolic click.

This is not an uncommon finding in the general population,
and, although not a critical care problem, it may be detected
in adolescents in the pediatric intensive care unit (PICU).
A third heart sound (S3) occurs in early diastole during
rapid filling of the ventricles. S3 is a low-frequency sound
best heard at the apex early in diastole, just after S2' S3
sounds like "ken-TUC-ky" and may be heard in normal
children. A loud S3 can occur as a result of resistance in
ventricular filling from volume overload or decreased
compliance and is sometimes referred to as a gallop rhythm.
It is audible in mitral regurgitation, left-to-right shunts,
CHF, and anemia?l
A fourth heart sound (S4) is produced by atrial contraction, indicates altered ventricular compliance, and is almost
never heard in normal children. 18,21 Like S3' S4 is a
low-frequency sound best heard at the apex. S4 is distinguished from S3 by its timing in the cardiac cycle, occurring
just before SI' S4 is often associated with systemic
hypertension, hypertrophic cardiomyopathy, or CHF.
Summation gallop is noted when S3 and S4 occur
simultaneously, producing a single sound. This heart sound
is a pathologic finding associated with heart failure.
A pericardial friction rub is a transient scratching,
grating, or squeaking sound that is high pitch. Indicative of
pericarditis or postpericardiotomy syndrome, it is best heard
between the apex of the heart and the left sternal border.
Cardiac Murmurs. Murmurs are the result of abnormal turbulent blood flow across septal defects, abnormal
valves, or abnormal great vessels. The location and quality
of the murmur are dependent on the defect that produces
the abnormal blood flow. Murmurs are described in terms of
timing, intensity, location, pitch, and quality.
The timing of a murmur is related to the cardiac cycle.
Systolic murmurs occur between S I and S2' during ventricular systole. They are best described as early, mid, or late
systolic murmurs. Holosystolic murmurs are heard throughout systole. Diastolic murmurs occur after S2 (early,
mid, late), during ventricular diastole. Continuous murmurs
occur throughout the cardiac cycle. Holosystolic and diastolic murmurs are never innocent.
The intensity of murmurs is graded on a scale from I to
VI and is described in Table 7-3. Assigning a specific
intensity to a murmur is subject to individual interpreta-

ltI
!iiGrade

TABLE

7-3

Intensity of Cardiac Murmurs

Description
Faintest murmur audible; often undiscovered
initially
Faint, but heard without difficulty
Soft, but louder than II
Loud, but not as loud as V; associated with a
palpable thrill
Loud. still audible when stethoscope is lifted
partially off the chest; associated with a
palpable thrill
Loudest murmur; remai ns audible when stethoscope
is lifted away from the chest

Chapter 7 Tissue Perfusion

tion, and discrepancies between examiners may exist.
When the same examiner assesses a child with a murmur,
trends and changes are appreciated in a timely manner.
Location is described as to where the murmur is best audible (left lower sternal border, midscapula, etc.) or according to the traditional landmarks, as illustrated in Figure 7-19.
Pitch of heart murmurs is described as high, medium,
or low. High-frequency (pitch) murmurs are best heard
with the diaphragm of a stethoscope; low-frequency murmurs are best heard with the bell. The quality of the murmur
is described with terms, including harsh, musical, blowing,
or rumbling.
Heart murmurs that are produced by structural cardiac
defects are called organic murmurs. Up to 50% of children
have innocent murmurs, without structural or functional
heart disease. Innocent murmurs are generally soft (grade
I or liN I), systolic, and of short duration, often with a
characteristic vibratory quality. Children with innocent
murmurs have no other symptoms and generally demonstrate normal growth. This diagnosis is usually made
on physical examination without ancillary testing 22

NONINVASIVE EVALUATION
AND DIAGNOSIS
Many noninvasive diagnostic tests are routinely used to
evaluate infants and children with a potential for cardiac
dysfunction. These tests include cardiac rhythm monitoring,
radiographic evaluation of the heart, and echocardiography.

Monitoring and Evaluating Cardiac Rhythm
Patients at risk for the development of cardiac arrhythmias
require careful monitoring, accurate diagnosis of the
rhythm, and assessment of potential or real hemodynamic
consequences. Primary cardiac arrhythmias, like primary
cardiac arrest, are unusual among infants and children.
Infants and children at risk for cardiac rhythm disturbance
are those with congenital or acquired heart disease (particularly following cardiac surgical procedures), severe electrolyte imbalance, ingestion of a toxic substance, congenital
complete heart block, and vagal sensitivity.
The clinical significance of an arrhythmia is determined
by its affect on hemodynamics, CO, and the potential for
degeneration to a lethal rhythm. Relative to adults, rhythm
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abnormalities in children can degenerate quickly and have
serious sequelae. Figure 7-20 illustrates the rapid (6-second)
deterioration of supraventricular tachycardia (SYT) to
ventricular tachycardia (YT) and ventricular fibrillation
(YF) in a 9-month-old with viral myocarditis. Infallls and
small children do not tolerate persistent bradyarrhythmias
and tachyarrhythmias; alterations in diastolic filling and
decreased CO associated with rhythm disorders occur in the
setting of a limited ability to adjust Sy'
Accurate assessment of cardiac rhythm disturbances
requires practice and understanding of four general principles. First, a systematic approach to ECG analysis must be
adopted and applied consistently so that nothing is overlooked. Second, changes that are observed are followed for
trends and clinical significance. Third, observed changes are
compared with age-dependent normal values (Table 7-4).
Finally, the rhythm disturbance is considered in terms of the
patient's clinical situation (i.e., acid-base or electrolyte
status, presence of structural defects, postoperative openheart surgery). Of importance to note is that a child with
heart disease can have a normal ECG, and conversely, a
child without heart disease can have an abnormal ECG.
Monitoring Leads. Most PICUs use bedside cardiac
monitors with three lead wires designated RA for right arm,
LA for left arm, and LL for left leg. These bipolar leads
monitor the leads I, II, and III via a positive, a negative, and
a ground electrode. MCL I (modified chest lead) can also be
monitored via three bipolar electrodes. The MCL I lead is
more valuable than lead II in evaluating abnormal ventricular conduction. Figure 7-21, A and B, compares the position
of the positive and negative electrodes in lead [l and MCl I .
Newer monitors provide multiple-lead monitoring
(Figure 7-22) that allow real-time recording of both the
bipolar leads (I, II, III, aY F , aY R , aY L ) and a chest lead
(V), allowing full disclosure of cardiac rhythm. Depending
on monitor configuration, one or more leads can be
displayed, as well as a seven-lead ECG. Multiple-lead
monitoring is particularly helpful in patients with structural·
or functional heart disease because these patients are prone
to arrhythmias that can be difficult to identify with lead II
alone (i.e., atrial ectopic tachycardia, junctional ectopic
tachycardia, atrial flutter). In addition, analysis of multiple
leads is helpful in differentiating SVT with aberrant
conduction from YT. lead selection is based on which lead
gives the cleanest electrogram, as well as the patient's
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Fig.7-20 Rapid (6-second) deterioration of supraventricular tachycardia (SVT) to ventricular tachycardia
(VT) and ventricular fibrillation (VF) in a 9-month-old with viral myocarditis. (Courtesy MAQ Curley.)
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Heart Rate
(beats/min)·

93-154
(123)
91-159
( 123)
91-166
(129)
107-182
( 148)
121-179
(149)
106-186
(141 )
109-169
(134)
89-\51
(119)
73-137
( 108)
65-133
(100)
62-130
(91 )
60-119
(85)

Frontal Plane
QRS Vector
(degrees)

+59to-163
(137)
+64 to -161
(134)
+77 to -163
(132)
+65 to +161
( 110)
+31 10 +113
(74)
+7 to +104
(60)
+6 to +99
(56)
+7 to +101
(55)
+6 to +104
(55)
+11 to +143
(65)
+9 to +114
(61)
+11 to +130
(59)

PR Interval
(sec)

0.08-0.16
(.11 )
0.08-0.14
(.11 )
0.07-0.14
(.10)
0.07-0.14
(.10)
0.07-0.13
(.10)
0.07-0.15
(.11 )
0.07-0.16
(.11 )
0.08-0.15
(.11 )
0.09-0.16
(.12)
0.09-0.16
(.12)
0.09-0.17
(.13)
0.09-0.18
(.14)

QRS
Duration
Vs

0.Q3-0.Q7
(.05)
0.03-0.07
(.05)
0.03-0.07
(.05)
0.03-0.08
(.05)
0.03-0.08
(.05)
0.03-0.08
(.05)
0.03-0.08
(.05)
0.04-0.08
(.06)
0.04-0.08

Q

Q

III

V6
(mm)t

(mm)U

4.5

2

6.5

2.5

5.5

3

6

3

7.5

3

6.5

3

8.5

3

6

3

5

3.5

4

4.5

(.06)

0.04-0.08

5-26
( 14)
5-27
(14)
3-24
(13)
3-21
(II)
3-18
(10)
3-20
( 10)
1.5-20
(95)
2.5-17
(9)
1-18
(8)
.5-14
(7)

(.06)

0.04-0.09
(.06)
0.04-0.09
(.07)

RV,
(mm)

3
3

3
.3

0-12
(5.5)
0-10
(4)

SV,
(mm)

0-23
(8)
0-21
(9)
0-17
(7)

0-11
(4)
0-12
(5)
0-17
(6)
.5-18
(4)
.5-21
(8)
.2-21
( 10)
.3-24
(12)
.3-25
(12)
.3-21
(ll)

R/SV,

.I-U
(2.2)
.I-U
(2.0)
.2-U
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1.0-U
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(2.3)
.l-U
(2.3)
.1-3.9
(1.6)
.05-4.3
(1.4)
.03-2.8
(.9)
.02-2.0
(.7)
0-1.8
(.5)
0-1.7
(.5)

RV6
(mm)

0-11
(4)
0-12
(4.5)
.5-12
(5)
2.5-16.5
(7.5)
5-21.5
( 11.5)
6.5-22.5
( 13)
6-22.5
( 12.5)
6-22.5
(13)
8-24.5
(15)
8.5-26.5
( 16)
9-25.5
(16)
6.5-23
(14)

SV6
(mm)

0-9.5
(3)
0-9.5
(3)
0-10
(3.5)
0-10
(3.5)
0-6.5
(3)
0-10
(3)
0-7
(2)
0-6.5
(2)
0-5
( 1.5)
0-4
(I )

0-4
(I)

0-4
(I)

R/SV6

.I-U
(2.0)
.I-U
(2.5)
.1-U
(2.2)
.I-U
(3.3)
.2-U
(4.8)
.2-U
(6.2)
.2-U
(7.6)
.3-U
(9.3)
.6-U
(10.8)
.9-U
( 11.5)
1.5-U
( 14.3)
1.4-U
(14.7)
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nt;l1rom Garson A: Electrocardiography. In Garson A, Bricker JT, Fisher DJ et aI, eds: The sciellce alld practice oj pediatric cardiology, Philadelphia. 1998, Williams & Wilkins.
~~.2% to 98% (mean).
~itNinety.eighlh percentile.

, IJ;~Millimeters at normal standardization.
~;(t, Undefined.
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Fig. 7-21 A, Placement of the positive and negative electrodes for lead II monitoring. B, Electrode
placement for MCL,. (From Curley MAQ: Pediatric cardiac dysrhylhmias. p 33. Bowie. Md. Copyright
1985 by Brady Communications Company.)

White

(red)
Fig. 7-22 Electrode placement for
five-lead configuration. A, Lead placement with a five-lead set. B, Chest
lead placement for the V electrode.

_-I--Red

Green ----1_

(green)

(black)

A

rhythm abnormality. Simultaneous monitoring of leads I, II,
and aV F allow for evaluation of P wave axis and morphology, thus providing timely recognition of atrial arrhythmias.
V I is used for the determination of right bundle branch
block, and V 6 is used for the determination of left bundle
branch block.23.24
Electrode Placement. Regardless of the lead that is
monitored, accurate positioning of the electrodes in their
precise anatomic locations improves the accuracy of the
cardiac rhythm tracing. The exception to this principle is the
placement of limb electrodes in the l2-lead ECG, which
may be placed anywhere on the extremity. Moving a chest
electrode a short distance from its designated location can
alter the appearance of the cardiac rhythm tracing dramatically. The RA and LA electrodes should be placed at the
respective shoulder and the LL electrode placed on the left

lower torso. Often, surgical incisions, dressings, transthoracic intracardiac lines, or chest tubes preclude the accurate
placement of chest leads. Therefore monitoring of the
anterior chest leads may have to be forgone rather than
placing the leads in an inappropriate position that could alter
waveform configuration.
Cardiac Rhythm Assessment. Ten factors are systematically assessed when evaluating cardiac rhythm. Applying this approach permits accurate detection and diagnosis of rhythm disturbances.
The first parameter to evaluate is HR. Metabolic
demands, age, and clinical status determine HR. There is a
gradual increase in average HR during the first month of
life, followed by an even more gradual decrease across
childhood and adolescence. Table 7-4 gives the normal
age-dependent ranges for HR.
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Sinus bradycardia is a HR that is lower than normal,
and sinus tachycardia is a rate that is faster than normal.
They are evaluated relative to the child's level of activity and clinical status. For example, a sinus tachycardia
of 200 beats/min is not an unexpected or abnormal
finding in a stressed, febrile, anemic infant. Conversely,
a sinus bradycardia of 90 beats/min can also be observed
in a sleeping infant. Most often, clinically significant
bradycardia is the result of hypoxia, acidosis, or vagal
stimulation.
Faster inherent rates are present in all of the potential
pacemaker cells located throughout the myocardium. As a
consequence, infants and children have faster escape
rhythms than those seen in adults. Therefore accurately
diagnosing an ectopic rhythm on the basis of HR alone is not
possible. When rapid heart rhythms are detected, the first
element in accurate interpretation of the rhythm is consideration of the patient's history and current clinical situation.
For example, sinus tachycardia (ST) is most often associated
with fever, anemia, or hypovolemia. Infants with SVT can
present with a several-day history of poor feeding, lethargy,
and CHF25 Incisional atrial reentrant tachycardia (IART),
historically known as atrial flutter, generally presents in
patients after atrial surgery (i.e., Fontan, Mustard, and
Senning procedures). VT is most often seen in patients with
history of severe metabolic or electrolyte imbalance, toxic
ingestion, cardiomyopathy, or cardiac surgery26
Sinus tachycardia is a secondary rhythm disturbance that
reflects the need for more CO in patients with increased
metabolic demands. Tachycardias such as SVT, AF (atrial
flutter), and VT, can produce signs of cardiac dysfunction.
Inadequate tissue perfusion, if present, is the consequence of
the rhythm disturbance, not the result of increased metabolic
demands.
Mechanism of onset is an important factor in the
diagnosis of tachycardia. ST is characterized by a gradual
acceleration of the HR. SVT and AF are tachyarrhythmias
with abrupt onset to rates of 230 to 320 beats/min. These are
most often the result of a reentry mechanism.
Two distinct pathways form a reentry mechanism
(Figure 7-23) with unidirectional block in one limb. After a
premature contraction the electrical impulse is blocked in
the first limb of the circuit but is conducted antegrade
(forward) through the second limb. The impulse then can
"reenter" the first limb and be conducted retrograde, or in
the other direction, with subsequent antegrade propagation
down the first limb. As a result of perfect reciprocal timing
of both limbs of the circuit, perpetuation of very rapid heart
rates occurs. Pacing terminates reentrant rhythms?? AV
node block with adenosine terminates most SVT because the
AV node serves as one limb of the reentrant circuit.
The second parameter for evaluation of a rhythm strip
is the regularity of the rhythm, as well as the presence of
grouped beats. Sinus rhythm is fairly regular, but some
variability is normal because of changes in vagal tone. Sinus
an'hythmia is common in children and reflects normal HR
variation with respiration. HR will increase with inspiration
and decrease with expiration.
SVT and AF are regular rhythms that generally do not
vary with patient activity or sleep. These phenomena can be

Fig. 7·23 Reentry circuit. (From Holbrook PRo Textbook
of pediatric critical care, Philadelphia. 1993, WB Saunders.
p 386.)

easily identified using the trend recordings of HR available
on some cardiac monitors. Group beating (i.e., clustering of
QRS complexes identified by examination of a long rhythm
strip) can be observed with sinus arrhythmia and type I and
type II second-degree heart block.
The third parameter to assess is the P wave. The P wave
is evaluated for amplitude (height), duration, and morphology. P wave size and duration correspond to the relative size
of the atria. Normally P wave amplitude is no greater than
3 mm, and maximal P wave duration is 0.10 seconds in
children over I year old (0.08 seconds in infants less than
I year old)D Tall P waves may indicate right atrial
enlargement, and wide P waves may indicate left atrial
enlargement. Bilateral atrial enlargement is indicated by
P waves that are both wide and tall 24 Figure 7-24, A,
illustrates altered P wave morphology reflective of right and
left atrial enlargement.
P waves should be upright and consistent in appearance in lead II. If they are not, an ectopic rhythm is
suspected. "Flutter" waves replace normal P waves during AF (Figure 7-24, B). However, this can be easily
missed in patients who have low-amplitude P waves after
extensive atrial surgery. With premature atrial contractions,
low atrial rhythm, or atrial ectopic tachycardia, P wave
morphology or axis will be different from the P wave in
sinus rhythm. 27 •28 This can be manifest as a negative P wave
in aVF' lead I, or lead II. In junctional rhythms, the P waves
are dissociated, absent, or inverted after the QRS complex
(Figure 7-24, C).29
The fourth parameter for evaluation is the PR interval.
The length of the PR interval varies both with age and HR.
(See Table 7-4 for age-dependent norms.) First-degree heart
block is defined as a PR interval longer than the norm for
age. It can be a normal variant caused by increased vagal
tone, and in this situation, it is a benign condition 30 Digoxin
can increase the PR interval at therapeutic doses; however,
first-degree AV block may be a sign of toxicity. PR
prolongation can also be seen in myocarditis, hyperkalemia,
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Fig. 7-24 A, Abnormal P waves in a pediatric patient, 1. Right atrial enlargement;
P waves measure 5 mm. 2, Left atrial
enlargement: P wave duration measures
0.12 second. B, Normal P waves replaced
by flutter waves in atrial flutter. (From
Curley MAQ: Pediatric cardiac dysrhythmias, pp 59, 88, 101, 102. Bowie, Md.
Copyright 1985 by Brddy Communications
Company.)
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Kawasaki disease, acute rheumatic fever, and corrected
(levo) transposition of the great arteries (L-TGA)Y
Short PR intervals occur in rhythms with AV dissociation, such as complete heart block or junctional ectopic
tachycardia (JET). Although no association exists between
atrial and ventricular contraction in these rhythms, occasionally the P wave appears just before the QRS with a very
short PR interval.
In ventricular preexcitation (WPW syndrome) the PR
interval is short on ECG. This condition is due to a manifest
accessory connection that allows rapid antegrade (forward)
conduction of a sinus beat to the ventricles at the same time
there is ventricular depolarization by the AV node. As a
result of the early activation of the ventricles, the PR
interval is short. Ventricular preexcitation is apparent on
ECG by the presence of a delta wave (Figure 7-25).

The fifth parameter for assessment is the P·QRS
relationship. Every P wave should be conducted to the
ventricles and produce ventricular depolarization and a QRS
complex. If a one-to-one P-QRS relationship does not exist,
heart block or AV dissociation is suspected. See Figure 7-26
for an illustration of various forms of AV block.
In patients with second-degree heart block, the rhythm
strip reveals more than one P wave for each QRS complex.
Second-degree heart block is classified in two groups:
Mobitz type I (Wenckebach) or Mobitz type II. In Mobitz

rype I, there is progressive prolongation of the PR interval
with eventual failure to conduct an atrial impulse to the
ventricles. The rhythm strip reveals progressive lengthening
of the PR interval and concomitant shortening of the RR
interval until a QRS complex does not follow a P wave.
Characteristic grouping of complexes is evident. Mobitz
type I second-degree heart block may reflect AV node
dysfunction in patients following intracardiac surgical
procedures near the AV node or in those with digoxin,
J3-blocker, calcium channel blocker, or quinidine toxicity. It
can be detected in people without pathophysiologic conditions, especially during sleep. Mobitz type I second-degree
heart block does not usually progress to third-degree
(complete) heart block. No treatment is indicated unless the
ventricular rate is excessively slow and CO is compromised
as a consequence. Permanent pacing is indicated in those
children with symptomatic Mobitz type I block, although
this is infrequent. 30
Mobitz type II second-degree heart block results in either
normal AV conduction or completely blocked conduction.
The atrial rate is normal (regular P waves), but the
ventricular rate (QRS) depends on the number of normally
conducted beats. On a rhythm strip, this is manifest by
occasional or a patterned block of AV conduction. A QRS
complex does not follow each P wave. This type of heart
block is at the bundle or lower and can progress to
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Fig. 7-24-<:ont'd C, Altered P wave morphology and location. J, Inverted P waves before the QRS complex characteristic of low atrial
rhythm. 2, Buried P wave within the QRS complex, atrial and ventricular
depolarization occur at the same time (junctional rhythm). 3, Inverted
P wave after the QRS complex ventricular depolarization first, then atrial
depolarization (junctional rhythm). (From Curley MAQ: Pediatric
cardiac dysrhythmias. pp 59,88, 101, 102. Bowie, Md. Copyright 1985
by Brady Communications Company.)
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p
First degree AV block

Second degree AV block

p

Mobitz type I
(Wenckebach phenomenon)

Fig. 7-26 Disturbances of atrioventricular (A V)
conduction. (From Park PK: How to read pediatric
ECGs, ed 3, Sl. Louis, 1992, Mosby.)

Mobitz type II

p

p

2:1 AV block

Complete (third degree)
AV block

third-degree heart block. 23 Ifthe patient is unstable with this
rhythm, intravenous isoproterenol, atropine, or epinephrine
may be helpful in increasing ventricular rate until pacemaker therapy is available.
Occasionally 2: 1 AV block is noted; this occurs when a
QRS follows every second P wave. Without conducting an
electrophysiology study, it is difficult to determine if 2: I AV
block is Mobitz type I or type II because the AV node can
develop a Wenckebach after every other sinus beat.
Third-degree, or complete heart, block (CHB) can either
be congenital or acquired. Regardless of the cause, the SA
node paces the atria, and either a junctional or ventricular
escape rhythm paces the ventricles. On ECG the atrial rate
is regular and faster than the ventricular rate, and no
relationship exists between the P waves and QRS.
Acquired CHB may result from severe metabolic derangement, such as hypoxia, acidosis, hypothermia, hypoglycemia, electrolyte imbalance (especially of potassium or
calcium), drug toxicity, acquired myocardial disease (including myocarditis), or as a consequence of open heart
surgery. In most cases, acquired CHB is transient, requiring
only temporary support. Administration of intravenous
isoproterenol or epinephrine (0.05-0.1 /lg/kg/min) to increase the ventricular rate is usually necessary. Temporary
pacing is accomplished via transvenous or transcutaneous
epicardial approach. However, esophageal atrial pacing is
not of benefit in CHB because atrial impulses cannot be
conducted to the ventricles. Permanent pacing is necessitated if acquired CHB persists for longer than 14 days
because the ventricular rate is too slow to support CO
and does not increase significantly to support metabolic
demands. 30.31
Congenital CHB is often associated with maternal
collagen vascular diseases, such as systemic lupus erythematosus. In addition, some 30% of infants with congenital
CHB have CHDs, including L-transposition, univentricular
heart, AV canal, and tricuspid atresia. 32 Infants with
congenital CHB are often diagnosed prenatally on fetal
echocardiogram. In some, the HR is so slow that severe
CHF is present at birth, and mortality is high in this group.

Infants who are asymptomatic at birth, except for the slow
HR, generally have an escape rhythm of 60 to 70 beats/min.
A mean awake HR of less than 55 beats/min is a poor
prognostic indicator. 32 - 34
In the symptomatic infant, administration of isoproterenol or epinephrine may be necessary to increase HR until
placement of a permanent pacemaker. In the asymptomatic
infant, close observation with frequent Holter monitoring is
necessary to evaluate for rate response with exercise,
ventricular escape rhythm, or mean HR. If CHF, syncope,
inability to increase HR, a long QT interval, VT, or
wide-complex escape rhythm develops, then placement of a
permanent pacemaker is indicated.
The P-QRS relationship may also be useful in diagnosis
of tachyarrhythmias (although it is often difficult to detect
P waves on ECG at very high heart rates). SVT can have
P waves conducted retrograde that follow the QRS. In JET
or VT, AV dissociation is present.
Many diagnostic tools are available to assist in the
assessment of the AV relationship during tachycardia. First,
AV dissociation can be assessed from the RA hemodynamic
waveform. On atrial pressure lines (central venous pressure,
left atrial pressure), cannon a waves are present in AV
dissociation, occurring when the atria contract against a
closed tricuspid or mitral valve (Figure 7-27). Second,
assessing the P-QRS relationship in more than one lead is
often useful. Figure 7-28 is a 12-lead ECG in a 9-year-old
with wide-complex tachycardia. In VI' AV dissociation is
evident, aiding the diagnosis of VT.
Finally, an atrial electrogram can be recorded using a
transesophageal electrode or an existing transthoracic atrial
wire placed during cardiac surgery. These maneuvers are
helpful in the diagnosis of atrial lachyarrhythmias or JET.
Atrial activity is detected with the transesophageal lead
because the lower esophagus lies posterior to the left atrium
(LA). An atrial esophageal lead is placed like a nasogastric
tube and slowly withdrawn to provide optimal visualization of atrial waves (Figure 7-29). An epicardial atrial
electrogram allows the direct recording of atrial activity.
When obtained simultaneously with a rhythm strip, atrial
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activation and AY association can be clearly identified
(Figure 7-30). In addition, atrial overdrive pacing to terminate reentrant arrhythmias can be accomplished via either
transesophageal or atrial epicardial wires. Less traumatic
than traditional cardioversion, atrial overdrive pacing is
useful when the patient is hemodynamically unstable or is
refractory to drug therapy.

The sixth assessment parameter is duration ofthe QRS
complex. QRS duration correlates with ventricular mass and

Wider than expected QRS complexes occur when ventricular impulse conduction is delayed or aberrant. For example, premature ventricular contractions (PYCs) and bundle
branch block (BBB) result in abnormally long conduction
pathways. PYCs are often benign; however, multiform
PYCs, couplets, or triplets warrant further investigation.
Electrolyte, acid-base status, and hemodynamic function
should be evaluated in critically ill children with PYCs.

becomes wider as the infant or child grows (see Table 7-4).

ELECTROGRAM
Atrium Vent.

Fig. 7-27 Cannon a waves in AV dissociation as the atria contract
against a closed tricuspid valve.

Fig. 7·28

Fig. 7-29 Anatomic relationship between the esophagus and the
cardiac chambers in infants. The ideal electrogram at midesophagus has an atrial spike that is equal to, or larger than, the ventricular
signal. V, Ventricle; LA, left atrium; ST, stomach. (From Walsh EP:
Electrocardiography and introduction to electrophysiological techniques. In Fyler DC. ed: Nadas 'pediatric cardiology, Philadelphia,
1992, Hanley & Belfus, p 147.)

Wide-complex tachycardia with AV dissociation evident in lead VI. (Courtesy M.A.Q. Curley.)

Chapter 7

Intraventricular conduction blocks can occur in either the
right or the left bundle branch because of CHDs or
myocardial inflammation. Right BBB is common after
surgical repairs that involve the ventricular septum. The type
of intraventricular block (that is, partial or complete BBB)
is monitored with serial ECGs but is not usually of clinical
significance for most pediatric patients.
Wide QRS complex tachyarrhythmias pose a significant
problem to caregivers in the PICD. Differentiating between
SVT with aberrant conduction and VT is critically important
because treatment of these two arrhythmias is quite differ-
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ent. The following factors are considered in making the
distinction between the two:
I. Rate. The rate of SVT is age dependent. The normal
rate of the SA node is 220 minus the patient's age;
anything faster than this is usually considered an
abnormal tachyarrhythmia. SVT and VT rates range
from 150 to 300 beats/min. 35
2. Rhythm. VT is generally a regular rhythm; SVT is
monotonously regular.
3. P-QRS relationship. In SVT the relationship is one to
one (I: I), whereas AV dissociation exists in VT. In VT
the ventricular rate is greater than the atrial rate. 35 (At
rapid heart rates, this can be difficult to determine
using a surface ECG.)
4. QRS duration. Generally, Wide-complex tachycardia
is considered VT until proven otherwise. In VT the
QRS duration is different than the sinus QRS and
wide at 120 to 140 milliseconds. In the majority of
patients with SVT, the QRS complex is normal and
narrow complex. However, up to 15% to 30% of
patients with SVT can have rate-dependent BBB,27
which is most often a right BBB best identified in V l'
5. Fusion complexes. Fusion complexes are created in
part by a normally conducted supraventricular impulse and in part by an ectopic ventricular impulse.
The result is in normalization of the QRS complex?3
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Atrial electrocardiogram; note the atrial rate in the top
lead is faster than the ventricular rate (QRS) in the bottom iead.

Fig. 7-30

Fig. 7-31

Figure 7-31 shows rhythm strips in which wide-complex
tachycardia is noted. The most crucial assessment in each
case is the impact of the rhythm disturbance on hemodynamics and patient condition.
Evaluation of QRS duration is helpful in monitoring
critically ill children with electrolyte imbalances or over-

Wide-complex tachycardia. (Courtesy M.A.Q. Curley.)
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Fig. 1-32 Prolonged QRS duration in tricyclic antidepressant ingestion; changes in a patient's ECG
over 8 hours. (From Kelley SJ: Pediatric emergency nursing, ed 2, Norwalk, Conn, 1994, Appleton &
Lange, p 234.)
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Fig. 1-33 Hyperkalemia prolongs cardiac conduction: the QRS duration and PR interval are prolonged,
and the P wave is broad.. (From Curley MAQ: Pediatric cardiac dysrhythmias, p 153. Bowie, Md.
Copyright 1985 by Brady Communications Company.)

dose. Tricyclic ingestion results in prolongation of the QRS
complex and provides a bedside guide to predict which
patients are at risk for significant complications (i.e.,
seizures, ventricular arrhythmias, and death) (Figure 7-32).
In patients with hyperkalemia, peaked T waves are noted
initially; however, this is a nonspecific sign because many
normal children can have peaked T waves. As the serum
potassium level continues to rise, cardiac conductivity is
decreased, resulting in bizarre wide QRS complexes. 24
Figure 7-33 represents the rhythm strip of a patient with
hyperkalemia.

The seventh assessment parameter is the ST segment.
The ST segment is evaluated from the J point (the junction
of the QRS complex and the ST segment) and compared
with the isoelectric line or baseline of the rhythm strip.
Normally the ST segment is not elevated more than I mm or
depressed more than 0.5 mm in children. An exception to
this is early repolarization syndrome in adolescents that is a
benign condition resulting in ST segment elevation of up to

4 mm?4 Abnormal ST segments are associated with
myocarditis, pericarditis, myocardial ischemia, potassium
abnormalities, severe ventricular hypertrophy, and intracranial pathologic conditions (Figure 7-34).
The eighth parameterfor assessment is the T wave. The
T wave is normally asymmetric, and measurement of
amplitude is difficult because of normal variability in
children. Low-voltage or flat T waves in multiple leads may
indicate ischemia. T waves should be upright in leads I and
II after 48 hours of age. T waves are normally inverted in V I
after 5 days of age until adolescence, at which point they
become upright?4 Abnormalities in the T wave are the result
of abnormal depolarization (such as that which occurs with
PVC) or when repolarization is abnormal (as in patients with
myocarditis).
Tall, peaked T waves are apparent in hyperkalemia,
LVH with volume overload, and intracranial hemorrhage. Flattened T waves are apparent in hypothyroidism,
hypokalemia, myocarditis, ischemia, or digoxin toxicity?3
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Depression of the ST segment with tachycardia. (Courtesy M.A.Q. Curley.)

Figure 7-35 shows T wave changes associated with changes
in serum potassium levels.
The ninth parameter evaluated is the QT interval. The
QT interval represents ventricular repolarization and varies
with HR, increasing with slower rates and decreasing with
rapid rates. Bazett's formula is widely accepted for calculation of the QT interval. However, the data in support of
Bazett's formula is from adults and has been extrapolated to
children. The QT interval has been found to be influenced by
gender and age. Adolescent girls have the longest QT
intervals 36 The QT interval is corrected for HR; however,
validity is questioned at very slow heart rates «50
beats/min) and in bigeminal rhythms. This measurement
must be made using the QT following three consecutive
sinus beats.
QTc = measured QT interval + square root of the RR interval
(expressed in seconds)
The QT interval ends at the end of the T wave. If a U wave
(see next section) is present and the U wave amplitude
is 50% or less of the T wave amplitude, then the QT
interval ends at the extrapolated downslope of the T wave.
The corrected QT should be less than or equal to
0.44 second, except in newborns where it may be up to
0.47 second.
Shortening of the QT interval is detected in patients
receiving digoxin and in those with hypercalcemia. Prolonged QT interval occurs with hypocalcemia, myocarditis,
hypomagnesemia, hypokalemia, hypothermia, organophosphorous insecticide poisoning, medication toxicity (i.e.,
haloperidol [Haldol], tricyclic antidepressants, cisapride,
erythromycin, procainamide, and amiodarone among others), and long QT syndrome (Figure 7-36).

Long QT syndrome is a genetic mutation of one of the
voltage-activated channels altering normal ionic flow, resulting in ventricular repolarization abnormalities. These
patients are predisposed to ventricular arrhythmias and
torsades de pointes. 37 Long QT syndrome should be
suspected in children with QTc prolongation, syncope,
palpitations, and family history of sudden death.

The tenth parameter assessed is the presence of
U waves. U waves are small positive deflections that occur
at the end of the T wave. Prominent U waves are apparent
in hypokalemia and myocardial ischemia.

Radiographic Evaluation
Chest radiographs (CXR) of the seriously ill pediatric
patient provide important information about heart size,
chamber enlargement, and PBF. Most of these data are
obtained from a standard anteroposterior (AP) and lateral
chest film. Oblique films may be helpful in the detection of
specific changes in cardiac shape and size.
Detection of cardiac enlargement is an important goal of
chest radiography. Heart size is determined by the cardiothoracic ratio. The largest transverse dimension of the heart
is compared with the widest intercostal diameter of the
chest. (The presence of a thymic shadow can make this
measurement difficult in infants.) Cardiomegaly is present
when the heart size is greater than one-half the width of the
thorax. The film should be taken during peak inspiration
because an expiratory film will falsely enlarge the cardiac
silhouette.3 8 In the AP film, the right cardiac border is the
right atrium, and the lower left border is the left ventricle.
The aorta should arch to the left and slightly displace the
trachea to the right. In the lateral film, the lower anterior
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A

B

Fig.7·35 Twave changes that resulted when the serum potassium fell from 7.9 to 2.1 mEqlL in a patient
with diabetic ketoacidosis. A, Serum potassium 7.9 mEq/L. B, Serum potassium 2.1 mEqlL. (Courtesy
MAQ Curley.)

Fig. 7-36

QTc prolongation in a girl with the congenital, long QT syndrome. QTc is 485 ms.

border is the right ventricle, and the posterior border is the
left atrium (upper) and left ventricle (Iower).39 Serial
changes in heart size should be monitored.
Assessment of the vascular markings on the CXR detects
alterations in PBF. With a large left-to-right shunt, PBF is
increased, resulting in increased size and prominence of the

pulmonary blood vessels well into the peripheral lung fields.
Patients with heart defects that result in decreased PBF have
diminished pulmonary vascular markings.
The skeletal aspects of the CXR are examined because of
the association between CHDs and congenital anomalies
(many of which have bony abnormalities). The pulmonary

Chapter 7 Tissue Perfusion

parenchyma is inspected because pneumonia and/or atelectasis can be a problem in the postoperative period and in
children with increased PBF.
Magnetic resonance imaging (MRI) adds substantially
to the cardiac evaluation. Historically, barium swallow esophagrams were used for the detection of atrial
enlargement and coarctation of the aorta. However, MRI has
largely replaced the use of barium swallow for these
indications.
MRI can complement echocardiography if findings on
the echocardiogram are equivocal. In some situations
(coarctation of the aorta in older children, thoracic vascular
abnormalities, or pulmonary vascular abnormalities), MRI
has replaced cardiac catheterization as the primary diagnostic tool. 40 The accuracy and quality of MRI images require
patient cooperation and limitation of movement. Many
children require sedation, particularly infants and small
children. The presence of metal near the heart may degrade
the quality of the image, so a careful history should be
obtained to determine the presence of permanent pacemakers, vascular clips, shrapnel, or other magnetic metal. MRI
should be avoided in children with permanent pacemakers
or defibrillators because these can pose a significant hazard
to the patient (i.e., reprogramming of generator, inappropriate function, ventricular fibrillation).

Echocardiography
Echocardiography provides the most complete noninvasive
assessment of cardiac structure, function, blood flow patterns, and pressure gradients. Echocardiography uses transthoracic ultrasound imaging. A pulse generator sends electrical pulses to a transducer that emits short bursts of sound
energy through the chest wall. The transducer then receives
the sound energy returning from the tissues and converts it
into an electrical signal that can be viewed on an image
processor. Transthoracic two-dimensional and Doppler
echocardiography have become the primary diagnostic tools
in the evaluation of children with congenital heart disease.
The ability of echocardiography to provide a detailed assessment of cardiac structure has allowed most children
with major CHDs to undergo primary complete surgical
repair without the need for cardiac catheterization. 41
M-mode echocardiography provides one-dimensional
imaging of the heart. With this technique, the transducer
emits a thin beam of ultrasound energy directed to a specific
area of the heart. Cardiac structures that lie along that beam
are viewed on a strip recording that shows the motion of the
structures over time. With this limited view, M-mode cannot
provide diagnosis of structural cardiac defects and is
primarily used in the evaluation of LV size and function.
Two-dimensional echocardiography provides a crosssectional view of the heart. This is accomplished by aiming
the ultrasound beam across an angle, viewing the structures
of the heart within that area. This produces a sector or image
of the structures within the area of the ultrasound beam. The
result is a detailed two-dimensional image of the entire heart
and associated structures, making it the primary tool for the
diagnosis of structural cardiac defects.
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Doppler ultrasound adds information to the twodimensional picture by evaluating the blood flow through
the heart. In this technique, sound waves are bounced off
moving blood, making it possible to measure the velocity of
its flow. Color Doppler uses computer technology to assign
a color to the various blood flow velocities, making it useful
in the evaluation of intracardiac shunts and valve regurgitation. Spectral Doppler displays the blood flow velocity and
pattern directly on the screen and is most useful in the
evaluation of intracardiac valve obstructions.
The primary indications for echocardiography in the
PICU include diagnosis of CHDs, identification of residual
cardiac lesions after cardiac surgery, presence of pericardial
effusion and/or cardiac tamponade, evaluation of cardiac
chamber volume and function, identification of intracardiac
thrombi or vegetations, and possibly the evaluation of
diaphragm movement (Figure 7-37). In addition, echocardiography is utilized to guide pericardiocentesis in the
setting of pericardial effusion or cardiac tamponade.
Echocardiography can be used to evaluate ventricular
function by measuring shortening fraction or ejection
fraction. Shortening fraction is the percent change in
ventricular diameter during systole and diastole, and ejection fraction is the percent of volume change. Normal
shortening fraction is 32 ± 4%, and a normal ejection
fraction is 65 ± 10%. Shortening fraction is calculated by
measuring the transverse diameter of the ventricle in
diastole and systole, where LV diastolic diameter minus
LV systolic diameter divided by LV diastolic diameter gives
shortening fraction. Ejection fraction is best measured by
obtaining biplane measurements of the ventricle from the
apex. The entire wall of the ventricle is traced, measuring
the volume during diastole and systole, where the LV
diastolic volume minus the LV systolic volume divided by
the LV diastolic volume gives the ejection fraction. These
data can only be accurately applied to the morphologic left
ventricle. Evaluation of a systemic right ventricle (Mustard
or Senning for TGA) or morphologic single right ventricle
(hypoplastic left heart syndrome) is generally performed
subjectively by the echocardiographer.
Both methods of evaluating ventricular function have
limitations. Shortening fraction depends on normal wall
movement and is only applicable to a structurally normal
left ventricle. Conditions that produce RV volume overload
(atrial septal defect, or severe tricuspid or pulmonary valve
insufficiency), wall motion abnormalities (myocardial infarction, synthetic septal patch), and paradoxical septal wall
motion can make shortening fraction inaccurate. Ejection
fraction requires biplane measurements from either the
apical or subcostal views and therefore are often difficult to
obtain. If the entire wall is not visualized, errors in tracing
can lead to inaccurate measurements.
Echocardiographic techniques using Doppler flow measurements to estimate CO are also available. These techniques are often inaccurate and not as reliable as invasive
measurements of CO using the Fick or thermodilution
methods.
Transesophageal
Echocardiography. Although
transthoracic echocardiography has become the primary
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Fig. 7-37 A, Echocardiogram of an infant with VSD (ventricular septal defect). B, Echocardiogram of a child with
ASD (atrial septal defect). C, Echocardiogram of an infant with
a small VSD ad an AP (aortopulmonary) window. LA. Left
atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

c

diagnostic tool in the evaluation of children with congenital
heart disease, specific circumstances may limit its use. For
example, the presence of multiple chest tubes, invasive
monitoring lines, and an open sternum may limit the accessibility necessary to achieve adequate images for diagnosis.
In these circumstances, transesophageal echocardiography
(TEE) may be indicated. TEE uses a flexible ultrasound
probe with a high-resolution ultrasonic transducer at the tip.
With the patient deeply sedated (and possibly intubated), the
probe is passed orally into the esophagus and placed in the
retrocardiac position, where two-dimensional imaging and
Doppler analysis provide high-quality evaluation of cardiac
structure and blood flow. When placed into the stomach,
subcostal views of the heart can be obtained from below the
diaphragm, providing a better image for measuring flow
velocities through the ventricular outflow tracts.

In the operating room, TEE is used before the initiation
of cardiopulmonary bypass to confirm the diagnosis, identify any additional diagnostic information that may alter the
surgical approach, evaluate AV valve insufficiency, and
assess cardiac function. Immediately following the separation from cardiopulmonary bypass, TEE is used to identify
postoperative structural abnormalities that require additional
surgical procedures and to evaluate postoperative cardiac
function that may impact medical management. In approximately 6% of pediatric cardiac surgery patients, TEE
findings prompt a return to cardiopulmonary bypass for
further surgery or for revision of the surgery.42,43 In 75% of
these patients, the problem identified by TEE was corrected,
and the patients had a good outcome. The most common
cardiac lesions requiring return to cardiopulmonary bypass
are tetralogy of Fallot and AV canal defects.
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Fig. 7-38

Fetal echo.

TEE is used in the catheterization laboratory during
device closure procedures to ensure proper placement of the
device and to evaluate adequate closure of the defect.
Occasionally it may be used during electrophysiology
studies for electrode placement, particularly in singleventricle patients.
TEE is also the best method to diagnose intracardiac
thrombi, particularly in the left atrium. This should be
performed in patients who have been in atrial fibrillation!
flutter for protracted periods to rule out systemic heart
thrombi before cardioversion because the risk for embolization is significant. 44 .45
Limitations of TEE include its use in small infants and
previous esophageal surgery, making passage of the probe
difficult. Cardiac lesions that are not well visualized with
this method include partial anomalous pulmonary venous
drainage, left superior vena cava to left atria connection, and
distal branch pulmonary artery stenosis. Although no
significant morbidity or mortality has been reported with
the use of TEE, care must be taken on removal of the probe
in intubated patients to prevent accidental endotracheal
extubation.
Fetal Echocardiography. The development of highresolution ultrasound scanners, along with the evolution of
Doppler and color Doppler capabilities, has led to the use of
ultrasonography in the prenatal diagnosis of fetal cardiac
anomalies (Figure 7-38). Fetal echocardiography is successful in the diagnosis of structural cardiac abnonnalities,
arrhythmias, and abnonnal cardiac function in fetuses as
early as 16 to 18 weeks' gestation. An elective evaluation,
however, is preferred between 18 to 20 weeks' gestation
when the cardiac valves are well developed and the heart is
an adequate size for study.
A primary indication for fetal echocardiography is the
presence of an abnormal four-chamber view of the fetal
heart on an obstetric ultrasound. When referred for this
reason, the occurrence of congenital heart disease is 50% to
80%.46.47 The presence of fetal risk factors for congenital
heart disease is another indication for detailed fetal echocardiography. These include the following: (1) previous
Occurrence of congenital heart disease in siblings or parents;
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(2) maternal diseases known to affect the fetus, such as
diabetes mellitus and connective tissue disease; (3) maternal
drug use, such as alcohol and lithium; (4) abnormalities of
other fetal systems, such as chromosomal abnonnalities,
diaphragmatic bernia, omphalocele, and polyhydramnios, or
oligohydramnios; (5) nonimmune hydrops; and (6) abnormalities of fetal heart rhythm. In this setting, structural
cardiac defects have been found in 9% of the cases and
rhythm abnormalities identified in 17% of the cases. 4S
A primary benefit of fetal echocardiography is the ability
to provide the family with diagnostic and prognostic information to facilitate planning and decision making. The diagnosis of severe structural heart defects, such as ductaldependant lesions, may detennine the site of delivery to
optimize surgical and medical management during the newborn period. For example, fetal diagnosis of hypoplastic left
heart syndrome is associated with improved postnatal outcome. 49 When the likelihood of fetal demise related to congenital heart disease is high, termination of the pregnancy
may be considered. In the case of fetal arrhythmias, early
management with antiarrhythmic agents, along with echocardiographic monitoring, may decrease the development of
fetal hydrops and improve clinical outcome. In the future,
fetal diagnosis of structural cardiac defects, along with the
possibility of fetal cardiac intervention and/or surgery, may
improve the outcome of specific high-risk defects.

INVASIVE EVALUATION AND DIAGNOSIS
Definitive diagnosis of cardiac structure and function may
require invasive diagnostic techniques. In the intensive care
unit, hemodynamic monitoring provides valuable infonnation regarding cardiovascular function. Definitive structural
and functional infonnation about the heart is obtained, in
some instances only by cardiac catheterization.

Hemodynamic Monitoring
Invasive hemodynamic monitoring of infants and children
in the PICU is routinely perfonned. Although tbe ability to
measure, monitor, and calculate many physiologic parameters related to cardiovascular perfonnance is valuable in
the care of critically ill pediatric patients, numeric hemodynamic data alone is inadequate for clinical decision making.
The sections that follow focus on the measurement of
hemodynamic parameters and the calculation of derived
hemodynamic data. The correlation of hemodynamic data
with clinical assessment infonnation and the effects of
various modes of therapy are integrated. Accurate clinical
decision making is based on the integration of hemodynamic monitoring data and sound clinical evaluation.
Fundamentals of Hemodynamic Monitoring. Invasive hemodynamic monitoring systems use a transducer
to convert one energy fonn to another. The physical energy
of BP is converted to an electrical signal that is amplified
and displayed. Disposable transducer systems are routinely
used and preferred to reusable systems. Disposable transducers have an improved dynamic frequency response, have
less pressure drift with changes in temperature, are cost
effective, and may decrease the risk of infection.
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Fig. 7-40 Phlebostatic axis. Crossing of two imaginary lines
defines the assumed position of the monitoring catheter tip within
the body (i.e., right atrial level). A, Line that passes from the fourth
intercostal space at the lateral margin of the stemum down the side
of the body beneath the axilla. B, Line that runs horizontally at a
point midway between the outennost portion of the anterior and
posterior surfaces of the chest. (From Darovic GO: Hemodynamic monitoring: invasive and non-invasive clin.ical applications,

Philadelphia, 1987, WB Saunders, p 126.)
Fig. 7-39 Arterial blood pressure-monitoring system. (From
Gardner RM, Hujcs M: Fundamentals of physiologic monitoring,
AACN Clin Issues Cr;t Care Nul's 4: 19, 1993.)

Figure 7-39 illustrates one example of an arterial BP
monitoring system. A radial artery catheter is connected
through a short piece of pressure tubing to a stopcock. The
stopcock near the insertion site is connected to a second
stopcock at the transducer with a longer pressure tube. The
transducer is connected to an infusion pump that delivers a
continuous infusion at a controlled rate. The transducer is
also connected to the monitor that displays the pressure
waveform and the numeric measurement of the BP. Basic
transducer setups vary among institutions. With the implementation of needleless access systems, most pressure
setups use methods for avoiding needles.
Setting the Zero Point for the Monitoring System.
All systemic arterial catheter transducers must be leveled to
an anatomically consistent point and zeroed to eliminate the
effects of hydrostatic and atmospheric pressure. The proper
technique for setting the zero point for a pressure monitoring
system is illustrated in Figure 7-40. The transducer must be
carefully positioned at the phlebostatic reference point,
which is the fourth intercostal space-midaxillary line.
Inaccurate transducer position can result in large errors in
pressure measurement, especially when pressures are low,
as when central venous or pulmonary artery wedge pressures are monitored. For example, a transducer positioned
15 cm above the phlebostatic reference point will result in a
venous pressure reading II mmHg lower than is actually the
case; a transducer located 15 cm below the midaxillary
line will result in a venous pressure reading II mmHg above
the actual pressure. These inaccuracies are the consequence of the effects of hydrostatic pressure on the BP
reading. When more than one pressure is monitored, all
transducers are placed in one holder to ensure accuracy
when correlating data.
When the transducer is accurately positioned, either the
stopcock at the patient's end of the system or the stopcock

at the transducer is opened to air and the monitor zeroed.
Care must be taken to ensure that excessively long lengths
of tubing between the patient and the transducer are avoided
and that the tubing does not hang below the transducer.
Unusual pressure readings should always prompt reassessment of the system position and rezeroing of the
monitoring system, especially if treatment changes are
anticipated based on the pressure measured. Changes in the
transducer or amplifier related to time and temperature and
changes in the patient's position relative to the transducer
can produce zero changes.
System Calibration. Transducer manufacturers calibrate the system sensitivity to within ±l %. Thus only
zeroing is required when using standardized, disposable
transducers. Checking the calibration with a column of air or
mercury is unnecessary and may introduce risk of system
contamination or embolism.
Optimizing System Accuracy. Hemodynamic pressure waveforms are dynamic, not static. The accuracy and
reliability of the system's transmission of a pressure
waveform to the transducer are crucial. To ensure accuracy
of invasive pressure monitoring, the following procedures
are necessary. in addition to the zeroing procedure described
earlier. 5U.51
I. All air bubbles in the system are eliminated. Air
bubbles result in underestimation of the systolic
pressure and overestimation of the diastolic pressure.
Air bubbles often are located in stopcocks when all
the ports have not been filled with fluid and at
connection points between tubings and between
tubings and stopcocks.
2. Blood clots are prevented by the continuous infusion
of flush solution. Thrombus formation on the catheter
has the same effects described when air bubbles are
present in the system.
3. Only noncompliant pressure tubing, in the shortest
lengths possible (no longer than 3 to 4 feet), is used.
Venous tubing, which is excessively compliant, or
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Fig. 7-41 A, Schematic illustration of a fast flush test. The
natural frequency is determined by measuring the distance (D)
between two consecutive oscillating peaks. This interval (millimeters) is divided by the paper speed (usually 25 mm/sec).
Damping coefficient is determined by calculating the ratio
between the amplitude of two consecutive peaks (A,/A,). This
ratio is then plotted on the scale illustrated to obtain the damping
coefficient. B, Scale for determining damping coefficient. Amplitude ratio on the right is referenced across to the damping coefficient on the left. Optimal systems have a high natural frequency
(20 to 25 Hz) and a damping coefficient between 0.5 and 0.75).
(A from Daily EK, Schroeder JS: Techniqnes in bedside hemodynamic monitoring. St Louis, 1989, Mosby; B from Gardner RM:
Direct BP measurement: dynamic response requirements, Anesthe-
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long lengths of tubing result in the same errors
described earlier.
4. The number of tubing connections is minimized. All
loose-fitting connections are corrected.
Ensuring that pressure monitoring equipment is properly
set up and maintained provides accurate and valuable data to
critical care personnel. Attention to detail ensures the
acquisition of accurate physiologic data.
Dynamic Response Validation. The ability of the
hemodynamic monitoring system to accurately transmit a
pressure wavefonn is a function of both the system's
"natural frequency" (analogous to a car tire bouDcing on a
highway) and its "damping coefficient" (how quickly the
car stabilizes after each bounce).52 The fast flush test
stimulates the hemodynamic monitoring system with high
pressure so that the natural frequency and damping coefficient can be observed. Opening and quickly closing the fast
flush device to temporarily interrupt the physiologic pressure waveform performs the fast flush test. A "square wave"
pressure, followed by oscillations that revert to the pressure
waveform being monitored, is observed (Figure 7-41, A
and B). Daily and Schroeder 3 detail the fast flush test
procedure.
Performing the fast flush test necessitates brief but rapid
infusion of flush solution into the vascular catheter. Small
arteries in patients with inadequate tissue perfusion may

spasm in response to rapid flushing. In this circumstance, it
is impossible to perform the fast flush test. However, natural
frequency is maximized in every patient's monitoring
system by meticulous attention to the factors listed earlier
that enhance system accuracy.
Arterial Blood Pressure Monitoring, Continuous
invasive monitoring of systemic arterial BP is frequently
necessary in the pediatric intensive care setting to ensure
accurate evaluation of changes in patient status and the
effects of therapies prescribed. Direct BP measurement is
preferred in patients with circulatory dysfunction because
impaired peripheral circulation and vasoconstriction render
indirect measurement inaccurate or impossible to obtain. In
addition, arterial cannulation for direct BP measurement
provides reliable access for blood sampling when frequent
laboratory evaluation, such as of arterial blood gases, is
required.
Arterial Cannulation Sites. The choice of an arterial
pressure monitoring site is based on the identification of an
artery that is large enough to accurately reflect systemic BP
and has adequate collateral circulation. The Allen test is
performed when the radial artery is selected for cannulation
to determine the adequacy of collateral circulation to the
hand. To do this. both the radial and ulnar arteries are
compressed until the hand blanches. The ulnar artery only is
released, and the hand is assessed for return of color in 5 to
7 seconds. Color returning within 7 to 15 seconds is

172

Part III

Phenomena of Concern

suggestive of slowed filling. If perfusion is delayed for more
than 15 seconds, collateral circulation is considered inadequate, and another arterial site is selected for cannulation 54 .55 Similar technique for evaluating other arterial sites
is necessary. For example, the posterior tibial and dorsalis
pedis artery combination is assessed when either is considered for cannulation.
Other considerations in the selection of an arterial
pressure monitoring site include easy access for blood
sampling, care of the line, and assessment of the insertion
site; avoidance of areas likely to be contaminated or where
wounds exist; and selection of an artery large enough to
permit blood flow around the catheter56 Arterial catheters
are not placed in extremities with vascular prostheses such
as those used for hemodialysis.
Possible sites for arterial cannulation and continuous
monitoring include the radial, dorsalis pedis, posterior tibial,
femoral, axillary, and umbilical arteries. The brachial artery
is generally avoided because it is an artery without sufficient
collateral circulation. Brachial artery occlusion with a
catheter has been associated with the loss of the entire distal
forearm. Temporal arteries are also avoided for cannulation.
Flushing of this vessel can result in retrograde infusion of air
or clot into the internal carotid artery and has been
associated with brain infarction.
The umbilical arteries can be cannulated for the first
several days of life before they become obliterated. In the
young infant, they provide reliable and safe arterial access.
Verified by radiographs, optimal position of the distal
catheter is either high, above the diaphragm at T4 to TID, or
low, at L3 to L4. These positions avoid the renal and
mesenteric arteries. In either position, perfusion of the lower
extremities is carefully assessed.
The radial artery is the most common and preferred site
for arterial cannulation because it is easy to access and has
good collateral blood flow via the ulnar artery. The arteries
of the foot may be used, but access is often more difficult to
obtain in small children. In addition, maintaining the
catheter in either the dorsalis pedis or posterior tibial artery
in position for proper functioning may be more difficult.
Often the foot cannot be positioned comfortably.
The femoral artery is also an artery with minimal
collateral circulation. However, this vessel is large enough
to provide adequate blood flow around a small catheter and
is therefore used for cannulation and monitoring. Careful
assessment of the distal extremity pulses and perfusion
should be evaluated frequently to observe for signs of
thrombosis and ischemia. When low CO states exist, there
may be an increased risk for distal ischemia, necessitating
careful monitoring. Cannulation of the femoral artery should
be avoided in the presence of occlusive vascular disease
involving the leg. In addition, care should be provided to
keep the site dressing free of urine or fecal contamination to
prevent catheter infection.
The axillary artery is a large artery with good collateral
circulation; therefore thrombosis with distal ischemia is
rarely seen. Retrograde embolism, however, is a potential
complication because of the proximity of the axillary vessel
to the aortic arch and cerebral vessels. Careful attention

must be given to avoid rapid flushing and the presence of
air or clot.
Arterial Pressure Analysis. Invasive BP measurement provides a moment-to-moment picture and a visual
display of systolic, diastolic, and mean arterial pressure.
Systolic arterial pressure (SAP) is the pressure exerted
within the systemic arterial vasculature during ventricular contraction. Diastolic arterial pressure (DAP) reflects
the pressure of the systemic arterial vasculature during
ventricular relaxation. Pulse pressure (PP) is the arithmetic
difference between the systolic and diastolic measurements
and is a function of SV and arterial capacitance. For example, PP is typically decreased or narrowed when intravascular volume is inadequate. Mean arterial blood pressure
(MAP) is the average pressure throughout the cardiac cycle.
It is calculated by one of two formulas (all measures
are in millimeters of mercury):
MAP = SAP + 2(DAP) + 3 or MAP = DAP + PP + 3
MAP is not the mathematical mean of the systolic and
diastolic BPs because diastole normally persists for approximately two thirds of the cardiac cycle. Electronic monitoring equipment performs the calculation of MAP automatically and provides a visual display of SAP, DAP, and the
mean pressure. MAP is dependent on blood volume and
the elasticity of the arterial walls and is representati ve of the
perfusion pressure throughout the capillaries.
The pressure wave that results from contraction of the
ventricle begins in the aorta. Arterial systole begins with the
opening of the aortic valve and rapid ejection of blood into
the aorta. Runoff of blood from the proximal aorta to the
peripheral arteries follows. The arterial pressure waveform
shows these events as a sharp rise in pressure that is
followed by a decline in pressure. As the ventricles relax and
the aortic valve closes, a small rise in arterial pressure
occurs, resulting in the dicrotic notch on the downstroke of
the arterial pressure waveform. Figure 7-42 shows a normal
arterial waveform.
The arterial pressure differs both in contour and in
measured value in various arterial locations. Impedance
increases as the pressure wave travels toward the periphery,
causing an increase in amplitude. The height of the pressure
wave and the measured systolic pressure are greater distally
than centrally. In addition, the more distal the location of the
arterial catheter, the sharper the systolic upstroke and the
less defined the dicrotic notch. The normally higher systolic
pressure in the lower extremities that is normal in older
children results in higher systolic pressures in the femoral
artery than in the arteries of the upper extremities.
The systolic arterial pressure rises immediately after ventricular depolarization, that is, after the QRS complex on the
rhythm strip. Delay is related to the catheter location and the
length of tubing between the catheter and transducer. The
dicrotic notch occurs after the T wave of the rhythm strip.
A decrease in the slope of the arterial pressure upstroke
reflects a decrease in the velocity with which blood is
ejected from the left ventricle, which is consistent with a
decrease in ventricular contractility. Ventricular outflow
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Fig. 7-42 Nonnal arterial pressure tracing. ECG. Electrocardiogram. (From Smith JB: Pediatric critical care, Albany,
NY, 1985. Delmar, p II I.)

0'-----------------------obstruction, produced by aortic stenosis or pericardial
tamponade, also decreases the slope of the arterial pressure
upstroke. A rapid, exaggerated upstroke and little area under
the pulse contour correspond to decreased SV and increased
vascular resistance, even when systolic BP is "normal" for
age. Decreased CO and increased SVR also elevate the
diastolic BP and narrow the PP. In the normally compliant
lung, excessive positive pressure may restrict venous return
to the heart. Therefore patients who are intravascularly
volume depleted or who require excessive positive pressure
may demonstrate a decrease in arterial pressure with
mechanical inspiration or high levels of positive endexpiratory pressure (PEEP).
Dampened waveforms occur when obstacles prevent
the pressure wave from being transmitted freely along
the system. Dampened waveforms have a characteristic
smoothed out appearance and are identified by a gradual
upstroke, rounded-out peak systole, poor dicrotic notch, and
narrow PP. Troubleshooting includes assessment of the
entire system from cannula to solution for catheter obstruction, clot formation, air in the system, and arterial spasm.
Overzealous flushing is avoided because it has been
associated with complications such as cerebral emboli.
Overshoot, resulting from high flow within a narrow
artery or high resonance within the catheter system,
produces a more than 20 mmHg pressure gradient. In this
case, dP/dT (the rate of the pressure rise over the time
interval) is high. This may be caused by rapid HRs,
excessive length of pressure tubing from the patient to the
transducer, use of compliant tubing, and air that amplifies
the wave. Overshoot can be avoided by using only
noncompliant tubing of the shortest possible length.
Arterial spasms may occur with catheter manipulation,
especially if peripheral perfusion is poor. Spasms are usually
self-limiting. During cannula insertion, lidocaine without
epinephrine may be used to flood the area, for example, up
to I m! of 20% (20 mg/ml) lidocaine or I mg/kgwhichever is less-may be injected.
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Effect of altered cardiac rhythm on the arterial pressure
waveform. (From Darovic GO: Hemodynamic monitoring: invasive and non-invasive clinical applications. Philadelphia, 1987,
WB Saunders, pill.)
Fig. 7-43

Cardiac rhythm abnormalities alter the arterial pressure
waveform. For example, in atrial fibrillation the arterial
pressure varies considerably depending on the RR intervals
and the corresponding time in anyone cardiac cycle for
ventricular filling (Figure 7-43). When a PVC occurs,
ventricular contraction is initiated early. The result is
diminished SV, reflected in a lowered arterial systolic
pressure. Isolated occasional PVCs are usually well tolerated because of the increased SV and arterial pressure with
the subsequent ventricular contraction.
Complications. Neurologic and vascular function of
the extremity can be compromised in the extremity with an
arterial catheter in place. Necrosis of the overlying skin is
characterized by skin that blanches during catheter flushing
progressing to skin that remains blanched. Small offshoots
of the radial artery that lack collateral circulation perfuse the
distal forearm. The tip of the cannula or the thrombus that
forms around the cannula within 48 hours may occlude these
vessels. Repositioning or removal of the cannula may be
necessary.
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Ischemia and necrosis of digits have occurred. Assessments of pain, blanched or pale areas beyond the cannulation site, pulselessness distal to the catheter, numbness and
tingling, or motor impairment are essential to avoid or
minimize these complications.
Local and systemic infection is a potential complication
of any invasive monitoring system. However, peripheral
arterial catheters may be associated with a substantially
lower risk of local catheter-related infection than in other
venous locations for comparable lengths of time. Although
the reasons for this are not completely understood, the
higher vascular pressures and increased flows at arterial
cannulation sites may contribute to this decreased risk.
Factors that predispose patients with arterial catheters to
increased risk of infection include inflammation at the
catheter insertion site, catheterization for more than 4 days,
or catheter insertion by cutdown. 57 .58 Unlike central venous
catheters, peripheral arterial catheters in the femoral area are
not associated with a greater risk of infection. 59
Although the pathogenesis of catheter-related infections is mUltifactorial, evidence shows that they may result
from the migration of skin bacteria from the insertion
site along the catheter, resulting in catheter colonization
and potential systemic infection. Therefore skin cleansing
of the insertion site and dressing regimens play a critical
role in the prevention of infection. Cutaneous antiseptics
and antimicrobial ointments have been examined in numerous studies. The use of 2% aqueous chlorhexidine has been
shown to be superior to either 10% povidone-iodine
or 70% alcohol in preventing central venous and arterial
catheter-related infections. 60 Recently, sustained-release
chlorhexidine patches have been used on various invasive
monitoring sites; however, the efficacy has yet to be
determined. The application of antimicrobial ointments to
the catheter site is generally avoided because its use has not
been proven to decrease catheter infections. In addition,
polyantibiotic ointments may increase the risk of fungal
catheter colonization and fungal sepsis. Transparent, semipermeable, polyurethane dressings have become popular
because they secure vascular devices well, and they provide
direct visualization of the catheter insertion site. However,
their use in the prevention of infection in arterial lines is
unknown. When transparent dressings are used, the dressing
is generally changed every 72 hours. When gauze is used,
the dressing should be changed every 24 hours to evaluate
the condition of the insertion site.
Arterial catheter infection is also prevented by maintenance of a sterile, closed system and use of heparinized
normal saline solution for catheter flushing to prevent
thrombus formation. The flush solution is changed every 24
hours, and the tubing system, every 48 to 72 hours. 61 The
Centers for Disease Control also recommend that if the
vascular catheter is suspected as a source of infection, it
should be removed and, if necessary, placed at another site.
The patient is assessed for unexplained fever and other signs
of infection.
Thrombosis of an artery can develop while an invasi ve
arterial pressure monitoring catheter is in place, after the
catheter has been removed, or as a consequence of multiple

arterial punctures, either to establish invasive monitoring or
sample arterial blood. Multiple arterial punctures increase
the risk of thrombosis, as does catheterization beyond
4 days, intermittent (versus continuous) flushing of the
catheter, and catheter size larger than 20 gauge. Patients
who experience hematoma formation at the arterial catheterization site and those with inadequate tissue perfusion, particularly if the administration of vasoactive medications is required, are at increased risk to develop
thrombosis. After an artery has been cannulated for invasive
monitoring, recannulation of the vessel can extend from
days to several weeks. 56
Thrombosis of an artery or at the catheter tip interferes
with accurate BP measurement and blood sampling. Thrombosis can be minimized by avoiding the problems that are
recognized to increase the incidence of thrombosis when
possible and by the use of tapered-tipped, Teflon-coated
catheters. When thrombosis is suspected, gentle aspiration
of the catheter is indicated. Forceful flushing can result in
embolization of the thrombus. If the catheter cannot be
aspirated, it is discontinued.
Air embolism can develop from air in the flush system or
when the system is opened to sample blood. Care in
preparation and maintenance of the system can prevent
the problem. Rushing of all arterial catheters should be
done slowly to avoid retrograde infusion and arterial
spasm.
Catheter Removal. When the arterial catheter is removed, pressure is applied at the insertion site for as long as
necessary to achieve complete hemostasis; this is followed
by application of a pressure dressing. Some recommend that
a syringe be attached to the catheter and negative pressure
applied while removing the catheter to minimize the risks of
leaving thrombus on the catheter tip within the blood vessel. 56 Peripheral neurovascular function is assessed. The insertion site is assessed for signs of infection, ecchymosis,
and local ischemia and necrosis. The catheter tip may be
sent for culture if infection is suspected.
Central Venous Pressure Monitoring. Catheterization of the central venous circulation is frequently
undertaken in critically ill infants and children for hemodynamic monitoring, infusion of parenteral nutrition, infusion
of vasoactive medications, infusions of fluid and electrolytes, and intravenous access when peripheral veins are
inaccessible. Hemodynamic monitoring of central venous
pressure (CVP) reflects intravascular volume status and RV
function. Low CVP measurements indicate hypovolemia,
whereas high CVP measurements indicate either hypervolemia or elevated right ventricular end-diastolic pressure
(RVEDP). Elevations of RVEDP are suggestive of RV
dysfunction. In healthy individuals, CVP may also be used
to monitor LV preload and function because RVEDP and LV
end-diastolic pressure (LVEDP) correlate well. However, in
patients who display a difference in right and left ventricular
function, CVP cannot be used to evaluate LV preload or
function. Severe respiratory disease and the use of positi ve
pressure ventilation at high pressures, hypothermia, massive
blood transfusion, and CHDs alter the relationship between
CVP and LVEDP. Pathophysiologic factors that increase
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PVR, such as hypoxemia and acidosis, also alter the
relationship. Use of pulmonary artery catheters or direct LA
catheters (e.g., in the postoperative cardiac surgery patient)
for evaluation of LVEDP and left heart function is necessary
in these situations.
Central Venous Cannulation. Central venous access in pediatric patients is obtained either by cutdown
or percutaneous technique after the administration of
sedation. The most commonly used sites are the internal
jugular, femoral, subclavian, and antecubital veins. Ideally,
the catheter is advanced to the caval-atrial junction. In this
position, there is little motion of the catheter with respect to
the heart, improving the accuracy of hemodynamic monitoring; less chance of inducing arrhythmias than when the
catheter is advanced within the right atrium; less chance of
cardiac perforation; and less thrombus formation because
blood flow is rapid and the vessel caliber is large 62 Central
venous catheters can be placed in the umbilical vein of the
newborn infant.
In patients younger than I year and weighing less than 6
kg, the internal and external jugular veins are often
considered for venous access because they enter the superior
vena cava with a straight course. The subclavian veins enter the central venous circulation at acute angles, which become less acute as the child growS. 63 The infraclavicular
approach to the subclavian vein is sometimes preferred
for long-term central venous catheterization in children,
although risks of pneumothorax, hydrothorax, and hemothorax exist.
The femoral vein provides a large vessel that is easily
identified and cannulated in both infants and children.
The basilic vein in the antecubital space is also easily
palpable, but the success rate in reaching the central venous
circulation is limited in small children. This site provides
successful central venous placement more often in children
weighing more than 20 kg. 63
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Monitoring of intravascular volume status and RV function can also be accomplished via a transthoracic right atrial
(RA) catheter inserted, most commonly, at cardiac surgery.
The RA line is used exclusively for hemodynamic monitoring rather than for infusion of fluids or medications, unless
other venous access is unobtainable or in the case of an
emergency.
Venous Pressure Waveform Analysis. The normal
central venous waveform is diagrammed in Figure 7-44.
The pressure changes within the right atrium are small,
consisting of three positive deflections-the a, c, and v
waves--each followed by a descent in pressure. The a
wave is the pressure rise produced by atrial contraction.
The c wave may appear as a distinct positive deflection,
as a notch on the a wave, or may be absent altogether. The
c wave reflects the slight increase in intraatrial pressure
that occurs with closure of the AV valve leaflets. It may be
absent in pediatric patients because the atria are very distensible in youngsters. The v wave is produced by increased
atrial pressure resulting from contraction of the ventricles,
which causes the AV valve leaflets to bulge into the
atria with concomitant atrial filling.
The descents that follow the a and c waves (the x and x'
descents) are produced by the decrease in pressure during
atrial relaxation and the downward pulling of the floor
of the atrium at the onset of ventricular systole. The descent
following the v wave (the y descent) is produced
by the opening of the AV valve leaflets and emptying
of the atria into the relaxed ventricles.
The pressure rises during atrial systole (the a wave)
and atrial diastole (the v wave) are nearly the same. As
a consequence, atrial pressure is monitored as the average
or mean of both pressure rises. However, RA pressure waveforms are characterized by a dominant or larger a wave,
compared with the v wave, whereas the reverse is true of
the LA waveform. The v wave is dominant on the LA pres-

10

o
Fig. 7-44 Nonnal central venous pressure wavefonn. Central venous pressure wavefonn with
simultaneous electrocardiogram. (From Clochesy JM, Breu C, Cardin S et aI, eds: Critical care nursing,
Philadelphia, 1993, WB Saundets, p 159.)
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Fig. 7·45 Elevated right atrial pressure with exaggerated a wave
(1) in a patient with right ventricle failure and increased resistance
to ventricular filling (2, x descent; 3, v wave). (From Daily EK,
Schroeder JS: Techniques in bedside hemodynamic monitoring,
St Louis, 1989, Mosby, p 102.)

Fig. 7-46 Elevated right atrial pressure with exaggerated v wave
(2) and rapid y descent (3) in a patient with tricuspid regurgitation
as a result of acute right ventricle (RV) failure. The a wave (1) of
approximately 26 mmHg reflects an elevated RYEDP and RV
failure. (From Daily EK, Schroeder JS: Techniques in bedside
hemodynamic monitoring, SI Louis, 1989, Mosby, p 103.)

sure tracing, and higher mean pressure is found in the
left atrium (4 to 12 mmHg) compared with that of the right
(3 to 7 mmHg).
Correlation of the atrial pressure tracing with the ECG
is helpful in differentiating the positive pressure deflections.
The a wave immediately follows the P wave on the ECG,
generally occurring in the PR interval. The c wave corresponds to the RS-T junction of the ECG. The v wave occurs
during the TP interval.
Atrial fibrillation results in the absence of uniform atrial
contraction, and consequently, no a wave is visible on the
atrial pressure tracing. Only the v wave produces a
distinct positive deflection.lfthe atria contract while theAV
valves are closed (AV dissociation), a large or cannon a
wave results.
Increased atrial pressure and elevation of the a
wave are also seen with ventricular dysfunction and hypertrophy. Other causes of increased resistance to ventricular
filling, such as AV valve stenosis or pulmonary hypertension, also exaggerate and elevate the a wave (Figure 7-45).
Severe AV valve regurgitation, which may occur with severe
ventricular failure or structural valve incompetence, produces marked elevation of the atrial v wave (Figure 7-46).
In addition, atrial septal defects, which increase flow into the
right atrium during ventricular systole, increase the size of
the v wave. Both the a and v waves are elevated in cardiac
tamponade.
Changes in intrathoracic pressure with ventilation
are readily transmitted through the relatively thin-walled
atria and great veins and are reflected in the CVP and atrial

pressure. During spontaneous and negative pressure ventilation, inspiration lowers the CYP (Figure 7-47). Positive
pressure ventilation increases the CVP during inspiration,
as does coughing and Yalsalva maneuver. The application
of PEEP to a patient's airway can also be transmitted
to the central vasculature and increase right atrial pressure
(RAP) and CYP. These circumstances can make the
interpretation of high venous pressure difficult in isolation.
Other clinical findings regarding the adequacy of venous
return, intravascular volume, and cardiac function are key to
accurate interpretation of numeric data.
Complications. During insertion of a central venous
catheter, there is potential for local tissue injury of adjacent
tissues and blood vessels. Inadvertent arterial puncture
is the most common injury, which is usually not significant
if the needle is immediately withdrawn and local pressure
applied. Localized hematoma formation may develop
from inadvertent arterial puncture or some venous punctures. This problem is minimized by use of a small-gauge
needle to locate the central vein, by attention to proper
technique, and by experience with central venous catheterization procedure.
Pneumothorax or hemothorax may be associated with
needle puncture of the pleura during central venous catheter
insertion. The subclavian approach is associated with
risks of injury to mediastinal structures as well, resulting
in pneumomediastinum, hemomediastinum, pneumopericardium, and pericardial tamponade.
Air embolism is a potentially fatal complication of central venous catheterization, which can occur during insertion
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Fig.7-47 Effect of spontaneous breathing on the central venous pressure waveform. (From Clochesy JM,
Breu C, Cardin S et ai, eds: Critical care nursing, Philadelphia, 1993, WB Saunders, p 159.)

of the catheter if the needle is not capped with a syringe.
It can also occur when IV tubings are changed or if they

are inadvertently disconnected. Proper attention to detail
at insertion and meticulous care of central venous catheters
and associated IV or hemodynamic monitoring tubings
prevent air embolism.
Complications that may occur after insertion of a central
venous catheter include infection and thrombosis. Perforation of vascular or cardiac structures is a potential risk but is
extremely rare.
All central venous lines are potential sources for local infection and sepsis. Contamination can occur at
the time of insertion if sterile technique is breached.
Contamination can also occur from downward migration
of normal skin flora after catheter placement. In addition,
catheter colonization can result from contaminated tubing,
pressure transducers, or IV flush solutions. Once the central
venous catheter is colonized, it may become a source for
disseminated infection, particularly in critically ill and immunocompromised patients. The risk of catheter-related
bloodstream infections is approximately 4% when central
venous catheters are used, compared with a 1% risk for
peripheral IV catheters. 64 Organisms most commonly associated with central line infections include Staphylococcus
aureus, Staphylococcus epidermidis, gram-negative bacilli,
and enterococcus.
Risk factors for infection include multilumen catheters,
internal jugular vein insertion, repeated catheterization,
presence of an infectious focus elsewhere in the body,
exposure of the catheter to bacteremia, absence of systemic
antimicrobial therapy, duration of catheterization, type
of dress ing, and the ex perience of the personnel inserting
the device. Most bloodstream infections related to IV
catheters originate from either the patient's bacterial flora or
from organisms on the hands of caregivers. Scrupulous
attention to aseptic technique at the time of catheter
insertion and during dressing changes is necessary to
prevent the invasion of organisms. Careful maintenance of
sterile IV solutions, tubings, and transducers is necessary.
Sterile technique is mandatory when dressing changes are
made. The dressing should be changed every 48 to 72 hours
and when dressings are soiled, wet, or not intact. Current
recommendations include cleansing with 2% aqueous chior-

hexidine and covering the site with a transparent, semipermeable dressing. When gauze is used to cover the insertion
site, the dressing should be changed every 24 hours to
evaluate the site. To avoid infection, the catheter should
be manipulated as little as possible and should be removed
as soon as it is no longer needed.
Catheter-associated bacteremia can be identified while
the infection is localized. Generally, a positive result on
culture of blood drawn through the catheter with more than
15 colonies denotes infection, even if a peripheral blood
culture result is negative. The patient then is at clear risk for
catheter-related septicemia. Most often the catheter is
withdrawn and replaced, if necessary.
Venous thrombosis and thrombophlebitis are associated
with the presence of a central venous catheter. Most patients
with thrombosis demonstrate edema of the arm, neck, and
face, which is localized to the involved side. When central
venous thrombosis is present, microembolization and pulmonary embolism can occur. If the patient's clinical
situation indicates pulmonary embolism, thrombosis of the
central veins is suspected. A venogram may be necessary to
confirm thrombosis, although treatment may be initiated
without radiographic confirmation. Treatment requires removal of the catheter and consideration of IV heparin or
thrombolytic therapy.
Superior vena cava syndrome is a potential complication
from central venous catheters placed in the superior vena
cava. When thrombus formation occurs around the catheter,
or the catheter itself obstructs the superior vena cava,
inadequate venous return from the head can occur, resulting
in head and neck swelling and discoloration. If this happens,
the catheter should be removed, and the vessel should be
evaluated for thrombus formation.
Catheter occlusion can result from blood clot or precipitant formation within the catheter. When blood clot
formation is suspected, a fibrinolytic drug can be infused
into the catheter in attempt to restore patency. With the
current unavailability of urokinase, tissue plasminogen
activator (t-PA) is being used for declotting central venous
lines. t-PA is a naturally occurring protein secreted by
vascular endothelial cells that converts inactive plasminogen to active plasmin. Synthetic t-PA binds plasminogen at
the site of a clot and converts plasminogen to plasmin,
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producing local fibrinolysis. For catheter declotting, a small
amount of t-PA is slowly injected into the catheter port,
avoiding excessive pressure. Approximately 2 ml of a
I mg/ml concentration of t-PA may be used for this
procedure. Once instilled, t-PA is allowed to dwell in the
catheter for 2 hours, at which time the port is gently
aspirated to evaluate the effectiveness of the therapy. A
second instillation may be necessary to fully dissolve
the clot.
Catheter Removal. The central venous catheter is
removed when the hemodynamic data obtained from it is no
longer necessary for clinical decision making and the
patient's condition permits administration of necessary IV
fluids via a peripheral catheter. Aseptic technique and
universal precautions must be ensured when the catheter is
removed. Having patients perform a Valsalva maneuver
prevents air entry into the central vein, if they are able to
cooperate and the maneuver is not contraindicated (e.g., by
increased intracranial pressure). In all patients, the catheter
is most safely removed at the end of inspiration, when
intrathoracic pressure is highest. The catheter is clamped
and withdrawn with a steady motion. After removal, manual
pressure is applied to the insertion site until hemostasis is
ensured. The insertion site is assessed for signs of inflammation or infection, and the catheter is inspected to check
that it has been removed in its entirety. The tip of the
catheter may be sent for culture if line sepsis is suspected.
Peripherally Inserted Central Venous Catheters.
Peripherally inserted central venous catheters (PICCs)
provide an alternative to other central venous catheters.
These catheters are typically inserted into the superior vena
cava by way of the cephalic and basilar veins of the
antecubital space. PICCs are associated with fewer mechanical complications, cost less than other central venous
catheters, are easier to maintain than short peripheral
catheters, and are associated with a lower rate of infection
than other central venous catheters. 58 ,65 Indications for the
use of PICCs in the PICU include the need for long-term
access, typically for antibiotic therapy, and the administration of parenteral nutrition. Blood products may be administered through larger PICCs.
Catheter site care is similar to that of other central venous
catheters. Dressing changes are performed every 72 hours to
once a week. When a gauze is used to cover the insertion
site, the dressing should be changed every day to evaluate
the site for signs of infection. Heparin flush protocols are
similar to those followed for other central venous catheters.
Pulmonary Artery Pressure Monitoring. Pulmonary artery (PA) catheters were first introduced in 1970 and
were used enthusiastically in critically ill adults during the
1970s and early 1980s. Recognition of serious potential
complications has resulted in more conservative use; that is,
a PA catheter is indicated only when the data obtained will
improve clinical decision making.
The PA catheter is valuable in the diagnosis and treatment
of critically ill patients with cardiopulmonary failure. It
measures RAP; pulmonary artery systolic, diastolic, and
mean pressures; and the pulmonary artery wedge pressure.
The PA catheter can be used for rapid determination of CO

using the thermodilution technique. Other parameters, such
as cardiac index, SVR, PVR, and ventricular contractility
indicators, can be derived from these data. The catheter can
be used to sample mixed venous blood for intermittent
analysis or, if equipped with a fiberoptic lumen, to continuously monitor mixed venous oxygen saturation.
PA Catheter Description. The multiple lumens of
the PA catheter provide the means to assess a variety of
physiologic characteristics of the cardiovascular system
(Figure 7-48). The standard quadruple lumen PA catheter is
available in three sizes: 5, 7, and 7.5 French (Fr). The 5 Fr
size is suitable for children weighing less than 18 kg; the 7
and 7.5 Fr catheters are used for larger children and adults.
The distal tip of the PA catheter is open and associated with
a lumen that runs the entire length of the catheter. The
inflatable balloon is positioned just proximal to the tip of the
catheter, When the balloon is inflated through its lumen, it
encompasses the tip of the catheter, reducing irritation of the
endocardium during insertion. In general, the thermistor is 4
cm from the tip of the catheter; however, thermistor position
can vary in custom-made thermodilution catheters. Insulated wires run through a third lumen to the thermistor hub,
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and these connect to the CO computer. The proximal lumen
of the PA catheter is located IS to 30 cm from the catheter
tip. The catheter size and specifications determine the
position of the proximal lumen. (Specifications of customdesigned catheters can vary; the reader is referred to the
package insert provided by the manufacturer.) Ideally the
proximal port will be located in the RA when the distal port
is in the PA.
Pulmonary Artery Cannulation. Before inserting
the PA catheter, the patient's serum electrolyte (especially
potassium, calcium, and magnesium), acid-base, and coagulation study results are evaluated. Hypoxemia, acidosis,
hypokalemia, hypocalcemia, and hypomagnesemia place
the patient at increased risk for the development of serious
arrhythmias. Abnormal coagulation can result in hemorrhage or extensive hematoma formation. 66 In anticipation
of possible ventricular arrhythmias, a lidocaine bolus
(I mg/kg) is prepared, and the defibrillator should be readily
available.
Catheterization of the pulmonary artery is most often
accomplished from the internal jugular vein, although the
subclavian, femoral, or external jugular veins may be
selected. The internal jugular is preferred because of a lower
incidence of pneumothorax associated with this approach
and because the catheter is easily secured in the neck area.
Before catheter insertion, each catheter lumen is flushed
with heparinized solution, inflating and inspecting the
balloon assess balloon integrity, and connecting the thermistor hub to the CO machine and watching for a temperature
assess thermistor integrity. Two pressure transducers are
prepared, leveled with the patient's phlebostatic axis,
connected to the monitor, and zeroed. The distal lumen of
the catheter is connected to the transducer to permit
waveform assessment during catheter insertion.
lnsertion of the catheter is usually performed through an
introducer (dilator) sheath that remains in place with the
catheter. A sterile sleeve is placed over the catheter and
attached to the introducer, permitting positioning and
manipulation of the catheter without contamination.
The catheter is advanced from the internal jugular vein to
the right atrium. When location within the right atrium is
identified from the pressure waveform, the balloon is
inflated to its full volume (about 0.5 to 1.5 ml; refer to
manufacturer specifications). With continuous waveform
monitoring (Figure 7-49), the catheter is carefully advanced
through the right ventricle and into the pulmonary artery.
Ultimately the PA catheter wedges, or is in the occlusion
pressure position, in a pulmonary artery branch. The balloon
is then deflated and the PA systolic and diastolic pressures
are continuously monitored. The pressures and waveforms
assessed during catheter insertion are documented as baseline data. Documentation of the length of catheter inserted
and the external markings at the exit site are helpful in
assessing and ensuring maintenance of the desired catheter
position.
Waveform Analysis. Measurement of the RA mean
pressure and analysis of the RA waveform during PA
catheterization is the same as previously described. As the
catheter passes through the tricuspid valve, the peak systolic
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RV pressure and the RVEDP are measured. The characteristic RV pressure waveform reflects the dynamic pumping
action of that chamber. Figure 7-50 depicts the normal RV
pressure waveform and illustrates the specific events that
occur during ventricular systole and diastole. The normal
peak RV systolic pressure range is 20 to 30 mmHg. RVEDP
is measured after atrial systole (the a wave on the pressure
waveform) and nornlally ranges from 2 to 8 mmHg. The
systolic portion of the RV pressure waveform corresponds to
ventricular depolarization and occurs during the QT interval
of the ECG. The diastolic portion of the waveform occurs in
the TQ period of the ECG.
Although RV pressure is not routinely monitored at the
bedside, the initial pressures and waveforms should be
documented as a reference. The RA pressure should be equal
to the RVEDP (in the absence of tricuspid valve disease).
The PA systolic and RV systolic pressures are also normally
equal (in the absence of pulmonary valve disease). As a
result, the RV pressure is monitored indirectly via these two
pressures. If the RV pressure waveform were noted on the
monitor subsequent to final catheter placement, it would
indicate catheter migration. If detected, withdrawal of the
catheter into the right atrium is indicated. From the right
atrium, the balloon can be reinflated and the catheter can be
refloated back to the pulmonary artery.
RV systolic pressure may be increased by a number of
clinical problems. Any condition that increases PVR results
in increased RV pressure, including pulmonary artery
hypertension (PAH), hypoxemia, adult respiratory distress
syndrome, pulmonary embolism, obstructive pulmonary
disease, or pulmonary venous hypertension. RV systolic
pressure may also be elevated by pulmonic stenosis (because of increased resistance to ventricular ejection) or ventricular septal defect (caused by Ieft-to-right shunting of
blood under high pressure). Increased RV diastolic pressure
is the consequence of the same factors that increase the atrial
pressure. Most often, increased RVEDP is the consequence
of the ventricular dysfunction characteristic of heart failure.
PA Pressure. The pressure waveform in the pulmonary artery is divided into three phases: systolic, diastolic,
and mean. Systolic pressure is representative of the rapid
ejection of blood into the pulmonary artery after RV
contraction and opening of the pulmonic valve. This is
depicted as a sharp rise in pressure on the waveform,
followed by a decline in pressure as the volume of blood
ejected declines (Figure 7-51). Normal PA systolic pressure
is the same as RV systolic pressure.
When RV pressure falls below the pressure in the
pulmonary artery, the pulmonic valve closes, creating the
dicrotic notch on the downslope of the waveform. Diastole
follows closure of the pulmonic valve, as runoff of blood
into the pulmonary vascular system occurs without any
further blood flow from the RY. The PA diastolic pressure is
measured immediately before the next systole and corresponds closely to the LVEDP, in the absence of pulmonary
vascular and mitral valve disease. The normal PA diastolic
pressure is 4 to 12 mmHg. Pulmonary artery mean pressure
(PAM) is calculated, as is mean systemic arterial pressure.
Normally the PAM pressure is 7 to 18 mmHg.
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Fig. 7-49 Wavefonns observed during insertion of a pulmonary artery catheter. A, Right atrial pressure.
B, Right ventricular pressure. C, Pulmonary artery pressure. D, Pulmonary artery wedge pressure. (From
Clochesy JM, Breu C, Cardin S et ai, eds: Critical care nursing, Philadelphia, 1993, WB Saunders, p 165.)

Fig. 7-50 Normal right ventricular pressure wavefonn (I, isovolumetric contraction; 2, rapid ejection; 3, reduced ejection; 4, isovolumetric relaxation; 5, early diastole; 6, atrial systole; 7, end
diastole). (From Daily EK, Schroeder JS: Techniques in bedside
hemodynamic monitoring, St Louis, 1989, Mosby, p 108.)
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Fig. 7-51 Pulmonary artery (PA) pressure waveform showing
phases of systole, dicrotic notch (pulmonic valve closure), and end
diastole. Normally, PA end diastole closely represents LVEDP.
(From Daily EK, Schroeder JS; Techniques in bedside hemodynamic monitoring, St Louis, 1989, Mosby, pliO.)

Fig. 7-52 Normal pulmonary artery wedge pressure waveform
showing a and v waves and x and y descents. (From Daily EK,
Schroeder JS; Techniques in hedside hemodynamic monitoring.
St Louis, 1989, Mosby, p 116.)

The systolic pressure in the PA corresponds with
ventricular depolarization. However, the length of the PA
catheter and monitoring tubing delay the signal somewhat.
PA systole occurs in the QT interval of the ECG.
High systolic PA pressures are the consequence of either
increased PBF, as with a left-to-right intracardiac shunt, or
increased PVR. Increased PVR is often observed in
pulmonary disease, pulmonary artery hypertension, pulmonary embolism, and severe heart failure. The pulmonary
artery diastolic (PAD) pressure may not accurately reflect
the LVEDP in patients with pulmonary disease or pulmonary embolism. Tachycardias, which shorten the diastolic
period of the cardiac cycle, falsely elevate the PAD pressure.
PA Wedge Pressure. When a PA catheter is properly
positioned, inflation of the balloon results in movement of
the catheter to a small branch of the pulmonary artery. The
balloon then occludes the vessel and obstructs forward
blood flow. The pressure measurement that is obtained is
referred to as the PA wedge (PAW) pressure or PA occlusion
pressure (PAOP). This pressure, transmitted across the
pulmonary veins to the catheter tip, is approximately the
same as LA pressure, and indicates LV filling pressure.
The PAW pressure waveform is similar to the RA or LA
waveform (a and v waves; most often the c wave cannot be
seen) because the pressure is produced by the same physiologic events (Figure 7-52). Normal, resting PAW pressure is
the same as LA pressure (i.e., 4 to 12 mmHg) and is measured as a mean pressure because the a and v waves normally are of the same amplitude.
As with atrial pressure monitoring, the a wave follows
the PR interval on the ECG and the v wave follows the
QRST interval. However, in PAW pressure monitoring, a
longer delay occurs between electrical and mechanical

events because of the time lag between cardiac contraction
and retrograde measurement in the pulmonary artery. In
addition, the length of the catheter and tubing contribute to
this lag time. The effects of rhythm disturbances on the PAW
pressure measurement are the same as described with atrial
pressure monitoring.
Abnormal PAW pressure occurs with a number of clinical
problems. The a wave may be elevated (cannon a waves)
with LV failure or mitral stenosis because these conditions
increase the resistance to LV filling. In addition, any
arrhythmia that interferes with AV synchrony (JET) will
result in cannon a waves because the atria is contracting
against a closed AV valve. The v wave is elevated with
mitral regurgitation, which may be the consequence of
either structural abnormality or severe LV failure (Figure
7-53). Elevated PAW pressure may also be the result of
intravascular volume overload, cardiac tamponade, or pericardial effusion. Decreased PAW pressure is seen in patients
with hypovolemia.
The PA diastolic pressure and the PAW pressure are
usually within I to 5 mmHg of each other when PVR is low,
pulmonary function is normal, and the mitral valve is
competent. An increase in the PA diastolic pressure to the
point that the gradient between it and the PAW pressure
is greater than 5 mmHg can result from tachycardia,
pulmonary artery hypertension, cor pulmonale, or pulmonary embolus. PAW pressure exceeds the PAD pressure only
in patients with mitral regurgitation.
Technical Problems in PA Monitoring. Mechanical
problems may interfere with accurate PA pressure monitoring. Dampening of the pressure waveform is the most
common problem. The overdampened waveform loses sharp
definition and appears rounded, the dicrotic notch is absent
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or poorly defined, the systolic pressure is measured falsely
low, and the diastolic pressure is overestimated. Overdampening may be the result of technical problems that can be
easily corrected. These include the use of an excessive
number of stopcocks (no more than three are recommended50) and the presence of air bubbles, blood, loose
connections, or kinked tubing. Excessively long or compliant pressure tubing may overdamp the system as well.
Overdampened pressure waveforms are also the consequence of problems with the catheter itself. Kinking of the
catheter can occur at the insertion site or internally, the
catheter can be wedged against the vessel wall, or fibrin can
be deposited on the tip of the catheter. Problems with
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Fig. 7-53 Elevated pulmonary artery wedge pressure with a
dominant and elevated v wave (2) as a result of mitral regurgitation. The a wave (1) is also elevated, indicating left ventricle (LV)
failure. In this case. the mitral regurgitation is most likely
functional secondary to LV failure and dilation. (From Daily EK,
Schroeder JS: Techniques in bedside hemodynamic //lonitoring,
St Louis, 1989. Mosby. P 119.)
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catheter kinking or position may be resolved by repositioning the catheter. However, if fibrin or clot deposition is
suspected, urokinase or t-PA can be used to clear the catheter
or it will have to be replaced.
Exaggerated oscillations of the pressure waveform, referred to as catheter "fling" or "whip," can occur when
blood flow is turbulent (Figure 7-54). This may occur if the
catheter is located near the pulmonic valve or coiled in the
RY or in patients with PAH or dilated pulmonary arteries S3
Catheter repositioning will correct the problem if its location was the source of the difficulty. In the latter situations,
accurate PA pressure monitoring is difficult at best and may
be impossible. When catheter fling does not resolve, only
the PAM pressure is measured (the PAD continues to be
monitored for catheter migration into the RY).
Catheter migration can result in several technical problems during PA pressure monitoring. The catheter may
spontaneously or accidentally migrate into the RY. The usual
signs of this are the detection of the lower diastolic pressure
(characteristic of the RY), presence of RY waveform on
the monitor, and ventricular arrhythmias (usually PYes).
The catheter can most often be repositioned by withdrawing the catheter into the RA and reinflating the balloon,
floating it out into the PA. BaUoon inflation while the
catheter is in the RY may damage RY trabecula.
Catheter migration into small pulmonary vessels can
result in spontaneous wedging of the catheter. In spontaneous wedging, there is potential for loss of blood supply to a
PA branch vessel with subsequent infarction. Overwedging
of the PA catheter, caused by overinflation or uneven
inflation of the balloon of the catheter, may result in PA
rupture. Overwedging is avoided by careful assessment of
the PA waveform as the balloon is inflated. The balloon is
inflated only until the morphology of the atrial waveform is
clearly appreciated (i.e., the appearance of a and v waves).
Overinflation results in loss of the waveform characteristics
and a linear increase or decrease in the pressure (Figure
7-55). If the catheter wedges at an unexpectedly low
inflation volume or jf spontaneous wedging occurs, prompt
repositioning of the catheter is necessary.
Accurate pressure measurement is dependent on maintenance of the monitoring system. It is crucial that the
phlebostatic axis be accurately determined and that the
transducer be accurately leveled at this reference point.
Changes in hemodynamic data may be the result from a
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Fig. 7-54 Pulmonary artery pressure waveform with catheter "whip" or "fling." (From Clochesy JM.
Breu C. Cardin S et ai, eds: Critical care nursing, Philadelphia, 1993, WE Saunders, p 171.)
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change in the patient's condition; however, before treatment
measures are undertaken, it is important to assess the system
for potential sources of error. A rapid assessment of the
transducer position, and rezeroing of the system, as well as
reassessment of the pressure waveform morphology, ensures
that the data is accurate.
Clinical Factors in PA Monitoring. A number of
physiologic and clinical factors affect PA pressure measurement. The first is PBF. Three physiologic zones of blood
flow have been identified in the lungs. 67 These zones are not
. anatomic divisions but correspond to the interaction among
pulmonary alveolar, arterial, and venous pressures and
gravitational forces in each zone that affect resulting blood
flow (Figure 7-56). Accurate PA pressure determination
necessitates that the catheter be positioned where PBF is
continuous (zone 3) and not affected by alveolar pressure.
Only in this position does the PA reflect LA pressure. In
zones I or 2, where alveolar pressure affects pulmonary
flow, the PA pressure reflects alveolar pressure and not the
downstream LA pressure.
Location of the catheter in zone 3 is confirmed by
waveform analysis and chest radiograph. Lateral chest
radiography, most accurately reveals that the tip of the
PA catheter is below the level of the left atrium. Catheter
location in zone 3 is also verified by the appearance of the
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characteristic atrial waveform when the PA catheter is
wedged. If the catheter is located in zone I or 2, wedging
produces marked respiratory variation and loss of the
characteristic atrial pressure waveform. 16
Pulmonary artery pressure (PAP) varies with both
spontaneous and mechanical ventilation. During spontaneous breathing, the pressure in the pulmonary artery follows
intrathoracic pressure (i.e., both the PA and PAW pressures
fall during inspiration and rise with exhalation). All hemodynamic pressures are read at one point in the respiratory
cycle, traditionally at end exhalation.
PEEP may be transmitted from the airways to the
pulmonary blood vessels and alters all intrathoracic pressure
readings. Note that this phenomenon is dependent on lung
compliance; if the lungs are stiff and noncompliant, there
may be little or no transmission of PEEP to the intrathorax.
Discontinuing PEEP is not recommended to obtain pressure
readings. First, if pressure readings are obtained without
PEEP, the patient's clinical situation is not accurately
depicted. Second, discontinuing PEEP can result in alveolar
collapse, rapid movement of interstitial fluid into the alveoli,
and deterioration in the patient's condition. 68 An estimation
of the effects of PEEP can be calculated: every 5 cm of
PEEP results in a 1.5-mmHg increase in PAW pressure
(Figure 7-57). In general it is better to disregard the

Balloon
deflation

~

t
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Fig. 7-55 Overwedging of the pulmonary artery catheter during halloon inflation. (From Clochesy JM,
Breu C, Cardin S et aI, eds: Crirical care nursing, Philadelphia, 1993, WB Saunders, p 172.)

Lung zones. Pulmonary artery wedge pressure estimates left atrial pressure (LAP) only when the catheter is in lung
zone 3 (capillaries below left atrium level), allowing for a continuous column of blood to exist from catheter tip to left atrium.
Pa, Pulmonary arterial pressure; PA, pulmonary alveolar pressure;
Pv, pulmonary venous pressure. (Reprinted with permission from
O'Quin R, Marini JJ: Pulmonary artery occlusion pressure: clinical
physiology, measurement and interpretation, Am Rev Respir Dis
128:319-326, 1983.)
Fig. 7-56
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ObtaIned PAWP 22.OmmHg
- 7.5mmHg
14.5mmHg eon.cted

Fig.7-57 Effects of positive end-expiratory pressure (PEEP) on measured pulmonary artery wedge pressure (PAWP). (From Gardner RM: Pressure monitoring, MCN Clin Issues Crit Care Nurs 4:113, 1993.)

mathematical effects of PEEP on PA pressures and follow
the data for trends. If a correction is made for the effect of
PEEP on the PA pressure. it is important that all caregivers
be consistent in the practice so that hemodynamic data is not
misinterpreted.
Complications. Because central venous access is
achieved for insertion of a PA catheter. the potential
complicalions of adjacent tissue damage are present during
PA catheterization. In addition, during flotation of the PA
catheter. arrhythmias. heart valve damage. and intracardiac
knolting of the catheter can occur. Intracardiac knolting
requires manipulation of the catheter under fluoroscopy.
withdrawal of the catheter. or, occasionally. surgical intervention. Tricuspid and pulmonary valve damage has been
associated with prolonged PA catheterizalion.
Cardiac rhythm disturbances that occur during insertion
of the PA catheter are usually self-limited. PVCs most oflen
cease when the catheter has exited the right ventricle. If
PVCs are sustained or if they progress to VT, the catheler is
withdrawn into the right atrium until the ectopy subsides.
Ectopy can reoccur following insertion and is usually
associated with either looping of the catheter in the heart or
migration into the ventricle. Rarely, a continuous infusion of
lidocaine is necessary to prevent ectopy and increase patient
tolerance of the PA calheter. Repositioning or removal of the
catheter may be necessary if the rhythm disturbance is
resislant to lidocaine.
Improper position of the PA catheter places the patient at
risk for pulmonary infarction and PA rupture. Pulmonary
infarction is most often lhe result of persistent wedging of
the calheter in a peripheral pulmonary arteriole or obstruction of a more central artery by an inflated balloon.
Prolonged balloon inflation is avoided and the catheler is
repositioned if spontaneous wedging occurs.
PA ruplUre leads to massive hemorrhage and death. Risk
factors for serious PA injury include PAH and hypothermia. 69 Imminem rupture may be preceded by only a small
amount of pulmonary bleeding evidenced by hemoptysis or
bloody endotracheal tube secretions. Falal hemorrhage may
occur without PA rupture in patients receiving anticoagulants. Usually PA bleeding and rupture are associated with
distal migration of the calheter and subsequent balloon

inflation. Children with PAH require extreme caution during
balloon inflation and measurements of PAW pressure. The
balloon should be inflated for only lWO to three respiratory
cycles and for no longer lhan 10 to 15 seconds. If the PAD
and PAW pressures correlate well. the PAD pressure is
substilUted for lhe PAW pressure and balloon inflation is
limited.
Local and systemic infection can develop in patients with
PA catheters. The risk for bacteremia increases when the
catheler is in place for more than 72 hours or lhe inserlion
site is infected. 16 Diagnosis and treatment of the child Wilh
a calheter-relaled infeclion are the same as for any child with
infection related to a central venous catheter.
Catheter Removal. The PA catheter is removed
once the data obtained with it are no longer needed 10 guide
clinical decision making and patient care. The catheler is
removed in the same manner as a central venous calheter. In
addition, as the catheler is wilhdrawn using a sleady mOlion,
lhe palienl's ECG is observed for lhe presence of transienl
arrhythmias thaI can occur while lhe calheler is in the RY. If
any resistance is encoumered during removal, lhe procedure
is discontinued until the patient can be assessed under
fluoroscopy for calheter knotting or kinking. A knotted
catheter may ensnare or perforate intracardiac structures
with forced removal. When the catheter is completely
wilhdrawn, hemostasis is achieved, and the inserlion site is
assessed and dressed wilh a dry. sterile dressing. The
catheter is assessed to ascertain that it was removed in its
entirely. The PA catheter is often exchanged for a multilumen central venous catheler placed over a wire to maintain
central venous access.
Left Atrial Pressure Monitoring. DireCl measurement of left atrial pressure (LAP) is reserved for cardiac
surgical patients in whom a transthoracic catheter is placed
at the time of operation. These catheters are used for
continuous, accurate assessment of LV filling pressure and
function during weaning and discontinuation of cardiopulmonary bypass, as well as during the acute postoperalive
period. RA and PA pressures may also be directly monilOred
after cardiac surgery.
LA Waveform Analysis. Analysis of the LA waveform is the same as that described for monitoring venous
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pressures. Given the proxImIty of the catheter to the
mechanical events produced by the heart's electrical activity, the correlation between the ECG and the pressure
waveform is close.
Complications and Catheter Removal. Transthoracic intracardiac monitoring of RAP and LAP has been
associated with arrhythmias secondary to catheter dislodgment into the ventricle, difficult removal, and tamponade
after catheter removal. 69 Although the incidence of complications is low, their potential risk is high and necessitates
special caution at the time of catheter removal.
Ventricular arrhythmias (PVCs) or an abrupt change in
the pressure and waveform indicates malposition of the
catheter. If these conditions become manifest, the catheter
must be repositioned or removed. LA lines are removed
when the data is no longer necessary for patient management, before chest tube removal, and when coagulation
profiles are normal. Mediastinal drainage with a chest tube
must be ensured, and blood should be readily available if
tamponade occurs.
Cardiac Output Determination. In the intensive
care setting, CO is measured by techniques that are based on
the Fick principle. The Fick principle uses the following
relationships to determine CO:
CO = V0 2 + rCao 2

-

Clio 2 ]

Under normal conditions, and in the absence of intracardiac
or intrapulmonary shunt, the amount of blood ejected from
the right ventricle equals the amount of blood ejected from
the left ventricle.
The Fick principle states that the difference between the
mixed venous and arterial oxygen content reflects oxygen
uptake by the blood as it flows through the lungs. In the
preceding equation, CO (the amount of blood flowing
through the lungs) is equal to oxygen consumption divided
by the difference between the oxygen saturations of mixed
venous blood (flowing into the lungs) and arterial blood
(leaving the lungs).
Calculation of CO with the Fick method requires
collection and measurement of exhaled gas volume and
oxygen content to determine V02 ; or V02 can be assumed by
using predetemlined tables, taking into consideration body
surface area, age, sex, and HR. This measurement is
considered the gold standard against which all other
measurements of CO are made 70 Until recently, this method
was only used during cardiac catheterization. With the
advent of continuous Spoz and Svo z monitoring, along with
bedside metabolic monitoring, this method is used in some
centers for continuous CO evaluation. 7 ! Inaccurate measurements are related to sampling errors of mixed venous
blood or exhaled gases, the length of the time over which the
measurements are made, and the presence of cardiac or
pulmonary shunts. 72
Indicator-Dilution Method. The indicator-dilution
method of CO determination is based on the principle that if
a known amount of indicator is added to an unknown quantity of blood flow, and the concentration of the indicator is
measured downstream, this concentration, along with the
timing of delivery, gi ves a measurement of flow.
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Fig. 7-58 Time-temperature cardiac output curve (From
Clochesy JM, Breu C. Cardin S et ai, eds: Critical care nursing.
Philadelphia, 1993, WB Saunders, p 172.)

The usual indicator for CO determination is a nontoxic
dye, indocyanine green, which is measured with a photodensitometer. A bolus of the dye is injected into the venous
circulation, and blood is sampled from an artery through the
densitometer to determine concentration. Use of the
indicator-dilution method for determining CO has been
refined to use a thermal indicator rather than dye. Dye
dilution is rarely used in the critical care setting.
Thermodilution Method. The use of a thermal
indicator was first introduced by Fegler in 1954 and further
refined by Swan and Ganz in 1971. 73 .74 This technique has
become known as thermodilution and has been shown to be
simple, rapid, accurate, and safe. Thermodilution uses a
balloon-tipped PA catheter; therefore it measures blood flow
through the pulmonary bed. In the absence of an intracardiac
shunt, PBF equals systemic flow.
Thermodilution is a modification of the indicator-dilution
technique, whereby a known volume at a known temperature of either 5% dextrose or normal saline is injected into
the right atrium or one of the venae cavae through the
proximal lumen of a PA catheter. The thermistor at the distal
end of the PA catheter measures the temperature decrease of
the blood as the cool solution (either room temperature or
previously iced) passes through the heart, and a timetemperature curve is produced (Figure 7-58). A computer
calculates the area beneath the curve and displays the CO in
a measurement of liters per minute. The values obtained
using thermodilution correlate well with the Fick method 71
However, as with other CO measurement techniques, there
are a number of potential sources of error in thermodilution
CO determination (Table 7-5).
In addition, structural heart disease may alter CO data
obtained by thermodilution. The presence of a left-to-right
shunt will increase PBF and overestimate systemic CO.
Conversely, obstruction to pulmonary flow will decrease
PBF and underestimate systemic CO. Therefore structural
heart disease may preclude the use of bedside thermodilution or at least prompt careful scrutiny of the obtained data.
Technical Consideration. Accurate CO measurement by thermodilution requires that the PA catheter be
properly positioned to ensure that the thermistor can
measure the temperature change occurring when the injectate is instilled. The PA waveform is assessed for damping
or wedging caused by catheter migration.
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7-5

Phenomena of Concern

Potential Sources of Error in Thermodilution CO Measurement

!fro

~50urce of Error

~yaulty computer or cables

m.~able connection not secure

Ik'

.[fA Catheter
FiPlotted proximal lumen
~:C,'.,atheter malposition

i':

~1,f:atheter kinking at entrance site or within the heart
..:fibrin growth on catheter

(Technique Related
~'In
.
~r:_ correct mjeclate
vo I ume
~~ilcorrec[ computation constant entered in computer
i!!,,: jectate temperature outside specified range
'neven, prolonged injectate delivery

Resulting Problem/Error

Wide discrepancy in CO measurements
No readings
PA or injectate temperature does not register
Difficulty injecting solntion; may be impossible to inject
Thermistor lying against small vessel wall because of catheter migration;
CO curve has low amplitude
Tip of catheter not in zone 3 lung; measured CO affected by ventilation
Difficulty injecting solution
Difficulty injecting solution; variations in core temperature measurements
CO values do not correspond to the patient's clinical condition

l:,

:. atient Related
''ll'atient
:
movement during measurement
, i~ardiac arrhythmias
?Mechanical ventilation
;"w CO slates
jIypotherrnia

...

~i"

.~

Variation in serial CO measurements
Oscillations of the baseline
Recirculation of thermal indicator; prolonged baseline drift
Low-amplitude CO curve because of small temperature difference
between blood and injeclate

The computation constant (specific to the catheter size,
volume, and temperature of the injectate) and the patient's
blood temperature, if not automatically measured and
recorded, are entered into the CO computer. These values
are incorporated into the computer's calculations to adjust
for the expected warming of the injectate as it travels
downstream. The connections between the injectate probe
cable, the thermistor coupling, the catheter-connecting
cable, and the computer are secured.
The patient is usually positioned supine with conservative elevations in the head of the bed (0 to 20 degrees). Flat
positioning is not necessary because measurements taken in
both the supine and modest head elevation positions have
been found to correlate, 16
Rapid, even injection within 2 to 4 seconds is essential to
ensure a smooth time-temperature curve 69 Injectate volumes are determined by patient and catheter size. Generally
5 or 10 ml are used; small thermodilution catheters used in
infants have the capability to use 3-ml injectate volumes
(if there is a corresponding computation constant on the
package insert). Hemodynamically unstable infants may not
tolerate frequent large injectate volumes because of volume
overload; therefore, 3- to 5-ml volumes can be employed. 71
Both iced and room temperature injectate can be used. Iced
injectate produces a larger thermal signal than solution kept
at room temperature and (given the lack of pediatric data)
should be used when injectate volumes are less than 10m!.
Timing of the injection with end expiration produces less
variable results because the effects of the phase of respira-

tion on PA temperature are eliminated. End-expiration is
judged most convenient and is most often used.
The CO computer displays the calculated CO approximately 15 seconds after the injection. A second and a third
determination of CO are made, separated by 45 to 90 seconds. The three measurements are averaged, unless a
measurement falls outside 10% of the middle value. In a
series, a CO value that falls outside the standard error of the
estimate (10%) is discarded, and the remaining two are
averaged or a fourth measurement is made.
Accuracy of the measurement is also assessed by
inspection of the thermodilution curve. The configuration
should be smooth with a rapid upslope to peak and a gradual
downslope to the baseline (see Figure 7-58).
Hemodynamic Calculations. CO, calculated in liters per minute (L/min), is the basis for calculation of
a number of additional, derived hemodynamic indices
(Box 7-4). The first is cardiac index, which is the
most accurate expression of CO in children because of variability in patient size. Calculations are performed automatically by the CO computer, necessitating that data entry be
accurate.
SV is equal to CO divided by the HR during the CO
determination. Normal SV depends on the patient's size and
activity level. SV index is obtained by dividing SV by the
patient's body surface area. As with cardiac index, this
normalizes the measurement to the patient's size.
The stroke work of the ventricle is a measure of the
ventricle's work during anyone cardiac contraction, as well
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Box 7-4

Derived Hemodynamic Parameters

Cardiac Index (CI)
Nonnal = 2.5 to 5 Llmin/m 2
CI =Cardiac outputIBody surface area
Stroke Index (SI)
Normal = 30 to 60 ml/beat/m 2
SI = Cardiac indexlHeart rate
Stroke Work Index (SWI)
LVSWI Nonnal = 56 ± 6 g_m/m 2
LVSWI = (MAP - PAWP) x SI x 0.0136
RVSWI Nonnal = 6 ± 0.9 g_m/m 2
RVSW = (PAM - CVP) x SI x 0.0136
Where:
LV = left ventricular
RV =right ventricular
CVP = central venous pressure
MAP = mean arterial pressure
PAM = pulmonary artery mean (pressure)
PAWP = pulmonary artery wedge pressure
SI =stroke index
0.0136 =conversion factor for pressure to work (measured
in grams)
Systemic Vascular Resistance Index (SVRI)*
SVRI = MAP - CVPICI x 80
Nonnal = 800-1600 dynes/sec/cm -5 or
10-15 Woods units/m 2 infants;
15-20 Woods units/m 2 1-2 years;
15-30 Woods units/m 2 child/adolescent
Where:
MAP = mean arterial pressure
CVP = central venous pressure
CI = cardiac index
Pulmonary Vascular Resistance Index (PVRI)
PVRI = PAM - PAWP(or LAP}ICI x 80
Normal = 80-240 dynes/sec/cm-s or
1-3 Woods units/m 2 over 8 weeks of age:
8-10 Woods units/m 2 under 8 weeks of age
Where:
PAM = pulmonary artery mean (pressure)
PAWP = pulmonary artery wedge pressure
CI = cardiac index
LAP = left atrial pressure
*Vascular resistance can be expressed as dynes/sec/crn-s or Woods units.
Dynes/sec/cm-~ are primarily used in the leu and Woods units in the cardiac
catheterization laboratory. Dynes/sec/cm- s can be converted to Woods units
by dividing by 80.

as an indicator of the effectiveness of the heart's pumping
function or functional capacity. Stroke work is the product
of the average pressure generated by the ventricle during
contraction multiplied by the SV ejected with that beat.
Stroke work is also indexed to the size of the patient.
Hypertension or increased vascular resistance, as well as
hypervolemia, increases the ventricle's stroke work. Stroke

~

Box 7·S

Tissue Perfusion

187

.

Indications for Cardiac Catheterization

Define cardiovascular anatomy: The morphology, position,
relations, and connections of the:
Systemic and pulmonary veins
Atria
Atrioventricular valves
Ventricles and outflow tracts
Proximal pulmonary and systemic arteries
Peripheral pulmonary and systemic arteries
Measure and calculate central and peripheral hemodynamics:
Blood pressure in the systemic and pulmonary arteries
and veins
Blood flow in the systemic and pulmonary circulation
Calculate shunts
Calculate vascular resistance in the pulmonary and systemic beds
Calculate valve areas
Evaluate cardiac pump function
Evaluate cardiac muscle function
Monitor changes in hemodynamics and cardiac function in
response to drug, respirator, or surgical interventions
Electrophysiologic studies and therapy
Myocardial biopsy

work is decreased with poor myocardial contractility, as is
seen in patients with CHF or shock.
Vascular resistance is another index of ventricular work,
representative of the force a ventricle must overcome to
eject its contents. To calculate SVR, the difference between
the MAP and CVP is divided by the CO. To calculate PVR,
the difference between the MAP and LA (or wedge) pressure
is divided by the CO. Both SVR and PVR measurements
are also indexed to the patient's size using Cl as the
denominator.

Cardiac Catheterization
Cardiac catheterization provides complete evaluation of
cardiac anatomy and hemodynamic function. Angiography
provides detailed information on coronary artery anatomy,
pulmonary collaterals, size and continuity of the branch
pulmonary arteries, cardiac chamber size, valvar size,
ventricular function, and ventricular septal defect (VSD)
size and location, to name a few. Measurement of intracardiac and peripheral hemodynamics aid in the assessment of
physiologic sequelae of heart disease. Because of technologic refinements in echocardiography, diagnostic catheterization and angiography are generally only necessary in
patients with unusual anatomy or inadequate echocardiographic windows. Not all patients with heart disease require
a cardiac catheterization (Box 7-5). The decision to perform
a catheterization should be carefully made based on patient
need. If the procedure or data obtained will not alter patient
care, then it may not be necessary.
Currently, interventional procedures for palliation or
treatment of congenital heart disease are performed during
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7-6

Normal Hemodynamic Values Obtained at Cardiac Catheterization

'k

c

a Wave

v Wave

Mean

2-10

2-10

0-8

.

Systolic

End Diastolic

Mean

15-30
15-30

0-8
3-12

9-16

100-140
100-140

3-12
60-90

70-105

!i(

[iLPressures (mmHg)
Right atrium
~':' Right ventricle
Pulmonary artery
PAW, left atrium
.. Left ventricle
";,,- Svstemic arteries

n?'

".

3-15

3-12

1-10

';,

~::.

J:L

TIrOxygen consumption index
i~;A.rteriovenous oxygen difference

110-150 (mllmin/m 2 ) at rest
30·50 mIlL or 3-5 mlldl
2.5-5 (Llmin/m2 )

~,Resistances (Woods units/m 2 )

~r' Pulmonary vasculac Under 8 weeks of age
~!::Over 8 weeks of age
Systemic vascular: Infant
1-2 years
~1'::
Chi Idladolescent

f:"
;t
I'illt"

8-10
1-3
10-15
15-20
15-30

irofA w. Pulmonary artery wedge.

catheterization. Therefore although diagnostic procedures
are performed often, interventional procedures continue to
keep most pediatric catheterization laboratories very busy.
Precatheterization assessment is critically important to
define the goals of the procedure and to prevent any
potential complications. A history, physical, and pertinent
laboratory investigations should be performed. Laboratory
data include a complete blood count because the hemoglobin and hematocrit values are used in hemodynamic
calculations. Acid-base, electrolyte, and glucose abnormalities should be corrected beforehand. A two-dimensional
echocardiogram should be obtained on all children before
cardiac catheterization to evaluate basic cardiac and venous
anatomy. These data assist in planning for vascular access
and help to minimize the use of contrast. Neonates, critically
ill patients, or those undergoing prolonged or interventional
procedures require deep sedation and intubation to provide
stabilization and prevent movement at inopportune times. 75
It is possible to transport patients supported by extracorporeal membrane oxygenation (ECMO) or ventricular assist
devices (VADs) to the catheterization laboratory if it is
believed that the data obtained will elucidate the nature of
the patient's problem or detennine future therapeutic
intervention.
The right side of the heart, the left side, or both may be
accessed according to the patient's anatomy or therapeutic
need. Right-sided heart catheterization is accomplished by
cannulation of the femoral vein, although the axillary,
umbilical (in neonates), or brachial can also be used. The
catheter is then passed antegrade in to the right side of the
heart. 76 Many children with complex congenital heart
disease have had multiple vascular procedures that adversely affect venous access. In these patients, percutaneous

transhepatic puncture is advocated. For this procedure, a
puncture is made in the lower margin of the Ii ver, and a
sheath is placed under fluoroscopic guidance. A needle and
guidewire can then be advanced through the liver into the
hepatic vein and toward the right atrium. 77 The left side of
the heart can be accessed retrograde via the femoral artery.
If the foramen ovale is patent or in the presence of an ASD,
the left side of the heart is accessed from the right atrium; or
a transeptal puncture across the atrial septum is used to gain
access to the left side of the heart. Any time the left side of
the heart is entered, the patient should be systemically
anticoagulated (usually with heparin).
Hemodynamic measurements can be obtained during
cardiac catheterization. Hemodynamic indices include intracardiac pressures and waveforms, pressure gradients
across the valves, cardiac index, shunt determinations, and
calculation of vascular resistances (Table 7-6). In addition,
changes in hemodynamics can be monitored following
intervention with drugs, oxygen, nitric oxide, or changes in
modes of ventilation. Blood sampling from different chambers in the heart allows measurement of oxygen saturation
(Figure 7-59). Intracardiac differences in oxygen saturation
aid in the calculation of shunt and CO indices.
Interventional catheterization is used to palliate or treat
congenital defects. Specific procedures include atrial septostomy, balloon valvuloplasty, balloon dilation, and coil or
stent placement. Atrial septostomy is often performed under
echocardiographic guidance to palliate transposition of the
great arteries, tricuspid atresia, or pulmonary atresia with
intact ventricular septum. However, in those patients with a
thick atrial septum, this procedure is aided by fluoroscopy in
the catheterization laboratory. Balloon valvuloplasty, or
dilation, is an attractive option that can delay or prevent
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Fig. 7-59 Hemodynamic indices and oxygen saturation normal values measured at cardiac catheterization. (© Copyright 1996. CIBA-GEIGY Corporation. Reprinted with permission from the Ciba
Collection of Medical Illustrations. illustrated by Frank Neller, M.D. All rights reserved.)

surgical intervention for pulmonary or aortic stenosis.
Indeed, this procedure is the treatment of choice for valvar
pulmonary stenosis (PS), including critical PS in the
newborn 75 .78 Aortic valve dilation is best accomplished if
the valve is trileaflet or bicuspid. Unicuspid or severely
dysplastic valves do not respond as well and can be left with
severe aortic regurgitation after the procedure. 78 .79 Coil
embolization is used to occlude patent ductus arteriosus
(PDA), unwanted systemic or venous collaterals, and
coronary artery fistulas. In some centers, PDA embolization
is the treatment of choice, avoiding surgery80; The exception
to this is the very small premature infant, whose size
precludes coil embolization. Collateral vessels are embolized if they contribute to persistent cyanosis or if they
interfere with PBF. Intravascular stents are used in a number
of conditions, including peripheral pulmonary stenosis that
is distal to the hilum of the lung, recurrent coarctation of the
aorta, conduit, and postoperative vessel stenosis. 75 .s , This
intervention has replaced surgery in many instances. In

addition, a number of stents respond to repeat balloon
dilation if stenosis subsequently occurs. 82 Device closure
for ASD and VSD is currently under Food and Drug
Administration (FDA) investigation at select centers.
Electrophysiology (EP) study is the evaluation of normal·
and abnormal impulse conduction performed in the catheterization laboratory. Often a special EP laboratory is
designed specifically for this procedure. EP study can
either be an intracardiac evaluation (using catheters with
monitoring and pacing electrodes) or a transesophageal
evaluation (using a transesophageal electrode and pacing
catheter). Indications include but are not limited to evaluation of mechanisms and characteristics of abnormal tachycardia, determination of response to therapy (pharmacologic, ablative, or surgical), determination of risk for sudden
death in WPW syndrome, evaluation of sinus node function
in patients with sinus node disease, and identification of
arrhythmia focus. The most common reason for radiofrequency catheter ablation in pediatrics is the treatment of
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SVT. 83 Once an arrhythmogenic focus or accessory connection is identified, radiofrequency catheter ablation can be
used to generate thermal injury, creating a localized lesion
that results in arrhythmia eradication. Currently a multicenter study is under way to evaluate the long-term outcomes
and complications in pediatric patients undergoing radiofrequency catheter ablation.
Complications associated with cardiac catheterization
include bleeding, vessel thrombosis, arrhythmia, and cardiac tamponade, and vessel perforation. The independent
risk of complication increases with young age «2 years),
critical illness, and during interventional procedures, for
example, devices or stents. Rarely, cerebral embolism or
death can occur. 84

PHARMACOLOGIC SUPPORT OF
CARDIOVASCULAR FUNCTION
Management of acute cardiovascular dysfunction is multifaceted. It may require (I) restoration of adequate, but not
excessive, intravascular fluid volume; (2) improvement of
myocardial contractility; (3) treatment of abnormal vascular
capacitance and resistance; or (4) correction of abnormal
cardiac rate or rhythm. Chronic cardiovascular dysfunction
is managed from these same perspectives; iuotropes are
administered to improve contractility, with diuretics given to
decrease volume load. New guidelines for care of adults
with chronic heart failure emphasize control of the underlying neurohormonal response to inadequate tissue perfusion. The SNS, renin-angiotensin system, and endocrine system individually and in combination influence
cardiovascular performance in patients with chronic heart
failure. Angiotensin-converting enzyme (ACE) inhibitors,
f)-blockers, aldosterone antagonists, angiotensin-receptor
blockers, and digoxin are used for the purpose of "resetting" neurohormonal balance. 85 Appropriate long-term pediatric studies of heart failure are needed. Chronic cardiac
rhythm disturbances are currently managed with phamlacotherapy or radiofrequency catheter ablation of the arrhythmogenic substrate. Heart failure and arrhythmias are discussed further in Chapter 18.
Compared with adults, immature animals and humans
respond differently to many medications. The response of
neonates to inotropes is attenuated 86 This may be the
consequence of developmental differences in the concentration of adrenergic receptors in a variety of target
organs. 87 .88 Differences including reduced ventricular compliance, greater ventricular interdependence, and reduced
myocardial contractile protein in the immature heart point to
structural and ultrastructural differences that are clinically important. As a related consequence, when compared
with older infants and adults, the young infant's heart
does not tolerate or respond well to volume loading. Care of
critically ill infants and children necessitates that caregivers appreciate both the limited response to augmented
preload and the reduced sensitivity of the heart and
vasculature to adrenergic agents, characteristic of some
patients in the PICU. An important caveat to efficacy is that

infants and children are subject to maturational factors and
adults are not.
The practical consequences of these differences have not
all been established; consequently, a precise age-based
paradigm for pharmacotherapy is not yet possible. Most new
drugs have not been adequately tested in pediatric patients
because of real and perceived barriers. Insufficient pediatric
sample size is an impediment to adequate clinical trials.
Many medications approved for use with adult patients and
used in children do not have FDA-approved labeling. The
pediatric dose of these medications is extrapolated from the
usual adult dose. The National Institutes of Health have
established a unit for pediatric pharmacology research, and
the FDA now requires expanded information about pediatric
use for all prescription medications 89 Scientific, randomized clinical trials, as opposed to anecdotal reports, will
provide the data necessary to determine pediatric safety,
efficacy, and dosing. 90 Pharmacologic management of all
critically ill patients requires vigilant assessment of drug
effect and side effect. However, special considerations are
necessary when dosing medications for pediatric patients:
infants and children continue to lack access to safety and
effectiveness data.

Intravascular Volume Restoration
Volume expansion to restore preload and ventricular filling
is essential in circumstances involving either absolute
(abnormal fluid losses) or relative (maldistributed fluid
volume) hypovolemia. Vascular access is of primary importance, followed by the timing and volume of fluid administered. It is critical to restore adequate perfusion before
irreversible tissue ischemia occurs. Aliquots of normal
saline (10 to 20 mlfkg) or 5% albumin (5 to 10 mVkg) can be
safely administered to pediatric patients over I to 15 minutes and repeated in 15 minutes. Two important exceptions
to the practice of fluid resuscitation in pediatric practice are
patients in cardiogenic shock and premature infants at risk
for intraventricular hemorrhage.
Important initial physiologic responses to fluid administration are a decrease in HR, broadening of the pulse
pressure or increase in BP (if hypotension was detected),
and improvement in tile quality of peripheral pulses. Fluid
administration continues until perfusion of the skin, kidneys, and central nervous system (CNS) improves, as
evidenced by brisk capillary refill and warm extremities,
adequate urine output, and appropriate level of consciousness. Infusion of 60 to 100 ml/kg of fluid may be required
over a brief period for patients with marked intravascular
volume depletion.
Diuretic Therapy. The kidneys respond to inadequate
renal perfusion by increasing sodium reabsorption. Volume
expansion follows, leading to systemic and pulmonary
circulatory congestion and elevated end-diastolic volume
and pressure. The fundamental aim is improving renal
perfusion with inotropic or vasodilating agents. However,
managing the relative fluid volume overload is critical.
Diuretic therapy interferes with sodium reabsorption at
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various sites along the nephron and increases excretion of
water. An integral part of treating CHF, diuretic therapy
decreases ventricular dilation and improves diastolic function by lessening the hemodynamic load and producing a
more efficient volume-pressure relationship. Pulmonary and
peripheral edema are decreased, and the work of breathing
is eased. 91 .92
Three classes of diuretics are commonly used to lessen
the congestion caused by heart failure in infants and
children. 85 Loop diuretics, primarily furosemide, are potent
medications that have a rapid onset and provoke brisk
diuresis, especially when administered parenterally. Thiazides, such as chlorothiazide, act in the distal tubules.
Thiazides are less potent than loop diuretics and are more
affected by low CO and reduced glomerular filtration rate.
Potassium-sparing diuretics, spironolactone for example,
also act in the distal tubule. They are weak diuretics most
often added to therapy to counteract the potassium depletion, which occurs with either loop di uretics or thiazides.
Furosemide. Furosemide is a potent loop diuretic that
inhibits the reabsorption of sodium and chloride in the
ascending loop of Henle and the distal renal tubule by
interfering with the chloride binding transport system.
Consequently, excretion of water, sodium, chloride, magnesium, and calcium is increased. Its primary use is to decrease
the congestion and edema associated with heart failure and
hepatic or renal disease in infants and children.
Furosemide is administered intravenously to patients
with acute or decompensated heart failure. The usual dose
is I to 2 mg/kg IV, and the dose can be repeated every 6 to
12 hours. The onset of action occurs within 5 minutes of
IV administration; duration of action is 2 hours. Furosemide can be administered undiluted, direct IV, at a
maximum rate of 0.5 mg/kg/min. When large doses (greater
than 120 mg) are required, the rate of administration should
not exceed 4 mg/min. It can also be diluted to a concentration of I to 2 mg/ml and infused over 10 to IS minutes.
Continuous infusion of 0.05 mg/kg/hr is titrated for clinical
effectiveness. Most often reserved for patients with refractory edema, continuous infusion maintains a constant blood
level of diuretic and elicits diuresis by limiting any
opportunity for the kidneys to retain sodium. 85
The oral dose of furosemide is I to 6 mg/kg/day divided
every 6 to 12 hours. It may be administered with milk or
food to decrease the gastrointestinal distress associated with
the oral solution. Onset of action is within 30 to 60 minutes
following oral administration, and duration of action is 6 to
8 hours.
Loop diuretics are potent; profound diuresis with excessive volume and/or electrolyte loss can occur. The cardiovascular effects include hypovolemia and hypotension.
Orthostatic hypotension can persist with dizziness, vertigo,
and headache accompanying it. Dehydration, hypokalemia,
hyponatremia, hypochloremia, and metabolic alkalosis can
develop. The oral solutions are manufactured with sorbitol,
which may cause diarrhea. Anorexia, vomiting, constipation, and abdominal cramping are other gastrointestinal
adverse reactions. Ototoxicity associated with furosemide
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may be transient or permanent. The risk for ototoxicity is
increased in the pretenn infant and when other ototoxic
medications are administered concurrently (aminoglycosides). The risk for ototoxicity may be minimized through
the use of continuous rather than bolus infusion to prevent
peak serum levels. 93
Ethacrynic Acid. Ethacrynic acid is a potent loop
diuretic with actions and adverse reactions like those of
furosemide. Most often, it is used in hospitalized patients
with critical, acute cardiac failure or those with refractory
CHF. An oral preparation for long-term administration is
available.
Ethacrynic acid is diluted with 5% dextrose or normal
saline to a concentration of 1 mg/ml and injected over
several minutes or infused over 20 to 30 minutes. It is a
tissue irritant; extravasation is avoided, and intramuscular or
subcutaneous injection is contraindicated. The usual intravenous or oral dose is 1 mg/kg/dose. Repeat intravenous
doses are not routinely recommended; however, if indicated,
repeat doses are administered every 8 to 12 hours. The oral
dose can be increased at intervals of 2 or 3 days to a
maximum of 3 mg/kg/day.94
Acute cardiovascular, fluid, and electrolyte adverse
reactions are like those of furosemide. Potassium depletion
can be pronounced. Oral preparations are administered with
food or milk to minimize gastrointestinal irritation, which is
also more pronounced than with furosemide. Ototoxicity
and tinnitus can occur.
Bumetanide. Bumetanide is a potent loop diuretic
that inhibits reabsorption of sodium and chloride in the
ascending loop of Henle, resulting in subsequent excretion of water, sodium, chloride, magnesium, calcium, and
phosphate. Primary indications for use are treatment of
refractory edema secondary to CHF, hepatic disease, or
renal disease.
Bumetanide can be administered intravenously, intramuscularly, or orally. Doses are equivalent regardless of the
administrative route. Usual dose in neonates is 0.01 to
0.05 mg/kg/dose every 24 to 48 hours. Infants and children
require 0.015 to 0.1 mg/kg/dose every 6 to 24 hours, with
a maximum dose of 10 mg/day. Oral preparations should be
administered with food to prevent gastrointestinal upset. IV
preparations are administered without additional dilution
over 1 to 2 minutes.
Contraindications include anuria and hypersensitivity.
Adverse reactions include profound diuresis with excessive
water and electrolyte loss, hypotension, nausea, muscle
weakness, and increased liver enzymes. The risk for
hypotension increases if given concurrently with other
hypertensive agents or ACE inhibitors.
Chorothiazide. Chlorothiazide is used in the management of edema associated with CHF or nephrotic
syndrome. It inhibits sodium reabsorption in the distal
tubules, causing increased excretion of sodium, chloride,
potassium, bicarbonate, magnesium, phosphate, and water.
Because it acts at the distal tubule, chlorothiazide is less
potent and less effective than the loop diuretics in low-CO
states when the glomerular filtration rate is decreased.
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The oral dose of chlorothiazide is 20 mg/kg/day in two
divided doses. Infants less than 6 months of age may require
up to 40 mg/kg/day. It is available in tablet and oral
suspension; both are administered with food. The IV dose
for infants and children has not been established. Doses are
extrapolated from the oral doses and have been used
safely.94 The IV dose is 4 mg/kg/day in two divided doses;
infants younger than 6 months receive doses of 2 to
8 mg/kg/day. IV doses are administered by direct infusion
over several minutes or infused in dextrose or normal saline
over 30 minutes. Extravasation of the parenteral solution is
avoided because the drug is irritating to tissue. The solution
must not be injected intramuscularly or subcutaneously.
Adverse reactions are similar to those associated with the
loop diuretics. Hypotension, hypokalemia, and hypochloremic alkalosis can occur, as can similar gastrointestinal side
effects. There are rare instances of prerenal azotemia,
intrahepatic cholestasis, and blood dyscrasias.
Metolazone. Metolazone is thiazide diuretic that
inhibits sodium reabsorption in the distal tubules, producing
increased excretion of water and sodium. It is used to
manage the edema associated with CHF and renal impairment. The most common indications for use in children are
the treatment of postoperative edema and/or CHF that is not
responsive to loop diuretics. Metolazone is administered
orally. The usual dosage in children is 0.2 to 0.4 mg/kg/day
divided every 12 to 24 hours, and it should be administered
with food to prevent gastrointestinal upset.
Contraindications to use include anuria, hepatic coma,
and hypersensitivity to metolazone, sulfa drugs, or thiazide
diuretics. Adverse reactions include orthostatic hypotension,
vertigo, headache, electrolyte abnormalities, nausea, and
blood dyscrasias. If given concurrently with digoxin, there
is an increased risk for digoxin toxicity secondary to
potassium and magnesium depletion 94
Spironolactone. Spironolactone is a potassiumsparing diuretic used to manage edema seen with excessive
aldosterone excretion (which may occur with chronic heart
failure or primary hyperaldosteronism), hypokalemia, and
hypertension. It competes with aldosterone for receptor
binding sites in the distal renal tubule. It may also block
aldosterone's effect on arterial smooth muscle. At the kidney,
it increases sodium, chloride, and water excretion while
conserving potassium and hydrogen ions. Spironolactone is a
weak diuretic most often added to therapy to counteract the
potassium-depleting effect of loop diuretics and thiazides.
Spironolactone is administered orally in doses of I to
3 mg/kg/day (or 60 mg/m 2 /day). It may be administered in
a single dose or divided 2 to 4 times.
Spironolactone can cause lethargy and drowsiness. Gastrointestinal effects are like those of other diuretic agents.
Azotemia can develop. Spironolactone is tumorigenic in rats
treated with 25 to 250 times the usual human dose. 94

Inotropic Therapy
Increased intracellular calcium concentration is the central
cellular event that enhances the contractility of the myocardium. Drugs that improve the inotropic performance of the

myocardium act at one of several steps in the sequence of
events that couple electrical excitation and mechanical
contraction. Cyclic adenosine monophosphate (cAMP) is a
pivotal mediator in many of the reactions that produce
myocardial contraction. Increased intracellular cAMP ultimately increases intracellular calcium concentration, which
affects myocardial systolic and diastolic function and HR.
The catecholamines augment cardiac contractility by action
that simulates the SNS receptors to increase cAMP concentration within the cell. Phosphodiesterase (PDE) inhibitors
also increase intracellular cAMP. Digitalis glycosides enhance contractility by a route not dependent on cAMP.
Sympathetic Nervous System (Adrenergic) Stimulation. Sympathomimetic agents interact with cell surface adrenergic receptors. Adrenergic receptors are gl ycoproteins with genetically related structure. They extend
between the internal and external surfaces of the cell
membrane and are transducers of signals or information
across the cell membrane; that is, stimulation of an
adrenergic receptor elicits an intracellular response. Table
7-7 is a classification of the adrenergic receptors and
indicates the physiologic responses to stimulation of each.
The medications listed (in order of their potency) are
receptor agonists. With the exception of the ai_receptor,
adrenergic receptors affect cell function by increasing the
intracellular concentration of cAMP.
Adrenergic receptors' sensitivity to stimulation changes
with a number of factors. Exposure of the receptors to
sympathomimetic agents causes receptor desensitization.
Endotoxin, tumor necrosis factor, and CHF also cause
receptor desensitization.
Phosphodiesterase Inhibition. The methylxanthines (theophylline) and the bipyridines (amrinone, milrinone) inhibit the PDE that inactivates cAMP, thereby
increasing cAMP concentration and leading to higher intracellular calcium and enhanced contractility. The PDE inhibitors are called inodilators because of their additional
vasodilatory effect. The bipyridines selectively inhibit only
PDE III, whereas the methylxanthines inhibit all three known
types of PDE. Consequently, the inotropic action of amrinone
and milrinone is more selective, compared with the limited
inotropic and marked chronotropic actions of theophylline. 95
Digitalis Glycosides. The digitalis glycosides act on
the heart through a mechanism independent of cAMP, but
the final outcome, increased intracellular calcium, is similar. 85 .96 Digoxin inhibits the sodium-potassium pump,
thereby increasing intracellular sodium concentration. The
secondary consequence is a shift in the sodium and calcium
exchange in favor of retaining more calcium within the cell.
The increase in intracellular calcium concentration translates into a positive inotropic effect.
Digoxin has been shown to exert a favorable neurohormonal effect, which occurs before and is separate from its
inotropic effect in adult patients. Through a mechanism not
yet clear, it potentiates parasympathetic discharge, which
decreases sympathetic outflow. Inhibition of sympathetic
discharge is likely accomplished by inhibition of the
baroreceptor sodium-potassium pump. The neurohormonal
effects of digoxin have Dot yet been studied in children. In
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Adrenergic Receptors, Physiologic Responses, and Sympathomimetic Agonists
Physiologic Responses

Agonist

Increase intracellular Ca. muscle contraction. vasoconstriction, inhibit insulin secretion

Epinephrine
Norepinephrine
Dopamine

Decrease cAMP, inhibit NE release, vasodilation. negative chronotropy

Epinephrine
Norepinephrine

Increase cAMP. inotropy, chronotropy. enhance renin secretion

Isoproterenol
Epinephrine
Dopamine
Norepinephrine

Increase cAMP, smooth muscle relaxation, vasodilation, bronchodilation, enhance glucagon
secretion, hypokalemia

Isoproterenol
Epinephrine
Dopamine
Norepinephrine

Increase cAMP, smooth muscle relaxation

Dopamine

Decrease cAMP, inhibit prolactin and 13-endorphin

Dopamine

f~fi'lodified
!~:fq,

from Notterman DA: Pharmacologic support of the failing circulation: an approach for infants and children, Probl Anesth 3:288·294, 1989.
Calcium; cAMp, cyclic adenosine monophosphate; NE, norepinephrine; D, dopamine.

TABLE

7·8

Recommended Digoxin Doses for Pediatric Patients

5:fntravenous Digitalization

~:Total

digitalizing dose = 30

~glkg/24 hours

~T'Maximum dose = 800 ~g IV
!:)'irst dose; Digoxin 15 ~g/kg IV

"i~Digoxin

7.5 llg/kg IV 8 hours after first dose
m:bigoxin 7.5 llg/kg IV 8 hours after second dose
~i:Begin maintenance digoxin (7.5 llglkg/day) 12 hours after
iif: third dose
lifi '

Enteral Digitalization
Total digitalizing dose = 40 llglkg/24 hours
Maximum dose = I mg PO/NG
First dose: Digoxin 20 ~g/kg PO/NG
Digox.in 10 llglkg PO/NG 8 hours after first dose
Digoxin 10 llglkg PO/NG 8 hours after second dose
Begin maintenance digoxin (10 ~g/kg/day) 12 hours after
third dose

I~'NG, N~sogastric (tube).

those with heart failure from a large left-to-right shunt,
contractility is often normal. The ameliorative effects of
digoxin in this group of pediatric patients suggest that
modulation of the autonomic nervous system may be
valuable. 85
Cardiac glycosides are prescribed for patients in whom
poor myocardial contractility is expected to persist beyond
a few days. The elevated HR associated with CHF is
reduced by digoxin, In patients with chronic CHF, digoxin
remains a mainstay of pharmacologic therapy.
Digoxin increases myocardial contractility in normal and
diseased hearts. When CHF is present, digoxin increases SV
and reduces elevated ventricular filling pressures. When
digoxin is administered to infants, contractility increases, as
judged by echocardiographic examination. Adult patients
with acute heart failure who were given a single dose of
digoxin experienced a 69% increase in LV stroke work
index, a 25% reduction in PAW pressure, and a 16% to 28%
increase in cardiac index. 97 Similar invasive hemodynamic
measurements have not been made in infants or children.

The kidney eliminates digoxin. Renal dysfunction that
impairs glomerular filtration interferes with elimination.
Hypokalemia increases digoxin binding to cell receptor
sites, accounting in part for digoxin-induced cardiac rhythm
disturbances during hypokalemia.
Dosage and Administration. Infants and young children eliminate digoxin rapidly and have a large volume of
distribution for the drug. Consequently, they require higher
doses of digoxin than do adults to achieve a therapeutic
plasma level of 0.8 to 2 ng/m!. Dosage is based on the age
of the patient, the indication for therapy, the route of
administration, and the presumed sensitivity of the myocardium to potential toxicity.96 There is substantial individual
variation in response to "usual" doses 94 Table 7-8 indicates
the recommended digoxin doses for pediatric patients. It is
important to note that inadequate renal function, electrolyte
imbalance, or evidence of myocardial irritability (i.e.,
arrhythmia) necessitates that the doses be reduced and,
during digitalization, the pace of digitalizing be slowed. Not
all patients require a digitalizing dose during drug initiation.

194

Part III

Phenomena of Con.cern

The need for digitalization is detennined by the child's
clinical condition and physician preference.
Serum digoxin levels are of limited benefit as a guide to
therapeutic response because there is wide variability in the
serum concentration required to achieve the desired response. However, serum digoxin levels are of benefit to
ensure that the dose gi ven is sufficient to achieve a measurable blood concentration and to confinn the clinical suspicion of toxicity. Serum levels are obtained 8 to 12 hours
after a dose of digoxin, preferably just before the next
scheduled dose. HR, rhythm, and the ECG; serum potassium, magnesium, and calcium; and blood urea nitrogen
(BUN) are closely monitored to avoid toxicity. Serum drug
concentration, in combination with clinical symptoms and
ECG confinnation, is used for monitoring digoxin toxicity.
Digoxin Toxicity. Toxic levels of digoxin are capable of
producing virtually every cardiac rhythm disturbance
known. Infants and children are most likely to develop
bradycardia and AV conduction delay. Sinus bradycardia is
produced by digoxin suppression of sinus node discharge.
All degrees of AV block can occur, sometimes associated
with ectopic atrial beats or JET. Ectopy and tachyarrhythmias are more common in adult patients, probably because
of myocardial irritability from ischemia. However, the
myocardium of infants and children is not less sensitive to
digoxin than that of older patients.
Digoxin toxicity can occur because of accidental or
intentional ingestion. One study reported fatal digoxin
overdose in one half of the cases of acute ingestion. 98
Toxicity can also occur because of dosing error or because
of a change in the patient's sensitivity to the drug or in its
pharmacokinetics. Assessment of the patient for predisposing factors (hypokalemia, renal dysfunction) is an important
initial step in treatment. Hypomagnesemia, hypoxemia,
myocarditis, and coadministration of catecholamines or
calcium all exacerbate digoxin toxicity. In patients receiving
constant digoxin doses with stable serum concentration,
digoxin toxicity can still develop if cardiac status deteriorates or metabolic disturbances develop96
Digoxin immune Fab (Digibind) is the antidote used to
treat life-threatening digoxin toxicity. It binds with free
molecules of digoxin and is then excreted by the kidney.
It should be reconstituted with nonnal saline and administered intravenously over 15 to 30 minutes. Dosing is
complex, so the reader is referred to a pediatric drug
reference book for further information. 94 Serum digoxin
levels rise precipitously after administration of digoxin
immune Fab; however, this reflects digoxin bound to
Digibind, so results will be clinically misleading. Hypokalemia can occur after administration, so potassium levels
must be monitored.

Catecholamines and Other Inotropes
Epinephrine. Epinephrine is an endogenous catecholamine that is produced and released from the adrenal gland
in response to stress. Its direct cardiac effects are the result
of stimulation of the ~-adrenergic receptors. Epinephrine
shortens systole by improving contractility and speeding
conduction through the AV node and Purkinje system. It

accelerates SA node firing. Epinephrine increases coronary
blood flow but also increases myocardial oxygen demand,
so the potential for a mismatch exists. It also decreases the
refractory period of ventricular muscle, causing a predisposition to arrhythmias.
The clinical effects of epinephrine vary with the rate of
infusion. At a low dose (0.05 to 0.2 J.l.g/kg/min), peripheral
vasodilation and increased HR and contractility are the
consequence of ~I- and ~2_adrenergic stimulation. The pulse
pressure is widened, SVR and PVR decrease, and SV and
CO increase if the patient's intravascular volume is adequate.
Increasing infusion rates result in stimulation of the
a-adrenergic receptors. Increased SVR and elevated SP
occur. Afterload increases and may ultimately affect CO if
the myocardium is unable to maintain Sv. Epinephrine is a
potent renal artery vasoconstrictor, potentially reducing
renal blood flow and urine output. However, the improvement in CO achieved with epinephrine may increase renal
blood flow.
Dosage and Administration. In pediatric patients, infusion rates of 0.05 to 0.3 J.l.g/kg/min are recommended in
treatment of shock associated with myocardial dysfunction.
Epinephrine may be most useful when combined with a
vasodilator for afterload reduction. When catecholamine
stores are depleted, epinephrine may be the inotrope of
choice. In asystole or pulseless arrest, the continuous
infusion dose is 0.0 I to I J.l.g/kg/min. The use of epinephrine
in Pediatric Advanced Life Support (PALS) is detailed in
Chapter 31.
Epinephrine is best administered through a central
venous line because infiltration from peripheral venous
administration can cause local tissue ulceration. Infusion
rate is controlled with a constant infusion pump. Epinephrine is compatible with both dextrose and nonnal saline
solutions; alkaline solutions are not used because catecholamines are inactivated at a higher pH.
Side Effects. Epinephrine may induce CNS excitation
marked by restlessness, fear, anxiety, or dread and a
throbbing vascular type headache. Tachycardia is always
produced, and atrial and ventricular ectopy and tachyarrhythmias are risks with increasing infusion rates. Severe
hypertension and anginal pain can occur. Severe mismatching of myocardial oxygen delivery with oxygen consumption and subsequent ischemia may be detected on ECG.
Local tissue injury from extravasation is reviewed in
Chapter 16.
Norepinephrine. Norepinephrine is the hormone
precursor of epinephrine and is the neurotransmitter of the
SNS. Norepinephrine raises SP and improves tissue perfusion in hypotensive patients who have normal or elevated
cardiac index. Although norepinephrine possesses a-and
~-adrenergic receptor activity, its a-adrenergic effects predominate at all but the lowest infusion rates. SVR rises
sharply because of a-adrenergic mediated vasoconstriction.
The peripheral, renal, splanchnic, and hepatic vascular beds
are constricted, as is the pulmonary vasculature. Cardiac
contractility is augmented, and SV and cardiac index rise, if
the increase in afterload can be tolerated. Chronotropy is
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opposed by reflex vagal activity, which slows the rate of
sinus node discharge.
The hemodynamic effects of norepinephrine limit its use
in pediatric critical care almost exclusively to treatment of
patients with septic shock. It is most often used to augment
vascular tone when shock persists after volume repletion
and administration of other inotropes. 8 .96
Dosage and Administration. Initial infusion rates are
0.05 to 0.1 I-!g/kg/min. Successful treatment results in
improved perfusion pressure, which maintains vital organ
function. The lowest possible dose that achieves improved
skin color and temperature, normalization of pH, and urine
output is used. Invasive monitoring is useful to evaluate
both SVR and PVR. The rate of infusion is titrated to a
maximum I to 2 I-!glkg/min.
Side Effects. Careful monitoring is necessary during
norepinephrine administration to prevent excessive increases in ventricular afterload and organ ischemia. If
norepinephrine elevates BP but does not improve clinical
evidence of tissue perfusion, continuing its infusion may
lead to ischemic injury of the extremities, widespread organ
failure, and death. 96 Profound hypertension can result from
inadvertent boluses or excessive infusion rates, resulting in
myocardial infarction or cerebral hemorrhage. Inpatients
with coronary artery thrombosis the area of infarct may be
extended. As is true with epinephrine, local extravasation
can cause ischemic necrosis and sloughing of superficial
tissues. Local tissue injury from extravasation is reviewed in
Chapter 16.
Isoproterenol. Isoproterenol is a synthetic catecholamine structurally related to epinephrine and norepinephrine. It has beta (~1 and ~) specificity and does not affect
a-adrenergic receptors. Its potent effects on the heart
include an increase in cardiac contractility, HR, and
conduction velocity. Stimulation of peripheral ~z-receptors
results in vascular smooth muscle relaxation, decreased
SVR, and a fall in diastolic BP. Widened pulse pressure is
detected because the systolic BP increases. Tachycardia may
be extreme because the decline in diastolic pressure
augments the chronotropic effect of the drug. In the face of
hypovolemia, hypotension may develop when isoproterenol
therapy is initiated. An increase in CO is ensured only if
circulating blood volume is adequate. Because HR and
contractility are increased, isoproterenol increases myocardial oxygen consumption. Simultaneous decreases in both
diastolic filling time and diastolic perfusion pressure may
impair myocardial oxygen supply and result in myocardial
ischemia. Myocardial ischemia, myocardial infarction, and
fatal myocardial necrosis have been reported in adolescents
receiving continuous isoproterenol infusion.
Isoproterenol also relaxes pulmonary vascular and bronchial airway smooth muscle. Historically, isoproterenol was
used in severe refractory status asthmatic us; however, newer
~z-selective intravenous agents have all but supplanted the
use of isoproterenol in this population. Once used to treat a
variety of shock states, newer drugs and an improved
understanding of the pathophysiology of shock have made
isoproterenol obsolete for this purpose. It is, however, still
employed to treat hemodynamically significant or atropine-
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resistant bradycardias. In addition, it is the chronotrope of
choice in the postoperative heart transplant patient to
augment HR in the denervated heart. In heart block resistant
to atropine, isoproterenol may be used until definitive
treatment with pacemaker placement occurs. Low-dose
epinephrine infusion may be better tolerated, however,
because it maintains diastolic coronary perfusion pressure
better than isoproterenol.
Dosage and Administration. Isoproterenol infusion is
initiated at a rate of 0.01 I-!g/kg/min and adjusted to a rate
of 0.05 to 0.1 Ilg/kg/min until the desired chronotropic or
hemodynamic effect is achieved.
Side Effects. Sustained tachycardia, vasodilation, and
the risk of myocardial ischemia limit isoproterenol's utility
in all but a select group of patients% HR, ECG, and BP are
closely monitored. ST segment changes or T wave flattening
are evidence of myocardial ischemia. Cardiac enzymes can
be followed to monitor for myocardial ischemia in those
patients receiving high doses. Isoproterenol can be safely
administered via a peripheral vein because extravasation of
the drug does not produce tissue necrosis.
Dopamine. Dopamine is a neurotransmitter in the
central and sympathetic nervous systems and is found in the
adrenal medulla, where it is the immediate precursor of
norepinephrine. Dopamine stimulates dopamine (DA) receptors (D I and D z) in the vascular beds of the kidney,
mesentery, and coronary arteries at low doses, producing
vasodilation. As the dose of dopamine increases, ~- and then
a-adrenergic receptors are activated. In addition to these
direct sympathomimetic effects, dopamine stimulates release of norepinephrine from sympathetic nerve terminals,
resulting in indirect sympathetic stimulation.
Renal blood flow and urine output increase with infusion
of dopamine at 0.5 to 2 Ilg/kg/min because of the selective
action at DA receptors that occurs at this dose. Low-dose
dopamine augments renal function, inhibiting tubular reabsorption of sodium and promoting sodium excretion via
increased renal blood flow. Low-dose dopamine reduces
renal and SVR, suppresses aldosterone secretion, and
interacts with atrial natriuretic factor. Renal effects are
enhanced by the combination of low-dose dopamine with
furosemide or prostaglandin 99 Infusion of dopamine at 2 to
5 I-!g/kg/min increases cardiac contractility and CO, with
little change in HR or vascular resistance. At doses of 5 to
6 I-!glkg/min, both BP and HR increase, although the
tachycardia is less than that seen with isoproterenol. Doses
up to 10 Ilg/kg/min further increase CO. At doses of more
than 10 I-!g/kg/min, increasing a-adrenergic effects are seen
with beginning increases in SVR and tachycardia. The
salutary effect on the renal vascular bed may be lost
when a-adrenergic effects predominate at doses greater than
IS I-!glkg/min.
There are data suggesting that infants have reduced
sensitivity to dopamine; however, the evidence is not
strong. IOO Notterman, DeBruin, and Metakis 100 also note,
importantly, that dopamine crosses the blood-brain barrier in
preterrn neonates and warn against its use for trivial
indications in this age-group. Although low-dose infusion of
dopamine is often administered to augment renal function
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among critically ill patients, there is no evidence of the
influence of this practice on the incidence of renal failure
resulting from poor perfusion.
Although dopamine is used widely in pediatric critical
care practice, little systematically collected data exist regarding its use. Dopamine has both inotropic and vasopressor properties, as well as the potential to enhance renal blood flow. Shock with cardiovascular dysfunction
and mild to moderate hypotension are improved with dopamine infusion. At moderate infusion rates, it is unlikely to
produce excessive tachycardia or arrhythmias, compared
with either epinephrine or isoproterenol. When hypotension
is marked and cardiac index is very low, epinephrine is the
drug of choice. Dopamine is not the agent of choice in
distributive shock when cardiac index is high and vascular
resistance is low. If BP is Donnal but cardiac contractility is
abnonnal, a pure inotrope, such as dobutamine or amrinone,
is preferable. 101
Dosage and Administration. As with other catecholamines, dopamine is not mixed with alkaline IV solutions
and is administered into a central vein using a continuous
infusion device. Significant skin injury from extravasation is
a risk with peripheral administration. Dextrose and normal
saline solutions are compatible.
Infusion rates of 0.5 to 2 f.lg/kg/min result in selective
DA actions on vascular beds. Infusion rates between 5 and
10 f.lg/kg/min produce dominant ~-adrenergic effects; doses
between 10 and 20 f.lg/kg/min have mixed a- and ~
adrenergic effects. a-Adrenergic effects begin to dominate
at infusion doses greater than 15 f.lg/kg/min and are
predominant with doses greater than 20 f.lg/kg/min.
Side Effects. Limb ischemia, gangrene, and extensive
loss of skin are associated with dopamine infusion in
peripheral veins and with extravasation because dopamine
both releases norepinephrine from synaptic terminals and is
converted to norepinephrine when metabolized. Local tissue
injury from extravasation is reviewed in Chapter 16.
Dopamine increases myocardial oxygen demand as increased contractility increases myocardial work. It is likely
to produce less myocardial oxygen supply and demand mismatch than epinephrine or isoproterenol because it is associated with less tachycardia; however, it is more likely to do
so than dobutamine or arnrinone.
Dobutamine. Dobutamine is synthesized to model a
catecholamine that has specific, selective inotropic action
with limited chronotropic or vasopressor activity. Infusion
of dobutamine produces prompt improvement in cardiac
perfonnance. With improved contractility, a decrease in
atrial filling pressures follows. A decrease in SVR and PVR
is associated with dobutamine. Tachycardia is unusual.
Improved CO, along with direct stimulation of the renal
dopaminergic receptors, improves renal blood flow and
urine output.
Dobutamine is most useful when the primary disturbance
impairing tissue perfusion is cardiac. Typical indications
include viral myocarditis, cardiomyopathies, or myocardial
infarction (Kawasaki disease). Dobutamine has been used as
a bridge for patients awaiting heart transplantation. Positive
inotropic effect and little increase in HR have been

demonstrated in children gi ven dobutamine for a variety of
shock states. Dobutamine is less effective in septic shock
than in cardiogenic shock. In postoperative cardiac surgery
patients, results have been uneven; children with some
CHDs had a positive inotropic response, whereas others did
not. Others demonstrated improved CO only because HR
increased. It has been postulated that those who did not
demonstrate improvement in inotropic response may not
have had significant impairment of contractility (as is the
case in many children undergoing surgery for CHDS)96
In adults with CHF, dobutamine increased myocardial
oxygen demand. However, in the absence of coronary
obstruction, coronary blood flow and oxygen supply also
increased, favorably affecting oxygen balance. 102 A similar
response can reasonably be expected in children with
depressed contractility and patent coronary arteries. Because
HR increases only modestly with dobutamine, the metabolic
demand anticipated is less than with inotropes associated
with significant tachycardia. Dobutamine is also less likely
to produce atrial and ventricular arrhythmias than other
inotropes, although these problems can occur.
Dosage and Administration. Oobutamine therapy is
initiated with a continuous IV infusion at 2 to 5 f.lg/kg/min.
Maximal effects are generally seen at doses of 10 to 15
f.lg/kg/min. The maximal therapeutic dose is not known.
Infusion is generally recommended via a central venous
line, although dobutamine does not have significant vasoconstricting effects.
Side Effects. Side effects include excessive HR and
arrhythmias, although both are less common than is the case
with other inotropes. Headaches, anxiety, tremors, and
excessive fluctuations in BP have been reported.
Amrinone. Amrinone produces positive inotropic actions on the heart and has both systemic and pulmonary
vasodilating effects. It is the first bipyridine to be widely
used in the United States for infants, children, and adults
with impaired myocardial contractility. Anuinone is a selective POE inhibitor that increases myocardial cAMP content
and provides a positive inotropic effect. It has profound
vasodilating action, also via increased cAMP. At the heart,
intracellular calcium is increased; it is blocked at the level of
the vascular smooth muscle. 103 Unlike other inotropes, POE
inhibitors improve cardiac perfonnance in the failing heart
with unchanged or reduced oxygen demand. This is possible
in part because systemic vasodilation reduces ventricular
wall stress. In addition, myocardial perfusion is increased
because coronary resistance is decreased. POE inhibitors act
synergistically with other catecholamines. They may be particularly useful for patients whose symptoms are refractory
to catecholamine therapy because of excessive SNS activation or adrenergic receptor down-regulation from lengthy
exposure to catecholamines. 103
For patients with CHF, arnrinone increases SV and
cardiac index while simultaneously decreasing SVR, CVP,
and LVEDP. Tachycardia is not observed, and both systolic myocardial contractility and diastolic relaxation are
improved.103-106 In children with a cardiac left-to-right
shunt, amrinone's pulmonary vasodilator effects appear to
be selective. In those with nonnal PAP and resistance, the
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hemodynamic effect was beneficial. In those with elevated
PAP and PVR, pressure and resistance were significantly
reduced, without causing systemic hypotension. 107 Amrinone effectively increases CO in children who have
undergone cardiac operations, including the Fontan procedure, arterial switch, and repair of complete AV septal
defect.108-IID Amrinone is useful in the treatment of both
acute myocardial failure and chronic CHF and has been
employed for patients with end-stage heart disease awaiting
cardiac transplantation. III
Dosage and Administration. Arnrinone is mixed in
normal saline (glucose solutions are not used) and is
administered by continuous IV infusion following a bolus
IV dose administered over 10 minutes. Critically ill
pediatric patients have a large volume of distribution for the
drug and require a loading dose of at least 3 mg/kg. The
recommended loading dose for adults is 0.75 to 1.5 mg/kg.
The higher dose is necessary to achieve serum concentrations similar to the therapeutic level for adults. 105. 106. I12 The
loading dose is 0.75 mg/kg, administered by IV bolus over
3 to 5 minutes and followed by continuous infusion. When
followed by a constant infusion, steady state is obtained
within I hour of initiating therapy, but the loading dose may
need to be repeated every 15 to 30 minutes. 94 .106 The usual
infusion dose is 5 to 10 Ilg/kg/min. Daily dose should not
exceed 10 mg/kg124 hours.
Side Effects. Hypotension is the principal concern,
particularly during administration of the loading dose.
Hypotension is more likely when patients have low CVP. It
is important to note that ventricular filling pressures may be
high in patients with heart failure, but when SVR is reduced
a relative hypovolemia may ensue. If hypotension occurs,
fluid therapy corrects the problem. Hypotension is avoided
by slow administration of the loading dose and by ensuring
adequate intravascular volume.
Amrinone may cause cardiac rhythm disturbances. In
adult patients, ventricular ectopy and brief episodes of VT
were seen in approximately 10% of patients, and sustained
VT or ventricular fibrillation was seen in 1%.113 The
incidence of supraventricular and ventricular arrhythmias in
pediatric patients is 3%.94 Arrhythmias may be related to the
patient's underlying pathophysiologic condition or to the
infusion rate.
Thrombocytopenia is a common adverse effect of amrinone when it is administered orally. With IV therapy, the
incidence of thrombocytopenia is far lower. When amrinone
is discontinued, the platelet count returns to normal within
several days.
Mi/rinone. Milrinone is a slightly newer member of
the bipyridine, inodilating agents with POE inhibiting
action. Its actions and indications for use are like those of
amrinone. Milrinone demonstrated potent inotropic effects
and a greater effect on both right-and left-sided heart filling
pressures (consistent with greater vasodilation) when compared with both dobutamine and nitroprusside in adult
patients with severe heart failure. 104 Milrinone administered
in pediatric patients with septic shock improved cardiac
index and decreased SVR.114.115 Pediatric and neonatal
patients demonstrated increased cardiac index and lowered
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SVR and PVR with milrinone infusion after surgery for
congenital cardiac defects.1l6.117
Dosage and Administration. Milrinone is administered
with a loading dose of 50 Ilg/kg infused over 10 minutes and
followed by a continuous IV infusion of 0.375 to 0.75
Ilg/kg/min. The volume of distribution of milrinone may be
different in pediatric patients, as it is for amrinone, but this
has not yet been systematically investigated and reported.
Milrinone is administered in normal saline or 5% dextrose
solutions.
Side Effects. Hypotension and cardiac rhythm disturbances occur with milrinone administration, as is the case
with amrinone. The incidence of thrombocytopenia with
milrinone is less than that seen with patients receiving
arnrinone.

Vasodilating Agents
Myocardial failure results in activation of a number of
compensatory mechanisms designed to maintain systemic
BP and perfusion of vital organs. Regardless of the cause of
myocardial failure, attempts at compensation are the same in
all. First, the ventricle dilates to increase EDV. Increased
EDV eventually exceeds the optimal level and is inappropriately elevated, as is end-diastolic pressure. Second is an
increase in adrenergic stimulation of the heart, augmenting
cardiac contractility and HR. Finally, SVR increases in
response to low SV, increased renin-angiotensin activity,
and other factors. In many patients with heart failure, SVR
is inappropriately elevated and will decrease Sv.
For patients with reduced SV and systemic vasoconstriction, inotropic support alone may be ineffective in restoring
adequate CO. In addition, inotropes (with the exception of
the new POE inhibitors) may exact a significant penalty by
increasing myocardial oxygen consumption. Vasodilating
agents in these patients are highly effective, augmenting CO
by changing preload or afterload conditions through relaxation of vascular smooth muscle.84.91.92 Venous vasodilators
increase the capacitance of the venous system, reducing
elevations in ventricular end-diastolic volume and pressure.
By reducing arterial vasoconstriction and afterload, arterial
vasodilators increase SV and CO. HR does not increase in
most patients treated with vasodilators. BP decreases only
slightly or not at all, as a result of increased Sv.
Vasodilators exert their positive effects on cardiac
performance while also decreasing myocardial oxygen
consumption. By decreasing preload and reducing ventricular size, in addition to decreasing ventricular systolic
pressure, myocardial oxygen needs are also reduced. Although the mechanism of action is not clearly known,
vasodilators also enhance ventricular compliance. Vasodilators shift the volume pressure curve to the right, where there
is a greater increase in EDV at a lower end-diastolic
pressure.
Vasodilators are classified based on their primary site of
action on either the arterial or venous or both (balanced)
sides of the systemic vascular bed (Table 7-9). Of note is
that all vasodilators, regardless of classification, exert some
effect on both the venous and arterial circuits. The selection
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of an appropriate vasodilator in children with cardiac shunts
is important (Table 7-10). Hemodynamic deterioration can
occur with balanced or venous vasodilators in the infant
with a large left-to-right shunt, whereas arterial vasodilators
improve systemic outpUl. 85
PDE inhibitors are often used as vasodilators because
their inotropic effect can be equally as beneficial. However,
when close and rapid titration of drug effect is needed,
medications with a short half-life (such as nitroprusside or
nitroglycerin) remain the vasodilators of choice 85 When
long-term afterload or BP reduction is required, ACE
inhibitors and third-generation ~-blockers have become the
agents of choice. Their additional neurohormonal modulation and ventricular remodeling effects are beneficial. 85
Sodium Nitroprusside. Sodium nitroprusside is a
balanced vasodilator, with approximately equal actions on
the venous and arterial circuits. It is useful to treat acute,
severe hypertension but is used more often as adjunctive
therapy in severe CHF or cardiogenic shock. Its role in
pediatric critical care may be modified as experience with
the PDE inhibitors expands.
Infusion of nitroprusside results in rapid, widespread, and
marked vasodilation affecting both the arterial and venous
systems. If SVR is not elevated, SV and cardiac index
decline and BP is reduced. HR increases reflexively.
However, when SVR is high and contractility is depressed,

~

7~9 Classification of Vasodilators
Based on Predominant Site of Action

TABLE

TABlE

7-10

Arterial

Balanced

Diazoxide
Nifedipine
Tolazoline
Hydralazine

Nitroprusside
Phentolamine
Captopril
Enalapril
Prazosin

as seen in patients with severe ventricular failure, the
reduction in afterload and preload that is achieved with
nitroprusside results in increased SV and cardiac index. The
increase in SV is proportional to the decrease in SVR. HR
declines and BP is unchanged. Nitroprusside is useful for
treating CHF and cardiogenic shock and as adjunctive
therapy for impaired ventricular performance in the immediate postoperative period following cardiac surgery.
Dosage and Administration. Nitroprusside has an extremely rapid onset and short duration of action. Peak effects
are noted within 2 minutes, and effects dissipate within 3
minutes of stopping an infusion. Administered by continuous IV infusion, the beginning dose is 0.5 )lg/kg/min. SVR
is generally reduced with doses between 1.5 and 2 )lg/kgl
min. Occasionally, doses as high as 5 to 10 )lg/kg/min are
required if vasoconstriction is profound.
Nitroprusside is administered in 5% dextrose solution
with an infusion pump. The solution is light sensitive,
requiring that solutions be used within 24 hours and that the
administration container and tubing be opaque or covered.
Side Effects. Hypotension is the most common problem
encountered with nitroprusside administration. It is rapidly
corrected by a reduction in the infusion rate but should
always prompt a reevaluation of the patient's intravascular
volume status as well.
Toxicity. Nitroprusside undergoes intravascular metabolism into both nitric oxide, the agent responsible for its
vasodilating effects, and cyanide. Cyanide is metabolized in
the liver to thiocyanate, which is then excreted by the
kidney. Accumulation of thiocyanate can develop in patients
with inadequate renal function, resulting in CNS excitation
evidenced by confusion, delirium, and seizures. Blood
thiocyanate levels are determined in patients with poor renal
function and in those who receive nitroprusside for longer
than 72 to 96 hours. Thiocyanate is cleared by dialysis.
Cyanide poisoning is the cause of death in animals given
massive doses of nitroprusside and has been reported in
humans. However, concern for cyanide accumulation has
probably been overstated. 96 Because an early sign of
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cyanide poisoning is lactic acidosis, serum lactate levels
should be monitored in patients receiving high dosages or
prolonged infusions of nitroprusside.
Nitroglycerin. Nitroglycerin is a venous vasodilator employed extensively in the critical care of adult
patients. Its major indication for use is myocardial ischemia
from coronary artery disease. Only in the last 10 to 15 years
has nitroglycerin been used to treat patients with CHF and
pulmonary edema. Another occasional indication is PAH.
The primary effect of nitroglycerin for patients with heart
failure is to reduce ventricular filling pressures by dilation of
systemic and pulmonary veins. Enlarging the venous
capacitance decreases filling pressures and ventricular
volume load, thus improving ventricular compliance. In
general, central venous, atrial, and PAW pressures are
reduced, without systemic hypotension. For patients with
acute CHF and pulmonary edema. nitroglycerin may be the
drug of choice, particularly if systemic BP is marginal.
Nitroglycerin does decrease arterial vascular resistance, but
to a lesser extent than does nitroprusside.
Nitroglycerin has been used in children with PAH
secondary to CHDs with increased PBE Some children with
preoperative PAH experience a decrease in PVR and an
increase in CO in response to nitroglycerin. The use of
nitroglycerin for treatment of idiopathic or primary PAH is
uncertain.
Dosage and Administration. Nitroglycerin migrates
into many plastics, resulting in substantial loss of medication potency when conventional polyvinyl chloride IV
administration sets are used. Dosage recommendations for
pediatric patients also are difficult to make because investigators have not reported whether special non-polyvinyl
chloride infusion sets were used. Experience with adult
patients leads to a suggested starting dose of 0.1 ~g/kg/min,
increasing the dose by 0.1 to 0.2 ~g/kg/min until the desired
effect is achieved. Administration of nitroglycerin with
non-polyvinyl chloride infusion sets is recommended to
minimize variation in dosage and the potential for error.
The nitrate pastes used among adult patients with
coronary artery disease have not been systematically investigated in pediatric patients.
Side Effects. Nitroglycerin administration increases intracranial pressure; adults report severe headache tbat
persists for several days with continued therapy. Cautious
use is necessary with patients in whom increased intracranial pressure is a potential problem. More commonly, as
with nitroprusside, hypotension complicates nitroglycerin
administration. Temporary cessation of the infusion or
reduction in the infusion dosage restores BP because the
duration of action of nitroglycerin is short. Adequate
intravascular volume is ensured, as well.
Nifedipine. Nifedipine is a vasodilator that blocks the
calcium channels in vascular smooth muscle and inhibits
contraction. Systemic and coronary artery relaxation and
vasodilation result; myocardial oxygen delivery is increased. Limited data are available regarding its efficacy in
acute heart failure in pediatric patients, but it has been used
in adults with cardiogenic pulmonary edema, chronic CHF,
vasospastic angina, and hypertension. In pediatric critical
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care, nifedipine has been used in hypertensive emergencies,lIS to treat patients with primary PAH,119 and in
children and adolescents with hypertrophic cardiomyopathy.
Truttmann and colleagues J2O cautioned against the use of
sublingual nifedipine in pediatric patients because its
BP-lowering effect is not predictable and excessive hypotension might occur.
Dosage and Administration. Nifedipine administered
sublingually, orally, or via a "bite and swallow" capsule has
a rapid onset of action. Effects are seen in 10 to IS minutes,
with peak action at 60 to 90 minutes. Patients with
hypertensive emergencies are administered a dose of 0.25 to
0.5 mg/kg, which can be repeated if needed every 4 to 6
hours. For patients with hypertrophic cardiomyopathy, the
dose is 0.6 to 0.9 mg/kg/day in three or four divided doses.
The maximum daily dose is I to 2 mg/kg/day.94
Toxicity. Calcium channel blockers have a direct depressant effect on the myocardium and must be used with
caution for patients with heart failure. However, nifedipine
has more profound vasodilating effects than myocardial
depression. Patients given nifedipine may experience headache and other symptoms and signs of vasodilation:
sweating, flushing, and feelings of warmth. Hypotension,
tachycardia, palpitations, and syncope can occur.
Diltiazem. Diltiazem is a calcium channel blocker
used for patients with angina from coronary vasospasm,
chronic stable angina, or hypertension. Recently it has
emerged as an effective agent for the termination of
paroxysmal SVT and atrial fibrillation or flutter. When used
for its vasodilating effects, a dose 1.5 to 3.5 mg/kg/day is
administered in three or four divided doses.
Angiotensin-Converting
Enzyme
Inhibitors.
Moderate to severe heart failure results in activation of
the renin-angiotensin-aldosterone system (RAAS), causing
compensatory fluid retention to maintain BP. However, the
vasoconstrictor substance angiotensin II contributes to
inappropriately elevated afterload in advanced heart failure.
It also stimulates catecholamine release at adrenal and
sympathetic nerve terminals. Catecholamines stimulate
release of renin at the juxtaglomerular apparatus, perpetuating a vicious cycle of excessive and continuous activity.
Inhibition of the renin-angiotensin system reduces afterload
and improves cardiac performance. The ACE irthibitors
(ACEls) have become practical agents for chronic afterload
reduction for patients with heart failure secondary to
hypertension, myocardial dysfunction, and intracardiac
left-to-right shunt.S5.91.92
ACEIs produce their effects through a number of
mechanisms. Angiotensin II production from angiotensin I
is inhibited, and norepinephrine release from sympathetic
nerve endings is inhibited. Also, ACEls block the enzyme
that degrades bradykinin, and circulating levels of this
potent vasodilator are increased. In addition, cardiac remodeling, a compensatory response to heart failure, is affected.
Cardiac remodeling involves compensatory hypertrophy.
Adaptive hypertrophy maintains the normal proportion of
myocytes (contractile elements) to nonmyocytes (noncontractile elements, specifically, collagen fibers) in the myocardium to preserve compliance and contractility. Aldoste-
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rone and angiotensin II playa role in collagen synthesis. 85
ACEIs prevent this development and actually reverse
maladaptive fibrosis. ACEIs produce clinical improvement
and reduce mortality for adult heart failure patients. 121.122
This may be the consequence of their salutary effects on the
myocardi urn and the down-regulation of overstimulated
compensatory mechanisms.
Captopril and Enalapril. Captopril and enalapril are
ACEls available as oral suspensions for infants and young
children. In patients with chronic heart failure, ACEIs
provide reduction in both afterload and preload. The
hemodynamic effect produced is similar to that seen with
nitroprusside: CO increases proportionately to the decrease
in afterload achieved. Because angiotensin II is inhibited,
aldosterone release is not stimulated, and potassium is
spared from renal excretion. Use in pediatric patients with
heart failure includes those with Kawasaki disease, dilated
cardiomyopathy, myocarditis, CHOs, and those with endstage heart disease awaiting transplantation. The hemodynamic improvement seen with ACEIs can be evidenced
shortly after the initiation of therapy. Adequate afterload
reduction is obtained, and CO is augmented as myocardial
function improves. However, cardiovascular remodeling is a
slower process, occurring over 6 to 12 weeks. 85
ACEIs are also useful in renovascular hypertension
and in treating patients with hypertension related to
immunosuppression following organ transplantation. BP is
reduced without postural hypotension or a reflex increase in
sympathetic nervous system activity. HR is usually not
affected.
Dosage and Administration. Captopril is administered
in a dose of 0.05 to 0.1 mg/kg every 8 to 24 hours to
neonates. Infants are prescribed 0.15 to 0.3 mg/kg/dose and
children receive 0.3 to 0.5 mg/kg/dose every 6 to 24 hours.
The maximum dose is 6 mg/kg/day; 2.5 to 6 mg/kg/day is
usually an effective dose 94 Enalapril is dosed at 0.1
mg/kg/day in one or two divided doses to a maximum of 0.5
mg/kg/day. Captopril is administered I hour before or 2
hours after meals, on an empty stomach. Enalapril may be
administered without regard to food. Enalapril is available
for IV administration for patients with severe hypertension
or acute CHF; 5 to 10 Ilg/kg/dose is administered every 8 to
24 hours.
Side Effects. First-dose hypotension can occur in
volume-depleted patients or those who are receiving intense
diuretic therapy. Tachycardia often accompanies hypotension. Lower initial doses, carefully titrated to the maximally
tolerated dose, are recommended. These effects can also
occur following a first higher dose. ACEIs can cause
immunologic side effects; the most common is a pruritic
rash, which is sometimes accompanied by fever. Neutropenia occurs in some patients and may be severe, necessitating that therapy be discontinued. Occasionally, because
ACEls impair the breakdown of bradykinin, life-threatening
angioedema develops. Increased levels of bradykinin in
the circulation may result in chronic cough. Renal side
effects include proteinuria. Potassium levels should be
monitored because hyperkalemia can occur with potas-

sium supplements, or potassium-sparing diuretics are gi ven
concurrently.
I3-Adrenergic Blocking Agents. ~-Blockers (esmolol) have been described for the management of pediatric
hypertension after surgical repair of coarctation of the aorta
and other cardiac operations. 123 Historically ~-bJocking
agents were considered to be contraindicated in patients
with heart failure because of their negative inotropic effects.
Recently attempts to modulate the neurohormonal responses
in heart failure have led to the inclusion of ~-blockers in
therapy. These agents increase LV ejection fraction, improve
contractility, reduce ventricular EOVs, decrease symptoms,
and increase survival in adults with cardiomyopathy.124
Initially, clinical symptoms may worsen as a result of
negative inotropic effects. However, the newest ~-blockers
(the third-generation medications such as carvedilol) have
added vasodilatory properties that improve their hemodynamic profile. 85 The exact mechanisms through which the
~-blockers improve cardiac performance in CHF are not
known. Likely, one of the important beneficial effects is
suppression of the deleterious effects of the catecholamines
on the failing myocardium. Increased SNS activity is
characteristic of heart failure in infants and children from
congenital and acquired causes. ~-Blockers can acutely
worsen heart failure. Precautions are necessary when
therapy is initiated. Therapy is contraindicated in patients
with significant bronchospasm, symptomatic bradycardia
or hypotension, heart block, and decompensated heart
failure. 125 Initiation of therapy with the lowest doses
of medication can minimize clinical deterioration. Worsening of clinical status is treated with diuretics. Only a
few studies report the use of ~-blockers in children with
heart failure.126.129 Clinical and ventricular function improvement was reported for some patients awaiting heart
transplantation.127.129 Low-dose ~-blocker therapy combined with digoxin and diuretics improved heart failure
scores in six infants with large left-to-right shunts. 128 Which
children may benefit most from ~-blocker therapy and
which ~-blockers are most effective have not yet been
determined.
Other New Agents. Angiotensin II receptor antagonists (AURA) have been approved for the treatment of
adults with hypertension. 125 Because they have a mechanism of action similar to the ACEIs, they are anticipated
to be effective in the treatment of heart failure. They
offer more complete blockade of the RAAS, and patients
tolerated the medication beller than the ACEIs. The
incidence of cough was decreased, and no episodes of
angioedema occurred. 130
Spironolactone, an aldosterone receptor antagonist, decreases ventricular fibrosis in cardiac remodeling, which
occurs with effective heart failure treatment. A new study
with adults combined spironolactone with conventional
therapy for heart failure, including ACEls. Morbidity and
mortality were reduced. 131 No formal studies with children
have been conducted, although spironolactone is used
routinely as a diuretic for children because of its potassiumsparing effect.
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Antiarrhythmic Agents
Recent advances in the understanding of cardiac electrophysiology have led to improved management of cardiac rhythm abnormalities. Newer, more specific antiarrhythmic agents are being developed, and older, more
traditional agents continue to undergo scrutiny in multicenter drug trials. As this evolution continues to take place,
some agents are withdrawn from use (e.g., encainide),
mechanisms of action are redefined, and indications for use
are revised. 132 Although most drug trials are performed in
adults, pediatric indications for antiarrhythmic agents continue to evolve.
With the advent of radiofrequency ablation for treatment
of many abnormal rhythms, drug therapy is often short term
and is based on efficacy rates, safety, and natural history of
the arrhythmia. Pharmacologic management can become
complex in patients who have resistant arrhythmias or when
ablation is not an option.
The Vaughan-Williams classification system for antiarrhythmics groups medications according to their predominant electrophysiologic effects. The system allows grouping
of agents with similar mechanisms of action and potential
clinical use but (like all classification systems) cannot
predict the efficacy of a given drug in an individual patient
(Table 7-11).
Class I Agents. Class I agents are "local anesthetics"
that block the sodium cell membrane channels, delay
repolarization, and have some anti vagal effects.

TABLE

,Class

7-11

Class IA Agents. Quinidine, procainamide, and disopyramide are the class fA agents. Quinidine is infrequently
used in children because of side effects (see later text),
procainamide is the most commonly used class IA antiarrhythmic in pediatrics, and disopyramide is rarely used.
Quinidine. Quinidine is the oldest of these agents and
is occasionally used for treatment of VT or VF (although
newer agents have replaced quinidine). It is a potent sodium
and potassium channel blocker with low-level etTects on
a-receptors.
Quinidine is given in a dose of 30 to 60 mg/kg/day in
three to four divided doses. A test dose (2 mg/kg) is
recommended to evaluate for idiosyncratic reactions or
syncope. IV administration is avoided. 94 In-hospital initiation is indicated because of proarrhythmic side effects.
Quinidine is metabolized by the liver, and elimination
half-life is 6 to 8 hours. This drug is extensively protein
bound, so hypoalbuminemia will increase serum levels.
Therapeutic levels range from 2 to 7 llg/ml, and toxic levels
are those exceeding 8 llg/ml.
Side effects are common and are experienced by at least
one third of patients. l33 These include gastrointestinal
disturbances, headache, tinnitus, thrombocytopenia, impaired vision or hearing, syncope, and hypotension. The
most significant side effects are cardiac, leading to potential
proarrhythmia. ECG effects commonly observed are PR,
QRS, and QT interval prolongation. Bradycardia and AV
block may be seen as well. Drug-induced torsade de pointes

Vaughan-Williams Classification of Antiarrhythmic Drugs

Major Action

ECG Effects

Examples

Sodium channel blockade

Ia: moderate decrease in conductivity, moderate
increase in repolarization

Quinidine
Procainamide
Disopyramide
Lidocaine
Mexiletine
Tocainide
Moricizine
Flecainide
Propafenone

Ib: mild increase in conductivity, shortened effective
refractory period

Ie: marked decrease in conductivity, little effect on
repolarization

"II

~-Adrenergic

blockade

Prolongs action potential and repolarization

IV

Calcium channel blockade

:Other

Digitalis glycosides

Slows conduction at AV node, decreases SA, AV nodal
automaticity
Slows conduction at AV node, decreases SA node
discharge rate
Decreases automaticity, slows conduction in AV node

9- ~-D- ribofuranosyIadenine

lWtJv.-• Atrioventricular;

i

Antagonizes endogenous catecholamines

Potassium channel blockade

'. III
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SA, sinoatrial.

Propranolol
Metoprolol
Nadolol
Atenolol
Esmolol
Amiodarone
Sotalol
Bretylium
Verapamil
Diltiazem
Digoxin
Adenosine
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is the most serious proarrhythmic effect that can lead to
sudden death.
Procainamide. Procainamide is commonly used in
the acute management of many lachyarrhythmias (SVT,
JET, atrial ectopic tachycardia) and is given as a continuous
IV infusionD4.135 Frequent dosing intervals make this a
difficult enteral drug for long-term use in infants and small
children. The sustained-release enteral form can be used in
older children and adolescents for long-term therapy.
Procainamide is a potent sodium channel blocker with no
alpha or beta effects.
An IV loading dose of procainamide is given at 5 to
l5 mg/kg over 5 to 30 minutes; in the presence of severe
hemodynamic compromise, it must be given more slowly. A
continuous infusion at 20 to 60 ~g/kg/min is titrated to keep
the procainamide blood level 4 to I0 ~g/ml. Plasma levels
are obtained 4 hours after initiation of therapy or after an
increase in dosage.94
Long-term oral therapy is dosed in the range of 15 to
50 mg/kg/day. This must be divided so that it is given every
4 to 6 hours, and older children may take a sustained-release
preparation.
Procainamide is metabolized by the liver and excreted by
the kidney. In patients with hepatic or renal disease, dosing
is adjusted accordingly. The liver metabolizes procainamide
to N-acetyl procainamide (NAPA), an active metabolite
with some mild antiarrhythmic effects. NAPA levels
are monitored during IV therapy and maintained at less than
30 ~g/ml. There is minimal protein binding.
With intravenous use, procainamide side effects are
dependent on plasma levels. Hypotension and negative
inotropy are associated with IV administration. Adverse
reactions include tachycardia, QRS and QT prolongation,
gastrointestinal disturbances, confusion, and AV block. In
children with atrial tachycardia and 2: I AV conduction,
procainamide may actually increase AV node conduction,
resulting in 1: I conduction and increased ventricular
rate. Chronic oral therapy is associated with a lupuslike
syndrome; 20% of patients may become symptomatic
and develop a positive antinuclear antibody (ANA).135
Procainamide may potentiate skeletal muscle relaxants.
Cimetidine, ranitidine, amiodarone, and ~-blockers can
increase procainamide and NAPA levels.
Class 18 Agents. Lidocaine, mexiletine, tocainide,
and moricizine are class IE agents. Lidocaine is the most
commonly used class IE agent prescribed in the pediatric
critical care setting. Mexiletine is not widely used in
children, although it is emerging as a therapeutic modality
for the treatment of congenital long QT syndrome caused by
sodium channel defects. 136 Tocainide and moricizine are
infrequently used in pediatrics.
Lidocaine. Lidocaine blocks the fast sodium channel
and shortens repolarization in abnormal cells, thus improving the overall homogeneity of repolarization with resultant
blockade of conduction. It also suppresses automaticity and
spontaneous depolarization. It is primarily used to control
symptomatic ventricular ectopy.
Lidocaine is administered as a continuous IV infusion
following a loading dose of l to 3 mg/kg; the typical

infusion rate is 20 to 50 ~g/kg/min. It is metabolized by the
liver, so the dose is decreased in the face of low CO or
hepatic disease. Active metabolites can accumulate and
cause CNS toxicity. Toxicity develops when serum levels
exceed 7 ~g/ml. 135
Major adverse reactions of lidocaine include disorientation, changes in level of consciousness, seizures, or apnea.
Nausea, vomiting, and blurred vision are less severe side
effects. Cardiac adverse reactions include bradycardia,
hypotension, heart block, or arrhythmia.
Mexiletine. Mexiletine is an oral agent structurally
related to lidocaine. Its primary effects are on the fast
sodium channels. No loading dose is required. Usual dosing
begins at 2 mg/kg per dose every 8 hours, and this can be
increased to 5 mg/kg/dose. The liver metabolizes mexiletine, so dosing is adjusted accordingly in patients. with
hepatic dysfunction. Adverse reactions are common, occurring in 20% to 70% of patients. 135 The most common
reactions are rash, gastrointestinal upset, and dizziness.
Class IC Agents. Class IC agents are potent sodium
channel blockers with variable effect on repolarization.
Flecainide and propafenone are class IC agents. They are
137
used for the chronic treatment of SVT and VT.
Flecainide. F1ecainide is a potent inhibitor of the rapid
sodium channel, slowing conduction in the atria, AV node,
ventricles, and Purkinje fibers. F1ecainide dosing is based on
body surface area (rather than weight) and has been found to
correlate best with serum trough levels. 137 Starting doses are
80 to 100 mg/m 2 , with no loading dose. Milk inhibits
absorption, so dietary changes can markedly affect serum
levels. A trough level of 200 to 1000 ng/ml is therapeutic.
Flecainide is excreted unchanged by the kidney because it is
not extensively metabolized by the liver. Half-life can be up
to 27 hours in infants and 6 to 8 hours in older children. 135
Flecainide is not given to patients with structural or
functional heart disease because the incidence of sudden
death is increased in this group. Flecainide is generally safe
in those with a normal heart. 138 The exception to this would
be the infant in incessant SVT who has CHF; once the
rhythm is controlled, heart failure is reversed. Blurred vision
can occur with overdose.
Propafenone. Propafenone has effects similar to flecainide; in addition, it has clinically significant ~-blocking
activity. The ~-blockade effects seem to vary with dose and
metabolism,132 and it is particularly efficacious in the
management of ectopic arrhythmias. Oral dosing begins at
150 to 200 mg/m 2 ; the maximum dose is 600 mg/m 2 ,
divided every 8 hours. The IV dose is 0.2 to 1.0 mg/kg given
over 10 minutes as a loading dose, and the maximum
loading dose is 2 mg/kg. Continuous infusions of 4 to 10
~g/kg/min are used. IV propafenone is associated with
significant hypotension, so concurrent IV fluid administration may be necessary. Propafenone should be used with
caution in children with structural heart disease because
sudden death has been reported in this group of patients. 139
Other side effects are similar to flecainide, including blurred
vision, paresthesias, and nausea.
Class II Agents. The class If agents are the ~
adrenergic blockers and are some of the most frequently
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used antiarrhythmics in pediatrics. The commonly used
agents are propranolol, atenolol, metoprolol, nadolol, and
esmolol. These agents differ in their ~-receptor "selectivity," half-life, and side effects. ~-Blockers inhibit catecholamine binding at the ~-receptor sites, resulting in a
decrease in HR, myocardial contractility, AV node conduction, and BE
~-Blockers are used as a single agent or in combination
with other antiarrhythmics to control SVT or to slow the
ventricular response to atrial fibrillation or flutter. 132.140
They are also the mainstays of therapy for congenital
long QT syndrome to help prevent the occurrence of
torsades de pointes associated with increased sympathetic
activity.
Propranolol is a nonselective ~-blocker that is most
commonly used to treat SVT in infants. Atenolol is the
second most commonly used ~-blocker in older children
and adolescents; it is long acting and is selective for
~I-receptors in the hean. Metoprolol is a selective ~I-agent
that is gaining favor in pediatric use. Nadolol is nonselective and long acting. Esmolol is an IV ~-blocker that is short
acting and is useful in the acute treatment of tachyarrhythmias in the PIeV.
Dosage and Administration. Atenolol, metoprolol, and
nadolol are oral agents only. Esmolol is administered
intravenously only. Propranolol can be administered both
orally and intravenously. However, IV administration,
panicularly in infants less that I year old, is associated with
significant bradycardia and hypotension. It is most often
avoided in this age-group because newer and safer intravenous agents are currently available.
Propranolol oral dosing begins at I mg/kg/day every
6 hours and can be adjusted upward to 4 mg/kg/day as
clinically indicated. The IV dose is O. I to 0.2 mg/dose over
5 minutes and necessitates vigilant monitoring for hypotension and bradycardia.
Atenolol is dosed at I to 3 mg/kg/day, given as a single
dose or divided twice a day. Metoprolol is used in
adolescents, beginning at 50 mg twice a day and increasing
to 150 to 200 mg twice a day as indicated. Nadolol dosing
begins at 0.5 to I mg/kg once daily, increasing to a
maximum of 2.5 mg/kg/d ay 94.134
Esmolol requires a loading dose of 100 to 500 J.!g/kg
given over 5 minutes. A continuous infusion is titrated to
therapeutic effect, at 50 to 200 J.!g/kg/min. Esmolol is an
ultrashort-acting ~-blocker; onset of action occurs in 2 to
10 minutes, elimination half-life is 7 to 10 minutes, and
duration of effect is up to 30 minutes.
Side Effects. ~-Blockers are negative inotropes, may
impair ventricular function, and worsen heart failure in
some patients. Acute negative inotropic effects are most
common with IV administration of propranolol. AV block,
severe bradycardia, hypotension, and asystole can occur. An
isoproterenol infusion or a temporary external pacemaker is
readied when IV propranolol is required. Hypotension can
also occur with esmolol at high doses (>200 J.!g/kg/min).
~-Adrenergic receptors in other organs can also be
blocked with class II agents, resulting in significant systemic
affects. Worsening of bronchospasm may occur in patients
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with reactive airway disease. The signs and symptoms of
hypoglycemia may be masked with ~-blockers; therefore
these agents are used cautiously in diabetics, and fasting in
all patients is to be avoided. Other side effects observed with
long-term therapy are fatigue, hypotension, mood changes,
lethargy, depression, vivid dreams, and nightmares. However, these effects are less common in the ~I-selective
agents. Slowing of the sinus node, with resultant bradycardia, can occur as well.
Class III Agents. The class III agents include amiodarone, sotalol, and bretylium. The primary mode of action
is prolongation of the refractory period. There are also
diverse drug-dependent etfects on receptor and ion channel
blockade.
Amiodarone. Amiodarone prolongs the refractory period by delaying the outward potassium channels
and prolonging repolarization. It is also a sodium channel blocker with concurrent noncompetitive u- and ~
adrenergic blockade and inhibition of presynaptic norepinephrine release.
Amiodarone is effective as a single agent or in combination with ~-blockers in the acute and chronic control of
SVT, atrial flutter, JET, and ventricular arrhythmias140-142
Amiodarone is useful in patients with structural and
functional hean disease because it is less of a negative
inotrope than other antialThythmics.
Dosage and Administration. Hospitalization for initiation of oral amiodarone is recommended to monitor for
proarrhythmic side effects (ventricular tachycardia, torsade
de pointes) during medication loading. The oral loading
dose is 10 mg/kg/day administered every 12 hours for 3 to
10 days. Neonates and infants may require loading doses as
high as 20 mg/kg/day because of erratic absorption in this
age_ group 25.141 Chronic oral therapy is 5 to 10 mg/kg/day
in a single dose. it may take several days to see clinical
effect with initiation of therapy because of the slow and
incomplete absorption. Amiodarone is highly lipid soluble
and metabolized in the liver to an active agent, desethylamiodarone. Both amiodarone and desethylamiodarone are
stored in a large volume of distribution in the body.
Therefore drug levels continue to be therapeutic for several
months after discontinuation of use. Half-life ranges from
26 to 100 days.94 Serum levels are not useful as a guide to
therapy because they correlate poorly with clinical effect.
Monitoring of blood levels may be helpful to assess if
absorption is occurring at all, panicularly in infants with
resistant SVT.
intravenous amiodarone has been shown to be clinically
effecti ve in the treatment of resistant life-threatening
tachyarrhythmias. The drug has a rapid onset of action (30
to 45 minutes), with arrhythmia suppression sometimes
occurring with the first dose.1 43 in a randomized, doubleblinded comparison trial between IV amiodarone and
bretylium for the treatment of VT and VF, amiodarone was
found to be more efficacious in preventing recurrences and
144
had fewer side effects than bretylium.
IV loading doses
begin at 5 mg/kg/dose administered over I hour, incrementally increased every 30 minutes to a maximum of 15 mg/kg
as clinically indicated. A continuous infusion of 10 to
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15 mg/kg/day may be necessary in some patients if needed
for sustained arrhythmia suppression. 142
Side Effects. The most common adverse reaction with
IV amiodarone is significant hypotension during the loading
dose. Hypotension is managed with administration of IV
volume and calcium. Clinically significant bradycardia or
AV block may occur, necessitating temporary ventricular
pacing.
The electrophysiologic effects of both oral and intravenous amiodarone include PR, QRS, and QT prolongation;
bradycardia; proarrhythmia; and AV block. ECGs are
monitored daily during drug initiation for QTc prolongation
because QTc prolongation can predispose patients to torsades de pointes.
Common noncardiac side effects include photosensitivity, chemical hepatitis, hypothyroidism or hyperthyroidism,
and corneal microdeposits. All patients taking amiodarone
should use high-grade sun screen (SPF > 15). Liver function
and thyroid function tests should be monitored every
6 months. Elevation of liver transaminases or hyperthyroidism may necessitate discontinuation of the medication.
Patients who have hypothyroidism benefit from thyroid
replacement therapy.132 Pulmonary fibrosis has been reported in adults receiving long-tenn amiodarone therapy.
This condition has been reported infrequently in infants and
children but can be identified on a CXR or pulmonary
function test. 145 Therefore all children receiving long-tenn
amiodarone therapy require periodic CXRs or (if applicable)
pulmonary function tests.
Amiodarone has a number of drug interactions. It inhibits
P-450 enzymes, so it may increase plasma concentrations of
digoxin, cyclosporine, flecainide, procainamide, warfarin,
and phenytoin. Dosage adjustment and monitoring of serum
levels of these drugs are warranted.
Sotalol. Sotalol has class III effects, as well as being a
nonselective ~-blocker. At lower doses, ~-blockade effects
predominate; at higher doses, sodium and potassium channels are affected to prolong the refractory period. Sotalol is
used for the treatment of refractory SVT and VT, often in
children with congenital heart disease.146.147 The starting
dose is 90 to 100 mg/m 2/day, incrementally increasing to
200 mg/m 2/day given in two to three divided doses. The
drug is excreted in the urine, and there are no active
metabolites. Serum levels are not helpful. Adverse effects
include headache, nausea, dizziness, fatigue, depression,
bradycardia, and proarrhythmia. The most serious side
effect is torsade de pointes, associated with QTc prolongation, although this is more commonly seen in adult patients
at higher drug doses.147.148
Bretylium. Bretylium has limited use in pediatrics
and is reserved for ventricular tachycardia that is refractory to other therapeutic interventions. With the advent
of IV amiodarone, its efficacy has been called into
question. 144 Bretylium prolongs the action potential and
refractory period. Initially it causes release of norepinephrine, then it subsequently prevents additional release and
reuptake. For life-threatening VT, the dose is 5 mg/kg IV
push, repeated every to to 30 minutes to a maximum
dose of 30 mg/kg. Continuous infusion rates are 15 to

30 Ilg/kg/min94 The primary adverse effect is hypotension
resulting from peripheral a-adrenergic blocking. Other
effects include flushing, bradycardia, syncope, confusion,
nausea, and vomiting. 135
Class IV Agents. Class IV drugs are the calcium
channel blockers. The predominant agents in use for
arrhythmia control are verapamil and diltiazem.
Verapamil. Verapamil is a calcium channel blocker
with its greatest effect on the SA and AV nodes. It is effective in suppressing enhanced automaticity and has some
a-adrenergic blocking effects. Initially it was used for acute
and chronic treatment of SVT. However, with the advent of
newer agents (particularly adenosine for acute treatment), it
is now primarily used as a second or third agent in resistant
SVT or in patients with hypertrophic cardiomyopathy. 149
Verapamil can increase the ventricular response rate in patients with WPW syndrome who are in atrial fibrillation, so
it should be avoided in this patient subset.
Dosage and Administration. Intravenous verapamil
should not be administered in infants younger than I year of
age because it can precipitate asystole and cardiovascular
collapse. In older children the dose is 0.1 to 0.3 mg/kg/dose,
and the maximum dose is 5 mg. Oral dosing ranges from 4
to 17 mg/kg/day in three or four divided doses. Elimination
half-life is 4 to 7 hours, and it is metabolized in the liver.
Low CO and hepatic dysfunction can increase half-life.
Side Effects. With oral therapy the most common
adverse effects are constipation, headaches, dizziness,
and rashes. Cardiac adverse effects include bradycardia,
AV block, and worsening of CHF resulting from its
negative inotropic effects. Coadministration of verapamil
with ~-blockers is contraindicated because of synergistic
negative inotropic effects. Intravenous administration in
infancy is contraindicated.
Diltiazem. Diltiazem was initially used for afterload
reduction in pediatrics; however, it is emerging as an
effecti ve antiarrhythmic for the control of SVT and atrial
flutter. It is a moderately potent calcium channel blocker
with no alpha effects. 150 Initial IV dose is 0.25 mg/kg as a
bolus over 2 minutes. A second bolus of 0.35 mg/kg can be
administered if necessary; this is followed by a continuous
infusion of 0.003 mg/kg/min.135.151 Oral dosing for children
has not been described. The usual dose for adolescents is 30
to 120 mg 3 or 4 times a day. This amount is adjusted
upward as needed to a maintenance dose of 180 to
360 mg/day. Adverse reactions include headache, postural
hypotension, bradycardia, and AV block.
Other Agents. Two additional medications are often
used in the management of pediatric arrhythmias. Digoxin is
probably the most widely prescribed antiarrhythmic in
children. Adenosine is an antiarrhythmic that is currently the
mainstay in emergency treatment of SVT.
Digoxin. Digoxin has both direct and indirect actions
on the myocardium. The indirect actions are due to
autonomic effects mediated by the PNS. The direct actions
are due to intracellular increase of calcium ions secondary to
inhibition of the Na-K membrane pump, resulting in
increased force of contraction. It also slows conduction
through the SA and AV node.
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Because digoxin has been used for so long. scientific
clinical efficacy trials have been limited to support its use as
an antiarrhythmic. Although digoxin is known to slow AV
node conduction, this effect is not maintained during periods
of increased sympathetic activity (exercise, stress, CHF).152
Many children with CHF develop tachyarrhythrnias and are
prescribed digoxin. Improved hemodynamics can contribute
to conversion to normal sinus rhythm; hence it is difficult to
know if digoxin prevailed as a positive inotrope or as an
antiarrhythmic. In addition, in patients with WPW syndrome, digoxin can increase impulse conduction antegrade
across the accessory tract, resulting in a rapid ventricular
response during atrial fibrillation and sudden death. 153
Nevertheless, digoxin continues to be prescribed by many
practitioners for control of SVT, atrial fibrillation, and atrial
arrhythmias. See Table 7-8 for digitalizing and maintenance
doses. When digoxin is administered intravenously, its
effects occur in 5 to 30 minutes, with peak effects in I to
4 hours. Coadministration of verapamil, propafenone,
and amiodarone increase serum digoxin levels. Digoxin
doses are adjusted to maintain therapeutic levels and avoid
toxicity.
Adenosine. Adenosine increases potassium channel
conduction and depresses the slow inward calcium current,
resulting in transient sinus bradycardia and AV block.
Adenosine is the drug of choice for the acute termination of
SVT by temporarily blocking the AV node. It can also be
helpful in the diagnosis of atrial ectopic tachycardia or atrial
flutter because it will block the AV node and slow the
ventricular response, allowing the identification of the atrial
arrhythmia.
Dosage and Administration. Adenosine can only be
given by rapid IV push (followed quickly with a 3- to 10-ml
flush); otherwise, it is ineffective as a result of rapid
systemic metabolism. Its onset of action is nearly immediate, and its half-life is less than 10 seconds; this is beneficial
in the ICU because multiple doses can be administered close
together, and side effects, if they occur, are short lived. The
initial dose is 100 ~g/kg, followed by incremental increases
of 100 to 300 ~g/kg/dose; maximum dose is 12 mg.
Adenosine is administered using a venous port closest to the
heart; a central line is preferable. Umbilical arterial catheter
administration is ineffective because the drug is metabolized
before reaching the heart.
Side Effects. Adenosine may produce transient shortness of breath and dyspnea as a result of bronchospasm,
Cardiovascular side effects include AV block, marked sinus
bradycardia, flushing, and hypotension. Generally, these
effects are short lived. Rarely, ventricular ectopy or atrial
fibrillation occurs.

MANIPULATION OF DUCTAL
PATENCY AND PULMONARY
VASCULAR RESISTANCE
The first hours and days after birth are characterized by
stabilization of the respiratory and cardiovascular systems.
Closure of the ductus arteriosus and the dramatic fall in PVR
are two of the most important events during the transition to
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establish normal postnatal blood flow patterns. Failure of
these events may result in excessive PBF or persistent
pulmonary hypertension of the newborn, respectively.
However, infants with some complex CHDs depend on
patency of the ductus arteriosus for survival after birth. For
example, neonates with decreased PBF may require a patent
ductus arteriosus to maintain adequate PBF, and neonates
with left-sided obstructive lesions may require a patent
ductus arteriosus to maintain adequate systemic blood flow.
In addition, the status of the pulmonary circulation is crucial
in the perioperative management of many children with
congenital heart disease.

Developmental Physiology
of the Pulmonary Vasculature
Fetal pulmonary vascular development parallels development of the lungs. From the sixteenth week of gestation, the
pulmonary arteries and the preacinar arteries that accompany the terminal bronchioles are present. Throughout the
remainder of gestation, respiratory units develop from the
terminal bronchioles and are accompanied by developing
intraacinar arteries and pulmonary capillaries. The preacinar
arteries have a muscular wall, as do the arteries at the level
of the terminal bronchioles. The intraacinar arteries are
largely nonmuscular. 6 ,154
In the fetus, normal gas exchange occurs in the placenta,
and PBF is low, supplying only nutritional requirements for
lung growth and performing some metabolic functions.
Only about 8% of the CO from both the right and left
ventricles perfuse the fetal lungs because of high PVR.
Conversely, SVR is low owing to the low-pressure placenta.
After birth, with initiation of ventilation by the lungs and
the subsequent increase in pulmonary and systemic arterial
blood O 2 tensions, PVR decreases, and PBF increases by
eightfold to tenfold to match systemic blood flow. The
decrease in PVR with ventilation and oxygenation at birth is
regulated by a complex and incompletely understood
interplay between metabolic and mechanical factors. Oxygenation and expansion of the lungs are independently
effective at decreasing PVR, and other factors, such as nitric
oxide and prostacyclin, have been identified as instrumental
in the drop in pressure. Previously closed peripheral arteries
are recruited for circulation; there is dilation of the
proximal, muscular arteries; and the peripheral vessels
continue to grow and branch. Although dilation of the
smallest and most distal vessels occurs across months and
muscle extension into the walls of the peripheral arteries
takes years,6.154 PVR decreases by 80% in the first hour
after birth and reaches adult levels during the first months of
life. Simultaneously, SVR increases owing to separation of
the newborn from the placenta. The consequences of the
resistance changes at birth (and other factors) are increased
PBF, improved oxygenation, and eventual closure of the
fetal shunts at the foramen ovale and ductus arteriosus.
Normal pulmonary vascular development can be disrupted by a number of problems. Abnormal structure and
function may be the consequence of maladaptation (the
fetal lung does not mature appropriately), maldevelopment
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(increased muscularization may be the consequence of
intrauterine insult or a CHD that obstructs pulmonary
venous drainage), or underdevelopment (pulmonary hypoplasia resulting from a condition such as diaphragmatic
hernia).6 Either acute or chronic fetal or postnatal hypoxia
prevents the anticipated fall in PVR after birth. Hypoxia
sustains the vasoconstricted state, and PYR and pulmonary
artery pressures remain high. CHD associated with decreased PBF may result in hypoplasia of the pulmonary
vascular bed and may increase PVR as a consequence. High
oxygen concentrations used in the treatment of neonatal
lung disease may be detrimental to both alveolar and arterial
growth and development.

Manipulating the Ductus Arteriosus
In the fetus, the ductus arteriosus is a large vascular structure
that diverts RV output away from the lungs and into the
descending aorta to be used for gas exchange in the
placenta. The vasodilating prostaglandins, PGE2 in particular, playa significant role in maintaining ductal patency in
the fetus. After birth, functional closure of the ductus occurs
over the first 12 to 15 hours, with complete closure
occurring in 50% of newborns by 18 hours and in 100% by
48 hours of life. The cessation of blood flow leads to
necrosis of the ductus smooth muscle and subsequent
fibrosis, resulting in permanent anatomic closure at 2 to
3 weeks of age. 155 Kennedy and Clark 156 first demonstrated
in 1942 that oxygen is responsible for constriction of the
ductus after birth. However, the biochemical basis for this
response remains incompletely understood.
Maintaining Ductal Patency: PGE,. In newborns
with CHDs that are dependent on patency of the ductus for
pulmonary or systemic blood flow, exogenous administration of PGE I may restore or maintain ductal patency.
This can improve arterial oxygen saturation, enhance
tissue perfusion, correct tissue hypoxia and acidosis, and
maintain systemic Bp157-IS9 Table 7-12 lists CHD types in
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7·12 Congenital Heart Defects
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TABLE

Improve Pulmonary Blood

~rFlowor

~i~Arteriovenous Mixing

To Maintain Systemic
Perfusion

Iii:"

Interrupted aonic arch
Cri tical coarctation of the
aorta
Hypoplastic left heart
syndrome
Critical aortic stenosis

which PGE I is indicated. Undoubtedly, since the FDA
approved PGE 1 for use in neonates with CHD in 1981, the
morbidity and mortality of these newborns have significantly decreased.
Infants with pulmonary atresia, tricuspid atresia, and
severe pulmonary stenosis can be better oxygenated after
initiation of PGE I ; improvement is generally seen within 30
minutes. Lack of dramatic improvement may indicate that
the ductus has maximally dilated, but pulmonary vasodilation with PGE I often enhances PBF and provides at least a
modest increase in arterial oxygen saturation. ls7 Infants
with other cyanotic CHDs, such as transposition of the great
arteries, may benefit from PGE I infusion by improving
arteriovenous mixing.
Infants with left-sided obstructive lesions may develop
cardiovascular collapse because ductal closure prevents
systemic perfusion. In those with interrupted aortic arch
(lAA), severe coarctation of the aorta, hypoplastic left heart
syndrome, and severe aortic stenosis, PGE , maintains ductal
patency with subsequent reversal of tissue hypoxia and
acidosis. Infants with these obstructive CHDs may not
respond as rapidly to PGE I as do cyanotic infants. Freed and
co-workers 157 found that infants with IAA had maximal
response in 90 minutes, whereas those with severe coarctation did not respond for up to 3 hours. In the case of a
critically ill newborn in whom either a cyanotic or obstructive heart lesion is suspected, PGE 1 is instituted quickly. The
infusion is maintained while definitive echocardiographic
diagnosis is obtained, and surgery is performed.
Dosage and Administration. PGE I can be administered
via central or peripheral IV or via an umbilical artery
catheter. Intravenous therapy is preferred because cutaneous
vasodilation may be more pronounced with intraarterial
administration. 160 The initial recommended infusion rate is
0.05 to 0.1 llg/kg/min. When improvement in arterial
oxygenation or systemic perfusion has been achieved, the
lowest dose that maintains the response is administered.
Typically, 0.05 to 0.2 llg/kg/min achieves the desired
clinical effect. The infusion is continued until surgical
intervention is provided or until further assessment shows
no need to maintain ductal patency.
Side effects. Side effects to PGE I infusion are fairly
common. Respiratory depression, evidenced by apnea or
hypoventilation, is very common. Cardiovascular side
effects, most likely related to vasodilation, include bradycardia, tachycardia, and hypotension. Infants weighing
less than 2 kg at birth experience the most significant
respiratory and cardiovascular side effects. 16O Less frequently observed side effects include seizures, jitteriness,
hypoglycemia, hypocalcemia, diarrhea, renal failure, and
clotting abnormalities. HiO

Manipulating Pulmonary
Vascular Resistance
Determinants of Pulmonary Vascular Resistance.
PVR is related to several factors and can be estimated
by applying the hydraulic equivalent of Ohm's law and
Poiseuille's law. 161 The hydraulic equivalent of Ohm's law
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states that the resistance to flow between two points along a
tube equals the pressure drop between these points divided
by the flow. For the pulmonary vascular bed, where Rp is
resistance and Qp is PBF, the pressure drop occurs from the
pulmonary artery (Ppa) to the pulmonary vein (Ppv), as
follows:
Rp = (Ppa - Ppv)/Qp
If the pressure in the pulmonary vein is substituted by left
atrial pressure (LAP) or pulmonary capillary wedge pressure
(Pcwp), then the equation is simplified as follows:
Rp = (Ppa - LAP)/Qp or Rp = (Ppa - Pcwp)/Qp
An increase in pulmonary artery pressure caused by
large communications at the ventricular or great vessel
level or pulmonary vasoconstriction secondary to alveolar hypoxia or other noxious stimuli increases PVR. An
increase in pulmonary venous pressure caused by leftsided inflow obstruction or LV dysfunction also increases
PVR. To maintain the driving pressure across the lungs,
this increase in pulmonary venous pressure also increases pulmonary arterial pressure, resulting in pulmonary edema, alveolar hypoxia, and further pulmonary
vasoconstriction.
Other factors that affect PVR can be defined by
Poiseuille's law, which describes the resistance to flow of a
Newtonian fluid through a straight glass tube of round
cross-section. When modified for the pulmonary circulation
to take into account the number of pulmonary arteries, the
following applies:

where I is the length of the pulmonary arteries, 7J is
the viscosity of blood, II is the number of arteries, and r is
the radius. As seen in this equation, changes in viscosity, the
number of small pulmonary arteries, or the radius of these
arteries affect PVR. Increasing the viscosity of blood
perfusing the lungs or decreasing the number of the small
pulmonary arteries (cross-sectional area of the pulmonary
vascular bed [nnr4 ]) increases PVR. Blood viscosity is
related to red cell number, fibrinogen concentration, and red
cell defomlability. PVR increases logarithmically with an
increase in hematocrit, and this relationship becomes
important with hematocrits above 55%. A decreased number
of small pulmonary arteries is seen in underdeveloped
pulmonary circulation, such as congenital diaphragmatic
hernia. As seen in the equation, small changes in the radius
of the small pulmonary arteries will have a dramatic affect
on PVR (r4 ); decreases in the radius increase resistance, and
increases in the radius decrease resistance. The two determinants of the internal radius are the amount of smooth
muscle present and active vasoconstriction and vasodilation.
The amount of smooth muscle found in the small pulmonary
arteries can be increased over time when the pulmonary
circulation is exposed to increased flow or pressure. After
surgical correction of the offending heart defects, these
changes in smooth muscle will slowly regress and normalize
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over months. However, pulmonary vasoconstriction and
vasodilation are very acute processes and are paramount in
regulating the pulmonary circulation in the perioperative
period.
Pulmonary Vasoconstriction and Vasodilation.
Hypoxia, acidosis, and ai-adrenergic stimulation are the
most important mediators of pulmonary vasoconstriction. 162
The ability of the pulmonary vasculature to constrict in
response to alveolar hypoxia is unique to the pulmonary
circulation and adaptive; it limits PBF in poorly ventilated lung regions, thereby preserving ventilation/perfusion
matching. Conversely, oxygen is a potent pulmonary vasodilator, selective to the pulmonary circulation with no systemic effects. Although the effects of the oxygen environment on the pulmonary circulation have been extensively
studied, their mechanisms remain poorly understood. Clinically, manipulating the amount of oxygen delivered to the
pulmonary circulation is crucial to the perioperative management of children undergoing cardiac surgery. A change in
systemic arterial pH is also a potent regulator of the pulmonary circulation. Acidosis produces vasoconstriction, and
alkalosis produces vasodilation. These effects are independent of the source (metabolic vs. respiratory) and solely
dependent on the pH. 163 The pulmonary vasodilating effects
of alkalosis are predominantly selective to the pulmonary
circulation. Lastly a,-adrenergic stimulation produces nonselective vasoconstriction, both pulmonary and systemic.
This may occur via the release of endogenous catecholamines, secondary to pain or agitation, or the administration
of exogenous catecholamines.
Hyperoxia and alkalosis most commonly induce pulmonary vasodilation. As previously discussed, these agents
induce selective pulmonary vasodilation. ~2-Receptor stimulation induces nonselective pulmonary vasodilation via
increased intracellular cAMP concentrations. Vasoactive
agents such as dobutamine and isoproterenol induce vasodilation via ~2-receptors.
Nitric Oxide. Nitric oxide (NO) is a labile humoral
factor that is locally produced in the pulmonary vascular
endothelium. It is a potent vasodilator, and its continuous
basal production is a very important regulator of normal
pulmonary vascular tone. In fact, aberrations in NO
production have been implicated in the pathophysiology
of pulmonary hypertensive disorders. 164 Nitrovasodilators
(i.e., sodium nitroprusside, nitroglycerin) are a class of
vasodilators whose clinical effects are secondary to the
stimulated release of NO. When administered, they produce
nonselective pulmonary and systemic vasodilation. When
NO is delivered directly into the airways (inhaled NO
[iNO]), it diffuses through the alveolar wall, crosses the
epithelial cell membrane, and reaches small pulmonary
arteries. Then, NO diffuses across the adventitia and enters
the vascular smooth muscle cell, where it initiates a cascade,
resulting in pulmonary vasodilation via increased intracellular cyclic guanosine monophosphate (cGMP). With entry
into the bloodstream, NO rapidly binds to hemoglobin and
is inactivated, resulting in potent selective pulmonary
vasodilation. 165 Large, randomized controlled studies have
demonstrated that iNO (5 to 80 ppm) improves oxygenation
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and decreases the need for ECMO in newborns with persistent pulmonary hypertension.I66-16~ In addition, noncontrolled studies have demonstrated that iNO does produce
potent, selective pulmonary vasodilation in many children
with postoperative pulmonary hypertension. 169 Case reports
also suggest that iNO administration during cardiac catheterization may aid in the evaluation of the vasoreactivity of
the pulmonary vascular bed, thereby distinguishing between
reactive, reversible pulmonary vasoconstriction versus residual anatomic pulmonary obstruction. 170.171 Its efficacy to
improve oxygenation, CO, or both in patients following
pulmonary-caval anastomosis or Fontan procedures is not
well documented. Optimal dosing of inhaled NO remains
unclear. The pulmonary vasodilating effects are dose dependent, whereas the improvement in oxygenation appears dose
independent. Doses of 80 ppm produce maximal vasodilation but may increase potential toxicities (see later text).
Currently, maximal doses of 40 ppm are recommended for
prolonged periods of administration, with a decreasing dosing strategy that weans to the lowest dose that maintains its
beneficial effects (2 to 5 ppm).
When iNO combines with oxygen, it is oxidized to
nitrogen dioxide (NO Z).I72 Inhalation of gas mixtures
containing high levels of NO z produces severe, acute
pulmonary injury with pulmonary edema. However, recent
advances in iNO delivery and monitoring systems have
significantly reduced the risk of NOz-induced lung injury
during iNO therapy.173 During inflammation, NO may
combine with superoxide anions to form peroxynitrate,
another potential lung toxin. 174 To date, this remains
theoretical, with no clear clinical evidence. NO that diffuses
into the intravascular space combines with hemoglobin to
produce methemoglobin. 175 At higher concentrations of NO,
clinically significant reductions of arterial oxygen content
may result (5% to 10%). At low concentrations, methemoglobin levels may increase but not to a level that interferes
with tissue oxygenation (2% to 5%). Methemoglobin levels
should be routinely monitored during iNO therapy. One of
the most important issues regarding iNO therapy is the
safety of acute withdrawal. Several studies have noted a
potentially life-threatening increase in PVR on acute withdrawal of iNO. 176 This rebound pulmonary hypertension is
manifested by an increase in PVR, compromised CO, or
severe hypoxemia. It can occur within hours after therapy is
discontinued and is independent of the patient's initial
response; patients with no initial pulmonary vasodilatory
response can have life-threatening pulmonary vasoconstriction on withdrawal. Therefore acute interruption of iNO
therapy must be avoided during suctioning, and the dose
must be slowly weaned before termination. Current FDA
approval for iNO is ljmited to neonates with hypoxemic
respiratory failure.

Increasing Pulmonary Vascular Resistance
Infants with single ventricle physiology (HLHS) or with
defects that result in parallel pulmonary and systemic
circulation (truncus arteriosus) require a balance between
pulmonary and systemic blood flow for support of optimal

hemodynamics. The former also frequently depend on a
PDA or surgically created shunt for pulmonary blood flow.
The balance of pulmonary (Qp) and systemic (Qs) blood
flow is critically important for survival and is ideally
maintained at I. A Qp/Qs of greater than one occurs with
excessive pulmonary blood flow and results in systemic
hypoperfusion and metabolic acidosis. A Qp/Qs of less than
one results from pulmonary undercirculation and results in
systemic hypoxemia. Due to the parallel relationship of the
pulmonary and systemic circulation in this population,
changes in the relative vascular resistance can result in
hemodynamic instability and death.
If pulmonary vascular resistance falls significantly, then
pulmonary blood flow will increase at the expense of
systemic flow. The administration of oxygen, hyperventilation, alkalosis, and systemic vasoconstriction may potentiate
pulmonary vasodilation and are avoided. Nonetheless some
infants continue to demonstrate pulmonary overcirculation
requiring additional therapeutic interventions.
Maneuvers to increase pulmonary vascular resistance
include hypoventilation, ventilation with hypoxic gas mixture (subambient oxygen) or added carbon dioxide (COz).m
To monitor clinical effect, Saoz and Svo z measurements
provide an estimate of adequate Qp/Qs. Excessively low
Svoz suggests pulmonary overcirculation with subsequent
low systemic blood flow. Clinical indicators of perfusion
(skin temperature, pulses, skin color) and blood gases are
monitored closely as well. Poor perfusion and metabolic
acidosis suggests decreased systemic blood flow.
Controlled mechanical hypoventilation will result in COz
elevation, increased PVR, and decreased pulmonary blood
flow. To prevent atelectasis, the rate is gradually decreased
while maintaining the same tidal volume. 178 This intervention requires neuromuscular paralysis to prevent the normal
physiologic increase in respiratory rate that occurs with
hypercarbia.
Hypoxic Gas Ventilation. Ventilation with subambient oxygen involves the addition of nitrogen (N z) to room
air to achieve an FIO z of 15% to 20%. This has been shown
to increase pulmonary vascular tone, increase PVR and PAP,
and decrease pulmonary blood flow.178o.178b Ideally systemic blood flow will improve as a consequence.
Dosage and Administration. Pure Nz (0% oxygen)
is blended into room air; as the N z flow increases, the
downstream FIOZ will fall. Usually the nitrogen can be
administered at low flows «2 Llmin) and is titrated to
therapeutic response. An oxygen-analyzing port is inserted
downstream for continuous monitoring and adjustment of
the desired FIOZ' This intervention can be used with
cannulae, hoods, manual ventilation bags, and ventilators.
Careful monitoring of gas mixture and FIOZ is imperative; if
bulk gas flow is turned off, the consequence will be delivery
of 0% oxygen.
Toxicity. Toxicity from Nz administration is secondary
to the sequelae of subambient oxygen and not to direct
delivery. As previously discussed, high flows of Nz will
significantly decrease inspired oxygen concentration; therefore careful monitoring is critically important. Chronic
hypoxia contributes to morphologic changes in the pulmo-
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nary bed with subsequent arterial medial thickening. 178b
Hence long-term therapy should be avoided.
Carbon Dioxide. Carbon dioxide is a potent pulmonary vasoconstrictor. The administration of CO 2 gas in
increasing increments of 1% FIC02 has been shown to
augment pulmonary vasoconstriction, increase PVR and
PAP, decrease pulmonary blood flow, and increase systemic
blood flow. 178c. 178d
Dosage and Administration. The usual concentration ofCOz in room air is 0.03%. The addition of CO 2 to the
inspired gas mixture is titrated to clinical effect; usually an
FICOZ of I % to 4% is sufficient and does not result in a
subambient gas mix. Different concentrations of COz have
different magnitudes of effect on PVR. 178e In general the
Pacoz is kept between 40 and 50 mrnHg. Inspired CO 2 gas
can be used with hoods, manual ventilation bags, or
ventilators.
Toxicity. Toxicity is generally the result of the sequela
of CO2 administration. The lowest possible FlC02 should be
administered to prevent excessive pulmonary vasoconstriction. Monitoring of inspired gas mix and arterial blood gases
will prevent complications. Significant elevation of Paco z
will produce cerebral vasoconstriction and an ensuing fall in
cerebral perfusion. Careful monitoring of neurologic status,
anterior fontanel, and head circumference is important in
these critically ill infants.

PACEMAKER THERAPY
Technologic advances in pacemaker therapy and a greater
understanding of the electrophysiologic mechanisms of
cardiac rhythm abnormalities have contributed to the safety
and efficacy of temporary and permanent pacing in children.
In the PICU the most common indication for temporary
pacing is transient heart block associated with congenital
heart surgery. In addition, many nonsurgical patients may
require temporary pacing to support CO in the presence of
symptomatic bradycardia. Overdrive pacing can be effective
in the termination of tachyarrhythmias, such as atrial flutter
and SVT. It is also implemented as an adjunctive therapy to
establish AV synchrony in postoperative JET. Temporary
pacing can be accomplished through the use of epicardial,
trans venous, esophageal, and transthoracic noninvasive
pacing electrodes. Permanent pacing is not discussed
because this therapy rarely warrants lCU management.

Indications
Bradyarrhythmias. Sinus or AV node dysfunction
after surgical repair of congenital heart disease is the most
common cause of symptomatic bradycardia in infant~ and
children. Transient AV block is thought to be the result of
surgical manipulation or suturing near the conduction
system, but it can also be secondary to acid-base or
electrolyte abnomlalities. Depending on the surgical procedure performed, temporary atrial or ventricular epicardial
pacing wires are placed in the operating room for use if
indicated. Atrial epicardial pacing wires can also be used
to obtain an atrial electrogram to assist in the diagnosis
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of tachyarrhythmias. Postoperative heart block usually
resolves within 7 to 14 days, with subsequent restoration of sinus rhythm. 31 When AV node recovery does
not occur and temporary external pacing is required for
longer than 10 days, permanent pacemaker implantation is
recommended. 179
Congenital CHB can occur in infants with and without
structurally normal hearts. The risk for heart failure,
syncope, and sudden death exists in both groups; however, those with structural heart disease have greater
morbidity and mortality rates associated with CHB. Pacing
is indicated for one or more of the following: CHF,
ventricular rate less than 55 in infants and less than 40 in
adolescents, QTc prolongation, syncope, or frequent ventricular escape beats. 34
Conduction disturbances, heart block, and subsequent
bradycardia can occur secondary to infection. Although rare,
viral myocarditis is associated with AV node block and
ventricular arrhythmias. 18o Often this phenomena is transient; however, the rare patient will require temporary
supportive or permanent pacing.
Other Rhythm Disturbances. Although less common than brady arrhythmias in infants and children, other
rhythm disturbances may be treated with temporary or
permanent cardiac pacing. SVT, atrial fluller, and JET can be
pace terminated with both temporary or permanent devices.
Newer innovative indications for pacing include hypertrophic cardiomyopathy, congenital long QT syndrome,
and cardioinhibitory neurally mediated syncope. Generally,
these children undergo implantation of a permanent pacemaker without the need for temporary pacing.

Temporary External Cardiac Pacing
A temporary pacing system consists of a generator, connecting cable(s), and pacing leads. Lead and generator selection
is determined by clinical indication and institution preference. PICD nurses should be familiar with the specific
device used in their unit.

Temporary Pacing Leads
Epicardial Leads. These leads are routinely placed
after most cardiac surgeries. Epicardial pacing leads vary
somewhat among manufacturers, but in general, they are an
insulated multifilament stainJess steel wire with the pacing
end consisting of a solid electrode that fixates to the heart.
A needle is connected to the proximal end to bring the lead
out through the chest wall, the needle is then broken away,
and the remaining end functions as the contact pin to
connect to the cable. Physician preference and clinical
indication determine lead placement. Two pairs may be
placed on the free wall of both the right atrial and ventricular
epicardium; or one epicardial lead is placed on the
respective chamber, and the second of the pair is secured to
the sternum or subcutaneous tissue. Either method of lead
placement results in a bipolar configuration. The epicardial
lead is always the negative (-) pole, and the skin is the
positive (+) pole.181.182 If there are two functional epicardial
leads, they can be used as either (+ or -) pole. Atrial leads
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can be used to pace the atrium and provide AV synchrony in
the presence of sinus node disease or JET. However, the
presence of complete AV node block precludes the use of
single-chamber atrial pacing. In this situation a dualchamber system, using atrial and ventricular leads, provides
the best physiologic support. Occasionally only ventricular
leads are placed for backup support in the event of acute
bradycardia. When both atrial and ventricular leads are
placed, the atrial leads are brought out through the chest to
the right of the sternum, and the ventricular leads are
brought out to the left of the sternum. To aid in easy, rapid
identification of the pacing leads, it is helpful to label them
accordingly as soon as the patient arrives to the PICU from
the operating room.
Ideally, epicardial leads will sense the underlying rhythm
and pace reliably. However, these leads are made for shortterm use, so sensing and pacing abilities usually decrease
with time. IHZ In addition, in children who have undergone
previous cardiac surgeries that result in epicardial adhesions
and scar tissue, myocardial pacing thresholds (minimum
amount of current to consistently pace the heart) may be
high. Scarring (that occurs over days in the immediate postoperative period) around the lead also elevates pacing and
sensing thresholds. This must be monitored closely and
pacemaker settings adjusted accordingly.
Temporary Transvenous Leads. Transvenous pacing leads are placed percutaneously through the femoral, jugular, or subclavian veins into the right atria
or ventricle. The pacing catheter is a self-contained bipolar
system with two pins at the proximal end for placement
into the connecting cable or generator. The most common indication for this type of pacing is temporary
support of the child with congenital CHB or to support
children with temporary heart block secondary to myocarditis or infection.183.184
This form of pacing has several limitations in children.
First and foremost, ventricular perforation can occur because these pacing leads are rather stiff, and for best results
the catheter tip should be positioned into the RV apex.
Ventricular perforation can result in loss of capture,
pericardial effusion, and cardiac tamponade. Second, lead
dislodgment with subsequent loss of capture can occur in up
to 25% of temporary trans venous pacing systems. 185 Finally, the risk of infection increases if the catheter is in place
for greater than 72 hours because it is placed like a central
line. These pacing catheters should be cared for in the same
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manner as a central line, performing sterile dressing changes
according to unit or hospital protocol. 186
TransesophageaJ Leads. Bipolar pacing catheters
designed for positioning in the esophagus just behind the left
atrium permit temporary atrial pacing, as well as recording
of an atrial electrogram. Generally, this system is used for
the diagnosis (transesophageal electrophysiology study) and
termination of SVT. Occasionally it is used for treating
symptomatic bradycardia when the AV node is intact
(because esophageal pacing is ineffective in the presence of
AV node block). For consistent capture of the atrium,
high-energy outputs are required. This stimulus can be quite
painful for the child, so sedation and analgesia is necessary.
Temporary Pulse Generator. The pulse generator is
battery powered and contains the internal software to both
sense the patient's native rhythm and to provide the
electrical stimulus (output) to depolarize (capture) the
myocardium. These devices can vary slightly among manufacturers, but in general, they allow rapid manipulation of
HR, mode of pacing, timing intervals, electrical output, and
sensitivity.
Many devices include the manually operated ability to
temporarily provide rapid atrial pacing (rates of 200 to 800
beats/min) for burst atrial pacing in an effort to terminate
SVT or JET. Although lifesaving, operation of this mode
requires close patient monitoring and personnel skilled in
burst atrial pacing.
Pacing Modes. Modem pacemakers offer a number
of features in an effort to replicate physiologic cardiac
rhythm and provide rhythm modulation as clinically indicated. To facilitate common understanding among healthcare providers, the North American Society of Pacing and
Electrophysiology (NASPE) and the British Pacing and
Electrophysiology Group (BPEG) devised a generic pacemaker code (NBG code) to describe the types and function
of different devices (Table 7-13). The five-position code is
for permanent pacemakers; temporary devices use the first
three codes. In practice the pacing mode is described as the
three letter acronym that corresponds to the NBG code.
The first letter corresponds to the chamber paced
(A, atrium; V. ventricle; D, dual or both). The second
letter corresponds to the chamber sensed (A, atrium;
V. ventricle; D, dual or both). The third letter corresponds
to the generator activity in response to sensing (0, none;
T, triggered; I, inhibited; D, dual, both inhibited and
triggered).

o = dual

IV
Programmable
Functions

V
Antitachyarrhythmia
Function

0= none

0= none
P = pacing (antiarrhythmia)
S =shock
o = dual

P = simple

programmable
M = multiprogrammable
C =communicating

R =rate modulated
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For example: AAI mode indicates that the atrium is
paced, the atrium is sensed, and the generator is inhibited if
it senses native atrial electrical activity (a P wave). As
expected, this mode of pacing is contraindicated in the
presence of complete AV node block. VVI mode provides
single-chamber pacing and sensing in the ventricle only, and
pacing is inhibited in the presence of native ventricular
electrical activity (R wave). This mode provides HR
support, but it does not provide for AV synchrony because it
has no pacing or sensing function in the atrium. AOO, VOO,
and DOO pacing provide asynchronous pacing in the
atrium, ventricle, or both chambers, respectively. These
modes are to be avoided (except in emergencies where VOO
is best) because intrinsic activity is not sensed and
competition can occur. Competition is when the generator
continually paces without regard for the patient's intrinsic rhythm. If left unchecked, it can result in "R on
T" phenomena, with possible development of ventricular
tachycardia or fibrillation.
The best physiologic mode of pacing is DDD. This mode
paces and senses both atrium and ventricle. In addition, it
provides triggered and inhibited activity in response to
sensed native electrical activity. If the sinus rate is sufficient
and heart block is present, the generator will sense the P
wave, wait the preset AV interval (corresponds to PR
interval on surface ECG), and then begin "looking" for a
native R wave. If AV conduction does not occur and there is
no native R wave, the generator will pace the ventricle. This
behavior can occur over a range of operator preset atrial
rates and is referred to as "tracking." So if a patient has a
physiologic increase in sinus rate, the pacemaker can
respond accordingly, increasing the ventricular pacing rate
to increase CO and meet metabolic demands.
Pacemaker Settings. The newer generators allow
the setting of the mode, pacing rates, timing intervals,
output, and sensing to best facilitate support of cardiac
rhythm and hemodynamics. Figure 7-60 shows one type of
temporary generator.
In single-chamber pacing (AAI, VVI) the rate determines
how low the patient's HR must fall to activate pacing. For
example: If the low rate is set at 100, the generator is
inhibited (will not pace) as long as the intrinsic HR is above
100 beats/min. If the intrinsic HR falls below 100 beats/min,
the pacemaker will begin pacing. In the DDD mode, there
are two rate settings-low and high rate. The low rate
indicates how low the intrinsic sinus rate must fall before the
generator paces the atrium. The high rate determines
the tracking rate of the ventricle in response to an increase
in the sinus rate. If the sinus rate exceeds the high rate, the
generator will exhibit Wenckebach or 2: I AV blocking
behavior (the P wave is sensed, but there is not corresponding ventricular pace) to prevent rapid ventricular pacing in
response to atrial tachycardia or flutter. The high rate set is
dependent on the preset timing intervals.
The timing intervals that can be manipulated on temporary generators include AV interval and postventricular atrial
refractory period (PVARP). The AV interval corresponds to
the PR interval on ECG and is the time between atrial sense
or pace and ventricular sense or pace. This interval is not
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available for programming in single-chamber pacing. The
duration of the AV interval should be long enough to allow
physiologic atrial contraction with subsequent diastolic
filling. In the DDD mode, this interval will adjust automatically (to a certain extent) according to changes in the
patient's HR. The PVARP is the time interval during which
the atrial lead does not sense or respond to intrinsic atrial
activity. This is protective in two ways. First, it can prevent
ventricular pacing in response to premature atrial contractions. Second (and more importantly), it prevents sensing of
retrograde P waves that can follow ventricular pacing if the
AV node is capable of retrograde conduction. The phenomenon of atrial sensing of retrograde P waves with subsequent
ventricular tracking and pacing is responsible for pacermediated tachycardia (PMT). Therefore the PVARP should
be long enough to prevent PMT but short enough to
allow sensing of increased sinus rates (usually about
275 milliseconds).
Output is the electrical current that depolarizes the
myocardium. This is programmed as milliampere (mA); the
higher the mA the higher the output. The minimum amount
of output required to consistently capture the chamber being
paced is the capture threshold. Capture can be determined
by the consistent presence of a P wave after atrial pace and
a QRS after ventricular pace. Usually the output is set 2 to
3 times higher than the capture threshold to allow a margin
of safety.

Fig. 7-60 Temporary external demand. dual chamber pacemaker.
(Copyright 1998 by Medtronic, Inc. Reprinted with permission.)
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Sensing behavior of the generator implies the ability to
recognize intrinsic atrial or ventricular depolarization.
Sensing in the atrium is determined by the amplitude of the
P wave and in the ventricle, by the amplitude of the R wave.
This is programmed as millivolts (mV); lowering the mV
setting increases sensitivity, and increasing the mV setting
decreases sensitivity. For example: If the ventricular sensitivity is set at 10 mV, the intrinsic R wave amplitude must
be greater than or equal to 10mV to be sensed appropriately.
If the intrinsic R wave amplitude drops to 5 mV (less than
10 mV), it will not be sensed. So decreasing the programmed setting to 5 mV will increase the sensitivity
because now the R wave will be sensed if it is 5 or 10 mV.
The level at which the generator consistently senses intrinsic
activity is termed the sensing threshold. Generally, the
programmed sensing setting should be half the sensing
threshold (e.g., if threshold is 8, sensing should be set at 4);
this provides a margin of safety and ensures appropriate
sensing as P and R wave amplitudes vary.

Nursing Care of Patients With
Temporary External Pacemakers
Nurses who care for patients supported by temporary pacing
should be thoroughly familiar with the specific devices used
in their units and with the unit's policies and procedures
regarding temporary pacing. All of these children require
continuous ECG monitoring and close observation. In
addition, a number of nursing interventions should be
followed to prevent complications.
The pacing leads can deliver extraneous electrical current
to the heart, producing microshock and the subsequent
development of lethal arrhythmias. The PICD environment
is replete with electrical equipment (IV pumps, electric
beds, ventilators, lamps, etc.) that are capable of current
leakage. All electrical equipment must be serviced regularly,
and all plugs must have a ground prong. Patients vulnerable
to microshock should not use electric hair dryers, fans,
razors, and curling irons. Low humidity and carpeted floors
increase the occurrence of static electricity, both of which
can contribute to microshock. Care should be taken to prevent exposure of uninsulated pacing leads or cables. When
in use the entire system should be kept intact. If the leads are
not being used, they should be isolated and protected by
placing in a glove, finger cot, or dry glass phlebotomy tube.
If the leads remain attached to the connecting cable, then the
end of the cable should be isolated or placed in the generator. Some centers recommend using gloves when handling
transvenous or epicardial leads. 187
Infection is always a nosocomial risk of any invasive
intervention. Transvenous pacing catheters should be treated
like central lines, with dressing changes carried out according to unit policy. The care of epicardial leads is less well
defined. The site should be cleansed daily and kept clean and
dry. The type of agent used for site cleaning, the type of
dressing, and frequency of dressing change vary greatly
among centers. 186 Site care is often difficult because of the
proximity of epicardial leads to chest tube sites. The care of
epicardial pacing leads is an area that would benefit greatly
from nursing research to help delineate practice.

Another challenging aspect of care in this population is
the prevention of inadvertent pacemaker adjustment by
inquisitive, mobile infants and toddlers (or siblings). Many
of the newer devices have a lockout setting to prevent such
an occurrence. Older devices have a plastic shield that
should be kept on at all times.
Although nursing practices vary among institutions,
every effort should be made to determine capture and sensing thresholds on a daily basis. Frequently in the postoperative period, thresholds increase, and daily assessment will
allow settings to be adjusted accordingly. See Box 7-6 for
guidelines for the systemic assessment of capture and sensing thresholds.
Timely recognition and intervention of pacemaker dysfunction are critically important. Always evaluate the patient
first. In emergencies, cardiopulmonary resuscitation (CPR)
should be instituted while someone else simultaneously
troubleshoots the pacing system. If the patient is hemodynamically stable, then one can proceed with troubleshooting, as described next. Pacemaker-dependent patients
should have a fresh battery or extra generator at their
bedside in the event of battery depletion.
Troubleshooting
Pacemaker Dysfunction. The most common reasons
for abnormal pacer function are undersensing, oversensing,
and noncapture (Table 7-14). Fusion beats do not denote
abnormal pacemaker function but should be corrected to
prevent competition.
Undersensing occurs when the pacemaker fails to detect
intrinsic cardiac depolarization and continues to pace
regardless of the native rate of rhythm. This can result in
competition or R on T phenomena with the possible
development of lethal arrhythmias. Possible causes are lead
fracture or disconnection from the heart or generator,
sensitivity set too low (higher mV number on generator), or
low battery. To correct this problem, make sure that all
connections are tight, replace the battery, change leads
and/or increase the sensitivity setting by adjusting the
sensitivity control to a smaller number.
Oversensing occurs when the device detects noncardiac
electrical events (extraneous electrical sources, muscle
movement) and interprets them as cardiac depolarization.
The pacemaker is then inhibited when it should not be,
which can produce significant bradycardia or asystole in
pacemaker-dependent patients. Causes of oversensing are
shivering, chest wall fasciculation caused by emergence
from depolarizing neuromuscular blocking agents, or ungrounded electrical equipment. Measures to prevent this
problem include decreasing sensitivity (adjust sensing
level to higher number) and removing all ungrounded
equipment.
Loss of capture occurs when the output stimulus from
the pacemaker fails to depolarize (capture) the myocardium.
This can result in loss of atrial kick in the case of atrial
pacing, or it can result in clinically significant bradycardia in
pacemaker-dependent patients. Causes include lead disconnection or fracture, low battery, output set too low, or an
increase in the pacing threshold caused by edema or
scarring. Interventions include ensuring all connections are

Chapter 7 Tissue Perfusion

~

213

Box 7-6

Guide to Pacemaker Checks

Note: This should not be done if the patient is pacemaker
dependent with an unstable underlying rhythm.
1. Patient is connected to the pulse generator and is monitored continuously on ECG.
2. Set pulse generator's rate 10 beats/min slower than
patient's intrinsic rate. (The "sense indicator" wi II
flash regularly.) Do not continue if the patient becomes
hemodynamically unstable.
3. Reduce output (mA) to the minimum value of 0.1. (Doing
this avoids risk of competitive pacing.)
4. Increase the sensitivity value until the ECG indicates that
the pulse generator is delivering its output pulses asynchronously. (The sense indicator will stop flashing, indicating a loss of sensing. The "pace indicator" will start
flashing. Capture is not likely to occur at the minimum
output [rnA) value.)
5. Decrease the sensitivity value until the ECG indicates that
asynchronous pacing is no longer occurring. The sense indicator light will start flashing, indicating that sensing
has been restored. (The pace indicator will stop flashing.)
The value when this occurs is
the sensing threshold for the chamber being
sensed.

tight, changing leads, replacing the battery and/or increasing
the output in the noncaptured chamber.
Fusion beats are noted when an atrial pacing spike
occurs simultaneously with a native P wave, or a ventricular
pacing spike occurs simultaneously with a native QRS. In
the case of atrial fusion, decreasing the rate is helpful so that
the pacemaker will be inhibited; also, atrial sensing can
be increased. In the case of ventricular fusion, either the
rate can be decreased (VVI mode), the AV interval can
be prolonged (DOD mode), or ventricular sensing can be
increased.

Noninvasive Transthoracic Pacing
Temporary transthoracic cardiac pacing is used primarily
during emergency situations for the treatment of hemodynamically significant bradycardia that does not respond to
oxygen, hand ventilation, epinephrine, or atropine. The
primary advantage of this mode is that application can be
achieved without interruption of CPR.
Most modern defibrillators have multifunction pads that
allow both defibrillation and noninvasive transthoracic
pacing (NTP). Therefore a single set of pads can be used for
both emergent interventions. NTP can be used in the
single-chamber (VVI) demand mode if the patient is
connected to the ECG on the defibrillator, or it can be used
asynchronously. Unfortunately a high output current (40 to
60 mAl is usually required to consistently capture the
ventricle secondary to chest wall impedance. 185
Implementation of NTP. The posterior multifunction electrode is applied on the patient's back to the left of
the spine and below the scapula (Figure 7-61 j. Positioning

6. Set sensitivity value to half ('/2) the sensitivity threshold
value. This provides a margin of safety, allowing for
continued sensing during threshold variation.
Example: Sensitivity threshold = 5 mV
Set sensitivity =2.5 mV
7. Ensure rnA is at lowest value.
8. Set pulse generator at least 10 beats/min faster than the
patient's intrinsic heart rate. (The pace indicator will be
flashing regularly at the set rate.)
9. Increase the output (rnA) to gain I: I capture. This value
is the stimulation threshold for the chamber being paced.
(The pace indicator will be flashing. and the sense
indicator will not flash.) If the patient does not tolerate
pacing, turn down the rate or rnA (remember the
threshold) until the patient's native rate is present.
10. Set the output value 2 to 3 times higher than the threshold
value. This safety margin will allow threshold variation
while maintaining capture.
Example: Stimulation threshold =2.5 mA
Set output =5 to 7.5 mA
11. For continuous pacing, set the pulse generator rate appropriate for age and clinical condition. For backup pacing,
set the generator rate at an age-appropriate lower level.

the electrode over large bony areas is best to be avoided
because bone increases the impedance to pacing. The
anterior electrode is placed in the V 2 to V5 position on the
precordium. In the vernacular, a "heart sandwich" is made
with the pacing electrodes. If the electrodes are used
for a prolonged period, they should be changed every 24
hours. Prolonged use decreases the effectiveness of the
contact gel.
The pacemaker is turned on, the rate is set at an
age-appropriate level, and the output is increased until
consistent ventricular capture is demonstrated on the monitor. As with any emergency cardiac maneuver, a pulse
should be palpated to ensure adequate CO.
Troubleshooting Common NTP Problems. The
most common clinical problems encountered with NTP are
painful stimulation, undersensing, and loss of capture.
Painful Stimulation. NTP is quite painful because
high outputs are required to pace the heart; this also
produces chest muscle contractions. Sometimes the contractions are so severe that the patient appears to be levitated off
the bed. Pain is minimized if the pacing threshold is set at
the lowest effective level. Almost uniformly, conscious
patients require sedation.
Undersensing. Unnecessary pacing may occur when
the pacemaker does not sense the patient's intrinsic HR.
Most often, contact between the electrode and the patient's
skin is inadequate. Adherence may lessen across time,
especially in the presence of diaphoresis, and should be
checked regularly. When the multifunction electrodes are
changed, it is important to remember to tum off all
pacemaker controls or turn the function control knob to
"monitor only" to avoid accidental electrical shock.
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Postoperative Left Ventricular Dysfunction
Failure to wean from cardiopulmonary bypass
Refractory left ventricular dysfunction in the intensi ve
care unit

Preoperative Left Ventricular Support
Anomalous left coronary artery
Pretransplant bridge

B

Medical Support
Myocarditis
Kawasaki disease
Sepsis with ventricular dysfunction
Persistent ventricular arrhythmias
From Hawkins lA, Minich LL: Intra-aortic balloon counterpulsation in pediatric
cardiac patients. in Duncan BW, ed: Mechanical circulatory support for
pediatric cardiac parients, Washington DC. Marcell Decker (in press).

Fig. 7-61 Positions of the multifunction electrodes for noninvasive transcutaneous pacing. A, "Heart sandwich" is made with the
pacing electrodes. B, Posterior electrode is applied to the back left
of the spine and below the scapula. (Courtesy Zoll Medical
Corporation, Burlington, Mass.)

successful option in the management of pediatric patients
with reversible cardiac dysfunction.

Loss of Capture. Loss of capture can occur because
of changes in patient position, which may decrease adherence of the electrode or loosen pacer connections. Measures
to prevent poor contact between the electrode and the
patient's skin are crucial.
Changes in the patient's physiologic status can influence
pacemaker capture. With all types of cardiac pacing, the
pacing threshold may change with electrolyte imbalance,
acid-base imbalance, myocardial ischemia, hypoxia, and
new drug therapy. Reassessment of the pacing threshold
with any of these changes is necessary to avoid loss of
capture.

The primary indicatioll for mechanical circulatory support is
persistent low CO despite maximal medical therapy. Before
the decision is made to provide mechanical support, cardiac
dysfunction should be deemed reversible. Whenever possible, a neurologic examination should be performed to
evaluate for the presence of a neurologic insult that would
exclude a reasonable recovery. In cardiac surgery patients
who are not able to be weaned from cardiopulmonary
bypass or who demonstrate postoperative low CO, residual
structural lesions should be ruled out before the initiation of
mechanical support. The definition of maximal medical
therapy and the threshold for initiating mechanical support
may be individualized. For example, mechanical support
may be initiated earlier in postoperative neonates with
single-ventricle physiology because their ability to compensate is limited. Finally, providing support for persistent low
CO early avoids prolonged end-organ ischemia and worse
clinical outcomes.
The choice of mechanical support method is largely
dependent on institutional experience and support. Specific
indications for IABP in children include poor peripheral
perfusion, persistent metabolic acidosis, mixed venous P0 2
persistently less than 25 torr, urine output less than I
ml/kg/hr, and LA pressure greater than 20 mmHg. 188
Cardiac arrhythmias secondary to inadequate coronary
blood flow may also be an indication for IABP therapy.
Clinical situations that may warrant the use of lAB P therapy
are listed in Box 7-7. Contraindications in children include
the presence of a patent ductus arteriosus, recent coarctation
of the aortic arch repair, significant aortic valve insuffi-

MECHANICAL SUPPORT OF
CARDIOVASCULAR FUNCTION
Mechanical circulatory support after the failure of conventional medical management is now an established treatment
option for infants and children with reversible cardiac
dysfunction. The modalities available for support, however,
are limited because of small patient size and available
technology. In adults with LV failure secondary to cardiac
surgery or myocardial ischemia, the intraaortic balloon
pump (IABP) has been widely used with high success rates
and is the primary method for mechanical circulatory
support. In children, the success of ECMO in neonates with
pulmonmy dysfunction has led to its application as the
primary method for mechanical circulatory support in
infants and children. With the introduction of pediatric
centrifugal pumps, however, the VAD has also become a

Indications for Mechanical
Circulatory Support
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ciency, severe LV dysfunction, and irreversible myocardial
dysfunction. Coagulation disorders are a relative contraindication, potentially leading to uncontrolled bleeding at the
insertion site.
With the limited cardiac support from the IABP. many
institutions provide VAD or ECMO support for patients with
cardiac dysfunction. Although ECMO was more commonly
used in the past. the introduction and success with centrifugal VADs have made this a reasonable option in children
who do not require pulmonary support. Indications for
the use of ECMO and VAD for cardiac support are noted
in Box 7-8.
Although the choice between VAD or ECMO for cardiac
support may largely depend on institutional experience and
preference, specific clinical criteria in addition to understanding the advantages and disadvantages of each modality,
may assist in the selection of the appropriate mode of
support for a particular clinical situation. When pulmonary
support is required in addition to cardiac support, ECMO is
preferred. However,-many children with hypoxemia secondary to LV dysfunction and pulmonary edema may no longer
require pulmonary support after the decompression of the
left ventricle with an assist device. When cardiac support
alone is required, either left ventricular or right ventricular,
a VAD is sufficient for support. If biventricular support is
required, a biventricular assist device (BVAD) (one VAD for
the right ventricle and one for the left ventricle, used in
series) or ECMO may be used. Some institutions prefer
ECMO in this situation because it requires only two
cannulation sites compared with four cannulation sites
required for BVAD. This factor may be particularly impor-

~

Box 7-8

Indications for the Use of ECMO and VAD
for Cardiac Support

Inability to wean from cardiopulmonary bypass
Postoperati ve
Low cardiac output
Cardiac arrest
Intractable arrhythmias: intractable ventricular tachycardia
(VT) or junctional ectopic tachycardia (JET) with hemodynamic compromise
Pulmonary hypertension not responsive to medical therapy
and nitric oxide
Nonsurgical reversible myocardial injury
Acute myocarditis or cardiomyopathy
Bridge to transplantation
Preoperative or postoperative pulmonary dysfunction
Persistent pulmonary hypertension in neonates
Pulmonary hemorrhage
Postbypass pulmonary dysfunction
Neonatal respiratory distress or meconium aspiration in a
neonate with congenital heart disease
From Reddy YM, Hanley FL: M.echanical support of the myocardium. In Chang

AC

et

aI, eds: Pediatric cardiac intensive care, Baltimore. 1998. Williams

& Wilkins.

ECMO, Extrdcorporeal membrane oxygenation; VAD. venrricular assisl device.

tant when BVAD is indicated in neonates. In the clinical situation where a VAD is used to support one ventricle, the dysfunction of the other ventricle may be
unmasked, making it necessary to transition the child to
BVAD or ECMO.
Some authors suggest that small patient size is an indication for ECMO for cardiac support; however, recent success
with the VAD in young infants has been reported.189.191 In
one series, 38 of 53 patients supported with a VAD weighed
less than 6 kg, and the probability of weaning was similar to
that for the older patients. This included the successful VAD
support of a 1.9-kg baby with Taussig-Bing anomaly and
arch obstruction who was placed on a VAD after a postoperative cardiac an·est. 189
The presence of an intracardiac communication (patent
foramen ovale or atrial septal defect) may be a contraindication for a VAD. In this case, the use of a left ventricular
assist device (LVAD) would result in a right-to-Ieft atrial
shunt and systemic arterial oxygen desaturation. A right
ventricular assist device (RVAD) would result in a left-toright atrial shunt and decreased systemic CO. ECMO may
be the therapy of choice in this situation. Contraindications
for both ECMO and VAD may include severe dysfunction of
other organ systems (specifically, CNS) before support
initiation and extreme prematurity.191
ECMO and VAD systems can be used to resuscitate children having cardiac arrest in the PICU after cardiac surgery.
The advantage of the VAD system for resuscitation is the
short time it takes to assemble and prime the extracorporeal
circuit (approximately JO minutes). In this case, CPR is
initiated, the chest is opened, and the cannulas are placed. At
this point the VAD circuit is primed and ready to implement,
resulting in shorter resuscitation times. The recent use of
rapid-deployment ECMO systems, however, has demonstrated success with ECMO as a method of support during
cardiac arrest. 192 Modified ECMO circuits that are vacuum
and carbon dioxide primed are available to initiate support
within IS minutes of notification of their need.
Advantages and disadvantages of each system exist. The
primary advantage of ECMO is that it is more widely
available in pediatric centers because of its use for
pulmonary support in neonates. In addition, ECMO can use
peripheral neck or groin cannulation, whereas VAD cannulation requires a sternotomy with direct access to the atria
and aorta or pulmonary artery. The prinnary advantage of the
VAD is the simplicity of the circuit, making it easy to
assemble. prime, and maintain. In addition, the absence of
an oxygenator in the VAD circuit results in less anticoagulation requirement, less blood trauma, and less bedside
nursing support. ECMO traditionally uses two nurses at the
bedside, one for patient care and one for circuit maintenance
and monitoring, whereas the VAD circuit uses one nurse for
both the patient care and circuit inonitoring. Circuit
monitoring for the VAD is usually a shared responsibility
among the nurse, physician, and perfusionist. Finally, the
VAD or BVAD more effectively performs LV decompression. With ECMO support the presence of LV distension
often requires LA venting with an additional cannula or
balloon atrial septostomy.
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Intraaortic Balloon Counterpulsation
The IABP uses the principle of counterpulsation. With the
balloon placed in the upper thoracic aorta, it inflates at
the onset of diastole with aortic valve closure and deflates
at the onset of systole with aortic valve opening. Inflation of
the balloon results in displacement of blood volume, thereby
augmenting diastolic pressure and coronary artery blood
flow. Deflation of the balloon results in aortic afterload
reduction and reduction in aortic impedance to LV ejection,
thereby decreasing myocardial work and increasing CO.
Additional benefits seen in adults include a reduction in
LAP, LVEDP, and PA pressure. 188 RV function has also been
shown to improve in adults receiving IABP therapy for
cardiogenic shock. 193
Despite its widespread use in adults, the application of
IABP in pediatric patients has been limited. Historically, the
unavailability of small balloon catheters has been the
primary limitation for its use in infants and children.
Currently, however, the use of IABP has increased in some
centers with the development of smaller balloons that can be
used in infants. The relative small size of the femoral artery
in comparison with the size of the catheter, the increased
compliance of the immature aorta, and the limited improvements in CO continue to limit its use in pediatric patients. In
addition, higher heart rates in children make it difficult to
synchronize the IABP, and there is no direct support of the
right ventricle. The increased compliance and distensibility
of the immature aorta have been suggested to reduce both
the afterload benefits and the diastolic augmentation in
children younger than 5 years of age. 194 Other investigators,
however, have demonstrated clinical improvements in
diastolic augmentation in even young infants. 195 Finally,
increases in CO have not been quantified in pediatrics and
presumably do not exceed the 10% gains reported for adult
patients. 196 Therefore IABP must be used in adjunct with
pharmacologic support to optimize CO. The use of inotropic
support may not allow sufficient rest of the sick ventricle.
For severe myocardial dysfunction, mechanical support
modalities that can maximize CO and provide ventricular
rest may be warranted.
Equipment and Insertion. The balloon pump consists of two components: the balloon catheter itself and the
console that regulates balloon inflation and deflation.

TABLE

Pediatric balloons range from 2.5- to 20-ml inflation
volumes, mounted on catheters from 4.5 to 7 Fr. These
catheters, unlike the adult-size balloons, do not contain an
arterial pressure lumen for monitoring the central aortic
pressure. The guidelines for choosing an appropriate-size
catheter are delineated in Table 7-15.
The IABP console regulates the pumping of helium gas
into the balloon chamber. The light weight of helium allows
the gas to be displaced rapidly in and out of the balloon. The
console controls allow operator regulation of the IABP
triggering and timing of balloon inflation and deflation. A
variety of ECG or arterial pressure signals can be used to
regulate the balloon triggers, or what the pump should
recognize as systole and diastole. The operator can then
fine-tune the balloon timing, including both inflation and
deflation points, to optimize hemodynamic parameters.
The balloon may be inserted in the intensive care unit,
cardiac catheterization laboratory, emergency room, or
operating room. The femoral artery is the most common site
for insertion. Although percutaneous insertion is used in
adults, catheter placement in infants and children requires
surgical exposure of the common femoral artery, a 4- to
5-cm longitudinal arteriotomy, and placement of a sidearm
synthetic graft around the artery and catheter. Once in the
vessel, the catheter is advanced to the thoracic aorta and
positioned with the tip of the balloon I to 2 em distal to the
left subclavian artery. The catheter is then sutured in place
and covered with a sterile occlusive dressing. When
hemostasis is achieved, a heparin infusion is initiated
to maintain a partial thromboplastin time (PTI') of 40 to
60 seconds.
The catheter is then connected to the gas lil)e of the IABP
console, and pumping is started. If femoral artery cannulation is impossible, the catheter may be inserted via
sternotomy directly into the aortic arch or possibly into the
external iliac artery through an anterior flank incision.
Balloon Timing. Optimal timing of balloon inflation
during diastole and deflation before systole is crucial
(Figure 7-62). With a second set ofECG electrodes attached
to the patient and the IABP console, initial timing is
obtained from the R wave of the ECG tracing while
monitoring the arterial pressure waveform. In this mode the
IABP uses ECG signals to determine systole and diastole,

7-15 Guidelines for Sizing Intraaortic Balloon Pump Catheters in Children
Weight
(kg)

Balloon
Volume
(ml)

Catheter
Size

<8
8-13
13-18
18-40
>40

2.5
5.0
7.0
12.0
20.0

4.5
5.5
5.5
7.0
7.0

1"

~<I

~1-2.5

~2.5-5

,",i

ffi:5-12
~>12

;.'

~::From Hawkins lA. Minich
~il!ediarric cardiac
llii
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(Fr)

Balloon
Length
(em)

Balloon
Diameter
(mm)

10.7
12.8
14.2
17.8
19.4

6
8
9
10
19.4

LL: Intra-aortic balloon counterpulsation in pediatric cardiac patients. in Duncan BW. ed: Mechanical circulatnry .nipport/or

patients, Washington DC, Marcell Decker (in press),
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B

A

Fig. 7-62 Intraaortic balloon position during inflation (A) and deflation (B). (Courtesy Datascope
Corporation.)

automatically deflating with R wave sensing to avoid
balloon inflation during systole. Balloon inflation is timed to
occur with the midpoint of the T wave, which coincides with
the onset of diastole. 197
Once initiated, timing is adjusted manually to obtain
maximal diastolic augmentation and a maximal decrease in
peak systolic pressure. This can be achieved through the
comparison of augmented (balloon-assisted) and nonaugmented beats on the arterial waveform when the IABP is
inflated every other beat (1:2 augmentation). Timing of
balloon inflation just before the dicrotic notch (before the
onset of diastole) has been advocated to increase the
duration of assisted diastolic perfusion. 198 Use of the arterial
waveform, however, may not be accurate because of the
delay between the central aortic pressure and the peripheral
arterial pressure that is frequently monitored in children. In
this case, the observed dicrotic notch may not accurately
reflect diastole; therefore, if the balloon is inflated during
this time, it may actually be during late diastole, and
deflation may not occur until after systole has begun. Some
investigators believe the best timing can be obtained when
initial triggering is obtained from the ECG in combination
with M-mode echocardiography. With this method, echocardiography provides simultaneous images of the balloon
and the aortic valve, allowing precise adjustments to be
made so that balloon inflation and deflation coincide with
aortic valve closure and opening. 199
Rapid heart rates in children may require special timing
considerations. In the past, 1:2 balloon assistance was
advocated when the HR exceeded 160 beats/min 2uo Recent
improvements in compressor response time and the use of
echocardiographic timing, however, have allowed better
tracking ability at very high heart rates, allowing I: I balloon
assistance. In this situation, the gas is shuttled back and forth
quickly, causing more rapid diffusion of the helium, which

results in the need for manual filling of the balloon every
I to 2 hours.
When optimal timing has been achieved, hemodynamic
benefits are evident both clinically and on the arterial BP
tracing. Diastolic augmentation should reach suprasystolic
levels, meaning the balloon-assisted diastolic pressure
becomes the highest point on the waveform. Afterload
reduction is evidenced by a decreased systolic pressure
following balloon inflation, as well as by lowered aortic
end-diastolic pressures (Figure 7-63). In reality, these
"ideal" tracing landmarks are not always evident, despite
clinical improvements in CO and tissue perfusion. Additional indications, such as decreased HR, and improvements
in urine output, mixed venous oxygen saturation, and
peripheral perfusion should be monitored to evaluate the
effectiveness of the balloon pump.
Continuous hemodynamic and HR monitoring provides
evidence of the need for IABP timing adjustments, which
- should be made for signs of deteriorating clinical status, a
change in cardiac rhythm, or HR changes greater than
10 beats/min.20 1 Improper IABP timing can result in
suboptimal cardiac support or severely compromised cardiac ejection.
Nursing Care. Care of the child receiving IABP
therapy requires expert nursing knowledge of cardiac
physiology, as well as knowledge and skill of the IABP
device. The potential infrequent use of this therapy makes it
difficult to maintain nursing competency and experience.
Typically, nursing care is provided by two nurses: one to
care for the patient and one to monitor and manipulate the
balloon pump. Nursing care responsibilities include manipulating the pump, monitoring hemodynamics, evaluating the
effectiveness of the therapy, assessing the progression of
cardiac failure, monitoring for complications of the therapy,
and providing family education and support. Nursing care
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Arterial pressure waveform characteristics during intraaortic balloon counterpuisation therapy.

may be more complex than in adults because of the
challenges of timing requiring frequent manual timing and
the difficulty in the interpretation of IABP waveforms.202
Once IABP therapy is initiated and minor adjustments in
balloon timing are complete, an hourly assessment is
performed that includes recording of IABP parameters,
evaluation of hemodynamic parameters, assessment of leg
perfusion distal to the catheter, urine output, and laboratory
results 202 The ECG tracing and the IABP waveforms are
constantly monitored to interpret the effectiveness of
balloon pumping. Timing is evaluated every I to 2 hours
along with the manual filling of the balloon.
Continuous monitoring and evaluation of the effectiveness of IABP support are crucial. Frequent assessment of
hemodynamic parameters should reveal the anticipated
benefits of IABP counterpulsation, including signs of
increased CO, decreased SVR and filling pressures, and
improved end-organ perfusion. Failure to achieve these
parameters may be the result of improper IABP timing,
arrhythmias, catheter dislodgment or damage, or worsening
ventricular function.
Catheter migration may result in decreased perfusion of
either the kidneys or left arm. An abrupt cessation of urine
output may indicate downward balloon migration with
obstruction of the renal arteries. Upward balloon displacement can result in obstruction of the left subclavian artery,
resulting in impaired left arm perfusion. Correct IABP
position should be evaluated with a daily chest radiograph.
Careful assessment of the cannulated lower extremity is
also important. The quality of peripheral pulses should be
assessed before and after balloon placement to note changes
from baseline. Asymptomatic loss of palpable distal pulses
occurs commonly after IABP insertion and often does not
progress to severe limb ischemia. If systemic output is
improved after balloon placement, tissue perfusion to the

cannulated leg may improve despite diminished distal
pulses. Signs of more severe obstruction to blood flow,
including pain, pallor, or mottling, and decreased sensation
or loss of motor function should be aggressively evaluated.
Weaning From IABP. Weaning from IABP can be
initiated when hemodynamics are stable, pharmacologic
support has been significantly reduced, and improvements in
cardiac function are evident. Echocardiography is often used
to evaluate LV shortening fraction and ejection fraction to
document improvements in ventricular function before
weaning from IABP.
Weaning to discontinuation of support is usually performed over a 24- to 48-hour period. Weaning is achieved
by decreasing the frequency of augmentation from every
beat (I: I) to every second, fourth, or eighth beat (I :2, 1:4,
I :8). During this process the nurse monitors and evaluates
the patient for signs of failure to wean, including signs of
decreased CO and tissue perfusion, increased fi lling pressures, and cardiac arrhythmias. Pharmacologic support may
be increased at this time to optimize cardiac function. If
weaning is tolerated, the catheter is removed surgically, and
the incision is closed. Embolectomy catheters may be used
immediately after catheter removal to remove any clot
trapped in the femoral artery.lss Careful assessment of distal
extremity pulses and perfusion following the discontinuation of therapy is critical to identify thrombus formation or
distal embolization of clot.
Outcomes. In 1980, Pollock and co-workers l94 reported the use of IABP in 14 children between 1.5 and
18 years of age following cardiac surgery. Although six
children (43%) were long-term survivors, no child under the
age of 5 years survived. They concluded that young children
with minimal CO and immature aortas could not be
adequately augmented with the IABP. Later, this same series
was reported with additional patients. With the improve-
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ments in equipment, they reported the successful augmentation of CO in a 2-kg infant with LV failure of unknown
cause. The total number of patients over a lO-year period
was 38 with a 37% survival. In this group, the patients with
the highest mortality were those who were postoperative
Fontan patients.
The largest series to date reports the use of IABP in
43 patients over a 15-year period. This series included
both postsurgical and medical patients ranging in age from
5 days to 18 years, weighing 4.2 to 40 kg; 19 of the patients
were less than 3 years of age. In this series, 51 % of the
patients were weaned from the IABP, and 42% were
long-term survivors. With increased experience over the
15 years, improvements in technology, and the implementation of echocardiographic timing, the more recent survival
in this group has improved. Since 1994, reported survival
has been 78%.188
Complications reported with the use of lABP include
limb ischemia, renal failure, mesenteric ischemia, balloon
rupture, vessel perforation, hematoma, and wound infection.
The increased experience and improved technology, however, have shown a decrease in these complications. Pollock
and colleagues 194 reported that 14% of the patients suffered
severe leg ischemia, 14% experienced renal failure, and 7%
had abdominal distension. More recently, Hawkins and
Minich l88 reported that over the last 10 years, complications related to IABP therapy have been few. In 22 patients, I patient had limb ischemia and I developed sepsis; however, neither complication required removal of
the lABP.

Ventricular Assist Devices
A VAD is an extracorporeal pump that takes over a variable
percent of left or right ventricular output. It is used in
situations of life-threatening ventricular dysfunction. Although several types of VADs exist, the centrifugal pump is
most commonly used for temporary cardiac support in
children. The primary advantage of the VAD is its ability to
support 100% of the CO, thereby allowing the inotropes to
be weaned and the heart to sufficiently rest and recover. In
addition, the VAD is a simple extracorporeal circuit and
pump that requires little manipulation once support has been
initiated.
Pneumatic VADs can be used in adult-size children,
usually in the setting of bridge to transplantation. They
consist of a paracorporeal air-driven blood pump, and an
electropneumatic driving system that provides pulsatile
blood flow. The blood pump circuit consists of short
segments of tubing that connect directly to the intracardiac
cannulas, artificial ventricles that house a blood chamber,
and an air chamber separated by a polyurethane membrane.
The console allows adjustments of HR, drive pressure, and
percentage of systole to optimize hemodynamics. The
system can be operated in an asynchronous mode or
triggered by the ECG for cardiac synchrony. Although there
are case reports of their use in small children, pneumatic
VADs are currently limited secondary to size constraints,
flow requirements, and the need for multiple pumps, with

different stroke volumes to accommodate a wide range of
pediatric sizes.
The centrifugal VAD pump transports blood through an
extracorporeal circuit by imparting kinetic energy to it
(Figure 7-64). Power is applied to a magnetic pump head
that rotates a magnet in a cone-shaped impeller that, in turn,
rotates the blood inside the cone, creating a centrifugal force
that transports the blood through the circuit. There is no
obligatory volume displacement by the pump, and the flow
through the circuit is both preload and afterload sensitive.
Venous return to the pump is active and not dependent on
gravity. The revolutions per minute (rpm) are set to achieve
a desired flow (CO) through the circuit. Blood flow through
this extracorporeal circuit is continuous and nonpulsatile.
There is no reservoir, oxygenator, or heat exchanger present;
therefore, it is a completely closed system.
When a LVAD is indicated, the extracorporeal circuit
consists of a LA cannula connected by a short segment of
tubing to the cone segment of the pump. The cone segment
is connected by another short segment of tubing to an aortic
cannula. When RV assist is indicated, RA and PA cannulas
are connected to the pump tubing and pump. When
biventricular support is indicated, the left atrium and aorta
are connected to one pump, and the right atrium and
pulmonary artery are connected to a second pump. When a
VAD is indicated for a single-ventricle heart, the cannulas
are place in the common atria and the aorta. In all cases, a
flow probe is present on the inflow (aortic/pulmonary artery)
tubing. This measures the flow, or CO, provide by the VAD.
Equipment and Insertion. The Bio-Medicus (Medtronic) system is the most common VAD used in children
who require mechanical cardiac support. This system
consists of a Bio-Console, the Bio-Probe monitoring system, a disposable Bio-Pump circuit, and an emergency
handcrank. The Bio-Console contains the operator controls,
monitors, and alarms, as well as the pump receptacle. It
operates on standard line voltage or battery power. Two
pump sizes are available for support: the BP-50 Bio-Pump
is used for patients weighing less than 10 kg, and the BP-80
Bio-Pump is used for patients weighing more than 10 kg.
The '!4-inch tubing fits the BP-50 with a complete priming
volume of approximately 180 mI, and 3/.-inch tubing fits the
BP-80 with a priming volume of 350 m!. Both pump sizes
fit the same drive unit. The pump is equipped with an
internal battery that will maintain pump function when there
is not AC power. The battery, when charged, lasts approximately 45 minutes at a 3500-RPM pump speed. The
cannulas used for standard cardiopulmonary bypass are used
for the VAD.
The initiation of VAD support can occur in the PICU or
in the operating room. When initiated in the operating room,
every effort is made to control the surgical bleeding before
initiating mechanical support. When possible, the patient is
weaned from cardiopulmonary bypass, the heparin is
reversed, and clotting factors are administered. Following
this, VAD support is' initiated with limited and controlled
anticoagulation.
The cannulas are placed via open sternotomy and
connected to the extracorporeal circui t that has been primed
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with 5% albumin or whole blood. The pump head is placed
into the console, and blood flow through the circuit is
initiated by increasing the RPMs to achieve a desired
extracorporeal flow (CO). The percentage of CO provided
by the VAD depends on the degree of myocardial dysfunction. Generally, flow is increased until desired mean
systemic arterial pressure and atrial pressures are achieved.
Hemodynamic parameters, peripheral perfusion, color, urine
output, and systemic arterial blood gases are immediately
evaluated for signs of improved oxygen delivery.
The cannulas are securely sutured in place, and the
mediastinum is left open and covered with a Silastic patch.
Occasionally in older children, the sternum is left open, and
the skin is closed. A continuous infusion of heparin is
initiated to maintain an activated clotting time (ACT) of
160 to 200 seconds, depending on VAD flow rates.
Management. Care of the patient requiring centrifugal VAD support requires a highly skilled, multidisciplinary
approach to provide a safe environment, minimize complications, and promote optimal recovery. Hemodynamic
parameters are monitored and evaluated continuously. Mean
systemic arterial pressure is usually maintained at 40 mmHg
or greater in neonates and 60 mmHg in older children. 203
The arterial line will have variable pulsatility depending
on the amount of nonpulsatile flow provided by the
VAD. Therefore the MAP is monitored as a measure of
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Fig. 7·64 Left ventricular assist
device support with Medtronic BioMedicus centrifugal device. (Copyright
1990 by Medtronic, Inc. Reprinted
with permission.)

CO. As ventricular function improves and VAD support is
decreased, pulsatility on the arterial waveform should
improve. Pulse oximetry may also be difficult to monitor
because of the absence of distal pulses. In this case, blood
gas analysis should be used to evaluate systemic arterial
oxygenation.
The pump RPM is adjusted to provide a CO that results
in an atrial pressure (RA or LA) of 6 to 10 mmHg. When an
isolated LVAD is used, RA pressure is used to monitor
volume status and is maintained between 5 to 10 mmHg.
When RA pressure is elevated, RV dysfunction should be
suspected. With an isolated RVAD, LA pressure is used to
monitor volume status, assuming the left ventricle is
working adequately. In any case, atrial pressures are always
maintained over 5 mmHg to prevent any air from being
entrained into the circuit. This is especially important when
an LVAD is used because the entry of air could result in
cerebral or coronary air embolism.
A systemic continuous infusion of heparin is provided to
avoid clot formation in the cannulas and extracorporeal
circuit. When a full CO is provided by the VAD, ACT is
titrated to about 150 to 180 seconds. When pump support
is less than 50% of CO, ACT is titrated to about 180 to
200 seconds. Lower ACT (160 to 180 seconds) may be
maintained if tubing coated with the Carrneda BioActive
Surface is used. 191 The patient's hematocrit should be
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maintained at about 40%, depending on the patient's
physiology, to optimize oxygen delivery. Inotropic support
will vary, depending on the phase of the assist device period.
During the early support phase (initial 48 hours) when
nearly 100% support is provided, inotropic support should
be minimal and used to support the non-pump-assisted
ventricle (5 ~g/kg/min of dopamine, no epinephrine),
allowing optimal rest of the sick ventricle. During the
weaning phase, inotropic support will need to be increased
to achieve acceptable bi ventricular function.
Because the centrifugal VAD has no obligatory volume
displacement, the flow through the circuit is both preload
and afterioad sensitive. Changes in the patient's preload and
systemic and pulmonary vascular resistances will alter the
flow through the circuit. For example, if the patient loses
blood volume, flow through the VAD will decrease. If SVR
increases on a patient receiving LVAD therapy, this will also
result in a decreasing flow through the circuit and potentially
increasing the volume load on the left ventricle. VAD flow
alarms must be monitoring closely to detect changes in
circuit flow.
During VAD support, it is crucial that all hemodynamic
parameters are monitored and evaluated continuously to
recognize changes in VAD flow, ventricular function,
volume status, and VAD complications. Specific troubleshooting for hemodynamic parameters and complications
are listed in Box 7-9.
Nursing Care. Specific nursing responsibilities when
caring for patients on a centrifugal VAD include the
following: (I) maintaining the safety and security of the
extracorporeal circuit; (2) houriy monitoring of the circuit
for air and clot formation; (3) monitoring hemodynamic
parameters, VAD flow, and signs of adequate oxygen
delivery; (4) thermoregulation; (5) skin care; (6) assessment
and management of comfort; (7) observing for complications; and (8) support and education of the family. Collaborative responsibilities include troubleshooting, treatment of
complications, and management of emergencies.
Nurses have a primary responsibility to ensure the safety
of the patient's environment and to prevent complications of
therapy. Specific safety interventions for the VAD include
the following: (l) securing the cannula(s) to the patient;
(2) securing the circuit tubing to the patient and the bed;
(3) maintaining system security during procedures, such as
radiographic examinations, and position changes; (4) ensuring that emergency electrical power is maintained; (5) appropriately setting hemodynamic and VAD alarm limits; and
(6) carefully observing for air or thrombus formation in the
circuit. Although thrombus formation can occur at any
location in the circuit, it is more likely to occur where
connections exist, for example, in the connectors between
the cannulas and the circuit tubing. The surgeons should be
alerted of any thrombus formation. When thrombus is
removed, the patient is temporarily removed from VAD
support while the thrombus is evacuated; therefore interventions must be implemented to support the heart during this
time. Air can enter the circuit if the atrial pressure falls
below 5 mmHg. For small amount of static air, the surgeons
should be alerted and plans made to remove it. If large
amounts of air have entered and are moving toward the
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Box 7-9
Troubleshooting Patients on the Centrifugal
Ventricular Assist Device

Left Ventricular Assist Device (LVAD)
Low Left Atrial (LA) Pressure
Consider: hypovolemia, right ventricle (RV) failure, excessive
pump support, LA line in the pericardial space, malfunctioning
LA line

High Left Atrial Pressure
Consider: volume overload, worsening left ventricle (LV)
failure, inadequate pump support. LA line near the mitral valve
or wedged in the atria or pulmonary vein

Low Right Atrial (RAJ Pressure
Consider: hypovolemia. PFO or ASD, RA line in the pericardial
space

High Right Atrial Pressure
Consider: volume overload, RV failure. RA line in the RV or
wedged in the atria, PHT

Right Ventricular Assist Device (RVAD)
Low Right Atrial Pressure
Consider: hypovolemia, excessive pump support. RA line in
the pericardial space

High Right Atrial Pressure
Consider: worsening RV failure, inadequate pump support,
volume overload, RA line near the tricuspid valve or wedged in
the atria

Low Left Atrial Pressure
Consider: hypovolemia, malpositioned LA line, PFO, or ASD
High Left Atrial Pressure
Consider: LV failure, malpositioned LA line, volume overload,
increased afterload in systemic circulation

RVAD or LVAD
Deteriorating Blood Gases
Consider: worsening heart failure, primary pulmonary problem. ASD, or PFO

Inability to Maintain Adequate Flow
Consider: hypovolemia, malpositioned cannulas, thrombosis
of cannulas or circuit, kink in the circuit tubing, increased
afterload

Excessive Mediastinal Hemorrhage
Consider: overheparinization. consumptive coagulopathy, cannula dislodgment, surgical bleeding
PFO, Palent foramen ovale; ASD. atrial septal defect.

patient, it may be necessary for the nurse to emergently
clamp the aortic/pulmonary artery cannulas to prevent air
entry to the patient. When the cannulas or tubing are
clamped, the patient will be acutely removed from VAD
support and resuscitative measures should be implemented.
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Maintaining the patient's temperature is also crucial.
Without a heat exchanger in the centrifugal VAD circuit.
pediatric patients, especially neonates and infants. may
quickly become hypothermic. Every effort should be made
before the initiation of therapy to warm the patient. Such
interventions include increasing the ambient room temperature, placing a warming device under or over the patient.
and placing a warming blanket under the extracorporal
circuit tubing. In addition. the patient's temperature should
be monitored continuously to avoid sudden drops in
temperature. Cooling from the extracorporeal circuit may
mask the presence of a fever. Other signs of infection should
be monitored closely.
Careful monitoring of hemodynamic parameters, along
with VAD flow, will provide information regarding adequacy of oxygen delivery and recovery of ventricular
function. Atrial alarm limits should be set at 5 mmHg so that
the nurse is immediately alerted immediately to low atrial
pressures. Interventions must be implemented to prevent the
entry of air into the circuit. These include volume administration or lowering of the VAD flow until atrial pressure
increases to 6 to 10 mmHg. Changes in atrial pressure, BP.
and VAD flow may indicate changes in preload or afterload
and should be evaluated immediately.
Interventions to maintain skin integrity and prevent other
complications of immobility must be implemented. Patients
can safely be turned side to side even small amounts to
assess the skin and prevent breakdown on pressure points.
When doing so, one nurse should hold the cannulas and
circuit tubing to prevent accidental kinking or disconnection. When possible, the use of a pressure-reducing air
mattress should be considered before implementation of
VAD therapy. Typically these patients receive continuous
infusions of analgesics and sedatives and intennittent
neuromuscular blocking agents.
Bleeding is the most common complication associated with VAD use and therefore must be carefully
assessed and managed by the PICU team. Common causes
include surgical bleeding, anticoagulation, and coagulopathy. Assessment for bleeding complications includes
strict monitoring of chest tube output, evaluation of
hematocrit and coagulation studies, monitoring for signs
of cardiac tamponade, and observing the open chest
for accumulation of blood. Packed red blood cells, fresh
frozen plasma, and platelets may be administered to
maintain hemostasis. Careful attention must be made,
however, to the risk of thrombus fornlation in the extracorporeal circuit when fresh frozen plasma and platelets
are administered. Cryoprecipitate and vitamin K are generally avoided because of the potential for acute thrombus
formation. 204
Potential emergency situations include cardiac arrest,
circuit disruption, and pump malfunction. Box 7-10 outlines
general guidelines for the management of these emergencies. Specific measures for resuscitation should be established in each institution and for individual clinical situations. Emergency resuscitation with open chest cardiac
compressions poses a risk of cannula disruption; however,
the exact risk is unknown and may not necessitate the
avoidance of compressions. Clamps are kept at the bedside

~
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Box 7·10

General Guidelines for the Management
of VAD Emergencies

""

In the event of a cardiac arrest:
BiVAD:
Turn pumps to full cardiac support
RVAD or LVAD:
CPR to resuscitate the heart
Defibrillation for ventricular fibrillation
In the event of a circuit disruption:
Outside the chest:
Clamp the circuit tubing or cannulaes
Inside the chest:
Notify surgeons immediately-CPR
In the event of pump malfunction:
Hand crank for power failure
Notify surgeons and perfusionis!s immediately
Evaluate cardiovascular status--CPR
VAD, Ventricular assist device; CPR, cardiopulmonary

resu~citation.

for prevention of hemorrhage with circuit disruption and to
prevent air entry into the aorta. Clamps can be placed onto
the circuit tubing while the pump is running. The centrifugal
nature of the VAD flow prevents increases in circuit pressure
and leak when clamped.
Weaning From VAD. Weaning from the VAD is
accomplished when the patient's hemodynamics have improved and there is echocardiographic evidence that ventricular function has recovered. Typically, recovery can be
observed when there is a return of a pulsatile waveform on
the peripheral arterial trace on high levels of device support
(80% of the CO provided by the VAD).'9' Weaning to
discontinuation of therapy can take place in the operating
room or the PICU and usually occurs over several hours.
Once inotropic support is optimized, the VAD flow is
gradually decreased while carefully evaluating the patient's
hemodynamics. When the VAD flow is at a minimum, HR,
systemic arterial BP, atrial pressure. and arterial blood gases
are evaluated for signs of adequate oxygen delivery. In
addition, transesophageal echocardiography is performed to
evaluate ventricular function. When medical therapy is
optimized, mechanical support is completely withdrawn.
After discontinuation, the patient should be closely monitored for signs of low CO. The chest may be left open until
adequate ventricular function and hemodynamic stability
have been ensured.
Outcomes. Several small series report the use of centrifugal ventricular assist devices in children. 189-191.205-208
The most common indications for VAD support were the
failure to wean from cardiopulmonary bypass and postoperative low CO. In these series, duration of support ranged
from I to 8 days (mean of approximately 43 hours), and
survi val ranged from 3 I% to 70%. Thuys and colleagues 189
reported VAD use in 34 postoperative infants weighing under 6 kg, with the most common diagnosis being hypoplastic
left heart syndrome. Sixty-four percent of these infants were
weaned from VAD, and 31 % survived to hospital discharge.
Del Nido and associates 190 reported 70% survival in children receiving VAD support after repair of anomalous origin
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of the left coronary artery from the pulmonary anery (ALCAPA). These demonstrate the role that diagnosis may have
on survival.
In a larger series, Duncan and co-workers 191 reported the
use of VAD support in 29 children with cardiac disease.
Survival in this group was 41 %, with the most common causes of death being ventricular failure and multiple organ system failure. Patients who did not demonstrate return of ventricular function within 48 to 72 hours
of the institution of support either died or required
cardiac transplantation. Costa and colleagues 208 reported
the highest mortality to be in patients requiring support
for postoperative low CO, emphasizing the importance of
early institution of therapy to avoid multiple organ system
failure.
Potential complications of VAD therapy include bleeding, circuit thrombus fonnation, infection, air emboli,
neurologic damage, hemolysis, and mechanical problems.
Bleeding secondary to anticoagulation, surgical bleeding, or
coagulopathy is the most common complication of VAD
support. Duncan and co-workers 191 reported that 44% of
VAD patients experienced excessive bleeding. Risk factors
included chest cannulation and need for initiation of support
in the operating room. Thuys and associates 189 reported
thrombus formation in the VAD circuit to be the most
common complication, occurring in 38% of patients. Of
these patients, four required pump head changes, one
required circuit change, and eight required no intervention.
In the series listed previously, serious infections, including mediastinitis, pneumonia, and positive blood cultures,
have been reported in up to 30% of patients requiring VAD
support. Potential predisposing factors may include preoperative infection, delayed sternal closure, use of invasive
monitoring lines and catheters, mediastinal exploration for
bleeding, and prolonged ventilatory support. Measures to
decrease infection include frequent handwashing, strict
aseptic technique during contact with invasive lines, prompt
removal of nonessential lines and catheters, aggressive
pulmonary hygiene measures, and use of sterile technique
during open sternal dressing changes. Additional reported
complications, such as hemolysis and mechanical problems,
are less common but must be carefully assessed in all VAD
patients.

Extracorporeal Membrane Oxygenation
for Cardiac Support
ECMO consists of an extracorporeal circuit that contains an
oxygen membrane, a pump, and a heat exchanger. Like the
VAD, ECMO can support a variable amount of the CO. The
primary advantage over the VAD is its ability to provide
both oxygenation and cardiac support. The disadvantage
compared with the VAD is the complexity of the circuit and
the increased need for anticoagulation. ECMO for cardiac
support is used primarily in postoperative cardiac surgery
patients who suffer from low CO in addition to hypoxemia
or pulmonary hypertension. Its use in children with cardiomyopathy or myocarditis has also been described. The use
of ECMO for the resuscitation of pediatric patients with

hean disease following cardiac arrest has also been reported
with successful outcomes.I92.209
Equipment and Insertion. Techniques and systems
used for ECMO support are well described in Chapter 8. In
brief, a servoregulated flow system driven by a pump with
a membrane oxygenator and a heat exchanger is used. Blood
is drained by gravity through the venous cannulas into
the servoregulated system. Although a roller pump is
commonly used in the ECMO circuit, a centrifugal pump
can be used in its place. Premembrane and postmembrane
pressures are monitored. Venoarterial support is used in the
majority of patients; however, in cardiac patients suffering
isolated pulmonary dysfunction, venovenous ECMO may
be used.
Initiation of support can occur in the PICD or the
operating room. For cardiac patients, the site of cannulation
will vary depending on surgical preference and the clinical
situation. Patients who require immediate postoperative
support or those who require support during resuscitation
usually have transthoracic cannulas placed directly into the
RA appendage and the aorta. Peripheral cannulation via the
neck or femoral vessels may be used in patients who require
support later in their postoperative period. In general, large
venous cannulas are required secondary to the high flow
rates used for cardiac support. In addition to the RA and
aortic cannulas, the placement of an LA cannula is often
necessary. Blood return to the left atrium, along with the
increased LV afterload resulting from the high flow rates to
the ascending aorta, can cause increases in LVEDP and LAP.
To adequately rest the left ventricle and prevent pulmonary
edema, a LA cannula is placed to decompress the left
ventricle. This cannula is connected to the venous tubing of
the ECMO circuit with a Y connection. When transthoracic
cannulas are used, the chest is usually left open and covered
with a Silastic patch.
Management. The ECMO procedure for cardiac
support is similar to that required for acute respiratory
failure in children; however, the goals of support are
different. In the patients requiring ECMO for acute respiratory failure, pump flows are adjusted to achieve satisfactory arterial oxygenation. In patients with low CO after
cardiac operations, the goal is to maintain adequate tissue
perfusion while providing complete or nearly complete
cardiac bypass to prevent cardiac distension, minimize
myocardial energy expenditure, and maximize the chance of
cardiac recovery. Once support is initiated. flow rates
are adjusted to provide a systemic MAP of approximately
40 mmHg in neonates and 60 mmHg in children and atrial
pressures of 4 to 8 mmHg. Patients are assessed for a
reversal in their shock state, including improvements in
peripheral perfusion, increases in urine output. reversal of
metabolic acidosis, and improvements in systemic and
mixed venous oxygen saturations. Generally, flow rates of
IDO to 2DO mllkg/min are required to support perfusion and
allow ventricular rest. Once stabilized, inotropic infusions
are minimized to reduce their <idverse effects on the hean
and allow ventricular rest. Mechanical ventilator settings
can be minimized to prevent barotrauma and allow pulmo-'
nary recovery. Nonpulsatile flow provided by the ECMO
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circuit results in a dampened arterial waveform and the
inability to use pulse oximetry.
Children on ECMO usually receive prophylactic antibiotic therapy; however, broad-spectrum coverage is generally
avoided. Antibiotic coverage is indi vidualized when specific
organisms are cultured. Anticoagulation is provided by a
continuous infusion of heparin administered via the ECMO
circuit. Heparin is titrated to achieve an activated clotting
time of 180 to 220 seconds. Parenteral nutrition is initiated
within 24 to 48 hours. Enteral nutrition is avoided until full
recovery of the hypoperfusion state has occurred. Typically,
continuous infusions of analgesics and sedatives along with
intermittent doses of neuromuscular blocking agents are
administered.
Patients who are oliguric or anuric can receive renal
replacement therapy through peritoneal dialysis or hemofiltration. A hemofilter can be placed from the arterial tubing
to the venous tubing, essentially providing continuous
arteriovenous hemofiltration. This can provide both solute
clearance and fluid removal until renal function improves.
Countercurrent dialysate flow can be provided when additional solute clearance is required.
Weaning From ECMO Support. In general, patients
are maintained on full ECMO support for 48 to 72 hours
before any attempt to wean. The duration of ECMO when
used for cardiac support is less than when used for acute
respiratory failure. The technique for weaning is also
different. When weaning for respiratory failure, pump flow
is decreased as pulmonary function improves. When used
for cardiac failure, pump flow is gradually turned down
while maintaining adequate filling pressures and systemic
BP. Pump flow is gradually reduced in small increments
over a 12- to 24-hour period. During this time, ventilator
settings are increased to achieve adequate oxygenation,
ventilation, and acid-base status. Inotropic support is also
increased to optimize myocardial function. The pulse
contour on the systemic arterial tracing is closely observed,
along with other signs of adequate systemic perfusion. Atrial
pressures usually rise to normal or elevated levels. augmented by volume administration as indicated. Transesophageal echocardiography may be performed during the
weaning phase to assess myocardial contractility and
ventricular ejection in relation to systolic BP as blood flow
pump is decreased. Once optimal CO and pulmonary
function are achieved, the patient is tried off ECMO for
a brief period, followed by decannulation. The chest is
often left open after the discontinuation of ECMO until
optimal hemodynamics and oxygen saturation have been
achieved.
Nursing Care. Caring for the patient receiving ECMO
for cardiac support requires two nurses. One nurse provides
direct patient care while the second nurse provides the
monitoring and manipulation of the ECMO circuit. Nursing
care for the ECMO patient is well described in Chapter 8.
Specific nursing considerations are made for the patient
receiving ECM 0 after cardiac surgery. These are related to
the assessment and management of cardiac function and the
recognition and management of complications secondary to
the use of cardiac ECMO.
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Monitoring Cardiac Function. MAP, RA pressure,
and LA pressure are continuously monitored. Increases in
atrial pressures may indicate worsening cardiac function
or volume overload, whereas decreases in atrial pressures
may indicate improving ventricular function, excessive
ECMO support, or hypovolemia. Isolated increases in LA
pressure may indicate inadequate LV decompression and
should be addressed. When a LA cannula is present for
LV decompression, flow through it may be sluggish and
should be carefully monitored. When thrombus forms in
the LA vent, the tubing should be changed to avoid left
atrial and ventricular distension. HR and rhythm must also
be supported to optimize hemodynamics. Cardiac arrhythmias should be promptly treated with antiarrhythmic
medications or pacemaker therapy to maintain a normal
sinus rhythm. Additional signs of adequate oxygen delivery should be monitored closely to ensure adequate
extracorporeal support. Systemic arterial pulsatility should
improve when cardiac function has recovered, despite high
levels of ECMO support. Some patients experience systemic hypertension when receiving cardiopulmonary bypass from ECMO and may require afterload reduction. This
may be related to the renin-angiotensin response to
nonpulsatile flow.
Assessment and Management of Complications.
Bleeding is a major complication of ECMO when used for
cardiac support and may require multiple exploration of
the mediastinum to remove blood and to evaluate for
surgical bleeding. Multiple suture lines, the use of cardiopulmonary bypass, the need for systemic heparinization, delayed sternal closure, and the use of multiple
drainage tubes and monitoring lines result in generalized
chest bleeding. In addition to chest bleeding, significant
gastrointestinal, pulmonary, and intraabdominal bleeding
has been reported. Nursing interventions include careful
monitoring of blood loss, specifically through the chest
tubes. Assessment of the mediastinum under the Silastic patch is crucial to evaluate the accumulation of
mediastinal blood and the possible development of cardiac tamponade. Replacement of blood in addition to
platelets and fresh frozen plasma is often necessary.
Although bleeding can be treated with transfusions, massi ve transfusions can result in pulmonary impairment that
may impact morbidity and mortality. Ionized calcium levels
may fall when large amounts of blood transfusions are
administered. Adequate replacement of calcium must be
given to prevent negative inotrope associated with
hypocalcemia.
The nursing team must provide the prevention, assessment, and management of other potential complications.
Most commonly these include neurologic complications,
infection, and renal failure. Although the patients typically
receive continuous infusions of analgesics and sedatives,
the intermittent use of neuromuscular blocking agents
allows periods when a neurologic examination can be
performed. Clinical evidence of seizures must be reported
and managed aggressively. Neonates should receive head
ultrasounds when abnormal neurologic examinations are
present. The prevention of infection and the early iden-
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tification of infection are crucial. Prevention strategies
include meticulous dressing and wound care, sterile technique and maintenance of a sterile environment for
mediastinal explorations, limited entry into the ECMO circuit and invasive catheters, and meticulous handwashing. Although signs of infection must be monitored, it
should be remembered that fever may be masked by the
heat exchanger and changes in platelet count may be altered by the use of the extracorporeal circuit. Elevations
in white blood cell counts and positive cultures must
be aggressively treated. The presence of renal failure may
be managed by hemofiltration through the ECMO circuit.
Strict monitoring of intake and output and frequent evaluation of laboratory data are critical to avoid complications
related to hypovolemia, hypervolemia, or electrolyte
disturbance.
The stress of ECMO therapy after cardiac surgery affects
family coping. The severity of illness, sight of the extracorporeal circuit, and increased risk for morbidity and mortality
are particularly stressful to families.2 IO Preparation for
visiting, regular communication, and providing accurate
information is important. As with any critically ill child,
families must be supported in their attempts to be involved
in their child's care, regardless of their acuity.
Outcomes. Over the last decade, several centers have
reported the use of ECMO for cardiac support. 191.21 1-218 In
these series, success with weaning from ECMO support was
reported in 52% to 75% of patients, and survival to hospital
discharge has occurred in 33% to 58% of patients. In a
recent larger series, Duncan and colleagues 191 reported the
use of ECMO for cardiac support in 67 patients, with an
overall survival of 40.3%.
Several authors have attempted to detemline outcomeassociated factors for pediatric cardiac ECMO. 19 1.216-218 In
these series, factors associated with mortality included the
presence of residual cardiac defects, the presence of
single-ventricle physiology, the need to initiate ECMO
support in the operating room immediately following
cardiopulmonary bypass, renal failure, and the lack of return
of ventricular function after 72 hours of ECMO support.
Black and co-workers 216 reported the maximum time
required for ventricular recovery among 31 postcardiotomy
patients was 6 days; all children supported longer than 6
days died. Duncan and colleagues l9 ! concluded that there
were no ECMO survivors with a serum pH below 7.38 or
serum bicarbonate below 22 mmol/dl at 24 hours of ECMO
support. This finding presumably reflected the impact of
significant hypoperfusion before the initiation of ECMO
support.
The use of ECMO to resuscitate children having cardiac
arrest after cardiac surgery has demonstrated better results
than in other patient populations.192.209.215 In one series
in which eleven cardiac patients were resuscitated with
ECMO, 91 % were weaned from ECMO, and 64% were
discharged from the hospital. The reasons for better
outcomes in pediatric patients with cardiac disease may be
related to witnessed arrests in the PICO, the use of open
chest CPR, the degree of core cooling, and the possible
acute yet reversible cause of the arrest, such as cardiac
arrhythmias.

Complications reported with cardiac ECMO include
bleeding, infection, renal failure. neurologic complications,
multiple system organ failure, and mechanical problems.
When comparing ECMO and VAD therapy for cardiac
support, all complications occurred more often in ECMO
patients. 191 In one series,survival was low «22%) in
patients who had any complication.2 18 Bleeding is the most
common complication associated with cardiac ECMO,
occurring in approximately 40% of patients. Excessive
blood loss has been shown to be a risk factor for death in
ECMO-supported patients. 191 In this series, risk factors for
excessive bleeding included chest cannulation and the need
for ECMO support in the operating room.
Neurologic complications include seizures, intracranial
hemorrhage, embolus or thrombus, and anoxic encephalopathy. Although these complications may not result in death,
they have a significant impact on morbidity. Other than
intracranial hemorrhage, it may be difficult to determine if
the neurologic complications result from the ECMO or the
pre-ECMO condition.
Infection occurs in approximately 25% of patients
receiving cardiac ECMO support.191.217 Most often these
infections include mediastinitis, pneumonia, and sepsis.
Renal failure occurs in approximately 20% of patients and
often requires hemofiltration. 191 .2!8
Mechanical problems occur more often in ECMO
support than VAD support; however, they may not be
a~sociated with a significantly higher mortality. The increased mechanical problems are presumably related to the
increased complexity of the ECMO circuit. The presence of
the oxygenator is a significant source of morbidity, resulting
in trauma to blood elements and activation of systemic
inflammatory and coagulation cascades.

SUMMARY
This chapter has provided a review of fetal development
of the heart and fetal circulation and the circulatory
changes that occur at birth. Normal fetal cardiovascular
development provided a mechanism to introduce congenital
heart disease. The physical properties of the cardiovascular
system were reviewed next; including an overview of
essential anatomy, the function of the heart's electrical
system, the cardiac cycle, and regulation of CO. Attention
was directed at the effects of maturation on cardiovascular
function.
The second major focus of the chapter was assessment of
the cardiovascular system. Both physical assessment and
noninvasive evaluation were reviewed. Discussion of intensive care unit monitoring of cardiovascular function and
cardiac catheterization followed.
Sections that detailed cardiovascular support to maintain
adequate tissue perfusion concluded the chapter. Pharmacologic support, pacemaker therapy, and mechanical support
were discussed. Because cardiovascular failure and inadequate tissue perfusion (ire the final common pathophysiologic pathways in a variety of critical illnesses and injuries
in infants and children, critical care nurses must master
complex therapies and technologies aimed at restoring
health to this patient population.
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upport of oxygenation or ventilation is integral to the
practice of pediatric critical care nursing because the
majority of critically ill infants and children require
interventions to stabilize the pulmonary system. I.2 Although
general principles of care are similar within all age groups,
striking differences do exist among them.
Pulmonary system functioning continues to mature
throughout childhood. Developmental immaturity of the
pulmonary system places the infant and young child at risk
for organ system dysfunction. Respiratory failure is the
number one factor contributing to cardiopulmonary arrest in
the pediatric population?
This chapter discusses principles of oxygenation and
ventilation as they pertain to critically ill or injured children.
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Part '"

Phenomena of Concern

Essential embryology, anatomy, and physiology are reviewed. Pulmonary assessment is presented, followed by a
discussion of pulmonary intensive care monitoring, diagnostic testing, and mechanical support of ventilation. The
chapter concludes with a discussion of nursing care issues
related to infants and children who require alternative
modes of pulmonary support.

ESSENTIAL EMBRYOLOGY
The human lung is designed for the single purpose of gas
exchange across an intact alveolar-pulmonary capillary
membrane. The lungs enrich blood with oxygen and
eliminate carbon dioxide. Pulmonary function is immediately essential to extrauterine life. Embryonic development
is detailed next (Fig. 8-1).

Pulmonary development is divided into five stages,
named to reflect histologic maturation of the lung 4 The
duration of each stage can only be approximated because
fetal growth is somewhat individualized. The lung first
appears as a ventral outpouching of the primitive foregut in
the embryonic period, days 26 to 52 of gestation. The
foregut is eventually divided into a dorsal portion, the
esophagus, and a ventral portion, the trachea and the lung
buds. The primary bronchial buds split into two buds 011 the
left and three buds on the right, thus gi ving shape to the
developing bronchial tree. 5 The left lung bud develops into
two main bronchi and two lobes. The right bud forms three
main bronchi and three lobes. This early developing
bronchial tree is nourished by the main pulmonary artery.
The pselldoglandlliar period follows the embryonic
period from day 52 to week 16 of gestation. During
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Fig. 8-1 Successive stages in the development of bronchi and lungs. A to C, 4 weeks; D and E, 5 weeks;
F,6 weeks; G, 8 weeks. (From Moore KL, Persaud TVN: The developing human, ed 5, Philadelphia, 1993.
WB Saunders. p 230.)
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this period, all major conducting airways including terminal bronchioles are formed. Arterial supply throughout
the bronchial tree becomes more evident. The diaphragm, derived from the fusion of the pleuroperitoneal
folds, is formed during the eighth to tenth week of
gestation. 6
Development of respiratory bronchioles characterizes the
canalicular period, weeks 17 to 24 of gestation. Each
bronchiole ends in two or three thin-walled dilations called
terminal sacs or primitive alveoli 7 The rich pulmonary
vascular bed continues to develop as capillaries proliferate
around the terminal bronchioles.
The saccular period, characterized by intense vascularization of the lung and loss of its glandular appearance,
occurs during the weeks 28 to 36 of gestation. Elastic fibers,
important in true alveolar development, begin to develop.
For the first time, close contact between the air spaces and
the pulmonary capillaries is established. There is concurrent
active development of the lymphatic capillaries. The first
true alveoli are present at 34 weeks; gas exchange is
possible but not optimal.

blood
capillary
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The final period of development is the alveolar period,
week 36 to term. Here, further refinement of the terminal
sacs and formation of the walls of the true alveoli occur
(Fig. 8-2). Columnar cells within the alveolar wall differentiate into type I and type II cells. Type I cells provide the
alveolar surface area necessary for gas exchange. Type II
cells secrete surfactant, a complex lipid substance that forms
a monomolecular film over the walls of alveoli and is
responsible for lowering alveolar surface tension. Surfactant
is necessary for sustained inflation of the lung. Surfactant
production increases during the later stages of pregnancy,
especially during the last 2 weeks of gestation. Infants born
prematurely are at risk for surfactant deficiency, which
results in respiratory distress syndrome (RDS).
An important note is that the pulmonary system continues to mature after birth. Postnatal maturation continues
until at least the eighth year of life and perhaps into early
adolescence. Although alveoli increase in size after birth,
pulmonary maturation is primarily due to an increase in the
number of respiratory bronchioles and primitive alveolialveoli that have the potential for forming additional alveoli
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Fig. 8-2 Diagrammatic sketches of histologic sections, illustrating
progressive stages of lung development. A, Late canalicular period
(about 24 weeks). B, Early terminal sac period (about 26 weeks).
C, Newborn infant (early alveolar period). Note that the alveolarpulmonary capillary membrane is thin and that some of the
capillaries have begun to bulge into the terminal sacs (future
alveoli). (From Moore KL, Persaud TVN: The developing human,
ed 5, Philadelphia. 1993, WB Saunders, p 231)
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Changes in Respiratory System Dimensions With Growth
Newborn to
1 Month

10
7.5
40/57
4
26
4
0.3
0.07
0.2
0.1
0.03
0.05
2.8
50
3.4
0.21

Infant

1·5 Yr

14
9
42/67
5
34
4
20113
0.4
0.12
0.3
0.12
0.07
0.06-0.07
6.5

15.5
10.5
45/81
8.5
50.5
6.5
38/20
0.5
0.2
0.3
0.14
0.07
0.08-0. I0
12.5

0.3

0.46

(Table 8-1). During the postnatal period, tracheal diameter
triples, alveolar dimensions increase fourfold, and alveoli
numbers increase tenfold, resulting in 24 million alveoli
present at birth and 200 to 600 X 106 alveoli present in the
adult. 8
Congenital anomalies or malformations of the lower
respiratory tracl are relatively rare. Congenital diaphragmalic hernia occurs in approximately I in 2000 births,
whereas tracheoesophageal fistula occurs in I in 2500
births.? A congenital diaphragmatic hernia occurs when the
diaphragm fails to completely separate the pleuroperitoneal
cavity into the abdominal and Ihoracic cavities. As Ihe
herniated abdominal viscera continue to grow and develop
within the chest throughout gestation, pulmonary development is compromised. A tracheoesophageal fistula or
communication between the trachea and esophagus results
from incomplete di vision of the foregut into the respiratory
and digestive systems. Pulmonary agenesis or absence of
one lung results from the failure of a lung bud to develop.
Congenilal cysts of the lung form by dilation of the terminal
or larger bronchi. 9 If multiple cysts are present, the lung
may have a honeycomb appearance on x-ray film.

ESSENTIAL ANATOMY AND PHYSIOLOGY
Airways
The airway can be divided inlo three major areas: the
supraglottic airway, the glottis, and the intrathoracic airway.
The supraglottic airway includes the nose, the nasooropharynx, and the epiglottis. The glottis includes the vocal
cords, subglottic area, and cervical trachea. The intratho·
racic airway includes the thoracic trachea, the mainstem

6·8 Yr
19
1l.5
57
10

79

12·14 Yr

25
14.5
64
11
112

8
65/44

81/56

0.15

0.17

0.10-0.20
32
123
24
0.56

0.15-0.25

Adult

28
16.5-18.5
90-150
15-16
200-250
12
138/116
0.7
0.4
0.5-0.6
0.2
0.2
0.3
64-75
175
70
1.8

bronchi, and the lungs. Each of these areas bas unique
features in the infant and young child.
Supraglottic Airway. The nose, lined with ciliated
mucous epithelium, serves as the passageway for air. The
nasal structures are protective in that they heat, humidify,
and filter inspired air. The nasal passages are narrow, and
any factor that further decreases the diameter, for example,
secretions, edema, or bleeding, will increase airways
resistance and compromise ventilation. The newborn is
considered an obligate nose breather for at least the first few
months of life. Some infants do not mOUlh breathe until 5 to
6 months of life. Therefore any obstruction to the infant's
nares causes respiratory distress, for example, choanal
atresia. The area from the nasal cavity to the nasopharynx is
abundantly lined wilh lymphoid tissue, the adenoids or
pharyngeal tonsils, which can also obstruct the upper
airway.
The mouth of the young child is small, and the tongue is
large in relation to the mandible. The palatine tonsils are
localed at the junction of the mouth and oropharynx.
Although the tonsils are thought to prevent upper airway
infection, large tonsils can potentially obstruct the airway. In
addition to the small mOUlh and large tongue, the infant has
a large head, soft neck, and weak shoulder girdle. In total,
these factors predispose infants to airway obstruction by
position alone. To maintain an open airway in an infant with
an altered level of consciousness, the head is placed in a
neutral position, and a small roll is placed under the
shoulders.
Glottis. The infant's epiglottis is omega shaped and
floppy. The epiglottis enters the anterior pharyngeal wall at
a 45-degree angle and projects more posteriorly than in the
older child. These factors make visualization of the glottis
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Fig. 8-3 Comparative anatomy of adult and infant airways. (From Thomas DO: The ABCs of pediatric
emergencies, RN 49:34-41, 48, 1986.)

difficult in the infant and young child. 1O The epiglottis is
also very susceptible to trauma and infection, which may
cause edema and airway obstruction.
The larynx of the infant is more cephalad than in the
older child. The glottis, the area between the vocal cords, is
located between the second and third vertebrae in infants
and descends to the fourth and fifth cervical vertebrae in
adults. The infant's vocal cords are approximately 50%
cartilage and thus are less distensible than in the older child.
The cricoid ring, the only complete ring of cartilage in the
pediatric airway, is the most narrow portion of the upper
airway in infants and children, whereas the glottis is the
most narrow portion of the adult upper airway (Fig. 8-3). [n
the newborn, the cricoid ring is approximately 6 mm in
diameter, which places infants at particular risk for airway
obstruction in this area.
Thoracic Airway. From the larynx, air passes through
the trachea, which is short in the infant-approximately 4 to
5 cm long from the cricoid to the carina. The trachea is
approximately 7 cm long in the young adolescent. The
bifurcation of the trachea at the carina forms the right and
left mainstem bronchi. Because the right mainstem angles
down more vertically and is somewhat larger that the left,
objects aspirated into the airway commonly lodge in the
right mainstem bronchus.
The lower airways are smaller and less developed than in
the adult. Airway obstruction results in increased airways
resistance. Factors that impact airways resistance include
the length and radius of the airway. Critically important in
infants and children is airway radius. According to Poiseuille's law, resistance to airflow is inversely proportional

Normal
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1 mm
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( R«_1_)
radius'

x-Sect
Area

116x

!75%

13x

J.44%

Fig. 8-4 Effects of edema on airways resistance in the infant
versus the adult. Nonnal airways are represented on the left and
edematous airways (I-mm circumferential edema) on the right.
Resistance to flow is inversely proponional to the radius of the
lumen to the fourth power for laminar flow and the fifth power for
turbulent flow. The net result is a 75% decrease in cross-sectional
area and a sixteenfold increase in resistance in the infant versus
44% and threefold, respectively, in the adult. (From Cote C, Todres
!D: The pediatric airway. In Ryan IF, Todres JD, Cote C et ai, eds:
A practice of anesthesia for infants and children, New York, 1986,
Grune & Stratton, p 39.)

to the fourth power of the radius for laminar flow (I/r4 ) and
to the fifth power for turbulent flow (I Irs). Thus a reduction
in diameter by half reduces laminar flow to one sixteenth of
its former level. To maintain the same flow requires a
six teen fold increase in pressure, which significantly increases the work of breathing. II As noted in Fig. 8-4, minor
reductions in the already small-diameter pediatric airway
result in a large reduction in the cross-sectional area.
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The walls of the tracheobronchial tree are composed of
smooth muscle. The airways of the newborn contain
little smooth muscle; however, by 4 to 5 months of life,
enough smooth muscle is present to cause airway narrowing
in response to an irritating stimulus. Smooth muscle
development by I year of age is comparable with that of an
adult.
Developmental changes also take place in the alveoli
and the terminal bronchioles. The terminal bronchioles
continue branching during the first year of life. The number
and size of alveoli continue to increase until at least 8 years
of age. These changes are responsible for the increased
respiratory surface area available for gas exchange in the
older child and adult. At birth, the interstitium of the lung
contains little collagen and elastin. This may explain the
frequency of alveolar rupture in the premature infant.
Collagen and elastin production increases in the postnatal
period. 12
Little collateral ventilation exists in infants and young
children. Pores of Kohn, which allow interalveolar communication, first appear between the first and second years of
life. 13 Canals of Lambert, which allow bronchiole-alveolar
communication, start to form after age 6. 14 With age, both
structures allow ventilation of alveoli distal to an obstructed
airway. Absence of collateral pathways contributes to patchy
atelectasis when airways disease is present in infants and
young children. 12

Thoracic Cavity
The ribs. vertebrae, and sternum provide the bony framework of the thoracic cavity. Within the thoracic cavity lie
three lobes of lung on the right, two lobes of lung on the left,
and the mediastinum, which is off center to the left
containing the heart, great vessels, esophagus, and trachea.
The entire thoracic cavity is lined with parietal pleura,
whereas the lungs are encased by visceral pleura. In health,
the potential space between the pleura is filled with just
enough fluid to allow the two pleura to glide over each other
during ventilation. In illness states, the pleural space may fiJI
with air (pneumothorax), fluid (pleural effusion), blood
(hemothorax), lymph (chylothorax), or pus (empyema).
The contour of the thoracic cavity changes shape over
time. The infant's thorax is round at birth with the anteroposterior diameter equal to the transverse diameter (I : I).
This gradually changes, so that by 6 years of age the thorax
reaches the adult diameter (I: 2). In infancy, the chest wall
is thin. with little musculature, and is highly compliant. The
muscles of respiration include the diaphragm, intercostal,
accessory, and abdominal muscles. The diaphragm is the
most important muscle of respiration because it is responsible for most of the inspiratory effort. The phrenic nerve,
formed by components of the third, fourth, and fifth cervical spinal nerves, supplies the diaphragm with both motor
and sensory innervation. The intercostal and accessory
muscles are poorly developed in infants, so they contribute
little toward respiratory effort. The infant uses abdominal
muscles to assist with ventilation. This combination of
muscle use gives the appearance of seesaw breathing-that
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Fig. 8-5 Expansion and contraction of the thoracic cage during
expiration and inspiration, illustrating especially diaphragmatic
contraction, elevation of rib cage, and function of intercostals.
(From Guyton AC: Textbook of medical physiology, ed 8.
Philadelphia, 1991, WB Saunders.)

is, a paradoxical movement of the chest and abdomen.
Seesaw breathing becomes exaggerated when intrapulmonary compliance decreases.
The infant's chest wall is very compliant, which allows
(I) passage through the birth canal and (2) removal of
intrapulmonary fluid before the first breath. In the presence
of respiratory disease, the diaphragm contracts, and the
chest wall moves inward on inspiration. In the older child or
adolescent, the chest wall is rigid. When the diaphragm
contracts, the rib cage is elevated, and the chest wall moves
outward (Fig. 8-5). The soft, flexible rib cage of the infant
makes retractions a prominent feature in respiratory distress
and prevents the generation of high intrathoracic pressures
needed to reexpand collapsed al veoli.

Pulmonary Circulation
The lungs receive blood from both ventricles. Unoxygenated blood flow from the right ventricle reaches the lungs by
way of the pulmonary arteries. The pulmonary arteries
divide into two systems: the conventional and the supernumerary. Conventional arteries travel with the airways,
dividing as the airways divide. Supernumerary arteries,
which exceed the conventional arteries in number, provide
blood supply directly to the gas-exchanging units. Pulmonary vessels. similar to airways, develop with growth. (See
Chapter 7 for an in-depth discussion of pulmonary vascular
development and resistance.)
The left ventricle provides oxygenated blood to the lungs
by way of three bronchial arteries. The bronchial arteries
perfuse the bronchi, bronchioles, lymph nodes, and visceral
pleura. Pulmonary venous drainage returns to the right and
left atria. The right atrium receives blood via the bronchial
veins, and the left atrium receives blood via the pulmonary
veins. Bronchial arteries do hypertrophy in the presence of
pulmonary infection. Hemoptysis may begin in these
bronchial vessels in disorders such as cystic fibrosis. 4
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Lymphatic System
The major function of the lymphatic system is to return
interstitial fluid to the systemic circulation. As blood flows
through the pulmonary capillaries, plasma is filtered into the
interstitium, where it collects in lymphatic channels and is
returned to the circulation by the lymphatic system.
Lymphatic drainage can significantly increase in certain
disease states, for example, in patients with pulmonary
edema. Most fluid is returned to the systemic circulation by
the lymphatic system scattered throughout the lung parenchyma, whereas another set of lymphatic vessels returns
lymphatic drainage over the surface of the lung within the
pleura. In conditions in which the major lymphatic drainage
through the thoracic duct is blocked, lymph may back up to
form a chylous effusion.

Pulmonary Metabolism
The lungs have the only capillary bed in which the entire
blood volume passes. Considering this, the pulmonary
capillary circulation is uniquely suited for exercising a
controlling influence on a number of circulating vasoactive
agents. These include activation of angiotensin I to angiotensin II; inactivation of bradykinin, serotonin, prostaglandin E (PGE), and PGF2 ; and partial inactivation of norepinephrine and perhaps histamine. In addition to modulating
bronchial and pulmonary vascular diameter, the systemic
effects of these agents include increased capi Ilary permeability, platelet aggregation, and peripheral vasodilation.

Control of Respiration
The neural and chemical control of respiration involves an
intricate balance of numerous factors that serve to maintain
Pa02' Pac02' and pH at levels that promote cellular
functioning. Nervous system control of breathing includes
the cerebral cortex through the corticospinal tracts to the
respiratory muscles and autonomic control through the
medulla and pons of the brainstem.
Expansion of the thoracic cavity on inspiration occurs by
stimulation of the phrenic nerve, which innervates the diaphragm, and stimulation of the spinal nerves, which innervate the external intercostal muscles. If expiration must be
facilitated, stimulation through the spinal nerves causes contraction of the internal intercostal and abdominal muscles.
Rhythmic discharge of neurons in the medulla oblongata
produces spontaneous respiration. Although specific pacemaker cells that drive respiration have not been identified,
two groups of respiratory neurons in the medulla influence
respiration: the dorsal respiratory group (DRG) and the
ventral respiratory group (VRG). The DRG is the source of
rhythmic drive to the contralateral phrenic motor neurons,
and the VRG innervates ipsilateral accessory muscles and
provides inspiratory and expiratory input to the intercostal
muscles. Rhythmic discharge of the medullary neurons is
modified by centers in the pons and by afferent information
from the vagus nerve stretch receptors in the chest.
The pneumotaxic center is located in the rostral section
of the pons. Stimulation of the expiratory neurons inhibits
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the inspiratory center in the medulla; thus the pneumotaxic
center works with the medulla to generate regular cyclical
respirations. The apneustic center is located in the middle
and caudal pons. Stimulation of this center along with a
vagotomy produces apneustic respiration, a respiratory
pattern characterized by extremely prolonged inspiratory
periods.
Scattered throughout the upper airway, trachea, and lungs
are mechanoreceptors that provide information to the
respiratory center via the vagus nerve. These receptors
include slowly adapting stretch receptors, rapidly adapting
stretch receptors, and C fibers. Slowly adapting receptors
(SARs) are activated by increases in lung volume; when
stimulated, the SARs are responsible for prolonging expiratory time. Rapidly adapting receptors (RARs) are activated by lung inflation and a variety of chemical substances
(histamine and prostaglandin) and cause an increase in
respiratory rate (RR). C fibers are also activated by chemical
substances (histamine, prostaglandin, bradykinin, and serotonin) and cause apnea, followed by rapid, shallow
breathing.
Central chemoreceptors, responsible for the dramatic
increase in minute ventilation (V E) when Paco z levels are
elevated, are located in the medulla. Medullary chemoreceptors monitor H+ ion concentration of cerebrospinal fluid
and brainstem interstitial fluid. Although H+ and HC0 3ions are unable to cross the blood-brain barrier easily, CO 2
readily penetrates and immediately hydrates to form carbonic acid (H ZC0 3 ), which dissipates into H+ and HC03 -.
The concentration of H+ ions in the brain's interstitial
fluid parallels Pacoz and acts as a stimulus to increase
respirations.
The peripheral chemoreceptors include the carotid body
located near the bifurcation of the internal and external
carotid arteries and the aortic bodies located near the arch of
the aorta. The carotid bodies are sensitive to Pa02 and
potentiated by H+ ion and Pacoz concentration; aortic bodies
are sensitive to circulatory changes. Afferent nerve fibers
from the carotid and aortic bodies ascend to the medulla to
increase ventilation as necessary. Chronic sustained hypoxia
decreases the carotid bodies' response to low Pa02'

Oxygen Transport
"Adequate" oxygenation can only be defined when tissue
oxygen supply matches tissue oxygen demand. Essential
factors to be considered include (I) alveolar-pulmonary
capillary oxygen transport, (2) oxygen transport in the
blood, and (3) cellular respiration. Table 8-2 provides a
summary of oxygenation profile parameters.
Alveolar-Pulmonary Capillary Oxygen Transport.
Between the extremely thin alveoli walls is an almost solid
network of interconnecting capillaries. Gas exchange occurs
throughout the alveolar-pulmonary capillary membrane of
all the temJ.inal portions of the lungs. Oxygen and CO 2 move
across the seven-layer alveolar-pulmonary capillary membrane by passive diffusion from an area of high partial
pressure to an area of low partial pressure (Fig. 8-6).
Diffusion is directly proportional to the gradient of partial
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Fig. 8·6 Cross·section of pulmonary capillary membrane. (From
Guyton AC: Textbook oj medical physiology, ed 8, Philadelphia,
1991, WB Saunders.)

pressure across the alveolar-pulmonary capillary membrane,
the alveolar-pulmonary capillary surface area, and the gas
solubility. Diffusion is inversely proportional to the thick·
ness of the alveolar-pulmonary capillary membrane and the
molecular weight of the gas.
According to Dalton's law of partial pressures, the total
pressure of a mixture of gases is equal to the sum of the
pressures of the individual gases. The total pressure of gas
in the atmosphere, the atmospheric pressure, is 760 mmHg
at sea level. Thus partial pressures of a component gas
depend on the fraction of the total mixture occupied by that
gas. Room air contains 21 % oxygen; thus oxygen exerts a

partial pressure of 21 % of760 mmHg, which is 160 mmHg.
At high altitudes, the percent concentration of oxygen does
not change, but the absolute number of molecules in a given
volume does. For example, at SODO feet, atmospheric
pressure is 632 mmHg; 2l % of 632 mmHg is 133 mmHg.
As gases are inhaled into the upper airway, they are
warmed and humidified. The pressure of water vapor
depends on the temperature of atmospheric gas. At high
temperatures, atmospheric gas has more water in vapor
form, whereas the opposite is true with low temperatures.
Water vapor exerts a pressure of 47 mmHg at 30° C. Water
vapor reduces the partial pressure of inspired oxygen; 760 47 = 713; 21 % of 713 is 149.7 mmHg.
Alveolar ventilation refers to the portion of ventilation that undergoes gas exchange. Inspired gas is mixed in
the alveoli with gas that contains water vapor and CO 2 ,
Alveolar partial pressure of oxygen (PA02 ) is calculated
using the alveolar gas equation: PA02 = PI02 - Pac02/RQ.
The inspired partial pressure of oxygen (PI02) is corrected
for water vapor (47 mmHg) and is PI02 = (Pb - 47) x FI02'
The value of CO 2 is corrected by the respiratory quotient
(RQ), which takes into consideration that more O 2 is
consumed than CO 2 is produced. In room air, at normal
barometric pressure (Pb) and normal Pac02' with an RQ of
0.8, the PA02 is equal to 99.7 mmHg; PA02 = (760 47) x 0.21 = 149.7 mmHg - 40/0.8.
The partial pressures of alveolar gases equal atmospheric
pressure; any increase in one alveolar gas is associated with
a decrease in another. Decreases in pUlmonary uptake of
oxygen are related to either diffusion or ventilationperfusion deficits. For example, diffusion defects occur
secondary to problems affecting the diffusion of gases over
the alveolar-pulmonary capillary membrane (interstitial
edema), whereas ventilation-perfusion deficits occur secondary to problems affecting alveolar ventilation (atelectasis) or alveolar perfusion (cardiovascular collapse).
Considering that the PA02 is close to IOD mmHg and
the normal venous partial pressure of oxygen (Pvo,) is
40 mmHg, the alveolar-capillary diffusion gradient- for
oxygen is about 60 mmHg. The capillary-alveolar diffusion
gradient for CO 2 is significantly less (46 - 40 mmHg = 6
mmHg); but CO 2 is 24 times more soluble than oxygen, and
its molecular weight is greater than oxygen. Differences in
solubility and size make CO2 20 times more diffusible than
oxygen. Pa0 2 better reflects ventilation to perfusion match-
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ing, whereas Paco2 better reflects the adequacy of alveolar
ventilation.
Oxygen Transport in the Blood. Oxygen is carried
in the blood in two forms: in combination with hemoglobin
and dissolved in plasma. Oxygen binds rapidly and reversibly with hemoglobin to form oxyhemoglobin (Hb0 2).
Almost all oxygen is carried as oxyhemoglobin.
The arterial oxygen contelll (Ca0 2) describes the total
amount of oxygen carried by arterial blood. Ca0 2 (mil
dl) = (Hgb x 1.34 x Sa02) + (Pa0 2 x 0.003). For example:
with a hemoglobin (Hgb) concentration of 15 g/dl of blood,
arterial saturation (Sa0 2) of 98%, and a Pa02 of 100 mrnHg,
Ca02 (ml/dl) = (15 x 1.34x98%) + (100 x 0.003); Ca02 =
19.7 + 0.3; Ca02 = 20 mild!. When fully saturated, 1 g
of hemoglobin carries 1.34 ml of oxygen; plasma carries
only 0.003 ml of oxygen per mmHg O2 per deciliter. The
Pa02 gives excellent information regarding lung function,
whereas Pa02 assumes an insignificant role in oxygen
transport. The Ca0 2 clearly demonstrates the highly significant role of hemoglobin in oxygen transport. Alternative
shortened formulas for Ca0 2 calculation eliminate the Pa0 2
portion of the equation. Note that once hemoglobin is fully
saturated at 100%, the only way to dramatically improve
Ca02 is through erythrocyte administration, increasing
hemoglobin concentration.
Oxygen-Hemoglobin Affinity: Oxyhemoglobin
Dissociation Curve (ODC). The oxygen-carrying capacity of blood is directly related to hemoglobin concentration
and the affinity of oxygen for hemoglobin. Although Pa02
contributes little to Ca02, Pa0 2 plays a major role in
determining the affinity of oxygen for hemoglobin as
described by the sigmoid-shaped ODC (Fig. 8-7, A).
The S-shaped curve facilitates alveolar capillary uptake
of oxygen (the association process) and tissue release of
oxygen (the dissociation process). Over the upper flat
portion of the curve (>70 mmHg ~ oc), hemoglobin bond to
oxygen is favored. A large change in oxygen tension results
in a small change in oxygen saturation/content. Hemoglobin
remains fully saturated, providing a consistent oxygen
content/saturation over a wide range of oxygen tensions
commonly found in the alveolar capillary bed. Over the
steep portion of the curve (P02 of 10 to 40 mmHg),
hemoglobin release of oxygen is favored. A small drop in
oxygen tension results in a large drop in oxygen saturation/
content. This ensures delivery of large quantities of oxygen
to the tissue capillary beds.
The affinity of oxygen for hemoglobin may change and
shift the position of the ODC to the right or left. The P02
at which hemoglobin is 50% saturated, the Pso' is used
as a marker for the relative position of the ODe. At a
pH of 7.4 and temperature of 37" C, Pso for hemoglobin A is 27 mmHg. A shift to the left (decreased Pso )
means that oxygen is more tightly bound to hemoglobin;
a shift to the right (increased Pso) means that oxygen is
readily released from hemoglobin (see Fig. 8-7, A). A
shift to the right has little effect on the association
process, but the dissociation process is enhanced. For
example, at the upper flat portion of the curve, slightly
less than 100% saturation occurs; but at the steep portion
of the curve, significantly more oxygen is unloaded to the
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tissues. The opposite is true of a shift to the left; the
association process is enhanced, whereas the dissociation
process is diminished.
Principal modulators of oxygen-hemoglobin affinity
include temperature, Pe02/pH, and the concentration of red
blood cell 2,3-diphosphoglycerate (DPG) (an enzyme that
accumulates in response to sustained periods of impaired
oxygen delivery).
Hyperthermia results in a decreased oxygen affinity
(right shift), whereas hypothermia results in a increased
oxygen affinity (left shift). Clinically, oxygen becomes more
available to the tissues when there is an increased metabolic
need marked by hyperthermia.
Known as the Bohr effect, increased H+ ion concentration shifts the ODC to the right. Associated with
the hydration of CO 2 to carbonic acid (HC03 ), acidosis
results in decreased oxygen affinity. Clinically, a shift to
the right favors the release of oxygen for aerobic metabolism in the more acidotic CO 2-rich environment of tissue
capillary beds.
The organic phosphate 2,3-DPG decreases oxygen affinity for hemoglobin, resulting in an increased oxygen release
to the tissues. Increased levels of 2,3-DPG are associated
with chronic anemic and hypoxic states, for example, in
patients with cyanotic heart disease and chronic lung
disease; decreased levels are found with inorganic phosphate deficiency and in sepsis. Also, 2,3-DPG concentrations decrease with advanced red blood cell age, for
example, in banked blood.
In infants and children, a cluster of ODCs exist (see Fig.
8-7, B). As mentioned, at a pH of 7.4 and temperature of
37° C, the Pso for hemoglobin A is 27 mmHg. Hemoglobin
A, adult type hemoglobin. consists of two a-chains and two
~-chains, with each containing a heme group with iron. Fetal
hemoglobin, hemoglobin F, consists of two a-chain and two
y-chain units. The transition from fetal to adult hemoglobin
starts to occur just before birth in full-term infants and is
complete by 6 months of age. Term newborns have
approximately 70% hemoglobin A and 30% hemoglobin F.
Compared with hemoglobin A, hemoglobin F has an
increased oxygen affinity. Under similar conditions, Pso at
birth for hemoglobin F is 19.4 mmHg. Pso then shifts to
approximately 30 mmHg by I I months of age. The left shift
of fetal hemoglobin allows higher oxygen saturation at
lower oxygen tensions. This is crucial for adequate oxygenation of the fetus because placental blood normally provides
a P0 2 of 35 to 40 mmHg.
Oxygen delivery (00 2), the amount of oxygen delivered
to the tissues, is equal to Ca0 2 x cardiac index (CI) x a
conversion factor of 10, which changes the Ca02 measurement from deciliters to liters; 002 = Ca02 x Cl x 10. Normal
00 2 is 620 ± 50 ml/min/M 2 Barcoft ls identified three
separate causes of inadequate 002: hypoxia, anemia, or
stagnant flow. Hypoxia occurs secondary to a low arterial
oxygen saturation, for example, hypoxia associated with
ventilation-perfusion mismatch. Anemia occurs secondary
to low hemoglobin concentration, for example, anemia after
hemorrhage. Stagnant flow occurs secondary to low cardiac
output, for example, shock states. The clinical significance
of alterations in the determinates of 00 2 are reviewed in
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Fig. 8-7 A, S-shaped oxyhemoglobin dissociation curve (ODC) facilitates alveolar capillary uptake of
oxygen (association process) and tissue release of oxygen (dissociation process). B, Age-dependent ODes.
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8-3 .Clinical Significance of Alterations in the Determinates of 002

002 = Cao l x CI x 10, where Cao l (mIldi) = (Hgb x 1.34 x Sa0 2 ) + (Pau 2 x 0.003)
iii::'
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~.'.
.
,.·Anemla
ro~ Stagnant flow
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12-15
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t~JlJP2' Oxygen delivery; Cao2 , arterial oxygen content; el, cardiac index; Hgb, hemoglobin; Sao 2 , arterial oxygen saturation; Pau."
1J~r,pf oxygen. Bold numbers represent abnormal values.
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Interrelationship Between Sv0 2 and V02

Normal Sii0 2 and Increased V0 2

Compensation effective-increased supply ( 00 2 ) to preserve
venous reserve

Decreased Sii0 2 and Increased V0 2

Compensation ineffective or impossible-patient using
venous reserve

Increased Sii0 2 and Decreased V0 2

Decreased need
Increased supply
Decreased use (sepsis, left shift to ODC, cyanide toxicity)
Left-to-right shunting (CHD, AV malformations, AV fistulas,
loss of autoregulation of blood flow, vasodilated states)

3ADP
3 ATP ...~------=:.:.:.
~

membrane

Do 2 , oxygen delivery;
ODC, oxyhemoglobin dissociation curve; Sv0 2 , venous oxygen saturation;
V0 2 , oxygen consumption.

A V, Arteriovenous; CHD, congenital heart disease;

~
Membrane

CYTOPLASM

Fig. 8·8 Oxidative phosphorylation produces massive quantities
of ATP. (From Guyton AC: Textbook of medical physiology, ed 8,
Philadelphia, 1991, WB Saunders.)

Table 8-3. Deficits occur in isolation or in combination.
Also, parameters compensate for the other; for example,
tachycardia increases after hemorrhage. Clinical management strategies are directed toward correction of the primary
problem and supporting compensatory mechanisms.
Cellular Respiration. Tissue oxygenation is dependent on microcirculation regulated by arteriolar and precapillary sphincter tone and 00 2 , Capillary oxygen moves from
erythrocytes, through plasma, and into tissue by diffusion.
Adjustments in microcirculation can enhance oxygen
extraction and preserve organ metabolism. Precapillary
sphincters, located at the arterial end of each capillary,
maintain capillaries open or closed depending on the
metabolic requirements of the specific tissue bed. A local
increase in H+ ion concentration shifts the ODC to the right
to augment hemoglobin release of oxygen.
All cells are dependent on a continuous supply of
oxygen to support aerobic metabolism necessary for the
synthesis of high-energy compounds (adenosine triphos-

phate [ATP]) essential for cell life and function. Most
cellular oxygen is consumed by the mitochondria to drive
oxidative phosphorylation (Fig. 8-8). In the absence of
oxygen, electron transport activity decreases, and cells start
to produce ATP anaerobically from the conversion of
pyruvate to lactate. Not only is this process less efficient
(20 times less ATP is produced), but also lactic acid lowers
tissue pH and depletes cellular nicotinamide adenine
dinucleotide (oxidized [NAD+]) necessary for aerobic
glycolysis.
Oxygen delivery does not provide information about the
adequacy of tissue oxygenation. For example, in septic
shock 00 2 is high, but blood is shunted across tissuecapillary beds without unloading oxygen. Indirect methods
of assessing the adequacy of tissue oxygenation include
monitoring mixed venous oxygenation, oxygen consumption, and oxygen extraction ratio.
Blood returning from various regions of the body
becomes well mixed in the right ventricle. To avoid regional
contamination, true mixed venous oxygenation is monitored
from the pulmonary artery. Pulmonary artery catheters,
designed specifically for continuous Sv0 2 monitoring, are
available in sizes designed specifically for the pediatric
population. The interrelationship between Sv0 2 values and
V0 2 is noted in Box 8-1.
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Reflecting metabolic requirements, oxygen consumption

CV02 ) is the amount of oxygen used by tissues. '102 is
assessed as the net oxygen difference between the amount of
oxygen entering tissue and the amount of oxygen leaving
tissue. '102 can be approximated by using a modified version
of the Fick equation: '10 2 = (Cao z - Cv0 2) x CI x 10, where
Cv02 = (Hgb x 1.36 x Svo z) + (pvo z x 0.(03); Cvo z norm is
15 mlldl or vol%. The conversion factor of 10 is necessary
to change deciliters to liters. Resting '102 in infants and
young children is almost twice that of an adult. The
significantly higher '102 reflects the metabolic requirements
of continued growth, that is, growth adds a metabolic
burden. Factors that affect '102 are noted in Table 8-4.
Oxygen extraction ratio, OzER, is a ratio of VO z to D0 2
(oxygen consumption to oxygen delivery or availability).
The 02ER represents the proportion of D0 2 that is actually
used by the tissues. 02ER is calculated as follows:
OzER = (Ca0 2 - Cv02)/Caoz x 100. The OzER is normally
25%. This means that only 25% of the oxygen delivered to
the tissues is actually utilized. This apparently low OzER is

protective in that significantly more O 2 can be extracted if
necessary to maintain adequate tissue delivery when '102
increases or D02 decreases. The 02ER increases when the
demand for 02 increases (fever, pain) or the supply of 02
decreases (decreased hemoglobin, Sao z, or cardiac index);
the 02ER decreases when demand for O 2 decreases (hypothermia, adequate sedation, and chemical paralysis) or when
supply, relative to demand, increases. The OzER is not a
valid measure when the Cv02 is contaminated with right-toleft blood shunted across anatomic cardiac defects.
Physiologic oxygen supply dependency describes the
normal biphasic relationship between D02 and '102 (Fig.
8-9). Initially when 00 2 falls, oxygen extraction increases to
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A
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Oxygen Consumption (V0z)
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Fig, 8-9 A, Normal and pathologic relationships of oxygen
,:onsumption (Vo,) and oxygen delivery (Do,). The normal critical
002 is shown as the vertical line separating the independent and
dependent portions of the normal V0 2 and 002 relationship. The
pathologic relationship is characterized by greater critical Do,
compared with the normal relationship. In animal models, the
~athologic relationship has a plateau of V02 , and increased critical
002 is clearly identified. However, clinical studies have not shown
a plateau of \:0 2 in .individual patients who have pathologic
dependence ofVo, on 00 2 , B, Normal and pathologic relationships
of oxygen extraction ratio (ER) and Do,. The critical oxygen ER is
the extraction ratio at the critical 002 shown as the vertical line
corresponding to the critical Doz determined by the Oo,tVo,
relationship above. In the normal relationship, oxygen ER continues to in~rease below critical oxygen ER, but not enough to
maintain V02 constant. In the pathologic relationship, oxygen ER
remains relatively constant, and therefore '102 is dependent or' 002 ,
In amma! models, pathologic dependence of V02 on Do, is
characterized by lower critical oxygen ER than normal. (Adapted
from Russell lA, Phang PT: The oxygen delivery/consumption
controversy: approaches to management of the critically ill, Am J
Respir Crit Care Med 149:533-537, 1994.)
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maintain V02 until a critical level of D0 2 is reached. At this
critical level of Do z, referred to as critical oxygen transport,
V02 pro~ressively decreases and becomes linearly dependent on D0 2. Metabolic demands are met on the flat portion
of the curve as long as the 02ER can increase to meet tissue
demands for oxygen.
In contrast, pathologic oxygen supply dependency. describes an abnomUlI relationship between D0 2 and V0 2;
02ER remains low, and V0 2 is linearly dependent on D0 2
over a wide range of values (see Fig. 8-9). This abnormal
VOr D02 relationship is thought to occur in several disease
states, for example, adult respiratory distress syndrome
(ARDS) and sepsis. 16
Under normal circumstances, organ blood flow (oxygen
supply) is distributed to match organ metabolic need
(oxygen demand). Control of oxygen flow to match
metabolism is regulated by the resistance of capillary
vessels. This event, along with alterations in hemoglobin
affinity, enhances peripheral oxygen extraction to sustain
tissue metabolism. When D0 2 decreases or if V02 increases
and systemic blood flow is distributed to match metabolic
need, the 02ER (an average of each individual organ oxygen
extraction) should increase. If systemic blood flow is not
distributed to match metabolic need, hypoxia and a low
02ER result.

Pulmonary Ventilation
Ventilation, the process of inspiration followed by expiration, is accomplished when the diaphragm functions to
move air in and out of the lungs. When the thoracic cavity
changes in size, pressure gradients are created between the
intrapleural space, intraalveolar space, and the atmosphere.
The external pressure exerted on the thorax is atmospheric
at 760 mmHg. Intraalveolar pressure, which is in direct
communication with the atmosphere, is also 760 mmHg.
Intrapleural pressure, the pressure between the visceral
and parietal pleura, is subatmospheric at 757.5 mmHg or at
-2.5 mmHg.
Inspiration is an active process in that energy is required
for the contraction of inspiratory muscles that expand
the thoracic cavity. As the thoracic cavity expands, intrapleural pressure becomes increasingly subatmospheric at
-6 mmHg. Intraalveolar pressure also becomes subatmospheric, and air moves in bulk flow from the atmosphere to
alveoli, where diffusion can occur.
Expiration is a passive process in that the muscles of
respiration relax and the size of the intrathoracic cavity
decreases. When the muscles relax, the elastic properties of
the lung followed by the elastic properties of the chest wall
pull the thoracic cavity back to a resting position. As the size
of the intrathoracic cavity decreases, intraalveolar pressure
becomes supraatmospheric, and air moves in bulk flow from
the alveoli to the atmosphere. Because of normal increased
airways resistance during expiration, passi ve expiration
requires more time than inspiration.
Compliance. Compliance refers to the stretchability,
distensibility, or elasticity of the lungs and thoracic structures. The elastic properties of the lungs and chest wall

245

allow the thoracic cavity to return to a resting state after
inspiration. Compliance describes the relationship between
volume (V) and pressure (P) (~V /M) and is an indicator of
elastic recoil and surface tension of the lung. Total
compliance is the product of lung compliance and chest wall
compliance. Clinically, total compliance is approximated by
dividing the plateau pressure minus the positive endexpiratory pressure (PEEP) into measured tidal volume
(V T ): 11 VIM = VT + P p1a , - PEEP. (The plateau pressure is a
pause pressure obtained at end inspiration.) For example, if
the VT /plateau pressure - PEEP were 60 ml + 15 cm H20,
the total lung compliance is approximately 4 ml/cm H 20.
Lung compliance is measured in either a dynamic or
static state. Dynamic compliance is equal to V T divided by
the transpulmonary pressure. The transpulrnonary pressure
(PL) is the difference between the alveolar pressure and the
intrapleural pressure. Because dynamic compliance is measured during breathing, airways resistance and respiratory
rate influence it. Static compliance (Cst) is equal to VT
divided by PL at the cessation of airflow. Because Cst is
measured under zero-flow conditions, it reflects the elastic
properties of the lungs. r 7 Clinically, PL can be approximated
by subtracting intraesophageal pressure (as measured by an
esophageal catheter or balloon placed in the lower third of
the esophagus) from proximal airway pressures (using an
adapter placed on the endotracheal lUbe) at the same point in
a single breath. Similar results can also be achieved by
measuring volume and flow by respiratory inductance
plethysmography. A curve relating 11V to I1PL is constructed; the slope of the curve describes lung compliance
(Fig. 8-10). Shifts to the right indicate decreased lung
compliance.
The pressure/volume characteristics of the lungs are not
linear; at very high and very low lung volumes, changes in
pressure produce little change in volume (the flatter the

Q)
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Pressure
Fig. 8-10 Pressure (P)/volume (V) curve relating !1P to t.V is
constructed; slope of curve describes lung compliance. (From
Guyton AC: Textbook of medical physiology, ed 8, Philadelphia.
1991, WB Saunders.)
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curve, the stiffer the lungs). The lower inflection point (PRex)
on the PN curve reflects a sudden increase in compliancespecifically, the point at which small increases in transpulmonary pressure produce large increases in pulmonary
volume. The upper inflection point reflects a sudden
decrease in compliance-specifically, the point at which
small increases in transpulmonary pressure produce small
increases in pulmonary volume. Volume/pressure relationships also differ during inspiration and exhalation; more
pressure is required to increase volume during inspiration
than the reciprocal during exhalation.
Lung compliance changes with age, normally decreasing
with increasing age and changes with disease, for example,
surfactant-deficient ARDS. Thoracic compliance can be
significantly reduced in many clinical states, for example, in
patients with scoliosis, muscular dystrophy, or obesity and
in the postoperative patient with surgical splinting.
Airways Resistance. Total pulmonary resistance is
affected by (I) radius, length, and number of divisions of
bronchi; (2) diameter and length of the endotracheal tube;
(3) gas flow; and (4) character of gas flow. Airways
resistance, or the rigidity of the bronchioles and thoracic
structures, refers to the ease of air movement through
conducting airways. Airways resistance is the pressure
required to move a volume of gas at a given flow rate.
Airways resistance is the product of the peak inspiratory
pressure (PIP) minus the plateau pressure divided by the gas
flow (Raw = PIP - Pplat + V).
The volume of gas that is pulled into the lungs and forced
out of the lungs is inversely related to airways resistance.
Until 5 or 6 years of age, small peripheral airways contribute
up to 50% of total airways resistance compared with only
20% in adults. IS Diseases that affect the small airways, for
example, bronchiolitis and asthma, can cause a significant
increase in airways resistance and work of breathing in the
younger, more vulnerable age group.
During normal spontaneous ventilation, the airways
widen during inspiration and become narrow on exhalation. Autonomic nervous system regulation of bronchiolar
smooth muscle can decrease (sympathetic) or increase
(parasympathetic) airways resistance. Bronchiolar smooth
muscle is also very sensitive to chemicals, such as histamine
and low CO 2 levels. causing bronchoconstriction, whereas
high CO2 levels cause bronchodilation.
Time Constants. The tidal flow of gas into and out of
the lung depends on the compliance of the alveoli and
the resistance of the airways. The relationship between
compliance and resistance determines the actual rate
of alveolar filling and emptying. The relationship between these two properties can be expressed mathematically as the time constant (Fig. 8-11; time constant =
resistance x compliance). The time constant is expressed in
seconds as the product of compliance and resistance. One
time constant is the measure of the time necessary for the
alveolar pressure to reach 63% of the total change in airway
pressure. About 99% of pressure equilibration occurs
within three to five time constants. The longer the time
constant, the longer alveolar filling and emptying will take
(Fig. 8-12).

Increased airways resistance prolongs the time necessary to fill alveoli with air; likewise, a region of low
compliance takes more time to fill with air than an area of
high compliance. Pulmonary disease affecting either airways resistance or lung compliance exhibits nonhomogeneous time constants, that is, areas with both prolonged
and normal time constants. Alveoli with normal time constants fill with air first, followed by alveoli with prolonged
time constants. As respiratory rates increase, alveoli with
normal time constants may overfill and compress alveoli
with prolonged time constants. Overdistended alveoli become less compliant because they have reached their elastic
limit.
An appreciation of time constants is especially important
when managing the infant or child who requires mechanical ventilation because a wide range of ventilator settings
can be employed to manage clinical conditions with dif-

RA-RB
CAoCA
TCA-TCe
EXAMPLE 1

RA>Re
CA-Ce
TCA>TCe

RA"RB

CAXe
TCA>TCe

Fig. 8-11 Effect of changes in resistance and compliance on the
distribution of gas between lung units. In example I, resistances
(R) and compliances (C) and thus time constants (TC) between
lung units A and B are equal, and no redistribution of gas occurs if
inspiration ends before the lung units are filled to maximal
capacity. In example 2, TC of A is lengthened by increasing its
resistance. Both will eventually altain the same volume because the
compliances are the same, but unit A will take longer to fill. If
inspiration ends prematurely, gas will be redistributed from B to A.
In example 3, TC of A is lengthened by increasing its compliance
relative to B while the resistances of both remain equal. The less
compliant unit B will never inflate to as great a volume as A. If
inspiration ends prematurely, gas will be redistributed from B to A.
(From Helfaer MA, Nichols DG, Rogers MC: Developmental
physiology of the respiratory system. In Rogers MC, ed: Textbook
of pediatric intensive care, ed 2, Baltimore, 1992, Williams &
Wilkins, p 112.)
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ferent combinations of resistance and compliance states
(Table 8-5).
Pulmonary Volumes. Pulmonary volumes and capacities are defined and illustrated in Fig. 8-13. Changes in
body position can affect pulmonary volumes and capacities.
In a prone position, values may decrease if abdominal
contents exert pressure on the diaphragm, and to a lesser
extent, increased pulmonary blood volumes may decrease
available space for pulmonary air.
Dead space is the volume of inhaled air that does not
participate in gas exchange. Anatomic dead space includes
the volume of conducting air that fills the nose, mouth,
pharynx, larynx, trachea, bronchi, and the distal bronchial
branching that does not participate in gas exchange (Fig.
8-14). NomlaJ anatomic dead space is approximately 2
ml/kg. Alveolar dead space refers to the volume of gas that
fills alveoli whose perfusion is abnormally reduced or
absent. Factors that contribute to alveolar dead space
include hypotension, compression of the alveolar capillary
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bed, and pulmonary embolus. Physiologic dead space is the
sum of both anatomic and alveolar dead space. Dead space
ventilation (V D) refers to the amount of gas ventilating
physiologic dead space per minute. Physiologic dead space
is usually expressed as a fraction of tidal volume (V rJY T)'
The normal V rJY T ratio is 0.3, that is, 30% of the volume
of each breath does not participate in gas exchange.
Minute ventilation ( VE) is the volume of air that moves
in or out of the lungs per minute. Minute ventilation is the
product of tidal volume and respiratory rate. Alveolar
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Fig.8-12 Exponential rise and fall of lung pressures and volumes
during inspiration and expiration in terms of time constants. (From
Chatburn RL: Principles and practice of neonatal and pediatric
mechanical ventilation, Respir Care 36:578. 199 I.)

Fig.8-13 Pulmonary volumes and capacities. Tidal volume (VT):
volume of air entering and leaving lungs during a single breath in
a resting state, 6 to 8 mVkg. Inspiratory reserve volume (IRV):
amount of air that can be inspired over and above resting tidal
volume. Expiratory resenle volume (ERV): air remaining in lungs
at the end of a normal expiration that can be exhaled by active
contraction of expiratory muscles. Residual volume (RV): amount
of air remaining in lungs after maximal expiration. Vital capacity
(VC): sum of normal VTo IRV. and ERV; infants. 33 to 40 mVkg;
adults. 52 ml/kg. l/lspiratOlY capacity (IC): sum of IRV and VT .
FUllctiollal residual capacity (FRC): sum of ERV and RV; infants.
30 mllkg; adults, 34 mVkg. Total IUlIg capacity (TLC): amount of
air in lungs after a maximal inspiration; infants. 63 mllkg; adults,
86 mVkg. (From Guyton AC: Textbook ofmedical physiolog)~ ed 8,
Philadelphia. 1991, WB Saunders. p 285.)

TABLE 8-5 Effect of Varying Compliance and Resistance States on Time Constant
and Associated Conditions
Compliance

Resistance

Time Constant

Clinical Conditions

Decrease

Normal

Short

Increase
Normal
Normal

Normal
Decrease
Increase

Long
Short
Long

Increase
Decrease

Increase
Increase

Long
Long/short

Pneumonia
Pneumothorax
Atelectasis
Neuromuscular disease
Postbronchodilalor
Airway obstructions
Intubated patient
BPD.COPD
Bronchiolitis

i=~PD. Bronchopulmonary dyspla,ia;

.r.=-"

COPD. chronic obstructive pulmonary disease.
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Fig. 8-14 Dead space ventilation continues down to the respiratory uniL(From Thompson JM, McFarland GK, Hirsh JE et aI, eds:
Mosby's clinicalnursillg, ed 4, St Louis, 1997, Mosby, P 125.)

Fig. 8-15 Lung volumes in infants and adults. Note that tidal
breathing in the infant takes place in the range of closing capacity
(CC) of the lung. Vc. Vital capacity: FRC, functional residual
capacity. (From Smith CA, Nelson, NM: The physiology of the
newborn infant, ed 4, Springfield, III, 1976, Charles C Thomas,

ventilation eVA) is the volume per minute that ventilates all
perfused alveoli and is the difference between minute
ventilation and dead space ventilation eVA = VE - Y D)· CO 2
production is dependent on metabolic rate, whereas CO2
elimination from the lungs is determined by the effectiveness of VA (Y T, RR, Y D). Adequate al veolar ventilation is
present when the Pac02 is maintained less than 40 mmHg
with a normal VE. With hyperventilation, VE is high, driving
down the Pac02 ; whereas with hypoventilation, VE is low,
driving up the Pac02 .
Forced vital capacity (FVC) is the volume of air forcibly
exhaled after inhaling to total lung capacity. The volume of
gas exhaled over time is usually plotted out to include the
volume exhaled in I second (FEY,) and the volume exhaled
in 3 seconds (FEY,). Patients with airway obstruction show
a reduced rate of airflow on exhalation. The smaller the ratio
of FEY I to FYC, the more difficult it is to exhale.
Preexpiratory and postexpiratory FYC measurements are
used to assess the effectiveness of bronchodilating drugs in
patients with obstructive airways disease.
Functional residual capacit)' (FRC) is the amount of air
remaining in the lungs at the end of normal expiration. With
atelectasis, FRC falls as the number of alveoli that
participate in gas exchange decreases. Airway closure
occurs in dependent areas of the lung at low volumes. The
lung volume at which airway closure occurs is called closing
capacity. In adults, closing capacity is usually at residual
volume (amount of air remaining in the lungs after maximal
expiration). In infants, closing capacity is at FRC as a result
of reduced elastic tissue, so closing capacity may be present
during normal tidal breathing (Fig. 8-15). Pulmonary
diseases that affect the relationship between tidal volume,
FRC, and closing capacity contribute significantly to

p 207.)

ventilation-perfusion mismatch and hypoxemia. PEEP,
which increases FRC above closing capacity, helps to limit
alveolar collapse.
Work of Breathing. Work of breathing, defined as
the pressure generated by the respiratory muscles to move
a volume of gas, can be divided into three components:
(I) compliance work-required to expand the elastic forces
of the lung; (2) resistance work-required to overcome the
viscosiry of the lung and thoracic cage; and (3) airways
resistance-work required to overcome resistance to gas
flow (Fig. 8-16). Under normal situations, most of the work
of breathing is expended during inspiration to overcome the
elastic properties of the lung.
Pulmonary disease can increase the work of breathing of
any or all of the three components. Rapid respirations and
increased airways resistance can cause expiratory work to
surpass inspiratory work. Small changes in the work of
breathing can significantly increase the metabolic rate and
oxygen demand, resulting in respiratory muscle fatigue.

Ventilation/Perfusion Ratio
Gas exchange becomes optimal when both ventilation and
pulmonary blood flow are equally matched. Under normal
conditions, the ventilaTion-to-perfusion ratio (V /0.) is not
equal to 1.0. This discrepancy is due to gravitational forces
that create regional differences in intrapleural pressures and
pulmonary vascular pressures.
During spontaneous breathing, a greater proportion of air
and perfusion is directed toward dependent areas of the
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Fig.8·16 Graphic representation of three different types of work
accomplished during inspiration. (From Guyton AC: Textbook of
medical physiology, ed 8, Philadelphia, 1991, WB Saunders.)

lung. In the upright patient at rest between breaths,
intrapleural pressures at the top of the lung are more
negative than at the base of the lung, creating larger alveoli
at the apex and smaller, more compliant alveoli at the base.
During spontaneous inspiration, ventilation is preferentially
distributed to the more compliant alveoli at the base rather
than the apex. Similarly, gravitational forces distribute
perfusion of the lung greatest in the base and lowest in the
apex. However, in total, ventilation is greater than perfusion
at the apex, and perfusion is greater than ventilation at the
base. This results in an overall V/Q of 0.8.
West and colleagues 19 described regional differences in
lung perfusion in upright adults (Fig. 8-17). West's zone I
conditions occur when the mean pulmonary artery pressure
is less than or equal to alveolar pressure (PA > Ppa > Ppv).
Zone I conditions are present in the apices of an upright
adult and are characterized by a lack of pulmonary blood
flow and gas exchange. West's zone II conditions are
characterized by pulmonary artery pressures greater than
alveoli pressure (Ppa > PA > Ppv). Zone II conditions are
present in the midportion of the lung, and blood flow is
determined by a balance of arterial and alveolar pressures
not influenced by venous pressures. West's zone III conditions are characterized by pulmonary artery and venous
pressures that exceed alveolar pressures (Ppa > Ppv > PA).
Zone III conditions are located at the base of the lung, and
blood flow is a function of the two vascular pressures.
Although similar research in the pediatric population does
not exist, it is reasonable to assume that zone II and ill
conditions are similar in younger age groups. Because the
height of the lung is reduced when lying flat, zone I
conditions probably do not exist in the supine position,
especially in the infant population. 20

Fig. 8·17 Zones of perfusion In the lung. (From West lB, Dollery
CT, Naimark A: Distribution of blood flow in isolated lung:
relation to vascular and alveolar pressures, J Appl Physiol 19:713,
1964.)

Ventilation-Perfusion Abnormalities. Intrapulmonary shunting is the major cause of clinical hypoxemia.
Characterized by a low V ratio, a shunt refers to venous
blood that travels from the right to left side of the circulation
without ever coming in contact with ventilated lung. Two
categories of shunts exist: an anatomic shunt and a capillary
shunt. An anatomic shunt refers to normal or abnormal
right-to-Ieft connections, for example, bronchial, pleural,
and thebesian veins (the pulmonary circulation) or right-toleft congenital heart defects. A capillary shunt occurs when
alveolar-capillary blood flow comes in contact with nonventilating alveoli, for example, atelectasis, pneumonia, and
pneumothorax. As expected, mixing oxygenated and unoxygenated blood significantly impacts oxygenation, and
hypoxemia results (Fig. 8-18).
Normally, an almost immediate diffusion of gases occurs
over the alveolar-capillary membrane, so arterial and
alveolar gas concentrations are similar. Venous blood
passing nonfunctional alveoli creates an admixture of
venous and arterial blood, decreasing Pa0 2. Venous admixture represents the ratio of shunted blood (Qs) to total
pulmonary blood flow (Qt). The Qs/Qt ratio is calculated
using the shunt equation: Qs/Qt = (CPC02 - Ca02)/(Cpco2 Cv0 2), where CpC02' Cao 2, and Cv02 are the pulmonary
capillary, arterial, and mixed venous oxygen contents,
respectively. The Cpc02 is computed using the alveolar gas
equation (PAD? = PI02 - PacoiRQ, where PI02 = [760 47] x Flo2, and-RQ = 0.8). The Qs/Qt normally ranges from
3% to 7%; changes greater than 5% are considered
significant. Work of breathing significantly increases when
Qs/Qt is greater than 15%.

/0.

250

Part III

Phenomena of Concern
PO,(mmHg)

//

98.2'%
satura-

95.8%
satura-

too"",

ti/

'f

20

100 F:0=~20§=:::4~0=~60~::::a~0~ ..
10",0~_12rO~
80
74% satura-

too

Mean saturation
a9"/o

1-----,£
'#- 60

.~

i

40

~ 20
Cl

40

Fig.8-19 Dead space uni!. (From Swedlow DB: Capnometry and
capnography: the anesthesia disaster early warning system, Semin

Anesthesia V[3]: 194·205, 1986.)

Effect of V/Q scatte~ 0." Pao, and Sao,. Three lung
units with low. mid, and high V{Q ratios and PA02 of 40, 80,
and 120 mmHg. Because of the shape of the ODC, the mean
Pa02 is only 57 mmHg, and the mean saturation is only 89%. (From
Nunn IF: Applied respiratory physiology, ed 2, London, 1977,
Butterworths, p 284.)
Fig. 8-18

When a pulmonary artery catheter is not available to
provide the mixed venous blood specimen necessary for
calculating an intrapulmonary shunt, an alveolar-arterial POz
difference (A-aDoz) or PaozIFl0 2 ratio can be used to
estimate the percent shunt. The alveolar partial pressure of
oxygen (PAOZ) is again calculated using the alveolar gas
equation: PAO z = PJ0 2 - PaCoz/RQ, and the Pa0 2 is obtained
from a standard arterial blood gas (ABO) report. To obtain
an A-aDoz, the Pa0 2 is subtracted from the calculated PAOZ'
Normally, the A-aDoz should be less than 20 mmHg. The
Pa02/FI0 2 ratio calculation is straightforward; the norm is
greater than 286.
The magnitude of the shunt helps to determine what
effect increasing the FI02 might have on the Paoz. If the
shunt is insignificant, changes in the Paoz will occur in
direct proportion to changes in FIO Z' If the shunt is
significant, increases in FI02 will not impact Paoz. PE~P !s
used to increase FRC, which potentially decreases Qs/Qt
and the risk of oxygen toxicity associated with the use of
high F102 . Continuous assessment of the entire oxygenation
profile is required to balance excessive PEEP, which may
contribute to cardiac depression, and inadequate PEEP,
which may contribute to progressive pulmonary hypoxemia.
In addition to the actual amount of shunted blood, the
Cvoz of shunted blood also impacts Ca02' The Ca02 will fall
if the shunted blood (Cv0 2 ) is more hypoxic secondary to
increases in V0 2 or decreases in D0 2.
Characterized by a high V ratio, dead space refers to
alveoli that are ventilated but not perfused (Fig. 8-19). As
discussed, Paco2 is determined by alveolar ventilation in
relation to CO 2 production. Alveolar ventilation is compromised by increased dead space ventilation.

/0.

Physiologic dead space is calculated by the physiologic
dead space/tidal volume ratio: VrJVT = (Pac02 - Pec02) +
Paco2' This is measured by drawing an arterial sample to
obtain a Pacoz and by collecting the patient's expired air in
a Douglas bag or similar device for several minutes to obtain
a P EC02 (partial pressure of carbon dioxide in the mixed
expired air).
Calculating an end-tidal COz-Pacoz gradient, the
A-aDcoz can also approximate dead space ventilation. In
dead space units, mixed venous CO 2 is approximately 46
mmHg; alveolar CO 2 is 40 mmHg in the perfused unit, as is
the pulmonary vein draining that unit. The alveolar CO 2 in
the unperfused lung is zero because no blood has supplied it
with COz. Down-line, the arterial CO 2 is an average of only
the units perfused (40/1 = 40 mmHg), and ETco 2 is an
average of all units ventilated (4012 = 20 mmHg). Thus with
50% dead space ventilation, the A-aDco, will be 20 mmHg.
To compensate for increasing VrJVT: VE must increase.
Increases in V E increase the work of breathing in direct
proportion to increasing VrJVT' Thus assessment of VE
(respiratory rate and tidal volume) and Pac0 2 levels are
helpful tools in assessing dead space. If VE increases, Paco2
levels should decrease if VrJVT is normal; if VE increases
and Paco2 remains the same, VrJVT is probably increased,
or pulmonary blood flow is decreased. The Pac02 is
maintained at normal levels as long as the VA can be
maintained.
Various pulmonary diseases accentuate ventilationperfusion abnormalities resulting in significant alterations in
oxygenation and CO 2 removal. In fact, positive pressure
ventilation alone immediately contributes to V mismatching; preferential ventilation is switched to nondependent
areas, while preferential perfusion continues to dependent
areas. Various physiologic mechanisms attempt to match
ventilation to perfusion. For example, ventilation is altered
by high CO 2 levels, which result in bronchodilation,
whereas low CO2 levels result in bronchoconstriction.
Pulmonary arteriolar smooth muscle is very sensitive to the
partial pressure of oxygen; increased alveolar oxygen results
in vasodilation, and decreased alveolar oxygen results in
vasoconstriction. This mechanism, known as hypoxic put-
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monary vasoconstriction (HPV), attempts to enhance perfusion of well-ventilated alveoli and limit perfusion to
unventilated alveoli. Many drugs used in the intensive care
unit (lCU) can attenuate HPV. Propranolol and dopamine
enhance HPV, whereas nitric oxide, calcium channel blockers, vasodilators, p-agonists, and anesthetic agents diminish
HPV. Pulmonary arteriolar smooth muscle is also very
sensitive to H+ ion concentration, which is directly related to
CO 2 concentration. An increase in H+ ion concentration
results in vasoconstriction and shunting of blood away from
poorly ventilated alveoli, with high alveolar CO2 levels to
better-ventilated alveoli.

ASSESSMENT OF PULMONARY
FUNCTIONING
History
Patient assessment begins with data collection to describe
the scope of the patient's problem, to identify the progression of illness, and to help delineate the initial management
plan. Especially in patients with chronic respiratory illnesses, parents provide excellent data, particularly regarding
the success of past management strategies.
When obtaining a medical history, interview depth and
content are individualized to the age of the patient, the
relevancy of information as it relates to the present illness,
and the urgency of the current problem. For example, prenatal, natal, and postnatal history is relevant for infants admitted with a respiratory illness within the first year of life.
If a perinatal history were significant, knowledge of whether
the infant ever required assisted ventilation is important.
Extensive questions about medication and environmental
allergies are critical in patients with reactive airways disease. Questions related to fever are important if infection is
suspected. Questions related to dietary intake, exercise tolerance, and schoolwork may give clues related to the chronicity of the illness. As a general rule, infants and young children should not experience more than five uncomplicated
upper respiratory infections per year. In patients with
chronic respiratory illness, activity tolerance, oxygen dependency, home ventilator settings, and successful coping strategies provide meaningful baseline information.
Questions related to the onset of the present illness are
also important. Acute-onset illnesses include asthma, pneumonia, and upper airway obstruction. Aspiration of a foreign
body is suggested when the onset of distress is acute,
especially in the inquisitive toddler. Chronic or recurrent
illnesses suggest infection or an unresolved foreign body but
also allergic or immunologic problems, late-presentation
congenital anomalies, or extrapulmonary problems, such as
heart disease or cancer.

Physical Assessment
Inspection. When first approaching an infant or
young child, note the child's position of comfort. Infants and
children normally assume a wide variety of positions to
enable ventilation and limit the work of breathing. Classic

251

(yet rarely seen) positions include that of a drooling
3-year-old with epiglottitis whose survival depends on
maintaining an upright position, usually tripod, with neck
extended. Also classic is the older child with cystic fibrosis
who while exhaling through pursed lips prefers to sit
forward with arms supported on an overbed table. As a
general rule, support the patient's attempts to find and
maintain his or her own position of comfort.
Note the patient's facial expression; even young infants
appear tense, tired, and anxious when gas exchange is
inadequate. Integrate the patient's level of consciousness
into the examination; hypoxia is reflected as anxious,
restless, and irritable behavior, whereas hypercapnia produces drowsy and obtunded behavior. Note the presence of
pallor or cyanosis. Skin color should be consistent with the
individual's race. Cyanosis, a late sign of respiratory
distress, is evident when more than 5 g of reduced
hemoglobin is present per deciliter of blood. Patients who
are chronically cyanotic exhibit clubbing of their distal
phalanges.
Assess the rate, rhythm, and effort of breathing. Breathing is usually quiet and effortless; inspiration should be the
only active phase of respiration. Respiratory rates in infants
and children are highly variable, depending on age, medical
history of lung disease, activity, anxiety level, and temperature. Respiratory rates are determined while the patient is
at rest. Normal breaths per minute range from 30 to 60 in
newborns, 20 to 40 in early childhood, and 15 to 25 during
late childhood, reaching adult levels by age 15. Tachypnea
is often the first sign of respiratory distress. With time,
infants especially will fatigue and decrease their respiratory
rates. The pattern of tachypnea followed by bradypnea with
intermittent periods of apnea is a ominous sign.
Abnormal respiratory patterns are described in terms of
rate, depth, and pattern (Table 8-6). Respiratory patterns
vary considerably during the first year of life; that is,
I minute the infant breathes slowly, but then the next
minute, the infant breathes more rapidly. Apnea lasting
greater than 15 seconds accompanied by duskiness, cyanosis, or respiratory rates greater than 60 breaths per minute is
considered significant in the newborn. 21
Normal inspiratory/expiratory (I:E) ratio is I: 2. Prolonged inspiration occurs with upper airway obstruction,
whereas prolonged expiration occurs with lower airway
obstruction. Inspiratory stridor may also be present with
upper airways disease, whereas expiratory wheezing is
present with lower airways disease. Grunting, forced
expiration against a partially closed glottis accomplishes the
same effect as pursed-lip breathing in older children. Both
occur in an attempt to maintain FRC, thus oxygenation.
When present, consider oxygen administration if not already
in place.
Note the shape of the chest. Chest deformities can limit
vital capacity. Scoliosis is a lateral curvature of the spine at
the extreme, resulting in an S-shaped configuration. Kyphosis is an exaggeration of the normal posterior convexity of
the thoracic spine. In pectus carinatum, the sternum is
displaced in an anterior position; in pectus excavatum, the
sternum is displaced posteriorly.
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Phenomena of Concern

Abnormal Respiratory Patterns

;: Type

Description

Potential Etiologic Conditions

!iiApnea

Absent

hBradypnea

Slow for age

l;[Dyspnea

Difficult or labored breathing

Central neurologic depression
Obstructi ve sleep apnea
Hypothermia
Drug-induced respiratory depression
Increased intracranial pressure
Metabolic alkalosis (intestinal
obstruction)
Acute distress (pneumothorax)
Chronic distress (cystic fibrosis)
Internlittent distress (asthma)
Central neurogenic hyperventilation
Diabetic ketoacidosis
Asthma
Pulmonary edema
Pulmonary disease
Nonpulmonary disease
Metabolic acidosis
Increased metabolic need
Anxiety
Severe diarrhea
Salicylate toxicity
Chronic renal insufficiency
Inborn errors in metabolism
Stimulation of the apneustic center
(located in the middle and lower pons)
along with vagotomy
Cerebral dysfunction at level of medulla
Cerebral dysfunction at midbrain level
Bilateral diencephalon dysfunction
Cerebral dysfunction at the level of
the pons

E:

;:"

Deep and rapid for age
Deep (fast or slow)
Intolerant of supine position
Rapid for age
Rapid for age

'i:"

:~

HVApneustic
i2.,

Extremely prolonged inspiratory periods

;jLAtaxic
ii[.Central neurogenic hyperventilation
(;:Cheyne-Stokes

Unpredictable, irregular
Rapid, deep
Cyclic hyperpnea-apnea pattern
Irregular cluster

~

~k;luster

11'

:;'c-:·

Fig, 8·20 Locations of retractions. (From Whaley LF. Wong DL:
Nursing care of infants and children, ed 5, St Louis, 1995, Mosby,
P 1340.)

Note how the chest moves. Early in infancy, diaphragmatic breathing is predominant and thoracic excursion is
minimal; this reverses by 7 years of age. Diaphragmatic
breathing produces a paradoxical breathing pattern: on
inspiration, the lower ribs are pulled in while the abdomen
is pushed out; the opposite is true on expiration. Paradoxic
breathing becomes exaggerated-that is, it takes on a
seesaw appearance-when pulmonary compliance is decreased. If paradoxic breathing is replaced by thoracic
breathing in an infant, diaphragmatic dysfunction is suspected; if thoracic breathing is replaced by abdominal
breathing in a child, parenchymal disease is suspected.
During a patient's deep breath, confirm symmetric chest
excursion. Unequal chest excursion is' associated with
atelectasis, pneumonia, thoracic trauma, or pneumothorax.
When respirations are labored, accessory muscles are
recruited to support ventilation. The sternomastoid, scaleni,
pectorals, internal and external intercostals, and abdominal
muscles may contract visibly. Head bobbing, or extension of
the neck on inspiration, indicates the use of neck accessory
muscles. Nasal flaring on inspiration is often observed with
labored respirations. Suprasternal, substernal, supraclavicular, and intercostal retractions may occur (Fig. 8-20).
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Normal Breath Sounds

,"Breath Sound

I:E Ratio

Pitch

Intensity

Location

#:oBronchial
,;:
lliOBronchovesicular

[ $; E
1= E
I> E

High
Moderate
Low

Loud
Moderate
Soft

Large airways
Midairway and peripheral lung fields
Peripheral lung fields

~Vesicular

f;;/:E, Inspiratory-to-expiratory.
r1i:

Retractions of the upper chest are associated with upper
airways disease, whereas retractions of the lower chest
usually suggest lower airways disease, As the work of
breathing increases, so do oxygen requirements. Metabolic
acidosis follows respiratory acidosis when the work of
breathing exceeds the ability to provide adequate tissue
oxygenation.'
Assess for the presence of a characteristic cough: for
example, gradual or sudden onset, productive or nonproductive, dry or congested, associated with decreased or increased activity, able or unable to sleep, and associated with
a febrile or afebrile state. A barking or croupy cough is
present with laryngotracheobronchitis or epiglottitis. A
progressive cough-that is, from dry to wet-is characteristic of congestive heart failure. Coughs caused by bronchitis or pneumonia are congested. If a cough is productive, the
sputum is described in terms of color, consistency, and odor.
The significance of sputum color is as follows: white or
clear with bronchitis or viral infections; yellow or green
with bacterial infections; pink or frothy with pulmonary
edema; and rust color with tuberculosis.
Palpation and Percussion. The entire chest wall
is palpated for tactile fremitus, that is, palpable vibrations
transmitted from the lung to the chest wall when the
patient speaks or cries. Fremitus should be symmetric. increased transmission is noted over areas of consolidation, for example, pneumonia or atelectasis. Decreased or
absent transmission is noted over areas of decreased
airflow, for example, in asthma, pneumothorax, or pleural
effusion.
Percussion helps to determine whether the underlying
tissue is air filled, fluid filled, or solid. The infant's round
chest normally produces a hyperresonant pitch. A resonant
pitch, indicating healthy lung, is present by age 6. After age
6. hyperresonance may indicate the pathologic presence of
air, for example, with a pneumothorax. A resonant pitch
before 6 years of age or a dull pitch thereafter indicates
consolidation, for example, atelectasis, pneumonia, or
pleural effusion.
Crepitus, or subcutaneous emphysema, occurs when free
air enters subcutaneous tissue. When palpated, crepitus feels
crunchy, creating a crackling sensation over the skin surface.
Subcutaneous air may follow tracheotomy or any disruption
in the larynx or trachea. Crepitus may also occur after a
thoracentesis around the wound site or dissect large surface
areas, as in patients with severe air-leak syndrome. Crepitus
is usually self-limiting and does not require treatment;
resolution occurs by reabsorption after resolution of the

primary problem. On rare occasions, tracheal compression
may require surgical intervention.
Auscultation. Three types of breath sounds can be
auscultated in infants and children: bronchial, bronchovesicular, and vesicular (Table 8-7). Symmetry, comparing
right and left sides, allows patients to serve as their own
control. Progressing systematically from top to bottom,
assess the pitch, intensity, and duration of each breath
sound. Assess for (I) the presence and location of normal
breath sounds, (2) the presence of normal breath sounds
heard over abnormal locations, and (3) the presence of
adventitious breath sounds.
Breath sounds are usually louder in infants and young
children because the thinner chest wall brings the stethoscope closer to the origin of the sounds. Bronchovesicular
sounds are usually auscultated throughout the lung periphery. Although seldom heard in infants, displaced bronchial
breath sounds may indicate consolidation. Because breath
sounds are easily transmitted throughout the small thoracic
cavity, referred breath sounds are prevalent in infants and
young children. Even when a significant pneumothorax is
present, breath sounds can be auscultated over collapsed
areas. Decreased breath sounds do occur in older children
with obstructed bronchi, hyperinflated lungs, pneumothorax, or pleural effusion.
Three types of adventitious breath sounds can be
identified: crackles. wheezes, and pleural rubs 22 Crackles
are discrete, noncontinuous sounds that can be simulated by
rolling a lock of hair between the fingers near an ear.
End-inspiratory crackles (previously termed crepitant rales)
result from the reopening of previously collapsed alveoli,
for example, during pneumonia and congestive heart failure.
Early inspiratory crackles (previously termed rhonchi) may
be heard in the airway of patients with obstructive airways
disease. Loud inspiratory and expiratory crackles may be
heard with bronchiectasis.
Wheezes are musical sounds produced by the rapid
passage of air through narrowed airways. Wheezing occurs
more commonly in infants because of the size of their
airways. Although wheezes are typically expiratory, they
may be heard on both inspiration and expiration. During
normal spontaneous ventilation, intrathoracic airways widen
during inspiration and narrow on exhalation, whereas the
opposite is true of extrathoracic airways. Because maximum
resistance to airflow occurs during expiration in intrathoracic airways and during inspiration in extrathoracic airways, expiratory wheezes usually indicate lower airway
problems, and inspiratory wheezes usually indicate upper
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airway problems. The disappearance of wheezing in a
severe asthmatic may be disconcerting because it may
indicate that the patient is no longer moving air through
narrowed airways.
Pleural rubs result from the friction generated by the
movement of inflamed pleural surfaces over one another.
Pleural rubs are usually painful, loud yet low pitched,
synchronous with respiration, and confined to a small
surface area.
When assessing adventitious sounds, the location and
timing-that is, when in tbe respiratory cycle they are
auscultated-are noted.

Assessment of the Intubated Infant or Child
When caring for an infant or child with an endotracheal tube
(ETI), assessment priorities include patient safety and
comfort. Assess the security of the ETI, and ensure that the
tape securing the ETT is adherent to the skin and ETT.
Compare the ETT exit markings at the lip or naris line with
those noted immediately after intubation or after the ETT
was last repositioned. Assess for the potential of ETIinduced pressure necrosis to the naris or comer of the
mouth. If present, reposition and retape the ETI as soon as
possible.
Once ETT security has been addressed, determine
whether the ETI itself is causing respiratory distress.
Inadequate ETI size will precipitate signs and symptoms of
upper airway obstruction. Determine whether excessive
ETI length may contribute dead space. If the patient is
hypercapnic, consider shortening the ETI to a reasonable
length (approximately 5 mm) after confirming correct ETT
placement on chest x-ray film with the patient's head in
neutral position.
Assess the comfort level of the infant or child. Provide a
level of sedation necessary to ensure airway maintenance.
This is highly individual because patient tolerance may be
high or extremely low. Freedom sleeves or limb restraints
are essential to prevent unintentional extubation. Ensure that
the ETI and tubing are supported to allow head movements
but prevent accidental extubation, especially in the active
infant and child. Drain oxygen delivery tubing of condensation on a regular basis to prevent inadvertent water entry
into the patient's airway and unnecessary weight on the
patient's ETI. All equipment necessary to reintubate the
individual infant or child, as well as an emergency tracheostomy tray, should be readily available in the unit.
Patients with oral and nasal ETTs are assessed in a
similar manner. Awake children with oral ETIs may require
a bite block to prevent biting down on the ETI. Children
with an altered level of consciousness and oral ETT may
require an oral airway. In addition, nasal ETIs can obstruct
eustachian tubes, which empty into the nasopharynx. There
should be a high index of suspicion for middle ear infections
and sinusitis whenever caring for patients with nasal ETTs.
In general, intubated patients should be positioned with
their head of the bed elevated to decrease the incidence of
nosocomial pneumonia. Although similar pediatric data do
not exist, the supine body position is a well-established risk

factor for nosocomial pneumonia in adult patients supported
on mechanical ventilation. 23 Nosocomial pneumonia results
from the microaspiration of colonized oropharyngeal secretions. Factors influencing oropharyngeal colonization include enteral nutrition, antacids, and gastrointestinal reflux.
When caring for an infant or child with a new tracheostomy tube (TI), priorities again include patient safety and
comfort. Tracheostomy hclders are assessed for security,
and the entire neck is assessed for skin breakdown under the
tracheostomy holder. The character of the tracheostomy site
is assessed for infection, and dressings or sponges are
examined for drainage. If the patient is connected to a
ventilator, potential pressure points created by the TI
adapter should be cushioned. Finally, an extra same-size
tracheostomy tube should be positioned in clear view at the
bedside in case of an emergency.
Intubated patients require instruction on how best to
establish and maintain communication with family and
caregivers. The inability to communicate, no matter how
temporary, has been consistently identified as a major source
of ICU-related stress. Costell0 24 reviewed current options to
establish and maintain commnnication in cognitively appropriate pediatric ICU patients. These interventions include
the use of an unaided yes/no response, picture and alphabet
boards for pointing, magic slates or felt-tip pens for writing,
and small typing and communication systems using prerecorded voice for pressing. Whichever system is used, it
seems reasonable to prepare the patient (if possible) for the
loss of voice and offer a range of options that would be
reasonable in the sedated intubated pediatric patient.

Assessment of the Ventilated Infant or Child
Assessment of the infant or child supported on mechanical
ventilation includes (I) assessing patient-ventilator synchrony, (2) validating the ventilator settings and alarm
systems, and (3) assessing for the presence of air leaks
around uncuffed endotracheal or tracheostomy tubes.
Start by assessing the patient's level of comfort. Does the
infant or child appear anxious? Is chest expansion adequate
during a delivered breath? Is the I:E ratio normal? Is the
inspiratory time too short? Does the patient have enough
time to exhale before receiving another breath? Is the patient
able to generate a sufficient number of adequate spontaneous breaths? Is the patient tachypneic?
Next check the ventilator settings to ensure that the
patient is supported on the intended settings. Ensure that
alarm settings are activated and are within a tight range to
call immediate attention to problems.
Assess for the presence of an air leak on end inspiration.
Air leaks are not uncommon in infants or children with
uncuffed ETIs, especially when pulmonary compliance is
low. Air leaks should be quantified. When measured tidal
volumes are significantly compromised, air leaks can be
addressed by ventilator or patient manipulations. Ventilator
manipulations include those that result in increasing the
delivered tidal volume to compensate for the air leak.
Patient manipulations range from simply changing head
position to reintubating the patient with a larger ETI or TI.
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If a cuffed ETT or TT is in place and delivered tidal
volumes are compromised, consider inflating the cuff with
just enough volume to eliminate the air leak. This minimaL
occlusion voLume (MOY) technique is accomplished by
placing a stethoscope over the larynx and slowly inflating
the cuff until sounds cease over the larynx. Once the air leak
is eliminated, cuff pressures are obtained to ensure that the
cuff pressure is less than 20 mmHg. Most tubes will seal at
pressures between 14 and 20 mrnHg. The amount of
pressure and volume to obtain a seal and prevent mucosal
pressure depends on tube size and design, cuff configuration, mode of ventilation, and the individual's airway and
arterial pressure. Mucosal ischemia occurs when lateral wall
pressure exceeds capillary perfusion pressure, resulting in
decreasing mucosal blood flow. 25 Iatrogenic complications
from cuff inflation include tracheal stenosis, necrosis,
tracheoesophageal fistula, and tracheomalacia.
If cuff total occlusion is unnecessary, consider the
minimaL Leak voLume (MLV) technique. Here a stethoscope
is again placed over the larynx. The cuff is inflated then
slowly deflated until a small air leak is heard at end
inspiration. Check to ensure that the air leak is occurring at

less than 20 mrnHg inflating pressure or directly measure the
cuff pressure.
When patients are chemically paralyzed, assessments
include the adequacy of the paralysis. This may be assessed
by one of two methods: "daily honeymoon" or train-of-four
monitoring. With a "daily honeymoon" technique, continuously administered neuromuscular blockade is temporary
discontinued until the patient is observed to move. Initial
movements often include abdominal fasciculations. Trainof-four monitoring is used when spontaneous breathing
would potentially cause the patient harm, for example, when
the patient is receiving maximal ventilatory support and
patient effort/asynchrony would cause barotrauma or desaturalion. In train-of-four monitoring, two electrodes are
placed in line along the distal ulna and then connected to a
nerve stimulator that delivers four electrical stimuli at preset
intervals 26 Ordinarily, stimulation of the ulnar nerve
produces four serial thumb adductions (Fig. 8-2\). With
neuromuscular blockade (induced by nondepolarization
agents), this response fades; that is, each successive twitch
becomes weaker. As blockade increases, the last twitch is
obliterated, then the third, and so on. When train-of-four

TOF Suppression and Degree of Neuromuscular Blockade
Approximate
Percentage of Block

TOF Suppression

Four responses

0-75

Three responses

75--80

Two responses

80-90

One response

90

No response

100

Clinically Rele.vanl Levels of Neuromuscular Blockade
Percentage

of Blockade

@@

TETANUS

Cllnieallnlerprelalion

90-95

Conditions may be suitable for endotracheal
intubation and long-term mechanical
ventilation

80-90

Block may be adequate for short-term
relaxation and long-term mechanical
ventilation

75

Maintenance doses may be needed to
extend duration of relaxation

RED

@@
reF

INTENSITY: Increases
progressively as
the dial is turned
from setting
1 through 10

Fig. 8-21
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~75

Patient may be susceptible to rapid reversal
with cholinesterase antagonists

<75

Patient's spontaneous recovery is probably
satisfactory

Train-of-four (TOF) monitoring.
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8·8 Assessment of the Ventilated Patient

Primary Survey
~neral

Appearance

Skin color
tube size, cuffed or uncuffed, amount
of dead space
Spontaneous respiratory effort
Respiratory excursion-ventilator and spontaneous breaths
Abdominal distension
Level of responsiveness or comfort
Muscle tone
Respiratory rate
Ventilator + spontaneous = total
Airway~ndotracheal

Presence of subcutaneous air

Breath sounds
Equality
Normal and adventitious
Quality of spontaneous and ventilator breaths

Air leak

Endotracheal tube
Chest tubes
Noninvasive gas monitoring

Spoz' ETco z, tidal volume
Secondary Survey
Ventilator settings and safety check
Blood studies

Chest x-ray films
Hemodynamic and oxygenation profiles

Arterial blood gases
Hemoglobin
stimulation elicits only one twitch, spontaneous respirations
are suppressed. Continuous infusion rates are titrated or
additional boluses of chemical muscle relaxants are administered to maintain a single twitch in the train-of-four
response. Table 8-8 provides a summary of the primary and
secondary assessment parameters for the ventilated infant
or child.

NONINVASIVE PULMONARY INTENSIVE
CARE MONITORING
With the recognition of technical difficulties and associated
risks of invasive pediatric monitoring, an explosion in the
use noninvasive monitoring techniques has occurred. As
alternative monitoring techniques become available in the
pediatric population, it is essential that they be valid and
reliable. Pediatric monitors must not only accommodate the
wide range of sizes but also be sensitive enough to detect
both the rapid and small quantitative physiologic changes
that often hallmark states of pediatric crisis. Low arterial
pressures, cardiac outputs, and oxygen reserves matched
with high oxygen requirements offer little buffer and require
rapid detection.
Effective clinical use of any technology requires an
understanding of what is actually measured, how it is
measured, and the patient care requirements for applying
that technology. This section focuses on these issues as they
relate to noninvasive monitoring of pulmonary function.

Pulse Oximetry
Continuous monitoring of oxygen saturation has made a
significant impact on patient assessment. Unlike measuring
ABGs, pulse oximetry provides continuous arterial hemo-

globin saturation (Spoz) data and almost immediate detection of hypoxemic events.
Because oxygen is primarily transported in blood chemically attached to hemoglobin, Spoz monitoring provides
a more complete picture of the patient's oxygenation
status. Saturation monitoring also provides a more reliable
indicator of hypoxemia during extreme shifts of the
ODC: inadequate oxygenation despite a Pa02 greater than
50 mmHg during a shift of the ODe to the right or adequate
oxygenation despite a Pa02 less than 50 mrnHg during a
shift of the ODC to the left. In the upper part of the ODC,
small changes in Sa02 correspond to very large and
potentially toxic levels of Pa02. Bucher and co-workers z7
reported that when Spo2 was maintained at less than 96%,
the Pa02 was never higher than 100 mmHg. The researchers
proposed that maintaining the patient's Sp02 around 96%
would prevent hyperoxia. Manufacturers claim an error
factor of less than 3% at a Spo2 greater than 70%.
Mechanism of Measurement. Pulse oximeters
measure the absorption of two wavelengths of light passed
through pulsating tissue (Fig. 8-22). Oxyhemoglobin and
reduced hemoglobin absorb varying degrees of light. For a
gi ven site, the light absorption of bone, tissue, venous blood,
and arterial blood remains constant except for the absorption
from the added blood volume associated with arterial
pulsation. The varying absorption is translated into two
waveforms, and the ratio between the amplitude of these
waveforms is used to calculate the Spo2'
Pulse oximeters update Sp02 with each heartbeat. They
provide accurate data to heart rates of 250 beats/min. A high
correlation between heart rates obtained from a cardiac
monitor and Sp02 monitor helps to establish the reliability of
Sp02 data. Qualitative analysi's'of perfusion is also available
by assessment of the perfusion bar, which pulsates with each
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Fig. 8-22 Pulse oximeters measure absorption of two wavelengths of light passed through pulsating tissue. Oxyhemoglobin
and reduced hemoglobin absorb varying degrees of light. For a
given site, light absorption of bone, tissue, venous blood, and
arterial blood remains constant except for absorption from the
added blood volume associated with arterial pulsation. Varying
absorption is translated into two waveforms, and the ratio between
the amplitude of these waveforms is used to calculate Spo,.
(Reprinted by permission of Nellcor Puritan Bennett, Pleasanton,
Calif.)
heartbeat. An audible tone varies in pitch according to
saturation. This feature is very important during procedures
that may affect Sa02; attention can be paid to the procedure
while listening for changes in the tone of the pulse oximeter,
indicating changes in saturation.
Sensors contain three optical components: two light
sources (red and infrared) and one light receiver. To function
properly, the sensor must be positioned so' that the light
source and photodetector oppose one another (see Fig.
8-22). Sensors are available in various shapes and sizes to
facilitate monitoring at different locations and with varying
patient sizes. If the patient is sensitive to adhesive, it can be
removed with adhesive remover. The sensor is then attached
using a gauze dressing. All sensor sites are assessed
frequently for skin abrasion and circulatory impairment.
Pressure necrosis may occur when a sensor is placed too
tightly or for prolonged period.
To enhance performance, the appropriate probe for the
size of infant should be used. In infants with right-to-Ieft
shunting, the right hand is used for preductal Sp02, and the
left hand or either foot is used for postductal SP02'
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Troubleshooting. Interference with Sp02 readings
typically result from problems related to the signal-to-noise
ratio. Too little signal may result from poor perfusion or
improper probe placement; too much noise may result from
excessive motion, ambient light, electrocautery, or a venous
pressure wave.
Sensors incorporate ambient light protection, but strong
light sources-for example, fluorescent, procedural, and
bilirubin lights-may interfere with Sp02 measurement.
Problems with ambient light are easily resolved by covering
the sensors with a blanket. Patient motion may also affect
system performance. Occasionally, a large dicrotic notch
may be sensed as a separate arterial pulse, resulting in twice
the actual heart rate. Any event that significantly reduces
arterial pulsation will affect Sp02 readings. Although
accurate to extremely low mean arterial pressures, pulsations may be lost with severe hypotension, with low cardiac
output states, or in patients receiving venoarterial extracorporeal membrane oxygenation. Oximetry may also fail in
patients with severe anemia or hemodilution, for example,
when the hemoglobin is less than 5 g/d\. High bilirubin
levels do not affect Spoz readings. To help eliminate this
problem, newer pulse oximetry models have incorporated an
algorithm to help identify motion and poor perfusion
artifact 28
Significant venous pulsations can also lead to inaccurate
low Sp02 readings. This occurs when a sensor is wrapped
too tightly; when the sensor is placed on a dependent limb;
or during decreased venous return states, such as increased
intrathoracic pressure or congestive heart failure or during a
Valsalva maneuver. Falsely low readings can also occur if
the finger probe is malpositioned beyond the fingertip.2 9
Because of the different ways saturation is measured,
pulse oximetry data cannot be validated by other saturation
measures. Pulse oximeters are calibrated to read functional
hemoglobin or the percentage of hemoglobin available to
bind with oxygen. Saturation readings obtained with ABG
reports are calculated from Paoz values and thus may be
invalid because of shifts in the DOC. Specific requests for a
measured Sa02 with a co-oximeter in the laboratory will
provide fractional Sa02 readings, for example, carboxyhemoglobin and methemoglobin. All carboxyhemoglobin will
be counted as oxyhemoglobin by the pulse oximeter, so the
Sp02 may be misleadingly normal in carbon monoxide
poisoning. When methemoglobin levels are less than 20%,
the pulse oximeter will add half the actual percent to the
Sp02 reading. When methemoglobin levels are greater than
20%, the pulse oximeter will always read 85%. The impact
of methemoglobin levels on pulse oximeter values is
important when medications that increase these levels are
prescribed (dapsone and nitric oxide). Lastly. when high
concentrations of fetal hemoglobin are present, because of
absorption differences. the laboratory co-oximeter reports
erroneously high carboxyhemoglobin and low oxyhemoglobin fractions.
Clinical Applications. Saturation monitoring is considered a standard in most pediatric ICUs. Spoz readings are
particularly helpful as a continuous monitor of intrapulmonary shunt (Qs/Qt) and during pulmonary care and titration
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Fig.8-23 A, Normal V/Q ratio. B, Dead space units-high V/Q
ratio. C, Shunt units-low V/Q ratio. (From Swedlow DB:
Capnometry and capnography: the anesthesia disaster early warning
system, Sen/in Anesthesia V[3]:194-205. 1986.)
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of oxygen therapy. Continuous monitoring of Spoz levels
during ventilator weaning eliminates the need for repeated
blood gases.

End-Tidal CO 2 Monitoring
Until recently, the only method to quantify the adequacy of
ventilation was through assessment of ABGs. End-tidal COz
monitoring provides a noninvasive, continuous real-time
measurement of end-exhaled CO 2 gases. Normally, if ventilation and perfusion are well matched, the ETcoz closely
approximates the Pac02 (Fig. 8-23, A). As illustrated, mixed
venous CO 2 (blood returning from the systemic circulation)
is approximately 46 mmHg. Carbon dioxide rapidly diffuses
into the alveolar space until the alveolar pulmonarycapillary COz and the alveolar COz become equal at 40
mmHg. Thus down-line at the sampling points, arterial and
ETc02 should be approximately equal at 40 mmHg. In those
with normal lungs, the A-aDc02 gradient (difference between alveolar and arterial COz) is usually less that 2 to
3 mmHg with ETcoz lower than arterial PC02' Changes in
the noninvasive ETcoz will continuously reflect changes in
the invasive Pac0 2 or the A-aDcoz gradient.
Mechanism of Measurement. The most common
device used to measure COz concentration in exhaled gases
is the infrared' analyzer or capnometer. The analyzer makes
use of the fact that gaseous COz absorbs infrared light
within a specific wavelength range, specifically waves about
4.3 Jlm in length. As this narrow band of light is projected
through a gas sample, an attenuation of the light beam
resuits, and the intensity of attenuated light is measured. The

greater the concentration of COz, the greater the absorption
and less infrared detection by the sample detector cell.
The two basic types of sampling techniques are sidestream and mainstream. With the sidestream capnometer,
the gas sample is continuously aspirated from the respiratory circuit through a small-bore tube leading to a sensing
chamber within a monitor. With the mainstream capnometer,
the sensor is incorporated between the ventilator circuit and
an artificial airway.
An advantage to the sidestream monitor is that it can be
used in the intubated or nonintubated patient. In the
nonintubated patient, the aspirating tube is placed at or a few
centimeters into the naris. The patient may not tolerate this
technique, or the results may not be acceptable if mouth
breathing is present. Also, if the monitor entrains room air,
the readings will be falsely low, providing a false sense of
security when alveolar hypoventilation is present. Further
disadvantages to the sidestream capnometer include a total
delay time,30 a falsely low ETc0 2 created by high aspirating
flow rates, and potential for analyzer contamination if water
and mucus is drawn back into the monitor. An airway
adapter with water trap has been designed to address the last
problem.
Mainstream capnometers require intubation and have
two main advantages. First, delay time is less, and second,
water or moisture is less apt to affect sensor function. Also,
the mainstream capnometers have been reported to more
accurately reflect ETc02 data in pediatrics 30 A disadvantage, especially in pedia'trics, is that some sensors are heavy
and require support to avoid tension on the ETT and the size
may add excessive dead space.
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Fig. 8-24 A, Slow-speed capnogram recorded at 12.5 mm/sec.
B, Fast-speed capnogram recorded at 25 mm/sec. (From Curley
MA, Thompson IE: End-tidal CO 2 monitoring in critically ill
infants and children, Pediatr Nurs 16:397, 1990.)

Capnometers used in the pediatric population must be
able to rapidly respond to changes in CO 2, respond to the
small exhaled volumes, and be sensitive to track small
changes in CO 2,
Clinical Applications. Capnography is the recording
and analysis of waveforms produced by changes in the level
of exhaled CO2, Capnograms can be recorded at a slow
(12.5 mm/sec) or fast (25 mm/sec) speed (Fig. 8-24). The
vertical axis represents CO 2 concentration, whereas the
horizontal axis represents time. Slow recordings are suitable
for trending baseline and ETco2 levels. Fast recordings
allow individual waveform analysis. Any factor that alters
CO 2 production, CO 2 transport to the lungs, alveolar
ventilation, V/o. ratio, and CO 2 transport to the sampling
site will affect the ETco2 .
Capnogram Analysis: Slow Speed. Changes in
CO 2 production are usually matched by changes in minute
ventilation, so ETc0 2 levels should remain constant. In those
unable to alter their tidal volumes or respiratory rates
sufficiently, increased production will be manifested by
increased ETc0 2 whereas decreased production will be
manifested by decreased ETco2. Fever, pain, stress, increased muscle activity (seizures and shivering), sodium
bicarbonate infusion, increased carbohydrate intake, malignant hyperthemIia, and hyperthyroidism all increase CO 2
production. Hypothermia and increased fat intake decrease
CO 2 production.
As discussed, alveoli can only eliminate CO 2 that is
presented by the pulmonary capillary membrane, so changes
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in lung perfusion will be reflected in the capnogram (see
Fig. 8-23, B). The ETc02 will fall in shock states, when
excessive positive end-expiratory pressure (PEEP) is used,
or in those with a pulmonary embolus. These states are
characterized by a high ventilation/perfusion ( V/0.) ratio or
dead space units (see previous discussion). The A-aDc02
gradient can be followed to detect insidious shock and
evaluate response to treatment.
During a cardiac arrest, the ETco2 acutely disappears,
reappearing only when circulation is restored by effective
cardiac resuscitation. The extent to which advanced life
support measures maintain cardiac output can be rapidly
assessed by ETc02 monitoring (Fig. 8-25, A).
With alveolar hypoventilation, the arterial and ETc0 2
both increase. Hypoventilation may occur in those with
central nervous system depression, with neuromuscular
disease, and in the chemically paralyzed patient with
inadequate ventilator parameters.
When hypoventilation is severe (where air only in the
conducting airways is moved), the ETc02 will decrease. With apnea, the ETco 2 disappears completely
because CO 2 is no longer transported from the lungs to the
gas-sampling point (see Fig. 8-25, B). Capnography is thus
a good apnea alarm because periods of apnea can be
confirmed, timed, and documented. The ETc02 reappears
after ventilation is restored and usually overshoots previous
readings.
Alveolar hyperventilation decreases ETc02 and arterial
CO 2, An important application ofETco2 monitoring is in the
cerebral hypertensive patient in whom CO 2 retention
produces pronounced cerebral vasodilation and further
compromises intracranial pressure.
The pat~ophysiologic effects of shunting, characterized
by a low V/Q ratio, are seen in many pulmonary disease
states (see Fig. 8-23, C). In shunt units, those that are
perfused but not ventilated, mixed venous CO 2 is approximately 46 mmHg. The alveolar CO 2 is 40 mmHg in the
ventilated unit, as is the pulmonary vein draining that unit.
The alveolar CO 2 in the unventilated unit is 46 mmHg
because it is in equilibrium with its pulmonary capillary
membrane. Down-line, the arterial CO2 is an average of aU
the lung units perfused (46 + 40/2 = 43 mmHg), and ETc02
is an average of all units ventilated (4011 = 40 mrnHg). Thus
with a 50% shunt, the A-aDc02 will be only 3 mmHg. An
undramatic A-aDc0 2 gradient but a dramatic decrease in
arterial saturation characterizes shunt units.
ETc0 2 monitoring of unstable, intubated, chemically
paralyzed patients helps to reduce iatrogenic injury.31 ETc02
monitoring helps to determine correct ETT placement
because little or no CO 2 reading can be gained from the
esophagus. ETco 2 monitoring also allows rapid detection of
ETT displacement (see Fig. 8-25, C).
ETco2 monitoring can be an effective, noninvasive way
to monitor alveolar ventilation in patients who are being
weaned from mechanical ventilation. Ventilator rates can be
gradually decreased to the lowest point at which the patient
can comfortably maintain effective alveolar ventilation. If
the ETc02 rises or if the patient appears to be working too
hard, as evidenced by rapid spontaneous respiratory rates,
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Fig.8-25 Slow-speed capnograms. A, Cardiac arrest. Decreased perfusion to the pulmonary vascular bed
will gradually decrease the ETc02 . B, Apneic episodes. ETc0 2 disappears during apneic episodes, then
overshoots previous readings. C, Endotracheal tube (ETI) displacement. ETc02 will fall to zero when ETI
is displaced. D, Weaning ventilator support. Note that ETc0 2 is lower during spontaneous breaths than
during ventilator breaths. (From Curley MA, Thompson JE: End-tidal CO 2 monitoring in critically ill
infants and children, Pediatr Nurs 16:397, 1990.)

ventilator rates can be returned to previously acceptable
settings.
In patients with chronic pulmonary disease, the ETco 2 of
spontaneous breaths may be much lower than the ETc02 of
larger ventilator-initiated breaths (see Fig. 8-25, D). Generally, stability of the ETc02 during spontaneous and ventilator breaths indicates the patient's readiness for weaning
ventilator breaths. Use of this assessment parameter is
especially helpful in weaning patients when there is
uncertainty as to whether they can physiologically resume
the work of breathing. Noninvasive gas monitoring is less
traumatic for the patient in relation to the pain and anxiety
of ABGs.
Capnogram Analysis: Fast Speed. The normal capnogram, recorded at a fast speed, is illustrated in Fig. 8-24,
B. At the beginning of exhalation, the CO 2 concentration is
zero as primarily dead space of the conducing airways
empties of its CO 2-free gas (A-B). As exhalation continues,
there is a steep rise in CO 2 tension when dead space gas
mixes with CO2-rich alveolar gas (B-C). Levels quickly
reach a near-constant horizontal plateau representing CO 2rich alveolar gas that has been in equilibrium with the
pulmonary capillary membrane (C-D). The end point of this
segment, the highest value of CO 2 concentration at the end

of normal exhalation in the upper right comer of the
waveform, is the ETco2 (D). Immediately following ETco2,
the CO2 concentration falls, indicating dilution of CO 2-rich
gas with CO2-free inspired gas (D-E). Finally, only inspired
gas is present at the gas-sampling port, producing the
inspiratory baseline. Capnographic characteristics vary and
can be diagnostic of certain disease states.
First assess the baseline CO2 level. Baseline CO2 should
be zero because it primarily represents previously inspired
dead space, CO 2-free gas. Any increase in baseline indicates
that rebreathing is occurring (Fig. 8-26, A).
Next assess the slope where dead space gas mixes with
CO 2-rich alveolar gas. The slope should be nearly vertical to
the plateau phase. Occasionally, the slope is significant to
the point at which the plateau disappears (see Fig. 8-26, B).
This is caused by lung units emptying at different rates,
prolonged exhalation secondary to small airway obstruction
(asthma) or a partially kinked Err. A good alveolar plateau
ensures that the ETc02 is a reliable estimate of mixed
alveolar gas.
Capnograms can be useful in assessing the effectiveness
of bronchodilator treatments in the asthmatic patient or
racemic epinephrine treatments in the patient with laryngotracheobronchitis. A decrease in the slope, less peaking of
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Fig. 8-26 Fast-speed capnograms. A, Rebreathing. Rebreathing will produce a
gradual increase in the baseline; recorded at slow and fast speeds. B, Plateau
disappearance. Asthma: increased slope, peaking of the ETco 2 , and loss of
plateau. C, Plateau reappearance. Decreased slope, less peaking of the ETco2 ,
and beller plateau after bronchodilator treatment; D, CO2 blip; occurs as trapped
CO 2 gas is released at end elthalation. E, Cleft in the alveolar plateau: indicates the return of spontaneous breathing. F, Staircase effect; pneumothoralt.
(From Curley MA, Thompson JE: End-tidal CO 2 monitoring in critically ill
infants and children, Pediatr Nurs 16:397, 1990.)
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the ETc02> and an increase in plateauing all correlate with a
positive response to treatment in the patient with severe
obstruction (see Fig. 8-26, C).
With atelectasis, a CO 2 blip followed by a sharp terminal
rise in ETc02 appears as trapped air at end exhalation is
released (see Fig. 8-26, D). These blips and peaks can be
smoothed out when adequate PEEP is applied. Capnography
provides rapid feedback on the effects of changing ventilator
settings that control minute ventilation, tidal volume, and
respiratory rates. The necessity for frequent ABGs can be
avoided.
Partial neuromuscular blockade or return of voluntary
function is first seen in capnograms as a cleft in the alveolar
plateau (see Fig. 8-26, E). This is caused by the rush of
COrfree gas as the diaphragm contracts. Capnograms can
provide early information that more chemical-paralyzing
agent is needed.
Descending limb analysis also provides information. A
staircase effect on the descending limb is seen when a
pneumothorax is present (see Fig. 8-26, F). When chest
tubes are in place, a staircase effect may indicate chest tube
obstruction.

ETcoz monitoring provides a continuous real-time monitor, thus closer surveillance of the adequacy of ventilation.
ETc02 does not completely replace ABGs because the
ETc02 measure is not the same as the Pac02 in many clinical
situations. ETcoz monitoring also provides information that
is not derivable from ABGs alone. The A-aDcoz gradient
can render a ETc02 useful rather than being a limitation.
Presence of an appreciable gradient indicates a serious V/Q
disturbance, whereas closure of the gradient indicates
effective treatment or improvement of lung disease. Capnography provides a useful adjunct to the more frequently
used methods ofrespiratory system assessment and provides
early detection of potentially dangerous trends that can be
reversed before crises result.
Pedi-CAP. Pedi-CAP (Nellcor, Hayward, Calif.) is
a disposable pediatric end-tidal CO 2 detector that is
useful when correct ETT position is in question. 32 Specifically, when attached to an ETT, the nontoxic indicator
located within the cap responds to exhaled CO2 by
changing color from purple to yellow. The pediatric size
limits dead space to 3 ml and is recommended for patients
weighing I to 15 kg.
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Single-Breath CO 2 Monitoring
Single-breath CO 2 (SBco2) monitoring integrates ETc0 2 and
VT measurement. SBc0 2 allows the accurate measurement
of airway and alveolar dead space and CO2 production. The
V ofV T ratio is used to assess minute ventilation and wasted
ventilation. CO 2 production is used to evaluate changes in
metabolism and CO2 elimination. SBc02 analysis offers the
precision to differentiate the alveolar dead space from airway dead space; quantification of alveolar dead space may
be directly related to effective pulmonary perfusion 33 •34

INVASIVE PULMONARY INTENSIVE CARE
MONITORING
Critically ill patients require rapid titration of therapy based
on astute and accurate assessments of hemodynamic and
oxygenation data. The instruments that provide data have
evolved significantly in recent years. What has also developed is how we use hemodynamic and oxygenation profile
data to optimize care. For example, the cardiovascular and
respiratory systems are interrelated. Alterations in one
system often elicit a change in the other. Achieving and
maintaining optimal functioning of both systems are fundamental objectives in critical care. This section reviews
invasive monitoring of cardiopulmonary function in critically ill pediatric patients, including the clinical significance
of direct and derived data and the importance of trending the
determinates of 002 and 02 use.

Blood Gas Analysis
Blood gases are analyzed for two major reasons: (I) to
directly assess the patient's oxygenation and ventilation
status and (2) to provide information regarding the patient's
acid-base status. Blood gas analysis can be performed using
arterial, venous, or capillary blood. Arterial blood gas
(ABG) analysis provides primary information about the
adequacy of the lungs to oxygenate blood. Venous blood gas
(VBG) analysis provides indirect information regarding
tissue perfusion and V02 . Capillary blood gas (CBG)
analysis provides limited information that can be trended
over time when arterial and venous blood gases are
unavailable.
Limitations associated with blood gas analysis include
the procedure. Unless vascular access is available, a painful
and perhaps time-consuming procedure is performed. Blood
gases are expensive, require the removal of oxygen-carrying
cells from the patient, and provide only intermittent data.
Blood gases are also not infallible. They can be altered by
the amount of air left in the syringe, the amount of heparin
in the syringe, the amount of time the specimen sits before
analysis, and hyperventilation or breath holding if the
patient cries during the procedure. 35
Arterial Blood Gases. ABGs are obtained through an
existing arterial line or by arterial puncture. The sites most
commonly used for arterial puncture include the radial,
dorsalis pedis, posterior tibial, and femoral arteries. The
femoral artery is the last choice because hemorrhage
and hematomas are difficult to control in this area and

because of the high potential for limb ischemia if artery
damage occurs.
To perform an arterial puncture, a setup typically
consisting of a 23- or 25-gauge butterfly needle attached to
a 1- to 3-ml heparinized syringe is prepared. Preheparinized
syringes are now available and should be used to save
pharmacy expense, by avoiding the waste of discarding
partially used vials of heparin (I : 1000 Vlml concentration);
nursing expense, in the time it takes to prepare a heparinized
syringe; and laboratory expense, in having to repeat an ABG
with an erroneously low pH linked to having too much
heparin in the syringe.
Before attempting arterial puncture, the adequacy of
collateral circulation is assessed. The Allen test is used to
assess the adequacy of ulnar collateral flow when the radial
artery is considered for arterial puncture. Here the hand is
elevated above the heart, and while compressing both ulnar
and radial arteries, the hand is passively opened and closed.
When the hand appears pale, ulnar compression is released
while radial compression is maintained. If the hand flushes
or if the pulse oximeter Sp02 on any of the fingers of the
hand returns to normal, ulnar competency is considered
adequate. A similar evaluation of the foot is accomplished
before dorsalis pedis puncture. The dorsalis pedis is
compressed, and the big toe is blanched by compressing the
toenail. Collateral flow is considered adequate if the toenail
flushes when pressure is released.
Under controlled circumstances, EMLA cream should be
used to ease the patient's discomfort. The pain and anxiety
associated with arterial puncture will alter the infant's or
child's breathing pattern and obscure results. After removing
all air from the syringe and capping it with an occlusive
barrier, ABGs are immed.iately sent to the laboratory on ice.
Excessive air will distort the gas results, and ice will slow
metabolism in the blood sample. Apply firm pressure to the
puncture site for 5 minutes or until bleeding stops. Once
bleeding stops, apply a pressure dressing. Because of patient
discomfort and the potential for vasospasm, hematoma
formation, and neurovascular compromise, arterial cannulation should be performed if frequent sampling is required
to manage the patient's condition.
Venous Blood Gases. To obtain a representation of
systemic perfusion and V02, a true mixed venous blood
sample is obtained from the distal port of a pulmonary artery
catheter. Venous blood gases obtained from more peripheral
sites vary considerably, depending on the V02 of nearby
organ systems. This is especially true during shock or septic
states. When obtaining a mixed venous sample, the mixed
flushlblood discard and blood specimen is drawn slowly
over 2 minutes from the distal port of a pulmonary artery
catheter. This time frame is necessary to prevent "arterialization" of the specimen (i.e., pulling blood over the
alveolar pulmonary-capillary membrane) that would produce erroneously high mixed venous oxygenation data. The
Pvc02 should always be higher than a simultaneous drawn
Paco2; if not, the mixed venous specimen is probably
arterialized. After drawing the mixed venous sample, care is
taken to adequately flush the lumen to prevent clot
formation, especially in the smaller PA catheters.
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Capillary Blood Gases. If peripheral perfusion is
adequate, CBG data will correlate with arterial pH, Pae02'
and HC0 3 . Because adequate peripheral perfusion is necessary for arterial correlation, capillary blood gases are
usually not an option in critical care. To maximize
CBG-ABG correlation, an "arterialized" CBG is obtained.
This is accomplished by collecting a free-flowing blood
specimen from a site that had been wrapped in a warm
(45° C) wet cloth for 5 to 7 minutes. Skin-puncturing
devices designed for blood glucose monitoring can be used
for CBGs. CBGs are usually drawn from the medial or
lateral surface of the heel in infants or from one of the digits
in older infants and children.
Interpretation. Blood gas analyses typically report
the pH, P0 2, Pe02' S02' HC03 , and base excess (BE)/base
deficit (BD). Normal ranges are noted in Table 8-9.
According to Dalton's law of partial pressures, the total
pressure of a group of gases is equal to the sum of the partial
pressures of the individual gases in a mixture. When oxygen
and carbon dioxide dissolve in blood, they exert a pressure.
The P02 and Pe02 reflect the partial pressures of dissolved
oxygen and carbon dioxide in blood. The S02 is the percent
hemoglobin saturation with oxygen; when 100% saturated,
each gram of hemoglobin carries 1.34 ml of oxygen. The
Pa02 and Sa02 reflect the adequacy of oxygenation, whereas
the Paco 2 reflects the adequacy of ventilation.
The Pae02 level can only be influenced by pulmonary
function. Two abnormal conditions are associated with
changes in Pae02: respiratory acidosis and respiratory
alkalosis. A decreased pH and increased Paco2 evidence
respiratory acidosis. Respiratory acidosis is caused by
decreased CO2 elimination, that is, hypoventilation. Respiratory alkalosis is evidenced by an increased pH and
decreased Pae0 2. Respiratory alkalosis is caused by an
increase in CO 2 elimination, that is, hyperventilation.
The pH is inversely proportional to H+ concentration. As
H+ concentration increases in the blood, the pH falls; when
H+ ion concentration decreases in the blood, the pH rises.
Bicarbonate (HC0 3-) is a base that buffers H+ concentration. The BElBD mainly reflects an excess/deficit concentration of bicarbonate that can only be influenced by
nonpulmonary function.
Donlen 36 described a three-step method that is helpful in
interpreting blood gases. First, the pH is evaluated for
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acidosis or alkalosis. Next, analyzing HC03 , BElBD, and
Pco2 levels identifies the origin of the disorder. This step is
followed by an assessment of compensation. See Chapter 9
for interpretation of acid-base imbalances.

Oxygenation Profile Monitoring
Invasive oxygenation profile monitoring is extremely helpful in patients with acute respiratory failure to help manage
Fl0 2 and mechanical ventilation. Patient management is
directed toward resolution of the primary problem while
titrating therapy to achieve an optimal physiologic, oxygenation, and hemodynamic slate and limiting the potential for
iatrogenic injury. Normal parameters may not be optimal in
these patients. The most challenging aspect of care is to
identify and support optimal parameters (which change
almost constantly) for an individual patient. Another important factor is to trend the parameters over time and assess
whether they make clinical sense and correlate with changes
in the physical examination.
Monitoring Oxygen Supply and Demand. The
goal in managing critically ill patients is to ensure adequate
O 2 supply with respect to demand. Each phase of oxygenation is monitored: (I) gas exchange over the pulmonary
capillary membrane, (2) oxygen transport in the blood, and
(3) oxygen consumption. All three parameters are interrelated in that changes affecting one phase affect the others.
Gas exchange over the pulmonary capillary membrane is
assessed by calculating the alveolar-arterial P02 difference
(A-aD02). To obtain an A-aD02, the Pa02 (obtained from an
ABG report) is subtracted from the PA02 (calculated using
the alveolar air equation: PA02 = PI02 - Pae02/RQ). Normally, the A-aD02 should be less than 20 mmHg. .
When mixed venous gases are available, the Qs/Qt ratio,
the ratio of shunted blood (Qs) to total pulmonary blood
flow (Qt), is calculated using the shunt equation: Qs/
Qt = (Cpe02 - Ca02)/(Cpe02 - C\i02), where CPC02' Cao2•
and CV02 are the pulmonary capillary, arterial, and mixed
venous oxygen contents, respectively. The alveolar air
equation is used to provide data for the CPC02' The Qs/Qt
normally ranges from 3% to 7%. Shunt fractions greater
than 50% are not uncommon in patients with severe ARDS.
Oxygen transport in the blood refers to the amount of
arterial O2 available for tissue use. D02 is the amount of 02

Normal Blood Gas Values

Parameter

Arterial

Mixed Venous

Capillary"

pH

7.35-7.45

7.31-7.41

7.35-7.45

~~, saturation

:~~~7~mHg

~~;8~~Hg

t::::: ::~::

Pco,
HCO,
Total CO 2 content
Base excess/deficit

35-45 mmHg
22-26 mEqIL
23-27 mEqlL
+2 to -2

40-50 mmHg
Same as arterial
Same as arterial
Same as arterial

Same
Same
Same
Same

as
as
as
as

arterial
arterial
arterial
arterial
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leaving the heart to be delivered to tissues. Oxygen delivery
is calculated by D02 = Ca02 x CI x 10. Normal D02 is
620 ± 50 mllminIM 2
Oxygen reserve is the amount of oxygen returned to the
venous side of the circulation not used by the tissues.
Oxygen reserve is calculated in a similar manner to D02 but
includes the Cv02. The oxygen reserve = Cv02 x Cl x 10.
The high oxygen reserve, more than 400 mlIminIM 2, serves
as a protective mechanism to prevent tissue hypoxia during
periods of hypermetabolic need.
Oxygen consumption (V0 2 ), the total amount of oxygen
consumed by the body per minute, is calculated as the
difference between the 002 and oxygen reserve; that is,
(Ca02 - CV02) x CI x 10. Normal resting V02 in infants and
young children is twice that of adults; varying with age, the
V02 ranges from 120 to 200 mllminIM 2. The higher V0 2 in
the younger age group (approximately 175 mllminIM 2) is
due to the additional metabolic burden of growth. "Adequate" D02 is considered to be 4 times V02.
The arterial-venous oxygen difference (a-vD02 = Ca02 CV02) reflects tissue O 2 uptake. Normally, only a 3 to 5.5
mlldl difference exists between the Ca02 and the CV02, again
reflecting 25% oxygen use.
The 02ER represents the percent of oxygen delivered
to t!ssues that is actually used. The 02ER indicates adequacy
of 002 with respect to V0 2. The rate of oxygen consumption!
availability is calculated by: a-vDoiCa02 x 10. Normal
02ER is 25 ± 2%.

5v0 2 Monitoring
Pediatric-size oximetry pulmonary artery catheters allow
continuous monitoring of mixed venous oxygen saturation
(S\102)' The technology is very similar to pulse oximetry
except that the sensor sits at the end of a pulmonary artery
catheter and continuously monitors Sv0 2. Mixed venous
oxygen saturation continuously reflect.s the interaction
among all variables impacting 002 and Vo,.
As V02 increases, the body compensate~ by increasing
oxygen supply in an effort to preserve venous reserve.
Sympathetic stimulation increases both cardiac output and
minute ventilation, so Sv0 2 remains unchanged.
If compensation starts to deteriorate or is ineffective or
impossible (e.g., the cardiac output, Sa02, or hemoglobin is
or cannot be further maximized), threefold increases in
tissue extraction can occur to prevent hypoxemia. A
decreased Sv0 2 indicates that the patient is using venous
reserve; alterations of more than 5% lasting for more than 5
minutes are considered significant.
Decreased Sv0 2 can result from increased V0 2 or
decreased D0 2 . Factors that impact V02 are noted in Table
8-4. Factors that decrease D02 include a myriad of problems
affecting cardiac output, hemoglobin concentration, and
saturation. Primary interventions are always focused to
correct the primary problem, followed by interventions
focused to support compensatory mechanisms.
Although SV02 trends are critically important in patient
care management, one of the greatest benefits of continuous
S\102 monitoring is assessment of patient tolerance to care
procedures. Patients with little oxygen reserve have negli-

gible tolerance to basic care activities, such as repositioning
and physical care. In addition, these extremely vulnerable
patients may undergo desaturation with suctioning, no
matter how cautiously the procedure is performed. Trending
the patient's ability to recover from necessary procedures is
helpful in determining how best to administer care, for
example, separating or clustering care.
Increased Sv02 can result from decreased V02 or
improved D0 2. Factors that decrease V02 include sleep, adequate sedation and pain relief, normothermia, chemical paralysis, and anesthesia. Pathologic issues that decrease V0 2
include right-to-left shunting associated with sepsis and cyanide toxicity associated with nitroprusside administration.
Factors that improve D0 2 include interventions that optimize
cardiac output, hemoglobin concentration, and saturation.
Convergent oximetry-that is, decreasing Sa02 and
increasing Sv0 2--equates with cell death, whereas divergent oximetry-that is, increasing Sa02 and decreasing
Sv02--equates with cell life.

PULMONARY DIAGNOSTIC STUDIES
Radiologic Procedures
Serial chest x-ray films are used to monitor the progression
of disease and response to therapy and to confirm various
tube placements preventing iatrogenic injury. Although the
quality of portable films varies, they are often performed
in lCU settings. Fundamental skills in x-ray interpretation
are necessary because critical care nurses are often the
first individuals to assess the chest x-ray film and are
responsible for manipulating various tubes into position.
Access to films is even more prevalent, given the increased
use of computerized systems that directly image films in
the lCU.
Just before obtaining a chest x-ray film, it is important to
ensure the best quality film possible by removing anything
from the patient's chest that would obscure the image. The
head and neck are placed in alignment, and the head is
positioned in a neutral position. Neck flexion or extension
would displace the Err. Radiation precautions for patients
include gonad shielding.
When evaluating a film, one interprets the characteristics
of and relationships between structures of varying density
ranging from air, fat, and water to bone. If the structure is
not dense (air-filled alveoli, pneumothorax, air in the
stomach), the x-ray beam passes through the tissue, resulting in a dark gray or black image on the film. A very dense
structure (bone) will block most of the x-ray beam,
preventing it from reaching the film and resulting in a light
gray or white image. Usually, lung is translucent, whereas
the heart, blood vessels, liver, spleen, and muscle appear
opaque on x-ray.
As illustrated in Fig. 8-27, the trachea has a tubelike
appearance and is visible in the midline of the anterior
mediastinal cavity. The trachea bifurcates into the right and
left mainstem bronchi at approximately the level of the
fourth rib. The bronchi are usually not clearly visible but
have a tubelike appearance if surrounded by consolidated
lung. The heart is visible in the anterior left mediastinal
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Fig.8-27 Chest x-ray film with landmarks. A, Endotracheal tube
I cm above the carina. B, Carina. C, Left subclavian introducer tip.
0, Pulmonary artery catheter tip in the RUL. E, Nasogastric tube
tip off film in region of duodenum. (Courtesy Robert Cleveland.
MD. Radiology Department, Children's Hospital, Boston, Mass.)

cavity and should occupy less than one half of the thoracic
cavity. The clavicle and ribs are evaluated for continuity.
The lung parenchyma is usually not visible throughout the
lung fields except for white lines radiating from the hilum,
which represent the pulmonary vascular tree. Pulmonary
vascular markings are usually visible in the proximal two
thirds of the lung. If the density of the lung changes, for
example, with atelectasis, pneumonia, pulmonary edema, or
hemorrhage, the lung will appear more opaque. When
structures of similar density, for example, the heart and
atelectatic lung, are positioned side by side, they cannot be
differentiated from each other, so the heart border disappears. The heights of the right and left diaphragm are
compared for symmetry. The costophrenic angles should be
well defined and taper into points. The dark gastric bubble
is seen under the left diaphragm.
Major problems such as a pneumothorax, or a displaced
airway, central line, or feeding tube, should be identified so
that immediate interventions can occur. 37 The patient's ETT
should be visualized within the trachea midway between the
carina and clavicles. The radiopaque markings on the ETT
should end 2 to 3 cm above the carina-the point at which
the right and left mainstem bronchi bifurcate. When
assessing ETT position, head position is first assessed to
ensure a neutral position. If the neck were flexed, the ETT
would be displaced downward; if the neck were extended,
the ETT would be displaced upward. When the ETT is "too
high," the tip is positioned at the level of the clavicles.
When the ETT is "too low," the tip is positioned near the
carina or down either mainstem bronchi-most often the
right because it is more vertical than the left. When the ETT
intubates either bronchus, hyperinflation of the affected lung
occurs along with hypoinflation and atelectasis of the
un intubated lung.
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Lung tissue normally fills the chest, so pulmonary
markings should be equal and visible out to the rib margins.
If the pulmonary markings are replaced with a dark edge,
consider a pneumothorax. When significant, the trachea may
deviate away from the collapsed lung. If a dark line
encircles the mediastinum, consider a pneumomediastinum.
The patient's central line should sit high within the right
atrium. The patient's pulmonary artery catheter should sit
within the main pulmonary artery or proximal within the
right or left pulmonary artery. The patient's nasogastric tube
should sit within the stomach. Landmarks include the right
atrium (RA), which is located to the right of the sternum and
extends down to the diaphragm. Above the RA is the
superior vena cava (SVC). The left ventricle (LV) is to
the left of the sternum and rests on the diaphragm. Above
the LV is the left atrium (LA), and above that are the
pulmonary arteries (PAs). The stomach sits under the left
diaphragm.
Other radiologic procedures of the pu.lmonary system
include fluoroscopy, angiography, and V/Q and computed
tomography (CT) scanning. Fluoroscopy images the dynamic process of ventilation and thus is very useful during
pulmonary artery catheter insertion in a small infant and in
assessing diaphragmatic function. Pulmonary angiography
is a radiologic study of the pulmonary vessels used to
delineate pulmonary arteriovenous malformations and pulmonary embolus. V/Q scanning includes two complementary tests involving the inhalation and IV injection of
necular material for the purpo.se of deternlining the match of
ventilation to perfusion. V/Q scanning provides valuable
information in the lung transplant patient. Before sequential
single-lung transplant, a V/0. scan is used to help determine
the better lung to maintain ventilation while the other lung
is being transplanted. CT scan images correlate closely with
macroscopic appearances of the lung, so in the context of
diffuse lung injury, they represent a substantial improvement over chest x-ray films.

Bronchoscopy
Technologic advances have provided the opportunity for
even the smallest of neonates to benefit from bronchoscopy.
Two types of bronchoscopic examinations are available:
rigid and flexible. Rigid bronchoscopy is often performed in
the operating room under general anesthesia, whereas
flexible bronchoscopy is often performed within the ICU
environment. Bronchoscopes have all or some of the
following features: fiberoptics for visualization and ports for
ventilation, suction, retrieval of objects, or collection of
specimens.
Box 8-2 provides a summary of the potential indications
for bronchoscopy. Rigid bronchoscopy offers a large channel, so it is used predominately for the retrieval of a
foreign body and control of bleeding in the presence of
massive hemoptysis. The three most common techniques
employed through flexible bronchoscopy include bronchoalveolar lavage, transbronchial biopsy, and bronchial
brushing.
Nursing care during a bedside bronchoscopic examination is generally supportive; the priority is ensuring a safe
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environment. Anesthesia, if indicated, is provided by an
anesthesiologist. Conscious sedation and coaching the patient through the procedure are nursing responsibilities.
Emergency medications should be prepared before the procedure and access to a vascular line maintained during the
procedure. Potential complications include laryngospasm,
hypoxia, cardiac dysrhythmias secondary to hypoxia or vagal stimulation, bronchial tears, pneumothoraces. pulmonary hemorrhage, epistaxis, subglottic edema, contamination of the lower airway with upper airway flora, and
oversedation.

~

Box 8·2
"

Potential Indications for Bronchoscopy

Rigid Scope

Foreign body removal
Tissue mass removal
Massive hemoptysis
Establishment of an airway in patients with an upper airway
obstruction
Flexible Scope

Evaluation of stridor
Persistent or recurrent atelectasis
Identification of infectious organisms
Hemoptysis
Difficult intubation
Abnormal cry or hoarseness
Vocal cord paralysis
Evaluation of a mass lesion
From Behnke M, Koff PH: Patient assessment. In Koff PB, Eitzman D, Neu J.
eds: Neonatal and pediatric respiratory care. ed 2. 5t Louis, 1993.
Mosby. P 45.

TABLE

8-10

RESPIRATORY SUPPORT
Oxygen Therapy
The goal of oxygen therapy is to relieve hypoxemia,
decrease the work of breathing, and reduce myocardial
stress. 38 Oxygen, considered a medication, is administered
in the lowest possible concentration to support life while
avoiding toxicity. Pulmonary toxic effects of oxygen are
progressive and include diminished mucociliary clearance,
capillary endothelial damage, interstitial edema, and destruction of type I pneumocytes. Subsequent progression
includes hyperplasia of the type II pneumocytes, interstitial
fibrosis, and then death. 39
Environmental gases are warmed and humidified to
100% relative humidity. Proper humidification of inspired
gas prevents drying of the tracheobronchial tree, which may
cause impaired ciliary acti vity. inflammatory changes, and
retention of thick secretions 38 Providing warmed humidified gas is particularly important in infants who are sensitive
to heat loss and in patients with a bypassed upper airway, as
in those who are intubated.
When the airway is secure and the patient is spontaneously breathing, oxygen can be delivered as needed by
several modalities. These include simple mask, partial or
nonrebreathing mask, face tent, nasal cannula, oxygen hood,
hut tent, and mist tent. Any of these delivery devices can be
regulated to achieve desired oxygen concentrations. Table
8-10 summarizes the advantages and disadvantages of
several commonly used oxygen delivery devices.

Oxygen Delivery Devices
Simple Face Mask. The most common type of
oxygen delivery device is the simple face mask. Available in
a wide variety of sizes, these masks are designed to deliver
oxygen through a cone-shaped face piece with open

Oxygen Delivery Devices
FlO,

Flow Rate (Umin)

Advantages

Disadvantages

0.35-0.55

Child: 3-5
Adolescent: 5-10

Easy to use

To 0.60

Variable-adjust to keep
reservoir partially filled
Variable-adjust to keep
reservoir partially filled

Delivers higher

Patient may overbreathe flow rate
and entrain room air
ca, retention at low flow rates
Patient intolerance
Same as for simple face masks

To 1.0

FIO,

Delivers higher FIO z
Can be used to administer
other gases (Hea,)
Ease of use
Patient tolerance

Variable

25 ml/min to 6 Llmin

To 1.0

10-15

Patient tolerance
Patient access

To 0.5

10-15

Provides cool mist

Same as for simple face masks

FIO Z varies
Gastric inflation at high flow rates
May occlude with nasal secretions
Noise level
Limited to infant~ younger than
I year
Limited and variable FIO,
Cumbersome

from Wilson BG, Desautels DA: Oxygen therapy. In KoffPB. Eirzman D, Neu J. eds: Neonatal and pedilllric respiratory care. ed 2. 51 Louis, 1993,
asby.
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exhalation ports. The FI02 is influenced by the size of the
mask, the patient's ventilatory pattern and tidal volume, and
oxygen flow. As tidal volume increases, FIOZ is decreased as
more environmental air is pulled in (entrained) through the
exhalation ports. Too small of a mask will decrease inspired
FIO z; a mask too large will add excessive dead space. An
FI02 of 0.35 to 0.55 can be achieved when oxygen flow rates
of 3 to 5 Llmin in a child and 5 to 10 L/min in the adolescent
are used. 40
Face masks are not usually tolerated by infants and small
children. This age group does not understand the benefit of
a tight-fitting mask blowing moist air on their face. If the
patient struggles, hypoxemia will worsen as V02 increases
while DO z remains unchanged. There is also an increased
risk of aspiration if the infant or child vomits into the mask.
Partial Rebreathing Mask. A partial rebreathing
mask is similar to a simple face mask with an added
reservoir bag. The purpose of the reservoir bag is to collect
the first third of the patient's exhaled gas, dead space gas
that is high in oxygen and low in carbon dioxide. Allowing
rebreathing of this gas mixed with a fresh oxygen source
will allow an F102 as high as 0.6. 40 Entrainment of room air
is reduced, and rebreathing of carbon dioxide from the mask
is prevented by maintaining an oxygen flow rate into the bag
that is greater than the patient's minute ventilation. This is
determined by adjusting the flow rate high enough to keep
the bag from completely deflating during inspiration;
generally, gas flows at 10 to 12 Llmin are required. 3
Nonrebreathing Mask. A nonrebreathing mask is
similar to the partial rebreathing mask except that one-way
exhalation valves are incorporated into the sides of the mask
to prevent entrainment of room air and a valve is placed at
the reservoir bag to prevent gas flow back into the bag
during exhalation. The patient can only draw gas from the
oxygen-rich reservoir bag and displace gas through the
exhalation valves. To achieve maximum oxygen concentration, the mask must fit snugly. When the mask fits properly
and the reservoir is inflated, this device can provide an FI02
close to 1.0. 40
Most disposable nonrebreathing masks are manufactured
with one exhalation valve removed. This safety mechanism
allows the patient to breathe room air if gas flow into the
mask is interrupted. This type of nonrebreathing mask
(manufactured with only one exhalation valve) is only
slightly more effective in delivering high FI02 than a partial
rebreathing mask.
Face Tent. Sometimes referred to as a shovel or scoop,
a face tent is a soft plastic mask that fits close to the chin but
is completely open around the patient's face. This device is
better tolerated by infants and children because the face is
accessible, allowing the patient to use a pacifier, eat, or talk?
The downside of this device is that even at high flow rates,
an FI02 in excess of 0.4 is difficult to achieve.
Nasal Cannula. A nasal cannula provides a lightweight, less restrictive system for oxygen delivery. The
device consists of either soft plastic prongs that are inserted
into the nares or slits within soft plastic tubing that direct
oxygen toward the posterior naso-oropharynx. It is difficult
to predict and control the FI02 using these devices. The FIO z
depends on the flow rate of oxygen, the patient's spontane-
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ous minute ventilation, peak inspiratory flow, the volume of
environmental air inhaled by the patient, cannula position,
the proportion of nose to mouth breathing, and the size of
the upper airway, which provides an anatomic oxygen
reservoir?8 Changes in any of these parameters result in
changes in the F102.
In infants, low-flow flowmeters are used to allow more
precise titration of gas flow. Titrations in flow rates are made
based on the desired Spoz and blood gas. Oxygen flow
(Llmin) should not exceed the patient's predicted minute
ventilation (VT x RR). Excessive flow rates may cause
gastric distension and vomiting. 41
Nasal cannulas are useful in clinical situations in which
the infant or child requires less precise and low FI02
concentrations for extended periods. Nasal cannulas allow
the patient to use a pacifier, eat, or talk while receiving a
continuous flow of oxygen. To maintain skin integrity,
cannulas can be taped to small pieces of Duoderm Extra
Thin (Convatec, Princeton, N.J.) placed directly on the
maxilla. Potential problems include otitis media, sinusitis,
and a local reaction to the plastic prongs.
Oxyhood and Hut Tents. An oxyhood is a clear
plastic enclosure that fits over the infant's entire head and
neck. A hut tent is a small tent frame with canopy that fits
over the infant's upper body. Capable of delivering an F102
of 1.0, both require a flow rate of 10 to IS Llmin to flush out
exhaled COz. Oxygen may layer within the hood or hut,
producing a higher oxygen concentration at the bottom of
the device. Oxygen concentrations are continuously monitored close to the infant's head with high and low alarm
limits set on the oxygen analyzer. 38
Oxyhoods are well tolerated by infants because free head
movement is allowed, in addition to the use of pacifiers and
other comfort measures. Hut tents allow the infant handmouth self-stimulation. One potential problem is the noise
level produced by incoming gas. Also, the delivery of cold
gas can result in considerable stress to small infants;
therefore heating and humidification must be provided.
. Mist Tent. Mist tents are clear plastic enclosures that
fit over the patient's entire body, providing cool aerosol and
low to moderate concentrations of oxygen. The F102 varies,
depending on total gas flow, tent volume, and the tightness
of seal around the bottom of the tent. Again, higher levels of
oxygen are found lower in the tent. An FI02 of up to 0.5 can
be achieved at flow rates of 10 to 15 Llmin if patients are
left undisturbed. However, leaving a critically ill patient
undisturbed is usually not an option within the ICU
environment. In addition to limited patient access, the mist
may also compromise caregiver observation of the patient.
For comfort, frequent linen changes are necessary. For fire
safety, patients are instructed not to play with any electrical
or friction toys within the tent.
Resuscitation Bag-Valve-Masks. Bag-valve-mask
ventilation provides a method of ventilating a patient with
ineffective or absent respirations. Resuscitation bags and
face masks are available in a wide variety of sizes to
accommodate the wide range in pediatric size. Correctly
sized masks provide an airtight seal around the patient's face
from the bridge of the nose to the cleft of the chin. Round
masks function well in small infants, whereas anatomically
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correct masks reduce the potential for ocular pressure that
precipitates vagal stimulation and tend to provide a better
seal in older children. Masks should have a small undermask
volume to decrease dead space and prevent rebreathing.
Clear masks are preferred because continuous assessment of
the patient's color and early identification of regurgitation
are possible 3
Bag size is selected to accommodate patient lung
volume. Two types of resuscitation bags are available:
self-inflating and anesthesia.
Self-Inflating Bags. Self-inflating bags consist of a
standard l5/22-mm connector for mask or endotracheal tube
connection, a nonrebreathing valve assembly that also
regulates inspiratory and expiratory pressures, a pressure
release valve, and a self-inflating bag with distal ports for
oxygen and a reservoir to entrain room air. The oxygen gas
inlet has a one-way valve that fills the bag with oxygen. At
10 L/min of oxygen flow, the self-inflating bag will deliver
an Fl02 of 0.3 to 0.8; higher concentrations can be achieved
if an oxygen reservoir is attached to the room air port.. The
bag automatically fills independently of gas flow.
During bag inflation, the gas val ve opens, entraining
room air or oxygen from the reservoir. During bag compression, the gas intake valve closes, and the patient valve
is opened. During patient exhalation, the nonrebreathing
valve closes, and exhaled volumes are displaced into the
environment.
To avoid barotrauma, most self-inflating bags are
equipped with a preset (or adjustable) pop-off valve that
allows a maximum peak inspiratory pressure of 30 to 35 cm
H2 0. Although appropriate in the intubated patient, preset
valved bag-valve-masks have limited use in extubated
patients with poor lung compliance who require high
inflating pressures for adequate tidal volume. Also, because
of the bag-valve assembly, self-inflating bags cannot be used
to provide supplemental oxygen to a spontaneously breathing patient. Even if the pediatric patient could generate
sufficient negative pressure to open the val ve, the added
work of breathing is not optimal. Also, some self-inflating
bags are designed to deliver volume only when the bag is
actually compressed.
Anesthesia Bags. Sometimes called flow-inflating or
"Mapleson" bags, anesthesia bags inflate when a gas is
deli vered into the bag. These bags consist of a standard
15122-mm connector for mask or endotracheal tube connec-
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tion, a gas inlet port, pressure gauge port with manometer,
a corrugated reservoir tube, a non-self-inflating reservoir
bag, and a distal adjustable gas escape port or pop-off valve.
Careful adjustment of flow is required to maintain volume in
the reservoir tube and bag while also flushing out exhaled
gases. When the reservoir bag is compressed, the patient
receives tidal volume from the oxygen source and corrugated reservoir tube. Flow rates 2 to 3 times the patient's 'it E
are usually adequate to keep the bag half inflated between
breaths.
Careful adjustment to gas escape is required to provide
adequate tidal volume, peak inflating time and pressure, and
end-expiratory pressure. High inflation pressures, continuous positive airway pressure (CPAP), and ventilatory rates
are matched by high flow rates to adequately inflate the bag.
Improper use may result in pulmonary barotrauma (high
flow, low escape), insufficient washout of exhaled gases
(low flow, low escape), or insufficient tidal volumes (high or
low flow, high escape). To prevent barotrauma, an in-line
manometer should be used to monitor and deliver appropriate levels of peak inspiratory and end-expiratory pressures.
Because of the continuous flow, anesthesia bags can be used
to provide oxygen and CPAP in the spontaneously breathing
patient.

Airway Adjuncts
The goals of airway management include recognition and
treatment of obstruction, prevention of aspiration of gastric
contents, and promotion of adequate gas exchange. 42
Repositioning the patient using a chin lift or jaw thrust may
relieve upper airway obstruction. Although endotracheal
intubation may be required, nasopharyngeal or oropharyngeal airways are simpler devices when assisted ventilation is
unnecessary.
Nasopharyngeal Airways. A nasopharyngeal airway is a soft rubber tube that, when properly positioned,
extends below the base of the tongue. Nasopharyngeal
airways rarely induce vomiting, so they can be used in both
the conscious and obtunded patient. Available in sizes 12 to
36 Fr, the size chosen should fit snugly within the naris
without causing sustained blanching? The 12 Fr size usually
accommodates an infant. Appropriate length is determined
by measuring the distance from the tip of the nose to the
tragus of the ear (Fig. 8-28, A).

B

Fig. 8-28 A, Placement of nasopharyngeal airway. B, Oropharyngeal airway. (Adapted from Cote CJ,
Todres ID: The pediatric airway. In Cote CJ, Ryan JF. Todres ID et ai, eds: A practice of anesthesia ill
illfallts alld childrell, ed 3, Philadelphia, 1999, WB Saunders.)
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Care measures include maintauung skin integrity and
tube patency. Potential complications from nasopharyngeal
airways include epistaxis and ulceration of the tip of the
nose. Laryngospasm may occur if the airway is too long and
impinges on the epiglottis. Nasopharyngeal airways should
not be placed in those at high risk for uncontrolled bleeding
(e.g., anticoagulated patients) and in those with head or
facial trauma at high risk for cribriform plate fracture.
Oropharyngeal Airways. An oropharyngeal airway
is a rigid plastic device that curves over the base of the
tongue, pulling it forward away from the pharyngeal
wall. Because of the potential for induced vomiting and
laryngospasm, oropharyngeal airways are placed only in
unconscious patients. Oropharyngeal airways are used to
(I) relieve airway obstruction caused by the' tongue,
(2) facilitate oropharyngeal suctioning, and (3) facilitate
endotracheal suctioning and ventilation when the patient is
biting down on an oral ETT. The correct size for an
oropharyngeal airway is determined by placing the airway
next to the patient's face with the phalange next to the teeth.
The tip of the airway should reach the angle of the jaw (see
Fig. 8-28, B). The airway is inserted by depressing the
tongue with a blade and inserting the airway to follow the
natural curve of the tongue. Inserting the airway upside
down then rotating it 180 degrees may cause damage to
fragile oral mucosa.
Care measures include maintaining skin integrity of the
lips, tongue, and mouth. A misplaced oropharyngeal airway
will result in airway obstruction by pushing the tongue back
in the oropharynx. Complications of oropharyngeal airways
include trauma to the lips, teeth, tongue, and surrounding
soft tissue. 42
Endotracheal Tubes. ETTs are constructed of soft
plastic (polyvinyl chloride). The proximal end is fitted with
a standard IS-mm male adapter. The tip is beveled to allow
smooth passage through the nares, and a side hole ("Murphy
eye") provides ventilation in the event of distal obstruction.
ETT labeling includes the size of the ETT, a radiopaque line
down the entire length of the ETT, and distance hatch
markings (in centimeters) that provide reference points to
facilitate tube placement. A distal vocal cord marker is
placed at the level of the glottic opening to ensure that the
tip of the ETT is in a midtracheal position. 3
Uncuffed ETTs are typically used in children younger
than 8 years of age because the cricoid cartilage serves as a
physiologic cuff. When air leaks around ETTs become
unmanageable, cuffed ETTs may be used. Soft cuffs,
low-pressure high-volume cuffs, exert low and equal lateral
tracheal wall pressure to minimize the potential for tracheal
injury. The inflating tube is constructed with a distal
one-way valve and a "pilot" balloon that indicates the
presence of air within the cuff.
Approximate ETT size can be calculated using the
following formula: ID = 16 + age in years'" 4 (where ID is
the internal diameter in mm). Usually, a 3- to 3.S-rnm ETT
will accommodate term newborns, whereas a 4-mm ETT
can be used in infants younger than I year of age. A quick
check can be made by comparing the outside diameter of an
ETT with the patient's little finger. Table 8-11 lists
recommended sizes per age of the patient.
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Endotracheal Intubation. Indications for endotracheal intubation include establishment of a secure airway in
patients with a diminished gag or cough reflex and the need
for controlled ventilation. Before endotracheal intubation,
the patient is positioned in a sniffing position, and equipment is prepared (Box 8-3). An adequate cardiac and pulse
oximetry tracing is ensured. A suction source and Yankauer
are made available to clear the oropharynx of thick

8·11 m and .Suction
Catheter Sizes

tABLE

Err Size (mm)
.~ewbom

:.' months

3-3.5 uncuffed
3.5-4 uncuffed
4-4.5 uncuffed
4.5 uncuffed
5 uncuffed
5.5 uncuffed
6 cuffed or uncuffed
6.5 cuffed or uncuffed
7-8 cuffed
7.5-8 cuffed

Suction Catheter Size
6-8 Fr
8 Fr
8-10 Fr
8-10 Fr
10 Fr
10-12 Fr
12 Fr
12-14 Fr
14 Fr
14-16 Fr

-

~

Box 8-3

'.

.

Intubation Equipment Checklist .

Patient
Monitoring equipment
Good cardiac tracing
Strong Spa2 pulse indicator
Good A-line tracing or operational blood pressure cuff
Medications
Sedation
Muscle relaxant

Equipment
Oxygen
Adequately sized mask
Resuscitation bag to provide FI02 of 1.0
Suction
Large-bore Yankauer or tonsil-tip suction
Sterile suction catheters that will fit the selected endotracheal tube (E1'f)
Laryngoscope
Handle. correct size and shape of blade. strong light
source
E1'fs
Calculated size--{)ne size larger and smaller than
calculated
Stylet to fit the selected E1'f
Water-soluble lubricant for nasotracheal intubation
Magill forceps for nasotracheal intubation
Adhesive tape and skin protector
Appropriately sized nasogastric tube with attached catheter
tip syringe
Gloves and goggles-per universal precautions
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8-12

Intubation Medications
Dose (duration)

Comment

0.05-0.1 mg/kg IV (1-2 hr)
1-5 ~glkg IV (0.5-1.5 hr)

May cause respiratory depression
Respiratory depression; large doses given rapidly
may cause bradycardia and chest wall rigidity
Respiratory depression; histamine release
producing bronchospasm and hypotension

0.1-0.2 mglkg IV (2-4 hr)

0.5-2 mg/kg IV (10-15 min)
Intubation: administer with glycopyrrolate

0.3 mg/kg IV

2-3 mg/kg (4-8 min)

2-4 mg/kg IV (5-10 min)
1-2 mg/kg

~r:
cC.

Useful in hypotensive patients because of catecholamine release (increases HR and BP);
potent bronchodilator; increases ICP; spontaneous respirations maintained but may cause
laryngospasm; copious secretions
Minimal cardiovascular effects; decreases
cerebral metabolic rate, cerebral blood
now, intracranial pressure.
Short acting; less sedation on awakening; dosedependent cardiovascular depression; pain on
injection
Potent myocardial depressant; decreases peripheral vascular resistance and may precipitate
CV collapse in the patient with MC dysfunction and hypovolemia; will produce apnea
in doses greater than 4 mg/kg; decreases
cerebral metabolic rate, cerebral blood
now, intracranial pressure

uromuscular Blocking Agents

". polarizing
jlccinylcholine (Anectine)

Infants: 2 mg/kg
Children: 1-2 mg/kg
Adolescents: 1-1.5 mg/kg (3-12 min)
Administer with atropine

Decrease HR: may increase intracranial, intraocular, and intragastric pressure; arrhythmias
common with second dose; may cause
massive elevation in serum potassium in
patients with severe burns, crush injuries,
spinal cord injury, and neuromuscular disease;
known trigger for malignant hyperthermia;
myoglobinuria in healthy children

. R, Hean rate: B?, blood pressure: IC?, intracranial pressure: Cv, cardiovascular; MC, myocardial.

secretions, vomit, or blood. An appropriately sized resuscitation bag and mask are needed to pre/reoxygenate the
patient with an F102 of 1.0. To visualize the vocal cords, the
large floppy epiglottis in infants and children is raised using
a straight Miller laryngoscope blade.
The sedatives, narcotics, anesthetics, and neuromuscular
blocking agents commonly used to facilitate intubation are
noted in Table 8-12. Neuromuscular blocking agents are
divided into two groups: depolarizing and nondepolarizing
agents. Depolarizing agents mimic the action of acetylcholine but produce prolonged depolarization of the neuromuscular junction. Nondepolarization agents bind to acetylcholine receptor sites, preventing depolarization of the
neuromuscular junction. Use of neuromuscular blocking
agents are contraindicated when the ability to establish an
artificial airway is in question or difficulty in maintaining
adequate ventilation is anticipated. 43 Only time will reverse
the effects of a depolarizing agent, whereas pharmacologic

Continued

reversal of nondepolarizing agents can be obtained by
increasing the concentration of acetylcholine at the neuromuscular junction. Administration of an anticholinesterase
inhibitor plus muscarinic antagonist will accomplish this
effect (see Table 8-12).
Unless contraindicated, the depolarizing agent succinylcholine is recommended for intubation because of its
rapid onset (45 to 60 seconds) and short duration (5 to
10 minutes). For intubation, succinylcholine is usually
administered with an anticholinergic agent (atropine) to
prevent excessive vagal effects related to the initial release
of acetylcholine. If succinylcholine is contraindicated, a
rapid-acting nondepolarizing agent, for example, either
atracurium or vecuronium, can be used. To produce a more
rapid effect, a priming dose (one-tenth the intubating dose)
is administered 5 minutes before the intubating dose.
The technique of endotracheal intubation depends on the
indication for intubation and the condition of the patient.
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Intubation Medications--cont'd
Dose (duration)

Comment

~Neuromusc~ar Blocking Agenls--cont'd
~'!!iondepolanzmg

Ii'

I¢isatracurium besylate (Nimbex)

mill

I~Vecuronium bromide (Norcuron)

ml.~

~':Pancuronium bromide (Pavulon)

f

0.1-0.2 mg/kg IV (15-20 min)
0.1-0.2 mg/kg/hr infusion
0.1-0.15 mg/kg/dose rv (children: 35 min;
infants: 70 min)
0.06-0.1 mg/kg/hr infusion
0.1-0.15 mg/kg IV (30-90 min)

J~
tocuronium (Zemuron)

0.6-1.2 mglkg IV (20-30 min; 45-60 min)

!i!¥:'
lilt',
lli'1i'

lil1!

~i~apacuronium (Raplon)

IifiJ.i'

1.5 mg/kg
(10-15 min)

Mild histamine release; hypotension;
neither renal nor hepatic function
necessary for excretion; active
metabolites
Minimal CV effect
Elimination: liver
Vagolytic effect increases HR; may
increase BP
Elimination: liver and kidney (repeated
doses contraindicated in renal
failure)
Minimal cardiovascular effect; rapid onset
of action using-larger dose; possible
alternative to succinylcholine for
rapid-sequence induction; hepatic
clearance
Onset 60-90 sec-alternative to succinylcholine
for rapid-sequence induction

eversal Agents
Anticholinesterase Inhibitors
0.06 mglkg; max 2.5 mg
0.1-0.25 mg/kg; max 10 mg

Reverses the effects of nondepolarizing neuromuscular blockade; always precede with
atropine

0.02-0.03 mg/kg; min 0.1 mg/max 2 mg

Used to prevent bradycardia, salivation,
bronchospasm. and gastrointestinal
hypermotility

0.01 mg/kg
1-2 mg/kg IV qh

There are many accepted techniques for ETT placement.
ETTs may be placed nasally or orally, patients may be fully
awake or receive some combination of sedation and analgesia, and patients may be pharmacologically paralyzed or
breathing spontaneously. Common approaches in the intensive care setting include nasal, rapid sequence, awake oral,
unconscious oral, and fiberoptic bronchoscopy. Whatever
approach is used, the patient's vital signs and oxygen saturation are continuously assessed. The intubation procedure is
immediately interrupted and the patient receives hand ventilation with a bag-valve-mask if desaturation occurs.
Nasotracheal intubation is preferred if intubation is
anticipated for a long period. Nasotracheal ETTs are more
comfortable for the patient, allow continued oral stimulation, are easier to secure, and are less apt to be displaced.
Complications associated with nasotracheal intubation include epistaxis, trauma to adenoids, pressure necrosis to the
naris, obstruction of the eustachian tube, and sinusitis.

Given 2 min before suctioning may prevent
elevations in ICP

If nasotracheal intubation is performed, the ETT is
lubricated, inserted nasally, and gently advanced until the tip
is visualized in the pharynx. The laryngoscope is then used
to visualize the cords, and the Magill forceps are used to
direct the tip of the tube through the vocal cords. Contraindications of nasotracheal intubation include fracture of the
cribriform plate with a cerebrospinal leak, bleeding disorders, and nasal deformities.
Orotracheal intubation can be performed rapidly and
is associated with minimal complications. A curved
Macintosh laryngoscope blade is inserted into the vallecula above the epiglottis, whereas a straight Miller blade
is passed over the epiglottis to rest above the glottic opening. Once the vocal cords are visualized, the ETT is advanced. Stylets are used to stiffen and shape ETTs to facilitate insertion. When used, stylets are positioned proximal to
the side hole and should not protrude through the end of the
ETT because this may cause vocal cord damage.
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Fig. 8-29 A to E, Effect of head position on EIT position. (From Donn SM, Kuhns LR: Mechanism of endotracheal tube movement with change of head position in the neonate. Pediatr Radiol
9:37-40, 1980.)

Rapid-sequence intubation is used to decrease the risk of
aspiration of gastric contents. Patients at high risk for
aspiration include those with a full stomach caused by prior
oral intake or decreased gastric emptying, resulting from
pain, shock, or increased abdominal pressure. The procedure
is accomplished by an IV infusion of a rapid-acting
anesthetic or sedative, for example, some combination of
thiopental sodium (Pentothal), methohexital sodium (Brevital), ketamine, or midazolam with a muscle relaxant, usually
succinylcholine. Cricoid pressure is applied to prevent
passive regurgitation, and the Err is inserted orally. If the
patient's gag and cough reflex is intact, gastric decompression occurs before intubation. This technique should not be
attempted if anatomic abnormalities that potentially may
prevent rapid intubation are present.
Fiberoptic bronchoscopy is used if endotracheal intubation is expected to be difficult. Here, an Err is threaded
over a fiberoptic bronchoscope. Once the scope passes
through the vocal cords, the previously threaded Err is
advanced forward into position. The flexible fiberoptic
scope is also useful in evaluating vocal cord movement
before extubation. 10
Intubating a patient with increased intracranial pressure
(ICP) is specifically challenging. The goal is airway access

while averting cerebral hypertension associated with increased mean arterial pressure and hypercapnia. Intubation
is accomplished by anesthetizing the patient in an effort to
blunt expected cardiovascular responses. After preparing
the equipment, an anesthetic dose of thiopental sodium
(4 mg/kg) is administered, followed by vecuronium (0.10.2 mg/kg). Thiopental decreases cerebral oxygen consumption and thereby lowers cerebral blood flow and ICP.
Vecuronium is a nondepolarizing neuromuscular blocking
agent chosen to avoid histamine release and sympathetic
stimulation. Lidocaine (1.5 mg/kg IV) is also administered
to diminish cardiovascular reflexes activated with intubation. The patient is then hyperventilated to decrease Pacoz
and then intubated.
Also challenging is intubating the patient with a compromised airway secondary to a large mediastinal mass.
These patients are able to stent their airways open through
spontaneous chest movement. If respiratory muscle function
becomes impaired (through sedation, anesthesia, or neuromuscular blockade) a large mediastinal mass can collapse
the airway, leading to sudden and complete airway obstruction despite positive pressure ventilation. The goal is to keep
the patient breathing spontaneously until radiation or
chemotherapy can reduce the size of the mass.
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Fig. 8-30 Chest radiographs demonstrating impact of small movements of ETT. In the first radiograph
(A), right mainstem bronchus is intubated and left lung has collapsed. After withdrawing ETT just I cm
(8), left lung is partially reinflated.

Correct Placement. Once the EIT is placed, the
patient receives hand ventilation, which is done cautiously
with a resuscitation bag while EIT position is evaluated.
Correct EIT positioning is marked by observation of
condensation within the ETT, bilateral chest excursion,
symmetric breath sounds, nomlal ETcoicapnogram, and
adequate oxygenation. Auscultation of breath sounds is
best accomplished at the apex of each axilla; auscultation over the stomach rules out esophageal intubation.
Unilateral chest excursion marks mainstem bronchus intubation, whereas breath sounds will not be heard with
esophageal intubation. End-tidal CO 2 monitoring helps
confirm correct ETT placement; a capnogram is possible
only with endotracheal intubation.
After securing the EIT, a chest radiograph (with the head
in a neutral position) is obtained to confirm proper tube
position in the trachea midway between the carina and
clavicles. Once correct placement is established, continued
assessment of EIT position can be accomplished by noting
the depth of its insertion at regular intervals, that is,
documenting the mark on the tube that appears at the child's
lip or nares and carefully monitoring bilateral breath sounds.
Care is taken whenever moving an intubated infant or child.
Neck flexion shortens the mouth-to-carina distance, thus
displacing the uncuffed ETT tip downward and increasing
the danger of endobronchial intubation (Fig. 8-29). Neck
extension increases this distance, promoting accidental
extubation. Increased respiratory distress, grunting, crying,
or vocalization indicating air movement through the glottis
hallmarks inadvertent extubation.
Securing the fIT. Once EIT position appears satisfactory, the EIT is secured. To prevent inadvertent extuba-

tion, two people perform the procedure of taping or retaping
an EIT. One person is responsible for immobilizing the
head and holding the tube with the specific EIT markings at
the naris or lip line, while the other person is responsible for
the actual taping procedure. Breath sounds are auscultated
before and after taping. EIT position is changed from one
side of the mouth to the other during a tape change to
prevent pressure necrosis.
Numerous methods to secure EITs in the pediatric
population have been described. Benjamin, Thompson, and
O'Rourke44 reported a relatively low 3% incidence of
accidental extubation with the use of white cloth adhesive
tape slit down the middle, resulting in a Y configuration. For
an oral ETT, the skin of the upper lip and EIT are prepped
with tincture of benzoin and then allowed to dry. The EIT
is positioned so that it will be attached to the least mobile
area of the mouth, that is, the upper lip away from the corner
of the mouth. One arm of the Y is attached to the upper lip,
and the other arm of the Y is wrapped around the EIT. A
second piece, mirroring the first but started from the
opposite side of the mouth, can be placed for added security.
For a nasal ETT, the nose, upper lip, and EIT are prepped
with tincture of benzoin and then allowed to dry. The untorn
piece of tape is applied to the nose; one arm of the Y is
applied to the upper lip, and the other arm is wrapped around
the EIT. A second Y can be applied, positioning the untorn
arm on the cheek; one arm of the Y layers is placed over the
first piece on the upper lip, and the other is wrapped over the
first piece on the EIT. While taping a nasal EIT, care is
taken to avoid excessive pressure to the skin at the nasal
septum and outer upper ridge of the naris. Care is also taken
to avoid gaps in the tape when wrapping the EIT. Gaps fill
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with secretions, which eventually loosen the tape. First
applying Duoderrn (Convatec, Princeton, N.J.) to the face
and then attaching the tape to the Duoderm may protect
sensitive skin.
Complications from endotracheal intubation can occur
during laryngoscopy, any time during the intubation period,
or after extubation. Complications occurring during the
intubation procedure include dental and soft tissue trauma,
aspiration of gastric contents, esophageal intubation, right
mainstern intubation, and cardiac dysrhythmias from hypoxia. Obstruction of the EIT from secretions, kinking, or
biting; accidental extubation; and increased resistance to
breathing are the common complications during the intubation period. 42 Later complications include laryngeal and
tracheal edema or damage, acquired subglottic stenosis, and
the inability to extubate.
Extubation. The reported incidence of inadvertent
extubation in pediatric intensive care units (PICUs) ranges
from 3% to 13%.45 Although whether this variability is
related to differences in patients or in patient care practices
is unclear, several risk factors for accidental extubation have
been identified. Infants may be at particular risk because
their tracheas are shorter and head movement alone can
dislocate the EIT. 46 Scott and associates45 found that
spontaneous extubation was more likely to occur in a patient
who is younger, has a large amount of secretions and EIT
slippage, and a higher level of consciousness. In this
particular study, 29% of those patients reintubated after an
accidental extubation had at least one subsequent unplanned
extubation, and 88% of the patients who had spontaneous
extubation did so despite restraints. In another study,47 level
of sedation, lack of two-point or more restraints, and the
performance of a patient procedure at the bedside were
identified as critical factors contributing to accidental
extubation. Various methods are employed to secure the
EIT, but to avoid spontaneous extubation or inadvertent
advancement of the tube, frequent assessment of the patient
and the position and stability of the EIT are required. To
rule out right mainstem bronchus intubation (Fig. 8-30),
auscultation compares bilateral air movement at the third
intercostal space midaxillary line-a point at which referred
breath sounds from the opposite lung are less likely to be
heard. Restraints, which are necessary to prevent the child
from removing the EIT, are not used in isolation. Measures
to reduce anxiety should also be taken, including the use of
anxiolytics or sedatives, decreasing noxious or threatening
stimuli, and encouraging family presence and participation
in care.
Once the indications for intubation have been resolved,
extubation may be considered. Enteral feedings are stopped
for 2 to 4 hours before extubation is attempted. Sedation is
avoided before extubation so that the patient's cough and
gag reflexes are intact and active. The EIT is suctioned, as
well as the oropharynx. Care is taken to remove secretions
above the ETT cuff; the cuff is then deflated on exhalation.
The ETT is removed on exhalation, followed by delivery of
humidified oxygen by mask or hood.
Symptoms of hoarseness and croupy cough may occur
after extubation. Those at high risk include patients younger
than 4 years of age and those with a cuffed EIT. Also

prevalent are patients who have experienced traumatic or
repeated intubations, excessive movement of the EIT, or
airway abnormalities or infection. Postextubation croup
usually resolves with cool mist or humidity, as well as the
use of racemic epinephrine. The action of racemic epinephrine is unclear; however, benefit may be related to its topical
mucosal vasoconstriction effect. Until a wellness trajectory
can be predicted, feedings and deep suctioning are withheld
and familiar sources of comfort are provided to avoid
vigorous crying. If reintubation is necessary, management of
second or subsequent extubation attempts include dexamethasone (Decadron), 0.5 mg/kg up to a maximum of 4
mg, 6 hours before extubation, at the time of extubation, and
6 to 12 hours after extubation. 48
Cricothyrotomy. In an emergency, when other methods of gaining airway access have failed, a cricothyrotomy
can be performed. The cricothyroid membrane is a relatively
avascular membrane that extends from the cricoid to thyroid
cartilage. It is palpated as an anterior and midline transverse
indentation between the two cartilages. The membrane can
be punctured and the underlying trachea entered percutaneously using a large-bore cannula. The 14-gauge cannula is
directed in the midline caudally and posteriorly at a
45-degree angle. A cricothyrotomy can also be accomplished surgically with a short horizontal incision. After
incision, a 3-mm EIT can then be threaded into the tracheal
opening.
Tracheostomy Tube. Similar to EITs, ITs are available in a wide variety of sizes and styles. Variations in TT
specifications are found among manufacturers (Table 8-13).
For example, a standard 3.5-mm EIT is comparable with a
Shiley pediatric 0 and a Portex pediatric I TT. Companies
also provide custom IT lengths on request. As with ETTs,
low-pressure, high-volume cuffed TTs are used when air
leaks become unmanageable. Larger sizes may have an
inner cannula that can be removed for cleaning. No data
support the necessary frequency of cleaning inner cannulas,
thus this should be determined by individual patient need.
Indications for tracheostomy include an acute upper
airway obstruction, prolonged need for mechanical ventilation, and prevention of aspiration. TTs are inserted into an
incision made below the cricoid cartilage through the
second to fourth tracheal rings. Elective tracheostomy is
performed in the operating room. When performed within
the rcu environment, nursing care and responsibility are
similar to those followed for any sterile invasive procedure.
Priorities include continued patient monitoring and safety.
Postoperative tracheostomy holders are left intact for the
first 3 days after surgery and are not changed. For added
security, the outer phalange of the TT is often sutured to the
skin to avoid inadvertent decannulation. Until the stoma is
secure, reinsertion of a TT could be quite difficult. Routine
care includes (I) assessing the TT holders for security,
(2) assessing the character of the skin under the TT and
holders, and (3) stoma care.
Tracheostomy holders should be secure enough to hold
the TT in place but not too tight as to cause pressure necrosis
of the neck. When assessing skin integrity, the entire
circumference of the neck is assessed with particular
attention given to the infant's skin folds. Available in a wide
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Tracheostomy Tube Specifications

Shiley Inner
Diameter (mm)

Portex Inner
Diameter (mm)

Shiley Outer
Diameter (mm)

Portex Outer
Diameter (mm)

3.1
3.4
3.7
3.1
3.4
3.7
4.1

2.5
3.0
3.5
2.5
3.0
3.5

4.5

5.0
5.5

Same
5.2
5.8
Same
5.2
5.8

4.0
4.5

6.0

6.5

5.0
Same

7.0
8.0

7.1
7.7
8.3

4.8

5.5

variety of sizes, soft foam Velcro tracheostomy holders are
used because they are less traumatic to the skin.
Traditional stoma care includes cleansing the skin with
one-half strength HzO z and applying antibacterial watersoluble gel and a dry, sterile split-gauze tracheostomy
dressing. Care is taken to avoid displacing the IT with
multilayered tracheostomy dressings. Once the stoma is
healed, sterile dressings are replaced with sponges to collect
secretions as necessary.
Skin surrounding the stoma and chin is assessed for
pressure ulcers secondary to the IT phalange or IT
connector. The phalange of the TI may need to be shaved
down to eliminate pressure points. Skin around the tracheostomy site and chin can be protected using Duoderrn or
moleskin.
Tracheostomy masks provide humidified gases to the
airway. General principles are similar to those of face
masks, except that tracheostomy masks are secured gently to
avoid decannulation in the active patient. Various styles of
trachea-to-ventilator or resuscitation bag connections are
available. The ideal connector provides little dead space and
the greatest range of motion to the head and neck.
Changing a TI may be necessary after inadvertent
decannulation, when secretions compromise the inside
diameter, or routinely per institutional norm. The surgeon
who originally placed the TT usually performs the first TI
change. Any individual variance is noted for future reference. Subsequent IT changes are accomplished by the
nurse. If the infant or child is going home with the IT,
parents are invited to participate in the procedure. If not for
education, the parents' presence can provide a source of
comfort for their infant or child. The patient is held NPO for
2 to 4 hours. Sedation is considered according to the
individual infant or child. All equipment, including a
correctly sized face mask and one size smaller IT, is
prepared. The new same-size IT is examined, the obturator
is removed and replaced, the balloon is tested (if appropriate), and the TT is lubricated with a water-soluble gel. The
patient's TT is suctioned, followed by vigilant removal of
upper airway secretions. The patient is positioned supine
with a small roll placed behind the shoulders. The patient is

5.0
5.5

4.5

Shiley Length
(mm)

Portex Length
(mm)

30

Same
Same
Same
30
36

32
34
39

40
41
42

44

46

40
44
48
50
52

preoxygenated with an F10z of 1.0. On exhalation, the
existing TI is removed following the natural curve of the
tube, then the new IT is immediately inserted in a similar
manner. Slight tension should be expected. If the TT cannot
be reinserted, the patient is reoxygenated using a face mask
and resuscitation bag while the stoma is gently occluded
with a gloved finger(s). When the patient is adequately
reoxygenated, reinsertion of the same size or one size
smaller IT is reattempted.
Consideration of the patient's need for and ability to
communicate may affect the choice of replacement TI.
Several fenestrated "talking" TIs are currently available
and have been used in small pediatric patients with variable
success.
If none of the specialized TIs are appropriate, the
Passy-Muir Speaking Valve (PMSV; Passy-Muir Inc.,
Irvine, Calif.) may be used. The PMSV is a one-way,
positive closure, Silastic membrane valve that attaches to
the universal adapter (15 mm) of the TT. During inhalation
the valve is opened, allowing air into the lungs. At
exhalation the valve closes, forcing air through the vocal
cords, nose, and mouth. Engleman and Turnage-Carrier49
described the use of PMSV in infants and children younger
than 2 years of age when infant tracheostomy may lead to
later difficulties in language acquisition and articulation. Of
the 29 children in the trial, 24 (83%) tolerated the PMSV on
the first trial, and another 21 % produced vocalizations on a
subsequent trial.
Absolute contraindications for PMSV use include the
lack of air leak around a tracheostomy tube or upper airway
obstruction; relative contraindications include frequent aspiration and thick, unmanageable secretions. 50 .51 Nursing
care centers on patient teaching and assessment. Initial trials
are usually limited to a few minutes and slowly increased
with patient tolerance. Ventilator volumes, pressures, and
FIOz are adjusted to compensate for losses. PEEP may need
to be decreased to compensate for auto-PEEP.
Decannulation of the tracheostomy patient usually occurs
as a planned admission to the ICU. In preparation for
decannulation, the child's IT may be replaced with a
progressively smaller IT. Because of the size of the
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pediatric airway, this maneuver may not be an option in
infants and small children. Removal occurs as per IT
change (see preceding text), but the patient is usually held in
an upright position on the parent's lap. Sterile gauze is
placed over the stoma after IT removal. Supplemental
humidified oxygen may be administered. The patient is
assessed for increased work of breathing, stridor, and
desaturation. Length of ICU observation after decannulation
depends on the patient, family, and system. The stoma will
close in 48 to 72 hours postdecannulation.
Suction Catheters. Numerous types of suction catheters are available in various distal tip configurations.
Common features include measured distance markings in
centimeters, a blunt tip (beveled or straight), and side holes
(one to four). In pediatrics, comparing the actual size of
the distal opening is especially important when comparing
manufacturers. Outside diameters of suction catheters are
similar, whereas the size of distal openings may vary.
Because smaller catheters are used in the pediatric population, smaller distal openings further compromise the
ability to suction thick secretions. The amount of suction
applied is regulated to prevent hypoxia and mucosal
damage. Appropriate negative pressure includes 60 to
80 mmHg in infants under I year of age, 80 to 120 rnmHg
in children I to 8 years of age, and 120 to 150 mmHg
in children over 8 years of age.

Airway Management
Nasopharyngeal and oropharyngeal suctioning is indicated in patients who cannot clear secretions in their upper
airway or to elicit deep breathing and a cough. The
nasopharynx is suctioned first because it is considered
cleaner than the oropharynx. Catheter size should fit
comfortably into the naris using water-soluble lubricant.
Appropriate insertion length is determined by measuring the
distance from the tip of the nose to the tragus of the ear. To
minimize mucosal injury, the catheter is inserted next to the
nasal septum and advanced caudally. After inserting to
appropriate length, suction is applied, and the catheter is
slowly withdrawn in a rotating manner.
EndotrachealSuctioning. Because endotracheal intubation prevents an effective cough and both bypasses and
impairs normal mucociliary clearing mechanisms, endotracheal suctioning is an important intervention for intubated
patients. Endotracheal suctioning is not, however, a benign
procedure. Suctioning has been associated with a host of
negative side effects and complications, including hypoxia,
pulmonary artery hypertension, 52 dysrhythmias, atelectasis,
trauma to the trachea and bronchi, and increased ICP. It
seems reasonable that one of the most commonly performed
procedures in the PICU, which is associated with serious
risks, should be guided by sound clinical research data.
Unfortunately, much of what constitutes "routine suctioning
technique" is guided more by ritual than scientific rationale. 53 .54 Many suctioning practices of concern to pediatric
critical care nurses, including hyperoxygenation, hyperinflation or hyperventilation, depth of suctioning, endotracheal instillation of normal saline, and the frequency of

endotracheal suctioning, have been examined. Devices
intended to minimize suction-induced hypoxemia have also
been considered. Each will be discussed in the following
section.
When suctioning an artificial airway, although ideal,
using a catheter size of no more than one half of the inside
diameter of the tube is impractical in the pediatric population. In reality, the largest suction catheter that can
comfortably fit down the ETT or TT is used (see Table 8-11).
Hyperoxygenation is a maneuver designed to reduce
hypoxemia associated with suctioning. This step is accomplished in children by increasing the Fr0 2 to 1.0 before
(30 seconds), during, and after (at least I minute) the
suctioning procedure. The Fr02 can be delivered via the
ventilator or manually using a resuscitation bag. Because
hyperoxia should be avoided, the amount of supplemental
02 administered during suctioning is determined by the
patient's arterial oxygenation. Oxygen saturation, monitored
continuously by pulse oximeter, can generally be maintained between 92% to 94% by increasing F102 10% to 20%
over baseline requirements, but the actual F102 used is based
on each individual patient's needs. 55
Hyperinflation and hyperventilation are additional techniques used during suctioning to lessen hypoxemia, presumably by reinflating collapsed lung segments. However, no
uniform definition exists for either maneuver. Generally,
hyperinflation entails delivering several breaths before
suctioning (and after each pass of the suction catheter) using
either a manual resuscitation bag or the ventilator circuit.
Each of these breaths is approximately 1.5 times the
patient's usual tidal volume. Alternatively, peak inspiratory
pressure (PIP) is increased approximately to em H 2 0 above
the patient's usual requirements. Using PIP to guide
hyperinflation may be more appropriate in pediatrics because children are usually intubated with uncuffed ETTs and
have a variably sized leak around the tube. In clinical
practice, however, hyperinflation is often accomplished by a
brief period of hand ventilation with the tidal volume or PIP
determined by "feel," chest wall movement, and values
shown on noninvasive monitors during the maneuver (e.g.,
pulse oximetry and end-tidal CO2 ), Similarly, hyperventilation is often not standardized but consists of some increase
in ventilatory frequency over the patient's respiratory rate.
Considerable research has focused on the efficacy of
hyperoxygenation, hyperinflation, or hyperventilation in
reducing suction-induced hypoxemia. Some combination of
the three techniques probably provides the best protection
from arterial oxygen desaturation. 55 However, that combination has yet to be clearly defined, especially in infants and
children. Until consensus is reached, guidelines should be
flexible enough to encourage clinicians to design procedures
tailored to the individual needs of the patient.
In contrast, research data already exist to direct the depth
of E7T suctioning. Deep endotracheal suctioning has been
routinely performed in PICUs. However, evidence associating that practice with bronchial perforation 56•57 and acute
histologic changes in the tracheobronchial tree should
change that technique. Using an animal model, Kleiber,
Krutzfield, and Rose 58 have demonstrated that merely
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CD - low dead space ET tube adapter with irrigation port
® - 7.5mm a.D. manifold adapter with temperature port and
proximal airway line adapter
® - catheter flush port
® - calibrated catheter 5 to 25 cm
® - visible color calibrated rings

® - protective catheter sleeve

o - secretion viewing window

® - closed locking control valve
® - suction fitting with cap
Fig. 8-31 Ballard's Trach Care closed-system suction catheter. (Courtesy Ballard Medical Products,
Draper, Utah.)

inserting a suction catheter into the Err until resistance is
met (i.e., to the carina or mainstem bronchus) causes as
much tissue damage as insertion to resistance with the
subsequent application of suction.S8 Because of the alignment of the right middle lobe with the trachea, this type of
chronic irritation of the bronchial mucosa can lead to
persistent right middle lobe atelectasis (resulting from
airway narrowing because of inflammation or stenosis),
especially in infants. For these reasons, catheter insertion should stop short of the carina. An appropriate depth
for endotracheal suctioning can be ensured by premeasuring and marking the suction catheter or using a numerically calibrated catheter marked in centimeter increments and inserted I cm past the corresponding markings
of the Err. 58
Once the catheter is inserted to the proper depth, suction
is applied, and the catheter is withdrawn. Sterile technique
should be employed. Each pass of the catheter is considered
a suction event that should not exceed 10 to 15 seconds in
duration 59
The endotracheal instillation of normal saline is an
example of a widely practiced nursing routine that is not
supported by research. 6o .61 Normal saline has been used for
the purpose of loosening or thinning tenacious secretions,
but because mucus does not readily mix with saline, the
effect is probably more that of a lavage 62 As such, it may
enhance secretion clearance through cough stimulation 63
but may also cause mucosal irritation with little effect on
mucous clearance. 60 Bostick and Wendelgass M found that
the use of normal saline neither improved postsuctioning
Pa0 2 nor increased the amount of secretions retrieved. Other
studies suggest that providing adequate systemic hydration 65 and warming and humidifying inspired gases 66 are
more appropriate interventions for thinning secretions.

Furthermore, saline instillation may dislodge viable bacteria
from a colonized ETT into the lower airway, contributing to
the development of nosocomial pneumonia. 67 In total,
although the pediatric research is scarce, routine use of
normal saline with Err suctioning should be avoided.
The frequency of endotracheal suctioning is determined
by careful patient assessment. Endotracheal suctioning
should not be performed on a routine basis. Assessment of
the need for endotracheal suctioning includes coarse breath
sounds, increased PIPs during volume-controlled mechanical ventilation or decreased VT during pressure-controlled
ventilation, patient's inability to generate an effective
spontaneous cough, visible secretions in the airway, changes
in monitored flow and pressure graphics, suspected aspiration of gastric or upper airway secretions, clinically apparent
increased work of breathing, deterioration in arterial blood
gases, and radiologic changes consistent with retention of
pulmonary secretions, specifically, pulmonary atelectasis or
consolidation.S9 Evaluating a patient over time and documenting assessments permit early detection of clinical
changes and recognition of individual patient responses that
will guide subsequent interventions. Clinical outcomes to
evaluate after endotracheal suctioning include improvement
of breath sounds, decreased PIP with narrowing PIP-PPlaleau,
decreased airway resistance or increased dynamic compliance, increased VT during pressure-limited ventilation, and
improvement in ABGs or Sp02.S9
Several devices have been designed to ameliorate
suction-induced hypoxemia. Two such devices, oxygen
insufflation catheters and closed tracheal suction systems,
may be especially useful when high levels of Fl02 and PEEP
are required. Oxygen insujffation catheters can increase
Pa0 2 during suctioning by permitting simultaneous delivery
of O 2 during the procedure or alternate delivery of oxygen
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Fig. 8-32 Postural drainage positions. A, Anterior apical segment; sitting. B, Posterior apical segment;
silting. C, Anterior segment; lying flat on back. D, Right posterior segment; lying on left side. E, Left
posterior segment; lying on right side. F, Right middle lobe; lying on left side. (From Thompson JM,
McFarland GK, Hirsh JE et aI, eds: Mosby's clinical nursing, ed 4,1997, pp 201-202.)
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Fig. 8-32, cont'd G, Left lingula; lying on right side. H, Anterior segments; lying on back. I, Right lateral
segment; lying on left side. J, Left lateral segment; lying on right side. K, Posterior segments; lying on
stomach. L, Superior segments; lying on stomach. (From Thompson 1M. McFarland GK, Hirsh JE et ai,
eds: Mosby's clinical nursing, ed 4, 1997, pp 201-202.)
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or suction. Unfortunately, their use is limited in infants and
children because of the smaller Ell size.
One factor contributing to suction-induced hypoxemia is
the necessity of interrupting the patient's regular ventilatory
cycle during the procedure. A closed tracheal suction system
(CTSS), however, permits mechanical ventilation (including
PEEP) to continue during suctioning. 68 One type of CTSS
consists of a suction catheter in a plastic sheath that remains
attached to the ventilator circuit with an adapter, a suction
control device, and an irrigation port for tracheal lavage and
rinsing of the catheter (Fig. 8-31). While stabilizing the
adapter with one hand, the nurse uses the thumb and
forefinger of the other hand to advance the catheter the
desired depth into the Ell through the protective sheath; the
procedure can easily be performed by one caregiver.
Because the CTSS is left in place for 24 hours, suctioning
can be accomplished quickly and immediately, without
taking time to assemble supplies. 69 Hyperoxygenation,
hyperinflation, and hyperventilation are still provided using
the ventilator. 7o CTSS is reported to be as effective as
conventional open suction techniques in maintaining oxygenation 71 and in clearing secretions,72 and it may have
added benefits of preventing nosocomial lower respiratory
tract infections 73 and avoiding aerosolization of contaminated secretions.
Concerns about CTSS include decreased effectiveness of
suctioning, excessive negative pressure, and aUlocontamination. 74 Because of the smaller ETTs used in the pediatric
population, the concern over the accumulation of secretions
within the Ell and its affect on internal Ell diameter,
increased airway resistance, and impaired gas flow is of
special concern. Glass. Grap, and Sessler74 recently reported
that Ells in adult patients were markedly narrowed (mean
internal diameter of 0.64 mm) by the buildup of secretions
after CTSS. 74 The duration of intubation (not Ell size or
amount of secretions) was associated with the degree of
narrowing.
Suction catheters as small as 6 Fr are available. Mosca
and colleagues 75 compared closed with open Ell suctioning in 11 preterm infants. Significant reductions in heart rate
and Sp02 were observed after open suctioning; the magnitude and duration of these negative effects were significantly
reduced with closed suctioning.

Chest Physiotherapy
Chest physiotherapy (CPT) consists of many procedures,
including postural drainage, percussion, vibration, and
coughing. The goals of these interventions are to improve
mucociliary clearance, to increase the volume of sputum
expectorated, and to improve airway function. 76 Kirilloff
and co-workers 77 reviewed the literature with regard to the
efficacy of CPT in acute and chronic illness in adults. They
concluded that CPT appeared beneficial in patients with
large amounts of secretions and those with lobar atelectasis
as well. Patients with chronic illnesses associated with
increased mucous production (e.g., cystic fibrosis) clearly
benefited from CPT. In contrast, CPT did not help patients
in status asthmaticus and caused bronchospasm and hypox-

emia in some acutely ill patients. The component activities
of CPT were not uniformly associated with positive results.
Postural drainage was usually effective, although directed
coughing (teaching the patient cough techniques) may be as
efficacious. No data have shown a beneficial effect of
percussion or vibration. Because these studies were of adult
patients, caution should be used in generalizing the results to
infants and children. The mixed findings suggest, however,
that CPT is not uniformly effective in pediatric disorders,
and further research is certainly needed. 78
Postural drainage uses gravity to move lung secretions
from smaller peripheral lung segments into larger, more
central airways where coughing or suctioning clears the
secretions. A variety of positions are employed to drain
different lung segments (Fig. 8-32). The chest x-ray film
guides the intervention, and the patient is positioned to drain
areas identified as needing improvement. The patient is kept
in a position for 15 minutes or 5 minutes if combined with
percussion and vibration. Patient tolerance often controls the
variety of positions used during postural drainage. Also,
several positions are contraindicated in some patients, for
example, Trendelenburg in the cerebral hypertensive patient
or in the patient with gastric reflux.
In conjunction with postural drainage, chest percussion
and vibration help mobilize secretions from nondependent
lung segments to central airways for removal. Chest
percussion and vibration may improve the effectiveness of
postural drainage. Percussion is performed using a cupped
hand or percussion cup and rhythmically "clapping" the
chest wall. Chest percussion is performed only over the rib
cage and not over a bony prominence, for example. the
clavicle, scapula, vertebrae, and sternum. Vibration is
accomplished by shaking the chest on exhalation using the
hands in tremorlike movements. Mechanical vibrators can
be used in' small infants. Gentle chest vibration is used apart
from chest percussion in patients with thrombocytopenia or
in those at risk for bone injuries or fractures, for example,
patients with osteogenesis imperfecta. Both maneuvers are
useful in conditions in which large amounts of sputum are
produced, for example, cystic fibrosis, bronchiectasis, retained secretions, and lobar atelectasis.
Deep breathing and coughing are useful only in the alert
cooperative patient. Games, such as bubble blowing and
incentive spirometers, also increase the depth of inspiration
in patients who may not take deep breaths on their own.
Deep inspiration prevents atelectasis, promotes lung expansion, improves oxygenation, and provides an opportunity for
patients to actively participate in their own care. 79 Forced
exhalation helps to clear secretions. If patients are unable to
cough spontaneously, naso-oropharyngeal or tracheal suctioning may be necessary to stimulate a cough to help
remove mobilized pulmonary secretions.
Bronchial hygiene is not a benign procedure. The benefits
of selected maneuvers-specifically, percussion and postural drainage-have been challenged 80 Transient, yet
significant, decreases in Pa02 may follow chest physiotherapy. Also, the presence of a focal abscess theoretically
presents a risk to the contralateral lung for contamination
during postural drainage 39 Individualized care is warranted.
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Troubleshooting Triple-Chamber Chest Tube Drainage·Systems

Drainage tubing: Tight connections; no kinks, compressions,
or dependent loops
Fluid-filled depelldellt loop or kink impedes draillage:
Straighten tubing and anchor to the bed linen
Collection chamber: Positioned below the patient's chest;
assess volume and character of drainage
No change ill drainage:
None if drainage is stopped
Check for patency of tubing
Consider milking chest tube if obvious clots are present
Large volume of drainage aCClimulated in a shari time:
Assess for signs and symptoms of hypovolemia-report
drainage
Collection chamber is full:
Change the unit-{mce prepared, switch units without
clamping chest tube
Water-seal chamber: Filled to appropriate level; bubbling
present; fluctuations if to gravity
Warer seal is underfilled (so no effective seal is present):
Fill the water seal to the 2-cm level with sterile water or
saline
Water seal is overfilled (creating more resistance for air
escape from the pleural space):
Using the self-sealing diaphragm, remove enough fluid to
return the water seal to 2 cm
Contilluous bubbling ill the water-seal chamber (air leak
between the patient and system):
Locate the source by systemically and momentarily
clamping the system from the chest wall to unit
Bubbling will stop when a clamp is placed between the
air leak and unit
If the bubbling never stops, the unit may be cracked, so
change the urut

Tighten/reband loose connections
Report if new bubbling occurs
Intermittent bubbling in water-seal chamber:
Expect bubbling when suction first applied
Patient may have a small air leak
No fluctuatiollS or bubblillg in the water-seal chamber of a
patiem with gravity drainage, and the solution has crept
up to a fixed position:
Lung has reexpanded-expect equal breath sounds and
easy respirations
Tubing is obstructed-eheck for dependent loops or
kinks
Large fluctuations ill the water-seal chamber of a patient
wirh graviry drainage:
High intmpJeural negative pressure on inspiration indicative of increased work of breathing
Suction control chamber: Filled to appropriate level; gentle
continuous bubbling; if suction is off, tubing detracted from
suction source and open to air
Suctioll control chamber is underfilled 10 prescribed level:
Fill to prescribed level with sterile water or saline,
then tum on the suction until gentle bubbling
occurs
Suction comrol chamber is overfilled from prescribed level:
Using the self-sealing diaphragm, remove enough fluid
to obtain the prescribed level, then turn on the suction
until gentle bubbling occurs
Bubbling in the suction comrol chamber is too vigorous:
Wall suction is set higher than needed-turn down
No bubbling in rhe suctioll comrol chamber
Reconnect wall suction
Tum up wall suction until gentle bubbling occurs

Data from Erickson RS: Mastering the ins and outs of chest drainage. pan I. Nursing 89 May. 37-43; Pan 2, June. 46-49. 1989.

Chest Tubes
The primary purpose of a chest tube is to reestablish full
expansion of the lung and evacuate air, fluid, or blood from
the pleural space as rapidly and simply as possible. Chest
tubes vary in size from 10 to 36 Fr and 10 to 18 inches long,
and they consist of vinyl, silicone, or latex nonthrombogenic
material. The distal end that sits within the pleura has a
number of drainage holes to prevent occlusion; the proximal
end is connected to the chest drainage system.
Chest tubes are inserted at the bedside under sterile
conditions and while the patient is under local anesthesia.
The inseltion site depends on the problem. A chest tube
inserted for a pneumothorax is placed at the second
intercostal space at the midclavicular line because air will
rise to the apex. Alternative sites, especially in female
patients, include a more lateral position in the third to fifth
intercostal space with the chest tube threaded up into the
apex. A chest tube inserted for any type of fluid collection is
placed at the fifth to seventh intercostal space at the
midaxillary line because gravity will pool fluid to the base

of the lung. Once in place, the chest tube is sutured to the
skin to prevent displacement and taped to prevent lateral
movement. An occlusive dressing consisting of petrolatum
gauge and a dry, sterile, split gauze is applied. Placement is
confirmed on chest x-ray film.
The chest drainage system removes air or fluid from the
pleural space and prevents the backflow of air and fluid into
the pleural space. All connection points are banded to ensure
that the system remains airtight. Chest tube milking or
stripping is not advised because transient high negative
pressures cause patient discomfort, inflict tissue trauma, and
may cause bleeding. Special circumstances may necessitate
chest tube stripping; for example, to keep a chest tube patent
in a patient who is hemorrhaging while blood component
therapy is administered to enhance patient clotting. Clamping chest tubes is also not advised. Once clamped, trapped
air and fluid accumulate in the pleural space, and a tension
pneumothorax may result. If clamping is necessary to
precisely identify the location of an air leak. clamps are left
on only for several breaths per test site location.
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Drugs. Used for Aerosol Thera~y
Dose

Peak Onset Duration

Comments

," Sympathomimetic
~ide effects common to class include muscle tremor, tachycardia, hypokalemia, dysrhythmia, hypertension, anxiety, headache, and
-1, dizziness)
~Ibuterol (Proventil 5%,
0.25-0.5 ml in 2.5 ml*
0.5-1 hr
Bronchodilation
~rVentolin)
6-8 hr
~2-Selective
fL,'
Continuous
nebulization:
0.3
mg/kg/hr
to
a
maximum
of
15
mg/hr
g,.
~JSoetharine (Bronkosol 1%)
0.2-0.5 ml in 2.5 ml*
15-60 min
Bronchodilation
1-2 hr
Less cardiac effect than isoproterenol
0.5-1 hr
0.1-0.3 ml in 2.5 ml*
Bronchodilation
4-6 hr
Less cardiac effect than isoproterenol
0.25 mg in 2 ml*
5-20 min
Bronchodilation
6-8 hr
~,-Selective
Continuous nebulization: 0.3 mg/kg/hr to a maximum of 15 mg/hr
l;i:~

0.25-0.5 ml in 2.5 ml*

2-4 min
1-2 hr

Reduces mucosal swelling by vasoconstriction

0.05 mg/kg (max 2.5 mg)

Ihr
3-4 hr

Synergistic with ~2-agents; more
effective in large airway
bronchospasm; may cause
mucous plugging, tachycardia,
hypertension

0.25-1 mg

1.5 hr
6 hr

1-2 ml in 2.5 ml* q6h

Enhanced mobilization of
secretions
Foul smelling-may cause nausea
May cause bronchospasmadminister with a bronchodilator

20-125 mg in 4 ml*; twice
daily
80-240 mg in 4 ml*; twice
daily
Nonintubated: 2 g in 33 ml*
over 2 hours, 3 times/day for
3-5 days
Intubated: 6 g in 100 ml* over
16 hours for 3-5 days
300 mg in 6 ml* (daily for
treatment; monthly for
prophylaxis)

Gram-negative bacteria
Cystic fibrosis; use preservativefree solution
Respiratory syncytial virus
Caregiver precautions are essential

Prophylaxis against Pnelllnocystis
carin;;
Caregiver precautions are essential

··.oata from Lough M: Medicated aerosol therapy. In Blummer JL, ed: A practical guide to pediatric intellsive care. 5t Louis. 1990. Mosby, pp 978-980.
~,.Normal saline is used as the diluent.

Closed chest rube drainage systems use gravity or suction
to restore intrapleural negative pressure. Chest tubes are
connected to an underwater seal drainage system so that air
can only escape from and not enter the pleural space, A
Heimlich flutter valve or bottle of saline can be used as
a temporary measure until a chest tube drainage sys-

tern is available. The early bottle systems have been
replaced by disposable triple-chamber chest drainage systems. Basic principles are exactly the same whatever system
is used.
The triple-chamber systems consist of (I) a drainage
collection chamber connected to (2) a water-seal chamber
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connected to (3) a vacuum-control chamber. All three are
positioned side by side in a molded plastic disposable unit.
Step-by-step instructions for setting up these disposable
systems vary and are included in the package inset or printed
on the unit itself. The units can be hung below the level of
the chest on the crib using the attached hanger hooks or are
positioned on the floor using the built-in stand.
The first chamber is graduated so that chest drainage can
be accurately measured. The second chamber (directly
connected to the first) provides the water-seal chamber that
prevents air from reentering the chest. When the system is
placed on gravity drainage, respiratory fluctuations in the
water-seal chamber reflect normal fluctuations in intrapleural pressure and thus indicate an intact system. Bubbling in
this chamber indicates a air leak within the system. When all
connection points are occlusive, the air leak can come only
from the patient. To verify the source of an air leak, the chest
tube and connecting tubes are systemically clamped at
various levels. Once a clamp is located between the air leak
and the water seal, the bubbling will stop. The third chamber
controls the amount of suction applied to the chest tube
when wall suction is connected to the system. Suction is
necessary for rapid pulmonary reexpansion. The fluid level
within the unit determines the amount of suction applied to
the chest tube; usually a negative 15 to 20 cm H 20 is
adequate. Wall suction is adjusted to produce continuous
bubbling within the suction chamber. Turning up the wall
suction only causes more bubbling within the suction
chamber as more air is pulled into the system. Vigorous
bubbling creates more noise that can be distracting to the
patient and hastens fluid evaporation. Safety features vary
but usually include both high negativity and positive
pressure release valves. See Box 8-4 for troubleshooting
triple-chamber chest drainage systems.
Removal of a chest tube is performed when the lung has
reexpanded, the air leak has resolved, and drainage has
ceased. After providing adequate analgesia, stay sutures are
removed, and the chest tube is pulled on exhalation. An
occlusive dressing consisting of petrolatum gauge and a dry,
sterile gauze is then applied.

reservoir and becomes nebulized. A baffle in front of the gas
stream removes larger particles, returning them for renebulization, while smaller particles (I to 5 J.lm in diameter) are
delivered to the patient's airway. Flow rates of 6 to 8 Llmin
are necessary to achieve an adequate particle size to reach
the conducting airways. If possible, the patient is instructed
to take slow, deep breaths through the mouth and hold at end
inspiration 84
Ultrasonic nebulizers generate ultrasonic sound waves
directed at the air-liquid surface, producing a cloud of
fine particles whose diameter varies depending on the
frequency of the sound used. The small-particle aerosol generator (SPAG) unit is a pneumatically operated
nebulizer used for ribavirin therapy. Aerosol therapy for the
intubated patient is accomplished by either hand bagging the
medication or by placing the nebulizer in the ventilator
circuit. 85
Table 8-14 lists some of the more common agents used
for nebulization. Clinical responses to aerosol therapy are
closely assessed because of the varying amount of medication reaching the distal airways. Because of variable delivery, optimal dosages are determined by the clinical responsiveness of the individual patient. An important note is that
aerosol therapy also delivers free water to the patient and a
mode of bacterial transmission to the lower respiratory tract.
Bronchodilators, affecting sympathetic and parasympathetic airway receptors, are by far the most common. Inhaled
sympathetic agents stimulate ~2-receptors producing bronchodilation. In addition, sympathomimetics inhibit mast cell
degranulation, reduce mucous gland secretion, augment
mucociliary clearance, and improve respiratory muscle
contractility. Sympathomimetics vary in their peak onset
and duration of action. Newer agents are ~rselective,
limiting ~ I cardiovascular side effects. Continuous nebulized bronchodilator therapy is popular in the ICU setting 86
Continuous nebulization of albuterol 87 and terbutaline 88 is
safe, provides more rapid clinical improvement, and is cost
effective.

Inhaled Medications

The primary objective of mechanical ventilation is to
improve the balance of ventilation to perfusion, the most
common cause of impairment of oxygenation and CO2
removal. 89 In the presence of disease, ventilation often
exceeds the level of perfusion (high V/Q), or perfusion may
exceed the level of ventilation (low V/Q). Overventilation
results in dead space ventilation (wasted ventilation) and an
increased Paco 2. On the other hand, underventilation results
in a physiologic shunt and a decreased Pao z. When
mechanical ventilation is instituted, perfusion to welJventilated regions may decrease from the effects of positive
pressure, which may necessitate delivery of larger than
physiologic minute volumes to maintain an acceptable
Pac02. Any ventilator maneuver that has the potential to
increase intrathoracic pressure may impair cardiac output
and tissue perfusion and ultimately impair cellular gas
exchange. Fig. 8-33 summarizes the physiologic differences
in thoracic pressure under conditions of spontaneous versus
positive pressure ventilation.

Inhalation is commonly the most optimal method of
delivery of medications into the respiratory tract. Aerosolization of medication is often better-tolerated, safer, and
more effective than systemic administration. Aerosols consist of particulate water suspended in gas. Theoretically, the
smaller the size of the aerosol particle, the more distal the
particles are deposited into the bronchial tree. Airway
resistance and breathing pattern also influence the amount of
medication reaching the airways 8 J In the adult population,
approximately 10% of nebulized medication reaches the
lung periphery in nonintubated patients,82 whereas 1.2% to
4.8% of the nebulized medication reaches the lung periphery
in intubated patients. 83
A small-volume nebulizer (SVN) is commonly used to
aerosolize medications. Particles are generated by passage
of a high-velocity gas stream (usually oxygen) across a tube,
creating a Bernoulli effect; the medication is pulled from the
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SPONTANEOUS
VENTILATION

CONTROLLED
VENTILATION

Volume
FRC

+-

~

+

Alveolar
pressure o-k::--~C===~-

+

Intrapleural
pressure 0-+--------

Indications for Initiating
Assisted Ventilation
The indications for mechanical ventilation in the pediatric
population are mainly subjective. The younger the patient,
the more subjective the indications become. Standard
spirometry is seldom used in pediatrics as an indication for
mechanical ventilation. Vital capacity requires an alert and
cooperative patient not affected by pain, characteristics
rarely found in critically ill patients under 6 years of age.
Muscle function, chest wall disorders, and parenchymal
disease affect vital capacity. Acute muscle weakness only
slightly affects vital capacity.
Physiologic measurements define respiratory or ventilatory failure. Respiratory failure is described as PaoiFI02
ratio less than 200. Ventilatory failure is described as an
acutely elevated or rising Pac02 greater than 60 mmHg with
respiratory acidosis. Other physiologic parameters include increased work of breathing, which is described as a
respiratory rate twice baseline with the use of accessory
muscles.

Types of Ventilators

+

Flow

0+---1'------->;--

Fig. 8-33 Physiologic differences in thoracic pressures under conditions of spontaneous versus positive pressure ventilation. FRC, Functional residual capacity; I, inspiration; E. expiration; flow, pulmonary blood flow. (From Dupuis YG:
Vemilarors: rheory and clinical applicarion, ed 2, St Louis, 1992,
Mosby.)

Managing the pediatric patient supported on mechanical ventilation presents a particular challenge because
this group of patients require a wide variety of interventions that technology can now offer. To uniquely
separate pediatric mechanical ventilation from that of
neonates and adults is difficult because the practical
applications are similar. What is essential to safe and
effecti ve ventilation of this population is knowledge of
time constants, V
relationships, and ventilator options
and strategies. Having previously discussed time constants
relationships, this section discusses ventilator
and V
options and strategies in terms relevant to the pediatric
patient.

/0.

/0.

Technologic advances continue to provide numerous options to support the patient in acute respiratory failure. Ventilators are described according to which ventilation variable
is controlled in the inspiratory phase of each cycle. 90
Pressure Controlled. Most infant ventilators are
pressure controlled so that peak pressure remains constant,
but tidal volumes change as compliance and resistance vary.
A continuous gas flow provides the patient a source of fresh
gas for spontaneous breathing. Infants weighing less than
IO kg often receive ventilation from pressure-limited
time-cycled ventilators.
Volume Controlled. Most adult ventilators are designed to deliver a preset tidal volume. Flow is the variable
controlled by the ventilator to deliver a consistent volume.
Because flow and volume are functions of each other, these
machines are called volume controllers. Airway pressure
varies with resistance and compliance during a volumecontrolled breath.
Pressure Controlled and Volume Controlled.
The newest generation of ventilators offer several modes in
which pressure or volume can be the control variable. It is
the actual operational mode that is most relevant to clinical
management because it best describes the interaction
between patient and machine.

Modes of Ventilation
Pressure, volume, flow, and time are used as phase variables
that determine the parameters for each ventilatory cycle. 90
The trigger variable describes the variable used to initiate
inspiration. The limit variable describes the variable in
which a preset value cannot be exceeded during inspiration.
The cycle variable describes the variable used to end
inspiration. Baseline variables describe the variables that are
controlled during expiration. Combinations of these four
phase variables describe the various modes of ventilation.
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Indications and Special Considerations for Commonly Used Ventilator Modes

ventilation (CV)

Ii
. i
~"

!MV pressure controlled

"".".

~l_'

Indications

Special Considerations

Chest wall instability
Central nervous system dysfunction
Respiratory muscle paralysis

Dynamic patient needs not accounted for
Respiratory muscle inactivity leads to muscle
atrophy

Infants approximately less than 10 kg where
pressure is desired control variable

VT will vary with patient compliance and

Ii;

~T

!ili"

Iii"

rr!SUvlV volume controlled
l;~ii;'::

~l
I.

Older infants or where volume is the desired
control variable

WL."

IJI~t:
--.'.i,:'

-iF--,

~Iirressure control ventilation (PCV)

i;i
ff.g

~lF.
il~~tssure support ventilation (PSV)
!J1if1'

VT should be closely monitored
PIP should be lower than in volume-limited
modes
Mean airway pressure may be higher than in
volume-limited modes

Failure to wean
Muscle reconditioning
Asynchrony

Backup SIMV rate may be provided
Patients with E'IT less than 4 mm may
prematurely cycle breath
Patients with large ETI leaks may not cycle
off breath appropriately
Patient must be able to trigger pressure
support (PS) breath with ease

Weaning
Muscle conditioning
Asynchrony

Patient triggered
Premature termination prevented with E'IT
less then 4 mm
Patients with large leaks may not cycle off
breath

Conditions with decreased functional residual
capacity

Should provide continuous flow
Patient must be spontaneously breathing

,rJ1Y:
!~'jE

~f{:

~fIow synchronization PSV
.

i~
~;

I'

~jLContinuous

positive airway

mm pressure (CPAP)
1!!;;,
~fEn:
b

.

resistance

VT delivery may be limited in larger patients
Continuous flow available for spontaneous
breaths
The smaller the patient, the more relative VT
lost to the compressible volume of the
ventilator tubing
VT may vary in presence of E'IT leaks and
changes in compliance and resistance
Demand valve spontaneous flow systems
may have poor response to high respiratory rates. Addition of continuous flow
(2-5 L1min) may help

Patients with low compliance or high
resistance states
ARDS
Unilateral lung disease
Large E'IT leaks

;,:
~.
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Endotracheal tube; ARDS. adult respiratory distress syndrome; VI> tidal volume; SIMV, synchronized intermittent mandatory ventilation; PIp, peak

~FPlfatory

pressure.

The major indications and special considerations for commonly used ventilator modes are summarized in Table 8-15.
Controlled Ventilation. Controlled ventilation (CV)
generally refers to a volume-controlled mode whereby all
breaths are determined by the preset machine parameters
and are completely independent of the patient's respiratory
efforts or breathing pattern. This mode is poorly tolerated in
spontaneously breathing patients and offers no benefit over
other modes that allow the patient to initiate a ventilator
breath on demand or to breathe in between mechanical
breaths. This mode of ventilation is used in chemically
paralyzed patients when spontaneous breathing can be
potentially detrimental, for example, in the patient with a
flail chest.

Intermittent Mandatory Ventilation. Intermittent
mandatory ventilation (IMV) allows a patient to breathe
spontaneously from a continuous flow or demand valve
in between preset mandatory breaths that are either pressure controlled or volume controlled. The patient is
thereby able to breathe at his or her own rate and comfort
level. V
matching is mixed because the spontaneous
breaths result in increased ventilation to dependent lung
regions, whereas the mechanical breaths result in increased
ventilation to nondependent lung regions. This mode is
thought to be beneficial for weaning because the patient is
able to maintain the use of his or her respiratory muscles and
provide increasing spontaneous support as the IMV or mandatory rate is gradually decreased. The clinician should be

/0.
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aware that the work of breathing may increase a~ the patient
assumes responsibility for more of the ventilatory load.
Synchronized IMV. The synchronized IMV (SIMV)
mode, as with IMV, offers preset mandatory breaths but
synchronizes these breaths with a patient effort that is
generally detected by a circuit change in pressure or flow.
The theoretical advantages are that the patient will not have
a mechanical breath superimposed on a spontaneous one
and that patient's work will be more synchronous.
Pressure Control Ventilation. Pressure control ventilation (PCV) is a mode that is comparable with pressurecontrolled SIMV, in that a preset pressure is reached with
every breath. However, in PCV a very high initial flow rate
allows an almost immediate rise to the preset PIP. This PIP
is then sustained throughout the preset inspiratory time. One
theoretical advantage of tills mode is that gas distribution is
enhanced during the sustained PIP plateau.
Pressure Support Ventilation. The pressure support
ventilation (PSV) mode of mechanical ventilation augments
only the patient's spontaneous efforts with a preset level of
airway pressure. In PSV, the inspiratory pressure plateau is
reached early in inspiration and is maintained until inspiratory flow decreases to approximately 25% (may be clinician
set) of initial peak flow. At this point, inspiration ends, affording the patient control of inspiration and expiration. PSV
can be used alone or in conjunction with a mandatory mode,
such as SIMV and PCY. Pressures of 5 to 30 cm H 2 0 are
typically set; pressures of 5 to 15 cm H20 are ideal. VT can
be variable as the patient's pulmonary mechanics change.
The pediatric patient unable to tolerate weaning will
demonstrate decreased spontaneous tidal volumes leailing to
atelectasis, increased work of breathing, and an increased
respiratory rate. In such patients, PSV may reverse this
spiral and decrease patient work. Although the benefits of
PSV are untested in pediatrics, the authors have found this
mode to be useful in achieving patient comfort during a
protracted weaning process. Generally, the authors judge
PSV to be beneficial if the patient's respiratory rate drops
and work of breathing decreases.
A few unique problems are encountered when PSV is
used in infants and small children. First, the increased airway resistance posed by smaller ETTs (less than 4 mm) may
precipitate premature termination of PSV; that is, inspiration
ends because of the high resistance created by the airway
and not because of the patient's respiratory effort. This will
reduce the effectiveness of PSV in augmenting VT . Modem
ventilators allow adjustments to the inspiratory flow or rise
time to help prevent this termination. Second, if a significant
ETT or TT air leak is present, the ventilator may be unable
to sense the decrease in flow that normally occurs at end
inspiration. When this happens. the patient loses control
over end inspiration because the ventilator automatically
uses a built-in time limit to end inspiration.
Flow-Synchronized Pressure Support Ventilation.
Microprocessors and the evolution of sensor technology
have made possible patient-synchronized ventilation in
infants and small children. A number of systems are
available that allow the patient's spontaneous breathing
effort to trigger positive pressure breaths.

Ventilator breaths can be triggered by a drop in patient
airway pressure, the detection of a set inspiratory volume,
and even the chest or abdominal movement preceding a
spontaneous breath. However, the measurement of inspiratory flow is one of the most sensitive methods of patient
triggering. Flow triggering requires the use of a flow sensor
to detect a spontaneous breathing effort. This sensor
generates a flow signal that the ventilator uses to detect a
spontaneous breath. A machine-assisted breath is initiated
when the ventilator senses an inspiratory flow rate equal to
the set trigger sensitivity.
The availability to patient-trigger ventilator breaths
provides the option of two patient-triggered modes of
mechanical ventilation-SIMV and assist/control (AlC).
SIMV delivers a fixed number of mandatory breaths that are
synchronized with the patient's spontaneous breathing
efforts and allows unassisted spontaneous breathing between mandatory breaths. With AlC, every patient effort that
meets the trigger sensitivity criteria initiates a machineassisted breath.
Although the term flow synchronization has generally
been applied to the use of flow to trigger ventilator breaths,
the inspiratory flow signal can also be used to cycle (terminate) the inspiratory phase of ventilator breaths. The VIP
Bird with flow synchronization uses the inspiratory flow
signal to both trigger and cycle ventilator breaths. With flow
cycling, the inspiratory phase is terminated when the inspiratory flow rate falls to a preset percentage of the peak
inspiratory flow rate for that breath. Thus ventilator rate and
inspiratory time are primarily a function of the patient's
ventilatory drive and respiratory mechanics. However, manipulating the flow cycling threshold, which is adjustable
from 5% to 25% of peak flow rate, can also influence inspiratory time. The ability to flow trigger and flow cycle provides a high level of patient regulation of ventilation.
The potential benefits of flow-synchronized ventilation
(and patient-synchronized ventilation in general) include enhanced gas exchange (particularly oxygenation), decreased
incidence of barotrauma, decreased incidence of jntraventricular hemorrhage, decreased need for heavy sedation and
paralysis, and a decrease in the duration of mechanical
ventilation.
Continuous Positive Airway Pressure. CPAP is a
spontaneous mode that provides a constant preset distending
pressure. This constant pressure increases FRC and prevents
atelectasis. Increased lung volume increases pulmonary
compliance and thus decreases the work of breathing. Low
levels of CPAP are considered "physiologic" whenever the
upper airway is bypassed with an ETT or TT. When these
low levels-for example, a CPAP of 3 to 5 cm H2 0-are
reached, extubation is usually considered. On CPAP, the
resistance imposed by smaller pediatric ETTs may result in
a higher work of breathing than the patient might experience
extubated. Therefore it is common to extubate from low
rates of 4 or 6 breaths per minute.
Pressure-Controlled Inverse Ratio Ventilation.
This mode of ventilation describes the delivery of volume at
a preset Plr, whereby the time spent in inspiration exceeds
that of expiration. In pressure-controlled inverse ratio
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ventilation (PCIRV), PIPs are reached early in inspiration,
creating a decelerating flow wave pattern and square
pressure wave pattern. VT depends on inspiratory time, PIP,
and the patient's pulmonary mechanics. The square pressure
plateau wave facilitates alveolar recruitment and allows a
more even distribution of gases within the lung in patients
with nonhomogeneous lung disease. 91 Prolonged inspiratory
times allow higher mean airway pressures (MAPs) while
limiting PIPs and PEEPs and maintaining Pa0 2 . Shorter
expiratory times deter alveoli from falling below their
closing capacity.
Patients supported on PCIRV require nursing assessment
of alterations in cardiac output and pulmonary barotrauma
occurring secondary to an inadequate expiratory phase,
hyperinflation, and the development of auto-PEEP. 92 The
altered breathing pattern may also give patients a feeling of
fullness that can be uncomfortable, making them artXious
and restless, increasing their work of breathing and
increasing \;02 . 93 Analgesia, sedation, and chemical paralysis are required for patient comfort and compliance.
Airway Pressure Release Ventilation. In this mode
of ventilation, the patient breathes spontaneously at a
positive baseline (CPAP). Periodically, this baseline is
released to a lower pressure level for I to 2 seconds,
allowing CO2 to be exhaled. Airway pressure release
ventilation (APRV) is an alternative mode to improve
oxygenation with lower mean airway pressures.
Mandatory Minute Ventilation. Mandatory minute ventilation (MMV) is a mode of computer-generated
ventilation that ensures the deli very of a predetermi ned
minute ventilation distributed between spontaneous and
ventilator breaths. If the patient's \; E is calculated to be low,
additional breaths are delivered to the patient. One disadvantage of this mode is that the quality of the patient's
spontaneous breaths is not considered. A rapid, shallow
pattern is not distinguished from a slow, deep pattern
because the \; E is the same. Altered respiratory patterns can
lead to acid-base disturbances and atelectasis 94
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and CO2 retention by adding unnecessary dead space.
Excessive PEEP also impedes venous return to the chest,
which will eventually decrease the patient's cardiac output
and oxygen delivery.
Peak Inspiratory Pressure. PIP is the pressure that is
reached and sustained during inspiration. PIP is directly
adjusted in the pressure-limited modes but varies with
compliance and resistance in the volume-limited modes.
Mean Airway Pressure. Measured in cm H2 0, MAP
is the average airway pressure over a respiratory cycle. 95
Factors that increase MAP during pressure-controlled ventilation include increased inspiratory flow, increased PIP,
increased Ti, increased PEEP, and increased F. MAPs over
12 cm H2 0 are considered significant. This parameter is a
monitored value on most ventilators.
Fraction of Inspired Oxygen. Flo2 is the inspired
oxygen concentration. Fr0 2 levels less than 0.6 are generally
considered safe. 91
Flow Rate. Flow rate is the continuous flow of
ventilator gas adjusted in liters per minute. Pressurecontrolled ventilators require adequate flow rates for the
delivery of PIP, for optimal VT, and for a continuous source
of gas for spontaneous breaths. Flow rates determine the
time it takes to reach PIP during inspiration. When flow
rates are low, PIP is reached at the end of inspiration,
decreasing the plateau phase; if flow rates are high, PIP is
reached early in inspiration, increasing the plateau phase. 91
The inspiratory plateau affects gas distribution; the longer
the plateau, the better the distribution of gas throughout the
lung (Fig. 8-34).
Alarm Systems. For patient safety, ventilator alarms
remain activated within a tight range at all times. Most
ventilators are equipped with an inspiratory line pressure
alarm to detect a sudden loss in pressure (disconnect) and a
sudden increase in pressure (obstruction). Other alarms
include gas supply, FI0 2 , gas humidity and temperature, and
electricity failure. Ventilator alarms that allow a 10- to
IS-second automatic reset are safer for the patient because
the human factor is eliminated.

Ventilation Parameters
Tidal Volume. In a volume-limited mode, VT is set
directly in cubic centimeters (cc). In a pressure-limited
mode, VT is determined by the difference between PIP and
PEEP; this is referred to as delta P (M' = PIP - PEEP).
Frequency. Frequency (F) is the ventilator rate adjustable in breaths per minute.
Inspiratory Time. Inspiratory time (Ti) together with
F determines the I:E ratio. Prolonging Ti generally improves
oxygenation by increasing the time the alveoli remain
distended participating in gas exchange. Faster Ti and longer
expiratory times are used to prevent hyperinflation in
patients with airways disease. Some venti lators offer an
inspiratory hold or pause that prolongs Ti.
Positive End-Expiratory Pressure. PEEP is the pressure that is sustained at the end of expiration. PEEP
improves oxygenation by increasing FRC, preventing alveolar collapse, and enhancing the ratio of ventilation to
perfusion. Excessive levels of PEEP cause hyperinflation

Initiation of Mechanical Ventilation
Before initiating mechanical ventilation, the clinician evaluates the patient's pulmonary mechanics by "feel" during manual hand ventilation using an anesthesia bag
and attached manometer. Initial ventilator settings are
then matched to those identi fied as optimal during hand
ventilation.
An alternative strategy is to begin with the suggested
ventilator settings listed in Table-8-16, which take into
consideration anticipated time constants. Faster rates without stacking of breaths can be used in patients with lung
disease states characterized by short time constants (lungs
quickly fill and empty). Slower rates and longer expiratory
times are used in patients with lung disease characterized by
long time constants (lungs take a long time to fill and
empty). Once the patient is receiving mechanical support,
ventilator settings are fine-tuned within established ABO
parameters and measured pulmonary mechanics.
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Ventilator Strategies
Mechanical ventilation has two goals: to maintain mean
lung volume and to maintain alveolar ventilation. As
mentioned, reduction in V/o. imbalance must also be a
consideration, and although ventilator manipulations may
optimize ventilation, the V/0. relationship is best viewed as
a dynamic phenomenon. The clinician's challenge is to
achieve acceptable minute ventilation with respect to
perfusion in the presence of an adequate mean lung volume.
Factors to assess on initiation of mechanical ventilation are

included in Box 8-5. Some newer ventilators have automated modes to initiate or wean the ventilator.
The Hamilton Galileo ventilator (Hamilton Medical Inc.,
Reno, Nev.) uses a complex algorithm to assess the patient's
respiratory mechanics. The ventilator then chooses the
amount of pressure support to achieve a clinician and
ventilator set goal. This mode is a rules-based strategy
called adaptive support ventilation (ASY). The Servo 300
(Siemens, Danvers, Mass.) has automode, which automatically switches the patient from a control mode to a
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TABLE 8-16 Suggested Initial Ventilator
Settings for Various Time Constants
Long Time
Constant

Normal Time
Constant

Short Time
Constant

8-10 mVkg
8-IS
>1:4

6-10 ml/kg
10-20
1:2
3-S

6-8 mVkg

O-S

IS-30
1:[

>S

r,iV,., Tidal volume; F, frequency; I:E, inspiratory/eKpiratory; PEEP,
'~sitive end-expiratory pressure.
,;:-.,

..

~

Box 8-5

.

Factors to Assess on Initiation
of Mechanical Ventilation

1. Baseline breath sounds (quality, adequate expiratory

time)
2. Decreased work of breathing (decreased respiratory rate,

severity of retractions, nasal flaring, grunting, etc.)
3. Chest excursion and symmetry
4. Chest x-ray film (ETI position, improved lung volume,
pathologic condition)
S. Pulmonary mechanics (decreased airways resistance,
increased compliance, and FRC [time constants,
auto-PEEP])
6. Arterial blood gases (improved oxygenation, decreased
Paco 2 , and improved pH)
7. Need for noninvasive monitoring
8. Need for muscle relaxants, sedation (chemical restraint)
9. Need for pulmonary hygiene
10. Need for aerosolized or systemic bronchodilator therapy

spontaneous mode when the ventilator senses a patient's
spontaneous breath. These modes continue to grow in
popularity, but little pediatric data exists.

Making the Right Maneuver
Paco2' Paco2 is inversely related to minute ventilation (VE) (V E = V T X F). A portion of V T is composed of
dead space volume (V D) and therefore will not participate in
gas exchange. V D is related to body surface area and
normally accounts for 30% of VT' In patients supported on
mechanical ventilation, V D may be as high as 50% to 60%
from the effects of positive pressure on the airways.
Accordingly, changes in ventilator parameters can alter V D'
Any tubing or adapters distal to the patient ventilator will
add mechanical dead space because this volume acts as an
extension of the patient's airway. Mechanical V 0 should be
kept to a minimum.
Pao 2 • The most basic control of Pao2 is FI02 . The
relationship between FIOz and Pao z is not as straightforward
as that between Pacoz and VE' This is due to the effects of
water vapor pressure in the lung and oxygen diffusibility
relative to the (diseased) alveolar-pulmonary capillary
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membrane. The degree and pattern of ventilation and V/o.
ratio also affect Paoz. The MAP is a very useful index of the
overall effect of changes in ventilation variables and is
directly related to Paoz. Any maneuver that alters MAP has
the potential to change Paoz. The five factors that affect
the MAP include (I) PIP, (2) PEEP, (3) inspiratory time,
(4) inspiratory flow, and (5) increased respiratory rate with
same inspiratory time. Optimal MAP is found when gas
exchange is efficient and beyond which alveolar overdistension occurs. 96
Chest X-ray Film. In general, there should be radiologic evidence of improved lung volume. The ninth anterior
rib above the dome of the diaphragm evidences adequate
lung volume, although aeration is relative to surrounding
structures. Assuming the film is taken during inspiration, the
diaphragm should be neither elevated nor flattened. Hypoaeration is managed by increasing PEEP or Ti.
Auto-PEEP. In situations in which the F is high or the
patient has long time constants, the clinician should check
for the presence of auto-PEEP or intrinsic PEEP. Auto-PEEP
refers to the spontaneous development of PEEP at the
alveolar level as a result of insufficient expiratory time. 97
Auto-PEEP can be detected in a noncontinuous flow
ventilator system and is checked by occluding the expiratory
limb of the ventilator at end expiration. If auto-PEEP is
present, the baseline pressure (PEEP) will rise as expiratory
flow continues from the patient. The level of auto-PEEP is
clinically important because its presence may contribute to
enhanced oxygenation or CO 2 retention. Although the
presence of I to 3 cm H 2 0 of auto-PEEP may not be
clinically deleterious, this number should be monitored in
appropriate patients because it is a dynamic number (unlike
set PEEP) and can change rapidly.
Blood Gas Monitoring. Whenever possible, ABGs
should be obtained in the newliventilated patient to assess
for improved gas exchange. If arterial access is not
immediately possible, a venous blood gas may be helpful in
assessing acid-base status. Pulse oximeters continuously
and noninvasively assess oxygenation. ETc02 monitoring is
useful; however, the presence of large ETT leaks can result
in inaccurate low readings, and some monitors will not read
accurately at high (>30) respiratory rates.
Bronchial Hygiene. Adequate suctioning is essential
in the pediatric patient. Smaller ETT diameters predispose
these patients to airway obstruction. The relative small size
of the conducting airways places the child at increased risk
for significant compromise from the effects of infection,
edema, and secretions. Partial or complete obstruction of the
bronchioles and bronchi can result in air trapping and
atelectasis. What may seem like an insignificant amount of
secretions may have a significant impact on airways
resistance.
Sedation. Ensuring an adequate level of comfort for
the patient receiving mechanical ventilation is fundamental
to humane care. Artificial airways and imposed breaths are
poorly tolerated by an alert child. Because of developmental
immaturity, one cannot depend on patient cooperation. In
fact, if a toddler, for example, cooperates with a stranger
when the parents are not present, one would question the
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child's level of consciousness. In addition to parents,
analgesics and sedatives are often used to help the patient
tolerate both the ICU environment and the treatments
involved. Chemical restraints should be used in combination
with physical restraints. In assessing agitation, it is important to determine what comes first-hypoxia or agitation. A
distressed intubated patient may be trying to indicate
inadequate ventilator settings, an obstructed ETI, a pneumothorax, pain, or the need for a more quiet environment.
The use of neuromuscular blocking agents may be indicated
in the sedated patient in acute respiratory failure when
ventilator support is escalating and the child is asynchronous with or fighting the ventilator. These agents are not
used indiscriminately because they remove critically important assessment signs, such as activity and comfort levels.
Positioning. The supine position and the length of
time an intubated patient is kept supine are potential risk
factors for aspiration of gastric contents 23 •98 Unless contraindicated, all intubated patients should be positioned in a
semirecumbent position.

Special Considerations in Ventilating
Pediatric Patients
Endotracheal Tube Leaks. Because of the use of
uncuffed ETIs in young children, leaks are often present
and can compromise ventilation if they are excessive. An
ETT leak detected above an inspiratory pressure of 20 cm
H2 0 is generally desirable because this may help reduce the
occurrence of airway trauma and postextubation swelling,
yet this may in tum limit the ability to deliver an adequate
VT in patients who require higher PIP. Very large ETI leaks
may cause autotriggering of mechanical breaths on some
ventilators where loss of PEEP may be sensed as the
patient's inspiratory effort. It is therefore important to assess
ETT leaks periodically by hand ventilating the patient with
a manometer in-line to note at what pressure the leak begins.
A volume-monitoring device can further quantify leaks.
Many of the newest ventilators have the capability to
measure volume at the patient airway, which can accurately
quantify an ETI leak. Leaks are notoriously variable and
can vary with ETT position, head position, and fluid
balance. If a leak is thought to be compromising ventilation,
reintubation may be necessary with a larger tube.
EIT Resistance. Reducing the diameter of a tube by
one half results in a sixteenfold decrease in flow through
that tube. The small ETI diameters used in children cause
a substantial increase in flow resistance and therefore a
significant increase in the work of breathing. For this
reason, children are usually not extubated from ventilator
rates less than 4 to 6 breaths/min. The work imposed by
the pediatric ETI is often compared with "breathing
through a straw." Attentiveness to this phenomenon is
especially important in the child with a history of
significant respiratory failure.
Compressible Volume. The compressible volume of
a ventilator circuit refers to the amount of the tidal volume
that is lost with each breath to displacement and compression of the volume of the ventilator tubing. This portion of

the breath never enters the patient's lungs. Ventilator tubing
has a measurable compliance or distensibility that can be
used to distinguish the actual delivered tidal volume from
the lost compressible volume. This is the compressible
volume factor. The loss of compressible volume is particularly important in volume-limited ventilation when small
tidal volumes are used. For example, in a situation in which
tubing has a compressible volume factor of 3 ml/cm H2 0
and peak inspiratory pressure is 40, the set tidal volume
would be reduced by 120 ml (3 x 40). The loss of volume is
quite relevant in pediatric mechanical ventilation because of
the small volumes used. For instance, if a tidal volume of
200 ml were set in the previous situation, the delivered
volume would be approximately 80 m!'
Ventilator Limitations. Infants and small children
may have difficulty using the assist-control mode of
ventilation because they need to inhale a greater proportion
of their VT before creating enough negative pressure to
trigger the ventilator's sensing mechanism. Once triggered,
the response time may be too slow to support the faster
pediatric respiratory rate. An inadequate response time can
lead to an increased work of breathing. A similar problem
occurs during spontaneous ventilation; usually gas flow is
delivered to the circuit when a demand valve is activated by
negative airway pressure. This demand valve may be too
difficult for the pediatric patient, so a continuous-flow
reservoir is typically added to the circuit in patients
weighing less than 15 kg. Providing a low level of added
continuous flow may alleviate the problem, allowing the
child to spontaneously breathe without triggering the
demand valve system.
Volume Monitoring. Monitoring of VT should be
considered in the patient for whom one of the aforementioned variables might compromise the delivery of a
consistent tidal volume. This may involve intermittent
checks to note changes after setting changes or continuous
monitoring in patients with large or variable ETI leaks. VT
monitoring is now easily accomplished with equipment
specifically designed for the pediatric population, including
Bournes Neonatal Volume Monitor-NVM (Bear Medical
System, Riverside, Calif.), Bicore (Bear Medical System,
Riverside, CaliL), Ventrak (Novametric Medical Systems,
Wallingford, Conn.), and Partner IIi (Bird Medical Corp,
Palm Springs, Calif.). Ventilator settings can be adjusted to
deliver a specific VT (mUkg). A constant VT will stabilize
the FRC and allow immediate corrective action for acute
changes. Computers, used in conjunction with volume
monitors, allow calculation of respiratory mechanics, for
example, compliance, resistance, time constants, work of
breathing, flow/volume loops, and pressure/volume curve.
Scalar tracings of flow, pressure, and volume of each breath
allow bedside graphic interpretation (see Fig. 8-34).

Complications of Mechanical Ventilation
Rapid deterioration in the pediatric patient is often attributable to one of the factors listed in Box 8-6. The incidence of
pneumothorax in pediatrics has been reported to be between
4.5% and 8% and in some studies has been correlated with
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2.
3.
4.
5.
6.

Box 8-6

.

Common Respiratory causes of Rapid
Clinical Deterioration
.

Err position change
Large or positional Err leak
Excessive secretions
Bronchospasm
Development of auto-PEEP
Pneumothorax

It:I

TABLE

8-17

Complications

. ofMechanical Ventilation
Pneumothorax
Pneumomediastinum
Pneumopericardium
Pneumoperitoneum
Subcutaneous emphysema
Pneumonia
Septicemia
Dislodgment
Occlusion
Accidental extubation
Erosion
Stenosis
Air trapping (auto-PEEP)
Decreased venous return
Decreased cardiac output
Increased pulmonary vascular resistance
Decreased urine output
Increased antidiuretic hormone
Decreased hepatic blood flow
Increased intracranial pressure

iff-.

.

ff1decbamcal

i1fi·-:
~,.

Ventilator malfunction
Disconnection

mortality.44 Certainly, this complication must be recognized
promptly and treated. In patients with reactive airways
disease, sudden development of bronchospasm may occur in
the absence of a precipitating event and result in significant
compromise. As previously mentioned, auto-PEEP is a
dynamic phenomenon that can have adverse effects and
should be periodically checked if the clinical picture is
suggestive of its presence. Acute ETf obstruction is
common in pediatrics, and if it is suspected, the patient
should be reintubated if an attempt to clear the tube is
unsuccessful. The instrumented pediatric airway is difficult
to maintain because of patient size and lack of cooperation.
Slight changes in Elf position can result in right mainstem
intubation or accidental extubation. Finally, an increasing
ETT leak can occur from resolving airway edema or diuresis
resulting in decreased VE or failure to hold PEEP.
General complications of mechanical ventilation are
listed in Table 8-17. The major side effects of CPAP and
PEEP include hemodynamic complications and pulmonary
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barotrauma. Increased intrathoracic pressure leads to decreased systemic venous return resulting in decreased
cardiac output. These hemodynamic effects can be easily
monitored with a pulmonary artery catheter. Esophageal
pressure monitoring can also approximate optimal levels of
CPAP and PEEP. Esophageal pressure should increase
slightly with each increase of CPAP and PEEP until optimal
levels are reached. After that, esophageal pressures will
increase exponentially with only slight increases in CPAP
and PEEP. In addition to producing pulmonary barotrauma,
overdistension increases V D and results in a rising Pac02 .
When faced with progressively worsening ABGs, one
strategy is to cautiously decrease inflating pressures when
the possibility of overinflation is present.

Guidelines for the Weaning Process
Weaning from mechanical ventilation accounts for approximately 40% of the time that critically ill children with
respiratory failure are supported on mechanical venti lation. 99 Weaning patients from mechanical ventilation involves assessing the patient's readiness to wean, optimizing
factors that can facilitate weaning, selecting the appropriate
weaning method, and continually assessing the patient's
progress. 100 Studies have shown that on average, objective
measures based on frequent testing of the patient's ability to
tolerate decreases in ventilator support result in earlier
initiation of weaning. 101 For example, using a preweaning
CPAP trial may help determine if a patient is ready for
extubation, avoiding the weaning process altogether.
The picture of weaning readiness is a collective assessment of improving lung function; sepsis in control; decreasing heart rate, weight and central venous pressure (CVP);
improving cardiovascular performance; good tissue perfusion; less noisy breathing; nutritional balance; and normal
serum albumin and total calcium. 99 Patient response to
weaning includes increasing respiratory rates, decreasing
Pac02> and increasing arterial pH. 99
In the adolescent, adult criteria can be used as guidelines:
a vital capacity of 15 to 20 ml/kg, negative inspiratory force
(NIF) of -20 cm H2 0, tidal volume of 6 to 10 ml/kg, and a
maximum voluntary ventilation (MVV) of greater than
twice the minute ventilation. 102 For pediatric patients, the
best indication for weaning is respiratory rate. Pediatric
patients respond to respiratory compromise by decreasing
tidal volume and increasing respiratory rate. During weaning, regardless of the strategy, the respiratory rate should be
below 2 times the baseline.
The modes most commonly used to wean patients
include CPAP, SIMV, and PSv. Mechanical support is
gradually decreased one parameter at a time until a minimal
amount of support is reached. Usually, the longer a patient
has been supported on mechanical ventilation, the longer the
weaning process. Because of respiratory muscle atrophy, a
period of muscle reconditioning is required before extubation. This is accomplished by progressi vely exercising the
respiratory muscles to rebnild endurance. Chronically ventilated patients are not weaned at night because adequate rest
is critically important to success.
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Starting with the most potentially toxic parameter,
settings can be gradually weaned or the patient can be
switched to PSv. Generally, Ti is returned to normal; the
F102 is decreased by 2% to 10% to maintain a Sp02 greater
than 90%; PIPs are decreased by 2 to 5 cm H20 to the low
20s to maintain VT in the 5 to 7 mUkg range; PEEP is
decreased to 3 to 5 cm H20, provided that oxygenation is
adequate on low F102; and rate is decreased by 1 to 2 breaths
slowly over hours to days (depending on tolerance) to
maintain a Pac02 within normal limits for the patient and to
allow spontaneous breaths without excessive work of
breathing.
When ventilatory rates are weaned to a low rate of
6 breaths per minute in an infant or 4 breaths/min in a child,
or successful trial of 3 to 5 cm H20 of CPAP has been
accomplished, extubation is considered if criteria
are reached-that is, good gases on an FI0 2 less than
0.5, adequate cough and gag, and thin or moderate
consistency in the character of secretions. Note that infants
are extubated from higher rates because of the increased
airways resistance created by the smaller ETT.
The major benefit of PSV is that it reestablishes the
patient's control over breathing, improves patient-ventilator
synchrony, decreases diaphragmatic muscle fatigue, and
reduces the work of breathing. PSV eliminates the shallow
ineffective spontaneous VT associated with progressive
tachypnea and atelectasis that may occur during more
traditional weaning methods.
Curley and Fackler99 identified three patterns of progress
when weaning pediatric patients with acute respiratory
failure from mechanical ventilation-specifically, the sprint,
consistent, and inconsistent patterns: the sprint subset,
weaned in I day; the consistent subset, weaned every day;
and the inconsistent subset, did not wean every day. Patients
at risk for inconsistent weaning are those admitted with a
sepsis/shock ARDS trigger; those discharged with more
functional disability; and those who experienced more days
of mechanical ventilation and had a higher oxygenation
index during weaning.
Although no pediatric protocols currently exist, Kollef
and colleagues 103 showed that protocol-directed weaning
from mechanical ventilation, performed by nurses and
respiratory therapists, was safe and resulted in shorter
duration of mechanical ventilation when compared with a
traditional practice of physician-directed weaning. Protocoldirected weaning resulted in the earlier initiation of weaning
and more rapid progression of weaning to extubation. Key
features include developing a unit-based protocol, strict
entry and exit criteria, nurse and therapist education, and
on-site clinical support.
After extubation, the patient may benefit from a 20%
increase in F102 or nasal/facial CPAP or noninvasive
positive pressure ventilation (bilevel positive airway pressure [BIPAP]) if lung volume is a problem. Nasal/facial
CPAP or BIPAP may help prevent alveolar collapse and is
weaned as tolerated-usually, if the patient struggles more
when it is on, it is time to take it off. The patient is observed
for long-term endurance failure.

~

Box 8-7

Indications for NPPV Support

I. Acute respimtory failure (early intervention to prevent

2.
3.
4.
5.
6.
7.
8.

deterioration as an alternati ve to endotracheal intubation
in patients who can control their airway)
Following endotracheal extubation as a bridge to complete
separation from ventilatory support
Obstructive sleep apnea
Hypoventilation syndromes
Progressive neuromuscular disease
Chronic respiratory failure in which tracheostomy may
not be an option (e.g., cystic fibrosis)
Thoracic cage abnormalities
High-level paraplegic trauma

NPPI/. Noninvasive positive pressure ventilation.

Nasal/Facial Continuous Positive Airway Pressure. Relatively low levels of CPAP can be administered
to spontaneously breathing extubated patients using specialty nasal prongs or masks. The success of this strategy is
variable but may be used as either a continuous or
intermittent bridge to extubation in the chronically ventilated patient. The success of nasal CPAP in infants depends
on the degree of mouth breathing and crying present. The
success of facial CPAP in the child depends on patient
tolerance and a mask that adequately fits the patient. Side
effects include gastric distension; a nasogastric tube can be
used to continuously vent the stomach.

Noninvasive Positive Pressure Ventilation
Commonly referred to as BIPAP, noninvasive positive
pressure ventilation (NPPV) provides ventilatory support by
nasal mask, pillows, or facial mask. Box 8-7 outlines
the still-evolving multifaceted indications for NPPV in the
pediatric population. I04 Generally, NPPV can be used
(I) early in patients with acute respiratory failure to help
stabilize deterioration, (2) as a bridge to unassisted breathing in difficult-to-wean patients, (3) as a treatment option in
patients who require only intermittent ventilatory support, or
(4) as a temporizing agent in patients with end-stage disease
in whom the trajectory of illness is unclear. NPPV candidates should have a patent natural airway and an adequate
respiratory drive. Patients can continue to eat and speak and
are free of the discomfort and complications associated with
an artificial airway.
The NPPV system may be totally patient triggered, or a
ventilator rate may be set. The mode is pressure controlled
with continuous flow that compensates for the leak that
occurs around the mask. Two levels of positive pressure are
set: one for inspiration (lPAP) and one for expiration
(EPAP). This mode allows the ventilator to cycle between
baseline pressure (EPAP) and pressure support (IPAP).
NPPV augments VT in response to a spontaneously breathing patient's inspiratory effort. The degree of support is
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determined by a clinician-selected inspiratory pressure and
expiratory or baseline pressure.
The American Respiratory Care Foundation's consensus
statement on NPPV recognizes two levels of support. Type I
support is defined as providing life-sustaining support that if
terminated could be life threatening. 105 Type II support is
beneficial, but interruption is not life threatening. Patient
placement (ICU/non-ICU) is determined on an individual
case-by-case basis. NPPV can be safely provided out of an
ICU environment when system supports are available, when
the patient's trajectory of illness is clear, when the patient can easily call for help when necessary, and when
the patient is able to maintain spontaneous ventilation
without NPPV.
Complications of NPPV are the same as positive pressure
ventilation (e.g., barotrauma or decreased cardiac output)
but also include facial skin breakdown and the inability to
determine the exact concentration of oxygen delivered.
Nursing care for patients receiving NPPV includes selecting
the appropriate face mask and headgear and then helping the
patient breathe comfortably with NPPV support. The mask
should fit snugly along the lateral boarder of the nose and
rest on the upper lip but not extend more than two thirds up
the bridge of the nose. Inserting pressure-relieving material
(e.g., hydrogels [Spenco Medical Corp., Waco, TX]) between the face mask and bridge of the nose and alternating
different facial appliances may help decrease the severity of
pressure ulcers in this high-risk area.
The patient should be monitored for air leaks around the
mask. Headgear is adjusted to ensure that pressure targets
are achieved, and a chin strap may be needed during sleep
to minimize mouth leaks. The patient should also be
monitored for gastric distension. With NPPV, air may be
swallowed or forced down the esophagus. To manage this,
IPAPs can be decreased (if tolerated), or an NGT can be
used to decompress the stomach. Spo2 monitoring is used to
adjust oxygen concentration.

Negative Pressure Ventilators
Iron lungs, cuirasses, and raincoats create negative abdominal pressure, allowing the diaphragm to distend and draw
air into the lungs (Fig. 8-35). A negative pressure ventilator
(NPV) is pressure controlled; tidal volumes are dependent
on the patient's transthoracic pressure and thoracic compliance. Increased transthoracic pressures augment FRC, limit
intrapulmonary shunting, and improve systemic oxygenation. Tidal volumes can be measured at the patient airway
using a spirometer.
NPVs are generally used for nontracheotomized patients
who cannot tolerate noninvasive positive pressure ventilation. NPVs may be used continuously, intermittently, or at
night to pemlit the patient to rest. Patients with hypercapnic
respiratory failure secondary to alveolar hypoventilation
syndromes or neuromuscular or chest wall mechanical
problems may benefit from NPVs. NPVs may also benefit
the postoperative cardiovascular surgery patient who requires assisted ventilation but would benefit from lower

Fig. 8-35
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Raincoat negative pressure ventilator.

pulmonary artery pressures and enhanced pulmonary and
central venous return.
Blaufuss and Wallace 106 delineated the nursing care
issues involved in caring for patients supported on NPVs.
These patients are at risk for airway obstruction and
pulmonary aspiration. Nasojejunal tubes are recommended
for enteral feedings. Hypothermia secondary to convective
cooling as air is pulled through the collar may become an
issue. Maintaining skin integrity and vascular access requires proactive interventions. Patients commonly experience claustrophobia, helplessness, and sleep deprivation, so
diversional therapy is also very important.

ALTERNATIVE THERAPIES
High-Frequency Ventilation
High-frequency ventilation (HFV) has become increasingly
popular in supporting infants and children with acute
respiratory failure (ARF) who cannot receive ventilation by
traditional means. Conventional mechanical ventilation
(CMV) is not without risk; the delivery of normal VT to a
patient with sick, noncompliant lungs necessitates high
inflating pressures. However, decreased compliance is not a
global phenomenon, and regions of high compliance become overdistended. 107 These extreme swings in airway
pressure, from PIP to PEEP, contribute to the incidence of
pulmonary barotrauma and associated air leak syndrome, for
example, pneumothorax, pneumomediastinum, pneumopericardium, pneumoperitoneum, and pulmonary interstitial
edema (PIE).
With HFV, small VT (equal to or less than Vo ) delivered
at high frequencies maintains constant lung volumes at
airway pressures just above alveolar closing pressure. The
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Direct alveolar
ventila lion

Fig. 8-36 Modes of gas transport during high-frequency ventilation. HFO. High-frequency oscillation. (From Villar J et al:
Non-conventional techniques of ventilatory support, Crit Care
Clin 6:579, 1990.)

lungs stay inflated while both volume and pressure peaks
and valleys associated with continuous forced opening and
passive closing of alveoli are avoided. One potential, but
unsupported, benefit of HFV is the reduction of iatrogenic
ventilator injury while maintaining adequate gas exchange
using similar MAPs but lower PIPs associated with CMY.
Definition. HFV is a broad term used to describe
numerous techniques of ventilation that deliver VT less than
the patient's dead space at supraphysiologic rates. In adults,
HFV is operationally defined as 60 or more breaths/min or
I hertz (Hz). This definition has obvious limitations in sick
infants and children, who normally have respiratory rates
within this range. A better definition for the pediatric
population is the use of ventilatory rates greater than 150
breaths/min at VT that approaches anatomic VD'
Mechanism of Gas Transport in HFV. CMV attempts to simulate spontaneous ventilation by delivering
gas in bulk volume that approximates VT at physiologic respiratory rates. Gas transport in the larger airways
occurs primarily by bulk convection of 3 times V D'
whereas diffusion is important in the terminal airways and
alveoli.
Traditional physiology, based on bulk flow, cannot
explain the mechanism of gas exchange in HFY. In 1915,
Henderson and others noted that when smoke was blown
down a tube, it formed a thin spike; the quicker the puff, the
thinner and sharper the spike. Correlating their observation
to panting dogs, they believed that gas exchange, sufficient
to support life, was possible when VT was less than VD'
lOg
Chang and Harl
identified five mechanisms of gas
transport thought to be important in HFV: (I) convection,
(2) pendelluft flow, (3) Taylor dispersion, (4) asymmetric
velocity, and (5) molecular diffusion (Fig. 8-36).
Convection refers to the bulk flow of inspired gas to the
level of the alveoli. Unlike CMV, HFV delivers VT equal to
at least one half to three quarters of anatomic VD' Direct

alveolar ventilation becomes less pronounced as VT approaches VD' 109 Pendelluft flow refers to interregional gas
mixing or the movement of gas between neighboring lung
units dependent on time constants. Pendelluft flow is
enhanced during HFV and facilitates interregional gas
mixing of adjacent lung units. Taylor dispersion describes
the distribution of gas moving in a column: axial dispersion
and radial diffusion. Gas flowing through a straight tube
forms a parabolic (bullet-tipped) velocity profile, with the
highest velocity occurring at the center. This effect disperses
gas across the front of the moving column of gas (axial
dispersion) and facilitates molecular diffusion around its
periphery (radial diffusion). Asymmetric velociry is the
mixing of inspiratory and expiratory gases in the airway.
Inspiratory gas (02) moves toward the alveoli in the center
of the airway, and expiratory gas (C0 2) moves away from
the alveolus along the periphery. Molecular diffusion, the
process of gas transport across the alveolar pulmonarycapillary membrane, is the primary mechanism of gas
transfer between the alveolus and blood. The literal shaking
of the chest during HFV probably enhances molecular
diffusion.
Although gas transport during HFV is thought to be a
function of all five mechanisms, observations made in the
laboratory setting using rigid uniform cylinders cannDt be
applied to humans with a complex tracheobronchial tree.
The exact mechanisms of gas exchange in HFV are
controversial but probably vary in different areas of the
lung, in different disease states, and with different techniques employed.
Classification. The early days of HFV were characterized by device confusion, that is, a technology in
search of a disease. 110 Since that time, a variety of HFV
techniques have been used in clinical trials. Four techniques are in clinical use today: high-frequency positivepressure ventilation (HFPPV), high-frequency jet ventilation (HFlV), high-frequency flow interruption (HFFI), and
high-frequency oscillation ventilation (HFOV). Table 8-18
provides an overview of these techniques. When analyzing
research related to HFV, the method of HFV, as well as the
ventilation strategy, is important.
HFPPV, considered by many to be an extension of
CMV, employs a standard ventilator modified with lowcompliance tubing so that adequate VT can be delivered
using short Ti. 109 Flow is intermittently delivered to the
patient through a pneumatic valve located at the airway.
Effecti ve ventilation can occur within an open or closed
system. When closed, the system allows an accurate
determination of VT because environmental air entrainment
does not occur. Tidal volume is delivered via a standard ETT
with the inspiratory phase the only active phase of the
respiratory cycle. Expiration is achieved by passive lung
recoil. Ventilation frequency, V T , F102 , and Ti can be
controlled. Starting frequencies are usually in the range of
60 to 120 breaths/min (I to 2 Hz), VT of 3 to 4 mllkg, and
Ti of 20% to 33%."1 Heijman and co-workers 112 cautioned
that high frequencies may limit VT and compromise actual alveolar ventilation despite an increase in minute
ventilation.
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Overview of High-Frequency Ventilation Techniques
HFPPV

HFJV

HFFI

HFOV

High-pressure gas source
Continuous or valved
fresh gas flow
>V o
Passive
Variable

High-pressure gas source
Jet catheter with continuous fresh gas bias flow
xV o
Passive
Triangular

High-pressure gas source
Valved flow interrupter

xV o
Passive
Triangular

Piston pump
Continuous fresh
gas flow
<Vo
Active
Sine wave

None
60-120
(1-2 Hz)
Siemens

Yes
60-600
(1-10 Hz)
Bunnell
Universal

None
300- 1200
(5-20 Hz)
Emerson
Infant Star

None
60-3600
(1-60 Hz)
Hummingbird
Sensormedics

iWi,Pata from Coghill CH, Haywood IL, Chatburn RL et al: Neonatal and pediatric high-frequency ventilation: principles and practice, Respir Care
1Ij[36:596-609, 1991: Martin LD, Rafferty IF, Walker LK et al: Principles of respiratory support and mechanical ventilation. In Rogers Me. ed: Textbook
i1i'P/pediatric intensive care, Baltimore, 1992. Williams & Wilkins. pp 134-203.
~!:~FPPV. High-frequency positive-pressure ventilation; HFJV. high-frequency jet ventilation; HFFI, high-frequency flow interruption: HFOV.
~ll~gh-frequency oscillation ventilation.
l;:;i;~~

HFJV delivers small bursts of gas from a high-pressure
source into the patient's trachea through an injector port
of an Err designed specifically for jet ventilation (Fig.
8-37, A). The burst of gas, representing inspiration, is the
only active phase of the ventilatory cycle; expiration
depends on passive lung recoil. Tidal volumes are generated
by the jet volume plus varying volumes entrained by a
Venturi effect from a parallel continuous low-pressure flow
circuit. Entrainment occurs when the jet burst entering the
airway under high pressure creates an area of low pressure behind the entry point. Gas from the upper airway is pulled into the low-pressure area, giving additional VT to each jet pulse. The volume delivered depends on ventilator settings and pulmonary mechanics,
such as airway resistance. The presence of a large backpressure may impede gas entrainment and jet flow. Frequencies range from 4 to IO Hz. Concerns with this mode
of HFV include providing adequate humidification and
the need to reintubate a critically ill patient with the
special ETT.
HFFI, considered a hybrid of HFJV, provides small
bursts of gas at high frequencies into the ventilator circuit
rather than the patient's trachea. Ventilation occurs through
the interruption of high-pressure gas flow by either a shutter
system or rotating ball device (see Fig. 8-37, B). Compared
with HFJV, humidification is better, a special ETT is
unnecessary, and gas entrainment does not occur. 113 Frequencies can be adjusted to 20 Hz.
HFOV uses a piston acting across a low-bias flow circuit
to deliver small volumes of gas through a standard Err (see
Fig. 8-37, C). Gas is pushed in, and as the direction of the
piston reverses, similar volumes are extracted from the lung.
The primary difference between HFOV and other modes of
HVF is that exhalation is active, not entirely dependent on
passive lung recoil. Active exhalation not only enhances
CO 2 removal but also reduces the incidence of stacking of
breaths causing inadvertent increases in lung volume. I 14

Because of the active exhalation phase, very fast rates from
60 to 3600/min or I to 60 Hz can be used.
Equal power is applied to both inspiratory and expiratory
phases. As long as the inspiratory and expiratory time
constants of the lungs are equivalent, equal volumes of gas
are delivered and extracted. Time constants are rarely equal,
and at 50% Ti at high frequency, air trapping can occur,
resulting in an increase in lung volume. As long as Ti is less
than 40% of the respiratory cycle, mean alveolar pressure
will not exceed mean proximal airway pressure. I 15
Oscillatory ventilation holds lung volume constant,
which not only eliminates potential mechanical damage
from the opening and closing of the delicate small airways
and alveoli but also eliminates the need for high peak
pressure breaths needed to reopen closed alveoli. Lung
volume is held relatively constant to enhance alveolar
recruitment.
Clinical Issues. Coghill and colleagues 109 noted that
regardless of the technique used, the most consistent
observation in HFV is that CO2 elimination is usually easily
accomplished. CO2 elimination is related to both VT and
frequency; but unlike CMV, VT appears to be more
important in HFV.
Delivered VT increases with Err size and decreases with
frequency. I 13 In HFPPV and HFN, Pacoz increases when
the frequency passes a threshold level as a result of
decreased delivered VT . Insufficient expiratory time «66%)
will cause an increased lung volume and impedance to lung
inflation at higher frequencies. During HFOV, increasing the
frequency will decrease the Pacoz until a plateau is reached.
HFOV eliminates COz faster than expiratory-passive forms
of HFV. In HFJV, the position of the jet cannula tip in the
airway is also an important factor; the closer the tip is to the
carina, the better the COz elimination.
As in CMV, MAP and its correlate-lung volumelargely determine oxygenation. Compared with CMV, some
proponents of HFV believe that oxygenation can be

296

Part III

Phenomena of Concern

air~

oxygen
blender

A

to
endolrachaal
tube

molor
and

frequency
control

B

to

source ....

r--~-'" hlgh
impedance

gas

R

I
rOlating
ball
valve

I

expiratory

"

limb

'0

endotracheal
tube

fresh
gas
source
piston

pump

c

-

•L

_.J--~===:-.-:_---------,
...
~ endot~:Chear
tube

motor
and
frequency
control

Fig. 8-37 A, Schema of high-frequency jet ventilation system.
B, Schema of high-frequency flow interruption system. C, Schema
of high-frequency oscillatory ventilation system. (From Chatbum
RL: High-frequency ventilation. In Blummer JL, ed: A practical
guide to pediatric intensive care, ed 3, St Louis, 1990, Mosby,
pp 957-958.)

accomplished using lower MAPs. However, MAPs measured at the proximal airway are probably different than
alveoli pressure. I 16 Comparisons of oxygenation between
CMV and HFV at similar proximal airway pressures have
not necessarily ensured equivalence of mean alveolar
pressure and lung volumes. I I I PIPs are lower with HFV
because of smaller delivered VT'
During CMV, there is a gradual increase in alveolar
pressure during inspiration. At end inspiration, alveolar
pressure may become supraatmospheric and restrain pulmonary capillary blood flow. Increased intrathoracic pressure

associated with positive pressure ventilation also decreases
venous return, stroke volume, and cardiac output. Attempts
to limit these adverse circulatory effects prompted enthusiasm for HFV. However, studies comparing cardiac output
and other hemodynamic variables during HFV and CMV at
equal mean alveolar pressures in animals have failed to
reveal significant differences. III
The effects of HFV on the pulmonary circulation and
V/Q matching have not been adequately defined. Humorally
mediated attenuation of the hypoxemic pulmonary vasomotor response during HFV may contribute to pulmonary
venous admixture and arterial desaturation. 111
In the setting of intracranial hypertension, the negative
impact of high intrathoracic pressure on cerebral circulation
is well documented. Decreased respiratory variation in
intrathoracic and central vascular pressures during HFV
should diminish phasic swings in ICP. Total and regional
blood flow does not appear to be different during HFV
and CMV.
The early use of HFJV was complicated by necrotizing
tracheobronchitis (NTB) characterized by epithelial erosion,
loss of ciliated cells, squamous cell metaplasia, and infiltration of the mucosa by neutrophils. lo7 Symptoms of NTB
include acute airway obstruction and aspiration of necrotic
debris from the airway. Possible pathogenesis of NTB
includes inadequate humidification of delivered gas and
extremely high-velocity jet flows. 1I3 Although data conflict
regarding the effect of HFV on mucociliary transport,
without adequate humidification, mucous clearance becomes a problem.
Studies investigating the effects of HFV on lung water
and edema formation have produced contradictory findings.
Pulmonary compliance and surfactant activity have been
studied and suggest that mechanical pressure-volume relationships and surfactant activity of the lung are not
negatively influenced during HFV. III
Eucapnic apnea has been observed with HFV. This
apneic state associated with HFV is mediated by chest wall
receptors and vagal afferent fibers and appears to be
independent of chemical respiratory drive and lung volume
changes.
Clinical Applications_ Compared with the neonatal
population, the use of HFV in infants and young children
has received less attention. Although the benefits of HFV in
pediatrics are unproved, pediatric applications include
major pulmonary air leaks, interstitial pneumonia, ARDS,
and congenital diaphragmatic hernia. II 0 Research is needed
to determine when, if, and what type of HFV can improve
patient outcome. Using HFOV and an aggressive volume
recruitment strategy, Arnold and co-workers 117 demonstrated an improvement in oxygenation and a lower
frequency of barotrauma compared with conventional
ventilation.
The most persuasive indication for HFV is pulmonary
air leak. Bronchopleural fistulas, major airway disruptions,
and pneumothoraces respond favorably to HFV. 1I8 Healing of disrupted airways occurs more rapidly in the presence of lower tidal swings in airway pressure associated
with HFV. III
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HFPPV and HFJV have been used in short-term support
of ventilation during airway procedures such as bronchoscopy and laryngoscopy. Airway visualization is enhanced
and ventilatory motion is decreased with these techniques
of HFV.
Nursing Care of a Patient Supported on HFOV.
Nursing care of the patient supported on HFOV centers
around vigilance in monitoring and in preventing complications. 1l9 Although monitoring is critical, constant vibration of the child's body and noise from the ventilator limit
traditional assessment methods. Auscultation of heart,
breath, and bowel sounds is difficult if not impossible. The
only time auscultation is possible is during a suctioning
procedure when the patient is being hand ventilated. Most
patients on HFOV are chemically paralyzed and sedated.
Because it is difficult to detect fine movements that hallmark
the need for additional chemical paralyzing agent, continuous infusions guided by peripheral nerve stimulation provide a more reasonable approach to the use of chemical
paralysis in this population. Electroencephalograms (EEGs)
cannot be used to assess for the presence of seizure activity.
Possible autonomic symptoms of seizure activity include
cyclic increases in heart rate and blood pressure, dilated
pupils, and, possibly, worsening blood gases.
Impaired Gas Exchange: Hypoxemia and Hypercapnia. The goal of HFOV is to reduce or eliminate
hypoxemia and hypercapnia using similar MAPs but lower
PIPs than used with CMV while minimizing the risk of
barotrauma and oxygen toxicity. Frequent ABGs are necessary with the initiation of therapy but should be delayed
because changes in ventilator settings may take up to an
hour to be reflected in the patient's ABGs. Baseline ABGs
are individualized; lower Pa02 «50 mrnHg) and higher
Pac0 2 (>70 mmHg) may be tolerated as long as the pH
remains greater than 7.25. Acidosis is managed with
trometharnine (THAM), a non-C02 -generating buffer. Spoz
monitoring provides an ongoing trend in oxygenation.
Oxygenation profiles provide data regarding the adequacy
of 002 compared with Voz.
Improved Oxygenation: Optimize Lung Volume.
To ensure adequate alveolar recruitment, the MAP is
initially set 5 to 8 cm H20 higher than that required on
CMy' IZO The MAP is increased in 1- to 2-cm HzO
increments until the Sp02 is greater than 90% with a baseline
FI02 of 0.6 or until overinflation is evidenced on chest x-ray
film. Appropriate MAPs will increase alveolar recruitment
and lung volume and thus oxygenation, whereas excessive
MAPs will cause overdistension, air trapping, and V10
mismatch and impair oxygenation.
Ventilation strategy for the manipulation of MAP varies
among disease categories. I10 The goal in a patient with
diffuse alveolar disease (DAD) characterized by a noncompliant, surfactant-deficient lung is high volwne. Alveolar
recruitment to maintain optimal lung volume is a priority;
thus high MAPs are used while the FIOz is maintained less
than 0.6. The goal in air leak syndrome (ALS) is low
voillme, to promote lung healing and recovery. Attempts are
made to decrease or maintain MAPs until air leak is resolved
tolerating higher F102'
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Patient supported on high-frequency oscillation ventilation in prone position.

Fig. 8-38

Other factors to be considered include improving Do z,
limiting Voz, and altering pulmonary mechanics; for example, sedation, muscle relaxants, repositioning, suctioning,
and managing bronchospasm. If chest wall vibration suddenly decreases, decreasing lung compliance, pneumothorax, additional atelectasis, ETT obstruction or malposition,
and hyperinflation with V10 mismatch are considered.
Prone position may improve V/O matching (Fig. 8-38).
"Best" positioning is reevaluated daily as patient tolerance
permits.
Improve CO2 Elimination: Frequency and Tidal
Volume. As discussed, alterations in VT will have a much
greater effect on CO 2 elimination than changes in frequency.
Adjusting the oscillatory amplitude, which is the power
control, controls CO 2 elimination. Power is responsible for
the volume of air exchanges with each oscillatory cycle. The
power is adjusted until adequate chest wiggle, that is, LlP,
VT' is achieved. Given the attenuation of airway pressure
from the proximal airway to the distal airways, predicting
exactly how much pressure is transmitted to the lungs is
very difficult. Presumably, the larger the ETT, the greater the
pressure transmission.
Starting frequencies employed with HFOV (which approximate the resonant frequency of lung) are 15 Hz in
neonates and 5 to 10 Hz in older children. If maximum 6.P
is unable to improve ventilation in older children, a
secondary strategy includes decreasing frequency and increasing power to increase VT and expiratory time. If an
elevated Paco z persists, a 10% increase in VT can be
obtained by increasing the Ti toward 50% of the cycle. This
maneuver is used with caution because higher frequencies
and Ti close to 50% may result in increased lung volume and
stacking of breaths. Follow-up chest x-ray films are used to
assess for overinflation.
Weaning. The patient's lung compliance often improves rapidly and requires aggressive weaning of the
airway pressure to avoid overdistension and development of
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pneumothoraces. Signs of improvement are often subtle,
that is, increase in the percent piston displacement using the
same power, improved tolerance to hand ventilation and
procedures, improving Sp02 with an H0 2 less than 0.6, and
resolving air leaks. Frequency is not weaned even in the
event of an improved patient condition. Airway pressure is
decreased by 1- to 2-cm increments every 12 to 24 hours,
followed by close observation. In the event of decreasing
Sp02 and lower Pa02, a chest x-ray film is justified to assess
for atelectasis from the decrease in MAP. Increasing the
MAPs back to the original settings or perhaps I to 2 cm
higher helps reexpand collapsed alveoli.
No guidelines help determine the best time to return to
CMY. CMV may be reinitiated when MAPs are weaned to
15 to 20 cm H20 with an FI02 of less than 0.6, air leaks are
resolved, chest x-ray film has improved, and the patient is
able to tolerate suctioning without prolonged periods of
desaturation. 121 Some patients have been extubated directly
from HFOV without returning to CMY.
Potential for Injury. Pulmonary toilet for the patient
on HFOV is challenging for several reasons; in addition to
the lack of indicators (breath sounds cannot be auscultated,
and high peak pressure ventilatory alarms do not exist),
patient tolerance is extremely low as demonstrated by
prolonged periods of recovery after suctioning. Although the
patient receiving HFV does not seem to require more
frequent suctioning than the patient receiving CMV, the
effectiveness of HFV is extremely sensitive to a buildup of
secretions in the ETI. 114
Frequency of suctioning depends on the disease, fluid
balance, recent chest x-ray film findings, ABGs, and Sa02.
Initially, patients with alveolar disease may require suctioning once daily and then progress to every 12 hours as
tolerated; patients with ALS may need suctioning as little as
every 24 to 36 hours.
Because most patients are intolerant of suctioning, the
procedure may include premedication with lidocaine and
preoxygenation with the ventilator by increasing the FI02 to
1.0 and MAPs 2 to 4 cm H20 15 to 20 minutes before
suctioning. Because it is impossible to mimic the ventilatory
pattern or rate of HFOV, the oscillator is turned off, and the
MAP is maintained during the suctioning procedure. A
minimal number of suction passes are made using an in-line
suctioning device. Vibrations are used if the patient's
platelet count is greater than 50,000 and the patient is
hemodynamically stable.
Because oxygenation is critically dependent on lung
volume, rerecruitment procedures may be necessary after
the suctioning procedure. After the patient reaches presuctioning Spo2' the FI02 and MAPs are returned to baseline as
tolerated.
Patients supported on HVOF are at high risk for
aLterations in skin integrity secondary to immobility.
Eggcrates are used, whereas air mattresses are avoided
because they may affect the resonant frequency of the chest.
The ventilator is moved from one side of the bed to the other
every 12 to 24 hours so that the patient's head can be fully
repositioned. Lastly, these patients also experience an
increased number of radiologic procedures and require strict
maintenance of shielding techniques.

Optimal Sensory Perception. The loud cadence of
HFOV, along with other ICU monitoring devices, often
results in an altered sleep and rest pattern. Earshields,
earpl ugs, and music are used in a therapeutic manner to
hallmark "safe times."
Altered Coping: Child and Family. Stress precautions are taken to help control the environment for these
liable infants and children. In addition to the stress related to
having their child require an extraordinary level of care,
parents require support in understanding the apparently
unnatural breathing pattern. Data regarding the memories
of children supported by this ventilatory strategy are
nonexistent.

Extracorporeal Membrane Oxygenation
Despite significant advances in ventilator therapy, some
patients with ARF will fail to respond and die unless
alternative therapy is available. l22 Extracorporeal membrane oxygenation (ECMO) is prolonged cardiopulmonary
bypass performed at the bedside. It is an alternative
intervention for patients in profound respiratory or cardiopulmonary failure who are refractory to maximal conventional therapies. ECMO supports the cardiopulmonary
system so that toxic high positive airway pressures and
levels of oxygen can be avoided while permitting resolution
of a reversibLe pathologic condition.
ECMO is considered "standard rescue therapy" in
supporting critically ill neonates in ARE Based on its
success in the neonatal population, some centers have
extended the use of ECMO to a carefully selected group of
pediatric patients. 123 However, some very important differences exist between these two patient populations: pulmonary vascular reactivity significantly decreases after 2 weeks
of age; diseases that cause pediatric ARF are not as
homogeneous as those that cause neonatal ARF; and most
causes of pediatric ARF involve pulmonary parenchymal
dysfunction. In the pediatric population, ECMO is not
considered "rescue" therapy but a supportive intervention
that may prevent iatrogenic injury related to oxygen and
ventilator support. 124
Current Application. There are no precise indications for ECMO in the pediatric population. ECMO
may be helpful in a pediatric patient with reversible
disease that can be resolved within the feasible time
limit for maintaining ECMO. A typical pediatric ECMO
course for pulmonary support is usually much longer than
a pediatric ECMO course for cardiac support-2 to 4
weeks compared with 4 to 5 days. ECMO may be
considered when the disease trajectory is directed toward
the patient's demise, the patient is refractory to maximal
conventional therapy, and there is still potential for good
neurologic outcome. Maximal conventional therapy, ill
defined and controversial among centers, includes optimal ventilator, pharmacologic, or surgical therapy. In
describing maximal conventional ventilation, the "process
of care" becomes important. Some centers derive excellent results from alternative ventilator management techniques-some with high-frequency ventilation, and others
with ECMO. The success of anyone therapy at a
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Box 8-9

~ . Contraindications ofECMO Support

.

Multisystem organ failure
Severe neurologic damage
Irreversible lung damage
Greater than 7-10 days on high ventilator pressures and

Evidence of a significant intrapulmonary right-to-left
shunting; >30% during maximal conventional therapy
Static compliance <0.5 ml/cm H,o/kg
Pa02 <50 mmHg; Paco 2 >50 mrnHg with MAPs >18 cm
H2 0, barotrauma, hypotension/arrest
Alveolar-arterial O2 gradient (A-aD0 2 ) >580 with PIPs >40
cm H2 0 will predict 8I % mortality in children
Oxygenation index (01) >0.4 predicts 77% mortality in
children
Present twice more than 30 minutes apart despite maximal
conventional therapy

FI02

Prolonged period since injury occurred
Slow escalation of therapy
Bronchoalveolar lavage and biopsy: increased
macrophages
Prolonged shock (base deficit -5; oliguria; decreased MAP
for> 12 hours)
Current or prior cardiac arrest with unknown neurologic
status
Condition incompatible with normal healthy childhood
(institutional care, incurable disease, metastatic cancer)

ECMO, Extracorporeal membrane oxygenation; MAPs, mean airway pressures.

particular institution may not be able to be replicated in
another.
Pediatric ECMO has been used successfully to support
patients with reversible single-organ failure, that is, ARF
before iatrogenic lung injury or multisystem organ failure
(MSOF) develops or to support patients after cardiovascular
surgery for congenital heart disease (see Chapter 7). Criteria
for patients with pulmonary dysfunction are difficult to
establish because the specificity of various measures is not
exact; most criteria are unit dependent (Box 8-8). One
common theme is that the patient will die of reversible ARF
unless ECMO is offered.
Compared with indications, contraindications of ECMO
support are easier to identify. Factors include those that
preclude a quality outcome or a successful ECMO run
(Box 8-9). Identifying reversible pulmonary disease is
difficult. In children, diseases that cause respiratory failure
leading to interstitial inflammation may result in pulmonary
fibrosis and necrosis. Lung biopsy or documentation of fixed
pulmonary vascular resistance may be necessary to rule out
irreversible lung damage. The extent of pulmonary fibrosis
is related to the severity and duration of the interstitial
inflammation, as well as to the duration of high positive
airway pressures from mechanical ventilation. Typically, a
patient's primary problem will shift from respiratory failure
to ventilatory failure when fibrosis becomes significant.
ECMO Circuit. There are two options when providing
ECMO support: venoarterial (VA) and venovenous (VV). In
VA ECMO, blood is drained from the venous circulation via
a cannula placed in the right atrium, and oxygenated blood
is returned to the arterial circulation through a cannula
placed in the aortic arch. In VV ECMO, blood is drained in
a similar manner, but oxygenated blood is returned to the
venous circulation through a cannula commonly placed in
one of the common femoral veins. A double-lumen cannula
(DLC) (Kendall Healthcare Products, Mansfield, Mass.)
placed in the right internal jugular vein has been used
successfully to provide VV support. 125 Use of the DLC is
currently limited by the 14 Fr cannula size, which can only
accommodate neonates of up to 4 kg. Larger and smaller
cannula sizes are under development.
Although VA ECMO is currently more widely used, VV

ECMO, Extracorporeal membrane oxygenation; MAp, mean airway pressure.
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Box 8-10

.

Comparisons of VA andVVECMO·

VA ECMO
Provides cardiac and pulmonary support
Decompresses the pulmonary vascular bed
Carotid artery is used
Potential lethality of emboli
Coronary artery blood flow is derived from the left ventricle
«Pao2 )
WECMO
Provides only pulmonary support-does not supporr cardiac
function
Normal pulmonary circulation is maintained
Can sti II assess pulmonary artery pressures-<:annot use
thermodilution cardiac output
Provides higher Sv0 2 saturations to the pulmonary vascular
bed, so it may help decrease PYR and heal the lung
May require a 20% increase in flow to compensate for
"pump recirculation"
Requires standard ventilator management
Selective perfusion is not a problem-myocardial circulation
maintained
Normal pulsatile pulse contour is maintained
Carotid artery is spared
May develop problems with the femoral vein related to
chronic venous insufficiency or edema
Longer cannulation time-two sites
Less concern over emboli-returning blood to the venous
system
ECMO, Extracorporeal membrane oxygenation; PVR, pulmonary vascular

resistance; VA, venoarterial;

vv,

venovenous.

ECMO is gaining popularity. Box 8-10 contrasts the major
differences between VA and VV ECMO support. Contraindications to VV ECMO include the patient in cardiac failure
and the patient with inadequate venous access. An advantage of VV ECMO is that it may limit the physiologic
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consequences of microemboli. Most children receIving
long-term VAECMO support die of MSOF, probably related
to microemboli from the ECMO circuit.
Regardless of whether VA or VV ECMO is used, the
ECMO circuit remains the same (Fig. 8-39). Blood is
drained by gravity from the venous cannula in the right
atrium down to a 30- to 50-ml polyethylene bladder that is
servoregulating the hemopump. This venous reservoir is in
direct contact with a microswitch that can sense a decrease
in bladder size, indicating a diminished venous blood
supply. Insufficient drainage into the bladder causes the
bladder to collapse, which automatically shuts off the pump.
Known as "bladder chalter," this may be a result of
hypovolemia; excessive flow; or a kinked, malpositioned, or
inadequately sized drainage cannula. Failure of the pump to
shut off in response to a loss of venous blood supply could
result in air emboli or right atrial suction.
From the bladder, blood is drawn into a hemopump,
where either a centrifuge or roller pump propels the blood
forward. Pump flow regulates the volume of blood sent
through the oxygenator; as a result, the pump flow also
regulates the patient's Pa02 . The flow is usually maintained
at 70 to 120 ml/kg/min. The blood is pumped into the
membrane oxygenator for oxygenation and CO2 removal.
The membrane oxygenator is a flat silicone envelope tightly
wound into a coil that divides the membrane into two
compartments; ventilating gas flows down on one side, and
blood is pumped up on the other. Oxygen, measured in liters
per minute, is administered via a sweep gas. Because the
membrane is 6 to 7 times more permeable to carbon dioxide
than oxygen, carbogen (5% carbon dioxide and 95%
oxygen) is usually added to prevent or correct hypocapnia.
Premembrane and postmembrane pressures are monitored
for the early detection of circuit malfunction. Premembrane
pressures are kept below 300 mmHg to avoid red cell and
platelet destruction; postmembrane pressures should be
between 200 and 300 mmHg. A rise in postmembrane
pressures indicates occlusion or kinking of the return
cannula.
Arterialized, the blood leaves the oxygenator and flows
into the heat exchanger, which in the pediatric patient may

be housed within the oxygenator. Blood flows through
seven stainless steel rods that are surrounded by a water
bath warmed to 39° C. This temperature allows ambient
cooling as the blood returns to the patient through the
return cannula placed in the right common carotid artery
(aorta) in VA ECMO or through the selected venovenous
cannula in VV ECMO.
The "bridge" links the drainage and return lines.
This connection allows the patient to be excluded from
the ECMO circuit without fear of blood stasis and
associated clot formation. Clamped during ECMO support,
the bridge is opened during elective or emergent isolation
from ECMO.
Cannulation. ECMO cannulation is a surgical procedure performed in the PICU. The patient is chemically
paralyzed to avoid respiratory movement, which may
precipitate an air embolus during venous cannulation.
Fentanyl (20 Ilg/kg) is used for anesthesia, keeping the heart
rate and blood pressure within a tight 10- to 20-point
range. 126 The surgical team, including scrub nurse, controls
the sterile environment, which includes the surgical space,
instrument tables, suction, and electrocautery; all personnel
within 6 feet ofthe operative field wear caps and masks. The
bed is raised to facilitate venous drainage, and the patient is
positioned with a roll under the shoulders and the head
turned to the left for neck cannulation. Routine prepping and
draping are performed.
The critical care nurse maintains access to the patient,
including the airway and preferably a large-gauge central IV
line to administer emergency medications, platelets, and
heparin. Access to the arterial line is desirable but is not
always possible. Concentrated platelets (amounts varies
with circuit size) is administered as the sternocleidomastoid
incision is opened. The carotid sheath is exposed, and the
vessels are isolated. The largest possible venous cannula (16
to 28 Fr) is selected and inserted into the right internal
jugular vein. The large cannula size and multiple side ports
usually allow venous drainage equivalent to the normal
resting cardiac output of most patients. The arterial cannula
(12 to 22 Fr) has one large distal opening and is inserted into
the right common carotid artery. Heparin, 30 Ulkg, is

Fig. 8-39 ECMO circuit: from the right atrium, blood
drains by gravity to a blood reservoir, is pumped to the
membrane oxygenator, heated, and then returned to the
patient.
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administered intravenously as the cannulas are inserted. In
VV ECMO, a separate surgical team cannulates the femoral
vein. An alternate cannulation site in the cardiac surgical
patient includes a transthoracic approach. Another unit of
concentrated platelets is administered as the incision(s)
is(are) closed.
When cannulation is complete, the patient is connected to
the ECMO circuit, the clamps are released, and the ECMO
flow is started at 100 ml/min. ECMO flow is gradually
increased over 5 to 10 minutes to a rate of 80 to 120
mUkg/min while the adequacy of venous return and Spo2 are
assessed.
As VA ECMO flow increases, inotropic support can be
gradually weaned. By increasing the nonpulsatile flow in VA
ECMO, it is possible to assume approximately 80% of the
patient's cardiac output, which is evidenced by a narrowing
of the arterial pulse pressure (Fig. 8-40). Hypertension and
bradycardia may result from a too rapid increase in VA
ECMO flow or too slow an inotropic wean. Time may
resolve these effects, but antihypertensive medications, for
example, hydralazine 0.1 to 0.4 mg/kg IV, may be
necessary.
In VV ECMO, no change should occur in the patient's
pulse pressure. Inotropic agents usually cannot be immediately weaned, and continuous mixed venous saturation
monitoring (Sv0 2) of the drainage line is used to assess for
pump recirculation. The goal is less than an 80% Sv0 2 in the
drainage line. Pump recirculation is suspected when the
Sv02 of the drainage line is equal to or greater than SP02'
After the incisions are dressed, the patient is repositioned. The patient's head is placed in a midline position.
Nursing Care of a Patient Supported on ECMO.
Care of the patient requires the ability to rapidly assess a
complex critically ill patient and intervene appropriately
using clinical practice guidelines. Throughout the ECMO
course, the nurse works in collaboration with other members
of the team and side by side with the ECMO specialist.
The bedside nurse is responsible for the overall care of
the patient. The ECMO specialist performs all circuit
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manipulations, adjusts the level of anticoagulation, and
regulates pump flow within the parameters set by the
physician. 127 Although the ECMO specialist administers
medications through the circuit, the nurse is responsible for
preparing the correct drug dose, properly diluted and
correctly labeled, before giving it to the ECMO specialist
for administration.
Impaired Gas Exchange. The patient remains intubated and ventilated while supported on VA ECMO, but
minimal ventilator settings are used to avoid further
barotrauma. These settings are individualized but usually
include PIPs of less than 35 cm H 20, PEEP of 8 to 12 cm
H 20, and Fl0 2 of 0.21 to 0.40. The ventilator rate may be set
at 5 to 10 breaths/min with a tidal volume of less than or
equal to 8 ml/kg. Patients are not routinely chemically
paralyzed, so normocapnia will continue to stimulate
respiratory efforts and help to maintain respiratory muscle
tone and coordination.
The underlying disease, the patient's immediate condition, and progress dictate individualized pulmonary toilet
and airway care. Suctioning may be needed as often as every
3 hours or may be therapeutically delayed to once every
12 hours. Manual deep inflation breaths help to maintain
alveolar volume. Lung compliance and aeration are assessed
with every pulmonary intervention. Aggressive bronchial
hygiene is often limited because of systemic heparinization,
but with adequate platelet counts, it may be safely accomplished. Bronchoscopy and bronchoalveolar lavage can be
helpful if persistent areas of atelectasis and consolidation
are present. Bronchodilators-for example, albuterol and
terbutaline-may be helpful in the bronchospastic patient.
Arterial and mixed venous blood gases are closely
monitored. With an ECMO flow rate of 100 ml/kg/min,
arterial blood saturation should be greater than 95%. The
mixed venous blood gases should have a normal pH, a Pv02
greater than 37 mrnHg, and Svo2 of 70%. In VA ECMO,
adequate Pa0 2 levels are accomplished through manipulating the ECMO flow rate. The higher the rate, the more blood
that interfaces with the membrane oxygenator, resulting in a
higher Pa02. Adjustments for Pac02 levels are made through
the addition and manipulations of carbogen. With the
inclusion or increase of carbogen, there is also an infusion
of additional oxygen, so the oxygen sweep gas may need to
be decreased. In summary, to increase the Pa02' the blood
flow is increased; to decrease the Pac02, the gas flow is
increased.
Care of the patient supported on VV ECMO is similar to
the care of the patient supported on VA ECMO. With normal
pulmonary blood flow, the lungs contribute significantly to
gas exchange. Ventilator settings are maintained at settings
that avoid iatrogenic injury. Pulmonary toilet is aggressive;
arterial and venous blood gases dictate changes in ventilator
management. There are fewer manipulations of the ECMO
flows and sweep gases than on VA ECMO.
Daily chest x-ray films reflect the disease process and
document patient progress. Complete opacification, or
"white out," is common for the ECMO patient. This
phenomenon is thought to be related to the sudden
withdrawal of distending airway pressure on conversion to
ECMO and to the blood-circuit surface interaction that

302

Part '"

Phenomena of Concern

initially causes the release of vasoactive substances. 128 Both
changes are associated with generalized capillary leak and
interstitial pulmonary fluid shifts. This condition may
further compromise the pulmonary status during the first 24
to 48 hours of ECMO support.
Iatrogenic complications of maximal mechanical ventilation before ECMO-that is, pneumothoraces-are not
uncommon. If a pneumOlhorax were to develop while the
patient was supported on VA ECMO, signs and symptoms
would include an increase in Pa02 and a decrease in
peripheral perfusion, followed by a decrease in venous
drainage and progressive hemodynamic deterioration. The
presence or absence of air leaks is documented. Persistent
pulmonary air leaks may be managed by decreasing the
mean airway pressure to just under the pressure associated
with an air leak. Chest tube patency is maintained with
water-seal drainage or suction set at 20 cm H2 0. Stripping
of chest tubes is controversial, especially in the heparinized
patient. All chest tube drainage is documented and may
require colloid replacement.
Alterations in Cardiac Output. The ECMO circuit
contains approximately twice the blood volume of the
patient. VA ECMO flow overrides the patient's inherent
cardiac output, which significantly narrows the pulse
pressure. Once the pulse pressure is lost, the mean arterial
pressure guides nursing interventions, inotropic support, and
fluid administration. Norn1al mean arterial pressure is age
dependent, but a value greater than 60 mmHg is considered
baseline. Even though resuscitative events before ECMO
often leave the patient in a positive fluid balance, equilibration between the patient's own circulation and the ECMO
circuit often requires additional colloid.
Hypotension may result from hypovolemia, an insufficient flow rate, and sepsis-related vasodilation, or oversedation. Associated clinical signs include pallor; prolonged
capillary refill; cool, mottled extremities; and decreased
urinary output.
Persistent hypovolemia, evidenced by a decreased mean
arterial pressure, frequent "bladder chatter," and Svo2 less
than 70%, requires volume administration. Packed red cells
(PRCs), fresh frozen plasma (FFP), or 5% albumin 10 to 20
mllkg may be given to maintain the mean arterial pressure
and hematologic parameters. After volume expansion, the
use of vasopressors, such as dopamine, may be considered.
Hypervolemia, inadequate sedation, or excessive environmental stimuli may be primary or secondary causes of
hypertension. Diuretics, antihypertensives, or sedatives are
used; stress precautions are enforced; and the underlying
cause for hypertension is investigated and managed.
Hypervolemia may result from pre-ECMO resuscitative
efforts, fluid retention caused by prerenal oliguric states, or
third spacing from capillary leakage resulting from sepsis. A
diuretic regimen, sometimes accompanied by the use of
25% albumin, may be employed.
Idiopathic hypertension is common in the pediatric
ECMO patient. The nonpulsatile flow, characteristic of VA
ECMO, downloads baroreceptors. The kidneys may also
interpret the nonpulsatile flow as a low-flow or hypotensive
state, stimulating renin release and activation of the

renin-angiotensin and aldosterone system. The net result is
vasoconstriction and sodium and water retention. With
normal pulmonary vascular resistance, overriding the patient's inherent cardiac output with VA ECMO may be
impossible. Hypertension may result from the two cardiac
outputs existing within a single circulatory system. Because
oxygenation is determined by the ECMO flow rate, lowering
the flow to treat hypertension will compromise oxygenation.
Hypertension exacerbates bleeding, so it is aggressively
managed in the ECMO patient. Antihypertensive drugs,
such as hydralazine, may be used for blood pressure control.
In addition, nitroprusside, nitroglycerin, phentolamine, and
diazoxide have been used in refractory situations. Shortacting I)-blockers, which depress the patient's native cardiac
output, are used cautiously because if an unexpected
interruption of ECMO support occurs, cardiac output would
be significantly reduced.
VV ECMO provides no cardiac override. The native
cardiac output remains fully pulsatile; thus a normal arterial
pulse pressure is maintained. Cardiac output is augmented
as with any critically ill patient.
Environmental stimuli, anxiety, and pain contribute to
patient stress. Controlling the environment and clustering
nursing care to allow periods of uninterrupted sleep become
a nursing priority. Effective nursing intervention requires
coordinating respiratory therapists, physicians, and other
staff in providing their care in a sequence that maximizes a
calm, quiet atmosphere. In addition, minimizing the numbers of bedside personnel and providing adequate sedation
aid in reducing anxiety.
Alteration in Fluid and Electrolyte Balance. The
goal of fluid management is to promote diuresis while
maintaining adequate tissue perfusion, nutrition, and hematologic values. 126 This goal requires astute assessment of
hypotension, tachycardia, decreased urine output, poor
capillary refill, and "bladder chatter." Administration of
fluids and drugs is easily accomplished via the ECMO
circuit. A multiple-port manifold is used to deliver maintenance intravenous (IV) fluid, parenteral nutrition and
10% intralipids, and numerous medications through a
bladder port. The heparin drip is infused through a separate
port that allows minuscule changes in dosage to be recognized immediately, independent of the rates of the other
solutions.
The patient's total hourly IV rate is usually restricted to
three-quarters maintenance to avoid fluid overload, which
can compromise ventilation and weaning from ECMO. As
with normal ventilation, there is an insensible water loss
over the ECMO membrane. The daily volume of this loss is
dependent on the size of the membrane and gas flow.
Prerenal oliguric states may be related to hypotensive
insults before ECMO support, the dehydrating regimen
while on ECMO, or the primarily nonpulsatile VA ECMO
blood flow. Blood urea nitrogen (BUN) values frequently
increase during ECMO support. Aggressive diuretic therapy
with furosemide is administered to return patients to their
dry weight. Low-dose dopamine (2.5 Jlglkg/min) is often
used to augment renal perfusion.
For patients who are resistant to diuretics, ultrafiltration
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can be incorporated within the ECMO circuit and used for
fluid removal. Heparinization and access are nonissues in
ECMO. Priming the hemofilter requires approximately 50
ml of blood; therefore additional colloid is kept available to
compensate for this diversion. Blood is diverted from the
oxygenator, ultrafiltrated, and then returned to the bladder.
The volume of ultrafiltrate removed is determined by the
patient's condition, dry weight, and estimated volume of
fluid excess. The use of the hemofilter has little impact on
serum electrolytes. However, rapid removal of excess fluid
may result in dehydration with attendant elevations in BUN.
The clinical signs of dehydration-that is, sunken eyes, dry
mucous membranes, dry skin with poor turgor, and a
depressed anterior fontanelle in the infant-are monitored.
Accurate documentation of fluid balance is maintained, and
the use of an ongoing cumulative balance sheet over the
entire ECMO course is helpful in evaluating the total fluid
status of the patient. Acute renal failure, as evidenced by
anuria, progressive hyperkalemia, and increased BUN and
creatinine, is managed with hemodialysis placed similarly
within the ECMO circuit.
Alteration in Hemostasis. Activated clotting times
(ACTs) are closely monitored to guide the degree of
heparinization necessary to avoid clot formation within the
circuit and prevent untoward systemic bleeding. When the
initial postcannulation ACT is 300 seconds, a heparin drip
is started at 10 U/kg/hr. ACTs are performed hourly at the
bedside, and the heparin drip is titrated to maintain the
ACT between 180 and 220 seconds. Several factors, such
as low flow rates, bleeding, renal function, or platelet
administration, may alter this range. A low flow rate caused
by bladder chatter may require higher ACTs; the slower
the flow, the greater the chance of clot formation within
the circuit. Diuresis and platelet administration both require
an increase in heparin dosage. The kidneys excrete heparin,
so a lower ACT can be expected after a large diuresis;
the opposite is true in renal failure. Platelets contain
heparinase, an enzyme that metabolizes heparin; therefore
the heparin dose is increased when platelets are administered. Before platelet administration, a baseline ACT is
performed, and if it is less than 200 seconds, a heparin
bolus equal to one half of the hourly infusion dose is
administered. When half of the platelets have been infused,
a repeat ACT is performed and treated. In addition to a
bolus dose, the heparin drip rate may need to be increased
by 10 to 20 U/hr at this time. Another ACT is checked
at the end of the platelet transfusion and is treated if
necessary.
Because the membrane and the pump both contribute to
platelet destruction, daily platelet transfusions may be
necessary to maintain a platelet count greater than 100,000.
If fluid volume is an issue, the platelets may be concentrated
or "spun," which in itself destroys some platelets. Thus a
greater increase is seen in the posttransfusion platelet count
if the platelets are administered in their unconcentrated
form. Platelets can be given directly to the patient via a
peripheral or central IV line or infused through the circuit
postmembrane. Infusion into the circuit premembrane results in platelet aggregation within the membrane, which
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diminishes platelet effectiveness and increases the possibility of clot formation in the membrane.
Prothrombin time is kept below 17 seconds. An elevation
of 3 seconds over control will require FFP of 10 to 20 ml/kg.
Partial thromboplastin times (PTTs) are not followed because they will always be greater than 100 as a result of
heparinization. Large volumes of chest tube drainage may
require replacement of FFP at the rate of 0.5 ml per milliliter
of drainage.
Fibrinogen levels are maintained at 200%. One to three
units of cryoprecipitate are given to correct low fibrinogen
levels but cannot be infused through the circuit because the
factors are destroyed by the heat exchanger.
As with any systemically heparinized patient, precautions are necessary to avoid bleeding. Insertion of all
vascular lines, nasogastric tube, bladder catheter, or other
indwelling tubes should be accomplished before the initiation of ECMO. No intramuscular medications should be
given, nor should finger or heel sticks be performed. Should
manipulation or replacement of an indwelling catheter be
necessary during ECMO, a platelet transfusion before the
event helps avoid or minimize bleeding. All large catheters
should remain in place for the duration of ECMO support to
avoid hemorrhage on removal. The topical administration of
a microfibrillar collagen hemostat (Avitene) and absorbable
gelatin (Gelfoam) may control cannula site oozing witb a
pressure dressing. Uncontrollable bleeding may require
surgical exploration of the wound, and all site bleeding
should be measured and counted as output.
Unlike the neonatal population, spontaneous intracranial
bleeding is rare in the pediatric population. In the United
States, a 20% incidence of extracranial bleeding in seen in
neonates; the incidence more than doubles to 50% in the
pediatric population. Assessment of fluids, vasopressors,
antihypertensives, diuretics, and blood product replacement
requires constant vigilance. Persistent hypovolemia, especially increasing red blood cell requirements, is a warning
sign of occult bleeding. Subtle clinical signs include
increased pallor, agitation, increased respiratory rate, and
decreased capillary refill. All bodily secretions are checked
for the presence of blood. Pulmonary hemorrhage is obvious
by bright red blood endotracheal secretions or massive chest
tube drainage. Mucous membrane bleeding, most often
involving the oronasopharynx, may require packing. Gastric
bleeding becomes evident through nasogastric tube drainage
or melena. Abdominal girths are monitored; abdominal
x-ray and ultrasound studies may confirm any abdominal
bleeding.
Maintaining an adequate platelet count and a lower ACT
can minimize most bleeding. Unfortunately, the progression
of almost any bleeding process during ECMO is almost
inevitable.
A continuous infusion of arninocaproic acid (Amicar;
Lederle Parenterals, Carolina, Puerto Rico) has been helpful
in controlling bleeding in high-risk patients. 129 Amicar
stabilizes clot formation through inhibition of thrombolysis.
Amicar inhibits both plasminogen activator substances and,
to a lesser degree, antiplasmin activity. It also slows the
production of plasmin, which lyses fibrin and fibrinogen.
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After cannulation, Amicar, 100 mg/kg, is administered
diluted in equal volumes of 5% dextrose in water or normal saline through a peripheral IV over 5 to 10 minutes. A constant infusion of 30 mglkg/hr is then infused via
the ECMO circuit. Therapeutic dosage is achieved when
a daily plasminogen activator time is greater than 120 seconds. ACTs remain in the 180- to 200-second range. Amicar
is discontinued if bleeding is not a problem after 72 hours.
Potential Alterations in Nutrition. Transpyloric
enteral or parenteral nutrition provides the child with the
necessary 80 to 100 kcal/kg for healing to occur. If the
patient is fluid restricted, then ultrafiltration can be used to
permit earlier initiation of full nutrition. Pettignano and
colleagues 130 reported that full enteral nutrition in patients
supported on either VV or VA ECMO was well tolerated,
provided adequate nutrition, was cost effective, and was
without complications. Otherwise, the ECMO circuit is
limited to 10% intralipids at I g/kg/day because the fat may
interfere with membrane function. Any additional or more
concentrated intralipid solution is delivered through a
peripheral or central IV. Usually patients initially are given
ranitidine (Zantac) to inhibit gastric acid secretion. Gastric
pH is monitored routinely. The nutritional status may be
evaluated by following serum albumin and total protein
levels, by stringently monitoring fluid balances, and by
clinical observation.
Alteration in Comfort. With rare exceptions, the
pediatric ECMO patient is a previously healthy child who
perceives and reacts to pain and is subject to fear and
anxiety. The pediatric patient supported on ECMO for ARF
lives prone for at least 3 weeks in an overstimulating
environment with little opportunity for long periods of
undisturbed rest. Constant infusions and bolus doses of
morphine sulfate are used to alleviate discomfort. 13I Fentanyl is avoided because of membrane binding and patient
tolerance. The ECMO circuit continuously binds close to
1000 IJ.g of fentanyl, and tolerance, achieved at different
times, increases approximately 10% per day.132
The ECMO patient is at risk for cannula displacement
with excessive head or shoulder movement. The head is
supported in an optimal position, but sedation must be
sufficient for patient safety. Benzodiazepines such as
lorazepam (Ativan) or midazolam (Versed) are used for
sedation and amnesia. The goal is to provide the patient with
a comfortable ECMO course while still allowing neurologic
evaluation and periodic social interaction. Depending on the
level of sedation achieved, the patient may require premedication with a narcotic or sedati ve for suctioning, dressing
changes, or other noxious procedures.
Maintaining skin integrity can be a particularly challenging when caring for the pediatric ECMO patient. Hypervigilance is essential. A low air-loss bed and gel pillow placed
under the occiput are often used. It is not impossible to
slightly tum the patient on a routine basis to minimize
pressure points, visualize the back, and provide skin care.
Other nursing comfort measures include, but are not limited
to, passive range of motion and repositioning of the
extremities, hand rolls, and skin and mouth care.
With organization of nursing and medical procedures, the

patient should have periods to simply rest undisturbed.
During these times, listening to favorite music or television
programs may be relaxing. Radios and tape decks may be
used; headphones may be carefully placed on the older
child. The presence of the child's family often provides the
most comfort.
Preventing Iatrogenic Injury
Sepsis. Although the potential for sepsis increases with
ECMO support, it is very difficult to detect. The usual first
sign of sepsis is fever, but temperature instability is blunted
by the heat exchanger. A consistently low platelet count,
often an indicator of sepsis, is unreliable because of the
degree of platelet consumption by the circuit. A persistent
elevation in white blood cells, with or without a significant
shift in the differential, or positive cultures may be the only
dependable sign. Blood, urine, and tracheal aspiration
cultures are obtained every other day. Prophylactic antibiotics (ampicillin, oxacillin, cefotaxime) are administered
throughout the ECMO course. Gentamicin levels are closely
monitored. Because of slow gentamicin excretion, higher
trough levels result, necessitating the extension of dose
intervals to every 18 hours.
Accidental Decannulation. In a properly sedated,
carefully monitored ECMO patient, accidental decannulation is rare. The patient becomes most vulnerable during any
examination or exploration of the insertion site, being
moved for procedures or linen change, or during patient
transport.. Accidental decannulation can result in death by
exsanguination. Emergency action includes applying very
finn pressure to the cannulation site and clamping the
remaining cannula. There may be no chance for recannulation without entering the thoracic cavity.
Cardiac Arrest. In the event of a cardiac arrest,
cardiac compressions are unnecessary in patients supported
on VA ECMO because pump flow can be increased to
provide optimal cardiac output for organ perfusion. Compressions with ventilations are still necessary in the patient
supported on VV ECMO.
Mechanical Failure. Occasionally a portion of the
ECMO circuit will malfunction, requiring the patient to be
immediately isolated from the system. There is a specific
sequence of clamping the ECMO circuit when corning off
ECMO: (I) clamp the venous cannula, (2) unciamp the
bridge, and then (3) clamp the arterial cannula. Clamping in
this sequence allows the venous drainage to stop before the
arterial return is clamped, increases the patient's blood
volume, and helps prevent hypotension. The patient's
ventilator settings are increased, and colloid and drugs,
including chemical paralyzing agents, are administered as
needed. The gas source is removed from the membrane to
prevent air emboli; system repairs are performed by the
ECMO specialist, and therapy is resumed as soon as
possible.
Normally, the rapid, high-volume blood flow through the
circuit inhibits clot formation. However, treating hemorrhage in the pediatric ECMO patient requires lower heparin
doses, which may result in an increase in clot formation. The
bridge is one portion of the system that has the potential for
blood stagnation. Periodic opening of the bridge provides a
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flush of blood that remixes pooled blood and reduces the
potential for clot formation. Small clots that form on the
membrane may decrease its overall efficiency but may not
be life threatening. Occasionally, a clot will form and
enlarge in a ponion of the circuit that will require
replacement of that section of the circuit or, in some cases,
changing the entire ECMO circuit.
The multiple access ports and connectors increase the
potential for air emboli. Air on the venous side is allowed to
drift down to the bladder, where it may be aspirated from a
bladder port. Air on the arterial side is a life-threatening
emergency. Here, air can be forced across the bridge into the
venous side of the circuit and then aspirated out.
The maximum efficiency of the membrane is often
limited to approximately 2 weeks but may be further
restricted in the presence of low flow rates or ACT
ranges. The premembrane pressure should be less than
300 mmHg to avoid red blood cell and platelet destruction. A rise in this pressure, especially when accompanied
with a change in ABGs, indicates a failing membrane.
Because CO2 transfer is dependent on gas flow and the
surface area of the membrane, a rising Paco 2 can be a
sensitive indicator of loss of functioning membrane. If the
sum of both premembrane and postmembrane pressures is
greater than 700 mmHg, a very real danger of membrane
rupture exists.
The area where the ECMO tubing is compressed by the
pump's rollers is called the "raceway." The raceway is
advanced several times during the ECMO course to avoid
constant pressure on the same portion of tubing. Areas of
wear could eventually rupture, causing rapid blood loss. All
caretakers must use eye protection, as delineated by
universal precautions, at ECMO bedspaces.
In the event of a pump failure, a hand crank may be used
to propel blood manually. A fully charged backup generator
should be located at the bedside at all times.
A failure or improper setting of the thermostat of the
heater can result in the exchanger's water bath either cooling
to room temperature or overheating to unacceptable limits.
A cooled water bath will result in a hypothermic, mottled,
bradycardiac, and hypotensive child. The patient will
become feverish, tachycardiac, and hypertensive if the
heater temperature becomes excessive.
Alteration in Parental Role. In rapid succession,
parents are faced with a PICU admission, information of a
grave illness and possible death, and requests for permission
to use life-supporting technologies that have no guarantees
for outcome and a long list of potential complications.
Often, the child must be transported to an ECMO center,
separating the parents from home, family, and support
systems.
Meeting the parents either before cannulation or soon
after to explain what they will see and hear in the ECMO
bedspace is necessary. The high-technology environment is
taken to the extreme with ECMO. Seeing the child
connected to so many machines with his or blood circulating
outside the body is frightening. Parent-oriented ECMO
literature may be helpful in reinforcing explanations.
Time is allotted for the patient's team to talk with the
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parents and answer their questions. Honest, pertinent
information is the base on which the parents will make
future decisions regarding changes in life support. Given the
potential complications of pediatric ECMO, predictors are
unreliable. Hope is always supported by acknowledging the
positive or neutral aspects of the child's condition, accepting
the parents' future plans that include the child, and
displaying guarded optimism. Only when the decision is
made to temlinate all support is hope tempered with reality.
Although nursing plays an enormous role in parental
support, talking with another parent whose child was
supported on ECMO may be invaluable. Several regional
ECMO parent support groups are available with parents
of ECMO survivors providing telephone contact with new
ECMO parents. The parent support groups provide a
supportive forum for the intimate exchange of feelings
and ideas.
Coming off ECMO. It may take as little as 5 days or
as long as 6 weeks for indicators of improved pulmonary
function to occur. These include a clearing chest x-ray film,
increasing lung compliance, and normalizing blood gases.
On VA ECMO, the child's Pa02 represents a mixture of
pump blood and the blood that traverses his or her native
cardiopulmonary circuit. With flows held constant, any
decrease in Pa02 represents an increase in patient contribution. Early in the course of ECMO, the patient contributes
little, so pump flows are maintained at high levels. As the
patient's pulmonary status improves, ECMO support can be
titrated in one of two ways.
Weaning. In concert with improved lung function,
pump flows are gradually decreased and ventilator settings
are increased. Vital signs, pulse oximetry, and ABGs are
monitored. The pump flow is weaned down to 20% to 30%
of the original rate, and, if tolerated, the patient is clamped
off ECMO. With this method, the patient is continuously
challenged over many hours or days.
Cycling. Cycling is a time-limited method of trailing
off ECMO. The patient is chemically paralyzed and sedated,
all ventilator settings are increased, and the flows are
gradually turned down until total flow is decreased to
30 ml/kg/min. If these steps are tolerated, the patient is
clamped off ECMO. Following vital signs, pulse oximetry,
and ABGs, the ventilator support is gradually decreased. If
the patient can realize a Pa02 greater than 60 mmHg and a
Pac02 less than 45 mmHg on reasonable ventilator settings,
the decision is usually made to decannulate. If these
parameters cannot be met, the patient is cycled again at a
later time, with modified ventilator settings to promote
alveolar recruitment, after aggressive pulmonary care to
mobilize secretions, or with inotropic support. The goal is to
minimize O 2 toxicity and barotrauma but to wean ECMO
support as soon as possible. With this method, the patient is
challenged only once or twice a day for a short time, and the
low flow rates that are associated with thromboemboli can
be avoided. After cycling, flows are gradually increased, and
the patient is observed for rebound hypertension.
In either case, once the patient is excluded from the
ECMO circuit, the bridge between the arterial and venous
tubing is opened, and ECMO circulation continues. When
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weaning or cycling is completed, the patient is placed back
on ECMO while the decision to continue or stop ECMO
support is made. This is unnecessary when weaning or
cycling from VV ECMO. In VV ECMO, the ventilator
settings are increa~ed as in VA ECMO, but the oxygen
source to the membrane is capped. The ECMO blood flow
continues to circulate through the patient, as well as the
system.
Nursing responsibilities during cycling include reassuring the patient and parents that all the additional activity is
controlled and assessing the patient's tolerance to weaning.
Accurate documentation of vital signs, pulse oximetry,
ventilator settings, and laboratory results is also necessary. If
it is likely that the patient will be isolated from the ECMO
circuit, all infusions are transferred to a peripheral or central
IV. The heparin infusion remains in the circuit, but the dose
is reduced by 50% until the patient is again supported on
ECMO and an ACT is rechecked.
Decannulation. Decannulation is a surgical procedure performed in the PICU. The patient is anesthetized and
paralyzed, all infusions are transferred to a peripheral or
central IV, and the heparin drip is discontinued. The patient
is prepped and draped, with the nurse maintaining access to
a patent IV for any necessary drug administration. Two units
of platelets are given postdecannulation. If cannulation and
the ECMO course have done minimal damage to the vessels,
the surgeon may attempt reconstruction. Otherwise, both are
ligated. Advances in cannulas and technique allow vessel
repair. 133 If the carotid artery is ligated, collateral flow to the

right cerebral hemisphere is maintained by the external
carotid and vertebral arteries. Complications and long-term
problems related specifically to iigation or repair of the
carotid artery are unknown.
Postdecannulation, patient movement is limited until all
clotting factors have returned to baseline. Narcotics are
slowly weaned; the patient is assessed for iatrogenic physical withdrawal. A smooth transition can be accomplished by
switching the patient over to longer-acting narcotics, for
example, methadone in equal analgesic doses.

SUMMARY
Caring for an infant or child who requires support of
oxygenation or ventilation is inherent to the practice of
pediatric critical care nursing. Even so, there is not a
significant amount of nursing research to help guide it. This
chapter presents selected principles of oxygenation and
ventilation as they pertain to critically ill or injured infants
and children. As discussed, pulmonary system functioning is
essential for life and because of developmental immalUrity,
the pediatric patient is at high risk for system dysfunction.
The next decade brings hope for primary prevention to
avoid pediatric critical illness involving the pulmonary
system. The next decade also brings new therapies, for
example, intratracheal pulmonary ventilation and liquid
perfluorocarbon ventilation. 134,135 As new therapies become
available, what constitutes conventional and unconventional
support of the pulmonary system will be redefined.
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Acid-Base Balance
Ann Powers

DEFINITION OF ACID-BASE BALANCE

DEFINITION OF ACID-BASE BALANCE

REGULATION OF ACID-BASE BALANCE

Normal metabolism results in the production of acids. An
acid is a proton or hydrogen ion (H+) donor, and a
base is a proton or hydrogen ion acceptor. A large
number of potential hydrogen ions exist in the body, most
of which are buffered and therefore not in free form. The
nonnal concentration of free H+ in the extracellular fluid
(ECF) is extremely small, approximately 40 nmEqlL,
which is equivalent to one millionth of a mEqlL concentration of sodium. The term pH expresses the negative
logarithm of free H+ concentration. The relationship is
inversely proportional in that as free H+ concentration
increases, pH decreases, and vice versa. A normal arterial
pH of 7.40 correlates with a free H+ concentration of 40
nmEqlL. For each O.QJ-unit (U) change in pH from 7.40,
H+ concentration changes I nmEqlL in the opposite
direction, provided that the pH range is between 7.20
and 7.50.
Normal metabolism produces hydrogen in the form of
volatile and fixed acids. To maintain pH within its normal
narrow range of 7.35 to 7.45, acids must be buffered or
excreted. A buffer is defined as a substance that reduces the
change in a solution's free H+ concentration when an acid or
base is added to it. In other words, the presence of a buffer
in a solution increases the amount of acid or base that must
be added to change the pH.
The largest amount of acid load in the body is in the form
of carbonic acid (H 2 C0 3 ), which is a volatile acid. Carbonic
acid is formed, or dissociated, into either hydrogen and
bicarbonate or carbon dioxide and water. This is illustrated
by the following equation:

Buffer System
Respiratory System
Renal System
ELECTROLYTES AND ACID-BASE BALANCE
MATURATIONAL FACTORS
ANALYZING ACID-BASE BALANCE
ACID-BASE DISTURBANCES

Respiratory Acidosis
Respiratory Alkalosis
Metabolic Acidosis
Metabolic Alkalosis
MIXED ACID-BASE DISORDERS

Respiratory Acidosis With Metabolic Alkalosis
Respiratory and Metabolic Acidosis
Respiratory Alkalosis With Metabolic Acidosis
Respiratory and Metabolic Alkalosis
Triple Acid-Base Disorders
SUMMARY

II patients who are admitted to the pediatric critical
care unit are at risk for acid-base disturbances that
may complicate their underlying disorder and further
compromise their overall status. Acid-base balance is
maintained through a variety of physiologic processes,
which may be disrupted with serious illness or injury. Knowledge of acid-base balance is essential to the
practice of pediatric critical care nursing so that appropriate assessment, monitoring, and intervention can be
provided in a timely manner to optimize the child's
outcome.
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The specific reaction (dissociation or formation of
carbonic acid) is determined by the underlying acid-base
environment.
Hydrogen that is generated in the form of a fixed acid
includes lactic acid, ketoacid, phosphoric acid, and sulfuric

~

Box 9·1

.

Physiologic Effects.of Alterations in pH

.

Increase pH
Increase

REGULATION OF ACID-BASE BALANCE

Insulin-induced glycolysis
Responsi veness to catecholamines
Lactate production

Three systems function interdependently to regulate and
maintain acid-base balance. They are the buffer, respiratory,
and renal systems.

Decrease

Krebs cycle oxidations in muscles and renal cortex
Gluconeogenesis in the renal cortex
2,3-Diphosphoglycerate concentration with a corresponding
left shift in the oxyhemoglobin dissociation curve
Vascular tone and resistance
Decrease pH
Increase

Glycolysis
Lipolysis
Krebs cycle oxidations in muscles and renal cortex
Gluconeogenesis in the renal cortex
2,3-Diphosphoglycerate concentration with a corresponding right shift in the oxyhemoglobin dissociation curve
Pulmonary vascular resistance
Decrease

Quantities of liver glycogen
Lactate production
Insulin secretion and binding to receptors
Pancreatic amylase secretion
Threshold for ventricular fibrillation
Respoosiveness to catecholamines
Peripheral vascular resistance
Mesenteric blood flow
Pulmonary macrophage function
Granulocyte function
Immune response

Buffer System
The buffer system can be activated within seconds and thus
is considered the first line of defense against changes in pH
(Table 9-1). The most important of these buffers is the
bicarbonate-earbonic acid (HC0 3--H 2C0 3 ) pair, which is
responsible for buffering ECF. This buffer pair consists of a
weak acid (H 2 C0 3 ), which is activated when the pH is
threatened by a strong base, and a weak base (HC0 3 -),
which is activated when the pH is threatened by a strong
acid. Whenever a buffering reaction occurs, the concentration of one member of the pair increases while the other
decreases. The bicarbonate-earbonic acid system is assessed
clinically by arterial blood gas pH, Pc0 2 , and HC0 3 -. In
clinical settings where arterial plasma HC0 3- measurement
is unavailable, it can be estimated as being approximately
I mEqlL less than the venous serum total CO 2 content as
measured with electrolytes. Therefore an elevated total CO 2
would suggest buffering of a strong base. Arterial blood gas
analysis also reveals whether other systems (respiratory or
renal) are involved in maintaining or attempting to restore
acid-base balance.
A simple and clinically relevant way of relating pH to
alterations in the acid-base ratio is:
pH = Base/Acid = HC0 3 -1H 2 C03

Data from Czekaj L: Promoting acid base balance. In Kinney MR el al. eds:
MeNs clinical referellcefor ailicaJ care nursing, St Louis. 1998. Mosby,
pp

acid. These are buffered by extracellular bicarbonate and
eventually excreted by the kidneys. Dietary intake of acids
and alkal i are also metabolized and buffered to prevent
changes in pH balance.
Biochemical processes are extremely sensitive to minute
changes (0.1 to 0.2 U) in body fluid pH. Cardiac, central
nervous system, and metabolic function may be significantly
altered by changes in pH. Box 9-1 summarizes the physiologic effects of alterations in pH. An interval of 1 pH unit
(6.8 to 7.8) is the widest range compatible with human life.

=20/1

The second most abundant buffer pair is hemoglobin and
oxyhemoglobin, an important buffer of carbonic acid. As

135-144.

TABLE

9-1

Buffer System Pairs
Weak Acid

Carbonic acid (H 2 C0 3 )
Hemoglobin (Hb)
Oxyhemoglobin (Hb0 2 )
Plasma protein (HPr)
Acid organic phosphate (NaRHP04 )
Acid inorganic phosphate (NaH 2 P04 )

Weak Base

Sodium bicarbonate (NaHC03 )
Potassium hemoglobinate (KHb)
Potassium oxyhemoglobinate (KHb0 2 )
Proteinate (NaPr)
Alkaline organic phosphate (Na 2 P04 )
Alkaline inorganic phosphate (NaHP04 )

% Total Buffer Action

53
35
35
7
3
2

,;Prom Baer CL: Regulation and assessment of acid base balance. In Kinney MR et ai, eds: AAeNs clinical reference for critical care nursing. ed 3.
FIi:,
York, 1993. McGraw-HilI.
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blood passes from the arterial to the venous end of a
capillary, cellular COz enters erythrocytes and combines
with water to fonn carbonic acid. At the same time,
oxyhemoglobin gives up its oxygen to the cells, some of
which becomes reduced hemoglobin carrying a negative
charge. The hemoglobin ion then attracts the H+ from
carbonic acid, resulting in a weaker acid than carbonic acid.
When this system is active, the exchange demonstrates why
erythrocytes tend to give up oxygen more rapidly when Pco z
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is elevated (as in respiratory acidosis), resulting in a shift to
the right of the oxyhemoglobin dissociation curve. Erythrocytes hold on to oxygen when Pco z is decreased (as in
respiratory alkalosis), resulting in a shift to the left in the
oxyhemoglobin dissociation curve (Fig. 9-1). This is tenned
the Bohr effect. I
The protein buffer pair is the most abundant intracellular
and ECF buffer. Proteins are composed of amino acids,
which contain at least one carboxyl and one amine group.
The carboxyl group tends to function like an acid, whereas
the amine group tends to act like a base. Thus proteins can
act as both acid and base buffers.
The phosphate buffer pair, which works in the same
manner as the bicarbonate--{;arbonic acid pair, is an important regulator of both erythrocyte and renal tubular pH. This
buffer pair consists of acid-alkaline organic and inorganic
sodium phosphate.

Respiratory System

PC02

N

20
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80

100

Fig. 9·1 pH effect on oxyhemoglobin dissociation curve. (Modified from Shapiro B: Clinical application of blood gases. ed 5,
St Louis. 1994. Mosby.)

Ventilation also plays a major role in maintaInIng pH
balance. The respiratory system can activate changes in pH
within I to 3 minutes and can eliminate or conserve CO 2
(which directly affects acid-base status) more quickly and
efficiently than all the buffer systems combined.
As discussed, when a strong acid is present in the body,
the bicarbonate--{;arbonic acid buffer pair is activated to
buffer the acid. This results in a net increase of carbonic
acid, which dissociates into CO z and HzO. Carbon dioxide
is then eliminated by the lungs (Fig. 9-2). An increase in H+
concentration in the blood stimulates the breathing center in
the medulla to increase the respiratory rate, which facilitates
CO z elimination. If, on the other hand, pH is elevated
secondary to an increase in HCO]-, the respiratory center is
inhibited, and the respiratory rate decreases. This results in

Equilibrium

Decreased H + ion
concentration

Fig.9·2 Regulation of hydrogen ion concentration by the respiratory system. (From Baer CL: Acid-base
balance. In Kinney MR et ai, eds: AACN's clinical reference for critical care nursing, ed 3, St Louis, 1993,
Mosby. P 211.)
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CO 2 retention, which then becomes available to form
carbonic acid, which buffers the excess bicarbonate. The
respiratory system is thus able to compensate for changes in
pH related to metabolic disorders (e.g., diabetic ketoacidosis) by regulating Pc0 2 , which alters the bicarbonatecarbonic acid ratio. The respiratory system cannot, however,
produce any loss or gain of hydrogen ions. Respiratory
compensation is activated within minutes and is usually
fully functional within I to 2 days.

Renal System
Compared with the respiratory system, which operates by
passive CO 2 diffusion, the kidneys control acid-base balance through several highly developed acti ve transport
processes. Renal compensation is a slower process, requir-

EXTRACELLULAR
FLUID

TUBULE

Fig. 9-3 Chemical reactions for (I) secondary active secretion of
hydrogen ions into the tubule, (2) sodium ion reabsorption in
exchange for the hydrogen ions secreted, and (3) combination of
hydrogen ions with bicarbonate ions in the tubules to form carbon
dioxide and water. (From Guyton AC: Hllmall physiology alld
mechallisms of disease, ed 6, San Diego. 1996. Harcourt. Brace.)

ing I to 2 days for complete activation, with disorders
resulting in respiratory alkalosis, and 3 to 5 days to be fully
functional, with disorders resulting in respiratory acidosis.
The length of time a primary acid-base disturbance has been
present is an important factor in determining the expected
degree of renal compensation.
The kidneys react to changes in pH by regulating the
excretion or conservation of Wand HC03 - (Fig. 9-3). A
low pH stimulates excretion of H+ into the urine. As H+
enters the urine, it displaces another positive ion, usually
Na+. At the same time, HC0 3- is reabsorbed in exchange for
the H+. The Na+ is then reabsorbed into the tubule cell,
where it combines with HC0 3- to form NaHC0 3 • which is
then available to buffer other H+ in the blood. The rale ofH+
excretion, and therefore the rate of HC03 - reabsorption, is
proportionate to arterial Pc0 2 . This reaction is reversed for
increases in pH.
The transport of H+ in the renal tubules is facilitated by
the buffer's phosphate (as previously discussed) and ammonia, which is classified as a base. Most ammonia is
converted to urea by the liver and is eliminated from the
body in urine. The remaining ammonia combines with H+
to form the ammonium ion (NH 4 +) in the renal tubules
(Fig. 9-4). NH/ also displaces Na+ and is eliminated in the
urine. The Na+ is then reabsorbed into the tubule cells,
where it combines with HC0 3- to form NaHC0 3 , which is
absorbed into the blood to buffer excess H+.
The amount of H+ excreted in the urine can be measured
by determining the amount of alkali required to neutralize
the urine and is called titratable acidity. As a result of H+
and NH4 + excretion, urine usually has an acidic pH of 6. In
the clinical setting, checking urine pH can be a useful indicator of the degree of renal compensation when assessing
acid-base status. For example, a low or acidic blood pH will
be accompanied a few days later by a low or acidic urine pH
when renal compensatory mechanisms are active. The
reverse is true in alkalotic states.

ELECTROLVTES AND ACID-BASE BALANCE
EXTRACELLULAR

TUBULE

FLUID

Fig. 9·4 Primary active transport of hydrogen ions through the
luminal membrane of the tubular epithelial cell. Note that one
bicarbonate ion is absorbed for each hydrogen ion secreted, and a
chloride ion is secreted passively along with the hydrogen ion.
(From Guyton AC: Humall physiology alld mechallisms ofdisease,
ed 6. San Diego. 1996. Harcourt. Brace.)

In the clinical setting, recognizing how H+ interacts with
other ions is extremely important so that metabolic and
electrolyte imbalances can be anticipated and managed in a
timely and appropriate manner. Fig. 9-5 illustrates the
location of the major concentrations of electrolytes that are
affected by acid-base balance. As discussed, an increase in
plasma CO2 results in an increased renal excretion of H+ and
reabsorption of HC0 3 -, which then buffers excess H+ in the
body. This is a very important compensatory mechanism
that can stabilize pH.
Potassium (K+) also interacts in very important ways
with H+; the two share a reciprocal relationship. When H+
concentration is elevated in the ECF, as occurs in metabolic
acidosis, H+ moves into the cell, and K+ moves out. This
exchange allows H+ access to the intracellular protein
buffers, which can minimize changes in pH. However,
during this process, the shift in K+ from the intracellular
fluid (lCF) to the ECF results in hyperkalemia. A shift in a
very small amount of the ICF K+ will produce a significant
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increase in ECF K+ concentration and may lead to the
potentially lethal cardiac dysrhythmias associated with
hyperkalemia (see Chapter 11). When H+ concentration is
decreased (as in metabolic alkalosis), H+ moves out of the
cell, and K+ moves in, which can result in a hypokalemic
state. Cardiac dysrhythmias are also possible with hypokalemia but are usually not life threatening.
Sodium is affected by H+ balance, as previously discussed. When H+ concentration is elevated, Na+ is displaced
in the renal tubules so that excess H+ can be eliminated in
the urine. The displaced Na+ is reabsorbed, which tends to
increase HC0 3- reabsorption. Normally, this process alone
does not affect pH. However, if tubular Na+ reabsorption is
significantly elevated (as in prolonged sodium deprivation),
a metabolic alkalosis with hyponatremia may result.
The chloride ion (Cn can also contribute to acid-base
imbalance because it usually follows Na+ passively. An
increase in Cl- results in a decreased reabsorption of HC0 3 -
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with Na+ in the renal tubules, which can result in a
metabolic acidosis associated with hyperchloremia. The
reverse of this (increase in HC0 3 - resulting in a decreased
reabsorption of Cl- with Na+) can result in a hypochloremic
metabolic alkalosis.
Calcium (Ca+) is another ion that is affected by acid-base
balance. Maintaining Ca+ levels within their normally
narrow range is critical to normal neuromuscular and
cardiac function. When pH is normal, 40% of the total
plasma Ca+ is bound to protein (mostly albumin) and 60%
is present as ionized calcium in the plasma. Changes in pH
alter the amount of Ca+ bound by proteins, which, in tum,
alters ionized Ca+ levels. A change in pH of 0.1 U will effect
a corresponding change in protein-bound calcium of
0.12 mg/dl. When metabolic alkalosis is present in a child
with a low serum Ca+, the ionized Ca+ is likely to be very
low and can lead to neuromuscular and cardiac dysfunction.
In a child with a metabolic acidosis and a low Ca+ level, the

Metabolic Balance
pH 7.35 - 7.45

ECF

ECF

Metabolic Acidosis

Metabolic Alkalosis

pH < 7.35 - 7.45

pH> 7.35 - 7.45

104 NLort

ECF

ECF
Ca++
2.5 NL or.j,

Fig. 9-5 Location of major concentrations of electrolytes that affect acid-base balance (in mEqIL). ECF,
Extracellular fluid; ICF, intracellular fluid. (Redrawn from Mathewson-Kuhn M: Pharmacotherapeutics: a
nursing process approach, ed 3, Philadelphia, 1994, FA Davis.)
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ionized Ca+ may be within normal limits. Chronic metabolic
acidosis increases renal clearance of Ca+. NaHCO} administration reestablishes normal calcium reabsorption.

MATURATIONAL FACTORS
The systems that regulate and maintain acid-base balance
become fully operational at different developmental periods. The buffer systems are functional in utero. Respiratory system control of acid-base balance is mature in
newborns, provided that pulmonary function is adequate.
Any respiratory, neuromuscular, or neurologic disorder
that alters CO2 elimination can result in an acid-base
disturbance.
Renal system control of acid-base balance is not fully
functional at birth. Newborns have a limited ability to
excrete hydrogen and ammonium ions. Because H+ excretion matures rapidly, the ability of the kidney to excrete a
maximal acid load is achieved by 2 months of age in both
term and preterm infants. Ammonium production may not
fully mature until age 2. Newborns also have a low serum
bicarbonate level, which is secondary to a lower renal
threshold for bicarbonate. The mechanism for this is
unknown, but it may be related to an expanded ECF volume
and immaturity in the transport capacity for bicarbonate
reabsorption. Because of these immature renal functions,
infants have a diminished renal capacity for dealing with
acid-base disturbances.

ANALYZING ACID-BASE BALANCE
Before discussing specific acid-base disturbances, a review
of terminology and guidelines for analyzing acid-base
balance are presented. The terms base excess and base
deficit are often used in the clinical setting in relation to
acid-base balance. Base excess describes the presence of an
excessive amount of base (HCO}-) or a deficit in the amount
of fixed acid (not including H2CO}).
Base excess or deficit can be determined clinically by
application of three rules. 2 These rules assist in determining if a disorder is respiratory, metabolic, or mixed. Rule I
states that an acute change in Pc0 2 of 10 torr is associated
with an increase or decrease in pH of 0.08 U. Normally, if
pH is 7.40, the Pc02 would be 40 torr in the absence of
metabolic acidosis. Application of rule I would reveal the
following:
Pco 2 50 (40 + 10) = pH 7.32 (7.40 - 0.08)
Pco 2 30 (40 - 10) = pH 7.48 (7.40 + 0.08)

Rule II states that for every 0.0 I-V change in pH not caused
by a change in Pc02, there is a 2/3 mEqlL change in the base.
For example, if the pH is 7.26 and the Pc0 2 is 50 torr, the
increase in PC02 would indicate respiratory acidosis. The
calculated pH would be 7.32 (according to rule I). Because
the measured pH is 7.26, there is a pH difference of 0.06 V
By applying rule II (6 x ¥3), the calculated base deficit
would be 4 mEqlL. Thus a metabolic and respiratory
acidosis are both present.

Rule III states the following:
Total body bicarbonate deficit =
Base deficit (mEqlL) x Patient's weight (kg) x 0.3

HCO}- is located primarily in ECF, which is equal to 30%
of body weight; thus total base deficit can be determined by
multiplying base deficit by body weight by 0.3. In a lO-kg
child with a PC02 of 50 and a pH of 7.24, the Pc0 2 is 10 torr
above normal, suggesting that the pH would be 7.32 if the
child had a respiratory acidosis. The unexplained pH
difference of 0.08 U must therefore be attributed to a
metabolic acidosis with a base deficit of 6 mEqlL (according
to rule II). Application of the preceding equation would
reveal the following:
Total bicarbonate deficit = Base deficit x Weight (kg) x 0.3
18 = 6 x 10 x 0.3

To avoid overcorrection and a rebound metabolic alkalosis, total bicarbonate correction is not recommended. One
quarter to one half of the calculated dose is most often
used. Note that the usual recommended dose of NaHC0 3
for correction of moderate metabolic acidosis, I mEq/kg,
(which is approximately one fourth of the calculated
dose), is very close to the more complicated calculation using rule III. Therefore a standard dose of I mEg/kg
is acceptable for quick determination of bicarbonate
replacement.

ACID-BASE DISTURBANCES
The buffer, respiratory, and renal compensatory mechanisms function interdependently at specific time intervals to restore acid-base balance. Signs and symptoms and
the clinical significance of acid-base disturbances are
directly related to the rate at which the pH changes.
Disorders that develop slowly, such as chronic renal
or respiratory failure, allow time for maximum compensation to occur and thus are accompanied by minimal
changes in pH. Rapidly progressing or sudden insults,
such as a cardiac arrest, allow little or no time for
compensation to occur, resulting in profound alterations in
pH that may be fatal if immediate and effective intervention is not initiated. The arterial blood gas (ABG) is
the most useful diagnostic tool in detern1ining acid-base
imbalances in the clinical setting. Normal blood gas values
are listed in Table 9-2. The steps used to analyze arterial
blood gases to determine the acid-base imbalance are
illustrated in Fig. 9-6.

Respiratory Acidosis
Respiratory acidosis is an excess of ECF carbonic acid that
is caused by conditions resulting in hypoventilation and CO 2
retention. These conditions are summarized in Box 9-2.
Buffer response to hypercapnia occurs immediately and is
complete within 10 to 15 minutes. Renal compensatory
mechanisms are activated within 2 to 5 hours but take 3 to
5 days to function at maximum capacity.
Signs and symptoms depend on the severity of the
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Fig. 9-6 Arterial blood gas analysis to determine acid-base imbalance. B.D., Base deficits. (From
DonIen J: Interpreting acid-base problems through arterial blood gases. Reprinted with permission of
Crit Care Nurs 3:38, 1983.)

T"'£9-2 .o,mal Blood Ga. ValUe.

iij.,~.,t.·~.api1lary

Parameter

Arterial

Mixed Venous

Capillary

pH
P0 2
O2 saturation
Pc0 2
HC0 3
Total CO2 content
Base excess

7.35-7.45
80-100 mmHg
95%-97%
35-45 mmHg
22-26 mEqlL
20-27 mEqlL
+2 to -2

7.31-7.41
35-40 mmHg
70%-75%
40-50 mmHg
22-26 mEqlL
20-27 mEqlL
+2 to-2

7.35-7.45
Less than arterial *
Less than arterial
35-45 mmHg
22-26 mEqlL
20-27 mEqlL
+2 to -2

POz is approximately 10 mmHg less than arterial POz except when decreased tissue perfusion is present, that is, cardiovascular collapse or

!!ibypothennia. In these states, capillary samples will not accurately reflect arterial Po2 •
iii;;

respiratory acidosis (Table 9-3). Changes in respiratory
function, such as decreased respiratory rate and shallow
breathing, occur secondary to the underlying problem that
has triggered the alveolar hypoventilation. Dyspnea is
caused by stimulation of the respiratory center in the
medulla and peripheral chemoreceptors that are triggered by a decrease in blood pH. Cardiovascular effects
such as tachycardia, increased cardiac output, and increased
blood pressure occur secondary to sympathetic stimulation
and epinephrine release from the adrenal medulla. This
mechanism is stimulated by hypercapnia and a low pH.
Although receptor response to catecholamines is blunted
in acidosis, this is initially offset by a surge in catechol-

amine release. Acute hypercapnia has opposing effects on
peripheral vasculature. Vasodilation occurs by its direct
effect on vascular smooth muscles. Vasoconstriction is
simultaneously produced by catecholamine release. This
usually results in either a mild vasoconstriction or
vasodilation.
Important exceptions to this occur in the pulmonary
and cerebral vessels. Cerebral vascular resistance decreases and cerebral blood flow increases proportionately with an increase in PC02' whereas the opposite
occurs in the pulmonary vascular bed. Increased cerebral
blood flow precipitates the headache associated with
hypercapnia and respiratory acidosis. An acute increase
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Box 9·2

Disorders Associated
With Respiratory Acidosis

Acute Obstructive Airway Disorders

Croup
Epiglottitis
Foreign body
Asthma
Bronchiolitis
Chronic Obstructive Airway Disorders

Bronchopulmonary dysplasia
Cystic fibrosis
Pulmonary Restrictive Disorders

Pneumonia
Aspiration
Adult respiratory distress syndrome
Pulmonary edema
Interstitial lung disease
Pleural effusion
Pneumothorax
Flail chest
Kyphoscoliosis
Pierre Robin syndrome
Neuromuscular Disorders

Muscular dystrophy
Multiple sclerosis
Spinal muscular atrophy
Guillain-Barre syndrome
Brainstem injury or tumor
Botulism
Spinal cord injury or tumor
Myasthenia gravis
Diaphragmatic paralysis
Pickwickian syndrome
Poliomyelitis
Central Nervous System Depressants

Narcotics
General anesthesia
Sedatives
Cerebral trauma or infection
Brain tumor
Circu latory crises
Cardiac arrest
Severe pulmonary edema
Massive pulmonary embolism
Iatrogenic Causes

Inadequate mechanical ventilation
Hyperalimentation with high carbohydrate content
Sorbent regenerative hemodialysis

in Pc0 2 may preCIpItate pulmonary vasospasm, resulting in an abrupt increase in pulmonary vascular resistance and decreased pulmonary blood flow. Any increase in pulmonary vascular resistance may worsen
the underlying disorder responsible for the respiratory
acidosis.
The pathophysiologic effects on the central nervous
system (CNS) are unclear. Cerebrospinal fluid (CSF) pH
changes in relation to blood pH. CO 2 permeates the
blood-brain barrier, so increases in arterial Pc0 2 are seen
immediately in the CSF. However, the CSF contains fewer
buffers than the blood, so CSF pH falls more dramatically,
which may contribute to the CNS symptoms that occur with
respiratory acidosis. CNS symptoms can vary greatly in
different individuals. For example, similar increases in Pc0 2
cause some children to become somnolent and others to
become apprehensive and agitated.
In respiratory acidosis, the arterial pH is less than 7.35,
the Pc0 2 is greater than 45 torr, and the HC0 3- is normal or
elevated (depending on the degree of renal compensation).
It is important to note that hypoxemia may be a very late
sign of respiratory acidosis; therefore cyanosis may not be
present until the child progresses to respiratory failure.
Serum potassium increases 0.1 mEqlL for each O.I-U
decrease in blood pH and therefore would be normal to
slightly elevated with respiratory acidosis. Blood lactate
levels fall slightly, and phosphorus becomes mildly elevated. Urine pH may be decreased, again depending on the
degree of renal compensation.
Clinical management of respiratory acidosis is directed
toward reestablishing effective ventilation and treating the
underlying problem. The child may require intubation,
mechanical ventilation, or a change in the ventilation plan
while the primary problem is being treated. Oxygen and
NaHC0 3 may be given based on the ABG results. Although
hypoxemia does not usually affect acid-base balance, a P0 2
of less than 35 torr may induce a lactic (metabolic) acidosis.
NaHC0 3 is administered only to correct severe metabolic
acidosis. Effective ventilation must be established before the
administration of NaHC0 3 ; otherwise, the acidosis will
worsen.
The clinical significance of respiratory acidosis depends
on the child's general health and the physiologic effects of
the acidosis and hypoxemia. Nursing assessment parameters
include vital signs, noting heart and respiratory rate, rhythm,
character, and pattern; blood pressure, perfusion status,
peripheral and distal pulses, level of consciousness, and
urine output; muscle strength and movement; oxygenation
status, noting color of nail beds and mucous membranes,
and Sa0 2 ; gastrointestinal function; degree of comfort; and
laboratory data.
Nursing interventions include positioning the child to
optimize ventilation, administering oxygen, and suctioning
to clear the airways and enhance CO 2 elimination. Care is
directed to minimize 02 consumption by providing an
environment with minimal stimulation and uninterrupted
periods of rest. Inherently important is providing the child
and family with appropriate explanations, support, and
reassurance.
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li!'Jtespiratory Acidosis
i;i)ecreased respiratory rate
~Shallow breathing

it·

~pyspnea

~1:Tachycardia
~i'Headache
f~:

liliDecreased responsiveness
~;IDisorientation
iRestlessness
(Apprehension
~Agitation

!f:Fatigue
j;iWeakness
ri!Diminished reflexes

~£Seizures
~:n'
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Signs and Symptoms Associated With Acid·Base Imbalance
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~cNausea
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and vomiting

1""

~L
~:;
uV'·

!!,'

Respiratory Alkalosis

Metabolic Acidosis

Metabolic Alkalosis

Hyperventilation
Breathlessness
Cardiac dysrhythmias
Hypotension
Extremity and perioral
paresthesias
Vertigo
Syncope
Anxiety
Nervousness
Confusion
Decreased level of
consciousness
Decreased psychomotor
performance
Hyperreflexia
Muscle cramps
Twitching
Tetany
Seizures

Tachypnea --.. Kussmaul
respirations
Tachycardia --.. bradycardia
Cardiac dysrhythmias
Hypotension
Poor perfusion with a
grayish pallor
Decreased peripheral pulses
Increased capillary refill time
Decreased urine output
Decreased level of
consciousness
Congestive heart failure
Fatigue
Drawsi ness
Confusion
Apathy
Unresponsiveness
Seizures
Nausea and vomiting
Abdominal distension
and pain

Hypoventilation
Cardiac dysrhythmias
Decreased perfusion
Hypotension
Confusion
Lethargy
Unresponsiveness
Hyperreflexia
Muscle cramps
Twitching
Tetany
Seizures
Nausea, vomiting, and
diarrhea

Respiratory Alkalosis
Respiratory alkalosis is an ECF deficit of carbonic acid
caused by conditions resulting in alveolar hyperventilation
and CO 2 deficit. Rare as a primary problem, disorders
associated with respiratory alkalosis in children are summarized in Box 9-3, Buffer response to hypocapnia begins
immediately and is complete within 10 to 15 minutes. Renal
compensatory mechanisms are activated within 2 to 5 hours
in respiratory alkalosis and take I to 2 days to be fully
functional.
Hyperventilation results from stimulation of the respiratory center in the medulla and stimulation of peripheral
chemoreceptors and nociceptive receptors in the lungs.
Hyperventilation may also occur when signals from the
cerebral cortex override the chemoreceptors, as in voluntary
hyperventilation.
Heart rate increases secondary to sympathetic stimulation and the resultant catecholamine release from the
adrenal medulla, This response can cause atrial and ventricular tachydysrhythmias. There is usually no major change in
cardiac output and blood pressure in awake children.
Cardiovascular response to hypocapnia differs in anesthetized children. Although tachycardia may not develop,
cardiac output and perfusion may decrease. This response
occurs secondary to increased intrathoracic pressures associated with passive hyperventilation, resulting in decreased
venous return. Pulmonary vasodilation occurs with hypocapnia; however, peripheral vasoconstriction also occurs.
This results in decreased blood flow to the skin and
contributes to paresthesias. Cerebral blood flow (CBF) is

also drastically reduced secondary to cerebral vasoconstriction. This vasoconstriction decreases intracranial and intraocular hydrostatic pressure. Cerebral oxygen consumption
does not decrease when blood flow is reduced, so cerebral
hypoxemia and hypoxia may develop, leading to lightheaded ness, syncope, anxiety, altered levels of consciousness, and seizures.
Calcium binding, resulting in hypocalcemia, occurs with
alkalemia. This condition also contributes to the development of seizures, as well as neuromuscular irritability,
hyperreflexia, muscle cramps, twitching, and tetany.
In respiratory alkalosis, the arterial pH is greater than
7.45, the Pc0 2 is less than 35 totT, and the HC0 3- is normal
or decreased (less than 25 mEqlL). Potassium concentration
decreases 0.1 mEqlL for each O.I-U increase in pH and
therefore should be normal or slightly decreased. Urine pH
is normal to increased, depending on the degree of renal
compensation.
The clinical management of respiratory alkalosis is
directed toward restoring effective ventilation and treating
the underlying cause. Sedation, breathing exercises, and
relaxation with controlled breathing can correct the imbalance (if the child is developmentally capable of participating
in such activities). Administration of 3% to 5% CO~ and
neuromuscular paralysis with intubation and mechanical
ventilation may also be necessary if respiratory alkalosis is
severe and other measures are ineffective.
The clinical significance of respiratory alkalosis depends
on the presence and extent of neuromuscular effects.
Seizures from respiratory alkalosis can be life threatening.
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Box.9-3

.

D~ord~rsAsspclated
withJtespiratory Alkalosis

Box 9-4

~ Disorders Associated
.

With Metabolic Acidosis

I

Intoxications

Increased Anion Gap (Normochloremic)

Alcohol
Salicylate
Paraldehyde
Xanthine

Cardiovascular collapse
Diabetic ketoacidosis
Lactic acidosis (tissue hypoxia)
Starvation
Drugs/toxins (methanol, ethanol, salicylate, fructose, sorbitol,
cyanide, carbon monoxide, paraldehyde)
Organic acid metabolism (pyruvate)
Hepatic failure
Renal failure
Congenital enzymatic defects
Glucose 6-phosphate deficiency
Fructose l,6-diphosphatase deficiency
Pyruvate carboxylase deficiency
Methylmalonic aciduria

Increased Intracranial Pressure

Meningitis
Encephalitis
Head trauma
Vascular accidents
Brain lesions
Pulmonary Disorders

Pneumonia
Pulmonary edema
Pulmonary emboli
Increased Metabolic Rate

Fever
Hyperthyroidism
Exercise
Anemia
Gram-negative sepsis
Interstitial lung disease
Miscellaneous

High altitude
Voluntary hyperventilation
Anxiety
Hysteria
Hepatic failure
Congestive heart failure with hypoxemia
Mechanical ventilation

Nursing assessment parameters include vital signs, noting
heart and respiratory rate, rhythm, character, and pattern,
blood pressure, perfusion status, peripheral and central
pulses, level of consciousness, and urine output; muscle
movement and strength; sensation in the extremities and
around the perioral area; and seizure activity.
Nursing interventions with respiratory alkalosis include
maintaining seizure precautions. If age and clinical condition indicate, interventions may include assisting with
relaxation and slow breathing techniques or having the child
breathe through a paper bag. Care is directed toward
providing a safe environment with age- and conditionappropriate activities, minimal stimulation, and uninterrupted periods of rest.

Metabolic Acidosis
Metabolic acidosis is an ECF deficit of bicarbonate caused
by conditions that result in a loss of bicarbonate or an
increase in fixed acids. These conditions are summarized in

Normal Anion Gap (Hyperchloremic)

Diarrhea
Intake of chloride-containing compounds (HCI, NH 4 Cl,
CaCI2' MgC1 2 , arginine HCI, cholestyramine)
Hyperalimentation
Pancreatic, small bowel. or biliary tubes or fistulas
Ureterosigmoidostomy, ileal conduit
Carbonic anhydrase inhibitors (acetazolamide)
Extracellular fluid volume expansion
Mineralocorticoid deficiency (adrenal disorders)
Renal tubular acidosis
Early uremic acidosis

Box 9-4. Note that the most common cause of metabolic
acidosis in the pediatric population is insufficient tissue
perfusion. Situations that produce an increase in fixed acids
result in a normochloremic acidosis with an increased anion
gap. Situations that cause a bicarbonate loss result in a
hyperchlorernic acidosis with a normal anion gap. The
normal range for the anion gap is 8 to 16 mEqlL and is
calculated using the following formula:
Anion gap =Na+ - (0- + HC0 3-)
Buffer and respiratory compensatory mechanisms are activated within minutes with metabolic acidosis. Respiratory
compensation results in an increased respiratory rate to
eliminate excess CO 2 ; however, it is not usually effective in
correcting the imbalance.
Signs and symptoms depend on the severity of the
metabolic acidosis (see Box 9-4). Tachycardia results from
sympathetic stimulation and the subsequent release of epinephrine from the adrenal medulla, which is stimulated by
acidosis. As pH falls below 7.10, heart rate progressively
slows. This reaction is most likely related to the inhibitory
effect that acidosis has on the action of catecholamines or
accumulation of acetylcholine caused by the inhibition of
acetylcholinesterase. Ventricular dysrhythmias are usually
related to the electrolyte imbalances seen with acidosis, particularly hyperkalemia. Acidosis also decreases the fibrilla-
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tion threshold, so the child is at greater risk for ventricular
fibrillation. As pH falls from 7.40 to 7.20, the negative
inotropic effect of acidosis and the positive inotropic effect
of catecholamine release offset each other so that effective
myocardial contraction is maintained. However, as pH falls
below 7.20, the negative inotropic effect dominates, which
results in poor perfusion and hypotension. Calcium entry
into the cell is also inhibited at this point, which further
decreases effective myocardial contraction. Although epinephrine facilitates calcium entry into the cells in early acidosis, this becomes inhibited as H+ concentration increases.
Infants and children who are receiving p-adrenergic antagonists or calcium channel blocking agents, as well as those
who are chronically stressed and have limited endogenous
catecholamine stores, are more susceptible to the negative
inotropic effects of acidosis. A pH of less than 7.20 also
effects arterial and venous tone. The arterial system dilates
while the venous system constricts, which forces blood to
flow centrally. This increases the workload of the heart and
can result in congestive heart failure.
Tachypnea results from stimulation of the respiratory
center in the medulla. Kussmaul respirations develop with
acute severe metabolic acidosis as the child increases tidal
volume and respiratory rate to improve oxygenation and
eliminate CO2, Oxygen delivery to the tissues is enhanced
by metabolic acidosis as the oxyhemoglobin dissociation
curve shifts to the right (see Fig. 9-1). However, if acidosis
progresses, glycolysis slows, and red blood cell 2,3diphosphoglycerate (DPG) is depleted, which eliminates the
beneficial Bohr effect as previously described. Hypoxemia
and tissue hypoxia then progress. Neurologic changes are
related to decreased perfusion to the brain, hypoxemia,
hypoxia, and metabolic and electrolyte imbalances.
The gastrointestinal symptoms associated with metabolic
acidosis are likely related to either ketogenesis or electrolyte and biochemical changes that accompany acidosis.
Normal tone and contraction of the gastrointestinal tract are
altered, resulting in abdominal pain, distension, nausea, and
vomiting.
In metabolic acidosis, the arterial pH is less than 7.35, the
Pc0 2 is decreased (a normal or elevated PC02 would indicate
failing respiratory compensation and the development of
respiratory acidosis), and HC0 3- is less than 25 mEqlL.
Serum potassium is elevated 0.1 rnEqlL for each 0.01 U
decrease in pH; chloride is normal or elevated (depending
on the cause); and urine pH is normal or decreased, again
depending on the cause of the acidosis.
Clinical management of metabolic acidosis is directed
toward identifying and treating the underlying problem and
would include restoring fluid and electrolyte imbalance,
preventing or treating a catabolic state, and providing
adequate ventilation. Bicarbonate losses should be replaced
in severe acidosis. NaHC0 3 is now used conservatively,
most often indicated for a pH below 7.20, when there is
depressed myocardial function, and when compensatory
respiratory efforts cannot be maintained and respiratory
failure is imminent. NaHC0 3 should be administered to
achieve a slight undercorrection and thus prevent a rebound
metabolic alkalosis from occurring. A recommended dose of
I mEq/kg will provide approximately one fourth to one half
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of calculated bicarbonate losses (see previous discussion
under Analyzing Acid-Base Balance). Adverse effects associated with NaHC0 3 administration include a transient
increase in Pc02, which may further compromise cellular
function, myocardial contractility, and cerebral acidosis.
Hyperosmolarity, hypernatremia, and iatrogenic metabolic
alkalosis may also occur. The alkalosis may decrease
ionized calcium and potassium levels, shift the oxyhemoglobin dissociation curve to the left (inhibiting 02 release to
the tissues), and predispose the patient to life-threatening
dysrhythrnias. The potential risks and benefits must be
carefully considered in individual clinical situations when
deciding if NaHC0 3 is indicated. It is critical to remember
that to maintain the buffering capacity of NaHC03 , effective
ventilation or mild hyperventilation must be present.
The clinical significance of metabolic acidosis depends
on the severity of the disorder. The body does not tolerate changes in H+ concentration well. Without appropriate intervention, metabolic acidosis will progress to lifethreatening alterations in cardiac, neurologic, and metabolic
function. Nursing assessment parameters include vital signs,
noting heart and respiratory rate, rhythm, character, and
pattern, blood pressure, perfusion status, peripheral and
central pulses, level of consciousness, and urine output;
seizure activity; gastrointestinal function; intake and output;
muscle strength; signs of hyperkalemia; the child's level of
comfort; and appropriate laboratory data.
Nursing interventions include administering medications
and fluids, positioning the child to optimize ventilation,
maintaining seizure precautions, and providing comfort
measures for gastrointestinal upset. Care is directed toward
providing a safe environment with age- and conditionappropriate activities, minimal stimulation, and uninterrupted periods of rest.

Metabolic Alkalosis
Metabolic alkalosis is an ECF excess of HC0 3- caused by
conditions resulting in excess base because of loss of H+,
reabsorption of HC0 3-, or loss of other ions (i.e., chloride,
sodium). These conditions are summarized in Box 9-5.
Buffer and respiratory compensatory mechanisms are activated immediately with metabolic alkalosis. Respiratory
compensation results in a decreased respiratory rate to
conserve CO2; however, this response is ineffective and
does not correct the imbalance.
Hypoventilation results from stimulation of the respiratory center in the medulla, which attempts to conserve Pc0 2
by decreasing alveolar ventilation. This condition may result
in hypoxemia, which can further compromise the child's
status. Cardiac dysrhythmias with a subsequent decrease in
cardiac output and blood pressure usually occur secondary
to hypoxemia or hypokalemia.
Changes in level of consciousness occur secondary to
decreased CBF, which results from the cerebral vasoconstriction that is associated with alkalosis. Seizures can
develop secondary to hypoxemia, hypocalcemia, or hypomagnesemia. Calcium binding increases with alkalemia,
resulting in hypocalcemia. Magnesium levels decrease in
relation to calcium. Hypocalcemia also contributes to the
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Disorders Associated
With Metabolic Alkalosis
Vomiting
Gastrointestinal suctioning
CI--wasting diarrhea
CI--deficient formula
Diuretics
Hypokalemia
Hypocalcemia
Hypochloremia
Exogenous alkali intake: HC0 3 -, citrate, lactate, acetate
Excessive steroid use
Renal failure
Extracellular fluid volume depletion
Cystic fibrosis
Excess mineralocorticoid
Hyperaldosteronism, Cushing's syndrome. adrenogenital
syndrome
Laxative, licorice abuse
Excessive tobacco chewing
Bartter's syndrome

development of neuromuscular irritability, muscle cramps,
and tetany. Gastrointestinal effects are usually associated
with the underlying problem, which results in nausea,
vomiting, and diarrhea.
In metabolic alkalosis, the arterial pH is greater than
7.45, HC0 3- is greater than 30 mEqlL, base excess is
greater than +2, and Pco2 is normal or elevated. Serum
electrolytes usually reveal a hypokalemia, with a 0.1 mEqlL
decrease in potassium for each 0.0 I U increase in blood pH.
Hypocalcemia and hypochloremia may also be present.
Urine chloride is usually decreased, and urine pH is normal
or increased; the degree depends on the cause.
The clinical managemell1 of metabolic alkalosis is
directed toward identifying and treating the underlying
cause of the imbalance. This approach usually involves
expanding ECF volume with saline, administering chloride
(arginine or ammonium chloride if the NaCl is insufficient
to replace the lost ion), correcting hypokalemia with
potassium chloride, and facilitating excretion of HC0 3 with carbonic anhydrase-inhibiting diuretics (e.g., acetazolamide) or dialysis if renal impairment is present.
The clinical significance of metabolic alkalosis depends
on the severity of the disorder and the accompanying
neuromuscular and respiratory effects. Nursing assessment
parameters include vital signs, noting heart and respiratory
rate, rhythm, character, and pattern, blood pressure, perfu c
sion status, peripheral and central pulses, level of consciousness, and urine output; neuromuscular function; muscle
movement and strength; Chvostek's and Trousseau's signs
for hypocalcemia; strict intake and output; stooling pattern
and characteristics; and laboratory data.
Nursing interventions with metabolic alkalosis include
administering medications and fluids, maintaining seizure
precautions, and providing comfort measures for gastroin-

testinal upset. Care is directed toward providing a safe
environment with age- and condition-appropriate activities,
minimal stimulation, and uninterrupted periods of rest.

MIXED ACID-BASE DISORDERS
Mixed acid-base disturbances often occur in infants and
children with a variety of multisystem problems. Mixed
disturbances can result in excessive or diminished compensation. The clinical significance of the imbalances depends
on the net change in pH.
In general, mixed disorders that drive the pH in opposite
directions (respiratory acidosis with metabolic alkalosis) are
better tolerated because each compensates for the other to
keep the pH near or within normal limits. Mixed disorders
that drive the pH in the same direction (respiratory and
metabolic acidosis) have profound effects on pH because
compensation is impossible. Because the body is unable to
tolerate significant changes in pH, mixed disorders can
significantly alter cardiac, neurologic, and metabolic function and be life threatening without appropriate intervention.
Treating each component of the mixed disorder simultaneously is important to avoid exacerbating one while
correcting the other. Accurate interpretation of ABGs and
monitoring of the child's clinical response to therapy are
critical nursing interventions because the patient's response
to therapy may be asynchronous.

Respiratory Acidosis
With Metabolic Alkalosis
Respiratory acidosis and metabolic alkalosis can occur in
children with obstructive pulmonary disease (e.g., bronchopulmonary dysplasia, or cystic fibrosis) who are receiving
diuretics as part of their management plan. Such children
usually live in a state of compensated respiratory acidosis
secondary to CO 2 retention related to their pulmonary
disease. Chronic diuretic therapy with potassium-wasting
drugs (such as furosemide) can lead to hypokalemia and
metabolic alkalosis. A similar scenario also occurs in
children with congestive heart failure and chronic respiratory acidosis who are receiving long-term diuretic therapy.
The pH with this mixed imbalance is usually near or within
normal limits because of compensation. If, however, the pH
rises with the metabolic alkalosis, respiratory drive may be
depressed in the medulla, resulting in a decrease in P0 2 and
an increase in Pc0 2 • which can progress to respiratory
failure.
Clinical management of this mixed imbalance is directed
toward correcting the metabolic alkalosis, which is accomplished by administering sodium and potassium chloride to
facilitate renal excretion of HC0 3-. This must be done
cautiously to avoid inducing or exacerbating congestive
heart failure. Although pH may fall to acidemic levels, this
will stimulate respiration and subsequently increase P0 2 and
decrease Pc02 levels. Oxygen must be administered carefully because increasing the P0 2 above the patient's normal
threshold may depress the respiratory drive in the medulla.
Knowing the baseline ABG status for the patient with
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chronic lung disease is extremely helpful in establishing
appropriate treatment goals.
Nursing assessment and interventions would be the same
as those listed under each disorder. Consideration must be
given to these children's underlying disease process and to
the degree that they are compromised when planning,
implementing, and evaluating clinical management.

Respiratory and Metabolic Acidosis
Respiratory and metabolic acidosis may develop in infants
and children with chronic obstructi ve pulmonary disease
who are in shock, who have any type of metabolic acidosis
and develop respiratory failure, and in those who suffer
cardiopulmonary arrest. Compensation is not possible with
this mixed disorder, and the pH falls dramatically, even
when changes in Pc0 2 and HC0 3 - are moderate. The clinical
significance is related to the fall in pH and can result in
cardiac, neurologic, and metabolic dysfunction.
Clinical management ofthis imbalance is directed toward
careful correction of both the respiratory and metabolic
component to normalize pH. Knowing the baseline status of
the patient with chronic lung disease is helpful, as previously discussed. Special consideration must be given to the
care of these children because the goal will be to return them
to their baseline compromised status, which will include
normalizing pH but not necessarily other ABO parameters.
Mechanical ventilation may be necessary to eliminate
excess CO 2 and return these children to their baseline status.
NaHC0 3 is usually administered after adequate ventilation
is established. Nursing assessment and intervention are as
discussed under each disorder.

Respiratory Alkalosis
With Metabolic Acidosis
The mixed imbalance of respiratory alkalosis with metabolic acidosis may be seen in children with hepatic failure.
The respiratory alkalosis is due to hyperventilation (secondary to restrictive lung capacity with liver enlargement), and
the metabolic acidosis is due to hepatic failure with lactic
acidosis, renal failure, or renal tubular acidosis. This
imbalance can also' occur in children with chronic renal
failure and acute sepsis. The respiratory alkalosis develops
secondary to the hyperventilation that accompanies sepsis,
and the metabolic acidosis is associated with the renal
failure. Salicylate intoxication also results in a respiratory
alkalosis, which is related to stimulation of the breathing
center in the medulla, and metabolic acidosis, which occurs
secondary to disruption of the Krebs cycle with accumulation of lactic and other organic acids.
Clinical management of the child with this mixed
imbalance is directed toward correction of the underlying
problem. The pH is usually close to or within normal limits
because of effective or excessive compensation and may not
require specific treatment. Nursing assessment and interventions are as discussed under each disorder.
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Respiratory and Metabolic Alkalosis
The combination of respiratory and metabolic alkalosis is
seen in children with chronic hepatic failure who are
receiving diuretics or who develop vomiting. The respiratory alkalosis is due to hyperventilation from restrictive lung
disease related to hepatic enlargement, and the metabolic
alkalosis is due to potassium or fixed acid loss related to
diuretic therapy or vomiting (respectively). This condition is
also seen in children with chronic respiratory acidosis (from
chronic lung disease) with appropriately elevated HC0 3 levels who are supported on mechanical ventilation and are
overventilated, resulting in a drastic fall in PC02 leading to
respiratory alkalosis. Neither disorder is able to compensate
for the other, and pH rises dramatically.
Clinical management of this imbalance is directed toward
treating the underlying problem and normalizing the pH.
The respiratory component is managed by treating the cause
of hyperventilation or adjusting the ventilator. The metabolic component is corrected with sodium and potassium
chloride. Fluids must be administered cautiously to avoid
inducing congestive heart failure or pulmonary edema.
Nursing assessments and interventions are as listed under
each disorder.

Triple Acid-Base Disorders
Triple acid-base disorders may occur in children with
disorders affecting more than one body system, such as
those with chronic liver failure. Hyperventilation and
respiratory alkalosis result from restrictive lung capacity
related to the enlarged abdomen. Metabolic alkalosis occurs
if the child is receiving diuretics, develops vomiting, or
requires nasogastric suctioning. Finally, metabolic acidosis
may develop secondary to renal tubular acidosis, diarrhea,
uremic acidosis, and lactic acidosis. Clinical management of
such a complicated disorder involves careful assessment and
correction of each component simultaneously to normalize
pH. Nursing assessment and intervention would include
those listed under each disorder.

SUMMARY
Acid-base disturbances are associated with many disorders
and diseases seen in the pediatric critical care unit. The
nurse must be able to accurately assess the child's acid-base
status, to recognize imbalances, and to anticipate the
potentially life-threatening complications that may result
from them. Appropriate interventions can then be implemented to prevent or minimize these complications and thus
improve the patient's outcome.
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Intracranial Dynamics
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ESSENTIAL EMBRYOLOGY

U

nlike in other organ systems, functional immaturity of
the neurologic system is extremely obvious when
approaching the infant and young child in the pediatric
intensive care unit (lCU). Neurologic developmental immaturity affects every aspect of care: nurses' approach to
patients, assessment strategies, and management priorities.
Neurologic dysfunction may be primary or may occur
secondarily from other major organ system dysfunction, for
example, cardiovascular collapse or acute respiratory failure. Compared with other organ systems, the neurologic
system is unforgiving. Cells within the central nervous
system cannot regenerate; short periods of inadequate
perfusion may result in long-term devastating outcomes.
Although infants may compensate for significant neurologic
deficits, older children and adolescents may require extensive rehabilitation.
Based on the Role Delineation Study implemented by the
American Association of Critical-Care Nurses (AACN)
Certification Corporation, approximately 10% of pediatric
critical care practice involves caring for patients with
neurologic dysfunction. I Because of the pervasiveness of
neurologic alterations in critical care patients, requisite
knowledge of the neurologic system is essential. This
chapter reviews essential neurologic embryology, anatomy,
and associated physiology. Neurologic assessment is presented, followed by a discussion of neurologic intensive
care monitoring and diagnostic testing.

ESSENTIAL ANATOMY AND PHYSIOLOGY

Microscopic Structures
Extracranial Structures
Brain
Cerebrospinal Fluid and the Ventricular
System
Spinal Cord
Peripheral Nervous System
Autonomic Nervous System
Central Nervous System Circulation
INTRACRANIAL PRESSURE DYNAMICS

Modified Monro-Kellie Doctrine
VolumelPressure Relationships
Cerebral Blood Flow
NEUROLOGIC ASSESSMENT

History
Physical Examination
Assessment of the Neurologically Impaired
Child
Neurologic Assessment of the Chemically
Paralyzed Child
NEUROLOGIC INTENSIVE CARE MONITORING
INTRACRANIAL PRESSURE MONITORING

ESSENTIAL EMBRYOLOGY

ICP Monitoring Systems
ICP Waveform Analysis
ICP Trend Recordings
Nursing Implications

The third week of human development is a period of rapid
embryonic development with differentiation of the three
primitive germ layers: ectoderm, mesoderm, and endoderm.
The ectoderm layer gives rise to the central nervous system
(CNS), consisting of the brain, spinal cord, and other
structures, for example, the skin.
The notochord, a cellular rod, develops during the
third week of gestation, defining the primitive axis of the
embryo and giving it some rigidity. The embryonic ectoderm over the notochord (neuroectoderm) thickens to
form the neural plate. On approximately the eighteenth

MONITORING CEREBRAL FUNCTION

Continuous EEG Monitoring
Evoked Potential Monitoring
NEURODIAGNOSTIC STUDIES
SUMMARY
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Fig. 10·1 Diagrammatic sketches of the brain vesicles indicating the adult derivatives of their walls
and cavities. 'The rostral (anterior) part of the third ventricle forms from the cavity of the
telencephalon; most of the third ventricle is derived from the cavity of the diencephalon. (From Moore KL,
Persaud TVN: The developing human: clinically oriented emblyology, ed 5, Philadelphia, 1993,
WB Saunders, p 40 I.)

day of embryonic development, the neural plate invaginates to form the longitudinal neural groove with two
adjacent neural folds. At the end of the third week, the
neural folds move together and begin to fuse' to form
the neural tube. Fusion of the two neural folds begins
centrally and expands toward the future brain (rostrally)
and the sacral area (caudally). The rostral end closes
first, followed 2 days later by closure of the caudal end.
The cranial two thirds of the neural tube develops further
to form the future brain, and the caudal one third becomes
the spinal cord. The neural tube canal becomes the
ventricular system of the brain and the central canal of the
spinal cord. The process of embryonic development from
neural plate formation to neural tube development is
referred to as neurulation and is complete by the fourth week
of gestation.
As the neural folds fuse, the neural tube separates from
the surface ectoderm. During this fusion, groups of neuroectoderm cells lying on the crest of each neural fold separate
from the neural tube. These neuroectoderm cells, collectively called the neural crest, form a mass between the
surface ectoderm and neuroectoderm. The neural crest cells
differentiate into a number of cells in the peripheral nervous
system, autonomic nervous system, cranial and skeletal
nerves, and some skeletal nerves and muscular components
of the head.
During the fourth week and before closure of the caudal
and rostral neuropores, three primary brain vesicles begin to
appear that later develop into the brain (Fig. 10-1). The most
rostral vesicle is the forebrain, or prosencephalon, the
midclle vesicle is the midbrain, or mesencephalon, and the
most caudal vesicle is the hindbrain, or rhombencephalon.

During the fifth week, with further development, two of
the primary vesicles subdivide to form secondary vesicles.
The prosencephalon develops into the telencephalon and the
diencephalon, and the rhombencephalon develops into the
metencephalon and the myelencephalon. The mesencephalon remains unchanged.
A longitudinal groove, called the sulcus limitans, forms
along the lateral surface of the neural tube canal during the
fourth week. This groove subdivides the dorsal part (alar
plate) of the spinal cord from the ventral part (basal plate).
These plates form longitudinal bulges that extend most of
the length of the spinal cord. This regional separation is
important in terms of spinal cord function. The alar plate
is later associated with afferent function, and the basal plate
is associated with efferent function.
Most abnormal development of the CNS results from
failure of the neural tube to close properly during the fourth
week of development. Defective closure of the caudal
opening of the neural tube (caudal neuropore) produces
malformations of the spinal cord and the overlying tissue.
These malformations, collectively referred to as spina
bifida, range in severity from minor, clinically insignificant
defects (spina bifida occulta) to severe defects with
neurologic deficits (myelomeningocele). Defective closure
of the rostral opening of the neural tube (rostral neuropore)
results in severe malformations of the brain, for example, anencephaly or exencephaly. Other CNS malformations may result from faulty histogenesis of the cerebral
cortex, interference with cerebrospinal fluid (CSF) circulation and absorption, and defective formation of the
cranium. Table 10-1 summarizes congenital malformations
of the CNS.
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Description

. -~ Posterior fontanel

Paflelal bone
Coronal suture .I!!!,,---'

Absence of most of cerebral hemispheres and calvaria
Herniation or protrusion of brain
and meninges
through a defect in the
skull
Protrusion of saclike cyst containing
meninges and spinal fluid through
a defect in the vertebral arch
Protrusion of saclike cyst containing
meninges, spinal fluid, and
portion of the spinal cord with its
nerves through a defect in the
vertebral arch
Downward displacement of brainstem and cerebellum through the
foramen magnum and into spinal
canal. Hydrocephalus from CSF
obstruction occurs in majority of
cases

Almost complete absence of cranial
vault. Often associated with vertebral column defect
Premature closure of one or more of
the cranial sutures
Small calvaria and brain with
normal-sized face

- Occipital bone

Fig. 10·2 Location of the anterior and posterior fontanelles.
(From Betz CL. Hunsberger M, Wright S: Family-centered nursing
care of children, ed 2, Philadelphia, 1994, WB Saunders, p 124.)

Neurons come in a variety of sizes and shapes with a
number of different functions. Most neurons have three
components: a cell body, dendrites, and an axon. The cell
body contains a nucleus but lacks the ability to reproduce
itself. The dendrites carry nerve impulses to the cell body,
and the axon(s) conducts impulses away from the body.
Numerous descriptive terminology exists to classify neurons, based on their location, morphology, and function.
Glial cells (neuroglia) compose approximately 50% of
CNS tissue volume and outnumber neurons by a factor of
10. There are different types of glial cells with different
functions. Oligodendroglia in the CNS and Schwann cells in
the PNS form myelin sheaths around axons to increase the
speed of conduction of an impulse. Other types of glial cells
assist with metabolic functions, remove cellular debris, and
form special contacts between neuronal surfaces and the
circulation.

Extracranial Structures

ESSENTIAL ANATOMY AND PHYSIOLOGY
The nervous system is divided into the peripheral nervous
system (PNS) and the CNS. The PNS is composed of the
cranial and spinal nerves, and the CNS is composed of the
brain and spinal cord. The basic unit of the nervous system
is the neuron. The following section briefly discusses each
of the microscopic and macroscopic structures of the nervous system, as well as the CNS coverings, the ventricular
system, and cerebral circulation.

Microscopic Structures
The two basic cellular elements of the nervous system are
neurons and glial cells. The neuron is the primary cell of the
CNS and is responsible for detecting environmental changes
and initiating body responses. Neuroglial cells of the eNS
and PNS provide nutrition and structural support to the
neurons.

The skull (cranial vault) consists of two components:
neurocranium and viscerocranium. The neurocranium is a
protective covering of the brain, and the viscerocranium is
the skeleton of the jaw. At birth, the newborn's skull is
cartilaginous and consists of eight bones: one frontal, one
ethmoid, one sphenoid, two temporal, two parietal, and one
occipital. The flat bones are separated by dense, white,
fibrous connective tissue membranes called sutures. These
sutures accommodate the rapid growth of brain tissue,
which is greatest during the first 2 years of life. Several
sutures join together at six areas to form fontanelles
(Fig. 10-2). The posterolateral fontanelles and the anterior
fontanelle close during the first and second years of life,
respectively, from growth of surrounding bone.
Meninges is the term given to describe the three
membranous connective tissue layers that cover and protect
the brain and spinal cord (Fig. 10-3, A). The outermost layer
is the dura mater (dura) and consists of two thick,
membranous layers. The outer (periosteum) layer adheres to
the inner surface of the skull and the vertebral column. The
inner layer of the dura divides the two cerebral hemispheres
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along the median longitudinal fissure (falx cerebri), the
cerebral hemispheres from the cerebellum and brainstem
(tentorium cerebelli), and the two cerebellar hemispheres
(falx cerebelli) (Fig. 10-3, B).
The middle covering is named after the Greek word
arachne. which means "spider web." This arachnoid layer
is a transparent avascular covering with many thin strands of
collagen called trabeculars. The trabeculae are believed to
help suspend the brain within the meninges 2
The pia mater (pia) is the innermost meningeal layer. It is
a very delicate, clear membrane that directly adheres to the
surface of the brain, following all of the contours of the
brain and spinal cord. The arachnoid and pia layers are
collectively called the leptomeninges and are sometimes
referred to as the same entity.
The outer layer of the dura normally adheres closely to
the inner table of the skull, especially in the infant. A
potential space (epidural or extradural) may develop from
bleeding that causes separation of the dura from the skull.
The space between the dura and arachnoid layers is the
subdural space. It is narrow and contains a small amount of
serous fluid that prevents adhesions from forming between
the two layers. The subarachnoid space is between the
arachnoid and pia layers. This space is relatively large and
contains circulating CSF.

Brain
The brain is divided into three gross anatomic units: the
cerebrum, the brainstem, and the cerebellum. The cerebrum

Superior sagittal sinus _ _---,

is further subdivided into the telencephalon and the diencephalon, and the brainstem is subdivided into the mesencephalon (midbrain), the metencephalon (pons), and the
myelencephalon (medulla).
Telencephalon. The telencephalon is composed of
the right and left cerebral hemispheres and the basal ganglia.
The cerebral hemispheres are mirror images divided from
each other by the med.ian longitudinal fissure. The surfaces
of the cerebral hemispheres have convolutions, and each of
these ridges is known as a gyrus. Each gyrus is separated by
a shallow groove (sulcus) or a deep groove (fissure). The
outer layer of the cerebral hemispheres or cortex is gray and
consists primarily of cell bodies. The inner layer is white
and consists of myelinated axons. Axons that pass from one
lobe to another in the same hemisphere are known as
associative fibers. Axons that pass between hemispheres,
such as the corpus callosum, are known as commissural
fibers. Axons that pass from a cerebral hemisphere to other
areas of the CNS are known as projection fibers.
The basal ganglia, including the caudate nucleus, putamen, globus pallidus, claustrum, and amygdala, is a collection of gray matter nuclei located deep in the white matter
of the cerebral hemispheres on either side of the midline.
General function of the basal ganglia includes unconscious
control of lower motor centers. Damage or dysfunction of
the basal ganglia may produce disturbances of muscle tone
and various abnormal involuntary movements.
Anatomic fissures divide each of the cerebral hemispheres into four lobes: the temporal, parietal, frontal, and
occipital (Fig. 10-4). These lobes have some distinct

Arachnoid villi

Periosteum

Bone
Dura mater
~_ _

Arachnoid

A

Fig. 10-3 A, Cranial meninges. Arachnoid villi shown within superior sagittal sinus are one site of
passage of cerebrospinal fluid into the blood. (From Chaffee EE, Lytle 1M: Basic physiology and anatomy.
Philadelphia, 1980, JB Lippincott.)
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Fig. 10-3. cont'd B, Dural folds and venous sinuses. (Copyright 1996 by ClBA-GEIGY Corporation.
Reprinted with permission from the Ciba Collection of Medical Illustrations, illustrated by Frank Netter,
MD. All rights reserved.)
Central fissure (Rolando)

Frontallobe _ _~,-

Qccipitallobe

Transverse
fissure

Temporal lobe

Fig. 10-4 Lateral aspect of the left cerebral and cerebellar
hemispheres. (From Hickey JV: The clinical practice of neurological and neurosurgical nursing, ed 2, Philadelphia, 1986,
JB Lippincott, p 32.)
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functions; however, they are not precise, and considerable functional overlap is found among lobes. Some neuroanatomy texts consider a fifth lobe, called the insula, which
is buried deep in the lateral sulcus and has no known function in humans. Although oversimplified, functional descriptions of the four lobes are given for purposes of general
orientation. (Refer to neuroanatomy references at the end of
this chapter for a more detailed discussion of cortical
function.)
The frontal lobe is the largest lobe of the cerebral
hemispheres. The central sulcus (fissure of Rolando) divides
the frontal lobe from the parietal lobe, and the lateral
cerebral fissure (fissure of Sylvius) divides the frontal lobe
from the temporal lobe. The frontal lobe has four general
functional areas: the primary motor cortex and premotor
areas are involved in the initiation of voluntary movements,
Broca's area is involved with written and spoken language,
and the prefrontal cortex is the origin of "personality."
Injury or impainnent of the frontal lobe may cause
personality changes, altered intellectual functioning, memory deficits, language deficits, or impaired body movements.
The temporal lobe is separated superiorly from the
frontal lobe by the lateral cerebral fissure. Posteriorly, it is
divided from the occipital lobe by an imaginary line from
the parieto-occipital fissure. General functions of the
temporal lobe include reception and interpretation of
auditory information, expression of emotional and visceral
responses, and retention of recent memory. Injury or
impairment of the temporal lobe may cause an inability to
interpret sensory experiences.
The parietal lobe is separated from the frontal lobe by the
central sulcus and from the temporal and occipital lobe by
the parieto-occipital fissure. The parietal lobe is associated
with three general functions: initial processing of tactile and
proprioceptive infonnation, comprehension of language
(together with the temporal lobe). and orientation of spatial
relationships and time. Injury or impairment of the parietal
lobe may result in language dysfunction. aphasia, and motor
and sensory loss in the lower extremities.
The occipital lobe is relatively small and sits on the
tentorium cerebelli. The rostral border is the parietooccipital sulcus. The lateral surface is poorly delineated
from the parietal lobe and is composed of a number of
irregularly shaped lateral occipital gyri. The major function
of the occipital lobe is reception and interpretation of visual
stimuli. Injury or impairment of the occipital lobe may
impair vision.
Diencephalon. The diencephalon is a paired structure
on each side of the third ventricle between the cerebral
hemispheres (Fig. 10-5). It protrudes over the most rostral
end of the brainstem, and some consider it a part of the
brainstem. It is divided into the thalamus, the hypothalamus.
and the epithalamus.
The thalamus is the largest subdivision of the diencephalon. It is an egg-shaped nuclear mass, part of which
surrounds the third ventricle. The enlarged lateral and caudal
portions of the thalamus overlie the midbrain structures. A
very simplistic description of its function is that of a relay
station. However, it also performs complex, interrelated

functions; it transfers sensory input to the cerebral cortex,
controls electrocortical activity, and assists to modulate
motor functions. Damage or dysfunction of the thalamus
may result in impaired consciousness.
The hypothalamus, as its name indicates, lies below and
anterior to the thalamus fonning the floor and walls of the
third ventricle (see Fig. 10-5, B). Although small, it has
many vital functions. It plays an important role in physiologic homeostasis by regulating visceral, endocrine, and
metabolic activity. It also regulates such functions as
temperature control, sleep, hunger, and emotion. Damage or
dysfunction of the hypothalamus may cause alterations in
vegetative, endocrine, and metabolic functions, for example,
coma and diabetes insipidus (see Chapter 23).
The epithalamus is made up of the pineal gland and some
small neural structures. The pineal gland or epiphysis is a
small, cone-shaped body attached to a stalk. It is attached
midline to the roof of the third ventricle (see Fig. 10-5, C).
The exact function of this gland is not well understood.
However, apparently it may function as a biologic clock
regulating both physiologic and behavioral processes.
Mesencephalon (Midbrain). The mesencephalon is
one of three structures that compose the wedge-shaped
brainstem. The mesencephalon is the smallest of all of the
five divisions of the brain and is located rostrally on the
brainstem between the diencephalon and the metencephalon
(Fig. 10-6). The mesencephalon is further divided into three
areas: the tectum, the tegmentum, and the paired cerebral
peduncles. The tectum is made up of two upper rounded
projections (superior colliculi) and two lower rounded
projections (inferior colliculi). These four projections are
associated with visual and auditory functions. The body of
the mesencephalon where fiber tracts pass is referred to as
the tegmentum. Also situated in the tegmentum are the
nuclei from the oculomotor nerve and the trochlear nerve. At
the base of the mesencephalon are a pair of fiber bundles
(cerebral peduncles) that are continuations of descending
fibers. Damage or dysfunction of the mesencephalon may
cause impaired consciousness, decerebrate posturing, and
neurologic hyperventilation.
Metencephalon (Pons). The metencephalon is located between the midbrain and the medulla. It is ventral
(anterior) to the cerebellum, separated from it by the fourth
ventricle (see Fig. 10-6). The ventral portion of the
metencephalon is called the basis pontis. It contains
longitudinal descending fiber bundles, pontine nuclei, and
transverse fibers that connect with the cerebellum. Dorsal to
the basis pontis is the tegmental portion of the metencephalon. The tegmentum contains collections of cells and fibers
that fonn the reticular fonnation that is continuous with the
medulla and midbrain. Also within the tegmentum are
cranial nerve (CN) nuclei V, VI, VII, and VIII and ascending
and descending fiber tracts. Damage or dysfunction of the
metencephalon may cause impaired consciousness; deep,
rapid, periodic breathing; and impaired muscle function
innervated by CN V through VIII.
Myelencephalon (Medulla). The myelencephalon
is also called the medulla or medulla oblongata. It is located
below the pons ventral to the cerebellum (see Fig. 10-6).

Chapter 10

Intracranial Dynamics

329

corpus
callosum

subthalamus

A
B

hypothalamus

thalamus

C

lateral geniculate

Fig. 10-5 Different views of the diencephalon. A, Left midsagittal surface. B, Midsagittal surface
dissected exposes dorsal surface of thalamus. C, Dorsal view of thalamus. D, Lateral view of brainstem and
diencephalon. (From Romero-Sierra C: Neuroanatomy: a conceptual approach, New York, 1986, Churchill
Livingstone.)

The fourth ventricle is located in the dorsal midline of the
myelencephalon. Like the pons and midbrain, the myelencephalon contains ascending and descending fiber tracts. It
also contains CN nuclei IX through XII. The reticular
formation originates from the medulla containing cardiac,
respiratory, and arousability centers. Damage or dysfunction
to the myelencephalon may cause impaired vital functions,
alteration in consciousness, ataxic breathing, and loss of gag
and corneal reflexes.
Cerebellum. The cerebellum is a wedge-shaped structure that lies in the posterior fossa dorsal to most of the
brainstem and inferior to the tentorium. It is divided into two
lobes or hemispheres by a midline structure, the vermis, and
is anchored to the brainstem via three pairs of fiber bundles
called the cerebellar peduncles. The dorsal surface is

arranged in multiple small folds, giving it a banded external
appearance and increasing its surface area. The cerebellum
is primarily concerned with coordination of voluntary
movements, control of muscle tone, and maintenance of
equilibrium. Damage or dysfunction of the cerebellum may
cause a variety of problems with coordination, gait, and
general motor function.

Cerebrospinal Fluid and
the Ventricular System
Deep within the brain is the ventricular system, which
consists of four interconnecting chambers that produce and
circulate CSF (Fig. 10-7). The two paired lateral ventricles
are the largest of the four chambers and are contained within
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DIENCEPHALON

OCULOMOTOR NERVE (III)

}

>~::FACiAL NERVE AND
NERVUS INTERMEDIUS (VII)

VESTIBULOCOCHLEAA NERVE lVIII)

ABDUCENS NERVE (VI)

GLOSSOPHARYNGEAL NERVE (IXI
VAGUS NERVE (Xl AND
'.
BULBAR ACCESSORY NERVE (XI)--'" •

SPINAL ACCESSORY NERVE (XII
ROOTLETS OF HYPOGLOSSAL NERVE

J

OLIVE NEAVE (Xl AND
VAGUS

BULBAR ACCESSORY

MEDULLA

NERVE (XI)

HYPOGLOSSAL NERVE (XII)

1-~~"
Fig. 10-6 Ventral surface of the human brainstem and diencephalon. (From Gilman S, Winans SS:
Manter & Gatz:' essentials of clinical neuroanatomy and neurophysiology, ed 6, Philadelphia, 1982,
FA Davis.)

the cerebral hemispheres. Each lateral ventricle is divided
into five parts: an anterior hom, a body, an atrium, a
posterior hom, and an inferior hom.
The lateral ventricles communicate with each other and
the third ventricle through the interventricular foramen
(foramen of Monro). The third ventricle is a small, narrow
slit that connects with the fourth ventricle through the
aqueduct of Sylvius. Unlike the lateral and third ventricles,
which communicate only with other parts of the ventricular
system, the fourth ventricle also communicates with the
subarachnoid space. Circulation of CSF occurs between
the ventricular system and the subarachnoid space around
the brain and spinal cord via three openings: the paired
foramina of Luschka (lateral) and the midline foramen of
Magendie.
CSF is produced primarily by the choroid plexus, present
in all four ventricles, and to a lesser degree by the brain
parenchyma. Its primary functions are protection, nutrition,
and fluid and electrolyte balance of the CNS tissue. The
microscopic structure of the choroid plexus is a three-layer
membrane: choroid capillary endothelium, pial cells, and
choroid epithelium. CSF is formed by active transport. CSF
is a colorless liquid that has an ionic composition similar to
that of plasma, but it is low in proteins and cells (Table
10-2). The rate of production of CSF is relatively constant
at 0.35 mUkg/min and is unaffected by systemic blood
pressure or intraventricular pressure.
After CSF circulates in the subarachnoid space over the
cerebral hemispheres and around the spinal cord, it travels

back to the superior sagittal sinus, where it is reabsorbed by
the arachnoid villi (see Fig. 10-7). These villi are small
arachnoid projections that function as one-way valves
between the subarachnoid space and the sagittal sinus. They
allow CSF to enter the dural venous blood but prevent blood
from entering the subarachnoid space.
Disturbances may occur in CSF production and circulation that may result in dilation of the ventricular system with
an excessive increase in head size in the infant (hydrocephalus). The three conditions that produce hydrocephalus are
obstruction of CSF circulatory pathways, diminished reabsorption of CSF, and overproduction of CSF. The most
common of these causes is obstruction of the CSF pathways
from either congenital or acquired conditions. Malabsorption of CSF is rare; it is occasionally seen with a
subarachnoid hemorrhage when the arachnoid villi are
obstructed from debris. Overproduction of CSF may be
caused by a choroid plexus papilloma.

Spinal Cord
The spinal cord is a long, cylindric structure, encased within
the vertebral column. Rostrally, it begins at the foramen
magnum and extends caudally to the level of the second
lumbar vertebra (L2), where it becomes cone shaped (conus
medullaris). The spinal cord is covered with the same three
meningeal layers as on the brain.
A cross-sectional view of the cord reveals a centrally
located H-shaped area of gray matter that consists of
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Fig.10·7 Ventricular system. (Copyright 1996 by CIBA-GEIGY Corporation. Reprinted with permission
from the Ciba Collection of Medical Illustrations. illustrated by Frank Netter. MD. All rights reserved.)
neuronal cell bodies and their processes (Fig. 10-8). The
gray matter has two anterior (ventral) horns and two
posterior (dorsal) horns. The anterior horns contain motor
neurons (lower motor neurons) that supply skeletal muscles.
and the posterior horns contain neurons that are associated
with sensory input to the spinal cord. The size of the gray
matter varies. dependi ng on the number of structures
innervated at a particular spinal cord level. For example. the
gray matter is larger in the cervical and lumbosacral areas
because innervation of the extremities occurs from these
areas of the cord.
Surrounding the gray matter is white matter composed of

10·2 Normal Cerebrospinal'Fluid
(>1 Month of Age)

TABLE

Appearance
Glucose
Protein
Cell count
Leukocytes
Pressure

Clear
Colorless
2/3 of blood sugar
>60 mg/dl
15-45 mg/dl
<5/mm 3
5/mm 3
60- 160 mm H2 0
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Back (dorsal)
Right half Left half
Column of white matter
Dorsal horn of gray matter
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,r;i7'i~--

Dorsal root - - - -

2. Lateral
3. Anterior

Dorsal root ganglion - - -

Spinal nerve _ _-oJ

' - - - - - Ventral root

Ventral horn of gray matter _ _...J

Front (ventral)

Fig. 10·8

Cross-section of the spinal cord.

~

TABLE 10·3 Common Ascending
. .". . and Descending Spinal Tracts

m;;,?:,

rractName

Function

jscending (Sensory)

~fPo.;.;"
..... rsal (posterior) spino-

Proprioception

I

Proprioception

lie

cerebellar
':l¥entral (anterior) spino~. cerebellar
!I!f~ateral spinothalamic

.•

~I'~'.;~. ntral (anterior)

Pain, temperature
Touch, pressure

':: _spinothalamic

Ilescending (Motor)
ICorticospinal (pyramidal
Iiili tracts)
f!1;' Ventral (anterior)
corticospinal
~rCLateral
corticospinal
;t)t-

iF

~ubrospinal

Skilled voluntary movements
Skilled voluntary movements
Fine movements, muscle
tone
Aids equilibrium. extensor
muscle tone
Posture, muscle tone
Mediates optic and auditory
rellex movement

myelinated nerve fibers. The nerve fibers consist of one of
three types: long ascending fibers from the spinal cord to the
brainstem, cerebellum, or brainstem nuclei; long descending
fibers from the cerebral cortex or brainstem nuclei to the
spinal cord gray matter; and short fibers that interconnect
various segments of the spinal cord. Descending and
ascending fibers that have similar functions tend to travel
together and are called spinal tracts. Numerous tracts are
arranged together to form a funiculus. Table 10-3 summarizes the most common ascending and descending tracts.

Peripheral Nervous System
Spinal Nerves. Within the PNS are 31 pairs of spinal
nerves with related branches and ganglia. They form from
the convergence of the ventral (motor) efferent and dorsal
(sensory) afferent rootlets that exit the spinal cord through
the intervertebral foramen. The paired spinal nerves are
divided into five segments: cervical (8), thoracic (12),
lumbar (5), sacral (5), and coccygeal (I). Spinal nerves are
numbered after the vertebral level from which they exit.
Because there are eight cervical spinal nerves, they take
their number from the vertebral level below their exit. The
remaining spinal nerves are numbered to correspond to the
vertebral level above their exit.
Cranial Nerves. There are 12 pairs of cranial nerves,
with their nuclei originating from the CNS. Because they
connect the CNS with peripheral structures, they are
generally classified as belonging to the PNS. Most of the
cranial nerves have both sensory and motor functions,
although some have purely sensory or motor functions.
Damage directly to cranial nerves or to surrounding
structures can often be determined by assessing cranial
nerve function. Fig. 10-9 illustrates the cephalocaudal
location of CN nuclei 1 through XII. Table 10,4 outlines CN
function, how each is tested according to age, and the
clinical significance of abnormal findings.

Autonomic Nervous System
The autonomic nervous system (ANS) has structures that
are located in both the CNS and the PNS; however, most
consider it part of the efferent division of the PNS. The ANS
unconsciously regulates three types of body tissue: cardiac
muscle, smooth muscle, and most glands. The ANS is
divided structurally and functionally into two parts: the
sympathetic and parasympathetic nervous system. Both systems are based on a two-neuron pathway. The first neuron is
referred to as a preganglionic neuron and the second, a
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Fig. 10-9 Cranial nerves (Copyright 1996 by CIBA-GEIGY Corporation. Reprinted with pennission from
the Ciba Collection of Medical Illustrations. illustrated by Frank Netter, MD. All rights reserved.)

postganglionic neuron. With few exceptions, these two systems have neurons that stimulate and control the same organs (Fig. 10-10). Because the parasympathetic and sympathetic systems have antagonistic functions, they are usually
maintained in balance. An imbalance can occur between the
two systems in one of two ways: by increasing the stimulus
from one system or by decreasing the stimulus from the
other system.
Parasympathetic System. The parasympathetic system is the division of the ANS that usually dominates
when a person is resting. The neurotransmitter acetylcholine is released in the synapse between the parasympa-

thetic postganglionic neurons and the effector organ. Activation of the parasympathetic system produces responses
such as increased peristalsis, decreased heart rate, and
secretion of intestinal enzymes. Administration of exogenous sources of acetylcholine or stimulation of a nerve that
contains many parasympathetic nerve fibers (e.g., the
vagus nerve) produces a characteristic parasympathetic
response.
Sympathetic System. The sympathetic nervous system is responsible for increasing the overall energy level of
the body when necessary to overcome a stressful situation,
whether it is physical or psychologic. Unlike the parasym-
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10·4 Assessment of Cranial Nerve Function
Testing

_tanial Nerve

'!h

-i~k,. "
. · · ~ Ifactory

I

Function

Infant

Child

Smell

Usually not assessed. young
infant responds to strong odors
with generalized movement,
but testing is unreliable

Vision

Introduce a bright light and
observe for a blink response
in the newborn, Observe older
infants' ability to pick up small
objects

Assess each nostril separately
using common odors (e.g.,
soap, mints, orange). Testing
is unreliable in very young
children
Visual acuity tested in young
child through recognition of
familiar objects at various
distances. The older child can
be tested with Snellen chart
or measuring tape with
numbers. Ophthalmoscopic
examination performed at end
of session in young child.
The child is instructed to
fixate on a distant object
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Altered Level of
Consciousness

Clinical Significance

Not tested

Must have patient cooperation.
Damage to the nerve or
olfactory bulbs can alter
or result in loss of smell

Assess pupillary
response to
light

Any abnormality requires further
investigation. Lesions in the
optic chiasm generally produce
bi lateral but nonhomonomous
defects. Lesions behind chiasm
produce homonomous field
defects in both fields of vision.
Lesion of the eye and optic
tract produce visual defects in
the visual field of one eye
only. Papilledema may indicate
elevated intracranial pressure.
The optic disc is pale, gray,
and poorly developed in the
infant. The child's retina is
lighter than the adult's. Failure
of pupil constriction to light
may indicate optic nerve
damage or oculomotor nerve
paralysis

!.\ii

&
. ~...m~culomotor
£\~~I;,
I~;!:

.,

Pupillary constriction,
extraocular movements, elevation of
upper eyelid

IV-Downward and
inward movement
of the eye
VI-Lateral movement of the eye
III-All other extracellular movements

Motor division:
muscles of
mastication
Sensory division:
innervation of the
face with three
branches (ophthalmic, maxillary,
mandibular)

Assess pupillary response; shine a
bright light in each eye starting
from the outer periphery of the
visual field. Assess consensual
response by shining a bright
light in one eye and observing
for constriction in the other
eye. Assess accommodation
by noting convergence and
constriction as a bright light
is brought toward the nose.
Assess eyelids for ptosis
(drooping). Extraocular movements are tested with cranial
nerves III, IV, and VI (see
below)
Assess the six fields of gaze; note
conjugate movement of the
eyes as a bright object is
moved from the midline into
each of the six fields of gaze

Same as infant

Assess the six fields of gaze
with the infant

Tested with
efferent portion
of oculocephalic and
oculovestibular
responses

Test strength of muscles by
assessing the infant sucking on
a finger or nipple. Test rooting
reflex. Test corneal reflex by
lightly touching the cornea
with a cotton wisp. Observe
for blinking and tearing

Palpate the temporal and masseter muscles whi Ie the chi Id is
clenching; assess for strength
and symmetry. Observe jaw
movement for symmetry
while talking, laughing,
crying. Test the three regions
of the face (eyes closed) for
sensation. Test the corneal
reflex as in the infant

Assess corneal
reflex

Assess pupillary
response to
light

Elevated intracranial pressure
may produce unequal pupils;
unreactive or sluggish pupillary
response to light; or dilated
pupil(s). Roving eye movements may be present in the
comatose patient with intact
nerve

Binocular fixation usually present
by 3 months of age. Nystagmus normal in premature
infants and neonates. Damage
to cranial nerve IV can cause
diplopia and altered downward
movement. Dysconjugate gaze
after 6 months of age may
indicate blindness. A paralysis
of gaze may indicate a lesion
or dysfunction of various parts
of the brain. Be prepared to
protect airway if oculocephalic
or oculovestibular responses
absent (negative)
Damage to the motor division can
result in impaired mastication.
Damage to the sensory division
may impair facial sensation or
cause pain, Tears are usually
not present in infants less than
2-3 months of age, Use of
contact lenses may diminish or
abolish corneal reflex
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Neurological assessment of the infant and toddler, Crit Care Nllrs 3:87, 1983: Slota Me: Pediatric neurological assessment, Crit Care Nllrs 3: I06. 1983.
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Testing

Function

Infant

Child

Motor division: motor
innervation of facial
muscles and mouth
Sensory division:
taste in anterior two
thirds of tongue

Facial tone can best be observed
during crying and smiling.
Movement should be symmetric. Testing for discrimination of taste not possible

Cochlear division:
hearing
Vestibular division:
balance

Hearing can be assessed in
newborns by testing the
acoustic blink ret1ex: a loud
noise by the infant will
produce a blink response.
Older infants will stop moving
when listening to sound or
move head in direction of
sound. Vestibular function is
not routinely tested. Oculovestibular response may be
tested in patient with altered
mental status
Assess together with cranial
nerve X. Stimulate a gag ret1ex
by touching posterior portion
of the tongue. Note hoarse or
stridorous crying

Motor innervation of the face
can be tested by asking the
child to make a "mad" face
and observe facial tone while
smiling or crying. Ask the
child to "puff out" his or her
cheeks. Sensation tested by
applying various substances
to the anterior tongue
Hearing is tested using a variety
of high- and low-pitched
sounds. Vestibular function
not routinely tested. Oculovestibular response (caloric
testing) may be tested for
complaints of tinnitus or
vertigo. May also be tested in
patient with altered mental
status

Sensory innervation to
the pharynx and
posterior one third
of the tongue

Assess together with cranial
nerve X. Instruct the child to
say "ah" and note movement
of the soft palate. Movement
should be upward. Stimulate
a gag ret1ex. Observe child's
ability to swallow without
pain or choking. Note excess
drooling or coughing

o

Altered Level of
Consciousness

Clinical Significance

Not tested

Damage to the nerve can produce
facial paralysis or weakness
and loss of taste sensation to
the anterior tongue

Tested with afferent portion of
oculocephalic
and oculovestibu)ar responses

Damage to the nerve can result in
impairment of hearing, deafness, vertigo, tinnitus, and
nystagmus. A normal response
to caloric testing in the awake
patient is jerk nystagmus,
nausea, and/or vomiting.
Caloric testing in the comatose
patient with brainstem damage
produces no response (i.e.,
eyes are fixed)

Assess gag ret1ex

Damage to the nerve can result in
dysphagia, dysarthria, impaired
sensation, excessive drooling.
stridor. and autonomic nervous
system changes related to the
vagus nerve
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Sensory division:
innervation to the
larynx and pharynx
Motor division: innervation to the palate
and pharynx and
parasympathetic
functions
Motor innervation of
the sternocleidomastoid muscle and
the upper portion of
the trapezius muscle

Observe for normal side-to-side
head movement

'~~~

Motor innervation to
the tongue

!~odified from Slota MC:
~)

Observe the tongue or fasciculations, asymmetric movement
or atrophy

Ask the child to shrug his or
her shoulders against the
pressure of your hands, Ask
the child to tum his or her
head side to side against the
pressure of your hand.
Observe for strength and
symmetry
Same as the infant

Not tested

Fasciculation is occasionally
seen in denervating diseases.
Damage to this nerve can
result in asymmetric shoulder
posture, impaired strength, and
difficulty moving the head
from side to side

Not tested

In pyramidal disorders, the
tongue may be spastic.
Unilateral damage to the
nerve or its nucleus can cause
deviation of the longue toward
the side of the lesion. Damage
to this nerve can cause paresis,
paralysis, fasciculations, or
atrophy

Neurological assessment of Ibe infant and toddler, Crir Care Nurs 3:87, 1983; Slota MC: Pediatric neurological assessment, Cr;t Care Nltrs 3:106, 1983.
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Fig. 10-10 Diagram of the autonomic nervous system, including parasympathetic or craniosacral fibers
and sympathetic or thoracolumbar fibers. Note that most organs have a double nerve supply.
(From Chaffee EE, Lytle 1M: Basic physiology and anatomy, Philadelphia, 1980, JB Lippincott.)

pathetic system, whose postganglionic neurons secrete
acetylcholine, sympathetic postganglionic neurons secrete
norepinephrine. Activation of the sympathetic system with
release of norepinephrine produces a characteristic response: bronchiolar dilation, increased heart rate and

contractility, vasodilation of blood vessels to vital organs,
and pupillary dilation. Similarly, if a person is administered
an exogenous source of epinephrine or if the parasympathetic system is blocked, the body mimics responses that
directly result from sympathetic activation.
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Arterial supply of the brain. (From Mettler FA: Neuroanatomy, ed 2, St Louis, J 948, Mosby.)

Central Nervous System Circulation
In comparison with other organs of the body, the brain's
metabolic demands for glucose and oxygen are very high.
The amount of glucose and oxygen required by the brain per
minute is referred to as the cerebral metabolic rate of
glucose (CMR glucose) and the cerebral metabolic rate
of oxygen (CMRO z). The CMR glucose is approximately
4.5 to 5.5 mg/loo g/min, and the CMRO z is approximately
3 to 3.5 milloo g/min. To meet these metabolic demands,
approximately 20% of the body's cardiac output must be
continuously delivered to the brain. 3
Arterial System. The predominant arterial flow to the
brain is from two systems: the paired carotid arteries
anteriorly and the paired vertebral arteries posteriorly (Fig.
10-11). The majority of cerebral blood flow (CBF) is
supplied by the internal carotid arteries, which originate
from the common carotid arteries. The internal carotid
arteries further subdivide into the anterior and middle
cerebral arteries. The anterior cerebral artery supplies blood
to the basal ganglia of the corpus callosum, the medial
surface of the cerebral hemispheres, and the superior surface

of the frontal and parietal lobes. The middle cerebral artery
supplies blood to the frontal lobe, the parietal lobe, and the
cortical surfaces of the temporal lobe. Occlusion of the
anterior cerebral artery may lead to weakness or hemiplegia
on the contralateral side of the body. Occlusion of the
middle cerebral artery may cause aphasia and contralateral
hemiplegia.
The paired vertebral arteries originate at the subclavian
arteries. They join to form the basilar artery on the ventral
surface of the brainstem at the junction of the pons and
medulla. The basilar artery proceeds rostrally, and at the
level of the midbrain, it divides to form the paired posterior
cerebral arteries. The vertebral-basilar arteries supply blood
to the posterior sections of the cerebral hemispheres, the
cerebellum, and the brainstem. Occlusion of the vertebralbasilar arteries may cause a variety disorders, such as
sensory loss, visual loss, and contralateral hemiplegia.
At the base of the brain, the posterior cerebral arteries,
the posterior communicating arteries, the internal carotid
arteries, the anterior cerebral arteries, and the anterior
communicating artery fuse to form the circle of Willis. As
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these large conducting arteries leave the circle of Willis,
their diameter becomes smaller to form arterioles and pial
arteries. These smaller arterioles branch off at 90-degree
angles into the brain parenchyma and are called penetrating
or nutrient arteries.
Venous System. The two systems of venous drainage
in the brain consist of superficial and deep veins, all of
which are valveless (see Fig. 10-3, B). In general, the superficial veins drain venous blood from the cerebral hemispheres and empty into the dural venous sinuses. The deep
veins drain internal structures and empty centrally into the
great cerebral vein (of Galen), which eventually empties
into the straight sinus. All venous drainage ultimately exits
at the base of the skull via the internal jugular veins. Obstruction of venous outflow may cause headaches, cerebral
edema, or cerebral hypertension.
Blood-Brain Barrier. Blood-brain barrier is the term
used to describe the anatomic structures and physiologic
processes that separate the brain and CSF compartments
from the blood compartment. Anatomic barriers include the
arachnoid layer, the blood-CSF barrier, and the cerebral
capillary barrier. All barrier sites are characterized by cells
with tight junctions between them. These tightly connected
cells function as a single layer of cells, allowing precise
regulation of chemicals among the brain, CSF, and plasma.
The blood-brain barrier protects the CNS by preventing
passage of potentially harmful molecules from the blood to
the brain. However, this barrier is equally effective in
preventing the passage of many antibiotic and chemotherapeutic medications. Consequently, a reduced number of
therapeutic agents are available to treat CNS disorders. The
blood-brain barrier may be altered from a number of CNS
insults, for example, chemical, physical, biologic, or infective insults.
Spinal Cord. The arterial supply of the spinal cord
originates from the vertebral arteries and radicular arteries.
At the base of the skull, the vertebral arteries give rise to the
posterior spinal arteries and the anterior spinal artery, which
descend alongside the spinal cord. Radicular arteries originate from the thoracic and abdominal aorta and enter the
spinal canal through the intervertebral foramen. The radicular arteries and the spinal arteries eventually connect.
Venous drainage of the spinal cord is via a series of
plexiform channels, which in turn drain into the radicular
veins. There are no valves in the spinal venous network.

r

TABl£ 10-5 NormallCP in Infants
and Children
Age Group
Newborn

Infants
Children
Adults

NormallCP (mmHg)

0.7-1.5
1.5-6.0
3.0-7.5
<10

,:- ata from Welch K: The intracranial pressure in infants. J Neurosurg
~Z:693-699.

1980.

change in one or more of the other volume compartments to
maintain equilibrium. With reciprocal changes in volume,
abnormal increases in ICP can be di verted.
Brain tissue represents the largest volume component of
the intracranial space, composing approximately 80% to
90% of the total. This volume may be increased by the
presence of neuropathologic conditions such as cerebral
edema or a brain tumor. The cerebral blood and CSF
compartments each represent 5% to 10% of intracranial
volume. The total cerebral blood volume may be altered in
the same way that CBF is controlled, for example, by
arterial carbon dioxide tension (Pac~) and arterial oxygen
tension (Pa0 2 ), or by local pH. CSF volume may also be
increased by mechanisms described earlier (see Cerebrospinal Fluid and the Ventricular System).
Because the skull is not rigid until closure of the
fontanelles and fusion of the cranial sutures (which occurs
around 5 years of age), the Monro-Kellie hypothesis is often
thought not to apply in the infant and young child. Although
in the first 3 years of life, slow increases in intracranial
volume are accommodated by increasing head circumference, rapid or unabated increases in intracranial volume
overburden this adaptive mechanism. Studies also suggest
that expansion of the skull evidenced by increased head
circumference occurs only after critical rcps have been
reached. 4 At best, the nonrigid container in the young child
tends to make the signs and symptoms of cerebral hypertension less striking. Astute nursing assessment to detect
subtle changes in neurologic status is therefore necessary to
avoid secondary neurologic injury.

Volume/Pressure Relationships

INTRACRANIAL PRESSURE DYNAMICS
Modified Monro-Kellie Doctrine
The Monro-Kellie doctrine, which has been modified over
the years, provides the basis for understanding the determinants of intracranial pressure (ICP). This doctrine states that
the skull and relatively inelastic dural sheath provide a rigid
container filled to capacity with nearly noncompressible
contents. The three volume components of the intracranial
space are brain tissue, CSF, and blood. The most important
concept of this doctrine is that if there is a change in anyone
of the volume compartments, there must be a reciprocal

Normal rcp varies in different age groups (Table 10-5).
Derived from the age-dependent norms, increased ICP is
also age dependent. Clinically, pressures greater than 15
mmHg are considered elevated, pressures between 20 and
40 mmHg are considered moderately elevated, and ICPs
greater than 40 mmHg indicate cerebral hypertension.
rcp is dynamic and fluctuates with each heartbeat and
respiration. ICP increases momentarily with certain activities and physiologic responses, including coughing or
sneezing and during Valsalva maneuvers and rapid eye
movement (REM) sleep. Temporary increases in intracranial
volume and subsequent rcp are normally well tolerated.
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1) Normal ICP- Good Compliance
2) NormallCP-Poor Compliance
3) Increased rCP-Poor Compliance
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Fig. 10-12 Intracranial volume/pressure curve.
(Adapted from Becker OP, Mickell J, Keenan R: In
Shoemaker We, Thomson WL, eds: Critical care:
state of the art, Fullerton, Calif, 1981, Society of
Critical Care Medicine, p I.)
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Intracranial Volume

CSF volume manipulation is a major adaptive mechanism
when the subarachnoid space and ventricular outflow tracts
are patent. Along with decreased production and increased
reabsorption, CSF is translocated from the brain to the
distensible spinal subarachnoid space. When compensation
is maximized, slit ventricles and absence of sulci are viewed
on computed tomography scan. To a lesser degree, reducing
total cerebral blood volume or brain mass may also offset an
increase in ICP.
The patient's adaptive capacity is dependent on the
volume of the mass lesion, its rate of expansion, the total
volume of the intracranial cavity, and the relative volume of
blood and CSF that is available for displacement. When
adaptive mechanisms are obliterated, ICP will increase
rapidly, often with minor changes in cerebral blood volume.
The intracranial volume/pressure relationship curve describes how much intracranial volume produces how great a
change in ICP (Fig. 10-12). Elastance is the term used to
describe the change in pressure that occurs with a change in
volume into the intracranial space; elastance = ~ P/~ V.
Compliance is the inverse of elastance and is used to
describe the same volume/pressure relationship when pressure changes are induced; compliance = ~ Vic:,. P.
The relationship between intracranial volume and ICP is
not linear. The intracranial volume/pressure (VIP) curve has
three distinct phases: flat, exponential, and increased ICP.
Phase I, the flat portion of the curve, illustrates normal ICP
with good compliance. At this point, compensation is
effective in that the volume added is equal to the volume
removed from the intracranial compartment. Phase 2, the
exponential portion of the curve, illustrates normal ICP with
poor compliance. Here, the intracranial compartment is
described as "tight," adaptive capacity is reached, and any
further small increase in volume produces disproportionately large increases in ICP that may not return to baseline.
Phase 3 illustrates increased ICP with poor compliance.
Compensatory mechanisms have been exhausted. The
exponential relationship of the VIP curve explains the

rep
mmHg

70
60
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t.O

30

20
10 4--~"":::::';""'-UNITS OF VOLUME
Variation in the volume/pressure curve. Diagram to
illustrate how changes in the gradient of the pressure/volume curve
mean that different volumetric changes are needed to produce a
given pressure change: less where the curve is steep and more
where the curve is flatter. Alternatively, the same volume change
will produce greater and lesser changes in pressure. dP, Change in
pressure; dV, change in volume. (From Miller JO: Increased
intracranial pressure: theoretical considerations. In Pellock JM.
Myer EC, eds: Neurological emergencies in infants and children,
Philadelphia, 1984, Harper & Row, p 65.)
Fig. 10-13

variability in ICP response among individuals and also in
the same individual at different times.
The critical point when compensation is lost varies and
depends on such factors as the rate of volumetric change,
systemic arterial pressure, and osmotic therapy. Age has also
been found to be a variable, with the younger child having
less buffering capacity.5.6 Thus when speaking of intracranial compliance, a series of compliance curves exist rather
than a single curve (Fig. 10-13). For example, the first V/P
curve (dv l ) may represent the acute increase in ICP that
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occurs within 24 to 48 hours after head trauma. The second
VIP curve (dv z) may represent the 48- to 72-hour delay in
increased ICP after a hypoxic-ischemic episode. The last
VIP curve (dv 3 ) may represent the slow increase in ICP that
occurs in a patient with a brain tumor. The collaborative
management goal is to shift the patient's ICP down to the
right of one curve or, better yet, to improve intracranial
compliance and shift the patient's ICP to a new VIP curve on
the left of the curve.

Pressures

Flow gradient

ICP>MAP>CVP

No Flow

Cerebral Blood Flow
The normal rate of CBF is approximately 40 ml/IOO g/min
in newborns and 53 mllIOO g/min in older children. 7 A
severe and prolonged increase in ICP may cause a lethal
reduction in CBF. A progressive increase in intracranial
volume may cause obstruction of the CSF pathways,
eliminating the primary means of buffering increased ICP.
In addition, increased ICP may cause venous outflow
obstruction and compensatory arterial hypertension. As a
consequence, capillary pressure increases, predisposing the
brain to cerebral edema. The end result is a further increase
in intracranial volume that ultimately may precipitate
herniation of brain structures and a reduction in CBF.
As mentioned earlier, the brain requires constant and
consistent delivery of blood flow to meet its high metabolic
demands. The determinants of CBF are arteriolar radius,
blood viscosity, perfusion pressure, and length of the
vascular bed. Practically speaking, the length of the vascular
bed and blood viscosity remain constant. Therefore the
important variables of CBF are cerebral perfusion pressure
and arteriolar radius.
Cerebral Perfusion Pressure. Cerebral perfusion
pressure (CPP) represents the pressure drop between the
inflow (arterial) pressure and outflow (venous) pressure.
Traystman 8 identified three separate conditions that require
consideration (Fig. 10-14). In condition I, the ICP is greater
than the mean arterial pressure (MAP), and both are greater
than the central venous pressure (CVP). When these
conditions are present, CBF is impossible. In condition II,
the MAP is greater than the ICP, and both are greater than
the CVP. Here, the CPP is calculated as MAP minus the
ICP. In condition III, the MAP is greater than the CVP,
and both are greater than the ICP. Here, the CPP is
calculated as MAP minus the CVP. Clinically, the
CPP = MAP-ICP unless the CVP is significantly elevated;
then the CPP = MAP-CVP. Because it is possible to have
a normal ICP but no blood flow (thus no oxygen extraction)
through damaged areas of the brain, some research centers
trend cross-brain oxygen consumption and metabolic rates
with ICP and CPP.
Normal CPP is unknown in the pediatric population, but
it is thought that a CPP greater than 50 mmHg is necessary
for adequate cerebral perfusion. CPPs less than 40 mmHg,
because of cerebral hypertension or systemic hypotension,
are thought to be the cutoff point between good-quality
survival and poor outcomes. This critical point is much less
in the neonate. In this age group, normal CPP is thought to
depend on weight and be about 30 mmHg. 9

II

MAP>ICP>CVP

CPP=MAP-ICP

III

MAP>CVP>ICP

CPP=MAP-CVP

Fig. 10-14 Three separate conditions that require evaluation
when calculating cerebral perfusion pressure. CV?, Central venous
pressure; IC?, intracranial pressure; MAp, mean arterial pressure; Pa, arterial pressure; Pcs/. cerebrospinal fluid pressure;
PCI'. central venous pressure; Q, flow. (Adapted from Monillaro
NA: The physiology and pharmacology of the microcirculation,
New York, 1983, Academic Press, pp 237-238.)

Cerebral Autoregulation. Normally, CBF matches
the cerebral metabolic rate (CMR). For example, when the
CMR increases, there is a concomitant increase in CBF;
when CMR decreases, there is a concomitant decrease in
CBF. This compensatory process, known as autoregulation,
matches CBF with CMR and is accomplished by either
cerebral vasoconstriction or vasodilation. This mechanism is
believed to occur from a myogenic mechanism located in
the muscular arterioles. 10 Changes in arteriolar transmural
pressure produce changes in arteriolar radius by vasoconstriction or vasodilation.
Under normal circumstances, autoregulation is maintained when the CPP ranges from approximately 60 to 160
mmHg. 11 If these limits are exceeded, CBF is passively
dependent on CPP. The upper limit of CPP may be higher in
individuals with chronic hypertension. Furthermore, autoregulation may be altered locally or globally with CNS
insult. If CBF is greater than the CMR, hyperemia occurs,
which is a common finding after pediatric head trauma.
When CBF is less than the CMR, cerebral hypoxia ensues,
which is a common finding during pediatric resuscitation.
Chemical Regulation. In addition to pressure autoregulation, CBF is also affected by chemical autoregulation.
Both Pacoz and Paoz affect CBF and cerebral blood volume

Chapter 10

by altering cerebral arteriolar radius. High levels of Pae0 2
cause vasodilation of the cerebral vasculature with an
increase in CBF and therefore an increase in cerebral blood
volume. Conversely, a decrease in Pae02 produces a
decrease in CBE Thus lowering Paco2 with hyperventilation
is a clinically useful tool for emergent management of
intracranial hypertension.
In contrast to Paco 2, the cerebral vasculature seems to be
somewhat less sensitive to Pa02. Hypoxia, Pa02 less than
50 mmHg, increases CBF by producing a vasodilatory
response. Conversely, hyperoxia produces a mild vasoconstrictive response with only a modest decrease in CBE The
critical lower limit of Pa02 that causes a increase in CBF
may be lower in the neonate. 8 Newborns are relatively
hypoxic (normal Pa02 range of 65 to 70 mmHg) compared
with infants and young children, and the actual delivery of
oxygen to the tissues is affected by the percentage of fetal
hemoglobin. '2

NEUROLOGIC ASSESSMENT
CNS development is incomplete at birth, maturing over the
first several years of life. Maturation reflects myelinization,
dendritic arborization, increases in synaptic connections,
increases in glial cell population, and changes in neurochemical properties. As a result, the infant has incomplete
cortical integrative function and has immature neuromuscular control. Therefore neurologic assessment of the infant
and young child requires a developmental approach that
reflects the age and temperament of the child.
The neurologic examination not only requires developmental adaptation, but the condition of the patient must be
considered. Consequently, the focus of the examination
occurs on two levels. The first level involves a comprehensive assessment of both the central and peripheral nervous
systems. It is usually performed in an outpatient or nonacute
setting and is intended to diagnose or rule out neurologic
dysfunction. The second level of a neurologic examination
is usually performed in an acute care setting. It is conducted
at prescribed intervals and focuses on significant deterioration (often life threatening) or improvement of the nervous
system. The following section describes the components of
neurologic assessment in the infant and young child. The
critical care nurse is challenged with adapting these
components to the age, temperament, and condition of
the child.

History
The neurologic history provides the framework for guiding
the neurologic examination. The data obtained from the
history assist the critical care nurse in formulating preliminary nursing diagnoses that are either supported or rejected
by the physical examination. The length of the interview, the
specific questions, and the tinting depend on whether the
child has a static, a progressive, or an acute condition.
Taking of history may need to be delayed if the parents are
not present and the child is preverbal or if the child's
physical status is life threatening.
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The first component of the neurologic history is the chief
complaint. Whenever possible, the school-age child should
be asked questions directly. Preschool children are less
reliable and, like the preverbal child, often require their
parents to describe the problem.
Once the chief problem has been stated, questions are
asked to obtain information leading up to the present illness.
Questions should be formulated so that the nurse can
determine whether the patient's condition is progressive or
static, focal or generalized, and acute or insidious.
Specific questions that must be addressed regarding the
patient's history depend in part on the patient's age and
present illness. For the infant and young child, a summary of
the antenatal, perinatal, and postnatal courses should be
obtained. This includes but does not exhaust questions
regarding maternal infections, drug intake during pregnancy, gestational age, and Apgar scores. A history of
meconium staining, neonatal seizure activity, or oxygen use
necessitates further investigation. Medical history should
also include a chronologie list of the child's developmental
milestones, which is then compared against established
norms (see Chapter 2).
For the older child who was previously healthy, questions
should be asked to differentiate between metabolic and
structural causes of neurologic dysfunction. For example,
has the child had a recent fall or been exposed to chemical
toxins, or does he or she have an endocrine disorder such as
diabetes?
The family history should include questions regarding
neurologic illnesses in family members, as well as specific
signs and symptoms that may have a neurologic basis.
Most neurodegenerative disorders are transmitted as a
recessive gene, and some epilepsies are transmitted as a
dominant trail. 13

Physical Examination
For the awake, stable chi ld, vital signs, height, and weight
should be measured. The general appearance of the child
should be observed-in particular, dysmorphic features,
asymmetries, cutaneous lesions (e.g., cafe au lait spots,
angiomas), condition of scalp and hair, palmar creases, and
unusual odors.
Skull Examination. For infants, the neurologic assessment includes a skull examination. Head circumference
should be measured on admission and repeated at regular
intervals as determined by the patient's condition. The
largest circumference (occipitofrontal) should be consistently measured and plotted on a head growth chart. Because
head growth reflects brain growth, a significantly small head
circumference may indicate impaired brain growth. In
contrast, an unusually large head may be a manifestation of
hydrocephalus or some other abnormal fluid accumulation
or tissue growth. The nonnal rate of head growth in the first
12 months of Ii fe is 2 cm per month for the first 3 months,
1 cm per month for the fourth through sixth months, and
0.5 em per month for the remaining 6 months. 14
The cranial sutures and associated fontanelles should be
palpated gently. The posterior fontanelle usually closes
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within the first few months of life, and the anterior fontanelle remains open until approximately 12 to 18 months of
life. In a U. S. study,IS the average diameter of the anterior
fontanelle at birth was found to be 2.1 cm. However, an
unusually small or large fontanelle may not, by itself, reflect
an abnormality in the infant. Its presence should be correlated with other clinical findings. Ideally, the fontanelle
should be palpated while the infant is sining upright and in a
quiet state. Normally, the fontanelle feels soft and flat or
slightly depressed compared with the surrounding skull.
The cranial sutures should be palpated to determine if
they are overriding or widely separated. Overriding sutures
from head molding in the birth canal may be a normal
finding in the newborn. However, it may also represent
premature closure of the sutures (craniosynostosis) or
inadequate brain growth. Widely separated sutures may
suggest hydrocephalus.
Transillumination is a simple, noninvasive technique
used to detect abnormal fluid collection within the scalp and
beneath the calvaria. Its use is restricted to the first 9 to
12 months of age because of the thickness of the skull
beyond this age. Many commercial instruments are available, but a battery flashlight with a rubber adapter (fits close
to the skull) is very reliable. The light source is placed on the
infant's skull, usually starting at the anterior fontanelle. In
the normal full-term newborn, the frontal area has a larger
rim of transillumination (as much as 3 cm) compared with
the occipital area. 16 An area of increased or asymmetric
transillumination should be noted.
If time and the patient's condition permit, the calvaria
should be auscultated for bruits. Although the presence of a
bruit in young infants may be normal, a particularly loud or
asymmetric bruit may be heard with an intracranial vascular
malformation. An extreme downward rotation of the eyes at
rest and paralysis of upward gaze are known as the
"setting-sun" sign. It may be intermittent and is seen in
some children with increased ICP. It is a common clinical
characteristic of hydrocephalus. A similar appearance may
be seen with abnormal retraction of the upper eyelids
(Collier's sign) from lesions affecting the costal midbrain
and third ventricle. When the cranial sutures are separated
because of increased ICP, Macewen's sign or a "cracked
pot" sound maybe heard during percussion of the skull.
Level of Consciousness. Consciousness is a state of
awareness of self and environment. There are two physiologic components of consciousness: content and arousal.
Content is controlled by cerebral function, and arousal is
controlled by physiologic mechanisms that originate in the
reticular formation. Dysfunction of the cerebral hemispheres
or the reticular activating system (RAS) of the upper
brainstem, hypothalamus, and thalamus will produce an
alteration in consciousness. 17 Altered states of consciousness are on a continuum ranging from the extremes of
complete consciousness to coma. For the patient with
minimal alteration in consciousness, mental status is assessed. For more severely altered states, coma scales may be
required to assess level of consciousness.
Mental Status. Cortical growth occurs both quantitatively and qualitatively within the first 2 years of life.

Consequently, the mental status (cerebral function) portion of the neurologic examination is individualized according to the infant and young child's age. Specific areas
to assess in the infant and young child include alertness
and level of activity, quality of cry, feeding patterns,
language development, and presence or absence of primitive
reflexes.
Ideally, the young infant's state of alertness is assessed
during a period when stress is at a minimum. Usual patterns
of sleep and wakefulness are assessed and evaluated based
on the infant's age, nutritional state, and quality of sleep
within the previous 24 hours. In general, extreme states of
agitation or lethargy are noted.
Normally, the infant's cry is loud and energetic. Abnormal cries include ones that are difficult to elicit, associated with cyanosis, high pitched, weak, monotonous, or
moaning. IS
Normal feeding behavior includes a strong suck and good
suck-swallowing coordination. Therefore if the young child
cannot finish a bottle without tiring or becomes cyanotic, or
if the child has excessive gagging and choking, these
reactions should be noted.
Normal speech and language skills develop over several
years. These skills depend on normal development of motor
control of the oral musculature. Therefore if the child
deviates significantly from established norms, the gag reflex
and tongue movements are tested for coordination and
strength.
In the older awake child, a comprehensive evaluation of
mental status includes attention, alertness, orientation,
cognition, memory, affect, and perception. Most of the
assessment can take place during normal conversation with
the child. Care should be taken when determining which
questions to ask the child. Questions are individualized
according to the child's age and temperament.
Motor Function. Assessment of motor function is
adapted to the age of the child. A variety of primiti ve
reflexes are normally present in the infant, and determining
their presence or absence is an important component of the
neurologic examination. The disappearance of primitive
reflexes reflects increasing maturation of the cortex. As
myelinization progresses, higher cortical centers become
functional and gradually suppress these reflexes. Abnormal
findings include the persistence of a primitive reflex
significantly beyond the normal time of disappearance or the
reappearance of a primitive reflex.
Normal motor development proceeds cephalocaudally
and proximodistally. Early in life, movements are more
generalized and reflexive. Fine motor control follows
development of gross motor control. The infant's extremities are assessed for muscle symmetry, mass, and tone.
When examining the young infant, the head is maintained in
a midline position to prevent an asymmetric tonic neck
reflex. In infants less than 3 months of age, increased flexor
tone is normal. 19 The newborn's hands are usually closed;
however, they may open and close spontaneously while
sleeping or when very quiet. Hands that are always closed
after 2 months of age represent an abnormal finding, which
is correlated with other neurologic findings to determine its
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significance.! R Definite hand dominance is usually not
present until the second or third year of life. Hand
preference in infants younger than 24 months may indicate
weakness or spasticity of the other hand 20
Reflexes
Deep Tendon Reflexes. Testing deep tendon reflexes
helps to evaluate both the lower motor neurons and the
motor and sensory fibers within a particular spinal level. In
the older child, deep tendon reflexes are readily tested and
graded narratively or by using a stick figure. The most
common reflexes examined are the biceps, triceps, brachioradialis, patellar, and Achilles reflex. Hyperreflexia may
indicate corticospinal dysfunction or may be a response
from an abnormal "spread" of responses, that is, abnormal
contraction of muscle groups that usually do not contract
when a reflex is being tested? I Hyporeflexia may be seen
with lower motor unit dysfunction.
In infants, some deep tendon responses are not present at
birth and when present are less reliable because of the
immaturity of its corticospinal tracts. In general, responses
in the infant that require further investigation include
reflexes that are very brisk, are asymmetric, or deviate from
previous assessments. 19,20 Ankle clonus is often present in
the newborn period, but it is rarely sustained and usually
disappears by 2 months of age.
Superficial Reflexes. A positive Babinski reflex, that
is, dorsiflexion of the foot and fanning of the toes after
stroking the sole laterally from heel to toe, is normally
present in the infant. This response disappears in the second
year of life at approximately 18 to 24 months of age.
Persistence or reoccurrence of this response is pathologic,
indicative of dysfunction of the corticospinal tracts or the
motor area of the cerebrum. Abdominal and cremasteric
responses are present at birth. The abdominal response is
elicited by stroking the abdomen from a lateral position
moving to the umbilicus in all four quadrants. A normal
response is slight muscle contraction and movement of the
umbilicus toward the stimulus. The cremasteric response is
elicited in males by stroking downward on the inner aspects
of the upper thigh. The scrotum should contract and elevate.
Unilateral absence of the abdominal response and absence
or asymmetry of the cremasteric response may indicate
corticospinal dysfunction.
Sensory Function. Responses to sensory testing in
the infant are more variable and less reliable than in the
older child. However, the infant should respond to light
stroking of the extremities. With normal sensory function,
the infant will usually withdraw the limb being tested.
Vibration sense may be tested by placing a tuning fork over
bony areas. In response, the infant will usually stop all
movement and display a look of surprise. Proprioception
cannot be tested at this age. Pain sensation is tested at the
end of the examination by nail bed pressure.
In the older child, sensory function can be tested in the
usual fashion. For initial screening, light touch and superficial pain are tested in all four extremities. If abnormalities
are suspected or detected, more thorough segmental sensory
testing is indicated, including temperature, vibration, pres-
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sure, and position sensations. Fig. 10-15 is a drawing of
segmental sensory innervation of the body.
Cerebellar Function. Cerebellar function of the older
child and adolescent can be evaluated in much the same way
as in the adult. Rapid alternating movements, as well as
finger-to-nose, finger-to-finger, and heel-shin testing, is
possible. Maneuvers to evaluate the young child and infant
are less precise. Much information can be obtained by
observing the young child in play, noting tremors, dysmetria, and truncal swaying. Once again, familiarity with
age-dependent motor skills when determining the adequacy
in which a child performs a maneuver is important.
Cranial Nerve Function. With the exception of the
olfactory nerve, all of the cranial nerves originate in the
brainstem. An evaluation of their function provides valuable
diagnostic evaluative information about the child's neurologic status. The specific cranial nerves that should be tested
and the order in which they are tested depend on the age and
condition of the child. A complete cranial nerve assessment
is usually not needed for routine screening. Table 10-4 lists
the 12 cranial nerves, how they are tested according to age,
and the clinical significance of abnormal findings.
Funduscopic Examination. Normally, the funduscopic examination reveals a red reflex that is orange-red
and fairly uniform in color, a creamy pink optic disc with an
indented center (physiologic depression) and smooth margins, and veins (slightly wider than arteries) that have no
light reflex and manifest slight pulsations. Papilledema,
represented as blurring of the nasal and upper edges of the
optic elisc, is commonly seen with increased ICP in the older
child. Papilledema is an unusual finding during infancy
because the cranial sutures usually spread and the head
enlarges in response to chronic increases in ICP. Retinal
hemorrhages may be present with significant head injury
and subarachnoid hemorrhage (commonly associated with
"shaken baby syndrome" in child abuse). Decreased
peripheral retinal vascularity is seen in infants with retrolental fibroplasia.

Assessment of the Neurologically
Impaired Child
The child with an altered level of arousal requires frequent
clinical assessment of neurologic function. Patterns of
pathophysiologic responses and their evolution provide
valuable information about the location, extent, and progression of neurologic dysfunction. Five assessment parameters are critical to the neurologic evaluation: level of
consciousness, motor function, respiratory patterns, cranial
nerve response, and vital signs. The neurologic assessment
of the child begins with assessment of level of consciousness. Cerebral hemispheric function is determined by
assessing motor function. As neurologic dysfunction
progresses caudally, characteristic respiratory patterns may
occur. In late stages with lower brainstem dysfunction,
abnormal cranial nerve responses occur, followed by abnormal vital signs.
Level of Consciousness. Consciousness is described
as the state of awareness of self and environment. 17 Level of
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Fig. 10·15 Radicular cutaneous fields. (From Swaiman KF: Neurologic examination of the older child.
In Swaiman KF, Ashwal S, eds: Pediatric neurology: principles and practice, ed 3, St Louis, 1999, Mosby,
pp 14-30.)
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Reduced wakefulness: reduced attention,
confused, drowsiness alternating with
hyperexcitability
Disorientation, fear, irritability, visual
hallucinations, agitation; patients
may be loud, offensive. and
suspicious
Mild to moderate reduction in alertness.
reduced interest in environment, increased periods of sleep
Unresponsive except to vigorous and
repeated stimuli
No motor or verbal response to
environment

-lDala from Plum F, Posner JB, The diagnosis o/stupor and collla. ed 3,
1iI.;.iladelphia, 1982. FA Davis.

consciousness is the most important initial assessment and it
is fundamental to understanding higher cortical functioning.
All neurologic findings must be interpreted based on state of
consciousness and awareness. Accurate and consistent
assessment of level of consciousness can indicate if the
patient's condition is improving, deteriorating, or remaining
static. There is a range of altered states of consciousness and
a number of ways to label and define these states. Table 10-6
defines commonly used terms to describe various states of
consciousness. More important than labels are the patient's
actual behaviors and responses.
Numerous coma scales have been developed, most
notably the Glasgow coma scale (GCS; Table 10-7).
Originally developed as a prognostic tool for patients with
head injury, the GCS also helps to identify the depth of coma
by standardizing assessments. 22 It allows serial reassessment that reflects the patient's condition at a specific point
in time. Despite its widespread application, the GCS has
limited use with preverbal infants and intubated patients. As
a result, a number of modifications have been developed.
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Ltd, 1975.

Tables 10-8 and 10-9 are examples of coma scales adapted
for infants and neonates.
The GCS yields a score of 3 to 15 based on the best
response to stimuli in three categories: eye opening, verbal
response, and motor response, When using a stimulus to
assess level of consciousness, the least noxious stimuli is
used first. For example, start with a voice stimulus, then
progress to touch; if the patient is still unresponsive, apply a
painful stimulus. Care is taken to avoid harming the patient,
especially when coagulation factors are abnormal. Nail bed
pressure is a reliable stimulus because it can be consistently
reproduced by numerous individuals. The exact stimulus
that provides a minimal response is documented so that
progression of neurologic defects can be easily identified.
Careful assessment is necessary to differentiate between appropriate withdrawal to stimuli, which involves cortical activity, and a spinal cord stretch reflex, which does not.
Motor Function. In addition to assessing motor
response with the GCS, motor function is also evaluated in
terms of symmetry of re<;ponse and the presence of pathologic signs. Normally, posture is controlled by the interaction between higher inhibiting brain centers and lower exciting brain centers. In the comatose patient, some degree of
cortical control over motor function may be lost, allowing
primitive postural reflexes to emerge. Spontaneous motor
movement may occur in the unconscious patient. Localization represents movement of an extremity across the midline
of the body toward the opposite extremity receiving a pain-
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ful stimulus. In the comatose patient, both localization and
spontaneous movement are favorable prognostic signs.
When there is severe dysfunction of the cortex and
subcortical white matter and preservation of the brainstem,
decorticate posturing emerges. Typically, decorticate posturing includes flexion of the upper extremities and extension
of the lower extremities. Decerebrate posturing represents
dysfunction of the cortex and brainstem at the level of the
pons. It is manifested by extension of the upper and lower
extremities with rigidity. No motor response to noxious
stimuli (bilateral flaccidity) in all four extremities is an ominous sign and is one criterion for brain death determination.
Care must be taken to rule out other causes of flaccidity,
such as stroke or spinal cord injury. Fig. 10-16 schematically
illustrates decorticate and decerebrate posturing.
Respiratory Patterns. Alteration in respiratory pattern is an early and reliable sign of neurologic dysfunction.
Breathing is primarily regulated by metabolism in the
so-called respiratory centers of the brainstem and by behavior in the forebrain. The presence of two major breathing
centers at different levels of the brain sometimes produces
characteristic breathing patterns that reflect the location of
the neuropathology. Table 10-10 describes the most common pathologic respiratory patterns and their neuropathologic location. 17 Even though the presence of characteristic
breathing patterns is well described, overlap in patterns may
occur, or patterns may change very rapidly. The most ominous breathing pattern is one that is irregular and slow progressing to apnea (ataxic).
Cranial Nerve Response
Pupil Size and Reactivity. Pupillary size and reactivity are regulated by the autonomic nervous system, an
intact afferent connection of CN II and CN III nucleus.
Pupillary size changes almost continuously because of the
interaction of parasympathetic and sympathetic fibers.
Stimulation of parasympathetic fibers causes the pupil to
constrict (miosis), and stimulation of sympathetic fibers
causes the pupil to dilate (mydriasis). Because the brainstem
contains adjacent areas that control both pupillary reactivity

and arousal, testing pupillary response provides valuable
information regarding the presence and location of brainstem dysfunction producing coma. Fig. 10-17 illustrates
autonomic and cranial nerve control of pupillary response.
Both pupils should first be observed and the exact size
noted. The usual range in size varies between 2 and 6 mm.
The size of the pupil changes with age, being the smallest
during infancy and the largest during adolescence.2 3 •24 Most

10-10 Pathologic Respiratory
Patterns and Their Neuropathologic
Location

TABLE

Location

Description

Bilateral
Hemispheric
Diencephalon

Periodic breathing;
phases of hyperpnea alternating
with apnea
Sustained, rapid,
and deep
hyperpnea
Prolonged inspiration with a
pause at full
inspiration
Irregular pattern;
deep and
shallow breaths
occur randomly

Rostral
Brainstem
Tegmentum
Mid- or caudalpontine level

Medulla

Hypothalamus

Oculomotor
nucleus

A

B

Fig.10·16 Pathologic posturing occurring in severe brain injury.
A, Extension posturing (decerebrate rigidity). B, Abnormal flexion
(decorticate rigidity). (From Betz CL, Hunsberger M. Wright S:
Family-centered nursing care ofchildren, ed 2, Philadelphia, 1994,
WB Saunders, p 1726.)

Fig. 10-17 Pupillary responses to light stimulation in differentiating ocular or optic nerve disease from oculomotor nerve
dysfunction. (From Vannucci RC, Young RSK: Diagnosis and
management of coma in children. In Pellock JM, Myer EC, eds:
Neurological emergencies in in/alliS and children. Philadelphia,
1984, Harper & Row.)
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children have equal-sized pupils, but a I-mm discrepancy
between pupils (anisocoria) may be normal (i.e., for patients
with a known discrepancy). Extremely small pupils may
indicate opiate effects, pontine hemorrhage, metabolic
encephalopathy, or lower brainstem compression. Pupils
that are widely dilated and unresponsive result from CN III
compression commonly seen with transtentorial herniation
or from the midbrain lesion in the area of the EdingerWestphal nucleus. 23 The acute appearance of this pupillary
finding is an ominous and late sign requiring immediate
attention. Other common causes of dilated and unreactive
pupils include severe hypothermia, anoxia, ischemia, and
ingestion of atropine-like substances.
After observing the pupils for size and equality, reactivity
to light is tested. To test the pupils' reaction to direct light,
use a light with a narrow, bright beam. Test each eye independently by covering or closing one eye while testing the
other. Approach the eye from the periphery to avoid constriction of the pupil by accommodation. Once the eye is
exposed to the direct light, the pupil should constrict briskly.
Document the pupils' response and grade how briskly the
pupil constricts using consistent labels or a numerical scale.
For example, "both pupils are 3 mm in size and react to light
briskly."
Consensual or indirect light response refers to the
pupillary constriction that occurs in the eye opposite the eye
being stimulated with light. The normal consensual pupillary response represents transmission of light to the brainstem where the Edinger-Westphal nucleus activates the
parasympathetic efferent fibers of both pupils 23 Abnormalities in the direct light response or the consensual response
can help determine whether damage has occurred to the
optic nerve (CN II) or to the oculomotor nerve (CN III).
Ocular Movements. Eye movements are controlled
by both voluntary cerebral hemispheric centers and involuntary control centers in the brainstem. These areas interact
with three paired cranial nerves (III, IV, and VI) that
innervate the extraocular muscles that control ocular movement (Fig. 10-18). Normally, the eyes move together
synchronously, that is, conjugate eye movements.

3rd

6th

----,.._+_
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Abnormal eye movements include nystagmus, dysconjugate eye movements, and extraocular palsies. Nystagmus
refers to a repetitive, involuntary oscillation of one or both
eyes. The usual planes of nystagmus are horizontal, vertical,
and rotary. Horizontal nystagmus is seen normally with
extreme lateral gaze, with the use of certain drugs (e.g.,
anticonvulsants, barbiturates, alcohol), and sometimes with
cerebellar dysfunction. 25 •26
Conjugate eye movement is controlled by several different areas of the brain: frontal gaze center, occipital gaze
center, and medial longitudinal fasciculus (MLF). Thus
damage to several parts of the brain can cause dysconjugate
eye movements.
Extraocular palsies of cranial nerves III, IV, and VI can
also cause abnormal eye movements. However, their presence is less precise in identifying a specific area of
brainstem dysfunction because they may also result from
increased lep.
Owlocephalic Response (Fig. 10-19, A). In the
comatose patient, the integrity of the brainstem can also be
assessed by testing the oculocephalic response (doll's eye
maneuver). This maneuver determines the integrity of
cranial nerves III, VI, and Vlll. It can onl y be performed
in the unconscious patient or in an infant younger than
2 months of age 27 After clearing the cervical spine for
injury, the test is performed by briskly turning the head from
side to side. With an intact brainstem, the eyes will deviate
to the opposite side the head is turned and then slowly turn
in the direction the head is rotated. 28 With severe brainstem
injury, the patient's eyes remain midpositioned or fixed
while the head is turned.
Owlovestibular Response (see Fig. 12-19, B).
Like the oculocephalic response, the oculovestibular response (cold calorics) can be used to assess the integrity of
the brainstern. This test is performed by first elevating the
head of the bed 30 degrees, confirming an intact tympanic
membrane and dura, and removing cerumen from the
external canal. The reflex is elicited by injecting water
(usually 30° C) into the external canal. With an intact
brainstem in the unconscious patient, there is slow conjugate
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Fig. 10-18 Three paired cranial nerves-III, IV, and Vl-<:ontrol ocular movement. Cranial nerve VII
closes the eyelid; cranial nerve III elevates the eyelid. (Modified from Goldberg: Clinical neuroanatomy
made ridiculously simple, Miami, 1995, MedMaster.)

350

Part III

Phenomena of Concern

A

~:;;:~~~~~~~r--

Frontal cortex

---"O<+i-+- Medial longitudinal fasciculus
Decreased firing

Relative increased firing
of vestibular nerve

--+...,....

<t>-!-=!--- of vestibular nerve

c
Normal
III Medial rectus subnucleus
of oculomotor complex
Lethargy
VI Pontine gaze center and
abducens nucleus innervating

lateral rectus muscle

B

_ _ Fast phase
(corrective, cortical) pathway
........~ Slow phase
(active, vestibular) pathway

Fig, 10-19

(ii)

S

Obtundation
Stupor

~

Coma

<D>

4i>

_ _ Cold water

<> -~

<Db

---

A, Oculocephalic response. Band C, Oculovestibular response.

movement of the eyes toward the stimulus followed by fast
return to the midline. A patient with a low brainstem lesion
would have eyes that remain at midposition and fixed.
Vital Signs. Changes in vital signs, indicative of
brainstem dysfunction, occur before cardiopulmonary arrest. Cushing's triad includes the classic signs of increased
systolic pressure, widened pulse pressure, and bradycardia.

Neurologic Assessment of the Chemically
Paralyzed Child
Neuromuscular blocking agents are commonly used as adjunctive therapy in critically ill infants and children. These
agents cause skeletal muscle relaxation by altering the response of acetylcholine at the neuromuscular junction?9
After an appropriate dose of a neuromuscular agent is injected, the onset of effects is rapid. Motor weakness
progresses to flaccid paralysis in the following sequence:
eyes and fingers; limbs, neck, and trunk; intercostal

muscles; and, finally, the diaphragm. Recovery of muscles
occurs in the reverse order. The most common indications
for use in children are to (I) improve controlled ventilation,
(2) stabilize or maintain ICP, and (3) decrease oxygen
consumption.
Despite the advantages of neuromuscular blocking
agents, their use precludes most of the neurologic assessment. Because peripheral skeletal muscle paralysis is
present, the patient will be unable to respond to commands
and is unresponsive to standard tests of motor function,
reflexes, and sensation. However, because these agents are
unable to cross the blood-brain barrier, consciollsness and
normal sleep-wake cycles are preserved. These patients are
able to hear and feel pain. Consequently, sedatives and
analgesics are always administered concurrently. Pupillary
reflexes can be tested, and abnormal responses indicate the
same clinical significance as in the nonparalyzed patient.
Normal oculovestibular and oculocephalic responses are
blocked with neuromuscular blocking agents.
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Autonomic function is preserved; thus changes in vital
signs can be used to assess the patient's responsiveness. An
increase in the baseline heart rate may indicate the patient is
responding to parents or experiencing pain, anxiety, or a
seizure. Pain or anxiety is usually accompanied by a
sympathetic response with diaphoresis (sweaty brow). The
only clue of a seizure may be an abrupt increase in heart rate
and blood pressure. An electroencephalogram (EEG) is used
to determine cerebral electrical activity.
If the patient's condition permits, intennittent withdrawal
or reversal of the agent allows determination of the
neurologic status. Recovery from neuromuscular blockade
may be prolonged because of certain physiologic states or
concurrent administration with other medications. More
precise monitoring of neuromuscular activity, as well as
confirmation of patient flaccidity, may be determined by a
peripheral nerve stimulator (see Chapter 8)29

NEUROLOGIC INTENSIVE
CARE MONITORING
Caring for the pediatric patient at risk for neurologic deterioration is uniquely challenging. The collaborative goal is to
preserve cerebral functioning. Although clinical examination provides invaluable information, it is often lost in the
critically ill child. Bedside neurologic monitoring augments
the clinical examination and provides continuous insight
into the CNS environment. The following section focuses on
major monitoring modalities, presenting general principles,
current devices, and essential elements of nursing care.

INTRACRANIAL PRESSURE MONITORING
Only when the ICP is known can therapy to manage cerebral
hypertension be rationally directed. rcp monitoring is
considered in comatose patients with a known potential for
developing intracranial hypertension. ICP monitoring has
several clinical benefits. First, it assists in the detection of
increasing rcp and compromised CPP before changes seen
in the neurologic examination. This is especially true when
the neurologic examination is diminished by therapy, such
as administration of anesthetics or chemical paralysis.
Second, it assists clinical evaluation of intracranial compliance, for example, VIP response testing. Third, rcp monitoring evaluates the effectiveness of therapeutic interventions. Finally, it provides prognostic data of the patient's
clinical status.
Knowledge of ICP and CPP allows precise titration of
therapy intended to prevent secondary neurologic injury
from cerebral ischemia or herniation. Successful control of
ICP and CPP after hypoxic-encephalopathic injury does not
ensure intact neurologic survival. Sustained late increases in
ICP indicate a profound primary neurologic insult. 30 ICP
monitoring in this patient population is used more for
prognostication than to avert further neurologic injury31.32
Although an ICP greater than 15 indicates reduced
adaptive capacity, a normal ICP does not reliably reflect
normal intracranial compliance or adequate adaptive capacity. To determine intracranial compliance or identify the
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patient on the VIP curve, direct or indirect VIP response
testing is helpful.
With direct compliance testing, an intensivist injects 0.1
to I ml of sterile normal saline without preservative into an
intraventricular catheter (IVC) and notes the resultant
change in ICP. Although unreliable with enlarged ventricles,
the value derived is the ratio of change in lCP to the amount
of volume introduced. Miller13 noted that reduced cerebral
adaptive capacity was present when an injection of approximately 7% of the intracranial volume into an IVC caused a
increase in the mean rcp of greater than 4 mmHg/ml.
Similar information can be obtained by removing CSF.
Currently, indirect methods of testing intracranial compliance are more common because of the potential risks of
adding volume into a tight intracranial compartment and
infection related to opening the system.
Indirect compliance testing involves trending the patient's response to procedures known to increase ICP. All
nursing interventions to some extent affect lCP in the patient
with reduced adaptive capacity. A significant response is
defined as a 10-mmHg increase in ICP lasting more than 3
minutes. The intensivist may also elect to apply unilateral or
bilateral internal jugular compression or abdominal pressure
to provide a rapidly reversible unquantified volume challenge to the intracranial space.

ICP Monitoring Systems
rcp monitoring has evolved over the last three decades.
Pioneered in the 1970s, fluid-coupled systems first became
available for patient use 34 Approximately 10 years later,
fiberoptic-tipped catheters were introduced, followed by
microsensor-tipped catheters in the I990s. Depending on the
system, a variety of intra- and extracranial locations can be
monitored. Although technologic improvements in rcp
monitoring have been made, all of the monitoring systems
have advantages and disadvantages. The ideal ICP monitoring system is accurate and reliable, free of complications,
and inexpensive.
Fluid-coupled systems are similar to traditional hemodynamic monitoring systems but do not contain a slow
continuous-infusion device. They have an external straingauge transducer that is coupled to the patient's intracranial space via a fluid-filled line. IVCs have traditionally
been the gold standard for ICP monitoring because they are
reliable and accurate, relatively inexpensive, and can be
recalibrated.
Disadvantages of fluid-coupled systems include obstruction of the catheter tip with tissue or blood and inaccuracies
in readings resulting from system problems with fluid-filled
tubing (e.g., air bubbles, kinks, and loose connections). In
addition, CSF fluid drainage and rcp monitoring cannot
occur simultaneously. Furthermore, the external transducer
must be maintained at a fixed reference point. Typically, this
reference point is institution specific, determined by the
preference of the neurosurgical team, that is, at the head
(lateral ventricle) or at the heart (right atrium). The lateral
ventricle is approximated by positioning the transducer at
the level of external auditory meatus or at the top of a
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triangle fonned by the external auditory meatus, the outer
canthus of the eye, and behind the hairline. Positioning the
transducer at the fourth intercostal space at the midaxillary
line approximates the right atrium. Regarding the reference
point that is chosen, it must be consistently used, and the
monitored data must be used as trend data and not as
independent decision points. Consistency in readings can be
enhanced if the ICP transducer, when referenced to the head,
is attached to the head dressing or secured to an arm board
resting on the patient's shoulder. The combination of
disadvantages and significant improvements in other ICP
monitoring technology has all but eliminated fluid-coupled
systems in many centers.
Fiberoptic systems use catheters that are light-sending
and light-receiving systems that respond to the movemelll of
a mirror-diaphragm located at the tip. Light is analyzed by
a microcomputer and converted to an analog signal that
displays the mean ICP. The Camino fiberoptic system
(Camino Laboratories, San Diego, Calif.) has been available
since the 1980s and is widely used in most institutions. It
consists of a disposable 4 Fr catheter with a miniaturized
fiberoptic transducer at the tip (Fig. 10-20). The portable
Camino monitor interfaces with a conventional monitoring
system for wavefonn display. The Camino catheter can be
placed at any number of locations: intraventricular, intraparenchymal, SUbarachnoid, epidural, or the fontanelle.
Unlike fluid-coupled systems, the Camino catheter allows
direct intraparenchymal monitoring, providing extremely
clear recordings of ICP waveforms 35
Like all ICP monitoring systems, advantages and disadvantages exist and vary according to fiberoptic placement.
Fiberoptic systems eliminate the need for a fluid path, which
typically requires frequent intervention that may place the
patient at a higher risk of infection. Because the transducer
is located in the tip of the catheter, there is no concern about
where to level the transducer. Another advantage is that the
fiberoptic catheter slips through the rvc, so CSF can be
drained while also obtaining ICP measurements.
Each Camino catheter is calibrated by the manufacturer
and is not adjustable. Before insertion, the catheter's zero is

matched to the Camino monitor by turning a screw at the
hub of the catheter. Anytime afterward, the Camino
monitor's zero and calibration are matched to the bedside monitor by depressing the "CAL" bulton on the
Camino monitor and simultaneously adjusting tbe bedside
monitor. Once inserted, the catheter cannot be rezeroed;
24-hour drift is reported as less than I mmHg. 36 •37
One disadvantage of fiberoptic catheters is that they
require gentle handling, especially during insertion and
manipulation. Fiberoptic breakage requires replacement at
an increased risk and cost to the patient. 35 .38 The rigid
catheter cannot be tunneled and stands straight up from the
point of insertion, so it must be protected (Fig. 10-2 I).
Another disadvantage is the cost of purchasing an additional
monitor. However, the cost may be justified by the other
advantages of the system and because the monitor is
portable, allowing continuous ICP monitoring during highrisk patient transport.
Catheter-tip strain-gauge catheters were approved for
use in the I990s. The Codman Microsensor ICP system
(Codman, Johnson & Johnson, Raynham, Mass.) is an
example of this type of monitoring system and consists of a
miniature strain-gauge pressure sensor positioned at the tip
of a lOO-cm flexible nylon tube. Like the fiberoptic-tipped
catheter, several locations can be monitored, including
subdural, parenchymal (with or without a bolt), and
intraventricular. The microsensor transducer is also calibrated before insertion, and unlike fluid-coupled systems, if
drift presents, it cannot be corrected. It is used with a
pressure monitor that interfaces with a wide variety of
patient bedside monitors.
Accuracy and stability of this system have been documented when compared with standard ventricular fluid
pressure as measured with an external transducer39 One
study monitored this system for stability and found maximal
drift of I mmHg over 9 days.40 If these results can be
replicated, the rnicrosensor offers a distinct advantage over
other systems.
Similar to the fiberoptic-tipped catheter, the microsensor
transducer can monitor a variety of intracranial locations

Fig. 10-20 Camino fiberoptic system. (Courtesy Camino Laboratories. San Diego, Calif.)

Fig. 10-21

Patient monitoring with a Camino fiberoplic system.
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and can drain CSF while monitoring ICP. It also eliminates
the need for repeated alignment of the transducer to the
patient's head and rezeroing. False readings caused by fluid
tubing obstructions are eliminated. One advantage over
fiberoptic-tipped catheters is that the microsensor transducer
is housed in flexible nylon tubing, which is resistant to
costly breakage and allows tunneling under the scalp.
Assuming replication studies can confirm the reliability and
stability of the microsensor transducer, disadvantages are
few. The major concern is cost, especially if institutions
have made prior investments in other expensive systems.
Intracranial Catheter Locations. As stated previously, ICP monitoring systems can be placed in a variety of
locations. However, the most accurate and reliable locations
for monitoring are the lateral ventricles followed by the
parenchyma. Currently, subarachnoid, subdural, and epidural locations are less reliable and are used less often" J
An intraventricular catheter is a radiopaque catheter
placed within a lateral ventricle for purposes of ICP monitoring, CSF drainage and sampling, intrathecal medication
administration, and direct compliance testing. The IYC
provides high-quality waveforms and is considered the
"gold standard" of ICP monitoring unless error is introduced through the measurement system.
While the patient is under local anesthesia, an IYC is
inserted through a burr hole on the nondominant side at
the intersection of the level of the pupil and external
auditory meatus in the area of the coronal suture. The right
side is usually chosen until hand dominance can be
identified after 3 years of age. During insertion, the head is
steadied; the patient will feel pressure and hear the sound of
the turning drill. The IYC is inserted into the frontal horn of
the lateral ventricle using a stylet. This area is chosen
because it has little or no choroid plexus, which may
obstruct the IYC, and also avoids penetration of vital brain
areas. When the ventricles are compressed or shifted, it may
be difficult to place the lYe. However, collapsed ventricles
are not considered a contraindication to catheter placement
because pressures may be adequately monitored as long as
waveforms remain distinct.
Location is verified when CSF is returned. If fluidcoupled or microsensor transducer systems are used, the
IYC is tunneled 2 to 3 cm under the scalp and brought out
through a separate incision. The separate incision allows the
natural defenses of the skin to prevent organisms from
gaining access to the CNS. This level of prote~tion is not
possible with a Camino lYe. The Camino fiberoptic system
is secured directly into the bolt attachment, which is
screwed into the skull.
Controlled CSF Venting. A distinct advantage of
IYCs is a reduction of CSF volume accomplished through
controlled continuous or intermittent CSF drainage. To
avoid ventricular collapse, drainage is accomplished against
a positive pressure gradient of at least 15 mmHg. To
accomplish this, the intraventricular drainage system drip
chamber is placed approximately 27 cm above the reference
point of the external auditory meatus. In this position, CSF
will automatically drain when the ICP is greater than
20 mmHg. (Because mercury is 13.6 times heavier than
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H 20, I mmHg is equal to 1.36 cm H 20.) Care is taken to
avoid the risk of uncontrolled CSF loss with incorrect
stopcock position or drainage position.
Intermittent CSF venting follows preset guidelines that
include (\) the level of ICP at which to initiate drainage,
usually greater than 15 mmHg after nursing measures to
decrease ICP are unsuccessful (see Chapter 20); (2) the
frequency of drainage, usually every hour; (3) the time
interval for drainage, usually 5 minutes; and (4) the maximal
amount of CSF, which depends on CSF production and
degree of obstruction. Some institutions prescribe CSF
drainage at a rate that matches the rate of CSF production.
This is approximately 0.35 ml/min or 21 ml/hr in an
adolescent and 0.30 ml/min or 18 ml/hr in a young child. A
regimen such as this may avoid ventricular collapse with
ICP spikes. Drainage also provides a check for IYC patency.
Because the amount of drainage reflects the degree of
ventricular obstruction, the amount and character of CSF
drainage are trended over time. Care is taken to clamp the
drainage system before changes in the patient's head
position in relation to the drainage device. 42
Intraparenchymal monitoring is possible with
fiberoptic-tipped catheter and microsensor transducer catheter systems. Both systems provide high-fidelity ICP
waveforms that are transmitted through brain tissue. Catheter insertion with the Camino fiberoptic catheter is similar
to that of a subarachnoid bolt. Once the bolt is placed, the
fiberoptic catheter is inserted through the bolt into the brain
parenchyma approximately 0.5 to I cm beyond the surface
of the dura. To prevent kinking or dislocation, the catheter
is looped and attached to the head dressing. With the
Cadman microsensor, two insertion options are available
with parenchymal placement: catheter insertion through a
subarachnoid bolt or catheter tunneling without a bolt.
Intraparenchymal monitoring has replaced fluid-coupled
subarachnoid bolts and epidural monitoring in many centers.
Patient Complications. ICP catheters not only have
technical problems but also potential patient-related complications. The two most commonly cited complications are
infection and intraparenchymal hemorrhage. Although longterm morbidity and mortality are rare complications of ICP
devices, increased costs may be associated with catheter
replacement or additional medical treatment.
Infection. Defining infection associated with ICP
devices varies among studies, depending on the methodology. Some studies define infection as a positive CSF culture,
whereas other studies use a positive culture of the actual ICP
device as their operational definition. Clinically, Mayhall
and colleagues 43 found that CSF pleocytosis was more
significantly related to the diagnosis of ventriculitis or
meningitis than were fever and leukocytosis.
Based on an extensive review of the literature, bacterial
colonization of an ICP device was reported as 5% for IYCs,
5% for subarachnoid bolts. 4% for subdural, and 14% for
43
intraparenchymal catheters. Colonization of ICP devices
increases significantly after 5 days.43A5 Even though there is
a rising risk of colonization the longer an IYC is in place,
Halloway and others found no advantage in prophylactically
exchanging catheters for prolonged monitoring (>5 days).45a
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Despite widely reported colonization of devices, clinically
significant infection is rarely associated with rcp monitoring devices. 35 .46.47 Furthermore, research does not support
using prophylactic antibiotics either systemically, in line, or
at the incisional area.43.48.49
Hemorrhage and Hematoma. Similar to infection,
significant bleeding from rcp monitoring is rare. The
incidence of hematoma with all rcp devices is 1.4%. When
bleeding does occur, parenchymally placed catheters are
the usual cause, with a reported incidence of I % to
5%.35.44.4 7.50.51 Although parenchymal catheters are generally considered safe, alternative monitoring sites are considered in patients with coagulopathies.

ICP Waveform Analysis
rcp waveforms mimic in shape but are of lower amplitude
than the arterial waveform (Fig. 10-22). Respiratory
fluctuations alter the baseline through transference of

P,

Fig. 10·22 ICP wavefonns. (From McQuillan KA: Intracranial
pressure monitoring: technical imperatives, AACN CLin Issues Crit
Care Nul'S 2:623-636, 1991.)

tI

pressure through the venous system. Waveform clarity
depends on the location of the device and the monitoring
system used. Because of narrow intracranial pulse pressures, rcp is monitored in the mean mode. The scale that
permits adequate waveform definition, usually 20 to
40 mmHg, is used.
The rcp waveform has three or more descending
sawtooth peaks. The first three components are always
present. Additional peaks vary and are thought to be caused
by retrograde venous pulsations. Their clinical significance
has not been established. PI' the percussion wave, is a sharp,
fairly consistent peak generated primarily by the arterial
pulsations of the choroid plexus that are modified by the
viscoelastic properties of the brain. P2 , the rebound or tidal
wave, is variable in shape, ending on the dicrotic notch. P3'
the dicrotic wave, immediately follows the notch, tapering
down to the diastolic portion unless retrograde pulsations
add a few more peaks.
Waveform changes have been associated with decreased
adaptive capacity.52.53 With cerebral vasodilation, the pulse
wave becomes less restrained by the arterioles and is
allowed to pass to the compliant capillaries and veins. Signs
of decreased adaptive capacity include a P 2 equal to or
higher than P t , followed by an increase in the waveform
pulse pressure (Fig. 10-23). rf compliance continues to
decrease, the diastolic component will elevate, and the
waveform will become rounder; then, at higher ICPs, it will
assume a triangular shape.54 Given the predictable, evolving
waveform pattern that indicates decreased intracranial
compliance,55 rapid therapeutic interventions and environmental adjustment should be possible. Additional nursing
research is necessary to confirm this.
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Fig.10·23 Signs of decreased adaptive capacity include a P2 equal to or higher than PI' followed by an
increase in the waveform pulse pressure. Two-year, 9·month toddler with decreased cerebral compliance.
Note wavefonn change from A to B. (Courtesy MAQ Curley.)
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Chapter 10

ICP Trend Recordings
In addition to continuous ICP waveform assessment, trend
recordings (25 mm/min) allow detection of baseline elevations over time. They can also correlate ICP with therapeutic
interventions. Last, they can identify Lundberg A, B, and C
waves (Fig. 10-24), which are not true waves but are
graphically displayed ICP waveforms that are trended over
minutes or hours.
A waves or plateau waves are spontaneous, rapid, irregular increases in ICP 50 to 100 mmHg over baseline lasting 5
to 20 minutes per wave, followed by a rapid decrease in ICP.
A waves progress through four phases generated by a complex interaction between systemic arterial pressure, intracranial compliance, and cerebrovascular autoregulation. 56 The
A wave begins with the drift phase, which is characterized
by a progressive decrease in MAP. The plateau phase follows as hypotension decreases the CPP, stimulating autoregulatory cerebral vasodilation and resulting in an increase in
cerebral blood volume and ICP. The ischemic phase ensues
when progressive cerebral hypertension produces brainstem
ischemia and activates the Cushing's response to increase
both MAP then CPP. The resolution phase terminates the A
wave when cerebral perfusion improves, decreasing cerebral
vasodilation, cerebral blood volume, and ICP. In summary,
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Fig. 10-24 A to C, Lundberg A, B, and C waves (From

McQuillan KA: Intracranial pressure monitoring: technical imperatives, MCN Clill Issues Crit Care Nurs 2:623-636, 1991.)
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plateau waves are observed in patients with preserved cerebral autoregulation but reduced pressure-volume compensatory reserve. 57
A waves are clinically significant, reliably signaling
reduced intracranial compliance. The more square the shape
of the wave, the greater the reduction in intracranial
compliance. A waves are associated with impaired CBF.
Patients with cerebral hypertension die of diminished
cerebral perfusion during plateau waves. A waves may be
accompanied by transient neurologic deficits, for example,
pupil dilation, headache, and vegetative responses, which
include sweating, flushing, and bradycardia.
B waves are sharp rhythmic increases in ICP to 50 mmHg
lasting 30 seconds to 2 minutes. B waves may precede A
waves, indicating a progressive loss of cerebral compliance.
B waves may occur before a seizure; during headache,
posturing, or isometric movement; or accompany respiratory compromise and decreased level of consciousness.
C waves are normal rhythmic rcp fluctuations associated
with respirations. They are considered benign but may
indicate an increase in venous pressure or a decrease in
venous outflow.
Monitoring ICP trends allows a proactive management of
cerebral hypertension. Anticipating care by using an individualized protocol to decrease ICP may prevent secondary
neuronal injury. Pressure waves greater than 20 mmHg and
lasting for more than a few minutes, especially if associated
with a change in neurologic status or the inability to
maintain CPP greater than 50 mmHg or ICP less than 15
mmHg, require immediate intervention. Occult seizure
activity should be considered a potential problem when
increased ICP is unresponsive to standard management.

Nursing Implications
Priorities for nursing care of patients who require rcp
monitoring include (I) keeping the ICP monitoring system
intact and operational, (2) ensuring the accuracy of the data,
and (3) limiting iatrogenic injury. Both rcp and CPP are
constantly assessed throughout any intervention to evaluate
the patient's response to therapy. Trends in patient tolerance
of care are noted over ti me.
The accuracy of data obtained from ICP monitoring is
assessed from waveform analysis. Good-quality tracings
correspond with good measurements, unless the transducer
is leveled inaccurately when using fluid-coupled systems.
As with hemodynamic monitoring transducers, I inch out of
position will produce a 2-mmHg deviation in measurement,
higher readings with the transducer too low, or lower
readings with the transducer is too high. ICP measurements
should always correlate with the neurologic examination
and reflect clinical interventions.
Because the cranium is compartmentalized, Weaver,
Winn, and Jane S8 found significant differences in ICP
measurements (using a fluid-coupled subarachnoid bolt)
between the ipsilateral and contralateral side of a focal
supratentorial lesion. They recommend that supratentorial
subarachnoid pressure be measured ipsilateral to the site of
the focal lesion. Pressure increases in nonpathogenic
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compartments occur only after herniation. Note that with the
fiberoptic system, intraparenchymal pressures more accurately reflect ipsilateral and contralateral pressures. 59 lVCs
and bolts measure supratentorial pressure. Patients with a
posterior fossa mass or infratentorial lesion must be
observed carefully for the development of respiratory and
cardiovascular distress even when normal or low supratentorial ICP is present.
When calculating CPP, controversy exists over where it
is best to reference fluid-coupled transducers. The basis of
the controversy is that two different reference points are
created when the head of the bed is elevated in a patient with
a ventriculostomy referenced at the lateral ventricle and
arterial line referenced at the right atrium. In this scenario,
ICP may be underestimated, and CPP may be overestimated.
Some try to remedy this problem by referencing both
transducers at either the head or the heart. Whichever
method is used, it is imperative that it be used consistently
to allow CPP trending over time.
Currently, there is lack of nursing research to guide
clinical practice in the care of patients with ICP devices.
Protocols usually reflect central line protocols. It seems
reasonable that ICP devices function under different principles because they exist within a system protected by the
blood-brain barrier. This natural barrier limits high antibiotic and immunoglobulin concentration, so theoretically,
risk of infection may be increased.
Until nursing research is available, some recommendations can be made. Site care includes use of an occlusive dry
sterile dressing. Dressings are changed every 72 hours to
inspect the insertion site for signs and symptoms of infection
and CSF leakage.
Even though fluid-coupled ICP monitoring is being used
less often, infection control practices must be enforced.
'Currently, no data suggest that ICP monitor tubing should be
changed with the same frequency as arterial and venous
pressure lines. 60 Strict aseptic technique is used whenever
the system is opened. Before insertion, the monitoring
system is prepared in a nontraveled area while masks and
gloves are worn. All systems should be maintained as closed
systems and left intact unless contaminated.

MONITORING CEREBRAL FUNCTION
Neurophysiologic studies are an important component of the
diagnostic evaluation in the infant and child with suspected
neurologic dysfunction. Although ICP monitoring provides
information about the neurologic environment, EEG and
evoked potential monitoring provide information about
actual neurologic functioning. The goal of continuous
neurologic monitoring is to detect a decline in a patient's
condition before physical signs and symptoms present. This
approach is particularly critical in patients in which the
physical examination has been eliminated; for example,
chemically induced paralysis to control ventilation.

Continuous EEG Monitoring
Continuous bedside EEG monitoring provides information
about the spontaneous electrical activity produced by the

outer 20% or 6-mm surface of cerebral cortex located near
the electrodes. The EEG does not provide information on
white matter or brainstem function. It is useful for detecting
status epilepticus, nonconvulsive seizures, metabolic disorders, intracerebral tumors, and coma. It is also used to
monitor patients who may experience a decline in CBF or
other ischemic events.
EEG monitoring is used most often in the pediatric
intensive care unit (PICU) for identification of seizure
activity (Fig. 10-25, A). Undetected and untreated seizure
activity can result in neuronal death. 61 Continuous EEG
monitoring is also essential when managing therapeutic
barbiturate coma 62 •63 Barbiturate coma is used to suppress
CMR and requirements. The goal of barbiturate coma is
burst suppression---electrical activity progressing to an
isoelectric line, then resumption of electrical activity (see
Fig. 10-25, B). Length of burst suppression depends on drug
levels; the higher the level, the longer the isoelectric line.
When barbiturate coma is used to manage intractable
seizures, abnormal cerebral electrical activity is suppressed
completely to permit the return of normal activity.64 If
inadequate barbiturate doses are used, the therapeutic
benefit may not be realized; whereas if excessive doses are
used, cardiovascular instability may result.
EEG monitoring also permits indirect visualization of the
effects of compromised CBF associated with significant
episodes of cerebral hypertension. When CBF is compromised, normal EEG rhythms are reduced in both amplitude
and frequency.6s An isoelectric EEG results when CBF is
less than 12 to 15 millOO g/min (see Fig. 12-25, C).""
EEGs also provide a prognostic tool to predict return of
cognitive function after an hypoxic-ischemic injury. Poor
neurologic outcomes have been correlated with slower
frequencies, amplitude suppression, and a static EEG
frequency spectrum over time. 67 In the absence of barbiturates, burst suppression is an ominous finding after a major
hypoxic-ischemic injury to the brain 6H Although not absolute in drug overdose or hypothermia, cerebral silence (as
evidenced by an isoelectric EEG) has been used as a
criterion for confirming brain death. EEG activity may
persist in some patients with cortical necrosis; survival is
possible because EEGs do not assess brainstem activity.
Waveform Analysis. EEG waveforms are described
in terms of frequency, amplitude, velocity, distribution,
regularity, and specific pattern (Table 10-11). The EEG
traditionally records voltage over time from 16 channels.
Waveform frequency is described in hertz (Hz) or cycles per
second. Waveform amplitude, measured from peak to peak,
is described in microvolts (~V). Waveform velocity describes the rate of climb and descent of waves; for example,
a spike has a duration less than 80 milliseconds (ms),
whereas a sharp wave has a longer duration.
As noted in Table 10-11, waveforms correlate with
level of consciousness and range from high frequency-low
amplitude to low frequency-high amplitude. Background
alpha activity is regulated by brainstem neurons known as
"pacemaker" cells. Right and left hemispheric symmetry
is analyzed by assessing lead pairs clustered down the
EEGpage.
EEG interpretation is complex, especially in the pediatric
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Fig. 10-25

A, Seizure activity. (Courtesy MAQ Curley.)

population, where individual maturational factors complicate EEG interpretation. For example, in the newborn,
cortical activity is irregular in frequency and incidence.
Asymmetry and asynchrony may be normal throughout
infancy. Alpha rhythms are slow to develop and may not
reach adult range until 10 to 12 years of age. 66
Seizure activity begins with a change in background
activity, followed by generalized low-voltage fast activity,
which increases in amplitude and slows in frequency. This
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pattern progresses to generalized polyspikes and wave
patterns from I to 4 HZ 69 Different seizure classes generate
specific spike and wave patterns. As expected, focal seizures
are asymmetric. Focal seizures with secondary generalization can be identified and tracked on the EEG. Postictal
activity can be identified as diffuse depression of background activity.
EEG analysis depends on pattern recognition placed in
the context of the patient's changing clinical picture.
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Fig. 10-25. cont'd B, Burst suppression: electrical actIvIty progressing to an isoelectric line, then
COl/til/lled
resumption of electrical activity. (Courtesy MAQ Curley.)

Accurate interpretation requires years of experience and
analysis of enormous amounts of data.
Two-lead bipolar (pairs) systems can screen for seizure
activity (Fig. 10-26). These single-channel systems use five
electrodes: two placed over each mastoid process, two
placed over each temporal area, and one ground electrode
placed over the middle of the forehead. Esposito and
Westgate 70 describe using the Siemens EEG cassette in a

PICU setting. This system reflects EEG activity only within
close proximity of the electrode pairs, one set at a time.
Computerized EEG Recordings. Computerized
EEG (CEEG) recordings are useful for continuous monitoring in the critical care setting. They facilitate recognition of neurologic alterations before the development of
clinical signs. A variety of CEEG devices and monitoring techniques are available in graphic form for use at
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Fig. 10-25, cont'd

C, lsoelectric EEG. (Courtesy MAQ Curley.)

the bedside. The common feature among them is their
7I
ability to compress hours of data into useful graphics.
Used only as a trending device. processed EEG recordings
do not replace the need for periodic l6-channel EEG
assessment.

First-generation processed EEG monitors include the
Cerebral Function Monitor (CFM; Criticon Inc., Tampa,
Fla.). This system is a single-channel, single-lead bipolar
trend recording of EEG amplitude and variability. Three
electrodes are used: one placed over each parietal area and

360

Part III

Phenomena of Concern

EEG Waveforms
Frequency
(Cycle/sec)

Amplitude
(Peak-Peak)

Area

State

13-30Hz

10-20 ~V
Intermittent

Frontal and
central

Awake
Eyes open

8-13Hz

Infant: 20 ~V
Child: 75 ~V
Adult: 50~V

Dominant
rhythm
of occipital and
parietal

4-7Hz

Child: 50 ~V
Adult: 10~V

Temporal
or central area
in children to
age 3

Drowsiness
Encephalopathies

Frontal

4th-stage
sleep-<:oma
Structural lesions
Normal in young
children

1-4Hz

100 ~V

one ground electrode placed over the frontal area. The lower
printout records amplitude: 0 to 10 !lV, then 10 to 100 1lY.
The upper printout records frequency: top, 0 Hz, and
bottom, 16 Hz. The paper speed condenses about 2 minutes
of EEG activity into a I-cm tracing. Two characteristics are
assessed: the overall amplitude, reflecting the average of
cortical activity, and the width, reflecting the degree of
variability in cortical activity. High, wide tracings indicate
high EEG voltages with considerable variability in peakpeak amplitude. Conversely, a low, narrow tracing results
from low voltage with little variability in amplitude. The
limitation of this system is that it cannot assess regional
activity because only two leads are used.
The CFM is helpful in the PICU to assess EEG trends
and identify classic EEG patterns. 72 For example, episodic
high-voltage activity suggests the presence of seizure
activity. Progressive increase in EEG amplitude correlates
with improved neurologic outcome following a hypoxicischemic event; the opposite is associated with a poor neurologic outcome. Presence of EEG activity during periods of
increased ICP suggests that adequate CPP is maintained. 65
Finally, a "comb" pattern indicates burst suppression. 73
Another first-generation processed EEG recorder is
compressed spectral array (CSA). Here, raw EEG data are
rearranged from voltages versus time to amplitude versus
frequency during a sampling period (Fig. 10-27). Frequency
is on the horizontal axis with delta waves on the left and beta
waves on the right. The power spectrum is then plotted and
stacked vertically into a three-dimensional representation
for trend analysis.
Because CSA compresses a significant amount of data,
critical events may be smoothed together, including, for
example, burst suppression and seizure activity. Like the
CFM, CSA is helpful in the assessment of EEG trends and
identification of classic patterns. CSA is particularly helpful

Waveform

Awake
Eyes closed

in the prediction of outcome from coma. A fluctuating
frequency spectrum carries a more favorable prognosis than
an invariable type.74
Aperiodic analysis, Lifescan (Neurometrics, Inc., San
Diego, Calif.), is considered a second-generation processed
EEG recorder. Aperiodic analysis assesses each wave
vector and displays it in a three-dimensional glass box. Two
sets of leads are used; the negative electrode is placed
behind the ears; the positive electrode, in the frontal area;
and ground electrode, in the center of the forehead.
Frequency bands are positioned from left to right: 0.5 Hz
to the left and 30 Hz to the right. To enhance visualization,
waves are color coded; beta waves are yellow, alpha waves
are green, subalpha are magenta, theta are light blue, and
delta waves are dark blue. Waveform amplitude is approximated by vector height. Time is expressed on the
diagonal. The activity edge, a white line on the top of the
each box, trends changes in both frequency and amplitude
over time (Fig. 10-28).
The acronym SAFE can be used to systematically assess
the Lifescan recording. S represents symmetry between the
left and right cerebral hemispheres, A represents vector
amplitude, F represents vector frequency, and E represents
acti vity edge. Vector height should vary over time and from
one frequency to another. Vector distribution should also
vary over time. The activity edge should reflect symmetry
between the left and right hemisphere and vary symmetrically over time.
Narcotics produce a gradual shift of the activity edge to
the left, reflecting an increase in delta activity. Cerebral
ischemia also produces a left shift of the activity edge, with
a reduction in amplitude at all frequencies. Unilateral
ischemia produces an asymmetric shift to the left, whereas
bilateral ischemia produces a symmetric shift to the
left. Burst suppression decreases alpha/beta activity and
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Fig.10-26 Two-lead bipolar (pairs) systems. (From Esposito N, Westgate P: Continuous EEG monitoring
in the PICU, J Pediatr Nurs 2:272-277, 1987.)
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Fig. 10-27 A to D, Cerebral function monitor. C, Compressed spectral array (CSA) of raw EEG display
shown in A. CSA represents a 2-second update rate with a frequency band of 0.5 to 30 Hz. D presents CSA
of raw EEG display shown in B. At the onset of an electrographic seizure, CSA increases in frequency as
the spike and wave activity occurs.

increases delta/theta activity. The activity edge shifts far to
the left and then back to the right. Alterations in temperature
produce high or low activity at all levels; the edge shifts
bilaterally to the right or left.

Evoked Potential Monitoring
Evoked potential (EP) monitoring provides a computerized
summation of the electrical potentials produced by specific
neural pathways in response to an external stimulus. EP
monitoring is useful because the nerve pathways tested are
less sensitive to drug effects. In addition, the waveforms
correlate to the anatomy of the sensory tracts. EP monitoring
offers the possibility of assessing structures not seen with
EEG (Fig. 10-29).
Each EP is a series of waves plotted as voltage versus
time. The amplitude (voltage) and latencies (time) reflect
conduction and processing of sensory information through
the CNS. The EP is assessed for changes in the presence and
absence of waves, individual latencies, interwave latencies,
and relative amplitudes. Again, maturational factors are
important because development affects interwave latencies
in children less than 2 years of age. 75
Loss of transmission or slowed conduction (increased
latency) indicates functional injury related to cerebral
hypoxia, compression, or other factors that affect cerebral
metabolism. Decreased amplitudes are related to decreased
CBF. Loss of transmission after a particular wave identifies
the specific level of dysfunction (Table 10-12).

The three EP modes are visual, somatosensory, and
auditory. Multimodal EPs (MEPs) assess several different
tracts to provide specific information regarding various
components of the CNS.
Generated by a flashing light, visual evoked potentials
(VEPs) assess the integrity of the retinal-occipital pathway.
York and associates 76 found that increases in ICP secondary
to either cerebral edema or hydrocephalus produced characteristic alteration in VEPs (increased latency of wave N2 )
through compression of intercerebral visual pathways. The
relationship establishes a reliable noninvasive method of
estimating lCP. 77
Somatosensory evoked potentials (SEPs) assess the
integrity of the sensory pathways from the peripheral nerve
to the sensory cortex from either the median nerve in the
wrist or the posterior tibial nerve in the ankle to the cerebral
hemispheres. SEP is useful in identifying the level of spinal
cord injury. An absent waveform below the region of spinal
injury indicates a complete injury, whereas the presence of
the wave indicates an incomplete lesion. Presence or return
of SEPs often precedes clinical improvement and offers a
favorable prognosis.
Brainstem auditory evoked responses (BAERs) are
often used in monitoring the critically ill patient. BAERs
measure the change in EP in the auditory pathways to the
brainstem in response to a noise (click). Electrodes are
placed on top of the head and in the external auditory meatus. After ensuring patency of the auditory canal and an
intact tympanic membrane, repeated clicks are delivered
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Lifescan Brain Activity Monitor. A, Normal display. B, Seizure activity. C, Barbiturate coma.
Burst suppression. E, Bilateral ischemic event. (Courtesy Diatek Neurometrics, San Diego, Calif.)

Fig. 10-28

n,

through an earpiece at about 10 Hz while "white noise"
masks stimulation to the other ear. Click intensity is increased about 60 decibels above minimal hearing threshold.
The signal is amplified 50,000 times, and averaging is performed over a lO-ms sweep after each click. Usually, over
2000 clicks are averaged.
The time measured from peak to peak, known as the
interpeak latency, is unaffected by changes in the intensity
of the stimulus and peripheral hearing apparatus. Normal
BAERs suggest the absence of lesions when toxic or
metabolic comas or a diffuse cortical process is present.
BAERs are unaffected by barbiturates, so they are useful to
monitor brainstem integrity during therapeutic coma. If

BAERs are normal in the comatose patient, nursing care can
be planned to provide appropriate auditory stimulation.
Decreasing amplitude or increased latency of wave Y
indicates brainstem compression secondary to increased
ICP. Loss of wave Y indicates severe brainstem dysfunction
and suggests central herniation. In brain death, BAERs are
not conducted past wave I. Brain death may also include
wave I, but the integrity of the peripheral auditory apparatus
cannot be validated.
MEPs combine the use of several EPs for localization of
defects and prognostic evaluation. 78 With brainstem dysfunction, SEPs and BAERs are abnormal, whereas YEPs are
normal. With hemispheric dysfunction, YEPs and BAER
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Fig. 10·30 Schematic view of sensory pathways involved in the
generation of multimodality evoked potentials. Sensory input
generating somatosensory and auditory evoked potentials traverses
more caudal regions of the brainstem than does sensory input for
visual evoked potentials. (From J Neurosurg, vol 56, Jan 1982.)

Fig. 10-29 Brainstem auditory evoked potentials (BAEPs). Neural generations of the BAEPs. It is most likely that each wave has
components arising from different generators that include brainstem nuclei and white matter tracts. 1 to Vll. waveforms. (From
Wiznitzer M: In Blumer JL. ed: A practical guide 10 pediatric
intellsive care, St Louis, 1990, Mosby.)

It) Evoked10·12Potentials
Brainstem Auditory
.

EP limitations are present when ocular, auditory, or
peripheral nerve disease is present. Also, EPs test only
specific nerve tracts. The frontal lobes, cerebellum, and
cognitive function are not tested.
Computerized processing of multilead EEG and EP
allows total brain mapping. Moment-to-moment variations
in the brain's spontaneous or evoked electrical activity are
displayed on a computer monitor in the form of multicolored
maps. Different colors and color shades are used to indicate
the magnitude of positive and negative EEG voltages
simultaneously measured from various scalp locations.
Mapping techniques can be useful in identifying functional
abnormalities not distinguished by anatomic or metabolic
studies.

TABLE

jb
!!1,wave
~i--

Location

Level of Pathway

Acoustic nerve (CN VIII)
Cochlear nuclei
Superior olivary complex
Lateral lemniscus
Inferior colliculus
Medial geniculate
Auditory radiations

Peripheral receptor
Medulla
Pons
Mid to upper pons
Midbrain
Thalamus
Thalamocortical

and SEP cortical EPs are abnormal, but BAER and SEP
subcortical EPs are normal (Fig. 10-30). If all EPs are
dysfunctional, global dysfunction is probably present.
As a prognostic indicator in coma, 80% of patients with
mild abnormalities in MEP awaken within 30 days, and 90%
of patients with mild EP abnormalities at 14 days make a
good neurologic recovery. oS Goodwin, Friedman, and Bellefieur 79 studied BAERs and SEPs in 41 children ranging in
age from 6 weeks to 18 years. When assessing survivor
outcome, determined both at discharge and by follow-up
examination conducted I to 3 years later, no false pessimistic predictions had been made, and only two were falsely
optimistic.

NEURODIAGNOSTIC STUDIES
Under nonemergent circumstances, patient and family
preparation precedes all procedures. Nursing responsibility
includes augmenting the primary information provided by
the attending physician. Specific concerns that are often
addressed by nurses include how the procedure is performed. what the expectations of the patient will be during
the procedure, what the patient will experience during the
procedure, the anticipated response of the patient to the
procedure, and how the parents might help the patient
through the procedure.
A lumbar puncture involves the insertion of a spinal
needle into the su barachnoid space for the purposes of
measuring spinal fiuid pressure and obtaining CSF for
laboratory analysis (see Table 10-2 for normal CSF characteristics). During the procedure, the nurse continuously
monitors the patient while helping the patient maintain a
side-lying position with hips and neck flexed. Under local
anesthesia, the spinal needle is inserted into the L3-4 or
L4-5 vertebral interspace. A manometer is used to measure
opening and closing spinal pressures. CSF samples are
collected in tubes to allow visualization and laboratory
analysis. Usually, CSF cell count and Gram stain are
obtained first, followed by CSF chemistries and then CSF
culture.
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A lumbar puncture should not be performed in patients at
high risk for bleeding or in those with increased ICP. In
patients with increased ICP, withdrawing CSF from the
spinal compartment may create a significant pressure
differential between the cerebral and spinal compartments.
This disequilibrium results in further compression and
herniation of thalamus and midbrain through the tentorial
notch and may eventually cause infarction of these structures. Consequently, the fundi are checked for papilledema
before performing a lumbar puncture 63
CBF measurements are very important when monitoring the balance between cerebral oxygen supply and
demand, especially when autoregulation is lost. Modifications of the Fick principle (the uptake of a substance by an
organ is equal to the amount of the substance that enters it
minus the amount that leaves it) can be used to approximate
the CMR. Cross-brain concentration gradients of glucose
(CMRlglu), lactate (CMRL), and oxygen (CMR0 2 ) have
been used. For example, the CMR0 2 is equal to the CBF
multiplied by the difference between the cerebral arterial
and venous oxygen difference (avD02 ).
Normally, CBF matches the CMR0 2 . When autoregulation is intact, changes in the CMR0 2 will be matched by
reciprocal changes in CBF, and cerebral avD0 2 will remain
constant. The CMR02 and CBF are often modulated by
alterations in temperature, seizure activity, and certain
medications-for example, narcotics, sedatives, and analgesics. When autoregulation is lost, changes in CMR02 do not
produce reciprocal alterations in CBF, and the avD02 can
serve as an indicator of the adequacy of CBF. 80
Although cerebral arterial blood can be sampled from
any artery, cerebral venous blood should not be contaminated by extracerebral blood. To accomplish this, Goetting
and Preston 81 described a method of percutaneous cannulation of the jugular venous bulb by retrograde advancement
of a catheter placed into the jugular vein (Fig. 10-31).
Oximetric catheters placed in the jugular venous bulb
have been used to continuously monitor cerebral venous
saturation. The ratio of CMR0 2 to CBF can be expressed as
the cerebral extraction of oxygen (CE0 2), which is the
difference between arterial saturation (Sa0 2 ) and jugular
bulb saturation (Sj02).80,82 The CE02 can serve as a
continuous trend monitor of cerebral oxygen supply and
demand, Increased CE0 2 indicates either decreased extraction or increased delivery. Decreased CE0 2 indicates either
increased extraction or decreased delivery,
Similar to pulse oximetry, cerebral oxygen saturation can
be noninvasively evaluated with near infrared spectroscopy (NIRS) examination of cytochrome c oxidase and
hemoglobin (INVOS 3100; Somanetics, Troy, Ny),83 Infrared light (650-1100 nm) can penetrate extracerebral tissue
and return with valuable information about the attenuation
of that light. Intracerebral cells capable of attenuating light
include oxyhemoglobin, deoxyhemoglobin, and oxidized
cytochrome c oxidase, all of which are important in oxygen
delivery,
Inhalation or injection of xenon-I 33, a radioisotope, is
also used to assess CBF. 33Xe study is based on the
principle that the rate of uptake of an inert diffusible gas is
J
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Fig. 10-31 Jugular venous bulb SVo 2 monitoring. Skull x-ray
demonstrating proper catheter tip position. Arrow indicates jugular
bulb (From Goetting MG, Preston G: Jugular bulb catheterization:
experience with 123 patients. Crit Care Med. 18: 1220-1223, 1990.
Copyright by Williams & Wilkins, 1990.)

dependent on blood flow. 68 This study can be accomplished
rapidly and provides useful information when cerebral
hypoperfusion associated with stroke, massive cerebral
hypertension, or brain death is suspected,
Cranial ultrasound uses sound waves to identify cranial
structures of different densities. In infants with open
fontanelles, serial cranial ultrasound can assist in accurate
identification of the ventricular system and is helpful in the
rapid identification and management of intraventricular
hemorrhage. Ultrasound technology has also been used to
monitor CBF by Doppler ultrasonography.84 The velocity
of CBF is measured by sound waves reflecting back from
moving red blood cells through the anterior cerebral artery.
After closure of the anterior fontanel, the circle of Willis is
insonated via the temporal bones. Direction of flow can also
be identified with color imaging. Although an isolated
number is of little significance, serial numbers are valuable
in trending the course of a patient.
Skull and spine x-rays are the most common radiologic
tests performed on the neurologic system. A variety of skull
and spine views are selected to identify fractures, abnormal
calcification, and tissue densities. Suture lines may appear
widened in the patient with cerebral hypertension. In the
multiple-trauma patient, spinal cord immobilization is
essential until spinal x-rays are read as negative by a
radiologist.
Computed tomography (CT) and magnetic resonance
imaging (MRI) have revolutionized neurodiagnostic imaging. These noninvasive studies provide clear visualization of
neuroanatomy. CT differentiates tissues by x-ray density.
Areas of low density (air) appear dark, and areas of high
density (bone) appear white. CT with contrast is used to
enhance visualization of blood vessels, well-vascularized
lesions, and localized alteration in the blood-brain barrier.
The use of contrast media is contraindicated in patients with
acute renal failure and in those with a positive history of

366

Part III

Phenomena of Concern

allergy to contrast media. CT scan uses about the same
amount of radiation as a standard skull series.
The MRI image is formed by the tissue-specific realignment of protons when short radio frequencies are applied
from a strong external magnetic field to move them out of
uniform alignment. When moved, the atoms resonate and
emit signals based on nuclear density and realignment time.
The signals are tracked on an image revealed on a
high-resolution screen.
CT scans are selected when global neuroanatomic
information is needed, for example, ventricular size, shift,
and distortion of brain tissue in the patient with cerebral
hypertension. MRI delineates between tissue structure (e.g.,
white and gray matter differentiation); thus MRI can be
helpful in evaluating brain tumors, especially when located in the posterior fossa, where x-ray artifact from
adjacent bone obstructs the CT view. Because personnel and
metal objects cannot be in immediate proximity to the
patient during MRI, its use in critical care is extremely
limited.
Transporting the critically ill patient to radiology for either CT or MRI places the patient in an extremely vulnerable position. Transport requires forethought and teamwork,
and planning for potential emergencies is key. Patients and
personnel with implanted magnetic devices should not be
near an MRI because the magnetic field may dislodge or
interfere with the function of the device. Expecting infants
and young children to cooperate by holding still during the
examination, especially during the loud knocking MRI
sounds, is unrealistic. Sedation in this age group is often
used to accomplish both CT scan and MRI.
During cerebral angiography, radiopaque contrast medium is injected into the carotid artery, and sequential skull
x-rays films are taken to track medium flow throughout the

cerebral vasculature, Cerebral angiography is used to
delineate arteriovenous malformations or to assess the
circulation to a brain tumor. Common to any angiographic
procedure is a potential for arterial spasm, embolism, and
thrombosis, Allergic reaction to the contrast medium may
occur. Hematoma formation at the injection site is another
potential risk. Patients may report a burning or warm
sensation for about 20 to 30 seconds when the medium is
injected.
Positron emission tomography (PET) scans provide information regarding cerebral metabolic function. Positronemitting isotopes, which readily cross the blood-brain
barrier, are either inhaled or injected, When the positrons
(positive electron charge) come in contact with electrons
(negative electron charge), gamma rays are released. The
intensity of the gamma rays is then measured by a
computerized detector that creates an image indicating the
pattern of metabolic activity, The half-life of the nuclides is
extremely short, so there is no risk of radiation exposure to
either patients or caregivers. Although use in critical care is
limited, PET scanning has been found to be valuable in
locating epileptic foci in infants and young children before
excision.

SUMMARY
In summary, care of the patient at risk for neurologic
compromise is inherent to the practice of critical care
nursing. The astute neurologic examination, repeated at
frequent intervals by an expert clinician, is the most reliable
monitor of neurologic functioning. When neurophysiologic
monitoring and studies are used in combination with history
and physical examination, the diagnostic process is complete, and clinical judgment is optimized.
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Fluid and Electrolyte
Regulation
Kathryn E. Roberts

suited to meet their homeostatic requirements, critical
illness often overburdens them. A disturbance in fluid
and electrolyte balance affects the ability of the kidney to
regulate water and many hormones (see Chapter 21).
This, in turn, affects regulation in a number of body
systems, including the cardiac and respiratory systems. For
these reasons, a major goal of critical care management is to prevent major fluctuations in electrolyte
concentrations and to stabilize fluid in the correct compartment. When critical imbalances occur, astute assessment and rapid intervention can determine a successful
outcome. The nurse's responsibility is to observe for
insidious changes and to initiate interventions that will
correct imbalances. An awareness of fluid and electrolyte regulation guides the nurse in anticipating potential
problems and ensuring that appropriate interventions take
place.

MATURATIONAL IMPACT OF FLUID AND ELECTROLYTE
REGULATION

Composition of Body Fluids
Total Body Water
Regulation of Water and Electrolyte Balance
ASSESSMENT OF FLUID AND ELECTROLYTE BALANCE

Movement of Fluids and Electrolytes
Fluid Volume Regulation
MONITORING FLUID AND ELECTROLYTE BALANCE

Clinical Assessment
Laborato,ry Tests
SUPPORT OF FLUID AND ELECTROLYTE REGULATION
ALTERATIONS IN FLUID VOLUME BALANCE

Fluid Volume Deficit
Fluid Volume Excess

MATURATIONAL IMPACT OF FLUID
AND ELECTROLYTE REGULATION
Composition of Body Fluids

ELECTROLYTE DISORDERS

Sodium
Potassium
Calcium
Chloride
Phosphate
Magnesium

Fluid and electrolyte homeostasis occurs when fluid and
electrolyte balance is maintained within narrow limits
despite a wide variation in dietary intake, metabolic rate,
and kidney function. Body fluids are composed primarily of
water and electrolytes.
An electrolyte is a substance that develops an electrical
charge (ion) when dissolved in water. Those substances that
develop a positive electrical charge are called cations (i.e.,
potassium, K+; sodium, Na+; calcium, Ca++; and magnesium, Mg++). Electrolytes that develop a negative charge are
called anions (i.e., chloride, CI-, and bicarbonate, HC0 3-).
Electrolytes are regulated by intake, output, acid-base
balance, hormonal influence, and cellular integrity. Nonelectrolytes are small solute particles that do not carry an
electrical charge when dissolved in water. Examples are
simple sugars (i.e., glucose), proteins, oxygen, carbon
dioxide, and organic acids.

SUMMARY

T

he concepts of fluid and electrolyte balance apply to
a broad spectrum of pediatric critically ill children.
Many disease states alter the intake and elimination of
fluids and electrolytes, but physiologic immaturity places
infants and children at higher risk for the consequences of
imbalance. Fluid and electrolyte regulation is dependent
on renal function. The kidney provides for the maintenance of the body's internal environment that supports
cellular processes. Although the immature kidneys are well
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Total Body Water
Water constitutes approximately 65% to 80% of body
weight. Total body water (TBW) varies from person to
person and is dependent on several factors: age, gender,
skeletal muscle mass, and fat content. The water content of
adipose tissue is approximately 10% as compared with a
water content of 73% in lean body tissues. J Thus the amount
of fat in the body determines, to a major degree, the amount
of water.
As the infant and child mature, TBW, as a percentage of
body weight, changes. During the first year of life, the total
body fluid percentage decreases, with the most rapid change
occurring in the first 6 months. 2 TBW accounts for 75%
80% of body weight in the newborn, 70% at 6 months, and
65% at I year of age. In children, the percentage of total
weight as body water decreases steadily until the adult
percentage (55% to 60%) is reached at about 8 years of age 3
(Table 11-1). On the average, obese children and women
generally have lower percentages of TBW as water. TBW is
distributed in two separate compartments: the intracellular
fluid OCF) compartment and the extracellular fluid (ECF)
compartment (Fig. II-I).
In addition to the changes in the percentage of TBW as
body weight, infants and young children have a relatively
higher percentage of ECF compartment compared with
adults. More than half of the infant's body weight is ECF
compartment. This decreases quickly over the first 6 to 8
weeks of life, and by 3 years of age, body fluid components
more closely resemble those of the adult with an ECF
compartment of approximately 20% to 23% and an lCF
compartment of 40% to 50%.1.2
Intracellular Compartment. ICF consists of all
liquid within the cell membranes of the body and is the
largest fluid compartment, accounting for 40% of the body
weight of the child by 1 year of age (see Table 11-1). Much
of the ICF compartment is found within muscle cells. The
primary electrolytes of the lCF compartment are potassium
and phosphate. The ICF compartment contains only small
quantities of sodium and chloride ions and almost no
calcium ions. The cells contain 4 times as much protein as
the plasma.

Extracellular Compartment. The extracellular compartment is not a homogenous compartment. It is composed
of interstitial fluid (ISF), plasma, and transcellular water
(TSW). The lSF bathes all of the body cells and includes
lymph fluid, the largest component of ECF compartment.
ISF volume accounts for approximately 20% of TBW.
Plasma is the liquid component of whole blood, contained
within the vascular system. Although plasma accounts for
only 8% of TBW, it is essential to the functioning of the
cardiovascular system. TSW is composed of the fluids
found in pleural, pericardial, synovial, peritoneal, and joint
spaces. In addition, TSW includes the secretions of the salivary glands and pancreas and fluid in the respiratory and
gastrointestinal tracts. The function of TSW is to either
lubricate or cushion. TSW accounts for a small portion of
TBW; however, it can increase during certain disease
states. 4
The serum or plasma portion of the extracellular compartment contains the electrolytes found in the ECF
compartment and a large amount of protein. The plasma
proteins determine colloid osmotic (oncotic) pressure, with
the most abundant plasma protein being albumin. Albumin,
because of its size, remains in the vascular space and exerts
a differential osmotic force or oncotic pressure between the
capillary lumen and the interstitial space. The consequence
is maintenance of volume in the intravascular space.
Oncotic pressure is also important in the kidney, influencing
filtration and reabsorption of water and solutes.

OUTPUT
Kidneys

Lungs
Feces
Sweat
Skin

~
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11-1 Changes in Total Body
Water (TBW) and Body Compartments
During Development

~

TABLE

TBW
(% Body
Weight)

Extracellular
Fluid (% Body
Weight)

Intracellular
Fluid (% Body
Weight)

72-79
59

32-44
25

62

21
18

35-40
33
41
39

58

Fig. ,,-, Fluid distribution-body compartments. (Adapted
from Guyton AC, Hall JE: Textbook of medical physiology. ed 9,
Philadelphia, 1996, WB Saunders, p 298.)
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The ECF compartment contains large quantities of
sodium and chloride ions; reasonably large quantities of
bicarbonate ion; and small quantities of potassium, calcium,
magnesium, phosphate, sulfate, and organic acid ions. The
ECF compartment makes up just 20% of body weight in the
adult but 50% in full-term infants. J The infant's entire ECF
compartment volume is replaced every 3 days. By the age of
I year, ECF compartment decreases by one half and declines
very slowly thereafter (see Table 11-1).

Regulation of Water and Electrolyte Balance
A dynamic relationship exists between the extracellular and
intracellular fluid compartments. This relationship maintains
cellular homeostasis through the exchange of fluids and
electrolytes. The compartments are kept separate by the
structural and functional integrity of cell membranes. Both
passive and active processes regulate the movement of
water and solutes across the cell membrane. The selective
permeability of the cell membrane and the specific active
transport activity of the cell determine the characteristics of
intracellular and extracellular fluid compartments. A profound alteration in anyone of the fluid compartments can
disrupt cellular health and may result in a fatal systemic
response.
Homeostatic maintenance of fluid balance ensures
that TBW remains constant. The aim is to have intake
equal output plus insensible water loss. Intake is composed of water from enteral or intravenous solutions and
fluid metabolically produced through oxidati ve metabolism
(300 ml/24 hours). Intake is regulated mainly through the
mechanism of thirst. This mechanism cannot be relied on
to obtain adequate intake in critically ill infants and children
because they may not be able to demonstrate or respond
to thirst.
Output of fluids and electrolytes is regulated by the
integumentary, respiratory, digestive, and renal systems. All
of these systems work together to protect adequate elimination and retention of body water. Several factors, such as
humidity and ambient temperatures, affect the amount of

iii

11-2 Fadors Known to Influence
Insensible (Evaporative) Fluid Losses

TABLE

iii-'

I~llcreased Insensible Loss

Decreased Insensible Loss

'JiHyperthermia*
~llilncreased activity
~Jtyperventilation

Hypothermia
Decreased activity
Sedation
Humidified air

" diant wannerst
~ototherapyt

m Besunder 18: Abnormalities in fluids. minerals, and glucose. In
er JL. 00: A practical guide to pediatric intensive care, ed 3,
ouis, 1990, Mosby. P 546.
creases sensible losses by 12% per Celsius degree above 38° C.
creases insensible losses by 40% to 50% in infants less than 1500 g;
rcentage may be higher in larger infants.
.Increases insensible losse~ by approximately 40% in infants less than
_500 g; percentage may be higher in larger infants.
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water lost. Factors affecting insensible water loss are
presented in Table 11-2.

ASSESSMENT OF FLUID AND
ELECTROLVTE BALANCE
The kidneys, in conjunction with the endocrine system, are
responsible for maintaining the body's fluid and electrolyte
balance. The regulation of fluid and electrolytes in designated compartments (intracellular and extracellular) is
dependent on the osmotic pressure, colloid osmotic pressure, hydrostatic pressure (pressure exerted by a liquid) in
the vascular spaces, and capillary permeability. Hydrostatic
pressure is produced through the action of the cardiovascular and lymphatic systems. The force of cardiac contractions
generates capillary hydrostatic pressure.
The tern} colloid osmotic pressure (COP) is used to
distinguish the osmotic effects of the colloid from those of
dissolved crystalloids such as sodium. COP is a pulling
force generated by plasma proteins that opposes fluid
filtration from the capillaries. The plasma proteins are large
colloid molecules that disperse in the blood and sometimes
escape into the tissue spaces. Both the intravascular and
interstitial compartments contain plasma proteins, including
albumin, the globulins, and fibrinogen. Albumin, the smallest and most abundant of the plasma proteins, accounts
for about 70% of the total osmotic pressure. Albumin
provides for the return of fluid to the vascular compartment
from the tissue spaces. When plasma protein concentration falls acutely, plasma oncotic pressure falls, and fluid
may leave the vascular space, resulting in third spacing of
fluid.

Movement of Fluids and Electrolytes
For water and electrolytes to function effectively in the
body, a regulatory process that controls fluid movement is
required. The regulatory process is dependent on the
concentration of the specific fluid or electrolyte (osmolality)
and on the functioning capacity of the renal system. Fluids
move constantly from one body compartment to another and
then remain in specific compartments until an inequality in
concentration of electrolytes develops. Then, movement
once again occurs. Movement is through one of four
transport mechanisms: osmosis, diffusion, filtration, and
active transport.
Osmosis is the movement of water through a semipermeable membrane from an area oflower solute content to an
area of higher solute activity (with lower activity of water
molecules) (Fig. 11-2). Osmosis occurs only when the
membrane is more permeable to water than solutes. The
force of the movement, or shift, of water depends on serum
osmolality, which controls distribution and movement of
water between compartments.
Osmolality refers to the concentration of particles
(proteins and electrolytes) per liter of water. The osmolality
of a solution does not depend on the size, molecular weight,
or electrical charge of the molecules. Osmotic pressure of a
solution is described by the terms osmole and milliosmole.
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The osmolar concentration of a solution is called the
osmolality when the concentration is expressed as osmoles
per kilogram of water. The terms tonicity and osmolality are
used interchangeably.
Serum osmolality can be estimated by the following
formula:
Serum osmolality = 2(Serum Na) + Glucose/ 18 + BUN/2.8

where BUN is blood urea nitrogen.
Normally, the amount of water that diffuses in and out of
the cell is balanced, and the volumes within the extracellular
and intracellular fluid compartments remain constant. Because water moves freely between the blood, ISF, and
tissues, changes in the osmolality of one body compartment

.
OsmosIs

)

Fig. 11·2 Osmosis at cell membrane when sodium chloride
solution is placed on one side of the membrane and water on the
other side. (From Guyton AC: Textbook of medical physiology,
ed 8, Philadelphia, 1991. WB Saunders, p 45.)

produce a shift in all other compartments. Consequently, in
most cases, the osmolality of the plasma is equal to the
osmolality of other compartments.
Water moves from the ECF compartment to the ICF compartment if the ICF compartment osmolality increases
(Fig. 11-3). Conversely, if the ECF compartment osmolality
increases, water will shift from the ICF compartment into
the ECF compartment (see Fig. 11-3). When the movement
of water causes a concentration difference, the cells either
shrink or swell, depending on the direction of the net movement. Isotonic solutions (0.9% saline) do not cause cells to
either shrink or swell. Hypertonic solutions (one with
greater than 0.9% saline) cause cells to shrink by moving
water from within the cell to the ECF compartment, which
has less sodium than the cell. Hypotonic solutions (such as
5% dextrose and 0.2% normal saline) cause cells to swell.
Diffusion is the movement of a substance (electrolytes
and nonelectrolytes) from an area of higher concentration
to one of lower concentration through a solution or gas
(Fig. 11-4). Diffusion ceases when equilibrium occurs.
Electrical potential differences and pressure differences
across the pores of a semipermeable membrane also
influence diffusion, although the most important factor
determining the rate of diffusion is the concentration
difference. The greater the concentration difference, the
greater the rate of diffusion.
Molecules moving via simple diffusion must possess one
of two capabilities: lipid solubility or a negative charge. The
lipid-soluble molecules, such as oxygen, carbon dioxide,
and alcohol, are able to diffuse readily through the lipid
component of the cell membrane. Chloride is an example of
a negatively charged particle able to pass easily through the
membrane pores.
Filtration is the transfer of water and dissolved substances through a semipermeable membrane from a region

+

t

Plasma Osmolality

Plasma Osmolality

--

x

x

x
Cell shrinks
•

x

Cell swells

Represents amount of osmotically active solute

Fig.11-3 Fluid movement with changes in osmolality. (From Toto KH: Regulation of plasma osmolality:
thirst and vasopressin, Crit Care Nurs Clill North Am 6:662, 1994.)
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of high pressure to a region of low pressure. The force
causing filtration is hydrostatic pressure. An example of
filtration is the passage of water and electrolytes from the
arterial capillary bed to the ISF in response to blood
pressure. The pumping action of the heart causes the
hydrostatic pressure. 2
Movement against a concentration or electrochemical
gradient is known as active transport, and energy, in the
form of adenosine triphosphatase (ATPase), is required for
the activity (Fig. 11-5). The transport occurs somewhat like
a "pump" in the membrane of the cell, driven by the energy

A

B

10M UREA

1M UREA

Fluid Volume Regulation
Water is the most abundant component of the body.
Although serving a vital role in the regulation of body heat
through insulation or evaporation, water further serves as
the diluent for cell solids and as a message carrier among the

Peritubular
Capillary

Cell
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generated by cellular respiration. Regulation and distribution of sodium and potassium within the interstitial and
the intracellular fluid compartments are via the sodiumpotassium pump. Active transport is necessary to move
sodium from the cells to the ECF compartment. The active
process of pumping sodium out of the cells forces potassium
into the cell.
An example of the effects of the sodium-potassium pump
is seen in children with severe bums. The injury causes more
sodium than water to be drawn into the interstitial spaces.
This decreases the efficiency of the sodium pump, which
allows more water and sodium to enter the intracellular
space. The increased osmotic pressure gradient drives
potassium out of the cell. The loss of water and sodium from
the intravascular space results in the increased secretion of
aldosterone and antidiuretic hormone (ADH) as compensatory mechanisms, which contributes to the retention of
sodium and water.
Not only is energy required to move substances against a
concentration gradient, but a carrier substance is required
for the transport of sodium, potassium, chloride, sugars, and
amino acids. Carrier substances are either a protein or a
lipoprotein. The protein carriers function by providing an
attachment site for the specific substance to be transported.
The lipoprotein facilitates the solubility of the substance in
the lipid portion of the cell membrane.

Fig. 11-4 Simple diffusion. A membrane permeable to urea
separates two solutions. Side A contains a tenfold greater
concentration of urea than side B. Random motion of individual
solute molecules results in net movement of urea from A to B.
(From Wright E. Schulman G: Dynamics of body water: principles
of epithelial transport. In Maxwell MH, Kleeman CR, Narins RG,
eds: Clinical disorders of fluid and electrolyle metabolism.
New York, 1985, McGraw-Hill, p 17.)

Interstitium
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B
Fig. 11-5 A, Basic mechanism for active transport of sodium through a layer of cell. This figure shows
active transport by the sodium potassium pump, which pumps sodium out of the basolateral membrane of
the cell and simultaneously creates a very low intracellular sodium concentration, as well as a negative
intracellular potential. The low intracellular sodium concentration and the negative potential then cause
sodium ions to diffuse from the tubular lumen into the cell through the brush border. B, Net mechanism
for active transport of sodium from the tubular lumen all the way into the peri tubular capillary. (From
Guyton AC: TeXlbook of medical physiology, ed 9, Philadelphia, 1996, WB Saunders, p 54.)
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cells, tissues, and organs of the body. Water also provides
the body with form and structure.
Renal regulation of water and sodium is the most
important mechanism of volume regulation. This occurs
through normal functioning of the nephron in conjunction
with certain hormonal factors, including ADH, aldosterone,
and natriuretic factors. 4
Nephron. Sodium is filtered at the glomerulus and is
reabsorbed by the renal tubules. In the normally functioning
nephron, 99% of the filtered load of sodium is reabsorbed.
However, changes in the glomerular filtration rate (GFR)
affect the amount of sodium that is reabsorbed or excreted.
The GFR increases over the first 2 years of life, stabilizing
in a range between 30% to 50% of adult levels by the end
of the first year and reaching adult levels by the age of
2 years. s During times of volume expansion, the GFR
increases, and sodium and water excretion are increased in
an attempt to return intravascular volume to normal levels.
In contrast, in times of volume depletion, the GFR
decreases, and more sodium and water are retained in an
attempt to restore intravascular volume. I
Antidiuretic Hormone. ADH, or vasopressin, is
manufactured in the hypothalamus of the brain and is
released by the posterior pituitary gland. ADH acts on the
cells of the renal collecting ducts to increase their permeability to water, promoting a simultaneous increase in ECF
compartment volume and decrease in urinary output through
selecti ve reabsorption of water without sodium.
Three major stimuli for the regulation of ADH secretion
are (I) plasma osmolality, (2) changes in the ECF compartment volume, and (3) changes in arterial blood pressure.
When sufficient water is not being taken in or excessive loss
occurs, serum osmolality rises. A small increase in serum
osmolality of 1% to 2% is sufficient to cause ADH release,
which acts at the nephrons, signaling them to conserve water
and produce a more concentrated urine. ADH is released
when the osmotic pressure of the ECF compartment is
greater than that of the cells (e.g., during hyperglycemic and
hypernatremic states). When osmotic pressure of the ECF
compartment is less than that of the cells, ADH is inhibited,
causing renal excretion of water? When the blood pressure
falls or blood volume decreases, ADH is also released.
ADH has a direct vasoconstrictor effect on the blood
vessels, resulting in elevation of blood pressure. Other
stimuli affecting ADH secretion are angiotensin II, drugs
(opiates, nicotine, barbiturates, alcohol), stress, and severe
pain. Release of angiotensin II, stress reaction, and severe
pain cause release of ADH and thus increase blood pressure.
Opiates, barbiturates, and alcohol reduce ADH secretion and
are associated with decreases in blood pressure.
Aldosterone. The adrenal cortex secretes aldosterone, which is a mineralocorticoid and a primary influence
in fluid homeostasis. Sodium depletion, increases in potassium concentration, angiotensin II, and adrenocorticotropic
hormone (ACTH) stimulate aldosterone release. The distal
renal tubules, sweat glands, salivary glands, and intestines
are the receptors of aldosterone activity.
Aldosterone causes the renal retention of sodium and
water in exchange for the excretion of potassium and

hydrogen. When the serum level of sodium falls, aldosterone is secreted. This leads to sodium and water retention in
the renal tubules. Potassium is then given up by the renal
tubules in a further effort to increase sodium levels. When
aldosterone secretion is inhibited, potassium is retained, and
sodium and water are excreted. Aldosterone helps regulate
blood volume by regulating sodium retention.
Natriuretic Factors. Natriuretic factors are saltlosing hormones that influence blood pressure and blood
volume. These factors are produced by the hypothalamus
and by the left and right atrial walls of the heart. The
natriuretic hormone produced by the heart is atrial natriuretic factor (ANF). ANF is released when the atria are
stretched, as in volume overload. Once released, ANF acts
on the kidneys, where sodium reabsorption is inhibited, and
a salt diuresis results.

MONITORING FLUID AND
ELECTROLVTE BALANCE
A significant focus in the management of fluid and
electrolyte balance involves monitoring for the occurrence
or worsening of imbalances. Monitoring for fluid and
electrolyte imbalances requires an understanding of the
physiologic mechanisms behind the imbalances in addition
to the clinical signs.

Clinical Assessment
Clinical assessment of the critically ill infant or child is a
critical component in monitoring fluid and electrolyte
balance. Suspicious findings often precipitate validation
with invasive monitoring or diagnostic testing. Table 11-3
summarizes the clinical signs and symptoms associated with
the most common fluid volume and electrolyte imbalances.
Key components of the cardiovascular system include the
assessment of the patient's cardiac output and perfusion:
heart rate, blood pressure, strength and quality of central and
peripheral pulses, capillary refill time, color of the mucous
membranes, and perfusion of extremities. 6 The presence of
edema or hepatomegaly is assessed. A gallop rhythm,
indicative of volume overload, may be noted on cardiac
auscultation. Changes in the patient's electrocardiogram
(ECG) may indicate various electrolyte imbalances. Table
11-4 summarizes the ECG abnormalities associated with
various electrolyte imbalances.
Respiratory system examination includes an assessment
of the patient's respiratory effort, an increase or decrease in
respiratory rate and depth, and work of breathing. The
presence of rales on auscultation, indicating fluid volume
excess, is observed.
Key components of the neurologic examination include an assessment of the patient's level of consciousness (i.e., confusion, lethargy, orientation) and presence
of seizures. In addition, the patient is assessed for hyporeflexia or hyperreflexia, muscle cramps, paresthesias,
tetany, and Chvostek's or Trousseau's sign. Chvostek's
sign is twitching of the facial muscle in response to
gentle percussion at the top of the cheek just below the
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11-3 Clinical Signs and Symptoms Associated With Common Fluid
andElectl"olyte Imbalances

TABLE

;;if-~!

~mbalance

Clinical Signs and Symptoms

);1:

truid volume deficit

!3',;lli'Iuid volume excess

~ftyponatremia
jk':

hjf:Na <135 mEqlL
~,
!i1iHypernatremia
iflC',
~,' Na >145 mEqlL
iIypokalemia
<3.5 mEq/L
~}liyperkalemia
jlW. K >5.5 mEqlL
llHypocaIcemia
:@
Ca <8 mg/dl

p;tK

If

~ypercaIcemia

arCa >10.5 mg/dl
11lliH'
, ',, ypochloremia
Mi c ..
i~ICI <95 mEqlL
liii:Hyperchloremia
iii" Cl > 108 mEqlL
!=i:'
~i
fPypophosphatemia
~r:' PO. <3 mg/dl
!l!F'"~

~~;JiIyperphosphatemia

l.tPO. >4.5 mg/dl

~~ypomagnesemia

1&'; :

1~:Mg <1.4 mEqlL

liiJlypermagnesemia
111:... Mg >2.5 mEqIL
iii;

TABLE

Acute weight loss, J. urine output. J. central venous pressure, altered level of consciousness, dry skin
and mucous membranes
Acute weight gain, edema. i central venous pressure, tachypnea, hepatomegaly
Lethargy, disorientation (may progress to seizures or coma), muscle cramps, nausea/vomiting
Irritability, lethargy, i muscle tone, coma
Muscle weakness, abdominal distension, paralytic ileus, lethargy, irritability, hyperreflexia, tetany,
nausea/vomiting
Muscle weakness, confusion, ascending paralysis, altered cardiac function, nausea, diarrhea,
hyperactive bowel sounds
Tingling around the mouth or in fingenips/hands, Chvostek's or Trousseau's signs, muscle cramps,
lethargy, seizures, hypotension
Lethargy, stupor (can progress to coma), seizures, anorexia, nausea/vomiting
Hyperirritability; agitation; muscle weakness; tetany; slow, shallow respirations
Muscle weakness; decreased level of consciousness; deep, rapid respirations
Irritability, disorientation, tremors, seizures, hemolytic anemia, J. myocardial function, potential
respiratory failure, potential coma
Tachycardia, hyperreflexia, abdominal cramps, nausea, diarrhea, muscle tetany
Neuromuscular excitability, vertigo, ataxia, nystagmus, tetany, respiratory depression, tachycardia,
hypertension, confusion, dizziness, headache, hallucinations, seizures, coma
Lethargy, muscle weakness, inability to swallow, ,J. gag reflex, bradycardia, hypotension, hyporeflexia

11-4 ,Common ECG Abnormalities Associated With Electrolyte Imbalances

.,
'Iectrolyte Imbalance

ECG Findings

l!Rypokalemia
I!~yperkalemia

Flattened, inverted T waves; presence of U waves
Tall, peaked T waves, followed by widened QRS and prolonged PR interval; can progress to
ventricular arrhythmias and cardiac arrest
Prolonged QT interval
Shortened QT interval
Premature ectopic beats
Premature ventricular contractions, ventricular tachycardia, ventricular fibrillation
Prolonged PR, QRS, and QT intervals; AV block

~5I

Il-iypocalcemia
l'i~ypercaJcemia

~~ypophosphatemia

:1':'--

•

~ypomagneseml3

!lIyperrnagnesemia

zygomatic bone. Trousseau's sign is carpopedal spasm
produced by prolonged blood pressure cuff inflation (>3
minutes). Both of these signs are clinical manifestations of
hypocalcemia.
The renal examination provides important information
regarding fluid volume status. This examination includes an
assessment of the patient's urine output and urine specific
gravity, hourly assessment of intake and output, and patient
weight. Trends in weight gain or weight loss are assessed
using the same scale with notations of any items weighed

with the child (i.e., arm board, dressings). The severity of
alterations in fluid volume is estimated by changes in body
weight (I liter of water is equivalent to 1 kg of body weight).
Significant increases in weight gains are 50 g124 hours in the
infant, 200 g124 hours in the child, and 500 g/24 hours in the
adolescent.
The skin and mucous membranes are examined for
moisture and elasticity. The skin in a patient with a fluid
volume deficit is typically dry and warm. Mucous membranes may also be dry.
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Laboratory Tests
Urea is measured in the blood as blood urea nitrogen (BUN)
(normal level: 8 to 25 mg/dl). Urea is produced as the end
product of protein metabolism and occurs as the result of the
breakdown of ammonia in the liver. An elevated BUN may
be associated with reduced renal blood flow secondary to
fluid volume depletion. However, it may also be elevated as
the result of increased protein intake. A decreased BUN is
associated with fluid volume excess and with malnutrition
or liver failure. 2
Creatinine (normal level: 0.6 to 1.2 mg/dl) is an end
product of protein metabolism synthesized in muscle cells
and excreted by the kidney. An elevated creatinine usually
indicates volume depletion or impaired renal function. A
decrease in creatinine may be seen with fluid volume excess.
Creatinine is a more specific indicator of kidney function
than BUN because nonrenal causes of creatinine elevation
are minimal. However, creatine may also rise in instances of
muscle injury (crushing injuries, burns, etc.) independent of
renal function. 4 Therefore the BUN/creatinine ratio is a
more accurate indicator of fluid volume status than either
value alone.
The BUN/creatinine ratio (normal value: 10: Ito 15: I)
is useful in evaluating hydration status. An elevation in the
BUN/creatinine ratio is associated with a decrease in renal
perfusion or increased protein metabolism. A decrease in
this ratio may be due to low protein intake, hepatic
insufficiency, or repeated dialysis. The patient with an
increase in both BUN and creatinine who maintains a ratio
of 10: I may have intrinsic renal disease?
Serum sodium levels (normal value: 135 to 145 mEqlL)
are closely related to fluid volume status. However, this
value alone is not an indicator of volume status. Both
fluid volume depletion and excess can be associated
with a normal, decreased, or elevated serum sodium. As a
result, serum sodium must be evaluated in light of the
physical findings, water balance, and other laboratory
values.
The serum osmolality (normal value: 280 to 295
mOsmIL) is determined mainly by serum sodium concentration. An elevated osmolality may indicate hypernatremic dehydration, hyperglycemia, or an elevated BUN.
A decreased osmolality is seen in patients who are
hyponatremic and may be seen with euvolemia, hypovolemia, hypervolemia.
Hematocrit (normal values: males, 40% to 52%; females, 37% to 46%) is the percentage of red blood cells in
plasma. Plasma volume is ECF and red cell volume is ICF.
Changes in plasma volume may result in changes in the
hematocrit. An elevated hematocrit is seen in fluid volume
depletion, and a decreased hematocrit is seen in fluid
volume excess. However, these changes may only be
interpreted in terms of fluid balance in the absence of
changes of red cell mass (i.e., bleeding or hemolysis).
Total protein values (normal level: 6.3 to 8.2 g/dl) are
affected by changes in volume status in a similar manner to
hematocrit values. An elevation in total protein reflects a
volume-depleted state. A decrease in total protein is the
result of the dilutional effect of a volume-overloaded state.

Urine specific gravity (USG) (1.010 to 1.030) and urine
osmolality (50 to 1200 mOsm/kg) are a reflection of the
kidney's ability to concentrate and dilute. In states of
volume depletion associated with normal kidney function,
both the USG and the osmolality are typically elevated. The
urine volume is usually diminished except in the instance of
an osmotic diuresis. In volume-overloaded states, the urine
is typically dilute with a decreased USG and osmolality and
an increased volume. However, infant kidneys have a
limited ability to concentrate urine,2 and USG values may
not be as helpful in the assessment of fluid volume status in
this population.
Urine sodium values tend to vary with changes in
volume status in much the same manner as USG and
osmolality values do. Urine sodium is typically decreased in
volume-depleted states and increased in volume-overloaded
states. In volume-depleted states, the kidneys attempt to
hold onto water and sodium in an effort to restore and
maintain intravascular volume. In volume-overloaded
states, the kidneys attempt to excrete water and sodium.
Exceptions to this occur in renal failure in which the kidney
loses its ability to concentrate urine. As a result, urine in
renal failure may be dilute, and urine sodium values will not
change, regardless of volume status. 4

SUPPORT OF FLUID AND
ELECTROLYTE BALANCE
Intravenous (IV) therapy is the most common type of
therapy used to support the balance of fluids and electrolytes. It allows more rapid replacement of fluids and
electrolytes than oral administration. 6 In addition, oral
administration is not always the most practical method in the
critically ill infant or child. Table 11-5 describes the most
commonly used IV solutions in critically ill children.
Diuretics are commonly used to increase the urine output
and excretion of sodium and chloride. These agents act by
decreasing the rate of sodium reabsorption by the kidney
tubules, which in turn leads to natriuresis and diuresis 8
Diuretics are most commonly used to decrease extracellular
volume. For the most part, diuretics can be grouped into
three major classes: loop diuretics, thiazide-type diuretics,
and potassium-sparing diuretics. Table I I-6 provides an
overview of some commonly used diuretics.
IV administration of electrolyte supplements is another
therapy in the management of fluid and electrolyte imbalances. Table 11-7 presents suggested guidelines for the
administration of these solutions.

ALTERATIONS IN FLUID
VOLUME BALANCE
Fluid Volume Deficit
Etiology. Fluid volume deficit is defined as negative
body fluid or water balance. When extracellular volume
depletion is present, hypovolemia exists, and circulatory
collapse can result. In infants and children, fluid volume
deficit and dehydration are terms often used interchange-
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Composition of Common Parenteral Fluid Solutions

'!':"

~.-

Ionic Concentrations (mEq/l)

~;;

it..solution

it"

Solute

Glucose
Glucose

Concentration
(g/dl)

5
10

pH

lactate

4.7
4.6

Calculated Osm
(mOsm/l)

250
505

5.3
5.3

77
154

77
154

155
310

4.9

77

77

280

4.6

34

34

320

4.6

77

77

405

4.6

154

154

560

6.3

130

5.1

65

2

5.0

26

0.8

0.5

0.31
0.60
0.03
0.02

4.7

130

4

3

5

6.9

154

NaCI
NaCI

0.45
0.9

Glucose
NaCI
Glucose
NaCI
Glucose
NaCI
Glucose
NaCI

2.5
0.45
5
0.20
0.45
5
0.90

Lactate
NaCI
KCI
CaCl 2

0.31
0.60
0.03
0.02

Glucose
Lactate
NaCl
KCI
CaCl z
Glucose
Lactate
NaCI
KCI
CaCl 2
Glucose
Lactate
NaCl
KCI
CaCl z
Albumin
NaCl

2.5
0.155
0.30
0.015
0.01

5

4

3

109

.015

54

28

14

275

265

4
0.062
0.12
0.006

22

5.5

280

0.004
5
109

154

28

515

310

0.9

ably. Fluid volume deficit is a common problem in critically
ill infants and children. Negative water balance occurs from
(l) excess loss of fluids and electrolytes, which can result
from diarrhea or vomiting; (2) shifts of fluids and electrolytes into nonaccessible third spaces, such as in the severely
burned child or following abdominal surgery; and (3) decreased intake of fluid and electrolytes, such as in the child
who has nothing by mouth (is NPO)9
Excessive fluid volume loss and loss of electrolytes are
major contributing factors to dehydration in infants and

children. Increased insensible water loss may occur with
bums, hyperventilation, fever, renal or gastrointestinal
disease, increased ambient temperature, diaphoresis, and
cystic fibrosis. As much as 400 to 2000 mUm2 of water may
be lost each day in children losing fluid as a result of
diaphoresis. 10 Tn cystic fibrosis, not only is excessive fluid
lost, but sodium losses in sweat may vary belween 50 and
130 rnEqlL. II Tncreased renal waler loss occurs as a result
of osmotic diuresis, central diabetes insipidus, impaired
tubular response to ADH, renal IUbular dysfunction, and
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Diuretic Overview
Diuretic Mechanism of Action

T excretion of Na and

Dose

Complications

J, serum K, Na, Mg
Volume depletion
Ototoxicity
Metabolic alkalosis

CI by inhibiting

reabsorption

1-2 mg/kg/dose IV
2-4 mg/kg/dose PO
0.25-0.5 mg/dose IV
0.01-0.02 mg/kg/dose PO

J, NaCI entry into cell

Volume depletion

J, serum K, Na
Metabolic alkalosis
10-20 mg/kg/day PO
0.1-0.4 mg/kg/day PO

T serum K
Metabolic acidosis

Depresses reabsorption of Na
Depresses excretion of K
1.3-3 mg/kg/day PO

J, osmotic pressure

Volume depletion

J, serum K, Na
Metabolic acidosis
0.25-2 g/kg/dose IV
,$i.;

14'Pata from Sherbotie JR, Kaplan BS: Diuretics. In Yaffe SJ, Aranda JV, eds: Pediatric pharmacology: therapeutic principles in practice, Philadelphia,
liiil992, WB Saunders, pp 524-534.
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TABLE

11-7

~Electrolyte

WE:

>otassium (chloride)

Suggested Guidelines for Administration of Electrolyte Solutions
Administration Guidelines

Monitoring

Hypertonic saline (3%) may be given for severe
hyponatremia «120 mEqlL) when the patient is
symptomatic. The amount of hypertonic saline
solution needed can be calculated by the following
formula: mEq Na =(0.60) (body weight in kg)
(125 - Na). Discontinue infusion when serum
Na reaches 120-125 mEqlL and begin water
restriction.

Monitor serum sodium frequently.
Administer through large vein.
Maximum rate: 1 mEq/kg/hr.

IV push or undiluted potassium is never
administered.
Recommended maximum dose is 0.5 mEq/kg/hr in
children, although dosages of 0.25-1 mEq/kg/hr
may be used for severe depletion.
Recommended maximum concentration for solution for
peripheral lines is 40 mEq/L to prevent local irritation
at infusion site.
Recommended maximum concentration for infusion for
central lines is I mEq/2 m!.
Infusion rates of less than 0.3 mEq/kg/hr and concentrations of less than 60 mEq/L are usually adequate for
replacement and maintenance of potassium.

Continuous ECG monitoring is
necessary during KCI intermillent
infusion(0.5 mEq/kg/hr).
Monitor serum potassium levels
frequently.
Use with caution in patients with
renal impairment (avoid use if
patient is anuric or severely
oliguric).

Cominued
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11-7 Suggested Guidelines for Administration of Electrolyte Solutions--:-cont'd

~

~!Iectrolyte

Administration Guidelines

Monitoring

Administer slowly (no faster than 50 mg/min for CaCI 2 ;
100 mg/min for Ca gluconate) into a central line (in an
emergent situation, may be given into a peripheral line
if no central access is available).
May be administered by continuous infusion via peripheral intravenous line. Maximum concentration should
not exceed 20 mg/m!.
Administer boluses in a dextrose or saline solution with
no additives. Calcium is incompatible with many
medications. Boluses are not administered in parenteral
nutrition solutions or with intralipids.

Monitor intravenous site closely.
Necrosis and sloughing will occur
with extravasation.
Monitor patients taking digoxin who
are receiving calcium supplements
closely because elevated calcium
levels precipitate digoxin-related
arrhythmias.
(Monitor for bradycardia, hypotension, and cardiac arrhythmias.)

~»hosphorus

Potassium or sodium phosphate can be diluted in IV
maintenance fluids; infusion rate should not exceed
0.05 mmoUkg/hr. The usual dose for both is
0.15-0.33 mmoUkg/dose IV over 6 hours.

Side effects associated with
rapid administration include
hypotension.

, ,?IMagnesium (sulfate)

Administration by IV push is not recommended but in
emergent situations may be diluted to 10 mg/ml and
given slowly over 3-5 min. Dose should not
exceed 150 mg/min. ECG should be monitored
during administration.
Infusions are recommended to be diluted to <10 mg/ml
and infused over at least 15-30 min. Maximum
concentration is 200 mg/m!.

Monitor patient closely for signs of
hyperrnagnesemia. Cardiac arrest
may occur with magnesium levels
of 12-15 mEqrL.

!C',

~!~alcium (chloride, gluconate)
~ii::

~}

i:i

i
!!'I'

~ti

I~'

I

sodium wasting conditions. 12 Gastrointestinal water loss
from diarrheal disease is ordinarily the most common cause
of excess fluid volume loss in infants and children.
In the critically ill child, fluid volume loss through "third
spacing" is a common cause of fluid volume deficit. Third
spacing occurs when extracellular fluid compartment volume is shifted into cavities, where it accumulates and is
physiologically inaccessible for use by the body. Third
spacing develops in ascites, pancreatitis, bums, peritonitis,
sepsis, and intestinal obstruction.
Fluid deficit produced by inadequate intake is primarily
caused by unreplaced normal insensible water loss. Examples of underlying clinical problems that contribute to
decreased intake are coma, dysphagia, debilitation, impaired
thirst, or anorexia. In addition, intake may not be adequate
if ongoing losses are undetected or excessive.
Pathophysiology. Dehydration is usually classified
on the basis of the serum sodium level because the level
in dehydrated patients may be low, normal, or high,
depending on electrolyte losses. Dehydration is classified as
hyponatremic when serum sodium levels are less than
130 mEqlL, isonatremic when serum sodium levels are
130 to 150 mEqlL, and hypematremic when serum sodium
levels are above 150 mEqlLY These forms of dehydration
are also hypotonic, isotonic, and hypertonic, respectively,
because plasma osmolality reflects sodium concentration.
However, the two sets of terms cannot be used interchangeably because changes in tonicity do not always indicate
sodium concentration.

Hyponatremic dehydration occurs when there is a
proportionately greater loss of sodium compared with fluid
loss. This often results when a child who is experiencing
diarrhea or vomiting at home is given a hypotonic fluid such
as water. An osmolar gradient results and produces a fluid
shift from the hyponatremic extracellular space into the
intracellular space, increasing the ECF compartment loss.
Isonatremic dehydration occurs when equal amounts of
fluid and electrolytes are lost. When there is no osmolar
gradient and isotonicity exists, the resultant fluid volume
depletion is primarily extracellular.
Hypernatremic dehydration is characterized by an increased osmolality of the ECF compartment, which results
in a shift of fluid from within the cells to maintain osmolar
equilibrium. 9 ICF compartment volume is depleted, and
ECF compartment loss is less than expected.
Critical Care Management. In addition to the previously discussed components of the physical examination,
an estimate of the degree of dehydration is made, based on
the child's physical examination and weight loss (Tables
11-8 and 11-9). An estimate of fluid loss is made by
considering that I g of weight is equal to I ml of fluid.
Adelman and Solhaug 13 also note that fluid loss can be
approximated by capillary refill time. Specifically, a capillary refill of less than 2 seconds is associated with a fluid
loss of less than 50 ml/kg; capillary refill time of 2 to 3
seconds is associated with losses of 50 to 90 ml/kg; and
capillary refill time greater than 3 seconds occurs with losses
of 100 ml/kg or more.
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TABLE 11·8

Clinical Assessment of Severity of Dehydration

F~

~,;Signs and Symptoms

:'\,

~,G:eneral Appearance and

~'!nfants and young children

Moderate Dehydration

Severe Dehydration

Thirsty, alert, restless

Thirsty, restless or lethargic but
irritable to touch or drowsy

Drowsy, limp, cold, sweaty,
cyanotic extremities, may
be comatose

Thirsty. alert, restless

Thirsty, alert, postural
hypotension

Usually conscious, apprehensive,
cold, sweaty, cyanotic extremities, wrinkled skin of fingers
and toes, muscle cramps

Normal rate and strength

Rapid and weak

Rapid, feeble, sometimes
impalpable

Mild Dehydration

Condition

~.

IDi.~;:·
~~~

iili-Dlder children and adults
~

jJj'

Jii

~:E

@~J

~adial
!l:~

pulse

i!r
Hi;

~iRespiration

Normal

Deep, may be rapid

Deep and rapid

1:':Anterior fontanelle

Normal

Sunken

Very sunken

l§ystOJiC blood pressure

Normal

Normal or low
Orthostatic hypotension

Low, may be unrecordable

Pinch retracts immediately

Pinch retracts slowly

Pinch retracts very slowly
(>2 seconds)

Normal

Sunken (detectable)

Grossly sunken

i1'[]I'e ars

Present

Absent

Absent

fp):Mucous membranes

Moist

Dry

Very dry

Normal

Reduced amount and dark

None passed for several hours,
empty bladder

m~;;

lrt~

!RSkin elasticity
~~~,

!iW:
ill!!

W;:13yes

iti\'

1'~"

l1lrYrine output

i~:~;
~¥ody weight loss

3%-5%

6%-9%

~IO%

ii!iEstimated fluid deficit

30-50 m1/kg

60-90 mUkg

~IOO

ml/kg

iV'
Ibata from Adelman RD, Solhaug MJ; Pathophysiology of body fluids and fluid therapy. In Behonan RE. ed; Nelson textbook oJ pediatrics, ed 15.
j['-Philadelphia, 1996, WB Saunders. pp 185-222.

=iT'-

TABLE 11-9

til

~i;ECF

Effects of Type of Dehydration on Physical Signs

volume

~jiCF volume

Isonatremic Dehydration
(Proportionate Loss of
Water and Sodium)

Hyponatremic Dehydration
(Loss of Sodium in Excess

of Water)

Hypernatremic Dehydration
(Loss of Water in Excess
of Sodium)

Markedly decreased

Severely decreased

Decreased

Maintained

Increased

Decreased

Gray
Cold
Poor
Dry
Dry
Sunken and Soft
Sunken
Lethargic
Rapid
Low

Gray
Cold
Very poor
Clammy
Slightly moist
Sunken and soft
Sunken
Coma
Rapid
Very low

Gray
Cold or hot
Fair
Thickened, doughy
Parchedt
Sunken
Sunken
Hyperirritable
Moderately rapid
Moderately low

~rhysical signs
~.

!r.i".

Skin color*

~~ii Temperature

i,i!: Turgort

~~:;, Feel
lffii"
jiir:' Mucous membranes

flii.

Eyeball

~k,: Fontanelle

lirQj'- Pulse*
Psyche

~" Blood pressure*
!ill'..
Jf·

!I'Data from McCarthy PL: General considerations in the care of sick children. In Behonan RE. ed; Nelson textbook oJpediatric.., ed 14. Philadelphia. 1992.
~iwB Saunders, pp 17 1-21 L
~:*Signs of shock rather than of dehydration itself.
!li:tReflects magnitude of fluid loss from ECF.
i!4Tongue often has shriveled appearance because of loss of cellular fluid.
ij'ECr; Extracellular fluid; fCr; Intracellular fluid.
.
~.-.
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Initial therapy for the child with a fluid volume deficit is
directed toward quickly expanding ECF compartment volume to treat or prevent shock. Repeated boluses of 10 to
20 ml/kg of Ringer's lactate or normal saline (NS) is usually
administered. For the child with severe dehydration, rapid
fluid resuscitation with up to 60 mIlkg may be necessary.
Peripheral perfusion, heart rate, urine output, and blood
pressure are monitored to determine the child's response to
therapy.
Once initial resuscitation has been accomplished, therapy is directed toward definitive water and electrolyte
replacement. For isotonic or hypotonic dehydration, one
half of the calculated fluid loss is replaced along with
maintenance fluids over the next 8 hours, usually with 5%
dextrose and 0.45% NS. 14 The calculated fluid loss can be
determined by multiplying the assessed percentage of dehydration by the child's body weight. For example, a lO-kg
child who is 10% dehydrated has lost 10% of his or her body
weight. or 100 mIlkg, for a total fluid loss of 1000 m!. 14
Calculation of maintenance fluid is presented in Table

It) of Maintenance Fluid
TABLE

11.,10

~.j',

Calculation

rJ'er Day Body Weight (kg)
sr.~

Fluid Requirements/Day

100 ml/kg
1000 ml + 50 mllkg for each
kg above 10
1500 ml + 20 ml/kg for each
kg above 20
Fluid Requirements/Hr

4 mllkg
2 mllkg for each kg
above 10
1 mVkg for each kg
above 20

TABLE

11·11
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11-10. Potassium chloride (20 mEqlL) may be added once
urine output has been established. Ongoing losses may be
replaced concurrently with Ringer's lactate. The other half
of the calculated loss along with maintenance fluid is replaced over the next 16 hours, usually with 5% dextrose and
0.45% NS with 20 mEqlL of potassium. The resuscitation
bolus of Ringer's lactate or NS is not included in the calculation to determine deficit and maintenance needs. 14 An example of fluid replacement in a dehydrated child is presented in Table II-II.
Fluid resuscitation as described earlier is the initial
treatment, if appropriate, for moderate to severe dehydration. After initial therapy, further replacement is calculated
as maintenance plus estimated fluid deficit given evenly
over the next 48 to 72 hours, with 5% dextrose and 0.2% NS
being the fluid of choice. Fluid replacement that occurs too
rapidly can precipitate neurologic complications hallmarked
by seizure activity.
An additional early consideration for the child with
hyponatremic dehydration is sodium replacement. If
the child is severely hyponatremic (serum sodium
<120 mEqlL), a 3% solution of sodium chloride (NaCl) can
be rapidly given. Four ml/kg is usually given over 10 minutes to return the serum sodium level to 125 mEqlL. 14
The extent of hypernatremic dehydration is more difficult to assess because water moves from the intracellular to
the extracellular space, thus preserving the circulating
volume. Seizures may develop before or during replacement
therapy and are thought to be the result of intracellular
dehydration. Long-term neurologic sequelae and death may
result.
Serum Na correction in hypernatremia takes place no
faster than 0.5 to I mEqlL/hr because rapid correction of
serum sodium can lead to cerebral edema. During replacement therapy, serum sodium levels are monitored every 4
hours. If serum sodium levels decrease too rapidly, the rate
of hydration is decreased or the sodium content in the
replacement fluid is increased. If levels decrease too slowly,
the rate of hydration is increased. If the child demonstrates
neurologic symptoms, cerebral edema is suspected and
treated.

Fluid Replacement in Dehydration

i~o calculate the fluid requirements for a 20-kg child who is 10% dehydrated (serum sodium level of 132 mEqIL).
:if<,peficit
20 kg xl0% (or 100 ml/kg) = 2000 ml
,jfJtviaintenance
(10 kg x 4 ml/kg/hr) + (10 kg x 2 ml/kg/hr) = 60 ml/hr
n;

~j:rime

Administered Fluid

j,,,!

t'.O-30 minutes

20 ml/kg Ringer's lactate

[:;;30 min-8 hours

1/2 the deficit (1000 ml)/8 hours = 125 ml/hr + maintenance fluids (60 ml/hr) or 185 ml/hr of
Ds .45 NS + 20 mEqlL potassium
1/2 the deficit (1000 ml)1I6 hours = 63 ml/hr + maintenance fluids (60 ml/hr) or 123 ml/hr of
Ds .45 NS + 20 mEq/L potassium

~t,c
~~;

~'9: 24 hours
~~-

..

iil'rom Wetzel Re: Shock and fluid resuscitation. In Nichols DG et al. eds: Golden hour: the handbook of advanced pediatric life .fl(pport, SI Louis, 1996,

~)fosby.

!j:WS, Nonnal saline.

"Y
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Fluid Volume Excess

ELECTROLYTE DISORDERS

Fluid volume excess or fluid volume overload is defined as the actual excess of total body fluid or
a relative excess in one or more fluid compartments. 6 It
occurs when there is (I) increased sodium concentration and
water volume because of retention and/or excessive intake,
(2) decreased renal excretion of water and sodium, and
(3) decreased mobilization of fluid within the intracellular
space. 6 The major causes of excess fluid volume in critically
ill infants and children are cardiorespiratory dysfunction,
renal dysfunction, and inappropriate secretion of ADH, in
which serum sodium levels are decreased in the presence of
fluid overload.
Pathophysiology. As with dehydration, fluid volume
overload may be classified as isotonic, hypotonic, or
hypertonic. The most commonly occurring types of fluid
volume overload are isotonic and hypotonic 6
Isotonic fluid excess or hypervolemia occurs when excess fluid is in the ECF compartment in both the intravascular and interstitial spaces. Common causes of isotonic fluid
excess include excessive fluid administration or the use of
hypotonic fluids to replace isotonic losses. The hypervolemia causes an increase in blood pressure, which results in
an increased venous return to the heart or increased preload.
This increased preload causes stretching of the myocardium
and an increase in cardiac output. This response stimulates
an increase in the GFR, which results in increased excretion
of water and sodium.
Hypotonic fluid excess is also known as water intoxication. Common causes include syndrome of inappropriate
antidiuretic hormone (SIADH) (see Chapter 23), excessive
water intake, and congestive heart failure. This condition
occurs when the excess fluid is hypotonic to other body
fluids, resulting in a decrease in plasma osmolality. The
resulting osmotic gradient causes ECF compartment to shift
into the ICF compartment. Overexpansion of all body fluid
compartments and dilutional electrolyte deficits then occur.
Critical Care Management. The goal of management is to restore fluid balance, correct any electrolyte imbalances that may be present, and eliminate or control the
cause of the fluid volume excess. The critically ill infant or
child with fluid volume excess has the potential to develop
heart failure and pulmonary or cerebral edema, which are
potentially life-threatening complications. Excessive ECF
compartment volume is usually treated by eradicating the
underlying causes, as well as reducing the excessive volume. General fluid volume excess is treated with fluid restriction and the use of diuretics (if renal function is adequate). Low-dose dopamine may be useful to increase renal
blood flow and promote sodium and water excretion. Sodium restriction may be used to indirectly decrease fluid
retention.
Children with certain conditions, such as septic shock,
may manifest signs and symptoms of pulmonary edema,
despite the presence of hypovolemia. This occurs because of
increased capillary permeability, which results in capillary
"leak." Therefore interventions may be required to treat the
pulmonary edema, increase the ECF compartment volume,
and treat the underlying shock.

Sodium

Etiology.

Sodium is the major cation of the extracellular compartment. It regulates the voltage of action potentials in skeletal
muscles, nerves, and the myocardium. The action or
diffusion potential of the cell membrane occurs in response
to the sodium and potassium concentration in the ECF
compartment and the ICF compartment. Sodium plays a
significant role in the maintenance of acid-base balance
through combining with anions such as chloride and bicarbonate. Sodium is also responsible for the maintenance of
water balance (volume) in the ECF compartment through
maintenance of the osmotic pressure (osmolality). Consequently, imbalances in water and sodium often occur together and are equated with alteration in serum osmolality. Extracellular sodium concentration is normally 135 to
145 mEq/L. The intracellular sodium concentration is usually 3 to 5 mEq/L.
Sodium is actively absorbed by the intestines and
excreted by the kidneys and skin. The kidneys regulate
sodium excretion primarily under the influence of the
renin-angiotensin-aldosterone system. Renin is released by
the kidneys in response to sodium concentration changes in
the tubular fluid. The major factors that influence sodium
excretion are GFR and aldosterone. Alterations in the
sodium levels in the body are often the result of clinical
conditions involving fluid volume excess or deficit.
Hyponatremia

Etiology. Hyponatremia is defined as a serum sodium
concentration below 135 mEq/L. It is usually a secondary
manifestation of another disease state. In the critically ill
child, hyponatremia may occur as the result of excess water
retention in the ECF compartment, sodium loss from the
ECF compartment, or both. Hyponatremia may occur in
conjunction with hypovolemia, euvolemia, or hypervolemia. However, true hyponatremia must be differentiated from pseudohyponatremia. Pseudohyponatremia is
a falsely low serum sodium value that may occur in
patients with hyperlipidemia, hyperproteinemia, or both. In
children, diabetes mellitus is the most common cause of
pseudohyponatremia.
Pathophysiology. Decreases in serum sodium cause
a shift in water from the ECF compartment to the ICF
compartment, resulting in generalized cellular swelling or
edema. In the brain, where there is limited capacity for
expansion, the development of cerebral edema can have
catastrophic consequences (i.e., cerebral herniation and
death). The severity of the sodium deficit and the speed with
which it occurs have the most impact on the severity of
the clinical symptoms. Serum sodium levels of less than
120 mEq/L are associated with seizures and coma. This is
related to the development of cerebral edema, resulting from
cellular swelling, and may be severe enough to cause
cerebral herniation and death. Children who develop hyponatremia less acutely (over several days to weeks) may be
asymptomatic or may develop only lethargy, nausea, and
vomiting.
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Hyponatremia occurs most often with hypervolemia
in situations when the retention of water exceeds that
of sodium. Causes include water intoxication, nephrotic
syndrome, cardiac failure, cirrhosis, renal failure, and
SIADH. In this situation, the hyponatremia is usually
dilutional, so true total body sodium is normal or even
elevated.
Hyponatremia in conjunction with hypovolemia is less
common but may occur with renal or extrarenal losses.
Losses may occur through diarrhea and vomiting, third
spacing, or other disorders such as bums. Other causes
include excessive use of diuretics, osmotic diuresis, and
adrenal insufficiency.
Critical Care Management. The management of a
child with hyponatremia varies depending on the relationship to fluid volume. In severe symptomatic hyponatremia
with hypovolemia, serum sodium levels are rapidly elevated
to 120 to 125 mEqlL by infusion of a hypertonic 3% saline
solution. The amount of 3% saline necessary to raise the
serum sodium level is judged to be 4 ml/kg or is calculated
by the formula 15:
(125 mEq/L - Observed Na+ zmEq/L) x
Body weight (kg) x 0.6 Llkg

A solution of 3% saline contains approximately 0.5 mEq
NalmL and is given at a rate of I mEq/kg/hr (see Table
11-7). Serum sodium levels are monitored closely. If shock
is present because of hypovolemia, 0.9% NS is given
rapidly. Ongoing losses are replaced, and specific treatment
of the underlying cause is given.
Correction of hyponatremia with hypervolemia is directed toward treatment of the underlying cause. Administration of saline to increase sodium levels is not recommended because total body sodium may be normal and
saline infusion may expand the ECF compartment, worsening the situation. TBW may be decreased by fluid restriction
up to as much as 50% maintenance.
Hypernatremia
Etiology.
Hypematremia is defined as an excess of
sodium in the ECF compartment. It exists when serum
sodium levels exceed 145 mEqlL. Hypematremia may occur
as the result of pure sodium excess or of water deficit. Pure
sodium excess is unusual but has been reported as a result of
feeding improperly mixed high-sodium rehydration solutions or formulas to infants or to older children who cannot
gain water by themselves. 16 Sodium excess may also occur
as the result of excessive administration of sodium bicarbonate during resuscitation endeavors.
In addition to an actual increase in sodium, hypematremia can result from losses of water or from water deficit in
excess of sodium deficit. 17 Conditions that produce fluid
deficit and hypernatremia include diabetes insipidus, diabetes mellitus, excess sweating, increased insensible water
loss, diarrhea, dehydration, and lack of thirst. 16
Pathophysiology. Typically, when serum sodium begins to rise, the body responds with the release of ADH and
stimulation of the thirst mechanism in an attempt to retain
water and decrease serum sodium. However, in the critically
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ill infant and child, this response may not be sufficient to
prevent the serum sodium from continuing to rise.
Hypernatremia initially causes a generalized shrinking of
cells as fluid moves from the ICF compartment to the ECF
compartment. Central nervous system (CNS) dysfunction
often accompanies serum sodium concentrations over 158
mEqlL. 9 The CNS changes are thought to be the result of
several mechanisms, including intracellular dehydration;
shift of fluid from brain cells to cerebral vessels leading to
subdural, subarachnoid, and intracerebral bleeding; decreased microvascular perfusion related to increased blood
viscosity caused by increased plasma osmolarity; and
intracranial bleeding caused by damage to the bridging
veins as brain content contracts away from the skull. 15 Symptoms progress from restlessness and irritability through
ataxia and tremulousness, tonic jerks, seizures, and eventually to death if uncorrected. 16 Although the severity of the
symptoms is directly related to the level of excess sodium,
recovery from the CNS dysfunction appears unrelated, and
neurologic sequelae are common?
Critical Care Management. Hypernatremia may
produce serious problems related to CNS dysfunction (see
Table 11-3). The severity of the initial clinical signs is not
predictive of the degree of residual neurologic impairment.
Therefore although careful attention must be directed at
monitoring the child with hypematremia, evaluating children at risk for hypematremia is also important to prevent
neurologic dysfunction from occurring. Frequent assessments of the child's neurologic status, fluid gains and losses,
and serum sodium levels are done throughout the treatment
of hypematremia.
Treatment of hypematremia is directed toward removal
of excess sodium, if present, and correction of the underlying disorder. If fluid volume deficit is severe and shock is
present or imminent, volume expansion must be undertaken,
regardless of sodium levels. Isotonic solutions such as NS or
Ringer's lactate solution are used in initial treatment. After
initial stabilization and blood pressure recovery, hypotonic
fluids may be administered to bring sodium levels down at
the rate of 0.5 mEqlL/hr. 16 More rapid reduction is
associated with neurologic morbidity and mortality. Administration of fluid without sodium is never indicated, even
during correction.
Children with hypernatremia and fluid volume deficit are
at significant risk for cerebral edema and seizures with rapid
correction of fluid deficit. Volume deficits are replaced over
48 to 72 hours after initial intervention to prevent shock.
For children with increased total body sodium and
overhydration, excess sodium may be removed through the
use of diuretics and decreased sodium administration if
renal function is intact. If renal function is not intact,
dialysis may be required. 18

Potassium
Potassium has four major roles in the body. As the primary
intracellular cation, potassium plays an important role in the
action potentials in the nervous system, skin and smooth
muscles, and the cardiac conduction system. Acid-base
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balance is enhanced through the maintenance of electroneutrality of the body fluids. In cell anabolism, potassium is
released from cells when the body relies on cell catabolism
for energy. The biochemical reactions related to carbohydrate metabolism and synthesis of proteins also require
potassium. Maintenance of intracellular osmolarity is accomplished through the sodium-potassium (active transport)
pump (see Fig. 11-5). The normal range of serum potassium
is 3.5 to 5.5 mEq/L, with a concentration of 160 mEq/L
inside the cell.
Potassium excretion is enhanced by aldosterone, an
increase in cellular potassium, and increased activity of the
distal portion of the nephron. Aldosterone is the primary
controller of potassium secretion by the kidneys.
Hypokalemia
Etiology. Hypokalemia is defined as a potassium
deficit in the ECF compartment, with a serum potassium
concentration of less than 3.5 mEq/L. Hypokalemia occurs
as the result of either a true deficit of potassium or a shift in
potassium out of the intravascular space into the intracellular space. Excessive renal secretion, excessive gastrointestinal losses, and excessive sweating or decreased intake of
potassium (rare) 19 can cause a true deficit of potassium. A
shift of potassium out of the intravascular space into the
intracellular space can be caused by an increased cellular
uptake of potassium, which occurs with alkalosis or as the
result of excessive secretion or administration of insulin, or
in relation to increased cell production.
Pathophysiology. Serum potassium levels may not
always provide an accurate representation of total body
stores of potassium. Intracellular stores of potassium are
quite high, and when a deficit in extracellular stores occurs,
small quantities of intracellular potassium can be exchanged
into the extracellular space. As a result, serum levels of
potassium may remain within normal limits even though
body stores are somewhat depleted. However, once this
quantity of exchanged potassium is depleted, decreased
serum potassium levels will indicate a decrease in total body
potassium. 19 In addition, a decrease in serum potassium may
be seen even though total body stores are adequate, as is
seen when alkalosis is present, because alkalosis causes a
shift of intravascular potassium into the cells.
Increased renal excretion of potassium typically occurs
as a result of increased mineralocorticoid activity, acid-base
disturbances, or increased sodium delivery to the nephron.
Hyperaldosteronism increases renal wasting of potassium
and can cause severe hypokalemia. Primary hyperaldosteronism occurs as the result of adrenal adenomas and adrenal
hyperplasia. Secondary hyperaldosteronism is seen in patients with nephrotic syndrome, congestive heart failure, or
malignant hypertension 2
Acid-base disturbances can cause deficits in potassium
stores and hypokalemia as the result of increased potassium loss via the kidneys.23 A decline in serum potassium
accompanies respiratory and metabolic alkalosis because
potassium ions move into the cells to maintain the transmembrane electrical potential. However, the most severe
potassium deficiencies occur with metabolic alkalosis. In

patients who are alkalotic, potassium is taken up by the cells
from the ECF in exchange for hydrogen ions. In the initial
stages of alkalosis, the serum hypokalemia that occurs is
not reflective of body stores. However, as the alkalosis
progresses, a marked depletion of body stores occurs as the
result of increased exchange of potassium for hydrogen
ions. The direction of the change in pH is opposite the
change in serum potassium values.
The use of potassium-losing diuretics, such as thiazides
or furosemide, results in increased sodium delivery to the
distal nephrons. When this occurs in the presence of
increased aldosterone concentrations, an increased amount
of potassium is secreted into the tubular fluid and then lost
in the urine. 19
Gastrointestinal (GI) losses are a common cause of
potassium depletion. The potassium concentration of gastric
fluids is higher than that of serum concentration. Excessive
losses of these fluids (i.e., through vomiting or nasogastric
suctioning) can result in hypokalemia. This condition occurs
because of an actual loss of potassium and as the result of
the metabolic alkalosis associated with the GI losses.
Critical Care Management. Patients at risk for
hypokalemia are monitored for ECG changes and alterations
in their neuromuscular assessment (see Tables 11-3 and
11-4). The most significant problems caused by hypokalemia are related to cardiac dysfunction and muscle paralysis,
including paralytic ileus. Treatment of hypokalemia is
indicated whenever the serum potassium level falls below
3 mEq/L or the child exhibits symptoms related to hypokalemia. 15 Oral replacement is preferred if time and the child's
condition penni!. A dose of 0.5 to I mEq/kg (maximum,
20 mEq) usually corrects the hypokalemia if ongoing losses
are controlled. 15 This dose may be repeated every 4 to
8 hours. If IV replacement is required, concentrations up to
40 mEq/L are considered safe. The underlying cause of the
hypokalemia is considered and treated.
In severe cases of potassium depletion, in which serum
potassium levels are below 2.5 mEq/L, IV potassium
replacement is used. Dosages of 0.25 to I mEq/kg/hr may
be given to correct severe depletion. The correction of
hypokalemia is not an emergency and should be accomplished slowly because too rapid a correction may cause
lethal hyperkalemia. Table 11-7 provides additional recommendations for administration. Continuous ECG monitoring
for T wave assessments and frequent determination of serum
potassium levels are critical to avoid complications associated with hyperkalemia.
If the child is alkalotic, potassium is replaced as the
chloride salt because chloride depletion often accompanies
hypokalemia?O If the child is hypokalemic and acidotic,
serum potassium levels at a normal pH are lower. Thus
correcting the pH before the hypokalemia can make the
serum potassium level dangerously low2o
Hyperkalemia
Etiology. Hyperkalemia is an excess of potassium in
the ECF, existing when the plasma potassium level exceeds
5.5 mEq/L 21 The four general categories of causes are
altered renal excretion, impaired extrarenal regulation, shift
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from the intracellular to extracellular fluid, and increased
potassium intake. 22 Pseudohyperkalemia is relatively common and may be produced by conditions such as an
increased white blood cell count above loo,Ooo/mm 3 or a
platelet count greater than 750,ooO/mm 3 .9 A release of
intracellular potassium during the clotting process results
in the abnormal serum potassium level seen in that
circumstance.
Pathophysiology. Alterations in renal excretion of
potassium may result from either a decrease in the GFR or
a decrease in potassium secretion by the renal tubules?!
Conditions associated with altered renal excretion include
renal dysfunction and the administration of potassiumsparing diuretics such as spironolactone and triamterene. 22
Children with long-standing or congenital urologic abnormalities are likely to demonstrate subtly impaired renal
potassium excretion. Reflux nephropathy, prune-belly syndrome, and obstructions associated with bilateral hydronephrosis are likely to be associated with dysfunction of
tubular epithelium leading to abnormalities of potassium
excretion?2
Impaired extrarenal regulation may be produced by
such conditions as diabetes mellitus and adrenocortical insufficiencies or administration of drugs such as heparin,
~-blocking agents, and angiotensin-converting enzyme
(ACE) inhibitors. The absence of insulin limits the uptake of
potassium from the ECF compartment. 12 Decreased mineralocorticoid activity impairs excretion of potassium by the
kidney and colon, whereas drugs such as heparin or ACE
inhibitors limit aldosterone release from the adrenal gland. 22
The shift of potassium from intracellular to extracellular
fluid may be produced by rapid cell breakdown, which can
accompany cancer chemotherapy, burns or trauma, metabolic acidosis, hyperosmolar states, rhabdomyolysis, or the
administration of succinylcholine. 22 In these cases, normal
body stores of potassium may be available despite abnormal
serum levels.
Hyperkalemia may also be produced by excessive intake
of potassium, usually in the form of IV fluids or the oral
ingestion of medications or food substances high in
potassium. Although hyperkalemia may occur in young
children by this mechanism, hyperkalemia related to excessive intake is most often linked with impaired renal
function.
Critical Care Management. Hyperkalemia is one of
the most dangerous electrolyte imbalances because of the
potential to cause sudden death. I Hyperkalemia can eventually result in ventricular arrhythmias and cardiac arrest? 1
Treatment of hyperkalemia depends on the clinical
presentation. Potassium levels less than 6.5 mEqlL may
require only discontinuation of fluids containing potassium
along with close monitoring of serum potassium levels.
Increasing potassium excretion with sodium polystyrene
sulfonate (Kayexalate), especially in patients with diminished renal function, also helps to decrease potassium levels.
Kayexalate, I to 2 g/kg, is given orally (PO), by nasogastric
(NG) tube, or preferably, by rectum in a dextrose or sorbitol
solution. Sorbitol precipitates diarrhea, which aids in
potassium excretion. Kayexalate can be given every 6 hours
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orally or nasogastrically or every 2 to 6 hours rectally.
Because Kayexalate may bind calcium and magnesium,
symptoms related to deficiencies in these electrolytes may
occur.
Potassium levels higher than 6.5 mEqlL or those
producing ECG changes are treated immediately. In the
presence of life-threatening arrhythmias, calcium gluconate
at 100 mg/kg or calcium chloride at 20 mg/kg may be given
to reduce the cardiac toxicity associated with hyperkalemia. 24 Calcium increases the cardiac threshold potential,
thereby reducing membrane depolarization and reestablishing a more normal relationship between resting membrane
potential and firing threshold?4 The onset of action of
calcium is within minutes, and the effects last for about
30 minutes.
Redistribution of potassium from the ECF compartment
to ICF compartment decreases the elevated serum potassium
level. This is accomplished by the administration of sodium
bicarbonate, I to 2 mEq/kg, injected intravenously over 3 to
5 minutes. Sodium bicarbonate lowers the serum potassium
level within 30 to 60 minutes, with the effects lasting several
hours. Blood pH is monitored in children receiving this
therapy. Children with respiratory failure are carefully
evaluated because sodium bicarbonate increases carbon
dioxide (C0 2) production and may worsen respiratory
acidosis if CO 2 cannot be excreted by the lungs.
Glucose, 0.5 g/kg, accompanied by regular insulin,
0.1 U/kg, may also be used to shift potassium into the ICF
compartment. Cellular uptake of potassium from the ECF
compartment is enhanced with combined glucose and
insulin administration. The decrease in serum potassium
level associated with glucose and insulin therapy may last
several hours?4
Albuterol, a ~2-adrenergic agonist, causes an acute
decrease in plasma potassium and is another treatment
option for hyperkalemia. Albuterol activates the sodiumpotassium pump and stimulates the ~2-receptors of the
pancreas to release insulin, thereby shifting potassium into
the cells? I It is administered via inhalation or IV infusion.
The recommendation is that albuterol be administered in
conjunction with insulin because of the additive effect of the
two drugs?'
The diuretic furosemide (Lasix) may also be used to aid
in children with adequate renal function. However, the
amount of potassium removed is unpredictable. Therefore
diuretics are used only as an additional treatment modality.
The most rapid mechanism for potassium removal is
renal replacement therapy (see Chapter 21). Although
peritoneal dialysis may be used, it must be started early to
be effective. Continuous venovenous filtration or hemodialysis is used when potassium levels are lethal and
emergency life-saving treatment is necessary.

Calcium
Calcium, along with phosphorus and magnesium, plays a
critical role in nerve transmission, bone composition, and
regulation of enzymatic processes. Balance of these three
electrolytes is maintained through intestinal absorption and
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renal excretion. The majority of calcium (98% to 99%)
is stored in the skeleton and teeth, and the remainder is
found in soft tissue and serum. Approximately 50% of
serum calcium is ionized; the rest is bound to protein or
anions. Only ionized calcium is used by the body for
essential processes such as cardiac function, muscular
contraction, nerve impulse transmission, and clotting.
Therefore the ionized calcium level is of greatest physiologic significance. Because ionized calcium level has little
relationship to total serum calcium, direct measurement of
ionized calcium is critical whenever a clinically important
situation exists in which calcium levels may playa role.
Total serum calcium levels range between 9 and II mg/dl;
ionized calcium levels range between 4.4 and 5.4 mg/dl
(1.14 to 1.29 mmollL).
The roles of calcium in the body are conduction of
electrical impulses in cardiac and skeletal muscles, activation of clotting mechanisms, involvement in the coagulation
process, formation of bones and teeth, and mediation of
hormonal production. Calcium also activates serum complement, a major factor in the function of the immune
system. Calcium lines the pores of all cells and, with its
positive charge, controls the ability of sodium to enter
during depolarization because like charges repel each other.
Consequently, calcium aids in the maintenance of cellular
permeability.
Calcium regulation takes place through many different
factors. Vitamin 0-1,25 controls the intestinal absorption of
calcium. Parathyroid hormone (PTH) regulates renal excretion of calcium. PTH secretion varies inversely with ionized
calcium levels and is inhibited by hypomagnesemia and
vitamin 01.25.2 5 Vitamin 0, PTH, and serum phosphate
levels control bone deposition and resorption of calcium.
Normally, because of the constant activity of bone
deposition and resorption, there is little net change in serum
calcium. However, when this activity is disturbed, bone is a
reservoir to balance serum calcium levels. PTH, along with
vitamin 0-1,25 can change the degree of bone resorption.
With increased levels of PTH, release of calcium from the
bone is increased.
As mentioned earlier, PTH controls renal calcium
regulation in the distal nephron. Renal calcium reabsorption
increases with increases in serum PTH.

~

Hypocalcemia

Etiology. Hypocalcemia is a decrease of calcium in
the ECF and exists when serum calcium levels are below
8 mg/dl in full-term infants and older children and when
ionized calcium levels are below 4 mg/dl. Hypocalcemia in
children may be related to protein malnutrition because
decreased albumin for binding leads to decreased calcium
levels. Other causes are listed in Box 11-1. Alterations in
acid-base balance may also result in hypocalcemia.
Pathophysiology. Though the definition of hypocalcemia reflects a deficit in ECF concentration, the majority of
calcium is bound either to bone or to protein. Because serum
stores are replaced through the action of PTH, most
discussions of hypocalcemia are related to parathyroid
function. In addition, absorption of calcium from the
intestinal tract, excretion from the kidneys, and bone
rebuilding help regulate the available stores.
Approximately 40% of the total serum calcium is bound
to protein. Changes in plasma protein levels affect total
serum calcium levels. Hypoalbuminemia decreases total
serum calcium, and increased levels have the opposite
effect. Changes in serum albumin levels affect calcium. For
every I mg/dl change in albumin from the normal value, a
corresponding 0.8 mg/dl change occurs in ionized calcium. 26 The binding of calcium to protein is affected by pH.
If the pH is normal, approximately 40% of the total plasma
calcium is bound to the serum albumin. An increase in pH
as seen with alkalosis increases binding and decreases
ionized calcium. Even though the ionized calcium level is
changed, total serum calcium levels may be unchanged.
Critical Care Management. The child with hypocalcemia may be asymptomatic but requires monitoring for
clinical signs and symptoms (see Table 11-3), with particular attention paid to neurologic, neuromuscular, and
cardiac examinations. In addition, these children are monitored for changes in their ECG (see Table 11-4).
The total serum calcium, magnesium and phosphate
levels, and serum ionized calcium are useful laboratory tests
in managing hypocalcemia. Arterial blood gases may
demonstrate respiratory alkalosis as a cause of hypocalcemia. Because hypocalcemia may be linked to parathyroid
dysfunction, complete evaluation may include analysis of
PTH levels. In addition, because hypocalcemia is associated

Box 11-1

Causes of Hypocalcemia

Hypoparathyroidism (primary or surgically induced)
Hypomagnesemia
Hyperphosphatemia
Inadequate vitamin D
Decreased intake
Malabsorption syndromes
Protein malnutrition
Parenchymal liver disease
Anticonvulsant therapy

Nephrotic syndrome
Renal failure
Acute pancreatitis
Bums
Gram-negative sepsis
Chemotherapy
Transfusion with citrate·preserved blood
Certain medications: arninoglycosides, glucagon, phenobarbital, phenytoin

Dala from Metheny NM: Fluid and electrolyte balance: nursing considerations. ed 2. Philadelphia. 1992, JB Lippincott, pp 98-100.
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with hypoproteinemia, plasma protein levels may be evaluated (Table 11-12).
Two major areas of concern in the child experiencing
hypocalcemia are neuromuscular dysfunction and altered
cardiac function. Treatment of hypocalcemia is directed at
both identification of the underlying cause and correction of
the alteration. Treatment of underlying conditions that are
causing hypocalcemia is considered. Respiratory alkalosis is
readily treatable. If hyperphosphatemia exists, correction is
necessary because administration of calcium may cause
deposition of calcium-phosphate salts. A calcium-phosphate
product in a dose higher (total serum calcium x phosphate)
than 80 mg/dl is avoided. '5 Because hypomagnesemia
affects PTH release and correction of hypocalcemia, this
complication is considered and treated if hypocalcemia is
severe or persistent. Any other underlying conditions, such
as renal disease or hypoproteinemia, are also treated.
Acute hypocalcemia, especially in the child with impending neuromuscular or cardiovascular collapse, requires
restoration of the serum ionized calcium level. Treatment is
provided by IV administration of either calcium gluconate
(9 mg elemental calcium/ml) or calcium chloride (36 mg
elemental calcium/ml). The dosage for calcium gluconate is
100 mg/kg; the dose for calcium chloride is 10 to 20 mg/kg.
Less thrombophlebitis and tissue necrosis with extravasation is noted with calcium gluconate, although all solutions
with calcium salts are capable of causing tissue damage with
extravasation. For this reason, calcium salts are administered through a central vein. Calcium is used cautiously in
the digitalized child because calcium may potentiate digoxin
toxicity. Rapid administration of calcium may cause bradycardia and asystole, and thus ECG monitoring and slow
administration (50 mg/min for CaCI 2 ; 100 mg/min for Ca
gluconate) are indicated (see Table 11-7).
Hypercalcemia
Etiology. Hypercalcemia is an excess of calcium in the
ECF compartment and exists when the total serum calcium
level exceeds 10.5 to II mg/d1. 6 However, symptoms are not
usually noted until the serum calcium level is higher than
12 mg/dl. Levels higher than 15 mg/dl may be life
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11-12 Normal Laboratory Values
in Assessment of Calcium Alterations

TABLE

Normal Values
ill!':'

1!~:'

~'
l~i
~.,

Calcium (total)

~:~l~t

Adolescent
!j!. Calcium (ionized)
[;(.
Plasma protein (total)
j:e,

7.0-12.0 mg/d]

8.0-11.0 mg/dl
8.5-11.0 mg/dl
4.4-5.4 mg/dl

~" ~~;:~: g:~2":~)

4.7-7.4 gldl
5-7.5 g/dl

·,~.;~!'.c

6.5-8.6 g/dl

~:'

Child (1-15 yr)
Serum parathyroid hormone
[;. C-terrninal
K N-terminal

400-900 pg/ml
200-600 pg/ml
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threatening. Hypercalcemia is not a common occurrence. [n
general, it is caused by excessive amounts of calcium moving from the bones and intestines into the ECF compartment. A pseudohypercalcemia may be seen in children with
a fluid volume deficit when an increase in serum calcium
levels is caused by a concentrational effect. Specific conditions associated with hypercalcemia may include iatrogenic
overtreatrnent of hypocalcemia, malignancies or neoplasms,
immobility, hypophosphatemia, hyperparathyroidism, vitamin D intoxication, use of thiazide diuretics, hypophosphatasia, and familial hypercalcemia. It is seen most commonly
in the critically ill child concurrently with hyponatremia and
hyperkalemia and as chronic renal failure resolves.
Pathophysiology. Hypercalcemia occurs when calcium influx into the ECF compartment overwhelms the
calcium regulatory hormones (PTH and vitamin D) and
renal excretion mechanisms or when an abnormality of one
or both of these hormones exists?7 As discussed earlier,
protein and pH also affect calcium levels. Increased albumin
levels result in increased serum calcium levels. A decrease
in serum pH as seen with acidosis increases ionized calcium.
In this situation, more calcium is removed from proteinbinding sites and is available for participation in chemical
reactions.
Critical Care Management. Patients who are at risk
for and those with hypercalcemia are identified and monitored for the clinical manifestations of hypercalcemia (see
Table 11-3), with emphasis placed on the neurologic and GI
examinations. The ECG is monitored for changes (see Table
11-4). Laboratory values are monitored and may include
serum calcium, ionized calcium, and plasma protein levels
and parathyroid hormone concentration (see Table 11-12).
Because serum calcium levels above 15 mg/dl may be
life threatening, immediate attention is directed at reducing
the amount of calcium in the ECF compartment in addition
to treating the underlying disorder. This is accomplished by
administration of IV fluids to dilute the calcium in the ECF
compartment. Loop diuretics, such as furosemide, may also
be used to enhance calcium excretion. 17 These therapies can
also produce losses of sodium, potassium, magnesium, and
phosphate.2 5 Thiazide diuretics restrict calcium excretion
and are therefore contraindicated in the management of
hypercalcemia. 28 Vitamin D and antacids with calcium are
not administered.
Additional therapies may be used to treat the underlying
disorder. If excessive bone resorption because of malignancy or immobility is a problem, calcitonin (lOU/kg TV
every 4 to 6 hours), mithramycin (25 J..Ig/kg IV over
4 hours), prednisone (I to 2 mg/kg/day IV divided into four
doses), and indomethacin (I mg/kg/day) may inhibit the
process. 25 Calcitonin is the least toxic and works by
impeding PTH-induced bone resorption. It peaks at about I
hour after administration.
Mithramycin is a toxic antibiotic that inhibits osteoclastic
activity, but it depresses liver, kidney, and bone marrow
function. Prednisone inhibits osteoclastic activity and intestinal absorption of calcium. Indomethacin acts only when
bone resorption is the result of prostaglandin-secreting
tumors, which are rare. IV or oral phosphorus preparations
may be used to increase bone deposition of calcium,

388

Part III

Phenomena of Concern

although they are not used in patients with hyperphosphatemia or renal failure because of the risk of calcification in
the soft tissues.

Chloride
Chloride is the most abundant anion found in the ECF
compartment. Its major role is as a buffer in the maintenance
of acid-base balance. Chloride, with sodium, also maintains
serum osmolality. Chloride competes with bicarbonate for
the cations in ECF compartment to establish electrical
neutrality. Passively attracted to positively charged cations,
chloride ions balance the positively charged electrolytes in
ECF compartment and create sodium chloride (NaC\),
hydrochloric acid (HCI), potassium chloride (KCI), and
calcium chloride' (CaCI 2 ). Because chloride is usually
combined with one of the major cations in the body, changes
in serum chloride levels usually indicate changes in other
electrolytes or in acid-base balance. 17
Chloride ions are highly concentrated in gastric secretions and perspiration. Factors influencing excretion are
acidosis and alkalosis because as serum levels of bicarbonate change from the secretion of hydrogen ions, reciprocal
changes in the serum chloride commonly occur. 13 Normal
serum chloride levels in children are 95 to 108 mEqlL.
Hypochloremia
Etiology. Hypochloremia is a deficit of chloride in the
ECF compartment, which exists when serum chloride levels
are below 95 mEqlL. The most common causes of
hypochloremia include 01 losses, renal losses, and loss of
chloride through excessive sweating. 6
Pathophysiology. Hypochloremia may occur in conjunction with metabolic alkalosis. When chloride decreases,
bicarbonate increases in an effort to maintain the electrical
neutrality of the ECF compartment. Thus as the chloride
decreases, the kidneys retain extra bicarbonate ions to
balance the sodium ions. This in turn results in a hypochloremic metabolic alkalosis. Chronic lung disease (respiratory
acidosis) may also be associated with hypochloremia. This
condition results from the renal compensation and reabsorption of bicarbonate, which occurs in response to the
respiratory acidosis.
Hypochloremia may also occur when the loss of chloride
from the body exceeds sodium losses. It may be caused by
excessive loss of gastric secretions or prolonged diarrhea or
as a consequence of excessive use of potent diuretics.
Urinary losses of chloride may exceed sodium losses during
correction of metabolic acidosis and during potassium
deficiency. Hypochloremia may occur as the result of limitation of chloride intake, which might accompany saltrestricted diets, and excessive sweating, such as that seen
with the febrile child.
Critical Care Management. Table 11-3 lists the
clinical findings seen in a child with chloride loss that is
disproportionate to sodium loss. When there has been
proportionate loss of sodium and chloride, clinical findings
are characteristic of those found in hyponatremia and fluid
volume deficit. Laboratory values are monitored and may

include serum chloride, serum sodium, and bicarbonate
levels and pH. The pattern characteristic of hypochloremia
is a decreased serum chloride, decreased serum sodium, and
increased pH and bicarbonate levels. 13
Prevention of chloride deficit is an important goal of
management. The use of IV solutions containing chloride as
opposed to water will help to prevent such a deficit.
Treatment for hypochloremia includes treating the primary underlying cause while correcting the imbalance. The
imbalance is usually corrected through the administration of
sodium chloride, potassium chloride, or ammonium chloride. Three fourths of the imbalance is often replaced with
sodium chloride, and the remaining one fourth is replaced
with potassium chloride. Ammonium chloride is used
instead of potassium chloride if serum potassium levels are
elevated?6 A 0.9% solution of sodium chloride is used to
correct chloride imbalance. The dose varies, based on the
child's normal fluid volume requirements. Usually potassium chloride is given in a dose of 0.5 to I mEq/kg over a
1- to 2-hour period. The dosage of ammonium chloride is
calculated by multiplying the serum chloride deficit by the
ECF compartment volume (approximately 20% of body
weight in kilograms)?9
Hyperchloremia
Etiology. Hyperchloremia is an excess of chloride in
the ECF compartment and exists when serum chloride levels
exceed 108 mEqlL. Causes of hyperchloremia include
excessive chloride intake, usually associated with medication administration, and conditions that lead to metabolic
acidosis with excessive loss of bicarbonate ions, such as
diarrhea, renal failure, and administration of isotonic saline
solution. I?
Pathophysiology. Hyperchloremia may present as a
metabolic acidosis. The metabolic acidosis occurs as the
result of a decrease in bicarbonate, which results in an
increase in chloride, or as the result of an accumulation of
hydrogen ions.
Hyperchloremia may also result from an excess of chloride ions being ingested or retained. Excess intake causes
bicarbonate ions to be released in the kidney tubules, resulting in decrea~ed serum bicarbonate levels. Chloride excess
also occurs as the result of administration of cortisone
preparations, which cause sodium retention; severe diarrhea,
which results in a loss of bicarbonate ions; head injury and
sodium retention; and acute renal failure. 6 A pseudohyperchloremia may be seen in fluid volume deficit as the
result of a concentrational effect on serum chloride values.
Critical Care Management. When chloride excess
occurs proportionately to sodium excess, the signs and
symptoms associated with hypernatremia or fluid volume
deficit predominate. Laboratory values including serum
chloride, sodium, and bicarbonate levels and pH are
monitored. The pattern of laboratory values seen in hyperchloremia includes elevated serum chloride and sodium and
decreased bicarbonate and pH levels. The changes in pH and
bicarbonate levels reflect the acid-base disturbance that
accompanies hyperchloremia rather than the hyperchloremia itself.
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Treatment of hyperchloremia includes identification of
the underlying cause and correction of acid-base disturbances and electrolyte and fluid imbalances. Fluids (either
oral or IV) may be increased to dilute the excess chloride. In
an emergency, sodium bicarbonate may be administered to
correct the underlying metabolic acidosis. Diuretics may be
used to eliminate chloride, as well as sodium.

Phosphate
Phosphate, like calcium, is present in large quantities in
bone. Eighty-five percent of phosphorus is held in the bone
with calcium. Ten percent of phosphorus is found in the ECF
compartment. Phosphorus is also found in the teeth and soft
tissues, and 5% of the total level is in the ICF compartment.
Phosphorus, the primary intracellular anion, exists in a
variety of forms as phosphate and elemental phosphorus.
Phosphates (components of phosphoproteins and phospholipids) play a significant role in intracellular energyproducing reactions. In addition, phosphates influence tissue
oxygenation, CNS function, carbohydrate use, and leukocyte function. Tissue oxygenation is dependent on the ability
of red blood cells (RBCs) to transport oxygen to the tissues
and on 2,3-diphosphoglycerate (2,3-DPG), an organic phosphate in RBCs that binds hemoglobin and decreases its
affinity for oxygen. The kidney plays the major role in
phosphorus homeostasis. More than 90% of plasma phosphate is filtered at the kidney, and most reabsorption occurs
in the proximal tubule.
Serum phosphorus levels are higher in the pediatric
population because of the high rate of skeletal growth. The
normal serum phosphate level may be as high as 6 mg/dl
in infants and children, compared with levels of 2.5 to
4.5 mg/dl in adults.

Hypophosphatemia
Etiology. Hypophosphatemia is defined as an abnormally low concentration of inorganic phosphorus in serum.
In children, levels below 3 mg/dl are usually defined as
hypophosphatemia, although symptoms may not be present
until the level is below 2 mg/dl. 12 Levels lower than I mg/dl
may be life threatening. Hypophosphatemia may occur as
the result of a total body deficit or may be a reflection of a
shift of phosphorus into the cells. The major causes of
phosphate deficiency are severely limited intake, shift of
phosphate from the ECF compartment into the cell, decreased absorption from the GI tract, and increased renal
phosphate excretion.3°
Pathophysiology. Because phosphorus is abundant
in normally consumed foods and beverages, limited intake
of phosphate is related to vomiting or long-term starvation.
Cellular shifts of phosphorus may occur during rapid
cellular growth or hypermetabolic states. Intestinal malabsorption of phosphate may occur because of excessi ve use of
antacids, which bind phosphorus in the GJ tract, and
malabsorption syndromes in which watery stools result,
such as Crohn's disease or ulcerative colitis. 31 Malabsorption of phosphate also occurs in the presence of increased
calcium levels. Increased renal phosphate losses occur with
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rapid catabolism and destruction of body tissue. Metabolic
acidosis is the predominant finding when this mechanism of
phosphate loss is present. In children, bums may also produce hypophosphatemia as a result of renal wasting. 32 In
addition, diuretic administration may lead to renal tubular
leaks.
Hypophosphatemia is also seen in children with diabetic
ketoacidosis (because of renal wasting), as a concurrent
finding with administration of cytotoxic agents for treatment
of tumors, with phosphate-poor parenteral hyperalimentation, and when low-phosphate diets are used to treat renal
failure. 17
Hematologic changes are commonly encountered with
hypophosphatemia. Hemolytic anemia may result from
inadequate ATP for maintenance of the red cell membrane.
Oxygen-hemoglobin binding capacity drops as a result
of reduced availability of 2,3-DPG 6 Leukocytes demonstrate decreased phagocytosis, and platelet abnormalities are
also seen. The platelet abnormalities may account for
increased epistaxis and GI bleeding in children with
hypophosphatemia. 13
Critical Care Management. Patients with or at risk
for hypophosphatemia are assessed carefully for the clinical
manifestations of this electrolyte imbalance (see Tables 11-3
and 11-4). Severe hypophosphatemia can affect multiple
body systems and may result in coma and respiratory
failure. Serum phosphorus, pH, and bicarbonate levels are
monitored.
As with all electrolyte imbalances, the first step in the
treatment process is to identify the underlying cause and
take steps to correct it. Then, replacement of phosphorus is
undertaken. Replacement is generally done very slowly
because the actual serum level may not reflect a deficit in the
intracellular compartment. Unless acute symptoms are
present, phosphate depletion is treated by enteral administration of phosphorus to to 20 mg/kg/day divided into
several doses to minimize diarrhea. I 5 Parenteral administration of phosphates is usually restricted to children with
levels below I mg/eIl. 3D The dose generally recommended is
0.15 to 0.33 mmol/kg given as a continuous infusion over at
least 6 hours (see Table 11-7). Subsequent dosages are based
on the response to the initial dose. Either potassium or
sodium phosphate may be used, with the potential complications associated with hyperkalemia or hypematremia.
Other adverse effects of phosphate administration include
hyperphosphatemia, which may result in hypocalcemia, and
hypotension. Care must be exercised in the administration of
parenteral phosphorus. It must be well diluted to avoid
irritation of the blood vessels, extravasation, or infiltration
leading to tissue necrosis. Administration of large quantities
of phosphorus may lead to precipitation with calcium if
levels are not carefully monitored. 17

Hyperphosphatemia
Etiology. Hyperphosphatemia is defined as an excess
of phosphate in the ECF compartment and exists when
phosphate levels exceed 4.5 mg/dl. Hyperphosphatemia
may be produced by chronic renal failure, rapid cell
catabolism, excessive intake of phosphates, neoplastic
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diseases, hypoparathyroidism, and excess consumption of
vitamin D metabolites. 6 • 17 Elevated phosphate levels seldom
become a concern unless renal excretion of phosphorus is
impaired.
Pathophysiology. In chronic renal failure the renal
tubules no longer excrete phosphorus, despite continued
uptake in the GI system. The disruption in renal function
accompanied by a decreased GFR leads to impaired
phosphate elimination.
Rapid cell catabolism leads to the release of the cellular
phosphorus stores into the ECF compartment. Children
being treated with chemotherapy for neoplastic disease of
lymphatic origin may also develop hyperphosphatemia
because of leakage of phosphates into the circulation as a
result of cytolysis?
Hyperphosphatemia may also be seen in children at times
of rapid growth because serum phosphate levels may reach
6 mg/dl during these periods. Vitamin D, which increases
absorption of phosphorus in the GI tract, may be helpful in
providing phosphorus for bone growth and cellular function.
Critical Care Management. Patients with hyperphosphatemia are monitored for the clinical manifestations
of hyperphosphatemia and hypocalcemia (see Table 11-3).
An inverse relationship exists between phosphorus and
calcium in the ECF compartment. Therefore in conditions
producing hyperphosphatemia, hypocalcemia also exists.
The relationship between these two imbalances accounts for
the fact that the clinical signs and symptoms associated with
hyperphosphatemia are the same as those found in the child
experiencing hypocalcemia. If the hyperphosphatemia is not
associated with a hypocalcemia, phosphorus may precipitate
into body tissues as phosphate salts, and conjunctivitis,
pruritus, or renal deposits may occur. 6
Serum phosphate and calcium levels are monitored. An
elevated phosphate level is seen in conjunction with a
clinically significant decreased serum calcium value.
Treatment should be directed both at determining the
underlying cause and correcting the imbalance. Hyperphosphatemia may be treated using dietary restrictions of
phosphorus. If this diet does not result in lowered phosphate
levels, aluminum antacids may be used. The antacids bind
with the phosphate in the intestines and thus facilitate
elimination. Adequate hydration and correction of hypocalcemia also enhance phosphate elimination. If increased
phosphorus is not the result of an influx of phosphorus
related to renal failure, the administration of sodium
bicarbonate may be used to enhance renal excretion of
phosphorus 6 For the child with life-threatening symptoms,
fluids to increase renal phosphate losses, treatment of
hypocalcemia, or dialysis may be indicated.

Magnesium
Magnesium is the fourth most abundant cation in the body
and the second most abundant intracellular cation. The
distribution of magnesium is similar to that of potassium and
is approximately 60% in the mineral component of bone,
40% in the body cells, and less than I% in the ECF
compartment. The major roles of magnesium can be divided

into three areas: enzyme and biochemical activation, mediation of skeletal muscle tension, and inhibition of electrical
activity at the neuromuscular junction. Magnesium serves as
a cofactor in numerous enzyme reactions that involve
transfer of a phosphate group: metabolism of glucose,
pyruvic acid, and ATP. Magnesium has a similar role to
calcium as an inhibitor of electrical activity in neuromuscular function. Magnesium acts directly on the myoneural
junction, affecting neuromuscular irritability and contractility of cardiac and skeletal smooth muscle.'
The serum magnesium concentration is regulated by the
kidney, GI tract, and bones. However, the kidneys are the
primary regulators. The kidneys have an extraordinary
ability to conserve magnesium and with decreased intake of
magnesium excrete less than I mEq/day. When the concentration of magnesium in the glomerular filtrate exceeds
certain limits, large quantities of magnesium are lost in the
urine. 33 Reabsorption occurs in the ascending limb of the
loop of Henle and is modulated by the serum concentration
of ionized magnesium.
Serum magnesium levels are a poor indicator of total
body stores because less than I% of total body magnesium
exists in the serum. Normal magnesium levels in the child
are 1.5 to 2.5 mEqIL. Magnesium levels show small
variations, correlating directly with changes in serum
calcium and inversely with phosphorus. 27 About 35% of the
available magnesium is bound to protein.

Hypomagnesemia
Etiology. Hypomagnesemia generally exists when the
serum magnesium level is less than 1.4 mEqlL. However, a
decrease in serum magnesium is not always synonymous
with a decrease in body stores. Two principal causes of
decreased magnesium in the ECF compartment are decreased absorption or increased excretion. 3o
Pathophysiology. Decreased intestinal absorption of
magnesium may occur intrinsically or may be drug induced
(i.e., laxatives). Conditions that may be associated with
decreased absorption include pancreatitis, chronic or severe
diarrhea, prolonged nasogastric suctioning, prolonged vomiting, intestinal and biliary fistulas, and malabsorption
syndromes 33
Increased renal excretion of magnesium can occur with
the use of diuretics, in particular, loop diuretics and
thiazides. Patients with conditions causing a rapid diuresis
(i.e., diabetic ketoacidosis and hyperosmolar, hyperglycemic, nonketotic coma) also demonstrate an increased
excretion of magnesium. Aminoglycoside antibiotics and
antineoplastic agents may induce hypomagnesemia in children because these drugs cause renal magnesium wasting. 34
Hypomagnesemia may also be related to lack of magnesium
administration during the time the child is NPO or caused by
malnutrition.
Other imbalances seen with hypomagnesemia are hyponatremia, hypokalemia, hypophosphatemia, and distal renal
tubular acidosis. Hypomagnesemia may damage the ATp·
dependent sodium, potassium, phosphate, and hydrogen
pumps, which would cause excess urinary losses of these
electrolytes. 35

Chapter 11

Critical Care Management. The infant or child with
a decreased serum magnesium level is monitored closely for
the clinical manifestations of hypomagnesemia (see Table
11-3). Despite generalized neuromuscular excitability, respiratory muscle depression and hypoventilation may occur,
creating a need for mechanical ventilation. 3D Continuous
ECG monitoring is indicated to assess for arrhythmias (see
Table 11-4).
In addition, the child may present with many of the same
clinical signs that are found with hypocalcemia. The signs
and symptoms of hypomagnesemia are often compounded
by the coexistence of hypocalcemia and hypokalemia. When
these electrolyte disturbances are persistent, hypomagnesemia may also exist.
Serum magnesium, potassium, and calcium levels are
monitored. Decreased serum magnesium levels are accompanied by decreased potassium levels in 50% of children
evaluated. 34 Urine magnesium levels are also decreased and
may be monitored.
Treatment of hypomagnesemia is directed at identification of the underlying cause and correction of the imbalance.
With severe magnesium deficiency resulting in symptoms
such as ventricular arrhythmias or seizures, IV magnesium
sulfate may be diluted to 10 mg/rnl and given slowly over
3 to 5 minutes. Subsequent doses may be repeated if
necessary, based on the child's response and serum magnesium levels. Adequate renal function is ensured before
treatment is undertaken because if function is diminished,
hypermagnesemia resultsY Other complications of parenteral magnesium administration include neuromuscular
and respiratory depression, hypotension, and malignant
arrhythmias.
Although oral and intramuscular magnesium administration may be more easily accomplished, neither can be relied
on to correct a serious deficit. Intramuscular magnesium
absorption is erratic, based on the amount of subcutaneous
fat tissue. Intestinal absorption of oral magnesium is
extremely variable. If either intramuscular or oral replacement is chosen, careful attention must be directed at
monitoring serum levels.
Hypermagnesemia
Etiology. Hypermagnesemia is defined as an excess of
magnesium in the ECF compartment. Hypermagnesemia
exists when the serum magnesium level exceeds 2.5 mEqlL.
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Hypermagnesemia occurs far less often than hypomagnesemia. This condition most commonly occurs as the result of
underlying chronic renal disease. Transient increases in
serum magnesium levels may accompany ECF compartment deficit or excessive administration of magnesiumcontaining drugs?
Pathophysiology. Hypermagnesemia may occur as
the result of an increase in magnesium load or a decrease in
GFR. An increase in magnesium load is rare but may occur
with the administration of large doses of magnesiumcontaining electrolyte supplements, laxatives, or antacids in
the patient with compromised renal function. A decrease in
GFR is typically associated with chronic renal disease, acute
renal failure, or hypovolemia. 27 The result is inadequate
filtration and excretion of magnesium.
Critical Care Management. Because hypermagnesemia is a rare occurrence, the nurse must maintain a high
index of suspicion in those patients who are at high risk (see
Table 11-3). In addition, the child is monitored for ECG
changes. Severe hypermagnesemia may lead to coma or
cardiac arrest. Laboratory values are obtained and may
include serum magnesium level and renal function tests,
including BUN and serum creatinine.
Treatment of hypermagnesemia is directed at both
correction of the imbalance and identification and treatment
of the underlying cause. Calcium gluconate or other calcium
salts may be administered because calcium is an antagonist
to magnesium and often reverses the cardiac manifestations
of hypermagnesemia. IV hydration facilitates renal excretion of excess magnesium in the presence of normal renal
function. If renal dysfunction is apparent, dialysis may be
indicated.

SUMMARY
This chapter has presented the regulation and assessment of
fluid and electrolyte balance in the critically ill child. Care
of the critically ill child depends on accurate assessment and
complete understanding of the unique interrelationships of
these substances. Minor deviations in electrolyte and fluid
balance may produce profound complications in children.
Therefore careful attention to signs and symptoms and appropriate intervention to alleviate the abnormality and correct the underlying cause may reduce the severity and length
of time of critical illness.
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Nutrition Support
Judy Verger
Greg Schears

The risk of malnutrition for critically ill children is increased by their higher metabolic needs and by other associated conditions common to the pediatric intensive care
population. Congenital heart disease, bronchopulmonary
dysplasia, gastrointestinal reflux, and other chronic conditions commonly lead to feeding difficulties and can predispose critically ill children to undernutrition and growth failure. 5 Compared with adults, children have proportionately
larger obligate energy needs. The major metabolic organs
make up a larger proportion of body weight. These higher
energy requirements combined with lower macronutrient
stores result in children being less able to withstand nutritional deprivation.
Protein-calorie malnutrition is a deficiency of both
protein and energy and has a detrimental effect on a number
of major body systems. Malnutrition causes mobilization of
muscle protein stores and negative nitrogen balance. Malnutrition may be a cofactor in morbidity and death in
patients with hypermetabolism and organ dysfunction. 6 .7
Protein and calorie depletion dramatically compromises
immunocompetence, resulting in an increased risk of
infection with a reduction in the number of T lymphocytes,
a decrease in B-cell function, changing cytokine activity,
diminished interleukin-2 response, and impaired wound
healing.8-10 Protein, carbohydrates, fats, and various vitamins and minerals are responsible for synthesis and collagen
strength and therefore wound integrity.
The heart and lung muscles, like other muscles in the
body, require sufficient protein and calories to perform their
physiologic activities. II Without adequate protein and energy support, the patient can experience a decrease in
ventilatory drive and respiratory efficiency; decrease in
surfactant, resulting in a change in pulmonary compliance;
decrease in diaphragm mass and muscle atrophy; decrease
in vital capacity; and decrease in clearance of bacteria by the
lungs. 12 . 13 Weaning from mechanical ventilation may be
inhibited. Hypomagnesemia and hypophosphatemia may
specifically contribute to respiratory muscle depletion. 14 . 15
Structural and functional effects on the cardiac muscle have
been demonstrated as a response to malnutrition. 16 Vitamin

PATIENT RESPONSE TO STARVATION AND CRITICAL ILLNESS
NUTRITION ASSESSMENT

Patient History
Dietary History
Physical Assessment
Anthropometric Measurements
Biochemical Indices
Other Methods of Assessment
NUTRITION MANAGEMENT

Determining Energy Needs
Nutrient Distribution
Immune-Enhancing Additives
Collaborative Interventions
SUMMARY

N

utrition is an essential component of caring for critically ill children. Nutritional interventions can improve
patient recovery and survival. I Both an acquired and a
preexisting tendency toward protein-energy malnutrition
(PEM) has been documented in hospitalized children.2.3 In
the 1980s, Pollack and associates 2 .3 found that 16% to 19%
of pediatric intensive care unit (PICU) patients were malnourished. Those children at risk for serious nutritional deficiencies were younger than 2 years of age and had medical
problems rather than surgical problems. Acute PEM has
been linked to higher mortality and increased physiologic
instability.4 The value of nutrition in health and disease is
now being established. In today's healthcare environment,
early nutritional assessment is considered best practice. Nutrition support started within 24 to 48 hours of admission
to the critical care unit is the current standard of care.
Designer formulas with specific additives that are thought to
enhance immune function show promise. A variety of
delivery methods, including postpyloric enteral tube placement, supports the value and safety of early nutrition.
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and trace element deficiencies may affect cardiac performance. Other physiologic conditions associated with malnutrition include the gastrointestinal changes of gut
mucosal atrophy, decreased intestinal motility, bacterial
translocation, malabsorption, and decreased pancreatic
function. 17.18

~

12·1 Metabolic Response of Stress
Versus Starvation ,"
'.

TABLE

PATIENT RESPONSE TO STARVATION
AND CRITICAL ILLNESS
An understanding of the dramatic differences of the body's
response to starvation and the catabolic effects of stress is
important for safe and effective nutritional support of
critically ill children (Table 12-1). Unlike critical illness,
which results in rapid PEM, starvation produces malnutrition in days to weeks. The process of starvation results from
a decrease of nutrient intake with normal nutrient use. This
phenomenon essentially represents no stress to the body.
Carbohydrate stores are usually consumed within 24 hours.
The breakdown of amino acids from protein (gluconeogenesis) is initiated to supply glucose. If starvation continues
for several weeks, the body adapts to lack of glucose.
Protein use is reduced, nutrients are conserved, and body fat
becomes the major energy source. Starvation causes a
decrease in the child's metabolic rate and total energy
expenditure. Little or no activation of metabolic mediators
occurs, and no increase in insulin resistance exists.
The metabolic response of critical illness is very different
from that of simple starvation. 19•zo Hypermetabolism is
characterized by hyperglycemia, and normal use of nutrients
is altered. This response is coordinated by catecholamines,
cortisol, glucagon, and growth hormone and characterized
by use of nutrients from all sources 21 Interleukin-6 is an
integral mediator for the physiologic response to injury.2 z
Interleukin-I and tumor necrosis factor also participate as
mediators for the stress response.
Catecholamines released in response to the stress of
injury or illness create a diabetic-like response by increasing
the mobilization of glucose and resistance to insulin. Epinephrine suppresses insulin, leaving additional glucose
available for energy needs. Glucagon antagonizes the anabolic effect of insulin, leading to more hyperglycemia and
protein breakdown. Glucocorticoids trigger gluconeogenesis, converting amino acids to glucose. Endogenous protein
breakdown is accelerated to provide glucose to meet energy
needs. Much of protein degradation comes from the wasting
of skeletal muscle and results in an increased loss of nitrogen through the urine. Amino acids may supply up to 25% of
the energy in the stressed patient, resulting in a higher respiratory quotient (RQ) than with starvation.2 3 Fat mobilization, use, and depletion are also increased. Cortisol acts to
enhance the catecholamine effect by breaking down fat into
free fatty acids.
The metabolic response to critical illness is not preventable; however, nutrition support can minimize protein
loss.21.24 The catabolic effect of breaking down cellular
materials, which occurs during critical illness, precludes
growth and organ development. When catabolism exceeds
anabolism, the synthesis of cellular materials, body tissues
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are lost and weight decreases. Catabolism and anabolism
cannot occur simultaneously. The degree of increase in
energy expenditure and protein catabolism is proportionate
to the severity of illness and previous nutritional status of
the child.2 s For example, a child with a minor infection does
not have as much energy expenditure and protein breakdown as a child with sepsis. This increase in energy
expenditure plays a major role in the development of PEM
in the intensive care unit (ICU).

NUTRITION ASSESSMENT
The nutritional assessment of a critically ill child requires
various methods and tests. No single clinical, biochemical,
or growth measurement gives a complete picture of a child's
nutrition status. The process of nutritional assessment is
dynamic and must allow selection of varying assessment
methods throughout the child's ICU stay.
The purpose of the nutritional assessment is to identify
the presence or absence of malnutrition, determine the
child's nutritional requirements and preferred alimentation
method, and assess the effects of any nutrition intervention.
A systematic review of the child's history and physical
examination combined with accurate anthropometric and
laboratory measurements are required.

Patient History
A reliable and complete history is the first step in accomplishing a nutritional assessment (Box 12-1). These data aid
in providing a basis for subsequent assessment parameters.
Valuable information can be gathered from watching the
parent feed the child. Review of the child's medications
is also helpful because of the possible effect of these
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Box 12·1

Patient and Family History

Birth data and prenatal history
Gestational age
Birth weight, length, head circumference
Maternal nutrition
Chronic illnesses
Congenital or chromosomal abnormalities
Relevant trauma, illness, surgery
Level of gastrointestinal function
Oral feedings
Tube feedings
Parenteral nutrition
Feeding history
Ability to suck
Frequency and amount of intake
Vomiting or spitting up
General appetite
Food preparation
Who feeds child
Bowel pattern (diarrhea, constipation)
Weight loss or gain
Medications
Family or lifestyle factors
Socioeconomic status
Travel
Hygiene practice
Stress within family
Data from Hobenbrink K: The pediatric patient. In Lang C, ed: Nutritional
support in critical illness. GaitherSburg, Md. 1987, Aspen Publication,
pp 33-59.

medications on the gastrointestinal tract and their potential
for causing nutritional disturbances.

Dietary History
The child's dietary history and an analysis of the child's
current diet to determine nutritional composition and
quantity are important. Knowledge of the child's preadmission intake may be particularly helpful for the chronically ill
child in the ICU. To collect information regarding the child's
preadmission diet, parents can be asked to recall the child's
intake in the past 24 to 48 hours. Calorie count is the best
method to document a child's current diet. The child's
enteral and intravenous intake for a 24-hour period can be
recorded and analyzed.

Physical Assessment
A careful physical examination is performed with a specific
interest in uncovering subtle signs of deficiencies in
macronutrients (protein, energy) and micronutrients (vitamins, minerals, and trace elements) (Table 12-2). The goal
of the physical examination is to corroborate and add to
findings of the history. Among the clinical signs that may
provide evidence suggesting nutritional deficiencies are the
child's general appearance; subcutaneous fat and muscle
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wasting; neuromuscular irritability; and skeletal structure,
including signs of bone disease and bone tenderness. A
decrease in muscle strength precedes a reduction in nitrogen
and protein levels in malnutrition?6 The condition of the
gums, teeth, hair, skin, and eyes are assessed for signs of
nutritional depletion. The child may also have diarrhea,
constipation, or vomiting. Because the origin of these signs
may not be nutritional, further testing is necessary to
determine the cause.

Anthropometric Measurements
Assessment of growth is a vital component in the care of
critically ill children. Anthropometric measurements including weight, length, height, head circumference, triceps skin
fold, and midarm circumference are noninvasive and easily
taken. Weight, length, height, and head circumference are
traditionally considered convenient clinical measurements
and can serve as minimum standards for the average ICU
patient.
Plotting weight, stature, head circumference, and body
mass index (BMI) on growth charts is essential to identifying growth patterns that are indicative of acute or chronic
malnutrition. Weight for age, height for age, head circumference, weight for stature, and BMI can be plotted using
National Center for Health Statistics (NCHS) charts.2 7
Standard growth charts can be found in Appendix II. Special
growth charts are also available for children with special
health problems such as trisomy 21 and prematurity.
Weight is used as a gross indicator of body fat and protein
stores. For the typical pediatric patient in the ICU, weight is
measured on a calibrated pan or sling scale. The scale is
accurately calibrated with whatever gown, sheet, diaper, or
equipment is needed for the child. Arm boards, casts, and
other heavy items are estimated and then subtracted from the
total weight. Ideally the child is weighed with the same scale
and at the same time each day.
The child is weighed on admission as a baseline and daily
a~ the child's acuity permits and until the child's growth
pattern has stabilized. Weekly weight trends are more relevant than daily fluctuations in assessing a critically ill child's
growth. An unexplained weight loss of greater than 10% of
the child's admission weight places the child nutritionally at
risk.2 8 The frequent changes in body water content from the
occurrence of capillary leak syndrome with edema reduce
the effecti veness of weight as an indicator of changes in
body mass and therefore nutritional status.
Obtaining the child's length and height assists in
estimating ideal body weight and monitoring length and
height variations over time. After I to 2 years of age, a
healthy infant's height and weight normally proceed along
the same percentile. Length and height are affected when
undernutrition occurs chronically. Recumbent length measurement is typically obtained on children from birth to
2 years of age. Standing height is obtained on ambulatory children who are 2 to 18 years of age. Because most
critically ill children cannot stand, limited options are available. Direct measurement of a child with a tape measure will
sacrifice accuracy. For children up to 36 months of age, a

396

Part III

TABLE

12-2 Selected Clinical Findings Assoc:iated With Nutritional DefiCiencies/Excesses

trointestinal

~~dapted

Phenomena of Concern

Finding

Nutritional Deficiency/Excesses to Consider

Underweight, short stature
Overweight
Edematous, decreased activity level

Calories
Excess calories
Protein

Decreased fat fold
Increased fat fold
Edema

Calories
Excess calories
Protein, thiamine

Moon face, diffuse depigmentation

Protein

Pale

Anemia

Lack of curl, dull altered texture, depigmented,
easily plucked, thin
Hair loss
Coiled, corkscrew-like

Protein
Zinc, biotin, essential fatty acids
Vitamin A, ascorbic acid

Angular stomatitis

Riboflavin

Swollen, bleeding

Ascorbic acid

Caries
MoUled, pitted enamel

Fluoride
Excess fluoride

Smooth, pale, atrophic
Red, painful, denuded, edema

Anemia, B complex
Niacin, riboflavin, vitamin B 12

Spoon-shaped, koilonychia

Iron

Decreased muscle mass (wasting)

Protein, calories

Ataxia, sensory loss, motor weakness
Psychomotor change, confusion, irritable
Loss of vibratory sense, deep tendon reflexes
Sensory loss, motor weakness
Peripheral neuropathy

Vitamin B ,2 , vitamin E, chromium
Protein, chromium
Thiamine, vitamin B '2
Thiamine
Pyridoxine

Generalized dermatitis
Symmetric dermatitis of skin exposed to
sunlight, thickened pressure points, trauma
Petechiae, purpura, ecchymosis
Scrotal, vulval dermatitis

Zinc, biotin, essential fatty acids, tryptophan
Niacin

Dry (xerosis) conjunctiva
Photophobia
Conjunctival pallor

Vitamin A
Zinc
Anemia

Costochondral beading, pigeon chest
Harrison's groove, knock-kneed or bowed legs,
craniotabes, frontal and parietal bossing, open
anterior fontanelle
Epiphyseal enlargement
Bone tenderness, hemorrhages

Vitamin D

Vitamin D, ascorbic acid
Ascorbic acid, copper

Hepatomegaly (fauy infiltration)

Protein

Tachycardia, cardiomegaly, congestive heart failure
Cardiomyopathy

Thiamine
Selenium

Hypothyroidism, goiter
Glucose intolerance

Iodine
Chromium

AItered taste
Delayed wound healing
Parotid enlargement

Zinc
Zinc, ascorbic acid, protein
Protein

from Figueroa-Colon R: Clinical and laboratory assessmenl of the malnourished child. In Suskind R, Lewinter-Suskind L, eds: Textbook of

'-'ediatric nutrition, ed 2, New York, t993, Raven Press, p 195.
.Ii'

Ascorbic acid, vitamin K
Riboflavin
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length board can be used. The recumbent measurement may
result in approximately I to 2 cm greater length than an
upright height measurement. The length of a nonambulatory
child of age 3 to 18 years can be estimated by measuring
lower leg or upper arm length and comparing the measurement to a standard. 29 This technique is an estimate of linear
growth in children when height and length cannot be reliably assessed using traditional means. Upper arm length is
measured from the acromion to the head of the radius.
Lower leg length is measured from the superior medial border of the tibia to the inferior border of the medial malleolus
with the child sitting and one leg crossed over the other
horizontally.
BMI for age is calculated in children greater than 2 years
of age from the child's weight and height measurements.
BMI assists the clinician in making a judgment of whether
the child's weight is appropriate for his or her age. In older
children and adolescents, 8MI closely relates to body fat. A
child with a measurement of less than the 5th percentile may
have growth failure, and further nutritional assessment is
warranted. A measurement of greater than the 95th percentile may be considered ovemourished.
Head circumference measurement also contributes to a
complete nutritional assessment. Head circumference
changes with chronic malnutrition. The brain is often
preferentially spared for growth during malnutrition and
only slows its growth with long-term chronic malnutrition.
Reductions in weight and height precede a nutrition-related
change in head circumference. Serious malnourishment
during critical stages of brain development may cause
diminished brain and head growth and impaired developmental and intellectual potentials. Measurements are obtained in children of up to 36 months of age using a flexible,
nonstretchable tape measure. The head is measured at the
greatest circumference around the frontal bones, superior to
the supraorbital ridge and over the occipital prominence.
The recommendation is that infants age I week to 15 months
have a head circumference measurement each week and
children age 15 months to 3 years have their head
circumference measured every 3 to 4 weeks.
Triceps skinfold (TSF) and midarm circumference
(MAC) assist in the assessment of muscle mass and
subcutaneous fat content, respectively. These measurements
require the use of constant tension calipers such as Lange or
Holtain skinfold calipers and a nonstretchable tape measure.
Because approximately 50% of the body's adipose tissue is
located in the subcutaneous tissue, TSF provides an estimate
of body fat stores. Skinfold calipers pinch the skin and its
underlying subcutaneous tissue over the triceps midway
between the shoulder (acromion) and the elbow (olecranon).
To ensure accuracy, this process is repeated three times
using established techniques. Midarm circumference is used
in combination with TSF to estimate skeletal muscle mass
and somatic protein reserves. To measure MAC the diameter
of the arm is determined by using a tape measure over the
same area of the arm used when measuring TSF. These
measurements are then compared with age- and sex-specific
standards.
The child's measurements are compared with standards
established by the Ten State Nutrition StudyJO Excessive fat
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stores and muscle mass are indicated by a greater than 95th
percentile, and depletion in fat stores and muscle mass is
indicated by less than the 5th percentile. The accuracy
of both TSF and MAC may be affected by fluid shifts
and edema.

Biochemical Indices
Laboratory data can be used to evaluate biologic functions
dependent on nutrition. Of equal importance to assessing
protein and calorie deficits is assessment of micronutrients.
Serum and urine assays provide objective information to
support dietary assessments, physical findings, and anthropometric measurements. Cholesterol levels below normal
are seen in malnourished patients and correlate with mortality.31 Biochemical measurements serve to identify nutritional deficiencies that are not found clinically (Table 12-3).
Plasma Proteins. As a means of quantifying a child's
body protein stores, certain proteins that circulate in the
body can be measured. 28 .32 Protein measurements, however,
reflect body stores with varying degrees of precision. Many
physiologic and pathologic factors seen in critically ill children, such as liver disease, renal failure, trauma, infection,
and inflammation, also affect body protein and make the
interpretation of these measurements difficult.
Prealbumin is sensitive to acute visceral protein changes
and may be the most helpful protein measuremem in the
critically ill patient. 33 Prealbumin closely correlates to
nitrogen balance. Prealbumin levels are significantly decreased in the flow phase of injury.34.35 Prealbumin has a
relatively short half-life (2 days) and smaller body pool than
albumin. Prealbumin decreases rapidly with lower than
normal protein or energy intake and produces a significant
rise with adequate protein and calorie replacement. Prealbumin is partially catabolized by the kidneys and increases
with renal insufficiency.3 5 Prealbumin aids in the transport
of thyroxin and is also affected by infection and trauma.
Serum albumin, the major protein synthesized by the
liver, was one of the first biochemical markers identified for
malnutrition. A low level of serum albumin has been associated with a decrease in dietary protein intake and an increase
in morbidity and mortality.36 Once released into the plasma,
albumin has a half-life of 20 days and reacts very slowly to
changes in protein intake. Albumin levels are affected by
hepatic disease, as well as infection, injury. hydration of the
child, renal failure, intestinal disease, ongoing protein losses
from drainage tubes or wounds, and exogenous infusion of
albumin. Short-term reductions in intake may decrease albumin synthesis but have little effect on albumin levels because of the low turnover rate and large pool size of albumin
within the body. In children older than age I year, serum
albumin levels of 2.8 to 3.5 gldl may indicate mild protein
depletion, whereas severe depletion may be indicated by
serum albumin levels less than 2.1 g/d!. The nonsensitivity
and nonspecificity of albumin make it a poor indicator of
acute malnutrition in a critically ill child. Its major role is in
the assessment of the severity of chronic malnutrition.
Transferrin is also used to reflect protein status in the
hospitalized child. This plasma protein is synthesized by the
liver. Transferrin is used to transport the majority of the iron
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Bii>chemicallndkes
Age
Neonate
Birth-1 rno
tein
Blood
Serum albumin (g/dl)
Retinol binding protein (mg/dl)
Blood urea nitrogen (mg/dl)
Prealbumin (mg/dl)
Transferrin (mg/dl)
Fibronectin (mg/dl)
Urine
Creatininelheight index

Infant
1·12 rno

Child
1-4 yr

Child
5-B yr

Child
9·18 yr

~2.5

~3

~3.5

~3.5

~3.5

2-3
7-22
20-50
170-250
30-40

2-3
7-22
20-50
170-250
30-40

2-3
7-22
20-50
170-250
30-40

2-3
7-22
20-50
170-250
30-40

3-6
7-22
20-50/60
170-250
30-40

>0.9

>0.9

>0.9

>0.9

>0.9

~30

~30

~30

~30

~30

~20

~20

~20

~20

~20

<20

<20

<20

<20

<20

lacin
Serum folate (ng/ml)
Red blood cell folate (ng/dl)

>6
>160

>6
>160

>6
>160

>6
>160

>6
>160

amin K
rothrombin time (seconds)

11-15

11-15

11-15

11-15

11-15

$10

$10

$10

$10

$10

>0.2

>0.2

>0.2

>0.2

>0.2

<15

<15

<15

<15

<15

tamin A
Plasma retinol (g/d\)
ltamin D
25-0H-D, (ng/ml)
iboflavin
. Red cell glutathione reductase
stimulation effect (%)

min E
ed blood cell hemolysis test (%)
in C
Plasma (mg/dl)

iarnine
Red blood cell transketolase
stimulation effect (%)
. tamin B'2
Serum vitamin B 12 (pg/ml)

~2OO

~2oo

~2oo

~2oo

~2oo

n
Hematocrit (%)
Hemoglobin (g/d\)
Serum ferritin (ng/ml)
Serum iron (g/dl)
Serum total iron-binding capacity (g/d\)

31
12
>10
>30
350-400

33
12
>10
>40
350-400

36
13
>10
>50
350-400

39
14
>10
>60
350-400

36
13
>10
>60
350-400

nc
Serum zinc (g/dl)

80-120

80-120

80-120

80-120

80-120

~.

..-dapled from Klish W: Nutritional assessment. In Wyllie R. Hyams J, eds: Pediatric gastroimestinal disease, Philadelphia. 1993, WB Saunders, p 1108.

in Ihe plasma. Transferrin has a half-life of approximately
8 days and therefore is more sensitive than albumin to
protein deficiency. A transferrin level of 100 to 170 mgfdl
may reflect moderate malnutrition, and a level of less
than 100 mgfdl may indicate severe malnutrition. Transferrin is known to rise rapidly during iron deficiency and
may be affected by other nonnutritional factors, including
nephrotic syndrome, neoplastic disease, and liver disorders.
Retinol-binding protein levels also vary with proteinenergy status. Relative to the other visceral proteins,
retinol-binding protein has a very short half-life (10 to

12 hours). However, retinol-binding protein is not used
often for diagnosis of malnutrition because it is present only
in very small concentrations. Serum levels may rise in liver
disease and renal insufficiency and be lowered in vitamin A
deficiency.
Urine Screening for Somatic Proteins. Although
urine is sometimes difficult to collect, urine screening for
creatinine and urea nitrogen can be valuable in assessing the
nutrition status of the critically ill child. Creatinine height
index (CHI) reflects muscle mass, assuming that renal function is normal. Creatinine, the metabolic product of creatine,
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is stored in muscle and excreted by the kidney at a relati vely
constant rate. Creatinine excretion is measured in a 24-hour
urine collection. The 24-hour creatinine excretion of the
patient is divided by a 24-hour creatinine excretion of the
same-height child and multiplied by 100 to obtain an index:
24-Hour urine creatinine excretion (mg)
x 100
24-Hour urine creatinine excretion of
same-height child (mg)
In the well-nourished child the CHI is 90% to 100%.
Severe protein-calorie malnutrition is indicated by a CHI
under 40%, moderate depletion is indicated by a CHI of
40% to 60%. and mild depletion is indicated by a CHI of
60% to 80%.32 Creatinine excretion can be affected by
hydration state and catabolic states. Patients taking diuretics
and those with renal disease are likely to have low
excretions of creatinine?B
Urea nitrogen excretion also requires 24-hour urine
collection and can be used to estimate nitrogen balance and
assess catabolic state. Nitrogen balance determines the state
of metabolic balance or protein turnover by subtracting
nitrogen excretion from nitrogen intake. Nitrogen balance is
calculated as follows:
(Protein intake [g124 hours]/6.25) (Urine urea nitrogen [g/24 hours] + 4)
Protein intake is divided by 6.25 to determine the intake
of nitrogen. This factor is the average nitrogen intake in I g
of dietary protein. A constant of 4 is added to urine urea
nitrogen to account for the other body nitrogen losses (stool,
skin, etc.). If the answer to this equation is above zero. the
patient is adding lean body mass and is in an anabolic state.
This result indicates growth or recovery from an illness. If
the number is negative or below zero, the child is catabolic
and losing protein or lean body mass. This state suggests the
need to add protein alone or a combination of protein and
calories to the diet. In addition to malnutrition, a negative
nitrogen balance may also be caused by hypoperfusion,
fever, sepsis, shock, and steroid therapy.

Other Methods of Assessment
Body Composition. Measurement of body composition is currently being used in some settings for nutritional
analysis and involves the estimation of body components.
Different methods exist with varying accuracy, technique,
and applicability to the child in the ICU. For the majority of
these tests, their relationship to patient outcome has not yet
been demonstrated. 28.32
Two methods of measuring body composition include dual-energy x-ray analysis (DEXA) and total body
water (TBW). Bone mineral content (BMC), fat free mass
(FFM), and percentage of body fat (%BF) can be
determined by x-ray examination. This noninvasive method
is especially helpful in detecting bone loss in children.
TBW uses isotopes to measure FFB and %BF. Small
amounts of isotopes are administered to the patient. The
concentration of the isotopes is then measured in the urine
to estimate TBW.
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Indirect Calorimetry. Calorimetry is the process of
measuring energy expenditure and is based on the premise
that energy is produced by thermal reactions. Energy
expenditure was initially measured in a laboratory setting by
directly quantifying heat dissipating from a subject. With the
advent of indirect calorimetry, measuring energy expenditure can now be done at a patient's bedside. 37 Indirect
calorimetry is now the reference standard for energy
expenditure. Indirect calorimeters assist in evaluating caloric needs and measuring the use of various nutrients in
critically ill children 38-4o
Metabolic carts brought to the bedside measure the rate
of pulmonary gas exchange. Using a sophisticated analyzer,
carbon dioxide and oxygen levels in inspired and expired air
are measured and compared to determine energy expendi4142 0 xygen consumptIOn
. an d carbon d"d
ture.·
lOX) e prod uction represent valid measurements of intracellular metabolism. The amount of oxygen absorbed across the lung is
assumed to be equal to the amount of oxygen consumed for
metabolic processes.
Metabolic carts are capable of calculating a child's respiratory quotient (RQ) or ratio of carbon dioxide molecules
produced to molecules of oxygen consumed. 43 The determination of RQ assists in evaluating overfeeding and substrate
use. The RQ varies from 0.7 to 1.2 depending on the metabolite. 44 An RQ of I reflects pure carbohydrate metabolism;
whereas an RQ of 0.82 suggests protein metabolism, and an
RQ of 0.71 suggests fat use. 45 The administration of large
glucose concentrations has been associated with increased
carbon dioxide production, which may lead to an increased
RQ.42 Edes, Walk, and Austin 44 suggest when RQ is greater
than I, total calories may be decreased. When RQ is less
than 1 but greater than 0.85, carbohydrates are being converted to fat. 7 Fat calories can be substituted for carbohydrate calories when further reduction of the RQ is seen as
beneficial to the child. Simply adding fat calories, however,
may not benefit the child if total calories are in excess of his
or her needs. Edes, Walk, and Austin 44 also suggest that
those patients receiving long-term ventilatory support or
patients who will not undergo weaning for several days may
not benefit from a reduction in RQ or a change in the diet to
high-fat feedings. The goal is to keep the child, once fed, at
an RQ of equal to or slightly lower than 0.85 to 0.9. 7 •35
Although indirect calorimetry predicts energy expenditure with much higher confidence than the traditional
formulas, this method has some limitations. 42 Measurements are affected by oxygen concentrations of greater than
40% to 60%. Higher oxygen concentrations broaden the
margin for error. The reproducibility of the measurements
is also affected by loss of exhaled volume from a leak
in the system. The expense of the necessary equipment,
the importance of an experienced technician, and the
continued need to standardize equipment in the pediatric
population have limited the use of indirect calorimetry in
many PICUs.

NUTRITION MANAGEMENT
Nutrition management of the child in the ICU involves
providing protein and calories sufficient to address the
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child's stress-related needs while enhancing protein and calories for growth and supplementing vitamins and
minerals.Preventing malnutrition is easier than recovering
from the effects of undernutrition. Specialized nutrition support is initiated with specific therapeutic goals. Various organ systems and disease entities may benefit from tailored
interventions. 46 During the beginning phase of critical illness, the goal of therapy is to stabilize lean body mass. After
the initial hypermetabolic period, nutritional goals broaden
to include improvement of visceral protein, replenishment
of muscle glycogen and mineral stores, and provision of
positive anabolic growth. The correction of the organ system
dysfunction associated with malnutrition may take days to
weeks. The ultimate plan for nutritional support depends on
the basal metabolic needs, the nutritional condition of the
child, the metabolic response and nutrient requirements of
critical illness, the child's age, and the ability to provide
parenteral and enteral therapy. Although brief nutritional
inadequacies may have limited consequences if adequate
oral intake is not expected, children admitted to ICUs should
receive nutrition support within 24 to 48 hours after their
admission. Those children with injury or sepsis or those who
are admitted to the PICU in a malnourished state are particularly vulnerable and require the highest priority.

Determining Energy Needs
Estimation of the child's energy needs is essential for
providing nutrition support. The energy requirements of a
critically ill child are highly individualized and may vary
widely. Some researchers have found a trend of increasing
energy needs during the first week after injury or sepsis with
a peak during the second week of admission. 47 Others have
reported total energy expenditure close to resting energy
expenditure for trauma patients who are deeply sedated48
and no significant difference between preoperative and
postoperative needs 49 ,5o Ventilated patients with little work
of breathing may only minimally increase their energy
expenditure.
Because metabolism affects energy needs, whatever
changes metabolic response affects caloric and nutrient
needs of the child. More than 60% of the child's energy
needs are necessary for daily function of the heart, kidneys,
and brain. These body organs make up 16% to 17% of the
body weight of a child, compared with 5% to 6% of the body
weight for adults. Basal metabolic rate (BMR) is the energy
required to maintain functional cellular activities at complete rest in a fasting state. Infants have a higher metabolic
demand per kilogram, requiring a larger percentage of
calories for growth. During infancy, BMR is approximately
50 kcaUkg/day; by adolescence the caloric needs of the
child have decreased by 50% to 20 kcal/kg/day5 BMR is at
its highest level per kilogram up to the age of 24 months.
BMR is affected by a variety of factors other than age, In
both starvation and obesity, BMR decreases. For every 10
increase in temperature, there is a 10% to 14% increase in
metabolic rate. Drugs such as caffeine, ~-blockers, and
catecholamines increase BMR. Pathologic states, such as
respiratory failure, increase BMR.
Establishing caloric needs of critically ill children is

TABLE

12-4

Stress Factors

;::epresentative Stress State

Stress Factor

~'
li!<,-'

~imple

0.9

~-$epsis

1.3
1.5-1.6
1.3
1.5

starvation
(moderate)
I[&psis (severe)
!lJl1'rauma: central nervous system (sedated)
Ii'rrauma: moderate to severe
!!IBums
(proportionate to bum size)
it"
'~atch up growth

Up to 2
1.5-2.0

·.'ollack M: Nutritional support of children in the intensive care unit. In
,. uskind R, Lewinler-Suskind L, eds: Textbook of pediatric nutrition.
~. 2, New York, 1993, Raven Press, p 214; Jew R: The Children's
~ asp/tal of Philadelphia pharmacy handbook and formulary, Ohio,
'c998. Lexi-Comp.
i~

challenging. Although the recommended daily allowance
(RDA) guidelines are standard for estimating the energy
needs of healthy children, these recommendations exceed
basic energy expenditure by approximately 20% to 50% and
are not reliable estimates of for critically ill children. 5I More
accurately, caloric needs for critically ill children are
approximated by calculating resting energy expenditure
(REE) and multiplying by activity and injury stress factor
(Table 12-4), Although REE and BMR are often used
interchangeably, REE is approximately 10% higher than
BMR, reflecting a measurement time closer to the consumption of food. The World Health Organization (WHO) REE
recommendations have been proven relatively accurate for
children older than I year of age.2 9.52 Activity and stress
factors are used to adjust for increases in energy expenditure
as they relate to illness and activity. For obese children
(those greater 120% of ideal body weight), the Schofield
height/weight equations may be more useful. 53 -55 Indirect
calorimetry, as previously discussed, may also be used to
estimate caloric needs, especially in cases when multiple
processes are occurring simultaneously.
Once determined, REE is multiplied by a stress and
activity factor. Cerra56-58 initially quantified the metabolic
effect of various types of activities and degrees of stress.
Routine activities common to the ICU were found to affect
oxygen consumption and energy expenditure 59 (see Chapter 8). A decrease in energy expenditure may occur with
paralysis (58%) and with sedation and pain relief (5% to
10%).60.61 In the late 1990s, many authors contested the
initial stress factor guidelines suggested by Cerra. 38 .62
Studies done using indirect calorimetry to measure REE
found energy expenditure to be lower than previous research
using other methods to estimate increased caloric needs.
Results from pediatric studies examining measured
energy expenditure in the critically ill child have confirmed
energy expenditure above REE.49.50.63 In practice, for the
majority of critically ill children with moderate stress from
trauma, sepsis, or surgery, REE can be multiplied by a factor
of 1.5 to 1.6 or a 50% to 60% increase above REE. 35
Otherwise, the well-nourished child on bed rest with
moderate stress, for example, skeletal trauma, may require
REE times 1.2 to 1.3 or 20% to 30% above REE. Long-term
growth failure may require an increase of 50% to 100%
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Comparisons of Macronutrient Needs

L""
~eterm

l!Infant«12months)
~oddler (1-2 years)
~irreschool (3-5 years)
~JiSchool (7-12 years)
!~;AdOlescent (13-18 years)

Total Calories
(kcal/kg/day)

Protein
(g/kg/day)

Carbohydrates (%)

Fat (%)

100-120
80-110
85-95
80-90
70-80
40-65

2.5-3.5
2.0-3.0
1.5-2.0
1.2-2.0
1.0
1.0

34-39
35-65
50-55
55-60
55-60
55-60

39-43
30-55
30
30
30
30

~daPted from Huddleston K. Ferraro-McDuffie A, Wolff-Small T: Nutritional suppon of the critically ill child. Crit Care Nurs Clill North Am 5:68. 1993;

~ta from Hobenbrink K. Oddlesitson : Pediatric nutrition suppon. In Shronts E. ed: NutritiOIl support dietetics. Gaithetsburg. Md. 1989. Aspen
!P'ublications. p 231; Pereira G, Barbosa N: Controversies in neonatal nutrition, Pediatr Clill North Am 33: I, 1986; Jew R: The Children's Huspital of
~'fhiladelphia pharmacy halldbook alld formulary, Ohio, 1998, Lexi-comp. p 375.
W.J;

above REE. Stress factors of over 2 are commonly reserved
for children with bums.
Although adequate nutrition is essential for the critically
ill child, overnutrition cannot be overlooked as a potential
complication. 37M Overfeeding with excessive calories may
cause hyperglycemia, added nosocomial infections, hepatic
dysfunction, and congestive heart failure; may worsen respiratory insufficiency; and may increase metabolic rate.13.65-67
Altered body weight changes energy expenditure. 64 The
work of breathing may be affected by an increase in adipose
tissue throughout the abdomen and chest. Increases in oxygen consumption and hypercapnia, which may result from
overfeeding, can interfere with weaning. 68 Storage of fuels
such as glycogen and adipose are associated with significant
increases in energy expenditure. 69 Elevations in the RQ can
be attributed to the metabolism of an increased carbohydrate
load. Some have even recommended permissive underfeeding in the adult population, providing a hypocaloric, hypoprotein diet in the first days after injury or sepsis. 7o.7t
Despite the reported overestimation of energy expenditure, formulas continue to be standard for determining
caloric needs of critically ill children. 72 Some speculate that
because of improvements in the treatments and procedures,
these equations are no longer predictive. 73 In practice,
clinical response to feeding is the best indicator of caloric
adequacy.

Nutrient Distribution
Once a child's total caloric needs are estimated, macronutrient distribution of kilocalories is determined. Appropriate
amounts of vitamins, minerals, and trace elements are also
added. Providing a mixed fuel source for patients is
recommended 74 (Table 12-5).
Macronutrient Needs. Protein provides amino acids
for continuous tissue synthesis and repair, transport of nutrients, and maintenance of immune function. Protein requirements change, as does metabolic rate. 75 .76 Dietary protein is
an important determinant of postinjury nitrogen balance. As
a child gets older and metabolic needs decrease, so will the
need for protein. The RDA provides guidelines for protein
intake. These recommendations are based on minimum protein intake necessary to maintain nitrogen balance. 5 I One
gram of protein equals 4 calories. Infants require 10% to

20% protein, and children older than 2 years require 10% to
15% protein in the diet. 29 Nitrogen balance is possible at
levels of nitrogen intake exceeding the rate of protein catabolism. In patients with head injury, however, protein catabolism was not reduced despite an intake of twice the calculated requirements. 77 Early feeding of ICU patients with
small peptide-based protein has improved nitrogen balance
and returned prealbumin to normallevels. 78
Nonprotein calories are provided to the body by carbohydrates and fat. Carbohydrates ingested primarily as
disaccharides, starches, and polysaccharides are the major
source of energy for the body. Depending on the source, I g
of carbohydrate equals approximately 4 calories. A high
glucose load may also cause hyperglycemia and hepatic steatosis. 66 Carbohydrates often supply approximately
35% to 65% of the infant diet and 55% to 60% of the diet
for children older than 2 years of age.2 9 Fat is essential to
cell integrity and provides a high caloric content. Fat has the
highest caloric density of any nutrient, with I g of fat equal
to approximately 9 calories. In general, to avoid essential
fatty acid deficiency, 4% to 8% of the total calories ingested
should be from a lipid source. 18 The recommendation is for
approximately 30% to 55% of the full-term infant's diet and
30% of the diet for children older than 2 years of age be
provided by fat?9 Infant metabolism requires a greater
dependence on fat for energy. 5
To ensure maximum use of protein, calculating the ratio
of nonprotein calories to nitrogen may be useful. The
amount of nitrogen reflects protein in the diet. One gram of
nitrogen is equal to 6.25 g of protein. In the typical
American diet, the ratio of nonprotein calories, those from
carbohydrates and fat, to grams of nitrogen is approximately
200 to 300 calories to I g of nitrogen. The inefficient use of
amino acids, along with an increase in excretion of urinary
urea nitrogen by the critically ill, suggests the need for
higher protein intake. 34 Providing nonprotein-to-nitrogen
ratios of approximately 80: I to 100: I for highly stressed
patients may maximize nutritional support. Lowering the
ratio of nonprotein calories to nitrogen may benefit children with high protein needs caused by burns, continuing
losses through chest tube drainage, nasogastric suctioning,
intractable diarrhea, and substantial blood IOSS7 For critically ill patients, increasing the fat portion of the nonprotein
energy requirement by shifting away from the carbohydrate
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TABLE 12·6 Vitamins, Minerals, and Trace Elements
Fat-Soluble Vitamins
Vit.A
(/1g)

!

j;1i'

'~_emales

I~

Vito D
(/1g)

0.0-0.5
0.5-1
1-3
4-6
7-10

375
375
400
500
700

11-14
15-18
19-24

1000
1000

10
10
10

11-14
15-18
19-24

800
800
800

10
10
10

1000

Vito K
(/1g)

Vito C
(mg)

Thamine
(mg)

Riboflavin
(mg)

3
4
6
7
7

5
10
15
20
30

30
35
40
45
45

0.3
0.4
0.7
0.9
1.0

0.4
0.5
0.8

10
10
10

45
65
70

50

1.3
1.5
1.5

1.5
1.8

8
8
8

45
55
60

50
60

1.1

1.3

1.1

1.3

60

l.l

1.3

Vito E
(mg)

7.5
10
10
10
10

Water-Soluble Vitamins

60

60

1.1

1.2

1.7

Niacin
(mg NE)

Vit.8 6
(mg)

Folate
(/1g)

Vit.8 12
(mg)

0.3
0.5
0.7
1.0
1.4

5
6
9
12
13

0.3
0.6
1.0
1.4

25
35
50
75
100

17
20
19

1.7
2.0
2.0

150
200
200

2.0
2.0
2.0

15
15
15

1.4
1.5
1.6

150
180
180

2.0
2.0
2.0

1.1

;]i~,

_:~dapted with permission from Recommended dietary allowances: 10th edition. Copyright 1989 by the National Academy of Sciences. Courtesy of the

.. ational Academy Press. Washington, D.C.
"~ormal height and weight for age.

portion may decrease hyperglycemia and prevent respiratory failure. 79
Micronutrient Needs. Micronutrients are an essential part of the critically ill child's diet. Children have
increased requirements of calcium and phosphorus. Guidelines established by the RDA for vitamins, minerals, and
trace elements are used as recommendations for providing
micronutrients (Table 12-6). For the critically ill child,
individually calculated amounts of vitamins and electrolytes
are often necessary. Replacement of these elements is
guided by monitoring appropriate serum levels. These
deficiencies may affect the metabolic processes that are
necessary for recovery. Deficiencies may have occurred
before the child's critical illness or from inadequate
replacement of current needs. If deficiencies exist, supplementation is necessary. Trace elements such as zinc, copper,
chromium, manganese, selenium, iodine, molybdenum, and
iron are important for growth and development. Small
infants also have a reduced capacity to store minerals. 5

Immune-Enhancing Additives
Amino acids such as glutamine, arginine and others;
nucleotides; OJ-3 fatty acids; recombinant growth hormone;
and antioxidant vitamins have a role in maintaining the
structure and function of the gut and in treating the stressed,
hyperrneLabolic patient. 23 ,80-82 Glutamine is important in
protein synthesis and may be the principal means of nitrogen
transfer from the muscle to visceral organs. 83 During
hypermetabolic states, glutamine is consumed at higher
concentrations by the gastrointestinal tract and may reflect
an increase in meLabolic need. The addition of glutamine to
enteral and parenteral nutrition may improve nitrogen
balance, enhance intestinal mucosal repair, minimize villous
atrophy, and reduce bacterial translocation 84.85 Arginine
may reduce protein breakdown, which may have a potent
effect on depressed immunity and also enhance the body's

wound healing ability.86,8? Although the evidence is inconclusive, adjusting the protein source to include branchedchain amino acids (valine, isoleucine, and leucine) has also
been identified by some to benefit patients during injury or
sepsis 88 Nucleotides have also been added to various
formulas to influence immunocompetence. 8o An increase in
ro-3 fatty acids potentiates the immunoregulalOry properties
of fat emulsion. 89 An OJ-6 to OJ-3 fatty acid ratio of 2: I may
benefit the critically ill child. By reducing triglyceride level
in the plasma and thereby decreasing the risk of coronary
heart disease, ro-3 fatty acids make a valuable addition to the
diet. The OJ-3 fatty acids may also have a positive effect on
atherosclerosis, hypertension, inflammatory disease, and
ventricular dysrthyIhias. 90 -92 Administration of growth hormone has been shown to decrease RQ and to contribute to
a positive nitrogen balance. 93 -95 However, in septic patients,
no improvement in protein status was noted. 96.97 Diets with
arginine, OJ-3 fatty acids, and ribonucleic acid may increase
muscle protein levels, improve nitrogen balance, reduce
weight loss, and improve immune function 98 However,
immune-enhancing formulas have not proven advantageous
to all patient populations. 99. tOO Vitamin C, vitamin A,
riboflavin, and pantothenic acid are indicated for wound
healing. 101 Zinc loss is directly related to severity of illness.
It is sequestered in the liver during stress and is used in
essential metabolic pathways]5

Collaborative Interventions
Delivery of nutrients to a critically ill child is often
challenging. If oral intake is inadequate or not feasible,
nourishment by another delivery method is necessary.
Enteral Feeding. When oral intake is insufficient in a
child with adequate digestive and absorptive capacity, enteral tube feedings are initiated. Increasing evidence confirms that enteral feeding is superior to parenteral nutrition
with regard to gut structure and function. 102,103 However,
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Minerals

Males

Females

Trace Elements

Calcium
(mg)

Phosphorus
(mg)

Magnesium
(mg)

Iron
(mg)

Zinc
(mg)

Iodine
(mg)

0.0-0.5
0.5-1
1-3
4-6
7-10

400
600
800
800
800

300
500
800
800
800

40
60
80
120
170

6
10
10
10

5
5
10

10

10

40
50
70
90
120

10
15
20
20
30

11-14
15-18
19-24

1200
1200
1200

1200
1200
1200

270
400
350

12
12
10

15
15
15

150
150
150

40
70
70

11-14
15-18
19-24

1200
1200
1200

1200
1200
1200

280
300
280

15
15
15

12
12
12

150
150
150

45
50
55

Age* (yr)
Infants
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controversy remains regarding whether parenteral nutrition
alone or overfeeding itself is the cause of the perceived
inferiority of parenteral nutrition. I04 The enteral mode of
therapy preserves the normal sequence of nutrient delivery.
In addition, this mode is safer and less costly. Enteral nutrition is associated with reduced morbidity and mortality,
decreased potential for bacterial translocation into mesenteric lymph nodes, improved host response, higher pancreatic enzymes and disaccharidase activities, and enhanced
nutrieill use, compared with parenteral therapy. lOS-lOB Enteral support may be essential for continued production
of immunoglobulin A (lgA).lol Reduced IgA may allow
introduction of foreign substances into the lymphatic system
via the gut. 109
Despite the common practice during the initial phase of
critical illness of withholding enteral nutrition to prevent
feeding intolerances and avoid gut malfunction, early
enteral feedings have significant benefits. 110-1 16 Seemingly
small amounts of nutrients administered enterally benefit the
integrity and function of the 01 tract. Therefore, when it is
not possible to provide full nutrition support with enteral
feedings, trophic feedings should be initiated to provide gut
protection (see Appendix VII). Although use of parenteral
nutrition for up to 2 weeks may not cause mucosal atrophy,
evidence does indicate that impairment of absorptive
capacity may occur when nutrients are not supplied directly
to the gastrointestinal tract. 1l7 - 119
Few contraindications to the exclusi ve use of enteral
feedings exist, the most significant of which include or
obstruction involving the entire small intestine, caloric
requirements beyond those which safe enteral feedings can
provide, and active upper 01 bleeding l20 (see Appendix
VII). Withholding enteral feedings is also considered for
patients who require endotracheal intubation or extubations
within 4 hours, hemodynamically unstable patients with
escalating therapy, and patients with significant graft versus
host disease. In addition, an infant at risk for developing

10

Selenium
(mg)

necrollzmg enterocolitis may need a delay in enteral
feedings for I to 2 weeks. Enteral feedings in the past have
been avoided in the initial phases of critical illness because
of the potential for gastric stasis. Although hemodynamic
instability is a contraindication for some, complications may
be avoided by placing the feeding tube in the child's
duodenum or jejunum.
Selection of Formulas. Human breast milk, along
with a variety of formulas, is available for the enteral
nutrition of infants (Table 12-7). The selection of these
enteral products is based on the child's age-related nutritional needs, underlying physiologic and pathophysiologic
conditions, clinical status, and 01 function.
Breast milk has long been recommended as the ideal
food for infants and is given strong consideration for the
critically ill infant. 121 Human milk provides essential
immunologic benefits, growth-stimulating properties, and
a balance of nutrients and digestive substances.I22-125
Human milk proteins provide amino acids for growth,
as well as for digestion, host defense, and possibly tis126
For infants at greater risk of infection,
sue maturation.
breast milk may be especially beneficial. The decreased
infection rate in breast-fed infants has been attributed by
some to IgA and other antimicrobial properties found
in human milk. The fat in human breast milk is thought
to be more absorbable because of the positioning of the
fatly acids. Iron, zinc, and other nutrients, except chloride,
tend to be more bioavailable in human milk. While the
infant is in the intensive care unit, breast-feeding mothers
require support. 127·129 Providing staff support to the mother
at regular intervals, as well as continued staff education, has
been found to improve the duration of breast-feeding. 130
Mothers offered a quiet place in a private room can use
manual or electric breast pumps to express milk for their
infant. Breast milk can then be stored in glass or plastic
containers in the refrigerator for 24 to 48 hours, in the
freezer compartment of refrigerators for 2 to 3 weeks, or in a
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Breast Milk and Selected Infant Fcmnulas
Kcal/ml

lleast Milk
,l:ow's Milk
,i:
jiferm Protein Formulas
i$imilac
'!Enfamil

Carbohydrate

Fat

Protein

(g/dl)

(g/dl)

(g/dl)

0.67

7.2

4

1.05

0.67
0.67

7.2
6.9

3.6
3.8

1.5

0.67

7.2

3.4

1.6

0.67

6.9

3.8

1.6

0.67

7.8

3.2

2.3

.67

6.9

3.8

1.5

0.67

6.8

3.6

2.0

0.67

6.9

3.6

2.0

0.81

8.6

4.4

2.2

0.81
0.75

8.9
7.7

4.1
4.1

2.4
1.9

7.9

3.0

2.1

0.67

8.8

2.6

2.2

0.67

9.1

2.7

1.9

0.67

6.8

3.7

1.8

1.4

1'"

:~arnation Good Start

Components

Lactose; soy, coconut oil; nonfat milk
Lactose; coconut oil, soy; nonfat milk, demineralized whey
Hydrolyzed whey, whey protein concentrate;
lactose maltodextrins; palm oil, safflower
oil, soy oil
Lactalbumin; coconut, com oi I; lactose;
reduced sodium

CT.Containing Formulas

term Infant Formulas
:inulac Special Care
I (24 cal/oz)

.'1:.

Com syrup solids, lactose; MCT oil and com
oil; sodium caseinate
Com syrup solids; milk protein isolate; palm,
soy, coconut, sunflower oil
Com syrup solids, sucrose; soy and coconut
oil; soy protein isolate, L-methionine
Com syrup solids, soy and coconut oil; soy
protein isolate, L-methionine
Com syrup solids, lactose; MCT oil, com
and coconut oil; nonfat milk, demineralized whey
Same as above
Nonfat milk with whey protein; sunflower,
soy, MCT and coconut oil; corn symp

Sucrose, modified tapioca starch; com oil;
casein hydrolysate
Com syrup solids, modified tapioca starch;
com oil and MCT oil; casein hydrolysate
with amino acids
Tapioca starch, sucrose; MCT oil, safflower
oil, soy oil, casein hydrolysate with amino
acids

tA.dapted from Abad-Sinden A, Sutphen 1: The practical use of infant formulas. In Wyllie R. Hyams J. eds: Pediatric gastrointestinal disease. Philadelphia.
)93. WB Saunders, p 1084; data from American Academy of Pediatrics. Committee on Nutrition: Pediatric lIU1ri'iOIl halldbook. ed 3, Elk Grove Village.
. " 1993, American Academy of Pediatrics; Jew R, ed: Pharmacy halldbook alld fonnulary. The Children's Hospital of Philadelphia, Ohio, 1998.
"'xi-Comp. p 375.
I:, CT, Medium-chain triglyceride.
,:'

deep freeze of -200 C for 3 to 6 months and given to the
infant as needed. 131 Frozen milk is thawed quickly under
running water. Once the milk is defrosted, it can be refrigerated for 24 hours.
If breast milk is not available, a variety of commercially
prepared formulas can be given. For most patients, resuming
their previously established diet is most appropriate. Otherwise, evaluation of the child's age and nutritional needs is

necessary to determine the most appropriate formula. Standard formulas for infants younger than 12 months of age
contain whole protein and require intact biliary, pancreatic,
and intestinal function. Although based on breast milk, formulas tend to have higher levels of polyunsaturated fat and
lower levels of monounsaturated fat. Formulas also lack the
range of complex carbohydrates found in breast milk. Infant
formulas tend to have higher concentrations of some nutri-
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Selection of Infant Formulas «1 Year of Age)

term infant

It

'~34 Weeks' gestation

Formula Description

Example of Formulas

60:40 whey/casein or casein formula

Enfamil
Similac
Carnation Good Stan

Whey hydrolyzed; hypoaJlergenic
Premature infant formula

~~~

I~

!ncomplicated lactose intolerance; casein

IW'·

Lactose·free soy protein
Isolate formula (sucrose and com-free also
available)

'~~rgan dysfunction (e.g., renal, cardiac)

Low renal solute load

,..,,,,'; ,.senSILJve
~~i'

~'"'

-~iarrhea management
~.evere

steatorrhea associated with bile acid
.--:i"deficiency, ileal resection, or lymphatic
Itanomalies; fat malabsorption

·~.1.\.l
•. . .• .• .• . I ergy to cow's milk (casein) and soy

1

·"'protem

"W:·

Soy protein containing fiber
Infant formula with MCT oil

Hypoallergenic casein hydrolysate; peptide
based

1\;:

.~bnormal nutrient absorption, digestion, and

-"of transport; generalized malabsorption;

'li' severe intractable diarrhea; protein calorie

Hydrolyzed casein with part of fat from
MCT oil (lactose-free); peptide based

Simi lac Special Care
Neosure
Enfamil Premature
Lacto·free
Prosobee
Isomil
Similac PM 60/40
Good Start
IsomilOF
Portagen
Pregestimil
Alimentum
Nutramigen
Pregestimil
Alimentum
Pregestimij
Alimentum

~>malnutrition

~

.. bnormal nutrient absorption and transport;
!!ill.- malabsorption of protein and fat; intract.~,:.able diarrhea; protein calorie malnutrition

Hydrolyzed casein with percentage of fat from
MCT oil (lactose·free and sucrose-free);
peptide based; 100% Amino acid based

Pregestimil
Neocate

,.;'c:

~~~apted from Wilson SE, Dietz WH Jr, Grand RJ et a1: An algorithm for pediatric enteral alimentation, Pediarr Ann 16:233, 1987; Hendricks K, Walker
Manual of pediatric nurritian. ed 2, St Louis, 1990, Mosby.

iiW:

j~CT,

Medium-chain triglyceride.

ents compared with breast milk because the bioavailability
of the nutrients contained in formula is lower. For children
younger than I year of age, standard formulas have the same
caloric densities, are of nearly identical osmolalities (250 to
320 mOsm), and provide similar calories (20 calories/ounce
[calloz] or 0.67 calorie/mi). The type of infant formula can
be selected based on the child's needs (Table 12-8) (see
Appendix VII). Cow's milk-based formulas for healthy full·
term infants (e.g., Similac, Enfamil with Fe) contain lactose
as the major carbohydrate. Soy and coconut oil blends provide fat for the majority of these formulas. Lactose-free
cow's milk-based formulas (e.g., Lacto-free) are also avail·
able for infants with suspected lactose intolerance. Soybased formulas (e.g., Isomil, Prosobee) may also be recommended for infants exhibiting a primary or secondary
lactose intolerance. Specialized formulas (Pregestimil, Alimentum, and Neosure) are available for infants who have
malabsorption problems or are intolerant of the carbohydrates, fats, or protein contained in standard infant formulas.
When fortified breast milk is not available, preterm infants
require nutrient dense formulas (e.g., Similac Special Care).
Formulas are prepared and refrigerated when opened for no
longer than 24 hours.
For children older than I year of age, various formula
options are available (Table 12-9) (see Appendix VII).

Pediatric formulas (e.g., Pediasure, Nutren Jr.) are specifically designed for children I to 10 years of age. These
formulas provide a higher caloric value with an increase in
grams of protein and carbohydrate and a decrease in fat
content, compared with infant formulas. Higher amounts of
calcium, phosphorus, and vitamin D with similar osmolarity
to infant formulas (325 mOsmlkg) are also characteristic of
pediatric formulas. Peptide-based formulas (e.g., Peptamin
Jr.) are available for children with malabsorption problems.
Elemental formulas such as Pediatric Vivonex may also be
necessary for some children with severe problems. Pediasure with Fiber and Nutren Jr. are also available with fiber
and are considered for children with diarrhea, constipation,
neuromuscular disease, and immobility.
Adult formulations are generally used in children older
than 10 years of age. These products range in caloric density
from 1 to 2 kcallml and in general have a higher osmolarity
(450 to 810 mOsmIL). Standard adult formulas require the
patient to have normal digestive capacity. These formulas
are isotonic, providing I cal/ml with a relatively high
carbohydrate-to-fat ratio and intact or almost intact protein.
Selection of these formulas is based on standards similar to
those of infant formulas (Table 12-10) (see Appendix VII).
Complete or standard lactose-free formulas (e.g., Isocal,
Ensure) are adequate for the majority of patients. Fiber-

TABLE

12·9 Selected Pediatric and Adult Formulas
Calories
(kcal/ml)

Protein
(giL)

Fat
(giL)

Carbohydrate
(giL)

21
30

42
50

127
110

30
30

50
38.5

110
137.5

6.7

20.9

30

1.06
1.5
1.06
1.06
2

54.9
34

37.2
53

44

44

70
70
57

36.8
80
37

145
200
133
151.7
250
145

1.5

57
56
62.5

57
28
93.7

161
132
105.5

1.96
1.8

19.4
38

46
3

366
206

J

40

1.5
1.78
1.5
1.5

94
44

39
68
36

63
82

68

2

79

1.06
1.35

1

127

135
169
106
142

92

i~dapted from Committee on Nutrition. American Academy of Pediatrics: Pediatric nl/trition handbook, ed 3. Elk Grove Village, Ill, 1993, pp 380-384;

~ata

from Jew R, ed: Pharmacy handbook andforml/lary, The Children's Hospital of Philadelphia, Ohio, 1998, Lexi-Comp, pp 425-438.
Medium-chain triglyceride.

'~CT,
i:~i'

TABLE

12·10 Selection of Older Child and Adolescent Formulas

Requiring Fiber
")'Abnormal 01 tract
'L~i:

Formula Description

Suggested Formulas

Nutritionally complete for age group

Pediasure
Nutren Jr.
Pediasure with Fiber
Peptamin Jr.
Neocate plus one
Vivonex Pediatric
Ensure
Osmolite
!socal
Ensure Plus
Magnacal
Oxcepa
Pulmocare
TraumaCaJ
Crucial
Peptamen
Vivonex TEN
Amin-Aid
Lipisorb

Nutritionally complete with fiber
Peptide based
MCT containing
Elemental
Nutritionally complete

1'-'.

~gher protein/calorie needs (e,g,. bums)

!it':

~ignificant

pulmonary compromise

ll>
[Significant trauma requiring very high
1[, protein needs
Abnormal Of tract functioning

(:

Nutritionally complete with high protein/calorie
formula
High-fat formulation
High-protein formulation
Peptide based

'Adapted from Hendricks K. Walker W: Manl/al of pediatric nl/lrition, ed 2, 5t Louis, 1990, Mosby, pp 91-92.
i¥CT, Medium-chain triglyceride; C/, gastrointestinal.
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Methods for Increasing Caloric Density of Infant Formulas
Advantages

Disadvantages

Recommendations

Simple, easy
Maintains standard ratio of
protein, fat, and
carbohydrate

Increases solute load
May prolong gastric emptying,
especially if >24 kcalJoz
May cause diarrhea
May precipitate dehydration in
patients at risk for excessive
losses

Monitor renal status
Monitor for symptoms of reflux,
abdominal distension
Monitor for symptoms of
dehydration

Relati vely easy

May increase solute load
High caloric density

See recommendation for other
additives

When used in excess, may
increase work of breathing
May cause osmotic diarrhea
Base formula may fall short of
RDA for protein
Overall vitamin and mineral
content may be below RDA

Monitor respiratory status
Monitor stool output; check stool
for reducing substances
Monitor total daily protein
Supplement vitamins and
minerals as required

enriched formulas (e.g., Ensure and Sustacal with Fiber)
may be useful for patients receiving tube feedings on a
long-term basis or for those patients with diarrhea or
constipation. Vivonex and Peptamen may be considered for
older children with impaired gut perfusion. These formulas
are usually isotonic to slightly hypertonic and provide
I kcallml. Fiber-containing formulas may be beneficial in
normalizing bowel pattern and maintaining a healthy gut
mucosa.
Predigested or elemental formulas are usually hyperosmolar solutions that contain oligopeptides or amino acids as
protein and oligosaccharides or disaccharides as carbohydrate. These formulas are appropriate for older children and
adolescents with malabsorption problems because they
require minimal digestion and are almost completely
absorbed. Predigested or elemental formulas typically provide I callml. Elemental formulas reduce bile acid excretion, which is one of the reasons that they are useful for
malabsorption problems.
Specialized formulas vary in amino acid and nutrition
distribution. Higher visceral protein levels have been

demonstrated in patients receiving peptide-based formulas
instead of those containing intact protein. 78 Formulas are
now available that have been designed specifically with the
needs of patients with adult respiratory distress syndrome
(e.g., Oxcepa) and stress-induced hypermetabolism (e.g.,
Crucial, Impact).80.114 Increased dietary component such as
glutamine, arginine and <0-3 fatty acids when supplied in
large quantities appear to have beneficial affects on bum
133
patients.
A diet supplemented with arginine, (J)-3 fatty
acids, and ribonucleic acid (Impact) has also shown a
positive immunologic effect. 98
Formula Enhancement. There are several methods
of providing increased caloric density of formula above
standard (Table 12-11). Calorically enhanced infant and
adult formulas are available. These formulas may be used
for patients who require fluid restriction or those who
require a higher caloric intake. Many infant formulas are
now commercially available in concentrations of 24 calloz
(0.8 callml) and 27 calloz (0.9 callml). Also, when
reconstituting infant formulas, calories can be increased
above the formula's standard caloric concentration by using
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less free water. High-calorie adult formulas usually contain
1.5 to 2 cal/m!. When providing concentrated formulas to an
infant or child, being conscious of the increasing renal
solute load is important.
Single modular components can also be added to
standard formula in the form of protein, fats, or carbohydrates. Protein can be added to the diet to increase protein
density. Fat modules, such as medium-chain triglyceride
(MCT) oil (7.7 cal/mI) and microlipids (4.5 cal/ml), can be
added in small volumes to existing formulas to increase
caloric density. Smaller volumes avoid separation of fat in
the formula and reduce the chance of overwhelming the
absorptive capacity of the intestine, which may occur with
a large bolus of lipid. MCTs are more easily absorbed, better
utilized, and smaller and have greater water solubility.
Carbohydrate modules like Moducal (19 kcal/tbsp) and
Polycose (2 cal/ml) provide supplemental carbohydrates.
Protein modules such as Casec (4 g/tbsp) can also be added
to the diet. A human milk fortifier can also be used to
increase the caloric content of breast milk. Two packets per
50 ml provide 24 cal/oz. Protein, calcium, phosphorus, and
vitamin concentrations are also increased with human milk
fortifier. A higher risk of nutrient imbalances can occur
when modular units are added to the diet, and therefore extra
care must be taken to adhere to the recommended nutrient
distribution guidelines.
Implementing and Advancing Feedings. Establishing a goal of therapy improves the implementation
process of any feeding regimen. Feeding into the gut can
meet the child's nutritional needs or be instituted to
stimulate gut mucosal integrity and function. Using a
systemic approach to the initiation of feeding is helpful (see
Appendix VU).
Delivery Methods. Adequate delivery of enteral
feedings can be accomplished by several methods 134 (Table
12-12). The route chosen for enteral nutrition depends on
the level of GI function, the expected duration of tube
feeding, and the child's potential for aspiration. Feeding the
child into the stomach allows gastric acid and other
hormones to respond normally in the digestive process.
Typically, gastric feedings enable the child to tolerate a
larger osmotic load with a lower incidence of dumping
syndrome, allow more flexibility in feeding schedule, and
have greater mobility between feedings. Gastric feedings
also incur less administrative expense. 135 The gastric
feeding site is recommended when there is minimal risk of
aspiration. Enteral tubes may be inserted into the duodenum
or jejunum in children with the potential for difficulties in
tolerating feeding from inadequate gastric motility or with
an unacceptable risk of aspiration from a depressed gag
reflex and gastroesophageal reflux (GER). Placing the tube
past the pyloric sphincter reduces the risk of aspiration and
is recommended with increasing regularity as the method
of enteral feeding administration for critically ill children.1.I34.136 Montecalvo and associates 137 found that for
patients administered nasojejunal feedings, a higher prealbumin level and a higher percentage of their caloric goal
was met. When tubes are placed past the pylorus, a gastric
decompression tube may be necessary.

An orogastric, nasogastric (NG), or intestinal tube can be
placed for temporary enteral feedings (see AppendiX VII).
Orogastric tubes are appropriate for infants younger than 4
weeks of age. The oropharynx is used to avoid potential
airway obstruction in these obligate nose breathers. Nasoenteric tubes are commonly placed in older infants and
children. Tubes composed of soft, nonreactive materials,
such as silicone or polyurethane, are desirable. These tubes
are long-Ia~ting, pliable, and less likely to cause nose
irritation. 135 Decompression tubes are never used for
feeding children because of the risk of aspiration. With
feeding, aspiration becomes more likely because the side
holes of decompression tubes often lie proximal to the
stomach.
Although the method of placement for gastric tubes is a
standard nursing procedure, various methods for transpyloric placement of feeding tubes have been reported in the
literature. 138 - 143 At the bedside, Chellis and colleagues 138
placed postpyloric enteral tubes using nonweighted silicone
6 Fr and 8 Fr 36-inch tubes in critically ill children with a
93% success rate using air insufflation, a prokinetic agent
(e.g., metoclopramide [ReglanJ), and positioning. To use
this method of tube placement, the operator first marks the
tube at the gastroesophageal junction (measured from mouth
to ear to xiphoid process) and then the pylorus (measured by
continuing the tube to left or right costal margin) (Fig. 12-1,
A). Initially, the child is placed supine with the head of the
bed elevated 15 to 30 degrees. The stomach is decompressed, and the tube is inserted to the gastroesophageal
junction. If no signs of coiling or tracheal intubation are
evident, the patient is turned to the right lateral oblique
position, and the tube is advanced at 1- to 2-cm intervals
until air is auscultated over the right upper quadrant (RUQ).
Reglan 0.1 mg/kg is given intravenously, and while
instilling 5 to 10 ml of air and auscultating the abdomen, the
tube is advanced I cm at a time. Placement occurs when
sounds change from resonant low-pitched gurgles to highpitched propagating crackles near the RUQ and the operator
is unable to withdraw air (see Fig. 12-1, B). The tube is then
advanced 5 to 10 em to ensure placement in the distal
duodenum or jejunum. 138 The inability to aspirate insufflated air was 99% predictive of correct tube placement in
critically ill children using the technique documented by
Chellis and associates. 144 Another technique using feeding
tubes with a pH sensor predicted greater than a 95% success
rate when the pH was measured. 139.145 The use of ranitidine
(Zantac) may invalidate the use of pH as an indicator of tube
placement.
Checking tube placement is an essential component of
delivering enteral feedings. The traditional method of air
insufflation into the tube and auscultation of a "whooshing"
sound can no longer be recommended. This method may be
misleading and dangerous to the patient. 146-149 Metheny and
associates 150 demonstrated that sounds generated by air
insufflation through small-bore feeding tubes are unreliable
for indicating tube placement. In addition, these tubes often
migrate from the intended location. Also, aspiration can
contribute infomlation that may help identify tube location l51 ; however, fluid alone does not ensure that the tube is

TABLE
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Enteral Feeding Sites and Routes

Route

Advantage

Orogastric

Allows for normal digestive processes and hormonal responses
Tolerance of larger osmotic loads
Decreased incidence of dumping
syndrome
Greater mobility between feedings
Greater flexibility in feeding schedule and formula choice
Does not obstruct nasal passage

Nasogastric

Easy intubation

Gastrostomy

Allows patient greater mobility
Feedings are generally well
tolerated
Larger-diameter feeding tube
lessens chances of tube
obstruction
Does not obstruct the airway

intestine

Feed enterally despite poor gastric
motility and persistent high
gastric residuals
Lessens the chances of gastric distension, gastroesophageal reflux,
pulmonary aspiration
Nasojejunall
nasoduodenal
Jejunostomy

Disadvantage

May increase salivary flow and make
clearance more difficult
Nasal, esophageal, or tracheal irritation
Easily dislodged by an uncooperative
child
Easily dislodged by a forceful cough
May stimulate gag
Caretaker must be trained
Limited long-term compliance in the
home care setting
May require a surgical procedure for
placement
May result in increased
gastroesophageal reflux
Occasional leakage around the
insertion site
Skin irritation and infection
Risk of intraabdominal leak with
peritonitis
Less mixing of formula with
pancreatic enzymes
Limited choices of feeding schedule
and formula selection
Greater risk of bacterial overgrowth
Greater risk of bowel perforation
Changes small bowel intestinal flora
More complicated placement; tube
may be more easily displaced
during peristalsis
Technically difficult to place

Indications

Contraindications

Usually first consideration
for enteral nutrition

Delayed gastric emptying
Pulmonary aspiration
Gastroesophageal reflux
Intractable vomiting
Impaired or absent gag
reflex

Infants <4 weeks of age
Nasal passage obstruction
Basilar skull fracture
For short-term use

Older infant or child
with gag reflex

Prolonged enteral nutritional
support

Same as for the stomach

Congenital upper gastrointestinal (GI) anomalies
Inadequate gastric motility
Following upper GI surgery
Patients with increased risk of
aspiration

Nonfunctioning GI tract

Same as for the stomach
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For intermediate-term
nutritional support
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Jejunal feedings for >6 mo
For postoperative nutritional
management of abdominal
surgery while a paralytic
ileus exists
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i!\dapted from Hendricks R, Walker Wi Manual of pediatric nutrition, ed 2, 5t Louis, 1990, Mosby, pp 74-75.
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Part III

Phenomena of Concern

Costal margin

A

B
Fig. 12-1 After pyloric tube placement. A, Measure feeding tube: establish distance from nares to ear to
xiphoid, make first mark; continue tube to right or left lateral costal margin, make second mark. B, Insert
tube, auscultate over right upper quadrant, passing tube at 1- to 2-cm intervals. (From Chellis MJ, Sanders
SV, Dean JM et al: Bedside transpyloric tube placement in the pediatric intensive care unit, lPEN 1
Parenter Enteral Nutr 20:88-90, 1996.)

in the correct position.ls 2 Fluid may be inadvertently
aspirated from the pleural space or lung. The aspirate's pH
must be checked with pH paper to ensure correct placement. 153.154 An acidic pH of less than 4 indicates that the
tube is in the stomach when gastric acid inhibitors are not
used, and a highly alkaline pH of greater than 7 indicates
intestinal fluid. ls5 Because of questions regarding the
reliability of traditional methods for checking tube placement, an abdominal radiograph is the definitive method for
confirming correct tube placement. 134.154

For those children requiring a prolonged enteral delivery
system, a gastrostomy or jejunostomy is indicated.IS6.158
Traditionally, gastrostomy tubes have been placed surgically. For these children, GER becomes a common problem. Gastrostomy tubes can cause skin breakdown and
reduced gastric capacity. Traditional gastrostomies do not
provide stabilization of the tube at the stoma and therefore tend to migrate in and out of the abdominal cavity,
causing enlargement of the stoma and inadvertent removal
of the tube.
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With the advent of percutaneous endoscopic gastrostomy
(PEG) tubes, a safe nonsurgical option can now be offered
to children requiring this delivery method.159-161 Under
endoscopic guidance, a feeding tube is placed through a wall
puncture. 162 The placement of a PEG tube may be done at
the bedside or in the endoscopy suite with intravenous
sedation or, in the case of young uncooperative children, in
the operating room under general anesthesia. The PEG tube
is stabilized by crossbars internally and externally in a
subcutaneous fistula created between the gastric mucosa and
abdominal wall. When anesthesia is not used, the intraoperative and postoperative complications are avoided. Feedings can usually be introduced within 24 hours.
Skin level profile and nonreflux devices, such as the
Button, Gastroport, and Mic- Key, are an option for children
requiring long-term feeding tubes.163.165 The Button is a
type of ga~trostomy device that has a mushroom dome with
a one-way antireflux valve in the stomach. The Button sits
flush against the skin, reducing migration along the GI tract
and the risk of accidental removal. A well-developed
gastrostomy stoma is needed before placement of a BUllon.
The Mic-Key can be used for both feeding and decompression. 166 This device operates like a Foley catheter and is
held in place with a balloon.
A jejunostomy can also be placed in a child with longterm nutrition support needs. This route is employed in
those children who are at increased risk for gastric aspiration
or who have undergone extensive gastric or duodenal surgery.167 Endoscopic jejunostomy requires a similar placement method to a PEG, although it is technically more
difficult. 156
Intermittent and continuous feedings are two techniques
of administering enteral feeding. Intermillent tube feedings
mimic normal eating pallerns by allowing the gut to rest.
Intermittent bolus feedings are often preferred for older
children or those children with no history of or potential for
feeding intolerance. These feedings are typically administered via gastric tubes because the stomach is needed as a
reservoir for the large volumes of formula administered.
Gastrostomy tube feedings are commonly given by the
bolus method. Bolus feedings do not require a feeding pump
and therefore are typically less expensive and increase
patient mobility. A suggested feeding schedule for infants
I to 3 months of age is five to seven feedings per day,
decreasing the frequency to three to four feedings per day by
the time the child is 6 months old.
In the acute phase of critical illness, continuous feedings
may be better tolerated than bolus feedings. 168 Continuous
feedings typically decrease the risk of aspiration and are
indicated for children with a significant risk of respiratory
distress. Infants with smaller gastric capacity and those
children with the potential for GER especially benefit from
continuous feedings. Continuous feedings can be delivered
throughout the day or while the child is asleep. Transpyloric
and continuous feedings are preferred in head-injured
patients to prevent aspiration and achieve maximum caloric
intake. 143 Feedings via the duodenum or jejunum require
formula to be infused continuously to avoid distension of the
bowel, fluid and electrolyte shifts, and diarrhea. A potential
risk of formula contamination exists with continuous
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feedings because of the longer amount of time that fom1Ula
is at room temperature.
The common practice is to start with clear liquids if the
child has a questionable ability to protect the airway and to
dilute formulas to one-half strength at the onset of enteral
feedings. Fonnula dilution, however, is often unnecessary
unless the child is receiving hypertonic feeds, has been
given nothing by mouth for greater than 2 weeks, is at risk
for gut ischemia, or is malnourished before admission (see
Appendix VII). If graded feedings are preferred for nutritional support, it is reasonable to start with 50% of the
therapeutic goal of the appropriate formula and then
increase each feeding by 25% as tolerated. If the goal of
feeding is to provide trophic feedings to protect the gut,
advancement is slow. In this case, half-strength formula is
maintained at 0.5 ml/kg/hr for 2 to 3 days. Increasing the
infusion rate 2 ml/hr every 12 hours has been recommended. 169 Use of free water should be considered,
especially for patients who are receiving calorically dense
formula or if constipation is an issue.
Monitoring Enteral Therapy.
Monitoring enteral
feeding and evaluating tolerance are important aspects of
caring for the child with enteral feedings (Table 12-13).
When caring for critically ill children, evaluating complications, taking preventative steps, and intervening when
appropriate are important responsibilities for the healthcare
provider (Table 12-14).
GI complications, including diarrhea, constipation, nausea, and vomiting, with or without subsequent aspiration has
been reported in the enterally fed patients. 134 Smith and
colleagues l70 reported that 63% of critically ill mechanically ventilated patients who were tube fed had associated
diarrhea. Hypertonic formula, excessive volumes, and rapid
infusion rates are often blamed as the cause of diarrhea.
Edes, Walk, and Austin,44 however, concluded that formula
is often not responsible for diarrhea in tube-fed patients.
Hyperosmolar electrolyte replacement and medications, especially when infused undiluted into the intestinal tract, can
contribute to diarrhea. 171 Sorbitol, an ingredient in many
drug preparations. is often linked to diarrhea. 44
Treatment for diarrhea depends on its cause. Diarrhea is
significant when it affects growth. Reducing substances of
the stool are checked to evaluate the source of the diarrhea.
Eliminating or reducing problem nutrients, such as fat or
lactose, may manage diarrhea. Changing the delivery rate or
the administration method from intermillent to continuous
or adding dietary fiber to the feeding may also be useful. The
addition of some antidiarrheal agents to the formula has
been noted to decrease loose stool.
Constipation may occur as a result of a low-fiber diet or
inadequate fluid intake. Adding fiber or choosing a highfiber formula may eliminate constipation in the critically ill
child. Constipation may also be avoided by increasing
dietary free water.
Vomiting and nausea occur in patients who are tube fed.
Vomiting may have its origin in esophageal lUbe placement
or as a consequence of delayed gastric emptying. Lower
esophageal sphincter incompetence with gastric reflux and
pulmonary aspiration may occur. Large volumes, fast rates
of infusion, hyperosmolar formulas, and hypertonic medi-
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Enteral Feedings: Patient-Monitoring Guidelines
Intermittent
Feedings

Continuous
Feedings

Possible
Complications

Check each stool

Check each stool

Diarrhea
Constipation

Reduce the rate of feed,
change formula, or use
continuous feeds
Adequate hydration; use
tiber-containing formulas; use stool softeners,
if indicated

Daily until 48 hours if
negative results; prn
thereafter

Daily until 48 hours if
negative results; pm
thereafter

Gastrointestinal irritation

Evaluate cause

Daily during advanccment; pm thereafter

Daily during advancement;
prn thereafter

Carbohydrate intolerance

Dilute feed, change
formula

Daily until 48 hours;
thereafter pm if pH
greater than 60

Daily until 48 hours;
thereafter prn if pH
greater than 6.0

Carbohydrate intolerance,
bacterial overgrowth

Dilute feed, change
formula

As necessary

ql2h and pm

Feeding intolerance

Evaluate cause
Adjust feeds prn

q4-8h then daily

q4-8h then daily

Fluid imbalauce

Adjust fluid intake, adjust
concentration of formula

Daily during advancement; thereafter pm

Daily dUling advancement;
thereafter prn

Glucose intolerance

Reduce feeds, give insulin,
continuous feeds

R

Therapy

lMetabolic

'l'J'
.
\.' nne speci ti c gravity

Comments

Itserul11 electrolytes
\\~

~jii'.

I

~!i

}comPlete nutrition
. assessment

q24-48h during advancement; thereafter pm

q24-48h during advancement; thereafter pm

Weekly

Weekly

Every feed

q4-8h

Reinsert tube in contralateral nares with
changes
Use skin barrier
Avoid angulation when
taping

Every feed

q4-8h

Flush tube with warm
water
Flush after medications
If occlusion persists, Rush
with Viokase enzyme
solution

Every feed

q3-4h

Tube displacement

Reposition tube

Secure tube independent of
position

Every feed

q3h

Aspiration

Maintain upper body
position of 30 degrees
during feeds and for
30-45 min thereafter

Especially important for
children with gastroesophageal reflux and
altered gastric motility

Electrolyte imbalance

Readjust formula as needed

Electrolyte imbalances in
tube-fed patients are
usually associated with
underlying medical
conditions
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Common Complications of Enteral Feedings

astrointestinal
iarrheaJdumping syndrome

omiting, nausea, GER,
pulmonary
aspiration

Causes

Prevention/Intervention

Medications
Rapidly delivered formula
Hypertonic formula
Hypertonic medications
Substrate intolerance
Bacterial contamination of formula
Lack of fiber
Concomitant antibiotic therapy
Mucosal atrophy and malnutrition
Impactinn
Low fi ber intake
Inadequate fluid intake

Decrease delivery rate
Alter formula carbohydrate and electrolyte
content
Recognize or avoid if possible drugs that
result in diarrhea
Use parenteral nutrition or elemental formula
Recognize and eliminate the source of the
contamination
Avoid lactose-containing products

Fat intolerance
Bowel ileus
Swallowing excess air
Improper tube placement
Infusion rate too rapid
Large residuals
Hyperosmolar formula
Hypertonic medications
Gastroesophageal reflux
Gastric hypomotility
Failure to irrigate feeding tube regularly
Formula too viscous for diameter of feeding
tube
Administration of medications via feeding tube

I tract perforation

Improper tube placement

asal, pharyngeal, esophageal
irritation

Improper skin care
Extended use of polyvinyl tubes

etabolic Distnrbances
. uid and electrolyte imbalance

Cardiac andlor renal insufficiency
Hypertonic medications
Severe protein-calorie malnutrition
Malabsorption
Inadequate fluid intake
Insufficient insulin production or use
Trauma or sepsis
Excessive carbohydrate intake

High protein intake
Renal immaturity or dysfunction
Liver disease
Metabolic dysfunction (e.g.. inborn errors of
metabolism)
Inadequate mouth care
Improper formula-mixing technique
Use of contaminated equipment or supplies
Long hang time of formula
Negative oral experiences (e.g., traumatic tube
intubation)
o positive oral experiences (e.g.. thumb
sucking, nipple feeding)

Add fiber or choose a high-fiber formula
Increase free water intake
Add prune juice
Reevaluate tube placement
Consider continuous or transpyloric feedings
Metoclopramide may be given to enhance
motility
Reduce carbohydrate content of formula
Reduce rate andlor concentration as indicated
Aspirate air from feeding tube before feedings
Position patient on the right side

Flush tubing with water
Enzyme solution
Replace tubing
Follow manufacturer's recommendations for
tube size
Stop feedings, confirm placement by chest
x-ray film
Evaluate appropriateness of tube size
Periodically change naris used for feeding tube

Evaluate cause and treat
Increase fluid intake as indicated
Decrease formula concentration

Give insulin
Reduce flow rate
Reduce carbohydrate content of formula
Avoid abrupt cessation of feedings
Monitor glucose levels
Decrease protein content of the feeding

Routi ne mouth care
Use clean technique when mixing formula
Change delivery setups every 24-48 hours
Hang formula for 4-8 hours only
Provide pacifier for non-nutritive sucking
Implement oral stimulation program

1:,Adapted from Hendricks K, Walker W: Mallual a!pediutric Ilutritioll, ed 2. St Louis, 1990, Mosby, pp 106-107.
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cations may contribute to the risk of nausea and vomiting.
Excessive air in the stomach from air spillage of positive
pressure ventilation and air flushing of feeding tubes also
may lead to vomiting. Checking abdominal girth every
12 hours may help to identify feeding intolerance in jejunal
feedings.
Pulmonary aspiration may be the most serious common
complication of enteral tube feeding. 13.167 A high incidence
of GER exists in patients with both orotracheal and NG
tubes. 172 To reduce vomiting and the risk of aspiration,
administering formula continuously rather than by the bolus
method, and placing the tube past the pylorus may be useful.
Also recommended to reduce (but not eliminate) GER is
elevating the head of the bed 30 to 40 degrees during
feeding and for a period after feeding. While advancing the
diet and when abdominal distension or vomiting occurs, a
routine of checking and refeeding residual gastric contents
before each feeding is recommended. 173 If half the feeding
or 2 hours of continuous feedings are aspirated, jejunal
feeding should be considered (see Appendix VII).
To detect silent aspiration, pulmonary secretions may be
checked for the presence of glucose with oxidant reagent
strips or by placing a small quantity of blue food coloring in
the formula. Respiratory distress may indicate aspiration or
stomach distension. For those children with cuffed endotracheal tubes, inflation of the cuff may reduce the likelihood
of aspiration. 174 A gastric emptying agent such as metoclopramide (Reglan) or erythromycin may be given to assist in
gastric motility and to improve gastric emptying. 175.176
Nasal and pharyngeal irritation and tube occlusions are
among the cornmon technical complications of feeding
tubes. Maintaining skin integrity is critical to preventing
nasopharyngeal erosion. Polyurethane and Silastic pediatric
tubes allow longer use of each tube and reduced rate of
tissue irritation and erosion. I Frequent assessment of the
naris is essential to identify skin breakdown, and routine
skin care of the area is recommended. Replacing feeding
tubes once per month will rotate pressure areas and may
help to reduce tube occlusions. When enteral tubes are
changed, using the contralateral naris is recommended.
Clogging of the feeding tube may occur, especially when
using tubes with small diameters. Thick formula remaining
in the tube and highly viscous medications increase the
likelihood of this type of complication. Aspiration of
residuals also has been identified as a contributing factor in
tube occlusion. 177 Checking tube placement only when
dislodgment is suspected may reduce this complication.
Continuous feedings are 3 times more likely to obstruct the
feeding tube. 178 To ensure enteral tube patency and prevent
tube occlusion, water or saline may be flushed through the
tube routinely before and after checking residuals. For bolus
feedings, the tube may be flushed after each feeding, and for
continuous feedings, the tube may be flushed every 8 hours.
To relieve an obstruction, warm water alternating with air
has been suggested. 134 Also, an enzymatic solution containing pancrelipase (Viokase) has been found to be helpful (see
Appendix VII). Preventing infection related to enteral
feeding is a necessary aspect of the care of a tube-fed child.
A child who is receiving enteral feedings and nothing by
mouth needs routine mouth care with saline or an antimi-
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crobial mouthwash. This important aspect of care provides
comfort and prevents infection in the oral cavity. Tube
feeding is an almost perfect medium for bacterial growth.
Contamination can occur while the feeding is mixed or
during administration of the formula. To reduce the risk of
infection and prevent formula contamination, feeding bags
and delivery sets are changed every 24 to 48 hours. A supply
of formula lasting no more than 4 to 8 hours is to be hung
at one time. Adding new formula to remaining formula is to
be avoided.
Metabolic monitoring to prevent electrolyte and other
nutrient imbalances is key for patients on nutritional support. Children receiving high-caloric formulas require frequent testing of urine specific gravity, sugar, and acetone.
Monitoring serum electrolytes, liver function tests, triglycerides, complete blood count, and serum proteins, such as
prealbumin, may be necessary. Use of high-caloric formulas
can lead to increased renal solute load and potential
dehydration.
Enterostomy tubes carry the additional potential complications of wound infection or dehiscence, skin irritation
from leakage of gastric contents around the tube site,
inadvertent traumatic removal of the tube, obstruction of the
pylorus, and small intestine adhesion. 134 The gastrostomy
site is inspected daily for redness, swelling, and drainage,
and the site is cleaned with soap and water. Bacitracin
ointment may be applied and the site dressed. 162 A stoma
adhesive or skin barrier can be used to protect the skin. For
the child with a gastric Button, the device is rotated in a full
circle during cleaning. 165
Enterally administered medications and d.l1lg-nutrient
interactions can cause difficulty for the enterally fed
critically ill child. I7I . 179 Food can have a significant effect
on drug absorption (Table 12-15). Administration of hypertonic medications may cause gastric distension, nausea,
vomiting, and diarrhea. 44 Tube placement can affect absorption and bioavailability of medications. Hypertonic preparations (e.g., potassium chloride elixir, hyperosmolar antibiotic suspension) must be administered in the stomach to
avoid GI intolerance. High-fat diets can alter the release of
theophylline and result in toxic serum concentrations of the
drug. 171 Absorption of phenytoin, phenobarbital, and aspirin
may be impaired when mixed with enteral productS.180.181
Apparently an interaction between phenytoin and the
sodium, calcium caseinates, and calcium chloride is found
in many formulas. A decrease in absorption of many
antibiotics in the presence of food has been demonstrated. I 71
Also, ingesting vitamin C may inhibit the therapeutic effect
of warfarin sodium (Coumadin).
General recommendations for administering medications
through a feeding tube include flushing the feeding tube
with a bolus of water before and after administering the
dJ1Jg, preventing the mixing of drugs before administration,
diluting hyperosmolar or irritant medications, giving liquid
medications when possible, and crushing tablets to a fine
powder before administration 182 (see Appendix VII).
Transitioning to Oral Feeding. A critical component in the care of any infant who is not fed by mouth is the
promotion of the suck-swallow reflex. Transitioning tube
feedings to oral feedings can be a challenge. Children who
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TABLE

Phenomena of Concern

12·15 Effects of Nutrients on Absorption of SelectedOrugs

Decreased Drug Absorption
With Food in the Stomach

Delayed Drug Absorption
With Food in the Stomach

Enhanced Drug Absorption
With Food in the Stomach

Ampicillin
Aspirin
Captopril
Cephalexin suspension
Tetracycline
Erythromycin stearate
Hydrochlorothiazide
Nafcillin
Penicillins
Phenobarbital
Rifampin

Acetaminophen
Aspirin
Cephalexin
Sulfonamides
Cimetidine
Digoxin
Furosemide
Quinidine
Ciprofloxacin

Chlorothiazide
Diazepam
Erythromycin estolate
Erythromycin ethylsuccinate
Hydralazine
Propranolol
Spironolactone
Theophylline
Griseofulvin
Macrodantin

I~dapted from Miller M: Nutrient-drug interactions in children. In Suskind R, Lewinter-Soskind L, eds: Textbook ofpediatric nutrition, New York, 1993,

"'."~. aven Press, p 254.
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have had few positive oral experiences often develop an oral
aversion, This problem is particularly common in the
medically fragile patients who are technology dependent.
Nonnutritive sucking appears to enhance physical growth
and assist the child in the transition from tube feedings to
oral feedings, Nonnutritive sucking is believed to increase
nutrient absorption from the gUt. 183 ,t84 Studies involving
premature infants demonstrated earlier weaning from gavage feeding when the infant was provided with opportunities for nonnutritive sucking, To encourage the transition
to oral feedings, these early pleasurable feeding experiences assist in reducing the risk of food aversions. t85 For the
child receiving chronic enteral feedings, an oromotor
stimulation program is an especially important adjunct to
tube feeding, Referral to an occupational therapist is
considered for infants not accepting nonnutritive sucking,
Although it may take months to years for some children to
achieve the transition, it is important to always keep in mind
the goal of weaning the child from tube feedings to oral
feedings,
Parenteral Nutrition. Parenteral nutrition (PN) is
composed of a hypertonic solution of water, glucose, amino
acids, vitamins, minerals, trace elements, and an isotonic
lipid emulsion, PN is a lifesaving technology for some
patients, When the critically ill child's 01 tract is unable to
absorb nutrients or when the enteral route cannot be used for
a prolonged period, PN can greatly benefit the child, PN is
also considered for patients with intractable vomiting from
acute pancreatitis and with severe diarrhea from disorders
such as inflammatory bowel disease, paralytic ileus, and
small bowel obstruction, 173, 186 In children, PN is delivered
over 24 hours and via continuous infusion pump.
Selection of Route. PN may be given via the
peripheral or central route. 187, t88 The hypertonic fluids of
PN require a large-diameter, high-flow vein, with a dedicated port, The choice between peripheral and central routes
is based on the child's nutritional needs, clinical condition,
and expected duration of illness. The peripheral route is
designed to supplement oral intake or to meet short-term
nutritional needs (less than 7 days) without high nutritional

requirements, The peripheral route is limited by the glucose
content of the fluid and is restricted to 10% to 12,5%
dextrose solutions,
The central route provides a larger, more stable vein that
can tolerate higher intravenous glucose concentrations, t89
To administer PN centrally for relatively short periods, a
catheter is typically placed in the distal superior vena cava,
via the internal or external jugular or subclavian vein with
the catheter tip just above the right atrium, The inferior vena
cava via the femoral vein may also be used. The femoral
vein is usually avoided because of the increased risk of
contamination,
Another alternative to percutaneous central line access is
a peripherally inserted central catheter (PICC).190-192 A
PICC is a long, flexible silicone catheter designed to be
inserted into the median basilic or cephalic vein via the
antecubital space, The catheter is threaded until it reaches
the inferior vena cava or the superior vena cava. This type
of catheter may also be placed in the large saphenous vein
and advanced to the inferior vena cava, particularly in
neonates.
For those patients who require long-term PN, catheters
can be placed surgically, The Broviac catheter was the first
long-term, small-lumen, flexible catheter. The Hickman
catheter was introduced shortl y thereafter, followed by the
development of various other single-lumen and multi lumen
long-term catheters,187,t93 Implantable ports are also considered for long-term access and may offer less risk of
infection, A subcutaneous pocket, usually on the chest, is
created to implant the device, All central catheters require
radiographic confirmation of catheter placement before
infusing PN,
Composition of Parenteral Nutrition. The PN
formula is tailored to meet the critically ill child's nutritional
and fluid requirements (Table 12-16), Children with special
nutritional needs resulting from renal disease, hepatic
disease, and other conditions may require modified formulations,194 Initiating PN is a step-by-step process,
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Formulating a Total Parenteral Nutrition Solution
Full-term Infant

Child

Begin

Advance

Maximum

Begin

Advance

Maximum

t~'-

4-6
5-9

2-3
3-4

10-12
14-17

4-6
5-9

2-4
3-6

10-12
14-17

I'at 20% concentration (g/kg/day)

1-2

I

3-3.5

1-2

1

3

~:arbohydrate (g/kg/day)

Iii·~

I~otein (g/kg/day)
~dapled

.

2-2.5

..

3 ..

.

1.0-2 .

2

from Huddleston K, Ferraro-McDuffie A, Wolff-Small T: NutntlOnal suppol1 of the cntlcally ill child, Cra Care Gill North Alii 5:72, 1993.

~: Monitor nutritional parameters and tolerance and advance as indicated.

!ilL

Parenteral protein is supplied in the fonn of synthetic
crystalline amino acids combining essential and nonessential amino acids. Protein provides 4 kcal/g. The type of
formulation chosen is based on the child's age and disease
state. The selection of the type of amino acid solution may
affect the protein use, patient tolerance, and ability to avoid
deficiencies. Generally I g of protein is equivalent to I g of
amino acid. Standard PN has inadequate amounts of
tyrosine, cystine, and glutamine for infants and children.
Trophamine has a similar amino acid pattern to breast milk
and is designed for children younger than 6 months of age.
Trophamine has higher amounts of tyrosine and histidine,
which are essential for infants. Novamine provides essential
and nonessential amino acids appropriate for children older
than 6 months of age. Special amino acid solutions for
children with special needs are also available. Aminosyn RF
has a higher ratio of essential to nonessential amino acids
and is available for patients with renal failure. Hepatasol is
a preparation enriched with branched-chain amino acids for
children with severe liver disease. Glutamine added to
parenteral formulations may decrease the degree of intestinal atrophy when enteral feedings are not administered. 195
The usual recommendation of parenteral amino acids is 2 to
3 g/kg/day of protein for infants, I to 2 g/kg daily of protein
for older children, and 1 to 1.5 g/kg daily of protein for
adolescents 5 Nitrogen retention is reduced when protein is
supplied parenterally. Therefore when administering protein
parenterally, amino acids are supplied in a higher concentration. Children who are well hydrated with normal renal
function can receive the full amount of protein recommended at the onset of therapy. When advancing amino acid
concentration is necessary, daily increases of 0.5 g/kg are
recommended for neonates, whereas I g/kg daily is recommended for older infants and children. 196 Care is taken not
to administer greater amounts of protein than recommended
because azotemia, hyperammonemia, and an increase in minute ventilation and oxygen consumption may occur.
Dextrose is the principal form of carbohydrate supplied
and the common energy source of most parenteral regimens.
Calories from carbohydrates may provide as much as 40%
to 60% of the diet. In parenteral solutions, unlike enteral
formulas, dextrose provides 3.4 callg, with 10% dextrose
providing 0.34 kcallml and 20% dextrose providing 0.68
callml. Dextrose is often started at a 10% concentration and
then gradually increased over 2 days or as tolerated. With

gradual increases in the dextrose concentration, the pancreas
is given time to increa~e its insulin response and avoid
hyperglycemia and glucosuria with a secondary osmotic
diuresis. 197
Fat is supplied in the fonn of a lipid solution produced
from either soybean oil alone or a mixture of safflower and
soybean oils with egg yolk phospholipid and glycerin as the
emulsifying agent. Fat emulsions concentrated at 20% have
200 gIL of fat and 2 callml. In general, higher fat emulsions
allow a decrease in carbohydrate administration and may
reduce the child's carbon dioxide production and RQ. These
lipids are stable for a moderate period at room temperature.
The use of intravenous fats provides a concentrated source
of energy while preventing essential fany acid deficiency. To
achieve this goal, at least 4% to 8% of the child's diet must
be from fat. To prevent essential fatty acid deficiency
(EFAD), 0.5 to I g/kg/day of Intralipids is recommended. 29
The percentage of fat in the diet, however, should not exceed
50% to 65% of the total calories, or 3 to 4 g/kg daily. Fat
intolerance, as indicated by elevated serum triglycerides,
may interfere with immune function and should be avoided.
When administering lipids, it is important to consider the
allergies to soy products and eggs.
Implementation and Advancement. A suggested
method of introducing and advancing PN is to begin on day
I with 2 g/kg of lipid emulsion and 10% dextrose and then
on day 2 to advance the lipids by 1 g/kg daily along with
advancing the dextrose 5% to 10%. The initiation phase can
take 3 to 5 days. A filter is placed on the dextrose and amino
acid solution to trap precipitate. Fat emulsions traditionally
have been administered separately to prevent clogging of
the intravenous catheter; however, modern lipids can be
mixed into triple-mixed total nutrient admixtures l98 Total
nutrient admixture (TNA) adds the lipid emulsion to the
amino acid and dextrose solution. When administering
lipids, an in-line filter is never used because the particles are
too large. This method of mixing is economical and
conserves nursing and pharmacy time. TNA is a less stable
emulsion that traditional PN. Discontinuation of PN is
recommended when the GI tract is able to absorb 70% of the
child's caloric needs.
Electrolytes, vitamins, and minerals must be added to
parenteral solutions to provide nutrients essential for metabolism and cellular function. Pediatric and adult multivitamin preparations are available. Not much definitive
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infonnation is available concerning the parenteral requirements for vitamins or minerals available for critically ill
children. Current guidelines reflect the needs of children
who are healthy and are fed orally. The pediatric multivitamin solution used for infants and children younger than II
years includes vitamin K, lower amounts of the B vitamins,
and larger amounts of vitamin D. The adult fornlUlation
MVI-12 is used for children older than II years. Calcium
and phosphorus are necessary for proper bone growth and
metabolic functions. Sodium, potassium, calcium, phosphorus, and magnesium are added separately to PN preparations. Depending on the underlying disease and condition,
sodium and potassium can be provided in salt fonns of
chloride, acetate, or phosphate. Zinc, copper, chromium, and
manganese are added as trace elements. Intravenous iron is
administered to children not receiving iron by enteral
means. In children with renal failure, calcium amounts are
decreased, and magnesium, phosphorus, and potassium are
eliminated.
The dextrose-amino acid component ofTPN is stable for
up to 30 days; however, with the addition of vitamins and
minerals, the solution becomes highly unstable. Refrigeration in a dark place is required, and the solution should be
used within 24 hours.
Water is also an essential part of PN. Typically, fluid
requirements are calculated by body weight and may be
adjusted according to the child's fluid needs. For example, a
child with high insensible water loss through a drainage
tube, diarrhea, respiratory failure, infection, or elevated
temperature may require increased fluids, whereas a child
under a radiant wanner or with cardiac disease may require
fl uid restriction.
Medications can also be mixed or added to TPN to
decrease cost, restrict fluids, decrease time, and reduce the
risk of potential contamination of the PN. 179 Drug compatibility varies (Table 12-17). PN solutions can inactivate or
reduce drug potency and cause precipitation of electrolytes
and medications. Drug compatibility is assessed for pharmacokinetics and physical stability.
The success of PN is ensured by effective administration;
evaluation of the child's response to therapy; and close,
frequent monitoring of complications (Table 12-18). All
parenteral nutrition is administered by maintaining a constant rate via an infusion. To establish a baseline of
comparison, initial monitoring of the patient on parenteral
nutrition includes complete laboratory assessment of fluid
and electrolytes, acid-base, renal, hepatic, and nutritional
status. During the initial stages of administration, parenteral
nutrition requires daily monitoring of many laboratory
values. As changes in parenteral solutions become unnecessary and as the disease acuity pennits, less frequent
monitoring is needed. Hourly accurate intake and output and
frequent assessment of fluid requirements are also indicated.
Parenteral nutrition is fraught with complications (Table
12-19). The major catheter-related complication is infection, and local and systemic infections can occur. The most
common infections result from Staphylococcus aureus and
Candida albicans. Fat emulsions provide an excellent medium for gram-positive, gram-negative, and fungal growth,

12.-17 Compatibility of Selected
Drugs With Parenteral Nutrition

TABLE

~
iii"
!fiE)

1::-

I

I;;'

Drugs

Compatibility

Amikacin*
Amphotericin B
Ampicillin
Cefazolin
Ceftriaxone

Incompatible
Incompatible
Incompatible
Incompatible
Compatible

~~~o;::~~~nnicol

~~~~:~::~

Corticosteroids

Ii g::~:m

Compatible

Gentamicin*
Imipenem-cilastatin

~f~' ~!o~~~:::id'

Compatible
Incompatible

~:;:::~'

;.;i;-.
....

I

t
~t

Phenytoin

'~~~~~i~i~:

I:;'

Vecuronium

~~~;:t~~I~le

Incompatible

~~~~::1~:~

Compatible

Ii-;Reprinted with permission of Miyagawa C: Drug-nulrient interactions
critically ill patients. Cri/ Care Nurse 13:69-90, 1993..

W

tt~~Incompatible WIth

parenteral nutntlon contamlng hepann.

~ilmi

whereas crystalline amino acid and dextrose solutions primarily support fungal infections.186.199 More susceptibility
to catheter infection has been observed with central versus
peripheral Jines, lower limb catheterization versus upper
limb, and catheters exiting the neck (internal jugular) versus
those exiting the upper chest (subclavian), and multilumen
catheters.2 oo Sepsis related to PN may result from contamination at the insertion site and migration of bacteria along
the catheter. 20 1Patients who recei ve mechanical ventilation
via artificial airways seem to be at increased risk for infection. The bacterial colonization associated with mechanical
ventilation may contri bute to thi s increased risk.202
Preventing catheter-related infection is one of the major
challenges in caring for the child receiving PN.2°3-205
Adherence to regular and meticulous care of the catheter and
site is essential. Strict aseptic technique, including use of an
antiseptic agent, is used to clean and maintain the site. 206 A
transparent, moisture vapor penneable dressing is then
placed over the insertion site and changed at least once a
week or when soiled. Daily monitoring of local and
systemic signs of infection is important, including observing
for redness, pain, swelling, and exudate at the site; fever;
and chills.197.207 Tunneling of the catheter through the
subcutaneous tissue before entering the vein may reduce the
risk of infection. 20 Unnecessary use of the catheter for blood
transfusions or blood sampling is discouraged. To ensure
sterility during infusion of PN, a 24-hour expiration period
is recommended from time of hanging the f1uid_ Tubing is
changed daily or with every new bottle or bag, using aseptic
technique.
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Monitoring Parameters for Parenteral Nutrition Support

"Variable

Admission

qh

q8h

Daily

Weekly

As Indkated

':'Growth
~iWeight
E[!i

x

~'Height
!b~
','Head circumference «3 yr)
t~Skinfold thickne"
~',Midarm circumference
~''FIuid balance (I & 0)
i"'remperature
{'Vital signs
~',Urine glucose/acetone
'ii: Catheter site/function

X
X
X
X
X
X
X
X

:iSodium
iI: Potassium
i;:Chloride

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

rCO z

~,Glucose
,}Blood urea nitrogen
,':,Creatinine

~Triglycerides

';:Cholesterol
i:Calcium
W0
:i' Magnesi urn
[Phosphorus
!Vitamin B 12
:'Folate
," ,
[:':Albumin
~1:AJanine aminotransferase (ALT)
i:Aspartate aminotransferase (AST)
!:',Alkaline phosphatase
~,Total and direct bilirubin
'.[[Lactate dehydrogenase
!i'Oamma,glutamyltransferase (GGT)
Ellron
~'Copper
!'Zinc
k!!
~,Selenium

"Ammonia
;:Complete blood (cell) count
i,~ Platelet count
Iii"

X
X
X

x
X

X
X

~',Biochemical Indices

;!\(-.,

X (l,3x1wk for chronically ill,
stable patients)
X (monthly)
X (monthly)

X

X
X
X
X
X
X
X

(xl
(xl
(xl
(xl
(xl
(xl
(xl

wk)
wk)
wk)
wk)
wk)
wk)
wk)

X
X
X
X

X
X
X
X

X (xl wk)
X (xl wk)
X (xl wk)

X
X
X
X
X (monthly)
X (monthly)
X
X
X
X
X
X
X

X (monthly)
X (monthly)
X
X
X

X

i;:Data from Heird W, Parenteral support of the hospitalized patient In Suskind R, Lewinter,Suskind L, cds, Textbook of pediarric nutrition, New York,
::,1993, Raven Press, pp 225,238, adapted from The TPN handbook, ed 5, Boston, 1993, Boston Nutrition Support Service, Children's Hospital.

Whenever catheter-related septicemia is suspected, obtaining blood culture samples is a reasonable recommendation. If the child develops a fever, blood cultures are drawn
from the central line and peripheral vein, and antibiotics are
started. Cultures are repeated if the initial blood culture
result is positive and continued until culture results are
negative.
The metabolic complications of PN usually are related to
the nutrient components of the parenteral solution. 2os
Hyperglycemia is the most common metabolic complica-

tion. 209 ,210 Avoiding hyperglycemia is a prime consideration
when increasing the amount of dextrose. Frequent monitoring of glucose metabolism by serum and urine glucose
levels is helpful in evaluating hyperglycemia. Hypoglycemia may be seen when dextrose is abruptly stopped.
Administering 10% dextrose solution is recommended if the
catheter becomes plugged or must be discontinued. Hypercholesterolemia, phospholipidemia, and hypertriglycemia
may occur, especially when increasing the amount of lipids
administered. Monitoring lipid clearance by routinely
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12·19 Complications of Parenteral Nutrition
Cause

Intervention

Contamination at insertion site
Contamination of infusate
Equipment contamination

Regular and meticulous site care
Use an in-line filter
24-Hour hang time for parenteral nutrition
solutions
Refrigerate solutions until used
Change tubing every 24 hours or with each
bottle
Treat with appropriate antibiotic

Excessi ve intake because of hyperosmolarity or
high infusion rate

Monitor infusion hourly
Monitor serum and urine glucose
Decrease infusion rates
If parenteral nutrition stopped suddenly, infuse
10% dextrose solution
Decrease amino acid content of parenteral
solution
Correct composition of parenteral solution

Abrupt cessation of infusion
Excessive amino acid intake
ectrolyte, vitamin disorders
ypercholesterolemiaJ }
l.!!.·. phospholipidemia

I~ypertnglycemla

il1watty ~cid deficiency
Iflepallc disorders

Excessive or inadequate intake
Character of or excessive use of lipid emulsion
Limited fat intake

Reduce lipid rate and monitor
Extend length of infusion
Provide 4%-8% linoleic acid
Avoid excessive calories as protein

~l,1'echnical

i!?eripheral-infiltrations,
~rphlebitis,

I . extravasation

i"

High osmolarity of infusate
Prolonged use of single vein
Break in system

lAir embolism

Frequent blood drawing
Prolonged use of single vein
Break in system

litneumothoraxlhemothorax

Technique complication

ientral thrombosis

!!!i'"

r

1'..:

~~atheter breakage
If!:'"

~X

Prolonged catheter use, defective, inadvertent
puncture

checking triglyceride levels becomes important Appropriate adjustments of nutrients in the infusion may prevent or
correct complications.
Other catheter-related complications include the technical complications associated with catheter insertion and use
of a venous access system. Catheter malposition, dislodgment, and thrombosis may also occur during use of a venous
access system. Clotting within the catheter may be related to
the frequency of blood drawing. Facial swelling, edema of
the neck and chest, difficulty with the infusion of fluid, and
neck pain are all signs of potential catheter thromboSiS211.212 The signs and symptoms of thrombosis may be
subtle and delayed until complete occlusion of the vein
occurs 213 Thrombolytic agents can be used to prolong
catheter life and reestablish catheter patency. Urokinase
dissolves clots by triggering the body's own fibrinolytic
system and was widely used for catheter clearance until a

Check site every 30 min to I h and move
peripheral IV as necessary
Clamp catheter
Rotate IV site
Check site every 30 min to I h
Change catheter sites routinely
Monitor sites hourly
Immediately clamp catheter
Place patient in Trendelenburg position
with right side up
Sedate during insertion
Radiologically confirm placement
Clamp catheter and repair

recent citing by the manufacturer. Agencies are now using
streptokinase to lyse systemic clots and tissue plasminogen
activator for catheter clearance.

SUMMARY
Children in rcus have demonstrated both an acquired and
preexisting tendency toward protein-energy malnutrition.
The changes in metabolic demands generated from injury
and sepsis make these children's nutritional needs very
complex. Nutritional support can positively affect the
recovery and survival of hospitalized patients. The nutrition
received in childhood may have significant consequences
as the child grows, making further work in the area
imperative. When caring for a critically iII child, understanding and advocating for the child's metabolic needs are
essential.
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Clinical Pharmacology
Donna M. Kraus

PEDIATRIC AGE GROUP TERMINOLOGY

multiple drug interactions. This chapter will review pediatric pharmacokinetics, pharmacodynamics, drug dosing,
therapeutic drug monitoring, medication administration, and
drug interactions in the PICU patient.

MONITORING PARAMETERS
PEDIATRIC PHARMACOKINETICS

Absorption
Distribution
Metabolism
Elimination

PEDIATRIC AGE GROUP TERMINOLOGY
The normal developmental maturation of body composition,
physiologic parameters, weight, and size that occur throughout infancy and childhood dramatically influence pharmacokinetic parameters, phannacodynamics, and dosing recommendations of medications in children. In fact, pediatric
dosing recommendations are usually specified according to
specific age group terms. For many drugs, the mg/kg
recommended dose is different for children of different
ages. I Categorizing an individual by the wrong age group
term could result in significant overdosing or underdosing of
the patient. Therefore it is important for PICU clinicians to
know the definitions of the various age group terminology.
These terms are listed in Table 13-1.

PHARMACODYNAMICS

Dosing of Medication in Critically III Children
Therapeutic Drug Monitoring
MEDICATION ADMINISTRATION IN THE

PICU

IV Administration
Pediatric Dosage Forms
Pediatric Medication Administration Decision
Making
PRINCIPLES OF DRUG INTERACTIONS

MONITORING PARAMETERS

T

he safe and rational use of medications in critically ill
children requires a thorough understanding of pediatric
pharmacology and proper medication administration. Agerelated differences in drug disposition, metabolism, excretion, and pharmacodynamic effects, coupled with the special
pharmacologic considerations of the critically ill, can make
the pediatric intensive care patient a phamlacotherapeutic
challenge for the clinician. Critically ill children usually
receive multiple medications; many of which are extremely
potent and require careful titration. Oftentimes the use of
medications in critically ill children falls outside of the
product labeling approved by the Food and Drug Administration (FDA). In addition, the proper dosage form and
concentration of many medications may not be readily
available for these patients. Thus the PICU patient is at a
great risk for many drug misadventures including miscalculation of doses, use of non-optimal or untested doses,
improper dilution and administration of medications, and

Many clinical monitoring parameters used in adults for
assessing medication efficacy or toxicity are also used in the
critically ill child. However, normal values for infants and
children may differ. One must be aware of these differences
in laboratory parameters and normal vital signs in order to
adequately monitor pharmacotherapy in PICU patients. For
example, children, especially neonates and young infants,
have lower blood pressures and higher respiratory and heart
rates, compared to adults. Proper references should be
consulted for the normal values for age when providing
clinical care to critically ill children.

PEDIATRIC PHARMACOKINETICS
Pharmacokinetics mathematically describes the concentration of a drug or its metabolites in the body (i.e., in the
blood, body fluids and tissues) over a period of time?
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13·1

.

~.;

Definition of Age Group Terminology

li'.

The time from conception until birth. More specifically, gestational age is defined as the number of
weeks from the first day of the mother's last menstrual period (LMP) until the birth of the baby.
Gestational age at birth is assessed by the date of the LMP and by physical exam (Dubowitz score).

f!J'ostnatal age (PNA)

Chronologie age since birth

ii!:p.
¥,,,. ostconceptional
~!,:age (PCA)
i~Neonate

Age since conception. Postconceptional age is calculated as gestational age plus postnatal age
(PCA = GA + PNA).

\m,Gestallonal age (GA)

~l

~:
~I,

i®i
ur;

liC
ii[~remature neonate
il;,

A full-term newborn 0-4 weeks postnatal age. This term may also be applied to a premature
neonate whose postconceptional age (PCA) is 42-46 weeks
Neonate born at <38 weeks gestational age

i\],[ull-term neonate

Neonate born at 38-42 weeks (average -40 weeks) gestational age

I~fant

1 month to I year of age

¥hildiChildren
fJ:'
l\'~dolescent

1-12 years of age

~;Adult

> 18 years of age

!!!O

13-18 years of age

eproduced with pennission from Takelomo CK, Hoddiog JH, Kraus DM: Pediatric dosage handbook, ed 6, Hudson, OH, 1999, Lexi-Comp, 13.

Clinically, pharmacokinetics is used to describe the timedependent changes of the drug plasma concentrati()n following administration of a medication. The concentration of
a drug in the plasma is dependent upon numerous factors
including: the absorption of the drug from the site of
administration into the systemic circulation, distribution of
the drug into tissues and fluids of the body, metabolism or
biotransformation of the drug, and elimination or excretion
of the drug from the body. Mathematic pharmacokinetic
models can be used to characterize absorption, distribution,
metabolism and elimination of a drug and can predict the
drug concentration in the plasma at a given time. This is
clinically important. For many drugs, the plasma drug
concentration is proportional to the concentration of the
drug at the receptor site. Therefore the plasma concentration
can be related to the pharmacodynamic and cI inical effects
of the drug.) This section will define pharmacokinetic
terminology and discuss important age-related differences
in drug absorption, distribution, metabolism, and excretion
as they clinically relate to the PICU patient.

Absorption
Administration of medication by any route, except intravenous, requires the drug to be absorbed from the site of
administration into the systemic circulation. Once a drug
reaches the systemic circulation, it can then be distributed
throughout the body and to the drug receptor site (i.e., site
of drug action). "Bioavailability" is a pharmacokinetic term
that estimates the extent of absorption of a drug. Bioavailability is defined as the percent of an administered dose that
reaches the systemic circulation. 4 Several factors can affect
drug bioavailability, including the dissolution characteristics
of the dosage form (e.g., capsule, tablet, sustained-release
product), physicochemical characteristics of the drug (e.g.,
solubility, degree of ionization, salt from), route of administration, and extent of metabolism by the liver or gut before
the drug reaches the systemic circulation. Drugs that are

administered orally must first pass through the gastrointestinal mucosa and into the portal circulation of the liver
before reaching the systemic circulation. Therefore orally
administered drugs can be metabolized by enzymes located
in the gastrointestinal mucosa or the liver before reaching
the systemic circulation. This phenomena is called the
"first-pass effect." A large first-pass effect will result in a
lower bioavailability for a drug and a larger difference
between the recommended oral and intravenous doses.
Drugs that are administered IV do not have to pass through
the liver to reach the systemic circulation. Therefore IV
drugs do not have a first-pass effect and have a bioavailability of 100%. Propranolol is an example of a drug with an
extensive first-pass effect; its oral bioavailability is only
30% to 40%. I The usual oral dose of propranolol to treat
arrhythmias in children is 0.5 to 1 mg/kg gi ven every 6 to
8 hours, whereas the recommended IV dose is only 0.01 to
0.1 mg/kg. As one can see by this example, the bioavailability of a drug must be taken into consideration when
changing the route of administration of a medication. If it is
not, serious and potentially fatal overdoses or underdoses
may occur. Other examples of drugs with low bioavailability
and significant differences between the IV and oral dose
include: hydralazine, labetalol, midazolam, morphine, and
verapamil. I
Bioavailability may also be different for different dosage
forms of the same drug. For example, the oral bioavailability
of digoxin elixir can be as low as 70%, whereas the
bioavailability of digoxin capsules can be 100%.1 This 30%
difference in bioavailability dictates that a dosage adjustment must be made when one dosage form is changed to the
other. Thus bioavailability needs to be considered not only
when changing the route of administration, but also when
changing dosage forms.
Many factors can affect the absorption of enterally
administered medications in the pediatric intensive care
patient Significant age-related maturational changes of
gastric emptying time, gastric acidity, intestinal motility and
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integrity, enzymatic activity, biliary function, and bacterial
colonization occur during the first 2 years of life and can
influence drug absorption. For example, gastric emptying
time can be delayed in neonates for as long as 6 to 8 hours
and adult values may not be reached until 6 to 8 months of
age. 5 Disease states, drugs, and diet may also influence
gastric emptying time and gastrointestinal motility. A longer
gastric emptying time may delay drug absorption in the
small intestine. This can result in a decreased peak serum
drug concentration and a longer time to reach the peak
concentration of an enterally administered medication.
Gastric acidity and duodenal pH also affect drug
ionization and absorption. 5 •6 Drugs are absorbed across
membranes in the un-ionized form. In general, acidic drugs
are better absorbed in an acidic environment because these
drugs would be in the un-ionized form. However, a basic
drug in an acidic environment will be mostly ionized and
therefore less well absorbed. Similarly, in an alkaline or
more basic environment, acidic drugs will be ionized and
less well absorbed, whereas basic drugs will be un-ionized
and better absorbed. Therefore age-related changes in
gastric pH can affect drug absorption. Gastric acidity is
decreased in neonates, especially in preterm newborns. 7
This decrease in gastric acid output is often termed "relative
achlorhydria" and results in a higher (more alkaline) gastric
pH. This may result in a decrease in the bioavailability of
acidic drugs (e.g., phenobarbital, phenytoin) and an increase
in the bioavailability of acid-labile drugs (e.g., ampicillin,
erythromycin, penicillin).5,g Although gastric acidity is
generally lower in the neonatal period, maximal gastric acid
output does not reach adult values until 2 years of age. 5,7
Thus infants and young children may have age-related
differences in drug absorption related to gastric pH.
Differences in the formulation of an enterally administered medication can also affect drug absorption. Sustainedrelease products are made to release a drug over an extended
period of time (e.g., 12 hours). However, in young infants,
the gastrointestinal transit time may be less than 8 hours.
Thus the use of a sustained release preparation (such as
theophylline) in a young infant, may result in incomplete
and highly variable absorption (i.e., the sustained release
product may be excreted in the stool before the drug is
completely absorbed). This is why fast (or prompt) release
oral products (i.e., non-sustained-release products) are
usually used in neonates and infants. I
The absorption of enterally administered medications
may also be delayed or decreased in patients who have
decreased perfusion to the gastrointestinal tract (e.g., critically ill patients, patients in shock, patients with congestive
heart failure) or decreased gastrointestinal function (e.g.,
postoperative patients recovering from anesthesia). Therefore medications are not usually administered enterally to
these patients. In addition, medications commonly used in
PICO patients may influence gastrointestinal drug absorption. Anticholinergics may prolong gastric emptying time
and delay drug absorption, while metoclopramide may
shorten gastric emptying time and hasten the time to drug
absorption. 9 Medications that are used to increase gastrointestinal pH, such as antacids, histamine-2 receptor blockers
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(e.g., cimetidine, ranitidine) and proton pump inhibitors
(e.g., omeprazole) may also affect the absorption of medications. For example, the oral absorption of ketoconazole
(which requires an acidic pH for proper absorption) is decreased by these agents. I Medications, such as B-blockers,
may decrease liver blood flow and increase the oral bioavailability of certain drugs that normally rely on liver blood flow
for a large first-pass effect,9
Even food can interfere with the absorption of drugs and
some medications are better absorbed on an empty stomach.
Continuous NG feedings can decrease the enteral absorption
of phenytoin, carbamazepine, hydralazine, levothyroxine,
and warfarin. III These drug-nutrient interactions require
holding enteral feedings for a period of time (to allow the
drug to be absorbed), close monitoring of the patient, and
measurement of serum drug concentrations.
For some of these agents (e.g., phenytoin, carbamazepine) holding the feedings for 2 hours before and 2 hours
after a dose is recommended, if possible. 1,10 If the continuous feedings cannot be interrupted for that period of time,
the IV route of administration or alternative drugs may need
to be considered. Sucralfate will interact with continuous
enteral feedings by binding to the protein in the food. It is
not recommended in these patients because of the prolonged
period of time that feedings would need to be held. 10
The rectum has been used as an alternative route of
pediatric drug administration, especially when the oral route
is not feasible and IV access is not readily available.
However, routine use of the rectal route is discouraged,
especially for certain drugs (e.g., aminophylline) because of
unpredictable drug absorption and potential toxicities. 8 In
general, the slow and unpredictable absorption by this route
of administration makes rectal administration of medications in the intensive care setting undesirable. II However, if
one utilizes the proper drug and dosage formulation, rapid
and efficient rectal absorption can occur. For example,
rectally administered diazepam and valproic acid have been
used to treat status epilepticus. In fact, rectally administered
diazepam solution for injection produced comparable serum
concentrations to IV use and rectal use of valproic acid
syrup produced concentrations similar to those from oral
administration. 12,13 A recently marketed diazepam rectal gel
formulation (Diastat) is approved for use in children <':2
years and adults for intermittent episodes of increased
seizure activity. 1 Rectal administration of diazepam, rnidazolam, and morphine has also been successfully used for
analgesia or pre-anesthetic sedation in children.])
Drug absorption following intramuscular (1M) administration is dependent upon several factors including: blood
flow, muscular contractions, muscle mass, and physicochemical characteristics of the drug. 5 ,6,8 In critically ill
patients with low cardiac output or hypotension, the rate and
extent of 1M drug absorption may be decreased as a result of
compromised perfusion of the injection site. In addition, the
low degree of muscular activity and muscle contractions in
immobile, severely ill, or paralyzed PICO patients can also
decrease the rate of 1M drug absorption. Because 1M absorption is also affected by the surface area of the muscle over
which the medication has spread, patients with a low muscle
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mass to total body mass ratio (e.g., neonates) may also
display a decrease in 1M absorption of drugs. The physicochemical properties of a drug also play an important role in
1M absorption. Phenytoin, for example, will precipitate at
the site of 1M injection, due to its physicochemical properties and the relative pH of the muscle. 8 This precipitation or
crystallization of the drug acts as a depot of medication in
the muscle. Absorption of the drug is decreased initially, but
the medication continues to be absorbed over a prolonged
period of time (even after the 1M injections are discontinued). The erratic absorption of 1M phenytoin, and the pain
associated with precipitation ofthe drug in the muscle, make
the 1M route of administration unacceptable for this medication. 14 Fosphenytoin, a prodrug of phenytoin, is water soluble and is FDA approved for 1M administration in adults;
however, limited studies in children have been conducted. I
Although certain drugs, such as the aminoglycosides, penicillins, and phenobarbital, can be administered 1M, in general, because of variable absorption, the 1M route of administration should be avoided in critically ill pediatric
patients. 1,11
The potential absorption of medications through the skin
should not be overlooked in the PICU patient. Percutaneous
absorption of drugs can be increased in neonates, especially
preterm newborns, as a result of the increased hydration of
the skin, decreased thickness of the stratum corneum (outer
layer of the epidermis), and the higher ratio of surface area
per kilogram body weight. 5.6 Toxicities have been reported
following topical application of boric acid, corticosteroids,
epinephrine, hexachlorophene, iodine, and salicylic acid in
neonatal patients. 15 Although skin barrier development may
be fulJy developed by 2 to 3 weeks after birth, IS it is
important to remember that the ratio of body surface area to
kilogram body weight is still increased in infants and young
children, compared to adults. Because of this higher surface
area/weight ratio, infants and young children will absorb
more drug per kilogram for an equal application of topical
medication. In addition, disruptions in the integrity of the
skin, such as abrasions, open lesions, or bums, and occlusive
dressings can also increase the percutaneous absorption of
medications in any aged patient. Therefore the young PICU
patient may potentially be at risk for toxicities from the
topical application of medications.

Distribution
Once a drug is absorbed or enters the bloodstream (i.e., the
central compartment), it then can be delivered to other sites
in the body, including the site of action and the site of
elimination. Drug "distribution" is the process of drug
movement to the various body tissues, organs, and fluids.
The "distribution phase" refers to the time during which the
drug is distributing throughout the body. Clinically, for
many drugs, the serum drug concentration ajier distribution
more closely correlates with the concentration of drug at the
receptor site. Thus serum concentration determinations for
most drugs must be obtained after the distribution phase.
Some drugs (like digoxin) have a very long distribution
phase (6 to 8 hours). I If a digoxin serum concentration is

obtained too soon after the dose, it will reflect drug in the
central compartment and will be extremely elevated. This
example illustrates the importance of understanding the
concept of distribution phase as it clinically applies to
the PICU patient.
The "volume of distribution" (Vd) represents the hypothetical volume that would "account for the total amount of
drug in the body if it were present throughout the body at the
same concentration found in the plasma. ,,4 Clinically, a
small volume of distribution indicates that the drug has
minimal distribution and is largely retained in the central
compartment (e.g., in adults, the Vd of gentamicin is
0.25 Llkg). A large volume of distribution indicates that the
drug distributes well into peripheral compartments (tissues,
organs and body fluids) and may even concentrate in certain
tissues or organs (e.g., in adults, the Vd of digoxin is
7 Llkg). I For a given drug, provided other factors remain
constant, patients with larger volumes of distribution will
require larger doses to obtain the same serum concentration
as patients with smaller volumes of distribution. Understanding the variables that affect drug distribution will help
explain some of the special dosing requirements of critically
ill pediatric patients.
Drug distribution is dependent upon the physicochemical
properties of the drug (molecular weight, degree of ionization, solubility in water and lipids) and various patientspecific physiologic factors. These factors include: the
composition and size of body compartments (e.g., total body
water, intracellular and extracelJular water, and adipose
tissue), membrane permeability, pH, protein binding, and
hemodynamic variables such as cardiac output, tissue
perfusion and regional blood flow. 16 Many of these factors,
especially body composition and protein binding, are age
related and can be influenced by various disease states
observed in PICU patients.
Total body water and extracellular water, when expressed
as a percentage of weight, are increased in the newborn and
decrease throughout childhood with increasing age. The total body water of a full-term newborn is 75%, but it is 60%
in a three-month old and 55% in an adult. 17 Extracellular
water is approximately 50% of body weight in premature
infants, 35% in infants 4 to 6 months old, 25% in a l-yearold child, and 19% in adults. 18 The higher total body water
and extracellular water observed in newborns and infants
generally results in a larger Vd for water-soluble drugs,
compared with older children and adults. Additionally, the
Vd for aminoglycosides (e.g., gentamicin) and other drugs
that distribute into the extracellular water compartment
roughly correlates to the volume of the extracellular water
compartment. The Vd for these drugs is larger in neonates
and infants; therefore a larger mg/kg loading dose is needed
to achieve similar initial concentrations compared to older
children and adults.
The Vd for gentamicin can also be increased in patients with increased extracellular water, such as those
patients with ascites, third spacing, or congestive heart
failure. In fact, the mean Vd for gentamicin in prcu
patients (0.42 Llkg) was found to be greater than the mean
Vd reported in children in the literature (-0.31 Llkg).'9

Chapter 13

This larger Vd and other alterations in pharrnacokinetic
parameters suggest that critically ill children may need
initial gentamicin doses closer to 9 mg/kg/day to produce
therapeutic serum concentrations (using traditional q8h
dosing) rather than the standard recommended doses of
7.5 mg/kg/day.
In contrast, smaller milligrams per kilogram loading
doses of fat-soluble drugs (e.g., diazepam) are recommended in neonates and young infants. Neonates and young
infants have much less adipose tissue compared with adults.
The adipose tissue content of a preterm newborn is only 1%
to 2%, but it is 15% in a term newborn. 17 This lower amount
of adipose tissue (and the higher water content of adipose
tissue in newborns) may result in a decreased Vd for
fat-soluble drugs, and thus smaller mg/kg loading doses for
fat-soluble drugs.
The plasma protein binding of many medications is lower
in neonates and infants for several reasons. Neonates have
(I) a decreased affinity for drugs by fetal albumin; (2) lower
concentrations of binding proteins (e.g., albumin, alpha,acid glycoprotein); (3) a lower plasma pH (which can
decrease binding of acidic drugs to protein); and (4) higher
concentrations of endogenous substances (such as bilirubin
and free fatty acids) or other substances acquired transplacentally (e.g., medications, hormones) that may compete
with medications for protein-binding sites. 5 .2o The affinity
of albumin for acidic drugs and total plasma protein
concentrations increase with age and may approach adult
values at 10 to 12 months of age. 6 Thus PICU patients less
than I year of age may have an age-related decrease in
protein binding compared to older patients. In addition,
PICU patients with disease states that result in low
concentrations of albumin or total protein, acidosis, hyperbilirubinemia, or uremia may have decreased protein
binding for certain drugs. Clinically, these changes are
important for drugs that are highly protein bound, such as
phenytoin, valproic acid, and warfarin.
Decreased protein binding results in an increase in the
percent of drug that is free or unbound in the plasma. This
higher proportion of free drug or "free fraction" can result
in an increase in the Vd for a medication, as only the free or
unbound drug can cross membranes and distribute into tissues. One would think that an increase in the free fraction of
a drug would also lead to an increase of free drug at the
receptor site and thus an increased drug effect. However, the
free or unbound drug is also available to distribute into
tissues where the drug has no receptors and is available to
organs for metabolism (inactivation) or elimination from the
body.9 The overall result of decreased protein binding is that
the free fraction of the drug in plasma is increased, the free
concentration of the drug is not significantly altered, but a
decrease in the total concentration of the drug occurs.
Therefore changes in protein binding will alter the clinical
interpretation of serum drug concentrations. An example
will help to illustrate this point. The therapeutic range of
phenytoin in a patient with normal protein binding is 10 to
20 f.lg/mJ. If normal protein binding of phenytoin is considered to be 90%, then the normal free concentration would be
I to 2 f.lg/ml (10% of 10 to 20). Therefore if a patient with
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normal protein binding had a serum phenytoin concentration
of 10 f.lg/ml, and their free fraction was 10%, then their free
concentration would be I f.lg/ml. Remember it is the free
concentration that best correlates with drug effect. If a patient had low protein binding (such that their free fraction
was 20%), but their serum phenytoin concentration was only
5 fig/ml, their free concentration would still be I f.lg/ml
(20% of 5). If a clinician only looked at the measured serum
phenytoin concentration, they may misinterpret it to be subtherapeutic, when in reality it is comparable to a concentration of 10 fig/ml in a person with normal protein binding.
This example illustrates the importance of identifying clinical situations that alter protein binding. In this case, a measurement of the free or unbound concentration of phenytoin
can be determined to better assess therapy.

Metabolism
In general, most drugs are relatively lipid soluble and need
to be converted into more polar (water-soluble) compounds
in order to become inactivated and excreted from the body.
However, there are a few exceptions to this statement. Some
medications (e.g., enalapril) are inactive "prodrugs" that
need to be metabolized into an active form (enalaprilat)
before they can have a pharmacologic effect. Other drugs
may have active metabolites that contribute to the pharmacologic effect of the drug or that may accumulate with
decreased renal function and cause toxicities. For example,
meperidine is metabolized to normeperidine, an active
metabolite that can accumulate in patients with renal
dysfunction and cause tremors or seizures. 1These examples
illustrate the importance of understanding the metabolism of
medications used in PICU patients.
Drug metabolism can take place in a variety of sites (e.g.,
GI tract, skin, plasma, kidney, lungs), but most drugs are
metabolized in the liver via hepatic enzymes and most drug
metabolites are eliminated by the kidneys or biliary tract.
Drugs may undergo hepatic metabolism via Phase I and
Phase II reactions. During Phase I reactions the molecular
structure of the drug may be altered via oxidation, reduction,
demethylation, and hydrolysis. Phase II reactions are synthetic in nature and include conjugation with glucuronide,
sulfate, glycine, hippurate, and glutathione; methylation;
and acetylation. 21
Both Phase I and Phase II biotransformation reactions are
significantly decreased in the newborn, but increase (mature) with age. However, the degree of enzyme maturation
at birth varies for the different hepatic enzyme reactions and
the different enzyme pathways mature at different rates and
for different substrates (drugs). For example, for Phase I
reactions, the level of activity of cytochrome P-450 hepatic
enzymes in full-term newborns is only - 50% of the adult
value?2 This results in decreased oxidation of certain
medications (e.g., phenobarbital, phenytoin, theophylline,
diazepam).5.21 However, cytochrome P-450 oxidative reactions can mature relatively early in relation to other
enzymes. The hydroxylation of phenobarbital and phenytoin
increases to adult levels as early as 2 to 4 weeks after birth
in full-term newborns, but can be delayed in infants who are
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born premature. Although oxidative metabolism is reduced
in the newborn, it increases to 2 to 5 times that of an adult
by I year of age. This has important clinical relevance. For
drugs that are primarily excreted by the liver, metabolism
helps detennine the drug's clearance from the body (i.e., the
amount of blood or plasma completely cleared of the drug
per unit time). Clearance of the drug helps detennine the
recommended maintenance dose. Drug that have a high
clearance will require a higher mg/kg maintenance dose,
whereas drugs with a low clearance will require lower
mg/kg maintenance doses. Thus for drugs that are primarily oxidized by the P-450 enzyme system (e.g., phenobarbital), the recommended maintenance doses will be lower on
a mg/kg basis during the neonatal period (3 to 4 mg/kg/
day), but will significantly increase during the first year of
life and throughout early childhood (I to 5 years: 6 to
8 mg/kg/day). Interestingly, this high P-450 enzyme activity
in early childhood decreases during adolescence to a lower
level in adulthood (see Figure 13-1). The age-related
changes in P-450 enzyme activity will, in part, ,dictate the
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Fig. 13-1 P-450 Enzyme activity. A, Traditional view of cytochrome P-450 development. The development of functional PA50
activity is traditionally viewed as being limited in newborn infants
but increasing in tbe first year of life to levels in toddlers and older
children that generally exceed adult capacity. Near the onset of
puberty, oxidative drug biotransformation begins the decline to
adult levels. B, Developmental profiles of hypothetic cytochromes
P-450. Not all P-450s share the "traditional" developmental
profile. Overall drug biotransformation capacity represents a
composite of the individual drug metabolism patbways and is
dependent on the isoforms and amounts of P-450s (and other drug
metabolizing enzymes) expressed. Therefore for a given pediatric
patient, the apparent drug metabolism "phenotype" is a function of
tbat individual's unique complement of drug metabolizing enzymes and stage of development (vertical arrows). (From Leeder
JS, Keams GL: Pharmacogenetics in pediatrics: implications for
practice. Pediatr Cli" North Am, 44:67, 1997).

mg/kg maintenance doses for drugs metabolized by this
system. Therefore after early childhood, the mg/kg maintenance dose of phenobarbital decrease to 4 to 6 mg/kg/day
for 5 to 12 year old patients and I to 3 mg/kg/day for
adolescents and adults. I Prediction of doses based on
maturation of hepatic enzymes can be complex because
different enzymes mature at different rates, and more than
one enzyme may be involved in the metabolism of a drug.
For example, the hydroxylation of theophylline matures to
adult levels by 40 weeks postconceptional age, but clearance of theophylline does not significantly increase until
55 weeks postconceptional age, when the N-demethylation
pathway matures?3 Like phenobarbital and other drugs that
are metabolized via the P-450 enzyme system, the clearance
of theophylline (and therefore the dose of theophylline on a
mg/kg/day basis), increases dramatically during the first
year of life and exceeds adult values on a per kilogram basis
in early childhood.
Phase II reactions, such as acetylation, glucuronide
conjugation, and glycine conjugation are also decreased in
the newborn; however, methylation and sulfonation are
functionally more mature at birth. 21 •24 Most infants younger
than 2 months are phenotypically slow acetylators. This
results in decreased acetylation of drugs such as sulfonamides and hydralazine. In general, glucuronide conjugation
does not fully mature until 6 to 18 months of age, but
maturation of glucuronide conjugation differs for different
substrates. Because of the decreased rate of conjugation,
metabolism of drugs such as chloramphenicol, corticosteroids, lorazepam, morphine and trichloroethanol (active
metabolite of chloral hydrate) can be significantly decreased
in neonates and young infants. In fact, the "gray baby
syndrome" (manifested by shock and cardiovascular collapse) was caused by the accumulation of chloramphenicol
in neonates who were not given reduced doses to accommodate the reduced metabolism of the drug. Glycine
conjugation is an important pathway for the metabolism of
the preservatives benzyl alcohol and benzoic acid. This
pathway is decreased in neonates, but matures by approximately 8 weeks of age. Because of this decreased metabolism, neonates (especially pretenn neonates) who are given
excess benzyl alcohol and benzoic acid may develop the
"gasping syndrome." This potentially fatal syndrome consists of severe metabolic acidosis, gasping respirations and
mUltiple organ system failure?5 As a result of these
problems, the FDA advises the use of preservative-free IV
medications, diluents, and solutions in neonatal patients 26
In addition to age-related differences in drug metabolism,
certain disease states and drugs utilized in the PICU may
increase (induce) or decrease (inhibit) hepatic enzyme
activity. Decreased cardiac output, decreased liver perfusion,liver dysfunction, or hypoxia may decrease the activity
of hepatic enzymes and decrease drug clearance. This
decrease in drug clearance may result in an increase in drug
levels and toxicities, unless proper dosage adjustments are
made (see dosing of drugs in hepatic failure below). Drugs
that inhibit specific hepatic enzymes can decrease the
metabolism of other drugs that are nonnally metabolized by
those specific hepatic enzymes. Inhibition of an enzyme that
nonnally metabolizes a drug can cause significant eleva-
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tions of drug concentrations and toxicities. For example,
erythromycin inhibits certain P-450 enzymes, and can
increase the serum concentrations of drugs metabolized by
those enzymes (e.g., midazolam, carbamazepine, phenytoin,
cisapride, cyclosporine, theophylline). 1 The elevation in
serum drug concentrations can cause serious toxicities. In
contrast, drugs that induce hepatic enzymes, such as
phenobarbital, phenytoin, and rifampin, may increase the
metabolism of medications that are normally metabolized
by these enzymes. This can result in subtherapeutic serum
concentrations of the concurrently administered agent. For
example, rifampin induces certain P-450 hepatic enzymes
and may decrease the serum concentrations of drugs such as
barbiturates, methadone, digoxin, verapamil, quinidine,
cyclosporine, corticosteroids, warfarin, theophylline, chloramphenicol, ketoconazole, and oral contraceptives. 1 The
decrease in serum concentration may be very significant.
For instance, an alternative form of contraception should be
strongly considered in women taking both oral contraceptive agents and rifampin (even short courses of rifampin).
Before starting any medication, each potential drug interaction should be carefully evaluated. For many drug interactions involving hepatic metabolism, avoidance of an agent,
dosage modification, or close monitoring may be advised.
To better evaluate specific drug-drug interactions, a more
detailed text should be consulted.1. 27

Elimination
Several pharmacokinetic terms need to be defined to better
understand drug elimination. Total body clearance is the
intrinsic ability of the body to remove drug from the plasma
or blood. 4 It does not indicate the amount of drug being
removed from the plasma or blood, but indicates how much
plasma or blood would be totally cleared of the drug if it
were present. Therefore clearance is usually expressed as
milliliters per minute (i.e., volume per time). In pediatrics, .
clearance is standardized per kilogram (mVmin/kg) or per
body surface area (mlfmin/meter) to better compare individuals of different ages and body size. Total body clearance
is actually the sum of drug clearance of each organ of
elimination. For many drugs, total body clearance is equal to
hepatic clearance plus renal clearance. Renal clearance is
determined by the clearance of unchanged drug in the urine.
In the liver, drug clearance can occur via biotransformation
to a metabolite and/or excretion of unchanged drug into the
biliary tract. Half-life is an indirect measurement of
clearance that is used to quantify elimination. Half-life is the
time it takes for the drug concentration to be decreased by
one-half (Figure 13-2). Clearance and volume of distribution determine half-life. Although half-life is not a very
good indicator of drug elimination, it does help to determine
an appropriate dosing interval for medication regimens. It
also can be used to determine the time it takes to achieve
steady-state and the time for a drug to be completely
removed from the body. Steady-state (Figure 13-3) occurs
when the rate of drug administration is equal to the rate of
drug elimination; the drug concentration remains constant at
steady-state. 4 When a patient begins a new medication
regimen, it will take 3 to 5 times the half-life of the drug to

431

reach steady-state. Thus it will take a longer period of time
to reach steady-state for a drug with longer half-life. For
example, if the half-life of a drug is I hour, it will take 3 to
5 hours to reach steady-state. If the half-life of a drug is 24
hours, it will take 3 to 5 days to reach steady-state. Similarly,
it takes the body 3 to 5 times the half-life to remove a drug
from the body, once a medication is discontinued.
For many drugs and metabolites, the kidney is the most
important route of excretion. The kidney has three physiologic functions: glomerular filtration, tubular secretion, and
tubular reabsorption. Renal elimination of medications is
dependent on the balance of these three functions. Some
drugs are primarily eliminated by glomerular filtration (e.g.,
aminoglycosides, vancomycin). Clearance of these agents
(and therefore dosing) is well correlated with glomerular
filtration rate. Other drugs are also eliminated by proximal
tubular secretion (e.g., penicillins, thiazides, furosemide).
Tubular reabsorption of drugs also affects total body
clearance. Therefore age or disease-related changes in any
of these renal functions can affect the renal clearance and
dosing of medications used in the PICV.
At birth, all three physiologic functions of the kidney
(glomerular filtration, tubular secretion and tubular reabsorption) are decreased in the newborn compared to adults.
This results in a decreased clearance for drugs that are
eliminated via the kidneys. Therefore the maintenance doses
of these drugs must also be reduced. Renal function matures
with age. However, the rates of maturation for the individual
physiologic functions are different, making it difficult to
predict the renal clearance of drugs that are eliminated by
more than one of these mechanisms. At birth, glomerular
filtration is only 10 to 20 mlfmin/1.73 m 2 ; it doubles by
2 weeks of age, but does not reach adult values until 3 to
5 months of age. 28 •29 Tubular secretion is only 20% to 30%
of adult values at birth; it reaches adult values at approximately 8 to 10 months of age, and values 10 times higher
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Fig. 13-2 The half-life of a drug can be calculated by plotting the
logarithm of the serum drug concentration (following a dose given
at time 0) versus time. The half-life of a drug is the time it takes
for the serum drug concentration to fall by one-half. In this
example, the serum drug concentration is 4 mg/L at 3 hours and
falls to 2 mg/L at 6 hours. Thus the half-life (tl/2) of the drug is 3
hours.
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Fig. 13·3 Steady-state occurs when the rate of drug administration is equal to the rate of drug
elimination. This produces drug concentrations that are constant. Steady-state occurs at 5 times the drug's
half-life. (Clinically, 3 to 5 times the drug's half-life is used to estimate steady-state). In A, an intermittent
dose of a drug with a half-life of 5.5 hours is administered every 6 hours. Serum drug concentrations
increase after each dose to a peak amount and then decline to a trough concentration (right before the next
dose is given). With repeated dosing the peak and trough concentrations increase (as a result of drug
accumulation) until steady-state is achieved. At steady-state, all the peak concentrations are equal and all
the trough concentrations are equal. In this example, steady state occurs at 27.5 hours (5 times the half-life
of 5.5 hours). In B, the same drug is administered via a continuous infusion at the same dose per day.
Steady-state occurs at the same time (27.5 hours or 5 times the half-life of 5.5 hours). Because the same
amount of drug was given per day, the steady-state concentration in B is equal to the average steady-state
concentration in A.

than birth by I year of age. 5 •6 Tubular reabsorption is
decreased in the neonate and the nonnal diurnal variation in
urinary pH is not evident until 2 years of age. Thus the
kidney's capacity for clearance via all three physiologic
functions may not be fUlly developed until 2 years of age.
Clinically then, PICU patients less than 2 years of age may
have age-related alterations in renal clearance of medications that are normally eliminated by the kidney. This is·
probably more significant for patients who are I year of age
or less. Medical conditions, such as decreased cardiac
output, decreased renal perfusion, renal disease, and asphyxia may also decrease glomerular filtration and drug
clearance. Whenever renal function is decreased, proper
dosage adjustment of drugs that are normally eliminated by
the kidney, must be made so that accumulation of drug and
toxicity does not occur (see dosing of drugs in renal
failure below).

PHARMACODYNAMICS
Phannacodynamics is the study of the time-dependent
actions or biologic effects of a drug in the human body that
result from the interaction of the drug and its receptor?
Phannacodynamics uses mathematic models to describe the
relationship between the drug dose or the plasma concentration and the pharmacologic effect of the drug. One such

model is the sigmoidal model (Figure 13-4), which approximates an S-shaped curve. 30 In this model, the pharmacologic effect of the drug only slightly increases as one begins
to increase the dose or concentration. As the dose or concentration continues to increase, the pharmacologic effect of the
drug then increases greatly, almost in a linear fashion. As
one continues to increase the dose even higher, a leveling off
of the effects occur. This leveling off of the curve indicates
that there is a maximum amount of drug, above which no
further increase in effect is seen. In conjunction with the
phannacologic effects, adverse effects or toxicities that are
dose or concentration related may also occur. Phannacodynamic modeling tries to identify a dose that will produce an
optimal level of phannacologic effect, with a minimal
amount of dose-related side effects.
Pharmacodynamic modeling may also help identify the
range of therapeutic serum drug concentrations. Concentrations below the therapeutic range are usually subtherapeutic and concentrations above the therapeutic range
are usually toxic. Serum drug concentrations are only useful when they closely relate to the concentration of drug at
the receptor3l The "therapeutic index" of a drug uses the
'serum concentrations of the therapeutic range and is the
ratio of the maximum serum concentration in the therapeutic
range to the minimum serum concentration in the therapeutic range. If a drug has a "narrow therapeutic index," it
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Fig. 13·4 Pharmacodynamic model. In this graph, the probability of response for a pharmacologic effect
(efficacy) and toxicity are plotted versus the logarithm of the serum drug concentration. The efficacy line
displays the traditional sigmoidal shaped curve. In this example, as the serum drug concentration increases
from 0 to 4 mg/L, the probability of a pharmacologic effect is low and barely increases. At concentrations
from 6 to 30 mg/L the probability of effect increases greatly, almost in a linear fashion. Note that as
concentrations increase to greater than 30 mg/L the probability of an effective response does not
significantly increase. However, the probability of toxicity continues to increase with increasing serum drug
concentrations. The shaded area represents an identified therapeutic range of 10 to 20 rng/L. At these
concentrations, the probability for efficacy would be about 50% to 85%, although the probability for
toxicity would be only 10% to 30%.

means that the serum concentration (or dose) that produces
a subtherapeutic effect is very close to the serum concentration (or dose) that produces a toxic effect. Proper
monitoring of serum drug concentrations for drugs with a
narrow therapeutic index can optimize dosing and pharmacologic effect, while minimizing toxic effect (see therapeutic drug monitoring below).

Dosing of Medication in Critically III Children
The pharmacodynamics and pharmacokinetics of a drug
must be taken into consideration when dosing guidelines are
designed. Pediatric dosing guidelines must take into account
all of the developmental pharmacokinetic issues discussed
above, plus any age-related differences in pharmacodynamic response. Medications are dosed in PICU patients
according to their age and body size (either weight or body
surface area). Pediatric doses are usually expressed as
mg/kg/day or mg/kg/dose with the dosing interval specified. Potent medications that are given as continuous
infusions (such as catecholamines), are dosed as flg/kg/
min. 1 For many drugs, the mg/kg dose is different for
different age groups. Although there is a good correlation of
body surface area with body functions (i.e., cardiac output,
glomerular filtration rate) and growth and development,
measurement of body surface area can be difficult (espe-

cially in small infants). Therefore surface area is usually
used to dose certain medications that require very accurate
dosing (e.g., chemotherapeutic agents).
Normally, for most PICU patients, the individual's actual
body weight (total body weight) is used to calculate mg/kg
doses. However, special dosing considerations must be
made for certain medications in patients who are extremely
obese. Unfortunately, very few studies have examined the
pharmacokinetics and dosing of drugs in obese pediatric
patients. Therefore much has to be extrapolated from studies
performed in obese adults. Several pharmacokinetic differences exist between obese and non-obese adults 32 •33 In
obese patients, the Vd per kilogram of actual body weight
will be decreased for water-soluble drugs (e.g., gentamicin).
This is expected, because the excess weight in obese
patients is adipose tissue, and water soluble drugs will not
penetrate well into adipose tissue. However, the Vd per
kilogram of actual body weight for lipid-soluble drugs is
less predictable, with an increase in Vd for some lipidsoluble drugs (benzodiazepines, carbamazepine, verapamil)
and a decrease in Vd for others (cyclosporine, propranolol).
This suggests that other factors besides lipid-solubility play
an important role in tissue distribution. 32 Generally, total
body clearance of drugs that are hepatically metabolized by
oxidation, reduction, or conjugation is not decreased in
obese patients. However, clearance may be increased for
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prednisolone, halothane, and some benzodiazepines. Renal
clearance of aminogylcosides in Llhr is significantly higher
in obese adults compared with the non-obese?3 These
pharmacokinetic differences require that different dosage
adjustments be made for different drugs. For example, in
obese patients, the dose of lorazepam and vancomycin
should be based on total body weight. 32 •33 Vecuronium,
however, should be dosed on ideal body weight. The initial
dose of an aminoglycoside should be based on an adjusted
body weight, which is calculated by adding the ideal body
weight to 40% of the difference between the total body
weight and the ideal body weight 33 Subsequent doses of
aminoglycosides should be based upon serum drug concentrations. Practical guidelines for dosing other drugs in obese
adults have been proposed. 32.33 Clinical use of these
guidelines, especially in obese children, requires close
monitoring of the patient and serum drug concentration
determinations to best optimize the dose.
Loading Doses. As stated before, when a dosing
regimen is started, it will take 3 to 5 times the half-life of the
drug to achieve steady-state. If the dosing regimen has been
properly designed, it should achieve a steady-state serum
drug concentration that is therapeutic. However, for drugs
that have a long half-life, it will take a longer time to reach
steady-state and therefore a longer time to reach a therapeutic serum drug concentration. If the time it will take to
achieve the steady-state therapeutic drug concentration is
too long for the clinical condition being treated, then a
loading dose may be given. In other words, a loading dose
is given to rapidly achieve a therapeutic serum drug
concentration; it will NOT affect the time it takes to get to
a steady-state condition. 4
An example may better illustrate this point. Let's say we
have a 4-year-old patient who requires phenobarbital to
control his active seizure activity. The half-life of phenobarbital in this child may range from 37 to 73 hours. I
Therefore if just a maintenance dose of phenobarbital was
started, we could expect steady-state to occur in approximately 5 to 15 days (3 to 5 x 37 to 73 hours). If the
maintenance dose was correct, then the patient would also
achieve therapeutic serum concentrations at around the
same time (5 to 15 days). Obviously, 5 to 15 days is too long
to wait for a therapeutic effect, so a loading dose of
phenobarbital should be given. The loading dose will
rapidly achieve a therapeutic serum concentration, so that
the patient's seizure activity can be controlled. After the
loading dose, the patient should be started on a phenobarbital maintenance dose. It will still take 5 to 15 days of
phenobarbital maintenance therapy to achieve steady-state.
However, this patient's serum concentration should remain
in the therapeutic range during this time. As the phenobarbital concentration from the loading dose begins to decline
over time, the phenobarbital concentrations from the maintenance doses should accumulate over time. The overall
result will maintain the concentrations within the therapeutic range.
Dosing of Drugs in Renal Failure. When PICU
patients develop significant renal dysfunction, the dose of
medications that are renally eliminated must be reduced or

the dosing interval for these drugs must be lengthened. With
either method, the amount of drug that the patient receives
per day is reduced. If the dose of a renally eliminated drug
is not adjusted in a patient with renal dysfunction, the drug
will accumulate in the patient and clinical toxicities may
occur. Box 13-1 lists some common PICU medications that
may require dosage reduction in patients with clinically
significant renal dysfunction. Dose reduction may be
required at different levels of renal dysfunction based on
creatinine clearance. Dose reduction also depends on the
amount of drug that is eliminated unchanged in the urine.
Thus for a given creatinine clearance, the degree of dosage
reduction will be different for different drugs. Several
methods of adjusting the dose of medications in renal failure
have been described. 1.l1.34 Serum drug concentrations of
certain medications (e.g., amikacin, digoxin, gentamicin,
tobramycin, vancomycin) should be monitored in patients
with renal dysfunction to optimize the dose.
Patients with renal failure and other conditions may also
undergo dialysis, which can remove medications from
the body. The amount of drug removed by dialysis de.

Box 13-1
CommonPICU Medications That May
Require Dosage Reduction in Patients
With Significant Renal Dysfunction
Acyclovir
Arnikacin
Amoxicillin
Ampicillin
Atenolol
Aztreonam
Bretylium
Captopril
Cefazolin
Cefepime
Cefotaxime
Cefotetan
Cefoxitin
Ceftazidime
Ceftizoxime
Cefuroxime
Cephalothin
Cimetidine
Codeine
Digoxin
Disopyramide
Enalapril
Enalaprilat
Enoxaparin
Famciclovir
Famotidine
Fentanyl
Aecainide

Fluconazole
Ganciclovir
Gentamicin
Hydralazine
Imipenem-Cilastatin
Lisinopril
Meperidine
Meropenem
Methadone
Methicillin
MezlociIlin
Milrinone
Morphine
Nizatidine
Oxacillin
Pancuronium
Penicillin
Pentamidine
Piperacillin
Procainamide
Quinidine
Ranitidine
Sulfamethoxazole
Ticarcillin
Tobramycin
Trimethoprim
Vancomycin
Verapamil

Specific dosing guidelines to reduce the dose of these drugs when used in
patients with renal dysfunction can be found in TakclOffiO CK, Hooding JH.
Kraus DM: Pediatric dosage handbook, ed 6. Hudson, Ohio, J999.
Lexi-Comp.
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pends upon several properties of the drug (i.e., molecular size/weight, water solubility, protein binding and volume of distribution), as well as the type of dialysis
used. 34 Significant differences in drug removal occur between hemodialysis, peritoneal dialysis, and the three main
types of continuous renal replacement therapy (CRRT) (i.e.,
continuous arteriovenous or venovenous hemofiltration
[CAVH/CVVHj, continuous arteriovenous or venovenous
hemodialysis [CAVHD/CVVHDj, and continuous arteriovenous or venovenous hemodiafiltration [CAVHDF/
CVVHDFj).35 (See Chapter 21.) Doses of medications for
PICU patients undergoing dialysis must be individualized
and serum drug concentrations should be monitored to help
optimize doses.
Dosing of Drugs in Hepatic Failure. Many drugs
are eliminated by the liver, either by metabolism to inactive
forms or by excretion via the biliary tract. Therefore these
drugs must be used with caution and doses may need to be
decreased in patients who have hepatic dysfunction or
biliary tract obstruction. If doses of hepatically eliminated
drugs are not decreased in patients with hepatic dysfunction,
the drug may accumulate and clinical toxicities may occur.
Certain drugs, such as valproic acid and felbamate, are
contraindicated in patients with hepatic dysfunction because
they are hepatotoxic. I Common PICU drugs that are
significantly metabolized by the liver include carbamazepine, cyclosporine, diazepam, ketamine, midazolam, labetalol, lidocaine, phenytoin, procainamide, propranolol, and
vecuronium. Dosage reduction may be required at different
levels of hepatic dysfunction (e.g., moderate or severe) and
will depend upon the percent of drug that is eliminated by
the liver. Specific guidelines for dosing of many drugs in
hepatic dysfunction are not well developed. Unlike how
serum creatinine can easily assess renal function, there is not
one simple clinical marker that can reliably assess the
degree of hepatic dysfunction in a patient. Thus for certain
medications, dosage adjustment may be made based on
clinical assessment of hepatic function, liver enzymes,
and/or bilirubin serum concentrations. Oftentimes, the dose
may be adjusted based on the patient's clinical response and
signs of drug toxicity or adverse effects. Serum concentrations for specific hepatically metabolized drugs (e.g.,
carbamazepine, cyclosporine, lidocaine, phenobarbital, phenytoin, procainamide) should be monitored to best optimize
therapy.

Therapeutic Drug Monitoring
Many medications that have a narrow therapeutic range are
utilized in the PICU and require therapeutic drug monitoring
(e.g., aminoglycoside antibiotics, phenobarbital, phenytoin,
theophylline, and vancomycin). Proper obtainment of serum
drug concentrations in relation to the dose and duration of
therapy is essential in order to best interpret the concentrations and make correct dosage adjustments. Table 13-2 lists
the therapeutic range and time to obtain serum concentrations for these agents. The peak serum drug concentration
(i.e., the maximum concentration achieved) occurs shortly
after administration of an IV dose, or after absorption into
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the blood stream when the drug is administered via other
routes. The trough serum drug concentration (i.e., the
minimum concentration achieved with a dosing regimen)
occurs right before the next dose. The optimal time to
measure the peak and trough serum drug concentration has
been determined with clinical studies for each drug. These
studies have related the drug concentrations obtained at
certain times to the optimal clinical effect. Therefore drug
concentrations must be drawn at the appropriate times in
order to best utilize their results.
It is also important for PICU clinicians to document the
time that the dose was administered (i.e., start and stop time
of the infusion) and the time that the serum drug concentration was obtained. Using this information, the dose, other
patient information, and the results of the serum drug
concentrations, the clinical pharmacist can calculate the
patient's individual pharmacokinetic parameters and optimize the dose. One should remember that drawing blood
samples from central catheters where the drug was just
infused may falsely elevate the drug concentration, even if
extra blood is taken from the catheter. The measured serum
drug concentrations and calculated pharmacokinetic parameters should always be utilized in conjunction with the
patient's clinical condition.

MEDICATION ADMINISTRATION
IN THE PICU
IV Administration
Pediatric total daily fluid requirements (in mllday) are much
smaller than adults. In addition, pediatric patients cannot
tolerate large volumes of fluid. Therefore the volume of
fluids that an IV medication can be delivered into a pediatric
patient is limited. Additionally, the rate of drug infusion is
also limited. This is not only because of the limitations of
volume, but also because of the limitations of the physicochemical properties of the drug and the adverse effects it
may cause in high concentration to the smaller diameter
veins. This problem is compounded in the PICU patient who
may be fluid restricted because of renal, respiratory or
cardiac disease. II Table 13-3 lists the maximum concentration, method of infusion and rate of infusion for select PICU
medications.
The method of IV drug administration in pediatric
patients can affect drug delivery. The slow IV infusion rates
for maintenance fluids used in infants and young pediatric
patients (e.g., <25 mllhr) can cause a delay in drug delivery,
especially if medications are administered via volumetric
chamber devices (Metriset or Buretrol). Even when factors
such as tubing diameter, drug volume, and infusion rates
have been taken into consideration, the actual delivery of
drug to the patient may be delayed up to 2 hours if these
devices are used 36 In addition, administration of drugs at a
Y-site, instead of using a syringe pump at the site closest to
the patient, can also affect drug delivery. A delay in peak
aminoglycoside concentrations of 1.5 hours and a mean
decrease in peak concentrations of 2.5 ~g/ml was seen in
neonates, when tobramycin was administered via Y-site
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TABLE 13·2 Blood Level Sampling Time Guidelines
!pc

Infusion Time

Therapeutic Range

When to Draw Levels

Peak: 20-30 llg/ml
Trough: < 10 llg/ml

Peak: 30 min after end of 3D-min infusion
Trough: Within 30 min before next dose
Peak: I hr after 1M injection
Trough: Within 30 min before next dose

4- 12 11g/ml

Just before next dose

Peak: 15-25 llg/ml

~~.' PO
~f:
:",;J::ydosporine
tt'IV/PO
[¢L

Peak: 90 min after end of 3D-min infusion
Trough: JlIst before next dose
Peak: 2 hr post-PO dose

BMT 100-200 ng/ml
Liver transplant 200-300 ng/ml
Renal transplant 100-200 ng/ml

Jlist before next dose

Ii""

Age and disease related: 0,8-2 ng/ml

6 hr postdose to just before next dose

~Ethosuximide PO

40-100 llg/ml

Just before next dose

~f1ucytosine PO
!!i.,.

25-100 llg/ml

Peak: 2 hr after at least 4 days of therapy

iii:!. IV

Phenytoin: 10-20 llg/ml

Peak: 2 hr after end of an infusion
Peak: 4 hr after 1M injection

Peak: 4-10 llg/ml
Trough: 0,5-2 llg/ml

Peak 30 min after end of 3D-min infusion
Trough: Within 30 min before next dose
Peak: I hr after 1M injection
Trough: Within 30 min before next dose

j!Drug
~Fi'
~iArnikacin

.

sulfate

~ir IV

30 min

"~j
"J;'
·iL.. .•."•.'.",.•. IM

l

,~!r'

~~tarbamazepine

I'#Chloramphenicol
!iL
iill"· IV
ii1!'

30 min

~;

~tDigoxin IV/PO

f~~i

t~rosphenytoin (measure phenytoin levels)

ill!!'(·IM
ift.,

~"Gentamicin

~B;

I~l

IV

lr~r 1M

'"
"T..
~~J'\,.

30 min

~iPhenobarhilal

15-40 Jig/ml

Trough: just before next dose

\WL PO, IV

10-20 Ilg/ml

Trough: just before next dose
Post-load/peak: I hI' after end of infusinn

10-20 Ilg/ml

Peak: 30 min after end of 30-min infusion

~'Phenytoin

~f(

I

. I"

•;!.'.•.(. .Th eophylline
'l,.l, IV bolus

30 min

~ii: Continuous infusion

16-24 hI' after the stan or ehange in a constant IV infusion
Peak: I hI' postdose
Trough: Just before next dose
Peak: 4 hI' posldose
Trough: Just before next dose

fit

PO liquid, fast-release tablet (Somo-phyllin,
~i:
Slo-Phyllin liquid and tablet)
~!. PO slow-release (Theo-Dur, Slo-Phyllin GC,

"~I.·..
ir~!

Slo-bid)

~TobramYCin

~. IV

30 min

Peak: 4-10 Ilg/ml
Trough: 0.5-2 Jig/ml

Peak: 30 min after end of 30-min infusion
Trough: Within 30 min before next dose
Peak: I hI' post-1M injection
Trough: Within 30 min before next dose

60 min

Peak: 5-10 Ilg/ml
Peak: 1-3 Jig/ml

Peak: 30 min after end of 60-min infusion

l!i'

~L. 1M

~C

m"T···'
'
ijli,'nmethopnm
~fi IV, dose 20 mg/kg

~,

IV, dose 8-10 mg/kg
f PO

I

Peak: I hI' postdose

'k:

jyalproie aeid

50-100 Jig/ml

Trough: Just before next dose

Peak: 25-40 Ilg/ml
Trough: 5-15 Jig/ml

Peak: 20-30 min after end of 60-min infusion'
Trough: Within 30 min before next dose

Ji. PO

lolt(!!

fW'iiiVaneomyein
w:
';;:":

'1: :

"~~some institutions may draw vancomycin peak

60 min

I hour ancr I-hour infusion and accept the lower range of therapeulic.

!r:rom TakelOIllO CK, Hooding JH, Kraus DM: Pediatric do"age handbook, ed 6, Hudson, OH, 1999, Lexi-Comp,
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It)TABLE 13-3

Maximum Concentrations of Select Medications for IV Infusion
in Pediatric Patients

I~g

.".:

ii,

picillin

lm'
~Wretylium
~!i

Iii'
Ill!":

IT~-~
~~ eftriaxone

,- irnetidine

:~-

'. butarnine
parnine

Method of Infusion/Rate

Maximum Concentration

Intermittent infusion over 30 min
Usual: infuse over 20-30 min
Maximum: 0.36 mg/kg/min, no faster than 25 mg/min
Peripheral infusion over 2-6 hr
CVP over 2-6 hr
IVP over 3-5 min: max: 100 mg/min
Intermittent infusion over 15-30 min
Life-threatening situation:
IVP over <30 sec
Non-life-threatening situation:
Slow IVP over at least 8 min
Intermittent infusion over 10-30 min
Intermittent infusion over 15-30 min
Slow IVP over at least IS min
Continuous infusion
Continuous infusion

5 mg/ml
I mg/m1
25 mg/ml
0.1 mg/ml
0.5 mg/ml
100 mg/ml
30 mg/ml

Continuous infusion
Intermittent infusion over 30-60 min
Slow IV over 15 min
Continuous infusion

Continuous infusion

Intermittent infusion over 15-30 min
Slow IVP over at least 5 min
Intermittent infusion over 30-60 min
.
Slow IV over IS min
Intermittent ird'usion over 60 min

50 mg/ml
10 mg/ml
40 mg/ml
6 mg/mI
15 mg/ml
5 mg/ml
3.2 mg/ml
6 mg/ml has been used in
large veins in extreme
fluid restriction
64 Ilg/ml
2 mg/ml
10 mg/ml
20llg/ml
64 Ilg/ml ha~ been used in
extreme fluid restriction
4llg/ml
16 Ilg/ml has been used in
extreme fluid restriction
0.5 mg/ml
2.5 mg/ml
2 mg/ml
10 mg/ml
5 mg/ml

:. dapted from Taketomo CK, Hooding JH, Kraus OM: Pediatric dosaMe halldbook. ed 6, Hudson. OH, 1999. Lexi-Comp.
..""

compared to the syringe pump?7 Therefore inappropriate IV
drug administration can result in lower measured peak
concentrations, and calculations of inappropriately large
volumes of distribution and prolonged half-life for a drug.
Whenever calculated pharmacokinetic parameters seem
suspiciously high or low, the method of drug administration
should be closely evaluated.
Certain methods of drug delivery may also cause medical
problems. In adults patients, many drugs are administered
via IV "piggyback" or in IV "riders." With this method of
administration, the dose of medication is added to 50 or 100
ml of D sW or NS. This method of drug delivery should not
be used in small patients (e.g., those <10 kg), because of the
excess amount of fluid, free water (from DsW), and sodium
(from NS) that will be delivered. Other potential problems
or errors in pediatric drug administration techniques are
listed in Box 13-2.

Pediatric Dosage Forms
Pediatric patients, especially those who are critically iII, are
not able to swallow solid dosage forms. However, not all
oral drugs are commercially available in a liquid formulation. Oftentimes, an extemporaneous liquid preparation
must be compounded by the pharmacist using either an oral
solid dosage form or an injectable product. 1,38 Information
regarding the preparation and stability of pediatric extemporaneous formulations is Iimited. 39 In addition, extemporaneous products take much time to prepare and may not be
readily available at all institutions.
The lack of liquid medications results in alternative
methods to administer solid dosage forms to pediatric
critically ill children. In general, regular-release tablets may
be crushed, and administered either orally or through a
nasogastric (NO) tube after being mixed with a small
amount of water. This can be done, unless the medication
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Box 13·2

Potential Errors in Drug
Administration Techniques

Factors Involving Drug (Dose) Preparation
• Inappropriate dilutions
• Similarity in appearance of dose units
• Loss of potentially large amounts of drug dose in the dead
space of a syringe; infusion V-site, etc.
• Unsuitable drug formulations for administration
Unlabeled or undesirable ingredients in dosage forms
Undesirable drug concentrations and/or osmolalities
• Errors in interpreting drug orders and/or dose calculations

Factors Involving IV Drug Administration
Loss of drug consequent to routine changing of IV sets
• Reduction in serum concentrations for drugs with rapid
plasma clearance that are infused slowly
• Extreme increase in plasma drug concentrations consequent
to rapid infusion of drugs with small central compartment
volume of distribution
• Delayed infusion of total dose when IV line is not flushed
Inadvertent mixture of drugs by the manual IV retrograde
method
• Large distance between the site of drug infusion into an IV
line and the insertion of the line into the patient
• Potential loss of large volume doses in the overflow
syringe with the IV retrograde technique
• Possible loss of drug because of binding to IV tubing
Use of large intraluminal diameter tubing for small patients
Infiltrations not detected by pump alarms
Infusion of multiple medications/fluids at different rates by
means of a common "hub"
• Oscillations in fluid/dose rate of potent medications infused
with piston-type pumps
Factors Involving Other Routes of Drug Administration
• Loss in delivery (nasogastric tube dead space) or from oral
cavity
• Leakage of drug from 1M or SC injection site
• Expulsion of drug from the rectum
Misapplication to external sites (i.e., ophthalmic ointment
in young infants)
From Blumer JL. Reed MO: Principles of neonatal pharmacology. In Yaffe S,
Aranda IV, eds: Pec!iolr;c pharmacology: therapeutic principles in praclice.
ed 2, Philadelphia, 1992. WB Saunders. p. 168.

will produce irritation to the oral mucosa, is extremely bitter
in taste (does not apply to NG use), contains dyes or could
directly stain mucosal tissue or teeth, or is potentially
carcinogenic 40 Enteric-coated, sublingual, and extendedrelease dosage fonns should not be crushed. Enteric-coated
tablets are designed to stay intact in the acid environment of
the stomach and to release the drug in the intestines. If
enteric-coated tablets are crushed and administered gastrically, the drugs (I) may cause stomach irritation when they
come into contact with the stomach mucosa; (2) may be
destroyed by the acids in the stomach; or (3) may have an
earlier onset of action. Sublingual tablets are meant to be
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rapidly absorbed via the blood vessels under the tongue and
in the mouth. This rapid absorption and fast onset of action
will be lost if sublingual tablets are crushed and administered into the stomach or intestines. Extended-release
dosage forms commonly have one of the following abbreviations after their trade name: CR (controlled release), CRT
(controlled-release tablet), LA (long acting), SR (sustained
release), TR (time release), TD (time delay), SA (sustained
action), XL (extended release), or XR (extended release).
These products are designed to release the drug slowly over
a prolonged period of time. Thus the amount of drug
contained in extended-release dosage fonns is typically
greater than regular-release dosage fonns. If extendedrelease dosage forms are crushed and administered, all of
the drug contained in the tablet or capsule will be released
and absorbed at one time, resulting in very high serum
concentrations and toxicities in the patient.
A comprehensive listing of oral dosage fonns that should
not be crushed has been published recently.40 A summary of
some common PICU medications that should not be crushed
is listed in Table 13-4. Oftentimes the mg strength of a
commercially available tablet may be too large for a child.
In general, regular-release tablets can be cut in half to
administer partial doses, but enteric-coated and extendedrelease products should not be cut.
Transdermal patches are occasionally used in older
children and adolescents to deliver certain medications.
These products can be used intact, provided that the milligram strength of the transdermal delivery system and dose
delivered is appropriate for the patient's age and body size
(i.e., weight), Different types of transdermal patches exist
and some types should not be cut to deliver partial doses.
For example, transdermal patches for cionidine (CatapressTTS) and fentanyl (Duragesic) are membrane-controlled
systems. If these types of patches are cut, the semipenneable membrane can be damaged and the rate of drug
delivery may be affected. Contents of the patch reservoir
may also leak. In addition, by cutting the patch, the patch
may not adhere to the skin as well and the drug's stability or
potency may be affected by exposure to air or sunlight.
Therefore these patches should not be cut. 4 !
Partial doses of patches may be delivered by covering a
portion of skin with an impermeable adhesive bandage (i.e.,
blocking the patch). The area of the skin covered with the
adhesive bandage should be proportional to the amount of
dose reduction. An adhesive bandage may then be placed
over the whole system to secure it in place. 41

Pediatric Medication Administration
Decision Making
Critically ill pediatric patients are often given highly potent
medications that are dosed by body weight and administered
by continuous IV infusion. In emergency sitUations, drugs
such as dopamine, dobutamine, epinephrine, norepinephrine, and isoproterenol, need to be mixed appropriately and
prepared for immediate administration. Proper calculation
of the patient's dose, concentration for infusion, and
milliliter-per-hour infusion rate are essential. Errors in
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TABLE 13·4 Common PICU Medications That Should Not be Crushed
Irype of Formulation

Example Drugs

Comments

Biscodyl
Erythromycin
Ferrous sulfate
Pancrelipase
Sulfasalazine

Use
Use
Use
Use
Use

Acetazolamide
Carbamazepine
Chlorpromazine
Diltiazem

Use regular tablets or extemporaneous liquid preparation
Use suspension or regular tablets
Use liquid preparation or regular tablets
Open capsule (do not crush beads); mix with applesauce and
swallow immediately (do not chew) or flush beads down gastric
tube with sterile water
Open capsule (do not crush beads); flush beads down gastric lUbe
with sterile water; or use extemporaneous liquid preparation
Open capsule (do not crush beads); mix with apple juice and flush
through gastric tube
Use regular tablets
Use liquid form
Gastric tube: Mix capsule with apple juice or cranberry juice; stable
30 min after mixing
Jejunostomy tube: Dissolve capsule in 8.4% sodium bicarbonate to
make final concentration of 2 mg/ml
Use regular tablets or extemporaneous liquid preparation
Use liquid preparation
Use regular tablets or extemporaneous liquid preparation
Use liquid preparation
Use liquid preparation
Use regular tablets or extemporaneous liquid preparation

~_.

Disopyramide
Lansoprazole
Metoprolol
Morphine
Omeprazole

Procainamide
Propranolol
Quinidine
Theophylline
Valproic Acid
Verapamil

suppository or powder form
suspension form
liquid form
powder form
suspension or regular tablets'

'iAdapted from Mitchell JF: Oral dosage forms that should not be crushed: 2000 update, Hosp Pharm 35:553-557. 2000: Engle KK. Hannawa TE:
Am J Health S,\'j" Pharm 56: 1441-1444, 1999:
~iilnd Taketomo CK. Hoddll1g JH. Kraus DM: PedlUtrlc dosage handbook, ed 6, Hudson, OH, 1999, LeXl-Comp.

~Iechniques for administe~g oral medications to c~itic.al care patients receiving continuous emeral nutritio~.

I~URegular

,,,'

tablets" means regular-release tablets (i.e., not extended release. not enleric coated, not sublingual)

calculations can result in significant overdose (and toxicities) or underdose (and lack of response), To complicate
matters, many different combinations of concentration and
rates can be used to deliver the same ~g/min dose, Basically,
there are three ways to calculate doses for proper administration of these agents: (I) the standard concentration
method; (2) the "rule of 6s"; and (3) individualization of
concentrations based on rates of infusion and dose, Each of
these methods requires knowing the patient's weight and the
intended ~g/kg/min dose. Then, if the concentration is
known, the rate of administration can be calculated; if an
intended rate of administration is known, the concentration
of the infusion can be calculated.
Standard concentrations for continuous infusions can be
developed by weight, so that the rates of infusion are
acceptable when the medication is dosed within the usual
dosage range,42 For example, standard concentrations for
dopamine can' be 200 ~g/ml for infants 2 to 3 kg; 400 ~g/ml
for infants 4 to 8 kg; 800 ~g/ml for children 9 to 15 kg and
1600 ~g/ml for patients> 15 kg. To calculate the ml/hr rate
of infusion, first multiply the ~g/kg/min dose times the kg
weight, then times 60 (minlhr) and divide by the standard
concentration. For example, let's say we wanted to deliver a
dose of dopamine at 5 ~g/kg/min to a 10-kg infant. Multiply

5 ~g/kg/min times 10 kg to get 50 ~g/min; multiply this by
60 minlhr to get 3000 ~g/hr; then divide by the standard
concentration of 800 ~g/ml to get 3.75 ml/hr and round to
3.8 ml/hr. So, for this patient, 3.8 ml/hr of an 800 ~g/ml
solution will provide 5 ~g/kg/min. The advantage of
standard concentrations is that nO patient calculations are
needed to prepare the IV bag, Thus the IV bag can be
quickly prepared or hung while the dose and rate are being
calculated.
The rule of 6s is based on the fact that there are
60 minutes in an hour. With this method, a calculation based
On the patient's body weight is made to detennine the
amount of medication to add to 100 ml of solution. Because
the calculation uses the rule of 6's, the ml/hr infusion rate
very easily relates to the dose in ~g/kg/min. For dopamine
and dobutamine, 6 times the patient's body weight is added
to 100 ml; then I mllhr will equal I ~g/kg/min, For
epinephrine, norepinephrine, and isoproterenol, 0.6 times
the patient's body weight is added to 100 ml; then I ml/hr
will equal 0.1 ~g/kg/min. 1 Let's use this method to deliver
a dose of dopamine at 5 ~g/kg/min to a 10-kg infant.
Multiply 10 kg x 6 to get 60; this is the amount of drug
(60 mg) that should be added to 100 ml ofIY solution. Then
I mllm will equal I ~g/kg/min and 5 mllhr will equal
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5 llg/kg/min. This method has the advantage of utilizing a
milliliter-per-hour rate that very simply relates to the
llg/kg/min dose. However, the disadvantage of this method
is that patient-based calculations must be performed in order
to make the IV solution.
With either of these methods, the mllhr rate may be too
large for some patients (e.g., if the patient requires fluid
restriction). To individualize the concentration of the
infusion, first multiply the llg/kg/min dose times the
kilogram weight, then multiply times 60 (minlhr) and divide
by the intended rate of infusion. For example, let's say we
wanted to deliver a dose of dopamine at 5 llg/kg/min to a
10-kg fluid-restricted infant at 2 mllhr. First multiply
5 llg/kg/min times 10 kg to get 50 llg/min; multiply this by
60 min/hr to get 3000 llg/hr; then divide by the intended rate
of infusion of 2 ml/hr to get a concentration of 1500 llg/ml.
For this patient, 2 mllhr of a 1500 llg/ml solution will
provide 5 llg/kg/min. This method has the advantage of
being able to select the amount of fluid that the patient
receives. However, it requires patient-specific calculations
in order to make the IV solution.
Each PICD team should decide which of these methods
to use to calculate continuous infusions of emergency
medications. Some institutions elect to use a combination of
methods. For example, standard concentrations can easily
be prepared by the PICD staff during emergency situations.
If the patient then requires fluid restrictions, the pharmacy
can perform the necessary calculations to concentrate the
infusion.
Changing patients from the IV route of administration to
the oral or enteral route can result in significant cost savings.
However, clinicians should keep in mind that patients
should not be switched to the enteral route until the GI tract
is well perfused and functioning. Otherwise, GI absorption
may be compromised and the pharmacologic effects of the
drug may be decreased. In addition, the oral versus IV
bioavailability of the specific medication needs to be
addressed when changing routes of administration (see
Absorption above). If a drug with low oral bioavailability is
gi ven orally in the same dose as IV, an underdose will occur
and minimal systemic effects may be seen. However, if a
drug with low oral bioavailability is given IV in the same
dose that is recommended orally, an overdose will occur and
toxicities will result. Thus the recommend dose of a
medication should be verified when changing routes of
administration.

PRINCIPLES OF DRUG INTERACTIONS
Interactions can occur between two drugs (drug-drug interaction) or between a drug and a nutrient (drugnutrient interaction). Drug-drug interactions can be pharmacokinetic or pharmacodynamic in nature. Pharmacokinetic
drug-drug interactions result from alterations in absorption,
distribution, metabolism or elimination. Absorption may be
altered if a drug changes gastric pH, GI motility, GI mucosa
or flora, alters the first-pass effect, or complexes with another drug in the GI tract. Drugs may affect distribution by
altering protein binding. Metabolism may be altered when
drugs inhibit or induce hepatic enzymes, or if two drugs
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compete for metabolism by the same enzyme. Drugs may
affect excretion by altering renal elimination of unchanged
drug or hepatic elimination via the biliary tract. 27 Examples
of pharmacokinetic drug-drug interactions and drug-nutrient
interactions have been given throughout this chapter.
Pharmacodynamic drug interactions occur when one
drug modifies the pharmacologic effect of another. This type
of interaction may take place at the receptor level, may
include different cellular mechanisms of action, may involve alterations of the cellular environment, or may occur
from the neutralization of one drug by another in the body. 27
At the receptor level, drugs may act as agonists (by
stimulating the receptor), or antagonists (by blocking the
receptor). (Some drugs may act as partial agonists by both
stimulating and blocking the receptor.) An example of a
drug-drug pharmacodynamic interaction that occurs at the
receptor level would be albuterol and propranolol. Albuterol
is a B-adrenergic receptor agonist, and propranolol is a
B-adrenergic receptor antagonist (B-blocker). If these two
drugs are administered in the same patient, the bronchodilation effects of albuterol would be blocked by propranolol.
Clinically, bronchoconstriction may be observed.
Two drugs may interact because of different cellular
mechanisms of action that may either increase or decrease
the pharmacologic response. For example, diuretics may
enhance the antihypertensive effects of captopril, and
indomethacin may decrease the antihypertensive effects of
propranolol. Each of these drugs has a different mechanism
of action. Drugs may interact by altering the cellular
environment. For example, diuretics such as furosemide
may cause hypokalemia which may increase the risk of
digoxin toxicities. Drugs may also interact by neutralization.
For example, protamine will neutralize heparin and reverse
its pharmacologic effects.
Clearly the PICD patient is at risk for drug-drug and
drug-nutrient interactions because of the many medications
that they receive. The clinician should be aware of these
problems and evaluate all drugs and nutrients for potential
adverse interactions. In addition, clinicians must be aware of
physical and chemical incompatibilities of IV medications.
Certain medications will precipitate with or inactivate other
medications. For example, when furosemide is injected into
IV lines containing amrinone or milrinone, a precipitate will
form. Aminoglycosides can be inacti vated by penicillins.
Sodium bicarbonate is incompatible with calcium salts,
catecholamines and atropine and should not be mixed with
or administered with other medications. Other incompatibilities of common PICD medications are listed in the
Appendixes.
In summary, PICD patients require many special pharmacologic considerations. The age-related and disease state
differences of pharmacokinetics and pharmacodynamics in
these patients, along with the lack of appropriate dosage
forms and use of multiple medications, can pose a pharmacotherapeutic challenge for the clinician. By having a better
understanding of clinical pharmacology, including pharmacokinetics, pharmacodynamics, drug dosing, therapeutic
drug monitoring, medication administration, and drug interactions, the PICD clinician will be better equipped to
optimize the care of critically ill children.
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Thermal Regulation
Mary Frances D. Pate

resulting from both environmental and maturational factors
(Table 14-1). Critical care nurses play an essential role in
protecting patients from adverse environmental factors and
in identifying patients at risk from maturational factors that
may impair effective thermoregulation.
Many patients in the pediatric intensive care unit (PICD)
may experience a risk for altered body temperature-the
state in which the individual is at risk for failing to maintain
body temperature within a normal range. J Abnormal body
temperature may be the result of illness (such as infection,
surgery, or shock) or its therapy.
Internal factors that contribute to or are risk factors for
altered body temperature include pathophysiologic and
treatment-related factors. For example, traumatic brain injury or congenital central nervous system (CNS) malformations may produce recurrent, transient elevations in body
temperature. In contrast, certain hypothalamic lesions produced by cerebrovascular hemorrhage, neurosurgical procedures, or tumors may result in low body temperature,
resulting from decreased ability to produce heat. Furthermore, a depressed or injured CNS results in a diminished
response to cold and minimizes shivering as a means of
generating heat.
Shock states limit peripheral perfusion in response to
hypotension and endogenous catecholamine-mediated subcutaneous vasoconstriction. These responses reduce peripheral blood flow, thereby diminishing heat dissipation and
resulting in increased core temperature.
Treatment-related factors leading to alterations in body
temperature include medications (e.g., vasopressors or
sedatives), parenteral fluids or blood transfusions, renal
dialysis, anesthesia, and surgery. For instance, anesthesia
inhibits most of the body's heat-producing and heatconserving mechanisms. When infants or children are unconscious or paralyzed (either pharmacologically or nonpharrnacologically), postural changes are no longer possible
because muscular activity is obliterated. Anesthetic agents
may also depress the hypothalamic thermoregulatory center,

ESSENTIAL PHYSIOLOGY OF TEMPERATURE REGULATION

Physiologic Control of Body Temperature
Behavioral Control of Body Temperature
Mechanisms of Thermoregulation
NURSING INTERVENTIONS TO MAINTAIN NORMOTHERMIA

Assessment and Maintenance of Normal
Body Temperature
Assessment of Temperature Imbalance
Thermoregulation Devices
ABNORMALITIES OF BODY TEMPERATURE REGULATION

Hyperthermia
Drug Fever
Malignant Hyperthermia
Nursing Care of Patients With Elevated
Body Temperature
Hypothermia
Nursing Care of Patients With Decreased
Body Temperature
SUMMARY

H

eat is a natural byproduct of metabolism. It is constantly produced and continuously lost to the environment. When the quantity of heat produced is equal to
the amount lost, homeostasis exists. If heat production
and heat loss are not in balance, body temperature will rise
or fall.
Normal thermoregulatory function serves to maintain
body temperature within a narrow range. Both environmental and maturational factors can cause or contribute to
ineffective thennoregulation-the inability to maintain normal body temperature in the presence of adverse or
changing environmental factors. J Critically ill infants and
children are at high risk for ineffective thermoregulation
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causing vasodilation and depression of the metabolic rate,
thereby reducing heat production and increasing heat loss.2
Induced hypothennia for extracorporeal circulation, exposure to cold ambient temperature, and exposure of the thoracic cavity during open heart surgery are specific treatmentrelated risk factors for infants and children. The
consequences of intraoperative hypothennia are often not
manifested until the postoperative phase. Small incremental
drops in temperature markedly increase oxygen consumption at a time when oxygen supply to tissues is marginal,
resulting in hypoxemia. 3
Pediatric critical care nurses are in a position to appreciate a variety of environmental, situational, and individual
factors that can result in either altered body temperature or
ineffective thermal regulation. Care of infants and children
based on an understanding of the dynamic interface between the patient and the environment can maximize the
nurse's ability to assist patients in maintaining a normal
body temperature despite the stress of illness. Regardless of
the thermoregulatory issue with which the nurse is confronted, interventions that are evidence based are critical to
the well-being of the patient.

~

Physiologic Control of Body Temperature
Heat production and heat loss are controlled in two
states. First, the transfer of heat to the body skin surface
from the central core establishes an internal thennal
gradient. Second, heat is dissipated from the skin surface to
the surrounding environment. This balance is critical to
nonnal thermoregulatory function and is summarized in
Fig. 14-1.
Body temperature regulation is controlled almost exclusively by intricate nervous system feedback mechanisms
located in the hypothalamus. Heat-sensitive neurons located
in the preoptic area of the hypothalamus are the body's most
influential temperature receptors. These receptors respond to
rising temperature by increasing their impulse output and to
falling temperature by decreasing their output.
Additional temperature receptors found in the skin
consist of both wannth and cold receptors. There are 4 to
10 times as many cold as warmth receptors. These receptors
convey nerve impulses to the hypothalamus, where the
information is used to regulate body temperature. Receptors
in the spinal cord itself, the abdomen, and other internal
body structures also transmit signals, primarily cold signals,
to the CNS to help in temperature control. Peripheral
thermoreceptors dispatch signals to the posterior hypothalamus, where they are integrated to control heat loss and heat
production. 4 This "hypothalamic thermostat" is the primary
temperature control mechanism in the body.
The Body's Response to Heat. Overheating of the
hypothalamic thermostatic area increases the pace of heat
loss by two essential processes. The first prompts the sweat
glands to boost evaporative heat loss from the body. The
second inhibits sympathetic centers in the posterior hypothalamus. This reaction allows vasodilation and, consequently, increased heat loss from the skin. 4
The Body's Response to Cold. When the body cools
down to a normal temperature (37 C), several mechanisms
reduce heat loss and escalate heat production. Vasoconstriction of the epidermal vessels is one of the body's earliest

TABLE 14-1 Factors fCeiated to
Ineffective Thermoregulation
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Fig. 14-1

Thermoregulation. <Reprinted by permission of Neonatal Nerw 13:15, 1994, Fig. I.)
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efforts to enhance heat conservation. The posterior hypothalamus mobilizes the sympathetic nervous system and
initiates powerful vasoconstriction throughout the body.
This effect decreases conduction of heat from the internal
core to the skin. When vasoconstriction develops, the only
heat loss that persists is that via the fat insulators of the skin.
Vasoconstriction can diminish heat loss eightfold and can
very forcefully conserve heat. When the temperature of the
hypothalamic thermostat falls below normal body temperature, the elimination of sweating is absolute. This response
arrests evaporative cooling except for insensible evaporation (e.g.. from the respiratory tract).4
The body also increases heat production in the event of
cold stress. This occurs in three distinct ways when
body temperature drops below 3T C. First, hypothalamic stimulation of shivering occurs. The primary motor
center for shivering is located in the posterior hypothalamus.
Cold stress stimulates and heat inhibits this nerve center.
When muscle tone is increased to a critical level in response
to cold stress, shivering begins. As a result, heat production
can increase 4 to 5 times the normal amount.
Second, chemical thermogenesis commences. The rate of
cellular metabolism increases as a result of sympathetic
stimulation or circulating epinephrine. In the adult, this
generally accounts for an increase in heat production of no
more than 10% to 15%. In infants, however, chemical
thermogenesis can increase the rate of heat production as
much as 100% and is a crucial mechanism. 4
Thermogenesis in infants is different than in older
children or adults. In infants, brown fat is the biochemical
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Fig. 14-2 Physiologic consequences of cold stress in infants.
BAT, Brown adipose tissue. (From Blackburn ST, Loper DL:
Maternal. fetal. and neonatal physiology, Philadelphia, 1992.

WB Saunders. p 692.)
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substance used in chemical thermogenesis. Brown fat cells
are approximately one-half the size of white fat cells.
Brown fat is found in the subcutaneous tissue, adjacent
to the major blood vessels of the neck, abdomen, and
thorax, between the scapulae, and in large quantities in the
suprarenal areas. At birth, 2% to 6% of the infant's body
weight consists of brown fat 2 Brown fat cells contain
finely scattered lipid droplets and are rich in cytoplasm in
mitochondria, which facilitates energy transformation and
heat production.
Cold stress produces a release of norepinephrine and
thyroid hormones. This response in tum triggers a lipolytic
process in the brown fat stores. Triglycerides in the fat are
broken down into fany acids and glycerol. These fatty acids
then enter the thennogenic pathways that produce the
common pool of metabolic acids. Besides thermogenesis,
glycolysis may be stimulated, resulting in a transient
increase in serum glucose levels. Because infants are unable
to shiver or actively alter their environment, they depend on
nonshivering (chemical) thermogenesis, that is, use of
brown fat, to increase heat production. s
If cold stress is sustained, increased thyroxine production
results in an elevated rate of cellular metabolism throughout
the body. This mechanism requires several weeks to become
operative. and thus it cannot be considered a primary
response to cold stress. 4 (See Fig. 14-2 for a summary of
physiologic consequences of cold stress.)

Behavioral Control of Body Temperature
The most obvious thermoregulatory responses are behavioral. 6 When the temperature of the preoptic area of the
hypothalamus rises, this produces the sense of being warm;
cooling of the skin and possibly other receptors produces the
awareness of being cold. Older children and adolescents
who experience either of these sensations usually take steps
to reestablish a feeling of comfort.
Effective behavioral control of temperature depends
on both an intact sensory-motor system and an ability to
communicate perceptions. For example, regulation of body
temperature is inadequate below the level at which the
sympathetic nerves leave the cord in spinal cord transection.
This occurs because the hypothalamus can no longer control
skin blood flow or the degree to which sweating is possible.
To maintain thermal homeostasis, the affected person needs
to rely on responses to cold and hot sensations in the region
of the head to make suitable behavioral and environmental
4
adaptations.
Critically ill infants and children have a limited ability to
alter their environment in response to their perception of
temperature variations. Moreover, their ability to communicate their perceptions is often limited by their developmental stage and the severity of their illness.

Mechanisms of Thermoregulation
The normal body temperature measured rectally is 37 0 C.
Practitioners have assumed that rectal temperatures are 10 C
higher and that axillary temperatures are 10 C lower than
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.Box 1.4-1

.

~ .Comparable Clinical Temperatures

in a Resting Afebrile Subject With
Rectal Temperature as a Reference

Rectal approximately 37° C
Oral 0.3°-0.5° C lower than rectal
Esophageal 0.2° C lower than rectal
Pulmonary artery 0.2°_0.3° C lower than rectal
Tympanic membrane 0.05°-0.25° C lower than rectal
Bladder temperature 0.1 °_0.2° C lower than rectal
Axillary temperature 0.6°-0.8° C lower than rectal
From Hohzclaw BJ: Monitoring body temperature. AAeN CUn Issues eri! Care
NUTs 4:49, 1993; Holtzclaw B1: New trends in lhermomerry for the patient
in the ICU. Crit Care Nurs Q 21:18.1998.

oral temperatures. However, studies have demonstrated that
the difference is considerably less 7 (Box 14-1). The core body
temperature varies by I.l 0 C during the day, with the highest
temperature occurring in late afternoon or evening and the
lowest occurring around 4 AM. Presumably, this holds true
in critically ill infants and children. Once thought to be the
result of exogenous factors, such as muscular exercise or
feeding activity, it is now clear that these periodic fluctuations
in temperature are the result of the operation of an endogenous system. 8 Despite the influence of certain conditions that
alter the regulation of body temperature, among them fever,
the human organism is capable of immense thermoregulatory .
adaptations and changes.
Circadian cycles influence childhood temperature. Temperature variation is one of the earliest rhythms to develop
in infants and begins to appear after the first week of life.
These rhythm changes develop progressively until the age
of 5 years, when the adult pattern is present. 8
The stability of body temperature varies inversely with
the size of the body. This means that in infants with a rapid
metabolic rate and somewhat large body surface area, the
oral and rectal temperatures may vary through a range
perhaps twice that of adults. 9 Because of the infant's small
size, increased ratio of body surface area to mass, and
elevated thermal conduction rate, the thermoregulatory
ability of infants is restricted and easily overwhelmed by the
environment? Conversely, adults exhibit very stable body
temperature mechanisms.
Heat Loss. The amount of heat loss that occurs varies
according to atmospheric conditions, such as the speed of air
currents passing over the body and the relative humidity of
the air. The common modes of heat loss are via (I) radiation,
conduction, and convection from the skin; (2) evaporation of sweat and insensible perspiration; (3) warming and
humidifying of inspired air; and (4) urine and stool. Only the
first two are under direct physiologic control. Of the sources
under direct control, radiation accounts for approximately
50% of the total heat loss and convection, about 15%. Most
of the remainder (about 30%) occurs through evaporation
of water. 9
Radiation is the loss of heat that radiates from the body to
surroundings that are cooler than the body itself. It involves

the transfer of heat between two objects, independent of the
environmental temperature. The difference in temperature
between the body and objects in the environment directly
affects the rate at which a body cools via radiation 9 For
example, radiative heat losses can occur even when nude
infants are in warm but transparent, single-walled incubators, particularly when near a cold wall or window. The total
radiating surface of infants or children also influences heat
loss. In fact, radiative heat loss is proportionately greater in
smaller infants and children and represents the most serious
source of heat loss for this group?
Conductive heat loss involves the transfer of heat
between two surfaces that are in direct contact with each
. other. The intensity of conductive heat loss depends on the
temperature gradient between the body and the surface it
contacts, the total body surface area, and the conductivity of
the material contacting the body. In addition, physiologic
factors influencing conductive heat loss are the velocity of
cutaneous blood flow and the thickness of the body's
subcutaneous insulating tissue 2
Convection is simply the movement of air. Heat loss by
convection refers to heat conducted to the air and then
carried away by convection currents. Insignificant amounts
of convection always occur because heated air naturally
rises away from the body. The degree of convecti ve heat loss
depends on several conditions, including the temperature of
the air, volume of airflow, and the specific heat of the
flowing air. Exposure of infants or children to drafts or
increased airflow causes convective heat loss and is a
stimulus for increased oxygen consumption.
Evaporative losses, primarily through the skin and lungs,
account for a significant portion of heat loss. Infants are
particularly vulnerable because their skin is thinner than that
of older children, which increases evaporative losses. When
water evaporates from the skin. 0.58 calories of heat are lost
for every gram of water that evaporates. Under normal
conditions, nearly 20% of the total body heat loss occurs
from evaporation. Little can be done about this in terms of
body temperature regulation because evaporative heat loss
results from continuous diffusion of water molecules at any
body temperature. However, excessive evaporative loss can
be controlled by regulation of sweating, primarily by
environmental manipulation.
Besides transepidermal evaporation, the respiratory system also serves as a route of evaporative heat loss.
Evaporative losses via the respiratory tract are higher in
infants as a result of their higher minute ventilation (the
product of respiratory rate and tidal volume) in relation to
body weight. Adequate environmental humidity minimizes
evaporative losses from the lungs and skin surfaces.
Physical factors affecting the rate of evaporation include
relative humidity, velocity of airflow, and minute ventilation. Physiologic factors include infants' ability to sweat and
their rate of minute ventilation?
The neutral thermal zone of infants is the range of
ambient temperatures at which the metabolic rate is minimal and temperature regulation is achieved by nonevaporative physical processes? The neutral thermal environment
(NTE) is further described as the ambient temperature and
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humidity in which the control of body temperature is
achieved by vasomotor adjustments, with minimal oxygen
consumption and heat production. This narrow range of
temperatures in infants varies with gestational age, postnatal
age, weight, and clothing. With increasing age and weight,
the NTE widens, and lower environmental temperatures are
tolerated. 10
Sweating. Sweating is an important means of controlJing heat balance. FulJ-term infants, for example, begin
to sweat with rectal temperatures of 37.5° to 37.9° C and an
ambient temperature higher than 35° C. As body temperature rises, the anterior part of the hypothalamus is stimulated. The impulses from this area are transmitted through
the anatomic pathways to the spinal cord and through the
sympathetic outflow to the sweat glands in the skin
throughout the body.4 When the body temperature increases
as little as 1° C, the sweat glands secrete large amounts of
sweat to the skin surface. 11 This reaction produces evaporative cooling of the body. The rate of sweating varies
according to environmental factors.
Excessive sweating can deplete extracellular fluid levels
of electrolytes, particularly sodium and chloride. Cholinergic sympathetic nerve fibers ending on or near the glandular
sweat cells elicit the secretions, which contain large
amounts of sodium chloride. Similar to its effect on the renal
tubules, aldosterone works in the sweat glands by augmenting the rate of active reabsorption of sodium by the ducts.
This process also carries chloride with it because of the
electrical gradient that develops across the epithelium
with the reabsorption of sodium. Aldosterone can minimize the loss of sodium chloride in sweat when the
plasma concentration is already low. Becoming acclimated
to the heat can diminish this loss because of increased
aldosterone production resulting from decreased salt reserves in the body.4

NURSING INTERVENTIONS
TO MAINTAIN NORMOTHERMIA
Nurses can help to maintain the body temperature of critically ill infants and children within normal limits primarily
by managing external factors. The environment may be manipulated based on the principles of conduction, convection,
radiation, evaporation, and the impact of each on body temperature. Factors such as ambient air temperature, humidity,
airflow velocity, and the temperature of objects in direct
contact with children's skin are all considered part of the
environment. Each of these factors should be considered
when making alterations to support an NTE.
Keeping infants and children (especially their heads),
clothing, and bed linens dry can minimize evaporative
losses. Humidifying and warming inspired gases can minimize evaporative and conductive losses from respiratory
mucosa. In contrast, gases may be humidified and cooled
when infants or children are hyperthermic. High humidity
tends to reduce insensible water losses and evaporative
losses; however, it also encourages the growth of gramnegative bacilli on the skin, including Escherichia coli and
Pseudomonas aeruginosa. Hence, a relative level of humid-
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ity, approximately 50%, provides optimal environmental
conditions. 12
Conductive heat losses can be reduced by ensuring that
cold surfaces are not in direct contact with children's skin
and by using various types of thermal insulation, such as
blankets and head coverings. Nurses can position children to
avoid drafts and maintain the environmental temperature
within the neutral thermal zone to avoid convective losses.
Increasing the room temperature, using external heating
devices, and applying thermal insulators, such as plastic or
aluminized plastic sheeting, can minimize radiant heat loss.

Assessment and Maintenance of Normal
Body Temperature
The medical and surgical treatment of critically ill or injured
infants and children often aggravates heat loss through skin
and body cavity exposure, administration of cold intravenous fluids and blood products, and anesthetic administration. Hypothermia may contribute to inaccuracies in patient
assessment and may complicate resuscitation of injured
infants or children. Because the risk for alterations in body
temperature are greater for critically ill infants and children,
assessment of temperature and the body's thermoregulatory
capabilities must be accurate and ongoing.
Frequent monitoring of critically ill infants' or children's
body temperatures is necessary to establish baseline parameters and to guide nursing interventions. Temperature should
be measured at recommended intervals for age and condition. Various techniques are used to measure core, regional,
and skin temperatures in critically ill infants and children.
Each is evaluated based on its relative advantages and
disadvantages. The method selected is based on individual
patient needs and the net balance of advantages and
disadvantages of the system accurately monitoring body
temperature. The site selected for estimating infants' or
children's temperatures is recorded and used consistently in
serial measurements. Because of the inaccuracy of many
thermometers in clinical use, the same thermometer is used
consistently for an indi vidual patient. To decrease the
possibility of inaccuracy, electronic and infrared devices are
regularly scheduled for calibration. 13
Internationally, the Celsius scale is the standard of
temperature measurement. However, in the United States,
the Fahrenheit scale is still widely used. Nurses may not be
comfortable with converting temperatures from one scale to
another and also may not be aware of the severity of
temperature changes when measured on the Celsius scale. 13
tore Temperature Monitoring. The core or central
temperature is the temperature of the blood flowing through
the branches of the carotid arteries to the hypothalamus.
Pulmonary artery catheters and esophageal, tympanic, or
nasopharyngeal probes monitor the temperature of blood,
which approximates the temperature of the carotid artery
and may be used for continuous assessment of core
temperature. 14 Although useful, esophageal and nasopharyngeal temperature probes are not routinely used in PICU
settings. Urinary bladder temperature (UBT), using a
urinary catheter with an indwelling temperature-sensing
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element, may also be measured. Tympanic thermometers
have been found to be less accurate than esophageal readings but more accurate than rectal, axillary, or bladder readings for core temperature over a wide range of temperatures
in pediatric surgery patients. 15
The accepted standard for measurement of core body
temperature is a thermistor in the pulmonary artery.16
Pulmonary artery temperatures are approximately 0.2 0
lower than blood returning from the brain. 15 Because of the
invasive nature, pulmonary artery temperature is only
assessed in critically ill infants and children who also
require advanced hemodynamic monitoring.
Peripheral Temperature Monitoring. Noncentral
temperature measurement does not reflect core temperature
but, rather. regional temperature. Regional temperature is
affected by a variety of factors that may affect regional
blood flow, such as intravascular volume, vascular tone, or
environmental conditions. These methods are convenient
and useful in monitoring changes and trends in temperature
but lack the accuracy of most core temperature techniques.
In contrast to core temperature reading techniques, regional
temperature monitoring can detect physiologic decompensation in response to persistent hypothermia or hyperthermia. When hypothermia persists, for example, children's
increased metabolism fails to compensate fOT the body
cooling and results in regional blood flow shifts, causing
metabolic acidosis and. eventually, apnea. 14
Generally, regional temperatures are mea~ured using
electronic thermometers. Temperature measuring sites include the oral, rectal, and axillary locations. In the critical
care setting, the oral route is infrequently used, whereas
rectal or axillary routes predominate. Measuring rectal
temperature is generally unnecessary. The risk of rectal
perforation. cross-contamination, and the repeated invasiveness of the procedure are probably not warranted, particularly in young infants. 7 • IO Rectal temperature probes can be
influenced by the presence of stool in the rectum. which can
act as an insulator and produce markedly delayed responses
to core temperature changes? In addition, relying solely on
rectal temperature measurements that may not reflect rapid
changes in core temperature may lead to delayed recognition of temperature extremes. Rectal probes and temperatures are always avoided in infants and children with
inflammatory bowel disease, absolute neutropenia, or evidence of coagulation disorders or thrombocytopenia. Axillary temperatures are less hazardous to patients but have
been shown to underestimate core temperature and be
affected by ambient temperature 7
Skin temperature may be measured either by electronic
thermometers or by electronic skin temperature thermistor
probes that provide continuous assessment. They are a
useful adjunct to other standard temperature-measuring
devices but can be affected by poor perfusion, equipment
dysfunction, or improper application. Critically ill patients
who require the use of overbed warmers or warming
blankets are continuously monitored for skin temperature
with appropriate alarms for underheating or overheating.
When skin temperature is continuously monitored. temperature is also measured periodically with an electronic
thermometer.

For critically ill infants or children, a combination of
temperature-measuring techniques is often indicated. This
approach is necessary to detect variations in temperature
that occur in response to physiologic dysfunction associated
with critical illness or injury. Because significant differences
may occur between peripheral and core temperatures.
critical care nurses require skill in interpreting the implications of these differences considering the patient's physiologic status.

Assessment of Temperature Imbalance
Wide variations in temperature produce alterations in cardiac output, oxygen consumption, and insensible water
losses. With hyperthermia, heart rate increases, whereas
with hypothermia, heart rate commonly decreases. Blood
pressure can also be affected. For instance, blood pressure
and cardiac output drop precipitously as hypothermia becomes more severe. Cardiac dysrhythrnias. such as conduction delays and abnormal atrial and ventricular rhythms,
may be evident. Respiratory rates may also vary. For example. hypothermic infants may experience periods of apnea or
shallow breathing; in contrast, infants or children with fever
or hyperthermia may become tachypneic.
Neurologic function may be impaired when infants or
children experience temperature imbalance. For example,
severe hypothermia (a core temperature lower than 35 0 C)
may complicate neurologic assessment as pupils dilate,
level of consciousness declines, reflexes and respirations
diminish, and varying degrees of amnesia occur. Cerebral
blood flow has been estimated to decrease 6% to 7% for
every 10 C decrease in body temperature. 17 This is of
particular concern for infants or children who have experienced multiple trauma or multiorgan dysfunction syndrome. All patients with hypothermia are monitored for
changes in level of consciousness, signs of irritability or
lethargy, diminished ability to arouse, and changes in
muscle tone. Hence, measures to promote thermal neutrality
are instituted as early as possible to ensure accurate
neurologic assessment. Seizures may occur after periods of
hypothermia as a result of ischemic brain injury and cerebral
edema.
Oxygen consumption and tissue perfusion are important
assessment parameters. Oxygen saturation using arterial or
mixed venous blood can provide an important indicator of
oxygen consumption. Often oxygen saturation of mixed
venous blood indicates changes in physiologic status before
changes in heart rate, pulmonary capillary wedge pressure
(PCWP), or blood pressure are evident. 18 Supplemental
oxygen may be necessary to combat hypoxemia, particularly
in hypothermic infants and children.
Tissue perfusion assessed from skin color, temperature,
and capillary refill must be routinely monitored. Pale, cool
skin is an early manifestation of the vasoconstrictive
response to cold stress or a decrease in core temperature.
With hyperthennia, the skin may appear flushed as vasodilation occurs. Flushing may also come about because
oxygen is not liberated from hemoglobin as readily when
either low temperatures or overheating occurs. 19 Evidence
of sweating is monitored in hyperthermic children.
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Increased muscle activity is associated with heat production, whereas diminished muscle activity is often indicative
of reduced heat production. Infants and children who are
experiencing either elevated or reduced temperature may
manifest changes in motor activity and therefore are
monitored for such changes.
Routine assessment for the presence of shivering permits
early detection and intervention. Shivering develops in a
predictable fashion, beginning with masseter contractions
and then proceeding to contractions of the trunk and long
muscle groups. It culminates with generalized body shaking and teeth chattering. 20 Assessment for the presence of
shivering includes palpation of the mandible for vibration and
close inspection of facial, neck, and chest muscles for
fasciculation. Core and peripheral temperatures are routinely
assessed and compared. Assessment for shivering is continued until central and peripheral temperatures are normal. 18
Fluid balance and renal function are carefully monitored
when body temperature becomes deranged. Because the rate
of fluid loss increases as a result of hyperthermia, adequate
hydration is maintained. Adequate hydration prevents the
complications of dehydration and promotes heat dissipation.
When infants and children are hypothermic and peripherally
vasoconstricted, fluids are carefully regulated during rewarming. When patients have vasoconstriction, fluid requirements are diminished; as warming occurs, the intravascular space expands, thereby increasing fluid requirements
to maintain cardiac output. Infants' and children's ability to
concentrate urine is impaired as hypothermia worsens.
Acute tubular necrosis may occur as a result of diminished
cardiac output and renal perfusion and myoglobinuria. Measurement of fluid balance enables nurses to prevent fluid
overload or deficit. Fluid deficit following a period of hypothermia is often the result of increased insensible water loss
during rewarming.
Laboratory data are routinely monitored to detect metabolic, biochemical, and hematologic derangements often
associated with thermal instability. For example, excessive
sweating can deplete extracellular fluid levels of electrolytes, particularly sodium and chloride. Serum electrolytes,
blood urea nitrogen, creatinine, measures of acid-base
balance, serum and urine osmolarity, hemoglobin, hematocrit, platelets, and other specific biochemical determinations
are assessed regularly.
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Hypothermia may cause metabolic acidosis. Acidosis
coupled with hypothermia results in a left shift in the oxyhemoglobin dissociation curve, thereby impairing oxygen release at the tissue level. Arterial blood gases are monitored
closely, and measures are instituted to prevent episodes of
hypoxemia and acidosis. Hyperthermia can cause biochemical changes, depending on the underlying cause.
Hypoglycemia is another common finding in infants who
experience alterations in temperature. This condition results
from depletion of gl ycogen stores in the attempt to maintain
core temperature in the normal range. In contrast, a transient
hyperglycemic response is a common finding in older
infants and children with alterations in temperature. This
condition occurs as part of the body's response to stress,
which liberates glucose to fuel the response.
Laboratory studies used in determining the source of
fever or hyperthermia may include indirect and direct
studies. Indirect studies, such as the white blood cell count
and the erythrocyte sedimentation rate, reflect the body's
response to infection. Indirect tests may serve as screening
devices for identifying subgroups of infants and children at
high risk of occult bacteremia (Table 14-2). Direct studies
include blood and urine culture and sensitivity and rapid
tests for detection of bacterial antigen. Direct tests allow
detection of the specific causative organism. 21
Other diagnostic tests may include cerebrospinal fluid
examination or urinalysis. In addition, examinations such as
radiographs; ultrasounds and computed tomographic (CT)
scans; magnetic resonance imaging (MRI); or other nuclear
medicine studies of the lungs, abdomen. and other organs
may be indicated to determine the underlying cause of the
temperature derangement.

Thermoregulation Devices
Maintaining a neutral thermal environment and a normothermic body temperature are common nursing goals when
caring for critically ill infants and children. Various thermoregulation devices are used regularly in the critical care
setting. This is particularly crucial when transferring infants
or children to other units within the hospital or to another
facility.
Warming Devices. In addition to manipulating environmental conditions to alter the ambient temperature,

Risk of Occult Bacteremia
Low Risk

High Risk

>3 yr
<39.4° C
>SOOO and <IS,OOO
Normal

<2 yr
>40° C
<SOOO or > IS,OOO
Abnormal
History of contact with Haemophillls i/lflllellzae or
Neisseria me/lillgitidis
History of bacteremia
Immunologic impairment

IFrom Kline MW, Lorin MI: Fever without source. In Oski FA, DeAngelis CD, Fcigin RD cl ai, eds: OSkrf principles and practice of pediatrics,
l~1'biladelphia, 1999, Lippincott Williams & Wilkins. p 844.
r~~BC, While blood cell.
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specialized equipment is often necessary to maintain an
NTE. Various types of devices are used for this purpose. For
infants, some type of closed warming device is commonly
used, such as single- or double-walled incubators. These
convection-warmed devices are used for thermal regulation
of the infant's ambient air. Standard closed incubators
control infant temperature by recirculation of warmed and
humidified air. Infant size and postnatal age determine the
temperature of the air in the incubator. 10 Plastic blankets or
heat shields inside the incubator also reduce convective and
evaporative losses. Disadvantages of this type of device
include heat losses when the incubator is entered, potential
variations in both incubator and infant temperatures during
heating cycles, and diminished accessibility of infants for
assessment and treatment. 22
Open radiant warmers are useful to regulate temperature,
particularly when infants and children require frequent
monitoring and interventions. A radiant warmer consists of
an electrically heated element that emits radiation within the
infrared region of the electromagnetic spectrum. Radiation
within this range allows optimal absorption of the energy by
the skin. Heating of the skin causes vasodilation and
increased blood flow to the skin. Moreover, it provides an
avenue for heat transfer from the skin surface to the blood
and eventually to deeper structures.
The advantages of radiant warmers include a superior
servocontrol mechanism, greater consistency in surface temperature, improved patient access, and easier cleaning. The
disadvantages associated with infrared radiation used in radiant warmers include risk of cataracts, flash bums of the
skin, and heat stress 22 In addition, radiant warmers promote
insensible water loss, increase oxygen consumption, and
slightly increase metabolic rate in infants, depending on
weight and gestational age. Fluid requirements may be increased by 10% to 20%, particularly when radiant warmers
are used in conjunction with phototherapy. Hence fluid requirements are adjusted depending on clinical and biochemical data. Radiant warmers are generally servocontrolled
with the temperature probe attached to the abdomen. 19
Servocontrolled devices automatically adjust heat output
to maintain the temperature at a predetermined level in
response to changes in patients' skin temperature. Some use
an anterior abdominal wall temperature servocontrol mechanism to regulate skin temperature within a thermal-neutral
range (36° to 36.5° C) by automatic air temperature
control. 19 Core temperature is measured frequently when
servocontrol is used to avoid overheating if the skin sensor
loosens. In addition, accurate assessment of the infant's
temperature may be compromised when a servocontrol
device is used because the temperature is regulated to
maintain the temperature at the predetermined level.
For older children, external heat sources, such as radiant
warmers or heating blankets, are often used. Circulating
water mattresses may be used to raise a patient's temperature and reduce conductive heat losses. Water-filled heating
blankets are used judiciously in infants and children because
when children are cold and peripherally vasoconstricted, the
ability of surface capillaries to dissipate heat is diminished,
increasing the risk for bums. Hence continuous monitoring
of temperature and assessment of responses to interventions

for rewarming are crucial to avoid tissue injury. The fluid
temperature in the heati ng blanket should never exceed
39° C, and several layers of material are placed between the
patient and the heating blanket to avoid burns?3
Forced air heating blankets have been shown to be the
most clinically effective warming device intraoperatively24
This modality transfers the greatest amount of heat to the
patient, when compared with other warming modalities.
When rapid rewarming is necessary, cardiopulmonary
bypass may be used. This technique allows direct perfusion
of the central circulation with warmed blood, reducing
cardiac irritability and the risk of ventricular fibrillation and
cardiac arrest. Alternatively, body cavities such as the chest,
peritoneum, or gastrointestinal tract may be irrigated with
warmed fluids.
Cooling Devices. When infants or children become
hyperthermic, surface cooling techniques, such as removing
heat-conserving clothing or blankets or packing in ice, may
be used. Most commonly, external cooling blankets are
applied, and in the majority of cases, the decision to use this
modality is made by the critical care nurse. 25 A comparison
of the effectiveness of posterior versus anterior positioning
of the blanket and cooling effectiveness after placement is
needed. If the blanket is placed posteriorly, care is taken to
avoid decubitus ulcers. A recent development in cooling is
the use of cold air blankets. These blankets are thought to be
more comfortable for patients and may be more effective
than circulating water blankets; however, this assumption
has not been substantiated by research studies?5 Whatever
method is used for surface cooling, the patient's vital signs,
perfusion, and skin integrity are assessed frequently. If
additional temperature reduction is needed, body temperature can be reduced by core cooling. Lavage of gastric or
peritoneal cavities and the administration of iced intravenous fluids can achieve this goal.
Extreme variation in temperature, hypothermia or hyperthermia, can result in death or serious injury, and thus alarm
systems and range controls of all equipment used to regulate
temperature require regular testing.

ABNORMALITIES OF BODY
TEMPERATURE REGULATION
Hyperthermia
Hyperthermia is a state in which a person has a sustained
elevation in body temperature (more than 37.8° C orally or
38.8° C rectally) because of internal or external factors. I
Internal factors, such as fever, malignant hyperthermia, or
heat-related illnesses, and external factors, such as extreme
environmental conditions or accidental overheating, contribute to the development of hyperthermia. The most
common cause of hyperthermia is fever. Although relatively
uncommon, malignant hyperthermia may also necessitate a
patient's admission to a critical care unit.
Fever is distinguished from other types of elevations
in body temperature. First, the "set-point" is that temperature around which body temperature is regulated by the
thermostat-like mechanism in the hypothalamus. "Hyperthermia" is that situation in which body temperature ex-

Chapter 14

ceeds the set-point. This usually results from conditions
producing more heat than the body can dissipate (e.g., in
heatstroke, aspirin toxicity, or hyperthyroidism). "Fever" is
an elevation in the set-point such that body temperature
is regulated at a higher level. 26 In any discussion of fever, it
is important to remember that fever is a symptom, not a
disease, and should be viewed as reflecting an underlying
disorder.
Fever may result from abnormalities in the brain itself,
the presence of toxins that affect the brain's temperature
control areas, infection, dehydration, or other causes. 4
Generally, fever results from a pyrogen-mediated elevatioo
in the hypothalamic set-point. The major problems resulting in fever include an increase in the hypothalamic
thermoregulatory set-point, excess heat production, and
defective heat lossY
Instrumental in resetting the hypothalamic thermostat are
pyrogens, substances that cause the set-point to be increased. These pyrogens may be proteins, breakdown
products of proteins, or certain other substances (e.g.,
lipopolysaccharide toxins secreted by bacteria). Pyrogens
may be present during disease states. When the set-point is
elevated, all the body's efforts turn to decreasing heat loss
and increasing heat production. Heat production is increased
via increased muscle tone, activity, and metabolic rate,
whereas heat loss is decreased through peripheral vasoconstriction. 28 These changes help the body to reach its new
temperature within hours. 4
The pathophysiologic mechanism of fever includes the
production of hormonelike mediators by macrophages and
cells of the reticuloendothelial system. This results in (I) an
increase in CNS production of prostaglandin E2 , which
increases the hypothalamic set-point and temperature; (2) an
increase in neutrophil release from the bone marrow; (3) a
decrease in serum iron and zinc; (4) a change in hepatic
protein production; and (5) an increased T-lymphocyte
proliferation. Interleukin-l (IL-l) is a substance common to
these pathways 29 Undesirable effects of fever are listed in
Box 14-2.
For healthy infants and children, these demands pose no
particular threat. For those with underlying disease, especially that involving the heart or lungs, the increased
demands are potentially harmful or even fatal. In susceptible
infants and children 6 months to 5 years old, fever can
precipitate seizures. Generally, these seizures are benign,
but they are very upsetting to both parents and children and
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Box 14-2
Undesirable Effects of Fever

Patient discomfort
Increased metabolic rate
Elevated oxygen consumption
Increased carbon dioxide production
Increased cardiovascular and pulmonary system demands
From Lorin Ml: Pathogenesis of fever and its treatmenL In Oski FA, DeAngelis
CD. Feigin RD el aI. eds: Oski's principles and practice of pediatrics.
Philadelphia. 1999. Lippincott Williams & Wilkins. pp 848·850.
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may result in invasive, expensive, and probably unnecessary
procedures?8
Febrile conditions share several characteristics. Chills
occur when the hypothalamic set-point abruptly rises to a
higher-than-normal level because of tissue destruction,
presence of pyrogenic substances, or dehydration. As the
body attempts to attain its new temperature setting, the
blood temperature is lower than the set-point temperature
for several hours. Autonomic responses to increased body
temperature occur, such as chills, vasoconstriction, and
shivering. When the blood temperature reaches the set-point
temperature, the person feels neither hot nor cold. As long as
the factor producing the fever continues, the body temperature is regulated normally but at a higher level. If the factor
producing the fever is suddenly removed, the set-point
abruptly decreases to its normal lower level. The body then
feels "overheated" and reacts with intense sweating and hot
skin, resulting from a general vasodilation caused to
dissipate heat more quickly. This reaction is known as the
"crisis" or "flush.,,4

Fever has several other causes. Traumatic brain injury or
congenital CNS malformations can produce recurrent,
transient elevations in body temperature. Other noninfectious causes of fever are (I) iatrogenic (e.g., heavy blankets,
overdressing, mechanical); (2) thrombophlebitis, resulting
from intravenous catheterization; (3) infusions of irritating
fluids; and (4) endocrine disorders. Certain hypothalamic
lesions produced by cerebrovascular hemorrhage, neurosurgical procedures, or tumors may produce decreased thermoregulatory ability. Drugs that produce fever include lysergic
acid diethylamide (LSD), cocaine, amphetamines, phencyclidine (PCP), salicylates, anticholinergics, prostaglandin
E\, and tricyclic antidepressants. 30.3 \
Treatment of Fever. The decision to treat fever can
be difficult. An important principle is that not all fevers
need to be treated; body temperature does not always need
to be completely normal. The importance of fever as an
indicator of disease, not as inherently harmful, should be
expressed to the patient's significant others, who may be
experiencing "fever paranoia.,,32 Recommendations for
treatment include (I) high fever (40 0 C or above), (2) fever
in infants and children at risk for febrile seizures, (3) fever
in infants and children with underlying neurologic or
cardiopulmonary disease, or (4) fever in any situation in
which heat illness (e.g., heatstroke) is suspected. Treating
fever for patient comfort should not be condemned. 28 Once
the decision to treat a fever has been made, the choice
of a specific modality is based on a number of considerations. Because fever is the result of an elevated
hypothalamic set-point, the most logical means of treating
the fever is by restoring the set-point to a normal leveL
Aspirin, acetaminophen, and ibuprofen all work in this
way. Aspirin and acetaminophen are equally effective at
similar doses. Ibuprofen is effective at a slightly lower dose
and has a longer duration of action. Given the minimal
difference in the effectiveness of aspirin and acetaminophen, selection should be based on potential toxicities and
cost rather than effi cacy 28
In therapeutic doses, aspirin is the most toxic of the
choices. Potentially serious side effects are gastritis, gastro-
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TABLE 14·3 Use of External
Cooling Methods for Treating
Elevated Temperature
'ji,;:-

i~oling Method

Indications

Very young infants
Severe liver disease
History of hypersensitivity
to antipyretic drugs
High fever (>40 C)
History of febrile seizures,
neurologic disorders,
or brain damage
Infection plus suspicion
of overheating
Septic shock'
Heat illness
0

.~ rom Lorin MI: Pathogenesis of fever and it. treatment. In Oski
~A, DeAngelis CD, Feigin RD et al, eds: Oski sprillciples alld praclice

External cooling devices may also be effective in reducing
body temperature.
Treatment of fever associated with suspected bacteremia generally includes antibiotics. Ideally, with the
emergence of antibiotic-resistant organisms, blood cultures are obtained before instituting antibiotic therapy33
Specific antibiotic recommendations are directed at the
most common bacterial pathogens. In any case, the
patient is followed carefully to monitor the effectiveness
of the treatment regimen. When infants and children are
critically ill and febrile, parenteral antibiotic therapy may
be initiated in tandem with the diagnostic workup. Infants
younger than 30 days, children with underlying disorders
that predispose them to serious bacterial infections, and
children who appear toxic are generally treated with
antibiotics before culture results are returned, to decrease
the possibility of an overwhelming sepsis. 21 Moreover, if
the source of the fever is determined to be infectious,
proper infection control and therapeutic measures are
initiated.

lig! pediatrics,

Philadelphia, 1999, Lippineou Williams & Wilkins,
f,,p'850.
F!!:mMay require cold sponging.
il';:~".

intestinal bleeding, diminished platelet functioning, decreased urinary sodium excretion, and lowered immune
response. These effects are seen often with aspirin, less
often with ibuprofen, and not at all with acetaminophen. In
fact, acetaminophen has no side effects at therapeutic levels.
However, one study found that when administered rectally,
the absorption of acetaminophen was found to be erratic?5
Aspirin, and possibly ibuprofen and naproxen, because of
their pharmacologic similarity, has been implicated in the
development of Reye's syndrome. 28
Another method of fever reduction is external cooling,
generally by sponging with tepid water. This may be used
with or without the administration of antipyretic medications. Henker 5 provided evidence that the combination of
acetaminophen with sponging was significantly more effective in decreasing temperature than acetaminophen alone.
External cooling is the treatment of choice for heat-related
illnesses. Its use in fever is generally recommended only if
a heat-related illness may be the partial or total cause of the
elevated body temperature 28 (Table 14-3).
Sponging as a method of fever reduction usually adds
nothing other than discomfort when used with previously
well infants or children with non-life-threatening fever.
When ice water is used, cooling is more rapid and more
uncomfortable; therefore it is used only in the case of heat
illness. Sponging is useful in infants or children with
neurologic disorders because many have abnormal temperature control mechanisms and respond poorly to antipyretics. Sponging is preferable in infants and children with
demonstrated hypersensitivity to antipyretics or in those
who have liver disease. Sponging is normally done with
tepid water (approximately 300 C). Alcohol is not used
because the fumes may be absorbed through the lungs and
possibly skin, and it may produce alcohol intoxication 28

Drug Fever
Fever may be a complication of drug therapy. This response
to medications can increase the duration of hospital stay and
the number of diagnostic tests performed. 34 Particular drugs
associated with drug fever include phenytoin, histamine
blockers, procainamide, and antibiotics, most notably sulfonamides. 35 Drug fever is considered if a clinically improved patient develops an unexplained fever after receiving
drugs known to produce febrile reactions 7 to 10 days after
their institution. Drugs that raise the basal metabolic rate,
produce increased skeletal muscle activity, or lower cutaneous blood flow may produce an increase in body temperature that will normalize after the drug is stopped]O Drugassociated fever can be extremely elevated in some patients
and can take up to 5 days to resolve after discontinuation
of the drug. 35

Malignant Hyperthermia
Malignant hyperthermia (MH) is a hypermetabolic cnsls
triggered by the administration of a certain quantity of
potent volatile anesthetic agents or a depolarizing muscle
relaxant, usually succinylcholine (SCH). The mean age of a
patient experiencing a MH episode is 22 years of age. 36 MH
is a familial disease, but the mode of genetic transmission
remains unclear. The syndrome was originally thought to be
transmitted as an autosomal dominant trait. Further investigation suggests that the irtheritance in most families is
multigenetic with variable expression. 3 ? Reports of MH
vary between countries. In the United States, the incidence
is highest in the Midwest. 36
The incidence of MH ranges from I in 14,000 pediatric
patients to I in 40,000 adult patients. The difference in
occurrence may occur because adults are often induced
with sodium thiopental and a nondepolarizing muscle
relaxant, both of which inhibit triggering of MH. Children,
on the other hand, are often induced with halothane
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followed by SCH, a combination that constitutes an effective trigger for MH 37
The site of the primary lesion implicated in the pathogenesis of MH is skeletal muscle and is related to disturbed
calcium metabolism. Traditional theory is that a defect in the
muscle cell membrane causes loss of control of intracellular
ionized calcium levels, leading to an increase in calcium in
skeletal muscle and abnormal muscle activity. As hyperthermia continues, the myoplasmic calcium concentration remains elevated, producing continued muscle contraction
and heat production. A new developing theory is that MH is
a disorder of the ion channels that control skeletal muscle,
that is, a channelopathy.38.39
Initially, an anesthetic-induced increase in aerobic and
anaerobic metabolism occurs, manifested by massive production of heat, carbon dioxide, and lactic acid. This results
in respiratory and metabolic acidosis, along with a rapid
increase in temperature. Tachycardia is accompanied by
other signs of circulatory and metabolic stress. Abnormal
muscle activity develops, which may progress to wholebody rigidity. An increase in muscle permeability produces
increased serum levels of potassium, phosphorus, calcium,
sodium, and creatine phosphokinase (CPK). Muscle edema
develops, and an excessive release of myoglobin from
muscle results in gross myoglobinemia. Disseminated intravascular coagulopathy and cardiac or renal failure may
develop. Death may result from a combination of gross
electrolyte disturbances, especially hyperkalemia, leading to
cardiac failure. 37 •38
The clinical course of MH is extremely variable. It can be
fulminant, rapidly progressing to metabolic acidosis and
death if not diagnosed and treated promptly. Rarely, the
onset can be delayed for some hours. The sequence and
severity of clinical events depend on (1) the types and concentrations of anesthetics involved, (2) the nature and extent
of underlying myopathy, and (3) the promptness of diagnosis and initiation of appropriate treatrnent 43
The first systemic effect of MH is increased metabolism
(increased oxygen consumption and carbon dioxide production). The cardiovascular and respiratory systems respond to
this increased demand by increasing their output. Therefore
the first clinically evident signs and symptoms of MH are
tachycardia and tachypnea. However, an increased end-tidal
carbon dioxide value precedes these signs and symptoms40
(Table 14-4).
Tachycardia occurs in 96% of all patients with MH
within 30 minutes of anesthesia induction. 41 Rapid ventricular arrhythmias (e.g., bigeminy and ventricular tachycardia) may occur. Tachycardia and/or dysrhythmias usually
occur before fever. and thus MH is suspected when these
signs occur, unless there are other obvious causes for them.
Cardiac arrhythmias result from the stress of MH on the
myocardium. probably caused by the hypermetabolic state.
The electrocardiographic tracing shows tall, peaked T
waves, and/or ST-segment depression 42
Muscle rigidity mayor may not occur. If seen, it
usually occurs first in the muscles of the jaw, extremities,
or chest usually after the administration of SCH. Instead
of relaxing. the jaw tightens, making intubation and ven-
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Clinical Presentation

of Malignant Hyperthermia

~binical Findings

Laboratory Findings

,i1!tachycardia
J!:rachypnea-spontaneous
Ire: ventilation
~,iUnstable blood pressure
ilifever-rapid rise (laC
rot
~1'" every 15 min)
i~Sustained rise (to 43° C)
~.E.igidity--especiallytrismus
'i<::yanosis-----<1ark blood in
,:::surgical field, mottling
!~ of skin
:!?tofuse sweating

Marked elevation of
end-tidal carbon dioxide
Hypercarbia--eentral venous
and arterial
Acidosis-respiratory and
metabolic
Central venous and arterial
desaturation
Hyperkalemia
Elevated creatine phosphokinase (CPK),
myoglobinemia

IIV·
tic,.;-

.:

f..f:

;§iFrom Ryan IF: Malignant hyperthermia. In Ryan IF, Todres lD.
C1, et aI, eds: A practice of anesthesia for infallls and children,
~~ 2. Philadelphia. 1993. WB Saunders. pp 417-428; Gronert GA.
Ilt\nlognini IF, Pessah IN: Malignant hyperthermia. In Miller RD, ed:
w;~ne"lhesia, 2 vols, ed 5, New York, 2000, Churchill Livingstone,
~'i'>p 1033-1052.
~Cote

if'

tilation difficult or impossible. 42 Facial muscle fasciculation may be present. Rigidity then travels through other
skeletal muscles.
Fever is the clinical hallmark of MH and results from
many biochemical derangements. It is a somewhat late sign
and may not occur at all if dantrolene is promptly administered. 43 Without treatment, the body temperature can rise
10 C every 5 minutes and exceed 43 0 C. 38
Patients undergoing anesthesia are observed for evidence
of fever. Signs of fever during surgery include hot, flushed
skin; a hot anesthetic rebreathing bag; and hot tissue around
the operative site. A change in skin color may accompany
the development of MH. Flushed, rosy skin (similar to the
familiar "atropine flush") may occur from the increased
production of body heat. To dissipate the heat, vasodilation
occurs. The flushed skirt subsequently becomes mottled and
then cyanotic. Simultaneously, the surgeon notes dark blood
at the operative site. 43
Treatment of MH includes early recognition, discontinuation of the anesthetic agent, cooling, hyperventilation with 100% oxygen, restoration of acid-base balance,
administration of medications to treat dysrhythmias, and
38 44
relax skeletal muscle contractions. . All interventions
are carried out simultaneously. In addition, dantrolene
sodium is administered without delay because MH is
potentially fatal if not treated immediately with this
medication. The mortality rate from MH reached 70%
before the use of dantrolene. Earlier diagnosis of MH and
advent of dantrolene have decreased the mortality rate to
less than 5%.3 8
Dantrolene is a lipid-soluble hydantoin derivative with
direct effects on skeletal muscle. It is given intravenously.
initially 2 mg/kg, increasing to a total of 10 mg/kg. Dosing
in this manner provides therapeutic blood levels with a
half-life of at least 10 hours in children and adults. 38
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Nursing Care of Patients With Elevated
Body Temperature
Hyperthermia may be treatable by nursing intervention
alone (e.g., by correcting external causes such as inappropriate clothing for environmental conditions, exposure to the
elements, or dehydration). In other cases, such as MH,
nursing intervention alone is insufficient, and medical and
other interventions may be necessary.
The impact of core hyperthermia on an already compromised patient can be deleterious. Oxygen consumption
rises 10% to 12% for every 1°C temperature elevation 45
The increased metabolic demand in response to hyperthermia may produce progressive metabolic acidosis, as
oxygen delivery to the tissues is compromised. 46 Arterial
blood gases and biochemical balance are monitored closely
to detect acid-base imbalances and hypoxemia. Proper
treatment of acidosis is promptly instituted to prevent
untoward effects.
Sustained tachycardia in hyperthermic infants and children may compromise myocardial perfusion and diastolic
filling and may lead to greater stress on an already
compromised heart. Moreover, infants or children experiencing hyperthermia are observed for sweating and peripheral vasodilation, both of which greatly increase loss of heat
from the skin.
Regardless of the measures instituted to reduce temperature, shivering is not stimulated. Shivering is a normal
compensatory response to heat loss, but in the hemodynamically compromised patient, the effects can be deleterious.
Shivering increases metabolic rate, carbon dioxide production, and myocardial oxygen consumption, all of which
eventually increase the myocardial workload. Arterial oxygen saturation decreases and systemic vascular resistance
and heart rate increase with shivering. In addition, oxygen
consumption increases 500%,47 and the production and
accumulation of lactic acid accelerate, which may culminate
in lactic acidosis.
Nurses focus on determining the proper combination of
interventions to reduce temperature and avoid shivering. If
shivering develops, measures are instituted to avoid the
metabolic and hemodynamic consequences. Appropriate
nursing interventions for shivering modify the rate of heat
loss from the skin and interfere with the body's determination of heat loss.48 Various techniques have been suggested.
Intravenous narcotics have been used to suppress shivering
but may also produce side effects such as nausea or
hypotension. 49 An alternative is wrapping the extremities
with towels during surface cooling with a hypothermia
blanket. 48
Psychologic support is particularly important when
dealing with critically ill infants and children who are
further distressed by both the discomfort of fever and its
treatment. Interventions are based on the developmental
stage and cognitive ability of the patient.

14-5. At low body temperatures (below 34° C), the hypothalamus functions minimally, and below 29° C, it cannot
regulate temperature at all. Loss of temperature-regulating
capability produces a rapid decrease in body temperature and eventually results in death. 4 When temperature
drops low enough to trigger thermoregulatory control
mechanisms, shivering thermogenesis and a generalized
catecholamine release occur. Responses of the sympathetic nervous system prompt many other physiologic responses to produce the diagnostic characteristics of hypothermia (Box 14-3).
Infants and childr,en are among high-risk groups for
hypothermia, especially if unconscious, immobile, sedated, or malnourished. Mild hypothermia often can be
observed in infants and children admitted to critical care
units because of cold ambient temperatures. Box 14-4
outlines predisposing factors. Moderate to severe hypothermia is often present in patients who have suffered
trauma, exposure, drowning, ingestion of poisons, or shock.
Infants or children with unexplained altered responsiveness are evaluated for hypothermia by measuring core
temperature. 50
Many pharmacologic agents may contribute to hypothermia. Phenothiazines and barbiturates exert a direct effect
on the anterior hypothalamus, decreasing its responsive-

It)

14-5 Levels of Clinical
Hypothermia

TABLE

Temperature (0 C)

iformothennia
(14iId hypothennia
l~oderale hypolhennia
'~vere hypothennia

37
32-35
28-32
<28

Weimbach D, Jurkovich OJ. Genlilello LM: Accidental hypothermia. In
nvik A. Ayres SM, Holbrook PR el aI. eds: Textbook ofcritical care.
~ 4. Philadelphia, 1999. WB Saunders. pp 377-383.

!""

Hypothermia
Hypothermia is defined as any core body temperature less
than 35° C. Degrees of hypothermia are detailed in Table

Data from Carpenito U: Nursing dio/:no:'1is: application 10 clinical practice.

ed 8, Philadelphia, 2000. JB Lippincott. p 147.
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ness to cold. Neuromuscular blocking agents and phenothiazines decrease the body's ability to engage in shivering
thermogenesis. Vasodilators inhibit the peripheral vascular
vasoconstrictor response and increase heat loss, thus decreasing temperature stability. Long-term use of vasopressors depletes catecholamine reserves and alters receptor
function, thus impairing the peripheral vascular response
to cold stress. 5U
One clinical phenomenon that may produce severe
hypothermia is cold water drowning (i.e., drowning in
freezing water). Even in warm climates, however, the
temperature of pool water can be significantly lower than air
temperature. Moderate water temperatures are lower than
body temperature. The relatively large body surface area of
infants and children predisposes them to rapid heat loss in
water. As a consequence, small infants or children can
become hypothermic even in relatively warm ppol water in
a moderate climate.
Therapeutic, induced, or controlled hypothermia is used
to reduce metabolic demands during cardiac surgery.
Induced hypothermia for cardiac surgery involves both
systemic and cardiac cooling. Systemic hypothermia is
achieved by cooling the blood as it circulates through the
heat exchanger of the cardiopulmonary bypass pump.
Cardiac hypothermia is achieved directly by a cooled
perfusate. Initially, a regional temperature gradient occurs
because the core (heart and brain) is cooled first and the
peripheral tissues remain warm. Gradually, the skin temperature drops and eventually approximates the core temperature as heat is dissipated. During this time, the body's
inherent thermoregulatory mechanisms cease, resulting in
profound hypothermia. 51 Rewarming is initiated by warming the blood circulated through the body and discontinuing
extracorporeal circulation. During this phase, the core is
warmed first, and the regional and peripheral areas (rectum,
bladder, and skin) remain cooler, creating another temperature gradient. As the patient's thermoregulatory function
returns, the patient is vulnerable to shivering.

Box 14·4

... .

~ .. Factors Predisposing Infants and Children
.to Thermal Instability

.

Relatively large body surface area
Relatively limited nutritional reserve
Impaired cardiac, renal, hepatic, or endocrine function
Impaired behavioral, neural, and endocrine responses (from
underlying physical and physiologic states)
Impaired neuroendocrine response (from pharmacologic
agents)
Cardiopulmonary resuscitation, anesthesia, or extended
radiographic procedures
Data from Brink LW: Abnormalities in lempemture regulalion. In Levin DL,
Morris Fe, eds: Essentials of pediatric illlensive ('are, New York. 1999,
Churchill Livingslone. pp 548-559, and 5t Louis, Qualily Medical Publishing; and Heimbach D, Jurkovich GJ, Gemilello LM: Accidenlal hypothermia. In Grenvik A. Ayres SM, Holbrook PR et al. eds: Textbook of critical
care, ed 4, Philadelphia. 1999. WB Saunders, pp 377-383.
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Nursing Care of Patients With Decreased
Body Temperature
Once the diagnosis of hypothermia is made, continuous core
body temperature measurement is initiated while evaluating
thorougWy for risk factors (Table 14-6) and potential
complications. Important assessments following the diagnosis of hypothermia include (I) electrocardiographic monitoring (significant arrhythmias may occur because of
myocardial irritability); (2) arterial blood pressure monitoring; and (3) frequent evaluation of acid-base status, serum
electrolytes, and blood glucose levels. External and/or core
rewarming is instituted promptly.
Interpretation of arterial blood gas results in the hypothermic patient may necessitate the use of correction curves
or values on rewarmed specimens. This is recommended
because low temperatures cause carbon dioxide solubility to
change, forcing the oxygen dissociation curve to shift to the
left. When a specimen is drawn from a hypothermic patient
and warmed to 37° C, the solubility of carbon dioxide decreases, resulting in a higher Paco z and lower pH than exists
in the patient. Paoz values are corrected for temperature
because warming the blood increases the solubility of oxygen and results in Paoz values significantly higher than in
the patient. 5o According to Shapiro and Cane,5Z however, if
the patient's temperature is 35° to 39° C, little is to be gained
in correcting blood gas values. If the patient's temperature
falls outside this range, it may be clinically useful to correct
blood gas values with an uncorrected Paoz less than 60 torr
or an uncorrected Pacoz less than 30 torr because these
values may be higher than actual measurements.
Shi vering thermogenesis begins at temperatures of 30° to
35° C. This condition results in a small increase in heat
production, whereas oxygen consumption and metabolic
rate increase significantly. Transient hyperglycemia may
result from glycogenolysis in the liver and muscles. The
catabolism of fat can produce ketosis. Lactate production
ends in metabolic acidosis, and compensatory respiratory
alkalosis follows. These changes peak at 34° to 35° C. 50
As hypothermia deepens, shivering thermogenesis
ceases. Nonshivering thermogenesis occurs as the core
temperature falls below 30° C. Heat production and
metabolic rate both fall below baseline requirements at this
point. 50,53 Total oxygen consumption is proportionately
decreased. There is a 6% fall in oxygen consumption for
every degree Celsius that the core temperature decreases.
However, the extent of reduction of metabolism varies in
each organ system 5U When the temperature is normal,
oxygen consumption is highest in the kidney, which is the
organ most rapidly affected by hypothermia.
Cold diuresis is a term used to describe the renal response
to cold. This response denotes adequate urine output despite
a significant impairment in renal blood flow and glomerular
filtration rate, Diuresis may continue despite systemic
hypotension, dehydration, and hyperosmolarity, presumably because of a defect in renal tubular reabsorption of
water.50
Changes in the cardiovascular system occur with hypothermia. The initial catecholamine-induced tachycardia is
transient. During the phase of shivering thermogenesis,
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TABLE

Phenomena of Concern

14·6 Risk Factors for Hypothermia

,: Cause

Mechanism

1"

H~Exposure

Increased heat loss, especially conductive heat loss (wet clothes or immersion) or
convective losses (wind)

HJ-Trauma
~Prowning

-~

~:CNS

depression
i1Read injury
gr. Cerebral hemorrhage, tumor, or infection
JifDrug-induced
~~Narcotics

Direct central effect on thalamic temperature center

CNS depression and vasodilation
C S depression
a-Adrenergic block, impaired shivering thermogenesis, lowered set-point
CNS depression (and associated trauma, exposure, and impaired behavioral responses)
CNS depression with vasodilation

~Baroiturates

rrPhenothiazines
~'Alcohol
~:General anesthesia

jj::

in'Endocrine Abnormalities

~~lIypoglycemia

Impaired thermogenesis, limited metabolic response to cold

J1;;Hypothyroidism

~lIypopilUitarism

~'Spinal

Impaired hypothalamic response to cold
Interrupted sensory afferent
Inability to sense cold
Impaired central reflex and behavioral responses

Cord Transection

i[~ ;-

til':

f~k1n Disorders

Increased transdermal water and heat losses

i5T'

~throdermas

§lillums

~~tevens-Johnson

syndrome

~!ifherapeutic
!ll;:

CNS depression

i'imrreatment of Reye's syndrome
f~~ardiopulmonary bypass

iii

14-7 Cardiac Dysrhythmias
in Hypothermia
.

TABLE

~i;Core Temperature
<34° C

.",--

Arrhythmia
Atrial fibrillation (more severe
bradydysrhythmias noted with
cooling)
First-degree atrioventricular block
Third-degree atrioventricular block

iffipata from Brink LW: Abnonnalities in temperature regulation. In Levin
iii::DL. Morris Fe. cds: Essentials afpediatric intensive care, New York,
~1999, Churchill Livingstone, p 553, and 5t Louis, Quality Medical
~lPobljshing.

there is a decrease in cardiac conductivity and automaticity and an increase in the refractory period. 5o Table
14-7 outlines the characteristic cardiac effects of various
levels of hypothennia. These arrhythmias may not be
treatable until core rewanning occurs. However, electrocardiographic monitoring may be useful in identifying

the severity of hypothennia. The J-point elevation, for
example, is potentially useful in diagnosing the severity of
hypothermia. 50
Another significant effect of hypothennia is hemodynamic. Both myocardial contractility and vasomotor
tone are impaired by hypothennia. This effect may
produce profound hemodynamic collapse. During rewarming, significant hypotension may occur in response to
peripheral vasodilation. Severe hypothermia may make
cardiac resuscitation impossible, and thus rewanning
should continue during resuscitation. 54 Resuscitation is
continued until a core temperature of at least 30° C has
been obtained, particularly if the primary cause of the
cardiac arrest is hypothennia. Resuscitation efforts are
applied thoughtfully in the severely hypothennic child.
Core temperature below 28° C places the child at high risk
for ventricular fibrillation, which may be induced by
cardiac compression. If the child presents with a nonarrest
cardiac rhythm, chest compression is not implemented,
even in the face of severe bradycardia. However, chest
compression is necessitated in patients with asystole or
ventricular fibrillation 49 Hypothennic patients are not
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declared legally dead until a core temperature of 32° C
or greater is achieved. 55
The respiratory system shows less uniform effects.
Initially, cold stimulates tachypnea. Shivering thermogenesis may produce compensatory alkalosis; however. below
30° C, hypoventilation is often seen. Central apnea occurs as
hypothermia progresses. 50 In addition, oxygen consumption
rises and may produce hypoxia.
The CNS response varies with the degree of hypothermia. Mild to moderate hypothermia can produce
confusion and behavioral changes. As the core temperature continues to drop, stupor worsens, and coma results.
Below 26° C, unresponsiveness; flaccidity; and fixed,
dilated pupils follow. The CNS can benefit from the
reduced metabolic and oxygen demands that result from
hypothermia. Factors that determine the degree of benefit include (I) degree and duration of hypothermia,
(2) underlying disease processes, (3) cardiorespiratory
status, and (4) prior or concomitant medication usage.
Because the effects of hypothermia on the CNS may be
profound, rewarming to a temperature higher than 35° C
is recommended before evaluation of brain death is
undertaken 50
Pharmacologic effects of hypothermia are varied. Moderate to severe hypothermia produces such a serious
decrease in metabolic rate that oxygen consumption and
the rate of biochemical reactions slow considerably. As
a result, drug levels and effects are difficult to evaluate in hypothermic patients. Decreased cardiac output,
dehydration, slowed hepatic metabolism, impaired glomerular filtration, and abnormal renal tubular filtration
and reabsorption can all result in reduced drug clearance. 50 Hypothermia, for example, elevates the toxic dose
of digitalis, whereas it decreases the inotropic dose.
Potassium- and calcium-induced cardiac arrhythmias are
possible because of increased myocardial sensitivity during
hypothermia. Finally, temperatures below 26° C depress the
cardiotonic effects of catecholamines; mild to moderate
hypothermia, however, enhances their effects. 50 Other
pharmacologic effects include heightened sensitivity to
anesthetic agents and barbiturates. Both barbiturates (because of their depressant effect) and phenothiazines (because of their (X-adrenergic blocking effects) potentiate
hypothermia.
With body temperature below 30° C, hyperviscosity and
hypercoagulability of the blood may occur. This results from
a rising hematocrit level resulting from the cold diuresis that
accompanies hypothermia. Infection is also a danger as a
result of neutropenia, and coagulopathies can be accentuated
because of thrombocytopenia. 50
Generally, external warnling devices are used to return
the patient's temperature to the normal range in the case of
mild to moderate hypothermia (i.e., core temperature of
30 0 to 35° C). Radiant warmers, heating blankets or pads,
warmed blatlkets, and head coverings are commonly used.
Reflective blankets (lightweight metallic blankets that
reflect up to 80% of radiant heat to the body)56 and buntings
insulated with Thinsulate 57 have been recommended. A

Thermal Regulation

457

combination of modalities may be superior to a single
rewarming technique. 58
When instituting such measures, nurses are vigilant in
their assessment of the patient's responses to the treatments.
Radiant warmers are used only with the servocontrol
option to avoid thermal injury to the skin. Heating pads
and blankets and other warming devices are used with
caution. Critically ill infants or children are not likely to be
able to perceive a thermal injury or communicate it to
nurses.
Severe hypothermia (core temperature lower than 30° C),
for example, as a result of cold-water submersion, often
requires active internal warming methods in addition to
external warming measures. In such circumstances, measures such as heated humidified air, warmed intravenous
fluids, and gastric or colonic lavage with warmed solutions
or peritoneal dialysis may be implemented. 53 Extracorporeal
rewarming (ECR) may be required in the most severe
circumstances. 49 ECR has been advocated as a rewarming
technique in hypothermic patients to reduce the problems of
rewarming shock, dysrhythmias, and thermal injury associated with external warming devices. 17 .59
ECR diverts a significant portion of the patient's
cardiac output through the extracorporeal membrane oxygenator and blood warmer. Gradual rewarming is facilitated by maintaining a wamling gradient of approximately 10° C between the perfusate in the extracorporeal
circuit and the patient's core temperature until body
temperature reaches a normal range. 6Il Slow rewarming
avoids the sudden recirculation of cold. acidotic blood
from the vasoconstricted peripheral vascular beds to the
central circulation. This phenomenon, called "rewarming
shock" or "afterdrop," is manifested by a continued
decline in core temperature and serum pH after removal
from the cold. 53 Because rapid rewarming increases the risk
of ventricular fibrillation, gradual rewarming is the goal
in any severely hypothermic patient, regardless of the
intervention selected. Throughout the rewarming phase, the
patient is closely monitored for cardiac dysrhythmias and
coagulopathies resulting from systemic heparinization if
ECR is used. Another option is the use of continuous
arteriovenous rewarming. Femoral arterial and venous
catheters and the patient's own blood pressure create a
circulatory system that drives blood through a heat
exchanger. 53

SUMMARY
The incidence of altered body temperature and ineffective thermoregulation is significant among patients in
the PICU. The risks to physiologic stability in critically
ill infants and children are high. Critical care nursing
practice can correct environmental factors leading to
altered body temperature, support thermoregulatory processes, provide physical comfort during interventions to
normalize body temperature, and ensure physiologic stability in patients with altered body temperature or ineffective thermoregulation.
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Host Defenses
Mary Jo C. Grant

ESSENTIAL EMBRYOLOGY

H

ost defenses are of considerable importance to the
pediatric critical care nurse because of the age and
vulnerability of the patient population and the complexities
of critical care illness and the critical care environment.
Host defenses may be altered because of developmental,
situational, or congenital stressors. Whatever the process or
mechanism of alteration, the outcome of altered host
defenses ranges from hyperactivity of the immune system, manifested clinically as hypersensitivity (allergies or
autoimmune disease), to hypoactivity of the immune
system, manifested as an increased susceptibility to infection. This chapter focuses on the most common alterations
in host defenses experienced by the pediatric critically ill
patient.
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SUPPORT OF IMMUNE FUNCTION

The fetus and neonate occupy a special niche in terms of
immunity and the external environment. The developing
immune system must learn to tolerate host constituents
while preparing to battle with external pathogens. The fetal
immune system is capable of significant immune reactivity
fairly early in life. Protective immune responses are present
in the human fetus as early as the seventh week of gestation,
shortly after recognizable T cells can be detected. Before
7 to 12 weeks of gestation, protection against infection must
be provided exclusively by the mother. Further protection
of the developing fetus is provided by transplacentally
acquired maternal immunoglobulin G (lgG). Beginning at
8 to 10 weeks and accelerating during the last trimester, this
placental transfer is active and specific for IgG. The
newborn is more susceptible to infection than the adult. The
development of normal immunity is a gradual process,
probably reflecting the effect of progressive and continuous
exposure to antigenic stimulation. The human immune
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Phenomena of Concern

system matures rapidly; in normal children, most immune
functions assume adult values at 2 to 3 years of age. I

MATURATIONAL ANATOMY
AND PHYSIOLOGY OF
THE IMMUNE SYSTEM
The most notable function of the immune system is host
defense, or the active protection of the host from invading
microorganisms. The other functions of the immune system
are related to host defense but serve in the role of proactive
maintenance. Homeostasis, the second function of the
immune system, is the process by which the immune system
maintains a balance between the old and new immune cells
as a part of normal physiologic functioning. Homeostasis is
the removal of old cells and debris resulting from normal
catabolism, growth, and injury. Homeostasis keeps the
body's internal environment clean and easy to survey. The
third function of the immune system, surveillance, is
the process in which the immune cells differentiate self from
mutated self cells (nonself).
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Human lymphocyte antigens (HLAs) are inherited
from parents: one set of HLAs is inherited from the mother, and the
second set is inherited from the falher. Each set of inherited
antigens is co-dominant (i.e., each set is co-expressed on the
surfaces of the pertinent body cells).
Fig. 15·1

Nonspecific Versus Specific Immunity
Every person, whether healthy or immunocompromised, is
in contact with millions of actual and potential microorganisms on a daily basis. The well-orchestrated, complex, and
efficient cadre of defenses provided through the immune
system is a barrier to these invaders. Host defenses can be
classified as nonspecific or specific. Nonspecific defenses
are generic host responses to a foreign agent. These responses are not tailored to an individual agent but are the
same responses to any agent at any time. Nonspecific host
defenses include first and second lines of defense, the natural barriers and the inflammatory responses, respectively. In
contrast, specific defenses depend on the exposure to a foreign agent, recognition of the agent as foreign, and the host's
individual reaction to that agent. The specific immune responses of the host are the third line of defense and include
humoral immunity (immunoglobulin) and cell-mediated
immunity.

Concept of Human Defense
Normal immune defense is maintained through the protection of self and the destruction of nonself. To perform host
defense, yet maintain the integrity of self, a genetic blueprint
(deoxyribonucleic acid [DNA] code) at the molecular level
assists the immune system in discriminating self from
nonself or altered self. Nonself is composed of foreign or
alien molecular structure and is referred to as antigenic, or
as an antigen.
The specific immune system discriminates between self
and nonself through the major histocompatibility complex
(MHC) molecules for each species. The MHC molecules
specific to the human species are human leukocyte antigens
(HLAs). HLAs are inherited according to mendelian laws,
with a genotype determined by one paternal and one
maternal haplotype. Close relatives share some of these

antigens, whereas identical twins share all of these antigens.
Fig. 15-1 reflects the diagrammatic representation of inheritance of the HLAs in a family.
Although first discovered on white blood cells and coined
"human leukocyte antigens," HLAs are actually located on
the surfaces of most nucleated cells in the body, as well as
platelets. HLAs of the MHC are divided into two classes
(class I and II) based on function, types of cell antigens
expressed on the cell membrane surfaces, and structure.
Class I includes HLAs A, B, and C antigens and is found on
all nucleated cell surfaces and platelets. Class II includes
HLAs D and DR antigens and is located nearly exclusively
on the surfaces of certain immune cells (macrophages and
B lymphocytes).
Once thought to be important only in the transplantation
process, HLAs are now known to playa comprehensive role
in determining self versus nonself and in autoimmune
disease processes. Class I antigens serve as identification
markers of self and assist in the elimination of cells infected
with intracellular microorganisms, mutated or malignant
cells, or rejection of tissue grafts. Class II antigens serve as
identification markers of exogenous antigens and assist in
the elimination of extracellular microorganisms.

The Lymphoid System
The lymphoid system is composed of tissues, organs, and
interconnecting vessels and is responsible for the production, maturation, storage, and activation of host defense
cells, particularly the lymphocytes. The lymphoid system is
divided into primary or secondary lymphoid tissues. Pri-
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mary (central) lymphoid tissue or organs are sites for
lymphopoiesis (development and maturation of B cells and
T cells), whereas secondary (peripheral) lymphoid tissues
and organs are the environment in which immune cells are
activated to conduct host defense.
Although traditionally primary and secondary lymphoid
tissue is categorized as two discrete groups, there are
exceptions to this approach. For instance, the bone marrow,
although thought of as a primary lymphoid organ, is also
considered a secondary lymphoid organ because it stores
lymphocytes. Conversely, the spleen and liver, usually
categorized as secondary organs, can serve as primary
organs. In the face of bone marrow failure, the spleen and
liver can become the centers of hematopoiesis?
Primary Lymphoid Tissue and Organs. The primary (central) lymphoid tissues include the thymus and the
bone marrow. The thymus gland is an encapsulated structure
located in the anterior mediastinum directly behind the
sternum. The thymus is very large relative to fetal body size
at birth (10 to 15 g), reaches peak mass at puberty (30 to
40 g), and then begins and continues to involute throughout
adult life. The primary function of the thymus is the
maturation and differentiation of T cells. In addition, the
production and secretion of thymosin and other thymic
hormones influence lymphopoiesis and the maturation and
differentiation of the various subsets of T cells.
The human bone marrow is the location for hematopoiesis, a series of events that begin with the pluripotent
stem cell and progress to the development of a full line
of functional blood cells. Through hematopoiesis, the
pluripotent stem cell is capable of creating all lines of
differentiated cells, including erythrocytes, granulocytes,
monocytes and macrophages, lymphocytes, and platelets.
In adults, hematopoiesis occurs in red bone marrow
contained primarily in the flat bones, such as the sternum,
ribs, skull, iliac crest, and proximal ends of long bones.
However, in infancy, hematopoiesis occurs in nearly all
bones. The bone marrow is also the location for B cell
maturation and differentiation.
The bone marrow and associated hematopoietic function
may be altered by many diseases and treatments. Malignancies can have a direct impact through bone marrow
infiltration by malignant cells or an indirect impact through
the side effects of cytotoxic agents. Other diseases affect
hematopoiesis through destruction of an indi vidual cell line,
such as that occurring in acquired immunodeficiency
syndrome (AIDS) (helper T cell) or all cell lines, such as
those in aplastic anemia (pluripotent stem cell). Bone
marrow aspiration and biopsy provide quantitative and
qualitative information regarding bone marrow function.
Secondary lymphoid Tissue and Organs. The
secondary organs include the lymph system, spleen, liver,
and the mucosa-associated lymphoid tissues (MALTs),
including the tonsils and Peyer's patches of the gut. The
secondary tissues and organs serve as the environment in
which the white blood cells (WBCs), specifically the
lymphocytes, travel to and enter any part of the body to
perform their host defense functions. Lymphocyte storage
and activation occur in the secondary lymphoid tissues.
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Bone marrow, in addition to being a primary lymphoid
organ, is also a secondary lymphoid organ.
Lymphatic System. The lymphatic system is composed of nodes, lymphatic fluid (lymph), and lymphatic
vessels and is an accessory route by which fluids can flow
from the interstitial spaces into the blood. The lymphatic
vessels parallel the venous system and drain into either the
thoracic duct or the right lymphatic duct and eventually into
the central venous circulation.
The amount of fluid or lymph collected and transported
through the lymphatic system is approximately 120 ml/hr. 3
As the lymph is transported through this network, it also
travels through lymph nodes. Lymph nodes are strategically
located at junctions of lymphatic vessels and are usually
kidney-shaped, bean-size organs. The lymph node serves as
a filtering station for the WBCs to identify, process, and
remove particulate matter or antigens. The lymph node also
adds lymphocytes to the lymph fluid to increase the numbers
of circulating lymphocytes. A lymph node biopsy and
lymphangiography reveal information on the function of the
lymphatic system.
Spleen. The spleen is the largest lymphoid organ and
lies in the upper left quadrant of the child's abdomen. It
comprises two types of tissue: red pulp and white pulp.
The red pulp, containing venous sinusoid areas, is primarily
involved with the destruction and removal of old or
damaged erythrocytes, whereas the white pulp contains
lymphoid tissue. The function of the spleen is to filter the
blood as it travels through the splenic tissue. Antigens are
trapped in the filtering mechanisms, where resident B cells
and T cells are activated and destroy the antigen.
After loss of the spleen (surgical splenectomy or
autosplenectomy resulting from sickle cell anemia), patients
experience an increased risk of overwhelming postsplenectomy infection (OPSI), predominantly from encapsulated
bacteria. In the asplenic pediatric patient, this risk is
exacerbated because of other immunologic deficits, such as
diminished phagocytic and complement function and reduced immunoglobulin levels. In the asplenic patient, the
Ii ver assumes the spleen's role in clearing mature and
damaged red blood cells (RBCS)2
Liver. Located in the upper right quadrant of the
abdomen, the liver serves as a filtering organ for the blood
returning from the gastrointestinal (GI) tract. Venous
sinusoids within the liver are lined with large, fixed
macrophages, referred to as Kupffer cells, which are highly
phagocytic. Because venous portal blood has drained from
the intestines, it usually contains considerable quantities of
particulate matter and bacteria. Kupffer cells are capable of
removing more than 99% of all particulate matter in the
portal venous blood before the blood completes its course
through the entire sinusoidal passages. 4
Laboratory tests, such as for hepatic enzymes and
bilirubin, can indicate the quality of liver function. A liver
biopsy or noninvasive procedures, such as computed tomography (CT) or magnetic resonance imaging (MRI), provide
information on the structure and function of the liver.
Mucosa-Associated Lymphoid Tissues. Throughout the body there are dispersed aggregates of nonencapsu-
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15-1 Normal White Blood Cell
(WBC) Values

TABLE

leu Type

Differential (%)

Absolute
Number (mm 3 )

100
9000-30,000
9400-34.000
5000-19,500
6000-17,500
5500-15,500
4500-11,000
5000-10,000

<I

3000-7000
2800-5600
150-600
50-400
25-100

2-8

100-800

60-70
56
3-6
2-5

20-40
60-88*
3-21 *
5-10*

1000-4000
600-2200
100-400
50-400

, ":'.odified from Tribelt D: Immune system function: implications for
i;4':ritical care nursing practice. Crit Care Nurs Cli" North Am 1:727,
:: 89; Behrman RE, Vaughn VC TIl, eds: Nelson/ex/book o/pediatrics.

.:. 13, Philadelphia. 1989. WB Saunders.
.Percentage of total lymphocyte count rather than percentage of lotal
~C count.

lated lymphoid tissues. These tissues, MALTs, are found in
a variety of places, especially in the submucosal areas of the
Gl (peyer's patches, tonsils), respiratory, and urogenital
tracts. s These tissues function like other secondary lymphoid tissues but are strategically placed close to potential
sites of invasion. Both macrophages and lymphocytes are
present to allow nonspecific and specific activity, respectively, to occur as needed.

Cells of Host Defense
White Blood Cells. WBCs, or leukocytes, are the
mobile units of the immune system and are colorless blood
cells that defend the body against infection. These cells are
categorized as granulocytes, monocytes and macrophages,
and lymphocytes. Granulocytes are critical in engulfing and
phagocytizing microorganisms and are nonspecific in nature. They are further categorized as neutrophils, eosinophils, and basophils. Monocytes and macrophages also
engulf microorganisms but more importantly are a link
between the nonspecific and specific immune responses.
Lymphocytes (B and T cells) are the key players in specific.
acquired response. Table 15-1 reviews the normal values for
each of the WBCs, and each is discussed separately.
Neutrophils develop and mature in the bone marrow for
approximately 10 days. They spend approximately 12 hours
in the circulation before migrating to the tissues, where they

live for only a few days. The primary function of neutrophils
is to move to the site of invasion and destroy microorganisms through the process of phagocytosis. Neutrophils are
the first WBCs to respond and the most numerous WBCs
found at the site of tissue injury.
A mature neutrophil is described as a polymorphonuclear
leukocyte (PMNL) or segmented neutrophil because of the
appearance of the nucleus. Normally, segmented neutrophils
or "segs" constitute the majority of circulating neutrophils.
Neutrophilia, an increased number of circulating neutrophils, is often accompanied by an increase in the number of
bands because the bone marrow releases a supply of neutrophils in response to the body's demands without regard to
the cell's maturity or readiness for release. Neutrophilia is
also observed in situations that stimulate secretion of epinephrine, adrenocorticotropic hormone (ACTH), or adrenal
corticosteroids and cause increases in cardiac output. Therefore neutrophilia is observed in patients experiencing infection; stress response from surgery, hemorrhage, or emotional
distress; and metabolic disorders, such as diabetes. The presence of greater than normal numbers of immature neutrophils in the circulation (neutrophilia) is clinically significant
because the immature neutrophil's ability to phagocytize is
less effective than that of a mature neutrophil and. more
importantly, may signify that a problem exists.
Neutropenia, a decreased number of circulating neutrophils, is often associated with a pathologic or malignant
condition. Conditions such as aplastic anemia or treatment
with cytotoxic agents result in neutropenia. Neutropenia is
technically defined as less than 3000 cells/mm 3 of absolute
neutrophils.
Eosinophils. Eosinophils account for approximately
2% to 5% of the circulating WBCs in healthy, nonallergic
individuals but up to 50% in patients with parasitic
infections or (less often) allergic conditions. 6 Following
maturation in the bone marrow, the eosinophil is released
into the circulation and remains there for a brief time before
migrating to the tissues. Unlike other cells, eosinophils can
recirculate back and forth from the circulation to the tissues.
Their time in the tissues is approximately 12 days. Although
eosinophils have the ability to phagocytize, the process is
less efficient than that of the neutrophil. The eosinophil's
role in host defense is not exactly known but is believed to
be involved in the "turning off" of the immune response
because it arrives last to the site of infection.
Eosinophils, like neutrophils, basophils, and mast cells,
can be triggered to degranulate. Degranulation is the process
in which intracellular granules fuse with the target cell's
plasma membrane and cellular contents are released to the
outside of the cell. If the target is too large to phagocytize,
the eosinophils can shower the target with toxins located in
their granules.
As previously mentioned, eosinophilia, an increased
number of circulating eosinophils, is observed in patients
with parasitic infection and allergic conditions. It is also
observed in patients with chronic skin infections, GI
conditions, such as ulcerative colitis and Crohn's disease,
and rare conditions such as hypereosinophilia. Eosinopenia,
a decreased number of circulating eosinophils. is observed
in pi atients with acute mononucleosis and other acute
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infections, as well as conditions or therapies stimulating
adrenal steroid production.
Basophils and Mast Cells. Basophils represent the
smallest proportion of granulocytes in the circulation,
usually less than I% of circulating WBCs. The basophil's
production, distribution, and lifespan are not thoroughly
understood. Basophils possess granules containing heparin,
histamine, and other mediators, which can degranulate with
the proper stimulus. Basophilia, an increased number of
circulating basophils, is seen in leukemia and is seen less
often with allergies and infectious diseases such as tuberculosis, influenza, and chickenpox. A decreased basophil
count is observed in patients with allergic reactions or in
those who are receiving prolonged steroid therapy.
The mast cell is often indistinguishable from the basophil,
but the two cells do differ. Mast cells do not circulate in the
bloodstream but instead are found throughout the body's
tissues, particularly the skin and mucosal linings of the
respiratory and GI tracts. Like the basophil, mast cells store
granules with histamine and other potent mediators that are
important in the inflammatory response and tissue repair.
When the mast cell or basophil is inappropriately activated,
these granules may lead to an allergic response. Because mast
cells do not cirCUlate, the suffixes "philia" and "penia" are
not usually used to refer to abnormal numbers of mast cells.
An abnormal accumulation of mast cells is termed mastocytosis and can range from benign skin lesions to organ
infiltration resulting in organ dysfunction and death.
Monocytes and Macrophages. Monocytes are
large, nongranular leukocytes with kidney-shaped nuclei
that make up 2% to 8% of total circulating WBCs. After
their release from the bone marrow, monocytes spend only
a brief time in the circulatory system (12 days) before they
migrate to their primary site of action, the tissues. Following
migration into the tissue, monocytes undergo differentiation
into macrophages. Like neutrophils, monocytes (in the
circulatory system) and macrophages (free and fixed, but
usually in various tissues) have the ability to phagocytize.
Because monocytes are circulating WBCs, they can be
quantified in the differential WBC count. Monocytosis, an
increase in the number of circulating monocytes, is observed
in patients with viral, parasitic, or rickettsial infections,
although this finding may indicate a recovery phase and may
be a favorable sign. A decrease in the circulating monocyte
count, monocytopenia, is not clinically significant but may
be observed in patients with human immunodeficiency virus
(HlV) infection or in patients receiving prednisone therapy.
The macrophage is capable of phagocytizing larger and
greater numbers of particles than the neutrophil. It has a
primary role in nonspecific defense through its phagocytic
activities but also in specific defense by its processing and
presentation of the antigen to the helper T cell. Thus the
macrophage serves as a link between the nonspecific and
specific host defenses. The macrophage is also involved in
the production and release of cytokines. It produces
interleukin-I (IL-I), a known pyrogen and mediator of the
inflammatory response. The macrophage also produces
interferon in the presence of viral invasion.
Lymphocytes. The lymphocyte is a small, mononuclear cell that makes up 20% to 40% of the circulating
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WBCs. The lymphocyte is produced in the bone marrow and
migrates to other parts of the body for differentiation and
maturation into several distinct subsets of lymphocytes.
Lymphocyte subsets include B cells. T cells, and natural
killer (NK) cells based on differences in their immune
function and surface molecules (phenotypic markers).
Although these cells are normally measured in the
periphery, lymphocytes circulate through a network of
interconnected passages referred to as the recirculating
pathway. In the recirculating pathway, lymphocytes survey
the body for invading organisms or antigens by traveling
among the blood, lymphatic vessels, lymphoid tissue, and
bone marrow and back to the blood. Lymphocytes can also
be found in specialized tissue collections, spleen, thymus,
mucosa of the GI tract, and many other body tissues.
Lymphocytosis, an increase in the number of circulating
lymphocytes, is seen in patients with viral infections, such
as infectious mononucleosis and infectious hepatitis, lymphocytic leukemia, and lymphoma. Lymphopenia, a decrease in the number of lymphocytes, is commonly seen in
patients with congenital immunodeficiencies, AIDS, uremia,
or Cushing's disease or after the administration of cortisol
or ACTH.
B Cells. B cells make up approximately 10% to 15% of
the total lymphocyte count, with alterations in the number
of B cells considered clinically significant (Table 15-2). The
B cell is primarily responsible for humoral immunity
through its transformation into a plasma cell that secretes
immunoglobulin. Humoral immunity primarily protects the
host from bacterial infection and viral invasion.
The term immunoglobulin refers to a group of serum
proteins that are composed of antibody molecules. Immunoglobulins are specialized molecules synthesized by
plasma cells serving as flexible adapters connecting immune
cells and antigens. Antibody is the term reserved for an
individual immunoglobulin molecule, one for which the
"destiny" antigen is known. The primary purpose of the
antibody is to bind to its destiny or predetermined antigen
and either neutralize it or enable the cells of the immune
system to destroy it.
Immunoglobulins are composed of polypeptides (chains
of amino acids) formed into a basic Y-shaped structure. The
basic immunoglobulin molecule consists of two identical
long (heavy) chains and two identical short (light) chains
held together by chemical bonds (Fig. 15-2). Both the heavy
and the light chains have a variable segment at one end of
the molecule and a constant segment at the other end of the
molecule. The variable segment binds to the antigen for
which it was made, and is referred to as the antigen-binding
fragment (Fab)7 Although the variable segment is unique,
the sequence of amino acids that creates the constant
segment of the immunoglobulin molecule remains identical
within each class of immunoglobulin and is thus referred to
as the constant fragment (Fc).
Human immunoglobulin molecules are divided into five
classes based on the structure of their constant segments:
IgG, IgA, IgM, IgE, and IgD. Phagocytes and other immune
cells have receptors on their surfaces into which the constant
Fc portion of the Ig molecule fits. This receptor is called an
Fc receptor. Table 15-3 is a review of the major classes of
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15·2

Lymphocytes: Laboratory Analysis and Clinical Significance of Alterations

!!.:teU
Type
--- ,!

it
cells
i!':i

Total Lymphocyte Count (%)

Absolute Count (per mm 3 )*

Clinical Significance of Alterations

60-88

600-2200

Decreased:
Malignant disease
AIDS
Postviral infection (temporary)
Severe combined immunodeficiency
DiGeorge syndrome
Nezelof syndrome
Increased:
Graves' disease

34-67

493- 1191

Decreased:
AIDS

10-49

182-785

Decreased:
Overall lymphopenia

3-21

100-400

Decreased:
X-linked hypogammaglobulinemia
Selective deficiency of IgG/IgNIgM
Lymphoma
Multiple myeloma
Nephrotic syndrome
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50-400
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Increased:
Lymphocytic leukemia
Lupus erythematosus

IJl from Fischbach Ff: A manual of laboratory and diagnosis lesls, ed 4, Philadelphia, 1992, JB Lippincott; Tribett D; Immune system function:
~mplicalions for critical care nursing practice, Crit Care Nurs North Am 1:727, 1989.
~,: esc values most accurately reneci the older child or adolescent. Recent evidence reveals that absolute lymphocyte counts may be higher in the infant
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young child.

Antigen-binding site

••

Variable
region (Fab)

II Constant
region (Fc)

Fig, 1S-2 Structure of immunoglobulin molecule. Fab segment is
variable and attaches to its destiny or predetermined antigen. Fc
segment can attach to any cell that has an Fc receptor. (From
Schindler LW: The immune sysrem-how il IVorks. United States
Department of Health and Human Services, Bethesda, Md. NIH
publication number 92-3229, p. 6, 1992.)

human immunoglobulins with their respective serum levels,
mechanisms of action, and location.
T Cells. After production in the bone marrow, T
cells differentiate in the thymus and are rereleased into the
circulation, where they make up 80% of all lymphocytes. In
general, T cells are responsible for cell-mediated immunity,
which protects the host from infections with intracellular
organisms, such as viruses, fungi, protozoa, and helminth

parasites. T cells are also involved in the elimination of
mutant or tumor cells and are involved in the immune
response triggered during tissue graft or organ transplant
rejection.
During differentiation in the thymus, T cells develop
into one of four distinct subclasses: helper T cell, suppressor
T cell, cytotoxic T cell, or memory T cell. Helper T cells
have many functions, such as producing lymphokines,
which then stimulate the cloning and differentiation of
B cells. Helper T cells are also active in several nonspecific
host responses, such as attracting macrophages and neutrophi Is. Following helper T cell activation and the production
of Iymphokines, suppressor T cells are activated. Suppressor
T cells curb the immune response. Cytotoxic T cells (effector cells) are responsible for direct destruction of target cells
in the specific immune response. Memory cells are fonned
with the initial antigen contact and are involved in subsequent contacts with the antigen.
Because helper T cells orchestrate the entire immune
response, it is essential to have adequate numbers of these
cells. Nonnally, there are twice as many helper T cells as
there are cytotoxic and suppressor T cells. Although some
clinicians measure the ratio of helper T cells to cytotoxic and
suppressor T cells, this comparison is less clinically useful
than absolute numbers or percentages of the T cell subclasses. Alterations in the numbers of T cells and their subclasses are considered clinically significant (see Table 15-2).
Natural Killer Cells. NK cells make up approximately 5% to 10% of the total lymphocyte count. Many
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Human Immunoglobulins

% in Serum

Location

Activity and Function

75

Intravascular, extravascular

Opsonization
Neutralization
Complement fixation

15

Found in mucous membrane secretions,
intravascular

Neutralization
Prevention of surface attachment

10

Intravascular

Agglutination
Complement fixation

~~~gE

0.1

Bound to mast cells and basophils

Release of histamine and other mediators from
mast cells and basophils

O

<I

Located on surface of B cells

Function not yet defined
May be important to B cell differentiation

1:1

lig
Wi:U;)o

ifLt\dapted from Grady C: Host defense mechanisms: an overview, Semin Onco{ Nllrs 4:92. 1988.
,.,,:,

teons are used to describe the NK cell; it is often referred to
as "null," "blank," or "non-T non-B cell" because of the
lack of T or B cell identification markers. The NK cell is a
member of a group of large, granular lymphocytes (LGLs)
with nonspecific cytotoxic abilities that act through a
mechanism similar to that of cytotoxic T cells. The target cell
for the NK cell is the tumor cell or virally infected cell. The
NK cell's cytotoxic abilities are nonspecific in nature because
the cell can destroy its target without prior sensitization.
LGLs may be stimulated in the laboratory with
interleukin-2 to become lymphokine-activated killer (LAK)
cells. Although these cells remain nonspecific, they respond
to a greater diversity of targets than the NK cell. Protocols
employing LAK cells are undergoing clinical trials in the
treatment of many malignancies.

ASSESSMENT OF IMMUNE FUNCTION
In comprehensive assessments of the critically ill child, the
inclusion of an immunologic component is imperative.
Assessing tbe patient's host defenses begins with the
identification of risk factors. The critically ill child displays
many factors that are known to impair host defense or
immune function. These risk factors include young age;
presenting illness and associated interventions; poor nutritional status; and past medical history, including immunization, childhood diseases, and stress. Although these
factors and their associated effects are reviewed in other
sections of this chapter, they must be assessed as part of the
patient history and addressed in the patient's plan of care.
Assessment of childhood immunizations, in addition to
immunizations received for foreign travel, is included in the
patient's history. With the discovery and use of vaccinations,
the incidence of several childhood infectious diseases has
been greatly reduced and, in some cases, eradicated 8
Compliance with immunization schedules is credited to
many school systems, which mandate up-to-date immunization records for matriculated children. However, many
young children not yet enrolled in school may lack
immunizations.

The results of recent tuberculosis screening, either
through skin testing or chest radiographs, are included in the
patient's history. Blood component transfusion history
includes the patient's experience with and total number of
past transfusions, as well as the year in which these
transfusions occurred. These data help identify patients who
may have developed antibodies to cells or substances in
blood components and patients who are at risk for bloodborne infections, such as hepatitis B or C, cytomegalovirus
(CMV), and my.
Adolescents and young adults sbould also have a
sexual history completed because sexual activity is a risk
factor for impaired immune function. Unprotected sexual
intercourse increases the likelibood of exposure to and
acquisition of HIV infection and other sexually transmitted diseases. This risk is increased with intercourse involving multiple, homosexual, or intravenous drug-abusing
partners.
The child's past medical history should include details
of chronic or recurrent infections. A careful, detailed
history assists in separating the immunologically competent
child from the child with "too many infections." A healthy
young child may experience six to eight respiratory
infections per year and more than eight if the child is
exposed to siblings or other children in day-care settings. 9
Cues, such as repeated infections without a symptomfree interval, increased dependency on antibiotics, unexpected or severe complications to infection, or infection
with an unusual or opportunistic organism, are often a
significant part of the history of a child with primary
immunodeficiency.
Although a primary immunodeficiency may be suspected
in the young child who presents with a life-threatening
infection in the first year of life or with a history of chronic
or recurrent infections, it is also important to consider
nonimmunologic causes of "too many infections." In In
addition to exploring the medical history of the patient, a
comprehensive family history is helpful. Primary immunodeficiencies, in particular, may have a clear pattern of
inheritance. 9
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First Line of Defense
The most primitive defense mechanisms of any host, healthy
or compromised, are the natural barriers that provide
protection from the environment. The major components of
the first line of defense include the unique functions of each
of the following tissues and organ systems: integumentary,
respiratory, GI, genitourinary, and ophthalmologic. These
barriers include epithelial surfaces with their unique physical, chemical, and mechanical capacities that impede the
entrance of microorganisms. The structure and function of
each of these barriers vary; therefore each is discussed
separately, followed by the developmental alterations noted
in the infant and young child. Barriers and their unique
characteristics are summarized in Table 15-4. Any sign of a
disruption in host defense or an infectious process is noted,
documented, and addressed in the patient's plan of care.
Table 15-5 ret1ects physical assessment findings from the

TABLE 15-4 Barriers: The First Line
of Defense

Intact skin
Intact mucous membranes
Acidic pH
Bacterial interference
Sweat glands-lysozyme
Sebaceous glands-sebum/fatty acids
Intact mucous membranes
Aerodynamic filtration
Humidification
Mucociliary transport system
Bacterial interference
Alveolar macrophages
Lysozyme
Secretory IgA
Sneeze. cough, gag reflexes
Intact mucous membranes
Gastric acidity
Pancreatic and intestinal secretions
Intestinal motility
Bacterial interference
Secretory IgA
Phagocytic cells
Breast milk (lactating females)

mi.~'

Ii.

!E:~

it

~nitourinary

It

Flushing action of urination
Acidic pH of urine
Length of urethra (male)
Prostatic secretions (male)
Acidic pH of vagina (female)
Secretory IgA
Bacterial interference

Ii'IEye
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Lysozyme

~~ ..
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~~,i.

Ii
i,~"

Ili'
;;r

Flushing action of tearing
Secretory IgA
Blink reflex

')\dapted from Adams A: External barriers to infection, NuT.< CIi" North

!i'iAn' 20: 146, 1985.
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immunologic perspective. Pediatric critical care nurses can
easily incorporate an immunologic assessment into a routine
nursing assessment.
Laboratory assessment of the first line of defense
includes cultures of sputum, wound, stool, urine, and other
body t1uids. Bedside analysis of gastric and urinary pH
assists in determining the status of the child's chemical
barriers.
Colonization and Bacterial Interference. All
body tissue and organ systems exposed to the external
environment are composed of epithelial cell surfaces. These
epithelial surfaces are normally colonized by indigenous
bacterial flora that aid in the process of host defense and the
prevention of infection. Colonization, the residence of
microorganisms, is int1uenced by a variety of environmental
factors, including dietary intake, sanitary conditions, air
pollution, and hygienic habits. II Generally, two types of
t10ra are harbored by a host: normal resident (indigenous)
t10ra that, if disturbed, reestablishes residency easily, and
transient flora that may colonize the host for varying
periods, from hours to weeks, without taking up permanent
residence.
The presence of indigenous bacterial t10ra is thought to
prevent or retard colonization by other potentially harmful
organisms through a variety of mechanisms, but the exact
phenomenon of bacterial interference is not completely
understood. Known mechanisms of indigenous flora that
prevent or retard colonization by other organisms include

~

15~5 . Immunologic Physical
Assessment Findings

TABLE

~c

~rcategorylSystem

,1',"

~~~kin/hygiene

~:,

I

f:~i;.tobility/comfort

1.

1'

~'Respiratory

;Ie

t],;

~;:

Assessment Findings

Altered temperature, diminished turgor,
dehydration, signs of infection. oral
lesions, breaks in integrity, purpura.
palpable lymph nodes. rhinitis
dermatitis, urticaria, eczema
Decrease in level of activity, muscle
weakness, fever, chills, joint swelling
or tenderness
Altered rate/depth of respirations,
wheezing, crackles, bronchospasm,
cough, hypoxemia
.

iifCardiovascular
r~,:,

Vasculitis, pale skin and mucous membranes

iiJH!3astrointestinal

Altered bowel sounds, vomiting,
chronic diarrhea, hepatosplenomegaly, protuberant abdomen (not age
appropriate)

:~h;U'

I~

. I;;

eurologic

Altered level of consciousness, deficits
in sensory andlor motor function,
diminished cranial nerve function
(blink, lear, cough. swallow, and gag)

itodified from Rosenthal CH: Immunosuppression in the pediatric
ynticaJ care patient, Crit Care Nllrs Clin North Am 1:781, 1989.
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competition for the same nutrients, competition for the same
receptors on host cells, and production of products that are
toxic to other organisms. In addition, indigenous flora
provides continuous stimulation and keeps the immune
system alert to respond.
Although the newborn's skin is essentially sterile at
birth, 12 the acquisition and maintenance of normal epithelial
flora contribute to the newborn's development of the first
line defense. Within 48 hours, the newborn begins to colonize organisms that are easily obtained from the environment, nursery personnel, and family. Within approximately
6 weeks of age, the newborn's skin flora is quantitatively
comparable to that of older children and adults. 13
Integumentary: Skin and Mucous Membranes.
The intact skin is an effective physical barrier to the
penetration of microorganisms. Few organisms can directly
and effectively penetrate the skin; instead they must rely on
a vector (an organism that will transmit infection), a primary
lesion, or a (synthetic) device for entrance. II Few organisms
find the skin conducive for growth because the skin is a
generally dry, mildly acidic (pH 5 to 6) environment.
Besides containing secretory IgA, sweat also posses sufficient salt to create a high osmotic pressure. 14 In addition,
desquamation, or the natural sloughing. process, hampers
residence on epithelial surfaces.
The skin serves as a chemical and physical barrier for the
body's internal environment through the secretion of lysozyme and sebum. Secreted by the sweat gland, lysozyme can
attack and lyse the cell membranes of gram-positive and
gram-negative bacteria. Sebum, secreted by the sebaceous
glands, is an oily substance that has been postulated to have
antifungal and antibacterial properties, although none of
these claims have been substantiated.
The external epithelial surfaces are not the only ones with
these physical and chemical properties. Mucous membranes
and the internal epithelial surfaces are colonized with
numerous organisms that assist with the phenomenon of
bacterial interference. Virtually all secretions of mucous
membranes contain lysozyme, as well as IgA and IgG, and
significant amounts of iron-binding proteins, such as lactoferrin. Lactoferrin, among other iron-binding proteins,
maintains the level of free iron below the level in which
bacteria flourish.
The newborn's skin is about I mm thick at birth and
increases to approximately twice that thickness at maturity.
The newborn has scant amounts of stratum corneum, the
barrier component of the skin, resulting in increased skin
permeability.4 The stratum corneum develops quickly and is
considered an adequate barrier at 2 weeks of age. It is
similar to that of the adult by about 4 months of age.
The sebaceous glands at birth are well developed and are
active during the neonatal period under the influence of
maternal androgens acquired transplacentally.4 Following
the neonatal period, the sebaceous glands involute and
produce only small amounts of sebum until puberty.
The sweat glands are formed with associated patent ducts
by the end of the second trimester of gestation, 15 although
sweating has a delayed onset of several days in the newborn.
Sweating is noted first on the face, then on the palms of the
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hands and feet, and later on the remainder of the body. The
differences noted in sweating may be related to the
immaturity of autonomic (sympathetic) control of sweating
rather than the structural immaturity of the glands. Complete
neural control of sweat glands is noted between 2 and
3 years of age. Diminished sweat production may result in
lower quantities of bactericidal and fungicidal substances
and, in some, alteration in the physical barrier of the infant
or young child's skin.
Respiratory System. The respiratory tract has numerous nonspecific and specific defense mechanisms. The
nonspecific mechanisms are composed of the aerodynamic
filtration; the mucociliary transport system; sneeze, cough,
and gag mechanisms; and alveolar macrophages. Many
foreign particles come into contact with the mucous
membranes of the respiratory tract because of the turbulent
airflow that is characteristic of the upper airway and
tracheobronchial tree. Most particles escaping this filtration
system are eliminated by the mucociliary transport system,
by being entrapped in mucus and swept upward by the cilia
and then expectorated or swallowed. These mechanisms are
normally efficient and eliminate approximately 90% of
inhaled particles.
Another major function of the upper respiratory tract,
humidification, aids the filtration capacities of the lung.
Small hydroscopic organisms or particles absorb water from
the moist respiratory tract, enlarge in size, and are more
easily phagocytized. II The respiratory tract has detoxification defenses that include diluting substances with bronchial
secretions and alveolar fluids and phagocytizing substances
by the alveolar macrophages.
The small airways of the infant and young child make a
significantly greater contribution to airway resistance compared with those in the adult" This increase in resistance to
flow places the child at greater risk for airway occlusion
resulting from edema or inflammatory exudate. Normal
defense mechanisms of the respiratory tract may be disrupted by such narrowing or obstruction.
Gastrointestinal System. Defense mechanisms of
the GI tract include saliva; antibacterial effect of gastric
acid, digestive enzymes, pancreatic secretions, intestinal secretions, and bile; intestinal motility; and indigenous
f1ora.",16.17 Most organisms enter the GI tract through the
mouth and are readily destroyed either in the mouth by
saliva containing antimicrobial factors, such as lysozyme
and IgA, or in the stomach by the highly acidic (normal
gastric pH <4) environment. Organisms in partially digested
food particles encounter both a thick intestinal mucous layer
and an intact mucosal epithelium as deterrents to their viability. Pathogen attachment to mucosal epithelium is also
discouraged through peristalsis.
Secretory IgA, a component of the third line of defense
(specific immune response), is the predominant immunoglobulin on all mucosal surfaces. It assists in the prevention
of attachment and invasion of microorganisms and in the
limitation of the amount of food antigen that enters the
systemic circulation from the GI mucosa. 7
Secretory IgA is a form of antibody that is particularly
adapted to the unique needs of the GI tract. Its three unique
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features are that it is a double molecule, resists digestion,
and does not activate complement. The epithelial cells of the
GI tract provide secretory IgA with a molecule called the
"secretory piece." This secretory characteristic prevents
secretory IgA from being easily destroyed by the various
digestive secretions and enzymes. At birth, newborn saliva
contains no secretory IgA, although half of infants have
detectable secretory IgA levels by 28 days of age. 18
Mellander and co-workers 19 have found that levels of
secretory IgA can increase toward adult levels within a few
weeks of life if the host is subjected to intense exposure to
microbes. Secretory IgA concentrations rise more quickly
than serum IgA concentrations. Some evidence indicates
that there are only a few secretory IgA~producing cells in
the submucosa of the GI tract at birth and that breast-feeding
may be required to obtain optimal levels of secretory IgA in
that area,z°
Young children's serum level of IgA remains low for
months, and they are dependent on an exogenous source
of IgA. Breast milk provides this exogenous source of
IgA, as well as lactoferrin, lysozyme, and lymphocytes. 17
Breast milk can offer as much as 0.5 to I g of secretory
IgA antibodies to the fully breast-fed infant daiIy.21 This
amount of secretory IgA is equivalent to approximately
one-third that normally produced by an average adult for
defense.
Breast milk, with its many components, may aid the
infant's mucosal defenses, but the exact role that each of
these components plays is still undefined. It is generally
accepted that breast milk provides the GI tract some
protection from food allergies and microorganisms until the
infant's mucosal immune system matures. Colostral antibodies do not cross the newborn's gut after the first 24 hours
of life and do not have a role in the newborn's systemic
immunity.22
An additional chemical property of the Gl tract is the
acidity of the stomach. At birth, the gastric pH is approximately 6, but normally reaches a pH of 2 to 3 within the first
24 hours of life. Acidity of the stomach gradually increases
through childhood, and then it plateaus to adult levels at
10 years of age. Peristalsis propels the antigen through the
GI tract, decreasing the opportunity for the antigen to settle
and attach. The continual shedding of epithelial cells in the
intestinal tract also limits the efficacy of an infectious
process.
Peristaltic motion is intact at birth, with evidence that
even the newborn's peristaltic contractions occur at the
same frequency as the adult's,z' However, unlike the adult's,
the newbom's intestinal epithelium allows certain molecules
to pass into the systemic circulation. The maturation of the
intestinal epithelium is thought to occur in response to
hormones and a variety of growth factors.
Genitourinary Tract. Organisms in the lower urinary
tract are normally eliminated during urinary evacuation. In
addition, normally acidic urine maintains the sterility of
urine. In the male, the length of the urethra provides a
physical protective barrier to pathogens. Antimicrobial
substances, such as prostatic fluid secretions and secretory
IgA, also assist in urinary tract defenses.

The female's vagina supports a large amount of indigenous microorganisms, primarily lactobacilli. The epithelial
surfaces of the vagina contain increased amounts of glycogen, which is then metabolized into lactic acid by the bacterial flora. This creates an acidic and unfavorable environment for most potential pathogens.
Urine levels of secretory IgA may be an indication of the
degree of risk for urinary tract infection (UTI). Fliedner and
co-workers24 found that girls with a history of a UTI have
lower levels of secretory IgA in the urine during noninfected
periods than girls without previous UTIs.
Ophthalmologic Defenses. The eye is equipped
with eyelashes and the blink reflex to mechanically augment defenses. Tearing is the major external defense for the
eye. Tears drain through the lacrimal duct and deposit
organisms into the nasopharynx for the mucociliary transport system to eliminate. Tears contain high concentrations
of lysozyme. Tearing is present by approximately 6 weeks
of age, and lysozyme levels in the normal infant and the
adult are comparable.

Second Line of Defense
Penetration of microorganisms into the internal environment
signifies a breach of the first line of defense. Once the
internal environment is threatened through an extrinsic
insult (vascular access, Foley catheter, burn, trauma, etc.) or
an intrinsic insult (thrombosis, malignancy, etc.), the second
line of defense is triggered. These secondary defenses, like
first-line defenses, are nonspecific and occur immediately
and independently of the body, recognizing the specific
antigen. Preexisting cell types and chemical mediators form
the second line of defense, which consists of inflammation,
phagocytosis, and complement activation.
Inflammation. The goals of the inflammatory response are distinct and are consistently well described in the
literature; these goals are to localize, dilute, and destroy the
offending antigen (if present), to maintain vascular integrity
and minimize tissue damage, and to transport cells and
substances to the area requiring tissue repair. The inflammatory process is triggered by any cell or tissue injury. The
hallmark of the inflammatory response is the release of
chemical mediators, such as histamine, bradykinin (and
other kinins), serotonin, and prostaglandins. The process
generally begins as a localized response accompanied by
classic symptoms that include erythema, edema, warmth.
and pain. The systemic response marks the inability of the
local response to fulfill the goals of containment and is
manifested by leukocytosis, neutrophilia, fever, and others.
The mechanisms of the localized inflammatory response are
described first.
The immediate response to injury is vasoconstriction so
that the formation of the fibrin plug and margination of
leukocytes, erythrocytes, and platelets can begin. The brief
period of vasoconstriction is followed by a longer period of
vasodilation, manifested by redness, heat, and increased
capillary permeability. Increased capillary permeability
allows plasma and cells to leak out of the vascular space and
attend to the tissue injury. The result of this plasma and cell
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movement into the tissue is interstitial swelling (edema) and
the formation of an inflammatory exudate. Although the
development of swelling may be physically restricting in the
inflamed area, the inflammatory exudate ultimately assists in
accomplishing the previously stated goals of inflammation.
Pain of the inflammatory site is the result of various events,
but predominant it is the release of kinins and swelling or
restriction of the site.
In response to the inflammation, leukocytes are released
from the bone marrow and marginating pool into the
circulation. Leukocytosis is indicated by an increase in
WBC count from a normal count up to 30,000 cells/mm 3 .
The cells and bacteria at the site of cellular or tissue injury
release substances that attract neutrophils to the site within
minutes of the initial insult. The neutrophil response in
inflammation predominates for the initial 24 to 48 hours.
Monocytes are subsequently attracted to the site to augment
the neutrophil's phagocytic activity.
Once in the general area of the inflamed tissue, the neutrophil will line up against the blood vessel wall (pavement)
and migrate through the epithelial gaps of the vessel into the
interstitial space by a process called diapedesis. Once in
the injured tissue, the neutrophil and other phagocytes continue their purposeful movement, referred to as chemotaxis,
to the site of inflammation. Chemotactic substances are
chemical substances that attract or move phagocytes to
necessary sites.
Following the initial neutrophil response to inflammation, the monocyte and macrophage response predominates.
This phase of the inflammatory process varies, depending on
several factors. If a virus is present, the monocyte arrives
and produces a-interferon, which has antiviral properties.
The monocyte may also migrate into the tissue to further
differentiate into a macrophage and efficiently phagocytize
bacteria, cellular debris, and dead neutrophils. The acti vated
macrophage may then release the cytokine IL-l to act as an
endogenous pyrogen that causes fever and inhibits further
microorganism growth. The monocyte and macrophage
response is a vital link between the nonspecific and specific
immune responses. The response signifies the need for
specific cells to enter the inflammatory response.
If the amount or virulence of a microorganism is
overwhelming or the injury is extensive, signs of a systemic
inflammatory process can be seen (leukocytosis, neutrophilia, malaise, inability to gain weight or weight loss, and
fever). The American College of Chest Physicians (ACCP)
and the Society of Critical Care Medicine (SCCM) held a
consensus conference to provide a conceptual and practical
framework of various clinical syndromes (bacteremia,
sepsis, trauma, etc.) involving a systemic inflammatory
response 25 The proposed terminology recognizes that the
host is an active participant in the immune response to both
infectious and noninfectious insults. Although the details of
the proposed terminology can be found elsewhere,25 the
term systemic inflammatory response syndrome (SIRS) is
the most applicable to this chapter. SIRS is defined as a
systemic or nonlocalized response to a variety of infectious
but also noninfectious insults. 25 As previously mentioned,
the ACCP-SCCM consensus conference has proposed
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objective criteria characterizing the SIRS (see Chapter 27
for further information about SIRS).
The presence or absence of the inflammatory response is
directly assessed by the nurse, with phagocytosis and
complement activation indirectly demonstrated by pus
formation and fever. All disruptions in epithelial surfaces are
assessed for the cardinal signs and symptoms of the
inflammatory response. It is important to note those
situations in which the cardinal signs of the local inflammatory response (redness, inflammation, induration, and
drainage) may be diminished or absent in newborn infants,
neutropenic patients, or patients recei ving medications
suppressing the inflammatory response. In addition, the
newborn may have a delayed or limited ability to localize
infection. In these patients, the most reliable sign of local
inflammatory response is often pain at the site of infection.
In critical care patients, fever is the most reliable sign of
systemic inflammation. Fever is caused by pyrogens, exogenous or endogenous substances that cause the hypothalamus
to adjust the temperature set-point upward. Exogenous pyrogens are derived outside of the host and are commonly
microbial products, toxins, or the microbes themselves. The
lipopolysaccharide produced by gram-negative bacteria is
an example of an exogenous pyrogen and is commonly
called an endotoxin. Endogenous pyrogens are polypeptides
that are produced by host immune cells, most commonly
IL-l produced by the monocyte and macrophage. Numerous
other cytokines, including tumor necrosis factor (TNF),
a-interferon, and IL-6, are also pyrogenic.
Temperatures above 39° C can contribute to host defense
by augmenting T cell and B cell activity and leading to
cytotoxic T cell generation and immunoglobulin synthesis.
In addition, in vitro microbial growth is suppressed at
elevated temperatures. Despite these advantages in host
defense, fever is often treated with antipyretics and other
fever-reducing measures. This is especially true in the
critically ill child because fever increases the child's already
high metabolic rate. Whether reducing an elevated temperature adversely affects the outcome of patients with fever
is debated?6
Phagocytosis. The primary role of phagocytic cells is
to destroy foreign substances or microorganisms. Once
phagocytes are mobilized, the process of phagocytosis may
begin. Phagocytosis is multiphasic. Neutrophils (and other
white cells) recognize the target to be ingested, attach,
ingest, and finally digest the target through a variety of
intracellular antimicrobial mechanisms. Phagocytes ingest
organisms by nonspecific mechanisms; that is, they are not
specifically sensitized to the antigens of the particle they
ingest. Fig. 15-3 presents a schematic representation of
phagocytosis.
To function effectively, the neutrophil and other phagocytes must be able to migrate to the site of inflammation and
then ingest and kill the target cell through bactericidal
acti vity. An important note is that the contact between the
phagocyte and the target cell is mediated by opsonins, and
phagocytosis of these target cells may be diminished
because of the reduced quantities of circulating opsonins,
such as complement proteins or immunoglobulins. Although

472

Part III

Phenomena of Concern

Schematic representation of phagocytosis
showing ingestion process and intracellular digestion.

Fig.15-3

bactericidal actIvlly of the newborn phagocyte has been
reported as normal or equal to adult bactericidal activity,
strong evidence has shown that bactericidal activity is
diminished in the presence of stress or secondary illness,
such as respiratory distress syndrome or sepsis.27.28
Although the quantity of peripherally circulating neutrophils is similar in the infant and the adult, the infant has
considerably smaller numbers of stored neutrophils per
kilogram of body weight than the adult. The infant's smaller
neutrophil storage pool results in less ability to repeatedly
replace the number of circulating neutrophils; therefore the
infant's neutrophils can easily be depleted in the face of an
infection, leading to neutropenia.
The storage pool of neutrophils also contains various
stages of developing neutrophils that are released at a time
of need. 29 The result may be the release of neutrophils that
are too immature to effectively function during times of
increased demand or diminished supply. Release of immature neutrophils can be observed in all patients, but animal
data suggest that it maybe exaggerated in the infant and
young child.
Another developmental difference noted in the inflammatory response is the movement and mobility of phagocytic cells, particularly the neutrophil. Data suggest that the
newborn's neutrophil chemotaxis is altered 30 This neutrophil chemotactic hypoactivity remains unchanged for the
first 24 months of life and may not reach adult activity until
approximately 16 years of age. 31 Monocyte chemotactic
activity in infants and children is less well understood. Klein
and co-workers 31 found that monocyte chemotaxis in the
infant and young child under the age of 6 years may be
extremely poor and significantly less than that of older
children and adults.
The available data suggest that the ability of the human
neonate to increase neutrophil production in response to
infection may be limited. 30 The infant's neutrophils have
less ability to aggregate and are less deformable than the
adult's.n The phagocyte's capacity for deformability is

essential for chemotaxis and for movement through small
intercellular spaces. The infant's neutrophil surface is more
rigid, which may impair the neutrophil's movements though
capillary walls and bone marrow sinusoids. This effect may
partially explain impaired chemotaxis and thus the inability
to localize infection.
Impaired phagocyte function increases the infant and
young child's risk of infection and impairs their ability to
localize infection. The clinical consequence is a higher
incidence of severe recurrent bacterial infections.
Complement System. The complement system is a
complex group of more than 20 interacting proteolytic
enzymes and regulating proteins that are found in plasma
and extracellular fluids. The complement system, like the
coagulation system, reacts sequentially in a series of
enzymatic reactions in a cascading manner (Fig. 15-4).
Complement may be activated by several factors, such as
the release of plasmin or protease from damaged cells or
microorganisms, the formation of antigen-antibody complexes, the presence of viruses or bacteria in the circulation,
the release of endotoxin by gram-negative bacteria, or the
aggregation of immunoglobulins or platelets. The complement system consists of two separate but interrelated
enzyme cascades: the classical pathway and the alternative
pathway. Both pathways lead to the generation of C3 and
C3b and a final common pathway. Activation of the classical
pathway is only initiated by antibody-antigen complexes,
whereas the alternative pathway does not have an absolute
requirement for antibody for activation 33 The importance of
the alternative pathway is that by not requiring specific
antibody, it provides an early protective mechanism that is
effective before the development of specific immunity.
Activation of either pathway of the complement cascade
leads to enhancement of inflammation, mediation in the
opsonization process, mediation of lytic destruction of cells,
and assistance in chemotaxis. 34
Complement proteins gradually increase to 60% to 80%
of normal adult levels at birth for the classical pathway and

Chapter 15

Classical pathway
Activated by:
Antigen-antibody complexes

Alternative pathway
Activated by:
Plasmin
Proteases
IgA complexes
Bacterial polysaccharides

C3 * C 3 b

Membrane attack
complex (MAC)
Fig. 15-4 Complement system consists of two separate but
interrelated enzyme cascades: classical and alternative pathways.
Each is activated by different stimuli, but the result is a final
common pathway leading to enhancement of inflammation,
assistance in chemotaxis, mediation of opsonization, and target
membrane rupture. (Adapted from Frank MM: Complement
and kinin. In Stites DP, Terr AI, Parslow TG, eds: Basic and
clinical immunology, ed 8, Norwalk, Conn, 1994, Appleton &
Lange, p. 125.)

lower percentages for the altemati ve pathway,30 but serum
complement levels are not within normal adult range until
about 3 to 6 months of age. Low complement levels at birth
may contribute to the newborn's afebrile and absent
leukocytic response to infection.

Third Line of Defense
If nonspecific defenses fail, a specific acquired response is
triggered. The specific immune response is complex and still
not fully understood. Specific immunity is composed of two
different mechanisms: humoral immunity (HI), primarily
involving the B cell, and cell-mediated immunity (CMI),
primarily involving the T cell. Each of these two forms of
immunity involves different cells, mediators, and means of
function, but significant interaction and interdependence
occurs between the two immunities.
The distinguishing features of an acquired immune response are specificity, heterogeneity, and memory. Specificity refers to the characteristic by which an individuallymphocyte responds to its destiny or predetermined antigen.
Specific immunity is also characterized by heterogeneity.
Heterogeneity is the involvement of a variety of different
cells and cell products that work together in diverse ways to
protect the host. Memory, an attribute acquired by lymphocytes while participating in a first immune response with an
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antigen, enables lymphocytes to recall subsequent exposures to their destiny antigen. This first encounter with an
antigen triggers a primary immune response. A second
or subsequent exposure to an antigen, occurring months
to years later, will stimulate an accelerated and augmented response because of the immunologic memory of
lymphocytes.
The third line of defense, specific immunity, is assessed
through a comprehensive examination of the patient's
history, clinical course, and data from laboratory testing.
Laboratory testing is used to reveal the immune system's
ability to recognize and process foreign antigens, recall
previous exposure to antigens, and produce normal amounts
of effector cells to the antigens. The laboratory tests also
evaluate the competence of these effector cells to antigens.
Testing is often categorized into those tests that measure
individual elements of the immune system (quantitative)
and those tests that measure the immune response to an
antigen (qualitative).
Acquisition of Specific Immunity. Specific immunity may be "acquired" either actively or passively. Specific
immunity is acquired actively when the body is exposed to
a particular antigen, mounts an immune response to that
antigen, and results in the formation of immunologic
effector and memory cells. Contracting mumps or receiving
a vaccine is an example of actively acquiring specific
immunity, Specific immunity also may be acquired passively through the transfer of sensitized cells or their
products (i.e., immunoglobulin) from one person to another.
Maternal transfer of antibody across the placenta to the fetus
is an example of passively acquiring specific immunity. The
characteristics of passive and active specific immunity are
contrasted in Table 15-6,
Components of Acquired Immunity. The specific
immune response (Fig. 15-5) is often divided into three
phases or limbs: afferent, central, and efferent. The afferent
limb involves the recognition and presentation of an antigen
to the B cell or T cell. The central limb involves the cloning
and differentiation of activated cells, as well as the production and release of cytokines. The efferent limb involves the
actual elimination of the target cell or antigen, Memory cells
are developed during the central and efferent limbs of the
specific immune response.
Recognition Phase (Afferent Limb). The first
phase of the specific immune response involves the recognition and processing of the antigen. Each lymphocyte
(B cell, helper T cell, and cytotoxic T cell) requires the
formation of a complex with the antigen-presenting cell and
antigen to recognize the antigen as foreign and begin the
activation process. The manner in which a B cell and a T cell
recognize an antigen is different.
The B cell recognizes its destiny antigen when the
antigen contacts the immunoglobulin projecting from the
B cell's surface. Although most B cell recognition of
antigens occurs with great assistance from the T cells,
certain antigens can trigger B cells with little T cell
assistance. This response is sometimes called "T cell
independent" activation and occurs most often with exposure to encapsulated bacteria, such as Haemophilus infiuenzae and Streptococcus pneumoniae. B cells activated in this
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manneT do not form memory cells to protect against futuTe
exposuTe to the microbe; in addition, these B cells can only
produce the IgM class of antibody.
In contrast to the B cell, T cells recognize antigen only
when the antigen is combined with HLAs. Class II HLAs
are required for helper T cell activation, whereas class I
HLAs are required for cytotoxic T cell activation.
Helper T cell antigen recognition begins with a macrophage ingesting an antigen and converting (processing) the
antigen into a form that is easily recognized by the helper T
cell. The macrophage reexpresses the antigen on its cell
membrane along with the class II HLA DR antigen. The
antigen-HLA complex is then presented to the unprimed
helper T cell and combines with the T cell destiny antigen
receptor. Helper T cell antigen recognition is also facilitated
by numerous cytokines, such as lL I, which is produced by
the macrophage during its processing of the antigen. Other
signals may be required for helper T cell activation and are
the focus of intense research.
Cytotoxic T cells require antigen to be combined with
class I HLAs. For example, a cell infected with a virus
projects viral antigens on its surface in combination with the
cell's class I HLAs. The antigen-HLA complex is then
presented to the appropriate, unprimed cytotoxic T cell and
combines with the T cell destiny antigen receptor. IL 2,
produced by the helper T cell, serves as a second signal for
the cytotoxic T cell.
In utero, maternal host defense mechanisms shield the
fetus from exposure to environmental antigens, and the
placenta provides a shield from maternal host defenses.
Although the infant is born with the capacity to perform
nonspecific host defenses, the product of immunologic
experience (specific host defense) is acquired. Before 7 to
12 weeks of gestation, exclusively the mother must provide
protection against infection. Further protection of the
developing fetus is provided by transplacentally acquired
maternal IgG. Beginning at 8 to 10 weeks and accelerating

during the last trimester, this placental transfer is active and
specific for IgG. By 14 weeks of gestation, the thymic cortex
and medulla are demarcated and B lymphocytes in blood
reach normal adult levels.
Preparation Phase (Central Limb). Once an antigen is presented to the unprimed lymphocyte, the second
phase of the specific immune response, the preparation
phase. begins. During this phase, lymphocytes undergo
activation, cloning. and differentiation to form effector cells
and memory cells. (The cloning of lymphocytes during the
preparation phase accounts for the lymphadenopathy that
accompanies infection. The lymph nodes are swollen
because of the extensive cloning of the activated Band
T cells.) Fig. 15-6 is a review of the primary and
secondary clonal expansion of lymphocytes in response to
an antigen.
Produced by activated lymphocytes, cytokines function
as regulators of the immune response. They serve as
intercellular signals to support the growth and differentiation of various immune cells, the cytotoxic mechanisms of
killer cells, and other effector cell functions.
In the past, certain cytokines were believed to be
produced only by the lymphocytes; these were referred to as
Iymphokines. Others were believed to be produced only by
monocytes or macrophages and were referred to as monokines. Lymphokines and monokines are now known to be
produced by many classes of cells; hence, the term cytokines
is the most accurate. However, the terms lymphokine and
monokine continue to be commonly used.
Effector cells are immune cells that produce the expected
result of antigen destruction. Effector cells include helper
T cells, which augment the entire immune response; B cells,
which indirectly attack the invader through the secretion of
antibody from plasma cells; and cytotoxic T cells. which
directly attack the invader. The preparation phase culminates with the creation of effector cells for effective and
efficient elimination of the target. Memory cells produced
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Fig. 15-5 Grand scheme of specific, acquired immunity is made up of humoral (immunoglobulin)
immunity (HI), orchestrated by the B cell, and cell-mediated immunity (CMI), orchestrated by the T ceIL
Note the interdependence between the Band T cells. The three phases of specific immune response
are indicated by the numbers in the figure: (I) recognition phase, (2) preparation phase, and
(3) elimination phase. Activated helper T cell expresses IL-2 receptors and produces B cell growth
factor (BCGF) (IL-4) and B cell differentiation factor (BCDF) (IL-6). B cell activation usually requires
three signals: following the binding of the B cell with its destiny antigen (first signal), BCGF (second
signal) stimulates proliferation of the B cell. BCDF (third signal) induces differentiation. Two signals
are needed for cytotoxic T cell activation, binding of the cytotoxic T cell receptor with the class I
HLA-antigen complex and IL-2 production. The activated helper T cell expresses IL-2 receptors
and produces IL-2, which triggers cloning of helper T cells and production of cytokines, such as
BCDF (IL-4) and BCGF ([L-6). (Adapted from Goodman JW: The immune response. In Stites DP,
Terr AI, Parslow TG, eds: Basic and clinical immunology, ed 8, Norwalk, Conn, 1994, Appleton &
Lange, p. 43.)
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Fig. 15·6 T cells and B cells carrying specific antigen receptors are produced in the primary lymphoid
organs and from the unprimed lymphocyte pool. After activation by their destiny antigens, lymphocytes
clone and differentiate into either effector cells (e.g., cytotoxic T cells, helper T cells, or antibody-secreting
plasma cells) or memory cells. This cellular proliferation constitutes the primary response. When memory
cells are again stimulated by their destiny antigens, they will clone also (secondary response). Some of
these memory cells mature into effector cells, whereas other memory cells remain as memory cells, thus
increasing the size of both effector and memory cell pools. (From Davey B: Immunology: afoundation text,
Englewood Cliffs, NJ, 1990, Prentice Hall, p. 23.)

after activation circulate throughout the body to survey for
subsequent encounters with that antigen.
Activation of helper T cells occurs early in the immune
response because of their pivotal role in the orchestration of
many other immunologic events. For instance, activated
helper T cells secrete IL-2, which assists in the cloning and
differentiation of themselves, other helper T cells, and
cytotoxic T cells. Activated helper T cells also playa key
role in B cell activation through the secretion of B cell
growth factor (BCGF) and B cell differentiation factor
(BCDF) and other cytokines.
Two communication signals are required for activation of
the helper T cell. One signal is completed through the
binding of the helper T cell with the macrophage. The
second signal is obtained through the secretion of IL-l,
which is produced during macrophage processing of the

antigen. These two signals result in helper T cell expression
of IL-2 receptors on its surface membrane and the production of IL-2. The primary function of IL-2 is to amplify the
response initiated by the binding of the helper T cell and
macrophage and to amplify the growth of additional helper
T cells expressing IL-2 receptors.
Most often, activation of the B cell requires three signals:
one signal from the antigen and two (or more) signals from
the activated helper T cell. After the binding of the B cell
with its destiny antigen, BCGF (IL-4) stimulates proliferation of the B cell. BCDF (IL-6) induces the activated B cell
to differentiate into antibody-secreting plasma cells. A
number of B cells do not differentiate into plasma cells but
form a pool of memory cells. The speculation is that these
memory cells receive insufficient amounts of BCDF to
become antibody-secreting plasma cells.3 5
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Schematic representation of changes in weight and composition of the thymus gland with
maturation, showing involution of gland with age. (From Bellanti JA, Kadlec JV: General immunobiology.
In Bellanti J, ed: Immunology lll, Philadelphia, 1985, WB Saunders, p. 44.)

Fig. 15·7

Acti vation of the cytotoxic T cell, like that of the helper
T cell, requires two signals. The first signal is the binding of
the cytotoxic T cell receptor with the class I antigen
complex; the second signal results from the IL-2 produced
after helper T cell activation.
Developmental alterations of the central limb are primarily noted in the development of lymphoid cell lines and their
respective function. Cytokine production and release (lL-I,
IL-2, BCGF, and BCDF) necessary for activation, differentiation, and cloning of lymphocytes are intact and effective.
By the ninth gestational week, the thymus has begun to
develop and becomes populated with precursor T cells,
called thymocytes. Direct contact with the various regions
of the thymus epithelium is thought to be required for
development of mature T cells. The thymocytes mature as
they progress from the outer to inner regions of the thymus.
Within the thymus, there are three distinct stages of
thymocyte differentiation, described according to their
surface markers. 36 .37 The most immature thymocytes are
found in the periphery of the cortex. Mature thymocytes are
found in the thymic medulla and express either the CD4 or
the CD8 surface marker. These cells also express class I
HLAs. 36 -38 Fig. 15-7 shows a pictorial representation of
thymus gland changes with age.
The numbers of mature T cells gradually increase in the
fetal circulation with gestational age. However, the numbers
of T cells present at birth vary and may depend on the
method used for measurement. Sources reporting slightly
elevated levels, compared with that of an adult, state that
this finding is related to the increased numbers of suppressor
T ceLIs found in the newborn. 2o .39 Other sources report significantly lower percentages than those found in the adult. 4o
Alterations in T cell response can be illustrated by
delayed hypersensitivity skin testing in which the infant and

young child may not react to certain intradermal antigens.
Altered helper T cell response may also be illustrated
clinically by altered B cell production of immunoglobulin.
Because helper T cells play a key role in influencing the
class of immunoglobulin that is made, a deficiency in helper
T cells (number or function) can result in an alteration in the
type of immunoglobulin produced by B cells. A normal
mature response is the elicitation of an IgM antibody
response followed by an IgG antibody response within 6 to
7 days. In the newborn, the IgM response can last for 20 to
30 days with no subsequent IgG response. This diminished
reaction was previously thought to be solely the result of
lack of previous antigen exposure; however, the reduced
number and function of helper T cells also contribute.
B cell differentiation is a discontinuous process that
occurs in two distinct stages: antigen·independent and
antigen-dependent phases. The first stage, which is genetically predetermined, involves the differentiation of stem
cells into pre-B cells. Although the first stage of B cell
differentiation begins in the fetal liver, further B cell
differentiation occurs in the bone marrow when that location
becomes the primary site of hematopoiesis (at 20 weeks'
gestation).38 The earliest cells committed to antibody
production are termed pre-B cells, and they lack surface
immunoglobulins 41 B cells with surface immunoglobulin
are found in the fetal peripheral blood, bone marrow, and
spleen by the eleventh week of gestation but are generally
restricted to the IgM class. As development continues, the
remaining classes and subclasses of immunoglobulin appear
on the surface of the mature B cell clones.
The second stage of B cell differentiation is initiated by
the binding of an antigen to the unprimed, resting B cell.
After contact with antigen, activated B ceLIs clone and
differentiate into plasma cells to secrete antibody from a
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Fig.1S-8 Developmental stages of B cells. Diagram depicts discontinuous stages of development: antigen
independent and antigen dependent. Earliest cells are tenned pre-B cells and contain immunoglobulin M
(lgM) in their cytoplasm. Immature B cells contain IgM on their surface (slgM). As development
continues, remaining classes of immunoglobulin appear on the surface of mature B cell clones (also
depicted with an s before Ig). The antigen-dependent phase begins antigen binding to the unprimed mature
B cell, which then differentiates into plasma cells and memory cells (not depicted in figure). (Redrawn from
Lawton AR. In Twomey JJ, ed: The pathophysiology of human immunolo[?ic disorders. Baltimore, 1982,
Urban & Schwarzenberg.)

TABLE

15·7

Serum Immunoglobulins in the Fetus, at Birth, and Age With Mature I.evels
Synthesis by Fetus
(Gestation-Weeks)

10.5 weeks
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Age at Which Adult Levels
Are Achieved

10%
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I year
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Small amount

12 weeks

IIO%t

4-10 years
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i~rom Rosenthal CH: Immunosuppression in the pediatric critical care patient, Crit Care NUTS Cli" North Alii 1:775, 1989.
..··"Crosses pIacen t a.
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than or equal to maternal level.

single immunoglobulin class or into memory B cells. Fig.
15-8 presents B cell differentiation.
Despite early differentiation of the B cell population, the
infant's B cells are deficient in producing comparable adult
levels and subclasses of immunoglobulins. Serum Ig levels
and degree of synthesis at birth and the age in which the
levels are comparable to the adult are reflected in Table
15-7. Although the IgG level seems comparable in the newborn and adult, the level reflects the transplacental acquisition of maternal antibody during, primarily, the third trimester of gestation. The infant is lowest in immunoglobulin
concentrations at about 4 to 5 months of age when maternal
IgG begins to decrease through natural catabolism and when
infant synthesis of immunoglobulin is low. 3u This period is
referred to as one of physiologic hypogammaglobulinemia,
and during this time, the infant is most susceptible to infections caused by viruses, Candida, and acute inflammatory
bacteria (Staphylococcus aureus, S. haemolyticus, Streptococcus plleumoniae. H. infiuenzae type B, and Neisseria

meningitidis). This state can range in duration from patient
to patient and can be prolonged to such an extent that the
young child suffers from recurrent and severe infections.
Numerous explanations are given for minimal synthesis
of fetal and newborn immunoglobulin. The rare numbers of
plasma cells and small amount of immunoglobulin synthesized by the fetus are thought to reflect the normally sterile
intrauterine environment and lack of antigenic exposure in
utero 40 Maternal antibodies in the newborn's circulation
may exert a strong immunosuppressive effect on the infant's
ability to mount an independent immune response and to
subsequently produce antibodies. In addition, the dominance of newborn suppressor T cells 20 and bilirubin levels
higher than 15 mg/dl 42 have also been implicated in the
increased numbers of newborn immature B cells and
decreased Ig production.
As the infant's exposure to antigen increases, a repertoire
of antibodies to antigens is developed, and the memory
component to humoral immunity is heightened through the
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development of the various IgG subclasses. Intrauterine
infection may also accelerate the fetus's immunoglobulin
production dramatically. Following intrauterine infection
and the experience with such intense antigenic stimulation,
the infant may be born with adult levels of IgM and
increased levels of IgG and IgA. 38
Elimination Phase (Efferent Limb). The actual
elimination of the target cell or antigen occurs in the efferent
limb of the specific immune response. To ensure effective
destruction of the antigen, the efferent limb usually consists
of a dual response by circulating antibody (HI) and effector
T cells (CMI). Specific immunity elimination of the antigen
occurs through the mechanisms of immunoregulation,
cytotoxicity, and memory.
lmmunoregulation. Immunoregulation is not well understood but appears to be the fine balance and feedback that
occur between the helper T cells and suppressor T cells.
When properly balanced, there is just enough of an immune
response to eliminate the invading organism but not enough
to cause host injury.
Data on the immunoregulatory function of pediatric
T cells are complex. Investigators note that adult T cells are
better equipped than newborn T cells at helping B cells
synthesize immunoglobulin. 43 Newborn T cells exhibit
more suppressor activity compared with adults. Controversy
exists regarding the basis of these findings. These findings
may be partly related to newborn helper T cells being less
functional (see Cytotoxicity), whereas other investigators
suspect an intrinsically more functional suppressor T cell or
enhanced suppressor T cell function as a remnant of fetal
life. Altman, Handzel, and Levin 44 suggest that the fetus has
increased suppressor T cell activity to prevent maternal
rejection, but this increased suppressor activity remains
apparent after birth. In summary, this question remains: Is
increased newborn suppressor T cell acti vity (I) the result of
the immaturity of newborn helper T cells; (2) related to
newborn suppressor T cells being intrinsically more active
than those of adults; or (3) a remnant of fetal life to prevent
maternal rejection':!
Cytotoxicity. The actual killing of antigen is accomplished through cytotoxic T cell activity and is sometimes
called cell-mediated cytotoxicity. Cell-mediated cytotoxicity includes three basic yet distinct phases: (I) the effector
cell binds to the target or antigen; (2) it degranulates,
showering the target cell membrane with toxins that destroy
the antigen; and (3) certain cytokines are released by
activated cytotoxic T cells (i.e., TNF and y-interferon),
which can, by themselves, cause direct cytotoxic effects and
death of the targeted cel1. 45
Cytotoxicity is diminished in the newborn period,40
whether the elimination of the target is through the activity
of the cytotoxic T cell, NK cell, or antibody-dependent
cellular cytotoxicity (ADCC) (see Antibody-Antigen Interaction). The reason for this finding is unknown but may be
related to the newborn T cell's diminished ability to produce
cytokines, such as y-interferon and IL_4. 38 ,46 Reduced
y-interferon appears to be related to the reduced numbers of
memory T cells. As previously reviewed, once the macrophage presents the antigen to the helper T cell, the activated
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T cell secretes y-interferon and IL-2. y-Interferon subsequently activates the macrophages to ingest and kill the
invading intracellular pathogen. Macrophages that are not
y-interferon activated do not kill as efficiently. The clinical
consequence of this phenomenon is a diminution of
macrophage antiviral properties 39 ,47 and may contribute to
the severity of viral illness seen in many newborns.
Although NK cell activity is diminished, cytotoxic
activity from LAK cells is not diminished. The addition of
TL-2 in vitro to nonspecific lymphocytes results in the
recruitment of cells that display strong nonspecific cytotoxic
activity. Newborns have been found to have an equivalent,
if not a heightened, degree of LAK cell cytotoxic activity.4H
Antibody-Antigen Interaction. The six major antibody
antigen interactions are neutralization, agglutination, precipitation, opsonization, complement fixation, and lysis. When
antibody neutralizes a microorganism, it renders the microorganism ineffective or incapable of action. Thus when
enough antibody molecules bind to a microorganism, it may
no longer pose a risk to a host cell. Antibody may also bind
to toxins, thus preventing the toxin from attaching to and
poisoning a host cell. Antibody can also agglutinate or
precipitate an antigen, rendering it inactive by causing it to
fonn clumps or solidify, respectively.
Antibody greatly enhances nonspecific immune responses. For instance, opsonization, the process in which
antibody coats the antigen, greatly enhances the ability of
phagocytes to engulf the foreign particle. The binding of
antibody to antigen may also lead to activation of the
complement cascade. Certain complement components produced in this process are tremendously important in
enhancing phagocytosis through opsonization, attracting
phagocytes through chemotaxis, and lysing bacteria.
Antibody molecules can be instrumental in destroying an
antigen through ADCC. During this process, the variable
segment (Fab) of the antibody molecule attaches to an
antigen while the constant segment (Fc) fits into the Fc
receptor on a monocyte, neutrophil, eosinophil, NK cell, or
cytotoxic T cell. This antibody Fc receptor connection
stimulates the involved immune cell (monocyte, neutrophil,
eosinophil, NK cell, or cytotoxic Tcell) to release poisonous
chemicals to destroy the antigen by lysis.
As previously mentioned, ADCC depends on antibody
(immunoglobulin). The diminished ability of newborns to
destroy target cells via ADCC is related to reduced levels of
antibody or reduced B cell production of immunoglobulin.
Clinical ramifications of this finding include the increased
number of bacterial infections noted in infants.
MemO/y. Memory cells reside in the host to await
subsequent exposures to their destiny antigen. The memory
cell reacts in subsequent exposures to that antigen by
producing an augmented response, as compared with the
primary exposure.
The secondary response to an antigen characteristically
differs from the primary response in that there is a shorter
latent period, a more rapid rate of antibody synthesis, and a
higher peak titer of antibody that persists for a longer period.
In addition, the dose of the antigen required to elicit a
secondary response is nonnally much less than that required
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to initiate a primary response. These differences are directly
related to the number of antigen-sensitive cells, called
memory cells.
The infant and young child have fewer memory cells.
The reduced secondary immune response in these patients
may be the result of either the reduced numbers of memory
cells or a reduced effectiveness of these cells during
secondary immune response.

DIAGNOSING DYSFUNCTION
Laboratory Tests
White Blood Cell Count
Total wac Count. The normal total WBC count is
5000 to 10,000 cells/mm 3 and may vary, depending on the
time of day. However, total WBC count varies with the age
of the infant and young child. The WBC count only reflects
the circulating WBCs, not those WBCs marginated to vessel
walls, circulating in the lymphatic system, or sequestered in
body tissues. As a general screening test for immune
function, the total WBC count serves as an indicator of the
inflammatory response or disease states, presence of an
infection, and response to therapy.
Increases and decreases in the total WBC count from
normal levels are called leukocytosis and leukopenia,
respectively. Leukocytosis is usually the result of an
increase in one type of WBC rather than a proportional
increase in all types of WECs and commonly indicates the
presence of infection. Leukocytosis can result from release
of additional WBCs from the bone marrow in response to
infection, trauma, and physical or emotional stress, but it
also can be the result of increased production of abnormal
WBCs, as in leukemia. Any condition that increases blood
flow or cardiac output will result in the recruitment of
WBCs into the circulation from the marginating pool.
Leukopenia, on the other hand, is associated with conditions
that either depress the bone marrow's hematopoietic function or stress the bone marrow by exceeding bone marrow
supplies or ability to replenish supplies.
Differential wac Count. The differential WEC
count is a report of the five different types of WBCs
(neutrophils, basophils, eosinophils, monocytes, and lymphocytes) as a percentage of the total WEC count. The
reported percentage for each cell type determines the
number of mature circulating WBCs and the absolute
number of the various types of WBCs. The differential count
evaluates the bone marrow's ability to produce those
particular cells. The differential WBC count also reflects the
morphology of cells, such as the presence of abnormal
WBCs or atypical lymphocytes. Lymphocyte subclasses are
not a component of the differential WBC count and are not
routinely quantified because the process requires specialized
equipment. However, the AIDS epidemic has increased the
availability of lymphocyte subclass measurements because
these measurements are integral to treatment decisions in
these patients. Neutropenia, rather than neutrophilia, is a
common observation noted in septic newborns and young
infants. This finding is most likely the result of several

mechanisms, including depletion of a relatively small
neutrophil storage pool, a disturbed regulation of bone
marrow release, and an inability of the stem cells to
proliferate at a faster rate. 49
Under certain clinical conditions, the WBC differential
may reveal an excess of immature WBCs or an excess of
aged WBCs. These alterations are often referred to as
"shifts." The presence of an excess number of immature
cells (bands) is called a "shift to the left." It is usually
an indication of severe infection in which an increased
quantity of immature neutrophils is released from the bone
marrow. The more severe the infection, the greater the shift
to the left noted in the differential count. A "right shift"
usually refers to an increased number of circulating mature
neutrophils, which can be observed in patients experiencing
pernicious anemia, morphine addiction, or vitamin deficiency (folate or Bn>.
On the other hand, some clinicians use the term right shift
in a different context. Instead of viewing a shift as a
reflection of the developmental stage of neutrophils (immature versus mature), a shift is viewed as the type of cell
excessively prominent. In this context, a "right shift"
indicates lymphocytosis seen in viral infections. Considering the different meanings, it is important and accurate to
describe the laboratory observation rather than merely
stating "shift to the right" or "shift to the left."
Absolute Neutrophil Count. The absolute neutrophil count (ANe) quantifies the total number of circulating
neutrophils per cubic millimeter. The ANC includes mature
neutrophils ("polys" and "segs") and immature neutrophils
("bands"). The ANC serves as a reliable barometer of the
patient's degree of risk of infection in that the lower the cell
count and the longer the time the patient experiences
the neutropenic state, the higher the patient's risk of infection. In general, the risk of infection significantly increases
if the ANC falls to certain levels (slightly increased with
an ANC of 1500/mm3 , moderately increased with an ANC
of looo/mm 3 , and greatly increased with an ANC of
500/mm 3 ). However, the patient's primary disease process
also influences the risk of infection. Patients with a low
ANC are at high risk of infection from their own GI flora
in addition to exogenous gram-negative bacteria; grampositive bacteria, such as S. allrells and S. epidermitis; and
fungal infections, such as from Candida and Aspergillus. To
calculate an ANC, see Table 15-8. The absolute cell count
may be determined for any cell type using the same process
shown in Table 15-8.
Absolute Lymphocyte Count and Lymphocyte
Subsets. Although lymphocyte counts were once thought
to be comparable in patients of all ages, recent evidence
refutes this belief. This is exemplified in the change in
prophylaxis of Pnelllnocystis carinii pneumonia in infants
and children with HIV infection. Prophylaxis in young
children is no longer started at lymphocyte counts below
200 cells/mm 3 but rather at higher and more age-appropriate
levels. Apparently, although the total lymphocyte count and
lymphocyte subsets are an equivalent percentage of the total
WBC count in all ages of patients, the infant and young
child's higher WBC count yields greater absolute numbers

Chapter 15

~

15-8 Calculation of Absolute
Neutrophil Count (ANC)

TABLE

IN.

~tr:

f~"

l!:!.

Obtain patient's total WBC
count.

;.1: Translate the total WBC

~if'

count into an absolute
~': number ("k" means
~ 1000 cells).
~~

I~'

Obtain WBC differential *

I; .~~I~~? ~~~,r::~~:~:~ of
1',

~ij;4. Translate the percentage of

It,:
~_.r. _.:
~

WBC=5 klmm'
5 x 1000 = 5000
Absolute WBC count =
5000!mm'
Polys = 60%
Bands = 10%
60% + 10% = 70%
70% + 100 = 0.7

"polys" plus "bands" into
an absolute number by
dividing by 100.

Multiply the absolute WBC
. ~;. count by the absolute "poly"
,\~.: plus "band" count.
!l!1'1"'5

5000 x 0.7 = 3500
ANC = 3500!mm'

enerally, the WEC differential count is based on a sample of 100
Is. In persons with severe leukopenia. the differential count may be
d on a sample of 50 cells. Conversely. in persons with leukocytosis,
differential count may be based on a sample of200 cells. Regardless
the number of cells used for the count. the individual cells will
resent an overall percentage of the total, and the same procedure
lined above is used to determine an ANC.
Ithough bands are immature neutrophils, they are included in Ihe
C because Ihey are relatively functional.

of lymphocytes and subsets of lymphocytes. Therefore age
is an important consideration in the interpretation of the total
lymphocyte count and subsets of lymphocytes, especially in
children with my infection. so .sl
Other Laboratory Tests

Erythrocyte Sedimentation Rate. The erythrocyte
sedimentation rate (ESR) is a laboratory test that is a
nonspecific indicator of systemic inflammation. In many
cases, the ESR is so nonspecific that it has little clinical use.
However, in the immunocompromised child, it may be one
of the few objective measurements of response to therapy or
relapse. The ESR is useful as a prognostic marker for
evaluating the resolution of certain infectious diseases
during therapy (e.g., osteomyelitis).
C-Reactive Protein. C-reactive protein (CRP) is normally present in low levels in serum; levels' increase several
hundred times within 6 to 8 hours after onset of infection or
injury. With successful antimicrobial treatment, CRP levels
fall rapidly. A normal CRP or ESR level does not exclude a
pathologic condition.
Complement System. The complement system is
sometimes evaluated because of the pivotal role these
proteins play in the inflammatory response and in humoral
immunity. The most common test of the function of the
entire complement cascade is the CHso , which measures the
function of the classical and terminal complement pathways.
When defects in the alternative pathway are being considered, an analogous test evaluating alternative-pathway
function is requested 34 Individual complement proteins,
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such as C3 and C4, can be quantified and the function of
certain complement components evaluated. C4 levels are
critical to the function of the classical pathway, with normal
serum levels ranging from 10 to 30 mg/dl. A reduction of
levels of individual complement proteins or CH so can be the
result of either underprodl.!.ction of complement or excess
complement activation or both. Therefore additional complement function testing may be necessary to identify the
exact nature of the presenting patient problem. Serum
. complement activity is reduced in preterm infants in
proportion to the magnitude of their immaturity. 52 In
contrast, complement levels in healthy full-term infants
range from 60% to 100% of those in healthy adults.
Total Immunoglobulin Levels. The total Ig level
and levels for the various classes and subclasses can be
determined. Normal Ig levels vary with age; therefore use of
age-adjusted values is emperative for all comparisons. Ig
levels can be diagnostic for congenital primary immunodeficiencies. However, if Ig levels are normal despite suspected immunodeficiency, an examination of the function
and effectiveness of the immunoglobulin to an antigen may
be indicated (qualitative testing).
Serologic Testing. Serologic testing for either antibodies or antigens can also be performed to detect current or
past infection (bacterial, viral, fungal, or parasitic). A
well-known example of serologic testing is the enzymelinked immunosorbent assay (ELISA) that is used to screen
blood products for and identify persons infected with HIY.
The presence of antigens of a particular organism is an
indication that the patient is currently infected with that
organism. For example, the presence of Clostridium difficile
toxin in the stool indicates the child is infected with
C. difficile.
The presence of antibodies to a microorganism indicates
an infection; the particular class of antibody can indicate if
the infection occurred in the past, is occurring acutely, or is
chronic. During an acute infection the initial manufactured
Ig is IgM. If the infection is particularly severe, the microorganism's antigens may overwhelm and exceed the neutralizing capacity of antibody, resulting in the presence of
measurable antigen in the serum. Later, the main Ig manufactured is IgG, and the antigen will no longer be measurable because the immune response successfully eradicated
the infection. A child with an acute CMV infection will have
anti-CMY IgM, whereas anti-CMY IgG would indicate past
CMY infection. During chronic infections, the serum may
contain both IgG and IgM antibodies to the microorganism,
as well as antigens of the microorganism.
Delayed Hypersensitivity Testing. Cell-mediated
immune function (T cell responsiveness) is evaluated by
using delayed hypersensitivity (DH) skin testing. Testing
involves the intradermal administration of antigens and is
reliable in children who are over I year of age. The premise
of DH skin testing is that if sensitized T cells to that antigen
are present, the injection will cause the body to mount an
inflammatory response. DH skin testing is performed by
using one or more of the following widely accepted antigens injected intradermally: intermediate-strength Candida,
Trichophyton, tetanus, streptococcal antigens, or mumps
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antigen. Because DH response depends on the T cell's prior
exposure to the specific antigen, as well as normal cellular
chemotaxis. remembering developmental differences in the
infant and young child is imperative. The demonstration of
intact DH skin testing confirms the presence of functional
CD4+ T cells and excludes most of the congenital defects in
cell-mediated immunity.53
In contrast to DH skin testing, immediate hypersensitivity testing determines a patient's sensitivity to allergens such
as dust, and animal hair. DH and immediate hypersensitivity
skin testing differ in purpose, immune cells involved,
antigens used, technique of administration, and the time that
the tests are read.
Chest Radiograph. The chest radiograph is a valuable tool for assessing the second line of defense. However,
just as other signs and symptoms of infection are masked
during neutropenia, the chest radiograph may be unreliable
in revealing pneumonia in the immunocompromised child.
particularly the child with neutropenia. The immune response in the neutropenic child may be so diminished that
even in a child with fulminant pneumonia, the chest film
may appear normal. In this patient population, once the
neutrophil count begins to increase to a near-normal level,
the chest x-ray film result may often worsen, revealing the
existing pneumonia.

SUPPORT OF IMMUNE FUNCTION
Support of the immune system includes maintaining external barriers, infection control procedures, and manipulation
or augmentation of the immune system. Maintenance of
these practices help to limit the incidence of nosocomial
infections that can result from impaired host defenses.

Maintain External Barriers
The incidence of nosocomial infection reflects the numerous
invasions of the child's natural barriers (first line of
defense). Intact skin and mucous membranes can be
preserved by maintaining adequate perfusion and oxygenation and accurate fluid intake (including modification for
fever and daily insensible water losses). The pediatric
intensive care unit (PICD) nurse most often performs a
complete assessment of the child's skin integrity during the
daily bath and associated activities. Any sign of redness or
disruption in the skin are monitored. Adding small measures
to routine nursing care can contribute significantly to host
defense. For example, using a nonacetone adhesive remover
when loosening tape or electrodes (ensuring that this
solution is removed) and skin preparation solutions before
applying dressings can preserve the outer layers of the
child's epidermis. Routine and careful mouth, eye, and
perineal care may protect the child's mucous membranes
and body orifices.
Endotracheal tube (ETT) intubation affects the first and
second lines of defense by directly bypassing the respiratory
tract's local host defenses, increasing the incidence of
bacterial colonization, and acting as a foreign object in the
airway. In bypassing the upper respiratory tract, the ETT

facilitates direct access of microorganisms to the lower
respiratory tract. The presence of the ETT decreases the
effectiveness of the cough reflex by interfering with glottic
closure. Local mucosal irritation and trauma and repeated
introduction of suction catheters impede the function of the
mucociliary transport. 54
Respiratory secretions and the ETT itself can act as
reservoirs for bacteria, specifically Pseudomonas aeruginosa. 55 - 57 Proliferation of bacteria occurs because the
ETT serves as a haven for bacteria growth and is sequestered from host defenses and antibiotics. 58 Colonization of
the child's airway occurs within 72 hours of intubation 59
Aspiration of bacteria from a previously colonized
oropharynx or tracheobronchial tree constitutes the cause of
the majority of nosocomial pneumonias. Despite inflation of
the cuff, aspiration around an ETT cuff can occur. 60 With the
use of uncuffed ETTs in the pediatric population, the
incidence of aspiration can be assumed to occur often. One
survey reports aspiration in up to 70% in intubated infants
and children. 61
The mere presence of the ETT can lead to increased
mucous secretion, stagnation of mucus, airway inflammation, and tracheal mucosal injury.60 As a reflex to any
foreign object in the airway, secretion of mucus is increased
and results in stagnation and pooling. The tracheal mucosa
may be traumatized by the pistonlike motion of the ETT tip
along the tract of tube insertion during breathing, as well as
by cuff injury (in the older child) to the tracheal wall. This
mechanical trauma evokes an inflammatory response and
bacterial colonization. 60 •62 Pistonlike motion may be increased in the younger critically ill child because of the
presence of an uncuffed ETT.
Promoting the evacuation and cleansing of organ systems
such as the respiratory, 01, and genitourinary tracts is vital.
Each of these epithelial-lined tracts is protected with a
combination of secretory IgA, lactoferrin, lysozyme, and
acidic lipid secretions that decrease pathogen takeover.
Recognizing the importance of pulmonary, gut. bowel, and
urinary evacuation in limiting the growth of enteric flora can
diminish the child's risk of infection. 63-65 Nursing interventions may include implementing pulmonary toilet, maintaining adequate hydration, monitoring bowel activity, establishing a bowel routine, and facilitating the patency and
functioning of the 01 or urinary drainage systems.
Narcotics, often used to facilitate artificial ventilation,
affect the function of cilia and pulmonary macrophages.
Lack of movement increases the risk for atelectasis and
subsequent superinfections. Antacids and H2 blockers alter
gastric acidity and thus alter the gastric fibra. Chest tubes
also contribute to poor clearance of respiratory secretions by
creating resistance to chest wall movement because of pain
and immobility.66 The result is poor clearance of respiratory
secretions, decreased compliance with pulmonary toilet
exercises, and thus increased incidence of pneumonias.
The presence and duration of use of intravascular lines
significantly increase the child's risk for bacteremia and,
subsequently, nosocomial infection. Infection rates are
highest when catheters are placed under emergency conditions. All catheters must pass through the first line of
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defense, the epithelial surface, either through direct percutaneous or surgical cutdown insertion. With the passage of
the catheter through the skin surface, the catheter has the
potential to become colonized with indigenous or hospitalacquired flora. In addition, a fibrin sheath soon forms around
the inserted catheter and provides an environment for
bacterial growth and migration down the catheter and
toward the bloodstream. These catheters may also become
contaminated through the infusing solution or entry sites,
such as stopcocks and injection ports, and by microorganisms from other infected sites in the bod y67.67a
The 1996 Centers for Disease Control and Prevention
(CDC) Guidelines for Prevention of Intravascular-DeviceRelated Infection suggest that intravenous tubing and
transducers of regular intravenous fluids be changed only
every 72 hours; lipids, blood, and blood products be
changed every 24 hours; and dressings be replaced only
when the dressings becomes damp, loosened, or soiled. The
guidelines make no recommendations for frequency of
catheter replacement except for pulmonary artery catheters,
which is 5 d ays 68
Many critically ill children require nasogastric (NG) tube
placement, and the result is essentially the same in all
patients, regardless of age. Tubes placed through the nose
place a patient at risk for obstruction of the ostia of the
sinuses and eustachian tubes. The presence of the tube is
thought to hinder the closure of the esophageal sphincter and
to promote the reflux of gastric contents, leading to a risk of
aspiration pneumonia. 59 Because 25% to 35% of children
younger than 6 months of age are thought to experience
some degree of reflux without the placement of a gastric
tube,61 the placement of a gastric tube significantly increases this risk.
A urinary catheter attached to a closed urinary drainage
system facilitates bacteremia in the host in a variety of ways.
During placement, the catheter will "push" or "drag"
urethral organisms into the bladder, and the indwelling
catheter enhances bladder colonization by serving as a
conduit for organism growth and movement. 69 Urine can no
longer flow through the urethra and flush microorganisms
from the body.
Diagnosis of a UTI may be challenging because the
infant or young child is often unable to communicate the
presence of symptoms. In addition, the child in the PICU
may often have multiple reasons for a fever or abdominal pain. 70 Children often have age-specific signs and
symptoms of UTIs 71 and experience more asymptomatic
bacteriuria than adults. 72 These findings pose an increased
risk of delayed recognition and treatment of UTI in
children. The diagnosis is established by urinalysis and
urine culture. Infection is defined as more than lOO,OOO
organisms per milliliter of voided urine, 1000 or more
organisms per milliliter from urine obtained by catheterization, or any organisms from urine obtained by bladder
aspiration.
The importance of handwashing cannot be overemphasized. Unfortunately, handwashing is often forgotten. Studies of intensive care units and outpatient facilities have
shown that physicians wash their hands less than 50% of the
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time before and after they examine a child. 73 Hands should
be washed before and after each patient contact.

Provide Nutritional Support
The link between nutritional status and immunocompetence
has been established 39 The PICU nurse has an active role in
determining the timing, route, and tolerance of nutritional
support. In the critically ill child, the GI tract is used to
provide nutritional support, if appropriate. The use of the GI
tract for enteral feeding, rather than parenteral nutrition, is
well documented as being advantageous because it decreases the incidence of bacterial translocation across the
gut lining. 74 In addition, infants with lactating mothers are
given breast milk as a component of their nutritional support
because of the many advantages of brea~t milk in mucosal
immunity.
If the child is able to take nutrition by mouth, encouragement of the child's food and fluid intake includes
consideration of the child's likes and dislikes, the manner in
which the child prefers food (fried versus boiled), and the
time at which the child is accustomed to eating. The PICU
nurse ensures that the child has a "safe time" to eat without
actual or perceived interruption, threat, or invasion. The
child's developmental needs are especially important to
consider in the promotion of nutritional intake.

Reduce Stress
Investigators of psychoneuroimmunology, the exploration
of the interactions between the brain and the immune system
and the influence on health, suggest that stress adversely
affects immune function. 75 .76 A growing body of evidence
has demonstrated an inverse relationship between stress and
immune function; the end result is an increased susceptibility to infection. 77 The immune system and nervous system
are interconnected by a complex system of chemical signals
in the form of cytokines and hormones. Through these
signals, each system communicates with and influences the
functioning of the other system. The immune system
communicates with the nervous system through cytokines
released by activated immune cells. The nervous system
influences immune system functioning through the action of
hormones such as ACTH released from the pituitary (under
the influence of the hypothalamus), norepinephrine released
from the sympathetic nerves, epinephrine released by the
adrenal medulla, and glucocorticoids released by the adrenal
cortex. 76 Data from animal studies suggest that stress,
unaccompanied by injury, depresses CMI. 78 The individual's cognitive, behavioral, and physical response to stress
may also modulate or amplify the effect of stress on the
immune system. In other words, stress alone may not be as
immunosuppressi ve as maladaptive coping to stress. 75 The
young child is particularly vulnerable to psychologic stress
because of limited or immature cognitive and developmental levels and lack of understanding of the critical care
environment and interventions 79
Reducing stress in the critically ill child can be a
challenge. Recognizing the child's cognitive and physical
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age and the associated developmental tasks and fears is the
first step in planning stress reduction for the child. A basic
stress-reducing intervention includes respecting the child
as an individual and respecting the right to privacy and
personal body space. Recognizing and accepting the child's
need for regression while providing as calm, caring, and
reassuring an environment as possible are vital to the coping
of the critically ill child and family. Reducing the stress
of parents and siblings has an indirect but beneficial effect
on the child and should be incorporated into the child's
plan of care.

Optimize Patient Comfort
Striving for and establishing comfort in the pediatric critical
care patient are important not only because of the bodymind link of psychoneuroimmunology but also in assisting
the child's relative degree of cooperation with the environment, staff, and nursing and medical regimens. Nurses often
play a pivotal role in determining the need for and the
adequacy of analgesics and sedative medication. Administration of analgesics, sedatives, and narcotics (opiates) aids
in comforting the child during physically and psychologically painful experiences. However, long-term use of these
medications may also alter immune function and host
defenses. The PICU nurse maintains the balance between
enhanced child comfort and overmedicating, which may
reduce immune function.

Prevent Infection
The Hospital Infections Program (HIP), a part of the CDC's
National Center for Infectious Diseases, has a major role in
providing information and guidance to hospital infection
control programs. Coordinated by the HIP, the National
Nosocomial Infection SurveiUance (NNIS) system collects
data on the incidence of nosocomial infections in more than
150 U.S. hospitals. The Hospital Infection Control Practices
Advisory Committee (HICPAC) was established in 199 I to
provide advice and guidance to the HIP and the CDC
regarding the practice of hospital infection control and
strategies for surveillance, prevention, and control. 80
Limit Exposure to Reservoirs. Prevention of infection can be facilitated by limiting the child's exposure to
reservoirs, which are environments in which organisms replicate and persist. The child's room and bedside area are
damp dusted64 and the floor mopped 12 every 24 hours and
monitored for standing collections of water or other liquids. 64 All containers of normal saline or sterile water for
irrigation purposes are labeled with date and time opened
and replaced every 24 hours. It is also important to avoid
contamination of these solutions during use. Humidity is
provided in the PICU environment for the benefit of the
infant and child's small airways and for reduction of organisms that thrive in dry environments. 64 Medical equipment
and supplies that must be kept sterile or aseptic include
medications, total parenteral and enteral nutrition, humidifiers, face masks, manual resuscitation bags, large-bore suction catheters, suction tubing, and canisters. 64 .6s Other po-

tential reservoirs include hand lotions,65 baby oil and bath
supplies, nonprescription ointments, and children's toys.
Proper handwashing decreases the transmission or reduces carriage of potential nosocomial pathogens by the
contaminated hands of healthcare workers. In general, hands
should be washed before and after patient contact; after
contact with body fluids and substances, mucous membranes, nonintact skin, and objects that are likely to be
contaminated; before performing invasive procedures; and
after removing gloves. 8o
In addition to the environment, supplies, and equipment,
healthcare workers, parents, siblings, and other visitors
within the critical care environment are potential exogenous
reservoirs. Some 15% to 20% of healthy individuals are
carriers of S. aureus in the nasal antrum and could
potentially shed these organisms into the environment. 6s
Healthcare workers and visitors may also be infectious with
other bacterial or viral organisms.
Visiting policies and traffic control measures must limit
unnecessary visitors and limit the PICU environment to
essential staff, patient family members, and significant
others. All persons entering the PICU (including pediatric
visitors) require compliance with strict hand washing procedures before and after patient visitation. SOa Thorough,
frequent handwashing remains the most important method
of preventing the transmission of pathogens between the
patient and healthcare team member or visitor. 12.64.65
Healthcare workers require protection from the significant infectious risks inherent in patient care; conversely,
patients and other heal thcare workers need to be protected
from exposure to healthcare workers with communicable
diseases. Integrating management and prevention strategies
to accomplish these two goals requires close collaboration
between hospital infection prevention and control programs
and occupational health departments.
A comprehensive employee health program does not
replace sound judgment in detennining exposure of infectious persons to critically ill infants and children. The nurse
has an active and vital role in patient advocacy and carefully
monitors self, team members, and visitors for evidence of an
infectious process. Patients with altered host defenses
should not be cared for or visited by infectious persons
without appropriate safety precautions. Guiding infectious
persons in delaying their visit or in handwashing and using
disposable masks in the child's room may lower the risk of
transmission. Unlike exogenous reservoirs, which are often
identified, disinfected, or eliminated, little can be done to
eradicate pathogens from the endogenous reservoir, the
patient 6S Many opportunistic organisms are present in a
patient's system and may cause infection in a patient in a
compromised state. 65 .81
Prevent Antigen Exposure. In addition to identifying the known allergies of the infant or young child,
recognition of the numerous substances that the child is
exposed to on a daily basis in the PICU and identification of
potential or actual antigens are critical. Most critical care
units minimize the presence of flowers, plants, and pets in
the unit and encourage other age-appropriate sources of
pleasure, such as mobiles, radios, and tape players. Flexi-
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bility and exceptions are common in the PICU environment
and are evident by the use of closed terrariums rather than
potted plants, changing water in flower vases every 8 hours,
or showing videotapes or photographs of pets in between the
planned visits by pets. Recognizing the presence of potential
antigens and vectors of infection is important. Awareness of
their impact on the child and other patients in the unit and
planning interventions accordingly are vital.
Consider the Cost/Benefit Ratio of Invasive
Techniques. Exposure to invasive medical devices or
procedures represents a significant risk for nosocomial
infection. Despite the risks, these devices and procedures
are an integral part of the pediatric critical care environment
and will continue to be in the future. Assisting in the careful
comparison of the benefits versus the risks of these invasive
techniques is important because most preventable infections
are related to the use of invasi ve devices or procedures.
Once the decision is made that the benefit outweighs the
risk, care is taken to follow institution-specific standards for
invasive techniques and procedures, as well as the care and
maintenance of the invasive devices.
Survey for and Identify Infection. Monitoring
fever patterns is essential to assist in the identification of the
cause of infection. With the exception of the newborn and
young infant, the body's ability to mount a febrile response
usually remains intact and therefore is the best indicator of
infection. 82 Gram-negative sepsis is often accompanied by a
pattern of intermittent fevers. whereas a slowly rising but
steady fever may indicate the presence of a fungal infection. 82 Fever may also be a manifestation of a reaction to
certain medications, such as antibiotics. In this situation,
fever closely follows the medication administration, and the
medication may temporarily be discontinued to evaluate
whether the fever resolves. Close attention to the proper use,
method. and care of the temperature-taking device is
prudent because treatment decisions are made with the data
obtained from temperature taking.
Identification of the source of infection becomes a
primary concern in the presence of the febrile patient.
Particular attention is targeted toward the lungs and the skin
(especially sites of intravenous insertion access, and perioral
and perirectal areas). All indwelling catheters, whether
suspected or not, are sampled for culture. In addition, two
peripheral blood samples are obtained from separate venipuncture sites. Other cultures the nurse may anticipate
include routine urinalysis and urine culture. a stool examination and culture (if diarrhea is present), and a chest
radiograph. In the febrile neutropenic patient, these cultures
and diagnostic tests are anticipated, despite the absence of
other clinical symptoms 83

Treat Infection
Antibiotic therapy is anticipated in a critically ill child with
signs and symptoms of infection. Recognition of the goal of
antibiotic therapy by all members of the healthcare team is
important. This includes knowledge of whether the drug is
empiric or definitive therapy for a suspected or an established infection. 84 The properties of an ideal antibiotic are
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demonstrated efficacy through controlled clinical trials,
nontoxic effects, no alteration in normal patient or environmental flora, facilitation of rapid discharge of the patient
from the hospital, and inexpensive cost.
Antimicrobial Therapeutics. Antibiotics are among
the most widely prescribed drugs in the acute care setting,
often accounting for 15% to 25% of inpatient pharmacy
budgets. The rational use of antibiotics in the ICU continues
to present a challenge to the healthare provider. Antibiotics
are typically used in three basic ways: (I) for treatment of
primary infections; (2) for treatment of secondary or
iatrogenic infections; and (3) for prophylaxis of potential or
anticipated infections. 85 Treatment rationales include prophylactic treatment, direct or therapeutic treatment, presumptive treatment, and empiric treatment.
Antibiotic selection is an ongoing process with continual
evaluation of the indications for antibiotic therapy, the
patient's response, and laboratory data. 84 During the course
of therapy, additional information is used to adjust the
antibiotic regimen to ensure coverage against all suspected
or identified microorganisms. The patient's response or lack
of response and side effects may lead to the adjustment of
the antibiotic regimen. This may result in an antibiotic that
has more or all the properties of an optimal antibiotic.
Broad-spectrum antibiotics are usually begun immediately after careful initial examination and collection of
specimens for culture and sensitivity testing. Selection of
broad-spectrum antibiotics is often based on organisms
typically found in a particular institution, whether the
patient is neutropenic and the duration of the neutropenia,
organisms associated with unique patient populations, and
the underlying pathophysiologic condition (e.g., renal failure). Broad-spectrum antibiotic therapy is never a substitute
for the careful evaluation of the suspected infection.
Pretreatment specimens are always desirable to determine
the infectious organism; therefore all desired cultures are
accurately obtained in a timely fashion. 52 Once the appropriate antibiotic regimen is chosen, the medication must be
administered as soon as possible. Regardless of the method
of antibiotic delivery (slow intravenous push, metered
chamber, or syringe pump), close attention to the rate of the
administration, location of administration. and the dead
space of the intravenous tubing ensures that the child
receives the drug completely and consistently.
Antibiotic serum drug concentrations (SDCs) are obtained, when appropriate. These are often ordered by the
practitioner as peak and trough drug levels. Results are used
to adjust drug doses to maximize therapeutic efficacy (to
ablate microorganism growth) while minimizing or avoiding toxicity. The determination of when a SDC is obtained
is based on the underlying condition of the patient and the
point at which the drug reaches a steady-state condition. In
the clinical setting, this is often defined according to a
specific drug regimen (e.g., following the third administered
dose of gentamicin). However, in the critically iII child or
the child with organ dysfunction resulting in altered
elimination of that drug, SDC may be obtained after the first
administered dose. To reach and maintain a therapeutic
SDC, it is imperative that all antibiotic doses be given on
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schedule, regardless of other scheduled diagnostic procedures or regimens.
SDC specimens are accurately collected and labeled to
ensure that the derived data are accurate. The actual time the
specimen was drawn, as well as the antibiotic infusion start
and completion times, should be noted directly on the
laboratory specimens. Administration techniques can produce misleading SDC results if the delivery time is
miscalculated86 The administration time, administration
method, infusion duration, specimen collection container,
collection time, and concomitant administered medications
influence the SDC obtained.
Trough levels are always obtained before administration
of an antibiotic dose. Peak levels vary depending on the
class of antibiotic; for example, aminoglycoside peak
concentrations are obtained from 30 to 60 minutes after a
30-minute infusion, whereas vancomycin peak concentrations are obtained 60 minutes after a 60-minute infusion. If
toxicity is suspected, SDCs may be obtained at any time in
the dosing schedule.
Many procedures are available for testing the susceptibility of various microorganisms to antiinfective drugs. The
greatest dilution of antibiotic associated with the inhibition
of bacterial growth is called the minimum inhibitory
concentration (MIC). If the sample can be diluted further
without a recurrence of bacterial growth, then this dilution
is also the minimum bactericidal concentration (MBC) for
the drug. MIC and MBC values provide some indication of
the potency of the antibiotic with regard to the infecting
pathogen.
Simultaneous use of two or more antimicrobials is
applied to achieve a broad spectrum of antimicrobial
activity when empirical therapy is initiated to minimize the
possibility that drug resistance might emerge to a single
antimicrobial agent and to exploit synergistic antimicrobial
properties.
Antimicrobial-Resistant
Microorganisms. The
rapid emergence of pathogens resistant to multiple anthnicrobial agents (e.g., vancomycin-resistant enterococci,
gram-negative bacteria producing extended-spectrum
/3-lactamases) and the widespread dissemination of these
resistant microorganisms constitute an unprecedented crisis
for hospitals worldwide. The mechanisms involved in the
emergence and spread of antimicrobial resistance are
complex but are facilitated undoubtedly by intense selection
pressure caused by overuse and misuse of antimicrobial
agents in hospitals, particularly newer broad-spectrum
agents. 86a Dissemination of resistant strains is facilitated by
poor compliance with handwashing and isolation precaution
procedures.
At least eight distinct mechanisms of antibiotic resistance
have been described in bacteria. Resistant enterococci to
vancomycin has been classified as A, B, or C based on levels
of resistance to vancomycin. One method of resistance is
enzymatic inhibition, which is due mainly to the production
of enzymes that inactivate antibiotics, cause alterations of
bacterial membranes (both outer and inner membranes), and
alter binding capacity of the antibiotic. Further resistance
has been demonstrated by enteric gram-negative organisms,

which have the capacity to actively efflux tetracycline back
across the cell membrane. Resistance to a wide variety of
antimicrobial agents, including tetracyclines, macrolides,
and aminoglycosides, may result from alteration of ribosomal binding sites. Failure of the antibiotics to bind to its
target site or sites on the ribosome disrupts its ability to
inhibit protein synthesis and cell growth. Large glycopeptide molecules prevent the incorporation of precursor
antibiotic targets, such as vancomycin in the cell wall.
/3-Lactam antibiotics inhibit bacteria by binding covalently
to penicillin-binding protein in the cytoplasmic membrane.
In gram-positive bacteria; resistance to /3-lactam antibiotics
may be associated either with a change in the affinity of
penicillin-binding protein for the antibiotic or with a change
in the amount of penicillin-binding protein produced by the
bacteri urn. 87
New drug discoveries have remained one step ahead
of the bacterial pathogens. Nonetheless, the rapid evolution of resistance has limited the duration of the effectiveness of specific agents against certain pathogens. The
best hope for the future is the development of a greater
understanding of how antimicrobial resistance spreads
and the implementation of effective infection control
strategies. New antimicrobial agents have had a substantial impact in decreasing human morbidity and mortality rates over the past half-century. Expanding surveillance
of antibiotic resistance determinants and exercising caution
in dispensing antibiotics to maximize their continued
efficacy are critical to the continued effectiveness of these
agents. S7
Antifungal Drugs. Amphotericin B is considered by
most to be the gold standard for systemic antifungal drugs.
It is the agent to which all new antifungal drugs must be
compared before clinical acceptance. Fluconazole is the first
in a series of new triazole antifungal agents providing an
effective and less toxic therapy than amphotericin B. Many
other antifungal agents are available, including f1ucytosine,
itraconazole, griseofulvin, synthetic imidazoles, and topical
nystatin.
Antiviral Drugs. Antiviral drugs such as acyclovir
and ganciclovir are effective in the treatment of localized
and disseminated herpes simplex virus infections. Amantadine and rimantadine have been used against influenza A
viruses. Considerable controversy surrounds the use and
true clinical effectiveness of ribavirin. Ribavirin may be of
clinical value in the treatment of severe lower respiratory
tract viral infections caused by influenza A and B viruses
and respiratory syncytial virus. Currently the American
Academy of Pediatrics suggests use in selected patient
population only (see Chapter 19).
Antiprotozoal Drugs. Pentamidine isethionate is
considered a second-line drug for the treatment of P. carillii
pneumonia in patients who fail to respond to co-trimoxazole
(trimethoprim-sulfamethoxazole) and used increasingly in
patients with AIDS.
Antimalarial Drugs. Chloroquine is used primarily for the treatment of malaria; however, today many
chloroquine-resistant and multi drug-resistant strains of malaria exist. Quinine is also indicated for malaria prophylaxis
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or in the treatment of the acute disease; however, the drug is
much less effective and more toxic than chloroquine. 88

Immunotherapy and Immunomodulation
Immunotherapy involves the use of immune factors, alone
or in combination, to enhance immunity or prevent unwanted physiologic responses and tissue destruction. These
factors include immunoglobulin (e.g., antitoxins, monoclonal antibodies), WBC transfusions, and cytokines. 8iotherapy is a broad term used to refer to various biologic
treatment modalities employed to augment, restore, or
modify the immune response or hematopoiesis. Through
advanced biotechnologic methods, such as recombinant
engineering techniques, many naturally occurring immunologic substances in the body are produced in sufficiently
large quantities for clinical trials and therapeutic application. 89 •9o Biotherapy may be used to augment or restore the
immune system in the treatment of cancer, immunodeficiencies, HIY disease, and septic shock. Biotherapy is also used
to suppress or restrict the immune response, such as in the
prevention, diagnosi s, or treatment of graft rejection and
graft versus host disease (GYHD) or in the treatment of
autoimmune disease. Biotherapy has also become a new tool
to reverse drug toxicity. Certain forms of biotherapy have
nonclinical applications; they are used in the laboratory to
diagnose diseases or infections, determine blood and tissue
types, and differentiate between B cells and T cells.
An important nursing consideration for the use of
biotherapy, because it is often investigational, is to ensure
that the informed consent process is complete. In addition to
the parents' or guardians' consent, it is important to obtain
the child's assent, when appropriate, to participate in the
research process and protocol.
Another significant nursing implication in caring for the
child receiving biotherapy is knowledge about the contraindications, complications, and side effects. In general, the
long-term effects of biotherapy are unknown; hence, this
therapy is used only when clearly indicated, part of a
research protocol, or for compassionate use. Complications
of therapy are variable and may be acute or chronic, nearly
universal, or rare. Each biotherapy agent has unique side
effects, but most agents are associated with a flulike syndrome of fever, chills, myalgia, headache, and fatigue.
Biotherapy generally involves the administration of one
form or a combination of the following: (I) immunoglobulins; (2) cytokines, such as colony-stimulating factors
(CSFs), interferons, or interleukins; (3) monoclonal antibodies (MoAbs); (4) genetically engineered enzymes; (5) autologous activated immune cells (tumor-infiltrating lymphocytes [TILs] and LAK cells); and (6) gene transfer therapy.
Each category of biotherapy is discussed individually, but as
with all other immunologic events, these substances do not
act independently or in isolation.
Immunoglobulin. Intravenous
immunoglobulin
(TYIg) is a solution of immunoglobulin contammg many
antibodies normally present in adult human blood. It is
obtained from plasma-pooled whole blood of thousands
of diverse adult donors, ensuring a broad spectrum of
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antibodies. Immune globulin therapy is rapidly shifting
from standard pooled preparations to specific immune
globulin preparations. High-titer specific immune globulin
preparations are prepared by screening or immunizing
donors. Examples include cytomegalovirus immune globulin (CMY-Ig), respiratory syncytial virus immune globulin
(RSV-Ig), and varicella-zoster immune globulin (YZIg).
Hepatitis B immune globulin (HBIg) is used to prevent
hepatitis B infection, and YZIg can prevent or modify the
course of chickenpox in immunocompromised patients.
Intravenous immunoglobulin. More than 90% of
IYIg solution consists of IgG. The manufacturing process
ensures that the levels of IgA and IgM are low to reduce the
rare incidence of anaphylaxis (predominantly resulting from
anti-IgA antibodies) and hemolytic transfusion reaction
(predominantly resulting from IgM antibodies of the ABO
and Rh blood system).
IYIg has many clinical applications, but the mechanism
of action may vary related to the disease state for which the
IYIg is given. Table 15-9 illustrates the various disease
states and clinical conditions for which IYIg has been
administered; however, the efficacy in many of these states
remains unclear. 91 It was initially developed to provide
passi ve immunity and prevent infections in persons with
primary immunodeficiencies who were unable to produce or
maintain adequate level s of IgG.
IYIg is used in many other clinical conditions because it
has immunomodulatory effects that are not well characterized but are the focus of intense research. Evidence of these
immunomodulatory effects has led to the use of IYIg in the
treatment of inflammatory or autoimmune conditions such
as Kawasaki syndrome or, rarely, idiopathic thrombocytopenic purpura (ITP).
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Several brands of IVIg are available in the United States;
all are purified and processed to remove or inactivate HIV,
hepatitis B virus, and other microorganisms. Dosages for
IVlg may vary tenfold depending on the disorder for which
it is being administered. IVIg is given by slow infusion
usually over several hours, with an initial infusion rate of 0.5
mI/kg/hr for 30 minutes, gradually increased at subsequent
15- to 3D-minute intervals to a maximum of 2 to 4 ml/kg/hr.
The patient should be observed for acute reactions; slowing
or stopping the infusion for 15 to 30 minutes usually
alleviates the reaction.
As the result of a significant number of adverse-event
reports of renal dysfunction and acute renal failure associated with the administration of IVIg, the U.S. Food and
Drug Administration recently published recommendations
for IVIg use. Preliminary evidence suggests that IVIg
products containing sucrose may pose a greater risk for this
complication. 92
Respiratory syncytial virus immune globulin.
RSV-Ig contains high titers of RSV immune globulin.
Concerns about the requirement of monthly administration
requiring intravenous cannulation and infusion over several
hours and the fluid volume and protein load have restricted
the use of RSV_Ig. 92a Efforts have been directed to the
development of a monoclonal IgG antibody and prophylaxis
against RSV. A randomized, multicenter, double-placebocontrolled trial involving 1502 premature infants with or
without chronic lung disease receiving palivizumab prophylaxis reduced the incidence of RSV hospitalizations by 55%
compared with placebo recipients (p <0.(01).93 Current
recommendations include considering palivizumab in neonates who meet predefined criteria. Palivizumab is not
indicated for infants with congenital heart disease and for
the treatment of RSV disease.
CMV-Ig. CMV-Ig ensures high titers of CMV-specific
antibody and is highly efficacious in the prevention and
treatment of CMV infections in kidney and bone marrow
transplant patients. 94 Several products with a high antibody
titer to a specific pathogen have been available for many
years to prevent, modify, or treat a variety of infections. 73
Cytokines. Cytokines are soluble substances produced
primarily by cells of the immune system that act as powerful
communication signals between cells. In this sense, cytokines function much like hormones or neurotransmitters.
Cytokines regulate or influence the immune response by
affecting a variety of cellular activities, especially in regard
to HI and CMI. Like antibodies, cytokines are generally
released in response to the presence of antigen 95 ; however, unlike antibodies, cytokines are not specific to a
particular antigen.
Cytokines can be categorized as CSFs, interferons, and
interleukins. Other cytokines, such as TNF-a, Iymphotoxin (TNF-~), and IL- I, have unique effects that defy
categorization.
Colony Stimulating Factors. CSFs are involved
principally in the production of neutrophils and monocytes. They were discovered because of their ability to
stimulate the formation of colonies of granulocytes, monocytes, and macrophages in cultured bone marrow cells and

were named according to the primary cell colony type that
they elicited.
CSFs are a group of glycoproteins that are extensively
involved in hematopoiesis, the process by which blood cells
proliferate, differentiate, and mature. 96 ,96a Each CSF binds
to and activates the corresponding receptors found on the
surface of its target cell (each CSF may have a variety of
target cells).96,96a Upon binding to its receptor membrane,
the CSF signals the target cell to initiate particular intracellular processes, such as protein synthesis and replication of
genetic material, which leads to differentiation, cloning,
maturation, and, in some cases, functional activation of that
target hematopoietic cell.96,900
Recombinant CSFs, produced by genetic engineering,
have three major therapeutic applications. Two applications
are to restore hematopoietic function by raising cell counts
from suppressed levels and to augment hoSi defense against
infection by enhancing the sensitivity and function of
immune cells. The third application is an indirect role in
containing or eliminating malignant cells. By far the most
common applications of CSFs are to reverse anemia,
thrombocytopenia, and neutropenia following cytotoxic and
radiation therapy during the treatment of cancer. Bone
marrow suppression, with its consequent risks of lifethreatening infection or bleeding, is the primary doselimiting factor of cytotoxic drugs for the treatment of cancer.
CSFs accelerate bone marrow recovery, which reduces the
period of severe neutropenia and thrombocytopenia, thereby
permitting higher doses of chemotherapy and possibly
higher rates of remission or cure. Research is ongoing in
using various CSFs for these multiple purposes.
Five major endogenous human CSFs are granulocyte
CSF (G-CSF), granulocyte macrophage CSF (GM-CSF),
macrophage CSF (M-CSF), interleukin-3 (IL-3), and erythropoietin, Table 15-10 reviews individual CSFs according to
their cellular source, action, and therapeutic application.
Interferons. Interferons are substances produced
by the immune cells primarily in response to viral infection.
All of the interferons are antiviral, antiproliferative (cloning), and immune modulating, but the different types of
interferons may vary in efficacy when exerting these effects.
Like other biologic response modifiers (BRMs), interferons
cause a flulike syndrome. 97 ,98 Table IS-II lists the various
interferons with their respective cellular sources, actions,
and therapeutic applications in pediatric critical care.
Interleukins are a form of BRMs that have received much
attention. More than 17 interleukins have been identified,
and their unique function and contribution to the immune
response are not completely understood. IL-2, the most
commonly administered interleukin, increases lymphocyte
proliferation (cloning) and NK cell activity.99.101
Lymphokines and Monokines. During infection,
genes for nearly all the cytokines are expressed. The
cytokine family, through a complex web of interactions,
functions to initiate and then regulate both proinflammatory
and antiinflammatory responses. 102 Considerable experimental and clinical interest has focused on the proinflammatory cytokines TNF-a and IL-I as important early
mediators in the pathogenesis of sepsis and meningococcal
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Selected Colony-Stimulating Factors (CSFs)
Cellular Source

Adion

Therapeutic Application

Renal cells

Stimulates production and speeds
maturation of erytbrocytes

Reverse anemia related to:
• Chronic renal failure
• HIY disease
• Zidovidine therapy for

T cells

Stimulates growth of precursors to
granulocytes, macrophages, RBCs,
platelets. and mast cells

Reverse thrombocytopenia related to:
• Cancer therapy

Monocytes
Macrophages
Endothelial cells
Fibroblasts

Stimulates growth and activation of
neutrophils

Reverse neutropenia related to:
• Cytotoxic therapy
• Radiation therapy
HIV disease
• Congenital neutropenia
• Cyclic neutropenia

Monocytes
Macrophages
Endothelial cells
Fibroblasts

Stimulates growth and activation of
monocytes

Expedite boile marrow recovery
following autologous bone marrow
transplant

T cells
Endothelial cells
Fibroblasts

Stimulates the growth and activation
of neutrophils, eosinophils, and
macrophages
Enhances ability of macrophages
and neutrophils to ingest bacteria
and kill antibody-coated tumor
cells

Expedite bone marrow recovery
following autologous bone
marrow transplant

my

- .: ta from Herberman RB, ed: Cetus immllllOprimer series. Part 3. Cytokines, Emoryville, Calif, 1989, Cetus Corporation.
::"Jt is relatively easy to transfuse RBCs to reverse anemia or platelets to reverse thrombocytopenia. In contrast, granulocyte transfusions to reverse

'. Ulropenia are logistically difficult to perform. In addition. their therapeutic efficacy has not been reliably established.
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Selected Interferons
Adion

T, B, NK cells
Macrophages

Enhance NK activity
Antiviral
Induces HLA-I antigen expression
Induces fever
Generates cytotoxic T-cells
Induces macrophage killing of tumor cells

Non-Hodgkin's lymphoma
Hepatitis B
HIV disease
Under investigation in:
Hepatitis B or C

Fibroblasts
Macrophages
Epithelial cells

See <x-interferon actions

Multiple sclerosis

T and NK cells

Antiviral
Induces HLA-I antigen expression
Induces microorganism and tumor cell killing
of macrophages
Regulates action of certain cytokines
Increases NK cell activity
Induces production of T cell suppressor
factor
Increases expression of Fc receptor

Chronic granulomatous disease
Under investigation in:
HIV disease
Rheumatoid arthritis
Chronic mycobacterial infections
(Mycobacterium avium)

Fibrobla~ts

Epithelial cells

...

Pediatric Critical Care
Therapeutic Application

Cellular Source

ata from Herberman RB, ed: Cetus immunoprimer series. Part 3. Cytokines, Emoryville, Calif, 1989, Cetus Corporation.
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disease, as demonstrated by a correlation between morbidity
and mortality and high serum levels of TNF-a and IL-l. 103
The basis for the potential therapeutic use of these two
cytokines in human disease states involves two clinically
distinct hypotheses: (I) excessive cytokine production
results in host immune injury leading to severe shock, and
(2) deficient cytokine production renders a host susceptible
to infection by invasive pathogens. Research and future
clinical trials will attempt to inhibit endotoxin release or
limit T F-o. and IL- I production and function. Current
clinical trials are also focusing on the TNF-o. and IL-l
synthesis with the administration of corticosteroids either
before or during antibiotic administration and the use of
pentoxifylline a methylxanthine derivative to block TNF-o.
transcription and production. 103
Monoclonal Antibodies. MoAbs are laboratoryproduced antibodies for a single destiny antigen. The
process in which MoAbs are produced in the laboratory is
reflected in Fig. 15-9. MoAbs are used to prevent, diagnose,
and treat graft rejection and GVHD; perform diagnostic
testing; treat disease (e.g., cancer, autoimmune disease); and

monitor response to treatment to eliminate toxins and
reverse drug toxicity. Each therapeutic application of
MoAbs is discussed separately.
The use of monoclonal antiendotoxin antibodies to
inhibit the binding of endotoxin to its target cell is
promising although more effective if given earlier during
sepsis syndrome. 104 Anti-T cell MoAbs, such as OKT3,
are effective agents widely used in heart, liver, pancreas, and bone marrow transplants to prevent, diagnose,
or treat graft rejection or GVHD. To prevent graft rejection,
OKT3 is administered to prevent the child's mature T cells
from rejecting the grafted or transplanted organ. To
prevent GVHD in bone marrow transplant patients, the
donor marrow is incubated with anti-T cell MoAbs
before the marrow is infused into the recipient to purge
the donor marrow of immunocompetent T cells. MoAbs
can also be used to monitor subsets of T cells at the site
of organ graft to assist in the diagnosis or monitoring of
graft rejectionl05.106
MoAbs may also be used on serum, urine, and stool
samples to diagnose infections with microorganisms such as

Cells fuse into
a hybridoma
U
Antibody-producing
plasma cell

"~l
'<;.
II

Cancerous
plasma cell

Monoclonal
antibodies

Fig. 15-9 Target antigen is injected into a mouse, stimulating the mouse plasma cells to produce
antibodies to that destiny antigen. Mouse plasma cells are then harvested and fused with inunortal
laboratory-grown plasma cell. These cells are then cloned and referred to as hybridornas. This hybridoma
will secrete the "made-to-order" antibody for an indefinite period. Through this process, research has
mimicked the immune system's humoral immuniry. (Adapted from Schindler LW: The immlllle
system-how it works. United States Department of Health and Human Services, Bethesda, Md. 1992, NIH
publication number 92-3229. p. 22.)
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herpes simplex virus, streptococci, and Chlamydia. In
addition, MoAbs assist in the identification of cells and
tissues (e.g., B cell and T cell differentiation or HLA or
blood typing).
MoAbs to various tumor antigens or tumor products can
be used to confirm the diagnosis of certain types of cancers
(glioma, cancer of the pancreas, lung, kidney, and others). A
radioactive tracer can be attached to MoAbs so that after the
MoAbs are administered, a body scan may reveal where the
cancer is located within the body.
Antitumor MoAbs can also be used therapeutically.
They attach to tumor cells, opsonizing these cells, and
enhancing the tumor cells' destruction. Antitumor antigen
MoAbs that are attached to toxins are called conjugated
MoAbs. Often these conjugated MoAbs are combined with
radioactive or other agents to assist in the treatment of
various cancers, such as acute lymphocytic leukemia. In
theory, these will attach solely to the tumor cells rather
than harming healthy cells. 107
More commonly in the PICU, MoAbs are used to reverse
drug toxicity or minimize toxic effects. For example, in a
child experiencing digoxin toxicity, the MoAb Digibind
"binds" to the excess digoxin, preventing it from exerting
its toxic effects. MoAbs to microbe toxins have been
developed against Escherichia coli and P. aeruginosa to
name a few. Murine MoAbs against TNF may improve
survival in certain patients; however, at this time, clinical
usefulness is limited. IDS
Integrins and Selectins. Neutrophil adherence to
and migration through the capillary endothelium is a critical
early event in the acute inflammatory response. The
adhesive interactions between leukocytes and endothelial
cell surfaces are regulated by two families of glycoproteins:
the integrins and the selectins. Monoclonal antibodies to
integrins and selectins are being tested in animal models. 103
Genetically Engineered Enzymes. Some diseases
affecting children occur as a consequence of genetic defects
that result in the lack of one or more key enzymes for cell
growth and metabolism. For such diseases, genetically
engineered enzyme replacement therapy may halt the
disease process. This involves administering the deficient
enzyme in adequate amounts. Because such endogenously
administered enzymes may last only a short time within the
body, molecules such as polyethylene glycol (PEG) can be
attached to the enzyme to prolong its half-life. 109
Autologous Activated Immune Cells. LAK cells
and TILs are forms of biotherapy that are undergoing
investigation as a treatment of cancer. In some clinical trials,
the cells have effectively produced tumor regression in
cancers that were unresponsive to conventional therapy.
Both forms of therapy involve removing lymphocytes from
a person with cancer, activating these cells with IL-2, and
then returning the activated cells to the patient. Theoretically, either type of activated cell would be expected to lyse
tumor cells while sparing normal cells.
In LAK cell therapy, the patient is first given IL-2 and
then undergoes pheresis in which lymphocytes are removed.
These lymphocytes are incubated with IL-2 and then
returned to the patient in the hope that these cells will attack
the tumor. TILs are normal lymphocytes that are harvested
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directly from the patient's malignant tumor. Thus in contrast
to LAK cells, TILs are theoretically "programmed" against
the tumor cells from which they are found. TILs are also
incubated with IL-2, stimulated to clone, harvested, and
reinfused into the patient. 110.111

ALTERATION IN IMMUNE FUNCTION
Transient Immune Dysfunction
Etiology. The critically ill child often experiences
iatrogenic interference to host defenses. Common PICU
diagnostic and therapeutic interventions interfering with
host defense and immunologic function include anesthesia
procedures 112.113; pharmacologic interventions such as neuromuscular blockers, narcotics, sedatives, and barbiturates;
immunosuppressive therapies such as chemotherapy, radiation, and corticosteroids; and extensive blood component
administration. 114 The child is also subjected to numerous
invasive procedures in the PICU, such as tracheal intubation, and catheterization or cannulation of body orifices and
cavities. Each of these stressors disrupts the child's physical,
mechanical, and chemical barriers and increases the risk of
nosocomial infection.
Transient immune dysfunction may result indirectly from
the cause for the child's admission to the PICU. Severe
musculoskeletal trauma, thermal injury, or major surgery
are examples of overwhelming tissue injuries that can produce transient immunocompromise. Regardless of the type
of tissue injury (trauma vs. thermal injury), the resultant
immunocompromise is similar and involves all components
of the immune system. Infection is the most frequent fatal
complication after major tissue injury78.115; the more severe
the injury, the greater the immune system dysfunction and
the higher the risk of sepsis and death. 78 Every investigated
component of the immune system has revealed an alteration
in function after major tissue injury.
Incidence. In addition to penetration of the natural
barriers as described earlier, the younger the child in the
PICU, the higher the risk for infection. Infants I month old
or younger have a 2 to 3 times higher risk for infection than
patients who were at least 2 years 01d. 116
Several studies of nosocomial infections in hospitalized
patients suggest that infection rates are actually lower in the
pediatric patient population compared with adults. II7- 120
The cumulative incidence of nosocomial infections (number
of nosocomial infections per 100 discharges) for pediatric
services and normal newborn nurseries is lower than for
most other services. Length of hospitalization is an important factor in assessing rates of nosocomial infection
because the cumulative probability that an indi vidual will
experience at least one nosocomial infection increases with
increasing exposure to the hospital. To minimize the effect
of differences in length of hospitalization, rates of nosocomial infection are expressed as an incidence density (the
number of nosocomial infections per 1000 patient days).121
The majority of nosocomial pneumonias are caused by
bacteria and are associated with mechanical ventilation. 12la
The rate of ventilator-associated pneumonia has been
reported at 6 per 1000 ventilator days,122 which includes
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viral causes of pneumonia. Mechanical ventilation is a
major risk factor not only for nosocomial pneumonia but
also for sinusitis and otitis media because the nasotracheal
tube interferes with normal drainage of the ostia of the
sinuses and the eustachian tube. 121 The majority of nosocomial pneumonias are polymicrobial and often include both
gram-positive and gram-negative bacteria. The pathogenesis
of ventilator-associated pneumonia is complex but can be
reduced to two general mechanisms: aspiration of microorganisms colonizing the stomach and oropharynx and inhalation of contaminated aerosols.
Rates of bloodstream infection associated with central
venous catheters in PICUs are reported to be 8 per 1000 central line days. This is higher than rates reported in adult
ICUS. 122 These data do not distinguish rates of infection
associated with specific catheter types, nor do these distinguish which catheter is the source of the infection in patients
with multiple catheters. A recent review suggests that rates
of bloodstream infection are lower in totally implanted (0.1
to 0.7 infections per 1000 catheter days) than tunneled (0.4
to 7.8 per 1000) catheters. 123 Arterial line-related septicemia ranges from 0% to 4%124.125 depending on populations,
definitions of infection, practices related to insertion, and
duration of use. 126 Current information is not sufficient to
state whether the site of insertion of central venous catheter
affects the risk of infection. Nearly a third of infections are
caused by coagulase-negative staphylococci. Other grampositive bacteria, including S. aureus and Enterococcus species, account for another third.
Patients undergoing surgical procedures are at risk for a
variety of nosocomial infections. A I-year study of more
than 600 pediatric patients undergoing surgical procedures
found that surgical-site infection was the most common
nosocomial infection after surgery, occurring in 3.5% of
patients. 127 A study of more than 300 children undergoing cardiovascular surgery found an infection rate of
7.1%.128 Infection rates were higher among patients in
whom the sternum was left open after surgery (27.6% in
patients with open sternums vs. 5% in patients with closed
sternums), although this occurrence may be related to
severity of illness.
UTls are not the most common nosocomial infection in
the pediatric population, as they are in the adult population,66.69 but are second to upper respiratory tract infections.
UTIs represent only 10% or less of all hospital-acquired
infections in children in the National Nosocomial Infections
Surveillance System report,122 although the incidence is
higher in the critically ill child.
Pathophysiology. The interference of the lines of
defense create an environment that facilitates the development of nosocomial infection. Malnutrition leads to a
mosaic of changes affecting both nonspecific and specific
host defenses.129.130 Factors that interfere with adequate
tissue perfusion and oxygen delivery, such as hypoxemia,
shock, and hypothermia, affect inflammatory response,
phagocytosis, and wound healing. The efficiency of neutrophils in killing bacteria is related to a level of oxygen in
the tissues not just in the circulation. For example, because an activated phagocyte's oxygen consumption increases 10 to 20 times over its resting metabolism,131 it must

have access to adequate oxygen to perform its phagocytic
functions.
All patients with chronic renal failure, regardless of age,
experience a high incidence of infection, with approximately 40% of patients dying of an infectious complication. 132 Although data are inconclusive and often contradictory, many factors in the patient with renal failure are
thought to contribute to altered host defenses and increased
susceptibility to infection.
The primary immune abnormality seen in patients with
both acute and chronic renal failure is lymphocytopenia and
a sequestration of lymphocytes to the bone marrow. 132
Apparently the uremic state and its effect on the blood sera
are responsible for the defects seen in cellular immunity.
Washed uremic lymphocytes incubated in normal blood sera
respond normally, as opposed to lymphocytes in uremic
blood sera. 132
Hypothermia and cardiopulmonary bypass are often
used during cardiac surgery. Induced hypothermia has also
been associated with an increased risk for bacterial infection. 78 • 133 Laboratory studies reveal that the increased
risk of infection may be a result of depressed neutrophil
migration in low-temperature states. 134
Gram-positive cocci account for approximately one half
of the isolates of surgical-site infections. 134a S. aureus is the
most common isolate, but coagulase-negative staphylococci
and Enterococcus species are also common. Cardiopulmonary bypass can be viewed as an iatrogenic cause of immune
dysfunction. The movement of the immune cells and
proteins through the heart-lung bypass machine causes
cellular destruction, complement activation, and other
changes that result in impaired immune function 78 It has
been reported in animals and adults that the rapid flow
through the bypass machine results in decreased complement levels, decreased immunoglobulin levels, increased
leukocyte adherence, depressed phagocytosis, and a transient neutropenia. 135 Similar findings are reported in children after cardiac surgery.136 Depressed complement levels
have been noted postoperatively in children and were still
observed 24 hours after surgery.136 This finding is in
contrast to the observation in adults of a return to
preoperative complement levels within 4 hours postoperatively.137 Other immunologic findings following pediatric
cardiac surgery include lymphopenia, decreased helper
T cells, and decreased levels of IgG and IgM. 136 Minimal
information is available on the effect of extracorporeal
membrane oxygenation (ECMO) or cardiac assist devices
on host defenses.137n.137b
Critical Care Management. Malone and Larson 138
demonstrated the introduction of the Occupational Safety
and Health Administration (OSHA) Blood-borne Pathogen Exposure Control Plan, and Body Substance Isolation and a barrier hand foam were associated with a
significant reduction in nosocomial infection rates. The CDC
has developed a comprehensive guideline for the prevention
of nosocomial pneumonia. 139 Empiric antimicrobial therapy
of nosocomial pneumonia in the patient supported on
mechanical ventilation should be guided by Gram stain of the
endotracheal aspirate. Treatment duration has not been
studied, and, generally, 10 days of therapy are given. 121
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Potential bloodstream infections are evaluated with at
least two blood cultures, including at least one blood culture
drawn by venipuncture before the institution of antibiotic
therapy. Empiric antimicrobial therapy for suspected bloodstream infection while awaiting culture results is based on
local knowledge of the relative frequency and susceptibility
patterns of nosocomial pathogens. Empiric treatment should
include an antibiotic effective against gram-positive bacteria
and most gram-negative bacteria.
The majority of critical care management focuses on
maintaining external barriers. Review the previous section
for specific interventions that protect and enhance the first
and second lines of defense.

Primary Alterations in Immune Function
Etiology and Incidence. More than 40 primary immune deficiency disorders are currently recognized by the
World Health Organization. Most are clinically heterogeneous and probably represent similar manifestations of separate defects in a particular cellular or molecular pathway.
The overall incidence of primary immune deficiency has
been estimated at approximately I case in 10,000 individuals in the population. Antibody deficits constitute approximately 50% of immune deficiencies; T cell defects are
next at 30% to 40%.'40 The relative distribution of immunodeficiencies is shown in Fig. 15-10. Primary immunodeficiencies are conventionally divided into disorders involving B cells, T cells, phagocytes, complement, or a
combination.
B Cell Disorders. B cell deficiency states are associated with quantitative or qualitative antibody deficit caused
by (1) lack of all immunoglobulin classes (e.g., aganunaglobulinemia), (2) lack of one immunoglobulin class (e.g.,
IgA deficiency), (3) lack of immunoglobulin subclass(es)
(e.g., IgG2 deficiency), or (4) lack of functional antibody.
B cell deficiencies are often intertwined with T cell

Cellular

Deficiencies

Antibody
Deficiencies

Relative distribution of primary immunodeficiencies.
(From S~iehm ER: Immunodeficiency disorders: general considerations. In Stiehm ER. ed: Imnlllllological disorders in infants and
children. ed 3, Philadelphia, 1989, WB Saunders, p. 158.)
Fig. 15-10
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dysfunction. Patients typically present with recurrent bacterial infections l41 Antibody deficiencies are the most common B cell disorders and are present in approximately one
half of the patients with primary immunodeficiency.9.142
Because patients with B cell disorders have a diminished
ability to form immunoglobulins, they are unable to
generate effective antibody-antigen interactions. 143
The pattern of infection associated with B cell disorders is characteristically recurrent sinopulmonary tract
infections with encapsulated bacteria and, less frequently,
gram-negative organisms. '43 Pyogenic bacteria, such as
pneumococci, meningococci, streptococci, H. influenzae,
and enteroviruses are common etiologic organisms. Patients
with antibody deficiency should not receive live virus
vaccines.
T Cell Disorders. T cell disorders are present in
approximately 40% of patients with primary immunodeficiencies 142; however, 75% of these cases are associated
concomitantly with antibody deficiencies. Patients with
T cell disorders have a limited ability to produce mature
T cells and therefore are unable to assist with the activation
of the immune response.
T cell defect may be due to a stem cell defect, a thymus
defect, an enzyme deficiency, or a postthymic defect. The
DiGeorge syndrome is an example of a T cell deficiency
secondary to a thymus defect. Patients with T cell deficiency
present primarily with opportunistic infections or autoimmune disease.
Phagocytic Disorders. Patients with phagocytic disorders have either an insufficient number or inadequate
function of neutrophils and monocytes or macrophages.
Impaired phagocytic function may be further classified as
chemotactic, opsonic, ingestion, or killing defects. Children
with neutrophil dysfunction experience recurrent infections
of the skin and soft tissue, abscesses, lung infections, and
periodontal disease. Patients with phagocytic disorders
involving inadequate functioning are considered at risk for
infection despite a "normal" WBC count. Infections should
be treated aggressively with prolonged use of systemic
antibiotics and surgical drainage of abscesses.
Complement Deficiencies. Deficiencies have been
described for each of the key components of complement;
however, an increase in the susceptibility to infection is
commonly noted for deficiencies in C2, C3, C5, C6, C7, and
CS?9 Infection patterns vary depending on which component of complement is deficient. For instance, infections in
a child with deficiencies of C2 and C3 are similar to those
in a child with a B cell disorder. The child with a
complement deficiency in terminal complement components
(C5 through CS) has infections from meningococcal or
gonococcal organisms. 39
Combined Immunodeficiencies. Several rare disorders are based on a combined immunodeficiency of both
HI and CM!. These disorders are the most severe of all the
immunodeficiencies because the child is unable to form
antibody and lacks T cells to orchestrate the immune
response and to destroy cells infected with intracellular
microorganisms. Persons with combined Band T cell
disorders suffer from multiple severe infections (bacterial,
fungal. viral, and protozoal), diarrhea, and muscle wasting.
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A well-known example of a combined Band T cell
disorder is severe combined immunodeficiency disease
(SCID). SCID is a rare inherited disorder occurring in only
I in I million live births in the United States. SCID may be
caused by several immunologic abnormalities, but all
result in the lack of development or function in B cells and
T cells.

Acquired Immunodeficiency
Human Immunodeficiency Virus
Etiology and Incidence. HIV disease is defined as
the spectrum from exposure to the virus until death. AIDS is
that part of the HIV disease spectrum during which
opportunistic illnesses have begun to develop until death.
Pediatric AIDS refers to those cases that have been reported
in children under 13 years of age. In 1981, 16 cases of AIDS
were first reported among children below the age of 13. 144
By June 1999, 8596 cases of pediatric AIDS had been
reported. 145
From 1982, when the first cases of AIDS in children were
reported, through June 1997,7902 cases of AIDS had been
reported in the United States. 146 Of these cases, the majority
were infected through mother-infant transmission, with a
smaller number infected through receipt of infected blood,
blood products, or tissue or through receipt of contaminated
blood products used for hemophilia treatment. The number
of children with perinatally acquired HIV disease has
steadily declined since 1993 from over 900 per year to
225 in 1998. From 1996 to 1997, the number of children
who were diagnosed with HIV declined 40%, principally
reflecting several factors: the continued success of efforts to
reduce perinatal transmission through promoting voluntary
HIV testing and zidovudine therapy for pregnant HIVinfected women and their infants 145 and increased use of
antiretroviral drugs to treat HIV infection in pregnant
women.
Worldwide, the HIV epidemic has left an estimated 8.2
million children orphaned and 1.1 million children living
with HIy' 147 Through December 1997, 641,086 persons
with AIDS had been reported to the CDC by state and local
health departments. Of these, 1.2% were children younger
than 13 years old.
By midyear 1999, 1803 children were reported to be
living with HIV and 3669 to be living with AIDS. A total of
4975 children with AIDS have died, the majority of whom
were African American, followed by Hispanics, making up
the second largest ethnic group.145 Of the 678 children
reported with AIDS in 1999, 91 % had a mother with or at
risk for HIV infection, 4% were infected through blood or
blood products, 3% were hemophiliacs or had a clotting
disorder, and 2% had other or no reported risks. 145
Adolescents tend to become infected by routes of transmission associated with risky behaviors. These include unprotected sexual intercourse with infected partners, intravenous
drug use, and contamination with infected blood. 148
Despite a decreased number of children diagnosed with
mv, more children affected by this disease are being
admitted to PICUs for intense medical and nursing manage-

ment because of multisystem organ involvement and
subsequent organ failure, The average length of hospital stay
in 1997 was 8.1 days. 145
Extraordinary progress has been made in developing
highly active antiretroviral therapies (HAARTs), as well as
continuing progress in preventing and treating opportunistic
infections (OIs). HAART has reduced the incidence of OIs
and extended lives substantially. In addition, prophylaxis
against specific OIs continues to provide survival benefits
even among persons who are receiving HAART. 149 However, in comparison with Caucasians, African Americans
received inferior care on six selected measures of service
and pharmaceutical use. 150 Compared with children who
died in 1990, HIV-infected children who died in 199'6 were
significantly older, more symptomatic, and more likely to
have a greater number of organ system involvement and to
have received antiviral therapy and 01 prophylaxis. 151
Pathophysiology and Transmission. A great deal
of information has been learned about the transmission of
HIV since it was first isolated in 1983. HIV is a very fragile
virus and cannot survive for long periods once it is outside
the body. The length of time it does survive depends on the
size of the droplet that the virus is in and the concentration
of HIV within that droplet. 152 The larger the droplet, the
longer the survival time of the virus. HIV is killed as the
droplet dries.
HIV has been isolated from all body fluids, including
blood, semen, vaginal fluid, tears, saliva, sweat, sputum,
urine, breast milk, and cerebrospinal fluid. It has also been
isolated from some body tissues, including bone marrow,
lymph nodes, and brain tissue. 153-155 Blood, semen, vaginal
fluid, and breast milk are the only fluids that have been
implicated in the transmission of HIy' 156
Body fluid exposure is dependent on two variables: the
amount of viral particles present within the fluid and the
ability of that fluid to reach the target T4 lymphocytes. For
HIV to produce an infection, it must be able to enter the
recipient's bloodstream and attach itself to the T4
lymphocyte.
There are three modes of transmission for HIy'155.157-160
The first is unsafe vaginal or anal sexual contact with an
infected individual. Direct inoculation with infected blood
or blood products is the second mode of transmission.
Mechanisms that allow this transmission to occur include
inoculation through transfusions, needles not cleansed
properly after intravenous drug use, inoculation with
infected blood through small cuts, and inoculation through
needlesticks or percutaneous exposure. The risk of transmission through blood transfusions has significantly decreased since 1985, when the ELISA was implemented into
the process of blood screening. Since 1985, all donated
blood has been screened for the presence of HIy' 161
The third mode is vertical transmission from mother to
fetus or during birth. Vertically infected children exhibit a
bimodal pattern disease of progression. '62 About 10% to
25% of infected children develop profound immunosuppression, Pneumocystis carinii pneumonia, severe encephalopathy, organomegaly, and mUltiple opportunistic infections in
the first few months of life; without treatment, few of these
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children survive more than 2 years. 163 Most children have a
slower progression to AIDS with mean times to AIDS of 6 to
9 years. 162 Factors contributing to the variable rates of
disease progression include the route and timing of infection, the amount and phenotype of the virus, and host
immunogenetic factors. l64
Being an HIV-positive mother does not guarantee
that her baby will develop HIV disease. However, babies
born to infected women will test positive because of
maternal antibody transmission to the fetus during development. 165 ,166 Maternal antibodies remain in the baby's
system for up to 15 months l61 ; therefore it is not currently
possible to determine the true HIV status of a baby until the
effects of maternal antibodies have resolved. The widespread use of zidovudine has led to a decline in the number
of children becoming perinatally infected with HIV. The rate
of mother-infant transmission has declined by 50% or more
in many areas of the United States. 167 Because the number
of children born to HIV-infected women each year has
remained about the same in recent years, the declining
transmission rate has already contributed to fewer children
being reported with AIDS nationwide. Several maternal,
delivery, and newborn factors appear to be associated with
higher risk for mother-infant transmission. One of the
maternal risk factors most consistently found across studies
is the stage of the mother's HlV infection, as measured by
clinical, immunologic, or virologic markers. 167 Also, if a
woman has given birth to an HIV-positive baby in the past,
there is a 65% chance that the woman will give birth to
another HIV-positive baby.168
Zidovudine (AZT) has proved to be effective in the
prevention of perinatal transmission of HIV. 169 In a study of
364 HIV-positive women, AZT therapy was associated with
a 67.5% decrease in perinatal transmission. As a result of
this study, the Public Health Service recommends that
HlV-positive women be informed that AZT substantially
reduces the risk of HIV transmission to their unborn baby
but does not eliminate it. Also, because this study did not
examine teratogenicity, the recommendation is that AZT not
be started before the fourteenth week of gestation if it is
being given for the sole purpose of reducing perinatal
transmission. 169
Incubation Period. When HIV was first identified, the
belief was that individuals were diagnosed as being HlV
positive, developed AIDS, and then died within a very short
time. The pace of HlV disease progression in children is
accelerated compared with adults. This difference is presumably a consequence of the acquisition of infection at a
time of immunologic immaturity and the availability of
increased numbers of susceptible target cells. Children
infected through non vertical routes may have a course more
similar to that of adults, with longer median time to AIDS
diagnosis and death. l64 The mean age of AIDS diagnosis
is 12 months for children with disease acquired through
perinatal transmission and 24.4 months for children with
transfusion-acquired disease. 17o
Viral Replication. HlV is classified as a retrovirus. A
retrovirus must first translate, or convert, its RNA into DNA
to replicate. Once translation has taken place, the virus can
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then insert itself into host DNA, which allows the host cell
to produce more retroviral particles. 171 The translation from
RNA to DNA requires the presence of reverse transcriptase,
an enzyme that is present in retroviruses but not present in
normal host cells. 153 Some of the current therapies to slow
the progression of HIV disease are reverse transcriptase
inhibitors that prevent this translation from taking place.
Initially, HlV enters the bloodstream of the host and
attaches itself to the CD4 receptor, on the T4 helper
lymphocyte. Once this attachment has taken place, the virus
uncoats or sheds its outer envelope. The illV RNA is
transcribed into DNA via reverse transcriptase after the
virus is uncoated and inside the host cell. Once translation
is complete, the HIV replication process continues. Next,
the viral DNA is incorporated into the host DNA. At this
point, the virus can remain dormant for up to several years
or begin replication immediately.
At the end of a latent stage, the cell in which the virus is
located becomes activated by an antigen. It is uncertain what
antigen causes the cell to become acti vated. New virions are
formed and released into the bloodstream through a process
called budding. These new viral cells then attach to other
uninfected cells. The host cell ruptures, releasing many viral
particles at once and causing death to that cell. All the
particles released into the bloodstream can now continue the
cycle. This mechanism causes the immune system to be
gradually depleted of T4 cells, leaving the host open to
massive infections and malignancies, which eventually lead
to the individual's death.153.159,171,172
Fig. IS-II illustrates the process of viral replication.
There are two subsets of T cells: the T4 and T8 cells.
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Fig. 15-11 Replication cycle of human immunodeficiency virus.
The life cycle of HIV is shown with the point~ at which research
is ongoing for pharmacologic agents that may block viral
maturation, including points for inhibition of reverse transcriptase,
integrase, TAT transportation, and protease.
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T4 cells are also called inducer, or helper, cells and are
sometimes referred to as the conductor of the immune
system because of their immunomodulatory function. The
T4 cells release Iymphokines, which activate the other cells
of the immune system and signal warning that non host cells
are present. l72 The T4 cell is responsible directly or
indirectly for the induction of a wide array of functions of
multiple limbs of the immune response. as well as for
certain nonlymphoid cell functions. Decreased CD4 helperinducer cells with an expanded CD8 cell population result in
an inverted CD4/CD8 ratio, usually with a number much
less than I.
Classification. The CDC has developed a classification system to assist the healthcare provider in staging the
progression of HIV disease because of the huge spectrum
that exists. The system classifies infected children into
mutually exclusive categories according to infection status,
clinical status, and immunologic status. 173 This system is
outlined in Box 15-1.
Laboratory Diagnosis of HIV Infection. Polymerase chain reaction (PCR) is a procedure that examines an
individual's genes within the DNA strand to detect the
presence of HIY. HIV DNA PCR is the preferred virologic
method for diagnosing HIV infection during infancy. A
meta-analysis of published data from 271 infected children
indicated that HIV DNA PCR was sensitive for the
diagnosis of HIV infection during the neonatal period'74
HIV culture has sensitivity similar to that of DNA PCR for
the diagnosis of infection and is considered the gold
standard. 175 However, illV culture is more complex and
expensive to perform than is DNA PCR, and a definitive
result may not be available for 2 to 4 weeks.
The ELISA detects the presence of antibodies to the
whole virus. 176 Though the ELISA is sensitive and specific,
other antibodies within the patient's body can react with
the material used in the ELISA to produce a false-positive
result. 152 The Western blot test is designed to detect the
presence of anti-HIV-I antibodief. and antigens. The precise
criteria for what constitutes a positive Western blot test
remain controversial; however, it is used as a confirmatory
test for a positive ELISA.
Although use of standard and immune-complex dissociated p24 antigen tests are highly specific for HIV infection
and have been used to diagnose infection in children, the
sensitivity is less than that for the other HIV virologic tests.
This assay measures the amount of free viral protein (p24)
present in the plasma or tissue culture supernatant. p24
antigen testing alone is not currently recommended to
exclude infection or for the diagnosis of infection for infants
younger than I month because of a high frequency of
false-positive assays during this time. l77 Initial testing is
recommended by 48 hours of age because nearly 40% of
infected infants can be identified at this time. Infants
with positive virologic test results before age 48 hours
are considered to have early (i.e., intrauterine) infection,
whereas infants with negative virologic test results during
the first week of life and subsequent positive tests are
considered to have late (i.e., intrapartum) infection.
Because the routine tests are limited in infants, an
alternative approach is the repeated (longitudinal) collection

of serum samples and batch assay to establish a rising
anti-HIV antibody titer. The increasing titer is evidence of
HIV infection. Johnson and colleagues 178demonstrated that
up to 85% to 90% of infected infants will be detected by
6 months of age.
It is not uncommon for HIV antibody tests to be ordered
and performed in the PICV. Anxiety can develop in the
patient or parent because of a lack of understanding
concerning the meaning of the test or the possibility that the
test will be positive. Therefore pretest and posttest counseling is very important and required by law in many states.
PICU nurses must understand these tests, be able to explain
their meaning and purpose, and clarify the misconception
that a positive HIV test result equals AIDS. It is also
essential for nurses to be aware of local and national
resources of written literature to provide to the parents.
Evaluation of Immunologic Status. Human lymphocytes possess specific glycoproteins on their surface that
play an important role in cell activity and function. CD4+
lymphocytes are the primary targets of illV infection, and
the CD4 receptor is the primary binding site of HIV-l. The
loss of these cells is associated with development of the
characteristic DIs and malignancies of AIDS and an
important determinant of clinical staging. The numbers of
CD4 and CD8 cells are measured through the use of specific
monoclonal antibodies and flow cytometry.179
Clinicians interpreting CD4+ T lymphocyte number in
children must consider age as a variable. A pediatric clinical
and immunologic staging system for HIV infection has been
developed that includes age-related definitions of immune
suppression. Values should be obtained as soon as possible
after a child has a positive virologic test result for HIV and
every 3 months thereafter. 180
Viral burden in peripheral blood can be determined using
quantitative HIV RNA assays. Coincident with the body's
humoral and cell-mediated immune response, viral RNA
levels decline 6 to 12 months after acute infection, reflecting
the balance between ongoing viral production and immune
elimination. The HIV RNA pattern in perinatally infected
infants includes persistently high copy numbers for prolonged periods. 177 HIV RNA patterns may be correlated
with disease progression and mortality. However, the predictive value of specific HIV RNA levels for disease progression and death for an individual child is only moderate.
In addition, specimen storage, delay in specimen processing,
and different HIV RNA assays make direct extrapolation of
the predictive value of the HIV RNA levels difficult.
AIDS-Defining Illnesses. A wide range of manifestations of HIV infection are present in children. There
are generally two patterns of disease presentation: one that
is associated with a rapidly progressive disease with a
poorer prognosis and the other associated with a slower
process. However, regardless of the manifestation, once
a child develops an AIDS-defining illness. the prognosis
is poor.
AIDS-defining illness can be caused by viruses, fungi,
parasites, bacteria. or cancers. 181 One of these opportunistic
infections must be present for the diagnosis of AIDS to be
used. All of the organisms that cause these illnesses are
ubiquitous in nature.
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Box 15·1

Clinical Categories for Children With Human Immunodeficiency Virus (HIV) Infection

Category N: Not Symptomatic

Children who have no signs or symptoms considered to be the
result of HIV infection or who have only one of the conditions
listed in Category A.
•
Category: Mildly Symptomatic

Children with two or more of the conditions listed below but
none of the conditions listed in Categories Band C.
Lymphadenopathy (~0.5 cm at more than two sites;
bilateral = one site)
Hepatomegaly
Splenomegaly
Dermatitis
Parotitis
Recurrent or persistent upper respiratory infection, sinusitis,
or otitis media

•

Category B: Moderately Symptomatic

Children who have symptomatic conditions other than those
listed for Category A or C that are attributed to HIV infection.
Examples of conditions in clinical Category B include but are not
limited to:
Anemia «8 g/dl), neutropenia (<I000/mm'), or thrombocytopenia « IOO,OOO/mm') persisting 2:30 days
Bacterial meningitis, pneumonia, or sepsis (single episode)
Candidiasis, oropharyngeal (thrush), persisting (>2
months) in children >6 months of age
Cardiomyopathy
• Cytomegalovirus infection, with onset before I month of age
Diarrhea, recurrent or chronic
• Hepatitis
Herpes simplex virus (HSV) stomatitis, recurrent (more than
two episodes within I year)
HSV bronchitis, pneumonitis, or esophagitis with onset
before I month of age
Herpes zoster (shingles) involving at least two distinct
episodes or more than one dermatome
Leiomyosarcoma
Lymphoid interstitial pneumonia (LIP) or pulmonary
lymphoid hyperplasia complex
Nephropathy
Nocardiosis
• Persistent fever (lasting> I month)
Toxoplasmosis, onset before I month of age
Varicella, disseminated (complicated chickenpox)
Category C: Severely Symptomatic·

Children who have any condition listed in the 1987 surveillance
case definition for acquired immunodeficiency syndrome, with
the exception of LIP.
Serious bacterial infections, multiple or recnrrent (i.e., any
combination of at least two culture-confirmed infections
within a 2-year period), of the following types: septicemia,
pnenmonia, meningitis. bone or joint infection, or abscess
of an internal organ or body cavity (excluding otitis media,

•
•
•

superficial skin or mucosal abscesses, and indwelling
catheter-related infections)
Candidiasis. esophageal or pulmonary (bronchi, trachea.
lungs)
Coccidioidomycosis. disseminated (at site other than or in
addition to lungs or cervical or hilar lymph nodes)
Cryptococcosis. extrapulmonary
Cryptosporidiosis or isosporiasis with diarrhea persisting
>1 month
Cytomegalovirus disease with onset of symptoms at age
> I month (at a site other than liver. spleen, or lymph nodes)
Encephalopathy (at least one of the following progressive findings present for at least 2 months in the absence of
a concurrent illness other than mv infection that could
explain the findings): (a) failure to attain or loss of developmental milestones or loss of intellectual ability. verified by
standard developmental scale or neuropsychologic tests;
(b) impaired brain growth or acquired microcephaly demonstrated by head circumference measurements or brain
atrophy demonstrated by computed tomography or magnetic
resonance imaging (serial imaging is required for children
<2 years of age): (c) acquired symmetric motor deficit manifested by two or more of the following; paresis, pathologic
reflexes, ataxia or gait disturbance
HSV infection causing a mucocutaneous ulcer that persists
for> I month; or bronchitis. pneumonitis. or esophagitis for
any duration affecting a child> I month of age
Histoplasmosis, disseminated (at a site other than or in
addition to lungs or cervical or hilar lymph nodes)
Kaposi' s sarcoma
Lymphoma, primary, in brain
Lymphoma, small. noncleaved cell (Burkitt's), or immunoblastic or large cell lymphoma of B cell or unknown
immunologic phenotype
Mycobacterium tuberculosis, disseminated or extrapulmonary
Mycobacterium. other species or unidentified species,
disseminated (at a site other than or in addition to
lungs, skin, or cervical or hilar lymph nodes)
Myobaclerium aviwn complex or Mycobacrerium kansasii,
disseminated (at site other than or in addition to lungs, skin,
or cervical or hilar lymph nodes)
Pneumocystis carinii pneumonia
Progressive multi focal leukoencepha lopathy
Salmonella (nontyphoid) septicemia, recurrent
Toxoplasmosis of the brain with onset at > I month of age
Wasting syndrome in the absence of concurrent illness other
than HIV infection that could explain the following findings:
(a) persistent weight loss >10% of baseline OR (b) downward crossing of at least two of the following percentile
lines on the weight-for-age percentile chart (e.g., 95th, 75th.
50th, 25th, 5th) in a child 2:1 year of age OR (c) <5th
percentile on weight-for-height chart on two consecutive
measurements, 2:30 days apart PLUS (a) chronic diarrhea
(i.e., at least two loose stools per day for ~30 days) OR
(b) documented fever (for ~30 days. intermittent or constant)

*See Ihe 1987 AIDS surveillance case deflnilion for diagnosis crileria.
From Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children less than IJ years of
age; Official authorized addenda: human immunodeficiency virus infection codes and offic.:ial guidelines for coding and reporting ICD-9-CM, MMWR 43:RR-12,
1994.
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15·12 Clinical Manifestations
of Pediatric HIV Infection
TABLE

Infectious Complications
Pyogenic infections
Mycobacterial
Tuberculosis
Atypical*
Candidal infections
Tineal infections
Viral infections
Measles*
Cytomegalovirus*
Hepatitis A, B, C
Herpes zoster virus
Herpes simplex virus
Epstein-Barr virus
Pnewnocystis carinii*
Toxoplasma gondii*
Cryptosporidiosis
Cryptococcal infections*
Malignancies'
Lymphomas, particularly
non-Hodgkin's type

m Hoyt LG. OIeske 1M: The clinical spectrum of HIV infection in
ants and children: an overview. [n Yogev R. Connor E, eds:
gemelli of HlV illfeclioll ill illfallls and children, 51 Louis. 1992,
osby, pp 227-246.
Associated with a graver prognosis.

TABLE

Common clinical manifestations of HIV infection in
infants and children are listed in Table 15-12. The presenting
signs and symptoms are often nonspecific and may include
recurrent fevers, failure to thrive, diffuse lymphadenopathy,
hepatosplenomegaly, and anorexia. These may be caused by
chronic viral infection, malnutrition, and immunodeficiency.
The most common clinical manifestation early in the
disease process is lymphadenopathy. This condition is often
associated with hypergammaglobulinemia and splenomegaly. In addition, skin disorders, such as candidal dermatitis,
in particular, are common clinical manifestations.
Acute Respiratory Failure. Pulmonary complications leading to acute respiratory failure (ARF) are the most
common reason for admission of pediatric AIDS patients to
the PICU. Pulmonary diseases cause significant morbidity
and mortality in pediatric HIV patients. Table 15-13 outlines
the infectious and noninfectious pulmonary diseases that
can occur in HIV-infected children.
Pneumonias caused by Pneulllocystis carinii pneumonia
(PC), RSV, CMV, Mycobacterium avium-intracellulare,
P aeruginosa, Candida albicans, H. infit/enzae, S. aureus,
Klebsiella, and lymphoid interstitial pneumonitis (LIP) have
all been reported as reasons for ARF. Of these, PCP and LIP
are by far the most common.
Pneumocystis carinii Pneumonia. PCP remains the
most common opportunistic infection in children with HIV
infection. PCP was reported in 34% of U.S. children with
perinatally acquired AIDs through 1997. 146 PCP has been
shown to be an important cause of mortality among children
infected with HIY. In 1992 the estimated median survi val of
children after a diagnosis of PCP was 19 months. 182
PCP is considered either a protozoan parasite or a
fungus and exists as a cyst containing eight intracystic

15·13 Pulmonary Diseases in Children With AIDS'
Pneumocystis carinii, Toxoplasma gondi/, Strongyloides stercora/is

Viral

Respiratory viruses: respiratory syncytial virus. influenza virus, parainfluenza virus,
adenovirus
Measles
Opportunists: cytomegalovirus. herpes simplex. varicella zoster virus
Streptococcus pneumolliae, Haemophilus injlue1llae, Staphylococcus aureus
Nosocomial: enteric bacilli, Pseudomonas aeruginosa
Actinomycetes: Nocardia sp.
Mycobacterial: M. tuberculosis, M. aviwn-ill/racellulare

Fungal

r~%;::::di=~'

Cryptococcus neoformans, HislOplasma capsllialum, Coccidioides immitis, Candida sp.,
Aspergillus sp.

Pulmonary lymphoid hyperplasia
Lymphocytic interstitial pneumonia
Polyclonal polymorphic B cell Iymphoproliferative disorder

Bronchiectasis
Kaposi's sarcoma
liJirrom Berkowitz ill, Berkowitz FE. lohmon lP: The critically ill child and human immunodeficiency virus. In Rogers Me, ed: Textbook of pediatric
_.. ensive care, Baltimore. 1992, Williams & Wilkins.
~i::-
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bodies. 183 These bodies are released from the cysts and
form new cysts, which then attach to type I alveolar cells.
As a result, alveolitis and interstitial edema develop,
leading to ventilation perfusion mismatch, decreased pulmonary compliance, hypoxia, and an increased alveolararterial (A-a) gradient. 183
The clinical course of PCP is highly variable, ranging
from the acute onset of fever and marked respiratory distress
to a more insidious onset with a subacute course. The
presenting signs are often nonspecific and include fever,
cough, tachypnea, and hypoxemia. Chest auscultation may
be normal even with the presence of tachypnea and clinical
evidence of respiratory distress. Early in the course, the
chest radiograph may also be normal. As roentgenographic
findings develop, a diffuse bilateral interstitial pattern is
most often seen. Patients may rapidly progress to respiratory failure and death if the diagnosis of PCP is not made
early.
Guidelines exist for prophylaxis against pcp for children
infected with or perinatally exposed to HIv. I84 Prophylaxis
is determined by the child's CD4+ count, CD4+ percent, and
age. Trimethoprim-sulfamethoxazole (TMP-SMX) remains
the drug of choice for prophylaxis. Alternative regimens
include the use of dapsone or aerosolized pentamidine. 184
Because PCP is relatively safe, effective, and inexpensive
chemoprophylaxis is available, preventing PCP has been a
major priority in the care of children infected with HIV.
PCP may be diagnosed with noninvasive or invasive
techniques. Analysis of sputum, endotracheal secretions,
and gastric washings may show evidence of the organism
and is attempted first. Other methods may include bronchoalveolar lavage, transbronchial biopsy, or open lung biopsy. 175 Open lung biopsy is reserved for children in whom
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other methods have not provided a diagnosis. The latter
three are the most reliable methods for diagnosis. J 85
Management of the child with PCP includes oxygen
therapy, antibiotic therapy, steroids, positive end-expiratory
pressure (PEEP) or continuous positive airway pressure
(CPAP), and mechanical ventilation. The standard antibiotic
therapy for PCP is the administration of TMP-SMX or
pentamidine isethionate. TMP-SMX is given orally or
intravenously at 20 mg/kg/day, with the initial administration being intravenous. Oral administration can begin once
improvement has taken place. Because many patients
become neutropenic when treated daily with TMP-SMX,
administration 3 times a week may be used; this approach
appears equally effective and causes less neutropenia. 186
Therapy is recommended to continue for 21 days.
Intravenous pentamidine is instituted when no response
to TMP-SMX is seen. Aerosolized pentamidine, although
effective in adults with less severe cases of PCP, is of limited
use in children because of uneven delivery of the drug to the
smaller airways. 187 The recommended dose is 4 mg/kg/day
given in a single dose for 14 to 21 days. The drug is administered by slow intravenous infusion because hypotension
may result if administered rapidly. Side effects that may
result with use of pentamidine are hypoglycemia, hyperglycemia, neutropenia, thrombocytopenia, and azotemia. Table
15-14 lists the dosage and side effects of these drugs.
Lymphoid Interstitial Pneumonitis. LIP is a common
symptom of pulmonary involvement in children with HIV
infection. 188 LIP is very common in pediatric HIY infection
and has been found in up to 30% to 40% of HIV-infected
infants and children with pulmonary disease. 18s
LIP involves the diffuse lymphoid infiltration of the lung
parenchyma; a related disorder, pulmonary lymphoid hyper-

Treatl1lentOptionsfor Moderate to. Severe Pneumocy$ti$ Carinii Pneum~nia

~rimethoprim

Dose(s), Route, Frequency

5ide Effect(s)

15 mg/kg (TMP), IV, divided every 6-8 hr*

Rash,t fever, NN, i liver function tests,
i K+, neutropenia

3-4 mglkg, IV, once daily

Nephrotoxicity, i K+, .l. Ca 2+/Mg2+,
i amylase, .l.i glucose:!:

45 mg/m 2 , IV, once daily, plus 20 mg/m 2,
PO, every 6 h ± 100 mg, PO, once daily

Neutropenia, thrombocytopenia, rash, fever,
i liver function tests, hemolytic anemia
(check G6PD level), methemoglobinemia;
limited experience with children

1800 mg, IV, divided every 6-8 hr plus
30 mg (base), PO, once daily

Rash, NN, diarrhea, hemolytic anemia
(check G6PD level), methemoglobinemia;
limited experience with children

': (TMP)-sulfamethoxazole
., (SMX)
. entamidine isethionate
ii,r'rimetrexate plus
::~ leucovorin ± dapsones§

: .. dapted from Stansell JD, Huang L: Pneumocystis carinii pneumonia. In Sande MA, Votberding PA, eds: The medical managemellt oj AIDS, ed 5,
. adelphia, 1997, WB Saunders, p 287.
~.TMP-SMX is dispensed as a fixed combination.
f-MiJd rash that does not cause bullous skin lesions and does not involve mucous membranes can often be treated with antihistamines first and should
:" t necessarily result in discontinuation of

drug.

!fAvoid other nephrotoxic agents (nonsteroidal antiinflammatory agents, aminoglycosides, foscarnet, amphotericin B). Risk of hypotension can be
.-··nimized if infusion is given over a 2-

10

3-hour period.

:§A study is in progress comparing TMP-SMX with trimetrexate-dapsone (plus leucovorin).
]V, Intravenous; PO. orally; NN. nausea and vomiting; G6PD, glucose-6-phosphate dehydrogenase; i = increased; .J. = decreased.
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plasia (PLH), involves hyperplasia of bronchus-associated
lymphoid tissue. In the 1994 CDC Revised Classification
System for Human Immunodeficiency Virus Infection in
Children, LIP is classified as a category B symptom, one
attributed to and indicative of an mV-related immunologic
deficit. 149
Clinical manifestations of LIP can range from asymptomatic disease with isolated radiographic abnormalities to
severe bullous lung disease with pulmonary insufficiency.
Children with symptomatic LIP often present during the
second or third year of life with the insidious onset of
dyspnea, fatigability, tachypnea, cough, and occasionally
fever associated with salivary gland enlargement and
lymphadenopathy.IR9
Clinical and radiographic findings may lead to a presumpti ve diagnosis. However, the definitive diagnosis is
made by lung biopsy. The specimen will show the typical
lymphocytic infiltrates. LIP responds to systemic corticosteroids, but no controlled studies have been performed to
assess the efficacy of steroids for LIP. 189 Treatment with
steroids is usually reserved for patients with significant
hypoxemia and symptoms of pulmonary insufficiency,
including tachypnea, dyspnea on exertion, and exercise
intolerance.
Tuberculosis. Tuberculosis is less common in children than adult patients with AIDS. The increase in cases of
tuberculosis reported to the CDC between 1986 and 1992
not only represented a 20% increase in total cases but also
a 33% increase in the number of cases reported in
children. 19o Children with tuberculosis are almost always
infected by an adult in their environment, usually a close
household contact. It is less common in the child with AIDS,
with little information available on the incidence and
clinical characteristics.
Tuberculosis may be caused by either Mycobacterium
tuberculosis or M. bovis, although disease with M. bOllis is
seen only in the rare circumstances of vaccine-associated
infection. M. tuberculosis is a small, weak gram-positive
rod, which is a slow-growing, obligate aerobe.
Nonimmunocompromised children who develop primary tuberculosis demonstrate lymph node enlargement in
the hilar, mediastinal, and cervical areas. Pulmonary
infiltrates with consolidation, atelectasis, pleural effusion,
and tuberculous meningitis can also be seen. 191 The clinical
manifestations in HIV-infected children are usually nonspecific and include fever, weight loss, and cough. On chest
radiograph, localized patchy infiltrates and hilar lymphadenopathy are seen. Because of the immunosuppression
that accompanies the disease, skin testing alone is not
conclusive for diagnosis of tuberculosis. Cerebrospinal
fluid and blood cultures, in addition to gastric and bronchial
washings, are necessary. Children tend to swallow their
sputum, so acid-fast stains of gastric washings are more
helpful than sputum stains in establishing the diagnosis.
Gastric washings are obtained very early in the morning
before the patient has any oral intake.
Isoniazid, rifampin, pyrazinamide, and ethambutol or
streptomycin are recommended for initial treatment while
awaiting susceptibility results. In the case of disseminated

disease, a bactericidal agent may be used. The duration of
therapy ranges from 6 to 9 months, determined by infection
site, response to therapy, and the sensitivity of the organism.
A 12-month duration of therapy is recommended for those
children with miliary tuberculosis, bone and joint tuberculosis, or tuberculous meningitis. 192
Infection control is a critical nursing concern in caring
for children with HIV infection and tuberculosis. Children
with cavitary lesions, endobronchial tuberculosis, or positi ve gastric washing or sputum cultures are placed on
respiratory isolation. 193 Family members should wear a
tuberculosis mask during visits, and careful monitoring of
the infection status of these children is necessary.
Cardiovascular Dysfunction. Cardiac disease in
children with HIV infection may be common, extensive,
and clinically significant. Some suggest that approximately 20% of HIV-infected children will have some
type of cardiac complication, the two most common being
cardiovascular failure secondary to septic shock and
cardiomyopathy. 194
Cardiomyopathy is the second most common cardiac
PICU presentation of children with AIDS, with 33% of the
deaths occurring in the setting of significant cardiovascular
disease. 195 Although the degree of cardiac dysfunction may
be difficult to determine because of multiorgan involvement,
autopsy findings of these children have shown biventricular
dilation, myocardial hypertrophy, interstitial fibrosis, myocardial necrosis, and endocardial thickening. 196 Conduction
disturbances secondary to vasculitis, myocarditis, or fibrosis
have also been described. 197
Left ventricular dysfunction, often a precursor to dilated
cardiomyopathy and congestive heart failure; is the most
common cardiac manifestation of mv infection among
children. Left ventricular dysfunction is often asymptomatic
and is diagnosed echocardiographicaJly.195
Cardiac dysrhythmias have been reported in HIVinfected children, although the occurrence is uncommon and
nonspecific. Isolated incidences of ventricular and atrial
ectopy have been reported. 19H
The cause of HIV-associated cardiomyopathy is unknown. Many factors may be involved, including HIV
infection, infection with other agents, an abnormal host
response, and drug toxicity. 199 Despite the autopsy findings,
the pathogenesis of this dilated cardiomyopathy has yet to
be fully explained. The virus itself may cause myocardial
damage by releasing mediator-infected monocytes, or the
host immune system may play a role by producing an
autoimmune response. 200
Congestive heart failure is the predominant clinical
manifestation of later-stage cardiac involvement, although it
may be difficult to diagnose in the HIV-infected child.
Tachypnea and rales may be secondary to pulmonary
disease or insufficiency, tachycardia may be due to fever or
anemia, and hepatosplenomegaly is typically present in
many children with HIV infection. Therefore these symptoms cannot be relied on as specific to congestive heart
failure. From the experience gained at several institutions,
the most reliable clinical indicators of congestive heart
failure in these children are the presence of a gallop rhythm
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associated with tachypnea and tachycardia and cardiomegaly on chest x-ray film.194.201
Septic shock may be the primary cardiovascular cause for
PICU admission of HI V-infected children. Serious bacterial
infections often occur in children with AIDS. Streptococcus
pneumoniae; Salmonella, Pseudomonas, and Enterobacter
species; H. injiuenzae; Enterococci; S. aureliS and S, epidermidis; and E. coli have all been identified as causative
pathogens.
Nursing care for the HIV-infected child is the same as for
any child exhibiting low cardiac output secondary to septic
shock or cardiomyopathy and includes inotropic support,
afterload reduction, and appropriate antimicrobial therapy,
Treatment of congestive heart failure secondary to cardiomyopathy includes preload reduction and the administration
of digoxin for diminished pump function.
Central Nervous System Dysfunction. illV-related
central nervous system (C S) abnormalities are a common
and important complication of HIV disease in children,
causing significant morbidity and mortality. Encephalopathy
has been reported to be the presenting manifestation of AIDs
in as many as 18% of children?02 CNS dysfunction in the
HIV-positive child may be caused by secondary infection by
usual or opportunistic pathogens, as well as by primary HIV
infection of the brain.
Children may develop bacterial meningitis associated
with usual pathogens such as H. influenzae, S. pnel/moniae,
and N. meningilidis, as well as various gram-negative
bacilli. Meningitis and encephalitis may also result from
infection by numerous viral pathogens. Other CNS infections include mycobacterial and fungal meningitis. 203
Primary CNS lymphomas are the most common intracranial mass lesions that develop in children with HIV,
although they are relatively rare. The symptoms usually
seen are seizure activity, mental status changes, and
neurologic deficits.
The primary neurologic manifestation of HIV infection
of the brain is HIY encephalopathy, and it is present in
more than 50% of HIV-infected children. 183 This manifestation can present as a rapid course of deterioration or
may be static.
Children can exhibit signs of static encephalopathy,
demonstrated by an inability to achieve developmental
milestones in some or all areas. 204 Also, progressive encephalopathy has been reported in children, This condition has
been described as either a loss of developmental milestones or intellectual deficits, associated with impaired
brain growth; weakness with bilateral pyramidal tract
signs, ataxia, and, less commonly, seizures; and coma,z°4.205
In a study performed by Epstein and co-workers,206 the
most common CT scan finding was cerebral atrophy, with
secondary enlargement of the subarachnoid spaces and
ventricles, The damage to the CNS may be caused by the
direct effect of the virus in the brain tissue. Progressive
encephalopathy develops and worsens proportionally to the
increasing immunodeficiency.207 The most common neurologic diagnoses that necessitate admission of the HIVinfected child to the PICU are CNS infection, lymphoma,
and strokes.
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Strokes are an infrequent but potentially devastating
complication of AIDS. They may result from the inflammation of the cerebral blood vessels, causing an ischemic
infarction, or they may result from cerebral hemorrhage.
HIV-associated progressive encephalopathy is the clinical
corollary of the direct and indirect effects of CNS or
syste!TIic HIV infection. The predominant clinical neurologic findings include impaired brain growth, progressive
motor dysfunction, and loss or plateauing of neurodevelopmental milestones, Treatment includes antiretroviral drugs,
rehabilitation, immunomodulatory therapy, and psychoactive medications.
Hematologic Dysfunction. Hematologic dysfunction related to HIY infection includes autoimmune thrombocytopenia, anemia, leukopenia, granulocytopenia, and
lymphomas. 186 Primary bone marrow failure also occurs in
some children 203
Thrombocytopenia may be an early manifestation of HIY
infection. B cell dysfunction is postulated to lead to the
production of autoantibodies and immune complexes, resulting in peripheral platelet destruction?08 Therapies to
treat thrombocytopenia in the HIV-infected child include
corticosteroids, splenectomy, danazol, vincristine, and intravenous IgG ,z08
Anemia is a prominent diagnosis of HIV disease.
Although the anemia is generally mild and nonprogressive,
in a child with multiple opportunistic infections, this may be
significant. Many factors may cause anemia, one being that
the virus may infect erythroid precursors in the bone
marrow, inhibit the production of red cells, and cause
sequestration of the red cells in the spleen and liver,z°~
Zidovudine (AZT) may also cause anemia.
Leukopenia commonly occurs in children with HIV
infection, often in combination with anemia, Granulocytopenia can also occur and is usually accompanied by a left
shift in the differential portion of the complete blood count.
The cause is probably multifactorial, including immune
dysfunction resulting in hypogammaglobulinemia and production of autoantibodies and immune complexes. Antibodies against granulocytes have also been observed.
Malignancies, such as non-Hodgkin's lymphoma, have
been reported in HIY-infected children. These tumors are
almost always of B cell origin. Also, primary CNS
lymphoma has been reported in children with perinatally
acquired infection.
HIV-infected patients with anemia who are symptomatic
are recommended to recei ve transfusion of irradiated packed
RBCs, Also, G-CSF with erythropoietin for children with
zidovudine toxicity has been found to be effective in
correcting anemia?08 Further information regarding RBC
and platelet disorders is found in Chapter 24.
The primary method of treatment of HIY-associated
leukopenia and granulocytopenia is the use of granulocyte growth factors. Both recombinant GM-CSF and
G-CSF have been found to be effective, Short-ternl chemotherapy is usually the treatment of choice in children
with malignancies because most of these children will
not tolerate the immunosuppressive effects of long-term
chemotherapy.208
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Other Organ Dysfunction. Abnonnalities of all
organ systems can be seen in HIV-infected children, whether
induced by the HIV infection itself or by opportunistic
infections. Hepatitis is commonly seen without an easily
documented infectious cause. Pancreatitis with elevated
serum amylase and lipase levels has also been seen in
HIV-infected children. HIV-associated renal disease with
azotemia and proteinuria has been described in children.2°9
As many as 30% of HIV-infected children may develop one
of several fonns of renal disease. 183
Critical Care Management of the Patient With
HIV. In 1999 the U.S. Public Health Service and Infectious
Diseases Society of America developed disease-specific
recommendations for prevention of Ols and an immunization schedule for HIV-infected children.2 10 Prophylaxis to prevent the first episode of 01 in infants and
children infected with HIV include TMP-SMX against
PCP, isoniazid against isoniazid-sensitive M. tuberculosis,
c1arithromycin against M. avium, VZIg, and influenza
vaccine. 210 PCP occurs most often between 3 and 6 months
of age in perinatally infected children, so PCP prophylaxis
is recommended to be initiated at 4 to 6 weeks of life for
all HIV-exposed infants and continued until 12 months
of age.
Antiretroviral Therapy. Ongoing viral replication is
the driving force behind immunologic destruction. The goal
of antiretroviral therapy in children is to suppress viral
replication to extremely low levels; if replication continues,
ongoing mutation will lead to drug resistance. 175
As of January 1998, II antiretroviral agents were
approved for use in HIV-infected adults and adolescents in
the United States; 6 of these have approved pediatric
indications. The agents available fall into three major
classes: (I) nucleoside analogue reverse transcriptase inhibitor (NRTI) agents, (2) nonnucleoside analogue reverse
transcriptase inhibitor (NNRTI) agents, and (3) protease
inhibitor (PI) agents. NRTI agents are potent inhibitors of
the HIV reverse transcriptase enzyme, which is responsible
for the reverse transcription of viral RNA into DNA; this
process occurs before integration of viral DNA into the
chromosomes of the host cell. This is the first class of
antiretroviral drugs available for the treatment of HIV
infection. NRTI agents require intracellular phosphorylation to their active fonn by cellular kinases. The phosphorylated drug acts to competitively inhibit viral reverse
transcriptase and to tenninate additional elongation of viral
DNA after its incorporation into the DNA chain. Because
these drugs act as a preintegration step in the viral life
cycle, they have little or no effect on chronically infected cells in which proviral DNA has already been
integrated into cellular chromosomes. Although resistance
eventually develops to these agents during the course of
long-tern1, single-drug therapy, combination therapy with
these drugs may prevent, delay, or reverse the development
of resistance. 177
NNRTI agents specifically inhibit reverse transcriptase
activity by binding directly to the active site of the enzyme
without previous activation. At this time, no NNRTI agents
are approved for pediatric use; however, phase I trials are

underway. PI agents inhibit the HIV protease enzyme that is
required to cleave viral polyprotein precursors and to
generate functional viral proteins. The protease enzyme is
crucial for the assembly stage of viral replication that occurs
after transcription of proviral DNA to viral RNA and
subsequent translation into viral proteins. Because PI agents
act at a postintegration step of the viral life cycle, they are
effective in inhibiting replication in both newly infected and
chronically infected cells. 177 By 1998,85% of patients with
CD4+ T cell counts below 500/mm 3 were being treated with
PI or NRTIs.
In addition to the drugs listed previously, new classes of
drugs are being developed that will work at different points
in the viral life cycle. Among these are drugs that block
binding of HIV to cells and integrate inhibitors and zinc
finger inhibitors (zinc fingers are parts of proteins that bind
to nucleic acids and are essential for the assembly of new
virus particles).
Combination antiretroviral therapy is recommended for
HIV-infected children with clinical symptoms of HIV
infection (i.e., clinical category A, B, or C) or evidence of
immune suppression. Ideally, antiretroviral therapy should
be initiated in all suspected HIV-infected infants. Issues
associated with adherence to treatment are especially
important in considering whether and when to initiate
therapy. Antiretroviral therapy is most effective in patients
who have never received therapy and who therefore are less
likely to have antiretroviral-resistant viral strains. Lack of
adherence to prescribed regimens and subtherapeutic levels
of antiretroviral medications, particularly PI agents, may
enhance the development of drug resistance. Participation
by caregivers and child in the decision-making process is
crucial, especially in situations for which definitive data
concerning efficacy are not available. 177
Nutrition. Appropriate nutrition is a fundamental and
necessary part of a child's medical therapy. Nutrition
affects the management of children with HIV infection by
affecting GI tract function, CNS development, immune
function, recovery from infection, bioavailability of therapeutic agents, growth, and quality of life. Growth delay
affecting both height and weight is one of the earliest effects
of HIV disease in infants and children. Management
includes longitudinal assessment of growth-estimating
energy requirements, and dietary assessment. The approach
to maximizing nutritional support and avoiding malnutrition
in children with HIV infection is accomplished by attention
to the following goals of nutritional management: (I) treat
underlying GI or infectious diseases that interfere with
nutrient intake and absorption or increase nutrient loss and
(2) provide sufficient nutrition for catch-up growth. Tube or
parenteral feedings may be required. 175
Psychosocial Issues. As previously stated, developmental delays are a common occurrence in the child
with HIV infection. Nursing care involves assessment of
the child's developmental level and gearing communication at that level. In addition, some children may display
depressive symptoms, such as apathy, social withdrawal,
or anorexia.2 11 These symptoms are often an indication
of other issues, and a psychotherapist should be con-
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suited. Nurses caring for the child may also need to
consider that the child may have lost a parent to the same
disease. Excellent communication skills and support are
necessary.
A diagnosis of HfY infection also has a major impact on
the family. Often, the child may be diagnosed before the
parent. The psychosocial stress that the diagnosis of HIV
places on the family is unique in that in most cases, the child
and parent are both ill 211 Problems that are faced include
(I) coping with the diagnosis of a potentially fatal illness;
(2) dealing with the healthcare of the child; (3) approaching
the emotional, financial, and time demanding aspects of a
sick child; and (4) facing potential ostracism from family
members and the community209
Working with these families often poses a major
challenge for the PICU nurse. The sight of the ICU to a
parent who is also infected may be overwhelming because
it may represent to the parent his or her future. 212 Parents
may blame themselves and have difficulty even visiting
their child.
Many parents are also dealing with the problem of
substance abuse. Working with these families may be especially difficult for the nursing staff. Open communication, establishment of a relationship, and referral to appropriate resources are critical to family-centered care of the
child.

Infectious Diseases Unique to Pediatrics
Toxic Shock Syndrome. Toxic shock syndrome
(TSS) was first described in 1978 as a disease characterized
by high temperature, hypotension, and diffuse macular
erythroderma with desquamation I to 2 weeks after onset
of illness. In 1980, a profound increase in disease incidence
was recognized to be associated almost exclusively with
the use of superabsorbent tampons in menstruating women.
The mean mortality rate is 3%,212U primarily related to
adult respiratory distress syndrome, heart block, and
dysrhythmias.
TSS is a clinical diagnosis supported by the isolation of
S. aureus from a focal or enclosed infection, and in some
cases, TSS toxin-I (TSST-I). TSST-I is a very potent
stimulus in vitro for the release of IL-I B, TNF-a, and IL-2.TSS will become a fulminate disease without proper early
intervention. Untreated TSS may evolve to include shock,
cardiomyopathy, pericarditis, hepatitis, acute respiratory
distress syndrome, renal failure, disseminated intravascular
coagulation, and encephalopathy.
After the initial evaluation, if the patient is demonstrating signs of poor perfusion, intravenous (IV) fluids are
initiated immediately. While IV fluids are being administered, possible foci of infection are identified, foreign
bodies including sutures are removed, and Gram stains and
cultures are obtained. The mainstay of therapy consists of
supportive care aimed at preservation of vital organ function. Rapid reversal of hypotension is imperative; infusion
of large volumes of fluid may be necessary to maintain
an adequate cardiac output, venous return, and blood
pressure?13
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Antistaphylococcal J3-lactamase-resistant antibiotics are
given IV in maximally recommended doses. Commercial
preparations of IVlgs contain high levels of antibody to
TSST-I and potentially to the staphylococcal enterotoxins?13 Administration of IVlg has been shown to be
beneficial in a rabbit model of TSS, although it has not yet
been systematically studied in humans. Ongoing research
includes investigations into the use of MoAbs to IL-I, TNF,
and TSST_1. 214
Infant Botulism. Infant botulism was first recognized as a distinct clinical entity in 1976. Of all forms
of human botulism (food borne, wound, and infant), infant
botulism is now the most common in the United States.
More than 90% of reported cases come from the United
States, and within the United States, more than half of the
cases come from California, Utah, and southeast Pennsylvania. This finding is likely a consequence of high
concentrations of Clostridium botulinum spores in the soil
of these regions. 215
C. botulinum is a ubiquitous gram-positive, sporeforming, obligate anaerobe with soil and dust as its natural
habitat. Infant botulism typically affects previously well
infants within the first 4 to 6 months of life (median
10 weeks) and is caused by ingestion of spores of
C. botulinum that germinate and produce toxin in the GI
tract. The toxin irreversibly blocks the peripheral cholinergic ·synapses throughout the body, most importantly at the
neuromuscular junction. The toxin does not cross the
blood-brain barrier?16
Constipation is characteristically an early sign, followed
by signs of listlessness and becoming progressively more
weak. Symmetric descending paralysis is the rule; the
cranial nerves are the first so be affected. The diagnosis is
confirmed by detection of the organism or its toxin in the
infant's stool.
Aggressive respiratory and nutritional care are the
mainstays of treatment. Many infants require intubation and
prolonged mechanical ventilation. Physical and occupational therapies are crucial in maintaining range of motion
and functional positioning of patients. Prognosis for complete recovery is excellent with meticulous, supportive care.
Infant botulism is a self-limited illness lasting a total of 2 to
6 weeks with progressive symptoms. It is universally
recommended that honey and corn syrup not be fed to
infants younger than I year of age to prevent the occurrence
of infant botulism. 217
Rocky Mountain Spotted Fever. Rocky Mountain
spotted fever (RMSF) caused by Rickettsia rickettsii is the
most prevalent rickettsial disease in the United States,
and more than two thirds of patients are under 15 years
of age.
After the bite of an infected tick, R. rickettsii multiply within the endothelial cells of the small blood
vessels and then become widely disseminated, resulting in
the pathologic lesion of widespread vasculitis and a
resulting petechial rash. Clinical manifestations include
fever, rash, headache, meningoencephalitis, inflammation
of the heart, pulmonary edema, and myalgias. Rash is
present in 78% of patients and may be very atypical.
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The typical rash involves the palms and soles and begins
on the wrists and ankles to spread rapidly in hours up the
extremities?13.118
Diagnosis of RMSF is made on clinical and epidemiologic grounds. Nonspecific laboratory abnormalities include
anemia (30%), thrombocytopenia, and hyponatremia (50%).
Treatment consists of supportive care and either chloramphenicol, doxycycline, or tetracycline. Doxycycline is
thought to be most favorable in children younger than
9 years of age because of its documented effectiveness,
broader margin of safety, and reduced risk of drug-related
adverse effects 219
Reye's Syndrome. As acute postinfectious encephalopathy with hepatic dysfunction, Reye's syndrome (RS)
was first described by Dr. Reye in 1963. The case fatality
rate was 4 I% during the 1973 to 1974 outbreak and 12% in
1980, probably reflecting an improvement in the level of
sophistication of pediatric critical care. In 1980 a statistically significant association was noted between RS and the
use of aspirin for the preceding viral illness. no Over the past
decade, the use of aspirin in young children for minor viral
illnesses has decreased significantly, as has the incidence of
RS from a peak of 555 cases in 1980 to no more than
36 cases per year since 1987. 213 .221 This may be a reflection
of better diagnostic techniques and criteria for inborn errors
of metabolism that mimicked RS, as most patients originally
diagnosed with RS are now known to have metabolic
disorders. 222
Criteria for diagnosis of RS include acute onset of
disturbance in consciousness, elevation of serum glutamicoxaloacetic transaminase (SGOT) and serum glutamicpyruvate transaminase (SGPT) to twice-normal concentrations, and histologic changes consistent with the syndrome
seen in biopsy specimens of liver or postmortem material.
Persistent vomiting is usually the first symptom; as the
vomiting begins to decrease, confusion appears. The complete neurologic sequence progresses from stage I, in which
the child is frightened and confused, to stage Y, with a loss
of brainstem reflexes.
No specific therapy is available; intensive supportive care
is critical with respect to airway maintenance, tissue
oxygenation, and control of cerebral edema. Because Reye's
syndrome is now very rare, any infant or child suspected of
having this disorder should undergo extensive investigation
to rule out the treatable inborn metabolic disorders that can
mimic Reye's syndrome?21

EXPERIMENTAL THERAPIES
Gene transfer therapy is a revolutionary means of actually
replacing defective genes within the body.2lD This highly
experimental procedure was first used in children with SCID
related to ADA deficiencl 23 and in familial hyperlipoproteinemia, a lipid disorder. Like the administration of LAK
cells and TILs, one method of gene transfer therapy is a
multistep treatment that requires the removal of specific
cells from the patient, modification of these cells in the
laboratory, and return of the modified cells to the patient. 224.225 Gene transfer therapy shows tremendous potential in the cure of other diseases that are the result of a
defective gene, such as cystic fibrosis. 226
Nitric oxide is a membrane-permeable gas that functions
in the regulation of vascular tone, the inhibition of platelet
aggregation, and leukocyte adhesion and has antitumor and
antimicrobial activity. Increased production of nitric oxide
observed during septic shock may be largely responsible for
sepsis-induced hypotension and myocardial depressions.
The use of nitric oxide synthase inhibitors may improve
survival in severe septic shock by increasing mean arterial
pressure and restoring vascular responsiveness to catecholamines. At this time, beneficial effects on clinical outcomes,
including survival, only are suggested in human clinical
trials. 227

SUMMARY
Knowledge of immunology is increasingly important
for the pediatric critical care nurse for two reasons. All
PICU patients experience altered host defenses; most
commonly, these are changes in the structure and function of the first line of defense. In addition, the pediatric critical care nurse's knowledge of the immune system is often limited. With increasing technology and
expanding knowledge of the intricacies of immunologic events, expertise in the field of immunology is
imperative.
Caring for the child with altered host defenses is a
challenge. Children in the PICU are at risk developmentally
and situationally for altered host defense. Recognition of
this fact provides the basis for a thorough immunologic
assessment, which will further identify the child at risk.
Many of the interventions, including medical efforts,
involve expert nursing care to promote the best possible
outcome for the child.
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Skin Integrity
Sandy M. Quigley
Darlene E. Whitney

caused by rashes, dry skin, and sunburn are usually quickly
diagnosed and relieved with gentle cleansing and over-thecounter products.
Integumentary resilience and wound healing are influenced by maturation. Healthy children enjoy the benefits of
strong, supple skin that resists injury and heals quickly. The
bruises, scrapes, and cuts that are inevitable byproducts of
normal childhood development are usually healed with the
comfort of a loving caregiver and the application of a cartoon bandage. Critically ill or injured children, however, are
influenced by powerful internal and external factors that
place them at significant risk of developing wounds that will
not heal without nursing expertise.
Impairment in skin integrity places an already compromised child at risk for serious complications and significant
discomfort. Skin breakdown can negatively impact a child's
ability to eat, sleep, or move. Disruptions in the body's outer
layer of defense leaves a child vulnerable to infection.
Increased loss of fluids and a decreased ability to retain body
heat can add further stress to an already taxed child. Routine
skin care practices that promote skin integrity, that allow for
the early identification of children at high risk for breakdown, and that incorporate individualized preventive strategies can minimize complications.
Optimizing wound healing through skillful, scientifically
based care can improve patient outcomes, maximize resource allocation, and decrease cost. Pediatric critical care
nurses often provide an array of expert wound care.
Managing surgical wounds efficiently and effectively are
essential aspects of everyday nursing practice. Minimizing
the impact of iatrogenic wounds (including pressure ulcers,
irritant contact diaper dermatitis, and intravenous infiltrate
injuries) through aggressive prevention, early identification,
and prompt treatment is predominately a nursing responsibility. As direct bedside caregivers, nurses play an integral
role in promoting skin integrity and enhancing the potential
for positive patient outcomes.
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T

he skin is one of the largest, most accessible, and easily
examined organs of the human body. It provides a
variety of protective functions essential to life, facilitates
sensory input, and can be a source of great comfort or
discomfort. Easily seen and touched, the skin allows ready
access to information about its integrity. Illness and internal
organ dysfunction are also often evident through integumentary manifestations. In childhood, the routine discomforts
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INTEGUMENTARY STRUCTURE
AND FUNCTION
The skin consists of two distinct anatomic layers, the
epidennis and dermis, supported by underlying subcutaneous tissue. These layers, together with epidermal derivatives
including hair, nails, mucous membranes, and glands, make
up the functioning units of the integumentary system.

Epidermis
The avascular epidermis is the outermost layer of the skin.
It consists of five distinct cell layers and functions as a
protective barrier between the environment and the body, as
well as a membrane that holds in body fluids. The inner,
basal cell layer of the epidermis is nourished by the blood
supply of the dermis and is responsible for epithelial cell
division. As basal cells multiply, they are pushed up by the
remaining layers of the epidermis and are gradually filled
with keratin, a waterproofing protein. 1 The result of keratinization is 25 to 30 rows of dead, flat, dry, tightly adhered cells
making up the outermost layer of the epidennis. These keratinocytes provide an effective barrier against microorganisms and irritating chemicals and impede the exchange of
fluids and electrolytes between the body and the environment. The continual replacement and shedding of keratinocytes help to prevent excessive microbial colonization of
the skin surface. Melanocytes, which produce the granules
of melanin, are also found in the basal layer of the epidermis. The amount and distributjon of the cells that manufacture melanin, the brown pigment, determine whether we are
black or white 2 In black skin, the granules are larger and
more evenly distributed throughout the cell, whereas in
white skin, they are smaller and tend to be clumped together. 3 They are responsible for pigmentation and provide
some but not complete protection from ultraviolet rays.
Langerhans' cells are found throughout the epidermis and
serve the protective function of phagocytosis. 1
The epidermal layer of newborns and infants is thinner
and functionally immature as compared to adults. 4 Infants
experience higher levels of water loss and have a greater
permeability to chemicals than older children. s This, coupled with a larger ratio of skin surface area to body weight,
increases the risk of dehydration and the systemic toxicity
from transcutaneously absorbed chemicals. The thin epidermis is also more likely to blister and become damaged from
mechanical trauma and the use of adhesives.

Dermis
The dermis is a highly vascular layer of the skin secured
beneath the epidermis. It is comprised of collagenous and
elastic fiber connective tissue embedded with blood vessels,
lymphatics, nerve endings, hair follicles, and sebaceous
glands. Collagen, produced by fibroblasts and macrophages,
gives the skin substance, mechanical strength, and elasticity.
It allows the skin to withstand frictional stress and remain
pliable over joints. The dermal vasculature nourishes both
the dermal and epidermal cells, as well as facilitates thermal
regulation. Sebaceous glands secrete a mixture of fat,

cholesterol, protein, and salt called sebum. 1 Sebum helps to
keep skin soft and hydrated by limiting evaporation. Black
skin has more sweat glands to help with temperature control,
as it absorbs heat. 2
The dermal layer in infants and children is thinner and
produces less sebum. Dermal thickness increases slowly
after I year of age and doubles between the ages of 3 and 7.
Sebaceous glands are functional at birth, but sebum
production remains low until 8 to 10 years of age, providing
less protection against evaporation and drying. 6

Subcutaneous Tissue
Subcutaneous tissue, located below the dermis, is an
important supporting layer of the skin. It is composed of
adipose tissue embedded with the same structures found in
the dermis plus the secretory portion of sudoriferous, or
sweat, glands. Subcutaneous tissue serves as a cushion to
trauma, a heat insulator, and an important source of energy
metabolism. Sweat, which is a mixture of water, salt, urea,
acids, ammonia, and sugar, functions as a body temperature
regulator and waste eliminator. 1 Lysozyme is also secreted
by sweat glands and provides chemical protection against
harmful bacteria? Newborn infants have less subcutaneous
tissue than older infants and children and are therefore more
at risk for thermal instability.

PHASES OF WOUND HEALING
A wound is defined as tissue trauma associated with an
interruption in tissue continuity. Virtually all critically ill
children experience wounds from trauma, surgery, or
invasive procedures, including intravascular access. Wounds
are a potential source of significant morbidity and mortality.
Wound healing is the process in which injured tissue is
replaced through regeneration or repair. Regeneration is the
replacement of tissue with like tissue. Superficial and part.ial
thickness wounds of the epidermis and upper dennis heal by
regeneration. Some tissues, including subcutaneous and
muscle tissue, cannot regenerate and must heal by formation
of new connective tissue (scar) to fill the defect. Wound
healing affects and is affected by critical care management
decisions and has a profound impact on patient outcomes.
The cellular process of wound healing can be divided
into three phases: the inflammatory phase, the proliferative
phase, and the maturation phase (Table 16-1). Although
these phases overlap and intertwine, each has a predictable
sequence of events that distinguishes it. 8 - 12 When this
orderly cascade of events is allowed to proceed, most
wounds can be expected to heal in 3 to 4 weeks. If the
sequence is interrupted, healing will be delayed, and the
wound may become chronic in nature.

Inflammatory Phase
The first of the three phases of wound healing, the defensive
or inflammatory phase, is the body's immediate response to
injury and can last up to 6 days. The function of this phase
is to clear away dead cells and bacteria and to stimulate the
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Phases of Wound Healing

~"Phase

Clinical Observation

Cellular Activities

tt,IofIammatory Phase
iDypically begins at time of injury and la,ts
:: approximately 3 days

Erythema, warmth, edema,
and pain

VasocOIlsrriction: platelets form along injured

lit',

iTI)'roliferalive Phase
jj~Overiaps with inflammatory phase and
;),_. continues until wound is healed

blood vessels; platelets release vasoconstrictive substances and promote fibrin
clot to prevent hemorrhage
Vasodilarion: vasodilatory substances allow
leakage of plasma into wound
Leukocytes migrate through vessel walls to
phagocytose bacteria and foreign materials
Monocytes differentiate into macrophages,
which give rise to tissue repair process

\i'~

Beefy, red granulation tissue

Macrophages secrete growth-promoting

Thin, silvery, epithelial layer
surrounding granulation tissue

substances that mediate granulation tissue
and epi thelialization
Collagen symhesis: performed by fibroblasts;
provides tensile strength to wound
Angiogenesis: regeneration of a vascular
network to restore capillary system to
dermis
Epilhelializalion: cell migration across
a wound

Wound shrinkage

Commaion: myofibroblasts migrate through

;OJ:

f(

i';',

~f:~;

~C,
~;

~W

~t:····

tissue to facilitate closing the wound

~i

~;Maturation

Phase
~Begins 3 weeks after wounding and may
r:~
"'. continue for several years
~:

Shrinking, thinning, paling
of scar

il~~

p'j5

healing process by initiating a cascade of interdependent
reactions. The major events during this phase are hemostasis
and inflammation.
The vascular response in the inflammatory phase is responsible for the clinical observations of the wound. Immediately after the injury, a short period of vasoconstriction
lasting 5 to 10 minutes occurs. Vasoconstriction slows blood
flow through the area and aids in hemostasis. 13 This activates coagulation factors and causes platelet aggregation,
resulting in fibrin clot formation. The clot provides initial
wound closure and helps prevent excessive blood loss. Vasoconstriction is followed by acti ve vasodilation induced by
the release of bradykinin and histamine. 12 Vascular permeability increases, allowing serum to gain entry into the
wound. Fluid, protein, and enzymes normally found in the
intravascular compartment leak through the vessel walls
into the extracellular space, causing edema and erythema. 14
The cellular response during the inflammatory phase
triggers the healing cascade and begins the debriding process. During this period, vessel walls become lined with
platelets, leukocytes, and erythrocytes. Platelets release cytokines or growth factors, which are thought to trigger the
healing cascade and to stimulate the growth of local venular

Remodeling of tissue matrix as fibroblasts
migrate away from the wound while
fibrous bundles of collagen increase the
tensile strength of the scar

endothelial cells that give rise to new blood vessels. 15 Neutrophils migrate to the wound area to ingest bacteria and
debris. They are short lived (2 to 3 days) and become part of
the wound exudate. Macrophages orchestrate the healing
process through ingestion of debris, angiogenesis, and the
release of a protein that stimulates the formation of fibroblasts necessary for the next phase of wound healing. The
overall result of the inflammatory phase of wound healing is
control of bleeding and establishment of a clean wound bed.
Antiinflammatory agents, particularly corticosteroids,
given before the injury or during the inflammatory phase can
markedly reduce the necessary inflammatory response
needed to stimulate healing. t2 Vitamin A has been found to
counteract the antiinflammatory response of corticosteroids,
but when given systemically, it can also attenuate the
anticipated systemic steroid effect. A persistent decrease in
wound blood flow, as seen in dehydration or impaired
cardiac output, can also delay the onset of inflammation.

Proliferative Phase
The proliferative phase is the primary phase of cell
regeneration and repair that occurs approximately 4 to
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20 days after the injury. The major processes occurring
during this phase include macrophage replication, fibroblast
production, collagen synthesis, angiogenesis, epithelialization, and wound contraction. The clinical observations are a
moist, beefy red, granulation tissue surrounded by a thin,
silvery epithelial layer. As the phase progresses, epithelialization is completed. and wound contracture occurs, serving
to reduce the size of the wound defect.
The macrophages and platelets seen in the inflammatory
phase trigger many of the events that occur in the
proliferative phase.15a.16 Granulation tissue is beefy red,
moist, and friable and has a shiny, cobblestone appearance
as a result of newly formed coHagen and blood vessels
(Fig. 16-1). Fibroblasts are responsible for coHagen synthesis. Platelet growth factor, macrophage activity, lactic
acid, and ascorbic acid are necessary for fibroblast proliferation. 12 . 16 Fibroblast migration into the wound occurs
along local fibrin strands from the initial wound coagulation, as well as any remaining coHagen strands. Peak
collagen synthesis occurs from 5 to 7 days in primary
healing wounds and may continue for more than a year in
chronic wounds. lo Fibroblast activity and continued proliferation are dependent on the adequacy of local oxygen
supply and neovascularization.
Angiogenesis, or the development of new blood vessels.
takes place just behind the advancing edges of fibroblasts.
The immature collagen produced by fibroblasts provides
vital structural support for new friable capillaries. Without
the collagen support, these new blood vessels would not
be able to withstand the pressure of arterial blood flow.
Impaired perfusion, tissue hypoxia, and the lack of nutrients,
such as vitamin C, zinc, magnesium, and amino acids, wiH
retard the angiogenesis process.9.IO.12.16
Epithelialization is the migration of epithelial ceHs from
the wound borders to resurface the defect. NormaHy, new
cells form from the basal layer and migrate verticaHy.
However, when there is loss of epidermal tissue, adjacent
basal cells become reprogrammed. They appear to detach
from their basement membrane, divide, and migrate toward

Fig. 16-1 Granulation tissue-red, beefy, and shiny appearance
without evidence of infection.

and across the wound forming a sheet of epithelium. 12 Once
a single layer of epithelium develops, additional layers are
created from mitotic division of these epidermal cells. If any
hair follicles are present in the center of the wound, the
epithelial tissue around them will reproduce and form
islands of pink epithelial tissue that migrate toward other
islands. 17
The reepithelialization process can be rapid (i.e., 3 to
5 days in a partial thickness wound) or may require several
months depending on the size of the wound, nutrient supply,
and the wound environment. Optimal environmental conditions for epithelial migration are a moist, protected wound
bed free of necrotic tissue. A surface barrier that is
permeable to water vapor and oxygen and able to absorb
wound exudate while allowing for cell migration has been
demonstrated to improve wound healing. I g This is the
premise for many of the wound dressings that are discussed
later in the chapter.
Wound contraction is the final process that occurs
during the proliferative phase. Contraction is the process
by which a large wound with tissue loss is reduced in
area by the inward migration of normal tissue. 16 The
mechanism of contraction, which shrinks the wound, is
the generation of ceHular forces in the contractile elements of myofibroblasts. Wound contraction decreases the
amount of surface area that needs to be filled by granulation
and epithelialization. Effective contracture can only occur
if the surrounding tissue is pliable enough to aHow
movement. 19 Wound contraction is exemplified by the
closure of a tracheostomy, gastrostomy, or enterocutaneous
fistula. If the loss of tissue is too great and the defect is
not closed by contraction, surgical intervention may be
required.

Maturation Phase
The last phase of healing begins approximately 20 days
after the injury and continues or up to a year or longer.
Its primary purpose is to remodel the wound and provide a scar thai has maximum tensile strength. The
clinical observations of this phase include shrinking,
thinning, and paling of the wound scar. Black skin seems
to be more prone to overgrowth of scar tissue after
wounding (keloid scars), and when injured, it turns
blacker? A keloid is a benign dense growth of connective
tissue that forms in the dermis after trauma. The lesions
are often firm, raised, pink, and rubbery. They may be
tender or pruritic. Increasing wound strength is accomplished through the maturation of coHagen, the protein that
provides structural strength and integrity to body tissue.
CoHagen establishes the wound's tensile strength, the
maximum amount of pressure that can be applied to a
wound without causing rupture. 16 Collagen synthesis becomes mature, increasingly organized, and consequently
stronger during the maturation phase. In the first 2 weeks
of healing, a wound can regain 30% to 50% of its original
strength. By 3 months, the tensile strength of the wound
nears 80%. However, a wound wiH never regain more than
80% of its original strength. 19
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PROMOTING SKIN INTEGRITY
Routine practices that protect healthy skin surfaces are
essential standards of care in the pediatric intensive care
unit (PICU). All critically ill children share an increased
risk of skin compromise because of factors such as
suboptimal nutrition, impaired sensation, immobility, decreased tissue perfusion and oxygenation, immunosuppression, and the use of medical devices, restraints, and invasive
procedures. Furthermore, they are particularly vulnerable to
the adverse effects of compromised skin integrity, including
infection, discomfort, interference with needed treatments,
delayed wound healing, and prolonged hospitalization.
Healthcare providers need to be knowledgeable regarding
skin integrity characteristics of various ethnic groups.
Promoting skin integrity through nursing practice guidelines
can maximize the potential for achieving desired patient
outcomes (Box 16-1).
Assess and Individualize Skin Care Practices. Vigilant assessment of all skin surfaces (including oral mucosa
and eye integrity) supports the critical evaluation and
necessary individualization of skin care practice guidelines.
Identifying the adequacy of existing practice before significant alteration in skin integrity occurs is central to effective
care. Comprehensi ve documentation facilitates continuity,
assists in identifying trends, and is helpful with tracking
evolving issues.
Bathe Daily With pH-Balanced Cleanser. Daily
baths with a liquid, alcohol-free, and pH-balanced cleanser
supports the skin's protective barrier function and minimizes the risk for infection. The tightly adhered epidermal
cells of intact skin provide an effective physical barrier
against microbial invasion?O The epidermal surface is dry,
mildly acidic, continually shedding, and possesses the antimicrobial properties of sebum and lysozyme. 7 . 16 Healthy
skin is also colonized with indigenous bacteria that inhibit
the growth of potentially harmful microorganisms. The mechanical forces exerted with gentle cleansing facilitate the
protective shedding of epidermal cells. The shed layers are
darker if the nuclei have more melanin. Thus when the skin

. Box 16·1
~ Skin Care Practice Guidelines
Assess and individualize skin care practices
Bathe daily with pH-balanced cleanser
Keep skin surfaces dry
Use moisture barrier products on incontinent infants and
children
Maintain skin hydration
Avoid products that contain perfumes, alcohol, or latex
Minimize the use of adhesives
Minimize the impact of medical devices
Keep mucous membranes clean and moist
Keep eyes moist and protected
Maximize nutritional status
Support tissue perfusion and oxygenation
Promote immunocompetence
Minimize hazards of immobility
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of an African-American child is cleansed with an alcohol
wipe, for instance, the wipe will look darker than it does
when white skin is wiped, not because of dirt but because of
shed cells with rich melanin deposits? I Avoiding antimicrobial products for routine cleaning helps maintain the
skin's natural bacterial flora. Soap is alkaline and can
increase skin pH, creating a more hospitable environment
for bacterial growth. It removes protective sebum and
lysosome. Jackson 22 reports that black skin tends to be dry
and to use soap sparingly. Bar soap carries the additional
risk of supporting bacterial growth and acting as an
infectious reservoir. Infants are at greater risk for epidermal
drying and cracking because they produce less lubricating
sebum and may therefore benefit from less frequent washing
with minimal use of cleansers. Shampooing need only be
done once a week or after electroencephalogram (EEG) lead
removal. Smith and Burns 21 discuss the anatomic and
physiologic features of African-American hair and skin.
They report that the process of hair lubrication takes longer
to occur in African-American hair than in the hair of
Caucasians or Asians; therefore it is drier. Because it takes
longer to get a natural sheen between shampoos, African
Americans tend to wash their hair less often than do other
racial groupS.23 Often oil-based shampoos, not water based,
are used. Discussing hair care regimens with patients or
their families is important.
Keep Skin Surfaces Dry. Moisture is universally
noted as a major risk factor contributing to bacterial growth,
skin breakdown, and pressure ulcer development. Jiricka
and colleagues 24 concluded that skin breakdown was
4 times more likely in patients exposed to moisture. Skin
exposure to moisture from perspiration, secretions, wound
drainage, gastric output, urine, and stool leads to bacterial
growth, maceration, rashes, and, in extreme cases, cellulitis
that weakens the natural barrier of the epidermis 25 Measures to keep skin dry include maintaining a slightly cool
ambient temperature, careful attention to skin folds during
bathing, frequent linen and diaper changes, efficient removal or containment of excess exudates, and the consistent
application of topical products that provide a moisture
barrier to areas of the skin considered at risk.
Use Moisture Barrier Products on Incontinent
Infants and Children. Although all incontinent patients
can benefit from vigilant care and the routine application of
protective ointments, identifying children at increased risk
for developing perineal breakdown and implementing consistent prevention strategies can greatly reduce the incidence
of irritant contact diaper dermatitis. 26 Some common causes
that place children at risk for perineal breakdown include
increased moisture from urinary incontinence, coupled with
friction forces; short gut syndrome; changes in bowel flora
resulting in loose, watery stools; and intestinal adaption to
adjustments in enteral feedings. The initial impact of stool
on the perineum after closure of an ileostomy or colostomy
can also produce significant skin breakdown. Diapers should
be changed as soon as they are wet or soiled. Cleansing can
be done with a pH-balanced cleanser and water, mineral oil,
or disposable diaper wipes that are free of perfumes and
alcohol. Products containing alcohol are drying and irritat-
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ing to sensitive skin; therefore these products should be
avoided.
Avoid the frequent use of plain water and excessive
friction motion during cleansing. 27 Apply a protective
moisture barrier product with each diaper change. Choose
barrier products that are free of alcohol and perfumes, easy
to apply and remove, and cost efficient. Products such as
petroleum jelly, A&D ointment, or zinc oxide preparations
are often sufficient to protect at-risk skin.
Maintain Skin Hydration. Skin hydration is maintained through adequate systemic hydration and the judicious use of topical moisturizers. Children exhibit the
adverse effects of dehydration more readily than adults and
are particularly sensitive to fluid losses because they have a
proportionally higher body composition of water. Dehydration adversely affects tissue perfusion and is a factor in
pressure ulcer development. Even mild fluid volume deficits
can result in poor skin turgor and a dry, cracked epithelial
surface. This condition leaves the body vulnerable to
chemical absorption and bacterial invasion. Dry skin can
add to patient discomfort, and scratching can lead to further
breakdown. Identify and compensate for additional fluid
losses from stool and gastric output, fever, tachypnea,
diaphoresis, open wounds, radiant warmers, phototherapy,
and extracorporeal membrane oxygenation support to the
extent that each child's condition allows. Topical moisturizers applied to extremely dry skin will lessen fluid losses to
the environment and enhance patient comfort, but these
should be used cautiously on the thin and more permeable
epidermal layer of infants. Moisturizers are particularly
beneficial when adequate systemic hydration is contraindicated or when the underlying cause of integumentary
dehydration is the result of non-fluid-related factors, such as
liver dysfunction, radiation therapy, or autoimmune mediators (i.e., eczema).
Avoid Products That Contain Perfumes, Alcohol,
or Latex. Contact dermatitis is a hyperimmune-mediated
response to an antigenic product that results in a sequence of
inflammatory changes in the dermis and epidermis. Cutaneous manifestations can include erythema, swelling, vesicle
formation, pruritus, and ulceration. Use of multiple skin care
products containing chemicals increases the risk of ingredient interactions and skin sensitivity. Exposure to latex may
cause an allergic response, either locally at the site of
contact (Type IV), or an IgE-mediated systemic reaction
(Type I, anaphylaxis). Latex is found in a wide array of
medical devices and skin care products. Children at
increased risk for developing a latex allergy are those with
myelomeningocele and/or a history of chronic or recurrent
instrumentation of the genitourinary tract. At-risk children
should be placed on "latex precautions," and the use of
all latex-containing products should be carefully avoided
to minimize the risk of an allergic reaction (see www.
latexfree.com for an up-to-date list of latex-containing and
alternative, latex-free products).
Minimize the Use of Adhesives. Adhesive-based
products are widely used in the pediatric critical care setting.
Although often necessary, adhesives are a potential skin

irritant and can cause significant skin trauma if applied or
removed improperly. Use alternative products, including
gel electrodes, Velcro ties, Montgomery straps, and cloth
wraps whenever possible (Figs. 16-2 and 16-3). Moisture
vapor permeable, transparent film dressings allow better
visualization of underlying skin and may be less irritating.
Applying a thin pectin- or hydrocolloid-based product as
an "anchor" under adhesives wi II protect the ski n from
irritation and trauma caused by prolonged or repeated tape
removal. When tape is required, consider the use of skin
barrier films to provide a protective interface between the
skin and adhesive product. Avoid the use of benzoin as
a skin barrier under adhesives because it can irritate the
skin and has the potential to be absorbed systemically. To
prevent epidermal separation from the dennis, epidermal
stripping, adhesives should be secured around a tube or
line before being attached to the skin to limit tension on
the epidermal layer. Careful attention to the location of
devices before taping, such as securing endotracheal tubes
midline, and the use of padding under pressure points will

Fig. 16-2

Montgomery straps on a liver transplant patient.

Fig. 16-3

Chest wound with Stockinette.
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lessen the risk of localized pressure injury. When removing
adhesive-based products, the underlying skin should be
supported while applying gentle traction to the product
using water or an adhesive remover. Adhesive remover is
highly irritating and should be washed off the skin
immediately after applying to avoid the development of
contact dermatitis.
Minimize the Impact of Medical Devices. A
myriad of medical devices are used in the assessment and
treatment of critically ill children. Each line, tube, probe,
electrode, catheter, and dressing carries with it the potential
to disrupt the skin's protective barrier and to cause iatrogenic tissue injury. Limiting the adverse impact of medical
devices on the integumentary system requires careful adherence to manufacturers' guidelines on usage and care. General guidelines include using the fewest devices possible,
alternating pressure points regularly (moving oxygen saturation probes, blood pressure cuffs), padding areas of persistent pressure (nasal bridge from oxygen delivery mask),
minimizing the use of high-risk devices (heating lamps
and cooling blankets), and frequently assessing affected
areas.
Keep the Mucous Membranes Clean and Moist.
Oral cavity assessment and care provided every 4 hours
for intubated patients and every 8 hours for patients who
are not intubated, combined with suctioning of oral
secretions every 2 hours, can decrease the incidence of
nosocomial pulmonary infection. 28 Studies have also
shown that there are benefits to providing oral care at
least every 2 hours in critically ill adults, the elderly,
and adult oncology patients. 29 -32 Products that provide
atraumatic cleaning include soft bristle toothbrushes, toothettes, tap water, normal saline, sodium bicarbonate, hydrogen peroxide, and mouth rinses containing clorhexidine?I-34 Use of lemon-glycerine swabs and mouth rinses
that contain alcohol should be avoided to prevent chemical irritation and drying of the oral mucosa. 35 The hyperpigmented oral mucosa of many dark-skinned patients is
a normal finding. Nasal mucosa and lips should be
kept moisturized with the frequent application of petrolatum
or water-soluble lubricants. If the tongue becomes swollen
and exposed, it should be kept covered with petroleum
gauze to prevent drying. Significant tongue edema may require a dental consult to evaluate the benefit of using a
mouth guard or prop to prevent pressure injury. Dental appliances should be removed and cleaned regularly with
mouth care.
Keep Eyes Moist and Protected. Prevent corneal
epithelial breakdown by keeping eyes moist and protected
from chemical and foreign body irritants. Many critically ill
children are at risk for iatrogenic corneal injury because of
a diminished or absent blink response. Eye moisture can be
maintained with artificial tears or lubricant in nonparalyzed
children with insufficient tear production, incomplete lid
closure, or diminished blink response. Chemically paralyzed
children and those with absent blink response should have
their eyes protected with a moisture chamber created by
instilling normal saline drops every 2 hours and covering the
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eyes with plastic wrap to seal in the moisture 36 (Fig. 16-4).
The plastic wrap should be changed daily or more frequently
as needed to prevent infection.
Maximize Nutritional Status. Maximize each
child's nutritional status through careful assessment and the
early initiation of enteral and/or parenteral feedings. Most
critically ill children experience some degree of suboptimal
nutrition as a result of increased metabolic demands, altered
tolerance of enteral feedings, impaired intake, or preexisting
malnutrition. The assessment of nutritional status, the
calculation of protein-energy need, and the implementation
of nutritional support are multifactorial and require multidisciplinary collaboration. Nutritional deficits that contribute to pressure ulcer development include hypoproteinemia,
anemia, ascorbic acid deficiency, and trace mineral deficiency. These deficits alter the quality and integrity of the
components of soft tissue, particularly collagen?? The
release of stress hormones triggered by critical illness result
in the accelerated breakdown of protein for energy. Depletion of amino acids interferes with cell membrane integrity.
Capillary leak and hypoalbuminemia contribute to interstitial edema, which impedes the cellular exchange of metabolites and increases the skin's fragility by stretching collagen
fibers. 38 Insufficient intake of protein, calories, vitamins,
and minerals also has a profound effect on wound healing.
Consultation with the nutritional support team is helpful in
determining whether specialized enteral feedings or vitamin
and mineral supplementation would be beneficial. The early
initiation of enteral feedings and a proactive evaluation of
the need for central parenteral nutrition based on each
child's history and expected trajectory are essential in
maintaining skin integrity.
Support Tissue Perfusion and Oxygenation. Decreased cardiac output with inadequate tissue perfusion is a
final common pathway for a wide range of pediatric critical
care phenomena. Decreased perfusion of the skin and
subcutaneous tissue is mediated by the compensatory
mechanism of the sympathetic nervous system, which

Fig. 16-4

Eye moisture chamber.
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shunts blood flow to vital organs during low-output states.
Inadequate tissue oxygenation is usually the result of
hypoxemia in children, although hypovolemia alone can
have the same effect. 39 The impact of hypoxemia on the skin
is similar to that of inadequate tissue perfusion. Peripheral
vasoconstriction and hypoperfusion can contribute to delayed wound healing.
Promote Immunocompetence. Critically ill infants
and children are particularly vulnerable to acquiring nosocomial infections resulting from immature immune responses, multiple stressors, invasive procedures, and the use
of immunosuppressive therapies. 40 Disruptions in the epidermis from numerous catheters, surgical wounds and
drains, external fixation devices, and traumatic injury leave
the body susceptible to invasion from indigenous and
opportunistic microorganisms. Localized and systemic infection can place a child with immune dysfunction from
serious illness or injury at significant risk for increased
morbidity and mortality. Promoting immunocompetence
requires a multidisciplinary effort to address a broad
spectrum of care, including nutrition, iatrogenic stressors,
comfort or sedation, and medical alterations of immunologic function. Systemic infection increases the risk
of opportunistic skin infections, skin breakdown, and pressure ulcer development. 16.41 Preventing infection requires strict adherence to the Centers for Disease Control
and Prevention Guidelines (see www.cdc.gov), including
good handwashing, the appropriate use of barrier precautions, patient cohorting, the early identification and treatment of infections, and the proper maintenance of lines,
dressings, and medical devices. Children receiving immunosuppressive therapy are at additional risk for skin integrity
impairment as a result of increased skin fragility, decreased
elasticity, gingival hypertrophy, increased risk of avascular
necrosis. and interference with the normal phases of wound
healing. 16.42
Minimize the Hazards of Immobility. Impaired
physical mobility and sensation often accompany serious
illness and can predispose skin over bony prominences to
prolonged or excessive pressures. Pressure that compromises capillary blood flow to the skin and underlying soft
tissue results in inadequate tissue perfusion and oxygenation, metabolic acidosis, ischemia, and necrosis seen
clinically as a pressure ulcer. Routine assessment for
pressure ulcer risk and the early tracking of at-risk
patients into preventive protocols are essential in reducing the morbidity and mortality associated with pressure injury. However, virtually all patients can benefit
from frequent position changes, encouraging the highest
level of mobility possible, range-of-motion exercises, and
the judicious use of physical and chemical restraints.
Children confined to bed rest, those developmentally
unable to roll, and those with neuromuscular or sensation
impairment should be repositioned with small moves at
least every 2 hours. 43 .44 Removal of physical restraints at
least every 2 hours when a child is awake and every 4 hours
during sleep facilitates assessment of skin integrity and
perfusion.

PROBLEMS ENCOUNTERED
IN CRITICAL CARE
Pressure Ulcers
Pressure ulcers are localized areas of tissue destruction
that develop when soft tissue is compressed between a
bony prominence and an external surface for a prolonged period 45 (Fig. 16-5). Continued pressure on tissues compresses capillary blood flow, resulting in tissue
ischemia with eventual necrosis if pressure is not relieved.
The general belief is that the amount of pressure required
to collapse capillaries must exceed capillary pressure. Capillary pressures of 12 to 32 mmHg are commonly used
as the numerical "standard" for capillary closing pressure. 16 Whenever external pressure is exerted that exceeds capillary closing pressure, tissue hypoxia and cellular
death can occur. Pressure ulcers usually occur over bony
prominences, although pressure from external medical
equipment devices, such as face masks, endotracheal tubes,
abdominal binders, limb restraints, enteral feeding tube
flanges, and plaster or fiberglass casts, can result in pressure
ulcers.
Pressure ulcers can be debilitating to patients for weeks
or even months after development. The large expense to
prevent and the much greater expense to treat pressure
ulcers are of increasing concern in acute, rehabilitative, and
home care patients. Healthcare providers need to appropriately allocate finite resources while maintaining quality care
for patients with potential or actual alterations in skin
integrity. A plethora of nursing research is available on the
incidence, prevalence, and expense of pressure ulcer prevention and management in adults (most of which is noted
in the clinical practice guideline, Pressure Ulcers in Adults:
Prediction and Prevention, Agency for Health Care Policy
and Research 46 ). However, little empirical data exist to
guide pediatric nursing practices. Care of infants and children is extrapolated from practices developed primarily for
adults. Adding to this complexity are numerous wound
care products and specialty support surfaces of varying
costs thought to help prevent or manage pressure ulcers in

Fig. 16-5

Occiput pressure ulcer.
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children but that are derived from clinical trials conducted
with adults.
Risk Assessment. The most important nursing intervention in preventing skin breakdown in critically ill infants
and children is the early identification of risk factors. 47 In
1996, Quigley and Curley adapted the adult-based Braden
scale for Predicting Pressure Sore Risk,48 Modified Braden
Q scale (Table 16-2), for use in the pediatric population. The
Braden scale was selected because it has been extensively
tested in diverse adult clinical areas, including intensive
care, and contains vivid categorical descriptors. 25 ,49
The Braden Q scale is composed of seven subscales:
mobility, activity, sensory perception, skin moisture, friction
and shear, nutrition, and tissue perfusion and oxygenation.
All seven subscales are rated from I (least favorable) to 4
(most favorable). Each level is mutually exclusive, with
only one choice for each category. The range of possible
scores for the Braden Q is 7 (highest risk for skin breakdown) to 28 (no risk for breakdown). The Braden Q scale
was originally tested on 178 children on bed rest by a group
of expert pediatric nurses who scored the patients and who
concurrently rated each child's level of risk for skin breakdown as high, moderate, or low. Comparing the Braden Q
score with the subjective rating for each child showed that
children considered at low risk for skin breakdown scored
an average of 25 points on the Braden Q scale. Children at
moderate risk averaged 21 points, and children at high risk
for skin breakdown averaged 16 points. Confidence intervals indicated that children scoring less than 23 points were
at moderate or high risk for skin breakdown. Thus patients
with a Braden Q score of less than 23 points are considered
at risk for alterations in skin integrity.
The necessary frequency of reassessment of pressure
ulcer risk is unknown. Braden and Bergstrom50 explored the
impact of assessment intervals on the ability to optimally
predict pressure ulcers in a nursing home population. They
recommended that the interval for risk assessment should be
determined according to the stability of the patient population. 50 Carlson, Kemp, and Shott 51 found that among 82%
of the patients who had pressure ulcers, the ulcers developed
by the third day after admission to an ICU, indicating the
need to routinely monitor risk for pressure ulcers during the
initial days in the ICU. Quigley and Curley52recommend
that all pediatric patients with skin breakdown, as well as all
immobile patients, undergo a risk assessment evaluation by
a registered nurse on admission and every 24 hours
thereafter. Risk assessment, as the first step in the nursing
process, cannot be delegated to assistive personnel. 53 All
patients at risk for pressure ulcer development should have
a systematic skin inspection at least once every 24 hours,
particularly over all bony prominences.
Prevention and Risk Modification. Once a child at
risk for pressure ulcer development has been identified, a
management plan should be developed to modify or
eliminate known risk. Quigley and CUrl ey 52 developed a
skin care algorithm (Fig. 16-6) to establish practice guidelines for the prevention of alterations in skin integrity. After
a patient has been identified as being at risk for skin
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breakdown based on a Braden Q score of less than 23, a
prevention protocol is instituted. The protocol was extrapolated from the recommendations in the Agency for Health
Care Policy and Research (AHCPR) Clinical Practice
Guideline No.3, Pressure Ulcers in Adults: Prediction and
Prevention.54
Patient positioning and mobility are systematically assessed because it is generally accepted that unrelieved
pressure of sufficient duration leads to the development of
pressure ulcers over bony prominences. Both intensity and
duration of pressure are equally important. For example,
high pressures for short durations equal the same risk as low
pressures for long duration. Among experts, no general
agreement exists regarding the exact level of intensity or
duration needed for pressure ulcer formation.
Regular repositioning has been shown to significantly
decrease the incidence of pressure ulcer development. The
recommendation that at-risk individuals be repositioned
every 2 hours is derived from two classic studies. Kosiak 55
used animal control studies to demonstrate that pressureinduced ischemic injury occurs within I to 2 hours of
exposure. In his study, he applied 70 mmHg for I hour to rat
muscle fibers, and this caused no damage. However, an
application of the same pressure for 2 hours caused
"moderate" muscle damage. Norton, McLaren, and ExtonSmith 56 divided a sample of 100 hospitalized adult patients
into three groups based on the number of times they were
repositioned in 24 hours. The incidence of pressure ulcers in
the group turned every 2 to 3 hours was lower than the group
turned every 4 hours and the group turned 2 to 4 times a day.
They concluded that if pressure is not relieved by regular
2-hour changes in positioning, pressure ulcers would
eventually develop.
The AHCPR recommendations are that any individual in
bed who is assessed to be at risk for pressure ulcer
development should be repositioned at least every 2 hours if
this is consistent with the patient's overall goals. Evidence
shows that small shifts in body weight can be used as an
adjunct to the standard repositioning schedule to further
decrease the exposure of at-risk individuals to high pressure.57 Neidig, Kleiber, and Oppliger 8 significantly decreased the incidence of occipital pressure ulcers from
16.9% to 4.8% in a sample of postoperative cardiac surgery
children by instituting a prevention protocol in which the
primary intervention was repositioning the head at least
every 2 hours. The routine use of gel pillows under the
occiput of critically ill immobile infants is also warranted to
reduce pressure.
The way patients are repositioned is critically important
as well. Seiler and Stahelin 59 recommend repositioning
at-risk patients from supine to right and left 3D-degree
oblique positions. The 3D-degree oblique position more
evenly distributes pressure over the five major bony prominences. Alvarez60 identified the classic ulcer sites as being
over the sacrum, greater trochanter, ischial tuberosities,
lateral malleoli, and heels. When the patient is lying on his
or her side, all of the weight is distributed over one or two
bony prominences. The lateral decubitus position (surface at
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Daily reassessment

Establish a progressive
ambulation schedule
and reassess daily

Place on an overlay
mattress. If head is
immobile use Spenco
Pad or Gel Pillow

Institute Prevention Protocols
Place on 4-inch Eggcrate mattress (2-inch !
infants). Elevate heels oft bed. Do not
elevate HOB >30 degrees for >2
hours, Use trapeze if age-appropriate.
use a lift sheet if too heavy to lift oft
mattress, optimize nutritional intake

Please refer to the
diaper dermatitis algorithm

Establish an
aggressive turning
schedule (q2 hours)
and document on flow
sheet and reassess
daily

No

Yes
);~

Apply transpare'nt
film dressing over
~
••I aftected areas and
reassess daily

>'----+1

Yes

~

Consider an
air-fluidized
bed after
consultation
with a CNS/ET
nurse

Place patient on an
Eftca CC (height for
ECMO and rotation
for SP lung
transplant)

Place patient on a
air-fluidized bed or
mattress overlay after
consultation with
attending MD and ET
nurse

Fig.16-6 Skin care algorithm. (Reproduced with permission from Quigley S. Curley MAQ: Skin integrity
in the pediatric population: preventing and managing pressure ulcers, J Soc Pediatr Nurs 1:7-18. 1996.)
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90 degrees to the patient's back) should be avoided because
it places the skin over the greater trochanter and lateral
malleolus at greatest risk for pressure necrosis 5 Murdoch
and Storman 61 found that turning to a variety of positions,
including the prone position, was possible even in the most
critical patients. Colin and colleagues 44 compared the effect
of 30-degree with 90-degree turns on trochanteric and
retrotrochanteric oxygen supply in 20 healthy adults on a
foam mattress. After 20 minutes, a 90-degree turn position
caused significant trochanteric hypoxia, although retrotrochanteric hypoxia did not occur in the 30-degree position.
Therefore Colin and colleagues concluded that 30-degree
turns may be better in helping to prevent the development of
pressure ulcers.
Because of the small surface area of the heels, it is
particularly difficult to redistribute the pressure. Sheepskin
heel protectors have long been thought to offer some
pressure-reducing benefit. Norton and Young62 monitored the incidence of intraoperative acquired heel pressure ulcers in a pediatric surgical population receiving
epidural anesthesia after converting from sheepskin protectors to heel elevation. They reported no incidents of heel
pressure ulcers with intraoperative foot elevation, as compared with the reported occurrence of heel pressure ulcers when positioned with sheepskin protectors. To totall y rei ieve the pressure, the heels should be elevated
slightly off the bed surface. Suspending the heels can be
accomplished by distributing the weight of the leg across
a larger surface area based on the patients' size, using
positioning devices underneath the lower leg, and leaving the popliteal space free of pressure while supporting
the ankle. For example, some devices used include cotton gauze padding on premature infants and neonates and
infant blankets, pillows, or commercial positioning devices marketed to lift heels off the bed for infants to young
adults.
Shear and friction are forces that can lead to localized
skin breakdown and pressure ulcer development. A shear
injury occurs when the epidermal layer of the skin is pulled
in a direction away from its underlying dermis, causing
trauma to the basement membrane. Clinically, shear is
exerted when the head of the bed is elevated greater than
30 degrees or when a patient sitting in a chair slides down
in the chair. In these positions, the skin and superficial
fascia remain fixed against the bed linens or chair while
the deep fascia and skeleton slide downward. 54 As a result
of shear, blood vessels in the sacral area are likely to
become twisted and distorted, and tissue may become
ischemic and necrotic. 63 Shear forces may be a factor in
the development of undermining and deep tissue injury
seen in some sacral pressure ulcers. The head of the bed
should not be elevated more than 30 degrees for periods
greater than 2 hours unless medically contraindicated. A
draw sheet should be used when repositioning to avoid
dragging and pulling the epidermis away from underlying
tissue.
Friction, which is associated with blister and abrasion
development, occurs when the skin slides against linens or
the bed surface. Casts and orthopedic devices are other
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Staging of Pressure Ulcers

~,~

\!¥stage I

1m:
~=

~:~

[lC
~::
~',

,i"

Nonblanchable erythema of intact skin; the
heralding lesion of skin ulceration. Discoloration of skin, warmth, or hardness also may
be indicators. Note: Reactive hyperemia can
normally be expected to be present for
one-half to three-fourths as long as the
pressure-occluded blood flow to the area;
it should not be confused with a stage I
pressure ulcer.
Partial-thickness skin loss involving epidermis
and/or dermis. The ulcer is superficial and
presents clinically as an abrasion, blister,
or shallow crater.
Full-thickness skin loss involving damage or
necrosis of subcutaneous tissue that may
extend down to but not through underlying
fascia. The ulcer presents clinically as a
deep crater with or without undermining
of adjacent tissue.
Fun-thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle,
bone, or supporting structures (e.g.. tendon
or joint capsule). Note: Undermining and
sinus tracts may also be associated with
stage IV pressure ulcers.

sources of friction. 3? Placing a trapeze on a patient's bed, if
developmentally appropriate, to allow the patient to assist with lifting during repositioning decreases friction.
Using a lift sheet to facilitate moving a patient and not
dragging his or her s,kin across the linens or bed surface
also eliminates friction. Trauma to the epidermal layer over
bony prominences can be seen from the friction forces
generated by patients with frequent restless movements.
Friction injury can be reduced by the use of lubricants
(such as cornstarch and creams), protective dressings (such
as film dressings), and protective padding (such as genuine
sheepskin).46.64
The impact of nutritional status, fluid and electrolyte
balance, moisture, and tissue oxygenation and perfusion on
the development of pressure ulcer development has been
previously discussed.
Management. Despite the implementation of preventative skin care practices within the critical care environment, pressure ulcers may be difficult to prevent
and heal.
Staging. Assessment of injury is the first step in the
treatment of a patient with a pressure ulcer. The pressure
ulcer is staged according to the recommendations of the
International Association for Enterostomal Therapy (lAET)
and the National Pressure Ulcer Advisory Panel (NPUAP)
(Table 16-3). This classification serves as a guideline for
both assessment and intervention. However, a wound cannot
be staged if there is eschar or necrotic tissue present in the
wound bed because the depth of tissue damage cannot be
determined.
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Part III

Phenomena of Concern

IStagethe Pressure Ulcer I

Use moist NS
gauze or wound
gel with DSD
or hydrocolloid
dressing

Stage II: Apply
hydrocolloid dressing
Stage III or IV: Apply
moist NS gauze or
calcium alginate
under a DSD or
transparent dressing

Continue prevention
protocols and consult
with CNS/ET Nurse
Stage II:
Use a mattress
overlay

Continue prevention
protocols and daily
reassessment

Stage III or IV:
Use an air-fluidized
)-+-~ bed or mattress
overlay
Stage II-IV and
aggressive
pulmonary hygiene
required: use a
dynamic air-rotation
therapy bed

Fig. 16-7 Pressure ulcer algorithm. eNS, Clinical nurse specialist; DSD, dry sterile dressing;
ET. enterostomal therapist; NS. normal saline. (Reproduced with permission from Quigley S, Curley MAQ:
Skin integrity in the pediatric population: preventing and managing pressure ulcers, J Soc Pediatr Nw's
1:7-18, 1996.)

Pressure Ulcer Algorithm. Quigley and Curley developed a pressure ulcer algorithm (Fig. 16-7), which is
consistent with the AHCPR clinical practice guideline,
Treatment of Pressure Ulcers. S4 The purpose of the
algorithm was to standardize pressure ulcer interventions and decrease variation in treatment practices. There
has been an explosion of wound care products and
support surfaces, making product selection difficult and
complex. Pressure ulcer dressing selection is based on
wound location, the presence or absence of infection, the
presence of undermining or tunneling, the condition of
the periwound skin integrity, ease or difficulty of dressing application, and cost. No single dressing provides
the optimal environment for all pressure ulcers throughout the entire wound healing continuum. If a dressing is nonadherent and needs to be stabilized, whenever possible, Montgomery strap dressings (Johnson &
Johnson Medical, Inc., Arlington, Tex.) are used to
minimize epidermal stripping to the peri wound skin from

frequent adhesive removal. A pectin-based wafer can also
be applied on either side of the wound to serve as a tape
anchor. A protective barrier is recommended under tape to
protect the skin from further injury and irritation. Pressure ulcers change over time and require ongoing reassessment of the efficacy of the dressing in optimizing
wound healing.
Dressing Principles. When choosing a dressing,
there are seven basic principles that facilitate healing by
creating an optimal microenvironment. These principles are
to (I) remove necrotic tissue, which can be accomplished by
mechanical, chemical, or autolytic methods; (2) eradicate
infection-all wounds are contaminated, but not all wounds
are infected (indications for culture and sensitivity sampling
include signs of local or systemic infection or evidence of
bone involvement); (3) absorb excess exudate; (4) obliterate
dead space; (5) maintain a moist wound surface, which
facilitates cellular migration; (6) insulate the wound; and
(7) protect the wound from further trauma and bacteria.
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Tables 16-4 and 16-5 provide information on products that
meet these principles.
Therapeutic Support Surfaces. A variety of therapeutic support surfaces are available, categorized according
to their ability to counteract forces contributing to pressure
ulcer development (Tables 16-6 and 16-7). The capillary
closing pressure of 12 to 32 mmHg is used as a measure of
efficacy of support surfaces to minimize the occlusion of
capillary blood flow and pressure ulcer formation. Although
significant improvements had been made to bed frames, not
until the late 1980s were pressure reduction mattresses
introduced to replace foam overlays and reduce the need for
costly specialty rental beds. These mattress replacement
systems (MRSs) have multiple layers of high-resiliency,
antimicrobial solid foam, which more readily conforms and
distributes weight as compared with standard vinyl-covered
mattresses. The inner foam core quality is defined by density
(weight of one cubic foot of foam), with the higher density
foams ensuring that the original resiliency will endure after
repeated compressions, and indentation force load deflection (IFD), which is a measure of load-bearing capacity.
Most of the MRSs have water-repellent, antibacterial, nylon
top covers that offer benefits of low shear and low friction.
When MRSs are introduced, most institutions can safety
eliminate the use of 4-inch convoluted foam overlays.
Advances in medical technology have produced a
multitude of products to prevent and treat pressure ulcers,
including those that reduce pressure and those that relieve
pressure. Currently a universal set of evaluation criteria
related to the selection and use of different types of
pressure-reducing and pressure-relieving surfaces indicated
for a given patient situation is not available.
Pressure-reducing surfaces can lower the external pressure exerted over bony prominences, as compared with
standard hospital mattresses. Of importance to note is that
they do not consistently reduce pressure to less than
capillary closing pressure and therefore may not prevent
pressure ulcer development.
Pressure-relieving devices differ from pressure-reduction
devices in that they consistently maintain pressures less than
capillary closing pressures, allowing blood to flow unimpeded through the skin's microcirculation. Specialized
therapeutic beds are the largest and most sophisticated group
of pressure-relieving devices available. They are also
designed to reduce or eliminate damage from shear, friction,
and maceration on a short-term basis. Unfortunately, specialty beds are an expensive care option, and most institutions have limited resources available for bed rentals. The
use of therapeutic mattress overlays or beds is reserved for
those patients at high risk for skin breakdown despite
optimal nursing care. Children that often warrant and can
benefit most from this level of intervention include those
with skin grafts on a turning surface or extensive skin
integrity compromise, including burns, purpura fulminans,
and pressure ulcers on more than one turning surface.
Several types of specialty beds are currently available.
When deciding which bed is most appropriate for children,
a clear understanding of their present risk factors, treatment
goals, and projected illness trajectory is necessary.
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Static low-air-loss beds consist of independently inflated
air-filled cushions that provide pressure relief. They can
adjust manually to a variety of positions, and they are
available in small and crib sizes. Most are covered with
nonabsorbent nonstick sheets, and some have special
features, such as built-in scales. Disadvantages ofthese beds
include cost and bulky size, the fact that the bed does not
actively change the patient's position, and that the bed does
not absorb fluids, which may lead to maceration, infection,
and delayed wound healing. Children most likely to benefit
from this type of bed are those at high risk for developing
skin breakdown, those who tolerate some movement, and
those who do not have extensive wounds and in whom the
primary treatment goal is to prevent pressure breakdown
until their underlying condition has improved.
Kinetic therapy beds are a group of beds that can be
programmed to rotate a patient's position at set intervals.
Rotation beds are a type of kinetic bed in which the entire
bed frame moves to rotate the patient. They are often made
of flat, firm foam surfaces with foam support cushions and
straps. These beds are optimal for treating patients with
unstable traumatic injury in whom the treatment goals are to
prevent pressure breakdown, mobilize pulmonary secretions, and stimulate gastrointestinal mobility. Disadvantages
of these beds include cost, size, waterproof cushions that
may promote sweating and fluid contact with skin, and the
risk of shearing injury with movement. These beds are used
only until patients' initial traumatic injuries have been
stabilized and they can be safely moved to a bed with less
risk of shearing or maceration.
Another subgroup of kinetic therapy beds is the active
low-air-loss bed. These beds consist of independently
inflated air-filled cushions that either pulsate or rotate the
patient from side to side. The advantages that these beds
offer include selected pressure relief, a variety of bed
positions, cushions that dry quickly, and bed movement that
may stimulate capillary blood flow and loosen pulmonary
secretions. 65 Disadvantages include cost, size, and bed
movement that is relatively limited when compared with
manual turning. Children who benefit most from active
low-air-loss beds include those who do not tolerate manual
turning but require repositioning as an essential aspect in the
care of their underlying illness.
Air fluidized or static high-air-loss beds have absorptive ceramic beads that are blown by warm air to create
a fluidlike motion. The beads are contained within a thin
filter sheet. The beads absorb fluid and keep both the sheet
and patient continually dry. The filter sheet and chemical
makeup of the beads also help to reduce the risk of
infection. The fluid movement of these beds is superior
to air cushions in placing minimal pressure on tissues.
Temperature regulation of the bed's airflow can be
manipulated to meet patient care needs. Disadvantages
include cost, size, weight, the inability to adjust bed
height, limited bed positions, and the bed's drying effect, which may overly dry open wounds and thicken
pulmonary secretions. These beds are used when the
primary objective is optimal wound healing in infants and
children with severe skin disorders, movement disorders,
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Properties of Commonly Used Dressing Materials
Examples

/1)

3

Indications

Advantages

Disadvantages

Considerations

Stage III, IV

Absorb wound exudate,
protect wound. effecti ve
delivery of topical
solutions if kept moist.

When left to dry in the
wound, it may remove
viable tissue; labor
intensive.

Acuderm, Bio-e1usive,
Blister Film, Clear Skin,
Ensure It, Op Site,
Tegaderm, Omiderm,
Polyskin

Intravenous sites; superficial abrasions; blisters;
minor bums; donor sites;
stage i, II, or III
pressure ulcers

Adhesi ve can damage new
wound surface epithelium upon dressing
removal; nonabsorbent;
some products difficult
to apply; can promote
wound infection,

Cutinova Hydro, Comfeel,
DuoDerm, Restore,
Hydra Pad, intact,
[ntraSite. Sween-a-Peel,
Tegasorb, Ultec,
RepliCare

Stage i, II. or III pressure
ulcers; dermal ulcers;
donor sites; second
degree burns; abrasions

Maintains physiologic
environment; provides
bacterial barrier; transparent; conforms to
wound; waterproof;
reduces pain; can be
used with gauze to
absorb leakage.
Creates a moist environment by interacting with
wound fluid; provides
barrier to external
bacteria; protects from
reinjury; fosters autolytic
debridement; waterproof;
reduces pain; absorbent;
nonadhesive to healing
tissue; easy to apply;
flexible to mold over
difficull areas,

Helps to physically debridc
necrotic tissue; excellent
for packing and undermining; use rolled gauze
for packing large
wouods; pack loosely;
use wide mesh gauze for
debriding; do not use
cotton-filled materials
on wound surface.
Protect friable wound
margins; avoid in
wounds with infection,
copious drainage, or
tracts; change only
if dressing leaks.
Stretch and "lift off"
wound bed,
Frequency of changes
depends on amount
of ex udate (change
as needed for leakage);
avoid in wounds with
infection or in sinus
tracts; may cause
periwound trauma
when removed,

gauze/fine mesh

iP

1lI:" gauze

~1ii

1-

ID,~:r
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g;ii

~!!:,
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!!i,i
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~~oisture vapor
~.£:,

permeable
~il';! membranes
!t{,!
1m,,, (MVP films)
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~t,
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r~;

~4iydrocolloidS
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~'h
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l!ii"

,~[:.",
~~;;~:
~,:l
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1m',
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May soften and lose shape
with heat and friction;
the interaction between
wound exudate and
barrier material produces
a yellow to brown
drainage. which can be
confused with purulent
drainage,

Ii?

.

,iliFoam dresslllgs
:fi'. Polymeric and
li)f composite poly~~' meric dressing

til

~.;

Stage I, II. or III pressure
ulcers; dermal ulcers;
donor sites; bums;
abrasions; lacerdtions;
partial-thickness wounds;
graft sites; highly
exudative chronic
wounds; dressing for
tracheostomy drain sites.
Hydrophilic compounds
t.hat aUract bacteria,
exudate debris through
osmotic forces in
wound.
Heavily draining chronic
wounds; autolytic
debridement.

Insulates wound; provides
some padding; maintains
physiologic environment;
reduces pain; permits
some autolytic debridement; nonadherent to
wound.

Poor barrier; nontransparent; requires taping
of edges.

One layer usually absorbs
or wicks exudate while
another layer maintains
moist environment while
adhering to skin; change
every 24 hours or when
leaking occurs.

Absorbs in varying
degrees; maintains moist
environment; facilitates
debridement.
Decreases number of
dressing changes
required.

Can cause pain with application; requires cover
dressing; materials leak
from dressi ng edges if
not well taped; difficult
to remove from tracts
and deep pockets.

Carrington Gel, Geliperm,
IntraSite. Spand-Gel,
Dermal wound gel,
Biolex

Stage I, II, or III ulcers.

Requires a cover dressing;
variable absorbency.

Kaltostat, Sorbsan,
Curasorb, AIgosteri I,
AlgiDerm

Highly exudating wounds.

Good "filler" for small,
deep wounds; easy to
apply; maintains moist
environment; helps to
soften or slough eschar
in necrotic wound.
Nonadherent to wound;
absorbent dressing made
from seaweed; may be
used with infected
wounds; nonwoven fiber
dressings that convert
to a fiml gel/fiber mat
when mixed with wound
exudate.

Partially fill wound to
allow for expansion
of materials; not for
wounds with fistulas/
tracts that prevent or
hinder removal: monitor
electrolytes if copious
drainage; may increase
wound pH.
Avoid in infected wounds;
change every 8 hours.

AlIevyn, Biobrane,
Epi-Lock; Kontour.
LYOfoam. Primaderm,
Synthaderm; Viasorb;
Mitraflex

E;(i

~];,

!lit

IDI':

ltW
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,!~Wound

exudate
absorbers. powders,
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iii," pastes
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~Wound gels
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Bard Absorption Dressing,
Comfeel Ulcer Powder,
DuoDerm Granules,
Comfcel Paste,
DuoDerm paste granules, Hollister wound
exudate absorber.
Pharmaseal, HydraGram.
Envisan

t;j;'

~i:!

t!:
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from Hagclgans NA: Pediatric skin care issues for the home care nurse, Pediarr Nurs 19:504. 1993.

Requires less frequent
dressing changes: highly
absorbent; excellent for
packing and undermining; requires cover
dressing; characteristic
odor to dressing when
removed.
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TopicalAgents Used for Wound Care

&;,;!!

~category

Examples

Considerations

Nursing Intervention

tit
.
.
iiITsotomc solutIOns

Normal saline

Nontoxic to healing tissue; readily
available

Used for rinsing, irrigating, and packing;
used to cleanse wound before obtaining
a culture.

Acetic acid
0.25%

Cytotoxic to fibroblasts; effective against
Pseudomonas

Hydrogen
peroxide 3%

Cytotoxic to fibroblasts; potential for air
emboli when used as an irrigant under
pressure

Povidoneiodine 1%

Cytotoxic especially in detergent form;
when used at 0.001 % concentration,

Use as 0.25% solution for irrigating Or
continuous moist packing; discontinue
use as soon as granulalion tissue is
noted.
Avoid using as irrigant in deep wounds
or wounds with tunneling: limit use to
removing dried blood; dilute to \12
strength.
Use in concentration of 10% or less if
used for packing; change dressing frequently to maintain activity; discontinue when wound is clean and
granulating.
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Il~:(,Antiseptic solutions
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m't'

~~.

~tf:e:~;aa~::~~:~i~~l ~~:~~~:r~::r:iC
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potentially causes metabolic acidosis,
renal problems, cardiac instability if

IE

ii'

~;e:~: large wounds over a period

I',

Sodium
hypochloride

mil,)

~~7~i~~akin's

,.

Cytotoxic to fibroblasts at full strength;
used at 0.005% concentration, it has a
bactericidal with no cytotoxic effect

I;;

If used as packing. moisten frequently to
maintain activity; discontinue use when

;o:~:~t~:t~~:a~fa;~i:~:~~:~~:in:e~~ce
stinging.

TABLE 16·6

Pressure Reduction/Relief Devices
Examples

Aerofoam, BioGard,
DuraPedic, GeoMatt,
Ultra Form Pediatric

Aqua-Pedics (water and gel),
Tender Gel and Water,
Theracare (water and gel)

AeroPnlse, AlphaBed,
AlphaCare. BetaBed,
Bio Flote. Dyna-CARE,
Lapidus, PCA Systems,
Pillo-Pump, Tenderair
May be more effective than
foam; easy to clean; has
been documented in adult
studies to reduce pressure.

Surface materials are constructed to reduce friction
and shear and to eliminate
moisture; pressure relief:
can be used for prevention
and/or treatment of ulcers.

Inflation level must be
checked frequemly by
caregiver to maintain
therapeutic levels; may
cause increased perspiration
because of plastic surface.
Surface maltress and pump are
a rental item; not available
for cribs. Side rails on some
beds may not adequately
contain large patients.

.~eprinted from Hagelgans NA: Pediatric skin care issues for the home care nurse, Pediatr

Nllrs

19:504. 1993.

DermaGard, K-Soft,
KoalaKair, Roho,
Sof-Care, Tenderair

ACUCAIR. BioTherapy,
Clini-Care, CRS 4000,
RibCor Therapeutic
Mattress Pad
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16-1 Specialty Beds
Advantages

Disadvantages

Examples

~::

i~Specialty

beds are "high-tech" beds used in place of the standard hospital bed, are usually used on a rental basis, and are intended
for short-term use. They provide pressure relief and eliminate shear, friction, and maceration and in some cases provide lateral
!:.-'-' rotation and chest physiotherapy.
FlexiCair, Air Plus, KinAir,
~;1. Low·air·loss beds: surface
Provides pressure relief in any
Difficult for the patient to
Mediscus; Cribs: Pedcare,
I~ consists of inflated air
position; treatment for
move around in bed.
PediKair, PNEU-CAREI
cushions; each zone is
Stages II·IV pressure ulcers;
Pedi
~L . adjusted for opllmal
aVailable III pedlatnc cnb
!!i!": pressure relief for patient's
sizes. Ideal for treatment
"'.~.' body size: some models
of heel and occipital
have built-in scales.
pressure sores.
Airflow may dry out wound if CLINITRON, FluidAir Plus,
!~ Air-fluidized beds: air is
Treatment for deep-pressure
latex sheet is not used. Bed
Skytron
blown through silicone
sores, burns, posterior flaps;
weights 1500 lb; difficult to
beads to "float" patient.
draws fluid away from
transfer patient.
llh
pallent.
'~"3.
Continuous
lateral
Indicated
for
patients
with
a
Cushion based: Efica
Cost
J,k
(RESCUE), BioDyne,
j!!ii: rotation beds; cushion
high degree of immobility,
~:L beds: microprocessorsevere respiratory distress,
Table based: RotoRest, Keane
~;V controlled low·air-Ioss bed
and who are hemodynamiMobility
~i~<', •
;r.!,,' mflates and deflates
cally unstable when moved.
t~!;; cushions to achieve lateral
Must have stable spine. Table
}Lr
ii,:: rotation. Some models
based: same as above and
~;; include percussion, vibrasuitable for some patients
~,;: .. tion, pulsation. Some raise
without a stable spine.
patient high enough for
ECMO support. Table
11'··· based: Without low-air-Ioss
~f_ cushions, achieves lateral
'11,
rotation by turning complete
~: bed frame.
~:::

1'It
I!L
I:::

It.

;r
~';-

J!lPata from Doughty D: The process of wound healing: a nursing prospective. ProgressiollS 2:3-12. 1990; OIavis C. Barbour S: Pressure ulcer prevention
i!;"in critical care: state of the art, MeN 1:602-613.1990; Krasner D: Patient support surfaces. OSlOmy W<JlIlld Mallage 38:57-60.1991.
~Jl.eprinted from Hagelgans NA: Pediatric skin care issues for the home care nurse, Pediarr Nllrs 19:504, 1993.
~.his

list is a representative sampling of products, which is not intended to be all inclusive. No endorsement of any product is intended. Within each
~category, products must be individually evaluated on their efficacy as comfort, pressure-reducing, or pre~su~e-relieving devices. All products within a
~-calegory do not necessarily perform equally.
~CMO, EXlracorporeal membrane oxygenation.

.-,;.;,1

extensive skin breakdown, heavily draining or large open
wounds, or large grafted areas.
Alternating low-air-Ioss overlay mattresses are applied
over the existing hospital mallress. They are dynamic, using
electricity to alternately inflate and deflate and thus decreasing tissue interface pressures lower than capillary closing
pressure. Many overlays are pressure-reducing not pressurerelieving products. The advantages of these overlays are a
low daily rental fee (compared with entire specially bed
units), placement while patient is on bed, no storage of
existing hospital bed, quick deflation for emergencies, and
easy movement and cleaning of bed. Disadvantages are that
assembly is required, motor may be noisy, sensation of
inflation and deflation may bother the patient, and electricity
is required.
A variety of therapeutic support surfaces are available to
provide an environment to prevent or assist in the management of a pressure ulcer. Therapeutic support surfaces are
only one component of a comprehensive management plan.

Irritant Contact Diaper Dermatitis
Irritant contact diaper dermatitis is an inflammation of
the skin resulting from contact with urine and stool. The
resultant diaper dermatitis is often characterized by any of
the following: erythema, maceration, erosions, or a candidal
(monilial) rash throughout the perianal, perineal, and genital
area. The epidermal layer mayor may not be intact. The
more severe forms include ulcerations scallered throughout
the perineal area, sometimes including the genital area and
groin. At this phase, nerve endings are exposed, and pain is
experienced. The clinical features of a candidal rash are
erythema with "satellite" papules and pustules often associated with pruritus.
Diaper Dermatitis Algorithm. A diaper dermatitis
algorithm (Fig. 16·8) was developed to standardize the care
of patients with perianal, perineal, or bUllock skin impairment. The guidelines use pH-balanced skin cleansers, oatmeal or astringent soaks to promote healing, moisture barrier creams or ointments to protect the skin, and antifungal
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Phenomena of Concern

Regimen 1
Apply:
1. Stomahesive powder
2. Thick layer of Desitin
ointment
3. Stomahesive powder
pm

Regimen 4

Regimen 3

Regimen 2
Apply:
1. Thick layer of Desitin
ointment
2. Stomahesive powder
pm

Apply:
1. Myconazole powder
2. Thick layer of Desitin
ointment
3. Stomahesive powder
pm

Apply:
1. Lotrimin or Nystatin
cream
2. Thick layer of Desitin
ointment
3. Stomahesive powder
pm

With each diaper change:
• Use Sensicare cleanser pm; no soaps or diaper wipes
• Only wipe off ointment stained with stool

Every 12 to 24 hours:
• Remove entire ointment layer
• Reassess skin
• Domeboro or Aveeno soak pm
• Reapply all layers

Reassess ointment regimen q48-72h

1. Change Desitin to lIex
ointment
2. Apply Vaseline over lIex
for 48 hours, then reassess

1. Continue present skin
care regimen
2. Reassess q24h

Fig. 16-8

Diaper dermatitis algorithm.

topical products to treat candida) yeast infections that may
be associated with irritant contact diaper dermatitis.

Frequent diaper changes and proper cleansing of the skin,
with the application of topically applied barrier powders,
creams, or ointments, promote healing of compromised

skin. The practice of leaving the diaper area open to air or
blowing oxygen onto the skin is not supported in research.
However, researchers do know that the systemic circulation
of oxygen is critical to wound healing. Furthermore, wounds
heal more readily in a moist environment rather than a dry
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one. Leaving the diaper area open to air only facilitates the
recognition of when a patient defecates.
The use of pectin-based wafers, such as Stomahesive or
Duoderm (Convatec, Chicago, Ill.) over the buttocks is
not advised. Stool tends to accumulate around the edges
of the wafer, and the "meltdown" it produces within the
moist environment of a diaper can cause further trauma to
the skin on removal. Often the area with the most skin
integrity compromise is in the gluteal crease, and the barrier
wafers do not conform and adhere well. The use of heat
lamps is also strongly discouraged because they can burn the
perineal area.
The diaper dermatitis algorithm guides interventions
based on accurate assessment of skin integrity status. It is
not necessary to remove the entire protective barrier with
each diaper change. Each time the skin is cleansed, by
taking the barrier layer completely off, there is an increased
likelihood that new epithelial growth can be disrupted.
Therefore removing only that portion of the protective
barrier that is soiled is advised, along with reapplication of
the barrier layer. Every 12 to 24 hours it is recommended to
soak or bathe off the entire protective barrier layer to
reassess and document efficacy of treatment and skin
condition.
Therapeutic soaks or baths, such as oatmeal colloidal
soaks (Aveeno, S.c. Johnson & Son, Racine, Wis.), for 5 to
10 minutes every 12 to 24 hours may be indicated for relief
of irritated, pruritic skin, which is often associated with
candidal yeast rashes. Astringent agents, such as Domeboro
(Bayer Corp., Elkhart, Ind.), may be indicated for relief of
inflammatory skin conditions requiring "drying out" of
denuded, weepy skin.
Regimen 1. If the epidermal layer is not intact and no
candidal rash is present, then, as first layer, apply Stomahesive powder to absorb moisture and provide a dry base,
which will enhance the adherence of a moisture barrier
ointment or cream. Next, apply a thick layer of moisture
barrier, cover with powder for first 48 to 72 hours, and then
reevaluate and document skin integrity status. If no improvement occurs, refer to regimen I for the sequence of
moisture barrier layers to apply.
Regimen 2. If the epidermal layer appears intact
with the presence of erythema and no coexisting candidal rash, the regimen is as follows: Apply, as first layer,
a thick layer of zinc oxide-based ointment or cream (i.e.,
Desitin, Pfizer, Inc., New York, N.Y.) as a moisture barrier
layer to protect skin from contact with urine and stool.
Cover the barrier with Stomahesive powder (Convatec,
Princeton, N.J.) to decrease the adherence of the ointment
into the absorbent gel layer in disposable diapers for the
first 48 to 72 hours, then reevaluate and document skin
integrity status. If no improvement is seen, change the
barrier layer to Ilex paste (Medcom Industries, Grafton,
Mass.) covered with petroleum jelly for the next 48 to 72
hours, then reevaluate and document skin integrity status.
If no improvement is noted or skin integrity worsens,
change the barrier layer to Criticaid paste (ColoplastiSween
Corp., N. Mankato, Minn.) covered with Stomahesive
powder for 48 to 72 hours and then reevaluate and
document.

Fig. 16-9
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Extravasation injury.

Regimen 3. If epidermis is not intact and a coexisting candidal rash is present, then, as first layer, apply an
antifungal powder to open, denuded areas and antifungal
ointment or cream to surrounding intact skin and refer to
regimen I for the sequence of moisture barrier layers to
apply.
Regimen 4. If the epidermis is intact and a coexisting
candidal rash is present, then, as first layer, apply an
antifungal cream or ointment and refer to regimen I for the
sequence of moisture barrier layers to apply.
Evaluation. Daily evaluation and documentation of
the skin integrity are critical to assess the outcome of
interventions. Consistency is the key to a successful skin
care regimen. Changing the regimen with every nursing
shift only diminishes the ability to know effectiveness of
anyone particular intervention. Moderate to severe perineal
skin breakdown often does not show signs of healing for
several days, particularly if stool frequency persists. Therefore changes to a skin care program are not initiated until
after 48 to 72 hours after implementation.

Intravenous Infiltrate Injury
Virtually all critically ill pediatric patients have an intravascular access device in place for blood sampling, pressure
monitoring, or delivery of a wide variety of fluids and
medication. Intravenous therapy is an essential aspect of
care that carries significant risks, including extravasation
injury. Extravasation or infiltration is the leakage of intravenous fluid or medication into interstitial tissues. It is a
potentially serious complication that can cause morbidity
through direct skin and tissue damage (Fig. 16-9).
Infiltration occurs through cannula dislodgment, punctures in the venous wall, seepage around insertion sites, or
increased permeability of the infiltrate through damaged
endothelium. The extent of tissue damage sustained from
extravasation depends on the physical and chemical nature
of the infiltrate, the volume infiltrated, and the patient's
clinical condition at the time of the injury.66.67 Effects can
range from mild erythema, edema, and discomfort, which
resolve spontaneously to extensive necrosis and loss of
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epidennal, dennal, and subcutaneous tissue that require
extensive wound care over an extended period. Severe
extravasation injuries can impact limb function, sensation,
and cosmetic appearance.
Infiltrates that have the potential to cause the most
significant injury if extravasation occurs include those that
are hyperosmolar, vasoconstrictive, alkaline, poorly water
soluble, or directly cytotoxic. 68 Hyperosmolar fluids have
a higher osmolality than serum and are irritating to venous
endothelium, resulting in inflammation and capillary
leak. Once in the interstitial space, hyperosmolar agents
cause edema, vasoconstriction, ischemia, and necrosis.
Hyperosmolar solutions include dextrose concentrations
greater than 10% and those containing high amino acid or
electrolyte additives. Undiluted electrolytes including potassium, calcium, and bicarbonate also have extremely high
osmolalities.
Vasoconstrictive drugs cause tissue damage wheninfiltrated by reducing blood flow to the affected area, causing
localized tissue ischemia. Vasopressor medications such as
dopamine, dobutamine, epinephrine, and norepinephrine all
have the potential to cause vasoconstrictive tissue damage.
Alkaline agents, including sodium bicarbonate and sodium
thiopental, cause direct cellular injury once infiltrated.
Drugs with low water solubility, such as lorazepam, diazepam, phenytoin, digoxin, and nitroglycerin, can fonn cytotoxic precipitates if infiltrated undiluted. 68 Most antineoplastic agents are directly cytotoxic. Vesicants, such as
doxorubicin, daunorubicin, dactinomycin, nitrogen mustard,
vincristine, and vinblastine, carry the highest risk for extensive tissue damage if infiltrated. 67
Prevention. Prevention of extravasation injury begins
with careful selection of catheter type, size, and location. Ideally, collaborative decision making that accurately
reflects a child's current condition and anticipated trajectory guides vascular access placement. Often this goal
is unrealistic, given emergent patient conditions, difficult
or limited access sites, and evolving care issues. Central
venous access should be secured as soon as possible if
high-risk intravenous agents are required. Peripheral catheters made of soft plastic are better choices than rigid
steel needles, which have been shown to increase the risk
of infiltration. 69 When possible, a peripheral cannulation
site should be chosen that minimizes the risk of dislodgment from movement. Joint spaces should be avoided
because even when arm board restraint is used to limit
flexion, catheter displacement from rotation can result.
Manufacturers' guidelines on the proper dilution and
infusion rates of medications should be followed, whether
given centrally or peripherally. When an infusion pump
is used to deliver solutions peripherally, a volumetric
cassette pump with a maximum deli very pressure of less
than 20 pounds per square inch is safest. 68 Syringe pumps
often have higher flow pressures and should be used with
caution.
Management. Vigilant assessment of the intravenous
site once an infusion is in place is essential to detect early
signs of infiltration, prevent large volume infiltrates, and
minimize tissue injury. Signs to watch for include swelling,
blanching, coolness, firmness, leakage around the insertion

site, decreased flow rate, or increased resistance with
flushing. It is not appropriate to rely on patient-reported
discomfort to detect intravenous extravasation. Children
have relatively loose subcutaneous tissue that can hold a
significant amount of infiltrated fluid before becoming
painful, and many critically ill children are too young, too
sick, or too sedated to reliably alert anyone that an infiltrate
is occurring. Frequent observation is aided by not obscuring
the intravenous site with excessive tape, gauze wrap,
"welcome" sleeves, or protective covers. The use of a
transparent adhesive dressing facilitates visualization.
The goal of treatment after the identification of an
extravasation is to limit the extent of skin and tissue damage
incurred. For all infiltrates, the first intervention is to stop
the infusion and attempt to aspirate fluid through the
cannula. The catheter is left in place until a collaborative
decision is made on the administration of an antidote.
Further treatment is based on staging the infiltrate (Table
16-8). When staging an infiltrate, it is important to realize
that the extent of injury may not be apparent during the
initial assessment. Some infiltrates, including dopamine,
norepinephrine, calcium, potassium, sodium bicarbonate,
vancomycin, amphotericin B, dextrose concentrations of
20% or more, and most chemotherapeutic agents, can cause
progressive damage to tissues over hours to days.67
Treatment of stage I and II infiltrates usually includes site
elevation to decrease edema and the application of warm or
cold compresses. Warm compresses are applied to extrava-
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16·8 Staging of Intravenous
(IV) Infiltrates
..

TABU

~Stage

Characteristics
Painful IV site
No erythema
No swelling
Painful IV site
Slight swelling (0%-20%)
No blanching
Good pulse below infiltration site
Brisk capillary refill below infiltration site
Painful IV site
Marked swelling (30%-50%)
Blanching
Skin cool to the touch
Good pulse below infiltration site
Brisk capillary refill below infiltration site
Painful IV site
Extensive swelling (>50%)
Blanching
Skin cool to the touch
Decreased or absent pulse'
Capillary refill >4 seconds'
Skin breakdown or necrosis'

i",·

!i!ffrom Remmer L, Chan JJ: A pediatric protocol for management nf
~xtravasation injuries, Pediarr Nurs 19:424, 1993.
i'r*The presence of anyone of these characteristics constitutes a stage IV

iGmltrate (see Millam DA: Managing complications of IV therapy, Nun
~$8 J8:34-42, 1988).
vii"·
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sations of noncaustic solutions regardless of osmolarity.70
Warmth improves circulation to the affected area and
increases the rate of fluid absorption. Cold compresses help
to reduce ulceration when applied to infillrate sites of caustic
or highly irritating agents. 70 In addition to these measures,
stage III or IV infiltrates require immediate and aggressive
interdisciplinary intervention because they carry a high risk
for extensive deep tissue damage. 66 Despite aggressive
treatment, some extravasation injuries result in tissue
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damage that requires surgical intervention and extensive
wound care. A plastic surgery consult done soon after
discovery is helpful in addressing physical, functional, and
cosmetic issues.
Antidotes, Several substances have been found to
be useful in limiting the extent of tissue injury associated
with extravasations. 71 -73 These antidotes are administered
through the infiltrated catheter, multiple subcutaneous
injections, or topical application (Table 16-9). Hyaluroni-

Antidotes
Antidote

Dose

Hyaluronidase 15 VlmL
Hyaluronidase 15 U1mL
Hyaluronidase 15 U1mL
Cold compresses
Hyaluronidase 15 VIm!
Sodium bicarbonate 2.1 % dilution

0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
qid x 72 hr
0.2 ml x 5 doses SQ
Infiltrate area with 1-3 ml, leave for 2 min
and aspirate off again
0.2 ml x 5 doses SQ

Hyaluronidase 15 Vlml
Cold compresses
Sodium thiosulfate-1/6 M solution (4 ml of
10% sodium thiosulfate 100 mg/ml mixed
with 6 ml of sterile water)
Cold compresses
Sodium thiosulfate 1/6 M solution (dilute
as with cisplatin)
Cold compresses
Sodium thiosulfate 1/6 M solution (dilute
as with cisplatin)
Ascorbic acid
Hydrocortisone
Initial (first 24 hours):
Dimethyl sulfoxide (DMSO)
Hydrocortisone cream
Cold compresses
Subsequent 14 days:
Dimethyl sulfoxide (DMSO)
Hydrocortisone cream
or
Sodium bicarbonate 2.1 % dilution
Cold compresses
Hyaluronidase 15 Vlml or
nitroglycerin ointment 2%
Hyaluronidase 15 Vlml
Phentolamine
Neonates: dilute 2.5-5 mg
saline
All others: dilute 5-10 mg
normal saline
Nitroglycerine ointment 2%
Phentolamine
Neonates: dilute 2.5-5 mg
normal saline
All others: dilute 5-10 mg
normal sali ne

I~ounesy Kalhleen Gura.
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in 10 ml normal
in 10 ml

in 10 mI
in 10 ml

BS. RPh, Clinical Pharmacisl; Palricia A. Berry. RN; Staff Nurse

lnfiltrate 2 ml of this 1/6 M solution for each
100 mg of cisplatin
qid x 72 hr
Multiple SQ injections for a total of 4-5 ml

Multiple SQ injections for a total of 4-5 ml
50 mg SQ
50-100 mg SQ
Apply DMSO topically q2 hr, followed by
hydrocortisone cream and 30 min of cold
compresses
Apply DMSO topically q6 hr alternating
with hydrocortisone cream q6h

Infiltrate area with 1-3 ml, leave for 2 min
and aspirate off again
q8h until perfusion restored
0.2 ml x 5 doses SQ
4 mm/kg
0.2 ml x 5 doses SQ
Neonates: multiple SQ injections not to
exceed 0.1 mg/kg or 2.5 mg
All others: multiple 0.5 mg SQ injections
not to exceed 10 mg
4 mm/kg q8h
Neonates: multiple SQ injections not to
exceed 0.1 mglkg or 2.5 mg
All others: multiple 0.5 mg SQ injections
not to exceed 10 mg
4 mm/kg q8h

m. MICU, Children's Hospital. Boston.
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TABLE

16-9 Antidotes-cont'd

k1!Medication

Antidote

J;~.

xorubicin (Adriamycin)

entamicin
annitol
echlorethamine
.. (nitrogen mustard)

adiocontrast dye
. 'ampin
odium bicarbonate
eniposide (YM-26)

Initial (first 24 hours):
Dimethyl sulfoxide (DMSO)
Hydrocortisone cream
Cold compresses
Subsequent 14 days:
Dimethyl sulfoxide (DMSO)
Hydrocortisone cream
Phentolamine
Neonates: dilute 2.5-5 mg in 10 ml
normal saline
All others: dilute 5-10 mg in 10 ml
normal saline
Nitroglycerine ointment 2%
Hyaluronidase 15 Vlml
Warm compresses
Hyaluronidase 150 Vlml
Hyaluronidase 15 U/ml
Hyaluronidase 15 U/ml
Cold compresses
Sodium thiosulfate 1/6 M solution (dilute
as with cisplatin)
Hyaluronidase 15 Vlml
Sodium thiosulfate 1/6 M solution (dilute
as with cisplalin)
Hyaluronidase 15 Vlml
Phentolamine
Neonates: dilute 2.5-5 mg in 10 ml
normal saline
All others: dilute 5-10 mg in 10 ml
normal saline
Nitroglycerine ointment 2%
Hyaluronidase 15 Vlml
Hyaluronidase 15 VIm I
Nitroglycerin ointment 2%
Hyaluronidase 15 Vlml
Hyaluronidase 15 Vlml
Hyalnronidase 15 Vlml
Cold compresses
Hyaluronidase 15 Vlml
Hyaluronidase 15 Vlml
Hyaluronidase 15 Vlml
Hyaluronidase 15 Vlml
Warm compresses
Hyaluronidase 150 Vlml
Hyaluronidase 15 Vlml
Hyaluronidase 15 Vlml
Hyaluronidase 15 U/m!
Warm compresses
Hyaluronidase 150 Vlml
Warm compresses
Hyaluronidase 150 Vlml

\!;.:"

Dose

Apply DMSO topically q2h, followed by
hydrocortisone cream and 30 min of cold
compresses
Apply DMSO topically q6h alternating with
hydrocortisone cream q6h
Neonates: multiple SQ injections not to
exceed 0.1 mglkg or 2.5 mg
All others: multiple 0.5 mg SQ injections not
to exceed 0.1-0.2 mglkg or 5 mg
4 mm per kg q8h
0.2 ml x 5 doses SQ
1-6 ml SQ via multiple injections; repeat
over several hours
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
Inject 2 ml of solution for each mg of
mechlorethamine
0.2 ml x 5 doses SQ
Multiple SQ injections for a total of 4-5 ml
0.2 ml x 5 doses SQ
Neonates: multiple SQ injections not to
exceed 0.1 mg/kg or 2.5 mg
All others: multiple 0.5 mg SQ injections
not to exceed 0.1-0.2 mg/kg or 5 mg
4 mmlkg q8h
0.2 ml x 5 doses SQ
0.2 m\ x 5 doses SQ
4 mm/kg q8h
0.2 ml x 5 doses SQ
0.2 mL x 5 doses SQ
0.2 mL x 5 doses SQ
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
qid x 72 hr
1-6 ml SQ via mulliple injections; repeat
over several hours
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
0.2 ml x 5 doses SQ
qid x 72 hr
1-6 ml SQ via multiple injections; repeat
over several hours
qid x 72 hr
1-6 mL SQ via multiple injections; repeat
over several hours

~(:ourtesy Kathleen Gura, BS, RPh, Clinical Phannacist; Patricia A. Berry, RN; Staff Nurse rrr. MICU, Children's Hospital, Boston.
d;-
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dase is useful in treating most irritating but nonvasopressor
infiltrates. Hyaluronidase works by temporarily dissolving
normal interstitial barriers, allowing the infiltrated solution
to diffuse over a greater area, become dilute, and absorb
faster. The usual dosage is a concentration of 15 D/ml
administered by five subcutaneous injections of 0.2 ml each
into the affected area. 74 Hyaluronidase is most effective if
administered within 2 hours of the infiltrate, but benefits can
be seen up to 12 hours after extravasation. 75 Hyaluronidase
has few known side effects but may rarely cause urticaria.
Phentolamine is an a-adrenergic blocker that directly
reverses the vasoconstrictive effects of infiltrated vasopressor agents. The dosage range is 5 to IO mg diluted in 10 ml
of normal saline administered by multiple subcutaneous
injections of 0.5 mg each into the affected area. Phentolamine is most effective if given within 12 hours of the
extravasation. Careful assessment must be made before
treating a child with phentolamine because it has the
potential to cause significant hypotension caused by vascular smooth muscle relaxation. Phentolamine can also cause
tachycardia and dysrhythmias.
Glyceryl trinitrate in the form of transdermal nitroglycerin patches or ointment may be a safer and less invasive
treatment option than injections of hyaluronidase or phentolamine in the treatment of extravasations that result in
ischemia. The beneficial effects of topical nitroglycerin have
tX:en demonstrated in the treatment of children with
vasopressor extravasations. 76.77 parenteral nutrition extravasations,78 and purpura fulminans. 79 Nitroglycerin is a
nonspecific vascular smooth muscle relaxant that can
improve collateral circulation to localized areas of peripheral ischemia. The recommended dosage is 4 mm of 2%
nitroglycerin ointment per kilogram of body weight applied
topically over the affected area every 8 hours until perfusion
is restored 77 Local vasodilation effects occur within 15 to
30 minutes of application. To minimize the potential for
systemic hypotension, caution is taken in using topical
nitroglycerin on infants younger than 21 days old and in
children with existing skin breakdown because absorption
may be increased.
Hydrocortisone and dexamethasone may mitigate inflammation associated with infiltrate injury. Case reports
suggest that sodium thiosulfate, sodium bicarbonate, ascorbic acid, and sodium edetate may also be beneficial in treating some extravasation injuries. 68 It is thought that these
drugs help to inactivate some infiltrated drugs or decrease
their binding to cellular deoxyribonucleic acid (DNA).
Follow-up care for all intravenous infiltrate injuries
includes the ongoing assessment and documentation of
circulation, sensation, motor function, and wound appearance until healing is complete.

WOUND CARE
General Principles
Critical care nurses make assessments and plan interventions related to skin integrity and wound management on a
daily basis. These interventions can either enhance or delay

Skin Integrity

535

the wound healing process. Effective wound management
involves proper identification of the cause of the wound,
wound assessment, proper dressing selection, and systematic documentation. The wound location should be clearly
documented in relation to anatomic landmarks such as the
right scapula, left trochanter, or the right upper quadrant of
the abdomen. The wound size should be measured with the
length, width, and depth calculated in centimeters (not
compared with an object such as a dime). If it is a fullthickness wound, determine if tunnels or undermining are
present by gently "probing" with a sterile cotton-tipped
applicator. Document presence of tunnels in relation to the
hands of a clock (i.e., 3-cm tunnel at 6 o'clock) for objective
reassessment to determine wound progression. The presence
or absence of wound drainage should be assessed. Describe
the amount, color, and odor of exudate if present. The character of the wound tissue should be assessed, including the
presence of granulation tissue, slough (nonviable tissue), or
eschar. The presence of infection, which will damage tissue
or impair healing, should be assessed. The condition of
periwound skin integrity should be noted. Protecting the
healthy skin around the wound is essential. This can be
achieved by using skin sealants (3M No-Sting Protective
Wipes, 3M Healthcare, St. Paul, Minn.) or moisture barrier
creams (Aquaphor, Beiersdorf, Wilton, Conn.).
Successful wound healing depends on proper cleansing,
treatment of infection, wound debridement if clinically
indicated, a moist wound base, and proper selection of a
dressing. In 1962, George Winter80 revolutionized the
approach to wound care. His research demonstrated that
wound healing is optimized in a moist wound environment.
With a moist wound environment, collagen synthesis and
granulation tissue formation are improved; cell migration
and epithelial resurfacing occur fastee and scabs, crusts, and
eschars do not form. 81 If serous exudate dries in a wound
bed, epithelialization is delayed because epithelial cells are
forced to migrate below the eschar instead of migrating
across a moist wound bed. Routine general cleansing to
remove exudate and debris from the wound is indicated to
assess the wound bed and determine the appropriate
dressing. The general consensus among wound care experts
is that normal saline is the best wound cleanser and irrigant,
and it is cost effecti ve as well. Following wound cleansing,
the wound margins should be carefully patted dry.
Dressings should be considered in categories, and their
actions, indications, and contraindications should be known
so that the healthcare team can appropriately match the
right dressing to the right wound (see Table 16-4). The
principal function of a wound dressing is to provide an
optimal healing milieu. Wound healing is a dynamic
process, with changes occurring in the wound environment
at different stages of the healing process. Appropriate
dressing selection requires knowledge of dressing design
classifications and their ability to perform in specific
scenarios. Before a new dressing is applied, the old
dressing should be carefully removed and analyzed. Has
the previous dressing adequately absorbed the exudate, has
it protected the wound bed, has it adhered to new
granulation tissue, and has it provided a moist wound
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D

Fig, 16-10 A to C, Ten-year-old with Crohn's disease.
A, Right lower quadram (RLQ) prolapsed ileostomy; right abdominal wound with enterocutaneous fistula at II o'clock; midabdominal incision closed by primary intention. B, 16 days later:
RLQ ileostomy still prolapsed; 9 to 3 o'clock bed of granulating
tissue with evidence of epithelialization; midabdominal incision
healed-wound edges well approximated. C, 2'/2 months later:
RLQ ileostomy relocated to LLQ secondary to persistent emerocutaneous secondary fistula; continued granulation and reepithelialization of right abdominal wound. D and E, Newborn
with necrotizing enterocolitis (NEC) status post-bowel resection
with RLQ ileostomy and LUQ gastrostomy. D, Midabdominal
wound dehiscence with necrotic nonviable tissue; fascia intact.
E, Wound healed by debridement of nonviable tissue via moist
wound healing over 14 days. then surgically closed by tertiary
intention.

environment? Correct selection of a dressing is essential
for optimal wound healing.
AU dressings are classified as either primary or secondary
types, A primary dressing is placed in direct contact with the
wound bed and may provide absorptive capacity and
adhesion of the secondary dressing to the wound. A
secondary dressing is applied over a primary dressing to
provide further protection, absorption, compression, and
occlusion. Dressing changes should be made as frequently
as demanded by the accumulation of fluid and debris,
overload of absorbent material, and degree of infection.

E

Surgical Wounds
Wound closure occurs by primary, secondary, and delayed
primary or tertiary intention W ,17 Fig. 16-10 demonstrates
characteristics of this classification system. Primary intention refers to a wound that is surgically closed with the
edges approximated by sutures, staples, or tape. There is
minimal tissue loss and potential for infection. A wound
healing by secondary intention is left open and allowed to
heal by formation of new blood vessels and the production
of connective (scar) tissue. Examples of secondary-intention
healing are pressure ulcers and open abdominal wounds.
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Tertiary intention refers to wound healing with a delay
between injury and closure. Tertiary wounds are often
traumatic in nature, grossly contaminated, and left open to
facilitate drainage or staged debridement. These wounds
may be loosely packed and then sutured at a later date. 82
Primary Intention Wounds. Wounds closed by
sutures, tape, or staples are usually dressed with gauze and
a transparent film dressing. This dressing can be removed in
2 to 3 days. The suture line is kept clean and protected. The
size, type, and location of the wound, as well as surgeon
preference, determine if additional dressings or routine
cleansing are needed after the primary dressing has been
removed. Once staples and sutures are removed, usually
after 7 to 10 days, the wound is left open to air but protected
from trauma. If Steri-strips are used to approximate wound
edges, they are left undisturbed until they peel off. Those
incisions that include a Penrose drain may require frequent
dressing changes using sterile technique and absorbent foam
or gauze to absorb exudate. The use of Montgomery straps
(Johnson & Johnson Medical Inc., Arlington, Tex.) or pectin
wafers as tape "anchors" to hold the dressing in place may
be helpful to decrease contact dermatitis and epidermal
stripping that may occur with frequent dressing changes and
adhesive tape removal.
Draining Wounds. Open draining wounds are often
more of a challenge than closed defects and require diligent
effort toward the prevention of cross-contamination from
other wound sites and maintenance of surrounding intact
skin. Using universal precautions and adhering to the
institution's protocol for changing dressings are imperative
for reducing further bacterial contamination. Dilute solutions of povidone-iodine (Betadine), hydrogen peroxide,
Dakin's solution, or acetic acid preparations are prescribed,
although research has shown they may be toxic to fibroblasts
and granulation tissue (see Table 16-5). The current
recommendation in the literature is to avoid using antiseptics (i.e., Betadine, hydrogen peroxide, Dakin's solution) in
open wounds and to instead use them for what they were
intended--disinfection of intact skin. 83
If wounds have excessive drainage, such as that seen with
a fistula, that cannot be managed with gauze, exudate
absorbers, or calcium alginate dressings, a closed drainage
and suction system may be necessary. This method requires
the insertion of suction catheters at the wound skin edge.
These catheters should be placed over fine mesh gauze to
avoid contact with the exposed tissue or viscera. Another
alternative for collecting excessive drainage is to use a
pouching technique similar to that used for an ostomy. The
skin barrier is cut to fit the wound opening, thereby
protecting intact skin. The pouch, either a one- or two-piece
system, can then be applied. Applying a thin layer of barrier
paste to the edges of the wound may help to seal the barrier
and prevent leakage. The catheter drainage system and
pouch both prevent cross-contamination and facilitate accurate measurement of all drainage.
Another way to classify wounds is by depth of tissue
layers involved. Partial-thickness wounds are confined to
the epidermal and dermal layers and usually heal by
regeneration. Full-thickness wounds involve total loss of
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skin layers, epidermis and demus, and extend into subcutaneous tissue and possibly muscle and bone layers. These
wounds heal by connective tissue repair.
Vacuum-Assisted Closure System. The VacuumAssisted Closure (VAC, KCI, San Antonio, Tex.) device was
introduced to the market in the late 1990s to assist in wound
closure by applying localized negative pressure to draw the
edges of the wound to the center. VAC negative pressure therapy is applied via plastic tubing positioned in the
wound cavity or over a flap or graft that has been covered
with a porous nonadherent foam dressing. This pressuredistributing wound packing assists with the removal of
fluids from the wound into the VAC pump's measurement
canister. Negative pressure therapy stimulates the growth of
healthy granulation tissue. By allowing arterioles to dilate
and increase blood flow, the wound bed is better prepared
for flap and graft procedures. The VAC dressing provides a
moist wound environment, promoting migration of macrophages, fibroblasts, and epithelial cells across the wound
bed. Negative pressure therapy can be used on pressure
ulcers, dehisced wounds, and other chronic wounds. The
dressing is changed every 48 hours or as needed, depending
on drainage, and is covered by a moisture vapor-permeable
transparent film dressing to seal the wound.

Ostomy Care
An ostomy is described as a surgically created opening
(stoma) located in any portion of the small intestine, large
intestine, or the urinary tract that is exteriorized on the
abdominal surface to divert output. Most patients with an
ostomy diversion require pouches to be worn over their
stomas. The pediatric patient may have a gastrointestinal
(GI) or genitourinary (GU) diversion for a variety of
congenital or acquired anomalies. The ostomy is named in
respect to its anatomic origin, and its output reflects the
function of the affected portion of the bowel or urinary tract.
Often with infants, Gl ostomies are temporary (usually 3 to
12 months) to allow the bowel to heal and the child to
grow, although some are permanent. This can be a challenging opportunity for nursing to help the family learn
ostomy management skills while simultaneously fostering
child-parent bonding and the development of a positive
body image.
Urostomy Diversions. Urinary ostomies, however,
are an infrequent occurrence for the patient in the critical
care unit. Since the early 1990s the principal reasons for the
creation of urostomies are children born with bladder
exstrophy and cloacal exstrophy and children diagnosed
with rhabdomyosarcoma. Earlier, many children born with
myelodysplasia (spina bifida) often had urostomies created
because of dysfunctional or noncompliant bladders. Today,
alternative continent procedures such as Kock or Mitrofanoff pouches have virtually eliminated urostomy diversions in children. The continent urinary diversion is a
reservoir or pouch inside the abdominal cavity created by
augmenting or replacing the native bladder and using a
portion of either the stomach or small and large intestine. An
antireflux valve is constructed and located at the pouch
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outlet to hold the urine in the pouch. Then, a small,
skin-level stoma is brought through the abdominal wall
through which a catheter is inserted several times daily to
drain urine from the reservoir. The parent or child's
willingness and ability to accept the responsibility to
comply with the routine, clean, intermittent catheterization
required to empty the reservoir is an important determinant
in selecting candidates for this type of procedure.
Gastrointestinal Ostomy Diversion. Gastrointestinal ostomies may consist of a jejunostomy, ileostomy, or
colostomy. The stoma is constructed by bringing any portion
of the small or large intestine through the rectus muscle to
the abdominal wall. On occasion, a loop stoma or stoma
with a mucous fistula may be created. A loop stoma is
constructed by bringing a loop of bowel to the abdominal
surface and opening the anterior wall of bowel for fecal
output. A loop stoma and a stoma constructed with a mucous
fistula both have a proximal functional limb and a distal
defunctionalized limb. These stomas are often temporary
diversions. The ideal stoma should protrude about 2 cm,
allowing for effluent to project into the pouch and decrease
the likelihood of skin complications. Jejunostomy and
ileostomy stomas are always pouched regardless of patient
age because of the caustic contents of the effluent. A
colostomy, on the other hand, can be left without an
appliance, and stool can be collected in a diaper. Although
this practice may be done for an infant or toddler, it is not
a recommended practice by the authors. Furthermore, in the
ICU, this approach may not be feasible because of the risk
of infecting inva~ive lines, incisions, or open wound sites.
Management of the Pediatric Stoma

Gastrointestinal Ostomy Placement. Management
of the pediatric stoma and skin requires special considerations. The first of these is selection of a stoma site on the
abdominal surface. In the neonate or trauma victim. the
surgery is often emergent with no time for assessment of
the abdomen. In addition, it is difficult to predict physical
growth in a baby; therefore, selection of the stoma site is
rarely performed. ldeally, the stoma should be placed away
from the umbilical cord in newborns; below the belt line in
the older child; and away from groin folds, incisions, or old
scars to allow adequate surface area for the ostomy
appliance to adhere. A stoma placed in anyone of these
areas can make pouching adherence more difficult because
of hip movement or an uneven peristomal skin surface.
Gastrointestinal Stoma Assessment. The second
consideration is the postoperative assessment of the viability
of the stoma. Stomas constructed from intestinal mucosa
normally are moist and described as "beefy" red, whereas
stomas constructed from urinary tract, such as ureterostomies and vesicostomies, often appear moist and pink.
Edema is a normal postoperative finding and may occur
when a patient is fluid overloaded, giving the stoma a
translucent appearance. A light pink intestinal stoma may
indicate a low hemoglobin level. Ischemia. which may
indicate compromised perfusion or excessive bleeding, is
evidenced by deep red, purple, or black mucosal tissue.
Measurement of abdominal girth at the umbilicus, auscul-

tation of bowel sounds, and measurement of stool output is
part of routine assessment done every 8 hours. A transparent
pouch allows visualization and assessment of bowel mucosa
perfusion. Often, for the first 24 to 48 hours, the stoma is not
pouched for ease of visualizing perfusion of the mucosal
tissue. Impregnated petrolatum gauze dressings are applied
and changed every 8 to 12 hours to maintain integrity of the
moist mucosal surface.
Peristomal Skin. The third consideration is the condition of the peristomal skin. Optimally, it appears healthy
and intact, with no difference between peristomal skin and
the adjacent skin surface. Peristomal skin damage is
evidenced by the presence of erythema, maceration, denudation, rash, ulceration, or blister formation. It is often a
result of chemical damage from contact with the effluent or
contact dermatitis from skin care products used to pouch the
stoma.
Pouching Systems. The fourth consideration is the
pouching system. The advantages of pouching include
(I) protection of the peri stomal skin, (2) containment of
drainage, (3) elimination of odor, and (4) cost containment. 84 The components of a pouching system include a
skin barrier and a drainage pouch. Few pediatric products
are available, and these are listed in Table 16-10. They are
classified as fecal or urinary pouches. Urinary pouches have
small spouts attached to the pouch, which facilitate drainage
and have adapters that can be connected to drainage bags.
Fecal pouches can be categorized as either drainable or
closed end. Drainable pouches can open at the bottom to
facilitate emptying, and pouch clips are used to maintain
pouch closure. Closed-end pouches have no spout; therefore
these must be entirely removed to empty and are not commonly used in acute care facilities. Pouching systems are
available with either a precut opening (center opening has
already been created) or a cut-to-fit starter hole in the pectin
wafer. A cut-to-fit wafer can be custom cut for patients who
have irregularly shaped stomas. It also allows for adjustments to be made as the stoma changes in size. These
pouches can meet a variety of patient needs, compared with
those that have precut aperture. One- and two-piece systems
are available. The one-piece appliance incorporates the
pouch with the skin barrier and is flexible to contour over
uneven or rounded peristomal surfaces, whereas the twopiece system has a separate faceplate, which is a wafer with
a flange (plastic ring) and a compatible snap-on pouch. Most
two-piece systems are semirigid because of the plastic
flange and therefore perform best when there is a flat peristomal skin surface. A desirable feature is the ability to remove the pouch to visualize and examine the stoma without
removing the adhesive wafer.
The manufacturing of pediatric appliances has made
pouching less challenging, although often these specialized pouches can be too big for the abdomen of a small
infant. An alternative is to use a pediatric fistula pouch that
has a smaller pouching diameter. Most fi stula pouches have
an adhesive backing; therefore, a pectin barrier wafer
(DuoDerm Extra Thin or Stomahesive Wafer, ConvaTec,
Princeton, N.J.) must be cut to fit the adhesive separate from
or attached to the pouch.
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Pouch Application. The proper application of the
pouch is another consideration that can influence adherence
and decrease the risk of skin breakdown. The first few weeks
postoperatively, the pouch should be changed at routinely
scheduled intervals to monitor for any leakage under the
wafer or skin compromise. Waiting to change the appliance
only when leakage occurs often does not maintain optimal
peristomal and incisional skin integrity. Taping a leaking
pouch to reinforce the seal only traps stool under the barrier,
which leads to skin breakdown. Ideally, the process used to
pouch a stoma allows the appliance to remain in place for
several days and occasionally up to I week. However, the
activity of the child, the consistency of the effluent, stomal
protrusion, and the condition of the peristomal skin are just a
few examples of factors that can influence the wearing time.
Pouch Removal. The appliance is removed carefully.
Warm water and a soft cloth or gauze can be used to
facilitate its removal. Adhesive removers are also helpful
but are limited to use in full-term infants and children with
intact skin. The peristomal skin is inspected for breakdown,
and the stoma is assessed for physical changes. The skin can
be cleansed with mild soap and water and is dried
thoroughly before the application of a new appliance. It is
normal to have a small amount of bleeding from the stoma
when an appliance is manipulated around the vascular
stomal tissue. Persistent bleeding requires further surgical
evaluation.
Fitting an Appliance. The diameter of the child's
stoma is measured and a pattern is made. especially for an
irregularly shaped stoma. The internal diameter of the
barrier should be a '1,0_ to 'I,,-inch larger than the stoma. 85
The barrier should fit snugly but not so tight that it constricts
the stoma. In infants, particularly those having loop stomas,
prolapse (telescoping out) of the bowel through the stoma
may occur because of poor fascial support or increased
abdominal pressure. Surgical intervention is indicated if
prolapse is complicated by ischemia or bowel obstruction.
Prolapse is often managed conservatively with cold compresses if bowel is edematous or with manual reduction by
a surgeon if recurrent or severe. Reevaluating pouch
equipment is necessary to avoid mechanical trauma of the
stoma rubbing against wafer borders, particularly the plastic
flange of the two-piece systems. Cutting a "notch" 'h- or
'/4-inch deep at 12. 3, 6, and 9 o'clock allows for stomal
movement in and out of the abdominal cavity.
Warming the skin barrier between the nurse's hands for
1 to 2 minutes softens the pectin and allows for better
adherence to the skin. A barrier paste (see Table 16-10) can
be applied to the peristomal skin to fill in any irregular edges
or creases to make a smooth pouching surface. Most
preparations contain alcohol and bum when applied directly
to irritated skin. The paste is sticky and sometimes difficult
to control. Placing a small amount of paste into a syringe
allows a more precise application. 86 If the epidermis is
denuded, applying a thin layer of methylcellulose-based
powder to nonintact skin and then applying barrier paste will
minimize the irritation and promote healing. Another
strategy is to apply a pectin-based seal (Eakin Cohesive
Seals, distributed by ConvaTec, Princeton, N.J.) to the area
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where the epidermis is denuded and then pouch over the
Eakin seal. These pectin seals do not contain alcohol, are
malleable, and can be molded, rolled, or stretched to any
shape to accommodate peristomal skin irregularities. A
moistened cotton-tipped applicator can help to shape the
paste or the pectin seal around the stoma. When applying the
pouching system, the tail of the bag is directed in a
downward position to facilitate emptying. The pouch is
emptied when it is one-third to one-half full to decrease the
amount of weight that the appliance must support.
Peristomal Skin. The fifth concern when managing
pediatric stomas is the peristomal skin. The suggestions
previously stated regarding the appropriate pouch selection
and application techniques can reduce the incidence of skin
irritation.
Peristomal Breakdown. Despite meticulous techniques,
skin breakdown may still occur. Three of the more common
peristomal skin complications seen in the ICU are irritant
contact dermatitis. candidal infections, and mechanical
trauma. Peristomal irritant dernlatitis is an inflammation of
the skin resulting from contact with a chronic irritant, such
as fecal and urinary effluent, marked pH changes, ostomy
deodorants, or solvents. A skin-level or retracted stoma
increases the risk that effluent will "undermine" an ostomy
appliance and be in constant contact with the skin. Inappropriate technique in appliance care, such as cutting the appliance aperture too large and exposing peristomal skin to
effluent, or a variety of topical products used in the pouch
and on the skin can also lead to irritation. When multiple
products are used, there is the chance that the interaction of
these ingredients can increase the skin's sensitivity. The
cutaneous manifestations can vary in severity from erythema and swelling to ulceration and bleeding, resulting in
significant discomfort to the patient. A patch or skin test of
the products may be necessary to determine the cause. A
topical steroid may be needed to reduce the inflammation,
pain, and itching. Resizing the pouch and changing it as
soon as leakage occurs are other interventions. Finally, if
effluent is watery in consistency and leakage under the wafer persists, placing cotton balls in the pouch to "wick"
stool away from stoma may be indicated. Accurate output
measurement can be obtained by weighing the cotton balls.
Peristomal Candida I Infections. Fungal yeast infection
(Candida albicans) may be caused by moisture around or
under the appliance, the use of systemic antibiotic therapy
that alters the flora of the body, immunosuppressive medications, or chemotherapy. Candida is part of the normal flora
of the mouth, intestine, and vagina. In certain situations,
such as a leaking ostomy pouch or denuded skin, Candida
can be spread to the peristomal skin. The clinical features
include erythema and maceration of the skin, papules or
pustules, and characteristic satellite lesions (Fig. 16-11).
Dry skin usually limits the progression of the rash, and
patients typically have pruritus in the affected area. Treatment includes an evaluation and resizing of the appliance
opening to fit closely around the base of the stoma; the
application of an antifungal powder, such as Mycostatin
(Westwood Squibb Pharmaceuticals, Buffalo, N.Y.), sparingly to the affected area and the use of a sealant, such as
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TABLE

16-10 Ostomy and Skin Care
Products
.
.

barriers: used to protect skin
stomal effluent; to treat irrilin,· lated skin, allowing it to heal

Indications

Considerations

Examples

Solid wafer: protects skin; fits to base
of stoma; adheres to irritated skin;
increases pouch seal because of
added firmness to face plate

DuoDerm is used on irritated skin;
Durahesive is made for urinary
stomas and difficult-to-pouch
stomas; remainder of sol id wafers
are used with intact skin

Paste: fills in folds and creases,
making a smooth pouching area;
protects inner pouch seal around
stoma, increasing pouch system
wearing time
Seals: provide extra barrier to irregular skin surfaces around skin level
or retracted stomas or excoriated
skin
Powder: absorbs fluid from denuded
skin, thus allowing better adherence
of ostomy appliance to skin; can
be used in conjunction with other
barriers

All pastes must dry before pouching;
contains alcohol and will "sting"
when applied to irritated skin unless
powder applied to denuded skin
before application
Eakin seals are moldable pectin rings
that form gel to seal and protect
underlying skin

ConvaTec:
Stomahesive
DuoDerm
Durahesive
Hollister:
Premium Skin
Barrier
HolliHesive
United:
Soft & Secure
Coloplast:
Comfcel
ConvaTec:
Stomahesive Paste
Hollister:
Karaya Paste

Lightly sprinkle over denuded skin

ConvaTec: Eakin cohesive seals

ConvaTec:
Stomahesive
Powder
Hollister:
Karaya Powder

sealant: liquid copolymer that
provides protective layer to skin
surface by protecting skin from
force of removing tapes
adhesives

Used under adhesive tape and adhesive portion of ostomy face plate;
is not necessary under solid wafer
barrier; alcohol-based produces
should not be used on premature
infant or fragile skin

One piece: precut and cut to fit;
urinary and fecal drainage

Two piece: precut and cut to fit;
urinary and fecal drainage; snap-on
pouch to flange wafer

Most contain alcohol and will "sting"
irritated skin; compound tincture of
benzoin contains allergens that can
cause irritation; the bond formed
between benzoin and tape is stronger than underlying epidermaldermal bond; therefore when tape
is removed from skin of premature
infant where benzoin is used, it can
cause epidermal stripping; available
in wipes and liquid form
Usually has flexible barrier, which is
excellent for pouching stomas in a
crease or fold; most are odorproof

Good for flat pouching surface; pouch
can be removed or replaced while
face plate remains intact; wafer
flange and pouch flange must
match; snap-on system may be
painful in immediate postoperative
period; however, pouch and wafer
can be applied as one unit; odorproof

Alcohol-based products:
ConvaTec: AllKare
Smith & Nephew: Skin-Prep
Mentor: Skin Shield
Bard: Protective Film Barrier
Non Alcohol Based products:
Smith & Nephew: No-Sting; Stoma
Laboratories: Stoma Care
Benzoin preparations

ConvaTec:
Little Ones*
Active Life
Dansac*
Hollister:
Pouchkins
Incutech: Premie Pouch
Bard:
Fistula Pouch
(Fecal Only)
ConvaTec:
Little Ones*
SurFit
Hollister: Pouchkins
Coloplast
United

I'I.dapted from Hagelgans NA, Janusz BH: Pediatric skin care: issues for the home care nurse, part 2, Pediatr Nurs 20:72-73, 1994.
specifically for infants and young children.
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Candidal yeast rash surrounding colostomy.

No-Sting barrier (3M Healthcare, St. Paul, Minn.), before
applying the new ostomy appliance. Changing the pouch
every 24 to 48 hours may be indicated to reapply the antifungal powder and reevaluate the skin integrity based on the
severity of the infection.
Preterm Infant Considerations. Special considerations are necessary when caring for an infant with a
stoma, particularly if the patient is a preterm infant weighing
less than 2 kg. Maintaining pouch adherence may be quite
challenging because there are few pouch options and often
a limited pouching surface.
Preterm infant skin is more permeable, and therefore
ingredients contained in products must be fastidiously
examined before application. Diminished cohesion exists
between the epidermal and dermal layer, and the epidermis
can easily be traumatized. Minimize use of all tapes,
adhesives, sealants, and solvents on the skin. Use pectinbacked wafers and nonalcohol-based sealants to protect
peristomal skin. Gently peel ostomy wafers and adhesive
tape slowly, supporting the abdominal skin surface with the
fingertips to decrease the tension and pulling the epidermis
from the dermal layer. Monitor pouch adherence closely and
remove the appliance if effluent leaking under the barrier
adhered to the skin to avoid irritant contact dermatitis.
Cleansing agents that have a neutral pH or warm, sterile
water alone are the safest choices. Rubbing skin surfaces
should be avoided to prevent chafing and irritation.

Enteral Feeding Tubes
Enteral feedings are indicated for children with a functional
gastrointestinal tract who are unable to consume adequate
nutrients to meet their nutritional requirements. Data suggest that there are advantages to using enteral over parenteral nutrition to meet the nutritional requirements of the
critically ill patient (see Chapter 12). If it is clinically determined that enteral feedings are anticipated to be necessary
for a prolonged period, then a gastrostomy or jejunostomy is
created. A gastrostomy may be created by surgical, endoscopic. or radiologic approaches. Enteral feedings into the
jejunum may be accessed via radiographic guidance through

A

B

Fig. 16-12 A, MIC~ tube. B, MIC-KEY@ lUbes. (Courtesy
Kimberly-ClarkfBallard Medical Products, Draper. Utah.)

an existing gastrostomy site or surgically. The care and management of various feeding tubes and interventions for commotlly encountered problems are discussed here.
Some of the most common ICU problems of enteral
feeding tubes are inadvertent dislodgment, migration, tract
enlargement, peristomal skin compromise caused by leakage, and clogging of the tube lumen.
Preventing Dislodgment. Tube stabilization is critical, particularly the first 6 weeks postoperatively, as the
tract heals. Before stabilization, tube placement should be
determined if the tube is not sutured in place. If it is a
balloon-inflated device, such as a Foley or Mic Tube (Medical Innovations Corporation, division of Ballard Medical
Products, Draper, Utah) (Fig. 16- I2), securely hold tube at
abdominal surface, withdraw fluid from balloon, and then
gently reinflate. Check placement by gently pulling up on
tube until resistance is felt. If there is no skin compromise,
then apply split gauze around tube entry site. If it is a Foley
catheter, use the slit-tape method to secure tube. Slit the tape
in half, halfway down the length of the tape, and position the
tape to the halfway slit up to the base of the tube on the
abdominal surface. Apply the tape to the skin, wrapping
half of the slit end up and around the shaft of the tube. There
are several commercially available anchoring devices,
including the Hollister Drain Tube Attachment Device
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(Hollister, Libertyville, Ill.) and Flexi-Trak Anchoring
Device (ConvaTec, Princeton, N.J.). To further secure the
tube, a tabbed piece of tape is placed onto tube and pinned
to the patients' diaper. Routine daily cleansing of the
tube insertion site with normal saline or mild soap and
water to assess site is indicated. If tube is a ballooninflated low-profile skin level device, such as a MIC- KEY
(see Fig. 16-12) or Hide-A-Port (Ross Products Div.,
Abbott Lab, Columbus, Ohio), then checking balloon
inflation and taping across the external flange to avoid
inadvertent displacement if the balloon breaks constitute
sound practice.
Migration and Tract Enlargement. A variety of
french sizes, as well as shaft lengths, are available in
balloon-inflated, low-profile, skin-level devices. Ideally,
the intragastric end of the tube is gently placed against the
stomach wall, and the external flange is anchored on the
abdominal surface. If excess shaft length remains, the tube
can migrate in and out of the track. This scenario usually
results in granulation tissue protruding from the stoma site
and gastric juices leaking onto the peri stomal skin surface.
Granulation tissue is treated with silver nitrate cauterization
until no longer protruding from the stoma or with the
application of steroid creams (i.e., triamcinolone 0.1 % bid
for 5 to 7 days). The excess space between the abdominal
surface and the external flange is managed by placing gauze
or foam dressings to minimize the movement in and out of
the tract.
Peristomal Skin Compromise. Skin compromise is
treated with topical powders, such as Stomahesive powder
(ConvaTec, Princeton, N.J.), to absorb moisture, antifungal
creams or ointments to treat candidal yeast infections,
therapeutic soaks with Aveeno (S.c. Johnson & Son,
Racine, Wis.) or Domeboro (Bayer Corp., Elkhart, Ind.) to
promote healing and comfort, and gauze or foam dressings
changed daily and as needed.
If peristomal erythema or maceration is present from
excess gastric leakage onto the skin, then using a highabsorbency foam dressing may be indicated, such as
Allevyn (Smith & Nephew, Largo, Fla.) or Sof-Foam
(Johnson & Johnson, Arlington, Tex.), changed daily and as
needed. Concomitant superficial candidal yeast infections
often are present, evidenced by erythema, macular or
papular rash, and characteristic "satellite" lesions (Fig.
16-13). Treatment consists of a topical antifungal agent,
such as nystatin (Mycostatin) powder, and an absorbent
dressing. If left untreated in a moist environment, the
organisms may proliferate and increase in the surface area
affected. Often, when a peristomal candidal infection is
present, the patient may have a coexisting oral candidiasis
(thrush). Thrush appears as white, slightly raised patches
resembling milk curds, which, when removed, expose a
hyperemic area that may bleed slightly on the buccal
mucosa. Treatment usually is with topical nystatin oral
suspension 100,000 Vlml 0.5 to I ml placed inside of each
cheek tid for 7 to 10 days.
A referral is indicated to a qualified enterostomal therapy
nurse or clinical nurse specialist familiar with enteral tubes
if an increase in severity of peristomal skin compromise or
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Fig. 16-13 Candidal yeast rash surrounding gastrostomy tube.

no improvement with aforementioned interventions is seen
within 48 to 72 hours.

LEECH THERAPY
The medicinal use of leeches dates back to 1500 Be Egypt.87
Present-day leech therapy is used to relieve venous congestion at surgical sites with inadequate venous drainage and to
relieve damaging pressure on tissues adjacent caused by
large hematomas. The surgical disruption of small blood
vessels can lead to venous insufficiency, placing tissues at
risk for edema, thrombosis, and necrosis. Digit transplantation and free-flap tissue grafts, which are prone to venous
congestion, have increased survival rates when leech
therapy is used postoperatively until adequate collateral
circulation can be established. 87 Venous regeneration during
wound healing can take up to 22 days.
Leeches attach to skin with both ends of their body: a
sharp three-jawed feeding mouth and a rear anchor. Leeches
are efficient blood removers, sucking 5 to 15 ml of blood, up
to 10 times their body weight, within 15 to 60 minutes. 88
Leech saliva contains a potent anticoagulant called hirudin
that inhibits the conversion of prothrombin to thrombin and
prevents localized blood clotting. The major therapeutic
effect of leech application occurs during the postbite period
when the wound continues to ooze for up to 10 hours. 89
While feeding, a vasodilator in the leech saliva improves
blood flow to the area of attachment. 9o Leech saliva also
contains an anesthetic that facilitates painless feeding. 91
Once a leech is satiated, it will fall off of the skin.
Medicinal leeches, Hirudo medicinalis, require specialized care to ensure their health and containment. Vnfed
leeches are thin, slippery, efficient climbers and move
relatively quickly.89 They are generally stored in large,
specially designed containers filled with sterile water that
allow airflow and movement but prevent escape. Water in
the container should be changed every 3 to 5 days or sooner
if cloudy92 The container should be kept covered to block
out light and in a room temperature of 60° to 68°
Fahrenheit. 92 Estimating and ordering enough leeches for a
3-day period will help to ensure adequate availability for
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treatment while limiting the need to care for an excess
number of leeches.

Initiation of Therapy
Patients undergoing leech therapy are treated with prophylactic antibiotics to reduce the risk of infection from the
bacteria Aeromonas hydrophila found in the leech's digestive tract. 93 Antibiotics are often continued for I week after
completion of leech therapy to protect the open, slow-toheal bites from other infectious pathogens. Systemic anticoagulation may also be initiated before beginning leech
therapy and requires frequent monitoring of coagulation
parameters and hematocrit. The area to be leeched should be
elevated to reduce swelling and congestion. A transparent,
semipermeable dressing; gauze; or layer of bacitracin is
applied to the healthy skin surrounding the area to be
leeched 89.92 This discourages the leeches from attaching to
healthy skin. Orifices near the leech sites are packed to
prevent migration. An absorbent pad is placed under the area
to be leeched to help contain the expected continuous ooze.
Patient and family teaching before the initiation of therapy
is essential to allay the fear and anxiety that may accompany
this unfamiliar and unusual treatment. Therapeutic play,
role-playing, diversion, and shielding can be helpful.
Application. The frequency of leech application varies according to the degree of venous congestion present.
Intervals of I to 6 hours are often needed at the initiation of
therapy.92 As venous drainage improves, the therapy is
weaned slowly by gradually spacing applications and
carefully assessing for the return of venous insufficiency,
which is seen as edema and blue-purple discoloration. The
area to be leeched is cleaned with water and patted dry to
encourage attachment. Leeches are contaminated with blood
and require universal precautions when handled. After
preparing the site to be leeched, to prevent migration, the
leech is removed from its container using a nontoothed
forceps with a gauze pad underneath to prevent accidental
dropping. 89 The leech is placed on the skin and watched for
successful attachment, as evidenced by a rhythmic sucking
motion. If the leech does not attach, a drop of glucose water
is applied to the site. 92 If attachment is still not achieved, the
leech is removed and another tried. Refusal of multiple
leeches to attach could indicate inadequate tissue perfusion

and arterial insufficiency, which require immediate physician evaluation.
Monitoring. Once applied, the leech must be under
continuous observation to ensure that it has not migrated or
fallen off. Leeches should remain attached to the site for 15
minutes to I hour before they drop off or are removed.
Encouraging the wound to continue bleeding after the leech
is gone is an important aspect of leech therapy. The bite is
left uncovered and any locally formed clots are removed
gently with sterile gauze. The leeched area should be
actively oozing blood for up to 10 hours and should not
appear dusky or engorged. Evidence of venous congestion
should be evaluated and may necessitate more frequent
leech application. Patients undergoing prolonged leech
therapy must have frequent monitoring of their hematocrit
level. Leech therapy over a 3 days or more may necessitate
blood transfusions.
Removal and Disposal. Leeches generally detach
from the skin after becoming satiated. If the leech has not
dropped off after I hour, it should be removed by stroking
it gently with an alcohol swab until it falls off. 92 Stroking
the leech with an alcohol swab allows it to release its teeth.
Pulling the leech off can cause the teeth to remain in the skin
and cause the leech to regurgitate into the wound, increasing
the risk of infection. 92 A used leech should be picked up
with forceps and placed in a covered container of 70%
alcohol. The container should be discarded in a biohazard
waste receptacle in accordance with universal precautions.
Leeches are disposed of after a single use because they are
contaminated with the patient's blood and they may not be
ready to feed again for up to I month.

SUMMARY
This chapter has presented information about the pediatric
integumentary system and wound healing as they relate to
the critically ill child. The concepts are an essential part of
every critical care nurse's knowledge base in providing
quality patient care. Although nurses may not have control
over many of the factors that place critically ill infants and
children at risk for skin breakdown and delayed wound
healing, nurses have the ability to positively influence
patient care outcomes through knowledgeable assessment,
prevention, treatment, and evaluation.
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CHILDREN'S RESPONSES TO PAIN AND ANXIETY

ew technology and drug regimens for the treatment of
children with critical illnesses and injuries have led to
increasingly successful outcomes. However, with this success comes the clinical challenge of providing optimal
management of children's distress associated with intensive
care therapy. Nonpharmacologic and pharmacologic approaches to the relief of pain, anxiety, and agitation and for
the promotion of rest are well-recognized goals in the
nursing care of critically ill infants and children.
Discomfort is an almost universal consequence of critical
illness. Chest, endotracheal, and nasogastric tubes are unpleasant interventions associated with some degree of pain.
Exposure to an environment characterized by excessive
stimulation: bright overhead lights; strange noises associated with monitors, ventilators, suctioning; and medical
emergencies, even those involving other patients; and lack
of diurnal variation contribute to children's distress and anxiety often exhibited as agitation. Although young children
cannot always explicitly describe what stresses they are
feeling, older patients in the pediatric intensive care unit
(PICD) can do so and report their experiences while being
supported on mechanical ventilation. These patients indicate
that they experienced distress caused by pain, inability to
speak or reposition themsel ves when uncomfortable, the
tugging of ventilator tubing, the discomfort of being suctioned, and the hectic pace of the unit interfering with rest. 1.2
Pain is defined by the International Association of Pain 3
as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in
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terms of such damage." The implication of this definition is
that pain is both a sensory and emotional experience.
Anxiety is a sustained state of apprehension in response to a
real or perceived threat associated with motor tension,
autonomic activity, and vigilance scanning. Agitation is
excessive, often nonpurposeful motor activity associated
with internal tension and accompanied by anxiety, panic,
depression, delusions, hallucinations, and delirium. Delirium is the state of reduced ability to appropriately respond
to external stimuli, usually manifested as disorganized
thinking (rambling, incoherent speech), decreased level of
consciousness, altered sensory perception, disorientation, or
altered level of psychomotor activity, including agitation 4 A
key problem with agitation is the potential for physical
injury. Agitation can be the result of children experiencing
intolerable levels of pain and anxiety. However, agitation
can also result from hypoxia, bronchospasm, or inadequate
ventilatory support. Nurses are challenged to sort out what
the causes may be in agitated infants and children to provide
the appropriate interventions.
Pain and anxiety often coexist and magnify each other.
Minimizing pain and anxiety is an essential treatment goal
in the prcv, leading experts to develop treatment protocols
using psychosocial interventions, pharmacologic agents,
and the provision of the least stressful environment for children. The goals of analgesics and sedatives are to (I) alleviate anxiety or distress, (2) improve comfort, (3) facilitate
medical procedures, (4) promote sleep, (5) prevent later
memory of particularly distressing interventions, (6) tolerate
having an endotracheal tube, (7) enable safe and effective
ventilation, (8) reduce oxygen consumption, (9) control intracranial pressure, and (10) optimize cerebral perfusion
pressure.
Conventionally, pain management was initiated after
noxious stimuli, such as surgery. Recent advances in our
understanding of the responses to pain have generated interest in active intervention to prevent it from occurring. 5 Preemptive analgesia is a strategy in which analgesia administered before the painful stimulus is given to prevent or
reduce subsequent pain and analgesic requirements. The hypothesis is that this strategy prevents or reduces the "memory" of pain in the nervous system. The benefit of preemptive analgesia has been well established in animal studies,
although results from clinical studies are at best mixed. 6
Despite these mixed results, preemptive analgesia appears to
be an appropriate and humane goal of clinical practice.
During the last decade, interest and research regarding
pain in infants and children has mushroomed. A heightened
awareness of pain in such patients has led to improved
measures in the prevention, assessment, and treatment of
pain in all age groups.7-IO This shift in practice has been the
result of recent basic and clinical research, as well as more
attention to appropriate pain management by accrediting
healthcare organizations and national commissions. II However, even today, the general consensus is that pain and
anxiety are often underrecognized and undertreated. There
continues to be inadequate amounts of analgesics and
sedatives ordered by physicians and insufficient administration of these prescribed medications by nurses,z,7,1O.12.13

Despite advances in healthcare, unrelieved pain remains a
problem, and adults who can describe their hospitalization
continue to relate pain as a major stressor and their worst
memory of critical care.14.14a Examination of barriers to
effective pain management in children may help to explain
this suboptimal treatment.

BARRIERS TO EFFECTIVE PAIN
MANAGEMENT IN CHILDREN
Patients, families, and even healthcare professionals continue to have a lack of knowledge and many misconceptions
about treatment options, especially regarding the use of
opioids (narcotics) leading to addiction. These misunderstandings continue to prevent the timely and appropriate
treatment of patients of all ages. Confusion exists regarding
three terms associated with use of opioids: addiction,
physical dependency, and tolerance. These terms are often
used inappropriately and interchangeably, perpetuating misconceptions.
Drug addiction is defined as a pattern of compulsive drug
use characterized by a continued craving for a drug and the
need to use it for effects other than relief of symptoms such
as pain. 15 Persons who are addicted obtain drugs for their
mind-altering properties, not for medicinal purposes. A
behavioral pattern is established, characterized by spending
time acquiring or using drugs, abandoning normal social or
occupational activities because of the need for the drug, and
using the drugs despite adverse psychologic or physical
effects. 16 Public attention has been needed regarding the
very real concern of young people becoming abusers of
unprescribed substances, including narcotics. However, the
media campaign of constantly warning citizens to "just say
no to drugs" has not made it clear that this does not extend
to the use of narcotics under the supervision of healthcare
providers. (In light of the negative perception induced by the
using the word narcotic, the term opioid is used throughout
the remainder of the chapter when pertaining to medically
prescribed analgesics.) Parents continue to have fears that
their children will get "hooked" and become addicts. Yet
less than I % of children and adults treated with opioids for
medical reasons develop addiction, unless they have had
prior history of substance abuse,z·16,17 Therefore withholding adequate pain relief from a suffering patient on the
theoretical grounds of addiction is inappropriate.
Physical dependence means that the patient has developed a physical need for the drug, such that rapid withdrawal will manifest as a specific set of symptoms. It is a
well-recognized phenomenon that occurs after prolonged
opioid, benzodiazepine, barbiturate, and steroid administration or other nonprescribed substances, such as nicotine.
Tolerance is the development of a need to increase the dose
to achieve the same effect previously attained with a lower
dose. Patients appropriately treated with opioids, benzodiazepines, and barbiturates can become tolerant and physically dependent, and these terms are clinically important
only because they influence the choice of the appropriate
dosage and schedule for weaning patients from these
medicines.
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In addition, concerns exist regarding the safety of the
administration of opioids to infants and children. Opioids
are no more dangerous for children than they are for
adults when appropriately administered. Some differences
are found in opioid pharmacodynamics and pharmacokinetics used in infants younger than 6 months of age, but
adequate analgesia can still be provided safely with
appropriate dosages, intervals of drug administration, and
rate of administration of parenteral preparations. Even today an excessive and unfounded concern over young
children's immature metabolic capacity causing drug
accumulation and subsequent adverse effects has been
a major deterrent to administering opioids to pediatric patients. Acknowledgement that respiratory depression is a
serious and well-known side effect of opioids is appropriate. However, this effect rarely occurs in children.
Of important note is that pain acts as a natural antagonist to
the analgesic, and opioid side effects making respiratory
depression less likely in children who are experiencing
acute- pai n.
This apparent deafness to patients' complaints does not
reflect a lack of compassion. Instead, it is a product of
a pattern of a lack of knowledge about pain management
interventions and the need for easier methods of recognizing untreated pain. Physicians and nurses mistakenly
continue to believe that neuromuscular blocking agents
(NMBAs), such as pancuronium, have anxiolytic or
analgesic effects, as well as being unaware of the harmful
physiologic effects of unrelieved pain. Continued undertreatment reflecting limitations in training about pain
assessment, analgesic pharmacology, and behavioral interventions is still prevalent in healthcare. Also, a misunderstanding remains regarding neurodevelopment, such
as believing that young children do not have the neurologic
system maturity to feel pain, which may promote an
underestimation of children's pain experiences. Some
healthcare professionals hold onto the now refuted theory
that infants and young children have no memory of
painful or anxiety-provoking experiences, leading to the
erroneous conclusion that optimal pain management is not
necessary.
Healthcare professionals may cite the "resiliency" of
children or their ability to "bounce back" as indicators that
children do not feel pain as much as adults do. In fact,
children's ability to cope with distress through playing or
watching television is useful as a positive copillg mechanism. However, caregivers may interpret these observations
as children are not suffering, resulting in the withholding of
appropriate analgesics.
The reasons that pain has been ineffectively managed in
pediatric patients lie in the subjective nature of pain and the
need to verbally communicate its presence and intensity.
Developmental stages of young children may preclude
effecti ve communication of their pain. Pain is a complex
and individualized sensation that is difficult to quantify,
particularly for children. As early as 1968, McCaffery 7
recommended to those in clinical practice to consider that
"pain is whatever the experiencing person says it is, existing
whenever he say it does." However, assessment tools in
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which children can use self-report are limited to those who
are at the very least older than 3 years of age. Children
who are critically ill may have less ability to demonstrate behavioral signs of pain because of neurologic
deficits associated with their illness or suppression by
NMBAs. Therefore clinicians in the ICU rely on their own
informal observations to determine whether children are
hurting.
Even when children can self-report, it has been shown
that pediatric nurses do not routinely use self-report and
pediatric pain tools in their practice, despite their ease of use
and proven validity and reliability.8.17a Some nurses continue to use self-report only to confirm other indicators of
pain. 18 This discrepancy in practice may lead to large
variability in pain assessments and thus inconsistency in
pain management interventions for a child.
Inadequate documentation of pain management continues to lead to overall ineffective pain management. Pain
experts and organizations continue to stress the need to
make pain more visible. Unlike other vital signs, pain is not
displayed in a prominent place on the chart or at the bedside.
Strategies offered by pain organizations, such as the
American Pain Society, have recommended including the
measurement of pain intensity as a fifth vital sign, making
this data more available to those making treatment decisions. However, institutions have been slow to comply with
this recommendation. 7 Even when pain is assessed by
clinicians, failure to accept children's report of pain is still
a problem, especially if pain is reported in the absence of
objective signs of tissue damage. Few things dismay all
patients more than sensing that their doctors and nurses are
questioning whether their pain is "real."
Further complicating pain assessment strategies is the
premise supported by society that pain is to be expected
and endured, as evidenced with the phrases "no pain,
no gain," or "pain builds character," or that by asking for
analgesics, a person is being "weak." For children with
medical problems, this premise needs to be replaced with
"pain can kill." Children may deny pain if they believe they
are supposed to be brave or if they anticipate receiving an
injection for pain. For example, a child may suffer in silence
for fear of being given a "shot," particularly if he or she
does not understand the concept that asking for pain
medication will result in pain relief. Therefore children
often cannot or will not report pain to their care providers;
thus nurses must anticipate pain, recognize subtle indications of pain, and intervene to relieve pain.

ANATOMY AND PHYSIOLOGY
Pain involves a response of the peripheral nervous system,
the autonomic and skeletal motor systems, and the central
nervous system. A simple stimulus-response model is often
used to describe pain transmission and pain perception.
Although this model is useful, it must be remembered that
individual response to pain often defies straightforward
anatomic and physiologic explanation. A one-to-one relationship does not exist between a noxious stimulus and an
individual's response to the pain.
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Peripheral Nervous System
Nociception is the term used to describe normal pain
transmission. This process begins in the periphery (skin,
subcutaneous tissue, visceral or somatic structures), where
primary afferent neurons, called nociceptors, are distributed.
Nociceptors are free nerve endings with the capacity to
distinguish between noxious and harmless stimuli. When
tissue is exposed in sufficient quantity to noxious stimuli,
tissue damage occurs, followed by the release of chemical
substances, called mediators, from damaged cells, initiating
and facilitating the movement of the pain impulse from the
periphery to the spinal cord. Substance P is one of these
mediators that transmits pain by the ascending spinal tracts.
Prostaglandin E sensitizes tissues to bradykinin. Histamine,
potassium, and bradykinin are released from mast cells and
are actively involved in the inflammatory response to
painful injuries. Peripherally acting agents such as aspirin,
acetaminophen, and nonsteroidal antiinflammatory agents
(NSAIDs) inhibit prostaglandin synthesis and activation of
the nociceptors.
A stimulus is activated in response to thermal, chemical,
or mechanical trauma, causing an impulse to be transmitted
by nociceptor fibers. Two types of nociceptor fibers, C fibers
and A-delta fibers, are responsible for the transmission of
pain from the periphery to the spinal cord 6 The A-delta
fibers are thinly myelinated neurons that conduct impulses
at rapid velocity and have a low threshold for firing. Once
activated, these fibers are associated with what is described
as "first pain": a sharp, intense, and well-localized sensation. The C fibers are unmyelinated; they conduct impulses
at a slower speed and have a relatively high firing threshold.
They are associated with a later onset or "second pain,"
which is described as a poorly localized, dull, burning,
prolonged sensation.
Both A-delta and C fibers share the property of sensitization, which has clinical implications. Both nociceptors
become more sensitive and more reactive with repeated
episodes of noxious stimulation. Injuries such as bums,
bruises, and abrasions are often accompanied by hyperesthesia (increased sensitivity to mild stimuli) or hyperalgesia
(increased sensitivity to painful stimuli). The threshold to
sensory stimulation is decreased, and even commonly
innocuous stimulation is experienced as painful.
Peripheral nociceptors remain unmyelinated or thinly
myelinated throughout the life cycle from infancy to
adulthood. Lack of myelination does not imply lack of
conduction and perception but, rather, slower conduction.
Therefore the lack of myelination of peripheral nerves in
the infant does not support the assertion that infants
cannot appreciate pain. Moreover, the slower conduction
velocity characteristic of unmyelinated nerves may well be
offset by the shorter distances that the nerve impulse travels
in a small infant.

Spinal Cord
Pain stimuli are delivered by sensory neurons from the
peripheral site of trauma to the spinal cord. Nociceptors and
other sensory fibers travel to and converge on cells within

the dorsal hom of the spinal cord. The dorsal hom cells
activate several central mechanisms involved in the appreciation and response to painful stimuli. Some dorsal root
neurons initiate a protective, spinal reflex in response to
pain; for example, pulling one's hand away from a hot stove
even before the heat and burning are consciously realized.
Some dorsal hom cells are involved with inhibition of
further incoming nociceptive input. When these cells
become damaged from nerve injury and inhibition is
removed, pain sensation increases. Most importantly, dorsal
horn cells activate central transmission tracts that relay
peripheral input to higher brain centers. These messages
travel to the thalamus and, finally, to the brain.

Central Nervous System
The spinothalamic and the spinoreticular tracts are the main
central pathways of pain impulse transmission. These tracts
synapse in different areas of the thalamus and then continue
and ultimately terminate in various areas of the cortex. The
spinothalamic tract travels to and synapses in the lateral
thalamus. From here, the tract continues to and terminates in
the somatosensory cortex. The spinothalamic tracts "map"
information onto the somatosensory cortex so that individuals are able to identify and localize pain.
The spinoreticular pathway ascends to the brainstem
reticular formation. Some of these communications continue to the lateral thalamus and onward to the somatosensory cortex. Others travel to the medial thalamus, which
continues to the association cortex or, more specifically, to
the limbic system and the frontal cortex. These higher
cortical areas recruit a sophisticated response to pain, which
involves the appreciation of pain intensity, the desire to
escape from pain, and the anxiety that accompanies the need
to be rid of painful stimuli. This sophisticated response
determines the impact that emotions, personality, culture,
gender, past experience with pain, and the meaning of the
pain have on an individual's perception and response to
pain. The spinothalamic and the spinoreticular tracts are
completely myelinated by 30 weeks of gestation.
The cerebrum and thalamus are known as the control
centers that process and register the experience of pain.
Once the impulse enters the higher centers of the brain,
information about the pain, such as location and intensity, is
processed, as well as other factors that include fear of the
situation, past and present experiences, and the child's
current emotional status. In addition to receiving and
interpreting information from peripheral input, the central
nervous system acts as a sensory modulation system. The
brain may respond by blocking further pain impulses from
reaching the higher centers or by producing endogenous
opioids (i.e., endorphins), which saturate receptor sites
along the spinal cord and in the brain, providing an analgesic effect. These endogenous compounds are identical pharmacologically to morphine in their action on opioid receptors. Opioid receptors are present throughout the body, with
higher concentrations in the dorsal horn of the central nervous system. The action of endogenous opioids and opioid
analgesics on these central receptors is thought to provide
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analgesia. Opioid receptors are also present in many tissues
that are not involved in analgesia. The action of opioids on
these receptors is responsible for many of the side effects
and complications seen with opioid administration.

Physiologic Effects of Untreated Pain
and Anxiety
The importance of providing effective comfort measures
cannot be overemphasized as more clinicians recognize the
benefits of effective therapies beyond the obvious humanitarian reasons. Inadequate management leads to significant
deleterious consequences of a superacute and unnecessary
arousal of the stress response. All infants and children, even
the critically ill, respond to noxious stimuli with biochemical and physiologic responses that if untreated can lead to
increased patient morbidity and mortality 2 These responses
are well documented, including increases in respiratory rate,
heart rate, blood pressure, cardiac contractility, afterload,
dysrhythmias, and myocardial oxygen consumption?
The effects of unrelieved pain lead to inefficient ventilation, resulting in hypoxia. Respiratory dysfunction is the
most common result of pain associated with abdominal or
thoracic surgery because the child reduces the muscle
movement of his chest and abdominal muscles in an attempt
to splint the area and to prevent painful movements,
resulting in atelectasis. Also, splinting interferes with the
ability to cough and clear secretions, contributing to lobar
collapse and infection. The hormonal and endocrine responses to pain include the release of corticosteroids,
growth hormone, and catecholamines, as well as a decrease
in insulin secretion. This response leads to hyperglycemia
and a breakdown of carbohydrate and fat stores. Use of fat
for energy may cause metabolic acidosis, resulting from an
increase in blood lactate, pyruvate, ketone bodies, and fatty
acids. If allowed to continue, this catabolic process results in
a poor environment for healing.
Ongoing research efforts by clinicians emphasize the
importance of analgesia. Anand and co-workers l9 demonstrated that preterm infants undergoing frequent distressing
procedures (i.e., heel sticks, insertion of feeding tubes)
had marked changes in cerebral blood flow and oxygen
delivery. These changes were seen to be temporally associated with an increased risk for intraventricular hemorrhage and periventricular leukomalacia, thus leading to
significant neurodevelopmental sequelae. Pain impairs the
immune system and even enhances growth of cancerous
tumors.2.20.21

CHILDREN'S RESPONSES TO PAIN
AND ANXIETY
Historically, children have been undertreated for pain and
anxiety because of the belief that children neither respond to
nor remember painful experiences to the same degree as
adults. This is simply untrue. Now it is known that even
neonates experience pain. Studies of long-term effects of
early and prolonged exposure to pain during infancy
suggests a process whereby peripheral injury leads to
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changes in the structure and function of the pain system. 22
Longitudinal studies in preterm infants have shown that
repeated painful experiences have demonstrable and prolonged effects on the infant nervous system and behavior
long after the exposure to pain. Relationships between
neonatal pain and emotional temperament in infancy or
childhood further suggest the widespread distribution of
these neurobiologic changes. Studies indicate that repeated
painful procedures are associated with an increase in
depression, a pattern of "learned helplessness" insomnia,
feeding patterns, and impaired coping responses 9 . 22 Infants
circumcised at birth demonstrated an increased pain response to routine immunizations months later and that minimizing the pain of circumcision with lidocaine-prilocaine
(EMLA) attenuated the pain response?3
Preschool children are very egocentric in their thinking
and believe that all events and sensations originate from
their internal world. They have little understanding of causeand-effect relationships, often misconstruing the meaning
and cause of pain. They may view pain as a punishment for
past misdeeds or bad thoughts. Young children are to be
repeatedly reassured that procedures or painful experiences
are not punishments. Breakdowns in skin integrity from
cuts, abrasions, or incisions are extremely threatening to
children because of their fears of bodily injury and mutilation. They believe that all of their body and blood will leak
out. Band-Aids and dressings hold a special power for children as they fix the "leak" and hold the body in.
School-age children become more logical and reasonable
in their thinking. They are in the process of gaining greater
command over their world and tend to be achievement
oriented. Because these children are often organized by
"rules," they respond well to rituals to cope with painful
events. Once these rituals and routines are established, they
must be followed consistently to be effective.
Adolescents are capable of abstract thinking and have an
understanding of "if-then" relationships. Although capable
of adult-level problem solving, adolescents lack the life experiences that facilitate consistent mature responses. During
stressful situations, adolescents may vacillate between adult
responses and regression to immature behaviors.

TYPES OF PAIN
Clinicians must identify the type of pain to determine
appropriate interventions to relieve it. Pain is often categorized by duration, such as (I) acute (relatively brief pain that
subsides as healing takes place) or (2) chronic (pain existing
for as long as 3 to 6 months after the healing has presumed
to have occurred). Chronic pain treatment plans are complex, with the need for a multidisciplinary team to offer
multimodal approaches, usually with strong behavioral and
rehabilitation components.
Another method of classifying pain is by the inferred
pathophysiologic condition, specifically, either nociceptive
or neuropathic in origin. Nociceptive pain arises from
stimuli from somatic (bone, joint, muscle, skin, or connective tissue) and visceral (arising from organs such as the
gastrointestinal system) structures, as described in the previ-

552

Part III

Phenomena of Concern

JABLE17-1

Useful Mnemonic to Obtain a Pain History

Palliative and provocative factors

Quality
Region and radiation
Severity
Timing

What makes the pain better? (e.g., hot or cold packs, immobilizing painful
body part, repositioning, sleeping)
What makes the pain worse? (e.g., eating, fatigue, movement)
What does the pain feel like? (e.g., shooting, throbbing, stabbing, pulsing,
burning, tingling)
Where is the pain?
Does it spread anywhere else?
How bad is the pain?
Use pain-rating scales to aid communication of pain intensity
When did the pain start?
How long have you had the pain?
Is the pain constant or intermittent?

ous section on anatomy and physiology of pain. Somatic
pain is described as aching or throbbing and is generally
well localized. Visceral pain, which is characterized as deep
and aching, is often not well localized and referred to other
areas of the body. For example, visceral pain related to hepatomegaly may radiate to the right shoulder. Nociceptive pain
usually can be blocked by opioids, NSAIDs, and steroids.
Neuropathic pain is associated with injury, dysfunction,
or altered excitability of portions of the peripheral or central
nervous system, with the pain commonly described as a
burning, stabbing, "pins and needles," or shooting sensations along the damaged nerve tract. The level of intensity
and the duration of the pain often greatly exceed the time in
which the injury would be expected to resolve. Though
many mechanisms have been proposed, the general consensus is that the injury leads to repetitive spontaneous depolarization and transmission of pain. Patients at risk for this type
of pain are those who are recovering from surgery invol ving
nerves; illnesses associated with nerve damage, such as
Guillain-Barre syndrome; or those recei ving medications
associated with neuropathies as side effects, such as chemotherapy (i.e., vincristine). A specific type of neuropathic pain
that is particularly disturbing is that following an amputation of a limb, producing "phantom limb sensations."

PAIN ASSESSMENT
Successful assessment and control of pain depends, in part,
on a positive relationship between healthcare professionals,
children, and their families. For children who are able to
communicate their discomforts directly, pain assessment is
easier to obtain. However, fear, confusion, developmental
immaturity, and the severity of illness hinder children's
ability to communicate with caregivers. Children are quite
capable of describing many aspects of their pain. Through a
brief but comprehensive interview, the caregiver may learn
much about a child's pain. Fundamentally, caregivers are to
ask the child or parent what word they use for pain, such as
"owie" or "boo-boo." A basic assessment must include at
least the intensity (severity) and location of the pain. Further
assessment in a systematic manner can be done, if possible,
encompassing the description of the pain (sharp, pulsing,

dull), as well as its duration, any influencing factors
(aggravating or relieving), or any radiation to other areas.
Information regarding aspects of the pain such as using the
fonnat of "PQRST" will help to delineate the problem so
that management can be more effective (Table 17-1). In
many instances, such as postoperative care, nurses need to
be alert to a child's pain within the situational context. For
example, after bowel surgery, a child may experience incisional pain, as well as gas pain. It is important to differentiate between the two because incisional pain responds best to
opioids, whereas gas pain worsens with opioids and responds to increased activity and movement by the child.
Self-report is the most critical component of pain
assessment. Children are to be encouraged to describe their
pain because their statements reflect the most reliable
indicator of pain. When self-report is available, it represents
the "gold standard" for assessing children's pain?4

Self-Report Scales
The easiest and most accessible method commonly used in
assessing the presence of pain in adolescents and adults is to
ask them verbally to rate pain intensity with a 0 to 10 scale,
with 0 meaning no pain and 10 being the worst pain one
could ever imagine. To use the numeric scale, the patient
must be able to count to 10 and understand the principles
of rank and order. Therefore, for children between 3 and
13 years of age, scales better suited to their cognitive ability
are more useful.
Many pediatric self-report pain tools have been tested in
clinical settings with diverse populations to detennine their
reliability and validity. Several scales use pictures of faces
in various levels of pain for younger children to rate pain
intensity (Figs. 17-1 and 17-2). They present faces ranging
from happy and not hurting to sad and hurting arranged
linearly along a vertical or horizontal line. Younger children
tend to respond at the extreme points on pain-rating scales,
perhaps signifying their limited cognitive capacity to make
the discriminations of which older children are capable. The
Eland color scale is unique in that it addresses both pain
location and intensity (Fig. 17-3). The child is presented
with back and front views of a body outline and is asked to
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Fig. 17·2 Faces rating scale. Explain to the child that each face
is for a person who feels happy because he or she has no pain (hurt)
or sad because he or she has some or a lot of pain. Face 0 is very
happy because the person doesn't hurt at aiL Face I hurts just a
little bit Face 2 hurts a little more. Face 3 hurts even more. Face
4 hurts a whole lot, but face 5 hurts as much as you can imagine,
although you don't have to be crying to feel this bad. Ask the child
to choose the face that best describes how he or she is feeling. This
rating scale is recommended for persons of age 3 years and older.
(From Whaley L, Wong 0: Nursing care of infants and children,
ed 6, 1999. Copyrighted by Mosby, Inc. Reprinted by permission.
The Wong-Baker Faces Pain Scale may be reproduced for clinical
and research use, provided the copyright information is retained
with the scale.)

......

J:

~

Fig. 17-1 The Oucher was developed and copyrighted by Judith
E. Beyer, RN, PhD, 1983. New versions for African-American and
Hispanic patients are also available. (For copies and information,
contact: Judith E. Beyer, RN, PhD. School of Nursing, University
of Missouri-Kansas City, Kansas City, MO 64108.)

choose four color crayons to represent different levels of
pain. The location ofthe pain may be marked directly on the
body parts affected. Pain intensity is indicated by the color
that the child chooses to color or mark the painful part. The
Eland tool has been shown numerous times to be a very
sensitive tool for identifying painful locations. 25 Pain
intensity scales provide a means for communication between child and caregiver, as well as between caregivers.
Understanding how a child is rating pain intensity over a
continuum of time and activities gives more information
about the child's experience. Changes in therapy can be
geared to meeting the deficiencies in pain coverage.
Believing the child is important. If the child perceives
that he or she is not believed, he or she will not report
accurately, making assessment more difficult. If the child
fears that admitting pain will result in an intramuscular
injection or a painful examination, he or she will often deny
pain. Healthcare professionals must assure the child that he
or she will be included in deciding how to best treat the pain.

Observational Scales
Self-report tools are not feasible in children who are
preverbal (generally younger than 3 years of age) or unable

to communicate because of the severity of their illness. Yet
critically ill children who are unconscious, sedated, mechanically ventilated, or paralyzed may be experiencing severe
pain but unable to communicate to others. Clinicians are to
realize that pain will be expressed differently depending on
the age and development level. Learning each individual's
response to pain requires awareness and time to get to know
the child. The nurse is then able to make pain assessments
that incorporate the individual patient's behavioral responses to discomfort. Inferring pain from behavior is
fraught with difficulties, however, because there are frequent discordances between pain behavior and self-report.
The concordance between behavior and self-report of pain is
often best for brief, sharp pain, such as pain from a needle.
Behaviors seen with nonprocedural pain may differ dramatically from those seen in a child suffering from acute pain
episodes for invasive procedures. Overt signs of pain may
be suppressed. Instead, the child may sleep more, have a
decrease in appetite, and appear depressed and withdrawn.
On the other hand, a child who is experiencing pain may be
active and playing "normally" as a way to distract attention
from the pain and attempting to enjoy a favorite activity.
Behaviors such as watching television, playing, or sleeping
can be distraction strategies used for coping with acute pain.
Therefore clinicians are to be wary of depending on general
observation because it will often lead to underassessment
and therefore undertreatment of pain in children. The
absence of behaviors associated with pain does not indicate
the absence of pain.
Interpretation of behaviors of infants and children to
determine the presence of pain without a reliable and valid
assessment tool presents several problems. Pain estimates
may vary, depending on the behavioral criteria used by each
observer to infer pain. Although one health professional may
believe that a patient's behavior indicates pain, another may
interpret the behaviors as signs of anxiety or emotional
distress. Several behavioral observation pain scales have
been developed to help caregivers be more objective, systematic, and consistent in their assessment of pain behaviors. These scales use behavioral criteria, with some scales
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Mark each box with color child selects:
No pain

Mild pain

Moderate pain

Severe pain

No hurt

A little hurt

More hurt

Worst hurt

D

D

D

Fig. 17-3 Eland color scale. Redrawn with permission of the author, who also gives pennission for this
to be duplicated for use in clinical practice. (Permission from Joann M. Eland.)

also including physiologic criteria, therefore not depending
on the child's verbal ability or cooperation. Healthcare professionals need to recognize that these scales cannot, for the
most part, discriminate well between the physical response
of pain and other forms of stress or discomfort.
Researchers have defined specific distress behaviors as
indicators of pain: the character of any crying or other
vocalizations, facial expression, motor responses (ranging
from restlessness to not wanting to move at all), body posture such as guarding a body part, and general activity
or appearance of the child. These symptoms provide a basis for the development of observational tools reported in
the literature, including the CRIES and, more recently, the
FLACC. However, these nonverbal behaviors are not to
be used instead of or to refute a patient's verbal complaints
of pain.
The CRIES, an acronym of the indicators of the scale to
assist raters' memory of the assessment parameters, was
developed for determining postoperative pain in infants 26
(Table 17-2). Consisting of five physiologic and behavioral
indicators, each indicator is rated on a 3-point scale (0, 1,2)
that results in a total score ranging from 0 to 10. The
psychometric properties of the measure were established
with infants (32 to 60 weeks' gestational age) cared for in
NICDs and PICDs. Although tested thoroughly for reliabil-

ity and validity, the feasibility and clinical usefulness of the
measures have not been formally assessed. However, to date
the CRIES is the most promising measure available for
assessment of postoperative pain in infants 27
The FIACC, an acronym for the assessment criteria as
well, has been found to have interrater reliability and
. preliminary validity for scoring postoperative pain in
young children of ages 2 months to 7 years, thus providing
a simple consistent method for clinicians to identify,
document, and evaluate pain 28 (Table 17-3). A pain score
ranging from 0 to lOis derived from each category with a
subscore of 0 to 2. Further testing in other populations needs
to be done.
These scales have limitations in reliably selecting all
patients in pain and therefore must be used in combination with knowledge of the clinical and environmental
context of the pain assessment. Because these observations
may indicate other sources of distress, it is important to
examine the context or situation in which changes in the
behaviors are seen. Healthcare professionals may ask themselves: Given the infant's or child's diagnosis and treatments, is it reasonable to infer that this child is experiencing
pain? Do these behavioral changes respond to analgesics?
What other factors may be contributing to the child's
distress?
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CRIES Neonatal Postoperative Pain Measurement Score

lI'

~Criteria

iI;'

'i;!Crying
iiRequires 02 for
~J saturations >95%
~liIncreased vital signs

m!F
liii~xpression

l!i~leepless
~~Coding Tips for Using CRIES

1

2

No
No

High pitched
<30%

Inconsolable
>30%

HR and BP less than
or equal to preop
None
No

Increase in HR or BP <20%
of preop
Grimace
Wakes at frequent intervals

Increase in HR or BP >20%
of preop
Grimace/grunt
Constantly awake

if;~Crying

"':['=;:~t:
~J:
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~!;
I"~.,~.··•. ·.creased vital signs
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~t

~xpression
~~{
~~"

I,
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t~leepless
!i!;'
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W,ii

1Iii'
Iill,,'"
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The characteristic cry of pain is high pitched.
If no cry or cry that is not high pitched, score O.
If cry high pitched but baby is easily consoled, score I.
If cry is high pitched and baby is inconsolable, score 2.
Looks for changes in oxygenation. Babies experiencing pain manifest decreases in
oxygenation as measured by transcutaneous monitoring or pulse oximetry,
If no O2 is required, score 0, If <30% O2 is required, score I.
If >30% O2 is required, score 2. (Consider other causes of changes in oxygenation such as
atelectasis, pneumothorax, oversedation.)
Note: measure BP last because this may wake child, causing difficulty with other assessments,
Use baseline preoperative parameters from a nonstressed period.
Multiply baseline HR x 0.2; then add this to baseline HR to determine the HR, which is 20%
over baseline, Do likewise for BP. Use mean BP.
If HR and BP are both unchanged or less than baseline, score O.
If HR or BP is increased but increase is <20% of baseline, score L
If either one is increased >20% over baseline, score 2.
The facial expression most often associated with pain is a grimace, This may be characterized
by brow lowering, eyes squeezed shut, deepening of the nasolabial furrow, open lips
and mouth,
If no grimace present, score O. If grimace alone present, score L
If grimace and noncry vocalization grunt present, score 2.
This parameter is scored based on the infant's state during the hour preceding this
recorded score.
If he or she is continuously asleep, score 0,
If awakened at frequent intervals, score L If awake constantly, score 2.

Krechel SW, Bildner J: CRIES: a new neonatal postoperative pain mea..o;;urement score: initial testing of validity and reliability, Pediatr AlleSlh

!1:~':53-61.

1995, Neonatal pain assessment tool developed at the University of Missouri-Columbia.

lIil;'-
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TABLE
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FLACC Scale

it~·
fi~"
~;;::

~tegories
!If'

Scoring

.

o

1

2
Frequent to constant quivering
chin, clenched jaw
Kicking or legs drawn up
Arched, rigid or jerking
Crying steadily, screams or
sobs, frequent complaints
Difficult to console or comfon

lit-rom Merkel SI, Voepel-Lewis T, Shayevitz JR et al: The FLACC: a behavioral scale for scoring postoperative pain in young children, Pediatr Nurs
r~.'23:293-297, 1997.
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A major limitation for observational scales that depend on motor activity is that they cannot be used in
children with neurologic deficits or receiving NMBAs.
Researchers 29 ,3o recommend a continued effort to develop a
reliable and valid observational scale for such infants and
children.

Physiologic Indicators
Children in acute pain most often have an elevated heart
rate, respiratory rate, and blood pressure. The cardiovascular
and respiratory responses are a result of the release of
catecholamines from the adrenal medulla in the body's
preparation for "fight or flight." Preterm and newborn
infants may respond somewhat differently with an increase
or decrease in heart rate. 30" The magnitude and intensity of
the change in heart rate are related to the duration and
intensity of the stimulus and the temperament of the
individual infant.
The body cannot sustain the stress response for extended periods, Physiologic adaptation will occur, sometimes within minutes of the painful stimulus. Vital signs
will return to normal, and other physical parameters
associated with acute pain, such as sweating and pupillary
dilation, will cease. A nurse assessing a child for pain
may be misled by the presence of "normal" physiologic
parameters. Although appealing as concrete markers, physiologic indicators often are not sensitive for distress of a
prolonged nature. Other more complex modalities, such as
serum cortisol or endorphin levels, are relatively invasive
and not practical for real-time usage, and techniques such as
palmar sweat measurement require complex apparatus for
evaluation, which is well beyond most routine clinical
settings.

Other Considerations in Assessment
Culture plays a role in children's reports and responses to
pain. As racial and cultural diversity increases in the United
States, clinicians should be familiar with beliefs and
practices common to the cultural groups they serve and have
their pain assessment tools translated into languages of their
patients. A clear standard of care has emerged requiring that
routine measurement of pain be done at regular intervals
using consistent and valid criteria. II For critically ill infants
and children, this practice includes assessment intervals of
every 4 to 8 hours at a minimum,31 as well follow-up for any
pharmacologic and nonpharmacologic interventions administered to them.
In children who cannot report on their own pain, parent
ratings may be the best proxy measure available. Most
parents provide information on how to ask the children
about pain and which cues to look for. Parents appear to be
highly aware of particular behaviors exhibited by their
children when experiencing pain in the postoperative
setting. Parents' perceptions of their children's pain are also
important, and nurses can encourage them to participate in
pain assessment. 32 More needs to be known about parents'
rating of their own children's pain.

ASSESSMENT OF AGITATION
Agitation is a form of behavioral communication for
patients who are unable to communicate their discomfort
verbally because of age, illness, neurologic status, or
intubation. Agitation is not a diagnosis; it is simply a sign
that something is wrong and may be caused by lifethreatening events, such as hypoxia; emotional distress,
such as anxiety; physical distresses from pain or nausea;
drug reactions or withdrawal when physiologically dependent; or environmental factors. Environmental reasons for
agitation may be related to a cold or hot room temperature,
noises associated with anticipated unpleasant procedures, or
lack of parental presence.
Assessing and managing severe agitation in an infant
present a challenge to pediatric nurses. Nurses must constantly review a mental "checklist" of possible causes for
agitation in their patients using a calm, systematic approach
to determine the cause of the behavior, such as the rapid
decisions outlined in the algorithm in Fig. 17-4. If a patient
is supported on a ventilator, a quick check for technologic
causes by hand ventilation with a bag-mask device may
determine if this is the cause of the agitation. In general,
pain is to be considered and ruled out as a contributing
factor in a patient with repeated episodes of agitation. A trial
of analgesics, even in the absence of a clear pain source, is
appropriate and is to be included in the systematic approach
to managing agitation in a critically ill child.
Treatment of agitation becomes critical to reduce a
child's own harmful activities, such as self-extubation,
removal of arterial and venous catheters, increased systemic
and myocardial oxygen consumption, and a lack of cooperation with medical treatments. Opioids and sedatives are
administered to reach the desired clinical outcome to reduce
pain and anxiety. Undersedation is more easily detectable
because agitation behaviors include overt symptoms of
hypertension, tachycardia, respiratory distress, and physical
movements to displace catheters. However, oversedation is
often more difficult to assess because it has a more insidious
onset caused by drug accumulation and difficulty in
differentiating it from the severity of the underlying illness.
Noting oversedation is especially important because its side
effects include respiratory depression and problems in
weaning from the ventilator, hemodynamic instability,
gastrointestinal stasis, muscle wasting, and decreased ability
to communicate.1.33 Additional risks for prolonged effects
and toxicity from accumulated metabolites of sedatives
occur in some patients, such as those with renal or hepatic
failure, because of impaired excretion of these medications.
The goal of sedation is to provide a level of medication
to promote sleep and reduce anxiety for the child yet allow
caregivers to arouse him or her for assessment and provide
ongoing medical interventions. Specifically, sedation allows
compliance with mechanical ventilation but also prevents
awareness of the potentially very frightening environment
of the PICU. Nurses often rely on subjective methods to
determine the effectiveness of the sedative regimen rather
than standardized tools such as sedation scales, which
hampers consistent documentation of levels of sedation and
thus communication within the team of caregivers. A wide
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Remove source and/or
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Reduce stimulation
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Provide sedation

Reduce respiratory support
as tolerated

Fig. 17-4 Decision flowchart for assessment and management of agitated infants. (Adapted from
Gordin PC: Assessing and managing agitation in a critically ill infant, MCN Am J Matern Child Nurs
15:26-32, 1990.)

range of adjectives with ambiguous definitions are commonly applied to describe an appropriately sedated patient,
such as "snowed," "chilled," or "fidgety."
Clearly, a means of reliably measuring the level of sedation in rcu patients on a continuous basis, including both
physiologic parameters and behavioral responses to the therapy, would be advantageous. Currently, limited clinical research is available on the use of assessment tools for measuring the depth of sedation in the critically ill that could be
used to titrate sedatives. Plasma concentration monitoring
is generally not useful, and drug therapy monitoring is better accomplished using observational and objective criteria.

Observational Tools
One of the earliest scales to be developed was the Ramsey
scale, which is considered the criterion reference method for
assessing sedation. This tool is often used in adult and
pediatric rcu settings as the principal method for numerically ranking a patient's level of consciousness because of
its availability and ease of use. However, it has not been
tested for its reliability and validity. Other limitations are
that it is not designed to be a continuous method of
assessment, with overlapping categories not clearly defined.I.33.34 For example, it is not clear if the Ramsey score
is defined as a level I or level 4 for a patient who is asleep
but responds to a light stimulus by becoming anxious or

agitated. Also, it is not clear how to rate a patient's sedation
if he or she is unresponsive to a voice but yet is biting the
endotracheal tube (ETT). Responsiveness scales such as the
Ramsey scale have a major limitation regarding the need to
measure the arousability of the patient, which is counterproductive to the goal of sedation in a critically ill child
because he or she is repeatedly disturbed from rest.
Recently, other scales have been developed to overcome
these shortcomings. The Comfort Scale is an eightdimensional observational scale used to measure general
distress in prcu patients without requiring arousability as a
criteria 35 (Table 17-4). This tool encompasses the physiologic and behavioral responses associated with pain, anxiety, and fear. Following staff training of 2 hours, it is
reported to be clinically useful, valid, and reliable, with an
administration time of 3 minutes. Other critical care
professionals have demonstrated adequacy of sedation
within a target score ranging from 17 to 26 out of a total
score of 40. 36 Although not validated for preterm infants, it
has been used to assess levels of sedation and an increase in
agitation at the time of withdrawal of morphine infusion. 19
Two similar scales in the literature for adult rcu patients
are the Motor Activity Assessment Scale (MAAS) and the
Sedation-Agitation Scale (SAS). The MAAS categorizes
patients across a wide cognitive spectrum, from those
unresponsive to usual stimuli to those who are dangerously
agitated 33 (Table 17-5). Clear and concise descriptions are
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TABLE

11-4 Comfort Scale

li~riteria/Oescriptor

Score

tV'
Jm:'

Heart Rate Baseline

iWAlertness
Deeply asleep
~~. Lightly asleep
Drowsy
J.fr,.
~t Fully awake and alen
~\';, Hyperalert

4
5

It Calm

I

i

I

!Ii

2
3

~l'!-

~'talmness/Agitation

3m!:

~.

2

Slightly anxious

~l~ Anxious

3
4
5

I

Very anxious
!!<f" Pamcky
!!E:::

~Respiratory Response

~~: No coughing and no spontaneous respiration

1

Spontaneous respiration with little or no response to
~,i,
ventilation
ii,;~, Occasional cough or resistance to ventilator
Actively breathes against ventilator or coughs regularly
!Sfll
!iii:. Fights ventilator, coughing or choking

2

I..
fJe

3
4

5

f,j,1'

~;!J>hysical Movement
~;'i', No movement
l!11,;
i!~lL Occasional, slight movement
Jf,~,' Frequent, slight movement
iii,:, Vigorous movement limited to extremities
1!u:'
ilr," Vigorous movement including torso and head

'IOOd Pressure (MAP) Baseline

~~:

Criteria/Descriptor

I

2
3
4
5

Score
_

ii!),.

4

5

Muscle Tone
Muscles totally relaxed; no muscle tone
Reduced muscle tone
Normal muscle tone
Increased muscle tone and flexion of fingers
and toes
Extreme muscle rigidity and flexion of fingers
and toes

I

2
3
4
5

Facial Tension
Facial muscles totally relaxed
Facial muscle tone normal; no facial muscle
tension evident
Tension evident in some facial muscles
Tension evident throughout facial muscles
Facial muscles contorted and grimacing

I
2
3
4
5

I

2
3
4

5

Total Score = _ _

~om Marx CM, Smith P, Lowrie LH et aI: Optimal sedation of mechanically ventilated pediatric critical care patients, Crit Care Med 22: 163·170,

tlfCSc
'
(ore

2
3

_

Blood pressure below baseline
Ir~ Blood pressure consistently at baseline
Infrequent elevations of 15% or more (1-3)
~~: Frequent elevations of 15% or more (more than 3)
~J~ Sustained elevation ~ 15%

TABLE

I

Heart rate below baseline
Heart rate consistently at baseline
Infrequent elevations ~ 15% above
baseline (1-3) during observation period
Frequent elevations of ~ 15% above baseline
(more than 3)
Sustained elevation of ~ 15%

J

994.

11-5 Modified Motor Activity Assessment Scale
Description

Definition

Unresponsive

Minimal or no response to noxjous* stimulus; does not communicate
or follow commands.
Opens eyes or raises eyebrows or turns head toward stimulus or moves
limbs with noxious stimulus.
Opens eyes or raises eyebrows or turns head toward stimulus or moves
limbs with touch or when name is spoken; drifts off after stimulation; follows simple commands.
No external stimulus is required to elicit movement; calm, awakens
easily, and follows commands.
No external stimulus is required to elicit movement; picking at tubes
but consolable.
No external stimulus is required to elicit movement; attempting to sit
or move limbs to get up and inconsolable despite frequent attempts;
requires physical restraint, biting ETI.
No external stimulus is required to elicit movement; patient unsafeattempting to pull at ETT/catheters; desaturating; thrashing side-toside; climbing over the rail; striking at staff.

Responsive only to noxious stimuli
Responsive to touch or name

Calm and cooperative
Restless and cooperative
Agitated

Dangerously agitated, uncooperati ve

~~odified by Boston Children's Hospital from Devlin JW, Boleski G, Mlynarek M et al: Motor activity a"essment scale: a valid and reliable sedation scale
~'ror use with mechanically ventilated patients in an adult surgical intensive care unit, Cric Care Med 27: 1271-1275, 1999, via personal communication
~from Curley MAQ,
~*Noxious stimulus,

1999.
suctioning or 5 seconds of nail bed pressure.

len: Endotracheal tube.
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used for each of the six categories, with higher scores
indicating increasing levels of agitation. Beginning efforts
to establish validity and reliability of the MAAS are being
done in a surgical ICU setting with patients over 18 years of
age receiving mechanical ventilation,33 as well as in a
PICU. 37 Nurses have found the MAAS to be easy to use in
assessing and documenting the level of sedation following
administration of sedative agents, as well as accurately
reflecting the patient's true level of sedation. One problem is
that only motor ability is assessed, not physiologic indicators, such as heart rate, which might be useful in neurologically impaired patients.
The SAS involves rating agitated behavior that is already
occurring, such as thrashing movements, or actually stimulating the calmer adult to determine his or her arousability 34
Each patient assessment took 2 to 5 minutes, and studies to
indicate its use as a reliable and valid tool for describing
sedation and agitation in adult ICU patients have begun. 38
These scales are limited to those children with otherwise
normal neurologic responses because many criteria within
them require some form of motor movement. Researchers
have not defined the optimal level of sedation using either
the MAAS or SAS. For all three scales, clinicians must
know that the satisfactory or appropriate level of sedation
will vary from patient to patient and at different times for the
same patient. A clear end point as the optimal level of
sedation needs to be defined yet targeted for individual
patients.

Bispectrallndex
Anesthesiologists have long sought to catalog specific
electroencephalogram (EEG) changes induced by various
anesthetic and sedative agents. Despite predictions that the
EEG could be a clinically useful monitor of "anesthetic
depth," multiple technical problems and clinical complexities precluded its routine use as a monitor of anesthetic
effect. A recently developed EEG machine (Aspect, A-lOoo,
Natick, Mass.) converts the continuous output of the raw
EEG pattern into continuous trends for a number of derived
variables, such as the bispectral index (BIS).39 The BIS has
proven to be a valid and reliable measure of hypnotic drug
effect in the operating room, but it has only recently been
considered for use in ICU. Simmons and colleagues 38
explored use of this technique in assessing sedation as
propofol was titrated in adult patients supported on mechanical ventilation who were recovering from surgery or trauma
and comparing it with the SAS. The depth of sedation could
be better estimated by using the BIS than by using clinical
signs alone. 39
The BIS measures a state of the brain, not a concentration
of a particular drug. Interpretation of the BIS is predicated
on the assumption that sedation is intended to produce a
state of sleep that includes a lack of awareness and a lack of
recall, whereas analgesia is intended to produce a state of
reduced pain perception manifested by decreased autonomic
responses to noxious stimuli. In general, a HIS score is a
discrete value between 0 and 100, with awake patients
scoring in the mid to upper 90s, conscious sedation dropping
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the BIS to 70s to 80s, and general anesthesia having scores
in the 40 to 60 range. 38 No identification of a "best" level
of sedation has been determined. This new monitoring
technique is promising; however, more investigation is
necessary to determine the reliability of the HIS and how it
can be used to provide optimal sedation and analgesia,
including its economic impact, before it can be incorporated
into routine clinical practice in the future.

NONPHARMACOLOGIC MANAGEMENT
OF PAIN AND AGITATION
Although the research is not as well established, nonpharmacologic interventions for the reduction of pain and
agitation have long been recognized as enhancing or
complementary to other medical interventions. Key recommendations are that these interventions work best when
introduced early in the course of illness as a part of a
multimodal treatment approach and that they should not be
considered as a substitute for anaigesics 7 ,11 The best
management involves an integrated approach that considers
both pharmacologic and nonpharmacologic strategies with
the overall goal to provide comfort. A wide array of interventions is available and effective in making pain more
tolerable for some children, especially during medical procedures. 4o Still, nonpharmacologic interventions are often
neglected. However, many of these methods fall within the
independent scope of nursing practice and contribute to a
holistic approach to pain management building trusting relationships with children and their families.
Patients and parents are increasingly willing to try complementary and alternative therapies that involve mind-body
interactions, including meditation, prayer, massage therapy,
and healing or therapeutic touch, as part of their treatment. 41 ,42 Proponents of these interventions explain that by
receiving caring and purposeful touching of the skin or in
the form of pleasant distractions, the stress response is reduced. including a release of endogenous opioids, and pain
is relieved. More controversy lies in the insistence that human energy fields can be manipulated to promote comfort
and healing, such as that espoused by those who advocate
therapeutic touch. 43 ,44
Patients can learn to use music for both distraction and
relaxation, as found effective in many settings such as
PICUs or cancer units, particularly if patients are allowed to
choose the type of music they want to hear. 45 Having
available small, portable tape players with headsets to block
out environmental noises and building a library of audiotapes with a variety of musical styles and artists have been
found useful.
In addition, nurses are to take time to provide basic
comfort measures. Attention to mouth care, eye care,
preventing the pulling of tubes, itching, muscle cramps, and
thirst may calm an agitated patient. A child can be
positioned in neutral alignment, with all parts of the body
supported and the joints slightly flexed. Frequent position
changes are important and may be necessary more often
than every 2 hours, depending on the medical status of the
child. Positioning a patient so that self-calming behaviors
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(e.g., sucking a thumb or fingers) are supported is a simple
way to assist patients to cope with the stressors inherent in
PICU care.

Environmental Control
The PICU is a brightly lit and noisy place that is often
overwhelming even to healthy adults who visit and work
there. Thus the impact on sick infants and children as they
are surrounded by unfamiliar equipment that looks and
sounds threatening may be very disturbing. With the
combination of the critical illness affecting many vital
organs and the discomfort of many medical procedures, it is
not surprising that some children become confused, agitated, or even combative. Behavioral conditioning may
actually occur when a seemingly nonnoxious stimulus is
paired with an unpleasant experience on a regular basis.
Some common examples of this are the pairing of ventilator
alarms with suctioning and handling of extremities before
needlesticks for blood sampling or intravenous (IV) insertion. Some patients begin to expect that whenever they hear
a ventilator alarm or feel someone touch their foot that
something unpleasant will happen. This association can
result in agitated behavior that seems to occur without any
consistent pattern. Careful structuring of the patient's
experiences to "unlearn" these associations is necessary to
treat this cause of distress. However, preventing this type of
learning is much easier than unlearning it after a problem
develops. Using pleasant interventions, such as massage or
music, to provide a signal to the child that a particular period
is safe for them to relax is useful as well.
Promoting sleep both enhances psychologic health and
provides physical benefits by promoting growth and healing,
and it has become a focus of critical care study. Researchers
have acknowledged that it is not safe or realistic to provide
complete darkness or lack of assessment of a child in the
PICU at night; however, they do point out that noise could
be reduced by minimal alarm sounds and a concerted effort
by staff to communicate in lowered tones and to refrain from
past rituals of bathing children during the night shift. 46
Nurses can organize care by clustering assessments, medications, and interventions to allow maximum periods of
undisturbed rest and sleep. A lack of sleep results in
increasing anxiety and sensitivity to pain and discomfort,
hyperactivity, and aggression, all leading to delirium. ICU
psychosis, a pattern of agitation and delirium associated
with being in the ICU 3 to 5 days, is most often caused by
a combination of such factors as the patient's premorbid
coping mechanisms and the environment, including a
frightening atmosphere, lack of sleep, unusual and disturbing sounds, lack of windows, and deprivation of day-night
cycles. 47 Simple strategies such as reducing unpleasant
noises, such as applying rubber stoppers to the ends of
suction tubing when not in use, are useful. Decreasing
environmental stimulation has been particularly recommended for the treatment of mild opioid or benzodiazepine
withdrawal. 31 Because many interactions are potentially
threatening to children in the PICU, they may begin to
generalize their distress toward all approaches by care-

givers. When treatments and procedures are unexpected,
children are kept in a constant state of tension and readiness.
They may become distressed and hypersensitive to seemingly benign, routine procedures of care. Advocating for
protected periods in which children are allowed freedom
from the intrusive examinations and treatments, unless an
unstable condition arises, may provide a sense of control for
children. Whenever possible, nurses can provide a "routine" to children to introduce predictability into this chaotic
environment, which may then help them cope with the many
distressing experiences.
Infants and children with neurologic damage may be
unable to regulate their own motor responses to the
excessive sensory input of ICU. They may react positively
to swaddling because it provides boundaries to the incoming
stimuli and their ability to respond to it with disorganized
motor responses.
Toddlers and older children need to understand what is
happening to them. Not telling children that a procedure will
be painful reduces their trust in the PICU staff. Toddlers and
young children respond to brief honest explanations as to
what is happening to them, as well as having whatever
control is possible within the situation. The approach may
be as simple as saying, "I know that this will hurt; however,
if you take a deep breath and blowout slowly, it may hurt
less." It is important to follow a procedure with praise for
any cooperative behaviors. Even young children may be
assigned a small "job" such as holding the tape, pouring
saline on the dressing, or pulling off the old dressing. By
being active participants in their care, children feel more in
control rather than feeling controlled by their pain. Choices
can be offered to the child whenever possible. For example,
"Should we start with the bum dressing or the central line
dressing change?"
Children say that parents are their greatest source .of
strength when facing pain 24 Excluding a parent from
observing an invasive procedure has been the traditional
approach in PICUs, based on fears of parental interference
or because of the view that it is better for the parent "not to
see." This tradition is perceived by many parents as a major
source of anxiety at a time that parents may perceive that it
is crucial to the child's course of recovery to be there. A
study by Powers and Rubenstein 48 challenges these assumptions as they surveyed parents of children undergoing
intubation, central venous catheter placement, and chest
tube placement, as well as the nurses involved in the
procedure. Parental presence significantly reduced the
parental anxiety related to the procedure. The reasons for
this finding centered on the fact that the parents found that
the actual procedure was far less noxious than what they had
imagined and that they believed their presence was a
comfort to their child until the sedation was given. Also,
94% of the nurses found a parent's presence helpful to the
child and to the parents. None of the physicians in the study
thought that the parents interfered or were in the way of
them successfully performing all procedures.
Positive evidence has shown that parents are fairly
accurate in predicting how distressed their children will be
about an upcoming procedure. This finding seems to be due
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to the parents' knowledge of their children's usual pattern of
reactions. Nurses should advocate for parent involvement in
their children's care and praise them for providing soothing,
nurturing behaviors in this high-tech environment. Because
children may react to their parents' fears, parents should be
provided with adequate support so that they can be effective
with their critically ill child. They can learn how to use
many of the cognitivelbehavioral and physical comfort
strategies described in the next sections. 49

Cognitive Behavioral Techniques
Children have incredible inner resources that give them the
ability to cope with distress: their imaginations, their ability
to focus to the extent of being unaware of their surroundings, their ability to distract themselves through play, and
their motivation to try new things. Nurses may tap into these
resources and teach children, as well as their parents as their
children's coaches, systematic strategies to cope with
painful events.
This process can begin by assessing the degree the child
can follow directions. Distraction is a highly effective
method of relieving mild anxiety and pain because the child
pays attention to the activity, not the painful stimulus. 5o For
toddlers and preschool children, diversion activities such as
counting and reciting nursery rhymes are easy to do, work
well, and involve parental coaching of the children. Use of
soothing, familiar music in the form of lullabies or tapes
featuring the parents' voices may serve to divert children's
attention and permit relaxation.
Play therapy and medical play are important for any child
who is undergoing medical treatment. Through play, children gain more command and control over their hospital
experience. Most patients in the PICU may not be able to
actively participate in a program of medical play, but they
can benefit from hearing stories or tapes about the hospital.
As patients improve, more active play alternatives can be
offered. By allowing children to play with and manipulate
devices such as stethoscopes and needleless syringes, they
gain a sense of mastery over the objects and become less
sensitized to the presence of these objects at their bedside.
After a distressing procedure, nurses should encourage
children to express their feelings about pain. Medical play
with dolls is a way of "working through" what has
happened to them, whereas older children may want to draw
pictures. If developmentally appropriate, the child can be
encouraged to explore medical instruments, role-play procedures using dolls, and reenact procedures in a nonthreatening environment.
For children older than 6 years of age, focusing on a
pleasant mental picture or mentally traveling to a place of
contentment provides another means of coping with a
painful activity. Such guided imagery is most effective if all
of the senses are evoked (vision, hearing, smell, taste,
movement). Another approach would be to have the child
think of a favorite television show and becoming one of the
characters. This strategy can also be used to rehearse
mentally or prepare for a stressful situation, such as being a
soldier fighting a battle; to decrease feelings of powerless-
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ness. 50 A similar mind process is used when a child is
coached to use positive self-talk: "I will be okay; this
procedure will help make me well."
Controlled breathing to promote relaxation is another
easy technique to use with children as they focus their
attention on the movement of air in and out of their bodies
during the procedure or "blowing away the pain." This can
be followed with techniques promoting muscle relaxation of
voluntary skeletal muscles for older children. Use of props
such as blowing bubbles or party blowers have been found
to be helpful.
The specific interventions used with a specific patient
depend on the developmental stage, type of pain the child is
experiencing, and personal preference and, for optimal
learning, can be introduced and practiced when the child is
not agitated or distressed. Additional interventions such as
biofeedback and hypnosis are not as useful because they
require specialized training, and children in the PICU are
too tired or ill to participate.

Physical Comfort Measures
Massage techniques include simple rhythmic rubbing,
stroking, and kneading of muscle and soft tissues and are
effective in reducing edema, stiffness, and pain, especially
in myofascial trigger points. Trigger points are small,
circumscribed hypersensitive areas located within a tight
band of muscle that develop as a result of acute or chronic
muscle strain. Any area of the body can be massaged;
favorite sites are the back, hands, and feet. Clinicians are to
avoid massaging areas of thrombophlebitis, infection, or
tissue necrosis and malignancies. This technique can easily
be taught to parents.
For infants, rhythmic movement in the form of rocking
helps with relaxation and decreases pain. Nonnutritive
sucking with a pacifier is also comforting. Pretreatment of
newborns up to 6 weeks of age with oral sucrose has shown
a rapid and significant calming effect lasting for at least
4 minutes following a heellance. 9 The theory is that sucking
of sucrose reduces the stress response through endogenous
opioids because subsequent administration of naloxone
reverses the process.
Superficial heating or cooling techniques decrease sensitivity to pain. Because of the variable uses and contraindications to these techniques in relation to a specific injury,
nurses must collaborate with physical therapists for specific
uses. Warm compresses or a heating pad applied to the to
painful site promotes relaxation and healing by improving
circulation and availability of nutrients at the injured site, as
well as reducing inflammatory edema. Heat is not to be used
over areas of circulatory compromise or irradiated tissues.
Cold compresses or ice packs reduce muscle spasms, skin
sensitivity, inflammation, and joint stiffness. Precautions
should be taken to ensure that the hot or cold packs are
wrapped, allowing comfortable sensation of cold or heat
without damaging the skin. Nurses should rotate ice packs to
a new site at intervals no longer than 10 minutes.
Another form of cutaneous stimulation is transcutaneous
electrical nerve stimulation (TENS), a battery-operated
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device that deli vers a low-voltage electrical current through
electrodes placed on skin. This method is most often used
for musculoskeletal discomfort, phantom limb pain, or
postoperative pain and is usually monitored by a physical
therapist.

PHARMACOLOGIC MANAGEMENT
OF PAIN AND AGITATION
A variety of medications are currently available to manage
pain, including opioid and nonopioid analgesics, given
systemically by different types of deli very systems, as well
as regional and local anesthetic techniques. The goals of
therapy must be to optimize pain control while minimizing
side effects and adverse outcomes. For patients who are
anxious or agitated, sedatives or anxiolytics are used to
promote comfort by promoting relaxation and sleep, reducing anxiety, and increasing tolerance of common ICU
interventions. The intricacy of treating relatively brief
periods of acute, intense pain requires clinicians to follow
principles of thinking preemptively. Nurses must be familiar
with the time interval to onset of action, as well as expected
duration of action of any analgesic or sedative given to their
patients (Table 17-6).
The pharmacokinetics and pharmacodynamics of analgesics, anxiolytics, anesthetics, and sedatives are significantly altered in critically ill patients, requiring careful
attention to individualizing the regimen for a specific
patient. Drug toxicity may be a problem in critically ill
patients, especially those with renal or hepatic compromise
who are more likely to exhibit decreases in clearance,
which results in longer durations of action from accumulation of the opioids, as well as any active metabolites,
leading to prolonged sedation.

Opioids
Opioids remain the single most important group of medications for the relief of moderate to severe pain in PICU
patients. Analgesia is achieved primarily by binding to
/-l-receptors in the peripheral, spinal, and supraspinal opioid
receptors and, subsequently, inhibiting the release of several
neurotransmitters, including substance P from the primary
afferent terminals. In addition, inhibition of the conduction of pain up the spinothalamic tract by the opioid
prevents the fibers from signaling to the brain that a painful
situation exists.

Key Concepts Related to Opioids
Equianalgesia. Opioids bind to receptors with varying strengths, which contributes to different analgesic
potency between different opioids. 10 The term equianalgesia refers to the fact that different opioids require different
doses to provide approximately the same pain relief, usually
comparing all available opioids to a specific dose of
parenteral morphine. A common misconception is that the
more potent a drug is, the more therapeutically superior it is.
Potency is the ratio of the dose of two analgesics required to

produce the same analgesic effect. Fentanyl is more potent
than morphine because the dose of morphine required to
achieve the same analgesia as fentanyl is 100 times the
fentanyl dose. However, fentanyl is not a more effective or
superior opioid. Lack of knowledge regarding this concept
often leads to undertreatment of pain.
Recommended Dosages. Most clinicians find it
helpful to refer to a chart, such as Table 17-6, to provide a
list of doses, both oral and parenteral, that are approximately
equal to each other in their ability to provide pain relief.
Such tables provide an initial dose as they convert from one
opioid to another or when changing the route of administration; however, these guidelines are only to be considered
as dosing estimates. Traditionally, the child's weight has
been used to determine the starting opioid dose. Numerous
variables can influence the appropriate dose for the individual patient. The optimal dose is to be determined al ways
by titration. 51
Ceiling Dose. Most drugs have a ceiling dose in
which the recommended maximum dose is not to be
exceeded because no further benefit will be gained yet side
effects will be increased. However, opioids have no ceiling
dose for analgesia, meaning that as doses are increased,
further increases in analgesia continue to be achieved. Doses
of opioids are escalated until pain relief occurs or side
effects intervene. There is no predetermined maximum dose
of an opioid.
Considerable variation, as much as a tenfold difference,
is found among patients in their opioid requirements during
the postoperative period 52 All opioid analgesics have
recommended initial doses (see Table 17-6). For children
who remain alert and are still experiencing pain, it is safe to
titrate further doses, using doses equivalent to half the initial
dose. Opioid response increases linearly with the log of the
dose. Thus a dose increment of less than 30% to 50% is not
likely to improve analgesia significantly for those in
moderate to severe pain.52 Very high doses of opioids may
be required in patients with terminal cancer or extensive
burns (because ofhypermetabolism).53 This wide variability
reinforces the need for prompt and individualized attention
to unrelieved pain.
Tolerance. Continued exposure to opioids results in
tolerance, which is a pharmacologic property of opioids and
benzodiazepines in which higher doses are required to gain
the same effect. It is usually managed by increasing the
dose, although the addition of other analgesics, sedatives,
or both may be clinically beneficial. The rate at which
tolerance develops depends on the pattern of use. If
treatment is intermittent, adequate sedative and analgesic
effects are possible with standard doses of opioids and benzodiazepines for a longer period. However, if the drug is
given continuously, significant tolerance can develop more
quickly. Tolerance is not related to an increase in the rate of
metabolism but rather to alterations in receptor numbers and
sensitivities. When tolerance to a specific opioid develops,
incomplete cross-tolerance to other opioids develops. By
changing from one opioid to another, the analgesia achieved
is often improved with lower doses of the newer opioid,
even using appropriate calculations to account for differ-
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ences in potency. Therefore when patients are switched to
another opioid, the starting dose of the new drug can be
reduced to 50% to 75% of the equianalgesic dose to account
for this incomplete cross-tolerance. 52
Physical dependence is also a pharmacologic property
of opioids that is defined by a withdrawal syndrome
following sudden discontinuation of the opioid or administration of an opioid antagonist. Generally, physical
dependence is assumed to develop after 2 to 7 days of
opioid therapy?,3 1.49 Further details on how to wean a
patient from opioids are offered in a later section of this
chapter.

Management of Side Effects
Central nervous system effects include drowsiness, confusion. and dizziness, which can occur initially but usually
disappear within a few days. Nurses should ensure that a
sedated patient can be easily aroused during this time;
otherwise, this is a warning that further opioid doses could
lead to respiratory depression. A patient who has been in
severe pain may be sleep deprived; once the pain is
controlled, he or she may be "catching up" on sleep. This is
not a sign of overdosage as long as the patient is arousable.
Other effects from opioids include myoclonus, which is the
involuntary jerking of the muscles. Although the mechanism
for its cause is unclear, a benzodiazepine or barbiturate may
be useful in its management.
Clinically significant respiratory depression is the most
feared of the opioid-induced side effects. Like sedation.
tolerance to respiratory depression develops over days. The
longer the patient receives opioids, the wider the margin of safety. Patients most at risk are infants younger
than 6 months of age. A decreased metabolic rate and a
less restrictive blood-brain barrier predispose the neonate
to a greater risk of opioid-induced respiratory depression. Therefore correct dosing and careful monitoring are
crucial when newborns and young infants are treated with
opioids.
Pain is a potent respiratory stimulant and counteracts
opioid-induced respiratory depression. Patients do not
succumb to opioid-induced respiratory depression while
awake and in pain. 15 No additional doses of opioids are
to be given to children who are somewhat sedated but have
no signs of respiratory compromise. They are to be
assessed frequently for break-through pain and further need
for analgesia. Mild respiratory depression can be managed
by reducing the opioid dose. whereas with moderate to
severe depression, stimulation, airway support. and bagmask ventilation are to be considered. If administration of
opioid antagonists such as naloxone (Narcan) becomes
necessary, it is to be given in frequent low-dose boluses
because it is not a benign medication. Giving too much
naloxone or giving it too rapidly can increase sympathetic
activity, leading to hypertension, tachycardia, ventricular
dysrhythmias, vomiting, pulmonary edema, and cardiac
arrest, in addition to precipitating severe pain that is
extremely difficult to control. One method is to mix an
ampule (0.4 mg) with 10 ml of normal saline and slowly
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administer a dose of 0.5 ml IV every 2 minutes until
respirations improve. 15 Nurses should discontinue administering the naloxone as soon as patients are responsive
to physical stimulation and are able to take deep breaths.
Patients who have been receiving opioids for more than
I week may be exquisitely sensitive to anlagonists. 53 .54
Sometimes administering more than one dose of naloxone
is necessary because the half-life for naloxone is significantly shorter than that of opioids, thus requiring continuous monitoring for the first few hours. The goal is to
reverse the respiratory depression without compromising
analgesia. Obviously, the potential for respiratory depression is of less concern in infants and children receiving
mechanical ventilation.
Cardiovascular effects theorized as the result of histamine release can cause vasodilation, resulting in hypotension, especially when patients are hypovolemic or have poor
cardiovascular reserves. Pruritus, usually confined to the
face and hairline and not associated with a rash, is presumed
to result from the histamine release. Treatment consists of
giving antihistamines, such as diphenhydramine (Benadryl),
or changing to another opioid in which pruritus may not
occur. Infusions of low-dose opioid antagonists, such as
naloxone, sometimes prescribed for prevention and treatment of pruritus, have been proposed but require close
monitoring to ensure avoidance of reversing the analgesic
effects as wel1. 54 Genitourinary effects from increased
smooth muscle tone within the bladder can lead to sphincter
spasm and urinary retention. Tolerance develops quickly,
but urinary catheterization may be necessary for short-term
management.
Nausea and vomiting usually subside after a few days of
use of opioids. Slow and steady opioid titration helps to
reduce nausea. Historically, clinicians have added an
antiemetic with the additional idea that it will potentiate the
analgesic effect of the opioid. However, there is no scientific
basis for the belief that phenothiazines such as promethazine
enhance the analgesic effects of opioids. 54 In fact, some
studies indicate that promethazine increases sensitivity to
pain and increase the amount of opioids required to produce
satisfactory pain relief. 54
Constipation is of concern for those patients receiving
around-the-clock (ATC) opioid regimens of more than a few
days. Stool softeners often are not enough to prevent
constipation with chronic opioid use. Clinicians must be
vigilant to signs of constipation and consider administering
a laxative. Other therapies such as oral naloxone have
received some attention because it is poorly absorbed
following oral administration, and its effects may be limited
to the gastrointestinal system 52 without reversing the needed
analgesic effects.
Simply decreasing the opioid dose often is sufficient to
eliminate or make a side effect more tolerable, or if this
strategy is ineffecti ve, children may benefit from a change in
opioid. Some patients may not tolerate a particular opioid
but will do well with another. The exact reasons for this are
not fully explained. Vigilant pain assessment and evaluation
of the patient's response to the new opioid guide further
titration of the new opioid.
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Pharmacologic Managem~nt of Pain and Agitation
Approximate
Equianalgesic
Dose

Onset
of Action

Duration
of Action

Intermittent IV bolus: 0.05-0.3 mg/kg q2-4h
Continuous IV infusion: 0.03-0.06 mg/kg/hr
with initial bolus of 0.05 mg/kg
Oral: 0.15-0.3 mg/kg q4h
Intermittent IV bolus: 1-2 Ilg/kg
Continuous IV infusion: 1-3 Ilg/kg/hr
Epidural: continuous infusion: 0.4-1 Ilg/kg/hr
Intermittent IV bolus: 0.015 mg/kg/dose q4-6h

IV: 10 mg

IV: 2-10 min

IV: 2-5 hr

Infants and toddlers: 1-12 hr
Older children: 1-3 hr

IV: 0.1 mg

3-5 min

0.5-1 hr

IV:3 hr (may be up to 36 hr after
long-term infusions)

IV: 1.5 mg

2-10 min

3-4 hr

1-3 hr

Intemlittent IV bolus or oral: 0.1 mg/kg
(maximum: 10 mg/dose); for either route,
give q4h for 2-3 doses, then every 12 hr
as needed

IV or oral: 10 mg

IV: 10-20 min
Oral: 30-60 min

4-62 hr

~OXYCOdOne

Oral: 0.1 mg/kg q4h

Oral: 10 mg

10-15 min

IV: 4-6 hr
Oral: 6-8 hr;
increases to
22-48 hr with
repeated
doses
3-6 hr

Iroline magnesium

Oral: 10-15 mg/kg q8-12h (maximum: I g/dose
or 3 g/day)

NA

30-60 min

4-6 hr

NA

IV bolus: 0.5 mg/kg q6h (maximum: 30 mgt
dose with no more than 5 days of use)

NA

30-60 min

4-6 hr

NA

~!

ijii'

~prug
;i':to:pioid

Analgesics
Morphine

!/F
j[i~"

!lli:

iii
JJI'

!1!ifentanyl
1!1i.
!~L

~~l!
~l'J'

I

lH·ydromorphone
-:' (Dilaudid)
it.iethadone
I!i!-.

~;

ti~:

1';Hj~:Ji'

Initial Dose

I

~li1
U!l;;

~tonoPiOidS

~

1f. i. ;•.

trisal.icylate

Half-life With Active Metabolites

1.2-3 hr

j,'!. (TnlJsate)

,*etoralac
.;(Toradol)
m.~

I' Acetaminophen
II>,

(Tylenol)

~Gabapentin

r"Eft .. (Neurontin)

Oral: 10-15 mg/kg q4h (maximum: 75 mg/kgl
dose)
Oral: 5 mg/kg or 100 mg bid; increase gradually to 300-400 mg PO tid

NA

30-60 min

3-4 hr

NA

NA

NA

NA

NA

Oral and IV: 0.03-0.1 mg/kg q6h (maximum:
2 mg/dose)
IV bolus: 0.05-0.15 mg/kg
Continuous IV infusion: IV loading dose of
0.05-0.2 mg/kg followed by infusion of
1-2 /-lg/kg/min
Oral: 0.5-0.75 mg/kg (maximum dose: 20 mg)
IV bolus: 0.5-1 mg/kg followed by repeated
doses of I mg/kg q3-5min (maximum total
dose of 6 mg/kg)
POllV: 0.1-0.5 mg/day given in 2-3 divided
doses; maximum: 0.15 mg/kg/day
1M: 1-3 mg/dose q4-8h to a maximum of

NA

IV: 1-5 min
PO: 30-60 min
IV: 1-3 min
PO: 10-30 min

3-4 hr

10-20 hr

1-3 hr

2-20 hr

NA

1-10 min

1-4 hr

NA

NA

PO: 8 hr
IM/IV: 4-8 hr

NA

NA
NA

PO: Peak
concentration
2-6 hr
1M: 1-3 hr
IV: 1-2 hr
10-60 min
0.5-1 min

2-8 hr
3-10 min

8-30 hr

NA

0.5-3 min

5-20 min

8-12 min

if~Sedati veslAnxiolyticsl
110.
~~ .A nes th e t'lCS
!~Lorazepam

1""

IMidaZOlam
101i

NA

0.15 mg/kg/day

I:PrOpofol

POIPR: 25-50 mg/kg; may repeat x 1
IV bolus: 0.25-2 mg/kg/dose
IV continuous infusion: 5-100 /-lg/kg/min
IV bolus: 0.5-3 mg/kg
Continuous IV infusion: 50-200 /-lg/kg/min

NA

Vaster M, Krane El, Kaplan RF et ai, eds: Pediatric pain management and sedation handbook; 1997, St Louis, 1997, Mosby: S1. Jude Children's Research Hospital Pharmaceutical Department:
e',i'·orm,/Ia.rv handbook, Hudson, Ohio, 2000, Lcxi-Comp; Harvey MA: Managing agitation in critically ill patients, Am J Crit Care 5: 12, 1996; Yaster M, Berdc C, Billet C: The management of opioid and
Hm~en:lOclia,:epine dependence in infants, children, and adolescents, Pediatrics 98: 135-139, 1996; Gordin PC: Assessing and managing agitation in a critically ill infant. MCN Am J Matern Child Nul's 15:26-32,
Chambliss CR, Anand KJS: Pain management in the pediatric intensive care unit, Curr Opin Pediatr 9:248-253, 1997.
Not applicable or no available information.
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Specific Opioids
MOIphine is considered the "gold standard" of opioids. The
clearance of morphine is increased in patients with extensi ve bums or sickle cell disease, thus requiring higher doses
titrated to clinical effect. 2,53 Septic shock and renal disease
decrease the clearance of morphine and its active glucuronide metabolites, respectively.
Hydromorphone (Dilaudid) is similar to morphine with
anecdotal reports of less risk of pruritus. However, a
metabolite may accumulate in renal failure, resulting in
neurotoxicity and cognitive impairment.
Fentanyl has several advantages in the critical care
setting: a rapid onset of action; relative short duration,
which makes it useful for short-term procedural-related
pain; and because fentanyl administration is not associated
with histamine release, it has become a popular analgesic for
critically ill patients at risk for hypotension and bronchospasm. It is suitable for continuous infusions or transdermal
delivery. A new preparation, oral transmucosal fentanyl
citrate (OTFC), has good oral bioavailability by sublingual
absorption and can be used as an effective preoperative
analgesic and sedati ve, especially when IV access is not
available. However, several disadvantages with fentanyl by
any route are seen clinically. Tolerance and dependence
predictably develop much more quickly than with other
opioids, as soon as after only 5 to 10 days of continuous
fentanyl infusions, leading to frequent dose escalation 2 The
clearance is dependent on hepatic blood flow and thus may
be decreased in cardiac failure. Chest wall rigidity may
follow rapid IV administration of doses greater than which
would best be managed by administering a neuromuscular
blocking agent, naloxone, or both. More potent opioids
similar to fentanyl are sufentanil and alfentanil. However,
they are less useful in PICUs because of cost and familiarity
in dosing and do not offer any significant pharmacokinetic
advantage over fentanyl53
Methadone is a synthetic opioid with a long half-life
following IV or oral administration 2 and produces less
sedation and gastrointestinal effects than other opioids. Thus
it is useful in providing a smooth transition from IV to oral
opioids as an effective analgesic, while suppressing withdrawal symptoms even at low doses.
Oxycodone. often compounded with other agents such as
acetaminophen (Percocet), is also useful in mild to moderate
pain. However, this opioid is not available in a parenteral
form. Clinicians are to be mindful of the fact that although
there is no ceiling dose of oxycodone, there is one for
acetaminophen (75 mg/kg/day or 15 mg/kg/dose) to avoid
the risk of hepatic toxicity. Therefore clinicians can use the
noncompounded form, oxycodone, with its long-acting
form, called OxyContin, for those patients in which hepatic
toxicity is to be avoided. Hydrocodone (Lortab, Vicodin) is
also useful in treating mild to moderate pain. However, it is
available in the United States only as a compounded product
with acetaminophen.
No advantages of using meperidine over morphine have
been proven. Yet the use of meperidine has a distinct
disadvantage over other opioids; its metabolite (normeperidine) may accumulate in patients with impaired renal

function, leading to central nervous system irritability and
seizures. Therefore it is no longer recommended for
critically ill patients? Clinicians should not give naloxone
for meperidine-associated seizures because doing so will
only add to the neurotoxicity. By an unclear mechanism,
meperidine does provide effective reversal of shivering
secondary to anesthesia and amphotericin-associated rigors,
making an occasional bolus the only justified use of this
opioid.
Mixed agonists-antagonists opioids (nalbuphine, butorphanol) have the theoretical advantage of causing less
respiratory depression than pure opioids. Their use in severe
pain is limited by their ceiling effects and their potential to
reverse pure opioid agents previously given and precipitate
withdrawal 2 and therefore are not recommended for use for
continuing painful states, such as those that children
experience during critical illness.
Special considerations are necessary when gi ving opioids
to young infants. Generally, morphine given to infants
younger than 6 months of age tends to have a longer
elimination half-life and a lower clearance rate. 55 The
duration of action of morphine is highly variable among
infants in this age group. Because of the unpredictability
in response, opioid titration in young infants must be
conservative, with a recommended morphine starting dose
of 0.01 to 0.03 mg/kg. The infant's response to an opioid
dose is to be assessed carefully. Once the infant's response
is known, it becomes easier to titrate further doses of opioid.

Drug Delivery Systems
Medical conditions in PICU patients such as an ileus or
recent gastrointestinal surgery, along with concerns for poor
drug absorption, may preclude the use of oral agents. The
availability of IV access eliminates the necessity for
intramuscular injections to provide analgesia for children.
Traditional approaches to pain management have been
through as-needed (pm) doses of analgesics, which, by
design, dictate that patients experience reemergence of pain
before each new request, as well as requiring the child to
notify the caregiver that he or she is experiencing pain.
Younger children may not understand the concept between
requesting pain medication and obtaining pain relief,
whereas older children will often deny or endure pain to
avoid an intramuscular injection. Many as-needed dosing
regimens result in patients receiving no or little analgesics.
Analgesics are always more effective, actually with less
dosage, in preventing pain rather than overcoming established pain by "chasing it." An as-needed schedule is
appropriate for children who have intennittent (pain separated by pain-free intervals), unpredictable pain, or pain
related to specific activities.
PICU patients often experience pain continuously. Therefore effective pain management strategies include techniques that permit continuous delivery of analgesics, such as
ATC scheduled dosing or continuous infusions, and provision of additional analgesic doses for break-through
pain. 13 . 15 For continuous pain, effective analgesia requires
the maintenance of constant serum and cerebrospinal fluid
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concentrations of the opioids, achieved by continuous IV
infusions. For patients receiving continuous infusions of
opioids, titrating or adjusting the dose according to anticipated responses of the patients to problems or procedures
provides critical care nurses a prevention-based focus for
care. Continuous infusions avoid the peaks and troughs of
blood concentrations associated with side effects and
inadequate analgesia. On the other hand, bolus dosing offers
rapid onset of analgesia when the patient is either about to
experience pain or the level of pain intensity has suddenly
increased. "Rescue doses" are supplemental doses offered
to patients on ATC schedules to treat pain that "breaks
through" the baseline analgesic level. The size and frequency of rescue dosing vary with the route of administration. As baseline doses are escalated, rescue doses need to be
adjusted. Adjustment of the opioid dose is essential throughout the patient's course of illness.
A common way of offering patients an interactive
method of treating their own pain by way of selfadministration of the rescue. doses is with the use of
patient-controlled analgesia (PCA) devices. These devices
allow parenteral delivery of opioids on demand, according
to parameters set by the healthcare team. The pump can be
programmed to provide a background, continuous infusion
yet allow the child to push a button to deliver a rescue dose
at programmed intervals. Although the child may push the
PCA button frequently, the PCA device will only successfully deliver a opioid dose when the preset lockout time has
passed. For safety, a total hourly maximum setting limits the
overall availability of opioid to the patient.
Patients must be alert, oriented, and physically able to
push a button. Although usage of the PCA requires adequate
understanding of instructions by the child, pumps are
routinely effective in children 7 years of age and older and
have been used successfully in children as young as 5 years
of age. 10.24 For young children or those who are developmentally delayed and not cognitively able to understand
how to self-administer analgesics, some experts advocate
for family-controlled analgesia and nurse-activated dosing.
Potential candidates for parent-controlled analgesia are to be
considered carefully. Because the child's safety is paramount, caregivers are to carefully evaluate parents in terms
of their ability to provide parent-controlled analgesia.
Parents who successfully manage the care of a chronically
ill child at home may be very capable of assuming the
responsibilities for parent-controlled analgesia. They may
wish to retain some control over their child's care during a
hospital stay and are often familiar with hospital routines.
On the other hand, parents of children who are undergoing
a single elective procedure may not be the best candidates to
provide parent-controlled analgesia. These families are
unfamiliar with the hospital routine and the care of their
child after surgery.
PCA addresses the variations in analgesic requirements
between individuals. With a PCA, the patient is able to
finely titrate the amount of opioid delivered to simultaneously maximize analgesia and minimize side effects.
Patients gain an element of self-control when using PCA.
They are no longer as dependent on healthcare providers to
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ensure pain relief. Most patients report greater satisfaction
with pain relief when using PCA in comparison with more
traditional methods of pain management 6 Extensive experience has been reported with various opioids. A common
regimen for morphine includes a loading dose, if needed, of
0.05 mg/kg, followed by a moderate basal rate (0.03-0.06
mg/kg/hr), with rescue doses 30% to 50% of the hourly
continuous dose every 10 to 15 minutes.

Nonopioids
Nonopioids, including acetaminophen and acetylsalicylic
acid, or other NSAIDs, such as ibuprofen, are employed for
mild to moderate pain. Unfortunately, these medications do
have a ceiling effect that makes them inappropriate for
treating severe pain. However, they can be used in
combination with opioids to lower the opioid dose requirements and incidence of opioid-related side effects.
NSAIDs act peripherally to provide their analgesic effect
by interfering with the synthesis of prostaglandin, through
the inhibition of cyclooxygenase (COX). There are two
isoenzymes of COX: COX-I and COX-2. The COX-I
isoform is expressed primarily in the kidney, gastrointestinal
tract, and platelets. In contrast, the COX-2 isoform is found
in low levels in tissues but is induced during inflammation.
By selectively inhibiting the COX-2 isoform, prostaglandin
pathways are influenced, decreasing pain and inflammation
and avoiding the toxicities of the inhibition of COX-I. Most
NSAIDs are nonselective inhibitors of COX. At present, two
selective COX-2 inhibitors are available (celecoxib and
rofecoxib) for which platelet aggregation does not appear to
be effected at indicated dosages. 56 However, limited pediatric data is available for dosing, as well as side effects for
these selective COX-2 inhibitors. Also, the COX-2 inhibitors are not recommended for use in patients with advanced
renal disease.
Serious side effects of nonselective NSAIDs include
(I) gastrointestinal irritation and bleeding, (2) coagulopathies from decreased platelet aggregation, and (3) nephrotoxicity. Prolonged administration (greater than 5 to 7 days)
or concurrent use with other nephrotoxic drugs are to be
avoided, especially for children with preexisting renal
dysfunction 52 The nonselective NSAID, choline magnesium trisalicylate (Trilisate) is preferred in patients who
have a risk of bleeding because it has less effect on platelet
aggregation and no effect on bleeding time at the usual
clinical doses. 52
Ketorolac (Toradol) is the only parenteral NSAID with a
potency similar to opioids and has been shown to be
effective in postoperative pain in children, especially if
given preemptively and continued on an ATC schedule.
However, all NSAIDs are to be used with extreme caution
in patients with extensive surgical dissection, such as
posttonsillectomy, because clinical trials of NSAID therapy
have demonstrated increased postoperative blood loss.2
Also, ketorolac is useful in treating vasoocclusive crises in
sickle cell disease.
Acetaminophen is an effective oral analgesic and antipyretic with a low side-effect profile (no reduction in platelet
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actIvIty and minimal gastric irritation). However, It IS a
weak antiinflammatory agent, and hepatotoxicity is of
concern with doses of more than 75 mg/kg/day.

Medicines for Neuropathic Pain
Early recognition and aggressive therapy improve the
prognosis for the resolution of neuropathic pain. Although
some patients report relief using NSAIDs and other nonopioid analgesics, neuropathic pain is less responsive to
opioids than nociceptive pain 52.57 without dosages leading
to unacceptable side effects. Several classes of drugs that are
not traditional analgesics are more often useful, including
(I) tricyclic antidepressants such as amitriptyline (Elavil)
and (2) anticonvulsants such as gabapentin (Neurontin),
phenytoin (Dilantin), or carbamazepine (Tegretol).
The analgesic effects of tricyclic antidepressants (TCAs)
result from their pharmacologic activity of "calming"
damaged nerves, not through their antidepressant activity.
Because these drugs can cause cardiac rhythm disturbances,
baseline electrocardiograms (ECGs) may be indicated for
patients with heart disease or other risk factors for dysrhythmias. The anticonvulsant gabapentin has been used with
moderate success and avoids the concern with side effects of
TCAs, such as dysrhythmias. Both the TCAs and anticonvulsants require a period of at least 3 to 5 days to achieve
analgesic effects. Each is to be given an adequate period of
time at full dosage before adding the next because additional
drugs produce additional side effects. It is important that the
dose ordered is given each day, usually at night to avoid
daytime drowsiness, so that a steady state is achieved.

Local Analgesics
Injections, chest tube insertions, bone marrow aspirates,
lumbar punctures, and insertion of peripheral intravenous
needles (PIVs) are major sources of discomfort and distress
to children in the PICU. Children develop conditioned
anxiety responses to painful procedures and associated
objects. In addition, most children do not adapt to the
discomfort of repeated procedures over time but instead
experience greater levels of anxiety with repeated painful
procedures. Anesthetics delivered preemptively are given to
block the generation and propagation of the pain impulses
by peripheral nerves, yet children fear the pain associated
with subcutaneous drug delivery by needles. Increasing
interest in administering local anesthetics by other methods
has led clinicians to the use needleless approaches to
providing local anesthesia.
A combination of Iidocaine-prilocaine (EMLA) was the
first available and effective percutaneously applied anesthetic cream for use on intact skin, and it has been used to
provide local anesthesia for venipuncture and minor superficial procedures, with effective analgesia to a depth of
5 mm. However, effective analgesia requires this cream be
left in place for 60 to 90 minutes,58 precluding its use for
emergency procedures. Systemic absorption of EMLA is
extremely low, resulting in a wide margin of safety.
However, caution must be exercised when using this cream

on diseased skin and in young infants because of the
possibility of methemoglobinemia included by the metabolites of prilocaine. Amethocaine gel (Ametop), composed of
4% tetracaine, is a new topical anesthetic that requires a
shorter application time (30 to 45 minutes) for skin
anesthesia as a result of its greater lipophilicity than
EMLA. 59.60 Other advantages of Ametop include a lower
risk of methemoglobinemia and a longer duration of action
(4 to 6 hours) compared with EMLA. However, as of 2000,
it is available in the United Kingdom and Canada but not in
the United States.
A novel method for subcutaneous drug delivery of local
anesthetics is called Numby Stuff, which is a batteryoperated unit using iontophoresis as the method for administering ionizable drugs such as lidocaine through the skin
with the electrical current of a small battery. This method
shortens the administration time to 10 to 15 minutes,61 an
advantage in emergency procedures performed in the PICV.
However, the invasive procedure must be done immediately
after using Numby Stuff because the lidocaine rapidly
dissipates from the prepared site. Found to provide local
analgesia to a depth of 8 mm, it is useful in patients who
have chronic painful procedures, such as dialysis needle
insertion in pediatric patients. 61 Adverse side effects associated with the iontophoresis of lidocaine appear to be
limited to transient blanching and erythema at the site of the
drug delivery and dispersal electrodes. Some children do not
tolerate iontophoresis secondary to the electrical sensation
(tingling) associated with its use 61 PICU clinicians often
have to administer lidocaine to deeper tissues, which are not
penetrable by the creams or Numby Stuff. Because the pH
of lidocaine is acidic, especially if epinephrine is added to
prolong the analgesia by vasoconstriction, mixing the
lidocaine with sodium bicarbonate in a 10: 1 ratio, respectively, will hasten the effect and minimize the burning
sensation associated with nonbuffered solutions. 62

Epidural Analgesia
Delivery of drugs by the epidural route is accomplished by
threading a catheter through a needle into the epidural space
(Fig. 17-5). Diffusion of morphine or fentanyl through the
dura into the cerebral spinal fluid (CSF) and then into the
spinal cord directly to the analgesic action site (receptors in
the dorsal horn of the spinal cord) leads to direct analgesia,
eliminating many of the systemic side effects of opioids
without having any effect on motor or sympathetic function.
Potential side effects of the epidural opioid infusions include
the previously discussed effects associated with opioid administration. The risk of respiratory depression after intraspinal opioids occurs with concomitant therapy of intravenous opioids as well; therefore using both routes must be
done with caution, most often provided by having the anesthesiology service write orders for pain and sedation. It is
critical to monitor the patient's sedation level and respiratory status and to decrease the epidural opioid dose if excessive sedation is detected. Because infants under 6 months of
age are the highest risk for clinically significant, opioidinduced respiratory depression, many clinicians recom-

Chapter 17

Caring Practices: Providing Comfort

569

Skin and fat

:'i-i':'-':'.....-.f!i-- Spinous process

of vertebra
--'!~-

Spinal cord

-il+-- Ligament
HI+--- Dura mater

POSTERIOR

Fig. 17-5 Epidural space depicted with surrounding anatomy. (Modified from Sinatra R: Spinal opioid
analgesia: an overview. In Sinatra RS, Hard AH, Ginsberg B, Preble LM, eds: Acute pain: mechanisms and
management, St Louis, 1992, Mosby, P 107.)

mend that these patients be monitored by pulse oximetry or
cardiac/apnea monitors during administration.
Infusions of dilute concentrations of local anesthetics are
administered epidurally to provide synergistic effects with
the opioids, resulting in better analgesia and fewer side
effects at lower doses than would be possible if opioids were
administered alone. Evidence shows that a combination of
opioids and local anesthetics is more effective than using
either agent alone. 6 Children are subject to the adverse
effects of local anesthetics (sensory and motor deficits,
hypotension, and neurotoxicity, such as seizures). The
occasional occurrence of minor temporary numbness of
lower extremities usually is resolved easily by decreasing
the dose or removing the local anesthetic from the epidural
analgesia solution. To reduce adverse effects, doses are
carefully titrated to a maximum dose to avoid these
complications. The rate of a bupivacaine infusion is to be
maintained less than 0.4 to 0.5 mg/kg/hr. Lower doses in
infants younger than 6 months may be necessary because of
lower clearance rates in this age group.
Only preservative-free solutions that have been approved
for intraspinal use are to be used to prevent local damage to
the spinal cord. Catheters and IV tubing (without rubber
injection ports) that is distinctive for epidural infusions,
such as being color coded and boldly labeled, are recommended to prevent accidental introduction of unintended
medications into the epidural space. Infection of the epidural
space is a very rare (less than 0.0015%) but a serious
complication,54 especially if it leads to formation of an
epidural abscess resulting in spinal cord compression and, in
extreme cases, paralysis. This complication is thought to
be more common when epidural catheters are left in place
for a prolonged time, such as to treat chronic pain,54 and
are more often associated with poor aseptic technique or

migration of localized skin infection at the epidural catheter
entry site. Early signs and symptoms of an epidural infection
can be difficult to detect because skin site infection and
fever may not be present.
Puncture of epidural blood vessels during the placement
of the epidural catheterization leading to the formation of an
epidural hematoma that results in paraplegia is a potential
risk, although rare. This complication is best prevented by
careful screening of candidates for epidural catheter use,
such as establishing a minimal platelet count of 70,OOO/mm 3
and ensuring that coagulation test results are in the normal
range before placement.
Clinical signs of an abscess or hematoma of the epidural
space are similar: increasing diffuse back pain or tenderness,
pain or paresthesia on epidural injection, and bowel or
bladder dysfunction. As an epidural abscess or hematoma
grows within the epidural space, sensory and motor deficits
increase. Patient recovery without neurologic injury depends, in large part, on early recognition, followed by
confirmation of the compression by computed tomography
(CT) or magnetic resonance imaging (MRI). Treatment
ranges from antibiotics to surgical removal of the abscess or
hematoma.
Children can ambulate and perform all of the routine
recovery activities expected of them to the extent of their
medical or surgical condition. Research suggests that
epidural anesthesia in the postoperative setting may facilitate earlier recovery and improved outcome by reducing the
incidence of thromboembolisms and pulmonary and gastrointestinal complications after major surgery.63
Most state boards of nursing in the United States have
approved the administration of epidural boluses by nurses
who possess the necessary knowledge and skills and where
institutional policy and procedure support this function. 54
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Vascular uptake or injection of the local anesthetic directly
into the systemic circulation can result in adverse reactions
related to high blood levels of local anesthetic. Before
injecting a bolus, the nurse is to gently aspirate the catheter.
If other than a scant (less than I ml) of clear liquid is
aspirated, the nurse must collaborate with the anesthesia
staff before administering the bolus or continuing the
infusion. Free-flowing clear fluid (CSF) return indicates that
the catheter may be in the subarachnoid space. Free-flowing
blood aspirate return indicates that the catheter may be in a
blood vessel.

Sedatives
For both infants and children, adequate pain control may
preclude the need for other sedatives. However, if agitation
persists, agents such as benzodiazepines and barbiturates are
commonly used as first-line sedative agents. Proper selection and administration of drugs require knowledge of their
comparative effects, characteristics, and limitations. The
goal is to have the child be free from pain and anxiety,
able to tolerate medical procedures such as suctioning, but
able to be aroused easily from light sleep, enabling
effective neurologic assessment. For some patients, reaching the desired clinical outcome may require larger-thanrecommended drug doses. Dose response varies greatly not
only among patients but also over time within an individual
patient because of tolerance over time to the beneficial
effects leading to receptor down-regulation and competitive
drug interactions, as well as changes in pH, serum albumin,
autonomic activity, or renal and liver function. When a continuous infusion rate proves to be subtherapeutic, increasing
the rate alone is not effective. An additional small dose must
also be given, or it will take 4 to 5 half-lives to reach a new
steady state.
Benzodiazepines most commonly used in the PICU
include midazolam (Versed) and lorazepam (Ativan).
These agents possess sedati ve, anxiolytic, hypnotic, muscle relaxant, and anticonvulsant effects but no analgesic effects. Although they have minimal negative cardiovascular effects, dose-related effects include respiratory
depression, most commonly related to patient-specific
factors, such as age; concurrent disease; and drug cotherapy. The presence of active metabolites with all of
them except lorazepam complicates their use during
periods of prolonged use. Combinations of benzodiazepines
and opioids are synergistic in producing sedation. Tolerance
to the sedating effects has been reported in pediatric
patients. 49
Diazepam (Valium) has become less popular with the
arrival of newer, more water-soluble, less irritating, and
shorter-acting benzodiazepines. However, it is the least
expensive. When used over several days, diazepam is
stored in body fat, and active metabolites can accumulate,
leading to long half-lives (greater than 100 hours),
especially in those patients with renal failure. 64 Lorazepam
(Ativan) does not accumulate in lipid stores. Well absorbed
from oral and parenteral sites, it undergoes primarily
hepatic glucuronidation, a process relatively resistant to

hepatic dysfunction. In contrast to other injectable benzodiazepines, the pharmacokinetics of lorazepam do not
change significantly with critical illness. 53 Because of the
slower onset of action, alterations in continuous infusion
rates are to be preceded by a small bolus dose to avoid
excessi ve dose administration and oversedation. Many recommend it as the agent of choice for long-term sedation
in the ICU because of its lower cost and favorable
properties. 53
Midazolam (Versed) produces effective sedation, antegrade amnesia, and anxiolysis, with relatively few adverse
effects. The major risk is hypoventilation and subsequent
hypoxemia. Onset of action is very short (less than
3 minutes). A low-dose infusion of midazolam provides
smooth sedation without the peaks and troughs seen with
intermittent doses. In addition to an infusion, "rescue
doses" or intermittent doses ordered for break-through
agitation provide appropriate titration in response to a
patient's changing needs for sedation. Although promoted as
a sedative with a short duration, many studies challenge this
assertion, especially in the critically ill. 53 It has an active
metabolite that can accumulate over days of use and extend
the half-life to 12 to 20 hours in many patients,64 especially
in patients with renal failure. However, in ICU patients
without significant end-organ disease, clearance does not
appear to be decreased. The clearance may be reduced by
concurrent use of calcium-channel blocking agents, erythromycin, and triazole antifungal agents 53
For further details on these agents, see Table 17-6. Administration of high doses of benzodiazepines increases the
risk of developing moderate to severe withdrawal reactions.
All benzodiazepines appear to have an equal likelihood
of producing such physical dependence. Benzodiazepineinduced sedative and respiratory effects can be reversed
with incremental doses of flumazenil (Romazicon) 0.01
mg/kg every I to 2 minutes until a total dose of I mg is
given. 65 However, it is not effective in reversing barbiturates. Clinicians are warned to use this agent with caution
because administration may precipitate seizures, particularly in children taking benzodiazepines for seizure control,
as well as an increase in intracranial pressure from the
spontaneous awakening in a distressed state. Therefore
flumazenil is rarely used in the ICU.
Barbiturates are used in the ICU primarily for anesthetic
induction, cerebral protection, and treatment of seizures.
These agents possess long half-lives and are not as well
suited for routine sedation of critically ill patients because
they are difficult to titrate to achieve a desired sedative
effect without significant general depression of the central
nervous system, resulting in respiratory depression and
hypotension. However, they are useful for sedating patients
with acute head injury because they decrease cerebral
metabolic oxygen consumption by as much as 50%.
Barbiturates may actually increase a patient's sensitivity to
pain and are never substituted for analgesics. 53 Pentobarbital is the most commonly used barbiturate in the ICU to
induce barbiturate coma for improving control of increased
ICP for patients with severe head injury. Because it does not
have any active metabolites, its pharmacokinetics are not
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altered in renal failure. Hyperdynamic states, such as sepsis,
have correlated with increased barbiturate clearance.
To promote sleep and control agitation, choral hydrate
and haloperidol (Haldol) are recommended in specific
situations (see Table 17-6 for details regarding dosing).
Although choral hydrate is available for only oral or rectal
routes, it is rapidly absorbed and has the advantage of only
limited effects on cardiopulmonary function. However,
clinicians must be aware that it has no analgesic properties,
and excitement and delirium may result if given to patients
in pain 47 Because of the accumulation of active metabolites, its use is not recommended for infants younger than
3 months of age or patients with liver dysfunction. 66
Haloperidol has been found useful when less potent
sedatives are ineffective and has been found especially
beneficial for the treatment of delirium in critically ill
patients. 4 •66 This sedative-hypnotic has a rapid onset of
action, leading to minimal respiratory depression, and has
no active metabolites. However, adverse effects include
hypotension, dystonia, and extrapyramidal effects. Haloperidol may cause QT prolongation on the ECG, leading to
torsade de pointes (a specific form of ventricular tachycardia), and should be used with caution in conjunction with
other drugs that may also lead to this abnormality.
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discontinue those agents and begin a propofol infusion. This
will allow minute-to-minute balancing between oversedation and respiratory depression on one hand, yet prevent
anxiety related to the ventilatory weaning process on the
other. Propofol may also be an appropriate choice in ICU
patients with neurologic problems because it decreases
cerebral metabolic rate and intracranial pressure while
maintaining cerebral perfusion pressure. Propofol has no
analgesic effects; other analgesics must be added for
ongoing or procedurally related pain. One unusual effect is
discoloration of the urine to a green tint. Infusions for
critically ill adults have been found to be satisfactory and
safe. The cardiovascular and respiratory effects of propofol
are similar to those of barbiturates. Decreases in blood
pressure and heart rate are common after treatment with
propofol is started. Data on its use in children are limited,
and adverse events in this population have been reported,
centering on unexplained metabolic acidosis and hyperkalemia leading to cardiac arrest in pediatric patients who were
receiving an infusion of propofol. 69 .7o Why propofol might
produce metabolic acidosis is unknown. Some advocate its
use with caution in pediatric patients. 69 It is administered in
a lipid solution, which increases cost and can increase the
risk of infection. Transient elevation of triglycerides has
been reported.

Deep Sedation
Other agents may be used to offer a deeper level of sedation
associated with painful procedures or to increase tolerance
to the stresses of having mechanical ventilation. Ketamine is
a nonbarbiturate derivative of phencyclidine (PCP) that
produces "dissociative anesthesia," a cataleptic state in
which the eyes remain open with a slow nystagmic gaze.
Commonly classified as an anesthetic, when administered in
lower doses, it produces intense analgesia and amnesia67
(see Table 17-6 for specific dosages). Although the child
appears to be awake, he or she is not able to feel pain or
communicate. For those children with a risk of hypotension
from other sedatives, ketamine actually leads to the reverse,
an elevation in blood pressure. Clinicians should be aware
that it is a potent cerebral vasodilator, thus to be avoided in
children who are at risk for increased intracranial pressure.
A set of symptoms reported by older patients as visual,
auditory, proprioceptive, and strange illusions, called the
emergence phenomena, can occur when the drug is discontinued, especially in patients older than 16 years.
Propofol is an ultrashort-acting sedative-hypnotic agent
useful as a bolus for deep sedation for a stressful procedure
in nonintubated patients, as well as a bolus followed by a
continuous infusion for patients requiring mechaniCal ventilatory support in the ICU. Its advantages are its rapid onset
of action and rapid dissipation of effects 68 The patient's
level of sedation can be regulated by titrating the propofol,
much like blood pressure regulation by a dopamine infusion.
Although the half-life is I to 3 days, the sedative effects
typically dissipate within 5 to 10 minutes after the infusion
is discontinued, which makes it so useful. If the time to
extubate a patient is approaching and the patient has been
receiving other sedative agents, it may be appropriate to

Inhalational Agents
The use of inhalational anesthetic agents such as isofturane (Forane) is another alternative useful in providing
comfort to complex patients who are unresponsive to
maximal conventional therapy71 Advocates for their use
convey their benefits: rapid onset, rapid awakening on
discontinuation, and ease of control of the depth of
sedation. Additional benefit from its effect of bronchodilation makes it an attractive agent for patients who have
severe reactive airway diseases. However, several logistical
problems may limit their usefulness outside of the operating
room. Rules and regulations regarding who should regulate
the inspired concentration of the agent is complex and may
be not sanctioned to be done by nursing staff. Effective
scavenging devices are necessary to prevent environmental
pollution.

Discontinuation of Analgesics and Sedatives
Strategies to appropriately discontinue opioids and benzodiazepines in infants and children recovering from critical
illness are one of the most challenging aspects of critical
care nursing. Comprehensive management is based on
accurate and repetitive clinical assessment and a compassionate interplay of pharmacologic and nonpharmacologic
measures used in a complementary manner. The nurse
should assure the child and family that this does not mean
the child is addicted to the medicines. It means the child is
temporarily physically dependent on them in the same
fashion as steroids.
The ICU nurse must monitor for subtle clues indicative
of withdrawal while continuing to serve as an advocate for
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patient comfort. Early recognition and management of
withdrawal symptoms are imperative. Many of the signs and
symptoms associated with withdrawal are similar to those
associated with pain or the agitation itself. Use of an
objective assessment tool such as the Neonatal Abstinence
Scoring Tool (NAST) may assist the caregiver in identifying
the presence of withdrawal symptoms because it is easy to
overlook these individual symptoms or attribute them to
other causes when scoring. 72 As shown in Table 17-7, the
NAST was developed to assess and mange the opioidaddicted newborn; it identifies behaviors consistent with
withdrawal and assigns a score to each behavior. A score of
8 or greater indicates neonatal abstinence syndrome. Although the tool has not been validated for use in older
children, it may provide an objective means of assessment
for caregivers in the PICU setting. 49
Clinical features of opioid withdrawal include gastrointestinal dysfunction (poor feeding, uncoordinated sucking, vomiting, diarrhea), autonomic signs (dilated pupils,

TABLE

17·7

piloerection, increased sweating, nasal congestion, fever,
mottling), neurologic excitability (high-pitched crying, insomnia, hallucinations, increased motor tone, tremors,
seizures)3! Signs of withdrawal are more severe in older
children than in younger children and infants. Clinical
features of benzodiazepine withdrawal differ marginally
from those of opioid withdrawal. In addition to those
found in opioid withdrawal, severe anxiety, confusion,
perceptual disorders, depression, facial grimacing, choreoathetoid movements, dyskinetic movements of the mouth,
myoclonus, ataxia, poor visual tacking, and opisthotonos
have also been reported following abrupt discontinuance
of benzodiazepines. 73 Experts have found that some signs
of withdrawal (movement disorders) persist for up to
6 to 8 weeks after the discontinuation of midazolam
and are only partially responsive to treatment with other
benzodiazepines. 31
Symptoms are not only extremely uncomfortable for the
patient and anxiety provoking for the family, it may further

Neonatal Abstinence Score Sh~et
Signs and Symptoms

Excessive high-pitched (or other) cry
Continuous high-pitched (or other) cry
Sleeps < I hour after feeding
Sleeps <2 hours after feeding
Sleeps <3 hours after feeding
Hyperactive Moro renex
Markedly hyperactive Moro renex
Mild tremors when disturbed
Moderate to severe tremors when disturbed
Mild tremors when undisturbed
Moderate to severe tremors when undisturbed
Increased muscle tone
Excoriation
Myoclonic jerks
Generalized convulsions
Sweating
Fever of 37.2° C to 38.2° C (99° F to 100.8° F)
Fever >38.4° C (tolO F)
Frequent yawning (more than 3 to 4 times/interval)
Mottling
Nasal stuffiness
Sneezing (more than 3 to 4 times/interval)
Nasal flaring
Respiratory rate >60/min
Respiratory rate >50/min with retractions
Excessi ve sucking
Poor feeding
Regurgitation
Projectile vomiting
Loose stools
Watery stools

Score
2
3

3
2

1
2
3
I
2

3
4
2
I
3

5
I
I

2
I
I
I
I

2
I

2
I

2
2
3

2
3

I~dapled from Finnigan LP. KrOll RE, Cannaughton JF et al: A scoring system for evaluation and treatment of neonatal abstinence syndrome: a new clinical

![iiild research tool. In Morselli PL, Garattini S, Sereni F, eds: Basic and Iherapeulic uspeclS of perinatal pharmacology, New York, 1975. Raven Press;
~ii:prinled from the J Perillat Neonatal Nllrs July 1990. P 70.
.

-,
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complicate a patient's PICU course. The agitation accompanying withdrawal triggers the release of endogenous
catecholamines and other stress hormones such as glucagon
and corticosteroids that can lead to cardiovascular compromise. Attempts to wean from ventilatory support may be
disrupted by increasing oxygen consumption and carbon
dioxide production. Withdrawal symptoms expend energy
and calories needed for healing and may at times mimic the
onset of sepsis.
Previous use of other agents to control withdrawal, such
as phenobarbital, has been done to minimize withdrawal
symptoms. However, these have side effects of their
own. Therefore experts recommend the slow weaning
of their respective doses and converting to other agents,
such as methadone and clonidine, as useful in preventing withdrawal symptoms. Because of methadone's prolonged half-life, plasma levels of the drug will decline
slowly, allowing gradual weaning.'1 Some use methadone
in the weaning process at doses of 0.1 mg/kg given
enterally every 12 hours while gradually decreasing
and eventually discontinuing infusions of fentanyl and
morphine. 49
It is now known that u 2 -aderenergic receptors and
IJ.-opioid receptors activate the same potassium channel,
albeit via different proteins. Therefore administration of
c1onidine, an ~-aderenergic receptor agonist, is another
method of preventing opioid withdrawal symptoms; it may
"mimic" opioids at the subreceptor level, thus allowing
a decrease in the opioid dose without the occurrence of
signs or symptoms of withdrawal using oral doses of 3
to 5 IJ.g/kg every 4 to 8 hours? 1.49 In addition, clonidine's
central nervous system effects produce mild sedation and
a sense of well-being and calmness that also help
ameliorate the symptoms of withdrawal. Patients can be
weaned off the drug in I to 2 weeks as it is reduced by
0.1 to 0.2 mg each day.
Patients can benefit from institutions developing standardized approaches for such discontinuance of opioids and
benzodiazepines (Fig. 17-6). The general recommendation
is to avoid simultaneous decrease in both drugs at the same
time at intervals providing time for reassessment of the child
and attainment of a new steady state before the next
decrease in dose. Patients who have been treated with
continuous infusions of high doses of opioids require up to
2 to 3 weeks to be weaned. 31

NURSING'S ROLE IN PAIN MANAGEMENT
Nurses have primary responsibility for assessing children's
distress and coordinating pharmacologic, environmental.
and social interventions to optimize comfort. Their role in
providing patients and families with factual information
about pain and analgesics is an extremely important nursing
intervention directed toward breaking down the many
barriers to its effective management. Nurses need to
make pain management a priority, starting with establishing the standard in PICU that pain assessment be
done with the same frequency and attention as measure-
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ment of vital signs and checking the crash cart. Nurses
are in a crucial position to advocate for their patients with
the fundamental obligation to manage pain and relieve
patient suffering as a crucial element of their professional
commitment to patient care. These are not merely lofty
ideals; effective pain and anxiety management produces
myriad patient benefits, including reduced morbidity and
mortality. I I
Nurses' participation is necessary in developing and
establishing the institutional systems that promote quality
care in the area of pain management. Research has shown
that clinical protocols can be implemented by critical care
nurses to guide sedation strategies in such a way that the
duration of mechanical ventilation can be reduced at the
same time comfort can be provided 74 Nurses should
actively decide which pain assessment tools will be used
and ensure that they are readily available for staff and
patients to use. For example. a selection of pain assessment
tools may be compiled on a single sheet of paper, copied,
and placed on every bedside clipboard. Nurses can also
influence patient documentation systems to include a
specific section for pain assessments. Pain flow sheets 22
have demonstrated that patients who are assessed more
frequently experience less pain and receive more opioid
analgesics. Overall. there is still a lack of accountability
of healthcare systems, specifically critical care units, to
make pain as a recognized priority. Many experts advocate
that the first step is establishing a trigger point in the pain
intensity assessment scale, such as that pain needs to be
less than 50% of the total scale (i.e., less than 3 on a 0to 5-point scale), or a trigger point requiring an intervention
aimed at providing pain relief54
In recent years, extensive work in pain management
guideline development has been done. with accompanying
recommendations for quality improvement monitoring.
Nurses may be actively involved with the implementation of
well-recognized guidelines such as that of the Agency for
Health Care Policy and Research (AHCPR). II Increasing
efforts have been made by the Joint Commission on
Accreditation of Health Care Organizations to hold healthcare professionals responsible for assessing and relieving pain.7.75

SUMMARY
Caregivers must believe in the authenticity of a child's pain
and that the benefits of adequate analgesia far outweigh the
potential side effects. Adequate and early pharmacologic
interventions for pain relief minimize patient suffering,
maintain normal homeostasis, and improve a patient's
tolerance of ICU therapies and nursing interventions. The
appropriate selection and method of delivery of the pharmacologic strategy is determined by the intensity of the pain
experienced, the expected treatment goals, and the chi Id's
overall condition. Even for the sickest child, adequate
analgesia can be provided using the interventions, both
pharmacologic and nonpharmacologic, as outlined in this
chapter.
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Benzodiazepine Administration
Opioid administration

<5 days

I

•• D/C as tolerated
.. -

t.

Length of
therapy

.,,5 days

Intermillent

Method of
administration

•• Decrease rate of
infusion by 20% per i
day x 3 days

Continuous

,
Calculate hourly equivalent for lorazepam

Yes

Calculate hourly equivalent for morphine/methadone

If

Convert
to intermittent
dosing? .

".w_'.

No

,
•• Reduce total daily dose by 20-25%
:
with interval unchanged until reach
lorazapam equivalent of 0.1 mglkg/dose

•• Begin lorazepam at equivalent
dose q4h; IV or enteral

•• Reduce total daily dose by 20-25%
with interval unchanged until reach
morphine equivalent of 0.1 mg/kg/dose
,.,.
" ".,,-,.-- -'-'0 ....""'.J'-',
:-=""-'

•• Begin morphine IV at equivalent
dose q2h OR methadone at '/2
morphine equivalent dose q6h
.. ._- _.-.
,•..:;c._;:_ .._,
- "_.--.-_..

r;.-r

--~-.

•• Extend interval once/day
(q4h-q6h-q8h-q12h-q24h-D/C)
leaving mg/kg/dose the same
•• Extend interval once/day
(q4h-q6h-q8h-q12h-q24h-D/C)
leaVing mglkg/dose the same
OR for clinically stable patients
consider oral methadone dosing
(bid dosing of methadone may
be sufficient)
~

•..

~~. M"~_'

"; .•

",,.~.,_

..

,-.,,'-<;l'

_

"

i
-

.,

\

•• Decrease rate of infusion over 4-5 days
until mldazolam equivalent of 0.02 mglkg/hr
is reached; then D/C
•• Decrease rate of infusion over 4-5 days
until morphine equivalent of 0.02 mg/kg/hr
is reached; then D/C

...~

«'.'

";::"--. .,

..

-, ....

;----

-

..

,

".'-,.,-_.

",."

.

•• Assess patient for signs of
withdrawal or overdose.
If either situation present, reassess
dosing and interval.
If symptoms of withdrawal are present,
consider pm dosing of lorazepam
until symptoms are minimized.
If overmedication present, consider
reducing dose and interval.

•• Assess patient for signs of withdrawal
or overdose.
If either situation present, reassess
dosing and interval.
If symptoms of withdrawal are present,
consider pm dosing of opioid until
symptoms are minimized.
If overmedication present, consider
reducing dose and interval.

For weaning purposes, assume 1 mg
of lorazapam is equivalent to 1 mg of
midazolam.

Morphine is 50-100 times less potent
than fentanyl.
I1g of morphine = I1g of fentanyl x 50
divide by 1000 to obtain mg dose
For purposes of weaning, assume 1 mg
of morphine is equivalent to 0.5 mg of
methadone.

.

Fig.17-6

Algorithm for weaning benzodiazepines and opioids. (Data from Cincinnati Children's Hospital
Medical Center: Therapeutic concepts: narcotic/benzodiazepine withdrawal, 1996, pp 1-4.)
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Etiology and Clinical Presentation in Cyanotic
Infants

ardiovascular dysfunction necessitates admission to a
critical care setting across the lifespan. The percentage
of pediatric intensive care unit (PICU) patients with
cardiovascular dysfunction was 13% to 38% in one multicenter study' and 19% in the American Association of
Critical Care Nurses 1999 role delineation study.2 Cardiovascular dysfunction may be the consequence of hypovolemia, myocardial dysfunction, cardiac rhythm disturbances,
increased afterload, or pericardial tamponade. It is important
to note that myocardial dysfunction may be either the result
of a primary cardiac problem or the final pathophysiologic
consequence of a variety of other problems. Cardiovascular
dysfunction can result in a low-flow shock state and
inadequate tissue perfusion.
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Acyanotic Heart Defects With Increased PDF
Acyanotic Defects That Obstruct Flow
Cyanotic Congenital Heart Defects With
Decreased PDF
Cyanotic Congenital Heart Defects With
Increased PDF
Cyanotic Congenital Heart Defects With
Variable PDF
PERIOPERATIVE MANAGEMENT OF PEDIATRIC CARDIAC
SURGICAL PATIENTS

ASSESSMENT OF PATIENTS WITH
CARDIOVASCULAR DYSFUNCTION

Preoperative Preparation
Perioperative Techniques
Potential Postoperative Complications
Critical Care Management

The clinical picture of the patient with inadequate tissue
perfusion can be clearly identified because low cardiac output results in physiologic compensation that is readily apparent on physical examination.
A common first sign of physiologic distress in infants and
children is tachycardia. Tachycardia occurs with fever,
anemia, hypovolemia, dyspnea, activity, and excitement or

ACQUIRED HEART DISEASE IN INFANTS AND CHILDREN

Acute Myocarditis
Kawasaki Disease
Cardiomyopathy
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anxiety. In fact, it is an ominous sign of cardiac dysfunction
if heart rate does not increase in the face of physiologic
distress. Persistent tachycardia during sleep is generally
nonphysiologic and warrants further evaluation. In addition,
following trends in heart rate over time is useful.
Tachycardia related to physiologic distress is the result of
sympathetic nervous system (SNS) stimulation. SNS stimulation also results in increased minute ventilation, whereby
respiratory rate and depth can increase.
SNS stimulation also results in peripheral vasoconstriction. As a consequence, arterial blood pressure is maintained, even in situations when cardiac output is low. Vasoconstriction elevates the diastolic blood pressure and
narrows the pulse pressure, maintaining mean and systolic
pressure at normal levels. Peripheral vasoconstriction is
clinically apparent by weak peripheral pulses, cool extremities, pallor, mottling, and prolonged capillary refill. These
are classic early signs of low cardiac output and decreased
tissue perfusion, even in the presence of "normal" blood
pressure.
If increased heart rate and peripheral vasoconstriction are
not sufficient to support decreased cardiac output, continued
SNS stimulation results in regional redistribution of blood
flow to ensure perfusion of vital organs. Blood is shunted
away from the skin, gastrointestinal tract, kidneys, and
liver to maintain circulation to the heart, lungs, and brain.
Decreased perfusion of the skin and subcutaneous tissue
is evident in mottling and cooling of the extremities
(Fig. 18-1). Inadequate perfusion of the gastrointestinal tract
is apparent when infants or children develop feeding
intolerance that may progress to the development of
paralytic ileus and/or gastrointestinal necrosis. Decreased
urine output is the consequence of inadequate renal blood
flow because the glomerular filtration rate is decreased.
Acute tubular necrosis (ATN) can be the eventual outcome.
Impaired hepatic function is evidenced by abnormalities in
coagulation, the development of jaundice, and increases in
liver function tests.
Determination of electrolyte, acid-base, and substrate
abnormalities is important in the care of pediatric patients

IlL
Fig. 18-1 Marked mottling of the skin in infant with regional
redistribution of blood flow caused by congestive heart failure.

with impaired tissue perfusion because of their effect on
cardiac performance. These abnormalities occur as the
consequence of decreased tissue perfusion and can compound cardiac dysfunction. Serum electrolytes, calcium,
glucose, urea nitrogen, and creatinine are measured to
establish their baseline values in patients with low cardiac
output, with measurements repeated at intervals determined
by the individual patient's physiologic status.
Arterial blood gases, pH, and base excess or deficit
provide specific information about the adequacy of tissue
perfusion and oxygenation. Metabolic acidosis develops
when tissues are inadequately perfused, with the subsequent
development of anaerobic metabolism. Lactic and other
organic acids accumulate and require buffering by the buffer
bases. This results in rapid use of the base buffers and a
resultant base deficit. Metabolic acidosis causes decreased
myocardial contractility and decreased adrenergic receptor
sensitivity and predisposes to myocardial irritability and
lethal cardiac rhythm disturbances.

FINAL COMMON PATHWAYS
Regardless of the cause of inadequate tissue perfusion, if
cardiovascular performance cannot be restored, the outcome
is similar in all. The possible consequences include impaired
cardiac performance, cardiac arrhythmias, cardiac arrest,
pulmonary edema, acute respiratory distress syndrome, and
irreversible central nervous system ischemia. Clearly the
goal is to intervene successfully in a timely manner before
these devastating sequelae occur.

PROVIDING BASELINE SUPPORT
Baseline care of patients with cardiovascular dysfunction is
predicated on minimizing metabolic demands, support of
respiratory function, and provision of nutritional needs.
Therapy is escalated as indicated according to patient needs
and expected outcomes.
Conserving energy and minimizing stress lower oxygen
demand and reduce myocardial work. Promoting rest is of
primary importance. Close monitoring of physiologic status
allows the timely identification of adverse effects, and
clustering of care allows periods of undisturbed rest. If
extreme restlessness or irritability is present, the underlying
cause must be identified and corrected. If necessary,
sedation is provided to minimize anxiety and agitation.
Work of breathing is supported to conserve energy and
decrease metabolic demands. In children with left-to-right
shunt lesions or in congestive heart failure, concurrent
pulmonary edema, decreased lung compliance, low lung
volumes, and airway obstruction can be present. All of these
pathologic phenomena contribute to increased work of
breathing. tachypnea, retractions, rales, and orthopnea.
Often the supine position is not well tolerated because of
increased pulmonary congestion and decreased lung volumes. The best position for these children is in semiFowler's to facilitate displacement of blood in the systemic
venous bed and augment lung volumes. In addition, a
head-up position displaces the liver and abdominal organs
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downward, permitting greater chest excursion. Administration of diuretics helps to control pulmonary venous congestion and edema.
Administration of humidified oxygen may be necessary
to promote alveolar oxygen diffusion or to treat pulmonary
hypertension. However, because of its pulmonary vasodilatory effects, oxygen should be used judiciously in patients
with increased pulmonary blood flow or when trying to
balance pulmonary-systemic blood flow (as in hypoplastic
left heart syndrome) because this intervention can worsen
heart failure in these patients. Mechanical ventilation is
implemented to take over the work of breathing and to
minimize the metabolic demands of the respiratory muscles.
Metabolic rate is increased in children with cardiovascular dysfunction. Unfortunately, many infants and small
children cannot consume enough calories to meet metabolic
needs. Nutritional support is critically important in these
patients. Caloric needs are continually assessed, and growth
is monitored over time on an age-appropriate growth chart
(see Appendix II). High-calorie fOffimlas are often recommended for infants to maintain weight gain. Nasogastric or
nasojejunal feedings are implemented if the infant does not
demonstrate normal weight gain despite increasing caloric
density. The critically ill child will require monitoring of
serum protein, albumin, glucose, electrolytes, and lipids to
maximize nutritional support.
Maintenance of normal body temperature conserves
energy because both hypothermia and fever result in thermal
stress. Wide variations in body temperature produce alterations in oxygen consumption, affecting cardiac output.
Hyperthermia increases heart rate, whereas severe hypothermia can result in precipitous drops in cardiac output and
blood pressure.

CONGESTIVE HEART FAILURE
Congestive heart failure (CHF), regardless of the age of
the patient, is the inability of the cardiovascular system to
meet the metabolic demands of the body. Specific causes
and clinical presentations vary with age (Box 18-1 and
Table 18-1). Manifestations of CHF primarily are due to the
physiologic compensatory mechanisms that are results of
low cardiac output reflecting the body's attempt to compensate. To understand the pathophysiologic and clinical
manifestations of heart failure, the nurse must have a
thorough understanding of the normal determinants of
cardiac output (see Chapter 7 for review).
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left heart syndrome, coarctation) impose a pressure load on
the heart. Symptoms become apparent during the tirst few
days of life once the ductus arteriosus c1oses. 3" Anomalies
of the coronary arteries can result in myocardial ischemia
with subsequent ventricular pump dysfunction and heart
failure. Corrective or palliative surgery can result in
resolution of CHF or slow its progression.
Acquired heart disease is the most common cause of
CHF in children over I year of age. Acquired disease
includes cardiomyopathy, endocarditis, myocarditis, Kawasaki disease, and rheumatic heart disease. These diseases
(with the exception of rheumatic heart disease) result in
impaired myocardial contractility. Diminished contractility
can ultimately result in volume overload, with subsequent
pulmonary and venous congestion. Rheumatic heart disease
can result in significant mitral or aortic valve regurgitation,
cardiac dilation, and pulmonary congestion.
Tachyarrhythmias or bradyarrhythmias can result in heart
failure. Acute-onset tachycardia (supraventricular tachycardia, junctional ectopic tachycardia) can result in heart failure
if not identified and treated in a timely manner. Incessant,
chronic tachyarrhythmias (atrial ectopic tachycardia, premature junctional reciprocating tachycardia) can result in CHF
if the tachycardia occurs throughout the day. In some

~

Box 18-1

Causes of Heart Failure

Alterations in Workload
Volume Overloading of the Ventricles

Large left-to-right shunt
Ventricular septal defect
Atrioventricular septal defect
Patent ductus arteriosus
Valvular insufficiency
Aortic, mitral, pulmonary
Systemic arteriovenous fistulas
Pressure Overloading of the Ventricles

Obstruction to outfiow
Aortic stenosis
Pulmonary stenosis
Coarctation of the aorta
Obstruction to infiow
Mitral stenosis
Cortriatriatum
Tricuspid stenosis

Etiology

Alterations in Inotropic Function

Congenital heart defects are the most common causes of
heart failure in infants. Structural heart disease can impose
either a pressure or volume load on the heart. Defects with
a left-to-right shunt (ventricular septal defect, patent ductus
arteriosus) impose a volume load. Clinical manifestations
are dependent on the size of the shunt and pulmonary
vascular resistance. Generally, these infants become symptomatic within the first 6 weeks of life. Obstructive lesions
(particularly left-sided lesions: aortic stenosis, hypoplastic

Infiammatory disease
Electrolyte disturbances
Metabolic disease
Coronary artery lesions
Alterations in Chronotropic Function

Tachyarrhythmias
Profound bradycardia
Complete heart block
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TABlE 18·1
w..
ji"

Likely Causes of Heart Failure Related to Timing of Its Development

CHF at Birth or Shortly After

Myocardial dysfunction
Asphyxia
Sepsis
Hypoglycemia
Hypocalcemia
Myocarditis
Transient myocardial ischemia
Hematologic abnormalities
Anemia
Hyperviscosity syndrome (hematocrit >65%)

Structural abnornlalities
Tricuspid regurgitation
Pulmonary regurgitation
Total anomalous pulmonary venous return with
obstruction
Heart rate abnormalities
Supraventricular tachycardia
Congenital complete heart block

b':;'

iE"
fZ:'

CHF in the First Week of Life

Myocardial or heart rate abnormalities
Same as above, except asphyxia less likely as a cause
Structural abnormalities
Patent ductus arteriosus
Hypoplastic left heart syndrome
Aortic stenosis
Total anomalous pulmonary venous return
Coarctation of the aorta
Renal disorders
Renal failure
Systemic hypertension

Pulmonary abnormalities
Upper airway obstruction
Bronchopulmonary dysplasia
Central nervous system hypoventilation
Persistent pulmonary artery hypertension
Endocrine disorders
Neonatal hyperthyroidism
Adrenal insufficiency

~!!

~r:

CHF in Early Infancy (1-6 Weeks)

Myocardial abnomlalities
Endocardial fibroelastosis
Anomalous origin left coronary artery
Myocarditis
Dilated cardiomyopathy
Renal disorders
Same as above

Structural abnormalities
Coarctation
Ventricular shunt (VSD, AVSD, SV)
Aonic shunt (PDA, truncus, AP window)
Endocrine disorders
Hypothyroidism
Adrenal insufficiency

CHF After Infancy

Acquired heart disease
Cardiomyopathy
Myocarditis
Vasculitis (Kawasaki disease)
Other
End-stage pulmonary disease
Cystic fibrosis
Primary pulmonary artery hypertension
Tachyarrhythmia

Congenital heart disease
Preoperative patients
Eisenmenger's syndrome
Pulmonary stenosis (rare)
Ebstein's anomaly with increasing TR
Aortic regurgitation
Mitral regurgitation
With onset of tachycardia
Postoperati ve patients
Ventriculotomy
Large residual left to right shunt
Valvular regurgitation, especially MR, AR
Obstructed conduit or mechanical valve
Prosthetic valve malfunction
Coronary artery injury
Ventricular dysfunction

~AP' Aortopulmonary: AR, aortic regurgitation; AVSD. atrioventricular septal defect; CHF. congestive heart failure; MR, mitml regurgitation;
~dUC1US arteriosus: Sv. single ventricle; TR, tricuspid regurgitation; VSD, venlricular septal defect.

!i'-'-

PDA, patent
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patients, cardiomyopathy may be the result of incessant
abnormal tachycardias. Once the rhythm is controlled, the
cardiomyopathy resolves. Complete heart block with a slow
ventricular rate can be responsible for CHF; once the heart
block is treated, the CHF resolves as well.
Heart failure may develop as a consequence of acidemia,
hypoxia, lung disease, or drug ingestion. Low Pa02 , low pH,
and elevated Pac0 2 depress myocardial function and elevate
pulmonary resistance. Chronic lung disease results in
pulmonary hypertension and right heart failure. Inborn
errors of metabolism can result in cardiomyopathy and CHF.
Although rare, heart failure can be iatrogenically induced by
excessively rapid infusion of fluid, calcium channel blocker
overdose, and ~-blocker overdose.

Pathogenesis
The pathogenesis of heart failure is the result of interplay
between hemodynamic, neurohormonal, and cellular factors
and abnormal autonomic responses. The normal compensatory responses to heart failure initially serve to support
cardiovascular function for a limited period. However, if
protracted, these compensatory responses may actually be
detrimental to the failing heart (Fig. 18-2).
Determinants of Cardiac Performance. The factors that control cardiac output are preload or diastolic
volume; afterload or the ventricular wall tension developed
during ventricular ejection; contractility or the inotropic
state of the myocardium; and heart rate. In addition,
significant myocardial structural and maturational issues
affect cardiac output in neonates and young infants.
When compared with those in the adult, immature
myocytes are thinner, less compliant, and less well organized. The developing heart is also thought to have a relative
decrease in contractile mass, with a predominance of
noncontractile elements. At birth there is right ventricular
dominance that progresses to left ventricular dominance
over the first few months of life. 5.6 The newborn heart, at
baseline, functions at the peak of the Frank-Starling curve,
exhibiting a greater resting tension for any degree of stretch
indicating limited ventricular compliance. Therefore volume
loading and increased stretch can actually decrease cardiac
output. Because of a high intrinsic heart rate, the infant has
limited ability to increase cardiac output through an increase
in heart rate. Increases in afterload are not well tolerated in
neonates and infants because of limited compliance and
diminished contractile function.
In newborns the sarcoplasmic reticulum (SR) is poorly
organized and less well developed compared with adults.
Normally in mature cells the SR is the primary source of
intracellular calcium for modulation of contraction. However, because of relati ve immaturity, the newborn myocyte
is dependent on serum calcium for contraction. The
contractile proteins (actin and myosin) increase their sensitivity to calcium with maturation, increasing inotropic
response with age. 6 In addition. maturational changes in the
autonomic nervous system lead to developmental differences in response to autonomic stimulation by endogenous
and exogenous adrenergic agonists.
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(e.g., VSD)

/

ii Pulmonary venous congestion

l Systemic blooc flow
(chronic)

(2' to i LAP)
Intersitial pulmonary edema
i Lung H20 -> tachypnea
i Small airway resistance -> wheeZing
i Work of breathing

+/- alveolar edema ->rales

Growth failure

Regional redistribution
of blooc flow
lSkin
l Kidneys
+/-l Gltract

Impaired gas exchange -> lPa02, iPaC02

Systemic venous congestion
Hepatomegaly
+/- peripheral edema
Metabolic response
Hypermetabolism -> i V02
Acid·base status

+/- repiratory acidemia

A

CARDIAC FAILURE DUE TO SYSTEMIC PRESSURE LOAD
/

(e.g., coarctation) ~

iPulmonary venous congestion
(2' to i LAP)
Interstitial pulmonary edema
i Lung H20 -> tachypnea
i Small airway resistance -> wheeZing
i Work of breathing

+/- alveolar edema ->rales
Impaired gas exchange -> lPa02, iPaC02

Systemic venous congestion
Hepatomegaly
+/- peripheral edema

l.l. Systemic blooc flow
l ArteJial pulsations
Cold extremilies
Slow capillary refill

l.l. Systolic function
Impaired contractility

Regional redistribution
of blooc flow
HSkin
H Kidneys
H Mesenlery

Metabolic response
Hypermetabolism -> i Vo,
Acid·base slalus
Metabolic acidemia

Fig. 18-2

B

Diagrammatic representations of cardiac failure caused

by volume load (A) and pressure load (B). VSD. Ventricular septal

defect; LAP. left atrial pressure; Gl, gastrointestinal.

Hemodynamic Characteristics. The hemodynamic
abnormalities of heart failure are due to reduced ejection
(systolic dysfunction) or diminished ability to receive
venous return (diastolic dysfunction). In systolic dysfunction, there is impaired ventricular contraction with a
subsequent decrease in the ability to increase stroke volume
with volume loading. In this scenario, small increases in
afterload are not well tolerated, leading to a decline in
cardiac output. Conversely, small decreases in afterload may
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contribute to a significant improvement in cardiac output.
Causes for systolic dysfunction include lesions with left-toright shunts, dilated cardiomyopathy, and myocardial ischemia. Depending on the underlying cause, systolic dysfunction can lead to volume or pressure overload or both.?
Diastolic dysfunction is due to decreased ventricular
compliance requiring high venous pressures to support
ventricular filling. Causes of diastolic dysfunction include
lesions that limit ventricular filling (atrioventricular [AV]
valve stenosis, pulmonary venous obstruction), lesions that
contribute to reduced intrinsic compliance (hypertrophic
cardiomyopathy), and pericardial effusion or tamponade.
Neurohormonal Factors. A decrease in cardiac output triggers a neurohormonal response that is vital to
survi val in acute low-output states. This is accomplished
through enhanced activity of the SNS and the reninangiotensin-aldosterone system (RAAS). Initially, this results in improved contractility, fluid and sodium retention,
and vasoconstriction to support blood pressure. However,
when sustained, these compensatory mechanisms may
exacerbate hemodynamic abnormalities and accelerate myocardial cell death. Fig. 18-3 depicts the neurohormonal
response to low cardiac output and the consequences. SNS
stimulation initially improves cardiac output by increasing
heart rate, blood pressure, and ejection fraction. With
sympathetic stimulation, there is a subsequent increase in
ventricular afterload resulting from vasoconstriction. This
mechanism supports blood pressure acutely, but eventually
it contributes to increased ventricular work. Unfortunately,
the long-term sequelae of SNS stimulation lead to increased
myocardial oxygen consumption, increased ventricular wall
stress, and diminished myocardial oxygen supply.

RAAS stimulation causes salt and water retention, which
initially augments preload. Chronic sodium and water
retention results in long-term pulmonary congestion and
peripheral edema. Vasoconstriction is also augmented by
angiotensin II (following conversion of angiotensin I to
angiotensin II in the lung). In the short term, it serves to
maintain blood pressure for vital organ perfusion. Longterm effects are those of increased afterload: exacerbation of
systolic dysfunction and increased energy requirements.
Besides promoting salt and water retention, aldosterone is
also responsible for the development of ventricular fibrosis
and promotion of collagen synthesis in heart failure. These
mechanisms are responsible for decreased myocardial
capillary density, increased ventricular stiffness, and diastolic dysfunction. 6 . s
Increased SNS and RAAS activity contributes to cardiac
toxicity through cell necrosis and apoptosis. Necrosis is a
passive process characterized by inflammation that occurs
as a result of a number of cytotoxic mechanisms. Apoptosis
is an active process that is secondary to activation of genes
encoded for programmed cell death. Apoptosis is activated
in clinical conditions in which vascular remodeling, hypertension, and ischemia occur. 6
Cellular Factors. Ventricular dilation occurs in response to the increased stress imposed by volume or
pressure overload. An increase in ventricular end-diastolic
volume, even in the face of diminished fiber shortening,
supports stroke volume. However, chamber dilation requires
an increase in wall tension to maintain systolic pressure,
increasing myocardial oxygen requirements. This physiologic mechanism is limited in that excessive wall stretch will
exceed the heart's ability to contract forcefully. Conse-
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Fig. 18·3 Diagrammatic representation of consequences of neurohormonal response in heart failure.
(Adapted from Katz AM: Cardiomyopathy of overload, N Engl J Med 322: 100-110, 1990.)
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quently, a fall in systolic function and stroke volume will
occur. As mentioned previously, fibrosis and collagen
formation occur in heart failure with a subsequent loss of
myocytes. These phenomena contribute to progressive
cardiac dilation, decrease in capillary density, and a relative
deficit of energy-producing mitochondria. Because of
changes in calcium intrusion into the cytosol with energy
deficit, ventricular relaxation (Iusitropy) diminishes (relaxation is more sensitive to energy deficit than contraction).
Hypertrophy of the overloaded ventricle is a complex
process brought about by changes in actin, myosin, and
collagen contributing to cardiac remodeling. Adding new
sarcomeres aids the heart in adapting to chronic ventricular
overload. However, chronic hypertrophy is associated with
abnormal gene expression leading to progressive myocardial damage, fibrosis, and cell death. Chronic hypertrophy
prolongs the action potential, leading to electrophysiologic
abnormalities and cardiac rhythm disturbances. Hypertrophy also impairs relaxation of the heart, leading to diastolic
dysfunction. In infants and children, relief of increased
ventricular afterload allows regression of hypertrophy.
Abnormal Autonomic Responses. Acutely, SNS
compensatory activation improves cardiovascular function through an increase in chronotropic, inotropic, and
lusitropic responses. Over time, with sustained sympathetic overstimulation, a subsequent down-regulation of
~-receptors occurs. Ultimately the myocytes fail to respond
normally to endogenous and exogenous adrenergic agonists,
with a substantial decrease in responsiveness to adrenergic
stimulation.

Clinical Manifestations
The signs of heart failure in infants and children can be
subtle and are dependent on the underlying etiology and age
of the child. They can be organized into three general
categories: signs related to impaired myocardial performance and those resulting from pulmonary and systemic
venous congestion.
Impaired Myocardial Performance. The cardiac
manifestations of heart failure primarily are due to the
neurohormonal compensatory mechanisms that are activated because of low cardiac output. In addition, cardiac
failure presents additional specific symptoms related directly to poor myocardial function.
Cardiac enlargement on chest radiograph is a consistent
sign of impaired function, representing ventricular dilation
or hypertrophy. Only in the earliest stages of heart failure is
cardiac size normal. Tachycardia is commonly seen with
cardiac failure and represents an adaptive mechanism to
support cardiac output and oxygen delivery to tissues. An S3
gallop rhythm noted at the apex is often appreciated because
of rapid filling of a stiff, noncompliant ventricle 3 Vasoconstriction decreases peripheral perfusion, signaled by cool
extremities, weak peripheral pulses, slow capillary refill,
and mottling. In high output failure, pulse pressure may be
increased and arterial pulsation bounding. Severe anemia
(hemoglobin level lower than 5 g/dl) causes a similar
phenomenon. Vasoconstriction most often maintains blood
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pressure in the normal range, even when tissue perfusion is
inadequate. Hypotension is a late and ominous sign.
Many infants and small children in heart failure cannot
ingest enough calories to support growth, particularly with
the concurrent increase in metabolic demands. This phenomenon is usually secondary to fatigue and poor feeding.
As a result of sympathetic activation, diaphoresis with
feeding can be noted. 9 Severely ill infants may fatigue so
quickly with feeding that it is physically impossible for them
to take in an adequate volume of formula. Therefore growth
failure results, necessitating increasing caloric density of
formula or the institution of tube feedings.
Pulmonary Congestion. Pulmonary congestion occurs secondary to increased pulmonary blood flow, left
ventricular failure, or pulmonary venous obstruction. Normally the pulmonary lymphatics remove accumulated lung
fluid to prevent alveolar edema. If capacity of the lymphatics is exceeded because of pulmonary overcirculation or
pulmonary venous congestion, then pulmonary edema
ensues 3 Tachypnea is a common sign of heart failure
indicating pulmonary interstitial edema and decreased lung
compliance. Intercostal retractions, grunting, wheezing, and
cough may also be present. Older children will complain of
dyspnea on exertion or orthopnea. Rales are generally a late
sign and may not be appreciated in infants. Wheezing may
be due to broncmal edema or compression of the airways by
distension of the pulmonary arteries or left atrium.
Systemic Venous Congestion. Hepatomegaly is the
most consistent sign of systemic venous congestion. Enlargement of the liverreflects an increase in systemic venous
volume or right atrial pressure. Tenderness of the liver and
the absence of a firm, discrete liver edge can be elicited even
in older children with heart failure. Jaundice may occur with
hepatic congestion but is generally a late sign.
Systemic venous congestion can be evaluated in older
children by observing the jugular venous vein (this cannot
be assessed in infants). Normally when the cmld is supine
and lying at a 45-degree angle, the jugular vein should not
rise above the imaginary line drawn across the manubrium
of the sternum. If the vein is visible above this line, then
jugular venous distension is present, indicating CHF.
Peripheral edema is a rare finding in infants, although
periorbital edema can sometimes be detected. In older
children, peripheral edema and, occasionally, ascites and
generalized anasarca may be present 9 These clinical signs
are more often appreciated in the cmld with severely
compromised myocardial function.
Diagnosis. In addition to history and physical examination findings, the diagnosis of heart failure is aided by a
number of noninvasive and invasive laboratory studies.
Chest radiography is necessary to assess cardiac size; it also
permits assessment of pulmonary congestion. The electrocardiogram (ECG) is not particularly useful, unless an
arrhythmia is the cause for cardiac failure. Echocardiography permits assessment of myocardial function from ventricular dimensions, fiber-shortening rate, and ejection
fraction. Diastolic function is evaluated from estimates of
isovolumetric relaxation time, diastolic dimensions, filling
time, and other parameters.
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Critical Care Management
Treatment of cardiac failure is determined by the underlying
cause. Structural heart disease in infants or children who are
in CHF should be repaired or palliated in a timely manner.
Early surgical repair can lead to reversal of neurohormonal
and cellular abnormalities that lead to ventricular dilation
and hypertrophy. Preoperative use of prostaglandin E,
(PGE I) to maintain ductal patency in ductal-dependent
lesions permits stabilization and an elective approach to
surgery.
Medical management in acute heart failure is directed at
support of cardiac output through manipulation of preload,
afterload, and contractility. (See Chapter 7 for a complete
discussion on volume replacement and medications.) Volume status is normalized through diuresis and judicious
fluid management. Inotropes, either intravenous or oral, are
instituted to improve contractility. After/oad-reducing
agents are instituted if appropriate and are being used
increasingly to decrease ventricular work. If the cause of
heart failure is incessant, tachyarrhythmia antiarrhythmics
are used for conversion to sinus rhythm or for rate control.
Mechanical assist (ventricular assist device, intraaortic
balloon pump, or extracorporeal membrane oxygenation) is
used in the severely decompensated patient for temporary
support or as a bridge to heart transplantation (see Chapter
7, section on mechanical assist.)
Maneuvers to manipulate the pulmonary vascular bed are
implemented in select patients to maximize pulmonary:
systemic flow. Oxygen, alkalosis, hyperventilation, nitric
oxide, prostacyclin, and after/oad reduction decrease pulmonary vascular resistance, therefore augmenting pulmonary blood flow. These interventions are to be used in
patients with pulmonary hypertension and should be
avoided in children with large left-to-right shunts. In the
latter, increased pulmonary blood flow will be at the expense
of systemic flow, contributing 10 systemic underperfusion.
Inhaled carbon dioxide or nitrogen will increase pulmonary
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vascular resistance, decreasing pulmonary blood flow.
These two maneuvers are generally reserved for infants
with hypoplastic left heart syndrome or single-ventricle
physiology who require careful balancing of systemic-topulmonary blood flow.
Diuretic Therapy. In treating chronic failure, diuretic
therapy is aimed at correcting the clinical problems of
pulmonary and systemic venous congestion. Diuretic agents
are useful to maximize sodium excretion and thereby
increa~e the volume of urine excreted. Table 18-2 lists the
various types of diuretic agents useful as adjuncts in treating
patients with heart failure.
Because all diuretic agents increase sodium excretion,
hypovolemia and hyponatremia are potential complications
of their use. Acid-base imbalances can occur. Metabolic
alkalosis is common with administration of the potent loop
diuretics, owing to chloride depletion and volume contraction. Metabolic acidosis is a potential complication of
carbonic anhydrase inhibitors, but this usually is mild.
Hypokalemia is the consequence of potassium wasting.
Hypokalemia can be avoided by diuretics given every other
day, potassium supplementation, or the concurrent use of a
potassium-sparing diuretic.
Neurohormonal Modulation. As the understanding of the pathophysiologic mechanisms underlying heart
failure increases, so have novel therapeutic interventions.
Newer treatment modalities are aimed at blocking or
resetting neurohormonal overstimulation. Presently used
agents include angiotensin-converting enzyme inhibitors
(ACEIs), digoxin, ~-blockers, aldosterone antagonists, and
angiotensin-receptor blockers.
Angiotensin II is responsible for vasoconstriction, aldosterone secretion, myocardial fibrosis, and cellular remodeling in heart failure. ACEIs inhibit the enzyme responsible
for the conversion of angiotensin I to angiotensin II. They
also inhibit degradation of bradykinin and inhibit norepinephrine release, thus augmenting vasodilation. These

18-2 Diuretic Agents for Heart Failure
Action

Block Na and CI reabsorption widely at multiple medullary and cortical sites
Cautions: volume contraction (free water reabsorption is blocked); hypokalemia

Block Na and Cl reabsorption at the ascending limb; less loss of K
Caution: volume contraction (especially with metolazone)
Aldosterone antagonist; impairs Na reabsorption and increases K and H ion secretion
No effect on water production or reabsorption

. rbonic Anhydrase Inhibitors
-'cetazolamide

~>

~!f

Inhibits carbonic anhydrase to decrease Na and CI reabsorption at distal sites
Less effect on free water production and reabsorption, but K excretion is increased
Diuretic effects are mild only

;~l. Chloride ions: H. hydrogen ions; K, potassium ions: Na. sodium ions.
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agents have long been used for afterload reduction to
decrease ventricular wall stress and work. Angiotensin II
and norepinephrine (along with increased ventricular wall
stress) are also known to contribute to ventricular remodeling and fibrosis. ACEIs have been shown to prevent fibrosis
and limit myocyte necrosis and apoptosis. 10 Clinically, these
agents have been shown to produce symptomatic improvement and reduce mortality. 6
Digoxin is extensively used to treat heart failure,
improving hemodynamics through the enhancement of
systolic function. Digoxin also enhances parasympathetic
stimulation, therefore opposing sympathetic overstimulation. The mechanism by which digoxin potentiates parasympathetic stimulation is not well understood.
~-Blockers, albeit counterintuitive, have been shown to
improve ventricular function and decrease mortality in both
children and adults. These agents are usually employed once
diuretic, afterload-reducing, and inotropic medications have
been maximized. ll . n Mechanism of action is thought to be
the prevention and reversal of SNS-mediated myocardial
remodeling and dysfunction. Initially, ~-blockers can
worsen failure, so starting doses are low with slow
incremental increases in dose up to maximum therapeutic
dose or clinical effect. Dosage adjustment is tailored to
the patient and may take weeks. Cardio-selective thirdgeneration agents (carvedilol) are generally well tolerated
with few side effects. 14 Carvedilol is believed to have
antioxidant effects, theoretically providing protection
against cytotoxic biologic modifiers. 6 • 11 Further studies are
necessary to evaluate ~-blockers in children because of the
variable causes and natural history of heart failure in
pediatrics.
Aldosterone, as part of the RAAS, plays a significant role
in the pathophysiology of heart failure. It promotes sodium
and water retention, myocardial fibrosis, and collagen
formation. Spironolactone is an aldosterone-receptor antagonist, potassium-sparing diuretic long used in pediatrics to
avoid potassium replacement but is avoided in adults
because of potential hyperkalemia. The Randomized Aldactone Evaluation Study (RALES)8 demonstrated significant
clinical improvement and reduction in mortality in adults
with CHF who were prescribed spironolactone. This randomized, double-blinded study was halted prematurely
because the observed improvement in outcome in the
spironolactone group exceeded prespecified end points.
Mechanism of action is thought to be prevention of sodium
and water retention, prevention of myocardial fibrosis, and
blocking of collagen formation.
Angiotensin II antagonists (losartan, candesartan) are
new agents currently under investigation in adults to
selectively block angiotensin II receptors, mitigating the
effects of the RAAS. Currently they are used for patients
who are refractory to ACE inhibition, and are generally
prescribed concurrently.IO To date, no pediatric clinical
trials have been published.
Nutrition. Nutrition is one of the most important
aspects of the management of children in heart failure.
Small children and infants in heart failure often cannot
consume enough calories to support growth. Tachypnea and
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fatigue can interfere with normal nursing or nippling.
Many infants in heart failure require up to I SO calories/kg/
day. A number of biologic markers can be used to assess
nutritional status. In the PICU, serum albumin or prealbumin can be measured. Prealbumin is a better marker of
nutritional state because it has a shorter half-life than
albumin and correlates with positive nitrogen balance. In an
effort to maximize caloric intake, formula or breast milk can
be fortified to increase caloric density. In general, formula
should not be increased to greater than 30 calories/ounce to
prevent an excessive osmotic and protein load. Tube
feedings are implemented if the infant continues to fail to
thrive. These feedings can be nasogastric or nasojejunal,
given throughout the day or at night only. Any infant with
structural heart disease who does not gain weight appropriately on maximum calories and medical management
constitutes a medical failure and should undergo surgical
intervention.

CYANOSIS AND HYPOXEMIA
Cyanosis and hypoxemia are commonly encountered clinical problems in pediatric patients. Cyanotic infants often
present a confusing diagnostic picture. The first task is
differentiating cardiac disease from pulmonary disease in
these infants. A general rule of thumb is that children who
improve with oxygen have lung disease and those who do
not have cyanotic heart disease. In some cases, this does not
always hold true, prompting further diagnostic investigation. Echocardiography is an important diagnostic tool used
in concert with clinical presentation and other ancillary tests
(chest x-ray film, ECG).

Etiology and Clinical Presentation
in Cyanotic Infants
Structural heart diseases that produce cyanosis can have
decreased pulmonary blood flow (PBF) or variable PBF.
Defects that result in decreased PBF are characterized by
right heart atresia or right ventricular outflow obstruction
(severe pulmonary stenosis, pulmonary atresia, and tetralogy of Fallot). These defects are manifested by cyanosis
that is often severe following closure of the ductus
arteriosus, is intensified by crying, and may be episodic.
It is not relieved by the administration of oxygen, even
at high concentrations. Tachypnea not accompanied by
dyspnea, retractions, grunting. or nasal flaring (which are
also characteristic of pulmonary disease or edema) is
indicative of a cyanotic congenital heart defect with
decreased PBF.
Card.iac defects with left-to-right shunts and increased
PBF mayor may not develop cyanosis. Pulmonary
vascular resistance (PVR) determines the presence of
cyanosis in this population. If PVR is elevated, there can
be right-to-left or bidirectional shunting. This generally
occurs in the neonate. Once PVR falls to normal levels,
cyanosis will not be evident unless the infant develops a
concurrent respiratory illness. Mixing lesions, such as
transposition of the great arteries, develop severe cyanosis
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once the ductus arteriosus closes. Infants and children
with pulmonary venous obstruction with associated pulmonary hypertension will be cyanotic until obstruction is
relieved.
With recent surgical advances, many infants' defects are
repaired early, so long-standing cyanotic heart disease
is becoming less of an issue. However, a large number
of adolescents and young adults who received palliative
treatment in infancy never underwent surgical correction.
Eisenmenger's syndrome develops in the presence of longstanding increased PBF (left-to-right shunt). At some point,
depending on the size of the shunt and characteristics of the
patient, pulmonary vascular disease develops secondary to
pulmonary pressure and volume load. When pulmonary artery pressure exceeds systemic pressure, then shunt reversal
(right to left) and chronic cyanosis result. If PVR is not
reactive to pulmonary vasodilators (oxygen, nitric oxide),
then the patient is considered inoperable for repair of the
primary cardiac defect, and referral for heart-lung transplant
may be considered.
A number of other clinical clues help to differentiate
cardiac and pulmonary disease. Chest radiographs, although
not always conclusive, are often helpful in detecting
pulmonary disease in infants. Arterial blood gas analysis
may reveal helpful differential findings. In lung disease, the
Pac02 may be elevated, whereas it is normal or even
decreased because of tachypnea in patients with cardiac
disease. Acid-base balance is initially maintained, but
inadequate tissue perfusion, which may be the consequence
of ductal closure, results in lactic acidosis.
Pathogenesis of hypoxemia and cyanosis with respect to
specific cardiac lesions are discussed in the section on
congenital heart disease. Acute hypoxemia associated with
respiratory disease is discussed in Chapter 19.
Acute Hypoxia. Acute hypoxic episodes have the
potential to occur in critically ill infants and children for
various reasons, most of them pulmonary in nature. Acute
hypoxia produces pulmonary hypertension, which is usually
transient and reversible in healthy individuals. However, in
patients with preexisting heart disease, pulmonary hypertension (particularly in the postoperative cardiac surgery
patient) is not well tolerated. In these patients, hypoxia can
result in acute pulmonary hypertensive crisis. This serious
problem is characterized by an acute rise in pulmonary
artery pressure and central venous pressure (CVP) with a
subsequent fall in left atrial pressure (LAP), cardiac output,
and systemic oxygen saturation. Without timely intervention, metabolic and respiratory acidosis ensues, further
exacerbating pulmonary hypertension. Interrupting the vicious cycle of right ventricular dysfunction, inadequate
PBF, severe hypoxemia, and low cardiac output can be
extremely difficull. These crises may be fatal despite
aggressive attempts to reverse the condition. Interventions
include analgesia or sedation, hyperventilation with 100%
oxygen, maintenance of normothermia, and skeletal muscle
relaxation.
Chronic Hypoxia. Chronic cyanosis and hypoxemia
have deleterious effects on many body systems and have

been recognized for decades. These effects include changes
in the following tissues and organs:

I. Blood: Chronic hypoxia stimulates overproduction of
red blood cells in the bone marrow, resulting in
polycythemia. When polycythemia is severe (hematocrit of 70% to 75%), blood viscosity increases
dramatically. Despite elevated red cell counts, red cell
indices are frequently abnormal, with iron deficiency
anemia requiring iron replacement therapy. In the face
of hypoxemia, the body attempts to increase oxygen
delivery by increasing cardiac output. Therefore these
patients can have a "relative" anemia if hemoglobin
concentration is "normal" (e.g., following blood loss
or trauma). In this scenario, these patients will act like
they are anemic (hyperdynamic, with signs of increased cardiac output). Keeping hemoglobin level
between 16 to 18 gldl is beneficial in this population.
Thrombocytopenia, impaired platelet aggregation,
and reduction in clotting factors are additional complications of polycythemia. Bleeding disorders can
result, primarily in older children.
2. Central nervous system: As a result of polycythemia
and hyperviscosity, acute or transient cerebral insults
may occur from cerebral infarcts. Strokes can also
occur as a result of decreased defonnability of the
microcytic red blood cells. In addition to the risk of
stroke, an increased incidence of brain abscesses is
seen among those who are older. These can occur
because venous bacteria are shunted into the systemic
circulation without undergoing the nOlmal filtering
process afforded by the pulmonary macrophages.
3. Heart: Hypoxia evokes compensatory cardiac
changes, including coronary vasodilation and the
development of myocardial collateral circulation.
Hyperviscosity increases systemic and pulmonary
afterload and decreases coronary artery perfusion.
Consequently, myocardial function is depressed, leaving older cyanotic children with limited exercise
capacity.
4. Lungs: Increased viscosity contributes to increased
PVR. Increased PVR increases right-to-left shunting,
exacerbating cyanosis and hypoxia.
Treatment of Polycythemia. Generally, patients do
not exhibit symptoms until hematocrit reaches 70%. Clinically, manifestations include headache, joint and chest pain,
anorexia, and visual disturbances. Historically, these patients would receive a phlebotomy before the development
of symptoms. However, clinical effects are short lived
because hematocrit again increases as a normal physiologic
response to hypoxemia. Currently the recommendation is to
phlebotomize symptomatic patients only. This procedure is
performed as a partial exchange transfusion, removing small
a1iquots of blood and replacing them with normal saline or
albumin, down to a hematocrit of 60% to 65%. Patients
experience immediate symptomatic relief, but unfortunately,
some become quite dependent on this intervention and
frequently request it.

Chapter 18
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CONGENITAL HEART DISEASE
The incidence of congenital heart disease is approximately
1% of all live births. Worldwide, 1.5 million children are
born with a congenital heart defect yearly, and in the United
States, approximately 40,000 newborns are affected each
year. Of these children, 5% to 8% have associated chromosomal anomalies or syndromes. At least one third of the
infants born in the United States with a congenital heart
defect will be critically ill or require surgical therapy during
their first year of life. I 5 Despite major advances in the
management of these children, congenital heart disease
accounts for a large proportion of infant mortality and is a
major reason for admission to the PICU.
The etiology of congenital heart disease is a rapidly
growing field of interest and research. Known risk factors
include environmental exposures, drug exposures, maternal
diabetes, maternal reproductive history, and a family history.] 6 Despite these risk factors, the exact cause of congenital heart disease is poorly understood. Cardiac formation
begins on day 18 of gestation when the cardiac mesoderm
begins to form and ends on day 45 of gestation when the
ventricular septum has closed. 17 Each cardiac malformation
can be determined to have occurred during a specific time
during gestation. Like many congenital defects, cardiac malformation has often occurred before pregnancy is detected.
Although formation is complete early in gestation, the heart
continues to mature until well after birth.
In the past, there has been a reluctance to do primary
surgical repairs on neonates and young infants because of
the potential increased risk of cardiac surgery in these
patients. As a result, palliative and staged procedures had
been preferred. Refinements in surgical techniques, cardiopulmonary bypass, myocardial preservation, and postoperative management has led to the recent trend toward primary
repairs of congenital heart defects in neonates and young
infants. This current philosophy has resulted in a change in
the patient population and the patient care management in
PICUs today. Although the majority of patients are neonates
and young infants, many older children, adolescents, and
adults, who had previously received palliative treatment, are
reentering PICUs for additional surgery or for treatment of
sequelae.
Several classification systems exist to categorize congenital heart defects. One system that is clinically useful is
based on the presence or absence of cyanosis and an estimate of the volume of PBF. These characteristics are determined by physical examination and radiographic examinations and are diagnosed by echocardiography (Box 18-2).

Acyanotic Heart Defects With Increased PBF
Congenital heart defects that produce a left-to-right shunt at
varying points in the circulation lead to an increase in PBF.
The most common lesions associated with increased PBF
include patent ductus arteriosus, atrial septal defect, ventricular septal defect, and AV septal defect. (Table 18-3
summarizes the findings on cardiac examination, ECG, and
chest radiograph of children with these defects.)

Box 18·2

~ Classification of Congenital Cardiac Defects
Acyanotic Defects With Increased PBF
Patent ductus arteriosus
Atrial septal defect
Ventricular septal defect
Atrioventricular septal defect
Acyanotic Defects That Obstruct Flow
Coarctation of the aorta
Aortic stenosis
Pulmonary stenosis

Cyanotic Defects With Decreased PBF
Tricuspid atresia
Tetralogy of Fallot
Pulmonary atresia with intact ventricular seplum

Cyanotic Defects With Increased PBF
Total anomalous pUlmonary venous connection
Truncus arteriosus
Hypoplastic left heart syndrome
Cyanotic Defects With Variable PBF
Transposition of the great arteries
Double-outlet right veotricle
Double-inlet left ventricle
Single ventricle
PBF,

Pulmonary blood flow.

Patent Ductus Arteriosus. The ductus arteriosus is
formed during the fifth to seventh week of gestation. It is a
vascular communication between the junction of the main
and left pulmonary arteries and the lesser curvature of the
descending aorta just distal to the left subclavian artery. The
ductus is approximately I cm in length, slightly less than I
cm in diameter, and has a sphincterlike muscle in its wall.
The ductus begins to close within 10 to 15 hours of birth,
and closure is usually completed by 3 weeks of age.
Although a ductus can close spontaneously at any time other
than the newborn period, this is very unlikely to occur after
the age of I year because of the absence of normal
physiologic mediators that contribute to closure.
At birth, with the removal of the placenta (major source
of prostaglandin in utero) and with the concurrent onset of
respiration, PVR decreases with a subsequent rise in Paoz.
The combination of an increased Pao z and a fall in
prostaglandins results in ductal constriction. Eventually
anatomic closure occurs, and the ductus becomes fibrous,
forming the ligamentum arteriosus. If these processes do not
occur or are interrupted, a patent ductus arteriosus (PDA) is
the result (Fig. 18-4). Prematurity, hypoxia, and scarring of
the ductus from rubella during fetal life are all factors that
can prevent ductal closure.
The size of the shunt through the PDA is determined by
the relative pressure differences between the systemic and
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Cardiac Examination

Electrocardiogram

Chest Radiograph

"Machinery" murmur heard throughout systole and diastole; best heard
at left upper sternal border and
under left clavicle; palpable cardiac
thrill (with large PDA) at left
sternal border

May be nom1al or demonstrate left
ventricular hypertrophy

Increased pulmonary vascularity,
prominent pulmonary arteries,
enlargement of the left ventricle
and aorta

Normal S,; Soft systolic ejection
murmur best heard at second left
rcs; fixed and widely split S2

May be normal, but right axis deviation, right ventricular hypertrophy,
RSR' in V,

Same as above
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Increased pulmonary vasculature,
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ventricle, and pulmonary artery;
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Normal heart size and PBF

Left ventricular dominance and left
ventricular hypertrophy

Cardiomegaly, enlarged left atrium,
enlarged left ventricle, prominent
pulmonary vascnlar markings

Right ventricular hypertrophy

Normal or enlarged right atrium, right
ventricle, and pulmonary artery;
small distal pulmonary vessels;
variability in size of left atrium and
left ventricle

Same as for ASD

Same as for ostium secundum ASD

Same as for ASD

Systolic murmur best heard apically;
radiates to the axilla

Left ventricular hypertrophy

Enlargement of left ventricle and left
atrium

Combination of ASD, VSD, and
atrioventricular valve insufficiency
murmurs; no murmur may be
present; with pulmonary artery
hypertension, P2 is loud and
widely split

Left axis deviation and biventricular
hypertrophy

Cardiomegaly and increased pulmonary vascular markings

Loud, harsh systolic murmur localized
to left sternal border; associated
cardiac thrill
Rumbling murmur heard best at lower
left sternal border; radiates across
the left chest sometimes as far as
the midaxillary line; pulmonary
component of S2 loud and
widely split
Quieter heart murmur; loud single P z

;~D, Atrial septal defect; AVSD, atrioventricular septal defect; ICS, intercostal space; P2, pulmonary component of second heart sound; PBp, pulmonary blood now; PDA, patent ductus arteriosus; Sf' firs,
iJ\eart sound; S2' second heart sound; VSD, ventricular septal defect.
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PATENT DUCTUS

Fig. 18-4 Patent ductus arteriosus. Ao, Aorta; PDA. patent ductus
arteriosus; PT, pulmonary trunk. (From Pet/off JK: The clinical
recognition of congenital heart disease, ed 4, Philadelphia, 1994.
WB Saunders, p 510.)

pulmonary vascular beds and the size of the PDA. After
birth, with the normal fall in PVR and rise in systemic
vascular resistance, the shunt is left to right. If the PDA is
large or moderate in size, this will lead to pulmonary
overcirculation and left heart enlargement. However, if there
is some degree of lung disease or elevation of PVR, the
shunt can be bidirectional or right to left.
Clinical Presentation and Course. When occurring
in isolation, clinical symptoms vary with the size of the
PDA and the degree of shunt. Small PDAs may not be
appreciated on auscultation and can be hemodynamically
insignificant. Large PDAs can contribute to CHF once PVR
has fallen, These infants and children can have signs and
symptoms of CHF, including tachypnea, poor feeding, and
diaphoresis.
On auscultation the classic finding is one of a continuous
murmur audible in the left upper chest. However, if PVR is
elevated (with subsequent decreased shunt) or the PDA is
small, the murmur may be soft or inaudible. Generally, the
pulses are bounding, and in the older child the pulse
pressure will be wide (low diastolic pressure). Echocardiogram is adequate to make the diagnosis and in determining
the size and configuration of the PDA for possible coil
occlusion.
Management. Asymptomatic children with hemodynamically insignificant PDAs require no medical treatment
before elective closure between 2 to 5 years of age.
Endocarditis prophylaxis is necessary for dental work or
contaminated surgical procedures. 18 Controversy exists
regarding whether small "silent" PDAs should be closed
because the risks of intervention may exceed the lifetime
risk of endocarditis.
The premature infant or any child in CHF requires
anticongestive therapy with fluid restriction, diuretics, and
digoxin. If, however, CHF cannot be controlled by these
measures, then closure is recommended. Indomethacin, a
prostaglandin inhibitor, is advocated in the preterm population in an attempt to close the PDA without surgery.
Indomethacin is usually given at a dose of 0.2 mg/kg orally
or intravenously as a single dose and, if necessary, repeated
after 8 and 16 hours. Because indomethacin is an acetylsalicylic acid, it cannot be given to the infant with poor renal
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function, necrotizing enterocolitis, bleeding dyscrasias,
hyperbilirubinemia, internal bleeding, and shock or myocardial ischemia. When this drug is administered, close
assessment for signs and symptoms of abnormal bleeding is
crucial. Larger infants and older children may undergo coil
occlusion or surgical division of the PDA.
Coil Occlusion. PDAs can be coil occluded in the
catheterization laboratory if the PDA is of the right size and
configuration. Small to moderate, conically shaped PDAs
are most amenable to this intervention; however, a snareassisted technique has been used successfully to occlude
large PDAs. 19.20 The usual technique for coil occlusion
involves a retrograde approach via the femoral artery to the
PDA. One or more coil can then be deployed until a shunt
is no longer seen on angiography. Complications include
embolization of the coil into the pulmonary artery or aorta,
improper placement, or residual shunt 21 Benefits include
short hospital stay and no surgical incisions. In many
institutions, catheter occlusion is the treatment of choice for
PDA (with the exception of the preterm neonate).
Surgical Correction. Surgical repair of a large PDA is
performed off cardiopulmonary bypass and is recommended
for those patients with a large, unusually shaped, or short
PDA. Some centers will not coil occlude PDAs in small
patients because of the risk of embolization and pulmonary
artery occlusion with the device, so surgery is recommended. The defect may be ligated, divided, or occluded
with a hemoclip. The surgery is performed through a
posterolateral incision in the fourth left intercostal space
(ICS). In the neonate a hemoclip is used. In the older infant
or child, the ductus is usually ligated with heavy suture to
prevent recanalization or hemorrhage, which may occur
with incomplete ligation, or the ductus can be divided
between clamps and the severed ends closed by sutures.
Postoperative complications are rare except in the premature
infant, for whom other factors, such as respiratory distress,
complicate recovery. The incidence of laryngeal nerve palsy
of the vocal cords is about 4%, with smaller neonates at the
greatest risk. 22 Recently video-assisted thorascopic surgery
(VATS) has been successfully applied for closure of a PDA.
These patients are usually extubated in the operating
room and generally do not go to the PICO. Postoperative
issues include pain control and wound care. Assessment of
peripheral pulses, heart sounds, pulse oximetry, and breath
sounds is important. Rarely, ligation of nonductal vascular
structures (usually the left pulmonary artery) has occurred.
Atrial Septal Defect. An atrial septal defect (ASD)
exists when a nonphysiologic communication between the
left and right atrium persists beyond the perinatal period.
The atrial septum is formed between the fourth to sixth week
of gestation. The septum is composed of septum primum
and septum secundum. An opening, called the foramen
ovale, persists in the atrial septum throughout intrauterine
existence. This opening permits blood to bypass the lungs.
After birth, with an increase in left atrial pressure, the
foramen ovale closes. It should be noted that up to 30% of
normal adolescents and adults have a probe-patent, valvecompetent foramen ovale that is not considered an ASD and
is capable of producing an atrial shunt. 23 ASDs develop
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Fig. 18-5 Three locations of atrial septal defect (ASD). A, Sinus
venosus ASD; B, ostium secundum ASD; e, ostium primum ASD.
IVe, Inferior vena cava; LA, left atrium; LV, left ventricle;
MV, mitral valve; RA, right atrium; RV, right ventricle; SVC, superior vena cava; TV, tricuspid valve. (From Smith JB: Pediatric
critical care, Albany, NY, 1985, Delmar.)

from the defective development of the septum secundum or
the septum primum.
ASDs are classified according to their location in the
atrial septum. The most common site is at the center of the
atrial septum at the level of the foramen ovale; this is called
an ostium secundum ASD. If the defect occurs high in the
atrial septum, it is called a sinus venosus ASD. This defect,
located near the junction of the superior vena cava and the
right atrium, can also be associated with partial anomalous
pulmonary venous connection. When the defect occurs low
in the septum, it is identified as an ostium primurn ASD (Fig.
18-5). Primum ASDs are often associated with AV valvar
abnormalities or AV septal defects. A rare defect, the
coronary sinus type (unroofed coronary sinus), is located at
the roof of the coronary sinus.
The hemodynamic significance of ASDs depends on the
size of the defect, the location, associated cardiac anomalies,
and right heart compliance. During the postnatal transition
period, PVR is generally elevated, and right heart compliance is decreased; therefore shunting may be minimal at first
(even with large defects). In older infants and children, the
right heart is more compliant than the left; therefore the
atrial shunt is left to right. Left-to-right atrial shunt imposes
a volume load on the right heart, resulting in right heart
enlargement.
Clinical Presentation and Course. Children with
small shunts will be asymptomatic, and it is not unusual for
this defect to be missed until school age or adolescence.
Those with large shunts will have a systolic murmur and a
fixed, widely split second heart sound. With secundum
ASDs, clinically significant CHF and growth failure are
unusual, although this can occur with primum defects.
Echocardiogram is sufficient to make the diagnosis and to
determine the location and size of the defect, and cardiac
catheterization is almost never needed.

Management. Isolated secundum ASDs do not usually require medical management before elective surgical closure. Children with an ostium primum ASD
and associated AV valve abnormalities that present with
CHF are treated with anticongestive therapy. Small and
some moderately sized ASDs will close spontaneously
during the first few years of life. Closure of small,
hemodynamically insignificant (no right heart enlargement)
ASDs remains controversial because the risks of cardiopulmonary bypass may outweigh the benefits. Endocarditis
prophylaxis is not recommended for secundum ASDs. It is
generally agreed that moderate to large defects should be
closed in childhood to prevent the future development of
pulmonary vascular disease with subsequent pulmonary
hypertension.
Device Closure. For some centrally located secundum
defects that are not excessive in size (less than 22 mm),
closure with an occluding device can be done in the cardiac
catheterization laboratory.21 A number of devices are
currently under Food and Drug Administration (FDA)
investigation. Risks include embolization of the device,
thrombus, malposition, and residual shunt. Long-term risks
and outcomes have yet to be defined.
Surgical Correction. Repair is traditionally recommended between 3 and 5 years of age 24 Surgical correction
is performed by means of a median sternotomy incision.
Today many surgeons use a ministernotomy technique. The
child is placed on cardiopulmonary bypass, and either suture
or a patch of pericardium or synthetic material is used to
close the ASD. With sinus venosus defects the patch is
placed so as to close the ASD and to direct any anomalous
pulmonary venous drainage into the left atrium. Because of
the proximity of the sinus node to the sinus venosus baffle,
damage to the sinoatrial (SA) node can occur. Repair of
ostium primum defects can result in damage to the AV node
or bundle of His.
Intravenous vasoactive agents are rarely needed following surgery, and most patients can be extubated in the
operating room or shortly thereafter. Postoperative concerns
include pain control, bleeding, and wound care. Complications include heart block, residual shunt, AV valve regurgitation (particularly following primum repairs), and atrial
arrhythmias. The potential development of atrial arrhythmias remains a complication for a lifetime?5
Pericardial effusions are quite common following ASD
repair and may not manifest until after the child is
discharged from the hospital. A friction rub, increased heart
size on chest radiograph, and echocardiographic evidence of
pericardial fluid are diagnostic. Most effusions respond to
ibuprofen or steroids; rarely is pericardiocentesis indicated.
Ventricular Septal Defect. A ventricular septal defect (VSD) is a communication between the ventricles. The
ventricular septum is established in fetal life during the
fourth to eighth week of gestation. The ventricular septum is
formed from muscular and membranous tissues that fuse
with the endocardial cushions and bulbus cordis. If development of these tissues is interrupted in fetal life, a VSD
results. The size of a VSD varies from that of a pinpoint to
the absence of the entire septum. Types of VSDs include
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perimembranous, subpulmonary, muscular, and malaligned
canal type.
Generally, a VSD shunt is left to right; however, a
number of variables determine the direction and degree of
shunting. These include the size of the defects and the
relative pressure differences between the right and left
ventricle. Small VSDs can be hemodynamically insignificant with very little shunt; many of these close spontaneously during the first few years of life.
At birth, when PVR is elevated, there may be no or very
little shunt. However, during normal postnatal transition, as
PVR and right heart pressures fall below systemic pressures,
a left-to-right shunt will develop. Because this occurs over
time, many VSDs are not detected until 4 to 6 weeks of age.
Exceptions to this are very large VSDs that can produce
CHF early or lung disease that can contribute to prolonged
elevation of PVR, therefore protecting the pulmonary
vascular bed from overcirculation.
Once PVR normalizes, a left-to-right shunt with pulmonary overcirculation develops. The size of the shunt directly
influences the child's initial clinical presentation and the
effect of excessive blood flow on the pulmonary vasculature. Increased PBF will impose a volume load on the
left heart, with subsequent left heart enlargement. Over
time, pulmonary overcirculation contributes to progressive
structural and functional abnormalities in the pulmonary
vascular bed, with the subsequent development of pulmonary hypertension. 26
If the defect is not closed in a timely manner, then
irreversible pulmonary vascular disease can occur with fixed
(does not respond to pulmonary vasodilators) pulmonary
hypertension. In the presence of suprasystemic pulmonary
artery pressure, the ventricular shunt is reversed (right to
left) and the patient becomes chronically cyanotic. Fixed
pulmonary hypertension in the presence of left-to-right
shunt lesions is known as Eisenmenger's complex. These
patients are no longer candidates for primary cardiac repair
and require heart/lung transplantation. Fig. 18-6 illustrates
possible hemodynamic variations of VSD.
Clinical Presentation and Course. Children with
small VSDs will be asymptomatic and generally do not
develop CHF. Moderate to large VSDs will result in CHF in
the absence of pulmonary hypertension. Infants will display
tachypnea, poor feeding, and poor weight gain. Echocardiogram is sufficient to determine the size, location, and
hemodynamic significance of the VSD; cardiac catheterization is not indicated unless pulmonary vascular disease is
a concern.
Management. Spontaneous closure of small perimembranous or muscular VSDs occurs in up to 50% of
patients. Although controversial, many clinicians do not
recommend closing small VSDs that do not result in left
heart enlargement or cardiomegaly because the risks of open
heart surgery may outweigh the benefits of closure. However, data have shown that small VSDs are not necessarily
benign defects during adulthood because of the risk of
endocarditis, arrhythmias, and progressive aortic regurgitation 27 Endocarditis prophylaxis is recommended for all
patients with a VSD, regardless of the size.
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MODERATE VSO
PVR LOW BUT VARIABLE

D
EISENMENGER'S COMPLEX

A to D, Illustrations of small, moderately restrictive,
and nonrestrictive (large) perimembranous ventricular septal defect (VSD). PVR, Pulmonary vascular resistance; Ao, Aorta;
LA, left atrium; LV, left ventricle; PT, pulmonary trunk; RA, right
atrium; RV, right ventricle. (From Perloff J K: The clinical
recognition of congenital heart disease. ed 4, Philadelphia, 1994,
WB Saunders, p 402.)
Fig, 18·6

Children in CHF require anticongestive therapy consisting of diuretics, digoxin, and afterload reduction (ACE
inhibitors). Many of these infants also require nutritional
supplementation to increase the caloric density of their
formula or tube feedings. If the infant does not gain weight
appropriately despite medical management, then surgical
closure or pulmonary artery band is recommended.
Transcatheter Closure. Various umbrella devices are
currently under investigation for nonoperative, transcatheter
closure of VSDs. These devices are currently under FDA
investigation and are generally used in apical muscular
VSDs and in children who are considered poor surgical
candidates?1 Complications include embolization of the
umbrella arms and residual shunt.
Surgical Management. Pulmonary artery banding is
used in some patients who are deemed too small for
definitive correction, have multiple VSDs, or have medical
disorders that preclude definitive surgery.28 The band is then
removed in the operating room just before definitive
correction. Corrective repair of VSD is achieved via a
median sternotomy incision. Cardiopulmonary bypass and
deep hypothermia are required. Sutures or a patch are used
to close the defect. Most defects are closed through a
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transatrial approach; rarely is a ventriculotomy required.
Because of the proximity of the AV node and His bundle to
many septal defects, care is taken to avoid damage to
the conduction system because this can result in acquired
heart block.
Postoperative complications may include residual VSD,
heart block, low cardiac output, and junctional ectopic
tachycardia. In patients with elevated pulmonary pressures
preoperatively, right heart failure can occur. Aortic insufficiency can develop after repair of subarterial defects and is
identified by the presence of a widened pulse pressure and
a diastolic murmur,z9
In the absence of pulmonary vascular disease, most
patients can be extubated and weaned from oxygen quickly.
Those with pulmonary hypertension may require longer
ventilatory and oxygen therapy. If there is preoperative
pulmonary hypertension, then a pulmonary artery (PA)
catheter is usually inserted intraoperatively before closure of
the chest. Maneuvers to decrease PVR (oxygen, nitric oxide,
alkalosis) are implemented until PA pressures decrease or
normalize.
If concern remains about a residual VSD and a PA and
right atrial (RA) line are in place, then simultaneous PA and
RA oxygen saturations can be obtained to help evaluate for
a residual septal defect. A step up (increase) in the PA
saturation from the value obtained from the RA, especially
if the PA saturation is greater than 80%, strongly suggests
the presence of a residual VSD. In this scenario a
high-frequency systolic murmur will also be appreciated.
The exception to this would be the presence of equal
ventricular pressures without significant left-to-right shunt;
therefore a step up or murmur may not be appreciated.
Atrioventricular Septal Defect. An atrioventricular
septal defect (AVSD) generally involves a primum ASD, AV
valve abnormalities, and a VSD. However, this defect is
quite variable and is classified as balanced, unbalanced,
incomplete, and complete. When the ventricles are of equal
size, the defect is balanced. An unbalanced defect is when
one ventricle is larger than the other (i.e., right ventricle
[RV] dominant). An incomplete defect primarily consists of
a primum ASD and two AV valve orifices with a cleft mitral
valve. A complete defect consists of a primum ASD, VSD,
and a common AV valve with five leaflets. This defect is
prevalent in children with trisomy 21 (Down syndrome).
During fetal life, the endocardial cushions are responsible for the development of the mitral and tricuspid valves,
the upper ventricular septum, and the lower atrial septum.
The endocardial cushions also playa role in the placement
of the AV conduction system. These developments occur
between the fourth and eighth week of gestation. Inadequate
development of these fetal structures may result in a variant
of AVSD. The sections that follow contrast the incomplete
and the complete types of AVSD.
Incomplete AVSD. The infant or child with an
incomplete AVSD presents with an ostium primum ASD, as
well as variable degrees of AV valve abnormalities. A cleft
mitral valve (Fig. 18-7) is the classic associated anomaly.
Hemodynamic alterations are determined by the size of the
septal defect, degree of mitral valve incompetence, and
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Fig. 1S-7

Incomplete atrioventricular septal defect (AVSD).
B, cleft mitral valve.
IVe, Inferior vena cava; LA, left atrium; LV, left ventricle; RA. right
atrium; RV, right ventricle; SVC, superior vena cava; TV, tricuspid
valve. (From Smith IB: Pediatric critical care. Albany, NY, 1985,
Delmar.)

A. Ostium primum atrial septal defect;

Fig.1S-S Complete atrioventricular septal defect (AVSD). A, Ostium primum atrial septal defect; B, Common atrioventricular
valve; C, Ventricular septal defect. LA, left atrium; LV, left
ventricle; PV, pulmonary vein; RA. right atrium; RV, right ventricle.
(From Smith JB: Pediatric critical care, Albany, NY, 1985,
Delmar.)

PVR. Once PVR falls to normal, the shunt is left to right. If
the mitral valve is competent, despite an anatomic abnormality, hemodynamics will be the same as an ostium
primum ASD. A cleft mitral valve that is insufficient will
produce a left ventricular to right atrial shunt (through the
ASD) increasing the volume load on the right heart. If the
ASD is small, mitral insufficiency will increase LAP and
volume.
Complete AVSD, In the complete form of AVSD, an
ostium primum ASD, a VSD in the upper ventricular
septum, and a common AV valve are present (Fig. 18-8),
These defects generally allow significant left-to-right shunt
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(in the absence of pulmonary vascular disease) with
pulmonary overcirculation. The right atrium can receive
blood from two intracardiac sources. During systole, a left
ventricle to right atrial shunt can occur via the insufficient
mitral valve and the ASD. Blood can also enter the right
atrium from the right ventricle via the incompetent tricuspid
valve. This increase in right heart volume and pulmonary
overcirculation can contribute to the development of pulmonary hypertension if the defect is not closed in a timely
manner. Factors that play an important role in determining the degree of shunting are pulmonary resistance,
systemic resistance, ventricular pressures, and myocardial
compliance.
Clinical Presentation and Course. Infants and children with incomplete AVSD may be asymptomatic, or they
may have the same clinical symptoms as those with a
primum ASD. If mitral regurgitation is significant, then
signs and symptoms of CHF may develop. Those infants
with complete AVSD generally develop CHF early, unless
they have pulmonary hypertension.
Echocardiogram is sufficient to diagnose the defect, size
of the septal defects, and hemodynamic significance (heart
size and function). Cardiac catheterization is indicated if
pulmonary vascular disease is a concern or if questions
remain regarding anatomy and intracardiac pressures.
Management
Incomplete AVSD. The infant or child with an incomplete AVSD is treated in the same way as children with a
primum ASD. Endocarditis prophylaxis is indicated because
of mitral valve abnormalities. If CHF occurs secondary to
significant mitral insufficiency, then anticongestive therapy
is indicated with digoxin and diuretics.
Complete AVSD. An infant with complete AVSD generally requires anticongesti ve therapy once PVR falls and
the left-to-right shunt becomes significant (commonly by 2
months of age)30 These children are also at high risk for the
development of respiratory infections (particularly respiratory syncytial virus) and pneumonia, which may preclude
surgical repair at the time of active respiratory illness.
Therefore respiratory infections should be treated aggressively. Auscultatory or echocardiographic evidence of
developing pulmonary hypertension may also be an indication for surgical intervention.
Surgical Management. Surgery is recommended for
those who fail medical management or who fail to thrive.
Surgery is generally recommended before the child reaches
I year of age because the development of severe pulmonary
vascular obstructive disease is likely thereafter. Early repair
is indicated in patients with Down syndrome because of the
proclivity to develop early pulmonary vascular disease in
this population. Complete intracardiac repair of complete
AVSD is achieved between 6 and 12 months of age when
heart failure is present and generally not later than 2 years
of age in those without severe symptoms.
Corrective surgery is performed via a midline sternotomy
incision with deep hypothermia and cardiopulmonary bypass. An incomplete AVSD is repaired with autologous
(pericardium) or synthetic patch closure of the ASD and by
suturing the cleft in the mitral valve 30 Relative to synthetic
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patches, autologous patches have been associated with a
decreased incidence of hemolysis. Corrective repair of a
complete AVSD involves either a single- or two-patch repair
of the ASD and VSD and repair of the mitral or tricuspid
valves or both. The AV valves are reconstructed usi ng
available tissue from the common AV valve leaflets with the
objective of achieving valve competence. Mitral valve
replacement may be necessary on rare occasions. Close care
is taken during suturing to prevent heart block. Postoperative complications may include heart block, arrhythmias,
residual shunt, and AV valve insufficiency. A small percentage of these patients will require mitral valve replacement in
the future for persistent mitral regurgitation 28
Many of these patients will have transthoracic atrial
(right and left) and PA catheters in place for pressure
monitoring. The timely diagnosis of the cause of left atrial
(LA) and PA pressure elevation will dictate therapy.
Treatment of pulmonary hypertension includes oxygen,
sedation, alkalosis, normothermia, and possibly nitric oxide
(see Chapter 7). Elevation of LA pressure can indicate left
heart failure. Aggressive volume resuscitation should be
avoided because it can initiate a vicious cycle of annular
dilation, increased left AV valve regurgitation, low cardiac
output, and hypotension. Inotropes and afterload reduction
are the initial intervention. Mechanical support (intraaortic
balloon pump [IABPJ, ventricular assist device [VADj,
extracorporeal membrane oxygenation [ECMO]) or reoperation may be necessary. 30

Acyanotic Defects That Obstruct Flow
Coarctation of the aorta and aortic stenosis are two common
cardiac lesions that result in increased left ventricular work.
When occurring in isolation because no abnormal intracardiac connections are present, shunting of blood does not
occur, PBF is normal, and cyanosis is absent.
Pulmonary stenosis, unless very severe, is a third
common defect that does not produce cyanosis. If severe,
pulmonary stenosis will result in increased right ventricular
work and hypertrophy. (Table 18-4 summarizes the findings
on cardiac examination, ECG, and chest radiograph of
children with these defects.)
Isolated mitral stenosis, an uncommon defect, obstruct~
pulmonary venous return and does not cause an alteration
in oxygen saturation. Mitral atresia or marked hypoplasia
is representative of the spectrum of infants with hypoplastic left heart syndrome. Isolated mitral stenosis is not
discussed here.
Coarctation of the Aorta. Coarctation of the aorta is
a narrowing of the aorta distal to the left subclavian artery
at the insertion of the ductus arteriosus Uuxtaductal). Like
other congenital heart defects, aortic coarctation exists along
a spectrum; however, it is usually described as neonatal or
adult coarctation and typically presents in neonates, infants,
or older children. This lesion possibly exists as a result of
decreased antegrade blood flow across the isthmus during
fetal development. In addition, ectopic ductal tissue that
exists in the aorta at the insertion of the ductus arteriosus
may constrict at birth, resulting in aortic coarctation. 31
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TABLE 18-4 Acyanotic Congenital Heart Defects That Obstruct Flow
.1&

!Defect

Cardiac Examination

Electrocardiogram

Chest Radiograph

Systolic murmur left upper chest and midscapula; decreased or absent femoral pulses;
arm/leg BP gradient; upper extremity
hypertension

Varying degrees of left ventricular hypertrophy

Normal or cardiomegaly; enlarged left atrium
and left ventricle; dilated ascending aorta;
rib notching in children ovcr 8 years of age
with extensive collateral circulation

Ejection click best heard at the fourth ICS
to the left of the sternum; rough, harsh
mumJUr best heard at base of the heart
to the right of the sternal border
Palpable thrill best felt at the suprasternal
notch and at the second right ICS;
diminished S2
Similar to valvular AS, with absence of
ejection click
Normal S ,; absent ejection click; ejection
systolic murmur; palpable thrill may
be present

Left ventricular hypertrophy, or may be
normal

;IIJ1.'

',Ii~oarctation of the aorta

ii'T: :.
'j'

,J.:;l:

~jAortic

'iii;'"

stenosis

~ .,'.• .V":• ',alVUlar (mild to moderate)

1
I~,prn'"~I"
~:~,

~~':

'Ii>
1i1":

ijModerate to severe

~'

,;Subvalvular
~.;

~~.

:!W

jif

May appear nonllal; possible left ventricular
enlargement and dilated ascending aorta

iiYalvular (mild to moderate)

1;

ii

'!Ill"'"

llSevere
I·
~l

I~fundibular (fibrous

ring)

Left ventricular hypertrophy; possible ST
and T wave changes, or may be normal

Same as for mild to moderate AS; pulmonary
congestion may be seen

Same as for valvular AS

Similar to valvular AS, but dilation of aorta
absent
Ascending aorta smaller than normal;
descending aorta normal in size

Same as for valvular AS

Systolic ejection click after. followed by
systolic ejection murmur best heard at
upper left sternal border and radiating
widely; possible palpable thrill at second
left ICS; right ventricular lift
MurnlUr increased in duration and intensity,
obscuring S2; no ejection click audible
Similar to valvular PS, but no ejection click

Normal or right ventricular hypertrophy

Normal or right ventricular and main pulmonary artery enlargement; normal left heart
and pulmonary vascular markings

Right ventricular and right atrial hypertrophy

Same as above. with right atrial enlargement

Same as for valvular PS

No ejection click; short systolic munnur
ending before S2' best heard at third or
fourth left ICS; palpable thrill with severe
stenosis; bulging of lower precordium; right
ventricular heave
Systolic ejection murmur heard over sites of
obstruction, radiating through pulmonary
vasculature; occasional continuous murnlUr:
normal S I and S2; no ejection click

Same as for valvular PS

Right ventricular enlargement; normal pulmonary artery, left heart, and pulmonary
vascular markings
Same as for fibrous ring infundibular PS

i i:

Me·
~<;ubvalvular

',0,. ' Aortic Slenosis;

BP,

blood pressure;

ICS,

intercostal space;

PSi

pulmonary stenosis;

OJ

~
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3'

b'
3
3
o

.....
:J

~

:::T

~!Pulmonary stenosis
"-:

'V

Normal or RVH

RVH.

right ventricular hypertrophy;

Normal or variable enlargement of right heart
chambers and main pulmonary artery

Sf'

first heart sound;

S"

second heart sound.

~
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INFANTILE

Fig. 18-9 Schematic showing difference hetween infantile and adult forms of coarctation. (From
Castenada AR, Jonas RA, Mayer JE et al: Cardiac surgery of the neonate and infant. Philadelphia, 1994,
WB Saunders.)

Associated lesions include PDA, tubular hypoplasia of
the aortic arch, bicuspid aortic valve, patent foramen ovale,
ASD, and YSD. Aortic coarctation in neonates often
presents with a PDA and varying degrees of hypoplasia of
the distal aortic arch. Lower body perfusion is often
dependent on ductal patency. Associated cardiac lesions are
common, yet major collateral arteries are typically absent in
neonates.
Older children who present with the adult type of aortic
coarctation usually have an isolated discrete coarctation at
the location of the ligamentum arteriosum. This condition is
often associated with a bicuspid aortic valve; however, other
associated cardiac defects are unusual, and the proximal
aortic arch is typically well developed. Coarctation in these
children appears as an hourglass narrowing with associated
arterial collateral vessels between the upper and lower body.
Fig. 18-9 depicts both infantile and adult coarctation.
Coarctation of the aorta may be part of a spectrum of
left-sided obstructive defects referred to as Shone's complex. This spectrum includes varying forms of mitral
stenosis, hypoplastic left ventricle, subaortic stenosis, aortic
stenosis, and coarctation of the aorta. In addition, aortic
coarctation can appear in combination with other more
severe forms of congenital heart disease, including hypoplastic left heart syndrome, Taussig-Bing anomaly, and
transposition of the great arteries with tricuspid atresia.
Neonatal Coarctation. The pathophysiology of coarctation in newborns is dependent on the degree of aortic

obstruction, the patency of the ductus arteriosus, and the
presence of associated intracardiac lesions. Constriction of
the aorta in a neonate will result in left ventricular failure
and cardiovascular collapse. Although the PDA will supply
the lower body with blood flow, sudden closure will also
result in cardiovascular collapse. Left ventricular failure will
eventually lead to elevated LAP and pulmonary edema. The
presence of a YSD will result in a left-to-right shunt and
possible delay of left ventricular dysfunction.
Adult Coarctation. Constriction of the aorta leads to
increased afterload for the left ventricle with the development of left ventricular hypertrophy. Collateral arterial
vessels from the upper body to the lower body provide
adequate perfusion distal to the coarctation.
Clinical Presentation and Course
Neonatal Coarctation. Presentation of neonatal coarctation is dependent on the pathophysiologic condition,
specifically, the amount of constriction and the timing of
ductal closure. With severe coarctation and acute ductal
closure, neonates can have acute cardiovascular collapse,
metabolic acidosis, and end-organ ischemia. This can result
in intracranial hemorrhage, renal failure, and necrotizing
enterocolitis. When the development of the coarctation is
slow and ductal closure is delayed, these patients can
present in early infancy with CHF and differential blood
pressure between their upper and lower extremities.
Adult Coarctation. Adult aortic coarctation typically
presents in older children and adolescents on routine
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physical examination. Clinical signs include systemic hypertension, arm/leg pressure gradient, and diminished pulses
in the lower extremities. If undiagnosed, these patients can
develop complications such as myocardial infarction, cerebral vascular accidents, endocarditis, aortic aneurysms
and dissection, CHF, headaches, lower body symptoms,
and epistaxis.3 2
Management
Neonatal Coarctation. Neonates who present with cardiovascular collapse are aggressively resuscitated and
treated with a continuous infusion of PGE I to maintain
ductal patency and adequate lower body perfusion. In
addition to opening the ductus arteriosus, PGE 1 may relax
the area of aortic coarctation where ductal tissue exists. If
left ventricular dysfunction is present, the administration of
inotropic agents may be necessary. Administration of
sodium bicarbonate to correct the metabolic acidosis is
important to improve cardiac performance. Endotracheal
intubation and mechanical ventilation may be necessary for
the unstable neonate. In those infants with a VSD overoxygenation and hyperventilation should be prevented to avoid
lowering PVR and subsequent pulmonary overcirculation.
The overall goal should be the prevention of end-organ
ischemia. If this exists, reversal of the process with recovery
should be accomplished before surgery.
Adult Coarctation. The older child whose coarctation is
detected on routine physical examination requires close
assessment of blood pressure. Significant hypertension may
require the use of antihypertensive agents preoperatively. If
significant hypertension is present at rest, exercise restriction may be recommended. Antibiotic prophylaxis for
bacterial endocarditis prevention is recommended preoperatively and postoperatively in children with associated
bicuspid aortic valve.
Transcatheter Dilation. Balloon angioplasty performed
in the catheterization laboratory has been shown to be
successful in dilating both nati ve and recurrent coarctation
of the aorta. In general, balloon dilation of recurrent
coarctation is thought to be safer than native coarctation due
to supporting scar tissue that can reduce the risk of aortic
rupture. 33 However, with improved technique and skill
level, this intervention has been successfully used in some
centers to treat native coarctation 34 Risks of aortic rupture
are slightly increased in neonates.
In addition, stents have been successfully placed in
the aorta to relieve mild native and recurrent coarctation.
Because of the size of the introducer, this technology is
primarily reserved for school-aged, adolescent, and adult
patients.
Surgical Management. Neonates and infants with
ductal-dependent systemic blood flow are surgically repaired on presentation following adequate resuscitation and
recovery of end-organ ischemia. Children with systemic
hypertension who are otherwise asymptomatic have traditionally undergone surgery between the age of 3 to 5 years.
The current trend, however, is to repair on presentation to
avoid the postoperative complications of residual hypertension and postcoarctectomy syndrome.

The surgical technique used for repair depends on the
type of coarctation and institutional preference. Current
techniques include the resection-and-anastomosis technique, subclavian flap aortoplasty, and the synthetic patch
aortoplasty. These techniques are performed without the use
of cardiopulmonary bypass. When associated intracardiac
lesions are involved, the coarctation may be repaired
initially, followed by a later procedure for intracardiac
repair. When patent, the ductus arteriosus is ligated.
The coarctation repair is preformed via a posterolateral
thoracotomy incision. The aorta is temporarily clamped
proximal and distal to the coarctation. The resection-andanastomosis techniques most commonly include a resection
of the ductal tissue, coarctation, and narrowed segment of
the aorta, followed by an end-to-end or end-to-side anastomosis. The end-to-side anastomosis involves bringing the
distal end of the aorta more proximal and performing the
anastomosis underneath the aortic arch. The advantage of
the resection-and-anastomosis technique is the removal of
the ductal tissue along with the coarctation. The disadvantages include the potential for tension on the suture line, a
greater degree of technical difficulty, more extensive dissection, and the presence of a circumferential scar3 )
With the subclavian-flap angioplasty technique, the
subclavian artery is ligated, and an incision is made from the
proximal subclavian artery along the area of aortic coarctation. Hypoplastic tissue is removed, and the flap of
subclavian artery is folded down and used to patch the aorta.
Advantages of this approach include use of native tissue,
avoidance of tension on the suture lines, and no circumferential scar. Disadvantages include interruption of blood flow
to the left arm with potential growth alteration, retention of
abnormal ductal tissue in the aorta, and potential for
development of an aneurysm. 31
With the patch aortoplasty technique, the area of
coarctation is incised, and a patch of pericardial tissue or a
synthetic patch is placed to widen the area of hypoplasia.
The advantages and disadvantages of this procedure are
similar to the subclavian-flap technique; however, left arm
perfusion is not interrupted with the patch aortoplasty.
Systemic hypertension is the most common postoperative problem after surgical repair for coarctation of the aorta.
Although seen in neonates and infants, this is more common
in children and adolescents who have sustained longer
periods of altered lower body perfusion. The cause of
hypertension is thought to be multifactorial, including the
presence of increased catecholamines, derangement of the
RAAS, and disrupted baroreceptor response. 32 Systemic
hypertension can lead to bleeding along the aortic suture
lines or from collateral arteries if present. A continuous
infusion of sodium nitroprusside or esmolol is often
recommended to control hypertension. The short half-life of
sodium nitroprusside provides rapid initial treatment and
allows quick adjustments in titration. The presence of
postoperative hypertension may be transient or may last
for days or months. Long-term administration of afterloading agents, such as captopril or ~-blockers, may be
indicated. Maintenance of appropriate blood pressure also
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requires control of postoperative pain and agitation. These
interventions can be crucial in avoiding postoperative
bleeding.
Postcoarctectomy syndrome may be caused by mesenteric arteritis secondary to the introduction of pulsatile blood
flow to the lower body and subsequent vessel injury or reflex
vasoconstriction after surgery32 This syndrome is rarel y
seen in neonates and infants and is more common in older
children who have severe coarctation and preoperative
systemic hypertension. Symptoms include abdominal pain,
abdominal distension, nausea, ascites, fever, and leucocytosis. It is often associated with postoperative systemic
hypertension. Treatment includes nasogastric decompression and the administration of intravenous fluids. Oral
feedings are withheld until symptoms resolve.
Spinal cord ischemia is a potential complication that is
rarely seen in neonates and infants. The cause, although not
completely understood, may be secondary to abnormal
spinal artery anatomy or inadequate collateral circulation
during the aortic clamp time. A complete neurologic
assessment, specifically, evaluation of lower body movement, is critical to assess for this complication.
Additional potential complications that require nursing
assessment in the postoperative period include injury to
thoracic structures obtained secondary to the surgical
thoracotomy. Damage to the thoracic duct leading to the
development of a chylothorax, damage to the laryngeal
nerve leading to vocal cord paralysis and stridor, or damage
to the phrenic nerve leading to diaphragm paralysis are
possible complications that must be evaluated.
Residual coarctation may develop after neonatal and
infant repair during the first year after surgery. Management
may include reoperation or balloon dilation. Four-extremity
blood pressure assessment in the early postoperative period
is important to evaluate for a residual gradient between
upper and lower body measurements.
In addition to the observation and management of
potential complications, it is important for the nurse to
question the presence of associated intracardiac lesions,
especially in neonates and infants. This may alter the
postoperative management plan or present additional complications. For example, the presence of a large VSD may
alter the postoperative mechanical ventilation plan to avoid
excessive left-to-right intracardiac shunting and pulmonary
overcirculation.
Aortic Stenosis. Aortic stenosis can be defined as a
lesion that results in obstruction of blood flow from the left
ventricle to the aorta. Aortic stenosis is categorized into
three subgroups depending on the location of the obstruction. These include valvar aortic stenosis, subvalvar aortic
stenosis, and supravalvar aortic stenosis (Fig. 18-10).
Valvar Aortic Stenosis. Valvar aortic stenosis exists
along a spectrum of disease with variable obstruction. Most
patients have an isolated bicuspid aortic valve and remain
asymptomatic until they are adults. Valvar aortic stenosis in
neonates and young infants is commonly called critical
aortic stenosis and often presents in the neonatal period with
cardiogenic shock. In this case, the valve commissures may
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Fig. 18-10 Four locations of aortic stenosis (AS). A, Supravalvular AS; B, valvular AS; C. discrete subvalvular AS; D, idiopathic
hypertrophic subaortic stenosis. Ao, Aorta; CT, chordae tendineae;
FM, fibrous membrane; HPM, hypertrophic papillary muscle;
LA, left atrium; LV. left ventricle; MV. mitral valve;
pulmonary
vein. (From Smith JB: Pediatric critical care. Albany, NY, 1985,
Delmar.)

pv.

be fused, the valve annulus may be small, and the valve
leaflets may be thick and deformed. Neonates may also have
a hypoplastic ascending aorta and left ventricle. Older
infants may have valvar stenosis and left ventricular
hypertrophy. Older children usually have a bicuspid aortic
valve with thickened valve leaflets. Associated lesions
include supravalvar aortic stenosis, mitral val ve abnormalities, and coarctation of the aorta. Aortic insufficiency and
endocardial fibroelastosis may be present as a result of the
valvar aortic stenosis.
Neonates with critical aortic stenosis will receive systemic blood flow after birth through a PDA. The left
ventricle, however, will be dilated and poorly contractile,
and coronary perfusion may depend on retrograde flow and
be compromised. Left ventricular dysfunction will lead to
elevated LAP and the development of pulmonary edema and
pulmonary hypertension. When the ductus arteriosus closes,
circulatory shock can result with the development of renal
failure, necrotizing enterocolitis, and intracranial hemorrhage. Older children with valvar aortic stenosis typically
have left ventricular hypertrophy secondary to the chronic
pressure overload.
Clinical Presentation and Course. Neonates with
critical aortic stenosis present with dyspnea and tachypnea,
irritability, pallor, narrowed pulse pressure, oliguria, and
metabolic acidosis when the ductus arteriosus closes. Older
children are often asymptomatic, presenting with a murmur.
When moderate to severe obstruction exists, they can
present with syncope, exercise intolerance, angina, and
possibly sudden death.
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Management. Neonates with cardiogenic shock are
aggressively treated with a continuous infusion of PGE 1 to
maintain ductal patency and ensure systemic blood flow.
Mechanical ventilation, inotropic support, and administration of sodium bicarbonate are often necessary to treat the
shock. When the shock state has been reversed, invasive
intervention is performed.
The management of older children depends on their
symptoms and the severity of the obstruction. The presence
of a gradient greater than 50 mmHg across the obstruction
along with symptoms of angina or ST-T segment changes in
the ECG usually warrants surgical intervention?2 Asymptomatic children with mild to moderate obstruction may be
medically managed and followed for signs of worsening
obstruction. Vigorous physical activity may be limited in
these patients to prevent the risk of sudden death. These
patients are particularly prone to bacterial endocarditis and
require prophylaxis with antibiotic therapy for invasive
procedures. Treatment for valvar aortic stenosis in neonates
and young infants includes percutaneous balloon dilation or
surgical valvotomy or both.
Transcatheter Dilation. In balloon dilation, a balloon
catheter is placed retrograde across the aortic valve, the
balloon is inflated, and the valve is dilated. This approach
has reduced the need for surgical valvotomy in some
patients. In others, it serves to palliate the infant or small
child until definitive repair with a Ross procedure. When
aortic valve regurgitation is present or the balloon dilation is
not successful, a surgical valvotomy may be indicated.
Surgical Management. With the use of cardiopulmonary bypass, an aortic incision is made, and valve commissures are incised in a way that avoids worsening aortic
insufficiency.
In older children, the goal of management is to preserve
left ventricular function; therefore the obstruction must be
removed before permanent damage occurs. When surgery is
indicated, options include surgical valvotomy, valvuloplasty, or aortic valve replacement. Aortic valve replacement options include the Ross procedure or prosthetic valve
replacement. With the Ross procedure, the aortic valve is
replaced with a pulmonary autograft, and a pulmonary
homograft is placed in the right ventricular outflow tract
to the pulmonary artery. Coronary artery reimplantation
into the neoaorta is necessary with this procedure. Criteria
for the Ross procedure may include the presence of a normal
pulmonary valve, absence of pulmonary insufficiency, and
absence of rheumatic and connective tissue disease. Although with advances in surgical skill, these criteria are
being broadened. 35 Anticoagulation is not needed after the
Ross procedure, and the new aortic valve will grow with the
patient. Valve replacement may also include the use of a
mechanical valve. In this case, anticoagulation is required,
and the valve will need replacement when the patient grows.
The Konno operation is another surgical option for aortic
stenosis. In this procedure, the aortic valve is approached
through a right ventriculotomy and an incision in the
ventricular septum. A patch is used to augment the left
ventricular outflow tract, and the valve is replaced with a
mechanical valve or a pulmonary autograft. 32

Postoperative management depends on the age of presentation, the degree of obstruction, the condition of the left
ventricle before surgery, and the specific procedure performed. Neonates are typically very ill after surgery and
suffer from left ventricular dysfunction. Older children
usually have an uneventful postoperative course, unless
significant preoperative left ventricular dysfunction exists.
Left ventricular dysfunction may result in low cardiac
output and ventricular arrhythmias in the postoperative
period, requiring inotropic support, afterloading reduction,
and antiarrhythmics.
Specific surgical procedures have potential complications. For example, complete heart block can occur after the
Konno operation. Myocardial ischemia can occur after the
Ross procedure if problems arise with the coronary artery
translocation.
Postoperative echocardiography provides information
regarding the presence of aortic insufficiency. When present,
additional afterload reduction may be necessary. Anticoagulation is necessary with mechanical valve placement. This is
initially provided with continuous infusions of heparin,
followed by the initiation of warfarin therapy later in the
postoperative course. Anticoagulation can be difficult in
neonates and infants secondary to immature liver function
and unreliable metabolism of anticoagulation agents.
Subaortic Stenosis, Subaortic stenosis is described
as an obstruction to outflow from the left ventricle to the
aorta that is beneath the aortic valve. This defect is most
commonly an isolated lesion in older children. In neonates
and infants, it can exist in combination with a VSD or
coarctation of the aorta. Additional associated defects
include double-chamber right ventricle, AV canal defects,
and the presence of aortic insufficiency.32 Types of subaortic
stenosis include membranous, fibromuscular, and hypertrophic. Membranous stenosis consists of a discrete ring of
tissue beneath the aortic valve and is usually seen in older
children. Fibromuscular obstruction involves a segment of
muscle tissue that can extend from below the aortic valve to
the mitral valve. Hypertrophic cardiomyopathy includes a
variety of obstructive lesions; however, it usually involves
hypertrophy of the ventricular septum (see section on
hypertrophic cardiomyopathy).
Pressure overload of the left ventricle results in progressive left ventricular hypertrophy and possible failure.
Turbulent blood flow below the aortic valve can cause
abnormalities of the valve and lead to the development of
aortic valve insufficiency and regurgitation.
Clinical Presentation and Course. Although present at birth, subaortic stenosis is rarely severe enough to
cause symptoms in neonates and young infants. Older
children can present with aortic insufficiency, left ventricular failure, syncope, and angina. Bacterial endocarditis and
sudden death are potential complications.
Management. Surgical intervention will depend on
the type of subaortic stenosis and the presenting symptoms.
When a significant gradient develops, surgery is performed
to prevent left ventricular failure. The development of aortic
insufficiency and the presence of associated intracardiac
lesions may also warrant surgery. When surgery is per-
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fonned, a median stemotomy is used with the institution of
cardiopulmonary bypass. For discrete membrane formation
beneath the aortic valve, the membrane and muscle are
surgically removed through an aortic incision. When extensive muscle excision is required for a tunnel type of stenosis,
muscle is removed via an aortic incision or the Konno
procedure. A combined Ross-Konno operation may be
necessary for complex aortic stenosis with left ventricular
outflow tract obstruction 32
Postoperative management after the removal of a discrete
subaortic membrane is usually uneventful. When extensive
muscle removal is warranted, left ventricular dysfunction
and the development of left bundle branch block or
complete heart block are possible. Inotropic support, afterload reduction, and temporary or pennanent pacemaker
therapy may be indicated. Aortic insufficiency can develop
or worsen if present preoperatively. Mitral valve damage
can also occur with extensive muscle resection, resulting in
mitral valve regurgitation.
Supravalvar Aortic Stenosis. Supravalvar aortic
stenosis is defined as an obstruction to blood flow occurring
in the ascending aorta above the aortic valve. This can
include the presence of a fibrous membrane, hypoplasia of
the ascending aorta, or the presence of an "hourglass"
defonnity of the aorta. Supravalvar aortic stenosis is often
found in children with Williams' syndrome, who have
characteristic faces (elfin), developmental delay, and personality changes. Hypercalcemia, peripheral pulmonary
stenosis, aortic coarctation, and renal artery stenosis may
also be present in these children. Supravalvular aortic
stenosis occurs less often than all other fonns of aortic
stenosis.
As with other fonns of aortic stenosis, this type of
obstruction can result in left ventricular hypertrophy and
dysfunction from the pressure overload. When the coronary
arteries are filled under pressure from the obstruction,
coronary artery abnormalities and ischemia can result.
Clinical Presentation and Course. This disease is
progressive and often reoccurs despite surgical intervention.
Patients with Williams' syndrome should always be evaluated for the presence of supravalvar aortic stenosis. Symptoms include poor growth, exercise intolerance, angina, and
syncope. Bacterial endocarditis and sudden death are
possible complications. Indications for surgical intervention
include the development of a significant gradient, myocardial ischemia, clinical symptoms, and the development of
coronary artery abnonnal ities.
Management. Supravalvular aortic stenosis is amenable to operative treatment if the narrowing is discrete and
can be widened with insertion of a patch. Surgery is
perfonned via a median sternotomy and the use of cardiopulmonary bypass. A vertical incision of the stenosed area is
made, and a patch is inserted to enlarge the aortic diameter.
Secondary aortic valve damage may occur as a result of
this surgery.
Postoperative care is usually more complicated after
surgical intervention compared with other types of aortic
stenosis. Extensive suture lines along the aorta can result
in systemic hypertension and bleeding. Treatment with
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afterload-reducing agents may be required. When coronary
abnonnalities are present, myocardial ischemia may occur.
Aortic insufficiency may be present if aortic valve damage
is present preoperatively or is a complication of the surgery.
Pulmonary Stenosis. Pulmonary stenosis is the result of an obstructive lesion that interferes with blood flow
from the right ventricle to the pulmonary artery. This lesion
can occur at a number of locations in the right ventricular
outflow tract and pulmonary artery. Subcategories include
valvar pulmonary stenosis, subvalvular pulmonary stenosis,
and supravalvular pulmonary stenosis (Fig. 18-11). Valvar
pulmonary stenosis typically presents with a bicuspid valve
that is fused at the commissures. This is the most common
fonn of pulmonary stenosis. Subvalvular pulmonary stenosis includes double-chamber right ventricle and infundibular
pulmonary stenosis. Double-chamber right ventricle typically consists of a fibrous or muscle ring of tissue below the
pulmonary valve within the right ventricle. Infundibular
stenosis involves muscle extension in the right ventricular
outflow tract. Supravalvular pulmonary stenosis can occur
within the main pulmonary artery or within any of its
branches. Often, multiple areas of stenosis exist throughout
the pulmonary vasculature. This is a rare defect and may be
associated with other arterial abnonnalities.
Regardless of the specific location of the pulmonary
stenosis, the hemodynamic result is obstruction of blood
ejected from the right ventricle in systole. This obstruction
places a pressure burden on the right ventricle.

Fig. 18-11 Four locations of pUlmonary stenosis (PS). A, Branch
pulmonary artery stenosis; B, discrete supravalvular PS; C, valvular PS; D, subvalvular PS. NC, Inferior vena cava; LPA, left
pulmonary artery; RA, right atrium; RPA, right pulmonary artery;
RV, right ventricle; PA. pulmonary artery; SVC, superior vena cava;
TV, tricuspid valve. (From Smith 18: Pediatric critical care,
Albany. NY, 1985. Delmar.)
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Valvular Pulmonary Stenosis. Obstruction to ventricular emptying and the resultant increase in right ventricular pressure cause right ventricular and main pulmonary
artery enlargement. The right ventricle enlarges as its
muscular wall hypertrophies in response to the increased
afterload it must overcome. The main pulmonary artery
enlargement is characteristic of poststenotic dilation. However, pressure in the pulmonary trunk is normal or lower
than normal, and therefore the peripheral pulmonary vasculature and the left heart are unaffected. When severe valvar
pulmonary stenosis is present, right atrial pressure may also
increase, with resultant enlargement of the right atrial
chamber.
Subvalvular Pulmonary Stenosis. Double-chamber
right ventricle and infundibular pulmonary stenosis are
characterized by right ventricular hypertrophy that develops
in response to the increased pressure in the ventricle as it
pumps against an obstruction. However, the increased force
is dissipated over an area of obstruction that is larger than
that of valvular pulmonary stenosis, and, as a result, the
main pulmonary artery remains normal in size. Pressure in
the main pulmonary artery is normal or reduced.
Supra valvular Pulmonary Stenosis. Unlike the
other forms of pulmonary stenosis, supravalvular lesions
produce hypertension in the main pulmonary artery as well
as in the right ventricle. However, ventricular and pulmonary artery enlargement vary with the severity and location
of the lesions.
Clinical Presentation and Course. Children with
pulmonary stenosis are followed closely to detect, as early
as possible, progression of their stenosis with growth.
Although progression is less likely in children with pulmonary stenosis than in those with aortic stenosis, it is detected
by changes in the murmur (increased intensity, loss of
ejection click, the development of a palpable thrill),
increased right ventricular hypertrophy on ECG, or increased clinical symptoms. Children with pulmonary stenosis have a low risk of developing bacterial endocarditis, but
antibiotic prophylaxis with dental work or other surgical
procedures is generally provided.
Management. Treatment of pulmonary stenosis is
recommended when the pressure gradient across the right
ventricular outflow tract is 50 to 60 mmHg.
Transcatheter Dilation. Discrete valvular pulmonary
stenosis can be treated successfully by balloon valvoplasty
in the cardiac catheterization laboratory. In general, this
approach is quite successful, resulting in a gradient of less
than 50 mmHg, RV pressure of less than half systemic, and
mild pulmonary insufficiency. In many patients, this is the
treatment of choice without any required subsequent surgical intervention. Exceptions are those patients with dysplastic pulmonary valves.
Surgical Management. In patients who are not candidates for balloon dilation, surgical valvotomy is performed.
Cardiopulmonary bypass is used, and an incision is made in
the pulmonary artery. Incising the fused commissures as
widely as possible relieves valvular stenosis. The right
ventricular infundibulum is palpated through the newly
enlarged pulmonary valve to detect localized muscular or
fibrotic obstruction. Subvalvular stenosis is excised widely

by means of a right ventriculotomy or through an incision in
the pulmonary artery.
Postoperatively, children who have had repair of valvular
pulmonary stenosis may have some degree of pulmonary
valve regurgitation, but this is generally not significant and
is well tolerated. Patients who, before surgery, have
significant right ventricular hypertension and hypertrophy
may develop some degree of right-sided CHF postoperatively and require digoxin or diuretic therapy for variable
periods. Most children recover uneventfully and continue to
grow and develop normally.

Cyanotic Congenital Heart Defects
With Decreased PBF
Cyanotic structural defects with decreased PBF generally
have obstruction within the right heart in combination with
an intracardiac shunt. These lesions result in intracardiac
mixing and systemic desaturation. Tetralogy of Fallot and its
variants are the most common lesion in this subgroup. Other
lesions include pulmonary and tricuspid atresia. Table 18-5
summarizes the clinical, ECG, and radiographic findings of
this population.
Tetralogy of Fallot. Tetralogy of Fallot (TOF) accounts for approximately 10% of all congenital heart defects
(CHDs). It consists of four primary cardiac defects resulting
from hypoplasia of the right ventricular infundibulum.
These include a malaligned VSD, infundibular pulmonary
stenosis, right ventricular hypertrophy, and aortic override
of the ventricular septum (Fig. 18-12). These four defects
result in a spectrum of disease dependent on the variations
and degree of right ventricular outflow tract obstruction
(RVOTO). TOF can be further categorized as TOF with
pulmonary stenosis (TOF-PS) and TOF with pulmonary
atresia (TOF-PA).
Tetralogy of Fallot With Pulmonary Stenosis.
Although variations exist, typically the RVOTO seen in
TOF-PS includes hypoplasia of the infundibulum, pulmonary val ve stenosis, hypoplasia of the pulmonary annulus,
and hypoplasia of the pulmonary trunk. The branch pulmonary arteries are usually continuous and not hypoplastic.
The right ventricular hypertrophy is secondary to the
pressure load induced by outflow tract obstruction. The VSD
is always malaligned. In approximately 3% of patients with
TOF-PS, a second VSD exists that is usually muscular.
Additional anatomic abnormalities can include coronary
artery abnormalities, a right aortic arch, and a persistent left
superior vena cava.
The degree of RVOTO, which determines the amount of
obstruction to PBF, determines the pathophysiology of this
defect. With a large VSD, the two ventricles essentially
function as a single ventricle; therefore systemic vascular
resistance may also contribute to the amount of PBF. A
decrease in systemic vascular resistance can decrease PBF,
whereas an increase in systemic vascular resistance can
increase PBF. When RVOTO is minimal, there may actually
be a left-to-right shunt across the VSD, resulting in
pulmonary overcirculation and signs of CHF. These patients
often have systemic arterial oxygen saturations of greater
than 90% and are called "pink tets." When RVOTO is
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18-5 . Cyanotic Congenital Heart Defects With Decreased Pulmonary Blood Flow
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fulmonary atresia with
• ;;- intact ventricular
septum

Cardiac Examination

Electrocardiogram

Chest Radiograph

Loud systolic murmur with
palpable thrill along the
entire left sternal border;
single S2; prominent inferior
sternum and right ventricular
impulse
Heart murmur may be absent;
when detected, usually holosystolic blowing murmur of
tricuspid regurgitation and
continuous. "machinery"
murmur of PDA; single S2
No tricuspid S ,; S2 also often a
single sound: no pulmonary
S2; variable systolic (VSD
and PS) murmurs or diastolic
(mitral flow) murmur; often,
no murmur is audible

Right axis deviation and right
ventricular hypemophy;
occasional right atrial
hypemophy

Normal cardiac size with
concavity in main pulmonary
artery area; decreased pulmonary vascular markings; bootshaped heart silhouette; right
aortic arch common
Cardiomegaly with significant
right atrial enlargement;
decreased pulmonary
vascular markings

Absence of or decrease in right
ventricular forces; left
ventricular dominance

Left axis deviation; left ventricular, left atrial, and right
atrial hypertrophy; no right
ventricular forces

Normal overall heart size with
concavity in main pulmonary
artery area; right atrial, left
atrial, left ventricular, and
aortic enlargement; decreased
pulmonary vascular markings

Patent ductus arteriosus; P5, pulmonary stenosis; 51' first heart sound; 52. second heart sound; V5D, ventricular septal defect.

Fig. 18-12 Tetralogy of Fallot (TOF). A. Ventricular septal
defect; B, aorta overriding ventricular septum; e, pulmonary
stenosis; D, right ventricular hypemophy. Ao, Aorta; lVe, inferior
vena cava; LA, left atrium; LPA, left pulmonary artery; LV, left
ventricle; MV, mitral valve; PA, pulmonary artery; PV, pulmonary
vein; RA, right atrium; RPA, right pulmonary artery; RV, right
ventricle; SVC, superior vena cava; TV, tricuspid valve. (From
Smith JB: Pediatric critical care, Albany, NY, 1985, Delmar.)

moderate, there is protection from pulmonary overcirculation and a small right-to-left shunt across the VSD with mild
cyanosis and oxygen saturations of about 90%. These
patients are commonly asymptomatic. When RVOTO is
severe, there is a significant right-to-Ieft shunt across the
VSD with oxygen saturations of 70% to 80%. In these
patients, decreased oxygen saturations can lead to severe

hypoxemia and acidosis. The effect on the heart of these
changes in hemodynamics includes an increase in the size
and work of the right ventricle, The right atrium is usually
unaffected. An increased volume load on the left ventricle
results; however, it remains normally compliant.
Tetralogy of Fallot With Pulmonary Atresia.
With TOF-PA, no outflow exists from the right ventricle to
the pulmonary artery. The source of PBF is variable and
further aescribes the subcategories of this defect. In
newborns with valvar pulmonary atresia, the PBF is
dependent on a PDA. At the other end of the spectrum,
complete absence of a main pulmonary artery is evident, and
the presence of branch pulmonary arteries is variable. PBF,
in this case, is dependent on multiple aortopulmonary
collateral arteries (MAPCAs) (Fig. 18-13). The number,
size, and origin of the MAPCAs is variable and further
describes the pathophysiology and prognosis of TOF-PA.
Without forward flow from the right ventricle to the
pulmonary artery, a complete right-to-left shunt occurs
across the VSD. The amount of cyanosis and severity of
disease depend on the source of PBF, which is provided
either by the PDA or by MAPCAs. The presence of what
would be true branch pulmonary arteries is variable.
Neonates with TOF-PA and ductal-dependent PBF have a
normal pulmonary trunk and branch pulmonary arteries.
These neonates will be severely cyanotic and in extreme
distress when the ductus begins to close. Newborns with
TOF-PA and MAPCAs usually have an adequate source of
PBF in the early infant period; however, they will be
cyanotic. The amount of PBF and cyanosis depends on the
size, number, and condition of the MAPCAs.
Clinical Presentation and Course
Tetralogy of Fallot With Pulmonary Stenosis. Symptoms vary depending on the degree of RVOTO and shunt.
Patients can be asymptomatic and acyanotic or severely

604

Part IV

Final Common Pathways

Fig. 18-13 Tetralogy of Fallot with pulmonary atresia. In groups I and II, the pulmonary arteries are well
developed, and blood flow is supplied by a large patent ductus arteriosus. The main pulmonary artery is
absent in group 11. In group III, the ductus is either absent or very small. Both left and right pulmonary
arteries are diminutive, connecting to variable numbers of bronchopulmonary segments; the more
important sources of pulmonary blood flow are APCAs. In group IV, there are no mediastinal pulmonary
arteries, and all bronchopulmonary segments are supplied entirely by APeAs. (From Castenada AR, Jonas
RA, Mayer JE et al: Cardiac surgery of the neonate and infant. Philadelphia, 1994. WB Saunders.)

cyanotic and distressed. Persistent hypoxemia in infants
stimulates bone marrow production of red blood cells,
however, microcytic and hypochromic anemia can result
from deficient iron stores. Cyanosis eventually leads to
increased hemoglobin levels and hyperviscosity. RVOTO
and the degree of cyanosis worsens over time and hypercyanotic spells may occur more frequently with age. Patients
are at risk for cerebral abscess, cerebral vascular accidents,
or death resulting from hypercyanotic spells. Late' complications include bacterial endocarditis, hemorrhagic disorders, and complications of prolonged cyanosis. This disease
is progressi ve and there is no chance for spontaneous
recovery, therefore a definitive surgical repair is always
indicated. Early corrective surgery is preferred to normalize
the physiology and avoid these complications. Echocardiography is usually adequate to make the appropriate
preoperative diagnosis for patients with TOF-PS. Even with
multiple VSDs and abnormal coronary artery anatomy,
echocardiography has proven to be sufficient. Cardiac
catheterization may be indicated in patients with previous
palliation, symptoms suggestive of aortopulmonary collaterals, concerns about coronary artery anatomy, or pulmonary vascular disease.
Hypercyanotic Spells. Hypercyanotic or "tet" spells
can occur in infants and children with TOF-PS and are
probably caused by intermittent worsening of RVOTO.
Usually preceded by periods of agitation, these spells
include symptoms of increased distress followed by hyperpnea, worsening cyanosis, and syncope. If severe or
untreated, severe hypoxemia can result in brain injury or
death. Anything that distresses the infant can precipitate a
hypercyanotic spell. Careful attention must be paid to
patients who are admitted preoperati vely to avoid procedures that may stimulate a hypercyanotic spell.

Initial treatment includes oxygen administration, sedation, and volume expansion. If severe, a phenylephrine
infusion may be initiated to increase systemic vascular
resistance and therefore decrease the right-to-left shunt and
improve PBF. Positioning the infant or child in a knee-chest
position has been advocated to increase systemic venous
return and systemic vascular resistance; however, some
children may not be comfortable in this position, and their
distress may actually be worsened. Emergency surgery for
either a Blalock-Taussig shunt or a complete repair may be
indicated. The primary goal of early complete repair,
however, is to avoid these spells as the disease progresses,
thereby avoiding their complications.
Tetralogy of Fallot With Pulmonary Atresia. These
patients are cyanotic at birth because of the obligatory
right-to-Ieft intracardiac shunt. The degree of oxygen
desaturation depends on the source of PBF. Newborns with
ductal-dependent PBF have severe distress, hypoxemia, and
rapid deterioration when the ductus begins to close. Patients
with MAPCAs have variable oxygen saturations depending
on the number and level of obstruction to flow within the
MAPCAs. Unobstructed MAPCAs could possibly result in
pulmonary overcirculation and signs of CHF.
Management
Tetralogy of Fallot With Pulmonary Stenosis. Although
controversy exists regarding the timing and approach to the
surgical management of TOF-PS, the increasing trend is to
avoid palliation and to provide a complete surgical repair in
the neonatal or early infant period. However, some centers
prefer early surgical palliation followed by a complete
surgical repair in late infancy or early childhood. The goals
of early complete repair are to avoid complications of
surgical palliation, correct the cyanosis, avoid a second
surgery, and to normalize the cardiopulmonary physiology.
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Palliative shunts to increase pulmonary blood flow.
A, Blalock-Taussig anastomosis; B, Waterston anastomosis;
C, Potts-Smith-Gibson anastomosis; D, Classic Glenn anastomosis. (From Smith JB: Pediatric critical care, Albany. NY,
1985, Delmar.)

Fig. 18·14

The timing of a primary surgical repair in these patients
depends on the patient's symptoms and the institutional
philosophy. Patient subtypes of TOF-PS can be categorized
into three groups that can assist in the timing decision of
when to perform surgery. Patients with TOF-PS who have
ductal-dependent PBF and have cyanotic spells in the
newborn period when the ductus closes require surgery in
the neonatal period. Patients who are asymptomatic with
arterial oxygen saturations of 75% to 90% can be electively
repaired between I and 3 months of age or when they
become symptomatic. Patients with arterial oxygen saturations greater than 90% (pink tets) can electively undergo
repair between the age of 2 of 4 months. However, any
patient who becomes symptomatic, presenting with cyanosis or any history of hypercyanotic spells, should be
immediately considered for surgical repair or palliation to
avoid complications and possible death.
Palliative Surgical Management. Palliative surgical
intervention involves the placement of a systemic-topulmonary artery shunt to improve PBF. The modified
Blalock-Taussig shunt is generally performed. In this
procedure, a Gore-Tex shunt is anastomosed from the
subclavian artery to the branch pulmonary artery (Fig.
18-14). Although this is a low-risk procedure, potential
complications including branch pulmonary artery stenosis
with partial or complete occlusion, thrombosis of the shunt
resulting in acute worsening of cyanosis and possible death,
or the development of pulmonary vascular obstructive
disease, exist. In addition, with surgical palliation, the
patient's cardiopulmonary physiologic condition remains
abnormal and cyanosis persists, which may have long-term
effects on the developing organs.

Cardiovascular Critical Care Problems

605

Complete Surgical Repail: Through a median sternotomy, this surgery is performed with the use of cardiopulmonary bypass, aortic cross clamping, and the administration of cardioplegia solution. Any previously placed
aortopulmonary shunts are taken down, and the pulmonary
artery is reconstructed if necessarily. The surgical approach
for repair depends on the location and degree of RYOTO.
Without pulmonary valve annulus hypoplasia, the YSD,
subpulmonary artery stenosis, or pulmonary valve stenosis
can be repaired through a combined transatrial and transpulmonary approach, thereby avoiding a right ventricular
incision. When pulmonary valve annulus hypoplasia exists,
a right ventriculotomy is made. The YSD and RYOTO are
repaired through this incision, and a transannular patch or
infundibular patch is used to correct the RYOTO. Typically
these patches are made with the use of the patient's
preserved pericardial tissue. A patent foramen ovale (PFO)
is often maintained or incised to allow a right-to-left atrial
shunt in the presence of right ventricular dysfunction in the
postoperative period. This shunt allows the maintenance of
systemic cardiac output regardless of right ventricular
dysfunction. Cyanosis, which is usually well tolerated,
results. The PFO closes spontaneously when right ventricular dysfunction resolves.
Tetralogy of Fallot With Pulmonary Atresia. In neonates with TOF-PA and ductal-dependent PBF, a PGE!
infusion is maintained until a palliative shunt or complete
repair can be performed in the early neonatal period.
Diagnosis is made by echocardiography, and cardiac
catheterization is rarely required. Many centers prefer an
early complete repair to avoid the complications of
palliation and provide early normal cardiopulmonary physiology. After the initiation of cardiopulmonary bypass and
aortic cross clamp, a right ventricular incision is made in
all cases. Through this incision, the YSD is closed, right
infundibular obstruction is repaired, and a right ventricular to pulmonary artery valved homografl is placed.
These neonates often have left branch pulmonary artery
stenosis at the site of the ductus arteriosus, requiring
surgical repair. A PFO is often maintained to allow
right-to-left atrial shunting and the maintenance of systemic
cardiac output.
For patients with TOF-PA with MAPCAs, the surgical
approach is based on institutional preference, symptoms,
and the patient's individual anatomy and physiology.
Cardiac catheterization is always required to determine
the location, size, and flow patterns of the MAPCAs. The
goal of surgery is to unifocalize all aortopulmonary
collateral vessels to the true branch pulmonary arteries, to
place a right ventricular to pulmonary artery homograft
conduit, and to close the YSD. This can be accomplished
with a one-stage complete repair with YSD closure, a
complete unifocalization of the MAPCAs leaving the YSD
open, or through a staged unifocalization. In a staged
approach, the right and left collateral arteries are unifocalized through separate thoracotomy procedures. At a later
date, a midline sternotomy is performed to place a right
ventricle to pulmonary artery homograft conduit and to
close the YSD.
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Postoperative Management
Tetralogy of Fallot With Pulmonary Stenosis. The
primary postoperative issues after complete surgical repair
for TOF-PS include the management of right ventricular
dysfunction and arrhythmias. The development of right
bundle branch block is common secondary to the VSD
closure. Sinus tachycardia and junctional ectopic tachycardia (JET) are also common and may be difficult to
differentiate. Careful evaluation of the atrial waveform for
the presence of cannon a waves and an atrial ECG assist in
the diagnosis. Sinus tachycardia is a compensatory response
to improve cardiac output in the face of right ventricular
dysfunction. JET occurs frequently in postoperative neonates and infants, with heart rates as high as 180 to
230 beats/min. It usually presents during the first 24 hours
following cardiopulmonary bypass and is often associated
with hemodynamic instability, warranting treatment. Maintaining normothermia, core cooling to temperatures of
35° C, or the use of antiarrhythmic agents may be indicated.
The right ventricle is hypertrophied and noncompliant.
This, in association with cardiopulmonary bypass and the
surgical procedure, results in postoperative right ventricular
dysfunction. The degree of right ventricular dysfunction
depends on the amount of right ventricular hypertrophy, the
preoperative anatomy and pathophysiologic condition, the
amount of right ventricular infundibular muscle removal,
the requirement of a right ventriculotomy or transannular
patch, and the length of the cardiopulmonary bypass and
aortic cross clamp times. In general, pink tets require very
little RVOT muscle resection and do not require a right
ventricular incision or transannular patch. Their postoperative course is usually uneventful, resulting in endotracheal
extubation by postoperative day I or 2. Patients with more
complex anatomy and preoperative cyanosis require more
extensive surgery often prolonging their postoperative
recovery. The presence of a transannular patch results in
some degree of pulmonary insufficiency, which can contribute to the right ventricular dysfunction and prolong the
postoperative recovery. The presence of residual lesions,
including any residual VSD or RVOTO, also contributes to
the degree of right ventricular dysfunction. A transesophageal echocardiogram (TEE) is performed at the end of the
surgical procedure to evaluate for the presence of residual
lesions. If present, a return to cardiopulmonary bypass with
further surgery may be required.
Manifestations of right ventricular dysfunction include tachycardia and elevated right atrial pressures. The
high right atrial pressure is usually necessary to maintain
adequate preload for the right ventricle. If the foramen ovale
is patent, right-to-Ieft shunting may occur when right atrial
pressure exceeds left atrial pressure. This will maintain left
ventricular output, yet result in cyanosis. If a PFO is not
present, right ventricular dysfunction and failure can result
in inadequate systemic cardiac output and inadequate tissue
oxygen delivery. The management of right ventricular
dysfunction includes inotropic support, right atrial pressure
monitoring, evaluation of systemic cardiac output, observing for signs of atrial shunting, and the treatment of
situations that increase oxygen demands, such as fever,

agitation, and pain. Endotracheal intubation is usually
required until right ventricular dysfunction improves, as
indicated by diuresis and decreased requirement for inotropic support.
Tetralogy of Fallot With Pulmonary Atresia. Neonates
who undergo a complete repair for TOF-PA have a similar
postoperative course as do neonates following repair for
TOF-PS. The complications requiring treatment include
cardiac arrhythmias and right ventricular dysfunction. The
degree of right ventricular dysfunction, however, may be
less than that seen in patients with TOF-PS. This is
secondary to the absence of both extensive RVOT muscle
resection and a transannular patch. The presence of a right
ventricular to pulmonary artery homograft may result in
some degree of pulmonary insufficiency possibly contributing to right ventricular dysfunction.
The postoperative course for patients after surgical
procedures for TOF-PA with MAPCAs depends on the
specific procedure performed and the postoperative physiology. Potential complications following unifocalization
procedures include lung injury, right ventricular hypertension and dysfunction, problems with oxygenation and
ventilation, organ system dysfunction, and bleeding. Lung
injury can result from reperfusion injury, pulmonary contusions, or pulmonary hemorrhage and is manifested by
hypoxemia, pulmonary edema, and pleural effusions. The
need for endotracheal intubation and mechanical ventilation
is often prolonged until recovery occurs. Right ventricular
hypertension occurs secondary to the resistance created by
the small and abnormal pulmonary arteries and the resistance created by extensive suture lines. Right ventricular
dysfunction results from these factors in addition to the
reasons outlined for patients with TOF-PS. Oxygenation and
ventilation can be impaired because of abnormal lung and
pulmonary artery development, atelectasis, and the presence
of reactive airway disease, requiring bronchodilator therapy
and prolonged periods of mechanical ventilation. Bleeding
is secondary to the extensive suture lines required for the
unifocalization, the length of cardiopulmonary bypass, and
the presence of a coagulopathy. These patients are highly
complex to care for, especially when their physiology
remains abnormal in the postoperative period.
Pulmonary Atresia With Intact Ventricular
Septum. Pulmonary atresia with intact ventricular septum (PA-IVS) (Fig. 18- IS) is a rare congenital heart defect.
In this defect, atresia of the pulmonary valve results in
complete obstruction to blood flow from the right ventricle
to the pulmonary artery. In addition, the ventricular septum
is intact, and the right ventricle is hypertrophied. The right
ventricular size is variable, ranging from extremely hypoplastic to larger than normal. The tricuspid valve size and
structure are also variable, although it is often hypoplastic
and stenotic. The main pulmonary artery is generally of
normal size, and a large ASD is always present.
A significant finding in patients with PA-IVS is the
presence of abnormal coronary circulation. Approximately
10% of these patients have coronary artery stenosis or
atresia of the major coronary arteries. When this occurs, the
coronary arteries distal to the stenosis or atresia are perfused
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Fig. 18-15 Pulmonary atresia with intact ventricular septum.
A, Type I; B, type 2. Ao, Aorta; L4., left atrium; LV, left ventricle;
pI; pulmonary trunk; RA, right atrium; RV, right ventricle. (From
Perloff JK: The clillical recognitioll of congenital heart disease,
ed 4, Philadelphia, 1994, WB Saunders. p 599.)

via fistulas between the right ventricle and the coronary
artery bed. Coronary artery abnormalities are usually
associated with severe right ventricular and tricuspid valve
hypoplasia and occur when right ventricular pressure is
greater than systemic pressure.
With PA-IVS, no forward flow of blood occurs across the
pulmonary valve, and the right ventricle is hypertrophied
and noncompliant. Right ventricular pressure is often
supersystemic, and usually some degree of tricuspid valve
regurgitation exists. Pressure in the right atrium is greater
than that in the left, resulting in a right-to-left shunt across
the ASD and cyanosis.
When coronary artery stenosis or atresia exist, the distal
coronary artery beds are supplied with right ventricular
blood from fistulous communications. These intramyocardial sinusoids result in retrograde coronary blood flow from
the desaturated blood in the right ventricle to the coronary
arteries. As long as right ventricular hypertension persists,
this may not have an immediate impact in the neonate.
However, if the right ventricle is decompressed, distal
coronary artery perfusion will decrease, resulting in myocardial ischemia. Long-term perfusion of coronary arteries
from venous blood can result in both right and left
ventricular ischemia and subsequent fibrosis.
Clinical Presentation and Course. Neonates born
with PA-IVS are cyanotic secondary to the obligatory
right-to-left shunt across the atrial septum. Their PBF is
dependent on PDA; therefore when ductal closure occurs,
these infants will become severely distressed, hypoxemic,
and acidotic. Death can occur rapidly if emergency treated
is not initiated. The long-term course of these patients
depends on the indi vidual anatomy, ranging from singleventricle palliation to complete two-ventricle repair. In the
presence of coronary artery fistula with evolving myocardial
ischemia, cardiac transplant may be indicated.
Management. Management of the newborn with
PA-IVS includes the correction of hypoxemia and acidosis
and the administration of PGE I to maintain patency of the
ductus and ensure PBF. Endotracheal intubation and me-
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chanical ventilation are often required. Arterial oxygen
saturations should be maintained between 75% and 85%.
Administration of sodium bicarbonate and infusions of
inotropic agents may be necessary to treat hypoxemia and
acidosis. Echocardiography is performed to establish the
diagnosis of pulmonary atresia, right ventricular size, and
tricuspid valve morphology. In most instances, cardiac
catheterization is also necessary to determine the abnormalities in coronary artery anatomy and the presence of right
ventricular fistula. Cardiac catheterization can also provide
information regarding right ventricular pressure and tricuspid valve regurgitation.
A surgical procedure is necessary in the early neonatal
period to provide a reliable source of PBF. Given the
spectrum of this defect, the exact surgical procedure
depends on the individual anatomy and ranges from a
two-ventricular repair to a single-ventricle palliation. The
goal of neonatal surgery is to provide adequate oxygenation
with a balance of systemic and pulmonary circulations and
to provide forward flow across the pulmonary valve into the
pulmonary artery whenever possible. This approach allows
growth of the right ventricle, with the goal of achieving a
two-ventricle repair in the future. When the right ventricle is
extremely hypoplastic, however, a systemic-to-pulmonary
artery shunt is placed, the ductus is ligated, and the patient's
management is like that of other single-ventricle defects.
The presence of coronary artery fistula also determines
the surgical management. When present, the elevated right
ventricular pressure provides the coronary artery perfusion
to the distal bed. If forward flow is surgically provided
across the pulmonary valve, right ventricular pressure will
decrease, coronary artery perfusion will diminish, and
myocardial ischemia will result. In these patients, a
systemic-to-pulmonary artery shunt is placed, and the
patient's condition is managed like other single-ventricle
defects. A cardiac transplant may be indicated in the future.
In a small number of patients with PA-IVS, the right
ventricle is of normal size with mild tricuspid valve disease
and the absence of coronary artery fistula. In these cases,
reconstruction of the right ventricular outflow tract without
the placement of a systemic-to-pulmonary shunt can be
performed. However, in most cases a combination of
systemic-to-pulmonary artery shunt with right ventricular
outflow tract reconstruction is provided. Even when the
pulmonary valve and outflow tract are repaired, the small
size of the right ventricle, along with its limited compliance,
results in a decreased cardiac output ejected to the pulmonary artery. The systemic-to-pulmonary artery shunt is
necessary to provide adequate PBF. Additional future
surgery will most likely be necessary in these patients.
The overall goals for postoperative management depend
on the individual anatomy and the type of surgical procedure
performed. When severe right ventricular hypoplasia exists
and an isolated systemic-to-pulmonary artery shunt is
placed in the neonate, management is similar to that of other
neonates with single-ventricle palliation, with the goal of
balancing the systemic and pulmonary circulations (see
section on hypoplastic left heart syndrome). In addition, if
right ventricular sinusoids and abnormal coronary artery
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circulation exist, the patient should be carefully monitored
for signs of myocardial ischemia, including ECG changes,
ventricular arrhythmias, and signs of low cardiac output.
When a combination of right ventricular outnow tract
reconstruction and placement of a systemic-to-pulmonary
artery shunt is performed, the patient must be monitored for
signs of balanced circulations and right ventricular function.
Signs of pulmonary overcirculation, including wide systemic arterial pulse pressure, oliguria, poor peripheral
perfusion, metabolic acidosis, and elevated arterial oxygen
saturations, may indicate excessive PBF. In this case the
right ventricle may be adequate to provide an entire cardiac
output to the pulmonary bed, and the systemic-to-pulmonary
artery shunt may be too large or is not needed.
In older patients who receive a two-ventricle repair with
closure of the ASD and takedown of the systemic-topulmonary artery shunt, signs of right ventricular failure
should be monitored. Elevated right atrial pressure, signs of
low cardiac output, and the development of ascites or
pleural effusions may indicate right ventricular failure. This
situation may indicate the need for a communication
between the right and left atria to allow right-to-left shunting
and the maintenance of adequate systemic cardiac output.
Tricuspid Atresia. Tricuspid atresia consists of an
absent tricuspid valve and no opening from the right atria to
either ventricle. In most cases, tricuspid valve tissue is not
evident, but rather the noor of the atria is muscular. There
are varying degrees of right ventricular hypoplasia. A
communication between the left ventricle and the hypoplastic right ventricle exists via a VSD (bulboventricular
foramen) and can often be a site of obstruction to blood now.
The great vessels may be normally related or transposed.
Type I tricuspid atresia refers to absence of the tricuspid
valve with normally related great vessels, whereas type II

refers to absence of the tricuspid valve with transposition of
the great vessels. Further classification depends on the
degree of obstruction to PBF, which can be (I) pulmonary
valve atresia, (2) pulmonary valve stenosis, or (3) unrestricted PBF. An atrial communication is always present,
although it is often restrictive. A PDA is usually present at
birth, but closes spontaneously within a few days. Most
commonly, tricuspid atresia exists with hypoplasia of the
right ventricle, normally related great vessels, and some
obstruction to PBF (type Ib) (Fig. 18-16).
Regardless of the various defects associated with tricuspid atresia, blood now through the heart is essentially the
same. With no outlet from the right atria to the right
ventricle, the entire systemic venous return shunts across the
atrial septum from the right to the left atrium via a PFO or
an ASD. Here systemic venous blood mixes with pulmonary
venous blood and passes into the left ventricle. From the left
ventricle, some blood is ejected to the aorta, and some is
shunted across the VSD (bulboventricular foramen) out the
right ventricular infundibulum to the pulmonary artery. The
amount of PBF is determined by how restricti ve the VSD is
or the obstruction to now at the pulmonary valve. This
lesion is usually not ductal dependent unless coexisting
pulmonary atresia is present.
Clinical Presentation and Course. Infants with
tricuspid atresia present in the neonatal period with cyanosis
from the right-to-Ieft atrial shunt and a murmur. If PBF is
inadequate once the ductus arteriosus closes, neonates may
become distressed, hypoxemic, and acidotic. Rarely is
unrestricted PBF present, in which case signs of CHF would
be evident.
Management. If PBF is ductal dependent, a continuous infusion of PGE I is necessary to maintain ductal
patency. Although PBF may be decreased, it is usually not

TRICUSPID ATRESIA WITHOUT TRANSPOSITION

RV

RV --=O-.fffl-

PULMONARY ATRESIA
NO VSO

PULMONIC STENOSIS
SMALL VSD

NO PULMONIC STENOSIS
LARGE VSD

Fig. 18-16 Illustrations of tricuspid atresia with normally related great arteries. In all, the only outlet
for right atrial (RAJ blood is interatrial communication. Variations in ventricular septum and pulmonary valve are depicted. Ao. Aorta; LA, left atrium; LV, left ventricle; PT. pulmonary trunk; RV, right
ventricle. (From Perloff JK: The clinical recognition of congenital heart disease, ed 4, Philadelphia, 1994,
WB Saunders, p 616.)
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ductal dependent; therefore most neonates can tolerate
spontaneous ductal closure. A balloon atrial septostomy may
be necessary if the atrial septum is restrictive.
A palliative surgical procedure is usually required in the
neonatal period. Typically, a systemic-to-pulmonary artery
shunt is placed to improve PBF. If the atrial septum is
restrictive, an atrial septectomy can be performed at this
time to provide adequate mixing of blood at the atrial level.
In rare situations when PBF is excessive, a pulmonary artery
band is placed to limit pulmonary overcirculation and
optimize systemic blood flow. In either case, the presence of
right ventricular hypoplasia does not allow a two-ventricle
repair; therefore these patients require additional palliative
procedures for single-ventricle physiology, typically including the bidirectional Glenn anastomosis at 4 to 6 months,
followed by the Fontan procedure later in childhood. For a
complete description of these procedures, see the section on
hypoplastic left heart syndrome.
Some newborns with tricuspid atresia have relatively
balanced systemic and pulmonary blood flow and may not
require a surgical procedure in the newborn period. These
infants recei ve a primary bidirectional Glenn anastomosis in
infancy (4 to 6 months of age), followed by a Fontan
procedure later in childhood.
The postoperative management is~ues depend on the
preoperative pathophysiologic condition, specifically, the
presence of too much to too little PBF, and the surgical
procedure performed. Typically, a systemic-to-pulmonary
shunt is placed to provide a reliable source of PBF, and the
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goal of postoperative care includes the balancing of
systemic and pulmonary circulations (see section on hypoplastic left heart syndrome). Usually a regimen of oral
aspirin (5 to 10 mg/kg/day) is started in these patients to
maintain shunt patency.

Cyanotic Congenital Heart Defects
With Increased PBF
Cyanotic CHDs with increased PBF include total anomalous
pulmonary venous connection (TAPVC), truncus arteriosus,
and hypoplastic left heart syndrome (HLHS). These conditions can occur in isolation or in combination with other
structural defects. Table J8-6 summarizes the findings on
cardiac examination, ECG, and chest radiograph of children
with these defects.

Total Anomalous Pulmonary Venous Connection.
TAPVC results in anomalous pulmonary venous drainage
into a systemic venous structure rather than the left atrium.
Of note is that partial anomalous pulmonary venous return
can occur as well. In this defect some of the pulmonary
veins drain to the left atrium, and some drain abnormally to
systemic veins in the thorax or directly to the right atrium.
This can occur in isolation or in association with other
cardiac structural defects. In isolation, partial anomalous
pulmonary venous connection is uncommon, and patients
are often asymptomatic; therefore it is not discussed here.
The pulmonary venous system develops at about the third
week of gestation. The splanchnic plexus, which is con-

Cyanotic Congenital Heart DefedsWithlncreased Pulmonary Blood Flow
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Electrocardiogram

Chest Radiograph
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or absent
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SyslOlic ejection murmur best
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middiastolic murmur best
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hypertrophy, right ventricular
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Normal S" single S2' ejection
click; loud. continuous ePDA
type) mUOllUr with unrestricted
PBF; murmur shortened and
softened by decreasing PBF

Left ventricular hypertrophy;
bi ventricular hypertrophy
seen occasionally

Dominant RY impulse, decreased
impulse at apex; single S2 with
increased intensity; diminished
peripheral pulse; gallop rhythm
in some, soft systolic murmur
at LSB, middiastolic rumble
at apex

Right ventricular hypertrophy;
in some, right atrial
enlargement

Supracardiac: "figure eight" or
"snowman" configuration; all
defects: enlarged right atrium,
right ventricle, and main
pulmonary artery; increased
pulmonary vascular markings
Nonspecific except for alteration
in pulmonary vascular markings; may detect right-sided
aortic arch, and pulmonary
vessels may arise abnormally
high in the chest
Cardiomegaly, increased
pulmonary vascular
markings
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Hypoplastic left heart syndrome; iSB, left sternal border; PBF, pulmonary blood flow: PDA. palent ductus arteriosus: 5/. first heart sound;
second heart sound; TAPVC, total anomalous pulmonary venous connection.
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nected to the umbilical vitelline veins and the cardinal veins,
is in direct communication with the lung buds. The common
pulmonary vein, which arises in the common atrium, grows
to join the splanchnic plexus. Once the common pulmonary
vein and the splanchnic plexus are joined, the cardinal veins
and vitelline veins are no longer connected to the splanchnic
plexus. The pulmonary veins then drain into the left atrium
via the common pulmonary vein. Gradually, the common
pulmonary vein is absorbed into the body of the left atrium,

and four distinct pulmonary veins draining into the left
atrium persist. Failure in any ofthese embryologic processes
can lead to the malformation of the four pulmonary veins,
resulting in partial or total anomalous pulmonary venous
connection.
TAPVC may occur in four forms: (I) supracardiac,
whereby the pulmonary veins course via a vertical vein to
the innominate vein that drains into the superior vena cava
(Fig. 18-17, A); (2) cardiac, whereby the pulmonary veins

A
Supracardiac
TAPVC

B

Cardiac TAPVC

Fig. 18-17 Total anomalous pulmonary venous connection (TAPVC). A, Supracardiac connection to left
innominate vein. B, Cardiac connection to four separate veins. B', Cardiac connection by single common
orifice. C, Cardiac connection to coronary sinus. D, Infradiaphragmatic TAPVC via the portal venous
system. lAC, Interatrial communications; IVC, inferior vena cava. (Reproduced with permission. Garson
A, Bricker JT, Fisher DJ et al: The science and practice ofpediatric cardiology, Baltimore, 1998, Williams
& Wilkins.)
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drain into the coronary sinus or directly into the right atrium
(Fig. 18-17, B and C); (3) infracardiac, whereby the
pulmonary veins drain into a descending vein and join the
portal venous system (Fig 18-17, D); and (4) mixed, which
includes variants of the previous three forms. Supracardiac
TAPVC accounts for most of the cases. Essentially the
anatomic malformation is such that pulmonary venous
return is to the right atrium. Because of this defect, an
ASD is necessary for oxygenated blood to reach the left
atrium.
TAPVC may occur with or without obstruction in the
pulmonary venous pathway. TAPVC with obstruction occurs predominantly in the infradiaphragmatic type. Obstruction with infradiaphragmatic TAPVC can occur at a number
of sights along the anomalous venous pathway. Discrete
obstruction can occur from constriction of the vein as it
passes through the diaphragm. Diffuse obstruction occurs
when the anomalous attachment enters the portal system. A
restricti ve atrial communication will obstruct flow from the
right to left atrium, therefore obstructing pulmonary venous
return to the systemic circulation.
TAPVC With Obstruction. Blood from both the
pulmonary and the systemic venous systems returns to the
right atrium. However, because of the presence of an
obstruction in the pulmonary venous connection, pulmonary
venous flow to the right atrium is restricted. This results in
elevated pulmonary venous pressure with the subsequent
development of progressive pulmonary hypertension and
pulmonary edema. As PVR increases, so does right heart
pressure. Decreased right ventricular compliance and right
atrial hypertension result in a right-to-left shunt at the atrial
level producing systemic hypoxemia. This right-to-Ieft
shunt decompresses the right heart, so cardiomegaly does
not typically develop. Progressive hypoxemia contributes to
metabolic acidosis and end-organ failure. Without surgical
correction, death will ensue. Because of common clinical
features, TAPVC with obstruction is often mistaken for
persistent pulmonary hypertension of the newborn (PPHN).
Specific diagnosis with echocardiogram is critical because
therapeutic interventions for each are quite different.
TAPVC With Restrictive Intraatrial Connection.
An atrial connection (ASD or PFO) is critical to the
immediate survival of these infants. The size of the atrial
shunt determines the degree of mixing and subsequent
systemic oxygen saturations. A restrictive atrial communication results in right atrial volume overload, pressure
elevation, and enlargement. As PVR falls, pulmonary
overcirculation ensues that results in CHF and cardiac
dysfunction. Generally, this occurs over the first few weeks
of life, although clinical presentation can be variable.
Elevated right atrial pressure results in systemic venous
congestion.
TAPVC Without Obstruction. In the unobstructed
forms, free communication occurs between the two atria.
The relative pulmonary and systemic vascular resistances
and cardiac compliance determine atrial shunt. As PVR
falls, PBF increases, with subsequent volume load to the
right heart. If not surgically addressed in a timely manner,
pulmonary hypertension can develop secondary to pulmonary overcirculation.
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Clinical Manifestations and Course. Neonates
without obstruction may have mild to moderate cyanosis
dependent on the degree of atrial mixing and pulmonary
resistance. As PVR falls and PBF increases, the signs and
symptoms of CHF can develop. The physical examination
is often similar to that of a large ASD, although hepatomegaly or cyanosis may also be noted (atypical for isolated ASD).
Neonates with obstruction have quite different symptoms. These infants are typically critically ill, poorly
perfused, acidotic, and cyanotic. Institution of supportive therapies is necessary shortly after birth with intubation, mechanical ventilation, and inotropes. Some require
extracorporeal membrane oxygenation (ECMO) or highfrequency ventilation before surgery. Every effort should be
made to make the diagnosis before cannulation for ECMO
because emergent corrective surgery is the preferred
treatment.
Management. As mentioned earlier, neonates with
obstruction require early and aggressive intervention with
mechanical ventilation, inotropes, volume, correction of
acid-base disorders, maneuvers to decrease pulmonary
resistance (nitric oxide), and possibly ECMO. In some,
balloon atrial septostomy may stabilize the neonate's
condition. 36 If stabilization does not occur, a true surgical
emergency exists.
Management of TAPVC without obstruction is directed
toward controlling CHF with anticongestive therapy and
treating failure to thrive. If the patient is relatively asymptomatic, surgery can be performed at any age; however,
many centers believe that the optimal time is at presentation
or during the first year of life. Untreated infants who survive
to older childhood or early adulthood may develop fixed
pulmonary artery hypertension; therefore surgery should not
be delayed.
Definitive Surgical Correction. Surgical correction is
performed via a midline sternotomy incision using cardiopulmonary bypass and hypothermia. Some centers also
employ circulatory arrest during a portion of the perioperative period. Surgical repair involves anastomosing the
pulmonary venous confluence to the left atrium, resulting in
proper drainage. The connecting vein to the systemic venous
circulation is ligated, and the ASD is closed. Potential
postoperative problems include low cardiac output, respiratory insufficiency, pulmonary hypertension, and arrhythmias. TAPVC with obstruction has a high postoperative
mortality rate from pulmonary hypertension and respiratory
failure.
Monitoring PA and LA pressures in the postoperative
period can aid in the identification of residual or progressive
pulmonary venous obstruction that constitutes a surgical
emergency. Volume resuscitation is judicious because of
decreased left heart compliance. Maneuvers to decrease
PVR are employed in those patients with preoperative and
postoperative pulmonary hypertension.
Truncus Arteriosus. Truncus arteriosus is the result
of failure of the primitive arterial trunk (the truncus
arteriosus) to septate and divide into a distinct aorta and
pulmonary artery. The aorta and the pulmonary artery
normally develop from the common truncus arteriosus at the
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TYPE I

TY PE 2

TYPE 3

Fig. 18-18 Illustrations of various types of truncus arteriosus. In type I a shorl main pulmonary artery
arises from the truncus. In types 2 and 3 the branch pulmonary arteries arise directly from walls of the
truncus. LPA, Left pulmonary artery; RPA, right pulmonary artery. (From Perloff JK: The clinical
recognition of confienital hear! disease. ed 4, Philadelphia, 1994, WB Saunders. p 688.)

end of the third week and during the fourth week of
gestation. This occurs by virtue of the unique development
of conotruncal ridges that spiral and separate to form the
great arteries. Failure of septation of the common trunk
results in the persistence of a single vessel that gives rise to
the systemic and pulmonary arteries and contains only one
valve (truncal valve), which is often dysmorphic. The
truncus arteriosus overlies a VSD that is always seen in
conjunction with this defect and is an integral part of its
pathophysiology.
Truncus arteriosus exists in three anatomically distinct
variations. These occur with respect to the size and site of
origin of the pulmonary arteries. In type I, a short
pulmonary trunk arises from the truncus and divides into the
branch pulmonary arteries. In type 2, both branch pulmonary arteries arise in close proximity directly from the
truncus without a main pulmonary artery. In type 3, the
separate origins of the branch pulmonary arteries arise some
distance apart from the lateral sides of the aorta (Fig. 18-18).
Type 4 is characterized by no main or branch pulmonary
arteries with multiple small collateral arteries arising from
the descending aorta. This defect is really a misnomer and is
more appropriately described as a variant of pulmonary
atresia. Truncus arteriosus is a conotruncal anomaly and is
associated with the genetic syndrome commonly referred to
as 22q deletion 37
Because of the large VSD, right and left ventricular
pressures are equal. Mixing of oxygenated and deoxygenated blood occurs at the level of the ventricles. The single
great artery (truncus) arising from the right and left
ventricles recei ves the entire cardiac output of both ventricles. Flow to the pulmonary and systemic vascular beds is
secondary to the relative resistances. As PVR falls, PBF
increases, with subsequent pulmonary overcirculation and
the development of CHF. Because both great arteries arise
from the truncus, they will both have the same systolic
pressure, which is markedly elevated (relative to normal) for
the pulmonary artery, resulting in pulmonary hypertension.
The competence of the truncal valve can be quite
variable, ranging from normal to severe regurgitation to
stenotic. Truncal regurgitation results in ventricular volume
load, cardiac dysfunction, and worsening heart failure.
Truncal stenosis imposes a pressure load on both ventricles.

Clinical Presentation and Course. As PVR falls
and PBF increases, the neonate develops signs and symptoms of CHF. Cyanosis may become less pronounced over
the first few days to weeks of life because of a decrease in
right-to-Ieft shunt and an increase in PBF. A systolic murmur
is usually heard in the first few days of life, and the second
heart sound is single.
Management. Truncus arteriosus is usually diagnosed in the neonatal period. If left untreated, this lesion
carries a mortality rate of 87% by 6 months of age and 91 %
by I year of age 37 Initial management consists of anticongestive therapy, and early surgical intervention is now
generally recommended in the neonatal period. The only
absolute contraindication for surgery is Eisenmenger's
syndrome.
Definitive Surgical Correction. Surgery is performed
via a median sternotomy. Deep hypothermia with low-flow
technique or circulatory arrest is employed. The pulmonary
arteries are excised from the aortic root and anastomosed to
a valved conduit (homograft). The homograft is interposed
between the right ventricle and pulmonary arteries, resulting
in right ventricular to pulmonary artery continuity. The VSD
is patched in a manner that isolates the truncus arteriosus
and truncal valve to the left of the septum, where it functions
as the aorta. Surgery is repeated if the conduit becomes
stenotic or insufficient or as it becomes inadequate in size as
the child grows, requiring replacement with a larger one.
Caring for these infants can be challenging because of the
potential for the development of postoperative pulmonary
hypertension, right ventricular dysfunction, and arrhythmias
(particularly JET). The use of usual ventilatory and nursing
maneuvers to treat pulmonary hypertension helps to decrease PVR and pulmonary hypertensive crises. If pulmonary hypertension is unresponsive to these measures, nitric
oxide or mechanical assist (ECMO, VAD) should be
considered. Information obtained from a transthoracic PA
line helps to evaluate for pulmonary hypertension, residual
VSD, or RVOTO. Arrhythmias require immediate treatment
because they are poorly tolerated, particularly JET.
Hypoplastic left Heart Syndrome. HLHS includes
a spectrum of disease involving varying degrees of underdevelopment of the mitral valve, left ventricle, aortic valve,
and aorta (Fig. 18-19). Typical variations include aortic and
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Fig. 18-19 Hypoplastic left heart syndrome (HLHS). Asc ao,
Ascending aorta; Desc ao, descending aorta; LA, left atrium;
LV, left ventricle; PDA, patent ductus arteriosus; PT, pulmonary
trunk; RA, right atrium; RV, right ventricle. (From Perloff JK; The
clinical recognition ofcongenital heart disease, ed 4, Philadelphia,
1994, WB Saunders, p 727.)

mitral atresia, aortic and mitral stenosis, aortic atresia
and mitral stenosis, or aortic stenosis and mitral atresia.
Hypoplasia of the left ventricle is always present, making
it incapable of supporting systemic circulation. The aorta
is always hypoplastic but provides adequate coronary
blood flow in both the preoperative and postoperative
period. The left atria may be small. and an ASD or a
PFO exists. Occasionally the atrial communication can
be restrictive. HLHS is rarely associated with other cardiac anomalies. Associated extracardiac and chromosomal
anomalies may be present, including central nervous system
abnormalities. 3 !
Survival in the newborn period is dependent on a PDA to
maintain systemic circulation. When ductal closure occurs,
and without aggressive medical management, circulatory
shock develops rapidly, and death will result. With HLHS,
systemic venous blood returns to the right atrium normally.
and pulmonary venous blood returns to the left atrium
normally. With no outflow from the left atrium to the left
ventricle, there is a complete left-to-right shunt across an
ASD or a PFO. Mixing of blood occurs in the right atrium.
flows across the tricuspid valve into the right ventricle, and
out the pUlmonary artery. Some blood will flow to the lungs.
and some will shunt right-to-Ieft across the PDA to the aorta.
In the aorta, blood flow will be antegrade to the descending
aorta and retrograde around the aortic arch, head vessels,
ascending aorta, and coronary arteries. The amount of
systemic and pUlmonary blood flow will depend on the
relative resistance of the two vascular beds.
Clinical Presentation and Course. Typically newborns with HLHS present with cyanosis, respiratory distress. and variable degrees of circulatory collapse during the
first 24 to 48 hours of life. When cyanotic congenital heart
disease is suspected. an infusion of PGE 1 should be
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administrated immediately to maintain ductal patency and
sustain systemic circulation. Diagnosis of HLHS is made by
echocardiography. Cardiac catheterization is not necessary
to make the diagnosis. Because of short postpartum hospital
stays, a newborn with HLHS will occasionally be discharged home before diagnosis. Failure to make the
diagnosis can occur when the ductus arteriosus has remained patent and the systemic and pulmonary circulations
are adequately balanced. When the ductus arteriosus eventually closes, the patient will rapidly deteriorate, presenting
"late" with profound shock and signs of mUltiple organ
system failure. If resuscitation is successful, recovery of
end-organ ischemia may be necessary before surgical
palliation. The presence of a restrictive foramen ovale or
ASD will severely limit the left-to-right atrial shunt and
result in inadequate PBF. In this case, the neonate would
present early with severe cyanosis and metabolic acidosis.
In the current era, HLHS is often diagnosed on prenatal
ultrasound or fetal echocardiography. The advantage to
prenatal diagnosis is that the delivery and newborn resuscitation can be arranged before the birth. In fact, prenatal
diagnosis of HLHS is associated with improved preoperative hemodynamics and improved survival following neonatal palliation, compared with neonates diagnosed
after birth. 38
Preoperative Management. A PGE 1 infusion is
initiated immediately on suspicion of HLHS to maintain
ductal patency and ensure adequate systemic circulation. If
end-organ ischemia is present, support and adequate recovery of organ function are critical to provide optimal
conditions for the stage I palliative surgical procedure.
Often these patients require endotracheal intubation, mechanical ventilation, and inotropic support to optimize
hemodynamics. Metabolic acidosis should be aggressively
treated and may require the administration of sodium
bicarbonate or tromethamine.
The overall goal of medical management of any preoperative neonate with single-ventricle physiology is to
provide a balance of the systemic and pulmonary circulations. Newborns with single-ventricle physiology are often
dependent on a large systemic-to-pulmonary communication (the ductus arteriosus) for the delivery of blood to their
lungs or to their systemic circulation. When the ductus
arteriosus is widely patent (PGE J administration), the distal
PVR is often the major determinant of the balance of flow
between the lungs and body. Preoperatively, two major
clinical problems can be seen: pulmonary overcirculation or
pulmonary undercirculation. Pulmonary overcirculation occurs when PBF is so generous that it is at the expense of
systemic output. It is manifested as high systemic saturations (90%), poor peripheral perfusion, and low diastolic blood pressure. Because it is the result of a very
low distal PVR, management strategies are directed at
increasing PVR, which can be achieved by supporting
the infant by ventilation with a hypoxic gas mixture
(17% to 20% oxygen) or by inducing respiratory acidosis
(pH 7.25 to 7.35).
A hypoxic gas mixture is achieved by adding nitrogen to
the gas mix. The resultant decrease in alveolar P0 2 will
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augment pulmonary vasoconstriction and decrease PBF.
Supplemental nitrogen therapy has been shown to be
efficacious in maintaining systemic saturations of about
75% in infants with single-ventricle physiology without
long-term sequelae. J9
Respiratory acidosis may be achieved by decreasing the
minute ventilation or adding CO 2 to the ventilator gas
mixture. Available data suggest that the beneficial effects of
inhaled CO 2 are mediated through resulting respiratory
acidosis. Pulmonary vasoconstriction should result in an
improvement in systemic perfusion, an increase in diastolic
blood pressure, and a decrease in systemic oxygen saturation. 4o Clearly a potential advantage of using inhaled CO2 is
that the respiratory acidosis can be induced without the use
of severe hypoventilation, which may induce atelectasis.
Clearly these therapies have potential morbidity, and
extreme hypoxia and acidosis should be avoided. Pulmonary
undercirculation occurs when the PVR is too high, resulting
in severe hypoxemia despite a PDA. This is often the result
of failure of the PVR to normally decrease at birth, and
management strategies are directed at decreasing PVR. This
can be achieved by providing the infant ventilation with
100% oxygen and inducing an alkalosis (pH 7.50 to 7.55) by
a combination of hyperventilation and sodium bicarbonate
administration. Inhaled nitric oxide may also be beneficial in
this setting.
Typically, pulmonary overcirculation occurs in preoperative patients with HLHS because lowering of PVR in
the newborn period. Oxygen administration is generally
avoided to prevent pulmonary vasodilation and overcirculation. A systemic arterial oxygen saturation of 75% to 80%
usually indicates appropriate PBF.
Surgical Management. Current options for treatment include palliative reconstructive surgery, cardiac
transplantation, and withholding of treatment. With the
more recent improvements in reconstructive surgery and
associated outcomes in some centers, withholding of
treatment has becomes much less common. Cardiac transplantation has had success; however, the lack of available
neonatal donors has made this option less appealing.
Reconstructive surgery along the Fontan pathway has been
the most common approach to the overall management of
neonates with HLHS.
Stage 1 Palliative Reconstruction. The goal of neonatal
reconstructi ve surgery for HLHS is to provide a dependable
source of systemic and pulmonary blood flow. In addition,
efforts are made to provide the best conditions for future
bidirectional cavopulmonary shunt and Fontan operation.
Preventing problems such as ventricular hypertrophy, arrhythmias, pulmonary artery hypertension, tricuspid valve
regurgitation, and pulmonary artery distortion will provide
optimal conditions for later reconstructive procedures.
Success with the staged surgical approach to HLHS was
first described in 1983 41 The first-stage palliation, often
referred to as the Norwood procedure, accomplished two
primary objectives: the establishment of permanent unobstructed flow from the right ventricle to the aorta and
regulation of PBF. Through a median sternotomy and the
use of cardiopulmonary bypass, the ductus arteriosus is

ligated, and the main pulmonary artery is ligated from the
branch pulmonary arteries. An incision is made in the
descending aorta retrograde to the aortic valve, avoiding
injury to the coronary arteries. The pulmonary artery root is
then anastomosed to the aorta, and a homograft patch is used
to augment the wall of the neoaorta (Fig. 18-20). An
aortopulmonary shunt, most commonly a modified BlalockTaussig shunt, is placed to provide the single source of PBF.
An atrial septectomy is performed to allow adequate mixing
of systemic and pulmonary venous blood. Often, hypothermic circulatory arrest is used to perform the aortic reconstruction. However, recent attempts have been made to use
low-flow cardiopulmonary bypass via cannulation in the
head and neck vessels, thereby avoiding the potential
neurologic complications associated with circulatory arrest.
With this reconstruction, systemic and pulmonary venous
blood enter and mix in the common atria, enter the single
right ventricle via the tricuspid valve, cross the native
pulmonary valve, and enter the neoaorta. Blood will flow
antegrade to the systemic circulation, and the coronary
arteries will be perfused during diastole. When blood enters
the aorta, some will flow across the aortopulmonary shunt
into the pulmonary circulation.
Bidirectional Cavopulmonary Shunt. The goal of the
second-stage palliative procedure is to decrease the volume
load of the single ventricle, thereby decreasing work and
preserving myocardial function, tricuspid valve function,
and myocardial perfusion. Typically, the procedure performed is the bidirectional cavopulmonary shunt, commonly called the bidirectional Glenn shunt. Through a
median sternotomy, the superior vena cava is divided from
the right atria and anastomosed to the right branch
pulmonary artery. The modified Blalock-Taussig shunt is
removed, and the cardiac end of the superior vena cava is
oversewn (Fig. 18-21). The azygous vein is usually ligated

Reconmueted AReIIdInll Aorta

Fig. 18-20 Circulatory pathway after Stage I reconstructive surgery for HLHS. RA, Right atrium; Ao-PA shunt, aorta pulmonary
shunt; MPA, main pulmonary artery; lA, left atrium; LV, left ventricle; RV, right ventricle. (From Smith JB, Vernon-Levell P: Care of
infants with HLHS, MeN Clin Issues Crit Care Nurs 4:33, 1993.)
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to decrease a source of decompression of the upper systemic
veins to the atria. Additional surgical procedures that may be
performed at this time to optimize conditions for the Fontan
procedure may include a pulmonary arterioplasty and a
tricuspid valvuloplasty.

Fig. 18-21 Bidirectional superior cavopulmonary anastomosis
(bidirectional Glenn). (From Chang A, Hanley F, Wernovsky G
et al: Pediatric cardiac intensive care, Baltimore, 1998, Williams
& Wilkins.)
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With this anatomy, systemic venous blood from the head
and neck directly enters the pulmonary circulation. The
systemic venous blood from the inferior vena cava enters the
common atria, where it mixes with the coronary sinus and
pulmonary venous blood. This blood exits the heart through
the aorta, resulting in a systemic arterial oxygen saturation
of 75% to 85%. Although this decreases the volume load
and subsequent work of the single ventricle, problems with
this procedure include the late development of arterial
desaturation, pulmonary arteriovenous malformations, and
aortopulmonary collaterals. 42
Fontan Operation. The goal of the third and final
palliati ve procedure is to provide a separation of the
systemic and pulmonary circulations and correct arterial
desaturation. Many revisions of the Fontan operation have
evolved over the years in an attempt to improve the outcome
of patients with single-ventricle physiology. Currently, the
two procedures most commonly performed include the
intraatrial lateral tunnel Fontan and the extracardiac conduit
Fontan.
With the lateral tunnel Fontan operation, a right atrial
incision is made, and a Gore-Tex patch is sewn around
the orifice of the inferior vena cava along the lateral
wall of the right atria toward the superior vena cava. 42
The upper end of the superior vena cava is then anastomosed to the right branch pulmonary artery, creating a
tunnel from the inferior vena cava, through the right atria,
to the pulmonary artery (Fig. 18-22). The superior vena
cava has been previously anastomosed to the pulmonary
artery when the bidirectional cavopulmonary shunt was
performed.

Fig. 18-22 Lateral tunnel cavopulrnonary Fontan procedure. (From Chang A, Hanley F, Wernovski G
et al: 1998) Pediatric cardiac intensive care, Baltimore, 1998.Williarns & Wilkins.)
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Fig. 18-23 Extracardiac Fontan procedure. (From Chang A, Hanley F, Wemovski G et al: Pediatric
cardiac intensive care, Baltimore, 1998, Williams & Wilkins,)

With the extracardiac conduit Fontan operation, the
inferior vena cava is transected from the right atria. A
Gore-Tex conduit is sewn to the inferior vena cava and
connected to the right pulmonary artery (Fig. 18-23).
Possible advantages of this technique include the avoidance
of right atrial suture lines and the elimination of elevated
right atrial pressure, resulting in potentially fewer atrial
arrhythmias and effusions,
With either Fontan operation, all the systemic venous
blood is directly diverted to the pulmonary circulation, The
coronary sinus blood enters the atria, mixes with the
pulmonary venous blood, and is ejected into the systemic
circulation, resulting in a systemic arterial oxygen saturation
of approximately 95%. In some cases an atrial fenestration
(connection from the systemic venous connection to the left
atrium) may be inserted, which allows shunting of systemic
venous blood to the atria in the event of elevated pulmonary
artery pressure, thereby preventing complications of low
cardiac output and effusions.
Postoperative Management
Stage 1 Palliative Procedures. The primary goals in the
postoperative management of complex reconstructive procedures, such as the Norwood procedure, include the
management of low cardiac output and balancing of the
systemic and pulmonary circulations, Low cardiac output is
managed with continuous infusions of inotropic and
afterload-reducing agents. Volume administration is given
judiciously to avoid distension of the single ventricle.
Hemodynamics are monitored closely, and signs of low
cardiac output, including poor peripheral perfusion, oliguria, tachycardia, hypotension, and metabolic acidosis,
should prompt aggressive intervention. Delayed sternal

closure is often performed to prevent mechanical cardiac
tamponade in the early postoperative period. The hematocrit
is maintained greater than 45% to improve oxygen delivery
in the face of chronic arterial desaturation. Oxygen demand
is minimized with the aggressive management of pain and
agitation and the careful performance of nursing procedures,
Procedures, such as suctioning and dressing changes, must
be performed carefully to avoid a stimulus response that
may result in acute hemodynamic deterioration. Acid-base
abnormalities should be aggressively treated to avoid further
depression of myocardial function.
Similar to the preoperative setting, infants with singleventricle physiology who have a systemic-to-pulmonary
communication as their source of PBF (i.e., Norwood
procedure) may suffer from postoperative pulmonary overcirculation or undercirculation. In this setting, altering the
PVR, as previously described, may be lifesaving. In the
postoperative period, however, it must be remembered that
the surgically placed systemic-to-pulmonary communication (vascular shunt) may need to be modified if these other
measures fail.
Bidirectional Cavopulmonary Anastomosis. Postoperative management of these patients is fairly straightforward.
Typically, these patients can be extubated within 12 to
24 hours of surgery. Inotropic infusions are common after
the use of cardiopulmonary bypass, Two important postoperative management issues following the bidirectional
Glenn procedure include the assessment of elevated superior
vena cava (SVC) pressure (SVC syndrome), and hypoxemia. SVC syndrome can be the result of an obstruction at
the anastomosis site, pulmonary artery distortion, or elevations in PVR 42 Clinical signs include upper body plethora
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and edema, with demarcation across the chest. Significant
elevations in SVC pressure can limit cerebral blood flow and
result in cerebral ischemia. Prevention and management
strategies include elevating the head of the bed and keeping
the head and neck midline. This positioning optimizes
passive flow of blood from the head and neck to the
pulmonary circulation. If PVR is elevated, vasodilation with
oxygen and afterload-reducing agents may be necessary.
Frequent nursing evaluation for the development of SVC
syndrome, along with examination of the neurologic status,
is critical in the postoperative period because an increase in
SVC pressure can be detrimental to cerebral perfusion.
Atrial pressure is maintained at 6 to 8 mmHg to avoid
interference with pulmonary venous return to the heart.
Hypoxemia with Glenn physiology may be caused by
pulmonary venous desaturation (pneumothorax, pleural
effusion, pulmonary edema), systemic venous desaturation
(anemia, low cardiac output), or decreased PBF (elevated
PVR, pulmonary venous hypertension).42 When the systemic arterial oxygen saturation is less than 70%, careful
evaluation for these problems must be performed to identify
the cause and provide the appropriate treatment. Careful
respiratory assessment along with radiographic examination
will provide critical information regarding the cause of
hypoxemia. The patient's hematocrit should be maintained
at greater than 45% to optimize oxygen delivery compensating for the cyanosis.
Fontan Operation. The postoperative management of
patients after the Fontan operation may be dependent on the
type of procedure performed and the preoperative hemodynamics. Postoperative complications include low cardiac
output, hypoxemia, and effusions. Low cardiac output after
this operation is commonly caused by myocardial dysfunction or inadequate preload. Preload is completely dependent
on adequate PBF and pulmonary venous return to the single
ventricle. Therefore an elevation in PVR becomes a major
contributing factor in the development of low cardiac
output. Elevations in PVR may be demonstrated by a low
atrial pressure and an elevated systemic venous pressure. If
a fenestration is present, right-to-left shunting can occur,
providing adequate cardiac output in the face of elevated
PVR. Any obstruction in the systemic veins could also result
in inadequate PBF and low cardiac output. Myocardial
dysfunction is supported with the use of continuous
infusions of inotropic and afterload-reducing agents. Volume administration is frequently needed, particularly when
effusions result in excessive loss of fluid.
The cause of cyanosis in these patients is similar to that
seen with bidirectional Glenn physiology. In particular,
patients with Fontan physiology are at risk for the development of pleural effusions, which can result in hypoxemia. Vigilant pulmonary assessment along with radiographic examination is critical to determine the cause of
hypoxemia in these patients. When a fenestration is
present, cyanosis may be the result of right-to-left shunting
of blood. Typically, systemic arterial oxygen saturation in
unfenestrated patients is 95% to 97%. When a fenestration is present, the saturation depends on the amount of
shunting.
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PBF in these patients is completely dependent on passive
flow from the systemic circulation to the pulmonary
circulation. This results in a natural elevation of systemic
venous pressure, and any rise in PVR will further elevate
systemic venous pressure. These mechanisms result in the
leaking of serous fluid from the systemic veins to the
extravascular spaces. Pleural effusions, pericardial effusions, and ascites can develop. Chest tube output must be
carefully monitored to provide an adequate assessment of
fluid intake and output. Fluid replacement may be necessary
if losses become excessive. Diuretic therapy is frequently
administered to decrease the systemic venous pressure and
volume, potentially preventing the development of effusions. Typically, effusions resolve within I to 2 weeks
following surgery once the systemic veins have adapted to
higher pressures.
Infants and children who undergo procedures in which
caval-to-pulmonary communications are used (Glenn or
Fontan procedures) are dependent on a low PVR to maintain
adequate PBF and systemic output. Because PBF is
passively driven, minor increases in PVR may have
profound physiologic effects in the postoperati ve period.
Sedation, ventilator, and vasodilator strategies should be
implemented as described for patients with pulmonary
hypertension. However, despite these measures, these children have a very high morbidity and mortality rate.
Problems with increased PVR in this patient population
often indicate unfavorable physiology, Surgical options
(fenestration of the Fontan, takedown of the Glenn or
Fontan) must be considered before significant multisystem
organ dysfunction results.

Cyanotic Congenital Heart Defects
With Variable PBF
Some complex cyanotic CHDs present with a number of
anatomic variations that result in alterations in the volume of
PBF. Complete transposition of the great arteries is a
common defect in this group, whereas all others (doubleoutlet right ventricle, double-inlet left ventricle, and single
ventricle) are rare. These last defects are not discussed in
this text.
Transposition of the Great Arteries. In transposition of the great arteries (TGA), the aorta arises from the
morphologic right ventricle and the pulmonary artery from
the morphologic left ventricle. The most common form of
TGA occurs when the ventricles are normally positioned
and the aorta is anterior and to the right of the pulmonary
artery (D-TGA). Coexisting cardiac lesions occur in about
one half of infants with TGA. The most common is VSD
(with or without subpulmonary stenosis), coarctation or
interrupted aortic arch, and coronary artery abnormalities.
Between the third and fourth week of gestation, the
truncus arteriosus is divided into the pulmonary artery
and the aorta. This results from spiral growth of the
conotruncal ridges. Failure of the conotruncal ridges to
spiral or rotate completely results in transposing of the aorta
and the pulmonary artery relative to the ventricles. Therefore the aorta arises from the right ventricle, and the
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pulmonary artery arises from the left ventricle. Without a
PDA, PFO, ASD, or VSD, the result will be two parallel
circulations.
D-TGA, as initially described here, is contrasted to
corrected transposition of the great arteries (L-TGA).
Corrected transposition exists when the morphologic right
and left ventricles and AV valves are transposed. This results
in the pulmonary artery arising from the systemic venous
ventricle (right-sided, morphologic LV), and the aorta
arising from the pulmonary venous ventricle (left-sided,
morphologic RV). Therefore systemic venous blood (desaturated) flows to the pulmonary artery and pulmonary venous
blood (saturated) to the aorta, and cyanosis is not present.
L-TGA can occur in isolation or in combination with other
structural defects and is often associated with progressive
heart block. Heart failure can occur in young adulthood
because the morphologic RV serves as the systemic pump,
a function that it is not structurally intended to perform for
a prolonged period. The rest of this section focuses on the
identification and treatment of D-TGA.

The child with D-TGA essentially has two independent
parallel circuits of circulation. Venous blood from the body
flows to the right atrium, to the RV, and out the aorta to the
body and returns again to the right atrium. Thus systemic
perfusion is with persistently desaturated blood. Oxygenated blood from the lungs flows to the left atrium, LV, and
out the pulmonary artery to the lungs and returns again to
the left atrium. Thus the lungs are perfused with completely
saturated blood. The systemic arterial oxygen saturations are
dependent on adequate mixing with oxygenated blood.
Immediately after birth, the PDA and PFO are present.
These two structures allow mixing at the level of the
great arteries (bidirectional between aorta and pulmonary
artery through PDA) and the atrium (left to right through the
PFO) until the normal postnatal changes occur that induce
ductal and PFO closure (Fig. 18-24). Survival in these
patients is predicated on maintaining mixing until surgical
correction. 43
The infant with D-TGA and VSD generally has adequate
mixing across the VSD (bidirectional) and the PFO (left to
right).44 Desaturated blood will go from the RV to the
LV, and saturated blood will go from the left atrium to the
right; therefore these patients are only mildly cyanotic
but can develop pulmonary overcirculation when PVR falls
(Fig. 18-25).
D-TGA, VSD, and pulmonary stenosis (PS) may have an
appropriate amount of mixing with protection of the
pulmonary vascular bed (by PS) without pulmonary overcirculation. The degree of PBF is determined by the degree
of PS, which can be quite variable. Frequently the PS will

Transposition
Fig. 18-24 Diagram of circulatory pathways in transposition of
the great arteries. AO, Aorta; pv, pulmonary vein; LA, left atrium;
RA. right atrium; LV, left ventricle; RV, right ventricle; PA, pulmonary artery; Sv, systemic vein; PDA, patent ductus arteriosus.
(From Garson A, Bricker JT, Fisher OJ et aJ: The science and
practice of pediatric cardiology, Baltimore, 1998,Williams &
Wilkins.)

Fig. 18-25 Diagram of transposition of the great arteries indicating the possihle sites of mixing of blood between systemic
and pulmonary circulations (arrows). AO, Aorta; PA, pulmonary artery; LV, left ventricle; RV, right ventricle; RA, right atrium.
(From Garson A, Bricker JT, Fisher OJ et aJ: The science and
practice of pediatric cardiology, Baltimore, 1998, Williams &
Wilkins.)
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progress; therefore PBF will decrease, and the infant will
become progressively cyanotic. 45
Clinical Presentation and Course. Table 18-7 summarizes the clinical findings in infants with TGA. In infants
with simple D-TGA (without VSD), once the PDA closes,
the infant will develop significant metabolic acidosis,
cyanosis, and ultimately death if not treated. Those with
associated defects may be acyanotic or only mildly cyanotic.
Echocardiogram is sufficient to make the diagnosis;
cardiac catheterization is only required if concerns remain
about coronary artery anatomy or associated structural
defects.
Management. Management in the newborn is aimed
at ensuring adequate mixing and supporting systemic
oxygen delivery. Maintaining patency of the PDA with
prostaglandins will increase PBF and mixing. In addition,
balloon atrial septostomy is performed to augment mixing
and to decompress the volume load of the left heart.
Septostomy can be performed at the bedside under echocardiographic guidance or in the catheterization laboratory."
Rarely will an infant not respond to PGE 1 or balloon
septostomy. These children will have persistent cyanosis,
poor perfusion, and metabolic acidosis. Intravenous inotropes are instituted to support contractility. If pulmonary
hypertension is the cause of poor mixing, then maneuvers to
decrease PVR are implemented (oxygen, alkalosis, nitric
oxide). Some will require emergent surgery; however, these
unstable infants can have a difficult postoperative course.
Digoxin and diuretic therapy are indicated in the infant with
large VSDs and CHF.
Surgical Management. Surgical repair of TGA is an
example of progress and "change" in pediatric cardiac
surgery that has occurred over the last 30 to 40 years. Some
of the progress is the result of interest in "old" ideas. The
first repairs of TGA were attempts at anatomic correction,
that is, placing the pulmonary artery and aorta in their
normal anatomic positions. These operations, performed by
Bai ley and colleagues in 195446 and by Kay and Cross in

TABLE 18·7

iitVncomplicated TGA
';!:
i!

[~TGA

:i~TGA

"

with VSD

with VSD and
sub-PS
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1955,47 did not include transfer of the coronary arteries and
resulted in universal mortality. Mustard and co-workers also
performed an anatomic correction in 1954, with transfer of
the left coronary artery, but also without success.
The focus of attempts to repair TGA then shifted from
anatomic correction to "physiologic repair" by rerouting
pulmonary and systemic venous return through a baffle of
Dacron or pericardium, such that each atrium emptied into
the opposite ventricle (atrial switch procedure; Fig. 18-26).
First successfully applied by Senning,4S the procedure was
modified by Mustard. 49 Although risk of mortality was low,
long-ternl complications became apparent. Complications
include systemic (right) ventricular dysfunction, heart failure, exercise intolerance, and symptomatic atrial arrhythmias 50 .51 In general, the Mustard and Senning procedures
are no longer performed for straightforward TGA. However

Fig. 18·26 Atrial switch procedure, whereby atrial septum is
excised and atrial baffle is placed. Short, curved arrows designate
systemic venous flow through the baffle toward the mitral valve
(MV), left ventricle, and pulmonary artery. Bold arrow indicates
pu Imonary venous flow behind and around the baffle to the
tricuspid valve (IV), right ventricle, and aorta. lVe. Inferior vena
cava; SVC, superior vena cava. (From Emmanouilides GC,
Riemenschneider TA, Allen HD et al: Heart disease in infants,
children. and adoiescellls. Baltimore, 1995. Williams & Wilkins.)

Cyanotic Congenital Heart Defects With Variable Pulmonary Blood Flow (TGA)
Cardiac Examination

Electrocardiogram

Radiograph

Murmur may not be present,
single S2

Right ventricular hypertrophy,
possible right atrial hypertrophy, right axis deviation; may
be normal in newborn
Right ventricular hypertrophy
or biventricular hypertrophy

Cardiomegaly, narrow mediastinum, increased pulmonary
vascular markings; may be
normal in newborn
Cardiomegaly, narrow mediastinum. increased pulmonary
vascular markings

Right ventricular hypertrophy

Cardiomegaly, narrow mediasti·
num, decreased pulmonary
vascular markings

Single S2; holosystolic murmur
best heard at fourth ICS to
left of sternum; thrill may
be present
Single S2; holosystoJic murmur;
ejection systolic murmur best
heard along left sternal
border

Intercostal space; 52' second heart sound: sub-PS, subvalvuJar pulmonary stenos.is; TGA, transposition of the great arteries; VSD, ventricular septal

~'defecl.
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surgical innovations have resurrected this procedure for
select patients with complex AV and ventriculoarterial
discordance. The so-called double-switch procedure uses
the atrial (Mustard or Senning) and arterial switch procedures in an anempt to provide functionally normal hemodynamics. 52
Even before recognition of the long-term problems
associated with atrial correction of TGA, attempts at
developing a successful method of anatomic correction
continued. Interest heightened as complications of older
procedures became apparent. Jatene and associates 53 performed the first successful arterial switch operation (ASO)
in 1975. Initially, the ASO was used only in infants
diagnosed with TGA and a VSD. Use of the ASO was later
expanded to include those patients with TGA and intact
ventricular septum (IVS). Currently, the ASO is performed
with the same low mortality expected with either atrial
correction and is the operation of choice for infants with
TGA. ASO consists of transecting the aorta and pulmonary
artery and reanastomosing the great arteries to the correct
ventricle (i.e., PA to RV and aorta to LV). Transection of the
great artery is performed above the semilunar valve;
therefore the native pulmonary valve becomes the new
aortic val ve, and visa versa. The coronary arteries must also
be moved to the new aortic connection. Significant PS may
preclude the ASO because PS will become aortic stenosis
after the arterial switch. These patients may require an atrial
switch repair or an RV-to-PA conduit.
After the arterial switch, the left ventricle must be able to
eject against systemic resistance. Timing for surgical repair
is critically important because the LV will not be able to
function against systemic resistance if surgery is delayed.
This is due to the fact that the LV has become "deconditioned" because it has only been required to support the
low-resistance pulmonary vascular circuit. The exact time
when the LV becomes deconditioned is unknown, but
clinical experience would suggest that the LV remains
adequately prepared for at least 2 to 4 weeks after birth. 43
The exception would be a large unrestricted VSD in which
the LV and RV pressures are equal or the presence of PS. In
some infants who present late or in older patients with failed
atrial baffle procedures, concerns may arise about LV
function and ability to support systemic circulation. Under
these conditions a two-stage procedure may be undertaken
in select patients.54 The stages include banding of the
pulmonary artery to increase LV pressure (and work),
followed in a few days by the arterial switch and takedown
of the PA band.
After the ASO, myocardial ischemia or arrhythmias
resulting from the operative transfer of the coronary arteries
may occur. Ultimately this will produce left ventricular
dysfunction and possibly failure. This effect is manifested as
an increase in LA pressure, worsening mitral regurgitation,
poor peripheral perfusion, low blood pressure, and metabolic acidosis. Inotropic support is initially instituted, and
mechanical support can be implemented for those infants
who fail medical management.
Described and possible late complications include supravalvar PS, failure of the native pulmonary valve to

function in the aortic pOSItion, RVOTO, and possible
coronary artery abnormalities55

PERIOPERATIVE MANAGEMENT
OF PEDIATRIC CARDIAC
SURGICAL PATIENTS
Advances in the surgical management of infants and
children with CHDs have significantly affected postoperative management and outcomes. Improved understanding of
the anatomy and pathophysiology of structural defects and
neonatal physiology, along with technologic advances in
hypothermia, cardiopulmonary bypass, circulatory arrest,
critical care management, and pharmacologic intervention,
have combined to improve postoperative outcomes.56 Currently, many complex lesions are amenable to partial or
complete repair during infancy.
Repair of CHD early in life can prevent or diminish the
pathologic sequelae that result from prolonged abnormal
hemodynamics and cyanosis. However, unique features of
the physiologic responses of young cardiac surgery patients
continue to provide challenges to nurses and physicians
involved in their care.
Following birth, parents of critically ill infants are often
faced with the immediate transport of their infant to a
tertiary care center that is specifically equipped to treat
infants with congenital heart disease. Transport to a center
many miles away is coupled with the stress of unexpected
surgical intervention necessary to treat their newborn.
Prenatal diagnosis permits planning to expedite the management of the infant known to have a heart defect,57 as well
as affording time for parental preparation and education. In
addition, parents of older infants and children may not have
their usual support system immediately available and are
therefore not immune to the stress of cardiac surgery.

Preoperative Preparation
An uncomplicated operative and postoperative course for
cardiac surgery patients begins with preoperative assessment and preparation. All infants and children must have a
careful history and physical examination conducted before
surgery. It is important to evaluate for the presence of acute
illnesses (upper respiratory infection, pneumonia, otitis
media) that would necessitate rescheduling elective surgery.
Chronic medical problems, such as diabetes, asthma,
arrhythmias, and seizure disorders, .that would require
special management are identified.
Routine laboratory and radiology assessments are performed. A chest radiograph is obtained on all patients. For
those children having closed heart operations of an elective
nature, generally only a complete blood count and urinalysis
are required. Seriously ill patients and those scheduled for
open heart operations generally have coagulation studies,
platelet count, and serum electrolytes obtained in addition.
These tests may identify problems that would require
correction before or special attention during surgery.
Newborn infants with severe obstructive CHDs may
present with severe heart failure, poor perfusion, oliguria,
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and acidosis, or severe cyanosis as the ductus arteriosus
closes. Stabilization can be achieved for some with PGE!.
Infants with ductal-dependent heart lesions can be stabilized
when ductal patency is maintained, thereby increasing
systemic oxygenation. Preoperative measures to stabilize
the infant's physiologic status may prevent emergency
surgery in a very ill baby and possible subsequent end-organ
complications.
Another necessary prelude to corrective cardiac surgery
in some patients is the demonstration that PYR is either low
enough to allow safe surgery or can be lowered sufficiently
to allow recovery from surgery. Therefore cardiac catheterization' which allows the calculation of baseline PYR and
response to vasodilator therapy, has been the standard
method of preoperative evaluation of the pulmonary circulation. Unfortunately, this approach is not a very sensitive
indicator of perioperative morbidity and mortality. For
example, the fact that baseline PYR is high and cannot be
lowered does not prove that surgery cannot be performed
safely, and the fact that PYR can be lowered at cardiac
catheterization does not ensure a safe postoperative course.
In addition, exactly how high the PYR must be to preclude
surgical repair is uncertain. PYR more than 15 Wood units
is associated with very poor short- and long-term results,
although notable exceptions exist. For example, if the
patient has coexisting pulmonary disease, recatheterization
after intensive pulmonary therapy may show a decrease in
PYR. Similarly, if the patient lives at altitude, recatheterization after 4 or more weeks of oxygen therapy may show
a decrease in PYR. More studies are necessary to identify
better predictors of postoperative morbidity secondary to
pulmonary hypertension. 58

Perioperative Techniques
Since the introduction of the heart-lung machine nearly 40
years ago, efforts have continued toward the development of
safe and reliable methods to control circulation during
cardiac surgery. Refinement of these methods has improved
outcomes over the past years; nonetheless, cardiopulmonary
bypass, hypothermia, circulatory arrest, and aortic cross
clamping can precipitate physiologic derangements in major
organs during surgery that continue into the postoperative
period. 59
Cardiopulmonary Bypass. Cardiopulmonary bypass (CPB) provides tissue perfusion and oxygenation
through the use of a mechanical pump and oxygenator,
thereby bypassing the patient's own heart and lungs. To
reroute blood, cannulas are placed in the right atrium and in
the ascending aorta. Blood is removed from the right atrium,
circulated through the oxygenator, and returned to the
ascending aorta. Balanced crystalloid priming solution or
citrated whole blood are used to prime the pump and dilute
the hematocrit to 20% to 25%59 Heparin is used to prevent
clot formation within the circuit and oxygenator.
Myocardial Protection. Bypass of the heart and
lungs necessitates attention to protection of the myocardium
during cardiac surgery. Both hypothermia and chemical
preservation of the myocardium are currently employed.
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Hypothermia and Circulatory Arrest. Moderate
(20° to 25° C) and deep (15° to 18° C) hypothermia
decreases the body's oxygen consumption, thereby protecting the brain and other vital organs during low circulatory
flow with CPB. The protective effect of hypothermia is
generally attributed to decreased cellular metabolic activity,
reflected by both decreased oxygen consumption and
glucose use. Core or surface cooling may be used singly or
in combination. Surface cooling begins before the incision is
made and is facilitated by decreasing the environmental
temperature and through the use of hypothermia blankets or
ice packs. Core cooling is accomplished using the heat
exchanger in the bypass circuit. Heart rate and blood
pressure decrease as body temperature falls, with asystole
generally occurring between 22° to 24° C. In deep
hypothermia, cooling is continued to a body temperature of
less than 20° C. With deep hypothermia, circulatory arrest
(the cessation of CPB) can be used. This method allows
removal of intracardiac cannulas, thereby providing the
surgeon an unobstructed surgical field, which enables repair
of complex defects on very small patients.
Most data regarding the physiologic changes of organ
systems associated with hypothermic circulatory arrest are
based on animal research. Overall, these studies indicate
that relatively short periods of hypothermic arrest are not
associated with significant end-organ injury or dysfunction.
Nevertheless, potential complications include renal insufficiency, necrotizing enterocolitis, liver necrosis, and atelectasis secondary to a low-flow state.
Impairment of the functional integrity of the brain after
hypothermia and circulatory arrest has been the focus of
intensive investigation since the I 960s. Experimental animal studies indicate that cerebral hypothermia protects
against the development of, although it cannot prevent, metabolic and structural changes that lead to functional neurologic impairment59 Prolonged periods of cerebral hypothermia, without circulatory arrest, produce irreversible brain
injury in animal models. Adverse neurologic sequelae after
periods of hypothermia and circulatory arrest include seizures, choreoathetosis, paresis, rigidity, muscular hypotonia,
intellectual impairment, coma, and death. 59 A period of 45 to
60 minutes of hypothermia and circulatory arrest is judged
to be "safe. ,,59 A nomogram can be used to estimate the
probability of a "safe" circulatory arrest time (Fig. 18-27).
Aortic Cross Clamping and Chemical Myocardial
Protection. With initiation of CPB and cooling, the aorta
can be cross clamped to prevent backflow into the left
ventricle, thereby creating a bloodless surgical field. Decreasing metabolic and oxygen requirements with hypothermia achieves some myocardial protection from ischemia.
During CPB, electromechanical arrest is also achieved via
an injection of hypothermic (4° C) cardioplegic solution into
the aortic root. This results in immediate cessation of cardiac
activity. Although it is protective in the older infant and
child, efficacy of cold cardioplegia for myocardial protection in the immature myocardium remains to be defined.
The ideal cardioplegia solution would provide rapid and
complete cardiac arrest, maintain the myocardial electrolyte
environment, deliver substrates, wash out metabolites, and
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Fig. 18-27 Nomogram of probably safe circulatory arrest times
in patients at various degrees of hypothermia. (From Kirklin JW,
Barratt-Boyes BG, eds: Cardiac surgery, ed 2, New York, 1993,
John Wiley & Sons, p 74.)

maintain cellular pH at a protective level. 6o Although many
different solutions are used in cardiac surgery today, the
search for a "perfect" solution continues. Most cardioplegic
solutions are similar to extracellular fluid, with the exception of large amounts of added potassium to induce diastolic cardiac arrest. Increased concentrations of potassium
and magnesium (another component of cardioplegia) are
thought to prevent calcium influx, inhibit calcium release
from the sarcoplasmic reticulum, and reduce mitochondrial
uptake of calcium. This approach is believed to be protective because calcium release and uptake may be related to
ischemic cell membrane damage and to subsequent myocardial cellular swelling and death. Cardioplegic solutions provides myocardial protection because the heart is ideally
maintained in diastole with minimal metabolic requirements
and rebeating is prevented.
Rewarming. When the intracardiac repair is completed, surface and core warming are begun. If circulatory
arrest is used, then CPB is resumed and the aortic cross
clamp removed. Spontaneous ventricular contractions usually occur at a temperature of 30° to 32° C. If the heart does
not begin to beat spontaneously, electrical defibrillation may
be needed. When the body temperature is nearly normal,
bypass is discontinued.

Potential Postoperative Complications
The potential for complications is high following cardiac
surgery in infants and children. Timely assessment, identification, and intervention improve outcomes.
Inadequate Tissue Perfusion, Tissue perfusion is
dependent on the adequacy of cardiac output, which in the
immediate postoperative period may change rapidly. Continuous assessment of the patient's hemodynamic status by
evaluating peripheral pulses and temperature of the extremities, capillary refill, core temperature, arterial blood pressure, and filling pressures are key to the early identification
of problems. Tissue perfusion is dependent on myocardial
contractility, intravascular volume (preload), resistance to

ventricular ejection (afterload), and heart rate. Low cardiac
output and impaired perfusion can be the consequence of
(I) decreased intravascular volume from excessive losses,
inadequate replacement, cardiac tamponade, or excessive
diuresis; (2) increased systemic or pulmonary vascular
resistance from vasoconstriction or hypertension; (3) decreased ventricular contractility from myocardial injury
secondary to inadequate intraoperative protection, hypoxia,
acidosis, or electrolyte imbalance; (4) alteration in heart
rate or rhythm; or (5) inadequate intracardiac repair with
residual shunts or valve lesions. These causes are summarized in Table 18-8.
Inadequate Intravascular Volume. Adequate preload is essential to maintain cardiac output. Postoperatively,
volume replacement may be necessary because of postoperative bleeding, expansion of the vascular space during
rewarming, third spacing of fluid, or diuresis. Postoperative
bleeding may be surgical or due to inadequate heparin
reversal at the end of CPB. Coagulation disorders are
assessed and corrected. Surgical bleeding is suspected when
chest tube drainage is greater than 3 ml/kg/hr for over 3
hours or 5 to 10 mllkg in any I hour. Volume loss of this
nature is significant in light of total blood volume in infants
and children (i.e., neonates, 85 to 90 ml/kg; infants, 75 to
80 mllkg; children, 70 to 75 mllkg) and may require
reoperation.
The type and amount of fluid administered when preload
is inadequate are based on the patient's hematocrit and the
nature of the fluid lost. Packed red blood cells are
administered to patients who are bleeding or have a
significantly decreased hematocrit. Optimal hematocrit is
dependent on patient condition, operative procedure, hemodynamics, and residual defects. Fresh frozen plasma or
cryoprecipitate are administered to replace clotting factors.
To treat hypovolemia unrelated to bleeding, colloid or
crystalloid may be infused. Boluses of fluid or blood are
administered in volumes of 10 mllkg over several minutes
while filling pressures are carefully assessed. In general,
increasing LAP to greater than 14 to 16 mmHg rarely
provides any additional improvement in cardiac performance and may contribute to left ventricular dysfunction.
Tamponade. Cardiac tamponade causes compression
of the atria, restricts venous return to the heart, and results
in decreased ventricular preload. Because early cardiac
tamponade results from persistent surgical bleeding not
being sufficiently evacuated by the chest drains, mediastinal
or chest drainage tubes must be kept patent. Signs of
potential or real tamponade include abrupt cessation of chest
tube output, elevated venous pressures, equalization of atrial
pressures, neck vein distension, systemic arterial hypotension, and narrow pulse pressure. Associated hypotension
may not be responsive to volume administration. Cardiac
tamponade necessitates prompt intervention, such as Fogarty striping of chest tubes or surgical reexploration to
evacuate the pericardial hematoma and control bleeding.
Occasionally, in infants following complex surgery
myocardial swelling, chamber dilation, respiratory compromise, persistent bleeding, or the need for ECMO will
prevent chest closure at the conclusion of surgery. Leaving

Chapter 18

TABLE 18·8

Cardiovascular Critical Care Problems

623

Differential Diagnosis of Inadequate Tissue Perfusion

Cause

Critical Signs·

Inadequate Preload
Fluid volume deficit
Increased losses
Inadequate replacement
Cardiac tamponade
Pericardia! hematoma
Myocardial swelling

Low ventricular filling pressures
LAP. RAP <3-5
CYP <5-8
Acute increase in filling pressures
LAP, RAP, CYP rise
Acute decrease in chest drainage

Excessive Afterload
Increased SYR
Decreased tissue perfusion
SNS stimulation
Increased PYR
Hypoxia, hypercarbia
Suctioning
Agitation, pain

Normal to increased systemic arterial pressure
Cool, mottled extremities
Decreased peripheral pulses
Acute rise in PA pressures
Cyanosis
Bradycardia
Death (a potential consequence)

Myocardial Dysfunction
Chemical
Hypothermia
Acidosis
Electrolyte imbalance
Hypoxia
Functional
Preoperative dysfunction
Prolonged ischemic time
Residual hemodynamic problems
Cardiac rhythm disturbances

';~Seen in addition to the typical clinical signs of inadequate tissue perfusion.

High ventricular filling pressures
LAP, RAP >12
CVP >15-18

ECG abnormalities
.

~;CVP, Central venous pressure; ECG, electrocardiogram; VIp, left atrial pressure; RAP, right atrial pressure; SNS, sympathetic nervous system.
Eii-

the sternum open with the mediastinum covered with an
impermeable dressing is an option in this scenario. Once
myocardial swelling or bleeding has subsided and both
cardiac and pulmonary function have stabilized, the sternum
can be closed electively in the PICU usually 2 to 3 days after
surgery. Adjustment of ventilatory settings and inotropic
support may be indicated after chest closure because
significant changes in hemodynamics and respiratory physiology can occur. 61
Increased Systemic A fterload. Increased systemic
vascular resistance (SVR) is most often the consequence of
SNS stimulation in an attempt to compensate for low cardiac
output. Increased SVR may be poorly tolerated in the
postoperative period if myocardial performance is already
near maximal levels or if ventricular function is depressed.
Elevated SVR is signaled by normal to increased systemic
arterial pressure accompanied by cool, mottled extremities;
delayed capillary refill; poor peripheral pulses; and metabolic acidosis. Treatment is aimed at reduction of afterload
with vasodilator therapy.
Pulmonary Hypertension. The status of the pulmonary circulation is crucial in the perioperative management
of many children with congenital heart disease. This is most
pronounced is two subgroups of patients: those with
increased PBF or increased pulmonary venous pressure, in

which the development of pulmonary hypertension could
increase perioperative morbidity or mortality, as well as
exclude surgical options, and those with single ventricle
physiology, in which the status of the pulmonary circulation
will not only determine the level of oxygenation but also
determine systemic output.
Chronic and acute elevations in PVR remain a major
source of morbidity and mortality following surgical correction of congenital heart disease. Chronic elevation in
PVR results from structural changes of the pulmonary
vascular bed that decrease cross-sectional area. After
successful surgery, if these structural changes are reversible,
PVR will begin to decrease in the postoperative period.
However, complete normalization of the structural changes
may take months 26 ; therefore postoperatively the right
ventricle may work against an elevated PVR for a prolonged
period. Acute elevation in PVR results from the active
contraction of structurally abnormal pulmonary arteries
during a period of extreme vasoreactivity in the immediate postoperative period. This decreases cardiac output,
produces acidosis and hypoxemia, and may result in
significant morbidity and mortality. This period of extreme
vasoreactivity is caused by the degranulation of platelets
and leukocytes following CPB and hypothermia, with the
subsequent release of potent vasoconstrictors. The postop-
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erative management of patients with preoperative increases
in pulmonary arterial pressure and PYR is directed at
preventing acute pulmonary hypertensive crises during this
period of extreme vasoreactivity and subacute support of the
right ventricle. 62 Care of these children can be quite
challenging and requires a thorough understanding of the
pulmonary circulation.
Immediately after surgery with CPB, a period of enhanced pulmonary vascular reactivity is seen in children
with preoperative pulmonary hypertension. 63 This period of
enhanced reactivity, which may last up to approximately
5 to 7 days after CPB, is most likely a manifestation of
altered endotheliaUsmooth muscle cell interactions in a
previously altered pulmonary circulation. During CPB,
several factors, including the disruption of normal PBF,
complement activation, and neutrophil activation, induce
pulmonary vascular endothelial dysfunction. For example,
impaired endothelium-dependent pulmonary vasodilation,
altered eicosanoid metabolism, abnormal von Willebrand
factor (a marker of endothelial injury), and ultrastructural
changes of the pulmonary vascular endothelium have all
been noted in patients after undergoing CPB. This results in
increased vasoconstricting factors produced by the endothelium, such as endothelin I and thromboxane A2 , and
decreased vasodilating factors, such as nitric oxide.
Acute increases in PVR initiate a cascade of cardiopulmonary interactions that may lead to cardiovascular collapse. During pulmonary hypertensive crises, there is an
acute increase in right ventricular afterload, producing right
ventricular ischemia and failure. The resulting increase in
right ventricular end-diastolic volume shifts the intraventricular septum to the left, decreasing left ventricular volume
and cardiac output. Decreased cardiac output results in
decreased systemic perfusion and metabolic acidosis. Increased PYR and right ventricular failure also decrease PBF,
leading to increased dead space ventilation. Distension of
the pulmonary arteries and peri vascular cuffing with edematous fluid produce large and small airway obstruction,
respectively, worsening ventilation/perfusion mismatch and
lung compliance. Clinically, this may be manifested as
inability to move the chest wall with mechanical ventilation;
accidental extubation or pneumothoraces should also be
considered. These ventilatory derangements produce hypoxemia and hypercapnia. The resulting acidosis (either
metabolic or respiratory) and hypoxia further increase PYR,
perpetuating this cascade. 64
Prevention of pulmonary hypertensive crises is accomplished by avoiding those stimuli known to increase PYR,
including hypoxia, acidosis, agitation, overdistension of
the lung, and polycythemia. Alveolar hypoxia with systemic arterial hypoxemia and acidosis (metabolic or respiratory) increases PYR; their combination is synergistic.
Agitation and pain acutely increase PYR secondary to
catecholamine release and receptor activation 62 .64 Positive
pressure ventilation with high peak inspiratory and endexpiratory pressures overdistend the lung and increase PYR.
However, the appropriate use of positive pressure ventilation improves ventilation and oxygenation, which decreases
PYR. Polycythemia (hematocrits >55%) increases blood
viscosity and PYR.

Myocardial Dysfunction. Low cardiac output may
be due to myocardial dysfunction when signs of inadequate
tissue perfusion are accompanied by increased filling
pressures. Drugs, anesthesia, ischemia, hypoxia, acidosis,
extensive ventriculotomy, myocardial resection, or residual
hemodynamic abnormalities may depress myocardial performance. Both inotropic and afterload-reducing agents are
useful in improving cardiac performance. If pharmacologic
therapy is ineffective, a mechanical assist device or ECMO
may be useful.
Cardiac Rhythm Disturbances. Cardiac arrhythmias
are not uncommon after cardiac operations. Temporary
epicardial pacing wires are often placed before leaving the
operating room. Although many arrhythmias do not require
treatment because hemodynamics are not compromised,
treatment may be necessitated if the ventricular rate is either
too slow or too rapid to maintain adequate cardiac output. In
addition to specific treatment, it is important to correct
electrolyte and acid-base disturbances, if present. For
treatment of specific rhythm disorders, see the section on
cardiac rhythm disturbances.

Critical Care Management
The management of pediatric patients recovering from
cardiac surgery is best provided by a coordinated multidisciplinary team with expertise in cardiac surgery, cardiology,
anesthesia, intensive care, cardiac nursing, and respiratory
therapy. The primary objective in the care of these patients
is the ongoing assessment and monitoring of hemodynamic
parameters to detect postoperative problems as early as
possible, to intervene effectively, and to ensure adequate
oxygen delivery. Both invasive and noninvasive methods
are useful to monitor hemodynamic stability and tissue
perfusion. Heart rate and rhythm, preload, afterload, and
contractility are continuously assessed. Decisions to provide
pharmacologic or mechanical support are based on careful
attention to hemodynamic status.
Hemodynamic Assessment. Invasive hemodynamic monitoring and clinical assessment are the cornerstone of postoperative assessment. The critical care nurse
must possess not only astute clinical assessment skills but
also understand the use and limitations of technologic
assessment tools. For an in-depth review of invasive
hemodynamic monitoring, see Chapter 7.
Heart Rate and Rhythm. Arrhythmias have the
potential to compromise cardiac output if they interrupt
diastolic filling or AY synchrony. Continuous ECG monitors
heart rate and rhythm. The postoperative period represents a
period of physiologic stress; therefore heart rate is anticipated to be elevated.
Cardiac rhythm disturbances are not uncommon after
cardiac operations. Potential causes during the operation
include the surgical sequelae, effects of anesthesia, effects
of CPB or hypothermia, damage to the conduction system,
or high levels of endogenous or exogenous catecholamines.
Additional causes include metabolic and electrolyte imbalances, volume changes, hypoxemia, and temperature instability. Exogenous catecholamines can contribute to arrhythmogenesis, as can digoxin toxicity (particularly in the
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setting of hypokalemia). If arrhythmias are noted, potassium, magnesium, calcium, and phosphorus levels must be
checked and corrected to normal.
Ventricular arrhythmias and atrial fibrillation are uncommon outside the older adolescent or adult age group.
Automatic tachycardias such as atrial ectopic tachycardia or
JET are more common in infants than in the older child.
Conduction delay or heart block is associated with repairs of
septal defects, septal myectomy, and AV val ve abnormalities. For more complete review of arrhythmia management,
see the section on cardiac rhythm disturbances.
Systemic Arterial Blood Pressure. Continuous
monitoring of arterial pressure is achieved via an indwelling
arterial catheter and allows beat-to-beat assessment of blood
pressure. Noninvasive blood pressure measurements may
not be accurate in the early postoperative period because of
rapid changes in vascular tone and hemodynamics. The
potential for low cardiac output and inadequate tissue
perfusion is high in the early hours following cardiac
surgery and is related to a number of physiologic phenomena. These include fluid shifts, bleeding, rhythm abnormalities, and abnormalities of contractility and vascular tone. It
is important to remember that hypotension is generally a late
sign of low cardiac output. Data from direct measurement of
arterial pressure allows the timely identification of potential
postoperative blood pressure problems.
Monitoring Atrial Pressures. CVP or right atrial
pressure (RAP) provides information about the systemic
venous return and right heart preload and function. In the
absence of tricuspid valve disease, the CVP and RAP reflect
right ventricular end-diastolic pressure (RVEDP). Low
CVPs indicate hypovolemia. Right ventricular failure is
more common in infants than in adult patients. Elevated
RAP (often as high as 15 to 18 mmHg) may indicate right
ventricular failure or pulmonary hypertension.
LAP provides information about pulmonary venous
pressure and left heart preload and function. In the absence
of mitral valve disease, LAP reflects left ventricular
end-diastolic pressure (LVEDP). Low LAP indicates hypovolemia. Elevated LAP indicates left ventricular failure or
increased left ventricular afterload.
In addition to monitoring the mean atrial pressures to
determine preload and ventricular function, assessment
of the waveform yields important information about cardiac structure and function. Cannon a waves result from
increased resistance to ventricular filling (mitral or tricuspid stenosis, aortic or pulmonary stenosis, pulmonary hypertension) or when the atria contract against a
closed AV valve, as occurs with nodal rhythm or AV
dissociation. The a waves are absent in atrial fibrillation.
Tall v waves are seen in mitral or tricuspid regurgitation,
VSD, ASD, or CHF.
Monitoring Pulmonary Artery Pressure. Pulmonary artery pressure (PAP) monitoring provides information
about right ventricular function, right ventricular outflow
tract patency, PVR, pulmonary venous pressure, and pulmonary wedge pressure (if balloon-tipped catheter is used).
PAP is monitored as systolic, diastolic, and mean pressures.
PA diastolic pressure corresponds to the LAP in the absence
of pulmonary hypertension and mitral valve disease. Under
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normal circumstances, systolic PAP is the same as the right
ventricular systolic pressure.
Systemic or suprasytemic PAP in postoperative patients
can be life threatening, contributing to significant hemodynamic compromise. Measures to decrease PVR, such as
oxygenation, sedation, alkalosis, and possibly nitric oxide,
may be necessary.
Monitoring Oxygenation. Systemic arterial oxygen
saturation is routinely monitored by continuous pulse
oximetry. An understanding of the patient's unique postoperative physiology will assist in the interpretation of pulse
oximetry data. Invasive monitoring of mixed venous oxygen
saturation also provides important data regarding the
adequacy of oxygen delivery. This information is most
accurately obtained from a pulmonary artery catheter,
whereby a true mixed venous sample of blood can be
obtained. Continuous or intermittent monitoring of mixed
venous blood provides valuable information regarding
oxygen supply and demand. An elevation in mixed venous
oxygen saturation may occur in patients with high cardiac
output states or left-to-right intracardiac shunts. Decreased
mixed venous oxygen saturation may be seen in patients
with decreased cardiac output, anemia, decreased systemic
arterial oxygen saturation, and increased oxygen consumption states, such as fever.
Oxygen saturation measurements obtained from the right
atrium are dependent on the location of the catheter,
anatomy, and streaming (or blood flow) within the right
atrium or vena cava. Samples of blood from the SVC,
inferior vena cava (lYC), and coronary sinus will have
different oxygen saturations and may not accurately reflect
the mixed venous oxygen saturation. Blood samples from
the SVC may reflect a slight decrease in saturation relative
to IVC blood in the awake patient who is breathing room air.
However, the reverse is true in the deeply sedated or
anesthetized patient. 55 Blood samples obtained from the
coronary sinus or hepatic veins will be desaturated relative
to a true mixed venous sample (obtained from the PA).66
Right atrial oxygen saturations are monitored for trends;
interventions are determined based on these data along with
clinical correlation of patient condition.
Caring for Patients With Transthoracic Intracardiac Catheters. Transthoracic intracardiac catheters are
placed at the conclusion of surgery for hemodynamic
monitoring and management of postoperative patients.
These consist of directly placed RA, LA, or PA catheters. On
arrival to the PICU, chest radiographs demonstrate catheter
placement (Fig. 18-28). Most intracardiac catheters are
reserved for hemodynamic monitoring and the continuous
infusion of vasoactive medications.
Morbidity associated with the use of transthoracic
intracardiac catheters includes non function, thrombus, and
infection. 57 In addition, air or clot embolus from the LA line
can have devastating consequences if it embolizes to the
coronary or cerebral circulations. Careful attention must be
made to avoid any air entry into LA lines; therefore these
lines are typically used for monitoring of LA pressure only.
Once intracardiac lines are no longer indicated, specially
trained nurses or physicians accomplish removal in the
PICU. All possible data that may be needed from these lines
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Fig. 18-28 Transthoracic, intracardiac line locations. (From
Barker S: CV Nurse, Second Issue, 1993.)

are obtained before their removal. Examples include RA and
PA oxygen saturations, an LA tracing to demonstrate
elevated v waves, and a PA pullback pressure to assess
for RVOTO.
Morbidity associated with the removal of intracardiac
catheters include bleeding, need for intervention (chest
tube placement for hemothorax or pneumothorax, catheter
wiring for retained catheter, chest tube suctioning), and
hemodynamic compromise. Bleeding is the most common
complication and occurs more often with LA catheter
removal and in patients with genetic abnonnalities and
thrombocytopenia. Excessive bleeding can result in cardiac
tamponade, anemia, hypovolemia, hemothorax, and hemodynamic compromise. Careful assessment after the
removal of intracardiac catheters must be performed to
evaluate the development of these complications. Hemodynamic compromise occurs more often after the removal
of catheters in the LA or PA position and in patients with
thrombocytopenia,67
Respiratory Care. After undergoing cardiac surgery.
most patients arrive in the PICU intubated and mechanically
ventilated. Initial assessment of the patient includes auscultation of the lungs to detennine appropriate endotracheal
tube position and adequacy of ventilation. Chest radiographs
and arterial blood gas analysis help to support clinical
assessment. The size and position of the endotracheal tube
are documented, and the tube is secured in place.
Initially patients are ventilated with an FI02 of 1.0, unless
the patient has undergone palliation of single-ventricle
physiology with an aortopulmonary shunt. In these infants,
hyperoxia may decrease PVR and increase PBF at the

expense of systemic perfusion. These patients typically
receive an FI0 2 of 0.25 to 0.30. Fi0 2 is weaned rapidly in
most patients based on continuous pulse oximeter measurements of oxygen saturation or arterial blood gas. Although
this can be institution specific, generally volume-cycled
ventilation is used for postoperative support. Tidal volume
and rate are selected based on individual patient need to best
ensure ventilation and oxygenation. Titration of ventilator
settings is based on arterial blood gas analysis and clinical
condition. Occasionally. pressure-cycled ventilation is used
to support very small infants.
Suctioning of the endotracheal tube is reserved for
episodes of increased pulmonary secretions or episodes of
high airway pressure (caused by possible endotracheal tube
occlusion) and is executed with extreme caution. Ventilation
and oxygenation are ensured by manual ventilation before
and after each passage of the suction catheter, or an in-line
suction device can be used. In some patients, hand
ventilation with I ()()% oxygen and mild hyperinflation and
hyperventilation may protect them from hypoxemia and
hypercarbia during suctioning, although this technique
remains controversial. Patients with single-ventricle physiology or aortopulmonary connection can develop pulmonary overcirculation in response to hyperoxia or hypocarbia.
These infants should receive manual ventilation that simulates the mechanical ventilation while monitoring pulse
oximetry to ensure that PBF does not increase or decrease
dramatically. An in-line suction device can be quite helpful
in this patient population. Conversely, pulmonary vasospasm can be induced when ventilation with suctioning is(
inadequate, particularly in newborns and in infants and
children with pulmonary artery hypertension. Acute pulmonary hypertensive episodes can result in sudden decreases of
systemic cardiac output and cardiac arrest.
The length of time required for mechanical ventilation
depends on the complexity of the cardiac repair and the
postoperative course. It may be longer in patients with
pulmonary vascular congestion from large left-to-right
shunts or heart failure and in those with complex heart
defects. Mechanical ventilation is continued until the patient
is hemodynamically stable and able to sustain adequate
respiratory function independent of the ventilator. As the
patient awakens and begins to initiate respiration, the
ventilator can be weaned. Readiness for extubation is based
on physical assessment and arterial blood gas analysis.
Extubation can be accomplished when the patient is
hemodynamically stable with little or no inotropic support
on minimal ventilator settings, awake, able to clear pulmonary secretions spontaneously, and breathing spontaneously.
Patients who are unable to be extubated and do not have
pulmonary disease require investigation of potential cardiac
problems that could be contributory. Poor myocardial
contractility or residual defects may be responsible. Paralysis of the diaphragm from intraoperative injury to the
phrenic nerve may result in inability to extubate. Ultrasound
or fluoroscopic examination of the diaphragm assists in the
identification of this problem.
Vigorous diuresis in postoperative patients may result in
the development of metabolic alkalosis and can contribute
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to delayed extubation. Careful monitoring of fluid and
electrolytes and appropriate electrolyte replacement may be
helpful. Acetazolamide (Diamox) therapy or chloride replacement with arginine chloride may be helpful in the
ventilator-dependent patient whose total bicarbonate level
approaches or exceeds 40 mEqIL. These maneuvers may
help treat contraction alkalosis, thereby normalizing serum
bicarbonate, minimizing alkalosis, and resulting in improved respiratory effort.
Fluid and Electrolyte Replacement. Institutional
preference prevails in recommendations regarding postoperative intravenous fluids. Some institutions restrict sodium
intake for the first 24 hours, given the mild tendency for
sodium retention following CPB, administering 5% dextrose in water solutions to infants and children and 10%
dextrose to newborns. Solutions are changed to 5% or 10%
dextrose with 0.2% normal saline after the first postoperative day. Others recommend routine use of dextrosecontaining solutions with 0.2% saline on the first postoperative day to avoid hypovolemia. The volume of fluid
administered is generally restricted to 50% of maintenance
for patients who have required CPB for the first 24 hours.
Fluids are increased to full maintenance as determined by
patient physiology, clinical condition, fluid balance, chest
radiograph, and need for diuretics. In those patients not
requiring CPB, full maintenance fluids may be started
immediately after surgery. All sources of fluid intake,
including flushes of intravascular and intracardiac catheters,
are measured with care and included in the calculated fluid
requirement.
Fluid balance is assessed from heart rate, intracardiac
filling pressures, systemic arterial blood pressure, urine
output, and acid-base status. Volume is administered to
support filling pressures and cardiac output while preventing
fluid overload. In the immediate postoperative period,
rewarming can result in peripheral vasodilation and expansion of the vascular space, necessitating administration of
blood or colloid to maintain adequate intravascular volume.
Edema is present postoperatively to some extent in all
patients who undergo cardiac surgery with CPB and
hypothermia. Other contributing factors include length of
the surgery, type of procedure, and amount of fluid
administered intraoperatively. Total body water accumulation during cardiac surgery may be as much as 600 to
1000 ml. 56 After the first postoperative night, diuretics are
administered to augment diuresis and treat third spacing.
Low-dose dopamine (3 ~g/kg/min) may also be advantageous. The use of diuretics mandates attention to fluid,
electrolyte, and acid-base balance.
CPB, diuretic administration, and acid-base balance
affect serum potassium levels. Hypokalemia is known to
contribute to ventricular irritability,. especially in patients
receiving digoxin, and can cause rhythm disturbances.
Parameters for electrolyte replacement are specific to patient
condition and institutional preference. Hypokalemia is
treated with potassium chloride supplements of 0.25 to
I mEq/kg administered as a continuous infusion over I to
2 hours if urine output is adequate or added to the
maintenance fluids. Care is taken to ensure that potassium
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supplements are not administered rapidly or in an excessively concentrated infusion because of the potential for
hyperkalemic cardiac arrest. Hyperkalemia is rare, unless
postoperative renal dysfunction is present. Treatment consists of removing all potassium from intravenous fluids and
the administration of polystyrene sulfonate (I g/kg every
4 hours) by mouth or rectum until renal function improves.
Occasionally, hemodialysis is required.
Mild hyponatremia is common but does not often require
treatment beyond administration of diuretics and restriction
of free water intake. Patients with serum sodium less than
125 mEqlL are at risk for seizures and other neurologic
symptoms and require diuresis, water restriction, and
cautious administration of normal saline.
Hypocalcemia is most often seen in newborns, those with
DiGeorge syndrome, and in patients receiving large
amounts of blood products. Transfused blood is preserved
with citrate phosphate dextrose that produces precipitation
of serum calcium with subsequent hypocalcemia. Administration of serum albumin also binds ionized calcium,
resulting in hypocalcemia. Documented hypocalcemia requires replacement therapy to support contractility.
Infants are at risk for the development of hypoglycemia
because of high metabolic rate and limited glycogen stores.
Hypoglycemia can depress myocardial function and may
cause seizures.
Acid-base balance is monitored with care because
myocardial performance is adversely affected by acidosis.
Metabolic acidosis indicates impaired tissue perfusion,
usually the result of inadequate cardiac output. Treatment
necessitates correction of the underlying hemodynamic
problem or administration of intravenous sodium bicarbonate (I mEq/kg/dose). Adequate ventilation must be ensured
because the buffering action of bicarbonate results in the
formation of carbon dioxide. Tromethamine (THAM) is an
alternative buffering agent for patients with severe metabolic acidosis and impaired renal function or hypernatremia.
Renal Function. Urine output is a sensitive indicator
of cardiac output and tissue perfusion after cardiac surgery.
Urine output of I ml/kg/hr is anticipated in infants and
young children; 0.5 ml/kg/hr (or 20 to 40 ml/hr) is
expected urine production in older children and adults. If
urine flow decreases, but physical examination and laboratory results suggest adequate cardiac output, the diminished
urine flow is most likely caused by stimulation of hormones
designed to retain fluid and maximize cardiac output. These
hormonal modulators can be caused by CPB, low atrial
pressures, decreased renal blood flow, and decreased cardiac
output. The RAAS is stimulated by a decrease in renal blood
flow, restoring cardiac output by sodium and water retention, which increase intravascular volume. Urine output can
also be diminished by the secretion of antidiuretic hormone
(ADH) stimulated by CPB.
Diminished urinary output should not be the sale
indicator for the administration of diuretics. Other clinical
parameters should be used such as filling pressures,
hepatomegaly, fluid balance, and chest radiograph. Administration of tubular diuretics is not likely to alter the outcome
of vasomotor nephropathy, which may have resulted from
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diminished perfusion during CPB or subsequent hemodynamic instability. Acute renal failure can occur in infants
and children after open heart surgery. Serum potassium,
blood urea nitrogen (BUN), and creatinine are key to
assessing renal function. If, despite adequate cardiac output,
urine output remains inadequate with an upward trend in
BUN and creatinine or the development of hyperkalemia,
renal replacement therapy may be indicated with continuous
veno-veno hemofiltration or dialysis.
Thermal Regulation. Although induced hypothermia for cardiac surgery is reversed at the conclusion of the
procedure, core temperature may be low, and peripheral
vasoconstriction persists when the patient arrives in the
PICU. Hypothermia prolongs postoperative bleeding and
may delay hemodynamic stabilization; may lead to acidosis,
hypoglycemia, hypoxemia, increased PVR; and may induce
shivering. Active rewarming is achieved with warming
devices. Infants have a higher loss of heat via conduction,
convection, radiation, and evaporation and may be slow to
rewarm despite efforts to reestablish normothermia while
weaning off CPB.
Establishment of a neutral thermal environment (NTE) is
key to postoperative thermal regulation. Newborns and
small infants are cared for in an infant warmer bed using a
servocontrol mechanism. Postoperative assessment includes
measurement of core temperature and the differential
between core and peripheral temperatures, as well as
assessment of the extremities for coolness and capillary
refill. When cool extremities are noted with an elevated core
temperature, low cardiac output is suspected (tbis results
from redistribution of the cardiac output away from the
extremities). Conversely, loss of temperature regulation can
result in heat retention and a high core temperature.
Capillary refill is expected to be brisk when the cardiac
surgery patient has been rewarn1ed and hemodynamic
stability is achieved. In the newborn, normal refill may take
3 to 5 seconds owing to peripheral vascular adaptation.
Refill time longer than 5 seconds is abnormal and reflects
diminished peripheral perfusion.
Feeding and Nutrition. Generally, oral feedings are
begun as soon as possible. Some patients (mechanically
ventilated, infants who are poor feeders) may require
nasogastric or nasojejunal feedings. In patients who have
had straightforward cardiac repairs and are recovering well,
feedings can be rapidly advanced. Exceptions may include
newborns with umbilical artery catheters or those who had
limited gut perfusion preoperatively because of the association between necrotizing enterocolitis (NEC) and feeding.
Patients having repair of coarctation of the aorta are not fed
until hypertension is controlled and bowel sounds are active
to prevent reactive mesenteric enteritis and its complications. Nasogastric or transpyloric feedings are considered
early for patients unable to resume oral intake within 48 to
72 hours of surgery. Because of its expense, parenteral
nutrition is considered only if the gastrointestinal tract
cannot be used for an extended period postoperatively.
Newborns may require as much as 120 to 150 calories/kg/
day for weight gain. Older infants and children are likely to
have a similar increase in nutritional requirements.

Wound Care. Following cardiac operations, the surgical incision is generally covered with a dry sterile
dressing, separated from the chest tube and intracardiac
lines. After lines and chest tubes are removed, at approximately 24 to 48 hours, the dressing is usually removed, and
the incision is left uncovered.
A standard technique for wound care has not been
established for patients in whom sternal closure is delayed.
Maintenance of sterility and protecting the patient from
infection are priorities. A nonpermeable patch (Silastic,
Gore-Tex, bovine pericardium) is generally sutured to the
wound edges and then covered with a dressing. The site is
assessed continuously for fluid accumulation that can lead to
tamponade. The most common signs are fullness and
bulging of the membrane. Immediate evacuation of the
incision is indicated if this occurs. When the sternum is left
open, the water seal chamber of the chest tube collection
chamber should bubble, and the patient is kept sedated and
possibly chemically paralyzed.
Infection Prophylaxis. Most patients receive prophylactic antibiotics before surgery and in the immediate
perioperative period. When to terminate these antibiotics is
dependent on the individual center and is often open to
debate. Antibiotics given during the perioperative period can
decrease the risk of infectious complications, including
catheter sepsis, pneumonitis, urinary tract infection, and
mediastinitis. Unfortunately the increased use of broadspectrum antibiotics has encouraged the development of
multiple resistant organisms and fungi. Therefore the use of
empiric antibiotics should be carefully evaluated. Once all
invasive catheters and tubes have been removed, antibiotics
should be discontinued unless they are being given for a
documented or suspected infection.
Central Nervous System Assessment. Neurologic
complications after cardiac operations may be the consequence of cerebral ischemia, hypoxia, electrol yte imbalances, metabolic acidosis, hypoglycemia, or cerebral
emboli. Seizures are the most common neurologic complication. Hypoglycemia, hypocalcemia, and hypomagnesemia
are causes for seizures in infants, and therefore levels should
be monitored and replacement given as indicated. Anticonvulsants are administered as indicated for seizure control, and these may need to be continued for some months
after surgery.
Pain Management. An essential component of patient management after congenital heart surgery is the
maintenance of adequate analgesia and sedation to provide
comfort. Often a combination of drugs, such as opioids and
benzodiazepines, are used, thereby keeping total drug dose
to a minimum. Analgesia requirements for young children
can be difficult to assess, particularly when they are
paralyzed and supported on a ventilator. Increases in blood
pressure and heart rate and decrease in arterial oxygen
saturation are measures of inadequate anxiety and pain
control in critically ill infants and children, although these
physiologic changes may also be caused by a number of
other clinical conditions, including seizures.
Other approaches to postoperative analgesia are common, although intravenous narcotic analgesics are employed
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in most settings for at least 24 to 48 hours postoperatively.
Other interventions include local nerve blockade with
pleural catheters and epidural administration of narcotics.
The additional around-the-clock administration of acetaminophen (Tylenol) or nonsteroidal antiinflammatory drugs
(NSAlDs) is useful in augmenting pain control when given
concurrently with narcotics. 68

ACQUIRED HEART DISEASE IN INFANTS
AND CHILDREN
Acquired heart disease in pediatric patients includes a group
of diseases, sometimes of unknown cause, in which the
central feature is involvement of the heart muscle itself. An
exception is Kawasaki disease, in which the coronary
arteries are primarily involved. Idiopathic cardiomyopathy
is the term used to describe diseases involving the heart
muscle that are of unknown cause. These myocardial
diseases in infants and children are not the consequence of
ischemic, hypertensive, congenital, valvular, or pericardial
disease.6() Specific heart muscle diseases (also called secondary cardiomyopathy) have a known cause and include
myocarditis, hypertension, and tachyarrhythmias. Although
less common than CHDs, acquired heart disease in infants
and children can lead to significant cardiac dysfunction,
morbidity, and mortality.

Acute Myocarditis
Myocarditis is a generalized myocardial inflammation
characterized histologically by lymphocytic infihration
and myocardial necrosis. Myocarditis may result in impaired cardiac function that may be subclinical or asymptomatic. If the inflammation is severe, it can result in
critical sequelae, including CHF, arrhythmias, and possibly
death.
Etiology. Virtually any infectious agent can produce
cardiac inflammation. Myocarditis has been described
during and following a wide variety of viral, bacterial,
rickettsial, fungal, and protozoan infections. The most
common etiologic agents in North. America are viruses,
specifically Coxsackie and other enteroviruses. In addition
to infectious agents, drugs (doxorubicin [Adriamycin],
cocaine), chemicals (carbon monoxide), hypersensitivity
reactions, autoimmune diseases and vasculitis, or Kawasaki
disease may cause myocardial inflammation.
Incidence. Myocarditis has been documented in 25%
of pediatric autopsies. 69 •7o However, only 0.3% of patients
seen by pediatric cardiologists have clinically significant
evidence of myocarditis 71 A large percentage of asymptomatic or subclinical cases accounts for the discrepancy
between the autopsy findings and clinical incidence.
The incidence of myocarditis is highest in children
younger than I year of age. Between 5% and 12% of
children infected with either influenza viruses or Coxsackie
virus develop clinical myocarditis. Forty percent of older
children with infectious mononucleosis have myocardial
involvement that is most often subclinical 71 With the
advent of polymerase chain reaction (PCR), compared with
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enteroviruses, adenovirus has been identified more often as
a causati ve agent. 72
Pathogenesis. Infectious agents produce myocardial
damage by direct invasion of the myocardium, production of
a myocardial toxin, or immune-mediated inflammation of
the myocardium. Viruses injure myocardial tissue by direct
destruction of the myofibrils and by cytotoxic T cell
destruction of myocytes. Strong evidence shows that in viral
myocarditis, a cell-mediated immunologic reaction is a
principal mechanism of cardiac involvement. Adjacent cells
may be destroyed by complement-mediated antibody action.
The time between the onset of inflammation and the
initial clinical manifestations of disease varies. Generally
within a week of infection, myocardial necrosis develops.
However, the subsequent inflammatory and autoimmune
response to viral infection becomes the primary mediator of
clinical disease. Cellular immunity (T lymphocytes, macrophages), humoral immunity (antibodies), and cytokines
(tumor necrosis factor, interieukins) are responsible for
myocardial and coronary vascular injury. Vascular endothelial injury leads to vascular permeability with subsequent
myocardial edema, increased ventricular wall thickness, and
decreased ventricular function 73
Clinical Manifestations. The clinical presentation of
patients with myocarditis ranges from those who are
asymptomatic to those with severe cardiac dysfunction
progressing rapidly to fulminant CHF and death. Typically,
newborns and young infants manifest a sudden onset of
symptoms with rapid progression to critical illness.
Young patients with myocarditis present with lethargy,
fever, and tachycardia. Respiratory distress, cyanosis, and
vomiting may also occur. Older children present with fever,
malaise, myalgia, gastroenteritis, pharyngitis, and meningitis but generally do not appear as ill as infants. In addition
to tachycardia out of proportion to the fever, the cardiovascular examination reveals poor peripheral perfusion, thready
pulses, cool extremities, and pallor. The heart sounds may
be muffled if a pericardia] effusion is present. With severe
cardiac dysfunction, a gallop rhythm and a high-frequency,
hoiosystolic (loudest at the apex) murmur of mitral regurgitation may be auscultated.
Diagnosis. Many laboratory studies are indicated
when myocarditis is suspected. Typically, patients with
myocarditis have an elevated white blood cell count without
a left shift, elevated erythrocyte sedimentation rate (ESR),
abnormal liver function tests, and elevation of lactate
dehydrogenase (LDH) isoenzyme 1, creatine phosphokinase
(CPK) MB fraction, and troponin I. Of note is that
myocarditis can still be present with a normal ESR.
Bacterial infection is ruled out by blood culture. The
nasopharynx and stool are cultured for viral isolation.
Because viral cultures and convalescent viral titers may be
nonspecific for determining the cause, PCR is used to
amplify specific viral genomes through quantitation of
specific viral RNA (if it is present in the tissue). PCR is more
specific than culture for the amplification and identification
of the specific causative virus 74
Chest radiographs may demonstrate cardiomegaly. Pulmonary venous markings are increased when heart failure is
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present. The ECG can reveal life-threatening cardiac rhythm
disturbances that often accompany myocarditis. The classic
electrocardiographic changes for myocarditis are lowvoltage QRS, low or inverted T waves, and decreased or
absent Q waves in V5 and V6' Echocardiography is used to
evaluate cardiac function and detect the presence of a
pericardial effusion. Most often the left ventricle is dilated,
with increased left ventricular dimensions at end systole and
end diastole. Global myocardial depression or wall motion
abnormalities of the left ventricular free wall may be noted.
Historically the definitive diagnosis of myocarditis was
made by myocardial biopsy, the gold standard, which
demonstrates myocyte necrosis or degeneration associated
with inflammatory infiltration,72.75 the so-called Dallas
criteria. The Dallas criteria define the characteristics
of myocarditis from histologic examination of endomyocardial biopsy tissue obtained by cardiac catheterization
(Fig. 18-29) and permit accurate diagnosis and systematic
investigation of myocarditis. In addition, myocardial tissue
can be can be sent for PCR analysis to determine viral
etiology.
Unfortunately, the focal and patchy nature of myocarditis, as well as the small size of tissue samples obtained at
biopsy, makes it difficult to obtain a definitive diagnosis in
many cases, and false-negative results can occur. Therefore
the absence of a positive biopsy result does not rule out
myocarditis, and treatment is based on clinical symptoms
and other diagnostic findings.
Critical Care Management. Management of infants
and children with myocarditis remains supporti ve rather
than specifically aimed at a causative organism. Ensuring
bed rest during the acute phase (7 to 14 days) is often

recommended to decrease demands on the heart. In addition,
animal studies also suggest that bed rest during the acute
phase of myocarditis decreases viral replication and improve outcomes. 76 Administration of supplemental oxygen
or mechanical ventilation may be often necessary to
maintain adequate oxygen delivery in the face of CHF.
Because the potential for complete recovery of myocardial
function exists even in critically ill patients with myocarditis, treatment of cardiac dysfunction is aggressive.
Anticongestive Therapy. The overall goal of treatment in patients with myocarditis is to increase cardiac
output. In the critically ill patient, early and aggressive
therapy is instituted, usually combining inotropic and
afterload-reducing agents. Treatment includes single or
combination drug therapy with dobutamine, dopamine,
milrinone, amrinone, nitrovasodilators, or ACEIs. Dobutamine serves as an inotrope and is especially effective in
patients with refractory CHF. Milrinone and amrinone have
both inotropic and vasodilating properties that serve to
decrease ventricular work. Diuretic therapy is prescribed to
reduce volume load. (See Chapter 7 for an in-depth
discussion on vasoactive and diuretic medications.) The
goal of fluid balance is to provide adequate hydration to
preserve preload and provide adequate ventricular filling
pressures without fluid overload.
ACEIs provide afterload reduction by interfering with the
formation of angiotensin II (a strong vasoconstrictor). In
controlled studies, the use of ACEIs, such as captopril and
enalapril, has been effective in slowing the course of heart
failure, decreasing symptoms, and potentially prolonging
survival in patients with mild to severe left ventricular
dysfunction. 77 .78

Fig. 18-29 Myocardial tissue showing focal, interstitial, lymphocytic infiltrate, and myocyte degeneration. Degenerating myocytes show closely apposed lymphocytes around it and attached to the membrane.
(From Baker A: Acquired heart disease in infants and children, CriT Care Nars Clill NorTh Am 6: 183, 1994.)
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Some patients who recover from severe cardiac dysfunction require long-term oral anticongestive therapy. Digoxin,
furosemide, and an ACEI are commonly employed. Some
clinicians avoid administering digoxin during the acute
phase of illness because of suggested increased digoxin
toxicity in the inflamed myocardium. 73
Arrhythmia Management. With myocardial dysfunction, cardiac rhythm disturbances can be life threatening, and aggressive therapy is warranted. Supraventricular
tachycardia (SVT), ventricular ectopy, and heart block can
develop in a subset of patients with myocarditis. Tachyarrhythmias are controlled to help prevent further deterioration of ventricular function. Antiarrhythmic agents are
used to control symptomatic SVT, ventricular tachycardia,
and premature ventricular contractions. The possibility of
any negative inotropic or proarrhythrnic effects should be
considered when choosing an antiarrhythmic agent. If
second- or third-degree AV block develops, a temporary
transvenous or epicardial AV sequential pacemaker may
be used. Persistence of complete heart block beyond
2 weeks is an indication for elective placement of a
permanent pacemaker71 .79
Anticoagulation. Although controversial, anticoagulation therapy is used by some clinicians in patients with the
potential for thrombus formation as a result of severely
compromised ventricular function and stasis of blood flow.
Systemic mural thrombi can potentially embolize to the
cerebrovascular system, causing neurologic sequelae.
Coagulation parameters are followed closely, and therapy
is adjusted to maintain an adequate anticoagulatory state.
Because of the possibility of cerebral emboli, neurologic
status is monitored closely, and changes in the patient's
mentation or responsiveness are evaluated immediately.
Signs and symptoms of pulmonary emboli, which include
acute onset of shortness of breath, tachycardia, hypoxemia,
and chest pain, are assessed. The risk of systemic emboli is
also present and may manifest as a change in color,
temperature, or perfusion of an extremity.
Antiinflammatory Treatment. Suppression of inflammatory mediators may help limit the severity of illness
and shorten the clinical course. Unfortunately, no clinical
regimen consistently ameliorates the acute phase of illness.
Use of antiinflammatory agents, such as prednisone, azathioprine, and cyclosporin, is controversiaL 73 .Ro Initial animal
studies suggested a poorer outcome when steroids are
administered early in the course of illness (during viral
replication), suggesting that immunosuppression may enhance myocardial damage during this period. Subsequent
human studies have suggested a benefit, but the studies were
nonrandomized and are difficult to interpret because 45% to
50% of patients with myocarditis improve spontaneously. HI
The timing of this intervention accounts for the difference
in outcome, so consideration should be given to delaying antiinflammatory treatment until the phase of lymphocytic infiltration and myocardial necrosis is decreased. 82 . 83
NSAIDs have been associated with worsening of myocardial damage and increased mortality.73
Intravenous immune globulin ([VIO) has been reported
to have beneficial effect in patients with myocarditis. Left
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ventricular function improved and mortality decreased at I
year following presentation in patients treated with high
dose (2 g/kg) IVI0 84 . 85 Although the specific mechanism of
active is unknown, IVIO may interfere with the humoral
immunity and autoantibodies responsible for myocardial
cell damage. Associated side effects of IVIO are headaches,
chills, and malaise.
Other Therapies. Antiviral agents, immunomodulatory agent~, and antilymphocytic monoclonal antibodies are
all currently under investigation for treatment of myocarditis. Unfortunately, many of these agents work best immediately following viral inoculation, making clinical application difficult. Interferon and monoclonal antibody to the
infectious agent would provide specific effect and are under
investigation in animal models.
Mechanical Assist Devices and Extracorporeal
Support. If conventional therapy is unsuccessful, other
means of support may be attempted. Chang and coworkers 86 reported the successful use of a left ventricular
assist device in a patient with acute myocarditis. The use of
intraaortic balloon pump and ECMO has been reported in
patients who do not respond to conventional therapy;
however, experience is limited. If cardiac function fails to
improve, cardiac transplantation may be considered.
Preventing Complications. As is the case with any
critically ill patient, the high potential for nosocomial
infection is an important consideration. Multiple venous and
arterial lines are required for the infusion of cardioactive
drugs and continuous hemodynamic monitoring. Protecting
patients from infection and vigilant assessment for early
signs of localized or systemic infection are both important.
Decreased tissue perfusion in the acutely ill patient in
combination with immobility increases the potential for
ischemia and skin breakdown. Skin integrity is an important
concern. Attention is directed toward alleviating pressure,
repositioning to whatever extent is possible on a regular
basis, and employing methods to prevent skin breakdown.
Attention to the patient's nutritional requirements is
crucial to promote healing and to provide a positive nitrogen
balance. Because the acutely ill patient is usually not able to
take food orally, adequate nutrition must be provided
intravenously or enterally (nasogastric or nasojejunal).
Nutrition should be instituted early in the course of illness to
fulfill caloric requirements.

Kawasaki Disease
Kawasaki disease is an acute systemic vasculitis that was
first described in Japan in 1967. The acute illness itself is
self-limiting, but 15% to 25% of untreated children with
Kawasaki disease suffer damage to the coronary arteries,
resulting in dilation or aneurysm formation 87 Although
damage can occur in any medium-sized muscular artery, the
vessels most often affected are the coronary arteries, making
Kawasaki disease the leading cause of acquired heart
disease in children in the United States.
Etiology. The cause of Kawasaki disease is unknown.
An infectious agent is suggested for a number of reasons.
First, it is almost exclusively a pediatric disorder, suggesting
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the development of passive immunity by adulthood. Geographic outbreaks occur with an increase in the number of
cases in the late winter and early spring. Lastly, many
clinical similarities to other infectious diseases (i.e., scarlet
fever, adenovirus) are seen. However, there is no evidence
of spread from person to person. In the absence of a known
agent, several researchers have begun to explore the
possibility that the inflammation in Kawasaki disease may
represent a "final common pathway" and that one agent
may not be responsible. Epidemiologic studies have found
associations between the occurrence of Kawasaki disease
and recent exposure to carpet cleaning and residence near a
body of stagnant water; however, these data are weak, and
definitive cause and effect have not been established.
Kawasaki disease is reported more often among children
from higher socioeconomic groups and in those of Asian
descent.
Incidence. The first cases of Kawasaki disease in the
United States were described in the early 1970s. Although
Japanese children have the highest incidence of this illness,
Kawasaki disease occurs in all races. African Americans
have the second highest rate of occurrence; Caucasian
children follow. Eighty percent of cases occur in children
under age 5, with the greatest incidence in the toddler age
group (1- to 2-year-olds).88 Infants often present in an
atypical fashion, without fulfilling diagnostic criteria; however, this age group (especially infant males) has the highest
risk for the development of severe coronary artery disease.
Recent research has also documented a higher incidence of
coronary artery aneurysms in children older than 6 years of
age 89 Males are affected more often than females (1.5: 1).
The actual incidence of Kawasaki disease in this country is
not known because reporting to the Centers for Disease
Control and Prevention (CDC) is accomplished via a
voluntary, passive surveillance system.
Pathogenesis. The overall mortality in Kawasaki
disease is 0.3%, with almost all deaths related to the cardiac
sequelae. 90 Kawasaki disease causes diffuse acute vasculitis
of medium-sized arteries and small arterioles and venules
throughout the body, with a predilection for the coronary
arteries. The involvement of small peripheral blood vessels
is evidenced in the inflammatory signs and symptoms that
characterize this illness. During the initial acute phase,
inflammation of the small arteries and venules is evident.
Inflammation then progresses to involve the medium-sized
muscular arteries, including the coronary arteries, with the
potential development of coronary artery aneurysm. The
inflammatory process is an immune-mediated response in
which the T cells and macrophages produce inflammatory
cytokines that infiltrate the coronary arteries and myocardium. During the acute phase, there is often evidence of
pericarditis, myocarditis, and valvulitis. Enlargement (ectasia) of the coronary arteries can be seen by echocardiogram
as early as day 7 after the onset of fever. Affected vessels
may continue to enlarge for some time, reaching their
maximum dimension at approximately 28 days from the
onset of fever. In dilated vessels, the potential for thrombus
exists. Over time, affected vessels heal by the process of
myointimal proliferation, which can result in stenosis,
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Box 18-3
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~ CDC Criteria for Diagnosis
. of Kawasaki Disease

Fever >5 days unresponsive to antibiotics and at least four of
the five following physical findings with no other more
reasonable explanation for the observed clinical findings:
1. Bilateral conjunctival injection
2. Oral mucosal changes (erythema of lips or oropharynx,
strawberry tongue, or drying or fissuring of the lips)
3. Peripheral extremity changes (edema, erythema, or generalized or periungual desquamation)
4. Rash
5. Cervical lymphadenopathy >1.5 em in diameter
From Centers for Disease Control: Kawasaki disease-New York, MMWR
29:61-63. 1980.

especially at the distal ends of aneurysms. The myocardium
is involved directly in almost all cases, with myocellular
hypertrophy, degeneration of myocytes, and endocardial
changes that lead to myocarditis and decreased ventricular
function. Myocardial dysfunction is subclinical in most
patients.
Clinical Manifestations. A definitive diagnostic test
for Kawasaki disease does not exist. Rather, the diagnosis is
based on the presence of certain clinical criteria developed
by Dr. Kawasaki and outlined by the CDC (Box 18-3). The
presence of prolonged fever plus four of the five diagnostic
criteria, without evidence of another known disease, is
required to meet diagnostic criteria. The conjunctivitis in
Kawasaki disease is bilateral nonexudati ve with limbal
sparing. The lips and oropharynx are red. The filiform
papillae of the tongue slough off, creating the classic
"strawberry tongue." The hands may be edematous and red
in this phase. The rash of Kawasaki disease is never
vesicular or bullous. It is accentuated in the groin in 50% of
cases and often is accompanied by local desquamation of
this area. 91 The lymphadenopathy is nonsuppurative, with
one node at least 1.5 cm or larger in the anterior cervical
chain. In addition to these symptoms, a number of associated clinical and laboratory findings are often present and
support the diagnosis (Box 18-4). Irritability is often
extreme and may persist over the entire course of the illness.
Analysis of cerebrospinal fluid may demonstrate mild
aseptic meningitis. Arthritis occurs in one third of patients,
usually affecting the small joints initially with progression
to the large weight-bearing joints. Diarrhea, nausea, and
vomiting are not uncommon. Hydrops of the gallbladder and
abdominal pain may also be present. The diagnostic criteria
should be viewed only as a guideline because some children
develop aneurysms without meeting diagnostic criteria
(atypical Kawasaki disease). Atypical disease is especially
common in infants who often present symptoms with subtle
or incomplete findings.
Kawasaki disease is an acute, self-limiting illness.
Complete resolution of clinical symptoms and return of
laboratory results to normal often require 6 to 8 weeks. The
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Box 18-4

Associated Clinical and laboratory Findings
in Kawasaki Disease

Elevated sedimentation rate (resolves 6-8 weeks after the
onset of fever)
Leukocytosis with a left shift
Aseptic meningitis
Urethritis with sterile pyuria: microscopic examination
reveals mononuclear cells
Elevated liver transaminases: commonly 2-3 times normal
Thrombocytosis: peaking 3-4 weeks after onset
Hydrops of the gallbladder, right upper quadrant abdominal
pain
Anemia that persists until the resolution of inflammation
Irritability (can last for 6-8 weeks)
Diarrhea and vomiting

course of the illness can be divided into three stages: acute,
subacute, and convalescent phases.
The acute phase begins with the abrupt onset of fever,
which lasts for at least 5 days (average of I I days without
treatment). Over the first week, the diagnostic findings
become evident. All of the clinical features may not be
present at the same time, making the diagnosis challenging.
Small joint arthritis is seen in approximately one third of
patients. Echocardiography is performed at the time of
diagnosis to evaluate cardiac function and establish a
baseline for evaluation of coronary artery size and shape.
Mild to moderate CHF from myocarditis, left ventricular
dysfunction, and pericardial effusion may be detected.
Although unusual, cardiac rhythm disturbances may occur,
including first- or second-degree AV block, prolonged QT
interval, abnormal ST segment and T wave, and low R wave
amplitude.
The subacute phase begins with resolution of fever,
although multisystem involvement is still evident. During
this stage the characteristic periungual desquamation occurs
(peeling of the skin of the palms and soles beginning under
the fingertips and toes). Arthritis, if present, generally
affects the larger weight-bearing joints in this phase.
Laboratory studies reveal a hypercoagulable state with
significant thrombocytosis. The sedimentation rate continues to be elevated, and a normocytic, normochromic anemia
is common. In those patients who develop coronary artery
abnormalities, dilation or aneurysms become evident by
echocardiogram in this phase.
The third stage is a convalescent phase, during which
the child continues to recover and laboratory values return to
normal. Unfortunately (if untreated), although the child
seems clinically improved, coronary aneurysms may continue to enlarge during this stage, reaching their maximum dimension approximately 28 days from the onset of
illness.
Cardiac Findings. During the acute phase of illness,
at least some degree of myocarditis is present in all children
with Kawasaki disease, as demonstrated by both biopsy and
autopsy findings. 92 The majority of cases are subclinical;
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however, severe cases can result in CHF and cardiogenic
shock. Physical examination often reveals tachycardia and a
gallop rhythm during the acute phase (often out of
proportion to the degree of fever). Echocardiography can
reveal decreased left ventricular contractility in the acute
phase. This condition may persist for several months and is
improved by treatment with IVlG 93
In the acute phase, the most common ECG changes
include a prolonged PR interval and nonspecific ST and T
wave changes. The arrhythmias seen in the acute phase of
Kawasaki disease are not usually life threatening and are
consistent with myocarditis. Later, abnormal ECGs may
reflect myocardial infarction or ischemia in the most
severely affected patients.
Valvulitis can occur in the acute phase. Mitral regurgitation is sometimes present and is thought to be the result of
myocarditis in the acute stage or myocardial ischemia later.
Late-onset aortic regurgitation sometimes requiring valve
replacement is a late, rare finding. 94
The most important sequelae from Kawasaki disease are
coronary artery aneurysms. Of untreated children, 15% to
25% develop damage to the coronary arteries, resulting in
ectasia (dilation) or aneurysm formation of one or more
vessels. Duration of fever is the strongest predictor of
aneurysm formation: the longer the fever persists, the
greater the risk of the development of coronary aneurysms.69.95.96 Aneurysm formation and healing (regression)
is a dynamic process. In the acute phase of the illness,
inflammation of the coronary arteries causes weakness in
the vessel wall. Over the course of subsequent weeks, the
damaged vessel increases in diameter, resulting in ectasia or
aneurysm formation. The Japanese Ministry of Health
defines an aneurysm as an internal lumen diameter greater
than 3 mm in a child younger than 5 years of age or greater
than 4 mID in a child of age 5 years or older. In addition, any
segment that is 1.5 times larger than an adjacent segment is
considered abnormal, as is a vessel with an obviously
irregular lumen. These criteria are based on age and do not
take into account the differences in body size of individual
patients. Recent data show that body surface area (BSA)adjusted z-scores (standard deviations from the average) in
patients with Kawasaki disease were actually larger than
expected, even in patients with coronary arteries that would
be classified as nornlal by the Japanese criteria. 97
Coronary artery abnormalities are not often evident until
the second week after the onset of fever; however, they have
been detected as early as day 7 of illness. The affected
vessels can continue to enlarge through the fourth week of
illness, at which time their maximum dimension is generally
reached. Echocardiography is highly sensitive for detection
of enlargement of aneurysms in the proximal coronary
arteries.
Thrombocytosis occurs during the subacute phase of
illness, with platelet counts that can approach I million.
Sluggish blood flow through enlarged coronary vessels, in
combination with an elevated platelet count, increases the
risk of thrombosis in patients with aneurysms and places
these children at risk for the development of thrombus with
subsequent myocardial ischemia or infarction. At greatest
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Fig. 18-30 Right coronary arteriogram demonstmting giant
proximal aneurysm and smaller distal one.

risk for clot development are those with "giant aneurysms,"
which measure more than 8 mm in diameter (Fig. 18-30).
Over time, regression of aneurysms can occur. The
majority of healing occurs during the first year or two after
the onset of illness. In 50% to 66% of cases, the internal
lumen diameter of aneurysmal vessels actually returns to its
normal size by a process of myointimal proliferation. The
amount of healing or regression in an individual patient is
most closely related to the extent of damage. The larger the
aneurysm, the less likely it is to return to its normal size.
Regardless of the internal diameter of the coronary artery,
affected vessel walls are not truly "normal" in terms of
either histology or reactivity to coronary vasodilators
because of thickening and calcification that occurs in the
process of healing. 91 •98 These vessels may be at greater risk
of developing premature atherosclerotic disease. Although
less common, aneurysms may occur in other arteries, most
commonly the axillary (often palpable), subclavian, brachial, iliac, or femoral vessels and sometimes in the
abdominal aona and renal arteries. 99 These areas are
generally affected only in patients who also have significant
coronary aneurysms.
Over years, stenotic areas may develop in affected
coronary arteries, occurring most commonly at either the
proximal or distal end of aneurysms as the vessel walls heal
inward. The incidence of stenosis increases over the
lifespan, especially in patients with giant aneurysms. As a
consequence of progressive stenosis, blood flow to the
myocardium may be impeded or occluded. If adequate
collateral circulation has not developed, myocardial ischemia or infarction may result. Stenoses are not easily
detectable by echocardiogram, so patients must be carefully
monitored over time to detect myocardial ischemia by stress
testing, myocardial perfusion scans, and ECG. Cardiac
catheterization accurately detects stenotic areas and is
generally performed a year after the onset of illness or at

any time that noninvasive testing suggests signs of myocardial ischemia.
Management. The majority of patients with Kawasaki disease do not require critical care. Typically, a 1- or
2-day admission is necessary during the acute phase for
monitoring and providing IVIG. Those with acute ventricular dysfunction and symptoms of myocardial ischemia or
infarction and those who require systemic heparinization or
thrombolytic therapy also require close monitoring.
y-Globulin Therapy. The use of IVIG shortens the
acute phase of Kawasaki disease and decreases the risk of
coronary damage. loo This treatment is currently the standard
of care in Kawasaki disease. The recommended dose of
IVIG is 2 g/kg given intravenously in a single infusion over
8 to 12 hours. 101 In an National Institutes of Health funded,
multicenter study, y-globulin was shown to decrease the
incidence of aneurysms threefold to fivefold when given
within the first 10 days of illness. lOo For best outcomes,
IVIG should ideally be given within the first 10 days of
illness. However, it should be administered after this time to
any child diagnosed late with persistent fever, aneurysms, or
signs or symptoms of ongoing inflammation. Retreatment
with IVIG is given to patients who have persistent or
recrudescent fever 48 to 72 hours after the administration
of IVIG. 102
Careful cardiac monitoring is necessary during the
administration of y-globulin. Approximately 40 ml/kg of
fluid is administered with the y-globulin over an 8- to
I2-hour period. Patients with myocardial dysfunction can
experience acute CHF. Many centers administer diphenhydramine (Benadryl) before the infusion of IVIG to decrease
the risk of a reaction to this product.
Aspirin Therapy. Historically, aspirin has been given
as pan of the treatment for Kawasaki disease in both
antiinflammatory and antiplatelet doses. In prospective
studies, the administration of aspirin has never been shown
to have an effect on whether a patient develops aneurysms.
High doses of aspirin (20 to 25 mg/kg/dose every 6 hours)
are used initially for their antiinflammatory effect. When the
patient has been afebrile for 2 to 3 days, the dose is
decreased to an "antiplatelet" dose (3 to 5 mg/kg/day).
Low-dose aspirin is continued through the convalescent
phase and then discontinued in patients without coronary
involvement.
Antithrombotic Therapy in Patients With Aneurysms. Children with coronary aneurysms require longterm antithrombotic therapy. The potential for thrombosis of
the coronary arteries is actually greatest after the acute phase
when thrombocytosis occurs along with ongoing vasculitis,
creating a hypercoagulable state. This is especially true in
patients with rapidly increasing coronary artery dimensions
or with giant aneurysms. Aspirin therapy remains the most
common therapy for the majority of these patients. Dipyridamole (Persantine) is sometimes added at a dose of 3 to 6
mg/kg/day in three doses in patients, although its efficacy in
these situations has never been documented.
If "giant" aneurysms are diagnosed, systemic heparin
therapy is often instituted. especially in patients in whom the
aneurysms are rapidly increasing in size. When an adequate
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anticoagulation state is reached, oral warfarin (Coumadin) is
substituted and administered in addition to aspirin, maintaining an international normalized ratio (INR) in the 2.0 to
2.5 range. This is the most common regimen for patients
with giant aneurysms. Low-molecular-weight heparin is
occasionally used instead of warfarin; however, this treatment requires twice daily injections. Experience with newer
inhibitors of platelet aggregation, such as c1opidogrel and
ticlopidine, is very limited in pediatrics. The risks and
potential benefits of various anticoagulation regimens are
considered on an individual basis. 103
Patients taking chronic aspirin therapy should receive
yearly influenza vaccines. Other therapies should be substituted if the child develops influenza or varicella infection
because of the risk of Reye's syndrome. In addition, because
the varicella vaccine is a live vaccine, aspirin should be
substituted with another regimen for 6 weeks after recei ving
this vaccine.
Thrombolytic Therapy. Clots may occur even with
antithrombotic therapy, especially in patients with giant
aneurysms causing blood flow in the area of the aneurysm to
be very sluggish. Thrombolytic therapy is considered if clot
formation is detected, through either signs or symptoms of
myocardial ischemia or infarction or by echocardiography.
Because no large clinical trials have been conducted in
children, the use of thrombolytic agents is based on studies
in adults with coronary thrombosis. Urokinase and streptokinase have both been used to restore vessel patency. 104· 106
The earlier thrombolytic therapy is instituted after clot
formation or the onset of ischemic symptoms, the greater is
its efficacy. The adjunct use of other therapies such an
antagonists to glycoprotein Ilb-I1Ia receptor (i.e. Abciximab) have been encouraging in adults and small pediatric
studies; however, further data are required to determine
safety and efficacy in the pediatric population. 107 If reperfusion is achieved, systemic heparin therapy and aspirin are
administered to maintain vessel patency, followed by oral
antithrombotic regimens. Close assessment of laboratory
measures of coagulation and cardiac function is a priority in
these patients.
Anticongestive Therapy. CHF in patients with Kawasaki disease is most often a consequence of ischemic
cardiomyopathy, although it may occur acutely in patients
with marked myocarditis. In those rare patients, intravenous
inotropes and afterload reduction may be necessary. More
often, patients with CHF from ischemic disease and
coronary insufficiency require therapy with oral digoxin,
diuretics, ~-blockers, or ACEIs.
Surgical Intervention. Coronary bypass surgery, although technically difficult with small vessels, has been
performed in children with severe coronary artery disease.
The indications for bypass surgery in children are not well
established; however, surgery may be indicated if (I) coronary stenosis or occlusion is progressive, (2) collateral blood
supply is not adequate, (3) the portion of myocardium to be
perfused via the graft is still viable, and (4) the vessel
proximal to the planned graft site is healthy.99 In addition to
the technical difficulty of coronary artery bypass surgery in
pediatric patients, children often develop collateral circula-
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tion around a coronary occlusion over time. Because grafts
need to remain patent for many decades, surgery is usually
recommended only for those with life-threatening vascular
disease.
Coronary bypass surgery is contraindicated in patients
with acutely inflamed or excessively small coronary vessels.
Coronary artery anatomy in some also precludes bypass
operation. In adclition, the disease may damage the internal
mammary arteries (most often used as graft vessels in
children).
Interventional Cardiac Catheterization Techniques. Over the past decade, significant advances have
been made in catheterization interventions in patients with
Kawasaki disease. Percutaneous transluminal coronary angioplasty (PTCA) has been performed in children with
coronary artery stenosis with varying success. PTCA is a
more difficult technique in patients with Kawasaki disease
than in adults with coronary artery disease mainly because
the areas of stenosis are often very stiff and calcified. The
balloon pressures necessary to dilate these areas can
predispose the patient to late aneurysm formation. Rotational ablation techniques and stent placement have also
been used in this population. 108
Cardiac Transplantation. Cardiac transplantation
has been performed in a small number of patients with
Kawasaki disease. 109 This operation is obviously a last
resort for patients with severe ischemia and is only used in
situations in which surgery or catheter intervention is
not possible.

Cardiomyopathy
Cardiomyopathy is a disease of the heart muscle itself.
Cardiomyopathy may be idiopathic, primary (i.e., of unknown cause), or secondary to a known cause or systemic
disease that affects the heart muscle. Cardiomyopathy is
further classified into the following three types:
I. Dilated, characterized by ventricular dilation, systolic
(contractile) dysfunction, and signs and symptoms
ofCHF
2. Hypertrophic, usually with preserved or enhanced
contractile performance and diastolic dysfunction
(compliance)
3. Restrictive, marked by impaired diastolic filling
(Fig. 18-31)

Because of overlap, the distinction between one category
and the next is not absolute. The basic characteristics of each
type are outlined in Table 18-9. Restrictive cardiomyopathy
is rare in children and is not considered in the sections
that follow.
Dilated Cardiomyopathy. Dilated cardiomyopathy
(DCM) is the most common cardiomyopathy in pediatric
patients (characterized by increased ventricular volume with
ventricular dilation). OCM results from a group of diverse
disorders that affect myocarclial contractile proteins, leading
to decreased contractility. OCM is characterized by systolic
dysfunction. Typically, the left ventricle (and sometimes the
right) is enlarged, thin walled, and poorly contractile.
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Fig. 18-31 Comparison of three morphologic types of cardiomyopathy. Ao, Aorta; LA. left atrium; LV, left ventricle. (Modified
from Roberts WC, Ferrans VJ: Pathologic anatomy of the
cardiomyopathies, HI/m Porhol 6:287, 1975. In Wyngaarden JB,
Smith LH, Bennett JC: Cecil textbook of medicine, ed 19,
Philadelphia, WB Saunders, 1991, p 332.)

Etiology. The etiology can be heterogeneous and
multifaceted. In the majority of patients, the cause of DCM
is unknown, although a link to myocarditis is often
presumed. Myocarditis that leads to the development of
OCM is an important factor. In some patients with
"primary" cardiomyopathy, retrospective evidence of a
postviral disorder includes inflammatory changes on endocardial biopsy, high antibody viral titers, and others. 6u In
addition, research evidence shows that patients with idiopathic cardiomyopathy have abnormalities of both cellular
and humoral immunity. Antimyocardial antibodies, cytotoxic T cells, suppressor T cells, and natural killer cells have
been identified in some studies. lIn Possibly a prior myocarditis incorporates viral components in cardiac cells, which
then serve as an antigenic source that directs the immune
system to attack the myocardium.
Up to 25% of patients with idiopathic OCM have a
familial form of the disease. 111 This condition can be caused
by autosomal dominant inheritance, with first-degree relatives having the highest risk for development of OCM. 112
Familial disorders such as neuromuscular disorders and
inborn errors of metabolism are associated with the development of OCM. Ouchenne and Becker muscular dystrophy
are the most commonly encountered neuromuscular disorders that develop cardiomyopathy. m The inborn errors of
metabolism include but are not limited to, glycogen storage
disease, fatty acid oxidative disorders, and mucopolysaccharidosis. Endocardial fibroelastosis can also cause OCM.

Cardiovascular structural disease, arrhythmias (incessant
tachycardia), coronary artery disease, Kawasaki disease, and
hypertension may lead to OCM. Secondary myocardial
disease results from systemic causes in which the primary
illness is extracardiac. OCM may result from nutritional
deficiencies, carnitine deficiency, obesity, radiation, malignancy, drug toxicity (alcohol, chemotherapy), and other
systemic infections and illnesses. Il3
Incidence. OCM is the most common form of cardiomyopathy. Reported annual incidence in the United States is
2 to 8 cases per 100,000. 114
Pathogenesis. The ventricles become dilated and thin
walled and the atria become enlarged. Ventricular hypertrophy is sometimes seen, but the thickness of the ventricular
wall is inadequate for the degree of dilation present. Poor
contractility permits stasis of blood, particularly in the
ventricular apex, thereby setting the stage for thrombus
formation.
Histologic features include fibrosis, myocyte hypertrophy, possible necrosis, and occasionally lymphocytes. Structural changes in the mitochondria have been found on
electron microscopy. Genetic analysis has discovered mutations in beta-myosin, troponin, and dystrophin-all important cardiac contractile proteins.
Many of these patients develop arrhythmias, particularly
ventricular arrhythmias. These can be a significant cause of
sudden death in this population. 1IS
Clinical Manifestations. Pediatric patients with
OCM may be asymptomatic for months, despite systolic
dysfunction and ventricular dilation. Many present with
signs and symptoms of CHF. A few children are not
identified as having OCM until severe ventricular dysfunction occurs and cardiogenic shock with low output is
present. Occasionally, ventricular ectopy or syncope may be
the presenting sign.
Physical examination may reveal pulmonary congestion,
a quiet precordium, a prominent S3 gallop, and hepatomegaly. If left ventricular dilation and dysfunction are severe,
the murmur of mitral regurgitation may be heard at the apex.
Diagnosis. Chest radiographs reveal marked cardiomegaly and pulmonary edema (Fig. 18-32). The ECG may
be normal or can show nonspecific ST-T wave abnormalities, atrial enlargement, left bundle branch block, ventricular
strain, QRS prolongation, or sinus tachycardia. An important aspect is that the presence of left bundle branch block
is an ominous sign. II6 Echocardiography shows enlargement of one or both ventricles and provides quantitative
analysis of ventricular function. Shortening and ejection
fractions are both decreased, and in some, regional wall
motion abnormalities are detected. Mural thrombi may be
evident by echocardiogram, especially in the left ventricular
apex and left atrial appendage.
Histologic examination and PCR of myocardial tissue obtained via cardiac catheterization ll ? aid further
in elucidation of the cause. Cardiac catheterization also
aids in determining hemodynamic measurements and cardiac output.
Urine tests for organic and amino acids may be useful in
diagnosing metabolic or inborn errors of metabolism as the

TABLE

18-9 Classification of Cardiomyopathies
Dilated

Restrictive

Hypertrophic

Congestive heart failure,
particularly left sided
Fatigue and weakness
Systemic or pulmonary emboli

Dyspnea, fatigue
Right-sided congestive heart
failure
Signs and symptoms of
systemic disease: amyloidosis, iron storage disease, etc.

Dyspnea, angina pectoris
Fatigue, syncope, palpitations

Moderate to severe cardiomegaly; S" and S4
Atrioventricular (AV) valve
regurgitation, especially
mitral

Mild to moderate cardiomegaly;
S3 or S4
AV valve regurgitation; inspiratory increase in venous pressure (Kussmaul's sign)

Mild cardiomegaly
Apical systolic thrill and heave;
brisk carotid upstroke
S4 common
Systolic murmur that increases
with ValsaJva maneuver

Moderate to marked cardiac
enlargement, especially left
ventricular
Pulmonary venous hypertension

Mild cardiac enlargement
Pulmonary venous hypertension

Mild to moderate cardiac
enlargement
Left atrial enlargement

Sinus tachycardia
Atrial and ventricular
arrhythmias
ST segment and T wave
abnormalities
Intraventricular conduction
defects

Low voltage
Intraventricular conduction
defects
AV conduction defects

Left ventricular hypertrophy
ST segment and T wave
abnormalities
Abnormal Q waves
Atrial and ventricular
arrhythmias

Left ventricular dilation and
dysfunction
Abnormal diastolic mitral valve
motion secondary to abnormal compliance and filling
pressures

Increased left ventricular wall
thickness and mass
Small or normal-sized left
ventricular cavity
Normal systolic function
Pericardia! effusion

Asymmetric septal hypertrophy
(ASH)
Narrow left ventricular outflow tract
Systolic anterior motion (SAM)
of the mitral valve
Small or normal-sized left
ventricle

Diminished left ventricular
compliance
"Square root sign" in ventricular pressure recordings
Preserved systolic function
Elevated left- and right-sided
filling pressures

Diminished left ventricular
compliance
Mitral regurgitation
Vigorous systolic function
Dynamic left ventricular
outflow gradient

Fig.18·32 Chest x-ray film of infant with cardiomegaly and pulmonary
edema/congestive heart failure. (From Baker A: Acquired heart disease in infants
and children, Crit Care Nul's eli" North Am 6: 182, 1994.)

638

Part IV

Final Common Pathways

etiology. Molecular analysis, if available, may aid in the
diagnosis of genetic causes.
Critical Care Management. If an underlying cause
is identified, such as carnitine deficiency or a metabolic
disorder, this finding can direct specific replacement or
dietary interventions.
Anticongestive therapy is initiated to support cardiac
function. Diuretics are implemented for volume reduction.
The critically ill child may require intravenous inotropic
support and afterload reduction. Dobutamine and phosphodiesterase inhibitors will augment stroke volume. Dopamine
is usually kept at renal doses. The nitrovasodilators and
phosphodiesterase inhibitors augment vascular relaxation,
decrease resistance, reduce ventricular work, and may
improve LV relaxation. Frequently intubation and mechanical ventilation is necessary during acute illness for respiratory support and to decrease the metabolic work of the
respiratory muscles. Bed rest and or sedation are implemented as needed to decrease metabolic demands.
If the patient is well enough for oral agents. then digoxin
and ACEIs are frequently employed. Third-generation
~-blockers (carvedilol) have been found to decrease symptoms and improve survival in patients with DCM.14.118 It
has been postulated that ~-blockers lower adrenergic activity and prevent ~-receptor up-regulation, therefore attenuating one of the neurohumoral responses associated with
heart failure (see section on CHF).
Although controversial, some clinicians institute anticoagulation therapy in patients with intracavity stasis to
prevent thrombus formation in the dilated and poorly
contractile heart. Management of ventricular rhythm disturbances may be necessary for some patients. Selection of
antiarrhythmics is based on negative inotropic and proarrhythmic side effects. Amiodarone has been shown to be
efficacious in suppression of ventricular ectopy without
significant negative inotropic effects. 119.120 Occasionally a
patient with intractable, refractory ventricular tachycardia or
ventricular fibrillation will require implantation of an
internal automatic defibrillator.
Serial monitoring of cardiac function with echocardiography is performed to evaluate improvement or deterioration
after the institution of medical management. If the patient is
unresponsive to medical management or if symptoms are
rapidly progressive, cardiac transplantation may be considered. Ventricular assist devices have been used as a bridge to
transplantation in this population.
Hypertrophic Cardiomyopathy. Hypertrophic cardiomyopathy (HCM) is a heterogeneous disorder that is
characterized by a hypertrophied, nondilated left ventricle in
the absence of hypertension, coronary artery disease, aortic
stenosis, and coarctation of the aorta. Infants often have
biventricular hypertrophy.
The pathophysiologic consequence of histologic changes
and hypertrophy of the left ventricle is abnormal relaxation
or diastolic dysfunction. Diastolic dysfunction can lead to
exercise intolerance, cardiac rhythm disturbances, and
sudden death.
The age of onset can be quite variable, and sudden death
can be the first manifestation of HCM. Most patients present

in adolescence or early adulthood. Sudden death occurs
most often between 15 to 35 years of age, and many of these
patients are asymptomatic or only mildly symptomatic
before death. 114.121
Etiology. HCM is a familial, genetically linked autosomal dominant disease in at least 50% of cases. 122
Significant advances in molecular genetics have found a
large number of heterogeneous mutations in genes that
encode for myocardial contractile proteins. In HCM the
causative mutations are generally in the sarcomeric proteins
known as: beta-myosin heavy chain, troponin I, troponin T,
troponin C, light chains of myosin, and cardiac binding
protein. 123 Although a single family may share the same
genetic protein defect, clinical presentation and manifestations can be quite varied.
HCM has also been reported to be associated with tacrolimus124.125 and long-term high-dose steroid therapy.'26
Transient HCM has been reported in infants of diabetic
mothers and secondary to fetal distress. 127 Noonan's syndrome, Pompe's disease, Beckwith-Wiedemann syndrome,
and infiltrative diseases are also associated with HCM.
Incidence. Because the onset of HCM is so variable,
the absolute incidence is unknown. In addition, many
patients can have subclinical disease, making patient
identification difficult. Although reports vary, HCM may
have an incidence of up to 2.5% per 100,000 and accounts
for up to 30% of pediatric primary myocardial disease. I 14
Pathogenesis. Histologic features consistent with
HCM include fibrosis, myocardial cellular disorganization,
myocyte hypertrophy, scarring, and abnormal intramural
coronary arteries. Cellular disarray is interspersed throughout the left ventricle and can occur in areas of normal or
mildly increased thickness. The intramural arteries are
thickened with a narrow lumen and are found around areas
of fibrosis and scarring, implying a casual relationship
between small vessel disease and ischemia. 128 Myocardial
bridging (from hypertrophied muscle) has been reported in
10% of children with HCM and may cause compression of
the coronaries with subsequent ischemia. 129 All of these
factors may contribute to hypertrophy, impaired diastolic
function, arrhythmias, and sudden death.
Structural anomalies include left ventricular hypertrophy
and mitral valve abnormalities. Left ventricular hypertrophy
(LVH) is usually asymmetric. The anterior ventricular
septum and anterolateral free wall typically demonstrate the
greatest degree of wall thickening. The pattern and extent of
LVH exhibit marked heterogeneity among patients. Infants
less than I year old can have concentric LVH and right
ventricular hypertrophy. I 14 In infants and children, significant increases in hypertrophy can occur with age, particularly during the accelerated growth phase of adolescence.
Structural abnormalities of the mitral valve (MV) include
increased MV area, elongated leaflets, thickened leaflets,
and anomalous attachment of the papillary muscle directly
into the anterior leaflet without the interposition of the
chordae tendineae. MV abnormalities may be secondary to
asymmetric hypertrophy and altered flow dynamics.
Many of these patients have left ventricular outflow tract
obstruction (LVOTO). This condition can be quite variable
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and often is dynamic in that it worsens with exercise,
tachycardia, dehydration, or anemia. Obstruction can occur
in early, mid, or at the end of systole (which is the classic
finding). LVOTO can be secondary to septal hypertrophy,
anterior displacement of the papillary muscles, or malposition of the MV during systole. Systolic anterior motion
(SAM) of the MV causes coaptation of the anterior MV
leaflet with the septum producing LVOTO. SAM is felt to be
secondary to a high-velocity jet of flow through the LV
outflow tract (Venturi effect) or flow drag on the leaflet. The
duration and onset of SAM is directly related to the
magnitude of the LV outflow tract gradient. 128
Unlike the older child or adult, infants and young
children often develop RVOTO as well from septal hypertrophy. 114 The subpulmonary obstruction tends to be fixed
and not dynamic, contributing to overall right ventricular
hypertrophy.
Diastolic dysfunction is characteristic of HCM, resulting
from decreased chamber distensibility and increased chamber stiffness (poor compliance). Myocyte hypertrophy,
fibrosis, myocardial ischemia, and cellular disorganization
are all factors in diastolic dysfunction. Although diastolic
dysfunction is unrelated to the severity of outflow tract
obstruction or distribution of hypertrophy, it can be present
when symptoms and LVOTO are absent. 128
Myocardial ischemia occurs in many patients with HCM
and is believed to be responsible for myocardial fibrosis and
scarring. Potential causes of myocardial ischemia include
abnormal coronaries, increased oxygen demand that exceeds
delivery, or elevated ventricular wall tension from prolonged diastolic relaxation interfering with perfusion.
Other pathologic sequelae of HCM include mitral
regurgitation, arrhythmias, and, rarely, systolic dysfunction.
Mitral regurgitation is secondary to SAM and other MV
abnormalities. Arrhythmias are often seen in children with
HCM and can be both supraventricular and ventricular.
Sustained ventricular tachycardia is thought to be an
important cause of sudden death in adults, 130 but this factor
has not been shown in children. I 15 Systolic function is
usually supranormal; however, a patient can progress to a
DCM and subsequently develop systolic dysfunction.
Clinical Manifestations. The majority of people
with HCM are either asymptomatic or only mildly affected.
Often these patients are identified during screening after
detection of an affected family member. Early recognition of
HCM in children is important because of the increased risk
of sudden death in young patients. Death commonly occurs
during competitive sports or severe exertion in often
asymptomatic or mildly symptomatic children. Sometimes
the only previous symptom is syncope. Clinical symptoms
are not often appreciated in children over I year of age;
however, when they do occur, they consist of dyspnea,
exercise intolerance, chest pain. presyncope, and syncope.
Infants, on the other hand, are often quite symptomatic with
tachypnea, tachycardia, poor feeding, and CHF. Children
over the age of I year rarely present in CHF. 114
The physical examination may be completely normal in
asymptomatic patients. Most children however, have a left
ventricular lift, and the apical impulse is often displaced
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laterally and is unusually forceful. If LVOTO is significant,
a thrill may be palpable along the left sternal border. Often
a systolic murmur prompts the referral for evaluation by a
cardiologist; however, this sign is only found in 40% of
patients." 4 The second heart sound may be paradoxically
split, and third and fourth heart sounds are frequently
audible.
Diagnosis. Chest radiograph often demonstrates cardiomegaly with normal PBF. Most patients will have
abnormal ECGs, making this a useful screening tool for
HCM. ECG abnormalities include LVH, ST segment
changes, ventricular strain, deep Q waves, and QTc and
QRS prolongation UI Ventricular preexcitation and WolffParkinson-White (WPW) syndrome have also been associated with HCMI32.133
Echocardiography is the most useful tool in diagnosing
HCM. The degree of LVH, outflow tract obstruction,
systolic and diastolic function, MV abnormalities, and SAM
can be determined. Serial echoes can help monitor progression of disease and response to therapeutic intervention.
Invasive studies include cardiac catheterization and
radionuclide studies. Although echocardiography has all but
replaced cardiac catheterization as a diagnostic tool, occasionally biopsy is performed to diagnose mitochondrial
disorders as a cause. Thallium perfusion scans are used to
detect regional perfusion abnormalities.
If the patient has symptoms in infancy, metabolic studies
should be performed to identify causative factors such as
glycogen storage disease or mitochondrial disorders. Blood
and urine tests for amino and organic acids should be
obtained.
Critical Care Management. Overall management of
patients with HCM is directed toward alleviating symptoms
and reducing the risk of sudden death. Data regarding the
natural history of the disorder in pediatric patients are
limited. Some patients are stable without symptoms,
whereas others have symptoms that rapidly progress. The
prognosis for infants who present before I year of life is
poor, particularly if the initial presentation is CHF. 114
Alleviating Symptoms. Responses to therapeutic intervention can be highly variable, so therapy must be
individually tailored for symptom control. Treatment of
asymptomatic children is controversial. Many clinicians
treat asymptomatic patients (particularly if there is a
malignant family history of sudden death) to try to improve
the clinical course of the disease. Note that none of these
therapies to date have shown to improve survival, but rather
the goal is symptom control. Medical therapy includes the
use of negative inotropes, calcium channel blockers, and
antiarrhythmics (if warranted).
Negative inotropes such as P-blockers and disopyramide
improve symptoms of angina, dyspnea, exercise intolerance,
and presyncope. These agents are thought to decrease left
ventricular ejection acceleration with subsequent reduction
of SAM and LVOTO. 134
Calcium channel blockers are believed to improve LV
relaxation and filling and may reduce myocardial ischemia. 135 These agents are often lIsed in patients who
continue to have symptoms while receiving P-blockers.
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Verapamil has been used most often; nifedipine and
diltiazem have also shown beneficial effects. Care must be
used in patients with severe outflow tract obstruction
because the vasodilating properties of calcium channel
blockers in this scenario can be detrimental.
Arrhythmias are a frequent complication of HCM. QTc
prolongation, ventricular tachycardia, WPW syndrome, and
atrial fibrillation are associated with sudden death in adults
with HCM.129.136.137 Although whether this phenomena
holds true for children is uncertain, many clinicians treat
arrhythmias in symptomatic patients, particularly in those
with syncope. Amiodarone has been shown to be effective
in treating both atrial fibrillation and ventricular tachycardia. 135 Clinical effect, side effects, and concurrent
drug interactions determine the choice of a specific
antiarrhythmic.
Diuretics are used cautiously as high filling pressure are
required to augment cardiac output. Generally diuretics are
reserved for infants presenting in CHF. Positive inotropes
are contraindicated because they can worsen dynamic
LVOTO.
Surgical Intervention. Patients who fail medical management and who remain symptomatic may undergo surgical septal myectomy-myotomy for relief of LVOTO.
Myectomy-myotomy can relieve both the obstruction and
the mitral regurgitation. Reducing left ventricular systolic
pressure decreases myocardial oxygen demand and can
improve symptoms in many patients. 138 Perioperative mortality is low, and postoperative management is similar to that
of other open heart procedures. 139 Surgical myectomy has
not been shown to improve survival in patients with HCM.
The rare patient who remains symptomatic after medical
and surgical management or who progresses to the dilated
form of cardiomyopathy may be considered for cardiac
transplantation.
Dual-Chamber Pacing. In select patients who are
refractory to medical management, dual-chamber pacing has
been implemented. In some patients this approach can
decrease LVOTO and improve symptoms.140.141 The mechanism for improvement remains unclear. It has been
postulated that RV apex pacing, along with a short AV
interval, changes the septal activation sequence, resulting in
dyssynchronous septal contraction, improved diastolic filling, and ventricular remodeling. 142 Occasionally, pharmacologic prolongation of AV conduction time or AV node
ablation is required to maintain AV sequential pacing. This
treatment modality remains controversial and is not universally embraced by all clinicians. 143
Reducing the Risk of Sudden Death. HCM is a significant cause of sudden death in adolescents and young adults.
Risk factors include malignant family history of sudden
death from HCM, syncope, young age, and, in adults,
ventricular tachycardia on Holter monitoring. 144 The cause
of sudden death is presumed to be either a ventricular
arrhythmia or myocardial ischemia. Because sudden death
often occurs during exercise, the patient should be restricted
from engaging in strenuous exertion or competitive sports.
To date, predicting the clinical course of HCM is
impossible because it is so heterogeneous in presentation

and progression. Medical and surgical management help
control symptoms, but unfortunately, no intervention has
been shown to improve survival.

CARDIAC RHYTHM DISTURBANCES
Technologic advances and a better understanding of cardiac
electrophysiology have improved accurate diagnosis and
management of cardiac rhythm disturbances. In addition, an
expanding array of innovative treatment modalities, including new antiarrhythmics, pacing algorithms, and radiofrequency catheter ablation, have improved outcomes.
Arrhythmia diagnosis can be a relatively simple and
concise or challenging and complex. The management of
abnormal heart rhythms can range from simple vagal
maneuvers to antiarrhythmic medication, pacemaker placement, or radiofrequency catheter ablation. The sections that
follow detail the diagnosis and management of cardiac
rhythm disturbances in infants and children.

Etiology and Pathogenesis
A wide variety of structural and functional cardiac diseases,
along with systemic diseases, can be the underlying cause of
rhythm disturbances. Most arrhythmias are due to abnormal
impulse conduction (reentrant circuits), abnomlal impulse
generation (increased automaticity or an ectopic focus), or a
combination of both.
Generally the sinus node determines heart rate and
rhythm. In the presence of sinus node dysfunction or
suppression, the distal portions (AV node, His bundle) of the
conduction system will take over. The rate of sinus node
discharge is primarily determined by autonomic tone. In
addition, changes in the cellular milieu can affect sinus node
activity (i.e., temperature, pH, P0 2, and extracellular potassium and calcium concentrations).
The presence of an accessory connection, suture lines, or
scarring can form the substrate for reentrant arrhythmias.
These arrhythmias are triggered by an extrasystole and are
propagated over the substrate until they are terminated by
block (adenosine, pacing, and cardioversion) in one of the
limbs of the reentrant circuit. See the section on ECG
interpretation in Chapter 7.
All cardiac cells are excitable and can spontaneously
depolarize; this is called automaticity. Abnormal automaticity can occur anywhere in the conduction system or in
isolated myocytes (ectopic focus). Autonomic tone or
conditions that contribute to local changes in cell membrane
potential, such as excessive cardiac stretch, ischemia,
hypokalemia, and digoxin toxicity, affect these rhythm
abnormalities. Ectopic impulse initiation competes with and
can suppress normal sinus node activity. Automatic rhythms
are generally not responsive to adenosine or pacing for
termination.

Diagnosis
Many factors are considered when evaluating a child with a
rhythm disturbance. An accurate history is critically impor-
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tant, particularly because many arrhythmias do not happen
in a predictable manner. The ability to determine symptoms
depends on the age of the child; infants or small children
will not be able to adequately describe symptoms associated
with palpitations or tachycardia. Older children will be able
to identify triggering events, onset, and termination of
rhythm abnormalities. In evaluations, the onset and termination of arrhythmias should be identified. Older children
can easily describe the sudden onset and termination of
supraventricular tachycardia. Automatic tachyarrhythmias
are less easily identifiable because of their typical "warm
up" (slow increase in heart rate) and "cool down" (slow
deceleration). Associated symptoms and should be identified; these include chest pain, fatigue, light-headedness, and
syncope. Precipitating events should be investigated as well.
Past medical history of congenital or acquired cardiac
disease, infectious diseases, or genetic syndromes is investigated. Any family history of cardiac rhythm disturbance or
sudden unexplained death in young adults or teenagers
should also be investigated. The physical examination
concentrates on the cardiovascular system. Cardiac auscultation reveals abnormal murmurs, clicks, and other sounds
that are clues to the identification of structural heart disease.
The rate and regularity of the cardiac rhythm are assessed.
Physical signs that the rhythm disturbance compromises
cardiac function or tissue perfusion are noted.
Electrocardiogram. The surface 12- or IS-lead ECG
and the cardiac rhythm strip are important tools for ECG
interpretation and arrhythmia detection. However, such
recordings illustrate cardiac rhythm at a single point in time
and may not reveal abnormalities. The mechanism of the
arrhythmia also may remain unclear because P waves may
be difficult to visualize. Recording the ECG with an
esophageal electrode or from epicardial pacing wires
provides additional information when the heart rate is rapid
or when atrial activity is difficult to distinguish.
Current telemetty and arrhythmia monitoring units are
helpful in caring for patients with arrhythmias in the critical
care unit. These systems store electrocardiographic strips for
analysis and can recognize some types of specific rhythm
abnormalities.
Echocardiography. The echocardiogram is performed to evaluate cardiac structure and function. CHDs
often associated with cardiac rhythm disturbances are listed
in Box 18-5. Decreased ventricular contractility in the face
of a rhythm disturbance presents a dilemma. Has the
arrhythmia led to a poorly contractile ventricle or is a poorly
functioning heart the cause of the rhythm disturbance?
Baseline evaluation of ventricular function also is important
because antiarrhythmics may depress function further.
Electrophysiology Study. Invasive evaluation of the
conduction system is undertaken with an electrophysiologic
study (EPS). At cardiac catheterization, multiple catheters in
the right heart are used to record the ECG from various sites
(the SA node, AV node, and His bundle). With the aid of
pacing protocols and manipulation of automaticity (isoproterenol, atropine, ~-blockers), automatic foci or accessory
pathways can be located. In addition to definitive diagnosis
of a rhythm disturbance, EPS permits evaluation of medi-
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cation efficacy and therapeutic ablation of an arrhythmogenic substrate.

Sinus Node Abnormalities
Sinus bradycardia, sinus tachycardia, and sinus node disease
(SND) (also called sick sinus syndrome) may be seen in
pediatric patients in the PICU. Both sinus bradycardia and
tachycardia are fairly common and generally are not cardiac
in etiology; they result from other underlying causes. SND
is more common in children who have extensive atrial
incision lines or scarring (Fontan, Mustard, Senning) or who
have atrial pressure elevation or dilation (Fontan, mitral
stenosis, cardiomyopathy). 145
Sinus bradycardia is a heart rate less than the lower limits
for age. Sinus tachycardia is heart rate greater than
age-related normal values (see Table 7-7).
S D manifests as sinus bradycardia or sinus arrest or as
a combination of bradycardia and atrial tachyarrhythmias
(brady-tachy syndrome). SND can also contribute to the
development of junctional rhythm as a result of abnormal
sinus node suppression.
Etiology and Clinical Presentation. Sinus bradycardia may be caused by hypoxia, hyperkalemia, vagal
stimulation, increased intracranial pressure, hypothyroidism, sedation, anesthesia, hypothermia, or sleep. Cardiac
causes include sinus node dysfunction and medications
(e.g., digoxin or ~-blockers). Sinus tachycardia is a physiologic response to fever, sepsis, pain, anxiety, anemia,
hypovolemia, thyrotoxicosis or CHF, or it may be caused by
medications (e.g., catecholamines).
SND is most often seen in pediatric patients who have
had atrial surgery for CHD, most notably atrial baffling
procedures (Senning, Mustard) for transposition of the great
vessels or the Fontall procedure. Inadvertent trauma to the
SA node or its blood supply has been implicated in the
development of SND. Follow-up of patients who had a
Mustard, Senning, or Fontan procedure revealed SND in
50%.146.147 Also at risk for SND, although less commonly
affected, are those who have operations for ASD, AVSD,
Ebstein's anomaly, and anomalous pulmonary venous return. Infrequently, SND is seen in patients with unrepaired
mitral stenosis, ASD, or single-ventricle physiology.
Other nonsurgical causes of SND include myocarditis,
cardiomyopathy, and myocardial ischemia. Increased vagal tone can induce SND. Antiarrhythmics (e.g., digoxin,
~-blockers, calcium channel blockers, and type I medications) may cause sinus node dysfunction as a side effect.
Many pediatric patients with SND are asymptomatic
except when the heart rate is excessively slow. Children
with SND may not demonstrate a normal chronotropic
response (increase in heart rate) with exercise or stress.
Therefore these patients will complain of fatigue, exercise
intolerance, presyncope, or syncope. Infants may exhibit
poor feeding, lethargy, and CHF.
Critical Care Management. Treatment of sinus bradycardia requires the identification of the underlying cause
and assessment of hemodynamic significance. The majority
of children with sinus bradycardia respond to stimulation,
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Box 18-5
Congenital Heart Defects and Cardiac Rhythm Disturbances

Unoperated Congenital Heart Defects

Eisenmenger's Syndrome (Pulmonary Vascular Obstructive
Disease)
Ventricular arrhythmias (ventricular volume and pressure
overload)
Sudden death
Atrial fibrillation or flutter
Pulmonary Stenosis or Atresia and Cyanosis
SVT
Atrial fibrillation or flutter
Ventricular arrhythmias (especially with marked polycythemia)
Ebstein's Anomaly
SVT
WPW with SVT
Atrial flutter or fibrillation
AV block
Junctional rhythm
Ventricular tachycardia and fibrillation
Corrected Transposition oJ the Great Arteries
AV block (second or third degree)
WPW with SVT
Tricuspid Atresia
Atrial ectopy, flutter, fibrillation
Ventricular ectopy

Tetralogy oJ Fallot (in Older Palients)
Ventricular arrhythmias
SVT
Atrial Septal DeJects (in Older Patients)
Atrial flutter and fibrillation
SVT
Junctional and ectopic atrial rhythms
Sinus node dysfunction (sinus venosus ASD)
AV block (primum ASD)
Postoperative Arrhythmias in Congenital Heart Disease

Extensive Atrial Surgery/Repairs With Elevated Atrial
Pressure (Fonlan Procedure. Muslard or Senning Repair, TOlal
Anomalous Pulmonary Venous Return, Atrial Septal DeJect
(Rare/)
Supraventricular arrhythmias
SVT*
Incisional intraatrial reentrant tachycardia
Sinus node dysfunction
Si nus bradycardia
Ventricular arrhythmias (as patients age)
Ventricular Septal Surgery (Ventricular SepIaI DeJect,
Tetralogy oJ Fallot. AV Canal DeJecls, Subaorlic Stenosis)
AV conduction block
Ventricular tachycardiat

Aortic Stenosis and Coarctation oJ the Aorta
Ventricular arrhythmias (with marked elevation of left
ventricular pressure)
* An unusual form of SVT. junctional ectopic tachycardia. or accelerated junctional rhythm is seen most commonly after repair of tetralogy of Fallat or the Funtan repair.
tVenlricular tachycardia i!'l alsn noted after repair of the Ebstein's anomaly, coronary artery anomalies. single-ventricle defects with the Fantan procedure, and
D-transposition of the great arteries.

Svr. Supraventricular tachycardia; WPW; Wolff-Parkinsoll-White syndrome; ASD.

oxygen, or hand ventilation. Acute management, if the
bradycardia is refractory to the aforementioned interventions. is intravenous administration of atropine or epinephrine. Protracted, hemodynamically significant bradycardia
can be treated with temporary atrial pacing (in the absence
of AV node block) or isoproterenol.
Treatment of sinus tachycardia lies in remedying the
underlying cause of the physiologic response of the heart to
demands for increased cardiac output.
Treatment of SND is dependent on symptoms and
associated atrial arrhythmias. Permanent pacemaker implantation is indicated for excessively slow heart rates and
symptom control. SND and bradycardia increase the risk for
atrial fibrillation or flutter. 148.149 Therefore antibradycardia
pacing is advocated in this population to suppress the
development of atrial tachyarrhythmias. 145

atrio~eptal

defect; AY, atrioventricular.

Atrial Arrhythmias
Atrial arrhythmias can be the consequence of an automatic
or reentrant rhythm abnormality. Atrial arrhythmias include
premature atrial contractions. supraventricular tachycardia
(AV reentrant tachycardia, AV nodal reentrant tachycardia,
atrial ectopic tachycardia), atrial fibrillation, atrial flutter,
and intraatrial reentrant tachycardia.
Premature atrial contractions (PACs) are common, particularly in infants and children. Isolated PACs are a benign
condition (even if they occur frequently) and are not treated,
so they are not discussed here.
Supraventricular Tachycardia. SVT is the most
common rhythm abnormality in infants and children. SVT is
a broad term that encompasses a number of tachycardia
mechanisms. It can be caused by either a reentrant or
automatic mechanism (Box 18-6).
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Box 18·6

Types of Supraventricular Tachycardia

Reentry With an Accessory Connection
Wolff-Parkinson-White syndrome (manifest accessory
connection)
Atrioventricular nodal reentry tachycardia (AVNRT)
Atrioventricular reentry tachycardia (AVRT)
Incisional intraatrial reentry tachycardia (IART)
Permanent junctional reciprocating tachycardia

Ectopic Focus With Increased Automaticity
Atrial ectopic tachycardia (AET)
Junctional ectopic tachycardia (JET)

Etiology and Clinical Presentation
Reentrant SVT. The substrate for reentrant tachycardias is an accessory connection that allows propagation of
the tachycardia via retrograde conduction from the ventricles to the atria and antegrade conduction down the
AV node. 150 Reentrant mechanisms are responsible for
the majority of SVTs and by definition can be initiated
and terminated by pacing. Termination can also be achieved
by blocking one arm of the circuit (AV node) with
adenosine. Atrioventricular reentrant tachycardia (AVRT)
and atrioventricular nodal reentrant tachycardia (AVNRT)
are specific terms identifying the electrophysiologic cause
of the most commonly encountered forms of clinical SVT.
AVRT is most often encountered in infants and small
children. Substrate for the arrhythmia is an accessory
connection (AC) as previously described. Sometimes the
AC is not apparent on surface ECG in sinus rhythms. In a
subset of patients, the AC is apparent on ECG in sinus
rhythm (ventricular preexcitation); this suggests WPW
syndrome and is diagnosed by the presence of a delta
wave and short PR interval on ECG (see Chapter 7). To
truly diagnose WPW syndrome, the patient must have
ventricular preexcitation and SVT. Some individuals may
have ventricular preexcitation on ECG and no SVT, and
therefore they are asymptomatic. There is an increased risk
for sudden death in patients with WPW. Sudden death in
WPW is due to atrial fibrillation and the rapid anterograde
conduction of atrial fibrillation over the AC, resulting in a
rapid ventricular rhythm. Cardiac arrest has been reported as
the first rhythm abnormality in otherwise asymptomatic
patients with WPW. 151
AVNRT is a reentrant rhythm occurring within the AV
node with two distinct AV node pathways (dual AV node
physiology). This form of SVT usually manifests in
childhood or adolescence. Premature junctional reciprocation tachycardia (PJRT) is another reentrant tachyarrhythmia, but it is rare and is not discussed.
Both AYRT and AVNRT are clinically similar and
respond in like manner to therapeutic intervention. The most
common ages for occurrence of SVT are the first year of life
and puberty. Infants usually present with poor feeding,
pallor, and irritability. Up to 50% can present in CHE150.152
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Older children complain of palpitations or heart racing that
is sudden in onset and termination. They may have
associated chest pain, light-headedness and, rarely, syncope.
Any child with WPW syndrome and syncope warrants EPS
for risk stratification and documentation of life-threatening
arrhythmia and consideration of radiofrequency ablation.
Automatic SVT. Automatic SVTs are due to enhanced
automaticity or a discrete focus in the atrium. These rhythms
cannot be terminated or initiated by pacing, although the
rhythm can be suppressed by rapid overdrive pacing. Atrial
ectopic tachycardia (AET) and JET are the two forms
encountered most often in children. AET commonly presents in infancy, and it can be incessant or intermittent.153.154 This rhythm abnormality can be an important
cause of cardiomyopathy if not identified in a timely
manner. 155 (See discussion of JET under section on junctional arrhythmias.)
Clinically this rhythm can be difficult to identify because
it can mimic sinus tachycardia, as the rates may not be
excessively high. Palpitations are uncommon; more typically the patient presents in heart failure or with decreased
ventricular function.
ECG Characteristics. AVRT and AVNRT are manifested as a narrow complex, regular tachyarrhythmia that is
sudden in onset and termination. Retrograde P waves follow
the QRS but may be hard to identify in AVNRT. Rates
in infants are 250 to 300 beats/min; in children, up to
250 beats/min; and in adolescents, 150 to 220 beats/min
(Table 18-10).
The ECG in AET can be variable, depending on the
site of origin in the atria. It exhibits a warm-up and
cooldown on initiation and termination, atrial rates vary
from 130 to 300 beats/min. P waves before the QRS are
visible, but morphology is different from the P wave in
sinus rhythm. The PR interval is prolonged, particularly
at faster rates. This rhythm does not terminate with AV
block.
Critical Care Management. Management of SYT is
determined by the underlying substrate and clinical symptoms. Many patients with reentrant SVT will have infrequent, short episodes of tachycardia that require no intervention. The natural history of most reentrant SVT is benign
with an excellent outcome. Approximately 25% to 30% of
infants with reentrant tachycardia will have no clinical or
inducible SYT by I year of age. In addition, infants with
WPW syndrome can have loss of ventricular preexcitation
(delta wave) on surface ECG at I year. 152
In hemodynamically stable SYT that does not convert
spontaneously, vagal maneuvers may be successful. Note
that this approach will only terminate reentrant SVT, not
AET. The diving reflex can be elicited by applying ice to the
face or by submerging the face in ice water. Cold fat
necrosis can occur with prolonged applications of ice to the
face. It is recommended that ice be applied to the less fatty
areas of the infant's face and a cloth barrier be used. 156
Elicitation of the diving reflex works best with infants and
young children. Older children can be instructed to bear
down, blow against a thumb placed in the lips without
exhaling, or stand on their heads.
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TABLE 18-10 Characteristics of Sinus and Supraventricular Tachycardia

~History

S".

Sinus Tachycardia

Supraventricular Tachycardia

Febrile illness, dehydration, or volume loss

Lethargy or irritability, poor feeding, pallor,
diaphoresis without specific causation

Consistent with fever, dehydration, or bleeding

Signs of CHF: tachypnea, ralcs, dyspnea,
hepatomegaly, decreased tissue perfusion

Normal heart size, clear lung fields

Cardiomegaly, pulmonary edema

Heart rate usually >200 beats/min, slight variation
in R-R intervals, P waves visible, narrow QRS

Heart rate >220 beats/min, regular R-R intervals,
P waves may be retrograde or nondetectable (50%),
narrow QRS (>90%)

Usually normal

Ventricular dilation, dysfunction

~t

~Examjnation

fl:'"

~E!::hest x-ray
~!,ECG*

film

~l
"'.

E!;

~EchOCardiOgram
~~Pata from Hanisch
ifh.:t:~n

DG, Perron L: Complex dysrhythmias in infants and children. AACN Clill Issues Crit Care Nurs 3:255-267, 1992,
additional ECG finding, if the onset of the arrhythmia is captured: ST will manifest a gradual acceleration in heart rate as compared with the abrupt

of SVT.
~{:HF, Congestive heart failure: ECG, electrocardiogram.

~.onset

;g':.-

Patients with frequent sustained episodes require antiarrhythmic therapy for controL Acute termination of reentrant
SVT through AV nodal blockade is accomplished by adenosine. This must be given rapid intravenous push at a port
proximal to the patient, followed by a large-volume rapid
flush. Occasionally, reonset of SVT will occur despite temporary termination with adenosine. If the tachycardia is incessant and hemodynamically significant, intravenous
procainamide or amiodarone is used to convert to sinus
rhythm. These patients require close monitoring in the
PICU, frequent ECGs to evaluate for a~sociated QTc prolongation, and support of hemodynamics. Once the rhythm is
contrOlled, they can switch to oral antiarrhythmics.
Less critically ill patients with frequent SVT can be
managed with oral agents such as ~-blockers, digoxin,
amiodarone, flecainide, and verapamil, noting that intravenous verapamil is contraindicated in infants under I year of
age because of related cardiovascular collapse. (See the
section on antiarrhythmic therapy in Chapter 7 for detailed
review of the listed medications.)
AET can be quite resistant to pharmacologic therapy.
Although some children outgrow this rhythm, many develop
cardiomyopathy in the interim. Rate control is important,
particularly in the face of ventricular dysfunction. Many antiarrhythmics are ineffective, with class IC and III being the
most effective.153.154 Intravenous amiodarone is very effective in the critically ill child with AET. 157 Oral amiodarone,
sotalol, and f1ecainide are effective for chronic therapy.
Overdrive atrial pacing is sometimes used to terminate
reentrant SVT that is incessant and refractory to pharmacologic intervention. The atrium is paced (esophageal electrode or epicardial electrodes) at a rate faster than the SVT
rate for up to 30 seconds. Initially, if pacing is not
successful, the rate can be increased incrementally, but it
should not be so rapid as to induce atrial fibrillation. Pacing
will not terminate AET.
Radiofrequency catheter ablation is recommended for
any children with SVT, WPW syndrome, or AET who have
frequent episodes of tachycardia, are refractory to medications, have ventricular dysfunction, or syncope. Complications are rare (approximately 3%), and freedom from

arrhythmia recurrence is 70% to 90% (dependent on the
arrhythmogenic substrate).155.'5M
Atrial Fibrillation, Atrial fibrillation is rare in children with structurally normal hearts. However, in children
with atrial enlargement (Fontan, mitral regurgitation [MR],
Ebstein's anomaly, cardiomyopathy) or ventricular dysfunction, it can be hemodynamically significant. t49 Atrial fibrillation can be life threatening in patients with WPW syndrome who have rapid antegrade conduction across their AC.
Etiology and Clinical Presentation. Mechanism of
atrial fibrillation involves multiple reentry circuits within
the atria. These give rise to small, disorganized electrical
waves of acti vity. AV node conduction is variable, with an
irregular ventricular rate. In children, atrial fibrillation
generally occurs in the setting of congenital heart disease,
thyrotoxicosis, WPW syndrome, or cardiomyopathy. or it
can be familial. 150
Clinically these patients may be asymptomatic, with an
irregular heart rate often being a serendipitous finding on
routine examination. If the ventricular rate is rapid, the child
may complain of palpitations or heart racing. Patients with
WPW syndrome may present symptoms of tachycardia,
syncope, and cardiac arrest.
ECG Characteristics. No visible P wave with disorganized atrial activity is evident that results in either coarse
or fine fibrillatory waves. There is no discrete atrial activity,
and the ventricular rate is variable and irregular because of
variable AV conduction.
Critical Care Management. Atrial fibrillation is
unresponsive to pacing. Synchronized cardioversion is
necessary for conversion if the episode does not terminate
spontaneously (Box 18-7). Before cardioversion, it must be
determined how long the patient has been in atrial fibrillation. Intracardiac thrombus can form if atrial fibrillation has
been present for longer than 48 hours, despite anticoagulation. Therefore transesophageal echocardiogram must be
performed to evaluate for thrombus, given that the risk for
embolization is significant during cardioversion.
Intravenous procainamide may be helpful in converting
the rhythm or in making refractory atrial fibrillation responsive to cardioversion. Digoxin is effective in ventricular rate
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Box 18-7

~ Cardioversion and Defibrillation in Pediatric Patients
Indications

Multifunction Pad Size

Synchronized Cardioversion (R Wave Sensing Ensured)
Intraatrial reentry tachycardia (IART), atrial flutter or
fibrillation
Supraventricular tachycardia
Ventricular tachycardia
Not indicated for junctional ectopic tachycardia or chaotic
atrial rhythm

Less than 15 kg: pediatric
Greater than IS kg: adult

Standard
Base at upper right chest
Apex at left anterior axillary line

Defibrillation (Asynchronous)
Pulseless ventricular tachycardia
Ventricular fibrillation

Anterior·Posterior
Base on anterior chest over the heart
Apex on the back

Electrode Placement

Sedation

Energy Dose

If awake: choice of agent will vary with institutional and clinician preference and is based on the patient's clinical status,
Fentanyl, propofol, midazolam (Versed), lorazepam (Ativan),
morphine sulfate, or ketamine can be used as single agents
or in combination,

Synchronized Cardioversion
0,5-1 watt-second (joule) per kg
Repeat with 2 watt-second/kg if needed

Paddle Size

Defibrillation
2 watt-second/kg
Repeat with 4 watt-second/kg if needed

Infant: 4,5 cm
Child: 8 or 13 cm (ensure good contact with skin)
Adapted from Perry JC. Garson .1\: Diagnosis and treatmen( of arrhYlhmias. Adl' Pediarr 36: 177-200, 1989.

control by slowing AV node condttction, and it may be
helpful in improving hemodynamics to prevent recurrences,
Atrial Flutter/lntraartial Reentrant Tachycardia.
Classic atrial flutter (AF) is a regular reentrant atrial rhythm,
is usually found in infants with structurally normal hearts,
and is rare,149 Intraatrial reentrant tachycardia (IART)
accounts for most of the "atrial flutter" in children and often
occurs in patients who have undergone surgical correction
of congenital heart disease,
Etiology and Clinical Presentation, AF is rare but
can be seen in neonates with structurally normal hearts,
Often the diagnosis is made on fetal echocardiogram, The
atrial rates are usually 250 to 450 beats/min, with variable
AV conduction and ventricular rate, CHF can develop if
there is delay in making the diagnosis,
IART is a reentrant rhythm and has slow atrial rates (up
to 250 beats/min), which distinguishes TART from classic
AF Atrial surgery (Fontan, Mustard, Senning, ASD, and
TAPVR repair) is the usual cause of arrhythmia substrate_25.159 In addition, conditions that contribute to AV
valve regurgitation or stenosis with subsequent atrial
dilation (MR, mitral stenosis [MS], tricuspid regurgitation,
Ebstein's anomaly) are associated with IART. 5l,l48 Atrial
suture lines, atrial scarring, or abnormal atrial tissue caused
by chronic atrial volume and pressure overload form the
arrhythmia substrate. An atrial circuit, usually around the
suture lines, characterizes the reentrant course of IART, with
sufficient recovery time in one limb of the circuit to allow
tachycardia propagation. 1S9
Clinically, children with AF and IART usually present
with a fixed, (this can be the key to diagnosis) rapid heart

rate that does not vary with activity or physiologic state
(sleep). If the rate is slow, the patient may be asymptomatic,
If the ventricular rates are high, the child may complain of
palpitations, hem1 racing, fatigue, and exercise intolerance,
If not identified in a timely manner, CHF may ensue. The
development of IART often indicates poor hemodynamics
and is often seen in children with SND and bradycardia 51
ECG Characteristics. AF is characterized by rapid,
regular sawtooth flutter waves that are morphologically
different from the P waves in sinus rhythm, Variable AV
conduction is often present (usually 2: I), so the subsequent
ventricular rate is half the atrial rate.
IART is sometimes difficult to identify on ECG. The
atrial rate is usually 250 beats/min or less, without the
classic sawtooth flutter waves found in AF The P waves are
distinct from the sinus P wave and are frequently of low
amplitude. If 2: I conduction is present, the ventricular rate
will be slower than classic AF, making diagnosis difficult.
Although adenosine will not usually terminate the arrhythmia, it is helpful in making the diagnosis with ECG because
AV block will slow the ventricular rate, making the flutter
waves more apparent (Fig. 18-33), This arrhythmia should
always be suspected in any patient who has undergone a
Fontan, Senning, or Mustard procedure with a fixed,
nonvariable heart rate or with a heart rate that is more rapid
than expected.
Critical Care Management. In the neonate with a
structurally normal heart, AF is easily terminated with
synchronized cardioversion or atrial overdrive pacing. Late
recurrences are uncommon, and chronic antiarrhythmic
therapy is unnecessary,
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Fig. 18-33 ECG of infant in intraatrial reentrant tachycardia. To confirm diagnosis, a dose of adenosine
was given to produce AV block, making flutter waves more apparent.

IART requires conversion to sinus rhythm, along with
evaluation of hemodynamics. Medical or surgical interventions to maximize hemodynamics can help control recurrences. Some patients can present in asymptomatic IART
and in hindsight may have been in this rhythm for weeks or
months. These patients are at risk for the development of
intracardiac thrombi resulting from atrial stasis, even if
currently on anticoagulation therapy. The risk of embolic
phenomena is not insignificant in patients with atrial flutter
and can occur with cardioversion. l60 Therefore thrombi
must be ruled out with transesophageal echocardiogram
(TEE) before cardioversion. 161 Hemodynamically stable
patients with intracardiac thrombi present a therapeutic
dilemma. If clot is present in the left atrium, then many
clinicians advocate anticoagulation with repeat TEE before
cardioversion. The ideal period for anticoagulation has yet
to be detennined. However if ventricular function is
decreased, the patient is hemodynamically unstable, or if the
clot is on the systemic venous side of the heart, then
cardioversion is perfonned.
Synchronized cardioversion (0.5 to I watt/kg) is usually
effective in restoring sinus rhythm. Some patients are
refractory or may develop recurrence of IART. In this
scenario, intravenous procainamide or amiodarone may be
effective in either converting the rhythm or improving the
ability to electrically cardiovert. Chronic antiarrhythmic
therapy is individualized and can consist of amiodarone,
procainamide, P-blockers, or sotalol.
Rapid overdrive atrial pacing may also tenninate IART.
This must be performed in a controlled environment
because the atrium is paced at a rate just faster than the atrial
tachycardia rate. Rapid atrial burst pacing or the introduction of PACs after rapid atrial pacing will make one limb of
the circuit refractory, thereby terminating the arrhythmia.
This technique is most effective if the child has not been in
IART for a protracted period of time. Coexisting SND and
bradycardia are risk factors for the development of IART.
Therefore the recommendation is that these patients be
pennanently paced (modes AAI or DDD at rates of
about 80 beats/min) to prevent the development or recurrence of IART.
Radiofrequency catheter ablation, cryoablation, and the
Maze procedure have all been advocated as treatment for
incessant refractory IART. To date, the success of radiofre-

quency catheter ablation is less than satisfactory, with recurrence as high as 50%.162.163 Intraoperative cryoablation is
currently advocated in some Fontan patients during surgical
revision from intracardiac to an extracardiac Fontan, particularly because the atrium cannot be accessed for catheter
ablation after this procedure.I64.165 Antitachycardia pacemakers have been implanted during surgery in select patients to tenninate postoperative IART. 165 The Maze procedure is infrequently perfonned in children; however, in
adults it is advocated for control of AF or atrial fibrillation.
In this operative procedure, a number of surgical incisions
are made in the atrium (taking care to prevent injury to the
sinus node) to interrupt the reentrant circuit. This surgery
can be curative in up to 98% of adult patients. 166

Atrioventricular Nodal
and Junctional Arrhythmias
Junctional arrhythmias are the consequence of abnormal
automaticity in the AV node or HIS bundle, which produces
JET. They can also be due to sinus node slowing or disease
with subsequent junctional escape rhythm. Premature junctional beats or accelerated junctional rhythms are not life
threatening so are not discussed in detail. Treatment of SND
will generally abolish the junctional rhythm.
Junctional Ectopic Tachycardia. JET is an automatic tachycardia that can be difficult to diagnose and treat.
Etiology and Pathogenesis. JET is an automatic
tachycardia caused by enhanced automaticity of the AV
node or proximal His bundle. Most often, JET is a transient
phenomenon occurring acutely in infants or young children
after cardiac surgery (TOF, VSD, TGA). Rarely, JET is seen
as a congenital rhythm disturbance in infants with structurally normal hearts.
The pathophysiologic consequences of JET are the result
of both the sustained rapid heart rate and associated decrease
in ventricular filling caused by loss of "atrial kick" from AV
dissociation. In postoperative cardiac surgery patients,
profound hypotension and cardiovascular collapse may
develop. Infants with congenital JET develop left ventricular dysfunction over several months. 154
ECG Characteristics. The ECG of JET is characterized by a narrow QRS, the morphology of which is similar
to the postoperative sinus rhythm. (This can make it difficult
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Fig. 18-34 Atrial ECG of infant in junctinnal ectopic tachycardia
(JET). Top recording is from atrial epicardial wires; note that

junctional rate is slightly faster than atrial rate.

to distinguish it from an atrial tachycardia.) There is AV
dissociation with the ventricular rate faster than the atrial
rate. An atrial epicardial or transesophageal ECG is most
often necessary to differentiate JET from other types of SVT
(Fig. 18-34)
Critical Care Management. Postoperative JET is a
transient, self-limiting arrhythmia that resolves spontaneously in hours to days after onset. Mildly increased
junctional rates can be well tolerated, but rapid JET results
in hemodynamic instability or death. The goal of management is twofold: first, to restore AV synchrony and, second,
to slow the junctional tachycardia. AV synchrony is restored,
provided the heart rate is less than 200 beats/min, by
overdrive atrial or AV sequential pacing at a rate slightly
above the junctional rate.
In addition, this rhythm is catecholamine sensitive, so
every attempt should be made to decrease or discontinue the
infusion of exogenous catecholamines. Unfortunately, poor
hemodynamics exacerbate JET, so the risks and benefits of
intravenous inotropes must be individually balanced for
each patient. Hyperthermia and electrolyte imbalances are
treated vigorously.
Early intervention to slow the junctional rate is best
achieved by hypothermia to a core temperature of 34 0 C to
35° C, using a cooling blanket. Occasionally temperatures
as low as 33° C are necessary.167 To prevent shivering,
hypothermia necessitates sedation and chemical paralysis
with intubation and mechanical ventilation.
Pharmacologic therapy of JET is difficult. Digoxin is
generally ineffective in controlling JET, although it may
improve hemodynamics. Procainamide alone or in combination with hypothermia has been shown to be effective. 167
Intravenous amiodarone can be used if the JET is refractory
to cooling, pacing, or procainamide. 157
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ECMO has been used for emergency support of infants
with life-threatening JET. The aim of this therapy is
cardiovascular support until the arrhythmia spontaneously
resolves. 168 Rarely, catheter ablation has been implemented
as a lifesaving maneuver.
Most postoperative patients who develop JET do quite
well, as long as ventricular rate is controlled and hemodynamics are supported. If these two goals are not accomplished, death may ensue. Effective therapy usually results
in a ventricular rate less than 170 beats/min.
Atrioventricular Conduction Block. Three forms
of AV block are discussed here. For further review, see
Chapter 7.
Etiology and Clinical Presentation. First-degree
heart block is the consequence of slowed impulse conduction through the AV node. It is characterized by a prolonged
PR interval on the ECG with a P wave preceding each QRS
complex. These patients are asymptomatic because there is
no significant hemodynamic impact. This conduction disturbance does not necessitate intervention beyond the
identification of its cause. In pediatric patients, digoxin
administration is the most common cause of first-degree
heart block.
Second-degree heart block occurs when an occasional
or patterned block of AV conduction occurs. The ECG characteristics of Mobitz type I and Mobitz type II seconddegree heart block have been described in Chapter 7. Mobitz
type I second-degree heart block may reflect AV node
dysfunction in patients following intracardiac surgical
procedures near the AV node or in those with digoxin,
~-blocker, calcium channel blocker, or quinidine toxicity. It
may be seen in patients without cardiovascular disease,
especially during sleep. Most often, treatment is not
required because this conduction delay does not compromise cardiac output and it is unlikely to progress to complete
heart block.
Mobitz type II second-degree heart block is usually
related to His bundle or bundle branch block, most often
resulting from surgical injury. Progression to complete heart
block can occur.
Complete heart block (CHB) is also called third-degree
heart block. It can be related to structural heart disease
(L-TGA), it may be congenital in infants with normal
cardiac structure, or it may be acquired (myocarditis,
surgery). Regardless of the cause, the SA node paces the
atria, whereas an independent junctional or ventricular
pacemaker establishes the ventricular rhythm. Cardiac
output may be compromised if the ventricular rate is
excessively slow.
Congenital heart block appears infrequently and most
infants have a structurally normal heart. Structural defects
associated with congenital heart block are L-TGA, AV
septal defects, endocardial fibrosis, and left atrial isomerism. In infants without CHD, a strong association is
found between the incidence of congenital CHB and
maternal connective tissue disease, typically systemic lupus
erythematosus.
Low fetal heart rate usually leads to the prenatal
diagnosis of congenital CHB. Fetal echocardiography de-
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tects asynchronous and independent contraction of the atria
and ventricles. Fetal mortality is high. 169
After birth, infants with congenital CHB may be
asymptomatic, or they may be in severe CHF as manifested
by hydrops fetal is, tachypnea, and lethargy. Postnatal
mortality is increased if there is associated structural heart
disease. After infancy, children with congenital CHB and a
structurally normal heart may have exercise intolerance,
fatigue, sleep disturbances, or syncope. In these patients, the
ventricular rate and the ability to increase heart rate with
activity determine their symptoms.
Acquired CHB is most often seen as a complication of
intracardiac surgery near the AV junction, although it can
also occur secondary to endocarditis, myocarditis, or Lyme
disease. Surgical procedures with increased risk for CHB
include repair of VSDs or AVSDs, L-TGA, TOF, aortic
valve replacement, and mitral or tricuspid valve replacement,145 Postoperative or acquired CHB may be transient or
permanent. In the postoperative period, resumption of sinus
rhythm may take up to 2 weeks.
ECG Characteristics. The P wave in patients with
CHB originates in the SA node and is of normal
morphology. However, transmission through the AV node
is blocked, and an escape rhythm, usually generated by
a site high in the His bundle, ensues. The QRS complex
may be wide or narrow. The P-P interval is usually regular,
as is the R-R interval. The atrial rate is faster than the
ventricular rate.
Critical Care Management. Postoperative heart
block is managed acutely by temporary AV sequential pacing, ideally in the DDD mode. If the temporary pacemaker cannot sense the intrinsic atrial rate appropriately,
then a DVI or VVI mode can be used (see Chapter 7).
Implantation of a permanent pacemaker is recommended
in patients with postoperative heart block that persists for
14 days.79
The ventricular rate and symptoms determine acute
management of CHB. In severe symptomatic, hemodynamically significant bradycardia, a continuous infusion of
epinephrine or isoproterenol will increase the heart rate until
temporary pacing can be instituted. If the cause of CHB is
acquired (other than postoperative CHB), temporary pacing
may only be necessary until recovery of the AV node is
achieved. If the AV node apparently will not recover, then a
permanent pacemaker is needed.
Asymptomatic newborns with congenital CHB are monitored continuously for a number of days before discharge. In newborns, permanent pacing is indicated for
CHF, ventricular rate less than 55 beats/min, prolonged
QTc, wide QRS escape rhythm, or frequent ventricular
ectopy.169
Children with congenital CHB are followed closely
because symptoms can occur at any age. Exercise testing
and Holter monitoring are used to determine heart rate with
exercise and to detect ventricular arrhythmias. Frequent
ventricular ectopy, exercise intolerance, syncope, low heart
rate (6 to 10 years, less than 50 beats/min; 16 to 20 years,
less than 45 beats/min), QTc prolongation, or inadequate

heart rate response to exercise are criteria for pacemaker
placement, 170.171

Ventricular Arrhythmias
Infants and children have far fewer ventricular arrhythmias
than adults. Premature ventricular contractions and ventricular tachycardia are the ventricular rhythm abnormalities
most commonly encountered in pediatric patients.
Premature Ventricular Contractions. Premature
ventricular contractions (PVCs) are recognized on ECG as
an early QRS complex with morphology different than that
of the sinus QRS. Typically the duration of the QRS
complex is prolonged, and the complex is bizarre in
appearance. However, a nearly normal appearance and
duration of the QRS are not uncommon, particularly in
infants.
PVCs can either be single, clustered in groups of two

. Box 18-8
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Drugs Known to ProlongQTt .

Note: These drugs should be avoided if QTc is prolonged or if
long QT syndrome is present.
Adrenergic Agents

Adrenaline
Antihistamines

Terfenadine (Seldane)
Astemizole (Hismanal)
Diphenhydramine (Benadryl)
Antibiotics

Erythromycin
Sulfamethoxazole (Septra)
Pentamidine
Antifungals

Ketoconazole
Fluconazole
Itraconazole
GI Medications

Cisapride
Cardiac Medications

Quinidine
Procainamide
Disopyramide
SOlalol
Probucol
Psychotropic Medications

Amitriptyline
Phenothiazines
Haloperidol
Risperidone
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(couplets), or occurring in runs (three, four, five, etc., beats
in a row). Bigeminy occurs when every other beat is
a PVc. The morphology of the PVC should also be
evaluated because multiform PVCs may be more ominous.
PVCs that are single, uniform, and suppressed with
exercise and increased heart rate are benign and do not
require treatment in children with structurally normal
hearts. These are quite common, noted in as many as
18% of newborns, 6% of infants, 14% of children, and
27% of adolescents. 147 Conversely, children with structural heart defects, multiform PVCs, or couplets are at
increased risk for hemodynamic compromise or progression to a lethal ventricular rhythm. Careful surveillance is
necessary with periodic Holter monitoring, however, most
children with PVCs require only observation and no
intervention.

Fig. 18·35
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Electrolytes and pH should be monitored in hospitalized
children with PVCs, particularly after open heart surgery.
Potassium, calcium, and magnesium levels should be kept
normal with replacement therapy if necessary. Persistent
acidosis should be corrected.
Ventricular Tachycardia. Ventricular tachycardia
(VT) is a wide-complex tachycardia with AV dissociation,
the origin of which is the ventricle. The ventricular rate
will be faster than the atrial rate on ECG. This rhythm
can be due to abnormal impulse generation or conduction.
Hemodynamic significance of VT depends on the rate, the
presence of heart disease, and whether it occurs with
exercise. Occasionally a child in SVT will present with
wide-complex tachycardia. Clinically significant widecomplex tachycardia should be considered a VT until
proven otherwise.

Venrricular tachycardia in 6-month-old with severe left ventricular outflow tract obstruction.

Fig. 18-36 Ventricular tachycardia with torsade de pointes configuration. (From Holbrook PR: Textbook
of pediatric critical care. Philadelphia, 1993, WB Saunders, p 406.)
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Etiology and Clinical Presentation. Causes of VT
in infants and children include electrolyte or metabolic
disturbances, including acidosis, hypoglycemia, hyperkalemia, hypokalemia, hypercalcemia, hypomagnesemia, and
hypothennia. Other potential causes are drug toxicity
(digoxin, quinidine, procainamide, sympathomimetics, anesthetic agents, cocaine, caffeine, nicotine) and cardiac
pathologic conditions (cardiomyopathy, aortic stenosis,
myocarditis, cardiac tumors). VT has been implicated as
a cause for sudden death in patients after repair of TOF. 172
Idiopathic or congenital long QT syndrome is characterized by ventricular repolarization abnormalities that
can result in polymorphic ventricular tachycardia (torsades
de pointes) and sudden death. Idiopathic long QT can
be caused by drugs (Box 18-8) or electrolyte imbalances, most notably hypokalemia, hypocalcemia, and
hypomagnesemia. 173.174
Symptoms are dependent on the rate and hemodynamic effects of the VT. If the rate is slow, the tachycardia can be well tolerated, and the patient may be asymptomatic. Rapid rates can result in the sensation of
palpitations, light-headedness, syncope, or cardiovascular
collapse.
ECG Characteristics. VT occurs at a rate generally between 120 and 300 beats/min. The complexes are
wide and can be bizarre in appearance (Fig. 18-35).
However, if the VT focus is near the AV node, the QRS may
only be slightly prolonged. Torsade de pointes occurs in
the presence of QTc prolongation and is characterized as
a rapid, spiraling, polymorphic VT, as illustrated in
Fig. 18-36.
Critical Care Management. The hemodynamic significance of the rhythm disturbance, age, type of tachycardia, and associated symptoms determine management of VT.
Acute short-term management of hemodynamically significant VT is cardioversion. If the patient is stable, an
intravenous bolus of lidocaine followed by a continuous
infusion may convert the rhythm to sinus. Intravenous
amiodarone can be used in patients who are refractory to
lidocaine. Once the rhythm is controlled, attention is
directed toward identifying and correcting the underlying

cause. Synchronized cardioversion is necessary if the patient
is unstable.
Asymptomatic patients with slow ventricular rates and no
associated heart disease require no treatment. Various
antiarrhythmics can be used for chronic therapy, including
amiodarone, J3-blockers, flecainide, and propafenone (see
Chapter 7).175
Radiofrequency catheter ablation can be used to treat
some forms of VT, depending on the cause (right or left
ventricular outflow tract VT). Surgery to remove intracardiac tumors or to localize and cryoablate hamartomas is
advocated if the patient is symptomatic. Automatic internal
cardiac defibrillators (AICDs) are implanted in patients with
life-threatening ventricular tachycardia and fibrillation.
Patients with long QT syndrome should be treated with
chronic J3-blocker therapy and occasionally with anti bradycardia pacing. The development of torsade de pointes in
some of these patients has been shown to be adrenergic dependent-hence the importance of J3-blockers. Pacing
can help prevent bradycardia and "pause-dependent" torsade de pointes. J76 Treatment of hemodynamically significant torsade de pointes is intravenous magnesium.
Defibrillation is used in the patient with cardiovascular
collapse.
Ventricular Fibrillation. Ventricular fibrillation (VF)
results from erratic firing of multiple ectopic foci in the
ventricles, resulting in disorganized electrical activity,
ineffecti ve ventricular contraction, and death.
Etiology and Clinical Presentation. VF is uncommon in infants and children. It may occur in patients with
structural or functional heart disease or after prolonged
resuscitation attempts. VF results in pulselessness and
obvious cardiovascular collapse.
ECG Characteristics. An ECG without measurable
heart rate in which no P, QRS, or T waves can be
identified documents YF. An erratic, wavy baseline is
present (Fig. l8-37).
Critical Care Management. Cardiopulmonary resuscitation (CPR) is initiated to maintain circulation and
oxygenation while the defibrillator is readied. Rapid asynchronous defibrillation is performed up to three times
(2 watt-second/kg the first time and 4 watt-second/kg for

Fig. 18-37 Ventricular fibrillation. (From Curley MAQ: Pediatric cardiac dysrhythmias, Bowie, Md,
1985, Brady Communications, p 125. With permission of Appleton & Lange.)
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subsequent attempts). If YF persists, intravenous epinephrine (0.01 mg/kg) and lidocaine (I mg/kg) are administered
while CPR continues. Defibrillation (4 watt-second/kg) is
attempted 30 to 60 seconds after the medications are
administered. Persistent YF is treated with second doses of
epinephrine (0.1 to 0.2 mg/kg) and lidocaine (I mg/kg).
Epinephrine may be repeated every 3 to 5 minutes.
Bretylium (5 to 10 mg/kg) is considered. Defibrillation (4
watt-second/kg) is repeated 30 to 60 seconds after medication is administered 177 until YF is converted to sinus rhythm
or the situation is deemed hopeless and resuscitation
attempts are stop"ed.
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SUMMARY
Cardiovascular dysfunction may be the consequence of
cardiac rhythm disturbances or of structural, functional,
acquired heart diseases_ Heart failure, shock, or hypoxemia
are the potential final pathways. These phenomena are
multifaceted and can occur in any child in the PICU, not
only those with the primary diagnosis of heart disease. Care
of the critically ill child is optimized by attentive, accurate
cardiovascular assessment so that intervention is timely. A
sound knowledge base of cardiovascular pathophysiology is
important for any nurse caring for critically ill infants and
children.
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as knowledge of the causes and treatment of respiratory
failure.

RESPIRATORY FAILURE
MECHANISMS OF ABNORMAL GAS EXCHANGE
FINAL COMMON PATHWAYS

RESPIRATORY FAILURE

MECHANICAL ALTERATIONS: DISORDERS THAT INCREASE

Respiratory failure is frequently defined simply in terms of
blood gas abnormalities-for example, a Pa02 of less than
50 mmHg and a Paco2 greater than 50 mrnHg in a patient
who is spontaneously breathing room air. Quantifying
respiratory failure in this fashion, however, lacks specificity
and is ultimately inadequate. A child with a congenital heart
defect, for example, may have a Pa0 2 less than 50 mmHg
without respiratory failure. Similarly, a patient with a
diuretic-induced metabolic alkalosis may have an increase
in Paco2 to greater than 50 mmHg; however, this does not
indicate respiratory failure. In addition, in clinical practice,
blood gas tensions are often maintained with supplemental
oxygen. It follows that respiratory failure is more appropriately understood as an inability of the respiratory system
to fulfill its role in transferring oxygen (02) and carbon
dioxide (C0 2) to and from the venous blood in an amount
commensurate with the needs of the patient.
The advantage of this definition is that it emphasizes the
important link that exists between the function of the respiratory system and the metabolic requirements of the tissues.
For example, the infant with chronic lung disease may be
able to meet everyday metabolic demands, but when an
infectious process increases those demands, the child's respiratory reserve may be inadequate and respiratory failure
will ensue. In fact, fatigue from increased work of breathing,
rather than hypoxia, usually precipitates respiratory failure
in infants and children. Respiratory failure is also differentiated from respiratory distress, which is manifested by retractions, tachypnea, nasal flaring, and so on. The latter is a
judgment made by the clinician regarding the patient's work
of breathing or the patient's own perception of dyspnea and
does not necessarily imply respiratory failure. The child in
status asthmaticus, for instance, may have respiratory distress yet be able to meet metabolic needs. Compensatory
mechanisms, involving increased effort and use of addi-

THE WORK OF BREATHING

Upper Airways Disease
Lower Airways Obstructive Disease
Restrictive Disease
Mixed Obstructive and Restrictive Disease
Impairment of Respiratory Muscle Function
CIRCULATORY ALTERATIONS
ALTERATIONS IN CONTROL OF BREATHING
SUMMARY

A

Pproximately 24% of pediatric critical care practice
involves caring for patients with pulmonary problems. 1
Therefore knowledge of respiratory anatomy and physiology as well as familiarity with the common pathologies leading to respiratory failure are essential. This
chapter examines the physiology of the respiratory system
and the means by which physiology is altered by disease.
Respiratory failure is defined and the mechanisms of
abnormal gas exchange are reviewed. A short review of
the basic physiology of the developing respiratory system establishes the final common pathways of respiratory
failure: mechanical, circulatory, and regulatory alterations.
The remaining sections are devoted to specific disorders
associated with these final common pathways in infants
and children, exploring incidence, etiology, treatment,
and nursing management. Whether resulting from chronic
or acute processes, impending respiratory failure can be
extremely frightening for infants, children, and their families. Consequently, sensitivity and attention to the impact of
critical illness on children and their families is as important
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Box 19·1

.

Pediatric ICU Admission Criteria

1. Endotracheal intubation or potential need for emergency
endotracheal intubation and mechanical ventilation.
regardless of etiology.
2. Rapidly progressive pulmonary, lower or upper airway,
disease of high severity with risk of progression to
respiratory failure and/or total obstruction.
3. High supplemental oxygen requirement (FI0 2 0.5) regardless of etiology.
4. Newly placed tracheostomy with or without the need for
mechanical ventilation.
5. Acute barotrauma compromising the upper or lower
airway.
6. Requirement for more frequent or continuous inhaled or
nebulized medications that cannot be administered safely
on the general pediatric care unit.
Adapted from American Academy of Pediatrics Committee on Hospital Care
and Section on Critical Care Pediatric Section and Admission Criteria Task
Force: Guidelines for developing admission and discharge policies for the
pediatric intensive care unit Pediatrics 103:840-842, 1999.

tional respiratory muscles, can retard the development of
respiratory failure, even if it is at an increased energy cost.
In 1999, the American Academy of Pediatrics Committee
on Hospital Care and Section on Critical Care Pediatric
Section Admission Criteria Task Force developed guidelines
for admission and discharge criteria for pediatric intensive
care? For patients with severe or potentially life-threatening
pulmonary or airway disease, the admission criteria include,
but are not limited to, those listed in Box 19-1.

MECHANISMS OF ABNORMAL

GAS EXCHANGE

Mechanisms of impaired gas exchange in the lungs may
include diffusion, hypoventilation, shunt, and ventilationperfusion (\I10J mismatch disorders. Impediments in 02
diffusion do not represent a significant problem in children;
therefore we will concentrate on the remaining three.
Hypoventilation may be defined on the basis of reduced
minute alveolar ventilation [(tidal volume - dead space) x
(respiratory rate)] and inevitably results in an inability to
eliminate CO 2 , Because the increased alveolar CO 2 occupies space, 02 is displaced out of the alveolus and both
alveolar and arterial P0 2 are decreased. Supplemental 02'
however, can overcome this displacement, and restore Pa02
to normal (Fig. 19-1, B).
Normally, a small percentage of right ventricular output
is returned to the left atrium without passing through
ventilated areas of the lung. This represents a physiologic
right-to-Ieft shunt. Additional shunting of blood occurs
when collapsed alveoli continue to be perfused. Because
these alveoli are no longer ventilated, the blood circulating
through them is not oxygenated. This blood is mixed with
oxygenated blood from other ventilated areas, thereby
increasing pulmonary venous admixture, or causing an

abnormal right-to-left shunt. Pa0 2 decreases, but in this case,
supplemental 02 will not entirely abolish hypoxemia
because the shunted blood is not exposed to inspired O 2
(Fig. 19-1, C). Intrapulmonary shunting does not usually
result in an increase in Pac0 2 because the respiratory center
responds to hypoxemia by increasing ventilation.
ViQ mismatching is the most common cause of abnormal
gas exchange. If ventilation and blood flow are unequal in
various regions of the lung, impairment of both O 2 and CO 2
transfer results. Supplemental O 2 will, however, increase the
Pa0 2 to normal (Fig. 19-1, D).

FINAL COMMON PATHWAYS
The principal purpose of the respiratory system is to
exchange gases, O 2 and CO 2 , with the atmosphere. This
process requires the combined function of heart, blood
vessels, and lungs. It may be helpful to view the respiratory
system as a mechanical pump controlled by a complex
feedback system (Fig. 19-2). The pump includes the lung,
the chest wall, and the respiratory muscles (primarily the
diaphragm, but also the intercostal and abdominal muscles),
which, when acting on the chest wall (rib cage and
abdomen), expand and compress the lungs. Respiration is
regulated by the respiratory center in the brainstem. This
center is stimulated directly by CO 2 and hydrogen ions and
indirectly via central and peripheral chemoreceptors. In
addition, mechanoreceptors in the lung and chest wall
convey information about the status of the lungs. The central
nervous system integrates all of the data and acts on the
respiratory center where the respiratory pattern is established and conveyed through peripheral nerves like the
phrenic nerve to the muscles of respiration. The pulmonary
circulation completes the respiratory system by establishing
a close interface between inspired gas and the blood, which
permits delivery of 02 to the blood and removal of CO 2 ,
This conceptual model of the respiratory system also
delineates the three final common pathways of respiratory
failure. These involve mechanical, circulatory, and regulatory alterations. Mechanical (or pump) alterations in pulmonary function can be classified into two major categories:
illnesses that increase the work of breathing, and diseases in
which the respiratory muscles are unable to perform even
the normal amount of work. The former include disorders
that increase airway or pulmonary resistance (obstructive
disease), those that decrease thoracic compliance (restrictive
disease), and mixed disorders resulting in alterations in both
resistance and compliance (e.g., bronchopulmonary dysplasia [BPDl). The diseases that affect the respiratory muscles,
rendering them incapable of normal work, include disorders
of the peripheral nerves (Ouillain-Barre syndrome lOBS]),
the neuromuscular junction (infant botulism or myasthenia
gravis), and the muscle itself (muscular dystrophy). Circulatory alterations involve disturbances in the normal contact between blood and gas within the lungs; pulmonary
embolism (PE) and persistent pulmonary hypertension of
the newborn are characteristic examples. In these conditions, pulmonary circulation is reduced, physiologic dead
space increases, and gas exchange may be impaired. Finally,
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Fig. 19-1 Mechanisms of hypoxemia and effect of increased FlO, in patients with lung disease. In this
schematic representation. the normal lung is composed of two alveolar units with their respective
capillaries. A, While breathing room air, on the left, the FlO, in the alveoli (shown by the level of filling
of the alveolar units in the figure) is only 0.21. The alveolar Po, (PAO,. indicated by the shading inside the
alveoli), however, is sufficiently high to produce a normal Oz hemoglobin saturation in the pulmonary
capillaries (shown by the degree of shading inside the capillaries in the figure). Administration of an FlOz
of 1.0 barely increased the 0, content of the arterial blood. B, In the presence of hypoventilation, PAO, is
reduced in room air, and the capillary blood is poorly saturated. Administration of an FlOz of 1.0 increases
both the PAO, and 0, content of the capillary blood. C, An intrapulmonary shunt allows mixed venous
blood to pass through the lungs without being exposed to alveolar 0,. As a result, the arterial 0, content
is decreased. Supplemental 0, raises only the O2 content of the capillary blood that is not shunted; therefore
arterial 0, content increased only to a limited extent. D, In V/Q inequality, alveolar units that have a
decreased Po, exist in combination with others that have a nonnal P02 . Blood from these two types of units
mixes, resulting in a lower than normal arterial Oz content. Administration of Oz increases the PAO Z in both
hypoventilated and normal units, and the Oz content of the arterial blood increases as well. (Courtesy
J. Julio Perez Fontan, MD, and George Lister, MD, New Haven, Connecticut.)
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Fig. 19-2 Schematic drawing of the respiratory system. In this
schematic representation, the respiratory system consists of a
mechanical pump controlled by a complex feedback system. The
respiratory pump includes the lung. chest wall, and respiratory
muscles. Respiratory control is established by the respiratory
center in the brainstem and conveyed (via peripheral nerves) to the
muscles of respiration. Finally, the pulmonary circulation establishes an alveolar-capillary interface that permits gas exchange.

alterations in the control of breathing include primary or
secondary derangements in the breathing pattern such as
apnea and alveolar hypoventilation syndromes.

MECHANICAL ALTERATIONS:
DISORDERS THAT INCREASE
THE WORK OF BREATHING
Mechanical alterations in pulmonary function in infants and
children are often the result of illnesses that cause airway
obstruction. Because the signs and symptoms of obstruction
depend (in large part) on location, it is helpful to delineate
two categories of airway obstruction: extrathoracic or upper
airways disease (laryngotracheobronchitis, epiglottitis, foreign body aspiration, and pharyngeal obstruction) and
intrathoracic or lower airways disease (asthma, bronchiolitis, and tracheobronchomalacia).
The diameter of an airway is determined by the compliance of the airway wall, coupled with the deforming force
exerted upon it. The latter is the pressure difference between
the gas inside the airway and the tissues surrounding the
airway. This pressure difference, known as the transmural
pressure, varies during inspiration and expiration and differs
for extrathoracic and intrathoracic airways.
The signs and symptoms of obstruction depend on
location (extrathoracic or intrathoracic) and the direction of
airflow (inspiration or expiration). During inspiration, airway pressure becomes progressively more negative as the
alveoli are approached; a pressure gradient is necessary for
airflow to occur inside the airways. On expiration, the pressure within the alveoli becomes positive and the gradient is

reversed with pressures inside the airways being always
positive but diminishing toward the mouth. In contrast, the
influence of inspiration and expiration on the pressure outside the airway depends on whether the airways are extrathoracic or intrathoracic.
Extrathoracic airways (the pharynx, larynx, and a portion
of the trachea) are included in the tissues of the neck, where
the pressure can be considered to be zero or atmospheric.
Because intrathoracic airways are embedded in the chest,
however, the pressure affecting their airway caliber is the
pleural pressure. During inspiration, extrathoracic airways
have a transmural pressure that favors narrowing because
intraluminal pressure decreases, whereas the pressure exerted by tissues outside the airway remains constant. Intrathoracic airways dilate during inspiration as pleural pressure
becomes more negative than intraluminal pressure (i.e.,
transmural pressure decreases). During expiration, the situation is reversed; extrathoracic airways dilate as intraluminal
pressure becomes positive with respect to atmospheric pressure, and intrathoracic airways narrow as the pressure within
those airways decreases with respect to pleural pressure.
Airway obstruction causes an exaggeration of these normal
changes in airway diameter (Fig. 19-3).
Typical clinical manifestations accompany airway obstruction. First, and perhaps foremost, a relatively slow
respiratory rate helps to conserve energy. This can be readily
appreciated by breathing through a straw-it is much more
difficult to breathe rapidly than to breathe slowly. Additional
signs of obstruction include intercostal and/or substernal
retractions, which may be pronounced, and nasal flaring or
the use of accessory muscles of respiration. Based on the
previous discussion of airway dynamics, however, there are
substantial differences between extrathoracic (upper airways) and intrathoracic (lower airways) obstructiondifferences that can be detected by a careful clinical
examination (Table 19- I). Inspiration is prolonged in
extrathoracic obstruction, whereas the duration of expiration
remains unchanged. The opposite is true in intrathoracic
obstruction, in which expiration is prolonged and inspiratory
time unchanged. The adventitious sounds heard on auscultation also differ in extrathoracic and intrathoracic obstruction. Inspiratory stridor occurs in extrathoracic obstruction;
expiratory wheezing occurs in intrathoracic obstruction. Gas
trapping is not a predominant characteristic of extrathoracic
obstruction, but occurs often in intrathoracic obstruction.

Upper Airways Disease
The etiology of extrathoracic airway disease with obstruction may vary considerably, but the dynamic consequences
of the obstruction are the same: to overcome increased
resistance during inspiration, the child must create greater
negative pressure inside the airway segment downstream
from the obstruction. This segment of the airway tends to
collapse, worsening the obstruction and producing a characteristic inspiratory stridor. With extrathoracic obstruction
the child's respiratory rate is relatively low, mainly because
inspiration is prolonged. Suprasternal and subclavicular
retractions occur. In addition, nasal flaring and head bobbing
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Fig.19·3 Effect of the respiratory cycle on upper and lower airway obstruction. Upper airway obstruction
worsens during inspiration as intraluminal pressure decreases and the pressure outside the airways remains
constant (atmospheric pressure). Lower airway obstruction worsens during expiration when positive
pressures outside the airways (pleural pressure) exceed the pressure within the airways downstream from
the obstructiun. (Adapted from Fontan JJP. Lister G: Respiratory Failure. In Touloukian RJ, ed: Pediatric
trauma, 5t Louis, 1990, Mosby.)

TABLE 19-1 Differences Between Upper
and Lower Airway Obstruction on
Physical Examination

f~~espiratory rate
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H
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~l:_

+

~1'Wheezing

+

~1pas trapping

+

I;,

~t Increased;

!lo;i'

H,

unchanged; +, present; -, absent.

(neck extension during inspiration and flexion during
expiration) may serve to keep the airway open during
inspiration. In the pediatric intensive care unit (PlCU),
frequent causes of upper airways obstruction are laryngotracheobronchitis, epiglottitis, bacterial tracheitis, foreign
body aspiration, pharyngeal obstruction, and tracheobronchomalacia.

Laryngotracheobronchitis (Croup)
Etiology. Laryngotracheobronchitis (croup), a viral
illness, is the most commonly occurring upper airway
obstruction in pediatrics. It is characterized by airway
obstruction that is primarily subglottic. The etiologic
organisms are most commonly viral, and they include the
parainfluenza viruses (types 1,2, and 3) and influenza virus
A. Bacterial agents may cause laryngotracheobronchitis,
including Mycoplasma pneulIlotliae and COIynebacterium
diphtheriae; however, a bacterial basis is rarely seen.
Incidence. Laryngotracheobronchitis usually occurs
in late autumn and winter. More prevalent in males (ratio
1.5: I), infants and toddlers 3 months to 3 years old
are primarily affected, with incidence peaking at 9 to
18 months.
Pathogenesis. Children with laryngotracheobronchitis typically present following several days of symptoms
consistent with a viral upper respiratory infection: coryza
(dry inflammation of the nasal mucus membranes), sore
throat, cough, hoarseness, and low-grade temperature. The
child commonly has a low-grade fever, may complain of a
sore throat, but does not appear very ill. A typical "croupy"
cough and stridor develop as a result of swelling of the
airway (glottic and subglottic edema). Laryngotracheobron-
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chitis also affects other areas of the airway, but the
subglottic area is the most narrow air passage in young
children; therefore the clinical manifestations are primarily
related to this region. Older children, however, often have
tracheitis and even bronchitis.
Typically, laryngotracheobronchitis is a mild disease, and
most children can be treated as outpatiellls. Very young
infants appear more acutely ill and are often in more
respiratory distress than older infallls and children because
their airways have a smaller diameter; as a result, a modest
amount of edema produces a grater degree of airway
obstruction. Stridor and retractions even at rest, tachycardia,
restlessness, and cyanosis indicate progressive airway obstruction necessitating close monitoring in a PICU and
possibly airway intervention.
Critical Care Management. A child who presents
with a croupy cough, stridor, and respiratory distress is
carefully evaluated. An anteroposterior neck radiograph
usually depicts subglottic narrowing (referred to as the
"steeple sign"). Treatment for coup is usually symptomatic.
In most instances, treatment with cool-mist 0z is sufficient
to ameliorate symptoms. The efficacy of cool-mist therapy
has not been demonstrated; however, many physicians still
recommend its use.
In more severe cases, nebulized racemic epinephrine delivered using a small-volume nebulizer I: 1000 (0.5 mllkg;
maximum 4 ml) can provide transient reductions in stridor.
A recent meta-analysis of randomized colllrolled trials examined the effectiveness of glucocorticoid treatment in children with laryngotracheobronchitis. 3 •4 The review demonstrated that dexamethasone 0.6 mglkg as an initial dose
followed by 0.15 mg/kg every 6 hours and inhaled budesonide (2 mg) were effective in relieving the symptoms of
laryngotracheobronchitis as early as 6 hours after treatment.
In addition, fewer cointerventions are used and the length of
time spent in the hospital is decreased in patients treated
with glucocorticoids.
Heliox (30% Oz and 70% helium) may be used in
patients without a large Oz requiremelll. Because the density
of helium is lower than the density of air or 0z, helium will
rapidly flow through the narrowed upper airway, decreasing
the work of breathing and fatigue. Stridor scores have been
demonstrated to be lower with helium-Oz than with
0z-supplemented room air in patients with POstextubation
stridor. s In the unlikely event that endotracheal intubation is
required, endotracheal tubes 0.5 to 1.5 mm smaller in
diameter than usual for the child's age are used and are
prone to obstruction with thick secretions.
Nursing management of the child with laryngotracheobronchitis includes limiting activity that may increase
respiratory effort and exacerbate symptoms. The tachypnea
that accompanies agitation, for example, may cause an
increase in transmural pressure and airway turbulence, both
of which lead to further narrowing of the airway. Therefore
it is essential to minimize the child's anxiety. Encouraging
parental presence and participation in care may go a long
way in reducing fears associated with hospitalization.
Sedation should be used judiciously. Decreasing the number
of times the fearful patient is approached by hospital staff
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19-2 A Croup Scoring System
Based on Four Clinical Signs
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can minimize anxiety and its associated increase in the work
of breathing.
Close observation and monitoring of the child's respiratory status includes respiratory rate and effort, heart rate,
and Spoz. Use of a croup scoring system (Table 19-2) may
facilitate documentation of the progression or regression of
symptoms, and provide a more objective evaluation of the
efficacy of various interventions. 6 Intubated children are at
high risk for inadvertent extubation because of their young
age, mobility, and the difficulty of taping tubes to the face in
the presence of copious nasal secretions. Nursing vigilance
can minimize the risk by splinting the arms to prevent elbow
flexion and extreme care with tube position and fixation.
Low dose sedation may be useful, but muscle relaxants or
high-dose sedation are generally unnecessary.

Epiglottitis
Etiology and Incidence. Epiglottitis is a bacterial
infection of the laryngeal inlet usually caused by Haemophilus injluenzae type b (Hib). The diagnosis is often confused
with laryngotracheobronchitis because both problems present with inspiratory stridor and respiratory distress. The
patient with epiglottitis is most likely to be between 2 and 4
years of age. Causes of epiglottitis include Pneumococcus
group A, Streptococcus and Staphylococcus aureus, and
Hib. In 1988, Hib conjugate vaccines were introduced for
use in children aged 18 months to 5 years; the Advisory
Committee on Immunization Practices (ACIP) subsequently
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recommended them for routine use in infants in 1990.
Since the introduction of the Hib vaccine in 1988, the
incidence of epiglottitis has fallen dramatically, but the
vaccine does not offer complete protection and the disease can occur in immunized children. In the prevaccine era
(i.e., before 1988), Haemophilus influenzae caused approximately 95% of the Haemophilus influellzae invasive disease
among children aged younger than 5 years. During 1989
through 1995, Hib invasive disease among children aged
younger than 5 years declined 95% nationally. 7
Pathogenesis. There is an acute onset (usually less
than a day) of sore throat, high fever, muffled voice,
dysphagia, and lethargy. Dysphagia rapidly progresses to an
inability to clear oropharyngeal secretions and signs of
obstruction develop, including inspiratory stridor, tachypnea, cyanosis, and retractions. Lying down often increases
the degree of obstruction, so children with epiglottitis adopt
a characteristic posture: sitting forward, drooling, with
minimal head and neck movement. At this point, the child
often appears pale and restless. Because venti lation can be
maintained only in an upright position, the child should not
be forced into a recumbent position.
Critical Care Management. The maintenance of a
patent airway is the primary goal of therapy. Agitation may
precipitate laryngospasm and complete laryngeal obstruction, so no detailed physical examination, blood drawing, or
other invasive procedures are performed immediately on a
child presenting with signs and symptoms suggestive of
epiglottitis. It is especially important to avoid any attempt to
examine the pharynx before the child can be taken to the
operating room for direct visualization of the glottis under
anesthesia. 02 is given as unobtrusively as possible. Before
laryngoscopy, a lateral neck radiograph showing a very
swollen epiglottic shadow is typical and may be helpful in
cases if there is doubt about the diagnosis (Fig. 19-4).
However, radiographic examination should not delay therapy in a child in severe distress. In those instances, the child
is transported directly to the operating room in the parent's
arms. Although respiratory arrest can occur from total
airway obstruction, it is usually the result of a combination
of partial obstruction and fatigue.
The anatomy may be so distorted from inflammation and
edema that the glottic structures will be unidentifiable. As a
result of this extensive edema of the glottis, a wide selection
of endotracheal tubes with a smaller diameter than predicted, but sufficient length, are made available. Once an
appropriate level of inhalation anesthesia is reached, an
intravenous line is placed, and visualization of the glottis
and intubation are accomplished. The most experienced
individual skilled in intubation performs the intubation. In
the event that the examination induces laryngospasm and an
acute airway obstruction, a tracheostomy will be necessary.
Laryngeal and blood cultures are obtained before initiating
antibiotic therapy; third-generation cephalosporins (e.g.,
cefotaxime) are the antibiotics of choice. There is no
evidence to suggest that corticosteroids are helpful in the
treatment of epiglottitis.
Acute pulmonary edema has been described in children
with the relief of airway obstruction. This postobstructive
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Fig. 19·4 Lateral neck radiograph in epiglottitis. To define the
epiglottis, follow the posterior border of the trachea (A) (0 the
epiglottis (8). Instead of its usual sharp appearance, the epiglottis
is swollen. The supraglottic portion of the airway is dilated, while
the air column below the laryngeal level is well preserved (i.e.,
there is no subglottic edema). Please note that a radiograph should
not be obtained in any patient with clear signs and symptoms of
epiglottis.

pulmonary edema manifests itself immediately or within a
few hours of the relief of obstruction. Several mechanisms
have been proposed, including an increased left ventricular
transmural pressure gradient from the negative pleural
pressure generated against the airway obstruction. s
Once the child has been intubated, a primary goal is to
maintain the position and patency of the artificial airway.
Accidental extubation, particularly early in the course of
epiglottitis, is potentially disastrous. The majority of patients with laryngotracheobronchitis or epiglottitis are toddlers or preschoolers in whom egocentricity is prominent,
freedom of movement is essential, and separation from
parents is a major source of fear and stress. Elbow restraints
are necessary to prevent the child from removing the
endotracheal tube but are not used in isolation. Additional
measures to keep the child calm and quiet should also be
taken, including the administration of sedatives, decreasing
noxious or threatening stimuli, and encouraging continued
family presence and participation in care. If accidental
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extubation occurs, positioning the child in an upright
forward sitting position may facilitate air entry. Bag and
mask ventilation may be required if the child is unable to
maintain spontaneous ventilation. The child with epiglottitis
secondary to H. injluenzae will also require droplet precautions until 24 hours after the starl of effective antibiotic
therapy.
Planned extubation of the child is based on revisualization of the supraglottic structures, presence of a leak.
around the endotracheal tube, and clinical status of the
patient. Extubation can usually be accomplished within
48 to 72 hours after antibiotic therapy is started.

Bacterial Tracheitis
Etiology and Incidence. Bacterial tracheitis is
thought to be a complication of laryngotracheobronchitis
and closely resembles laryngotracheobronchitis. Bacterial
tracheitis can produce a complete airway obstruction as a
result of copious, mucopurulent secretions. A recent review
of 46 children admitted with bacterial tracheitis found the
mean age to be 69 months, 57% of whom required tracheal
intubation. 9
Pathogenesis. The child may actually appear to be
improving after an episode of virallaryngotracheobronchitis
when suddenly there is a new onset of stridor. It may be
distinguished from laryngotracheobronchitis because the
patient usually has a high fever and may appear very ill. A
lateral neck film shows subglottic swelling. In children,
predominant organisms include S. aureus and H. injluenzae. 10 Moraxella catarrhalis has been identified in 12 (27%)
of 45 bacterial respiratory cultures, whereas influenza A
virus was recovered from 18 (72%) of 25 viral respiratory
cultures in children with bacterial tracheitis. 9
Critical Care Management. The child who presents
with bacterial tracheitis may have significant respiratory
distress and a septic appearance. Management is focused on
maintenance of a patent airway and treatment of blood
pressure instability with fluids and catecholamines as
necessary. A superimposed bacterial pneumonia may coexist, and this is likely to cause the child to require mechanical
ventilation.
Foreign Body Aspiration
Etiology. A relatively common cause of airway obstruction in children is a foreign body lodged in the
tracheobronchial tree, commonly in the bronchi. Infants
usually inhale radiolucent food items (peanuts, seeds, pieces
of Carlot), whereas toddlers inhale radiopaque items (coins,
teeth, metal or plastic toy parts). The foreign bodies most
commonly found in a review of 639 patients were sunflower
seeds (21.1 %), beans (10.4%), watermelon seeds (10%), and
hazelnuts (9.8%). II
Incidence. Foreign body aspiration may affect any
age, but occurs most frequently in young children ranging in
age from 6 months to 3 years. In a retrospective review of
84 children and 28 adults, the peak incidence of foreign
body aspiration was found to occur during the second year
of life in children and during the sixth decade of life in
adults. 12

Pathogenesis. Signs and symptoms of foreign body
aspiration vary, depending on the location of the object in
the airway. A foreign body will usually lodge at or above the
larynx, in the trachea or a bronchus. Although a foreign
body preferentially lodges in the right bronchial tree in
adults, a central location (but not at all exclusive) with air
trapping is more common in children. 12 Children may also
present with acute asphyxia from tracheal obstruction,
wheezing when a mainstern bronchus is occluded, or they
may complain solely of a chronic cough or bloody sputum
if a smaller or more peripheral airway is involved. Foreign
bodies do not usually cause stridor unless the obstruction is
at or near the larynx. When a foreign body is lodged in a
lobar or segmental bronchus, unilateral physical findings
become prominent. Asymmetric breath sounds, absent air
entry, and unilateral prolongation of expiration may occur.
Critical Care Management. When foreign body
aspiration is suspected, a careful history may reveal a
choking episode several days, weeks, or months before
symptoms began. Ina series of 87 children with foreignbody aspiration, neither clinical signs or symptoms nor
radiology had sufficient diagnostic sensitivity, and especially specificity, on which to rely for the diagnosis. Only
the choking crisis, when present in the history, had good
sensitivity and specificity (respectively, 96% and 76%).13
Although most aspirated objects are radiolucent, diagnosis
may be aided by chest radiographs demonstrating unilateral
hyperinflation, atelectasis, or infiltrate (Fig. 19-5). Unilateral hyperaeration, atelectasis, and unilateral parenchymal
infiltration are the most common radiologic findings. II A
forced expiration radiographic technique often reveals
persistent air trapping in one location, a finding missed on a
conventional chest film because there is increased and
uniform expansion of the lung during inspiration. Fluoroscopy may also demonstrate persistent inflation during both
phases of respiration, indicating airway obstruction and
identifying the location of the foreign body. Even in the
absence of a definitive diagnosis, bronchoscopy under
general anesthesia is the diagnostic test and the treatment of
choice when aspiration of a foreign body below the carina is
suspected. The most frequent procedure in children is rigid
bronchoscopy. 12
The use of less direct methods, such as postural drainage,
may lead to total airway obstruction by freeing an object that
is too large to pass through the larynx. However, when an
exact diagnosis cannot be made and a lobar or segmental
obstruction is suspected, postural drainage and inhaled
bronchodilators may be employed for several days. If there
is no improvement, bronchoscopy is performed. For imminent complete obstruction follow Pediatric Advance Life
Support recommendations for foreign body aspiration. 14
Residual irritation after removal of a foreign body by
bronchoscopy or postural drainage may necessitate continued administration of supplemental 2 , vigorous pulmonary
toilet, and careful monitoring of the child's respiratory status
in the PICU. Parent education is also important to help
prevent future aspirations. This includes instructing parents
that children under 3 years of age are prime candidates for
aspiration accidents and aiding them in recognizing the
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Fig. 19-5 Foreign body chest radiograph. A, This AP chest radiograph reveals complete collapse of the
left lower lobe with partial aeration of the left upper lobe and lingula. The left main bronchus is well
demonstrated containing air through its proximal course where there is an abrupt obstruction to the
bronchial lumen. B, The AP view of the chest was obtained after the removal of bubble gum from the left
mainstem bronchus. Air is now demonstrated throughout the central aspects of the left bronchus including
into the periphery of the left lower lobe, which has undergone partial reexpansion compared with the view
in A. There is partial reexpansion compared with of the upper lobe as well. (Courtesy of Robert Cleveland,
MD, Radiology Department, Children's Hospital. Boston.)

importance of safeguarding their children from objects that
are commonly aspirated.

Pharyngeal Obstruction
Etiology and Incidence. Pharyngeal collapse or
obstruction is a commonly encountered short-term problem
in PICU patients. The largest group of patients at risk for
pharyngeal obstruction in the PICU are patients who are
comatose or are otherwise neurologically impaired. Other
high-risk groups are patients who have been extubated after
general anesthesia but are not yet fully awake, and those
who are heavily sedated. These patients may have little
difficulty maintaining a patent airway when awake, but
develop sonorous respirations and intermittent airway obstruction when permitted to sleep/rest in the supine position.
Pathogenesis. The pharynx, the most collapsible
portion of the extrathoracic airway, is formed by constrictor
muscles posteriorly and laterally and pharyngeal dilators
located predominantly on the anterior and lateral walls of
the pharynx. The constrictor muscles participate primarily in
swallowing, whereas the pharyngeal dilators are believed to
be important in airway maintenance. 15 During states of
decreased consciousness caused by sedati ves, anesthesia, or
primary central nervous system disease, the activity of these
airway muscles and their responses to various stimuli may
be depressed, leading to airway collapse during inspiration.

In addition, muscle relaxation may cause airway obstruction
by passive posterior displacement of the tongue.
Critical Care Management. Pharyngeal obstruction
can usually be overcome simply by side-lying or prone
positioning. Placement of a nasopharyngeal airway may also
be helpful if the child has an extremely flaccid pharynx or
excessive oral secretions. If airway collapse is complete,
endotracheal intubation is required.
Because level of consciousness may vary considerably,
patients recovering from general anesthesia require close
monitoring of both neurologic function and respiratory
status. Monitoring Spo2 ensures adequate oxygenation;
physical examination and arterial blood gases (ABGs)
provide information about the adequacy of ventilation.

Tracheobronchomalacia
Etiology and Incidence. This rare disease of infancy
and childhood is characterized by abnormally high compliance of the tracheal or bronchial wall. Marked delays in the
development of the supportive structures of large airways
precipitates severe airway obstruction during respiratory
maneuvers. The classification of infants with collapsing
airways is based on the anatomic area involved, for
example, tracheomalacia, tracheobronchomalacia, or bronchomalacia. Tracheomalacia without associated abnom1alities is rare. Most cases of abnom1ally compliant airways are

664

Part IV

Final Common Pathways

secondary to tracheoesophageal fistula or external compression of the airways by abnormal vascular structures.
Prematurity, low birth weight, BPD, and prolonged ventilation predispose patients to the most severe symptoms. 16
Whatever its origin, expiratory collapse of the airway occurs
because of inadequate cartilaginous and elastic supporting
structures of the trachea and bronchi.
Pathogenesis. Clinical signs and symptoms depend
on the location and length of the malacic airway and the
severity of the structural abnormality. If the affected
segment encompasses both intrathoracic and extrathoracic
portions of the trachea (as often occurs), the clinical
presentation includes both stridor and wheezing. If the
malacic area is only extrathoracic (larynx and trachea), there
is only stridor. Airway obstruction may be episodic and is
especially pronounced when intrathoracic pressure exceeds
airway pressure, for example during forced expiration with
Valsalva maneuvers, crying, or agitation. Increased respiratory rate (although slower than one would expect with the
degree of respiratory distress), intercostal retractions, and
grunting have been described in infants with severe tracheobronchomalacia. Wheezing and marked cyanotic spells
requiring immediate intervention have also been reported.
During an acute obstructive episode, breath sounds are
markedly diminished and hypoxemia and hypercarbia
develop. 17
Critical Care Management. The diagnosis of tracheobronchomalacia is confirmed by examining the airways
with bronchoscopy and/or fluoroscopy. Many infants with
minor degrees of tracheobronchomalacia and mild or
moderate symptoms require no intervention and improve
with growth. For infants with severe P.1alacia, however, a
tracheostomy is often required. The tracheostomy tube may
stint open a semiflaccid trachea, as long as the cannula
bypasses the affected area. However, a malacic segment
very low in the trachea, or involving the bronchi, will not be
supported by a tracheostomy tube alone. In this instance,
positive airway pressure during expiration (positive end
expiratory pressure [PEEP] or continuous positive airway
pressure [CPAP]) may produce the same effect by increasing airway transmural pressure during the critical expiratory
phase. Infants with acquired tracheobronchomalacia often
benefit from CPAP18 Some patients may require a positive
airway pressure as high as 25 em H2 0 to maintain airway
patency. 19
A tracheotomy with CPAP may be required by 75% of
premature infants and 25% of full-term infants with
tracheobronchomalacia. Seventy-one percent of all patients
will undergo decannulation without any other surgical
intervention. 16 In extreme cases of bronchomalacia, a pneumonectomy or lobectomy may be required because a segmental bronchial resection with end-to-end anastomosis is
not feasible. An alternative treatment for patients is a surgically implanted splint that serves to support the collapsing
bronchus.
Because tracheobronchomalacia is often a difficult problem to diagnose, it is important to carefully monitor and
document episodes that may represent airway collapse.
Agitation and attempts by the infant to forcefully exhale

cause airway collapse and complicate management; sedation and even muscle relaxation may be indicated in some
patients undergoing mechanical ventilation. Unexplained
periods of increased respiratory distress and arterial desaturation (with or without cyanosis) are noteworthy, especially in an infant on long-term ventilation. Documenting
events immediately preceding hypoxic episodes is also
important, because maneuvers that decrease transmural
pressure, for example, crying or straining, may cause a
malacic airway to collapse. When an infant with tracheobronchomalacia has acute respiratory decompensation, slow
hand ventilation with somewhat higher peak inspiratory
pressures than the infant's baseline often relieve the
obstruction. 17

Lower Airways Disease
As with upper airways disease, the respiratory rate of a child
with lower airways disease is relatively low. Other signs of
respiratory distress may also be prominent including retractions, the use of accessory muscles of respiration (sternocleidomastoids and abdominals), and nasal flaring. However, additional clinical findings distinguish intrathoracic
obstruction from its extrathoracic counterpart.
Normally, intrathoracic airways dilate during inspiration
(as transmural pressure decreases), and narrow during
expiration. These changes are exacerbated when there is
obstruction, particularly during expiration, resulting in a
prolonged expiratory phase and expiratory wheezes audible
on auscultation. Variable regional air entry may also be
present. The larger airways tend to collapse during forced
expiration, and the combination of large and small airway
obstruction leads to air trapping and hyperinflation of the
lungs. This may be evidenced by downward displacement of
the diaphragm on chest radiographs and a tympanic chest
on percussion. Two causes of intrathoracic airway obstruction that commonly lead to PICU admission are bronchiolitis and asthma.
Bronchiolitis

Etiology. Bronchiolitis is an acute inflammatory disease of the lower respiratory tract, resulting in obstruction of
small airways. A number of different viral pathogens cause
bronchiolitis. Respiratory syncytial virus (RSV) accounts
for most cases of bronchiolitis in which a specific agent can
be identified. Other viruses that cause bronchiolitis are
rhinovirus, parainfluenza virus type 3, adenovirus, and
influenza virus. Mycoplasma pneumoniae is usually associated with lower respiratory tract disease in older children.
Incidence. RSV is the most common cause of lower
respiratory tract disease in infants and young children
worldwide.2° In temperate climates, RSV infections occur
primarily during annual outbreaks, which peak during
winter months. With inpatient charges of $300 to $400
million per year in the United States, the disease burden of
RSV pneumonia is very high in terms of both morbidity and
economic costs. 20
\
From July 1998 through June 1999, 45 states reported
18,418 positive tests for RSV. In the United States,
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widespread RSV activity began in early November 1998 and
continued for 27 weeks, until late April. Timing of RSV
community outbreaks varied from onset (range: September
II to April 2) to conclusion (range: January 8 to June 18).
Overall, RSV outbreaks were observed earlier in laboratories in the South, later in Northeast laboratories, and latest in
the West. Although most positive tests (91 %) were reported
from the week ending November 27 through the week
ending April 30, RSV was detected throughout the year21
There is no significant difference between using nasal wash
and nasopharyngeal wash methods for collecting specimen
for RSV testing. 22
Severe manifestations of RSV infection (e.g., pneumonia
and bronchiolitis) most commonly occur in infants aged 2 to
6 months, and hospitalization rates for these diagnoses have
been used as an indicator for severe RSV disease among
young children. Secretory immunoglobulin A (IgA) antibody secreted in colostrum may provide a protective factor
in breast-fed babies. In the United States, bronchiolitis
hospitalization rates among children aged less than I year
increased substantially from 12.9 per 1000 in 1980 to
31.2 per 1000 in 1996; the reasons for this increase are
unclear.13 RSV infection among recipients of bone marrow
transplants has resulted in high mortality rates (83%).14
Pathogenesis. Bronchiolitis, an acute inflammatory
disease in the lower respiratory tract, is also a disease of the
lung parenchyma. Whether it is due to alveolar collapse
from obstruction, or to primary involvement of the terminal
airways and alveoli, many infants have a substantial restrictive component, which may predominate, usually causing a
more severe form of the disease. The principal abnormality
in gas exchange is hypoxemia. V/Q mismatching accounts
for arterial desaturation because hypoxemia is typically relieved with a modest amount of supplemental 02'
Most infants, in spite of an increased physiologic dead
space-to-tidal volume ratio, are able to maintain normocarbia by increasing minute ventilation.( VEl. Hypercarbia and
respiratory failure develop when the infant becomes fatigued and VE falls to predicted basal levels. The high VE is
due mainly to the increased respiratory rate, whereas tidal
volume is unchanged or somewhat lower than normal.
Respiratory muscle fatigue is not surprising considering that
most infants increase their work of breathing up to sixfold
during acute bronchiolitis. Tachypnea may represent the
presence of a restrictive component (alveolitis, edema, or
alveolar distension from hyperinflation), an overriding of
the mechanism by the infant's cerebral cortex (because
of agitation), and/or the work of a feedback mechanism
initiated by stretch receptors of the lung and chest wall.
Respiratory distress in bronchiolitis is caused primarily
by obstruction of small airways. This results from peribronchiolar cellular infiltration, interstitial edema, and the effects
of plugging of small airways by sloughed epithelium and
inflammatory exudates. The small size of the developing
airways makes infants particularly vulnerable to obstruction
owing to these mechanisms. Hypoxemia represents the
major abnormality in gas exchange and is the result of
underventilation of regions with relatively normal perfusion, that is, low ventilation to perfusion ratio.
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Respiratory insufficiency results when the infant, exhausted by the increased work of breathing, can no longer
maintain adequate minute VE' At this point, air entry is
greatly diminished, respiratory pauses and/or apnea may
occur, and the infant may develop a respiratory or metabolic
acidosis. Crying, feeding, and agitation may exacerbate
signs of respiratory distress. which include prolonged expiratory time, crackles and/or wheezing, and substernal and
intercostal retractions. Rapidly progressing respiratory distress, increasing O2 requirements, or an altered mental status
are indications for PICU admission and. possibly, assisted
ventilation. Smaller infants may also require PICU monitoring because exudates or edema in their small airways produces a comparatively greater degree of obstruction. Apnea
in RSV bronchiolitis is not due to upper airway obstruction
but rather to a complete absence of respiratory effort?5
Critical Care Management. The management of
infants with bronchiolitis has changed very little in the past
20 years. Therapy is still largely supportive, consisting of
02' mechanical ventilation, bronchodilators, and hydration.
Supplemental 02 is generally required by all infants with
bronchiolitis and generally reverses the hypoxemia caused
by V/Q abnormalities.
Inhaled bronchodilators may be beneficial; their use is
determined by the individual infant's response. Two metaanalyses of bronchodilators in bronchiolitis concluded
bronchodilators may produce modest short-term improvement in clinical features of mild or moderately severe
bronchiolitis 26 .27 Nebulized epinephrine is also commonly
a first-line therapy. Nebulized epinephrine results in significant improvement in clinical scores and airways resistance
in children hospitalized with bronchiolitis, causes acute
improvement in oxygenation, and decreases length of time
in the emergency department and admission rate to the
hospital. 28
Endotracheal intubation is indicated for signs of respiratory failure including worsening respiratory distress, severe
tachycardia. listlessness or lethargy. and poor peripheral
perfusion. It may also be required for increasing hypoxemia
(Pa0 2 less than 60 mmHg or O2 saturation less than 92% in
an F102 of 0.4), hypercarbia with respiratory acidosis,
metabolic acidosis, apnea, or bradycardia. The routine use
of PEEP in infants with bronchiolitis does not consistently
improve passive expiratory pulmonary mechanics and may
increase the risk of barotrauma from gas trapping 29
Nasal CPAP is a reliable alternative to support arterial
oxygenation in patients with respiratory failure who are alert
and vigorous enough to avoid hypercapnia and respiratory
acidosis while breathing spontaneously. In addition, because
the patients are able to speak and thus are capable of
expressing their feelings, the anxiety observed during
respiratory support can be reduced. 30
In a small randomized, double-blind, controlled, crossover study and nonrandomized, prospective study Hollman
and colleagues demonstrated that inhaled heliox improved
the overall respiratory status of children with acute RS V
lower respiratory tract infection 3 ] The beneficial effects of
heliox were most pronounced in children with the greatest
degree of respiratory compromise.
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A randomized placebo-controlled trial of nebulized
corticosteroids in acute RSY bronchiolitis demonstrated no
short- or long-term clinical benefits from the administration
of nebulized corticosteroids 32 A second randomized prospective study in infants hospitalized with acute RSY
infection showed no effect of systemic prednisolone treatment either in the acute state of RSY infection, nor in the
follow-up I month and I year after admission to hospital.
The authors concluded corticosteroid, whether by the
systemic route or by inhalation, should not be prescribed to
infants with RSV infection. 33
Ribavirin is generally indicated only to limit the duration
of viral shedding 34 A recent prospective, double-blind,
placebo-controlled trial of 41 previously well infants who
required ventilation for respiratory distress secondary to
RSY bronchiolitis demonstrated the lack of effectiveness of
aerosolized ribavirin in reducing the length of ventilation
and course of illness in infants with no underlying illness. 35
Because respiratory failure resulting from bronchiolitis
may occur precipitously, it is important to identify high-risk
patients upon hospital admission. Continuous monitoring
includes heart rate, respiratory rate, and O 2 saturation.
Frequent assessment of respiratory effort, breath sounds,
and level of consciousness helps detect subtle changes in
clinical status. The infant's response to interventions, for
example, bronchodilators or chest physiotherapy directs
future therapy and is closely evaluated and carefully
documented. Any activity that increases the infant's work of
breathing is avoided.
Initially, fluid replacement may be necessary to correct
fluid deficits resulting from increased insensible loss and
poor intake. After replacing losses, fluids are restricted to
maintenance requirements or somewhat less to reduce the
risk of developing pulmonary edema and further deterioration in respiratory function. The severely tachypneic infant
may need to be fed by transpyloric feeding tube 36 Before
endotracheal intubation, placing an oroenteric feeding tube
is preferred because a nasoenteric tube will occlude the
infant's naris and may worsen respiratory distress by
increasing airways resistance.
Attempts are made to maximize ventilation, including
elevating the head of the bed and positioning the infant
prone to permit freer diaphragmatic movement. When
mechanical ventilation is required, sedation may also be
necessary to facilitate coordination of the infant's respiratory efforts with the ventilator and minimize coughing
paroxysms.
Prevention. No RSY vaccines are available, although both live attenuated and subunit vaccines have
entered clinical trials. RSV immune globulin intravenous
(RSV-IVIG) and a humanized murine anti-RSV monoclonal
antibody (palivizumab) are recommended as prophylaxis for
some high-risk infants and young children (e.g., those born
prematurely or with chronic lung disease) to prevent serious
RSV disease. 37
Intravenous immunoglobulin is a solution of immunoglobulin containing many antibodies normally present in
adult human blood. It is obtained from plasma-pooled whole
blood of thousands of diverse adult donors, ensuring a broad

spectrum of antibodies. Immune globulin therapy is rapidly
shifting from standard pooled preparations to specific
immune globulin preparations. High-titer specific immune
globulin preparations are prepared by screening or immunizing donors. RSV-IVIG contains high titers of RSV
immune globulin. Concerns about the requirement of
montWy administration, requiring intravenous cannulation
and infusion over several hours and the fluid volume and
protein load have restricted the use of RSY-IYIG.
An examination of the effectiveness of RSV-IVIG in
reducing hospitalization for treatment of RSV in children
with congenital heart disease (CHD) demonstrated a significantly higher frequency of unanticipated cyanotic episodes
and of poor outcomes after surgery among children with
cyanotic CHD in the RSV-IVIG group (22 of 78,28%) than
in the control group (4 of 47, 8.5%; P<.OOl). At this time
RSV-IYIG should not be used for prophylaxis of RSV
disease in children with cyanotic CHD. 38
Efforts have been directed to the development of a
monoclonal IgG antibody and prophylaxis against RSV. The
Food and Drug Administration recently approved the use
of palivizumab, an intramuscularly administered monoclonal antibody preparation. Recommendations for its
use are based on a 1502-patient, randomized study demonstrating paiivizumab prophylaxis resulted in a 55% reduction in hospitalization as a result of RSV (10.6% placebo
versus 4.8% paiivizumab).39 Infants and children with
chronic lung disease, formerly designated bronchopulmonary dysplasia, as well as prematurely born infants without
chronic lung disease experienced a reduced number of
hospitalizations while receiving palivizumab compared with
a placebo (P<.OO I).
Both palivizumab and RSY-IVIG are available for
protecting high-risk children against serious complications
from RSV infections. Palivizumab is preferred for most
high-risk children because of ease of administration (intramuscular), lack of interference with measles-mumps-rubella
vaccine and varicella vaccine, and lack of complications
associated with intravenous administration of human immune globulin products. RSV-IYIG, however, provides
additional protection against other respiratory viral illnesses
and may be preferred for selected high-risk children,
including those receiving replacement intravenous immune
globulin because of underlying immune deficiency or HIV
infection. For premature infants about to be discharged
from hospitals during the RSV season, the American
Academy of Pediatrics recommends considering administering RSY-IVIG for the first month of prophylaxis. 37
RSY infection usually occurs after viral inoculation of
the conjunctivae or nasal mucosa by contaminated hands.
Guidelines developed by the Centers for Disease Control
and Prevention (CDC) addresses common problems encountered by infection-control practitioners regarding the
prevention and control of nosocomial pneumonia in U.S.
hospitals. Sections on the prevention of bacterial pneumonia
in mechanically ventilated and/or critically ill patients,
care of respiratory-therapy devices, prevention of crosscontamination, and prevention of viral lower respiratory
tract infections (e.g., RSV and influenza infections) have
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recently been expanded and updated. Traditional preventive
measures for nosocomial pneumonia include decreasing
aspiration by the patient (transpyloric feedings, elevating the
head of the bed at least 15 degrees), preventing crosscontamination or colonization via hands of personnel.
appropriate disinfection or sterilization of respiratorytherapy devices, use of available vaccines to protect against
particular infections, and education of hospital staff and
patients. 40 The CDC specifically recommends contact precautions for all patients with RSV.
Asthma (Reactive Airways Disease)
Etiology. Asthma (reactive airways disease) is defined
as recurrent, reversible episodes of wheezing, or dyspnea
caused by airway obstruction. It is classified as extrinsic
(an immunologic, allergic response), intrinsic (nonallergic,
often triggered by infection), exercise-induced, and/or
aspirin induced (the last two types being rare during infancy
or childhood).
Asthma is a multifactorial disease that has been associated with familial, infectious, allergenic, socioeconomic,
psychosocial, and environmental factors. Atopy, the genetic
predisposition for the development of an IgE-mediated
response to common aeroallergens, is the strongest identifiable predisposing factor for developing asthma. 41 Decreases in pulmonary functions and exacerbations of asthma
have been associated with ambient air pollutants (e.g.,
ozone, sulfur dioxide, nitrogen dioxide, acid aerosols, and
particulate matter), indoor pollutants (e.g., tobacco smoke),
and allergens (e.g., dust mites). Approximately 25% of
children in the United States reside in areas that exceed the
federal standard for ozone. 42
Incidence. Asthma is the most common chronic
illness in childhood and is characterized by vari.able airflow
obstruction with airway hyperresponsiveness. In the United
States, asthma affects an estimated 14 million to 15 million
persons, including 4.8 million (6.9%) aged younger than 18
years. During 1980 through 1993, asthma accounted for
3850 deaths among persons aged 0 to 24 years. In 1994, the
annual age-specific asthma death rate increased 118% (from
1.7 million to 3.7 per million population) and from 1980 to
1993, the annual hospitalization rate for asthma among
persons aged 0 to 24 years increased 28%.43 Although
asthma-associated mortality has increased among persons
aged less than 25 years, hospitalizations for asthma have
increased primarily among children younger than 5 years of
age. The increase among young children may be related to
changes in diagnostic practices, changes in coding and
reimbursement, or increases in morbidity.44
Pathogenesis. Asthma is a chronic inflammatory
disorder of the airways in which many cells and cellular
elements playa role, in particular, mast cells, eosinophils,
T lymphocytes, macrophages, neutrophils, and epithelial
cells. In susceptible individuals, this inflammation causes
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early
morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible, either spontaneously or with treatment. The inflamma-
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tion also causes an associated increase in the eXlstmg
bronchial hyperresponsiveness to a variety of stimuli. 45
It is hypothesized that airway inflammation can be acute,
subacute, and chronic. The acute inflammatory response is
represented by the early recruitment of cells to the airway.
In the subacute phase, recruited and resident cells are
activated to cause a more persistent pattern of inflammation.
Chronic inflammation is characterized by a persistent level
of cell damage and an ongoing repair process, changes that
may cause permanent abnormalities in the airway.41
Lung cells recovered from symptomatic patients with
asthma generate increased amounts of reactive oxygen
species (ROS). Animal and in vitro studies indicate that
ROS can reproduce many of the features of asthma. The
ability of ROS to produce the clinical features of asthma
may depend on an individual's lung antioxidant defenses.
Patients with asthma are reported to have reduced antioxidant defenses in peripheral blood, but little is known about
the antioxidant defenses of their lung cells. 46
The differences in the anatomy and physiology of the
lungs of infants place them at greater risk for respiratory
failure. These differences include greater peripheral airways
resistance, fewer collateral channels of ventilation, further
extension of airway smooth muscle into the peripheral
airways, less elastic recoil, and mechanical disadvantage of
the diaphragm. 41
Severe acute asthma, so-called status asthmaticus, does
not respond to routine therapy and necessitates hospitalization. Children whose asthma has caused even one episode of
respiratory failure may be more likely to have repeated
episodes of respiratory failure and its catastrophic complications, including hypoxic brain injury and death.
The child in status asthmaticus is usually pale and
restless, has severe wheezing, and is sometimes cyanotic.
Respiratory rate and heart rate are elevated, and a pulsus
paradoxus of more than 15 mmHg may be detected.
Vomiting and abdominal pain and distension are common,
as is dehydration. As airway obstruction increases during an
acute attack, ABGs change through a characteristic series of
stages. Arterial oxygen tension (Pa02 ) is decreased because
of a reduced \110. ratio caused by the simultaneous
occurrence of air trapping and atelectasis. Initially, hypoxemia stimulates the respiratory drive, and the Pac0 2
decreases, with a normal or slightly elevated pH. Eventually,
as muscle fatigue develops and compensatory mechanisms
fail, the Pac0 2 begins to rise, producing respiratory acidosis.
Respiratory rate and breath sounds decrease, and extreme
restlessness is followed by stupor and unconsciousness.
With progression, the Paco z increases even more, pH falls
with a superimposed metabolic acidosis, and Pa02 becomes
markedly reduced.
Critical Care Management. Treatment is directed at
ensuring oxygenation and adequate alveolar ventilation
while reversing the primary airway abnormalities: bronchospasm, mucosal edema, and overproduction of tenacious
secretions. Because patients in status asthmaticus are often
hypoxic, it is essential to provide supplemental O2 by
oxyhood, mask, or nasal cannula. Preexisting \110. imbalances may be worsened by treatment with sympathomimet-
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ics (agents that ablate hypoxic vasoconstriction in the lungs,
thereby increasing venous admixture [see later]); therefore
FI0 2 is adjusted during treatment to maintain a normal Spoz.
To review, sympathomimetics are differentiated by the
type of receptor they stimulate: alpha, beta I' or beta2.
a-Adrenergic receptors are located in the smooth muscles of
all vascular tissue. Stimulation of these receptors results in
constriction of arterial and venous vasculature. ~2-Receptors
are found in the heart. Stimulating these receptors increases myocardial contractility, automaticity, and heart
rate. ~2-Receptors are primarily found in the smooth muscle
of the lungs and skeletal muscle arterioles. Stimulation of
these receptors results in smooth muscle relaxation, causing
bronchodilation in the lungs and increased blood flow in
skeletal muscle. Generally, initial management begins with
administration of continuous nebulized ~z-agonists.
Short-acting inhaled ~2-agonists, such as albuterol and
terbutaline, are indicated for quick relief of acute symptoms.
Mechanism of action is bronchodilation through smooth
muscle relaxation following adenylate cyclase activation
and increase in cyclic adenosine monophosphate (cyclic
AMP) producing functional antagonism of bronchoconstriction. Combining a nebulized ~2-agonist with an anticholinergic (ipratropium bromide) may produce better bronchodilation. 47 Anticholinergics, such as ipratropium bromide,
cause bronchodilation through competitive inhibition of
muscarinic cholinergic receptors, reduce intrinsic vagal tone
to the airways, and may decrease mucous gland secretion.
Ipratropium bromide may provide some additive benefit to
inhaled ~2-agonists in severe exacerbations.
Parenteral corticosteroids are also started immediately.
Steroids act not only as antiinflammatory agents, but
increase the number of ~-adrenergic receptors, enhancing
the response of bronchial smooth muscle to both endogenous catecholamines and exogenous ~2-agonists. Therefore early steroid therapy combined with an adrenergic
agent is significantly more effective than the adrenergic
agent alone, even in infant~ and toddlers. 48 Clinically,
production of the thick tenacio~s sputum peculiar to asthma
is also controlled, and mucosal edema appears to be
decreased. Methylprednisolone (preferred over hydrocortisone because it has less effect on sodium and potassium
metabolism at high doses) is given intravenously in a dose
of I mg/kg per dose every 6 hours (maximum single dose
60 mg/day IV). Serious toxicity or adrenal suppression with
short-term therapy (less than 2 weeks) is unlikely. Patients
in respiratory failure, especially those receiving steroids,
routinely receive prophylactic treatment against stress-ulcer
bleeding.
Intravenous magnesium sulfate is also administered early
in the course. Magnesium sulfate, 25 to 50 mg/kg (up to a
maximum dose of 2 g) is administered in a 2-hour infusion;
specifically, in severe circumstances, the first half of the
dose may be given over the first 15 to 20 minutes, and the
remainder of the dose should be administered over 2 hours.
The maximum rate of infusion is 125 mg/kg per hour. Serum magnesium levels are obtained 12 hours after the infusion (normal serum magnesium levels = 1.9 to 2.5 mg/dl).
The efficacy of intravenous magnesium therapy for moder-

ate to severe asthma exacerbations in 31 pediatric patients
was evaluated in a randomized, double-blind, placebocontrolled, clinical trial. Children treated with intravenous
magnesium sulfate infusions for moderate to severe asthma
had significantly greater improvement in short-term pulmonary function. 49
When continuous inhaled bronchodilators, steroids, anticholinergics, and magnesium fail to correct hypoxemia and
hypercarbia, intravenous terbutaline may provide a reversal
of bronchoconstriction and avert the need for endotracheal
intubation and assisted ventilation. Terbutaline, a more
selective ~2-agonist, has few toxic effects. A loading dose
of 10 Ilg/kg of intravenous terbutaline is administered
over 5 minutes followed by a continuous infusion of 1 to
3 Ilg/kg/min. This maintenance dose may be increased by
0.5 Ilg/kg per minute as necessary, keeping the heart rate
under 200 beats per minute (bpm).
Leukotrienes are potent biochemical mediators released
from mast cells, eosinophils, and basophils that contract
airway smooth muscle, increase vascular permeability,
increase mucous secretions, and attract and activate inflammatory cells in the airways of patients with asthma.
Leukotriene modifiers, zafirlukast and zileuton, have been
demonstrated to improve lung function and diminish symptoms and the need for short-acti ng inhaled ~z-agonists in
mild to moderate asthma. Zafirlukast, a leukotriene receptor antagonist, or zileuton, a 5-lipoxygenase inhibitor, may
be considered an alternative therapy to low doses of inhaled
corticosteroids or cromolyn or nedocromil for patients older
than 12 years of age with mild persistent asthma.
Heliox has demonstrated mixed results when used during
acute asthma. During status asthmaticus in 18 patients,
inhaled heliox significantly lowered pulsus paradoxus,
increased peak flow, and lessened the dyspnea index 50 In
contrast, in a separate prospective, randomized, doubleblind, cross-over study of II children with status asthmaticus heliox did not show benefit. 5I
Theophylline and aminophylline are not recommended
because they appear to provide no additional benefit to
optimal inhaled ~2-agonist therapy and may increase
adverse effects. 4 I Intravenous isoproterenol is not recommended in the treatment of asthma because of the danger
of myocardial toxicity.52 Antibiotics are also not recommended for asthma treatment and are generally reserved
for patients with fever and purulent sputum or evidence
of pneumonia. 41
Most patients respond well to therapy. However, a small
minority will show signs of worsening ventilation, whether
from worsening airflow obstruction, worsening respiratory
muscle fatigue, or a combination of the two. Signs of
impending respiratory failure include a declining mental
clarity, worsening fatigue, and progressive hypercapnia.
Exactly when to intubate is based on clinical judgment.
Because respiratory failure can progress rapidly and can be
difficult to reverse, early recognition and treatment are
critically important. 4I Clinicians should be aware that
hypotension commonly accompanies the initiation of positive pressure ventilation, close attention should be given to
maintaining or replacing intravascular volume.
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Permissive hypercapnia or controlled hypoventilation is
the recommended ventilator strategy to provide adequate
oxygenation and ventilation while minimizing high airway
pressures and barotrauma. 41 It involves administration of as
high a H02 as necessary to maintain adequate arterial
oxygenation, acceptance of hypercapnia, and treatment of
respiratory acidosis with intravenous sodium bicarbonate.
Adjustments are made to the tidal volume, ventilator rate,
and I:E ratio to minimize airway pressures. Bronchodilators
are continued, and even in ventilated patients, aerosol
delivery is the route of choice. 53
Mechanical ventilation with heliox may improve the
(A-a) gradient in some patients with status asthmaticus.
Although this improvement adds little to routine therapy
with supplemental 2 , it does permit reduction in concentration of inspired 02 to levels that maximize helium
concentration and thus permit full benefits of heliox on lung
mechanics to be realized in even the most severely ill
asthmatics. 54
Until conventional therapy can be optimized, an intubated mechanically ventilated patient in status asthmaticus
may benefit from the use of an inhaled anesthetic that
produces a secondary effect of bronchodilation 55 Isoflurane
(Forane), a fluorinated ether, is one such agent. Isoflurane
has a low blood-gas solubility coefficient so that changes in
the concentration administered will result in an almost
immediate alteration of effect-a desirable feature in the
ICU setting. The dose of inhaled isoflurane dose is 0.5%
(increased in increments of 0.2%). At an inspired concentration of 2%, the hemodynamic side effects (hypotension,
tachycardia) may become pronounced and precipitate the
need for concomitant inotropic support. Potential adverse
reactions are dose dependent and incl ude respiratory depression, hypotension, and junctional dysrhythmias. Management of significant adverse effects includes disconnecting
the patient from the isoflurane and ventilating the patient
with an Fl02 of 1.0. Isoflurane is contraindicated in patients
with a known or suspected genetic susceptibility to malignant hyperthermia.
Before the introduction of this novel therapy in the ICU,
multidiscipl inary standards of care and practice guidelines
are created and additional nursing competencies are validated. Patients receiving an inhalation agent are continuously observed. In addition to standard ICU monitoring,
inspiratory and end-tidal isoflurane concentrations and core
temperatures are continuously monitored and recorded
hourly. End-tidal concentration should, in general, measure
within 0.1 % of the inspired concentration. Before suctioning a patient receiving isoflurane, a suctioning plan that
takes into consideration the almost immediate reversal of
anesthesia and bronchodilation is created, for example,
premedication consisting of lidocaine (I mg/kg) and ketamine (I to 2 mg/kg). Note that peak lidocaine effect is less
than I minute.
The importance of continuously monitoring the patient in
status asthmaticus cannot be overemphasized. Frequent
evaluations are necessary to assess the efficacy of sympathomimetics, and will direct the choice, and frequency of
administration, of inhaled bronchodilators. Respiratory as-
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sessments include respiratory rate and effort, as well as the
quality of air movement on auscultation. A fall in Sp02
below 90% is considered a sign of serious hypoxemia.
ABGs also document progression in respiratory failure with
an increase in Pac02 and acidosis. The child's level of
consciousness is frequently noted because a decrease in
mental status may signal impending respiratory failure.
Assessment of infants is dependent upon physical examination rather than objective measurements. Use of accessory
muscles, paradoxical breathing, cyanosis, a respiratory rate
greater than 60, and Spo2 less than 91 % are key signs of
serious distress. 41 Skilled nursing assessment is necessary
not only to monitor the effectiveness of interventions but
also to detect negative effects of therapy (Table 19-3).
Caring for the child with asthma after endotracheal
intubation presents additional nursing challenges. Routine
maneuvers to maintain airway patency may irritate airway
receptors and trigger bronchospasm and hypoxia. Heavy
sedation and, in some patients, neuromuscular blockade
may be required to achieve adequate ventilation and reduce
the risks of barotrauma caused by positive pressure ventilation. In particular, the risk of developing a pneumothorax,
already increased because of gas trapping, is great in
mechanically ventilated patients with asthma. Pneumothorax should be suspected if there is sudden clinical deterioration with hypoxemia, acidosis, hypotension, or the unilateral absence of breath sounds. Equipment to needle aspirate
extra-alveolar air (a large-bore intravenous catheter, stopcock, and large syringe) should be kept at the bedside, and
equipment necessary for chest tube insertion readily available. Chest physiotherapy is contraindicated during acute
exacerbations because it may aggravate the child and his or
her airways.
Laboratory studies may help detect actual or impending
respiratory failure, however these studies should not delay
initiation of treatment. An ABG is helpful in evaluating
Pac02 in patients with suspected hypoventilation. A complete blood count (CBC) may be appropriate in patients with
fever or purulent sputum; keeping in mind that modest
leukocytosis is common in asthma exacerbations and that
corticosteroid treatment causes a further outpouring of polymorphonuclear leukocytes within I to 2 hours of administration. It may be prudent to measure serum electrolytes in
patients who have been taking diuretics regularly and in
patients with coexistent cardiovascular disease, because frequent J32-agonist administration can cause transient decreased in serum potassium, magnesium, and phosphate.
Chest radiography is not recommended for routine assessment but should be obtained in patients suspected of a complicating cardiopulmonary process, such as pneumothorax,
pneumomediastinum, pneumonia, lobar atelectasis, or congestive heart failure. 41
Once an acute episode is controlled, parent and/or patient
education becomes a nursing priority. This begins with a
careful assessment of the family's understanding of the
disease process and the measures necessary to help prevent
future attacks.
Monitoring reactive disease in children is difficult
because of their inability to cooperate with lung function
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19-3 Actions and Clinically Significant Side Effects of Medications Used in the Treatment
of Asthma

TABLE

~nhaled Ilz,Agonist
~j; Albuterol
c.; (Ventolin)
iii,
Terbutaline
jE;
;I" (Brethine)
Metaproterenol
, ~';;(Alupent)

.

. ,'

·~,.ntichOlingeriC
Agent
bromide

1

:~pratropium

,,,

w

Actions

Side Effects

Bronchodilation (largely resulting from local drug
effect~ in the lungs)
Improve mucociliary clearance
Metaproterenol is somewhat shorter acting and less
selective for p-adrenergic receptors

Tachycardia (less than with systemic drugs)
Tremor and hyperactivity occur infrequently

Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle
causing bronchodilation.

Tachycardia, flushing, nervousness, headache,
drowsiness

Reduce inflammation
i p-adrenergic receptors (enhancing the response
of bronchial smooth muscle to catecholamines)

Gastric ulcerations
Adrenal insufficiency (with long-term therapy)

Bronchodilation via,
- Smooth muscle relaxation
~ Inhibition of antigen-induced release of histamine and other mediators of inflammation
i heart rate, contractility
! peripheral vascular resistance
H or i systolic blood pressure
i cardiac output

Tachycardia, hypertension, dysrhythmias, headache,
seizures, nausea, and vomiting

~~ orticosteroids

".- ethylprednisolone

'i'
.'5ystemic Ilz Agonist
'erbutaline
~T

tests, In the noncritical patient, the 88%-SAT may be
more effective than spirometry for identifying reactive
airways disease in young, uncooperative, or developmentally delayed children. The 88%-SAT consists of continuous measurement of Spoz while the subject breathes a
nonhumidified 12% 0z and nitrogen mixture for 10 minutes or until Spoz decreases to 88%, whichever occurs
first. 56
Prevention. One of the national health objectives for
the year 2000 is to decrease asthma morbidity, as measured
by a reduction in hospitalizations for asthma, among
children younger than or equal to 14 years to no more than
18.3 per 10,000 population. Hospitalizations and mortality
related to asthma can be prevented, in part, by improving
surveillance, diagnostic measures, and patient management;
providing patient education; targeting high-risk populations;
and evaluating interventions in the home environment (e.g.,
reducing levels of house dust mites and exposure to
environmental tobacco smoke)57
Prolonged breast-feeding and avoidance of early introduction of allergenic foods have been reported to reduce
eczema and food sensitization but not to reduce the
prevalence of asthma. 41 However, a report of 2187 6-yearold children indicated that the presence of the diagnosis of
asthma and wheezing occurring 3 times or more since I year
of age were associated with exposure to milk that was not
breast milk before age 4 months. 58
The literature is unclear as to when immunotherapy

should be initiated for childhood asthma. Although there are
suggestions that immunotherapy should be considered for
the child with mild or moderate asthma and dust mite
sensitivity when pharmacotherapy is not efficacious, the
immunomodulatory properties of immunotherapy may actually be more tailored for early intervention in asthma
rather than for use once symptoms have occurred. 41 ,59

Restrictive Disease
Reduced pulmonary compliance is another mechanical
alteration that can produce alterations in pulmonary function
and respiratory pump failure. When pulmonary compliance
is decreased, a greater airway pressure is needed to distend
alveolar units to the same final lung volume; that is, it takes
more pressure (and more work) to deliver normal lung
volumes Lo a stiff lung. To reduce the work of breathing yet
sustain minute alveolar ventilation, children with decreased
thoracic compliance breathe rapidly and shallowly. Diminished compliance also results in intercostal and subcostal
retractions, especially in the supple chest wall of the young
infant.
In addition to increasing the work of breathing, decreased
pulmonary compliance ultimately reduces functional residual capaciL0FRC, the amount of air that remains in the
lungs at the end of normal expiration). This reduction in
FRC may lead to alveolar collapse and result in increased
intrapulmonary shunting and hypoxemia.
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Frequent causes of decreased lung compliance in PICU
patients include pneumothorax, pneumonia, adult respiratory distress syndrome (ARDS), and congenital diaphragmatic hernia.
Pneumothorax

Etiology. A pneumothorax is a collection of air or gas
in the pleural space that may occur spontaneously but more
frequently results from trauma to the lung parenchyma. A
tension pneumothorax exists when air enters the pleural
space at such a rate that pressure in the pleural space
increases enough to produce circulatory and ventilatory
impairment. As extra-alveolar air accumulates, it compresses and shifts the mediastinum toward the unaffected
side. If a significant tension pneumothorax is not treated
promptly, venous return to the heart falls, cardiac output
decreases, and cardiopulmonary arrest ensues. Early detection and timely intervention, however, may prevent this
catastrophic chain of events.
Incidence. Although a spontaneous pneumothorax
during unassisted breathing is rare, alveolar overdistension
then rupture may be seen with the use of use high peak
inspiratory or end-expiratory pressures to achieve adequate
oxygenation and ventilation.
Pathogenesis. Patients who have regional differences
in lung compliance or airways resistance are at risk for the
development of extra-alveolar air. A pneumothorax may
occur, for example, in a child with ARDS when less affected
alveoli are overdistended by the pressure required to inflate
noncompliant areas of the lung. In the child in status
asthmatic us, a pneumothorax may result if airway obstruction during expiration leads to gas trapping and alveolar
hyperinflation.
A pneumothorax may also result from chest trauma. An
open pneumothorax (or sucking chest wound) occurs when
there is a penetrating injury that creates a communication
between the pleural space and the environment. Pleural
pressure and atmospheric pressure immediately equilibrate,
the lung collapses, and the mediastinum shifts toward the
unaffected lung. A small opening in the chest wall that
permits air entry but blocks its exit (or a closed lung injury,
caused by a broken rib, for example) may cause air to
accumulate in the pleural space and result in a tension
pneumothorax .
Once the alveolus ruptures, the gas it contains moves into
the interstitial space where it dissects into other fascial
planes or compartments. This results in air-leak syndrome,
for example, interstitial emphysema, pneumopericardium,
pneumothorax, pneumomediastinum, subcutaneous emphysema, pneumoretroperitoneum, and/or pneumoperitoneum.
Critical Care Management. The primary therapeutic goals are to identify patients at risk, closely monitor for
the signs and symptoms of a pneumothorax, and reduce or
eliminate factors that may contribute to the development of
extra-alveolar air.
A small, stable pneumothorax may go completely undetected until a chest radiograph reveals its presence (Fig.
19-6). If the pneumothorax increases in size, the child may
develop dyspnea, pleuritic chest pain, and tachypnea.

Fig. 19-6 Chest radiograph illustrating pneumothorax with
mediastinal shift.

However, a more dramatic presentation frequently occurs in
the P[CU setting. Commonly, the child undergoing positive
pressure ventilation has a sudden deterioration in oxygenation and ventilation as reflected in noninvasive monitors and
ABGs. The child becomes tachycardic and hypotensive
because of decreased venous return to the heart. A significant pulsus paradox us (a decrease in blood pressure during
inspiration) may also develop as [eft ventricular output is
further compromised by increasing intrathoracic pressures.
An infant who develops a large tension pneumothorax may
rapidly become hypotensive and develops bradycardia from
severe hypoxemia. On physical examination, there may be
decreased breath sounds and hyperresonance to percussion
on the affected side. However, in infants and small children,
breath sounds may be readily transmitted from the unaffected to the affected side, and a decrease in air entry may
not be as apparent. Transillumination with a high-intensity
light may be helpful in these patients; the side of the chest
containing the free air will transmit light well. [n older
patients, there may also be a contralateral shift of the
mediastinum with tracheal deviation toward the unaffected
side and lateral displacement of the cardiac apical impulse.
Occasionally, subcutaneous emphysema and crepitus may
also occur.
To detect the development of a tension pneumothorax, it
is necessary to identify and closely monitor those patients at
higher risk for developing extra-alveolar air. Patients
receiving positive pressure ventilation are assessed frequently to determine the adequacy of their ventilation and
detect untoward events, such as right mainstem intubation or
asynchronous breathing, which may lead to a pneumothorax. Nursing vigilance in these patients can prevent what is
sometimes an iatrogenic complication of treatment.
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A tension pneumothorax is a medical emergency that
requires immediate intervention. Evacuation of pleural air is
attempted whenever a patient has an acute deterioration that
is likely to be the result of tension pneumothorax. Although
a chest radiograph provides the definitive diagnosis, it
should not delay treatment of a suspected pneumothorax in
a patient with rapidly deteriorating circulatory function. In
the absence of a chest radiograph, transillumination or
physical examination can localize a pneumothorax. Initially,
a large-bore needle or catheter, attached by a stopcock to a
large syringe, may be used to rapidly evacuate the pneumothorax. Once the patient's condition has stabilized, a tube
thoracostomy can be performed to permit full reexpansion
of the lung and prevent reaccumulation of pleural air.
When a chest tube is required, assessment of the patient's
respiratory status is followed by a thorough assessment of
the chest tube and drainage system. The chest tube insertion
site is covered with an occlusive dressing and kept dry to
prevent maceration of the skin. Although usually sutured in
at the time of insertion, the chest tube or drainage tubing is
also taped to the child's chest wall to minimize the risk of
dislodgment. The chest tube is then connected to a drainage
system (see Chapter 8).

Pneumonia
Etiology. Most pneumonias in infants and children are
viral in origin. However, bacterial pneumonias are still an
important cause of severe illness in childhood. In the
immunocompetent pediatric patient, the major organisms
causing bacterial pneumonia are pneumococcus, streptococcus, and staphylococcus. Certain infectious agents are more
prevalent in certain age groups: Group B streptococci
predominate in the newborn; pneumococcus in the young
child I month to 6 years of age; and pneumococcus in the
older child. In the immunocompromised patient, Pneumocystis carin ii, fungi, and opportunistic bacteria such as
enteric and atypical mycobacteria are important causative
agents.
Incidence. Pneumonia is the most common Ii fethreatening lung disease in pediatric patients.
Pathogenesis. Pneumonia, an inflammatory process
in the lungs that progresses to alveolar consolidation, occurs
when pulmonary defense mechanisms are altered and an
infective agent invades the lung by aspiration or hematogenous spread. Pneumonia can occur anywhere in the lung.
As lobes or segments become filled with fluid,a;:;d cellular
debris, lung compliance and vital capacity decrease and the
work of breathing increases. Intrapulmonary shunting and
Y/o. mismatch result from continued perfusion of consolidated, airless lung and lead to significant hypoxemia. Signs
and symptoms of respiratory distress may develop, including tachypnea, dyspnea, cough, and intercostal retractions.
Usually, there are localized findings over the affected lung
segment with diminished breath sounds or adventitious
noises.
Patients with endotracheal intubation are particularly
vulnerable to nosocomially acquired pneumonia. Bacterial
colonization of the upper respiratory tract commonly occurs
in these patients and may promote pneumonia through

aspiration of these pathogens. In addition, the child with an
artificial airway may be at particularly high risk for
pneumonia because of impaired mucociliary clearance, the
frequency of airway invasion, and exposure to nosocomial
pathogens.
Aspiration pneumonia is an important phenomenon in the
PICU patient. When normal airway protective mechanisms
are impaired, gastric contents may be aspirated into the
airways. This may occur because of a decreased level of
consciousness or the presence of an endotracheal tube,
which inhibits the child's ability to occlude the larynx.
Critical Care Management. When bacterial pneumonia is suspected, appropriate antibiotic therapy is started
as soon as possible. Antibiotic coverage may be changed or
extended when the causative organism is identified and
antibiotic sensitivities established. Supplemental O 2 is
administered to maintain normal Spo2' If respiratory failure
ensues, endotracheal intubation and mechanical ventilation
are also required.
Nursing care of the patient with pneumonia is largely
supportive. Impaired gas exchange is monitored by following ABGs and SP02' When unilateral intrapulmonary
shunting predominates, patient positioning becomes critically important. Although pulmonary perfusion is predominately located along the dorsal regions, the pattern of lung
inflation depends on how the patient is being ventilated.
Lungs inflate from bottom to top during spontaneous breaths
and from top to bottom during positive pressure breaths.
Optimal position to enhance matching of ventilation to
perfusion in patients with unilateral pneumonia is best
determined at the bedside with the aid of Sp02 monitoring.

Acute Respiratory Distress Syndrome
Etiology. In 1967, Ashbaugh and others first described
a group of patients who, after injuries such as trauma and
sepsis, developed acute dyspnea and hypoxemia that failed
to respond to conservative therapy.60 Today we recognize
ARDS as a syndrome of inflammation and increased
permeability that is associated with a constellation of
clinical, radiologic, and physiologic abnormalities that
cannot be explained by, but may coexist with, left atrial or
pulmonary capillary hypertension 61 Although 63% of
pediatric patients present with more than one ARDS trigger
(an illness that has the potential to cause ARDS),62
precipitating factors include pneumonia (51%), sepsis
(33%), airways disease (18%), pulmonary aspiration (12%),
status-post bone marrow transplant (10%), trauma with
shock and multiple transfusions (8%), and near-drowning
(3%). Sepsis is associated with the highest (40%) progression to ARDS,
To facilitate early recognition and systematic study of
ARDS, the American-European Consensus Conference
on ARDS provided an operational definition for ARDS
in 1994 61 The group acknowledged the wide spectrum
of clinical presentation associated with ARDS. As noted
in Table 19-4, the term "acute lung injury" (ALI) was used
to describe the less severe end of the spectrum while
"ARDS" was used to describe the most severe end of the
speCtrum.
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19-4 .Recommended Criteria for Acute Lung Injury and Acute Respiratory
Distress Syndrome
.

TABLE

Timing

Oxygenation

Chest Radiograph

Acute onset

Pao 21F102 ratio ~3()() mmHg
(regardless of level of
PEEP)
Pao,lFJ02 ratio ~200 mmHg
(regardless of level of
PEEP)

Bilateral infiltrates seen on
frontal chest radiograph

Acute onset

Incidence. Although uncertain, ARDS is thought to
account for 3% of all PICU admissions and 8% of all PICU
days.63 Almost 12% of PICU admissions are admitted with
an ARDS trigger. Although published pediatric ARDS
mortality rates vary, the Pediatric Critical Care Study Group
describe overall mortality as 43%.64 With improvements in
supportive care and treatment, mortality rates appear to be
decreasing. 65 Fackler describes an 18% mortality rate in
extracorporeal membrane oxygenation (ECMO)-eligible
children and a 58% mortality rate in ECMO-ineligible
children. 62 Specifically, patients thought to be ineligible for
ECMO include those with ARDS for longer than 7 days, or
patients with chronic lung disease, compromised immune
systems, left ventricular failure, or profound acute neurologic injury. Of note, most patients who die with ARDS die
of multisystem organ failure-not single organ respiratory
failure.
Pathogenesis. Ware and Matthay reviewed what is
currently known about the biochemical mediators and
products of cellular damage contributing to acute lung
injury and recovery (Fig. 19-7, A and Fig. 19-7, B).65 The
predominant physiologic disturbance is an alteration in the
alveolar-capillary interface, which leads to increased capillary permeability and pulmonary edema. Under normal
circumstances, the permeability of the alveolar epithelium is
relatively constant. Fluid leaves the capillary bed via small
clefts located at the junction of the endothelial cells lining
the capillary walls, and the lymphatic system is capable of
removing excesses. However, when the alveolar capillary
membrane is disrupted, large amounts of fluid and protein
leak first into the interstitial space, overwhelming the
lymphatics, eventually entering the alveolus itself. As a
result of this process, for any given pulmonary capillary
pressure, lung water is greatly increased. Even at normal
pulmonary capillary wedge pressures of 5 to 10 mmHg,
there is fluid accumulation in ARDS. However, because
measures of lung water and gas exchange correlate poorly,
increased lung water is only partially responsible for the
refractory hypoxemia seen in ARDS. Of greater consequence is the YIQ mismatch associated with the multiple
disturbances of pulmonary circulation and alveolar aeration
seen in this disease.

Bilateral infiltrates seen on
frontal chest radiograph

Pulmonary Artery Wedge
Pressure

mmHg when measured
or DO evidence of left
atrial hypertension
~18 mmHg when measured
or no evidence of left
atrial hypertension
~18

The noncardiogenic pulmonary edema of ARDS results
in decreased lung compliance (C L ); that is, it takes more
pressure (and more work) to deliver normal tidal volumes
because the lungs are stiffer. If the force required to inflate
the lungs cannot be maintained, overall lung volume decreases, leading eventually to alveolar collapse and a net
reduction in FRC. As alveoli collapse, intrapulmonary
shunting occurs and hypoxemia develops. Ordinarily, the
pulmonary vessels constrict in the face of alveolar hypoxia,
a phenomenon called reflex hypoxic vasoconstriction. But in
ARDS, reflex hypoxic vasoconstriction may not be intact
and poorly ventilated areas continue to be perfused. Collapsed alveoli that remain perfused create a right-to-Ieft
shunt, increasing pulmonary venous admixture and causing hypoxemia. The opposite also occurs in the lungs
with ARDS; some alveoli may remain ventilated but are
not perfused. This may be the result of vasoconstriction,
emboli, or destruction of the capillary structure by the disease process. Such areas behave as dead space and may
increase Pac02 .
Although mechanical ventilation provides an indispensable tool for providing adequate gas exchange and resting
respiratory muscles in many disease states, in patients with
ALII ARDS the ventilator strategy required to maintain
adequate gas exchange may exacerbate lung injury and
cause ventilator-induced lung injury (VIU). In patients with
ALIIARDS, computed tomographic scanning has shown
marked heterogeneity in the pattern of lung injury along the
vertical axis (Fig. 19-8). Intrapleural pressures become less
negative along the vertical axis; speci fically, nondependent
alveoli are exposed to the greatest transalveolar pressure
(alveolar pressure-pleural pressure) so are largest in size,
whereas dependent alveoli are exposed to the least transalveolar pressure so are smallest in size. Gattinoini identified
three lung zones: responsive, nonresponsive, and recruitable
zones. The nondependent lung regions are considered
responsive in that they usually remain continuously open to
ventilation. The dependent lung regions are considered
unresponsive zones in that they usually become consolidated and/or atelectatic. The regions in-between the nondependent and dependent zones are considered recruitable
depending on the venti lation strategy.
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Fig. 19-7 A, The normal alveolus (left-hand side) and the injured alveolus in the acute phase of ALI
and the ARDS (right-hand side). In the acute phase of the syndrome (right-hand side), there is sloughing
of both the bronchial and alveolar epithelial cells, with the formation of protein-rich hyaline membranes
on the denuded basement membrane. Neutrophils are shown adhering to the injured capillary endothelium
and marginating through the interstitium into the air space, which is fi lied with protein-rich edema
fluid. In the airspace, an alveolar macrophage is secreting cytokines, interleukin-l, -5, -8, and -10 (IL-l,
IL-5, IL-8, and IL-IO) and tumor necrosis factor-a (TNF-a), which can act locally to stimulate
chemotaxis and activate neutrophils. Macrophages also secrete other cytokines, including IL-I,
IL-6, and IL-IO. IL-I can also stimulate the production of extracellular matrix by fibroblasts.
Neutrophils can release oxidants, proteases, leukotrienes, and other proinflammatory molecules, such as platelet-activating factor (PAF). A number of antiinflammatory mediators are also present
in the alveolar milieu, including IL-l-receptor antagonist, soluble tumor necrosis factor receptor, autoantibodies against IL-8, and cytokines such as IL-IO and IL-II (not shown). The influx of
protein-rich edema fluid into the alveolus has led to the inactivation of surfactant. MIF. Macrophage
inhibitory factor. (From Ware LB, Matthay MA: The acute respiratory distress syndrome, N Engl J
Med 342: 1339, 2000.)
. Conrinued
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B

Fig. 19-7, cont'd B, Mechanisms important in the resolution of ALI and the acute respiratory distress
syndrome ARDS. On the le,ft side of the alveolus, the alveolar epithelium is being repopulated by the
proliferation and differentiation of alveolar type II cells. Resorption of alveolar edema fluid is shown at the
base of the alveolus, with sodium and chloride being transported through the apical membrane of type II
cells. Sodium is taken up by the epithelial sodium channel (EnaC) and through the basolateral membrane
of type II cells by the sodium pump (Na+/K+-ATPase). The relevant pathways for chloride transport are
unclear. Water is shown moving through water channels, the aquaporins, located primarily on type I cells.
Some water may also cross by a paracellular route. Soluble protein is probably cleared primarily by
paracellular diffusion and secondarily by endocytosis by alveolar epithelial cells. Macrophages remove
insoluble protein and apoptotic neutrophils by phagocytosis. On the right side of the alveolus, the gradual
remodeling and resolution of intraalveolar and interstitial granulation tissue and fibrosis are shown. (From
Ware LB, Matthay MA: The acute respiratory distress syndrome, N Engl J Med 342: 1339, 2000.)

With marked heterogeneity, providing a noninjurious
mode of mechanical ventilation can be difficult. In addition
to oxygen toxicity, three types of ventilator-induced lung
injury (VILI) have been described: volutrauma, atelectrauma, and biotrauma. Volutrauma, stretch-induced alveolar injury, results from modes of ventilation that allow

end-inspiratory alveolar over distension. Atelectrauma,
shear-induced alveolar injury, results from modes of ventilation that allow end-expiratory alveolar collapse. 8iotrauma, nonpulmonary organ injury, results from end-organ
exposure to the pulmonary inflammatory mediators released
in response to an injurious mode of mechanical venti la-
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Fig. 19-8 Chest computed tomography images of a 4-year-old girl who developed acute lung injury after
laparotomy for gastric perforation. Note the dependent distribution of consolidated lung. (From Doctor A.
Arnold J: Mechanical support of acute lung injury: options for strategic ventilation. New Horizons 7:361, 1999.)

tion. 66 Evidence for the development of multisystem organ
failure secondary to VILI is building. Recently, Ranieri and
others were able to document that mechanical ventilation
could lead to an increase in cytokine levels in the lung as
well as the systemic circulation and that limiting recruitment/derecruitment and overdistention could limit the
inflammatory response. 67 They were able to document that
the concentration of inflammatory mediators in both blood
and bronchial alveolar lavage fluid was significantly lower
in the lung-protective strategy group.
Gattinoini and others have also described differences in
respiratory mechanics between ARDS originating from
pulmonary disease (direct lung injury, for example, pneumonia) and that originating from an extrapulmonary disease
(indirect lung injury, for example, sepsis).68 In patients with
direct ARDS they note a prevalence of pulmonary consolidation, stiffer lungs within a highly compliant chest wall,
moderate lung recruitment with PEEP, and a tendency to
overdistended alveoli placing the patient at risk for barotrauma. In contrast, in patients with indirect ARDS they note
a prevalence of pulmonary edema and collapse, compliant
lung within a stiffer chest wall, improved compliance and
major lung recruitment with PEEP placing the patient at risk
for hemodynamic compromise.
After the pulmonary insult, there may be a lag time of
several hours to several days before respiratory distress
develops. Then, dyspnea develops; the symptom is subjecti ve and can be reported only by an older child. In an infant,
increasing respiratory difficulty may be manifested as
agitation, sometimes progressing to somnolence. Tachypnea, with intercostal and substernal retractions in smaller
children and infants, may persist even after 02 administration, reflecting the need for increased minute ventilation.
Chest auscultation, which can be normal initially, eventually
reveals course rales and bronchial breath sounds. The fine,

basilar rales of congestive heart failure are often absent in
ARDS. Wheezing may also occur because of narrowing of
the terminal airways by peribronchial edema, decreased
lung volume, or secretions. The majority of patients require
intubation and mechanical ventilation.
Critical Care Management. The treatment for
ARDS remains largely supportive. 69 All patients require
supplemental oxygen. Although the extent to which the
condition is made worse by oxygen is unknown, oxygen
toxicity may occur after prolonged exposure to high
concentration of F102. In addition, the nitrogen present in an
FI02 less than 0.5 serves as an intra-alveolar splint. With
higher concentrations of 02' decreasing amounts of residual
gas remain in the alveoli, and reabsorption atelectasis may
occur. Therefore it is prudent to reduce FI02 as much and as
rapidly as possible. The goal is to maintain a Pa0 2 of 55 to
80 mmHg, Sp02 88% to 95%, in an FI0 2 less than 0.6.
As illustrated in Fig. 19-9, the pressure-volume curve of
the respiratory system in early ALIJARDS has been
described as sigmoid shape with a lower inflection point
(Pflex) representing the pressure required to reopen a
collapsed lung and an upper inflection point thought to
correspond to overdistention of open units. 70 Restated, the
lower inflection point represents a sudden increase in
compliance induced by recruiting alveoli that are open while
the upper inflection point represents a sudden decrease in
compliance induced by alveolar overinflation. The goal of
ventilator support in ALIIARDS is to "open" the lung and
keep it open during end-expiration while avoiding overinflation during end-inspiration. Optimal PEEP will obliterate
the lower inflection point and the use of tidal volume
(Vt)/pressure-limited ventilation will prevent an upper
inflection point. Although two conflicting studies exist
(Amato and colleagues and Stewart and co-workers), it
appears that this ventilation strategy improves oxygenation,
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Fig. 19·9 Pressure-volume relationships in ARDS. Intrapleural pressures become less negative along the
vertical axis; nondependent alveoli are exposed to the greatest transalveolar pressure so are largest in size.
whereas dependent alveoli are exposed to the least transalveolar pressure so are smallest in size. The
nondependent lung regions are considered responsive in that they usually remain continuously open to
ventilation, The dependent lung regions are considered unresponsive zones in that they usually become
consolidated and/or atelectatic. The regions in between the nondependent and dependent zones are
considered recruitable depending on the ventilation strategy, The compliance of each region varies as
reflected by its location on the pressure-volume curve.

TABLE

19-5 Optimal PEEP-FIO Z Concentration Combinations
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pulmonary compliance. weaning success, the incidence of
barotrauma, and 28-day mortality.71.72 It should be noted
that in day-to-day clinical practice, pressure-volume curves
are difficult to construct with the standard super syringe
technique and clinicians typically optimize end-expiratory
volume by targeting a change in tidal compliance. 73
PEEP is considered the mainstay of ARDS treatment.
When an optimal level of PEEP is added to positive pressure
ventilation, alveoli remain open throughout all phases of the
respiratory cycle to continually participate in gas exchange.
Without PEEP, alveoli collapse on end-exhalation and are
forced open during inspiration, causing alveolar atelectrauma. PEEP increases FRC by augmenting the volume of
expanded alveoli and by recruiting collapsed units reducing
intrapulmonary shunt. PEEP does not remove lung water but
improves arterial oxygenation by increasing the number of
ventilated alveoli. The implication for nursing is the need to
be certain that prescribed levels of PEEP are maintained,

including during endotracheal suctioning, after turning the
child, and so on.
As outlined in Table 19-5, the National Institutes of
Health (NIH) ARDS Network made recommendations on
appropriate PEEP-Flo 2 combinations in their low Vt
study74 When PEEP is increased in an attempt to recruit
collapsed alveoli, nondependent alveoli may become overdistended. The proportion of nonoxygenated blood increases
as the capillaries surrounding these overdistended areas are
compressed, increasing intrapulmonary shunting and hypoxemia. Dead space is increased in the overdistended units
and Paco 2 may climb. Daily chest radiographs in patients
with ARDS are necessary during the acute phase of the
disease, not so much to follow the pulmonary edema but to
evaluate potential complications of therapy. Complications
include pulmonary hyperinflation and air-leak syndrome
(barotrauma), Finally, PEEP may cause a decrease in cardiac
output primarily in patients with extra-pulmonary ARDS by
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decreasing systemic venous return to the heart. Myocardial
support may be necessary, including both the judicious use
of volume to increase preload and the administration of
inotropic agents.
As discussed, the traditional approach to mechanical
ventilation in the patients with ALUARDS was the use of
high Vt (10 to 15 ml/kg). This approach is thought to
contribute to the development of VILI, specifically, alveolar
volutrauma. Recently, the ARDS network compared this
traditional approach (Vt 12 ml/kg of predicted body weight,
plateau pressure of 50 cm H2 0 or less) to a low Vt strategy
(Vt 6 ml/kg of predicted body weight, plateau pressure of
30 cm H2 0 or less).74 The primary outcome variables were
death and the number of days without ventilator use from
day I to day 28 (ventilator-free days). The multicenter,
randomized trial was stopped after 861 patients were
enrolled because mortality was 22% lower in the low Vt
group (31 % versus 40%). The low Vt group also experienced more ventilator-free days (12 versus 10 days) and,
suggesting less lung inflammation, the low Vt group also
had a greater reduction in IL-6 concentrations. It was
concluded that in patients with ALIIARDS, mechanical ventilation with a lower Vt than traditionally used
results in decreased mortality and an increase in ventilationfree days.
Low Vt strategies will precipitate hypercapnia and a
compensated respiratory acidosis. In 1990, Hickling and
colleagues first proposed the importance of limiting positive
inspiratory pressures (PIP) by reducing Vt even if it resulted
in short-term hypercapnia and a deterioration of oxygenation. 75 In a prospective study, Hickling and others demonstrated decreased ARDS mortality using a low-volume,
pressure-limited ventilation with permissive hypercapnia
strategy.76 In this study, the mean maximum Paco z was 66.5
mrnHg (range 38 to 158) with a mean arterial pH of 7.23
(range 6.79 to 7.45).
In the low Vt study (described above) the ARDS network
study attempted to keep the patient's arterial pH between
7.3 and 7.45 with the use of increased respiratory rates,
decreased ventilator dead space, and the use of NaHCO).74
Potential side effects associated with the use of pernlissive
hypercapnia include decreased myocardial contractility,
cerebral vasodilation, decreased seizure threshold, and
hyperkalemia. Although there are no absolute contraindications to permissive hypercapnia, extremes in Paco z levels
should be modi fied in patients with concomitant cerebral
hypertension.
High-frequency oscillatory ventilation (HFOV) is an
alternative mode of ventilation that accomplishes the open
lung approach desirable in the management of patients with
ALI/ARDS (see Chapter 8). Although questionable, HFOV
is often reserved for those who fail conventional mechanical
ventilation; for example, when a patient requires a PIP
greater than 35 em H2 0, plateau pressures greater than 30
cm HzO, Paw greater than 18 em HzO despite permissive
hypercapnia or when chemical paralysis is required. Doctor
and Arnold reviewed the advantages for using HFOV,
specifically, (I) poorly compliant lungs can be aggressively
recruited and maintained, (2) the small Vt and pressure

swings may attenuate VILI, and (3) the different flow
delivery characteristics may improve V/Q matching. 77
When pediatric patients with ALIIARDS are ventilated
using HFOV, an optimal lung volume strategy is used;
specifically, Paw are initially set 5 to 8 cm H20 over what
was necessary on conventional therapy then adjusted in an
effort to decrease FiO z < 0.6. Compared with conventional
mechanical ventilation, Arnold and colleagues demonstrated
significant improvements in oxygenation with an optimal
lung volume HFOV strategy and, despite the use of a higher
Paw, HFOV was associated with a lower frequency of
barotrauma and improved clinical outcomes. 78
When conventional measures fail and the patient with
ARDS sti II has the potential for a good clinical outcome
than ECMO may be considered (see Chapter 8). To date,
more than 1700 children have been supported on ECMO for
respiratory failure with an overall survival rate of 55%.79
Although the technical aspects of ECMO are the same, the
duration of ECMO support for a pediatric patient with
ARDS is usually quite long-up to 2 months.
Considering the volume recruitment priority in ALII
ARDS, endotracheal suctioning (see Chapter 8) should be
performed only when clinically indicated. Specifically when
there is an increase in airways resistance, a decrease in
dynamic compliance, a decrease in delivered Vt, or an
increase in PIP with a widening of the PIP-Plateau pressure
difference. Recruitment maneuvers, for example the use of
higher PIPs or larger Vts breaths with longer inspiratory
times are necessary after the suctioning procedure to help
rerecruit unstable lung units that collapse with suctioning.
Although controversies abound regarding fluid requirement and restriction in ARDS, it is generally advisable to
keep patients relatively fluid restricted. The ultimate goal of
fluid therapy is to maintain an adequate cardiac output while
keeping microvascular pressures as low as possible. Diuretics may be helpful in shifting extravascular water into the
intravascular space if volume overload has occurred.
Furosemide is known to be effective in cardiogenic pulmonary edema by virtue of both its diuretic and nondiuretic
vascular properties. By lowering central filling pressures
through immediate vasodilation (independent of the later
diuresis), furosemide can reduce pulmonary shunting and
lung water in high permeability pulmonary edema as well.
Other treatment measures include attempts to maximize
O 2 delivery. The majority of O 2 is carried by hemoglobin;
therefore hemoglobin concentration and 0z saturation are
the important determinants of 02 content. Maintaining the
hemoglobin at normal levels optimizes O 2 carrying capacity
without increasing viscosity and limiting tissue perfusion.
Continuous Spo2 monitoring can prove invaluable in
monitoring pulmonary perfusion changes that occur during
various nursing interventions that may alter VIQ matching.
Blood pressure is a relatively poor index of cardiac output,
which may be measured directly when a pulmonary artery
catheter is in place. Noninvasive techniques for measuring
cardiac output, such as those based on ultrasound results,
provide a valuable alternative. To maximize the availability
of 0z at the cellular level, attempts are made to correct
factors that negatively influence oxyhemoglobin dissocia-
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tion, that is, shift the oxyhemoglobin dissociation curve to
the left and impair the release of oz to the tissues. Here
normothermia is again important, as is the avoidance of
metabolic or respiratory alkalosis.
Because hypoxemia is a primary feature of ARDS,
measures to reduce 0z consumption (Voz) are critically
important. In patients with very large intrapulmonary
shunts, fever, anxiety, and physical activity can increase
oxygen demand. This in turn decreases the Poz of mixed
venous blood (Pvo z), and ultimately lowers Paoz. Therefore
treatment of fever, reduction of anxiety, and sedation
are important. Muscle relaxants may be used, not so much
to reduce Voz (neuromuscular blockade will not reduce
Voz beyond that achieved by adequate sedation 8o ) but to
overcome desynchrony of the child's respiratory efforts
with mechanical breaths and prevent the complications that
may bring, for example, barotrauma (pneumothorax or
pneumomediastinum).
Hypercarbia is not a predominant feature of ARDS
except in severe cases. Here, noninvasive end-tidal COz
monitoring may not be as useful except in providing
trending information, because the difference between arterial COz and end-tidal values widens with severe V/0.
mismatching. What is ultimately important, however, is not
just the Paoz but the total amount of oxygen transported to
the tissues.
Prone positioning, as first suggested by Bryan in 1974,
is a relatively simple maneuver that improves oxygenation and lung mechanics in adults with severe impairments of gas exchange. 81 ,8z Data suggest that improved
oxygenation in the prone position is associated with
less variability in end-expiratory lung volume from the
dorsal to the ventral regions, resulting in a more even
regional inflation/ventilation along the vertical axis, in the
absence of a gravity perfusion distribution. 83 A preliminary study did show that pediatric patients improved
their oxygenation without serious iatrogenic injury after
early, repetitive and prolonged prone positioning. 84 The
improved oxygenation resulting from prone positioning
allows a reduction in the intensity of ventilator support
that may decrease VILI and facilitate patient recovery.
However, no randomized, controlled trial has evaluated the
safety and effectiveness of early and repeated prone
positioning on the clinical outcomes of pediatric patients
with ALI/ARDS.
Box 19-2 contains a nursing procedure on prone positioning. Candidates for prone positioning include patients
with ALI/ARDS. Patients not considered candidates for
prone positioning include those who are experiencing
symptomatic hypotension, patients supported on ECMO, or
patients with the following clinical problems: cerebral
hypertension, spinal instability, unstable long bone fracture,
or a nonpulmonary conditions that may be exacerbated by
the prone position (e.g., osteogenesis imperfecta or severe
skeletal deformities). For maximum lung protection, patients should be positioned prone early in their course of
illness for at least 16 to 20 hours/day. Patients are considered
"responders" to prone positioning if they experience a
20-mmHg or more supine-to-prone increase in the Paoz!F102
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ratio. Prone positioning is discontinued when the patient is
actively weaning from mechanical ventilation.
Patients who require neuromuscular blockade present
additional nursing challenges. Although the child may
appear calm after neuromuscular blocking agents have been
administered, sensory perception and level of consciousness
are not altered. Neuromuscular blocking agents have no
sedative or analgesic effects; therefore sedatives and/or
anxiolytics are always administered. Older children and
adolescents require reassurance that the paralysis is drug
induced and reversible. If painful procedures are to be
performed, or if the child's underlying condition or its
treatment is inherently painful, analgesics are also administered. Every effort should be made to reduce noxious
auditory stimuli around the child, scheduling care to permit
quiet time for sleep. The child's response to these interventions can be assessed by monitoring the physiologic
consequences of anxiety or pain, that is, tachycardia,
hypertension, and pupillary dilatation.
Periodically, the neuromuscular blockade is permitted to
wear off to perform at least a summary neurologic evaluation, as well as to determine the need for continued
blockade. At times, it may be impossible to allow the patient
a honeymoon period from neuromuscular blockade, for
example, in the patient who requires high ventilator
pressures who immediately has decompensation during
dysynchronous breaths. In these cases "train-of-four"
monitoring, that is, peripheral nerve stimulation, provides a
valuable alternative (see Chapter 8). Several researchers
suggest that the consequences of prolonged muscle disuse
brought about by neuromuscular blockade in young infants
may be more severe than in adults. Reports of microscopic
evidence of skeletal muscle growth failure with prolonged
use of neuromuscular blockade in preterm infants and
residual muscle weakness in newborns after receiving
pancuronium for several weeks raise issues relating to the
normal growth and development of muscle in the face of
prolonged paralysis. 85 It becomes obvious that neuromuscular blockade is used judiciously, especially in infants.
When neuromuscular blockade is necessary, extreme
vigilance is required to avoid tissue breakdown from
immobility. Chapter 16 provides a review of essential skin
and eye care required of the immobilized patient.
Several pharmacologic interventions (inhaled nitric oxide, surfactant, and steroids) have been suggested to help
manage ALI/ARDS. Nitric oxide is produced by many cell
types in the lung and plays an important physiologic role in
the regulation of pulmonary vasomotor tone by several
known mechanisms. Nitric oxide stimulates soluble guanyIyl cyclase, resulting in increased levels of cyclic guanosine
monophosphate (GMP) in lung smooth muscle cells. The
gating of K+ and Ca2+ channels by cyclic GMP binding is
thought to playa role in nitric oxide-mediated vasodilation.
Nitric oxide may also regulate pulmonary vasodilation by
direct activation of K+ channels or by modulating the
expression and activity of angiotensin II receptors. Administration of nitric oxide by inhalation (iNO) has been shown
to acutely improve hypoxemia associated with pulmonary
hypertension in humans and animals. 86 In addition, iNO will
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Box 19·2

Prone Positioning Procedure

Preparation for Turning

Create individually sized head, chest, pelvic, distal femoral,
and lower limb cushions using egg crate material (Eggcrate;
Span American Medical Systems, Greenville, SC) to allow
the patient's abdomen to be unrestrained from the
patient's bed and to provide skin protection,
L The chest cushion should measure slightly less than the
right-to-Ieft greater tubercle of the upper arm; equal to
the patient's anterior-posterior width; and wide enough to
cover the patient's sternum when compressed.
2. The pelvic cushion should measure slightly smaller than
the right-to-Ieft iliac crest and be slightly smaller than the
patient's anterior-posterior width.
3. The head pillow should allow the patient's head to be
slightly higher than his or her chest.
4. A small cushion should be placed under the distal femur
to elevate the patient's knees off the bed.
5. The lower limb cushion should elevate the patient's toes
off the bed.
Transpyloric enteral feed tube is inserted and checked for
placement.
The security of the endotracheal tube (ETT), vascular lines,
and Spo2 probe is assessed (by applying gentle traction)
and reinforced as necessary. The ETT is taped to the upper
lip on the side of the mouth that will end in the "up"
position. A protective layer of plastic tape is placed over
the ETT white adhesive tape to help prevent oral secretions from loosening the white adhesive tape while
prone.
If the patient is receiving a chemical paralytic ageIll, eye
protection is provided. Specifically, both eyes are
cleansed, lubricated, and covered with plastic wrap.
• If the patient is supported on high-frequency oscillatory
ventilation, a transparent film dressing is placed over the
anterior bony prominences to protect the skin from a
friction injury.
EKG electrodes are moved to the lateral aspects of the upper
arms and hips.
• The patient's oropharynx is sllctioned.
Nonessential vascular Jines and the patient's nasogastric tube
are temporarily capped. The start and end point of everything that is left attached to the patient is reviewed.
• The patieIll is premedicated with comfort medications.
Preplanning the Turn

Preplanning includes delineation of who is responsible
for what patient aspect (e.g., head/ETT: respiratory

improve V/Q matching by vasodilating the pulmonary
vascular bed associated with a ventilated alveoli.
Depending on the study, 40% to 60% of patients with
ALUARDS who receive iNO respond by improving their
oxygenation but the effect is rarely sustained over the course
of several days. In addition, patients receiving iNO have not
demonstrated an improvement in overall survival. Bohn
cautions against universal adoption of iNO in ARDS

therapist; chest/arms: Nurse I; hipsflegs: Nurse 2), and technique (smaller patients: levitate up, turn 45 degrees, pause,
then gently turn prone, place cushions after patient positioned prone; larger patients: using a draw sheet-gently
reposition the patieIll at the edge of the bed away from the
ventilator, tum 45 degrees, pause, position chest and
pelvic cushions then position patient prone on cushions).
During the tum the patient's head is kept aligned with his
or her body by the respiratory therapist-hyperextension
is avoided. The patient's arms are contained next to their
torso. Legs are supported so that the toes of the upper leg
point in the direction of the turn.
Patients are turned toward the ventilator without disconnecting the patient from the ventilator. The patient is talked
through the turn. If the patient requires ETT suctioning,
turning is delayed until the patient is suctioned and has
returned to presuctioning ventilator settings.
Immediately After the Turn

• The security and patency of all tubesflines is reassessed.
Capped off lines/nasogastric tube are uncapped!
reattached.
Position the patient:
I. Turn head to side and cushion head and ear with pressure
relieving material.
2. Cushion the upper chest, and pelvis using either a rolled
Eggcrate or foam pad-allowing the abdomen to protrude.
3. Flex amlS up.
4. Position knees and feet off bed using an appropriate sized
roll under the distal femur and lower leg.
Maintenance

Reevaluate oropharyngeal and endotracheal suctioning
routine.
Skin protection:
1. Use the skin care and pressure ulcer algorithm (see
Chapter 16).
2. Make slight adjustments to the patient's position at least
every 2 hours; when in the lateral prone pOSition the
dependent arm should be down at the patient's side and
nondependent arm should be flexed at the elbow up
toward the patient's head.
3. Consult with skin care nurse and physical therapy on all
patients as soon as possible after their first turn to assist
with skin protection and optimal positioning.
Elevate head of bed at least 15 degrees.
Chest films are obtained in the prone position.

because little is known about its biologic effects; in fact, he
notes that it may be time for a moratorium on human studies
87
while more bench research is done.
Potential toxicities to iNO include (l) methemoglobinemia, from the intravascular binding of nitric oxide to
hemoglobin and (2) nitric dioxide lung injury, produced
from the reaction of iNO with oxygen. Methemoglobin
levels are assessed and a level greater than 5% is
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considered toxic. Both iNO and N0 2 levels are monitored
during administration. N0 2 levels greater than 5 parts
per million (ppm) are considered toxic. High levels are
managed by increasing gas flow and/or blending the iNO
and oxygen gases closer to the point to delivery to decrease
exposure time.
Considering that one of the hallmarks of ALUARDS is
endogenous surfactant depletion and inactivation, many
have considered the potential impact of surfactant repletion
in its acute care management. Willson conducted a multisite,
prospective, unblinded, randomized controlled study to
describe the use of an exogenous calf lung surfactant
(Infasurf) in pediatric respiratory failure. 88 Forty-two patients with acute hypoxemic respiratory failure received
intratracheal surfactant (80 mllm 2 in four equal aliquots in
rotating positions, repeated once 12 hours later) within 24
hours of intubation. Patients who received the natural
surfactant early in the course of their illness showed rapid
improvement in oxygenation, were extubated 4.2 days
sooner, and spent 30% fewer days in the PICD than control
patients. In addition, there were no difference in mortality or
overall hospital stay and no serious adverse effects. A
definitive study is currently underway.
Steroids have long stimulated interest for their antiinflammatory properties. In patients with ARDS, data
regarding steroid use are contradictory. Several studies
indicate no benefit in the use of pharmacologic doses of
steroids even early in the course of the disease except in
specific instances-radiation pneumonitis and fat embolism
syndrome. As for treatment with high-dose steroids, no
improvement in survival rates have been demonstrated and
mortality may be higher because of an increase in the
number of secondary infections. 89
Recently Meduri and colleagues hypothesized that, if
administered before the development of end-stage fibrosis,
methylprednisolone could be effective in improving lung
function and outcome in patients with unresolving ARDS. 90
They conducted a randomized, double blind, placebocontrolled trial involving 24 adults with severe ARDS who
failed to improve by the seventh day of respiratory failure.
In an effort to contain the host defense response, the
experimental group (after demonstrating that they were not
infected by bronchoalveolar. lavage) received methylprednisolone. The initial dose was 2 mglkg per day and was
slowly titrated over 32 days. They were able to document improvement in lung injury, multiorgan dysfunction
scores, and mortality in the group receiving prolonged
methylprednisolone.
ARDS is not a disorder of the respiratory system
alone. Other organs may be adversely affected by the
primary disease process (e.g., sepsis), altered oxygen
transport, or alteration in organ function directly. Monitoring of various organ function is therefore crucial. The
brain may be negatively affected by inadequate O2
delivery leading to altered levels of consciousness, for
example, confusion, combativeness, or coma. Other organs
may be involved because, in a more limited way, they
undergo the same endothelial injury as the lungs. Therefore disseminated intravascular coagulation (DIC), acute
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renal failure (ARF), and hepatic dysfunction are common
in ARDS.
Mechanical ventilation may be necessary for weeks or
months, during which nutritional/caloric needs may greatly
exceed maintenance requirement. Nutritional adequacy is
established early in the development of ARDS because
sustained malnutrition can result in abnormalities in pulmonary defense mechanisms and pulmonary structure and
function and may limit the child's ability to wean from
mechanical ventilation. 91 See Chapter 12 for transpyloric
enteral nutrition.
Because the child's prognosis is frequently uncertain and
the intensive care course may be long and fraught with
multiple setbacks, parents of the child with ARDS require a
tremendous amount of nursing support. It is important to
develop a therapeutic relationship with the family early on,
to provide consistent and accurate information about their
child, and to involve the family in nurturing behaviors.
Congenital Diaphragmatic Hernia
Etiology. Congenital diaphragmatic hernia occurs
when the fetal diaphragm fails to develop normally, leaving
an opening between the thorax and the abdomen. This
permits the abdominal contents to enter the thoracic cavity,
interfering with normal development of the lungs.
Incidence. Congenital diaphragmatic hernia occurs in
approximately I in 2000 births and is the most common
cause of pulmonary hypoplasia in the newborn.
Pathogenesis. The diaphragm forms during the
eighth to tenth week of fetal life and separates the abdominal
and thoracic cavities. Because the left posterior aspect of the
diaphragm is usually the last to close, the most common
type of diaphragmatic hernia involves this area of the
muscle (foramen of Bochdalek). While the diaphragm is
forming, the midgut is developing within the umbilical
pouch. If the diaphragm has not completely closed when the
midgut returns to the abdominal cavity (about the tenth
week of gestation), abdominal structures can enter the
thoracic cavity-the stomach, large and small intestines in a
left-sided defect, or part or all of the liver in the less
common right-sided defect. The herniated gut then compresses the developing lung buds, arresting their growth on
both the ipsilateral and, to a lesser degree, the contralateral
side. As a result, the number of airways and alveoli is
markedly reduced. The number of pulmonary arteries is also
decreased and their distribution is abnormal. In addition, the
amount of smooth muscle in pulmonary arterioles is greater
than normal. 92 Therefore infants with congenital diaphragmatic hernia have both lung hypoplasia and increased
pulmonary vascular resistance.
At birth, the infant with a significant diaphragmatic
hernia is tachypneic and has marked intercostal and substernal retractions. Breath sounds are decreased or absent on the
affected side, and the point of maximum impulse (PMI) and
heart sounds are shifted to the unaffected side. Typically, the
infant's chest diameter is increased and the abdomen is
scaphoid. Gas-filled loops of bowel may be evident within
the chest on radiograph. Because the hypoplastic pulmonary
vascular bed is unable to accommodate the normal increase
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in postnatal right ventricular output, pulmonary hypertension develops. Blood is shunted right to left across the foramen ovale and patent ductus resulting in refractory hypoxemia and cyanosis.
Critical Care Management. Treatment of infants
with congenital diaphragmatic hernia involves the measures
used in initial resuscitation of the newborn, ventilatory
support, and surgical repair of the lesion. More aggressive
support includes the use of ECMO.
Not long ago, it was believed that immediate surgical
repair of acutely symptomatic congenital diaphragmatic
hernias would permit expansion of the lungs and improve
ventilation. However, rather than improving pulmonary
mechanics, Sakai and co-workers found that early repair
often decreases lung compliance 93 They attribute this
deterioration to postoperative distortion of the diaphragm
and chest wall and abdominal distension. Additional clinical
data now support a strategy of delaying surgical repair of the
defect until the infant's cardiovascular status is more
stable 94 . 96 Cardiovascular stability is attained by correcting
the acidosis, hypoxia, and hypotension that are often present
in these critically ill infants. Preoperative stabilization may
improve the infant's ability to tolerate surgery.
Often, infants with congenital diaphragmatic hernia are
diagnosed prenatally by ultrasound technique, and maternal
transport and delivery can be planned at a center equipped
to manage the critically ill newborn. Because bag-and-mask
ventilation may force air into the gastrointestinal tract and
further compromise ventilation, endotracheal intubation is
performed immediately after birth. 97 Achieving adequate
oxygenation (postductal Pa02 greater than 100 mmHg) and
purposefully producing a metabolic alkalosis may help
reduce pulmonary vascular resistance. A metabolic alkalosis
can be induced with an infusion of sodium bicarbonate or
tromethamine (THAM). This approach may be preferable to
aggressi ve hyperventilation, which poses the risk of barotrauma and pulmonary air leaks. 98 Commonly, sedation and,
as a last resort, neuromuscular blockade are necessary to
achieve adequate ventilation. For a more thorough discussion of pulmonary hypertension see Persistent Pulmonary
Hypertension of the Newborn (PPHN) later in this chapter.
Umbilical arterial and venous access is immediately
established to permit monitoring of ABGs and pH and blood
pressure and permit the administration of fluids and
medications. Hemodynamic support may include crystalloids, transfusions, and/or inotropic agents as needed to
maintain adequate peripheral perfusion.
Once the infant's condition has stabilized, the hernia is
surgically reduced. A primary repair is attempted, but if this
proves impossible, a prosthetic patch is used to close the
defect.
If maximal medical measures fail to support ventilation,
the infant is placed on ECMO (see Chapter 8). The defect is
then repaired after several days of stabilization on ECMO. 99
In large part, nursing care for the infant with a congenital
diaphragmatic hernia focuses on avoiding conditions that
increase pulmonary vascular resistance and is discussed
within the context of PPHN. Conditions that may increase
pulmonary vascular resistance are prevented, including

hypoxemia, acidosis, hypothermia, and hypoglycemia. For
the same reason, environmental stressors such as noise,
excessive light, and invasive procedures are also minimized.
Weaning mechanical ventilation in the infant with a
congenital diaphragmatic hernia presents many of the
challenges encountered in infants with BPD and is discussed
more thoroughly later. Reductions in ventilatory support
occur slowly, but steadily, while the infant's cardiopulmonary status is closely monitored. 97
The infant's hydration and nutritional status are carefully
monitored by evaluating the infant's intake and output, urine
specific gravity, liver size, skin turgor, weight, and growth
curve. A positive fluid balance may result in worsening
respiratory status, which may improve with judicious use of
diuretics. Nutritional adequacy promotes healing and
growth and decreases the risk of infection, which may
prolong the need for ventilatory support. 97
The infant born with a diaphragmatic hernia typically has
a lengthy hospital course that may include extremely
intimidating, highly technical interventions. Parents, who
may have begun anticipatory grieving at the time of an
antenatal diagnosis, require considerable support and are
encouraged to verbalize their questions and concerns. The
nurse at the bedside can intervene to help parents cope with
the sometimes-frightening PICU environment and permit
them to connect with their critically ill child.

Mixed Obstructive and Restrictive Disease
For the purpose of more clearly understanding mechanical
alterations in pulmonary function, various illnesses are
classified by their effect on airways resistance (obstructive
disease) or pulmonary compliance (restrictive disease).
However, characteristic abnormalities in BPD include both
increased airways resistanceloo.lo2 and decreased compliance. 102.103 Therefore BPD is truly a "mixed" disorder, that
is, both obstructive and restrictive in nature.
Bronchopulmonary Dysplasia (BPD)
Etiology. BPD, a term originally coined by Northway
and colleagues, represents a form of unresolved lung injury
of infancy. 104 Clinically defined as oxygen dependency at
I-month postnatal age, BPD most cornrnonly follows severe
hyaline membrane disease, but may also occur after meconium aspiration, pulmonary hemorrhage, congesti ve heart
failure, or severe neonatal pneumonia. Although disagreement exists regarding its primary cause, factors contributing
to the development of BPD may include O2 toxicity, positi ve
pressure ventilation and resultant mechanical lung injury,
chronic inflammation, and overhydration.
Incidence. Although not limited to the preterm infant,
BPD is most cornrnonly associated with prematurity and
occurs in up to 40% of mechanically ventilated infants
weighing less than 1500 g at birth. 105 Recovery is slow and
hospital readmission common, usually because of recurrent
respiratory tract infections or the development of significant
reacti ve airway disease. 106
Pathogenesis. Infants with BPD have both increased airways resistance and decreased compliance. These
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changes in pulmonary mechanics are most likely the result
of inflammation, atelectasis, overdistension, infiltration,
increased mucus secretion, and fibrosis, all of which are
known to occur in BPD.I07.108 Although minute ventilation
can be increased by breathing rapidly, this respiratory
pattern has the disadvantage of increasing dead space
ventilation. l07 These disturbances in pulmonary function,
along with an abnormal distribution of ventilation and
perfusion (V/Q mismatch), lead to characteristic hypoxemia
and hypercarbia.
Infants with BPD typically breathe rapidly and shallowly.
Increased work of breathing is evidenced by intercostal and
substernal retractions. Eventually, respiratory muscle fatigue may lead to episodes of apnea and bradycardia.
Crackles and bronchial sounds (sometimes associated with
wheezing and decreased air entry when bronchospasm
predominates) may be heard on auscultation. Both on
physical examination and radiographically, the infant's chest
is hyperinflated. Atelectasis also commonly occurs because
of inadequate clearing of secretions and airway obstruction. 107 With prolonged respiratory failure, pulmonary
hypertension develops, with signs of right-sided heart
failure including cardiomegaly, hepatomegaly, and fluid
retention. 107 Blood gas abnormalities include marked hypoxemia and hypercarbia.
Critical Care Management. Management of BPD
includes ensuring adequate oxygenation, optimizing ventilation, and maximizing the infant's nutritional intake. Oxygen,
although perhaps initially contributing to the development
of BPD, is the most important medication for the infant with
significant disease. Supplemental O 2 to maintain an Sp02 of
92% to 97% ensures adequate tissue oxygenation and prevents the pulmonary hypertension and cor pulmonale that
can result from chronic hypoxemia. 109 Improved growth has
also been demonstrated in infants with BPD treated with
oxygen during recovery. I10 However, because exposure to
high concentrations of oxygen may contribute to lung microvascular and cellular injury, hyperoxia is avoided.
Oxygen therapy, however, is not enough; 02 delivery to
the tissues is also optimized. A hemoglobin of 12 to 15 g/dl
maximizes 02-carrying capacity, and blood transfusions
may be necessary to maintain this level. In addition, factors
that impair the release of O2 to the tissues by negatively
affecting oxyhemoglobin dissociation, that is, hypothermia
and metabolic or respiratory alkalosis, are corrected or
avoided. Persistent CO2 retention results in a compensatory
rise in serum bicarbonate concentration that may be further
exaggerated by the use of diuretics; this requires close
monitoring of serum electrolytes.
The infant with BPD has bronchiolar smooth muscle
hypertrophy and hyperreactive airways. III Therefore bronchospasm, a condition in which constriction of smooth
muscle in the distal airway restricts airflow in and out of the
alveoli, commonly occurs in these infants, especially during
acute respiratory infections. Bronchodilators may be useful
in these circumstances. Theophylline may also increase
diaphragmatic strength and diuresis in infants with BPD. 112
Aerosolized beta agonists (e.g., metaproterenol, terbutaline,
or albuterol) are also commonly used in the treatment of
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bronchospasm in BPD.IOO.1I3-IIS (See previous discussion
on asthma for more detailed information regarding the
treatment of reactive airways.) In addition, diuretics may
relieve airway obstruction and improve compliance, probably because of a reduction in interstitial pulmonary
edema. 100
Because the infant with BPD is typically very slow to
wean from ventilatory assistance, management of mechanical ventilation becomes a central issue. Attempts to rapidly
reduce mechanical ventilation often meet with acute decompensation 24 to 48 hours later when the infant tires and
Pac02 climbs. Therefore it is important to move slowly and
allow adequate time for the infant to adjust to decreased
ventilator settings. In the infant with BPD, tachypnea with a
compensated respiratory acidosis may be "nonnal." Readiness for weaning from mechanical ventilation may best be
demonstrated by a persistent reduction in the infant's
baseline spontaneous respiratory rate and Paco2, accompanied by a sustained weight gain. 116
When the need for prolonged assisted ventilation is
anticipated, a tracheostomy may be considered. A tracheostomy decreases anatomic dead space and permits care to be
delivered outside of a critical care setting (at home in some
instances), and may prevent the development of subglottic
stenosis.11 7 However, decannulation may not be accomplished for 12 to 24 months even after assisted ventilation is
no longer needed.
In the face of increased work of breathing, caloric intake
as high as 170 to 200 KcaUkg per day may be required for
growth in BPD. 117 Nutritional needs are difficult to meet in
these infants, not only because of increased calorie demands, but also because of poor feeding tolerance and the
need for fluid restriction. Therefore nasogastric, nasojejunum, or gastrostomy tube feeding using concentrated
formulas and diuretic therapy to prevent fluid overload are
often necessary.
Nursing responsibilities in the care of infants with BPD
include ensuring adequate oxygenation and ventilation,
monitoring the efficacy of various interventions, and promoting growth and development. To appropriately adjust
FI02 and treatment regimens, it is especially important to
follow Sp02 during periods of stress (such as feeding), and
while administering various treatments. Wheezing or bronchospastic episodes, so-called BPD spells, are treated
promptly. Clinicians should document the frequency and
precipitating events when spells occur and assess the need
for additional 02' ventilatory support, and/or bronchodilators and the effect of each. Airway obstruction in BPD is, in
part, reversible with bronchodilators, provides an opportunity for early intervention during the course of the disease
and may possibly reduce its progression. 107
Minimizing agitation, and the hypoxemia and bronchospasm that often accompany it, is a primary goal. The
infant's individual temperament and sensitivities direct
nursing measures to reduce stress. These measures may
include controlling environmental noise and light, providing
therapeutic touch, permitting nonnutritive sucking, and
positioning for comfort. At times, sedation may also be
required; however, sedation should be administered only
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after determining that agitation is not the result of inadequate ventilatory support or airway obstruction. Necessary
procedures are spaced throughout the day to permit time for
recovery, and unnecessary interventions are avoided. For
example, clinical assessment and auscultation of breath
sounds, not time alone, guide the frequency of chest
physiotherapy and suctioning.
The nurse at the bedside may be in the best position to
assess the infant's response to reductions in ventilatory
support. Once readiness is established, weaning occurs
slowly, but on a regular schedule; this is true during the
infant's nursery course, and is also frequently necessary
when mechanical ventilation is required for respiratory
insufficiency later in life. Documenting the infant's respiratory rate and effort, response to activity, ETc02, and Spo2
after ventilator changes permits objective evaluation of how
well weaning is tolerated.
Infants with BPD are at high risk for growth failure into
at least their second year and, ironically, growth is the key
to recovery.IJ8 Nutritional assessment includes trending
weights, head circumference, and length (and plotting of the
infant's growth against a normal curve). Complicating the
task of providing sufficient caloric intake is the feeding
intolerance frequently experienced in infants with BPD.
Nasogastric feedings administered continuously or intermittently may be used, depending in part on the infant's
respiratory status. If gastric distension further compromises
chest expansion, a continuous infusion is preferred. An
intermittent feeding schedule and the use of a pacifier during
feedings, however, may help stimulate gastric motility and
reduce gastric residuals in some infants. Gastroesophageal
reflux and aspiration may also occur and can be minimized
by prone positioning with the head elevated to a 30- to
45-degree angle during and immediately after feedings.
Infants with BPD are often described as disorganized
feeders unable to coordinate sucking, swallowing, and
breathing. 119 In the chronically ill hospitalized infant, longterm use of tube feedings or parenteral nutrition can contribute to this behavior and may eventually lead to feeding
resistance. 119.120 Helping parents assume the responsibility
for feeding their infant and recognizing the social and emotional features of feeding, as well as the technical aspects, is
an important part of discharge planning. 120
Careful monitoring and early intervention are important in detecting and preventing developmental delay in
the chronically ill infant. Parental involvement is important in establishing a routine for their infant and providing appropriate stimulation. Resources for ongoing care
include child life, occupational, physical, and speech
therapy.

Impairment of Respiratory Muscle Function
Impairment of respiratory muscle function is another
mechanical alteration affecting the respiratory pump. In this
case, diminished respiratory muscle function results in
respiratory failure despite normal lung mechanics. GuillainBarre syndrome (GBS) is one example of the numerous rare
illnesses in which the chest wall and lungs are mechanically

sound, but a failure of the respiratory muscles driving the
pump leads to respiratory failure.
Guillain-Barre Syndrome
Etiology. GBS is an acute immune-mediated inflammatory disorder of the peripheral nerves and nerve roots
characterized by progressive paresis, paralysis, paresthesia,
and pain. Paralysis often involves the respiratory muscles.
Based on electrophysiologic and pathologic observations,
GBS is divided into demyelinating and axonal subtypes. The
acute motor axonal neuropathy (AMAN) involves predominantly motor nerve fibers with a physiologic pattern
suggesting axonal damage, whereas the acute inflammatory
demyelinating polyneuropathy (AIDP) involves both motor
and sensory nerve fibers with a physiologic pattern suggesting demyelination. 121
Incidence. Approximately I to 1.5 cases occur annually per 100,000 population with a mortality rate of 4% to
5%.122 Although GBS affects all ages (the youngest reported
case is a 4-month-old infant I23 ), children appear to recover
more quickly than adults.
Pathogenesis. Criteria necessary to establish the diagnosis of GBS are well established and are summarized in
Table 19-6. Typically, symptoms occur within 4 weeks of an
infectious process. The antecedent illness is often nonspecific, such as a mild respiratory infection or diarrhea.
Campylobacter jejulli, a major cause of bacterial gastroenteritis worldwide, is the most common antecedent pathogen.
It is likely that immune responses directed toward the
infecting organisms are involved in the pathogenesis of GBS
by cross-reaction with neural tissues. 124
Symmetric weakness usually begins in the lower extremities, although it can rapidly ascend to the upper extremities,
the trunk, and even the muscles innervated by the cranial
nerves. Autonomic dysfunction also occurs frequently in
children with GBS, involving the sympathetic and parasympathetic systems. Signs and symptoms of autonomic neu-
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19-6 Criteria for Diagnosis
of Guillain-Barre Syndrome

TABLE

~Features required

f::

for diagnosis

ii~":

fi1:
~;>

Progressive motor weakness
of more than one limb
Areflexia or marked hyporeflexia

""';:

~':Features strongly
~:.

~:
~~:~

I:;~.
t::~

i:~"

lit"

supporti ve of the
diagnosi s

Rapidly developing motor
weakness, but no progression
by 4 weeks into illness
Mild sensory signs or symptoms
Cranial nerve involvement
Onset of recovery 2-4 weeks
after halt of progression
Autonomic dysfunction
Initial absence of fever

Eipata from Asbury AK, Amason BG. Karp HR et al: Criteria for
~_diagnosis of Guillain-Barre syndrome, Ann Neurol 3:565-567, 1978.
." .
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ropathy include orthostatic hypotension, hypertension, pupillary disturbances, diaphoresis, cardiac dysrhythmias,
constipation, and urinary retention.
Approximately 30% of patients require mechanical
ventilation, and these patients are often hospitalized for
months before regaining the ability to walk. 122 When
respiratory muscle weakness occurs, the child breathes
shallowly and is unable to sigh. FRC is reduced, which leads
to atelectasis, hypoxemia, and eventually CO 2 retention.
Pooling of secretions with an absent or ineffective cough
further contributes to alveolar collapse and respiratory
compromise. Airway obstruction results from involvement
of the pharyngeal muscles, leading to airway collapse during
inspiration, passive posterior displacement of the tongue, or
an inability to swallow oral secretions. Evaluating cranial
nerves IX and X can assess pharyngeal muscle function.
When these nerves are involved, there is a decreased ability
to swallow or cough, decreased voice volume, and a
depressed gag reflex.
Critical Care Management. Supportive treatment is
the mainstay of therapy. In the early stages of the illness,
frequent careful assessments are necessary to detect impending respiratory failure, the most serious complication of
muscle weakness. Respiratory function can be monitored in
older children by measuring forced vital capacity (FVC).
When FVC falls to 15 mUkg, intubation and mechanical
ventilation are usually necessary. Although some children
are not dyspneic at this level of ventilatory compromise, the
risk of aspiration, atelectasis, and pneumonia is minimized
by early intervention. Ventilatory support is also indicated
whenever there is an increased risk of airway obstruction.
Specific therapy remains a topic of controversy. Because
of the inflammatory nature of the disease, corticosteroids
were evaluated in a single prospective randomized trail,
which failed to show beneficial effects. 125 Immunomodulation is used to improve the recovery rate and shorten
hospital stays. Plasma exchange was shown to be effective
in improving recovery time in GBS in several controlled
trials during the 1980s. Intravenous immunoglobulin (IVIg)
therapy has been shown to be equally effective for therapy
of GBS and its variants. Although the precise mechanisms
of immunomodulation by IVlg are unknown, it probably
directly inactivates specific antimyelin antibodies and indirectly inhibits their production. IVIg offers some advantages
over plasma exchange by being better tolerated in some
patients and being easily administered without special
equipment. However, because of the possibility of progression, the treatment of GBS patients requires qualified
neurologic and supportive care. 122 Intravenous immunoglobulin (lVlg) therapy in children with very severe GBS
was recently evaluated by Singhi and colleagues. 126 In the
IVlg group, onset of recovery of muscle power was
significantly earlier (day 14.8 of illness versus day 20.9,
P <.05) and the length of PICD stay significantly shorter
(20.5 days versus 50.5 days, P <.01).126
For older children with rapidly progressive disease,
plasmapheresis is now the accepted therapy. Plasmapheresis
involves the separation of plasma from cellular components
of the blood by centrifugation or filtration. The plasma is
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replaced with a crystalloid and albumin mixture added to the
blood cells and is returned to the body. Three controlled
studies of patients over 12 years old have demonstrated that
plasmapheresis decreases the severity and improves the
outcome of patients with GBS. 127- 129 In addition, Epstein
and Sladky retrospectively analyzed data from 9 children treated with plasmapheresis, comparing them with
14 similarly affected historical controls. l3o The time to
achieve independent ambulation was significantly shorter in
the treated patients and there were no significant complications from plasmapheresis. Therefore plasmapheresis is
generally recommended for children with severe and
worsening disease. 131 The recommended protocol is an
exchange of 200 to 250 ml of plasma per kg body weight
over 7 to 14 days. 128.132 Why plasmapheresis is helpful is
not known. It may be that antibodies such as antiperipheralnerve antibody or other myelinotoxic or immunopathogenic
factors are removed by pheresis.
When there is evidence of progressive disease and
significant muscle weakness, the child is moved to the
PICD, where frequent monitoring of respiratory status is
possible. This is especially true for younger children in
whom objective assessment of respiratory function is
difficult. 133 Respiratory assessments include respiratory
rate, pattern, and effort, as well as the quality of air entry on
auscultation. Oxygen saturations are monitored continuously by pulse oximeter. Once the child has been successfully weaned from ventilatory support, swallowing and
diaphragmatic function is assessed before removal of the
endotracheal tube. In a cooperative child, serial measurements of FVC are obtained at least every 4 hours while
muscle weakness is progressing. ABGs also document
progression toward respiratory failure with an increase in
Pac0 2 and acidosis. Swallowing ability is also evaluated, as
well as the strength of the child's cough and voice. The
child's gag reflex is tested periodically. Estimates of
peripheral muscle strength are valuable in tracking the
course of the illness to detemline whether muscle weakness
is worsening, has reached a plateau, or strength is returning.
Because autonomic dysfunction is possible, cardiac
monitoring is initiated and blood pressure carefully documented. Additional signs of excessive or inadequate activity
of the parasympathetic or sympathetic systems are noted
and treated as necessary (e.g., placement of a drainage
catheter in the case of urinary retention). Hypotension may
be especially problematic during plasmapheresis, but it is
generally responsive to intravascular volume expansion.
Pain and paresthesias are also commonly present. The
most common pain syndrome, present in 83% of 29 children
under the age of 6 years, was back and lower limb pain. 134
Lower back pain because of irritation of the nerve roots may
be relieved with the careful application of heat, although
more severe pain requires the use of analgesics. Successful
pain control in adult patients with GBS includes the use of
epidural morphine. 135 . 136
Because both sensory and motor losses occur, it is
important to turn and reposition the child at least every
2 hours. Therapeutic pressure-reducing devices may aid in
maintaining skin integrity, but they do not eliminate the
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need for a routine turning schedule. Passive range of motion
is also performed to prevent contractures.
Nutritional adequacy is established early in the course of
the illness to avoid excessive muscle wasting. Weakness and
dysphagia may necessitate the use of transpyloric feedings
and parenteral nutrition.
Especially during the sometimes frightening progression
of paralysis, it is important to reassure patients and their
families that a near complete, if not full, recovery is
expected.
Botulism
Etiology and Incidence. Infant botulism was first
recognized as a distinct clinical entity in 1976. Of all forms
of human botulism (food borne, wound, and infant), infant
botulism is now the most common in the United States.
More than 90% of reported cases come from the United
States, and within the United States, more than half of the
cases come from California, Utah, and southeast Pennsylvania. This is likely a consequence of high concentrations of
Clostridium botulinum spores in the soil of these regions. 137
Since 1973, a median of 24 cases of food-borne botulism,
3 cases of wound botulism, and 71 cases of infant botulism
have been reported annually to the CDC. New vehicles for
transmission have emerged in recent decades, and wound
botulism associated with black tar heroin has increased
dramatically since 1994. Recently, the potential terrorist use
of botulinum toxin has become an important concern. 138 It
is universally recommended that honey and corn syrup not
be fed to infants younger than I year of age to prevent the
occurrence of infant botulism.
Pathogenesis. C. botulinum is a ubiquitous grampositive, spore-forming, obligate anaerobe with soil and
dust as its natural habitat. Infant botulism typically affects
previously well infants within the first 4 to 6 months of life
(median 10 weeks) and is caused by ingestion of spores of
C. botulinum that germinate and produce toxin in the
gastrointestinal tract. The toxin irreversibly blocks the
peripheral cholinergic synapses throughout the body, most
importantly at the neuromuscular junction. The toxin does
not cross the blood-brain barrier.
Constipation is characteristically an early sign, followed
by signs of listlessness and progressi ve weakness. Symmetric descending paralysis is the rule; the cranial nerves
are the first so be affected. Infantile botulism is characterized by poor feeding, difficulty in handling secretions,
a weak cry, constipation, and generalized hypotonia. The
diagnosis is confirmed by detection of the organism or its
toxin in the infant's stool and supportive ancillary testing
to rule out other causes of neurologic dysfunction that
mimic botulism, such as stroke, the GBS, and myasthenia
gravis.
Critical Care Management. Treatment includes
supportive care and trivalent equine antitoxin, which reduces mortality if administered early. 138 Aggressive respiratory and nutritional care is the mainstay of treatment.
Many infants require intubation and prolonged mechanical
ventilation. Physical and occupational therapies are crucial
in maintaining range of motion and functional positioning of

patients. Prognosis for complete recovery is excellent with
meticulous supportive care. Infant botulism is a self-limited
illness lasting a total of 2 to 6 weeks with progressive
symptoms.

CIRCULATORY ALTERAnONS
The pulmonary circulation establishes the interface between inspired gas and the blood, thereby permitting delivery of O2 to the blood and removal of CO 2 , The second
final common pathway of respiratory failure involves
alterations in this circulation. Circulatory alterations disturb the normal contact between blood and gas within
the lungs. PE and PPHN are characteristic examples. In
these conditions, pulmonary circulation is reduced, physiologic dead space increases, and gas exchange may be
impaired.
Pulmonary Embolism
Etiology. PE occurs when materials traveling in the
bloodstream become impacted in the pulmonary arterial
bed. Although uncommon in childhood, PE may occur after
trauma or surgery, and may complicate a number of iJlnesses
and treatments. Thromboembolism is the most commonly
occurring form of PE and appears when a blood clot travels
from a peripheral vessel through the right side of the heart
and lodges in the pulmonary arterial bed. Pulmonary
thromboembolism may complicate sickle cell anemia,
rheumatic fever, and bacterial endocarditis, or may occur
with sepsis or severe dehydration. Risk factors in children
include presence of a central venous catheter, immobility,
heart disease, ventriculoatrial shunt, and trauma. 139
Incidence. PE is infrequently diagnosed in children,
although clinicians should always have a high index of
suspicion, especially when treating a child with the acute
onset of respiratory distress or cardiovascular shock. The
:incidence of PE in children has been estimated to be 3.7%
on postmortem examinations. 139
Pathogenesis. The degree of cardiopulmonary disturbance observed in PE depends on two elements: the
previous functional status of the heart and lungs and the
severity of the pulmonary vascular occlusion. 14o A major
pathophysiologic consequence of acute PE is increased
alveolar dead space. This increase occurs because lung units
continue to be ventilated despite diminished or absent
perfusion. Pulmonary infarction is an uncommon sequela of
PE owing to the fact that the lung has three sources of
oxygen: pulmonary arteries, the airways, and bronchial
arteries. 140
Hypoxemia is common in acute PE. Regional bronchoconstriction and atelectasis result in '11/0. inequality and
intrapulmonary shunting. Because the right ventricle has
poor tolerance for an increase in afterload, cardiac output
may become inadequate, and mixed venous saturations fall.
If pulmonary hypertension develops and there is a patent
foramen ovale (or septal defect), right-to-left shunting
within the heart also contributes to hypoxemia.
The child's increased respiratory rate usually compensates for the increase in physiologic dead space produced by
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the arterial occlusion. The Pac02 typically falls below 35
mmHg. However, Pac0 2 rises in children who cannot
adequately increase their minute ventilation (e.g., those with
restrictive lung disease, those with neuromuscular disorders,
or those receiving chemical paralyzing agents).
The child with a PE is dyspneic, tachypneic, and may
complain of acute chest pain. Breath sounds may be clear or
there may be scattered crackles. Radiographic findings are
nonspecific and may include atelectasis, localized infiltrates,
or a pleural effusion. Fever is also often present without
other signs of infection. Supportive radiographic tests
include a pulmonary angiogram and V/Q scan. Pulmonary
function tests may give abnormal results, but they are again
nonspecific. 140
Critical Care Management. Treatment consists of
02' hemodynamic support, anticoagulation, and thrombolytic therapy. The treatment of PE goes beyond attempts to
lyse the thrombus. In patients with acute respiratory failure,
endotracheal intubation and mechanical ventilation is instituted to ensure adequate tissue oxygenation and CO2
removal. High PEEP may be necessary to achieve oxygenation; however, this may impair venous return to the heart in
an already hemodynamically compromised patient. 140
Once the diagnosis is established, heparin therapy is
initiated to prevent further thrombosis. Heparin is given
for 7 to 10 days, and is usually initiated by a loading dose
of 50 units/kg followed by a continuous infusion of 10 to
25 units/kg/hr, and adjusted according to the child's
activated partial thromboplastin time (aPTf). A clotting
time of 1.5 to 2.0 times the normal mean aPTT value
(usually 50 to 70 seconds) is therapeutic. Approximately
24 to 48 hours after heparin therapy is initiated, warfarin
(Coumadin) is begun so that there is an overlap of at least
5 days. Because heparin does not dissolve the clot, a
thrombolytic agent such as streptokinase may also be used,
although its efficacy in PE is questionable.
Nursing priorities in caring for the child with a
PE include maintaining supplemental O2 (and ventilatory support, if it becomes necessary), evaluating the
child's cardiopulmonary status, and assessing the effects of
therapy.
Sp02 monitoring helps ensure adequate oxygenation. The
adequacy of ventilation can be determined by evaluating the
child's respiratory rate and effort and periodically measuring
ABGs. In addition, cardiovascular assessment including
heart rate, blood pressure, strength of peripheral pulses,
warmth of extremities, and adequacy of urine output helps
determine the need for inotropic support or volume
expansion.
Because hemorrhage is the major complication of
heparin (an untoward effect that may be compounded by
thrombolytics), it is especially important to carefully
monitor coagulation studies. Initially, aPTT values are
measured and the infusion rate adjusted frequently. Daily
monitoring is sufficient when a steady dose is achieved. The
child is also monitored for signs of bleeding including
petechiae, bloody emesis, stools, or gastric aspirates;
hemoptysis; and hematuria. Invasive procedures are avoided
or minimized.
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Persistent Pulmonary Hypertension
of the Newborn
Etiology. Persistent pulmonary hypertension of the
newborn (PPHN) is a condition in which the highresistance, low-flow pulmonary circulation of fetal life
persists after birth. It is characterized by systemic or
suprasystemic pulmonary artery pressures, with significant
right-to-left shunting through the ductus arteriosus or
foramen ovale. Desaturated venous blood is mixed with
saturated arterial blood, resulting in arterial hypoxemia and
tissue hypoxia. Right-to-Ieft atrial shunting may be caused
by diastolic dysfunction of the less compliant fetal right
ventricle or dysfunction of the tricuspid papillary muscle,
which causes tricuspid regurgitation.
Delayed relaxation of the pulmonary vascular bed is a
feature of many neonatal pulmonary problems, including
lung hypoplasia caused by mechanical compression (e.g.,
congenital diaphragmatic hemia), meconium aspiration
pneumonia, perinatal asphyxia, bacterial pneumonia, and
sepsis. It may also occur in the absence of obvious
triggering diseases, presumably because of abnormal muscularization of pulmonary arterioles or transient defects in
endothelial function. 141
It is possible that PPHN is a process that starts well
before birth; therefore birth history may be helpful in
identifying those at greatest risk for developing PPHN.
Typically, the infant is born at term or postterm, is
appropriate in size for gestational age, and had meconium
staining or birth asphyxia at the time of delivery.
Incidence. The incidence of PPHN is 1.9 per 1000
live births with a mortality rate of 11%.142
Pathogenesis. Manifestations of PPHN often involve
dysfunctional pulmonary vasoregulation, with suprasystemic pulmonary vascular resistance causing extrapulmonary shunting, pulmonary parenchymal disease causing intrapulmonary shunting, and systemic hemodynamic
deterioration.
Typically, the infant with PPHN develops tachypnea and
cyanosis soon after birth. Other signs of respiratory distress
also appear including grunting, nasal flaring, and intercostal
retractions. The quality of breath sounds depends upon the
underlying clinical condition; adventitious sounds are prominent in meconium aspiration, for example, but may be
absent in neonatal asphyxia. eonates with PPH also
demonstrate a wide spectrum of myocardial abnormalities,
ranging from mild dysfunction to severe biventricular
congestive failure.
The physical examination may be of limited value. A
finding of the presence or absence of a murmur is not
helpful. Neonates with PPHN may have the murmur of
high-velocity tricuspid regurgitation. The chest radiograph
may document the parenchymal disease, which is the
triggering factor for PPHN. Preductal and postductal blood
gas measurements have been used to differentiate PPHN
from structural heart disease. Right-to-Ieft shunting through
the ductus arteriosus and foramen ovale results in hypoxemia, which often proves refractory to supplemental 02'
Neonates with PPHN may have nearly normal preductal
(right arm, head) oxygen tension and oxygen saturation
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while the postductal (umbilical artery, left arm, lower limbs)
right-to-Ieft shunt causes lower oxygen tension and saturation. 141 Echocardiography can usually provide a definitive
structural diagnosis. In severe PPHN, hypoxemia is followed rapidly by the development of hypercarbia and
acidosis. Hypoxia and acidosis perpetuate the vicious cycle
of pulmonary vasoconstriction, pulmonary artery hypertension, and right-to-left intrapulmonary and intracardiac
shunting (Fig. 19-10).
Critical Care Management. Treatment in PPHN is
aimed at decreasing the ratio of pulmonary to systemic
vascular resistance, thereby reducing or eliminating rightto-left shunting. Historically, this has been accomplished by
hyperoxygenation, hyperventilation, and the use of nonspecific vasodilators. However, mortality in infants with PPHN
remained high, perhaps in part because of the complications
of such aggressi ve therapy, that is, pneumothorax, pneumomediastinum, barotrauma, and chronic lung disease. Various
therapies currently in use include oxygenation, alkalinization, high frequency ventilation, nitric oxide, and ECMO.
Hypoxemia causes reflex pulmonary vasoconstriction in
fetal sheep and adult dogs, and may well contribute to the
pathophysiology of PPHN. Therefore, in an attempt to
reverse pulmonary hypertension, infants with PPHN usually
receive high levels of supplemental 02' the most potent
pulmonary vasodilator available.
Through mechanisms that are unclear, an increase in pH
also decreases pulmonary vascular resistance. By increasing
arterial pH to a ..critical level" at which there is a fall in
pulmonary artery pressures, a reversal of right-to-left
shunting and an increase in Pa02 appear to be achieved in
many cases. The degree of respiratory alkalosis necessary to
reverse right-to-Ieft shunting sometimes cannot be achieved
with mechanical hyperventilation because of severe lung
disease or the development of a metabolic acidosis. There is
evidence to suggest, however, that respiratory alkalosis and
metabolic alkalosis are equally effective in attenuating
hypoxia-induced pulmonary vasoconstriction 98 However,

Hypoxia and Acidosis

Pulmonary Artery
Vasoconstriction

R --> L Shunting

Pulmonary Artery
Hypertension

Fig. 19-10 The vicious cycle of persistent pulmonary hyperten.
sion of the newbom.

no randomized, controlled trials of hyperventilation versus
conservative management are available. An infusion of
sodium bicarbonate may produce the desired degree of
alkalosis while avoiding the complications of aggressive
mechanical hyperventilation; however, serum sodium levels
are followed closely. Generally, an infusion of sodium
bicarbonate is begun and adjusted to maintain a pH of
7.45 to 7.50. Alternatively, THAM may be used if CO 2
retention or hyponatremia are a problem. A more conservative approach to mechanical ventilation can then be
pursued. To prevent the complications of mechanical
ventilation, the lowest PIP possible is used to achieve the
therapeutic goals.
Because hypoxemia may put the infant with PPHN at risk
for cerebral hypoxia, monitoring the infant's neurologic
status is important. In a study of 19 infants with PPHN (the
majority of whom had birth asphyxia), nine suffered
cerebral infarctions. '43 Furthermore, eight of the nine
infants with infarction had seizures detected by electroencephalogram (EEG) during periods of neuromuscular blockade. Routine EEGs may be warranted in these patients.
High-frequency ventilation is an alternative approach
used in some centers, primarily as a rescue treatment when
conventional therapy fails. In high-frequency ventilation,
extremely small tidal volumes and high rates are used to
provide gas exchange.
The recent discovery of the role of nitric oxide as the
endothelium-derived relaxing factor has delivered hope for
a selective agent to modulate the neonatal pulmonary
vascular resistance. 141 (For a description of iNO, see ARDS
on page 679.) Inhaled nitric oxide also reduces the extent to
which ECMO is needed in neonates with hypoxemic
respiratory failure and pulmonary hypertension. l44 However, again, long-term benefits to these infants have been
difficult to demonstrate.
ECMO (see Chapter 8) has been used to support patients
with PPHN in whom conventional medical management has
failed. The institution of ECMO permits correction of
hypoxemia and acidosis. National ECMO experience
(through July 2000) derived from ELSO (Extracorporeal
Life Support Organization) Registry reported 2227 patients
with the primary diagnosis of PPHN have been treated with
ECMO with an overall survival rate of 79%.'45 Once the
infant is placed on ECMO, ventilator support is reduced to
a minimum to avoid any further barotrauma or oxygen
toxicity to the lung. '45
An evaluation of treatment methods used in 12 Level 1II
neonatal intensive care units (before the widespread use of
iNO) demonstrated wide variations in practice. Hyperventilation was used in 65% of centers, with a range from
33% to 92%; continuous infusion of alkali was used in 75%
of centers, with a range of 27% to 93% of neonates. Other
commonly used treatments included sedation (94%; range:
77% to 100%), paralysis (73%; range: 33% to 98%), and
inotrope administration (84%; range: 46% to 100%).
Vasodilator drugs, primarily tolazoline, were used in 39%
(range: 13% to 81%) of neonates. 142
The nursing care of the infant with PPHN is directed
toward avoiding conditions thaI increase pulmonary vascu-
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lar resistance, detecting complications of therapy, and
whenever possible, minimizing those complications.
As stated earlier, hypoxemia results in increased pulmonary vascular resistance. In an infant in an unstable
condition with PPHN, even small reductions in FIOz can lead
to profound hypoxemia. Therefore consistent delivery of O 2
is assured. In the acutely ill infant during the first 24 hours,
or in infants exhibiting wide fluctuations in oxygenation,
attempts are made to maintain Pa02 at approximately 100
mmHg. Furthermore, maneuvers that cause hypoxemia, for
example, endotracheal suctioning, are avoided unless absolutely necessary. It is not uncommon for these infants to be
exquisitely sensitive to any type of tactile stimulation,
responding with precipitous drops in Sp02146 Prohibiting
unnecessary handling will help limit episodes of hypoxemia; therefore routine care (e.g., bathing or weighing the
infant) is inappropriate. Finally, sedation is used to minimize
agitation and its negative effect on pulmonary vascular
resistance.
Cold stress, hypoglycemia, and hypoxemia may all
result in acidosis that will increase pulmonary vascular
resistance. These conditions are avoided by carefully
controlling and monitoring the infant's environment and
response to therapy. Because ready access to the critically
ill infant is necessary, providing a neutral thermal environment is often not possible. Heat loss can be minimized,
however, with a radiant warmer. Frequent bedside monitoring of blood glucose is also performed. Preductal and
postductal Sp02 is monitored continuously and blood gases
followed to monitor acid-base status, especially when
alkalosis is being employed to reduce pulmonary vascular
resistance.
Careful assessments of oxygenation and systemic perfusion accompany changes in ventilator settings. In the neonate, a tension pneumothorax may present as sudden
hypotension, bradycardia, and hypoxemia and requires immediate needle aspiration and eventual placement of a chest
tube. In addition, excessive PEEP may cause an increase in
pulmonary vascular resistance. This may increase right-toleft shunting and decrease pulmonary venous return and
further reduce systemic flow of oxygenated blood.
Systemic blood pressure must be higher than pulmonary
artery pressure to reverse right-to-Ieft shunting; therefore
maintenance of adequate systemic blood pressure is essential to correct hypoxemia in PPHN. Intravascular volume is
assessed frequently by monitoring heart rate, blood pressure, liver size, capillary refill time, and warmth of
extremities. Hydration status can be further evaluated by
assessing fluid intake and urine output, urine specific
gravity, skin turgor, mucous membranes, and fontanels. As
stated earlier, infants with PPHN may have a variable degree
of myocardial dysfunction, therefore myocardial depressants such as hypoglycemia, acidosis, and hypocalcemia are
avoided. In addition, dopamine may be given to improve
cardiac contractility.
The infant undergoing high-frequency ventilation presents additional nursing challenges. These are usually the
most critically ill infants in whom conventional mechanical
ventilation appears to be failing, or whose course has been
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complicated by pulmonary interstitial emphysema, pneumothorax, or pneumomediastinum.
The initial PIP used in high-frequency jet ventilation is
based on the infant's requirements while on conventional
mechanical ventilation. Ordinarily, PIP is set 20% to 33%
below the pressure required during conventional treatment. 147 Some infants with severe pulmonary hypertension, however, may have acute deterioration when highfrequency jet ventilation is initiated at lower inflating
pressures. Therefore some clinicians suggest that PIP not
be lowered initially in infants with PPHN, but should be
gradually decreased as determined by the infant's response
to therapy (SP02 and ABGs).148 Ventilatory frequency can
be adjusted to deliver 300 to 540 cycles per minute (6 to
9 Hz), and is usually started at a rate of 420 cycles per
minute (7 Hz).
The infant receiving high-frequency jet ventilation requires continuous monitoring of heart rate, blood pressure,
and transcutaneous O 2 and CO 2, Although vibration of the
chest and body make monitoring of the infant's respiratory
rate impractical, absence of vibration may signal tube
obstruction or displacement, or a decrease in C L , for
example, with a tension pneumothorax. 147 Breath sounds
are also altered by the ventilator, but subtle changes can be
detected with frequent, careful examination.
As with any artificial airway, maintaining airway patency
is a primary nursing responsibility. It is possible to suction
the endotracheal tube through its main port while maintaining high-frequency jet ventilation. However, some clinicians
suggest that this practice may create shearing forces in the
trachea (produced by the combination of negative pressure
suction and high-frequency positive pressure breaths),
which may contribute to the development of necrotizing
tracheobronchitis. 148 This particular complication, a severe
airway injury that results in sloughing of the tracheal
mucosa, is reported with varying frequency and may result
from inadequate humidification of inspired gases, shearing
forces in the airway, or other factors that have yet to be
identified.

ALTERATIONS IN THE CONTROL
OF BREATHING
The last final common pathway of respiratory failure
includes disorders resulting from abnormalities or deficiencies in the control of breathing, resulting in hypoventilation.
This category includes alterations in the neuromuscular
control of upper airway patency and abnormalities in
respiratory drive that result in alveolar hypoventilation.
Apnea, both central and obstructive, and alveolar hypoventilation syndromes are considered.
Apnea
Etiology. Apnea is generally defined as the cessation
of breathing for more than 20 seconds or for a shorter period
when associated with hypoxemia or bradycardia. Central
apnea is characterized by a respiratory pause. In contrast,
respiratory efforts continue, sometimes quite vigorously, in
obstructive apnea, but there is an absence of airway flow
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caused by airway obstruction. A mixed picture of central and
obstructive apnea may also be observed.
Incidence. The prevalence of apnea of prematurity
varies inversely with gestational age. In all births the
incidence is 1%. 149 The prevalence of obstructive sleep
apnea is 0.7% to 2.9%; peak age of presentation is 2 to
4 years.ISO.151
Pathogenesis. Apnea of prematurity is most commonly central in origin, but obstructive apnea and mixed
disorders also occur. 152 Although the cause is unknown,
apnea of prematurity is thought to be related not only to an
immaturity of the central nervous system, but also to an
increase in chest wall compliance. More respiratory work is
required to generate a constant tidal volume when the chest
wall is highly compliant. Within this context, apnea may
represent a strategy to avoid fatigue.
Although central apnea is the classic apnea of prematurity, it occurs in a number of other conditions in which the
central nervous system is somehow altered. Sepsis, hypoglycemia, hypothermia, drug intoxication, trauma, and brain
tumors may result in apnea. In addition, because their
ventilatory response to hypoxia and sensitivity to CO 2 are
already depressed, young infants may be especially vulnerable to periods of apnea when they receive narcotics and
other respiratory depressants.
In obstructive apnea, upper airway collapse occurs
because of poor coordination of the muscles responsible for
airway maintenance. Obstructive apnea usually happens
during sleep and, in children, it is most often caused by
hypertrophy of the tonsils and adenoids. Although sleep is
the most common functional condition predisposing to
obstructive apnea, other factors that may depress airwaymaintaining activity include narcotics, sedatives, alcohol,
and some brainstem lesions, particularly those associated
with Arnold-Chiari malformation.
Central apnea is evidenced by a cessation of respiratory
activity and may be accompanied by a fall in Sp02 and heart
rate. In the preterm infant, respiratory pauses occur more
commonly in active sleep and often within the context of
periodic breathing. Frequently, these infants also have an
obstructi ve component to their apnea. 152
Critical Care Management. Physical examination
of the sleeping child with obstructive apnea reveals sonorous respirations, retractions, and breathing pauses that may
be associated with hypoxemia and bradycardia. Often,
vigorous movement occurs during sleep in an attempt to
overcome the airway obstruction. Brouillette and coworkers report serious sequelae, including cor pulmonale,
failure to thrive, permanent neurologic damage, and behavioral disturbances, hypersomnolence, or developmental
delay, in cases in which obstructive sleep apnea had gone
untreated. 153
Although it is unclear what effect apneic periods may
have on the preterm infant, frequent episodes accompanied
by hypoxemia are usually treated because they may lead to
additional neurologic complications. Nasal CPAP may help
by preventing lung deflation and chest distortion. Pharmacologic approaches include the use of theophylline or
doxapram hydrochloride to increase central respiratory

drive and/or improve CO2 sensitivity. 154 Although caffeine
has been used to treat apnea, Henderson-Smart and Steer
reported the results of a meta-analysis of two studies
examining a total of 104 infants receiving prophylactic
caffeine. 155 There were no meaningful differences between
the caffeine and placebo groups in the number of infants
with apnea, bradycardia, hypoxemic episodes, use of
ventilation or side effects in either of the studies. Alternatively, a loading dose of 6 mg/kg of theophylline is followed
by a dose of 2 mg/kg given two to three times a day to
maintain a serum theophylline level of 8 to 12 mglL.
Doxapram hydrochloride, an analeptic drug, is considered in
patients unresponsive to theophylline. To decrease toxic side
effects (seizures, hypertension, hyperglycemia, hypothermia) a loading dose of 3 mg/kg is administered over
15 minutes followed by a continuous IV infusion of
I mg/kg/hr.
Because adenotonsillar hypertrophy is the predominant anatomic cause of obstructive sleep apnea in childhood, tonsillectomy and adenoidectomy often provide the
cure. 153.156 Nasal CPAP may effectively relieve obstructive
sleep apnea in preterm infants 157 but has rarely been used in
children. 158 Tracheostomy is seldom required.
The primary nursing responsibilities in caring for the
infant or child with apnea are early detection of the event
and monitoring of the effects of treatment. All patients at
risk for central or obstructive apnea have continuous cardiac
and Spo2 monitoring. Careful observation and documentation of apneic episodes is essential in establishing the
etiology and guiding a treatment plan.

Alveolar Hypoventilation Syndromes
Etiology and Incidence. Alveolar hypoventilation
syndromes are rare conditions in which there is no upper
airway obstruction, but an insufficient respiratory drive
result in hypoventilation. These respiratory control deficits,
which originate within the central nervous system, may be
congenital (known as Ondine's curse) or acquired, and are
characterized by progressive hypoxemia and hypercarbia
during sleep, particularly quiet sleep.
Pathogenesis. The severity of hypopnea in congenital hypoventilation syndromes varies widely. The most
severe form, central hypoventilation syndrome, is usually
diagnosed soon after birth and may be associated with some
degree of hypoventilation even during wakefulness.
Alveolar hypoventilation may also be acquired following
a brainstem injury. Birth asphyxia can result in central
hypoventilation syndrome, as can encephalitis, tumors, and
brainstem trauma. 159-161
The child with alveolar hypoventilation usually has a
normal respiratory rate but breathes very shallowly (hypopnea). The respiratory rate is relatively fixed and does not
increase in response to progressive hypoxemia or hypocarbia. This phenomenon occurs during quiet sleep when the
child is totally dependent on automatic respiratory control
systems.
Critical Care Management. Theophylline may be
helpful in milder forms of the disorder. A number of other
respiratory stimulants have been evaluated in children with
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hypoventilation, but none has been uniformly effective. In
severe cases, ventilatory assistance with positive pressure
ventilation or phrenic pacing may be necessary.

SUMMARY
Caring for the patient with pulmonary dysfunction is
inherent to the practice of pediatric critical care nursing.
This chapter presents the pulmonary illnesses common to
pediatric critical care. Within the final common pathway
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framework of mechanical, circulatory, and regulatory failure, emphasis is placed on nursing and collaborative
interventions intended to both support the critically ill
patient and prevent iatrogenic injury. Much pediatric
specific nursing research is needed to help guide practice related to the care of this vulnerable population and
their families. Sensitivity and attention to the impact of
critical illness on children and their families is as important
as knowledge of the causes and treatment of respiratory
failure.

REFERENCES
I. Biel M, Eastwood JA, Muenzen P et al:
Evolving trends in critical care nursing
practice: results of a certification role delineation study. Am J Crit Care 8:285-290,
1999.
2. American Academy of Pediatrics Committee on Hospital Care and Section on Critical
Care Pediatric Section and Admission Criteria Task Force: Guidelines for developing
admission and discharge policies for the

pediatric intensive care unit, Pediatrics 103:
840-842. 1999.
3. Ausejo M, Saenz A. Pham B et al: The

effecli veness of glucocorticoids in treating croup: meta-analysis. 8MJ 319:595-600.
1999.

4. Ausejo M. Saenz A. Pham B et al: Glucocorticoids for crollp. Cochrane Database
Sys, Rev, 2, 1992.
5. Kemper KJ, Ritz RH. Benson MS et al:
Helium-oxygen mixture in the treatment of

6.

7.

8.

9.

10.

II.

12.

13.

postextubatjon stridor in pediatric trauma
patients. Crit Care Med 19:356-359. 1991Westley CR. Cotton EK. Brooks JG: Nebulized racemic epinephrine by IPPB treatment of croup: a double blind study. Am J
Dis Child 132:484-487. 1978.
Centers for Disease Control and Prevention:
Haemophilus influenzae invasive disease
among children aged <5 years-----{;alifornia.
1990-1996. MMWR 11:737-740. 1998.
Travis KW. Todres ID, Shannon DC: Pulmonary edema associated with croup and
epiglottitis. Pediatrics 59:695-698, 1977.
Bernstein T, Brilli R, Jacobs B: Is bacterial
tracheitis changing? A 14-momh experience
in a pediatric intensive care unit. Clin Infect
Dis 27:458-462. 1998.
Brook I: Aerobic and anaerobic microbiology of bacterial tracheitis in children. Pediatr Emerg Care 13:16-18. 1997.
Pasaoglu I, Dogan R, Demircin M et al:
Bronchoscopic removal of foreign bodies in
children: retrospective analysis of 822 cases.
Thorac Cardiovasc Surg 39:95-98. 1991.
Baharloo F, Veyckemans F, Francis C et al:
Tracheobronchial foreign bodies: presenlation and management in children and adults.
Chest 115:1357-1362, 1999.
Metrangelo S. Monetti C, Meneghini Let al:
Eight years' experience with foreign-body
aspiration in children: what i5 really important for a timely diagnosis? J Pediatr Surg
34:1229-1231.1999.

14. Chameides L. Hazinski MF, cds: Pediatric
advanced life support. Dallas, 1997, American Heart Association, American Academy
of Pediatric5.
15. Mathew OP, Sanl' Ambrogio G: Development of upper airway reftexes. [n Chernick
V, Mellins RB. eds: Basic mechanisms
of pediatric respiratory disease: cellular
and illtegrative, Philadelphia. 1991, B.C.
Decker.
16. Jacobs IN. Wetmore RF, Tom LW et al:
Tracheobronchomalacia in children. An'h
Otolaryngol Head Neck Surg 120: 154-158.
1994.
17. Gordin PC: Assessing and managing agitation in a critically ill infant. Maternal and
Child Nursing 15:26-32, 1990.
18. Panitch HB. Allen JL, Alpert BE et al:
Effects of CPAP on lung mechanics in
infants with acquired tracheobronchomala·
cia. Am J Respir Crit Care Med 150:13411346. 1994.
19. Kanter RK. Pollack MM. Wright WW et al:
Treatment of severe tracheobronchomalacia with continuous positive airway pressure (CPAP). Anesthesiology 57:54-56.
1982.
20. Howard TS, Hoffman LH. Stang PE. Simoes
EA: Respiratory syncytial virus pneumonia
in the hospital setting: length of stay. charges
and mortality. J Pediatr 137:227-232, 2000.
21. Centers for Disease Control and Prevention: Update: respiratory syncytial virus
activity-United States. 1998-1999 season.
MMWR 10:1104-1106, 1115. 1999.
22. Brenton S: RSV specimen collection methods: nasal vs. nasopharyngeal. Pedlatr Nurs
23:621·622, 629, 1997.
23. Shay DK, Holman RC. Newman RD et al:
Bronchiolitis-associated
hospitalizations
among US children. 1980-1996. JAMA 282:
1440-1446, 1999.
24. Wang EEL, Law BJ, Stephens D: Pediatric
Investigators' Collaborative Network on Infections in Canada (PICNIC): prospective
study of risk factors and outcomes in patients hospitalized with respiratory syncy·
tial viral lower respiratory tract infections.
J Pediatr 126:212-219, 1995.
25. Helfaer MA. Nichols DO, Rogers MC:
Lower airway disease: bronchiolitis and
asthma. In MC Rogers, DG Nichols. eds:
Textbook oj pediatric intensive care (ed 3).
Baltimore. 1996, Wil~ams & Wilkins.

26. Kellner JD. Ohlsson A, Gadomski AM et al:
Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis. Arch Pediatr
AdolescMed 150:1166-1172,1996.
27. Flores G, Horwitz RI: Efficacy of beta2agonisls in bronchiolitis: a reappraisal
and meta-analysis. Pediatrics 100:233-239.
1997.
28. Klassen TP: Recent advances in the treatment of bronchiolitis and laryngitis. Pediatr
Clin North Am 44:249-261,1997.
29. Smith PG, el-Khatib MF. Carlo WA: PEEP
does not improve pulmonary mechanics in
infants with bronchiolitis. Am Rev Respir
Dis 147:1295-1298, 1993.
30. Weksler N, Ovadia LJ: Nasal continuous
positive airway prcS6ure: an alternative
method for respiratory assistance, CUfl
Anesth 3:442-446. 1991.
31. Hollman G, Shen G. Zeng Let al: Heliumoxygen improves clinical asthma scores in
children with acute bronchiolitis. Crit Care
Med 26: 1731-1736. 1998.
32. Cade A, Brownlee KG, Conway SP ct al:
Randomized placebo controlled trial of neb·
ulized corticosteroids in acute respiratory
syncytial viral bronchiolitis. Arch Dis Child
82:126-130,2000.
33. Bulow SM, Nir M, Levin E et al: Prednisolone treatment of respiratory syncytial
virus infection: a randomized controlled
trial of 147 infants. Pediatrics 104:77.
2000.
34. American Academy of Pediatrics Committee on Infectious Diseases: Rea<;sessment of
the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics
97: 137-140. 1996.
35. Guerguerian AM. Gauthier M, Lebel MH el
al: Ribavirin in ventilated respiratory syncytial virus bronchiolitis: a randomized,
placebo-controlled trial. Am J Respir Crit
Care Med 160:829-834, 1999.
36. Chel~s MJ, Sanders SV. Dean JM et al:
Bedside transpyloric feeding tube placement
in the PICU. J Paremeral Enteral Nlltr
20:88-90. 1996.
37. American Academy of Pediatrics Committee on Infectious Diseases and Committee of
Fetus and Newborn: Prevention of respiratory syncytial virus infections: indications
for the use of palivizumab and update on
the use of RSV-IGIV Pediatrics 102:12111216, 1998.

692

Part IV

Final Common Pathways

38. Simoes EA, Sondheimer HM, Top FH Jr.
el al: Respimtory syncytial virus immune
globulin for prophylaxis against respiratory syncytial virus disease in infants and
children with congenital heart disease. The
Cardiac Study Group. J Pedialr 133:492499, 1998.
39. The IMpact-RSV Study Group: Palivizurnab, a humanized respiratory syncytial
virus monoclonal antibody. reduces hospitalization from respiratory syncytial virus
infection in high-risk infants. Pediatrics
102:531-537, 1998.
40. Centers for Disease Control and Prevention:
Guidelines for prevention of nosocomial

ment of severe childhood asthma. Pediatrics

53.

54.

55.

56.

pneumonia. MMWR 3:1-79,1997.
41. National Heart, Lung, and Blood Institute:
Guidelines for the diagnosis and management of asthma, Expen Panel Report 2.

57.

(National Institutes of Health Publication
No. 97-4051). Washington, DC, 1997. U.S.
Government Printing Office.

58.

42. Centers for Disease Control and Prevention:
Children at risk from ozone air poUulionUnited States, 1991-1993. MMWR 44:309-

312, 1995.
43. Centers for Disease Control and Prevention: Asthma Mortality and Hospitalization Among Children and Young AdultsUnited States, 1980-1993. MMWR 45:350353, 1996.
44. Weiss KB, Gergen PJ, Wagener DK: Breathing better or wheezing worse? The changing
epidemiology of asthma morbidity and mortality. Annu Rev Public Health 14:491-513,
1993.
45. National Heart, Lung. and Blood InSlitute:
Global initiative for asthma. (National Institutes of Health Publication No. 95-3659),
1995.
46. Smith U, Shamsuddin M. Sporn PH,
Denenberg M, Anderson J: Reduced superoxide dismutase in lung cells of patients
with asthma. Free Radie Bioi Med 22: 13011307,1997.
47. National Heart, Lung, and Blood Institute;
National Institutes of Health: Executive

59.

60.

61.

62.

63.

summary: guidelines fur the diagnosis and
management of asthma (Publication No.

91-3042A). Washington, DC, 1991, U.S.
Government Printing Office.
48. Connett GJ, Warde C, Wooler E et al:
Prednisolone and salbutamol in the hospital

64.

treatment of acute asthma. Arch Dis Child

70:170-173,1994.
49. Ciarallo L, Sauer AH, Shannon MW: Intravenous magnesium therapy for moderate to
severe pediatric asthma: results of a randomized, placeho-controlled trial. J Pedialr 129:
809-814, 1996.
50. Kudukis TM, Manthous CA, Schmidt GA
et al: Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the
treatment of status aSlhmaticus in children.
J Pediatr 130:217-224, 1997.
5 I. Carter ER, Wehb CR. Moffitt DR: Evaluation of heliox in children hospitalized with
acute severe asthma: a randomized cross-

over trial. Chest 109:1256-1261,1996.
52. Maguire JF, O'Rourke PP, Colan SD. Geha
RS, Crone R: Cardiotoxicity during treat-

65.

66.

67.

68.

88:1180-1186,1991.
Dhand R. Tobin MJ: Bronchodilator delivery with metered-dose inhalers in
mechanically-ventilated patients. Eur Respir
J 9:585-595, 1996.
Schaeffer EM, Pohlman A, Morgan S et al:
Oxygenation in status asthmatic us improves
during ventilation with helium-oxygen. Crit
Care Med 27:2666-2670, 1999.
Curley MAQ, Molengraft JA: Providing
comfort to critically ill pediatric patients:
isofturane. Cdt Care Nurs Clin North Am
7:267-274, 1995.
Wagner CL, Brooks JG, Richter SE et al:
The "88% saturation test": a simple lung
function test for young children. Pediatrics
93:63-67, 1994.
Buist AS, Vollmer WM: Preventing deaths
from asthma. N Ellgl J Med 331:1584-1585,
1994.
Oddy WHo Holt PG, Sly PD et al: Association between brea~t feeding and asthma in
6 year old children: findings of a prospective
birth cohort study. BM] 319:815-819, 1999.
Sigman K. Mazer B: Immunotherapy for
childhood asthma: is there a rationale for its
use? Ann Allergy Asthma lmmllnol 76:299305, 1996.
Ashbaugh DG, Bigelow DB. Petty TL,
Levine BE: Acute respirawry distress in
adults. LaIlCel 2:319-323_ 1967.
Bernard GR, Attigas A, Brigham KL et al:
The American-European Consensus Conference on ARDS: definitions, mechanisms,
relevant outcomes, and clinical trial coordination. Am] Respir Crit Care Med 149:818824, 1994.
Fackler JC, Curley MAQ, Green T et al:
Improved outcome in the acute respiratory
distress syndrome in children using a lung
protective ventilation strategy; lessons from
an aborted randomized clinical trial of
extracorporeal membrane oxygenation. In
review.
Davis SL, Furman DP, Costarino AT Jr:
Adult respiratory distress syndrome in children: associated disease. clinical course, and
predictors of death. J Pediatr 123:35-45,
1993.
Timmons OD, Havens PL, Fackler JC:
Predicting death in pediatric palients with
acute respiratory failure. CheJI 108:789797, 1995.
Ware LB, Matthay MA: The acute respiratory distress syndrome. N Ellgl J Med
242:1334-1349,2000.
Slutsky AS, Tremblay LN: Multiple system
organ failure: is mechanical ventilation a
contributing factor? Am J Respir Crit Care
Med 157:1721-1725, 1998.
Ranieri VM, SUler PM, Tortorella C el al:
Effect of mechanical ventilation on inflammatory mediators in patients with acute
respiratory distress syndrome: a randomized
controlled trial. JAMA 282:54-61, 1999.
Gattinoni L, Pelosi P, Suter PM et al: Acute
respiratory distress syndrome caused by
pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care
Med 158:3-11, 1998.

69. Moloney-Harmon PA: When the lung fails:
acute respiratory distress syndrome in children. Crit Care Niles Cli" Norlh Am 11:519528, 1999.
70. Roupie E, Dambrosio M, Servillo G et al:
Titration of tidal volume and induced hypercapnia in acule respiratory distress syndrome. Am J Respir Cril Care Med 152: 121128, 1995.
71. Amato MB, Barbas CS. Medeiros DM ct al:
Effect of a protective-ventilation strategy on
mortality in the acute respiratory distress
syndrome. N Engl J Med 338:347-354,
1998.
72. Stewart TE. Meade MO, Cook DJ et al:
Evaluation of a ventilation strategy to prevent barotrauma in patient" at high risk
for acute respiratory distress syndrome.
Pressure- and Volume-Limited Ventilation
Strategy Group. N Engl J Med 338:355-361,
1998.
73. Suter PM, Fairley HB, Isenberg MD: Effect
of tidal volume and positive end-expiratory
pressure on compliance during mechanical
ventilation. Chest 73:158-162, 1978.
74. Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes
as compared with traditional tidal volumes
for acute lung injury and the acute respiratory distress syndrome. N Engl J Med
342:1301-1308,2000.
75. Hickling KG, Henderson SJ. Jackson R:
Low mortality associated with low volume
pressure limited ventilation with pennissive
hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med 16:372377, 1990.
76. Hickling KG, Walsh J, Henderson S et al:
Low mortality rate in adult respiratory distress syndrome using low-volume, pressurelimited ventilation with permissive hypercapnia: a prospective study. Crit Care Med
22: 1568- I578. 1994.
77. Doctor A, Arnold J: Mechanical support for
acute lung injury: options for strategic ventilation. New Horizons 7:359-373, 1999.
78. Arnold JH, Hanson JH, Toro-Figuero LO
Cl al: Prospective, randomized comparison
of high-frequency oscillatory ventilation and
conventional mechanical ventilation in pediatric respiratory failure. Crit Care Med
22:1530-1539,1994.
79. Dalton H: Extracorporeal life support in the
new millennium: Forging ahead or fading
out? New HoriZOlls 7:414-432, 1999.
80. Palmisano BW. Fisher DM, Willis M, Gregory GA, Ebert PA: The effect of paralysis on
oxygen consumption in nonnoxic children
after cardiac surgery. Anesthesiology 61:
518-522, 1998.
8!. Bryan AC: Comments of a devil 's advocate.
Am Rev Respir Dis 110:143-144, 1974.
82. Curley MA: Prone positioning of patients
Wilh acute respiratory distress syndrome: a
systematic review. Am J Crit Care 8:397405, 1999.
83. Pelosi P, Tubiolo D, Mascheroni D et al:
Effects of the prone position on respiratory
mechanics and gas exchange during acute
lung injury. Am J ReJpir Crit Care Med
157:387-393, 1998.

Chapter 19
84. Curley MA. Thompson JE, Arnold JH: The
effects of early and repeated prone positioning in pediatric patients with acute lung
injury. Chest 118: 156-163. 2000.
85. Rutledge ML, Hawkins EP, Langston C:
Skeletal muscle growth failure induced in
premature newborn infants by prolonged
pancuronium treatment. J Pediatr 109:883886, 1986.
86. Weinberger B, Heck DE, Laskin DL et al:
Nitric oxide in the lung: therapeutic and
cellular mechanisms of action. Pharmaco!
Ther84:401-411. 1999.
87. Bohn D: Nitric oxide in acute hypoxic
respiratory failure: from the bench to the
bedside and back again. J Pediatr 134:387389, J999.
88. Willson DF, Zaritsky A, Bauman LA et al:
Instillation of calf lung surfactant extract
(calfactant) is heneficial in pediatric acute
hypoxemic respiratory failure. Members of
the Mid-Atlantic Pediatric Critical Care
etwork. Crit Care Med 27: 188-195,
1999.
89. Bernard GR, Bradley RB: Adult respiratory
distress syndrome: diagnosis and management. Heart Lung 15:250-255, 1986.
90. Meduri GU, Headley AS, Golden E et al:
Effect of prolonged methylprednisolone
therapy in un resolving acute respiratory
distress syndrome: a randomized controlled
trial. lAMA 280: 159-165, 1998.
91. Rochester DF, Esau SA: Malnutrition and
the respiratory system. Chest 85:411-415,
1984.
92. Bohn D, Tamura M, Perrin D et al: Ventilatory predictors of pulmonary hypoplasia in
congenital diaphragmatic hernia, confirmed
by morphologic a~sessment. J Pediarr Ill:

423-431. 1987.
93. Sakai H, Tamura M. Hosokawa Y et al:
Effect of surgical repair on respiratory
mechanics in congenital diaphragmatic hernia. J Pediarr III :432-438. 1987.
94. Breaux CWo Rouse TM, Cain WS et al:
Improvement in survival of patieOls with
congenital diaphragmatic hernia utilizing a
stralegy of delayed repair after medical
and/or extracorporeal membrane oxygenation stabilization. J Pediatr Stlrg 26:333338. 1991.
95. Langer JC. Filler RM. Bohn KJ el al: Timing
of surgery for congenital diaphragmatic
hernia: Is emergency operation necessary?
J Pediatr Stlrg 23:731-734, 1988.
96. Shanbhogue LKR. Tam PKH. Ninan G et aI:
Preoperative stabilization in congenital diaphragmatic hemia. Arch Dis Child 65: 10431044, 1990.
97. Kent PA. Curley MAQ: Challenges in nursing: infants with congenital diaphragmatic
hernia. Heart Lung 21 :381-389, 1992.
98. Schreiber MD. Heymann MA, Soifer SJ:
Increased arterial pH. not decreased paCO"
attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr
Res 20:113-117.1986.
99. Troug RD, Schena JA. Hershenson MB et
al: Repair of congenital diaphragmatic hernia during exrracorporeal membrane oxygenation. Allesthesialogy 72:750-753, 1990.

Pulmonary Critical Care Problems

100. Kao LC, Warburton D. Cheng MH el al:
Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: Result of a double-blind
crossover sequential trial. Pediatrics 74:3744. 1984.
101. Kao LC. Warburton D, Platzker ACG et al:
Effects of isoproterenol inhalation on airway
resistance in chronic bronchopulmonary
dysplasia. Pediatric.. 74:509-513, 1984.
102. Loeber N. Morray J, Kettrick R et al:
Pulmonary function in chronic respiratory
failure of infancy. Crit Care Med 8:596-601,
1980.
103. Wilkie R, Bryan M: Effect of bronchodilators on airway resistance in ventilator dependent neonates with chronic lung disease.
J Pediatr 111:278-282. 1987.
104. Northway WH, Rosan RC, Porter DY: Pulmonary disease following respirator therapy
of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 276,
357-368, 1967.
105. HiFi Study Group: High-frequency oscillatory ventilation with conventional intermiltent mechanical ventHation in the treatment
of respiratory failure in pretenn infants:
neurodevelopmental status at 16 to 24
months of posllerm age. J Pediatr 117:939946. 1990.
106. Gibson RL, Jackson JC, Twiggs GA et al:
Bronchopulmonary dysplasia. Survival after
prolonged mechanical ventilation. Am J Dis
Child 142:721-725, 1988.
107. Bancalari E. Gerhardt R: Bronchopuhnonary dysplasia. Pediarr Cli" Narth Am
33:1-23.1986.
108. Lee R. O'Brodovich H: Airway epithelial
damage in premature infants with respiratory failure. Am Rev Re;pir Dis 137:450457, 1988.
109. Goodman G. Perkin RM. Anas NG et al:
Pulmonary hypertension in infants with
bronchopulmonary dysplasia. J Pediatr 112:
67-72, 1988.
110. Groothuis JR, Gutierrez KM, Lauer BA:
Respiratory syncytial virus infection in
children with bronchopulmonary dysplasia.
Pediatrics 82: 199-203, 1988.
Ill. Smyth JA. Tabachnik E. Duncan WJ el al:
Pulmonary functinn and bronchial hyperreactivity in long-tenn survivors of bronchopulmonary dysplasia. Pediatrics 68:336340, 1981.
112. Fraak M: Theophylline: a closer look. Neonatal Network 6:7-13, 1987.
I' 3. Brudno D. Parder D. Slaton G: Response of
pulmonary mechanics to terbutaline in patients with bronchopulmonary dysplasia.
Am J Med Sci 297:166-168.1989.
114. Gomez-Del-Rio M, Gehardt T. Hehre D
et al: Effect of a beta agonist nebulization on
lung function in neonates with increased
pulmonary resistance. Pedialr Pulmollol 2:
289-291. 1986.
115. Motoyama E, Fort M. Klcsh K et al: Early
onset of airway reactivity in premature
infants with bronchopulmonary dysplasia.
Am Rev Respir Dis 136:50-57. 1987.
116. Morray JP. Fox WW. Kenrick RG et al:
Clinical correlates of successful weaning

117.

118.

119.

120.

121.

122.

123.

124.
125.

126.

127.

128.

129.

130.

131.

132.

133.

693

from mechanical ventilation in severe bron·
chopulmonary dysplasia. Crit Care Med
9:815-818. 1981.
Spitzer AR: Neonatal respiratory care. In
Dantzker D, Marini J. Dakow E. eds: Comprehensive respiratory care. Philadelphia,
1995. W.B. Saunders.
Meisels SJ. Plunkett JW. Roloff DW et aI:
Growth and development of preterm infants
with respiratory distress syndrome and bran·
chopulmonary dysplasia. Pediatrics 77:345352. 1986.
Lund CH, Collier SB: NUlrilion and bronchopulmonary dysplasia. ln Lund CH,
cd: Bronchopulmonary dYjplasia. Petaluma,
Calif. 1990, Neonatal Network.
Pridham KF, Martin R. SondeI S et al:
Parental issues in feeding young children
with bronchopulmonary dysplasia. J Pediatr
Nul'S 4:177-185.1989.
Lu JL. Sheikh KA. Wu HS el al:
Physiologic-pathologic
correlalion
in
Guillain-Barre syndrome in children. Neurology 54:33-39. 2000.
Sater RA. Rostami A: Trealment of GuillainBarre syndrome with intravenous immunoglobulin. Neurology 51 :S9-15. 1998.
Carroll JE. Jedziniak M. Guggenheim AM:
GuiLiain-Barre syndrome: Another cause of
the "floppy infant." Am J Di.' Child 131:
699-700, 1977.
Hahn AF: Guillain-Barre syndrome. Lallcet
352:635-641, 1998.
Hughes RAC. Newsom-Davis JM. Perkin
GD et al: Controlled trial of prednisolone in
acute polyneuropathy. Lancet 2:750-755,
1978.
Singhi SC. Jayshree M. Singhi P et al:
Intravenous immunoglobulin in very severe
childhood Guillain-Barre syndrome. Ann
Trop Paediatr 19: 167-74, 1999.
French Cooperative Group of Plasma Exchange in Guillain-Barre Syndrome: Efficiency of plasm exchange in Guillain-Barre
syndrome: role of replacement ttuids. Ann
Neurol 22:753-761, 1987.
Guillain-Barre Study Group: Plasmapheresis and acute Guillain-Barre syndrome. Nell.·
rology 35: 1096-1104, 1985.
Osterman PO, Lundmo G, Pirsbnen R et al:
Beneficial effects of plasma exchange in
acute inflammatory polyradiculoneuropathy.
Lallcet 2:1296-1299, 1984.
Epstein MA. Sladky JT: The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neural 26:448, 1989.
Shahar E. Murphy G, Roifman CM: Benefit of intravenously administered immune
serum globulin in patients with GuillainBarre syndrome. J Pediatr 116:141-144,
1990.
McKann GM. Griffin JW. Comblath DR
et al: Plasmapheresis and Guillain-Barre
syndrome: analysis of prognoslic factors
and the effect of plasmapheresis. Ann Neaml
23:347-353. 1988.
Ouvrier RA. McLeod JD. Pollard J: Acute
inflammatory demyelinating polyradiculoneuropathy. In Ouvrier RA. Mcleod JD,
Pollard J. eds: Peripheral neuropathy in
childlwod, New York., 1990. Raven Press.

694

Part IV

Final Common Pathways

134. Nguyen DK. Agenarioti-Belanger S.
Vanasse M: Pain and the Guillain-Barre
syndrome in children under 6 years old.
J Pediatr 134:773-776. 1999.
135. Connelly M. Shagrin J. Warfield C: Epidural
opioids for lhe management of pain in a
patient with the Guillain-Barre syndrome.
Anesthesiology 72:381-383.1990.
136. Rosenfield B. Burel C. Hanley D: Epidural
morphine treatment of pain in GuillainBarre syndrome. Arch Neurol43: 1194-1196.
1986.
137. Ferrari ND Ill. Weisse ME: Botulism. Adv
Pediatr Infect Dis 10:81-91, 1995.
138. Shapiro RL, Hatheway C. Swerdlow DL:
Botulism in the United States: a clinical and
epidemiologic review. Ann 11IIem Med 129:
221-228. 1998.
139. Buck JR. Connors RH. Coon WW et al:
Pulmonary embolism in children. J Pediatr
Surl! 16:385-390, 1981.
140. Evans DA, Wilmott RW: Pulmonary embolism in children. Pedia/r CUn NOrTh Am
41:569-584, 1994.
141. Zahka KG, Patel CR: Cardiovascular problett" of the neonate. In AA Fanaroff, RJ
Martin, eds: Neonatal-perinatal medicine:
diseases of the fetus and infant (ed 6).
St Louis. 1997, Mosby.
142. Walsh-Sukys MC. Tyson JE. Wright LL et
al: Persistent pulmonary hypertension of the
newborn in the era before nitric oxide:
practice variation and outcomes. Pediatrics
105:14-20,2000.
143. Kle<h KW, Murphy TF. Scher MS et al:
Cerebral infarction in persislenr pulmonary
hypertension of the newborn. Am J Dis
Child 141 :852-857. 1987.

144. Clark RH. Kueser TJ. Walker MW et al:
Low~dose nitric oxide therapy for persistent
pulmonary hypertension of the newborn.
Clinical Inhaled Nitric Oxide Research
Group. N Engl J Med 342:469-474. 2000.
145. Stork EK: Rescue therapies for cardiovascular failure. In Fanaroff AA. Martin RJ.
eds: Neonatal-perinatal medicine: diseases
of the fetus and infant (ed 6). St Louis, 1997,
Mosby.
146. Beachy P. Powers LK: Nursing care of the
infant with persistent pulmonary hypertension of the newborn. Clin Perinatal 11:681·
693, 1984.
147. White C. Richardson C. Raibstein L: Highfrequency ventilation and extracorporeal
membrane oxygenation. AACN Clinical Issues in Critical Care Nursing t:427-444,
1990.
148. Spitzer AR. Davis J. Clarke WT et al:
Pulmonary hypertension and persistent fetal
circulation in the newborn. elin Perillawl
15:389-413. 1988.
149. Henderson-Smart DJ: The effect of gesta·
tional age on the incidence and duration of
recurrent apnoea in newborn babies. Aus!
Paediat J 17:273-276. 1981.
ISO, Ali NJ, Pitson OJ, Stradling JR: Snoring,
sleep disturbance. and behaviour in 4-5
year olds. Arch Dis Child 68:360-366,
1993.
151. Gislason T. Benediktsdottir B: Snoring.
apneic episodes, and nocturnal hypoxemia
among children 6 months to 6 years old: an
epidemiologic study of lower limit of prevo
alence. Chest 107:963-966, 1995.
152. Robert.s JL, Mathew OP. Thach BT: The
efficacy of theophylline in premature infants

153.

154.

155.

156.

157.

158.

159.

160.

161.

with mixed and obstructive apnea and apnea
associated with pulmonary and neurologic
disease. J Pediatr 100:968-970. 1982.
Brouillette RT, Fernback SK. Hunt CE:
Obstructive sleep apnea in infants and children. J Pediatr 100:31-40. 1982.
Bairam A, Boutroy M. Badonnel Y et al:
Theophylline versus caffeine: comparative
effects in treatment of idiopathic apnea in
the preterrn infant. J Pediatr 110:636-639.
1987.
Henderson-Smart DJ. Steer PA: Prophylactic methylxanthine for preventing of apnea
in pretenn infants. Cochrane Database SYSf
Rev 2. CD000432, 2000.
Frank Y. Kravath RE. Pollak CP, Weitzman
EK: Obstructive sleep apnea and its therapy:
clinical and polysomnographic manifestations. Pediatrics 71 :737-742. 1983.
Miller MJ. Carlo WA, Martin RJ: Continuous (Xlsitive pressure selectively reduces obstructive apnea in preterm infants.
J Pediatr 106:91-94, 1985.
Guilleminault C: Obstructive sleep apnea
syndrome and its treatment in children:
areas of agreement and conuoversy. Pediatr
Pulmonol 3:429-436. 1987.
Brazy JE. Kinney HC. Oakes WJ: Cent tal
nervous system structural lesions causing apnea at birth. J Pediatr III: 163-175,
1987.
Jensen TH. Hansen PB, Brodersen P: Ondines's curse in Listeria monocytogenes brain
stem encephalitis. Acta Neural Scand 77:
505-506, 1988.
Quera-Salva MA. Guilleminault C: Posttraumatic central sleep apnea in a child.
J Pediatr 110:906-909, 1987.

Renal Critical Care
Problems
Lauren Sorce Grehn
Andrea Kline
Joyce Weishaar

flow potentially alters kidney function. Over time, hypoperfusion results in altered renal function because of changes in
the kidney itself. Intrinsic renal failure can occur as a result
of ingestion or administration of nephrotoxic agents, which
impair renal cell function and cause an alteration in renal
tubular reabsorption or secretion.
The clinical presentation and laboratory findings in ARF
vary. Following trends in a child's renal status over time best
identifies deteriorating renal function. Nursing vigilance,
which provides for early identification and management of
ARF, can prevent irreversible renal dysfunction.

EMBRYOLOGIC DEVELOPMENT OF THE RENAL SYSTEM
MATURATIONAL FACTORS

Structure of the Renal System
Function of the Renal System
ACUTE RENAL FAILURE

Prerenal Failure
Intrinsic Renal Failure
Postrenal Failure
Critical Care Management
RENAL REPLACEMENT THERAPY

EMBRYOLOGIC DEVELOPMENT
OF THE RENAL SYSTEM

Peritoneal Dialysis
Continuous ArteriovenousNenovenous
Hemofiltration
Hemodialysis

Renal system development goes through three successive
bilateral excretory systems in the embryo: the pronephros,
the mesonephros, and the metanephros. The pronephros is
evident in the embryo in the third week of gestation and
degenerates by the fifth week. This structure has no notable
excretory function, but it is necessary because it gives rise
to the mesonephric duct?
The mesonephric nephrons are noted at approximately
the middle of the fourth week of gestation and are caudal to
the pronephros. Glomeruli and proximal tubules can be seen
in the mesonephros, which is the first functional renal unit
of the embryo? The tubules empty into the mesonephric
duct, which develops an outgrowth to form the ureteric bud.
The ureteric bud in tum leads to the development of the
metanephros, the definitive kidney. As the metanephros
begins to function, the mesonephric ducts and tubules
degenerate in females. In males, they persist and become
incorporated into the genital system. 3
Development of the metanephros begins in the fifth week
of gestation. 3 The metanephros is formed from two different
embryonic tissues. The excretory portion, including the
collecting ducts, calyces, pelvis, and ureter, develops from
the ureteric bud. The metanephric blastema gives rise to
Bowman's capsule, most of the glomerulus, and the tubules
of the nephrons. The collecting ducts and the tubules then

SUMMARY

T

he renal system is an elaborate maze of complex
functions that maintains homeostasis in the body.
Although the kidney begins as a few tubules, it eventually
develops into an intricate organ responsible for homeostatic
balance. When the renal system is not functioning appropriately, this balance is in jeopardy. Renal dysfunction that
progresses to acute renal failure (ARF) may cause complete
cessation of function.
ARF can occur as a primary disease and cause critical
illness. In the child, the cause is generally intrinsic to the
kidney and urinary tract, compared with multisystem
diseases that affect the adult. [ When ARF is present as a
primary disease, the morbidity and mortality are less than
when it is associated with additional conditions, such as
multiorgan dysfunction syndrome.
The pathogenesis of ARF is multifactorial. Because renal
function is dependent on renal blood flow, any diminution in
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Fig. 21-1 A, Sketch of lateral view of 5-week-old embryo showing primordium of the metanephros, or
permanent kidney. B to E, Sketches showing successive stages of development of the metanephric
diverticulum (fifth to eighth week) into the ureter, pelvis, calyces. and collecting tubules. Renal lobes
illustrated in E are visible in the kidneys of newborn infants. External evidence of the lobes normally
disappears by the end of the first year. (From Moore KL: Before we are born: basic embryology and birth
defects, ed 2, Philadelphia, 1985, WB Saunders, p 171.)

make connections, giving rise to an anatomically complete
microstructure by 12 to 16 weeks gestation. 4 As the tubules
are developing, they are influenced by a variety of growth
factors? Fig. 21-1 provides an overview of embryologic
development of the kidney.
By full gestation, each human kidney contains approximately 1 million nephrons in different stages of development. The maturest nephrons are found in the renal medulla,
and immature nephrons are in the outer cortex. Although
maturation of the renal system continues after birth, no
additional nephrons are formed.

MATURATIONAL FACTORS
Structure of the Renal System
The kidneys occupy a large portion of the posterior
abdominal wall as a result of the ascent and rotation of the
kidneys during gestation. They are located in the retroperitoneal space in front and on both sides of the vertebral
column. A thin fibrous capsule composed of connective
tissue, lymphatics, and blood vessels covers each kidney.
The blood vessels, lymphatics, nerves, and ureter enter or
exit the kidney in the area known as the hilum. A
cross-section of the mature kidney demonstrates an outer
area of renal cortex tbat is approximately 1 em wide and an
inner area of renal medulla that is approximately 5 em wide.
About 85% of the nephrons in each kidney are located
within the renal cortex. The remaining 15% are called the

"juxtamedullary nephrons" and are located at the junction
of the cortex and medulla. The ureters are proportionately
shorter in infancy than in adults. As renal development continues, the ureters grow to adult proportions,
and the kidney reaches adult size by adolescence. The
kidney's weight is 10 times greater at maturity than at
birth. s Fig. 21-2 demonstrates the gross structure of the
kidney.
At birth, each kidney contains approximately I million
nephrons. Although these nephrons are in varying maturational stages, each has both a tubular and vascular
component. The arcuate artery branches within the kidney
to form the afferent arterioles. Afferent .arterioles then
divide into capillary tufts called glomeruli, which protrude
into Bowman's capsule. The tubular component of the
nephron is composed of Bowman's capsule, the proximal
and distal convoluted tubules, the loop of Henle, and the
collecting ducts.

Function of the Renal System
The permanent kidney has a complete microstructure by the
fourth month of gestation; nonetheless, renal development
continues until adolescence. During this time, the immature
kidney can ensure fluid and electrolyte balance, which is
essential for growth in the developing infant; however. it is
less capable of adjusting to the stress imposed by an acute
illness. Table 21-1 summarizes the limitation of immature
renal function.
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TABLE 21-1
1""IHl(;haracteristics

-t--- Collecting duct

Gross structure of bisected kidney.

Maturational Limitations of Renal Function

l::"~'

Mechanism

~,,Inability to excrete excessive sodium

Immature tubular function

~wer serum bicarbonate concentrations
~!nability to concentrate urine

Cannot generate a sufficient concentration gradient in the inner medulla

ililiow glomerular filtration rate
~i"

iY'-

~:Decreased
~!I,

'HI!..
11t!;

'ii!

renal blood flow

Limited capacity to reabsorb bicarbonate and secrete hydrogen ions
Low perfusion pressures, decreased surface area available for filtration, glomerular
permeability, and low glomerular plasma flow
High renal vascular resistance in afferent and efferent arterioles
Low cardiac output deli vered to kidneys
Possible incomplete sympathetic innervation

The newborn kidney receives approximately 4% to 6% of
the total cardiac output because of a lower mean arterial
pressure and high renal vascular resistance. The lower
percentage of the cardiac output supplied to the newborn
kidney compares with 20% to 25% of cardiac output
supplied to the mature kidney.6 Some data suggest that the
higher vascular resistance may be a response to the
renin-angiotensin system. 6,7 In addition, a decrease in

amount or effectiveness of circulating vasodilators, such as
endothelin-derived relaxing factor, may contribute to elevated renal vascular resistance. 6,7 Elevated renal vascular
resistance may also be a response to circulating catecholamines and digitalis-like peptides. However, an abrupt
decrease in catecholamines or slow decline in digitalis-like
peptide does not provide a substantial decrease in renal
vascu lar resistance. 7 .8
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Fig. 21-3 Tubular components of the nephron. (From Whaley LF, Wong DL: Nursing care of infanrs and
children, ed 6, 51 Louis, 1999, Mosby.)

The sympathetic nervous system may also play an
important role in renal hemodynamics in infants. Sympathetic innervation may be incomplete, and most of the
adrenergic receptor sites may be of alpha type, which
produce renal vasoconstriction when stimulated. s
Normal urine output averages between 0.5 mllkg/hr in a
well-hydrated adolescent to I mIIkg/hr in the child and 2
mlIkg/hr in the infant. Although normal urine specific
gravity is between 1.005 and 1.020, infants and children
younger than 2 years may not present with high specific
gravity because of renal maturational factors.
The urine produced in the newborn's kidneys is dilute.
The limited ability to concentrate urine in the newborn is
due to short loops of Henle with reduced sodium chloride
transport, high protein anabolism, and wide peripapillary
fornices 9 ,I0 The infant cannot excrete very dilute urine in
states of overhydration and may be unable to excrete very
concentrated urine in response to dehydration.
Renal blood flow (RBF) and glomerular filtration rate
(GFR) increase with gestational age. At birth. a variable
GFR, which decreases, increases, and decreases all within
the first few hours of life, is seen. The newborn's GFR
within the first 24 hours averages 25 mllmin/I.73 m2
During the first 3 months of life, GFR increases in relation
to body size, kidney weight, and surface area of the kidney.
Factors affecting the increase in GFR are increased arterial
pressure, increased RBF, increased filtration surface area,
and increased glomerular permeability.1O GFR then in-

creases at a slower rate until it reaches adult values between
12 and 24 months of age. 6 GFR may be calculated for
children. The calculation for children ages I to 6 years is
0.55 x length (in cm)/plasma creatinine (mg %). This yields
GFR in millimeters per minute on body surface area
corrected to 1.73 m2 .
Immature tubular function results in less efficient maintenance of sodium and water balance. The decreased urinary
excretion of sodium characteristic of the first year of life is
directly related to the low GFR and high reabsorption rates
at the level of the distal segment of the tubule. lo Functions
in the distal tubules depend on the actions of aldosterone and
antidiuretic hormone. In the infant, the distal tubule is
relatively insensitive to aldosterone. Hence the infant has
limited ability to respond to sodium excess or depletion and
may experience impaired secretion of potassium and hydrogen ions. These developmental factors continue to play a
role in fluid and electrolyte balance during the first 2 years
of life and help to explain the sensitivity of infants and
young children to fluid and electrolyte alteration.
Renal function is not limited to the formation of urine but
is also responsible for a variety of other activities that
maintain the internal stability of other body systems. These
activities include the mechanisms of secretion, reabsorption,
and active transport that take place in the renal tubules
(Fig. 21-3). Secretion clears the serum of unwanted substances. Reabsorption and acti ve transport allow substances
to be returned to the serum in appropriate proportions to
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TABLE

21-2

Renal Function

~:Function
'P'-

Mechanism

l:i'Formation of urine

Secretion, reabsorption, and
active transport
Hydrogen/bicarbonate ion secretion or absorption
Alteration in circulating blood
volume, renin-angiotensin
system
Secretion of erythropoietin
Activation of vitamin D

",

!i;Acid-base
balance
!;;'
:"'Maintenance of blood
",. pressure
'i!'£rythrocyte production
F
L'Calcium and phosphorus
'" balance
IjiYasodilation or vasocon~'; striction of the renal

{~i:

,.;;

IHypovolemia I
I Hypotension I
\~_------,I
I Renal Hypoperiusion I
~

ISimulates afferent arteriole baroreceptors I
~

Ii Renin release Uuxtaglomerular apparatus) I
Angiotensinogen (liver)

I

Angiotensin

Synthesis of prostaglandins

I

I

(pUlmonary capillary bed)

vasculature

maintain nonnal blood levels. The kidneys are also responsible for the excretion of foreign substances and byproducts
of metabolism, including urea, toxins, and medications. J I
Table 21-2 summarizes these functions.
Acid-base balance is regulated by the kidneys, lungs, and
chemical buffering systems. The kidney selectively secretes
or absorbs hydrogen and bicarbonate ions to maintain the
serum pH within nonnal range. Renal regulation of acidbase balance in the immature kidney has certain quantitative
differences. Though able to maintain a nonnal balance,
serum pH and bicarbonate levels are generally lower
because of low renal threshold for bicarbonate. lO Under
normal conditions the immature kidney is able to maintain
acid-base homeostasis, but when challenged with excess
acid, the immature kidney is unable to clear it efficiently
because of finite availability of urinary buffers. 10
The kidneys maintain blood pressure by both direct and
indirect means. This is accomplished by altering the circulating blood volume and activating the renin-angiotensin
system. The outcome of renin-angiotensin system activation
is contraction of vascular smooth muscle and aldosterone
secretion, which results in renal tubular reabsorption of
sodium and water (Fig. 21-4).
The kidney secretes erythropoietin, which stimulates
bone marrow to produce erythrocytes. Erythropoietin is
released in response to decreased oxygen delivery to the
kidneys resulting from low hematocrit or oxygen tension.
Several factors, including vitamin D 3 and parathyroid
honnone (PTH), regulate calcium metabolism. Vitamin D 3
is an essential cofactor for PTH in both bone and kidney.
After vitamin D 3 is absorbed by the jejunum and ileum, it
must be metabolized into its active fonn first by the liver and
then by the kidney. In its acti ve fonn, vitamin D 3 promotes
intestinal absorption of calcium and stimulates bone reabsorption of calcium. In the absence of vitamin D 3 , hypocalcemia and disturbances in bone mineralization occur.
Serum calcium and phosphate levels share an inverse
relationship (i.e., when serum calcium levels rise, serum
phosphate levels decline and vice versa). The interrelationship of calcium phosphate is progressively disrupted
during ARE When the GFR decreases, phosphate is
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Fig. 21-4

retained by the kidneys. Phosphate retention decreases
serum calcium levels. The azotemic state also interferes
with vitamin D activation by the kidneys, which is
necessary for intestinal absorption of calcium. Both factors
contribute to hypocalcemia.
The nephron also synthesizes prostaglandins, which are
important in the maintenance of RBF and glomerular
perfusion during changes in renal vascular resistance.
Vasodilation results in an increase in blood flow and GFR,
whereas the opposite occurs during vasoconstriction.

ACUTE RENAL FAILURE
ARF is the abrupt cessation of kidney function with or
without oliguria, resulting in fluid and waste product
accumulation. Traditionally, ARF has been divided into
three categories: prerenal, renal, and postrenal failure. These
categories are based on the site of the abnonnality thought
to be causing the renal insufficiency (Fig. 21-5).

Prerenal Failure
Pathogenesis. Prerenal failure is due to renal hypoperfusion from inadequate preload or heart failure (Table
21-3). There is no structural defect in the kidney itself.
Prerenal dysfunction can lead to decreased RBF, GFR, and
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OLIGURIA/AZOTEMIA
I

SUSPECT ARF
I

Obtain:

Clinical history
Physical examination
Biochemical profile
Urinalysis
Urinary indices
I

I

Diarrhea/vomiting/bleeding
Hypotension/low cardiac output
Unimpressive urinalysis
BUN/creat>20
Uosmol>500
FE Na <1%

j

I

Fluid overload
Hypertension
Drugs/chemotherapy
Multisystem involvement
Abnormal blood smear
Pigmenturia
"Active" urine sediment
Uosmol<350
FE Na >2%

+

Suspect Intrinsic Renal
ARF

Suspect Prerenal
ARF

•

Rehydration
Transfusion

'Of::

DIURESIS

PERSISTENT
URIA

~ OLr

Trial of diuretics/
dopamine
RECOVERY

+ ------'
Oliguria

•

Imaging studies
Renal biopsy

History of UTI
History of stones
Poor urinary stream
Full bladder
•ARF unexplained by
clinical/historical
findings

1

,

Suspect Postrenal
ARF
Catheterize the patient
Imaging studies

~

Maintain fluid balance
Electrolyte correction
Optimal nutritional support

RECOV~RY\

SURGICAL
CORRECTION

Significant fluid overload
CHF/pulmonary edema
Uncontrolled metabolic
acidosis/hyperkalemia
Uremia/hypercatabolism

•

DIALYSIS
SCUF

Fig. 21-5 Suggested approach to basic diagnostic and therapeutic management of acute renal failure
(ARF) in infants and children. BUN. Blood urea nitrogen; Uosmob urine osmolality; UTI. urinary tract
infection; FEN". fractional excretion of sodium; SCUF, slow continuous ultrafiltration. (From Ongkingco
JRC, Block GH: Diagnosis and management of acute renal failure in the critical care unit. In Holbrook PR:
Textbook of pediatric cri/ical care. Philadelphia, 1993, WB Saunders, p 592.)

ltI

TABLE

21·3

Causes of Prerenal Oliguria

liJ1AItered Cardiac Performance

Vasodilation

Altered Vascular Volume

Altered Blood Supply to the Kidney

!iiCardiogenic shock
~[jCongestive heart failure
WiCongenital heart disease
~". Postoperative myocardial
;-;'r··
';'
dysfunction

Septic shock
Anaphylaxis
Allergic
Transfusion
Vasodilating agents
Drug overdose
Liver failure

Intravascular volume loss
Hemorrhage
Third space
Edema
Peritonitis
Burns
Gastrointestinal loss
Vomiting
Diarrhea
Renal Losses
Excessive diuresis
Pancreatitis
Dermal losses

Surgical
Cardiac bypass
Aortic cross clamp
Umbilical arterial catheter displacement
Renal artery thrombosis

L

~:tlysrhythmias

!cardiomyopathy
[i'Myocarditis
1]cardiac tamponade
Jl,Positive pressure ventilation
[•. Pulmonary embolism
!f'
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urine output. Oliguria is a compensatory mechanism intended to restore intravascular volume when tissue perfusion is inadequate through conservation of sodium and
water. Venous return is increased, and tissue perfusion to
major organ systems may be improved.
The physiologic responses of the kidney to reduced blood
flow depend on the integrity of several intrarenal and
extrarenal mechanisms. Autoregulation is an intrarenal
mechanism by which the kidney can locally readjust its
vascular resistance and regulate blood flow. 12 By varying
arteriolar resistance, autoregulation allows organs to regulate blood flow in proportion to metabolic demand and
maintain a constant blood flow over a wide range of
perfusion pressures.
Autoregulation in the kidney is designed to maintain a
relatively constant RBF in the face of changing blood
pressure and renal perfusion pressure (RPP). Autoregulation
functions independently of humoral and neurogenic factors
and keeps RBF in a remarkably narrow range under normal
physiologic conditions. 12 To maintain a relatively constant
GFR, afferent arteriolar resistance varies in direct proportion to systemic pressure. Systemic hypotension is accompanied by afferent arteriolar vasodilation, which reduces
renal vascular resistance and improves RBF. This is an
initial short response, followed by vasoconstriction. Blood
is then shunted away from the renal cortex to the juxtamedullary nephrons. This results in tubular reabsorption of
water, sodium, and urea. 13 With significant vasoconstriction,
the kidney will shunt blood to the most vital organs (brain
and heart), which can be lifesaving in a patient with shock. 13
If delivery of oxygen to the kidney remains impaired after
compensatory mechanisms are applied, the patient is at risk
for acute tubular necrosis (ATN) of the kidney. Because
arterioles are present at either end of the glomerulus,
constriction or dilation of these arterioles alters the perfusion pressure through the glomerular capillaries and regulates glomerular filtration. Changes in GFR ultimately affect
the volume and content of the final urine product.
The extrarenal mechanisms that affect renal function
include alterations in cardiac output, systemic vascular tone,
antidiuretic hormone, corresponding distribution of systemic blood flow, and systemic blood pressure. The importance of the interplay of both intrarenal and extrarenal
factors is evident during the physiologic response of the
kidney to an acute episode of volume depletion or myocardial dysfunction. For example, a sudden reduction in renal
perfusion activates the renin-angiotensin system to normalize renal perfusion and maintain GFR (see Fig. 21-4). The
release of renin from the macula densa acts extrarenally to
increase systemic vascular resistance and improve systemic
blood pressure. In addition, renin stimulates the adrenal
cortex to release aldosterone, which acts to increase tubular
reabsorption of sodium followed by water. These responses
also serve to normalize renal perfusion, thereby maintaining
the GFR.
Primary or secondary renal vascular disease may cause a
partial or complete obstruction to blood flow, resulting in
renal ischemia. In infants, examples of obstruction leading
to ischemia include venous and arterial vein thrombosis.
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Umbilical venous catheters may lead to renal vein thrombosis, manifested by hematuria, proteinuria, or renal failure.
Renal artery thrombosis is more likely to present with
hypertension. Renal failure in either case is rare unless the
patient has a solitary kidney. Bilateral renal vein occlusion,
a more common vascular lesion in infants, has been
associated with asphyxia and congenital heart disease. 14
If compromised renal perfusion persists, the capacity of
the intrarenal and extrarenal mechanisms to maintain
homeostasis is jeopardized. Urine production decreases, and
azotemia may occur. If systemic pressure and volume are
not restored after a finite period, true, fixed intrinsic renal
failure ensues. Early detection of the subtle signs and
symptoms of intrinsic renal failure is crucial to facilitate
appropriate management to preserve renal function.
Clinical Presentation. Renal failure can be oliguric
or nonoliguric. Nonoliguric ARF describes renal dysfunction associated with a normal or excessi ve urine volume.
The key to early recognition is to be alert for signs of
decreased or increased urine volume in relation to overall
fluid balance. Acid-base disturbances may be detected early
in patients with prerenal failure. An unexplained metabolic
acidosis is a sign of decreased tissue perfusion, including
renal perfusion.
The diagnosis of renal failure is based on the presence of
azotemia. Serum blood urea nitrogen (BUN) and creatinine
levels provide an index of glomerular filtration. Both of
these substances are nitrogenous end products of protein
metabolism normally excreted in urine. As GFR decreases,
BUN and creatinine levels increase. In isolation, BUN is not
a reliable indicator of renal function because the level may
be affected by factors other than nitrogen excretion by the
kidney. Extrarenal factors that affect BUN concentration are
listed in Table 21-4. Creatinine is an end product of muscle
metabolism, which is excreted and eliminated at a constant
rate. Serum creatinine is relatively unaffected by extrarenal
factors and, therefore, is a more reliable indicator of
glomerular function. Because the level of serum creatinine
is a function of muscle mass, it is affected by age, muscle
mass, and body build. 15 In the face of decreased tubular
flow, a greater percentage of urea is reabsorbed into the
circulatory system, producing a significant elevation in
serum BUN. In the same circumstance, creatinine levels are
usually only slightly elevated. The serum BUN/creatinine
ratio may also help to differentiate prerenal from intrinsic
renal failure (Table 21-5).
Other laboratory values used to differentiate prerenal
failure from intrinsic renal failure include measuring tubular
reabsorption of sodium and water. Unlike the kidney with
parenchymal damage, the underperfused but functionally
intact kidney has the capability to actively reabsorb sodium
as a compensatory response to hypovolemia. When evaluating a patient with ARF, the single most informative
laboratory test is the fractional excretion of sodium (FE Na).
The FE Nu is calculated as follows:
(FEN.)

= (Urine [Na]lPlasma [Na])/(Urine [Crl/Plasma [Cr]) X 100

In patients with prerenal azotemia, the FEN. is usually less
than I%, and in patients with ATN, it is generally greater
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than I %. These levels may be altered by the administration
of diuretics. Loop diuretics inhibit the reabsorption of
sodium at the proximal tubule, which improves solute
excretion in the urine.
Reabsorption of water also requires a functionally intact
renal tubule. Measurement of urine specific gravity is a
simple and readily available procedure. A urine specific
gravity over 1.020 strongly suggests prerenal failure. The
increased concentration of urine indicates decreased RBF
and functioning compensatory mechanisms intended to
preserve circulating volume.
Chemical testing of the urine has been simplified by the
introduction of multiple dipstick tests that detect substances

TABLE 21-4· Extrarenal Factors That Affect"
BUN and Creatinine Levels

such as glucose, bilirubin, pH, protein, blood, and ketones
on a single impregnated paper strip. Dipstick tests can be
done quickly and accurately to gather information about the
capacity of the kidneys to maintain homeostasis during an
acute illness.
Emergent Management. Assessment and intervention to attenuate renal parenchymal damage are dependent
on recognizing high-risk situations that are associated with
prerenal failure. Those conditions that alter fluid volume
status and cardiac performance place patients at particular
risk. Patient outcome depends on early diagnosis and
management of inadequate renal perfusion and avoidance or
careful monitoring of patient response to nephrotoxic agents
listed in Box 21-1. Prompt evaluation and possible discontinuation of both nephrotoxic agents and supplemental
potassium may be warranted.
The first step in managing an oliguric patient is to assess
and ensure the adequacy of intravascular volume. On
physical examination, dry mucous membranes, tachycardia,
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Laboratory Values That Differentiate Causes of Oliguria
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hypotension, a sunken fontanelle, absence of tears, and
decreased urine volume indicate hypovolemia. Ongoing
assessment includes direct physical examination, as well as
monitoring hemodynamic variables that reflect volume
status.
Restoration of intravascular volume is the priority if
hypovolemia is detected, to ensure adequate cardiac output
regardless of whether renal damage has occurred. Except in
the presence of hypervolemia, a 10 to 20 ml/kg fluid
challenge, using any volume expander, is administered.
Unless the patient is in congestive heart failure, the fluid
bolus is repeated, followed by diuretics. After each intervention, the fluid volume status is evaluated. 13 Diuretics can
help distinguish prerenal from fixed renal failure and can
convert an oliguric to a nonoliguric state. Diuretics may also
be useful in restoring and maintaining normal water and
electrolyte balance and preventing further renal damage.
The desired outcome is to restore circulating blood volume
and increase urinary output.
Recovery from prerenal failure depends on astute nursing
care focused to attenuate the progression of irreversible
renal damage. Outcome is not only related to the underlying
cause of renal failure and extent of other organ system
damage but also to the ability of healthcare providers to
recognize patients at risk and intervene effectively.
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fraction remains nom1al, and tubular function is preserved.
Decreased filtration, in conjunction with usual oral intake,
results in retention of fluid and solute. Edema and hypertension are due to vascular and interstitial volume expansion. If solute filtration is significantly decreased, azotemia
with acidemia, hyperkalemia, and hyperphosphatemia become prominent. 16 Most children are not usually critically
ill and recover completely following treatment.
Hemolytic uremic syndrome (HUS) is a syndrome of
microangiopathic hemolytic anemia with multiorgan involvement. The pathologic state results from endothelial
injury and microvascular thrombosis with glomerular injury,
ARF, and, at times, cortical necrosis. 17 HUS is discussed in
more detail in Chapter 24.
Drug-induced nephritis is a common cause of ARF and
often has systemic manifestations of an allergic process. It
was first described in association with methicillin and has
also been described in relation to use of penicillins,
cephalosporins, sulfonamides, allopurinol, cimetidine, ciprofloxacin, and nonsteroidal antiinflammatory medications.
The clinical diagnosis can be suspected in the presence of
fever, rash, urine sediment revealing red cells and white
casts, acute rise in creatinine level temporally related to a
medication or infection, eosinophilia, mild proteinuria, and
signs of tubular dysfunction. However, cases have been

Intrinsic Renal Failure
Pathogenesis. Intrinsic renal failure refers to numerous conditions or primary physiologic events that produce
renal parenchymal damage involving the glomerulus or
tubular epithelium. Direct injury to the renal parenchyma
also can be caused by episodes of acute hypoperfusion or
adverse reactions to nephrotoxic agents.
Manifested by proteinuria and/or hematuria, intrinsic
renal failure may occur after extensive injury to the
glomerular capillary wall. Although the lesion is primarily
glomerular, entire nephrons can be destroyed, leading to
chronic renal failure. The most common causes of intrinsic
oliguria in the pediatric population are listed in Box 21-2.
More than 50% of cases of intrinsic renal failure in children
are the result of acute glomerulonephritis, hemolytic uremic
syndrome, and drug-induced nephritis.
Acute poststreptococcal glomerulonephritis (APSGN)
can occur sporadically, which is more common, or in
epidemics. It occurs most often in children of preschool and
early school-age years. Less than 5% of cases are seen in
children under 2 years of age, and 5% to 10% occur in adults
older than 40 years. 16 Twenty percent of asymptomatic
school children are carriers of streptococci. Though APSGN
may be seen without the usual prodromal illness, pharyngitis
and pyoderma are common antecedents to APSGN. 16
Treatment of the prodromal illness does not appear to
prevent APSGN but may prevent a rise in titers of
streptococcal-related antibodies.
The major physiologic disturbance of APSGN is reduced
GFR caused by decreased glomerular filtration surface from
both infiltration by inflammatory cells and decreased
basement membrane permeability. RBF is also decreased,
usually in proportion to the decreased GFR. The filtration
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Box 21-2

Causes of Intrinsic Renal Failure

Immune-Related
Glomerulonephritis
Systemic lupus erythematosus

Vascular
Hemolytic-uremic syndrome
Renal vein artery thrombosis
Disseminated intravascular coagulation
Thrombotic thrombocytopenia purpura

Interstitial Nephritis
Infectious
Drug-related
Malignant

Renal Trauma
Nephrotoxins
Endogenous
Transfusion reaction
Cytotoxic therapy
Tumor lysis
Exogenous
Anesthetic agents
Heavy metals
Organic solvents
Antibiotics
Pesticides
Radiographic contrast agents
Hyperalimentation
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described, especially with nonsteroidal medication use, in
which most of these symptoms are absent or variable.
Indications for biopsy include uncertainty of diagnosis,
advanced renal failure, or lack of spontaneous recovery after
cessation of medication administration. Acute interstitial
nephritis (AIN) is not medication dose dependent, and its
onset may occur from 3 to 5 days to weeks or months after
initiation of drug therapy. Major histologic findings on renal
biopsy include interstitial edema and interstitial infiltrates of
T lymphocytes and monocytes. Sometimes, eosinophils and
neutrophils with minimal changes in the glomeruli may be
seen. When infection is responsible for AIN, neutrophils are
present in large numbers. IR
The term acute tubular necrosis (ATN) is commonly
applied to nephrotoxic and ischemic renal injuries that
damage the tubular epithelium. Two types of histologic
changes are commonly observed in ATN: necrosis of the
tubular epithelium leaving the basement membrane intact,
commonly resulting from the ingestion of nephrotoxic
agents, and necrosis of the tubular epithelium and basement
membrane, commonly associated with renal ischemia.
Nephrotoxic injury can also be produced by chemical agents
that directly impair renal cell function, participate in
immune or inflammatory reactions, or aggravate an underlying renal disorder (see Box 21-2).
Ischemic injuries resulting in ATN occur during an acute
period of renal hypoperfusion. If ischemia persists, irreversible renal damage occurs. The amount of renal cell damage
depends on the length of the ischemic episode. It has been
reported that an ischemic time of 30 minutes or less to the
kidney may be well tolerated. In low perfusion states, the
autoregulatory properties of the afferent and efferent arterioles of the glomerulus become impaired. The pathologic
change produced by renal ischemia is destruction of the
tubular epithelium and basement membrane or cortical
necrosis. Early responses to ischemia are found in the brush
border of the proximal tubule. Even mild ischemia lasting
10 minutes can cause sloughing of the brush border and
changes in the proximal tubular histology. In more prolonged periods of ischemia, these changes progress to lethal
injury to cells and disruption of the basement membrane. 14
When the basement membrane is destroyed, epithelial
regeneration occurs in a random haphazard manner, often
leading to obstruction of the nephron at the site of necrosis.
Prognosis is therefore dependent on the extent of necrosis.
The mechanisms that lead to a decrease in GFR and
associated oliguria in patients with ATN have not been
clearly defined. Tubular backleak and obstruction theories
have been proposed to explain the oliguria associated with
ATN. The tubular backleak hypothesis proposes that glomerular filtration continues normally but tubular fluid
"leaks back" from the damaged tubular cells into the renal
interstitium rather than being excreted as urine. The tubular
obstruction theory proposes that ATN leads to the desquamation of necrotic tubular cells and formation of brush
border debris, which occludes the tubule lumina and
produce obstruction. 14 Cellular swelling as a result of the
initial ischemia may also contribute to obstruction and
perpetuate the ischemia. Intratubular pressure increases so

that net glomerular filtration pressure is reduced. Tubular
obstruction may be an important factor in ATN when
prolonged ischemia or ingestion of heavy metals or ethylene
glycol occurs.
Clinical Presentation. Infants and children withATN
often present with abrupt-onset oliguria or anuria. It is
important to recognize the onset of oliguria and differentiate
the cause leading to ATN from prerenal, intrinsic, and
postrenal disorders that may cause oliguria. Three phases
characterize the clinical course of ATN: oliguria, diuresis,
and recovery.
After exposure to a nephrotoxic agent or following an
ischemic event, oliguric ATN may develop immediately or
several days after renal cell damage occurs. This phase is
most often characterized by abrupt reduction in urine
production that continues for 24 to 48 hours, though this
may vary. During the oliguric phase, serum BUN and
creatinine levels rise. Other significant laboratory data
resulting from tubular dysfunction and inability to concentrate urine include urine specific gravity less than l.0 18, low
urine osmolality, and urine sodium greater than 10 mEqlL.
Potential complications during the oliguric phase include
hypervolemia causing congestive heart failure or pulmonary
edema; electrolyte imbalances, particularly hyponatremia
and hyperkalemia; and acid-base disturbances.
The diuretic phase of ATN usually lasts 5 to 7 days. Early
in the diuretic phase, urea clearance does not keep pace with
endogenous urea production despite more than adequate
urine output. BUN continues to rise. Later in the diuretic
phase, BUN decreases, and azotemia eventually disappears.
Because glomerular filtration and subsequent production of
urine is the first mechanism to recover, total body fluid and
electrolytes may be depleted if replacement is inadequate.
To achieve the goal of normovolemia with electrolyte and
acid-base balance, astute monitoring is essential. Tubular
reabsorption returns next and contributes significantly to the
overall improvement in renal function.
The recovery phase from ATN in infants and children is
usually longer than in adults; 2 to 4 months may elapse
before normal renal function returns. BUN and urine
laboratory values gradually return to normal, reflecting a
progressive restoration of GFR and tubular function. The
level of recovery is variable, especially if preexisting
medical problems or renal insufficiency are present. Some
patients may be left with some residual renal impairment,
such as a permanent decrease in renal function or a urine
concentrating defect. The primary cause of death during the
recovery phase is infection or complications related to the
primary illness that initially compromised renal function.
Nonoliguric ATN, increased urine output with elevated
BUN and creatinine levels, is commonly associated with
nephrotoxic agents, asphyxia, respiratory distress, and
congential anomalies in the newborn. Compared with
patients with oliguric ATN, patients with nonoliguric renal
failure have lower overall mortality rate. '4 Nonoliguria
facilitates fluid and nutritional management of ARE
Emergent Management. Currently, no therapy is
known to modify the course of intrinsic renal failure.
Management strategies for ATN are aimed at improving
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renal perfusion and removing the cause of the disease by
discontinuing the nephrotoxic medications. Some innovative medical therapies have been evaluated for reversal of
ATN, but none have proven effective in controlled human
studies. Therapy for non-ATN intrarenal failure may involve
steroids or other immunomodulating agents. To date, the
mainstay of therapy is supportive care and control of
complications during renal compromise. 19

Postrenal Failure
Pathogenesis. Postrenal oliguria results from an anatomic obstruction of the urinary tract and is uncommon in
children. Box 21-3 outlines the causes of postrenal oliguria,
which may result from obstruction of any portion of the
urinary system. Most urinary obstruction in children is the
result of a congenital problem. Obstruction increases
intratubular pressure and leads to a reduction in RBF and
GFR that is manifested by a decrease in urinary output.
Oliguria will not occur from unilateral obstruction unless
the contralateral kidney is absent or nonfunctional. In
children, especially infants, who present with oliguria alone,
the first consideration is to determine that the major
anatomic components of the renal system (arteries, veins,
ureters, and bladder outlet) are intact.
Anomalies in the urinary collecting system may restrict
urinary flow from the bladder. Urinary reflux can ultimately
increase hydrostatic pressure in the collecting ducts and
renal tubules. When hydrostatic pressure in Bowman's
capsule increases, GFR decreases, tubular reabsorption is
enhanced, and oliguria or anuria develops. Eventually, renal
insufficiency results from tissue atrophy.
Bilateral anatomic obstruction occurs more often in male
infants than in females because of congeni tal posterior
ureteral valves and/or urethral strictures. Postrenal oliguria
may occur in older infants who have an undiagnosed solitary
kidney that becomes acutely obstructed. The obstruction
may be the result of an anatomic abnormality or an acquired
intraluminal lesion, such as renal calculi, blood clot,
inflammation, and edema. Extrinsic compression of the
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urethral outflow tract by lesions such as periurethral abscess,
trauma, Wilms' tumor, or a neuroblastoma are rare but must
be suspected in any patient with acute bilateral obstruction.
Clinical Presentation. The infrequent occurrence of
obstructive uropathy in the critical care setting does not
diminish its importance because early diagnosis and correction can avert permanent parenchymal damage. Diagnostic
imaging techniq ues are used to determine the cause.
Children with postrenal oliguria often present with abdominal or flank pain. A palpable mass may suggest an
obstructed urinary system, although a mass may be associated with other causes of ARF, such as renal vein thrombosis
or polycystic kidney disease. A renal mass associated with a
palpable bladder, palpably enlarged kidneys, or abnormal
urinary stream in a male may suggest urinary tract
obstruction from posterior ureteral valves. 2o Young children
may be completely asymptomatic except for failure to
thrive. Analysis of urinary sediment associated with obstruction is usually normal unless a coexisting infection exists.
Ultrasonography can demonstrate bladder thickening, hydronephrosis, dilation of the posterior urethra, and posterior
urethral valves. The diagnosis is made by voiding cystourethrography. which delineates the val ves and confirms
findings necessary for surgical intervention.
Several invasive radiographic and urodynamic studies
can be used to assess the function of the renal system
through the detection of disturbances in voiding patterns and
structural defects. These include intravenous pyelography
(IVP), voiding cystourethrography (VCUG), renal angiography, and renal scan.
Emergent Management. The goal of treatment is
decompression of the urinary collecting system by removal
of the obstruction or by urinary diversion. Relief of the
obstruction may result in a marked increase in urine
formation because of increased REF and improved tubular
function. Immediate success of ablative therapy of the
obstruction can be demonstrated on VCUG, but resolution
of hydroureteronephrosis and reflux generally takes longer.
Periodic follow-up is required to detect delayed obstruction
caused by stricture or loss of bladder tone. 16
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Box 21-3

Postrenal Causes of Oliguria

Ureteral

Intrinsic
Stones
Blood clot
Ureteropelvic stenosis
Bladder

Blood clots
Neurogenic bladder
Urethral

Posterior urethral valves
Urethral stricture

Extrinsic
Tomor
Sorgical ligation
Radiation injury

As outlined in Table 21-6, altered renal function affects all
body systems. Clinical presentation depends on the length
and acuity of the disease process.
Maintenance of Intravascular Volume. During
ARF the regulatory factors that control intravascular volume
status may be inadequate. The primary goal in fluid
management in ARF is to achieve and maintain normal
intravascular fluid volume. Because children with ARF have
a spectrum of volume disorders, initial and ongoing
estimation of fluid status is important. This is monitored by
accurate intake and output assessment, weights, vital signs,
capillary refill, central venous pressure monitoring, and
presence of edema. Laboratory data including serum sodium
and FEN" also help determine fluid volume status.
Children with ARF and decreased intravascular volume,
despite an oliguric or anuric state, require prompt fluid
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21·6 Management Priorities
During Acute Renal Failure

TABLE
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manifested
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Metabolic acidosis
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Infection
Disruption in oxygen delivery,
coagulation
Pulmonary edema
Dysrhythmias, hypertension

resuscitation. A delay in therapy jeopardizes renal function
recovery, as well as other functions of major organs.
Conversely, ARF associated with volume overload requires
fluid restriction and diuretics. Hypervolemia is a common
manifestation of ARE Hypertension may result from the
increase in circulating volume and interplay of the reninangiotensin system.
Deteriorating renal function may also result in excessive
urinary output. Management strategies such as restricted
fluid intake and diuretic therapy contribute to a fluid volume
deficit. As a consequence, cardiac output and tissue perfusion may be impaired.
Maintenance fluid requirements are adjusted to the
evolving needs of the patient. Daily total output determines
intake. Daily intake includes oral and parenteral fluids.
blood products, and medications. Often overlooked intake
can include fluid for catheter or medication flushes and
endotracheal tube lavage with suctioning. This intake can
equal as much as 12 mUkg/day of fluid intake and as much
as 2.4 mEq/kg/day of sodium. 14
Daily output is the sum of urine output and insensible
losses, which include gastrointestinal, respiratory, and
evaporative losses. Other factors that influence precise
calculation of fluid needs include the humidity and temperature of the environment and the use of phototherapy,
warming devices, and mechanical ventilation. Sensible fluid
output includes urine, stools, emesis, tube drainage, ostomy
output, and fistula output. Insensible water output equals
approximately 750 mIlm1/day. Net insensible water loss is
approximately equal to one third of calculated maintenance
rate. Patients receiving humidified air have less insensible
losses; those with bums, tachypnea, or receiving thermal
warming therapy have higher losses. Fever increases a
patient's insensible water losses by 12.5% per degree
Celsius (C) above normal. 14 Although fluid balance can be
calculated and is monitored closely, ongoing assessment of
tissue perfusion is the best indicator of adequate intravascular volume.
Maintenance of Electrolyte Balance. Electrolyte
disturbances commonly occur during the course of ARF.

Alterations are related to changes in volume status and the
inability of the kidneys to regulate electrolyte balance.
Because the kidneys are responsible for 90% of potassium
excretion, hyperkalemia is a major life-threatening complication of ARF. The catabolic state of the patient further
elevates serum potassium. Because of the potentially lethal
nature of hyperkalemia, patients at risk require ongoing
assessment of laboratory values along with cardiac rhythm
assessment (see Chapter 12).
Attention must be given to the administration of
potassium-containing intravenous fluid, medications (aqueous penicillin G contains 1.7 mEq potassium per I
million units) and cold stored blood (blood stored for
10 days can contain up to 30 mEqlL of potassium).
Endogenously produced potassium in clinical states of
trauma, bums, and tumor lysis syndrome can increase serum
potassium.
Sodium imbalance is also prevalent in ARE Most
commonly, hyponatremia is iatrogenic, induced from overestimation of free water needs and inability to diurese excess
free water. Important to consider is the variability in the
amount of sodium excreted by the kidney. Induced diuresis
or the diuretic phase of nonoliguric renal failure can
significantly increase urine sodium loss.
Ongoing monitoring of serum sodium levels and urine
sodium excretion determines the appropriate type and
volume of fluid intake. Hyponatremia may deleteriously
affect the clinical status and prognosis of the patient with
ARE Serum sodium levels of 130 mEqlL or less indicate a
need for further fluid restriction. In a patient with a serum
sodium level of 120 mEqlL or less who is not responding to
fluid restriction or experiencing mental status changes, 3%
sodium chloride administration (513 mEqlL) is considered.
The calculation is for infusing 3% sodium chloride is as
follows:
mEq of Na

= (125 -

observed Na) x kg body weight x 0.6

Three percent sodium chloride is administered slowly
over 2 to 4 hours. An estimate of 12 ml/kg of 3% sodium
chloride will increase the serum sodium concentration by
10 mEqlL. 14
Hypocalcemia and hyperphosphatemia are additional
electrolyte disturbances that occur rapidly in ARE Phosphate levels increase because of the limited ability of the
kidney to excrete phosphate. This response occurs simultaneously with catabolic increases in phosphate released from
tissue. Hypocalcemia in ARF has multiple causes, including
hyperphosphatemia, vitamin 0 3 deficiency, and hypoalbuminemia. Ionized calcium levels must be monitored to
evaluate the unbound form of calcium, which determines
physiologic activity.
Parenteral or enteral calcium replacement therapy is
more efficient if hyperphosphatemia is managed first.
Elevated plasma phosphate concentrations result in the
precipitation of calcium phosphate in bone and soft tissues.
Reduction of the serum phosphate level is accomplished by
diminishing the absorption of phosphorus in the gastrointestinal tract. This usually results in an increase in the serum
calcium level. Limiting the intake of parenteral and enteral
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21-1 Daily Nutrient Intake Recommendations for the Child With Acute Renal Failure
Not Requiring Dialysis

TABLE
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sources of phosphate requires a thorough review of phosphorus content in all sources of intake.
Magnesium is another electrolyte that is affected by ARE
Commonly, patients with ARF have mild, asymptomatic
hypermagnesemia. Higher levels may be seen with injudicious use of magnesium-containing laxatives or antacids.
Hypomagnesemia can occur in patients with renal tubular
damage from nephrotoxic agents. Generally, this hypomagnesemia is asymptomatic, but if severe, it will result in
neuromuscular effects such as cramps, cardiac arrhythmias,
and seizures. 21
Maintenance of Acid-Base Balance. Impairment
of renal function results in the disturbance of acid-base
homeostasis. Metabolic acidosis is the predominant finding.
Renal tubular dysfunction results in the inability to reabsorb
filtered bicarbonate or regenerate bicarbonate used to buffer
the daily acid load 2J In a healthy person, dietary protein
metabolism results in daily generation of approximately I
mEq of fixed, nonvolatile acids per kilogram of body
weight. In ARF, inability to clear acids results in metabolic
acidosis. In uncomplicated ARF, the serum bicarbonate falls
by about I to 2 mEq!L/day. In hypercatabolic states, this
level can fall much faster. 21 The mild acidosis that
accompanies this isolated disturbance is compensated for by
the respiratory system. Disturbances in normal cellular
metabolism, caused by hypoxemia or altered tissue perfusion, result in anaerobic metabolism and lactic acid production. Other conditions such as ethylene glycol intoxication,
certain inborn errors of metabolism, diabetic ketoacidosis,
or the administration of medications may overwhelm renal
excretory capacity and worsen metabolic acidosis.
Before initiating treatment for metabolic acidosis, the
patient's ability to compensate for the imbalance is considered. Bicarbonate levels of 10 to 13 mEq!L may be managed
with administration of intravenous sodium bicarbonate.
Before administration, the clinical condition, including
current respiratory mechanisms and the potential effect of
sodium and volume bolus, must be evaluated. Severe
acidosis, particularly in an oliguric patient with fluid
overload, may prohibit administration of intravenous bicarbonate and may require emergent dialysis. 21
Maintenance of Respiratory Status. Complications of the respiratory system in children with ARF most
commonly are due to fluid retention with oliguria. This
condition may be demonstrated as pulmonary edema or
infection. Acute respiratory distress syndrome (ARDS) is
also a complication in critically ill patients with multiorgan

dysfunction syndrome (MODS) and ARE These children
require vigilant monitoring for respiratory distress and may
require intubation and mechanical ventilation.
Maintenance of Neurologic Status. A variety of
neurologic complications may occur. These patients may
exhibit symptoms ranging from mild myoclonus or muscle
twitching to seizures and uremic encephalopathy. Asterixis
and lethargy may be early signs of uremia. As ARF
progresses, the patient may demonstrate confusion, personality changes, seizures, and eventually a comatose state.
Generally, these symptoms respond promptly to dialysis. If
symptoms do not improve after initiation of dialysis, other
causes of mental status change must be considered, such as
a medication effect or a neurologic event. Seizures may be
due to uremia, hypertension, hyponatremia, or hypomagnesemia. Electroencephalogram abnormalities are common in
patients with uremic encephalopathy. These abnormalities
include loss of background alpha activity with the development of slow waves, progressing to diffuse slow wave and
spike activi ty21
Maintenance of Adequate Nutrition. Many disease processes precipitating or occurring simultaneously
with ARF place the child in a hypercatabolic state.
Children's nutritional needs are relatively large compared
with those of adults (Table 21-7). Normal infants have
twice the protein requirement of adults, which must be
maintained during critical illness to prevent a negative
nitrogen balance.! Studies in adults and children have
indicated that aggressive nutritional support decreases tissue
catabolism, which reduces the accumulation of acids,
nitrogenous wastes, and potassium. In addition, hypercatabolic states have been noted as a significant risk factor
for ARE 2t
Meeting a patient's nutritional requirements depends on
the function of the gastrointestinal tract, vascular access,
and severity of oliguria. Small and frequent enteral feedings
are the method of choice. Advantages to the use of the
enteral route include oral gratification, decreased risk for
septicemia because vascular access is not required, and
possible prevention of gut bacterial translocation.
When caloric needs cannot be met through the use of
enteral feedings, parenteral nutrition is necessary. With renal
replacement therapy, daily protein and caloric intake can be
generous (0.5 to I to g/kg/day of protein). If the BUN is
near 50, the patient may benefit from special "nephro"
hyperalimentation solutions, which contain essential amino
acids and various nonessential amino acids. Depending on
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the patient's serum electrolytes, solutions should contain
minimal sodium and no pOlassiumY In some cases,
especially in patients with oligoanuria, renal replacement
therapy may be necessary because of the high volumes of
fluid required to meet the child's nutritional needs, Daily
monitoring of electrolytes and frequent glucose monitoring
are required in the first days of parenteral nutrition.
Prevention of Infection. The patient with ARF is at
high risk for infection because of invasive monitoring and
catheters, surgical procedures, and a highly catabolic
metabolism. Between 50% to 70% of patients with ARF
develop infections, and administration of prophylactic
antibiotics does not appear to decrease the high incidence of
infection. The most common sites of infection are the chest,
urinary tract, and wounds. 21 Difficulty in meeting the
patient's nutritional needs compromises immune function.
In addition, the patient's ability to fight infection is
minimized as a result of defective chemotaxis, absolute or
relative granulocytosis, relative lymphopenia, and impaired
cell-mediated immunity. The need for indwelling bladder
and central venous catheters is reevaluated daily in light of
the high risk for infection.
Because manifestations vary, infection during ARF is
difficult to identify. Symptoms may include both hypothermia and hyperthermia. White blood cell count may be
elevated or diminished. Other subtle signs include tachycardia, tachypnea, lethargy, flushing, and localized inflammatory response. Surveillance cultures may be routinely
indicated.
Prophylactic antibiotics are not recommended. Aggressive treatment with appropriate antibiotics is indicated in the
case of proven infection. Dosage and frequency of antibiotics are based on renal function.
Maintenance of Hematologic Function. Hematologic complications in ARF include anemia, platelet dysfunction, bleeding disorders, and leukocytosis. Anemia
often results from failure of the kidney to produce erythropoietin and can occur as soon as 10 days after the onset of
ARF. Other causes of anemia include blood loss or
hemodilution from volume expansion.
Uremic platelets display defective aggregation and adhesion properties. Nitric oxide (NO) and prostacyclin, agents
that inhibit platelet aggregation, may be increased in uremia,
thus contributing to platelet dysfunction.
Bleeding disorders, in the presence of uremia, are
primarily attributed to platelet dysfunction and may be
potentiated by increased capillary fragility and anemia. The
platelet count is usually normal, but thrombocytopenia may
be present in patients with HUS or disseminated intravascular coagulation (DIC). Platelet dysfunction can be detected by a prolonged bleeding time, with the prothrombin
time and partial thromboplastin time remaining normal
except in the presence of DIe. The bleeding tendencies of
uremia can be corrected with red blood cell transfusions,
dialysis, or a vasopressin analog such as desmopressin
(DDAVP). Leukocytosis generally is due to infection or
acute catabolic stress 21 Monitoring for bleeding, especially
from multiple access sites, is imperative in this population.
Laboratory Studies. Although physical findings are

the best guide to adequacy of fluid volume status, several
laboratory tests support the presence of ARF.
Urinalysis. A urinalysis provides invaluable information when evaluating a patient with ARF. Intermediate
values may be found in patients with postrenal failure or in
those transitioning from prerenal failure to ATN. Use of
potent diuretics can invalidate these laboratory findings for
up to 24 hours. A urine dipstick with trace to I + protein may
be consistent with prerenal azotemia or ATN, but larger
amounts of protein suggest an interstitial nephritis or
glomerulonephritis. However, in an acute episode of congestive heart failure or malignant hyperthermia, significant
proteinuria may also be present. Urine dipstick tests do not
distinguish between hemoglobin and myoglobin. Therefore
a strong presumptive diagnosis of rhabdomyolysis with
myoglobinuria can be made by demonstrating a hemepositive urine dip in absence of red cells or on the
supernatant of the urine, an elevated serum phosphokinase
and aldosterone, and an normal serum color without
evidence of hemolysis. The presence of glucosuria when the
serum glucose level is normal may suggest a proximal
tubular lesion. However, falsely high values may occur in
the presence of urine protein, glucose, radiographic dyes, or
other high-molecular-weight substances 22
Osmolality. Although a considerable overlap can exist
among individuals, prerenal failure is usually associated
with a urine osmolality greater than 500 mOsmIL, whereas
parenchymal failure is associated with a urine osmolality of
less 400 mOsmIL.2 1
Specific Gravity. With prerenal azotemia, hepatorenal
syndrome, and early acute glomerulonephritis, the urine
specific gravity is generally elevated at greater than 1.020.
Patients with postrenal failure and ATN lose the ability to
concentrate urine and generally have a specific gravity
similar to that of plasma, which is approximately 1.010.
Urine Sediment. In prerenal failure, hyaline casts are
present in large numbers. Red cells and red cell casts may
indicate glomerulonephritis or vasculitis. Heavy oxalate or
hippurate may be noted in ethylene glycol ingestion. In
drug-induced interstitial nephritis, proteinuria, urinary sediment with hematuria (gross or microscopic), eosinophiluria, and casts may be found. In ATN, the classic urine
sediment is brown, containing renal tubular casts, renal
tubular cells, and coarsely granular casts 21 Infectious
causes of intrinsic nephritis often have white blood cell casts
in the sediment, indicating renal inflammation.
Serum BUN/Creatinine. The BUN-to-serum creatinine (Cr) ratio is normally 10: I. In prerenal failure, this ratio
may reach levels of 60: 1.
Antineutrophilic Cytoplasmic Antibody. The antineutrophilic cytoplasmic antibody (ANCA) is a sensitive
marker for detecting ARF caused by Wegener's granulomatosis, polyarteritis nodosa, and approximately 80% of cases
previously labeled "idiopathic" crescentic glomerulonephritis. ANCA may have a pathogenic role in activating
leukocytes and the resultant inflammatory injury, leading to
renal failure.
Without all supporting data available, prerenal azotemia
can be suspected if urine specific gravity is greater than
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1.016, urine sodium concentration is less than 20 mEqlL,
and the B UN/Cr ratio is greater than 20: I. The B UN/Cr ratio
can also be elevated in postrenal failure.
Imaging Techniques. The diagnosis of ARF is generally made based on clinical findings and laboratory results.
Imaging may determine the correct diagnosis when the
cause of ARF is unknown. Table 21-8 provides the various
imaging procedures that may be used to diagnose ARE
Plain Films of the Abdomen. Plain films are the
least expensive and most readily accessible imaging
technique. This procedure can document the size of the
kidneys, thus giving information on the duration of the
renal failure. Chronic renal failure is associated with
small kidneys, and enlarged kidneys may suggest an acute
process.
Gray-scale Ultrasonography. Gray-scale ultrasonography (US) is useful in detecting kidney and bladder
size. This imaging technique is generally accepted as
a method to exclude renal obstruction as the cause of
ARE ]t is also very accurate in detecting hydronephrosis.
False-negative results may be seen in patients with early
renal obstruction and dehydration. Echogenicity of the
kidney can also be evaluated with gray-scale US. Most
patients with ARF have normal kidney echogenicity
and parenchymal thickness. A decrease in parenchymal
thickness may be associated with underlying chronic
nephropathy.

IE

TABLE 21-8
Imaging Procedures in
the Diagnosis of Acute Renal Failure

Purpose

l~ifJat plate of the abdomen
\!t[:"or
nephrotomography
!if1';·

i:~'··

r:Ultrasonography

~!t
~!~lntravenous urography

~( with postvoiding film
hi

1i:;"

~i:Computed axial

!i!

tomography

For kidney size, calcification.
calculi, abnormal gas
collection
For kidney size, cysts, calculi,
hydronephrosis. mass
For kidney size. function,
hydronephrosis. hydroureter,
bladder size. bladder outlet
obstruction
Bener evaluation of retroperitoneal lesions: for renal
trauma, renal masses, site

of obstruction
For blood flow and function,
gallium-67 scan for acute
interstitial nephritis
For renal trauma, vascular
occlusion, polyarteritis
nodosa. renal vein
thrombosis
q,-:
','From Cadnapaphomchai P. Alvapati RK. McDonald FD: Differenlial
;;~diagnosis of acule renal failure. In Jacobson HR. Striker GE, Klahr S.
~:'eds: The principles and practice of nephrology. ed 2, St Louis, 1995.
!,[Mosby, p 562.
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Duplex Doppler Ultrasonography. Renal dynamics differ in prerenal, renal, and postrenal ARF. Duplex
Doppler US is capable of measuring the renal resistive
index, which can differentiate between the different categories of renal failure. This technique provides more information than the morphologic view of the kidneys. This device
is valuable in distinguishing between prerenal ARF and
ATN. Most patients with prerenal failure have normal
parenchymal flow, whereas patients with ATN demonstrate
markedly abnormal flow profiles and have increased pulsatility with loss of diastolic flow. The course of ATN may be
monitored with duplex Doppler US. Improvement on
Doppler flow can be seen before clinical signs of function
recovery. Duplex Doppler US is also useful in detecting
significant urinary tract obstructions.
Both gray-scale and duplex Doppler US provide information useful for diagnosis and management of specific
pathologic conditions such as hepatorenal failure, HUS,
acute renal thrombosis, and acute renal artery thrombosis. 23
Unenhanced Computed Tomography. This form
of radiologic testing adds clinically important information in
patients with indeterminate sonograms. Dilated ureters can
generally be located to exact location of obstruction.
Computed tomography (CT) can be very useful in detecting
renal calculi 23
Magnetic Resonance Imaging. ]n ARF, altered
corticomedullary changes can be noted on magnetic resonance imaging (MRI), although these changes are nonspecific. ]n suspicious postrenal failure, MRI is useful in
detecting obstruction and assessing hydronephrosis. Renal
perfusion can be assessed using bolus injection of paramagnetic media. MRI may be preferred to contrast-enhanced CT
in patients with ARF because no significant nephrotoxicity
has been reported related to paramagnetic contrast agents
used in common clinical practice?3
Excretory Urography. This imaging technique can
provide information regarding renal anatomy, chronicity of
disease, and presence of urinary tract obstruction with the
use of contrast. Dense urographic nephrogram and delayed
opacification of the dilated collecting system are indicators
of postrenal failure. Similar findings are also noted in
prerenal failure, acute glomerulonephritis, renal vein thrombosis, and occasionally ATN. Most patients with ATN and
acute bacterial nephritis show an immediate, dense, persistent nephrogram. Striated urographic changes are seen
primarily in acute pyelonephritis. ]n acute occlusion of the
main renal artery, the nephrogram is either absent or
extremely faint. Similar findings are appreciable in acute
cortical necrosis?3
Contrast-Enhanced
Computed
Tomography.
Contrast-enhanced CT is much more reliable than excretory
urography in detecting structural deformities of the nephrogram and requires considerably less contrast material.
Contrast-enhanced CT can generally identify acute renal
obstruction, both intrinsic and extrinsic. It is helpful in
identifying hydronephrosis, nephritis, and mass lesions such
as abscesses?3
Angiography. This imaging technique has been valuable in evaluating arterial or venous occlusion as a cause for
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ARF. Angiography demonstrates a characteristic pattern of
acute cortical necrosis and thromboembolic disease, both
arterial and venous. In many clinical situations such as
these, Doppler US, CT, and MRl have become the preferred
diagnostic tool. However, abnornlalities that directly involve the vessels create unique angiographic patterns and
are best diagnosed by angiography. There are parenchymal
diseases that indirectly alter blood flow, resulting in
angiographic findings, which are generally nonspecific.
Patchy or diffusely decreased nephrograms occur in many
disease states, such as ATN, acute glomerulonephritis, and
interstitial nephritis. 23
Iodinated intravenous contrast agents, which are necessary for excretory urography, contrast-enhanced CT, and
angiography, are nephrotoxic and pose a serious clinical
problem. Iodinated contrast media account for about 10% of
all hospital cases of renal failure, with azotemic patients at
greatest risk. Excretory urography, contrast-enhanced CT,
and angiography are only performed in the azotemic patient
when US, unenhanced CT, and MRI are unavailable. 23
Renal Biopsy. In cases for which the cause is unknown, renal biopsy can be a useful adjunctive tool for
diagnosis, intervention, and prognosis. The diagnoses for
which specific treatments are indicated include glomerulonephritis, vasculitis, and AIN. 18
Renal biopsy in the patient with ARF carries significant
risk because of the invasiveness of the procedure. These
patients are at increased risk for postbiopsy bleeding as a
result of coagulation disorders (including platelet dysfunction and abnormal platelet vessel wall interaction) and
anemia. Arterial hypertension and dialysis compound the
risk. Before renal biopsy, it is important to check the
prothrombin time, partial tlrromboplastin time, platelet
count, and bleeding time.
General postbiopsy patient care includes prone positioning on a rolled sheet or towel to promote hemostasis, strict
bed rest for 24 hours, frequent vital sign monitoring, urine
monitoring for macroscopic hematuria, and hematocrit
check. IS In renal disease, as with others, the least invasive
mode of diagnosis is the preferred diagnostic test.
Renal Pharmacology. Several issues are considered
when discussi ng pharmacology in renal failure. First,
various degrees of renal insufficiency may alter the kidney's
ability to clear medications, and toxic levels may develop.
Second, the initiation of renal replacement therapy may
further alter the therapeutic level of medications. Finally,
several medications can be considered to enhance renal
function to establish homeostasis.
Effect of Renal Insufficiency on Drug Elimination.
Renal insufficiency may alter elimination of many drugs in
the critically ill patient. With decreased function, the amount
of a drug normally eliminated by the kidney is decreased.
Drugs that are metabolized in the liver may require renal
function to eliminate metabolites. In renal insufficiency,
RBF and the ability of the kidney to extract drug are
decreased; therefore the total amount of drug excreted per
unit of time decreases.24 Consequently, inefficient drug
clearance may lead to metabolite accumulation and production of toxic effects. Adjustments to dosages may be

~

Box 21-4

Drugs Requiring Dosage Adjustment
in Reduced Renal Function

Acetaminophen
Acyclovir
Amikacin
Amphotericin B
Ampicillin
Ceftazidime
Cefuroxime
Digoxin

Diphenhydramine
Gentamycin
Imipenem
Penicillin G
Piperacillin
Ranitidine
Tobramycin
Vancomycin

required to maintain a steady therapeutic state. The goal is
to attain an effective drug level while avoiding toxicity.
Those drugs that have a wide therapeutic range may need no
adjustment because levels can fluctuate without reaching
toxicity.
Different methods can be used for adjusting medication
dosages in ARF. One method of dosage adjustment is to
deliver a loading dose to reach peak serum concentration,
followed by delivery of subsequent usual maintenance doses
at intervals determined by the elimination half-life of the
medication. 25 However, this approach can result in extended
intervals between doses, with possible subtherapeutic levels.
Another method of medication adjustment is to decrease
the dosage used with normal renal function and deliver the
medication at the usual intervals. This approach may
provide a more steady state of the drug. In addition, this may
be more the accepted method of dosing medications with a
narrow therapeutic range?5 Because of the pharmacokinetics of each drug, it is wise to consult the pharmacology
references for the proper dosage. Box 21-4 gives examples
of the drugs that require adjustments in renal insufficiency.
Many drug formularies determine the adjusted dosages of
medications according to the amount of the calculated
creatinine clearance.
Effect of Renal Replacement Therapies on Drug
Disposition. All renal replacement therapies affect the
elimination of drugs. The extent to which the drug is
dialyzed determines whether supplemental doses are necessary. The dialyzability of the drug is dependent on several
factors. The molecular size of the drug affects its ability to
pass through the membrane. Generally, small molecular
weight particles pass through the membrane and are
dialyzed. Another factor is protein binding of a drug, which
is the amount of drug secured to protein in the body.
Nonprotein-bound medication is available for dialysis.
Distribution affects dialysis in that a drug with a large
volume of distribution is less likely to be dialyzed.
Solubility is a factor because drugs with high water
solubility are more likely to be dialyzed because the
dialysate is an aqueous solution. Finally, plasma clearance
affects dialyzability of the drug. Plasma clearance is the sum
of the renal and the noorenal clearance. When nonrenal
clearance is high, the drug is less likely to be dialyzed?6
Table 21-9 gives examples of some of the drugs that are
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21~9 Considerations for Drug Prescription in Renal Failure: Supplement for Hemodialysis,
Special Considerations for Peritoneal Dialysis and Continuous Renal Replacement

TABLE

Hemodialysis

•
••
••
0
0
0

•

*.
*
**
.*
Conventional 0
Permeable membrane.*
0
*.
**
'12 dose**

UK
0
0

O'

Hemofiltration

+
0
0

0
0
0

o·
o·

o·
o·

++

++

++
++

++
++

3.5 mg/kg/day

++

+
+

O·

0*

++

++
0
0

UK
O·
O'

0
0

0*
0*
0

UK

UK

*.

UK

Peritoneal Dialysis

UK
0*

O'
O'
0
0

UK
0

UK
O'

UK
O'

NA

0
0*
0
0
75% ql2h

0
0
0
'12 dose
0
*
Yes

Likely to be removed
Likely to be removed

UK

UK

O'
O'

UK
UK

, ,~apted from Swan S, Bennett W: Use of drugs in patients with renal failure. In Schrier RW, Gottschalke CW, eds: Diseases of the kidney, ed 6, vol Ill,
ii:!!!J.oston, 1997, Little, Brown, pp 2963-3017.
1-.30% q24h; ++. dose for GFR <10 (dose for GFR 10-50 mVmin); *, ,'" normal dose after dialysis; **. dose after dialysis; 0*, unlikely; UK, unknown.

affected by the different types of renal replacement
therapies.
Drugs That Enhance Renal Output. Several agents
are available to enhance renal output in the presence of renal
disease. Table 21-10 outlines the more common agents
employed in the pediatric intensive care unit (PICU).
Loop Diuretics. Loop diuretics are the most common
diuretics used in the PICU. They are often prescribed to
promote urine output and to facilitate the change of oliguric
to nonoliguric ARF. 27 Loop diuretics inhibit the sodiumchloride co-transport mechanism in the thick ascending limb
of the loop of Henle. where 20% to 30% of sodium
reclamation occurs?8 Furosemide. a loop diuretic. also is
thought to reverse decreased GFRs?9 Furosemide is mainly

excreted in the kidney, whereas bumetanide undergoes
extensi ve hepatic metabolism and, of the two, is less likely
to be excreted. In addition, bumetanide appears to have a
more substantially favorable therapeutic index. When a
higher dose is required, it offers a substantial improvement
in the margin of safety?8
Adverse consequences are due to the effects of drugelectrolyte imbalance. fluid depletion, and acid-base balance. Ototoxicity occurs as a result of repeated doses,
especially in the presence of renal insufficiency. Newborns
do not eliminate loop diuretics efficiently because of
decreased renal clearance, which can contribute to the
prolonged half-life of the drug seen in early infancy.30 Rapid
fluctuations of fluid and electrolytes may be improved by
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TABLE 21·10
llherapeutic
i!i[tlass (Drug)

Drugs That Enhal:lce Renal Function

Use

Mechanism of Action

Elimination

Nursing Considerations

Management of edema
a"ociated with congestive heart failure
and hepatic or renal
disease.

Inhibits reabsorption of
sodium and chloride in
the ascending loop of
Henle and distal renal
tubule, thus causing
increased excretion of
water, sodium chloride,
magnesium, and calcium.

80% of IV dose
excreted in urine
within 24 hours; the
remainder is eliminated by other nonrenal pathways,
inclnding liver
metabolism.

Rate of administration is 0.5 mgt
kg/min; maximum infusion rate
is 4 mg/min. Adverse reactions
include hypokalemia, hyponatremia, dehydration, and
potential ototoxicity and
hearing loss.

Management of edema
secondary to congestive heart failure
or hepatic or renal
disease, including
nephrotic syndrome,

Inhibits reabsorption of
sodium and chloride in
the ascending loop of
Henle and proximal renal
tubule, thus causing
increased excretion of
water, sodium, chloride,
magnesium, calcium, and
phosphate,

Partial metabolism
occurs in the liver;
unchanged drug is
excreted in the
urine (50%),

Larger doses may be necessary in
patients with impaired renal
function to obtain the same
therapeutic response: light
sensitive. may discolor when
exposed to light. Adverse reactions include hyperglycemia,
hypokalemia, hyponatremia,
decreased uric acid excretion,
increased serum creatinine,

Promotion of diuresis
in the prevention or
treatment of oliguria
or anuria caused by
acute renal failure.

Increases the osmotic pressure of glomerular filtrate,
which inhibits tubular
reabsorption of water and
electrolytes and increases

Primarily unchanged in
urine by glomerular
filtration.

In-line 5-micron filter set should
always be used for mannitol
infusion with concentrations of
20% or greater, crystallization
may occur at low temperatures;
coutraindicated in severe renal
disease; adverse effects include
circulatory overload, congestive hean failure, hyponatremia, hypokalemia,

i"
~!i-oop Diuretics
Furosemide

I

~'f~ ..

Il.~

~'"
~

iJ&~:.'

~umetanide

IlliL

&,
Ij;
,~

~rf:

~I'{
~Osmotic Agents

it~i.iannitol
!t~~,

Ii'

I
li!':[

II!"

"",

'"'po,

from Bell C, Simon D. Sovcik J: Children'sformlliary handbook. Hudson, 1999, Lexi-Comp.
Intravenous.

if!¥.

using loop diuretic infusions rather than frequent doses to
maintain a steady state. This manner of delivery has proven
to have a greater cumulative diuretic effect with lower
doses, thus avoiding the effects of toxic levels.2 s .30.31
Funhermore, potential hypotension with bolus doses is
avoided, and hemodynamic stability is maintained. Regardless of the dosing, diuretic tolerance develops with prolonged use. The distal tubule is thought to be the site of
action responsible for development of tolerance, although
the mechanism is not known. Care is taken III using
increased doses in the presence of tolerance to avoid
toxicity.
An interesting nonrenal effect of the loop diuretics is an
improvement in pulmonary compliance in ventilated patients, which is thought to be a result of a variety of factors,
although the exact mechanism is unknown 30 Occasionally,
furosemide is administered as an aerosol to infants with
bronchopulmonary dysplasia to increase tidal volumes. This
action may provide an additional benefit in children with
respiratory distress secondary to fluid retention in ARE

Continued

Osmotic Diuretics. Mannitol is the principal osmotic diuretic used in the clinical setting. Mannitol not
only acts as an osmotic agent in the proximal tubule to
inhibit the reabsorption of water; it also increases renal
filtration pressure and causes a solute diuresis. Because
of the large fraction of filtrate normally reabsorbed from
the proximal tubule, the distal tubule panially attempts to
compensate for this loss. A profound diuresis can be
attained by combining mannitol with a more distally
acting diuretic. When compared with doses administered for cerebral edema, mannitol doses for ARF are
smaller and more freq uent to achieve the desired diuretic effect. Because acute mannitol toxicity is directly
related to its influence on extracellular osmolality, frequent measurement of serum osmolality during therapy
is important. 24 Care is taken in the use of osmotic diuretics in the presence of decreased renal function. Without elimination, accumulation can occur, leading to volume overload, hypematremia, and hyperkalemic metabolic
acidosis.2 8
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Drugs That Enhance Renal Function-cont'd

1w'

1il1herapeutic
~:C1ass (Drug)
"';',.

Use

Mechanism of Action

Elimination

Nursing Considerations

70%-90% excreted
unchanged in the
urine; enterohepatic
recycling.

When metolazone is used in combination with other diuretics.
there is an increased risk of
azotemia and electrolyte depletion; metolazone may cause
increased digoxin toxicity;
adverse reactions include hypokalemia. metabolic alkalosis.
hyperglycemia. and tinnitus.

Metabolized in the
liver. urinary and
biliary excretion.

Diuretic effect may be delayed
2-3 days; when combined with
angiotensin-converting
enzymes inhibitors (e.g.• captopril) may additively increase
the serum potassium; may
decrease digoxin clearance and
allenuate its inotropic effects;
adverse reactions include
arrhythmia, hyperkalemia,
dehydration. and hyponatremia.

Metabolized in the
plasma. kidneys. and
liver (75% to inactive metabolites.
25% to norepinephrine); metabolites are
excreted in the urine.

Administer into a large vein to
prevent the possibility of
extravasation; adm inistration
into an umbilical arterial
catheter is 110t recommended.

t¥.!!
~j,Thiazides
!ii<j,~

~i'Metolazone

fF·

t~1

I

ll:'f

~;:

~('

Treatment of edema in Inhibits sodium reabsorption
congestive heart
in the distal IUbule.
causing increased excrefailure and nephrotic
tion of sodium and water.
syndrome. especially
in patients with
as well as potassium and
impaired renal
hydrogen ions.
function.

lIni

jii!~

TIr'

~;i'

r.Wotassium-Sparing Agents
~~$pironolactone Management of edema
!l!i:
~[:
associated with excessive aldosterone
tiC
excretIOn; hyper~!';
tension.

If
~~l;·.:'

~~::
i!;~

W~,

W;';:

HfE~

Competes with aldosterone
for receptor sites in
the distal renal tubule.
increasing sodium. chloride. and water excretion
while conserving potassium phosphate and
hydrogen ions.

l®:.

~E
Iii'
!!;adrenergics
li~pamine
~;t::

m~!f'

~m:
'J!J;
ij"llJl'

~W'O

~c

i\~

Both systemic and
Lower doses of 2-5 Ilg/kgl
local renal dopamine
min are mainly dopamiactions used to
nergic stimulating and
enhance renal
produce renal and mesenoutput; systemically.
teric vasodilation.
dopamine increases
cardiac contractility.

Thiazides. Thiazides are not commonly used in the
PICU because they are exclusively enteral formulations and
have a relatively low ceiling of maximal diuretic effect. The
site of action overlaps with that of the loop diuretics 24
Metolazone also has effects in the proximal renal tubule.
therefore making it the favored drug in this class. Metolazone may be useful in combination with the loop diuretics to
achieve a greater diuretic effect or to overcome diuretic
tolerance.
Potassium-Sparing Agents. Potassium-sparing agents
administered independently may have little effect in increasing water excretion. but in combination with more proximally acting diuretics. they may effect a substantial increase
in the excretion of sodium and water,z4 Spironolactone has
a much longer half-life than other diuretics and is the more
common agent used in the PICU.
Dopamine. Dopamine has been found to be an effective
agent to enhance renal function. Renal dose dopamine. 2 to
5 Ilg/kg/min. is used when the desired effect of drug
infusion is to stimulate dopaminergic (DA) receptors
without altering blood pressure. The DA receptors are in the
renal arteries and the afferent arterioles. When stimulated,

the receptors cause renal vasodilation, resulting in improved
RBF. GFR, sodium excretion. and creatinine clearance 32
Dopamine also exerts a synergistic action with furosemide
via vasodilation and reversal of ischemia; thus furosemide
transport to the loop of Henle improves, subsequently
increasing urine output. The combination of low-dose
dopamine and furosemide can result in conversion of
oliguric to nonoliguric renal failure if adequate intravascular
volume and cardiac output are present.
An increase in urine flow does not represent an improvement in renal function, nor effect the natural history of the
disease that precipitated the renal failure. However, enhancement of urine output may be valuable in the management of hyperkalemia and fluid overload. 33

RENAL REPLACEMENT THERAPY
The rationale for initiating renal replacement therapy
includes the need to remove excessive intravascular volume
and correct significant alterations in electrolyte or acid-base
balance. Progressive hypervolemia may result in hypertension and, in the patient whose condition is previously
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Advantages and Disadvantages of Different Forms of Renal Replacement Therapy
Advantages

Disadvantages

Gradual process
Can be used in hemodynamically unstable patients
Vascular access beyond peripheral IV not required
No complex equipment needed
Inexpensive
o heparinization required
Greater mobility

Catheter malfunctions
Hyperglycemia
Slow clearance of fluid and electrolytes-not helpful
in hyperkalemic crises
Risk for catheter-related sepsis, peritonitis
Requires use of abdomen-not optimal status post
laparotomy
Large protein loss
Failure of treatment results in worsened hypervolemia
Fluid/electrolyte removal less controllable
Diminished ventilation with decreased diaphragm
compliance

Very effective with hypervolemia
Can be used in hemodynamically unstable patients
Continuous treatment allows constant readjustment in
therapy
Relatively inexpensive
Allows parenteral nutrition to be optimized without
risk of hypervolemia
Can add dialysis

Access complications: infection, clotting, blood leaks,
air emboli, bleeding
Requires vigilant monitoring
Heparinization often required
Not quickly effective with hyperkalemia
Hemofilter clotting requires immediate intervention

Quickly effective in fluid and catabolic overload
Intermittent therapy

Access complications: infection, clotting, bleeding
Requires special equipment and specially trained
personnel
Heparinization required
Fluid and electrolyte shift during therapy, hypotension
Disequilibrium syndrome

f.ftvvH, Continuous venovenous hemofiltration; IV, intravenous.
~-'

compromised, congestive heart failure and pulmonary
edema. Slow, steady increases in serum potassium eventually produce lethal cardiac dysrhythmias. Persistent metabolic acidosis contributes to neurologic deterioration. Other
electrolyte imbalances include hyponatremia, hypercalcemia, and an imbalance in the calcium-to-phosphorus ratio.
An elevation in BUN, with rapidly rising creatinine,
influences the decision-making process to initiate more
aggressive therapy. Inadequate nutrition delivery resulting
from fluid restriction required in the presence of limited
urine output has become a major indication to initiate renal
replacement therapy34
Treatment options, intended to mimic renal function,
include peritoneal dialysis (PD), continuous venovenous
hemofiltration (CYYH), and hemodialysis (HD). The benefits and limitations of each management option are
compared in Table 21-11. Determining the type of dialysis
to be used includes evaluation of hemodynamic stability,
cardiac performance, bleeding tendencies, the presence of
sepsis, respiratory issues, nutritional needs, cost, personnel
requirements, and local expertise. 3s
All renal replacement therapies function by diffusion or
convection. The components of the system include a
selectively permeable membrane separating the patient's
blood from a second compartment (Fig. 21-6). The membrane may be part of a dialyzer incorporated into an

extracorporeal circuit or it may be present in the patient,
such as the peritoneal membrane. The second compartment
may contain dialysate or form a simple reservoir that
collects ultrafiltrate from the plasma. Diffusion is the
primary mechanism of solute removal during dialysis. The
amount of solute removed depends on permeability of the
membrane, molecular weight of the solute, and the concentration gradient on both sides of the membrane. During
ultrafiltration, fluid is removed by the hydrostatic or osmotic
pressure gradient directed toward the second compartment;
solute is pulled with the water particles. This method of
solute removal (convection) is not as efficient at removing
small solute particles, such as urea.J 6

Peritoneal Dialysis
PD removes fluid and solutes slowly over 2 to 3 days.
Because of this time frame, the decision to initiate PD is
usually made early, when progressive deterioration in
patient status can be reasonably predicted. Earlier intervention is especially beneficial in some patients with multisystem organ failure, for example, in the patient with congenital
heart disease who develops ARF after cardiovascular
surgery. A study by Sorof and colleagues 3 ? suggests that
placing the PD catheter during cardiovascular surgery in
small infants and initiating PD within 24 hours of surgery
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Schematic representation of solute and fluid transport
across semipenneable membranes. A, Hemodialyzer. Plasma
concentration of small solutes (solid circles) in the blood inlet is
high. Because of the diffusive loss across semipenneable hemodialysis membrane (dotted line), plasma concentration in the blood
outlet is much lower. Thin arrow across the dialysis membrane
represents small amount of fluid loss (which is not necessary for
solute removal). High dialysate flow rate is necessary to maintain
the concentration gradient across the dialysis membrane. B, Hemofilter. Plasma concentration of small solutes in the blood compartment remains unchanged as blood travels the length of the fiber,
and is similar to their concentrations in the ultrafiltrate. Hemofiltration membrane (broken line) has relatively large pores, which
allow necessary removal of large volume of fluid (heavy arrow).
Replacement of fluid is infused into the blood outlet to lower
plasma concentration of solutes and compensate for fluid loss.
(From Cheung A: Hemodialysis and hemofiltration. In Greenberg
A, ed: Primer on kidney disease, ed 2, San Diego, 1998, Academic
Press, p 410.
Fig. 21-6

resulted in low complication rates and successful achievement of negative fluid balance.
PD can be successfully initiated in patients with limited
vascular access. In addition, because the removal of fluid
and solutes is accomplished in a slow manner, patients who
are especially sensitive to changes in vascular volume are
ideal candidates. PD may be the treatment of choice for ARF
in hemodynamically unstable patients or in patients with
coagulopathy. PD continues to be a favored modality in the
newborn or early infant population. 38 - 40
There are no absolute contraindications to PD. However,
some experts suggest that the presence of a ventriculoperitoneal shunt and severe respiratory distress are contraindications. Patients better suited to another type of therapy
include those with peritonitis, peritoneal adhesions, diaphragmatic defects or those healing from recent abdominal
surgery.
Principles of Therapy. The goal ofPD is established
before instituting therapy and is reevaluated on a daily basis.
For example, the daily goal may include removing a specific
amount of fluid over a defined period, decreasing the serum
potassium level to within normal limits, or decreasing the
BUN to 3 times normal. Achievement of established
multidisciplinary goals, ongoing monitoring of the patient's
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status, and prevention of complications require vigilant
assessment, intervention, and documentation.
With PD, the patient's peritoneum serves as the semipermeable membrane to allow movement of solutes by
diffusion and water by osmosis. As a semipermeable
membrane, the peritoneum allows some but not all molecules to move across it.
Dialysate fluid, containing a predetermined osmolality
and concentration of ions, is infused into the peritoneal cavity. Exchange of solutes and water occurs over
the peritoneal membrane. The osmotic gradient that drives
the ultrafiltration is created by the glucose in the dialysate. The greater the amount of glucose present, the greater
the gradient and the ultrafiltrate removed. Glucose may also
move from the peritoneal space to the child's intravenous
space, resulting in hyperglycemia. This occurrence is
usually temporary until the pancreas is able to increase
insulin production. Serum electrolytes diffuse across the
peritoneum until equilibrium is reached with the dialysate.
Urea and creatinine diffuse against a zero concentration
gradient because these two solutes' are not present in
dialysate. Therefore they are readily cleared from the serum.
The smaller the patient, the larger the ratio of peritoneal
space to body mass. Therefore, in general, PD is more
efficient in smaller pediatric patients.
Dialysate is commercially available as 1.5%, 2.5%, and
4.25% dextrose concentrations. Except for the addition of
glucose and the absence of potassium, dialysate is similar to
normal serum. Dialysate generally contains lactate as a
buffer. Because of the lactate base, the use of a standard PD
solution in a patient with impaired liver function or
metabolic acidosis caused by lactic acidosis can be harmful;
the substitution of bicarbonate for lactate may be necessary.
Table 21-12 shows the components of both standard lactate
and bicarbonate-ba~e dialysates. Potassium, heparin, antibiotics, or antifungal medications can be added to the
dialysate as needed. Systemic heparinization does not occur
in patients with heparin (250 to 500 UIL) added to the
dialysate. 41
Procedure. PD can be initiated with relati ve ease in
the PICU. Preparation of the patient includes obtaining a
baseline weight, abdominal circumference, and placing a
urinary catheter. The urinary catheter drains the distended
bladder, which decreases the risk of bladder puncture during
the procedure.
There are several types of peritoneal catheters. The
"acute" catheter is rigid and easy to place percutaneously.
The "chronic" catheter (most often the Tenckhoff catheter)
is a more flexible catheter that is tunneled through the
subcutaneous fat during a surgical procedure. The Tenckhoff
catheter may have a cuff that is placed at the level of the
peritoneum, which decreases the incidence of leakage.
Before starting the procedure, the PD system used both to
deliver dialysate to the peritoneal cavity and collect
peritoneal drainage is prepared. Dialysate can be delivered
manually or mechanically. Manual instillation requires
assembly of equipment, warming of the dialysate (for
patient comfort and to enhance solute clearance), and
frequent opening of the system to spike the dialysis bags.
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Fig. 21-7

Peritoneal dialysis cycler.

Peritoneal Dialysis
Solutions: Commercially Available .. .
Dialysate (lactate-Based)and Specialized
TABLE21-12

(Bicarbonate-Based) Solution
.~
IJJ7

~~

I~onstituents
~.L

.

Standard
Peritoneal
Dialysis Solution

Specialized
Bicarbonate
Solution

15, 25, 42.5
132

15, 25.42.5
92-100t
92-100

92
40

o

o
40t

The PD cycler may have various configurations and
controls. An example of a PD cycler is the Baxter Home
Choice shown in Fig. 21-7. It provides a relatively easy way
to maintain continuous PD, wann the dialysate, and display
the cycle status and the amount of spent dialysis per cycle.
All PD cyclers have a volume controller that contains an

Fig.21-8 Placement of peritoneal dialysis catheter. (From Hudak
C, Gallo B: Critical care nursing: a holistic approach, ed 6,
Philadelphia, 1994, Lippincott Williams & Wilkins, p 568.)

occlusion mechanism to regulate dialysate flow to and from
the patient. If the machine has a microprocessor, the PD
cycler can store the number of cycles and ultrafiltration
parameters in memory, even during electrical power interruptions. 42 Use of a cycler decreases the number of
connections and disconnections in a 24-hour period.
PO Catheter Insertion. Paracentesis is usually accomplished in the PICU. Patients younger than 2 years of
age, those with poor abdominal tone, those who require
chemical paralyzing agents for effective ventilation, or those
with a history of abdominal surgery may warrant catheter
placement in the operating room. The catheter is usually
placed 2 to 3 cm below the umbilicus in the midline, with
the tip of the catheter directed toward either the bladder or
the lateral pelvic gutters. Initially, 5 mllkg of ascitic
drainage should be removed, followed by initial instillation
of 5 to 10 ml/kg of dialysate. 41 To avoid excessive
ultrafiltration, 1.5% dextrose solution is used initially. Fig.
21-8 shows placement of the catheter in the body.
During the initial cycle, patient assessment includes evaluation for fluid infiltration around the insertion site, abdominal pain, grossly bloody drainage, fecal-contaminated
drainage, and cardiovascular or respiratory compromise.
After optimal catheter position is established, a purse-string
suture closes the incision around the PD catheter. An

Chapter 21

occlusive, dry, sterile dressing, which prevents kinking of
the PD catheter, is applied.
Catheter Maintenance. Each PD cycle or run consists of three phases: instillation, dwell, and drainage.
During the instillation phase, dialysate runs into the
peritoneum through the inflow line of the PD system. This
occurs rapidly by gravitational flow over 5 to 15 minutes.
The volume of dialysate instilled with each run is usually 10
to 20 mllkg in infants and 35 to 40 ml/kg in children.
Depending on patient tolerance, initial volumes can be
gradually increased. Increased PD volume increases efficiency of dialysis. However, in patients with tissue edema,
increased PD volume may cause dialysate fluid leakage.
During the dwell phase, both the inflow and outflow lines
are clamped. The dialysate remains in the peritoneal cavity,
allowing water and solute movement across the peritoneum.
This phase usually requires 30 to 60 minutes but is
dependent on many factors, such as surface area of the
peritoneal membrane. Maximal solute transfer occurs at the
beginning of the dwell phase. In general, shorter dwell times
remove greater amounts of fluid, and longer dwell times are
more efficient in solute removal.
The drainage phase begins when the clamp on the
outflow line leading to the drainage bag is opened. Although
the time required for drainage varies for each patient, the
average time is 15 to 20 minutes. Drainage can be enhanced
by repositioning the patient.
Modifications in PD therapy are made based on the
patient's clinical status, renal function, and laboratory test
results. The dialysate concentration is changed with relative
simplicity. Variations in concentrations can be obtained by
combining different osmolar solutions with each run. Even
though initial hyperglycemia may resolve with increased
endogenous insulin production, other related side effects
usually limit the use of highly osmolar solutions.
The volume of dialysate instilled depends on the patient's
tolerance during the dwell phase. Dialysate overfill is a
serious complication, as demonstrated by shortness of
breath, abdominal discomfort, distension, and pain. Instillation of smaller, more frequent volumes may accomplish
the desired goals in the patient who cannot tolerate runs of
more than 20 mllkg every hour.
Initial PD drainage is blood tinged. This bloody drainage
should clear after the first few runs. After this, PD drainage
takes on a characteristic straw color. Persistently bloody
drainage must be investigated. Likewise, development and
persistence of cloudy drainage can indicate peritonitis and
requires evaluation.
After the first few cycles, a predictable drainage pattern should develop. At times the catheter tip may migrate
away from the dialysate in the peritoneal cavity, or the
catheter may become occluded by the omentum, impingement of the abdominal organs on the catheter, or fibrin
deposits. In these situations, dialysate freely flows into but
not out of the peritoneal cavity. Interventions to increase
fluid drainage include changing the child's position, elevating the head of the bed, or turning the child gently from side
to side.
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Catheter-related problems also include leakage at the
insertion site. If the volume infused is greater than that
drained, the drainage tubing or catheter may be kinked
and require straightening, A clotted catheter requires
replacement.
Catheter leakage at the insertion site may also indicate
catheter displacement. If all PD catheter infusion/drainage
sites are contained within the abdomen, an extra external
stitch to stop oozing of fluid from around the insertion site
may be required. Sometimes catheter leakage results from
dialysate overfill, and volumes of dialysate may need to be
decreased.
The need for accurate documentation of intake and
output cannot be overstated. Twice-daily patient weights
may be used to validate fluid assessments if the patient's
condition permits. Weights are only useful if a consistent
scale is used and the patient is weighed at the same time of
day and during a specific phase in a PD cycle.
Laboratory studies are followed at a frequency determined by the acuity of the patient's condition. Following
trends of serum electrolytes, calcium, phosphorus, BUN,
and creatinine levels is routine. Close monitoring of the
patient's neurologic status is important because serum
electrolyte and acid-base imbalance may manifest in neurologic changes. Often the parents' observations and concerns about the patient's level of consciousness are early
warnings to the nurse and necessitate further evaluation.
The child's level of comfort is continuously monitored.
Especially important is the patient's perception of comfort
during the different phases of PD. Nonverbal signs of
discomfort include tachycardia, tachypnea or shallow
breathing, grimacing, splinting, and agitated or unsettled
behaviors. In some instances, slowing the rate of dialysate
infusion, decreasing the volume used per cycle, further
warming of the dialysate, or repositioning the child may
alleviate some discomfort. Analgesics and sedatives are
used in addition to comfort measures.
Complications. Distending the abdomen with large
volumes of dialysate may compromise the patient's respiratory status. Increased abdominal volume and pressure
prevent normal downward displacement of the diaphragm
and limit functional residual capacity. This effect may
predispose the patient to atelectasis with associated intrapulmonary shunting and increased work of breathing.
Fatigue, anxiety, and pain further compromise the patient's
ability to compensate for existing alterations in oxygenation
and ventilation.
Ongoing assessment of the patient's nutritional status
includes an appreciation of the protein loss across the
membrane during PD. This may potentiate nutritional,
immunologic, and infectious problems such as peritonitis.
Instillation of large volumes of dialysate into the
peritoneum may also compromise venous return and cardiac
output. This effect is especially true when intravascular
volume is limited. Close monitoring of cardiovascular status
is necessary, especially during the instillation phase. During
the drain cycle, hypotension may also be a problem,
often related to leaky capillary syndrome in patients
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suggestive of bacterial peritolllus. Maintaining a closed
system, specimens should be aspirated from the PD outflow
line and not the drainage bag. To prevent the possibility of
contaminated fluid from flowing back into the peritoneum,
the drainage bag is never elevated above the level of the
abdomen.
Peritonitis does not preclude PD therapy. Treatment
includes adding antibiotics to the dialysate. Some commonly used intraperitoneal antibiotics include vancomycin,
tobramycin, cefotaxime, and piperacillin. Appropriate systemic antibiotic administration for positive blood cultures is
required. Pancreatitis is also a frequent finding in patients
undergoing PD. Signs and symptoms include abdominal
pain, nausea, vomiting, low-grade fever, and elevated serum
lipase and amylase levels.
Documentation. Documentation is crucial to patient management. Fig. 21-9 is an example of a documentation flow sheet for cycler PD (the presence of tidal PD
addresses a fornl of PD not commonly used, wherein a small
amount of dialysate is purposely not drained from the
patient). If manually performed, documentation also includes the times at which (I) instillation of dialysate begins;
(2) instillation ends, and dwell time begins; (3) dwell time
ends, and drainage time begins; and (4) drainage time ends,
and a new run begins. These times are automatically

with decreased intravascular but increased extravascular
volume. 34
The greatest shift of water and solutes occurs within the
first part of the dwell phase. Patient discomfort and
respiratory and cardiovascular distress may force a time
limit on the dwell phase. These adjustments eventually
affect the number of cycles completed within the day,
potentially influencing the effectiveness of therapy. As the
patient's need for PD lessens, drainage time can be
gradually increased, resulting in fewer runs per day.
The use of an acute catheter placed percutaneously leads
to the possibility of leakage. Chronic catheters are tunneled
and often have cuffs to increase the effectiveness of the seal.
In general, the risk of peritonitis increases after day 3 of PD.
Guidelines for practice regarding the frequency of system
tubing change, catheter insertion site cleansing and dressing,
and frequency of catheter change are policies determined
within each institution. It is prudent to recommend care that
is similar to guidelines for intravascular lines.
Signs of peritonitis include cloudy PD drainage, fever,
abdominal pain and tenderness, and a change in the patient's
level of consciousness. Daily culture, cell count with
differential, and Gram stain of PD drainage are warranted.
Peritoneal cell counts exceeding 100 white celiS/ill or the
presence of greater than 50% neutrophils on differential is

The Children's Memorial Hospital
CYCLER PERITONEAL DIALYSIS FLOW SHEET
DATE:

HEATER BAG:
%0
LLAST BAG(i! different):_---"'%!llO_---I.L EXTRA FLUIDS:_---"'%!llO_----'-L
ADDITIVES TO BAGS:____________
%0
L
%0

WEIGHT(empty):

Q.CE.D or TIDAL PD

Total
Volume:

ml

Tidal
Volume: ------'l\.
TIME

#CYCLE
INITIAL
DRAIN

l

kg

'CYCLE
ULTRAFILTRATE
(actual amounl)

Therapy
Fill
hr min Volume:
Time:
Total (estimated) Full
UF:
ml
Drains:
'CUMULATIVE
ULTRAFILTRATE

ml

g

Last
Last
#
Cycles
Fill: __m_' Dextrose:
Tidal
UF
evcles
Volume:
ml per cyeie: _ _m_'

PROGRAM
CHANGES

ALARMS and COMMENTS

(day fill - Initial drain)

#1

• When cycler displays (+ ) UF, record on flow sheet as (- ): Patient net fluid loss (removed)
• When cycler displays (-) UF, record on flow sheet as (+): Patient net fluid gain (retained)
• Cycle and Cumulative UF will only be displayed at Full Drains on TIDAL program
• Cumulative UF does not include Initial Drain

Fig. 21-9

Peritoneal dialysis worksheet. (Courtesy The Children's Memorial Hospital, Chicago, IlL)

Avg.
Dwell:------.!!l!!l

SIGNATURE
(initials)
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programmed in the PD cycler and do not need to be
documented.
Ongoing assessment of drainage volume, compared with
instilled volume, is important in evaluating the patient's
fluid balance. The patient's fluid status is considered to
"positive" when the volume instilled is greater than the
volume drained. Positive fluid balance can be related to an
increase in the patient's serum osmolarity or to an occlusion
in the drainage system. If no occlusion is identified in the
drainage system and a continued positive fluid balance for
two or more runs is obtained, a change in management
strategy is required.
The patient is considered to be in "negative" fluid
balance when the volume instilled is less than the volume
drained. Negative balance, indicating removal of body fluid
volume, is generally a goal of PD; however, rapid removal
of volume may compromise the child's hemodynamic
status. Continuous evaluation of the child's tolerance to fluid
removal is necessary to determine the desired goal for
hourly fluid balance.
To calculate the 24-hour net body balance, the following
equation is used:
(Total amount of dialysate instilled + intake) (Total fluid drained from dialysis + output) =
Total body balance for 24 hours

To determine the effecti veness of PD, the net gain or loss
is calculated by the following equation:
Total dialysate intake - Total ultmfiltrate ootput = Net loss or gain

Additional documentation specific to PD includes patient
and parent education and assessment of their level of
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understanding and comfort with the information. Documentation also includes a description of the child's tolerance of
PD. Appearance of the insertion site, the presence of any
fluid leakage, and a description of the fluid drained out of the
peritoneal cavity are documented at each shift.

Continuous ArteriovenouslVenovenous
Hemofiltration
Continuous arteriovenous hemofiltration (CAVH) and continuous venovenous hemofiltration (CVVH) provide two
conceptually similar methods for slow, continuous removal
of fluid and solutes from the body, enabling continuous
adjustment in the child's fluid status. Slow continuous
hemofiltration is especially important in the critically ill
child in whom a predictable fluid and solute removal process
allows a more liberal approach to intravenous intake of
necessary nutrition and medications.
Hemofiltration can usually be successfully initiated in
patients in whom PD or hemodialysis is contraindicated.
Compared with hemodialysis, special equipment and the
need for extra personnel are minimized with CVVH.
Principles of Therapy. Uniquely different from
PD and HD, CVVH removes excessive fluid and solUles
through ultrafiltration. The process requires continuous
extracorporeal circulation of blood through a filter.
With CVVH, a hemopump is used to pump blood through
the hemofilter using two separate venous cannulas or
two separate ports from a single multilumen cannula
(Fig. 21-10). Different machinery is available for CVVH,
and the simplicity of the therapy is determined by the
machine.

Fig. 21-10 Pump-assisted continuous venovenous hemofiltration (CVVH). (Courtesy The Children's
Memorial Hospital, Chicago, Ill.)
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As blood moves through the highly permeable hemofilter, water and low-molecular-weight molecules are removed
through ultrafiltration. Variations in hemofilter size and
shape are commercially available. Cylindric hollow filters or
parallel plate filters are two commonly used types. Options
in membrane type, surface area, clearance rate, and volume
are commercially available.
Similar to that which occurs within the vascular space,
ultrafiltration occurs as the net result of the opposing forces
of hydrostatic and oncotic pressure. Hydrostatic pressure
(determined by the hemopump's blood flow rate) provides
the force necessary to filter blood on one side of the
membrane, as oncotic pressure (detennined by the concentration of plasma proteins) pulls fluid back into the system
on the other side of the membrane (see Fig. 21-6). Initially,
hydrostatic pressure is greater than oncotic pressure, and
thus water and small particles move out of the serum into the
ultrafiltration collection fluid. At this point, depending on
the concentration of plasma protein that establishes the
plasma oncotic pressure, water is pulled back into the
venous side of the circuit and ultrafiltrate (UF) is drained
into the collection bag.
UF has the same solute load as the patient's serum.
Potassium, sodium, chloride, urea, and creatinine are all
small molecules that freely move across the hemofilter.
Glucose and other moderate-size molecules move slowly
across the hemofilter. Plasma proteins, which are large-size
molecules, do not cross the hemofilter. Therefore all plasma
proteins are returned to the patient and UF is protein free.
As water and small molecules are removed, plasma
oncotic pressure increases. The net effect of oncotic and
hydrostatic pressures becoming more equal is a decrease in
the rate of ultrafiltration over time. At this point the patient's
serum osmolarity is maintained as sodium, potassium, and
chloride are removed and creatinine, urea, and glucose are
filtered in concentrations equal to that of plasma.
The process of fluid and solute removal has distinct
features that make hemofiltration the therapy of choice for
many children with ARE The slow process allows relative
hemodynamic stability during volume removal. In addition,
it is a continuous therapy, allowing constant readjustment
in the treatment plan as the patient's needs change.
Compared with HD, the extracorporeal circuit volume is
small and there is a relatively low risk of bleeding. This
aspect is especially important in infants and patients with
existing coagulopathy. The major advantage over PD is that
ventilation during hemofiltration is not affected by the
abdominal distention that occurs during the dwell phase
of each PD run.
A disadvantage to simple hemofiltration is that it does not
remove solutes such as urea as efficiently as desired for
some patients. Large solutes also are poorly cleared. Small
ones, although cleared, are removed slowly. Therefore
hemofiltration without dialysis may not be the therapy of
choice for patients with azotemia.
The clearest indications for simple hemofiltration are
fluid overload, which is resistant to diuretic therapy, and
electrolyte imbalance. One common use of hemofi ltration is
to improve nutritional intake for patients who cannot

tolerate a POSitive fluid balance. Increased amounts of
parenteral nutrition can be administered because excessive
fluid volume can be continuously removed. The controlled
fluid management specifically benefits patients with multisystem organ dysfunction syndrome (MODS). In addition,
some evidence suggests the effective clearance of cytokines
present in children with shock.
CAVH therapy works similarly to that described earlier
for CVVH. The main differences include access, adequacy
of cardiac output, and interactions with the system. CAVH
requires arterial access for blood removal from the body.
The driving force is the child's cardiac output. Thus if
cardiac output is less than optimal, the hemofiltration will
also be less than optimal. Use of a blood pump is not
generally required because the child's cardiac output drives
the system. Interactions with the system include raising or
lowering the ultrafiltration bag to decrease or increase the
ultrafiltration amount. Because CAVH is used much less
frequently than CVVH, the remainder of this section focuses
on CVVH.
Procedure. Venous cannulation sites must accommodate the largest size cannula possible because system
performance is directly related to the amount of blood flow
through the hemofilter. Infants have adequate filter flow
through 7 French (internal lumen) catheters. In the best
situation, a double-lumen catheter is used to eliminate the
need for two separate sites and catheters. Femoral and
jugular access are most common. If two separate cannulas
are used, drainage and return cannulas are generally the
same size for optimal flow. When the gauge of the drainage
cannula is less than optimal, improved circuit flow may be
achieved when the return cannula is one to two gauge sizes
larger than the drainage cannula. Return cannula size
determines resistance of blood flow back to the patient and
affects flow throughout the circuit. One venous cannula/line
often pulls more effectively than the other. If this is the case,
simply reversing the drainage and return lines may improve
system performance. The procedure for gaining vascular
access is the same as for any central line.
Preparation of the circuit is completed before gaining
vascular access. If access is obtained before preparation of
the circuit, the cannulas are heparin packed, then capped.
Assembly and priming of the circuit are institution
specific. General principles include the maintenance of
aseptic technique during flushing of the circuit with I to 3 L
of heparinized saline, the volume determined by the type of
filter used. The concentration of heparin may vary by
institution. The system is flushed to remove air and all traces
of glycerin, a byproduct of the sterilization process.
Most pediatric patients benefit from priming the hemofilter with packed red blood cells or 5% albumin; again, this
is done according to institution policy and patient size.
Depending on the size of the hemofilter, the circuit volume
varies.
A continuous heparin infusion, attached prefilter, is
necessary to keep the system from clotting. It is initially
infused at a rate of 10 U/kg/hr and then titrated to maintain
an activating c1o11ing time (ACT) within an individual
therapeutic range (usually 180 to 200 seconds or 10% over
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baseline). Patients with thrombocytopenia may not require
anticoagulation. Some centers prefer regional heparinization
of the hemofilter. This may be accomplished by infusion of
sodium citrate, which acts by binding with calcium ions.
Side effects of citrate include hypercalcemia, hypercitratemia, and metabolic acidosis 43
Once vessel access has been achieved and the circuit has
been primed, it is connected to the patient. The drainage side
is connected to the patient first. Clamps are used to assist the
team in establishing the extracorporeal circuit without air
entry or unnecessary blood loss.
Maintenance. Pump-driven CVVH provides the hemofilter with constant blood flow, which results in a
consistent ultrafiltration rate (UFR) that can be precisely
controlled. Ordered pump speed, adjusted in milliliters per
minute, depends on cannula size, intravascular volume, and
desired UFR with solute clearance. Pump speeds should be
maintained at a certain level depending on the size of the
patient to prevent filter clotting.
Fluids need to be infused through the appropriate site on
the circuit. Except for albumin, replacement fluids are
generally delivered before the filter. Fluid administration
before the hemofilter decreases the hematocrit, blood
viscosity, and oncotic pressure. In combination, these
factors improve blood flow through the hemofilter, decreasing the need for heparin therapy. Also, prefilter replacement
fluid administration may prolong the life of the filter and
circuit. 43
Albumin is administered after the filter because it may
decrease the patency of the hemofilter. Medications are also
administered after the filter to avoid hemofiltration of the
medication.
Monitoring. Fluid balance assessment and calculations require vigilant monitoring and documentation, which
may be time consuming. Older technology requires manual
calculation of fluid balance and use of additional infusion
pumps separate from the blood pump. This system requires
hourly evaluations of ultrafiltrate removed to determine
replacement fluids and hourly balance. The newest technology for CVVH therapy is a system that performs the therapy
independent of additional pumps or manipulations of the
circuit. The PRISMA pump (Gambro, Lakewood, Colo.) is
an example of this type of system (Fig. 21-11). This system
infuses and removes fluid based on a computerized
weighted system. When programmed, the system achieves a
net fluid removal per unit of selected time. This feature
saves nurses time by eliminating the need for routine
calculations and pump manipulations. It benefits the child
by providing immediate fluid replacement from continuously calculated data.
Hemofiltration requires ongoing monitoring of the patient and extracorporeal circuit. Circuit pressures are monitored as a safety alarm to immediately identify inadvertent
patient disconnection or changes in pressure in the system.
The PRISMA system has the advanced technology of a
detailed alarm system that displays alarms in a hierarchy
depending on potential risk to the child.
The child's volume status and cardiac output are affected
over the time of fluid removal. Trends in laboratory results,
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CVVHDF

Fig. 21-11 PRISMA machine in use with CVVHDF. Tube A
represents blood flow from patient to machine and through the
filter; B represents filtrated fluid, ultrafiltrate; C represents replacement fluid; D represents dialysate fluid; E represents blood flow
returning to patient.

intake and output totals, patient weights, and vital signs are
critical assessment parameters.
The cardiovascular examination is crucial. Perfusion. to
the extremities distal to the cannulated vessels may diminish. Ongoing assessment of the presence and quality of
pulses and sensation and movement of extremities is
necessary. Vigilant monitoring of the patient's hemodynamic status is critical. Inadvertent errors in calculating fluid
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removal may be discovered by decreases in the blood
pressure, central venous pressure or elevated heart rate.
Serum sodium, potassium, and chloride are removed in
proportion to the fluid volume filtered, and shifts in these
electrolytes occur as a result of the therapy. Changing
acid-base status may also affect electrolyte levels. The
volume and type of replacement fluid are readjusted, depending on the needs of the child. A reduction in the serum
BUN and creatinine level is gradually appreciated.
Nutritional management for the child receiving hemofiltration is usually welcomed in the previously fluid-restricted
child with large metabolic needs. Provision of optimal fluid
volume and calories are best determined by the multidisciplinary team, which includes the critical care team, renal
team, nutrition support services, and pharmacist. The
replacement fluid, generally a modified solution of lactated
Ringer's solution, can be a separate source of intake. In
some systems, the volume varies to ensure that the desired
volume of fluid removed matches the net volume of fluid
removed. In other systems, the replacement fluid remains
the same consistently, and net volume removed is based on
other intake and output of the patient and desired net
balance.
The critical process of addressing the high risk of
infection associated with this therapy begins with strict
adherence to aseptic technique. Surveillance cultures from
the circuit are institution specific and may be done daily.
Cannula care is the same as that given for any central line.
Meticulous attention to preventing contamination is necessary, and any need to enter the circuit warrants careful
consideration.
While receiving this therapy, the child's hematologic
status may be compromised by anticoagulation. Frequent
ACTs are necessary to evaluate the amount of heparin
needed. After an appropriate rate for continuous infusion has
been determined, the frequency of these tests may decrease,
and a partial prothrombin time may be used for monitoring. 44 Assessment of the child's ability to establish and
maintain hemostasis is ongoing. This assessment includes
checking for guaiac-positive nasogastric drainage or stool,
hematuria, oral/nasal or mucosal bleeding, petechiae, and
oozing from wounds or venipuncture sites. Neurologic
assessment is critical in the coagulation evaluation, especially in infants.
The impact of hemofiltration on the pharmacokinetics of
all drugs the patient is receiving is evaluated. Clearance of
nonprotein-bound drugs is enhanced with hemofiltration.
Anticipating enhanced clearance is critically important,
especially in the child who is vasopressor dependent.
Enhanced clearance of insulin and some antibiotics, including the aminoglycosides and cefuroxime, also occurs. In
general, because the extracorporeal circuit adds "body
surface area" to the patient, the dosage of all nonproteinbound drugs is increased (see Table 21-9). Both dosage and
timing of medication administration are best determined by
evaluation of peak and trough drug levels. Sieving coefficients, which describe the concentration gradient of a
molecule in the UF as compared with that of plasma, can be

used to calculate therapeutic dosages during hemofiltration
(Table 21- I3).
Hypothermia is another area of monitoring that is
important to the child receiving CVVH therapy. Because no
warming device is built into the commercially available
systems, careful temperature monitoring is necessary.45 This
factor is especially important in the small infant who has yet
to develop adequate thermoregulation.
The child's level of comfort is best evaluated with the
patient and parents. Changes in the child's heart rate and
blood pressure are integrated with assessments of behavior,
facial expression, playfulness, and interaction with others.
Hemofiltration should not cause pain. Use of analgesia is
generally not indicated. Sedation, in an adjusted dose for
renal failure, may be helpful in allowing the child to be less
anxious. thereby maximizing rest and preventing accidental
dislodgment of the cannula(s). Provision of some environmental control, the presence of parents, and a routine of
day-night activities may serve to minimize the child's fear
and lessen discomfort from unfamiliar physical and emotional feelings.
Using a complex technology to provide ultrafiltration at
the bedside has specific implications for the care of the child
and parents. The appearance of the blood circulating outside
the body can be frightening and worrisome to families.
Continuous observation and hourly monitoring may minimize the parents' sense of control and may maximize their
feelings of helplessness. Because of the presence of a large
central cannula, the child's mobility is usually restricted. It
is a nursing challenge to help the child find a comfortable
position and to include parents in the care of their child.
Addition of child life therapy to the healthcare team can be
invaluable for the mobility-restricted child.
Parents can best identify how much information they
would like to receive about the care required of their child
supported on CVVH. Knowledge about the need for hourly
collection of data and the frequency of blood draws from the
line may be helpful for some parents. The security
precautions inherent in the circuit and anticipatory information about the expected necessity for routine circuit changes
are examples of other kinds of information that some parents
may find helpful.
Complications. Ongoing monitoring of the circuit
requires skill and experience in troubleshooting complications. Unintentional decreases in ultrafiltration may be the
result of changes within the child or circuit. As circuit
flow diminishes, UFR decreases, and hemofilter patency is
at risk.
Inadequate blood flow through the circuit can also result
from cannulas that are too small, vascular access thrombosis, kinks in the tubing, or clotting of the hemofilter or
cannulas. Occlusion can occur anywhere in the circuit.
lnspecting the entire circuit for kinks and clots is a first step.
Prefilter hemodilution at 30 to 50 mUkg/hr may be helpful
in preventing clot formation. Prefilter volume is easily
removed by the filter.
When the hemofilter begins to clot, dark red streaks
appear. Another hint that the filter is clotting is an increasing

Chapter 21

TABLE

21-13

ntibiotics
ikacin
photericin B
picillin
efmenoxime
foperazone
.efotaxime
fotiam
efoxitin
eftazidime
eftriaxone
ephapirin
Hastatin
iprofloxacin
Iindamycin
xycycline
thromycin
uconazole
ucytosine
tamicin
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Drug Sieving Coefficients During Hemofiltration
Observed

Expected"

0.95
0.35
0.69
0.54
0.27
1.06
0.95
0.83
0.90
0.20
1.48
0.75
0.58
0.49
0.40
0.37

0.95
0.10
0.80
0.58
0.10
0.62
0.60
0.59
0.83
0.15
0.55
0.56
0.60
0.40
0.20
0.30
0.88
0.90
0.95
0.80
0.80
0.68
0.20
0.95
0.05
0.80
0.50
0.80
0.65
0.60
0.10
0.95
0.90

l.OO
0.80
0.81
0.90
0.84
0.71
0.55
0.93
0.02
0.80
0.68
0.82
0.30
0.30
0.05
0.90
0.80

Sieving Coefficients

Miscellaneous
Amrinone
Bromide
Chlordiazepoxide
Cisplatin
Clofibrate
Cyclosporine
Diathybarbital
Diazepam
Digoxin
Digitoxin
Famotidine
Glyburide
Glutethimide
Lidocaine
Lithium
Metamizole
N-Acetyl procainamide
Nizatidine
Nitrazepam
Nomifensin
Oxazepam
Phenobarbital
Phenytoin
Phosphomycin
Procainamide
Ranitidine
Theophylline

Observed

Expected"

0.80

0.70

LOO

l.OO

0.05
0.10
0.06
0.58

0.05
0.10
0.04
0.10
0.90
0.02
0.80
0.05
0.85
0.01
0.50
0.36

LOO
0.02
0.70
0.15
0.73
0.60
0.02
0.14
0.90
0.40
0.92
0.59
0.08
0.70
0.10
0.80
0.45
0.24
0.86
0.78
0.80

l.OO
0.40
0.90
0.65
0.10
0.40
0.10
0.60
0.10
0.90
0.86
0.85
0.47

:;§i'!

lirftom Golper TA, Marx MA: Drug dosing adjustments during continuous renal replacement therapies, 1m Soc NephroI66:S165-t68. t998.
;Ii-The expected coefficient assumes that protein binding is the sole determinant of drug sieving and that protein binding is in healthy subjects. Observed
~~oefficients correlate with expected coefficients with r = 0.74 and P < 0.001.

need for heparin to maintain ACTs between 180 and 200
seconds. To assess hemofilter patency, a rapid prefilter
flush of normal saline solution or heparinized normal saline
(I VIm!) through the hemofilter into the collection bag with
both lines clamped is administered. If an organized clot is
present within the hemofilter, the dark streaks will not
disappear with flushing.
Clotting within the hemofilter decreases the UFR and
necessitates hemofilter change. If the hemofiIter is totally
occluded, the circuit is replaced immediately to preserve
patency of the cannula. Once the new circuit is in place,
fluid and heparin management is reevaluated. With the new
circuit, improved ultrafiltration and fluid loss can be
anticipated. An increase in the heparin infusion rate may be
warranted to decrease the incidence of future clotting. If a
new circuit cannot be placed immediately, the circuit is

disconnected, and the cannula preserved by packing with
heparin (5000 V/ml).
The potential for a lethal occurrence of cannula disconnection warrants the frequent inspection of the entire circuit
for tightly secured connections. Two major concerns include
exsanguination and air emboli. If disconnection occurs,
aseptic reconnection needs to rapidly occur. Immediate and
temporary clamping of the circuit may prevent air entry. If
air is present in a CVVH circuit, it is removed by syringe
from the postfilter venous port before reconnecting and
reestablishing flow through the circuit.
Hemofiltration systems require a postfilter bubble detection system. If air is detected, the pump is automatically
stopped to halt the forward flow of blood. Air is then
manually removed. An additional problem related to the
actual circuit is spontaneous hemofilter capillary rupture.
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Rupture of hemofilter capillary fibers occurs if the transmembrane pressure exceeds the manufacturer's guidelines.
This problem is evidenced as a change in the UF color from
clear pale yellow to pink or red and requires immediate
removal and replacement of the hemofilter.
Documentation. Accuracy in documentation during
hemofiltration is critical to evaluate the effectiveness of the
therapy. Depending on the specific features of the therapy
used, equipment involved, and flexibility of the standard
PICU flow sheet, the documentation of hemofiltration can
take on many appearances.
Documentation of the intake and output vary, based on
institution documentation standards. Generally, sources of
intake are recorded as intravenous (IV) fluid, including
replacement fluid, dialysate (if used), nutritional infusions,
vasopressor infusions, heparin infusions, and sources of
gastrointestinal (GI) intake. Output includes ultrafiltrate,
urine, blood, and GI losses. Intake and output per hour are
recorded, as well as the net UF volume per hour.
Depending on the institution's documentation guidelines,
calculation of intake and output sections will vary. When
using the PRISMA system, calculation of the net fluid
removal rate (i.e., net negative 20 ml/hr body balance) will
be done, as opposed to calculation of the replacement fluid
(Fig. 21-12). In this calculation, the replacement fluids are
not calculated because the PRISMA automatically removes
the replacement fluids. The following equation is used:
Amount of hourly fluid intake - Amount of hourly output
[+ (Net negative hourly balance) or - (Net positive hourly
balance)] = Patient fluid removal rate to be set for that hour
Example: Prescribed net hourly balance is -20 ml) (the patient
is fluid overloaded)

Fig.21-12

Intake

Output

Hyperalimentation = 100 ml/hr
Vasopressors = 5 mJlhr
Enteral feeds = 5 ml/hr

Urine =7 ml
Gasuic drainage = 13 ml
Blood loss = 5 ml

ItO (Intake) - 25 (Output) + 20 (Net negative balance)

= 105

When the machine is set to remove 105 ml for that hour, the
patient will be net negative 20 ml.
Example: Using the same intake and output but the
prescribed net hourly balance is +20 (the patient is dehydrated)
ItO (Intake) - 25 (Output) - 20 (Net positive balance) = 65
When the machine is set to remove 65 ml for that hour. the
patient will be net positive 20 ml.

Using other systems, however, may require calculation and
hourly programming of replacement fluids. To do this, the
following equation is used:
Amount of replacement fluid to be given over upcoming hour =
Total UF volume in bag - Total amount dialysate
infused over previous hour - Total fluid intake
for previous hour (not including last hour's
replacement fluid) - Desired net UF volume per hour

Confirming the calculation to be used with the healthcare
team is imperative. Using the incorrect calculation may
cause severe fluid imbalance and resultant hemodynamic
instability in the critically ill child.
Routine documentation also includes the child's ACT
results, the blood pump speed, the appearance of the
hemofilter, and the UF color. Observations of the system and
arming of bubble detector alarms for safety maintenance
may be recorded in the form of a checklist.

CVVH flow sheet. (Courtesy The Children's Memorial Hospital, Chicago, Ill.)
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Observations of the child's coagulation status, tolerance
of the therapy, and the appearance of the catheter insertion
sites are generally best documented in the nursing note.
Education provided to the child and family and the
identification of further learning needs are included in the
record to ensure continuity of care for the child and family.
Modifications to Hemofiltration. Slow continuous
ultrafiltration (SCUF) is one modification to hemofiltration.
Ultrafiltration occurs according to the same principles
described for CVVH but at a slower rate without replacement fluid. Thus solute clearance is both inefficient and
ineffective. SCUF is used to prevent overhydration while
maintaining intravenous fluids and nutritional balance. The
desired hourly UFR is based on the patient's intake to
maintain hemodynamic stability.
Another variation to therapy, continuous venovenous
hemodiafiltration (CVVHD), differs from CVVH because it
enhances solute clearance through diffusion. CVVHD is
indicated for children with catabolic and uremic conditions
complicating ARF. This system allows dialysate to flow over
the outside surface of the filter countercurrent to blood flow
on the inside surface of the filter. This provides optimal
diffusion transport of solutes and urea from the patient's
blood to the Ufo CVVHD pulls larger molecules and
proteins across the filter. Hourly measurements from the UF
collection bag include the volumes of both dialysate infused
and UF removed. Subtraction of the hourly dialysate volume
infused from the volume collected in the UF collection bag
results in the volume of actual UF removed.
The amount of UF produced can be altered through the
interventions described under simple hemofiltration. Dialysate is usually prescribed by the nephrology team. High
osmolar dialysate concentrations further increase UFR.
Careful surveillance of the patient's hemodynamic status
and routine monitoring of electrolyte levels are essential in
evaluating the effectiveness of CVVHD for fluid and solute
clearance.
CVVHDF is CVVHD with filtration. This technology
uses both diffusion and convection to maintain fluid and
electrolyte balance and control azotemia. It differs from
CVVHD in that it uses a replacement fluid and CVVHD
does not. The specific type of hemofiltration used depends
on the clinical situation.

Hemodialysis
HD rapidly restores fluid, electrolyte, and acid-base balances and is more efficient in removing nitrogenous wastes
than any other currently available form of therapy. More
cumulative experience exists with HD than with any other
therapeutic modality for management of acute renal failure.
Newer single and dual-lumen vascular access permits HD in
smaller infants and young children. HD monitoring equipment and blood lines with minimal extracorporeal blood
volume make HD available for infants less than 5 kg. 34 HD
may be the treatment of choice for several reasons. It is
possible to calculate the amount of time necessary to remove
a particular solute load for a given patient. This capability
affords a sense of control and predictability in the manage-
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ment of life-threatening imbalances. In addition, depending
on the availability of an HD team and appropriate system,
HD can be rapidly initiated in the PICU. HD is also the only
treatment available for certain toxic ingestions. The charcoal
membrane used in HD removes some poisons, such as
chloramphenicol and theophylline, that are not cleared by
another type of membrane. Finally, HD may be the only
available intervention when PO is contraindicated.
Principles of Therapy. PO and HD use the same
principles that govern fluid and solute movement across a
semipermeable membrane. Diffusion and osmosis occur
relative to the concentrations and osmotic gradients present
between the child's serum and the dialysate. Similar to PD,
the goals of therapy determine which percentage of dialysate is used. Unlike PO, HD requires extracorporeal
circulation. A dialyzer pumps blood and dialysate through
the system in opposing directions. Countercurrent flow
provides an efficient exchange of solutes. The rate of flow
through the dialyzer and the length of each exchange can be
controlled.
Urea, creatinine, and potassium are usually present in
greater concentration in the patient's serum than in dialysate; therefore these solutes rapidly diffuse from the blood to
the dialysate and are removed from the body. Diffusion is
the predominant mechanism for effective clearance in
hemodialysis. Bicarbonate, an alkalizing agent present in
dialysate, moves from the dialysate to the blood and
provides treatment for metabolic acidosis. Additional molecules can be removed through convective dialysis, where
rapid fluid shifts from the blood to the dialysate tend to pull
solutes along.
Procedure. Before HD, intravenous access is evaluated or obtained. Although in rare situations native arteriovenous (AV) fistulas are available, femoral vein or superior
vena cava cannulation is common. Access usually requires
a catheter with a larger bore and a shorter length than
standard central venous catheters. The use of peripheral
veins in the pediatric population necessitates the use of
smaller catheters. Difficult volume and hemodynamic management may be the consequence. The smaller catheters
result in increased resistance to flow from the dialyzer
returning to the patient. This increased resistance results in
an increase in hydrostatic pressure in the dialyzer, thereby
increasing UF and fluid removal. Despite the associated risk
of infection with the use of femoral vessels, this location
may be the best choice. Venous cannulation of two separate
locations or one with double-lumen capacity may be used.
Several dialyzers are commercially available. The
choices for appropriate HD blood lines and dialyzer are
dictated by the body surface area and intravascular blood
volume of the child. When choosing a circuit, it is important
to keep the extracorporeal volume (tubing plus dialyzer) less
than 10% of the patient's total blood volume. 41 The smallest
circuit volume currently available is 45 m!. This system,
primed with whole blood, can be used in infants. In addition,
there is a selection of membranes for desired effects.
High-efficiency dialyzers employ membranes that have a
larger surface area so that small solutes may diffuse more
rapidly. High-flux dialyzers incorporate membranes that
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have larger pores and yield higher clearance of water and
larger solutes. 36
Maintenance. Detennined by the goals of therapy,
the HD team prescribes the length of exchange time.
Amounts of glucose, acetate, sodium, calcium, and potassium are variably added to the dialyzing fluid, depending
on the patient's situation. The length of one HD exchange usually extends over 2 to 6 hours. Some fonn
of heparinization is required to prevent clot fonnation
within the circuit, although 4-hour treatments may be
undertaken heparin free with new biocompatible membranes. 46 If heparin is needed, baseline coagulation profiles are necessary before initiating HD. ACTs are monitored to ensure the maintenance of a therapeutic dose
without toxic effects. ACTs between 150 and 200 seconds
permit adequate anticoagulation with minimal bleeding
risks.
Solute clearance depends on several factors, including
the rates of blood and dialysate flow and the surface area and
permeability of the membrane. The rate of urea and water
removal can be calculated. lnfonnation about the patient's
serum level of solute is an important component of this
calculation. The actual serum value, the rate of urea
production, the patient's metabolic rate, and the child's
protein intake all playa part in detennining the rate of urea
clearance.
The acceptable rate of solute clearance is affected by how
the child tolerates HD. Because solutes are rapidly removed
from the serum but slowly removed from the brain, an
osmolar gradient or disequilibrium between the intravascular and intracellular space may develop. This gradient
results in fluid shifts and cerebral edema. The child with
disequilibrium syndrome may exhibit confusion, irritability,
headache, nausea, vomiting, and seizure activity. This
syndrome seems to occur more when the BUN falls more
than 35% with therapy. Consequently, initial treatments may
be shortened to avoid this syndrome. Some centers use
intravenous mannitol (0.5 g/kg) during the initial exchange
to minimize disequilibrium effects.
Bedside HD of critically ill pediatric patients requires the
collaborative expertise of both PICU and HD nurses. Before
beginning HD, the expectations of each nurse are clarified.
Usually the PICU nurse continues to manage ongoing care,
the HD nurse manages the therapy, and together they
collaboratively manipulate vasopressors, volume, and fluid
and solute removal within established guidelines to manage
the patient through the procedure. Communication between
nurses is key because both will be continuously assessing
the patient.
Monitoring. Assessment of the patient's intravascular
volume status is an ongoing responsibility. When HD is
initiated, a relative hypovolemia may develop owing to the
external circulation of the child's blood in the amount of the
circuit volume. Progressive hypovolemia and hypotension
are possible as therapy progresses. It is not uncommon to
initiate or increase the dose of vasopressors during HD. The
treatment objective is usually to establish and maintain
intravascular nonnovolemia, but expedient and/or large
volume removal challenges this objective. Furthennore, the

flow rates may need to be decreased to maintain hemodynamic stability.
At the beginning of a HD session, hypoxemia may be
seen with a decrease in the arterial P0 2 by as much as
20 nunHg. A potential cause for this phenomenon is
activation of the complement system, which occurs when
a cellulose membrane is used. Another potential cause
for this phenomenon is hypoventilation, which may occur
with either an acetate or bicarbonate bath. The effect
usually peaks at 2 hours and usually recovers I to 2 hours
after the dialysis session. 36 Patients already receiving
oxygen therapy may require a higher percentage during this
period. The use of acetate as a buffer in dialysate may
contribute to the development of relative hypovolemia
because acetate decreases systemic vascular resistance.
Switching to a bicarbonate-based bath improves cardiovascular stabili ty.
Hypervolemia may occur if too much fluid is returned to
the patient. A common time for this imbalance is at the end
of an exchange when the child may be receiving additional
blood products. Additional HD time for fluid removal may
be required.
Dysrhythmias may occur from electrolyte or acid-base
imbalance. Hypotension, which decreases coronary perfusion pressure, and hypokalemia are two of the most common
causes of dysrhythmias during HD.
Part of the routine surveillance of the patient's coagulation status includes following trends in the platelet count and
monitoring ACTs. A relative thrombocytopenia may develop
as platelets adhere to the dialyzer membrane over time.
Frequent monitoring of the dialysate and the child's
temperature are important for several reasons. As for any
patient with central vascular access, the risk of infection
is increased. Daily surveillance cultures from dialysis
tubing and dialysate are generally a part of institutional
policy. Any elevation in temperature raises suspicion of
infection, and a septic workup results. Urea may function
as an antipyretic, and thus as the patient's serum urea begins
to drop, an occult fever may appear, warranting further
investigation. Hypothermia may also be identified, which
can be improved by increasing the temperature of the
dialysate bath. The standard dialysate bath is warmed to
37° C but may range between 35° C and 40° C depending
on the clinical circumstance. 41
Continuous monitoring of the child during HD includes
observation of the blood in the circuit for color and clots
and inspection of the circuit for leaks, loose connections,
and the characteristics of flow. Nurses must assess the
child's catheter insertion site or sites at each shift for skin
integrity, bleeding, and signs of infection. The HD circuit
uses pumps, thereby increasing the risk of air embolism.
An air bubble detector alarm system is critical to safe care
of the patient.
Documentation. Documentation during HD is a
shared responsibility between the HD and PICU nurse. The
HD nurse usually documents procedural infonnation, for
example, fluid intake, laboratory results, medication administration, and the amount of UF output. The PICU nurse
usually documents the child's tolerance of the procedure

Chapter 21

and observations and assessments of the family, as well
as identified needs and teaching. Documentation of information that is jointly monitored is institution specific.
Optimal use of the record by the entire healthcare team
essential.
Complications. Although HD is the more familiar
form of treatment for ARF, several potential complications
can result. Complications may be exacerbated in a patient
with small initial circulating volumes or hemodynamically
instability. Common complications of HD include hemodynamic instability resulting from UF and osmolar losses,
temperature irregularity, and complement activation 41 The
most common complication is hypotension, which may be
corrected by UFR reduction. Other complications include
dialysis disequilibrium syndrome and hypokalemia. The use
of heparin leads to the possibility of bleeding. Circuit
disconnection, infection, and transfusion reactions are other
possible complications. Close monitoring is the cardinal
rule. Communication between the bedside and the dialysis
nurse is essential.
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SUMMARY
Various therapies are now available to support the patient in
ARE Research in the identification of risk factors associated
with ARF may allow earlier intervention, which may
minimize the occurrence of ARF or limit mortality. Pediatric
nursing research is needed to help guide practice related to
the care of patients requiring renal replacement therapy.
Survival of the child with ARF who undergoes renal
replacement therapy depends on the age of the child and the
cause of the ARE Children who are young or small have
poorer survival rates than their older and larger counterpartS. 46 The presence of such conditions as MODS makes
the therapies available difficult to use because of the
baseline hemodynamic instability of the child. Care of the
patient in ARF is complex, requiring the combined expertise
of an extensive multidisciplinary team. Collaboration within
the team provides the best plan of care for each patient. The
challenge for nursing is to help facilitate team communication and advocate for care that is in the best interest of the
patient and family.
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Gastrointestinal Critical
Care Problems
Shari Simone

HEPATIC FAILURE

EMBRYOLOGY

Etiology
Consequences of Hepatic Failure
Complications of Hepatic Failure
Critical Care Management

ESSENTIAL ANATOMY AND PHYSIOLOGY

Motility
Secretion
Digestion and Absorption

SUMMARY

GASTROINTESTINAL AsSESSMENT

Abdominal Examination
Laboratory and Radiologic Assessment
wide variety of gastrointestinal (GI) problems occur in
infants and children that may require intensive nursing
care. Problems of the GI tract range from intussusception,
treated by simple reduction with barium enema (BE), to
fulminant liver disease with GJ bleeding. GI disorders rarely
occur in isolation but are often associated with other
congenital defects or with multisystem dysfunction, placing
infants and children with these disorders at high risk for
morbidity and mortality.
GI problems result in the final common pathways of
obstruction, GI and peritoneal inflammation, GI bleeding,
and hepatic failure. The existence of one of these final
common pathways often predisposes the child to the
development of another. For example, the infant with an
intestinal obstruction is at increased risk for developing
perforation and/or necrosis of the bowel with peritoneal
inflammation without prompt treatment. Critical care nurses
play a vital role in the recognition and prevention of the
progression of these final common pathways.

A

GENERAL PRINCIPLES OF MANAGEMENT

Gastric Decompression
Intravascular Volume Replacement
and Maintenance
Pharmacologic Management
GASTROINTESTINAL OBSTRUCTION

Esophageal Atresia
Duodenal Obstruction
Jejunoileal Obstruction
Intussusception
Toxic Megacolon
GASTROINTESTINAL INFLAMMATION

Gastroesophageal Reflux
Peritoneal Inflammation
Necrotizing Enterocolitis
Short Bowel Syndrome
Pancreatitis

EMBRYOLOGY

GASTROINTESTINAL BLEEDING

Acute Gastritis
Lower Gastrointestinal Bleeding
Esophageal Varices

The digestive tract and biliary passages develop from
the primitive gut. J As early as the third week of gestation the
primitive gut can be differentiated into the foregut, the
midgut, and the hindgut. The pharynx, esophagus, stomach,
duodenum (proximal to the opening of the bile duct), liver,
pancreas, and bile duct system develop from the foregut.

ABDOMINAL WALL DEFECTS

Omphalocele and Gastroschisis
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The duodenum distal to the opening of the bile duct,
jejunum, ileum, cecum, appendix, ascending colon, and
proximal part of the transverse colon are derived from the
midgut. Other parts of colon including the left one third to
one half of the transverse colon, the rectum, and the superior
part of the anal canal originate from the hindgut.
The esophagus and trachea are one tube until the fourth
week of gestation, when the tracheoesophageal septum
forms to separate the laryngotracheal tube and the esophagus. The esophagus is almost occl uded by the proliferating
epithelium during the fifth to sixth week of gestation. At
about 7 weeks, the esophagus elongates and reaches its final
length. By the end of the embryonic period, the esophagus
hollows (recanalizes).
The stomach is first distinguished as a dilation of
the gut during the fourth to fifth week of embryonic
development. The stomach rotates clockwise longitudinally
and moves from the neck region into the abdomen. The
growth rate of the stomach wall varies, forming lesser and
greater curvatures and giving the stomach its asymmetric
appearance.
The liver, gallbladder, and biliary duct apparatus begin
development during the fourth to fifth week of gestation
from the hepatic diverticulum. The liver grows rapidly and
soon fills most of the abdominal cavity. In the sixth week of
gestation, hemopoiesis begins, giving the liver a bright red
appearance. By the end of gestation, hemopoietic activity
subsides, liver growth slows, and its size relative to body
weight is reduced. The biliary apparatus is functional by the
thirteenth to sixteenth week.
Bile formation by the hepatic cells begins during the
twelfth week. Bilirubin (bile pigments) begins to form and
enter the duodenum during the thirteenth to sixteenth week
of development. Bilirubin gives duodenal contents a dark
green or meconium color. The biliary apparatus is functional
at the thirteenth to sixteenth week of gestation.
The pancreas is created from ventral and dorsal buds
and fuse in its final form during the seventh week of
gestation. Somatostatin-, glucagon-, insulin-, and pancreatic
polypeptide-containing cells appear at or before the tenth
week of gestation. Insulin secretion begins at about the
twentieth week.
The duodenum begins to develop early in the fourth week
of gestation, originating from the foregut and midgut. The
duodenum rotates with the stomach. During the fifth and
sixth weeks, the lumen of the duodenum narrows and may
be occluded by epithelial cells. By approximately the sixth
week, the gut lengthens rapidly and causes aU-shaped
region of the future jejunum and the entire transverse colon
to transiently herniate into the umbilical cord. The intestines
continue to develop within the umbilical cord. At the tenth
to twelfth week of gestation, while the intestines rotate
counterclockwise 270 degrees, reentry of the intestines
occurs. By the end of the embryonic period, the lumen
hollows. Further positioning of the small intestine, appendix, and transverse and sigmoid colon continues until the GJ
tract assumes its final anatomic position at the twentieth
week of gestation and becomes fixed to the posterior
abdominal wall.

The colon is formed at the sixth week of gestation by
division of the rectum and upper anaJ canal from the
urogenital sinus. The rectum arid the superior part of the
anal canal are also separated from the exterior by the cloacal (anal) membrane. This anal membrane normally
breaks down by the seventh to eighth week, forming the anal
canal.

ESSENTIAL ANATOMY AND PHYSIOLOGY
Growth and maintenance of the human body is dependent on
the digestion and absorption of nutrients and water. This
process begins in the oral cavity and ends at the anal
sphincter. The GJ tract is supported by a rich blood supply,
the lymphatic system, and intrinsic and autonomic nervous
innervation, which allows for food to be moved through the
body, where it is exposed to and absorbed by a large surface
area. A review of the developmental physiology of the
digestive tract is presented in Fig. 22-1.
The oral cavity includes the lips, tongue, cheeks, teeth,
taste buds, and salivary glands. These structures decrease
the size of food, stimulate saliva secretion, and move food
into position for swallowing.
The pharynx provides for the movement of food into the
esophagus. Food passes through the pharynx to the esophagus in approximately I second.
The esophagus is a channel for the passage of food from
the pharynx to the stomach. Along the length of the
esophagus are glands that secrete mucus to provide lubrication for the passage of food. The lower gastroesophageal
sphincter is located at the distal 2 to 5 cm of the esophagus.
This sphincter surrounds the opening of the stomach with
increased amounts of muscle and remains narrowed until a
wave of peristalsis moves through it.
The stomach is a pear-shaped organ with the esophagus
at the top end and the duodenum at the lower end. The
stomach is the most dilated part of the GJ tract and is an
easily distensible reservoir for food. In infancy, the stomach
usually is transverse. By approximately age 7 years, it is the
shape and position of the adult stomach. At birth, the
stomach has the capacity to hold approximately to to 20 ml.
By 3 months, the stomach's capacity is 150 to 200 ml, and
by age to years it is about 750 to 900 ml. Stomach capacity
is important to consider when providing enteral feedings for
the critically ill infant. The lining of the stomach is made up
of mucosal folds called rugae. Within these folds are chief,
parietal, and mucous neck cells that secrete various elements
of digestive juice. The newborn stomach mucosal wall is
thinner than that of an adult.
The liver and pancreas empty into the small intestine.
The pancreas lies parallel to and beneath the stomach and
has the internal structure identical to that of the salivary
gland. The major function of the pancreas is digestion and
utilization of dietary nutrients. The liver assists with
digestion by synthesizing bile acid.
The small intestine consists of the duodenum, jejunum,
and ileum and extends from the pyloric sphincter at the
bottom of the stomach to the ileocecal valve. The lining of
the small intestine consists of folds called villi that project

Chapter 22
Liver-Produces bile, which enters
the duodenum via ducts and lowers
the surface tension of fats. Bile
increases effectiveness of pancreatic
lipase. Deficiencies in quantity of
many enzymes in the neonate
result in difficulty metabolizing
large protein loads and make some
amino acids (cystine, taurine)
normally nonessential in adults,
essential in prematures and
neonates. Decreased concentration
of bile acids in neonates limits
ability to handle fal. Colostrum
has less fat than mature milk. Fat·
absorption ability reaches adult
level by 4 to 12 months of age.

---------\1_.'

Pancreas-Produces trypsin, :---IC?1E~~--.'""(".,.4
lipase, and amylase, which are
activated in the small intestine.
Also produces insulin and glucagon,
which influences body metabolism.
Feeding promotes rapid growth
and development and stimulates
maturation of pancreatic hormone
secretion after birth. Neonates digest
and absorb fat with more difficulty
than they do protein and
carbohydrates, which is thought
to be related to decrease in
pancreatic lipase.

Large intestine-Absorbs some
water and electrolyles. Most of
digestion complete. Remainder of
intestinal contents excreted as
feces. Colonization of large
bowel by bacteria stimulates its
growth after birth.
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Oral cavity-Ghewing breaks food
into small portions. Salivary mucin
and amylase mix with food and
initiate breakdown of complex
carbohydrates. At birth saliva has
low amylase activity « 5% of adult
levels) but reaches adult levels
by 6 months.

Lower esophageal sphincter
Gallbladder
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Stomach-Mixes food with gastric
juices (hydrochloric acid, mucus,
water, and enzymes). Enzymes
convert as follows:
Pepsin-proteins to proteoses
and peptone
Renin-easeinogen (in milk) to
casein
Lipase-lipids to fally acids
Holds only 10 to 20 ml at birth and
has a very rapid emptying time.
Rapidly grows following initiation
of feedings. Parietal cells are well
differentiated and producing
hydrochloric acid at 3 months
of age.
Small intestine-Villi secete intestinal juices containing enterokinase
(activates pancreatic trypsin, which
hastens protein breakdown) and
amylase (acts on carbohydrates).
Epithelial cells contain:
Peptidases-eonvert peptides to
amino acids
Lipase-ats to fally acids and
glycerol
Sucrase, maltase, isomaltase,
lactase-reduce disaccharide
sugars to monosaccharides
Absorbs water, carbohydrates,
proteins, fats, vitamins, and mineral
salts. Nutrients are returned to
circulation for use or storage.
Fragile at birth but thickens and
strengthens rapidly in response
to feeding. Secretory and absorbing capacity are well developed
at birth; digestive enzymes for
nutrients in milk are present
at birth.

Fig. 22·1 Developmental physiology of the digestive tracl. (From James SR, Mott SR: Child heallh
nursing: esselllial care of children and families, Reading, Pa, 1988, Addison-Wesley.)

into the intestinal lumen. Microvilli cover the membranes of
mature epithelial cells that make up the villus tip and form
the brush border region. The brush border contains digestive
enzymes and contributes to the transfer of nutrients and
electrolytes. This area is highly specialized for absorption.
Pitlike structures exist between villi called the crypts of
Lieberkuhn and are composed of absorptive cells and goblet
cells that produce mucus. Three sets of lymph nodes also
exist along the bowel.
The large intestine begins with the ileocecal valve at
the cecum. It includes the appendix and extends through the

ascending, transverse, and descending colon and ends at the
rectum and anal canal. the internal and external sphincters
are made up of the anorectal ring. In the large intestine, there
is an increase in the number of goblet cells.
An infant's intestinal length is proportionately larger than
that of an adult. This proportional increase allows for larger
amounts of fluid to be lost by the infant.
The physiologic and biochemical functions of the GI
tract are dependent on motility, secretion, digestion, and
absorption. At birth, most of these functions are present,
although some developmental differences in absorption,
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Box 22·1

DevelopmentalOifferences ·of Infant's
Gastrointestinal Tract . ..

Decreased pool of bile acid
Increased permeability to whole proteins
Increased gastrin and cholecystokinin level
Mucosal wall is proportionally longer
Immature pancreatic secretory function
Lower trypsin, chymotrypsin, and carboxypeptidase B levels
From Matil K: Development of the gastrointestinal tract. In Wyllie R,
Hyams JS, eds: Pediatric gastrointestinal disease, Philadelphia, 1993,
WB Saunders.

membrane permeability, and types of gastric secretions do
exist (Box 22-1).

Motility
Movement within the GI tract is initiated by muscle
contraction and is influenced by the nervous system, blood
flow, temperature, and hormones. 2 •3 The intestinal tract is
stimulated by distension, most often from the presence of
food. Peristalsis, the basic propulsive movement, is initiated
and moves the digested material through the alimentary
tract. Peristaltic movement occurs because a group of
muscles encircle the lumen of the gut and contract around
the digested material creating a pocket. As the muscles
below the pocket relax, the longitudinal layers of the gut
constrict and propel the contents forward.
During swallowing, food is transported from the posterior part of the mouth to the stomach. The process of
swallowing is initiated by the central nervous system.
Stimulation of receptors around the opening of the pharynx
elicits the swallowing reflex and protects the trachea. The
act of swallowing is primarily an automatic reflex for the
first 3 months of life. Swallowing starts to become voluntary
beginning at 6 weeks, and by 6 months it is fully voluntary.
The primary peristaltic wave spreads into the stomach in 8
to 10 seconds. If this primary peristaltic wave does not move
all the food to the stomach, secondary waves are initiated.
During peristaltic contractions, the stomach and duodenum
become relaxed and fill.
When the stomach is distended, peristaltic waves act to
mix the food. During this time, the pylorus remains almost
closed, allowing only water and other fluid to empty.
Periodically, the waves of peristalsis become markedly
stronger. The stronger pressure gradient results in the
semiliquid food called "chyme" to move into the duodenum. The rate of gastric emptying is influenced by the
osmolarity and volume of the food. Hypertonic feeds and
high fat content delay emptying. Once peristalsis has
developed in the newborn, the stomach empties in approximately 2 hours. The rapid transit time and small stomach
capacity contribute to the frequency and amount of feeding
and stools in infants. Human milk moves through the
stomach faster than cow's milk 4 In older infants and
children, gastric emptying occurs in 3 to 6 hours.

As chyme enters the small intestine, contractions similar
to those in the stomach occur. These peristaltic waves are
weak and function to move some of the chyme toward the
colon, spreading it along the intestine. Most of the chyme
will stay in the duodenum until additional food is eaten and
a new gastroenteric reflex intensifies peristalsis.
When chyme reaches the colon, contractions are poorly
coordinated. These sluggish but persistent movements may
occur several times each day. The result is a delay of 8 to 15
hours to move chyme from the ileocecal valve to the
transverse colon.
Defecation is stimulated when feces enter the rectum.
Peristaltic waves in the descending colon, sigmoid, and
rectum are initiated. Relaxation of the internal sphincter
results in contraction of the external sphincter. Voluntary
control of the external sphincter allows a person to inhibit
sphincter contraction, permitting defecation. Voluntary control of the external sphincter also allows for keeping the
sphincter contracted.

Secretion
Throughout the GI tract, glands secrete enzymes and
hormones used in digestion (Table 22-1). Mucus is also
secreted to lubricate and protect the alimentary tract. The
presence of food usually stimulates the glands in the region
of the food and the surrounding areas to secrete digestive
juices. The secretion of saliva by the parotid, submandibular, and sublingual glands begins the process of digestion
and absorption. Gastric secretion is regulated by the parasympathetic fibers of the nervous system and by hormonal
mechanisms. In the stomach, gastric pepsin initiates protein
digestion. Gastric lipase affects fat hydrolysis.
Pancreatic juice is released into the duodenum mainly in
response to the presence of chyme. The composition of the
pancreatic juice varies depending on the food substances
ingested. Large volumes of bicarbonate ions neutralize the
acid from the stomach. Also contained in pancreatic juice
are various enzymes that act on proteins, carbohydrates, and
fat. Pancreatic secretion, like gastric secretion, is regulated
by neural and hormonal mechanisms. Bile and bile salts
(end product of cholesterol metabolism and the largest
component of bile) are also released into the duodenum by
way of the bile duct apparatus. Bile is produced and secreted
by the liver and is essential for the absorption of fats and
fat-soluble vitamins from the gut. Intestinal glands are
stimulated by tactile stimulation, chemical irritation, distension, or motility within the gut.
Brunner glands and other cells of the intestinal mucosa
secrete mucus. The crypts of Lieberktihn secrete pure
extracellular fluid, supplying a vehicle for absorption of
substances from chyme. The large intestine is lined with
mucous cells that secrete only mucus.

Digestion and Absorption
Digestion and absorption by the GI tract provide the organic
molecules of fat, carbohydrates, and protein to provide
energy for the body to function. The gut prepares food by
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Selected Gastrointestinal Enzymes and Hormones

,,,,.,,allval v glands

Enzyme

Action

Ptyalin (salivary amylase)

Starch to smaller carbohydrates

Pepsin (chief cells) intrinsic factor
Gastric lipase
Gastrin

Protein to polypeptides
Triglycerides to glycerides and fatty acids
Stimulates gastric acid secretion in the presence of stomach
distension
Inhibits various hormones, secretions, and motor effects
Protein to amino acid
Protein and polypeptides to amino acids

Somatostatin*
Elastase
Trypsin
Chymotrypsin
Nuclease
Carboxypeptidase A and B
Pancreatic lipase
Pancreatic amylase
Cholesterol esterase
Phospholipase A,

Enteroglucagon
Brush border enzymes:
Aminopolypeptidase
Dipeptidase
Maltase
Lactase
Sucrase
Intestinal lipase
Gastrone
Secretin
Cholecystokinin-pancreozymin
(CCK-PZ)

Nucleic acids to nucleotides
Polypeptides to smaller polypeptides
Lipids to glycerol, glycerides, free fatty acids
Starch to two disaccharide units (maltose)
Hydrolysis of ester bonds in cholesterol and vitamins
A, D, and E
Phospholipid digestion
Inhibits gastric function
Polypeptides to smaller peptides
Dipeptides to amino acids
Maltose to glucose
Lactose to glucose
Sucrose, glucose, fructose
Fats to glycerides, glycerol, fatty acids
Inhibits gastric secretion in presence of fats, sugars,
and acids
Stimulates hepatic bile and pancreatic electrolyte and fluid
secretion in the presence of polypeptides and acids
Stimulates pancreatic enzyme secretion and gallbladder
contraction to release bile in the presence of fats

found in the pancreas and small and large intestine.

chemical and mechanical means so it can be absorbed
through the mucosal lining into the blood and lymph.
All major nutrients are absorbed in the small intestine.
Bile salts and vitamin B 12 are absorbed only in the terminal ileum. The large intestine is primarily concerned with
the absorption of water and electrolytes and functions in
the synthesis of vitamin K and some B complex vitamins. The resultant feces usually consist of three-fourths
water. The remaining one fourth is solid material, of which
approximately 30% is dead bacteria. The brown color is the
result of breakdown products of bilirubin called stercobilinogen. Table 22-2 lists the nutrients obtained through food
and their site of absorption.
Carbohydrate digestion begins in the mouth where food
mixes with ptyalin (also known as amylase), an enzyme
contained in saliva. Ptyalin hydrolyzes starch into maltose
and other small glucose polymers. Pancreatic amylase and

TABLE

22-2 • Nutrient Site of Absorption
Primary Sites of Absorption

Duodenum, upper jejunum
Jejunum. ileum
Jejunum, upper ileum
Duodenum, jejunum
Duodenum, upper jejunum
Jejunum, ileum
Jejunum, ileum
Duodenum
Duodenum
Duodenum
Jejunum, ileum
Terminal ileum
Stomach, small and large intestine
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various other enzymes from the brush border of the
intestinal epithelium are responsible for further digestion of
carbohydrates in the small intestine. Carbohydrates are
absorbed mostly in the form of a monosaccharide, such as
glucose, galactose, and fructose. Glucose transport is related
to the sodium-coupled glucose transport system. The
glucose and galactose transport rate in infants is low
compared with that in adults and apparently increases
during the first year of life. The digested products are
absorbed into the portal blood. Most of the carbohydrates
are used for energy, although some excess glucose is stored
as glycogen in the liver. Additional carbohydrates are
changed into fat and stored as triglyceride.
The digestion of protein begins in the stomach with
gastric acid secretion. These acids denature complex proteins, making them more conducive to the actions of
proteolytic enzymes. Pepsin begins the digestion of protein
in the stomach, providing approximately 10% to 30% of
total protein digestion. Protein digestion continues in the
small intestine under the influence of the pancreatic
enzymes and mucosal enzymes. Protein absorption occurs
mostly in the duodenum and jejunum in the form of amino
acids. As with glucose transport, the sodium transport
mechanism probably provides for amino acid transport.
Amino acids are used in production of enzymes, in synthesis
of plasma proteins, as components in liver structural
proteins, in the gut, and in other organs and muscles. In
certain conditions, amino acids are used in glyconeogenesis
to make glucose when glycogen stores cannot meet the
body's caloric needs. Valine, leucine, isoleucine, lysine,
threonine, tryptophan, phenylalanine, and methionine are
essential amino acids. Tyrosine and cysteine are semiessential because they can be synthesized only from essential
precursors.
Newborn proteolytic activity and absorptive function is
not fully developed. Intestinal permeability to whole proteins is increased in infants. s The increased permeability
allows for cow's milk proteins and other allergens to
traverse the intestinal wall. This may increase the infant's
susceptibility to GI allergies.
Appropriate fat digestion and absorption depends on the
proper functioning of the pancreas hepatobiliary system and
the absorptive sites within the jejunum, ileum, and lymph
nodes. Dietary fat is ingested primarily in the form of
long-chain triglycerides. Other dietary lipids that are used
by the body include small quantities of phospholipids,
cholesterol, and cholesterol esters. Most digestion and
absorption of fat occur in the small intestine, with the
majority of fat absorbed by the middle one third of the
jejunum. Lipolysis is dependent on the presence of bile acid,
phospholipase A2 , and pancreatic lipases. Triglycerides are
broken down to fatty acids and glycerol. Phospholipid
envelops the triglyceride. Bile salts and fatty acids form
micelles and attach themselves to the surface of epithelial
cells. Fatty acids then diffuse into the cell and re-form to
triglyceride molecules, which are released into the lymphatics and then to the systemic circulation. Mediumchain triglycerides are digested and transported through
the intestinal lumen faster than long-chain triglycerides.

Medium-chain triglycerides do not require bile salts and
pancreatic lipase for digestion.
In infants younger than I year of age, only 80% to 95%
of triglycerides are absorbed 6 A smaller pool of bile acid
results in the inefficient absorption of fat. To minimize fat
malabsorption, infants use alternative mechanisms to facilitate fat digestion.
Water absorption is dependent on movement of electrolytes. By diffusion water follows electrolytes across the
intestinal membrane by passing through membrane pores.
When chyme is dilute, water is absorbed through the
intestinal mucosa into the blood. The greatest proportion of
water absorption is in the jejunum and proximal part of the
large intestine.
The information available regarding mineral, vitamin,
and trace element absorption is limited. Electrolytes, like
water, are absorbed through membrane pores or by transport
into the blood. Greater absorption occurs in the proximal
rather than the distal portion of the small intestine.
Electrolytes are also absorbed in the large intestine. Sodium,
chloride, potassium, and bicarbonate are more easily absorbed because they are monovalent, whereas polyvalent
electrolytes, such as calcium and magnesium, are more
difficult to absorb. Absorption of calcium occurs by active
transport primarily in the duodenum, whereas phosphorus
absorption takes place mostly in the jejunum. Calcium and
phosphorus intake greatly affects phosphorus absorption.
The absorption of trace elements is dependent on the milk
source. Breast-fed infants are more efficient in absorbing
trace elements than infants who are fed cow's milk-based
formulas. 4

GASTROINTESTINAL ASSESSMENT
Abdominal Examination
Nursing assessment of the GI system is fundamental to the
care of infants and children who are critically ill, particularly when GI dysfunction is suspected or confirmed.
Assessment is initiated with serial abdominal examinations,
employing the basic techniques of inspection, auscultation,
percussion, and palpation. Unlike other system assessments,
auscultation is performed before percussion and palpation to
prevent changes in bowel sounds. The examination is also
performed with the patient in a completely supine position.
The abdomen is inspected for the presence of bruises,
wounds, scars, erythema, or discolorations; peristaltic waves
and/or pulsations; visible asymmetry, masses, bowel loops,
or protuberances; a flat, full, or scaphoid contour; distension; and umbilical and muscular abnormalities. Significant abdominal distension is a classic sign of intestinal
obstruction.
Serial auscultation of the abdomen is performed in all
four abdominal quadrants, noting the presence, or absence,
and character of bowel sounds with particular attention to
changes in sounds over time. Intestinal obstruction produces
high-pitched, tinkling sounds; nasogastric (NG) intubation
causes decreased or absent sounds. A quiet abdomen is
present during paralytic ileus, and an ominously silent
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abdomen may indicate perforation with peritonitis. Other
sounds, such as bruits, hums, and rubs, may also be heard
with auscultation. A friction rub may indicate peritoneal
inflammation.
Percussion is used to obtain information regarding
abdominal contents, including air and fluid, as well as the
size of intraabdominal organs and masses. Shifting dullness
is elicited in the presence of intraperitoneal fluid. The
normal liver and spleen are dull to percussion. Absence of
dullness over the liver may be found with pneumoperitoneum, or may be elicited when an air-filled loop of bowel is
located over the liver. Percussion of the liver more than 2 em
below the right costal margin (RCM) indicates hepatomegaly. Percussion of the spleen below the left costal margin
(LCM) indicates splenomegaly.
Palpation is used to obtain information regarding abdominal pain and tenderness and data regarding the size, shape,
and location of organs and masses. Palpation also is used to
detect free fluid. Superficial palpation is performed first,
followed by deep palpation. The liver is normally palpable
at the RCM or is nonpalpable. The spleen is not normally
palpable. Pain is the most common symptom in a patient
with an "acute abdomen" (abdominal condition requiring
urgent surgical evaluation). Deep palpation may be deferred
in these patients and on any patient with a known or
suspected abdominal mass because of the risk of rupturing
the encapsulated mass.
The presence of rebound tenderness indicates peritoneal
inflammation. The technique to elicit rebound tenderness
consists of the examiner exerting firm pressure in an area
away from the pain and then quickly releasing the pressure.
A positive response is an unequivocally painful reaction.
This technique is not used routinely with pediatric patients
because it is unnecessarily painful for the child and does not
reveal any new findings. Most children wince in response
only to the change in pressure exerted, and children who
have significant disease exhibit a painful reaction simply
with light palpation.
Measurement of abdominal girth provides objective data
regarding the degree of distension and is included in the
assessment of the abdomen. Serial measurements are
important to identify subtle changes, particularly in nonverbal children.
Monitoring all GI outputs, including emesis, gastric
devices, ostomies, and stool, is essential in determining
excessive output and potential electrolyte imbalances. Excessive gastric drainage can cause a metabolic alkalosis
resulting from hydrochloric acid losses. Excessive losses
from a new ileostomy or diarrhea can cause metabolic
acidosis due to sodium bicarbonate losses. The color,
character, and consistency of all GI output should be noted;
the amount is estimated or measured and included in output
calculations. Gastric drainage is tested for pH and blood,
and stool is tested for blood. The character and content of
emesis and stool are helpful in understanding the underlying
disorder. Bilious vomiting is a significant finding, indicative
of a proximal mechanical obstruction. Hematemesis indicates an upper GI bleeding site; hematochezia (bright red
blood from the rectum) indicates brisk mid-GI or lower GI
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tract bleeding. Melena is blood that has been digested
during passage through the GI tract. Melanotic stools
indicate slow upper or mid-GI tract bleeding. 7 Occult
bleeding (heme test positive without visible blood) is the
result of chronic blood loss.

Laboratory and Radiologic Assessment
Serial laboratory and diagnostic studies are obtained on all
patients with a GI disorder. Table 22-3 summarizes common
laboratory tests indicating GI dysfunction. Assessment of
liver function includes the measurement of hepatocellular
enzymes. The enzymes commonly measured are aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and alkaline phosphatase (ALP). Other enzymes that are
more specific to liver function but less frequently measured
include y-glutamyltransferase (GGT) and 5'-nucleotidase.
AST is an enzyme found also in the heart, kidney,
skeletal muscle, and brain and therefore not speci fic to Ii ver
function. However, the ALT enzyme is found primarily in
the liver and is therefore more specific for liver function. It
is important to remember that elevations in AST and ALT
are seen with hepatocyte dysfunction or failure. Clinical
assessment is correlated with diagnostic data to differentiate
hepatic from nonhepatic disease. ALP is an enzyme active in
the bone, intestine, and liver. An elevation in this enzyme is
an indication of decreased biliary functioning or obstruction.
The enzyme GGT is found in the hepatic and biliary system
and other tissues. It is often assessed with the measurement
of ALP to evaluate for biliary tract disease. Like GGT,
5'-nucleotidase is a liver-related enzyme used to investigate
the origin of increased serum ALP.
Diagnostic studies include plain abdominal films, nuclear
medicine scans, computed tomography (CT), magnetic
resonance imaging (MRI), ultrasound, and endoscopy.
Indications for these studies are presented in Table 22-4.
Plain abdominal films are done in two views to identify
air-fluid levels and provide an alternate view in addition to
a flat plate x-ray film. Small infants and older children who
are critically ill cannot be put in the upright position for a
second view and require either a cross-table lateral or left
lateral decubitus film. Chest radiographs are also obtained to
rule out abnormalities within the thorax, or concurrent
disease processes such as right lower lobe pneumonia, or
complications of severe GI dysfunction such as pleural
effusion. Contrast stndies help define Gf anatomy, aid in
diagnosis (e.g., of gastroesophageal reflux), or are treatment
measures, such as in the reduction of an intussusception
with a hydrostatic BE. Additional diagnostic studies are
warranted for specific disorders and are discussed specifically in the following sections.

GENERAL PRINCIPLES OF MANAGEMENT
In addition to ongoing assessment and monitoring, gastric
decompression, intravascular volume replacement and
maintenance, and pharmacologic management are general interventions indicated in response to GI pathologic
events.

772

Part IV

TABLE

Final Common Pathways

22-3

Indicators of Gastrointestinal Dysfunction
Pediatric Normal Value

Interpretation

Infant <54 unitsIL
Child 1-30 unitsIL
Infant 20-65 unitsIL
Child 0-35 unitsIL
Infant 150-420 unitsIL
2-10 yr 100-320 unitsIL
11-18 yr 100-390 units/L
Infant 150-360 unitsIL
Child 150-300 unitsIL
All ages <120 IUIL

Increases with hepatocellular injury

All ages 0.1-0.3 mg/dl
All ages 0.1-1.3 mg/dl
Infant <2 mg/dl
Child 0.2-1.3 mg/dl
Infant 10-15.9 sec
Child 10.8-13.9 sec
All ages 3.8-5.4 g/dl
Infant 29-70 !!g/dl
Child 0-50 !!g/dl
All ages 5-10 unitsIL
All ages <200 unitsIL

Gastric Decompression
Decompression of the 01 tract is one of the primary
interventions indicated in patients with a 01 abnormality. The goal of gastric decompression is to actively
remove air and secretions from an injured 01 tract. In 01
obstruction, which often precedes perforation, there is
dilation of the proximal bowel as peristalsis continues
against the distal obstruction. In addition, air and secretions
collect in the bowel lumen proximal to the obstruction.
Decompression is employed either continuously or intermittently to actively remove air and secretions from the upper
OJ tract.
The preferred position for intubation and gastric decompression in a child is semiupright. An NO or orogastric
(00) tube is inserted into the stomach via the esophagus.
The oral route may be preferred for young infants who are
obligate nose-breathers. For the purpose of decompression,
the largest possible double-lumen vented tube is used, such
as the Salem sump tube or a Replogle tube, for neonates.
Such tubes have a primary lumen to remove air and

Increases with hepatocellular injury
Increases with biliary obstruction and cbolestatic
hepatitis
Increases with rise in alkaline phosphatase
1ncreases with biliary obstruction and moderately
increases with hepatocellular injury
Increases with hemolysis
Increases with hepatocellular injury
Increases with biliary obstruction
Increases with vitamin K deficiency or hepatocellular injury
Reduces with hepatocellular injury (also dependent
on protein intake)
Increases with hepatocellular injury
Increases with biliary obstruction or cholestatic
hepatitis
Increases with pancreatitis (more sensitive and
specific than amylase)
Increases with acute pancreatitis; however, level
includes salivary and pancreatic isoenzyme;
therefore increase may be due to salivary inflammatory lesion (i .e., mumps)

secretions; the other lumen serves as an air vent to keep the
primary lumen from adhering to the stomach wall when
suction is applied. It is important to note that the air vent
lumen is not clamped off, and clogging with secretions
needs to be prevented. A slight hissing sound signals that the
tube is functioning properly. Patency may be maintained by
instilling 5 to 30 ml of air (depending on the size of the
child) into the air vent. The primary lumen can also be
irrigated with saline. The child maintains a nothing-bymouth (NPO) status, and excessive swallowing of air is
discouraged.
Repositioning the tube, as well as irrigating as described
earlier, may be indicated if there is doubt about the adequacy
of gastric decompression. If inadequate, abdominal distension and diaphragmatic elevation can develop, which then
compromise both respiratory and 01 function. In addition to
decompressing the 01 tract, NO and 00 tubes are used for
gastric lavage, the administration of various medications,
including antacids to prevent stress ulcer syndrome, and
collection and analysis of gastric aspirate.
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Diagnostic Studies for Gastrointestinal Disorders

!ii'"

~i'rocedure

Purpose/Comments

Examples of Abnormalities

~liiX-ray Examination
r,j!(Abdominal flat plate
~!rAbdominal cross table
fiC.
l;jfj)ecubltus

Evaluate organ size, position, gas patterns
(intraluminal and extraluminal), airl
fluid levels

Pneumatosis intestinalis (air in bowel
wall), TEF, small bowel obstruction,
perforation, ileus, ascites

Examine the esophagus and mucosal
integrity; diagnose structural
abnormalities
Examine the esophagus, stomach, and
duodenum, diagnose structural abnormalities, motor disorders, delayed
gastric emptying
Same as upper GI with follow-up spot
, films of esophagus. stomach,
duodenum, and small intestines;
diagnose small bowel abnornlalities
Examine the large intestine and
mucosal integrity; diagnose structural
abnormalities

Malrotation, esophageal or small bowel
strictures

fir·

ilfr"

:~Iuoroscopy
1!'Barium swallow
.J:!'o.

~{

j;,r
lffi"

~Vpper GI series

!""

~!tt

~~'
~~:

l::-'Upper GI with small bowel
follow-through

i

~:;

!1'T

I;
,
iiijiBanum enema
~'C

~i:

j1u"';

Gastroesophageal reflux (GER),
malrotation, volvulus, ulcerative
disease
Inflammatory disease (Crohn's and ulcerative colitis)

Intussusception, Hirschsprung's disease,
meconium ileus

r.~};ndoscopy

Ji;:F1ex,ble upper endoscopy
(esophagoscopy, gastroscopy,
I!'L
iiF dod
u enoscopy )

llfJ"
~"
l;§1'

~Endoscopic

retrograde

iii""
Iii!i,i
cholangiopancreatography (ERCP)

~!f1exible sigmoidoscopy or colonoscopy

fl~

Directly visualize the upper GI mucosa,
diagnose mucosal injury, lesions,
structural abnormalities, or source of
Gl bleeding
Directly visualize the biliary pancreatic
ducts
Directly visualize mucosa of large intestine, diagnose mucosal injury or source
of lower GI bleeding

Esophageal varices, severe gastritis

Obtain liver specimen without laparotomy

Biliary atresia. hepatitis (when etiology
and/or outcome uncertain)

Determine delayed gastric emptying
(defined as 50% of isotope meal
retained in stomach after 90 min
in absence of obstruction)
Determine liver and spleen size or presence of mass, abscess, or other abnormality (does not evaluate liver
function)
Determine liver excretory function
Evaluate location of bleeding (radioactive
isotope is taken up by gastric mucosal
parietal cells)

GER

Definitively image abdominal organs
(deferred in hemodynamically unstable
child)
Visualize organ structure, diagnose tissue
abnormalities rapidly and without
patient transport
Evaluate for vascular problems, definitive
imaging of solid organs, evaluate for
infection/abscesses, trauma

Hepatic hemangioma (i.e., KasabachMerritt syndrome), hepatic arteriovenous malformation
Hepatocellular disease. acute pancreatitis,
hepatic arteriovenous malformation

Pseudocyst, chronic pancreatitis, stones

~~Biopsy
!li'

~ercutaneous Ii ver biopsy

''''f
~"

i':"'

uclear Scans
IFiastroesophageal scintigraphy
!~W; (gastric emptying study)

~!i:

jii'
f.jf-'-:.

,ffitLIver-spleen

ffi~L

Lif'

V'
illi:!"

~epatobiliary excretion scan (HIDA)
~~Meckel scan
~~t

~jj;

i.'!i;'··

Biliary atresia
Meckel's diverticulum

~!Pther Imaging
i:'Magnetic resonance imaging (MRI)
~ib

mt:

!!lE

li:Abdominal ultrasound

~r'u"

II~:Abdominal

computerized

i~i tomography (CT) scan with contrast

I'".,'

i:

Pancreatitis, pseudocyst, hepatocellular
disease
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Intravascular Volume Replacement
and Maintenance
Fluid administration takes into account insensible losses
(supplied by maintenance fluids), estimated third-space
losses, and measured losses, which include NG and OG tube
secretions, ongoing GI bleeding, ostomy and fistula drainage, diarrhea, or losses from other tubes or drains and
wounds. 8 Measured losses are calculated and replaced at
specified intervals. Table 22-5 outlines electrolyte content of
GI secretions and comparable intravenous (IV) replacement
fluids.
If hypovolemia is severe, fluid resuscitation may be
required to correct hypovolemia and maintain a urine output
of I to 2 ml/kg/hour. As fluid returns to the intravascular
space, fluid retention or overload can occur and the
administration of diuretics may be indicated to aid in the
excretion of excess fluid. Meticulous monitoring of intake
and output is mandatory for these patients, as is ongoing
assessment for signs and symptoms of fluid volume deficit
or excess.

Pharmacologic Management
In most cases of actual or potential GI dysfunction, a variety
of pharmacologic agents are employed. These agents are
used to treat infection, excessive gastric acid secretion, and

[tI..

2.2-5 Solution for Replacing Losses.
of Gastric Secretions.
.

TABLE

Gastric Secretion
(mEq/l)
60-75
105-130
5-30
0-65

Replacement
Fluid 05%. 0.45 NS
+ 30 mEq/KCl/l
77
107
30

o

!i:(, ,

jom Filston HC: Fluid and electrolyte management in the pediatric
patient. S"rg Clin North Am 72: 1189-1205, 1992.

i~gical

~

GI bleeding. Pharmacologic agents include antimicrobials
to treat intraabdominal infection; histamine-receptor (H 2 )
antagonists and antacids to decrease and neutralize gastric
acid secretion; and vasoconstrictive and sclerosing agents to
decrease bleeding. The use of these medications are
described in the following sections conjunction with treatment for specific clinical conditions.

GASTROINTESTINAL OBSTRUCTION
True GI obstructions occur most commonly in the newborn.
Obstructions may be present in any portion of the gut from
the esophagus to the anus and are related to a variety of
causes (Table 22-6). The initial presentation, clinical
findings, and patient management vary, depending on the
type and location of the obstruction. A maternal history
of polyhydramnios may indicate a proximal obstruction
(i.e., esophageal atresia) because the fetus is unable to
properly digest amnionic fluid. Small bowel obstruction
commonly presents with bilious emesis and abdominal
distension. Failure to pass a meconium stool in the first
24 hours of life is suggestive of a distal obstruction (i.e.,
Hirschsprung's disease). The pathophysiology of obstruction is depicted in Fig. 22-2.

Esophageal Atresia
Esophageal atresia is a congenital anomaly in which the
esophagus is segmented with a blind pouch separating the
upper and lower portion. In most instances, there is also a
fistula connecting the distal esophagus and trachea. However, the use of the term "tracheoesophageal fistula" (TEF)
to describe all anomalies of the esophagus is incorrect.
There are several described types of tracheoesophageal
deformities. The three main types (Fig. 22-3) include
esophageal atresia with distal TEF, isolated esophageal
atresia, and TEF without esophageal atresia (H-rype). The
most common is esophageal atresia with distal TEF,
occurring in 85% of all cases. 9
Pathogenesis. The esophagus and trachea develop
embryologically at the same time. These structures are first

Causes of Intestinal Obstruction
~Mechanical Obstruction
·"i~iltraluminal
· ~tresia or stenosis
-\pyloric stenosis
':~oreign body
~. econium
;;,: edications
~{ holestyramine
':r.ntacid
~iKaolin
· i"arasitic infection
~m

"'"

Paralytic Ileus
Extrinsic
Malrotation
Volvulus
Hernia
Annular pancreas
Duplication cysts
Adhesionslbands
Tumor
Granulomatous process

Abdominal Conditions
Hirschsprung's disease
Intestinal pseudoobstruction
Severe gastroenteritis
Perforation of viscus
Peritonitis
Pancreatitis
Necrotizing enterocolitis
Toxic megacolon

Systemic Conditions
Trauma
Shock
Sepsis
Hypokalemia
Drugs
Diabetic acidosis
General anesthesia
Intussusception

Quan R: Bowel failure. In Levin DL, Morriss Fe, eds: Essentials of pediatric ill/eflSive care, 5t Louis, 1990. Quality Medical Publishing.
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common. The infant typically presents with bubbly oral
secretions and regurgitation of saliva, which cannot be
swallowed because of the blind proximal esophageal pouch.
Most babies with isolated esophageal atresia or esophageal
atresia with TEF present with tbis problem soon after
delivery. The diagnosis is made by careful placement of an
NG tube into the blind pouch. A simple chest radiograph
subsequently reveals a curled tube in the proximal esophageal pouch. With esophageal atresia and distal TEF, an
abdominal film typically reveals a distended stomach with
gas patterns throughout the small bowel. However, in the
infant with isolated esophageal atresia, the abdominal film
shows a gasless bowel pattern.
An infant with an H-type TEF usually presents at 3 to 4
months of age with a history of respiratory distress,
pneumonia, and some degree of cyanosis with feedings.
Direct bronchoscopic visualization is the diagnostic study of
choice. The tracheal end of the fistula can usually be
visualized through the membranous portion of the trachea. 9
Occasionally, a barium or water-soluble esophogram may be
used for diagnosis, but often this does not demonstrate the
fistula, and aspiration of the contrast material is a concern.
Critical Care Management. Once a diagnosis of
esophageal atresia with or without TEF is made, preoperative stabilization of the newborn is essential. Decompression
of the proximal pouch is of utmost importance in the

recognized as a ventral diverticulum of the foregut at 22 to
23 days after fertilization 9 The development of the esophagus and trachea is believed to occur by the proliferation of
endodermal cells on the lateral walls of the diverticulum.
Rosenthal theorized that these cell masses become ridges of
tissue that divide the foregut into two separate channels,
forming the esophagus and trachea. 1O This process is
completed by 36 days after fertilization. During the fourth
week of fetal life, interruptions in development may result in
abnormalities of the esophagus with and without fistula
formation between the two structures.
Associated Anomalies. Deformities of the esophagus and trachea occur early in intrauterine development
along with generalized organ differentiation and division.
Mesodermal maldevelopment caused by some unknown intrauterine event is believed to be the cause for multisystem
problems seen in many of these newborns. The majority of
these defects are grouped under the name VACTERL (Vvertebral, A-anal, C-cardiac, TE-tracheoesophageal, R-renal,
L-limb). Most series report the incidence of associated
anomalies with esophageal atresia-TEF deformities to be
between 30% and 55%. Cardiovascular disease is the most
common associated anomaly, followed by limb and genitourinary defects. 11.12
Clinical Presentation. As with other causes of proximal obstruction, a maternal history of polyhydramnios is
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Fig. 22·2 Pathophysiology of intestinal obstruction. (From Quan R: Bowel failure. In DL Levin,
FC Morris. eds: Essentials of pediatric intensive care, St Louis, 1990, Quality Medical Publishing.)

Fig. 22-3 Three forms of esophageal anomalies. A is the most
common form of esophageal malformation; B is the next most
common form; C is the classic "H" type fistula. (From Avery ME
et al: The lung and ils disorders in the newborn infant, ed 4,
Philadelphia, 1981, WB Saunders.)
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preoperative phase. This is accomplished using the general
principles of gastric decompression described earlier, except
that the Replogle tube is placed in the proximal esophageal
pouch, thereby removing oral secretions and preventing
pulmonary aspiration.
Operative Management for Esophageal Atresia
With Distal TEF. Primary repair is the best surgical
option and may be performed even in the small preterm
infant. 13 • 14 The operative approach is through a right
thoracotomy incision in which the fistula is first divided, and
then the two segments of the esophagus are anastomosed.
Operative Management for Isolated Esophageal
A tresia. In most cases of isolated esophageal atresia,
there is a long gap between the proximal and distal segments
of the esophagus, which precludes primary repair in the
newborn period. For a full-term baby with no other
abnormalities, usually only a feeding gastrostomy is placed.
Over the next several months of life, it is believed that the
esophageal segment will elongate spontaneously. I I During
this waiting period, the surgeon may choose to manually
stretch the upper and lower segments of the esophagus.
The second stage of surgical intervention typically occurs
when the chest x-ray film reveals overlapping of the
esophageal segments (or less than a vertebral body apart). At
this time, a primary end-to-end anastomosis of the esophagus is attempted. If for some reason the segments do not
come together easily, a circular or spiral myotomy of the
upper esophagus is performed. This procedure usually
provides I to 2 mm of extra length by dividing the outer
layer of the esophagus.
Conversely, for the sick preterm infant, this delayed type
of primary closure may not be optimal. There also may be
some infants in whom the gap between the esophageal
segments is so wide that primary repair is impossible. In
either of these cases, a cervical esophagostomy (exteriorizing the blind upper esophageal pouch in the neck region)
and gastrostomy are performed in the newborn period.
When the child reaches a weight of approximately 10 kg, an
esophageal replacement procedure is performed using a
piece of colon, small bowel, or stomach.
Operative Management of TEF. The operative
approach to an isolated TEF is through a right thoracotomy
or a right cervical incision. The fistula is divided primarily.
Surgical complications are rare.
Postoperative Management. After esophageal
atresia repair with or without TEF, the infant may require
ventilatory support. The infant may require paralysis and
prolonged mechanical ventilation if there is concern that the
anastomosis is under tension. After extubation, if the child
again requires assisted ventilation, the surgeon must be
present to make sure the intubation does not interrupt the
anastomosis. Oropharyngeal or nasopharyngeal suctioning
is performed with a suction catheter that is measured and
marked at the time of surgery to avoid the anastomosis site
during the suctioning procedure.
An extrapleural chest tube and drain are placed at the
time of surgery; an assessment of the color and consistency
of the drainage is important. The presence of mucous in the

collecting chamber may indicate a leak at the site of
anastomosis.
Gastric decompression remains essential in the postoperative period. This can be accomplished with either an NG
tube or a gastrostomy tube. If the surgeon has placed an NG
tube, it is important to remember that it passes through the
esophageal anastomosis. It is critical not to accidentally
remove or replace the tube in the immediate postoperative
period. Passage of saliva through the tube indicates that the
infant is able to swallow and that the esophagus is patent.
Enteral alimentation may begin on the third to fourth
postoperative day via the NG or gastrostomy tube. Care is
taken not to overdistend the stomach or allow the feeding to
back up into the esophagus. This may be accomplished by
using a V-connector attached to the NG or gastrostomy tube,
allowing the stomach to be vented at the same time the
feeding is delivered.
An esophagram is performed within I week postoperatively to evaluate the esophageal anastomosis. A leak is
present in about 50% of cases; however, most are asymptomatic and seen only on the esophagram. 15 Infants with a
significant anastomotic leak will have signs and symptoms
of respiratory distress and may require intubation. If no leak
is noted, the chest tube is removed and the baby may be
allowed to attempt full nutrition by mouth. Successful
transition to oral feedings usually takes several days to
accomplish.
Stricture (narrowing at the anastomosis site) formation is
common after repair of esophageal atresia with or without
TEE 16 Clinical symptoms include coughing, vomiting, and
failure to gain weight. Diagnosis is confirmed with an
esophagram. Infants commonly require several dilations to
relieve the stricture. 16 Gastroesophageal reflux (GER) is a
significant postoperative complication, with 20% of cases
requiring antireflux surgery.17 Tracheomalacia (collapsible
trachea) is another common problem, which is thought to be
due to an enlarged upper esophageal pouch or to inadequately formed or missing cartilage. 18 These infants may
present to the pediatric intensive care unit (PICU) with a
history of a chronic "barky" cough and respiratory distress,
which has been exacerbated by a respiratory infection and
potentially causing respiratory failure.

Duodenal Obstruction
Complete or partial duodenal obstruction may occur for a
number of reasons. Atresia, stenosis, annular pancreas, and
nonrotation or malrotation are the most common causes of
duodenal obstruction. Each of these anomalies has unique
characteristics that are important for optimal management.
Pathogenesis. During the fifth to sixth week of
intrauterine development there is a rapid growth of the
epithelial lining of the duodenum. However, the crosssection of the gut cannot accommodate this growth, which
obliterates the duodenal lumen. By the eighth to tenth week
of gestation, recanalization of the duodenal lumen occurs.
The absence of this recanalization process causes duodenal
atresia, stenosis, or intrinsic web formation. 19•2o
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Atresia results in complete obstruction of the duodenal
lumen by an intrinsic duodenal membrane made up of
mucosa or submucosa. This maldevelopment may result in
the formation of two blind ends of the duodenum connected
by a short fibrous cord with an intact mesentery; or two
blind ends with no fibrous cord and a V-shaped defect in
the mesentery separating the two pieces of the duodenum
(Fig. 22-4, A).
Duodenal stenosis is a partial obstruction of the lumen of
the intestine. An intrinsic web or diaphragm can cause a
partial obstruction. The child who has duodenal stenosis
may not become symptomatic until well beyond the
neonatal period?!
A congenital annular pancreas can create a situation of
either atresia or stenosis, depending on the degree of
pancreatic compression on the duodenum. The embryologic
development of the pancreas occurs simultaneously with
duodenal recanalization. The dorsal pancreas arises from the
dorsal wall of the duodenum, and the ventral pancreas
develops from the region between the duodenum and the
hepatic diverticulum. As normal gut rotation occurs, the
ventral pancreas grows around the right side of the duodenum until it meets with the dorsal pancreatic bud. An annular pancreas occurs when the tip of the ventral pancreas
becomes fixed to the duodenal wall and during rotation

Fig. 22-4 Various types of duodenal atresia-stenosis. A, Complete duodenal atresia with discontinuity in the muscular wall of
the bowel. B, Seromuscular layers may be in continuity with the
atresia as represented by a complete membrane. C, An annular
pancreas. which may create either atresia or stenosis depending on
the degree of pancreatic compression on the duodenum. (From
Ashcraft KW: Atlas of pediatric surgery, Philadelphia. 1994, WB
Saunders.)
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wraps around the right side of the duodenum to fuse with the
dorsal pancreas 22 The intestinal compression from the
pancreatic wrap causes the obstruction, as small segments of
pancreatic tissue partially or completely encircle the second
portion of the duodenum (Fig. 22-4, B).
Another critical aspect of duodenal embryology is related
to the positioning and fixation of the small bowel that may
result in nonrotation or malrotation. Obstruction can occur
when rotation and fixation do not occur correctly during
fetal development. During the fourth week of gestation, the
intestinal tract is elongating too rapidly for the abdominal
cavity to accommodate its growth. The intestinal tract grows
out of the abdomen into the umbilical cord. As the midgut
begins to return to the abdomen at about 8 weeks' gestation,
it rotates in a counterclockwise fashion around the superior
mesentery artery. This rotation should be completed by the
twelfth week. Fixation of the intestine inside the abdomen
with the ligament of Treitz settling in the left upper quadrant
and the cecum in the right lower quadrant should follow this
rotation. When rotation and fixation do not occur or are
incomplete, bowel obstruction as well as superior mesenteric artery (SMA) occlusion may ensue with resultant
ischemia and volvulus (Fig. 22-5, A, B, C).
Associated Anomalies. Diaphragmatic hernia and
abdominal wall defects are associated anomalies thought to
occur because development of the diaphragm and abdominal wall is related to the return of the small bowel into the
abdominal cavi ty 23 For example, if the pleuroperitoneal
membranes have not closed completely before the gut
reenters the abdominal cavity, the bowel is likely to pass
through that opening and fill the space in the chest,
resulting in a congenital diaphragmatic hernia. Omphalocele
occurs when the bowel does not completely return to the
abdominal cavity. Malrotation is always present with these
defects.
Down's syndrome is found in 30% of infants born with
duodenal obstruction.!9 The reason for this association is not
known. Abnormalities of intestinal rotation are also associated with heterotaxia, an abnormal arrangement of body
organs?4 Gl anomalies associated with heterotaxia include
a midline liver, malpositioned stomach, and intestinal
malrotation. In addition, major cardiac defects and asplenia
or polysplenia are common.
Clinical Presentation. A newborn with duodenal
obstruction initially appears healthy, but quickly becomes
symptomatic. An exception to this is the infant with an
in-utero volvulus who presents with massive abdominal
distension, respiratory distress, acidosis, and sepsis. A
maternal history of polyhydramnios can alert the caregiver
that an obstruction may be present. The infant with intestinal
atresia or stenosis usually develops bilious vomiting within
the first few days of life. Proximal small bowel obstructions
result in earlier and more forceful vomiting, whereas
abdominal distension is more pronounced with distal small
bowel obstructions. Dehydration and signs of shock occur
with delay in diagnosis. With pure duodenal atresia, the
abdominal film usually reveals the classic "double-bubble"
sign, in which the stomach and the first portion of the
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A

Fig. 22·5 Malrotation with volvulus. A, Nonnal small bowel
mesenteric attachment (as demonstrated by line). This prevents
twisting of the small bowel because of the broad fixation of the
mesentery. B, Malrotation of the bowel with the cecum overlying
the duodenum. C, Midgut volvulus around superior mesenteric
artery caused by the narrow base of mesentery. (From Ross AJ lIT:
Malrotation of the intestine. In PF Nora, ed: Operative surgery,
ed 3, Philadelphia, 1990, WB Saunders.)

duodenum are dilated, and distal bowel gas is absent. This
type of dilation can also be present with intestinal stenosis,
but there is usually some air below the area of dilation. If air
is seen below the double-bubble, a contrast upper GI is
performed to rule out malrotation and volvulus. 18
Critical Care Management. Surgical correction of
most duodenal obstructions is accomplished by a duodenoduodenostomy. Duodenoduodenostomy consists of excision
of the atretic portion of the bowel and connection of
duodenum to duodenum. In rare situations, to avoid atretic

bowel, duodenojejunostomy is performed, connecting duodenum to jejunum, leaving a portion of the duodenum
connected to the pancreas with the ability to drain bile. An
intrinsic duodenal web is repaired with duodenoplasty,
excision of the web, and closure of the lumen of the bowel.
Stabilization of infants with malrotation and volvulus by
gastric decompression, airway stabilization, and fluid resuscitation must occur quickly with subsequent transport to the
operating room. The twisting of the intestinal contents
results in partial or complete occlusion of the superior
mesenteric artery (SMA) and can rapidly cause ischemia if
untreated. The Ladd's procedure, as described by Ladd and
Gross, is required for correction of malrotation and volvu25
IUS.
The intestines are untwisted, assessed for viability,
and resected in areas of necrosis or perforation. Occasionally the entire small bowel is necrotic, making chances of
the infant's survival grim. Once a full assessment of the
bowel is made, the Ladd's peritoneal bands are divided and
the duodenum is mobilized and placed along the right side
of the abdomen. An appendectomy is performed and the
cecum and colon are placed on the left side. The appendix
is removed to avoid a later misdiagnosis because the
appendix is now located on the left rather than the right side.
This type of abdominal placement allows for a broad base of
mesentery, which prevents further volvulus.
Adequate decompression of the GI tract is the first goal
of postoperative management. Placement of a gastrostomy
tube for long-term decompression until bowel patency is
demonstrated is somewhat controversial. Some surgeons
believe this type of tube is essential, particularly in the
preterm infant, whereas others favor decompression with an
NG tube?6 Decompression is required until the upper Gl
tract drainage decreases, the drainage changes in color from
green to clear, and the baby begins to produce stool.
Adequate nutritional support can be provided with
operative placement of a transanastomotic feeding tube for
early enteral feedings with an elemental infant formula.
Peripheral or central total parenteral nutrition (TPN) is a
temporary alternative to enteral nutrition with the initiation
of feedings as soon as is possible.

Jejunoileal Obstruction
Atresia of the jejunum or ileum is a complete congenital
obstruction of the intestinal lumen at either location.
Stenosis of the jejunum or ileum is very rare and will not be
discussed.
Meconium ileus is one of the most common causes of
obstruction in the small bowel and in the newborn is the
earliest manifestation of cystic fibrosis. 27 Meconium ileus
occurs when inspissated meconium becomes lodged in the
small bowel, usually in the ileum, and complete obstruction
occurs because of the tenacity of the meconium. The viscous
nature of the meconium is usually caused by abnormal
intestinal secretions and by pancreatic insufficiency related
to cystic fibrosis. 27 There are two types of meconium ileus.
Simple ileus exists when there is an obstruction in the ileum
with dilated proximal bowel and microcolon below the
obstruction. Complicated ileus results in the same obstruc-
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tion and intestinal findings, plus volvulus, necrosis, and
perforation.
Pathogenesis. Defects in the arteriomesenteric structure are thought to be primarily responsible for jejunoileaJ
atresias. Atresia formation usually occurs early in gestation
when a cordlike band separates the two ends of the bowel or
when there is a total separation of the bowel resulting
from a V-shaped deformity in the mesentery. This type of
mesenteric vascular catastrophe, causing disruption of the
bowel, can occur late in intrauterine life. 19
Associated Anomalies. The relationship between
meconium ileus and cystic fibrosis has been well established. There are no other consistent abnormalities seen in
infants with jejunoileal atresia. 2M Rare reports of trisomy 21
have been associated with these atresias.
Clinical Presentation. An infant with jejunoileal
atresia usually presents with bilious vomiting and abdominal distension within the first few days of life. A maternal
history of polyhydramnios or amniotic bile staining may be
present. Passage of meconium mayor may not occur,
depending on the level and extent of the obstruction?O
The clinical presentation of meconium ileus is similar to
that of ileal atresia. An abdominal radiograph will reveal
distended loops of bowel, and the mixture of abnormal
meconium and air bubbles gives the intestines a groundglass appearance. 27 A water-soluble contrast enema is the
best diagnostic study and may be therapeutic in relieving the
obstruction.
Critical Care Management. Infants with meconium
ileus not complicated by peritonitis, bowel perforation,
pseudocyst, or atresia may be treated nonoperati vely with
the use of a high hyperosmolar enema. Therefore it is
essential that complications of meconium ileus be ruled out
before performing the procedure. Bowel ischemia or peritonitis should be suspected in infants presenting with
tenderness, rigidity, edema, or erythema of the abdominal
wall. Fluid resuscitation must be initiated and hemodynamic
stability achieved before transport to the operating room.
In simple meconium ileus, the hyperosmolar enema used
for treatment usually employs gastrografin, a water-soluble
contrast solution. The infant must receive intravenous fluids
at twice maintenance to compensate for fluid drawn into the
bowel lumen as a result of the hyperosmolar solution. The
enema is administered with fluoroscopic guidance to prevent complications, especially perforation. With successful
treatment, the infant passes a large amount of semisolid
meconium for the next 24 to 48 hours. Failure to pass this
meconium or progressive distension is an indication for
operationY
Surgical Management. Jejunal and ileal atresias
are usually managed with end-to-end bowel anastomosis.
The difficulty of the operative procedure is the result of
the disparity in the size of the proximal dilated bowel
and the small distal segment. The massively dilated segment
is usually resected and the anastomosis is done in an oblique
fashion to provide a wider opening.
Surgical repair of meconium ileus involves an enterostomy in the dilated segment of the ileum. The meconium is
carefully expressed out of the proximal and distal segments,
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using saline or N-acetylcysteine (Mucomyst) as irrigants to
help liquefy the meconium. In rare cases, when complete
removal of the meconium plug is possible, primary anastomosis is performed with a bowel that appears healthy.
Residual thick meconium usually remains, requiring an
ileostomy to vent the bowel. The technique of ileostomy
formation with meconium ileus is a Bishop-Koop anastomosis, in which the end of the proximal bowel is anastomosed to the side of the distal segment, leaving the end of
the distal area as a stoma. This vents the bowel but also
allows for installation of N-acetylcysteine or other irrigants
to flush out additional meconium or stool if needed. Because
the normal fecal stream can continue with this operation, it
is the procedure of choice for most surgeons 29
Postoperative Management. The postoperative infant requires an NG tube for proximal decompression,
respiratory support as needed, fluid and electrolyte replacement, and antibiotics. Close monitoring of temperature,
other vital signs, and urine output is essential. Abdominal
distension, vomiting, evidence of peritonitis, and a pneumoperitoneum present for more than 24 hours after surgery
suggests an anastomotic lead and requires immediate
reexploration. The infant remains NPO and should receive
parenteral nutrition until normal GI function returns; however, the more proximal the obstruction, the longer the
period of postoperative intestinal dysfunction. Enteral alimentation usually begins with a predigested formula. The
patient is observed closely for signs of malabsorption, such
as increased gastric residuals, diarrhea, bloody stools, and
presence of fecal-reducing substances.
If an ileostomy is present, N-acetylcysteine may be
instilled into the stoma to evacuate fecal contents from the
distal bowel. Initially, most of the stool is expelled through
the ileostomy, but with time, the infant will have more
output through the rectum. Once the meconium is cleared,
an elemental enteral diet is started. Pancreatic enzymes are
added when full-strength formula is begun, even if a firm
diagnosis of cystic fibrosis has not yet been established. A
complete cystic fibrosis workup is part of the postoperative
management of any child with meconium ileus.

Intussusception
Intussusception is the telescoping or invagination of proximal bowel into distal bowel. It can be classified as
idiopathic, associated with a specific lead point, postoperative, or chronic. The majority of cases are idiopathic,
wherein the intussusception occurs at or near the ileocecal
valve. Only approximately 5% of the cases have a specific
lead point 23 The most common lead point is a Meckel's
diverticulum, followed by polyps, duplications, tumors,
hemangiomas, and sutures lines or an appendiceal stump.
Postoperati ve intussusception occurs within 2 weeks of a
surgical procedure. It occurs most often in cases of
intraabdominal or retroperitoneal procedures, although it
has also been reported after thoracic and other procedures 3o
Intussusception is described as chronic when symptoms
occur for 14 or more days and are less severe. This usually
occurs in older children. 31 Patients with cystic fibrosis are
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prone to intussusception, and repeated reductions may be
required.
The exact etiology of idiopathic intussusception is
unknown. Possible causes include hypertrophied Peyer's
patch (lymphoid tissue in the distal ileum), a localized area
of hyperperistalsis, or viral gastroenteritis, with rotavirus
and adenovirus being cited.32-34 Older children with intussusception are usually found to have an anatomic abnormality, which is the associated lead point. Other types of
lead points include the thick, inspissated fecal material
seen in children with cystic fibrosis, or submucosal hemorrhage, exhibited in children with hemophilia and HenochSchonlein purpura. 35
Pathogenesis. When proximal bowel telescopes into
distal bowel, it pulls the mesentery along with it (Fig. 22-6).
The neck of the intussuscepted segment compresses the
entrapped bowel. This compression, plus the traction on the
mesentery, causes lymphatic and mesenteric venous obstruction, which eventually results in necrosis and gangrene
of the entrapped bowel and subsequent perforation if
treatment is delayed. Bowel dilation occurs proximal to the
intussusception.
Clinical Presentation. Typical presentation of intussusception is in an infant between 4 and 10 months of age,
with a history of vomiting and acute, intermittent crampy
abdominal pain. The child may stiffen and pull the legs up
to the chest during the attacks. Initially, the child may appear
normal between the episodes but becomes increasingly
lethargic. Late in the course, the stools become blood tinged
and progress to dark red mucoid clots or "currant jelly"
stools. In some children, altered level of consciousness is the
initial symptom, before GI signs or symptoms. In such
cases, the differential diagnosis includes a postictal state and
meningitis,36 Occasionally, a sausage-shaped mass will be
felt in the mid or upper abdomen. If symptoms persist longer

A
Fig. 22-6 Ileocolic intussusception. A, Beginning of an intussusception in which terminal ileum prolapses through the ileocecal
valve. B, Ileocolic intussusception continuing through colon. This
can be palpated as a mass in the right upper quadrant. (From
Schnauffer LS, Marboubi S: Abdominal emergencies. In GR
Fleischer, S Ludwig, eds: Pediatric emergency medicine, Baltimore, 1988, Williams & Wilkins.)

than 6 to 12 hours, plain abdominal films will reveal an
obstruction, which includes distended bowel loops and
air-fluid levels. Abdominal ultrasound may be helpful in the
workup of intussusception before BE. A positive or equivocal ultrasound identi fies patients who should undergo BE
for definitive treatment. 37
In cases of postoperati ve intussusception, the presentation is not as straightforward. The child may appear to be
doing well in the first few days postoperatively, then
develops vomiting or increased NG aspirate, which may be
attributed to a paralytic ileus. Plain abdominal films,
however, reveal an obstruction, with dilated loops of bowel
and air-fluid levels.
Critical Care Management. Initial management includes NG decompression, intravenous fluid resuscitation,
and intravenous antibiotics if symptoms have been present
longer than 24 hours or there is evidence of fever and
leukocytosis. The child is then adequately sedated before the
BE is performed, which serves as a diagnostic as well as
treatment measure. The air enema is gaining popularity
because it has been shown to be as effective as barium in
reducing the intussusception and is safer in the event of
perforation during the procedure. 38 One to three attempts at
hydrostatic reduction of the intussusception by controlled
BE are made, with the operating room team on standby for
surgical reduction if necessary. In idiopathic intussusception, BE reduction is successful in 65% to 75% of patients. 35
In cases in which there is a specific lead point, BE is less
successful and surgical reduction is necessary. In children 6
years of age or older, where tumors (chiefly lymphosarcoma) and other abnormalities serve as a lead point, a BE
may not be performed.
In patients who have had prolonged symptoms, bloody
stools, severe distension and tenderness, and signs of shock,
surgical intervention is warranted, after fluid resuscitation,
gastric decompression, and antibiotic therapy. BE is not
indicated in patients with postoperative intussusception
because the site is high in the ileum or the jejunum. Most
cases undergo successful manual reduction in the operating room.
Surgical reduction includes making a transverse right
upper quadrant (RUQ) incision and then the surgeon
"milks" the intussusception with his or her fingers, without
applying traction on the bowel. The bowel is then examined
for areas of necrosis or gangrene, perforations, and any
abnormalities that could have served as a lead point.
Resection is indicated if the intussusception is not reducible,
if there is nonviable bowel, if there are any perforations, or
if there is a specific lead point. An end-to-end anastomosis
is performed in most cases. An appendectomy may be done.
Postoperative complications are rare and are related to
the underlying pathology. The incidence of recurrence after
surgical reduction is 0% to 3%.38 Recurrent intussusception
requires surgical reduction.

Toxic Megacolon
Pathogenesis. Toxic megacolon is severe dilation of
the colon. It is the most serious complication of ulcerative
colitis, occurring in up to 5% of all patients with ulcerative
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colitis. 39 It is relatively rare in the pediatric population,
however, it represents a medical and potentially surgical
emergency.
Clinical Presentation. The clinical presentation of
toxic megacolon consists of abdominal distension, abdominal tenderness, fever, signs of dehydration (secondary to
third spacing), and electrolyte disturbances. High-dose
steroid therapy, associated with treatment of ulcerative
colitis, may mask some of the signs of toxic megacolon,
specifically fever and abdominal tenderness. The child with
toxic megacolon is at risk for colonic perforation, gramnegative sepsis, and massive hemorrhage. Diagnosis is
made by clinical examination and confirming abdominal
radiographs. Improper diagnosis or delays in treatment can
lead to rapid clinical deterioration. 39
Critical Care Management. Once the diagnosis of
toxic megacolon is made, careful monitoring with serial
radiographs of the abdomen and physical examinations are
important. Gastric decompression is accomplished via an
NG tube or, if necessary, a small bowel tube. The patient is
NPO and parenteral nutrition is initiated. If aggressive
medical management fails and the toxic megacolon persists longer than 48 hours, or if perforation and hemorrhage develop, surgical intervention and colectomy are
necessary.40
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of some degree. 42 Symptoms that lead to a differential
diagnosis of GER are presented in Box 22-2.
Critical Care Management. In a child with uncomplicated GER, the self-limiting factor of the disease may
preclude the need for medical therapy. Traditional noninvasive therapy consists of three elements: upright positioning,
thickened feedings, and frequent feeding. Positioning at a 45
to 60 degree angle in an infant seat or car seat has been
standard procedure for many years, but poor truncal tone
makes the seated, upright position detrimental because of
increased abdominal pressure. Placing a child prone with the
head of the crib elevated has been recommended. However,
a large controlled study failed to show a significant benefit
of head elevation when compared with prone flat positioning. 43 In addition to decreasing reflux, prone positioning
improves gastric emptying, decreases aspiration, and decreases energy expenditure. 44 The right-side-down lateral
position, although theoretically advantageous, has not been
definitively compared with prone positioning. The American
Academy of Pediatrics recommends that normal infants be
placed supine or side-lying for sleep to minimize the risk of
sudden infant death syndrome (SIDS), but specifically
exempts infants with GER. 45
Thickened feedings may be of benefit when significant
emesis and poor weight gain are associated with GER. This

GASTROINTESTINAL INFLAMMATION
Inflammation can occur anywhere along the GI tract or on
the surface of the peritoneum and occurs with varying levels
of severity. For example, a child may exhibit mild esophagitis as a result of GER or present with septic shock
resulting from an intestinal perforation and resultant peritonitis. GI inflammation, seen in critically ill infants and
children, results from GER, inflammatory bowel disease
(ulcerative colitis or Crohn's disease), peritonitis, necrotizing enterocolitis (NEC), and pancreatitis.

Gastroesophageal Reflux
Pathogenesis. GER is the return of stomach contents
into the esophagus as a result of incompetence of the lower
esophageal sphincter (LES). It has been estimated that GER
occurs in I in 500 live births and is one of the most common
symptomatic clinical disorders affecting the GI tract in
children. 41
Clinical Presentation. The major features of the
syndrome are effortless vomiting, failure to gain weight,
and aspiration pneumonia. GER may exist without obvious vomiting, and may produce such complications as
protein-losing enteropathy, neuropsychiatric syndromes,
and apnea.
Half of all infants vomit or spit up at some time during
the first 2 years of life, with only 5% having a significant
underlying cause. 41 Most children with GER present by 6
weeks of age with symptoms of vomiting or failure to thrive,
and outgrow the syndrome by approximately 18 months of
age. The greatest improvement occurs at about 8 to 10
months of age when the child sits upright. Fifty percent of
children with GER require medical evaluation and therapy

.

Box 22-2

.

~ Differential Diagnosis of Reflux Symptoms
Regurgitation. Vomiting
Pain. Esophagitis Symptoms
Cardiac pain
Pulmonary or mediastinal pain; chest wall pain (e.g.,
costrochondritis)
Nonesophagitis upper gastrointestinal inflammation (e.g.,
peptic ulcer disease)
Nonesophagitis dysphagia
Many possible causes of nonspecific irritability in infants
Functional; malingering

Respiratory Symptoms (Wheeze. Stridor. Cough, etc.)
Extrinsic compression (e.g., vascular ring)
Intrinsic obstruction (e.g., malformation, foreign body, cyst,
tumor)
Airways reactive to other stimuli (e.g., allergens. infection)
Infection, inflammation, cystic fibrosis, pertussis, asthma,
other
"Central" events (e.g., central apnea; "cough tic")

Neurobehavioral Symptoms (Sandifer's Syndrome.
Seizurelike Spells)
Seizures
Dystonic reaction to drugs
Vestibular disorders
Early pertussis
Adapted from Orenstein SR: Gastroesophageal reflux. In Stockman JA, Winter
RJ. eds: Current problems in pediatrics, Chicago. YearBook Medical
Publishers. 21:223. 1991. Reprinted from Wyllie R. HyallLs is. ects:
Pediatric gastrointestinal disease: pathophysioloKY. diagnosis. managememo Philadelphia. 1993. WB Saunders.
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measure does not reduce the incidence of reflux but may
reduce the amount of emesis. Small, frequent feedings allow
for adequate gastric emptying and may decrease the
incidence of vomiting caused by gastric distension.
Diagnostic studies in addition to clinical examination are
necessary to rule out causes of pathologic reflux. A barium
study of the esophagus, stomach, and duodenum (upper GI
series) is performed to rule out anatomical abnormalities
such as malrotation. Esophageal pH monitoring is used to
diagnosis and evaluate severity of reflux and is performed in
patients who have experienced an apparent life-threatening
event, reactive airway disease or recurrent pneumonias,
intractable crying, unresponsiveness to medical measures,
and GER symptoms after a fundoplication procedure. 46 A
pH probe is inserted down a naris and positioned at the
middle and lower thirds of the esophagus. The pH is
continuously measured and recorded by a computer pH
recorder for a 24-hour period. A pH of 4.0 denotes reflux of
gastric contents. The frequency and duration are recorded
including the number of episodes longer than 5 minutes, the
longest episode, and the percentage of time the pH is less
than 4.0. The nurse is instrumental in determining the
relationship of reflux to various activities such as sleep,
eating, position, and symptoms. These activities and symptoms are recorded on a bedside monitoring form.
Medications are added to the treatment regimen with
evidence of pathologic reflux. Prophylactic pharmacotherapy may be indicated during exacerbations of severe respiratory disease, mechanical ventilation, or aggressive nutritional rehabilitation with gastric feedings. 47 Prokinetic
agents, such as bethanechol and metoclopramide, are used
to raise LES pressure and promote gastric emptying.
Bethanechol is a cholinergic drug, and its potential for
exacerbating bronchospasm limits its use in children with
respiratory symptoms. Metoclopramide is a dopamine antagonist and has a narrow therapeutic range before central
nervous system side effects such as dystonic reactions may
be seen. 48 Cisapride, a prokinetic agent, which has been
shown to be effective in treating children with GER, is no
longer available because of reports of serious arrhythmias
during concurrent use of some antibiotics. 49.50 H2 antagonists are used successfully in children to prevent hydrochloric acid secretion in the stomach. 51 Cimetidine, ranitidine,
and famotidine are the agents most commonly used. Omeprazole is an agent that blocks the parietal cell proton pump
and effectively reduces acid secretion more completely than
H2 blockers. However, esophagitis relapse occurs with discontinuation and concerns about safety limit the use in
children. 52 .53 Antacids are best used as a supplemental therapy to H2 blockade to neutralize gastric acid. Sucralfate
is also beneficial as a mucosal barrier protectant. 54
Overnight continuous NG feedings are used to treat GER
in certain infants. This has proved effective in infants with
poor weight gain and delayed gastric emptying. It provides
for optimal caloric intake, and has a soothing effect on an
irritated esophagus.
Failure to respond to medical therapy or failure to
promptly diagnose GER may require surgical intervention. Antireflux procedures are typically performed for

Fig. 22-7 A, A sizable bougie is placed in the patient's esophagus
for the procedure to ensure that the wrap is not so tight that food
passage is obstructed. B, The fundus is then drawn around behind
the esophagus and C, interrupted sutures are used to construct the
360-degree wrap. D, When these sutures are tied, a cuff is formed
around the lower esophagus. E, Distension of the stomach creates
a valve that acts as a blood pressure cuff and can completely
compress the lower esophagus. (From Ashcraft KW: Atlas of
pediatric surgery, Philadelphia, 1994, WB Saunders.)

children who have not responded to medical management
and who continue to be unable to gain weight appropriately.
The Nissen fundoplication is the most commonly performed antireflux procedure in children, followed by the
Thai fundoplication and the uncut Collis-Nissen fundoplication. Most pediatric studies report the reduction or
elimination of reflux in more than 90% of patients after
surgical fundoplication. 55 .56
The Nissen fundoplication involves a 360-degree wrap of
the stomach around the distal esophagus, producing a tighter
gastroesophageal junction, thereby decreasing the reflux of
fluid back into the esophagus (Fig. 22-7). The Thai or
"loose" fundoplication provides only a 180-degree wrap of
the stomach, which is thought to provide adequate pressure,
producing antireflux. 57 ,58 The uncut Collis-Nissen uses a
neoesophagus that is created out of stomach, around which
the fundus is wrapped. 59
GI decompression using the gastrostomy tube that is
typically placed during the operative procedure or an NG

Chapter 22
tube is of utmost importance. In some instances a transpyloric feeding tube is placed through the gastrostomy stoma
to allow early introduction of enteral alimentation into the
small bowel. Pain management and respiratory support are
important aspects of postoperative care.

Peritoneal Inflammation
Peritoneal inflammation, or peritonitis, is associated with
high morbidity and mortality. Peritoneal inflammation may
occur with a rapid, abrupt onset or it may be the final
outcome in a progression that begins with acute obstruction followed by necrosis and subsequent perforation.
Peritonitis can be classified as either primary or secondary.
Primary peritonitis is a condition wherein there is no
obvious cause of contamination, but infection is indirectly
introduced into the peritoneal cavity through the bloodstream or lymphatics. Common organisms include both
gram-positive (Streptococcus pneumolliae, enterococcus)
and gram-negati ve (Escherichia coli, Klebsiella pneumoniae) bacteria. If more than one organism is found, perforation must be suspected. 60
Secondary peritonitis, also known as perforative peritonitis, occurs as a result of direct GI tract injury or
contamination. 61 This can develop after an injury to a main
intraabdominal blood vessel or solid organ, or after perforation of a hollow viscus. Secondary infection is relatively
common and may include generalized peritonitis or localized abscess formation.
Pathogenesis. Peritoneal inflammation occurs as a
result of either direct or indirect injury or contamination.
Contaminants include chemicals, blood, meconium, bacteria, or foreign bodies. A localized area of inflammation
usually occurs first. This local inflammatory process causes
exudation of fluid into the peritoneal cavity. The exudate,
rich in antibodies, complement, neutrophils, and macrophages, plays an important role in the body's defense
mechanism. The release of exudate into the peritoneal cavity
can successfully resolve the inflammatory process. Otherwise, contamination of the peritoneum extends with subsequent abscess formation or generalized peritonitis. In the
state of generalized peritonitis, bacteria and toxins are
absorbed by the peritoneal surface into the bloodstream,
causing bacteremia and endotoxemia. Hypovolemia occurs
as fluid shifts into the peritoneal cavity. Concurrent sepsis
from bacteremia can lead to the catastrophic result of septic
shock and death.
Clinical Presentation. The clinical presentation of
primary peritonitis is not usually consist with typical signs
of peritonitis but rather consists of more nonspecific signs
including poor feeding, lethargy, abdominal distension,
vomiting, and mild to moderate abdominal discomfort.
Immunocompromised patients and those with indwelling
catheters, such as a peritoneal dialysis catheter or ventriculoperitoneal shunt, are more susceptible.
Secondary peritonitis is associated with acute symptomatology. Abdominal pain is present and increases with
movement and with breathing, often leading to shallow,
rapid respirations. Abdominal wall spasm is exhibited, and
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it progresses from voluntary guarding in the early stages to
involuntary spasm as the inflammation worsens. Very young
infants do not exhibit abdominal wall spasm, but rather
abdominal wall erythema, discoloration, or cellulitis. Abdominal distension and rigidity are also manifested, and the
child is febrile and tachycardic. The complete blood count
reveals leukocytosis with a left shift (increased immature
neutrophils). Shifting dullness can be elicited on percussion
because of the large amounts of free fluids in the peritoneal
cavity. Anorexia, nausea, and vomiting are also exhibited,
and bowel sounds may be decreased or absent. Occasionally
diarrhea is present. As the inflammatory process progresses,
signs of hypovolemia and sepsis become more apparent.
Abdominal CT is the gold standard in evaluating patients
suspected of having an intraabdominal infection. 60 A
diagnostic paracentesis may be performed if a chronic
condition exists such as cirrhosis, nephrosis, and systemic
lupus erythematosus or in a patient with a ventriculoperitoneal shunt. Fluid obtained with paracentesis is analyzed for
cell count, protein concentration, pH, gram stain, and
culture. Values consistent with intraabdominal infection
include leukocytosis (>300/mm 3 ), low protein «3.5 gIL
because of hypoalbuminemia), and acidic fluid pH «7.35).
A positive gram stain of the peritoneal fluid is diagnostic but
is more commonly negative. Frequently, the same organisms
isolated from the peritoneal fluid are recovered in the
blood 62
Critical Care Management. In addition to frequent
physical examinations, serial abdominal girth measurements, laboratory monitoring and chest and abdominal
radiologic studies are necessary. Supportive care includes
ventilatory management, fluid resuscitation and inotropic
support if hemodynamically unstable, gastric decompression, broad-spectrum antibiotic coverage, and early initiation of parenteral nutrition. Antibiotics must cover the most
common organisms usually encountered with intraabdominal infection. These pathogens are those isolated in the
lower GI tract, typically aerobic microorganisms such as
£. coli (most common), Klebsiella, and occasionally,
Enterococcus. Anaerobic microorganisms include Bacteroides, most often B. fragilis. Other anaerobes occasionally
recovered include Fusobacterium and Clostridium. Infrequently, organisms such as P. aeruginosa. S. aureus, and
Candida may be isolated and are more common in
immunocompromised patients or patients receiving peritoneal dialysis. Antimicrobial agents must be started perioperatively and continued postoperatively to reduce the high
frequency of wound infection that follows with peritonitis.
Table 22-7 lists antibiotics frequently used for intraabdominal infection. Because of increased resistance of anaerobic
organisms to clindamycin, metronidazole is recommended
for anaerobic coverage. However, metronidazole is active
against only anaerobes, and therefore coverage of the
aerobic gram-negative organisms is also initiated. Antibiotic
regimens may include (l) ampicillin, gentamicin and
metronidazole; (2) ticarcillin-clavulanic acid and an aminoglycoside; or (3) imipenem and an aminoglycoside. 60
If signs of perforation occur or if the child's clinical
status deteriorates, surgery is warranted. Goals of surgery
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Antimicrobial Agents Frequently Used for Treatment of Intraabdominal Sepsis
Dosage (mg/kg)

Comments

30 mg/kg divided q8h

Resistant Bacteroides species in some areas
of country
Excellent activity against anaerobes; inactive
against aerobes

30 mglkg divided q6h

150 mg/kg divided q8h
150 mg/kg divided q8h
50-75 mg/kg divided ql2h

100 mg/kg divided q6h
240-400 mg/kg of piperacillin
component divided q6-8h
100-200 mg/kg of ampicillin q6h

40 mg/kg divided q6h

5-7.5 mg/kg divided q8h

2.5 mg/kg divided q8h

ikacin

15-22.5 mg/kg divided q8h
40-60 mg/kg divided q6h
90-120 mg/kg divided q6-8h

",,'

Variable activity against anaerobes; inactive
against PseLldomonas species
Variable activity against anaerobes; very active
against aerobic gram-negative rods
Variable activity against anaerobes; inactive
against PseLldomonas species
Active against EnterococcLls
Active against p-Iactamase producing strains
of S. aLlreLlS. H. injluenzae. B. fragilis.
Klebsiella. E. coli. and Acinelobacter
Same as ampicillin and organisms producing
p-lactamases such as S. aLlreLls. H. injlLlenzae,
E. coli. Klebsiella. Acinetobaeter, Enterobacler, and anaerobes
Active against all gram-positive cocci and
bacilli, including StaphylococcLls aureus and
Staphylococcus epidermidis resistant to
penicillins and cephalosporins, and activity
against enterococci
Reduced activity at acid pH and in anaerobic
environment of abscesses and deep tissue
infections
Treatment of documented or suspected gramnegative baci IIi including Pseudomonas
aerLlginosa
Treatment of documented gram-negative enteric
infection resistant to gentamicin
Treatment of documented multidrug-resistant
gram-negative infection
Treatment of documented multidrug-resistant
aerobic gram-negative infection

m Takemoto CK, Hooding JH, Kraus DM: Pediatric dosage handbook, ed 6, Cleveland, 1999-2000, Lexi-Comp.

include closure of perforations, removal of necrotic tissue,
drainage of abscesses, establishment of intestinal continuity,
and preservation of intestinal length.

Necrotizing Enterocolitis
NEC is a condition of patchy or diffuse necrosis of the
intestinal mucosa thought to result from a combination of
decreased blood flow, hypoxia, and bacterial invasion. 63 The
exact etiology of NEe remains unclear. It occurs most often
in premature infants, but it has been reported in full-term
babies and in infants and children whose preceding risk
factors have included polycythemia, cyanotic heart disease,
chronic diarrhea, or a prior anatomic GI obstruction M - 66

Pathogenesis. The pathogenesis of NEC is most
likely related to several factors. Early theories proposed a
relationship between enteral feeding, intestinal ischemia,
and infection. 67 More recent studies advocate the role of
these factors plus an immature GI function and immature
immune mechanisms as inciting factors for neonatal intestinal mucosal injury68.69 Other predisposing factors include
respiratory distress, hypothermia with associated stress
response, patent ductus arteriosus, umbilical artery catheters, and exchange transfusions. 66
In instances of hypoxic-ischemic injury, blood is shunted
to the brain and heart and away from less vital organs such
as the bowel. Vasoconstriction of the intestinal vasculature
occurs, followed by bowel ischemia and mucosal damage.
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Box 22-]

Staging Criteria for NEC

Stage 1 (Suspect)

History of perinatal stress
Systemic manifestations: temperature instability, lethargy,
apnea, bradycardia
01 tract manifestations: poor feeding, increased gastric
residuals, emesis (may be bilious or have positive results
for occult blood), mild abdominal distension, occult
blood in stool
Stage 2 (Definite)

Above history and signs and symptoms plus persistent occult
or gross OJ tract bleeding
Marked abdominal distension
Abdominal radiographs show significant intestinal distension
with ileus. small bowel separation, pneumatosis intestinalis
Stage] (Advanced)

Same signs and symptoms as in stage 2 plus deterioration in
vital signs
Evidence of septic shock or marked 01 tract hemorrhage
Abdominal radiographs show pneumoperitoneum
Modified from Bell MI, Ternberg JI., Reign RD el aI: Neonatal necrotizing
enterocolitis: therapeUlic decisions based upon clinical slaging. Ann Surg
1:187, 1978.

Bowel wall injury allows bacterial colonization and can lead
to extensive tissue damage, including necrosis. Enteral
feeding has been proposed as a contributing factor in NEC
because more than 95% of infants with NEC have been fed
enterally before its onset. 70 The volume of milk fed to
infants may also be a contributing factor. The rate of feeding
may exceed the infant's intestinal absorptive capability,
resulting in malabsorption. Malabsorbed carbohydrates
produce increased intestinal bacterial gas leading to abdominal distension. Abdominal distension may cause increased
intraluminal pressure and result in reduced mucosal blood
flow and ultimately intestinal ischemia. The bacterial gas
penetrates the perforated intestinal wall, resulting in the
diagnosis of free air on abdominal x-ray films. The entry of
bacterial gas into the submucosal tissue (intraluminal wall)
is called pneumatosis intestinalis.
Clinical Presentation. Any preterm infant should be
considered at risk for developing NEC. A high level of
suspicion is maintained even with subtle clinical changes,
such as an increased feeding residual, increased abdominal
distension, temperature instability, lethargy, and apnea.
Later indications of NEC include Hemoccult-positive
stools, discoloration of the abdominal wall, and visibly
dilated bowel loops. On physical examination, the infant
with NEC has abdominal tenderness, erythema, distension,
and irritability along with respiratory compromise.
Staging criteria for NEC is outlined in Box 22-3. Stage I
represents subclinical NEC in which clinical symptomatology is present but there are no radiographic findings. Stages
II and III have radiographic findings consistent with disease.
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Radiographic findings include pneumatosis, dilated loops of
bowel, or pneumoperitoneum. Progression from one stage to
another usually occurs within 24 to 48 hours after symptoms
arise. Once the infant is stabilized, disease progression
rarely occurs. Most episodes of perforation occur on
presentation. 66 .71
Critical Care Management. The management of
NEC is largely supporti ve. Certain measures are taken when
the diagnosis is suspected. The patient is made NPO with
NG decompression. Parenteral nutrition is provided while
the patient is NPO. Duration of NPO status is dictated by the
continued clinical and radiographic findings consistent with
NEC. Abdominal radiographs (flat plate and cross-table
lateral) are obtained when NEC is suspected and repeated
every 6 hours during the acute phase to monitor for
progression of disease. Laboratory studies include a complete blood count and differential to monitor for signs of
sepsis and GI bleeding associated with the disease. Serial
electrolyte and arterial blood gases (ABGs) are also
obtained to monitor for metabolic acidosis and electrolyte
disturbances associated with poor perfusion and advanced
disease. Inflammation and edema of the intestine results in
third spacing of fluid; which can cause significant fluid and
electrolyte derangements if adequate replacement is not
maintained. Infants generally require one and one half to
two times maintenance levels of fluids to maintain adequate
intravascular volume. Mechanical ventilation and inotropic
support are often required to stabilize the critically ill infant
in septic shock. Broad-spectrum antibiotic coverage is
initiated immediately including anaerobic coverage (i.e.,
metronidazole) if perforation is observed on radiographic
studies.
Indications for surgery include radiographic evidence of
intestinal perforation or clinical deterioration despite aggressive medical management. Preparation for the operation includes stabilization with GI decompression, respiratory and cardiovascular support, thermoregulation, fluid
resuscitation, and prevention of sepsis. The timing of
surgical intervention for a child with NEC is critical but
is a difficult management decision. Ideally the operation
should take place when the bowel is truly necrotic but
perforation has not occurred. If the operation occurs early,
there may be a large gray, thin, edematous area of bowel
that has no distinct boundaries, making surgical resection
more difficult. On the other hand, if operation occurs too
late the small bowel may be completely nonviable. Fig.
22-8 provides an algorithm for treatment of the neonate
with NEC.
Infants with fulminant NEC experience all the clinical
signs and symptoms previously described within hours and
exhibit rapid deterioration and multisystem failure. Immediate surgical intervention is required.
Postoperatively, fluid loss through the ileostomy is
closely monitored, noting the presence of blood. Fluid
management can be difficult in these patients because of the
increased fluid output coupled with third spacing of fluids.
Parenteral nutritional support and broad-spectrum antibiotic
coverage are continued. The reinstitution of enteral feeding
following adequate bowel rest and stable radiographic
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Fig. 22-8 Proposed algorithm for treatment of neonatal necrotizing enterocolitis_ (From Ghoury MJ,
Sheldon CA: Newborn surgical emergencies of the gastrointestinal tract, Surg Clin North Am
65:1083-1098, 1985.)

studies is performed slowly while monitoring for clinical
symptoms of NEe.
Long-term prognosis for infants with NEC is good if they
survive the initial critical period 72 Stomal closure can occur
between 6 weeks and 3 to 4 months of age, depending on the
child's enteral feeding tolerance. In some children, the
increased water loss from the ileostomy can force earlier
closure of the stoma. Before stomal closure, all children
undergo a BE to assess the distal segment of bowel for
stricture fonnation, a complication occurring after some
episodes of NEe. Stricture formation and acquired short
bowel syndrome (SBS) are the two major complications that
result from NEC. 73

Short Bowel Syndrome
SBS is defined as the absence of more than 50% of the small
bowel, which results in malabsorption of nutrients 74 .77
Wilmore reviewed cases of 50 infants younger than 2
months of age and defined SBS as residual jejunoileallength
of less than 75 cm. 75 Thirty years ago children with this
entity succumbed to the disease. Since that time, major
advances in venous access, parenteral-enteral nutrition,
understanding of bowel adaptation, and success with small
bowel transplantation have greatly improved the patients'
quality of life and chances for survival. 76
Massive bowel loss can occur as a result of prenatal or
postnatal causes. Before an infant is born, embryologic
maldevelopment or vascular accidents necessitate emergent
lifesaving surgery shortly after birth to correct the defect,
but in many situations surgery leaves the child with a

foreshortened small bowel. During infancy or childhood,
disease processes, vascular thrombosis, or trauma can result
in the same outcome_ Volvulus and NEC are the two leading
causes of SBS 75 ,78-80
Pathogenesis. After major small bowel resection,
there is a loss of intestinal mucosal absorptive surface area,
along with rapid transit time of intestinal contents, resulting
in inadequate ability of the gut to digest and absorb
nutrients.77.81 Depending on the severity of the symptoms,
the child's nutritional rehabilitation course can be short and
uncomplicated, or prolonged with multiple and severe
complications, which ultimately lead to death.
With significant loss of small intestine, the bowel
undergoes numerous changes_ In many patients, there is
excessive secretion of gastric acid, which can lead to
diarrhea, decreased function of pancreatic enzymes, bacteria
overgrowth, ulceration, hemorrhage, and denuded perianal
skin. 82.83 Jejunal resection results in a loss of brush border
enzymes, which impairs carbohydrate absorption. Stasis of
carbohydrate substrate in the bowel further leads to bacterial
overgrowth. Protein metabolism is hindered owing to
malabsorption of peptides and amino acids. Loss of
water-soluble vitamins including B 12 is associated with a
large jejunal resection. Ileal resection causes malabsorption
of bile salts, which leads to excessive fatty stools and
malabsorption of fat-soluble vitamins (A, D, E, and K)_77.83
Because of the ileum's potential for adaptation and
ability to transport bile acids and vitamin B 12' the ileum,
rather than the jejunum, is the most critical area to leave
intact. 20.83 The presence of the ileocecal valve aids in both
slowing small intestinal transit time, thus improving absorp-
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tion of nutrients, and decreasing the risk of colonization by
colonic bacteria. 81 .83 But in many cases, especially in
patients with NEC, preservation of the valve is impossible.
Studies have shown that long-term survival is possible with
an 11- to IS-cm jejunoileum and an intact ileocecal valve or
with 2S- to 40-cm small bowel without an ileocecal
valve. 75 .84
The exact length of the small bowel is difficult to
ascertain but is thought to be approximately three times a
person's linear length. The full-term neonate is estimated to
have between 200 and 300 em of small intestine. 8s Intestinal
length increases to 600 to 800 em by adulthood. For preterm
infants, it is important to note that the small bowel doubles
in length from the nineteenth to the thirty-fifth week of
gestation. Thus resection of the small bowel in a preterm
infant may have more severe consequences than for a
full-term infant. 28
Intestinal "adaptation" is the normal physiologic response of the small intestine after major resection. During
this process, there is a gradual increase in surface area
because of mucosal hyperplasia, villous lengthening, and
increased depth of the intestinal crypts. Three mechanisms
are involved in gut adaptation: luminal, hormonal, and
cellular factors 86
Clinical Presentation. Children with SBS regardless
of cause will present with some degree of diarrhea and
nutritional malabsorption. Significant diarrhea can result in
dehydration and electrolyte disturbances. Other clinical
findings may include vomiting, abdominal pain, and failure
to thrive. In addition, signs and symptoms of protein-losing
enteropathy such as edema (commonly periorbital, facial,
abdominal, leg and ankle) and hypoalbuminemia may be
evident. Protein-losing enteropathy is a pathophysiologic
process in which there is excessive GI protein loss due to
disruption of the intestinal lumen. Intestinal disruption
allows serum proteins to be spilled into the lumen as a result
of (I) mucosal erosion or ulceration, and (2) obstruction of
the thoracic duct with transmission back to the small
lymphatics in the small intestine. 87
Critical Care Management. After extensive bowel
resection, nutrition is provided with TPN to ensure that
nutrients, electrolytes, minerals, vitamins, and trace elements necessary for healing and growth are met. It is
important to remember that the central line is the "lifeline"
for a child with SBS. It is critical that the integrity and
sterility of the catheter be maintained to prevent iatrogenic
catheter loss.
Cholestatic liver disease is a common complication of
long-term TPN, especially in the preterm infant. The cause
for this is unknown but most likely is multifactorial. The
responsible factors include toxicity of amino acids, bile
acids, amino acid competition for transport across the
canalicular membrane, toxins in the TPN solution, and lack
of stimulation of biliary flow by the gut. 74 .S1 To reduce the
risk of TPN-induced jaundice, early enteral alimentation is
provided and the concentration of amino acids in the TPN is
limited to 2.5 g/kg/day.
Surgical intervention may increase the small bowel
absorptive surface. A bowel-lengthening procedure, which
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involves longitudinal division of a dilated segment of the
bowel, tubularization of the two segments and end-to-end
anastomosis, has been successful. This procedure, in theory,
doubles the segmental length of bowel.88 Other procedures
include reversed small bowel segments, prejejunal isoperistaltic colonic interposition, and replacement of ileocecal
value with a nipple valve intussusception 89.9o Unfortunately, the success rate of these procedures has not been
substantial. Small bowel transplantation is the procedure of
choice to eliminate the problems associated with SBS.
Long-term survival of a child with SBS is dependent on
transition from parenteral to enteral nutrition. Enteral
nutrition is essential to stimulate small bowel adaptation and
to prevent TPN-associated cholestasis 91 The optimal nutrient composition of enteral feedings in short bowel patients
is controversial. However, the initiation of enteral feeding
should begin with an elemental formula (i.e., Pregestimil in
children <1 year, Peptamen Junior> I year) administered
continuously and at a slow rate of infusion. Stool volume,
pH, reducing substances, and daily weight measurements
are closely monitored for feeding intolerance. As tolerance
is observed, the child can be advanced to small bolus feeds
during the day with resumption of continual NG or
gastrostomy feeding at night. TPN is tapered with increasing
enteral feeding volume while ensuring optimal caloric
intake. However, the transition from parenteral to enteral
nutrition is gradual and may take months or even years.
Byrne and colleagues described an approach to "rehabilitating" residual bowel with the administration of specialized nutrients (i.e., glutamine and long-chain triglycerides), growth factors (i.e., growth hormone, insulin-like
growth factor-I), and a high-fiber diet. 92 The researchers
reported improved caloric intestinal absorption and decreased stool output after a 3-week course of this therapy. A
similar study performed by Scolapio and colleagues failed
to demonstrate the same improvements. Experience in
children is lacking. Further research in children and adults is
needed to confirm these preliminary findingsy3
The goals of drug therapy in patients with SBS are to
reduce diarrhea, replace electrolytes, and treat complications. The most effective antidiarrheal agent for children
with SBS is loperamide. It is used to reduce GI motility,
thereby increasing nutrient contact time with the mucosa.
However, this delay in intestinal transit time may also
increase the child's risk for bacterial overgrowth. Bacterial
overgrowth is a difficult problem to treat in SBS patients. The choice of antimicrobial therapy is largely empiric
(i.e., metronidazole). Another agent used to treat highvolume secretory diarrhea is octreotide 94 Octreotide is a
somatostatin analogue that inhibits exocrine secretions
from the stomach, pancreas, and small intestine; reduces
splanchnic blood flow; and slows GI motility. Currently
there are varying reports of its effectiveness in treating
diarrhea. 81.83.86
Other more long-term problems include the reduction in
bile salt reabsorption, and malabsorption of fat-soluble
vitamins, calcium, magnesium, and zinc. Cholestyramine
is an ion-exchange resin that binds intraluminal bile acids
and is often used to reduce the effects of malabsorbed
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bile salts on the colon. Supplementation of fat-soluble
vitamins, calcium, and magnesium are imperative to prevent
complications, such as rickets or tetany. Vitamin B I2
supplementation is necessary in patients with a resected
ileocecal valve. Folic acid, electrolytes, and trace elements
are also essential if the levels are below normal.
The prognosis of children with SBS has dramatically
improved since the introduction of parenteral nutrition. In
addition, the success of small bowel transplantation may
improve the outcome of patients with minimal residual
bowel.

Pancreatitis
Pancreatitis is an acute inflammatory condition that results
from an autodigestive process within the pancreas. It is
relatively uncommon in children; however, it is being
increasingly recognized in patients with multisystem disease. 95 •96 Pancreatitis can present at any age and ranges in
severity from a mild to fulminant inflammatory process.
The most frequent cause of childhood pancreatitis is
blunt abdominal trauma, with child abuse identified in as
many as one third of these cases. 22 In addition to traumatic
pancreatitis, other common causes include viral infection,
drugs, multisystem disease, and congenital anomalies. 96
Pathogenesis. The exact mechanisms that initiate the
sequence of enzymatic reactions resulting in acute pancreatitis are unclear. It is proposed that the autodigestive
process results from premature activation of proteolytic
enzymes within the pancreas, or from the reflux of activated
enzymes into the pancreas from a distal obstruction. 22 .96
Both processes cause a localized inflammatory response. If
autodigestion is severe and extensive, vascular damage may
occur, causing hemorrhagic pancreatitis. In addition, release
of lipase into surrounding tissues can cause fat necrosis and
breakdown of calcium. Local inflammation in and around
the pancreas causes third spacing into the peritoneum and, if
uncorrected, can lead to hypovolemia and cardiovascular
collapse.
Clinical Presentation. Abdominal pain is the most
common symptom observed in acute pancreatitis. It is
described as sudden, constant, dull, epigastric, or periumbilical pain and may radiate to the back or is referred to the
left shoulder. Diffuse peritoneal signs such as guarding,
decreased or absent bowel sounds, and distension may also
be present. However, unlike in adults, symptoms in children
may be subtle with minimal abdominal pain or nonepigastric in origin. 95 In cases of hemorrhagic pancreatitis, a bluish
discoloration may be seen in the flank area (Grey Turner's
sign), indicating retroperitoneal bleeding. Periumbilical
discoloration (Cullen's sign), indicating intraabdominal
bleeding, may also be seen in cases of hemorrhagic
pancreatitis. Patients are febrile and exhibit nausea and
vomiting. In patients with fulminant pancreatitis, signs of
shock may be exhibited.
Initial laboratory analysis reveals markedly elevated
serum amylase and lipase, elevated transaminases (AST,
ALT), leukocytosis, elevated hematocrit (as a result of
hemoconcentration caused by intravascular fluid loss), and

hypocalcemia. Serum amylase level is typically elevated
within hours and remains elevated for 4 to 5 days. It is
important to remember that the serum amylase level reflects
salivary and pancreatic components. Fractionation of the
serum amylase can be readily performed in most clinical
laboratories; however, it is not commonly ordered because
of the specificity of the serum lipase level. Specificity is
increased when the serum amylase and lipase levels increase
at least threefold. Hypocalcemia is seen most often during
the first few days of illness but rarely is associated with
symptoms.
The plain abdominal radiograph may reveal a "sentinel
loop" (dilated loop of bowel located near the pancreas),
ileus, or a mass effect if a pseudocyst has developed. A
pseudocyst is a cyst-like mass filled with pancreatic fluids
extending out of the pancreas. Although a pseudocyst may
develop from any of the causes of pancreatitis, it is most
often a complication of traumatic pancreatitis. An abdominal ultrasound is useful in identifying both the presence and
extent of pancreatic damage and complications resulting
from acute pancreatitis. In addition to pseudocyst formation,
other complications include abscess formation, splenic vein
thrombosis, diabetes (usually temporary), and pancreatic
enzyme insufficiency (in cases of chronic, recurrent pancreatitis). Endoscopic retrograde cannulation of the pancreatic
ducts (ERCP) is helpful in defining abnormalities of the
pancreatic and biliary ducts that result in structural/obstructive pancreatitis. Abdominal CT is usually reserved for more
difficult patients or when the ultrasound results are unclear.
Approximately 20% of patients with acute pancreatitis have
a normal abdominal CT examination. 97
Critical Care Management. Management of the
patient with acute pancreatitis is multisystemic in approach,
with the primary goal of suppressing or halting the
autodigestive process. Strategies employed are aimed at
decreasing the activity of the pancreas and include NPO,
mai ntaining gastric decompression, and administering antacids and H2 blockers that act to decrease gastric acid
secretion.
Other goals of management include prevention of
hypovolemia and shock with adequate fluid resuscitation,
provision of respiratory and nutritional support, and restoration of nonnal pancreatic functions. Patients presenting
with or progressing to a fulminant form of acute pancreatitis
require comprehensive hemodynamic monitoring.
Frequent serial abdominal examinations, including abdominal girth measurement, and treating abdominal pain
with analgesics are an integral part of care. Broad-spectrum
antibiotics are also administered. While the patient is NPO,
nutrition is provided with TPN.
Laboratory studies to be monitored include amylase and
lipase, transaminases, electrolytes, albumin, complete blood
count with differential, ABGs, and serum calcium levels.
Hypocalcemia is a common metabolic complication of
pancreatitis and assessing for signs and symptoms including
irritability, muscle twitching, tetany, seizures, and the
electrocardiogram for lengthening of the QT interval is
imperative. Fever, tachycardia, and leukocytosis may occur
in the patient with acute pancreatitis in the absence of
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infection. However, infection should be suspected with high
fevers (greater than 39° C), significant leukocytosis (over
20,OOO//lL), or signs of clinical deterioration 22 Abdominal
CT with contrast is performed to identify pancreatic
necrosis, pancreatic fluid collections, or pseudocyst. In
addition, regular chest radiographs are obtained because
patients are at risk for developing pleural effusions and
acute respiratory distress syndrome (ARDS).
Efforts are made to treat acute pancreatitis medically and
to avoid surgery. Surgical treatment is usually reserved for
traumatic pancreatitis with ductal rupture, debriding necrotic and infected tissue, and draining of a pancreatic
abscess when percutaneous drainage has failed. 98

GASTROINTESTINAL BLEEDING
GI bleeding can vary in clinical presentation from acute
life-threatening shock to asymptomatic bleeding with stools
positive for occult blood. Bleeding can originate throughout
the GI tract. Causes of upper and lower GI bleeding are
listed in Tables 22-8 and 22-9.
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stress gastritis, is most commonly associated with severe
stress in the critically ill patient. Patients may develop
isolated gastroduodenal erosions or mucosal ulcerations in
multiple sites within the stomach and duodenum, Acute
gastritis occurs in critically ill children suffering from burns,
severe head trauma, major surgical procedures, sepsis,
multiple trauma, and respiratory failure. Critical care nurses
playa key role not only in the early detection (by evaluating
gastric aspirates) and treatment of upper GI bleeding but
also in the prevention of upper GI bleeding by identifying
children at risk and administering prophylactic medications
(i,e" H 2 blocker) as ordered.
The etiology of acute gastritis secondary to stress is
unknown but is, most likely, multifactorial. Potential causes
include impaired blood flow, increased secretion of acid and
pepsin, decreased production of mucus, decreased gastric
somatostatin level, alterations in levels of adrenal steroids
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22-9
Bleeding

TABLE

Lower Gastrointestinal

Acute Gastritis

Common

Less Common

A common cause of upper GI bleeding, regardless of age, is
acute gastritis. Acute gastritis, also referred to as erosive or

Anorectal lesions
Swallowed maternal blood
Milk allergy
Necrotizing enterocolitis
Midgut volvulus

Vascular malformations
Hirschsprung's
enterocolitis
Intestinal
duplication
Coagulopathy

Anorectal lesions
Midgut volvulus
Intussusception
«3 yr)
Meckel's diverticulum
Infectious diarrhea
Milk allergy
«4 yr)

Vascular malformations
Intestinal duplication
Acquired thrombocytopenia

Juvenile polyps
Meckel's diverticulum
Intussusception
«3 yr)
Infectious diarrhea
Anal fissure
Nodular lymphoid
hyperplasia

Henoch-Schtinlein
purpura
Hemolytic-uremic
syndrome
Vasculitis (SLE)
Inflammatory
bowel disease

Inflammatory
bowel disease
Polyps
Hemorrhoids
Anal fissure
Infectious diarrhea

Arteriovascular
malformation
Adenocarcinomas
Henoch-Schtinlein
purpura
Pseudomembranous colitis
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22-8 .Upper Gastrointestinal
Bleeding

TABLE

fge Group

Common

Less Common

£i:-Neonates
l1fO-30 days)

Swallowed
maternal
blood
Gastritis
Duodenitis

Coagulopathy
Vascular malformations
Gastric/esophageal
duplication
Leiomyoma

Gastritis and
gastric ulcer
Esophagitis
Duodenitis

Esophageal varices
Foreign body
Aortoesophageal
fistula

Esophagitis
Esophageal varices
Gastritis and
gastric ulcer
Duodenal ulcer
Mallory-Weiss tear
Nasopharyngeal
bleeding

Leiomyoma
Salicylates
Vascular malformation

Duodenal ulcer
Esophagitis
Esophageal varices
Gastritis
Mallory- Weiss tear

Thrombocytopenia
Dieulafoy's ulcer
Hematobilia

l,;~ " '"'
...

~

Il!fChiidren

l~iCl2 years)
~!'

l·. '

I.lf~;;. i.
~,

~

rtAdolescents
~,(1.2 years-adult)
~;

-

~i"

~ti

t~~rom

Hematobilia

Olson AD. Hillemeier AC: Gastrointestinal hemorrhage. In
f;fu)Vyllie R, Hyams 1S, eds: Pediatric gastrointestinal diJease: patho·
(hysiology, diognosis, management, Philadelphia, 1993, WB Saunders.

ji'

IU:from Olson AD, Hillemeier AC: Gastrointestinal hemorrhage. In

~l~"y11ie R, Hyams IS. eds: Pediatric gastrointestinal disease: patho-

!thysiology, diagnosis, managemelJ/, Ph~adelphia, 1993, WB Saunders.
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and catecholamines, and impairment in the local production
of prostaglandins.
Corticosteroid therapy has been implicated in causing
acute gastritis; however, there is no evidence-based research
to substantiate this claim. A large prospective descriptive
study in pediatric patients revealed that 10.2% of 1006
admissions developed clinical signs of GI bleeding, only
1.6% were considered clinically significant. 99 Other reports
demonstrate that patients with multitrauma, coagulopathy,
respiratory failure, or pediatric risk of mortality score
(PRISM) greater than 10 should receive prophylaxis to
prevent upper Gl bleeding.lOo.loz Nonsteroidal antiinflammatory drugs (NSAlDs) are known to cause both gastritis
and mucosal ulceration. 103
Gastric acidity has also been associated with an increased
risk of gastritis. Valentine and colleagues reported that
patients with a gastric pH greater than 3.5 had only a 4%
incidence of Gl bleeding, and patients with a gastric pH
greater than 5 had no overt GI bleeding. 104 However,
increased gastric pH may increase the risk of nosocomial
pneumonia by enhancing colonization of gram-negative
bacteria. Therefore the current recommendation is to administer prophylaxis only to high-risk patients, which
include those with respiratory failure requiring mechanical
ventilation for more than 48 hours and/or in those with
coagulopathy.los
The best gut protection is enteral feeding administered by
the NG route. If this is not possible or if the patient is
receiving transpyloric enteral feeding (and is identified as a
high-risk patient), stress ulcer prophylaxis is indicated.
Prophylaxis often will include an Hz blocker (i.e., ranitidine,
cimetidine) titrated to maintain gastric pH greater than 4.
Patients receiving an Hz blocker should be monitored for
thrombocytopenia. Sucralfate may also be considered as
adjunct therapy, which acts as a protective "barrier" by
coating the gastric mucosa. This agent may be more
convenient than an H 2 blocker because it does not affect the
gastric pH and therefore does not require pH monitoring.
Omeprazole is an agent that blocks the parietal cell proton
pump and effectively reduces acid secretion more completely than H2 blockers and has a longer duration of action
(12 to 24 hours). The disadvantage of this drug is the method
of administration. Omeprazole is supplied as capsules
containing enteric-coated granules. The administration of
the drug requires opening the capsule and dispersing the
granules in a solution to prevent clogging of the feeding
tube. However, obstruction of the feeding tube continues to
be a commonly reported problem. The use of antacids is
currently not supported secondary to the need for frequent
administration to effectively maintain an increase in pH,
leading to increased risk of reflux and microaspiration. 106

22·10 Signs and Symptoms
in Gastrointestinal Hemorrhage

TABLE
Fi'-,

~r;Sign

Indication

Site of Bleeding

lij,splenomegaly

Portal hypertension

~'Hemangioma

Multiple hemangioma syndrome

Esophageal varices
Portal gastropathy
Vascular malfonnation of GI tract

l~iaundice
~~i..-,~

ITelangiecta,ia
~.,

(~Hematemesis

!!!T"

ill"-

~;;

~~":tvIelena

mr
!!1HemalOchezia
l~:;

g~~

g:1I"
~;:"

iifNasogastric aspi~:: .rate: gross
1m" blood
71ft.:
,i:l',llpable purpura

~~~.
~odified from Olson

Bleeding from
above the ligament of Treitz
Bleeding from
above the ileocecal valve
Colonic bleeding,
massive upper
GI bleeding
Bleeding from
above the ligament of Treitz
Henoch-Schonlein
purpura
AD.

Upper GI tract

Upper GI tract or
small intestine
GI tracl

Uppcr GI tract

GI tract

HiUemeier AC: Gastrointestinal hemor-

~~age. tn Wyllie R. Hyams JS, eds: Pediatric gastrointestillal dis·
~!a:se: pathophYJiolog)~ diaKllOsis, management, Philadelphia. 1993.

lrro Saunders.

Clinical Presentation. GI hemorrhage can present in
several distinct ways (Table 22-10). Hematemesis describes
bright red vomiting or coffee ground-like emesis. This
suggests a bleeding source above the ligament of Treitz (at
the duodenojejunal junction in left upper abdominal quadrant). Hematochezia is the passage of bright red blood or
maroon-colored stool from the rectum. It is most commonly
associated with a colonic source of bleeding. Melena is the
passing of dark, black, tarry stools, which occurs in patients
bleeding from a site located above the ileocecal valve. The
black color is the result of the action of the bacteria on the
hemoglobin that has been converted to hematin. Borborygmi are deep rumbling abdominal sounds caused by the
rapid transit of blood through the GI tract.
Critical Care Management. Acute Gl bleeding can
result in massive exsanguination and shock. An NG lUbe is
inserted in the case of upper GI bleeding to prevent
aspiration of blood. Hemodynamic assessment guides administration of fluid, red blood cells (RBCs), and other
blood products until the patient can be transported to the
operating room for primary surgical intervention.
Radiographic studies play a limited role in the initial
investigation of Gl bleeding.

Lower Gastrointestinal Bleeding
Lower GI hemorrhage is rare in the pediatric population.
Individuals at risk are those with known coagulopathies,
such as hemophilia A or B, chronic liver disease, and portal
hypertension. Mucosal lesions, ulcers, polyps, arteriovenous
malformations, and inflammatory bowel disease are also
sources of lower Gl tract bleeding.

Esophageal Varices
Esophageal varices are the result of portal hypertension,
which can occur at any stage of liver disease. In hepatic
disease, portal hypertension is caused by cirrhotic changes
(intrahepatic scarring) that collapse and distort the hepatic
vasculature.
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Pathogenesis. When blood flow through the liver is
obstructed, portal venous pressure increases. The development of collateral circulation redirects the portal venous
blood flow through vessels of lower resistance and avoids
the obstruction. Collateral vessels develop in the abdominal
wall, rectum, lower esophagus, and stomach. These lowpressure veins eventually become distended with blood,
causing the veins to enlarge, developing into varices. The
development of collateral portal circulation may reduce the
portal pressure toward normal.
Clinical Presentation. The diagnosis of portal hypertension is based on clinical presentation, along with
information obtained from a variety of studies. Splenomegaly is generally the first sign of portal hypertension in
children. Hematemesis, melena, nosebleeds, or an unexplained decrease in hemoglobin level may also indicate
portal hypertension, although massive hematemesis is often
the first clinical sign in children. Barium studies can detect
relatively large varices but are unable to provide additional
clinically important information that can be obtained by an
ultrasound or endoscopy. An abdominal ultrasound is useful
in determining the presence and size of the portal vein and,
with Doppler, can determine the direction of the blood flow
through. the portal system. An upper endoscopy is currently
the best modality to determine the location and size of the
varices.
Critical Care Management. Hemorrhaging esophageal varices are a true medical emergency and require
prompt action. The cause of a bleeding episode is usually
unknown, but factors suggesting rupture include a sudden
increase in abdominal venous pressure as a result of physical
exertion, coughing, sneezing, vomiting, or slOol straining.
The first priorities are stabilization of airway, breathing, and
circulation. The child is turned on his or her side in a
semi-Fowler position with suction at the bedside to protect
the airway against possible aspiration or occlusion. In
addition to suction, accessibility of supplemental oxygen
and equipment for intubation and vascular access is ensured.
Close monitoring of vital signs and determination of
blood loss indicate the amount of fluid replacement necessary. During the resuscitation phase, it is vital that the blood
pressure be maintained. Isotonic crystalloid is administered
in boluses of 20 mllkg until systemic perfusion is restored or
whole blood is available. As the child's condition stabilizes,
the need for other blood products is determined by the
complete blood count and coagulation indices. Tn general,
fresh frozen plasma is administered to correct coagulation
abnormalities or with every two to three units of packed
RBCs (unless whole blood is used) to account for ongoing
loss of coagulation factors. Platelet transfusions are reserved
for patients whose platelet counts are less than 50,000 per
cubic millimeter.
Simultaneous with fluid resuscitation, an NG tube is
inserted to determine the volume of bleeding. Suspicion of
esophageal varices is not a contraindication for the insertion
of an NG tube. A large-diameter tube (10-16 French) is
passed to provide access for gastric lavage with roomtemperature normal saline. Room-temperature solutions
prevent hypothermia and its a~sociated side effects and are
better tolerated by the patient.
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Vasopressin is an antidiuretic hormone (ADH) that is
naturally excreted by the posterior pituitary. Administration
of this hormone produces a pharmacologic effect that
reduces bleeding in 35% to 50% of cases. 7 •107 Vasopressin
acts directly on GI smooth muscle and induces systemic
vasoconstriction. It also lowers portal venous pressure by
reducing splanchnic arterial blood flow.
Vasopressin is given through a central venous line at a
continuous infusion rate of 0.002 to 0.008 units/kg/minute
or 0.2 to 0.4 units/minute. Vasopressin infusion is continued
for as long as 24 to 36 hours and is slowly weaned if no
evidence of rebleeding exists.
Because vasopressin vasoconstricts the coronary and
renal arteries, it is important to closely monitor for
arrhythmias and hypertension. If bleeding does not cease or
if it reoccurs, further elevation of the vasopressin infusion
creates increased intravascular pressure because of excessive vasoconstriction. The increased pressure on the portal
system can precipitate greater blood loss.
Renal complications that accompany the use of vasopressin include fluid retention. Fluid intake should be limited to
two-thirds maintenance requirements. Strict intake and
output measurements are essential. Urine output of less than
0.5 mIIkg/hour in a child may be the result of fluid retention
from the use of vasopressin requiring titration of the
infusion.
Serum and urine laboratory values are obtained every 6
hours. Electrolyte and osmolality levels change significantly
with fluid retention. Signs of fluid retention include decreased serum sodium and osmolality levels, whereas urine
sodium and osmolality levels are increased. Liver dysfunction complicates the etiology of electrolyte disturbances.
Low serum sodium may indicate hyponatremia resulting
from vasopressin-induced free water retention. However,
the total body sodium may actually be increased because of
hepatorenal disease. The interpretation of serum sodium and
the administration of replacement sodium require extreme
caution.
Ascites and edema resulting from liver dysfunction may
worsen as a result of vasopressin-induced water retention.
Albumin may be administered in an effort to draw fluid from
the extracellular space into the vasculature. A preparation of
25% albumin is used to decrease the total fluid volume
administered. After the infusion of albumin, a dose of
furosemide (I mg/kg) is administered to facilitate diuresis.
It may be necessary to repeat this procedure until the serum
albumin and total protein levels normalize and fluid
retention resolves.
Octreotide has largel y replaced vasopressin in many
pediatric centers because of its more favorable profile. 107·109
Octreotide is a synthetic analogue of somatostatin that has
been proven in adults to be as effective as injection
sclerotherapy in controlling acute bleeding. 108 Somatostatin
reduces gastric blood flow and inhibits gastric acid and
gastrin production. Like vasopressin, it reduces portal venous pressure by decreasing splanchnic blood flow; however, it does not produce major systemic side effects.
Suggested dosing includes administering a 1 10 2 ~glkg
intravenous bolus followed by a continuous infusion of I to
2 ~g/kg/hour. 108 Currently there are no controlled studies
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on the use of somatostatin in children. Subsequent modes of
therapy such as balloon tamponade and sclerotherapy are
considered when medical therapy fails.
Balloon tamponade is performed with a SengstakenBlakemore tube (SBT). The availability of sclerotherapy has
significantly reduced its use. The SBT is available in two
sizes, pediatric and adult. The pediatric tube consists of
three lumens: one for gastric aspiration, one for inflating the
esophageal balloon, and one for inflating the gastric balloon.
The adult SBT has the addition of a fourth lumen for
aspiration of esophageal secretions. The SBT provides a
tamponade effect to the bleeding varices. Inflation of the
gastric balloon applies pressure to the vessels feeding the
varices and thus decreases the blood flow. Inflation of
the esophageal balloon allows pressure to be placed directly
on the varices. In children, the gastric balloon is inflated first
and if the bleeding continues, inflation of the esophageal
balloon is considered.
Once balloon tamponading is initiated, it is necessary to
keep children immobile. Activity can increase abdominal
and intravascular pressures, causing increased bleeding
activity. Therefore neuromuscular blockade may be necessary. Ventilatory support is necessary for as long as the SBT
is in place.
Bleeding is monitored by the amount of blood aspirated with intermittent suction. The blood pressure and
central venous pressure are continuously monitored and
near-normal parameters are maintained by volume replacement. It is important that hypertension be avoided. Complete blood count levels are monitored every 4 hours
until the hematocrit is stable. A hematocrit of 30 to 36
is adequate for these patients because hematocrits higher
than 36 have been shown to stimulate rebleeding as a
result of the increased intravascular pressure placing
stress on the varices. 107 Packed RBCs are administered to
raise the hematocrit. Coagulation indices and platelet counts
are monitored and blood products, such as platelets and
fresh frozen plasma, are given as described above. Vitamin
K may also be administered to replace factors II, VII,
IX, and X.
Complications commonly seen with the SBT are atelectasis and aspiration pneumonia. Atelectasis is the result of
increased intrathoracic pressure from the balloon, whereas
aspiration pneumonia occurs because of aspiration of
esophageal secretions. To prevent respiratory complications,
good pulmonary toilet is maintained. Balloon migration into
the esophagus or airway can result in possible asphyxia and
death. Esophageal perforation is a rare complication in
children and is considered a surgical emergency.
Sclerotherapy is the current primary treatment of acute
variceal bleeding in children. 109 The procedure is performed
under general anesthesia through a flexible fiberoptic
endoscope. A fine needle attached to a catheter is passed
through the biopsy channel of the endoscope. After identifying the varices, the endoscopist injects the sclerosing
agent into the varix or the surrounding tissue. The sclerosing
agent rapidly induces thrombosis and sclerosis of the vein,
and does minimal damage to the esophageal mucosa and
muscle.

A complication of sclerotherapy is hemorrhage. The
bleeding is often self-limiting, but it may be as severe as
the original episode. Some oozing is to be expected after the
procedure. Fever is a common complication, and alone is
rarely considered serious. A persistent fever may indicate a
bacteremia that is potentially lethal in the debilitated patient.
Intense pain may indicate an erosion or perforation of the
esophagus but, fortunately, is rarely seen.
The use of sucralfate after sclerotherapy for gastric
cytoprotection has become common practice. Sucralfate has
been demonstrated to be effective in the treatment of
esophagitis with minimal side effects, by acting locally to
form a protective barrier and increasing cytoprotection by
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Fig. 22-9 Types of portosystemic shunts. A, End-to-side portocaval (all portal flow is diverted to systemic circulation). B, Sideto-side portocaval (the major direction of portal flow is to the
systemic circulation, but the capacity for hepatic portal perfusion
is retained, depending on the resistance within the liver. C, Proximal splenorenal (the principal direction of portal flow is to the
systemic circulation: placing the shunt centrally minimizes the
angulation of the splenic vein). D, Distal splenorenal (major
direction of portal flow is to systemic circulation). E, Mesocaval
(vena cava is transected and proximal cava is anastomosed to side
of superior mesenteric vein. Major direction of visceral flow is
loward vena cava). F, Interposition mesocaval (hemodynamically
similar to mesocaval shunt. Autogenous vein graft is preferred for
creation of this shunt in infants and children. (From Karrer F, Lilly
JR, Hall RJ: Biliary tract disorders and portal hypertension. In KW
Ashcraft, TM Holder, eds: Pediatric surgery, ed 2, Philadelphia,
1993, WB Saunders.)
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stimulating prostaglandins and inactivating pepsin. 54 . IIO In
addition, an Hz blocker, such as ranitidine, is administered
to decrease gastric acid secretion.
Surgical options are considered if medical therapy is
ineffective. Shunting procedures divert the blood flow from
the liver and allow for decompression of the portal system.
Portacaval and splenorenal shunts are effective and control
hemorrhage from esophageal varices (Fig. 22-9). In children, mesocaval and central splenorenal shunts have been
successful even in very small infants. It was previously
believed that the vessels needed for successful anastomosis
and patent shunt were too small until a child was at least 7
years of age. It now seems that neither age nor size is a
limitation to a successful shunt. III
Liver transplantation is a consideration for children with
portal hypertension resulting from liver diseases known to
progress to liver failure and death. Liver transplantation is
discussed in Chapter 26.

ABDOMINAL WALL DEFECTS
Omphalocele and Gastroschisis
Omphalocele is a midline, umbilical defect of the ventral
abdominal wall in which the intestines herniate into a sac
consisting of peritoneum and amnion. Omphaloceles vary in
size and can be extremely large, containing the entire
midgut (distal duodenum, jejunum, ileum, ascending colon,
and first portion of the transverse colon), liver, and spleen.
The abdomen is, in this situation, small and scaphoid. If the
sac remains intact, the appearance of the bowel may be
fairly normal. Unfortunately in some cases the sac ruptures,
leaving the organs exposed to the amniotic fluid or to the
environment after birth.
Gastroschisis is an abdominal wall defect that usually
occurs to the right of a normal umbilical cord. There is no
sac covering the defect and the bowel usually appears thick,
foreshortened, hemorrhagic, and matted. The defect is
usually small and contains only the bowel. The clinical
differences between gastroschisis and omphalocele are
shown in Table 22-11.
Pathogenesis. The abdominal wall begins to develop
by the fourth week of intrauterine life and is formed from
cephalic, caudal, and lateral folds. Each of these folds is
composed of somatic and splanchnic layers. It is theorized
that if there is a failure of the normal embryonic folding and
fusing of the somatic layers of the lateral folds, the anterior
abdominal wall will not close completely. I 12
Omphalocele is thought to occur when the abdominal
wall does not form completely as the midgut elongates out
through the yolk sac, resulting in failure of the intestines to
return to the abdominal cavity. There are many theories
about the embryologic events resulting in gastroschisis, the
most plausible explanation is that of Shaw. 113 The developing embryo initially has both a left and right umbilical vein
as well as two arteries. By the eleventh week of gestation the
right umbilical vein has been obliterated, leaving a weakness at this site in the abdominal wall. It is theorized that this
weakness of the abdominal wall allows a rupture of the
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lateral umbilical ring with bowel protruding through the
defect, thus resulting in a gastroschisis.
Associated Abnormalities. Associated defects are
more common with omphalocele than with gastroschisis.
These can be divided into midline defects related to the
failure of closure of the embryologic folds, chromosomal
abnormalities, and other isolated abnormalities. Pentalogy
of Cantrell occurs with the defective cephalic fold. This
collection of defects includes intracardiac anomalies, ectopia cordis, sternal cleft, midline diaphragmatic hernia, and
upper abdominal omphalocele. Lower midline abnormalities are related to defects in the caudal embryonic fold.
These may include one or more of the following: cloacal
exstrophy (severe abdominal wall defect also exposing the
bladder), imperforate anus, colonic atresia, sacral vertebral
abnormalities, and meningomyelocele. Omphalocele has
been identified as a component of the Bechwith-Wiedemann
syndrome. Chromosomal abnormalities, including trisomy
13 through 15, 16 through 18, and 21, many of which are
incompatible with life, appear in approximately one third of
patients with omphalocele, and cardiac malformations are
present in up to 50%.114 The most common cardiac defect is
tetralogy of Fallot.
Clinical Presentation. Antenatal diagnosis of abdominal wall defects can usually be determined by ultrasound at approximately the fifteenth week of gestation. This

~

22·11
Diagnosis

TABLE

i~etor
I~ocation

miSize of defect
illF;"
i!¥lJmbilical cord
liSac
Itontents

Ik'

I!Bowel
J!1:'::
'I!!i."appearance
~~alrotation
~Small abdominal

I~ cavity

!t~ssociated
~':: anomalies

I::

(Coexisting
,...
d
iF
syn romes
!It"

~:
~J~~!
~,

I:

Clinical Differential
Gastroschisis

Omphalocele

Lateral 10 cord
Less than 4 cm
Normal insertion
None
Bowel, stomach

Umbilical ring
2-10 cm
Inserts in sac
Present
Bowel, liver,
spleen, bladder,
uterus, ovaries
Normal

Matted, foreshortened
Present
Present
Unusual (15%
atresia of
the gut)

Not observed

Present
Present
Common (37%67%) GI, genitourinary, CNS,
cardiovascular,
musculosk.eletal
Beekwith syndrome, cloaca,
trisomy 13-15,
trisomy 16-18,
exstrophy of the
bladder, pentalogy of Cantrell

Ifdodified from Grosfeld lL, Weber TR: Congenital abdominal wall
~l!efecls: gastroschisis and omphalocele. Curr Probl S/lrg 19; 165, 1982.
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prenatal determination assists the obstetrician to make a
decision regarding transfer of the mother to a tertiary care
setting. A cesarean section is usually indicated to prevent
rupture of the sac or damage to the exposed viscera. If the
defect has not been recognized before delivery, it is easily
seen at birth, and thus treatment begins quickly.
Critical Care Management. If a sac is present, care
is taken to prevent rupture. The defect is usually covered
with sterile gauze and wrapped in a figure-of-eight bandage
to prevent pressure on the exposed viscera. There are two
options for managing the exposed viscera. A saline-soaked
gauze pad covered with occlusive plastic dressing or a
bowel bag that covers the child's legs and abdomen, or dry
gauze soaked with saline before removal may be used.
These options prevent radiant heat loss that can occur with
saline-soaked gauze alone.
Respiratory assessment and stabilization are critical,
especially in the preterm infant in whom assisted ventilation
may be necessary. This is accomplished with endotracheal
intubation. Any mask or blow-by ventilation allows excess
air to enter the GI tract and should be avoided.
Gastric decompression is essential to empty the stomach
and prevent GI distension. Active decompression is accomplished with intermittent or continual suctioning, using a
large-bore NG or OG tube. Comfortable positioning also
calms the infant and prevents excessive crying and air
swallowing. The head of the crib is elevated when possible
to facilitate drainage.
Fluids are administered at twice maintenance requirement because of the fluid loss from the exposed bowel.
Antibiotics are administered and the child is prepared for the
operating room. As part of the preoperative workup,
assessment of associated anomalies is completed. Part of
this workup may be delayed until after surgery, but the
cardiac examination is completed before surgery, as well as
evaluation of any anomalies that may require emergency
surgical care.
Operative Management. Omphalocele and gastroschisis are repaired using one of two surgical approaches: a
primary closure or a staged repair. The primary closure
involves removing the sac from an intact omphalocele, and
opening the defect circumferentially. The bowel is examined
for areas of atresia or perforation. The abdominal wall is
stretched, and the viscera are carefully placed into the
abdominal cavity. Attempts to correct the malrotation are
not performed. The primary closure is successful if the
defect is small and the infant does not have other major
problems. With the primary closure, care is taken to avoid
compromise of respiratory status resulting from marked
elevation of the diaphragm, compression of the vena cava
resulting in impaired venous return, and impaired intestinal
blood supply. During the surgical procedure, when a
primary closure is being attempted, careful communication
with the anesthesiologist is essential to evaluate difficulty
with ventilation or perfusion. If either is significant, the
primary closure is aborted and a staged repair is done.
A staged repair is the procedure of choice for a large
defect, especially one in which the liver is involved. With
this technique, a single layer of Silastic material is sutured
to the abdominal wall around the defect and the viscera that

remains herniated. Over the next 7 to 10 days, the defect is
slowly reduced, usually on a daily basis by squeezing down
on the top of the Silastic silo, which pushes a small portion
of the contents of the defect into the abdominal cavity. 115.116
During this process, the infant is maintained on intravenous
antibiotics and the silo is bathed in an antibiotic solution.
When the defect is almost completely reduced, the infant
returns to the operating room for final closure. This process
of slowly reducing the defect needs to be completed within
I to 2 weeks or there is significant risk of wound infection.
Regardless of surgical technique, the length of hospitalization, parenteral nutrition requirements, and rate of complications are similar. 116
Postoperative Management. The goal ofpostoperative management includes maintaining a normothermic
environment; restoration of fluid and electrolyte balance;
provision of nutrition; and prevention of respiratory, circulatory, GI, and infectious complications. On return from the
operating room, the infant is placed in an isolette or warmer
bed to maintain normal temperature. Mechanical ventilation
may be necessary regardless of whether a primary or staged
repair is done. With primary closure, respiratory insufficiency is due to the significant pressure on the diaphragm
from the expanded abdominal cavity. Between staged
surgeries, the infant may have little need for ventilatory
support but may require mechanical ventilation immediately
after the reduction. Therefore the patient is often maintained
on low ventilatory settings until the defect is completely
closed.
The possibility of vascular compromise requires that the
lower extremities be assessed for color and capillary refill.
Pedal pulses are checked frequently. Elevating the infant's
legs may facilitate venous return. The infant will have third
space fluid loss, requiring twice-maintenance fluids and
the administration of albumin to prevent intravascular
hypovolemia.
Nutritional support is initially provided with TPN, but
within 4 to 6 weeks, even those infants with a staged repair
can begin elemental enteral feedings. The infant is observed
for signs of feeding intolerance, including increased gastric
residuals, abdominal girth, vomiting, and stool volume, and
presence of reducing substances in stool sample.
Survival of those with omphalocele is largely related to
the coexisting congenital anomalies, often necessitating
other surgeries. Infants with gastroschisis, however, have
increased incidence of residual bowel disease requiring
reoperation in 25% of cases. 1I6 In addition, an increased
incidence of GER has been observed in both gastroschisis
and omphalocele patients on follow_Up.117

HEPATIC FAILURE
Hepatic failure is the consequence of severe hepatocyte
injury or dysfunction resulting in multisystem complications, which include encephalopathy, cerebral edema, coagulopathy, renal failure, and hemodynamic instability. The
injury to the liver may be acute, resulting in fulminant injury
to the hepatocytes and rapid development of the clinical
signs of hepatic failure, without preexisting evidence of
liver disease. Fulminant hepatic failure (FHF) results in
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rapid clinical deterioration. In other instances, hepatic
failure is the result of chronic injury that has accumulated to
cause serious compromise of hepatic function and results in
end-stage disease. Regardless of the cause, the consequences and therapeutic modalities are the same. It is
important that the clinical course of hepatic failure and the
prognostic indicators be identified early to determine if
spontaneous hepatic regeneration and recovery are likely
with supportive therapies. Supportive therapies have been
shown to be unsuccessful in those patients with clinical
parameters suggesting progressive disease. Liver transplantation is the treatment of choice in these patients. 118.119

Etiology
Hepatic failure is rare in childhood. The causes of hepatic
dysfunction and failure in infants and children are divided
into two categories: fulminant failure and failure from
chronic liver disease. The incidence of anyone etiology of
liver failure is difficult to assess. One pediatric center
reported 81 children dying of hepatic failure between 1976
and 1983. 120 Biliary atresia accounted for 20 cases, metabolic disorders (tyrosinemia, cystic fibrosis, (XI-antitrypsin
deficiency, Wilson's disease, Zellweger syndrome) accounted for 22, and infectious causes were responsible for
15 cases. Cholestatic liver disease (Alagille's syndrome,
TPN-associated disease) accounted for 12. Miscellaneous
causes were cited for the remaining 5 cases.
The pediatric causes of liver disease are dependent on the
age of the child. 121 . 122 In the neonate, biliary atresia and
idiopathic hepatitis are the most common causes. In infants,
metabolic causes (galactosemia, glycogen storage disease,
tyrosinemia), except for Wilson's disease, occur more often.
In older children, especially adolescents, chemical or
acetaminophen intoxication, viral hepatitis, and Wilson's
disease are more typical.
Biliary Atresia. Biliary atresia is the result of a
progressive, idiopathic inflammatory process affecting the
intrahepatic and extrahepatic bile ducts. This inflammatory
process results in complete obliteration of the biliary tract.
Obstruction to bile flow causes cholestasis and progressive
fibrosis with eventual end-stage cirrhosis. Biliary atresia
occurs in approximately I in 15,000 live births. 123 It can
result in the development of end-stage liver disease within
the first year of life and remains the leading indication for
liver transplantation in children. 124 There are two forms of
biliary atresia. The fetal type occurs in 10% to 35% of
patients and is associated with congenital malformations
and anomalies. 123 In this type of biliary atresia, there is no
jaundice-free interval between the end of physiologic
jaundice of the newborn and the onset of cholestasis.
The more common type of biliary atresia presents at 4 to
8 weeks of life with persistent cholestasis and jaundice and
occurs in 65% to 90% of all cases. 123 These infants usually
have a normal birth history, passed normal meconium stools,
and had a jaundice-free interval.
Many etiologic agents have been explored. Biliary
atresia is not thought to be an inherited disorder, although
there are case reports of reoccurrences in families. 125. 126
The role of viral infections as an etiologic mechanism has
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been postulated. Preliminary studies have shown an association of biliary atresia and rotavirus but require further
investigation. 127
Infants with biliary atresia are generally full-term and
appear healthy despite being jaundiced. The gestational
history is unremarkable. Appetite and weight gain are
initially normal, but stools progressively become pale and
acholic (white, lacking bile pigment) during the first weeks
of life. The infant initially may have physiologic unconjugated jaundice progressing to a conjugated hyperbilirubinemia. This is generally recognized between 4 and 8 weeks of
age when the urine becomes dark and the stools acholic. The
total serum bilirubin is between 6 and 12 mg/dl, with
approximately 50% being conjugated. 128 Serum aminotransferases are mildly elevated, whereas ALP and GGT
are markedly elevated. Physical examination may reveal
hepatomegaly and, infrequently, splenomegaly.
No single test confirms the diagnosis of biliary atresia.
An abdominal ultrasound is performed to exclude other
causes of obstructive jaundice such as choledochal cyst. The
patency of the extrahepatic biliary system is demonstrated
by a nuclear scintiscan (HIDA scan). Evidence of radioactivity in the duodenum confirms a patent biliary system, thus
eliminating the possibility of biliary atresia. When there is
no evidence of excretion with the HillA scan, further
diagnostic evaluation is necessary in the form of a percutaneous liver biopsy. The histologic finding of intrahepatic
bile duct proliferation suggests a mechanical obstruction,
indicating the need for laparotomy and operative cholangiogram. If the extrahepatic system cannot be demonstrated by
cholangiogram, surgical intervention is necessary.
The most common surgical procedure performed to
establish biLe flow is the Kasai hepatoportoenterostomy
(Fig. 22-10). The residual biliary system is removed. The
surface of the Ii ver is dissected and an area through which
bile can drain is exposed. A limb of jejunum is made into

Liver

-->'1(---

Small intestine
inserted at
fibrous plate

Stomach

fJ~~~j:l~=-- Duodenum
Jejunum

Fig. 22-10 Schematic representation of a hepatic portoenterostomy (Kasai procedure) providing bile drainage in a case of
extrahepatic biliary atresia.
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a Roux-en-Y intestinal conduit to maintain the patency
of the intestine. Success of the procedure varies, depending on the age of the infant at the time of surgery and
the center performing the surgery, with one fourth to
one half of patients having inadequate drainage despite
the surgical intervention. lrnproved outcomes have been
shown when surgical intervention is performed before 2
months of age. 129
The two postoperative problems of consequence are
failure to establish bile flow and ascending cholangitis.
Ascending cholangitis is a frequent and severe complication
of a successful operation, occurring in 50% to 100% of
patients with established bile flow after a Kasai procedure. 129 Surgical and medical approaches have been attempted to decrease the incidence of ascending cholangitis.
Surgical modifications of the Kasai procedure have not had
great success. Medical approaches include choleretic agents
to improve bile flow, postoperative antibiotics, and longterm prophylactic oral antibiotics, all with limited success.
Long-term prognosis is guarded in infants with biliary
atresia. Establishment of bile flow and resolution of the
jaundice appears to be correlated with the best outcome.
Patients who remain jaundiced experience hepatic failure
between the ages of 2 and 10 years of age and require a liver
transplant. Those with established bile flow and resolution
of jaundice have a 90% chance of surviving past age 10
years. Survival to the third decade with a high quality of life
has been reported. 130.13 I
Arteriohepatic Dysplasia. Arteriohepatic dysplasia
(Alagille's syndrome or syndromatic bile duct paucity) is
characterized by a marked reduction of intrahepatic bile
ducts and chronic cholestasis. It occurs in association with
cardiac, vertebral, ocular, facial (frontal bossing, deep-set
eyes, beaked nose, and pointed chin are typical facies),
renal, and neurodevelopmental abnormalities. It is the most
common form of familial intrahepatic cholestasis, with a
wide variation in clinical symptoms in affected individuals. 132 The estimated incidence of Alagille's syndrome is I
in 40,000 births. 129 It is a genetic disorder inherited as an
autosomal-dominant trait, with the defective gene appearing
to be on chromosome 20. 133 However, the majority of
patients have no family history.
The number of interlobular bile ducts is often not
decreased on initial liver biopsy in infants with Alagille's
syndrome. 128 Over a variable period of months to years, the
intrahepatic ducts are lost and the condition becomes more
definable. Progressive liver disease develops in 10% to 20%
of patients with Alagille's disease. 129 There is no way of
predicting the progression of significant pathology. The
cause of the bile duct paucity is unknown. 129 It has been
suggested that an inability to secrete bile is related to the bile
duct loss in Alagille's disease. The relationship of the liver
disease to other systemic manifestations is unknown.
Structural lesions involving the heart, eyes, kidneys, skeletal
system. and genitalia are well described.
Alagille's syndrome generally presents in the first 3
months of life in the symptomatic patient. It is among the
more common causes for cholestasis and jaundice in the
newborn period and must be distinguished from biliary

atresia and choledochal cyst. Nonsymptomatic adults are
commonly undiagnosed until a related child with symptoms
is identified. Biochemically, infants with Alagille's syndrome have moderately to markedly elevated bilirubin, ALP,
GGT, and 5'-nucleotidase. There may also be mild to
moderate elevations in serum transaminases. These elevations may persist through childhood. Serum triglyceride and
cholesterol levels may be extremely elevated. Hepatomegaly is present in nearly all patients, whereas splenomegaly is
rare initially.
Jaundice is present in the majority of patients with
symptomatic disease. Pruritus is severe but rarely present
before 3 to 5 months of age. Xanthomas resulting from
cholestasis appear on the extensor surfaces of the fingers,
palmar creases, nape of the neck, buttocks, and inguinal
area. The formation of xanthomas is related to the severity
of the cholestasis and correlates with elevated serum
cholesterol levels. Diminished bile salt excretion results in
fat malabsorption and deficiency of fat-soluble vitamins,
which has profound systemic effects. Growth failure is
common with delayed pubertal development. Progression of
the disease to cirrhosis and hepatic failure was initially
believed to be an uncommon event that is now being
recognized more often.
Treatment goals include optimizing nutrition, preventing
or correcting of fat-soluble vitamin deficiencies, and relieving pruritus and xanthomas. Infants may require specialized
formulas with medium-chain triglycerides as the major fat
component for improved absorption. Some infants may
require continuous feeding to optimize caloric needs.
Vitamins A, D, E, and K supplementation is often required
secondary to fat-soluble vitamin malabsorption. Cholestyramine, a bile salt-binding resin, may be helpful in relieving
associated pruritus. Surgical intervention is not effective. A
small number of children progress to end-stage liver disease
and benefit from liver transplantation. 13I
a,-Antitrypsin Deficiency. ai-Antitrypsin deficiency is the most common metabolic disease in children
requiring liver transplantation. It is an autosomal-recessive
disorder, specifically the mutant ai-antitrypsin Z molecule.
This molecule is synthesized normally but is retained within
the endoplasmic reticulum of the hepatocyte. Although the
pathogenesis still remains unclear, it is theorized that the
accumulation of aI-antitrypsin in the endoplasmic reticulum
is directly related to the liver cell injury.134 The consequences include premature pulmonary emphysema and
chronic liver disease in infants and children. In the United
States, the prevalence has been described as I in 2000
individuals. It is more common among Caucasians of
Northern European ancestry.135
Infants with ai-antitrypsin deficiency generally present
in the first 2 months of life with persistent jaundice. The
serum transaminases are sHghtly elevated and the liver may
be enlarged. The liver disease may also be discovered later
in childhood or adolescence with hepatosplenomegaly,
ascites, or hemorrhage from esophageal varices. Many of
these children experience progressive liver dysfunction
requiring transplantation. The diagnosis is confirmed with a
low «70 mg/dl) serum a l concentration level and the
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Clinical Profile of Viral Hepatitis

Transmission

Fecal-oral, parenteral rare
Perinatal. sexual, parenteral
Parenteral, perinatal rare, sexual
infrequent
Parenteral, sexual, perinatal rare
Fecal-oral

Active
Immunization

Passive
Immunization

Chronicity

Incubation
Period

Yes
Yes
No

Yes
Yes
No

No
Common
Common

15-49 days
60-180 days
14-160 days

Indirect. against HBV
No

Indirect, against HEV
No

Common
No

21-42 days
21-63 days

;;1iiom Fishman LN, Jonas MM, Lavine JE: Update on viral hepatitis in children, Pediatr Clin North Am 43:58. 1996.
i::~;;

determination of the (XI-antitrypsin phenotype (piZZ).136
(X.-Antitrypsin is an acute phase protein synthesized in the
liver and will rise with tissue injury, inflammation, or
infection. Therefore children with (XI-antitrypsin deficiency
who suffer from pneumonia (for example) may have falsely
normal levels during the acute illness.
There is no specific therapy for liver disease associated
with (XI-antitrypsin deficiency. Children with progressive
liver failure have been treated with liver transplantation. 137
Wilson's Disease. Wilson's disease is an autosomalrecessive disorder of copper metabolism in which biliary
excretion of copper is inadequate and the excess accumulates in the liver, brain, kidneys, cornea, and skeletal system.
The disease has been recognized for approximately 60
years; however, the biochemical defect has yet to be
identified. Hepatic disease occurs when the copper overload
leads to the destruction of liver tissue. It occurs in I in
30,000 individuals. 136
The clinical symptoms of Wilson's disease rarely present
before the age of 6 years, more often in the second decade.
Hepatic dysfunction is the most common presentation in
children; however, the diagnosis is considered in older
children and adolescents with a neurologic abnormality.
Symptoms may be subtle initially and include malaise,
anorexia, and lethargy. Signs of progressive liver disease
such as jaundice, petechiae, hematemesis, and ascites may
also be present at diagnosis. Presentation with fulminant
hepatitis with progression to liver failure requiring transplantation does occur. Neurologic symptoms include gradual onset of clumsiness, dysarthria, drooling, tremors, loss
of fine motor skills, and psychologic disturbances. KayserFleischer rings, a greenish pigment encircling the cornea, (the result of copper deposits) is considered diagnostic
of Wilson's disease. Its absence, however, does not rule
it out.
The diagnosis of Wilson's disease may be difficult. The
majority of children with Wilson's disease have a low serum
level of the copper-binding protein ceruloplasmin, implying
a homozygosity (disease state) or heterozygosity (carrier
state). Urinary copper excretion is usually elevated. An
ophthalmologic examination for Kayser-Fleischer rings is
necessary. A liver biopsy may be necessary to determine the
amount of copper in the liver. Asymptomatic siblings should
also be screened for Wilson's disease. Treatment of Wilson's
disease is aimed at improving the excretion of copper

through chelation with penicillamine and decreasing dietary
intake of copper-containing foods.
Infection. Fulminant hepatic failure (FHF) is the
syndrome of acute liver failure complicated by the development of hepatic encephalopathy within 8 weeks of the
initial symptoms of liver disease without a history of
previous or underlying liver dysfunction. I18.138 Early recognition is essential because a delay in diagnosis and
treatment can often lead to a grave prognosis.
Viral hepatitis is the most common infectious cause of
FHF. 138 •139 Each of the five primary hepatotropic (affecting
the liver) viruses (A through E) has been implicated in acute
liver failure. Other agents (F, G), not yet identified, can also
be responsible for clinically evident hepatitis. 140 Table
22-12 highlights the clinical profile of the viral hepatitis
agents.
Hepatitis A virus (HAV) is a self-limited enteric infection
and rarely leads to hepatic failure in children.118.138 However, there are reports of HAV causing fulminant disease in
intravenous drug users and the elderly. I18 HAV infection is
diagnosed by the presence of anti-HAY IgM antibodies in
the serum. The presence of anti-HAY IgG antibodies in the
serum without anti-HAY IgM reflects immunity or past
resolved infection.
Hepatitis B virus (HBY) is the most common form of
hepatitis causing FHF worldwide. 139 HBY has been reported to cause FHF in infants vertically infected from their
mothers and in older children from blood transfusions. 141
Fortunately, the number of reported cases is decreasing in
the United States, which is most likely the result of a
heightened awareness of associated risk factors and vaccination of high-risk groups. 138, 142 The diagnosis of HBV
infection is made by the presence of hepatitis B surface
antigen (HBsAg) and hepatitis B core antibody IgM
(anti-HBc IgM) in the serum. IgM antibody to hepatitis B
core antigen must be present to differentiate between acute
and chronic infection.
Hepatitis C virus (HCY), also known as non-A non-B
hepatitis, has recently been implicated as a causative agent
in FHF, although this presentation is rare. 143 The diagnosis
is made by the presence of antibody to multiple HCV
antigens (anti-HCV) in the serum.
Hepatitis 0 virus (HOV), or delta agent, requires the
presence of coexisting HBY infection for its replication.
Superinfection with HOY can lead to FHEl.19 The diagnosis
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of HDV infection is made by the presence of antibody to
HDV (anti-HDV) in the serum.
Hepatitis E virus (HEV) is a self-limited enterically
transmitted infection that rarely causes FHF. 139 The diagnosis is made by the presence of antibody to HEV
(anti-HEV) in the serum.
Other viral agents that may cause FHF include Herpes
simplex virus (HSV), Epstein-Barr virus (EBV), and Cytomegalovirus (CMV) but are more frequently seen in
neonates or immunocompromised patients. HSV infection
may be acquired at anyone of three times: in utero,
intrapartum, or postnatally. Neonates commonly exhibit
disseminated disease in the first week of life with signs of
multiple organ involvement. Clinical findings include irritability, seizures, respiratory distress, jaundice, coagulopathy, and shock. Viral recovery in the blood, cerebrospinal
fluid, and bodily secretions may be difficult. Antiviral
treatment is often administered based on clinical presentation, EEG, and MRI findings.
EBV is the principal cause of infectious mononucleosis
but is also responsible for significant disease in immunocompromised children. 144 Clinical findings typically include exudative pharyngitis, lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis on complete blood
count, and elevated serum transaminases. The diagnosis is
confirmed by the detection of EBV-specific antibodies in the
serum.
CMV infections occur primarily in newborns and immunocompromised patients. The newborn presents with hepatosplenomegaly, jaundice, and less frequently purpura. The
immunocompromised child typically contacts the virus after
an organ transplant. The source of infection may be from the
grafted organ, transfused blood products, or reactivation of
a latent infection. Diagnosis is made with the CMV
antigenemia serum test.
Less frequent viral agents that may cause FHF include
adenovirus, enterovirus, parvovirus, and varicella-zoster
virus. Immune deficiency is suspected when these viruses
cause severe hepatic failure. Diagnoses are made by specific
serologic or histologic analysis or by culture of blood, urine,
stool, or liver tissue.
Drug-Induced Hepatic Failure. In children, druginduced liver injury represents 15% to 20% of cases of
FHF. 145 Drugs most commonly linked with hepatic failure
are acetaminophen, anticonvulsants (phenytoin, valproate),
halothane anesthesia, and isoniazid (IN H). 146 Hepatitis may
be caused by a direct injury or idiosyncratic process.
Acetaminophen ingestion is an example of an agent that
causes direct injury and can occur when taken in large single
doses (exceeding 140 mg/kg). Agents that cause an idiosyncratic reaction (i.e., phenytoin, valproic acid, halothane)
are thought to be the result of an immune-mediated
hypersensitivity response and/or a reaction to the metabolites of the ingested agent. 146

Consequences of Hepatic Failure
In children with hepatic disease, ongoing damage results in
decreased function, which includes the metabolic and

detoxification processes of the liver. The Kupffer cells'
phagocytic process is significantly diminished with hepatic failure, resulting in decreased filtration of blood and
placing the child at increased risk for infections. Decreased
bile salt synthesis results in fat malabsorption. In children, fat accounts for a large percentage of calories
consumed. Malnutrition and malabsorption of fat-soluble
vitamins A, D, E, and K result. Vitamin A stores are long
lasting, approximately to 2 years; thus a deficiency must
be long-standing before ill effects are noted. Failure to
absorb vitamin D results in demineralization of the bone
leading to osteomalacia, rickets, and pathologic fractures. Vitamin E malabsorption has neurologic consequences, such as peripheral neuropathies and diminished
deep tendon reflexes. Vitamin K deficiencies result in
coagulopathies, which are discussed later in this section.
Excessive accumulation of bile salts resulting from decreased extraction through the Ii vel' results in their deposition in the skin, causing intractable pruritus. Cholestasis
(biliary obstruction) causes direct hyperbilirubinemia and
jaundice.
The liver is crucial in the process of carbohydrate
metabolism. Initially, serum glucose levels are elevated, but
glycogen stores are decreased. If the liver is unable to
store glycogen or generate new glucose, the kidneys assume
the process of gluconeogenesis. As the hepatic failure progresses, hypoglycemia becomes a problem.
Protein metabolism is altered in hepatic failure. Altered
albumin synthesis results in low serum albumin levels.
Without adequate levels, the body is unable to maintain
oncotic pressure. Consequently, fluid leaks from the blood
vessels into the abdominal cavity and tissues, resulting in
ascites and edema.
The liver's ability to manufacture clotting factors is
impaired. Vitamin K absorption is influenced by the
decreased synthesis of bile salts resulting in a decreased production of vitamin K-dependent clotting factors
II, VII, IX, and X. Alterations in hemostasis are evidenced by prolonged prothrombin time, easy bruising, and
bleeding.
A failing liver is also unable to remove activated clotting
factors from the circulating serum. Hepatic necrosis causes
an inflammatory response, thus activating clotting factors.
Once acti vated, clotting factors circulate in the plasma, form
microthrombi, and consume platelets and fibrinogen. Disseminated intravascular coagulation (DIC) results when
fibrinolysis occurs and the liver is unable to synthesize
clotting factors.
The liver's inability to detoxify hormones, drugs, and
other harmful compounds results in a variety of clinical
manifestations. Continued circulation of aldosterone and
ADH contributes to the development of ascites and hepatorenal syndrome. Hepatorenal syndrome is a progressive
renal failure directly related to liver disease. The mechanism
causing the renal failure is unknown. The use of medications
metabolized by the liver is avoided. In addition, with
evidence of renal dysfunction, medications excreted by
the kidneys are adjusted based on calculated creatinine
clearance.

Chapter 22

Complications of Hepatic Failure
Hepatic Encephalopathy.

Hepatic encephalopathy
is the change in mental status that accompanies hepatic
failure. The encephalopathic agent responsible for these
changes has not yet been identified. Generally it is assumed
to be due to hyperamrnonemia; however, some patients with
obvious hepatic encephalopathy have normal serum ammonia levels. The appearance of hepatic encephalopathy is
variable. It depends on the extent of the liver damage, speed
of injury, degree of portal-systemic shunting, and contributing factors. The child with FHF may progress to coma and
unresponsiveness very rapidly, over several days, whereas
the child with chronic liver disease may have intermittent
alterations in mental status becoming more severe over time.
Some children with chronic liver disease do well until a
major insult occurs, such as a variceal hemorrhage, or until
an infection precipitates the onset of encephalopathic
changes.
Hepatic encephalopathy is traditionally divided into five
stages, which are outlined in Table 22-13. Passage through
the stages may be rapid. It is important to monitor the
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progression so that therapeutic support can be escalated. In
cases of chronic liver dysfunction, the deterioration may be
subtle. Changes in behavior, school performance, and
handwriting are the most commonly noticed symptoms.
Four hypotheses postulate the pathophysiology of hepatic encephalopathy. No single hypothesis completely
explains the process. 122 The ammonia hypothesis suggests
that ammonia accumulation in the brain results in encephalopathic changes. The synergistic neurotoxins hypothesis
suggests that encephalopathy and coma are a result of
accumulating toxins with synergistic effects augmented by
other metabolic abnormalities. An excessive production of
the brain inhibitory neurotransmitter, serotonin, and the
false neurotransmitter, octopamine, accompanied by a
deficient synthesis of excitatory neurotransmitters, norepinephrine and dopamine, result in encephalopathy and coma
and are the basis of the false neurotransmitter hypothesis.
The final hypothesis is the activation of the gammaaminobutyric acid (GABA)-benzodiazepine inhibitory neurotransmitteJ: GABA, the principal inhibitory neurotransmitter of the brain, is normal1y degraded in the liver;

22-13 Clinical Staging ofHepatic Encephalopathy
Stage I

Stage II

Stage III

Stage IV

Stage V

Alert, oriented,
slow mentation

Lethargic, confused, agitated

Slupor, arousal to

Unarousable

Unarousable

Restless, irritable,
short attention
span. disordered
sleep

Combative, sullen,
euphoric

Sleeps most of
time, marked
confusion

None

None

Incoordination,
tremor, poor
handwriting

Yawning, sucking,
grimacing. intention tremor
present, blinking

Decreased, marked
intention tremor

Absent

one

~{Asterixis

Absent

Present

Present (if cooperales)

Absent

Absent

[{Muscle tone

Nonna(

Increased

Increased

Increased

Flaccid

~~eftexes

Normal

Hyper-reflexic

Hyper-reflexic
extensor plantars

Hyper-reflexic
extensor plantars

Absent

Regular or hyperventilation

Hyperventilation

Hyperventilation

Irregular

Apnea

itt'
[~~Yerbal response

Nonnal

Confused, dysarthric

Incoherent

None

None

Obeys commands

Purposeful movements, may not
respond to commands

Localized appropriately to pain

Abnormal flexor,
abnonnal extensor posturing

None

Brisk

Brisk

Sluggish

Fixed

~:'Mental status
?f,~'-.

~~fcc'

gdkhavior
eli'

fE-

~~~
me
t~

~fSpontaneous

~,
~.

motor

activity

~ffu;.

I!i.'.;
~lt

.

ri;;
I,'

.!Y'!

i:··
..
iii"ResplralJons
!lib'

t!l,)~

tt

~!Motor response

~~,

If
r;.~'

~lPupils
g!
"'1<
.
~;,-,ye opemng

voice

Spontaneous

Brisk
Verbal stimuli

Verbal stimuli

Noxious stimuli

None

s"

~:Oculocephalic

Nomlal

Nonnal

Normal

Partial dysconjugate

Absent

Ipculovestibular

Nonnal

Normal

Nonnal

Partial dysconjugale

Absent

~:From

Treem WR: Hepatic failure. [n Walker WA
i:n.c. Decker.
Reprinted by pennission of Mosby.
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al. eds: Pediatric ga,'itrointe.'ltinal diseases: pathophysiology, diagnosis, manageme1l1. Toronto. 1991.
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however, during liver failure this process fails to occur,
resulting in increased circulation of receptors.
Hepatic encephalopathy occurs as liver destruction
progresses. The blood flow from the intestine is shunted
around the liver completely, bypassing viable hepatocytes.
Consequently, the filtration process of the liver does not
occur. It is also believed that alterations in the function of
the blood-brain barrier contribute to the development of
hepatic encephalopathy. The blood-brain barrier is essential
in preventing toxic substances in the systemic circulation
from entering the brain.
Cerebral Edema. Cerebral edema is the major cause
of mortality in patients with FHF, unlike chronic liver
disease. The rapid increase in the water content of the brain
in acute liver failure occurs from an alteration in the
blood-brain permeability. Cerebral edema raises intracranial
pressure (ICP) and can result in cerebral ischemia if not
recognized and treated promptly. Therefore ICP monitoring
is performed in some PICUs when patients reach stage III
encephalopathy.
Impaired Coagulation. The liver is the site of
synthesis for most of the coagulation factors (II, V, VII, IX,
X), fibrinolytic agents, and inhibitors of coagulation. With
the onset of hepatic failure, there are significant alterations
in the coagulation process. Prothrombin time is often
prolonged and is unresponsive to vitamin K. Coagulation
factors are reduced; however, factor V, which is vitamin K
independent, may be the most sensitive single indicator of
outcome of FHF. 147 Factor V has a half-life of 12 to 24
hours; therefore a rapid decrease in this level reflects
impaired synthesis resulting from rapidly developing hepatocellular injury. Fibrinogen levels are also reduced because
of decreased synthesis and increased consumption. Thrombocytopenia is present, commonly less than 100,000 per
cubic millimeter. Thrombocytopenia may be the result of
platelet sequestration as a consequence of hypersplenism, or
platelet-associated antibodies as seen in chronic active
hepatitis, or DIC. With these coagulation abnormalities,
patients with hepatic failure are at an increased risk for
major hemorrhage, most commonly originating in the GI
tract or the brain, potentially resulting in death.
Hepatorenal Syndrome. Oliguria is common in
both acute and chronic liver failure. Hepatorenal syndrome
is defined as unexplained progressive renal dysfunction
without obvious histologic lesions. It is characterized by
significant sodium retention without urinary sodium. Urinary sediment is present but without protein, cells, or casts,
and the oliguria is unresponsive to intravascular volume
expansion. Hepatorenal syndrome accounts for the majority
of renal impairment in FHF and is often associated with a
fatal outcome. 148

Critical Care Management
The management of FHF is largely supportive therapy that
requires a multisystem approach. Therapeutic mea~ures are
used to treat the complications of hepatic failure, including
those outlined above plus metabolic derangements, hemodynamic instability, and respiratory dysfunction.

The laboratory evaluation of FHF is extremely broad and
includes diagnostic tests to determine cause, assess liver
function, and to assess function of other organs. The nurse
plays a vital role in monitoring these laboratory values and
performing serial assessments. Neurologic assessment is
extremely vital for the detection of worsening encephalopathy and increased ICP and is initially performed every hour.
The patient will also require emergent invasive hemodynamic monitoring and therapeutic measures. Frequently,
these patients require intubation and mechanical ventilation
to protect their airway. Routine care includes placement of
a Foley catheter, strict intake and output, and appropriate
isolation techniques if infectious etiology is suspected.
The patient is made NPO, and an NG tube is placed with
evidence of GI bleeding or in the patient with stage III or IV
encephalopathy. An Hz blocker, such as ranitidine, is
administered to prevent stress ulcers. The dose is adjusted
based on evidence of renal dysfunction. An antacid is also
administered with pH lower than 4.0. TPN is initiated when
the patient is hemodynamically stable. However, the solution should contain a low amino acid concentration and trace
minerals must be held because of the accumulation of
copper and manganese in liver failure.
Deficits in intravascular volume are corrected and then
total fluids are restricted. Overhydration is avoided because
it may precipitate cerebral edema, ascites, and pulmonary
edema. However, intravascular dehydration may cause
hepatorenal syndrome, worsening encephalopathy, and hypotension. Therefore fluid management is best guided with
central venous pressure trends. Dialysis or hemofiltration
is indicated with severe renal insufficiency as evidenced
by oliguria, elevated creatinine level, severe metabolic
acidosis, hyperkalemia, hyperphosphatemia, and volume
overload.
Respiratory distress and/or failure are associated with
encephalopathy, and hepatorenal syndrome as evidenced by
hypoxemia and respiratory acidosis. The child requires
intubation for airway protection when stage III encephalopathy is reached. Hypoxemia may be exacerbated by the
development of pulmonary edema and treatment includes
increased positive end expiratory pressure.
Thrombocytopenia is treated when the platelet count
drops to less than 50,000 per cubic millimeter with I unitilO
kg. Fresh frozen plasma transfusion is given for evidence of
active bleeding. The hematocrit is maintained at 30% or
greater with 15 mI/kg packed RBC transfusions. Cryoprecipitate infusion is given for fibrinogen levels less than
100 mg/dI. Vitamin K (up to 10 mg intravenously) is
administered for 3 days to correct a prolonged prothrombin
time (PT).
Hypoglycemia is common and may cause an altered level
of consciousness. Hypoglycemia in the failing liver is the
result of defective gluconeogenesis and increased peripheral
insulin levels. Blood glucose is monitored closely and
replaced with intravenous dextrose when levels are less than
60 mg/dl.
ICP monitoring may be warranted for patients with
evidence of cerebral edema and increased ICP. However,
emergent treatment includes intubation and hyperventilation
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(if not already performed) and mannitol to induce an

osmotic diuresis. Hypotension is aggressively treated in
order to ensure adequate cerebral perfusion pressure.
Treatment of encephalopathy also includes the administration of Lactulose. Lactulose is used to reduce ammonia
levels and is administered by an NG tube at a dose of 0.5
mJJkg/dose up to 30 ml/dose every 6 hours. The dose is
adjusted to produce two to four loose stools per day. Strict
intake and output are required to avoid dehydration.
Benzodiazepines and opiates are used judiciously because of the concern of the role of GABA-benzodiazepine
receptor association with hepatic encephalopathy and the
potential for drug accumulation secondary to decreased drug
metabolism. The patient who requires sedation or analgesia
is gi ven small doses, which are titrated to effect. Continuous
infusions are contraindicated.
Patients with acute liver failure are at increased risk for
bacterial and fungal infections. Meticulous care of all
indwelling catheters and assessing frequently for signs and
symptoms of infection are crucial. Surveillance cultures and
aggressive treatment of presumed infection are essential.
Various liver-assist therapies have been introduced as an
alternative to the shortage of available donors for transplantation. Such therapies include plasmapheresis, hemodilu-
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tion, extracorporeal liver perfusion, and bioartificial liver.
These assist devices have been used to provide a bridge to
transplantation in case of irreversible damage or to gain time
for regeneration of the hepatocytes. Temporary clinical
improvement has been seen; however, further research is
needed to achieve successful long-term outcomes.149.J50
The appropriateness of orthotopic liver transplantation
(OLT) is an important aspect of care for the patient with
FHF. Survival rates for OLT approach 60% to 70% with
transplantation. However, 25% of patients listed die before
an organ becomes available. t50 This supports the urgency to
list patients while in stage II or III encephalopathy. Outcome
is dependent on prompt aggressive treatment of complications and early assessment for potential transplantation.

SUMMARY
GI problems in infants and children are extremely varied
and can be complicated and severe. Although the pathology
varies greatly, the nursing care and assessment follow
common pathways. GI nursing assessment, gastric decompression, intravascular volume replacement and maintenance, and pharmacologic management are of critical
importance to the survival of these infants and children.
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Endocrine Critical Care
Problems
Tara Trimarchi

endocrine disturbance is discussed within the context of
fluid deficit or excess with electrolyte imbalance, circulatory
failure, and hypoglycemia or hyperglycemia.

MATURATIONAL ANATOMY AND PHYSIOLOGY

Endocrine Regulation of Water and Electrolyte
Balance and Hemodynamic Stability
Endocrine Regulation of Energy Production
by Cells: Glucose Homeostasis

MATURATIONAL ANATOMY
AND PHYSIOLOGY

DISTURBANCES OF WATER BALANCE: FLUID VOLUME
DEFICIT

Endocrine Regulation of Water
and Electrolyte Balance
and Hemodynamic Stability

ADH Deficit (Diabetes Insipidus)
Increased Atrial Natriuretic Peptide Production
and Cerebral Salt Wasting Syndrome

Water is distributed in the human body as intracellular fluid
(70% of total body water) and extracellular fluid, which
includes plasma and interstitial fluids (30% of total body
water). Osmolality is an important factor regulating fluid
balance between the intracellular fluid (ICF) and the
extracellular fluid (ECF) compartments. Normal plasma
osmolality ranges between 270 and 285 mOsmIL. Sodium is
the major cation of the ECF and usually accounts for 90%
of the plasma osmolality. Hormones, such as antidiuretic
hormone. aldosterone, and atrial natriuretic hormone, act on
the kidneys to influence the reabsorption and excretion of
sodium and water, thereby regulating the concentration,
composition, and volume of body fluids and maintaining
osmolality within the normal range.
Antidiuretic Hormone (Vasopressin). Antidiuretic
hormone (ADH) is formed in the supraoptic and paraventricular nuclei of the hypothalamus and is stored in the
posterior pituitary. ADH increases the reabsorption of water
in the collecting ducts of the kidneys. Through the action of
ADH, water is returned to the vascular space, resulting in
increased blood volume and decreased water loss in the
urine. ADH secretion is regulated by plasma osmolality
receptors located in the brain and by stretch receptors
located in the ascending aorta and left atrium of the heart.
When the plasma osmolality is higher than 285 mOsmIL,
the osmoreceptors in the hypothalamus of the brain are
stimulated, resulting in a sensation of thirst and ADH
secretion. Through the ingestion of fluids and water

DISTURBANCES OF WATER BALANCE: FLUID VOLUME

ExcEss

ADH Excess (SIADH Secretion)
ADRENocoRnCAL HYPOFUNCTION: FLUID VOLUME DEFICIT
AND CIRCULATORY FAILURE

Adrenal Insufficiency/Adrenal Crisis
DISTURBANCES OF GLUCOSE HOMEOSTASIS

Hypoglycemia
Hyperglycemia
SUMMARY

T

he endocrine system is a complex physiologic network
that regulates growth, development, metabolism, and
sexual differentiation. This integrated system of feedback
loops depends on the stimulation or inhibition of glands that
secrete hormones into the bloodstream.
Frequently encountered endocrine emergencies in children can be grouped into the final common pathways of
alterations in fluid and electrolyte balance, circulatory
failure, and alterations in glucose homeostasis. This chapter
reviews the basic pathophysiology, diagnosis, and treatment
of selected endocrine problems. Recommendations for the
nursing management of the infant or child with a serious

805

806

Part IV

Final Common Pathways

reabsorption by the kidney, this response restores intravascular volume and maintains serum osmolality within the
very narrow range of 282 to 295 mmol/kg. I Decreased
blood pressure caused by hypovolemia or vasodilation
stimulates stretch receptors located in the ascending aorta
and left atrium and is also a stimulus for ADH secretion.
Mineralocorticoids (Aldosterone). Aldosterone is
secreted by the adrenal cortex. Aldosterone acts on the renal
tubules, resulting in the conservation of sodium and water
and the excretion of potassium in the urine. Under the
influence of aldosterone, sodium and water are returned to
the vascular space and urine production is decreased.
Aldosterone secretion is, in part, controlled by the reninangiotensin system.
The renin-angiotensin system is stimulated by decreased
renal perfusion, resulting from diminished blood volume
and reduced arterial blood pressure. When the juxtaglomerular apparatus of the kidneys senses a state of low perfusion,
the kidneys release renin. Renin stimulates the conversion
of angiotensin I (a protein produced by the liver) to
angiotensin II. Angiotensin II is a potent vasoconstrictor and
stimulates aldosterone release. In addition to aldosterone
release, some ADH is also released in response to angiotensin II. Vasoconstriction, in addition to the sodium and
water retention induced by aldosterone and ADH, serves to
restore blood pressure and volume.
Atrial Natriuretic Hormone (Atrial Natriuretic
Peptide). Atrial natriuretic hormone (ANH), or atrial
natriuretic peptide, is produced by the cells of the atria of the
heart. ANH has vasoactive effects on blood vessels,
including the glomerulus of the kidney, and acts to increase
glomerular filtration rate. Increased glomerular filtration rate
promotes increased urine production with an accompanying
increase in salt excretion into the urine. ANH may also
inhibit angiotensin II-mediated aldosterone and antidiuretic
hormone release. The stimulus for the production of ANH
and the role of ANH in sodium homeostasis are not
completely understood. However, brain injury appears to be
directly related to production of ANH. High atrial pressure
resulting in stretching of atrial cells is also implicated as a
stimulus for ANH production. 2
Adrenal Hormones: Glucocorticoids and Catecholamines. Glucocorticoids (primarily cortisol) are
produced and secreted by the adrenal cortex. Glucocorticoid
production is regulated by the anterior pituitary. As circulating cortisol levels decrease, adrenocorticotropic hormone
(ACTH) is secreted by the anterior pituitary gland. ACTH
signals the adrenals to secrete cortisol. Glucocorticoids have
the weak mineralocorticoid effect of enhancing water and
sodium reabsorption in the kidney, resulting in the return of
water to the vascular space.
In response to neuronal input, the adrenal medulla
produces the catecholamines epinephrine and norepinephrine. Catecholamines maintain blood pressure by increasing
vascular tone, heart rate, and myocardial contractility.
Catecholamine production is also dependent on the presence
of local cortisol in the adrenal cortex. During illness,
surgery, and trauma, increased production of glucocorticoid
hormones and catecholamines is essential for the mainte-

nance of the body's stress response. Inadequate cortisol and
catecholamine production may result in profound hypotension because of volume loss, electrolyte imbalance, myocardial depression, and poor arterial tone?

Endocrine Regulation of Energy Production
by Cells: Glucose Homeostasis
Glucose is the main energy source for all body cells. Protein
and fat are additional sources of energy. The endocrine
system regulates the use of energy sources and the
production of energy by cells. The hormones responsible for
regulating energy production include insulin, glucagon,
epinephrine, cortisol, and growth hormone.
Insulin is a hormone produced by the beta cells of the
pancreas. Insulin regulates glucose, protein, and fat metabolism. Insulin also enhances glucose uptake by cells. This
mechanism ensures that glucose is available for use as an
energy-generating substrate. In addition, insulin stimulates
protein synthesis and inhibits the breakdown of fat stores, or
lipolysis.
Insulin is released in the postprandial state. As nutrients are absorbed by the gut, blood glucose rises. The
release of insulin is stimulated by the rise in blood glucose.
Insulin places the body in an anabolic state. Glucose, in
excess of the needs of cells for energy production, is
taken up and stored in the liver and skeletal muscles as
glycogen. In addition, insulin stimulates the building of
proteins from amino acids and the storage of fatly acids as
adipose tissue.
Glucagon is produced by the alpha cells of the pancreas.
Glucagon counterregulates insulin secretion and the anabolic effects of insulin. Glucagon raises blood glucose by
stimulating the synthesis of glucose from glycogen stores in
the liver. Glucagon also facilitates the breakdown of
proteins, making amino acids available for gluconeogenesis,
and stimulates lipolysis. Glucagon release is stimulated by
hypoglycemia and neural impulses associated with the stress
response.
Epinephrine is produced in the adrenal medulla and is
released in response to sympathetic nervous system stimulation during stress. Epinephrine raises blood glucose by
causing the breakdown of glycogen stores in the liver and
skeletal muscle and by promoting gluconeogenesis, the
synthesis of glucose from noncarbohydrate substrates, such
as proteins and lipids. Epinephrine also induces lipolysis to
make fat available as a substrate for energy production by
cells.
Although relatively minor in importance, growth hormone and glucocorticoids (primarily cortisol) also regulate
cellular energy production. Cortisol is produced by the
adrenal cortex. Cortisol release is under the control of
ACTH and is, in part, stimulated by a stress response.
Glucocorticoids increase blood glucose and stimulate
lipolysis.
Growth hormone, produced by the anterior lobe of the
pituitary, stimulates protein synthesis, gluconeogenesis, and
lipolysis. As with cortisol and epinephrine, growth hormone
production increases during times of stress.
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Glucose Stores in the Body. Hepatic glycogen
stores are the initial glucose source in the fasting state.
Healthy children typically possess glycogen stores sufficient
for up to 8 hours of fasting. Infants' stores, however, are
limited and may be sufficient to maintain blood glucose for
approximately 4 to 6 hours of fasting. Following the
depletion of glycogen stores, gluconeogenesis accounts for
the primary glucose source. Well-nourished children can
also maintain blood glucose in the normal range for
approximately another 12 to 18 hours by converting to the
oxidation of fatty acids as a primary energy source. During
the process of oxidizing fatty acids, ketone bodies are
produced (~-hydroxybutyrate and acetoacetate), which can
be used as an energy source by muscle and brain cells.
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23-1 Antidiuretic Hormone (ADH)
Deficiency: Diabetes Insipidus
.

TABlE

Underlying Mechanisms
Iyuria
rine hypoosmolar (clear
in color)
ypematremia
rna hyperosmolarity
.rst, polydipsia
hydration or shock state

DISTURBANCES OF WATER BALANCE:
FLUID VOLUME DEFICIT
ADH Deficit (Diabetes Insipidus)
Neurogenic or central diabetes insipidus (01) is a condition
in which a deficit of AOH results in decreased reabsorption
of water by the distal tubules of the kidneys and loss of free
water in the urine. DJ is typically associated with central
nervous system disorders that damage or create pressure in
the area of the hypothalamus, pituitary stalk, or posterior
pituitary gland. Common causes of central DI in children
include central nervous system lesions such as craniopharyngiomas, pituitary gland or suprasellar tumors, or the
surgical resection of these tumors. Olson and colleagues4
reported a 20% incidence of DI after transphenoidal
pituitary surgeries, with the onset of the disorder occurring
as late as 2 weeks after the procedure. Traumatic brain
injury is also a common cause of D1. Finfer and co-workers 5
studied a series of 77 children with traumatic head injury
that progressed to brain death. Seventy-eight percent of the
children studied developed 01. Hypoxic-ischemic encephalopathy may result in DI as wel1. 6 In addition, Charmandari
and Brook 7 reviewed a series of 120 children with 01 who
did not have brain tumors or known brain injury, and they
reported that 01 is associated with a small, but otherwise
structurally normal pituitary gland and other hormone
deficiencies, such growth hormone and ACTH deficiency.
There are also familial degenerative disorders of the neurons
that secrete ADH. 1
01 may also be the result of a primary renal defect.
Primary renal 01 occurs when otherwise normal kidneys fail
to respond to ADH. Secondary renal DI is loss of ADH
sensitivity as a result of a known underlying renal disease or
other factors that interfere with the kidney's ability to
concentrate water, such as a protein deficiency, limited
sodium intake, hypokalemia, hypercalcemia, and certain
drugs (lithium, demeclocycline).
The signs and symptoms of central DI and underlying
causes are outlined in Table 23-1. Urine output of approximately 40 mllkg/day is typically encountered in cases of
01; however, up to 400 mllkg/day of urine output related to
DI has been reported. l Urinary water losses result in an ECF
deficit that may be significant enough to precipitate hypo-
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ADH deficit with resulting
diuresis
ECF volume depletion
Dehydration
Hypovolemia secondary to
ECF volume depletion
Cerebral hypoperfusion
caused by dehydration;
changes in cerebral cellular function resulting from
electrolyte abnormality

Gr.';'.

~CF, Extracellular ftuid.

volemic shock. Serum sodium may be extremely high
because of the ECF volume depletion. The child with an
intact thirst mechanism who is allowed to drink may be able
to orally replace urinary fluid losses and thereby maintain a
normal serum sodium and serum osmolality. However,
interference with drinking because of debilitating disease
may rapidly precipitate volume depletion.
Diagnostic Presentation. Diagnostic findings in DI
are outlined in Table 23-2. Low urinary osmolality (generally <100-200 mOsmIL) in conjunction with elevated serum
osmolality (>285 mOsmIL) and elevated serum sodium
(> 145 mEqlL) is diagnostic of DJ. These values reflect that
water has been inappropriately lost in the urine with a
resulting dehydration and plasma hyperosmolality. Stimulation tests such as the water deprivation test and vasopressin
test may be used to confiml the diagnosis. The water
deprivation test involves the restriction of all fluids until 3%
to 5% of body weight has been lost. Because of the risk of
hypovolemic shock, vital signs are monitored closely, along
with hourly serum sodium, serum osmolality, urine osmolality, and body weight. At the completion of the test,
vasopressin is administered subcutaneously or intranasally.
A rise in urinary concentration and decreased urine output
following the administration of vasopressin support the
diagnosis of central DJ. In cases of nephrogenic DI, no
detectable improvement in the ability of the kidneys to
concentrate urine is encountered after the administration of
vasopressin.
Critical Care Management. Care of the child with
central DI is outlined in Table 23-2. Interventions are
directed at the prevention of complications associated with
circulatory failure and hyperosmolar encephalopathy. Urinary losses in children with DI may be significant, and
failure to replace losses may result in hypovolemic shock.
High urine output may necessitate replacement on a
half-hourly or hourly basis. Careful monitoring of the
child's neurologic status is essential to detect early signs of
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TABLE

I'

23-2

Managing ADH Deficiency: Diabetes Insipidus (DI).

Panicipate in diagnostic workup
History
Risk factors

IIf Physical examination

I"~L.:

..••

,

~;:

.i'e, Laboratory tests
_:~

.if.
'fC
if'"

•

Stimulation tests

Pre:;~:' :;p~~~=::~;;~~m;,
dehydration, and shock

Jlj
iii;"
!;h,
i1~;,;

,iii

ri' Replace volume deficit and
ongoing losses

Replace ADH

Observe for signs of water intoxication secondary to overtreatment (correction of
hypernatremia should be no
greater than a decrease of
2 mEqfL/hr)

~H,

Polyuria, enuresis, thirst, weight loss, fatigue, anorexia
Recent CNS trauma, infection or surgery, known midline cerebral defects, kidney disease
(nephrogenic 01)
Dehydration: lethargy, increased skin turgor, lack of tears with crying, sunken fontanelle
Hypovolemia/circulatory failure: tachycardia; weak, thready pulse; skin cold, clammy;
delayed capillary refill; hypotension; depressed level of consciousness
Irritability or altered mental status caused by hypernatremia
Serum osmolality increased (>290 mOsmIL)
Serum sodium increased (> 145 mEqfL)
Urine osmolality decreased (<100-200 mOsmIL)
Hypematremia (<125 mEq/L)
Urine specific gravity decreased « 1.010)
Water deprivation test
Vasopressin test
Evaluate fluid balance:
Compare urine output to fluid intake
Measure urine specific gravity
Monitor weight trends every 8 hr
Assess onhostatic blood pressure, frequent vital sign assessments, neurologic checks,
and physical examinations
Bolus with 10-20 ml/kg of normal saline if hypotensive
Then 0.9% to 0.45% normal saline solution maintenance plus calculated replacement
over 24-48 hours (rate of replacement and concentration of IV fluids dependent on
serum sodium level)
Replace urine losses
Continue fluid replacement nntil vasopressin takes effect (urine specific gravity> 1.010,
and urine output decreased)
Administer vasopressin
Administer continuous infusion of vasopressin analog, such as aqueous arginine vasopressin, titrated repeatedly for maximum therapeutic effect. Typically, vasopressin
doses of approximately 1.5 mU/kg/hr are required; however, doses may range from
0.5 to 10 mU/kg/hr
Desired effect: urine volume decreased to <2 ml/kg/hr
Urine specific gravity increased to >1.010
Urine osmolality increased
Normalization of serum sodiUm/osmolality
Mental status changes, headache
Nausea, vomiting
Lethargy, weakness
Seizures, coma

Antidiuretic honnone; eNS, central nervous system; IV, intravenous.

r.~'

encephalopathy (headache, mental status changes) and
potential seizures caused by altered serum sodium levels. In
addition, encephalopathy is occasionally associated with
overly rapid correction of hypernatremia. The child who
presents with significant hypernatremia (> 155 mEqlL) is at
highest risk for hyperosmolar encephalopathy. Children
with severe hypernatremia, particularly hypernatremic dehydration that develops rapidly, require slow correction,
usually over a 36- to 48-hour period, to prevent hyperosmolar encephalopathy.
Vasopressin administration is also used to the treat
central DJ. The intravenous, subcutaneous, or intranasal

routes are all viable options for vasopressin replacement.
Desmopressin acetate (DDAVP), given intranasal1y, is a
commonly used intermediate-acting preparation for home
management. However, because of variability in absorption,
it is not the preparation of choice in the critical1y ill patient.
Children with DI who are receiving ADH replacement are at
risk for both dehydration (because of inadequate replacement of both ADH and fluids) and water intoxication
(because of overreplacement of water or overdoses of
vasopressin). Critically ill children and children who cannot
communicate are at increased risk for and often less able to
tolerate sustained fluxes in intravascular fluid volume.
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Therefore shorter-acting preparations such as vasopressin
(Pitressin or aqueous arginine vasopressin) or lypressin
(Diapid) are used to treat OJ in the critically ill population. Continuous infusion of vasopressin analogs such as
aqueous arginine vasopressin are most often used and are
titrated repeatedly for maximum therapeutic effect. 8 Typically, a vasopressin dose of approximately 1.5 mO/kg/hr
is required; however, doses may range from 0.5 to to
mU/kg/hr. 9 • 10
A rise in urine specific gravity and decrea~e in urine
output within I hour after the administration of a vasopressin analog indicate a therapeutic effect. Intravenous fluid
rates are readjusted once antidiuresis has been achieved to
prevent volume overload and water intoxication. Serum
sodium and osmolality are useful indices of water balance
and are usually obtained every I to 2 hours until an
appropriate vasopressin dose and rate of intravenous fluid
administration have been determined. Hourly monitoring of
urine volume and specific gravity are also necessary for the
determination of an appropriate vasopressin dose. Therapeutic goals that have been correlated with positive outcomes in the treatment of 01 include a urine output of 2 to
3 ml/kg/hr, urine specific gravity of LOID to 1.020, and
serum sodium of 140 to 145 mEqlL. 1I According to Lugo
and colleagues, II urine specific gravity is the most sensitive
marker of vasopressin responsi vity and appropriateness of
vasopressin dose, and urine output is the second most useful
marker of therapeutic response. In addition, Lugo and
co-workers I I report a lag in serum sodium and osmolality
normalization in relation to vasopressin administration.
Caution is exercised when administering vasopressin.
Vasopressin causes local and systemic vasoconstriction.
Children receiving vasopressin infusions must be monitored
closely for signs of diffuse tissue ischemia, such as lactic
acidosis, and local ischemia at the infusion site. 10

Although not routinely monitored, serum ANH levels are
high in children experiencing sodium loss from this
cause?
Because treatments for hyponatremia differ depending on
the underlying cause, it is important to distinguish cerebral
salt wasting syndrome from the syndrome of inappropriate
antidiuretic hormone (SIADH) secretion in children who
have a decreased serum sodium level. SIADH is the more
common cause of hyponatremia, particularly in children
with head injury. In contrast to cerebral salt wasting
syndrome, SIADH results in a markedly decreased urine
output and highly concentrated urine, along with fluid
retention. In SIADH, the dilutional effect of fluid retention
contributes to hyponatremia; thus fluid restriction, rather
than sodium replacement, becomes the mainstay of therapy?
Critical Care Management. Little research has
demonstrated the best practices for treati ng cerebral salt
wasting syndrome. Treatment usually includes replacement
of any volume loss with an isotonic saline solution and
sodium supplementation in the form of enteral sodium
chloride administration, or intravenous infusion of a 3%
sodium chloride solution 2
The use of 3% saline solution (a solution containing
0.513 mEq of sodium per milliliter of solution) for the
treatment of hyponatremia warrants very careful calculation
of the dose of sodium chloride required and close monitoring of the child during administration. Typically, the use of
3% saline solution is restricted to cases of symptomatic
hyponatremia with serum sodium levels' less than 125
mEqIL. The dose of 3% saline to be administered is based
on the amount of sodium necessary to correct hyponatremia
to a serum level of 125 mEqlL. The following calculation is
often used to determine this dose:

Increased Atrial Natriuretic Peptide
Production and Cerebral Salt Wasting
Syndrome

The total dose is administered slowly (often over 24 hours
or more) to avoid causing encephalopathy associated with
rapid correction of hyponatremia. Rises in serum sodium
level that exceed 0.6 to I mEq/ hr are considered dangerous
and contribute to the development of encephalopathy.
Frequent monitoring of serum sodium levels to follow the
rate of correction is necessary. Furthermore, because 3%
saline is hyperosmolar, the site of intravenous administration is monitored closely for signs of phlebitis and
subcutaneous tissue irritation indicative of extravasation. 10

Increased ANH production results in diuresis with loss of
sodium in the urine. Central nervous system injury appears
to be directly related to production of ANH and is the most
common feature of children with salt wasting syndromes.
Cerebral salt wasting syndrome typically occurs within the
first week after brain injury. Evidence shows that hypovolemic states induced by 01 and diabetic ketoacidosis;
conditions that affect the myocardium, such as hypertension,
congestive heart failure, and congenital heart defects; and
chronic lung disease, such as bronchopulmonary dysplasia,
may induce ANH production and a salt wasting syndrome.
Furthermore, cases have been reported of elevated ANH
levels in children with other endocrine disorders, such as
Cushing's syndrome and hyperaldosteronism?
Diagnostic Presentation. Cerebral salt wasting syndrome is defined by hyponatremia (serum sodium <130
mEqlL), in conjunction with normal or increased urine
output and normal or slightly elevated urine specific gravity.
In addition, increased sodium content (>80 mEqlL) is found
in the urine of children with salt wasting syndromes.

Sodium deficit (amount to be administered) =
0.6 x (Body weight in kg) x (125 - Measured serum sodium level)

DISTURBANCES OF WATER BALANCE:
FLUID VOLUME EXCESS
ADH Excess (SIADH Secretion)
SIADH secretion is a condition in which ADH is secreted
despite serum hypo-osmolality, hyponatremia, and euvolemia. Inappropriate ADH secretion results in increased
permeability of the renal distal tubules and collecting ducts,
with a resulting increase in water reabsorption and intravascular fluid volume, and a decrease in urine production.
As with 01, SIADH may be due to traumatic or hypoxic
ischemic brain injury or discrete diseases of the hypothala-
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ADH Excess (SIADH)

:Signs and Symptoms

r.,,~,

.

Dilutional hypervolemia
from decreased urine
production or increased
fluid retention
ADH concentrates urine by
increasing permeability
of renal collection tubule
Decreased renin-angiotensin II and aldosterone
result in sodium
excretion
Hyponatremia
Cerebral edema resulting
from fluid shift

~H,
..
-;,

Underlying Mechanisms

Antidiuretic hormone; SIADH, syndrome of inappropriate ADH.

mus, pItUitary stalk, or posterior pituitary, In cases of
traumatic brain injury, the onset of SIADH may be
delayed 4 ,12 SIADH is also encountered in patients who
have meningitis 13 and patients who have undergone spinal
manipulation, such as spinal fusion for scoliosis,14 In
addition, nonneurologic disorders, such as hepatic disease,
pulmonary diseases, high-dose chemotherapy, and bone
marrow or peripheral stem cell transplants, are also associated with the development of SIADH. 15 The classic signs
and symptoms of SIADH and the underlying mechanisms
are outlined in Table 23-3, Hyponatremia (serum sodium
<125 mEqlL) and hypo-osmolality (serum osmolality
<260 mOsmIL) both result from the dilutional effect of the
increased intravascular volume expansion, Worsening of the
hypo-osmolar state may precipitate a shift of free water from
the ECF to the ICF, which can result in cerebral edema,
Diagnostic Presentation. Diagnostic findings are
outlined in Table 23-4, The diagnosis of SIADH is made
when urinary osmolality is high, with low serum osmolality
and hyponatremia, in the face of a previously euvolemic
state, Damaraju and colleagues 16 report that monitoring
central venous pressure for the identification of increasing
intravascular volume is helpful in the detection and management of SIADH.

Managing ADH Excess (SIADH)
Participate in diagnostic workup
History
Risk factors
Physical examination

Prevent complications associated
. with water intoxication
or hyponatremia
Evaluate fluid balance

Evaluate for signs of
water intoxication
Restrict fluids
Treat acute hyponatremia

Nausea, vomiting, headache, weakness
CNS infection, trauma, surgery
Respiratory illness, positive pressure ventilation
Nausea, vomiting, weakness
Urine output decreased
Mental status changes (lethargy, irritability, headache, seizures, coma, pupillary changes)
Hypertension (late)
Hyponatremia «125 mEqlL)
Serum osmolality decreased in the face of a high urine osmolality «260 mOsm/L)
BUN normal or decreased
Increased fractional excretion of urine sodium
Urine sodium increased
Urine osmolality increased

Compare urine output to fluid intake
Measure urine specific gravity
Monitor weight trends every 8 hr
Headache, nausea, vomiting
Lethargy, weakness, irritability
Mental status changes, pupillary changes, seizures, coma
Usually equal to the amount of insensible losses or one-half to three-fourths maintenance
Loop diuretic (furosemide) 0.5-1 mg/kg/dose
Infusion of 3% NaCl solution; the dose of 3% saline to be administered is based on
the amount of sodium needed to correct hyponatremia to a serum level of 125 mEqlL
The following calculation is often used to determine this dose;
Sodium deficit (amount to be administered) =0,6 x
(Body weight in kg) x (125 - Measured serum sodium level)
The total dose is administered slowly (often over 24 hr or more) to avoid causing the
encephalopathy associated with rapid correction of hyponatremia

, '.~DH, Antidiurelic hormone; SIADH, syndrome of inappropriate ADH; BUN, blood urea nitrogen,
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Critical Care Management. Treatment of the child
with SlADH is outlined in Table 23-4. Interventions are
focused on the prevention of complications associated with
water intoxication and hyponatremia. Meticulous attention
to fluid balance is essential. According to a study of spinal
fusion patients by Brazel and McPhee,l4 administration of
isotonic saline solutions, rather than half or quarter normal
saline solutions, may help to prevent the development of
hyponatremia associated with SIADH in at-risk populations.
Once SIADH has developed, fluid restriction is the mainstay
of treatment. Early detection of neurologic changes associated with water intoxication is critical. Children with
SIADH are at risk for cerebral edema because the hyponatremic state allows free water to move from the ECF space
to the ICF space (including brain cells), which may result in
cerebral edema. Emergency treatment of hyponatremia may
be necessary if it is accompanied by neurologic symptoms,
such as depressed level of consciousness or seizure activity.
The standard approach to treating SIADH is fluid restriction
and, occasionally, the administration of a loop diuretic, such
as furosemide (Lasix) 0.5 to I mg/kg/dose, and infusion of a
3% sodium chloride solution to correct the hyponatremia. 16

ADRENOCORTICAL HYPOFUNCTION:
FLUID VOLUME DEFICIT
AND CIRCULATORY FAILURE
Adrenallnsufficiency/Adrenal Crisis
Adrenal insufficiency is associated with a variety of
conditions in which there is a deficiency of glucocorticoids
(primarily cortisol) and mineralocorticoids (aldosterone)
and may also result in decreased catecholamine synthesis
and release. The adrenal glands also produce androgens.
Androgens, however, have a less important effect on fluid
balance and hemodynamic stability.
Aldosterone deficiency causes decreased sodium and
water reabsorption and increased potassium reabsorption in
the renal distal tubules. Glucocorticoid deficits result in
intravascular volume loss, electrolyte imbalance, and decreased responsiveness to and synthesis of catecholamines,
which results in myocardial depression, poor arterial tone,
and hypotension. Together, aldosterone and glucocorticoid
deficiencies can cause profound hypotension. However, an
isolated glucocorticoid deficit in the face of a significant
stressor is sufficient to produce vasodi lation and shock.
Hypoglycemia may also ensue during states of adrenal
insufficiency.
Primary adrenocortical deficiency (Addison's disease) is
associated with conditions that impair the ability of the
adrenals to produce cortisol or aldosterone. Diseases such
as congenital adrenal hypoplasia, tuberculous adrenalitis,
autoimmune adrenalitis, adrenoleukodystrophy, and adrenal
hemorrhage cause primary adrenocortical dysfunction.
Primary adrenal insufficiency, often caused by adrenal
hemorrhage. is a known sequela of shock, particularly
septic shock. 17 Adrenal hemorrhage precipitated by coagulopathy resulting from sepsis or a systemic inflammatory response is referred to as the WaterhouseFriderichsen syndrome. Riorden and colleagues l8 studied
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126 cases of meningococcemia in children and reported
low cortisol levels and high ACTH levels, consistent with
primary adrenal insufficiency, in patients who died of
meningococcal disease. In addition, Briegel and associates 19 reported decreased requirement for vasopressors and
earlier resolution of multiple organ dysfunction syndrome
in adults with septic shock treated with stress dose
hydrocortisone. Similarly, Hatherill and co-workers 2o reported a 52% incidence of adrenal insufficiency in children
with septic shock on laboratory examination, but they did
not find that the children with adrenal insufficiency
experienced more organ system failure or higher morbidity.
However. despite such studies. there is a risk of inducing
immunosuppression with the use of corticosteroids, and
not enough additional evidence supports the routine
replacement of cortisol in patients with septic shock at the
present time. In fact. earlier, large adult trials have not
shown a clear benefit to the use of corticosteroids in
patients with septic shock.2°. 23 Shock states may also be
confounded by decreased production of catecholamine
resulting from damaged adrenal glands or by a phenomenon of diminished peripheral and myocardial catecholamine receptor responsivity.19.24.26
Secondary adrenocortical disease is due to intrinsic
hypothalamic or anterior pituitary dysfunction in which
there is low production or excretion of ACTH. Secondary
diseases include hypothalamic or pituitary tumors or central
nervous system trauma. Although adrenal function is intact,
cortisol is not produced because the adrenal glands do not
receive an ACTH signal from the pituitary gland to
generate cortisol. In addition, as in primary adrenal
insufficiency, shock states and sepsis, perhaps resulting
from systemic inflammation, may induce secondary adrenal
insuffici ency 27.28
Adrenal crisis may be precipitated in the child with
known adrenal insufficiency who is not given higher than
maintenance doses of steroids during times of illness,
surgery, or other significant stress. Adrenocortical insufficiency may also be iatrogenic, as seen with the administration of high-dose steroids over an extended period, resulting
in the suppression of the hypothalamic-pituitary-adrenal
axis. A fixed dose of exogenous cortisol (typically, cortisone
acetate or hydrocortisone 7 mg/m 2/day or 0.5 to 0.75
mg/kg/day) is normally sufficient to meet normal physiologic requirements. 9 However, if exogenous steroids are
abruptly withdrawn or if additional coverage is not provided
during stress or illness. the adrenals are unable to respond to
the demands for increased cortisol production because the
hypothalamic-pituitary axis has been suppressed. Regardless of the underlying dysfunction (whether primary, secondary, or iatrogenic), adrenal crisis may be precipitated
when the body is unable to respond to the demand for
increased glucocorticoid production. Signs and symptoms
of adrenocortical insufficiency and the underlying mechanisms are outlined in Table 23_5. 3. 10
Diagnostic Presentation. Diagnostic findings of adrenocortical dysfunction are outlined in Table 23-6. In
general, presentation is often that of profound circulatory
failure with component~ of hypovolemic, distributive, and
cardiogenic shock. In fact, the recommendation is that
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~. TABLE·23-5

. Adrenallnsufficienq

ii,$igns and Symptoms
11:\
I~~¢rum hyponatremia
~!~erum hyperkalemia
ITfu'.,~:

h1£:

Underlying Mechanisms

•

l'lihoCk.
.
.
il~: TachycardIa, hypotensIOn, weak rapId pulse, cold clammy
1:1,.;. skm, decreased perfusIOn, fever
,~ausea, vomiting, diarrhea, poor feeding, weakness, fatigue
il"M.·•.ental status changes, irritability
i!i1'

Jtf~i';

tii'

Illllypoglycemia

Mineralocorticoid effect (decreased sodium and increased potassium
reabsorption in distal tubule)
Glucocorticoid effect (decreased free water clearance)
Volume depletion
Vasodilation, myocardial depression, poor arterial tone, decreased
responsiveness and synthesis of catecholamines
Electrolyte imbalance
Central nervous system changes resulting from fluid deficit,
hypoglycemia, or electrolyte imbalance
Decreased gluconeogenesis

Diagnosis and Treatment of.Adrenocortical Dysfunction
Participate in diagnostic workup
History
Risk factors

Physical examination

Laboratory tests

Stimulation tests

Nausea, vomiting, diarrhea, fatigue, weakness, headache
Hypopituitarism, congenital adrenal hyperplasia, abrupt discontinuation of high-dose
steroids, known adrenally insufficient child who was ill and failed to receive stress
coverage, CNS lesions (trauma, tumor, hemorrhage, seizures, hydrocephalus),
shock, sepsis or systemic inflammatory response syndrome
Dehydration, fever
Mental status changes, headache, irritability
Shock (tachycardia, weak thready pulse, cold clammy skin, decreased perfusion,
hypotension)
Hyperkalemia
Hyponatremia
Hypoglycemia
Serum cortisol level decreased
Cortrosyn (adrenal function)
Metyrapone (pituitary function)

Prevent complications related to hypovolemic shock, hyperkalemia, hypoglycemia
Evaluate fluid balance
Compare urine output and fluid intake
Monitor weight trends
Measure urine specific gravity
Assess orthostatic blood pressure
Monitor electrocardiogram for changes
related to serum potassium level
Treat acute hypovolemia, hyponatreNormal saline bolus then 5% glucose in normal saline
Vasopressors
mia, or hypoglycemia
Plasma expanders
Treat acute hyperkalemia
Calcium gluconate 10 mg/ml IV (administered over 5 min)
Sodium bicarbonate 1-2 mEg/kg IV
Glucose and insulin: administer 1-2 g/kg of glucose, simultaneous with the administration of 0.3 U/kg of regular insulin, both given over I to 2 hr
Sodium polystyrene sulfonate (Kayexalate) I g/kg PR (in a 30% sorbitol solution) or
PO (in a 70% sorbitol solution)
Severe cases may necessitate dialysis
Replace mineralocorticoids
Fludrocortisone (Florinef) 0.05-0.2 mg PO daily
Replace glucocorticoids
Emergency management and "stress dosing": cortisol replacement in the form of
hydrocortisone at doses of 25-55 mg/m 2 or 2 to 4 times the normal physiologic
replacement dose is given by continuous infusion or IV bolus every 4 to 6 hr
Maintenance dosing: cortisone acetate or hydrocortisone 7 mg/m 2 /day or 0.5-0.75
mg/kg/day
Dehydration, shock
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adrenal insufficiency be considered in all patients with
shock refractory to the administration of catecholamines. 3 In
primary adrenal insufficiency, the skin and mucous membranes may appear darkened or "tanned" as a result of high
levels of pituitary ACTH precursors that are also pigments.
Pallor, however, may be seen in cases of secondary
insufficiency. In addition, patients may experience gastrointestinal upset and generalized weakness and malaise.
Associated electrolyte imbalances include hyponatremia
and hyperkalemia. Hypoglycemia may also ensue. Interestingly, plasma cortisol levels may be within normal range in
critically ill patients with adrenal insufficiency, making
diagnosis on the basis of cortical level alone unreliable.2 9
Critical Care Management. The treatment of the
child with adrenal insufficiency is outlined in Table 23-6.
Interventions are focused on the prevention of complications associated with shock and the correction of electrolyte
imbalances. Emergency resuscitation usually includes the
use of a solution of normal saline to expand the vascular
volume. Vasoactive and positive inotropic agents, such as
dopamine and epinephrine, may be used to increase
peripheral vascular resistance, heart rate, and myocardial
contractility. If the serum potassium exceeds 5.5 mEqlL,
strategies outlined in Table 23-6 may be used to manage
acute hyperkalemia.
Emergency replacement of glucocorticoids is achieved
intravenously using a soluble cortisol preparation such as
hydrocortisone, hemisuccinate, or 21-phosphate. Most often, cortisol replacement in the form of hydrocortisone at
doses of 25 to 55 mg/m 2 , or 2 to 4 times the normal
physiologic replacement dose, is gi ven by continuous
infusion or intravenous bolus every 4 to 6 hours. When the
child with primary disease can take medications orally,
mineralocorticoid replacement is added by gi ving fludrocortisone acetate (Florinef) 0.05 to 0.2 mg daily. As with
other endocrine disorders, meticulous attention to fluid and
electrolyte balance is an important aspect of the nursing care
of the child with acute adrenal insufficiency 9

DISTURBANCES OF GLUCOSE
HOMEOSTASIS
Hypoglycemia
Hypoglycemia is defined as a blood glucose level less than
60 mg/dl in an infant or child. Premature infants often have
blood glucose levels between 20 and 60 mg/dl. However,
despite the fact that glucose levels are naturally lower in
premature neonates, it is unclear if serum glucose levels in
the 20 to 60 mg/dl range adequately meet the metabolic
needs of their cells. Therefore in light of the profound
effects of hypoglycemia on the developing brain, a blood
glucose level less than 60 mg/dl should be considered
hypoglycemic, even in the neonate. Hypoglycemia is
induced by inadequate adaptation to fasting, as well as by
disorders resulting in insulin excess or decreased production
of hormones that counterregulate insulin. Typically, efforts
are aimed at maintaining a child's blood glucose level above
65 mg/dl.
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Inadequate glycogen storage resulting in decreased tolerance of fasting is a normal condition of infancy. It is particularly problematic in premature infants and infants who
are small for gestational age, are septic, or have congenital
heart disease. In addition, diseases that impair glycogen
storage, glycogen use, or gluconeogenesis, such as hepatic failure, or inborn errors of metabolism, such as glycogen storage disease type I or fructose 1,6-diphosphatase
deficiency, result in hypoglycemia during fasting states.
Disorders of fatty acid metabolism, such as medium-chain
acyl-dehydrogenase deficiency and carnitine deficiency,
or disorders of protein metabolism may also precipitate
hypoglycemia. Drugs that contribute to a reduction in
glucose stores or the body's ability to use glucose stores
include alcohol, sulfonamides, ~-adrenergic antagonists,
and salicylates]O
Hypoglycemia caused by hyperinsulinism or the overproduction of insulin is encountered in disorders such as
beta cell hyperplasia (nesidioblastosis) and beta cell adenomas. Children with hyperinsulinism are also vulnerable to
hypoglycemia because chronically high insulin levels inhibit counterregulatory responses and the use of the backup
energy sources of glycogenolysis, gluconeogenesis, and
fatty acid oxidation. In addition, increased insulin production is induced whenever a high concentration of glucose is
administered to the body. Transient hypoglycemia may be
encountered in any child when an infusion of high glucose
concentration is abruptly discontinued because hyperinsulin
production may persist after the sudden decrease in glucose
supply. Newborns of diabetic mothers often manifest
transient hypoglycemia because of hyperinsulin production
extending beyond the in utero period of exposure to high
glucose load. 31 Furthermore, any deficit of counterregulatory hormone production may induce a hypoglycemic state.
Hypopituitarism and adrenal insufficiency are associated
with deficiencies of cortisol, growth hormone, and epinephrine and also result in hypoglycemia. 32
Diagnostic Presentation. Because the brain has a
very high obligatory glucose requirement, nervous system
dysfunction is precipitated by hypoglycemia. A sensation of
hunger quickly occurs during states of glucose deficit, and
the stimulation of the adrenergic and cholinergic receptors
of the nervous system results in weakness, tachycardia,
tremor, and diaphoresis. Central nervous system abnormalities resulting from glucose deficit, such as headache,
depressed level of consciousness, and seizure activity, ensue
when hypoglycemia is persistent.
Accurate documentation of a blood glucose value less
than 60 mg/dl may be all that is needed to diagnose transient
hypoglycemia in the infant with a history of prenatal stress,
sepsis, maternal diabetes, prematurity, or congenital heart
disease or in the infant or child who becomes hypoglycemic
after rapid discontinuation of high-concentration glucose
infusions. Persistent hypoglycemia suspected to be associated with inborn errors of metabolism, hyperinsulinism, and
adrenocortical hypofunction (hypopituitarism, or primary
adrenal insufficiency) often requires confirmation by controlled fasting studies. A controlled fasting study can assist
in determining the child's ability to use alternative cellular
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energy pathways and to diagnose the underlying problem of
hyperinsulin production or counterregulatory hormone
deficiency.
Critical Care Management. The care of the child
with hypoglycemia is outlined in Table 23-7. The primary
goal in managing hypoglycemia is to prevent deleterious
central nervous system manifestations, such as seizures. If
the child is able to take fluids orally, treatment may simply
involve the provision of carbohydrate-containing fluids such
as glucose water, infant formula, or juice. Simple carbohydrates are most quickly absorbed and are therefore more
desirable than more complex sugars, such those in processed
foods or candy. If the child is unconscious or unable to take
fluids orally, glucose is administered intravenously. Glucose
0.5 to 2 g/kg, given as a 10% to 25% dextrose solution, can
be administered via continuous infusion or by bolus
administration. Blood glucose is measured immediately

after administering glucose to determine the effectiveness of
treatment. Levels are repeatedly assessed until the blood
glucose reaches the 80 to 120 mg/dl range 30 Guidelines for
the frequency of measuring blood glucose for the child at
risk for hypoglycemia are outlined in Table 23-7.
Long-term treatment of the child with persistent hypoglycemia is determined by the underlying cause. Mild
hyperinsulinism may be managed initially with oral diazoxide (Proglycem) 3 to 15 mg/kg/day and frequent feedings. If this regimen fails, a trial of a somatostatin analog
octreotide (Sandostatin) I to 10 Ilg/kg/day given subcutaneously may be initiated. Children who do not improve on
either of these regimens usually require a subtotal pancreatectomy. Children with inborn errors of metabolism are
generally treated by limiting fasting periods and by providing small, frequent feedings or continuous nasogastric
feedings of specialized formulas. Hypoglycemia related to

Managing Hypoglycemia

La!jOr,atolry tests
Fasting study laboratory tests

Child's age, length of fast
Infants: large or small for gestational age; history of maternal diabetes; preterm;
hypoxic, stressed, septic, congenital heart disease
Rapid discontinuation of high-concentration dextrose infusion
Adrenocortical hypofunction (primary. secondary. iatrogenic)
Adrenergic response
Signs of neuroglycopenia
Glucose (decreased)
Insulin, growth hormone, cortisol
Serum ketones
Lactates
Free fatty acids
Carnitine
Urine ketones, organic acids

Prevent central nervous system complications associated with hypoglycemia
Measure blood glucose
Immediately if symptomatic (pallor, irritability, difficult to arouse, diaphoretic)
q15min if blood glucose <50 mglDl
q30min-qlh: until blood glucose is consistently in 80-120 mg/dl range or if making
changes in glucose infusion rate/concentration
q2-4h if blood glucose is consistently in 80-120 mg/dl range and child is receiving
glucose infusion
Before meals or feedings if blood glucose in 80-120 mg/dl range and child is no
longer receiving glucose infusion doses
Manage acute hypoglycemia (blood
If no IV access and able to take POING, give 4-6 oz formula, glucose water, juice
glucose <60 mg/dl)
If IV access, increase IV glucose rate/concentration (5-20 mUkg 10% dextrose
solution IV or 2 ml/kg 25% dextrose solution)
If no IV access, symptomatic, and unable to take PO, give I mg glucagon intramuscularly. subcutaneously (Will not work with glycogen storage disease and children
who are glycogen depleted)
. Limit fasting demands
High-risk infant: provide glucose supplements orally or via IV infusion to maintain
glucose levels
Glycogen storage disease: Limit fasting to 3-4 hours (type I) or 6-8 hours (type 3)
Overnight nasogastric feedings
Fatty acid oxygenation defects: limit fasting to 10-12 hours
Treat underlying problem
Hyperinsulinism: diazoxide. somatostatin, subtotal pancreatectomy
Hypopituitarism: cortisol, growth hormone replacement
Intravenous; PO, by mouth; NG. nasogastric.
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cortisol or growth hormone deficiency is treated by replacing the deficient hormones. 9 .3 )

Hyperglycemia
Hyperglycemia is defined as a serum glucose level higher
than 120 mg/dl. Blood glucose values that exceed the renal
threshold (approximately 180 mg/dI) result in movement of
glucose into the urine and glucosuria. The excretion of
glucose in the urine may cause osmotic diuresis, leading to
dehydration and cardiovascular collapse. Passive loss of
sodium and potassium in the urine accompanies the osmotic
diuresis, and hyponatremia and hypokalemia may ensue.
However, in the case of osmotic diuresis, serum sodium
levels may be normal or elevated as a result of hemoconcentration. Serum may become hyperosmolar because of the
combined high solute loads from the hyperglycemia and
hypernatremia.
Hyperglycemia Caused by Excess of Counterregulatory Hormones. Adrenocortical hyperfunction
(Cushing's syndrome) causes the overproduction of glucocorticoids and induces hyperglycemia. The underlying
problem may be due to an abnormality of the pituitary
gland, which results in an overproduction of ACTH, an
abnormality of the adrenal glands, or severe stress response
resulting in the overproduction of cortisol, or it may be
iatrogenically triggered by the administration of exogenous
corticosteroids. High levels of circulating catecholamines,
which are also produced by the adrenal gland, may also
cause hyperglycemia. Stimulation of the sympathetic nervous system during the stress response, adrenal overproduction, or ectopic production by a pheochromocytoma or
neuroblastoma may increase circulating catecholamine levels. Furthermore, catecholamines administered exogenously
may also induce hyperglycemia.
Diabetes: Syndromes of Insulin Deficit or Resistance. Lack of insulin production is associated with beta
cell injury. Autoimmune beta cell destruction is the pathophysiologic mechanism underlying most cases of type I
diabetes mellitus. Acute pancreatitis may result in interference with beta cell function and temporarily decrease
insulin production. In addition, sclerotic changes in the
pancreas caused by cystic fibrosis may result in permanent
type I diabetes. Type II diabetes mellitus, on the other hand,
is a state of decreased cellular insulin receptor sensitivity.
Type II diabetes is less common in children.
In cases of both underproduction and decreased sensitivity to insulin, glucose cannot enter cells. Decreased glucose
uptake by cells results in increased blood glucose levels, the
use of alternative metabolic pathways for energy production, such as fatty acid oxidation, and a generalized state of
cellular energy deficit. Ketones, the byproducts of fatty acid
oxidation, may accumulate and result in an acidemia known
as diabetic ketoacidosis (DKA). DKA usually occurs in
cases of type I diabetes. In addition to the risk of developing
DKA, patients with diabetes also experience multiple
system organ damage as a result of persistently high glucose
load in the blood and chronic cellular energy deficit. Patients
with diabetes may also become prone to infection. Children
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with type I diabetes almost always require regular injections
of insulin to prevent hyperglycemia; however, type II
diabetes may be managed with specialized diets or oral
hypoglycemia agents. 33 - 35
Severe Glucose Deficit: Diabetic Ketoacidosis.
Fig. 23-1 outlines the progression of DKA. Children with
type I diabetes who are noncompliant with insulin administration and who are experiencing illness or severe stress
are at risk for developing DKA. DKA evolves as insulin
deficiency results in hyperglycemia and mobilization of
fatty acids and when the relati ve excess of counterregulatory
hormones stimulates gluconeogenesis. When gluconeogenesis occurs, body proteins and lipids are broken down,
making amino acid and fatty acid substrates available for
cellular energy production. In addition, relative lack of
insulin in relation to epinephrine, growth hormone, and, to
a lesser extent, cortisol further stimulates the mobilization of
fatty acids, the production of ketone bodies, and resultant
ketoacidosis. 33 -35
Significant hyperglycemia also results in a profound
osmotic diuresis and urinary electrolyte loss. Acidosis may
further compound electrolyte abnormalities, and dehydration may be severe enough to precipitate cardiovascular
collapse. As perfusion status worsens, lactic acidosis contributes to the falling pH. 33 -35
DKA is accompanied by total body sodium and potassium deficits resulting from osmotic diuresis. However, fluid
shifts between the ICF and ECF and significant hemoconcentration result in variable measured serum electrolyte
values. Serum potassium and sodium levels may be high,
normal, or low depending on the degree of intravascular
fluid volume depletion and metabolic acidosis. Acidosis
complicates the interpretation of the electrolyte values
because it induces temporary shifts of potassium from the
ICF to the ECE Potassium may then move back out of the
ECF and into ICF during correction of acidosis. Serum
phosphorous levels follow a pattern similar to potassium in
response to acidosis. 33 .35
Cerebral edema is a complication of the treatment of
DKA. The precise cause of cerebral edema in children with
DKA is unknown. It may occur at any time during the
24-hour period following the initiation of therapy. Risk
factors believed to be associated with cerebral edema
include a pH less than 7.0, glucose level higher than 800
mg/dl, hyperosmolality and hypernatrernia, use of bicarbonate to correct acidosis, too rapid correction of blood glucose,
and very young age.3 3 - 35 Interestingly, in addition to
cerebral edema, anasarca and pulmonary edema have been
reported in patients receiving treatment for DKA. 33 ,36
Diagnostic Presentation. Diagnostic findings in hyperglycemia and DKA can be found in Box 23-1 and Table
23-8. Urinary glucose measurements provide a useful initial
screening device for identifying the patient at risk, When the
urine test result is positive for glucose, a blood sample is
obtained to estimate the blood glucose, Bedside estimates
should be confirmed by a simultaneous laboratory measure.
A history of polyuria, polydipsia, and weight loss with
documented hyperglycemia assists in the diagnosis of
diabetes mellitus, particularly when accompanied by a
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Fig. 23-1 Diabetic ketoacidosis. (Modified from Thompson JM: Mosby's manual of clinical nursing,
ed 2, St Louis. 1989, Mosby. p 931.)

metabolic acidosis. Blood urea nitrogen (BUN) and creatinine levels provide an index of the degree of dehydration.
Arterial pH, serum bicarbonate levels. and degree of base
deficit reflect the degree of acidosis in the child with DKA.
Urine ketones are also routinely measured in the child at risk
for or experiencing DKA.
Critical Care Management
Hyperglycemia Without DKA. Care of the child with
hyperglycemia is outlined in Box 23-1. Definitive therapy
involves the identification and treatment of the underlying
cause of hyperglycemia. Nursing care is directed at the
prevention of complications associated with acidosis and
dehydration. A systematic process for screening patients at
risk for hyperglycemia is also outlined in Box 23-1.

Mild dehydration «5%) may be managed with oral fluid
replacement of calorie-free liquids. More severe dehydration (>5%), or if the child who is unconscious or refusing to
drink, requires intravenous fluid replacement.
Dietary management may be all that is required in some
cases of transient and mild hyperglycemia. Feeding the child
a low-concentrated carbohydrate diet may be sufficient to
correct hyperglycemia. Otherwise, insulin may be given as
four short-acting doses (before each meal and again at the
time of a bedtime snack). A second option is a split-mixed
dose of short- and long-acting insulin before breakfast and
again before dinner. Frequent monitoring of blood glucose
and monitoring for signs of hypoglycemia are essential with
insulin administration and help to determine the most

Chapter 23

~

Box 23-1

Diagnosing and Treating Hyperglycemia

I. Participate in diagnostic workup

History: Polyuria, polydipsia, weight loss, fatigue
Risk factors: Diabetes, significant stress, exogenous
epinephrine, steroid or L-asparaginase administration,
Cushing's syndrome, pheochromocytoma, glucagonoma
Physical examination: Dehydration, mental status changes
Laboratory tests: Hyperglycemia, hypematremia, cortisol
increased, glucagon increased, glucosuria
2. Detect hyperglycemia in patients at risk
Measure urine for glucose q 12h
If urine test result is positive for glucose, measure blood
glucose
If blood glucose is > 180 mg/dl, measure blood glucose
qid until blood glucose consistently <180 mg/dl
When blood glucose is consistently <180 mg/dl, resume
mea~uring urine for glucose q 12h
If subcutaneous insulin being given, measure blood
glucose 5 times per day (before breakfast, before lunch,
before dinner, before bedtime snack, and at 2 AM)
Additional measurements should be obtained as needed
when clinical symptoms of hypoglycemia or hyperglycemia are detected
3. Prevent complications of hyperglycemia (dehydration,
cerebral edema, weight loss)
Correct fluid or electrolyte imbalance:
Replace fluids lost as a result of osmotic diuresis orally
or intravenously
Low concentrated carbohydrate diet
Administer insulin subcutaneously as ordered
Evaluate fluid balance:
Compare urine output to fluid intake
Assess for orthostatic blood pressure
Weigh daily while spilling glucose in urine
Correct underlying cause:
Surgery: Pheochromocytoma, glucagonoma

It)
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23-8 Diabetic Ketoacidosis
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appropriate insulin doses. Children receiving most or all of
their calories intravenously are most easily managed using
an intravenous insulin infusion titrated to maintain blood
glucose values between 100 and 200 mg/dl.
Hyperglycemia With DKA. The prevention of complications related to dehydration, cardiovascular collapse,
acidosis, electrolyte imbalance, and cerebral edema is the
primary goal of the treatment of the child in DKA (Box
23-2). The first priority of care is to manage the dehydration.
An initial fluid bolus (5 to 20 ml/kg of normal saline) is
given over a 1- to 2-hour period. If the child continues to
experience circulatory failure after the initial bolus, a second
fluid bolus may be necessary. Remaining fluid deficits are
usually replaced over a 24- to 48-hour period, often as
0.45% normal saline containing potassium supplements.
(Potassium supplements are only added for children who are
hypokalemic and have evidence of adequate renal function.)

However, some practitioners administer isotonic saline for
extended periods to maintain an osmotic gradient that will
prevent intracellular fluid shifts and cerebral edema. Ongoing urine losses caused by osmotic diuresis, in excess of 2
to 3 ml/kg/hr, may also be replaced with intravenous
fluid 33 ,35.37.38
The second priority of care is to correct the acidosis and
to prevent further lipolysis. Insulin has an inhibitory effect
on ketone production; therefore the administration of insulin
is the key to correcting metabolic acidosis, An intravenous
infusion of regular insulin is the preferred method of
administering insulin in children with DKA. Initial insulin
doses are low; however, they are often be titrated to exceed
normal physiologic requirements to decrease serum blood
glucose levels and to inhibit further lipolysis and fatty acid
oxidation. Infusions of 0.05 to 0.1 U/kglhr of regular insulin
are commonly administered. Hyperglycemia is always
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Box 23-2

.

Treating Diabetic Ketoacidosis'

I. Participate in diagnostic workup

History: Polyuria, polydipsia, weight loss, fatigue, nausea,
vomiting
Physical examination: Dehydration, Kussmaul's respirations, facial flushing, abdominal tenderness, mental
status changes
Laboratory tests: Blood glucose, blood gas, electrolytes,
8 UN, creatinine, urioe ketones and glucose
2. Prevent complications related to dehydration or cardiovascular collapse, acidosis, hypokalemia, hyperkalemia, cerebral edema
Replace fluid or electrolytes lost as a result of osmotic
diuresis:
Resuscitate with 20 ml/kg of normal saline over a
l-hr period
Repeat bolus if heart rate elevated or hypotensive after
first bolus
Replace remaining deficit over the next 24 to 48 hr
with 0.9% or 0.45% normal saline
While providing insulin infusion: Infusions of 0.05-0.1
U/kg/hr of regular insulin, titrated to effect
Add 5% glucose to infusion when blood glucose reaches
300 mg/dl to prevent hypoglycemia
Add 10% glucose to infusion when blood glucose reaches
200 mg/dl (and patient is receiving 5% dextrose) to
prevent hypoglycemia
Replace potassium losses in IV fluids
Monitor ECG for signs of hyperkalemia and hypokalemia
Correct acidosis: Insulin infusion
Consider sodium bicarbonate for severe acidosis (pH
<7.0) (controversial)
Measure blood glucose:
Every hour until insulin infusion is discontinued
Every 2 hr until taking fluids orally and IV fluids are
discontinued
Five times per day after discontinuing IV fluids (before
breakfast, before lunch, before dinner, before bedtime
snack, and at 2 AM)
Additional measurements should be obtained as needed
when clinical symptoms of hypoglycemia are
detected
Monitor response to therapy: Vital signs (pulse, respirations, blood pressure)
g30-60min while on insulin infusion
g shift until ketones cleared
Weigh daily
Compare fluid intake to output
Measure urine ketones/glucose whenever blood glucose
>240 mg/dl
Detect and treat cerebral edema in a timely fashion:
Neurosigns hourly for 24 hr (mental status changes,
pupillary response)
Treat signs of cerebral edema immediately
BUN. Blood urea nitrogen; IV, intravenous: ECG. electrocardiogram.

corrected slowly (no more than a 10% decrease in serum
glucose level every hour). Rapid correction of hyperglycemia is associated with the development of cerebral
edema 33 .39 A 5% solution of glucose is added to the
intravenous fluid as the blood glucose decreases to approximately 200 to 300 mg/dl. When the child's blood glucose
decreases to approximately 200 mg/dl, the concentration of
glucose is increased to 10%. Blood glucose is measured at
least hourly while insulin is infused and should be measured
within 30 minutes after a change in either the dose of insulin
or concentration of glucose. The rate of the insulin infusion
is usually held constant at a dose that achieves a normal
serum glucose level and inhibition of further lipolysis, fatty
acid oxidation, and ketone production. Monitoring of urine
samples for ketones is used to identify the point at which
fatly acid oxidation has ceased.
Infusion of sodium bicarbonate is occasionally used to
correct severe acidosis (pH is less than 7.0) in children with
DKA. Severe acidosis may cause myocardial depression and
decrease the insulin sensitivity of cells. 40 However, the
use of sodium bicarbonate in the treatment of DKA is
controversial because bicarbonate administration may cause
intracellular acidosis and worsens cerebral edema. 40 Research investigating the outcomes of adults with DKA who
received bicarbonate therapy has demonstrated conflicting
results. Recently Green and colleagues 40 retrospectively
studied the use of bicarbonate for correction of acidosis
associated with DKA in children. Green and co-workers40
reported that administration of bicarbonate was unrelated to
final outcome and that children with pH as low as 6.73
recovered without administration of bicarbonate. However,
the study also did not find a correlation between adverse
events, such as cerebral edema, and bicarbonate therapy.
Sodium bicarbonate is administered intravenously in doses
of 0.5 to 1 mEq/kg, or when the base deficit is known,
according to the following formula:
mEg of bicarbonate = 0.3 x (Body weight in kg) x (Base deficit)· I
Monitoring for life-threatening cardiac dysrhythmias precipitated by either hypokalemia or hyperkalemia is initiated
for children undergoing treatment for DKA. Ventricular
ectopic beats often are due to hypokalemia, and peaked T
waves are indicative of hyperkalemia.
Monitoring for signs and symptoms of cerebral edema is
indicated for children undergoing treatment for DKA.
Indicators of cerebral edema and elevated intracranial
pressure include mental status changes, decreased pupil
reactivity, bradycardia, hypertension, and abnormal respiratory patterns. Cerebral edema in children with DKA may
require acute intervention such as supported respiration and
circulation, hype'rosmolar therapy, moderate hypothermia,
pharmacologically mediated reduction in cerebral metabolic
rate, and appropriate positioning (such as head elevation).

SUMMARY
The endocrine system stimulates and inhibits the secretion
of hormones into the bloodstream. Hormones regulate many
metabolic processes of the body, including fluid and
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electrolyte balance and glucose homeostasis. Disorders of
fluid and electrolyte balance and glucose homeostasis can
cause hemodynamic instability and may progress to circulatory failure and shock. Care of the child with endocrine
problems includes vigilant monitoring for the signs of
frank bemodynanlic instability and for the specific signs
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and symptoms of altered electrolyte levels, changes in
fluid volume stams, and states of abnormal glucose metabolism. Management of endocrine problems includes
replacement or restriction of electrolytes and fluid, the
replacement of hormones when appropriate, and support of
circulation.
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Hematologic Critical Care
Problems
Debbie Brinker
Patricia A. Moloney-Harmon

every cell and organ system in the body. In addition, organs
of the hematopoietic system, such as bone marrow, are
prone to the adverse effects of sepsis, trauma, shock, and
drugs used for critical illnesses. The majority of hematologic problems seen in critically ill children are acquired and
often present as an acute episode. I The more common
problems include disseminated intravascular coagulation
(DIC), vascular access thrombi, anemias, hemolytic uremic
syndrome (HUS), and blood dyscrasias.
This chapter focuses on assessment of hematologic
function, supportive and therapeutic interventions (i.e.,
blood product administration and apheresis), and alterations in hematologic function, including disorders of
coagulation and oxygen-carrying capacity. Disorders will
be discussed as final common pathways of altered hematologic function with emphasis on pathophysiology and
nursing care of the patient with DIC, sickle cell anemia
(SCA), and HUS.

ESSENTIAL EMBRYOLOGY
ESSENTIAL ANATOMY AND PHYSIOLOGY

Hematopoietic Organs
Blood Stem Cell
Composition of Blood
ASSESSMENT AND DIAGNOSIS OF HEMATOLOGIC DISORDERS

Clinical History
Assessment and Physical Examination
Monitoring Hematologic Function
SUPPORT OF HEMATOLOGIC FUNCTION

Blood Product Transfusions
Pharmacologic Therapy
Mechanical Intervention
DISORDERS OF COAGULATION

Immune Thrombocytopenic Purpura
Disseminated Intravascular Coagulation
Heparin-Induced Thrombocytopenia
Vascular Access Thrombi

ESSENTIAL EMBRYOLOGY
During embryologic development, blood formation can be
recognized as early as 3 weeks after conception. By the sixth
week of gestation, hematopoiesis (the production of red
cells, white cells, and platelets) moves from the yolk sac to
the liver, which is the main site of blood formation during
the middle portion of fetal life. Following the twemieth
week of gestation, hematopoiesis then moves to the bone
marrow; and following birth, it takes place almost entirely in
the bone marrow.

ANEMIAS

Anemia Related to Blood Loss
Hemolytic Anemia
Aplastic Anemia
Sickle Cell Disease
MIXED DISORDERS

Hemolytic Uremic Syndrome
Thrombotic Thrombocytopenic Purpura

ESSENTIAL ANATOMY AND PHYSIOLOGY

SUMMARY

Hematopoietic Organs
Bone marrow is the chief site for hematopoiesis. There are
two types of bone marrow: yellow marrow, which contains
a large percentage of fat cells; and red marrow, which
contains mostly blood cells. The infant and young child
have a larger proportion of red marrow because of the high

C

hildren in the pediatric intensive care unit (PICU)
experience a variety of hematologic problems that vary
in severity. This is partially because of the complex structure
and function of blood and its components, which affect
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Fig. 24-1 The origins and differentiation of blood cells. (From Martini F, Fundamentals of anatomy alld
physiology, ed 3, Upper Saddle River, NJ, 1995, Prentice-Hall. Adapted by permission of Prentice-Hall.
Upper Saddle River, NJ.)

requirements for red cell production. Early in life the red
marrow is contained in the medullary cavities of the long
bones. These cavities gradually fill with fat as the demands
for red cell production decrease until the adult distribution
of hematopoiesis (sternum, pelvis, vertebrae, cranium, ribs,
and epiphyses of long bones) are reached at puberty. In

disease states associated with anemias, hematopoiesis can
return to its former sites, including the long bones, skull,
liver, spleen, and lymph nodes. It may also take place in
the adrenal glands, cartilage, adipose tissues, and kidneys.
Fig. 24-1 illustrates the fonnation and maturation of blood
cells.

Chapter 24

Blood Stem Cell
Human bone marrow contains a pluripotent hematopoietic
stem cell precursor that is capable of differentiating into
erythroid, granulocytic, monocytic, megakaryocytic, and
certain lymphoid cell lines. This cell gives rise to the
marrow stem cell, which produces the precursor for
erythrocytes, granulocytes, monocytes, and platelets. Stem
cells are present in small numbers in blood and bone
marrow. Their turnover depends on the needs of the body. It
has been suggested that the structure of the stem cell is
similar to that of the lymphocyte.
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Box 24·'

Development of Red Blood Cells

Hemocytoblast
(Precursor of all blood cells)

J.
Prorubricyte or basophil erythroblast
(Synthesis of Hgb begins)

J.
Rubricyte
(Nucleus begins to shrink, more synthesis of Hgb)

J.

Composition of Blood
Blood is composed of plasma in which are suspended
certain proteins (such as albumin, &Iobulin), clotting factors,
and the blood cells. These include leukocytes (white blood
cells [WBCsj), erythrocytes (red blood cells [RBCsj), and
thrombocytes (platelets).
leukocytes. The main function of the leukocytes are
to fight infection; defend the body against foreign organisms
through phagocytosis; and produce, transport, and distribute
antibodies in the immune system. Leukocytes are discussed
in detail in Chapter 15.
Erythrocytes. Erythrocytes (RBCs) are the most
abundant component in the blood. They have biconcave
discs without nuclei and are extremely flexible. This allows
them to travel extremely fast and bend and twist as they pass
through tiny capillaries. Their elongated shape in the
capillaries allows for more surface area for the exchange of
oxygen and carbon dioxide.
After birth, the rate of hemoglobin (Hgb) synthesis and
production of RBCs decreases dramatically during the first
few days of life. Over the next few weeks, as the conversion
occurs from fetal to adult Hgb, and the threshold of
decreased venous oxygen saturation is reached, a physiologic nadir is created at about 7 to 10 weeks. A signal in the
form of increased erythropoietin production is sent to the
marrow, and erythropoiesis is stimulated, eventually leading
to an increase in Hgb, at about 3 to 4 months of age.
Premature infants reach their nadir earlier than term infants
and require a longer period of time to recover?
The main function of erythrocytes is the transport of
oxygen and carbon dioxide, which is accomplished through
Hgb, the major component of RBCs. Oxygen binds with
Hgb and then is released at tissue sites where gas exchange
takes place.
Fetal hemoglobin (Hb F) is present at birth and allows for
more efficient binding of oxygen at lower surface tensions.
Hb F constitutes 70% of the total Hgb at birth but declines
rapidly. By 6 to 12 months of age, Hb F has been mostLy
replaced by adult Hgb, although levels of I% to 2% of
Hb F remain throughout life. Hb F shifts the oxyhemoglobin
dissociation curve to the left so that oxygen bound to Hgb is
not readily released to the tissues. This may compromise
tissue oxygenation in newborns with diminished cardiovascular reserves.
RBCs are formed in the red bone marrow and progress
through the stages of development outlined in Box 24-1.

Normoblast
(Nucleus begins to disintegrate, more synthesis of Hgb)

J.
Reticulocyte
(Nucleus absorbed, strands of endoplasmic reticulum seen)

J.
Erythrocyte
(Mature RBC without nucleus or reticulum)

The mature erythrocyte is released into the circulation
where the average lifespan is about 120 days. This time span
represents the interval between the cell's release into the
circulation from the bone marrow and its destruction. When
the RBC ages, it is removed from the circulation by the
spleen, liver, and red bone marrow. When the hematopoietic
system is faced with a heavy demand for the production of
RBCs, such as with hemorrhage, immature RBCs are
released into the circulation. The number of immature cells
and their degree of immaturity reflect the severity of stress
placed on this body system. When the demand is great, the
number of reticulocytes may increase by 30% to 50%. With
an increased demand, the number of normoblasts may
appear in large numbers. In severe anemias, the percentage
of normoblast~ may be as high as 5% to 20% of the
circulating RBCs. Prorubricytes may also appear at this
time. This information is also important in differentiating
various types of anemias.
RBC production is also stimulated by decreased tissue
oxygenation because RBC production depends not only on
the actual number present in the circulation but also on their
ability to carry oxygen and carbon dioxide. When tissue
oxygenation is decreased, erythropoietin stimulates the stem
cells in the bone marrow to produce mature RBCs.
Erythropoietin is produced in the kidney and is released in
response to hypoxia and anemia. Table 24-1 lists the normal
RBC values at various ages.
Thrombocytes (Platelets). Platelet development
takes place primarily in the bone marrow. Platelets are the
smallest of the blood cell components. They are fragments
of megakaryocytes. Megakaryocytes mature in the bone
marrow and fragment, where each one releases approximately 5000 platelets into the blood. The lifespan of
platelets is approximately 7 to 14 days. Approximately 10%
to 15% of the circulating platelets are consumed in the daily
repair of small vascular injuries.
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Red Blood Cell Studies

a

Normal Values

Purpose

Clinical Significance

Millions of
cells/mm'
1 wk
2 wk
I mo
2 mo
3-6 mo
0.5-2 yr
2-6 yr
6-12 yr
12-18 yr
M
F

Measures total number of circulating RBCs

Increased in polycythemia, severe diarrhea, dehydration, acute
poisoning, during and immediately following hemon'hage
Decreased in anemia, diseases of bone marrow function, hemolytic and pernicious anemia, subacute endocarditis

% of packed
cells
3 days
2 mo
6-12 yr
12-18 yr
M
F

1-3 days
2 mo
6-12 yr
12-18 yr
M
F
throcyte sedimentation rate
(ESR)

a
3
3

0-10 mmlhr

3.9-6.3
3.6-6.2
3.0-5.4
2.7-4.9
3.1-4.5
3.7-5.3
3.9-5.3
4.0-5.2
4.5-5.3
4.1-5.1
Measures percentage of RBCs in a volume of blood

Increased in erythrocytosis, polycythemia, severe dehydration,
shock-when hemoconcentration rises considerably
Decreased in anemia, leukemia, acute massive blood loss, hemolytic reactions
Unreliable immediately after transfusions, hemorrhage

Measures oxygen-carrying capacity of the blood

Increased in hemoconcentration of the blood, CHF
Decreased in anemia: severe hemorrhage, hemolytic reactions
Unreliable immediately after transfusions, hemorrhage

Measures the rate at which RBCs settle out of
unclotted blood in I hr
Based on the fact that inflammatory and necrotic
processes result in aggregation of RBCs, which
makes them heavier and more likely to settle

Increased values found in infections, inflammatory diseases,
carcinomas, cell or tissue destruction, toxemia, nephritis,

44-72
28-42
35-45
37-49
36-46
g/dl
14.5-22.5
9.0-14.0
11.5-15.5
13.0-16.0
12.0-16.0

pneumonia, severe anemia

Decreased values found in polycythemia vera, sickle cell
anemia, CHF
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Infants

Children

~ean
corpuscular
!il!
ii.

volume (MCV)

fT
i'

!;,,;

'"

''":Mean
corpuscular
,to,

1

i.',', :: hemoglobin
,';' concentratIon
(MCHC)

f

"'from

1-3 days
0.5-2 yr
6-12 yr
12-18 yr
M
F

2%-5%
of total
RBCs
0.5-4.0%
of total
RBCs

Measures the number of immature RBCs (reticulocytes) compared with total RBCs
Indicates an increase in RBC production and/or a
decrease in RBC destruction

Increased in hemolytic anemia, sickle cell disease, leukemia, 3-4
days following hemorrhage, after splenectomy. following treatment of anemia
Decreased levels indicate that the bone marrow is not producing
enough erythrocytes and is seen in iron-deficiency anemia,
aplastic anemia, chronic infection, radiation therapy

11 m3

Measures the volume occupied by a single RBC and
indicates size of the cell:
Normocytic--{)f normal size
Microcytic-smaller than normal
Macrocytic-larger than normal

Decreased in anemia, thalassemia
Increased in liver diseases, deficiency of folate or vitamin B 12

Measure of the concentration of hemoglobin in an
average cell

Most valuable in evaluating therapy for anemia because the two
most accurate hematologic determinations (Hgb and Hct) are
used in thi s test
Increased MCHC usually indicates spherocytosis
Decreased MCHC indicates that a unit volume of packed RBCs
contains less hemoglobin than normal
May be seen in iron-deficiency anemia, thalassemia

Measure of the average weight of hemoglobin in
the RBC
Less accurate than MCHC because uses RBC count
in the calculation and that count may be inaccurate

Increased MCH associated with macrocytic anemia
Decreased value associated with iron-deficiency anemia

95-121
70-86
77-95
78-98
78-102

% Hgb/cell or g
Hgb/dl RBC
1-3 days
1-2 wk
1-2 rno
3 mo-2 yr
2-18 yr

30-36
29-37
29-37
30-36
31-37

1-3 days
I wk-l mo
2 rna
3-6 rna
0.5-2 yr
2-6 yr
6-12 yr
12-18 yr

%/cell
31-37
28-40
26-34
25-35
23-31
24-30
25-33
25-35

Fischbach F: A manual of loboratory diagnostic lesls, Philadelphia, 1980, 18 Lippincon; FOSler RL, Hunsberger MM, Anderson JJ: Family-cell/ered nursing care of children, Philadelphia,
~~989, WB Saunders,
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Fig. 24-2 The coagulation sequence. (From Hudak C, Gallo B, Lohr T, eds: Critical care nursing,
Philadelphia, 1973, JB Lippincott.)

The rate of platelet production and the level of circulating
platelets are thought to be controlled by thrombopoietin or
thrombopoiesis-stimulating factor. The level of circulating
catecholamines also has an effect on platelet levels. The
administration of epinephrine can immediately produce a
20% to 50% increase in the platelet count. This response is
likely to be the result of mobilization from the splenic pool.
Hypoxia also increases the number of circulating platelets.
Platelets playa primary role in the process of hemostasis.
Hemostasis is achieved by vascular spasm, formation of a
platelet plug, formation of a blood clot, and formation of
connective tissue, which permanently repairs the damaged
vessel. Vascular spasm reduces blood flow through a
damaged blood vessel to prevent further blood loss. When
platelets come in contact with the damaged blood vessel,
they adhere to the walls of the vessel at the site of damage.
Other platelets in the area are activated, and aggregation
occurs when these cells adhere to the first. Thus platelets
group together to repair the damaged vessel.
Coagulation is a complex process involving an intricate
series of reactions that include a number of different factors
present in the blood or the tissues. These substances
influence the mechanisms of clotting by promoting clotting
with procoagulants (clotting factors) or inhibiting clotting
with anticoagulants. Some are also involved in the removal
of a clot once it is formed. Each clotting factor acts as an

enzyme, which, when activated, proceeds in a stepwise
fashion to the next reaction. This is referred to as the clotting
cascade, or more appropriately as a clotting continuum,
because feedback is involved to activate and/or inhibit the
coagulation process (Fig. 24-2).
The first step of coagulation is the formation of prothrombin acti vator. This step is the most complex because it
involves a group of clotting factors involved in the extrinsic
and intrinsic pathways. The extrinsic pathway is activated
by trauma to the vascular walls and surrounding tissues.
Factor III must be released from the endothelial cells and
other tissues before activation can begin. When chemicals
released into the tissues at time of injury (tissue factor)
contact factor VII, sequential activation of factors X, V, II,
and I take place. These factors then convert factor X to
activated factor X.
When factor XII and platelets come in contact with
collagen in the damaged wall of a vessel, the intrinsic
pathway is activated. Factors XI, IX, VIII, X, II, and I are
then activated, followed by the activation of factor X.
With the help of factor V, activated factor X forms
prothrombin activator. Once this is formed, with the
assistance of calcium ions, prothrombin is activated. Prothrombin is converted to thrombin with assistance of
factor V. In the presence of thrombin and calcium ions,
fibrinogen is converted into fibrin. The fibrin threads form a

Chapter 24

Fibrinogen
Prothrombin
Tissue thromboplastin
Calcium
Proaccelerin
Proconvertin
Antihemophilic factor A
Christmas factor
Stuart-Prower factor
Plasma thromboplastin antecedent
Hageman factor
Fibrin stabilizing factor

network over the damaged area of the vessel, which traps
blood cells, platelets, and plasma. A blood clot is formed and
prevents further leakage through the damaged vessel. Within
minutes of formation, clot retraction pulls together the sides
of the damaged vessel.
Once formed, the clot may be the basis for new
connective tissue or it undergoes the processes of lysis and
dissolution. After a few hours, fibroblasts invade the clot,
and within 7 to 10 days, fibrous connective tissue is formed.
Plasminogen and plasminogen activator, which are trapped
within the clot with platelets and RBCs, ultimately produce
plasmin, which lyses the clot.
The extrinsic pathway is activated when factor III gains
access to the bloodstream; the intrinsic pathway is activated when blood comes in contact with an abnormal
surface. Regardless of the initiating mechanism, the end is
the same. Large amounts of thrombin are produced, which
is then followed by the transformation of fibrinogen to
fibrin. Table 24-2 lists the factors involved in the clotting
mechanism.

ASSESSMENT AND DIAGNOSIS
OF HEMATOLOGIC DISORDERS
On admission, infants and children may present with
primary diagnoses of bleeding and/or coagulation disorders,
or have coincidental findings discovered per history, physical examination, or laboratory results.

Clinical History
An admitting history includes questions regarding bleeding
disorders (e.g., patient or family history of hemophilia or
von Willebrand's disease), and whether a child bleeds or
bruises easily. It is important for a parent/historian to
distinguish "normal childhood bruising" over extremity
bones and bony prominences versus soft-tissue bruising
with no apparent cause.

Hematologic Critical Care Problems
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Other important issues include symptoms from decreased
or dysfunctional RBCs or WBCs. A history for anemia
(decreased RBCs) includes fatigue, listlessness, decrease in
activity or energy level, syncope, and pallor. An infectious
history (e.g., frequent sinus infections, joint infections, and
lacerations that do not heal) may be indicative of decreased
(or dysfunctional) WBCs. Immunosuppressive conditions or
therapies such as chemotherapy or antirejection drugs
posttransplant are important to evaluate in terms of WEC
and infection risk.

Assessment and Physical Examination
Physical examination of the child with a hematologic
disorder begins with observation of the child's general
appearance. The child may appear pale because of anemia.
Jaundice may be present if the child has a potential clotting
problem from hepatic dysfunction. Signs of clotting include
petechiae, purpura (small, red/purple areas that may be flat
in abnormal bleeding states such as DIC, or raised [palpable I areas in cutaneous vasculitis disorders such as HenochSchonIein purpura [HSP]), and ecchymosis.
Cardiovascular symptoms may manifest as massive
bleeding secondary to trauma with hemodynamic instability
and prolonged bleeding. Oozing from venipuncture, intravenous, or arterial puncture sites may also be present.
Pulmonary symptoms may include frank bleeding from
endotracheal tube or prolonged nose bleeds. Signs of
respiratory distress such as tachypnea and dyspnea (especially on exertion) correlated with a decreased Hgb value
may also be present. Neurologic symptoms of hematologic
dysfunction include signs of cerebral vascular accident
(CVA) or a central nervous system (CNS) hemorrhage as
evidenced by a change in the level of consciousness. The
child may demonstrate unilateral changes in reflexes (including pupils), circulation, sensation, or movement (CSM).
The major gastrointestinal (GI) manifestation of hematologic dysfunction is frank or occult bleeding in GI
contents. The presence of blood in the urine also may signal
a bleeding disorder.

Monitoring Hematologic Function
Multiple laboratory tests are used to monitor hematologic
function. The most common tests include the complete
blood count (CBC) and coagulation studies. It is important
to interpret the CBC based on age comparison normals
because growth and developmental changes occur in the
hematologic system. A summary of RBC studies is reviewed in Table 24-1 and coagulation studies are described
in Table 24-3.
Bone marrow aspiration is a common procedure performed to assess hematologic status. The bone marrow is
typically obtained from the posterior iliac crest. This
diagnostic procedure allows for assessment of marrow
cellularity, quantitative and qualitative changes in hematologic precursors (i.e., cytopenias), and evaluation for
disorders such as acute leukemia (discussed in Chapter 25),
and aplastic anemia.
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Coagulation Studies
Normal Values'

Purpose

Clinical Significance

150,OOO-4OO,OOO/mm'

Measures total number of circulating platelets

11-15 sec

Indirectly measures the ability of
the blood to clot and directly
measures a defect in phase II
clotting mechanisms (prothrombin, fibrinogen, factors V, VII, X)

Abnormally decreased in ITP; pernicious, aplastic, and hemolytic
anemia; drugs, especially chemotherapeutic agents; bone marrOw
malignancies
Abnormally increased after splenectomy and in certain cancers; may
predispose to thrombotic episodes
Prolonged in prothrombin deficiency; vitamin K deficiency;
deficiencies of fibrinogen; factors
V, VII, X; anticoagulant therapy;
severe liver disease; DlC

I~;·

~rrOthrombin time

Wi..
oJi~

(PT) or

~R

.

.

(internatIonal
l\Ef normalized ratio)

<1.2

!W;,

~Ij

~]?\cti vated partial
thromboplastin
time (APlT)

20-35 sec

Same as for PlT but more sensitive
and faster to perfornl

Same as PIT

~Fibrinogen

>150 mg/dl
<0.5 ~g/ml

Measures fibrinogen level
Measure of degradation of crosslinked fibrin

Decreased in liver disease, DIC
Increased in DlC

9-13 sec

Measures fibrinogen to fibrin formation; detects stage III of fibrinogen abnormalities

Prolonged with low fibrinogen
levels; anticoagulant therapy;
liver disease; DIC

ltri';

i

!i:~

ill'

.

f,ii:n-D,mer

~W~

lWY:.

lfuu-ombin time
'!h:;:.=
~·~.(IT); thrombin
~:. clotting time

~j;~rom

Fischbach F: A manual of laboratof)' diagnostic tests, Philadelphia, 1980. J.B. Lippincott; Foster RL, Hunsberger MM. Anderson JJ:
'fjJ'Family-cemered nursing care of children. Philadelphia, 1989. W.B. Saunders; Jackson BS, Jones MB: Hematologic anatomy and physiology. In Kinney
\It'¥R, Packa DR, Dunbar SB, eds: AAeN's clinical referellce for critical-care lIursing. ed 2, New York, 1988, McGraw-HilI.
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laboratory values vary by laboratory and are age dependent.

SUPPORT OF HEMATOLOGIC FUNCTION
There are a variety of interventions that are used to treat
hematologic dysfunction. These include blood product
transfusion therapy, pharmacologic interventions (i.e., anticoagulants and immune globulins), and mechanical interventions (i.e., apheresis).

Blood Product Transfusions
Critically ill pediatric patients may require blood product
administration for a variety of reasons. Knowledge of
special donor designation, modifications of the blood
products including special processing procedures, and the
potential risks of transfusions is essential for the provision
of care. Table 24-4 presents blood products commonly used
in the PICV, indications for these blood products, dosage,
and nursing implications.
Special Donor Designation. Blood administration
requires an understanding regarding donor-directed (designated) blood and human leukocyte antigen (HLA)-matched
blood products. With the concern regarding safety of blood,
most blood centers offer the ability for family and friends to
donate blood for a specific patient. Although this is not
possible for the emergent needs of a critically ill patient,
parents may request information from the blood blank
regarding donor-direction for postadmission transfusion
needs. Directed donations, however, have not offered a

safety advantage over ordinary banked blood derived from
anonymous volunteer donors. 3 There is a concern regarding
the potential for increased clerical errors resulting from the
additional steps in the donation process, as well as
inaccurate history disclosure. Directed donation from parents to neonates is not recommended because of maternal
alloantibodies and maternal antibodies in the infant's
circulation?
Another special donor situation occurs when HLAmatched platelets are required. Patients, especially after
multiple platelet transfusions, may develop antibodies to
antigens on platelets, and require HLA cross-matching to
minimize chance of reaction to the donor platelets in order
to receive an adequate rise in platelet count.
Patients who require ongoing (lifelong) transfusions
(e.g., sickle cell disease [SeD]) may develop multiple
alloantibodies to donor blood antigens, which make crossmatching difficult. This may cause a delay in availability of
blood products for these individual patients.
Knowledge regarding special donor requirements for
individual patients is important. It is vital to document the
number of products available for immediate transfusion and
to send patient blood samples when required for crossmatching to prevent a delay in product availability.
Modifications of Blood Products. Various methods
are available to modify blood products before administration to minimize the risks of transfusions for patients with
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special needs. Modifications include leukodepletion and
irradiation of blood products.
To reduce the risk of nonhemolytic febrile reactions,
leukocyte-depleted blood products may be transfused,
especially to patients receiving frequent transfusions.
Leukocyte-depleted blood products are ordered primarily
when it has been demonstrated or suspected that the patient
has previously experienced a febrile transfusion reaction.
Other indications for leukocyte-depleted blood products are
to prevent alloimmunization in recipients of frequent
platelet transfusions, to prevent cytomegalovirus (CMV)
infection when CMV-negative blood products are not
available, and in prospective renal allograft recipients.
Leukocyte depletion is usually achieved by prestorage or
bedside filtration-a process that removes 70% to 99% of
WBCs. Leukocytes can also be removed by washing RBCs
or by freezing and deglycerolyzing RBCs.3- 5
Leukocytes present in the transfused blood component can react against an immunosuppressed patient,
causing transfusion-associated graft-versus-host disease
(TA-GVHD). Irradiation destroys the leukocytes' ability to
engraft in the patient. Patients susceptible to TA-GVHD
include transplant recipients, severely immunocompromised patients, and those with lymphoma or acute leukemia. The incidence of TA-GVHD is not known, but
many oncology units and some neonatal centers routinely
use irradiated blood. 6 It is generally recommended that
patients at risk for TA-GVHD in the PICU receive
irradiated blood products. Irradiated blood products pose
no danger to healthcare personneL? Filtration of blood
products at the bedside includes use of a 170- to
260-micron filter, which is standard in blood administration
and platelet recipient sets. These filtered tubing sets should
hang no longer than 4 hours. Each set can be used for
up to four units if total time is less than 4 hours. WBC
filters (Pall filters) may also be used if leukofiltration is
indicated and has not been accomplished prestorage at the
blood bank.
Most transfusions can be administered without the use of
a blood warmer. However, transfusions of more than one
unit of blood every 10 minutes, and exchange transfusions
in neonates, mandate the use of a blood warmer to prevent
severe hypothermia, dysrhythmias, and cardiac arrest. Patients who are hypothermic before the transfusion, and those
who have cold agglutinin disease, also require warmed
blood products. When blood must be warmed, it is heated
via an inline system. Because RBCs heated above 37 0 C.
may hemolyze, only temperature-controlled devices designed specifically to warm blood should be used.?
Potential Complications. The most important potential complication associated with blood product administration is transfusion reaction. Transfusion reactions are
generally classified as hemolytic or nonhemolytic reactions.
Each reaction has some characteristic signs and symptoms,
but the type of reaction may be difficult to ascertain initially.
Table 24-5 summarizes reactions, signs and symptoms, and
treatments.
Acute Hemolytic Reactions. Acute hemolytic reactions are potentially the most serious of transfusion reac-

tions. A hemolytic reaction occurs when the blood product
recipient has antibodies to some antigen on the transfused
RBCs. The most common etiology of this antibody-antigen
reaction is ABO incompatibility. The most frequent source
of hemolytic reactions is mismatched blood, usually as a
result of clerical error. 4 .5 Hemolytic reactions may be either
immediate (fever, hematuria, etc.) or delayed. Delayed
reactions may occur 3 to 5 days after the transfusion, with
development of anemia and hematuria. Delayed reactions
from low antigen titers undetected during cross-matching
cause a slow build-up of antibody response; thus the delayed
symptoms occur.
Nonhemolytic Reactions. Nonhemolytic reactions
are generally classified into febrile and allergic reactions.
Febrile reactions, which are characterized by fever and
possibly shaking chills, are the result of an immune response
to infused WBCs or plasma proteins. Febrile reactions
usually occur in frequently transfused patients and are rarely
serious. However, because fever can be the initial manifestation of a life-threatening hemolytic reaction, the transfusion should be discontinued if the patient's temperature rises
10 C or more above baseline. Antipyretics may be administered to control the fever. Providing frequently transfused
patients with leukocyte-depleted blood products can prevent
febrile reactions. 3
The other common type of nonhemolytic reaction is an
allergic reaction. Most allergic reactions are mild, characterized by local erythema, pruritus, and urticaria. The
transfusion is stopped temporarily, and an antihistamine
preparation is administered. If the symptoms are mild and
resolving, the transfusion may be restarted slowly. Patients
who have had an allergic reaction to a transfusion may be
pretreated with an antihistamine drug before subsequent
transfusions.
Rarely, an anaphylactic reaction occurs. Features that
distinguish an anaphylactic reaction are bronchospasm,
hypotension, and absence of fever. These reactions, which
are typically apparent after administration of only a few
milliliters of the transfused blood product, occur almost
exclusively in IgA-deficient recipients. Collaborative interventions include the administration of epinephrine, fluids,
and corticosteroids. 3
Alloimmunization. Alloimmunization is another potential complication of receiving blood products, especially
in patients who receive multiple transfusions. Such patients
develop antibodies against antigens that they intrinsically
lack, but that are present on the surface of the cells that have
been transfused. Subsequent transfusions are affected; these
newly formed antibodies may destroy future transfused cells
that possess the targeted antigens. When platelets are
transfused to a patient alloimmunized against platelets, there
is no therapeutic effect; the patient is considered refractory
to platelet therapy. Single-donor or HLA-matched platelets
may offset the effects of alloirnmunization. When RBCs are
transfused to a patient alloimmunized against red cell
antigens, hemolysis of the donor's cells may result. Appropriate cross-matching should prevent a serious hemolytic
reaction. Using leukocyte-depleted blood components reduces the risk of alloimmunization.3· 5
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TABLE 24-5
,Reaction

jjii.(\naphylaxis
ih.
with infusion
lilt of only a few ml of
m~{Occurs

Ii.I

Cause

Signs and Symptoms

Treatment

Most often caused by
antigen-antibody
complexes involving
antibodies to IgA

Bronchospasm
Cough
Respiratory distress
Hypotension •

Discontinue transfusion
Keep vein open with NS (completely new
tubing set)
Notify physician
Administer epinephrine, steroids
Provide respiratory support
Use deglycerolized (washed) red cells in
future transfusions

Transfusion of ABOincompatible blood
resulting in hemolysis of red cells

Fever, chills'
Hypotension*
Hemoglobinemia
Hemoglobinuria
Lumbar pain (classic
sign)
Shock
Dyspnea
Diaphoresis
Anxiety (sense of
impending doom)
Chest pain
Restlessness
DlC

Stop transfusion
Keep vein open with NS (completely new
tubing set)
Notify physician
Treat shock and/or respiratory distress
Produce osmotic diuresis to prevent acute
tubular necrosis
Treat DlC

Recipients reacting to
poorly defined transfused antigens or
recipients' antibodies
reacting to transfused
leukocytes and/or
plasma proteins

Fever (mild to severe)*
Chills
Headaches
palpitations
Hives
Local erythema
Itching

Stop transfusion
Keep vein open with NS (completely new
tubing set)
Notify physician
Relieve symptoms (antipyretics. antihistamines)
If reaction mild such as urticaria and/or
slight fever and chills, may consider
continuing transfusion after antihistamine. May also consider premedication
and/or leukocyte-poor products for future
transfusions.

~\1
;•. '• .";•. '.• · product)
;~;:

.-

I

"~~.;._cute hemolytic trans.5c·.

fuSIOn reactIOn

>:-:
f .

~.i

=:'-.
,jj.~,
r·

1r'
!tf:~
If'

t~'t;

~~!
onhemolytic

831

Transfusion Reactions to Blood or Blood Products

r·

~!

Hematologic Critical Care Problems

~Consider bacterial contamination of product

,..-:.:,,-

Circulatory Overload. Circulatory overload is a potential complication of blood product administration, which
occurs when the transfusion volume exceeds circulatory
system capacity. Critically ill pediatric patients are at
increased risk of circulatory overload because of their
relatively small baseline blood volume and potentially
compromised cardiovascular, pulmonary, and renal systems.
This complication can usually be prevented by adjusting the
transfusion volume and flow rate based on the patient's size
and clinical stalUS. The blood bank can divide packed cells
into smaller aliquots and can provide "volume-reduced"
platelets to fluid-sensitive patients. Increased respiratory
support and diuretics may be necessary to treat circulatory
overload.
Citrate Toxicity. Citrate is a substance that is present
in the anticoagulant preservative solution added to most
blood products. In the body, citrate binds with serum
calcium, potentially causing hypocalcemia. The patients

most at risk for symptomatic citrate toxicity are those who
receive very rapid transfusions, those who receive multiple
transfusions over a relatively short period of time, and
patients with existing hepatic or renal dysfunction because
citrate is metabolized in the liver and excreted by the
kidneys.8
The serum calcium level of patients at risk for citrate
toxicity is checked before and during transfusions. When
toxicity in the presence of hypocalcemia is anticipated,
intravenous calcium chloride or calcium gluconate may be
administered prophylactically.
Transmission of Infectious Diseases. Transmission
of infectious diseases is a potential complication of blood
product administration. Although fear of acquiring HIV,
which causes AIDS, is generally the dominant concern of
transfusion recipients and their families, the chances of
contracting other infectious diseases, such as hepatitis or
CMV poses a more significant health risk.
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Approximately 2.5% of adult AIDS cases reported to the
Centers for Disease Control and Prevention (CDC) have
been related to transfusions. However, pediatric AIDS cases
have a much higher proportion of posttransfusion etiology.
The vast majority of patients with transfusion-acquired
AIDS were infected before 1985. Since 1985, all bloodcollecting facilities have used the HlV antibody test to
screen donated blood, which has significantly decreased the
risk of HIV transmission. The current risk of acquiring HIV
from a blood transfusion is unknown, but it is estimated to
be 1 in 420,000. There is evidence that the risk is declining
by 30% per year. 3
The exact incidence of posttransfusion hepatitis is
unknown. Hepatitis A virus (HAV) is usually transmitted by
the fecal-oral route. At one time, it was believed that
posttransfusion HAV infection was virtually nonexistent.
More recently, there have been reports in the literature that
document HAV transmission by transfusion. For example,
several nursery-wide outbreaks of posttransfusion HAV
infection among newborns have been reported. Fortunately,
none of these studies has demonstrated significant morbidity
from HAV9
In contrast, hepatitis B virus (HBV) has long been known
to produce posttransfusion infection, which can cause
significant morbidity and mortality. Despite the fact that all
blood is screened for hepatitis B surface antigen (HBsAg),
several prospective studies have documented that up to
1.7% of transfusion recipients develop HBV infection.
Possible explanations for this phenomenon include the
presence of infectious donors who are in the incubation
phase, before HBsAg testing would be positive, and
infectious donors with a serum level below the limits of
detectability with current assays.9
Non-A non-B hepatitis (NANBH) is the most common
posttransfusion hepatitis, accounting for about 60% of all
cases. Hepatitis C virus (HCY) has been confirmed to be the
cause of most, if not all, cases of NANBH. In adults, the
sequelae of NANBH are chronic active hepatitis in 40% to
50% of cases, and cirrhosis in 20%. Children who acquire
HBV or HCV during infancy usually have a persistent
viremia and chronic, mild liver disease, although cases of
childhood cirrhosis and hepatocellular carcninoma have
been reported. Adolescents may have a sustained neuroinflammatory activity that progresses into a more severe Ii ver
disease. 10
Since May 1990, all units of blood and blood products
have been tested for HCV antibody. Before routine testing,
the risk of transfusion-associated HCV infection was
estimated to be as high as I in 100. The estimate for
transmitting HCV is I in 80,000. II
CMV transmission is another potential infectious risk of
blood transfusions. Approximately 50% of the population
are potential transmitters of CMV. Fortunately, in the
majority of patients, CMV infection does not cause a
clinical illness.
However, two populations at risk for serious complications from CMV infection are neonates and immunocompromised patients. In infants born to mothers without detectable CMV antibodies, acquired CMV infections

can lead to atypical lymphocytosis, hepatosplenomegaly,
pneumonia, or death. In immunosuppressed children, such
as patients with oncologic disease and transplant recipients, CMY infection can cause life-threatening pneumonitis or hepatitis. Patients at risk for clinical CMV disease
should receive blood that has been screened for antibodies
to CMV. 8
Coagulopathy. Coagulopathy can occur during massive transfusion, which is defined as the replacement of
more than one blood volume. 12 During a rapid blood loss,
the body cannot replace more than a small fraction of
coagulation factors and platelets. Stored blood has also lost
platelets and coagulation factors, such as factor VIII, which
have become less acti ve. When multiple transfusions are
gi ven over a short period of time, it is generally recommended that for every three units of packed RBCs administered, the child also receive one unit of fresh frozen plasma
(FFP) and one unit of platelets. 13 Coagulation studies may
be done to determine specific component replacement.

Pharmacologic Therapy
Growth Factors. The development and usage of
engineered growth factors has dramatically changed the
support provided for RBC, WBC, and platelet stimulation.
Erythropoietin is a natural hormone produced by the
kidneys to stimulate RBC production. The genetically
engineered product (i.e., Procrit or Epo) is used for anemia
secondary to chronic renal failure, chemotherapy-induced
anemia, and for anemic Jehovah's Witness patients who will
not accept blood product transfusions. The product is
administered intravenously or subcutaneously.
WBC stimulation is promoted with granulocyte colony
stimulating factor (G-CSF, i.e., Neupogen) or granulocyte
macrocyte--colony stimulating factor (GM-CSF, i.e., Leukine). Its primary indication is prevention of chemotherapyinduced neutropenia. It also is administered for other causes
of neutropenia, such as drug-induced neutropenia or sepsis.
It may be administered intravenously or subcutaneously.
Other stimulating factors include platelet-stimulating
factor (e.g, Neumega), which may be administered for
postchemotherapy thrombocytopenia.
Immune Globulin Therapy. Indications for intravenous immune globulin (IYlg) administration in PICU
patients include primary and secondary immunodeficiency states, immune thrombocytopenic purpura (ITP), and
Kawasaki disease. Dosage and rate of administration of
IVlg depends on the product used. Current standard dosage
for ITP is I g/kg/day until therapeutic effect is noted (daily
infusion, up to 5 days). Research regarding giving lower
doses (e.g., 400 mg/kg/day) has proved efficacious for
patients with ITp' 14
Administration of IYIg requires an understanding of the
starting rate of each product and recommended titration of
the infusion rate to decrease the possibility of a severe
allergic reaction. Patients are assessed and monitored
closely for the spectrum of allergic reactions-mild to
anaphylaxis. Many reactions are rate dependent and subside
if the rate is slowed. If a patient has demonstrated a reaction,
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but has a continued need for IVIG therapy, premedication with diphenhydramine (Benadryl) and acetaminophen
(Tylenol) may prevent an allergic response.
Anticoagulants. Anticoagulants administered in the
PICU include heparin, low-molecular weight heparin
(LMWH) (e.g., Enoxaprin), warfarin (e.g., Coumadin),
tissue plasminogen activator (t-PA), or streptokinase (SK).
Table 24-6 summarizes these medications, including indications, dosages, laboratory tests, and implications for
nursing care. Specific information regarding heparininduced thrombocytopenia (HIT) and care of patients with
vascular access thrombi is discussed later in this chapter.
General nursing care for patients on anticoagulants
includes careful monitoring of platelet count and coagulation studies, avoiding intramuscular injections and plateletinterfering drugs (i.e., ASA and NSAIDs), observation for
frank and occult bleeding, and applying pressure (extended
time) for all venipunctures and line insertion sites.
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Mechanical Intervention
Apheresis. The term apheresis is derived from the
Greek word for removal. Apheresis is a therapeutic process
used to selectively extract abnormal blood components from
the circulation. It is also used to harvest peripheral blood
stem cells for storage and future transplantation, and for
single-donor platelet concentrate collection.
All apheresis procedures have certain basic principles in
common. Blood is withdrawn from the patient, pumped
through a cell separator that removes the desired component
by centrifugal force, and then returned to the patient. Each
procedure is labeled according to the major component
removed. Thus removal of leukocytes is termed leukapheresis, red cell removal is erythropheresis, and so forth.
Plasmapheresis, which is also called illlensive plasma
exchange, refers to the removal of plasma. 15
As with many advanced technologies, apheresis has been
used more extensively in adults than in children. However,

24·6 Anticoagulants
Indication

Dosage

Laboratory Testing

Nursing Implications

Prevention and/or treatment of DVT.
pulmonary embolus,
and venous or arterial thrombi

IV
0.75 mg/kg loading
dose IV over
10 min.
Initial maintenance dose
<I yr of age: 28
u/kg/hr
>1 yr of age: 20
u/kg/hr
Adjust heparin to maintai n APTT at 6085 sec

APTT
4 hr after loading dose;
every 4 hr until therapeutic level then
qid

If platelet count
<150,000 or bleeding

Same as for heparin
Patients in whom
venous access for
administration and
monitoring for standard heparin is
difficult

Treatment dose for
enoxaparin
(Lovenox)
<2 mo: 1.5 mg/kg/
dose ql2h
2 mo: 1.0 mg/kg/dose
ql2h
(Usual maximum dose
is 2 mg/kg q 12h)

CBC, PT, APTT at
baseline
Platelet count
Anti-factor levels
should be drawn
4-6 hr after SC dose
qd x 2 days
Weekly if therapeutic
level is reached

For platelet count
<150,000 or bleeding
occurs contact
physician

Same as for heparin
When patient has stable
APTT and can be
changed to oral
dosing
Patient who has
mechanical
valves

Oral
Day I: Loading dose
0.2 mg/kg (0.1
mg/kg following
Fontan or liver
dysfunction)
Day 2-4 loading doses
based on INR
response
(Dosage is age dependent and is adjusted
based on INR [usual
dose is 2.0-3.0 mg])

ProtimellNR
Measure daily for first
2-3 days, then
weekly after therapeutic level reached.
Consider monthly
checks if patient is
stable and on longterm therapy

Patient remains on
heparin with warfarin until lNR is
stable
Patients may require
dosage adjustments
because of dietary or
drug interactions
with warfarin

occurs, contact

physician; may be
secondary to liT

CBC, platelet count,
and PT qd

If!P7T. Activated partiallhromboplaslin lime; CBC. complete btood COUOl; OVT. deep vein thrombosis; INR. international normalized ratio; IV, intravenous;

~~ prothrombin time; SC. subcutaneous.
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pediatric apheresis use has increased substantially since the
early 1980s, with documented safety and efficacy for a
variety of conditions. Apheresis has been successfully
performed on very young and critically ill patients, but the
smaller and sicker the patient, the greater the risks
involved. ls - 18
Indications. The indications for apheresis in the PICU
patient are specific to the type of procedure. Plasmapheresis
is indicated for the following conditions.

I. HUS or thrombotic thrombocytopenic purpura (ITP).
Removal of circulating endotoxin andlor replacement of
normal platelet aggregating factors. Outcome has variable success rate in HUS but has documented efficacy
in ITP. 19.20
2. End-stage liver disease (immediately before transplant).
Removal of coagulant-poor plasma and replacement with
coagulant-rich plasma and cryoprecipitate, keeping the
patient euvolemic.
3. Autoimmune (including hemolytic disorders), hyperacute
GVHD posttransplant, Guillain-Bamf syndrome, and
acute hemolytic transfusion reaction. Removal of deleterious antibodies and immune complexes.
Erythropheresis is utilized for SCO patients in acute
crisis (especially acute chest syndrome) to remove sickled
RBCs and replace with normal RBCs. Leukopheresis is
primarily used for patients admitted with leukemia, with
WBCs fewer than ISO,OOO/mm 3 , at high risk for acute tumor
lysis syndrome, before administration of chemotherapy. The
procedure removes excessive leukocytes while leaving
RBCs and plasma.
Procedure. The preparation and implementation of
the apheresis procedure is typically the responsibility of the
apheresis team (usually a hematologist and a specially
trained apheresis nurse).
Vascular Access. The first, and often the most challenging, technical aspect to be considered in pediatric apheresis is the establishment of vascular access. A double-lumen
catheter is necessary to simultaneously remove and return
blood to prevent hypovolemia. Another line should be available for maintenance fluid and medication administration.
Priming and Anticoagulation. Priming of the
apheresis tubing for pediatric patients is usually accomplished with albumin or packed RBCs (PRBCs) because the
amount of extracorporeal blood necessary to fill the
apheresis equipment may represent a significant proponion
of the patient's blood volume (i.e., greater than 10%) and
priming with saline would dilute the patient's hematocrit
(Hct). Pediatric patients can become hypovolemic if the
tubing is not primed with a solution to replace the blood
being drawn off at the onset of the procedure. IS-I?
Anticoagulation with heparin and acid-citrate dextrose
(ACO) is required to prevent thrombus formation in the
tubing. It is crucial for nurses to monitor for side effects
(i.e., bleeding from heparin [decreased perfusion; hypotension)) and hypocalcemia from ACO/citrate toxicity.
Complications. There are a number of potential complications a~sociated with apheresis procedures in the PICU,
including hypovolemia, circulatory overload, hypocalcemia,

hypothermia, and bleeding. Patients are monitored carefully
for changes in condition to permit timely and appropriate
intervention. The apheresis team is responsible to manage
the apheresis procedure itself, whereas the critical care team
is responsible for patient assessment and monitoring.
Hypovolemia can occur if an excessive amount of the
child's blood is in the extracorporeal circuit, or from
depletion of albumin, causing a shift of fluid out of the
intravascular space. It is standard to have less than 15% of
the child's circulating blood volume in the circuit at any
given time?l The PICU nurse carefully monitors vital signs
and assesses perfusion for signs of shock. The rate of blood
removed may be slowed, albumin administered, andlor
fluids infused to correct hypovolemia.
The child who receives a large volume of albumin or
fluids in excess of amount infused may be at risk for
circulatory overload. Assessment for signs of fluid excess
includes increased central venous pressure (CYP), gallop
rhythm, crackles from pulmonary edema, andlor increased
postpheresis weight. The net fluid balance is calculated
postpheresis. Fluids during the procedure may be adjusted
or diuretics may be administered for symptomatic fluid
overload.
Children are at risk for hypocalcemia resulting from
loss of calcium in pheresed plasma and from citrate in the
anticoagulant, which inactivates calcium. Ionized calcium is
monitored during the procedure. Total calcium is inaccurate
because of fluctuating albumin. Calcium gluconate or
chloride is administered for clinical and/or laboratory signs
of hypocalcemia.
Hypothermia may result from the blood being circulated
in the extracorporeal circuit outside the body, exposed to
room temperature. This may exacerbate the temperature
instability of the critically ill child, especially those with
sepsis or neurologic compromise. Temperature is monitored
every 15 to 30 minutes and patients are assessed for other
signs of hypothermia such as bradycardia and shivering.
Caution is necessary when "cold" blood from the circuit is
infused into a right atrial line, which can cause severe
ventricular arrhythmias. Treatment includes increasing the
ambient room temperature, applying warmed blankets, and
potentially warming the circuit blood before returning it to
the patient.
A number of factors put the pediatric apheresis patient at
risk for bleeding complications, including preexisting coagulopathy, systemic anticoagulation, depletion of fibrinogen
and platelets owing to the apheresis process, and the
presence of a large intravascular line.
Prothrombin time (PT), partial thromboplastin time
(PIT), fibrinogen level, platelet count, Hct, and activated
clotting time (ACT) are measured before and after apheresis. These values help to determine the type and amount of
anticoagulant used during the procedure. The apheresis
nurse generally measures the ACT at the bedside at regular
intervals, and the citrate andlor heparin doses are titrated
accordingly. Normal ACT is 90 seconds; the desired ACT
during apheresis is usually 150 to 180 seconds. IS-I?
The child is monitored for clinical signs of bleeding
during and after the procedure. Platelets or other clotting
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factor transfusions may be necessary to replace those
depleted during apheresis. In rare instances, protamine
sulfate may be administered to reverse the anticoagulant
effects of heparin. All hematologic values are rechecked 24
hours after the apheresis procedure.

DISORDERS OF COAGULATION
Immune Thrombocytopenic Purpura
Etiology/Incidence. ITP is characterized by destruction of antibody-sensitized platelets by the reticuloendothelial system (RES), particularly the spleen. The child has
normal laboratory results, except for moderate to severe
thrombocytopenia «50,000/111).
ITP is acute in 80% of all pediatric cases, usually
following a viral illness. About 60% of children recover
within 4 to 6 weeks, and more than 90% recover within 3 to
6 months. 14 The true incidence is unknown, mostly because
the disease is transient. Children in the PICU may present
with primary ITP or secondary ITP from diseases such as
systemic lupus erythematousus (SLE) or HIY.
Pathogenesis. In most cases, ITP is mediated by
antiplatelet antibodies, resulting in an increased rate of
platelet destruction. The antibodies are also formed against
donor platelets. The spleen plays a major role in platelet
destruction; however, splenectomy is reserved for emergency treatment (e.g., uncontrollable hemorrhage in the
PICU patient).
Although serious bleeding is rare despite severe thrombocytopenia «30,000/111), critically ill infants and children
typically present with hemorrhagic symptoms, purpura, and
signs of platelet bleeding (i.e., petechiae). Hemorrhagic
blisters may be seen on the mucous membranes and lips.
Epistaxis is common. Infrequently, patients will have GI or
genitourinary (GU) bleeding. Intracranial hemorrhage is the
most feared complication, which occurs in 0.5% to 1.0% of
children, often at diagnosis. 22 Most children will have a
normal bleeding time and minimal symptomatology from
ITP alone when their platelet counts are greater than
30,000/111.
The natural history of ITP is more benign in children than
in adults. Treatment centers around conservative management until the condition improves sufficiently on its own.
Treatment for symptomatic patients (and those with platelet
counts less than 30,000/111) consists of steroids and immunoglobulins to suppress the immune response and prevent
platelet destruction. Splenectomy, although usually definitive therapy for ITP, is avoided because more cases of death
from postsplenectomy sepsis have been reported than from
hemorrhage in children with chronic disease 22
Hypervigilance is required in the assessment of children
with ITP, especially those with platelet counts lower than
30,000/111. Assessment includes observing for signs of
oozing and hemorrhage, as well as occult bleeding. Neurologic status, including level of consciousness and changes in
motor, sensation, and pupillary checks is monitored for
signs of intracranial hemorrhage. Pulmonary secretions, GI
content, and urine are observed and/or tested for occult or
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frank blood. If the patient has a distended abdomen, girth
measurements may be trended, and the patient evaluated for
GI bleeding. The skin and mucous membranes are assessed
frequently for signs of new bleeding. Invasive line and
venipuncture sites are observed for oozing and hemorrhage.
Bleeding is controlled, with additional pressure and dressings provided for extemal bleeding sites. Epistaxis control
measures are at the bedside. Protocols are institution
specific, but may include Neo-synephrine nose drops and
nasal packing material. In addition, ongoing monitoring is
required for the patient's coagulation and CBC results, type
and screen/cross-matching status, and availability of blood
products for the patient who has an emergent need.
Critical Care Management. ITP treatment includes
administration of steroids, TVIg or IV anti-D (i.e., Rhogam,
for Rh+ patients, or Winrho) to suppress the antibody
response to platelets. Emergent treatment for hemorrhage
includes transfusion of platelets because the patient may
receive a transient rise before antibody destruction of the
donor platelets. Transfusion of platelets is followed by
steroid and immunoglobulin administration to enhance the
platelet effect. Splenectomy is reserved for the emergently
bleeding patient or the patient who is at high risk for
bleeding and who is refractory after 24 to 48 hours of
supportive management (steroids and immunoglobulins).22
High-dose steroid administration, (methylprednisolone
30 mg/kg/day, or Prednisone I to 2 g/kg/day), in divided
doses and IVlg I g/kg/day are standard therapy for patients
who are at high risk for bleeding. For patients who are
Rh positive, intravenous Anti-D (Winrho), may be administered at an initial infusion dose of 25 to 50 Ilglkg.
Infusions of immunoglobulins may be repeated on subsequent days, following platelet counts closely. IV Anti-D
has demonstrated a 48- to 72-hour delay before the platelet
count increases, but has also demonstrated fewer reactions
than IVIg. 23
Patients are observed closely for signs of potential
infection because the patient will be immunosuppressed on
steroid therapy. Guidelines for the administration of IVIg
are followed with close monitoring for the occurrence of
allergic reactions.
Plasmapheresis may be considered in addition to steroid
and immunoglobulin therapy to provide an acute effect.
Plasmapheresis alone would be insufficient because the time
required to have an effect on the platelet count rise would
take about 2 to 5 days.22
Androgen therapy (i.e., danazol) and monoclonal antibodies have been used to decrease platelet antibody
production. Currently, these agents are not standard therapy
for the critically ill child with ITP. 22 .23

Disseminated Intravascular Coagulation
Etiologyllncidence. DIC is not a distinct disease, but
rather an abnormal coagulation syndrome which occurs
secondary to another disease process. 19.24 It is characterized
by excessive use of coagulation factors that exceeds the
ability to replenish these factors and results in the rapid
production of thrombin and activated factor X or excessive
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bleeding as a result of failure of clot formation. The onset
of DIC is usually preceded by massive activation of the
hemostatic processes. The leading cause is infection. Many
bacterial processes invoke activating factors that initiate the
intrinsic coagulation system. Endothelial and tissue damage
also enhance intrinsic stimulation as well as acti vate the
extrinsic coagulation pathway.
DIC may also occur secondary to shock, burns, malignancies, fat emboli, bemolytic transfusion reactions, or
immune disease. Other precipitating factors are hypoxia,
acidosis, and hypotension. DIC has actually been reported to
complicate more than 100 clinical disorders. 25
Pathogenesis. In DIC, there is acceleration of normal
coagulation, but the end result is bleeding. Excessive
production of thrombin and plasmin degrades fibrinogen to
fibrin, leading to further activation of the coagulation
system, deposition of fibrin in the microvasculature, activation of the fibrinolytic system, and platelet activation.
Consumption of clotting factors and platelets occurs and, as
the process continues, fibrin split products (FSPs) are
produced. If FSPs are not cleared from the circulation by the
RES, anticoagulation will be enhanced. Normally the RES
removes fibrin, activated clotting factors, endotoxins, and
FSPs from the circulation. Dysfunction of the RES owing to
shock or liver disease impairs removal of these substances.
leading to hypercoagulabiliry and Ole. With an increase in
circulating FSPs, there is decreased platelet function and
adherence, inhibition of thrombin, activation of complement, and further endothelial damage. The development of
microvascular thrombi and bleeding leads to cellular ischemia (Fig. 24-3).
The clinical presentation of DIC varies dramatically from
one patient to another. Onset may be sudden or gradual. It
may be difficult to differentiate clinical signs from those of
the underlying disease state. DIC may be suspected only
because of its known association with certain pathologic
states. Bleeding is the most obvious clinical sign of DIC. In
children, abnormal bleeding is often identified from ecchymoses or petechiae or in oozing from intravenous and
venipuncture sites. 19

Fig. 24-3 The pathophysiology of DIe. (From Dressler OK:
Patients with coagulopathies. In Clochesy 1M et ai, eds: Critical
care nursing. Philadelphia, 1992, WB Saunders.)

In its most extreme case, the child with DIC shows pallor
and circulatory failure, which is manifested by tachycardia
and hypotension. Purpura and overt bleeding that may
involve the pulmonary, cerebral, and intraventricular systems may be seen. In addition, thrombosis of the central and
peripheral veins may lead to gangrene and tissue necrosis.
Abnormal serum coagulation values are an early indication of Ole. Typical findings include anemia with RBC
fragmentation, thrombocytopenia, and prolonged PT, PTT,
and thrombin time. An increase in FSPs is the cardinal sign
of DIe. The greatest degree of diagnostic specificity is the
measurement of the o-dimer FSP fragment, which is a
breakdown product of cross-linked fibrin in either plasma or
serum. 26 •27 Fibrinogen levels are usually decreased but may
be normal in some cases. Factors V and VIII are normal or
may be extremely elevated. The presence of fragmented
blood cells or schistocytes may be seen and indicates fibrin
deposition in small vessels and a thrombolytic occurrence.
Many patients in the PICU are at risk to develop DIe.
Thorough nursing assessment is essential in the prompt
recognition and subsequent management of patients with
DIC. The skin, mucous membranes, and all drainage or
secretions are observed for obvious or occult bleeding.
Vital sign changes that may be indicative of bleeding and
hypovolemia are tachycardia, tachypnea, and hypotension.
It is important to remember that hypotension is a late sign in
the child. Changes in mental status, such as irritability,
restlessness, and lethargy, are signs of decreased cerebral
perfusion related to hypovolemia and may present in the
child with bleeding related to DIC.
Critical Care Management. Critical care management of patients with DIC is supportive, aimed at stabilization of cardiac status and restoration of fluid and electrolyte
balance. Specific treatment of the underlying disorder
includes correction of shock, acidosis, and electrolyte
imbalance, and antibiotic therapy for bacterial infections.
Replacement of coagulation factors is often necessary.
PRBCs may be administered for active bleeding. In
addition, if the child is actively bleeding and has a low
platelet count «20,00011l1), platelets are administered to
increase the platelet count to 60,OOOIIlI. If the platelet count
is higher than 50,OOOllli and the child is still bleeding, FFP
10 to 15 mllkg body weight is administered to replace
consumed clotting components. Cryoprecipitate is administered for fibrinogen levels below 7S g/dl to elevate
fibrinogen levels. Table 24-4 presents specific implications
associated with the use of these blood products.
Nursing care for the child receiving these blood products
consists of monitoring for reactions to blood products, signs
of fluid imbalance, and vital signs, including central venous
pressure. Intake and output volumes are also strictly
measured.
Controlling and preventing further bleeding is of paramount importance in caring for the critically ill child with
DIC. Vital signs and laboratory studies are monitored
frequently for changes that indicate bleeding. All output,
including urine, stool, and nasogastric drainage, is tested for
the presence of blood. All invasive sites are closely observed
for oozing or active bleeding. Intramuscular injections and
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rectal procedures are avoided because of the increased risk
for bleeding.
Heparin therapy for DIC is controversial because its
efficacy has not been proven?8 The rationale for administering heparin is the enhancement of antithrombin (AT) III
activity, a major inhibitor of thrombin. With thrombin
activity inhibited, degradation of fibrinogen to fibrin is
impeded and further development of microvascular thrombi
is slowed or halted. The concern about heparin therapy is the
potential risk of further bleeding. When heparin is administered, the child receives an initial intravenous loading dose
of 25 to 50 units/kg, followed by a continuous intravenous
infusion of 5 to 10 units/kg/hour. Supportive therapy with
platelet, FFP, and cryoprecipitate transfusions is continued.
The most valuable test for evaluating the effectiveness of
heparin is the fibrinogen level. Even with a severe decrease
in fibrinogen, the level should rise to a normal or nearnormal level within 24 to 48 hours of effecti ve heparin
therapy. 19.29
Assessing the child closely for the exacerbation of
bleeding related to heparin is critical because this is the
indication for discontinuation of heparin therapy. The child
is also reevaluated regarding the need for further replacement of platelets and coagulation factors. Protamine sulfate
may be administered to counteract the effects of heparin (I
mg for every 100 units of heparin). However, this is only
rarely necessary owing to the short half-life of heparin.
The duration of heparin therapy for DIC may vary from
12 to 24 hours in conditions when the underlying disease
may be treated effectively. Other conditions, such as
leukemia, may require therapy for as long as 2 to 3 weeks.
Partial exchange transfusions with heparinized fresh
blood or reconstituted FFP and PRBCs may be necessary
if fluid overload becomes a persistent problem and the
child continues to require large volumes of blood or
clotting factors. Removal of selected mediators also may
break the vicious, self-perpetuating cycle of Ole. Nursing
responsibilities related to apheresis have been discussed
previously.

Heparin-Induced Thrombocytopenia
Etiology/Incidence. HIT is typically characterized
by a 50% or greater decrease in platelet count after 5 or
more days of unfractionated (standard) heparin therapy. If a
patient has been exposed to heparin in the recent past (less
than 100 days), the presentation is often rapid, within the
first 24 hours of reexposure. The platelet count nadir is
usually around 50,000 Ill; however, in some postoperative
patients, mean platelet counts may remain above 300,000
Ill. 30 The platelet nadir is not related to the risk of
thromboemboli.
HIT is an uncommon complication of heparin therapy that can cause significant morbidity and mortality
in the PICU patient. The incidence of HIT is about 5% in
adult patients receiving unfractionated heparin, and unknown in pediatric patients. Twenty percent of patients with
HIT can have paradoxically thrombotic complications,
which can be devastating, including loss of limb or death.
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HIT usually occurs in patients 5 to 15 days after beginning heparin therapy, but can occur earlier in patients with
prior exposure to heparin. An unexplained drop in platelet
count in a patient receiving heparin should raise the
suspicion of HIT.
Pathogenesis. HIT is caused by an antibody-antigen
reaction on the surface of platelets with unfractionated
heparin. The mechanism by which HIT predisposes to
thromboemboli is by the production of platelet-derived
microparticles that are released in the circulation and
activate the coagulation system. HIT is an intensely
prothrombotic condition.
The pediatric patient suspected of having HIT needs to be
assessed closely for signs of clotting (increased bruising,
thrombus formation), or bleeding if the platelet count is
extremely low. Blood samples from patients are tested for
induction of platelet aggregation by heparin or serum
evaluation for specific antibodies.
Critical Care Management. Any source of heparin,
including LMWH (though it rarely causes HIT), is discontinued. This includes arterial and central line flush solutions.
If there is no evidence of thrombosis and no indication for
continuation of anticoagulants, discontinuation of heparin
will result in the platelet count returning to normal.
If a thrombus is present and a need for continuation of anticoagulant therapy exists, medications such as
danaparoid (Orgaran) and Ancrod may be administered
because they have minimal cross-reactivity with heparininduced antibody. Minimal data regarding drug selection
exists for the pediatric population.

Vascular Access Thrombi
Etiology/Incidence. The small size of a central venous catheter lumen predisposes the infant and small child
to the development of thrombi that can occlude the catheter.
Central line occlusion can be caused by chemical-related
thrombi, which develop from precipitates formed when incompatible solutions mix, and blood-related thrombi, which
are caused by inadequate flow rate or flushing of the lumen, with subsequent platelet aggregation and thrombus
formation.
Pathogenesis. Central venous catheters are thrombogenic because they are foreign to the body, they damage
vessel walls and disrupt blood flow, and some infusions
injure the vessels. Central venous catheter thrombotic
complications include clots at the tips that impair infusion or
withdrawal of blood, fibrin sleeves that are not adherent to
vessel walls but may occlude lines, and deep venous
thrombi that adhere to vessel walls with partial or complete
obstruction. 3o
The most common presentation is the child with a central
catheter from which blood cannot be withdrawn or into
which fluids cannot be infused. The obstruction may be
present in one or all lumens. Diagnostic work-up after
failure to obtain line patency with antithrombotic instillation
should include a venogram or Doppler ultrasound.
Emergent signs of superior vena cava syndrome may also
be present if a large vessel thrombus occludes venous
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ANEMIAS
TABLE

24-7

Vascular Access Occlusion

Therapy
Local Instillation
Amount

Guidelines

2 ml to each lumen
(or volume
required to fill
lumen)

Dwell x.l hr
Aspirate and flush
with NS
Repeat x I if
needed

3000 lUlml to fill

Dwell x I hr
Aspirate and flush
with NS and
attempt to aspirate blood
Consider administering antihistamine and
acetaminophen
to decrease
potential for
allergic reaction

lumen
(1.8-2.5 ml per
each lumen)

drainage from the upper body. Immediate diagnostic tests
include a venogram, and possibly a V/Q scan.
Critical Care Management. Prevention of central venous catheter occlusion requires adequate flushing, especially between incompatible medications, and
adequate infusion rates to keep lumens patent. Early
detection of line problems, including slow blood return,
mandates an increase in flushing frequency for heparinlocked ports, or early instillation of an antithrombolytic
agent.

Despite all efforts to maintain catheter patency, thrombi
may develop. If the line is blocked without evidence of
clinical compromise, an attempt is made to "dissolve" the
clot, using SK, which has a high allergic reaction potential,
or t-PA. Table 24-7 provides instillation guidelines for these
agents. Small local occlusive thrombus «I em) are treated
with local low-dose thrombolytic infusion therapy for 24 to
72 hours, or more rapidly if immediate central line patency
is required.
If the catheter is still not patent after local instillation, or
if it has occluded a: second time, further work-up is
indicated. If a large vessel thrombus is suspected, a
venogram or Doppler ultrasound evaluation is performedY
Close monitoring of coagulation studies (PT, APTT, and
fibrinogen) every 8 hours is performed after initiation of
therapy. Assessment for signs of bleeding (frank and occult)
and signs of movement of the thrombus (increased respiratory distress, or ECG changes secondary to pulmonary
embolus) is essential.
If pulmonary embolus is suspected (or documented by
V/Q scan), the central line is either left in place or
removed, depending on patient status, and heparin therapy
(followed by 3 months of Coumadin), or LMWH is
indicated. 33

Anemia is defined as a deficiency in RBCs, Hgb, total
volume, or any combination of the three, with the primary
problem of insufficient oxygen transported on Hgb to meet
cellular demand. 1.32 Patients with anemia may present to the
PICU as an emergency or with an acute exacerbation of a
chronic anemia. Overall, the main problems seen in children
with anemia of any etiology are ineffective gas exchange,
altered tissue perfusion, and altered fluid volume. Nursing
care is directed toward assessment and management of these
problems.
Anemia results from an excessive loss or destruction of
blood, an inadequate production of Hgb and RBCs resulting
from bone marrow failure or a deficiency state, or a
combination of both. 34 The pathophysiologic process producing signs and symptoms of anemia primarily relates to
the decreased oxygen-carrying capacity of the RBCs,
resulting in inadequate oxygen to meet tissue demands.
When a patient has excessive blood loss, pathophysiologic
changes occur due to hypovolemia, with inadequate cardiac
output for tissue perfusion.
The anemias seen in children are reviewed in Box 24-2
and discussed briefly in this section. SCA is discussed in
more detail because children with this disease present to the
PICU more frequently than do children with other types of
chronic anemia.

Anemia Related to Blood Loss
Etiology/Incidence. Acute or chronic blood loss
may produce anemia. With acute blood loss, the anemia is present after the loss of blood volume is replaced with extracellular fluid (ECF). Chronic blood loss
produces anemia when the body has expended its iron
reserve.
Pathogenesis. The clinical presentation of a child
with anemia related to blood loss varies greatly. Those with
chronic anemia often adapt to a low Hct and Hgb without
compromise. On the other hand, a previously healthy child
who has a sudden and dramatic reduction in Hct and Hgb
may present as an acutely ill child in respiratory distress/
failure and shock and require aggressive intervention.
Clinical manifestations of acute hemorrhage include signs
of shock (i.e., decreased level of consciousness, pallor, cool
extremities, poor peripheral pulses, prolonged capillary
refill, with a normal or low blood pressure, and possibly
respiratory distress symptoms resulting from inadequate
oxygenation). Bleeding may be obvious, with external
hemorrhage, or hidden with internal bleeding until perfusion
and oxygenation are severely compromised.
Laboratory tests to evaluate this type of anemia include
a CBC with RBC indices, platelet count, PT, PTT, serum
fibrinogen level, and FSP. During and shortly after an
episode of bleeding, the platelet count and serum fibrinogen
level may transiently decrease. The Hct and Hgb remain
relatively stable in the acutely bleeding child because 24 to
72 hours are necessary for the Hct and Hgb levels to
equilibrate and accurately reflect the total amount of
blood loss.
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Hemolytic Anemia .
· Box 24-2

~ Classification of Anemias of Childhood
A. Abnormal RBC production
I. Disorder of proliferation/differentiation
a. Aplastic anemia
b. Pure red cell aplasia
c. Erythropoietin deficiency
2. Disorder of DNA synthesis
a. Vitamin B '2 deficiency
b. Folate deficiency
3. Disorder of Hgb synthesis
a. Iron deficiency
b. Thalassemia
B. Increased RBC destruction
1. Intrinsic RBC abnormalities
a. Membrane defects
Hereditary spherocytosis
Liver disease
b. Abnormal red cell metabolism
Glucose-6 phosphate dehydrogenase deficiency
Pyruvate kinase deficiency
2. Extrinsic abnormalties
a. Mechanical destruction
Microangiopathic hemolytic anemia
Traumatic hemolysis (cardiac valve prosthesis)
b. Infection
Bacterial
Viral
Parasitic
c. Antibody-mediated
Alloimmune hemolytic disease of the newborn
Drug reaction
Autoantibody-mediated destruction of erythrocytes
d. Hypersplenism
C. Blood loss
I. Traumatic or gastrointestinal hemorrhage
2. Surgical
From Nugent OJ, Taranrino MD: Hematology-oncology problems in the
intensive care unit. In Fuhrman BP, Zimmennan 11, eds: Pediatric critical
care. 51 Louis, 1992, Mosby.

Critical Care Management, Treatment for acute
blood loss is aimed at restoring intravascular volume,
initially with crystalloid solutions, followed by blood. The
indication for RBC transfusion in the hemorrhaging patient
is impaired oxygen delivery to end organs. 1 Patients
primarily receive PRBCs as the component of choice. These
may be given concurrently with FFP if plasma coagulation
factors are also needed.
Chronic anemia is generally well tolerated, and transfusion is not usually necessary unless the Hgb falls below
6 to 7 g/dl. Because extracellular volume (ECV) is
increased in the child with chronic anemia, caution is taken
if the patient is transfused because volume overload is a
potential risk. The child is assessed carefully for congestive
heart failure and pulmonary edema during transfusion
therapy.

Etiology/Incidence. The average lifespan of a RBC
is 100 to 120 days. About I% of RBCs are removed from the
circulation each day and the same percentage is replaced by
new red cells (reticulocytes) released from the bone marrow.
Hemolytic anemia results when RBC destruction is abnormally high and the bone marrow compensatory mechanism
cannot keep pace with the loss of RBCs. Hemolysis of
RBCs may be caused by a variety of etiologies, as described
in Box 24-2. Causes of hemolysis can be attributed to
factors extrinsic to RBCs, such as in microangiopathic
hemolytic anemias (e.g., HUS and ITP), infections, and
autoantibodies (e.g., SLE). Intrinsic RBC defects may also
cause hemolysis, including hemoglobinopathies such as
glucose-6 phosphate dehydrogenase (G6PD), thalassemia,
and spherocytosis.
Pathogenesis. The child may have presenting symptoms, which vary from typical symptoms of mild anemia to
life-threatening complications from acute loss of oxygencarrying capacity and compromised tissue perfusion as
previously discussed.
Because hemolysis of RBCs is the cause of this anemia,
diagnosis is based on the fact that RBCs are undergoing
premature disruption. A decreased (or often unmeasurable)
haptoglobin, elevated lactate dehydrogenase (LDH), an
elevated reticulocyte count, and elevated serum levels of
unconjugated bilirubin are seen. Erythroid hyperplasia and a
decrease in the granulocyte to erythrocyte level are revealed
in examination of the bone marrow.
Critical Care Management. If the child is experiencing critical signs of diminished oxygenation and/or
tissue perfusion, PRBCs are administered. Blood products
are not ordered based on a specific number, but based on
cliniCal need for the patient with critical organ perfusion
problems. If the child is experiencing an autoimmune
hemolytic reaction owing to an underlying disorder such as
lupus or lymphoma, a cross-match may be unreliable. There
is an increased risk of severe transfusion reaction secondary
to underlying alloantibodies that are not able to be detected.
When required, transfusions should be given cautiously
because the transfused RBCs are also subject to destruction.
However, if the anemia is causing hemodynamic instability,
the child is transfused with type-specific blood in a sufficient
amount to stabilize the cardiovascular system, in spite of
incompatibility. Close assessment for fluid overload is
required because the child's ECF volume may be expanded
as a result of compensatory mechanisms to meet oxygen and
perfusion demands.

Aplastic Anemia
Etiology/lncidence. Aplastic anemia refers to a pronounced reduction in the number of RBCs, WBCs, and
platelets resulting from hypoplasia or aplasia of the bone
marrow in the absence of malignant disease. This type of
anemia may be congenital or acquired, resulting from
medications, infections, chemical exposure, or radiation.
There are many specific etiologies for aplastic anemia,
which include infections (e.g., Epstein-Barr virus and
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hepatitis), drugs (e.g., chloramphenicol), and idiopathic
causes. The majority of cases are idiopathic. 1
Pathogenesis. Children show the classic signs of a
low blood count. Anemia, pallor, and fatigue may be present
because of a decreased RBC count; increased susceptibility
to infections from a low WBC count; and ecchymosis,
petechiae, and epistaxis resulting from a low platelet
count. Bone marrow biopsy reveals a marked reduction in
all cells. Children with severe aplastic anemia may present
to the PICU with signs of decreased oxygenation resulting
from a reduction in the oxygen-carrying capacity of the
blood, cardiac failure, overwhelming infection, or massive
bleeding.
Critical Care Management. The treatment priority
for the child with life-threatening complications of aplastic
anemia is cardiopulmonary stabilization. RBC transfusions
are administered and platelet transfusions are indicated for
the child with signs of severe bleeding (e.g., GI bleeding).
All blood products are irradiated and filtered before
transfusion because of the risk of postlransfusion GYHD
related to sensitization of the recipient to HLA antigens in
the donated blood. Infections are treated with broadspectrum antibiotics or antifungal agents, if a fungal
infection is present.
Treatment specific to aplastic anemia includes androgen
therapy, immunosuppressive therapy, and bone marrow
transplantation. Bone marrow transplantation is the treatment of choice if a compatible donor is available. Chapter
25 provides information on the care of the child receiving a
bone marrow transplant.

Sickle Cell Disease
Etiology/Incidence. SCD refers to a group of hemoglobinopathies distinguished by the development of sickled
cells in response to deoxygenation. SCA is the most
common cause of SCD. SCA is an autosomal recessive
disorder in which the child produces sickle hemoglobin
(Hb S) rather than Hb A. The child with sickle cell trait has
inherited a sickle gene (Hb S) from one parent and a normal
hemoglobin gene (Hb A) from the other parent. This child is
always a carrier of SCA, although the trait does not progress
to anemia.
When the child inherits two Hb S genes, SCA results. The
red cells of SCA contain up to 80% to 100% of Hb S. This
is a potentially fatal disease that occurs predominantly in the
black race.
Pathogenesis. Sickling of the RBC describes the
change of a normal round RBC to a sickle-shaped one. The
sickling process begins with the substitution of valine for
glutamic acid on the beta chain of the hemoglobin molecule.
This process produces Hb S, which is less soluble than the
normal cell when deoxygenated. The decreased solubility
causes Hb S to become more viscous and change to the
sickle shape.
Once RBCs sickle, they are more fragile and easily
destroyed. They cannot flow easily through the capillary
beds and tend to become clumped, causing obstruction and
impediment to blood flow. Tissue hypoxia develops, which

promotes further sickling. As the hypoxia worsens, infarctions and necrosis can develop (Fig. 24-4).
There are several factors that cause Hb S to sickle
(Box 24-3). Hypoxia is a major determinant. Characteristics
of blood flow can also increase the tendency toward
sickling. Under normal circumstances, the cardiac output of
the child with SCD is elevated. This compensatory mechanism ensures that the transit time of blood between the
capillary and the lung is rapid so that sickling cannot occur.
However, any pathophysiologic process that affects pressure
(such as hypotension or pulmonary hypertension) or increases resistance (such as vasoconstriction or increased
Hct) promotes sickling.
The clinical presentation of children with SCD varies
greatly. The symptoms seen are usually the result of
(1) hemolysis of the cells and the compensatory mechanisms invoked by the subsequent anemia, and (2) thrombi in
the small vessels of various organs resulting from the
sickling. General symptoms seen in the child with SCD
include weakness, pallor, fatigue, tissue hypoxia, and
jaundice, as the result of RBC hemolysis. The heart may
become enlarged because of the higher cardiac output
demanded by the chronic anemia. Thrombi from the sickled
cells may cause progressive damage to multiple organs,
including the eyes, liver, and lungs.

~

Box 24-3
Factors ThatMay Promote Sickling

1. Pressure-related
a. Hypotension
b. Pulmonary hypertension
2. Resistance-related
a. Vasoconstriction
b. Increased Hct (>35%)
3. Desaturation-related
a. Hypoxemia
b. Acidosis
From Eskenazi AE, Gordon JB, Bernstein ML: Hematologic disorders in the
pediatric intensive care unit. In Rogers Me, ed: Textbook of pediatric
;Illens;l'e care, cd 3, Bahimore. 1996. Williams & Wilkins.
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Fig. 24-4 The "vicious cycle" of progressive sickling causing
intravascular occlusion. (From Eskenazi AE, Gordon JB, Bernstein
ML: Hematologic disorders in the pediatric intensive care unit. In
Rogers Me, ed: Textbook of pediatric intensive care, ed 3,
Baltimore, 1996, Williams & Wilkins.)
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Diagnosis of SCD and sickle cell trait are made through
a variety of tests. The most commonly used is a hemoglobin
electrophoresis. This assay separates the various types of
hemoglobin and quantifies the percentages of various
hemoglobins present. There are less sensitive tests that
determine the presence or absence of Hb S; however,
positive results require further screening with hemoglobin
electrophoresis. Diagnosis may be made prenatally by using
fetal blood obtained in placental aspiration or photoscope.
Critical Care Management. A PICU admission
often signals a life-threatening episode with a high risk of
morbidity and mortality for children with SCD. Outcome is
often dependent on which organs are affected, the type of
virus and/or bacteria causing the infection, if one is present,
and the degree of progressive damage that has already
occurred because of the disease. Nursing care is critical in
managing the effects of the SCD crises.
The child with SCD may have signs of respiratory
distress for a number of reasons. Pneumonia and pulmonary
infarctions occur more often in this patient population.
Splenic sequestration may also cause respiratory distress
because the engorged spleen pushes up on the diaphragm.
Hypoxemia causes increased sickling and, in tum, causes a
vicious cycle of deoxygenation related to anemia and
vaso-occlusive crisis. 35
Assessment of breath sounds on a regular basis is
imperative. The patient is observed for signs of respiratory
distress, and the lungs are auscultated to detect decreased
breath sounds along with abnormal sounds. Monitoring
arterial blood gases on a regular schedule and continuous
monitoring of oxygen saturation is essential. Oxygen by
face mask or nasal cannula may be the only respiratory
support that is needed. However, if the blood gases do not
demonstrate improved oxygenation and the child's respiratory status continues to deteriorate, intubation and ventilatory support are necessary. Daily chest films are routinely
performed to monitor progression or resolution of pulmonary complications.
Vaso-occlusive crises can vary in location, duration, and
intensity. During a sickling event, vaso-occlusion prevents
oxygen and nutrients from reaching the tissues. Pain is often
the cardinal sign of a vaso-occlusive event. The pain has
been described as being tremendously variable and unpredictable in onset, location, character, intensity, and duration. 36 Pain is the most common reason for emergency
department visits and hospital admissions. 37 On admission
to the PICU, the child's pain and level of analgesia is
assessed. Pain assessment requires that the health care team,
including the patient and family, be able to quickly
differentiate between pain from vaso-occlusive crisis and
pain from other complications of SCD 36 Pain intensity is
quantified by a chosen pain scale and documented on a
flowsheet to monitor progression of the pain over time.
Drug therapy is the treatment of choice for pain
associated with SCD. Ibuprofen or acetaminophen is used to
initially manage mild to moderate pain. Codeine may be
added if these are not effective. Severe pain may be treated
with immediate-release or sustained-release morphine, oxycodone, hydromorphone, or methadone, given either orally
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or intravenously around the c1ock. 35 Another recommended
regimen for pain management is intravenous morphine
sulfate given every I to 2 hours around the clock?8 A
continuous narcotic infusion may be considered because
bolus injections may not provide satisfactory analgesia
because of the short plasma half-life of the narcotic.
Patient-controlled analgesia (PCA) is an accepted method of
pain management for children who are able to and want to
manage their own pain relief. Two methods of PCA were
compared in children with SCD. Children who received
high-dose PCA with a low basal infusion required less
morphine, had shorter lengths of stay, and had lower pain
scores on day 2 of hospitalization when compared with
children who received low-dose PCA with high basal
infusions. 38
Additional medications have been used to treat pain
associated with a vaso-occlusive crisis. Intravenous methylprednisolone given in high doses has been shown to
decrease the duration of severe pain. 39 ,40 A parenteral
antiinflammatory drug (ketorolac) has been used for crisis
pain and has the advantage of avoiding the risks associated
with narcotics. However, one study did not demonstrate a
synergistic analgesic effect for ketorolac; a lower morphine
dose was not able to be used. 41 A case report presented the
development of ketorolac-induced irreversible renal failure. 42 Further study is needed to evaluate the effectiveness
of additional medications.
Hypovolemia is often seen in children with SCD in the
PICU. Fluid replacement depends on the clinical condition
and the results of the serum electrolytes, Hct, and coagulation studies. Children with splenic sequestration require
crystalloid and RBCs immediately to restore circulating
blood volume. Children in aplastic crisis require PRBCs
because of their decreased Hct level. Crystalloids may be
the only fluid replacement in vaso-occlusive crisis, depending on the degree of sickling and whether or not there is
ischemia or infarction of the affected organ.
Patients with SCD tolerate a low Hct level extremely
well, and transfusions should be initiated only when
absolutely necessary. The Red Blood Cell Administration
Practice Guideline Development Task Force of the College
of American Pathologists recommends that RBC transfusions are indicated only to prevent recurrent refractory
vaso-occlusive complications, stroke, or during certain
illnesses (Box 24_4).43 The potential for significant complications related to multiple transfusions include infection,
iron overload, and alloimmunization. Iron overload results
from the addition of 200 to 250 mg of iron added to the
body's iron stores with each transfusion. This results in
increased serum ferritin levels. If serum ferritin levels are
greater than 2500 to 3500 mg/ml and the child still requires
transfusions, chelation therapy is given. 44 Chelation therapy
removes iron from body tissue and allows it to be excreted
from the body. Deferoxamine is administered as a continuous subcutaneous infusion over 5 to 6 hours several times
per week. 35
Hydroxyurea has been used as an alternative to blood
transfusions as a means to prevent recurrent stroke. Hydroxyurea reduces the frequency of vaso-occlusive crisis,
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Box 24-4

Partial Exchange Transfusion in,thePICU
I. Preparation
a. Decision to transfuse
b. Insertion of venous and arterial catheters (or two largebore venous catheters, if possible)
c. Blood sent to laboratory for:
i. Complete blood count
ii. Quantitative sickle cell preparation (this appears to
correlate well with the quantity of Hb S noted at
electrophoresis)
Ill. Electrolytes and calcium determination
iv. Cross-match with PRBCs (sickle negative)
2. Procedure
a. Volume of packed cells (2 x Hct x 0.7 x wt [kg])
b. Rate
i. Adjust intravenous line so transfusion occurs over 4
to 6 hr (more difficult if over 1000 ml are to be
exchanged)
ii. Withdraw blood at 10- to IS-min intervals from
arterial line or large-bore venous catheter
iii. Balance maintained within 5% of blood volume
(blood volume, 80 ml/kg)
c. Monitoring
i. Heart rate and blood pressure (continuously)
ii. Hematocrit (every 2 hr, and at last hour)
iii. Electrolytes, calcium (at last hour)
d, Endpoint
i. Hematocrit 33% to 37% (add FFP to remainder of
PRBCs if Hct is >35%)
ii, % Hb S is <40% (initial screening by quantitative
sickle cell preparation. followed by chromatography
or electrophoresis)
From Eskenazi AE, Gordon 18, Bernstein ML: Hematologic disorders in the
pediatric intensive care unit. In Rogers MC, ed: Textbook of pediatric
intensive care, cd 3, Baltimore. 1996, Williams & Wilkins.

though the mechanism is unclear, It has been shown that
there is an increase in the proportion of fetal Hgb cells
within 8 to 12 weeks of beginning treatment. 45 ,46
The nurse monitors for reactions to blood products and
for signs of fluid imbalance. Children with SCD may require
frequent transfusions during an acute episode, which
increases the risk of volume overload. It is'critical to closely
monitor the patient for signs of fluid overload. The use of
short-acting diuretics before or after the transfusion may
help to prevent this complication. Other nursing responsibilities include monitoring vital signs and laboratory values
and maintaining an accurate record of intake and output.
Exchange or partial exchange transfusions are often used
for acute complications of SCA. The advantage of an
exchange or partial exchange transfusion over a simple
transfusion is that there is less risk for volume overload and
a more rapid reduction in the percentage of cells containing
Hb S. Preoperative exchange transfusions may be performed
for children with SCD requiring surgery to reduce the risk of
postoperative vaso-occlusive complications. Apheresis may
also be used in the treatment of acute complications of SCD.

Prophylactic transfusions, done on a regular basis (every 3
to 6 weeks), are showing signs of promise in reducing
complications associated with SCD. 47 Nursing responsibilities related to these procedures have been discussed in the
previous section.
SCD is considered a multiorgan disease because of the
risk of ischemia or infarction of many organs caused by
sickling of RBCs and vaso-occlusion, The organs most
commonly affected are the spleen, kidneys, and bone
marrow; however, involvement of the lungs and the brain
can also occur. Children with frequent episodes of intravascular sickling are at risk for progressive organ dysfunction
because of decreased tissue perfusion, ischemia, and necrosis. All organs can be affected during an acute episode, as
well as chronically. A complete and ongoing assessment of
all organ systems during an intensive care admission is
imperative.
A newer method of treating SCD is bone marrow
transplantation. Transplantation changes the electropheresis
pattern in the child's Hgb toward the donor's pattern 35 It is
considered a curative therapy. Patients can experience
GVHD and some have died from this complication.
Complications of Sickle Cell Disease. The most
common clinical manifestations of SCD are vaso-occlusive
crises, sequestration crises, and aplastic crises. These may
lead to life-threatening complications such as acute chest
syndrome, stroke, acute anemia, and sepsis, which require
admission to the PICU.
Vasa-occlusive Crises. The most common reason for
admission to the PICU is vaso-occlusive crisis with
ischemia or infarction of the occluded organ. Vaso-occlusive
crisis is an acute, painful episode that is the result of
intravascular sickling, occlusion of small vessels, and tissue
ischemia and infarction. The onset is acute and may be
precipitated by infection, hypoxia, fever, acidosis, dehydration, change in climate, and psychologic factors. However,
a predetermining factor is often not identified. The joints
and the extremities are most often affected,
Therapy for the child with vaso-occlusive crisis is aimed
at removing the precipitating cause, treating complications,
and preventing further crises, Treatment is supportive and
includes hydration, antibiotics, and pain management, as
discussed above. Oxygen is provided if the child is
hypoxemic in order to prevent further sickling and possibly
promote conversion of sickled RBCs to normal shape.
Acute Chest Syndrome. Acute chest syndrome is
the development of a new pulmonary infiltrate in combination with fever or respiratory symptoms in a patient with
SCD 48 It is the result of sickling of RBCs in the pulmonary
vasculature, which may cause intrapulmonary shunting and
abnormalities in ga~ exchange, These patients are also at
high risk for pulmonary infarctions from recurrent sickling
and pneumonia.
Signs and symptoms include pleuritic chest pain, hypoxia, tachypnea, retractions, and nasal flaring. The radiographic picture is consistent with pulmonary infiltrates. This
may progress to a complete "whiteout" of lung fields and
respiratory failure. Fever and an increased WBC count may
be seen with both infection and infarction.
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Box 24-5

Indications for Red Blood Cell Transfusion
in Sickle Cell Disease

Acute Simple Transfusion
Symptomatic Allemias Resulting From Blood Loss
Complicated pain crisis not relieved by other medical therapy
Aplastic crisis
Splenic sequestration
Accelerated hemolysis (such as caused by delayed hemolytic
transfusion reaction, warm autoimmune hemolytic anemia,
or sickle crisis)
Preoperative preparation for most surgeries
Chronic Simple Transfusion
Prevention of recurrent occlusive stroke (<30% Hb S)
Selected sickle cell disease pregnancies (such as recurrent
fetal loss, multiple gestations)
Possible role in recurrent chest syndrome and skin ulcers
Partial RBC Exchange Transfusions
Acute or impending stroke, including transient ischemic
attack
Fat embolism syndrome
Unresponsive acute priapism
Acute, rapidly progressive chest syndromes
Preoperative preparation for some major surgeries and eye
surgery
Simon TL, AuBuchon J, Cooper ES el at: Practice parameters for the use of red
blood cell transfusions, Arch PatllOl Lah Med 122:130-138, 1999.

Therapy for acute chest syndrome follows the general
principles of therapy for vaso-occlusive crises. Pain relief
is critical to allow effective pulmonary toilet and coughing.
Antibiotics are recommended in any febrile child with
acute chest syndrome because untreated bacterial infections
can be devastating for children with SCD. Oxygen is
necessary for the hypoxemic child to promote nonnal
oxygenation and prevent further sickling. Partial exchange
transfusion may be necessary even in the child with mild
symptoms to halt progression of the disorder (Box 24-5).
Recurrent acute chest syndrome is a criteria for bone
marrow transplantation. 48
Cerebrovascular Accident. CVA is most often the
result of thrombosis in the major cerebral arteries in younger
children and hemorrhage in older children. CVA affects
about 5% of children with SCD. 49
The diagnosis of CVA is made on the basis of clinical
signs. Unfortunately, warning signs of an impending CVA
are rare. Some children may complain of headache or
dizziness, but often the first signs are apparent only with the
CVA itself. These signs may be hemiplegia, aphasia, speech
difficulties, visual disturbances, seizures, or coma.
Upon admission of a child with neurologic signs
suggesting CVA, assessment includes a history and a
detailed neurologic examination. A CT or MRI is done to
rule out a lesion such as subdural hematoma if the history
(such as recent head trauma) suggests this. The CT is done
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without contrast materials because they may precipitate
sickling by drying out the RBCs. If there are no signs of
increased intracranial pressure, a lumbar puncture may be
done to rule out an infectious process. Angiography is
postponed until the child's condition is stable and the Hb S
has been decreased to below 10% by exchange transfusion.
The most critical intervention for the child presenting
with a CVA is a partial exchange transfusion to prevent
progression of the CVA. Other therapy is supporti ve. If the
child has experienced a large infarction, close monitoring
for intracranial hypertension is necessary. Anticoagulant
therapy is contraindicated. Bone marrow transplantation
may benefit the child who experiences recurrent strokes. 50
Splenic Sequestration. Splenic sequestration is a
life-threatening complication of SCD and one of the leading
causes of death in children with this disease. There is
massive engorgement of the splenic sinuses with blood and
a significant amount of the RBC mass becomes trapped in
the spleen. The result is an abrupt fall in hemoglobin levels,
which may result in death from circulatory failure. The
etiology of this complication is unknown and the severity of
the crisis ranges from mild splenic enlargement with
minimal decrease in hemoglobin level to substantial splenomegaly, life-threatening anemia, and shock.
Splenic sequestration is normally seen in infants and
children younger than 6 years of age because these chi Idren
have not yet undergone autosplenectomy. Autosplenectomy
is a process by which repeated episodes of infarction reduce
the spleen to fibrotic tissue with deposits of iron. By age 5
years, most patients with SCA have become permanently
asplenic because of this process. 51
Children with splenic sequestration have acute, severe
left upper quadrant pain, vomiting, acute onset of anemia, a
rapidly distending abdomen, and signs of hypovolemia. On
physical examination, there is severe hypotension, cardiac
enlargement, and splenomegaly. The Hct is often half the
patient's normal value, and there is usually a rapid
reticulocytosis with increased immature RBCs and moderate to severe thrombocytopenia.
Therapy for this crisis is the immediate transfusion of
PRBCs to restore intravascular volume and oxygen-carrying
capacity. Once the cardiovascular status stabilizes, the child
usually improves rapidly. The spleen shrinks within a few
days, and the thrombocytopenia resolves. Splenic sequestration may recur, usually within 4 months of the initial
episode. Emergency splenectomy for an acute crises is not
indicated so long as prompt attention to crisis is provided.
Aplastic Crisis. Aplastic crisis is a condition that
results from a primary erythropoietic failure often associated with a parvovirus infection. The cessation of bone
marrow function causes the Hct to decrease dramatically. If
the anemia is severe and the child is symptomatic or if
general condition is compromised, an intensive care admission may be necessary.
The child with aplastic crisis usually appears listless and
pale. Hemoglobin values are decreased and the reticulocyte
count is less than 1%.
Most aplastic episodes are mild and require no treatment.
Recovery is usually spontaneous with an elevated nucleated
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RBC count, followed by reticulocytosis in I or 2 days.
PRBCs may be administered to maintain a hemoglobin of
8 gldl or more if the anemia is severe.
Sepsis. Infection is the most common cause of death in
children with SCD. These children are immunocompromised because of decreased splenic function with the loss of
its filtering capabilities and diminished antibody function.
Infections in children with altered splenic function are usually caused by organisms such as Streptococcus plleumoIliae, Haemophilus influellzae. and Neisseria mellingitidis. 52
Children with SCD seem to be at particular risk for septic
shock caused by S. pnewllOniae.
In children with SCD, a temperature higher than 38.5° C,
band count greater than 1000/mm 3 , or a high erythrocyte
sedimentation rate (ESR) are treated with antibiotic therapy
regardless of whether they appear septic. Children who
appear septic are treated with antibiotics regardless of their
temperature.
Other Crises. The child admitted to the PICU with
SCD may experience a variety of other crises. As with acute
chest syndrome and CVA, any crisis may be precipitated by
infection, dehydration, fatigue, and hypoxia.
Bony crises may involve the marrow or the cortex of the
bone itself. The small bones of the hands and feet are
commonly affected in infants and toddlers, giving rise to
dactylitis or hand-foot syndrome. In all bony crises, pain,
fever, and leukocytosis are present. With bone cortex
involvement, pain, redness, and swelling over the affected
area are seen.
Abdominal crises are often the result of occlusion of the
mesenteric vessels or vessels of some of the viscera, such as
the spleen or the kidney. These crises are characterized by
acute abdominal pain, fever, malaise, anorexia, nausea, and
an increased WBC count. These symptoms are often
indistinguishable from an acute "surgical abdomen," and a
thorough history and surgical evaluation are required.
Patients with "crisis pain" usually remain in stable condition or improve slightly with supportive measures such as
hydration and analgesics. Patients with an acute surgical
abdomen do not improve with these measures, and instead
become more acutely ill.
Therapy for other crises is supportive. Adequate hydration must be maintained. Antibiotic therapy is indicated if
there is redness and swelling over a bone. Pain management
is crucial with all crises. For the child with an abdominal
crisis, pain management prevents atelectasis that occurs
because of splinting of the abdomen.

MIXED DISORDERS
Hemolytic Uremic Syndrome
Etiology. HUS is a clinical syndrome characterized by
the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS is the most common
cause of acquired renal failure in children. Although the
primary systemic effects are hematologic and renal, there is
potential for multisystem involvement, primarily of the GI
and neurologic systems.

HUS does not appear to have a single etiology but is a
syndrome of diverse causes. Numerous agents and predisposing factors have been associated with HUS, including
infectious organisms, medications, and hereditary traits, but
causality has not been definitively established.
Etiologic investigations of HUS have focused on infectious agents, specifically verotoxin-producing organisms
such as Escherichia coli. One particular strain of E. coli
(E. coli 0157:H7) has been identified as the most common
pathogen associated with HUS; 80% to 90% of stools
cultured from children with HUS are positive for E. coli
0157:H7. The most common source of contamination has
been undercooked beef, although enterohemorrhagic strains
of E. coli have also been found in unpasteurized juices and
dairy products 53 . 55
Other infectious organisms that have been less commonly associated with HUS are Shigella dysenteriae.
Salmonella typhi, Camphylobacter jejuni. S. pneumoniae,
Yersinia pseudotuberculosis, and coxsackie virus. 53 .55 HUS
patients who have positive cultures for one of these
enteropathogens (including E. coli) at the onset of their
illness are "typical" HUS patients.
"Atypical" HUS etiologies may also include a familial
form of HUS caused by a genetic deficiency of prostacyclinstimulating hormone. Other potential precipitating factors
include medications (e.g., cyclosporin A, mitomycin, chemotherapeutic agents, oral contraceptives), and conditions
such as pregnancy, malignancy, lupus erythematosus, and
malignant hypertension. 53 •55 It is unclear which of these
may cause HUS, which are chance simultaneous occurrences, or which are related to some third unidentified causal
factor.
Incidence. HUS most commonly affects children between the ages of 6 months and 4 years. Approximately 80%
of the cases of HUS occur in children under the age of 5
years 56 .57 The majority of reported cases of HUS (75% to
80%) occur between the months of April and September. 56 •57 No explanation for the age distribution or seasonal
variation of HUS has been established.
The incidence of HUS in North America has been
reported as two to four cases per 100,000 children younger
than the age of 5 years. 57 Some studies have documented an
increasing incidence of HUS since the early 1980s. The
increased occurrence of HUS has coincided with an
increased appearance of verotoxin-producing strains of
E. coli as pathogens in humans.
Pathogenesis. The major underlying mechanism of
injury in HUS is vascular endothelial damage. In the
postenteropathic (typical) form of HUS, the verotoxin, or
shiga-like toxin (SLT) released by E. coli or other organisms
initiates the endothelial damage. 53 The kidneys are the
primary site of endothelial disruption, but thrombotic
microangiopathy may be found in all organs.
Typically, damaged endothelial cells within the vasculature of the renal glomerulus swell and become separated from the basement membrane, creating a widened subendothelial space. Fibrin, platelets, and lipids are
deposited in the subendothelial space, which when combined with the swollen endothelial cells, produce thick-
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ened glomerular capillary walls and thus reduced capillary
lumen size. Small arterioles become thrombosed as a result
of local intravascular coagulation activation. Thus the renal
vasculature becomes obstructed by endothelial swelling
and/or thrombi, resulting in a reduced filtering surface and
renal ischemia. Consequently, the glomerular filtration rate
is significantly diminished, and acute renal failure develOpS.58 Histopathologic studies of renal tissue in children
with HUS have demonstrated glomerular thrombotic microangiopathy and cortical necrosis. 58
Thrombocytopenia in HUS is the result of both aggregation and destruction of platelets within the damaged
microvasculature. Normally, an anticlumping substance
released from the endothelium (prostacyclin) keeps platelet
aggregation in check. However, there is evidence that in
HUS, inappropriate platelet aggregation is facilitated by
diminished prostacyclin activity. "Familial" HUS may be
seen in patients who have a hereditary prostacyclin deficiency. The mechanism of prostacyclin inhibition in other
forms of HUS is unknown. More recently, studies have
demonstrated an increase in large von Willebrand factor
multimers in the HUS patient, which may be responsible for
systemic platelet aggregation and adherence. The result is
that significant numbers of platelets are "trapped" in
multiple microvascular thrombi or are injured and removed
from the circulation by the spleen.59 The pathogenesis of the
hemolytic anemia of HUS is also related to renal endothelial
disruption. Erythrocytes are mechanically damaged as they
pass through the swollen and occluded arterioles. The spleen
and liver remove these fragmented RBCs from the circulation, causing a progressive and severe anemia. An increase
in von Willebrand factor multimers have also been implicated in causing hemolysis because they promote adhesion
of young erythrocytes to endothelial cells.S9.60 The body
attempts to compensate by accelerating RBC production, as
evidenced by reticulocyte counts, which are often increased
2% to 20%.53
Although the kidneys are the primary location of
pathologic changes in HUS, extrarenal involvement occurs
in a significant proportion of patients. The GI system is
actually the first site of physiologic derangement in most
cases of "typical" HUS. Hemorrhagic colitis, frequently
caused by E. coli, precedes the onset of HUS in up to 90%
of patients. The mechanism of bowel injury is similar to the
renal pathophysiologic process: endothelial disruption and
thrombosis of the microvasculature, leading to ischemicl
necrotic tissue damage. GI complications of HUS include
perforation, obstruction, stricture, or intussusception of
the bowel. s3 It has recently been recognized that in up to
20% of HUS patients, the pancreas suffers comparable
hemorrhagic and necrotic damage. These microangiopathic
changes are hypothesized to be endotoxin mediated. Similar
hemorrhagic, thrombotic, and necrotic lesions have been
documented in the CNS, lungs, adrenal glands, and hearts of
some patients with HUS. S3 .58
HUS is not limited to renal, hematologic, and Gl
involvement. Approximately 30% of patients with HUS
experience neurologic dysfunction because of involvement
of the microvasculature of the brain and the direct neuro-
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logic effects of the toxins, similar to TIP, where the brain is
the primary affected organ. Neurologic sequelae may
include hemiparesis, cortical blindness, and a persistent
state of altered consciousness. 53
In the majority of HUS patients, the syndrome is
preceded by a prodromal illness. Approximately 90% of
children diagnosed with HUS have experienced gastroenteritis with some combination of diarrhea (usually bloody),
vomiting, and/or abdominal pain at the onset of their illness.
Less commonly, the diagnosis of HUS may be preceded by
an upper respiratory infection or by no specific signs of
illness at all. The average interval between onset of diarrhea
and diagnosis of HUS is I week. Patients with nondiarrheal,
"atypical" HUS are less likely to present with a prodromal
illness condition and commonly have a more aggressive
course. 53 Approximately one third of HUS patients are
febrile in the prodromal period 61
Initial physical assessment of the child with HUS
generally reveals a pale, lethargic, and/or irritable child,
with evidence of abdominal pain or tenderness. Inspection of the skin may reveal hemorrhagic manifestations, such as bruising, petechiae, or purpura. Admission
vital signs are usually within normal limits for age,
although some children may have tachycardia and/or
tachypnea if anemia is severe at presentation. Tachypnea
may also reflect an attempt to compensate for metabolic
acidosis resulting from renal failure. Hypertension may be
present, but usually it develops later in the course of the
disease.
Up to 10% of children with HUS present with seizure
activity. The etiology of seizures at presentation is usually
hyponatremia, but seizures may be the result of early CNS
microangiopathy.s7
Oliguria or anuria is present in more than 60% of
children who develop HUS. 56 Urine is usually grossly
hematuric. Laboratory analysis confirms acute renal failure, with rapidly increasing blood urea nitrogen (BUN)
and creatinine levels. It is not unusual for a child with
HUS to have a BUN level higher than 100 mg/dl and
a creatinine level higher than 4 mg/dl within the first
2 days of diagnosis. Urinalysis reveals proteinuria and the
presence of urinary casts. Serum electrolyte values may be
initially normal, or consistent with acute renal failure
(decreased sodium and calcium, increased potassium and
phosphorus).53
Hematologic analysis helps to confirm the diagnosis of
HUS. Microangiopathic hemolytic anemia is present. with a
Hct typically less than 25%. Microscopic examination of the
peripheral blood film reveals typical schistocytes (fragmented red cells). Thrombocytopenia (platelet count less
than lOO,OOO/I.tl) is present, but other coagulation values
(PT, PTT) are typically within normal limits, differentiating
this disorder from DIe. Commonly, the CBC also reveals
leukocytosis upon presentation.s'
If stool cultures are sent, the most common organism
identified is E. coli 0157:H7. Other potential enteropathogens are listed within the discussion of HUS etiologies.
Cultures from other sites are generally negative at
presentation.
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Diagnostic work-up of the patient with HUS is generally
limited to laboratory analysis. Occasionally, abdominal pain
and colitis lead to an exploratory laparotomy before the
diagnosis of HUS is made, especially if the rest of the
clinical picture is not consistent with "typical" HUS 53
Critical Care Management. Management of the
child with HUS is primarily focused on rapid recognition,
supportive care, and treatment of complications, which include acute renal failure, anemia, CNS dysfunction, and GI
symptoms. Goals of management focus on restoration and
maintenance of: (I) fluid and electrolyte balance, (2) renal
function, (3) optimal cardiovascular function and blood
pressure, (4) adequate RBC volume and functional platelets,
(5) neurologic function, and (6) GI function and nutritional
support.
Initially, the child with HUS may present with dehydration resulting from GI losses (diarrhea, vomiting)
and decreased oral intake. As the disease progresses, GI
losses generally diminish, and the child is at risk for fluid
overload from acute renal failure. Treatment consists of
strict intake and output with intravenous fluid adjustment, renal replacement therapy, and management of
hypertension.
Initial fluid replacement with intravenous solutions is
administered cautiously, with careful monitoring of serum
electrolytes and an ongoing assessment for fluid overload.
Subsequently, the patient with HUS is monitored closely for
signs of hypervolemia, including peripheral edema, tachycardia, hypertension, pulmonary edema, and increased
weight. In the oliguric or anuric patient, fluid intake is
restricted to insensible losses (approximately 30% maintenance) plus urine output replacement.
Nursing responsibilities include assessing for signs of
pulmonary edema, such as rales, hypoxemia, frothy sputum,
tachypnea, and increased heart size and infiltrates, which are
seen on chest radiographs. Serum electrolyte values are
monitored closely (every 6 to 8 hours), along with assessment for complications of electrolyte imbalances (e.g.,
hyperkalemia, hyponatremia). Careful monitoring and treatment of hyponatremia with fluid restriction and dialysis are
critical to electrolyte balance.
The majority of critically ill patients with HUS require
dialysis during the acute phase of their illness. The decision
to dialyze a patient is not based on absolute criteria, but on
an overall assessment of the individual patient's status.
Indications for dialysis include one or more of the following: anuria for longer than 24 hours, hypertension, pulmonary edema, hyperkalemia, and severe azotemia. Some
clinicians initiate dialysis prophylactically for BUN concentrations greater than 100 to 150 mg/dl. 56
Patients with HUS may receive peritoneal dialysis (PD)
or hemodialysis (HD), or continuous veno-venous hemofiltration with dialysis (CVVHD). The advantages of PD
are that fluid is removed gradually, so that hemodynamic
stability is ensured, and that PD does not require vascular
access. However, there are a number of disadvantages to
PD as compared with HD or CVVHD for the HUS patient.
The high glucose solutions used in PD may cause

hyperglycemia, especially if the patient has pancreatic
insufficiency caused by HUS. Probably the biggest disadvantage to PD in this population is the risk of
precipitating or exacerbating the abdominal complications
associated with HUS.
The main advantage of HD, aside from avoiding
involvement of the GI tract, is that it provides more precise
correction of fluid imbalance, electrolyte values, and acidosis. One disadvantage is that patients who are hemodialyzed
must be systemically heparinized for each procedure, which
may transiently increase their risk of bleeding.
CVVHD has been used with good results as a primary
renal replacement therapy for HUS patients with severe GI
inflammation and bleeding. 62 Primary advantages are that
the GI tract is avoided, CVVHD can be accomplished
in younger patients because of small filter sizes, and
hemodynamic stability can be optimally maintained in
comparison to HD.
Optimization of cardiovascular function may include
antihypertensive medications, vasoactive therapy with inotropes and vasodilators, as well as treatment of severe
anemia, bleeding, and fluid overload as previously discussed. Management of hypertension in the patient with
HUS is a collaborative responsibility. In addition to fluid
overload, hypertension is exacerbated by excessive renin
release by the kidneys caused by decreased renal perfusion.
Antihypertensives are required to control blood pressure in
up to 40% of critically ill patients with HUS. 53
The primary risk factor for bleeding in patients with HUS
is thrombocytopenia. However, in addition to a decrease in
the absolute number of platelets, there is evidence that the
HUS patient's circulating platelets are hyporesponsive to
aggregating agents, implying an additional platelet function
abnormality.59 It has been established that the platelets of
uremic patients in general do not function properly;
however, it is unclear whether there is an additional
mechanism compounding this "malfunctioning" in HUS
patients.
The child with HUS requires close monitoring for signs
of bleeding, such as bruising, petechiae, oozing from
invasive line sites, epistaxis, or upper and/or lower GI
bleeding. Procedures that may promote bleeding, such as
intramuscular injections and rectal instrumentation, are
avoided. In addition, the child is assessed for signs of occult
bleeding, such as increased abdominal girth, increased pulse
and respiratory rate, diminished peripheral perfusion, a
change in neurologic status, or hypotension (a late sign of
hypovolemia).53
Blood component replacement is generally not aggressive in patients with HUS because there is evidence that
transfused platelets and RBCs suffer the same damage in the
microvasculature as the child's intrinsic blood components
and may exacerbate the risk of thrombus formation.
Consequently, RBCs are generally transfused only when the
Hct falls below 15% to 20%, or sooner if the Hct is falling
rapidly or if the patient is symptomatically anemic 56 Most
HUS patients receive at least one blood transfusion during
the acute phase of their illness. Platelets are usually not
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administered until the platelet count is below 10,000 to
20,OOO/lll, or if there is active bleeding.
All blood products are administered slowly and timed to
coincide with dialysis when possible, to minimize the risks
of circulatory overload. All patients are monitored for signs
of a transfusion reaction
There are a number of potential risk factors for neurologic dysfunction in the HUS patient. There is evidence that
the microangiopathic process that obstructs perfusion in the
renal vasculature can develop in the cerebral vasculature.
Thus there is a risk of microthrombi or even large thrombus
formation in the cerebral arterioles, potentially leading to
infarction. In addition, thrombocytopenia coupled with
hypertension puts the patient with HUS at significant risk for
an intracranial hemorrhage.
Seizures, affecting about 10% of children with HUS, are
treated with short-acting anticonvulsants, (i.e., benzodiazepines), followed by fosphenytoin or phenobarbital for
sustained seizure contro1. 56
Vigilance by the nurse is required to monitor for changes
that may indicate neurologic damage. This can be challenging because patients are typically lethargic and/or irritable
upon admission because of uremia, anemia, and/or a
postictal state. Signs of focal infarction or hemorrhage
include hemiparesis, seizures, change in motor strength,
cranial nerve deficits, and a change in level of consciousness. Signs of increased intracranial pressure include
decreased responsiveness to stimuli, pupillary changes,
change in respiratory pattern, (late) decreased pulse, and
increased blood pressure with widened pulse pressure. A
brain CT or MRI may be required to identify infarctions,
edema, or hemorrhage so that neurologic recovery can be
optimized.
If there is clinical or radiologic evidence of neurologic
deterioration, therapeutic modalities aimed at the removal of
circulating endotoxin and the normalization of plateletaggregating factors may be instituted. Fresh plasma infusion
and plasmapheresis are the two most commonly employed
therapies. Because plasmapheresis is so successful in
treating TIP, which has similar pathophysiology to HUS, it
may improve neurologic outcome. Case reports have shown
efficacy, but studies have not demonstrated clinical significance in outcome 59 .60
Collaborati ve interventions to optimize neurologic functioning include control of seizures with anticonvulsants and
electrolyte balance. Standard interventions to reduce or
prevent rises in intracranial pressure are instituted if the
patient with HUS demonstrates cerebral edema on CT or
MRI. The only modification for the anuric patient is that
osmotic diuretics are not used because they draw fluid into
the intravascular space, which can not be excreted, thereby
exacerbating hypervolemia.
The patient with HUS is at risk for GI complications
resulting from vascular endothelial damage, thrombi, and
necrosis of bowel tissue. Careful monitoring of the patient is
the cornerstone of managing GI complications. The child is
assessed for abdominal tenderness, cramping, and distension, especially as compared with baseline status upon

Hematologic Critical Care Problems

841

admission. Abdominal girth is measured and recorded
each shift, and all gastric output is tested for the presence
of blood. Ranitidine is administered to prevent gastric
ulceration.
If a paralytic ileus or an acute abdominal process
develops, the patient with HUS is kept on a nothingby-mouth (NPO) status and a nasogastric tube is inserted
to decompress the stomach. Approximately half the children with HUS require parenteral nutrition during the
acute phase of their illness. The GI tract may require
serial evaluation with kidney, ureter, and bladder (KUB)
x-ray and/or abdominal ultrasound examination. Signs of
an acute bowel infarction, perforation, obstruction, or necrosis include tachycardia, hypotension, acidosis, vomiting,
and abdominal distension. Surgical intervention may be
necessary. 56
Nutritional support with total parenteral nutrition (TPN)
is instituted early to stop catabolism present on admission,
especially with the patient with diarrhea and vomiting. Once
diarrhea and GI inflammation has resolved, enteral nutrition
(nasoduodenal or jejunal) is instituted with formula requirements calculated in light of renal compromise. 53 .56
Pancreatitis, with both endocrine and exocrine involvement, has been recognized as a potential complication of
HUS, presumably resulting from the same mechanisms that
injure renal, GI, and cerebraltissue. 56 It may be difficult to
evaluate the patient with HUS for pancreatitis because the
clinical signs, abdominal pain and vomiting, may be present
because of another etiology. Patients with these signs are
made NPO regardless of whether a definitive diagnosis is
made. Serum amylase and lipase levels are followed, but
because these enzymes are partially excreted by the renal
route, levels greater than four times normal are necessary to
diagnose pancreatitis in patients with renal failure. 56 Abdominal ultrasound examinations may be performed; enlargement and sonolucence of the pancreas is consistent
with pancreatitis.
The nurse assesses the patient with HUS for hyperglycemia resulting from pancreatic insufficiency, which may
necessitate exogenous insulin administration. The anuric
patient cannot be monitored for glycosuria; therefore serum
glucose is measured every 4 to 8 hours. Serum glucose is
maintained at 100 to 200 mg/dl with insulin administration
carefully titrated by the nurse.
Antibiotic therapy for HUS and hemorrhagic colitis
caused by E. coli 0157: H7 is controversial, with conflicting
study results as to benefit, or even showing adverse
effects. 56.58 Other therapies studied at various times include
heparin, thrombolytic agents, prostacyclin infusion, gamma
globulin, and vitamin E. None of these therapies has consistently proved effective for HUS, but some are still used
in cases of severe disease, especially with cerebrovascular
involvement.
The mortality rate from HUS is approximately 5%.57.63
Of children with a one-time occurrence of HUS, 60% to
80% recover completely. Another 10% to 30% are left with
long-term sequelae, which include hypertension, chronic
renal failure, and neurologic complications such as hemipa-
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resis, seizures, blindness, and cognitive deficits. Currently,
less than 5% of all patients studied progressed to end-stage
renal disease and renal transplantation, but recent long-term
studies show evidence that in some post-HUS patients, renal
function declines after apparent recovery.53.57
Extensive analysis has been done to identify patients at
high risk for a poor outcome from HUS. Poor outcome is
generally defined as chronic renal failure, neurologic
sequelae, or death. Some investigators differentiate between
typical (or classic) and atypical HUS when discussing
prognosis. The typical form, which has a better prognosis,
affects young children (usually younger than 3 years old),
has a prodrome of bloody diarrhea, occurs during the
summer, and is nonrecurrent. Hereditary and other atypical
forms of HUS have a poorer prognosis in terms of morbidity
and mortality.56
Other factors that have been statistically correlated with
a poor outcome are high neutrophil count upon admission
(which may reflect the degree of endotoxin exposure), short
diarrhea prodrome before admission (which may reflect
a higher infectious dose of circulating toxin), higher
Hgb count upon admission (more invasive disease may
prompt admission before hemolysis has occurred), seizures
upon admission, bowel necrosis during the acute phase, and
longer duration of anuria during the acute phase.57
Although it is stiLI difficult to predict the long-term
outcome for an individual patient, even limited prognostic
information may be useful in guiding therapies and in
counseling parents of patients with HUS in the intensive
care unit.

Thrombotic Thrombocytopenic Purpura
Etiology/Incidence. TfP has traditionally been considered an "adult" counterpart to HUS, very similar in
pathophysiology, but with the CNS being the primary
affected organ in TTP.
TTP has been reported rarely in children, with 16
case reports in a 1998 MEDLINE search. 64 The disorder can present in infancy or childhood, and relapses
can occur at varying intervals. Etiology is similar to HUS,
with a viral prodrome before presenting symptoms. Case
reports of TIP secondary to HIV infection have been
reported. 65
Pathogenesis. The basic process in both HUS and
TIP is the deposition of fibrin in the microcirculation with
subsequent microangiopathic hemolysis and thrombocytopenia. The pathophysiology is unclear; however, the most
consistent hematologic feature is platelet aggregation with
the presence of unusually large von Willebrand factor
multimers. 59.65
Thrombocytopenia is the major complication in TIP,
followed by hemolysis. Pathophysiologic changes in the
brain and microvasculature of other organs cause the
presenting signs and symptoms.
Children most commonly (about 50%) present with
neurologic symptoms, ranging from dizziness, weakness,
lethargy to obtundation, and hemiparesis. 65 Other symptoms

include fever and bleeding (epistaxis and/or bruising).
Hematuria, oliguria (or anuria), and bloody diarrhea are
seen less often. Laboratory values are similar to HUS, with
a low Hct and low platelet count.
Despite excellent assessment and critical care management, the outcome for TTP in children is discouraging, with
38% mortality in the 16 reported cases. Microthrombi were
demonstrable in all major organs at autopsy. No pretreatment characteristics were identified as prognostic indicators
of relapse. 65
The critically ill child usually presents with profound
neurologic impairment, along with hemorrhage and, often,
renal impairment. Assessment and nursing care include
neurologic system observation for changes in level of
consciousness and/or signs of hemorrhage, respiratory
assessment for adequate oxygenation and ventilation, close
observation for signs of renal failure with strict intake and
output and urine testing, and hypervigilant assessment for
signs of frank and occult bleeding. CBC and coagulation
studies are monitored frequently and interpreted with the
clinical assessment to determine the need for blood product
administration.
Critical Care Management. The mainstay of treatment for TIP is plasmapheresis and excellent supportive
care. Plasmapheresis has been shown to be much more
beneficial in treating patients with TIP, as opposed to
treating HUS. 19 Treatment with blood products, including
PRBCs, platelets, and fresh frozen plasma are the mainstay
of supportive therapy.61.65 Recognizing the consumptive
nature of the pathophysiology of TIP, in the presence of
active hemolysis, transfused RBCs are hemolyzed in the
same manner as native RBCs. Transfused platelets may also
be destroyed and cause more microthrombi. Other therapies
that have been used with varying success include corticosteroids, high-dose IVIg, vincristine, antiplatelet agents, and
splenectomy. 19
IVIg and antiplatelet agents and steroids are also
administered with the goal of halting the peripheral platelet aggregation. Remission has been demonstrated with
the prophylactic use of FFP without plasmapheresis. 65
Children with renal impairment who need dialysis are
treated in the same manner as those with HUS-with
peritoneal dialysis, HD, or CVVHD being the therapeutic
modalities.
Care of the TIP patient requires the same level of
nursing expertise that is required for any child with
multisystem failure. The child with TIP is usually very
critical, with profound neurologic, renal, and other system dysfunction or failure. Nurses require skills in caring
for the patient undergoing pheresis and/or dialysis therapies
as discussed in previous sections. Line placement for
dialysis!pheresis is difficult in terms of access and bleeding
status of the patient. Hemodynamic monitoring of the
patient with impaired cardiovascular function may be
required, especially for the unstable child during dialysis!
pheresis procedures. Cardiovascular support with titration
of vasoactive infusions to optimize cardiac output may be
needed. Intubation and mechanical ventilation is often
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required for airway protection and to provide optimal
oxygenation and ventilation in the neurologically impaired
child.

SUMMARY
Critically ill children may experience a wide range of
hematologic problems related to a variety of causes. Anemia
and thrombocytopenia also may be part of the pathologic
process that brings children to the PICU. Children's
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response to medical and nursing interventions depends on
their preexisting state, the severity of their illness, and
length of time before treatment is initiated.
Caring for these children requires a collaborative approach. It is imperative that the nurse caring for these
children be vigilant for subtle but significant signs that occur
because of the complexity of the patient's needs and the
potential for rapid changes in the patient's condition. Expert
nursing management is essential to maximize the potential
for a positive outcome.
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Oncologic Critical Care
Problems
Tammara L. Jenkins

In the past, few children with malignancy were admitted
to critical care units because there seemed to be little
benefit to providing aggressive care. However, with the
remarkable advances made in pediatric oncology, critical
care technologies, immunology, and the treatment of infectious diseases, more children are recovering from cancer and
complications related to malignancies and aggressive treatment modalities 3
Children with oncologic or hematologic disease are
typically admitted to the pediatric intensive care unit
(PICU) for complications resulting from either local or
systemic manifestations of malignant tumor or disease, or
effects of antineoplastic therapy.3.4 To fully appreciate the
unique care needs of a child with malignancy, critical care
nurses require an understanding of the child's underlying
malignancy, as well as the likely causes of life-threatening
complications.
Children with malignancy may present to the PICU with
dysfunction of one or several organ systems. This chapter
provides an overview of general complications associated
with malignancies and their treatment, as well as complications specifically related to solid tumors, leukemias, and
bone marrow transplantation (BMT). Because many of these
complications may have other etiologies not related to
cancer, this chapter focuses on how complications may
manifest and be treated differently in children with oncologic disease.

CARE OF THE NEUTROPENIC PATIENT
GENERAL COMPLICATIONS OF MALIGNANCY

Infection and Sepsis
Pericardial Tamponade
Acute Respiratory Failure
Neurologic Complications
Hemorrhage
Typhlitis
COMPLICATIONS OF SOLID TUMORS

Acute Thmor Lysis Syndrome
Superior Vena Cava Syndrome/Superior
Mediastinal Syndrome
Spinal Cord Compression
COMPLICATIONS OF LEUKEMIC DISEASE

Hyperleukocytosis
COMPUCATIONS OF BONE MARROW TRANSPLANTATION

Special Considerations in the Bone Marrow
Transplant Patient
Infection
Pulmonary Complications
Acute Graft-Versus-Host Disease
Veno-occlusive Disease
SUMMARY

CARE OF THE NEUTROPENIC PATIENT
The neutropenic child presents a unique challenge to the
intensive care unit (ICU) team. Children who receive
chemotherapeutic agents or radiation therapy or who
undergo BMT typically become both neutropenic and
thrombocytopenic at some point during the course of their
disease or treatment regimen. The risk of infection has been
shown to increase when the number of circulating neutrophils is less than lOoo/mm 3 , with the risk of infection being
directly related to the extent and duration of the neutropenic
state. 5 Severe neutropenia, defined as an absolute neutrophil

C

ancer has been perceived by many people, health
professionals included, as a "terrible, hopeless disease
that leads to certain death." 1 But today a degree of optimism
prevails. The treatment of childhood cancers has made
tremendous strides in recent years, with 65% of children
with cancer now surviving more than 5 years after
diagnosis? Many childhood malignancies that were once
universally fatal are now potentially curable, such as acute
lymphoblastic leukemia (ALL).
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count (ANC) of 500/mm 3 or less, is the single most
important risk factor predisposing them to infection. 6
The decreased number of neutrophils that occurs in
children with malignancy may be the result of the production of inadequate neutrophils by the bone marrow, as seen
in acute leukemias, or the production of abnormal granulocytes that are incapable of participating in phagocytosis.
Antineoplastic chemotherapy, radiation therapy, and other
pharmacologic interventions used in the treatment of
malignancies, such as steroid administration, may contribute
to immunosuppression and neutropenia. 6 In addition, the
myelosuppression that causes neutropenia typically causes
concurrent thrombocytopenia, placing the patient at additional risk for hemorrhage and coagulopathies. Children
with neutropenia and thrombocytopenia are at high risk for
serious and life-threatening complications. Box 25-1 out-

~

lines assessment parameters and care considerations for the
child in the ICU with neutropenia and thrombocytopenia.

GENERAL COMPLICATIONS
OF MALIGNANCY
Infection and Sepsis
Despite progress made in the treatment of children with
cancer, complications related to infection remain a leading
cause of morbidity and mortality.6 As more aggressive
treatments are used in the treatment of childhood cancer,
more children become immunocompromised for a longer
period of time and subsequently become more susceptible to
infection. In addition to treatment intensity, the type of
tumor and the state of the disease also contribute to the

Box 25-1
.
Assessment Parameters and Care Considerations for the Child With Neutropenia and Thrombocytopenia

Assessment Parameters
Vital Signs
• Temperature at least q2h; in febrile patients increase to q1h

Assess for presence of fever (Reminder: the clinical signs
and symptoms of a normal immune response may be suppressed in severely neutropenic patients or patients receiving
steroid therapy; fever may be the only presenting sign of a
VAD infection)

Skin
Assess for breakdown, lesions, pain, and rashes, especially
in less visible areas (e.g., skin folds of bUllocks, axilla,
perineum, perianal area, breasts, and scrotum)
Assess any incision, wounds, or biopsy sites for drainage,
odor, erythema, inflammation, and pain

Neurologic
Assess for complaints of headache. neck stiffness, onhostatic
dizziness, changes in LOC, visual disturbances
Assess for complaints of sinus pressure, pain, congestion, or
drainage
Pulmonary
• Assess respirations and breath sounds for presence, absence,
or change in pattern, effort, or rate
Assess for changes in amount and color of sputum
Genitourinary
Assess for changes in genitourinary function, e.g.. frequency,
color. and appearance of urine; dysuria
Gastrointestinal
Assess bowel function, e.g., consistency, pain. frequency,
color, amount
Assess mouth and throat for presence of stomatitis, ulcers,
white patches, dryness. erythema, and dental problems
Assess mouth and throat for complaints of pain and
dysphagia
Vascular Access Devices
Assess catheter exit, entrance, sulUre. and tunnel sites for
signs of infection (e.g.. skin breakdown, erythema, pain.
tenderness, discharge, swelling, or warmth)

Special Care Considerations
STRICT HANDWASHlNG
Monitor CBCs with differential count every day and calculate ANC
Limit contact with individuals with signs and symptoms of
a suspected transmissible illness or disease
Avoid contact with persons recently immunized with live
vaccinations

•
•

•
•

•

Maintain skin integrity and excellent hygiene
Use lotion to prevent dry, cracking skin, and bathe with only
mild, nondrying soap
Prevent rectal trauma by avoiding rectal temperatures,
enemas, suppositories, or digital examinations
Administer stool softeners as necessary to prevent straining
during bowel movements
Avoid injections whenever possible, because of the risk of
abscess formation in the skin
Avoid use of tampons in adolescent females
Evaluate potential for CNS infection
Perform meticulous mouth and skin care using only soft
sponge toothbrushes in conjunction with frequent oral rinses,
even in the critically ill and intubated child
Maintain use of strict aseptic technique when performing
all invasive procedures or manipulating invasive tubes or
catheters
Avoid patient contact with fresh flowers. soil, potted plants,
or contact with stagnant water
Avoid contact with foods that may introduce pathogens into
the Gl tract (e.g., raw or undercooked meats, unwashed raw
fruits or vegetables, tap or unfiltered water)
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frequency and types of infection that occur. 6 The immunocompromised child presenting to the ICU with infection
typically demonstrates clinical manifestations of sepsis or
septic shock. Prompt recognition of signs of infection and
sepsis, and timely interventions, may significantly decrease
the risk of mortality associated with septic shock.
Pathogenesis. The development of infection in children with cancer may be related to compromise in a variety
of host defenses. The nature of the disease and the
myelosuppressive action of chemotherapy and radiation
therapy result in immune alterations that compromise a
child's ability to combat infection. Tumors themselves may
predispose children to infection. Primary or metastatic
tumors may cause obstruction that promotes infection by the
colonizing of organisms at the site of the obstruction. For
example, a child with Wilms' tumor may experience an
increased incidence of urinary tract infections as a result of
urinary obstruction caused by the tumor. 6 The tumor may
erode through the body's protective barriers, such as the skin
and mucosal surfaces, and permit the entrance of pathogens
into the bloodstream. These protective barriers may also be
broken by the numerous invasi ve diagnostic and therapeutic
procedures performed on critically ill children with cancer.
Venous access devices, biopsies, pressure monitoring devices, respiratory care equipment, and indwelling catheters
all provide direct access to the bloodstream for a variety of
pathogens.
Defects in cellular or humoral immunity further increase
the susceptibility to infection in children with certain
malignancies. Children with Hodgkin's disease and nonHodgkin's lymphoma are known to have impaired T-cell
and monocyte function as well as diminished B-cell
function. Patients with leukemia may have defective cellmediated immunity. Children who have undergone splenectomies are found to experience diminished antibody responses, the loss of specific phagocytosis factors, and loss of
the spleen's filtering functions. These factors increase the
susceptibility to infection with encapsulated organisms.
Corticosteroids can alter leukocyte mobilization, diminish
cell-mediated immunity, and impair phagocytosis 6 Chemotherapy and radiation therapy regimens before BMT contribute to impairment of cellular and humoral immunity. The
special aspects of infection in the pediatric BMT patient are
discussed in the Complications of Bone Marrow Transplantation section of this chapter.
Cancer treatment may contribute to new sources of
infection. Stomatitis is a common side effect of certain
chemotherapeutic agents, such as methotrexate (MIX),
actinomycin-D, adriamycin, and transplant chemotherapy.
Under certain conditions, septicemia can develop from
stomatitis. Damage that occurs to the gastrointestinal (GI)
mucosa from antineoplastic therapy may be the reason that
enteric organisms are often isolated in the cancer patient
with infection. Rectal fissures may occur and can be a
source of fulminant infection, usually by gram-negative
bacteria. 3.7.8
Malnutrition that often occurs in children with malignancies can increase susceptibility to infection by causing
impaired phagocytosis, decreased macrophage mobilization,
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and depressed lymphocyte function. Broad-spectrum antibiotic therapy, which is often used, can lead to alterations in
microbial colonization and overgrowth of resistant organisms present in the critical care environment. 6 In addition,
any critically ill child will be at an increased risk for
infection from the mere fact of being in a debilitated state
and in a critical care environment. 8
All of these factors put children with cancer at a
significant risk for bacterial, fungal, viral, and parasitic
infections. Box 25-2 identifies the most common pathogens
known to cause infection in neutropenic pediatric patients.
Bacterial infections, particularly caused by gram-negative
enteric bacilli, are often the most serious acute infections
occurring in children with cancer. Gram-positive organisms
isolated in serious infections are most likely associated with
venous access devices. 6
Fungal infections are particularly troublesome in children with cancer. The most commonly encountered fungal
infections in affected children include those from Candida
and Aspergillus species 9 Candida infections may range
from local infections, such as thrush, to widespread dissemination. Mucosal lesions, which often occur as a result of
cancer therapy, may provide a portal for Candida septicemia. Aspergillus is a ubiquitous fungus that aggressively
invades the sinuses, lungs, and brain and is extremely

.

.
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Box 25-2

Potential Causative Organisms in the Septic
Child With Malignancy

Bacterial Infections
Any gram-negative or gram-positive organism, including:
Escherichia coli
Klebsiella pneulIloniae
Pseudomonas aerugitlOSa
Bacteroides jragilis
Clostridium difficile
Mycobacterium spp.
Nocardia spp.

Viral Infections
Cytomegalovirus
Respiratory syncytial virus
Adenovirus
Herpes simplex virus
Varicella zoster virus

Parasitic Infections
Plleumocyslis carinii
Strongyloides stercoralis

Fungal Infections
Candida spp.
Aspergillus spp.
Adapted from Freifeld AG. Walsh TJ, Pizzo PA: Infectious complications in the
pediatric cancer patient. in Pizzo PA. Poplack DG, eds: Principles and
practice of pediatric oncology, ed 3. Philadelphia, 1997. Lippincott·Raven

Publishers, pp. 1069-1114.
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difficult to eradicate from the body.9- 11 It is often fatal in
severely immunocompromised children, such as those who
have undergone BMT or those who are severely neutropenic
following high-dose chemotherapy. Diagnosis of Aspergillus infection is often problematic because of difficulties in
culturing the organism 8
Viral infections may cause significant morbidity and
mortality in children with cancer because they have the
potential for rapid dissemination in immunocompromised
hosts. In addition, exposure to seasonal viruses, such as
respiratory syncytial virus (RSV) and adenovirus, may
cause severe upper and lower respiratory tract disease in the
immunocompromised patient. 11 The herpes virus group can
be responsible for a variety of infections. Herpes simplex
infections are usually more severe and prolonged in children
with malignancies. Dissemination can occur with mucosal
lesions, cellulitis, or pneumonia. Abnormalities in T-cell
function and diminished cell-mediated response to varicella
zoster can cause fulminant varicella, which may disseminate
to the liver, lung, and central nervous system (CNS). In
children who have had varicella zoster infection, herpes
zoster infection (shingles) can occur as a reactivation of this
virus. Children with lymphomas appear to have the greatest
risk for development of herpes zoster infection. 6
The most common cause of viral pneumonia in the
immunocompromised host is cytomegalovirus (CMV), especially in those who have undergone BMT. Pneumonitis is
the most common clinical consequence of CMV infection in
these children. The parainfluenza virus may also cause
significant respiratory failure. 6 •7 Parasitic infections in children with cancer are most commonly attributed to Pneumocystis carinii. This organism is responsible for serious
pneumonitis in this population, and if left untreated is usually fatal. 3 ,6
Although the pathogenesis of infection and sepsis may be
different in the pediatric patient with malignancy, the clinical progression and final common pathway of septic shock is
the same for any pediatric patient; hemodynamic instability,
circulatory collapse, and intractable lactic acidosis. Chapter
27 provides a detailed account of the pathogenesis, clinical
presentation, and clinical management of septic shock.
Clinical Presentation. Because shock may rapidly
ensue in these children, and host responses may be subtle,
early recognition and prompt treatment of infections are
imperative. 6 If infection is undetected and left untreated in
a patient with malignancy, especially one who is neutropenic, it may prove to be fatal in a very short course.
Detection of infection requires strong clinical judgment and
a careful search for signs and symptoms, which are often
covert. 8 Fever is the single most consistent indicator of
infection, in the neutropenic patient because the lack of an
inflammatory response prevents many of the classic signs
and symptoms of infection from appearing. In fact, fever
may be the only sign of an active infection in the severely
neutropenic patient, and may be crucial to diagnosis. 13
Diagnosis requires thorough physical examination, radiologic and laboratory evaluation (blood counts, electrolyte
levels, and coagulation studies), and cultures of any
potential source of infection. Surveillance bacterial and

fungal culture results of throat, urine, stool, and blood are
often routinely monitored twice weekly to allow for early
detection of infection. In addition, these same cultures are
typically obtained at a maximum of once per day if the child
develops a fever. If invasive lines are in place when the child
becomes febrile, they are considered potential sources of
infection. 6 Routine viral screenings during RSV season are
also recommended.
Critical Care Management. The only true treatment
for infection, sepsis, and septic shock is the administration
of antiinfectious agents, specific to the causative pathogen.
However, the inability to obtain blood cultures should never
preclude the timely administration of antiinfectious agents.
Broad-spectrum coverage begins immediately as soon as
sepsis is suspected. Empiric antibacterial therapy, generally
using a cephalosporin, aminoglycoside, and extendedspectrum penicillin, is initiated until culture and sensitivity
reports are available. When the child has a venous access
device, coverage for gram-positive organisms, such as vancomycin, is usually added 4 Typically, gram-positive coverage will be initiated until culture reports are obtained. Once
blood cultures rule out the existence of a gram-positive
organism, coverage for such organisms is discontinued
because of the increasing development of resistant organisms. There are a variety of antimicrobial agents available for use, and numerous complex antimicrobial regimens
have been developed by various institutions for treatment
of fever in the neutropenic child. Ultimately, the choice of
agents and regimens should be dependent on predominant
organisms, sensitivity patterns, and experience of the ordering practitioner. 6
In children with persistent fever and neutropenia, antifungal treatment should be added. Amphotericin B has
typically been the treatment of choice for fungal infections 9 . IO Unfortunately, amphotericin B is associated with
serious complications, most notably anaphylaxis and nephrotoxicity.9 If renal function is impaired, it may be necessary
to lower the dose of amphotericin B or administer the drug
on alternate d ays 9 Fever, chills, and rigors that commonly
accompany amphotericin B administration may be minimized by the administration of intravenous diphenhydramine, meperidine, and oral acetaminophen, as needed.
When side effects are severe, hydrocortisone may be added
to the infusion. The use of new antifungal agents, such as
appropriately engineered lipid formulations of amphotericin B, may preserve the antifungal efficacy with fewer
adverse effects. One such agent is amphotericin B lipid
complex (ABLC). ABLC, while not uniformly efficacious
for all fungal infections, has shown great promise in clinical
trials and is indicated for use in the treatment of invasive
fungal infections in patients who are refractory to or
intolerant of traditional amphotericin B therapy. 9
Viral and parasitic organisms are also suspected, especially in the event of pulmonary infection. For suspected viral infections, ganciclovir in combination with
intravenous immunoglobulin (IVIg) or acyclovir may be
administered. 6 Acyclovir is often used for the treatment of
varicella zoster, herpes simplex, and herpes zoster infections. It is also administered prophylactically to prevent
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stomatitis in BMT patients who are seropositive for herpes
simplex.
Although the use of aerosolized ribavirin has fallen out of
favor for the treatment of RSV infection in the general
pediatric population, it has been used with some success in
several studies of immunocompromised patients presenting
with RSV infection.12.14.17 Proponents of this therapy in the
immunocompromised patient advocate early use of ribavirin
to prevent the progression of RSV infection to the lower
respiratory tract. In addition, the increasing use of RSVimmunoglobulin (RSVlg), both prophylactically in the
at-risk patient and in combination with aerosolized ribavirin
for infected patients, holds promise in decreasing mortality
related to RS V infection. 17 However, despite these encouraging reports, further studies are necessary to determine
effective therapy for RSV infection in the BMT patient.
Prophylactic therapy against respiratory viruses, using
either respiratory syncytial virus immune globulin intravenous (RSV-IGIV) or palivizumab (an intramuscular monoclonal antibody), has recently been advocated for severely
neutropenic patients, such as BMT patients. Although
neither medication has been evaluated in randomized trials
in immunocompromised children, children with severe
immunodeficiencies may benefit from this prophylaxis.
The American Academy of Pediatrics recommends that
if severely immunocompromised children are receiving
standard immune globulin intravenous (IGIV) monthly,
physicians may consider substituting RSV-JGIV during the
RSV season. IS RSV-IGIV may also provide prophylaxis
against other non-RSV respiratory infections that palivizumab does not.
Parasitic infections are routinely treated with
trimethoprim-sulfamethoxazole (TMP-SMX). TMP-SMX
may also be given prophylactically in neutropenic patients
to prevent the onset of Pneumocystis carinii pneumonia
(PCP). Pentamidine isethionate is commonly administered
prophylactically to prevent PCP in immunodeficient (particularly HIV positive) and immunosuppressed patients. 4.6
The use of granulocytes in the management of sepsis,
although still controversial, is used for the neutropenic child
whose white blood cells (WBCs) have been suppressed.
Proponents of granulocyte transfusions believe that because
the child lacks intrinsic neUlrophils to combat infection,
administration of granulocytes may provide an extrinsic
bridge of WBCs available to fight infection until the
patient's own WBCs return. Saarinen and colleagues administered granulocyte transfusions to 10 children suffering
from documented life-threatening infections during profound, prolonged neutropenia. 19 They reported prompt and
vigorous bone marrow myeloid recovery immediately after
granulocyte transfusion in all 10 patients. However promising this mode of therapy may be, further studies are
warranted before granulocyte transfusions become part
of standard therapy. There are significant complications
that have been associated with granulocyte transfusions,
namely fever and chills, pulmonary complications such as
pneumonitis with the potential for respiratory failure,
transmission of blood-borne infections such as CMV,
and the induction of alloimmunization, which may jeopar-
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dize all future platelet transfusions. 19 In addition, there are
case reports of respiratory failure when granulocytes
were administered in close proximity to amphotericin B
administration. Because there have been no large generalizable clinical studies demonstrating improved outcomes
resulting from granulocyte transfusions, and given the risk
of respiratory failure, many practitioners continue to avoid
granulocyte transfusions. Instead, granulocyte-macrophage
colony-stimulating factor (GM-CSF) and granulocyte
colony-stimulating factor (G-CSF) have been used as an
alternative therapy to accelerate granulocyte recovery.
These cytokines, which accelerate hematopoiesis when
given following chemotherapy-induced neutropenia, have
been shown to reduce the severity and duration of neutropenia for some children. 19
Should sepsis progress to septic shock, the shock state is
managed as for any other patient presenting with sepsis or
septic shock. The only caveat to management of the
pediatric oncology patient with septic shock is that repeated
administration of chemotherapeutic agents, or administration of certain cardiotoxic chemotherapeutic agents, may
cause myocardial dysfunction, which in conjunction with
sepsis, may decrease the child's tolerance for fluid loading
and fluid resuscitation. Fluid management and inotropic
support in such cases may need to be augmented and guided
via hemodynamic monitoring, including pulmonary artery
pressure monitoring.

PericardiaI Tamponade
The etiology of pericardial tamponade in children with
cancer may be much different than that in other children
who present to the ICU with this clinical syndrome. Pericardial tamponade may occur as a direct result of a primary
tumor invasion into the pericardium, metastatic invasion
(such as with Hodgkin's disease or ALL), infection or severe
inflammation, or as a sequelae to radiation therapy, manifesting as either pericardial effusions or constrictive fibrosis.
Pericardial effusions may also be seen in children with
Wilms' tumor in whom a thrombus may extend into
the heart. 3.4
Pathogenesis. Acute pericardial tamponade is a rare
presentation for children with malignancies. More often,
chronic accumulation of fluid permits the pericardium to
stretch gradually over time and allows it to accommodate
large fluid volumes before cardiac tamponade occurs. 3 .4
Clinical Presentation. The classic signs and symptoms of acute pericardial tamponade do not differ from other
patient populations presenting with this clinical picture. For
a complete discussion of these classic signs and symptoms,
as well as pathogenesis and diagnostic techniques, please
refer to Chapter 18 (Cardiovascular Critical Care Problems).
Clinical presentation in the pediatric oncology patient may
be rapid, but more commonly is insidious in onset. Chronic
accumulation of fluid may present with more subtle signs
and symptoms, such as fatigue, dyspnea, cough, chest pain,
abdominal distention, and signs and symptoms of rightsided congestive heart failure. Early recognition of impending tamponade and intervention is important.
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Critical Care Management. The management of
pericardial tamponade is dictated by the degree of existing
circulatory compromise. Emergent care consists of pericardiocentesis, preferably performed via echocardiographic
guidance. For those children who are thrombocytopenic or
have evidence of other coagulopathies, platelets and fresh
frozen plasma may be needed before pericardiocentesis.
Pericardiocentesis in children with cancer is not only therapeutic but also allows collection of a specimen for malignancy diagnosis. Depending on the cause of the pericardial
tamponade, a "pig-tailed" catheter may be placed after pericardiocentesis to allow for drainage of any reaccumulated
pericardial fluid. 4 .20 Obviously, placement of such a catheter
places the child at great risk for infection and resultant
myocarditis. Meticulous care, including use of strict aseptic
or sterile technique, for both the catheter and catheter site
is provided.
Supportive care includes hydration, oxygen, and positioning to achieve maximum patient comfort. Definitive
therapy is directed toward treating the underlying cause.
Hematologic malignancies are treated with chemotherapy.
Solid tumors are removed or may be diminished by local
radiation or sclerosing therapy. In situations in which
prolonged palliation is warranted, a pericardia I window may
be placed. A pericardiectomy may be considered if the
above treatments fail, if there is an associated constrictive
pericardial disease, or if a pericardial window is not
technically feasible. 4

Acute Respiratory Failure
The development of acute respiratory failure in the child
with an oncologic disease commonly requires critical care
resources. The inability to ventilate and adequately oxygenate may occur from a variety of infectious and noninfectious insults, including pulmonary opportunistic infections
and chemotherapy or radiation therapy-induced pulmonary
disorders. Primary pulmonary malignancies are rare in
children and do not account for many ICU admissions, with
the exception of tracheal compression from a mediastinal
mass. 3 .6 Pleural effusions and pulmonary infiltrates are
two of the more common causes of acute respiratory failure
and the need for mechanical ventilation in children with
malignancy.
Pleural Effusions. Pleural effusions in the child with
cancer may occur for a variety of reasons, including
irritation of the pleural membrane by cancer cells, infection,
an extension of the tumor itself, or lymphatic or venous
obstruction of the pleura by a mediastinal mass. In addition,
chylous effusions may occur from obstruction of the
lymphatics. 3 Children at risk for pleural effusions include
those with leukemia, Hodgkin's disease and non-Hodgkin's
lymphoma, sarcomas, neuroblastoma, and Wilms' tumor. 3 .6
Signs and symptoms of a pleural effusion include
dyspnea, cough, pleuritic chest pain, tachypnea, and tachycardia. Physical examination may reveal dullness on percussion over the infected area. Diagnosis of a pleural
effusion involves techniques similar to those used for
pleural effusions from other disease processes. Chest

radiographs help confirm the presence of fluid in the pleural
space. Pleural fluid can also be examined for the presence of
malignant cells or to rule out infection. 6
Thoracentesis and possibly chest tube placement are
indicated to drain the fluid when it is causing respiratory
distress, or to make a diagnosis. In addition, sclerotherapy
may be necessary to prevent or delay formation of a new
effusion 3 Sclerotherapy employs agents such as tetracycline, talc, or bleomycin to cause adhesions and irritation in
the pleural or pericardial spaces. The procedure consists of
injecting these agents into the respective spaces, and may be
repeated for several days as needed. Ultrasound examination
may be helpful to guide the physician to the effusion area,
especially when the effusion is loculated. Therapy specific
to the disease process should be instituted.
Careful respiratory assessment and monitoring are necessary for the child with a pleural effusion. In addition, the
nurse needs to be aware of the procedure and possible side
effects of various sclerotherapy techniques. These side
effects are dependent on agents used but can include pain,
nausea and vomiting, infection, inflammation, hypoxia,
pneumothorax, and hemothorax.
Pulmonary Infiltrates. Tn a nonneutropenic host,
respiratory infections may be attributed to the usual causes
of community-acquired pneumonia. However, in the child
with malignancy who is neutropenic, bacterial pneumonias
may be one of the most common causes of pulmonary
infiltrates and can cause significant mortality. Gramnegative organisms are the most likely etiologic pathogens;
however, viral, fungal, or parasitic organisms should also be
considered because they are a common cause of infectious
pneumonitis in patients with prolonged neutropenia. 3
The incidence of protozoal PCP, which was once quite
common, has decreased greatly because of the use of
prophylactic TMP-SMX, although it still does occur in
immunocompromised hosts 6 Fungal pneumonitis is most
commonly diagnosed in a neutropenic host who has
received prolonged antibacterial agents without evidence of
clinical improvement. Aspergillus and Candida are the most
common causative organisms 6
As previously mentioned, pulmonary injury can be attributed to a variety of chemotherapeutic agents (Box 25-3)
and radiation therapy. Lung damage from chemotherapeutic
agents is often difficult to detect because such damage is
usually insidious in onset and is caused by the presence of
other sources of pulmonary injury such as infection,

~

lox 25-3
Chemotherapeutic Agents Associated
With Pulmonary Injury

Adriamycin
Bleomycin
Busulfan
Cyclophosphamide
Cytosine arabinoside
Methotrexate
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radiation, or metastatic lung disease, which can complicate
diagnosis. Some chemotherapy agents may cause dosedependent pulmonary changes, whereas others, such as
MTX, may actually cause an inflammatory-type hypersensitivity reaction. Drug-associated lung injury appears histologically as diffuse alveolar damage?! Radiation to the lung
fields can cause an acute inflammatory response of the lung
tissue (Fig. 25-1). Radiation damage to the lungs is related
to the total dose received, the dose rate, and the volume of
lung tissue irradiated. The more radiation that is administered to the lung fields, the greater the damage. 21
Clinical manifestations of acute respiratory failure resulting from pulmonary infiltrates include fever, cough (usually
dry and hacking), rales, dyspnea, hypoxia. cyanosis, and
tachypnea. The chest radiograph typically demonstrates a
diffuse infiltrative pattem 3 .4.8 (Fig. 25-2).
Differential diagnosis of respiratory dysfunction in the
child with cancer can be difficult and often requires invasive
techniques. Diagnostic testing includes cultures, serology,
radiologic studies including x-ray and chest computerized
tomography (CT) scans, arterial blood gas analysis, and
ventilatory function tests. Bronchoalveolar lavage (BAL)
may be used to obtain samples for testing and isolate the
causative organism. If this is unsuccessful, an open lung
biopsy may be necessary to differentiate infectious and
noninfectious causes. 6
Management of the child with cancer in acute respiratory
failure focuses on the support of respiratory and circulatory
function, minimizing the risk of pulmonary edema, and
aggressively identifying and treating infectious processes.
Broad-spectrum antibiotics are started immediately in the
child who develops fever and pulmonary symptoms. These
are instituted even before receiving results of diagnostic
testing because rapid progression to an overwhelming
pneumonia and sepsis can occur. 6
Supplemental oxygen is an essential aspect of therapy.
The amount of oxygen that is required can be determined by

usual methods of arterial blood gas monitoring and pulse
oximetry. The child with cancer has the potential for
enhanced oxygen toxicity as a consequence of previous
chemotherapy or radiation therapy, and thus is maintained
on the lowest amount of oxygen that results in sufficient
oxygenation. 7 .8
Most children with malignancy have limited energy
reserves resulting from disease progression, malnutrition,
and the toxic effects of chemotherapy and radiation therapy.
Any stress to the body places them at risk for sudden
deterioration in pulmonary function and respiratory failure,
necessitating the use of mechanical ventilation. The indications for mechanical ventilation in the child with malignancy are similar to those for any child suffering from
respiratory failure (see Chapter 19 for a complete discussion
of respiratory failure). There are, however, some unique
problems to consider in the population with cancer if
intubation is required.
The trauma of intubation may cause upper airway
bleeding in the child with malignancy because of thrombocytopenia, coagulation abnormalities, or mucositis that
already exists. Platelets, fresh frozen plasma, or vitamin K
may be necessary before intubation to minimize the risk of
bleeding 8 If intubation needs to be performed as an emergency, the oral route is preferred to the nasal route to diminish the risk of serious bleeding. Intubation can also increase
the risk of infection in the immunosuppressed patient population 3 An increased awareness of the need for strict aseptic
technique when performing an invasive procedure, such as
suctioning, is necessary for the immunocompromised child.
Tracheal aspirate cultures are obtained at least twice weekly,
and as needed if any changes in the color, odor, or amount of
secretions are detected.
Once the child has an artificial airway in place, positive
end-expiratory pressure (PEEP) is used at a level high
enough to maintain the oxygen concentration at 40% to 50%
or less to minimize the risk of toxicity.7.s High airway

Fig. 25-' Bilateral peritracheal and parahilar infiltrates resulting
from radiation pneumonitis.

Fig. 25·2 Bilateral ditfuse peripheral infiltrates in a 2-year-old
boy with lymphoma proven to be PCP, which is sparing the central
portions of the lung that are involved with radiation fibrosis.
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pressures and rapid ventilatory rates, although not preferred,
may be necessary to maintain adequate gas exchange. In
such cases, it is imperative that the child be adequately
sedated in order to optimize oxygenation and ventilation. 8 If
the child with acute respiratory failure is still receiving
potentially toxic chemotherapy or radiation therapy, these
treatments may need to be discontinued or modified to
prevent further lung damage?l High-dose corticosteroids
may also be added to the treatment regimen to decrease lung
inflammation.

Neurologic Complications
Seizures. As with many oncologic emergencies, seizures may occur in the child with malignant disease for
a variety of reasons, including tumor involvement, metastatic disease, or as sequelae of either drug therapy or disease progression. Astrocytomas, ependymomas, and malignant gliomas may occur in the central hemisphere and create
seizures. 4 Lymphomas, retinoblastomas, and rhabdomyosarcomas may metastasize and lead to seizures. 4 •7 .8 Chemotherapeutic agents, such as intrathecal MTX, L-asparaginase,
and vincristine, may actually induce seizure activity. Metabolic abnormalities associated with organ dysfunction, such
as hypocalcemia, hypoglycemia, hyponatremia, and uremia,
may also cause seizures. 3 And finally, neutropenia and
thrombocytopenia may place the child at risk for CNS infections, such as meningitis or brain abscesses, or intracerebral
hemorrhage.
Regardless of the cause, seizures in the child with
malignant disease should be treated the same as seizures in
any other child. Maintenance of airway patency and
adequate ventilation should be the priority because most
seizures are self-limiting. However, progression to status
epilepticus warrants emergent intervention and management
in the critical care environment. See Chapter 20 for
management of seizures and status epilepticus in the
pediatric patient.
Increased Intracranial Pressure/Herniation Syndromes. Although increased intracranial pressure (ICP)
and the risk of cerebral herniation is concerning in any
pediatric patient, it is of particular concern in the patient
with malignancy. The reader is referred to Chapters 10 and
20 for detailed discussion of the pathophysiology, clinical
manifestations and current management of increased fCP
and herniation syndromes in children. However, it is
important to note that the causes of increased ICP may be
different in the pediatric oncology patient, and the onset
may be either rapid or insidious.
Obviously, the child with a space-occupying lesion in the
brain is at risk for developing increased fCP. However,
children with any malignancy are at risk for increased ICP
because of the effects of either acquired or induced
neutropenia andlor thrombocytopenia. 3 .4 CNS infections,
with resultant cerebral edema, may lead to increased ICP in
this patient population. Cerebral abscesses from bacterial or
fungal sources are common causes of increased ICP in the
neutropenic patient. However, perhaps the most devastating
cause of increased ICP is intracerebral hemorrhage caused
by thrombocytopenia (Fig. 25-3). Massive bleeding into the

Fig. 25·3 Intracerebral hemorrhage in a l2-year-old female,
approximately 100 days after BMT for CML.

cranial vault may lead to rapid onset of intracerebral
herniation and brain death.
Symptoms of increased ICP and herniation syndrome are
no different in the pediatric oncology population than in the
general PICU population. However, there are subtle changes
in clinical presentation in the neutropenic and thrombocytopenic patient. Any subtle changes in level of consciousness or complaints of headache, nausea, or vomiting are
thoroughly investigated to rule out intracranial pathology.22
This is particularly challenging in the patient with malignancy because many therapies for malignancy routinely
cause sedation, nausea, and vomiting. Astute recognition
and early intervention are paramount for preventing the
catastrophic sequelae of increased ICP in these patients.
Definitive treatment is aimed at treating the underlying
cause of the increased ICP. Emergent surgical intervention
to debulk or remove space-occupying lesions or evacuate
intracerebral bleeds may be necessary, although these
patients are high surgical risks and there is a significantly
increased morbidity and mortality associated with surgical
intervention. 4 .22 CNS infections are treated with antiinfection therapy, and at times, emergent whole brain
irradiation may be necessary to reduce a rapidly growing
intracranial tumor. If bleeding is suspected, platelet or fresh
frozen plasma administration may be warranted. The use of
ICP monitoring devices is very controversial because of the
increased risk of bleeding and infection in neutropenic and
thrombocytopenic patients.

Hemorrhage
Hemorrhage in the pediatric patient with malignancy is most
often the result of thrombocytopenia, coagulopathies, or a
combination of both. Although the precipitating factors for
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Indications for Platelet Transfusion Support in Children with Cancer

the Presence of 5ignificant Hemorrhage"

In the Absence of Significant Hemorrhage

iliihrrombocytopenia of any severity (usually significant hemori~· rhage does not occur if the platelet count is >20,OOO/mm'
~\I';:unless other factors are present, i.e., infection, local
anatomic lesion)

Before major surgical procedure if platelet count is <50,OOO/mm 3

puspected platelet count dysfunction (e.g., aspirin) ine-

Before lumbar puncture or minor surgical procedure if platelet
3
count is <20,OOO/mm
In febrile patient with platelet count <20,OOO/mm 3 , especially in
a child with ANLL or who is extremely ill

If

Ill'."." .. spective of platelet count (a rare occurrence in today's

ii,

II"

practice)

I~

PI~t;!~td~~~~tri~~,ooo/mm3with

little likelihood of imminent

l!:ifrom Buchanan GR: Hematologic supportive care of the pediatric cancer patient. In Pizzo PA, Poplack DG, eds: Principles and practice of pediatric
JJi;rcology. ed 3, Philadelphia, 1997, Lippincott-Raven.
~~~Significant hemorrhage is defined as recurrent or severe epistaxis, gingival bleeding, extensive buccal blood blisters, gross GI hemorrhage (not just occult
t~lood in stool), retinal bleeding, extensive new cutaneous bleeding, suspected or proven internal hemorrhage. Bruises and scattered petechiae are not
~j;onsidered clinically significant hemorrhage.
~;'-

hemorrhage in this patient population may be somewhat
unique to the patient with malignancy, the final common
pathway is similar to any pediatric patient with disruption of
normal hematopoiesis and hemostasis. Thrombocytopenia is
one of the most common bleeding problems for patients
with malignancies. Bleeding may be easily managed or may
constitute a life-threatening emergency with catastrophic
insults to organ systems and the potential for circulatory
collapse.
Pathogenesis. Thrombocytopenia, defined as a platelet count less than 17S,OOO/mm3 , occurs as a result of tumor
involvement of the bone marrow, myelosuppression from
chemotherapy or radiation therapy, increased platelet destruction, or hypersplenism. 23 Coagulopathies, such as
disseminated intravascular coagulation, may occur as a
result of chemotherapy, vitamin K-dependent factor deficiency, liver insult or failure, or a variety of other causes.
See Chapter 24 for a complete discussion of both normal
and abnormal hematopoiesis and hemostasis.
Clinical Presentation. The clinical presentation of
hemorrhage in the pediatric patient with malignancy is essentially no different than in any other child with acute
bleeding and/or coagulopathies. Signs may be overt, such as
severe epistaxis or frank blood from a nasogastric tube, or
may be subtler, such as an increasing abdominal girth or
changes in level of consciousness. The critical care nurse
identifies patients at risk through close monitoring of laboratory data and is alert to any changes in clinical presentation
that may signify bleeding to prevent loss of circulating
blood volume that would predispose the child to circulatory
collapse.
Critical Care Management. Care of the thrombocytopenic patient is augmented to prevent breaks in skin
integrity or increased risk of spontaneous bleeding. Administering platelet transfusions to maintain a platelet count
above 20,OOO/mm 3 seems to be an accepted practice for
pediatric patients. Table 2S-1 provides guidelines for
platelet transfusion in the pediatric oncology patient.
However, despite these guidelines, indications for platelet
transfusions remain a subject of great debate in the pediatric

literature. Because most instances of intracranial hemorrhage seem to occur with platelet counts lower than
SOOO/mm 3 , proponents of prophylactic platelet transfusions
believe that maintaining a platelet count of greater than
20,OOO/mm 3 provides a degree of protection against catastrophic events. 23 Opponents, on the other hand, advocate
that transfusions are reserved for children with platelet
counts either below SOOO/mm 3 or between SOOO and
20,OOO/mm 3 who present with warning signs, such as
sudden increases in cutaneous bleeding, oral blood blisters,
or retinal hemorrhage. 23

Typhlitis
Children with malignancy may develop an acute abdomen
for much the same reasons as children without malignancy.
However, in the majority of cases, acute abdomen in these
children is directly related to the underlying malignant disease. Immunodeficient states put these children at the unique
risk of developing esophagitis, gastric hemorrhage, perirectal abscess, hemorrhagic pancreatitis, or acute hepatic enlargement from tumor. 3. 8 Other causes of GI complications
include complications of therapy, such as chemotherapyinduced ileus, and direct or indirect effects of tumor mass,
such as obstruction by a tumor or metastatic involvement of
the GI tract. One of the most worrisome abdominal processes unique to the immunodeficient host is typhlitis.
Pathogenesis. Typhlitis is a necrotizing colitis in the
cecum that typically occurs after administration of chemotherapeutic agents or disease- induced neutropenia. Although
it is most often associated with treatment for leukemias,
typhlitis may occur in any neutropenic patient. The pathophysiology appears to be multifactorial, involving loss of
bowel wall integrity, invasion of the cecal mucosa by
bacteria (most commonly Clostridium septicum or gramnegative bacteria such as Pseudomonas aeruginosa), and
decreased host immune defenses. This sequence of events
leads to bacteremia, and bowel wall inflammation, progressing to necrosis, fUll-thickness infarction, hemorrhage, and
potential perforation. 3 . 24 ,25
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25-2 Causes of Acute Renal
Impairment in the Child With
Malignancies

Box 25-4

TABLE

Criteria for Surgical Intervention in Typhlitis

Surgical intervention should be considered in the following four
circumstances:
I. Persistent gastrointestinal bleeding despite resolution of
neutropenia and thrombocytopenia and correction of
coagulation abnormalities
2. Evidence of free intraperitoneal perforation
3. Clinical deterioration requiring support with vasopressors
or large volumes of fluid, suggesting uncontrolled sepsis
from intestinal infarction
4. Development of symptoms of an intraabdominal process,
which, in the absence of neutropenia, would normally
require surgical intervention

!l:!;"

~himary Causes

Secondary Causes

,;00. ••

Ii"

\1'f). Renal tumor
~;h-

I;:~t;4: ~~~~~~:~toi:s:;2~~

Renal vessel obstruction

~5. Tumor Lysis Syndrome

~6. Paraneoplastic syndrome
~--.

fi,7. Hypertension

I. Chemotherapeutic/supportive
agents
Cyclosporine A
Cisplatin
Methotrexate
Amphotericin B
Ifosfamide
2. Radiation therapy

iF'

From Shamberger RC, Weinstein HJ, Delorey Met a1: The medical and surgical
management of typhlitis in children with acute myeloid (myelogenous)
leukemia, Cancer 57:603. 1986.

Clinical Presentation. Right lower quadrant pain is
typically the first presenting symptom of typhlitis. For this
reason, typhlitis is suspected in all children with malignancy
who present with such pain. Fever mayor may not be
present. Other signs and symptoms include nausea, vomiting, or watery or bloody diarrhea. Blood cultures may be
helpful in identifying causative organisms and directing
therapy. However, diagnosis is typically based on physical
examination and imaging studies, with computed tomography and ultrasonography providing the most sensitive
identification of typhlitis. 25 .26
Critical Care Management. Treatment of typhlitis is
centered around medical management with the administration of broad-spectrum antiinfectious agents?4.26 Surgical
intervention is controversial, with mortality rates ranging
from 20% to 100%.3 Because of the potential increase in
mortality, specific criteria for surgical intervention have
been recommended (Box 25-4). If left untreated, typhlitis
will progress to overwhelming sepsis and death.

COMPLICAnONS OF SOLID TUMORS
Acute Tumor Lysis Syndrome
Although renal failure in the child with malignant disease
may result from a variety of primary and secondary causes
(Table 25-2), one of the most dramatic causes of renal failure is acute tumor lysis syndrome (ATLS). ATLS results
directly from malignant cell degradation and the inadequate
ability of the kidneys to excrete the large quantities of uric
acid, phosphorus, and potassium released during cell lysis.
The syndrome, consisting of a metabolic triad of hyperuricemia, hyperkalemia, and hyperphosphatemia, is most commonly associated with the presence of rapidly proliferating
tumors, such as Burkitt's lymphoma and T-cell leukemia!
lymphoma. 27 .28 Patients most at risk for developing ATLS
are those who present with bulky abdominal tumors (such as
with Burkitt's lymphoma), elevated serum uric acid and
lactic dehydrogenase levels before treatment, and oliguria.

Serum uric acid levels may be elevated because of obstructive uropathy, whereas lactic dehydrogenase levels may be
elevated because of decreased venous return resulting from
compression by the tumor mass 22 .29 Oliguria before treatment is most often caused by tumor obstruction.
Pathogenesis. ATLS may occur either before therapy, as a result of spontaneous cell lysis, or it may occur I to
5 days after initiation of specific cytotoxic chemotherapy.8.27 Chemotherapy administration causes a profound
lysis of malignant cells in tumors with high growth
fractions, such as Burkitt's lymphoma, which has a doubling
time of anywhere from 38 to 116 hours. 3 Cell lysis causes a
rapid release of the intracellular components uric acid,
phosphorus, and potassium, all of which are nonnally
excreted by the kidney. Elevated uric acid, or hyperuricemia, results from the breakdown of nucleic acids from the
cells and the resultant release of purines. Uric acid, which
may also be promoted by lactic acidosis secondary to poor
tissue oxygenation in patients with high leukocyte counts,
precipitates in the collecting ducts and renal tubules, leading
to decreased renal clearance. 3 .7
Hyperphosphatemia occurs as a result of the release of
phosphates during tumor cells lysis. Lymphoblasts have up
to four times the phosphate content of nonnal lymphocytes. 3 •22 Hyperphosphatemia causes both precipitation of
calcium phosphate salts (which precipitate in the renal
tubules), and a resultant hypocalcemia. These huge quantities of intracellular metabolites released during cell lysis, in
addition to the precipitation of both uric acid and calciumphosphate salts in the renal system, overwhelm the ability of
the kidneys to clear them, leading to acute renal failure. 4.7
The third part of the metabolic triad, hyperkalemia,
occurs because of the release of potassium from the cells
during tumor lysis and is accentuated by the onset of renal
failure and the presence of acidosis. 22 Hyperkalemia is an
ominous sign, placing the child at risk for life-threatening
ventricular dysrhythmias and possibly cardiac arrest.
Clinical Presentation. Early recognition of the metabolic abnonnalities and renal failure associated with ATLS
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TABLE 25·3
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~::Hyperuricemia
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Clinical Manifestations of Acute Tumor Lysis Syndrome
Hyperphosphatemia

Hypocalcemia (resultant)

Hyperkalemia

Pruritic tissue changes
Inflammation of the eyes and joints

!t~,\

Anorexia
Vomiting
Cramps
Tetany
Altered level of consciousness
Neuromuscular irritability
Seizures
Lethargy
Numbness
Tingling of the extremities
Prolonged QT intervals

Muscles weakness
Paresthesia
Nausea
Diarrhea
Abdominal cramps
Acidosis
Asystole
Elevated T waves
Prolonged PR intervals
Depressed ST segments
Widened QRS

is crucial to preventing possible life-threatening complications. Clinical manifestations reflect these metabolic abnormalities and are outlined in Table 25-3.
Diagnostic evaluation begins with laboratory analysis,
including a CBC with differential to monitor the leukocyte
count, serum chemistries (including sodium, potassium,
chloride, bicarbonate, calcium, phosphorus, uric acid, blood
urea nitrogen, and creatinine), and urinalysis. An ultrasound
of the abdomen and retroperitoneum is performed immediately if abdominal mass lesions or renal failure are
present. 3.4 Continuous ECG monitoring of children with
ATLS will signal widened QRS complexes or peaked
T waves characteristic of hyperkalemia. However, in the
presence of high leukocyte counts, serum potassium levels
may be falsely elevated because of spontaneous lysis of
leukocytes, platelets, and erythrocytes. This pseudohyperkalemia differs from true hyperkalemia in that there are no
ECG changes, and actual potassium concentrations may be
determined from plasma analysis rather than serum. 3
Critical Care Management. The key to management of patients at risk for ATLS is prevention and early
identification of those who are most at risk for its development. Children with identified risk factors for renal failure resulting from ATLS may be admitted to the ICV
for early intervention, either before or after initiation of
chemotherapy.
Prevention of renal failure in children with normal urine
output, regardless of serum uric acid levels, involves
hydration, alkalinization, and allopurinol administration 3 .27
Hydration is achieved with the administration of crystalloids
(normal saline or D5W.45NS) at two to four times that of
maintenance fluid, roughly 3000 mllm 2 /day. Such aggressive fluid replacement serves to maintain hydration as well
as enhance renal excretion of uric acid and phosphates.
Sodium bicarbonate is added to maintenance fluids to
increase urine pH and limit or prevent the formation of uric
acid crystals in the collecting ducts that normally would
occur in an acidic environment. Alkalinization is adequately
achieved when urine pH is between 7.0 and 7.5, and is
discontinued when uric acid levels are normalized, usually
within 24 hours of starting therapy.3,27 If levels have not
normalized within this timeframe, bicarbonate administra-

tion may continue, but only until chemotherapy is started to
prevent the phosphates released during tumor lysis from
precipitating as calcium phosphate salts in the kidneys.4,7
Over-alkalinization to a urine pH greater than 7,5 may
aggravate symptoms of hypercalcemia by shifting ionized
calcium to its non-ionized form. 22 Because of the increased
risk of hyperkalemia, potassium is not added to the
hydration fluid, Diuretics may be administered to maintain
a urine output of at least I mllkg/hour,
Allopurinol is administered to decrease uric acid production. It accomplishes this by inhibiting the enzyme xanthine
oxidase, which is responsible for the formation of uric acid
from the purine breakdown products hypoxanthine and xanthine. 3.3o However, because allopurinol is excreted solely by
the kidneys, doses are decreased if renal failure develops.
Hyperphosphatemia may be prevented by the oral administration of binding resins such as aluminum hydroxide, which
enhances phosphate excretion in the stool. Calcium supplements are used with caution because an increase in serum
calcium while the patient is hyperphosphatemic may accelerate calcium-phosphorus precipitation. 3.22
For children presenting with oliguric renal failure and
increased serum uric acid levels, management is centered on
treatment of acute renal failure. Renal obstruction is ruled
out before initiating therapy. Once obstruction is ruled out,
and the child's volume status is determined, definitive
treatment may begin with the initiation of renal replacement
therapy (RRT). Choice of RRT will be dependent on the
child's hemodynamic stability and the severity of metabolic
abnormalities. 4.8.27
Immediate intervention for hyperkalemia is necessary if
serum potassium levels are greater than 6.5 mEqlL or
characteristic ECG changes occur. Chapter II outlines the
appropriate management of hyperkalemia. Emergent dialysis may be necessary in situations in which hyperkalemia
and renal failure cannot be managed with the measures
described. It may also be used in cases when neurologic
symptoms develop.3.4.7 Regardless of the presence of renal
failure, certain interventions are important for the management of any child with ATLS. Hemodynamic monitoring,
including arterial and central venous pressure monitoring is
necessary to guide and monitor fluid therapy. In the presence
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of renal failure and/or cardiopulmonary dysfunction, placement of a pulmonary artery catheter may be useful in
monitoring fluid balance for complications of aggressive
hydration, such as congestive heart failure or pulmonary
edema. 4 Additional nursing interventions are similar to
those for critically ill children who are experiencing acute
renal failure from any cause. Attentive monitoring includes
hourly urine outputs, urine pH and urine specific gravity
with each void, and frequent electrolyte levels (at least every
4 hours for the first 24 hours, and then every 6 to 8 hours).
Because ATLS often occurs in the presence of a high
leukocyte count, some practitioners have advocated the use
of leukopheresis, exchange transfusions, or low-dose steroids as treatment modalities to reduce the consequences of
massive tumor lysis. However, these modalities have not
been subject to any controlled analysis and are therefore not
recommended as standard therapy3

."......-

Superior Vena Cava Syndrome/Superior
Mediastinal Syndrome
The presence of thoracic tumors may pose a variety of
severe complications in the child with malignancy. Most
commonly, these complications are related to the presence
of anterior mediastinal masses. Anterior mediastinal masses
occur most commonly in children with metastatic diseases,
such as Hodgkin's disease and non-Hodgkin's Iymphomas?2 Other related malignancies include acute T-cell
lymphoblastic leukemia, mediastinal granulomas, neuroblastoma, rhabdomyosarcoma, and Ewing's sarcoma?'?
Pathogenesis. Two distinct clinical syndromes have
been associated with the presence of anterior mediastinal
masses: superior vena cava syndrome (SYCS) and superior
mediastinal syndrome (SMS). SYCS develops because of
either extrinsic compression of the superior vena cava
(SYC) by tumor invasion into surrounding anatomic structures, or by intrinsic obstruction of the SYC from tumor or
thrombotic complications of venous access devices 4 .22 True
SYCS without tracheal compression is a relatively rare
condition in children, occurring in approximately 12% of
children with malignant anterior mediastinal tumors at
presentation) (Fig. 25-4). More often, anterior mediastinal
tumor masses cause not only compression of the SYC, but
concomitant compression of the trachea or mainstem
bronchus and life-threatening airway obstruction. This
combination of SYCS and airway obstruction is termed

superior mediastinal syndrome.)
Both the SYC and pediatric airway are very susceptible
to obstruction and do not resist extrinsic mechanical com-

pression. The SYC is a thin-walled, potentially collapsible
vessel with a relatively low intraluminal pressure that is
located within a tight compartment formed by the mediastinum and sternum. The location of the lymph nodes, which
surround the SYC, and the thymus may also cause compression of the vena cava when involved with tumor or infection.3.4·22 Similarly, the pediatric airway is small and compliant, making it highly vulnerable to collapse if compressed
by a mediastinal mass. In addition, certain nonneoplastic
states, such as infection or bleeding into the retropharyngeal
space, may lead to tracheal compression or obstruction?·8

Fig. 25-4 Superior mediastinal mass with SVCS in a child with
lymphosarcoma.

Because of the close proximity of the SYC to the trachea
and other airway structures, the potential for SYCS or SMS
should be considered in all children presenting with anterior
mediastinal masses until proven otherwise. In SYCS, both
compression and obstruction of the SYC decrease venous
return from the head, neck, and upper thorax. The decrease
in venous return leads to a decrease in ventricular volume
and filling pressures, which in turn leads to a decrease in
ventricular output, creating a cycle of cardiac compromise
and shock. 4 .7 However, the onset of pronounced cardiac
compromise and shock may be varied in the pediatric
oncology patient. Similarly, compression of the pediatric
airway leads to inadequate oxygenation and ventilation,
progressing from respiratory distress to complete respiratory
failure.
SYCS or SMS resulting from rapidly growing tumors
may demonstrate a rapid onset of signs and symptoms. Yet,
if the obstruction has occurred over time, such as with a
slow accumulation of blood around the SYC or compression
or invasion by a slow-growing tumor, collateral blood flow
may have developed to allow for some degree of venous
return. The child may be able to compensate for some time
with collateral blood flow, yet eventually this flow will
prove ineffective and the child will exhibit more pronounced
symptoms of SYCS 3 Inadequate venous drainage from the
head and the development of cerebral edema may cause
seizures and increased ICP3.4.?
Clinical Presentation. Clinical manifestations of
SYCS and SMS are dependent on both the degree and
duration of obstruction. If the compression has increased
slowly over time, signs and symptoms of these syndromes
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may be more subtle and difficult to attribute to an exact
cause. Presenting signs and symptoms may be tachypnea,
wheezing, cough, and stridor. Acutely, a child may present
with fever, cough, and mild shortness of breath, progressing
to signs and symptoms of respiratory distress. Additional
clinical manifestations for both rapid or insidious onset
include hoarseness, dyspnea, chest pain, diaphoresis, jugular
venous distension, upper extremity edema, conjunctival
edema, and plethora and cyanosis of the face, neck, and
upper extremities.3· 7 •22 Fullness may be noted in the brachial
veins if the right arm is raised above the chest and evidence
of collateral venous circulation on the chest and abdomen
may also be present when SVCS develops over time.
Critical Care Management. SVCS and SMS are
potentially life-threatening emergencies that require prompt
diagnosis and recognition of signs and symptoms. In
emergent cases, diagnosis of SVCS or SMS is possible
through the history and physical examination, with confirmation via chest radiograph. If time allows, a CT scan or
magnetic resonance imaging (MRI) scan of the chest and/or
echocardiographic imaging assists in determining both the
location and extent of the tumor, as well as the degree of
obstruction. In addition, venograms may be useful if SVCS
is thought to be caused by a suspected thrombus within a
central catheter. 3,4,22
A CBC yields helpful information and is the least
invasive means of determining whether or not a leukemialymphoma syndrome exists. Diagnosis is attempted by the
least invasive means possible. A histopathologic diagnosis
via bone marrow biopsy or tumor biopsy is obtained as soon
as possible to initiate definitive treatment. However, in an
emergent situation in which airway compromise or cardiovascular instability may be present or impending, the
risk-versus-benefit ratio is assessed before performing such
procedures.
Initial management is centered on maintaining airway
patency and cardiovascular stability. The aggressiveness of
initial management is dependent on the child's presenting
clinical condition. The child is positioned in a semi-Fowler
position to improve gas exchange with supplemental oxygen administered as needed. 7 However, intubation and
mechanical ventilation may be required to protect the
airway against potential or actual obstruction until the tumor
bulk decreases. Children with SVCS or SMS are at a much
higher risk for complications, including death, during
intubation. They may suffer respiratory and/or cardiac arrest
when placed in a supine position for sedation and/or
anesthesia caused by further impedance of venous return
and airflow. 3 ,7.22
Neuromuscular blockade agents are avoided during
intubation of the child with actual or potential airway
obstruction, because the child will be unable to breathe
spontaneously should the practitioner not be able to pass the
endotracheal tube past the level of obstruction. In addition,
general anesthesia causes an increase in abdominal muscle
tone, a decrease in respiratory muscle tone, diminished lung
volumes and bronchial smooth muscle relaxation, and
absent caudal movement of the diaphragm. These changes
may exacerbate the effects of extrinsic compression of the
vena cava and airway. 3 General anesthesia is avoided
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whenever possible, and reserved for use with difficult
intubations. 3.8 Halothane is the preferred inhalational anesthetic agent for intubation of a child with a mediastinal mass
and severe airway obstruction. 8 Furthermore, in cases of
critical airway obstruction, elective or emergent intubation
is best achieved via fiberoptic bronchoscopy because the
bronchoscope may more easily be guided past the level of
obstruction, with the endotracheal or nasotracheal tube
being inserted over the bronchoscope.
Radiation therapy and chemotherapy tailored to the
histopathologic reports are the primary and preferred modes
of treatment. However, in emergent situations involving
airway compromise, empiric radiation therapy and/or chemotherapy may be instituted. 3 .22 In addition, surgical
removal or debulking of the tumor mass may be warranted.
Steroids may be given for cytoreduction of the tumor and to
reduce inflammation caused by tumor invasion or compression, providing symptomatic reliee· 22 Thrombolytic therapy is instituted in those situations when SVCS is associated
with intracaval thrombosis. Lange and colleagues describe
success with infusion of urokinase at 200 mg/kg/hour3
Frequent and careful assessment of cardiopulmonary
function is key to the management of the child with SVCS
or SMS. In addition, because of the risk of cerebral edema
and neurologic compromise, frequent neurologic assessment, including pupil size and reactivity, and level of
consciousness are performed. If swelling of the upper
extremities exists, the upper extremities are elevated to
promote venous return and the lower extremities are used
for venous access and blood pressure measurements.
Diuretics, if ordered to reduce edema, are administered with
caution to prevent dehydration and further decrease in blood
flow and cardiac output.

Spinal Cord Compression
Spinal cord compression (SCC), while typically not lifethreatening to most patients, causes severe neurologic
morbidity. Prolonged cord compression may cause irreversible paralysis, sensory loss, and sphincter incompetence. 22
Primary spinal cord tumors are rare in children. More often,
SCC is due to extrinsic tumor or metastatic tumor involvement that erodes the spinal column. Occasionally, the development of a spinal dural bleed related to lumbar puncture in
a thrombocytopenic patient may cause signs of compression.3,8 Lange and associates report that 4% of children with
cancer develop spinal cord dysfunction, usually related to
tumor compression. 3
Pathogenesis. Most SCC in children with cancer is
due to epidural compression from extension of paravertebral
tumor through the intervertebral foramina 22 (Fig. 25-5).
Metastatic spread to the cord parenchyma, as well as
secondary edema and ischemia, may also injure the spinal
cord. Metastatic spinal cord disease in children is most
commonly associated with sarcomas; however, neuroblastomas, lymphomas, leukemias, Wilms' tumor, or primary
tumors of the CNS have also been implicated. 3 •4 .8 Although
most SCC occurs during the terminal metastatic phase of
disease, it may be a presenting symptom in neuroblastomas
or lymphomas.
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Metastatic tumor at T9 with epidural disease and

sec.

Clinical Presentation. Signs and symptoms of SCC
are dependent on tumor location and the age of the child.
Back pain, both localized and radicular in nature, is seen in
up to 80% of children with SCC and may be exaggerated by
activities such as coughing and sneezing, straining, flexion
of the back, and leg raising. 4 ,22 Motor weakness is common,
yet rarely a presenting symptom. Sensory deficits are seen
less often, or when present are difficult to document,
especially in young children. 22 When present, sensory losses
typically manifest as numbness, tingling, and loss of sensation. Identification of the level of sensory loss may help
determine the extent of spinal cord involvement. Changes in
bowel or bladder habits may also indicate spinal cord involvement, typically below the level of the second lumbar
vertebrae 4
Critical Care Management. Any child with neoplastic disease and complaints of back pain is presumed to
have SCC until proven otherwise. Diagnostic evaluation
includes obtaining spine radiographs. although fewer than
half of children with SCC present with abnormal films.
Although lumbar myelography was the most useful diagnostic tool for SCC, MRI is now the diagnostic study of
choice for detemlining tumor location and the degree of
cord block. 22
Children presenting with back pain and neurologic
deficits or a history of progressi ve spinal cord dysfunction
receive an immediate intravenous bolus of dexamethasone
at a dose of I to 2 mg/kg, followed by emergent MRI study.
If there are no signs of neurologic deficit, nor signs of

progression of mild deficits, a lower dose of corticosteroids
is administered, followed by MRI study within 24
hours. 3.4.22 If the SCC is thought to be epidural in origin, the
spinal cord is decompressed immediately. Decompression
may be achieved via administration of high-dose dexamethasone, followed by emergent radiation therapy or surgical
decompression. Although there are no studies to support one
therapy over the other, both radiation therapy and surgical
intervention have unique benefits. Some tumors, such as
lymphomas and neuroblastomas, are particularly radioresponsive, providing a less invasive mode of treatment. On
the other hand, surgical decompression may be useful in
identification of tumor histology.3,4 Once tumor histology is
identified, the administration of tumor-specific chemotherapy may be of benefit.
Initial care of the child with SCC is centered on relief of
the compression by the methods discussed above. In
addition, adequate pain assessment and management is
necessary because SCC may be very painful. Once spinal
cord decompression is achieved, patient management is
similar to the care of any child with spinal cord injury.
Chapter 28 provides complete information on the unique
care needs of the child with spinal cord injury. The
prognosis for children with SCC typically reflects the level
of involvement at the time treatment is initiated. Patients
who are ambulatory upon presentation usually remain
ambulatory. However, although most adults who present
nonambulatory rarely regain function, more than half of
children presenting non ambulatory regain the ability to walk
after emergent intervention 3 .22

COMPLICATIONS OF LEUKEMIC DISEASE
Childhood leukemias may be classified as either acute or
chronic malignancies, and are thought to be due to the
malignant transformation of a single abnormal progenitor
cell with the ability to expand by indefinite self-renewal.31
The causes of this transformation are highly complex,
multifactorial, and are not yet fully understood. There are
both different types and subtypes of acute and chronic
leukemias, which are thought to occur as the malignant
transformation occurs at various points along the myeloid or
lymphoid stem cell lineages.

Hyperleukocytosis
Hyperleukocytosis is defined as a peripheral WBC count
exceeding 100,000/mm3 •3 The high numbers of circulating blasts cause capillary obstruction. microinfarction,
and organ dysfunction. Leukocyte counts greater than
300,OOO/mm3 are associated with a high risk of morbidity
and mortality. Hyperleukocytosis is most often associated
with the myeloid leukemias, as compared with the lymphoid leukemias. Lange and colleagues describe hyperleukocytosis as occurring in 9% to 13% of children
with ALL, in 5% to 22% of children with acute nonlymphoblastic leukemia (ANLL), and in most children
with chronic myelogenous leukemia (CML) in chronic
phase. 3
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Pathogenesis. The complications of hyperleukocytosis occur as sequelae of leukostasis, which causes increased
blood viscosity and impaired blood flow to many organ
systems. The aggregation of blast cells causes sludging in
the vascular system. Thrombus formation occurs as a result
of plasma being trapped between large blast cells. Although
this disruption to blood flow may occur in any organ system,
the small vessels of the lung and brain are most at risk for
devastating effects of hyperleukocystosis. 3 .7 .22
Leukostasis in the capillary beds of the brain or lung can
cause life-threatening complications. In the cerebral vasculature, local cell proliferation damages cerebral vessels,
leading to intracerebral hemorrhage and thrombus formation. In the lungs, alveolar damage occurs as blast cells
degenerate in the pulmonary vessels and interstitium,
releasing their intracellular contents. Respiratory failure
may ensue because of decreased numbers of functional
alveoli. Lactic acidosis may occur because of the poor
perfusion at the microcirculatory level, with resultant
anaerobic metabolism of the blast cells. And finally,
impairment of renal blood flow may lead to the same
metabolic consequences as previously discussed for ATLS,
namely hyperuricemia, hyperphosphatemia, hyperkalemia,
and potential renal failure.J· 22
Clinical Presentation. The clinical presentation is
most often manifested in the pulmonary system and CNS,
although presenting symptoms may be subtle or indistinguishable from other clinical states. Signs and symptoms are
generally dependent on the area of microcirculatory involvement. Pulmonary leukostasis can lead to a variety of
clinical manifestations, from dyspnea to cyanosis and
hypoxia requiring intubation. Both hypoxemia and lactic
acidosis may be present and identified via laboratory
analysis. CNS involvement may be observable by mental
status changes progressing from agitation and confusion to
delirium or stupor. Signs of increased ICP, such as blurred
vision, ataxia. retinal distention, or papilledema. may also
be present]
Diagnostic evaluation for children with suspected hyperleukocytosis includes a CBC with clotting times, arterial
blood gas analysis, chest radiograph, and CT scan. In
addition, a venogram or arteriogram may be performed if
vessel thrombosis is suspected.
Critical Care Management. Because of the potential for devastating CNS or pulmonary injury, establishment
and maintenance of effective oxygenation, ventilation, and
perfusion should immediately occur, especially in children
with WBC counts of greater than 300,000/mm 3 Treatment
for hyperleukocytosis is aimed at rapidly reducing the
number of circulating leukocytes. Management includes the
immediate institution of hydration, alkalinization, and
allopurinol administration, as discussed in ATLS management, as well as the prompt initiation of specific cytoreductive therapy.J.7·22 Cytoreductive therapy is discussed at the
end of this section.
As with any child with an oncologic disorder, these
children may require platelet and red blood cell (RBC)
transfusions. Platelet transfusions are administered when the
platelet count falls below 20,000/mm 3 to minimize the risk
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of cerebral hemorrhage. Platelets are not known to significantly increase blood viscosity. However. RBC transfusions
are used cautiously because this therapy may cause a further
increase in blood viscosity, precipitate leukostasis, and lead
to further organ dysfunction. It is often recommended that
RBC transfusions be given only for hemoglobin levels less
than 7 to 8 g/dl. Hemoglobin levels should not be raised to
greater than IO g/dl. 3.22
The approach to treating the child with a potentially fatal
WBC count remains controversial. Leukopheresis is one
treatment modality that is thought to be beneficial in
reducing a large tumor cell burden and decreasing the
metabolic load on the kidneys. Advocates of this form of
therapy believe it may reduce the WBC count by 20% to
60% while waiting for the effects of cytoreductive therapy
to occur7 .22 The disadvantages of leukopheresis include the
need for anticoagulation therapy to perform the procedure
and risk of bleeding, as well as difficulty obtaining vascular
access in small children, and the limited availability and
expertise for this intervention in many institutions. In small
children, exchange transfusion is often less difficult than
leukopheresis and may be performed instead. However, as
with leukopheresis, there are no studies to support the
effectiveness of either of these therapeutic modalities. 22
Some centers also recommend the use of emergent cranial
irradiation to prevent intracranial hemorrhage.
Children with leukostasis require careful pulmonary and
neurologic assessment for the development of complications
such as respiratory failure and cerebrovascular accident. In
addition, hematologic laboratory data is monitored frequently. Ventilatory management may be needed in situations of severe neurologic or respiratory deterioration.
There are various types of childhood leukemias and
current therapies for each malignancy. Numerous treatment
protocols exist for childhood leukemias. Both single and
a variety of multiple drug regimens have been developed
to treat childhood leukemias, with the choices of drugs
being highly dependent on the type of leukemia being
treated. However, despite the wide variety of chemotherapeutic drug regimens available, the common goal in the
treatment of childhood leukemias (particularly those presenting with hyperleukocytosis) is to induce and maintain remission, or lack of evidence of disease. The ability
to achieve complete remission quickly and to maintain
remission is directly correlated to overall prognosis and
degree of long-term survivability.) 1 Because of the desire to quickly induce remission, a child presenting with
hyperleukocytosis may require the administration of chemotherapeutic agents while in the PICD. Because the
administration of chemotherapeutic agents requires specialized training, the critical care nurse collaborates with
pediatric oncology specialists and is aware of institutional regulations regarding the administration of cytotoxic
agents.
An example of cytoreductive therapy during the induction phase of treatment of ALL is the administration of
vincristine and prednisone. This combination induces remission in approximately 85% of children with ALL. However,
the addition of L-asparaginase, an anthracycline (such as
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daunorubicin), or both has been shown to improve the rate
of remission from induction therapy to 95%?1
Although certain side effects, or toxicities, are inherent to
particular chemotherapeutic agents, there are several common toxicities that may manifest after the administration of
all chemotherapeutic agents. Even though chemotherapeutic
agents are meant to target malignant cells, they most often
cannot differentiate normal host tissue cells from malignant
cells. Certain normal host tissue cells, such as bone marrow
and mucosal epithelial cells, are particularly sensitive to the
cytotoxic effects of chemotherapeutic drugs, even when
these drugs are given in therapeutic doses. Common toxic
effects, because of this increased tissue sensitivity, include
myelosuppression (with resultant pancytopenia), nausea and
vomiting, alopecia, both oral and intestinal mucositis, and
liver dysfunction. 32 Ongoing research is focused on minimizing toxic effects of chemotherapeutic agents through the
development of new chemotherapy drugs and newer therapeutic means for blunting these toxic responses.

COMPLICATIONS OF BONE MARROW
TRANSPLANTATION
Special Considerations in the Bone Marrow
Transplant Patient
BMT is a burgeoning therapy that is no longer reserved
for the treatment of hematologic and oncologic malignancies. Clinical trials have either been conducted, or are in
progress, to study the efficacy of BMT for a wide variety of
nonneoplastic diseases, such as severe aplastic anemia,
chronic granulomatous disease, severe combined immunodeficiency, and autoimmune diseases, such as multiple
sclerosis, systemic lupus erythematosus, and juvenile rheumatoid arthritis. 33 . 35 In addition, although the term "BMT"
is still used as a general term to describe the collection of
hematopoietic precursor cells from bone marrow, these cells
may also be obtained from peripheral blood stem cells
(PBSC) or umbilical cord blood (VCB). These newer
methods of transplantation are used in the hopes of
preventing some of the complications of traditional BMT.
Discussion of the differences between these newer methods
is beyond the scope of this chapter. Recognizing the vast
complexity of state-of-the-art transplantation, this section
will review fundamental principles of BMT and common
complications associated with BMT.
There are two primary forms of BMT: allogeneic and
autologous. A third form of transplant is a syngeneic
transplant from an identical twin. Allogeneic transplantation
occurs when a designated donor contributes healthy bone
marrow, PBSCs or VCB to a patient with malignancy. The
preferred donor is a human leukocyte antigen (HLA)matched sibling, although unrelated HLA-matched donors
matched through an international registry or unmatched
related donors may be used. In order to accept the donor
marrow or cells, a sufficient degree of immunosuppression
must be provided to prevent acute rejection of the cells and
allow a "graft" to occur. This immunosuppression occurs
via a "conditioning" or "preparative" regimen in which the

patient's own marrow is either partially or fully ablated
using high-dose chemotherapy, with or without total body
irradiation (TBI).8.36 Once the patient's marrow is ablated,
the donor's marrow is intravenously administered to the
recipient with the hope that the donor's cells will engraft and
eventually become the patient's new marrow. Simply stated,
engraftment refers to the point at which the donor cells have
sufficiently established themselves as the patient's new
hematopoietic system. The point of engraftment is determined by laboratory analysis ofthe recipient's marrow, with
the exact number of cells required for engraftment dependent on the underlying disease and type of transplantation
performed. After transplantation, the recipient's hematopoietic system may be completely from the donor (known as
donor chimerism), completely from the recipient (known as
graft rejection with autologous recovery), or a mixture of
donor and recipient cells (referred to as mixed chimerism).
The most favorable outcomes occur with donor chimerism;
however, some degree of mixed chimerism may be present
with a clinical remission of disease??
Autologous BMT refers to the process in which patients
donate their own bone marrow or PBSCs for use later in
their treatment. This form of BMT is typically used for
patients with lymphomas or solid tumors.8.36.38 Preferably,
the marrow is collected when the patient is in complete
remission. Once collected, the marrow may be treated in the
laboratory with specific antitumor monoclonal antibodies or
selected chemotherapeutic agents, and then is cryopreserved. After receiving the conditioning regimen, the
patients' marrow is thawed and intravenously administered
back to the patient.8.36
Complications of allogeneic BMT include infections,
respiratory failure resulting from infectious or noninfectious
pneumonitis, acute and chronic graft-versus-host diseases
(GVHDs), and veno-occlusive disease (VOD).8.36 Although
autologous BMT does not have the same complications
associated with allogeneic BMT, it is associated with a
higher rate of recurrent disease.

Infection
Infection is the leading cause of morbidity and mortality in
patients who have undergone a BMT. The risk of lifethreatening infections is most worrisome during the first
3 months after transplantation, with the greatest risk
occurring during the first month. As the transplanted marrow
engrafts, the immune system recovers. Mature blood cells
are usually produced within 3 to 4 weeks. The initial month
of severe neutropenia is typically characterized by bacterial
and candidal infections 36 Vigilant attention to both the
prevention and prompt recognition of infections is crucial
during this time of pancytopenia and increased susceptibility (see Box 25-1 for a review of assessment parameters and
care considerations for the child with neutropenia and
thrombocytopenia). Although the use of full-protective
isolation for allogeneic transplant patients has fallen out of
favor, many facilities require the use of hepafilter rooms
for fully ablated BMT patients during the first month
posttransplant.
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In the 1- to 3-month period after transplantation, infections from viruses, fungi, and protozoans develop, especially in patients with GVHD. Serious viral infections, particularly as a result of CMV or reactivated herpes simplex
virus, are a major concern. The risk of infection progressively declines 3 months after transplantation. Autologous
BMT patients and allogeneic BMT patients without chronic
GVHD are at a lower risk of infection. However, allogeneic
BMT patients who have developed chronic GVHD are at
great risk for recurrent bacterial infections.3 6 Prophylactic
antiinfection medications are typically administered to
transplant patients as discussed earlier in this chapter.

Pulmonary Complications
Pulmonary complications occur in approximately 10% to
15% of pediatric BMT patients. 39 These complications are
often described according to the time that they occur in the
transplant process. Initially, lung damage may occur as a
sequelae of the conditioning regimen, most commonly as
a result of the irradiation. The lungs, more specifically
the interstitium, are particularly sensitive to the cytotoxic
medications and irradiation used during conditioning. 39 Scar
tissue may form in the interstitial space during the healing
process, interfering with gas exchange and respiratory
mechanics.
As with other infections, the most common pulmonary
infections during the first month posttransplantation manifest as gram-negative bacterial or fungal pneumonias.
Pulmonary edema, associated with pulmonary endothelial
cell damage caused by chemotherapy and radiation, is
another respiratory complication that can occur in the
second and third week after BMT. During the l- to 6-month
posttransplant period, interstitial pneumonias are common.
Causative organisms during this time include CMV as well
as idiopathic lung problems. After 6 months, pulmonary
dysfunction can be related to chronic GVHD or continued
immunologic deficiencies. Bacterial pneumonias continue
to occur during this time.
The most common form of interstitial pneumonitis (lP)
used to be CMV infection. However, with the routine
administration of prophylactic ganciclovir, this incidence is
decreasing. Instead, the most current form of IP is now
idiopathic IF in which no causative organism can be
identified. This increase in idiopathic disease may represent
unrecognized infections or the toxic effects of chemotherapy
or radiation therapy that has been administered as part of the
conditioning regimen. 37
RSV infection is of particular concern in the pediatric
BMT patient. A major factor for morbidity and mortality
seems to be whether the RSV infection has progressed to the
lower respiratory tract or remains in the upper respiratory
tract. Mortality rates for BMT patients with lower respiratory tract RSV infection, progressing to respiratory failure,
ranges between 31 % and 100%. Mortality depends on
factors such as the choice of treatment used, when the
treatment was initiated, and whether or not the patient was
engrafted at the onset of infection and disease. 14 . I7
Regardless of the cause of respiratory dysfunction and/or
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failure, once mechanical ventilation is required, the risk of
morbidity and mortality significantly increases. Primary
pulmonary parenchymal disease, in the setting of multisystem organ failure and/or hemodynamic compromise, has
been associated with very high mortality rates in both adults
and children. 40.4 1 Price and colleagues report an 18.8%
survival rate for intubated BMT patients, compared with a
65.7% survival rate in nonintubated BMT patients. 42 Likewise, Huaringa and associates report an 18% survival rate in
adult BMT patients who developed pulmonary complications and required mechanical ventilation 43 Nichols and
colleagues reported a 9% survival rate for pediatric BMT
patients with respiratory failure. 44 Most recently, Keenan
and colleagues reported a 16% survival rate for intubated
pediatric BMT patients who survived for 30 days postextubation. 45 In addition, this study identified major risk factors
for death for pediatric patients undergoing mechanical
ventilatory support. The risk factors included respiratory
failure as the reason for intubation, the presence of
pulmonary infection, and impairment of more than one
organ system, and were associated with survival rates of 4%,
6%, and 2%, respectively. The authors further reported that
the 2% survival rate applied if more than one organ system
was dysfunctional 7 days after intubation, and that no
children in their study survived if the combination of acute
respiratory distress syndrome, hepatic failure, and renal
failure were present. 45

Acute Graft-Versus-Host Disease
Acute GVHD remains a significant cause of morbidity and
mortality after BMT. 46 This form of acute rejection occurs
in up to 80% of patients after allogeneic BMT. 8 .47
Pathogenesis. Although acute GVHD is defined as
occurring within the first 100 days of transplantation, it
typically manifests within the first 2 to 5 weeks after
transplantation. 47 This disorder, which primarily affects the
immune system, skin, liver, and GI tract, results from
allogeneic donor cytotoxic T lymphocytes recognizing the
immunocompromised recipient, or host, as foreign and
attempting to reject the host. 8 . 36.46 The severity of GVHD
seems to be directly related to the number of T cells
transferred during transplantation, to the degree of HLA
differences between donor and recipient, and to the degree
of immunocompromise in the recipient. 47
Clinical Manifestations. Manifestations of acute
GVHD may occur as early as I to 3 weeks after transplantation. Skin manifestations usually begin with a maculopapular rash involving the palms and soles, which is often
intensely pruritic. This rash may resolve spontaneously or,
in the most severe forms, progress to bullae formation, and
severe sloughing and desquamation of the skin. 36 •46
Liver involvement may range from minimal jaundice
and mild elevations in liver function test values to complete liver dysfunction; however, hepatic failure with
encephalopathy resulting from GVHD is rare. 36 Intestinal
manifestations include severe diarrhea, nausea, vomiting
and crampy abdominal pain. The diarrhea is commonly
green, watery, mucoid stool mixed with fecal casts formed
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25-4 Criteria for Severity Index for Acute Graft-versus-Host Disease
Liver Involvement

Skin Involvement
Stage
(Max.)
I

2
3
4

Extent
of Rash
<2S%
2S%-SO%
>SO%
Bullae

Stage
(Max.)

o
Or
Or
Or

Gastrointestinal Involvement

Total Bilirubin
(mglIOO mil

Stage
(Max.)

o

<2.0

1-2

2.0-6.0

3

6.1-1S.0

4

>IS.O

Or
Or
Or

1-2
3
4

Volume of
Diarrhea (mIIDay)
<SOO
SOO-ISOO
>ISOO
Severe pain and ileus

,I·.,·

Mffrom Rowlings PA, Przepiorka D, Klein JT et al: IBMTR Severity Index for grading acute graft-versus·hoS1 disease: retrospeclive comparison with
~fGlucksbcrg grade. Br J HaemalO/97:855-864, 1997.
~iAssign Index based on maximum involvement in an individual organ syslem.

by the mix of stool and sloughed intestinal cells. In 13% of
patients, the diarrhea may be accompanied by anorexia and
dyspepsia. 3M7
A histologic diagnosis is usually necessary to rule out
other causative factors for the clinical signs and symptoms,
including chemotherapy, radiation, or infection. Diagnosis is
accomplished by biopsy of the involved organ, although
liver biopsies are often not possible in the immediate period
following BMT because of severe thrombocytopenia. The
severity of GYHD is graded on a scale of I to IV based on
the extent of damage to the organ (Table 25-4). The original
grading system, based on criteria developed in 1975, was a
subject of debate in the transplant community because of
considerable interobserver variation. In 1997 the International Bone Marrow Transplantation Registry (IBMTR)
proposed revised guidelines for grading of GYHD, and
validated the guidelines through retrospective analysis,
although no analysis has been performed in the pediatric
patient. 48 For example, the volume of diarrhea must be
adjusted by body surface area. Nonetheless, these guidelines
are used for determining treatment and predicting outcomes.
Children presenting with grade II GYHD or above are at a
higher risk of developing life-threatening infections and
complications.3 6 .46
Critical Care Management. The preferred treatment
for GYHD is prevention. Matching the donor and recipient
at the major histocompatability complex significantly reduces the incidence of acute GYHD. However, even when
a sibling donor and recipient have fully matched HLA
typing, moderate to severe GYHD may still occur because
of the presence of minor transplantation antigens not
detectable by current typing technology.3M6 In addition,
patients needing BMT may not have a matched sibling
donor. The use of matched or mismatched unrelated donors
is increasing in frequency, although such transplants remain
controversial. Newer BMT protocols are attempting to use
T-depleted marrow, in which T-cells are removed from the
marrow before transplantation in an effort to reduce the
immunologic response in the recipient. 36,49,50 The T cells
may then be reinfused at a later time, especially if needed to
fight infection. However, the use of T-replete marrow has
been associated with a higher incidence of acute GYHD,
and the combination ofT-depleted and T-replete marrow has

an increase in graft failure compared with BMT from a
matched sibling donor. 50 This increased risk of graft failure
and relapse may be due to the immune-mediated antileukemic effect of GYHD. 51
The use of medications to suppress, remove, or inactivate
T lymphocytes is also important in prevention. Immunosuppressive agents may include MTX, cyclosporine (CSP), antithymocyte globulin (ATG), and prednisone 8 ,36 The use of
two agents, typically MTX and CSP, may result in significantly less acute GYHD and are generally administered for
at least several months posttransplantation. 8 .36 Prevention of
GYHD also includes the irradiation of all blood products
administered to transplant patients to prevent the transfusion
of active T lymphocytes from product donors.
Should GYHD develop despite prophylaxis, immunosuppression may need to be intensified. Mild (grade I) cases
may not always require intervention, but more extensive
disease typically involves both increasing the dose of
cyclosporine and the addition of methylprednisolone to the
MTX and CSP prophylactic regimen. In severe cases,
medications such as ATG or thalidomide may need to be
added, although studies have not yet proven their efficacy in
children with acute GYHD. R.52 Mehta and colleagues report
efficacy of thalidomide in at least 50% of children with
chronic GYHD, but little or no efficacy in children with
exclusively acute GYHD 52
The skin is assessed at least every 8 hours. In cases
of grade I and II GYHD of the skin, minor maculopapular rashes, dry skin, and itching can be treated with
meticulous skin care and lubrication with lotions and
creams. In addition, mild nonirritating soaps are used.
Antihistamines may be administered for pruritus. More
severe cases of GYHD are rare, but total body sloughing
may occur and is treated similarly to thermal injuries or
diseases such as Stevens-Johnson syndrome or toxic epidermal necrolysis. As such, these cases may require skin
debridement. Awareness of high infection risk to these
children because of the loss of skin integrity is critical. The
skin is kept clean and dry, and adhesi ve tape is avoided. Skin
lesions are cultured as indicated. In addition, the presence of
severe GYHD skin involvement will require vigilant pain
assessment and management, typically using continuous
narcotic infusions. See Chapter 29 for discussion of the
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special care needs of children with severe loss of skin
integrity.
GVHD of the GI tract requires strict intake and output records, frequent (usually twice daily) weights, monitoring of electrolytes because stool output may be excessive, control of nausea and vomiting with antiemetics,
meticulous rectal care after each stool, and nutritional
support with hyperalimentation to allow for bowel rest.
The perianal area is assessed at least every 8 hours for
redness, fissures, or signs of abscess formation. The stool is
assessed for amount, color, and consistency. Because of the
potential blood loss through the GI tract, all stool is tested
for blood and frequent monitoring of hematocrit and platelet
values may be necessary. These children are also at an
increased risk for infection because of GI mucosal
breakdown.
Severe oropharyngeal mucositis may be present with
acute GYHD, although it may also occur as a result of
chemotherapy administration, radiation therapy, and infection. The degree of mucosal damage may range from
mild inflammation to severe ulceration, bleeding, and
potential airway obstruction.53 Regardless of the degree of
mucosal damage, pain and dryness are typically present,
causing a significant impact on quality of life. Because
there are no effective primary treatments for severe
oropharyngeal mucositis, management is focused on relief of symptoms. Although there are differing opinions across institutions on the specific management of
mucositis, current general management principles include pretransplant dental consultation (to eliminate dental
problems that may exacerbate mucositis) and basic routine oral care. In addition, the use of topical anesthetic agents (such as lidocaine), mucosal coating agents
(such as antacid solutions or hydroxypropyl cellulose),
antiinflammatory agents (such as topical benzydamine),
and saliva replacement agents may provide relief of
pain and dryness. Prevention of secondary infection is
crucial and may include the administration of topical
antibacterial and antifungal agents or systemic prophylactic
antiviral agents. 53

Vena-occlusive Disease
In the early days of BMT, veno-occlusive disease (VOD)
went essentially unrecognized as a separate disease process
because liver problems were common in the posttransplant
period. Patients often suffered from viral hepatitis, bacterial
and fungal infections, GVHD, and liver complications from
hyperalimentation. This is no longer the case, and VOD is
now recognized as a major complication of BMT, accompanied by significant morbidity and mortality.8.54
Important risk factors for the development of VOD
include preexisting liver disease or dysfunction, and the
use of busulfan (BU) as part of the conditioning regimen.
In 1996, Rozman and colleagues, on behalf of the IBMTR,
examined risk factors for hepatic VOD in 1717 recipients
of HLA-identical sibling transplants. 55 The authors reported that the relative risk of developing VOD after the
use of BU for conditioning was 2.8 compared with the
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use of TBI. In a subsequent study, the IBMTR reported
that deaths from VOD were more frequent in patients
receiving BU/CSP versus CSPffBI for the conditioning
regimen. 56
Pathogenesis. von is characterized by deposits of
fibrous materials that block small venules of the liver,
causing an obstruction to blood flow from the liver. 8
Sinusoidal outflow obstruction causes the fluid content of
the blood to be drained through the lymphatic system and
into the peritoneal cavity, leading to ascites.
Clinical Manifestations. Symptoms typically develop I to 3 weeks after BMT and are initially the result of
intrahepatic portal hypertension. Not all symptoms may
occur in all children. Clinical characteristics depend on the
degree of obstruction of hepatic blood flow. They include
sudden weight gain, right upper quadrant pain, hepatomegaly, ascites, jaundice, encephalopathy, increased total bilirubin with normal or mildly elevated liver function tests,
and coagulopathy. Some cases of VOD are self-limited with
spontaneous resolution, whereas others are progressive and
lethal. 54 Other liver diseases that may have more specific
treatments, such as hepatitis or GVHD, must be ruled out.
Typically, jaundice appears later in GVHD, and ascites is
not common in liver dysfunction caused by GVHD,
hepatitis, and viral or fungal infections54
Critical Care Management. Diagnostic testing includes ultrasound and CT scanning, which may reveal a
congested liver, ascites, or an enlarged portal vein. Doppler
detection of reduced portal vein blood flow in VOD has also
been described. 57 Liver biopsies may be performed, although they may be associated with a significant risk in the
oncology population because of thrombocytopenia.54
Management of VOD is primarily supportive to provide
time for the liver to heal. This is achieved by treating the
side effects of liver failure, including fluid overload, third
spacing, electrolyte imbalances, and coagulation abnormalities. The administrations of anticoagulants and thrombolytic agents have been only marginally successful when used
to prevent and/or treat VOD. 8 Orthotopic liver transplantation and thrombolytic therapy with agents such as tissue
plasminogen activator have been suggested as treatment
options. 54 ,58 Prophylactic use of prostaglandin E, has also
been described. 59 The prognosis of von is variable, with
most patients with mild to moderate von (maximum serum
bilirubin < I0 mg/dl) recovering from disease. However,
95% of patients with severe VOD die as a result of
multisystem organ failure,8

SUMMARY
New cancer treatment modalities are increasingly complex and aggressive, With refinement of these treatment
regimens, the use of high-dose intensive chemotherapy
and BMT will find broader application in cancer patients and patients with impaired host defenses Of immunodeficiencies, Children receiving these regimens will
more likely need, and benefit from, critical care resources at various points during their illness and treatment
regimen, Only by careful observation and frequent c1in-
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ical updates will the care of these patients be managed
successfully.
The transition to the critical care unit can often be a
difficult one. Most children have been hospitalized often.
Families are familiar with the oncology unit staff and
routines. This transition can be facilitated by the primary
nurse who can disseminate information regarding the child's
previous history and response to procedures to the entire
critical care team before the child's arrival, when time
allows. Parents should be empowered to remain involved in
their child's care to the fullest extent possible, especially
given the chronic nature of malignant disease. Multidisciplinary patient care conferences can be useful to discuss
treatment plans and allow expression of concerns regarding
therapy.

Ethical concerns, such as aggressi veness of therapy in
a "terminal" patient, end-of-life decisions, and even allocation of resources, may arise among the members of
the multidisciplinary team. Critical care nurses play a
key role in facilitating discussion regarding such concerns and seeking appropriate consultation from experts,
such as ethicists. The abundance of biomedical research
on the treatment of pediatric malignancies demonstrates
the hope that such patients will no longer be labeled as
having a "terminal" disease. It is essential that Clritical care
nurses strive to incorporate knowledge of the complexities
of care of the child with malignancy into their practice. The
nursing contribution to the team approach is a central one
that will lead to improvement in outcomes for these
children_
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olid organ transplantation has become accepted therapy
for end-stage failure of the heart, liver, kidney, lung, and
intestine. Generally, successful transplantation in adult patients preceded widespread application of these procedures
in the pediatric population. Transplantation has been performed in newborns, infants, and children and appears to
parallel the successful outcomes reported in adults (Table
26-1). However, many concerns of nurses caring for infants
and children are of little consequence in adult programs.
These include differences in technical detail related to the
small size of children; availability of appropriate-sized organs; the urgency of transplantation to maximize neurologic, psychologic, and physical growth; and awareness of
the psychologic changes patients undergo when making developmental transitions from infancy through adolescence.
This chapter discusses heart, lung, liver, intestine, renal,
and multivisceral transplantation in the pediatric population,
with a brief discussion of pancreas transplantation and the
future of islet cell transplantation research. The surgical
procedures for transplantation of different organs are
described, as well as the critical care nursing of the patient
in the immediate postoperati ve period. The quality of life
and long-term outcomes in pediatric solid organ transplantation are discussed, including growth and development,
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Transplants by Solid Organ and Age Group*

TABLE 26-1
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psychosocial adjustment, and physiologic concerns of
chronic rejection, immunosuppression, infections, and other
postoperative complications.

HISTORY
The history of solid organ transplantation spans only about
50 years. The first successful solid organ transplant performed in humans was a kidney transplant between twin
brothers in 1954 by Merrill and Murray in Boston. In 1963,
the first patient to undergo liver transplantation was a
3-year-old with extrahepatic biliary atresia who died of
hemorrhage on the day of transplantation. Subsequent
attempts in Denver, Boston, and Paris were unsuccessful
until 1967, when Starzl achieved the first human liver
transplant with extended survival. This 18-month-old child
with hepatocellular carcinoma survived for 13 months
before dying of metastatic disease despite good graft
function. I After extensive experimental work by Shumway
and Lower at Stanford University, Barnard in South Africa
performed the first successful cardiac transplant in 1967.
Demekov performed the first recorded orthotopic experimental pulmonary transplant in 1947 without immunosuppression. However, the longest survival period achieved was
10 days. Generally, experience with single lung transplants
was unsuccessful before the introduction of cyclosporine.
As early as 1959, Lillehei of Minnesota developed the
surgical techniques for small bowel transplantation. Intestinal allografts were found not only to be subject to rejection
but also to be able to mount a graft-versus-host (GYH)
reaction. The first pancreas transplant in a human was
performed in 1966; however, relatively few have been
performed in children.
In the early I960s, several events occurred that changed
the course of human clinical transplantation. First, the
development of tissue typing established methods to enhance histocompatibility. Second, methods for regular
dialysis treatment were developed that could be integrated
with transplantation. Third, methods for organ preservation

and cooling were developed. Finally, new, potent immunosuppressant drugs were developed.
Pioneering work during this time vastly increased
knowledge of the immune system. From a greater understanding of the immune system came a description of the
process of rejection and then attempts to alter the immune
response to promote tolerance and prevent rejection. Hitchings and Elion of the Burroughs Wellcome Research
Laboratories, working to synthesize purine and pyrimidine
derivatives to act as antimetabolites, developed azathioprine
(lmuran), which quickly replaced 6-mercaptopurine and
continues in clinical use today 2 The combination of steroids
with azathioprine treatment was reported by Starzl l to have
a synergistic immunosuppressive effect.
Over the years, other immunosuppressive treatments
were introduced. In the mid-1970s, Jean Borel discovered
the fungal peptide cyclosporin A, which is a powerful
immunosuppressant that has been found to be particularly
effective when combined with azathioprine and steroids.
Following the availability of cyclosporine in the early
1980s, improved survival led to a rapid increase in the
number of transplants. The use of this drug ushered in the
present era of transplantation.
The monoclonal antibody OKT3 was introduced to treat
rejection episodes in 1983. The potent immunosuppressive
agent, tacrolimus (Prograf; fornlerly FK506), was approved
by the Food and Drug Administration in April 1994, after a
clinical trial at the University of Pittsburgh. 3 The ability to
wean and withdraw steroids in pediatric patients is a
significant benefit of tacrolimus therapy. Many other pharmaceuticals, such as sirolimus, rituximab, mycophenolate
mofetil, and daclizumab are currently being explored for
their efficacy in immune suppression.

CURRENT CHALLENGES
Although organ transplantation has been lifesaving for many
children, it has also raised many questions and concerns.
The shortage of donor organs is the primary limiting factor
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in treating patients who could benefit from the procedure.
The imbalance between donor supply and patient demand
necessitates a procedure for selecting patients for transplantation considered most likely to benefit from the operation.
Selection criteria vary between organs and between transplant programs and include both medical and psychosocial
considerations.
Currently, approximately 2100 children, ranging from
newborns to 18 years of age, are awaiting organ transplants 4 Over the past 10 years, the percentage of cadaveric
pediatric donors has decreased from 26% to 19%.4 Many of
these children will die because of the shortage of organs;
thus other solutions have been proposed. Living related
donor transplantation is becoming a successful option for
transplantation of kidneys, liver segments, and lung lobes.
Segmental organ-sharing between recipients has also been
explored with some success. 5 Xenograft transplantation,
however, has historically been unsuccessful. raising ethical
and infectious disease concerns and provoking protests from
the public and animal rights groups. 6 Anencephalic infants
have been proposed as potential organ donors for infants,
and this possibility has raised many ethical questions. The
balance of risks and benefits for donors and recipients,
ability to obtain informed consent for these innovative
procedures, consideration of human and animal rights, and
equitable access and distribution of needed organs are
challenging issues.
Transplantation is the embodiment of high technology
and therefore high-cost medical care. The average hospital
charge for solid organ transplants runs well into the
hundreds of thousands of dollars. The financial requirements
for transplantation can be prohibitive if adequate funding or
insurance coverage is not available. Each candidate must
meet the financial requirements to maintain financial stability of the institution's transplant program. Currently, private
health insurance, the Federal Government's medical program, and combined Federal/State Medicaid programs
cover the cost of most transplants 4

EVALUATION PROCESS
A multidisciplinary approach is used in evaluating infants
and children for transplantation. The evaluation process has
several goals: (I) to determine that transplantation is the
only treatment option; that is, other conventional therapies
and treatment options are not likely to be successful; (2) to
rule out major systemic diseases or permanent damage in
other organ systems that would increase risk or preclude
transplantation; (3) to assess the ability of the child and
family to cope with the stresses of transplantation and
comply with the complex medical regimen; (4) to educate
the child and family to enable an informed decision
concerning transplantation; and (5) to establish rapport
between the child and family and the transplant team.
Developing a trusting relationship between the transplant
team and family, educating the family and child (at the
appropriate developmental level) to enable an informed
choice, and incorporating the family as members of the
child's caregiving and decision-making team are important
nursing goals that are initiated during the evaluation period.
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A thorough evaluation of the clinical status of the patient
and of the failing organ is undertaken to establish severity of
disease and prognosis. The principal indications for organ
transplantation in children are discussed in the introduction
to each organ section. Generally, contraindicalions to organ
transplantation include active infection; malignancy; active
substance abuse; and severe, pernlanent damage in another
major organ system that would result in the patient's demise
or poor quality of life.
An adequate social support system is crucial in considering transplantation in children because they are dependent
on others to provide care and nurturing. A dedicated
caregiver who will take responsibility for the child's care
after the transplant must be identified; ideally, two or more
caregivers share responsibility. Generally, every effort is
made to support the family in coping with the stress of
transplantation and providing adequate care for the child.
Psychosocial assessment and ongoing support and intervention by social services and child psychiatry services are
important.
Maintaining an optimal level of physical and emotional
wellness in the transplant candidate facilitates the necessary
strength to tolerate the evaluation and waiting phase of
transplantation and contributes to a successful outcome.
Ongoing physical assessment, educating the patient and
family about signs and symptoms of illness or progressive
failure, and promotion of health-related activities are
nursing interventions.
An important part of a transplant evaluation, particularly
in renal transplantation, involves tissue typing in an attempt
to match a recipient with the most compatible donor. The
body identifies the transplanted organ as foreign and
initiates a number of physiologic mechanisms to destroy the
new organ. Histocompatibility testing is performed to match
donor and recipient as closely as possible to reduce the
immune system response to foreign antigens and reduce the
incidence of rejection.
Histocompatibility testing varies with each organ. Organs
vary in their immunogenicity (likelihood of inducing
rejection). The lungs and bowel are most immunogenic, but
the heart is most likely to develop acute rejection. Some
organs, like the heart, exist singly, and the entire organ must
be used, so donations must come from cadaveric donors.
The kidney and segments of the liver and lungs may be
removed from living related donors, so tissue typing can be
more exact. Most organs can now be preserved for many
hours outside of the body, which allows tissue typing to be
performed. Other organs, the heart and lung in particular,
have shorter preservation times, which precludes routine
tissue typing.
The less antigenic the graft, the less the host will react
against it. In human transplantation when the donor and
recipient are identical twins and there is no antigenic
difference, the tissue is accepted without immunosuppressive agents. When the donor and recipient are siblings or
when a parent donor is used for an offspring, there is greater
statistical likelihood for antigen sharing between the donor
and the recipient than when a cadaveric or unrelated donor
is used. Patient outcomes are better when either a sibling
graft or a parent-child graft is used as compared with a
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cadaveric transplant. The improved outcome may also be
related to the shorter ischemic times when a living-related
donor graft is used.
The ABO and human lymphocyte antigen (HLA) systems
are the main antigen systems in the body. Both tissue typing
and tissue matching procedures may be performed before
transplantation. The ABO system identifies the presence or
absence of antibodies on most body tissues and on red blood
cells. The major blood groups are 0 (universal donor), A, B,
and AB (universal recipient). Transplants are performed
within blood groups but may be done with donors from a
compatible blood group; for example, B recipient receives
an 0 heart. Because O-type organs can be used by any blood
type and type 0 patients can only receive 0 organs, public
policy dictates that O-type organs be used in 0 patients first.
Some evidence shows that Ii ver transplants may cross
ABO-compatible groups.? RHO antigens, positive or negative, appear to have no role in graft rejection. Therefore an
O-recipient may receive an 0+ donor organ.
The HLA molecules are present on most cells and allow
the body to distinguish self from nonself (foreign antibodies). The presence of these antigens plays an important role
in graft rejection. The major histocompatibility complex is
the HLA genetic complex for each individual. HLA
molecules are divided into class I antigens (liLA, A, B, and
C antigens) and class II antigens (HLA-DR, DQ, and DP
antigens).
Matching procedures are performed to identify the
recipient's preformed circulating antibodies to donor antigens. Cross-matching can be done between a specific donor
and recipient before transplant to identify compatibility.
Cross-matching is also performed between a recipient and a
randomly selected panel of donor lymphocytes to measure
recipient level of antibody reactivity. This is known as a
percentage panel reactive antibody (PRA) and is established
as part of the evaluation process. A positive cross-match
denotes the presence of antibodies in the recipient serum
against donor lymphocytes and is a predictor of hyperacute
rejection. A high PRA means the recipient has been
sensitized to one or more foreign HLAs and makes finding
a suitable donor much more difficult. Serums from recipients with preformed antibodies indicated by a high PRA are
cross-matched against donor lymphocytes before transplant.
The transplant can occur if the cross-match is negative.
The United Network for Organ Sharing (UNOS) is a
nonprofit organization under contract with the U.S. Department of Health and Human Services to operate the Organ
Procurement and Transplantation Network (OPTN). In
accordance with government guidelines administered by the
Health Care Finance Administration (lICFA) in 1988,
regional organ procurement organizations (OPOs) were
designated to coordinate identification of potential donors
and organ recovery with transplant centers and participate in
public and professional educational activities to increase
organ donation. OPOs are involved in the procurement of all
solid organs in the United States. All organ transplant
candidates are listed in the UNOS computer. In collaboration with UNOS, each solid organ group has agreed on a
national organ distribution scheme to match organs with

recipients based on criteria such as ABO compatibility,
patient weight, recipient medical status, HLA compatibility,
presensitization, waiting time, and distance between donor
and recipient. There are speci fie criteria for each organ to
ensure equitable allocation of cadaveric organs among
qualified potential organ recipients. 4
The major factor that limits organ transplantation for all
that could benefit is the lack of donors. The percentage of
pediatric donors has decreased over tinle, although the
percentage of pediatric thoracic recipients has increased. 4
The shortage of donor organs has prompted some innovative
changes in practice in recent years. The age and weight
range for pediatric transplants has been broadened. Improvements in organ preservation have increased the length
of time that the organ remains viable outside the body and
therefore allows organs to be transported greater distances.
A preservation solution containing hydroxyethyl starch was
developed at the University of Wisconsin and has lengthened kidney and liver preservation times. Cardiac assist
devices are used at some centers to provide a bridge to
pediatric heart transplantation. Segmental liver transplants
increase the donor pool for young infants. Patients with
end-stage renal disease can be managed with dialysis until a
donor becomes available, but patients needing a heart or
liver often have little time to wait and may die before a
donor organ is found.
All pediatric cadaveric organ donors are declared dead
before removal of any vascular organ. Most states have
enacted brain death legislation in accordance with the
Uniform Determination of Death Act (see Chapter 20 for
brain death criteria).8 Federal Required Request legislation
requires that all family members be given the option to
donate or refuse to donate the organs of their loved one. In
addition, the OPO in the region must be notified by every
hospital of every death. Critical care nurses playa vital role
in identifying and caring for potential donors, participating
with the healthcare team and OPO in approaching family
members about organ donation, and in supporting the
family's ultimate decision.
The period spent waiting for an appropriate donor and for
the transplant to occur is one of great stress and anxiety for
patients and their families. Children normally regress in the
face of serious illness and return to their previous developmental level following recovery. Older children and adolescents may grieve the loss of their good health and former
lifestyle, especially if their illness has had a sudden onset.
The forced dependence and lack of control are very difficult
during the waiting period. All feel a sense of being
interminably "on hold," unable to make future plans.
Although many organ transplant candidates are stable and
can wait at home, some are critically ill and require
hospitalization. The fear that an organ will not be found in
time is heightened for these patients and families. The need
for invasive procedures, intravascular lines, ventilators, and
other mechanical support increases the risk of infection.
Serious infection may temporarily place a patient's candidacy on hold until the infection is treated. Critically ill
patients may develop multisystem organ failure that would
preclude organ transplantation.
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Children and families need emotional support and
reassurance during the waiting period. Critically ill children
waiting for organ transplantation require constant monitoring and frequent adjustment of treatment to maintain their
tenuous hold on life, as well as meticulous care to prevent
complications. The critical care team's efforts are temporizing, at best, because the therapeutic answer to the patient's
problem is organ transplantation.

PROMOTION OF GRAFT TOLERANCE
The clinical evolution of transplantation of foreign tissue
or organs has been successful because of development
of surgical technique, preservation technology, evaluation
of histocompatibility, immunosuppression, and induction of
donor-specific nonreactivity (tolerance).9 Investigation of
tolerance has been a key, multidecade research initiative. As
recognized early on in research related to bone marrow
transplantation, an immunologically active graft could turn
around and reject the new host, provoking graft-versus-host
disease (GVHD). For the defenseless recipient, the risk
of the disease was found to be proportional to the extent
of histocompatibility variance between the graft and recipient. Investigation continued with all avenues of research,
including HLA matching, preconditioning in the form
of total body irradiation or myelotoxic drugs, cell-mediated
immunity, experimentation with chemical suppression,
and the eventual adaptation of double- or triple-drug
immunosuppression. 9
Examination of long-term survivors in 1992 demonstrated that allograft acceptance may have been facilitated
by the presence of a small fragment of extramedullary
donor marrow, including stern cells, which had been
assimilated into the larger immunologic network of the
recipient. Movement was in both directions, so residual
leukocytes (chimeric leukocytes) were in both the donor
graft and the host. 9 Because of the observation, the
interaction was seen as bidirectional and mutually canceling (graft versus host and host versus graft); perhaps
explaining why all patients do not develop GVHD after
immunologically active organ transplantation or why HLA
matching is sometimes so poorly predictive of outcome.
Cell survival, then, depends on immunosuppression that
protects both cell populations equally. The discovery of
this "spontaneous leukocyte chimerism" led researchers to
believe that it occurred naturally after whole organ transplantation. Chimerism is not synonymous with tolerance,
but it is a requirement for acceptance of the graft and
a requirement for eventual tolerance. In fact, the longterm survi val of a graft indicates that donor leukocyte
chimerism has occurred and explains why immunosuppressant drugs can be eventually and permanently stopped
in some cases. 9
Although, historically, occasional attempts had been
made to improve graft outcome by infusing donor bone
marrow, the belief was that the donor cells would be
destroyed without preconditioning with radiation or myelotoxic drugs. The discovery in 1992 recognized a
window of opportunity in which donor bone marrow could
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be safely infused into the recipient, without preconditioning or deviation from normal immunosuppression practices. Recently this approach was used in a number of
kidney, heart, liver, and lung recipients who were given
donor bone marrow cells during organ transplantation
after revascularization occurred. Chimerism was produced,
which was estimated as 1000 times greater than that
naturally occurring in whole organ transplants. Data
indicated persistent chimerism, a trend toward donorspecific nonreactivity, and improved patient and graft
survival 9 Weaning from long-term immunosuppressive
therapy would be of obvious benefit to organ recipients.
Although an immunosuppressant drug-free Slate may never
be obtained, the goal is to move in that direction in
inducing tolerance.

Pharmacologic Immunosuppressant Therapy
Pharmacologic immunosuppressive therapy is initiated during the transplant procedure and maintained thereafter to
suppress the natural immune response of the host and
prevent or limit rejection of the transplanted organ. Although the rationale for immunosuppressive therapy has
remained the same through the years, the immunosuppressive protocols continue to vary according to the transplanted
organ, the transplant center, and the continuous research and
introduction of new improved agents. Maintenance immunosuppression refers to the medications that are used on
a long-term basis to prevent rejection. Other medications
are used on a short-term basis to treat acute rejection
episodes.
Immunosuppressant regimens continue to vary between
transplant institutions, but combination therapy using
double- or triple-drug protocols remains the practice of
choice. Combination therapy provides enhanced immunosuppression, as well as reduced drug toxicity because of the
lower dosages of each specific drug. As Fig. 26-1 depicts,
the immunosuppressive drugs act on different sites in the
immune system, therefore having varying effects on the
process of rejection and the extent of systemic side effects
experienced by the patient.
Ongoing research is exploring new approaches to standard immunosuppressive protocols that result in optimum
graft function by inhibiting the immune system and
decreasing the incidence of rejection, subsequently increasing the long-term quality of life for the child with a
transplanted organ. The most common immunosuppressive
agents used alone or in combination protocols to prevent
rejection and optimize graft function are cyclosporine,
tacrolimus, azathioprine, mycophenolate mofetil, and corticosteroids. Many complications are associated with immunosuppression, including hypertension, renal insufficiency,
posttransplant lymphoproliferative disorders, viral or opportunistic infections, drug toxicity, steroid-related complications (obesity, growth failure, bone disease), nephritis, and
cervical lymphadenopathy.
As with any pharmacologic therapy, knowledge is
required about the immunosuppressant medications and
other pharmacologic agents used to combat the adverse
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Fig. 26-1 Immunosuppressant functions. Cyelosporine and tacrolimus function as calcineurin inhibitors. Sirolimus inhibits target of rapamycin (TOR), which is a regulatory enzyme critical to immune
function and is the first agent in this distinct e1ass of immunosuppressants. TOR inhibitors alter
T cell proliferation largely through their inhibition of responsiveness to proliferative cytokines such
as interleukin-2. Ag, Antigen; APC, antigen-presenting cell; AZA, azathioprine; BQR, brequinar
sodium; CDK, cyelin-dependent kinase; CSA, cyelosporine; CTLA4-Ig, cytotoxic T-lymphocyte
antigen -4 immunoglobulin; Cyp. cyclophilin; FK506, tacrolimus; FKBP12, FK506 binding protein;
IL-2, interleukin-2; IL-2R, interleukin-2 receptor; MHC, major histocompatibility complex; LEF, leftunomide; MMF, mycophenolate mofetil; MZ, mizoribine; NFAT, nuclear factor of activated T cells;
NFkB, nuclear factor Kb; TCR, T cell receptor; TOR. target of rapamycin. (Courtesy Wyeth-Ayerst
Laboratories. From Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action
immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle
progression, Clin Biochem 31 :335-340, 1998.)

effects of immunosuppression, including the action, dosage
and administration, adverse effects, drug interactions, assessment parameters, and nursing implications. Because of
the many medical problems of transplant patients, complex
immunosuppressant protocols, and the large number of
medications each patient receives, correctly administering
medications and assessing patients for side effects become a
challenging and vital responsibility for nurses and families.
Pharmacologic agents used with transplant patients, including their indications, side effects, and nursing implications,
are detailed in Table 26-2.

Cyclosporine Modified (Neoral) and Cyclosporine
(Sandimmune). Cyclosporine is a potent immunosuppressive medication that is a metabolite of a soil fungus.
Introduced in 1978, it revolutionized immunosuppression,
substantially improving patient survival following transplantation. The drug's main mechanism of action is calcineurin inhibition, similar to tacrolimus. Cyclosporine does
cause anemia but has minimal effect on neutrophil response;
therefore some infection-fighting mechanisms remain intact.
A correspondingly lower incidence of severe infections in
cyclosporine-treated patients is found in some reports.
Text continued on p. 885
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~lmmunosuppressants
1~1:Cyclosporine (Sandimmune)

~~Cyclosporine.modified (NeoraI)
!k~~ Immunosuppressant

~~. Inhibits T cell proliferation
~" Metabolized by liver
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Side Effects
CNS toxicity: tremors, seizures, headaches, paresthesia, flushing, and
confusion
Nephrotoxicity; BUN, i serum creatinine; .L creatinine clearance, i K,
i uric acid
Hypomagnesemia
Hypertension
Hepatotoxicity
• Infection
• GI: anorexia, nausea, vomiting,
diarrhea
• Dermatology: gum hyperplasia and
hirsutism
Lymphoma

Nursing Implications
I. Observe for CNS symptoms.
2. Seizures managed with antiseizure
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t~~;
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TABLE 26-2 Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents

~~rug*

Ii",.
~r
Ii!".

Organ Transplantation

15.

medication and correction of other
derangements.
Tremors more pronoonced at higher
doses.
Headache is treated as symptoms
demand.
Monitor renal function and intake
and output closely.
Monitor cyclosporine levels: Levels
should be drawn at trough just
before the next dose is given.
Monitor blood pressure; patient may
need antihypertensive medications.
Monitor liver function tests (LFfs)
Observe for signs and symptoms of
infection.
Treat for G I symptoms as needed;
adjust dose if possible.
Provide good oral hygiene along
with routine dental care.
May use depilatory cautiously to
remove hair if desired for aesthetic
reasons.
Monitor chest x-ray film and do
frequent physical examination.
Cyclosporine level is increased by
some calcium channel blockers, antifungal agents, corticosteroids. and
various antibiotics (e.g., erythromycin,
clarithromycin).
Cyclosporine level is decreased by
phenobarbital. phenytoin, rifampin,
and carbamazepine.

Continued
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TABLE 26-2 Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents-cont'd
~j:acrolimus (Prograf;

Side Effects

Nursing Implications

Headaches
• Irritability
Insomnia
Nausea, vomiting
• Tremors
Hyperkalemia
Nephrotoxic effects
• Hypomagnesemia
Seizures
Ileus
Side effects increase with intravenous
administration or high blood levels.

1. Follow BUN and creatinine.
2. Do not mix with NaHC03 in IV
form.
3. Administer as a constant infusion.
4, Give 4 hours apart from alkalizing
drugs (such as NaHCO,) if given
orally.
5. Tacrolimus adheres to plastic surfaces;
levels should be drawn from a site not
used for administration.
6. Tacrolimus should not be mixed or
given with bicarbonate or Bicitra or
Carafate.
7. Tacrolimus levels are increased by
erythromycin, antifungal agents,
verapamil, cimetidine, diltiazem,
and some antidepressants,
8. Tacrolimus levels are decreased by
carbamazepine, rifampin, phenobarbital,
and phenytoin.
9. Monitor tacrolimus trough levels.

Anemia
Thrombocytopenia
Diarrhea
Hypercholesterolemia and hypertriglyceridemia (responds to existing
cholesterol-lowering agents)
Rash
Acne
Hypokalemia
Joint pain

I, Mix with 2 oz of water or orange juice
only. Do not administer the drug without
dilution.
2. After administering the medication, rinse
the container with at least 2 more oz
and administer to patient to be sure
entire dose was taken,
3. Sirolimus should be kept refrigerated,
not frozen.
4, Dose should be consistently taken with
or without food.
5, Dosage is administered once daily. Dose
should be given 4 hr after cyclosporine
or tacrolimus,
6, Prolonged half-life; therapeutic levels
are reached in 7-10 days. Blood levels
are not used clinically at the present
time.

formerly FK506)

i~'Potent immunosuppressant
lii'fInhibits T cell proliferation
Inhibits interleukin-2 (IL-2) production
~~Suppresses Iymphokine production
Metabolized and excreted in bile
Oral absorption is highly variable

Ii
I,i

I,

~i'Availability:
If~,::

!iiL Oral: capsule

~lv Injection
~sage:

!t0ral: 0.2 mg/kg/day divided bid
~4E: IV: 0.05 mglkg/day as continuous
~
infusion
~Tacrolimus ELISA whole blood trough:
~iC5-20 nglml

b
Iv
I.·.··.•.

It
i'jirolimus (Rapamune)

I..~•.
1*
mit'

N.ewest of the immunosuppressive

gil, agents

Indicated as primary immunosuppression with cyclosporine or for tacroli~iT mus rescue in liver, small bowel, and
~ .. heart recipients showing signs of
~~,
neurotoxicity, nephrotoxicity, or
E'.:o.;
I~' other complications
~ Structurally similar to tacrolimus
,~. Macrolide antibiotic that inhibits
~T T and B cell activity ,
'li~Synergistic effects with cyclosporine
ili',and tacrolimus
I~vailability: oral administration only;
!if.,., liquid, premeasured foil pouch, pill
l1e_ form available soon
~Dosage: variable
-10 mg/day; dosage calculated
~t·L based on other immunosuppressants
~r; in use

lin

a from Armitage JM, Fricker Fl, del Nido Pet al: A decade (1982-1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppres, J Thorac Cardiovasc Surg 105:464-472, 1993; Asante-Korang A, Boyle GJ, Webber SA et al: Experience of FK506lmmune suppression in pediatric
transplantation: a study of long-term adverse effects, J Heart Lung Transplant 15:415-422, 1996; Green M, Michaels M, Webber S et al: The
agement of Epstein-Barr virus associated post-transplant Iymphoproliferative disorders in pediatric soJid-organ transplant recipients, Pediatr Trans-

3:271-281, 1999; Jain A, Mazariegos G, Kashyap R et al: Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver
splantation, Transplantation 70:617-625, 2000: McAlister V, Gao Z, Peltekian K et al: Sirolimus-tacrolimus combination immunosuppression, Res Let
5:9201,2000; McGhee B, Howrie D, Kraisinger M et al: Pediatric drug therapy handbook &formulary. Department of Pharmacy, Children's Hospital
Pittsburgh, 1997, Lexi-Comp; Robinson BV, Boyle GJ, Miller SA et al: Optimal dosing of intravenous tacrolimus following pediatric heart transplanta• J Heart Lung Transplant 18:786-791, 1999; Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect
Its from blockade of signal transduction and inhibition of cell cycle progression, Clin Biochem 31 :335-340, 1998; Webber SA, Green M: Postsplantation Iymphoproliferative disorders: advances in diagnosis, prevention, and management in children, Prog Pediatr Cardial 00: 1-13, 2000,
III
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TABLE 26·2 Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents-cont'd .
Side Effects
Bone marrow suppression
Leukopenia
Thrombocytopenia
Anemia
Hepatotoxicity
Infection
GI: nausea, vomiting, diarrhea, mouth
ulcers
Pancreatitis
Muscle wasting

Nursing Implications
I.
2.
3.
4.
S.
6.
7.
8.
9.
10.

Monitor CSC and platelet counts.
May hold dose if WBC count <3000.
Monitor for signs of bleeding.
Monitor for signs of infection.
Administer blood products as
directed.
Monitor LFTs.
Observe for signs of liver
dysfunction.
Administer with food.
Provide good oral hygiene.
Monitor serum amylase and lipase
levels.

Increased susceptibility to infections
and malignancies, especially cutaneous
• Fever
Headache
Hypercholesteremia
• Diarrhea
Nausea
Vomiting
Dyspepsia
Leukopenia
Neutropenia
Anemia
Thrombocytopenia
Myalgia
• Hematuria
Cough

I. Antacids decrease mycophenolate
absorption.
2. Acyclovir and ganciclovir compete
with mycophenolate for renal tubular
secretion resulting in increased concentrations of both drugs.
3. Some children may require every8-hr dosing to achieve adequate trough
levels of> 1.0 Ilg/mL
4. Capsules should not be opened or
crushed.
S. Inhalation of the drug or direct
contact of the drug with the skin or
mucous membranes should be
avoided.
6. Dose adjustments are not necessary
in patients with renal dysfunction.

Infection
• Fluid retention: i weight, i Na reabsorption, i SP, i uric acid, edema,
moon facies, cushingoid appearance
Osteoporosis: J. calcium absorption;
leaches calcium from bone
Increased appetite
Mood swings, depression, irritability
Psychosis
• Fragile, sun-sensitive skin
Slow wound healing
Stomatitis
Acne and hirsutism
• Muscle weakness-proximal more
pronounced
• Nausea, vomiting, peptic ulcer

I. Steroids may increase glucose levels

2.

3.
4.

S.

in the blood and urine, requiring
insulin or oral hypoglycemics.
Cataracts or glaucoma may occur with
long-term treatment; provide ophthalmic
examinations.
Monitor serum electrolytes, glucose,
and blood pressure.
Doses should not be discontinued or
decreased abruptly without physician's
supervision.
High-dose steroids given IV push over
fewer than 10 min has resulted in
sudden death.

Continued
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TABLE 26-2 Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents-<:ont'd
.

!h;,olycIonal Antilymphocyte Antibodies
lirrl\ntithymocyte globulin-equine (Atgam)
~j!Antithymocyte globulin-rahbit
~:(Thymoglobulin)
Immunosuppressants
~: Cytotoxic antibody directed against
i:ii, antIgens expressed on human T
lymphocytes
i!\i,. Indicated for allograft rejection in
~: kidney, liver, small bowel, and heart
~!lt transplant recipients
~J~vailability: injection

I.

I:

~posage:

~~ .• Atgam: 15 mg/kg/day

f;if Thymoglobulin:
~r

1.5 mg/kg/day

i~

~~;
~".
~!,

irE!

Side Effects

Nursing Implications

• Fever, chills
Leukopenia, thrombocytopenia
Rash, pruritus, urticaria
Arthralgia, chest or back pain
Diarrhea, nausea, vomiting
Dyspnea
Headache
Hypotension
Night sweats
Pain at infusion site, thrombophlebitis
Anaphylaxis
Dizziness, weakness, faintness
Edema
Seizures
Tachycardia, pulmonary edema,
laryngospasm
Systemic infection

I. Monitor vital signs frequently during
infusion and every 4 hr after medication.
2. Premedicate with acetaminophen and
diphenhydramine; also may give
hydrocortisone.
3. Patient should remain on a monitor.
4. Administer via central or large-bore peripheralline; use of high-flow line will
minimize the occurrence of phlebitis or
thrombosis. Observe site frequently.
5. Record weight on chart.
6. Monitor baseline CBC, differential,
and platelets.
7. Infuse slowly over 2-6 hr; concentration
should not exceed I mg/m!.
8. Filter infusion with 0.2-5 micron filter.
9. Do not keep in diluted form more than
12 hr.
10. Do not infuse simultaneously with blood
products or other medications.
11. Have emergency crash cart and drugs
available.

Cytokine release syndrome
Headache
TaChycardia
Hypertension
Hypotension
Tremor
Aseptic meningitis
Seizures
Pruritus
Rash
Diarrhea, nausea, vomiting
Increased BUN, creatinine
• Joint pain
Photophobia
• Pulmonary edema
Fever

I. Severe pulmonary edema has occurred
in patients with fluid overload.
2. Drug is contraindicated in patients with
known hypersensitivity, those in fluid
overload, or patients with >3% weight
gain within prior week and high fever.
3. Store in refrigerator; do not freeze. Drug
should not be used if left out of the
refrigerator for more than 4 hr.
4. Dosage of concomitant immunosuppressants may need to be reduced.
5. First dose effect (llulike symptoms,
anaphylactic-type reaction) may occur
within 30 min to 6 hours, up to 24 hr after
the first dose. Cardiopulmonary resuscitation may be needed.
6. Corticosteroid administration is required
before infusion to decrease incidence of
reactions. Use for 3-5 days.
7. Patient temperature should not exceed
37.8° C at time of administration.

I

~\2

lie'
~f
ilil'!.
~:

~.MonoclonaJ

Antibody

~1:Muromonab-CD3(OrthocIone

OKT3)

~~Potent immunosuppressant

ii(t•. Treatment of acute

allograft rejection
Effecti ve in reversing acute hepatic
~:'= and cardiac rejection episodes
If.vailability: injection
IDosage:
~IC: <30 kg: 2.5 mg/day
>30 kg: 5 mg/day
I~ltematlve dosmg: 0.1 mg/kg/day up
,i~., to 5 mg

tr

I[
llli_.• . ,
~f.~..

If
LE='.

lli'h'

iK

ll!1:'

~r
Ife

llU:

~lf-

1!1',

~:;

ata from Armitage JM. Fricker FJ, del Nido Pet al: A decade (1982-1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppres, J nlOrac Cardiovasc SI/rg 105:464-472, 1993; Asante-Korang A, Boyle GJ, Webber SA et al: Experience of FK506 lmmune suppression in pediatric
transplantation: a study of long-term adverse effecls, J Heart LI/I/g TOOl/sp/alll 15:415-422. 1996; Green M, Michaels M. Webber Set al: The
gemenl of Epstein-Barr virus associated posH.ransplanl Iymphoproliferalive disorders in pediatric solid-organ transplant recipients, Pediutr TrallsIII 3:271-281, 1999: Jain A. Mazariegos G, Kashyap R et at: Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver
splantation, Transplantation 70:617-625. 2000; McAlister V, Gao Z, Pe]tekian K et al: Sirolimus-tacrolimus combination immunosuppression, Res Let
5:9201.2000; McGhee B. Howrie D, Kraisinger M et al: Pediatric drug therapy hal/dbook &formu/ary. Department of Pharmacy, Children's Hospital
Pittsburgh. 1997. Lexi-Comp: Robinson BV, Boyle GJ, Miller SA et al: Optimal dosing of intravenous tacrolimus following pediatric heart transplanta·bn. J Heart LI/I/g Tramp/allt 18:786-791, 1999; Sehgal SN: Rapamune (RAPA. rapamycin. sirolimus): mechanism of action immunosuppressive effect
suits from blockade of signal transduction and inhibition of cell cycle progression, Clill Hioc"em 31:335-340. 1998: Webber SA, Green M: Postsplantalion Iymphoproliferative disorders: advances in diagnosis, prevention. and management in children. Prog Pediacr Cardiof 00: 1-13,2000.
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(t:I TABLE 26-2

Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents-eont'd

!ii-Monoclonal Antibody
~jiPacJizumab (Zenapax)
~!iBasiliximab (Simulect)
11,'. Induction immunosuppressant
JjJ' Monoclonal antibody that prevents
~'" IL-2 from binding to the IL-2 receptor
~,' and inhibits the proliferation of activated T cells
l~~. Indicated in the prophylaxis of acute
ire! rejection in transplant recipients
~",Availability: injection

iK-

~ijl)osage:

~ii!: Paclizumab: I mg/kg x 5 doses 2
~~
weeks apart each
" Basiliximab: 12 mg/m 2 administered
~!
on day 0 and day 4 following
'§:;;.
transplant

r'

Side Effects

Nursing Implications

Uncommon adverse reactions:
GI: constipation, nausea, diarrhea,
vomiting, abdominal pain
Edema
• Headache
Very rare adverse reactions:
Chest or back pain

1. Daclizumab and basiliximab do not
cause the cytokine release syndrome
characteristic of OKT3 or antilymphocyte globulin use.
2. Filtering is not necessary.
3. No premedications are necessary.

• Fever

• Fatigue
Hypotension
• Dyspnea
Insomnia
Tachycardia
Bleeding

lli,Jrnmune Globulin

~~~ytomegalovirus immune globulin

~T intravenous, human (CMV.IGIV;
~!rf;j' Cytogam)
~:!'Atlenuation of CMV or EBV disease
associated with solid organ transplant
~}-Availability: injection
i;;,

liik

i~_Posage:

~'i'Prophylaxis: 150 mg/kg every 2
~L
weeks x 8 weeks (4 doses), 100
~;:;::
,,*' mg/kg at weeks 12 and 16
~:
(2 additional doses)
~:;, Treatment: 100 mg/kg every other
1:~:
day x 3 doses then 100 mg/kg
t,
B"
weekly: reevaluate; repeat

ii~~

•
•
•
•
•
•
•
•

•

hr,

~

is' -

~JJltravenous immune globulin (IVIG)
mi~, Used in conjunction with appropriate
~;; anti infective therapy to prevent or
~':' modify acute bacterial or viral
il1lF infections in patients with
~. immunodepression
~;. Immunodeficiency syndrome
~:fAvailability: injection
""
.,EDosage: highly variable 500 mg/kg/dose
&'_ every other day x 7 days

Flushing of the face
Diaphoresis
Muscle cramps
Back pain
Nausea and vomiting
Wheezing
Dizziness
Fever
Headache
Tightness in the chest
Hypersensitivity reactions
Chills
Hypotension
Arthralgia

Flushing of the face
Hypotension
Dizziness
Fever
Headache
Nausea and vomiting
Hypersensitivity reactions
• Chills
Diaphoresis
• Tightness in the chest
•
•
•
•

Administer IV only.
Administer as separate infusion.
Filters are not necessary.
If minor side effects occur, slow rate
or temporarily stop the infusion.
5. If anaphylaxis or hypotension occur,
discontinue infusion and use a
pharmacologic agent such as
diphenhydramine.
I.
2.
3.
4.

I. Do not administer 1M or Sc.
2. Fol low package insert for rate of
administration.
3. Monitor platelet counl.
4. Monitor vital signs closely.
5. Have epinephrine available.
6. Slowing or stopping the infusion often
allows minor symptoms to disappear.
7. Uncommonly used in solid organ
transplant patients.
Continued

Cyciosporine is metabolized by the liver and excreted via
bile into the feces.
Cyciosporine is available in an oral form (a liquid in an
olive oil base and capsules) and in an intravenous solution.
Absorption of the drug after oral administration varies
widely, and it is usually given on an empty stomach to
reduce the interference of food with absorption. Cyciospor-

ine is fat soluble, so its bioavailability in patients with
severe liver dysfunction is reduced. Children metabolize
cyciosporine more rapidly than adults and thus require
higher doses per kilogram of body weight and occasionally
a more frequent dosing schedule to maintain adequate levels
of immunosuppression. Many medications interfere with
cyclosporine metabolism (see Table 26-2).
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TABLE 26·2 Pharmacologic Agents Used in Solid Organ Transplant Recipients:
Immunosuppressants and Antiviral Agents-cont'd
~'

ifiDrug*
~>;

'~CYclOvir
r

(Zovirax)
Antiviral agent
:~ Used in the treatment of herpes
)!.. simplex and herpes zoster, varicella
zoster, and EBV infections

•S

'~vailability:

VOral: capsule, suspension
[' Injection
.,. sage: variable
IV: 750-1500 mg/m 2/day
Oral: 20 mg/kg qid

Side Effects

Nursing Implications

• Confusion, seizure, coma
• Rash
• Reversible neutropenia and
thrombocytopenia
• Myelosuppression
• Azoospemlia
• Nausea and vomiting
• Pancreatitis
Phlebitis
• Potential long-tenn carcinogenic effect
• Peripheral extremity pain

I. Monitor CBC, differential, platelets,
and serum creatinine.
2. Handle and dispose of according to
guidelines issued for cytotoxic drugs.
3. Administer by slow IV infusion over
at least I hr.
4. Infuse through large vein to minimize
risk of phlebitis.
5. Maintain patient's hydration status.
6. Use 0.22- or 5-micron filter.
7. Patient should have regular ophthalmologic examinations for worsening CMV
disease.
8. Dosage adjustment may be necessary in
patients with neutropenia, thrombocytopenia, or impaired renal function

• Abnonnal renal function
• Lethargy

I. Administer over I hour intravenously,
not to exceed a final concentration of
7 mg/ml.
2. Use with caution in those with renal
disease or receiving other nephrotoxic
drugs concurrently. Maintain adequate
urine output during first 2 hr after IV
infusion.
3. Use with caution in children with
underlying neurologic abnonnalities.
4. Monitor urinalysis, BUN, serum
creatinine, liver enzymes. and CBe.
5. Drug is incompatible with blood
products and protein-containing
solutions.

• Tremor

•
•
•
•
•
•

Seizure
Confusion, hallucinations, delirium
Agitation, insomnia, dizziness
Coma
Skin rash, diaphoresis
LFfs
Nausea, vomiting
• Phlebitis at injection site
Nephrotoxicity
Pain, sore throat

Cyclosporine is often administered intravenously in the
immediate posttransplant period. It is given as an infusion
over 2 to 6 hours or as a continuous infusion (preferred.)
Whole blood assays for cyclosporine may be falsely
elevated if blood samples are drawn through the same line
through which the drug is infused; therefore intravenous
(rV) lines used for administration of the drug should not be
used to draw samples for drug levels. IV cyclosporine may
be given until adequate levels of the drug are reached with
the oral preparation. Cyclosporine dosages are adjusted
based on trough levels, evidence of nephrotoxicity or other
major side effects, and during rejection. Generally, trough
levels are maintained at a higher level in the early
posttransplant period, and then doses are gradually tapered
to a lower long-term maintenance level.
Cyclosporine (and tacrolimus) administration, especially
at high blood levels, may also predispose patients to
seizures. Seizures associated with cyclosporine administration are more prevalent in children than in adults following

transplantation. Posttransplant patients are at risk for
seizures as a result of infection, metabolic derangements
(e.g., hypomagnesemia), fluid overload, use of steroids, 'or
hypertension. A decrease in cyclosporine dose or temporary
discontinuation of the drug may stop seizure activity.
Seizure activity should still be treated with antiseizure
medications and correction of electrolyte imbalances or
other treatable derangements. Long-term morbidity from
cyclosporine-related seizures is unusual.
Other adverse effects from cyclosporine administration
include other symptoms of central nervous system (CNS)
toxicity, such as headache, paresthesia, flushing, and confusion; nephrotoxicity; hypomagnesemia; hypertension; hepatotoxicity; infection; gastointestinal (GI) symptoms, such
as anorexia, nausea, vomiting, and diarrheas; gum hyperplasia; hirsutism; and lymphoma.
Tacrolimus (Prograf), Tacrolimus is a potent, selective anti-T cell immunosuppressant drug, whose mode of
action is similar to that of cyciosporine. IO Tacrolimus is
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a novel macrolide antibiotic derived from the soil fungus
Streptomyces tsukubaensis, found in the Tsukuba region
of northem Japan. Tacrolimus, cyclosporine, and sirolimus belong to a class of compounds whose cellular
activity depends on binding to specific cytosolic binding
proteins, called immunophilins. Tacrolimus and cyclosporine inhibit calcineurin, a phosphatase required for early
T cell activation. II
Tacrolimus holds promise for transplant recipients because of associated potency and action. The first human
trials of tacrolimus were conducted as rescue therapy for
liver graft rejection unresponsive to conventional immunosuppressive therapy.12 The efficacy of tacrolimus has been
demonstrated with pediatric cardiac, liver, intestinal, and
renal transplant recipients. Results of long-term study have
indicated that tacrolimus-based immunosuppression provides significant long-term benefits, including improved
graft and patient survival, reduced rate of rejection, less
hypertension, and lower steroid dosage requirements. 13
Clinical studies indicate that tacrolimus has very similar
side effects to cyclosporine. Hypertension may still occur
but to a lesser extent than with cyclosporine; hirsutism and
gingival hyperplasia are not seen with tacrolimus use. 14 In a
study of 49 pediatric heart transplant recipients who
received tacrolimus as the primary immunosuppressant, the
common cyclosporine side effects of hypertension, gingival
hyperplasia, coarsening of facial features, and hirsutism
were not seen. 14 Results of another study in pediatric liver
transplant recipients suggested that tacrolimus-based therapy may prove to have long-term benefits related to
improved patient and graft survival, reduced rates of
rejection, less hypertension, and the decreased requirement
for steroids. Reported toxicities in children are dose related
and include impaired renal function, headaches, nausea,
vomiting, paresthesias, and insomnia.
Absorption of tacrolimus appears to occur more rapidly
than cyclosporine, with peak plasma concentrations of
tacrolimus achieved in 0.5 to 4 hours. Tacrolimus is
metabolized and excreted in the bile with an associated
half-life of 4 to 14 hours. 15 Current tacrolimus pediatric IV
dosing is 0.02 to 0.05 mg/kg/day via a 24-hour continuous
infusion. The drug is administered through central or
peripheral IV access. Because tacrolimus adheres to plastic
surfaces, IV lines used for administration of the drug should
not be used to draw the drug level. Also, administration sets
should not contain polyvinyl chloride. Once whole blood
levelS of approximately 10 to 20 ng/ml are achieved with the
child tolerating oral intake, oral doses are prescribed. As
increased side effects of tacrolimus have been reported with
intravenous use, the child is switched to oral dosing as soon
as tolerated. The initial oral dose is 0.2 to 0.3 mg/kg/day in
two divided doses. Monotherapy with tacrolimus has been
achieved in 70% to 80% of patients by I year in one
center. 16
Sirolimus (Rapamune). Sirolimus, the newest of the
immunosuppressive agents, is structurally similar to tacrolimus and has synergistic effects with both tacrolimus and
cyclosporine. Unlike cyclosporine and tacrolimus, which
are calcineurin inhibitors, sirolimus inhibits the mammalian
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target of raparnycin (m-TOR), which is a regulatory enzyme
critical to immune function within the cytotoxic T cell.
Sirolimus is a macrolide antibiotic that inhibits T cell proliferation chiefly through the inhibition of responsiveness to
proliferative cytokines such as interleukin-2. Sirolimus may
cause significant bone marrow suppression, bone pain, and
serum lipid elevations. It has been used as a rescue agent in
liver, small bowel, or heart recipients experiencing neurotoxicity, nephrotoxicity, or persistent rejection with the use
of other immunosuppressants. Dosage is based on the indication and the amount of other immunosuppressant agents
in use and ranges from approximately I to 10 mg once daily.
It is usually used in addition to cyclosporine or tacrolimus.
Sirolimus is available in a liquid form, with the capsule
form soon to be available. It is mixed only with orange juice
or water for administration and is kept refrigerated. Absorption is affected by food; therefore the drug should be
consistently taken either with or without food 4 hours after
the dose of cyclosporine or tacrolimus. Because of the
prolonged half-life of sirolimus, therapeutic levels may not
be achieved for 7 to 10 days afler initiating the drug.
Complete blood count (CSC), differential, platelets, liver
function tests, and serum lipids should be monitored closely.
Acetaminophen may be used in management of the associated bone pain. Elevated cholesterol or triglycerides can be
managed by 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-COA) reductase inhibitors or fibric acid derivatives.
Azathioprine (Imuran). Azathioprine, an antimetabolite to DNA synthesis, is metabolized into 6mercaptopurine (6-MP), the active form of the drug. It was
first used as an immunosuppressant with renal transplant
patients in 1963. The combination of corticosteroids and
azathioprine was found to be more effective than either drug
alone and became the basic therapy for patients receiving
other grafts as well. Subsequently, many other drugs were
added to this combination, but they generally failed to
improve the therapeutic index until the development of
cyclosporine. Azathioprine prevents the rapid cell division
that occurs in the immune response, thus limiting the ability
of the body to generate cytotoxic T cells. Azathioprine is
toxic primarily to the bone marrow, and its use may cause
leukopenia. This effect results in an increased risk of
infection when azathioprine is used in higher doses.
Azathioprine is metabolized by the liver and excreted by
the kidney. It is available in oral and intravenous forms. The
oral form is readily absorbed from the GI tract.
Mycophenolate mofetil (CeIlCept). Mycophenolate mofetil is an immunosuppressant used in conjunction
with other immunosuppressant agents for the prophylaxis
and treatment of organ rejection in patients receiving allogeneic heart, liver, renal, and small bowel grafts; in management of GVHD in bone marrow transplant patients; and as
an add-on agent in place of azathioprine. Mycophenolate
mofetil is a prodrug metabolized into its active form mycophenolic acid by the liver.
Immunosuppression with mycophenolate may cause increased susceptibility to infections and malignancies, especially cutaneous. Side effects include hypertension, fever,
headache, hypercholesteremia, diarrhea, nausea, vomiting,
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dyspepsia, leukopenia, neutropenia, anemia, thrombocytopenia, myalgia, hematuria, and cough. Antacids decrease
mycophenolate absorption. Acyclovir and ganciclovir may
compete with mycophenolate glucuronide for renal tubular
secretion, resulting in increased concentrations of both
drugs. Other drugs that inhibit renal tubular secretion may
increase mycophenolic acid concentration.
Dosage for children is 1200 mg/m 2 /day divided every 8
to 12 hours. Alternative dosing is 30 to 45 mg/kg/day
di vided every 8 to 12 hours. Trough levels should be I
fIg/m\. Children often require dosing every 8 hours to
achieve therapeutic trough levels because of their rapid
clearance of the drug. Capsules should not be opened or
crushed. Inhalation of the drug or direct contact of the drug
with skin or mucous membranes should be avoided because
this agent may have teratogenic effects. I?
Corticosteroids. Corticosteroids are potent antiinflammatory agents that exert widespread systemic pharnlacologic effects. Included in this group of agents are the
endogenous glucocorticoids, cortisol, and the exogenous
agents prednisone and methylprednisolone (Solu-Medrol).
Steroids have several immunosuppressive properties and
are used both to prevent rejection and to treat acute
rejection episodes. Steroids interfere with macrophage
function, impairing antigen recognition. They inhibit both
interieukin- I (IL- I) and interleukin-2 (lL-2), causing a
decrease in the production of cytotoxic T cells. At high
doses (e.g., bolus doses of 500 to 1000 mg), corticosteroids
have a profound negative effect on the function of lymphocytes. The ability to recognize their target antigens is
impaired, and circulating lymphocytes are redistributed into
lymphoid compartments, where they avoid contact with the
transplanted organ.
.
Steroids are predominantly metabolized by the liver and
excreted by the kidney. Steroids are commonly given
intravenously at the time of surgery (as Solu-Medrol) and
then orally (as prednisone) following transplantation. The
oral preparation is usually well absorbed from the GI tract.
High doses of corticosteroids are given immediately after
the transplant to prevent rejection and then tapered to lower
maintenance levels over several days or weeks. Eventually,
attempts are made to wean the steroids altogether. Because
of the many toxic side effects of steroids, especially their
negative effect on linear growth in prepubertal children, low
maintenance doses are advantageous. The goal is to reach a
very low maintenance dose, or ideally, an every-other-day
dose schedule to improve growth in prepubertally children
and eventually wean steroids completely. Prednisone inhibits normal adrenocorticoid production of cortisol, so the
drug dosage is tapered before discontinuation to avoid
symptoms of adrenal corticoid insufficiency that occur if the
drug is abruptly stopped.
High-dose steroid therapy is usually the initial treatment
for rejection episodes. A 1- to 3-day "pulse" of high-dose
methylprednisolone given intravenously followed by an oral
prednisone taper to maintenance levels over 5 to 10 days is
a common treatment option. Most rejection episodes are
successfully treated with steroid treatment in addition to
optimizing the use of cyclosporine or tacrolimus.

Polyclonal Antilymphocyte Antibodies: Antithymocyte Globulin-Equine (Atgam). Antithymocyte
Globulin-Rabbit (Thymoglobulin). Immune globulin
preparations are produced by injecting an animal with
human thymocytes. The animal produces antibodies to the
human thymocytes, which are then separated and purified
into an immune globulin preparation. The antilymphocyte
sera is then infused into the patient, and the immunosuppressive effect is achieved through antigen-antibody binding
and the depletion of circulating lymphocytes.
This therapy has been used primarily to treat allograft
rejection episodes that are resistant to corticosteroid treatment. In addition, it may be used as an induction therapy to
delay cyclosporine or tacrolimus therapy for 2 to 4 weeks
posttransplant, thus minimizing potential nephrotoxicity
from calcineurin antagonism immediately after the operation. It is also used as an adjunct to other immunosuppressive therapy to delay the onset of the first rejection episode.
Before administration, prior sensitization to the heterologous globulin is assessed by giving a subcutaneous test
dose diluted with normal saline (Atgam only.) During daily
administration, premedication with an antihistamine and
acetaminophen will decrease the incidence of toxic reactions such as flushing, chills, fever, occasional anaphylactic
reactions, and serum sickness. Maintenance dose is regulated by monitoring T cell subsets.
Monoclonal Antibodies: Muromonab-CD3 (Orthoclone OKT3). Monoclonal antibodies are produced
by a hybridization technique that joins sensitized B cell
lymphocytes with murine myeloma cells and produces
monoclonal antibodies. The antibodies are targeted to react
with a specific subset of lymphocytes defined by surface cell
antigens. 18 Monoclonal antibodies are deri ved from a single
clone, so each molecule is an identical, highly specific
antibody to a specific antigen. In the case of OKT3, the
antigen is the CD3 cell surface receptor of the T
lymphocytes.
OKT3 acts on the immune system causing an immediate
decline in circulating T cells (as soon as 8 to 12 hours). This
prevents the lymphocytes from reacting with foreign antigens from the transplanted organ and inhibiting T cell
function. Because of its potency, OKT3 has different toxic
effects than the other immunosuppressant antibodies. Experience in renal, liver, and cardiac transplantation has
demonstrated its efficacy in treating rejection.
OKT3 has also been used prophylactically in the
immediate transplant period by some heart and renal
transplant programs. 19 The efficacy of prophylactic use of
OKT3 in decreasing rejection has not been established.
Some evidence now shows that prophylactic use of OKT3
may be associated with an increased risk of lymphoma
following heart transplantation in adults. 2o
OKT3 comes as an IV preparation and is given once daily
as an IV bolus infusion over I minute. Treatment for
rejection is determined by biopsy results, but it is usually a
10- to 14-day course. Premedication, of acetaminophen,
diphenhydramine, and corticosteroids, is given to decrease
adverse reactions, especially common with the first dose.
OKT3 administration has been associated with an increased
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incidence of cytomegalovirus (CMV) infection. Therefore
many patients receive CMV prophylaxis concomitant with a
course of OKT3. Because OKT3 is a murine-derived
protein, patients may develop antibodies to the drug, which
could limit the potency of the drug in the future treatment of
the patient. The manufacturer (Ortho Pharmaceutical Co.)
offers an immunoassay service to measure antibody titers to
OKT3. OKT3 is contraindicated in patients with known
hypersensitivity, those with fluid overload, or patients who
have had a greater than 3% weight gain within the prior
week. Serious side effects may occur, including pulmonary
edema and cytokine release syndrome.
Daclizumab (Zenapax) and Basiliximab (Simulect). Daclizumab and basiliximab are immunosuppressive monoclonal antibody products produced by recombinant technology. They prevent IL-2 from binding to the IL-2
receptor and inhibit the proliferation of activated T cells.
Daclizurnab and basiliximab are used as induction therapy
in the prophylaxis of acute rejection. as part of an
immunosuppressive regimen that includes other immunosuppressant agents. Daclizumab is given at the time of
surgery (usually I mg/kg) and every 2 weeks thereafter, for
a total of 5 doses. Basiliximab is administered on the day of
surgery (day 0) and on day 4.
Daclizumab and basiliximab do not cause the cytokine
release syndrome characteristic of OKTI or antilymphocyte
globulin, which often leads to a combination of fever,
respiratory difficulty, and hypotension. Adverse effects are
uncommon, and when they occur, they are mild and include
GI symptoms such as constipation, nausea, vomiting,
diarrhea, and abdominal pain. Other adverse effects, such
as edema, tremor, headache, oliguria, chest pain, fever,
fatigue, hypotension, dyspnea, insomnia, back pain, tachycardia, and bleeding, are very rare. They do not appear
to alter the pattern, frequency, or severity of adverse
reaction or infectious complications associated with other
immunosuppressants.
Immune Globulins. Immune globulins are sometimes used in conjunction with appropriate antiinfective or
antiviral therapy to prevent bacterial or viral infections in
patients with immunosuppression. For example, specific immune globulins, such as hyperimmune CMV immune globulin, may be used to attenuate CMV or Epstein-Barr virus
(EB V) infections. Rituximab (Rituxan) is a genetically engineered human monoclonal antibody directed against the
CD20 antigen found on the surface of normal and malignant
B lymphocytes. Rituximab is indicated for the treatment
of patients with relapsed or refractory, low-grade or fol·
licular, CD20-positive, B cell non-Hodgkin's lymphoma.
Preliminary case reports suggest rituximab may be beneficial in some patients with EB V-related posttransplantation
Iymphoproliferative disorder (PTLD), refractory to other
treatment. 17
Antiviral Agents. Antiviral agents, such as ganciclovir and acyclovir, are used as prophylaxis or treatment of
specific viruses, including CMV, EBV, and herpes simplex
and zoster, for immunosuppressed patients who are more
susceptible to devastating viral infections in the postoperative period.
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Other Agents. Several other treatments have been
tried to prevent or treat rejection following transplantation.
Some centers have used the anticancer agents cyclophosphamide (Cytoxan) and vincristine in patients with severe
rejection. Total lymphoid irradiation (TLI) has been used in
small groups of patients. With renal transplant patients, it
was used before transplantation in an attempt to induce
immune tolerance to the donor organ and decrease later
rejection. 21 It has also been used after heart transplantation
to treat intractable rejection. 22 New monoclonal antibodies
are being sought. Ideally, scientists hope to find a method for
inducing a state of true tolerance to the transplanted organ.
Long-Term Immunosuppression. Long-term immunosuppression can lead to other problems, most often
hypertension, renal insufficiency, cutaneous malignancies,
neurologic symptoms or findings, infections, and steroidrelated complications such as obesity, growth failure, bone
disease, and diabetes.

Rejection of the Organ Allograft
Because all the physiologic properties of the human immune
system have not been fully explained, the phenomenon of
rejection is not completely understood. Rejection is the
result of a series of complex immunologic responses in
which the recipient recognizes the donor organ as being
different from itself. Foreign antigens on the donor organ are
recognized by the host organism, and then through a number
of pathways, destruction of the donor graft occurs. This
process involves lymphocyte infiltration, cellular edema,
eventual cellular necrosis leading to organ dysfunction, and
later, if untreated, graft loss. A more complete discussion of
the immune system is found in Chapter 15.
Hyperacute rejection is a humoral-mediated immune
response, which occurs within minutes or hours of transplantation as the result of preformed circulating antibodies
to the donor. The organ sustains intense endothelial damage
with interstitial edema and clotting of the microvasculature.
The kidney appears most prone to hyperacute rejection,
whereas the liver and heart appear more tolerant of
transplant antigen incompatibility.7 Using ABO-compatible
donors and avoiding implants in cross-match-positive
recipients are standard practices to prevent hyperacute
rejection in renal and cardiac transplantation.
Acute rejection is a T cell-mediated immune response,
which may occur I to 2 weeks after transplantation and any
time thereafter. The T lymphocytes of the recipient are
activated by the surface antigens of the donor organ, causing
cellular infiltration of the transplanted organ with resultant
interstitial edema and cellular necrosis. Because of cellular
damage, acute rejection may interfere with normal organ
function. Immunosuppressive therapy after transplantation
is designed to prevent and treat acute rejection episodes.
Chronic rejection is a combination of both humoral and
cellular immune responses, which may occur 3 months after
transplantation but is more common after the first year. It
has an insidious onset, appears to be progressive, and results
in vascular damage to the organ, eventually leading to organ
failure. Retransplantation is the only known treatment.
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The diagnosis of acute rejection is different for each solid
organ transplant. In the following sections, the clinical signs
of rejection and the use of specific procedures to diagnose
rejection are described and discussed for each organ.

HEART, HEART-LUNG, AND LUNG
TRANSPLANTATION
Heart Transplantation. The treatment of end-stage
heart disease in infants and children with heart transplantation became available in the early 1980s following improved outcomes in adults and the introduction of cyclosporine. Heart transplantation is now a well-established
therapy for infants and children with end-stage heart disease
who have failed conventional medical and surgical therapies
or for whom no other therapies are possible.
The International Society of Heart and Lung Transplantation (ISHLT) provides a wealth of information about
cardiac transplantation in the annual report. 19 •23 A rapid
increase in the total number of pediatric heart transplants
occurred in the 1980s, reaching 324 transplants in 1990.
Since then, there has been a plateau in the total number of
transplants and a recent decline in the yearly total. These
data reflect a limit in available donor organs, yet the
number of potential recipients continues to increase. Heart
transplants in children 18 years of age and younger make
up about 10% of the total number of heart transplants
performed annually in the United States.
Infants make up about 25% of the pediatric heart
transplant population, with patients of ages I to 10 years and
those II to 18 years equally composing the rest of the group.
The main indications for pediatric heart transplantation are
congeni tal heart disease (75% of the infant group) and
cardiomyopathy (65% of the 11- to 18-year-old group).
The pediatric registry contains data on more than 4000
heart transplants performed from 1983 to 1999. 19 The
actuarial survival for this period was 78% at I year and 64%
at 5 years. Recent data from 1995 to 1998 suggest improved
early survival with a I-year actuarial survival of 82%. In
experienced centers, significantly better survival has been
observed. In all eras, the greatest mortality is in the first few
months after transplantation. Infant actuarial survival is
lower than that of other age groups because of a higher
incidence of early death. Primary graft failure is the most
common cause of early death in the first month after the
transplant. For those infants who survive the first year, late
survival is similar to that of other age groups. Some data
suggest that newborn recipients may have a long-term
survival advantage?4
Acute rejection, followed by infection, is the leading
cause of death I month to I year posttransplant in children,
as in adults. After 3 years, chronic rejection/posttransplant
coronary artery disease is the leading cause of late mortality
in children. The conditional half-life (for patients surviving
more than I year posttransplant) for all pediatric recipients is now estimated at 14.4 years, suggesting that
many children will survive to reach adulthood after heart
transplantation. 19

Powerful arguments have been made on both sides of the
"palliate or transplant" controversy for infants with hypoplastic left heart syndrome (HLHS). Those who argue in
favor of palliation cite the relative scarcity of donors, the
high incidence of early graft failure in this group of patients,
and the long-term morbidity and mortality risks after
transplantation. They propose that using pieces of an
infant's own heart to fashion some form of circulation
capable of sustaining life is preferable to using someone
else's tissue (i.e., a transplanted organ), with its attendant
need for immunosuppression. These patients would still be
potential transplant candidates if the palliative repair failed.
Many believe that the limited supply of donors should go to
infants with no other treatment options. Proponents of
transplantation believe it is a better alternative for infants
with HLHS, which requires several high-risk palliative
procedures without achieving normal cardiac structure or
function. They argue that having a normal heart offsets the
risks of chronic immunosuppression.
Several factors are considered in evaluating treatment
strategies. Ninety percent of mortality in both groups
occurred in the first year of life. The limited infant donor
supply and resultant longer waiting times are likely to
increase the number of infants who die while waiting for a
transplant. This pretransplant mortality negatively impacts
the outcome statistics for infants in the transplant option
group. Even with that fact in mind, a study comparing
outcomes at I year and 5 years for both treatment strategies
on patients from 1989 to 1994 reported better outcomes with
transplantation in both periods 25 However, the true incidence of late transplant complications, such as PTLD and
posttransplant coronary artery disease, will become more
apparent as pediatric survivors live 10 or more years after
transplant. With recent improvements in the surgical outcomes for stage I repairs in large referral centers, palliative
repair may become a more attractive option, and there may
be fewer infant transplants as a primary procedure for HLHS
in the future. Heart transplantation for infants with no other
treatment options will continue.
Heart-Lung and Lung Transplantation. Pediatric
combined heart-lung and lung transplantation have been
available since 1985, when the first successful pediatric
heart-lung transplant was performed at the University of
Pittsburgh. 10 The Registry of the International Society for
Heart and Lung Transplantation has received data on more
than 11,608 heart-lung and lung transplants worldwide (all
age groups), including 2510 combined heart-lung procedures from 124 centers, 5347 single-lung procedures from
153 centers, and 3751 double-lung procedures from 140
centers. 26 Children have received heart-lung, double-lung,
sequential bilateral single-lung, and single-lung transplants.
The 1998 data reported 15 heart-lung transplants in children
and 75 lung transplants in children?6
The number of heart-lung procedures has declined
steadily over the past 6 years, primarily related to limitations
in pediatric donor availability but also because of the
expansion of single- and double-lung transplants and the
strict, but necessary, criteria set for recipient eligibility.4
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(For example, potential recipients with cystic fibrosis who
have Pseudomonas cepacia in their airways or sinuses are
no longer placed on waiting lists in many centers. 27 ) Cardiac
repair and simultaneous bilateral or single-lung transplantation have been performed in some centers, which allows a
scarce donor heart to be used in a d.ifferent recipient.28
Single-lung transplantation offers a therapeutic option for
patients with lung disease without infection and for selected
patients with pulmonary hypertension and adequate cardiac
reserve. In some cases, a double-lung transplant may be
preferred over heart-lung transplant for children with
adequate cardiac function and inadequate pulmonary function. In addition, procurement of a cadaveric lung allograft
for a recipient requiring only a single or double lung
provides the use of the heart for standard orthotopic heart
transplantation in another recipient. Donors deemed unsuitable for heart-lung transplantation on the basis of a
unilateral lung pathologic condition, including trauma,
atelectasis, and even pneumonia, may be suitable for
single-lung and orthotopic heart graft procurement. Furthermore, selected donors with excessive vasopressor requirements, cardiac contusions, or arrhythmias may be viewed as
potential double-lung or single-lung donors. With the
increased success of lung transplantation, the fact that only
I in 20 donors has suitable lungs for transplantation has
prompted some surgeons to consider living-related segmental lung donors.
Children who are candidates for lung transplantation
have end-stage parenchymal or vascular lung disease
causing a significant impact on their daily activities. The
major indications for combined heart-lung procedures have
been primary pulmonary hypertension; pulmonary vascular
disease secondary to congenital heart disease, including
Eisenmenger's syndrome; and cardiomyopathy with pulmonary vascular disease. The major indication (almost 50% of
cases) for lung procedures has been cystic fibrosis. Congenital disease and primary pulmonary hypertension necessitate
other lung procedures. Other indications include interstitial
lung disease, arteriovenous malformations, GVHD, and
rheumatoid lung.
The operative mortality (less than 30 days) associated
with lung transplantation is approximately 18%. Early
mortality in lung transplantation has not been higher in the
pediatric age group, but fewer children under 2 years of age
have had lung transplantation.
Causes of death in lung recipients are similar for all
forms of lung transplantation. As in heart transplantation,
intraoperative technical complications (including primary
graft failure and hemorrhage) and cardiac complications
account for about one third of all deaths. Infections have
been reported in an additional one third of deaths, which is
higher than heart recipient rates. Most infections causing
mortality are related to viral and fungal infections. Antiviral
prophylaxis is used for at least 4 weeks after transplantation.
Cystic fibrosis patients are also at higher risk for severe
bacterial infections. They are often colonized with resistant
organisms. In addition, they may be malnourished, with
chronic subacute infections, such as sinusitis. In general,
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cystic fibrosis in children is challenging to manage. Triple
drug immunosuppression is avoided in these patients, and
aggressive, extended antimicrobial therapy is used. More
thorough pulmonary toilet is required to prevent or treat
pulmonary infections.
Rejection has not been as significant a cause of death as
in previous years, primarily because of new and innovative
immunosuppressive agents. However, most patients will
suffer one or two episodes of acute rejection in the first 3
months posttransplanl. The most significant long-term
complication of lung transplantation is chronic rejection,
characterized by obliterative bronchiolitis.
Posttransplantation lymphoproliferative disease is also a
potential complication, particularly in children with no
exposure to EBV and in children receiving lungs or
intestines, which have a more significant quantity of
donor-derived lymphatic tissue. Often, the infection occurs in the recipient's lung within the first year after
transplantation.
Survival in lung recipients has been lower than that in
heart recipients. Currently, little difference in survival rate is
apparent between the specific types of lung transplant
procedures. One-year survival is 66% for heart-lung, 68%
for single lung, and 74% for double-lung transplantation.
The 5-year survival rate for heart-lung transplantation has
been 41 %.26

Transplantation Procedures
Heart Transplantation Procedure. The operative
technique for cardiac transplantation in infants and children
is similar to that in adults except for modifications in those
with congenital cardiac anomalies. The operation is performed through a median sternotomy using cardiopulmonary bypass. Standard orthotopic heart transplantation
involves removing the recipient's diseased heart, retaining
the great arteries and back wall of the atria, and performing
biatrial anastomoses. The recipient's remaining atrial chambers may be large, and the donor and recipient atria may
contract asynchronously.
Bicaval anastomoses are becoming more common, especially in recipients with congenital heart disease. Total
cardiac transplantation leaves a small cuff of the recipient
left atrial tissue (the area receiving the pulmonary veins) in
place, but the right atrium is removed. The donor right
atrium is left intact, and the donor superior and inferior vena
cava are anastomosed to the recipient cava. 29 This technique
requires less dissection if the recipient atria have been
involved in previous operations and is less likely to damage
the sinus node.
Heterotopic heart transplantation leaves the recipient's
own heart in place and attaches the donor heart, via conduits
to the great arteries as a "piggyback" heart. Rarely
performed in children, heterotopic transplantation has a role
in patients with increased pulmonary vascular resistance
(PVR) as an alternative to heart-lung transplantation or
when the donor organ is too small for the recipient, but
transplantation is necessary because death is imminent. 29
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Donor selection and organ recovery require some adjustments for infants and younger children. Hearts can come
from donors larger than the recipient, sometimes more than
double the recipient's body weight. The recipient's failing
heart is often markedly dilated, so the mediastinum can
accommodate a larger heart. This may be especially
advantageous if increased PVR is present. Surgeons usually
remove extra donor aorta and pulmonary artery to use in
reconstruction of these vessels in patients with congenital
heart disease. Surgical techniques for cardiac transplantation
in patients with many congenital cardiac anomalies have
been described 29 . 3o

Heart-Lung and Lung Transplantation Procedures. Transplant techniques have been refined over the
past 20 years. In the past, bronchial anastomosis disruption
was an early cause of death. Use of steroids sometimes
impeded vascular supply to the transplanted donor bronchus, leading to bronchial air leaks, bleeding, stenosis,
mucosal necrosis with aspiration pneumonia, and infection]1 Consequently, steroid dosages have been greatly
reduced, and triple-drug immunosuppression is used for
most heart-lung and lung recipients.
Removal of the diseased heart and lunges) without
causing phrenic, recurrent laryngeal, or vagus nerve injury
is technically challenging. 29 The trachea is divided immediately above the carina, or the division is made on the
recipient's right and left mainstem bronchi as they emerge
from the mediastinum. 32 The donor heart and lungs are
prepared and removed en bloc after core cooling and
administration of cardioplegia to the heart. Reimplantation
of the heart-lung graft is accomplished by sequential
tracheal, caval, and aortic anastomoses.
The single-lung transplant is performed through a
thoracotomy. Choice of which lung to transplant is affected
by previous surgery, such as lobectomy (the opposite lung is
then chosen for transplant because no scar tissue is present),
size of the donor (if a relatively large lung is to be
transplanted, the left side is preferred because the left
hemidiaphragm is easier to mobilize downward to accommodate the lung tissue; however, oversized grafts are
avoided), and lung condition (the most diseased or damaged
lung is replaced).
When a single lung is transplanted or sequential transplantation of bilateral lungs is performed, the recipient's
pulmonary artery is clamped to determine if the patient can
tolerate the implantation without the use of cardiopulmonary bypass. This avoids the potential issue of platelet
destruction and other complications associated with bypass.
Once oxygenation has been established, the diseased organ
is removed with cauterization of bleeding and preservation
of essential nerves. The donor organ is placed, and three
major anastomoses are completed. First, the bronchial
anastomosis is completed. Second, the two major pulmonary veins from the one lung of the donor are attached to the
recipient's left atrium (larger children), or a section of the
atrial wall with pulmonary vein insertion points is implanted. Last, the pulmonary artery is anastomosed. The
recipient and donor pulmonary arteries are spread, and an
anastomosis is performed with very small "bites" through

all the layers of the vessel, using continuous sutures. 32
In a bilateral lung transplant, a "clamshell incision" or a
bilateral thoracostemotomy is used to provide full exposure
of the operative field. Patients over 20 kg are intubated with
a double-lumen endotracheal tube to allow selective,
unilateral lung ventilation. A pulmonary artery (PA) catheter
is placed to provide continuous assessment of PA pressures
and cardiac output. After cannulation of the PA, right
ventricular tolerance of both left and right PA clamping is
assessed, as well as identification of the "best lung" by
sequential ventilation and assessment of arterial blood
gases. If there is any question of right ventricular dysfunction, cardiopulmonary bypass is used to support the patient
through the transplant. If the patient is able to tolerate
unilateral lung ventilation and pulmonary artery clamping,
each lung is sequentially implanted.

Postoperative Care Following
Heart and Heart-Lung Transplantation
Many aspects of postoperative nursing care following
transplantation of thoracic organs are similar to the care of
infants and children after cardiopulmonary surgery (see
Chapter 18). Postoperative recipients require close monitoring and physical and hemodynamic assessment. A PA
catheter is often used to monitor right ventricular performance and PA pressures, especially if preoperative high
PVR is present. Cardiac output is assessed noninvasively by
the quality of peripheral pulses, capillary refill, skin
temperature and color, and urinary output. Serum electrolyte
levels, arterial blood gases, and chest tube drainage are
documented. Careful evaluation of heart and respiratory
sounds is necessary. Maintaining hemodynamic stability is
important while minimizing fluid overload and pulmonary
edema. Strict monitoring of intake and output (often while
maintaining a negative fluid balance) is required to avoid
fluid overload or hypovolemia.
Of particular interest in the postoperative lung transplant
patient is the reimplantation response. This is defined as the
morphologic, radiologic, and functional changes that occur
in a transplanted lung in the early postoperative period as the
result of surgical trauma, ischemia, denervation, lymphatic
interruption, and other injurious processes (exclusive of
rejection) that are unavoidable aspects of the transplant
operation. Functionally, the reimplantation response produces a temporary impairment of the ventilation/perfusion
ratio in the transplanted lung. Some transient impairment of
blood flow may also occur. The patient may present with
symptoms of adult respiratory distress syndrome (ARDS),
manifested as defects in pulmonary gas exchange, compliance, and vascular resistance, as well as an inability of the
disrupted lymphatic system to clear interstitial fluid. Subjectively, the patient becomes very anxious and complains
of shortness of breath. Examination of the patient reveals
diffuse rales, and chest x-ray film demonstrates pulmonary
edema. Treatment includes vigorous diuresis, chest physiotherapy, and reintubation if necessary. In addition to
reimplantation response, differential diagnoses include rejection and infection. Distinguishing among these diagno-
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ses, though often difficult, is essential to formulating a
treatment and nursing care plan. The incidence and severity
of the reimplantation response seem to be decreasing,
possibly because of beller preservation techniques.
Assessing for clinical signs of infection and rejection is
a primary nursing function. A small increase in temperature
can indicate infection. Fevers greater than 38° C require
prompt and aggressive workup. Persistent or productive
cough with or without fever or decrease in forced expiratory
volume in I second (FEY 1) require further investigation by
chest x-ray film and, frequently, bronchoscopy. (See also
sections on infection and rejection.) CMY and Pneumocystis
carinii are important opportunistic infections in heart-lung
or lung transplant recipients. The risks of infection by any
organism are directly related to potency and duration of
immunosuppression, donor selection, operating room technique, and postoperative exposure to pathogens.

Significant Postoperative Issues
and Complications
Organ-Specific Rejection

Organ-Specific Rejection: Heart. The principal mediators of cardiac allograft rejection are T lymphocytes?9
Humoral mechanisms are thought to be less significant
except in sensitized patients or perhaps in chronic rejection. Clinical signs of acute rejection of the heart in
infants and children are often subtle and nonspecific and
may be absent until rejection is severe. Signs and symptoms of rejection in infants include irritability, lethargy,
poor feeding, tachypnea, and tachycardia. Children may
demonstrate decreased exercise tolerance, marked fatigue,
elevated temperature, and signs of congestive heart failure. On auscultation, a gallop or pericardial friction rub may
be appreciated, and dysrhythmias may be detected. Rejection may impair contractility and result in low cardiac
output.
Additional diagnostic tests for acute rejection may be
helpful. Cardiomegaly may be seen on chest x-ray film.
Electrocardiogram (ECG) may show atrial or ventricular
dysrhythmias. Summation of ECG voltages may be decreased from the patient's baseline in severe rejection.
Hemodynamic data obtained via intracardiac lines or during
cardiac biopsy procedures may show increased filling
pressures, decreased right atrial saturation, increased right
ventricular end-diastolic pressure (RYEDP), and decreased
cardiac output during rejection episodes.
Echocardiograms are a useful noninvasive test in monitoring for rejection. The presence of increased posterior wall
thickness, decreased left ventricular volumes, decreased
ventricular function, and pericardial effusion suggests rejection and warrants further investigation. Systolic dysfunction
occurs late and usually indicates severe cellular rejection.
Boucek and colleagues)) described an increase in left
ventricular mass and other parameters on the echocardiogram as reliable markers for rejection in infants. Another
recent study by Santos-Ocampo and associates 34 found
echocardiogram indices of rejection less reliable early after
transplant when compared with biopsy results and signifi-
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cant variability in observations depending on the value
measured. Echocardiogram detection of diastolic dysfunction may not be a reliable indicator of graft rejection 29
Despite a number of possible noninvasive parameters,
right ventricular endomyocardial biopsy remains the "gold
standard" in the diagnosis of cardiac rejection. Histologic
grading for rejection is standardized based on criteria from
the ISHLT. 29 Mild rejection is characterized by minor
peri vascular and interstitial infiltrates. Moderate rejection
involves increased infiltrates and focal myocyte necrosis.
Severe rejection is manifested by increased inflammatory
infiltrates, multiple sites of myocyte necrosis, and interstitial
edema with or without hemorrhage. Although endomyocardial biopsy is the most reliable method currently available to
diagnose cardiac rejection, it is not infallible. There are
many anecdotal reports of patients with clinical signs of
severe rejection who had a negative cardiac biopsy result
and, conversely, patients who appeared well but had a
biopsy demonstrating rejection. The importance of experience and clinical judgment in weighing all available data to
reach a diagnosis and prescri be appropriate treatment cannot
be overemphasized in the field of transplantation, especially
when dealing with infants and children.
Biopsies are performed most frequently in the first few
months (as often as weekly in the first month) following
transplantation because risk of rejection is highest. The
length of time between biopsies is gradually increased over
the first 2 years. Many programs perform a biopsy on
patients once or twice a year for an indefinite period. After
patients require treatment for rejection, follow-up biopsies
are performed I to 2 weeks later to confirm resolution of
rejection. 29
The endomyocardial biopsy involves advancing a bioptome catheter into the right ventricle under fluoroscopy or
echocardiographic guidance and obtaining four to five tissue
samples for microscopic analysis. The procedure is usually
performed on an outpatient basis and takes approximately
one-half hour. In most centers, vascular access is through the
right internal jugular in all ages. Femoral veins may be used
in infants and young children. EMLA cream and local
anesthetic are often used at the puncture site. Some older
children may cooperate for the procedure without sedation,
but most children need some form of procedural sedation.
Uncooperative or higWy anxious patients may require
anesthesia. Pneumothorax and bleeding at the puncture site
are possible complications. Damage to the tricuspid valve is
possible after multiple biopsies, resulting in a flail tricuspid
valve. Perforation of the heart muscle is rare. Overall, the
procedure has low associated morbidity.29
The endomyocardial biopsy technique and the size of the
bioptomes used have been modified so that endomyocardial
biopsies can be performed in neonates, as well as in older
children. However, endomyocardial biopsy has some disadvantages in children: (I) a sampling error is inherent in the
technique; (2) it is an invasive technique, which is more
difficult to repeat in young children; and (3) anesthesia is an
added risk that is sometimes required. Researchers continue
to seek a more reliable, noninvasive test to identify
rejection.
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Acute rejection, along with infection, remains the leading
cause of death in the first year after cardiac transplantation. 19 Despite the initiation of triple-immunosuppression
therapy, most patients will have at least one rejection
episode, usually within the first 3 months after transplantation. Data from a prospective, multiinstitutional study
conducted by the Pediatric Heart Transplant Study Group
showed that the peak hazard for first rejection was at 2
months posttransplant, and the actuarial freedom from
rejection was 61 % at I month and 37% at 6 months.
Furthermore, the same study showed that although infants
younger than 6 months of age had similar rates of rejection
compared with older children, the mortality caused by
rejection was lower, suggesting that rejection may be a less
aggressive process in infants. 35 The critical care nurse plays
a vital role in monitoring infants and children for signs of
rejection in the early postoperative period. Prompt recognition of rejection and the institution of immunosuppressive
therapy increase the likelihood of successful treatment.
Treatment of episodes of rejection usually involves a
3-day pulse of methylprednisolone. If the rejection episode
is associated with graft dysfunction or is resistant to steroid
treatment, other agents, such as OKT3, are used. Therapy
tends to be aggressive because persistent rejection increases
the risk for chronic rejection.
Chronic rejection of the cardiac allograft is characterized
by posttransplantation coronary artery disease, which represents a growing concern in the long-term survival of
pediatric recipients. Pathologic findings in this condition are
different from atherosclerotic coronary artery disease. This
is a diffuse process of coronary artery luminal narrowing,
believed to be immune mediated, resulting in ischemia and
ventricular failure. The incidence of coronary artery disease
in children is less than adults, but children need to live with
the graft for a much longer period, and it may be that the
onset of the coronary artery disease is simply delayed.
Reviews have estimated the incidence of coronary artery
disease in children who have survived I year posttransplant
as 10% to 30%.24.36,37 In a multicenter study including 815
patients, 58 had angiographic or autopsy evidence of
coronary artery disease, and 49 patients died, including 5 of
10 who had undergone retransplantation. 38 Diagnosis can be
difficult, and some patients who die suddenly were found to
have coronary disease on autopsy. Coronary angiography is
known to be insensitive in diagnosis. Currently, no effective
medical therapies are known, and the only treatment is
retransplantation.
Organ-Specific Rejection: Lung. Rejection is common in the early weeks following transplantation. Lung
allografts initiate much stronger immune responses than
cardiac allografts alone. Rejection of the heart after heartlung transplantation is unusual; the lung suffers most of the
host immune response. 29 In the early period after transplantation, clinical manifestations of lung rejection may include
fever, increased work of breathing, new pulmonary infiltrates, and hypoxemia. However, mild or even moderate
rejection often is clinically silent or is characterized just by
mild dyspnea. Results of plain chest x-ray film and
ventilation scans may be completely normal, although in the

later stages, some abnormalities caused by alveolar involvement may appear. Radiographically and functionally, alveolar rejection is associated with transplant opacification and
decreased ventilation without a corresponding reduction in
blood flow.
Bronchiolitis obliterans (obliterative bronchiolitis [OB])
represents chronic rejection of the lung allograft. It is often
associated with a history of recurrent acute rejection
episodes or sometimes with strong immunologic response to
CMY. Onset is usually 6 months to 3 years after transplantation. It manifests as dyspnea with progressi ve small
airway obstruction and decreased function, often refractory
to augmented immunosuppression, which ultimately results
in respiratory failure. Clinically, the FEY 1 may also decline
rapidly and progressively. Secondary infection is common. 32 OB occurs in about 50% oflung transplant recipients
by 4 years posttransplantation 28 and becomes the main
cause of death after the first year posttransplantation,z9
Diagnosis is based on history, clinical presentation, chest
radiographs, and pulmonary function testing.
Definitive diagnosis of lung rejection, essential in asymptomatic rejection, is accomplished by transbronchial biopsy
(TBB.) Severity of acute cellular rejection is classified by
the amount and distribution of lymphocytic infiltrates
around the blood vessels and airways. Sensitivity of TBB in
the diagnosis of OB is poor because OB is characterized by
fibrous obliteration of small airways and TBB samples from
small airways are usually not obtained,z9 Biopsies are
performed for routine surveillance for asymptomatic acute
rejection and when clinical manifestations of rejection are
present. The initial routine biopsy is done before hospital
discharge and then every 3 months for 2 years. 29 For
long-term monitoring, patients can be provided with a
handheld peak flowmeter, which measures peak expiratory flow (PEF). Decreased PEF may be an indicator of
chronic rejection (OB). Exercise tolerance is monitored as
well; earlier desaturations with exercise may occur with
rejection.
Because of the increased incidence of rejection with lung
transplantation, children require higher levels of immunosuppression initially, resulting in increased toxicity and
other effects from the immunosuppressant drugs. Tripledrug immunosuppression is routinely used, yet early rejection still occurs often. Achieving monotherapy over time in
heart transplant patients is more common than in patients
who have received lungs. 29 Increased immunosuppression
and use of other pharmacologic agents may be successful in
treating acute cellular rejection. Augmented immunosuppression is often not effective in treating OB, but it may
slow the decline of small airway function. Even though the
heart is rarely involved in acute rejection in a heart-lung
transplant, the diagnosis of OB presents increased risk for
posttransplant coronary artery disease.
Infection. Infections are one of the leading causes of
morbidity and mortality in the immunocompromised child
after organ transplantation. The risk of infection is highest in
the first few months following transplantation, when immunosuppression is greatest. The incidence of infection has
declined in the past decade as a result of the continuous
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development of new immunosuppressive agents. These
agents are very specific in altering the immune response that
causes rejection while sparing other immunologic functions
that defend against infection. Using these new pharmaceuticals enables the steroid dose to be decreased, reducing the
risk of infection. In addition, increased knowledge about
posltransplant infections allows improved detection and
treatment. Also, the development of more effective antiviral
agents has aided in the prevention and treattnent of viral
infections.
Improvements in the diagnosis and management of
rejection have decreased the time interval of intense
immunosuppression, which was often associated with infections. It is recognized that the greater the amount and
duration of immunosuppression, the greater the likelihood
of infection. The following section reviews the risk factors
for infection in the child after transplantation; describes the
types of infections, their presentation and treatment; and
outlines the vital role of the nurse in prevention and
surveillance.
Risk factors for infection include the use of intense
immunosuppression, host characteristics, and the pediatric
intensive care unit (PICU) environment. Immunosuppression is at its highest level in the immediate posttransplant
period because this is when the risk of acute rejection is
highest. At the present time, all pharmacologic therapies
disturb normal immune defenses to some extent; none are
specific enough to block only the processes that cause
rejection.
Many patients, before transplantation, are immunocompromised secondary to their debilitating chronic illness,
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poor nutrition, or end-stage organ failure. A weakened host
then undergoes a major operation and requires complex
postoperative care involving the use of invasive equipment
and procedures that further compromise the body's defenses. The presence of an endotracheal tube, multiple
invasive lines, catheters, and drainage tubes breach the
normal external defense mechanism of the body and carry a
risk of infection. The PICU environment also predisposes
transplant patients to an infectious risk with exposure to
multiple organisms common in the hospital environment
and to numerous caregivers. Immunosuppression, a compromised host, and environmental concerns combine to
make infection a significant risk for the child recovering
from transplantation (see also Chapter 15).
Significant infections occur most often in the first 6
months following transplantation. Specific organisms are
typically responsible for infections occurring immediately
after transplantation, up to 6 months posttransplant, and
after 6 months posttransplant (Table 26-3). Most infections
in the first month are nosocomial infections, primarily
involving bacteria, and occur as a result of multiple lines
and invasive procedures or are related to preexisting disease
conditions and surgical manipulation. From I month to 6
months, opportunistic infections are most common and may
cause significant morbidity and mortality.
Opportunistic infections are caused by organisms common in the environment that rarely cause disease in an
immunocompetent host. In the immunosuppressed patient,
however, these organisms are capable of causing illness.
Infection can also result from exposure to an exogenous
source of a virulent pathogen, such as meningococcal

Infedious Complications Within the First 180 Days of Transplantation*

:iF'

Harly (0-1 Month)
~'"
jW,

Middle (0-6 Months)

Late (>6 Months)

Viral
Epstein-Barr virus (all transplant types;
less than middle period)
Varicella-zoster virus (all transplant
types)
Community-acquired viruses (all transplant types)

~.:

Vi ral
Cytomegalovirus (all transplant types and
seronegative recipients of seropositive
donors)
Epstein-Barr virus (all transplant types
and seronegative recipients; small
bowel-highest risk)
Varicella-zoster virus (all transplant
types)
Opportunistic Organisms
Pneumocystis carinii (all transplant
types)
Toxoplasma gondii (seronegative recipient of a seropositive donor heart)

i~

;;:~::~:~lIas/Burkholderia

~f:

Pneumonia-gram-negative organisms

~):lJacterial

if~am-neg~tive enteric bacilli (small

1,1\ bowel, hver, neonatal hearts)

If:seudomollaslBurkholderia spp.

fibroSIS)
ii!Pt'am-positive organisms (all transplant
t~
iJ,Jl'
[ types)
Ifungal
transplant types
!!iI~, (Iung~ystic

IAII

,~::iViral

iHerpes simplex (all transplant types)
I}losocomial respiratory (all transplant
i!!'V types)

~!h

(Iung~ystic fibrosis)

spp.

Bacterial
PseudomonaJlBurkholderia spp.
(Iung~ystic fibrosis; lung recipients
with chronic rejection)
Gram-negative bacillary bacteremia
(small bowel)
Fungal
Aspergillus spp. (lung transplants with

chronic rejection)

r~*Tom Green M, Michaels M: Infections in solid organ transplant recipients. In Long 55, Pickery LK. Prober CG. eds: Principles and practice ofpediatric
dIseases. New York. 1997, ChurchIll LIVIngstone. pp 626-634.
I~Infeclions are listed from most 10 least common for each time period.
~#lfectlOus
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meningitis; reactivation of an organism, such as herpes or
CMV; or endogenous invasion of a normally present
organism, such as overgrowth of GI flora. Sites of infection
after transplant include the lungs, CNS, wounds, skin,
mucous membranes, GI tract, and urinary tract.
Bacterial Infections. Bacterial infections are most
common in the first month after transplantation and are
similar to the organisms found in the postoperative surgical patient. Gram-negative bacilli including Pseudomonas
aeruginosa, Proteus species, Klebsiella species, and Escherichia coli are common infecting organisms, and both
Staphylococcus epidermidis and S. aureus are seen. Bacterial infections usually arise from organisms already colonizing the patient. Because of a disruption of anatomic and
mechanical defense systems, such as the skin, mucous
membranes, cilia, and mucosa of the GI tract, bacteria are
able to enter the body and cause infection. Common types of
bacterial infections are pneumonia, wound infections, line
sepsis, and urinary tract infections.
Unusual bacterial infections include Legionella, an
aquatic organism that causes pneumonia, and Nocardia,
commonly present in soil and decaying matter that enters the
body by inhalation and can cause pneumonia and infections
of the CNS. Both are often associated with environmental
hazards, such as construction or contamination in air
filtration systems.
Most surgical patients receive prophylactic antibiotics at
the time of surgery and for a short period after surgery to
prevent bacterial infection. The antibiotic chosen is a
broad-spectrum agent effective against the common organisms causing wound infections in a particular healthcare
setting. Prolonged use of prophylactic antibiotics raises
concerns about the growth of antibiotic-resistant bacteria
and fungi. Equally important in the prevention of bacterial
infections is removal of all invasive monitoring lines, tubes,
and catheters as soon as possible.
Viral Infections. Viruses comprise an important
group of infecting organisms after transplantation and
include herpes simplex viruses, varicella-zoster, CMV, EB V,
hepatitis virus, and the human immunodeficiency virus
(HIV). Viral infections can be primary or secondary.
Primary infections are caused the first time the individual
is exposed to the organism, including those that can
be transmitted from donor to recipient. A secondary
infection is a reactivation of the virus. Infants and
young children are more likely to have primary infections, whereas adolescents and adults are more likely to
have been exposed to most common viruses and have a
reactivation of a previous infection. Prospective recipients
and donors are carefully screened for negative titers to the
more common viral agents to assist with the prevention of
infection.
Herpes simplex viruses are divided into two types:
HSV-I is responsible for most herpes infections above the
waist, most commonly of the lips, face, and mouth; HSV-2
is responsible for herpes genitalia. HSV-I infections are
usually acquired during childhood and establish a permanent residence in most hosts. Herpes genitalia is acquired
through sexual activity.

HSV-l is usually a localized infection of recurrent
vesicles and low ulcerations on the lips and oral mucosa. It
can be diagnosed by its classic appearance, but viral cultures
provide the definitive diagnosis. HSV-I infection is common in the first month following transplantation. Treatment
of both HSV-I and HSV-2 infections is with acyclovir.
Varicella-zoster can be a dangerous infection for children
recovering from transplantation. Immunization before transplantation may be helpful in prevention of active disease
later. Outbreaks of chickenpox are common in childhood,
and transplant patients may be exposed many times. The
disease is likely to be more virulent in the immunocompromised host and can cause pneumonitis and significant
respiratory compromise. Children may be given varicella
immune globulin (VZlg) upon exposure to provide them
with antibodies to fight the disease. Treatment of active
infection is with IV acyclovir and reduction of immunosuppressant drug dosages in severe cases.
CMV is a significant viral infection that occurs after
transplantation. Infection with CMV can be a primary
infection in which a seronegative recipient receives a
CMV-positive blood transfusion, a CMV-positive donor
organ, or is exposed to infected individuals. Reactivated, or
secondary, infection occurs when a seropositive patient then
becomes immunosuppressed. Primary infections appear to
be associated with more serious and symptomatic morbidity
and may vary in intensity with the organ transplanted. CMV
is associated with rejection or acute glomerular injury in
renal transplants and with hepatitis and hepatic failure in
liver transplant recipients.
CMV is also a significant pathogen following thoracic
organ transplantation. There appears to be an association
between CMV and accelerated development of arterial
atherosclerosis in cardiac transplant recipients. 39 Generally,
CMV infection is more of a problem in lung recipients than
in heart recipients 29
The symptoms and severity of CMV infection are
variable. Patients who are most susceptible are seronegative
and receive a seropositive organ, have prolonged fever and
hematologic abnOimalities, or have intense immunosuppressive therapy. Infection usually occurs I to 3 months
posllransplantation. Common clinical findings include prolonged (may be high-grade) fever and hematologic abnormalities, including leukopenia, thrombocytopenia, and atypical lymphocytosis. Some patients may present with
malaise, anorexia, myalgias, and arthralgias. Disseminated
disease can affect many organ systems, including the lung,
liver, pancreas, kidneys, stomach, intestine, and brain, and is
associated with significant mortality. CMV was traditionally
regarded as the major infectious agent to complicate
transplantation. However, the introduction and effectiveness
of prophylactic use of ganciclovir (DHPG), a derivative of
acyclovir, has resulted in a dramatic decrease in morbidity
related to CMY.
Diagnosis is based on clinical presentation and confirmed
through viral culture, serology, and histology.40 CMV-pp65
is a rapid diagnostic method currently used that detects
CMV-specific antigens in peripheral polymorphonuclear
cells with a mixture of monoclonal antibodies. 41
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in addition to infection with CMV, transplant patients
may develop superinfections, most often in the lung. CMV
infection has been shown to suppress cell-mediated immunity, further impairing the body's ability to fight infection. Superinfections with opportunistic organisms such as
P. carinii may occur simultaneously.
Ganciclovir has led to improved outcomes for CMVinfected patients, with a clinical response evident 5 to 7 days
after initiation of therapy.42 Because of the high morbidity
and mortality associated with CMV infection following
transplant and, until recently, a lack of treatment for the
disease, there is much interest in preventing the infection.
The use of acyclovir for CMV prophylaxis with high-dose
oral therapy is supported in some protocols. The efficacy of
prophylactic use of CMV immune globulin in patients who
are seronegative and receive a seropositive organ has been
demonstrated.
EBV presents as a continuum of illness, and benign
symptoms may progress to more serious syndromes. EBV is
known to cause mild infections similar to mononucleosis in
patients following transplantation and more serious EB Vassociated malignant lymphoma (Burkitt's lymphoma), but,
most importantly, it is the major risk factor for the
development of PTLD months to years after organ transplantation. PTLD represents a spectrum of diseases characterized by the EBV-driven B lymphocyte proliferation
ranging from a mononucleosis-like illness to monoclonal B
cell lymphoma. 43
EBV disease is diagnosed in pediatric solid organ
recipients via clinical history and physical examination
findings in combination with laboratory confirmation 44
Risk factors include young age, EB V seronegative status
before transplantation of an organ from a seropositive donor,
and multiple episodes of rejection requiring treatment. The
child may have a history of lethargy or malaise usually
associated with febrile periods and anemia. Diarrhea (which
may be guaiac positive), protein-losing enteropathy, and
weight loss may suggest GI involvement. Patients may be
asymptomatic but more often present with findings of
peripheral adenopathy, hepatosplenomegaly, or exudative
tonsillitis. Less often, children present with neurologic
symptoms indicating CNS involvement. 44
Early diagnosis is vital for effective treatment. Diagnosis
is based on clinical manifestations, histopathology, laboratory studies, and radiographic findings. Radiologic examinations (including computed tomography) of the chest and
abdomen are performed to evaluate enlarged lymph nodes
and to look for occult foci of the EB V disease. Pulmonary
nodules are the most common macroscopic finding in heart
and heart-lung recipients 29 Biopsy is done if the lesion is
safely accessible to provide infortnation on histology.
Laboratory data using the EBER-I probe, which labels
EBV-encoded RNA in infected cells, is the most reliable
histologic stain for diagnosis of EBV infection. EBV titers
are not specific for active EBV disease. Some children who
were seronegative before transplant will have positive EBV
titers related to passive immunization with blood products.
The EBV-PCR (polymerase chain reaction) is a blood
test that identifies increased levels of circulating EBV-
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infected lymphocytes or EBV viral load. This test shows
promise in predicting risk of EB V infection before clinical
disease and in detecting disease in patients with symptomatic presentation. Elevated viral load in combination with
typical EBV symptoms appears to be diagnostic of EBV
disease and PTLD. 44 However, use of the EBV viral load is
limited, in that the viral load may be comparable in children
with EBV viral infections to those with EBV-PTLD and
some children may have an elevated viral load without signs
of active infection 44
Starzl was the first to suggest withdrawal or reduction in
the patient's immunosuppression in the 1980s. Since that
time, it has become standard in the treatment of patients
with PTLD and is often effective. However, rebound
rejection may then occur. Beyond the temporary discontinuation or drastic reduction ofthe immunosuppressive therapy,
the optimal management of EBV disease and PTLD in the
solid organ transplant remains controversial and varies
among centers. Depending on the transplant center and
individual strategies, other treatments include antiviral
therapies (e.g., acyclovir or ganciclovir), antibody therapies
(e.g., IVlg, CMV-IVIg [Cytogam]), interferon (may induce
aggressive rejection), radiation, chemotherapy, and surgical
resection of tumors in localized disease. Rituximab, a
genetically engineered, anti-CD20 monoclonal antibody, is
indicated for the treatment of certain CD-20 positive, B cell
non-Hodgkin's lymphomas and may prove effective in
treating CD20-positive, B cell PTLD.
Fungal Infections. The most common fungal infections following transplantation are those caused by the
Candida species of organisms; these infections occur in the
mouth, GI tract, and vagina. Oral candidiasis, known as
thrush, is a common infection in infants and also prevalent
in immunocompromised patients and those receiving broadspectrum antibiotics. Thrush appears as wet, white lesions
on the tongue and mucous membranes of the mouth, which
are painful and can impair oral nutritional intake. The
infection can spread through the GI tract, causing esophagitis, and can cause a Candida diaper rash. Transplant
patients often receive the topical antifungal drug nystatin
prophylactically to prevent Candida infections. Vaginal
infections caused by Candida present symptoms of itching,
irritation, and a malodorous white discharge. The offending
organism must be identified through appropriate diagnostic
tests because Trichomonas has a similar presentation. The
treatment of choice is clotrimazole suppositories.
Candida can become disseminated throughout the body,
usually through the GI mucosa, and cause serious infection.
The diagnosis can be difficult, and signs and symptoms
include a disseminated rash and swollen tender muscles,
persistent fever, eye pain, and eventual signs of CNS
disease. Treatment involves administration of IV antifungal
agents.
Several unusual fungal infections can present later in the
posltransplant period and are generally community acquired. All have an insidious onset and are difficult to
diagnose. Aspergillus can cause pneumonia, pulmonary
infarction, GI bleeding, and brain abscesses. Cryptococcus
enters the body through the lungs and disseminates to the
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CNS. Coccidioidomycosis disseminates to the lungs, CNS,
joints, and liver. Histoplasmosis causes disease in lungs and
CNS, liver, spleen, and lymph nodes. All these fungal
infections are treated with systemic antifungal agents.
Parasitic Infections. The most common parasitic
infections seen after transplantation are pneumonia caused
by Pneumocystis carinii (PCP) and infections with toxoplasmosis. Symptoms of Pneumocystis include an abrupt
onset of dyspnea, cough, hypoxemia, and fever. Bilateral
alveolar infiltrates are seen on chest x-ray film, and
definitive diagnosis is made with bronchoalveolar lavage or
transbronchial biopsy. Treatment is with IV trimethoprimsulfamethoxazole (Bactrim) or IV pentamidine. Prophylaxis
is maintained as long as necessary. When immunosuppressive therapy is significantly decreased, prophylaxis may be
decreased or eliminated. If patients are allergic to trimethoprim, they may be able to be desensitized or may receive
pentamidine inhalation therapy once per month.
Management of Infections. The critical care nurse
plays a vital role in the assessment of transplant patients
for infection. All caregivers must have a very high index
of suspicion for infection in this patient population. Signs of
infection may be subtle; may be masked by the use of
immunosuppressive agents, especially steroids; or may be
confused with rejection or other problems. An aggressive
approach to diagnosis is warranted because the consequences of untreated infection can be life threatening.
A complete head-to-toe physical assessment specifically
focused on possible signs or symptoms of infection should
be performed daily. All fevers should be taken seriously,
although many serious infections may present with little or
no fever. Complaints of headache, subtle mental status
changes, and fever are important signs of potential CNS
infection. Assessment of mental status, evidence of impairment of cranial nerves or sensory or motor function, and the
presence of meningeal signs are all critical elements of a
neurologic assessment. The mouth, tongue, and oral mucosa
should be carefully examined for evidence of thrush or
herpetic lesions. The lymph node chains of the head and
neck should be examined for signs of infection and
inflammation. Alterations in respiratory function can be key
signs of an infectious process, especially because pneumonia is a common type of infection following transplantation.
Tachypnea, dyspnea, cough, labored respirations, retractions, hypoxia, and rales and rhonchi on auscultation are all
important observations. Tachycardia, pulsus paradoxus, a
new murmur, and signs of pericardial effusion can sometimes be associated with an infectious process. Abdominal
distension, cramping and pain, nausea, vomiting, diarrhea,
and changes in the stool may be a result of infection. Cloudy
urine, burning on urination, or a change in the frequency of
urination may suggest a urinary tract infection. Pain or
inflammation of the joints should be noted. All skin surfaces
and mucous membranes should be examined closely for any
signs of infection.
Preventing infection is a critical nursing responsibility.
Isolation techniques after transplantation vary between
institutions and organ types, but the mainstay of all
prevention is good handwashing. A recent study comparing

strict handwashing to gown and glove isolation techniques
in children undergoing solid organ transplantation reported
a significant decrease in nosocomial acquisition of infections in both the handwashing group and the gown and glove
isolation group, despite an infection rate in the overall PICU
population that was not significantly different from the year
before the study throughout the year following the study.45
These data indicate that some infections may be preventable
in the solid organ transplantation population and that
implementation of interventions that may prevent nosocomial acquisition of organisms is beneficial to patients.
Surveillance of visitors and caregivers to prevent contact
with anyone actively infected and to observe for breaks in
handwashing technique is important. All invasive lines are
cared for with aseptic technique and discontinued as soon as
possible. Patients are extubated as early as possible, and
aggressive pulmonary toilet is carried out. Early ambulation
is an important goal. Meticulous skin and mouth care are
crucial to prevent further breaks in the body's defensive
barrier. The physical environment is kept clean. The
importance of nutritional status in preventing and treating
infection is recognized.
Decreased Cardiac Output Related to Ventricular
Dysfunction. Ventricular dysfunction leading to low
cardiac output after cardiac transplantation can be caused by
several factors. An ischemic injury to the donor heart
causing poor contractility can occur during retrieval, during
the cold ischemic time while the heart is being transported,
or during the implantation. Inadequate preservation and
prolonged ischemia times (longer than 6 hours) can
contribute to global ventricular dysfunction, although long
ischemia times have not been correlated with increased
early mortality.46 Ventricular dysfunction can be acute and
present in the operating room with poor cardiac effort,
difficulty weaning from bypass, and increased filling
pressures. More common is worsening ventricular function
over I to 3 days postoperatively with low cardiac output,
fluid overload, and ventricular dilation.
Treatment includes optimizing inotropic support, aggressi ve use of vasodilators, and measures to reduce PVR,
including use of nitric oxide. Ultrafiltration or dialysis may
be needed early after transplantation to manage fluid
overload and acute renal dysfunction caused by low cardiac
output and the nephrotoxic effects of cyclosporine or
tacrolimus. Assist devices such as extracorporeal membrane
oxygenation (ECMO) or left ventricular assist devices
(LVADs) should be considered for acute ventricular dysfunction when elevated PVR and other organ dysfunction is
thought to be reversible.
Decreased Cardiac Output Related to Increased
Pulmonary Vascular Resistance. Increased PVR in the
heart or heart-lung recipient resulting from long-standing
congestive heart failure before transplantation can cause
acute right ventricular failure in the immediate postoperative period. The donor heart, already stressed by a period of
cold arrest and cardiopulmonary bypass, must attempt to
pump against elevated PVR and may not be able to meet the
challenge. Right ventricular dilation and signs of right-sided
heart failure ensue with elevated right atrial pressures,
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tachycardia, dilated neck veins, hepatomegaly, pericardial
and pleural effusions, a gallop rhythm or tricuspid regurgitation murmur, and marked right ventricular dysfunction on
echocardiography.
Early and aggressive treatment to decrease PVR is
critical after transplant to limit right ventricular distension
and dysfunction. Patients who are known to have a high
PVR before transplant have usually been tested in the
catheterization laboratory for their response to drug therapy,
oxygen, and nitric oxide. Therapy is begun in the operating
room or early in the postoperative period to keep pulmonary
pressures as low as possible. Afterload reducers, such as
amrinone or milrinone, nitroprusside, and possibly prostaglandins, are used along with inotropic agents. Nitric oxide is
increasingly used in this setting. Other measures to reduce
PVR include sedation with or without chemical paralysis,
careful suctioning, good pulmonary toilet to prevent atelectasis, and avoidance of acidosis and hyperventilation.
Nursing interventions to decrease cardiac workload include
maintaining normal temperature, ensuring adequate pain
control, reducing environmental stressors, providing emotional support to decrease anxiety, providing proper nutrition, and ensuring adequate rest.
Decreased Cardiac Output Related to Bleeding,
Hypovolemia, or Hypothermia, Postoperative mediastinal bleeding and the risk of cardiac tamponade are of
particular concern after heart or heart-lung transplantation.
The native pericardium is often stretched by severe cardiac
dilation. The donor heart may be smaller than the patient's
nati ve heart, resulting in a large potential space in the
pericardial sac. Blood can easily accumulate and may
contribute to hypovolemia, decreased cardiac output, and
possible tamponade. Patients may also bleed in the absence
of a stretched pericardium. Chest tube drainage is closely
monitored, and measures to ensure adequate drainage of the
mediastinum are followed. Coagulopathies are monitored
and corrected. The patient is closely observed for signs
of tamponade, and prompt treatment is instituted if tamponade is suspected. Reoperation for bleeding is sometimes
necessary.
Hypovolemia and hypothermia are commonly seen
following cardiopulmonary bypass and may contribute to
decreased contractility in the newly transplanted heart.
Careful assessment of fluid balance and temperature is
followed by appropriate fluid replacement and rewarming.
Decreased Cardiac Output Related to Alterations
in Heart Rate and/or Rhythm. Change in heart rate
because of denervation of the donor heart and rhythm
disturbances may also lead to alterations in cardiac output
after transplantation. Because nervous system connections
to the heart are permanently severed during transplantation,
there is no autonomic control of heart rate. In the absence of
parasympathetic control, the resting heart rate is elevated.
The Valsalva maneuver and carotid massage are no longer
effective following transplantation. The sympathetic nervous system normally acts to increase heart rate. Loss of
sympathetic control impairs the ability to respond quickly to
the need for increased cardiac output. Slower mechanisms
that increase cardiac output include the Starling response,
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which increases stroke volume in response to increase in
venous return and the release of endogenous catecholamines
with both inotropic and chronotropic properties. Changes in
heart rate in response to increased metabolic demands such
as fever or exercise occur more slowly and depend on an
appropriate circulating blood volume to provide adequate
preload and normal contractility. The absence of a normal
compensatory reflex tachycardia may cause orthostatic
hypotension because of venous pooling. Vasodilation (especially resulting from vasodilating drugs or rewarming early
postoperatively) may lead to hypotension and a rapid
decrease in cardiac output because of reduced preload or
decreased afterload.
Medications that act on the autonomic nervous system
are ineffective. Digoxin loses much of its influence on heart
rate and rhythm but may be a useful inotropic agent and may
slow the sinus node. Atropine has no effect on heart rate in
the transplanted heart. Adenosine may have a more profound effect, so a lower dose is used initially. Calcium
channel blockers such as verapamil, which have negative
inotropic effects, are used cautiously. Because P-blockers
inhibit circulating catecholamines, which are important in
increasing heart rate in the transplanted heart, they may
blunt the heart rate response and are used with caution.
The ECG following cardiac transplantation will demonstrate two P waves representing both the donor sinoatrial
(SA) node and the recipient SA node, if the recipient's wall
of the right atrium containing the SA node remains in place
(Fig. 26-2). (This will not occur if the recipient's right
atrium is removed during transplantation.) Because the
impulse from the recipient SA node cannot cross the suture
line, there is no further stimulation of the conduction system
or cardiac contraction. The donor SA node initiates the
electrical stimulation through the conduction system, which
results in contraction.
Dysrhythmias are often seen in the early postoperative
period. After cardiac transplantation, children depend on an
adequate heart rate to maintain cardiac output; therefore any
dysrhythmia can have a negative consequence on cardiac
output. Bradydysrhythmias may be due to SA node dysfunction related to surgical trauma or ischemic injury during
preservation. These difficulties usually resolve with time.
Use of a temporary external pacemaker or continuous
intravenous isoproterenol will provide a faster heart rate and
enhance cardiac output. Ventricular and supraventricular
tachydysrhythmias may occasionally be seen and are more
difficult to manage. Pharmacologic therapy is limited
because the heart is denervated. Tachycardia limits the use
of many inotropic agents, and the negative inotropic effects
of most antidysrhythmics can have a deleterious effect on
contractility in the early postoperative period. Drug therapy
is used cautiously. Overdrive pacing or cardioversion may
be used as alternatives. The development of arrhythmias
after the first week posttransplant may be an early symptom
of rejection.
Prevention of Ventilation/Perfusion Mismatch.
Pulmonary perfusion and ventilation are closely monitored
in the postoperative period for patients who have received a
heart-lung or single- or double-lung transplants. Pulmonary
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Fig. 26-2
P waves.

,.

Rhythm strip after cardiac transplant. Arrows indicate recipient"s native (but unconducted)

perfusion can be assessed by monitoring end-tidal CO 2,
Ventilation can be assessed through evaluation of breath
sounds and arterial blood gases. To improve perfusion to the
transplanted lung, patients may be positioned with the
operative side down, as flow is related to gravity. Ventilation
to transplanted lungs can be enhanced by positioning the
isolated transplanted lung up. Variable positions may be
effective in improving ventilation, as airflow is compliance
dependent. If unilateral pulmonary edema is present, positioning the patient affected side down will help to optimize
arterial blood gases. When gases have improved, repositioning frequently will help to maintain ventilation.
Frequent assessment of airway clearance and provision
of thorough pulmonary toilet are essential. Suctioning is
only done above the level of the anastomosis. The patient's
ability to cough and clear the airway, chest x-ray film, breath
sounds, and characteristics of the sputum are used to guide
pulmonary care. Increased FI02 may be required to facilitate
pulmonary care. Incenti ve spirometer or other aids may help
in normalizing pulmonary function.
Alteration in Comfort. Postoperative pain management is essential to allow the child to gradually assume
independent airway control and ventilation. Pain medication
and alternative therapies (e.g., epidural catheters) are
provided in addition to supporting the parents' coping and
their ability to comfort their child. Providing rest periods
and a semblance of day-night cycling help to promote sleep.
Although isolation rooms are not required, placement of the
patient in a private room may be helpful both in the
prevention of infection and in providing a quiet, more restful
environment.

LIVER TRANSPLANTATION
Liver transplantation for children with end-stage liver
disease is currently available in many centers worldwide.
Approximately 400 children undergo liver transplantation
each year. Since 1983, liver transplantation has been
recognized as a nonexperimental treatment option for
children with end-stage liver disease. In the precyclosporine
era, 5-year survival statistics for children treated with
azathioprine were a dismal 30%. I With advances in
preservation methods, refined surgical techniques, and

improved immunosuppression protocols, some centers are
reporting beller than 90% I-year survival rates.
Indications for pediatric liver transplantation include
biliary atresia, metabolic diseases (<XI-antitrypsin deficiency,
tyrosinemia), familial cholestasis (Byler's disease, Indian
childhood cirrhosis, AlagiUe's syndrome), fulminant hepatic
failure, biliary hypoplasia, infectious hepatitis, idiopathic
cirrhosis, neonatal hepatitis, sclerosing cholangitis, congenital hepatic fibrosis, and carcinomas such as hepatoma and
hepatoblastoma. Biliary atresia is the most common indication for liver transplantation in the child (over 50% of the
cases per center).
The UNOS system for classifying liver transplant candidates by status has three categories. 4 Patients may be
assigned to status I (highest priority) when they are being
cared for in the intensive care unit and have a life
expectancy (without transplantation) of less than 7 days or
are hospitalized with OTC deficiency or Crigler-Najjar
disease type I. In addition, status I patients must have at least
one of the following criteria: fulminant hepatic failure,
mechanical ventilation, continuing or recurrent upper GI
bleeding, stage III or IV encephalopathy, refractory ascites
or hepatohydrothorax, biliary sepsis requiring vasopressor
support, primary nonfunction or hepatic artery thrombosis
of a graft, acute decompensated Wilson's disease, or
hepatorenal syndrome. Status lIB patients must have
documented, unresponsive GI bleeding, hepatorenal syndrome, bacterial peritonitis, refractory ascites or hepatohydrothorax, recurrent cholangitis, growth failure, ornithine
transcarbamoylase (OTC) deficiency, or Crigler-Najjar disease type I. All other patients are listed as status III.
Although the number of livers available to be transplanted has remained about the same in recent years, the
number of UNOS-listed patients continues to climb every
year. 47 The shortage of pediatric-sized organs and concerns related to preventing unnecessary deaths has led
researchers to explore methods for expanding the donor
pool.47 Deviations from the standard orthotopic liver transplantation procedure have been developed by producing
volume-reduced grafts based on segmental anatomy. These
modifications are referred to as technical-variant liver
transplantation. Currently, four procedures are being practiced for liver grafts, including the standard orthotopic
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whole liver transplant, reduced-sized liver transplantation
(RSLT), split-liver transplantation (SLT), and living-related
transplantation (LRT). The use of University of Wisconsin
(UW) solution has lengthened acceptable cold preservation
time to 18 to 24 hours, providing recovering surgical teams
additional time required to prepare recovered organs for
RSLT and SLT procedures 48 All of these procedures are
orthotopic procedures, which means replacement of the
native liver with the allograft. Back table preparation of the
newly recovered liver includes identifying vessels, reducing
graft size, and sending tissue for pathology examination of
graft quality before the recipient operation.

Liver Transplantation Procedures
The standard orthotopic liver transplant procedure involves removal of the diseased organ and replacement
with a donor organ in three stages: recipient hepatectomy
phase, anhepatic phase (recipient liver is removed and
graft is implanted), and reperfusion phase (achievement
of hemostasis and reconstruction of the hepatic artery
and biliary tract). After the child has been anesthetized
and positioned, a bilateral subcostal incision with xiphoid
extension and removal of the xiphoid process are performed. The suprahepatic inferior vena cava (lYe), the
infrahepatic lye, the portal vein, the hepatic artery, and,
when present, the common bile duct are isolated and then
clamped, after which the native liver is removed. This
begins the anhepatic phase, which ends when the donor liver
is reperfused. For children over 25 10 30 kg, venovenous
bypass is sometimes used to provide more stability during
the anhepatic phase. 48 As an alternative, vena cava flow can
be preserved by ligating the hepatic veins individually and
preserving the vena cava for segmental or "piggyback"
implantation. 48
During the hepatectomy and anhepatic phases of a
standard transplant, four vascular anastomoses are completed: (I) suprahepatic rYe, (2) infrahepatic lye, (3) portal vein, and (4) hepatic artery. After completion of the
infrahepatic lye anastomosis, the donor liver is flushed
with cold lactated Ringer's solution to remove air and the
preservation solution. The reperfusion phase occurs once the
portal vein anastomosis is completed and portal venous
blood flow is reestablished to the graft. A color change in the
allograft can be observed. Patchy areas of poorly perfused
parenchyma may persist until the hepatic artery anastomosis
is completed. Hemostasis is achieved during this operative
phase by suture ligation and cautery.48
Currently, transplantation of the liver in children is done
most often using a procedure called the piggyback hepatectomy, whereby the recipient's lye is preserved. The native
liver is removed with preservation of the recipient lYe. The
graft is connected to a confluence of recipient hepatic veins
(end-to-side "piggyback" to the skeletonized recipient vena
cava) and then to the arterio-aortic anastomosis.
After arterial reconstruction, bi liary anaslOmosis is done.
Biliary reconstruction in pediatric recipients is typically
performed with a Roux-en-Y limb of intestine (choledocho-
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jejunoslOmy), as the patient's native bile duct is usually
absent or inadequate in most children undergoing transplant.
In children with an adequate common bile duct, duct-to-duct
anastomosis may occur using a T tube to stent the bile duct
of the recipient. Yascular anomalies may require complex
arterial reconstructions or interposition grafts to the aorta.
Jackson-Pratt drains are placed under the diaphragm, and
the incision is then closed.
RSLTs involve cutting a whole liver and using the left
lobe for pediatric recipients. Although RSLT provides an
appropriate-size graft for the pediatric population, it does
not increase the number of recipients. Reducing the size
simply transfers it from the adult recipient pool to the
pediatric pool without increasing the overall supply of
organs.
The first transplantation with a reduced-size donor organ
liver graft was performed by Bismuth and Houssin in
1984.49 The procedure requires two surgical teams: one to
perform the graft reduction and one to perform the recipient
hepatectomy. Preparation of the graft involves dissection of
the bile duct system, followed by the hepatic artery, portal
vein, and hepatic veins. The recipient procedure parallels
standard orthotopic liver transplantation, except when there
is significant disproportion in donor organ size, in which
case the recipient lye is preserved and the donor liver is
placed in a "piggyback" position with only one caval
anastomosis to the recipient hepatic veins. 48
The SLT technique evolved from reduced-size liver
transplants. The first SLTs occurred in 1988 simultaneously
in the United States and Europe. 50 Initial results were
discouraging, and the procedure was almost abandoned;
however, the European clinicians continued to modify their
techniques. The advances included improved microsurgical
techniques using high magnification to repair blood vessels
and radiologic assessment of the graft using dyes to
facilitate the mapping of the vessels. Livers may be
removed from the donor and split into the right and left
lobes or split in situ in the donor. The right side of the
liver is almost always large enough for an adult recipient, and the smaller left side is given to the pediatric
recipient. The donor liver graft is prepared in the recipient
operating room, where hepatic resection is performed
through the principal fissure between the right and left
lobes. The right lobe graft is identical to that prepared for
a reduced-sized graft, retaining the portal vein and hepatic
artery. The left lobe graft usually requires vascular interposition grafts 50
LRThas evolved from the SLT procedure. Using a living
donor increases the donor pool of available organ segments
and allows intense and thorough evaluation of the donor
organ, thereby reducing the risk of graft nonfunction. 5 The
donor (usually a parent) undergoes a left lateral segment
hepatectomy, which is prepared as in SLT. Implantation of
the graft is similar to the split-liver procedure (Fig. 26-3).
The procedure usually requires venous grafts to bridge the
gap between the donor and recipient hepatic arteries and
portal veins. 48 The donor evaluation is usually conducted by
a physician who is not a member of the transplantation team.
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Fig. 26-3 Living donor liver transplant procedures. A, Left lateral segment of donor is divided at the
falciform ligament. Left hepatic vein and shan segments of left ponal vein (or hranch) and left hepatic
artery (or branch) are transected. B, To provide tension-free vascular anastomoses, parenteral or
cryopreserved donor veins are used as the portal vein and hepatic artery. Orientation of grafts with
choledochojejunostomy on the right is similar to cadaveric segmental implants. (From Colombani P:
Liver transplantation. In O'Neill JA, Rowe MI, Grosfeld JL et ai, eds: Pediatric surgery, St Louis, 1998,
Mosby, p 598.)

The initial screening includes a comprehensive assessment
of the potential donor and morphologic assessment of the
potential graft, including informed consent, medical and
psychiatric examinations, computed tomography volumetrics, and arteriography.48
Living-related grafts have been used most often as
primary grafts for stable (non-PICD patients) recipients
under the age of I year. Segmental grafts have had outcomes
comparable with size-matched whole pediatric liver grafts
for survival rates 51 In a consecutive series of 97 pediatric

recipients, no differences were seen in patient and graft
survival observed between patients who received a standard,
full-size graft and those who received a technical-variant
transplantation. However, those with technical-variant grafts
experienced more biliary complications, increased sepsis,
and higher postoperative intervention rates. 52 The regenerative capacity of the liver is such that the donor liver is
restored to its ideal mass in about 6 weeks 47 A significant
consideration in the use of living-related grafts is the
inherent risk of death for the donor. In many centers, the
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frequency of LRTs has decreased with the increase in
success of SLTs 50

Postoperative Care Following
Liver Transplantation
A preliminary nursing assessment is completed before
admitting the patient to the PICU. This assessment includes
an evaluation of preexisting disease factors and significant
psychosocial information. At the time of transplant, the
child may have numerous physical signs and symptoms,
including bleeding, severe ascites, pruritus, hepatorenal syndrome, malnutrition, and hepatic encephalopathy. Knowledge of the child's developmental status and family dynamics at the time of transplant assist with meeting identified
psychosocial needs.
The admission process for the postoperative liver transplant patient is similar to patients with any major abdominal
surgical procedure. Isolation procedures are required only
with those patients known to have preexisting, colonized,
drug-resistant body flora (e.g., methicillin-resistant S. aureus [MRSAj, vancomycin-resistant enterococcus [VRE]).
Standard PICU monitoring is used. A central line is used to
continuously monitor central venous pressure (CVP); PA
catheters are infrequently inserted.
"Liver ARCs" are completed first. A is for aeration. As
with any patient, airway management is the first priority. All
patients will return to the PICU intubated and supported on
a ventilator. B is for blood pressure. A cuff blood pressure
check is a priority; hypertension or hypotension is a
common postoperative assessment finding. C is for coagulopathies. All drains and incision sites are carefully assessed
for bleeding. The patient's prothrombin time (PT), partial
thromboplastin time (PIT), and platelet counts are assessed
at admission.
Coagulopathies and technical aspects of liver transplantation can precipitate the need for massive intraoperative
transfusions. The lengthy 4- to 18-hour operation, or the use
of massive volume exchange, and prolonged bowel exposure can predispose the patient to hypothermia. Normothermia can be achieved with heating lamps or a warming
blanket.
After the liver ABCs, a quick system check is performed.
The incision and Jackson-Pratt drainage are assessed. The
incision is often covered with an occlusive dressing. The
dressing should be dry and intact. The patient returns from
the operating room with Jackson-Pratt drains in place,
strategically positioned to prevent or allow early recognition
of complications. The lateral drain on the right side of the
patient is placed posteriorly in the right subdiaphragmatic
space. This drain allows the dome of the right lobe to seal
agai nst the diaphragm. The second drain on the right is
placed under the right hepatic lobe, leading up to the area of
the bile duct anastomoses. This drain allows the assessment
of a bile leak. The third drain, on the patient's left side, is
positioned in the posterior aspect of the left subdiaphragmatic space. Initially, drainage is bloody. Later, unusual
bloody drainage could be observed in any of the JacksonPratt drains. Drains are emptied every 2 hours. The
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hematocrit of the drain contents is checked if drainage is
excessive.
Laboratory tests are drawn expediently. Routine laboratory tests include hematology studies, a coagulation profile,
electrolytes, liver function tests, and an arterial blood gas. A
chest radiograph is obtained as well.
The admitting nurse receives a complete report from
anesthesia. The report includes organ ischemic time, the
length of surgery, current laboratory values, and a summary
of the operative course, including complications. The
intraoperative use of venovenous bypass is inCluded in the
operative report. If a reduction hepatectomy was performed,
assessment for signs of increased bleeding, biliary fistulas,
and infection from the raw surface is appropriate because
the incidence of these complications is greater with reducedsized grafts. 52 If a LRT is performed, the nurse should
receive information about the donor's condition.
The most significant and life-threatening immediate
complication that can occur is primary nonfunction of
the graft. Poor initial function may be associated with
a phenomenon called primary graft dysfunction from
ischemia-reperfusion injury in the donor organ during the
preservation period. In some of these cases of primary graft
failure, an urgent need arises for retransplantation.
Report on the visible condition of the liver is useful
information. The allograft should change from a pale tan
color to reddish-brown after anastomoses are complete.
After the arterial grafts are anastomosed, bile production
should occur. If hyperbilirubinemia exists preoperatively,
the urine appears dark orange in the early postoperative
period. The presence of these signs are excellent early
prognostic indicators of graft function.
For the first 5 consecutive days after placement, graft
function is assessed by ultrasound and liver biopsy (when
necessary). The ultrasound is used to assess vessel patency
and bile duct dilation. Concern is raised if the resistive index
of the hepatic artery is estimated to be less than 0.5 on
ultrasound. Other signs of poor graft function may include
hypotension, hyperkalemia, hypoglycemia, coagulopathies,
and decreased level of consciousness.
Liver function tests are helpful in assessing graft function
as well (Table 26-4). Alanine aminotransferase (ALT),
which is present in liver, kidney, heart, and skeletal tissue,
should be less than 40 in children. Increased ALT may
indicate acute hepatic rejection. Elevated aspartate aminotransferase (AST) (present in liver, heart, kidney, pancreas,
and brain tissue) may indicate ischemic injury, such as that
occurring with hepatic artery thrombosis. AST is the
last enzyme level to return to normal following injury.
y-Glutamyl transpeptidase (GGTP), present in liver, kidney,
prostrate, and spleen tissue, is normally less than 44 in
children. Elevation of GGTP may indicate bile duct
obstruction. Alkaline phosphatase (ALP) varies with age
because of increases during periods of rapid growth but may
also indicate hepatobiliary tract obstruction if elevated.
Because bilirubin is metabolized in the liver, elevations of
total bilirubin indicate liver disease or bile duct obstruction.
(See further discussion of liver failure and liver function
testing in Chapter 22.)
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(t) TABLE 26·4

Liver Function Tests

Biochemical
Indices

Newbornllnfant
Values

Child
Values

Alanine aminotransferase
(ALT)/(SGPT)

<50 lUlL

<40 lUlL

Aspartate aminotransferase
(AST)/(SGOT)

<50 lUlL

<40 lUlL

Alkaline phosphatase (ALP)

Newborn: <310
lUlL
I mo-I yr: <360
lUlL

1-9 yr: <290 lUlL
10-14 yr: <400
lUlL
>14 yr: <125 lUlL

y-Glutamyl
transpeptidase
(GGTP)
Ammonia
Direct bilirubin
Total bilirubin
Prothrombin time
(PT or protime)
Activated partial
thromboplastin
time
(APTT or PTT)
Total protein
Albumin

<120 lUlL

<44 lUlL

42-51 lLmollL
0.0-0.6 mg/dl
1-12 mg/dl

9-38 lLmol/L
0.0-0.3 mg/dl
0.2-1.3 mg/dl
10-12.8 seconds
24.4-33.2 seconds

4.4-7.3 g/dl
2.9-5.5 g/dl

6-8 g/dl
3.8-5.4 g/d!

From UPMC Health System. Department of Pathology: Laborotory
i"/ormatio,, manual. Pitt'burgh, 1998, Clinical Laboratories.
SGPT, Serum glutamic-pyruvic transamina«; SGOT, serum glutamicoxaloacetlc transaminase.

With a well-functioning graft, the patient may be
normotensive or hypertensive. Laboratory values may
reveal normoglycemia and resolving hypokalemia, hypocalcemia, and coagulopathies. The child should wake up 4 to 6
hours after admission to the PICU. Some patients who were
encephalopathic before transplant require more intensive
neurologic examinations. The patient's fluid status is reviewed. Because of third-space loss, the need for intraoperative fluid resuscitation is common. Several blood volume
replacements may need to be administered. Within 48 hours
after admission to the PICU, the patient should have
diuresis.
Intraoperative medications are reviewed. The transplant
operation is lengthy, and changes in anesthesia personnel
often occur. During report, immunosuppressive medications
and doses are double-checked by the nurse and operating
room personnel. Pharmacologic therapy is extensive and
includes immunosuppressive agents, PCP prophylaxis, antacids, antibiotic prophylaxis for several days, Candida prophylaxis, hepatic artery thrombosis (HAT) prophylaxis, and,
possibly, selective decontamination of the digestive tracl.
(See promotion of graft tolerance and immunosuppression.)

Significant Postoperative Issues
or Complications
Organ-Specific Rejection: Liver. Acute and chronic
rejection can occur after hepatic transplantation. Acute, or
cellular, rejection is characterized by the invasion of
mononuclear cells in the portal triads. (See discussion of
promotion of graft tolerance and rejection also.)
Symptoms of rejection are variable and often vague.
Symptoms commonly include fever, abdominal pain, and
graft tenderness; flushed skin, tachypnea, distended abdomen, irritability, loss of appetite, diarrhea, myalgia, and
septic appearance also occur. Subsequent swelling and
edema of the graft with increased vascular resistance may
lead to variceal bleeding or hepatic artery or portal vein
thrombosis. Changes in liver function laboratory studies
may provide the first indication that rejection is occurring
(see Table 26-4). An early but nonspecific indicator of
rejection may be a rapid increase in GGTP levels. A
subsequent increase in serum bilirubin and ALP and variable
changes with ALT and AST levels may be observed. A liver
biopsy may be performed if rejection is suspected and the
patient is unresponsive to medical therapy. With acute
rejection, some degree of mononuclear cellular infiltrate in
the portal tracts is found on biopsy.
With chronic rejection, there is disappearance of the
intrahepatic bile ducts with varying degrees of bridging
fibrosis. However, the liver has significant regenerative
capacity and may recover function even after severe
rejection. Therefore chronic rejection occurs less often in
liver recipients (less than 10% of pediatric patients) than in
heart, kidney, and lung recipients. 48
Because acute rejection is usually cell mediated, episodes
can be managed with increased immunosuppression. Some
centers also use induction therapy, with monoclonal antibodies or polyclonal globulins, for treatment of rejection.
Although acute rejection is common early in the posttransplantation period, triple-therapy immunosuppression has
helped to reduce the number and severity of acute rejection
episodes.
Infection. Infectious complications continue to be a
very significant cause of postoperative morbidity and
mortality in pediatric liver recipients, with up to 50% of
children affected. 48 Posttransplant infections are discussed in detail in the sections on heart-lung postoperative
issues. In liver transplant patients, early infections are
often bacterial and may originate in the abdomen related
to local ischemia, the incision, associated bleeding, or
bowel contamination or are from indwelling catheter
infections, the lungs, or the urinary tract. Children with a
failed Kasai procedure are prone to recurrent episodes of
cholangitis. 42 As most children undergo Roux-en- Y choledochojejunostomy, intraoperative infectious complications
include contamination of the bile ducts with yeast and
bacteria. 42
Infectious complications associated with HAT generally
occur within the first 30 days after transplant. 42 HAT can
precipitate areas of necrosed liver, abscesses, and bacteremia. Bile duct strictures with resultant cholangitis can
occur following HAT. Technical difficulties may necessitate
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reexploration of the abdomen wi th associated increased
incidence of fungal infection.
Viral, protozoal, and fungal infections, including CMV,
EBV, and PTLD, are also common infectious agents in the
liver transplant recipient. As a result of effective prophylaxis, PCP and CMV infections in transplant recipients has
declined. 53 PTLD occurs in 5% to 20% of liver transplant
recipients. 48 Incidence appears to relate to exposure history
of the donor and recipient and the type and amount of
immunosuppression. Mortality is high; patients are treated
with significant reduction or withdrawal of immunosuppression and antiviral agents.
Most posttransplant infections can be treated. Antibiotic
and antiviral prophylaxis and early recognition of symptoms
of infection have contributed to a decrease in morbidity and
mortality in transplant recipients in the last decade.48
Ineffective Airway Clearance and Breathing Patterns Resulting in Impaired Gas Exchange. Pulmonary assessment includes frequent auscultation of breath
sounds, interpretation of arterial blood gases, and monitoring of chest x-ray films. The child's coagulation status
determines the appropriateness of chest physiotherapy.
Gentle chest physiotherapy is performed if coagulopathies
persist. Once hemostasis is achieved, aggressive chest
physiotherapy is initiated.
Because of the liver-lung relationship, patients with fulminant and chronic hepatic failure may manifest pulmonary
signs of the failing liver. The pulmonary effects of chronic
liver disease are more prevalent in the adult population;
however, such complications have been reported in children. 54 Pleural effusions and arteriovenous collateral vessels
with ventilation/perfusion mismatch and resultant intrapulmonary shunting are reported complications.
Ineffective airway clearance is related to the long
abdominal procedure, large transverse abdominal incision,
and postoperative pain. Ineffective breathing patterns may
be related to diaphragm paralysis and abdominal distension
secondaIy to ascites, large donor liver, or bleeding. The goal
is to wean ventilator support within the first postoperative
day; at least 50% of the patients are extubated by the end of
the second postoperative day. However, many of the
children experience collapse of the right upper and right
middle lobes of the lung. Phrenic nerve paresis caused by
clamping of the upper vena cava and right mainstem
bronchus intubation contribute to lobar collapse. Also, the
potential for diaphragmatic paralysis exists if the right
phrenic nerve is injured during surgery. An elevated
diaphragm, seen on chest x-ray film, and decreased expansion of the right lower lobe with spontaneous respiration
may indicate phrenic nerve damage. Generally, if the child
is unable to tolerate extubation twice, an ultrasound
examination is used to confirm the suspected diagnosis. In
addition, poor nutritional status preoperatively may contribute to delayed weaning.
Persistent ascites may also limit tidal volume and impair
ventilation. A large donor liver, as well, may reduce
intrathoracic space and tidal volume. Emergent indications
for liver transplantation may necessitate widening the
candidate's weight range with an increased mismatch in
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donor to recipient size. Inability to close the abdominal
incision may further impair the patient's respiratory effort
because supportive musculature and associated resistance
will not assist the patient's ventilatory efforts.
Impaired gas exchange may be related to right pleural
effusion and intrapulmonary shunting. Preoperative ascites
may promote rapid fluid accumulation postoperatively. The
sympathetic response observed with acute rejection may
increase ascites accumulation 55 Treatment measures include the use of diuretics, albumin administration with
diuretics, and drainage of the accumulated pleural fluid by
thoracentesis or insertion of a pigtail catheter in the pleural
space.
Pulmonary infection is common. Common viral organisms include CMV, respiratory syncytial virus, adenovirus,
herpes simplex, and herpes zoster. Pulmonary Aspergillus
and systemic candidiasis may contribute to pulmonary
dysfunction.
Alterations in Tissue Perfusion. Beyond evaluation of airway and ventilation, close monitoring of vital
signs, hemodynamics, hemoglobin and hematocrit, intake
and output, and peripheral perfusion (including postoperative evaluation of pretransplant encephalopathy) and careful
observation for signs and symptoms of hemorrhage are vital.
Park and colleagues56 described the hemodynamic profile of 73 children with chronic Ii ver disease. Eighty-two
percent of the children had high cardiac output with a
cardiac index greater than 4 L/minJM 2 In four of the
children, there was evidence of intrapulmonary and arteriovenous shunting. After transplant, cardiac index decreased
by a mean of 35% (P < .001). The authors concluded that
transplantation improved chronic hemodynamic abnormalities (hyperdynamic state) in children with chronic liver
disease.
Greater than 70% of liver transplant recipients experience hypertension, with approximately 10% of these patients requiring long-term antihypertensive medications. 55
Mean arterial blood pressure in excess of 90 mmHg or
systolic blood pressure greater than 140 mmHg requires
treatment. Severe hypertension is most problematic within
the first postoperative week.
Several hypotheses exist regarding the cause of hypertension in liver transplant patients. These include alterations
in renin levels and immunosuppressant administration.
Vigilant nursing assessment of blood pressure will ensure
prompt treatment and minimize associated side effects,
which include seizures, subarachnoid hemorrhage, intraparenchymal hemorrhage, and coma.
Pharmacologic treatment of hypertension is institution
specific. Initially, the use of a nitroprusside infusion may be
necessary. Intravenous and oral drug therapy may include
use of renin-angiotensin inhibitors, peripheral vasodilators,
~-blockers, and a-adrenergic blockers. Commonly used
antihypertensives include nifedipine (Procardia), hydralazine (Apresoline), captopril (Capoten), and labetalol (Normodyne). Combination therapy is often prescribed. (See
management of hypertension in Chapter 18.)
Hypotension is infrequently seen and is usually associated with complications, for example, hemorrhage, graft
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failure, or sepsis. Patients may bleed from anastomotic sites
or the cut edges of segmental grafts. With graft dysfunction,
coagulopathies will persist despite ongoing administration
of fresh-frozen plasma, platelets, and crystalloids. Blood is
drained from the abdomen using multiple drains while
coagulopathies are corrected. Hypotension in the presence
of primary graft dysfunction is associated with alterations in
blood chemistry. Hypotension after the first 72 hours may be
an indication of intraabdominal sepsis. Hematology laboratory tests, coagulation profile, and serum pH are monitored
if hypotension exists.
Abdominal drainage and incisional oozing are carefully
assessed. The abdominal girth is assessed as frequently as
every hour. If drainage from the Jackson-Pratt is excessive,
a hematocrit of the drainage is obtained. Drainage of greater
than 80 mllkg/hr and decreased hemoglobin and hematocrit
values usually indicate surgical bleeding. Intraabdominal
bleeding and increased abdominal girth impede venous
return and may impair effective ventilation and oxygenation. If the patient was already extubated, mechanical
ventilation may need to be reestablished. Blood and fluid
replacement is ongoing. Often vasopressor therapy is
prescribed to maintain an acceptable blood pressure. If
surgical bleeding is suspected, the child returns to the
operating room for an exploratory laparotomy. If findings
suggest graft failure, the patient is relisted for a replacement
graft. Fluid resuscitation may be ongoing until retransplantation occurs.
HAT occurs in 5% to 30% of pediatric patients and can
lead to graft failure if adequate collateral circulation is not
established. HAT is suspected if liver function studies do not
begin to decrease within the first 48 hours after transplantation. HAT may cause biliary tract necrosis and secondary
cholestasis, biliary stricture, and recurrent sepsis. In one
third of the cases, the patient may be asymptomatic. 57
Symptoms occur in three forms: fulminant hepatic failure
with liver gangrene, biliary complications such as a bile leak
or biliary stricture, or chronic bacteremia with visible
intrahepatic abscesses. Portal vein thrombosis may also
occur.
Several causes of HAT are documented. Tzakis and
Stanl 57 report that HAT is usually caused by technical
problems, with contributing nontechnical factors. A lower
incidence of HAT is associated with transplantation of liver
fragments resulting from the larger size hepatic artery.
Treatment measures are initiated in the immediate
postoperative period to prevent HAT. Within 12 hours after
transplantation, daily ultrasound and Doppler examinations
are initiated to evaluate vessel patency. Additional diagnostic studies such as angiogram and liver biopsy may be
performed. Patients at risk because of technical difficulties
or other factors are placed on a protocol to maintain and
enhance blood flow through anastomoses. If a patient is
believed to be at high risk for development of HAT, a
heparin infusion may be initiated early in the postoperative
period. Subclinical anticoagulation is achieved with intravenous dextran 40 (Gentran 40), subcutaneous low-dose
heparin, oral aspirin, or dipyridamole (Persantine.) Dextran

40 draws water from the extravascular space, decreasing
blood viscosity and platelet adhesiveness. Rapid corrections
of coagulopathies are avoided. The patient's hematocrit is
maintained at 30% to minimize the incidence of HAT.
In some centers, hyperbaric oxygen (HBO) therapy is
used as an adjunct to anticoagulation. The hyperoxygenation
associated with this therapy is thought to decrease ischemicreperfusion injury or minimize the effects of any decreased
blood flow to the liver. Patients with HAT in one study were
treated within 24 hours of diagnosis with HBO therapy
twice daily for 2 weeks or until symptoms resolved. Perhaps
by aiding collateral development, HBO significantly delayed retransplantation but did not significantly affect
survival or retransplantation rates. 58 If medical management
is unsuccessful, HAT is treated in the operating room with
reanastomosis or retransplantation in primary graft failure.
Altered Renal Function. Impairment in renal function is common postoperatively as a result of fluid shifts;
persistent hypoproteinemia; diuretics; tense abdominal pressure affecting renal filtration pressure; and numerous
nephrotoxic agents, such as immunosuppressants and antibiotics. Patients are at risk for intravascular volume
depletion related to massive ascites or significant blood loss
caused by abnormal coagulation. In the immediate postoperative period, fluids are restricted. Fluid balance and blood
urea nitrogen (BUN)/creatinine ratio should be monitored
closely.
Oliguria is reported in over 50% of liver transplant
recipients on postoperative day I or 2. 55 Management of the
patient includes fluid restriction, diuretics, and low-dose
dopamine. Crystalloid replacement may be useful for
ensuring adequate intravascular volume; however, rarely is
urine output increased. Additional fluids are administered
with caution because fluid overload may precipitate edema
and ascites and worsen hypertension. Both cyclosporine and
tacrolimus are known to have nephrotoxic effects, so careful
monitoring of drug levels is important.
Polyuria rarely occurs but may be seen in patients
recovering from hepatorenal failure or acute tubular necrosis. Hepatorenal syndrome is associated with liver failure
and is usually irreversible.
Metabolic and Nutritional Deficits. Common
electrolyte derangements seen after transplant include hypocalcemia, hypokalemia or hyperkalemia, hypoglycemia
or hyperglycemia, and hypomagnesemia. Electrolyte, calcium, and serum glucose levels are obtained every 6 hours.
Hourly glucometer readings are obtained until normoglycemia is achieved.
Hypokalemia occurs more often, but hyperkalemia may
also be present after surgery. Potassium is usually not added
to intravenous fluids because of the risks of renal failure and
possible graft necrosis with a resultant increase in serum
potassium.
Hypocalcemia occurs frequently in patients. Causes of
hypocalcemia include citrate intoxification from the large
quantities of blood products administered, hypoproteinemia,
and liver membrane damage with subsequent shift of
calcium from the extracellular to the intracellular space and
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decreased ionized calcium resulting from metabolic or
respiratory alkalosis.
A "syndrome" of hypertension, metabolic alkalosis, hypematremia, hypokalemia, and relative oliguria has been described. 59 Proposed causes include large citrate load, multiple doses of diuretics, and nasogastric suction. However,
none of these adequately explains the "syndrome," because
it is short lived. Preoperative respiratory alkalosis may be
replaced by postoperati ve metabolic alkalosis as a result of
the citrate load in the blood products, nasogastric drainage,
fluid restriction, and diuretic therapy.
Hypomagnesemia is common with end-stage renal disease and can be exacerbated in the early postoperative
period. Magnesium-containing antacids, oral magnesium
gluconate, and intravenous magnesium sulfate may be
prescribed. Effects of magnesium on blood pressure may be
direct or through the influences on the internal balance of
potassium, sodium, and calcium. Hypophosphatemia may
be observed. Increased phosphate needs of the allograft for
the repletion of adenosine triphosphate may be the contributing factor.
Total parenteral nutrition is usually initiated within 24
hours postoperatively. Feedings are initiated as soon as
postoperative ileus resolves. Malabsorption and diarrhea are
common problems experienced postoperatively. Causes of
infectious diarrhea include CMV, Clostridium difficile. and
other enteric organisms. The malabsorption syndrome may
be transient, with an unclear etiology. Hypothesized causes
include manipulation of the bowel during surgery and
immunosuppressive drugs.
Biliary Tract Complications. Complications of biliary tract anastomosis occur in up to 20% of patients. 48
Strictures may occur, resulting in biliary obstruction.
Hepatic abscesses can occur if biliary obstruction is not
detected. Cholangitis and bile leaks also occur. Bile leakage
results most often from the cut edges of segmental grafts or
at the jejunal anastomosis. Symptoms of bile leakage
include fever, bacteremia, alteration in liver function tests
(LFTs), and evidence of fluid collection on ultrasound.
Treatment involves reoperation to repair or revise the biliary
tract anastomosis.
HAT should be suspected in patients with biliary
complications because arterial blood is the principal blood
supply to the bile duct graft. In the patient with a T tube, the
nurse may observe biliary sludge in the drainage. Sludge is
a chalklike substance composed of organic fibrous matrix
from the sloughing of the bile duct lining. Cholangitis and
biliary tract obstruction can occur with severe biliary
sloughing.
Altered Skin Integrity-Skin and Wound Issues.
The skin and visceral layers are generally closed. Normally,
the abdominal dressing is removed after 24 hours ,and the
incision is left open to air to promote healing. If donor liver
size or bowel edema precludes surgical closure, complex
wound care is required. An enterostomal therapy consult can
assist the bedside nurse and surgeons in providing optimal
wound care. Dressing changes over draining wounds are
required frequently and are accomplished with the use of
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Montgomery straps to limit patient discomfort associated
with tape removal (see Chapter 16).
For the majority of pediatric patients, a Roux-en-Y
biliary reconstruction is indicated; therefore a T tube is not
usually inserted. If present, T tube drainage is carefully
assessed, with normal drainage appearing bilious. Absence
of a color change in the drainage may indicate graft
dysfunction.
Alterations in Comfort. After liver transplantation,
the goal of pain management is to achieve a balance between comfort and ability to assess the patient's level of
consciousness, as hepatic metabolism of pain medication
may be impaired. The importance of evaluating mental status is crucial because graft function is imperative for metabolizing narcotics. Small IV narcotic doses are preferable to
the use of benzodiazepines or phenothiazines because in an
emergency, narcotic antagonists can be used to reverse the
narcotics and permit evaluation of hepatic encephalopathy.
Variations in narcotic dosing for pain management are
found among transplant centers. In some centers, the
administration of narcotics is generally avoided, and when
they are used, they are prescribed in reduced doses. Once the
liver demonstrates adequate functioning, with the patient
awake and complaining of pain, narcotics can be administered safely.

INTESTINAL AND MULTIVISCERAL
TRANSPLANTATION
Intestinal failure is described as the inability to maintain
nutritional intake and normal fluid and electrolyte balance
without artificial means or total parenteral nutrition (TPN).
Usually, failure occurs following significant loss of GI
absorptive function (massive resection) or major functional
abnormalities of the enterocytes, smooth muscle, or enteric
nervous system. 60 The most common cause of intestinal
failure in the pediatric population is short bowel syndrome
resulting from surgical correction of congenital or acquired
defects such as gastroschisis, midgut volvulus, intestinal
atresia, or necrotizing enterocolitis. Functional causes for
intestinal failure include disorders of motility such as
chronic pseudoobstruction or Hirschsprung's disease resulting from disorders of smooth muscle, enteric nervous
system, or total aganglionosis or disorders caused by
abnormal enterocyte function, such as microvillus inclusion
disease and radiation enteritis.
Although TPN has been a lifesaving therapy enabling
children with intestinal failure to survive many more years,
lifelong TPN may initiate a host of serious complications,
including sepsis, TPN-induced hepatic dysfunction, metabolic disorders, loss of venous access, and pulmonary
embolism. Thus far, the majority of candidates have
required liver and small bowel transplants because of the
resultant cholestasis from long-term hyperalimentation use.
Intestinal transplantation is viewed as a procedure that
improves the quality of life, similar to kidney transplantation. 60 Intestinal transplantation, either alone or as a
composite graft with other intraabdominal organs, is re-
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served for children with irreversible intestinal failure who
develop life-threatening complications related to TPN or
anatomic defects. 61
Intestines may be transplanted as an isolated intestinal
graft (intestinal failure alone), as a combined intestine and
liver graft (intestinal failure with hepatic dysfunction), or as
part of an abdominal multivisceral graft (extensive abnormalities of the GI tract and other organs). The status of the
other abdominal organs determines which organs will need
to be implanted in a multiorgan graft. Multivisceral transplants may include the stomach, liver, pancreas, spleen,
duodenum, and small bowel. Segments of the large bowel
may also be implanted but have been discontinued in at least
one center because of colon-related complications, including severe graft rejection and increased incidence of
infection 60 (Fig. 26-4). The combination of advanced
surgical techniques and the introduction of the immunosuppressant tacrolimus (formerly FK506) into clinical use
greatly increased survival rates for the liver and small bowel
graft or isolated small bowel transplant recipients. Data
concerning small bowel transplantation began to be reported
to UNOS in 1994. From 1994 to 1998, 173 of 249 intestine

transplants were reported to have been performed in
children ages 0 to 17 years 4
Each candidate is unique, and evaluation is tailored by
the transplant team following confirmation of the diagnosis
of intestinal failure. A thorough, multidisciplinary evaluation is done. Evaluation includes intestinal assessment
(anatomy, upper and lower GI barium and motility studies,
bowel histology), hepatic assessment (LFTs, albumin,
alpha-fetoprotein, PT, PTT, ultrasound, histology), vascular
access (Doppler ultrasound of central veins), nutritional
evaluation, infection screening, and other studies (CBC,
type and cross, BUN, creatinine, chest radiography, echocardiogram, ECG, ventilation/perfusion scan). Contraindications for small bowel transplantation include uncontrolled
sepsis; malignancy elsewhere in the body; HIV infection;
and severe cerebral, cardiac, or respiratory disease.
Many children who require a combined liver and small
bowel transplant will die from liver failure while awaiting a
donor because of the shortage of age- and size-matched
donor organs. 61 These candidates are listed according to
current UNOS intestine criteria. Status I patients have liver
dysfunction and line access problems as evidenced by no

Fig. 26-4 Types of intestinal transplantation. Combined intestine and liver graft (left); abdominal
multi visceral graft (middle); isolated intestinal graft (right). Large bowel (shaded area) could be
included as a composite of intestinal graft, although rarely done because of colon-related complications leading to poor patient outcome. IVC, Inferior vena cava; pv, ponal vein; HA, hepatic anery;
SA. splenic anery; SMA, superior mesenteric anery; SMV, superior mesenteric vein. (From Todo S, Reyes l:
Intestinal transplantation. In O'Neill lA. Rowe MI, Grosfeld lLet aI, eds: Pediatric surgery. St Louis, 1998.
Mosby, p 607.)
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access through the subclavian, jugular, or femoral veins.
Status 2 patients have no liver dysfunction and have line
access available in standard sites. The candidate may be
listed for an isolated intestinal graft, if cholestatic liver
disease is not present. If the child needs a liver graft, the
child is also listed with UNOS as a liver candidate. The ideal
donor is of the same blood type and of the same size or up
to 25% variance from the recipient. HLA matching is
random and not considered in recipient selection. Transplantation of CMV-positive liver and small bowel into a
CMV-negative recipient is not even considered unless the
recipient is dying of liver failure.

Intestine and Multivisceral Transplantation
Procedures
Grafts used in intestinal and multivisceral transplantation
are cadaveric with the exception of rare living-related
isolated intestinal transplantation. 60 Donor selection is
similar to the criteria for other organs. Because intestinal
mucosa is sensitive to ischemia, transplant surgeons are
cautious in using donors with a history of prolonged
hypotension or cardiac arrest. Donors receive gut decontamination through a nasogastric tube, as well as intravenous antibiotics. After graft retrieval, the lumen is irrigated
again for decontamination if the colon is included in the
graft.
Recipients require routine gut decontamination and
antibiotic prophylaxis as well. In an isolated intestinal
transplantation, the graft is revascularized by an anastomosis of the superior mesenteric artery of the graft to the
infrarenal aorta. Donor vein grafts may be used for venous
reconstruction. Each end of the graft is anastomosed to the
recipient bowel. A jejunostomy tube is placed for venting
and eventual initiation of enteral feeding. A terminal
ileostomy is used to facilitate endoscopic examinations and
biopsies.
Procurement of an abdominal multi visceral composite
graft takes approximately 3 to 4 hours. The graft is separated
as a back table procedure into separate intestinal, pancreas,
and liver allografts, which are then preserved before
reimplantation. Composite grafts are first connected to a
common conduit of the recipient's hepatic veins and then are
arterialized by anastomosis of the coeliac and superior
mesenteric arteries to the infrarenal aorta using a conduit or
homograft. Intestinal continuity requires an anastomosis
with both the native proximal and distal gut. A "chimney
allograft ileostomy" is accomplished to provide for surveillance of the intestinal allograft during the first few
postoperative months. When stable immunosuppression has
been accomplished, without rejection creating the need for
frequent endoscopic examination, the ileostomy can be
closed. 6l Ajejunostomy feeding tube is placed at the time of
the operation for venting and initiation of enteral feedings.
The surgical procedure can be challenging when the child
has had numerous previous surgical procedures, especially
if adhesions and portal hypertension are present. In addition,
when the child requires the implantation of multiple donor
organs, the surgical procedure is quite lengthy and the
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number of complications can increase. Surgical procedures·
vary depending on the organs transplanted and the condition
of the donor organs.

Postoperative Care Following Intestinal
and Multivisceral Transplantation
Care of children after intestine or multivisceral transplant is
similar to the care required of a liver transplant patient. The
main principles of the critical care management in the
postoperative period are immunosuppression and prevention
of rejection, prevention of infection, fluid balance, maintenance of nutritional status, assessment of graft function, and
long-term rehabilitation. 61 Because the number and type of
organs transplanted vary, assessment of each organ's function and engraftment are required. Additional concerns
include care of the large abdominal incision and the
ileostomy. Consultation with an enterostomal therapist in
the immediate postoperative period is helpful in preventing
impairment of skin integrity. Lengthy recovery periods are
anticipated because time is needed for the intestine to
become functional.

Significant Postoperative Issues
or Complications
Immunosuppression. The same protocols for postoperative immunosuppression are used in both isolated or
composite intestinal allograft recipients. A combination
protocol of tacrolimus and steroids is often used. Tacrolimus
is often initiated in the operating room via continuous
infusion, preferably peripherally. A trough level of 20 to 25
ng/ml is the initial goal, with reduction to 8 to 12 ng/ml after
6 to 12 months. Oral tacrolimus is started once GI motility
is observed.
Initial dosing of methylprednisolone is tapered over the
next 5 days to I mg/kg/day. Cyclophosphamide may be
given for 4 weeks and then switched to mycophenolate
mofetil or azathioprine. Prostaglandin is administered for
the first 5 postoperative days because of its beneficial
vasodilatory effects on renal and splanchnic vasculature that
may prevent microvascular thrombosis.
Organ-Specific Rejection: Intestines. Despite improved immunosuppression, rejection is still a major problem. (See also sections with discussion of promotion of graft
tolerance and rejection.) Rejection of the transplanted
intestine is assessed by clinical examination, endoscopic
observation, radiologic examination, and histologic evaluation of mucosal biopsies. 60 There are no biochemical indices
that reflect rejection of the intestinal allograft. Functional
studies and serologic assays are not reliable indicators of
rejection because graft dysfunction also occurs with preservation injury, hypoperfusion injury, and enteritis. 60 Clinical
signs of acute rejection include fever, abdominal distension,
abdominal pain, increased or decreased enteric output, and
watery diarrhea. Dusky stomal mucosa, mucosal edema, and
decreased peristalsis may be associated endoscopic findings.
Severe, acute rejection is characterized by severe diarrhea,
abdominal pain, abdominal distension, and metabolic aci-
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dosis. Endoscopic findings with severe acute rejection
include ulceration, mucosal sloughing, bleeding, and loss of
peristalsis. Chronic rejection is characterized by chronic
diarrhea, malabsorption, and weight loss. Gastric emptying
times may be evaluated radiologically, with prolonged
emptying times indicating rejection.
Endoscopic examinations are performed on a periodic
basis and if intestinal rejection is suspected from clinical
observations. The endoscopic examination yields valuable
information about the appearance of the graft's mucosa and
intestinal motility.
Infection. Infection is a common complication. (See
section on posttransplant infection in heart-lung.) Translocation of bacteria from the intestine to the bloodstream
can occur if bacteria seeps through damaged intestinal
mucosa into the bloodstream. Causes of translocation
incl ude intestinal overgrowth, sloughing of the mucosa,
rejection, and PTLD. Therefore broad-spectrum antibiotic
prophylaxis is ordered for the first 7 days, and bowel
decontamination is continued for the first 4 postoperative
weeks to minimize translocation caused by overgrowth.
Frequent blood and body fluid cultures are done, and
surveillance stool cultures are performed weekly. Quantitative culture with colonies of greater than 10 organisms
are considered significant only in the presence of systemic
sepsis or ongoing acute cellular rejection of the intestinal
allograft and are treated appropriately.62
CMV disease is also a risk, especially when a recipient
with CMV-negative serologic status receives an organ from
a CMV-positive donor. Prophylaxis for all patients is important in the prevention of active disease, with antiviral agents
and CMV immunoglobulin (Ig) used for high-risk patients.
Early identification of CMV disease can also facilitate more
effective treatment. Routine ileoscopy, biopsies of both the
small bowel and liver as needed, and routine serum antigen
testing (PP65) are performed. Treatment consists of ganciclovir and CMV Ig as first-line agents and foscarnet and
cidofovir as second-line agents, along with cautiously lowered immunosuppression. Treatment is continued until the
patient is symptom free and the PP65 is normal. Monitoring
should include BUN, creatinine clearance, urine output,
urine proteins, CBC, differential, platelets, LFTs, electrolytes, and observation for allergic reactions.
Assessment of Graft Function. Graft function and
viability are assessed in the operating room immediately
following graft reperfusion. Because the allograft may be of
varying lengths of the GI tract and different anatomic
structures or organs (may include stomach, small intestine,
duodenum, colon, liver), the assessment must be thorough,
aggressive, and mUltidisciplinary. There are not good
biochemical markers to indicate function. (See other sections for assessment of graft function for other abdominal
organs.)
Serum nutritional markers (transferrin, albumin, and
retinoic acid) and the absorption studies (o-xylose testing
and fecal fat content) are performed to evaluate intestinal
absorption abilities, assessing carbohydrate absorption and
fat metabolism. Motility is evaluated by barium GI series
with determination of duration of gastric emptying and

intestinal transit time. Most recipients experienced delayed
gastric emptying during the early postoperative period with
the initiation of oral feedings. This problem usually resolved
in about 3 months, but gastrostomy is required to alleviate
symptoms. 60
All intestine recipients suffer high stomal output and
diarrhea, sometimes requiring readmission for fluid and nutritional management. Pharmacologic measures, including
the administration of antidiarrheal agents, are used to decrease GI motility, but high stomal output may continue for
years in patients with rapid intestinal transit. Graft dysmotility may be related to graft denervation. Recently, enteric
ganglia at the roots of the celiac and mesenteric arteries have
been preserved in an attempt to slow intestinal transit. Evaluation of the outcomes of ganglia preservation requires additional follow-up.60 Many children requiring intestinal
transplant have never eaten before surgery, so during the
postoperative period an occupational therapist or feeding
specialist assists these children with mastery of this task.
Maintenance of Fluid and Electrolyte Balance.
The fluid shifts between the graft, lungs, and peripheral
tissues in the first 2 to 3 days can result in generalized fluid
retention combined with intravascular volume depletion.
Careful measurement of enteric output is essential, with
early surgeon notification of extremes of output. Assessment
of stomal output for volume, consistency, reducing substances, and bacterial overgrowth is performed. Excessive
output may indicate rejection and reflects poor absorption.
Enteral feedings are introduced to stimulate absorption as
soon as tolerated in the postoperative period. Total caloric
intake is maintained with parenteral nutrition, which is
decreased once enteral feedings are tolerated. The goal is to
achieve independence from TPN in all functioning grafts
within 4 to 6 weeks. Initiation of enteral feedings through
the jejunostomy tube is a gradual process, and the goal is to
wean TPN and tube feedings to an exclusi ve oral diet.
Enteral feeding is weaned by reducing daily duration of
administration as oral intake improves.
Graft-Versus-Host Disease. GVHD is another potential complication caused by the large quantities of
lymphoid tissue present in the intestine. Recipients of a liver
and intestine graft and isolated intestine transplants have
been treated with increased immunosuppression for GVHD,
which is diagnosed by the presence of a fine intermittent
pink skin rash and histologic diagnoses per intestinal and
skin biopsy. GVHD develops in about 10% of recipients, is
usually nonlethal, and occurs most often after reduction or
discontinuation of immunosuppression therapy.6o

KIDNEY TRANSPLANTATION
Substantial experience has been gained in providing care
and treatment to children with end-stage renal disease
(ESRD). These developments have allowed this patient
population the opportunity to live far longer than was
previously expected. Experience has demonstrated that
infants and very small children are not only acceptable
candidates for treatment but are also favored candidates
when outcome and quality of life are measured. During

Chapter 26

the last decade, patient and graft survival rates have
improved significantly related to more effecti ve immunosuppressive regimens, improved pretransplant dialysis, and
current postoperative monitoring and care. b3
In 1999, UNOS reported survival rates of cadaveric
kidney transplants in 1- to 5-year-olds to be 97.4%, 90.2%,
and 88.8% at I, 3, and 5 years, respectively, with living
related donation (LRD) transplant survival rates being
slightly higher. Overall survival rates of all types of kidney
transplant recipients steadily remain greater than 90% after
5 years in children of ages I to 18 years. 4
About 900 children are diagnosed with ESRD each
year. 63 The five most common diagnoses requiring transplantation were hypoplastic or dysplastic kidneys, obstructive uropathy, focal segmented glomerulosclerosis, reflux
nephropathy, and systemic immunologic disease. The cause
of ESRD in children also varies depending on age groups,
according to data reported to the North American Pediatric
Renal Transplant Cooperative Study (NAPRTCS).64 In
children younger than 5 years of age, congenital anomalies
and congenital nephrotic syndrome are the most common
causes. In adolescents, chronic glomerulonephritis is most
common. On the average, there is an interval of about 4 to
5 years between the onset of glomerular disease and the
onset of ESRD. The cause of each child's renal failure is
important information for the healthcare team and the
family. The identification of a hereditary renal disease has
implications for family members who may wish to be
considered as kidney donors. Because certain renal diseases
tend to recur in the transplanted kidney, this information can
influence the timing of the transplant, as well as the choice
of LRD versus a cadaveric donor.
Timing of transplantation takes into account patient age,
progressive growth failure and associated deterioration of
CNS structure and function, and the cause of the ESRD.
Historically, outcomes for small infants were not as
successful as older children, but improvements in surgical
technique and patient care now allow surgery in infants
weighing at least 6 kg or older than 6 months of age 65 One
study in long-term mortality has shown no significant
difference in the 5-year patient survival of those treated with
hemodialysis (95%), LRD renal transplant (88%), and
cadaveric renal transplant (85%).66 This is important to
consider in caring for the newborn or infant for whom
increased linear growth is preferred before transplantation.
However, almost all children with ESRD will not grow and
develop along normal curves. Because muscle mass is
normally more limited in children than adults, serum
creatinine levels will not correlate as well with the degree of
renal failure. Growth retardation may occur with serum
creatinine levels of less than 3 mg/dl. Children with
congenital nephrotic syndrome may suffer growth failure
despite aggressive medical management with serum creatinine as low as I mg/dl. They may require nephrectomy 6
weeks before transplantation to correct nutritional and
coagulation abnormalities. Children with oxalosis are often
transplanted early (kidney graft or liver and kidney graft) to
avoid prolonged renal insufficiency or dialysis that may
cause extrarenal accumulation of oxalate. b3
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Preemptive transplantation (transplantation before the
initiation of dialysis in the child with ESRD), although
controversial, will maximize growth; minimize social,
educational, and psychologic impacts of chronic illness; and
decrease the complications of dialysis. LRD can facilitate
optimal timing of preempti ve transplantation. Better outcomes are possible for both the donor and recipient because
surgery can occur when both are optimally healthy, kidney
ischemic times are short, the allograft function is usually
immediate, and immunosuppression may be initiated before
the transplant. 63
The principles of conservative medical management
of ESRD in children are based on maintaining metabolic balance and growth and development by diet and
drug therapy. When conservative management can no longer relieve the symptoms of uremia and permit the child to
function in peer, school, or family life, an alternative form of
treatment is necessary. With the availability of dialysis and
transplantation, conservative treatment should exclude the
need for drastic limitations on diet and activity.
Treatment options include chronic hemodialysis (usually
using Brescia-Cimino arteriovenous fistula on the forearm
or polytetrafluoroethylene graft if inadequate veins), chronic
continuous ambulatory peritoneal dialysis (CAPO) or continuous cycling peritoneal dialysis (CCPD), and transplantation. Although many patients are brought to an optimal
metabolic state with dialysis before transplantation, undergoing transplantation without dialysis is not unusual.
Dialysis allows time for the child's medical, surgical, and
urologic abnormalities, including metabolic derangements,
bladder outlet obstruction, bone deformities, immunizations, and dental care, to be corrected. A voiding cystourethrogram is used to evaluate the bladder. Many children
whose bladders were thought to be unusable may in fact be
surgically augmented so that these children may void
normally. Every effort is made to use the bladder; however,
when it absolutely cannot be used, diversion to an ileal or
colonic conduit may be performed. Central venous access is
initiated at the time of nephrectomy, dialysis, or transplantation. Bilateral nephrectomy, before or at the time of
transplant, is indicated in malignant hypertension that has
failed to respond to maximal antihypertensive therapy and
ultrafiltration by dialysis, for persistent infections, for
structural upper tract uropathies, and in congenital nephrotic
syndrome.
Pretransplantation evaluation is done by a multidisciplinary team. Standard evaluation includes the history and
physical examination and laboratory tests including hematology, coagulation studies, chemistry, urine analysis, and
blood bank screening. Blood bank screening includes ABO
type, hepatitis profile, HIV screen, HLA type, and anlileukocyte antibody screening. As a minimum, the donor and
recipient should be ABO compatible and have a negative T
cell cross-match. Ensuring that the recipient does not have
preformed antibodies against antigens on the donor's T
lymphocytes will prevent hyperacute rejection, which results in rapid, irreversible loss of graft function. Screening
may be repeated monthly while patients are on the waiting
list. Contraindications for transplantation include malig-
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nancy and active infection. Relative contraindications Include major systemic disease and profound disability.
The decision to use a living-related or cadaver donor is
dependent on the philosophy of the transplant center, as well
as the availability of a living-related or living nonrelated
donor (LNRD) and the family's wishes. LRD should be used
when possible, considering the improved graft and patient
survival rates. LRDs or LNRDs must be at least 18 years of
age, have two healthy kidneys, be highly motivated, and
meet the center's immunologic, medical, and psychosocial
parameters. Donors must also have ABO compatibility,
preferably share at least one haplotype for the serologically
detectable antigens, and have a negative T cell cross-match.
Medical evaluation confirms the health and renal function
status of the donor and is usually performed by a physician
other than the transplant surgeon.
When an LRD or LNRD cannot be identified, the child is
placed on the waiting list for a cadaveric kidney. The
waiting list has grown as the number of candidates has
increased, related to the surgical techniques available
currently for smaller infants. Patients in particular blood
groups are assigned points based on the quality of the
antigen match and the time of waiting. Extra points are
assigned for recipients with a PRA greater than 80%
(broader spectrum of anti-HLA antibodies), pediatric patients, previous donors who need a transplant, and medical
urgency.67 With all else being equal, patients with the
longest waiting time on the list are given priority. Some
patients are listed at more than one center, which increases
their chances of receiving an organ sooner by 86%.68
Allowing multiple listing may discriminate against patients
with less resources for travel and medical care or patients in
other geographic regions. In addition, follow-up care may
be more difficult for out-of-state patients.
While on the waiting list, monthly determinations of
sensitivity against a representative panel of lymphocytes are
made. Donor organs that match a recipient in ABO
compatibility and have an identical HLA match are offered
nationally first, then locally. Generally, the donor kidney is
selected on the basis of a negative cross-match between the
recipient's serum and lymphocytes from the donor. Other
criteria include current sensitization, length of time waiting,
and recipient's age. The donor should be older than 6 and
younger than 65 years old, normotensive, and otherwise
healthy and free of transmissible disease. Donors have been
declared brain dead and are maintained on life support
systems until the kidneys can be recovered.

Kidney Transplantation Procedures
Once the selection has been determined, recipients undergo
a final T cell cross-match and dialysis, if necessary. When
required, preoperative transfusions are administered at the
same time as dialysis to remove the potassium load from the
banked blood. They also receive a thorough evaluation of
current fluid and electrolyte status. Central venous access is
established, if not already available. The bladder is filled
with an antibiotic solution. Medications, including antibiotic
prophylaxis, corticosteroids, and immunosuppression induc-

tion, are administered. Because the primary immunosuppressants, cyclosporine and tacrolimus, are potentially
nephrotoxic, immunosuppression may be induced with
monoclonal or polyclonal antibodies or other agents and
administration of primary immunosuppressants delayed
until function of the new organ is ensured.
Transplantation in the very small child poses different
challenges because the donor kidney is usually relati vely
large. The abdomen must expand to accommodate a new,
larger organ, which while consuming much of the infant's
cardiac output, may impede venous return form the lower
extremities and impede respiratory efforts. On release of the
venous and arterial clamps following anastomoses of
vessels, the lower extremities and donor organ are reperfused, which may result in hypovolemia and acidosis. The
new organ may initially sequester blood and may produce
urine close to the infant's blood volume on a hourly basis,
resulting in hypotension. 63 It is essential that the CVP and
blood pressure are adequate when the vascular clamps are
removed. In addition, washout of the preservation solution
from the large organ into the infant recipient may result in
life-threatening hyperkalemia and hypothemlia. 63 Therefore
in infants and children receiving a large kidney, the CVP is
increased to 15 to 20 mmHg with infusion of crystalloids,
albumin, or packed red blood cells; sodium bicarbonate is
administered to counteract acidosis; the kidney is warmed;
urine output is replaced aggressively; and serum electrolytes
are monitored closely.63
Arterial and venous anastomoses are completed in
implantation of the donor organ; then the clamps are
removed when CVP is adequate. Maintaining blood pressure and filling pressures during reperfusion is vital.
Transfusions of blood and colloid may be necessary to
provide a circulating blood volume that is adequate to
perfuse the new kidney; ongoing, aggressive volume
replacement may be required if the donor organ is large. The
donor's ureter is anastomosed to the bladder mucosa of the
recipient. A ureteral stent may be required in small bladders.
The kidney and anastomoses are inspected and irrigated, and
the abdomen is closed. If the donor organ is making urine at
the end of the procedure, the peritoneal catheter (if in place
preoperatively) may be removed.
The surgical placement of the transplanted kidney in the
older child is generally similar to that in adults. Placement
of the anastomoses depends on the size of the child and the
size of the vessels.
Large adull kidneys that are transplanted into children
will decrease in size with time but will function adequately.
Conversely, cadaveric kidneys from small children that are
transplanted into adolescents undergo hypertrophy and
increase in function.

Postoperative Care Following Kidney
Transplantation
The patient usually is transferred directly from the operating
room to the PlCD, where monitoring continues. A chest
x-ray film confirms central line placement. A renal ultrasound is obtained to serve as a baseline for future
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comparison, as is a radionuclide scan, which confinns
perfusion to the newly grafted kidney.
It is not unusual to keep small infants, who have received
a large adult kidney placed intraperitoneally, intubated and
supported on a ventilator for several days. A central line is
usually inserted to monitor the effects of fluid loss on
circulating blood volume and to detennine replacement
therapy. Fluid and electrolyte status is measured meticulously, and output is replaced milliliter per milliliter. The
intravenous solution is adjusted frequently based on the
serum and urine electrolytes. Calcium losses can cause
problems. Immediate functioning of adult kidneys placed in
infants will necessitate larger amounts of fluid replacement.
Intraoperative bowel manipulation usually results in an
ileus. The patient will require a nasogastric tube and
parenteral nutrition until bowel function returns. A bladder
catheter is placed for bladder decompression and urine
output measurement.

Significant Postoperative Issues
and Complications
Organ-Specific Rejection: Kidney. Hyperacute rejection is currently uncommon because of screening of
blood type and antigens. When present, this rejection occurs
immediately postoperatively. Accelerated rejection is also
rare and is thought to be a secondary response resulting in
antibody fonnation after contact with an antigen to which
recipients were sensitized. This occurs 3 to 5 days after
transplantation and presents as a severe, sudden graft
dysfunction. (See also sections on promotion of graft
tolerance and rejection.)
Acute rejection is the most common (40% of LRD
recipients and 50% of cadaver recipients) and occurs most
often during the first 6 months (especially with cadaver
donors) but can occur at any time during the life of the
graft. 63 It is usually reversible when identified and treated
early. Clinical manifestations can be subtle. In the infant or
smail child who received a large lddney, early diagnosis of
rejection may be difficult because of the abundance of renal
parenchyma. By the time the BUN or creatinine level is
elevated, rejection may be severe. In one study, hypertension and fever were significantly predominant in the
rejection group; the creatinine level was elevated in only
45% of those with rejection. 69
In addition to monitoring serial creatinine, ultrasound,
radionuclide scans, and percutaneous renal biopsy are often
necessary to confinn the diagnosis of rejection. Renal
biopsy is important in the confirmation and management of
acute rejection, as the histologic severity of rejection can be
used to detennine the optimal therapy for the patient. The
parameters for diagnosing acute rejection in renal transplantation include fever, decreased urinary output, graft pain and
tenderness, increased BUN and creatinine levels, malaise,
weight gain, and hypertension. The use of cyclosporine and
tacrolimus has made the diagnosis of acute rejection more
difficult because of potential nephrotoxicity. A biopsy may
be required to differentiate between immunosuppressant
nephrotoxicity and early recurrence of the original disease.
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Other differential diagnoses for symptoms of rejection, such
as urinary obstruction, acute tubular necrosis (ATN), and
urinary extravasation, can usually be ruled out by ultrasound
and radionuclide scan.
Chronic rejection may occur after an episode of severe
acute rejection as early as the first few weeks posttransplantation, but often, it is a disorder characterized by progressive
ischemic loss of nephron mass secondary to vascular
lesions. Chronic rejection is characterized by a gradual
decline in glomerular filtration and an increase in permeability of the glomerulus to protein. The most common signs
of chronic rejection are hypertension, proteinuria, edema,
gradual rise in BUN and creatinine levels, and decreased
creatinine clearance. Clinical manifestations of chronic
rejection may not be evident until filtration rates are less
than 25% of nonnal.
Treatment for rejection may include increasing the level
of immunosuppression, adding adjunctive immunosuppressants or antibody therapy depending on the severity of
rejection, and increasing the dose of corticosteroids or
providing steroid boluses and recycling. Renal ultrasounds
are used to monitor rejection, but percutaneous renal biopsy
is the most reliable indicator of rejection. The rare patient
who demonstrates rejection refractory to treatment may be
treated with dialysis and antilymphocyte preparations.
Infection. Infection is a frequent cause of morbidity
and mortality in the renal transplant recipient. 63 (See discussion of infection in heart-lung section for details regarding
posttransplant infections.) Prominent among these infections are those with a large number of pathogens, mainly
gram-negative bacteria (greater in younger patients and
more prevalent in the first month) and opportunistic organisms such as PCP and CMY. The type of infection generally
varies by the time after transplant and the recipient's age.
Varicella-zoster. fungal infections. and protozoal infections
may also occur. Trimethoprim prophylaxis is initiated early
and is usually maintained as long as the immunosuppressants continue.
CMV disease is the major pathogen in the first I to 3
months posttransplant. 63 Ninety percent of the time, acquisition is by transplantation of a CMV-positive organ.
Patients who are CMV seronegative and are the recipient of
a kidney from a CMV-positive donor may be treated with
prophylactic CMV-specific immunoglobulin. The first dose
must be administered within 72 hours of the transplant, then
subsequent doses are given up to 16 weeks after the
transplant. Symptoms of CMV disease in these patients
include prolonged episodes of fever. fatigue, cold or flulike
symptoms, leukopenia, thrombocytopenia, abnonnal LFTs,
hepatomegaly or splenomegaly, decreased renal function,
and elevated BUN or creatinine level.
EBV infection may also occur in renal recipients. The use
of immunosuppressants to block interleukin-2 synthesis can
decrease the number of Virus-specific cytotoxic T cells,
which then allows viral replication and proliferation of
transformed B cells. Symptoms of tonsillitis, fever, hepatocellular dysfunction, focal brain or pulmonary disease, focal
GI tumors with bleeding, or perforation or infiltration of the
allograft may occur. Diagnosis is through EBV-PCR, titers,
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imaging, and renal biopsy. Treatment is with CMV-specific
immunoglobulin and ganciclovir (DHPG), decrease or
withdrawal of immunosuppressants, and chemotherapy,
reserved for ganciclovir-resistant patients. Many tumors that
occur in transplant recipients are lymphomas, specifically
non-Hodgkin's, B cell origin with EBV implicated. Treatment may include decreased immunosuppression, local
excision of masses, and chemotherapy. Cutaneous and other
tumors also occur.
The patient who tolerates the graft poorly and requires
large amounts of immunosuppressive drugs is the one most
likely to develop serious infections. For this reason,
vigorous immunosuppressive therapy is not pursued. Instead, rejection is allowed to proceed, and the kidney is then
removed and later replaced with a second transplant.
Fluid and Electrolyte Imbalance. After surgery, the
kidney may produce a massive diuresis, may remain totally
anuric, or may produce urine volumes between these
extremes. Serum and urine electrolytes are determined
frequently (as often as every 6 hours for the first 2 days). IV
fluids are administered based on the serum electrolyte levels
and urine volumes. Inadequate fluid and electrolyte replacement may precipitate hyponatremia, hypokalemia, and
hypotension. This response is especially important in the
very small child, in whom fluid shifts occur very rapidly.
Hypotension heralding hypovolemia must be prevented to
maintain adequate perfusion to the new graft and prevent
possible graft thrombosis.
Most patients with good allograft function will have
normal BUN and serum creatinine levels by the third or
fourth postoperative day. At this time, their management
includes routine fluid volumes. Often these patients have
been receiving hemodialysis before transplantation with
concomitant fluid intake restriction. Hypocalcemia, except
in the patient with severe hyperparathyroidism, usually
ceases to be a problem in the presence of good renal
function. Phosphorus regulation, however, may continue to
be problematic for the patient, now in the form of
hypophosphatemia. It is not unusual for the newly grafted
kidney to develop a "phosphate leak," requiring oral
phosphate supplementation for an indefinite period.
Decreased Urine Output. Graft function must be
evaluated when decreased urine output occurs postoperatively. The differential diagnosis for decreased output is
mechanical obstruction of the Foley catheter, hypovolemia,
ATN, rejection, and technical events such as vascular or
urologic complications. Posttransplant oliguria or anuria is
commonly caused by ATN or rejection (discussed earlier.) If
the transplanted kidney is experiencing ATN, it may produce
diuresis for a day and then become anuric and may not
secrete urine for days or weeks. This is more common as the
result of prolonged ischemia during cadaveric organ retrieval. The reversibility of this ischemic disease is difficult
to predict, and anuria may persist for several weeks before
adequate renal function begins. The child is maintained on
dialysis until the ATN has resolved. If hemodialysis is used,
it is important not to aggressively ultrafiltrate because
excessive fluid loss could result in thrombosis of the

allograft. Careful regulation of immunosuppressive agents
and other drugs excreted by the kidney is especially
important during this period.
Other causes for oliguria and anuria cannot be overlooked and are equally investigated. Diminished urinary
flow may be caused by obstruction of the bladder catheter or
stent by a simple kink or a clot. To rule out mechanical
obstruction, very gentle irrigation may be necessary to
ensure drainage.
Hypovolemia may be due to surgical blood loss or third
spacing of fluids, and it is particularly common when
patients previously had been receiving peritoneal dialysis.
Fluid boluses may be required. Occasionally, a very small
child returns from the operating room oliguric and in
congestive heart failure after having received a substantial
arriount of fluids and colloids within a few hours. Careful
fluid replacement, diuretics, or dialysis are necessary until
the intravascular volume status has normalized. Ultrasound
will rule out hemorrhage or graft compression.
An unusual and potentially preventable complication is
graft thrombosis. Renal artery or vein stenosis or thrombosis
may occur, as well as arteriovenous fistulas. Preliminary
data suggest that graft thrombosis may be an increased risk
for recipients younger than 6 years of age who have not had
prior dialysis, as well as children who receive cadaveric
grafts from young donors. Renal artery thrombosis is a
devastating complication, which demonstrates sudden anuria. Diagnosis is made by ultrasound, renal scan, or
exploratory surgery. Nephrectomy may be required. Venous
occlusion is less common; graft swelling, tenderness,
hematuria, and oliguria occur. Ultrasound will demonstrate
no venous flow, obstructed arterial flow, and swelling.
Venous thrombectomy may relieve the occlusion, but
nephrectomy may be required.
Occasionally the distal ureter, which is minimally
vascularized, becomes necrotic from ischemia, causing
obstruction and subsequent extravasation of urine into the
lower abdomen. Analysis of the leaking fluid may aid in
diagnosis. A renal scan will confirm this diagnosis. If the
leak is very small, a bladder catheter may be able to provide
adequate drainage until the leak has healed. Placement of a
nephrostomy tube or ureteral stent or reimplantation of the
ureter may be necessary.
Although rare, obstruction of the ureter or ureteropel vic
junction may also be caused by a clot, kidney stone, edema,
or stenosis. Swelling of the graft, increased serum creatinine, pain, and drainage may occur. Edema may resolve
spontaneously with resolution of the obstruction. Stenosis
may be treated successfully with percutaneous transluminal
dilation, a procedure with low morbidity and successful
long-term effects. If not successful. surgery may be
required.
Hypertension. Hypertension often occurs in children
who have received a renal transplant. The multiple risk
factors include acute or chronic rejection; side effects of
corticosteroids and cyclosporine; recurrence of primary
renal disease, arterial stenosis, and ischemia of native
kidneys; volume loading and forced diuresis; and excessive
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sodium and fluid retention. Effective treatment for hypertension is essential because poor control can cause seizures
and intracerebral bleeding, as well as accelerated deterioration of the graft. Hypertension may be severe and require
nitroprusside infusion. (See discussion of hypertension
management in Chapter 18.)
Posttransplant Erythrocytosis. Overproduction of
erythropoietin by the allograft occurs for an unknown
reason. Treatment is with angiotensin-converting enzyme
(ACE) inhibitors such as enalapril (Vasotec) or captopril
(Capoten.)
Gastrointestinal Complications. Prolonged ileus
after an intraabdominal transplant is not uncommon. Nasogastric drainage is important, and oral feedings should be
initiated as soon as bowel function is reestablished. If
feeding is delayed beyond 5 days, TPN may be initiated.
Transplant recipients have an increased risk of peptic
ulcer disease and hemorrhage with the administration of
high doses of corticosteroids. Gut prophylaxis is continued
until the corticosteroid doses are decreased.
Recurrence of Renal Disease. The recurrence of the
primary renal disease in the allograft is of great concern in
the pediatric recipient. Steroid-resistant nephrotic syndrome
with focal segmental glomerulosclerosis, hemolytic-uremic
syndrome (with diarrheal prodrome-low incidence of
recurrence; without prodrome-more likely recurrence),
oxalosis, and membranoproliferative glomerulonephritis
have all been reported to recur. Rapid damage to grafts from
oxalate deposition in oxalosis may occur, leading some to
consider oxalosis as a contraindication to kidney transplant
alone. In some cases, a liver and kidney graft is used during
transplantation. The liver is not damaged by the primary
disease, but implantation of a new liver cures the disease
and prevents recurrence of the kidney damage. Cystinosis,
another inherited metabolic disorder, results in the reappearance of cystine crystals in the allograft, but graft dysfunction, related to the recurrence of kidney disease resulting
from cystinosis, does not occur. Unfortunately, the extrarenal manifestations of cystinosis, such as deposition of
cystine crystals in other major organs, continue to persist
after successful transplantation.

PANCREAS AND ISLET CELL
TRANSPLANTATION
The number of pancreas transplantations performed for the
treatment of diabetes mellitus, especially in adults, has
increased dramatically in the last few years. More than one
half of the transplants reported to the International Pancreas
Transplant Registry have been performed since 1991.4 In
1995 a total of 3900 pancreas transplants were performed.
However, only II transplants were reported in the age group
of 5 years and younger and 9 transplants in the age group of
6 to 18 years. Since 1995 the number of annual isolated
pancreas transplants in all ages has more than tripled,
increasing to 368 in 1999 4 However, from 1994 to 1998, a
total of only 40 pancreas transplants have been performed in
children ranging from newborn to age 18 years. 4 The
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survival data from October 1987 to December 1997 shows
a I-year graft survival rate of 76.6% and a 4-year survival
rate of 63.9%.4
Diabetes is a chronic disease that affects more than
12 million Americans and is associated with permanent and
irreversible functional and structural changes in body cells.
The financial impact of this disease is staggering both to the
patient and to society. The goals of pancreas transplantation
are to improve the quality of life: to restore glucose control,
permit independence from insulin, and halt the progression
of complications. Pancreatic transplantation procedures are
performed in rigorously selected diabetic patients at this
time, very few of whom are children. Because generalized
immunosuppression (with its inherent risk of toxicity,
infections, and malignancy) is necessary to prevent rejection, pancreas transplantation has been Ii mited to patients
whose secondary complications of diabetes are, or predictably will be, more serious than the potential side effects of
antirejection therapy. Patients who require or who have had
a kidney transplant and who are obligated to immunosuppressive therapy meet this criterion. However, some nonuremic, non-kidney transplant patients are also in this
category, such as those with preproliferative retinopathy
who are at great risk for loss of vision or those with
albuminuria who have early but progressive diabetic nephropathy. Currently, most pancreas transplants are performed in adult uremic patients either simultaneously with
or 6 months to I year following renal transplantation. The
rationale is that an endocrine-functioning pancreas may
protect the renal graft and stabilize diabetic complications
and may also assist in monitoring pancreatic rejection.
Acute rejection is common. Renal biopsies can be performed to monitor rejection, but pancreatic biopsies are not
indicated because the pancreas is highly vascular.
Because of the morbidity of the pancreas transplant
procedure, the future for restored pancreatic function in
children may rest with islet cell transplantation. This
alternative to whole organ pancreaticoduodenal transplant is
attractive because it is simpler and may facilitate immunoalteration pretransplant. 7o In addition, successful islet
transplantation enables children with diabetes to avoid the
chronic and sometimes devastating complications of lifelong diabetes. Though not yet successful in adults (only 20
of 140 documented cases of insulin independence have
occurred), research is continuing. 70 Successful islet transplants require procurement of a sufficient number of islets
from a single pancreas, improvement of islet preparation
and preservation techniques, employment of techniques to
alter graft immunogenicity without alloimmunity and longterm immunosuppression to enable engraftment into the
recipient liver, and establishment of insulin independence
after the transplant. In March of 2000, the Juvenile Diabetes
Foundation awarded a 10 million dollar grant to explore the
possibility of islet cell transplantation in conjunction with
gene therapy to prevent rejection (Dr. Massimo Trucco of
Children's Hospital of Pittsburgh) In addition, research will
focus on the development of a vaccine to be used to prevent
diabetes in genetically susceptible children.
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QUALITY OF LIFE AND FOLLOW-UP

CARE ISSUES
The commitment to transplant in children with end-stage
organ failure can be one of the most challenging yet
rewarding programs undertaken by a transplant center. It
provides many avenues for highly skilled and sensitive
nursing care. Solid organ transplantation is a viable therapeutic option for critically ill children who will be limited in
either their lifestyle or their lifespan.
Children and families facing the process of transplantation deal with multiple issues. The developmental level of
the child, the family dynamics, and the fact that many of the
children are very young and have little or no participation in
or control over their own care necessitate increased family
and medical community commitment.
Children with organ failure are at risk of experiencing
physical and emotional problems similar to those of children
with other chronic or life-threatening illnesses. Although it
presents new challenges and requirements for care, transplantation offers the chance of long-term survival and
rehabilitation. Before transplantation, children often incur
repeated hospitalizations, which may involve separation
from family members, school, friends, and familiar environments. Throughout the process of transplantation, the
child is influenced by previous experiences with hospitals
and healthcare professionals and ongoing developmental
changes.
Severe stress for patients, family, and staff occurs during
the posttransplant period if rejection, infection, or other
complications delay or interrupt the progress of recovery.
Quality of life is affected by clinical problems such as
chronic rejection and noncompliance. Certain special programs, such as weaning steroids, withdrawing immunosuppressant therapy, and switching from cyclosporine to
tacrolimus in cases of severe hirsutism, have helped to
address these issues. Constant efforts at reassurance, support, and promotion of normal life patterns for child and
family must be provided. The PICU and acute care staff
must be aware of the individual family's coping patterns, as
well as their need to participate in the patient's care. When
living related donation occurs, the donor who needs to
mourn the loss of a body part can easily feel unappreciated
and ignored while the recipient is the focus of care. When
the donor is the child's parent, these are significant issues.
Other parenting issues are key in the immediate postoperative period. Weichler 71 reported an exploratory study
determining information needs of mothers of liver transplant
recipients. A l3-item, open-ended interview guide was
completed by eight mothers. The most prominent maternal
emotions were fear of the child's death and fear of organ
rejection. In the PICU phase, mothers reported feelings of
guilt over seeing their child with numerous invasive tubes in
place. The mothers perceived that the most important way
for parents to cope with these fears was to be as prepared as
possible for the transplant process. In the PICU, mothers
reported the following five consistent information needs:
(1) the purpose of the tubes, (2) liver enzyme laboratory
values, (3) child's blood pressure, (4) medications, and
(5) child's overall well-being. Three of the eight mothers

reported that they were too stressed to seek information
during the PICU phase.
Supervised viewing of the native organ with pathology
personnel may provide support to the parents. Parents have
reported that seeing their child's liver relieved the lingering
question of the necessity of the transplant at the time. If the
diagnosis or cause of liver failure (or other organ failure) is
unknown, meeting with the pathologist allows parental
questions to be asked, although they may go unanswered.
Returning the transplant patient to his or her home and
community may prove to be very stressful. The very small
child tends to be overactive for a few months until the
excitement of being well becomes exhausting and normal
childhood activity resumes. The adolescent, who is already
in a period of structural ego alteration, may have conflicts
about body image, identity, and dependency. A cushingoid
appearance and struggles with weight gain may make
returning to school difficult.
The family, having previously cared for the ill patient,
may find it difficult to let go and permit independent
activity. Previously submerged intrafamilial tensions may
become overt with the stresses of chronic illness, and the
family structure may disintegrate. Consideration must also
be given to the financial stresses that burden families of
transplant patients. With the exception of some specific
federal legislation for renal transplantation, the costs of
transplants must usually be covered by each individual
family's resources or private insurance.
Discharge planning should be initiated early in the course
of hospitalization. In addition to teaching the child and
family about the medications and required procedures,
discussion should be initiated around home issues such as
attending school or day care, travel and vacations, camps,
and pets. 72
Families should be aware that transplant statI need to be
notified when certain physical symptoms or changes occur.
These include fever, diarrhea lasting longer than 24 hours
(or 12 hours for intestine recipients), enlarged lymph nodes,
seizures, tremors, abdominal pain, headache, irritability,
disorientation, G1 bleeding, fatigue or lethargy, abnornlal
laboratory results, or new medications prescribed by other
healthcare providers. Patients and families should be taught
when to call with information and when it is appropriate to
take the chi Id to the emergency department.
Routine immunization schedules are initiated 3 months
after transplantation. Live, attenuated viral vaccines are
usually not administered to immunosuppressed children, but
well-child care may include inactivated vaccines as recommended by the transplant team. Influenza vaccine is given
annually. When possible, hepatitis B immunizations should
be administered before transplantation. Routine childhood
illnesses may be serious in immunosuppressed transplant
recipients. The transplant team must be made aware of
exposures so that decisions for care, such as immunoglobulins, can be made when appropriate and in a timely fashion.
Survival and quality of life issues have been examined in
several studies. Over the past 15 years, marked improvement has been seen in outcomes for pediatric heart,
heart-lung, and lung recipients, although there is a lower rate
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of survival for heart-lung and lung recipients than cardiac
recipients. 26 Most patients resume physical normal function,
although peak: exercise performance may be compromised. 29 Chronic rejection appears to be the principal factor
that limits survival in both groups.
Uzark and colleagues 73 conducted a multicenter study
involving 52 heart recipients, ages 8 to 16 years, who had
survived more than 3 months posttransplant. Using several
measures, they assessed family stress, resources, parental
coping, and child adaptation. They found that patients
experienced a dramatic improvement in functional status but
may be at increased risk for problems in psychosocial
adaptation. They noted an increase in behavior problems,
which were highly correlated with family stress. DeMaso
and colleagues 74 studied 23 patients of ages 3 to 20 years
and assessed psychologic functioning using the Children's
Global Assessment scale before transplant and at I-year
posttransplant. They also evaluated the impact of pretransplant psychologic function, family function, and posttransplant medical severity. Seventy-eight percent of patients had
good psychologic function posttransplant. Pretransplant
emotional status and family function correlated more with
posttransplant psychologic function than medical severity.
Two studies focusing on long-term outcomes in children
following heart transplantation report that rehabilitation and
quality of life have been good or excellent. 75 .76 In general,
quality of life for children after heart transplantation is
improved compared to pretransplant status, and recipients
cope well with the stressors of transplantation. One significant issue, particularly for adolescents, is noncompliance
with immunosuppressive therapy, which may have dire
consequences.
Quality of life issues in children following liver
transplantation have also been reported. 77 •78 Zitelli and
associates 78 noted that objective lifestyle changes in 65
children had improved from their pretransplant status and
that overall the children attended school, took fewer
medications, and experienced fewer days of hospitalization.
Zamberlan 77 interviewed 20 school-age children 3 to 6
years after liver transplantation who perceived their quality
of life to be good; however, many negative feelings about
physical appearance were expressed. The 20 children
expressed feelings of insecurity and loneliness, had difficulties in peer relations, and had higher anxiety scale
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scores as compared with a normal group on the Piers-Harris
Self-Concept Scale.
One of the key issues in quality of life for renal transplant
recipients is growth and development. As mentioned previously, children with ESRD do not have normal growth and
development before transplantation. After transplantation,
some children have an accelerated period of growth
(catch-up growth), others demonstrate some improvement
in growth, and others continue to fall behind on growth
charts. Data suggest that normal or accelerated growth after
transplantation is more likely to occur in infants or young
children, that growth may continue to be impaired if graft
function is not normal, that growth improves with less
steroid usage, and that other endocrine factors may affect
growth patterns. 63 Follow-up of renal transplant recipients
continues to focus on growth patterns. Manipulation of
steroid administration, including alternate-day dosing and
withdrawal of steroids, is continuing to be investigated.
Some investigators have reported improved growth, especially in prepubertal children, with administration of recombinant growth hormone 63
Studies of long-term outcomes in renal recipients have
been done, but outcomes would probably be better currently
with the improvement in immunosuppression therapy.63
Four studies of rehabilitation of pediatric renal recipients
were reviewed, and the majority of patients were leading
functional lives in terms of employment, family life, and
education_ 79 Children studied with greater than 10 years of
allograft function demonstrated high achievement in education, participation in sports and other extracurricular activities, and employment and generally were satisfied with the
quality of their lives. The major issue identified was
dissatisfaction with their appearance, especially in terms of
stature. 80 This is an issue that may begin to resolve with
earlier transplantation (and less growth disruption). and
decreased use of long-term steroids.
Further examination of the long-term effects on growth
and development, school performance, and emotional status
of children must occur now that there is a larger surviving
population of pediatric transplant patients. Future patient
issues of sexual maturation, fertility, and long-term drug
effects during the first and second generations will become
important. Creative approaches to facilitate treatment compliance must be developed and tested.
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Shock
Cathy H. Dichter
Martha A.Q. Curley

Shock, along with its associated reduction in effective tissue
perfusion, results from the loss of integrity of one or more
of the four essential components of circulation: blood
volume, cardiac pump, vascular tone, and cell function
(Table 27-1). Regardless of the cause, the final common
pathway of shock is cell destruction caused by either
ineffective tissue delivery or impaired use of essential
cellular substrates.
The extent to which shock contributes to morbidity
and mortality among critically ill infants and children is
directly related to the ability of caregivers to (I) rapidly
recognize the cluster of symptoms characteristic of shock;
(2) vigilantly attend to the administration and titration of
collaborative management strategies intended to interrupt the numerous pathophysiologic cascades associated
with shock; and (3) efficiently provide intensive nursing care.

CATEGORIES OF SHOCK

Low-Flow Shock
Maldistributive Shock
TRAJECTORY OF ILLNESS
PHYSIOLOGIC RESPONSES TO SHOCK

Neuroendocrine Activation
Anaerobic Metabolism
Fluid Shifts
Mediator Release
CLINICAL ASSESSMENT: RED FLAGS OF CARDIOVASCULAR
COLLAPSE

Low-Flow Shock
Maldistributive Shock
Hemodynamic and Oxygenation Profiles
COLLABORATIVE MANAGEMENT

CATEGORIES OF SHOCK

Supportive Treatment
Definitive Treatment
Enhance Substrate Delivery
Minimize Energy Expenditure
Optimize Nutrition

Although classified in a variety of ways, shock can be
divided into two major categories. Based on characteristic
blood flow, the categories are low-flow shock and maldistributive shock. Low-flow shock states are characterized by
decreased cardiac output. The low-flow state may be due to
hypovolemia, cardiac failure, or critical obstruction of blood
flow from the heart. Maldistributive shock states are
characterized by normal or increased cardiac output but an
abnormal distribution of blood flow. This category of shock
includes neurogenic shock, anaphylaxis, and, most commonly, septic shock. Clustering all shock states into these
two hemodynamically based categories provides clinically
relevant information. Not only do these two categories of
shock present differently fmm one another, but also the
primary interventions in each are different. However, it is
crucial to note the mixed nature of most forms of clinical
shock. For example, septic shock presents as maldistributive
shock but may progress to low-flow shock secondary to
myocardial depression.

PROACTIVE CARE: VIGILANCE

Newborns
Multiple Organ Dysfunction Syndrome
UNCONVENTIONAL THERAPIES
SUMMARY

O

ne of the most challenging clinical problems in
pediatric critical care is caring for the patient in shock.
Shock is a "state in which profound and widespread
reduction of effective tissue perfusion leads first to reversible, and then, if prolonged, to irreversible cellular injury. "I
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Box 27-1

25
50
75
Percent blood volume deficit

~ Causes of Shock
Low-Flow Shock (Hypovolemic)
Blood Loss
Water Loss
Trauma (e.g:, splenic rupture)
Vomiting and diarrhea
Gastrointestinal bleeding
Diabetes mellitus
Inadequate replacement
Diabetes insipidus

Plasma Loss
Capillary leak syndrome
Hypoproteinemia
Nephrotic syndrome
Burns
Peritonitis
Bowel obstruction
Low-Flow Shock (Cardiogenic)
Metabolic
Cardiac Tamponade
Hypoxemia, acidosis,
Coexisting Disorders
hypoglycemia, severe
Cardiac failure secondary to
electrolyte imbalance
congenital or acquired
Dysrhythmias
heart disease
Drug toxicity
Maldistributive Shock
Neurogenic
Anesthesia, spinal cord injury

Model for cardiovascular response to hypovolemia
from hemorrhage. (Reproduced with permission from Textbook of
pediatric advanced life .,upport, 1990. Copyright by American
Heart Association.)
Fig. 27-1

.

Septic Shock
Any infectious organism

Anaphylactic
Immune or nonimmune induced

Low-Flow Shock
The most common shock syndrome in infants and children
is low-flow shock resulting from acute hypovolemia. Any
illness or injury that results in an acute reduction in

circulating blood volume-that is, severe blood, plasma, or
body fluid loss-can cause hypovolemia and shock. The
decrease in intravascular volume can be absolute, as in
hemorrhage after trauma, or relative, as in nephrotic
syndrome when plasma moves out of the vascular space into
the interstitial space. Other common causes of hypovolemic
and low-flow shock in infants and children are listed in
Box 27-1.
The progressive pathophysiologic effects of intravascular
volume loss include decreased venous return, decreased
ventricular filling, decreased stroke volume, decreased
cardiac output, and then ineffective tissue perfusion. Following the loss of volume, a series of cardiac and peripheral
hemostatic adjustments are stimulated in an attempt to
support myocardial and cerebral perfusion pressures. In
previously healthy hypovolemic patients, systolic and mean
arterial blood pressures are often maintained until the blood
volume deficit reaches 25% (Fig. 27-1). The degree to which
compensatory mechanisms succeed in maintaining blood
pressure is determined by the infant's or child's preexisting
health status, particularly cardiac reserve, as well as the
volume and rate of blood or fluid loss and resuscitation
attempts.
Insufficient cardiac output despite adequate and at times
increased ventricular preload is the second cause of lowflow shock. In addition to congenital or acquired heart
disease, other important causes of cardiogenic low-flow
shock in the pediatric population include hypoxemia,
acidosis, posthypoxic-ischemic arrest, hypoglycemia, severe electrolyte imbalance, dysrhythmias, drug intoxication,
chest trauma (myocardial contusion), and outflow obstructions. The term obstructive shock is sometimes used to
describe the low-flow state that results from mechanical
obstruction to ventricular outflow from either decreased
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diastolic filling (tension pneumothorax, tension pneumopericardium, pericardial effusion, cardiac tamponade) or
increased ventricular afterload (massive pulmonary embolus). Compensatory mechanisms designed to support perfusion pressures often contribute to the progression of
cardiogenic shock.

Maldistributive Shock
Maldistributive shock results from an abnormal distribution
of blood volume. Hemodynamically, its defining feature is
an overall decrease in systemic vascular resistance (SVR).
Vasomotor paralysis, increased venous capacity, or abnormal shunting of blood past capillary beds results in the
abnormal apportionment of circulating blood volume that is
characteristic of maldistributive shock. In infants and
children, maldistributive shock may be neurogenic, anaphylactic, and, most commonly, septic shock (see Box 27-1).
Neurogenic maldistributive shock is characterized by
massive vasodilation from loss of sympathetic vasomotor
tone. Alterations in the regulation of vasomotor tone may be
due to either pharmacologic blockade (anesthetic agents,
morphine, barbiturates, antihypertensives) or traumatic
damage to the sympathetic nervous system (spinal cord
transection above TI). The resulting vasodilation leads to
increased vascular capacity in affected body parts, usually
the extremities, depriving vital organs of oxygen and
nutrients.
Anaphylactic maldistributive shock is caused by massive
release of mediators from tissue mast cells and circulating
basophils resulting from anaphylaxis or an anaphylactoid
reaction. Anaphylaxis, an immediate hypersensitivity reaction, may occur after sensitized individuals are exposed to
drugs, especially antibiotics, food, or insect venom. Mediated by the interaction of immunoglobulin E (lgE) antibodies (on the surface of mast cells and basophils) and the
antigen, primary mediators of anaphylaxis are released,
including histamine, serotonin, and others. Subsequently,
secondary mediators, such as bradykinin and prostaglandins, are synthesized and released. Although clinically
indistinguishable from anaphylaxis, an anaphylactoid reaction results from nonimmunologic release of mediators from
mast cells and basophils. Anaphylactoid reactions may
occur as a result of various medical agents, such as contrast
dye, protamine, muscle relaxants, and anesthetics? Anaphylactic shock is hemodynamically very similar to septic
shock with profound vasodilation and capillary leak. In
addition, patients often demonstrate urticarial rash, laryngeal edema, and severe bronchospasm. Unlike in the
emergency department, anaphylactic shock is an uncommon
phenomenon in the ICU.
The most common maldistributive shock in pediatrics is
septic shock. Zimmerman and Dietrich 3 describe septic
shock as a disease of intermediary metabolism induced by
an infectious agent (microorganism), which results in
physiologic and destructive host responses and corresponding fuel energy deficits. All organisms (gram-negative
bacteria, gram-positive bacteria, viruses, fungi, rickettsiae,
spirochetes, protozoa, and parasites) can initiate the multi-
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Common Etiologic Agents of Septic Shock

.

Neonate
(3-Hemolytic streptococci
Escherichia coli
Herpes simplex virus

Older Infant and Child
Haemophilus injiuenzae. type B*
Neisseria meningitidis
Slreptococcus pneumoniae
(3-Hemolytic streptococci
Nosocomial
Slaphylococcus aureus
Staphylococcus epidermidis
Pseudomonas
Candida
* As

a result of immunization with conjugated vaccines in the United Sl'3tes.
microbial causes of sepsis in immunocompetent children are limited.

system, subcellular metabolic derangements associated with
septic shock, but etiologic agents vary according to age and
immunologic status of the patient and the place of microbial
acquisition (community vs. hospital setting) (Box 27-2). In
pediatrics, gram-negative and gram-positive nosocomial
infections occur in almost equal proportions; the foci
primarily include skin and lungs. 4 Endotoxin release from
gram-negative bacteria (Fig. 27-2) or exotoxin release from
gram-positive bacteria are two prominent exogenous mediators that serve as triggers to this complex process. 5
The normal inflammatory immune response is triggered
when the microorganism gains access to the body's internal
environment. The inflammatory immune response is triggered in an effort to eliminate or neutralize the microorganism and its toxins, contain the microorganism invasion and
prevent its systemic access (bloodstream), and promote
rapid healing of involved tissues. 6 When the ability to serve
these functions is overwhelmed, there is systemic release of
the microorganism (and associated toxins) and subsequent
activation and release of various endogenous mediators and
cytokines, referred to as the systemic inflammatory response
syndrome (SIRS).
The interrelationship among SIRS, sepsis, septic shock,
and organ dysfunction was originally conceptualized by
Bone 7 and later adopted by the American College of Chest
Physicians and the Society of Critical Care Medicine 8 (Box
27-3). An important conceptual outcome of this work was
that inflammation (with or without infection) was identified
as a major pathogenic factor in the development of SIRS,
sepsis, septic shock, and multiple organ dysfunction syndrome (MODS). In addition, establishing consensus on the
use of terminology and diagnostic criteria facilitates clarity
and consistency so that clinicians can compare the results of
clinical research studies related to sepsis.
To determine the incidence of SIRS, sepsis, severe sepsis,
septic shock, and MODS in critically ill children, Proulx and
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Box 27-3

Definitions of SIRS, Sepsis,Septic Shock,
and Multiple Organ Dysfunction Syndrome

Infection
Microbial phenomenon characterized by an inflammatory
response to the presence of microorganisms or the invasion of
normally sterile host tissue by those organisms
Bacteremia
Presence of viable bacteria in the blood
Systemic Inflammatory Response Syndrome (SIRS)
Systemic inflammatory response to a variety of severe clinical
insults. The response is manifested by two or more of the
following conditions:
Temperature >38 0 C or <36 0 C
Tachycardia
Tachypnea
WBC >12,000 cells/mm J , <4000 cells/mm'. or >10% immature (band) forms

'"--'
ColI Wall

O· Specific Chain

Fig. 27-2 Phagocytosis of gram-negative bacteria releases endotoxin, which is a component of the bacterial cell wall. Endotoxin
is a lipopolysaccharide molecule with three components: lipid A, a
polysaccharide core, and an O-specific chain. Lipid A contains
most of the biologic effects of endotoxin, and O-specific chain is
a major antigen recognized by the body. (From Klein DM,
Witek-Janusek L: Advances in immunotherapy of sepsis, Dimens
Crit Care Nurs 11 :79, 1992. Copyright 1992 by Hall Johnson
Communications. Reproduced with permission. For further use,
contact the publisher at 9737 West Ohio Avenue, Lakewood CO
80226.)

colleagues 9 conducted a prospective cohort study involving
1058 consecutive pediatric intensive care unit (PICD)
admissions. SIRS occurred in 82% of PICD admissions;
23% had sepsis, 4% had severe sepsis, 2% had septic shock;
16% had primary MODS, and 2% had secondary MODS.
Compared with patients with primary MODS, secondary
MODS was associated with a longer duration of organ
dysfunction, longer length of stay after MODS diagnosis,
and a higher risk of mortality.
The hallmarks of septic shock are a maldistribution of
circulating blood flow, imbalance of oxygen supply and
demand, alterations in metabolism, and cardiac dysfunction, resulting in a myriad of pathophysiologic events
(Box 27-4).
Two specific causes of septic shock that require specific
mention are meningococcemia and toxic shock syndrome.
Meningococcemia, caused by the gram-negative diplococcus Neisseria meningitidis. is a particularly virulent infection in children. Clinical presentation is often dramatic, with
death often ensuing in a mailer of hours. Classic presentation includes purpura fulminans, initially described as
petechiae coalescing to diffuse purpuric ecchymotic lesions
(Fig. 27-3). Poor prognostic indicators include purpura
fulminans along with hypothermia, seizures, or hypotension
on presentation; white blood cell (WBC) count of less than

Sepsis
Presence of SIRS with infection. This systemic response is
manifested by two or more of the following conditions as a
result of infection:
Temperature >38 0 C or <36 0 C
Tachycardia
Tachypnea
WBC > 12,000 cellslmm 3 , <4,000 cellslmm', or > 10% immature (band) forms
Severe Sepsis
Presence of sepsis associated with organ dysfunction, hypoperfusion, or hypotension (e.g., lactic acidosis, oliguria, an acute
change in mental status)
Septic Shock
Presence of sepsis with hypotension, despite adequate fluid
resuscitation, along with the presence of perfusion abnormalities that may include, but are not limited to, lactic acidosis,
oliguria, or an acute alteration in mental status. Patients who are
receiving inotropic or vasopressor agents may not be hypotensive at the time that perfusion abnormalities are measured.
Multiple Organ Dysfunction Syndrome (MODS)
Presence of altered organ function in an acutely ill patient such
that homeostasis cannot be maintained without interventions
From the American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference: Definitions for sepsis and organ failure
and guidelines for the use of innovative therapies in sepsis, eril Care Med
20:864-874, 1992.
WBC, White blood cell.

5000 mm 3 ; and platelet count of less than 100,000 mm 3 . JO

Fulminant disease is often associated with bilateral adrenal
hemorrhage referred to as Waterhouse-Friderichsen syndrome. The severe, rapidly progressive cardiovascular
collapse associated with meningococcemia is thought to be
a result of endotoxin-induced myocardial depression.
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r.,ajor Pathophysiologic Changes Associated With Septic Shock

Maldistribution of
Circulating Blood Flow

Imbalance 01' Oxygen Supply
and Demand

Increased capillary
penneability
Vasodilation
Selective vasoconstriction
Loss of autoregulation
Microvascular thrombi
Vascular obstruction
Tissue edema
Cellular aggregation
Microthrombi
Fluid imbalances

v/Q mismatching
Intrapulmonary shunting
Maldistribution of blood
volume
Microcirculatory abnormalities
Oxygen extraction defects
Increased demand
Pain, fever
Tachycardia
Increased work of breathing
Restlessness or anxiety

Alterations in Metabolism

Cardiac Dysfunction

Hyperrnetabolism
Inadequate substrate
metabolism
Protei n catabolism
Liver dysfunction
Resistance to exogenous medication administration
Peripheral cell dysfunction

Decreased coronary artery
blood flow
Myocardial depressant factor
Decreased LV ejection fraction
LV dilation
Abnonnal ventricular
compliance

Modified from Secor VH: Primary events and mediator release, In Secor VH. ed: Multiple orxafl dysfunction and failure. ed 2. 5t Louis, 1996, Mosby, Table 1-2. p 12.

\110., Ventilation-perfusion ratio; LV, lef( ventricular.

27·2 Diagnostic Criteria of Toxic
Shock Syndrome

TABLE

>38.9° C
Diffuse macular erythrodenna
Desquamation (palms and soles)
1-2 weeks after onset of
illness
Systolic pressure less than the 5th
percentile for children <16 yr

ree or More Organ System Involvement Is Required:
Vomiting or diarrhea or both
Severe muscle pain or creatine
phosphokinase over twice upper
nonnal
Hyperemia (conjunctival, oral,
vaginal)
BUN over twice upper nonnal
and increased WBC in urine
(without UTI)
Total bilirubin, AST (SGOT), or
ALT (SGPT) over twice upper
nonnal
, ematologic
Platelets <IOO,aOO/mm'
Change in consciousness when
ntral nervous
fever and hypotension absent
system
Sterile blood, throat, CSF cultures
boratory results
(except for Staphylococclls
allrells); serologic test for Rocky
Mountain spotted fever, leptospirosis, or measles must be
negative

Fig. 21-3 Infant with purpura fulminans associated with
meningococcemia.

Close contacts of all patients with invasive meningococcal disease are at risk and should receive prophylaxis within
24 hours of the diagnosis of the primary case. Close contacts
include anyone who had contact with the patient's oral
secretions during the 7 days before the onset of disease in
the primary case. The chemoprophylactic drug of choice for
pediatric contacts continues to be rifampin. II Ciprofloxacin,
in a single oral dose, may be given to nonpregnant adults
older than 18 years of age.
Toxic shock syndrome (TSS), septic shock resulting from
toxin-producing strains of Staphylococcus aureus, can occur
in nonmenstruating women and in males. Risk factors
include surgical wound infections or focal (sinusitis, pneumonia, etc.) and systemic S. aureus infection. TSS is
probable when at least four of the five major diagnostic
criteria are fulfilled. Diagnostic criteria, defined by the
Centers of Disease Control and Prevention, are included in
Table 27-2. Individualized treatment includes antistaphylococcal antibiotics and control of the focus of infection.

~E

li" rom American Academy of Pediatrics: 1997 Red Book: Report oj (he

!l?,,'.

I!1-CommiTlee 011 IIIJectious Diseases, ed 24, Elk Grove Village, III, 1997,

l&~erican

Academy of Pediatrics.

~fJJUN, Blood urea nilrogen; WBC, white blood cell; UTI. urinary tract
f!]'::rifection; AST, aspartate aminotransferase; SGOT, serum glutamic·
,iPxaloacetic transaminase; ALT. alanine aminotransferase; SGPT, serum
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TRAJECTORY OF ILLNESS
Shock is a syndrome that reflects the body's attempt to adapt
to an insult and preserve vital organ function. The trajectory
of adaptation in shock can be divided into three phases: a
compensated stage during which blood pressure is maintained, although there is evidence of ineffective tissue
perfusion; an uncompensated stage that reflects the inadequacy of compensatory mechanisms in the maintenance of
blood pressure; and a refractory stage. Response to therapy
varies during these stages.
In the first phase, the body's intrinsic supportive mechanisms can generally maintain normal vital organ function.
Systemic blood flow is usually normal or increased.
Hemodynamic values and vital signs may be normal or
enhanced, reflecting the physiologic attempt to maintain
vital organ perfusion. Although some parameters may
appear enhanced, the body's total metabolic needs are not
met, as evidenced by lactic acidosis and 0liguria. 12 The
success of the body's intrinsic supportive mechanisms is
determined by the patient's preexisting state (e.g., volume
status and myocardial function), illness, time elapsed, and
treatment provided.
In the second phase, compensatory mechanisms are
insufficient to maintain blood pressure and effective oxygen
and nutrient delivery to the tissues. Delayed or inadequate
maintenance of intravascular volume or other iatrogenic
causes may play some role in the patient's deterioration.
More often, though, the body simply lacks sufficient
substrate for metabolic processes, or the cellular damage
sustained is such that available substrate cannot be used.
During this uncompensated period, clear evidence of poor
perfusion is seen both in clinical parameters, such as skin,
kidney, and brain, as well as in hemodynamic parameters,
such as blood pressure, oxygen saturation, and filling
pressures. Various tissues and organ systems experience
insults, and multiple organ dysfunction, such as acute
respiratory distress syndrome (ARDS) or disseminated
intravascular coagulation (DIC), may develop and hasten
the onset of the final stage and preclude recovery.
In the third phase, shock becomes irreversible. Damage
to vital organs such as the heart and brain cannot be reversed
with either time or therapeutic maneuvers.
Refractory or unresponsive septic shock has been
described as progressing through three phases: a
hyperdynamic-compensated phase, a hyperdynamicuncompensated phase, and a hypodynamic or cardiogenic
shock phase. 13 A previous assumption was that the hyperdynamic state ("warm shock") was consistently followed
by the hypodynamic state ("cold shock"); however, research has shown two flaws with this assumption. First, with
more generous use of hemodynamic monitoring and vigorous volume expanders, the incidence of hypodynamic septic
shock is not as common. In fact, in adults with septic shock,
approximately only 10% die of progressively deteriorating
cardiac output (hypodynamic).14 Second, the terms warm
and cold shock did not always correlate accurately with true
hemodynamic findings. Bone 7 therefore advises against
using the terms warm and cold shock. Although fluidresuscitated adults rarely display hypodynamic septic shock,

hypodynamic septic shock (low cardiac output rather than
low SVR) appears more common in fluid-resuscitated
children. ls In fact, low cardiac output, rather than low SVR,
is associated with pediatric septic shock mortality.I6-18 In
refractory septic shock, decreased SVR persists, but cardiac
output falls because of unresponsive myocardial depression.

PHYSIOLOGIC RESPONSES TO SHOCK
Although physiologic responses to the different types of
shock vary, patterns do exist within each category. The
common physiologic characteristic of all early shock states
is either reduced or ineffective oxygen supply relative to
tissue demand. Physiologic mechanisms such as increased
oxygen extraction in low-flow shock and increased cardiac
output in maldistributive shock attempt to compensate for
the uncoupling of oxygen supply and demand. Autoregulation maintains perfusion to the brain and heart by diverting
blood flow from the nonessential areas of the skin, gut, and
kidneys. With time, ongoing redistribution of blood flow can
lead to progressive dysfunction, and, ultimately failure of
major organ systems.

Neuroendocrine Activation
The neuroendocrine response, also known as the stress
response, consists of sympathetic nervous system (SNS) and
endocrine activation. The effects of SNS activation are
diverse and serve one of two primary functions: maintenance of cardiovascular and respiratory function and energy
and substrate mobilization.
Cardiac centers in the brainstem stimulate most of the
sympathetic nerves at once, causing an increase in cardiac
output, heart rate, and blood pressure. This stimulation
results in a tenfold increase in norepinephrine, producing
vasoconstriction in all vascular beds. With SNS stimulation,
the adrenal medulla also releases massive amounts of
catecholamines; epinephrine levels increase fiftyfold. Epinephrine increases both heart rate and myocardial contractility (unless limited by reduced or impaired myocardial
function) and increases tissue perfusion pressure by direct
vasoconstriction of all vascular beds except those in skeletal
muscle and the liver.
A fall in mean arterial pressure or pulse pressure results
in baroreceptor stimulation. Baroreceptor stimulation leads
to diminished parasympathetic stimulation and enhanced
sympathetic stimulation of the heart, producing positive
cardiac inotropy and chronotropy and arterial and venous
vasoconstriction. Low capillary hydrostatic pressure relative
to plasma oncotic pressure shifts interstitial fluid into the
intravascular compartment. The benefits of this "autotransfusion" are self-limiting because dilution of the hematocrit
and plasma oncotic pressure eventually results. Because
extracellular fluid volume is higher in children than in
adults, this mechanism may playa greater role in pediatric
shock than in adult shock.
When cerebral perfusion pressures reach very low levels
(below cerebral autoregulation-about 40 mmHg in older
children), a sympathetic surge produces massive vasocon-
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striction and a temporary arrest in the decline of blood
pressure and cardiac output. The central nervous system
(eNS) ischemic reflex maintains blood pressure by doubling
SVR and producing a fivefold increase in pulmonary
vascular resistance (PVR).
Metabolic alterations also result from neuroendocrine
activation, initially aimed at meeting increased body demands. Metabolic alterations are characterized by hypermetabolism, hyperglycemia, and hypercatabolism. 19 Fig. 27-4
illustrates the myriad effects on metabolism. Importantly,
hyperglycemia may be initially present because of epinephrine secretion. However, hypoglycemia develops, as hepatic
glycogen stores are depleted (usually in less than 12 hours)
and gluconeogenesis fails. Hypoglycemia should be care-
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fully scrutinized as a sign of adrenal insufficiency. Adrenal
insufficiency most commonly occurs in patients who have
purpura fulminans or those with a history of chronic steroid
use. In addition, any patient whose perfusion and blood
pressure is unresponsive to vigorous volume resuscitation
and vasoactive support should be evaluated for adrenal
insufficiency.2o

Anaerobic Metabolism
By definition, shock is congruent with hypoperfusion and
tissue ischemia. This results in local tissue acidosis caused
by decreased carbon dioxide clearance and anaerobic
metabolism. At a time when oxygen demands are greatest
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Fig. 27-4 Neuroendocrine effects on metabolism. As the body perceives stress or insult. neuroendocrine
compensatory mechanisms are triggered to provide more energy to meet the body's needs. ACTH.
Adrenocorticotropic hormone; CRH, corticotropin-releasing hormone. (From Kimbrell JD: Alterations in
metabolism. In Secor VH, ed: Multiple organ dy,function alldfai/ure. ed 2, St Louis, 1996. Mosby. p 149.)

928

Part V

Multisystem Problems

for tissue repair, effective oxygen delivery is insufficient.
Cellular processes therefore occur without oxygen (anaerobic metabolism), lactic acid accumulates, and metabolic
acidosis develops. Decreased oxygen consumption (V02 )
occurs secondary to reduced blood flow or maldistribution
of flow. Arterial pH and base deficit determination serve as
readily available markers of effective tissue perfusion and
oxygenation.
Lactate levels may help to determine the degree of tissue
perfusion. Lactate levels greater than 2 mmollL are generally considered to be indicative of shock 21 However, the use
of lactate levels is limited by the fact that it is a late marker
of tissue perfusion. Significant tissue ischemia is present by
the time lactate is elevated 2 In addition, because the liver
clears lactate, liver hypoperfusion or dysfunction may
markedly increase elevated lactate levels. Serial determinations of lactate have been used to assess the adequacy of
resuscitation interventions in shock.
Gastric intramucosal pH monitoring may also provide a
noninvasive method for the indirect measurement of tissue
oxygenation. 22 Gastrointestinal tonometry uses a standard
vented nasogastric tube combined with a silicone balloon
system permeable to CO 2 , When the saline-filled balloon is
placed in close proximity to the gastric mucosa, CO 2 gas
diffuses from the gastrointestinal mucosa into the balloon
tonometer. The CO2 measurement, used in conjunction with
the arterial blood bicarbonate, serves as an indirect estimate
of the intramucosal pH of the gut. Mucosal acidosis
correlates well with the onset of anaerobic metabolism in
response to sepsis or hypoxia 23 Casado-Flores and colleagues 24 report that low gastric pH «7.30) was associated
with an increased risk of mortality in PICU patients;
however, no relationship was found between gastric pH and
the development of MODS.

Fluid Shifts
Some category-specific hemodynamic changes and responses to shock also occur. Hypovolemic shock is characterized by low circulating blood volume and decreased
preload. Compensatory, generalized vasoconstriction takes
place, decreasing venous capacity and translocating venous
blood to the central circulation, thereby increasing preload.
A rise in blood pressure and cardiac output may follow.
The renin-angiotensin-aldosterone system (RAAS) and
antidiuretic hormone (ADH) also help restore intravascular
volume within minutes after hemorrhage or trauma. Renal
vasoconstriction and hypoperfusion activate the RAAS with
increased production and secretion of renin. Increased
plasma renin acti vity stimulates the release of angiotensin I.
Angiotensin I is converted to angiotensin II by the
angiotensin-converting enzyme (ACE) in the va~cular
epithelium of the lungs and in other tissues, including the
heart, adrenals, kidneys, and brain. Angiotensin II is a potent
vasoconstrictor that also stimulates the production of
aldosterone by the adrenal gland, increasing sodium and
water reabsorption in the renal tubules. Stimulated by an
increase in serum osmolality, vasopressin (ADH) secretion
from the posterior pituitary gland results in peripheral

vasoconstriction and increased reabsorption of water from
the renal tubules and collecting ducts. Stress precipitates the
release of adrenocorticotropic hormone (ACTH) from the
anterior pituitary, which then stimulates the adrenal glands
to release cortisol. Cortisol sensitizes arteriolar smooth
muscle to the effects of catecholamines.
In contrast to the low ventricular filling pressures seen
in patients with hypovolemic shock, the ventricular filling pressures in those with cardiogenic shock are high.
This is a consequence of both myocardial dysfunction and
loss of ventricular diastolic compliance and the additional
venous return brought about by the compensatory venous
constriction.

Mediator Release
A myriad of mediators is triggered in all shock states and
during their associated resuscitative interventions. The
release of mediators comes from not only the body's normal
protective host response but also endothelial damage and
ischemia or reperfusion injury. The endothelium, an active
metabolic organ, is subject to damage in shock, as well as by
other factors such as mechanical disruption, hypoxemia,
acidosis, and microorganisms?S When damaged, the endothelium is unable to perform its normal functions, that is,
anticoagulation and vasoregulation. Normally integral to
maintaining the fluidity of blood, damaged endothelium
displays procoagulant activity leading to thrombin formation and fibrin deposition. Vasoregulatory properties of the
endothelium, through nitric oxide production (among others), are also influenced. Damaged endothelium results in
widespread capillary permeability and massi ve fluid loss to
tissues and organs. The result of both endothelial malfunctions is further obstruction of blood flow and ischemia,
especially in the microvasculature.
Arachidonic acid, a normal constituent of all cell
membranes (except red blood cells), is released in a variety
of circumstances. Cytokines, catecholamines, neuroendocrine responses, tissue injury, hypoxia, or endotoxin can
liberate arachidonic acid from cell membranes 26 Arachidonic acid is metabolized through two major pathways: the
cyclooxygenase and lipoxygenase pathways. Metabolism of
arachidonic acid through the cyclooxygenase pathway
results in the formation of the cytokines thromboxane A2 ,
prostacyclin, and prostaglandins ~ and D2 . Thromboxane
produces pulmonary and systemic vasoconstriction and
enhances platelet aggregation. Prostacyclin decreases SVR
and PVR, increases vascular permeability, and inhibits
platelet aggregation. Prostaglandins decrease SVR, inhibit
platelet aggregation, increase vascular permeability, activate
production of cyclic adenosine monophosphate (cAMP),
and increase gastrointestinal smooth muscle contraction.
The metabolism of arachidonic acid through the Iipoxygenase pathway results in the formation of leukotrienes that
stimulate neutrophil and eosinophil chemotaxis and lysosomal release. The leukotrienes also increase SVR, produce
smooth muscle contraction, and increase vascular permeability. In total, arachidonic acid metabolism increases
capillary permeability, platelet dysfunction, maldistribution
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Fig.27-5 Toxic oxygen metabolite (TOM) formation in ischemia and reperfusion injury. TOMs produced
during reperfusion injury attract and activate white blood cells (WBCs), which can produce more TOMs
and other inflammatory mediators such as proteases. (From Huddleston VB, ed: Multiple organ failure;
a pathophysiological approach, Boston, 1991.)

of blood flow, and organ ischemia; causes pulmonary edema
and intrapulmonary shunting; and thus contributes significantly to MODS associated with shock. The kidney,
gastrointestinal tract, Ii ver, Iungs, and brain are at particular
risk. Dysfunction of any of these organs may preclude
successful treatment of shock.
Mediator release from ischemia or reperfusion injury
represents a shift in the traditional view that the pathophysiologic state of shock is a result of ischemic cellular damage.
New research reveals that tissue injury following shock is
not solely due to hypoxia but due to reperfusion and
subsequent inflammation. 27 Toxic oxygen metabolites and
neutrophils primarily mediate ischemia or reperfusion
injury. Tissue enzymes and substances undergo "transformations" during ischemia. When blood and oxygen in these
tissues are restored, molecular oxygen (02) reacts with these
"transformed" tissue enzymes and substances to produce
superoxide radicals 25 (Fig. 27-5). Reperfused tissues release
free radicals, lactic acid, potassium, and other substances
that are toxic to endothelium and the tissues and potentiate
the damage already experienced in the initial ischemic state.
Numerous mediators released are unique to septic shock.
The influential mediators of gram-negative septic shock
include endotoxin, tumor necrosis factor, and interleukin1.1 7 Endotoxin is one of the most powerful triggers of the
inflammatory immune response. A component of the gramnegative bacteria cell wall, this lipopolysaccharide is shed
when the bacteria multiplies or dies. Most prominent of

endotoxin's effects is the simultaneous stimulation of the
complement and coagulation cascades. UnremiUing activation of the complement cascade with associated histamine
activation contributes to common clinical findings of septic
shock. Continued activation of the complement cascade
results in increased capillary penneability, vasodilation, and
lysosome release. Histamine, derived from mast cells in
damaged tissues and from basophils in the blood, decreases
SVR, increases vascular permeability, and augments gastrointestinal motility.
Activation of the coagulation cascade occurs when both
the complement system and the inflammatory immune
response are triggered. The Hageman factor (factor XlI) has
a pivotal role in the interdependency between the coagulation cascade and the inflanmlatory immune response, as well
as other plasma enzyme cascades, such as kallikrein and
kinin. Activation of the coagulation and fibrinolytic systems
contributes to the high incidence of clotting abnormalities
and increases the incidence of vascular obstruction, tissue
ischemia, and organ dysfunction. The Hageman factor also
stimulates the production of bradykinin, a potent vasoactive
peptide found in plasma or tissue fluid. Bradykinin causes
venodilation, increased vascular permeability, bronchoconstriction, and constriction of gastrointestinal smooth muscle.
Tumor necrosis factor (TNF; cachectin), a cytokine
released from macrophages, leukocytes, and other immune
cells, is thought to be the major mediator of sepsis and
MODS. 5 .27 TNF enhances the inflammatory immune re-
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sponse, including fever, tachypnea, tachycardia, increased
vascular permeability, metabolic acidosis, and altered blood
distribution to organs, such as the gut and kidney.2 8 TNF
also stimulates the release of interleukin-l (IL-l), arachidonic acid metabolism, and the production of plateletactivating factor (pAF). In the presence ofTNF, complement
and clotting cascades are activated. 29 The net result is
sequestration of platelets, vasodilation, increased capillary
permeability, and microvascular constriction.
IL-I is a cytokine that is released by monocytes and
macrophages and works synergistically with TNF to perpetuate the inflammatory immune response and to release PAF.
The predominant effects of PAF produce vasodilation, activate platelet aggregation, and increase tissue permeability.
Patients in septic shock typically exhibit reduced left
ventricular ejection fraction and left ventricular diiation 30
In addition to adrenergic receptor dysfunction and impaired
myocardial intracellular calcium flux, myocardial dysfunction occurs secondary to the negative inotropic effects of
numerous chemical mediators, including myocardial depressant factors, endotoxin, TNF, complement products, and
leukotrienes. Myocardial depressant factors are hemodynamic inhibitory peptides released secondary to ischemia to
the splanchnic region. As in other organs, eventually
myocardial perfusion and oxygen consumption are disrupted in septic shock.

CLINICAL ASSESSMENT: RED FLAGS
OF CARDIOVASCULAR COLLAPSE
Shock is a dynamic process that requires vigilant assessment
and continuous patient monitoring and reevaluation. Clinicalor physical assessment findings reflect the consequences
of ineffective tissue perfusion. Early recognition of patients
both at risk and with the earliest indications of shock ensures
the best outcomes.
Unexplained and persistent tachycardia, that is, tachycardia not related to fever, anemia, pain, or agitation, is a
common but nonspecific finding in shock. Increased heart
rate is an attempt to compensate for inadequate stroke
volume. In addition, dysrhythmias, which impair cardiac
function, are not uncommon in pediatric patients with
electrolyte imbalance, metabolic acidosis, and hypoxemia.
All of these symptoms can occur in all shock states.
Unexplained persistent tachypnea, that is, tachypnea not
related to fever, anemia, pain, or agitation, is also a valuable
and early sign of shock. The evolving metabolic acidosis
associated with shock is compensated by an increase in
alveolar ventilation. Decreased CNS pH is a potent stimulus
to chemoreceptors located in the medulla to increase minute
ventilation. The rise in minute ventilation, through an
increase in respiratory rate, results in respiratory alkalosis in
the early stages of shock. When respiratory alkalosis is
present, the seriousness of a patient's condition may be
underestimated.

Low-Flow Shock
The red flags of low-flow shock are the signs of increased
SVR and decreased cardiac OUlPUt. To maintain blood

pressure in low-flow states, SVR increases, as blood
pressure (BP) is the product of cardiac output (CO) and SVR
(BP = CO x SVR). Because of a higher sympathetic tone
and an ability to maintain vasoconstriction for a long time,
children exhibit a remarkable ability to maintain blood
pressure in low-flow shock states. Peripheral vasoconstriction and an increase in SVR is an attempt to compensate for
the decrease in cardiac output. 31 Symptoms of increased
SVR can be assessed in three major organ systems: the skin,
kidneys, and brain.
Impairment of peripheral circulation is assessed by
examination of capillary refill, skin color and temperature,
and peripheral pulses. Normally, a child's extremities are
warm and pink with brisk capillary refill «2 seconds). The
child in low-flow shock, however, has poor peripheral
perfusion illustrated by the hallmark signs of low cardiac
output-delayed capillary refill (>2 seconds), cool extremities, and diminished peripheral pulses.3 2 To accurately
assess capillary refill from the arterial side of the circulation,
the extremity should be slightly elevated above heart level.
Although capillary refill is widely used, recent studies 33 ,34
have questioned its value.
Skin color changes may progress from pink, to pale, to
mottled, and then to a marbleized appearance. Pale skin may
be noted when the hemoglobin and hematocrit levels are
decreased. A core-to-skin temperature gradient greater than
2° C is considered significant. The temperature gradient
widens with progressive decreases in peripheral perfusion 35 Proximal-to-distal skin temperature gradients-that
is, changes in the position of the demarcation line between
warmth and coolness-can be trended as well.
In low-flow shock, peripheral pulses are difficult to
palpate. Weak pulses result from the narrow pulse pressure
characteristic of a diminished stroke volume and increased
SVR. The narrow pulse pressure occurs before systolic
pressures fall. Stroke volume and SVR determine systolic
blood pressure, whereas SVR reflects diastolic blood
pressure. When cardiac output falls, SVR increases to
maintain the blood pressure. The increased SVR increases
the diastolic component of the blood pressure and maintai ns
the systolic component. Because pulse pressure is a
sensitive indicator of stroke volume, it is an important
parameter to monitor.
Urine output, a reflection of kidney perfusion, is an
important assessment parameter in infants and children
experiencing shock. Particularly in hypovolemic patients,
urine output may decrease long before other signs of
ineffective tissue perfusion are evident. Renal blood flow is
dependent on cardiac output. Sudden decreases in renal
blood flow or pressure decrease the glomerular filtration rate
and result in decreased urine output and increased urine
specific gravity. Low urine output is defined as less than
0.5 to 1 mIIkg/hr in infants and children and less than 1 to
2 ml/kg/hr in newborns.
Signs and symptoms of inadequate cerebral perfusion are
often subtle in the early stages of shock. Level of consciousness is assessed developmentally. Infants frequently exhibit
a weak cry or poor suck. Infants normally do not tolerate
missed feedings or wet or soiled diapers, especially if they
have a diaper rash. Toddlers normally do not tolerate their
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parents' absence in a foreign environment for any period.
The child's sensorium may be clouded; response to stimuli
may be limited; and anxious, irritable, or lethargic behavior
may be present. As shock progresses, somnolence advances
to obtundation and is an ominous sign.
Unique to hypovolemic shock, physical signs may vary
between hypovolemic shock caused by dehydration, resulting in both intravascular and interstitial hypovolemia, and
hypovolemic shock caused by hemorrhage, resulting in
intravascular hypovolemia and interstitial euvolemia or
even hypervolemia] I Children with dehydration display
classic signs of interstitial hypovolemia. A sunken anterior
fontanelle, sunken eyes, dry mucous membranes, poor skin
turgor, decreased capillary refill, cool extremities, and
mental status changes are exhibited. The degree to which
these signs are evident depends on the degree of dehydration
(see Table 11-8).
The condition of a patient in cardiogenic low-flow shock
contrasts sharply to the patient with hypovolemic low-flow
shock in that intravascular volume is adequate or even
increased. In cardiogenic shock secondary to congestive
heart failure, the patient often appears "wet" and may have
a gallop rhythm. For example, diaphoresis, periorbital/sacral
or dependent edema, hepatomegaly, jugular venous distension, and rales with increased work of breathing are present.
In cardiogenic shock secondary to an outflow obstruction,
the patient may exhibit a low-voltage electrocardiogram
(ECG) and electromechanical dissociation (EMD). If cardiac tamponade is present, a significant pulsus paradox us,
greater than 10 mmHg, may be present.
Late signs and symptoms of low-flow shock include
progressive neurologic deterioration, hypotension, and bradycardia. The presence of even mild hypotension denotes
decompensated shock; therefore an observed fall of 10
mrnHg in systolic blood pressure should prompt aggressive
intervention. 12 The lower limit (5th percentile) of normal
systolic blood pressure can be estimated with the following
formula: 70 mmHg + (2 x age in years).12

Maldistributive Shock
The red flags of maldistributive shock are the signs of decreased SVR and increased cardiac output. To maintain
blood pressure in low SVR states, cardiac output must increase. Cardiac output is unevenly distributed, with some
tissues effectively and some tissues ineffectively perfused. Low SVR results in increased skin blood flow, resulting in septic shock patients having warm and dry skin.
Patients experiencing septic shock often appear flushed and
well perfused, with normal or brisk capillary refill despite
the ominous nature of their illness. They are often febrile
(>38° C) but may be hypothermic «36° C). Because neutrophil activation produces many of the early signs of infection and the inflammatory response, septic patients who
are neutropenic may not present symptoms in the typical
fashion.
In patients with high cardiac output, pulses are easily
palpated. Bounding pulses, a rare finding in a pediatric
physical examination, reflect a widened pulse pressure
occurring secondary to an increased stroke volume and
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decreased SYR. Urine output may initially be normal or
increased, despite a relative hypovolemia. Subtle changes in
mental status (e.g., confusion) may be present.
Late symptoms include those present in low-flow shock
states, as well as evidence of MODS. The patient manifests
signs and symptoms of low cardiac output. A narrowed
pulse pressure is present and correlates with reduced stroke
volume; progressive hypotension accompanies decreased
cardiac output. Clot and interstitial edema obstruct blood
flow through the periphery. Tissue acidosis causes arterioles
to dilate and venules to constrict, causing further pooling
and stasis of blood. Marked capillary leak and interstitial
and pulmonary edema are present. See Table 27-3 for phases
and clinical manifestations of septic shock.

Hemodynamic and Oxygenation Profiles
Table 27-4 provides a summary of the numerous hemodynamic and oxygenation profile changes associated with
low-flow and maldistributive shock states. Currently, a lack
of pediatric research is available to help guide collaborative
practice. Normal values are not necessarily optimal values
in shock. I?
Heart rate increases in all shock states. Mean arterial
pressure remains normal when compensatory mechanisms are effective but falls when compensatory mechanisms fail. Right atrial pressures (RAPs) and pulmonary
artery wedge pressures (PAWP) reflect right and left
ventricular preload, respectively. Both are decreased in
hypovolemic shock, because circulating blood volume is
inadequate. As ventricular function deteriorates in cardiogenic shock, RAP and PAWP increase. RAP and PAWP are
initially decreased in early septic shock as vasodilation leads
to venous pooling and decreased venous return. Both RAP
and PAWP increase in late septic shock, reflecting myocardial failure.
Pulmonary vascular resistance index (PYRI), reflecting
right ventricular afterload, is high in all shock states. In
septic shock, many factors, including pulmonary vasoconstriction, microembolic occlusion, and lung injury, necessitate the use of high positive end-expiratory pressure (PEEP).
All these factors increase PYRI and may contribute to right
ventricular dysfunction, placing the requisite hyperdynamic
state at risk. Systemic vascular resistance index (SVRI),
reflecting left ventricular afterload, increases to maintain
blood pressure in low-flow shock. SVRI remains low in
septic shock.
The cardiac index (CI) is decreased in low-flow states, is
high in early septic shock, but falls in late septic shock. Skin
temperature is directly proportional to cardiac output and
inversely proportional to SVRI. Even though cardiac output
is increased in septic shock, the left ventricular ejection
fraction (LYEF) is significantly decreased. The increased
cardiac output in septic shock is secondary to an increase in
heart rate and ventricular dilation, not an increase in
contractility. Overall myocardial performance is often
compromised by diffuse myocardial edema, circulating
myocardial depressant factor from splenic hypoperfusion,
adrenergic receptor dysfunction, and impaired sarcolemma
calcium flux. 5

TABLE

27-3

Phases and CliniCal Manifestations of Septic Shock
Sepsis

Hyperdynamic Septic Shock·

Hypodynamic Septic Shockt

Change in activity
Change in feeding
Change in response

Clouded sensorium
Irritability
Disorientation
Lethargy
Sinus tachycardia
Bounding pulses
Warnl, dry. flushed skin
Widened pulse pressure
± Diminished perfusion
± Mottled extremities
i J, Capillary refill
Generalized edema
Relative hypovolemia
Progressive hypotension
Tachypnea
Progressive hypoxemia
Fever or hypothermia
Hyperglycemia or hypoglycemia
Progressive metabolic acidosis
Leukocytosis/leukopenia
i Immature neutrophils (bands)
J, Urine output

Disorientation
Lethargy
Obtundation

Sinus tachycardia
Bounding pulses

Tachypnea
Fever or hypothermia
Respiratory alkalosis
Leukocytosislleukopenia
i Immature neutrophils (bands)

Sinus tachycardia
Weak. thready pulse
Dysrhythmias
Narrowed pulse pressure
Diminished perfusion
Mottled extremities J,
J, Capillary refill
Generalized edema
Hypotension
Pulmonary edema
Fever or hypothermia
Hyperglycemia or hypoglycemia
Severe metabolic acidosis
Leukocytosis/leukopenia

J, Urine output

. ala from Carcillo lA: Management of pediatric septic shock. [n Holbrook PR, ed: Textbook ofpediatric critical core, Philadelphia. 1993. WB Saunders,
[14-142; Robbins EV: Maldistribution of circulating blood volume. In Huddleston VB, ed: Maltisystem organ failllre: pathophysiolofiY and clinical
~·.plications, St Louis, 1992, Mosby, pp 85-108; Rosenthal-Dichter C: Septic shock. In Slota. MC. ed: Core curriculum for pediatric critical core nursing.
. l]'hiladelphia. 1998. WB Saunders. p 638.
~.',Hyperdynamic septic shock is characterized by increased cardiovascular findings and seemingly 'good' perfusion, the body's demands are still not
,'I<!equately met
~~Hypodynarnic septic shock may be accompanied by signs and symptoms of deteriorating organ dysfunction(s).

I

q

TABLE

27-4

Hemodynamic and Oxygenation Profile Changes in Shock
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Fig. 27-6 Abnormal V02 in sepsis. Sepsis may result in a hyperutilization slate (B) with increased V02 and inlact oxygen extraction ratio (OER) or in (e) a pathologic supply-dependence state
in which OER is nonexistent. *Critical 00 2 range; A, normal
Vo/Do 2 curve; B, elevated critical 00 2 range; C. supplydependent Vo2 . (Adapted from Carcillo JA: Management of pediatric septic shock. In Holbrook PR, ed: Textbook of pediatric critical care, Philadelphia, 1993, WB Saunders, p 130.)

Considering that shock represents an imbalance of
oxygen supply and demand, oxygenation profile monitoring
provides data necessary for informed individualized titration
of therapy. Oxygen delivery (D02) and oxygen extraction
ratio (OER) balance to maintain tissue oxygen consumption
(V02) over a very wide range (Fig. 27-6). When D0 2
decreases in low-flow states, OER increases to maintain
VOz' This continues until a critical D0 2 range is reached,
after which VOz depends on D02. This is referred to as
supply-dependent V0 2. Patients in septic shock require
higher D0 2 to maintain adequate tissue perfusion and to
avoid anaerobic metabolism'" Associated with poor outcome, a pathologic supply-dependent V02 may exist in
patients with septic shock. In this state, V0 2 is abnormally
supply dependent at normal or supernormal Do z rates. 36
Late in septic shock, there may be an uncoupling of the Do zV02 relationship.
Supply-independent V0 2 occurs secondary to an
endotoxin-induced impairment of oxidative metabolism, a
redistribution of blood flow away from the microcirculation,
and a severe impairment of mitochondrial oxygen use.
Although controversial, there may be no benefit to
increasing D0 2 beyond the point of V0 2 plateau. IS
Continuous mixed venous oxygen saturation monitoring
(Sv02) provides valuable on-line information about tissue
perfusion. In low-flow shock, the Sv0 2 is low, reflecting
decreased cardiac output and an increased OER. In septic
shock, the Svo z reflects the adequacy of the cardiac output
to maintain the hyperdynamic state and tissue extraction of
oxygen.
Like Sv02, the arteriovenous difference in oxygen
(a-v00 2) gradient is inversely related to cardiac output. The
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a-v002 gradient increases in low-flow states because tissues
extract more oxygen. In late septic shock, decreased D0 2
and a narrow a-vD0 2 are ominous signs.
Pollack, Fields, and Ruttimann l6 identified several pediatric predictors of outcome from septic shock. Survivors of
septic shock were able to maintain a normal or hyperdynamic state, that is, increased CI (3.3 to 6 LlminfM z), higher
V02 (>200 ml/minIM 2 ), and higher OER (>28%), and did
not experience significant pulmonary disease. On the other
hand, non survivors demonstrated low CI «3.3 L/minfM 2 )
and low and poor O 2 use «Vo z, <a-vD02, and lower OER),
had lower temperatures «37° C), and experienced pulmonary disease. In adult survivors of septic shock, the
characteristic hyperdynamic state (increased heart rate and
cardiac output with decreased SVR) begins to resolve within
24 hours. Nonsurvivors develop unresponsive hypotension
and progressive MODS?7 Pediatric patients who are fluid
resuscitated, unlike their adult counterparts, more commonly experience low cardiac output (vs. low SVR).16-18 In
addition, oxygen delivery (vs. oxygen extraction) appears to
be the major determinant of oxygen consumption. 38 Implications for management of septic shock include supporting
factors associated with positive outcomes and eliminating
factors associated with negative outcomes.
Interpreting and predicting hemodynamic and oxygenation profile changes in any shock state are done cautiously.
Changes may be due to the disease process, interventional
strategy (e.g., inadequate fluid resuscitation, catecholamine
selection), or the impact of the two on system maturation.
Patients may exhibit one hemodynamic picture and may
progress to another. For instance, children with persistent
shock often progress to worsening cardiac failure but may
resolve their shock state, requiring an alteration in hemodynamic support. IS More clinical research is definitely
needed in this area.

COLLABORATIVE MANAGEMENT
Patient management requires an appreciation of the overall treatment perspective38a.39; that is, essential treatment
includes both definitive treatment and supportive treatment. Definitive treatment is directed toward resolution of
the primary problem, whereas supportive treatment is
directed toward achieving an optimal physiologic, oxygenation, and hemodynamic state. Optimal states may not
reflect "normal" values but values that meet the dynamic
individual needs of the patient. The primary focus of
therapy is on improving tissue perfusion and oxygenation. Objective criteria may include supporting supplyindependent V02 and a normal OER while preventing
metabolic acidosis.
An integral component of the management of patients
experiencing shock is monitoring. Continuous patient assessment and noninvasive and invasive monitoring are
essential to adequately manage patients in shock. Changes
in the patient's physiologic status occur rapidly, and
mechanisms to quickly evaluate the effectiveness of therapy
are invaluable. Vigilant and repeated assessments of the
same clinical parameters facilitate trending and allow
optimal titration of therapies. Titration of pharmacologic
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agents to collaboratively detennined clinical and hemodynamic end points is necessary.
Alterations in tissue perfusion may affect the accuracy of
several of the standard noninvasive monitoring modalities
available in the PICD, that is, end-tidal COz (ETco 2 ) and
pulse oximetry monitors. For example, the ETco 2 reading
may not correlate with the Paco 2 ; however, ETco z reflects
pulmonary capillary blood flow. Alterations in pulmonary
perfusion associated with shock and the effectiveness of
therapy can be evaluated by assessment and trending of the
ETco z-Paco2 gradient. Pulse oximetry depends on a reliable
pulse, which may not be present in low-flow shock states.
To provide and titrate optimal therapy in maldistributi ve
shock states, hemodynamic and oxygenation variables
require quantification. The RAP nonnally quantifies right
ventricular preload, the equivalent of circulating blood
volume. Because ventricular compliance affects atrial pressure, an abnonnal relationship between ventricular preload
and work is seen. Pulmonary artery (PA) catheters are
necessary to evaluate left ventricular filling pressures and
cardiac output and provide a route to obtain true mixed
venous blood samples or provide continuous Svo z monitoring. Strategies to enhance successful PA catheter insertion
during low cardiac output states include stiffening the 5 Fr
PA catheter with iced saline through the PA port and
planning PA catheter insertion after a fluid bolus.
Sequential echocardiograms are also helpful in monitoring cardiac function. Echocardiography quantifies ventricular ejection fraction (nonnal 65%), quantifies the disparity
between right and left ventricular function, and detennines
whether pericardial effusions are present.

Supportive Treatment
When prioritizing the care of the critically ill patient in
shock, the ABCs of resuscitation are the supportive component of essential treatment. Immediate therapy includes
assessing for and establishing a patent airway, maintaining
oxygenation and ventilation, and improving perfusion while
the underlying cause of shock is detennined. Although
children usually have an adequate airway, as many as 80%
of children with septic shock may eventually require
mechanical ventiiation 40 Once elective endotracheal intubation and assisted ventilation are initiated, additional
interventions can be directed at circulatory support.
Establishing and maintaining vascular access is a priority
in treating shock. If venous access is not present, a protocol
for the establishment of venous access is recommended. 12
The preferred location of vascular access is the largest vein
that may be rapidly accessed without interrupting emergent
management. Although multilumen central lines are preferred because they allow simultaneous monitoring of
central venous pressure and a direct access to the central
circulation while minimizing the risk of tissue extravasation
with administration of vasoactive and caustic medications,
peripheral access can be initially used if already in place.
Previous adult and animal research has suggested a benefit of supradiaphragmatic access versus infradiaphragmatic
access. 41 The limited research involving young animals has

not shown the preference for supradiaphragmatic locations.
In fact, Gaddis and colleagues 42 report that a fluid bolus of
at least 5 ml effectively increases the delivery of peripherally injected medications into the central circulation. Besides intravenous routes of drug administration, the intraosseous (10) route is effecti ve for rapid fluid and drug delivery
and should be considered for children younger than 6 years
of age.

Definitive Treatment
Identification and treatment ofthe patient's primary problem
are of critical importance. These interventions constitute the
definitive component of essential treatment. For example,
controlling hemorrhage, cardioverting the tachydysrhythmia, or providing appropriate broad-spectrum antibiotic
coverage as soon as possible if sepsis is suspected or
documented is considered definitive treatment. Other definitive interventions in sepsis include locating, excising,
draining, and removing the focus of the infection, that is,
draining an abscess or replacing the central line.

Enhance Substrate Delivery
The therapeutic goal in any shock state is to enhance
substrate delivery (D0 2 ) to the tissues. This is of heightened
importance given that research shows that oxygen delivery,
rather than oxygen extraction, is the major detenninant of
oxygen consumption is pediatric patients. 38 This goal is
accomplished by maximizing cardiovascular perfonnance
and optimizing arterial oxygen content (Ca02 ). The major
emphasis is to improve tissue perfusion.
Maximize Cardiovascular Performance
Optimize Preload. Rapid intravascular volume expansion is guided by clinical parameters (noting end-organ
perfusion, including urine output) and hemodynamic parameters (most prominently central venous pressure [CVP]
monitoring). Early and aggressive correction of intravascular volume deficit is necessary to increase cardiac output and
to reestablish microcirculatory flow. Maintenance of the
hyperdynamic septic state and improvement of oxygen
consumption are critically dependent on vigorous fluid
administration. 40 Improvement in perfusion pressure and
oxygen delivery and consumption indicates successful fluid
resuscitation.
Fluid selection for optimizing preload is detennined by
the source of the fluid loss and the child's clinical condition.
As a general rule, isotonic crystalloids or colloids are
initially administered. Table 27-5 reviews the different
recommendations for fluid selection based on the cause of
the loss of fluid.
A long-standing controversy exists regarding the most
suitable fluid for shock resuscitation---crystalloids versus
colloids. Both have inherent advantages and disadvantages.
Crystalloid solutions (0.9% sodium chloride or lactated
Ringer's solution) are readily available and cost effective,
but approximately only one fourth of the volume infused
remains in the intravascular space. This necessitates the
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Recommended Therapies for Hypovolemic Shock by Etiology
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20 mVkg of 0.9% sodium chloride bolus.
Reassess for continuing signs of end-organ hypoperfusion (increased heart rate, decreased capillary refill,
depressed mental status, decreased urine output).
Repeat 20 ml/kg boluses until signs of shock abate.
If signs of end-organ hypoperfusion: follow recommendations as for dehydration.
If no signs of end-organ hypoperfusion: 20 mVkg of 0.9% sodium chloride nver 2 hours, followed by
more specific electrolyte-containing fluid.
If signs of end-organ hypoperfusion: follow recommendations as for dehydration.
If no signs of end-organ hypoperfusion: Parkland formula (begin with D5LR): total fluids (first 24
hours) = maintenance + (4 mVkg x %BSA bum) + other losses.
Administer '/2 of the fluids in the first 8 hours and the rest in the next 16 hours.
Reassess every 6-8 hours.
40-60 ml/kg of 0.9% sodium chloride bolus.
Reassess for continuing signs of end-organ hypoperfusion (increased heart rate, decreased capillary refill,
depressed mental status, decreased urine output).
May require 80-100 mVkg of fluid to stabilize.
20 mVkg of whole blood or components bolus.
Reassess for signs of anemia or continued bleeding and monitor hematocrit.

In"

l!J!!from Thomas NJ, Carcillo JA: Hypovolemic shock in pediatric patients, New Horiz 6: 126, 1998.
~~. cases of fluid-refractory shock:

~_May have ongoing fluid losses (sIool loss, urine output) greater than resuscitation fluids administered.

I!;.,May require addition of inotropic support.
L~May

require exogenous steroid therapy if history of chronic steroid use or purpura fulminans.
!(;~ay have unrecognized ongoing blood loss.
~SA, Body surface area; D5LR. 5% dextrose lactaled Ringer's solution.

administration of large quantities of crystalloid solution to
restore intravascular volume (potentially 4 to 5 times the
deficit). Note that the use of lactated solutions in patients
with impaired liver function is not recommended because it
increases blood lactate concentrations and renal loss of
sodium and potassium. 13
Colloids (albumin; synthetic plasma substitutes, such as
hetastarch and dextran; whole blood; packed cells; and fresh
frozen plasma [FFP]) contain relatively large molecules that
are impermeable to capillary membranes and therefore are
more likely to remain in the intravascular space. However,
these solutions are more expensive and may cause sensitivity reactions. Colloids are important for maintaining plasma
osmotic pressure and minimizing interstitial edema. In
treating shock, the ideal solution would expand the intravascular space but limit interstitial accumulation. Prevention of interstitial pulmonary edema is critically important to
prevent alterations in gas exchange.
With that being said, Schierhout and Roberts43 recently
conducted a meta-analysis of randomized clinical trials of
volume replacement with colloids compared with crystalloids in critically ill adults. Twenty-six studies (1622
patients) were included. Resuscitation with colloid solutions
was associated with a 4% increase in the absolute risk of
mortality (4 extra deaths for every 100 patients resuscitated). Because colloids are considerable more expensive
and are associated with a higher mortality in adults, their
continued use for volume replacement is not supported.
Blood is administered as soon as possible to replace

whole blood loss or to correct anemia. However, careful
attention to large-volume and rapid administration of blood
products is imperative because the patient is at risk for
hypothermia and poor metabolism of citrate, potentially
leading to ionized hypocalcemia, Both of these factors may
result in significant myocardial dysfunction. Autotransfusion devices, for example, cell-saving devices, scavenge
then return blood lost during spinal fusion and intrathoracic
surgical cases (when no enteric contamination has occurred). Albumin is commonly used if the hematocrit is
adequate. FFP and platelets are administered if clotting
abnormalities or thrombocytopenia exists. Synthetic plasma
substitutes (dextran and hetastarch) are relatively inexpensi ve but cause diminished platelet function.
Equally important as the type of fluid is the amount of
fluid administered. The most common error made in fluid
resuscitation is the inadequate or delayed volume administration. 31 The amount and rate of infusion depend on the
child's condition; 20 ml/kg of an isotonic crystalloid infused
over several minutes is a reasonable starting point. Repeated
boluses of the same amount are infused if no improvement
is seen in the child's clinical and hemodynamic parameters,
for example, improved perfusion, increased urine output,
decreased acidosis, and increased mean arterial pressure.
Fluids should be given with the goal of attaining normal
perfusion and blood pressure, recognizing that the average
fluid requirement in the first hour for septic shock patient is
60 mllkg but may be as high as 200 mllkg. 15 Carcillo, Davis,
and Zaritsky40 reported that aggressive fluid administration
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in excess of 40 ml/kg in the first hour after presentation to
the emergency department is associated with improved
survival, decreased occurrence of persistent hypovolemia,
and no increase in the risk of cardiogenic pulmonary edema
or ARDS in pediatric patients in septic shock. The researchers did not control for type of fluid used, crystalloids were
used preferentially, and colloids were used if the blood
pressure was unresponsive to crystalloids. Blood products
were also used if coagulation was a problem.
If patients with nonhemorrhagic hypovolemic shock fail
to respond to the initial 60 ml/kg of crystalloid fluid, they
are said to have fluid refractory shock. This subset of
patients may require a combination of large amounts of fluid
resuscitation, as well as catecholamine sUpport. 31 In addition, other possible complicating factors inel ude pneumothorax, pericardial effusion, ongoing intraabdominal fluid
loss (e.g., from volvulus, intussusception), gastrointestinal
ischemia, brainstem dysfunction, adrenocortical insufficiency, and pulmonary hypertensive crisis.
When managing children with cardiogenic or septic
shock, efforts to improve cardiac output and tissue perfusion
by volume augmentation are carefully monitored. The
volume of fluid that can be safely administered is contingent
on ventricular compliance. Monitoring of ventricular enddiastolic pressure (i.e., CVP or PAWP) permits early
detection of cardiac decompensation and provides an
important guide for fluid replacement. The vascular congestion associated with cardiogenic shock may be improved by
concurrent administration of albumin with diuretics (furosemide [LasixJ).
Perkin and Levin43a described a helpful method of
evaluating the effectiveness of volume replacement. Fluid is
administered until the patient's hemodynamic status is
corrected or the CVP exceeds the preinfusion value by
2 mrnHg or the PCWP within 3 mmHg. A CVP greater than
7 to 10 mmHg indicates myocardial dysfunction, excessive
right ventricular afterload, or volume overload. The authors
note that the absolute limitation to fluid administration is
persistent increase in ventricular filling pressure without
improvement in cardiac output.
Research indicates that outcome may be influenced when
aggressive fluid resuscitation (60 ml/kg in the first hour) is
coupled with goal-directed therapies. Ceneviva and colleagues44 examined 50 children with flUid-refractory (60
mllkg in the first hour) dopamine-resistant shock. After fluid
resuscitation, inotropes, vasopressors, and vasodilators were
administered to target and maintain normal CI and SVR. An
18% mortality was reported as compared with other studies
with a reported 58% mortality that used goal-directed
therapies without aggressive fluid resuscitation. 17
Emergency autotransfusion to maintain an adequate
perfusion pressure is enhanced by elevating the patient's
limbs or by gentle compression on the liver. The Trendelenburg position is used cautiously, especially when cerebral
perfusion pressures are questionable.
Optimize Contractility. Before, or concurrent with,
the administration of positive inotropic medications, negative inotropic states-for example, hypoxia, acidosis, hypoglycemia, hypokalemia, and hypocalcemia-must be rectified (Fig. 27-7). Acidosis depresses myocardial function and
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Fig. 27-7 Starling's law. Stroke volume and cardiac output are
increased in the hypovolemic, acidotic child (point A) by
increasing preload through volume infusion (point B), by restoring
ventricular function curve to a more normal one (point C), and by
correcting acidosis and metabolic abnonnalities. Myocardial function curve (and cardiac output) can potentially be shifted to a
supranormal value (point 0) with infusion of a positive inotropic
agent. (Modified from Crone RK: Acute circulatory failure in
children. Pediatr Clin North Am 27:525-537. 1980.)

renders sympathomimetic drugs ineffective. Poor outcomes
have been associated with a base deficit greater than 10
mEqlL in patients with cardiogenic or septic shock. Base
deficits greater than a negative 6 require correction. The
primary correction for metabolic acidosis secondary to
cardiovascular collapse is restoration of tissue perfusion.
With adequate tissue perfusion and oxygenation, metabolic
acidosis will self-correct. When the arterial pH is less than
7.20 and adequate ventilation has been established (i.e.,
Pac02 in the normal range for the patient), correction with
NaHC0 3 is indicated. The dose is calculated from the base
deficit (mEq NaHC0 3 = 0.3 [weight in kg] x base deficit).
The calculated dose usually approximates I to 2 mEq/kg. If
the serum sodium is greater than 150, tris-hydroxymethylamino-methane (THAM), a non-C0 2 -generating buffer, can
be used with cautious evaluation of hypoglycemia and
hyperkalemia.
Electrolyte shifts will occur when correcting metabolic
acidosis. As the pH increases, ionized calcium levels fall,
and potassium shifts into the intracellular space, decreasing
the serum potassium level. Calcium replacement may be
necessary to correct hypocalcemia (ionized calcium level
less than 1.3 mg/dl), occurring frequently in circulatory
failure, especially after administration of large amounts of
albumin, whole blood, or FFP.
After vigorous fluid resuscitation, pharmacologic therapy
is then used to enhance cardiovascular performance (Table
27-6). Sympathomimetics stimulate a-, ~-, and dopaminergic receptors throughout the body, causing a variety of
effects. There is appreciable interpatient variability in dose
and pharmacodynamic effect with most catecholamines.
Also, stress may deplete endogenous catecholamine stores
and down-regulate a-adrenergic receptor sites. 45 Individual
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27·6 Pharmacologic Therapy Used in Shock
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Vasoconstriction

Dysrhythmias

a

10-20

a>p

2-10

Vasoconstriction
Inotropy

>MV0 2
Dysrhythmias
<Renal BF

0.05-1.5

Vasoconstriction
Inotropy
Chronotropy

>MV0 2
Dysrhythmias
<Renal BF

Ibii

i:F
!!TEpinephrine
i~~

a and

/3

I!!:.

i!I:r
~:i'

~~butamine

13,

5-20

Inotropy

l
;i~odium
~

Tachycardia
Dysrhythmias
Vasodilation
Hypotension

NA

0.5-10 (light-sensitive)
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Cyanide toxicity

.,,,Nitroglycerin
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0.2-20

Vasodilation (venous)

<PVR
>ICP

NA

5-10 llglkg/min (load with up
to 3 mg/kg over 20 min)

Inotropy
Vasodilation

Dysrhythmias
<PVR
Thrombocytopenia

NA

0.75 to 1.0 llg/kg/min (load
with 75 llg/kg over 20 min)
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Vasodilation
Improves diastolic function
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':~Difficult to predict the dose-response effect. Management requires individual titration at the bedside.

~.:~V02' Myocardial oxygen consumption; BF, blood flow; PVR, pulmonary vascular resistance; V/Q, ventilation/perfusion; Ie?, intracranial pressure.

dose and drug titration are performed at the bedside and
based on both desired and observed clinical and hemodynamic outcomes. Frequently, more than one catecholamine
is administered at a time; finding the best combination and
dosage requires continuous assessment of clinical and
invasive hemodynamic parameters.
The rapid onset, controllable dosage, and ultra-short
half-life of catecholamines make them effective for treating
shock, especially in patients thought to have a vascular
component to hypotension. Dopamine, epinephrine, and
norepinephrine are the most often used exogenous catecholamines or vasopressors. Alternatively, patients with myocardial depression in the face of hypotension may benefit
from a ~,-inotrope, such as dobutamine. See Fig. 27-8 for an
example of the medical management for hemodynamic
support of the pediatric patient experiencing septic shock. 15
Dopamine is an endogenous catecholamine whose effects
depend on the patient's own endogenous catecholamine response (related to maturation) and releasable norepinephrine
stores (related to stress levels). Dopamine activates the dopaminergic and adrenergic receptors in a dose-dependent
manner. Dopamine's major advantage is that at low doses
(I to S I-!g/kg/min) it produces splanchnic and renal vasodilation and a decrease in SVR. The dopaminergic effect on

renal blood flow results in increased urine output. Dopamine
stimulates ~,-adrenergic receptors at moderate doses (S to
10 !1g/kg/min), resulting in a moderate positive inotropic
effect in patients with normal myocardial function. At
high doses (> 10 I-!g/kg/min), dopamine is primarily an
a-adrenergic agonist that causes tachycardia, renal vasoconstriction, and increased SVR. The resulting increased afterload may decrease cardiac output. When dopamine infusions greater than 20 !1g/kg/min are required to maintain
blood pressure, an epinephrine drip is preferable. 12 Dopamine is often used either in patients requiring no greater than
10 I-!g/kg/min or at low doses for its selective effect on renal
and splanchnic perfusion in patients who require other inotropes. Dopamine depresses prolactin and thyroid hormone
release, although the effect on thyroid function over prolonged infusion of dopamine is uncertain. Importantly, differential diagnoses of sick euthyroid syndrome and
dopamine-induced hypothyroidism should be considered in
chronically critically ill children 46 ,47
Epinephrine, also an endogenous catecholamine, mimics
SNS stimulation by providing a perfect balance of both a
and ~ stimulation. Epinephrine increases myocardial and
cerebral perfusion pressures. Its most pronounced action is
on the ~-receptors of the heart, vascular, and other smooth
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Fluid Resuscitation
(20 ml/kg) Trtrated to Clinical Indicators of Cardiac Output
May Require 40-60 ml/kg

~
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("Fluid-refractory Shock")

Respond to Fluid Therapy
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Dopamine
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Shock

/
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~
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Fig. 27·8 Proposed management of septic shock (American College of Critical Care Medicine Clinical
Practice Parameters). CO. Cardiac output; SVR, systemic vascular resistance.

muscle. Epinephrine may be particularly helpful in infants
and children because of its direct action on adrenergic receptors rather than through a release of stored norepinephrine
(depleted norepinephrine stores have been noted in the pediatric population). Epinephrine is effective in shock states in
which SVR is significantly low (septic shock and anaphylaxis). Hypotensive septic patients may not respond to 0.
agents in a normal manner, so higher doses (I to 1.5 Ilg/kg/
min) may be needed. 12 Renal blood flow will improve if
perfusion pressure improves. Because catecholamines increase myocardial oxygen consumption. signs of myocardial hypoxia or ischemia, such as ST segment and T wave
changes on the ECG, may occur during administration.
Norepinephrine (Levophed) has been repopularized,
especially in the treatment of septic shock. Also an
endogenous catecholamine, norepinephrine's potent vasoconstrictor effects overshadow its positive inotropic effects.
Starting dosage is 0.05 to O.lllg/kg/min. ~ Effects predominate at the lower dosage, whereas 0. effects predominate at
the higher dosage. Norepinephrine has been reported to
reverse hypotension in patients with septic shock who have
not responded to dopamine or combination dopaminedobutamine. It is thought to be particularly helpful in
patients with low SVR and high cardiac output shock states
(hyperdynamic septic shock).15
Dobutamine, a synthetic catecholamine, is a ~I-stimulant
that increases cardiac contractility but causes only a slight
increase in heart rate. Because the 0.- and ~2-adrenergic
receptors are not stimulated by dobutamine, SVR is usually
decreased, and only minimal vasoconstriction is occasionally observed. Effects do not depend on releasable norepinephrine stores. Dobutamine is very effective as a selective
inotropic agent in the normotensive patient with poor
perfusion secondary to diminished cardiac performance.

The starting dose is 5 to 10 Ilg/kg/min; if greater than 20
Ilg/kg/min is required to maintain blood pressure, epinephrine should be considered. Dobutamine is nOl as effective as
dopamine in infants younger than I year of age and in
patients with septic shock. 12 In cardiogenic shock, dobutamine will increase cardiac output, while decreasing CVP,
PAWP, PVR, and SVR. 46 In a volume-depleted or hypotensive patient, dobutamine may cause systemic and pulmonary
vasodilation and increased right-to-Ieft intrapulmonary
shunting and thus decrease cardiac output and oxygen
delivery despite improved contractility.46
Optimize After/oad. In low-flow states, blood pressure is usually supported by an increase in SVR. However,
in cardiogenic low-flow shock, the increased SVR may
further compromise myocardial function and further limit
cardiac output (Fig. 27-9). When heart failure coexists with
increased resistance to ventricular outflow (as evidenced by
increased SVRI or PVRI), the use of vasodilators, often in
combination with a positive inotropic agent, is indicated.
Factors that increase afterload-for example, hypothermia,
acidosis, hypoxia, pain, and anxiety-should be managed
before considering vasodilator therapy. By reducing the
resistance to left ventricular outflow, arterial vasodilators
increase the cardiac ejection fraction and increase stroke
volume. In contrast, venous vasodilators shift blood into the
periphery and reduce right and left ventricular end-diastolic
volume. Decreased end-diastolic volume reduces myocardial wall stress and improves myocardial perfusion. Most
vasodilators are classified as "balanced" and exert both
arterial and venous effects. Nitrosovasodilators (nitroprusside and nitroglycerine) are recommended as first-line
vasodilators. Inovasodilators, those agents with both inotrope and vasoactive properties, such as amrinone and
milrinone, are reserved for patients with vasodilator-
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Fig.27-9 "Afterload mismatch" present in low-flow cardiogenic
shock. CO, Cardiac output; SVR, systemic vascular resistance.

resistant low cardiac output or with cyanide or methemoglobin toxicity. 15 Regardless of the vasodilator chosen, note
that hypotension will result if administered to a hypovolemic patient. Fluids should be readily available at the
bedside.
Sodium nitroprusside is a direct-acting vasodilator that
relaxes both arteriolar and venous smooth muscle. The
subsequent fall in afterload and preload improves cardiac
output only when the reduction of outflow resistance
predominates over the effects of the reduced venous return.
The dose range for nitroprusside is 0.5 to 8 Ilg/kg/min.
Manifestations of toxicity (headache, nausea, palpitations,
hyperventilation, metabolic acidosis, and unexplained elevation of venous oxygen tension) have occurred at relatively
low doses, leading some to suggest a maximum infusion rate
of 4 to 8 Ilg/kg/min for adults and less for infants and young
children. Some precautions are necessary when the drug is
administered: monitor serum levels of thiocyanate and
cyanide and the toxic metabolites of nitroprusside; protect
the 5% dextrose infusion containing the drug from light.
Nitroglycerine also relaxes both arteriolar and venous
smooth muscle and is helpful in cardiogenic shock by
reducing left ventricular filling pressures and SVR. Compared with nitroprusside, nitroglycerine produces a smaller
reduction in preload and afterload and a smaller increase in
cardiac output. Intravenous administration is initiated at 0.1
Ilg/kg/min and gradually increased to achieve hemodynamic and clinical effect, usually up to 10 Ilg/kg/min.
Nitroglycerine is administered in specialized tubing (polypropylene or polyethylene) as it is adsorbed in polyvinyl
chloride tubing, especially in new tubing sets or at slow
infusion rates.
The inodilators, amrinone and milrinone, are nonglycoside, nonadrenergic, phosphodiesterase inhibitors that produce positive inotropic and vasodilator effects. An initial
bolus of arnrinone 0.75 to 3 mg/kg is required, followed by
a continuous infusion of 5 to 10 Ilg/kg/min. In this dose
range, amrinone reduces afterload and preload by its direct
effect on vascular smooth muscle. In children with de-
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pressed myocardial function, amrinone produces a prompt
increase in cardiac output. Because amrinone is a nonsympathomimetic inotropic agent, it may be of particular value
in patients with clinical problems that down-regulate
adrenergic receptor sites, such as septic shock. A close
analog of amrinone, milrinone has a greater positive
inotropic potency with the bone marrow suppressive effects
of amrinone. Recommended initial loading dose is 75 Ilg/kg
with initial infusion rates of 0.75 to I Ilg/kg/min. Lindsay
and colleagues 48 recommend that for every increase of 0.25
Ilg/kg/min, a 25-llg/kg bolus be administered. Because the
median half-life is 1.47 hours, immediate hemodynamic
effects may not be seen unless appropriate loading doses and
infusion adjustments are made. Both inodilators have long
half-life elimination compared with nitrosovasodilators.
Optimize Heart Rate and Rhythm. Changes in
heart rate directly affect cardiac output. However, increasing
the heart rate to optimize cardiac output is usually not an
option among pediatric patients. When tissue perfusion is
inadequate, heart rate is usually at or near peak capacity.
Excessively rapid heart rates associated with fever, volume
depletion, and endogenous catecholamine release secondary
to the stress response may limit ventricular diastolic filling
and compromise stroke volume and cardiac output. Aggressive management of dysrhythmias that occur secondary to
electrolyte imbalance and metabolic acidosis is warranted.

Maximize Substrate Transport
Arterial Oxygen Content. Although much clinical
attention is appropriately focused on optimizing cardiovascular performance in patients with shock, an equal amount
of attention must also be placed on the oxygen content of
blood perfusing the cardiovascular bed. Oxygen content is
optimized by maintaining adequate hemoglobin levels
(National Institutes of Health [NIH] guidelines recommend
greater than 10 g/dl), that is, a hematocrit that optimizes
D0 2 . Blood administration is required to correct both whole
blood loss and severe anemia.
Lucking and colleagues,49 studying children in hyperdynamic septic shock after volume loading and pharmacologic
support, found that despite an initial low OER, V02 could be
increased by augmenting D02 through packed red blood cell
(RBC) transfusion. The researchers noted that because V02
correlates with survival, consideration should be given to
enhancing V02 despite an initial low OER and high D0 2 •
Mink and Pollack 5o reported a similar study but found that
although D0 2 significantly increased after a similar RBC
transfusion, V0 2 did not change.
Not only are adequate levels of hemoglobin important,
but also hemoglobin saturation with oxygen is ensured by
providing adequate oxygenation and ventilation. Extreme
shifts in the oxyhemoglobin dissociation curve are avoided
by maintaining normal pH and body temperature.

Minimize Energy Expenditure
In addition to enhancing substrate deli very to the tissues, an
adjunctive strategy is to limit the patient's metabolic
demands. Early identification of clinical states that increase
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demand and initiation of interventions to decrease physiologic work benefit patients with little or no metabolic
reserve. Interventions include providing adequate support of
ventilation to decrease the work of breathing, early identification of both heat and cold stress (for each degree Celsius,
the metabolic demands change 13%), prevention of shivering, and providing periods of rest and adequate sedation and
analgesia. Nurses play an invaluable role in reducing the
anxiety and fear that patients and families experience during
critical illness and intensive care. The unfamiliar environment, painful procedures, and the potential for death that
accompany advanced shock are issues that nurses are in a
unique position to address.

Optimize Nutrition
Critically ill infants and children are at risk for malnutrition
because their metabolic needs far exceed their nutritional
stores and also because of the nature and duration of their
illnesses. Previously well-nourished infants and children
may develop nutritional deficiencies after 3 to 5 days of
serious illness and intensive care; infants and children who
have been hospitalized for some time before the development of shock may already be malnourished. Providing
nutritional support demands the same priority as providing
definitive treatment of shock. 51 In fact, Pollack, Ruttimann,
and Wiley52 have noted that critically ill children who
receive better nutritional support display improvement in
physiologic stability and outcome.
Data suggest that there are advantages to using enteral
over parenteral nutrition to meet the nutritional requirements of the critically ill patient. Critical illness is associated with gut atrophy and increased mucosal permeability to
bacteria and macromolecules such as endotoxin. The theory
is that the translocation of these products, or at least the
relative ischemia and subsequent reperfusion of the splanchnic organs, are somehow implicated in the development of
single or multiple organ failure. Food in the lumen of the gut
is cytoprotective. 53 Animal studies demonstrate that enteral
nutrition maintains mucosal integrity and the immunologic
function of the gastrointestinal tract, decreases bacterial
translocation, blunts the systemic inflammatory response to
a toxin load, and improves survival in experimental
hemorrhage and peritonitis. 54
Although little data is available to guide the nutritional
support of pediatric critical care patients, Curley and
Castill0 51 recommend the initiation of enteral nutrition as
soon as possible. The transpyloric versus gastric route of
feeding is preferred because critical illness impairs gastric
emptying. The efficacy of enteral nutritional support in
critically ill children has not been subjected to prospective
randomized clinical trials. However, Chellis and colleagues 55 demonstrated that early transpyloric feedings were
feasible and safe in the PICD, even with mechanically
ventilated patients receiving vasoactive support. Patients
achieved caloric goals within 48 hours after initiating
enteral feedings, tolerated feedings, and demonstrated no
complications such as aspiration or abdominal distension. In

addition, enteral feedings proved to be cost effective in
critically ill pediatric patients.
Parenteral feeding is reserved for the patient with a
nonfunctional gastrointestinal tract. Renal replacement
therapies, such as continuous venovenous hemofiltration
(CVVH), can be used to facilitate caloric delivery in
patients who are fluid restricted or in acute renal failure
(see Chapter 21).

PROACTIVE CARE: VIGILANCE
Preventing or minimizing the often lethal complications of
shock through anticipatory monitoring of evolving problems
is an important nursing activity. All organ systems are at risk
of hypoxia and acidosis, thus increasing the risk of organ
dysfunction and the development of MODS.

Newborns
Shock in the newborn period presents additional challenges
to the pediatric critical care nurse. Shock-induced acidosis

and hypoxia can increase pulmonary artery pressures and
precipitate right-to-left shunting through fetal channels
(foramen ovale or ductus arteriosus), resulting in significant
hypoxemia. The newborn in stress is often hypothermic
because of immature thermoregulation and has low serum
glucose and calcium levels as a result of limited intracellular
stores. Because of their large surface area/volume ratio,
infants lose heat rapidly to the environment. Alterations in
carbohydrate metabolism occur secondary to endogenous
epinephrine release. Epinephrine produces an initial increase in serum glucose levels that decreases rapidly with
depletion of hepatic glycogen stores and failure of gluconeogenesis. Anaerobic glycolysis elevates blood lactate and
pyruvate levels, contributing to acidosis. Stressed neonates
are at high risk for apnea, necrotizing enterocolitis as blood
is shunted away from the gut, and seizures caused by
hypoglycemia and hypocalcemia.

Multiple Organ Dysfunction Syndrome
MODS causes 97% of the deaths that occur in the pediatric
critical care unit. 56 The mortality associated with MODS is
directly related to the number of organ systems involved in
the dysfunction process. Failure of one system is associated
with I % mortality, whereas failure of two systems is
associated with II % to 26% mortality. Three- and foursystem involvement is associated with 50% to 62% and 75%
mortality, respectively.56.57 The most common organ system
involved in MODS is the respiratory system, followed by
the cardiovascular and neurologic systems. Criteria for
pediatric patients with MODS are detailed in Table 27-7.
Organ system dysfunction such as ARDS, DIC and
purpura fUlminans, acute tubular necrosis (ATN), gastrointestinal hemorrhage, and hepatic dysfunction is not uncommon in critically ill children with shock.
Ongoing assessment of pulmonary function is important
so that early detection and management of respiratory
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TABUi 27-7

Criteria for Pediatric Patients

With MODS

Woo,
Frgan System

Criteria

~ji

RR >90/min (infants <12 months)
RR >70/min (children 2:12 months)
Paoz <40 mmHg (in absence of cyanotic
heart disease)
Pacoz >65 mmHg
PaozlFloz <250 mmHg

i~

Ii18':"
~!;

illnCardiovascular

i

~i

I,~
!i1;\:'.
~iP-'
~

l~iJ;.
~:,!"eurologtc
J~L ..

Il

i1ilT

~ematolOgiC
:i~'!'·

i~l,
r~',

~'

~enal

Iii'

~i:

~u~astrointestinal

li:--

1+

E!!:Iepatic

I~:

I'"

Mechanical ventilation (>24 hr if

poslOperative)
Tracheal intubation for airway obstruction
or acute respiratory fai lure
MAP <40 mmHg (infants <12 months)
MAP <50 mmHg (children 2:12 months)
HR <50 beats/min (infants <12 months)
HR <40 beats/min (children 2:12 months)
Cardiac arrest
Continuous vasoactive drug infusion for
hemodynamic support
Glasgow coma scale score <5
Fixed, dilated pupils

pe~~;~:t~~ :i;~q~i~:~~~:~~:~~:~re

intervention)
Hemoglobin <5 g/dl
WBC count <3000 cells/mm 3

~i:~~~:n:~~~~~::::u1ar coagulation

(PT >20 sec or aPTT >60 sec
in presence of positive FSP assay)
BUN >100 mg/dl
Serum creatinine >2 mg/dl
Dialysis
Blood transfusion >20 ml/kg in 24 hr
because of gastrointestinal hemorrhage
(endoscopic confirmation optional)
Total bilirubin >5 mg/dl and SGOT or

~~O:~:it::;C:w~~eh~:;;~i:te
Hepatic encephalopathy 2:grade II

:irom Wilkinson 10, Pollack MM, Glass NL et al: Mortality associated
lj"iWilh multiple organ system failure and sepsis in pediatric intensive care,
fi.ZPediatr 111:324-328, 1987.
Blood urea nitrogen: FSP. fibrin split products: HR, heart rate;
'i,[f,DH. lactic dehydrogenase; MAp' mean arterial pressure; MODS. mul~'Jiple organ dysfunction syndrome; PT, prothrombin time; aP1T, actiii,y~ted partial thromboplastin time; RR, respiratory rate; SGOT, serum

1-1I'UN.

~~~lutamic-oxaloacetic transaminase;

WBC,

white blood cell.

failure can be ensured. Oxygen reserve is limited, and
compensatory mechanisms are maximized in shock states,
sharply decreasing the patient's tolerance of even brief
periods of hypoxia and respiratory acidosis. In patients who
develop ARDS, the mechanism of injury may involve
activation of complement proteins that promote aggregation
of granulocytes in the lung. Granulocytes release proteolytic
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enzymes and toxic oxygen radicals that cause direct lung
injury, Decreased pulmonary compliance and altered ventilation/perfusion (\'/0.) relationship result in increased intrapulmonary shunting and venous admixture. In cardiogenic
shock, left ventricular end-diastolic pressure of approximately 20 to 25 mmHg directly results in the development
of pulmonary edema. In septic shock, damage to the alveolar
pulmonary capillary epithelium produces a protein fluid leak
into the interstitium and alveoli. Early and appropriate
intervention in either case includes oxygen administration
and colloid-diuretic therapy. Endotracheal intubation, mechanical ventilation, and PEEP are used to support an
adequate functional residual capacity and limit intrapulmonary shunting (see Chapter 8).
DIC and purpura fulminans are both states associated
with systemic microvascular thrombosis. DIC results from
an activation of the coagulation cascade with subsequent
generation of thrombin. Because DIC often accompanies
shOCk states, blood coagulation studies are assessed early in
the patient's course. The primary strategy is to treat the
underlying process causing DIC, but when DIC is rapidly
progressing, the approach is to support the patient's
hemostatic system with blood component therapy as indicated. The acceptable minimum platelet count may vary
from one institution to another. FFP and cryoprecipitate are
used to correct prolonged prothrombin time, activated
partial thromboplastin time, and abnormal fibrinogen levels
when necessary.
Purpura fulminans specifically describes the extensive,
patchy, purpuric, and ischemic areas of the extremities and
buttocks noted in patients with fever, septic shock, and
DIC,58 often associated with meningococcal or Haemophiius influenzae infection. The pathophysiology involves
endotoxemia, vasculitis, DIC, and a low blood flow state,
resulting in widespread thrombosis of the venules and
capillaries, particularly of the superficial vascular plexus. to
Numerous therapies intended to limit tissue loss and prevent
gangrene are under investigation. Current therapies include
heparinization,59 plasmapheresis,60,6t sympathetic blockade,62 plasma protein concentrates such as antithrombin III
(AT_III)63 and activated protein C,M tissue plasminogen
activator65 .66 and nitroglycerin. Irazuzta and McManus 58
reported an increase in skin perfusion with the use of topical
nitropaste 2% (15 mg/2.5 cm; total 15 cm; every 6 hours).
Renal hypoperfusion reduces glomerular filtration and
stimulates aldosterone and antidiuretic honnone secretion,
which contribute to progressive azotemia with or without
oliguria. In shock, acute renal failure occurs on a continuum
from ATN to cortical necrosis. Albumin with diuretics and
low-dose dopamine augment renal perfusion and urine
output. Progressive hyperkalemia, refractory acidosis, and
hypervolemia may require renal replacement therapy.
Gastrointestinal hypoperfusion can lead to ulceration of
the stomach and intestines and increases the risk of
bleeding. Stress ulcer prevention with histamine (H 2 )receptor antagonist administration may control gastric
acidity and prevent gastric bleeding. In addition, gastrointestinal hypoperfusion disrupts the patient's gut barrier
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Sox 27·5

Unconventional Treatment for·Systemic
Inflammatory Response Syndrome
and Shock
Anticytokine Therapy

Monoclonal antibodies
Tumor necrosis factor
Interleukin-I
Complement fragment C5a
Receptor antagonists
Tumor necrosis factor
Interleukin-I
Platelet-activating factor
Thromboxane
Bradykinin
Antiendotoxin Therapy

Endotoxin monoclonal antibodies
Lipid A derivatives
Peptides and lipoproteins that hind endotoxin
Antioxidant Therapy

Allopurinol
Mannitol
Catalase
Superoxide dismutase
Iron chelators
Miscellaneous Antiinflammatory Therapy

Complement inhibitors
C I inhibitor
Arachidonic acid inhibitors
Ibuprofen (cyclooxygenase pathway)
Imidazole (thromboxane pathway)
Diethylcarbamazine (lipoxygenase pathway)
Leukotriene inhibitor
Protease inhibitors
Modulators of Coagulation

Antithrombin III
Aprotinin
Protein C
Heparin
Plasminogen activators
Anticlotting factor monoclonal antibodies
Nitric oxide
Miscellaneous Therapies

Gut decontamination
Antihistamines
Naloxone
Calcium channel hlockers
Adapted from Bone RC: A critical evaluation of new agents for the treatment of
sepsis. lAMA 266: 1686-1691. 1991. Copyright 1989 by American Medical
Associalion; Secor VH: Multiple organ dysfunction syndrome: overview
and conclusions. In Secor VH, ed: Multiple organ dysfunctiofl and Jailure,

ed 2. 5t Louis. 1996. Mosby, p 416.

function, leading to the translocation of bacteria and
endotoxin to the systemic circulation. Given that no current
therapies can increase mesenteric blood flow or prevent
ischemia or reperfusion-mediated gut injury, the alternative
is to provide at least tropic enteral feedings (full-strength
fonnula at 0.5 ml/kg/hr) to limit bacterial overgrowth 67
The liver may also fail to perform many functions, for
example, metabolism of drugs and hormones and conjugation of bilirubin. Medications, especially those metabolized
by the liver, are dosed with careful attention to drug plasma
levels and physiologic effect. Doughty and colleagues68
noted that children with multiple organ dysfunction can
have up to 90% reduction in their drug-metabolizing ability.

UNCONVENTIONAL THERAPIES
Numerous therapies related to the care and treatment of
patients in shock are currently under investigation. Therapies range from tube feeding for decreasing the risk of
translocation to innovative immunotherapy for minimizing
the inflammatory immune response and decreasing mediator
activity and damage. Given the conceptual shift recognizing
the role in the inflammatory immune response in all shock
states, therapies once thought only applicable to septic
shock may have more of a role in other shock states because
of their final common pathway-ineffective tissue perfusion
and cellular ischemia and death.
Unconventional therapies can be organized into (I) anticytokine therapy (including monoclonal antibodies);
(2) antiendotoxin therapy; (3) antioxidant therapy; (4) antiinflammatory therapy; (5) modulators of coagulation; and
(6) miscellaneous therapy. Many of the mediator therapies
focus on either neutralizing the mediator in the circulation or
blocking the interaction between the mediator and its
cell-surface receptors, thereby preventing the mediator from
affecting its particular target 69 (Box 27-5).
Monoclonal antibodies (MoAbs) to a myriad of mediators, as well as to endotoxin, have been developed. Although
two antiendotoxin antibodies (HA-IA and E5) showed initial promise,7o.71 results were suggestive rather than conc\usive n In addition, concerns were raised regarding the studies' methods and the efficacy and therapeutic potential of the
MoAbs. Given that overwhelming inflammation without a
septic source is common in shock states, other MoAbs, such
as anti-TNF or anti-TNF-receptors, have been developed
and are under investigation. A number of individual therapies used in combination will likely prove to be beneficial
for patients in shock states, especially septic shock 73
Antioxidant therapies are pivotal in the research arena
given the recent recognition that WBC activation and tissue and reperfusion injury are related to overwhelming
inflammation.
Endogenous endorphins play an important role in modulating SNS responses in all types of shock. Peripheral
endorphin effects may involve vascular and myocardial
depression, calcium transport, and modulation of macrophage responses. The opioid antagonist naloxone has been
found to rapidly reverse hypotension secondary to endotoxin and blood loss in animals. Naloxone has been used
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successfully in some children with septic shock who failed
to respond to conventional therapy. The response to
naloxone therapy has been inconsistent, and severe reactions
may occur.
Similar variable results have been obtained with the use
of corticosteroids in treating shock. Despite adverse effects
(superinfection, electrolyte imbalance, hyperglycemia, and
gastrointestinal bleeding),74 corticosteroid administration
may improve short-term survival and permit reversal of
shock in certain subgroups of septic shock patients. The
theory is that in septic shock, steroid administration before
antibiotic administration may help attenuate the inflammatory response secondary to endotoxin release? Bollaert and
colleagues75 examined the effect of steroid administration
on the reversal of shock, hemodynamics, and survival in
adult patients with late shock treated with catecholamines.
In this prospective, randomized clinical trial, the administration of steroids for greater than 96 hours resulted in
significant improvement in hemodynamics and survival.
Compared with 21 % of placebo-treated patients, 68% of
steroid-treated patients achieved a 7-day reversal of shock.
Long-term mortality (28 day) was also lower in the steroidtreated group (32% vs. 63%). Rates of compEcations between the two groups were not significantly different. Replication of this study is needed in the pediatric population.
Bactericidal/permeability-increasing protein (BPI) has
shown promise in the treatment of severe meningococcal
sepsis. BPI is proposed to kill meningococci and to bind and
clear the bacterial endotoxin, thus minimizing the systemic
inflammatory process. 76 Phase II and phase III clinical trials,
including pediatric trials, are underway and suggest that BPI
may have a therapeutic benefit in the treatment of Iifethreatening infections and conditions associated with bacteremia and endotoxemia.77.78 Specifically, when administered
early in the course of meningococcal sepsis, BPI may limit
the severity of purpura fulminans and improve limb salvage.
With regard to nutrition, immunonutrition may be associated with a reduction of ICU morbidity. Atkinson and colleagues79 examined the effects of enteral immunonutrition
on hospital mortality and length of stay in critically ill adults
(N = 369). In a prospective, randomized clinical trial, patients either received enteral feeds supplemented immuneenhancing ingredients (arginine, purine nucleotides, and (0-3
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fatty acids) or a control enteral feed. Although no significant
differences occurred in hospital mortality (even though the
immunonutrition group was sicker), a significant reduclion
in the length of mechanical ventilation and length of hospital
stay was noted in the immunonutrition group of patients.
This study reflects the future trend in examining immuneenhancing nutrition that may be clinically significant in a
patient's recovery from shock.
Plasmapheresis (removal of the child's blood, separation
of the plasma and blood cells, and reinfusion of the packed
cells in fresh plasma) and continuous renal replacement
therapies (continuous arteriovenous/venovenous hemofiltration (CAVHlCYYHJ) have also been used to remove septic shock mediators, endotoxin, or bacterial byproducts.
McManus and ChurchweU 80 identified coagulopathy (defined as PTT >50 seconds and fibrinogen <150 mg/dl) as a
poor prognostic indicator in meningococcemia and purpura
fulminans. The authors used plasmapheresis in severely
coagulopathic patients as a means of restoring normal
clotting factors without fluid overload. Although the sample
size was small, plasmapheresis was found to be safe and
effective in correcting coagulopathy and stabilizing hemodynamics. Also, evidence shows that plasma levels of some
mediators are lowered with the use of continuous renal
replacement therapies (CRRTs) ,8 I but the cEnical significance remains uncertain.
In summary, clinical investigations are underway on
numerous therapies. Inherent research challenges to these
trials are coupled with the difficulty in sorting out the
therapeutic benefit. Therapies may be deemed statistically
and cEnically insignificant merely because of the timing of
administration. Secor25 points out that timing may be as
critical as the therapy itself. Second, it is very unlikely that
a single therapy will "fix" or minimize the overwhelming
inflammatory response, given its intricacy and complexity.

SUMMARY
In summary, care of the pediatric patient in shock requires
multidisciplinary collaboration. Recognizing the child's
condition early, diligently tending to the administration and
evaluation of treatment, and preventing the onset of
common complications compose a challenging nursing role.
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alcohol. A recent study found that the majority of alcoholrelated child passenger deaths involve a child riding
unrestrained with a driver who has been drinking. 2 Nonintentional injury is not the leading cause of death in children
under I year of age; however, a recent study demonstrated
32.1 injury deaths per 100,000 infant years. 3 Other causes of
death include homicides, suicides, drownings, burns, and
falls. In the United States, it is estimated that more than
30,000 children suffer permanent disabilities from injury
every year. I
Blunt trauma accounts for 80% of all accidental injuries.
Blunt injuries are associated with rapid deceleration, which
occurs with motor vehicle incidents; or from direct blows,
the result of contact sports or child abuse. Penetrating
trauma accounts for the other 20% of injuries. Penetrating
trauma is most commonly the result of firearms or stab
weapons. If the late teenage years are included in the
pediatric population, blunt and penetrating trauma are
almost equal as the cause for injury.
Head injury is the most common injury seen in children
and accounts for 80% of all pediatric trauma deaths, due to
the larger proportion of body weight that the head of a child
provides. Skeletal injuries usually involve the long bones,
especially of the lower limbs. Other common injuries
include abdominal and thoracic. The kidneys, spleen, and
liver are not well protected in the child and thus are more
susceptible to trauma.
Regardless of the type of injury, the final common
pathways of trauma are tissue hypoxia secondary to
inadequate oxygenation and ventilation, hypovolemia, and
cerebral hypertension. The goal of pediatric trauma care is
to stabilize the effects of traumatic injury before irreversible damage occurs. Often, children will survive the
initial insult only to die later because of complications
such as malignant intracranial hypertension, sepsis, respiratory failure, or multiple organ dysfunction syndrome
(MODS). Vigilance by the nurse will help to prevent these
complications.
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rauma remains the leading cause of death in children. In
children between the ages of I and 19 years, injuries
cause more deaths than all diseases combined and are a
leading cause of disability. I The single largest cause of
trauma-related death is motor vehicle incidents. Approximately 24% of pediatric motor vehicle deaths involve
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INITIAL RESUSCITATION
Primary Survey
The initial resuscitation of the pediatric trauma victim is
guided by the principles of the primary and secondary
survey. The primary survey allows for the rapid identification of any life-threatening injuries and takes place when the
child is initially evaluated. The primary survey focuses on
the initial stabilization of the cardiopulmonary system,
which is covered in Chapter 31.
However, there are some specific points for the pediatric
trauma patient.
The child is assumed to have a cervical spine injury until
proven otherwise, so that manual in-line immobilization is a
critical aspect of airway management. An appropriately
sized rigid cervical collar can be applied, but immobilization
is maintained manually if a collar is not available. To
detennine the correct size, the collar is measured in width
from the top of the shoulder to the chin with the head in
neutral position. There are several collars available that take
pediatric cervical spine anatomy into account (Fig. 28-1).
While in-line manual cervical immobilization is maintained, the airway is opened using the jaw-thrust method.
The jaw-thrust maneuver alone may relieve airway obstruction. If the child does not respond, vomit, blood, or broken
teeth may be obstructing the airway. Severe maxillofacial
injuries or injuries to the larynx may also produce airway
obstruction.
If the child does not respond to positioning and suctioning, artificial ventilation with 100% oxygen and intubation
is indicated. A rapid-sequence intubation is appropriate for
the child with a full stomach or in the child with the

Fig. 28-1 Pediatric cervical spine immobilization collar. The
NecLoc Extrication Collar. Jerome Medical, is designed for prehospital extrication and transport of children, taking into account
cervical spine anatomy difference between children and adults.

potential for increased intracranial pressure (lCP). All
pediatric trauma victims are assumed to have a full stomach,
and a rapid-sequence intubation will minimize the possibility of regurgitation (Fig. 28_2).4
The application of cricoid pressure (Sellick's maneuver)
is performed during a rapid-sequence intubation to prevent
passive regurgitation of stomach contents into the pharynx.
In this technique, the upper esophagus is compressed against
the cervical vertebral column by applying anteroposterior
pressure on the cricoid cartilage (Fig. 28-2)4 Cricoid
pressure is maintained until correct placement of the
endotracheal tube has been confirmed.
In some uncommon instances, the child will require a
needle cricothyroidotomy. This technique is indicated in the
child with an obstruction below the larynx or with a
significant maxillofacial or airway injury. A 14- or 16-gauge
needle is inserted through the cricothyroid membrane to
establish the airway. If this is not possible, a surgical
tracheostomy is performed.
Assessment of the child's breathing status includes
observation for signs of respiratory distress, especially once
the airway is established. Significant thoracic injury may be
present even with minimal outward signs of trauma. If
respiratory distress, unequal breath sounds, and unstable
vital signs are present, a pneumothorax or hemothorax is
suspected and warrants immediate intervention. For a
pneumothorax, needle decompression of the chest is performed without waiting for confirmation of the diagnosis by
chest roentgenogram. A 14- to 20-gauge needle is inserted
into the fourth or fifth intercostal space at the midaxillary
line. After the initial rush of air occurs, a chest tube is
inserted into the same space.
If a hemothorax is suspected, a large-bore needle is
inserted at the same site used for evacuation of a pneumothorax. Fluid resuscitation is started before evacuation of the
hemothorax to prevent exsanguination. Excessive bleeding
through the chest tube may require clamping of the tube to
tamponade bleeding. If bleeding persists at a rate of equal to
or greater than 2 ml/kg/hr, an emergency thoracotomy is
indicated 4 A small amount of blood loss can quickly
produce hypovolemic shock in the child. Table 28-1
presents the four classes of hemorrhage, with clinical signs
and initial treatment for each stage.
The most crucial aspect of treatment for the hypotensive
pediatric trauma victim is restoration of the circulating
blood volume. An intravenous line is inserted, although this
may be difficult in the hypovolemic child. If venous access
cannot be obtained quickly, intraosseous access may be
attempted. If the response to an initial bolus of lactated
Ringer's solution or normal saline at 20 ml/kg is inadequate,
a second fluid bolus is given, also at 20 ml/kg. If shock still
persists, packed red blood cells (PRBCs) are administered at
10 ml/kg. Fluids are warmed by a fluid warmer before
administration to prevent hypothermia. Once shock has been
controlled, fluids can be deli vered at the maintenance rate.
If shock continues despite all interventions, other causes
are considered. The child may have developed a tension
pneumothorax, which requires immediate intervention. If
muffled heart sounds and pulsus paradoxus are present, the
child may have developed pericardial tamponade, which
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Fig. 28-2 Technique for oral endotracheal intubation in the pediatric trauma patient using cricoid pressure
and "manual in-line axial traction." The technique generally requires three individuals. The individual on
the left is applying cricoid pressure while the individual on the right holds the patient's head in a neutral
position with two hands using manual in-line traction. Before intubation and after in-line traction is
applied, the anterior portion of the cervical collar is removed. (From Tobias JD, Rasmussen GE, Yaster M:
Multiple trauma in the pediatric patient. In Rogers MC, ed: Textbuok of pediatric intensive care, ed 3,
Baltimore. 1996, Williams & Wilkins.)

TABLE
~:L

l~;class
lif

ill'"

28-1

Classes of Hemorrhage for Children

Blood Loss

Signs

Treatment

15% or less
40-kg child = 500 ml blood

Pulse: slight increase
SP: normal
Respiration: normal
Capillary refi II: normal
Tilt test:' normal

Crystalloids
Rule 3 : 1 (3 ml of RL : I .ml blood
loss). e.g., 500 mL blood
loss = 1200-1500 ml RL

20%-30%
40-kg child

Tachycardia> 150
SP: systolic decreased, decreased
pulse pressure
Tachypnea >35-40
Delayed capillary refill
Positive tilt test
Urine output normal (1 mllkg/hr)

Crystalloids
Rule 3: I as above, e.g.. 800 ml blood
loss =2100-2400 ml RL

30%-35%
40-kg child = 1200 ml blood

Blood pressure drop
Narrow pulse pressure
Urine output affected

Crystalloids
20 mllkg
Packed red cells
10 mllkg

40%-50%
40-kg child

Nonpalpable blood pressure and pulse
No response to verbal or painful
stimuli

Crystalloids
20 mllkg
Packed red cells

= 800 m]

blood

= 1600 ml

blood

j~f'rom Widner-Kolberg MR. Moloney-Harmon PA: Pediatric trauma. In Cardona VD, Hum PD. Mason PJB et aI, eds: Trauma nursing: from resuscitation
tlihrough rehahililalioll, ed 2. Philadelphia. 1994. WB Saunders.
~'*A till test is performed by sitting the child upright. The leSI is normal if the child can Slay up longer than 90 seconds and maintain blood pressure.
~B~ Blood pressure: RL. Ringer's lactate.
li!i~
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requires an immediate pericardiocentesis. If these are not
present and shock persists, immediate surgical intervention,
such as an exploratory laparotomy, is warranted.
Once airway, breathing, and circulation have been
stabilized, a rapid assessment for neurologic injury takes
place. Head injuries are common in children, and carry a
high incidence of mortality and morbidity.
Neurologic assessment during the primary survey consists of observation of the level of consciousness, pupil size
and reaction, and motor response. The Gla~gow Coma Scale
(GCS) or the AVPU (alert, verbal, pain, unresponsive) scale
can be used to determine initial level of consciousness. The
AVPU scale is defined in Box 28-1.
Control of intracranial hypertension, maintenance of
adequate cerebral perfusion and prevention of hypoxia are
the goals of stabilization for the child with a neurologic
injury. A secure airway is critical because hypoxia and
hypercapnia must be avoided. If the child is hypotensive,
fluids are given at the resuscitation dose, even if neurologic
injury is present. However, an isolated head injury rarely
causes shock. If shock is present, a high index of suspicion
for another source of bleeding should exist.
Once the cervical spine has been cleared by roentgenography, the head of the bed may be elevated. This will help
to decrease cerebral venous pressure and control intracranial
hypertension.
Exposure is an important component of the primary
survey. The child is completely exposed, to examine for
life-threatening injuries. This does, however, place the child
at risk for hypothermia. Hypothermia produces various
physiologic consequences, such as metabolic acidosis and
dysrhythmias, and can interfere with resuscitation efforts.
Radiant warmers and warmed intravenous fluids and
blood are used with pediatric trauma patients during

~

resuscitation. The child's core temperature is maintained
between 36° C and 38° C. If the child is hypothermic on
arrival to the unit, a warming blanket on the bed and warm,
humidified oxygen are used. See Chapter 14 for more
information on the management of hypothermia in the child.

Secondary Survey
The secondary survey follows the primary survey and the
initial stabilization of the cardiorespiratory system. The
secondary survey is the systematic evaluation of each body
system for injury. The order of the examination may vary
but normally proceeds in descending order of urgency.4 The
examination of the abdomen and perineum occurs last
unless otherwise indicated because this assessment produces
pain and the child's response may obscure other findings. As
the secondary survey is initiated, it is important to remember
that any child with one injury is assumed to have another
until proven otherwise. The examination is as gentle as
possible, and reassessment is continuous. In-depth assessment of each system is covered under system-specific
injuries later in this chapter.

TRAUMA SCORES
Reliable means of measuring injury severity and resulting
disability are necessary to scientifically assess care provided
to injured children 5 Numerous scoring systems that use
measures of anatomic or physiologic derangements to
quantify severity of injury have been developed. These
scores include the GCS; Trauma Score (TS); Circulation,
Respiration, Abdomen, Motor, Speech (CRAMS) Scale;
Revised Trauma Score (RTS); Abbreviated Injury Scale
(ArS); Pediatric Risk of Mortality (PRISM); and Injury
Severity Score (ISS). These scores are used for field triage,
quality assessment, scientific comparison of trauma patients,
and epidemiologic research. 5
A Pediatric Trauma Score (PTS) was developed in the
1980s because the existing scores did not take into account
normal pediatric physiologic parameters. The PTS considers
the unique anatomic and physiologic characteristics of the
child and uses these measures to predict childhood injury
severity.6 Table 28-2 illustrates the PTS. A score of 8 or less

Box 28-1
AVPUScale

A = Patient is alert
V = Patient responds to verbal commands
P = Patient responds to pain
U = Patient is unresponsive

TABLE 28-.2 Pediatric Trauma Score
Category
Component

+2

+1

-1

Size
Airway
Systolic BP

>20 kg

10-20 kg
Maintainable
50-90 mmHg
ObtundedILOC
Closed fracture
Minor

<10 kg

eNS
Skeletal
Cutaneous

Normal
>90 mmHg
Awake
None
None

Unmaintainable
<50 mmHg

Comatose
Open/multiple fractures
Major
Sum

~. rom Tepas JJ, Ramenofsky ML. Mollil( DL el al: The pediatric trnuma score as a predictor of injury severity: an objective assessment, J Trauma 28:427,

Ja988.

~!QP, Blood pressure; CNS, central nervous system: LOC. loss of consciousness.
~
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warrants transport to a pediatric trauma center. 6 In addition
to predicting severity of injury, the PTS identifies children
who are at immediate risk of mortality. Tepas and colleagues
found that a score of less than 6 predicted mortality.6
Orliaquet and associates determined that a score of less than
4 was associated with immediate risk of mortality.?
Most trauma scoring systems are based on anatomic or
physiologic dysfunction. The Trauma Injury Severity Score
(TRISS) methodology combines anatomic injuries and
physiologic dysfunction, using the RTS and ISS. The RTS
identifies the degree of neurologic and cardiovascular
dysfunction, and the ISS assesses multiple injuries. TRISS
methodology calculates the probability of survival for an
injured patient. 8 The most widely used method to assess
mortality in critically ill children is the PRISM score. Both
the ISS using TRISS methodology and the PRISM are
useful in pediatric trauma. PRISM stratifies patients into
low- and high-risk groups, which allows for accurate
prediction of resource utilization. PRISM also predicts
mortality risk in pediatric trauma, though not as accurately
as the TRISS methodology.9

SYSTEM-SPECIFIC INJURIES
Head Injury
Etiology/Incidence. Head injury is a common pediatric injury and the most common cause of traumatic death
in children. 1O Each year, approximately 22,000 acute
brain-injured children in the United States die, and another
29,000 are left with a permanent disability. Mortality in
children with severe head injuries is 6% to 10%, as opposed
to 30% to 50% in the adult with severe head injuries. II
Anatomic and physiologic differences in children make
them more susceptible to head injury and its consequences.
The cranial bones are thinner in children and offer less
protection to the growing brain. In addition, the size of the
infant head is large in proportion to body size. These
anatomic considerations predispose children to head injury.
Children's response to head injury differs in that they have
a lower incidence of mass lesions but a higher one of
intracranial hypertension. 11 Because children experience
intracranial hypertension more frequently, they are more
susceptible to a secondary head injury rather than a primary
head injury.
Pathogenesis. Traumatic brain injury (TBl) is characterized by primary and secondary injury. Primary injury is
produced by the trauma itself. It occurs immediately
following impact and may cause damage and/or death of the
neuronal cells. Axonal injuries, laceration of brain tissue,
contusions, skull fractures, and scalp injuries are examples
of a primary head injury. Hypoxic injury may also cause a
primary head injury if any of the neurons or astrocytes is
injured by hypoxia or ischemia. Secondary injury is
produced by the brain's response to trauma. It is a dynamic
process that evolves over a period of hours to days and
generally peaks 3 to 5 days after injury. Loss of cerebral
autoregulation, development of extracellular and intracellular edema, and a breakdown of the blood-brain barrier are components of secondary injury, which is com-
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pounded by systemic hypertension and hypotension,
hypoxia, and hypercapnia. Recent work has identified the
mechanisms that produce the components of secondary
injury after TBI. These include ischemia, excitotoxicity,
energy failure and resultant cell death cascades, secondary
cerebral swelling, axonal injury, and inflammation and
regeneration (Fig. 28_3).12
Previous work identified cerebral hyperemia as an
important factor in the development of intracranial hypertension in the head-injured child. However, Kochanak
and colleagues focused on the development of early
posttraumatic hypoperfusion. 12 Adelson and colleagues
used stable xenon-computed tomographic (CT) method to
assess cerebral blood flow in infants and children after
severe TBl. 13 Patients were assessed early after injury, and
posttraumatic hypoperfusion was common. In addition,
ischemia, defined as global cerebral blood flow less than
20 mIllOO g/min, was associated with a poor outcome.
Loss of vasodilators and amplification of vasoconstrictors
may be mechanisms that produce early posttraumatic
hypoperfusion (Fig. 28-4).12
Specific Head Injuries. There are a number of
specific head injuries that may be seen in children. Even
though these are discussed separately, each one may be an
element of a more serious brain injury.
Scalp lacerations are common in infants and young
children and usually do not require a hospital stay for
treatment. Because of the vascularity of the scalp, a large
amount of bleeding may result from a laceration. Once
underlying pathology has been ruled out, treatment is
minimal and consists of stopping bleeding and inspecting,
irrigating, and suturing the wound. Palpation and possibly a
skull film may rule out an underlying skull fracture.
Many children with head trauma have a concomitant
skull fracture. Most of these children have linear fractures.
The majority of linear fractures are uncomplicated and heal
spontaneously in 2 to 3 months. However, there are some
linear fractures that are considered serious, based on their
location. A fracture that crosses a major vascular structure,
such as the middle meningeal artery or the dural venous
sinus, has the potential of bleeding into the subdural or
epidural space. A complication of a linear fracture seen in
children is the growing fracture. With this complication, a
portion of the arachnoid membrane becomes trapped
between two edges of the fractured bone, producing a
leptomeningeal cyst. The child may present with a soft and
pulsating skull defect, seizures, and other neurologic defects. 14 This defect may resolve with age, or surgical
intervention may be necessary.
A depressed skull fracture is a fracture in which the inner
table of the skull is displaced by more than the thickness of
the entire bone. This represents a more severe injury because
a great deal of force is required to produce this situation. The
treatment of a depressed skull fracture is debridement and
elevation of the fragment within 4 hours. 15
A basilar skull fracture is a common type of skull fracture
in children and represents a significant blow to the head. A
basilar skull fracture usually involves a break in the base of
the frontal, ethmoid, sphenoid, temporal, or occipital bone.
The diagnosis is generally made on clinical presentation.
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Fig. 28-3 Categories of mechanisms proposed to be involved in the evolution of secondary
damage after severe traumatic brain injury (TBI) in infants and children. Three major categories for
these secondary mechanisms include ischemia. excitotoxicity, energy failure, and cell death cascades; cerebral swelling; and axonal injury. A fourth category, inflammation and regeneration,
contributes to each of these cascades. AA, Amino acids; BBB, blood-brain barrier; CBY; cerebral
blood volume; ICP, intracranial pressure. (From Kochanek PM, Clark RSB, Ruppel RA et al:
Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe
traumatic brain injury in infants and children: lessons learned from the bedside, Pediatr Cri/ Care Med
1:4-19, 2000.)
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Production of
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Fig.28-4 Schematic outlining putative mediators involved in the
production of early posttraumatic hypoperfusion and ischerrua
after severe traumatic brain injury (TBI). eNOS, Endothelial nitric
oxide synthase. (From Kochanek PM, Clark RSB, Ruppel RA et al:
Biochemical, cellular, and molecular mechanisms in the evolution
of secondary damage after severe traumatic brain injury in infants
and children: lessons learned from the bedside, Pedia/r Cri/ Care
Med 1:4-19, 2000.)

A history of impact at the back of the head raises the index
of suspicion. There may also be a loss of consciousness,
seizures, or other signs of neurologic deficit. On physical
examination, the child may show certain findings that are
indicative of a basilar skull fracture. Rhinorrhea, raccoon
eyes (periorbital ecchymosis), anosmia, and ocular motor
palsies may occur with anterior fossa fractures. Hematotympanum, otorrhea, vertigo, Battle's sign (mastoid ecchymosis), or unilateral hearing loss may occur with middle fossa
fractures. Hypotension, tachycardia, and changes in the
respiratory pattern may be indicative of brainstem compression that can occur with posterior fossa fractures. 14 Cerebrospinal fluid (CSF) leakage from the ear indicates
disruption of the leptomeninges, and CSF leakage from the
nose indicates leakage through the perinasal sinuses. Clear
drainage from the ears or nose is tested for the presence of
glucose because glucose is present in CSF. However,
because CSF is often mixed with blood and blood contains
glucose, the presence of glucose does not always confirm
that the fluid is CSF. If CSF is mixed with blood, as the
blood dries, an xanthochromic (yellow) halo will appear on
a dressing. The presence of a halo confirms the presence of
CSF. A serious potential complication of CSF leakage is the
development of meningitis. This is unusual, however, and
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Fig. 28-5 Cerebral contusion with mass effect and
midline shift.

the use of prophylactic antibiotics is controversial. The trend
has been to treat only documented cases of meningitis. 15
In general, most basilar skull fractures are uncomplicated. Skull films identify basilar skull fractures in only 10%
of cases. CT scans are indicated to identify the area of the
fracture and any underlying brain injury. Because tbe
cribriform plate is disrupted, insertion of nasotracheal and
nasogastric tubes is avoided. Most children with basilar
skull fractures require only 24 to 48 hours of observation
with frequent neurologic checks and can expect a full
recovery.
Concussion is the mildest form of traumatic injury to the
brain. With a concussion, the child momentarily loses
consciousness at the time of injury. The loss of consciousness is the result of the stretching and shearing forces in the
brainstem. '5 Diagnosis is usually made on a historical basis
based on a temporary loss of consciousness.
The nature of concussion is varied based on the age
group. Infants tend to have a less specific clinical presentation. They usually exhibit benign posttraumatic seizures,
vomiting, diaphoresis, pallor, and lethargy and do not
usually experience a loss of consciousness. '5 In the older
child, posttraumatic amnesia becomes an important finding.
The child may also complain of headaches, dizziness, and
fatigue and may show some behavioral changes. The child's
neurologic function usually normalizes in about I week,
though some symptoms may persist for months or even to I
year. This postconcussive syndrome is expected to resolve
completely.
Cerebral contusion is defined as an actual bruising or
microscopic bleeding of the brain, associated with temporary or permanent structural damage. A contusion is similar
to a concussion in that a transient or actual loss of
consciousness may occur; however, a contusion causes an
actual disruption of cerebral tissue to varying degrees, often

accompanied by parenchymal hemorrhage and focal edema.
The contusion may occur at the site of impact (coup injury)
or at a site opposite the impact (contrecoup injury). The
degree of injury is reflected by alterations in the child's
mental status. In a mild contusion, the return of consciousness is not as rapid as with a concussion and there is
retrograde amnesia. With mild retrograde amnesia, the
memory loss is only that of exact details of events occurring
immediately before impact. More severe amnesia manifests
itself by the memory loss extending for a period of hours
before the impact occurred. Children with more severe
amnesia often have some disorientation, slowed reaction,
headache, vomiting, and other mild neurologic abnormalities. Diagnosis of contusion is made based on focal
neurologic signs and CT scan. The most common pattern
seen on CT is that of multiple small hemorrhages surrounded by varying degrees of edema (Fig. 28-5).
Return to consciousness following rapid neurologic
deterioration may be seen in children with a cerebral
contusion. The cause in children is usually the result of
diffuse generalized cerebral swelling. The most common CT
scan finding among all children with an acceleration!
deceleration injury is diffuse cerebral swelling.
The incidence of cerebral contusion in infants is rare
compared with older children. This is attributed to several
factors. The skull of the infant is more pliable, and there are
less convolutional markers on the inner table. Because the
surface between bone and brain tissue is smoother, there is
less resistance to movement and surface injury is minimized. Also, the infant's brain is less myelinized; and
demyelinized brain tissue has a softer consistency, which
may reduce injury. 16
Treatment of a cerebral contusion depends on the
severity of the contusion. Treatment may be supportive
medical therapy, involving treatment of increased ICP if it
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Fig. 28-6 Epidural hematoma with mass effect and small
midline shift.

exists. Surgical treatment (removal of the contused tissue) may be necessary if medical management does not
control increased ICP or if significant shifts are seen on
CT scan.
An epidural hematoma refers to a collection of blood
above the dura. Epidural hematomas are less common in
children, especially infants, because of several reasons. The
dura is tightly adherent to the inner table of the skull,
especially at suture lines in infants and young children. Also,
the fixation of the middle meningeal artery does not occur
until approximately 2 years of age. Because the artery is not
embedded into the temporal bone until fixation occurs, it can
rotate and possibly avoid injury.
An epidural hematoma is a readily correctable lesion if
identified and removed before secondary injury to the
brainstem occurs. The classic lucid interval between the
initial loss of consciousness and subsequent rapid neurologic deterioration is much less common in children. tS More
often, the symptoms tend to be vague depending on the age
of the child and the location of the bleeding. Infants may
experience bulging fontanelles, separation of the sutures,
decreased hematocrit, and shock with significant bleeding.
In older children, an enlarging hematoma may cause
herniation into other areas of the brain, producing corresponding signs. The child may exhibit hemiparesis, hemiplegia, ipsilateral pupil dilation, posturing, or contralateral
limb weakness. Symptoms may be delayed for hours or days
if the source of bleeding is venous rather than arterial. If the
hematoma continues to enlarge and the compensatory
mechanisms of the brain become exhausted, temporal lobe
herniation and brainstem compression occurs. A progressive
decrease in the level of consciousness is the most significant
diagnostic sign for all age groups. If time permits, a CT scan
is performed, which will show a localized, high-density
lesion with mass effect (Fig. 28-6). If the child demonstrates
rapid clinical deterioration, immediate surgical intervention
without the benefit of a CT scan is necessary.

Treatment of choice is surgical evacuation of the
hematoma. This is performed as quickly as possible to avoid
increasing morbidity or mortality. Evacuation of the hematoma is by craniotomy with removal of the clot and control
of bleeding. Burr holes are technically difficult but may be
useful as a diagnostic procedure in the absence of CT scan
evaluation. 15 With prompt surgical intervention, the prognosis for the child with an epidural hematoma is good.
A subdural hematoma is a collection of blood in the
subdural space, often with associated cortical damage from
lacerated vessels or direct contusion. Acute subdural hematomas are almost always caused by a traumatic incident.
They are usually associated with a high mortality and
morbidity because of the fact that the lesion is often caused
by disruption of a cortical artery or a large bridging vein.
The impact required to produce this type of injury is
significant and is associated with severe contusion of the
underlying vein. Common causes of a subdural hematoma
are high-speed motor vehicle accidents, falls, assaults, and
violent shaking. One study demonstrated that subdural
hematomas were more likely to occur with inflicted head
injury rather than accidental injury. 17
The clinical presentation of a child with a subdural
hematoma is routinely that of a youngster who has sustained
a major head injury. The lucid interval seen with epidural
hematoma is not seen because the brain is so severely
injured. The child presents with profound neurologic
deterioration, and because of the force of impact, the mental
status is almost always affected.
Confirmation of the diagnosis of subdural hematoma is
made with CT scan (Fig. 28-7). The most effective treatment
is evacuation of the clot with control of bleeding and
possible resection of damaged brain tissue. 15 Even with
aggressive treatment, the prognosis for the child with a
subdural hematoma is less favorable than for the child with
an epidural hematoma. This is because of the associated
damage to the underlying brain tissue.
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Fig. 28-7 Left subdural hematoma with mass effect, midline
shift. and intraventricular hemorrhage.

Because a large number of children experience intracranial hypertension following severe TBI, collaborative management focuses on controlling increased ICP. Chapter 20
provides in-depth information regarding care of the child
with a head injury.

Spinal Cord Injury
Etiologyllncidence. Spinal cord injury is relatively
rare in children. Approximately 1100 children with spinal
cord injury are reported annually. 18 Motor vehicle accidents
are the leading cause of spinal cord injury in children. In
addition to occupant motor vehicle accidents, pedestrian and
bicycle motor vehicle accidents are common causes of
spinal injury in children. 18 Sports-related and recreational
injuries, child abuse, falls, and birth-related injuries also
account for a large proportion of pediatric spinal cord
injuries. 19
The type and severity of injuries seen in children differ
than from those seen in adults l8 Children experience a
higher incidence of cervical injuries and spinal cord injury
without radiographic abnormality (SCIWORA). There are a
number of factors related to this, but the most significant
factor is the inherent differences between the pediatric and
adult spine. The development of the pediatric spine is a
continuous, dynamic process. Development is characterized
by changes in the geometric configuration of the vertebrae;
development of the ossification centers; closure of the
epiphyseal plates; changes in the characteristics of the
ligaments and soft tissues; and changes in osseous shape,
size, strength, and integrity.20 Even though the epiphyses
fuse at different ages, most epiphyseal plates are fused by 8
years of age. Multiple ossification centers are present at
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Fig. 28-8 A lateral view depicting compression from displaced
bony elements causing spinal injury. This is a common mechanism
of primary spinal cord injury in children because of their
hyperrnobile vertebral column. (From Allen EM, Boyer R, Cheney
WB et al: Head and spinal cord injury. In Rogers MC, ed: Textbook
of pediatric intensive care, ed 3, Baltimore, 1996, Williams &
Wilkins.)

birth but continue to develop throughout childhood. The
vertebral bodies are wedge-shaped, and the vertebrae are
mostly cartilaginous. The vertebral facets tend to have a
horizontal orientation, and they become more vertical and
ossify between 7 and 10 years of age. Before this time, they
provide minimum stability to the vertebral column. The
head of the infant and young child is large in relation to the
neck, and the paraspinous muscles are not well developed.
The vertebral ligaments and soft tissue are more elastic than
in adults. These features all contribute to creating hypermobility of the neck and a tendency toward SCIWORA,
severe ligamentous injury, and upper cervical spine injuries
(Fig, 28_8),21
These differences make the children susceptible to
different patterns of injury compared with adults. The types
of injuries change as the biomechanical and anatomic
features of the spine become more adult-like; however, the
adult spinal characteristics and patterns of injury are not
fully seen until after the age of 15 years?l
Pathogenesis. Younger children between the ages of
o and 8 years often sustain soft tissue injury without
fractures. This is related to hypermobility and osseous
immaturity. Manifestations of soft tissue injuries include
SCIWORA, ligamentous dislocations, subluxation without
fracture, growth plate injuries, and epiphyseal separations.
In contrast, adolescents experience more "true" fractures
than ligamentous or growth plate injuries.
Hypermobility of the child's spine is the most critical
determinant of injury?1 Hypermobility protects the spinal
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cord from injury because force is dispersed over multiple
vertebral levels. Hypermobility also accounts for the low
incidence of spinal injury in the child and the patterns of
injury. When spinal injury does occur, it is usually severe
and accounts more often for complete loss of function in the
child than in any other age group?1
Sixty percent to eighty percent of vertebral injuries in the
first 10 years of life involve the cervical region, especially
the upper portion (occiput through C_3).18 Significant
ligamentous injuries have a propensity for the upper cervical
spine. Atlanto-occipital dislocation (separation of the occipital condyles from the atlas) results in severe craniovertebral
junction instability and can cause fatal neurologic injury.
Immediate internal fixation is necessary to preserve neurologic function because halo immobilization may not maintain alignment and traction with tongs may cause distraction
of the craniovertebral junction, even with a small amount of
weight.
Atlantoaxial dislocations (subluxations) are usually not
fatal. Subluxation at the Cl-C2 level is better tolerated than
subluxation at the lower levels because the spinal canal is
larger at C- I. Rotatory subluxation occurs with injury to the
capsular ligaments. Anterior subluxations often occur in
conjunction with rupture of the transverse ligament of the
atlas and with relaxation of other atlantoaxial ligaments.
Posterior subluxations occur with injury to the dens.
Anterior or posterior instability is seen best on flexion
and extension radiographs. Rotatory subluxations are apparent with a CT scan. Rotatory subluxations greater than 40
degrees cause facet interlock and require external reduction
and internal fixation. 23
Young children are susceptible to dislocations without
fractures at all levels of the vertebrae, though this tends to
occur mostly in the cervical region. Fracture characteristics
change with vertebral maturation. Younger children tend to
experience epiphyseal separations and growth plate fractures, whereas adolescents usually sustain more adult-like
fracture patterns. Most cervical spine injuries in adolescents,
like adults, occur at the C5-C6 level.
Occipital condyle fractures are extremely rare in children. These fractures are usually stable, though they can
cause cranial nerve dysfunction. Fractures of the atlas or
axis are also uncommon in young children; these fractures
tend to occur more often in adolescence.
Fractures of the thoracic or lumbar spine in children often
occur in the T ll-L2 region where the rigid thoracic
segments join the more mobile lumbar segments. Again,
these injuries tend to involve the soft tissues and the
ligaments, which result in cartilaginous or growth plate
injuries. Children restrained by lap belts involved in motor
vehicle accidents may sustain fractures in the rnidlumbar
region.
As previously mentioned, a group of children experience
SCIWORA. The hallmark of this entity is the presence of a
spinal cord injury even though radiographic studies are
normal. Flexion-extension views and CT scans are also
normal. The injury occurs because of the immature pediatric
spine where momentary intersegmental damage causes
disruption of the cord without disrupting bones or ligaments.

Four mechanisms are proposed for SCIWORA. These
include longitudinal distraction, hyperflexion, hyperextension, or ischemic spinal cord damage. 24 The inherent
elasticity of the spinal column can cause the spinal cord to
be susceptible to a longitudinal distraction mechanism. The
horizontally oriented facet joints result in greater mobility
but less stability. Forward movement of the upper cervical
spine is facilitated, causing a flexion injury. Hyperextension
of the cervical spine causes inward bulging of the ligamentum f1avum and increased thickness in the spinal cord. This
can reduce the diameter of the spinal canal by as much as
50% and allow for direct damage to the spinal cord. In
addition, the anatomy and biomechanics of the occipitoatlantal junction cause the vertebral arteries to be susceptible
to compression during hyperextension. This can result in
temporary occlusion leading to ischemia and infarction. 25
Injuries experienced by children with SCIWORA tend to
be devastating. Children with SCIWORA often present with
delayed onset of neurologic deficit, although the reasons for
this are not known. The delayed onset follows what appears
to be an insignificant injury but once onset ensues, it
progresses rapidly to a severe, permanent neurologic deficit.
This may occur several hours to days after injury; however,
in retrospect, a history of subtle neurologic symptoms is
often elicited. 24
Critical Care Management. Any child who has
experienced head or facial trauma or who complains of neck
pain is suspected of having a spinal cord injury. Clearance
of the cervical spine requires anteroposterior, lateral, and
open-mouth views of the cervical spine. 18 It is critical that
the cervical spine films include views of C7 and T I. These
views are obtained by gently pulling the shoulders downward to visualize the seven cervical vertebrae.
Because of the possibility of SCrwORA, occult fractures
and vertebral malalignment are ruled out by CT scan. In
addition, children with head and neck injuries are questioned for the presence of transient neurologic symptoms
that may indicate SCIWORA.
There are some considerations when evaluating cervical
spine films in the child. The vertebral bodies of the child are
less rectangular than those of the adult. These bodies have a
biconcave appearance, which can give the impression of a
compression fracture. This can be ruled out by comparing
all the vertebral bodies, because the nonnal vertebral bodies
will all appear the same. In addition, angulation in the infant
spine is more extreme than in the adult. This is due to the
fact that the infant spine is very cartilaginous and, especially
at the C2-C3 level, vertebral offsets may appear. These may
give the impression of subluxation.
Initial management of spinal cord injury begins with
appropriate resuscitation and stabilization of the spine. Data
indicate that a high proportion of children younger than 15
years of age with spinal cord injury die immediately or
within the first hour after injury.18 As many as 50% of
children with spinal cord injuries may die in the field, and
among the children who survive the initial injury, another
25% will die during the initial period of hospitalization. 26
Children who do survive the initial 3 months have a better
chance of survival after 5 years compared with other age
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Fig. 28-9 Children vs. adults: Differences in pediatric head-tobody relationship and spinal alignment. (Courtesy Jerome
Medical.)

groups with spinal cord injury.2 6 The high initial mortality
suggests that critically injured children do not tolerate
severe neurologic injury or multisystem trauma.
Initial immobilization of the child with suspected spinal
cord trauma is standard. However, using a standard backboard to achieve immobilization may be problematic. Young
children have a disproportionately large head (the head
represents 25% of total body length in infancy and only 14%
in adulthood), and when positioned on a flat surface, the
head may be forced forward, causing it to flex. This
difference is demonstrated in Fig. 28-9. Therefore when
immobilizing the young child, the occiput is lower than the

Differences in Head Shape
and Location of Ear
Fig. 28-10 Children vs. adults: The anterior neck length, measured from chin to chest, is negative in infancy and peaks in
preadolescence. The occipital angle (the angle between the occiput
and the neck) is very steep in infancy compared with the adult.
(Courtesy Jerome Medical.)

body. In determining the correct size collar, it is also
important to take into account chin to chest differences and
differences in head shape and location of the ear (Fig.
28-10). New pediatric spinal immobilization devices that
take these differences into account are made especially for
children (Fig. 28-11).
Initial management includes attention to airway, breathing, and circulation. Hypotension is assumed to result from
bleeding until proven otherwise. Spinal neurogenic shock,
often resulting from complete upper spinal cord injury, may
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Fig. 28-11 The Miami Jr. collar, Jerome Medical. is designed to
address the growth transition of the head, neck, and upper body
from birth through preadolescence. The collar is available in three
sizes specifically designed for children: PI (ages 0 to 2), P2 (ages
2 to 6), and P3 (ages 6 to 12).

occur at the time of injury. The triad of symptoms are
hypotension, bradycardia, and hypothermia. These symptoms result from the sudden loss of sympathetic outflow
from the cervicothoracic region. The loss of vasomotor tone
is treated with a low dose norepinephrine (Levophed)
infusion at 0.1 to 1.0 Ilg/kg/min. Atropine, 0.0 I to 0.02
mg/kg/dose, may be used to treat increased parasympathetic
tone. Atropine may be repeated every 5 to 10 minutes as
necessary, used alternatively or concurrently with norepinephrine?? Volume expansion is also appropriate. In addition, with spinal shock, there is a temporary but complete
loss of segmental reflex activity22 These children have
flaccid, areflexic limbs with no sensory or sphincter
function. Priapism may also be present. Gradually, after 7 to
21 days, segmental reflex function returns and spasticity
occurs?2
The administration of methylprednisolone may have
significant benefit if administered within the first 8 hours
after injury. An intravenous bolus of 30 mg/kg followed by
a continuous infusion of 5.4 mg/kg/hr for 23 hours has been
recommended. 15
The use of external orthotic devices depends on the
nature of the injury and the age of the child. A stiff molded
collar may be useful to restrict cervical movement and is
suitable for muscular injuries, atlantoaxial rotatory subluxation, and nondisplaced atlas fractures. However, these
collars are not truly effective in immobilizing the cervical
spine but serve more as a reminder not to move the neck.
Complete reduction and immobilization of the cervical
spine may be accomplished by the use of traction. However,
the halo jacket is considered the preferred immobilization
device because it completely stabilizes the head, yet allows
for patient mobility (Fig. 28-12). Care focuses on prevention
of dislodgment, loosening, and pin protrusion, especially in
young children. Other potential complications are decubitus
ulcers, brain abscesses, and pin site infection.
Treatment of thoracic and lumbar spine injuries is based
on the characteristic of the fracture and the presence of pain,
spinal deformity, or neurologic deficits. Children with more
than 50% compression of the height of the vertebral body,

spinal instability, kyphotic deformity, or severe intractable
pain are treated with open reduction and internal fixation.
Children with less than 50% compression are treated with
surgical decompression of the spinal cord andlor nerve
roots. 22
Unstable fractures and dislocations, progressive neurologic deficits with an incomplete cord injury, or compound
wounds are treated surgically. Persistent instability despite
the use of external orthotic devices requires internal fixation.
Ongoing care of the child with a spinal cord injury
revolves around supporting the child's physiologic and
psychosocial needs. In addition to managing the initial
resuscitation and care of the stabilization device, attention is
focused on supporting the child's oxygenation and ventilation status, if necessary. The child with a spinal cord injury
will suffer neuromuscular failure if the lesion is at C4 or
above. Injuries above the Tl level result in paralysis of the
intercostal muscles, and injuries above TlO-TI2 result in
paralysis of the abdominal muscles. This may have implications for younger children who are abdominal breathers.
Also, abdominal muscle involvement will limit effective
coughing.
Assessment of ventilatory parameters is important, especially vital capacity. Once baseline vital capacity has been
obtained, values are obtained at least every 4 hours. If vital
capacity decreases over time, diaphragmatic failure is
occurring and ventilatory support is necessary. Ventilatory
support may be permanent or temporary, depending on the
level of the injury. If the injury is at C3-C4 or above,
lifelong ventilatory support will be necessary.
The psychosocial needs of the child with a spinal cord
injury and the family of the child are tremendous. Especially
with a high cord injury, the child no longer has control over
the most basic bodily functions. For the adolescent, a time
of developing complete independence has now become a
time of complete dependence. Interventions revolve around
sensitivity to the needs of children or adolescents as they
experience changes in their ability to interact and be
independent.
Family needs are also enormous as they face the prospects of a permanent change in their lives as well as the life
of the child. The family is assisted with coping with the
change and with regaining their preinjury level of functioning or attaining a higher level of functioning.
Early involvement in a rehabilitation program is critical.
If the child is in a center that has a rehabilitation program,
involvement may begin on the day of injury. Concentration
on a bladder and bowel program, prevention of contractures
and decubitus ulcers, and relief of spasticity are three major
areas focused on by the rehabilitation program.

Thoracic Injury
Etiology/lncidence. Thoracic trauma accounts for
one of the highest mortality rates in children, second only to
head injury?S Morbidity associated with thoracic injury is
also an issue. Peclet and colleagues found that children who
suffered thoracic injury were more severely injured than
those who did not 29 Seventy percent of the children in this
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study required admission to the intensive care unit, and
twenty percent required surgical intervention. Thoracic
injury, when combined with injuries to other systems,
increases the severity of injury and requires extensive
resource use.
A unique feature of the child who has sustained thoracic
trauma is the compliant thorax resulting from the flexibility
of the bony and cartilaginous structures. It is not unusual,
therefore, for the child to have major internal injury from
compression of the chest without fracture of the bony
thorax. A child's mediastinum is freely mobile and capable
of wide anatomic shifts. This creates the potential for
life-threatening situations such as dislocation of the heart,
angulation of the great vessels, compression of the lung, and
angulation of the trachea. Children with any type of
traumatic injury experience aerophagia, which results in
gastric dilation that limits diaphragmatic excursion and
leads to reflex ileus. In a small child, this also can
compromise ventilation and gas exchange.
Serious thoracic injury is most commonly the result of
blunt trauma. Motor vehicle-related and bicycle-related
injuries account for the majority of thoracic trauma. 18 Falls
and child abuse are also common causes of thoracic injury
in children. The presence of serious thoracic injury increases
the potential for mortality by a factor of 10.
Pathogenesis. The pathogenesis of thoracic injury is
related to the specific injury. Regardless of the injury, the
pathogenesis may include impaired oxygenation and ventilation, and/or decreased cardiac output.
Rib Fractures. The incidence of rib fractures in
children is less than in the adult. The decreased incidence
can be attributed to the incomplete ossification of the
pediatric skeleton, which results in more flexibility in the
bones. The presence of rib fractures in a child suggests
severe traumatic force. Fractures of multiple ribs have been
directly correlated with an increase in mortality.3D
Injuries associated with rib fractures vary according to
the fracture site. The four upper ribs are protected by the
shoulder girdle and are less likely to fracture. Fractures of
ribs one through four suggests injury to the bronchial,
tracheal, or great vessels.

The most commonly fractured ribs are the middle ones
(four through nine). Often, these ribs penetrate lung tissue,
causing serious damage. Pneumothorax and hemothorax
often accompany middle rib fractures.
The lowest three ribs are not attached to the sternum and
can withstand a great deal of force without breaking.
Fractures of these free-floating ribs are often accompanied
by liver, spleen, or kidney laceration.
Signs of rib fractures are localized pain on movement or
deep breathing and crepitus on palpation. The child may
breathe shallowly to decrease pain, leading to hypoventilation. Treatment of rib fractures is aimed at rest and pain
relief.
Flail Chest. Flail chest occurs when there are multiple
fractures of the same rib, or when there are fractures of the
rib and sternum. The configuration of the fractures results in
a floating rib segment. The chest wall becomes unstable as
the flail segment moves paradoxically to the rest of the chest
wall (Fig. 28-13).
As the diaphragm descends with inspiration, subatmospheric pressure allows the flail segment to move inward
toward the negative pressure. The flail segment moves outward as the diaphragm rises with expiration. The paradoxic
movement causes a decrease in tidal volume by preventing the lung from fully expanding and causing atelectasis. Ventilation/perfusion mismatch results. Children with
a flail chest often have an accompanying pulmonary contusion. Hypoventilation, combined with the contusion and
shunting, accounts for the morbidity associated with a flail
chest.
Treatment of an uncomplicated flail chest is similar to
that of rib fractures. Rest, analgesia, and meticulous
pulmonary toilet are the primary treatments. Children with
significant impairment of gas exchange may require pneumatic stabilization, which consists of intubation and positive
pressure ventilation. Judicious use of intravenous fluid and
good pulmonary toilet are also recommended.
Traumatic Asphyxia. Traumatic asphyxia occurs almost exclusively in children because of their compliant
chest wall and absence of valves in the superior and inferior
vena cava. Direct compression against a closed glottis
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Fig. 28-13 Flail chest. There is a paradoxic segment of the chest
wall and loss of the normal bellows mechanism. (From Jones KW:
Thoracic trauma. In Mayer TA, ed: Emergency management of
pediatric trauma, Philadelphia, 1985, WB Saunders.)

Fig. 28-14 Open pneumothorax results in ipsilateral lung collapse, mediastinal shift, and impaired ventilation of the opposite
lung. (From Jones KW: Thoracic trauma. In Mayer TA, ed:
Emergency management of pediatric trauma, Philadelphia, 1985,
WB Saunders.)

causes an acute increase in intrathoracic pressure with
accompanying obstruction of vena caval drainage. A marked
increase in venous pressure occurs, causing extravasation
from the capillary bed and hemorrhage from the brain and
other organs. Traumatic asphyxia may occur as the result of
automobile wheels passing over the chest of the child or
when the child is trampled. Often the child is lying on soft
ground, which allows for compression without sternal or rib
fractures.
Signs and symptoms of traumatic asphyxia include
cyanosis of the face and neck; petechiae of the head, neck,
and chest; and retinal and subconjunctival hemorrhages.
Signs of disorientation and respiratory distress may be
present. Pulmonary contusion and pneumothorax often
accompany traumatic asphyxia.
Treatment for traumatic asphyxia and associated injuries
is symptomatic. Increased Iep may result from prolonged
asphyxia and is treated accordingly.
Pneumothorax. Pneumothorax is the most common
manifestation of thoracic injury, caused by blunt or penetrating trauma. Pneumothorax can range from a small, single
pneumothorax to a life-threatening tension pneumothorax or
open pneumothorax.
Simple pneumothorax occurs when air enters the pleural
space, secondary to tears in the tracheobronchial tree, the
esophagus, or the chest wall itself. Because the thorax is
flexible, a pneumothorax may be present without rib
fractures. Symptoms of a pneumothorax range from none to
severe respiratory distress. Physical examination may reveal
decreased breath sounds and hyperresonance to percussion
over the injured area. If the child is stable, a chest
roentgenogram is obtained to confirm the diagnosis.
Treatment of a pneumothorax varies. The child in severe
respiratory distress requires needle thoracostomy first,
followed by tube thoracostomy. The child who is stable
requires only a tube thoracostomy. A very small pneumothorax «15%) in the asymptomatic child may require only
observation.
Tension pneumothorax results when air enters the pleural
space but is unable to exit. The trapped air accumulates,

increasing intrapleural pressure, which causes the affected
lung to collapse. The air continues to accumulate, causing
the mediastinum to shift and compress the contralateral
lung. Excessive shift in the mediastinum results in vena cava
compression, a decrease in venous return to the right side of
the heart, and, ultimately, a decrease in cardiac output. If
tension pneumothorax is not corrected immediately, cardiovascular collapse and death occurs.
Signs of tension pneumothorax include severe respiratory distress, absence of breath sounds and hyperresonance
over the affected lung, cardiovascular instability, and
tracheal shift to the unaffected side. A needle thoracentesis
is the immediate treatment of choice. Thi s relieves the
tension, allowing the mediastinum to shift back. Once the air
is evacuated, a chest tube insertion is performed.
The third type of pneumothorax is an open pneumothorax. An open pneumothorax occurs when there is an opening
in the chest wall, usually resulting from penetrating trauma.
The opening allows air to move freely in and out of the
pleural space. With a large wound, the mediastinum moves
to one side or the other, depending on the phase of
respiration. During inspiration, air moves through the
wound. The lung collapses, and the mediastinum moves
toward the functioning lung. During expiration, air exits
through the wound, the lung partially reexpands, and the
mediastinum shifts back (Fig. 28-14).
The child with an open pneumothorax often shows signs
of restlessness, cyanosis, subcutaneous emphysema, and
mediastinal shift. In addition, a sucking sound may be heard
as air moves through the open wound. The open wound is
covered immediately with an airtight seal. Sterile towels or
a gloved hand can be used until a dressing is applied. Once
the patient has stabilized, a petroleum jelly gauze is applied.
Hemothorax. Hemothorax occurs when blood accumulates in the pleural space, causing collapse of the affected
lung. Hemothorax can occur secondary to blunt or penetrating injury. Blood collects in the pleural space, causing the
affected lung to collapse. Injury to the heart, great vessels,
or other thoracic structures may lead to the development of
a hemothorax.
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Signs and symptoms of hemothorax include respiratory
distress, decreased or absent breath sounds, and dullness to
percussion over the affected area. Shock may develop
because children can lose up to 40% of their total blood
volume into a hemothorax?8
Treatment of a hemothorax varies slightly from that of a
pneumothorax. Blood is immediately evacuated from the
pleural space with a chest tube; however, intravenous access
is established before evacuation to allow for fluid resuscitation. The chest tube is placed in the seventh or eighth
intercostal space, which drains the hemothorax, reexpands
the lung, and allows for monitoring of ongoing bleeding.
Blood volume is rapidly replaced. Any child who exhibits
blood loss of more than I to 2 mllkg/hr is prepared for a
thoracotomy.
Pulmonary Contusion. Pulmonary contusion is one
of the most common thoracic injuries seen in the child and
is the most common cause of potentially fatal chest injury.
It is often seen in the absence of bony injury. Pulmonary
contusion is suspected whenever the child has a thoracic
injury, especially if there is bruising noted on the chest.
Pulmonary contusion occurs when the lung is traumatized, causing bleeding from the capillary endoihelium.
Resultant increased capillary permeability allows for the
development of both alveolar and interstitial edema. Impaired gas exchange results, causing ventilation/perfusion
mismatch and decreased compliance.
Signs and symptoms of pulmonary contusion may not
initially be evident. Signs of respiratory distress may
develop within several hours after injury and may include
wheezing, hemoptysis, fever, rales, and signs of hypoxemia.
Chest roentgenograms will demonstrate patchy densities,
but this may not occur for 24 to 48 hours after the initial
injury (Fig. 28-15). Tyburski and colleagues demonstrated
that the severity of pulmonary contusion on x-ray films
combined with Paoz/Fl02 ratio was valuable in detennining the need for ventilatory assistance and predicting
outcome. 31
Treatment of pulmonary contusion is dependent on the
severity. Mild contusions may be managed with oxygen,
analgesia, pulmonary toilet, and judicious fluid management
to prevent large increases in interstitial pulmonary edema.
Severe pulmonary contusions, which significantly alter
respiratory function, may require intubation and mechanical
ventilation. A pulmonary artery catheter is often placed to
monitor pulmonary capillary wedge pressure to closely
monitor fluid status. Albumin may be used for osmotic
purposes; serum osmolarity is maintained at 300 mOsm.
Diuretics may also be used to decrease the amount of
pulmonary interstitial fluid.
Ventilatory interventions include the use of high-flow
oxygen and positive end-expiratory pressure (PEEP). The
pulmonary status is continuously evaluated with serial
monitoring of arterial blood gases and continuous monitoring of Sp02 and end-tidal CO 2 , Because the child may be on
a high amount of PEEP, close monitoring for the development of airleak syndrome is critical.
Other interventions for the child with a pulmonary
contusion include positioning, observation for signs of

Fig. 28-15
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Pulmonary contusion.

infection, and meticulous pulmonary toilet. Optimal position to enhance matching of ventilation to perfusion in
patients with a pulmonary contusion is best determined at
the bedside with the aid of Spo2 monitoring.
The child with pulmonary contusion may be at risk for
the development of acute respiratory distress syndrome
(ARDS), although one study demonstrated a low incidence
of ARDS following pulmonary contusion or multiple
trauma. 32 A recent study demonstrated the effectiveness of
pressure control inverse ratio ventilation (PCIRV) in patients who develop ARDS following blunt chest trauma. 33
PcrRV was shown to be an effective mode of ventilation in
patients with ARDS following blunt chest trauma; however,
there are complications, including auto-PEEP and decreased
cardiac output. 33 Intermittent prone positioning has been
shown to recruit collapsed lung tissue and improve gas
exchange in trauma patients with blunt chest trauma and
severe ARDS.34
Cardiac Tamponade. Cardiac tamponade occurs
when blood accumulates in the pericardial sac, increasing
pericardial pressure. The increase in pressure alters the
pumping mechanism of the heart. resulting in a decrease in
cardiac output. Stab wounds are the most common cause of
tamponade in the trauma patient. Firearms can also produce
tamponade and cause sudden death. Blunt trauma rarely
results in tamponade. Signs and symptoms of acute tamponade are the classic triad of jugular venous distension,
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hypotension, and muffled heart sounds, although these may
be difficult to detect in the child. The short, fat neck of the
child makes assessment of venous distension difficult. Also,
the thin chest wall allows for increased transmission of
sound. Another classic sign is the presence of a pulsus
paradoxus of greater than 10 mmHg. Tamponade is suspected in children with persistent hypotension despite fluid
resuscitation. In the absence of hypovolemia, an increased
central venous pressure may be noted. Initial treatment of
pericardial tamponade is pericardiocentesis. If pericardiocentesis is not successful, or if tamponade reoccurs,
operative intervention is warranted.
Commodio Cordis. Commodio cordis occurs in children and is the result of the sudden impact to the
precordium. It results in cessation of normal cardiac
function. The child may experience a life-threatening
dysrhythmia that is refractory to resuscitation. 35 Most
children do recover; however, some patients require longterm antiarrhythmic drugs, pacemakers, inotropic drugs, or
intraaortic balloon pumps. Significant mortality and morbidity are associated with this injury.18
Myocardial Contusion. Myocardial contusion occurs when traumatic forces cause local injury to the
myocardium. Dysrhythmias may occur secondary to injury.36 Children suffering from myocardial contusion are
less likely than adults to have dysrhythmias or alterations in
cardiac function??
Signs of myocardial contusion are chest pain and
alteration in cardiac function. Chest wall bruising and
tenderness may not be present, making a high suspicion of
injury an important diagnostic factor. A 12-lead echocardiogram is obtained on all patients with a suspected contusion.
One third of children with nonpenetrating myocardial
trauma will develop S-T segment and T-wave changes
during the first 24 to 48 hours after injury like those seen
with myocardial ischemia and infarction?8
Significant elevations in serum glutamic-oxaloacetic
transaminase (SOOT) and lactate dehydrogenase (LDH)
occur with hemorrhagic shock, so these alterations are not
significant for myocardial contusion. 38 Two-dimensional
echocardiography may be used to detect ventricular wall
motion abnormalities and determine ventricular ejection
fraction.
Using serial cardiac isozyme studies may be helpful in
making the diagnosis of contusion, but there are questions
about the value of enzyme use. 39 For example, the
myocardial band of creatine kinase (CK-MB) may be
elevated, but false-positive results are often seen in trauma
patients. 40 Increases in serum levels of CK-MB also occur in
patients with chronic renal failure or skeletal muscle
damage 41 Elevations in CK-MB have been shown to
correlate poorly with the extent of myocardial injury. Serum
levels of greater that 4% to 6% may be indicative of
damage 42
Measurement of levels of cardiac troponin I (cTnI) may
be more useful because levels correlate more closely with
myocardial contusion than do CK_MB 43 cTnI is a specific
biochemical marker of myocardial injury. Measures of this
marker may help to indicate myocardial contusion because

serum levels are not increased in patients with severe acute
or chronic skeletal muscle injury. The normal level for cTnI
is 0.03-0.14 ng/ml; levels of greater than 0.15 ng/ml
indicate cardiac inj ury 42
Treatment of myocardial contusion involves treatment
of symptoms. Long-term sequelae of myocardial contusion in children are unknown. Aneurysm, myocardial
rupture, and postcontusion pericarditis have been reported in
adults.
Aortic Rupture. Aortic rupture, although rare in the
pediatric population, can occur secondary to blunt trauma.
Common sites of injury are the descending aorta distal to the
level of the ligamentum arteriosum, which is associated
with horizontal deceleration injuries; and disruption of
the ascending aorta, secondary to vertical deceleration
injuries. 44
Injuries may vary from a small tear in the intimal lining
to complete transection. Signs and symptoms of injury will
range from no external sign of injury to cardiopulmonary
arrest. Discrepancies between pulse in the upper and lower
extremities and between blood pressure in the limbs are
suggesti ve of aortic trauma.
Interventions for the patient with aortic injury include
assisting with diagnostic procedures such as an aortogram.
Fluid resuscitation is started immediately, and the patient is
prepared for immediate thoracotomy.
Diaphragmatic Rupture. Rupture of the diaphragm
occurs most commonly following blunt trauma in which
there is a sudden increase in intraabdominal or intrathoracic
pressure against a fixed diaphragm. The left hemidiaphragm
is most commonly injured. The diagnosis is often missed
when the child is asymptomatic.
The most common presenting symptoms are chest pain
and shortness of breath. Unilateral diaphragm dysfunction
accompanied by herniation of intraabdominal contents into
the chest cavity causes these symptoms. Physical examination may reveal decreased breath sounds or auscultation of
bowel sounds over the affected lung. The mediastinum may
shift to the contralateral side and the abdomen will appear
scaphoid in the infant and young child. Chest roentgenogram may reveal diaphragmatic displacement, loops of
bowel in the thorax, or the presence of a nasogastric tube in
the thoracic cavity (Fig. 28-16). Surgical repair of the
diaphragmatic tear is required.
Tracheobronchial Injury. Tracheobronchial tree injury is rare in the child because of the elasticity of the thorax
and the mobility of the mediastinum. Blunt tracheobronchial
injury can result from a variety of forces, including shearing,
compression, and vertical stretch. Injuries most commonly
occur at the take-off point of a mainstem or upper lobe
bronchus.
Signs of a tracheobronchial disruption include mediastinal or subcutaneous emphysema, hemoptysis, airway obstruction, pneumothorax with persistent airleak, and massive atelectasis refractory to treatment. Bronchoscopy is the
most reliable means of diagnosing the site and extent of
injury. Treatment is variable, depending on the thoracic
injury, tolerance of the child, and associated lesions.
Surgical repair of the lesion may be indicated; however,
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Fig. 28-16

X-ray film positive for diaphragmatic hernia.

conservative treatment by thoracic drainage or lesion
intubation has been effective. 45
Critical Care Management. Critical care management of the child with thoracic trauma is injury specific.
Chapters 7, 8, 18, and 19 provide information about
assessment and management of children who develop the
final common pathways of respiratory failure and low
cardiac output.

Abdominal Injury
Etiology/Incidence. Abdominal injuries in children
are not common; however, the failure to promptly diagnose
these injuries and successfully manage them accounts for
increased mortality and morbidity. Usually, serious injury to
the head or limbs is obvious, whereas serious abdominal
injury tends to be subtle.
Features of a child's physical maturity may place the
youngster at increased risk for injury. For a number of
reasons, the abdomen of a child is at greater risk for
injury than an adult's abdomen. The smaller size of the
abdomen predisposes the child to multiple rather than single
injuries because energy from the impacting force is dissipated. The large solid organs, which are most often injured,
are covered with only a very flexible rib cage and a less
developed abdominal musculature, which provide little
protection. 46
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Abdominal trauma continues to be the leading cause of
morbidity and mortality in children, with blunt trauma
accounting for the majority of injuries. Examples of
mechanisms that result in intraabdominal injury include
falls, pedestrian accidents, bicycle accidents, and motor
vehicle crashes. 47 The mechanism of injury is similar in
these examples and results in blunt trauma, better defined as
injury occurring when kinetic energy is transferred to the
intraabdominal organs through the abdominal wall.
Penetrating injuries are often caused by gunshot, stabbings, or impalement on an object. These mechanisms may
cause injury to any or all of the abdominal organs and
vessels. Hollow viscus injuries are more common with
penetrating trauma. 4
Pathogenesis. The pathogenesis of abdominal
trauma is related to the specific abdominal organ injured.
The most frequent final common pathway is severe
bleeding.
Spleen. The spleen is the most commonly injured
abdominal organ in childhood. Splenic injury usually
follows blunt trauma to the upper abdomen or lower thorax.
Recent advances in understanding splenic function have
revolutionized the treatment of splenic injuries; pediatric
surgeons in particular have championed nonoperative management of this injury type 48
The spleen is located in the left hypochondrium, where in
older children and adolescents, the lower rib cage covers the
spleen entirely. In infants and small children, the rib cage
does not extend down far enough and is also more pliable
than the ossified adult rib cage. Therefore the pediatric
spleen is not adequately protected by the rib cage.
The child with a splenic injury usually receives a blow to
the left upper quadrant with or without an associated rib
fracture. The child often experiences pain in the left
shoulder, in the left upper quadrant, or in the left part of the
chest with breathing. Bruising, abrasions, nausea, and
vomiting may be present. Heart rate and blood pressure may
be normal, or mild tachycardia and hypotension may occur.
A mass may be palpable in the left upper quadrant. The child
may have a positive Kehr sign (pain in the left shoulder),
Turner sign (ecchymosis in the left flank), and/or Cullen
sign (ecchymosis around the umbilicus). Ecchymosis in the
left upper quadrant or left flank is a strong indication of
injury.48
Laboratory analysis is often normal in a child with
splenic injury, but if abnormalities are seen, they are usually
a decreased hematocrit and leukocytosis in the 20,000 to
30.000 mm 3 range. Both chest and abdominal x-ray films
may be suggestive of splenic trauma; Box 28-2 presents
these findings. An abdominal x-ray film alone will not
confirm the diagnosis of splenic trauma. It will, however,
provide evidence to confirm the clinical findings. CT is used
to evaluate splenic injuries. CT is also used to increase the
use of nonoperative management of splenic injuries and
splenic salvage. 49
Treatment is aimed toward splenic preservation. The
spleen has three main functions: clearance and phagocytosis
of particulate matter from the blood, antibody formation,
and hematopoiesis. It performs these functions through a
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Box 28·2

..

X-ray Examination Findings Suggestive
of Splenic Injury

Chest X-ray Findings
Lower left rib fractures
Elevation of the left hemidiaphragm
Pleural effusion
Abdominal X-Ray Findings
Raised left hemidiaphragm
Stomach dilation or medial displacement
Opacification of the left hypochondrium
Downward displacement of the transverse colon
Fluid between coils of intestines
From Scorpio RJ. \Vesson DE: Splenic trauma. In Eichelberger MR. ed:
Pediatric trauma: prevention, acute care, rehabilitation. St Louis, 1993,

Mosby.
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TABLE
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Spleen Injury Scale

Injury Description

itli

~[Hematoma
~co;.

Subcapsular, nonexpanding, <10% surface
area
Capsular tear, nonhleeding, <I cm parenchymal tear

;i·U

:~t~ematoma
JE~.
iF::'·i!",'

~i.aceration
~:,-

&.
~c

.,-Hematoma
~[~~-

~m>
~E:~j

combination of specific microanatomy and a high rate of
blood flow. Originally thought to be expendable, it is now
realized that the spleen plays a critical role in combating
infection. Appreciation of the increased risk of overwhelming postsplenectomy sepsis in children has led to a
heightened awareness of the importance of splenic preservation, especially in the pediatric age group. Currently,
postsplenectomy sepsis is a well-recognized syndrome that
can occur days to years following removal of the spleen.
More specifically, the spleen is recognized as a source of
antibodies against Haemophilus injluenzae, pneumococcus,
and meningococcus. Preservation of even a portion of the
spleen provides some protection against postsplenectomy
infection. As a result, strategies for splenic conservation
have been developed and splenorrhaphy, which refers to
suturing of the spleen, is often performed when operative
management is necessary48
The spleen may be preserved by nonoperative means as
well; in fact, most children with splenic trauma can be
treated this way. Nonoperative management is recommended for the child who maintains stable vital signs,
requires less than one-half blood volume replacement, and is
free of other abdominal injuries that require surgery49 If the
child is monitored nonoperatively, close monitoring in the
intensive care unit is required for at least 24 hours. Vital
signs are assessed frequently, and hematocrit and hemoglobin are measured at least daily. Strict bedrest is maintained
until there have been no requirements for blood for 48
hours. At this point, ambulation can occur and the child can
be discharged home. Discharge is determined by the severity
of injury based on the splenic injury scale. Complications of
nonoperative management are primarily associated with
rebleeding. This complication is indicated by unstable vital
signs, decreasing hematocrit and hemoglobin, and worsening findings on abdominal examination.
After discharge, the child may return to school but should
refrain from vigorous activities for a period of time,
depending on the severity of the splenic injury. A case report

28·3

~'taceration
:~""

Subcapsular, 10%-50% surface area, intraparenchymal, nonexpanding, <5 cm
diameter
Capsular tear, 1-3 cm parenchymal depth,
does not involve a trabecular vessel
Subcapsular, >50% surface area or expanding; ruptured subcapsular or parenchymal
hematoma; intraparenchymal hematoma
>5 cm or expanding
>3 cm parenchymal depth or involving
trabecular vessels
Ruptured intraparenchymal hematoma with
active bleeding
Laceration involving segmental or hilar
vessels producing major devascularization (>25% of spleen)
Completely shattered spleen
Hilar vascular injury that devascularizes
spleen

~Jirom Lynch JM, Meza MP, Newman B et a1: Computed tomography
~£:grade of splenic injury is predictive of the time required for
H~'fadiographic healing. J Pediarr Surg 32: 1093-1 096.
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recently described a boy who experienced splenic trauma,
which was managed nonoperatively. Thirty-eight days
postinjury, he experienced splenic rupture after low intensity
swimming and one dive from the side of the pool 50 Lynch
and colleagues determined that the time to radiographic
healing is directly proportional to the severity of splenic
injury, based on the Spleen Injury Scale (Table 28-3).51
Based on Lynch's work, the mean time to radiographic
healing in Grade I, II, Ill, and IV injuries is 3.1, 8.2, 12.1,
and 20.7 weeks, respecti vely.
If the child requires operative management and splenic
preservation is not possible, a splenectomy is required.
Standard principles of postoperative care will apply; however, because these children are at risk for overwhelming
postspleneclomy infection (OPSI), protection from infection
is critical. This is accomplished through vaccination and
prophylactic antibiotics. Vaccines available are those against
pneumococcus, H. injluenzae type B (HIE), and Neisseria
meningilidis. The use of the pneumococcal and HIE
vaccines is strongly recommended. These vaccines are
administered in the postoperative period.
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Even with vaccines, antibiotic prophylaxis is suggested,
especially in infants and young children. Penicillin prophylaxis is recommended to continue until adolescence. Amoxicillin is advocated by some instead of penicillin because it
is effective against HIB. Erythromycin may be used as an
alternative to penicillin for children with a penicillin
allergy.48
Not surprisingly, patient compliance with antibiotic
regimen prophylaxis is poor. In addition, infections can still
occur. Therefore it is critical that parent teaching include
recognition of signs of infection and prompt medical
attention for initiation of antibiotics.
Liver. Liver injuries are a major cause of death in
children with blunt trauma. Severe liver injuries are
associated with significant blood loss, and exsanguination is
the most common cause of death. A shearing force results
from sudden deceleration and consequently, the pattern of
injury in the liver parenchyma can vary widely and be very
diffuse. Right lobe injury is more prevalent than left;
fortunately, the majority of right-sided injuries are superficial and simple. In contrast, left-sided injuries tend to be
deeper and more complex. 52
Children with liver injuries experience pain in the right
upper shoulder or right upper quadrant tenderness. They
may also have bruising, seatbelt markings, and abrasions.
Hypotension may be present if major bleeding is occurring.
Fractured ribs are a common concomitant finding.
Initial laboratory tests include a complete blood
count (CBC), urinalysis, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and amylase. Elevations in AST and ALT appear to correlate with hepatic
injury.52
Management of children with hepatic injuries is similar
to the treatment for splenic injuries. Nonoperative management for the hemodynamically stable child is the treatment
of choice. Nonoperative management, however, mandates
that the child be followed closely in the intensive care unit
with frequent monitoring of blood work. Hematocrit levels
are assessed every 4 hours or more often, if indicated by
clinical condition. Once the liver transaminase normalizes,
the child can ambulate; however, activity is restricted until
complete healing has occurred. Delayed bleeding has been
reported to occur as late as I month after injury.52
Operative management is indicated if the child exhibits hemodynamic instability, transfusion requirements of
greater than 33% to 50% of the circulating blood volume
in 24 hours, signs of peritoneal irritation, or a pneumoperitoneum or other abdominal injuries that require surgical
repair52 .53 In the case of a severely injured liver, such as
a lobar fracture, the initial management is to control the
massive bleeding. Hemodynamic instability, defined by the
need for a blood transfusion in excess of 25 mllkg within
the first 2 hours, is a strong indicator of major hepatic
vascular injury which is associated with a high mortality
rate. 53 If liver resection is required, it also carries a high
mortality rate. 52
Pancreas. Pancreatic injury is relatively uncommon in
children. Because of its relative protection in the retroperitoneum, occurrence of injury is documented in only 3% to
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Box 28-3
Classification of Pancreatic Injury

Class I
Class II
Class III
Class IV

Contusion or laceration without duct injury
Ductal transection or parenchymal injury with
probable duct injury
Proximal transection or parenchymal injury with
probable duct injury
Combined pancreatic and duodenal injury

From Jobsl MA, Canty TG, LynCh FP: Management of pancreatic injury in
pediatric btunl abdominal trauma. j Pedialr Surg 34:818-823. 1999.

12% of all cases of severe abdominal trauma. The diagnosis
of pancreatic injury, short of intraoperative inspection, is
often difficult and given the current preference of nonoperative management of most pediatric abdominal injuries,
delays are common. 54 Traumatic pancreatitis commonly
results from blunt trauma compressing the pancreas over the
body of the vertebral column, causing contusion and/or
parenchymal disruption with or without ductal disruption
(Box 28-3). Because of the retroperitoneal location of the
pancreas, associated injuries involving the duodenum,
stomach, extrahepatic biliary system, and the spleen are
common. Injury resulting from pancreatic trauma is usually
devastating because of extensive bleeding and tissue damage from pancreatic and biliary secretions.
Children who have experienced pancreatic trauma usually have diffuse abdominal tenderness, abdominal pain,
vomiting, and findings of associated injuries. Hemodynamic
instability may be present, resulting from massive retroperitoneal bleeding or massi ve sequestration of third space fluid
losses.
Although serum amylase level remains one of the most
useful indicators in detecting pancreatic injury, elevated
levels also occur with other diagnoses or injuries such as
appendicitis, bowel perforation, mesenteric thrombosis, and
salivary gland trauma. In addition, initial serum amylase
levels do not correlate with the severity of pancreatic
injury55 An important consideration is the trend of amylase
elevations. Although a single elevated level may not be
indicative of pancreatic injury, a trend of increasing levels
may be. Also, a high level followed by decreasing levels
may indicate pancreatic contusion without ductal injury.56
Other diagnostic methods, including serum lipase levels, CT
scan, and ultrasound, are limited by low sensitivity and
specificity for acute injury when performed as part of the
initial evaluation 54
The preferred treatment of traumatic pancreatitis is
nonoperative, if there is no evidence of ductal disruption.
The use of nasogastric suction to rest the gastrointestinal
(GI) system is a major treatment modality. Also, total
parenteral nutrition is important and is continued for at least
3 weeks to allow for bowel rest. In addition, serial physical
examinations are important and the child is monitored for
signs of infection. Complications include the development
of pancreatic fistulas and pseudocyst formation.
Operative management is indicated for patients who have
pain, fever, ileus, or elevated serum amylase levels that
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persist or develop. Also, external drainage or partial or total
pancreatectomy may be performed for children who have
findings of traumatic pancreatitis at the time of operative
exploration for other intraabdominal injuries.
Gastric and Intestinal Injury. Hollow visceral injury is uncommon and occurs in less than 2% of the
children evaluated for blunt abdominal trauma. 57 In recent years, however, the incidence is increasing as a result
of improved recognition and societal influences such as
urban violence and child abuse. Also, the widespread
availability of guns has led to an increase in penetrating
injury, which most commonly affects the hollow visceral
organs. 58
Hollow viscus injuries are difficult to diagnose. The only
early sign of this type of injury may be a subtle degree of
abdominal tenderness. Specific solid-organ injuries are
useful indicators for hollow viscus injuries. Injury to the
pancreas is associated with hollow viscus injury because the
C-loop of the duodenum encircles the head of the pancreas
and is at high risk when the pancreas is injured. 59
Abrasions or contusions in the upper abdomen should
raise the index of suspicion for stomach injury. Bloody
gastric drainage, tympanic sounds when percussion is
performed over the liver, detection of free air, and a
nasogastric tube in abnormal position on an x-ray film are all
indicative of stomach injury. If the stomach perforates, the
child develops a board-like abdomen with intense pain.
Peritonitis develops within hours, and surgery is always
required.
The small intestine can be ruptured by even mild
abdominal trauma. Perforation of the small intestine may
result from compression, such as that which occurs with lap
belts. The child with ruptured intestines may have minimal
symptoms, yet frank peritonitis is inevitable. Surgical repair
is always required. Perforation of the small bowel has low
mortality and complication rates if surgery takes place
within 24 hours of injury.60
The colon and rectum are rarely injured, and when they
are, injury is usually due to penetrating trauma. 61 The child
presents with signs of free air or peritonitis on x-ray films.
Surgical repair is necessary.
Critical Care Management. Assessment of the child
with a suspected intraabdorninal injury includes a careful
history of the incident including mechanism of injury,
consideration of the child's subjective complaints, and
meticulous physical examination. In addition, appropriate
and accurate diagnostic evaluations are essential. Caring for
a child with an intraabdominal injury necessitates a multidisciplinary approach. Essential team members include, but
are not limited to, surgeons, intensivists, pediatric nurses,
and radiographic specialists. 62
Evaluation of children with blunt abdominal trauma
continues to present a significant challenge. Physical
examination alone does not allow for enough sensitivity for
accurate diagnosis; thus clinicians need to rely on more
objective diagnostic methods for a more thorough assessment. With respect to penetrating trauma, however, this is
rarely an issue because exploratory laparotomy is indicated
in nearly all cases. 63
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28-4 Peritoneal Lavage Results
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Mason PJB: Abdominal injuries. In Cardona VD, Hurn PO,
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Historically, diagnostic peritoneal lavage (DPL) and CT
have been considered the standard methods for evaluating
blunt abdominal trauma. DPL is helpful for deciding if
laparotomy is indicated in hemodynamically unstable patients (Table 28-4). CT provides more precise information
about the severity of injuries if the patient can tolerate the
scanning procedure. More recently another diagnostic tool,
ultrasonography (US), has been used for evaluating blunt
abdominal trauma. US has been used in Europe and Japan
since the 1980s, and its usefulness has recently been
acknowledged in the United States M The decision as to
which diagnostic method to apply, however, is often
controversial.
Advocates of US propose that it is a quick and efficient
method for evaluating patients who have sustained blunt
abdominal trauma, US can be performed simultaneously
with ongoing resuscitation measures in the emergency
department, thus eliminating the need to transport the child
to radiology. It is also safe, inexpensive, and noninvasive
and can easily be repeated. US invol yes no radiation or
contrast use and causes minimal discomfort. It is also the
method of choice for patients with clotting disorders or
adolescents who may be pregnant. Ultrasound waves are
transmitted well in abdominal organs, soft tissue, and fluids,
such as urine, bile, blood ascites, and pleural fluid; they are
not transmitted in air-containing organs such as the lungs
and the GI tract. Direct localization and grading of the organ
injury by US is not possible in most cases and time should
not be spent attempting to quantify the severity of the lesion.
The goal is to demonstrate the presence of a significant
hemoperitoneum in an unstable patient, which establishes
the need for immediate laparotomy.63
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Despite enthusiastic support for US as a diagnostic tool
for evaluating blunt abdominal trauma, many clinicians
recommend a cautious approach when considering its use.
Although abdominal US can be a very powerful tool to
rapidly triage a sick and unstable child in the emergency
department, it can also have a high false-negative rate; thus
many clinicians strongly advise against relying solely on
abdominal US for definitive management. 65 US is a
valuable screening method to determine the need for further
diagnostic testing; however, it is often believed that it should
not replace DPL or CT in the evaluation of intraabdominal
injury.
The management of blunt abdominal trauma in children
has changed significantly in the past decade as a result of
advances in diagnostic imaging and an improved understanding of the healing processes in the spleen and liver. In
the past, mandatory laparotomy was the accepted mode of
treatment for proven or suspected hemoperitoneum. Such
treatment modalities have been replaced with intensive
observation of patients able to be stabilized with supportive
therapy. Numerous pediatric centers throughout the country
have experienced very high success rates with nonoperative
management of blunt abdominal trauma. As a result, a
concomitant reduction in morbidity and mortality has
occurred. 66 In addition, nonoperative management has been
shown to decrease risks associated with blood transfusions
and the length of hospital stay.67
Although nonoperative management of abdominal injuries is the most frequent and preferred treatment of
choice, it is essential to clarify that "nonoperative" is not
synonymous with "nonsurgical." Expert surgical consultation is required in all but the most trivial of abdominal
injuries. If nonoperative management is to be successful,
meticulous observation in an intensive care setting is
essential.
Immediate treatment focuses on cardiopulmonary stabilization, if appropriate. If the child is hemodynamically
unstable, an intravenous line is placed, ideally above the
diaphragm in case of rupture of the hepatic vein and the
inferior vena cava. Resuscitation fluids are administered. If
the child is managed nonoperatively, close monitoring of
vital signs (especially trends) and appropriate serum levels
is mandatory. Indications for laparotomy include massive
bleeding, unstable vital signs in spite of aggressive fluid
resuscitation, requirements for more than one half of the
child's circulating blood volume for replacement, severe
abdominal distension associated with hypotension, penetrating injuries, and some blunt injuries.
Penetrating wounds of the abdomen require surgical intervention. Penetrating injuries often result in bleeding or perforation of the hollow viscera; therefore peritoneal irritation or hemorrhagic shock appears early. If
signs are not evident, significant injury may still exist and
surgical exploration is still indicated. Penetrating wounds
may result in evisceration of the abdominal contents. The
organs are not replaced into the abdomen and are not
allowed to kink or twist. The abdominal organs are covered
with moist, sterile dressings until surgical repair can take
place. 4
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Genitourinary Injuries
Etiology/Incidence. Genitourinary injuries occur often in children, with 90% the result of blunt abdominal
trauma. Trauma to the genitourinary tract is strongly
suspected in the patient with multiple injuries, because
symptoms may be obscured by concomitant injuries.
Unique anatomic features of the child's genitourinary
system allow for an increased risk of renal and bladder
injury. A child's bladder lies higher in the abdomen, as
compared with an adult's bladder that rests in the pelvic
region; weaker abdominal muscles in the child are thus less
protective of the bladder. In addition, underdeveloped
abdominal musculature along with decreased perirenal fat
offers less protection to the kidney. The kidney is proportionately larger in relation to the rest of the body. Also. the
kidney may retain fetal lobulations, which allows for easier
parenchymal disruption because these tobulations are less
resistant to blunt forces. 68
Children with congenital renal abnormality are more
vulnerable to injury from blunt trauma than other children.
The hydronephrotic, ectopic, or diseased kidney is prone to
injury from even minor trauma. The incidence of renal
injury in children who have a preexisting anomaly or disease
is between 5% and 21%.69
Pathogenesis. Approximately 80% of genitourinary
injuries result from blunt trauma and the remaining 20%
from penetrating trauma. The mechanism of renal injury as
a result of blunt abdominal trauma may be direct or indirect.
With a direct injury, the kidney is crushed against adjacent
viscera, ribs, spinal column. or abdominal wall. An indirect
injury, or decelerating injury, primarily causes contusion or
laceration. Renal injuries as a result of indirect mechanisms
are difficult to detect, and only an accurate description of the
injury will lead to the correct diagnosis.
A variety of classifications of renal injuries are described
in the literature-some in terms of minor and major; others
in terms of degree of contusions, lacerations, and tears. A
classification of renal injuries is presented in Fig. 28-17.
A child who has sustained blunt trauma may be
asymptomatic or complain of abdominal or flank pain.
Hematuria, which is the hallmark sign of renal injury, may
occur in 90% of cases, yet there is no correlation between
the magnitude of injury and the degree of hematuria. Also,
the absence of hematuria does not exclude the possibility of
renal injury if there are other findings that strongly suggest
it. Plain abdominal x-ray films are rarely helpful; up to 85%
are normal in spite of proven kidney injury. Instead, the
excretory urogram (IVP) is the standard for diagnosis of
renal injury. However, hypotension with low perfusion can
cause poor upper urinary tract visualization and may make
the IVP a limited imaging technique.
US provides anatomic, not functional, information. Ease
of use because of its portability and absence of radiation
make it a helpful tool with respect to locating a kidney if it
is not visualized with IVP. Doppler-enhanced US may
provide information on renal perfusion and verify the
integrity of the vascular pedicle of the kidney. CT continues
to be the standard imaging study for acute renal trauma in
children, primarily because there is more accurate display of
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Fig. 28-17 Composite of the five classes of blunt renal injury:
I, contusion; 2. laceration; 3. transection; 4, fragmentation;
5, pedicle injury. (From Hensle TW. Dillon P: Renal injuries.
In Touloukian RJ, ed: Pediatric traumLl. ed 2, St Louis, 1990,
Mosby.)

renal injury and better visualization of nonvascularized
areas of renal tissue. 69
Although significant controversy exists with regard to the
management of renal trauma, the ultimate goals are to
prevent mortality, reduce immediate and long-term morbidity, and preserve as much functioning renal parenchyma as
possible. 7o Considering that patients with renal trauma often
have associated injuries, the immediate management of the
patient is determined more by the patient's general clinical
state than by the renal injuries. Renal injuries, in and of
themselves, are rarely life threatening; hypovolemic shock
in patients with renal injury is nearly always due to
associated trauma.
The management of blunt kidney injury in children is
dependent on the stability of the child and the extent of the
injury. Approximately 85% to 95% of renal injuries are best
managed nonoperatively.71 Injuries in this category include
contusions and simple lacerations. Successful results can be
anticipated with nonoperative management if the child is
maintained on bed rest with monitoring of laboratory
studies, vital signs, and urinary status. The remaining 5% to

15% of clinically stable patients with major renal trauma
elicit controversial opinions with regard to operative versus
nonoperative treatment. Some centers advocate routine
exploration and repair of such injuries, whereas others
advocate conservative management. There is less controversy concerning management of penetrating trauma than
there is about management of blunt renal trauma. Most
penetrating renal injuries require surgical exploration during
laparotomy for associated intraabdominal injury. A minor
renal stab wound without associated intraabdominal injury
may be observed in a child with stable vital signs and
with radiographic evidence of parenchymal function. In
contrast, gunshot wounds almost always require surgical
exploration. 69
The incidence of ureteral trauma in children is low but is
suspected after severe blunt trauma or penetrating injury to
the abdomen. When ureteral injury does occur, the most
common is the separation of the ureter at its junction with
the renal pelvis. This may occur as a result of a sudden
extreme flexion of the trunk that stretches the ureter. This
injury is more likely in children because of their hyperextensible and hypermobile spine. 72
Attention to the description of injury is essential for a
correct diagnosis. IVP is the best screening test for ureteral
injury; it will be manifested as urinary extravasation or a
decrease in collecting system visualization or both. Operative repair is required for such injuries, and recovery is
usually without sequelae if the injury is recognized early and
treated appropriately.72
In the child, the bladder is considered an abdominal
organ and therefore vulnerable to external trauma. As the
bony pelvis grows, the bladder eventually becomes a pelvic
organ and more protected from injury. Although penetrating
trauma to the bladder, such as from a gunshot or stab wound,
can occur, blunt trauma to the abdomen is the more common
cause of injury. Blunt injury most commonly results from
motor vehicle accidents, falls, crushing injuries, or blows to
the abdomen. 72 Bladder rupture is most often defined as
extraperitoneal or intraperitoneal. Intraperitoneal rupture of
the bladder occurs following a sudden rise in the intravesical
pressure resulting from a blow to the pelvis or lower
abdomen (seat belt injury). The increased pressure ruptures
the dome of the bladder, which is the weakest and most
mobile part of the organ. Treatment of intraperitoneal
rupture requires surgical intervention because continued
intraperitoneal spillage of urine leads to metabolic derangements, such azotemia and acid-base disorders, which
potentially lead to death of the child. 72
Extraperitoneal bladder ruptures are seen almost exclusively in association with pelvic fractures. The bladder is
usually sheared on its anterior lateral wall, near the bladder
base. Treatment of extraperitoneal bladder rupture is best
accomplished through a selective approach. The extent of
the injury and the sex of the child are important considerations when formulating a treatment plan. With the exception of large or complicated extraperitoneal rupture, bladder
catheter drainage permits complete healing in most cases.
This approach is advantageous because it does not convert
a closed pelvic fracture to an open one. If the suspected
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injury is due to penetrating bone fragments, surgical
exploration to remove or reduce the bone fragments is
preferable in order to prevent persistent leakage and
. 69
sepsIs.
Urethral injuries in the female are rare because of a short
urethra. Urethral injuries are seen most often in males
because the male's urethra is longer and less well protected.
In males, urethral injuries are generally divided into two
types: posterior and anterior. Posterior injuries include those
of the prostatic and membranous urethra, above and
including the urogenital diaphragm; anterior injuries include
those of the bulbous and penile, or pendulous, urethra below
the urogenital diaphragm. Almost all injuries of the posterior
urethra in males occur in conjunction with fracture of the
bony pelvis. Most of these injuries are due to motor vehicle
accidents involving automobiles, motorcycles, or pedestrians. Shearing forces of the bony disruption cause urethral
injury. Most injuries of the anterior urethra are due to blunt
trauma to the perineum. The bulbous urethra is crushed
against the pel vic arch as the patient falls astride an object.
Common mechanisms of injury include straddling a fence,
having a foot slip from the rung of a ladder, or hitting a
bump in the road while riding a bicycle and coming down
hard on the seat or the crossbar. 72
Management of urethral injuries is individualized depending on the severity and extent of injury. Minor and
incomplete anterior injuries may be able to be managed with
temporary suprapubic diversion; more severe anterior injury
may require diversion and staged urethroplasty. A common
complication of this type of injury is stricture formation.
Posterior injury, usually caused by pelvic fracture, is more
difficult to manage. Most clinicians agree that posterior
urethral tears require suprapUbic diversion and delay of
treatment of any resultant stricture. Although some clinicians favor early operative intervention, many advocate
treatment delay because complications such as stricture,
incontinence, and impotence are infrequent. 69
Injuries to the male genitalia may be the result of blunt
trauma or penetrating injury. Examples of blunt trauma
include falls or kicks, whereas penetrating injuries may be
due to falls onto sharp objects such as glass, fences, sticks,
and so on. Injury to the penis may be caused by a falling
toilet seat in a child being toilet trained; zipper injuries are
also common, particularly in uncircumcised males who
catch the redundant foreskin in the zipper of their pants.
Testicular trauma in males can also occur during sporting
events if the child is hit or kicked in the scrotum.
Management of such injuries depends on the type and
severity of the injury.
Perineal injuries of young females may occur as a result
of falls on sharp or blunt objects or straddle injuries. It is
important to pay careful attention to the history; if it is not
consistent with the type and degree of injury, sexual abuse
is suspected. In any injury to the female vulva or vagina,
urethral or rectal injuries are also considered. Management
of the injury will depend on the extent and severity of the
injury.
Critical Care Management. The abdomen and flank
are examined carefully to detect the presence of pain,

Trauma

969

masses, abrasions, contusions, or flank ecchymosis (Grey
Turner's sign), all of which may suggest retroperitoneal
bleeding. Considering that genitourinary injuries are rarely
life threatening, knowledge about the location, type, and
extent of injury is necessary as a guide to determine
appropriate treatment. A detailed history and physical
examination are critical. Details of the method of injury are
elicited from the patient, family. or others who may have
been present. Signs and symptoms of genitourinary trauma
will vary depending on severity, location, presence of
associated injuries, and the child's general condition.
Urinalysis is performed early in the evaluation of every
child who suffers significant trauma.
Some form of radiographic investigation is necessary to
exclude injury to the urinary tract if a child presents with
hematuria, a history of a deceleration injury, or abdominal
trauma. The specific imaging method may vary depending
on the clinical status of the patient, the capability of the
institution, and practitioner preference. Radiographic imaging may include [YP, renal scan, cystogram, US, CT scan,
and renal angiography. The type and role of radiographic
evaluation is a controversial subject. In the past, IYP was
recommended for all patients with hematuria; currently,
many practitioners are reluctant to expose all children to a
potentially serious reaction to contrast medium, and unnecessary radiation and expense. Instead, they recommend that
IVP be used in children with physical findings of renal
injury, evidence of significant blood loss or hematuria, or
when renal artery injury is suspected. CT scans have become
more widely used and are often the procedure of choice for
many practitioners. The major benefit of CT scan is that all
organs in the upper abdominal and retroperitoneal areas can
be simultaneously evaluated. 72
The management of genitourinary injury is primarily
nonoperative and is aimed at prevention of complications
and maintenance of function. 69 Management involves close
monitoring for signs of complications and progress of
healing.

Orthopedic Injury
Etiology/Incidence. Musculoskeletal trauma is common in children; it occurs in approximately 20% of all
trauma sustained by children. 73 Skull and clavicle fractures
are most common at birth; however, during the first year of
life, fractures are rare. Fractures that occur during the first 2
years of life may be an indication of skeletal problems, bone
disease, or child abuse. In children 2 years of age through
adolescence, fractures of the upper extremity occur more
often than fractures of the lower extremity.73 Fractures of
the femoral shaft peak during toddler and adolescent years
with the primary mechanisms also being age dependent.
Falls are the primary mechanism of injury for children
younger than 6 years of age, motor vehicle-pedestrian
incidents for children 6 to 9 years old, and motor vehicle
incidents for adolescents. 74
Motor vehicle incidents are a common cause of fractures
and are associated with the more serious injuries. For
example, the unrestrained child in a car can be tossed around
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the inside in a crash and actually ricochet off the interior
structures multiple times. A child pedestrian can be thrown
a long way with significant force upon impact.
Falls are another common cause of fractures. Children
may fall from great heights, resulting in numerous fractures
along with other injuries. Additional causes of fractures
include sports-related trauma, penetrating injuries, and child
abuse. With child abuse, fractures are a common manifestation, second only to skin injuries.
Children are susceptible to fractures because of the types
of activities they engage in and because of their immature
skeleton. Many fractures, such as hairline or greenstick
fractures, are not serious, but intraarticular or epiphyseal
plate fractures have serious potential for growth plate
disruption.
Children have different complications from fractures
than adults. Growth disturbances will follow epiphyseal
plate fractures. Osteomyelitis resulting from an open
fracture or an open reduction from a closed fracture tends to
be more extensive in a child. This infection has the potential
to damage the epiphyseal plate, resulting in growth disturbance. Volkman ischemia (resulting from vascular compromise) of the nerves and muscles, posttraumatic myositis
ossificans, and refracture are more common in children. 75
Tom ligaments and dislocation are less common in
children. The ligaments are strong and resilient; in fact, the
ligaments are stronger than the associated epiphyseal plates.
A sudden extension on a ligament at the time of injury

results in the separation of the epiphyseal plate rather than
a tom ligament.
This is also true of the fibrous joint capsule. The type of
injury that would produce a traumatic dislocation of the
shoulder in an adult will produce a separation fracture of the
proximal humeral epiphysis in a child.
Children's fractures heal more rapidly because of the
osteogenic activity of the periosteum and endosteum. The
osteogenic activity is very active at birth, decreases progressively throughout childhood, and remains constant from
adulthood to old age.
Pathogenesis. The mechanism of bone injury involves external forces acting on the body and the bony
structures (direct impact) or internal forces caused by
muscle contraction or ligament stress (bending force). Bone
breakage is produced by loading forces where the ability of
the bone to store and dissipate energy by temporary
deformation has been exceeded. Loading forces include
bending, tension, compression, torsion, and combined
loading. These forces can be applied along the bone's long
axis or along the traverse axis. The magnitude and rate of
loading will determine the extent of bone deformation.
Epiphyseal fractures are of particular concern in children.
As mentioned earlier, these injuries have the potential to
produce growth disturbances in children by causing progressive angular deformity and limb length discrepancies 76
Epiphyseal fractures have been classified according to the
Salter-Harris classification (Table 28-5).

Salter and Harris Classification of Epiphyseal Plate Fractures

W
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Description

Management

Prognosis

Complete epiphyseal separation
without fracture; most common in
younger children with thick epiphyseal plates

Closed reduction and cast
immobilization

Excellent unless the blood supply to
the epiphysis is compromised

Most common epiphyseal fracture;
separation of epiphyseal plate with
a fracture through the metaphysis,
producing a triangular fragment

Closed reduction and cast
immobilization

Excellent unless the blood supply to
the epiphysis is compromised

Fracture through part of the epiphyseal plate and extending into the
joint

Open reduction and internal
fixation usually required

Good, with restoration of normal
joint surface and vascularity

Fracture completely through the
epiphyseal plate and extending
through a portion of the
metaphysis

Open reduction and internal
fixation

At risk for interrupted longitudinal
growth unless there is perfect anatomic alignment, which must be
maintained until complete healing

Crush injury to an area of the epiphyseal plate that is nondisplaced
with no fracwre line visible on
roentgenography

Immobilization and non-weight
bearing for a minimum of
3 weeks to prevent further
compression

Poor. Injury is frequently identified
only in retrospect after growth
disturbance has occurred

•.

,oy C: Musculoskeletal trauma. In Joy C. edt Pediatric trauma nursing. Rockville, Md, 1989, Aspen Publishers.
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Types of fractures seen in children are presented in Fig.
28-18. Greenstick fractures are common in small children
and are characterized by an incomplete fracture of the bone
with a portion of the cortex and periosteum still intact.
Trans verse fractures are seen in infants and small children
with the fracture line across the bone at a right angle to the
longitudinal axis of the bone. Spiral fractures are caused by
torsional forces, such as when the extremity rotates while
the body remains in a fixed position. This injury is
commonly associated with child abuse. Comminuted fractures are seen more often in older children and adolescents
and are the result of a high-impact force such as a fall from
a high height or a high-speed motor vehicle accident.
Pelvic fractures may occur as the result of a severe injury,
such as that associated with a motor vehicle accident. The

Transverse - Results from angulation force

or direct trauma.
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most important aspect of the fracture is not the fracture itself
but associated complications such as internal bleeding from
tom vessels and extravasation of urine from bladder rupture
or urethral injury. Pelvic fractures are classified as stable or
unstable, depending on whether the fracture interferes with
the stability and integrity of the pelvic ring. Stable fractures
do not transgress the pelvic ring, therefore they do not
interfere with the stability of the pelvis in relation to weight
bearing and do not require reduction. Unstable fractures
include separation of the symphysis pubis, an opening in the
pelvic ring, movement of one half of the pelvis, or a bucket
handle fracture, in which the fractured half of the pelvis rolls
forward and inward. 75 Usually these fractures result from a
crush injury that occurs when the child is run over by a
vehicle.

Impacted - Results from severe trauma
causing fracture ends to jam together.

Oblique - Results from twisting force.
Compressed - Results from severe
force to top of head or os calcis or
acceleration/deceleration injury.

Spiral- Results from twisting force with
firmly planted foot.

Comminuted - Results from severe direct

trauma; has more than two fragments.

Fig.28·18

Mosby.)
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Greenstick - Results from compression
force; usually occurs in children under
10 years of age.

AVUlsion - Results from muscle mass contracting
forcefUlly, causing bone fragment to tear off
at insertion.

Types of fractures. (From Budassi-Sheehy S, ed: Manllal of emergency care, St Louis. 1990,
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Box 28-4

Abnormalities Associated
With Musculoskeletal Trauma

Blood loss associated with a specific injury
Neurologic or vascular deficit distal to the injury
Visible deformity, shortening, or angulation of a limb
Partial or complete loss of a digit or limb
Increase in limb circumference that worsens
Manifestations of pelvic fracture
Crush injury
Any injury suspected of resulting in compartment syndrome
Abnormal muscle or tendon function
Point tenderness or muscle spasms
Bruising
Swelling
Crepitus
Abnormal movement between joints or a joint

A serious musculoskeletal injury that may be seen is an
amputation. Amputations may occur as the result of power
tools, farm machinery, railroad accidents, or sharp objects.
Amputations are classified as partial or complete with
varying degrees of tissue and bone injury. A guillotine type
of amputation involves a wound that has clean, well-defined
edges, and has the best prognosis for reimplantation. A crush
amputation is the separation of the body part with extensi ve
damage to the soft tissue, bone, nerve, and blood vessels.
This wound has a poor prognosis for limb salvage.
Patient Management. As with any trauma patient,
the first focus is on the ABCs (airway, breathing, and
circulation). A detailed musculoskeletal assessment takes
place during the secondary survey. Observation along with
palpation of each bone and joint will help to identify
abnormalities. These abnormalities are listed in Box 28-4
and are documented once identified. Observation for spontaneous movement always takes place before manipulation
of the extremity. Manipulation of the injured extremity may
inflict pain and interfere with further examination.
Once the injuries are recognized, the first priority is to
estimate blood loss and then follow with a neurovascular
assessment. Components of the neurovascular assessment
are included in Box 28-5. Extremities are compared
bilaterally. Neurova~cular status is monitored frequently for
the first 24 hours after injury, after application of a cast or
traction, after surgery, and after any treatment, including
temporary splinting.
Assessment after an amputation injury also first focuses
on the ABCs. Blood loss is estimated, but with a complete
amputation, the severed blood vessels retract and clamp
down, resulting in effective clotting and minimal bleeding.
The child with an orthopedic injury requires monitoring
for the development of compartment syndrome. Compartment syndrome is progressive vascular compromise caused
by an increase in pressure within an anatomic space that
causes circulatory impairment and compromised tissue
function within that space. Direct bleeding and inflammation may cause increased pressure within a compartment. In

Fig. 28-19 The four compartments of the lower leg. (From
Robertson WW: Crush injury and compartment syndrome. In
Eichelberger MR, ed: Pediatric Trauma: prevelllion. acuTe care.
rehabililaTion, St Louis, 1993, Mosby.)

~

Box 28-5

..

Components of a Neurovascular Assessment

Circulation

Color
Temperature
Capi llary refill
Edema
Pulses above and below the injury
Sensation

Numbness
Tingling
Level of pain
Motion of Extremities

Coordinated
Symmetric
Strength

addition, a decrease in the size of the compartment caused
by the constriction of a splint or cast may produce
compartment syndrome. This syndrome can occur anywhere
in which fascia binds muscle groups however, it tends to
occur most often in the four components of the lower leg
(Fig. 28-19).
The manifestations of compartment syndrome are seen
with the "five P's":
I. Pain, which is described as extreme, occurs out of
proportion to the apparent injury. Pain may also occur
with passive movement of the affected extremity.
2. Paresthesia, specifically numbness or tingling, may
occur. The child may also exhibit a decreased ability
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to discriminate between two points on the affected
extremity.
3. Pallor is a late sign, and delayed capillary refill may be
present.
4. Paralysis or a progressively weakening muscle is another
late sign.
5. Pulselessness occurs only after compartment pressures
are extremely high because the larger arteries remain
open until then. Therefore an injured extremity with a
strong pulse does not rule out compartment syndrome.
Diagnosis of compartment syndrome is based on the
presence of these symptoms and on increased interstitial
pressure. This pressure can be directly measured using a
variety of systems that use a needle or a catheter connected
to a pressure transducer and monitor. Interstitial pressures
exceeding 30 to 35 mmHg are indicative of compartment
syndrome.
The initial treatment of fractures involves controlling
bleeding, assessing neurovascular status, and then applying
splints or traction. A closed fracture will require anatomic
alignment and splinting. An open fracture requires wound
irrigation, debridement, fracture alignment, and stabilization
in the operating room. Continuous monitoring for signs of
complications, such as infection or compartment syndrome,
is critical.
Amputations require special attention. Initially, if severe
bleeding is occurring, direct pressure with a soft dressing is
applied and the extremity is elevated. If there is minimal
bleeding, a sterile dressing is applied to the stump, which is
then splinted and elevated. Tourniquets and clamps are
contraindicated because they may cause tissue ischemia and
vessel damage. Intravenous access is obtained for fluid
resuscitation and antibiotics.
The goal of care for the amputated body part is to reduce
ischemia time. The body part is gently rinsed with normal
saline to remove visible dirt. It is then wrapped in moist,
sterile gauze, placed in a sealable plastic bag, and then put
on ice for transport to the operating room or to another
center. The body part is never placed directly in saline or ice
because moisture absorbed by the tissue will result in
sweUing and necrosis.
Postoperatively, the child's neurovascular status is frequently assessed. Leech therapy alleviates venous engorgement that may compromise the graft (Chapter 16 provides
information on leech therapy). Sp02 monitoring of the reimplanted body part provides early information about the development of arterial compromise. Anticoagulants may be
given to prevent hemostasis in the reimplanted vessels, so
measures to prevent bleeding are initiated. Antibiotics are
administered to prevent or treat infection. Psychosocial support is crucial, especially if the child loses the body part, to
help the child and family cope with a changed body image.
Compartment syndrome requires immediate treatment if
pressures exceed normal limits. The limb is placed in a
neutral position because elevation results in further compromise of arterial flow. Cast or constricting bandages are
opened and removed. If the symptoms and excessive
pressures continue, a fasciotomy may be performed to
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release pressure and maintain extremity circulation. The
incision will be left open for a period of time with the limb
splinted in a functional position. A dressing is applied to the
open wound, and, if after 24 hours the muscle is considered
viable, saline dressings are applied and changed daily until
the wound is closed. 77
Pain management is an important issue for those caring
for children with musculoskeletal injuries. Results of a study
examining pain in children suggest that children hospitalized with orthopedic conditions experience a higher number
of painful occurrences and symptoms than children hospitalized with other conditions. 78 Occurrences such as postoperative pain, pain with moving, and pain associated with
traction and pins were rated as causing more pain than
injections, venipuncture, and intravenous insertion. Recommended methods for pain control include oral or intravenous
medication, patient-controlled analgesia, and nonpharmacologic methods. 79 Chapter 17 provides in-depth information
regarding pain management.

PRIORITIES FOR MULTIPLE TRAUMA
Airway management and maintenance of adequate oxygenation is of critical importance in the child with multiple
injuries. Many children with multiple trauma have an
unmaintainable airway or inadequate respiratory effort.
Also, shock and the child's physiologic response to trauma
leads to an oxygen debt. Definitive airway control is
obtained through intubation while maintaining cervical
spine immobilization. Children with evidence of tension
pneumothoraces or hemothoraces require emergent decompression before, or with, intubation.
Priorities in addressing circulation include controlling
bleeding and stabilizing hemodynamic status. Aggressive
fluid resuscitation is necessary for the hypotensive child,
even in light of a potential head injury. Maintaining cerebral
blood flow and oxygen delivery adequately minimizes
neurologic injury. Hypotension and decreased cerebral
oxygen delivery have been shown to potentiate secondary
injury and worsen outcomes in head injury.8o Fluids have
been shown to reduce mortality and improve neurologic
.
outcomes. 81
Patients with severe thoracoabdominal injuries and
concomitant head trauma provide a challenge to prioritization. Patients with severe bleeding who are unresponsive to
fluid and blood administration require emergent surgical
intervention. Assessment and management of chest and
abdominal injuries is generally prioritized based on the
assumption that correction of hemorrhagic shock is the
optimal treatment for head trauma. R2
Orthopedic injuries are of secondary importance in the
resuscitation of the child with multiple injuries. However,
appropriate treatment is necessary to prevent long-term
disability and may be life saving. Fractures require splinting
with emergent reduction if there is evidence of neurovascular compromise. Open fractures require surgical intervention, but treatment does not defer resuscitation of more
serious injuries. Potentially life-threatening fractures that
require urgent treatment are femur and pelvic fractures.
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Delayed treatment of these injuries has been associated with
poor outcomes. 83

CHILD MALTREATMENT
History
Varying forms of child abuse have been accepted by society
for many centuries. In earlier times, children who were
considered undesirable for religious or economic reasons or
because they were defective or female were often destroyed;
such actions were culturally sanctioned. During the fourteenth century, unwanted children were thrown into the
Thames; during the Industrial Revolution, young children
were forced to work long hours in hazardous settings with
unhealthy conditions.
The first legal intervention on behalf of a child occurred
in 1874 in the United States. Ironically, the case was brought
to court by the American Society for the Prevention of
Cruelty to Animals (SPCA). The SPCA was able to demand
legal protection for a child who was regularly beaten by her
adoptive parents on the basis that she belonged to the
Animal Kingdom. Most states did not adopt laws requiring
reporting of abuse until the 1960s and 1970s. Today, all 50
states have laws requiring the reporting of child abuse. The
public became more acutely aware of this concern when Dr.
Henry Kempe coined the phrase "battered-child syndrome"
in 1962. Despite the progress that has been made in this
area, child maltreatment continues to be a serious social
problem.

The Spectrum of Child Abuse
Children of any race, age, religion, sex, and socioeconomic
group can be victims of child maltreatment. Compared with
other medical conditions during childhood, the data indicate
that more children are affected by maltreatment than all
other serious illnesses combined. There are also many cases
of abused and neglected children that do not come to the
attention of social service agencies. 84 Over the years, the
issue of child maltreatment has evolved such that it is now
a multidisciplinary problem requiring contributions and
interventions from medicine, nursing, public health, sociology, psychology, law, and social work. Although it is
generally beneficial to have a variety of disciplines involved, this can also be a cause for concern. Efforts in
problem solving may be uncoordinated, and fields that may
have historically been at odds with one another need to
cooperate with the common goal of preventing and eliminating child abuse. 84

Incidence of Abuse
Almost four decades have passed since Kempe and colleagues published their landmark description of the battered
child. Since that time there continue to be many challenges,
including gaining an understanding of the problem and
striving to develop better systems for improved reporting
and more effective intervention. Despite the fact that all 50

states have laws that require the reporting of abuse,
under-recognition continues to be a problem. 85 Although the
true incidence of child abuse is unknown, the data indicate
that the numbers have increased significantly in the last l5
years. This increase, however, is controversial as to whether
the numbers represent increasing societal recognition of the
problem or real changes in the rates of maltreatment.84
Flaws in the existing data collection systems exist because
every state uses its own definitions of abuse and neglect and
applies its own standards of proof when substantiating
whether maltreatment occurred.
A recent study examined children who were victims of
abuse over a 10-year period. Children injured by child abuse
compared with nonintentional injury were more likely to be
younger and to have a preinjury medical history. They were
more likely to be injured by battering and shaking and to
sustain intracranial injury. They also were more likely to be
admitted to intensive care and have a longer length of stay.86

Defining Child Maltreatment
Child abuse can take on many forms and is difficult to define
and standardize. Physical abuse is a form that is often easy
to identify and recognize; other forms such as emotional and
psychologic abuse are just beginning to be acknowledged.
Still other forms of abuse such as child pornography and
prostitution remain difficult to identify and manage.
Unfortunately, the term child maltreatment is subject to a
variety of interpretations and definitions. In addition to a
lack of clear definitions, inadequate professional experience,
and lack of training and motivation to report, disagreement
exists about how responsible parents should be for the safety
of their children. A general definition of child maltreatment
may be described as an act that endangers a child such that
substantial risk to his or her health, safety, development, or
mental well-being is created. Various forms of child
maltreatment exist, including physical abuse and neglect,
sexual abuse, and emotional abuse and neglect.
Physical Abuse. The physical abuse of children is a
concept that remains difficult to define. Although the
definition depends largely on the mores and values of the
times, most health care workers agree that physical abuse
involves the nonaccidental injury of the child at the hands of
the caregiver87 When making an assessment of physical
injury, two elements are essential to consider. First is
whether the explanation given is plausible as a means of
causing the injury, and second is whether the developmental
level of the child is consistent with the history.84 Physical
injuries labeled by the parents as self-inflicted accidents
require certain motor skills on the part of the child; thus
knowledge of child development is essential.
Physical Neglect. Identifying the scope of the problem of neglect is nearly impossible because of the inability
to give clear and consistent answers to the question of what
constitutes neglect of a child. Typically defined as an act of
omission rather than commission, neglect mayor may not
be intentional. It is sometimes obvious and other times
nearly invisible. 88 Although neglect can result in obvious
physical signs such as malnutrition, other forms, such as
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Box 28·6
Examples of Neglect

Delaying or failing to provide physical or mental health care
Inadequate supervision
Lack of protection from household/environmental hazards
Poor personal hygiene
Poor nutrition
Inappropriate substitute child care

emotional neglect, can have a destructive impact on a child's
future development. Neglect may also be fatal as a result of
inadequate physical protection, failure to provide the essential necessities of life, and inadequate health care (Box
28-6). A note of caution, however, is not to define as willful
neglect a case in which an impoverished or uneducated
family is providing, in truth, the best care possible within
their means.
Sexual Abuse. Sexual abuse refers to contacts or
interactions between a child and an adult when the child is
being used for sexual stimulation of the perpetrator or
another person. Sexual abuse may also be committed by a
person under the age of 18 if that person is significantly
older than the victim or when the perpetrator is in a position
of power or control over the victim. Subsequent sexual
activity is defined as abusive because the child does not have
the cognitive ability to understand the deviance of the act
nor of age to give consent. Most sexual abuse is neither
disclosed immediately nor reported to authorities subsequent to disclosure. Many times victimization comes to light
because of an unintentional report from the child victim,
such as confiding in a friend. 89
Sexual abuse can be assaultive or nonassaultive. Assaultive abuse produces physical injury and, often, severe
emotional trauma. Nonassaultive abuse often results in little
or no physical injury, yet the child who is chronically
sexually misused often suffers a severe disruption in the
development of his or her own sexuality. Sexual abuse is the
least reported form of child abuse, particularly nonassaultive, chronic abuse.
Munchausen Syndrome by Proxy. Munchausen
syndrome by proxy (MSBP) is a form of child abuse that has
been recognized for approximately 20 years. The syndrome
occurs when a child's parem or guardian falsifies a medical
history or actually causes an illness or injury to the child in
order to gain attemion from hospital medical staff. The
child's mother usually manifests the induction or fabrication
of illness; however, fathers or other guardians may also
demonstrate the behavior. Additional elements of MSBP
include denial of responsibility for illness and resolution of
symptoms when the child is separated from the perpetrator.
Generally, clinicians regard MSBP as different from other
forms of child abuse for three reasons: (1) it seems that
MSBP may be symptomatic of a psychiatric disturbance in
the perpetrator, (2) mortality and morbidity rates are higher,
and (3) MSBP seems to be premeditated rather than
motivated by acute frustration and impulsive behavior9o
Although difficult to differentiate who has the condition,
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parent or child, MSBP is a complex interaction between
parent, child, and the medical establishment. The priority is
to ensure the child's safety and to prevent further harm.

Histories Suggestive of Child Maltreatment
Obtaining an accurate history in cases of pediatric injury is
usually challenging but even more so in the case of
suspected child maltreatment. To make the correct diagnosis, nurses, physicians, and other members of the team need
to be suspicious for its possible occurrence. When a
clinician is concerned about the mechanism of injury, the
extent of the injury, or the timing, child abuse is considered. 85 Physicians and nurses are often dependent on family
members for an explanation of an injured child's condition
because many children may be too frightened, too young, or
too ill to give an explanation. Even when they are able to do
so, many children are unwilling to accuse the adult who
cares for them of abuse. Also, it is rare for an adult to
spomaneously admit to inflicting injuries.
Other clues or presentations suggestive of child abuse
include denial of the existence of injuries or how they
occurred, an explanation inconsistent with the physical
findings, and a marked delay in seeking medical attention. A
history of prior trauma is important to note, and reviewal'
the medical record may reveal a pattern indicati ve of prior
abuse. All details of the elected history are carefully
evaluated in the context of their consistency or discrepancy
with the physical findings.

Physical Examination
The physical examination of the battered, sexually abused,
or neglected child is critical. Sometimes, physical injuries
not revealed in the history may be discovered. The absence
of external injury, however, does not rule out abuse.
Children with significant head or abdominal trauma may not
have any outward visible signs of trauma. Documentation
of physical findings is an important component of the
examination. Physical signs of possible abuse are listed in
Box 28-7.

Radiographic Examination
Radiographic studies are invaluable in the diagnosis of
intentional injuries. Skeletal surveys, CT scans, bone scans,
and magnetic resonance imaging (MRI) scans are all useful.
Radiographic evidence of intentional injuries is presented in
Box 28-8.

Psychosocial Interventions
Maltreatment of children is a family problem. The effects
reach much further than the abused child and his or her
perpetrator. Issues revolve around partners or spouses who
allow the abuse to occur, and many times the partners abuse
one another as well. Siblings of abused children may also be
abused or be witnesses to the maltreatment. Many parents
were maltreated in their own childhood. Because it is a
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Box 28-7

Physical Signs of Possible Abuse in the Child

Skin and Subcutaneous Tissue
Cradle cap, diaper rash, uncleanliness, and other evidence of
unconcern or unawareness of infant needs
Cigarette bums, bite marks (human, insect. etc.; infected or
not), grab marks, belt lashes (also the characteristic loop
lamp cord welts)
Ecchymosis, hematomas, abrasions, and lacerations unusual for
the child's developmental age
Injury to the external genitalia, anus, and rectum
Marks on the neck from strangling by hand or rope
External ears traumatized by pinching, twisting, or pulling
Unusual skin rashes that defy dermatologic diagnosis
Bums, particularly of the soles of the feet, hands, or buttocks
Skeletal System
Tenderness, swelling, and limitation of motion of an extremity
Periosteal swelling
Deformities of the long bones

Ears
Ruptured eardrums from blows to the head
Face
Periorbital ecchymosis
Displaced nasal cartilages
Bleeding from the nasal septum
Fracture of the mandible
Mouth
Lacerated frenulum of the upper lip
Loosened or missing teeth
Bums of the lips or tongues
Chest
Deformity of the chest and limitation of motion due to fracture
of the ribs
Subcutaneous edema
Hemothorax

Head
Cephalhematomas
Irregularities of contour resulting from skull fractures
Signs of intracrani,al trauma

Abdomen
Signs of peritoneal inritation from ruptured organs
Abdominal masses from hematomas

Eyes
Subconjunctival hemorrhages
Traumatic cataracts
Retinal hemorrhages
Papilledema

Central Nervous System
Lower motor neuron paralysis from spinal cord injury
Upper motor neuron paralysis from intracranial injury
Neurologic signs varying with location and extent of the
injury

From Widner-Kolberg MR: Recognizing child abuse and neglect and what 10 do about it. Presented at Pediatric Issues in Multisystem Tmuma Conference, Walnut Creek,
CA. 1991, Symposia Medicus.
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Box 28·8
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~, Radiographic Evidence of Intentional Injuries
Multiple Fractures
In different stages of healing, including:
Single blow fractures in infant
Epiphyseal separation
Spiral fracture in the young
Fractured ribs
Fractured spine'
Cortical Metaphyseal Fragmentation
"Chip" fractures or "comer spurs" partially separated from
the metaphysis

Traumatic Involucrumt
Exuberant calcifying new bone formation secondary to
subperiosteal forces and hematoma (grasping, shaking,
and torsion forces); may produce "bucket-handle" images
(extension of hematoma beyond the end of the shaft)
Skull Fracture*
Witht or without subdural hematoma
Suture Separationt
Hemorrhage' without fracture
Increasing head circumference in infant-whiplash forces from
shaking alone can cause

From Widner-Kolberg MR: Recognizing child abuse and what to do about it. Presented at Pediatric Issues in Multisystem Trauma Conference, Walnm Creek, CA. 1991,
Symposia Medicus.
"'Cerebrospinal injury, subduraL intraventricular, and/or intracerebral hemorrhage are most serious complications and principle causes of death and pennanent crippling.
tNot visible radiographically umil 7 to 18 days after trauma.
:+Evident immediately after trauma.
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family problem, the issue is understood, treated, and
prevented in the context of families 91
The child victim of abuse and the family need comprehensive psychosocial intervention. This intervention is best
provided by a trained mental health professional, such as a
clinical nurse specialist, social worker, or psychologist who
specializes in the care of child maltreatment victims. The
status of the child and the parent-child relationship are
assessed and treatment is based on that assessment. The
approach is one of nonjudgmental support and probing for
relevant information. Even though the nurse caring for
the child will probably not do the in-depth psychosocial intervention, it is still essential that the parent or
caretaker be treated in a nonjudgmental manner. Although
difficult, partnership with the parent (should he or she be
the perpetrator) is still possible so long as it is made
explicit that the focus of all work is the child's welfare.
Professional style is mutually respectful and as inclusive of
parents as possible while still maintaining the child's
safery.92

Considerations for the Practitioner
in Suspected Child Maltreatment Cases
Reporting Child Maltreatment. All 50 states have
enacted laws requiring practitioners and other persons to
report child maltreatment. Some states are more specific
than others as to those who are mandated to report, but states
that list these professionals usually include physicians,
nurses, other medical professionals, counselors, social
workers, and school personnel 87 These laws also have a
number of provisions designed to remove legal impediments
to reporting. These provisions include immunity from civil
and criminal liability for reporting, abolition of doctorpatient privilege in situations of suspected maltreatment,
and penalties varying from nominal fines to imprisonment
for failure to report. 93
Protection for the Child. Abused and neglected
children are often too young and too frightened to seek help
themselves. Because of their physical and psychologic
immaturity, they are helpless against the cruelty of their
caregivers. In the instance of suspected abuse, a decision is
made whether it is safe to return the child to his or her home.
If hospitalization is required due to a medical condition, the
matter is temporarily solved. If hospitalization is not
medically warranted, the practitioner, in concert with a
social worker or protecti ve services worker, makes the
decision. The custody and possible placement of children
during the investigative process is often controversial and
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therefore entails careful scrutiny of a number of factors such
as age of the child, nature of the injury, past treatment of
injuries, and family characteristics. Such a decision is not
made lightly because it could result in additional harm to the
child, even a potentially fatal injury. Severity of abuse is not
always the contributing factor to removal, instead, perceived
future risk is of greater significance,87
Documentation. Inadequate documentation of pediatric injuries often makes the diagnosis of child abuse
difficult. Thorough, well-documented histories and complete physical examinations are essential, as well as
information about the presence of witnesses to the injury.
Even minor injuries require thorough evaluation and history
because bruises are a common occurrence in children who
have been maltreated. The inadequacy of documentation
points to the need for concrete tools to improve documentation and continued education about the signs of child
abuse. The abused child's hospital record is part of the
substantive evidence that is used in court; thus detailed
descriptions are critical. Failure to recognize and document,
in accurate detail, the presence of injuries and the pattern of
illnesses that are possibly related to child abuse may lead to
recurrent trauma or death,94

SUMMARY
Pediatric trauma is a national epidemic. It is the leading
killer of children between the ages of I and 14 years and is
a major cause of disabling injuries. This is a major concern
to society when one considers the tragedy to the family, in
addition to the implications of the loss of work potential, the
length and cost of rehabilitation, and the effects on growth
and development.
Children have been shown to have a better potential for
recovery than adults from traumatic injury.7,95 Expert care
can maximize this potential. Expert care includes precise
assessment, formulation of diagnoses based on assessment,
and collaborative interventions guided by appropriate diagnoses. Research has demonstrated the positive impact
nursing care has on the trauma patient; however, more study
is needed, especially in the pediatric population, Research
priorities for trauma nursing have been identified. 96
Nurses are in a key position to provide leadership in the
area of pediatric injury prevention. They can educate
legislators and the public about how to manage this public
health epidemic. Children can be protected by further
research in all areas of pediatric trauma, including trauma
prevention, resuscitation, and nursing interventions to further maximize outcome.
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Thermal Injury
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wound closure is achieved. The rehabilitative and reconstructive phase can continue for the rest of the individual's
life. Every organ system is affected by an injury to the skin
that involves 25% total body surface area (TBSA) or more.
Burns affecting more than 50% TBSA have a prolonged
critical care phase that may last weeks or months.

ETIOLOGY OF PEDIATRIC BURN INJURIES
PATHOPHYSIOLOGY

Zones of Injury
Classification of Burn Wounds
INJURY TYPES

Thermal Injuries
Electrical Injuries
Chemical Injuries
Inhalation Injury
Circumferential Burns
Exfoliative Disorders

ETIOLOGY OF PEDIATRIC BURN INJURIES
Most childhood burn deaths occur as a result of house fires,
in which children are unable to escape the heat and smoke.
Many causes, including careless handling of smoking
materials, unsafe cooking and heating practices, faulty
wiring, use of candles, and match play have been associated
with these fatal fires. The causes of injury are varied, and
most are unintentional injuries. However, the possibility of
intentional injury is a major concern because it has been
reported that between 8% and 24% of admissions to bum
units are related to child abuse by burning. 4 .5
Children at greatest risk are those who cannot protect
themselves. An infant relies totally on others for protection,
whereas a preschooler can be taught to tell an adult when
matches or lighters are found and to "stop, drop, and roll."
Children with neurologic disorders, disabilities, and developmental delays also present a higher risk from inability to
protect themselves and have a higher incidence of preventable injuries, have extended hospitalizations, and bear
significantly higher mortality risks. 6
Overall, burn injuries in children tend to' follow patterns
related to both developmental level and the socioeconomic
environment of the child. Scalds are the leading cause of
burn injury for young children and account for 58% to 67%
of all burn injuries. 7 .8 Most scald injuries are related to the
handling and consumption of hot food and liquids. Food
prepared in microwave ovens, as well as hot coffee and
soup, are often involved. The pattern of splash and dripping
is a common finding across the upper body and lap. These
wounds are painful and may be very deep, depending on the
nature of the scalding liquid and the time that the skin was
exposed to it. Grease scalds from kitchen fryers can produce

CRITICAL CARE MANAGEMENT

Emergent (Shock) Phase
Transfer and Referral Priorities
Acute Phase
BURN OUTCOMES
SUMMARY

F

ire and bum injuries are second only to motor vehicle
accidents as the leading cause of death in children of
ages I to 4 years in the United States. They are among the
leading causes of injury and death in children of ages I to 19
years. Severe bums are considered the most catastrophic
injury a person can survive, resulting in disfigurement, pain,
emotional distress, and tremendous economic costs. I
Burn care has progressed dramatically in the last 20
years, in large part as the result of the establishment of
specialized burn centers. Advances in fluid and electrolyte
resuscitation, early excision and wound c1osure,2.3 and
nursing care in this area have increased the probability of
surviving massive bums.
Burn injury is divided into three phases. The emergent or
shock phase begins at the time of injury and extends until
fluid resuscitation is complete. The acute phase lasts until
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Zones of Ischemia

t

Dermal-epidermal
junction

Fig. 29·1

Zones of ischemia.

serious injury because the hot grease cools slowly and is
difficult to remove.
Hot household tap water is an important cause of lower
body scald injuries, especially in the bath. Because children's skin is thinner than that of a young adult, even short
exposure to water at 140° F, a common setting for home
water heaters, can cause tissue destruction in fewer than 5
seconds in children and in less time in small infants. 9
Children may unintentionally tum on the hot water faucet
when left unattended in the bathtub and be unable to get
away from it. Adult supervision, setting water heaters
between 120° and 130° F, and checking bath water
temperature before placing a child in the tub are key to
preventing these injuries.
As children become more mobile and curious, their
exposure to household burn hazards expands. Electrical
bums to the oral cavity are seen in infants and toddlers after
chewing on the connection between appliances and extension cords. Contact burns from hot irons, ovens, wood
stoves, and radiators occur in all ages. Ingestion of
household chemicals can lead to devastating gastrointestinal
damage, and even when diluted, cutaneous contact with
these chemicals can cause full-thickness burns.
Match and fire play are a problem for the school-age
population but have been recognized in children as young as
2 years of age. Flame burns associated with clothing ignition
can cause serious injury from both heat and melting fabrics.
Ignition of flammable liquids is seen in children old enough
to work on their bikes or mow the lawn. Flash burns
involving flammable liquids and explosives add a chemical
component to the bum. Cigarette smoking and other
risk-taking behaviors contribute to the burn problem for
adolescents. With the increasing availability of the Internet,
adolescents have found recipes for a variety of explosive
and flammable mixtures.
There are seasonal and regional differences that affect the
pattern of bum injury. Summer brings fireworks, barbecues,

and sunburn. Winter brings alternative heating sources, such
as electric space heaters, kerosene heaters and wood stoves.
Traditional birthday celebrations may involve lighted
candles. Cultural and socioeconomic factors, such as
housing, heating, and cooking traditions, may also influence
the risk and patterns of burn injury in any community.
Most people who die in house fires are overcome by the
smoke and are unable to escape. Those that survive are at
high risk for an inhalation injury as are those who are burned
in an enclosed space or have burned facial areas. Inhalation
injury continues to be the number-one cause of death in
thermally injured patients and can occur with or without
associated bums. lo Inhalation injury may not always be
evident initially, but carbon monoxide poisoning, thermal
damage, and inhaled toxic chemical damage all affect
survival.

PATHOPHYSIOLOGY
Burn severity depends both on the intensity of the heat and
the duration of its contact with the skin. The magnitude of
the physiologic response depends on the type, size, location,
and depth of the burn. All body systems are potentially
affected as the body adapts to compensate for the alterations
in normal function.

Zones of Injury
Thermal damage to tissue is described in three zones (Fig.
29-1). The area of superficial damage is the zone of
hyperemia, appearing warm and red. The middle area of
damage is the zone of stasis, where the microcirculation is
damaged and changes in capillary permeability allow fluids
to leak from the vascular system into the interstitial space.
This leads to local edema and shock when extensive wounds
are present. The deepest area is the zone of coagulation.
wherein heat-damaged cells occlude blood vessels. The
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Burn Depth Categories
Superficial
Partial Thickness
(First Degree)

Partial Thickness
(Second Degree)

Full Thickness
(Third Degree)

Scald, flash, flame,
contact, chemical,
ultraviolet light

Scald, flash, flame, contact, chemical, ultraviolet light

Scald, flash, flame, contact, chemical, electrical

Dry, no blisters
Minimal or no edema
Erythematous

Moist blebs, blisters
Underlying tissue mottled pink and
white
Good capillary refill

Dry, leathery eschar
Mixed white, waxy, pearly
Khaki, mahogany, soot-stained

Very painful
Rapid heat loss

Very painfu I

Rapid heat loss
Insensate
Less rapid heat loss

Epidermal layers only

Epidermis, papillary and reticular
layers of dermis
May include fat domes of subcutaneous layer

Down to and may include subcutaneous tissue
May include fascia, muscle, and
bone

2 to 5 days with no
scaning
May have some
discoloration

Superficial, 5-21 days with no
grafting
Deep partial, 21-35 days with no
infection
If infected, converts to full thickness

Small areas may heal from the edges
after weeks
Large areas require grafting

obstructed microcirculation prevents the humoral components of the immune response from reaching the burned
tissue.

Classification of Burn Wounds
Classification of burn depth requires skilled clinical judgment. Surface appearance provides only a clue to the actual
tissue damage below. Burns are rarely of uniform depth
throughout. Appearance, pain, and tissue pliability are all
used to assess wound depth. The type of burning agent and
the extent of skin exposure combine to form challenging
clinical presentations.
Bum depth is classified as partial thickness or full
thickness (Table 29-1). Superficial partial-thickness burns
involve only the epidermis. Deep partial-thickness burns
involve the epidermis and the dermis but spare epidermal
appendages necessary for epidermal regeneration. Fullthickness burns involve the epidermis, dermis, epidermal
appendages, and sometimes subcutaneous tissues, such as
fat, muscle, and bone. Any burn wound can be converted to
a deeper thickness if infection, hypoxia, desiccation, or
further mechanical tissue damage develops.
Burns are also described by measuring the size of the
TBSA burned. For children, this size is determined using a
Lund and Browder or Berkow chart, which takes into
account the proportional body changes that occur during
growth (Fig. 29-2). Deep partial- and full-thickness burns
on body parts are charted as a percent of the whole.
Superficial partial-thickness injuries are not part of the
calculation because the integrity of the skin is not broken.

Affected areas are measured and combined to determine
TBSA burned. This percent TBSA becomes important in
calculating fluid resuscitation and nutritional needs after
burns.
A number of other methods are used for determining
TBSA burned in children. The palmar method may be used
in smaller or more scattered burns. This method equates
the palm of the child's hand with I % of the body surface
area. Another method is the baby rule of nines (Fig. 29-3).
This method is used primarily in children younger than
3 years of age and allows for the relative di fference in
head size and lower extremity size in children compared
with adults. Of all the methods, the Lund and Browder
chart is preferred for children because it takes into account
the variation in distribution of body surface area in children
of different ages. II

INJURY TYPES
Thermal Injuries
Thern1al injuries include three subclassifications: scald
injuries, contact injuries, and flame injuries. All three types
are governed by the principles of thermodynamics; thus the
depth and severity of injury are dependent on the duration of
contact and properties of heat or cold transference of the
injury source. This becomes particularly relevant when
examining a scald injury because the transference of heat by
a liquid results in a greater zone of stasis. This zone will
evolve over the first 72 hours, resulting in a more significant
injury than on first assessment.
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Electrical Injuries
Electrical injuries are caused by the conversion of electrical
energy into heat energy, which coagulates body tissues.
Electrical injuries can be divided into two categories based
on th'e voltage to which the tissue was exposed. Low-voltage
injuries are those sustained with contact with less than 1000
volts, including house current (lIS to 220 volts). Highvoltage injuries are those with contact with greater than
1000 voltage lines and include high-tension wires (up to
250,000 volts).
Electrical injuries in children occur most often in the
infant and toddler and adolescent age groups. Infants and
toddlers, while exploring their environment, often put
everything they find into their mouth. Saliva, which serves
as an excellent conductor, creates a current pathway from

the electrical source and through the child's tissues. Thus the
majority of these injuries are low-voltage injuries from
plugs or cords and result in oral commissure burns. 12 The
structure of extension cords, including holiday light sets, is
a neglected area in legislation and federal standards for
injury prevention. Voluntary standards are maintained by
most manufacturers via independent laboratory approval
and have contributed to some solutions, such as extension
cords being manufactured with safety caps for unused plugs.
However, this precaution is not universal and does not
address cord-biting or cord-sucking injuries. 13
The adolescent usually comes in contact with electricity
as an unintentional sequela of risk-taking behavior such as
climbing power poles or trees, as a result of tangled kites in
high-tension wires, from lightening strikes, from contact

Chapter 29 Thermallnjury

Fig. 29-3 Baby rule of nines allows for proportionate difference in head size related to lower extremity size in children
younger than 3 years of age compared with adults. Note that head
is 18% of the total body surface area (TBSA) in children versus
9% TBSA in adults. Lower extremity is then 14%, rather than 18%
in adults. (From Kravitz M: Thermal injuries. In Cardona V et aI,
eds: Trauma nursing: resuscitation through rehabilitation, Philadelphia, 1994, WB Saunders, p 710.)

with transformers, or from household electrical appliances.
Of the injuries seen in the adolescent group (11 to 18 years
of age), 76% to 90% are high-voltage injuries, resulting in
amputation, deep muscle involvement, fasciotomy, and
significant morbidity. In addition, 60% to 90% of the
adolescents sustaining high-voltage injuries are male. 12 • 13
Prevention of high-voltage injuries as a result of adolescent
risk-taking behavior remains an ongoing challenge to
prevention educators.
Although most injuries occur because of direct physical
contact with an electrical source, the child may not have to
actually touch the current source to sustain injury. Electrical
current has been known to jump or "arc" from the source to
electrically conductive substances in its search for a path in
which to "ground." This holds true for current flowing
through the body, because it may arc from one area of the
body to another (e.g., across flexed joints). Additional injury
can occur by electrical contact with clothing causing
ignition, resulting in surface bums from burning fabrics and
inhalation injury from the smoke and toxic chemicals
produced by the burning clothing.
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The physiologic impact of an electrical injury on the
body is very unpredictable, causing damage by three
mechanisms: (I) direct injury caused by the effect of the
electricity on the body, (2) thermal damage as electricity is
converted into heat, and (3) trauma resulting from a fall or
severe muscle contraction following the electrical injury. 12.14 Direct injury caused by electrical contact includes
vascular aneurysms and destruction of muscle and red blood
cells, resulting in myoglobinuria and hemoglobinuria. In
addition, vascular thrombosis formation; cardiac arrhythmias; myocardial damage; neurologic impairment; ophthalmologic injuries; rupture of the tympanic membrane; and,
with forceful tetanic contractions, fractures and tendon
rupture are other sequelae of direct injury by electrical
contact. Extensive cellular destruction can also result in
massive infusion of intracellular potassium into the circulation. The resulting hyperkalemia can rapidly reach toxic
levels or produce lethal dysrhythrnias.
Thermal damage caused by the electrical injuries is often
difficult to assess. Where the current enters the body, there
may be only a small entrance wound. The current then
follows a path of least resistance and explodes out of the
body where the body is in contact with a grounding source,
resulting in one or more exit wounds. Massive tissue edema
can result in compartment syndrome with further tissue
destruction. Because the extent of tissue destruction is often
hidden under normal-appearing skin, fluid loss into the
interstitial spaces may go undetected. This can lead to
inadequate restoration of the circulating blood volume
during fluid resuscitation. The sum of these effects may
result in local tissue destruction and intravascular coagulation so severe that amputation of the necrotic tissue becomes
essential.
Management of pediatric electrical injuries begins with a
detailed understanding the history of the injury, including
type and strength of voltage, duration of contact, presence or
absence of water, and associated trauma workup for
suspected fall or injury. Blood chemistry abnormalities are
monitored, including serum electrolytes, as well as skeletal
and cardiac enzymes indicative of skeletal or cardiac muscle
destruction. Cardiac rhythm, regardless of voltage level, is
monitored for dysrhythmias. Assessment for myoglobinuria
and compartment syndrome, including circulation sensation
and movement distal to the injury, is essential.

Chemical Injuries
Chemical injury results from the thermal energy produced
when strong acids or alkalis come in contact with body
tissue. Strong acids and alkalis are the most common causes
of chemical bums in children. In infants, injury is common
from household cleaning chemicals, such as lye, ammonia,
sulfuric acid, and laundry detergents. Older children are
injured in school laboratory accidents or when "experimenting" at home. In addition, older children may be injured by
gasoline-soaked clothing or by exposures related to their
first jobs or home activities.
Chemicals destroy skin by coagulation necrosis, which
may progress over time. The severity of the injury is
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dependent on the chemical properties, the concentration of
the chemical, and the duration of contact with skin or
mucous membranes. Care for children with chemical
injuries includes obtaining a thorough history of the
accident with the type and duration of contact and rinsing
the affected area with copious amounts of water until a bum
center consult can be obtained, as well as frequent assessment of the affected area.

Inhalation Injury
Inhalation injury, often called smoke inhalation, is a
condition associated with exposure to the heat and toxic
fumes produced by fire conditions in a closed space.
Complete and incomplete combustion of materials commonly found in the everyday environment produces extreme
heat, toxic fumes, and a reduction in the environmental
oxygen concentration, often reducing it to 16% or less.
The identification of a person who has sustained an
inhalation injury is often difficult. Clinically, a person who
is at risk has the following characteristics:
• Burned in a closed space or standing upright as their
clothing burned
• Burns of the face or neck
• Singed eyebrows, nasal hairs, and hairline or facial hair
• Carbon particles in the mouth or nose or carbonaceous
sputum
• Brassy cough, hoarseness, or stridor
• Significant serum carboxyhemoglobin level (greater
than 15%)9
These children warrant close observation and immediate
intervention if respiratory distress develops. Early or
prophylactic intervention, particularly in young children, is
essential for survival.
The inhalation injury produced by fire conditions has
four components. First, thermal injury occurs in the upper
airways because of exposure to high environmental temperatures and superheated gases. Direct heat damage is
usually limited to the upper airway because the moist
mucous membranes act as a heat exchanger, lowering the
temperature of the inhaled gases before they cross the vocal
cords. In fire conditions, the upper airway extracts excess
heat from inhaled gases. This protects the lower airway
(below the vocal cords) from thermal damage. The sole
exception to this is the inhalation of steam. Steam has a
heat-carrying capacity that is approximately 400 times the
capacity of ambient air. This allows the steam to pass
through the vocal cords with little heat loss in the upper
airway, thus creating thermal burns below the vocal cords.
The exposure to hot gases produces diffuse edema throughout the upper airway, resulting in airway obstruction. The
edema rapidly advances and peaks at about 6 to 12 hours
after injury.
Extensive burns of the head and neck or hot liquid
aspiration can produce such massive edema in local tissues
that the airway is compromised. Although not a true
inhalation injury, these injuries may present with similar
clinical signs and symptoms. Suspicion of aspiration or

extensive head or neck bums is treated by protecting the
airway with an endotracheal tube (ETT) until the edema
resolves. Because of the small comparative size of children's airways, intervention in the form of endotracheal
intubation is often required. 15
Another aspect of inhalation injury occurs when carbon
monoxide (CO) combines with the hemoglobin molecule to
reduce the oxygen-carrying capacity of red blood cells. CO
is a clear, colorless, odorless gas produced by the incomplete combustion of organic materials, such as wood, paper,
cotton, gasoline, and others. Incomplete combustion occurs
because insufficient oxygen is available in fire conditions.
Depending on the carboxyhemoglobin levels, the child may
experience symptoms ranging from mild intellectual dysfunction to apnea and cardiac arrest (Table 29-2). The
binding of CO to hemoglobin can be reversed by the
administration of 100% oxygen. Experiments attempting to
quantify the elimination half-life of CO by nonrebreathing
face mask or by ETT intubation demonstrate a range of 26
to 146 minutes. 16
Hyperbaric oxygen (HEO) therapy may also be indicated
for the child with CO poisoning, although its use remains
controversial. A child undergoing HBO treatment is put into
a hyperbaric chamber and is exposed to 100% oxygen at a
pressure higher than atmospheric pressure. This method has
shown to aid in displacing CO from the hemoglobin
molecule, thus providing increased amounts of available
oxygen and reversing the toxic effects of CO. 17
Another sequela of inhalation injury is hypoxia caused by
exposure to fire conditions wherein environmental oxygen is
rapidly consumed by combustion. This results in environmental oxygen concentrations that reduce the FT0 2 , so Pa02
levels of 50 to 60 mmHg are commonplace. Combined with
CO exposure, the reduced FI02 worsens the tissue hypoxia
and its consequences.
The inhalation of toxic gases from the fire may produce
a chemical pneumonitis. The combustion of commonly
found materials liberates toxic gases, which can include

~

29-2 Physiologic Effects of Carbon
Monoxide Exposure
.. .

TABLE

~:p.rboxyhemoglobin
~iL~vel (%J

>60

Physiologic Effects
Headache, dyspnea, confusion,
lapse of attention, loss of peripheral vision
Irritability, faulty judgment, dim
vision, nausea, vomiting, easily
fatigued
Tachycardia, tachypnea, confusion,
hallucinations, ataxia, syncope,
convulsions, coma
Often fatal

ted from Cohen MA, Guzzardi W: Inhalation of products of
mbuslion. Ann Emerg Med 12:628-632, 1983.
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hydrogen sulfide, hydrogen cyanide, hydrogen chloride,
acrolein, mustard gas, nerve gas, and many others. When
these gases come in contact with the epithelium lining the
tracheobronchial tree, they form corrosi ve acids that destroy
the cilia and underlying tissue. Toxic materials also adhere
to soot particles that are inhaled, providing an additional
source of toxic exposure and debris that must be cleared.
Toxins are absorbed into the general circulation, where they
can have systemic effects (e.g., production of hydrogen
cyanide, which causes immediate respiratory dysfunction).
The initial response of the lung is bronchorrhea followed by
a sloughing of necrotic tissues. The increased debris
formation plus the loss of the cilia results in atelectasis. The
clinical symptoms may present hours to 7 days later.
There are three time periods following injury when the
damage caused by these toxic agents occur. Immediately
after the exposure to fire conditions, hypoxia associated with
decreased environmental oxygen concentrations, CO poisoning, and airway edema from exposure to hot gases
develops. During the 24 to 48 hours following injury,
pulmonary edema is associated with the toxicity of inhaled
gases and fluid resuscitation. After 48 hours, the effects of
atelectasis and pneumonia become evident as a clinical
picture similar to acute respiratory distress syndrome
(ARDS) develops.
The presence of skin involvement further complicates the
management of inhalation injury. Skin damage that involves
more than 25% TBSA results in diffuse capillary leak
throughout the body, including the lung. The increase in
interstitial water surrounding the alveoli reduces effective
gas exchange and increases the patient's volume requirements. Inhalation injury can increase the body's fluid
requirement up to 37% over calculated fluid resuscitation
needs. The assessment of fluid balance becomes increasingly complicated, and pulmonary edema is a common
complication. The treatment of pulmonary edema is usually
reduction of the infused fluid volume in increments until
symptoms disappear. 18
Full-thickness, circumferential surface burns of the neck
and chest wall can compromise pulmonary function even
further. When inelastic eschar surrounds the chest, a
corsetlike effect is created. Edema continues to occur in the
burn wound, compressing the tissues of the chest wall
inward and compromising the vital capacity. Relief is
provided by escharotomies (incisions through the eschar)
that allow the chest wall to expand. Escharotomies to relieve
chest compression are usually performed within the first 24
hours after injury, but extensions of the escharotomies may
need to be done as the edema continues through the
emergent phase.
Surviving the initial inhalation injury is not the end of the
child's pulmonary problems. The child may develop ARDS
following hypoxic or hypovolemic insult or as a component
of septic shock associated with bacteremia from wound
debridement, intravascular lines, urinary tract infections, or
pneumonia.
The long-term sequelae of inhalation injury include
bronchiolitis obliterans, cylindrical bronchiectasia, and tracheal stenosis associated with prolonged intubation or
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tracheostomy. Children whose respiratory units are destroyed at a young age have a better prognosis for long-term
respiratory function than do school-age children or adolescents. As the young child grows after the injury, the
remaining respiratory units can increase in surface area
more than would normally be expected to compensate for
the units that were destroyed.

Circumferential Burns
Full-thickness circumferential burns of the torso or extremity present a special problem for the child. As mentioned
earlier, circumferential burns to the torso may impede a
child's ability to ventilate. Similarly, circumferential areas
of full-thickness bums to extremities are nonelastic and
produce a tourniquet effect that diminishes blood flow to the
affected area. As edema occurs in the affected area and the
tissue cannot stretch, the child experiences numbness and
tingling distal to the injured area, loss of motor function and
sensation, and severe pain. Release of pressure must occur
and requires surgical intervention by escharotomy or
fasciotomy (Fig. 29-4). An escharotomy involves an incision through the burned tissue down to the subcutaneous fat
layers to restore blood supply. A fasciotomy is necessary
when the escharotomy has not restored adequate perfusion
and the injury has extended into the muscle. This procedure
involves a deeper incision through the fascia covering the
muscle compartments and allows the expansion of compressed or edematous areas of muscle.

Fig. 29-4 Diagram shows preferred sile of escharotomy
incisions. (From Finkelstein JL, Schwartz SB, Madden MR et al:
Pediatric bums: an overview, Pediarr Clin North Am 39: 11451163, 1992.)
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The best time to perform an escharotomy varies and is
based on frequent assessment of the affected area, distal
circulation, sensory motor function, and pulses, as well as
respiratory effort and peak inspiratory pressures with torso
bums. If an escharotomy is performed, blood loss may be a
problem as circulation is restored and is monitored. If the
escharotomy is performed too late, necrosis of the entire
extremity distal to the injury site, compartment syndrome,
and gangrene can develop.

Exfoliative Disorders
Although not considered thermal injuries, several diseases
including toxic epidermal necrolysis (TEN), epidermolysis
bullosa, and purpura fulminans are increasingly being
treated in bum units. Bum units have been demonstrated to
coordinate resources to manage these large complex wounds
and reduce mortalityl9.21
TEN is a rare, severe form of epidermal sloughing occurring most often as a result of a severe drug-induced reaction.
In addition to epidermal sloughing, the epithelial linings of
the gastrointestinal tract and respiratory tract and the mucous membranes of the eye and oropharynx may also
slough. TEN is manifested by fever (all cases), conjunctivitis (32% of cases), sore throat (25% of cases), pruritus (28%
of cases), malaise, and a rash with a positive Nikolsky's sign
(a sloughing of sheets of epidermis in response to light
touch)?2 Drugs that often trigger TEN include sulfonamides, nonsteroidal antiinflammatory drugs, anticonvulsants, penicillins, and allopurinol. Milder forms of the same
disease process include erythema multiforme and an intermediate form known as Stevens-Johnson syndrome.
Staphylococcal scalded skin syndrome (SSSS), a syndrome clinically similar to TEN, is caused by a staphylococcal skin infection usually occurring in children younger
than 5 years of age. Some strains of staphylococci produce
an epidermolyric toxin that causes the epidermis to cleave at
the upper malpighian and granular layers. The presentation
of SSSS is very similar to TEN, also presenting with a
positive Nikolsky's sign. Differentiation between these two
diseases is generally done by histologic examination of a
skin biopsy or sample.

stabilization techniques because traditional adhesives do not
stick to slippery, wet, edematous skin. With oral intubation,
care is taken to protect the commissures of the mouth from
erosion by the ties used to hold the ETI in place. Creativity
and nursing vigilance to ensure the protection of these areas
can significantly reduce the need for difficult oral or lip
reconstruction. This may include the use of elastomer oral
commissure pads; the use of double tracheostomy ties to
secure the tube; or additional padding with dressings or
4 x 4's under the ties, above the ears, or at the back of the
head (Fig. 29-5).
Ventilatory support is provided as needed. Oxygen at
100% is continued for any child with CO poisoning
until carboxyhemoglobin levels are below 15%. In cases
of inhalation injury, conventional mechanical ventilation
modes may not provide sufficient ventilatory support and
necessitate the use alternative ventilatory therapies?3.25
Maintenance of fluid balance is an important component of the emergent phase. Establishment of intravenous access with a large-caliber catheter is essential
because fluid resuscitation is vital to the initial management

CRITICAL CARE MANAGEMENT
Emergent (Shock) Phase
As with any other trauma, initial management pnonlIes
focus on support of airway, breathing, and circulation
(ABCs). For the burned patient, the first priority is to stop
the burning process, then proceed with the ABCs.
Thorough and ongoing assessment of the airway is key in
the initial nursing care. Immediate intubation is considered
if a facial burn, upper airway edema, or an inhalation injury
is present. Ensuring an adequate airway is crucial because
delay may make intubation difficult or impossible as a result
of massive swelling.
Maintenance of a stable airway may require creativity,
including the use of tracheal ties or other nonadhesive

Fig. 29-5 Securing oral endotracheal tubes requires creativity
and attention to prevent oral commissure erosion, as well as
possible accidental extubation. Pictured here, elastomer oral
commissure pads are used to prevent injury, with two tracheostomy
cotton twill ties providing stability and ensuring tube security.
(Photo courtesy Topliffe L and Lopez A. 1999.)
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of a major burn. A urinary catheter is inserted to evaluate
the patient's response to the burn and fluid resuscitation
efforts.
A nasogastric tube is placed for gastric decompression
and monitoring in patients with major injuries. Children
with major burns are at risk for postinjury paralytic ileus.
Thus the nasogastric tube is critical to prevent vomiting and
aspiration. 9 Enteral feeding should begin as soon as possible
after the injury to promote normal function of the gut and to
decrease potential for bacterial translocation across the
gastric mucosa.
Pertinent information about the circumstances of the
injury is obtained, and a secondary survey for other injuries
is performed. Other important data include weight; known
allergies; medical history; chronic medication, drug, or
alcohol use; and tetanus prophylaxis within the past. 5
years. 9
Cardiovascular Response. In large body surface
area (BSA) burns, profound vascular changes lead to fluid
shifts in burned and unburned tissue. There is a loss of
intravascular volume into the interstitium. Local increases in
vascular pernleability are the result of direct heat damage
that causes large fluid and protein losses through the wound
itself. Mediator-induced cell damage appears to contribute
to changes in cellular function in nonburned tissue, contributing to the overall edema that occurs after a large burn
injury. The fluid and protein shifts are most pronounced in
the first several hours because of the combined effect of
increased permeability and an imbalance in osmotic pressures. If not treated, these changes lead to bum shock,
characterized by hypovolemia, hypoproteinemia, decreased
oxygen tension, and increased tissue pressure.
Cardiac compromise is a factor in bum injury, although
compared with the adult population, the issue is minimized
by the child's ability to compensate with an increased heart
rate. Initially, cardiac output falls abruptly but returns to
30% of the preburn level within 30 minutes of injury. If
resuscitation is adequate, cardiac output returns to preburn
levels within 36 hours.2 6 Thereafter cardiac output increases .
to supernormal levels and may remain elevated for some
time, which is typical of the hypermetabolic response to
thermal injury. Both metabolic and immune factors playa
role in myocardial dysfunction following burn injury, but
the exact mechanism has not been identified. I I
Metabolic Response. Immediately following thermal injury, the emergent (shock) phase ensues. This phase,
lasting for 24 to 48 hours, is characterized by decreases in
cardiac output, oxygen consumption, and body temperature.
After the emergent phase is the acute phase, during which
the metabolic rate increases and persistent tachycardia,
tachypnea, hyperpyrexia, and body wasting are seen. 1 The
metabolic rate increases in proportion to burn size in a linear
relationship up to 1.55 times basal levels. 1.27 Maximal levels
are attained between the fifth and twelfth postburn day;
however, increased metabolic output remains until wound
closure occurs. II It is unclear whether the metabolic rate
returns to baseline even at complete wound closure or how
protracted the elevated levels remain in terms of weeks,
months, or years.
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Hypermetabolism mandates increased cardiac output and
oxygen use, which produces an increase in blood flow to the
visceral organs and burn wound. The visceral organs do not
increase oxygen consumption; however, the burn wound
requires increased blood flow to provide nutrients for wound
healing to occur.
Immune Response. Infection is me leading cause of
morbidity for burn patients. Persistently open wounds, increased metabolic needs, decreased nutritional intake, loss
of plasma protein, and suppression of the host defense
mechanism all contribute to the burned patient's susceptibility to infection. An altered immune response follows thermal injury, with defects related to both the altered host
environment and the injury-triggered host deficiency state.
The skin barrier is lost, providing an open portal of entry for
microorganisms. Neutrophil function is diminished, and opsonization is decreased, leaving the child increasingly susceptible to local and systemic infections. Thus in the critical
care management of a burned patient, emphasis is placed at
maintaining as aseptic an environment as is feasible.
Fluid Resuscitation. Fluid requirements for the first
24 hours vary between 2 and 4 ml/kg of body weight
multiplied by the percent TBSA burn. Various fOlmulas are
used for determining the volume of fluid resuscitation (Table
29-3). These calculations are only guidelines; rate increases
or decreases in fluid resuscitation are based entirely on the
individual patient's response (urinary output, hemodynamics, and ventilatory status). Rate and fluid choices vary
depending on the type of fluid used, patient age, size of burn,
and the presence of associated injury. The rate of infusion is
systematically decreased over the first 24 to 48 hours to
adjust for expected fluid shifts to the intravascular space.
Insensible losses and maintenance needs are added above
the rates established by these formulas to accurately meet
patient requirements.
Fluid overload has serious consequences for children,
resulting in pulmonary, cerebral, and local tissue edema.
Tissue oxygenation is compromised because of extracellular
edema, particularly in burned tissue. Individual patient
response is monitored closely, and fluid replacement is
optimized. Cardiac filling pressures and cardiac index can
be used to titrate vasopressors during the resuscitative
phase. Fluid replacement and circulatory support are
planned to adjust for anticipated fluid shifts. Changes in
electrolyte balance. hematocrit level, or osmolality are
treated in the context of known burn pathophysiology.
Colloid solutions may be included in the resuscitation
therapy, generally after the first 24 hours, in an attempt to
maintain fluids in the intravascular space or provide
necessary plasma elements.
Evaluation of Fluid Resuscitation. The adequacy
of fluid resuscitation for the burned child can be monitored
by assessment of urine output, cardiovascular status, acidbase changes, mental status, and body temperature. Hourly
urine output is a critical criterion for the evaluation of fluid
resuscitation. A gauge for the resolution nf burn shock is the
point at which the child is able to maintain adequate urine
output for 2 hours while receiving fluids at me calculated
maintenance rate.2 8 The goal for urine output is 1 to 2
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Fluid Resuscitation Formulas
Type and Volume of Fluid
First 24 Hours

Second 24 Hours

Colloid: 0.5 mllkg/% burn
Crystalloid: Lactated Ringer's
1.5 mllkg/% burn
D5W: 2000 mllm 2
Urine: 30-50 mllhr (adult); 1-2 ml/kg/hr (child)
Rate: '12 in first 8 hr
'I. in next 8 hr
'I. in last 8 hr
Calculation of volume: use bum area up to 50% TBSA,
>50% TBSA calculate at 50% TBSA

0.25 ml/kg/%
Lactated Ringer's 0.75 ml/kg/% bum
1500-2000 ml
Same
'/2 of first 24 hour's colloids
+ crystalloids

Colloid: none
Crystalloid: lactated Ringer's
4 mllkg/% bum
D5W: none
Urine: 50-70 mllhr (adult); 1-2 mllkg/hr (child)
Rate: '12 in first 8 hr
'/4 in next 8 hr
'/4 in last 8 hr
Calculation of volume; use total bum area for all size burns

700-2000 ml (adult) as needed to
maintain urine output
None
Sufficient to maintain urine output
Same
'12 of first day's lactated Ringer's

Colloid: none
Crystalloid: Na+250 mEq/L
Cl- 150 mEqlL
lactate 100 mEqlL
D5W: "liberal" free water by mouth
Urine: 30·40 mllhr (adult); 1-2 ml/kg/hr (child)
Rate; average 30 mI/hr
Calculation of volume; titrate to urine output not burn size

None
D5W

Ij5W 5% dextrose in water; TBSA, lotal body surface area.
mVkg/hr in the child and 30 to 50 ml/kg/hr in patients
greater than 50 kg.
A mild metabolic acidosis occurs with bum shock but
usually resolves within 18 to 24 hours of injury. Children
younger than 2 years of age, because of their inadequately
developed buffer system, are especially prone to the
development of metabolic acidosis 29 Serum pH is monitored closely, and bicarbonate is given if the acidosis
becomes severe or if circulating blood volume is restored
without resolution of acidosis.
Mental status is a critical guide to evaluate the adequacy
of fluid resuscitation. A child in an obtunded state requires
a thorough assessment because the burn injury itself does
not directly affect mental status. If obtunded because of
shock, fluid resuscitation should restore the child's normal
sensorium. If this is not the case, other causes of altered
level of consciousness are considered, including concurrent
trauma issues that might have occurred during the accident,
as well as hypoglycemia.
Pediatric burn patients are particularly affected by
alteration in temperature because of their greater BSA. In
addition, they are less able to shiver because of relatively
small muscle mass, which limits their ability to generate
heat. 9 Patients with large burns are at risk for hypothermia

until skin coverage is achieved. Exposure during procedures
and dressing changes may produce rapid hypothemnia.
Efforts by patients to maintain temperature increase oxygen
consumption and energy expenditure and add to the stress of
the burn injury.
The environment is kept free of drafts and warmer than
normal to allow a normal temperature (37° to 37.5° C) to be
maintained. Use of warm blankets, head covering, reflective
blankets, and warming shields are nursing measures that
effectively raise the body temperature. Increasing environmental humidity can decrease evaporative losses from wet
dressings and exposed body surfaces. Continuous monitoring with a rectal probe may be appropriate initially. Warmed
intravenous and irrigation solutions and a warming blanket
may be considered if profound hypothermia develops.
Wound Care. As the child's respiratory and cardiovascular status is stabilized, attention can be directed toward
the management of the burn wounds. Immediately following
injury, clothing is removed, and a total survey of the body is
performed in a clean, warm environment. In children with
large bums, assessing only a portion of the body at a time
may be necessary to maintain the child's temperature. This
approach becomes increasingly important in the infant and
young child because heat loss is rapid and physiologic
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consequences are significant. Classification of depth and
determination of TBSA involvement are verified. Less
obvious areas of injury, such as the scalp and oropharynx,
are examined for evidence of thermal injury. Regular
assessment of peripheral pulses is performed on involved
extremities.
Surgical escharotomies may be required during the
resuscitation phase to restore effecti ve circulation to extremities and digits. After the escharotomy has been performed,
the neurologic status of the affected limb is assessed
frequently because peak edema fonnation does not occur
until 24 hours after the bum?8
Wounds are cleansed with antibacterial soap and sterile
water or normal saline. Loose tissue is mechanically
debrided, and the prescribed topical agent is applied. Topical
agents are not applied if the child is to be transferred to a
burn center; instead the wounds are wrapped in clean dry
dressings. The initial dressings are wrapped loosely, particularly in the hands and feet, to allow anticipated swelling.
The head and extremities are elevated for comfort and to
minimize fluid accumulation. Access to peripheral pulses is
anticipated, so dressings are wrapped to allow periodic
assessment of circulation. Wound management varies with
physician preference, but current therapy generally involves
total removal of all devitalized tissue as soon as feasible.
Comfort Management. Most extensive burn injuries have components of superficial and partial- and
full-thickness injuries. Superficial and partial-thickness
injuries are very painful. Full-thickness injuries initially are
anesthetic, but as the wounds are debrided, the nerve
endings in the deeper layers of tissue become exposed,
resulting in very painful lesions. In addition, wound
contraction inhibits joint mobility, so range-of-motion
exercises, activities of daily living, and dressing changes are
painful and anxiety producing. Intravenous narcotics are
indicated for the pain associated with burns. The medications of choice are morphine sulfate and fentanyl. Anxiolytic
medications such as midazolam or lorazepam are especially
important for comfort management and when providing
ventilatory support. Medications are given in small doses
and titrated to relieve distress without complicating ventilation. The recommended approach is that all medications
be given intravenously during the emergent phase because
of unreliable uptake from edematous tissues when given
subcutaneously or intramuscularly.
In addition to pharmacologic management of pain,
interventions such as relaxation techniques and distraction
may be appropriate. These approaches also provide a means
for family members to be involved in the care of the child.
Every effort is made to meet the patient's need for comfort
and psychologic support. Consideration is given to associated injuries, past medical history, and the developmental
needs of the child.
Psychologic Support. During the resuscitative phase
of care, patients may be awake and alert. Survival. loss of
control, and adaptation to an unfamiliar environment are the
focus of psychosocial support systems. The ability to
communicate needs is impaired as a result of the treatment
of pain, anxiety, and respiratory function.
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Box 29-1
American Burn Association Criteria
for Patient Transfer to a Burn Center

I. Partial-thickness burns greater than 10% total body

surface area (TBSA)
2. Burns that involve face. hands, feet, genitalia, perineum,
and major joints
3. Full-thickness burns in any age group
4. Electrical bums, induding lightning injury
5. Chemical bums
6. Inhalation injury
7. Burn injury in patients with preexisting medical disorders that could complicate management
8. Burn patients with concomitant trauma in which the bum
injury poses the greatest risk of morbidity or mortality
9. Burned children in hospitals without qualified personnel
or equipment for the care of cbildren
10. Bum injury in patients who will require special social,
emotional, or long-term rehabilitative intervention

The child and family should be informed of the
procedures taking place and included in the overall plan of
care. Efforts to reassure and calm the family are important
components. Social services, psychiatry, chaplaincy, and
other hospital resources can be involved as needed.

Transfer and Referral Priorities
The American Bum Association has identified the type of
injuries that require referral to a specialized bum center
(Box 29-1). The patient with electric, chemical, or thermal
injury requires immediate assessment and stabilization at
the closest appropriate hospital. There, hospital personnel
complete a primary and secondary assessment and evaluate
the patient for potential transfer. Clear documentation of
procedures and care provided accompany the patient to the
receiving hospital. The use of transfer agreements between
regionalized bum centers and outlying community hospitals
are considered to facilitate orderly transfers and to meet
continuing education needs. 9 Some suggest that the early
transfer of the child with acute bums may shorten the length
of hospitalization and reduce complications 30

Acute Phase
Wound Care and Coverage. After stabilization has
been achieved in the emergent phase, attention is directed
toward closing the burn wound. The first step in this process
is the assessment of wound depth and the surface area
involved. The depth and extent are variable, depending on
the intensity of the source and the duration of contact with
the source of injury. Over the first 48 to 72 hours after injury,
the wounds continue to evolve. The ultimate depth of the
injury, especially in scald and chemical injuries, may not be
evident until this evolution is complete.
The goals of wound care become the preservation of as
much viable tissue as possible, removal of all necrotic
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tissue, control of the growth of microorganisms on the
wound, and creation of an environment that is conducive to
wound healing. Where extensive full-thickness skin loss
occurs, the deficit must be replaced by some form of
autograft or permanent skin substitute. These goals are
achieved in a myriad of ways, but the ultimate outcome is
the same-wound closure with intact, durable skin.
The first step in the preservation of viable tissue is the
recognition of that which is viable. Viable tissue is pink,
moist, warm, and sensate (depending on the depth of the
wound). Viability is a reflection of the degree of perfusion of
the tissue, the availability of adequate substrates for tissue
repair, and the degree of exposure to such noxious agents as
bacteria and fungus, some topical agents, and cleansi ng
solutions. Debriding dressings, mechanical trauma, shearing
forces caused by movement, and desiccation (drying) of the
wound bed contribute to loss of viable tissue. Episodes of
hypotension, hypoxia, and poor perfusion of the wound bed
can also reduce tissue viability.
The activities of the burn care team are directed toward
the preservation of viable tissue. Specifically, the focus of
care is to maintain adequate tissue perfusion, provide
adequate nutritional resources, prevent desiccation, reduce
shear and mechanical trauma, and critically evaluate dressing materials that are being used on a particular wound. In
addition, keeping the wound free of debris and necrotic
tissue, reducing the exposure of the wound to toxic topical
agents and cleansing solutions, and providing permanent
wound closure by early excision of eschar and grafting as
soon as possible are the tenets of the burn care team.
Controlling all of the variables that influence tissue
viability is not possible, but care should be taken to reduce
known risks to tissue survival while considering the
requirements of the whole child. When the viability of a
specific tissue is uncertain, it is often best to allow the body
to demarcate the line between viable and nonviable. This
dilemma often occurs when the viability of fingers or toes is
in question.
Debridement of necrotic tissue is the second component
in wound care. It can be achieved in a number of ways,
including dressings, blunt and sharp debridement with
hydrotherapy or showers, and primary excision under
anesthesia. Regardless of the methods selected by the burn
team for the individual patient, providing adequate pain and
anxiety relief is essential. Intravenous or oral narcotics and
anxiolytic agents must be given in adequate doses during
these procedures. Assessment of the child's pain and anxiety
is performed throughout the procedure, and additional
medication is administered, as needed. 3o•
Many dressing materials are on the market, with new
ones being introduced often. The specific properties and
recommended uses for a product must be understood by
caregivers. Inappropriate use of a product can actually be
detrimental to the wound. The choice of material is
generally directed by the goal of the therapy. If debridement
ofthe wound is the goal, one of the least expensive and most
commonly available materials is wide mesh gauze (WMG).
WMG is laid in a single layer over the wound. It may be
impregnated with a cream topical agent before application

or soaked with a liquid topical agent after a bulky outer
dressing has been applied.
Many biologic dressings are available. These materials
include human cadaver allografts, porcine xenografts,and
several biosynthetic materials (manufactured materials impregnated with collagen). The biologic dressings must be
applied to clean wound beds because they decrease evaporative water loss from the wound and create a warm moist
environment. Biologic dressings placed over contaminated
wounds facilitate the growth of microorganisms and result
in deepening of the wound. At the first sign of purulent
drainage, increasing local inflammation, or systemic signs
of sepsis, the biologic dressing that is not adherent to the
wound bed is removed, and the wound is inspected and
cultured.
The ideal coverage of the debrided full-thickness burn
wound is skin grafts from the child's own body. Autologous
skin grafts, the patient's own skin, remains the only
permanent, durable closure for the burn wound. Autografts
may be harvested from unburned areas of the body.
Split-thickness autografts include both epidermal and dermal elements and vary in thickness from 0.015 to 0.04 em.
Epidermal appendages are spared so that the donor site will
heal in 10 to 14 days. The donor site is then available for
reharvesti ng.
Full-thickness grafts include epidermis, dermis, and
sometimes fat and muscle tissue. Because no epidermal
appendages remain, the donor site must be either primarily
closed or grafted with a split-thickness skin graft. Fullthickness grafts in large surface area bums are a very limited
resource. They are therefore reserved for hand and facial
reconstruction and for coverage of open joints.
Several artificial skin replacement products are in the
research and development phases or newly available on the
market. These products, in whole or part, remain integrated
with the patient's body or are gradually replaced by the
body's own tissue?1 One such artificial skin, Integra,
developed by Burke and Yannis, provides a dermal template
with a temporary "epidermal" membrane. The artificial skin
consists of a collagen mat with a Silastic membrane
(temporary epidermis) on one side. The full-thickness burn
wound is excised and Integra is sutured in place with the
collagen side down. Over about 4 weeks the collagen mat is
replaced by the body's own collagen. The Silastic membrane, which until this time has reduced evaporative water
losses from the wound, is removed at 3 weeks. A very thin
split-thickness skin graft or epithelial cell cultures are then
applied to the neodermis. The neodermis and split-thickness
graft form a durable skin replacement with a cosmetically
acceptable appearance.
Epithelial cell cultures (e.g., Genzyme) are additional
commercially available products that can be used as part of
the coverage plan for the extensively burned child. A
postage stamp-sized skin biopsy of normal skin is obtained
and sent to specific tissue culture laboratories. In the
laboratory, the epidermis is mechanically separated from the
dermis. Enzymes are then added to the epidermal tissue to
produce a single-cell suspension. The single-cell suspension
is then inoculated into special tissue culture media. In about
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10 days, the epidermal cells have grown into confluent
sheets. These sheets are treated with an enzyme, Dispase, to
release them from their attachments to the plastic flasks. At
this time they can be transferred to the patient's tissue;
however, in most instances, the surface that they would
cover would be insufficient to meet the patient's needs.
These primary cultures are then treated with enzymes to
produce a single-cell suspension that is again inoculated into
tissue culture media and incubated for another 10 days. The
cultured epithelial sheets are then Dispase-released from the
flasks, clipped to Vaseline gauze carriers with surgical clips,
and transported to the operating room for application to the
patient.
This process requires approximately 21 days. At this
time, the equivalent of 2 m2 of epithelial cell cultures
become available to the patient. During this waiting period,
the wounds are excised and covered with some form of
biologic or temporary dressing.
The epithelial cell cultures are applied to the excised
wound beds and are secured in place with either sutures or
surgical staples. Care is taken to handle the cultures as little
as possible because even minor mechanical trauma results in
the death of the epithelial cells involved. Postoperatively,
the wounds are dressed with dry dressings, and the areas are
immobilized. In approximately 7 days, the Vaseline gauze
backings are gently removed. Thin glistening sheets of
epithelial cells can be seen as the backings are very gently
removed from the tissue. The coverage remains very fragile
for several weeks, requiring nonadherent dressings and great
care in handling.
The durability of epithelial cell cultures is never the same
as normal skin but rather is like that of thin split-thickness
grafts. They can, however, provide lifesaving coverage for
the child with extensive full-thickness bums. With any
method of wound coverage selected by the bum team,
coverage must be pursued aggressively if the child is to
survive and avoid systemic sepsis and shock.
Regardless of the type of wound covering, it is critical
that the child's wound be assessed at least daily for signs of
deterioration. Signs of wound infection must be identified
early before systemic infection develops. Clinical manifestations include discoloration of eschar (dark red, brown, or
black), conversion of a split-thickness injury to a fullthickness one, rapid acceleration of the eschar, reddened
necrotic lesions in unburned skin, discoloration of unburned
skin at the wound edge, and accelerated circular subcutaneous edema with central necrosis.
Infection Control. The goals for the burned child
related to infection control include the following:
• Prevent the transmission of microorganisms from the
child to the environment and other patients.
• Prevent the transmission of microorganisms from the
environment and other patients to the child.
• Control or eradicate microorganisms that are not part
of the child's normal flora.
Creating physical barriers between the burned child and the
environment helps to prevent the transmission of microorganisms from the child to the environment and other patients
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and from the environment and other patients to the child.
These barriers can be created in a number of ways,
depending on the architecture and resources of the individual unit. The child can be cared for in a single room or in a
laminar flow unit on an open ward. Barriers can include
plastic aprons, gauntlets, gloves, hats, and masks or
isolation gowns, gloves, hats and masks. Standard precautions require the addition of goggles or face shields if a
reasonable risk exists for splash and splatter of body fluids
or tissues.
An environment that is conducive to wound healing is
warm and moist and has sufficient substrates for cell maturation and division. 32 Unfortunately, this environment is also
conducive to the growth of microorganisms. These organisms compete with the body's cells for available substrate
and produce toxins that inhibit the repair of the damaged
tissue. The wound, therefore, is kept warm, moist, and as
clean as possible, if wound healing is to be facilitated 32
Topical agents are applied to the wounds to control the
growth of microorganisms on the wound until permanent
coverage is achieved. The appropriateness of a specific
agent for a specific wound depends on the characteristics of
the topical agent, the wound, and the clinical experience or
preference of the bum team. Table 29-4 lists the properties
of the various agents and their limitations.
Nutritional Management. The burned child has
increased nutritional requirements related to the hypermetabolic state and the energy needed to heal wounds. Calculated nutritional needs are based on basal metabolic rate,
physical activity, and stress-induced energy needs (Table
29-5). Caloric requirements are estimated based on the BSA
involved in a burn injury, as well as the child's daily
requirements based on growth needs, and may range from
1.2 to 1.5 times their basal metabolic rate. 33 ,34 A nutritional
consult is planned on admission to determine caloric,
carbohydrate, and protein goals with a systematic plan to
meet these goals. Formulas vary for determining the exact
nutritional needs, and some may calculate as much as twice
the normal caloric and protein requirements. Adequacy of
nutritional support can be evaluated from calorie counts;
laboratory values, including prealbumin and albumin levels;
metabolic cart measurements; biweekly weights; and the
status of wound healing.
Oral nutrition is the preferred method of feeding;
however, oral intake is often insufficient because of
anorexia, intubation, and an inability to voluntarily take in
all the calories required. Providing supplemental enteral
feedings via flexible feeding tubes is often indicated in these
situations to achieving calorie and protein goals. Feeding
tubes can be placed into the small bowel via the gastric
pylorus to minimize issues with decreased gastric motility
or high gastric residuals. Some bum centers continue enteral
postpyloric feedings during surgical procedures to make it
possible to achieve nutritional goals. 34 Other centers successfully use a program of intragastric feedings, sometimes
combined with a limited intravenous hyperalimentation
program 2 .35
The use of a limited intravenous hyperalimentation
program may be required in patients with prolonged
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TABLE 29·4 Topical Agents

~Jopical Agent

Effectiveness

Side Effects

Ease of Use

Pain

Cost

~Silver sulfadiazine

Broad-spectrum
Minimal eschar
penetration

Dose-related
neutropenia
Sulfa allergies
Do /lot use in
patients with
toxic epidermal
necrolysis
Development of
pseudoeschar

Semiclosed
dressings
Changed bid-qid
Residue must be
washed off with
each dressing
change

Cooling; least
painful

$34.35
(400 g)

Broad-spectrum
Only penetrates
2-4 mm into
bum wound

Hypoallergenic
Leaches electrolytes
from wound,
especially
sodium and
potassium
Methemoglobinemia
Environmental
staining

Bulky ('/2-inch thick),
wet dressings
Changed bid-qid
Must be soaked
q2h to maintain
wetness
Stains skin and environment black
Surrounding normal
skin must be
protected from
staining with
petrolatum-based
gauze

Stings briefly on
application or
soaking

$ 9.75
(liter)

Broad-spectrum
including
Pseudomo/las
Rapid and deep
wound penetration

Inhibits spontaneous epithelial
regeneration
Carbonic anhydrase
inhibitor causing
metabolic acidosis as a result of
HCO) wasting
Sensitivity rash

Semiclosed
dressings
Changed bid-qid
Residue must be
washed off with
each dressing
change

Burning feeling for
15-20 min

$126.00
(453 g)

Broad-spectrum,
including fungi

Iodine absorption
through wound
increasing serum
iodine levels
Iodine allergies
Environmental
staining

Semiclosed or wet
dressings
Changed bid-qid

Stinging pain

$3.86
(480 ml)

Broad-spectrum in
concentrations of
0.025%-0.125%
Safe for use as a
wet dressing over
tendons and open
joints (used rarely
in United States)

Can macerate
normal tissue
Unstable, use fresh
Keep in a dark
place
Drying to tissue

Wet-wet dressings
Wet-dry dressings
(debriding)
Changed bid-qid
Soak q2h

Stings

<$1.00
(gal)

Broad-spectrum
but no fungi
coverage

Sensitivity rash to
sulfa drugs

Dressing can be
removed moist
or dry
Changed qd

None

Collagenase:
$29.95 (15 g)
Polysporin:
$10.00 (10 g)

No antimicrobial
properties
Keeps wound moist

Can macerate tissue

Wet-wet dressings
Wet-dry dressings
(debriding)
Changed bid-qid
Soak q2h

Stings

A few cents

I!!Lp

I

(Silvadene,
~, Flamazine) 1%
i~, in water-miscible
i';.: cream base
~~.

~~
~

I~i1ver nitrate solu-

Ii
i

I!

tion 0.5% in

~.,

I
I!';

!if:F
~;'"

~j:i

.X

~i:;""

jlMafenide acetate
(Sulfamylon)
10% in waterj~'miscible cream
base

:Itrc

I,t

!{
(~,

I

I:

I~ovidone iodine
(Betadlne) 1%

1E'~~YPOChlorite
IPakin'S

i"fuso,

~iC'

~ .;.!.!
..

~ :,;

~\.

ll!~ollagenase

Ii;· (Santyl) ~nd
~1 . . polysponn
~ .. , powder

If
.
it;Normal saline
iii':;. 0.45% or 0.9%

I-I:r

!ifC

iL
iEJ)ata from Medical Economics Company: The red book, Montvale, NJ, 1999, Medical Economics.
1&:::
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Nutritional Support for Pediatric Burns*
Basal Metabolic Rates: Infants and Children

1]

It-·

A_g_e_1_W_k_to_10_m_o

48-

Age 11 to 36 mo

_

Age 3 to 16 yr

Thii'"

Metabolic Rate
(kcal/hr)

~~Weight (kg)

Male or Female

Weight (kg)

Male

Female

Weight (kg)

Male

Female

8.4
9.5
10.5
11.6
12.7
13.8
14.9
16.0
17.1
18.2
19.3
20.4
21.4
22.5
23.6
24.7

9.0
9.5
10.0
10.5
11.0
11.5
12.0
12.5
13.0
13.5
14.0
14.5
15.0
15.5
16.0
16.5

22.0
22.8
23.6
24.4
25.2
26.0
26.8
27.6
28.4
29.2
30.0
30.8
31.6
32.4
33.2
34.0

21.2
22.0
22.8
23.6
24.4
25.2
26.0
26.9
27.7
28.5
29.3
30.1
30.9
31.7
32.6
33.4

15
20
25
30
35
40
45
50
55
60
65
70
75

35.8
39.7
43.6
47.5
51.3
55.2
59.1
63.0
66.9
70.8
74.7
78.6
82.5

33.3
37.4
41.5
45.5
49.6
53.7
57.8
61.9
66.0
70.0
74.0
78.1
82.2

~it;

Metabolic Rate
(kcallhr)

Metabolic Rate
(kcallhr)

k;'

3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
10.5
11.0

ij;~om Allman PL.

Dillner OS. eds: Metabolism. Bethesda. Md. 1968. Federation of American Socielies for Experimental Biology.
to appropriate sex. identify metabolic rate (kcaVhr).
~iiand multiply metabolic rate by 24 hours. For burn patients. multiply BMR by 1.2 to 1.5 to account for hypcrmetabolic state of burn injury.

ini..-yo calculate basal metabolic rate (BMR). determine the age and weight of the patient. read across
:ill:

paralytic ileus, an inability to meet caloric needs by other
routes, or other gastrointestinal abnormalities making the
enteral route impractical. Consideration is given to providing necessary proteins, vitamins, trace elements. and lipids
necessary for wound healing and growth. I
Comfort Management. Comfort management is an
essential issue in the acute phase, as it was in the emergent
phase. Comfort management for the acutely ill child with a
large surface area burn is complicated by many factors. The
hypermetabolic state of the patient accelerates use of
narcotic and anxiolytic medications J6 Assessing the severity of the child's pain and fear is often difficult because of
the child's growth and developmental level, level of
consciousness, and ability to communicate. All of these
factors influence the nurse's ability to assess the level of
discomfort and the child's responses to interventions. Pain
assessment tools are useful in helping the alert child to
express pain.
Often the child is too ill to express discomfort, and the
nurse can only rely on physiologic parameters. This is
particularly true if the child has been chemically paralyzed
to facilitate mechanical ventilation. Liberal amounts of
analgesics and anxiolytic medications are provided. A child
with planned interventions including dressing changes,
positioning, physical therapy, and chest physiotherapy
recei ves appropriate premedication based on the response to
previous interventions.
Intravenous narcotics, particularly morphine sulfate and
fentanyl, have become the standard for pain management.

Severe pain requires continuous infusions of intravenous
narcotics. For very painful procedures, such as dressing
changes, when premedication may not provide adequate
comfort or analgesia, bolus doses of narcotics and anxiolytic
drugs are used. For the alert school-age child and adolescent, patient-controlled analgesia is effective. Nonpharmacologic pain management strategies, such as distraction,
guided imagery, hypnosis, music, and providing the child
with opportunities to exercise control, can be effective in the
acute phase, as well as in the resuscitative phase. These have
been found to be successful adjuncts to the traditional
pharmacologic management of pain and anxi ety J6 Their
application for a specific child should address the child's
growth and developmental level, level of consciousness, and
willingness to participate in these strategies, as well as the
skill of the nurse or caregi ver.
Mobility. Patients with burns are often immobilized
for periods of time, placing them at risk for associated
complications. Movement is restricted initially by pain,
bulky dressings, and splints. Bed rest and sedation also place
the burned child at risk for the hazards of immobility. Later,
scar contractures, discomfort of healed wounds, muscle
wasting from disuse, and loss of stamina affect the ability to
move about comfortably. To maintain optimal physical
functioning, the patient's mobility is considered from
admission. Active and passive range-of-motion (ROM)
exercises are done with every dressing change and throughout rehabilitation and recreational therapy activities. Nursing care involves routine position changes for the patient on
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bed rest, comfort and protection from nerve damage, and
maintenance of joints in extended functional positions.
Physical and occupational therapy consultation and
participation in their own daily care can maximize burned
children's functioning through the hospital stay and beyond.
Involvement in exercise and self-care activities has important short- and long-term benefits for the child. Patients
benefit from being out of bed as soon a~ feasible. Pressure
wraps or garments must be applied to grafted legs to help
compensate for vascular instability in the newly grafted skin
when the child is out of bed or ambulating. Many problems
of wound contracture, hypertrophic scarring, and impaired
mobility can be limited when these issues are addressed
early.
Psychosocial Issues. Emotional support for the family and patient is critical throughout this prolonged critical
illness. Nurses are instrumental in providing this support
and in coordinating support from others. The early involvement of social service and mental health professionals is
essential in supporting the child and family. Maintaining
contact with the child's peers, school teachers, and other
members of the community ultimately eases the child's
return to a normal life. 2
As the child begins to recover and passes through critical
illness toward rehabilitation, the concerns of the child and
family shift toward the child's ability to physically function
and the child's ultimate appearance. Children with facial and
hand scars have the most difficult time dealing with their
changed appearance. The child's body image changes with
growth and development, producing new challenges to
coping through the different developmental stages. Parents
and siblings share these struggles.
For the child who is unable to survive the injury, support
for the family becomes the focus of resources. The team's
goals are to help them grieve for their lost child and begin
to rebuild their lives as they heal their own emotional
scars. 37
Nursing staff and other caregivers need to support
themselves and each other through this emotionally draining
experience, Establishment of clear boundaries and involvement with patients and families may aid to prevent vicarious
trauma and maintain objectivity. Support groups, workshops, and individual discussions help professionals to

support the family and care for themselves. Open discussions surrounding the ethical issues that often surround the
care of these children are an invaluable resource to the staff
who participate.

BURN OUTCOMES
Successive improvements in burn care, technology, regionalization of burn centers, and improved fluid and electrolyte
resuscitation have substantially increased survivability of
major burn injuries, especially in children. The costs of this
improved treatment, in terms of allocation of scarce
resources, economic, as well as ethical, have called into
question the wisdom of providing maximum care instead of
comfort care in patients with massive bum injuries.
Outcomes research, a strategy to provide benchmarks to
compare future results with care provided, has recently
begun to exanline this question. Physical appearance and
functional outcomes examined in patients with greater than
80% TBSA burns found that over 80% were independent in
basic activities of daily living, indicating that most pediatric
bum survivors satisfactorily adapt to their functional limitations even after severe injuries.3 8 In addition, the massively burned patients have a quality of life comparable with
the age-matched population. This finding also suggests that
although the cosmetic and functional impairments may be
irreparable and life-lasting, high-quality acute care, skillful
multidisciplinary aftercare, and family support can yield
positive long-term outcomes for these children 39

SUMMARY
The child who sustains a major burn injury faces and
overcomes multisystem assault with the help of an interdisciplinary team. A vast array of professionals participates in
the effort to restore the child's physiologic and emotional
integrity. An essential part of this team is the child's parents,
who must help the child with integration into the community
and development into a productive member of society.
Today, physical survival from devastating burn injury can
almost be ensured. The challenge for professionals in the
future is to ensure that survival is meaningful for the child,
family, and the community.
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Toxic Ingestions
Maureen A. Madden

P

oisoning continues to be a significant cause of pediatric
injury. Five percent of all accidental childhood deaths
are related to poisoning. Methods of exposure to toxic
agents vary, with ingestions accounting for the majority of
exposures. I The 1998 Annual Report of the American
Association of Poison Control Centers Toxic Exposure
Surveillance System reported more than 2 miUion human
exposures to toxins that year. Fifty-three percent of the cases
involved children younger than 6 years of age. Males
predominated in the ingestions under age 13, whereas
teenage cases involved more females. I The majority of
the 755 fatalities were associated with ingestion and
inhalation exposures. Children younger than 6 years accounted for 2.1 % of the fatalities, whereas adolescents
accounted for 5.9%.
The substances involved most often in human exposure
are not the most toxic but the most readily accessible. Some
of the more common agents involved in pediatric exposures
are cosmetics, cleaning fluids, analgesics, plants, and cough
and cold preparations. Toxic effects do not often occur with
these substances because children usually do not ingest
amounts sufficient to produce toxicity.
Other agents ingested less often but that do not require
large exposures to produce toxic effects are barbiturates,
clonidine, iron, theophylline, antidepressants, alcohols, cocaine, and caustics. The ingestion ofthese substances causes
the greatest percentage of hospitalizations, intensive care
unit (rCU) admissions, and fatalities in pediatric poisonings.
Table 30-1 compares the most common with the most toxic
substances ingested.
Characteristics that place children at risk of ingestions differ for various age groups. Toddlers are newly
mobile, curious, and anxious to explore their environment through reaching, climbing, and tasting. They are
without suicidal intent. Usually only one substance is

COMMON PRINCIPLES OF EMERGENCY AND CRITICAL
CARE MANAGEMENT
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TABLE 30-1 Most Common Versus Most
Toxic Agents Ingested
rost Common"

MostToxict

~osmetics

Analgesics
Antidepressants
Stimulants/street drugs
Cardiovascular drugs
SedativeslHypnotics
Alcohols
Chemicals
Gases and fumes
Cleaning substances
Anticonvulsants
Asthma therapies
Antihistamines
Hydrocarbons
Automotive products
Hormones/Hormone
antagonists
InsecticideslPesticides

"._ '-leaning substances
fi\nalgesics
~Iants

IFforeign bodies
"Cough/cold preparations

~:.ropicals

, esticides/lnsecticides
tamins
"'. timicrobials
I[GI preparations
l s/Crafts/Oftice supplies
:'" "ydrocarbons
~

if.:

..

.

~nlJhlstanunes

!Hormones and hormone
,ll:-antagonists
tl~\1;

,from

I

Lilovitz TL, Klein-Schwartz W, Caravali EM el al: 1998

~ual Report of Ihe American Association of Poison Control

?~.'.:
'.".'.'.,nlers Toxic
Exposure
,1,7:435-487,
1999.
•.

Surveillance Syslem, Am J Emerg Med

r~ost common in pediatric exposures for younger than 6 years
'tot age.

':~Listed

COMMON PRINCIPLES OF EMERGENCY
AND CRITICAL CARE MANAGEMENT
Initial evaluation of the patient in whom a toxic ingestion is
known or suspected includes establishing a patent airway,
effective ventilatory pattern, and adequate perfusion. Primary measures to stabilize the patient's condition are based
on the priorities of resuscitation. In the secondary phase of
evaluation, clinical signs that identify the toxin are observed, and appropriate treatment is initiated. Fig. 30-1
provides an algorithm for management of the patient with a
known or suspected toxic ingestion.

Toxidromes
After initial evaluation and stabilization, the examination
focuses on the assessment of the central and autonomic
nervous system; eye findings; changes in skin, oral, and
gastrointestinal (GI) mucosa; and odors. These areas represent the ones most likely affected in toxic syndromes. The
clinical syndromes, called toxidromes, comprise a constellation of signs and symptoms that suggest a specific class of
poisoning, Toxidromes help identify the toxin so that
appropriate treatment can be initiated in a timely manner.
The most common toxidromes are sympathomimetic, theophylline, sedati ve/hypnotic, opiate, anticholinergic, and
cholinergic. 3 -4 Table 30-2 presents the toxidromes with
associated symptoms and causative agents.

in order of frequency in human exposures.

involved, and the amount ingested tends to be small and
nontoxic. Toddlers often present for evaluation soon after
ingestion,
An increasing number of significant pediatric exposures
in children younger than 6 years of age involve ingestion of
a grandparent's or other elderly caretaker's medicine. These
agents, often in sustained-release dosage forms, tend to be
more toxic to children.
Most adolescent ingestions occur in the home and are
intentional rather than accidental. They are associated with
academic difficulties, social adjustment problems, failed
romances, family issues, or the death of a loved one.
Adolescent ingestions commonly involve multiple substances, they are a result of either suicide attempts or
substance abuse, and commonly a delay occurs between
ingestion and when medical attention is sought.
At present, 65 poison control centers serve 257.5
million of the estimated 270.3 million people living in
the United States. I Poison control centers have streamlined
the most efficient methods of diagnosing and treating
poisonings. Other significant contributions made by the
centers include education, prevention, research, and legislation, For example, the development of child-resistant
containers (resulting from the Poison Prevention Act of
1970) is credited with significant reduction in morbidity and mortality from accidental ingestions, particularly
aspirin products 2

Identification of Toxin
The goal of identification is to determine which patients are
at risk for toxic effects. An additional goal is to minimize
intervention for children not at risk for toxic effects because
the majority of pediatric ingestions result in no harm to the
child. 5 For the vast majority of patients, the clinical
condition rather than the specific ingredients of the ingestion
directs the management. This approach does not preclude
treating specific toxins or toxidromes, but rather enforces
the concept of basic clinical management and resuscitation
techniques. 6
A thorough history is obtained, including type and
amount of ingestion if known; the possibility of multiple
agents; time of ingestion; time of presentation; any history
of vomiting, choking. coughing, or alteration in mental
status; and any interventions performed before presentation
at the medical facility, Regardless of the history of the
substance ingested by a child or adolescent, serum and urine
toxicology screens may be necessary to rule out the
possibility of unknown ingestants, Appropriate laboratory
studies include basic serum chemistry studies in symptomatic patients, confirmation of suspected toxins, and the
determination for the need of specific antidotal therapy. Toxicologic analysis in children is most valuable to
identify serum drug levels, but unexpected findings rarely
lead to changes in management. 7 •8 Suicide attempts include evaluation for unreported agents, including salicylates and acetaminophen. because most adolescents with
suicidal intent are unreliable when reporting ingested
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Assess neurologic status
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~
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monitoring, and antidote recommendations
~

Airway protection and immobilization
~

Gastric tube placement
~

Obtain gastric and urine toxicology screens
~

Lavage and/or charcoal when indicated
~

Ongoing supportive therapy

Fig. 30·1

TABLE 30-2
I·"

Management of the patient with a suspected toxic ingestion.

Toxidromes

•

~iltOXldrome

Symptoms

Causative Agent

;,ympathomimetic
(stimulant)

Restlessness, excessive speech and motor activity, tremor,
insomnia, tachycardia, hyperthermia, mydriasis,
hallucinations

Amphetamines
Phencyclidine (PCP)
Cocaine
Other stimulants

!iti,.
~:

I;

~eophylline

(specific

l!iJ.
"
)
~E sympath
omlmelIC

I'

i.~.;:.-.:.i: ~_yp"mk

l

~4i"

OOi~

~iliAn· . h I'
~1:'

IE·

tIC

0

.
merglc

~;:"

F·

[

~.

Sedation, confusion, delirium, hallucinations, coma, paresthesia, diplopia, hlurred vision, slurred speech, ataxia,
nystagmus

Barbiturates
Benzodiazepines

Altered mental status, miosis, unresponsiveness, shallow
respiration, bradypnea, bradycardia, hypotension,
decreased bowel sounds, hypothermia

All narcotic agents
Heroin
Clonidine

Fever, flushing, tachycardia, urinary retention, dry skin,
blurred vision, mydriasis, decreased bowel sounds,
ileus, myoclonus, psychosis, hallucinations, seizures.

Some mushrooms
Cyclic antidepressants
Antihistamines
Atropinics
Over-the-counter sleep preparations

coma

~: ..

I-~

Tachycardia, hypotension, cardiac dysrhythmias, tachypnea, agitation, seizures, vomiting with epigastric pain

bolinergic

Salivation, lacrimation, urination, defecation, emesis,
diarrhea, bradycardia

Organophosphates
Insecticides
Some mushrooms
Severe black widow spider bites
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agents. There is limited data and information to distinguish
lethal concentrations of certain drugs and toxic substances
in children. 5 ,9.IO

The Unknown Toxin
When the name or the amount of a poison ingested is
unknown, the incident is unwitnessed, or the history is
vague, the child is treated as though a harmful substance
was consumed. If elements of the history provided are
contradictory or questionable, it is especially important to
rule out the possibility of trauma as a cause of the patient's
physical injuries. Physical assessment focuses on the potential for unreported traumatic injuries, as well as significant
details related to the ingestion, and a clinical presentation
that suggests a toxidrome. The availability of antidotes such
as naloxone (Narcan), glucose, oxygen, diphenhydramine
(Benadryl), physostigmine, digoxin immune Fab (Digibind), methylene blue, deferoxamine, N-acetylcysteine
(NAC) (Mucomyst), calcium gluconate, and glucagon is
necessary when the ingestion of a toxic substance is suspected. 10, I J The local poison control center can provide
details regarding the indications and guidelines for use of
these antidotes, Further emergency and critical care management is guided by the principle of simultaneous stabilization, diagnosis, and treatment.
Further management focuses on GI decontamination.
Once the ingestant is correctly identified, the management
can focus specifically on principles related to that toxin.

Gastrointestinal Decontamination
Reducing the life-threatening potential of an ingested
substance is an early treatment goal and depends on the
effectiveness of several different treatment modalities.
These modalities may include decreasing absorption of the
toxin, altering metabolism, increasing elimination of the
ingested substance, or administering a specific antidote or
other suitable therapy.12
Decreasing Absorption
Gastric Emptying. The best gastric emptying technique to employ depends on clinical status. An individualized approach based on the timing of ingestion, type of
substance, and amount of the ingested substance in conjunction with the clinical status will dictate treatment decisions.
Gastric emptying is performed when a benefit is anticipated and one of the following conditions exist: the
substance does not bind to activated charcoal, it is difficult
to remove by gastric lavage (e.g" large pills), the opportunity to use activated charcoal is significantly delayed, or the
child presents within I hour of ingestion with significant
central nervous system (CNS) symptoms. Gastric emptying
has limited benefit if attempted more than I hour after
ingestion because most toxins have already been absorbed
or passed through the pylorus. Ipecac-induced emesis and
gastric lavage are two techniques used for gastric emptying.
Ipecac. when recommended, is the agent of choice for
forced emesis, Ipecac is very useful in the home for

immediate treatment of accidental ingestions. However, it is
no longer favored in the clinical setting because it causes
significant delay in the administration of activated charcoal
because of prolonged vomiting. Ipecac acts as both a local
gastric irritant and a central stimulant, triggering the
vomiting center in the reticular formation. The result is
coordinated muscular activity of the stomach and small
intestine, producing emesis, Dosages of 10 ml for infants
older than 6 months, 15 ml for children 1 to 12 years, and
30 ml for children older than 12 years usually produce
emesis in 20 minutes. 13
Ipecac is contraindicated in infants younger than 6
months of age, with the ingestion of strong caustics (acids or
alkalis) or hydrocarbons, and in the presence of neurologic
impairment. Other contraindications are loss of the gag
reflex and ingestion of agents likely to cause rapid onset of
CNS depression or seizures (e.g., clonidine, cyclic antidepressants, lindane, cocaine, and isoniazid).
Gastric lavage evacuates the stomach and augments
decontamination in the presence of residual toxins. The
substance is flushed through a large-bore nasogastric or
orogastric tube (28 to 38 Fr) with room temperature fluids
until the yield is clear. The tube size required for effective
lavage may be too large for pediatric patients; the largest
bore tube, known as an Ewald tube, can be placed only in
adolescents, Tracheal intubation precedes lavage for patients in whom the gag reflex is diminished and ability to
protect the airway is compromised to avoid the hazards of
vomiting and subsequent aspiration.
Gastric lavage is no longer considered the standard of
care in pediatric patients. There is a lack of strong clinical
evidence supporting the efficacy of lavage in improving
outcomes of poisoned patients. But gastric lavage is still
recommended if the amount ingested is very large, if
presentation takes place within I to 2 hours of ingesting
agents that delay gastric emptying (e.g., barbiturates,
anticholinergic drugs), if sustained-release and insoluble
compounds have been ingested, or if the agent is particularly
toxic 2 ,13,14 Because activated charcoal is very effective, it is
given at the initiation of the lavage procedure and possibly
repeated at its conclusion. Gastric lavage is contraindicated
with caustic and hydrocarbon ingestions.
Activated Charcoal. Activated charcoal reduces absorption of a toxin by binding with it in the GI tract. It is best
administered by nasogastric or orogastric tube to small
children who may refuse to drink it because of its poor
palatability and gritty texture. The commonly recommended
dose of I g/kg may result in undertreatment with pediatric
ingestions, but alternative recommendations depend on
knowledge of the amount ingested. If the amount ingested is
known, a total charcoal dose is administered, determined by
a charcoal to ingestant ratio of 10 g: I g, The total volume of
fluid required to achieve this dose may require division into
smaller aliquots (15 to 25 g) given every I to 2 hours. The
extended dosing regimen may provide for increased efficacy
in preventing absorption of sustained-release agents. When
the amount of the ingestant is unknown, then a dose of
I g/kg is recommended. Preparations of IS g, 25 g, or 50 g
of acti vated charcoal are commercially available. Adminis-
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tration of the entire premixed preparation that most closely
approximates the child's weight is reasonable and often
meets or exceeds the recommended I glkg dose.
Activated charcoal binds all organic substances but is not
effective with alcohols and glycols, hydrocarbons, caustics,
heavy metals such as lead, mercury, lithium, and arsenic, or
agents with rapid onset. 15 Ideally, charcoal is administered
within 2 hours of the ingestion. The first dose of activated
charcoal is most effective in children when combined with
a properly dosed cathartic such as sorbitol. Once bound to
the charcoal, sorbitol propels the toxin rapidly through the
intestinal tract, decreasing intestinal transit time. Subsequent doses of activated charcoal are administered without
cathartics to avoid severe diarrhea, fluid shifts, and electrolyte abnormalities, resulting in complications such as
hypernatremia and seizures.
The patient's ability to tolerate charcoal varies. Charcoal
administration is usually followed by periods of vomiting, especially when it has been preceded by ipecac or
when given with sorbitol. It is difficult to determine
whether nausea has subsided in young children who are
unable to completely describe physical symptoms. The
potential hazards of vomiting and aspiration are significant
for patients with diminished ability to protect the airway, and intubation is indicated before administration of
charcoal.
Priorities for patients who receive charcoal include
positioning in left lateral decubints with the head of the bed
elevated, ensuring that suction is readily available to protect
the airway if vomiting occurs, and immobilizing the child to
maintain intravenous patency and the position of the gastric
tube. The presence of bowel sounds is assessed before
administering charcoal because absent bowel sounds may
indicate development of an ileus or obstruction. Charcoal is
contraindicated in these situations.
Enhancing Elimination. Multiple-dose activated
charcoal has been shown to enhance elimination of certain agents. This is a separate role for activated charcoal
in addition to preventing absorption. Repeated dosing
has been shown to enhance elimination of toxins by
interrupting hepatic recirculation of the ingested drug or
its metabolites, adsorbing after initial absorption, or
adsorbing tOltins secreted across the gastric membrane
into the bowel lumen by a GI dialysis effect. This role is
well described for several drugs, such as theophylline,
phenobarbital, salicylates, carbamazepine, and phenytoin.
Drugs in a bound state adsorbed to activated charcoal are
nontoxic. 15
Whole Bowel irrigation. Whole bowel irrigation has
emerged as a new modality to augment gastric decontamination, particularly for sustained-release or enteric-coated
preparations, drug-filled packets, and ingestions not adsorbed to activated charcoal (i.e., heavy metals). A polyethylene glycol-balanced electrolyte solution (Golytely or
Colyte) hastens the evacuation of substances from the GI
tract without creating fluid and electrolyte shifts. The
irrigating solution is infused via a nasogastric tube at a rate
of 15 to 40 mllkg/hr and continued until the rectal effluent
is clear or until radiopaque tOltins disappear or pass into
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the cecum on a kidney-ureter-bladder film. Whole bowel
irrigation is contraindicated with bowel obstruction, perforation, or ileus 5
Alkaline Diuresis. Forced diuresis with alkalinization
of urine pH may enhance the removal of toltins that are
weak acids via ion trapping. Alkalinization of urine will
shift the acid-base equilibrium of weak acids from the
uncharged state to ions that do not readily cross cell
membranes. This causes the ions to be trapped in the renal
tubular lumen, reducing reabsorption and enhancing excretion. Urinary alkalinization is accomplished by administering intravenous sodium bicarbonate until the urine pH
approaches 7.5. The intravenous solution is infused at a rate
of 1.5 to 2 times maintenance volume for the patient to
maintain urine output at a minimum of 2 ml/kg/hr. Alkaline
diuresis has been predominately used to enhance elimination of salicylates and phenobarbital. 5 . 12 This technique is
limited by the risk of intravascular volume depletion and
potential for excessive alkalinization.
Extracorporeal Methods. Extracorporeal methods
of drug removal are useful in certain life-threatening
ingestions when substantial absorption of the toxin has
already occurred. Methods of extracorporeal drug removal
include peritoneal dialysis, hemodialysis, hemoperfusion,
and plasmapheresis. The decision to use extracorporeal
removal techniques is based on the clinical features of the
poisoning. Dialysis or hemoperfusion is considered when
the child's condition progressively deteriorates despite
intensive supportive therapy. These techniques are highly
invasive and have proven to be beneficial with a limited
number of toxins.
Dialysis eliminates toxic substances by movement of
solutes across a semipermeable membrane as a result of a
concentration gradient. The effectiveness of peritoneal
dialysis and hemodialysis depends on the molecular weight,
lipid-water solubility, protein-binding properties, time of
ingestion, and plasma concentration of the toxin. Peritoneal
dialysis is far less effective than hemodialysis and is used
only occasionally in acute ingestions. Hemodialysis has
proven to be effective in enhancing elimination of salicylates, ethylene glycol, methanol, lithium, and isopropanol.!3
Hemoperfusion involves the passage of blood over an
adsorbent matrix material of charcoal or resin. Although
hemoperfusion is preferred over hemodialysis for several
toxins, hemodialysis is more readily initiated and is often
used instead. Hypotension and thrombocytopenia are potential complications of hemoperfusion. Plasmapheresis separates harmful substances from the plasma by continuous
centrifugation. Substances that are eliminated best by this
method have small volumes of distribution and tight plasma
protein-binding properties.
The sections that follow detail the care of children who
have ingested potentially harmful toxic substances. Pharmaceutical agents include acetaminophen, barbiturates, carbamazepine, c1onidine, iron, theophylline, and cyclic antidepressants. Nonpharmaceutical agents discussed are the
alcohols (methanol, ethylene glycol, isopropanol, and ethanol), drugs of abuse (cocaine, heroin, methadone, and
phencyclidine [PCP]), and household toxins (caustics and
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TABLE 30-3 Systems Most Commonly
Affected by Pharmaceutical Toxins

~
.

TABLE 30·4 Systems Most Commonly
Affected by Nonpharmaceutical Toxins

Agent

Systems Involved

Agent

Acetaminophen
Barbiturates

Hepatic
Neurologic
Cardiovascular
Renal

Alcohols
Methanol
Ethanol
Isopropyl alcohol

Carbamazepine

Neurologic
Cardiovascular
Hepatic
Renal

Ethylene glycol

Neurologic
Cardiovascular
Respiratory
Renal

Caustics

Gastrointestinal

Hydrocarbons

Respiratory
Neurologic
Cardiovascular
Hepatic
Renal

Clonidine

Neurologic
Cardiovascular

Iron

Cardiovascular
Neurologic
Metabolic
Hepatic
Renal
Gastrointestinal

Theophylline

Cardiovascular
Neurologic
Gastrointestinal
Metabolic

Cyclic antidepressants

Neurologic
Cardiovascular

Systems Involved

Neurologic
Neurologic
Neurologic
Cardiovascular
Gastrointestinal
Renal

Acetaminophen

1~taminoPhen

Acetaminophen sUlfa{
(Nontoxic)

hydrocarbons). Tables 30-3 and 30-4 list these substances
and also indicate the body system(s) most often affected.

PHARMACEUTICAL TOXINS

Cytochrome P-450
chain

I \

Nontoxic state

I

Acetaminophen
Etiology/Incidence. Acetaminophen is used commonly as an antipyretic and analgesic in the pediatric
population and is contained in more than 100 products. Its
availability in the home makes it more accessible to children
than other household products. It is one of the most common
drugs associated with intentional and accidental overdoses.
Acetaminophen ingestions are potentially more harmful in
adolescents than in young children because the quantity
consumed is usually greater. Therefore adolescents are two
times more likely to manifest toxic blood levels and six
more times more likely to develop hepatotoxicity than are
young children. 16
Pathogenesis. Acetaminophen reaches peak serum
levels 30 minutes to 4 hours after administration. I? However, peak plasma levels may not occur with an overdose
until 4 or more hours after ingestion, especially with
extended release or combination products that include
agents that slow gastric motility.
The toxic dose of acetaminophen after a single acute
ingestion is 150 mg/kg for children and approximately 7 g
for adults. Acetanlinophen is rapidly absorbed from the
stomach and small intestine and is normally metabolized by

glucuronide
(Nontoxic)

Glutathione

I

Mercapturic acid
(Nontoxic)

Overdose

\

1 Glutathione stores

\

Toxic intermediate
metabolites

\

Hepatocellular
damage
Fig. 30·2 Metabolism of acetaminophen. (From Agran PF, Zcnk
KE, Romansky SG: Acute liver failure and encephalopathy in a
15 month old infant, Am J Dis Child 137:1107-1114,1983.
© American Medical Association.)

conjugation in the liver to nontoxic agents, via sulfate and
glucuronide conjugates, which are then eliminated in the
urine (Fig. 30-2). Toxic amounts overwhelm the normal
pathway of metabolism, resulting in metabolism in the liver
through the mixed function oxidase cytochrome PA50
system to a toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). Normally, NAPQI, a free radical, is
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detoxified by conjugation with glutathione to form the
nontoxic and renally eliminated mercapturic acid. In overdose, the sulfation increases ultimately causing depletion of
glutathione stores. The depletion of glutathione inhibits
normal formation of the nontoxic mercapturic acid; the toxic
NAPQI accumulates and binds to vital proteins and the lipid
bilayer of hepatocytes. This results in hepatocellular death
and subsequent centrilobular liver necrosis. 18 Hepatotoxicity becomes evident when aspartate transaminase (AST),
alanine aminotransferase (ALT), bilirubin, and prothrombin
time (PT) are elevated. There is a delayed toxicity associated
with acetaminophen and the elevation in liver function
studies is usually not evident until 24 to 72 hours after
ingestion.
The course of acetaminophen toxicity is generally
di vided into four phases. Phase I occurs up to the first 24
hours following ingestion. The patient is usually asymptomatic during this phase. The physical assessment of the
patient may reveal symptoms induding anorexia, nausea,
vomiting, malaise, and diaphoresis. Young children often
vomit earlier than older children and rarely exhibit diaphoresis. Abnormalities in AST, ALT, bilirubin, PT, or international normalized ratio (INR) are not seen. The risk of
toxicity can be determined by plotting a 4-hour-afteringestion acetaminophen level on the Rumack-Matthew
nomogram (Fig. 30-3). This nomogram should not be relied
on to accurately assess the risk of toxicity following
multiple acetaminophen ingestions, extended-release formulations, chronic ingestions, or coingestion of multiple
agents.
Phase 2 occurs 24 to 72 hours after ingestion. The patient
may appear to feel better and exhibit decreasing symptoms
of phase I. However, AST, bilirubin, and PT/INR begin to
increase and right upper quadrant abdominal pain may occur
if antidotal treatment has been delayed or not initiated.
Phase 3 begins 72 to 96 hours after ingestion. Jaundice,
coagulopathy, hepatic encephalopathy, recurrence of nausea
and vomiting occur with a tender hepatic edge present.
Hepatotoxicity is indicated by significantly elevated AST
(>1000 lUlL), ALT, bilirubin, PT, and INR. Peak elevation
of AST occurs during this phase.
Phase 4 has complete resolution of symptoms or complete resolution of organ failure, occurring typically 7 days
to 3 weeks after ingestion. The majority of patients with
acetaminophen overdose survive with supportive care in
conjunction with antidotal therapy. However, approximately
4% of patients who develop severe hepatotoxicity go on to
develop hepatic failure, with less than half resulting in death
or transplantation. 18
Critical Care Management. A reliable history is
obtained to determine the time of the poisoning and to rule
out the possibility of coingestants. Activated charcoal with
sorbitol is recommended to prevent development of a toxic
serum level. A serum acetaminophen level is drawn 4 hours
after ingestion. If the time of ingestion is unknown or
exceeds 8 hours, a level is drawn and empiric antidotal
therapy with NAC is initiated.
If the serum level of acetaminophen exceeds 150 mg/L at
4 hours after ingestion (possible hepatic toxicity on the
nomogram), NAC (Mucomyst) is administered. NAC acts
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Fig. 30-3 Acetaminophen toxicity nomogram. Area above line
indicates probable hepatotoxic reaction. Area below line indicates
no hepatotoxic reaction. (From Rumack BH, Peterson RC, Koch
CG et al: Acetaminophen overdose, Arch Intern Med 141:380,
1981. ©1981, American Medical Association.)

as a chemical substitute for glutathione by providing
sulfhydryl groups to detoxify NAPQI so it does not bind to
hepatic macromolecules. NAC is diluted to a 5% concentration before administration. It can be mixed with a citrus
or carbonated beverage to decrease its pungent smell and is
administered orally or by lavage tube. Small children may
be at risk of fluid overload or hyponatremia with the 5%
dilution. If vomiting occurs within I hour after administration, the dose is repeated.
NAC is very effective when administered within 24
hours of toxic acetaminophen ingestion, with optimal
benefits seen when administered within 8 hours of ingestion.
The initial enteral dose of NAC is 140 mg/kg, followed by
70 mg/kg every 4 hours for a total of 17 doses 19 It has
recently been shown to reduce morbidity and mortality, even
if presenting greater than 24 hours postingestion with
evidence of hepatotoxicity. The optimal dose or dosing
frequency in this situation is unknown, so the conventional
dosing guidelines are used. The endpoint of maintenance
(70 mg/kg every 4 hours) dosing is resolution of laboratory
abnormalities or death. For extended-release acetaminophen, levels are obtained at 4 and 8 hours after ingestion.
NAC is initiated if either level is above the lower line on the
nomogram. An intravenous form is available in Canada and
Europe but is available only as an investigational drug in the
United States. Intravenous administration may be indicated
if persistent vomiting exists. The 20% NAC enteral preparation may be diluted to a 3% solution with D5W and
administered intravenously by filtration through a 0.22micron filter. 18
Liver function studies and neurologic status are monitored to assess for signs of hepatic encephalopathy. Altered
mental status in the presence of elevated liver enzymes can
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progress to hepatic coma and death in severe acetaminophen
ingestions.

Barbiturates
Etiology/Incidence. Barbiturates are a class of
sedative-hypnotic agents and include phenobarbital and
pentobarbital. Indications for prescribed use include induction of sleep, sedation, and inhibition of epileptiform
activity. Barbiturates are classified according to their
duration of action: ultrashort, short, intermediate, or long
acting (Table 30-5). In this drug class, barbiturates that are
highly lipid soluble have a more rapid onset and a shorter
duration of action, as well as a greater degree of hypnotic
activity compared with those that are less lipophilic.
Duration of action, however, does not correlate with the
serum half-life of these medications. 20
CNS effects are related to the brain tissue concentration
of barbiturate. The effect of barbiturates is primarily on the
CNS through inhibition of neurotransmission across neuronal and neuroeffector junctions. Therapeutic doses of
barbiturates do not produce toxic effects unless used in
combination with other medications or alcohol. Approximately three times the therapeutic dose of a barbiturate is
necessary to produce the side effects of overdose.
Pathogenesis. Barbiturates have a very narrow therapeutic index (i.e., the difference between an effective dose
and a lethal dose is small). Barbiturates are usually taken
orally. When taken with liquids, absorption is hastened;
when taken with food, absorption is slowed. Serum levels
are only somewhat indicative of toxicity because of the
discrepancy between plasma and brain tissue concentration.
Patients most at risk for death are those who are not treated
despite elevated serum levels: greater than or equal to 3
mg/dl for short-acting barbiturates, greater than or equal to
7 mg/dl for intermediate-acting barbiturates, and greater
than or equal to 10 mg/dl for long-acting barbiturates? I
Short-acting barbiturates, particularly those with high lipid
solubility, are considered more toxic than the longer-acting
forms?O Short-acting agents are absorbed in the small
intestine and transformed in the liver to inactive metabolites,
which are excreted predominantly in urine. Phenobarbital, a
long-acting agent, is only partly metabolized in the liver.

TABLE

30·5 Classification of Barbiturates

by Duration of Action
Short to
Intermediate

trom
~

~

Ultrashort

Amobarbital

Hexobarbital

Butabarbital
sodium

Methohexital
sodium

Pentobarbital
sodium
Secobarbital

Thiopental sodium

Bertino JS. Reed MD: Barbiturate and nonbarbiturate sedative
'ypnolic intoxication in children, Pediatr Clio North Am 33:705. 1986.

..

At toxic levels, barbiturates primarily act as depressants
of the CNS and cardiovascular system. The medication,
dose, and route of ingestion influence the effect of the
overdose on the child. In addition, children metabolize
barbiturates faster than adults. The initial signs and symptoms of toxicity are slurred speech, ataxia, lethargy,
nystagmus, headache, and confusion or coma. As toxicity
becomes more severe, deep tendon and brain stem reflexes
may be depressed, but this usually occurs well after
respiratory depression occurs. Shock may occur secondary
to medullary depression, peripheral vasodilatation, or diminished myocardial contractility. Other findings may
include hypoglycemia, hypothermia, and bullous skin lesions 20 The child may demonstrate miosis early, with a
common late presentation of dilated pupils unresponsive to
light. Early deaths occur as a result of respiratory arrest,
cardiovascular dysrhythmias, and circulatory collapse,
whereas delayed deaths are due to acute renal failure,
aspiration pneumonitis, pulmonary edema, and cerebral
edema.
Respiratory dysfunction results from depression of the
respiratory control centers in the brainstem. The neurogenic
drive to breathe may be obliterated and the mechanisms
that affect respiratory rhythm may be altered. As respiratory depression continues, hypoxemia and hypercarbia
develop. The cough reflex may be suppressed, and the child
may experience laryngospasm resulting from inhibition of
smooth muscle activity.
Critical Care Management. Management of a patient with a suspected barbiturate overdose, as with any CNS
depressant, begins with an assessment and stabilization of
the airway. Once the airway is protected, whether with
intubation or an active gag reflex, gastric emptying by
lavage can be attempted, followed by administration of
acti vated charcoal and a cathartic. If phenobarbital is
identified as the toxic agent, multiple doses of activated
charcoal may be administered.
If warranted by inadequate gas exchange, the unconscious patient is placed on mechanical ventilation. For the
patient who presents in shock, aggressive intravascular
volume replacement is begun with crystalloid fluid (20
mllkg). Assessment for adequate renal function is essential.
Cardiovascular and nervous system dysfunction is
treated primarily with supportive care. Temperature is assessed regularly to prevent hypothermia-induced ventricular
fibrillation. If the child is hypothermic, the first line of
treatment is to prevent further heat loss.
Respiratory dysfunction is managed by ensuring a patent
airway and adequate gas exchange. Assessment of arterial
blood gases and serum pH guides intervention. The presence
of aspiration pneumonitis requires treatment with antibiotic
therapy.
Cardiovascular dysfunction treatment includes volume
replacement as needed. If volume replacement does not
resolve hypotension, continuous infusion of dopamine (I to
20 llg/kg/min) or dobutamine (2 to 12 llg/kg/min) may be
required.
With phenobarbital, alkalinization of the urine (maintaining urine pH >7.5) with sodium bicarbonate is helpful
with excretion. This is best accomplished by intravenous
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administration of I to 2 mEq/kg of sodium bicarbonate
followed by 2 to 4 mEqlkg over the next 6 to 12 hours.
Although, alkalinization without forced diuresis remains common, recent studies comparing multiple-dose
activated charcoal to alkalinization have shown that
multiple-dose activated charcoal is far more effective in
shortening the elimination half-life?" It is important to
maintain urine output at greater than I mUkg/hr; therefore
forced diuresis may be necessary in renal dysfunction.
Forced diuresis is accomplished by administration of one
or more fluid challenges followed by intravenous furosemide (I to 2 mg/kg). Overdose of long-acting barbiturates (phenobarbital) may respond well to hemodialysis
or hemoperfusion because the lower protein-binding capability allows them to be removed via these techniques.
Extracorporeal elimination is considered only for patients
whose clinical condition is deteriorating despite aggressive
therapy.22

Carbamazepine
Etiology/Incidence. Carbamazepine (Tegretol) is
used for treatment of partial complex and tonic-clonic
seizures, trigeminal neuralgia, and bipolar affective disorder. Carbamazepine inhibits sodium channels by reducing
their ability to recover from inactivation, preventing another
action potential, thereby raising the seizure threshold. It is
structurally related to cyclic antidepressants, exhibiting
similar clinical symptoms including CNS and respiratory
depression, anticholinergic symptoms, and cardiac conduction abnormalities. Carbamazepine is available for oral
administration in tablets, caplets, extended-release, and
suspension formulations.
Pathogenesis. A normal therapeutic loading dose of
carbamazepine is 5 to 10 mg/kg. Any ingestion above this
range is considered toxic. Carbamazepine is lipophilic with
an erratic absorption. There is no simple correlation between
drug dose and plasma concentration. Peak levels usually do
not occur for 3 to 8 hours after ingestion and may occur as
long as 24 hours after ingestion with a large overdose. The
length of therapy (single dose versus long-term therapy), the
patient's age, and interactions with other medications
influence plasma drug concentration. Also, children metabolize carbamazepine more rapidly than adults. Carbamazepine metabolism is increased when administered with
phenobarbital and phenytoin and decreased with erythromycin. Therapeutic serum concentrations differ, depending on
whether carbamazepine is used alone or in conjunction with
other medications. For single-drug therapy, a therapeutic
level of carbamazepine is 4 to 12 ~g/ml. When used with
other antiepileptic medications, a serum concentration of 4
to 8 ~g/ml is the therapeutic range?J Serum levels poorly
correlate with toxicity. Treatment of overdose is based on
the patient's clinical condition rather than the serum level.
Table 30-6 correlates the stages of intoxication with serum
levels and signs and symptoms.
Carbamazepine is metabolized by the liver via oxidation
and conjugation, into a pharmacologically active metabolite
with some inactive products, and excreted in the urine.
Carbamazepine exerts some anticholinergic effects, delay-
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ing gastric emptying time. Following acute ingestion, the
CNS and cardiovascular systems are the most affected, with
some hepatic and renal system involvement.
Carbamazepine toxicity produces prominent neurologic
signs and symptoms. In mild to moderate toxicity, nystagmus, drowsiness, and ataxia are common 24 At higher serum
concentrations, symptoms in children include dystonia,
choreoathetosis, seizures, and stupor. Other clinical symptoms of toxicity include nausea, vomiting, respiratory
depression, hypothermia, and coma. The patient's neurologic status may wax and wane following carbamazepine
overdose, with increased absorption in stage 4, when normal
peristalsis resumes.
Cardiac conduction delays, dysrhythmias, and hypotension indicate cardiovascular system dysfunction. These
effects are the result of the fact that carbamazepine chemical
structure is similar to that of cyclic antidepressants.
Acute hepatic dysfunction occasionally occurs following
carbamazepine overdose. Alteration in renal function may
include hyponatremia and syndrome of inappropriate antidiuretic hormone (SIADH). These side effects can be
present with long-term administration of carbamazepine and
aggravated by overdose.
Critical Care Management. Upon presentation, assessment of the airway is made and stabilization with
intubation is performed, especially if CNS depression is
present. Emesis is not used with carbamazepine, but gastric
lavage may be performed once a secure airway is present
and if the child presents within I hour of ingestion.
Multiple-dose activated charcoal is the therapy of choice in
carbamazepine overdose. Repeated doses are recommended
because the serum half-life of carbamazepine may be
reduced by as much as 50% with this therapy, which
decreases enterohepatic recirculation and increases elimination 25 Catharsis is not recommended because of the
potential for increased systemic absorption as a result of
increased drug distribution throughout the GI tract.26

1Jl.

30·6 Stages of· Carbamazepine
Overdose With Serum Level and
Clinical Signs

TABLE

Serum Level

liii,: I

11

>25

~g/ml

Iii'

~JII

Clinical Signs
Stupor or coma. abnormal
pupillary reaction to light.
respiratory depression

15-25 Ilg/ml

Irritability, combativeness,
choreiform movements.
hallucinations

![,I1I

11-15 ~g/ml

Nystagmus, drowsiness. ataxia

~~:IV

<II j.lg/ml

Normal mental examination,
mild atax ia, may relapse to
earlier stages

~:;

11
iM.....,

liP

rF
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The need for intensive monitoring is anticipated following significant ingestions of carbamazepine. Children are
monitored in the ICU until their condition has remained
stable for 24 hours because of the risk of relapse during
stage 4 with increased reabsorption. Concretions of carbamazepine are suspected when plasma levels rise or the
manifestation of symptoms is delayed?3 An abdominal
radiograph is performed to confirm this diagnosis, and
surgical intervention with gastrotomy may be necessary.
Neurologic dysfunction with respiratory depression may
require tracheal intubation and mechanical ventilation. The
combative patient is protected from injury. Paradoxic
seizures may occur with toxic carbamazepine levels and are
treated with benzodiazepines or phenobarbital. 27
Cardiovascular dysfunction is assessed by ECG monitoring for conduction delays and dysrhythmias and hemodynamic monitoring for hypotension. Hypotension is treated
with fluid boluses, and if unresponsive to fluid, vasopressors
are initiated.
Alteration in hepatic function is assessed by liver
function studies. Conventional therapy, including monitoring serum glucose levels and administration of clotting
factors for prolonged clotting time, is recommended for
hepatic dysfunction. Carbamazepine can be removed by
charcoal hemoperfusion, but this therapy is reserved for
patients who are not responding to multiple doses of
activated charcoal or who are clinically worsening even
with aggressive management. 4
At high carbamazepine levels, vasopressin secretion can
be stimulated, leading to fluid retention, SIADH, and
hyponatremia. Monitoring of serum electrolytes, particularly sodium and for adequate urinary output, is necessary to
identify SIADH. Treatment with water restriction and
sodium supplementation is initiated promptly.

Clonidine
Etiology/Incidence. Clonidine is the most commonly used centrally acting antihypertensive and is now
indicated for migraine headache prophylaxis; attention
deficit/hyperactivity disorder; Tourette's syndrome; and
management of opioid, ethanol, and nicotine withdrawal.
Clonidine can cause significant toxicity in children. Clonidine centrally stimulates postsynaptic a-adrenergic receptors, which inhibits sympathetic discharge and produces
decreased peripheral vascular tone, heart rate, stroke volume, and cardiac output. 28 Clonidine also inhibits uptake of
norepinephrine by neuronal tissues, producing CNS depression. Clonidine is available in 0.1-, 0.2-, and 0.3-mg tablets
and transdermal patches. The transdermal patches contain
2.5, 5.0, or 7.5 mg of clonidine and are designed to release
0.1, 0.2, or 0.3 mg of clonidine per day over a period of
1 week. 29
Pathogenesis. Clonidine is well absorbed from the
Gl tract, metabolized by the liver, and excreted unchanged
primarily in urine. Its effects are evident 30 to 60 minutes
after ingestion and peak approximately 2 to 3 hours
following oral administration, with effects up to 8 hours.
Antihypertensive effects are present for as long as 24 hours

following an oral dose. Overdose in children has been
documented with as little as a O.I-mg dose or by dermal
exposure, mouthing, or ingestion of a transdermal patch. A
discarded transdermal patch contains enough clonidine to
produce overdose symptoms in a child.
Clonidine overdose invol ves an exaggeration of the
clonidine pharmacologic properties primarily affecting the
CNS and the cardiovascular systems. The majority of
children develop symptoms within 1 hour of a clonidine
overdose. There is no progression or development of
symptoms or toxic effects more than 4 hours after presentation to the hospital. 30
CNS dysfunction mimics narcotic overdose, where
miosis, coma, and respiratory depression are the hallmarks.
Symptoms vary from lethargy, somnolence, stupor, or coma,
and are postulated to be from inhibition of the uptake of
norepinephrine by the neurons, which then blocks noradrenergic activity?] Patients who are severely obtunded
may have decreased ventilatory effort and hypoxia and may
require intubation and mechanical ventilation to maintain
adequate respiratory effort. Other CNS symptoms include
hypothermia, which is attributed to a-adrenergic receptor
stimulation of the serotonin-acetylcholine pathways, causing decreased metabolic heat production and increased heat
loss?9 Cool, pale skin is presumed to be the result of
vasoconstriction. Hypotonia, hyporeflexia, and irritability
may also be seen.
Cardiovascular system dysfunction depends on the
plasma level of clonidine. Serum levels of higher than 10 to
15 mg/ml stimulate the release of norepinephrine, which
causes the peripheral a-receptors to vasoconstrict, resulting
in transient hypertension. The hypertensive phase is shortlived because clonidine overdose triggers a centrally mediated sympathetic inhibition causing hypotension. Patients
with a serum level lower than 10 mg/ml present with
normotension or hypotension. Sinus bradycardia, a known
side effect, is commonly noted in children with clonidine
overdose?O Conduction abnormalities including first-degree
heart block and second-degree atrioventricular block are
seen in both overdose and therapeutic dosing. Patients with
underlying conduction dysfunction and the very young are
most at risk for sinus bradycardia and conduction delays.28
Critical Care Management. If clonidine ingestion is
suspected, emesis is contraindicated because of the risk of
rapid CNS and respiratory depression. Activated charcoal
administration with or without prior gastric lavage can be
considered if instituted early. Gastric lavage has limited
utility because clonidine is rapidly absorbed and patients
typically present following the onset of symptoms.
Appropriate therapy focuses on respiratory and hemodynamic status. Most clonidine overdoses respond well to
supportive measures. If hypotension and shock are present,
the child is treated with infusion of 20 ml/kg of intravenous
fluid and placed in the Trendelenburg position. If signs of
shock do not resolve with those measures, an infusion of
dopamine (5 to 10 ~g/kg/min) is begun.
Patients usually require supportive and symptomatic
treatment in the critical care setting for less than 24 hours
following clonidine overdose. Careful monitoring of vital

Chapter 30

signs, including temperature, is necessary. Hypothermia is
treated with passive rewarming to maintain a normal body
temperature. Tracheal intubation and mechanical ventilation
are instituted if respiratory effort is absent or inadequate to
maintain normal serum oxygen and carbon dioxide levels.
Control of the airway protects the child from aspiration and
subsequent respiratory compromise.
Cardiovascular dysfunction treatment is based on the
child's symptoms. Bradycardia associated with cardiovascular compromise is responsive to intravenous atropine
(0.10 mg/kg); although repeated doses may be necessary
because of the long half-life of clonidine. 2K •3o Hypotension
is treated first with volume infusion, and then with
dopamine infusion, as described in the initial management
section. Treatment with a nitroprusside infusion (0.5 to 0.8
l.I.g/kg/minute) is instituted for a hypertensive phase only if
end-organ compromise is noted. Dysrhythmias resolve with
decreasing serum clonidine levels and usually do not require
treatment.
Naloxone (Narcan) is recommended for treatment of all
patients with clonidine overdoses in which CNS, cardiovascular, or respiratory depression is present. 32 Naloxone was
first used because of the similarity in clonidine overdose
symptoms to opioid toxicity. The interaction between
clonidine and opioid receptors is poorly understood, but
several patients experiencing clonidine overdose have
responded well to naloxone. The initial naloxone dose is
0.0 I mg/kg, and if no response is noted, a repeat dose of 0.1
mg/kg is administered. A continuous infusion of naloxone
may be necessary secondary to its short half-life.

Iron
Etiology/lncidence. Iron ingestion is one of the more
common childhood ingestions because of the availability of
iron and iron-containing compounds in the household. The
similarity of colors, shapes, and flavorings between multivitamins and other iron-containing products and candy
makes them especially enticing to children. Iron supplementation is prescribed for pregnant women, and iron is a
common component in both pediatric and adult multivitamins. Elemental iron is available in combination with
gluconate, sulfate, or fumarate salts; each preparation has
varying amounts of elemental iron. Cases of iron ingestion
rarely require intensive care management if toxicity is
recognized and treated promptly. Iron supplements used to
be the leading cause of fatal ingestions in children, but the
incidence is now declining. The Food and Drug Administration (FDA) mandates that all iron-containing preparations
display a warning label to inform of potential toxicity for
children with accidental overdose.
After ingestion in normal doses, 10 to 15 mg of iron is
absorbed daily through the GI tract 33 Ferrous iron is
absorbed into the mucosal cells of the duodenum and
jejunum and is oxidized to ferric iron, where it is bound to
ferritin, an iron storage protein. It is then released into the
plasma, where it is bound to transferrin, an iron-specific
binding globulin. Iron bound to transferrin is nontoxic.
With acute iron overdose, the total serum concentration
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of iron exceeds the total iron-binding capacity. Excess free
iron is directly toxic to the vasculature and leads to the
release of vasoactive substances including serotonin and
histamine. Excess quantities of ferritin lead to vasodilation
resulting in increased vascular permeability and fluid loss,
with subsequent hypotension and metabolic acidosis. 34 The
free iron is deposited in the liver, spleen, and kidneys. These
iron deposits cause pathophysiologic changes in the mitochondria, result in free radical formation and lipid peroxidation that contribute to necrosis, cell death, and tissue
injury.4 Metabolic acidosis develops as a result of poisoning
of the mitochondria, compromising cellular respiration and
producing lactic acidosis. Serum iron levels peak 2 to 4
hours following ingestion, and begin to fall 6 hours after
ingestion. Table 30-7 shows the correlation between serum
iron levels and toxicity. An iron concentration higher than
350 Ilg/dl is indicative of moderate to severe toxicity.35
Pathogenesis. The pathophysiology of iron toxicity
is related to the development of metabolic acidosis. Iron
toxicity is mediated through both local and systemic effects.
Acute iron poisoning in children follows the classic five
clinical stages of iron toxicity. The initial stage begins from
30 minutes after ingestion to no later than 6 hours and is the
result of the corrosive effects of iron on the GI mucosa. The
child complains of nausea and moderate to severe abdominal pain and presents with vomiting, diarrhea, or GI
hemorrhage. Vomitus and stools may be dark gray or black
because of the presence of iron. In severe poisoning, the
child may present with hypotension, shock, and coma. If a
child presents in coma shortly following an iron ingestion,
the prognosis for neurologic recovery is poor. 36
The second phase of iron toxicity is described as the
latent stage. The child is asymptomatic, with mild lethargy
present. It is a deceptive period that occurs 6 to 24 hours
postingestion, but this phase may be absent in children with
severe poisoning.
Profound toxicity is evident with patients who progress
to the third phase, 12 to 48 hours after ingestion. Shock
results from the free iron, causing venous pooling, which
creates relative hypovolemia, vasodilatation, and poor

~

30-7 Serum Iron Level and
Potential Severity of Intoxication

TABLE

~tserum Iron Level

Potential Toxicity

<100

None

100-350

Minimal toxicity

350-500

Moderate toxicity; chelation usually
not necessary

500-1000

Severe toxicity; start chelation
immediately

>1000

Potentially lethal; start maximum
chelation immediately

ljiiFrom Hcnretig FM, Temple AR: Acute iron poisoning in children. Clin
Med 4:579. 1984.

Ifni>
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cardiac output. Subsequent poor perfusion and ischemia
results in a worsening metabolic acidosis. An iron-induced
coagulopathy may cause increased bleeding and exacerbate
hypovolemia. Systemic signs of toxicity include lethargy,
hyperventilation, hypoglycemia, seizures, and coma.
The fourth stage of iron toxicity consists of hepatic injury
or failure. This may occur 2 to 3 days after severe iron
ingestion. It is thought to be a direct result of uptake of iron
by the liver's reticuloendothelial system. Alterations in
glucose metabolism, coagulopathies, and hepatic encephalopathy accompany hepatic failure.
The final stage occurs days to weeks after the iron
overdose and only rarely occurs. The initial gastric insult
can progress to gastric outlet obstruction secondary to
development of strictures, stenosis, or scarring. 34
Critical Care Management. Toxicity is dependent
on the amount of elemental iron ingested. Ingestion of more
than 20 mg/kg of elemental iron produces GI effects;
ingestion of more than 60 mg/kg causes systemic toxic
effects; and ingestion more than 250 mg/kg is potentially
lethal. Iron levels may not correlate with amount ingested
and clinical symptoms. Children who ingest greater than 20
mg/kg or who are symptomatic, regardless of serum level,
need to be treated. Following stabilization of the airway,
breathing, and circulation, GI decontamination procedures
are considered. Activated charcoal does not bind to iron and
therefore is not utilized. Gastric emesis may have limited
benefit in a child who has already vomited several times and
may obscure the severity of toxicity based on GI symptoms.
Gastric lavage to remove pills and fragments may be
ineffective if the tablets are large or several hours have
elapsed since ingestion. If lavage is used, only normal saline
or tap water is used. Other compositions, including sodium
bicarbonate, have been studied as lavage solutions. They
have not shown any greater benefit, and potential risks with
electrolyte imbalances have limited their utility.34
Whole bowel irrigation has become the standard of care
for severely poisoned patients with large GI burdens of iron.
After lavage, an abdominal radiograph is obtained to document the presence of retained iron tablets in the stomach and
pylorus. If present, irrigation with polyethylene glycol electrolyte lavage solution (Golytely) enhances stooling while
quickly emptying iron from the GI tract. 37 This solution is
instilled at room temperature into the stomach via nasogastric tube at 250 to 500 ml/hour for children younger than
5 years and up to 2 Llhour for adolescents. Whole bowel
irrigation continues until diarrhea is produced and the effluent resembles the infusate. If lavage and whole bowel irrigation are unsuccessful in removing intact iron tablets, emergency gastrotomy may be considered 35
Chelation therapy, which binds iron into a soluble
complex, is initiated in the emergency department after a
baseline urine sample is obtained, with intravenous deferoxamine at a maximum dose of 15 mg/kg/hour for children
in whom severe intoxication is suspected. The daily
maximum recommended dose is 360 mg/kg/day, with a
limit of 6 g. Hypotension may occur with the infusion of
deferoxamine and may limit the rate of infusion. Deferoxamine combines with iron to form ferrioxamine, which is

excreted by the renal system; it appears that deferoxamine
cannot remove iron once bound to transferrin but can chelate
free iron and iron being transported between transferrin and
ferritin. }}.34 The urine changes to "vin rose," a pink color,
shortly after chelation begins. Serum iron levels are
followed during chelation therapy. Chelation is discontinued
when the serum iron level falls below 100 ~.g/dl, the child
appears clinically well, the anion-gap acidosis has resolved,
and there is no further urine color change. 36
Initial laboratory studies include complete blood count
(CBC); serum electrolytes including glucose, renal, and
hepatic function; blood type and cross-match; total ironbinding time; a serum iron level 2 to 6 hours after ingestion;
and coagulation studies. These values help to guide management, especially for the child who is asymptomatic at
presentation. Initial management also includes close monitoring for the known side effects of iron toxicity. Intravenous access is obtained in any child with suspected
moderate to severe toxicity so that hypotension, metabolic
acidosis, hypoglycemia, and blood dyscrasias can be treated
promptly. Continuous monitoring of the adequacy of the
child's airway, breathing, and circulation, particularly blood
pressure, is necessary.
Patients who manifest clinical signs and symptoms of
toxicity, such as metabolic acidosis, hemodynamic instability, and lethargy, are managed in an ICU and are discharged
only after 24 hours of clinical stability following therapy.
Cardiovascular assessment includes central venous pressure
monitoring to provide a guide to the patient's volume status
and fluid management. Periodic assessment of serum
hemoglobin and hematocrit levels is necessary to track
blood loss via the Gl tract. All stools and emesis are tested
for presence of blood. Blood loss via stools or emesis is
replaced. Volume replacement with blood components or
other fluids is initiated early in the treatment of hypotension.
Intravenous infusion of catecholamines, such as epinephrine
(0.2 to 2.0 ~g/kg/min) or dopamine (l to 20 )lg/kg/min),
may be required to treat hypotension that is refractory to
volume replacement.
Neurologic dysfunction management is primarily supportive. If the child has inadequate cough or gag reflexes,
tracheal intubation is performed and mechanical ventilation
instituted. Acid-base balance is assessed by serial measurement of serum pH and bicarbonate ions. Intravenous sodium
bicarbonate is administered as necessary to treat metabolic
acidosis.
Hepatic failure requires assessment and treatment of
hypoglycemia and coagulopathy. Hypoglycemia is treated
with intravenous infusion of dextrose-containing solutions,
the concentrations of which are titrated to maintain the
serum glucose level above 80 to 100 mg/dl. Increased PT,
partial thromboplastin time (PTT), or clinical signs of
bleeding are treated with infusion of the appropriate clotting
factors.
Renal function is assessed by hourly measurement of
urine output and periodic monitoring of specific gravity,
blood urea nitrogen (BUN), and serum creatinine. If acute
renal failure occurs, continuous hemofiltration or hemodialysis can be used to remove ferrioxarnine, as well as other
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metabolic end products 34 Renal transplantation may be
necessary if the renal system does not recover following iron
toxicity.
GI dysfunction is monitored by serial assessment of
abdominal girth and tenseness and for the presence of blood
in gastric contents and stool. H2 blockers may be administered to protect the upper GI tract. If GI perforation is
suspected, the child requires an exploratory laparotomy to
identify and manage areas of necrosis. Peritonitis is treated
with appropriate antibiotic therapy. All severe icon overdoses require follow-up several weeks after ingestion to
evaluate for GI complications, such as strictures and
stenosis, which may require surgical intervention.

Theophylline
Etiology/Incidence. Theophylline is most commonly
used in children as a bronchodilator to relieve bronchospasm associated with asthma. The therapeutic serum level
ranges from 10 to 20 mglL. Each 1 mg/kg of theophylline
raises the serum level by 2 mglL. Theophylline is available
in liquid, capsule, tablet, and suspended-release preparations. Maintenance dosages vary with each child based on
weight, concentration of the preparation, and extent of
illness. Theophylline toxicity is characterized by serum
levels higher than 20 mglL. Acute toxicity is affected by the
type of preparation ingested, route of exposure, age-related
clearance rate, and drug and nondrug interactions. The toxic
effects following chronic overdose do not correlate with
serum drug levels. Precipitating factors associated with
theophylline overdoses include dosage errors, accidental
ingestions, suicide attempts, respiratory tract infections, or
erythromycin administration. 38
Pathogenesis. Pharmacologic properties of theophylline include CNS stimulation, positive chronotropic and
inotropic effects, antagonizing adenosine activity, reduction
of peripheral arteriolar resistance, relaxation of bronchial
smooth muscle, inhibition of mast cell degranulation,
increase in renal blood flow and glomerular filtration rate,
and increases in gastric acid and pepsin secretion. These
processes are accelerated in situations when theophylline
toxicity occurs. Theophylline toxicity primarily affects the
Gl tract, CNS, and cardiovascular system. 4 The most
common symptoms of theophylline toxicity include nausea
and vomiting, tachydysrhythmias, seizures, hypotension,
metabolic acidosis, and hypokalemia. Severe toxicity will
also produce hematemesis and bloody diarrhea.
Patients are at risk from the cardiac effects with severe
overdoses secondary to excessive catecholamine stimulation
of the myocardium exacerbated by hypokalemia, hypocalcemia, hypophosphatemia, metabolic acidosis, and an increased myocardial oxygen demand. Altered cardiac output
results from supraventricular dysrhythmias such as sinus
tachycardia, atrial tachycardia, atrial flutter, and atrial
fibrillation. Ventricular dysrhythmias may develop, but
sustained dysrhythmias that require prolonged therapy are
rare. Serious dysrhythmias occur most often in young
patients with acute theophylline overdoses when serum
levels exceed 50 Ilg/m1.39 Theophylline's ~2 effects, which
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reduce peripheral vascular resistance, are responsible for
severe hypotension and reduced myocardial perfusion
associated with toxicity.
CNS disturbances include agitation, headache, confusion, tremulousness, hyperreflexia from cerebral excitation,
and seizures. In acute intoxication, seizures are infrequent
and are usually focal and brief. Theophylline causes an
increase of cyclic adenosine monophosphate (cAMP) by
inhibiting the activity of phosphodiesterase, the enzyme
responsible for metabolizing cAMP. This results in smooth
muscle relaxation, peripheral vasodilation, myocardial stimulation, and CNS excitation.
Other metabolic disorders that may result from theophylline overdose are hyperglycemia from increased gluconeogenesis, and glycogenolysis caused by catecholamine
release. Hypokalemia occurs early and is the result of
potassium moving into the cells secondary to hyperglycemia, loss of potassium through vomiting, and the diuretic
action of theophylline. All of these may contribute to the
cardiac dysrhythmias. 38
Critical Care Management. In severe overdose,
gastric lavage and activated charcoal with a cathartic may
both be used, up to 4 hours after ingestion with regular
preparations and up to 8 to 12 hours after ingestion of
sustained-release preparations. Emesis is not typically
employed because of rapid onset of seizures and protracted
vomiting caused by toxicity. If vomiting inhibits the instillation of activated charcoal, an antiemetic may be administered because activated charcoal is very effective in reducing serum theophylline levels. For severe intoxication,
multiple-dose charcoal has been indicated. Initial laboratory
studies necessary are theophylline level at presentation, followed by repeat levels in 2 to 4 hours, serum electrolytes,
glucose, calcium, and baseline coagulation studies. Seizures
are treated with a benzodiazepine followed by phenobarbital
if the seizure does not resolve. It may be necessary to intubate the child and to provide ventilatory support and neuromuscular blockade to help control the seizure activity.3 8
Priorities include monitoring for cardiac dysrhythmias.
The patient's electrolytes are carefully evaluated over time
and rapidly corrected if a dysrhythmia develops. These
dysrhythmias usually resolve spontaneously as the theophylline level returns to the therapeutic range. If the patient is
unstable or not tolerating the dysrhythmia, treatment with
low doses of propranolol (0.02 mg/kg IV) repeated every
5 to 10 minutes (with a maximum of 0.1 mg/kg IV) is
recommended 4o The desired response to propranolol when
treating hypotension, sinus tachycardia, atrial fibrillation,
and rapid ventricular rates is a return to the patient's
baseline parameters for blood pressure and cardiac rhythm.
Esmolol is another effective agent currently under investigation for use with theophylline toxici ty38 One case study
reports effective treatment of tachycardia and hypotension
with administration of intravenous esmolol, an ultra-shortacting ~-blocker, in a 500-llg/kg bolus over I minute,
followed· by a 50-llg/kg/min continuous infusion. 4 \ Propranolol and other nonselective ~-blockers are used cautiously in asthmatic patients because they may cause
bronchospasm.

1012

Part V Multisystem Problems

Maintaining seizure precautions and ongoing assessment
of level of consciousness is necessary to limit the degree of
cerebral anoxia caused by seizure activity. Because a
correlation exists between the length of seizure activity and
morbidity and mortality, seizures are controlled as soon as
possible. Lorazepam (0.05 mg/kg TV) is indicated for
immediate cessation of seizure activity and is administered with phenobarbital (10 mg/kg) for continued seizure
control.
The effectiveness of anti emetics in theophylline toxicity is variable. Recommendations include the use of metoc10pramide (2 mg/kg TV) or ranitidine (l to 2 mg/kg/day
TV) to control vomiting and increase the tolerance of
charcoal. Metoclopramide and ondansetron may be more
beneficial because they promote gastric motility and do
not lower the seizure threshold. Multidose activated
charcoal is typically used rather than whole bowel irrigation because of the risk of irrigation decreasing the
effectiveness of the charcoal. However, whole bowel
irrigation is beneficial with ingestion of sustained-release
preparations.
Hemoperfusion is effective at enhancing the elimination
of theophylline and is instituted early in treatment, when
patients with protracted vomiting do not allow the instillation of charcoal. Indications for hemoperfusion include
unstable hemodynamics, uncontrolled seizures, inability to
give charcoal despite antiemetic therapy with persistent
elevation in theophylline levels after 6 to 8 hours, extensive
hematemesis, serum theophylline levels between 40 and 60
~g/ml in chronic overdoses or 90 and I00 ~g/ml in acute
overdoses. 4 In some circumstances, it may be beneficial to
perform whole bowel irrigation and charcoal hemoperfusion
simultaneously. The patient is assessed for signs of thrombocytopenia, hypocalcemia, and infection at the catheter
insertion site when hemoperfusion is in progress.
Other interventions include administration of potassium,
phosphate, and sodium bicarbonate with subsequent monitoring oflaboratory values to evaluate the resolution of toxic
effects.

Cyclic (Tricyclic) Antidepressants
Etiology/lncidence. The cyclic antidepressants are
the most widely prescribed pharmacologic treatment for
depression in adults and children. Tricyclic antidepressants
are one type of this class of drugs. The cyclic antidepressants can be divided into the first-generation and secondgeneration antidepressants. The first-generation, or tricyclic,
antidepressants were developed in the 1960s. The secondgeneration cyclic antidepressants were released during the
1980s and I990s to improve the therapeutic index, decrease
side effects and adverse reactions, and reduce the incidence
of serious toxicity. As the mechanisms of action have become more selecti ve, the incidence of cardiac and neurologic toxicity has decreased. In addition to depression, children also are prescribed cyclic antidepressants for treatment
of hyperkinesis, sleep disorders, school phobias, and enuresis. Adults are prescribed cyclic antidepressants for depression, chronic pain, and sleep disorders. The more com-

mon tricyclics include amitriptyline (Elavil), desipramine
(Norpramin), imipramine (Tofranil), whereas the secondgeneration antidepressants include amoxapine (Asendin),
fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil),
and bupropion (Wellbutrin).
Pathogenesis. When ingested, cyclic antidepressants
are initially rapidly absorbed from the GI tract, unless
anticholinergic effects decrease the rate of absorption by
slowing GI motility. The drugs have large volumes of
distribution and are largely protein bound. The drugs bind to
proteins at a certain pH, typically a more alkaline pH;
therefore acidemia may increase the amount of unbound or
free drug in the pTasma. Serum levels are of little use in
overdose because of the extent of protein binding and
volume of distribution. These drugs are highly lipid soluble,
sparingly water soluble and extensively metabolized on the
first pass through the liver. 42 Cyclic antidepressant toxicity
primarily affects the central nervous and cardiovascular
systems accompanied by anticholinergic crisis. Toxicity is
mediated by anticholinergic effects, quinidine-like effects
on cardiac function, direct a-receptor blockade, and inhibition of catecholamine reuptake in the CNS and peripheral
nervous system. A quinidine-like effect is the membrane
depressant effect on the myocardium through inhibition of
sodium channels. Symptoms of toxicity develop within 4 to
6 hours but may be delayed for up to 24 hours. 43
Cyclic antidepressant toxicity may progress rapidly,
initially presenting with anticholinergic signs and progressing to lethal dysrhythmias and hypotension. Anticholinergic
effects on the CNS include respiratory depression, agitation,
lethargy, hallucinations, hyperthermia, ataxia, choreoathetoid movements, seizures, and coma. Peripheral anticholinergic effects include hypotension, decreased GI motility, dry
and flushed skin, urinary retention, sinus tachycardia,
mydriasis, and hyperreflexia. 42 ,44,45 Seizures occur in 10%
to 20% of patients with tricyclic antidepressant overdose
and are most likely to occur in comatose patients 46
Cardiovascular dysfunction often accompanies cyclic
antidepressant overdose because of the increase in the
polarization period. Decreased cardiac output may occur as
a result of myocardial depression or dysrhythmias. Cyclic
antidepressant's quinidine-like effects slow cardiac conduction and causes myocardial depression, prolonging the PR
and QRS interval. These measurements should use the
standard lead for pediatric QRS measurement, the precordial
lead Vs' The widened QRS interval provides the best
measurement of tricyclic antidepressants, with an interval of
more than 100 milliseconds seen as evidence of serious
overdose (Fig. 30-4). Increased repolarization time facilitates ventricular tachycardia, ventricular fibrillation, or
asystole. 44 Decreased inotropy is evidenced with general
signs of decreased cardiac output and hypotension.
Seizures and coma with severe overdose dominate
neurologic dysfunction. Respiratory failure can occur from
C S depression, seizure-related apnea, upper airway obstruction, or pulmonary edema. Because acidosis increases
the amount of free drug in the serum, even mild hypoventilation may potentiate dysrhythmias and aggravate the poor
inotropic performance of the myocardium.
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Fig. 30-4 Electrocardiogram in a patient with a prolonged QT interval following tricyclic antidepressant
overdose.

Critical Care Management. Cyclic antidepressant
overdose is suspected if a child presents in coma or with
symptoms compatible with anticholinergic crisis. Initial
interventions are to secure an airway and stabilize vital
signs. Symptoms of toxicity develop rapidly after ingestion
with deterioration in clinical status occurring within I hour
after ingestion and life-threatening events most often
occurring within 2 hours. 42 Emesis is contraindicated
because of the rapid onset of CNS depression or seizures.
Lavage is indicated for patients with altered level of
consciousness. Following lavage, activated charcoal and a
cathartic are recommended. Intubation is recommended
before gastric decontamination to minimize the risk of
aspiration. Because of the tight protein binding, he moperfusion, hemodialysis, and forced diuresis have no role in the
management. Alkalinization of the serum is the preferred
method for reducing acute cardiovascular side effects. A
sodium bicarbonate infusion alters the pH, increasing
protein binding of the drug and reducing the amount of free
drug available, resulting in decreased toxicity.
Primary treatment of respiratory dysfunction is directed

toward achieving and maintaining the patency of the airway.
Intubation and mechanical ventilation are initiated promptly
for patients in whom oxygenation and ventilation are at risk.
Arterial blood gases are assessed for both hypoxia and
acidosis because these problems are known to increase the
frequency and recurrence of dysrhythmias.
Cardiovascular dysfunction may result in hypotension.
Treatment begins with a 20 mVkg fluid bolus of normal
saline or lactated Ringer's solution. If these measures are
ineffective in returning the blood pressure to normal range.
a continuous infusion of phenylephrine (0. I to 0.5 /lg/kg/
min), norepinephrine (0.05 to 1.0 /lg/kg/min), or dopamine (5 to 30 /lglkg/min) may be required 42 .44 These
medications exert predominantly direct a-agonistic effects
and counteract the a-adrenergic blockade of the cyclic
antidepressants.
Treatment of dysrhythmias begins with ensuring adequate ventilation, followed by sodium bicarbonate infusion.
Mild metabolic alkalosis (pH>7.45 to 7.55) has proven to
be effective in narrowing widened QRS complexes, correcting hypotension, and in decreasing the incidence of dys-
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rhythmias in cyclic antidepressant overdoses. 4 ,33 Hyperventilation to induce respiratory alkalosis is thought to be less
effective for controlling dysrhythmias, Serum sodium levels
are monitored during and following administration of
sodium bicarbonate, If sodium bicarbonate therapy is
ineffective for controlling dysrhythmias, lidocaine (I mg/kg
IV) is given as a bolus and followed with a continuous
infusion (10 to 50 Ilg/kg/minute),
Seizures or coma can manifest neurologic dysfunction,
Diazepam (100 to 250 Ilg/kg IV over 3 minutes) is the drug
of choice for immediate use in cyclic-related seizures,
Seizures are usually brief and respond to benzodiazepines, If
the patient fails to respond to benzodiazepines, barbiturates
or propofol may be used, Phenytoin is not recommended
because of its limited efficacy and data suggesting prodysrhythmic effects, Coma usually resolves within 24 hours
of ingestion.
Parasympathetic nervous system dysfunction requires
intervention as necessary, Urinary retention, evidenced by
bladder distension, may require placement of an indwelling
catheter, Constipation may result from slowed peristalsis,
although the use of activated charcoal and cathartics may
promote elimination and relieve this symptom, It is important to assess the patient for the presence of active bowel
sounds before the administration of charcoal because
paralytic ileus is common and is a contraindication to its
use. Patients are monitored in an intensive care setting on a
cardiac monitor until symptom free for 24 hours,

NONPHARMACEUTICAL TOXINS-THE
ALCOHOLS AND DRUGS OF ABUSE
Methanol
Etiology/Incidence. Methanol, also known as wood
alcohol, is a colorless, flammable liquid with a distinctive,
somewhat pleasing odor. It is a common component of
household substances such as windshield washer fluid,
antifreeze, carburetor fluid, Sterno fuel, varnishes, solvents.
gasohol, moonshine, duplicating fluids, and paint stripper or
remover. Methanol itself is not toxic but its metabolites are;
therefore early recognition of toxicity is imperative. Methanol is potentially toxic with ingestion of only a single
mouthfuL
Pathogenesis. Methanol is completely absorbed by
the GI tract with peak levels 30 to 90 minutes after
ingestion, Once absorbed, approximately 85% to 90% of
methanol is metabolized in the liver and the remainder is
excreted unchanged through the lungs and kidneys, Methanol is metabolized by the hepatic alcohol dehydrogenase
pathway and creates the toxic metabolites, formaldehyde,
and formic acid. Formic acid, the principal metabolite,
inhibits mitochondrial respiration, which results in tissue
hypoxia and lactic acidosis. The toxic formic acid accounts
for the majority of the anion gap, metabolic acidosis, and
ocular toxicity, Formaldehyde has a short half-life, lasting
only minutes, Formic acid is much more slowly metabolized
and degradation is folate dependent, so it bioaccumulates
and is responsible for the toxic effects seen, 17,47.48 Methanol

toxIcity produces a triad of symptoms affecting the GI,
CNS, and ocular systems,
There is an asymptomatic latent period of 24 to 72 hours
after methanol ingestion, which is shortened when large
amounts are ingested. The latent period occurs while the
toxic metabolites accumulate and it may be prolonged with
coingestion of ethanoL The initial symptoms include headache, lethargy, dizziness, nausea, vomiting, and abdominal
pain. Visual disturbances and severe acidosis develop after
these initial symptoms, The visual complaints include
decreased visual acuity, hazy vision, photophobia, and
snowstorm-like "snowflakes" in the visual field.
Initially, there is little CNS depression and the child may
appear anxious with dyspnea or Kussmaul's breathing, If
untreated, the metabolites increase, causing severe metabolic acidosis and the patient's level of consciousness
deteriorates from lethargy progressing to coma,
The vision dims with advanced optic nerve toxicity, and
hyperemia of the optic disks, retinal edema, and fixed
dilated pupils may be present. The accumulation of formic
acid causes optic papillitis, retinal disease, and optic
atrophy, all of which can result in permanent blindness. 27
Patients who develop coma, convulsions, and apnea have
a poor prognosis. Death usually results from circulatory
collapse or respiratory arrest.
Critical Care Management. Methanol ingestion results in an elevation in the osmolal gap because it alters the
volume of water in serum accompanied by an increased
serum anion gap and hypoglycemia. 47 Osmolal gap is
defined as the difference between measured and calculated
osmolality. Early in a patient's clinical course (under 12 to
24 hours), before methanol has been completely metabolized, rapid diagnosis of methanol toxicity can be made on
the basis of the presence of an osmolal gap (Box 30-1).
Calculated osmolality is subtracted from measured osmo-
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lality and nonnally does not exceed 10 mOsmlkg. The
elevated osmolal gap gradually resolves as methanol is
metabolized, toxic metabolites fonn, and an anion gap
metabolic acidosis devel ops 48
Under nonnal circumstances, the anion gap is 12 to 16
mmollL. An elevated anion gap occurs later in the clinical
course of patients with methanol ingestion because of
retention of nonvolatile organic acids. Calculation of the
osmolal and anion gap is useful for the initial management
of patients in whom methanol ingestion is suspected
because it identifies the presence of hannful substances,
therefore eliminating delay in treatment while specific
laboratory levels are awaited. For a patient who is symptomatic, is acidotic, or has a peak level of 20 mg/dl of
methanol, treatment is initiated with an ethanol infusion.
Patients who appear neurologically impaired are intubated to ensure an adequate airway and effective ventilation.
Although the benefits of charcoal administration are unknown in methanol ingestions, charcoal is usually recommended, especially if ingestion of multiple substances is
suspected.
Treatment of metabolic acidosis includes correction of
pH and base deficit by administration of sodium bicarbonate. AlLhough acidosis may be reversed, ocular damage
associated with the toxic effects of methanol metabolism
often persists.
Alcohol dehydrogenase has a greater affinity for ethanOl
than methanol, therefore ethanol infusions are used to
inhibit methanol metabolism to toxic metabolites of fonnaldehyde and formic acid, which promotes its excretion
unchanged by the lungs and kidneys. Ethanol is administered in a 5% to 10% solution intravenously or orally in a
20% to 30% solution. A loading dose (7.6 to 10 rnlJkg) is
administered intravenously in 10% dextrose solution over
30 minutes. Maintenance dosage is 0.15 ml/kg/hr orally of
95% ETOH solution or 1.4 ml/kg/hr intravenously of a 10%
ethanol solution, until a serum level of 100 mg/dl is
achieved.
Alcohol dehydrogenase inhibitors (ADHs) are generally
maintained until methanol levels are less than 20 mg/dl. The
FDA recently approved fomepizole (4-MP, Antizol) for
ethylene glycol poisoning, and it is being researched for its
utility with methanol toxicity. Fomepizole has a greater
affinity for alcohol dehydrogenase versus ethanol or methanol and has a better safety profile than ethanol. 47 In
addition, folic acid is being recommended to enhance the
folate-dependent metabolism of fonnic acid. The pediatric
dose of sodium folate is I mg/kg every 4 to 6 hours.
Hemodialysis enhances the elimination of methanol and
its toxic byproducts and is indicated in patients with a serum
level of 50 mg/dl, severe metabolic acidosis, ingestion of
more than 40 ml or in the presence of neurologic or visual
disturbances 33 •48 Higher doses of ethanol are required
during hemodialysis because ethanol is easily dialyzed. 49
Maintenance doses of 250 to 350 mglkg/hour are required
to achieve and maintain the necessary serum level.
Patient monitoring includes evaluating arterial blood
gases, blood alcohol level, and serum glucose level to assess
the effectiveness of ethanol administration. Glucose is
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monitored closely because glycogen stores are depleted
rapidly after methanol ingestion. Complications of dialysis,
such as infection and hypoglycemia, are recognized and
treated early.

Ethylene Glycol
Etiology/Incidence. Ethylene glycol is a colorless,
sweet-tasting liquid with a faint odor found in pennanent
types of antifreezes and coolants. It is also contained in latex
paint, glass cleaners, stains, dyes, waxes, inks, and a variety
of household cleaners, including floor waxes and polishes,
shoe polishes, and surface cleaning solutions. Ethylene
glycol ingestions have been attributed to its bittersweet
taste. Ethylene glycol poisonings usually occur as isolated
instances with children. In adolescents and adults, toxicity
commonly occurs when ethylene glycol is ingested as an
ethanol substitute.
Pathogenesis. Ethylene glycol is rapidly absorbed,
peaking in the bloodstream within I to 4 hours of ingestion.
Once absorbed, a significant amount is eliminated by the
kidneys; however, renal toxicity is acute and progressive.
Once renal compromise is present, almost all of the ethylene
glycol is then metabolized in the liver by alcohol dehydrogenase to glycolaldehyde, glyoxylic acid, oxalic acid, and
fonnic acid. As with methanol, the toxicity of ethylene
glycol results from its metabolites. Ethylene glycol produces
CNS depression, and its metabolites cause metabolic anion
gap acidosis, hypocalcemia, further CNS depression, and
tissue damage. 48 After a delay of 12 to 24 hours, oxalate
crystals may appear in the urine (when oxalic acid chelates
serum calcium) and is deposited in the tissues, causing acute
renal failure, metabolic acidosis, and cardiac and CNS
toxicity. Ingestion of an amount as small as 1.4 to 1.6 mllkg
can be lethal.
Three clinical stages of poisoning have been described.
Progression and severity of signs in these stages depend
on the ingested dose. Stage I occurs from 1 to 12 hours
after ingestion and is characterized by nausea, vomiting,
metabolic acidosis, oxalate crystalluria, and progressive
central nervous signs including elation, slurred speech,
confusion, nystagmus, depressed deep tendon reflexes,
myoclonic jerks, and seizures without the characteristic
ethanol odor on the breath. Hyperemia of the CNS
produces symptoms of inebriation, such as ataxia, swpor,
and coma. A result of calcium oxalate crystal deposition
in the leptomeninges, vessel walls, and peri vascular spaces
is meningoencephalitis.
After the first 12 to 18 hours, tachycardia, tachypnea,
mild hypertension, congestive heart failure, cyanosis, and
pulmonary edema leading to cardiorespiratory failure characterize the second stage. Myocardial and pulmonary
dysfunction occur as a result of accumulation of the toxic
intennediate and deposition of calcium oxalate crystals in
the heart and lungs.
The third stage occurs I to 3 days after ingestion and is
marked by flank pain, hematuria, proteinuria, oliguria, acute
tubular necrosis, and renal failure. Damage to the renal
tubules is thought to be caused by the byproducts glycolal-
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dehyde, glycolic, and glyoxylic acid, during ethylene glycol
metabolism. 33
Critical Care Management. Ventilatory support, if
needed, is initiated immediately. Emesis is contraindicated
because of the risk for CNS depression. Gastric lavage is
indicated for patients presenting within several hours after
ingestion of massive amounts or if gastric motility is slowed
by another ingestant or coma. Activated charcoal does not
bind to ethylene glycol and is not used.
Ethanol administration blocks ethylene glycol metabolism and development of toxic metabolites through alcohol
dehydrogenase binding. A loading dose of ethanol is given
when there are clinical signs and a history of ethylene glycol
ingestion, severe or persistent metabolic acidosis, or a blood
ethylene glycol level of 25 mg/dl or higher. Ethanol loading
is also recommended for patients who are awaiting ethylene
glycol semm determinations or hemodialysis. The antidote,
fomepizole, is a potent inhibitor of ADH and was approved
by the FDA for the treatment of ethylene glycol poisoning.
Reports indicate that the intravenous administration of
fomepizole every 12 hours prevents renal damage and
metabolic abnormalities associated with the metabolism of
ethylene glycol to its toxic metabolites. 50
In cases when ethylene glycol concentration is higher
than 50 mg/dl or renal failure exists, hemodialysis is
recommended. Thiamine (0.25 to 0.5 mg/kg) and pyridoxine (I to 2 mg/kg) administration are thought to decrease
oxalate production. The prevention of oxalate crystal
formation and subsequent deposition in the kidney are
benefits of forced diuresis in the treatment of ethylene glycol
intoxication.
Priorities for critical care management include meticulous assessment of intake and output to ensure adequate
hydration despite forced diuresis. Care is aimed toward
enhancing clearance of ethylene glycol and its metabolites.
If hemodialysis is required, care is focused on the maintenance of normal hemodynamics and fluid and electrolyte
balance during therapy. Ethanol administration is continued
until the ethylene glycol level reaches zero.
Close monitoring of blood gas and calcium determinations are necessary for early detection and treatment of
metabolic acidosis and hypocalcemia. Intravenous sodium
bicarbonate (I to 2 mEq/kg) is indicated because ethylene
glycol is metabolized faster than methanol, resulting in a
more profound metabolic acidosis. Calcium chloride (10 to
20 mg/kg/dose) is required to reverse the hypocalcemia
effects of calcium oxalate precipitation in the semm.

isopropanol is excreted unchanged by the kidneys. The liver
is responsible for about 50% to 80% of isopropanol
metabolism converting it to acetone. The kidneys primarily
excrete acetone with some excretion through the lungs. The
half-life of isopropanol is 4 to 6 hours and that of acetone is
16 to 20 hours. Acetone acts as a CNS depressant and the
prolonged CNS depression seen with isopropanol ingestion
is related in part to the acetone's effect.
Isopropanol toxicity produces CNS effects including
depression, ataxia, confusion, stupor. and coma. The depression has been described to be 2 to 3 times more profound
than ethanol ingestions. 47 Patients may appear intoxicated
but do not smell like alcohol; rather they have the fruity odor
of acetone. Hyperglycemia, inconsistent pupil size, miosis.
and depressed or absent deep tendon reflexes are other eNS
manifestations characteristic of isopropanol toxicity.
As a myocardial depressant, acetone causes altered
cardiac function with profound hypotension and has been
noted to be a poor prognostic sign. Patients may have sinus
tachycardia but usually no other cardiac dysrhythmias.
Impaired GI system function results from the effects of
isopropanol as a local irritant. GI symptoms such as
gastritis, abdominal pain, vomiting, and hematemesis usually occur as a result of isopropanol ingestion. Renal tubular
necrosis, myopathy, and hemolytic anemia have also developed after ingestion of isopropanol.
Critical Care Management. Supportive care is the
primary treatment. Airway protection is crucial to prevent
aspiration should vomiting occur. Emesis is not recommended because of the rapid CNS depression associated
with isopropanol. Gastric lavage is recommended because it
may limit absorption and helps to decrease the local
irritation in the lining of the stomach. Serum isopropyl
alcohol level confirms and quantitates alcohol level, but the
clinical presentation is a better indicator of prognosis.
Therapy for isopropanol ingestion is fairly nonspecific.
focusing mostly on general supportive care. Maintaining
adequate ventilation and normotension is the primary goal.
Care of children with isopropanol toxicity necessitates
close monitoring for and correction of fluid and electrolyte imbalances. If hypoglycemia develops. the patient
will require adjustment of intravenous glucose infusions
to maintain serum glucose in the normal range of 80 to
120 mg/dl.
Hypotension is treated with fluid boluses (20 ml/kg IV)
and vasopressor support if needed. Hemodialysis is used
when serum isopropyl alcohol levels are greater than 400
mg/dl or hypotension is refractory to treatment.

Isopropanol
Etiology/Incidence. Isopropyl alcohol is a clear,
colorless solution, found in rubbing alcohol, antifreeze, skin
lotions, and glass cleaners. Parents may use isopropanol for
sponging a child to reduce fever with isolated cases resulting
in stupor or coma. Consequently, this practice is strongly
discouraged.
Pathogenesis. The peak absorption of isopropanol
occurs in about 30 minutes because of rapid GI absorption
with complete absorption in 2 hours. Isopropanol is a eNS
and cardiac depressant. Approximately 20% to 50% of

Ethanol
Etiology/Incidence. Ethanol is found in alcoholic
beverages, perfumes, cologne, cold preparations, aftershave,
mouthwash, and antiseptics. Blood ethanol levels less than
50 mg/dl can produce mild intoxication in children;
however, a lethal dose has been estimated at 3 mg/kg
equivalent (e.g., 5 to 10 ounces of mouthwash or I to 2
ounces of cologne).4 Ethanol is more likely to be ingested
than some other substances because these products are used
daily and are usually within reach of young children.

Chapter 30 Toxic Ingestions
Pathogenesis. Ethanol is rapidly absorbed from the
gastric tract, peaking in the serum 30 to 60 minutes after
ingestion when the stomach is empty. Absorption is delayed
when food is present in the stomach and total absorption
may take up to 6 hours. A total of 90% is metabolized in the
liver by alcohol and aldehyde dehydrogenases with some
oxidation. The kidney excretes the remainder. Ethanol
affects the reticular activating system, causing direct CNS
depression, decreased motor function, and decreased level
of consciousness. At high concentrations, ethanol is an
anesthetic and can cause autonomic dysfunction, hypothermia, and hypotension with subsequent coma and death from
respiratory depression and cardiovascular collapse.
Ethanol ingestion may be manifested clinically by
flushed face, diaphoresis, agitation, or ebullient and loquacious speech resulting from early disinhibition. This may
progress to ataxia, slurred speech, blurred or double vision,
drowsiness, stupor, depression, or coma. Significant intoxication is characterized by the presence of an osmolal gap
(see Box 30-1). Ethanol metabolism causes impaired
gluconeogenesis during the Krebs cycle. Profound hypoglycemia can ultimately lead to convulsions and coma in the
pediatric patient, but the prognosis for children who ingest
ethanol is generally good.
Critical Care Management. The initial treatment for
ethanol intoxication involves providing supportive measures
such as airway protection, oxygen, and monitoring fluids.
Emesis is contraindicated because of rapid CNS depression.
Gastric lavage may be recommended when the child is seen
within 30 to 60 minutes after ingestion and CNS depression
is present. Charcoal and forced diuresis are ineffective
because the liver is the primary metabolic pathway. Cardiac
and respiratory support is necessary in addition to the
initiation of an intravenous infusion of 10% dextrose if
hypoglycemia exists.
Supportive therapy with ongoing monitoring of vital
functions until toxic effects subside is the primary focus of
intensive care. Children who ingest ethanol require frequent
serum glucose and ethanol determination and assessment for
changes in mental status. Reassuring parents by noting signs
of improvement in clinical status is helpful as the child
progresses through the recovery period. The patient needs to
be protected against aspiration. If hypoxia develops, the
patient may require intubation and mechanical ventilation.
Intravenous fluids are administered to replace urinary losses
and correct electrolyte imbalance, acidemia, and hypotension. If hypotension is refractory, vasopressors may be
necessary. Hypothermia is treated with passive rewarming;
and normothermia is the goal. Maintaining seizure precautions is necessary until symptoms of neurologic toxicity
abate. If the blood ethanol.level is greater than 300 to 350
mg/dl and clinical deterioration progresses despite supportive care, hemodialysis is used 4

Cocaine
Etiology/Incidence. Grown in Peru and Bolivia,
cocaine is an alkaloid that is extracted from the leaves of the
Erythroxylum coca plant. It is crystallized as hydrochloride
salt. prescribed as a local anesthetic and mucous membrane
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vasoconstrictor, and used illicitly as a CNS stimulant. The
adulterants with which cocaine is diluted for illicit use
include local anesthetics, sugars, stimulants, toxins, and
inert compounds and may also exert toxic effects 51
Cocaine may be injected intravenously, sniffed intranasally, ingested, or applied to the mucous membranes.
Cocaine can also be smoked in its free-base form known as
"crack." Children may be exposed to cocaine by passive
transmission via the placenta in utero, or in breast milk, or
by inhalation of crack vapors. 52 Cocaine is well absorbed by
all mucous membranes, metabolized by liver esterases and
plasma cholinesterase, degraded nonenzymatically, and
excreted in the urine as its primary metabolite, benzoylecgonine. 53 Cocaine levels in blood may be detected within
several minutes of ingestion. They peak in J5 to 30 minutes
and persist for up to 8 hours. 54 Cocaine may be detected in
urine within I hour of ingestion or administration and
persists for up to 3 days in children and 5 days in neonates
following exposure.
Pathogenesis. Three systems primarily affected by
cocaine's toxic effects are the neurologic system, the
cardiovascular system, and the respiratory system. Cocaine
stimulates the sympathetic nervous system, and an overdose
is especially toxic to the brain and heart. Cocaine stimulates
the presynaptic release of dopamine, norepinephrine, serotonin, and acetylcholine in the CNS. It alters normal
intraneural communication by augmenting the effects of the
catecholamines, norepinephrine, and dopamine. Cocaine
stimulates the "fight or flight" mechanism, evidenced by
clinical signs of stimulation of norepinephrine secretion.
Signs and symptoms are dose related, with low doses
producing euphoria and CNS stimulation and high doses
producing anxiety, agitation, paranoid delusions, mydriasis,
hypertension, hyperthermia, tachycardia, and cardiac dysrhythmias. 4 As cocaine continues to stimulate norepinephrine and dopamine release, the cardiovascular and neurologic systems demonstrate progressive stimulation that may
progress to exhaustion, producing coma and cardiopulmonary arrest.
Cardiovascular dysfunction is first manifested by sinus
tachycardia or supraventricular dysrhythmias followed by
hypertension, peripheral vasoconstriction, ventricular ectopy. and occasionally, ventricular fibrillation or asystole.
These signs may occur as a result of the toxic action cocaine
exerts on the tissues of the myocardium directly. or because
of its effect of sensitizing the heart to the actions of
norepinephrine and dopamine. 44 Evidence of a toxic dose is
seen when heart rate and blood pressure peak and begin to
fall, ventricular dysrhythmias become more frequent, and
the patient begins to show signs of shock with decreased
peripheral perfusion and cyanosis. Progression of signs
includes ventricular fibrillation, circulatory collapse, and an
ashen appearance before cardiac arrest. Cocaine-induced
coronary artery vasoconstriction may also cause myocardial
ischemia or infarction related to increased myocardial
oxygen demand and cocaine's thrombogenic potential. 53
Neurologic dysfunction begins as the cerebral cortex is
stimulated. Dysfunction is further evident with talkativeness, hyperalertness, mydriasis, and nausea and/or vomiting
occurring. As stimulation continues and cocaine affects the
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functions of the medulla, the child becomes hyperthermic,
develops hyperreflexia, and may have seizures. As the CNS
becomes exhausted, the child becomes comatose with
flaccid paralysis.
Tachypnea and increased depth of respiration evidence
the early stimulation phase of the CNS. Later, depression of
the medullary respiratory center occurs, the child becomes
more dyspneic and may progress to cyanosis and respiratory
failure. Seizures, or respiratory depression secondary to
antiepileptic medications, may also contribute to respiratory
failure in cocaine toxicity. Cerebral vascular accidents,
including subarachnoid hemorrhage, cerebral infarction,
transient ischemic attacks, and seizures have been reported
with cocaine toxicity. Seizures may develop secondary to
infarction or hemorrhage, and the majority are single,
generalized, and not associated with any lasting neurologic
deficits 53
Critical Care Management. Because cocaine is
absorbed quickly with smoking, snorting, or injection, no
treatment can decrease its absorption or enhance its excretion. If cocaine is ingested, GI decontamination may be
considered after initial stabilization of airway, breathing,
and circulation. Initial management of cocaine exposure
depends on the phase at which the patient presents for care.
Adequate cardiovascular and respiratory function is ensured. Assessment of cardiovascular function includes heart
rate and rhythm, blood pressure, and peripheral perfusion.
Respiratory evaluation includes assessment of both respiratory rate and depth, with pulse oximetry or arterial blood gas
analysis as needed. Intravenous access is obtained promptly
and vital signs are monitored frequently. Continuous core
temperature monitoring is initiated to assess for hyperthermia. Emesis is not used, but activated charcoal and a
cathartic may be given for oral ingestions. Whole bowel
irrigation has been used safely to remove packets and crack
vials in drug smugglers.
Cardiovascular dysfunction is initially treated with fluid
resuscitation. There is significant controversy regarding the
use of antidysrhythmics with cocaine ingestion. The majority of antidysrhythmic agents are contraindicated because
they exacerbate the problems of coronary artery spasm,
ischemia, infarction, and ventricular arrhythmias. A lidocaine bolus (I mg/kg) and continuous infusion (10 to 50
!!g/kg/min) may be required to suppress ventricular arrhythmias if no other alternatives are present. Benzodiazepines
slow the heart rate, may have an additive antiarrhythmic
effect, and are added, if not already used, only to offer
protection against the combined proconvulsant effect of
lidocaine and cocaine. If unable to determine whether the
dysrhythmia is from ischemia or sodium channel blockade
with QRS widening, sodium bicarbonate and benzodiazepines are given first, followed by lidocaine if dysrhythmias
persist. 53 Nitroglycerin may be used to relieve chest pain
and angina. Severe hypertension resulting from vasoconstriction is best treated with sedatives such as diazepam
(40 to 200 !!g/kg IV) or lorazepam (30 !!g/kg/day in three
or four doses intravenously) in an effort to control hypertension, calm the patient, prevent seizures, and decrease
hypertonicity. If these measures fail to control hypertension,

a continuous infusion of nitroprusside (0.2 to 10 !!g/kg/min)
may be necessary. Pulmonary artery pressure monitoring
may be indicated to estimate the left heart filling pressures
and to guide management.
Use of a tool such as the Glasgow coma scale or the
Pediatric Coma Scale guides neurologic assessment. Seizures may be treated with diazepam (I ()() to 250 !!g/kg) or
lorazepam (50 !!g/kg) given intravenously over 3 minutes.
Hyperpyrexia is aggressively treated with cooling blankets
or tepid baths, avoiding shivering, which increases body
temperature. Respiratory dysfunction management includes
maintenance of a patent airway as the first priority. Oxygen
may be administered to prevent complications of hypoxemia. Intubation is considered if the child is unable to
maintain a patent airway, adequate cough, or gag reflexes; if
seizures compromise respiratory function; or if arterial
blood gas analysis demonstrates hypercarbia. Mechanical
ventilation may be required to treat respiratory insufficiency
or respiratory failure.

Heroin
Etiology/Incidence. Heroin is an illicit semisynthetic narcotic agent initially developed as a less-addicting
morphine substitute. It originally gained popularity in the
1970s, but now a resurgence of heroin use and abuse has
occurred in the 1990s. Heroin has become cheaper and more
readily available in the past few years, and a new generation
of young heroin users has developed novel patterns of
abuse.
Heroin acts as a pro-drug that allows for rapid CNS
absorption, providing euphoric and toxic effects. All routes
of administration rapidly absorb heroin with intravenous
heroin at serum peak levels within I minute. Intranasal and
intramuscular heroin reach peak levels in 3 to 5 minutes, and
subcutaneous heroin reaches peak levels within 5 to 10
minutes. Heroin is seven times more toxic than intravenous
morphine and the route of administration strongly affects the
drug's potential for overdose or death. The majority of
nonfatal and fatal heroin overdoses occur when injected
intravenously.
Pathogenesis. Heroin is highly lipid soluble with
rapid and complete uptake into the CNS that produces a
feeling of intoxication. Heroin produces opiate intoxication
syndrome consisting of altered mental status, miosis, and
respiratory depression. It reacts with three types of receptors, mu, kappa, and delta, to produce a wide range of
changes in the CNS. Initial effects include euphoria,
sedation, impaired thinking, miosis, and mild decrease in
blood pressure and urinary retention. Toxic ingestions
produce hypotension, bradycar.dia, depressed respiration,
agitation, uncontrolled muscle movements, hallucinations,
headache, nausea and vomiting, stupor, coma, seizures, or
death 54
The mu receptors are responsible for most of the
analgesic effects, respiratory depression, delayed GI motility, miosis, and euphoria, whereas kappa agonists, independent of the mu receptors, produce analgesia, respiratory
depression, and dysphoria. Delta receptors work to mediate
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spinal analgesia. Centrally mediated respiratory depression
is caused by a direct effect on the brainstem, reducing
responsiveness to carbon dioxide. Respiratory depression is
the dominant symptom and the most common cause of death
in heroin overdose. Heroin crosses the blood-brain barrier
within 15 to 20 seconds and achieves a high brain level of
both heroin and its metabolites. In the CNS, heroin is
quickly hydrolyzed to a substrate that is metabolized over 20
to 30 minutes to morphine. Heroin and its metabolites both
have significant agonist and analgesic effects on the CNS.
Any circulating heroin can be hydrolyzed in the peripheral
tissues of the kidneys and liver to morphine. The byproducts of morphine are water soluble and readily excreted
in urine and bile 55
Critical Care Management. Heroin intoxication is
usually witnessed, and identification of the toxin is known.
Initial management includes assessment of adequacy of
ventilation and airway stability. The majority of patients will present with inadequate respiratory effort and
require assistance with bag-valve-mask breathing and
oxygen delivery. If ingestion of heroin is confinned,
parenteral naloxone therapy is initiated. If the patient does
not respond to naloxone within 10 minutes, or the airway
is unstable, then intubation is performed. If the patient is
breathing well without support, naloxone is not administered, and the patient is observed. Emesis is contraindicated because of rapid absorption of heroin and CNS
depression.
Gastric decontamination with whole bowel irrigation and
activated charcoal is used in cases of body packers or
"mules" who attempt to smuggle large numbers of concentrated drug packets by ingesting them. These individuals are
typically asymptomatic but are at risk for delayed and
prolonged toxicity from packet rupture. If symptomatic, a
continuous infusion of naloxone can be administered in
conjunction with gastric decontamination.
Ongoing management typically consists of supportive
care, primarily of the respiratory system with assisted
ventilation, until the CNS depressive effects are no longer
present. In the hypoventilating patient suspected of heroin
overdose, an initial dose of naloxone (0.1 mg/kg) may be
given, followed by a higher dose (maximum 2 mg) if no
response is seen in 3 to 5 minutes. The short duration of
action of naloxone may require multiple doses until
respiratory compromise is no longer present. A chest
radiograph is obtained for patients who clinically present
with a significant cough or poor oxygenation.
Naloxone treatment of heroin overdose is associated with
complications, including seizures, tachycardia, severe agitation, nausea and vomiting, diaphoresis, and hypertension.
Heroin has a I % to 3% associated risk of inducing
noncardiogenic pulmonary edema, whereas naloxone is
associated with a 1.6% rate of complications, including
seizures and arrhythmias. 55 Patients with heroin overdose
and respiratory compromise require observation and cardiorespiratory monitoring until cessation of clinical symptoms.
Patients are carefully evaluated to rule out coingestion,
especially benzodiazepines, which contribute to a much
higher complication rate.
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Methadone
Etiology/Incidence. Methadone is a synthetic narcotic that is used in the treatment of heroin addiction and
withdrawal. Methadone is unrelated to morphine but is
similar in mu effect. It replaces the illicit substance with a
legal, oral, and long-acting agent, but excessive dosing may
cause toxicity. Methadone will produce symptoms similar to
heroin intoxication and overdose. Children are particularly
susceptible to the effects of methadone overdose, with
respiratory depression and death potentially occurring with
a lO-mg dose.
Pathogenesis. Methadone is very lipid soluble and
well absorbed from the GI tract into the blood stream with
a long elimination half-life of 15 to 20 hours in children.
Methadone is 70% to 90% bound to albumin and plasma
proteins. The oral duration of action is 6 to 8 hours initially
and 22 to 48 hours after repeated doses. It is hydrolyzed with
a fairly extensive metabolism on first pass through the liver.
Methadone is excreted in sweat and saliva, and 10% is
excreted unchanged along with metabolites in urine and
stool. 54
Methadone can produce mild side effects such as
drowsiness, lightheadedness, weakness, euphoria, dry
mouth, and urinary retention with proper dosing. Symptoms
of methadone overdose include marked drowsiness, confusion, tremors, nausea and vomiting, cold and clammy skin,
hypotension, hypothermia, bradycardia, miosis, seizures,
stupor leading to coma, and severe respiratory depression 56
Critical Care Management. Methadone has a slow
onset of action and a very long duration of effect. All
patients who present with methadone toxicity require
hospitalization and monitoring. Initial management consists
of assessment and stabilization of respiratory effort. Intubation is performed for all patients with significant respiratory
depression. If respiratory depression is not immediately
addressed, cyanosis, hypoxia, and apnea may develop. The
major cause of death in methadone toxicity is respiratory
arrest.
Emesis is contraindicated. Activated charcoal may
be worthwhile because gastric motility is slowed by
methadone.
The majority of critical care management is supportive in
nature. The child may require intubation and mechanical
ventilation support until respiratory depression subsides.
The patient is initially NPO, and intravenous fluid is given
for hydration. Naloxone is given intravenously as a continuous infusion, starting with a loading dose (0.005 mg/kg)
followed by an infusion of 0.0025 mg/kg/hr, tapering
gradually as symptoms resolve to avoid relapse. Hypotension is treated with fluid boluses (20 ml/kg) and if refractory
may require inotropic support.

Phencyclidine
Etiology/Incidence. Phencyclidine (PCP) was developed in the 1950s as a dissociative anesthetic-analgesic. It
was the prototype of a drug combining analgesic and
anesthetic actions without respiratory or cardiovascular
depression. PCP produced dysphoric effects and was rapidly
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adapted as a street drug after being removed from the
pharmaceutical market. PCP is easily and cheaply synthesized from readily obtainable ingredients. It typically used
by polydrug abusers 57
PCP can be smoked, snorted, or ingested. [t has a rapid
onset of action and may elicit drug-induced psychosis with
flashbacks lasting for weeks.
Pathogenesis. PCP is a highly lipid-soluble drug,
which is also soluble in water and alcohol. It is metabolized
by the liver to hydroxyl and glucuronide and then excreted
in the urine as an inactive complex within 12 hours of
ingestion. PCP is thought to block the calcium channel
influx, which results from glutamate binding.
PCP primarily affects the CNS, stimulating a-adrenergic
receptors and potentiating catecholamines. The major effects are psychologic, sympathomimetic, cholinergic, and
cerebellar. People may have sharply contrasting responses to
PCP. It has profound effects on thinking, alters time perception and sense of reality, affects mood, and may create a
dreamlike, euphoric, or depressed state. Intoxication with
PCP may produce negative effects including disorientation,
confusion, anxiety, irritability, paranoid states, hostility, or
beUigerence. Dangerously violent behavior may develop. 58
At high doses, PCP abuse may produce nystagmus, hypertension, tachycardia, salivation, flushing, sweating, dizziness, blurred vision, ataxia, and CNS stimulation or depression. The symptoms are quite variable, and children present
with miosis, choreoathetosis, and seizures more often than
adults. 57 The presence of hypertension, abnormal behavior,
and miosis in children strongly suggest PCP poisoning.
Most fatalities associated with PCP poisoning are related to
violent actions rather than the toxicity of the dose. 19
Critical Care Management. Initial management
consists of assessing and maintaining adequate respiration,
circulation, and thermoregulation. To prevent self-injury. the
patient is safely restrained, using physical and chemical
methods as necessary. If the patient has a history of recent
ingestion of PCP, GI decontamination is initiated. Gastric
lavage may be performed once the patient's anxiety or
agitation is weU controlled. Activated charcoal effectively
absorbs PCP and increases its nonrenal clearance. Unless
there are specific contraindications, sorbitol is administered
with the activated charcoal. Alkaline diuresis, hemoperfusion, and hemodialysis are not beneficial because of the
substantial protein binding, high lipid solubility, and limited
renal excretion of PCP.
The continuation of supportive treatment until resolution of symptoms is the primary treatment. If seizures
occur, benzodiazepines can be used in addition to treating agitation. Hyperthermia is treated with passive cooling techniques. The patient is kept weU hydrated to
lessen the effects of rhabdomyolysis and prevent deposition of pigment in the kidneys, which could lead to renal
failure.
The majority of patients rapidly regain nomlal CNS
function within several hours of using PCP. However, some
patients may remain comatose or exhibit bizarre behavior
for days or even weeks after ingesting high doses. Patients

who may have an underlying psychiatric disorder may also
have symptoms for an extended period.
The major complication of PCP is from injuries related to
behavior, including self-inflicted injuries, injuries from
exceptional physical exertion, or injuries from resisting
physical restraints. Patients who have ingested PCP appear
to be unaware of their surroundings and pain because of
PCP's dissociative anesthetic effects.

HOUSEHOLD TOXINS
Caustics
Etiology/Incidence. A caustic is a substance that
causes functional and cellular damage on contact with body
surfaces. The injury results as neutralization of the substance takes place at the expense of the tissues, releasing
thermal energy and causing burns. Caustics are classified as
strong acids or alkalis and can be found in most homes. The
incidence of caustic injuries to the esophagus has increased
significantly since the use of concentrated liquid alkaline
cleansers became popular. In addition, many accidental
childhood ingestions occur as a result of the substances
being placed or stored in easily accessible and familiar
containers such as milk cartons and soda cans. Common
sources of acid exposure include toilet bowel cleaner,
swimming pool products, and battery fluid. Household
sources of alkali agents include drain openers, lye, hair
permanent products, and oven cleaners. The skin, eyes,
respiratory tract, and GI tract are all systems affected by
caustic injury. Ingestion of caustics causes the most
life-threatening and long-term morbidity. 59
The majority of caustic burns to the esophagus are a
result of sodium hydroxide or lye ingestions and most often
occur in children younger than 5 years of age. 60 Commercial
ammonia is an alkali that causes ulcers or full-thickness
burns to the esophagus after ingestion and irritation to the
lungs or pulmonary edema after inhalation. Toilet bowl
cleaners that contain sulfuric, hydrochloric, or phosphoric
acid burn the oropharyngeal mucosa and are usually spit out
on contact. Detergents and bleach are commonly ingested
by children and produce local irritation without causing
necrosis.
Pathogenesis. Esophageal burns produced by the
ingestion of caustic agents are classified as first-degree
burns, which produce hyperemia and superficial desquamation; second-degree burns, which result in blisters and
shaUow mucosal ulcers; and third-degree burns, which
produce deeper ulceration into the esophageal muscle. Caustics can affect a variety of regions along the
GI tract in addition to the esophagus because of the agents'
low surface tension and ability to spread to a large
surface area.
The location of the injury varies but can involve the
cricopharyngeal area, impression of the aortic arch and left
bronchus, lower esophageal sphincter, and stomach. Greater
damage occurs in these locations because the ingested agent
may become stagnant. Granular agents may imbed in the
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tissues of the oropharynx or proximal esophagus, whereas
liquid agents produce damage along the entire esophagus to
the stomach lining. When the lower esophageal sphincter is
involved, the resting pressure decreases, causing reflux of
the agent back and forth between the esophagus and
stomach. This is usually followed by violent regurgitation.
Acids produce a coagulating necrosis in the stomach and
esophagus, resulting in eschar formation. This limits deep
penetration into the tissue, but leads to metabolic acidosis
and pooling of acids in the stomach.
Alkaline agents usually affect the mouth, esophagus, and
stomach. However, it is possible to have esophageal burns
without oral involvement if the agent is swallowed rapidly.
The alkali acts as a solvent on the lipoprotein lining, causing
a liquefaction necrosis with inflammation and deep penetration into the mucosal, submucosal, and muscular layers of
the esophagus and stomach. This is followed several days
later by saponification of mucosal fats and proteins,
thrombosis of adjacent blood vessels, cell necrosis, and
tissue degeneration. Sloughing develops 4 to 7 days after
ingestion when bacteria invade the injured areas. The
development of strictures can occur anytime between 21 and
42 days after exposure 61
Critical Care Management. The identity, concentration, pH, and amount of substance ingested are important to
ascertain. Depending on the severity of injury, the patient
may present with physical findings of impending airway
obstruction. If possible, gentle or fiber-optic intubation is
preferred over blind nasotracheal because of the increased
risk of soft-tissue perforation. Emesis is contraindicated
because of the reexposure to the caustic agent. Gastric
lavage is also contraindicated for both acid and alkali
ingestions. Large liquid acid ingestions may benefit from
nasogastric suction because pyloric sphincter spasm may
prolong the contact time with the gastric mucosa. Activated
charcoal is relatively contraindicated because of poor
adsorption and endoscopic interference. If the gag reflex is
intact, dilution may be beneficial in the ingestion of solid or
granular alkaline material if performed within 30 minutes
of ingestion. The child can be given a small amount of
tap water (5 ml/kg) to dilute the substance, but the risk
of inducing emesis is weighed against the benefit of
dilution. Acids are not diluted with water because of
excessive heat production. All small children, symptomatic
patients, and those with altered mental status are admitted
for observation and subsequent endoscopy to evaluate the
extent of injury.
Hydration accompanied by NPO for 12 to 24 hours until
the extent of the injuries has been determined is initiated.
The child requires close observation for drooling or the
presence of lesions in the oral mucosa, stridor, hoarseness,
subcutaneous air, respiratory distress, acute peritonitis, and
hematemesis in the early stages of hospitalization. Airway
edema or obstruction may occur up to 48 hours after an
alkaline exposure, and delayed perforation may occur up to
4 days after an acid exposure.
The child who has sustained first-degree bums is
assessed for the ability to tolerate liquids and slowly
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advanced to a regular diet. For children with second-degree
and third-degree bums or evidence of perforation, the
administration of antibiotics and antacids may be indicated. These children may also need parenteral nutrition
and an endoscopy 2 to 3 weeks after the ingestion to
evaluate the extent of esophageal dysmotility or stricture
formation. Repeated esophageal dilations may be required
if strictures develop.59.61 Long-term sequelae may require
surgical intervention to repair the severely damaged
esophagus.

Hydrocarbons
Etiology/lncidence. Fully 60% of all hydrocarbon
exposures involve children and 90% of hydrocarbon-related
deaths involved children, younger than 5 years of age.
Hydrocarbons are defined as all-organic compounds made
of predominately carbon and hydrogen molecules, including those derived from petroleum distillation. Hydrocarbons are classified into four different categories: aliphatics
(paraffins), aromatics, alicyclics or cycloparaffins, and
halogenated products. Aliphatic hydrocarbons are found in
the form of petroleum distillates such as furniture polish,
lamp oil, lighter fluid, propane, and isobutane. Aromatic
hydrocarbons, such as benzene, toluene, and xylene, are
found in glues, nail polish, paints, and paint removers.
Alicyclic hydrocarbons are otherwise known as turpentine,
cyclopropane, and cyclohexane. Halogenated hydrocarbons, such as carbon tetrachloride, chloroform, methylene
chloride, Freon, and trichloromethane, are particularly
harmful because they produce various forms of systemic
toxicity.
Pathogenesis. The pulmonary system is predominately affected by hydrocarbon ingestion. The CNS, GI,
cardiac, and dermatologic systems are also commonly
affected with rare hematologic, hepatic, and renal effects.
Aliphatic hydrocarbons produce minimal systemic toxicity
but may cause pulmonary injury, depending on their
viscosity and ease of aspiration. Alicyclics can produce
pulmonary aspiration and direct CNS depression. Aromatic and halogenated hydrocarbons can cause cardiac
arrhythmias in addition to aspiration and CNS depression
(Box 30-2).
The risk of aspiration depends on the viscosity, surface
tension, and volatility of the substance. The lower the
viscosity and surface tension and the higher the volatility,
the greater the risk of aspiration. 62 Products with low
viscosity pose a high aspiration hazard because of the
tendency to spread over a large surface area. Chemical
pneumonitis may develop from as little as a few milliliters
of a hydrocarbon. Aspiration usually occurs at the time of
ingestion or upon emesis. Large amounts of most alicyclic
and aromatic hydrocarbons can be tolerated by ingestion if
not aspirated. Agents that are not aspirated easily but that
cause systemic toxicity (i.e., the halogenated hydrocarbons)
induce neurotoxicity. Benzene, in addition, is associated
with aplastic and acute myeloblastic anemia because of its
ability to injure bone marrow.
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Box 36-2
.
_~ Clinical Manifestations.o.f
. .... Hydrocarbon Ingestion
I. Pulmonary dysfunction
Tachypnea, dyspnea, adventitious breath sounds, oxygen
desaturation, cyanosis
2. CNS dysfunction
Euphoria, agitation, restlessness, confusion, seizures, coma
3. Cardiovascular dysfunction
Ventricular dysrhytbmias (tachycardia, fibrillation)
4. Gastrointestinal dysfunction
Oropharyngeal irritation, gastric irritation, vomiting.
hematemesis
5. Hepatic dysfunction
Elevated liver enzymes, hepatomegaly
6. Renal dysfunction
Urine positive for albumin, cells, casts

The ingestion of a hydrocarbon causes irritation of the
mouth, pharynx, and gastric mucosa and is usually followed
by vomiting. Aspiration of these substances, which are lipid
solvents, leads to hydrocarbon pneumonitis within 12 to 24
hours after exposure and is typically accompanied by rapid
development of low-grade fever. 62
Hydrocarbons disrupt surfactant, cause direct injury to
the epithelium and pulmonary capillaries and create bronchospasm, alveolar instability, and collapse resulting in
atelectasis and pulmonary edema. Symptoms exhibited
include coughing, retractions, grunting, tachypnea, dyspnea,
cyanosis, and severe hypoxia. Physical examination is
characterized by rales on auscultation, rhonchi, wheezing, or
decreased breath sounds. Positive radiographic findings,
such as perihilar densities, basilar pneumonitis, atelectasis,
and consolidation, have been noted as early as 2 hours after
ingestion. 63 Other pulmonary complications include pneumatoceles, emphysema, pleural effusion, pneumothorax,
pneumomediastinum, and pneumopericardium.
Halogenated and aromatic hydrocarbons are well absorbed by the GI tract and pulmonary system. This enables
them to cause direct CNS depression resulting in headache,
dizziness, ataxia, lethargy, changes in mental status, and
seizures. Patients can also exhibit signs of narcosis, inebriation, or coma. 4
Inhalation of halogenated hydrocarbons has been known
to cause fatal ventricular dysrhythmias resulting from
myocardial sensitization to catecholamines. The pathophysiologic effect of inhalation of these substances causes
increased ventricular irritability, predisposing the heart to
ventricular fibrillation.
All hydrocarbons produce symptoms of Gr distress
including nausea, vomiting, hematemesis, and diarrhea.
Absorption varies, depending on the type of hydrocarbon.
Aliphatic hydrocarbons have minimal absorption, whereas
alicyclic, aromatic, and halogenated hydrocarbons can have
significant GI absorption.
Halogenated hydrocarbons have been known to produce
centrilobular necrosis. Specific types include carbon tetra-

chloride and chloroform, which induce fatty degeneration of
the liver, resulting in necrosis. 64
Many halogenated hydrocarbons that produce hepatic
dysfunction also cause renal tubular acidosis. Damage
occurs directly to the proximal tubule and the loop of Henle
from carbon tetrachloride. This leads to acute renal failure
between I and 7 days after exposure. 64
Critical Care Management. Ingestion of hydrocar. bons commonly leads to gagging with pulmonary aspiration. Aspiration may lead to the rapid development of
chemical pneumonitis and intubation, and mechanical
ventilation is initiated quickly, preferably using a cuffed
endotracheal tube. Once initial stabilization is achieved,
consideration of gastric decontamination is considered.
Gastric emptying remains a controversial recommendation.
Because the majority of hydrocarbons do not cause
systemic toxicity but have significant risk for causing
pulmonary injury, emesis and gastric lavage are not
recommended. When there are no contraindications, gastric
emptying may be helpful for hydrocarbons that have
inherent toxicity, have been ingested with a toxin, or have
been used to stabilize a toxin or when a large volume
of hydrocarbon is ingested. Hydrocarbons that have
inherent toxicity include CHAMP: C--camphor, Hhalogenated hydrocarbons, A-aromatic hydrocarbons,
M-hydrocarbons associated with metals, and Phydrocarbons associated with pesticides 65
Children with a history of hydrocarbon ingestion are
monitored for signs of pulmonary aspiration, including
coughing, choking, or gagging and oxygen desaturation on
pulse oximetry. If these signs are present, a chest radiograph
is necessary to evaluate potential parenchymal injury.
Clothes are removed, copious bathing is done, and eye
irrigation performed if necessary to reduce absorption by
other routes.
Admission to the rcu is warranted in children with
severe parenchymal injury and pneumonia. Care of these
patients includes mechanical ventilation and close attention
to maintenance of a patent airway, effecti ve pulmonary
toilet, and routine monitoring of arterial blood gases until
symptoms of respiratory compromise subside. Pulmonary
dysfunction and radiographic changes detem1ine the degree
of mechanical support required in the acute phase of
parenchymal injury. Severe injuries may require the use of
extracorporeal membrane oxygenation.

SUMMARY
Children who have ingested pharmaceutical or nonpharmaceutical toxins are a critical care nursing challenge in
the emergency department and the ICU. The effects of a
toxic ingestion may be systemic, involving many organ
systems. Finely tuned collaboration between nurses, physicians, and poison experts is necessary for a positive
outcome for these patients. Intentional ingestions necessitate the involvement of psychiatry. Accidental ingestions
require education and reinforcement by the health care
team for caregivers and children to decrease the probability
of a reoccurrence.
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Resuscitation and Transport
of Infants and Children
Mary Fallon Smith
Aimee Lyons

of the techniques taught in these courses can greatly
improve the success rate of pediatric resuscitation efforts.
This chapter begins with a discussion of the epidemiology of cardiopulmonary arrest in infants and children.
Research that influenced standards of pediatric resuscitation
are discussed. The standards for pediatric advanced life
support are reviewed, emphasizing nursing care issues.
Management and coordination of the transport of critically
ill children are then outlined.

EPIDEMIOLOGY OF CARDIOPULMONARY ARREST IN CHILDREN
EnoLoGY OF CARDIOPULMONARY ARREST
RED FLAGS OF IMPENDING CARDIOPULMONARY ARREST
STRATEGIES FOR PREVENTION OF CARDIOPULMONARY
ARREST
COlLABORAnVE MANAGEMENT

Airway Management and Breathing
Circulation
Evaluation of Interventions
Diagnostic Studies
Family Care
Documentation

EPIDEMIOLOGY OF CARDIOPULMONARY
ARREST IN CHILDREN
Intentional and nonintentional InJunes remain the most
common cause of death in children over I year of age,
followed by cancer and congenital anomalies. J Half of all
infant deaths are caused by one of four diagnoses: congenital anomalies, prematurity or low birth weight, sudden
infant death syndrome (SIOS), and respiratory distress
syndrome. 2 The data show a much higher incidence of
deaths in the infant population (711 per 100,000) than in all
other pediatric ages combined (38 per 100,000).
The average age of children requiring cardiopulmonary
resuscitation (CPR) reported from a large urban pediatric
center was 1.98 years of age with a median age of 5
months. 3 Children under the age of I year accounted for
roughly half of all cases reported in a review by Young and
Seidel. 4 The incidence of adolescent CPR was shown to be
intermediate between that of children and adults. These
statistics are helpful in identifying age groups at higher risk
for cardiopulmonary arrest.

POSTRESUSCITATION MANAGEMENT
INTERFAClLlTY TRANSPORT

History
Transport Process
RESUSCITATION PERFORMANCE IMPROVEMENT
SUMMARY

P

ediatric resuscitation offers a challenge to the pediatric
critical care nurse. Participating in resuscitation attempts requires specialized knowledge and skills. Consideration of the potential impact of the child's developmental
maturity integrated with nursing's humanistic approach to
supporting families in crises is a vital aspect of care.
Educational programs in advanced pediatric life support
are now widely available, including the Emergency Nursing
Pediatric Course (ENPC) and Trauma Nursing Core Course
(TNCC) from the Emergency Nurses Association and
Pediatric Advanced Life Support (PALS) provider course
from the American Heart Association. These courses provide an excellent means of preparing nurses to manage
emergent situations when caring for children. Consistent use

ETIOLOGY OF CARDIOPULMONARY
ARREST
Cardiac arrest resulting from primary cardiac dysfunction is
a rare occurrence in the pediatric population. s Pediatric
cardiac arrests occur after a prolonged disruption in
homeostasis produced by the final common pathways of
respiratory failure or cardiovascular collapse.
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Survival Rates
in Pediatric CPR

TABLE

31·1

Survival Rate (%)

8.4
24

~t:

Intensive care unit

20
26

li!!

Drowning
Asystole

]!!

VTNF

30
6

I:

~l!.
¥!C

Age <1 year

5

J;Adapted from Young KD, Seidel JS: Pediatric cardiopulmonary
AIIII £1/1"8 Med 33: 195-204, 1999.
~;;CPR, Cardiopulmonary resuscitation; VF, ventricular fibrillation:
f~'VT. ventricular tachycardia.

~ifresuscitalion: a collective review,
jff.'

In a secondary cardiac arrest, widespread organ dysfunction occurs not only during the arrest but also during the
period preceding the arrest. Pediatric resuscitation attempts
are often very difficult and prolonged because the precipitating events, such as a prolonged period of hypoxemia,
acidosis, and organ hypoperfusion, must be corrected, and
ongoing secondary organ dysfunction must be reversed.
Secondary cardiac arrest also predisposes patients to severe
or irreversible organ damage, for example, poor neurologic
outcome or multiorgan dysfunction syndrome (MODS).
Respiratory failure is imminent when the respiratory
system is unable to fulfill its role in gas exchange. The
causes of respiratory failure are varied and result from both
intrinsic and extrinsic factors. Any shock state can contribute to insufficient tissue perfusion and cardiovascular
collapse. In contrast, a small segment of the pediatric
population suffers from significant cardiac disease such as
complex congenital heart disease (CHD), posH;ardiac
surgery myocardiaUconduction system dysfunction, myocarditis, and cardiomyopathy.
One of the major features that distinguishes pediatric
patients suffering cardiac arrest from adults is that the
causes in children are di verse. Young and Seidel 4 conducted
a collective review of the current body of knowledge
regarding survival rates and oU!comes in pediatric CPR. The
review encompassed data from 44 studies over 27 years for
a total of 3094 patients. A summary of their findings,
outlined in Table 31-1, reflects the diverse characteristics
regarding pediatric cardiopulmonary arrest. A noteworthy
finding was that patients in respiratory arrest who did
not deteriorate into cardiac arrest had a 75% hospital
discharge rate.
In a series of pediatric CPR cases occurring in the
hospital, LUdwig 3 found that the most common diagnoses of
hospitalized patients requiring resuscitation involved the
respiratory system. Cardiac and central nervous system
abnormalities occurred at relatively the same rates but half
as often as respiratory disorders. Other causes included
gastrointestinal and multisystem disorders. In their experience, 80% of children who arrested followed the pathway of

respiratory distress, respiratory failure, and then cardiac
alTest.
Regardless of the setting, one dramatic finding in
pediatric resuscitation research is that the type of arrest
significantly influences outcome. Although the causes of
pediatric cardiac arrest vary across settings, the outcomes
are equally dismal. The survival rate and long-term neurologic outcome for children who suffer pure respiratory arrest
with timely intervention are dramatically better than those
of secondary cardiac arrest, even when intervention is
rapidly initiated. There was a 25% mortality rate for
children who experienced a respiratory arrest and an 87%
mortality rate when cardiac arrest occurred. 4 An exception to this is the near-drowning patient. Children who
receive rapid early advanced life support have a survival rate
closer to 35%6

RED FLAGS OF IMPENDING
CARDIOPULMONARY ARREST
Nurses, by early recognition of the prearrest state, can
significantly affect patient outcome. This intervention requires expertise in recognizing the red flags of impending
cardiopulmonary alTest. These include clinical signs of
compensation for respiratory distress and cardiovascular
collapse that are present in the clinically unstable pediatric
patient. Many believe that "children deteriorate rapidly,"
but in reality, they are exquisitely capable of compensating
until they can no longer support vital organ function. The
clinical manifestations of compensation are related to failure
of oxygen delivery to end organs, such as the skin, brain,
kidney, and cardiovascular system.
Even if vital signs are within the normal range for the
patient's age, if they are incongruent with the child's clinical
need, they are considered red flags. Faster heart rates can be
expected when, for example, the patient is active, anxious,
anemic, dehydrated, febrile, or in pain. Faster respiratory
rates can be expected, for example, in the active, febrile
child or when there is significant past medical history of
chronic pulmonary disease. Faster heart and respiratory
rates indicate a need for increased cardiac output or minute
ventilation. Rates incongruent with need are considered red
flags.
Manifestations of oxygen deprivation to the skin include
circumoral pallor, mottling, grayish color, cyanosis, diaphoresis, and decreased capillary refill time. Pallor and mottling are earlier indicators of decreased oxygenation and
deteriorate to cyanosis once compensatory reserves are
depleted.
Red flags of respiratory distress are listed in Box 31-1.
Tachypnea, a salient symptom, occurs as the patient
attempts to maintain minute ventilation when tidal volume
is compromised. Retractions become more pronounced
when lung compliance continues to decrease within the
highly compliant chest wall of the pediatric patient.
Airway problems often precipitate pediatric arrests because pathologic processes that cause airway narrowing
exponentially compromise gas flow within the airway.
Patients position themselves to maximize their airway; they
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B.ox 31·1
Respiratory Distress: Red Flags

~

Box 31·2

Cardiovascular Collapse: Red Flags

Early Signs

Early Signs

Tachypnea
Mechanics of breathing
Retractions
Nasal flaring
Head bobbing
Grunting on exhalalion
Air entry: stridor or wheezing
Change in breath sounds
Prolonged inspiratory time-stridor
Prolonged expiratory time-wheezing

Tachycardia
Altered perfusion
Skin
Prolonged capillary refill
Increased core-to-skin temperature gradient
Brain
Altered level of consciousness or activity
Decreased response to parents
"Worried" appearance
Kidneys
Decreased urine output
Decrease in pulse quality

Late Signs

Skin color changes---dusky or cyanotic
Apnea or irregular respirations
Change in level of consciousness or activity
Bradycardia

sit up, lean forward, and extend their neck. Inspiratory
stridor is present with upper airway disease, whereas
wheezing may be heard on auscultation in lower airway
disease. Inspiratory times are prolonged in upper airway
disease; the opposite is true in lower airway disease.
Grunting on expiration occurs as an infant attempts to
maintain functional residual capacity (FRC).
Changes in the patient's level of consciousness or activity
depend 011 the patient's primary alteration in gas exchange.
With hypoxia the patient usually becomes restless, agitated,
and irritable. Hypercapnia usually produces opposite symptoms; the patient usually becomes sonmolent and lethargic,
has decreased muscle tone, loses interest in the environment, or, even more ominous in a toddler, is less reactive to
a parent's departure.
Late signs of respiratory distress often include apnea and
decreasing level of consciousness or activity, followed by
bradycardia. Much energy is expended trying to maintain
oxygenation and ventilation. Infants, especially, tire and
exhibit periods of apnea.
Arterial blood gases (ABGs) that are incongruent with
the patient's clinical presentation serve to quantify the
patient's ominous status. When a patient begins to tire,
Pac02 levels climb despite tachypnea, and Pa02 falls despite
increasing F102. Pulse oximeters have facilitated rapid
detection and intervention during transient periods of
arterial desaturation. The end-tidal CO 2 (ETc02 ) increases
with the Pac02, then precipitously falls as pulmonary
perfusion becomes compromised. 7
Red flags of cardiovascular compromise include tachycardia and alterations in perfusion to the skin, brain, and
kidneys (Box 31-2). Tachycardia, the first sign of a stressed
cardiac state, serves to maintain cardiac output when stroke
volume is compromised by inadequate preload, increased
afterload, or myocardial dysfunction. The smaller the child,
the more reliant on heart rate to maintain cardiac output.
Blood pressure is usually not helpful as an early sign of

Late Signs

Decreased response to pain
Flaccid tone
Hypotension
Bradycardia

deterioration because increased systemic vascular resistance
(SYR) maintains blood pressure when the cardiac output is
decreased.
Hypotension is not evident until approximately 25% of
the intravascular volume is lost. The estimated circulating
blood volume in children represents approximately 8% of
the body weight or 80 mIlkg. For example, a 5-kg infant
may be expected to have a circulating blood volume of
400 ml; 8% of 5 kg is equal to 400 g or ml (l g = I ml). A
25% blood loss in a 5-kg infant is 100 ml.
Early symptoms of low cardiac output are the signs of
increased SVR and are best assessed in end-organ perfusion
of the skin, brain, and kidney. Signs include capillary refill
longer than 2 seconds, a mottled or marbleized skin
appearance, an increased core-to-skin temperature gradient,
an altered level of consciousness, a worried appearance, and
decreased urine output (less than I mIlkg in an infant or
0.5 mllkg in a child older than 2 years).
Infants' temperatures drop, and serum glucose and
calcium levels fall when infants are stressed. Late symptoms
of cardiovascular collapse include decreased response to
pain, flaccid muscle tone, hypotension, and bradycardia.
These symptoms are directly related to progressive intracellular acidosis and hypoxia.
Severe hypoglycemia may also lead to cardiac compromise. The clinical manifestations are similar to cerebral
hypoxia. Hypoglycemia may also lead to secondary failure
of oxygen delivery as a result of hypoperfusion.

STRATEGIES FOR PREVENTION
OF CARDIOPULMONARY ARREST
Although the outcome for pediatric patients who suffer
cardiac arrest is grim, existing research has identified a
number of factors that may improve outcome. These factors
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include prevention, early recognition, and monitoring of
children in distress 8
Prevention of a pulseless state is critical. Early application of both basic and advanced life support to prevent a
pulseless state has been related to improved outcome. 3.4
This intervention is especially critical in the prehospital
phase of care. Pediatric patients are often brought to the
emergency department with minimal treatment in the field. 9
Many emergency medical service (EMS) systems train and
equip their emergency medical technicians (EMTs) primarily to provide adult life support. This leads to prolonged
periods of hypoxia and hypoperfusion in children who are
critically ill during transport. This issue is being addressed
through emergency medical services for children (EMS-C)
programs across the country.IO Advanced training in prehospital critical care should lead to the prevention of a
significant number of cardiopulmonary arrests in children.
Prevention strategies also apply to the emergency department setting. Pediatric resuscitation is challenging for
emergency department staff because of the diverse range in
the age and size of the children who come to the hospital
with impending cardiopulmonary arrest. Lanoix and Golden II recommend enhancing pediatric resuscitation rooms
in emergency departments by color coding all equipment,
displaying a simplified wall chart of pediatric parameters,
and suspending monitoring equipment from the ceiling. A
weight-based quick reference for pediatric emergency
medications and infusion drip rates can be used to expedite
drug administration. A sample is shown in Fig. 31-1.
Implementing any of these recommendations will save time
and anxiety during resuscitation efforts.
The emergency team can also take steps to improve
outcomes of patients who come to the hospital with multiple
trauma. Data have shown that delays in the provision of
definitive care for children who have been critically injured
increase mortality and morbidity rates. 12 Implementation of
a formal pediatric trauma team that can be rapidly mobilized
expedites treatment and facilitates early involvement of the
necessary specialists.
In all settings, the key factor in preventing the deterioration of respiratory failure or shock to cardiopulmonary
arrest is in being prepared. Nurses playa crucial role in this
area. Nurses ensure that the emergency equipment of the
correct size is available and operating, in case it is needed.
This equipment includes a resuscitation bag and mask,
.suction set up with both tonsil tip and endotracheal suction
catheters, laryngoscope handle and blade, a stylet and an
endotracheal tube (EIT) (including one size above and
below). Resuscitation and intubation drugs can also be
prepared in case they are needed.
One major factor influencing outcome in the pediatric
population that has probably received the least amount of
empiric review is the role nurses play in the recognition of
the prearrest state. Nurses playa critical role by recognizing
the red flags of respiratory distress and cardiovascular
compromise that are present in the clinically unstable
pediatric patient. The mark of a true nursing expert is skill
in assessing these red flags, anticipating deterioration in

patient status, and advocating for changes in collaborative
management when early signs of distress are evident.

COLLABORATIVE MANAGEMENT
The alphabetical approach to resuscitation is the same for
all age groups, but pediatric resuscitation requires an
emphasis on support of ventilation, as well as an awareness
of the influence of maturation on respiratory and cardiovascular system performance. The goal is to restore stability
as soon as possible by reestablishing vital organ perfusion
and oxygenation, especially to the brain. Neurologic outcome appears to be directly related to the child's response
to initial resuscitation efforts rather than postresuscitation
interventions.
Very little clinical research on resuscitation of pediatric
patients exists, largely because the overall incidence of
cardiopulmonary arrest in infants and children is low. Much
of the data that guide pediatric practice are derived from
animal models with ventricular fibrillation (VF) that are not
reflective of causes most commonly seen in pediatric
arrests. 13 As new research becomes available, revisions to
the existing standards can be anticipated.

Airway Management and Breathing
Positioning is the first step in airway management. Infants
should be placed in the "sniffing position" by a head
tilt--<:hin lift or jaw-thrust maneuver that brings the angle of
the chin up 90 degrees from the bed (Figs. 31-2 and 31-3).
This maneuver prevents hyperextension of the airway and
allows maximal ventilation. In contrast to the neutral head
position in the infant, a child's head is positioned slightly
farther back. Roth and colleagues 14 found the jaw-thrust
maneuver to be more effective than the head tilt--<:hin lift
maneuver in maintaining an open airway in unconscious
children. If any secretions, blood, or vomitus are noted in
the posterior pharynx when the airway is positioned, they
should be immediately suctioned with a rigid tonsil-tip
suction device to clear the child's airway.
Airway adjuncts may be required to maintain a patent
airway in children who are spontaneously breathing. An
oropharyngeal airway is indicated for unconscious patients
to relieve obstruction from the tongue. It is sized by placing
it next to the patient's face with the flange at the corner of
the mouth and the tip at the angle of the jaw. IS The airway
is placed by using a tongue depressor to displace the tongue
downward. It is then inserted into the mouth following the
natural contour of the tongue.
A nasopharyngeal airway is indicated for conscious
patients with intact gag reflexes. It is also useful in children
with nasopharyngeal edema. The length should approximate
the distance between the nares and the tragus of the ear. Its
diameter should be slightly smaller than that of the nares. It
is inserted by lubricating and gently passing it along the
floor of the nostril into the nasopharynx.
Once a patent airway is established. the spontaneously
breathing patient with compromised ventilation or perfusion
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•• High dose epinephrine (1:1,060), to be used for En route and as second
dose I.V, (First ETTdose in newborns should be a standard dose) . . ..
"Per anesthesia requesta!ull10 cc syringe of the abOve thiopental dilution shall be
~ra~~~pdurip~!Ih ~le.cti~e iptubatiop.

~1ll_::jrr:i::,:;::ri.:'l:l;:11"::"_J~Miili'lllt~illfi:1JIJ

,.,.;..

Mix eo mgs. (1.5 cc's

Fig. 31-1 Pediatric emergency medications reference guide sample: 19 kilograms. (Courtesy Children's
Hospital, CPR Committee, 1999.)
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Fig.31-2 Opening airway with head tilt-chin lift maneuver, One
hand is used to tilt the head, extending the neck, Index finger of
rescuer's other hand lifts the mandible outward by lifting on the
chin, Note that the angle of the chin is 90 degrees from the bed,
Head tilt should not be performed if cervical spine injury is
suspected, (From Textbook of pediatric advanced life support,
Dallas, 1994, American Heart Association,)

Fig. 31-3 Opening airway with jaw-thrust maneuver, Airway is
opened by lifting the angle of the mandible, Rescuer uses two or
three fingers of each hand to lift the jaw while other fingers guide
the jaw upward and outward, (From Textbook of pediatric
advanced life support, Dallas, 1994, American Heart Association,)

requires oxygen to be delivered at the highest possible
concentration, A nonrebreather mask is the preferred method
unless the patient requires assisted ventilation, 16
Patients who are not breathing spontaneously require
manual ventilation with a bag-valve-mask and 100%
oxygen, The mask should be fitled as close as possible to the
size of the child's face, A properly fitted mask provides an
airtight seal and minimizes rebreathing, Effective venti la-

Fig. 31-4 Cricoid pressure (Sellick maneuver), (From Textbook
of pediatric advanced life support, Dallas, 1994, American Heart
Association.)

tion with 100% oxygen should be consistently maintained
because children do not tolerate even short periods of
hypoxia. When pressures greater than 15 cm H2 0 are
necessary to adequately ventilate the patient, the Sellick
maneuver (pressure over the larynx on the anterolateral
surface of the cricoid cartilage) can be used to collapse the
esophagus against the cervical vertebrae (Fig. 31-4), This
maneuver may prevent aspiration in the un intubated patient.
Healthy lungs of infants and children are normally very
compliant and accept large tidal volumes (V T ) at low
pressures. The delivered VT is the amount needed to provide
normal chest excursion, usually 7 to 10 mllkg. Care is taken
because most pediatric resuscitation bags are capable of
delivering volumes in excess of the individual needs of the
patient. Self-inflating bags deliver volume until the pressure
exceeds that of the pop-off valve, which is usually 30 to
35 cm H20. Self-inflating bags only deliver an FI02 of 0.5 to
0.6 unless a gas reservoir is present. In contrast, anesthesia
bags refill with fresh gas, thus delivering an Ft02 of 1.0.
Anesthesia bags are also capable of a wider range of peak
inspiratory pressures (PIPs) and positive end-expiratory
pressure (PEEP) and thus are useful in patients with poor
lung compliance. Use of excessive pressures places the
patient at risk for barotrauma; therefore anesthesia bags
should be operated by experienced personnel, with pressures
monitored and controlled using an attached pressure gauge
and gas escape val ve.
Children have a greater propensity for air swallowing
when distressed. This, along with increased trachealesophageal proximity, places the child at risk for gastric
distension during positive pressure bag-valve-mask ventilation. In addition to the risk of pulmonary aspiration, gastric
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Box 31-3
",'
Steps in Rapid-Sequence Induction Process

Organize equipment and personnel
Administer 100% oxygen
Administer premedications
Administer sedatives and paralytics
Intubate
Confirm endotracheal tube placement

distension elevates the diaphragm, compromISIng lung
expansion and tidal volume. Gastric decompression, using
the largest nasogastric tube that the nares can accommodate
comfortably, should be accomplished early in the resuscitation effort.
Patients requiring assisted ventilation need to be intubated as soon as possible by a provider who is skilled in
pediatric intubation. Early endotracheal intubation is recommended because it secures the airway, facilitates the use
of PEEP, and provides a route for the administration of
select resuscitation drugs when venous access is delayed.
However, for children who require intubation in out-ofhospital settings, effective bag-valve-mask ventilation may
be preferable. Gaushe and colleagues 17 found that scene
time was prolonged and fatal complications more likely
when children were intubated in this setting. They recommended that emergency medical systems should focus
training on providing effective bag-valve-mask ventilation,
along with prompt transport, and defer endotracheal intubation until the patient arrives in the emergency department.
The safest method for intubating when there is risk of
aspiration of gastric contents is by rapid-sequence induction
(RSI). This method is performed following a sequence of
steps involving preparation, preoxygenation, premedication,
sedation, and paralysis. Box 31-3 outlines the steps in the
procedure. Indications for RSI are respiratory arrest, need
for airway control, Glasgow coma scale score of less than 8,
shock, and respiratory failure. The RSI medications are
selected based on the child's hemodynamic status, preexisting conditions, and institution-specific policies. Guidelines
for medication selection in RSI are outlined in Table 31-2.
Once RSI is accomplished, the patient is intubated.
Various methods for determining correct ETT size have
been proposed. Appropriate ETT size often approximates
the diameter of the patient's little, or fifth, finger, but this
method is somewhat inaccurate and does not offer an
opportunity to anticipate equipment needs before a patient's
arrival in the emergency department or critical care unit. The
following formula also accurately predicts correct ETT size:
(Age in years + 16) + 4.
Clearly, the ETT size chosen should be the largest that
adequately ventilates the lungs while filling comfortably
through the glottis and the cricoid cartilage. Smaller sizes
increase airway resistance, result in excessive air leaks, plug
easily with secretions, and by themselves may ultimately
cause respiratory failure. The nurse may anticipate anatomic
variation by choosing three ETT sizes (one larger and one
smaller than the calculated size).
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TABLE 31-2
Gilid~lines for
'Rapid-Sequence Intubation.,
(RSI) Medications.
'

RSI Medication
A. Pentothal
B. Succinylcholine
C. Atropine (under age 7)
A. Lidocaine
B. Pentothal
C. Pancuronium om mg/kg
(defasciculating dose)
followed by succinylcholine
OR: Rocuronium 1.2 mglkg
D. Atropine
A. Ketamine
B. Succinylcholine
C. Atropine
,:"ypotension

A. Midazolam

c~tJntraindications to

A. Pentothal
B. Rocuronium
C. Atropine

~Iisuccinylcholine

'5f (hyperkalemia, renal
"jfdisease, muscular
::,_ disease, bums)
-'l,:

A. Pancuronium
B. Lorazepam
A. Fentanyl
.: unesy Collaborative Practice Group, Emergency Department,

,L.' dren's Hospital, Boston.

Stylets are used to provide rigidity and direct the tip of
the ETT up through the glottic opening. To avoid airway
trauma, caution is taken to ensure that the stylet does not
extend beyond the Murphy's eye or the tip of the ETT
during intubation.
Confirmation of ETT placement is achieved most accurately by exhaled CO 2 detection (Fig. 31-5). Auscultating
breath sounds high along the midaxillary line, the axillas,
and the stomach further confirms ETT placement. Because
of the thin chest wall and subsequent prevalence of referred
breath sounds, slight change in the pitch of the patient's
breath sounds may indicate right mainstem intubation in
infants and children. Right mainstem intubation is a
common problem in the pediatric population because of the
standard length of ETTs and the variation in sizes of
children. Additional clinical indicators of correct ETT
placement include the presence of condensation in the ETT
on expiration and symmetric chest excursion with manual
ventilation. On chest radiographs, the ETT should be 1 to 2
cm above the carina or halfway between the carina and
clavicles. The carina approximates the level of the fourth
rib; therefore the tube should approximate the level of the
third.
In rare instances, alternative methods to establish an
airway may be necessary. Laryngeal mask airways may be
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End-tidal CO 2 monitor and endotracheal tube taping

inserted as an alternative to a tracheal tube. They are
available in sizes to accommodate infants and children.
Surgical airways include cricothyrotomy and tracheostomy.
Because of the close proximity ofthe cricoid cartilage to the
vocal cords, a cricothyrotomy is always considered as a last
resort, especially in children younger than age 12. Emergency tracheostomy is rarely performed.
Once intubated, the ETT is held firmly in place, and
markings on the ETT in relation to the nares or lip line are
noted while the tube is taped in place. The most common
method of securing the ETT involves cutting two pieces of
I-inch tape that are tom in half and spiraling one half of
each piece up the ETT. The other half of each piece is
secured to the upper lip (see Fig. 31-5). The head is
positioned at midline or maintained in a neutral position,
particularly during radiographic determination of placement. Excessive flexion of the patient's neck may force an
uncuffed ETT down onto the carina, and extension of the
neck or rotation of the head may dislodge the ETT
completely.
Continuous assessment of the adequacy of ventilation is
always a priority. The magnitude and duration of hypoxia
sustained during a period of respiratory distress or arrest
adversely affect the myocardium, ultimately influencing
myocardial response to resuscitation if cardiac arrest develops. Spontaneous breaths are supported with humidified
oxygen at an FIO Z of 1.0.
Short-term hyperventilation may be advantageous in the
initial management of hypercapnia, and it provides a
compensatory alkalosis in the patient with metabolic acidosis. However, sustained hyperventilation should be avoided
because it may compromise cerebral blood flow and
promote cerebral anoxia.

Circulation
In case of cardiac arrest, the primary goal in resuscitation is restoration of hemodynamic stability. After stabilization of the airway and establishment of adequate
ventilation, pulses are immediately assessed to determine

the need for cardiac compressions. This section expands
on the traditional concept of circulation to include measures focused to improve tissue perfusion: vascular access
and the administration of intravenous fluids, followed by
resuscitation medications.
Cardiac Compressions. Cardiac compressions are
indicated if pulses are absent or the pulse rate is less than
60/min with inadequate perfusion. Compression rates are
recommended based on studies that have demonstrated a
relationship between the faster rates and higher mean
arterial pressures, cardiac index, and cerebral blood flOW. 18
Many studies are investigating the mechanism of
blood flow and techniques to improve blood flow during
CPR. However, controversy continues regarding the precise
mechanism of blood flow during closed chest cardiac
compression. Recent studies suggest that open cardiac
compression produces better coronary and cerebral perfusion pressures. J9 This technique is most commonly reserved
for resuscitation of trauma patients. Interposed abdominal
compression and active compression-decompression CPR
techniques are currently being evaluated in children. 20
Establishing Vascular Access. Establishing vascular
access to administer fluids and drugs is a priority once
adequate oxygenation, ventilation, and compressions have
been addressed. Obtaining venous access can be difficult
and frustrating in the hemodynamically stable pediatric
patient and worse in a patient in an arrest situation. During
an arrest, the largest and most accessible vein that does not
interrupt resuscitation is the preferred site for vascular
access.
Establishment of percutaneous peripheral access is limited to three attempts or 90 seconds, whichever occurs first.
The team then needs to consider other techniques and routes
of administration. Several methods of venous access are
commonly used in children. The steel needle (butterfly) is
adequate for infants whose condition is stable but is not
recommended during resuscitation because of the risk of
infiltration, especially when administering caustic medications and fluids at high rates. Over-the-needle catheters are
preferred because they can be inserted deep into the vein,
thereby decreasing the risk of infiltration. Larger sizes that
facilitate more rapid infusion rates are recommended.
Central lines provide access for volume replacement,
rapid medication administration close to effector sites, and
central venous pressure (CVP) measurement. Complications
associated with this access option are reported more often in
the pediatric age group. Therefore this procedure should be
delegated to the more experienced provider to limit the
iatrogenic complications of hemorrhage, pneumothorax,
hemothorax, embolism, cardiac injury, or infection. IS
Supradiaphragmatic central lines, the jugular and subclavian veins, are preferred, based on the theory that higher and
more rapid peak serum drug concentrations are produced
when medications are administered via this route than via
more peripheral sites. However, neckline placement often
interferes with the resuscitation attempt, and data are
insufficient to support improved outcomes. Current recommendations still consider long catheters placed above the
diaphragm from the femoral vein to be adequate. IS
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Intramedullary venous system demonstrates position of
intraosseous needle in medullary sinusoids. Blood may be aspirated from sinusoids to confirm position of needle. (From Spivey
WH: Intraosseous infusions, J Pediatr III :639-643, 1987.)

Fig.31-6

The intraosseous route for fluid and drug administration
has regained popularity. An intraosseous infusion is recommended as an alternative means to deliver intravenous fluids
and medications in children when vascular access is
inadequate or unavailable within three attempts or 90
seconds, whichever comes first. 18 The success rate for this
method in older children is lower; however, it is a
reasonable alternative. zoa lntraosseous infusion is accomplished by insertion of a bone marrow needle with stylet into
the medullary cavity in a direction away from the epiphyseal
plate (Fig. 31-6). The preferred site is the broad flat portion
of the anteromedial surface of the tibia approximately I to
2 cm below the tibial tuberosity or above the femur's
external condyles (Fig. 31-7). Successful insertion is demonstrated by (I) loss of resistance from the bony cortex,
(2) aspiration of bone marrow, and (3) free flow of fluid
without extravasation. The intraosseous route is acceptable
for volume expansion with blood, plasma, colloids, or
crystalloid. Average gravity flow rates of 100 ml/hr can be
accomplished in the infant, whereas much higher flow rates
have been reported when a pressure infuser is used. Drug
levels achieved via the intraosseous route are similar to the
peripheral venous route.
Complications associated with intraosseous infusion are
rare. These complications may be prevented by limiting the
amount of time they are in place and by avoiding the use of
hypertonic solutions. The only absolute contraindication for
the use of intraosseous access is placement within a recently
fractured bone.
Fluid Resuscitation. Most children suffering cardiopulmonary arrest require volume restoration or expansion
because of excessive losses, venous pooling, vasodilation,
and capillary leaking. Often, because of hesitancy in
administering large volumes of fluid rapidly to small
children, too little fluid is administered too late.
Volume restoration precedes the use of vasoactive drugs
in resuscitation. The amount of volume administered
depends on the extent of fluid deficit based on an estimate of

Fig. 31-7 Recommended sites for intraosseous infusion. (From
Manley L, Haley K, Dick M: Intraosseous infusion: rapid vascular
access for critically ill or injured infants and children, J Emerg
Nurs 14:63-68, 1988.)

volume lost and presence of ongoing losses. It is not
uncommon for children to require large amounts of fluid for
resuscitation 21 Several 20 ml/kg fluid boluses are required
before any improvement in the patient's clinical response is
appreciated. Controversy surrounds the type of fluid that
should be administered during a resuscitation attempt.
Colloids and synthetic colloids, such as 5% albumin and
hetastarch, are true volume expanders and generally remain
within an intact vascular space after administration. Colloids
are not used in patients with capillary leak syndrome (e.g.,
those patients with trauma, sepsis, or burns) because of
the high associated risk of respiratory distress syndrome.
Approximately 20% to 25% of isotonic crystalloids, such as
normal saline and Ringer's lactate, leak from the intravascular space shortly after administration; therefore volume
replacement with crystalloid may require 20% to 25% more
than the estimated loss. The advantage of using crystalloids
is that they are relatively inexpensive and readily available.
The routine use of large volumes of high dextrosecontaining fluids during fluid resuscitation for hypovolemic
shock is avoided. This may result in significant hyperglycemia with resultant osmotic diuresis.
When hemorrhage occurs, the volume of red blood cell
administration can be approximated by multiplying 4 mt/kg
by the difference, in grams, between actual and desired
hemoglobin. In cases in which the hemoglobin is unknown,

1034

Part V Multisystem Problems

TABlE 31-3 Physiologic Approach
to Resuscitation,' .
',: Airway
": 'Breathing (oxygenation + ventilation)
, ~,:, Circulation (perfusion)
Asystole
Bradycardia

AV block

PVCs

Ventricular
tachycardia

Ventricular
fibrillation

Oxygen
Epinephrine (bolus
and infusion)
Atropine
Oxygen
Atropine or
isoproterenol
Epinephrine infusion
Pacemaker
Oxygen
Lidocaine
Procainamide
Oxygen
Cardioversion at
0.5·1 J/kg
Amiodarone
Lidocaine
Magnesium
Oxygen
Shocks at 2 J/kg
May repeat doub·
ling joules
Consider: epinephrine
Amiodarone
Lidocaine
Magnesium

Volume restoration
Decrease excessive intrathoracic pressure
Relieve cardiac tamponade
Correct asynchronous cardiac rhythms
Correct hypoxemia, acidosis, hypothermia
Question congenital outflow obstruction
Treat sepsis, drug overdose, anaphylaxis
Consider vasodilators if CHF is present
Correct hypoxemia, hypoglycemia, K+
and Ca+
Correct acidosis: ventilation (NaHC0 3 )
Positive inotropic agents: epinephrine,
dobutamine, dopamine, amrinone
Primary management includes correction
of hypoxemia, acidosis, hypoglycemia,
potassium and calcium imbalance,
hypothermia, vagal stimulation, and drug
toxicity

".V, Atrioventricular; CHF, congestive heart failure;

PVCs. premature

. ntricular contractions.

10 mlIkg of packed red blood cells or 20 mllkg of whole
blood is administered to restore blood volume.
Resuscitation Medications. Patients with persistent
hypotension and poor perfusion following aggressive fluid
resuscitation may require catecholamine support to restore
effective cardiac output. Table 31-3 outlines a physiologic

approach to resuscitation that helps to organize intervention
priorities. Drugs, compared with airway and breathing, are
often less essential in resuscitation of infants and children.
Correction of hypoxemia and acidosis and the restoration of
tissue perfusion are primary goals. However, the child's
response to resuscitation efforts is poor in the face of
uncorrected imbalances, such as pH, glucose, potassium,
and calcium. Hypothermia further contributes to metabolic
acidosis, which renders the myocardium refractory to
electrical and pharmacologic intervention. Vagal stimulation
may result in refractory bradydysrhythmias. In addition,
toxic ingestions may compromise respiratory and cardiac
function, requiring immediate intervention. Successful resuscitation depends on correction of such factors, with
interventions beyond restoring adequate ventilation.
A great deal of individual physiologic variation, depending on system maturity, is present in the pediatric population. Children and adolescents are able to maintain cardiac
output when heart rate decreases by increasing stroke
volume. However, sick infants have relatively fixed stroke
volumes, so cardiac output depends primarily on heart rate
and rhythm. A relatively fixed stroke volume, characteristic
of the infant for the first 6 to 12 months of life, is the result
of limited ventricular compliance and contractility. Both
are less than in the mature heart because of the greater
proportion of noncontractile myocardial tissue relative to
contractile myocardial mass?2 In addition, increased interventricular interaction is especially evident in the small
infant; that is, the degree of filling of one chamber affects
the degree of filling of another22 Therefore if a large volume
of fluid loads the right ventricle or if pulmonary hypertension is present, the interventricular septum will bulge toward
the left and compromise left ventricular filling. Knowledge
that infants lack myocardial function sufficient to respond
to volume loading or overcome excessive afterload is
important.
Sympathetic nervous system immaturity is another factor
that requires consideration in seriously ill infants. Sympathetic innervation of the myocardium is incomplete at birth;
therefore infants are less responsive to endogenous and
exogenous stimulation of the sympathetic nervous system. 23
As a result, the use of catecholamines in infant resuscitation
does not reliably produce the same effect as in the older
child. Moreover, predicting the cardiovascular effect of any
dose of any agent is difficult. Infants may require higher
doses per kilogram of infused catecholamines, but their use
requires continuous monitoring and titration of individual
hemodynamic affects. Because of sympathetic immaturity,
infants are more sensitive to parasympathetic stimulation
and experience more vagal-induced bradydysrhythmias than
older children.
In summary, determination of how best to individualize
the use of catecholamines to improve cardiac output is based
on the maturity of the patient. Receptor density and
responsiveness, ventricular compliance, and stroke volume
all improve with age.
The primary resuscitation drugs used in pediatric advanced life support are outlined in Table 31-4. All dosages
are based on kilograms of body weight. It is important to
closely estimate body weight using a reference chart or a
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31-4 Primary Pediatric
Resuscitation Drugs

TABLE

Dose

,':
1

',,,' agnesium

...:.~-

Nursing
Implications

(VIlO: O.Olmg/kg
(1: 10,000)
ET: 0.1 mg/kg
(1:1 ,000)
Repeat doses: 0.1
mg/kg (l: I 000)

Instill 2-3 ml
normal saline
following ET
administration

0.02 mg/kg
(min 0.1 mg)

Masks hypoxia
induced bradycardia: morutor
O 2 saturation
Causes pupillary
dilation

I mEq/kg

Flush with normal
saline before
and after administration

20 mg/kg

Administer slowly

<20 kg: 0.1 mg/kg
>20 kg: 2 mg

Short duration may
result in return
of symptoms

0.1-0.2 mg/kg
(max 12 mg)

Give rapid IV push
Follow with immediate normal
saline flush
May cause transient bradycardia

5 mg/kg
Repeat dose: 5 mg/kg
Max: 15 mg/kg/day

Monitor for hypotension

I mg/kg

Give rapid bolus

25-50 mg/kg
Max' 2 g

Use for presence
of torsades
de pomtes

Broselow tape. The Broselow method bases dosages on
patients' length. The tape is placed along the patient's side,
and the appropriate drug dosages for the patient are
preprinted on it. Suggested emergency cart medications are
found in Appendix IV.
Epinephrine. During an asystolic arrest, the initial
beneficial effect of any catecholamine is mediated through
its alpha effect. 18 Epinephrine is the catecholamine of
choice during resuscitation because it is direct acting and
provides a perfect balance of alpha and beta stimulation.
Alpha stimulation causes peripheral vasoconstriction that
improves myocardial perfusion pressure generated during
closed chest compressions, thus enhancing oxygen delivery
to the heart. Epinephrine dramatically increases myocardial
blood flow, cerebral blood flow, and subsequent cerebral
oxygen uptake. Its effect redistributes carotid blood flow to
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the cerebral circulation and coronary blood flow to the
myocardium, which then stimulates spontaneous cardiac
contractions. Restoration of coronary artery perfusion pressures is essential for the return of spontaneous circulation.
This effect is critical in infants and children because most
arrest rhythms are unstable slow rhythms not related to heart
block.
Guidelines for administering an epinephrine infusion are
outlined in Chapter 27. Side effects of a peripheral
epinephrine infusion include compromised skin and extremity blood flow.
Atropine. Atropine, a parasympathetic nervous system blocker, produces both positive chronotropic and
dromotropic effects. It is indicated for slow arrest-related
rhythms, that is, bradycardia and atrioventricular blocks
resulting from structural heart disease. 18
Slow rhythms during resuscitation most often occur as a
result of hypoxemia. As a consequence, atropine is unlikely
to be efficacious in this situation. Atropine also blocks
hypoxemia-induced bradycardia. Therefore careful monitoring of oxygen saturation through pulse oximetry is indicated, and prolonged attempts at intubation are avoided.
Inadequate atropine doses stimulate vagal nuclei and
produce paradoxical bradycardia. This affect is avoided by
using the full vagolytic dose.
Sodium Bicarbonate. During an arrest, poor ventilation and low-flow states produce mixed respiratory and
metabolic acidosis. Inadequate tissue perfusion results in
anaerobic metabolism and subsequent lactic acid production. In addition, the circulation of poorly oxygenated blood
further contributes to tissue hypoxia and subsequent ischemia. The priority in managing acidosis is restoration of
ventilation and tissue perfusion. An in-depth discussion of
acid-base imbalance is included in Chapter 9.
Sodium bicarbonate (NaHC0 3 ) serves as a buffer by
combining with the hydrogen ion (H+) to form carbonic acid
(H 2 C0 3 ), then CO 2 and H2 0. It is not a first-line drug in
resuscitation. It is indicated when severe acidosis is
documented related to prolonged cardiopulmonary arrest. It
is also indicated for treatment of hyperkalemia and tricyclic
antidepressant overdose.
Because CO 2 crosses the blood-brain barrier and cell
membranes more rapidly than HC0 3 , transient increa~es in
CO 2 produced by NaHC0 3 administration can paradoxically worsen cerebrospinal fluid and inrracellular acidosis.
In hypoxic states, NaHC0 3 administration decreases myocardial contractility, cardiac index, and blood pressure and
may worsen electromechanical dissociation. Because respiratory failure is often the precipitating event in cardiopulmonary arrest among infants and children, this population is
at greater risk of severe intracellular acidosis because of
impaired CO2 elimination.
Many other physiologic disturbances occur with excessive NaHC0 3 adminisrration. Potassium shifts into the
intracellular space; a 0.1 rise in pH typically results in a 0.5
mEqlL decrease in serum potassium. Hypernatremia and
hypocalcemia result. Hyperosmolar states may also result
from increased serum sodium produced by NaHC0 3 administration. The intravascular shift of free water that results
from hyperosmolarity may be lethal because it has been
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implicated in intracranial hemorrhage in infants. To prevent
this, NaHC0 3 is diluted I: I with sterile water in infants
younger than 3 months unless 4.2% infant NaHC0 3 is
available (0.5 mEq/ml). NaHCO) is not recommended until
the patient has been adequately oxygenated and ventilated,
CPR has been initiated, epinephrine has been administered
without success, and a venous pH of 7.0 or less or an arterial
pH of 7.2 or less has been documented. 18
Calcium. Calcium increases myocardial contractility,
increases ventricular excitability, and increases conduction
velocity through the ventricles. It is indicated in the
management of documented total or ionized hypocalcemia
(commonly seen in stressed infants) and in the management
of the adverse cardiac effects associated with hyperkalemia,
hypermagnesemia, and calcium channel blocker overdose. It
may also be indicated for children who have received blood
with citrate-phosphate-dextran used as a preservati ve.
Glucose. Glucose is indicated to treat documented
hypoglycemia. Infants have limited glycogen reserves and
when stressed, particularly in the presence of sepsis,
experience acute marked hypoglycemia. Hypoglycemia
depresses cardiac contractility and may precipitate seizure
activity. Symptoms of hypoglycemia, which include decreased perfusion, diaphoresis, tachycardia, and hypotension, mimic those of hypoxemia.
Conversely, some evidence shows that hyperglycemia
worsens neurologic outcome. 24 Rapid-response blood glucose screening methods should be used to guide administration of glucose.
Naloxone. Naloxone is an opiate antagonist that
reverses the effects of narcotics, such as respiratory
depression and hypoperfusion. It is indicated when narcotic
overdose is suspected to be the cause of cardiopulmonary
arrest. It is rapid acting and has a short half-life. For cases
in which complete reversal is not desired, such as with
patients on morphine drips, naloxone may be titrated to the
desired effect.
Adenosine. Adenosine is an endogenous purine nucleoside. It exerts a strong depressant effect on the sinus and
atrioventricular (AV) nodes. It slows conduction through the
AV node and causes interruption of the reentry pathway. It
is indicated for the treatment of supraventricular tachycardia
(SVT). If the cause of the tachyarrhythmia is not a reentry
mechanism, adenosine will not terminate it but may assist
with identifying the underlying rhythm by producing a
transient AV blockade. The half-life of adenosine is less than
10 seconds with duration of less than 2 minutes.
Amiodarone. Amiodarone is a lipid-soluble antiarrhythmic that may be used for atrial and ventricular
arrhythmias. It produces vasodilatation and AV nodal
suppression. It also inhibits the outward potassium current,
which prolongs the QT interval. Amiodarone also inhibits
sodium channels, which slows ventricular conduction. Its
most acute side effect is hypotension. It is a highly complex
pharmacologic agent with potential for long-term complications. Its long-term use should be directed by an expert
such as a pediatric cardiologist.
Lidocaine. Lidocaine increases the fibrillation threshold by reducing the automaticity of ventricular pacemakers.
It is indicated for ventricular fibrillation and ventricular

tachycardia, which are rare events in children. Once the
bolus doses of lidocaine have been effective, a lidocaine
infusion is initiated. Guidelines for administration of a
lidocaine drip are outlined in Chapter 27.
Lidocaine is metabolized by the liver. Therefore its dose
is modified for children with inadequate liver function or
decreased perfusion to the liver. Symptoms of lidocaine
toxicity that initially appear are alterations in the central
nervous system such as nausea, decreased mental status, and
seizures. Depression of cardiac function may occur later as
a result of toxicity.
Magnesium. Magnesium is a major intracellular cation. It inhibits calcium channels and causes smooth muscle
relaxation. It is used in the treatment of torsades de pointes
or documented hypomagnesemia.
Routes of Drug Administration. Routes of drug
administration for resuscitation include central venous,
endotracheal, intraosseous, and intracardiac. Ideally, resuscitation drugs are administered close to adrenergic receptor
sites located on the arterial side of the circulation. To ensure
that a bolus medication is delivered into the central
circulation rapidly, each medication is followed with a rapid
2- to 5-ml normal saline flush. Continuous infusions of
vasoactive medications can be initiated at 5 to 10 times the
usual rate while heart rate and blood pressure are continuously monitored. When the desired effect is evident, the
infusion rate is decreased. Another option is to administer
the continuous infusion through a Y connector with a
faster running intravenous line. Care is taken when titrating
either line.
The intraosseous route is acceptable when venous access
is delayed. The intraosseous route, considered similar to a
peripheral venous route, is acceptable for all resuscitation
drugs.
Although data in humans are limited, several resuscitation drugs defined by the acronym LEAN (lidocaine,
epinephrine, atropine, and naloxone) may be administered
by the tracheal route if intravenous access is unavailable.
These drugs are rapidly absorbed when given by the tracheal
route, having a direct cardiac effect. Ten times the standard
intravenous dose is recommended via the tracheal route
(i.e., 0.1 mg/kg of the I: 1000 solution).18 Both epinephrine and atropine have a prolonged effect after tracheal
administration; thus less frequent administration may be
required.
All tracheal drugs should be diluted with 2 to 3 ml of
normal saline and injected deeply into the tracheobronchial
tree using a needleless syringe and attached suction catheter
or feeding tube. Injection is accomplished after passive
exhalation, and a resuscitation bag is used to distribute the
drug throughout the lung periphery. Sterile normal saline is
the only diluent recommended for this procedure, in
volumes not to exceed 5 ml in infants or 10 ml in
adolescents.
The intracardiac route for drug administration is a last
resort, primarily because the procedure interrupts cardiopulmonary resuscitation. Other iatrogenic complications include cardiac tamponade, pneumothorax, and coronary
artery laceration. If a drug is inadvertently injected into the
myocardium, it may cause intractable VP.
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Slow Rhythms. Slow rhythms are the most common
arrest-related rhythm disturbance in infants and children.
Because of heart rate dependency, the hemodynamic effect
of bradydysrhythmias may be significant in an infant or
child. Slow arrest-related dysrhythmias are related to either
hypoxic-ischemic insults or structural heart disease. 18 Occasionally, primary bradycardic arrests occur in children
with congenital complete heart block or in an infant
during procedures that cause vagal stimulation (e.g., oralpharyngeal stimulation or a Valsalva maneuver related to
painful procedures).
Slow rhythms associated with hypoxic-ischemic insults
are often wide QRS complex without P waves. Slow
rhythms associated with structural heart disease are often
related to heart block or sinus node dysfunction. Priorities
for managing bradydysrhythmias start with the resuscitation ABCs (airway, breathing, and circulation) and then
progress if severe cardiopulmonary compromise is present
(Fig. 31-8).

Cardiac Dysrhythmia Management. During cardiopulmonary arrest in infants and children, hypoxic and
acidotic blood circulates through nonnal coronary arteries
under extremely low perfusion pressure. As a consequence,
the majority of pediatric cardiopulmonary arrest-related
dysrhythmias occur as a result of metabolic dysfunction and
not from coronary artery disease. Therefore the emphasis in
pediatric resuscitation is on reestablishing adequate oxygenation, ventilation, and tissue perfusion, not on complex
rhythm analysis and its drug management.
Unstable rhythms that require treatment are those that
compromise cardiac output and those that have the potential
to deteriorate into a lethal rhythm. Extremes in heart rate are
of no concern unless the effecti ve cardiac output does not
match the patient's clinical need. The clinical assessment
parameters of blood pressure, heart rate, and end-organ
perfusion (specifically to the brain, skin, and kidneys)
provide rapid measures of the adequacy of cardiac output
and effectiveness of intervention strategies.

-BLS Algorithm: assess and support ABCs
as needed
- Provide oxygen
-Attach monitor/defibrillator

!
No

-Observe
-Support ABCs
- Consider transfer or
transport to ALS
facility

Is bradycardia causing severe cardiorespiratory compromise?
(poor perfusion, hypotension, respiratory
diffiCUlty, altered consciousness)

During CPR
Attempt/verify

-Tracheal intubation and vascular
access

Yes

Perform chest compression
if despite oxygenation and
ventilation:
-Heart rate <60/min in infant
or child and poor systemic
perfusion

Check

• Electrode position and contact
• Paddle position and contact
- Pacer position and contact
Give

• Epinephrine every 3 to 5 minutes
and consider alternative medications:
epinephrine and dopamine infusions
Identify and treat possible causes

• Hypoxemia
• Hypothermia
• Head injury
• Heart block
• Heart transplant
(special situation)
•Toxins/poisons/drugs

Epinephrine'
-IV/lO: 0.01 mg/kg
(1:10,000; 0.1 mUkg)
•Tracheal tube: 0.1 mglkg
(1:1000; 0.1 mUkg)

- May repeat every
3 to 5 minutes
at the same dose
Atropine' 0.02 mg/kg
(minimum dose: 0.1 mg)

- May be repeated once

Consider cardiac pacing
'Give a tropine first for bradycardia due to suspected
increased vagal tone or primary AV block.
Fig.31-8

I

~

Ilf pulseless arrest develops, see

PALS bradycardia algorithm. ABCs, airway, breathing, circulation: ALS, advanced life support;

IV, intravenous. (From American Heart Association: Guidelines 2000 for cardiovascular care, Circulation

2000, 102(suppl):129 1-1342, 2000.)

)1

Pulseless Arrest Algorithm (Fig. 31-10)
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In an arrest, cardiac pacing may be helpful in managing patients with slow rhythms resulting from structural
heart disease. Pacing can be accomplished by external
(transcutaneous), transvenous, or epicardial electrodes. Pacing in the hypoxic-ischemic cardiac arrest patient is rarely
successful. Even if ventricular capture is accomplished,
pacing does not improve myocardial contractility and tissue
perfusion.
Fast Rhythms. Fast rhythms are expected in critically
ill pediatric patients. Unstable fast rhythms fall into two
main categories: those with narrow QRS complexes and
those with wide QRS complexes. The differential for narrow
fast rhythms include sinus tachycardia (ST), supraventricular tachycardia (SVT), atrial flutter (AF), or atrial fibrillation
(At). One can easily mistake a rapid ST for SVT. Key
diagnostic features of ST include rhythm variability and a
heart rate that is congruent with the patient's need for
increased cardiac output. Key diagnostic features of SVT
include a monotonous rhythm and a heart rate in excess
of the patient's clinical need. ST is a symptom reflecting the patient's need for increased cardiac output, whereas
unstable SVT is a primary cardiac rhythm disturbance
requiring primary intervention. AF and Af are rare cardiac rhythms in groups other than pediatric patients with
complex CHD.
The differential for wide-complex fast rhythms is aberrantly conducted SVT or VT. Distinguishing between the
two may be impossible in a patient whose condition is
unstable. Because wide-complex SVT is extremely rare in
the pediatric age group, all wide-complex fast rhythms are
considered to be VT until proven otherwise.
Pediatric groups at risk for ventricular tachydysrhythmia
as a terminal rhythm include children requiring prolonged
resuscitation, infants beyond the neonatal period, older
children, and children with CHD. A critical cardiac mass
along with sympathetic maturity characteristic of infants
beyond 6 to 12 months of age is thought to be necessary for
ventricular tachydysrhythmias to occur. During prolonged
resuscitation attempts, many doses of catecholamines,
which stimulate the sympathetic nervous system, are often
administered. Children with CHD who have arrests more
often exhibit bradycardia but are 3 times more likely than
those without CHD to exhibit ventricular tachydysrhythmias. Supporting the critical mass theory, many children
with CHD usually have cardiac enlargement. Metabolic
causes of ventricular dysrhythmias include hyperkalemia,
hypoglycemia, hypothermia, and tricyclic antidepressant
overdose.
Treatment of all unstable fast rhythms includes synchronized cardioversion at 0.5 J/kg (Fig. 31-9). If unsuccessful,
the joules are doubled, and cardioversion is repeated.
In VT, lidocaine administration before cardioversion
may result in a higher conversion rate. Lidocaine is
administered in a dose of I mg/kg every 10 to 15 minutes. A continuous lidocaine infusion of 20 to 50 Ilg/kg/min
is useful after conversion to normal sinus rhythm (NSR)
if the patient has structural heart disease, has multiple
premature ventricular contractions (PVC), or recurrent
VT or VE

Absent (Collapse) Rhythms. Absent (collapse)
rhythms include asystole, VF, and pulseless electrical
activity (PEA). These rhythms are considered hemodynamically significant because all three fail to produce cardiac
output.
Asystole, like bradycardia, is a common pediatric arrest
rhythm. The management goal is to improve oxygenation
and perfusion (Fig. 31-10).
VF and pulseless VT, which are managed in a similar
manner, are uncommon pediatric rhythms. The overall
frequency of VF and VT is 10%.4 Immediate shocks at 2
J/kg is the most important determinant of successful
conversion to NSR. The pulse and cardiac rhythm are
reevaluated after each shock attempt. If unsuccessful, the
joules are doubled, and the patient is defibrillated twice in
rapid succession. With the advent of automated external
defibrillators (AED), shocks in the field are more readily
available. AEDs are recommended for use in children older
than 8 years old. Their use in the field has shown to be as
effective for children as for adults 25
Epinephrine may improve coronary artery perfusion
pressure, increasing the effectiveness of shocks. The epinephrine dose is increased after the first dose as for asystole
and repeated every 3 to 5 minutes. Lidocaine may be used
to increase the fibrillation threshold but should not delay
defibrillation. Metabolic problems, such as calcium, potassium, magnesium, or glucose imbalance, and hypothermia
or drug intoxication (e.g., with digitalis or tricyclic antidepressants), are continually reassessed and corrected. If VF
reoccurs, the previous successful energy level for shocks
are used.
Amiodarone is the next medication of choice for
treating VF. Lidocaine may be used as an alternative.
Magnesium is indicated for VF with a torsades de pointes
pattern.
PEA is characteristic of organized cardiac electrical
activity without effective cardiac output. PEA is usually a
slow Wide-complex rhythm, for example, junctional or
idioventricular rhythm. When PEA is caused by hypovolemia, tension pneumothorax, or pericardial tamponade, a
narrow-complex, rapid heart rate may be seen. Causes also
include hypoxia and acidosis.

Evaluation of Interventions
Patients require thorough and frequent reassessment of
their airway, breathing, and circulation throughout the
resuscitation process. Initial improvement in a patient's
condition may not be sustained because of underlying causes. The child's response to the interventions
must be closely monitored. Reestablishment of end-organ
perfusion is a positive indicator of successful patient
outcome.
If the patient does not respond despite aggressive
efforts to resuscitate, a decision to terminate the resuscitation must be made. This is a very difficult decision and
is most often made collaboratively by the resuscitation
team. Several laboratory and clinical findings influence the
decision to terminate resuscitation efforts. These include
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10BLS Algorithm: assess, support ABCs

I oInitiate CPR

I

oSee pulseless arrest algorithm

I

to Pulse present?
No

I

Yes
1

0Provide oxygen and ventilation as needed
oAttach monitorldefibrillator

QRS duration normal for age
(approximately ';;0.08 sec)

I 012-lead ECG if practical
0Evaluate QRS duration

I

QRS duration wide for age
(approximately >0.08 sec)

OurIng evaluation
I Evaluate the tachycardia l - oProvide
oxygen and ventilation as needed

H

Evaluate for tachycardia

r--

oSupport ABCs
oConfirm continuous monitorlpacer attached
oConsider expert consultation
oPrepare for cardioversion (consider sedation)

Identify and treat possible causes
oHypoxemia
oHypovolemia
oHyperthermia
oHyper-Ihypokalemia and metabolic disorders
oTamponade
oTension pneumothorax
oToxins/poisons/drugs
oThromboembolism
opain

1
Probable sinus tachycardia
oHistory compatible
oP waves presenVnormal
oHR often varies with activity
oVariable RR with constant PR
olnfants: rate usually <220 bpm
°Children: rate usually < 180 bpm

Probable supraventricular tachycardia
oHistory incompatible
op waves absenVabnormal
oHR not variable with activity
oAbrupt rate changes
°lnfants: rate usually >220 bpm
°Children: rate usually >180 bpm

Probable ventricular tachycardia
olmmediate cardioversion
0.5 to 1.0 Jlkg
(consider sedation, do not delay
cardioversion)

IConsider vagal maneuvers I
(no delays)

I

Immediate cardloversion
oAttempt cardioversion with 0.5 to 1.0 Jlkg (may increase to
2 Jlkg if initial dose is ineffective)
oUse sedation if possible
oSedation must not delay cardioversion
or
Immediate IVIlO adenosine
oAdenosine: use if IV access is immediafely available
oOose: Adenosine 0.1 mglkg IVIIO (maximum first dose: 6 mg)
oMay double and repeat dose once (maximum second
dose: 12 mg)
oTechnique: use rapid bolus technique

-

Consider alternative medications
oAmiodarone 5 mglkg IV over
20 to 60 minutes
or
oProcainamide 15 mglkg IV over
30 to 60 minutes
(Do not routinely administer
amiodarone and procainamide
together)
or
oLidocaine 1 mglkg IV bolus
(wide-complex only)
oConsult pediatric cardiologist
012-lead ECG

fig.31-9 Algorithm for pediatric tachycardia with poor perfusion. CPR, Cardiopulmonary resuscitation;
NS, nonnal saline; ECG, electrocardiogram; IV, intravenous. (From American Heart Association:
Guidelines 2000 for cardiovascular care, Circulation 2000, I 02(suppl):I29 1-1342, 2000.)
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-BLS Algorithm: assess and support ABCs
as needed
- Provide oxygen
-Attach monitor/defibrillator

-----11 Assess rhythm (ECG)

,..-

NotVFNT
(Includes PEA and asystole)

VFNT

Attempt defibrillation
- Up to 3 times if needed
-Initially 2 J/kg, 2 to 4 J/kg,
4 J/kg'

)f-----------------------,

During CPR
ANemptlverify
-Tracheal intubation and vascular
access
Check
- Electrode position and contact
- Paddle position and contact

Epinephrine
Give
-IV/IO: 0.01 mglkg
-Epinephrine every 3 to 5 minutes
1-----+-1 (
'd h' h d
f
d
(1:10,000; 0.1 mUkg)
_Tracheal tube: 0.1 mglkg
conSI er Ig er oses or secon
(1:1000; 0.1 mUkg)
and subsequent doses)

Attempt defibrillation
with 4 Jlkg* within 30 to
60 seconds after each
medication
* Pattern should be CPRdrug-shock (repeat) or
CPR-drug-shock-shockshock (repeat)

Antiarrhythmic
- Amiodarone: 5 mg/kg
bolus IVIIO
or
- Lidocaine: 1 mg/kg bolus
or
IV/IO/PT
- Magnesium: 25 to 50 mg/kg
IV110 for torsades de pointes
or hypomagnesemia
(maximum: 2 g)

-

Attempt defibrillation
with 4 Jlkg* within 30 to
60 seconds after each
medication
-Pattern should be CPRdrug-shock (repeat) or
CPR-drug-shock·shockshock (repeat)

Epinephrine
-IV/IO: 0.01 mg/kg
(1:10,000; 0.1 mUkg)
-Tracheal tube: 0.1 mglkg
(1 :1,000; 0.1 mUkg)

Consider alternative medications
- Vasopressors
_Antiarrhythmics (see box at left)
_Buffers
Identify and treat causes
-Hypoxemia
- Hypovolemia
- Hypothermia
- Hyper-/hypokalemia and
metabolic disorders
-Tamponade
-Tension pneumothorax
- Toxinslpoisonsld rugs
- Thromboembolism

, - Continue CPR
up to 3 minutes

I

,Alternative waveforms and higher doses are
I Class indeterminate for children.

Fig.31-10 Algorithm for asystole and pulseless arrest. CPR, Cardiopulmonary resuscitation; IV, intravenous; 10, intraosseous. (From American Heart Association: /999 Handbook of emergency cardiovascular care for healthcare providers, Dallas, 1999, AHA.)
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prolonged acidosis, iatrogenic causes of arrest, and the
absence of spontaneous circulation after 30 minutes of
resuscitation. 26

Diagnostic Studies
For patients who are responsive to resuscitation interventions, a variety of laboratory and radiologic studies are
indicated during and following successful resuscitation
depending on the child's underlying diagnosis. Laboratory
studies may include a complete blood count, serum glucose,
electrolytes, blood culture, blood typing, and arterial or
venous blood gases. Other laboratory studies commonly
completed are urinalysis, urine culture, and cerebrospinal
fluid analysis.
The most common radiographic study indicated is a chest
radiograph to identify any cardiac or pulmonary problems,
as well as to identify ETT placement. Other radiographs,
computed tomography (CT), and magnetic resonance imaging (MRI) may be indicated to identify any other injuries or
pathologic processes that may be suspected.

Family Care
Throughout the crisis of resuscitation, parents require
information and support. Information is best provided
according to the individual needs of the parents. For
example, some parents may want updates every 5 minutes, whereas others may want to know only the outcome
when resuscitation attempts are over. A critical nursing
intervention is to keep families accurately informed and
assured that everything possible is being done to assist their
child.
Providing parents with a pri vate place is essential, both
for them and for parents of other critically ill children. A
member of the team who has an established relationship
with the parents, such as the nurse, member of the clergy, or
social worker, ideally stays with the parents, especially if
they are alone.
Whether stabilization occurs or attempts to resuscitate
are unsuccessful, parents should be given options to see,
touch. or hold their child as soon as possible. Some parents
may wish to remain at their child's bedside during the
resuscitation attempt. Although this may seem difficult for
caregivers, each family is assessed individually. Elements of
protocols for parental presence may include educating staff
in resuscitation methods and in providing options for
parents, especially parents of children whose conditions
have been deteriorating over time and in whom CPR can be
expected. When death is imminent, the child is allowed to
die in the presence or in the arms of parents.
A movement is underway fostering parental presence
during resuscitation because of nursing's moral imperative
to preserve the wholeness, integrity, and dignity of the
family unit. 27 The Emergency Nurses Association position
statement supports this philosophy?8 It seems reasonable to
initiate flexible programs to facilitate parental presence
during pediatric CPR, especially with parents of chronically
critically ill patients.
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Documentation
Ongoing documentation of resuscitation events is crucial.
Accuracy is enhanced if the person responsible for documentation has no other role in the resuscitation attempt and
is positioned in close proximity to the code leader and
patient. Fig. 31-11 illustrates an example of a resuscitation
flow sheet that facilitates documentation. Effective resuscitation flow records provide precise information about code
events, include the patient's response to therapy, and
minimize the time required for documentation during and
after the code.
Postresuscitation documentation has a summary statement that includes the time and duration of the arrest, ETT
size and markings compared with the lip or nares line,
catheter sizes and length of insertion, all intravenous fluid
administered, blood work and blood loss, drugs and dosages
administered, and the patient's and family's response to
therapy.

POSTRESUSCITAliON MANAGEMENT
Patient care goals after cardiopulmonary resuscitation include further stabilization of oxygenation, ventilation,
cardiac output, and tissue perfusion. These goals are vital for
neurologic preservation. Two major concerns include the
potential of iatrogenic trauma from the resuscitation attempt
and multisystem dysfunction resulting from organ hypoperfusion with hypoxic and acidotic blood.
The ABCs are also useful in organizing postarrest
stabilization measures. Assessment starts with an evaluation
of the adequacy of the airway. Assessment parameters
include the airway size, presence of an ETT leak, and the
security of the ETT. If a cuffed ETT is placed, cuff volume
and pressures are checked. This is important in pediatrics
because cuffed ETTs are infrequently used and can potentially cause a significant amount of airway damage in a short
period. The placement and patency of the nasogastric tube
(NGT) is also assessed. After decompressing the stomach
with a large-volume syringe, the NGT is connected to
intermittent suction. A chest radiograph is usually indicated
to evaluate pulmonary disease, assess for iatrogenic injury,
and check tube placement, that is, ETT, central lines, or
chest tube positioning.
Serial ABGs are assessed throughout the resuscitation
attempt. Exhaled CO 2 detection is continuously monitored
as well. Saturation monitoring resumes when the patient's
pulse pressure is adequate. Once the airway is stable,
optimal ventilator parameters are identified. Airway pressures sufficient to provide adequate chest excursion and at
least 95% saturation are noted during hand ventilation.
Keeping the patient's FI02 at 1.0, airway pressures are
matched with the ventilator. Once the patient is supported
on the ventilator, the patient's ABGs are reanalyzed in
20 minutes, and further adjustments in PIPs and PEEPs,
tidal volume, and FlO2 are made.
Vascular access is reassessed for adequacy, patency,
and security. Additional vascular access may be indicated and, after fluid resuscitation, can be accomplished in
a controlled manner. Intraosseous lines are discontinued as
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soon as possible after adequate direct vascular access
has been obtained. The skin surrounding peripheral intravenous sites requires particular attention. The potential
for iatrogenic injury from intravenous infiltration is
high. Immediate consultation to plastic surgery may be
indicated.
The initial set of vital signs includes temperature
assessment. Patient exposure and administration of large
quantities of unwarmed intravenous solutions during the
arrest place the patient at risk for postarrest hypothermia.
The hypothermic patient benefits from rewarming measures,
for example, warm blankets and overhead radiant warmers
or lights.
As soon as possible after resuscitation, a baseline
neurologic examination is performed and documented. The
neurologic examination is placed in context of the prearrest neurologic status and drugs used during or immediately after resuscitation (e.g., atropine, dopamine, and
chemical paralyzing agents). Atropine and dopamine act
synergistically to cause pupillary dilation, the duration
of which cannot be accurately determined because routine half-life calculations are probably invalid following
resuscitation.
In addition to ABGs, initial postresuscitation blood
work includes studies to evaluate oxygen-carrying capacity, fluid balance, system function (especially renal and
liver function), and coagulation profiles. Urine output is
evaluated, and if not already present, a Foley catheter is
placed.
Patients are usually poorly perfused, acidotic, and
hypotensive after a cardiac arrest. The most common reason
for poor perfusion in this case is cardiogenic shock, the
result of arrest-related myocardial ischemia. Patients may
benefit from a 10- to 20-ml/kg fluid bolus administered over
several minutes. If ventricular or pulmonary compliance is
poor, a fluid bolus is administered with caution. Continuous
infusions of inotropic agents (e.g., epinephrine, dopamine,
and dobutamine) can be used to augment contractility and
enhance tissue perfusion. Drug therapy is based on clinical
presentation. Management of shock is discussed in depth in
Chapter 27.

INTERFACILITY TRANSPORT
Following resuscitation, some patients may require transport to a pediatric facility that can best meet their evolving
needs. Interfacility transport offers a system to ensure that
all patients receive an appropriate level of care. According
to the American Academy of Pediatrics (AAP),29 the goal of
pediatric interfacility transport is to improve outcomes in
critically ill or injured neonates, infants, and children who
are not in proximity to a hospital that provides the required
level of care.

History
With the development of critical transport services throughout the country, the AAP developed guidelines for air and
ground transportation of pediatric patients. These guide-
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lines provide a framework for minimum goals for pediatric
and neonatal critical care transport programs. Federal
guidelines also govern interfacility transports. The Consolidated Omnibus Reconciliation Act of 1985 (COBRA)3o
and the Emergency Medical Treatment and Active Labor
Act (EMTALA)31 regulations state that interfacility transport cannot be used as a method to avoid initial assessment,
stabilization, or intervention, especially with regard to a
patient's ability to pay. All necessary means to stabilize
the patient are attempted before transport. Regionally,
hospitals should have written interfacility transfer agreements outlining the level of responsibility of both receiving
and referring facilities throughout the transport process.
Thus when a transport occurs, preset agreements are
already in place, and compliance with federal guidelines
is ensured.

Transport Process
Once the healthcare team at the referring institution
recognizes the need for specialty services, a decision to
transport to a tertiary facility is made. Once an interfacility
transport team is activated, the patient is prepared.
The goal is optimal stabilization of the patient. The patient's condition and the trajectory of the disease process
are considered. The ABCs of stabilization help to ensure that
the patient is physically prepared for transport. Airway
patency is checked. If any question remains concerning the
ability of the patient to maintain a patent airway, a transport
team will intubate the patient. Once the airway is stabilized,
adequate ventilation and oxygenation are ensured. Circulation is then assessed and stabilized. Obtaining intravenous
access is critical. In most instances, at least two patent
intravenous lines are preferred during transport. Necessary
measures are taken to prevent thermal instability. While
patient stabilization is underway, the patient's medical
record, laboratory reports, radiographs, and CT scans are
copied. Fig. 31-12 provides the standard approach for each
patient requiring transport.
Team Composition. Transport programs have various team compositions, which include physicians, nurses,
respiratory therapists, paramedics, and EMTs. All pediatric
teams have members who are experts in the management of
critically ill infants and children. A wide variety of team
compositions exist, and to date, no single composition is
preferred over the other.
Patient safety and available medical care during transport are factors to consider in composing the team for a
particular transport. There are multiple team compositions
to choose from, depending on a hospital's location to the
tertiary center. Local basic life support (BLS) and advanced
life support (ALS) systems offer rapid response times, but
they are adult oriented and have a limited ability for
advanced pediatric resuscitation techniques. Adult-based
critical care transport services offer both flight and ground
resources but often have limited expertise in the care of
the neonatal and pediatric patient. Specialized pediatric and
neonatal transport systems offer experienced nurses, respiratory therapists, physicians, and emergency medical
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Children's Hospital Transport Program Patient Care Protocols
Standard Approach to the Patient
1. Follow universal precautions. If a contagious disease is suspected or there is potential for exposure to blood or body fluids, take
appropriate measures to protect the transport team members and the patient.
2. Perform a primary survey to identify, and initiate treatment for, life-threatening problems with airway, breathing and circulation.
3. Obtain additional history from health care providers, the patient, and the family.
4. Perform a physical assessment, including vital signs.
5. Initiate patient monitoring, to include:
a. ECG and respiratory rate
b. Pulse oximetry (Sp02)
c. Non-invasive blood pressure (NIBP)
d. Additional monitoring as indicated based on the patient's condition
6. Monitor and maintain the patient's body temperature.
7. Perform appropriate diagnostic tests.
Provide treatment to stabilize prior to transport based on the applicable Children's Hospital Transport Program Patient Care Protocol(s)
and/or orders from the medical control physician.
a. Unless otherwise specified, follow the Children's Hospital Intensive Care Unit Nursing Policies and Procedures for nursing care and
medication administration
9. Obtain informed consent from parentIs) or guardian(s) for treatment and transport. If no parent or guardian is available, refer to the
administrative policy.
10. Obtain copies of the medical records and x-rays. For neonatal patients, also obtain copies of the mother's records.
11. Provide psychosocial support for the patient and the family.
12. Contact the medical control physician to discuss patient management and/or disposition.
13. Contact the receiving nursing unit and provide a focused report on the patient's condition.
14. Initiate transport as soon as the patient's condition permits.
15. Apply passenger safety restraints to the patient to the extent that the patient's condition permits.
16. Continuously monitor the patient's condition and provide appropriate treatment during transport. Notify the medical control physician
of any significant changes in the patient's condition.
17. Document pertinent data and events using the transport flow sheet; document adverse events on a Children's Hospital incident report.

8:

Fig.31-12

Sample patient care protocol. (Courtesy Children's Hospital Transport Program, Boston, 1999.)

personnel skilled in the care of critically ill infants and
children.
The patient's severity of illness and the risk for deterioration determine the team composition and their level of expertise. A child who is currently stable but has a potential to
deteriorate during the transport necessitates a team that is
not only capable of caring for this child in a mobile environment but has the expertise necessary to restabilize the
patient.
Regardless of the composition, the transport nurse is
often considered the team leader. The transport nurse's
role is to coordinate the stabilization of the child before
transport, provide continuous evaluation and monitoring of
the patient's physiologic status, and provide patient management under guidelines throughout the transport. The
nurse is responsible for patient and team safety at all times.
The transport nurse maintains awareness of the potential
risks involved and is able to react accordingly in a mobile
environment. Pediatric or neonatal transport nurses maintain
certifications in pediatric advanced life support (PALS),
Neonatal Resuscitative Program (NRP), critical care certification (CCRN), BLS, and the trauma nurse certification
course (TNCC) or advanced trauma life support (ATLS).
Education of Team Members. Education and training for transport team members are intense. Didactic and
interactive skill sessions are part of many training programs.
Not only are team members expected to manage multiple
medical and surgical emergencies, but they are also trained
to perform advanced technical procedures. Didactic sessions
build on the clinician's knowledge base and introduce

specific aspects of transport management, such as air flight
physiology, interpreting radiographs, and providing care in
a mobile environment. Procedure skill stations for the
development of advanced skills such as bag-mask ventilation; tracheal intubation; intravenous, intraosseous, and
central venous line placement; shocks; cardioversion; and
arterial puncture are implemented in many programs.
Simulated cases consisting of computer-controlled mannequins that imitate crisis situations are often part of the
education process. Team building and communication
skills are also important components of the education
program.
Didactic sessions, simulation, and procedure skill stations introduce team members to transport protocols.
Protocols provide the standard of care for the transport team
when working outside of the hospital setting. An example of
a protocol for management of respiratory distress and failure
can be found in Fig. 31-13. If team members need to deviate
from the established protocols the medical control physician
(Mep) is called for advice.
Team Safety. A major consideration for a transport
team is the safety of the team members and patient. Team
orientation to ground and air safety, protective clothing,
physical fitness, emergency planning, wilderness survival,
stress management, and debriefing sessions are aspects
that are imperative to safe team performance. 29 Without
safety training, the team can be unaware and unprepared
for the potential risks that can occur during transport. For
example, team members must know how to use the
emergency exits in the planes and rotor-wing aircraft, avoid
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Children's Hospital Transport Program
Patient Care Protocols
Pediatric Respiratory
Distress and Failure
Definition: Respiratory distress describes a patient's efforts to increase minute ventilation in order to compensate tor impaired gas
exchange secondary to pUlmonary or other systemic disease. Respiratory failure occurs when compensatory mechanisms fail,
and oxygenation and ventilation become inadequate. Respiratory failure may occur without the presence of respiratory distress.
Clinical presentation:
1. History: Dyspnea, rapid andlor labored breathing, difficUlty speaking or swallowing, diaphoresis, fever, cough, drooling.
2. Physical exam: Tachypnea, grunting, nasal flaring, retractions, tachycardia, anxiety, pallor (respiratory distress); head bobbing,
paradoxical movement of the abdomen and chest, decreased responsiveness, decreased respiratory effort and rate, gasping
respirations, cyanosis (respiratory failure). The exam should include assessment for stridor, wheezing, asymmetry of breath sounds,
rales, and rhonchi.
3. Laboratory data: Arterial blood gas, chest x-ray films, plus lateral and anteroposterior neck films.
Differential diagnosis:
1. Upper airway obstruction: croup, epiglottitis, foreign body obstruction, bacterial tracheitis, smoke inhalation
2. Lower airway obstruction: status asthmaticus, foreign body aspiration, bronchiolitis, bronchiectasis
3. Parenchymal or interstiliallung disease: pneumonia, pulmonary edema, pulmonary hemorrhage, pulmonary contusion
Evaluation and Treatment:
1. Assess the airway, and provide management as indicated according to the Airway Management protocol.
2. Assess breathing, including respiratory rate, effort, air entry, and breath sounds. Provide intervention as follows:
a. Provide supplemental oxygen to any patient with respiratory distress, according to the Oxygen Therapy protocol.
b. Assist ventilations using a bag and mask with F102 = 1.0 for patients with respiratory failure or impending respiratory failure as
evidenced by decreasing level of consciousness, decreasing respiratory rate and/or effort, head bobbing, paradoxical abdominal
movement, deep retractions, and/or cyanosis.
c. Utilize a pressure manometer when delivering positive-pressure ventilations unless using a device with a pop-off valve.
d. Perform endotracheal intubation when indicated according to the Aitway Management protocol.
e. Perform cricothyrotomy when indicated according to the Cricothyrotomy protocol.
3. For patients with signs of upper airway obstruction and suspected airway edema:
a, Administer racemic epinephrine 2,25% solution 0.5 ml in 3 ml 0.9% NaCI by nebulizer.
b. If croup is suspected, administer dexamethasone (Decadron) 0.5 mglkg IV. Dexamethasone may be administered 1M if vascular
access is not available.
c, If epiglottitis is suspected, contact the medical control physician.
4. If anaphylaxis is suspected, administer:
a. Epinephrine 0.01 mglkg (0.01 ml/kg) of 1:1,000 solution SC (maximum dose 0.3 mg [0.3 mil)
b. Diphenhydramine (Benadryl) 1 mglkg IV
c, Methylprednisolone (Solumedrol) 2 mglkg IV
5. For patients with signs of bronchospasm, administer bronchodilator therapy as follows:
a. For acute, severe distress, administer epinephrine 0.01 mglkg (0.01 mllkg) of 1:1,000 solution SC (maximum dose 0.3 mg [0.3 mil).
b, Administer albuterol 2.5-5 mg in 3 ml 0.9% NaCI by nebulizer or two to four "puffs" by MOl, and repeat as needed.
c. Administer ipratroprium bromide (Atrovent) by nebulizer or MOl, up to three doses.
d. If reactive airway disease is suspected, administer methylprednisolone (Solumedrol) 2 mg/kg IV. Do not administer if the patient
has already received steroids at the referring hospital within the past 6 hours, unless a lower dose was administered or the patient
experienced vomiting after administration of oral prednisone.
e, If the patient remains significantly bronchospastic, consult with the medical control physician regarding administration of continuous
albuterol by nebulizer or terbutaline by continuous intravenous infusion.
6. For patients who have chronic respiratory insufficiency and are maintained on noninvasive ventilation, continue CPAP or BiPAP as per
the patient's usual settings, and consult with the medical control physician regarding adjustment of ventilatory support for transport.
7. For patients who are chronically dependent on mechanical ventilation:
a, Consult with the medical control physician regarding use of the patient's portable ventilator for transport and adjustment of settings.
b, If the patient deteriorates, remove the patient from mechanical ventilation and provide manual ventilations using a resuscitation bag.
c. Consider obtaining a blood gas (venous or arterial) prior to transport, if clinical assessment of oxygenation andlor ventilation cannot
be reliably performed.
d. Monitor the patient with continuous pulse oximetry and capnography during transport.
8. For patients who require initiation of ventilatory support via endotracheal tube or tracheostomy on transport:
a. Provide ventilatory support using F102 of 1.0 except as outlined in the Oxygen Therapy protocol, using the following:
1. A resuscitation bag using an inflating pressure to produce adequate chest rise, a PEEP of 3 to 5 cm H20, and a rate that provides
adequate ventilation; OR
2. A transport ventilator using an inflating pressure to produce adequate chest rise, a PEEP of 3 to 5 cm H20, and a rate that provides
adequate ventilation.
3. Consult with the medical control physician if higher levels of PEEP are required.
b. If the patient deteriorates, remove the patient from mechanical ventilation and provide manual ventilations using a resuscitation bag.
c. Consider obtaining a blood gas (venous or arterial) prior to transport, if clinical assessment of oxygenation and/or ventilation cannot
be reliably performed.
d, Monitor the patient with continuous pulse oximetry and capnography during transport.

Fig.31-13 Respiratory distress and failure protocol. (Courtesy Children's Hospital Transport Program,
Boston, 1999.)
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a spinning tail rotor, and troubleshoot equipment failures
in any mode of transport. Many teams do not share patient
information with the pilots until acceptance or denial of
the transport has been determined. Pilots do not need
patient status information to cloud judgment when making
decisions about the ability to fly safely based on weather
conditions.
Mode of Transport. Response time, weather, and
team capabilities are factors that are carefully considered
when choosing the mode of transport. Modes available for
transport include ground ambulances, rotor-wing aircraft (helicopters), and fixed-wing aircraft (propeller planes
and jets). In some cases, weather may necessitate that a
ground ambulance be used even if the distance is significant.
Time of day and traffic conditions may necessitate a rotorwing transport to save time because of traffic delays on the
ground.
Time is another factor that influences the mode of
transport chosen for a parricular patient. A 2-hour ground
transport of a child who is thought to have a rapidly
expanding intracranial bleed is not appropriate, and the
referring hospital team chooses the most rapid means of
transporting the child safely to the tertiary facility. Another
factor to keep in mind is the number of transfers required if
the patient is air transported. The more often a patient is
transferred to and from different vehicles (i.e., emergency
deparrment to ambulance, ambulance to helicopter, helicopter to ambulance, ambulance to receiving unit), the higher
the likelihood of adverse effects, accidental extubation, and
displacement of intravenous lines. Altitude may also increase the risk of adverse affects. However, the time that
is saved by flying may compensate for the potential
risks.
Equipment. Each transport program requires specialized equipment to safely transport the pediatric or neonatal
patient. Essential for every team is pediatric-sized airway
and intravascular access supplies (Fig. 31-14). Monitoring
equipment requires pediatric or neonatal modes. Pediatricor neonatal-size ECG leads, oxygen saturation probes, and
immobilization equipment such as c-spine collars and back
boards are essential for safe and efficient patient transport.
Pocket-sized pediatric or neonatal drug cards are helpful for
quick reference. Transport equipment also includes specialized comfort measures for this unique population, including
pacifiers, stuffed animals, and security objects. Many
pediatric or neonatal transport teams have configured
ambulances to include TVs and VCRs and CD players to
create a relaxing and nontraumatic transpOlt environment
for the child.
Communication. Team communication begins with
the call from the referring hospital, clinic, doctor's office, or
local 911 emergency system. Any referring physician should
have rapid and direct access to a transport team. For many
programs, this point of contact is usually accomplished by a
toll-free number, which is answered in the transport
program's dispatch center. Initial information, such as
patient name, age, weight, referring physician, referring
facility, phone number, and diagnosis, is gathered by the

dispatcher or communication specialist who then transfers
the call to the MCP (Fig. 31-15).
At the same time the transport team is notified, mobilization begins. Once the MCP has discussed the patient's
current condition with the referring institution and given any
medical advice necessary for stabilization, the MCP then
contacts the transport team to update them on the child's
status.
Cell phones and long-range alpha pagers are used to
maintain communication between the transport team and the
MCP when out in the field. Dispatchers can also link the
team to the MCP by land radio access. The communication
method must be continuous and reliable. A backup communication system should be available in case the primary system malfunctions. Continuous verbal contact between the transport team and MCP is essential in case
medical direction is necessary when the team is out on a
transport.
Communication between the team and referring institution is also essential. Many transport teams contact the
referring institution en route to obtain reports from the
nurses or physicians who are caring for the child, which
accomplishes two goals. First, the team has an up to-date
picture of the patient so that they can adequately prepare
the equipment and medication needed en-route, and, second, critical scene time is decreased when the report has
been given before arrival. When the team arrives, only a
brief update is necessary, and patient care can begin
immediately.
The transport team is also responsible for communicating
patient status and estimated time of arrival to the unit at the
accepting facility. This can be done through the dispatcher
or other communication system. Before leaving the referring
institution, the team communicates with the MCP about
patient status and the plan for transport.
On arrival to the accepting unit, the team is responsible
for ensuring that the accepting physicians and nurses receive
a comprehensive report on the child's condition and care to
date. Once the patient's care has been transferred to the
accepting medical team, a follow-up call is made to the
referring physician stating the patient's condition on arrival.
This is the final piece of communication from the team to
the referring institution.
Communication between the transport team and the
patient's family is extremely important. The team must fully
inform the parent or guardian about the risks and benefits of
transporting their child, the differential diagnosis, and what
is to be expected from the transport team. The parent or legal
guardian must sign or verbally give consent for medical
treatment and transport. Transport of a child is traumatic to
many parents, and open communication from the team can
help parents deal with the process.
The decision to have a parent ride with the team to the
receiving facility is governed by state laws and team
policies. If the parent rides with the team, two goals can be
accomplished. The child may be less anxious with the parent
in the ambulance, and the parent's anxiety level may be
decreased. The parent will also be available immediately at
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BLACK SUPPLEMENTAL PACK-CHILDREN'S HOSPITAL
TRANSPORT TEAM
VENOUS ACCESS:

THORACOTOMY/
THORACENTESIS:
2 each 1OF, 12F chesttubes
1 sterile Kelly clamp
2 thoracentesis kits:
23G butterfly
19G butterfly
3-way stopcock
60cc syringe
Xeroform gauze
1 Y-connector
2 5-in-1 connectors
2 Hemlich values
1 roll 3" foam tape

1 5.5F Arrow CVL kit
1 guide wire
2 intraosseous needles
2 each 3.5, 5.0 umbilical
catheters
1 each 3.5, 5.0 dbllumen
umbilical catheters
1 transport instruments tray
2 3.0 silk sutures
2 #11 blades

IV
SUPPLIES:
1 each:
500cc NS
500cc 05 ' /.
500cc 010W
250cc5%
albumin

RESPIRATORY:

1 self inflating
resuscitation bag with
PEEP vaive
1 each neonatal,
pediatric ventilator
circuit
1 meconium aspirator
1 "premie" kit
1 Survanta kit

blood tubing
pressure bag

RED MEDICATION PACK-CHILDREN'S HOSPITAL
TRANSPORT TEAM

I 1 pediatric emergency medication reference guide

1 calculator

.,

c:

2 methylprednisolone 62.5 mg/ml-2 ml

"<:5 _

,.,'"
E'>

1 dexamethasone 10 mg/ml-10 ml

E

"'0
>0

"''''
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Iii
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1 ondansetron 2 mg/ml-2 ml
2 xylocaine 20/0-2 ml amps
1 heparin 1000 ll!ml-10 ml

I

.S 0,
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o E

·Q>o -E
"0
0

"'~~

8 phenobarbitol
130 mg/ml

1 diphenhydramine
50 mg/ml-1 ml
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1 naloxone 1 mg/ml-2 ml
2 phenytoin 50 mg/ml-5 ml
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1 phytonadione 2 mg/ml-1 mt
1 erythromycin opthalmic 3.5 gm
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2 lidocaine 20 mg/ml-5 ml
1 epinephrine 1:100D-30 ml
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12 lcc syringes

4 30cc syringes

12 18G needles

IV drip labels

12 3cc syringes

4 60cc syringes

4 25G needles

1 glucagon kit

12 lOcc syringes

4 27G needles
12 interlink needles

Fig. 31·14 Transport equipment pack list. (Courtesy Children's Hospital Transport Program,
Collt;lllled
Boston. 1999.)
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ORANGE TRANSPORT PACK-CHILDREN'S HOSPITAL
TRANSPORT TEAM
rubber bands, tourniquet
black pen
oral airways (1 each): 5, 6, 7, 8, 9
nasal trumpets (1 each): 14, 16, 18,20,22,24,26
1 500cc anesthesia
bag
1 1L anesthesia bag
2 02 supply tubings
1 manometer with
tUbing and adaptor

Anesthesia face masks
(1 each):
neonate
infant
toddler
pediatric
small adult
large adult

IV Catheters
(4 each):
14G
16G
18G
20G
22G
24G

Syringes (5 each):
1cc
3cc
lOcc
2 armboards
6 18G needles
6 interlink needles

Tegaderm
4X4 gauze
alcohol pads
betadine pads
(6 each)

1
1
1
1

Nebulizer Kit:
1 20cc btl ventolin 5 mglcc
1 15cc btl racemic epinephrine
3 single dose Atrovent 0.5 mgl2.5cc
5 amps terbutaline 1 mglcc
4 saline "bullets"
1 neb setup with mask and ett
adaptor

Interlink:

5 hep lock caps
5 blue connectors
3 slip-adaptor
T-connectors

Thermometer

Blood culture bottle
(5) lancets
1 each:
large red, green,
blue, purple lab
tubes, green/purple
microtainers

(5) 10cc vials
NS
1 roll each:
1" adhesive tape
1" silk tape
Co-flex

set ECG leads
each neo, pedi, adult sat probe
each Critikon BP cuffs: #1, #2, #3, #4, #5
each HP BP cuffs:#1, #2, #3

23-way
stopcocks

1 each pedi, adult Easy cap
EtC02 supplies (1 each):
ett adapter, supply tubing,
pedi, adult cannulas

Intubation roll:
1 roll 1· adhesive tape

2 bezoin applicators
1 lOcc syringe
1 each neo, pedi McGill forceps
2 laryngoscope handles
laryngoscope blades (1 each):
Miller 0, 1, 2, 3
W-H 1.5
Macintosh 1, 2, 3, 4
1 each pedi, adult stylets
extra laryngoscope bulbs (small and large)
2 AA batteries
2 C batteries
swivel adapter
Endotracheal tubes (uncuffed up to size 5, cuffed ;"5.5):
2 each: 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5
1 each: 7.0, 7.5, 8.0

Fig. 31-14, (ont'd

Butterflies:
(2 each):
19G
21G
23G
24G

For legend see p. 1047.
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USE PLATE OR PRINT
PT NAME:
MR#:

DATE: _ / _ / _ TIME(MILITARY): _ _
PERSON PROCESSING CALL:
_
PT NAME:----==-=_
DOB: _ / _ / _
SEX: Do" D9
AGE:
IF NEONATE, GEST. AGE:_ _
PRELIM DIAGNOSIS:
_

LABS:

REFERRING MD:
REFERRING HOS"""'P,..,.IT=-A-,--,L-:-------DED DPEDS DDR DSCN DOTHER
_
CITY, STATE:
_
CALL BACK #:
_
PCP:
PHONE:
ALLERGIES:
---EXPOSURES:
_

OTHER:
BLOOD GAS #1 :

ADVDCD

BLOOD GAS #2:

ADVDCD

HISTORY/COURSE/INTERVENTIONS:

RECOMMENDATIONS:

-++< >-<

Diff%:
p
BLM-

XRAY RESULTS:

SIGNATURE:

WGT: __kg T__ HR__ RR__ BP__
02 SAT:
02 DELIVERY:
CUFFED YES/NO
DETTITRACH SIZE:
ACCESS:D PIV X_ SIZE:_ DIO DUAC
DUVc 1 2 LUMEN DCVL 1 23 LUMEN DALINE
RATE:
IVF: TYPE:
RATE:
TYPE:
RATE:
TYPE:

_

D CONSULT, REFERRED TO:
_
NOTIFIED: DTEAM DAMBULANCE DCOPP
DATTENDING DRECEIVING CHARGE RN/MD
TEAM COMPOSITION: DRN/RN DRN/RN/HO D
RN/RN/BACK-UP MD DBMF DCH RN/BMF
DREF HOSP TEAM DOTHER
_
ACCEPTING SERVICE/FIRM:
ATTENDING:

_
_

UNIT: D7N DP5 DP6 DEDDOTHER:

_

IF NO TRANSPORT, REASON:

_

NEURO STATUS:

IF NO CH BED, ALTERNATIVE ARRANGEMENT:

Fig.31-15 Transport intake fonn. (Courtesy Children's Hospital Transport Program, Boston, 1999.)
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evaluation at the referring facility, during transport, and
on arrival at the receiving facility. Treatment efforts
and the patient's ongoing clinical status are documented throughout the entire transport process, beginning
at the referral facility and continuing to the accepting
facility.
The line of responsibility to the patient is blurred when a
transport team is called. 34 There is no clear point in the
transport process that separates the responsibilities of care
among the referring facility, the transport team, and the

the receiving hospital to give the child's medical history and
to sign any consents for treatment. If the parent or parents
are driving to the receiving facility, the team should supply
directions to the facility and advise them not to follow the
ambulance.
According to the Joint Commission on Accreditation of Healthcare Organizations (JCAHO).33 The transport medical record serves as a basis for evaluating the patient's condition and treatment. The transport medical record should contain the patient's medical

Children's Hospital Transport Team
In Patient Tracking Form

Call:

For QUALITY ASSURANCE

ARH:
DRH:

DCH:

ACH:
Database:O
Charges: 0
Date of Transport:

_

Time of Transport:

_

Referring Physician:

_

Nurse:
Referral Center:

_
_

Address:

Transport Team Members:
RN/RN:
Resident: -:-:-:MD to "make" team:
Ref Hasp. Req. MD: :-;
MD per Medical Control:

_
_
_
_
_

_

Phone Number:
Preliminary Diagnosis:
Age/Gestational Age:

_

In-Patient Unit admitted to:
_
Transferred to:
Date of Transfe-r-:--------~

_

APGARS:

_
-'-3

-'-5

Brief History:

_

Significant EventS/Procedure done on transport (by whom/# of attempts):

En Placement by CXR:
Transport Opportunities for Improvement

Taped at:

CXR on arrival:
Follow-up

_

_
_

Initial ABG on Admission to CH
Final Diagnoses and Disposition
Quality Assurance Surveillance Indicators
Hyperventilation-PaC0 2 <30
Olnitial ABG hypoventilation pH <7.25
Accidental extubation en-route
Loss of IV access
Hypothermia/rectal temp <35SC
Departure from receiving hospital >1 hour

o
o
o
o
o

OFailure to bring equipment
ORan out of 02 or Air
ORight main intub. on arrival CXR
OBroken equipment
_
Departure from CH >30 minutes
OTransfer to ICU within 24 hours

o

Fig. 31-16 Transport team quality assurance form. (Courtesy Children's Hospital Transport Program,
Boston, 1999.)
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accepting facility. The amount of responsibility tends to
gradually shift throughout the transport process. The accepting facility begins to take some responsibility when they
agree to accept the child and give treatment recommendations. The transport team and receiving facility become
more responsible as the team becomes more involved in the
patient care. Once the patient arrives at the receiving facility,
the responsibility of the referring facility continues to
diminish. Transport agreements between referring facilities
and transport teams can help clarify some of the haziness of
liability. All recommendations, arrangements, and interventions are documented in the medical record throughout the
transport process.
Evaluation. A continuous performance improvement
(PI) program is an important component of any transport
program. A PI program ensures delivery of quality patient
care and safe team performance. The PI process can identify
potential system problems, resolve identified problems
related to patient care and program operations, and provide
ongoing evaluation of strategies implemented to resolve the
problem (Fig. 31-16).
Keys to a successful transport, regardless of mode or
team composition, include careful and continuous monitoring of patient status. EITs are well secured before transport
to decrease the risk of accidental extubation. Continuous
ETco 2 measurements during transport provide ongoing
information about the child's airway status. Intravenous
lines require protection so that turbulence, rough driving
conditions, or patient transfers do not cause inadvertent

OAlOI VARIABLES:
Level of response requested
DCode Blue
D"STAT" (Specify:

displacement. In addition to being secured, intravenous sites
are visible and easily accessible during transport to monitor
for infiltration and to access quickly in emergency situations. Keys to remember in emergency situations (arrest,
extubation) are to have emergency equipment easily accessible. Having at least one round of code medications in an
easily accessible place like a chest or arm uniform pocket
will enhance immediate administration if the child requires
pharmacologic intervention. Protocols and reference materials must be easily accessible during transport. In addition,
all transport equipment must have a 4-hour battery life in
case of power failure.

RESUSCITAnON PERFORMANCE
IMPROVEMENT
Nurses with specialty education in pediatric emergency
and critical care are a valuable asset to pediatric resuscitation teams. Their positive impact can be further
enhanced through coordinated training programs within
institutions that focus on the code team approach to pediatric resuscitation. Monthly interdisciplinary mock codes
in which objective criteria are used to evaluate knowledge
acquisition and skill performance are excellent ways to
assess the program. As part of a system-wide quality
improvement plan, pediatric mock codes help to perfect
skills while also helping to consolidate individual and
team roles. In addition, system deficiencies, such as
availability of personnel, paging difficulties, impossible

EVENT VARIABLES:
Witnessed
DYes
DNo

_

Were there issues with:
D Locating the site of the emergency
Describe:
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Initial Condition
Conscious?
Breathing?
Pulse?

DYes DNo
DYes DNo
DYes DNo

Types of monitoring at time of event
D ECG
Initial Rhythm

_

Dldentifying medical leadership
Comments:

_

DObtaining emergency equipment
Comments:

_

DEquipment function
Comments:

_

DTransfer of patient after resuscitation
Comments:

_

D Family members
Comments:

_

Comments on any factors which could be improved:

DSp02

DVF

D Arterial Pressure
DCVp
Immediate Cause
D Dysrhythmia
D Shocklhypolension
D Respiratory failure/arrest
D Neurologic event
D Other

DVT
DPEA
D Bradycardia
DSVT
DAsystole
DNSR
DST
DOther

To be completed by nurse recorder
For 01 Purposes only - not to be placed in the medical record

Fig. 31-17 Code blue quality improvement tool. (Courtesy Children's Hospital, CPR Committee.
Boston. 1999.)

_
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drug dilutions, and malfunctioning equipment, can be
identified in a benign setting. Mock codes also ensure that
resuscitation team members are familiar with crash cart
contents. Appendix IV (Emergency Cart Contents) contains
a list of PICU crash cart contents. It is important that crash
cart contents reflect the patient population of the unit
because items that may be appropriate for a pediatric
cardiovascular surgical unit may be inappropriate for a
multidisciplinary PICU. However, standardizing in-patient
pediatric unit crash carts is essential so that code team
members can work rapidly from any crash cart in any
location. Specialty items, such as cast cutters on an
orthopedic unit, can be accommodated in boxes attached
to the· generic crash cart.
Every resuscitation attempt requires evaluation as a
potential opportunity for system-wide improvement. Survival rates and patient outcomes should be an integral part
of the resuscitation team's PI program. Strategies that
proved successful can be highlighted through retrospective
review. Fig. 31-17 illustrates an example of a perfonnance
improvement assessment tool used by a CPR committee to
evaluate resuscitation events. A child's potential death
represents one of the most stressful experiences any staff
member can encounter. Team conferences after successful
and unsuccessful resuscitation attempts provide the entire
healthcare team with an opportunity for mutual support.

SUMMARY
Three major characteristics distinguish cardiopulmonary
arrest in infants and children. These are the diverse causes of
the arrest, the fact that most cardiopulmonary arrests can be
prevented in infants and children, and certainty that primary
cardiac arrest is unusual. Research demonstrates significant
differences in overall survival and neurologic outcome in
children depending on the type of arrest; survival is belter in
those who experience only respiratory arrest. Therefore
early recognition and intervention to prevent a pulseless
state are critical. Survival rates have been shown to be
higher when the interval between cardiac arrest and
intervention is shorter. Despite these factors, which would
provide the infant and child an apparent advantage, survival
among pediatric patients experiencing cardiopulmonary
arrest is poor.
Critical care nurses, working collaboratively with other
healthcare professionals, are in a unique position to appreciate the anatomic, physiologic, and maturational factors
that affect the pediatric patient's response to resuscitation
efforts. The essence of caring for the critically ill pediatric
patient includes the ability to rapidly identify signs of
compensation, intervene, and prevent cardiopulmonary
arrest. Nurses are in a key position to make a critical
difference in improving the currently dismal pediatric
outcomes.
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Fig. A1-2 Age-specific percentiles of blood pressure (BP) measuremellls in girls-birth to 12 months of age; Korotkoff phase IV
(K4) used for diastolic BP. (From National Heart, Lung, and Blood
Institute, Bethesda, MD: Report of the second task force on blood
pressure control in children-l 987. Reproduced with permission
of Pediatrics, vol. 79, p. I. Copyright © 1987.)

Fig. A1-' Age-specific percentiles of blood pressure (BP) measurements in boys-birth to 12 months of age; Korotkoff phase IV
(K4) used for diastolic BP. (From National Heart. Lung. and Blood
Institute. Bethesda, MD: Report of the second task force on blood
pressure control in chiJdren-1987. Reproduced with permission
of Pediatrics. vol. 79, p. I. Copyright © 1987.)
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Growth Charts

*Growth charts used with permission of Ross Products Division, Abbott Laboratories, Columbus, OH 43216, from NCHS Growth
Charts. © 1982 Ross Products Division, Abbott Laboratories.
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GIRLS: BIRTH TO 36 MONTHS
PHYSICAL GROWTH
NCHS PERCENTILES·

_ _ _ _ _ _ _ RECORD

NAME

#
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Normal Immunization
Schedule

Fig. A3-1 Recommended Childhood Immunization Schedule. (Approved by the Advisory Committee on
Immunization Practices [ACIP], the American Academy of Pediatrics [AAP], and the American Academy
of Family Physicians [AAFP].)
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Normal Immunization Schedule
Recommended Childhood Immunization Schedule
United States, January-December 2001

Vaccines 1 are listed under routinely recommended ages. I Barslindicate range of recommended ages for immunization. Any dose not given
at the recommended age should be given as a "catch-up" immunization at any subsequent visit when indicated and feasible. ~
indicate vaccines to be given if previously recommended doses were missed or given earlier than the recommended minimum age.

Information in bold has been added by the American Academy of Family Physicians (AAFP).

Age~
Vaccines ....

Birth

1
mo

Hepatitis B2

Hep B #1

2
mos

4
mos

12
mos

6
mos

15
mos

DTaP

DTaP

DTaP

II

H.influenzae

Hib

Hib

Hib

Hib

Inactivated
Poli0 5

IPV

IPV

Pneumococcal
Conjugate 6

PCV

PCV

Varicelia B

I. HepatitisA9

4-6
yrs

Hep B #3

Diphtheria,
Tetanus,
Pertussis 3

Measles, Mumps,
Rubella?

24
mos

11-12
yrs

14-16
yrs

I
Hep B #2

type b4

18
mos

II
II
I

-

DTaP3

IPV5
PCV

HapS
DTaP

I

Td

I

IPV5

PCV
MMR

MMR7
Var

MMR7)

-

-VarB
Hep A-in selected areas 9

Approved by the AdVisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the Amencan Academy of Family PhySICians (AAFP).

IThis schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines as of November 1,2000, for children through IR years of
age. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are
indicated and its other components are not contraindicated. Providers should consult the manufacturers' package inserts for detailed recommendations.
Llnfants born to mothers who are negative for hepatitis B antigen (HB-Ag) should receive the first dose of hepatitis B (Hep B) vaccine by age 2 months. The second
dose should be at least 1 month after the first dose. The third dose should be administered at least 4 months after the first dose and at least 2 months after the second dose,
but not before 6 months of age for infants.
Infants born to HB-Ag-positive mothers should receive hepatitis B vaccine and 0.5 ml hepatitis B immune globulin (HBJG) within 12 hours of birth at separate sites.
The second dose is recommended at I to 2 months of age and the third dose at 6 months of age.
Infants born to mothers whose HB-Ag status is unknown should receive hepatitis B vaccine within 12 hours of birth. Maternal blood should be drawn at the time of
delivery to determine the mother's HB-Ag status; if the HB-Ag test is positive. the infant should receive HBIG as soon as possible (no later than I week of age).
All children and adolescents who have not been immunized against hepatitis B should begin the series during any visit. Special efforts should be made to immunize
children who were born in or whose parents were born in areas of the world with moderate or high endemicity of hepatitis B virus infection.
3The fourth dose of DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine) may be administered as early as 12 months of age. provided 6 months have elapsed
since the third dose and the child is unlikely to return at age 15 to 18 months. Td (tetanus and diphtheria toxoids) is recommended at 11 to 12 years of age if at least 5 years
have elapsed since the last dose of OTP (diphtheria, tetanus, and pertussis), OTaP, or DT. Subsequent routine Td boosters are recommended every 10 years.
"Three Haemo[Jhilu.\' i'!fluenzae type B (HIB) conjugate vaccines arc licensed for infant use. If PRP-OMP (Pedvax-HIB or ComVax [Merck]) is administered at 2 and 4
months of age. a dose at 6 months is not required. Because clinical studies in infants have demonstrated that using some combination products may induce a lower immune
response to the HIE vaccine component, OTaPIHJB combination products should not be used for primary immunization in infants at 2, 4, or 6 months of age unless approved
by the Food and Drug AdministraLion for these ages.
~An all-IPV (poliovirus vaccine inactivated) schedule is now recommended for routine childhood polio vaccination in the United States. All children should receive four
doses of fPY at 2 months, 4 months, 6 to 18 months, and 4 to 6 years of age. Oral polio vaccine (DPV) should be used only in selected circumstances. (See MMWR,

May 19.2000/49 (RR-5): 1-22.)
&rhe heptavalent conjugate pneumococcal vaccine (PCY) is recommended for all children 2 to 23 months of age. It is also recommended for certain children 24 to 59
months of age. (See MMWR, Oct. 6, 2000/49 (RR-9); 1-35.) The full AAFP Clinical Policy on Pneumococcal Conjugate Vaccine is available at www.aafp.orglpolicy/

camp/24.html.
7The second dose of measles, mumps. and rubella (MMR) vaccine is recommended routinely at 4 to 6 years of age, but may be administered during any visit provided aL
lea~t 4 weeks have elapsed since receipt of the first dose and that both doses are administered on or after fhe nrst birthday. Those who have not previously received the
second dose should complete the schedule by the 11- to 12-year-old visit.
flVaricella (Var) vaccine is recommended at any visit on or after the first birthday for suscepti~le children; that is. those who lack a reliable history of chickenpox (as judged
by a health care provider) and who have not been immunized. Susceptible persons 13 years of age or older should receive 2 doses, given at least 4 weeks apart.
9Hepatitis A (Hep A) is shaded to indicate its recommended use in selected states or regions, and for certtlin high-risk groups; consult your local public health authority. (See
MMWR. 48(RR-12): 1-37, Oct 01. 1999.)
For additional information about the t'Gccines listed above, please visit the National immunization Program Home Page or http://www.cdcgovlnipl or ('(ill the National
Immunization Hotline or 800-232-2522 (English) or 800-232-0233 (Spanish).
Full AAFP immunization policies can be found at the AAFP website, www.aafp.orglclinical.

Emergency Cart Contents

Standard Code Cart S~pplies
Number

llirCart
Exterior
9

~Medication labels
~'~xtension cord

Drawer#3:A1RVVAY
In/ubation Tray
Benzoin
Cloth tape. I in.
latex-free
Styleltes
Lidocaine jelly
Lubafax jelly
Afrin spray
Magill forceps
Yankauer suction
Laryngoscope handle
Laryngoscope blades

~Gloves. nonsterile
lln;·

p~Backboard

!fEquipment checklists
NlCode- Blue fonns
~ifSh
.
if;,
arps contamer
~;'Oxygen lank with regulator
jm·
f:t'elf-~nflating resuscitation bag with masks (adult. child.
iiiii lOtant)

,~!jDrawer #1: MEDICATIONS

~rSmall medication

tray (see attached contents list)

~''Large medication tray (see attached contents list)
~IReference book
[1'

!~Calculator

Number

Endotracheal tubes

10 each

Batteries
Laryngoscope bulbs
Ambu masks

~:Drawer #2: NEEDLES/SYRINGES
~,Syringes
~

j'~',.

1lJ .

¥i;;Needles

TB 3 ml (3 cc).
10 ml (10 cc)
Heparinized
18. 22. 25 gauge

mtMicrotai ners
1I!jAlcohol wipes
1';:Gauze. 2 x 2 in
i[Sterile 0.9% NaCI
[<::InterLink cannu la
catheters
~'fButlerfly needles

m,IV

:~'T-connectors

r--Super STAT fonns

10 ml
24-14 gauge
21. 23. 25 gauge

4
4 each
4
I box
I box

Oral airways
Nasal airways
Tongue depressors
Mapleson F resuscitation bag with
oxygen tubing
Oxygen flowmeter
with nipple adapter

10

4
4 each
4 each
4
4

4
I roll
Pedi. adult

Infant, adult

Miller O. I. 2. 3
Macintosh 2. 3
WisHipple 1.5
2.5-5.5 uncuffed
5.0-8.0 cuffed
C.D.AA
Small. large
Neonate. infant.
toddler, child.
small adult,
adult
Size 5-9
Assorted sizes
500. 1000 cc

I each

I
I
I
I
2
2
I
I
I
2

tube
packet
each

each
each
each

2 each
2 each
I each

] each
2
I each

Contil1l1ell
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Emergency Cart Contents

Standard Code Cart Supplies-:-cont'd
Number

!;Drawer #4: IV THERAPY
:~yringes
30 ml (30 ccl,
i
60 ml (60 ccl
~;tsloOd collection
Red, purple,
~~~;' .. tubes
blue, green,
IE'
I arge red

.I

~~.':;:::::::::';:=b

IS 18,
g

'liExtension tubing
'~~tOPCOCkS' 3-way

1

,~olusets

Mini, macrodrip

IllPiluze sponges,

}iil~~a~~n

I~~OUmiqUets,

4 each
2 each

2 each
4
4
4
I each
I box

'/2 in. 1 in, 2 in

I roll
each
I roll

Small, med,
large

I each

latex-

Number

Drawer #5: MISCELLANEOUS
Suction Supplies
Suction canister with
tubing
6, 8, 10, 12, 14 Fr
Suction catheters
0.9% NaCl for
3-ml ampules
instillation
Gastric drainage
Feeding tubes
Salem Sump tubes
Catheter tip syringe
Catheters
Central venous,
Arrow

#?:b •'free

;~boards

;<,

.fly spike
~~uture on curved
,:: needle
kelly clamp
i~andaids, assorted
.;Betadine wipes
:'Bloocclusive
111[ dressing
:'lnterLink
!il;'if:: .: T-connector
D;~ solutions

3-0 silk

'.
I
Ii,.

-""Ibumin

h"i:

4
4

2
1 each
1 box
4
4

1
I:

Pressure, Cook

LR, NS, D5W,
D51/2NS,
500 ml
250 ml

I each

Oxygen/Nebulizer Therapy
Nonrebreather
oxygen mask
Hand-held nebulizer
with ETI adapter
MOl chamber
for ETI
Oxygen tank key
Other
Betadine
Blood pressure cuffs

&"

s;

~!L_.

,f",

"Wi;

It

Face shields
Flashlight

5,8 Fr
10, 14, 18 Fr
60 ml

1 each
4

I each
I each

2

4 Fr, 8 cm
double lumen
7 Fr, 12 cm
triple lumen
3.0 Fr single
lumen
5.0 Fr single
lumen
Adult, pediatric

Infant, child,
adult

I each

I bottle
I each
4
I
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STANDARD CODE MEDICATIONS

~

TABLE A4-2

~:Generic Name

U/'i

Small Code Cart Tray
Brand Name

I:Atropine sulfate
li:Calcium Chloride
!llDextrose
lpextrose
ID'pinephrine
~~pinephrine

iiLidocaine
i£;Sodium bicarbonate
I:Sodium bicarbonate

lJI

TABLE A4-3

Xylocaine
Neut

Volume

0.4 mg/mI
10% (100 mg/ml)
25% (250 mg/ml)
50% (500 mg/ml)
I: 1000 (I mg/ml)
I: 10,000 (0.1 mg/ml)
2% (20 mg/ml)
4.2% (0.5 mEg/ml)
8.4% (I mEg/ml)

I ml
10 ml
10 ml
50 ml
30 ml
10 ml
5 ml
5 ml
50 ml

Brand Name

Strength/
concentration

Adenocard
Ventolin
Ventolin

3 mg/ml
90 ltg/puff
0.5% (5 mg/ml)

3 ml

~pinephrine.

Cordarone
Bretylol
Decadron
Benadryl
Dobutrex
Inotropin
Vaponefrin

Ircracemlc
j~JJ·uroseml'de
jffi;
HmHydralazine
~Jnsulin, regular
!i@Mannitol

Lasix
Apresoline
Humulin
Osmitrol

~i:'Adenosine

, Ibuterol MOl
lfjfJbuterol

if!""
~iodarone

~retylium
~":
w1)examethasone
IDiphenhydramine
~obutamine

~

il';Popamine
ll."_'L

ilf.

'i·Naloxone
ii;Nitroprusside

lID;~ancuronium
iltPhenylephrine

~~Phenytoin

W~Succinylcholine
!t.
~Revised 8/15/00.

1:5,,:-'

5
3
2
2
I
4
2
4
2

Volume

Number

Comments

Prefi lied syringe
Prefi lied syringe

Narcan
Nipride
Pavulon
Neo-Synephrine
Dilantin
Anectine

Comments

20ml

2
I
I

For inhalation only
For inhalation only

50 mg/ml
50 mg/ml
5 mg/ml
50 mg/ml
12.5 mg/ml
40 mg/ml
2.25%

3 ml
10 ml
5 ml
1 ml
20 ml
5 ml
20 ml

6
I
2
2
2
3
I

For inhalation only

10 mg/ml
20 mg/ml
100 u/ml
20% (20 g/
100 m!)
0.4 mg/ml
25 mg/ml
I mg/ml
10 mg/ml
50 mg/ml
20 mg/m]

2 ml
I ml
10 ml
500 ml

4
2
I
I

1 ml
2 ml
10 ml
2 ml
2 ml
10 ml

5
I
1
3
5

•

II'".

.t:";

Number

Large Code Cart Tray

!i]":"

~~":'
~~Generic Name
?JL1Jii·

Strength/Concentration

]
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PICU Code Cart Medication Drawer Layout
CODE CART MEDICATION DRAWER LAYOUT
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2

Phenylephrine 10 mglml, 1 ml

X

1

Esmolol 100 mglml, 10 ml x 1

~

'c::>o

Hydralazine 20 mglml, 1 ml

'0

0

Labetolol 5 mglml, 20 ml

E

2

X

2

X

.~

Nitroglycerin 5 mg/ml, 10 ml

Q.

0

X

0

CD

0

Norepinephrine 1 mglml, 4 ml
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Nitroprusside 25 mg/ml, 2 ml

2
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~
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Q.

I

o

E

:g,

:
Calcium chloride
I
1oomglml,:
10mlx4
I

Naloxone 0.4 mglml,
1 ml x 5

W

I

~

E

I

I

:

-----------------<----------------i

cr

I
I
I

W

E

~

6

Lidocaine 1% (10 mglml), 2 ml

X

5

Lidocaine 2% (20 mglml), 2 ml

X

5

Lidocaine 4% (40 mglml), 50 ml

X

1

Procainamide 100 mglml, 10 ml

X

2

I

Calcium gluconate
100 mglml,
10 ml x 4

Normal saline
10 ml x 10

UJ'o

E.1i2

eft.
<t
to

X

I

~ ~ a;
~

Adenosine 3 mg/ml, 2 ml x 2
Amiodarone 50 mg/ml, 3 ml

as

:

Verapamil 2.5 mg/ml, 2 ml

x

2

L

_

:
I

'#-

I
I
I

<t

cO

Mannitol 25% (0.25 glml), 50 ml x 2

~ ~ r----------------~----------------~

e:

E
~ ~:
:c :c I

§ §:

'8

en

15
~

:
:

Sterile water for injection I
10 ml x 10
:

:--------------------------------

Magnesium sulfate
500 mglml,
2 ml x 4

:
I

:

I

I

I

I

I

I

Dextrose 25% bristojet (0.25 glml),
10 ml X 2
DeX1rose 50% (0.5 glml), 50 ml

X

2
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Critical Care Registered
Nurse (CCRN) Certification
Examination BlueprintPediatric Program
I. CLINICAL JUDGMENT (80%)
Assess, plan, intervene/implement, and evaluate a plan
of care for a patient with each of the following
conditions:
A. Cardiovascular (19%)
I. Myocardial conduction system defects (e.g.,
congenital heart block, Wolff-Parkinson-White
syndrome, prolonged QT interval)
2. Acute congestive heart failure/pulmonary edema
3. Hypertensive crisis
4. Cardiogenic shock
5. Congenital heart defect/disease
6. Hypovolemic shock
7. Acute inflammatory disease (e.g., myocarditis,
endocarditis, pericarditis)
8. Arrhythmias (e.g., supraventricular tachycardia,
Vtach, Vfib, atrial fib, atrial flutter, acquired
heart blocks, junctional rhythms, 2nd- and 3rddegree block)
9. Cardiomyopathies (e.g., hypertrophic, dilated,
restricti ve)
10. Cardiac trauma
B. Pulmonary (24%)
I. Acute respiratory failure
2. Respiratory distress syndrome (e.g., acute respiratory distress syndrome)
3. Acute respiratory infections (e.g., acute pneumonia, croup, strep pneumonia, epiglottitis,
respiratory syncytial virus, cystic fibrosis)
4. Status asthmaticus
5. Pulmonary hypertension
6. Thoracic trauma (e.g., lung contusions, fractured ribs, hemothorax, pulmonary hemorrhage)
7. Pulmonary aspirations (e.g., aspiration pneumonia. foreign-body aspiration)
8. Air-leak syndromes (e.g., pneumothorax)
9. Bronchopulmonary dysplasia
10. Apnea of prematurity (e.g., infant apnea, reflux
apnea)

II. Congenital anomalies (e.g., sequelae of dia-

phragmatic hernia, diagnosis and management
of tracheoesophageal fistula, tracheal malacia,
tracheal stenosis)
C. Endocrine (4%)
I. Diabetes insipidus
2. Syndrome of inappropriate secretion of antidiuretic hormone
3. Diabetic ketoacidosis
4. Acute hypoglycemia
5. Adrenal disorders (e.g., adrenal insufficiency,
inborn errors of metabolism, hyperthyroidism,
hypothyroidism)
D. Hematology/Immunology (4%)
1. Organ transplantation (e.g., liver, bone marrow,
kidney, heart, pancreas)
2. Life-threatening coagulopathies (e.g., disseminated intravascular coagulation, idiopathic thrombocytopenia purpura, hemophilia)
3. Immunosuppression (e.g., congenital [severe
combined immunodeficiency syndromeJ, acquired [human immunodeficiency virus, acquired
immunodeficiency syndrome, neoplasms])
E. Neurology (10%)
I. Encephalopathy (e.g., hypoxic-ischemic, metabolic, infectious, edema)
2. Head trauma (including shaken baby)
3. Spinal fusion
4. Acute spinal cord injury
5. Space-occupying lesions (e.g., brain tumors)
6. Hydrocephalus
7. Intracranial hemorrhage/intraventricular hemorrhage (including stroke)
8. Neurologic infectious diseases (e.g., meningitis)
9. Seizure disorders
10. Congenital neurological abnormalities (e.g.,
spina bifida, myelomeningocele, arteriovenous
malformation)
II. Neuromuscular disorders (e.g., muscular dystrophy, Werdnig-Hoffman)
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F. Gastrointestinal (5%)
I. Acute gastrointestinal (GI) hemorrhage
2. Hepatic failure/coma (e.g., portal hypertension,
fulminant hepatitis, biliary atresia, hyperbilirubinemia)
3. GI abnormalities (e.g., volvulus, malrotation,
intussusception, short bowel syndrome, Hirschsprung's disease)
4. Bowel infarction/obstruction/perforation (e.g..
necrotizing enterocolitis)
5. Acute abdominal trauma
G. Renal (3%)
I. Acute and chronic renal failure (e.g., acute
tubular necrosis)
2. Life-threatening electrolyte imbalances (e.g.,
potassium, sodium, phosphorus, magnesium, calcium)
3. Renal trauma

H. Multisystem (11%)
I. Septic shock/systemic immune response syndrome (e.g., meningococcemia)
2. Toxic ingestions (e.g, drug/alcohol overdose,
poisoning)
3. Asphyxia (e.g., near drowning, traumatic)
4. Bums
5, Hemolytic uremic syndrome
6. Multisystem trauma (e.g., child abuse)
II. PROFESSIONAL CARING AND ETHICAL
PRACTICE (20%)
A. AdvocacylMoral Agency (4%)
B. Caring Practices (4%)
C. Collaboration (4%)
D. Systems Thinking (2%)
E. Response to Diversity (2%)
F. Clinical Inquiry (2%)
G. Facilitator of Learning (2%)

Multidisciplinary ICU,
Children's Hospital, Boston,
Clinical Practice Guideline
Enteral Nutrition Support

I. When and where should enteral
feedings be started in the various patient
populations cared for in the MICU?

Advances in enteral feeding techniques, venous access, and
enteral and parenteral nutrition have made it possible to
provide nutritional support to almost all critically ill
pediatric patients. Despite the abundant literature and
widespread use of nutritional therapy, areas of nutritional support remain controversial and wide variations in
practice exist. Therefore a multidisciplinary task force was
convened to critically appraise the literature and make
recommendations on enteral nutrition and gut protection
practices to the Multidisciplinary Intensive Care Unit
(MICU) Committee.
Whenever possible, prospective randomized clinical
trials (PRCTs) were evaluated. Published reports were also
reviewed when PRCTs were unavailable. Each conclusion is
graded on the strength of evidence:

A. Critically ill patients are often hypermetabolic
early in their illness, especially when it is complicated by sepsis. The hypothesis that nutritional
support is clinically beneficial has not been supported by well-designed clinical trials. I
B. The rationale for nutritional support is based on
clinical judgment. Nutritional support is often
considered in patients who are unlikely to consume
adequate nutrients for a prolonged period. In
adults, the data suggest that critical depletion of
lean tissue occurs after 14 days of starvation. 1
C. Pediatric patients, because of higher metabolic rates
and energy needs for growth, are more susceptible
to under-nutrition than adults. The younger the
patient, the more rapid and severe the clinical
consequences of under-nutrition and starvation. The
current standard of care is to initiate nutritional
support in adults who will or have had 7 days of
inadequate energy intake. Studies of pediatric body
composition and energy reserves suggest a 5-day
cutoff for well-nourished children, and 3 days for
malnourished children and premature infants. 1.2
D. Data suggest that there are advantages to using
enteral over parenteral nutrition to meet the
nutritional requirements of the critically ill patient.
Critical illness is associated with gut atrophy and
increased mucosal permeability to bacteria and
macromolecules such as endotoxin. It has been
postulated that the translocation of these products,

A: Supported by PRCT or metaanalysis of PRCT
B: Supported by well-designed, nonrandomized, prospective, retrospective, or case cohort-controlled
studies
C: Supported by uncontrolled published experiences,
case reports, or expert opinion
The following three topical areas of enteral nutritional
support were addressed:
1. When and where should enteral feedings be started in
the various patient populations cared for in the MICU?
II. Which enteral feeding tubes should we be using in the
MICU? What is "best practice" in maintaining these
enteral feeding tubes in the MICU?
III. What enteral feedings should be administered and how
should they be started and advanced? How is enteral
feeding tolerance best assessed?
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or at least the relative ischemia and subsequent
reperfusion of the splanchnic organs, are somehow
implicated in the development of single- or
multiple-organ failure. Food in the lumen of the
gut is cytoprotective.] Animal studies demonstrate
that enteral nutrition maintains mucosal integrity
and the immunologic function of the gastrointestinal tract, decreases bacterial translocation, blunts
the systemic inflammatory response to a toxin
load, and improves survival in experimental hemorrhage and peritonitis. 4
E. Trauma patients fed by enteral nutrition have
fewer complications than patients given parenteral
nutrition (B). However, it is not clear whether
enteral nutrition support provides a specific benefit
or whether total parenteral nutrition (TPN) itself or
overfeeding with TPN is associated with increased
infections. I
F. The efficacy of enteral nutritional support in
critically ill children has not been subjected to
PRCTs. Chellis and colleagues demonstrated that
early transpyloric feedings were feasible, welltolerated without complication of aspiration or
abdominal distension, and cost effective in critically ill pediatric patients (B). 5 All patients were
mechanically ventilated; 76% were on one or more
vasoacti ve agents.

Recommendations
Unless contraindicated, all MICU patients should receive enteral nutritional support as soon as possible after admission.
Enteral feedings are contraindicated in the following
patients:
• Patients who may require endotracheal intubation or
extubation within 4 hours.
• Hemodynamically unstable patients requiring escalation of therapy.
• Patients with a postoperative ileus.
• Patients with active upper gastrointestinal bleeding.
• Patients at risk for necrotizing enterocolitis or other
causes of intestinal ischemia (as suspected on abdominal film or in patients post-major anoxic injury with
renal and liver dysfunction).
• Patients with intestinal obstruction.
• Patients post-allogenic BMT (bone marrow transplantation) who have graft-versus-host disease or postBMT patients before gut recontamination.
• Patients whose care is being redirected.
When enteral feedings are indicated, patients should be
fed by the following routes:
• Oral route, if the patient is alert, un intubated, with a
strong cough and gag reflex
• Nasogastric route, if the oral route is inaccessible and
the patient has a strong cough and gag reflex
• Nasojejunal route, if the patient is at high risk for
aspiration, such as those with a depressed gag reflex,
delayed gastric emptying, and gastroesophageal reflux

The risk of aspiration determines whether feedings are
placed in the stomach or jejunum. Gastric feeding is
preferable (even in the intubated patient) because it allows
the normal digesti ve process and hormonal responses to
continue. Gastric acid secretion may be important for
bactericidal effect. When compared with jejunal feeding,
gastric feeding allows tolerance to large osmotic loads with
less frequent cramping, distension, diarrhea, and a lower
likelihood of dumping syndrome.
Transpyloric feeding is indicated in patients at high risk
for aspiration, such as those with a depressed gag reflex,
delayed gastric emptying, and gastroesophageal reflux 6
Small-bowel feedings can usually be performed even in the
presence of gastric atony and colonic ileus. Concomitant
gastric decompression may be required.? If jejunal feedings
are selected, patients at risk for gastric ulceration should
also receive gut protection.
Of note, Montecalvo and others reported that adult patients fed by nasojejunal tubes (NJTs) received a significantly higher proportion of their daily caloric goal, had a
significantly greater increase in serum prealbumin concentrations, and had a lower rate of pneumonia than in similar
patients fed by continuous nasogastric tubes (NGTs)8
Ibanez and others also reported a high incidence of gastroesophageal reflux (GER) in adult patients with orotracheal
intubation and NGTs 9 The presence of a 7F NGT was a risk
factor for GER. Semirecumbency did not prevent GER, but
the incidence rate was lower than in the supine position.
If enteral feedings are contraindicated, parenteral nutrition should be initiated.

!la. Which enteral feeding tubes should we
be using in the MICU?
Name

Size

Corpak

6 Fr (22 in)
8 Fr (36 in)
6 Fr (20 in)
8 Fr (36 in)
6 Fr (30 in)
8-10 Fr (48 in)

Kangaroo
Accusite pH
Zinetics

Stylet Weighted

Yes
Yes
No
Yes
Yes

No
No
No
Yes
No

Costlea
$9.19
$11.07
$7.32
$8.36
$45.00

Krafte-Jacobs and others compared transpyloric feeding
tube placement using a pH-assisted placement versus
standard placement in critically ill children. 1O Results
indicated that 97% of patients in the pH-assisted group had
successful placement after the first attempt, compared with
53% in the standard group. The average time for successful
placement was 6 minutes. If placement was not successful,
a second placement attempt was made after metoclopramide
(Reglan) administration. All patients in the pH-assisted
group had successful placement after the second attempt,
compared with 78% of patients in the standard group. The
pH-assisted method was associated with decreased radiation
exposure and cost savings when compared with a standard
placement technique (A).
Weighted enteral tubes are used by the GI service in
patients with a history of vomiting.
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Recommendations
Use nonweighted enteral feeding tubes (EFTs) for gastric
placement and pH-guided EFTs for jejunal placement.
Although the pH-guided NJT is more expensive, it may
reduce hospital and patient costs by eliminating the use of
fluoroscopy.
Metoclopramide (Reglan) may be used to facilitate transpyloric intubation. Metoclopramide accelerates gastric emptying
and intestinal transit from the duodenum to the ileocecal valve
by increasing the amplitude and duration of esophageal
contractions, the resting tone of the lower esophageal sphincter, and the amplitude and tone of the gastric (anrral)
contractions, and by relaxing the pyloric sphincter and
duodenal bulb, while increasing the peristalsis of the duodenum and jejunum. These effects help coordinate gastric,
pyloric, and duodenal motor activity. Following IV administration, the onset of action on the gastrointestinal tract is I to
3 minutes; effects persist for I to 2 hours. A single IV dose is
0.1 to 0.2 mg/kg in patients under 6 years; 2.5 to 5.0 mg in
patients 6to 14 years; and 10 mg in patients 14 years and older.
When pH-guided EFT are used the pH should only be
rechecked if there is potential dislodgment. All EFTs should
be replaced on a monthly basis.

lib. What is "best practice" in maintaining
these enteral feedings tubes in the MICU?
Recommendations
A systemwide policy and procedure should be developed to
address the following issues II:
A. Flush EFT before and after medication administration
I. Rationale
a. Evaluate the patency of the tube
b. Clear formula residue or inadequately crushed
medications
c. Prevent physical and phannacokinetic incompatibilities
2. Flush solution: water or nonnal saline (to avoid
dilutional hyponatremia)
3. Flush volume
a. 3 mI minimum plus I ml per year of age up to
10 years
b. 10 to 30 ml after age 10 years (more fluid can
be used if desired)
B. Dilute liquid medications before administration (A)
I. Rationale
a. Prevent obstruction by viscous solutions
b. Prevent physiologic consequences of undiluted
medications
I) Irritation to the gastric mucosa
2) Gastric distension and diarrhea resulting
from hyperosmolar drugs
2. Diluent solution: water or normal saline
3. Diluent volume
a. Dependent on medication volume (e.g., 2 to
3 times medication volume)
b. 10 to 30 ml after age 10 years (more fluid can
be used if desired)
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C. Crush and dissolve tablets thoroughly before administration (C)
I. Rationale: Prevent tube obstruction
2. Methods: Crush tablet to a fine powder within
unit-dose packet using mortar and pestle or
Kelly clamps, or crush between two medication cups
3. Diluent solution: warm water
4. Diluent volume
a. I mllyr of age to 10 years
b. 10 to 30 ml after age 10 years (more fluid can
be used if desired)
5. Do not crush enteric-coated, sustained-release,
chewable, sublingual, or buccal fonnulations (C)
a. Rationale
I) Prevent tube occlusion from incompletely
dissolved medications
2) Prevent altered drug efficacy
a) Sustained-release: avoid potential adverse effects associated with higher than
expected peak concentration followed by
subtherapeutic levels
b) Enteric-coated: avoid stomach irritation or destruction of drug by gastric
acids
c) Chewable tablets: difficult to crush and
uneven particles can block feeding tubes
d) Sublingual and buccal drugs: lose effectiveness when delivered by an unintended route
b. Use alternative drug formulation or therapeutically similar drug
I) In some instances, the injectable fonn of the
medication may be given orally. Factors
impacting this decision include:
a) Type of salt
b) Drug stability in the gastric pH
c) First past metabolism (enteral dose may
require a large volume of parenteral
medication for equivalent effect)
d) Oral fonn may require a prodrug to
ensure bioavailability
D. Administer each medication separately, flushing with
water between medications (C)
I. Rationale
a. Prevent pharmacokinetic incompatibilities
b. Prevent tube occlusion
2. Flush solution: warm water or normal saline
3. Flush volume
a. 3 ml minimum then I mllyr of age to 10 years
b. 10 to 30 ml after age 10 years (more fluid can
be used if desired)
E. Avoid adding medications to enteral feeding formula
I. Rationale: prevent physical and pharmacokinetic
incompatibilities
a. Changes in drug potency and bioavailability
b. Viscosity, consistency, and particle size
c. Avoid formula contamination
F. If medications are best absorbed on an empty stomach
and patients are receiving continuous feedings, hold
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feedings for a time before and after medication
administration
l. Rationale: to optimize drug absorption
2. Time interval
a. 15 minutes (C)
b. some drugs, such as phenytoin, may require I to
2 hour formula-free intervals before and after
administration
G. Consult phannacy about medication administration
via EFTs (C)
I. Rationale
a. Prevent tube obstructions (C)
b. Optimize medication efficacy
2. Availability of liquid dosage form
a. Use liquid dosage form when available (C)
b. Not all liquid medications are suitable for EFT
delivery
1) Acidic liquid medications (e.g., elixirs) tend
to clump in enteral formula
2) Liquid medications with sweeteners often
contain sorbital, which is also a cathartic
3) Concentrated liquid medications tend to be
thick and need to be diluted with water,
especially in NJ tube fed patients
3. Optimal routes: NGT, NJT
4. Drug-formula compatibilities: Unlike IV-TPN
drug coadministration guidelines, the effects of
mixing drugs and enteral formulas have not
been well defined. The routine mixing of medications in enteral feeding formulations should be
discouraged.
5. Alternative therapeutic equivalents

Guidelines for Maintaining EFTs
I. Flush EFTs before and after checking for residual
gastric contents (C)
a. Rationale: Aspiration of gastric contents causes
coagulation (especially with low pH of gastric fluid
and with caseinate-based formulas)
b. Flush solution: water or normal saline
c. Flush volume
I) 3 ml minimum plus I mUyr of age to 10 years
2) 10 to 30 ml after age 10 years (more fluid can
be used if desired)
2. Flush all EFTs routinely (C)
a. Rationale: Retrograde migration of gastric juices
can occur (low pH causes increased obstruction)
b. Frequency options
I) Every 4 to 6 hours regardless of continuous
feeding
2) Every 4 to 6 hours if NOT on continuous
feeding
3) Whenever feedings are interrupted or feeding
rates are decreased
c. Flush solution: water or nonnal saline
d. Flush volume
1) 3 ml minimum then I ml/yr of age to 10 years
2) 10 to 30 ml after age 10 years (more fluid can
be used if desired)

3. Guidelines for managing obstruction of EFTs
a. Irrigation solution
I) Room-temperature or warm water is the preferred agent (A)
2) Coca-Cola (or other carbonated beverage) or
cranberry juice is seldom effective and should
not be used
3) If water fails to clear the EFT, use the following
enzyme solution:
a) In a medication cup, prepare a slurry consisti ng of the contents of I viokase capsule,
I sodium bicarbonate tablet, and approximately 10 to 30 ml of warm water (viokase,
a pancreatic enzyme, needs a basic environment to be acti ve)
b) Instill the slurry into the EFT; wait about 1
hour to ensure that the enzyme solution has
maximal contact with the obstruction
c) Withdraw the contents from the EFT (slurry
and obstruction), avoiding excess force to
prevent catheter damage
d) Irrigate the EFT with warm water before
resuming use

ilia. What enteral feedings should
be administered and how should
they be started and advanced?
The following recommendations are considered "best
practice" and are supported by uncontrolled published
experiences, case reports, or expert opinion.
A. What to feed (specific formulas are examples)
I. Resume previously established schedule or follow
the recommendations in the following table:
Premature

(<2 kg)
Normal
intact gut

<lyr

Breast milk, Breast milk,
Enfamil
Enfamil
Premature
with Iron

Lactose
intolerant
History of
constipa·
tion or
diarrhea,
neuromusculardisease, or
immobility
Fluid restricted

Lacto-free,

Renal
disease
Impaired gut
perfusion

PM 60/40

Prasabee

1 to
10 yr

>10yr

Pediasure,
Nutren Jr

Isocal,
Ensure

Isacal,
Pediasure,
Nutren Jr
Ensure

Pediasure
with
Fiber

Kcal dense

KCal
dense

Semielemental
Elemental

Ensure

with
Fiber,
Jevity

Ensure Plus,
Nutren
1.5 or 2.0

Osmolile

Pregestimil,
Pepta·
Alimentum
menJr
Neocate
Neocate +1,

Peptamen.
VitalHN
Vivonex

Pediatric
Vivonex

B. How to Feed: Bolus versus Continuous
I. If possible, resume previously established feeding
method and schedule
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2. Gastric route
a. Use bolus feedings (more "physiologic")
I) <6 months: every 3 hours
2) >6 months: every 4 hours
b. Use continuous gastric-tube feedings if an
intermittent bolus poses a significant risk of
respiratory distress, reflux, and aspiration 12
3. Transpyloric route: use continuous feedings
C. How to initiate feedings
I. Establish the goal of therapy
a. Enteral nutrition: calculate full caloric requirements and advancement plan
b. Trophic feeding: stimulate gut mucosal integrity and function, begin feeding within 24 hours
of admission at low rates 4
2. For nutrition
a. Strength
1) If the patient's ability to protect airway is
questionable begin with clear liquids
2) Start with full strength feeding UNLESS the
patient:
a) Is receiving a hypertonic feeding (>600
mOsm)
b) Has been NPO (nothing by mouth) for
more than 2 weeks
c) Was malnourished before admission
d) Is at risk for gut ischemia
3) If starting with 1/2 strength, increase to full
strength after 24 hours
b. Starting volume
I) Bolus: calculate half the volume of fullstrength formula needed to meet maintenance caloric requirements, then divide by
the number of feedings per day (C)6
2) Continuous 5 to 20 ml/kg/day; start low in
patients at risk for gut ischemia
c. How to advance
1) Bolus: increase by 25% each feeding as
tolerated
2) Continuous: <1 yr: 1 to 5 ml per hour every
3 to 4 hours; > 1 yr: 5 to 20 ml per hour every
4 hours
d. Consider the use of free H 2 0
I) As per routine before admission
2) If constipation an issue
3) If the patient is receiving calorically dense
feedings
4) To meet total fluid requirements
5) Volume, if intake is not a concern: 30 to
50 ml bolus
a) After tube medications OR

1083

b) After bolus feedings OR
C) Every 4 hours

3. Tropic feedings
a. Use full-strength formula as above
b. I to 2 mllhr
c. Route: NGT or NJT

IIIb. How is enteral feeding tolerance
best assessed?
Although the process is poorly understood, critical illness can seriously impair gastric emptying. Despite the
presence of a functioning, intact small bowel, gastroparesis and duodenogastric reflux can lead to feeding intolerance. In addition, gastroparesis and gastroesophageal
reflux can lead to nosocomial pneumonia. Separately,
opiate administration also contributes to altered intestinal
motility.
Erythromycin is a well-known prokinetic, but concerns
regarding the use of an antibiotic in another role, with the
risks of generating bacterial resistance, make it an unpopular
choice. 3
Only one PRCT was relevant to pediatric feeding
intolerance. 13 Only two issues-diarrhea and residualswere addressed.
A. What to assess
I. Bolus gastric feedings: check and refeed residual
before each feeding while advancing
a. If more than half the previous bolus feeding or
twice the hourly rate
b. If transitioning to jejunal feedings
2. Jejunal feedings: check abdominal girth every 12
hours while advancing; increasing abdominal distension may indicate reeding intolerance
3. Eliminate the practice of routine checking of
gastric residuals; the practice is not researchbased and precipitates feeding tube obstruction
and the unnecessary cessation of feedings. Do
check residuals if abdominal distension or retching
occurs 14.15
B. Expect loose stools « 15 to 20 mllkg/day)
I. If diarrhea is present, check other etiologies
before stopping feedings (e.g., Hz antagonist,
antacids--especially magnesium-containing, antibiotics, serum albumin level, Clostridium difficile,
sorbital content of current medications). Before
stopping feedings, send stool for reducing sugars
and fat.
2. Consider the use of antidiarrheal agents (for
nonseptic patients)
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CHILDREN'S HOSPITAL NEONATAL I PEDIATRIC TRANSPORT DATA BASE
(PRINT I SIGN I INITIAl BELOW) "'INITIAL EACH SECTION OF DB AS COMPLETED

NAME:
DATE:

TEAM MEMBERS

--'--'--

RN:
_ _ _ KG

AGE: _ _ 008: - 1__'__ WGT:

RN:

REF. HOSP./UNIT:

MD:

REPORT RECEIVED FROM:

EMT:

TIME CALL RECEIVED:
ARRIVE RH:
""

...

TIME

--

--

TEAM MOBILIZED: _ _ _

DEPARTRH: - - ARRIVE CH:

..

--

EMT:
MCP:

.VITALSIGNS

PT
ISOl.
TEMP TEMP.

HR

MEDICATIONS

NEURO
NIBP

RESP

CONTINUOUS
INFUSIONS

PUPILS
ABP

MAP

L.-----R

/ 1/
/ '/
/ 1/
/ 1/
/ /
/ /
/ /
/ /
/ /
/ /
/ /

/
/
/
/
/
/
/
/
/
/
/

/
/
/
/

/
/
/
/

/
/
/
/

/

1/

/

GCS

A

B

C

D

REFERENCE TABLES
AGE

W

premature

1

premature

'-2
2·3

1 moolh"
"""""'

'4Sfmill

135
'25
'20
'30
'20
115

•

6"""'"

7
'0

2-3 years
4·5 years
6-8 years
lo-T2yr
> 14 yr

12-14
16-18

, yea<

.........
100
100

20-26
J2 - 42
>50

75
70

Glasgow Coma sew.'
BntMotor
ee.tVefbI,I
(}.1 year
0-2 years

~.Irtc:

ftee9. n••

SVttotIcBP'
42~

·40
-40
·40
24 - 35
24 - 3S
20·30
20-30
20 -30
12-25
12-25
12-18

10

SO:a: 10
60:1:: 10
80:1: 16
89,.29

DlntokBr
21 :1:8
28:l:: 8
37:l:: 8

46% 16
603: 10

96,30

66:1'.25

99:1::25
99:1::20
lOOt: 15
'10:t 17
1I8:l:: 20

64'25
65,20
60% 10
60",10
60%10

o-tyeaB
•. spontaneo\Js
3.10 shout
2. 10 pain
1. no responC8

~: txaliz&spain
4. l\exion witMrawaJ
3. t1exionr'dooorticate
2. extension/decerebrate
1.

no response

0-1 years
4. spontanlIous
3. to shout
2. to pain
1_ no I'9spor1Ce

>1 year

~:=espain

4. flexion wilndrawal

3. l1exionldeconicate

2. extension/decerebrate
1. no response

Re.u.eitArtlon Equtpment I Drugs Based on Length Weight or Age
Length (em)
Weight (kg)
Age (y..,..)

Bag mask
Oral airway

58-70
5-7

0.'
inta~

inlarof

.........
""""'
EfT"".....
"'''''''''''''''' ,"''''
LkheCatheter
.....
eh..IT""

-Su:::tioncatnetet
Stylot

70-3'

8-"
1
child
smaletlikl

....

05-95
12·14

,
...."'""'"

3.00.5

3.51•.0

OF

1M...
8-"lf

51'

SF

4.01•.5
2Mil&l"
10F
SF

...F

8-'(lf
8-"lf

'Of
Hlf

,5-2llf

2G-24F

10-12F

95-107 107·124
15-17
'8-24
3

oh'"
oh'"

....

,
"'"
oh'"

'·5

ad",
S.O
2-

10F

1(lf

.-

SF
10-12F
10-12F
2o-2.F

'"

12-1.F
10-12F
24-32F

,....

124-138

138-156

8-"

>12

,.."

childla<1i1l:

"."

5.'

""-"
.....
'0

,,,

,,,

sma" adult
ad'"
2-3'
,(If

1'-1Bf
12F
28-32F

312F

,,18F

'OF

~:~Cry, smite, coo
3. fiappropriate rrt. scream
2. grunts
1. no response
.
2·5 years
5. appropriate wolds
•. inappropriate words
3. cries or $<:fearns
2. grunts
1. no respon&e
> 5 years
5 orienled
4. dlsori&rlted but converses
3. inappropriate worda
-2. incomprehensible
1. no response

Total score indicate5lhalll1jury IS mild [13 15). moderate (9-12). or severe (se).

Patient Fe.tuf..
Size (kg)

Pediatric Trauma SCore'
Sc<><e .,
Score .1
,20
10-20

Airway
Syslolic BP (mmHg)
Mental stalus
.
Openwoun<l

Extr8mirv frltCtUreS

noon.'
>90
.wake

00""

~

SCClftl-1

<10

mainlainable Non-maintainable

50-90
oblunded
.....oc
dosed

<50

como_

ooen~~1tioIe

'A IOtaI score of S 8 suggests ItMI need !of a specialized trauma center. A score of
< 1 predcts a tnoItality rita of > 98%. a acorn of" predict$ - 50% l'I"lOl1aIity, and a
score 01> 8 predicts < 1'" tnor\8Iiry.
Ramnofsky. J rraums 1988: 28:1038

.~
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SITE

LINES

UACTA~ED @

SOLUTION

UVCTA~ED @

--

A

/

SAFETY CHECK:

B

/

RES~ONSE ~RIORITY

C

/

PATIENT SAFETY RESTRAINTS

/

D

TOTAL

VENTILATOR ALARMS

INTAKE

GROUND

OUTPUT

AIR PROVIDER

~
~
~
~
~

/

~
~
~
~

i/
/
/
/

~
~

ETC02

Fi02

PI~

MODE

VI

iT

PEEP

PAW

SITE

PC02
pH

RATE

P02

TC02

/ /
1/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /

/
/
/
/
/
/
/
/
/
/
/

/
/
/
/
/
/
/
/
/
/
/

/

/
/
/
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CHIEF COMPLAINT:

_

HPI:

_

REF. HOSP. MEDS & TIMES:

_

REF. HOSP. PROCEDURES:
PERINATAL:

MAT. AGE_ G

P_ SAB_ TAB_ BLOOD TYPE_ AB_ GBS_ HEP_ HIV_ CHLY

SEROLOGY_ PRENATAL STEROIDS YIN
SIG. MAT. PMHx:

_

LABOR

PERINATAL COMPLICATIONS

ROUTE OF DELIVERY

ANESTHESIA

o

o MAT FEVER
o MATHTN
o FETAL DISTRESS
o ABRUPTION / PREVIA
o PRECIPITOUS DELIVERY
o OTHER,
_

o VAGINAL 0 VBAC
o SPONTANEOUS
o FORCEPSNACUUM
o CESAREAN SECTION

o GENERAL

NO

DYES

o SPONTANEOUS
o SPONT / AUGMENTED
o INDUCED
RUPTURE OF MEMBRANES

o AROM
o SROM

HRS I DAYS PTD

AMNIOTIC FLUID

HRS / DAYS PlO

o CLEAR

DATE OF DELIVERY _ _/_ _/ _ _
DR RESUSCITATION:

0 NONE

PRIMARY

o
o

0 BLOWBY 02

VITAMIN K 0

0 SUCTION BELOW CORDS

NONE

o
o
o

EMERGENCY

HEP B VAC 0

TIME OF DELIVERY

SPINAL / EPIDURAL
LOCAL

PRESENTATION

REPEAT

0 MECONIUM 0 BLOODY

wks (dates 0 uls 0 exam 0)

NEONATAL: GEST. AGE.

o

o

o
o

EYE CARE 0

VERTEX
BREECH
TRANSVERSE

STATE SCREEN 0

APGARS. _ _' _ _ '0

0 BAG/MASK

0 BAG/ETT

0 CPR

0 MEDS

PMH:

_

CURRRENT PT. MEDS:

1."'#;(31&1

_

_

IMMUNIZATIONS: UlO N / Y

_

EXPDSURES:N/Y

SIGNIFICANT FAMILY HISTORY:

_

SPIRITUAL/SOCIAL/CULTURAL:

_

iiMA;iJit·ii' -----------------------------------------PRIMARY CARE PROVIDER:

_

PARENT I GUARDlAN(S):

CHECKLIST:

o CHART COPY (IES)
o XRAY COPIES
o LABWORK
CONTROLLED SUBSTANCES:

_

o
o
o
o

PARENTAL CONSENT(S)

RECEIVING HOSPITAL:

INFO SHEET TO PARENT (S)

RECEIVING FIRM

CALLBACK TO MCP

RECEIVING SERVICE

COPP NOTIFIED

REPORT GIVEN TO

AMOUNT TAKEN

AMOUNT USED

AMOUNT WASTED

<--J _ _ -

_

PHONE(-! _ _ -

_

PHONE (_ _) _ _ -

_

PHONE

0 CHILDRENS

0 OTHER

UNIT

_

NOTIFIED 0
NOTIFIED 0

AMOUNT RETURNED

INITIALS

MS04

_

FENTANYL

_
_

MIDAZOLAM
LORAZEPAM
PENTOTHAL
OTHER

_
-'--

--,-

_
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NEUROLOGICAL I MUSCULOSKELETAL
FONTANEL
o FLAT
o FULUSOFT
o DEPRESSED
o BULGING

TONE
o JITTERY / SPASTIC
o HYPERTONIC
o NORMAL
o HYPOTONIC
o FLOPPY

HEADCIRC.
- - - CM

MOTOR STRENGTH
o RESISTS FORCE AI L
o MIN. RESISTANCE AI L
o RESISTS GRAVITY All
o NO RESISTANCE R / L

LOC
o ALERT/ ORIENTED
o ALERT! DISORIENTED
o LETHARGIC
o OBTUNDED
o STUPOROUS
o COMATOSE
o PHARMACOLOGICAL
SEDATION/PARALYSIS

REFLEXES
o COUGH
o GAG
o SUCK
o MORO

OTHER
o NUCHAL RIGIDITY
o CSF RHINORRHEA
o CSF OTORRHEA
o CAPUT
OCEPHALOHEMATOMA
o VPSHUNT
o HIP CLUNKS L / R

1\

RANGE OF MOTION
o NORMAL
o CONTRACTURES:

COMMENTS
RESPIRATORY

.

AIRWAY
o ORAL
o NASAL
o CPAP: PRONGS / NPT
o ETT' SIZE CUFF YIN
TAPED AT
CM 0 SECURE

-

TRACH SIZE

TYPE

-

---

CHEST TUBES
o LEFT: SIZE _ _ o SX 0 HV
o RIGHT: SIZE
o SX 0 HV

PATTERN
o REGULAR
o IRREGULAR
o APNEA
o KUSSMAUL
o CH-STOKES

..

SKIN COLOR
o PLETHORIC
o PINK
o PALE
o ASHEN
o MOTTLED
o JAUNDICED
o CYANOTIC

SUBSTERNAL
SUPRASTERNAL
SUBCOSTAL
INTERCOSTAL

BREATH SOUNDS
o STRIDOR
o WHEEZES INSP / EXP

o GRUNTING
o FLARING

LEFT
o CLEAR
o RALES
o RHONCHI
o DIMINISH.
o ABSENT

CXRREPORT:

COMMENTS

I

EFFORT
RETRACTIONS:
o
o NONE
o MILD
o
o
o MOD
o
o SEVERE

...

.

PERFUSION / SKIN
CAP REFILl_ SEC
OEDEMA 1+ 2+ 3+
o DEPENDENT
o GENERAL
o DRY
o MOIST
o DIAPHORETIC
o WARM
o COOL

PULSES
RADIAL
FEMORAL
PEDAL

DESCRIBE:

o REGULAR

FOUR EXTREMITY BPS
~I

~I

.

..

.

OTHER
o JVD
LIVER _ _CM BELOW RCM
SPLEEN TIP PALPABLE
o NO o YES

MURMUR
RGT o NO
o YES

-------

LFT

..

..

CAROIOVASCULAR

EKG
o IRREGULAR

RIGHT
o CLEAR
o RALES
o RHONCHI
o DIMINISH.
o ABSENT

OSINUS

.

_ _CM
o PACED

OTHER:

~ 0 GALLOP
S3 S4
~

COMMENTS

..

GASTROINTESTINAL
ABDOMEN
o SOFT
o FLAT
o ROUND
o DISTENDED
o FIRM
GIRTH

o
o
o
o

NONTENDER
TENDER AT _ _
VISIBLE LOOPS
ERYTHEMA

BOWEL SOUNDS
o ABSENT
o HYPOACTIVE
o ACTIVE
o HYPERACTIVE

GENITOURINARY

NUTRmON

o

NPO

GASTRIC TUBES
o NGT: SIZE TYPE
o NJT SIZE TYPE
TYPE
o OGT. SIZE o GT: SIZE TYPE
o PATENT
o PLACEMENT CONFIRMED
o DRAINAGE

-----

SINCE

HR

---

DIET:

STOOL: HEM +/-

- - CM

o EMESIS: HEM +/.
o BILIOUS
o PROJECTILE

BREAST 0
BOTTLE 0

COMMENTS:
LABORATORY RESULTS
CULTURES:
o BLOOD
o CSF
0 URINE
o TRACHASP
CX @ RHiCH
DCSF:
GLUCOSE
PROTEIN
RBC
WBC
P_ L_ M_
BLOOD TYPE:

CHEMISTRIES:

INTEGUMENT
KEY:

CBC:

++< >-<

AS - ABRASION
L

DIFF'%:

P
L

CA:___ PT:___
Bill:
AMYL:

PTT:
LIPASE'

- LACERATION

C - CONTUSION
I

B

-INCISION

FX - FRACTURE

M

B - BURN
R - RASH

_

OTHER LABS:

_

RADIOLOGY:

_

o

- DRESSING

T

- TENDERNESS

COOMBS:
COMMENTS:

o
o
o
o

AMBIGUOUS
NORMAL MALE
NORMAL FEMALE
FOLEY: SIZE

URINE:
o CLEAR
o SEDIMENT
o AMBER
o YEllOW
o HEMATURIA

--

INDEX
A

ACTH,806
Actinomycin 0, 533t
Activated charcoal, 1002. 1003
Activated partial thromboplastin time (APTT), 828t
Active immunity, 474t
Active transport, 373
Acute chest syndrome, 842, 843
Acute gastritis, 789, 790
Acute GVHD, 869-871
Acute hemolytic transfusion reaction, 831 t
Acute hypoxia, 588
Acute inflammatory demyelinating polyneuropathy
(AlDP),684
Acute interstitial nephritis (AIN), 740
Acute lung injury (ALI), 672-681
Acute lymphoblastic leukemia (ALL), 866, 867
Acute motor axonal neuropathy (AM AN), 684
Acute myocarditis, 629-631
Acute poststreptococcal glomerulonephritis (APSGN), 739
Acute renal failure (ARF), 735, 736; see also
Renal critical care problems
Acute respiratory distress syndrome (ARDS), 672-681
Acute respiratory failure (ARP), 498, 858-860
Acute tubular necrosis (ATN), 580, 737, 740
Acute tumor lysis syndrome (ATLS). 862-864
Acyclovir
anti infectious agent, as, 856-857
antidote, as, 533t
antiviral agent, as, 886t
renal failure, 747t
Adaptation, 20
ADCC, 479
Addison's disease. 811
Adenosine
cardiac arrest, 205
dosage/administration, 205
resuscitation drug, as, 1035t, 1036
side effects, 205
ADH, 374. 805
ADH deficiency, 807-809
ADH excess, 809-81l
Admission criteria, 656
Adolescents
developmental care, 4l
developmental characteristics. 37-40
hospitalization, and, 40, 41
Adrenal insufficiency/adrenal crisis, 811-813
~-Adrenergic blocking agents, 200, 203
Adrenergic receptors, 192. 193t
Adrenocorticotropic hormone (ACTH), 806
Adriamycin, 534t, 858
Adult CCRN examination, 7
Adult learning theory, 96, 99
Advanced life support; see Resuscitation efforts
Advocacy, 119
Advocacy/moral agency, 9, 10
Aerosol therapy, 281, 282, 282t

A-delta fibers, 550
A waves, 355
AACN, 6, 7
AACN Certification Corporation, 7, 8
ABCX model of crisis, 50
Abdominal injury, 963-967
Abdominal palpation, 153
Abdominal response, 345
Abdominal wall defects, 793, 794
Abducens nerve, 327, 333, 335t
ABG analysis, 262
Abnormal autonomic responses, 585
Abnormalities of body temperature regulation
drug fever, 452
hyperthermia, 450-452
hypothennia, 454-455
malignant hypothermia, 452-453
Abnormal respiratory patterns, 252t
ABO system, 878
Absent (collapse) rhythms, 1038
Absolute neutrophil count (ANe), 480, 481 t
Absorption, 770
Accentuated heart sounds, 154
Accessory nerve, 327, 333, 337t
Accommodation, 20, 73
Accountability, 82
ACE inhibitors (ACEIs), 199, 200
Acetaminophen
fever treatment, in, 45 I, 452
nonopioid, as, 567
overdose, 1004-1006
pain management, 565t, 567-568
Acetazolamide, 586t, 713
Acetylcholine, 142
Acetylcysteine, 282t
Acid-base balance, 309-321
analyzing. 314
base excess/deficit, 314
buffer system. 310, 311
electrolytes, 312-314
metabolic acidosis, 317t, 318. 319
metabolic alkalosis, 317t, 319, 320
mixed disturbances, 320, 321
renal system, 312
respiratory acidosis. 314-317
respiratory alkalosi s. 317, 318
respiratory system, 3 II, 312
triple acid-base disorders, 321
Acid-base disturbances, 314-320
Acoustic nerve, 327, 333, 336t
Acquired immune response (specific immunity), 473-480
Acrania, 325t

Page references in italics denote figures: page references
followed by "t" denote tables.
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Index

AET,643
AF,645
Afferent arteriole, 733
Afterdrop, 457
Afterload, 147-148
Age group tenninology, 425, 426t
Agenesis of corpus callosum, 325t
Aggression, 76
Agitation, 548, 556-559
pz-Agonists, 668
AIDP, 684
AIDS; see HIV infection
AIIRA, 200
AIN,740
Air embolism, 174, 176-177
Air-fluidized beds, 525, 529t
Airway adjuncts, 268-276
cricothyrotomy, 274
endotracheal tubes, 269-274
intubation medications, 271 t, 272t
nasopharyngeal airway, 268, 269
oropharyngeal airway, 269
suction catheters, 276
tracheostomy tubes, 274-276
Airway management, 276, 277
Airway pressure release ventilation, 287
Airways resistance, 246
Alagille's syndrome, 795
Alanine aminotransferase (ALT), 772t
Albumin, 371, 397, 772t, 829t
Albuterol, 282t, 385
Alcott, Louisa May, 3
Aldactone, 378t
Aldosterone, 374, 447, 587, 806
Alessio, Joan, 5
ALl,672-681
Alkaline diuresis, 1003
Alkaline phosphatase (ALP), 772t
ALL, 866, 867
Allen test, 262
Allogeneic transplantation, 868
Alloimmunization, 830
Allowing to die, 117
Alteplase, 838t
Alupent 5%, 282t
Alveolar dead space, 247
Alveolar gas equation, 240
Alveolar hypoventilation syndromes, 690
Alveolar period, 235
Alveolar-pulmonary capillary oxygen transport, 239-243
Alveolar ventilation (V A)' 240, 248
AMAN,684
Amantadine, 486
American family demographics, changing. 49
Amikacin
hemofiltration, 759t
intraabdominal sepsis, 784t
IV infusion, 438t
renal failure, 747t

Aminophylline, 438t, 533t
Amiodarone
cardiac arrest, 203
dosage/administration, 203, 204
renal failure, 747t
resuscitation drug, as, 1035t, 1036
side effects, 204
Amitriptyline, 568
Ammonia, 772t
Ammonia hypothesis, 799
Amphotericin, 533t
Amphotericin B
antifungal drug, as, 486
hemofiltration, 759t
IV infusion, 438t
renal failure, 747t
Amphotericin B lipid complex (ABLC), 856
Ampicillin
hemofiltration, 759t
intraabdominal sepsis, 784t
IV infusion, 438t
Ampicillin and sulbactam, 784t
Amrinone
cardiac arrest, 196, 197
dosage/administration, 197
hemofiltration, 759t
shock,939
side effects, 197
AMSA,533t
Amsacrine, 533t
Amylase, 772t
Anaphylaxis, 831 t
Anatomic dead space, 247
Anatomic shunt, 249
Anatomy, maturation, 462
Anatomy of pain, 549-551
central nervous system, 550-551
peripheral nervous system, 550
spinal cord, 550
ANCA,744
Anderson, Peggy, 107
Anectine, 270t, 702
Anemia, 838-840
Anencephaly, 325t
Anesthesia bags, 268
ANF,374
Angiography, 745, 746
Angiotensin II, 149, 150
Angiotensin II antagonists, 587
Angiotensin II receptor antagonists (AIIRA), 200
ANH,806
Anion gap, 318
ANLL,866
Anthropometric measurements, 395-397
Anti-T cell MoAbs, 490
Antibiotic SeI1Jffi dI1Jg concentrations (SDC), 485, 486
Antibiotics, 485
Antibody, 465, 479
Antibody-dependent cellular cytotoxicity (ADCC), 479

Index

Anticoagulants, 833
Anticonvulsants, 700
Antidiuretic hormone (ADH), 374, 805
Antigen-binding fragment (Fab), 465, 479
Antihemophilic factor A, 827t
Antimalarial drugs, 486.
Antimicrobial-resistant microorganisms, 486
Antimicrobial therapeutics, 485
Antineutrophilic cytoplasmic antibody (ANCA), 744
Antiprotozoal drugs, 486
Antithymocyte globulin-equine, 884t, 888
Antithymocyte globulin-rabbit, 884t, 888
uJ-Antitrypsin deficiency, 796, 797
Antitumor MoAbs, 491
Antiviral drugs, 486
Anxiety, 548
Aortic arch, 134, 135
Aortic rupture, 962
Aortic sac, 132
Aortic stenosis (AS), 153t, 596t, 599-60 I
Aortic valve dilation, 188
APACHE study, 72
Aperiodic analysis, 360
Apheresis, 833-835
Aplastic anemia, 839, 840
Aplastic crisis, 843
Apnea, 252t, 689, 690
Apneustic, 252t, 348t
Appendix, 767
APSGN,739
APTT, 828t
Arachnoid layer, 326
Arachnoid villi, 326
Arcuate artery, 733
ARDS, 672-681
ARF, 498, 735, 736, 858-860; see also Renal critical care
problems
Arginine, 402
Arnold-Chiari malformation, 325t
Arrhythmia; see Cardiac rhythm disturbances
Arterial blood gas (ABG) analysis, 262
Arterial blood gas analysis, 3 J5
Arterial blood pressure monitoring, 171-174
Arterial blood pressure monitoring system, 170
Arterial cannulation sites, 171, 172
Arterial oxygen content (Cao2 ), 241
Arterial pressure analysis, 172, 173
Arterial switch operation (ASO), 620
Arteriohepatic dysplasia, 795
Arteriovenous malformations (AVMs), 705-707
ASO,620
Aspartate aminotransferase (AST), 772t
Asphyxial cardiac arrest, 716
Aspirin, 451, 452, 634
Assertive communication, 76
Assimilation, 20
Asthma, 667-670
Asymmetric velocity, 294
Asystole, 1038
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Ataxic, 252t, 348t
Atelectrauma, 675
Atenolol, 203
Atgam, 884t, 888
Ativan, 570
ATLS, 862-864
ATN, 580, 737, 740
Atrial arrhythmias, 642-646
Atrial ectopic tachycardia (AET), 643
Atrial electrocardiogram, 163
Atrial fibrillation, 644, 645
Atrial flutter (AF), 158, 645
Atrial natriuretic factor (ANF), 374
Atrial natriuretic hormone (ANH), 806
Atrial septal defect (ASD), 590t, 591
clinical presentation and course, 592
device closure, 592
management, 592
surgical correction, 592
Atrioventricular conduction block, 647, 648
Atrioventricular nodal reentrant tachycardia
(AVNRT),643
Atrioventricular nodaVjunctional arrhythmias, 646-648
Atrioventricular reentrant tachycardia (AVRT), 643
Atrioventricular septal defect (AVSD), 590t, 594, 595
Atrioventricular valves, 134
Atropine
aerosol therapy, in, 282t
intubation medication, as, 271 t
resuscitation drug, as, 1035
spinal cord injury, 958
Atrovent, 282t
Attachment, 22-23
Auscultation
lungs, 253, 254
tissue perfusion, 153, 154
Auto-PEEP, 289
Autologous BMT, 868
Automatic SVT, 643
Autonomic nervous system regulation of blood flow, 149
Autonomic responses, abnormal, 585
Autonomy, I I I
Autoregulation of blood flow, 149
Autosplenectomy, 843
AV block, 647
AVMs, 705-707
AVNRT,643
Avoidance, 73
AVPU scale, 950
AVRT,643
Axillary artery, 172
Azathioprine, 883t, 887
Azotemia, 736-741
AZT, 495, 501
Aztreonam, 784t
B
B cell differentiation factor (BCDF), 476
B cell disorders, 493
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Index

B cell growth factor (BCGF), 476
B cells, 465
B waves, 355
Baby Doe cases, 120
Baby Doe regulations, 110
Baby rule of nines, 983, 985
Bacterial interference, 468
Bacterial meningitis, 709
Bacterial tracheitis, 662
Bactericidal/permeability-increasing protein (BPI), 943
BAEPs, 364
BAERs, 362-364
Bag-valve-mask ventilation, 267, 268
Ballard's trach care closed-system suction catheter, 277
Balloon angioplasty, 598
Balloon tamponade, 792
Balloon valvuloplasty, 188
Barbiturate coma, 356
Barbiturates
intracranial hypertension, 700, 718
overdose, 1006, 1007
sedative, as, 570
Basal metabolic rate (BMR), 400
Base deficit, 314
Base excess, 314
Basilar skull fracture, 951
Basiliximab, 885t, 889
Basis for intervention, 49-50
Basis pontis, 328
Basophilia, 465
Basophils, 465
BBB, 162, 163
BCOF,476
BCGF,476
Bechwith-Wiedemann syndrome, 793
Bedside contact, 57-61
Behavioral objecti ves, 100
Benner, Patricia, 86
Benzodiazepine withdrawal, 572
Benzodiazepines, 570
Bereavement, 63, 64
Berkow chart, 983
Best interest principle, 109
Betadine, 994t
Bethanechol, 782
Bicarbonate-carbonic acid buffer pair, 310, 311
Bidirectional cavopulmonary shunt, 614-617
Bidirectional Glenn shunt, 614
Bidirectional superior cavopulmonary anastomosis, 6/5
Bilateral atrial enlargement, 158
Bilateral diffuse peripheral infiltrates, 859
Bilateral peritracheal and parahilar infiltrates, 859
Bile, 768
Biliary atresia, 795
Bilirubin, 772t
Bio-Console, 220
Bio-Medicus (Medtronic) system, 220, 22/
Bio-Pump, 220
Bioavailability, 426

Biochemical indices, 397-399, 398t
Biotherapy,487
Biotrauma, 675
BIPAP,292
BIS,559
Bispectral index (BIS), 559
Biventricular assist device (BVAD), 216
Bladder rupture, 968
Bleomycin, 858
Blood, composition, 823-827
Blood-brain barrier, 340
Blood cells, 822
Blood gas analysis, 262, 263
Blood gas values, 263t, 315t
Blood level sampling time guidelines, 436t, 437t
Blood pressure, 150, 151, 1055. /056
Blood product transfusions, 828-832
Blood stem cell, 823
Blood urea nitrogen (BUN), 376,737, 738t
Blunt kidney injury, 968
Blunt renal injury, 968
BMI,397
BMR,400
BMT,868-871
Body composition, 399
Body fluids; see Fluid and electrolyte regulation
Body mass index (BMI), 397
Body temperature; see a/so Thermal regulation
abnormalities of, 450-457
assessment and maintenance of normal body
temperature, 447-448
assessment of temperature imbalance, 448-449
behavioral control of, 445
cooling methods for treating elevated temperature, 452t
ineffective thermoregulation, 444t
mechanisms of thermoregulation, 445
physiologic control of, 444-445, 445
risk of occult bacteremia, 449t
thermoregulation, 444
thermoregulation devices, 449-450
Bohr effect, 241
Bolus feedings, 411
Bone marrow, 463, 821
Bone marrow aspiration, 827
Bone marrow transplantation (BMT), 868-871
Borel, Jean, 876
Botulism, 503, 686
Bowman's capsule, 733
BPO, 682-684
BPO spells, 683
BPI,943
Brachial artery, 172
Braden Q scale, 519
Bradyarrhythmias, 209
Bradypnea, 252t
Brain, 326-329
Brain death, 722, 723
Brain herniation syndromes, 696
Brain mapping, 364

Index

Brain tumors, 707-709
Brain volume reduction, 700
Brainstem, 328, 329, 330
Brainstem auditory evoked potentials (BAEPs), 364
Brainstem auditory evoked responses (BAERs), 362-364
Brainstorming, 77
Breast milk, 403, 404t, 470
Breath sounds, 253
Bretylium, 204, 438t
Brevital, 270t
Broad-spectrum antibiotics, 485
Bromide, 759t
Bronchiolitis, 664-667
Bronchopulmonary dysplasia (BPD), 682-684
Bronchoscopy, 265, 266
Bronkosol 1%, 282t
Brown fat, 445
Bubble blowing, 280
Buffer, 309
Buffer system, 310. 311
Buffer system pairs, 310t
Bulbus cordis, 132, 133
Bumetanide
diuretic, as, 191, 378t
heart failure, 586t
renal failure, 748t
Bumex,378t
BUN, 376, 737, 738t
BUN/creatinine ratio, 376, 744, 745
Bundle branch block (BBB), 162, 163
Burkitt's lymphoma, 862
Burn depth categories, 983t
Burn injuries, 981-997
acute phase, 991-996
cardiovascular response, 989
chemical injuries, 985, 986
circumferential burns, 987, 988
classification of wounds, 983
comfort management, 991
critical care management, 988-996
electrical injuries, 984, 985
etiology, 981, 982
exfoliative disorders, 988
fluid resuscitation, 989, 990
immune response, 989
inhalation injury, 986, 987
metabolic response, 989
pathophysiology, 982, 983
psychologic support, 991
SSSS, 988
TEN,988
thermal injuries, 983
transfer to burn center, 991
wound care, 990-993
zones of injury. 982
Burnout, 80
Burst suppression, 356, 358
Busulfan, 858
Butorphanol, 566

1095

Button, 411
BVAD,216
C
C fibers, 550
C-reactive protein (CRP), 481
C waves, 355
Calcium
clotting factor, as, 827t
fluid/electrolyte regulation, 379t, 385-388
hypo/hypercalcemia, 386-388
resuscitation drug, as, 1035t, 1036
Calcium antagonists, 718
Calcium salts, 533t
Call-mediated cytotoxicity, 479
Calorimetry, 399
Camino fiberoptic system, 352
cAMP, 192
Canalicular period, 235
Canals of Lambert, 238
Cancer; see Oncologic critical care problems
Candesartan, 587
Candida, 541

Candidal yeast rash, 542, 543
Cannon a waves, 161, 162
Cao2 ,241
Capillary blood gas (CRG) analysis, 263
Capillary refill time, 153
Capillary shunt, 249
Capnograms, 259-261
Capnography, 259
Capnometer, 258
Captopril
cardiac arrest, 200
dosage/administration, 200
side effects, 200
Capture threshold, 211
Carbamazepine, 568, 1007, 1008
Carbon dioxide (C0 2 ), 209
Carbon monoxide exposure, 986t
Cardiac compressions, 1032
Cardiac dysrhythmias in hypothermia, 456t
Cardiac cycle, 142-144
Cardiac glycosides, 193
Cardiac index (CI), 187
Cardiac monitors, 155
Cardiac murmurs, 154, 155
Cardiac musculature, 139
Cardiac output, 144-148, 185-187
Cardiac performance, determinants, 583
Cardiac rhythm disturbances, 640-651
AF/IART, 645, 646
atrial arrhythmias, 642-646
atrial fibrillation, 644, 645
atrioventricular nodal/junctional arrhythmias, 646-648
AV block, 647, 648
diagnosis, 640, 641
etiology/pathogenesis, 640
JET, 646, 647

1096

Index

Cardiac rhythm disturbances---cont'd
PVCs,648
sinus node abnormalities, 641, 642
SVT, 642-644
ventricular arrhythmias, 648-65 I
VF, 649-651
VT, 648, 649
Cardiac rhythm assessment, 156-165
Cardiac tamponade, 622, 960, 961
Cardiomegaly, 165
Cardiomyopathy, 635-640
Cardiopulmonary arrest, 716, 1025-1026;
see also Resuscitation efforts
Cardiopulmonary bypass (CPB), 450, 621
Cardiopulmonary resuscitation (CPR), 11 5
Cardiovascular critical care problems, 579-654
acute myocarditis, 629-631
arrhythmia, 640-65 I; see also Cardiac rhythm
disturbances
baseline support, 580-581
cardiomyopathy, 635-640
cardiovascular dysfunction, assessment, 579-580
CNS assessment, 628
congenital heart disease, 589-620; see also Congenital
heart disease
critical care management, 624-629
cyanosis/hypoxemia, 587, 588
feeding/nutrition, 628
final common pathways, 580
fluid/electrolyte replacement, 627
heart failure, 581-587; see also Congestive heart failure
hemodynamic assessment, 624, 625
HIV infection, and, 500
infection prophylaxis, 628
intracardiac catheters, 625, 626
Kawasaki disease, 631-635
pain management, 628, 629
perioperative techniques, 621, 622
postoperative techniques, 622-624
preoperative preparation, 620, 621
renal function, 627
respiratory care, 626
thermal regulation, 628
wound care, 628
Cardiovascular dysfunction, assessment, 579-580
Cardiovascular system
antiarrhythmic agents, 201-205
cardiac catheterization, 187-190
cardiac rhythm monitoring, 155-165
disease states; see Cardiovascular critical care problems
echocardiography, 167-169
hemodynamic monitoring, 169-187;
see also Hemodynamic monitoring
inotropic therapy, 192-197
intravascular volume restoration, 190-192
invasive evaluation/diagnosis, 169-190
mechanical circulatory support, 215-226;
see also Mechanical circulatory support
noninvasive evaluation/diagnosis, 155-169

Cardiovascular system---cont'd
pharmacologic support, 190-205
physical assessment, 152-155
physical examination, ISO-ISS
radiographic evaluation, 165-167
tissue perfusion; see Tissue perfusion
vasodilating agents, 197-200
vital signs, 150-152
Cardioversion, 644-646
Care perspecti ve, 113, 114
Caring practices, 9,10-11, 17-46,47-67
Carmustine, 533t
Catecholamines, 194, 806
Catheter-associated bacteremia, 177
Catheter fling whip, 182
Catheter knotting/kinking, 184
Catheter occlusion, 177
Catheter-tip strain-gauge catheters, 352
Cause-and-effect diagram, 77
Caustic bums, 1020, 1021
CAVH, 755, 756
CBF,342
CBG analysis, 263
CCNS program, 8
CCRN blueprints using synergy model, 8t
CCRN certification, 7, 8
CCRN-Pediatric certification, 8
Cecum, 767
CEEG devices, 358-362
Cefmenoxime, 759t
Cefoperazone, 759t
Cefotaxime
hemofiltration, 759t
intraabdominal sepsis, 784t
renal failure, 747t
Cefotiam, 759t
Cefoxitin, 759t
Ceftazidime, 759t, 784t
Ceftriaxone, 438t
hemofiltration, 759t
intraabdominal sepsis, 784t
renal failure, 747t
Cefuroxime, 747t
Celecoxib, 567
CellCept, 883t, 887, 888
Cellular factors, 584-585
Central apnea, 690
Central chemoreceptors, 239
Central cyanosis, 152
Central herniation, 696, 698t
Central hypoventilation syndrome, 690
Central nervous system (CNS), 550
Central nervous system circulation, 339, 340
Central nervous system dysfunction, SOl
Central neurogenic hyperventilation, 252t, 348t
Central venous cannulation, 175
Central venous catheter occlusion, 837, 838
Central venous pressure monitoring, 174-178
Centrifugal VAD pump, 220-224

Index
CE0 2 ,365
Cephapirin, 759t
Cerebellar astrocytomas, 707
Cerebellum, 329
Cerebral angiography, 366
Cerebral autoregulation, 342
Cerebral blood flow (CBF), 342
Cerebral blood volume reduction, 699, 700
Cerebral contusion, 953
Cerebral edema, 697, 800, 815
Cerebral function monitor (CFM), 359, 360, 362
Cerebral metabolic rate (CMR), 342
Cerebral peduncles, 328
Cerebral perfusion pressure (CPP), 342
Cerebral resuscitation, 719
Cerebral salt wasting syndrome, 809
Cerebrospinal fluid, 329, 330, 331 t, 365
Cerebrospinal fluid volume reduction, 70 I
Cerebrovascular accident (CVA), 843
Cerebrum, 326
Certification, 7, 8
Cervical collar, 948
CFM, 359, 360, 362
Charcoal administration, 1002, 1003
CHB, 161,647,648
CHD; see Congenital heart disease
CHDs, 135, 136
Chemical injuries, 985, 986
Chemical paralyzing agents, 699
Chemical thermogenesis, 445
Chest percussion and vibration, 280
Chest physiotherapy (CPT), 280
Chest radiographs (CXR), 165, 166, 482
Chest tubes, 281-283
Cheyne-Stokes, 252t, 348t
CHF; see Congestive heart failure
CHI, 398
Child abuse, 974-977
Child health questionnaire, 13
Child maltreatment, 974-977
Child's best interests, 109
Children's Hospital neonatal/pediatric transport data base,
1085-1089
Chimerism, 879
Chloral hydrate, 565t
Chloramphenicol, 533t
Chlordiazepoxide, 759t
Chloroquine, 486
Chlorothiazide, 191, 192, 378t
Choice, 74
Choline magnesium trisalicylate, 564t
Christmas factor, 827t
Chronic hypoxia, 588
Chronically critically ill child, 41-44
developmental care, 42, 43
family care, 43, 44
impact of chronic illness, 42
impact of critical care, 42
impact on family, 42
response to chronic illness, 43t
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Chvostek's sign, 374
Chyme, 768
CI,187
Cilastatin, 759t
Cimetidine
acute gastritis, 790
GER,782
IV infusion, 438t
Cingulate herniation, 696
Ciprofloxacin, 759t
Circulatory alterations, 686-689
Circulatory overload, 831
Circumferential burns, 987, 988
Cisapride, 782
Cisatracurium besylate, 271t
Cisplatin, 533t, 759t
Citrate toxicity, 831
CK-MB,962
Class I agents, 201
Class I antigens, 462
Class IA agents, 20 I
Class IB agents, 202
Class IC agents, 202
Class II agents, 202, 203
Class II antigens, 462
Class III agents, 203, 204
Class IV agents, 204
Clindamycin
hemofiltration, 759t
intraabdominal sepsis, 784t
renal failure, 747t
Clinical advancement process, 96
Clinical categories for children with HIV infection, 497
Clinical development
clinical advancement process, 96
facilitating clinical learning, 96
RN I, 87, 88t, 97t, 981
RN II, 87, 89t, 94, 97t, 98t
RN III, 90t, 94, 97t, 98t
RN IV, 92t, 95, 97t, 98t
skill acquisition model, 86
Synergy Model, 7-8, 12-13,86
Clinical inquiry, 12
Clinical judgment, 9, 10
Clinical manifestations of heart failure
diagnosis, 585
impaired myocardial performance, 585
pulmonary congestion, 585
systemic venous congestion, 585
Clinical manifestations of pediatric HIV infection, 498t
Clinical pharmacology, 425-442
absorption, 416t, 426-428
blood level sampling time guidelines, 436t
calculating doses, 439-441
distribution, 428, 429
dosage forms, 438-439
dosing of medication, 433-435
drug interactions, 441
elimination, 431-432
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Clinical pharmacology-cont'd
IV administration, 435, 438, 438t
medications that should not be crushed, 440t
metabolism, 429-431
pediatric age group terminology, 425, 426t
pediatric pharmacokinetics, 425-432
pharmacodynamics, 432-435, 433
therapeutic drug monitoring, 435
Clinical practice guidelines (CPGs), 12
Clofibrate, 759t
Clonidine, 1008, 1009
Clopidogrel, 635
Closed-end pouches, 538
Closed tracheal suction system (CTSS), 280
Closing capacity, 248
Clotting cascade, 826
Clotting continuum, 826
Clotting factors, 827t
Clouding of consciousness, 346t
Clubbing, 152
Cluster, 252t
CML,866
CMR,342
CMR0 2 ,365
CMV, 798, 830, 832, 896
CMV-Ig, 488
CNS, 550
CO 2 , 209
CO determination, 185-187
CO equation, 144
Coaching, 75, 76
Coagulation, 826
Coagulopathy, 832
Coarctation of aorta, 595-599
Coarctation of the aorta, 136
Cocaine intoxication, 1017, 1018
Code blue quality improvement tool, 1051
Code blue record, /043
Codman Microsensor ICP system, 352
Cognitive appraisal, 18
Cognitive behavioral techniques, 561
Coil embolization, 189
Cold air blankets, 450
Cold diuresis, 455
Cold shock, 941
Cold stress, 445
Collaboration, II, 73
Collaborative governance, 75
Collagen, 512
Collagenase, 994t
Collecting duct, 733
Collier's sign, 344
Colloid osmotic pressure (COP), 371
Colonization, 468
Colony stimulating factors (CSFs), 488, 489t
Color, 152
Color Doppler, 167
Colostomy, 538
Coma, 346t, 347t

Combined immunodeficiencies, 493, 494
Combined Ross-Konno operation, 601
Comfort scale, 557, 558t
Commitment, 74
Comrnodio cordis, 962
Common cardinal vein, 132
Communicating hydrocephalus, 712
Communication, 74
Community support groups, 45
Compartment syndrome, 972, 973
Competencies important to the patient, 9
Competency-based orientation program, 102-104
Competency statement, 102
Competent nurse (RN II), 87, 89t, 94, 97t, 98t
Competition, 73
Complement deficiencies, 493
Complement system, 472, 473, 481
Complete AVSD, 594, 595
Complete heart block (CHB), 161, 647, 648
Complexity, 8
Compliance
lung, 245, 246
tissue perfusion, 146
volume/pressure relationship, 341
Complicated ileus, 778
Compressed spectral array (CSA), 360, 362
Compromise, 73
Computed tomography (CT), 365, 366
Computerized EEG (CEEG) recordings, 358-362
Conceptual foundation for caring practice
adaptation/mastery, 20
copi ng, 18-20
stress, 17, I8
stressors during hospitalization, 20-22
Conceptual framework, 8t
Concussion, 953
Conduction system, 140
Conductive heat loss, 446
Confidence, 74
Conflict resolution, 73
Confluence of sinuses, 327
Congenital annular pancreas, 777
Congenital cardiac defects, classification, 589
Congenital CHB, 161
Congenital diaphragmatic hernia, 236, 681, 682
Congenital heart block, 647, 648
Congenital heart defects (COOs), 135, 136
Congenital heart disease, 589-620
acyanotic heart defects, 589, 590t
atrial septal defect (ASD), 591-592
AS, 599-601
ASD,591-592
AVSD,594-595
coarctation of aorta, 595-599
HLHS,612-614
patent ductus arteriosus (PDA), 589-591
PDA,589-591
PS, 601, 602

Index
Congenital heart disease-cont'd
pulmonary atresia with intact ventricular system,
606-608
TAPVC, 609-611
tetralogy of Fallot, 602-606
TGA, 617-620
tricuspid atresia, 608, 609
truncus arteriosus, 611, 612
VSD, 592-594
Congenital rubella syndrome, 136
Congestive heart failure, 581-587, 582t
acquired heart disease, 581
causes, 581, 582t
clinical manifestations, 585
congenital heart failure, 581
diagnosis, 585
diuretic therapy, 586
etiology, 581-583
hemodynamic characteristics, 583, 584
neurohormonal factors, 584, 585
neurohormonal modulation, 586, 587
nutrition, 587
pathogenesis, 583-585
Consciousness, 344, 346t
Constant segment (Fc), 465, 479
Constipation
botulism, in, 686
enteral feeding, and, 411
opioid use, and, 566
Containment, 27
Content evaluation, 101
Continuing education, 105
Continuous arteriovenous hemofiltration (CAVH),
755, 756
Continuous arteriovenous rewarming, 457
Continuous bedside EEG monitoring, 356-362
Continuous feedings, 411
Continuous lateral rotation beds, 529t
Continuous murmurs, 154
Continuous positive airway pressure (CPAP), 286
Continuous venovenous hemodiafiltration (CVVHD), 761
Continuous venovenous hemofiltration (CVVH), 755-761
Contractility, 148
Contrast-enhanced CT, 745
Controlled breathing, 561
Controlled CSF venting, 353
Controlled ventilation (CV), 285
Conus cordis, 133
Convection, 294
Convective heat loss, 446
Conventional arteries, 238
Cooling devices, 450
COP, 371
COPE program, 54
Coping, 18-20,53
Core temperature monitoring, 447, 448
Coronary circulation, 139, 140
Corrected transposition of the great arteries (L-TGA), 618
Corticosteroids, 701, 888
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Cortisol, 806
Coumadin, 635, 833t
Courage, 74
COX-I isoform, 567
COX-2 inhibitors, 567
COX-2 isoform, 567
CPAP, 286
CPS, 621
CPGs,12
CPP, 342
CPR, 115
CPT,280
Crackles, 253
Cranial deformities, 325t
Cranial meninges, 326
Cranial nerves, 332, 333, 334t-337t
Cranial ultrasound, 365
Craniosynostosis, 325t
Craniotomy, 709
Creating opportunities for parent empowerment
(COPE),54
Creatinine, 376, 737, 738t
Creatinine height index (CHI), 398
Cremasteric response, 345
Crepitant rales, 253
Crepitus, 253
Cricoid ring, 237
Cricothyrotomy, 274
CRIES neonatal postoperative pain measurement score,
554, 555t
Crisis theory, 50-51
Critical aortic stenosis, 599
Critical care experience, impact on families, 47-67
Critical care internship programs, 102
Critical care management of patients with
cardiac failure, 586-587, 586t
HIV, 502-503
Critical care nurses, 11
Critical care nursing
history, 3-5
nurse advocacy, 119
Critical care problems; see Final common pathways,
Multisystem problems
Critical care registered nurse (CCRN) certification
examination blueprint-pediatric program,
1077-1078
Criticism, 76
Crohn's disease, 536
Croup, 659, 660
CRP, 481
Cryoprecipitate, 829t
Crypts of LieberkUhn, 768, 769
CSA, 360, 362
CSF, 329-331, 365, 568
CT scans, 365, 366
CTSS, 280
Current challenges, 71, 72
Current environment, 14, 15
Cushing's syndrome, 815
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CV,285
CVA,843
CVVH, 755-761
CVVH flow sheet, 760
CVVHD, 761, 846
CVVHDF,761
CXR, 165, 166
Cyanide poisoning, 198
Cyanosis, 152, 251, 587-588
clinical presentation, 587-588
etiology, 587-588
Cyclic antidepressant overdose, 1012-1 14
Cyclic GMP, 679
Cyclooxygenase (COX), 567
Cyclophosphamide, 858
Cyclosporine
hemofiltration, 759t
immunosuppressant therapy, in, 880, 88lt, 886
renal failure, 747t
Cytokines, 474, 488
Cytomegalovirus (CMV), 798, 830, 832, 896
Cytosine arabinoside, 858
Cytotoxic edema, 697
Cytotoxic T cells, 466
Cytotoxicity, 479
Cytovene, 885t
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D
D-dimer, 828t
D-TGA,618
Dacarbazine, 533t
Daclizumab, 885t, 889
Dactinomycin, 533t
Daily adapting, 81
Daily bedside contact, 57-61
Daily honeymoon technique, 255
Dallas criteria, 630
Dalton's law of partial pressures, 263
Damping coefficient, 171
Dantrolene. 453
DAP, 172
Daunorubicin, 533t
DCM, 635-638
Dead space, 247, 250
Dead space ventilation (V D), 247
Death
after support, 45
bereavement, 63, 64
children's development of concepts about, 44
helping after, 45
PICU, and, 44-45
talking to children about, 45
Decision-making models, 117-119
Decreased adaptive capacity, 701
Deep breathing and coughing, 280
Deep endotracheal suctioning, 276
Deep sedation, 571
Deep tendon reflexes, 345
Defense mechanisms, 19,20, 20t

Deferoxamine, 841
Defibrillation, 645, 651
Deficiencies, complement, 493
Degranulation, 464
Dehydration, 376-381
Delayed hypersensitivity (DH) skin testing, 481, 482
Delegation, 81, 82
Delirium, 346t, 548
Delta agent, 797
Denial,20
Dependency, 22
Depressed skull fracture, 951
Derived hemodynamic indices, 186, 187
Dermis, 512
Desired results, 81
Desmopressin acetate (DDAVP), 808
Developmental disruption, 22
Developmental characteristics
adolescents, 37, 38t, 40
first year of life, 22
infancy, 26
neonatal period, 26
parent-infant attachment, 22-23
preschoolers, 31
school-age children, 34
toddlers, 28, 29t
Developmental stages
adolescents (12 to 21 years), 37-41
impact of hospitalization, 26, 28, 30, 31, 33, 34, 36,
40-41
infants (0 to 12 months), 22-28
preschoolers (3 to 5 years), 31-34
school-age children, 34-37
toddlers (1 to 3 years), 28-31
Dexamethasone, 535
Dextrocardia, 135
Dextrose, 417
Dextrose 10%, 533t
DH skin testing, 481, 482
DHPG,885t
DI, 807-809
Diabetes, 815
Diabetes insipidus (DI), 807-809
Diabetic ketoacidosis (DKA), 815-818
Diagnostic peritoneal lavage (DPL), 966
Dialysis, 1003
Diamox, 713
Diaper dermatitis algorithm, 529-531
Diaphragmatic rupture, 962, 963
Diarrhea, 411
Diastolic arterial pressure (DAP), 172
Diastolic murmurs, 154
Diathybarbital, 759t
Diazepam
antidote, as, 533t
hemofiltration, 759t
sedative, as, 570
DIC, 835-837, 941
Diencephalon, 328, 329, 330

Index
Diers, Donna, 15
Diet; see Nutrition support
Differential WEC count, 480
Diffusion, 372, 373
DiGeorge syndrome, 627
Digestion, 768-770
Digibind, 194
Digitalis glycosides, 192
Digitoxin, 759t
Digoxin, 192-194; see also JET
antiarrhythmic agent, as, 204, 205
atrial fibrillation, 644, 645
heart failure, 587
hemofiltration, 759t
recommended doses, 193t, 194
renal failure, 747t
toxicity, 194
Digoxin immune Fab, 194
Digoxin toxicity, 194
Dilantin, 568, 747t
Dilated cardiomyopathy (DCM), 635-638
Dilaudid, 564t, 566
Diltiazem, 199, 204
Discomfort, 547; see also Pain management
Discontinuation of analgesics and sedatives, 571-573
Disease states; see Final common pathways, Multisystem
problems
Disorders
B cell, 493
Phagocytic, 493
T cell, 493
Displacement, 20
Disseminated intravascular coagulation (DIC),
835-837,941
Distal convoluted tubule, 733
Distraction, 561
Diuresis, 455
Diuretic therapy, 191, 586, 586t
Diuril, 378t
Diving seal reflex, 720
DKA, 815-818
DNA PeR, 496
DNARorders, 115
D02 ,241,243t
Dobutamine
antidote, as, 533t
cardiac arrest, 196
dosage/administration, 196
IV infusion, 438t
renal failure, 747t
shock, 938
side effects, 196
Dopamine
antidote, as, 533t
cardiac arrest, 195, 196
dosage/administration, 196
endogenous catecholamine, as, 937
IV infusion, 438t
renal failure, 749t

Dopamine-<:ont'd
side effects, 196
standard concentrations, 440
Doppler ultrasonography, 365
Doppler ultrasound, 167
Dorsal aorta, 132
Dorsal respiratory group (DRG), 239
Dosage forms, 438, 439
Dosing of medication, 433-435
Double ABCX model, 50, 51
Double-outlet right ventricle, 133
Down's syndrome, 777
Downes, John J" 5
Doxorubicin, 534t
Doxycycline, 504, 759t
DPL,966
Drainable pouches, 538
Draining wounds, 537
Dressings, 524, 526t, 527t, 535, 536
DRG,239
Drowning, 719
Drug absorption, 416t, 426-428
Drug addiction, 548
Drug clearance, 431
Drug compatibility chart, 1073, 1075
Drug delivery systems, 566-567
Drug distribution, 428, 429
Drug elimination, 431, 432
Drug fever, 452
Drug-induced hepatic failure, 798
Drug-induced nephritis, 739
Drug interactions, 441
Drug metabolism, 429-431
Dry drown ing, 719
DTIC, 533t
Ductus arteriosus, 153t, 206, 589
Duodenal obstruction, 776-778
Duodenal stenosis, 777
Duodenum, 766
Duplex Doppler ultrasonography, 745
Dwyer instrumentation, 725
Dynanlic compliance, 245
Dysfunction, 480, 50 I, 502
Dyspnea, 252t

E
Early inspiratory crackles, 253
Early PICU programs, 5
EBV, 798, 897
EBV-PCR, 897
ECF compartment, 370, 371
Echocardiography, 641
ECMO, 298-306
accidental decannulation, 304
alteration in cardiac output, 302
alteration in comfort, 304
alteration in fluid/electrolyte balance, 302-303
alteration in hemostasis, 303
alteration in parental role, 305
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ECM0---<:ont'd
cannulation, 300, 30 I
cardiac arrest, 304
cardiac support, 224-226
contradiction, 299
current application, 298-300
cycling, 305
decannulation, 306
mechanical failure, 304, 305
nursing care, 301-305
PPHN,688
sepsis, 304
VAlVV, compared, 299
weaning, 305
ECR,457
Edema, 152
EDV, 144
EEG monitoring, 356-362, 559
EEG waveforms, 360t
EFE, 136
Effector cells, 474
Efferent arteriole, 733
Ejection fraction, 144, 167
Eland color scale, 552, 553, 554
Elastance, 341
Elavil,568
Electrical injuries, 984, 985
Electrocardiogram, 641
Electrolyte disorders, 382-391
calcium, 385-388
chloride, 388
magnesium, 390, 391
phosphate, 389, 390
potassium, 383-385
sodium, 382, 383
Electrolytes; see Fluid and electrolyte regulation
Electrophysiologic study (EPS), 189, 641
ELISA, 481, 496
Emancipated minor statute, III
Embryology, 461-462
Embryonic period, 234
Emergency cart contents, 1069-I072t
EMLA,568
Empowerment, 74
Enalapril
cardiac arrest, 200
dosage/administration, 200
renal failure, 747t
side effects, 200
Encephaliti's, 711, 712
End-diastolic volume (EDV), 144
End-inspiratory crackles, 253
End-systolic volume (ESV), 144
End-tidal CO 2 monitoring, 258-261
Endocardial Ii broelastosis (EFE), 136
Endocrine critical care problems, 805-819
adrenal insufficiency/adrenal crisis, 811-813
cerebral salt wasting syndrome, 809
01,807-809

Endocrine critical care problems---cont'd
DKA,815-818
glucose homeostasis, 806, 807
hyperglycemia, 815-818
hypoglycemia, 813-815
regulation of water/electrolyte balance, 805, 806
SIADH, 809-811
Endotoxin, 471
Endotracheal instillation of normal saline, 277
Endotracheal suctioning, 276, 277
Endotracheal tubes (ETTs), 269-274, 482, 1031, 1032
Energy needs, 400, 401
Enrico, Roger, 78
Enteral feeding, 402-416
breast milk, 403, 404t
complications, 414t
delivery methods, 408-411
formulas, 403-408, 404t, 405t, 406t, 407t
monitoring, 411-415
skin care, 542, 543
transition to oral feeding, 415, 416
Enteral feeding sites and routes, 409t
Entry nurse (RN I), 87, 88t, 97t, 98t
Environmental control, 560-561
Environmental sources of PICD-related stress, 52t
Enzyme-linked immunosorbent assay (ELISA), 481, 496
Eosinopenia, 464
Eosinophilia, 464
Eosinophils, 464
EP monitoring, 362-364
EP study, 189
Ependymomas, 708
Epicardial leads, 209, 210
Epidermis, 512
Epidural analgesia, 568-570
Epidural hematoma, 954
Epidural space, 569
Epiglottis, 236, 237
Epiglottitis, 660-662
Epilepsy, 703-705
Epinephrine
antidote, as, 534t
dosage/administration, 194
glucose homeostasis, 806
IV infusion, 438t
resuscitation drug, as, 1035
shock, 937, 938
side effects, 194
Epiphyseal fractures, 970
Epithalamus, 328
Epithelialization, 514
EPS, 189,641
Epstein-Barr virus (EBV), 798, 897
Equianalgesia, 562
ERCP, 788
ERV, 247
Erythema multi forme, 988
Erythrocyte sedimentation rate (ESR), 481, 824t
Erythrocytes, 823

Index
Erythromycin
antidote, as, 534t
drug metabolism, in, 431
hemofiltration, 759t
renal failure, 747t
Erythropoietin (EPO), 489t
Escharotomy, 987, 988
Esmolol, 203
Esophageal atresia, 774-776
Esophageal varices, 790-793
Esophagus, 766, 767
ESR, 481, 824t
Essence of pediatric critical care nursing, 3-68
ESV, 144
ETc02,258-261
Ethacrynic acid, 191, 586t
Ethanol intoxication, 1016, 1017
Ethical deliberation, 108
Ethics, 107-127
addressing conflict, 122-124
autonomy/informed consent, III, 112
balancing benefit and harm, 108-110
care perspective, 113, 114
CPR, 115
defined, 108
environments that support ethical practice, 124-126
euthanasia, 117
forgoing life-sustaining treatment, 114-116
justice, 113
MPH&N, 115, 116
pain management, 116, 117
respect for persons/role of children, 110, III
truth telling, 112
Ethics committees, 125
Ethics education, 126
Ethics rounds, 126
Ethylene global poisoning, lOIS, 1016
Etomidate, 270t
Etoposide, 534t
EITs, 269-274, 482, 1031, 1032
Euthanasia, 117
Evaluation tools, 101
Evaporative losses, 446
Evoked potential (EP) monitoring, 362-364
Evolution of family-centered care practices, 47-49
Evolution of pediatric care nursing, 3-8
Excretory urography, 745
Exencephaly, 325t
Exfoliative disorders, 988
Expert nurse (RN IV), nt, 95, 97t, 98t
Expiration, 245
Expiratory reserve volume (ERV), 247
Extended-release dosage forms, 439
External cooling, 452
External cooling blankets, 450
Extra heart sounds, 154
Extracardiac Fontan procedure, 616
Extr{\cellular fluid (ICF) compartment, 370, 371
Extracorporeal membrane oxygenation; see ECMO

Extracorporeal drug removal, 1003
Extracorporeal rewarming (ECR), 457
Extraperitoneal bladder rupture, 968
Extravasation injury, 531-535
Eye moisture chamber, 517
F
Face masks, 266, 267
Face tent, 267
Faces rating scale, 553
Facial nerve, 327, 333, 336t
Facilitated child visitation intervention (FCVI), 62
Facilitator of learning, II
Factor V, 800
False neurotransmitter hypothesis, 799
Falx cerebri, 326, 327, 696, 697
Family-centered care
evolution of, 47-49
key elements, 48
Family context of childhood critical illness, 61-63
Family demographics, 49
Family power resources model, 44t
Famotidine, 759t, 782
Fasciotomy, 987
Fast flush test, 171
Fast rhythms, 1038
Fast-speed capnogram, 259, 261
w-3 fatty acids, 402
FCVI,62
Fecal pouches, 538
Femoral artery, 172
Femoral vein, 175
FEN., 737
Fentanyl
cannulation, in, 300
intubation medication, as, 270t
pain management, 564t, 566
Fetal cardiac output, 137
Fetal circulation, 136, 137
Fetal echocardiography, 169
Fetal hemoglobin (Hb F), 823
Fetal pulmonary vascular development, 205
Fetal stress response, 137
Fever, 451, 452
Fever reduction, 451, 452
FHF, 794-80 I; see also Hepatic failure
Fiber-optic systems, 352
Fiberoptic bronchoscopy, 272
Fibrin stabilizing factor, 827t
Fibrinogen, 827t, 828t
Fibroblasts, 514
Fick principle, 185
Filtration, 372, 373
Final common pathways
cardiovascular, 579-654
endocrine, 805-819
gastrointestinal, 765-804
hematologic, 821-850
neurologic, 695-730
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Final common pathways-eont'd
pulmonary, 655-694
renal,731-764
F102 ,289
First-degree heart block. 647
First-pass effect, 426
First units, 3, 4, 5, 6
Fishbone technique, 77
Five Temptations of a CEO, The, 74, 82
Fixed split, 154
FLACC scale, 554, 555t
Flail chest, 959, 960
Flamazine, 994t
Flecainide, 202
Flexible bronchoscopy, 265
Flow-inflating bags, 268
Flow-synchronized pressure support ventilation, 285t, 286
Flowcharts, 77
Fluconazole
antifungal drug, as, 486
hemofiltration, 759t
renal failure, 747t
Flucytosine, 759t
Fluid and electrolyte regulation, 369-392
acid-base balance, 312-314
clinical assessment, 374, 375
composition of body fluids, 369
electrolyte disorders, 382-391; see also Electrolyte
disorders
fluid volume deficit (dehydration), 376-381
fluid volume excess, 382
fluid volume regulation, 373, 374
insensible water loss, 371 t
IV therapy, 376
laboratory tests, 376
movement of fluids/electrolytes, 371-373
regulation of water/electrolyte balance, 371
total body water, 370
Fluid-coupled systems, 351
Fluid resuscitation, 989, 990, 1033
Fluid volume deficit, 376-381
Fluid volume excess, 382
Fluid volume overload, 382
Fontan operation, 615-617
Fontanelles, 325
Food; see Nutrition support
Foramen magnum, 696
Forane, 571, 669
Forced vital capacity (FVC), 248, 685
Foreign body aspiration, 662, 663
Foreign body chest radiograph, 663
Forgoing life-sustaining treatment, 114-116
Formulas, 404-408
Fosphenytoin, 428
Fostering professional advancement, 105
Four-unit respirator, 5. 5
Fractional excretion of sodium (FEN a)' 737
Fractures, 971
Frank-Starling law, 145, 146

Frank-Starling ventricular performance curves, 146
FRC,248
Free radicals, 718, 719
Fresh frozen plasma, 829t
Friction, 523
Frontal lobe, 328
Full-thickness circumferential burns, 987
Full-thickness wounds, 537
Fulminant hepatic failure (FHF), 794-801
Functional residual capacity (FRC), 248
Funduscopic examination, 345
Fungal yeast infection, 541
Furosemide
diuretic, as, 191, 378t, 385, 701
heart failure, 586t
hydrocephalus, 713
pulmonary edema, in, 678
renal failure, 747t, 748t
Fusion beats, 213
FVC, 248, 685
G
GABA,799
Gabapentin, 565t, 568
Gallbladder, 767
Gamma Glutamyl Transferase (GGT), 772t
Ganciclovir, 885t, 897
Gas exchange over the pulmonary capillary
membrane, 263
Gastric and intestinal injury, 966
Gastric decompression, 772
Gastric emptying, 1005
Gastric lavage, 1005
Gastroesophageal reflux (GER), 781-783
Gastrointestinal bleeding, 789-793
Gastrointestinal critical care problems, 765-804
abdominal examination, 770, 771
abdominal wall defects, 793, 794
acute gastritis, 789, 790
anatomy/physiology, 766-770
digestion/absorption, 768-770
duodenal obstruction, 776-778
embryology, 765, 766
esophageal atresia, 774-776
esophageal varices, 790-793
gastric decompression, 772
gastroschisis, 793, 794
GER, 781-783
hepatic failure, 794-80 I; see also Hepatic failure
intravascular volume replacement/maintenance, 774
intussusception, 779, 780
jejunoileal obstruction, 778, 779
laboratory/radiologic assessment, 771-773
lower GI bleeding, 790
motility, 768
NEC, 784-786
omphalocele, 793, 794
pancreatitis, 788, 789
peritonitis, 783, 784

Index

Gastrointestinal critical care problems-cont'd
pharmacologic management, 774
SBS, 786-788
secretion, 768
toxic megacolon, 780, 781
Gastrointestinal enzymes/honnones, 7691
Gastrointestinal hemorrhage, 790
Gastrointestinal inflammation, 781-789
Gastrointestinal obstruction, 774-781
Gastrointestinal ostomy diversion, 538
Gastrointestinal ostomy placement, 538
Gastroschisis, 793, 794
Gastrostomy tubes, 410
GBS, 684-686
GCS, 346, 347
Gene transfer therapy, 504
General health assessment, 151
Genitourinary injuries, 967-969
Gentamicin/gentamycin
aerosol therapy, in, 282t
antidote, as, 534t
hemofiltration. 759t
intraabdominal sepsis, 784t
IV infusion, 438t
renal failure, 747t
Gestational age (GA), 426t
GFR, 374, 734
GI problems; see Gastrointestinal critical care problems
GI tract, 766-768
Glasgow coma scale (GCS), 346, 347
Glenn physiology, 614-617
Glial ceLIs, 325
Global cerebral ischemia, 715-719
Glomerular filtration rate (GFR), 374, 734
Glomerulus, 733
Glossopharyngeal nerve, 327, 333, 336t
Glottis, 236, 237
Glucagon, 806
Glucocorticoids, 806
Glucose, 385, 1036
Glucose homeostasis, 806, 807
Glutamine, 402
Glutethimide, 759t
Glyburide, 759t
Glycerol, 700
Glyceryl trinitrate, 535
Glycopyrrolate, 271 t
GM-CSF, 489t
Goal selection, 81
Goulding, Erna, 5
Graft-versus-host disease (GVHD), 490, 869-871,
879,910
Granulation tissue, 514
Granulocyte (G)-CSF, 489t
Granulocytes, 464
Gray-scale ultrasonography (US), 745
Great cerebral vein (of Galen), 327
Greenstick fractures, 971
Growth charts, /057-/065
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Growth hormone, 806
Guided imagery, 561
Guidelines and levels of care for pediatric intensive care
units, 5-6
Guidelines for maintaining EFTs, 1092
Guillain-Barre syndrome (GBS), 684-686
GVHD, 869-871, 879, 910
H

H-type TEF, 775
HAARTs, 494
Hageman factor, 827t
Haldol, 565t, 571
Half-life, 431, 43/
Halo jacket, 958, 959
Haloperidol, 571
Halothane, 865
Handwashing, 483, 484
Hardiness, 18
Harrington rod instrumentation, 725
HAT, 906
HAV, 797, 832
Hb F, 823
HBO therapy, 986
HBV, 797, 832
HCM, 637t, 638-640
Hct, 824t
HCV, 797, 832
HD,751-753
HDV, 797
Head circumference, 397
Head injury, 951-955
Head tilt-chin lift maneuver, 1030
Health-illness continuum, 14
Heart, 139-142; see also Cardiovascular system,
Tissue perfusion
Heart failure; see Congestive heart failure
Heart murmurs, 154, 155
Heart rate, 144, 145, 150
Heart rhythm, 145
Heart sandwich, 215
Heart valves, 139
Heart's electrical activity, 141, 142
Heart-lung transplantation; see Heart/lung transplantation
Heart/lung transplantation, 890-900
alteration in comfort, 900
bacterial infections, 896
bleeding, 899
complications, 893-900
fungal infections, 897
hypovolemia/hypothermia, 899
increased PVR, 898, 899
infection, 894-898
organ-specific rejection, 893, 894
parasitic infections, 898
postoperati ve care, 892, 893
rhythm disturbances, 899
transplantation procedures, 891-892
ventilation-perfusion mismatch, 899, 900
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Heart/lung transplantation---cont'd
ventricular dysfunction, 898
viral infections, 896, 897
Heat loss, 446
Heating blankets, 450
Heel pressure ulcers, 523
Height, 395
Heliox, 660, 668
Helper T cells, 466
Hematocrit (Hct), 376, 824t
Hematologic critical care problems, 82l-850
anemia, 838-840
apheresis, 833-835
assessment/physical examination, 827
blood product transfusions, 828-832
blood stem cell, 823
clinical history, 827
coagulation studies, 828t
composition of blood, 823-827
DIC, 835-837
dysfunction, 501-502
embryology, 821
hematopoietic organs, 821, 822
HIT,837
HUS, 844-848
ITP,835
mechanical intervention, 833-835
mixed disorders, 844-849
monitoring, 827
pharmacologic therapy, 832, 833
RBC studies, 824t, 825t
sickle cell disease (SCD), 840-844
TTP,848
vascular access thrombi, 837, 838
Hemodialysis (HD), 751-753
Hemodynamic calculations, 186, 187
Hemodynamic characteristics, 583-584
Hemodynamic monitoring, 169-187
arterial blood pressure monitoring, 171-174
cardiac output determination, 185-187
central venous pressure monitoring, 174-178
fundamentals, 169-171
left atrial pressure monitoring, 184, 185'
PICCs, 178
pulmonary artery pressure monitoring, 178-184
Hemofiltration, 755-761
Hemoglobin (Hgb), 824t
Hemoglobin-oxyhemoglobin buffer pair, 310, 311
Hemolytic anemia, 839
Hemolytic uremic syndrome (HUS), 739,
844-848
Hemoperfusion, 1003
Hemorrhage, 949t
Hemostasis, 826
Hemothorax, 960, 961
Heparin, 833t
Heparin-induced thrombocytopenia (HIT), 837
Hepatic artery thrombosis (HAT), 906
Hepatic encephalopathy, 799, 800

Hepatic failure, 794-801
Alagille's syndrome, 796
at-antitrypsin deficiency, 796, 797
biliary atresia, 795, 796
cerebral edema, 800
CMV, 798
complications, 799, 800
consequences of, 798
critical care management, 800, 801
dosing of medication, 794
EBV, 798
hepatic encephalopathy, 799, 800
hepatorenal syndrome, 800
HSV, 798
viral hepatitis, 797, 798
Wilson's disease, 797
Hepatic injuries, 965
Hepatitis A virus (HAV), 797, 832
Hepatitis B virus (HBV), 797, 832
Hepatitis C virus (HCV), 797, 832
Hepatitis D virus (HDV), 797
Hepatitis E virus (HEV), 798
Hepatorenal syndrome, 800
Heroin intoxication, 1018, 1019
Herpes simplex virus (HSV), 711, 798, 896
Heterogeneity, 473
Heterotaxy, 135
Heterotopic heart transplantation, 891
HFFI,295
HFJV, 295
HFOV, 295-298, 678
HFPPV, 294, 295t
HFV,293-298
Hgb,824t
HICPAC, 484
HIDA scan, 795
High-frequency oscillatory ventilation (HFOV), 678
High-frequency ventilation (HFV), 293-298
Highly active antiretroviral therapies (HAARTs), 494
HIP, 484
Histograms, 77, 78
Historical tradition, 15
HIT,837
HIV DNA PCR, 496
HIV infection, 494-503
AIDS-defining illnesses, 496-502
antiretroviral therapy, 502
classification, 496, 497
etiology/incidence, 494
evaluation of immunologic status, 496
incubation period, 495
laboratory diagnosis, 496
nutrition, 502
pathophysiology/transmission, 494, 495
psychological issues, 502, 503
viral replication, 495, 496
HIV patient
critical care management, 502-503
nutrition and, 502
psychosocial issues, 502-503

Index

HLAs, 462
HLHS, 609t, 612-614
HOCM,136
Holistic pediatric critical care nursing, 1-68
Hollow viscus injuries, 966
Holosystolic murmurs, 154
Hospital Infection Control Practices Advisory Committee
(HICPAC), 484
Hospital Infections Program (HIP), 484
Hospitalization, impact on
adolescents, 40-41
preschooler, 31, 33
school-aged child, 34, 36
toddlers, 28, 30
Host defenses, 461-509
acquired immunodeficiency, 494-503; see also
HIV infection
cells of, 464-467
complement system, 472, 473
embryology, 461-462
experimental therapies, 504
first line of defense (barriers), 468-470
human immunoglobulins, 467t
immunotherapy/immunomodulation, 487-491
infection, 484-487
infectious diseases, 503, 504
inflammation, 470, 471
laboratory tests, 480-482
lymphoid system, 462-464
maintain external barriers, 482, 483
nonspecific vs. specific immunity, 462
nutritional support, 483
passive vs. active immunity, 474t
patient comfort, 484
phagocytosis, 471, 472
primary alterations in immune function, 493, 494
second line of defense, 470-473
stress, 483, 484
support of immune function, 482-491
third line of defense (specific immunity), 473-480
transient immune dysfunction, 491-493
white blood cells (WBCs), 464
HPV, 251
HSV, 798
HSV-I, 896
HSV-2,896
Human defense, concept, 462
Human immunodeficiency virus; see also HIV infection
classification, 496
etiology, 494
incidence, 494
laboratory diagnosis, 496
pathophysiology, 494-496
transmission, 494-496
Human leukocyte antigens (HLAs), 462
Humoral regulation of blood flow, 149, 150
HUS, 739, 844-848
Hut tents, 267
Hyaluronidase, 535
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Hybridoma, 490
Hydraulic equivalent of Ohm's law, 206, 207
Hydrocarbon ingestion, 1021, 1022
Hydrocephalus, 712-714
Hydrocodone, 566
Hydrocortisone, 535
Hydromorphone, 565t, 566
Hydroxyurea, 841
Hyperbaric oxygen (HBO) therapy, 986
Hypercalcemia, 387
Hypercarbia, 679
Hyperchloremia, 388
Hypercyanotic spells, 604
Hyperdynamic septic shock, 932t
Hyperglycemia, 815-818
Hyperinflation, 276
Hyperinsulinism, 813
Hyperkalemia, 384, 385
Hyperleukocytosis, 866-868
Hypermagnesemia, 391
Hypernatremia, 383
Hyperosmolar therapy, 700
Hyperoxygenation, 276
Hyperphosphatemia, 389, 390
Hyperpnea, 252t
Hyperthermia, 450-454
Hypertrophic cardiomyopathy (HCM), 637t, 638-640
Hypertrophic obstructive cardiomyopathy (HOCM), 136
Hyperventilation, 276, 699
Hypervigilance, 55
Hypocalcemia, 386, 387
Hypochloremia, 388
Hypodynamic septic shock, 932t
Hypoglossal nerve, 327, 333, 337t
Hypoglycemia, 813-815
Hypokalemia, 384
Hypomagnesemia, 390, 391
Hypoxemia, 587-588
acute hypoxia, 588
chronic hypoxia, 588
Hyponatremia, 382, 383
Hypophosphatemia, 389
Hypoplastic left heart syndrome (HLHS), 609t, 612-614
Hypothalamus, 328
Hypothermia, 454-457
Hypoventilation, 656, 657, 690
Hypoxemia, 679, 688
Hypoxia, 716
Hypoxic ischemic encephalopathy, 715-719
Hypoxic pulmonary vasoconstriction (HPV), 251
I

I :E ratio, 251
IAA,206
IABP therapy, 217-220
IART, 158, 645, 646
Ibuprofen, 451, 452
IC,247
ICF compartment, 370
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ICP monitoring, 351-356
ICP monitoring systems, 351-354
ICP trend recordings, 355
ICP wavefonn analysis, 354
ICU psychoses, 21, 560
Identifying roles, 81
Idiopathic cardiomyopathy, 629
Idiopathic thrombocytopenic purpura (ITP), 487-488
IgA, 467t, 470
IgO,467t
IgE, 467t
IgG,467t
IgM,467t
IL-I, 488, 490
LL-2, 476, 491
IL-3 (Multi-CSF), 489t
Ileal atresias, 778, 779
Ileocolic intussusception, 779, 780
Illnesses; see Final common pathways, Multisystem
problems
Imipenem, 759t, 784t
Immediate hypersensitivity skin testing, 482
Immobilization, 53
Immune-enhancing additives, 402
Immune function
acquisition of specific immunity, 473
alterations, 491-504
bacterial interference, 468-469
barriers, 468t, 482
colonization, 468-469
complement system, 472-473, 473
components of acquired immunity, 473
elimination phase, 475
first line of defense, 467-470
gastrointestinal system, 469-470
genitourinary tract, 470
inflammation, 470-471
integumentary, 469
nutritional support, 483
ophthalmologic defenses, 470
phagocytosis, 471-472, 472
preparation phase (central limb), 474-479, 475
primary alterations, 493-494
recognition phase (afferent limb), 473-474, 475
respiratory system, 469
second line of defense, 470-473
support of, 482-491
third line of defense, 473-480
thymus gland, 477
transient, 491-493
Immune globulin therapy; see IVIG
Immune globulins, 465, 467t, 889
Immune system; see also Host defenses
nonspecific versus specific immunity, 462
physiology of, 462-467
Immune thrombocytopenic purpura (ITP), 835
Immunity, passive and active comparison, 474t
Immunoglobulins, 465, 467t, 487, 889; see also IVIG
Immunologic physical assessment findings, 468t

immunomodulation, 487
Immunoregulation, 479
Immunosuppressant functions, 880
Immunotherapy, 487
Impact evaluation, 101
Impairment of respiratory muscle function, 684-686
Imuran, 883t, 887
IMY,285
In-service education, 104
Incisional atrial reentrant tachycardia (IART), 158
Incomplete AYSO, 594, 595
Incubators, 450
Indicator-dilution method, 185
Indigenous flora, 468, 469
Indirect calorimetry, 399
Ineffective thennoregulation, 443, 444t; see also
Thennal regulation
Infancy, 22-28
developmental care, 27, 28
developmental chart, 23t-25t
hospitalization, and, 26, 27
neonatal period, 26
parent-infant attachment, 22, 26
Infant botulism, 503, 686
Infant development, 23t
Infant fonnulas, 404-408
Infant instability assessment, 98t
Infasurf, 681
Infection
costlbenefit ratio of invasive techniques, 485
limit exposure to reservoirs, 484
prevent antigen exposure, 484
treating, 485-487
Infectious diseases, 503, 504
Inferior patrosal sinus, 327
Inferior sagittal sinus, 327
Infiltrate injury, 531-535
Inflammation, 470, 471
Infonned consent, III, 112
Infratentorial herniation, 696
Infundibular stenosis, 601
Ingesting toxins; see Toxic ingestions
Inhalation injuries, 986, 987
Inhalational anesthetic agents, 571
Inhaled medications, 281, 282
Inhaled NO (iNO), 207, 208, 679-681
Initial contact, 57
Inodilators, 192
Inotropic therapy, 192-197
INR (international nonnalized ratio), 828t
Insensible water loss, 371 t
Inspection
lungs/pulmonary system, 251-253
tissue perfusion, 152
Inspiration, 245
Inspiratory capacity (IC), 247
Inspiratory/expiratory (I: E) ratio, 251
Inspiratory reserve volume (IRV), 247
Institutional ethics committees, 125

Index
Insulin, 747t, 806
Integrity, 125
Intellectualization, 20, 53
Intensive care unit syndrome, 21
Intercavernous sinus, 327
u- Interferon, 489t
B- Interferon, 489t
y- Interferon, 489t
Interferons, 488, 489t
Integumentary system; see Skin integrity
Interleukins, 488
Interlobar artery, 733
Interlobular artery, 733
Intermittent CSF venting, 353
Intenruttent mandatory ventilation (IMV), 285
Intermittent tube feedings, 411
Internal vertebral fixation devices, 725
International normalized ratio, 828t
Internship programs, 102
Interrupted aortic arch (IAA), l36, 206
Interstitial edema, 697
Interventional catheterization, 188
Intervention strategies, 56
Intestinal/multi visceral transplantation, 907-910
Intestinal obstruction, 774-781
Intraaortic balloon pump (IABP), 217-220
Intraatrial reentrant tachycardia (lART), 645, 646
Intracardiac catheters, 625, 626
Intracellular fluid (ICF) compartment, 370
Intracranial dynamics, 323-368
assessment of chemically paralyzed child, 350, 351
assessment of neurologically impaired child, 345-350
autonomic nervous system, 332-338
brain, 326-329
central nervous system circulation, 339, 340
cerebral blood flow, 342, 343
cerebrospinal fluid/ventricular system, 329, 330
EEG monitoring, 356-362
embryology, 323, 324
EP monitoring, 362-364
extracranial structures, 325, 326
ICP monitoring, 351-356
level of consciousness, 344, 346t
medical history, 343
microscopic structures, 325
Monro-Kellie doctrine, 340
neurodiagnostic studies, 364-366
neurologic system, 343-350
peripheral nervous system, 332
physical examination, 343-345
reflexes, 345
spinal cord, 330-332
volume/pressure relationships, 340-342
Intracranial hypertension, 695-703
Intracranial pressure monitoring, 351-356
Intracranial tumors, 707-709
Intracranial volume/pressure curve, 341
Intrafacility transport, 1043-1051
Intraosseous infusion, 1033
Intraparenchymal monitoring, 353
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Intratracheal pulmonary ventilation, 306
Intravenous (IV) therapy, 376
Intravenous immunoglobulin; see IVIG
Intravenous infiltrate injury, 531-535
Intraventricular conduction blocks, 163
Intrinsic renal failure, 739-74l
Intubation, 254, 268-276; see also Airway adjuncts
Intubation equipment checklist, 269
Intubation medications, 271 t, 272t
Intussusception, 779, 780
Invasive hemodynamic monitoring; see Hemodynamic
monitoring
Ipecac, l005
Ipratropium, 282t
Iron ingestion, 1009-10 II
Irreversible brain damage, 715-719
Irritant contact diaper dermatitis, 529-531
IRV,247
Ischemia, 716
Ischemic-anoxic injury, 716
Isoelectric EEG, 356, 359
Isoetharine, 282t
Isoflurane, 571, 669
Isolated esophageal atresia, 776
Isopropanol ingestion, 1016
Isoproterenol
cardiac arrest, 195
dosage/administration, 195
IV infusion, 438t
side effects, 195
ITP, 487, 835
IV administration, 435, 438
IV therapy, 376
IVC,353
IVIg
Guillain-Barre syndrome, 685
hematologic problems, 832
immunotherapy, 487, 487t
Kawasaki disease, 634
organ transplantation, 885t

J
lackson, Phil, 73
lameton, Andrew, 108
law-thrust maneuver, 948, 1030
lejunoileal obstruction, 778, 779
lejunostomy, 411
lET, 646, 647
lob stress, 80; see also Stress
lohnson, lanet, 5
lugular foramen, 327
lugular venous bulb SVo 2 monitoring, 365
lunctional arrhythmias, 646
lunctional ectopic tachycardia (lET), 646, 647
lustice, 113
luxtamedullary nephrons, 732
K
Kangaroo care, II
Kasai hepatopoftoenterostomy, 795

1110

Index

Kawasaki disease, 631-635
Kayexalate, 385
Kayser-Fleischer rings, 797
Ketamine, 270t, 565t
Ketoralac/ketorolac
nonopioid, as, 567
pain management, 564t
SCD,841
Kidney, 732-735
Kidney transplantation, 910-915
complications, 913-915
decreased urine output, 914
erythrocytosis, 9\5
fluid/electrolyte imbalance, 914
gastrointestinal complications, 915
hypertension, 914, 915
infection, 913, 914
organ-specific rejection, 913
postoperative care, 912, 913
recurrence of renal disease, 9\5
transplantation procedures, 912
Killian, Karen, 6
Kinetic therapy beds, 525
Knowing the patient, 10
Konno procedure, 600, 60 I
Korotkoff sounds, 151
Kupffer cells, 463
Kussmaul, 252t
Kyphosis, 251

L
L-TGA,618
LA waveform analysis, 184, 185
Laboratory tests
absolute lymphocyte count, 480-481
absolute neutrophil count, 48lt
Chest radiograph, 482
complement system, 481
C-reactive protein, 481
delayed hypersensitivity testing, 481-482
differential WBC count, 480
erythrocyte sedimentation rate, 481
lymphocyte subsets, 480-481
serologic testing, 481
total immunoglobin levels, 48\
total WBC count, 480
white blood cell count, 480-481
Lactate dehydrogenase (LDH), 772t
Lactoferrin, 469
LAK cell therapy, 491
LAK cells, 467
Large intestine, 767
Large mediastinal mass, 272
Laryngotracheobronchitis, 659, 660
Lasix
diuretic, as, 378t, 385, 70 I
hydrocephalus, 713
renal failure, 747t
Lateral tunnel cavopulmonary Fontan procedure, 615

Law of Laplace, \47
Leadership, 71-83
assertive communication, 76
coaching, 75, 76
conflict resolution, 73
defined, 72
empowerment/accountability, 74, 75
listening, 78, 79
measuring success, 82
morale building, 79, 80
stress management, 80
systems thinking, 12, 76-78
teamwork, 72, 73
time management, 80-82
vision/values, 72
Leadership Engine: How Winning Companies Build
Leaders at Every Level, The (Tichy/Cohen), 82
LEAN, 1036
Leech saliva, 543
Leech therapy, 543, 544
Left atrial pressure monitoring, 184, 185
Left atrium, 132
Left ventricle, 132
Left ventricular assist device (LVAD), 221, 222
Left ventricular end-diastolic pressure (LVEDP), 625
Left ventricular hypertrophy (LVH), 638, 639
Left ventricular tract obstruction (LVOTO), 638, 639
Length, 395-397
Leptomeninges, 326
Leukemic disease, 866-868
Leukocytes, 464, 823
Leukocytosis, 480
Leukopheresis, 867
Leukostasis, 867
Leukotrienes, 668
Level I PICU, 5, 6
Level II PICU, 5, 6
Level of consciousness, 344, 346t
Levocardia, 135
Levophed, 938
LGLs,467
Lidocaine
antiarrhythmic drug, as, 202
hemofiltration, 759t
increasing ICP, 702
intubation incubation, as, 271 t, 272
intubation medication, as, 272
resuscitation drug, as, 1035t, 1036
Lifescan brain activity monitor, 360, 363
LIP, 499, 500
Lipase, 772t
Liquid perfluorocarbon ventilation, 306
Listening, 78, 79
Literature, 6
Lithium, 759t
Liver, 463, 767, 798
Liver ABCs, 903
Liver function tests, 904t
Liver injuries, 965

Index
Liver transplantation, 900-907
alterations in comfort, 907
alterations in tissue perfusion, 905, 906
altered rena) function, 906
biliary tract complications, 907
complications, 904-907
ineffective airway clearance, 905
infection, 904, 905
liver function tests, 904t
metabolic/nutritional deficits, 906, 907
organ-specific rejection, 904
postoperative care, 903, 904
skin/wound issues, 907
transplantation procedures, 901-903
UNOS classification, 900
Living-related transplantation (LRT), 90 I
LMWH,833t
Local analgesics, 548, 568
Long QT syndrome, 136, 165, 649
Long-term immunosuppression, 889
Loop diuretics, 191,747
Loop of Henle, 733
Loop stoma, 538
Lorazepam
pain management, 565t
renal failure, 747t
sedative, as, 570
Lortab, 566
Losartan, 587
Loss of capture, 212, 214t, 215
Low molecular weight heparin (LMWH), 8331
Low VT strategy, 678
Low-air-loss bed, 525, 529t
Low-air-Ioss overlay mattresses, 529
Lower airways disease, 664-670
Lower esophageal sphincter, 767
Lower GI bleeding, 789t, 790
LRT,901
Lumbar puncture, 364, 365
Lund and Browder chart, 983, 984
Lung compliance, 245, 246
Lung transplantation; see Heart/lung transplantation
Lungs; see Oxygenation and ventilation
Luque rod instrumentation, 725
LVAD, 221, 222
LVEDP, 174,625
LVH, 638, 639
LVOTO, 638, 639
Lymphatic system, 239, 463
Lymphocyte counts
absolute, 480-481
subsets, 480-481
Lymphocytes, 465-467
Lymphocytosis, 465
Lymphoid interstitial pneumonitis (UP), 499, 500
Lymphoid system, 463-464
liver, 463
lymphatic system, 463
mucosa-associated lymphoid tissues, 463-464
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Lymphoid system-cont'd
primary lymphoid tissue and organs, 463
secondary lymphoid tissue and organs, 463-464
spleen, 463
Lymphokines, 474, 488
Lymphopenia, 465
Lysozyme, 469
M

M-mode echocardiography, 167
MAAS, 557, 558t
MAC, 397
Macewen's sign, 344
Macronutrient needs, 40 I
Macrophage, 465
Macrophage (M)-CSF, 489t
Mafenide acetate, 994t
Magnesium
fluid/electrolyte regulation, 379t, 390, 391
hypo/hypermagnesemia, 390, 391
resuscitation drug, as, 1035t, 1036
Magnesium sulfate, 668
Magnet hospital values, 79
Magnetic resonance imaging (MRI), 167, 365, 366
Mainstream capnometers, 258
Major histocompatibility complex (MHC) molecules, 462
Malignancy; see Oncologic critical care problems
Malignant hyperthermia (MH), 452, 453
Malrotation, 777, 778
MALTs, 463, 464
Managing crises, adaptive tasks, 51
Mandatory minute ventilation (MMV), 287
Mannitol
antidote, as, 534t
diuretic, as, 378t
hydrocephalus, 713
intracranial hypertension, 700
renal failure, 748t
MAP, 172, 289
MAPCAs,603
Mapleson bags, 268
Marfan's syndrome, 136
Massage techniques, 561
Mast cells, 465
Mastery, 20
Mastocytosis, 465
Mature minor statute, III
MBC,486
McBride, Angela, 3, 12
MCH,825t
MCHC,825t
MCV,825t
Mean arterial blood pressure (MAP), 172
Mean corpuscular hemoglobin (MCH), 825t
Mean corpuscular hemoglobin concentration
(MCHC), 825t
Mean corpuscular volume (MCV), 825t
Mechanical circulatory support, 215-226
ECMO, 224-226
IABP therapy, 217-220
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Mechanical circulatory support-----cont'd
indications for, 215, 216
VADs,220-224
Mechanical support for ventilation, 282-293
auto-PEEP, 289
blood gas monitoring, 289
bronchial hygiene, 289
complications, 290, 291
compressible volume, 290
endotracheal lUbe leaks, 290
ETI resistance, 290
initiation procedures, 287
meaning, 291, 292
modes of ventilation, 284
NPPV, 292, 293
NPV,293
positioning, 290
sedation, 289, 290
types of ventilators, 284
ventilation parameters, 287
ventilation strategies, 288-290
ventilator limitations, 290
volume monitoring, 290
when needed, 284
Mechanoreceptors, 239
Mechlorethamine, 534t
Meconium ileus, 778, 779
Mediators, 550
Medical play, 561
Medically provided hydration and nutrition (MPH&N),
115,116
Medication administration; see Clinical pharmacology
Medicinal leeches, 543
Medtronic Bio-Medicus centrifugal device, 220, 221
Medulla, 328, 329, 330
Medullary chemoreceptors, 239
Medulloblastoma, 708
Methylprednisolone, 841
Memory, 473, 479
Memory cells, 466, 479
Meninges, 325, 326
Meningitis, 709-711
Meningocele, 325t
Mental development; see Developmental stages
Meperidine, 566
MEPs, 362-364
Mesencephalon, 328
Metabolic acidosis, 317t, 318, 319
Metabolic alkalosis, 317t, 319, 320
Metamizole, 759t
Metaproterenol, 282t
Metastatic tumor, 866
Metencephalon, 328
Methadone, 564t, 566
Methadone intoxication, 1019
Methanol ingestion, 1014, 1015
Methicillin, 534t
Methohexital, 270t
Methotrexate, 858

Methylprednisolone
asthma, 668
fibrosis, 681
renal failure, 747t
spinal cord injury, 958
Metoclopramide, 782
Metolazone
diuretic therapy, in, 192
diuretic, as, 378t
heart failure, 586t
renal failure, 749t
Metoprolol, 203
Metronidazole
hemofiltration, 759t
intraabdominal sepsis, 784t
renal failure, 747t
Mexiletine, 202
Mezlocillin, 759t
MH, 452, 453
MHC molecules, 462
Miami Jr. collar, 958
MIC,486
Mic-Key,411
Microcephaly, 325t
Micronefrin, 282t
Micronutrient needs, 402
Midarm circumference (MAC), 397
Midazolam
intubation medication, as, 270t
pain management, 565t
renal failure, 747t
sedative, as, 570
Midbrain, 328, 330
Milrinone
cardiac arrest, 197
dosage/administration, 197
renal failure, 747t
shock, 939
side effects, 197
Minimal leak volume (MLV), 255
Minimal occlusion volume (MOV), 255
Minimum bactericidal concentration (MBC), 486
Minimum inhibitory concentration (MIC), 486
Minors, III, 112
Minute ventilation (V E)' 247
Mist tents, 267
Mithramycin, 387
Mitomycin, 534t
Mixed acid-base disturbances, 320, 321
Mixed obstructive/restrictive disease, 682-684
MLV,255
MMV, 287
MoAbs, 490, 491, 942
Mobitz type I second-degree heart block, 159
Mobitz type II second-degree heart block, 159, 647
Modified Blalock-Taussig shunt, 605, 614
Modified Braden Q scale, 519, 520t, 521t
MODS, 743, 923, 924, 940-942
Molecular diffusion, 294

Index
Monoclonal antibodies (MoAbs), 490-491, 490t, 942
Monocytes, 465
Monocytopenia, 465
Monocytosis, 465
Monokines, 474, 488
Monro-Kellie doctrine, 340
Montgomery straps, 516, 524, 537
Moral dilemmas, 108; see also Ethics
Moral distress, 108
Moral uncertainty, 108
Morale building, 79, 80
Moricizine, 202
Morphine
intubation medication, as, 270t
pain management, 564t, 566
renal failure, 747t
Motility, 768
Motor activity assessment scale (MAAS), 557, 558t
MOV, 255
MPH&N, 115, 116
MRI, 167, 365, 366
MSBP, 975
Mucomyst, 1005
Mucomyst 20%, 282t
Mucosa-associated lymphoid tissues (MALTs), 463, 464
Multidisciplinary lCU, Children's Hospital, Boston,
clinical practice guidelines, 1079-1084
Multimodal EPs (MEPs), 362-364
Multiorgan dysfunction syndrome (MODS), 743
Multiple aortopulmonary collateral arteries
(MAPCAs), 603
Multiple organ dysfunction syndrome (MODS), 923, 924,
940-942
Multiple-lead monitoring, 155
Multisystem problems
oncology, 853-873
organ transplantation, 875-919
resuscitation, 1025-1053
shock, 921-945
thermal injury, 981-997
tox ic ingestion, 999- 1024
trauma, 947-979
Multivisceral transplantation, 907-910
Munchausen syndrome by proxy (MSBP), 975
Murmurs, 154, 155
Muromonab-CD3, 884t, 888
Musculoskeletal disorders, 724, 725
Musculoskeletal trauma, 969-973
Mutuality, 49
Mycophenolate mofetil, 883t, 887, 888
Myelencephalon, 328, 329
Myelogenous leukemia (CML), 866
Myelomeningocele, 325t
Myocardial contusion, 962
Myocardial performance, impaired, 585
Myocarditis, 629-631
Myocardium, 140
Myoclonus, 563
Myofibrils, 140

N
N2 ,208
N-acetyl procainamide, 759t
N-acetylcysteine, 1005
NAC, 1005
Nadolol, 203
Nafcillin
antidote, as, 534t
hemofiltration, 759t
NaHC0 3 , 1035, 1036
Nalbuphine, 566
Naloxone, 1035t, 1036
NANBH, 797, 832
NAPQl, 1004, 1005
NAP SIG, 6-7
Narrow therapeutic index, 432
Nasal cannula, 267
Nasopharyngeal airway, 268, 269, 1085
Nasopharyngeal and oropharyngeal suctioning, 276
Nasotracheal intubation, 271
NAST, 572, 572t
National Nosocomial Infection Surveillance (NNIS)
system, 484
Natriuretic factors, 374
Natural killer cells, 466-467
NBG code, 21 Ot
Near drowning, 719-722
Near infrared spectroscopy (NlRS), 365
ebulization, 281, 282
NEC, 784-786
NecLoc extrication collar, 948
Necrotizing enterocolitis (NEe), 784-786
Negative pressure ventilator (NPV), 293
Neglect, 974, 975
Neonatal abstinence scoring tool (NAST), 572, 572t
Neonatal and pediatric special interest group
(NAP SIG), 6-7
Neonatal arousal scale, 347t
Neonatal lCU, II
Neonatal period, 26
Neoral, 880, 88lt, 886
Neostigmine, 271 t
Nephrons. 374, 732, 734
Nephrotoxic agents, 738
Nesidioblastosis, 813
etilmicin, 759t
Neumega, 832
Neural tube defects, 325t
Neurocranium, 325
Neurodiagnostic studies, 364-366
Neurohormonal factors, 584
Neurohormonal modulation, 586-587
Neurologic assessment, 343-350
Neurologic critical care problems, 695-730
AVM,705-707
brain death, 722, 723
brain herniation syndromes, 696
brain tumors, 707-709
cerebral edema, 697
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Neurologic critical care problems-eont'd
hydrocephalus, 712-714
hypoxic ischemic encephalopathy, 715-719
intracranial hypertension, 695-703
meningitis, 709-711
musculoskeletal disorders, 724, 725
near drowning, 719-722
neuromuscular disorders, 723, 724
status epilepticus, 703-705
TBI, 714, 715
viral encephalitis, 711, 712
Neurologic system; see Intracranial dynamics
Neuromuscular blocking agents (NMBAs), 549, 699
Neuromuscular disorders, 723, 724
Neurons, 325
Neurontin, 565t, 568
Neuropathic pain, 552, 568
Neutral thermal environment (NTE), 446, 447
Neutropenia, 464, 853, 854
Neutrophilia, 464
Neutrophils, 464, 472
New York Heart Association (NYHA) grading
system, 151
Nicardipine, 747t
Nifedipine
cardiac arrest. 199
dosage/administration, 199
toxicity, 199
Nimbex, 271 t
Nissen fundoplication, 782
Nitrazepam, 759t
Nitric oxide (NO), 207, 504, 679
Nitrogen (N 2 ), 208
Nitrogen balance, 399
Nitrogen dioxide (N0 2 ), 208
itrogen mustard, 534t
Nitroglycerin(e), 199, 939
Nitroprusside, 198
Nizatidine, 759t
NK cells, 466, 467
NMBAs,549
NMPMC, 56-61
NNIS system, 484
NNRTI agents, 502
NO,207
N0 2 ,208
Nociception, 550
Nociceptive pain, 551
Nociceptor fibers
A-delta fibers, 550
C fibers, 550
Nociceptors, 550
Nomifensine, 759t
Non-A non-B hepatitis (NANBH), 797, 832
Nonbreathing mask, 267
Noncommunicating hydrocephalus, ·712
Nonhemolytic, 831 t
Noninvasive positive pressure ventilation (NPPV),
292, 293

Noninvasive transthoracic pacing (NTP), 213-215
Nonlymphoblastic leukemia (ANLL), 866
Nonnutritive sucking, 416, 561
Nonoliguric ARF, 737
Nonopioids
acetaminophen, 567-568
ketorolac (Toradol), 567
NSAIDs,567
Nonpharmacologic management of pain and agitation,
559-560
Nonshivering thermogenesis, 455
Norcuron, 271t
Norepinephrine
antidote, as, 534t
cardiac arrest, 194, 195
dosage/administration, 195
IV infusion, 438t
shock, 938
side effects, 195
Normal blood pressure, lOSS, 1056
Normal immunization schedule, 1067, 1068
Normal saline, 277
NPPV, 292, 293
NPV,293
NRTI agents, 502
NSAIDs,567
NTE, 446, 447
NTFS, 57
NTP,213-215
5'-Nucleotidase, 772t
Nucleotides, 402
Numby Stuff, 568
Nurse competencies, 9-12
Nurse-family mutuality, 49
urse-sensitive outcomes, 12-13
Nursing cutbacks, 71
Nursing mutual participation model of care, 56-61
Nursing Report Card for Acute Care Settings, 13
Nursing shortage, 71
Nursing taxonomy of family satisfaction (NTFS), 57
Nutritional deficiencies/excesses, clinical findings
associated with, 396t
Nutrition support, 393-424
anthropometric measurements, 395-397
biochemical indices, 397-399, 398t
breast milk, 403, 404t
collaborative interventions, 402-420
complications, 414t, 420t
delivery methods, 408-411
dietary history, 395
drugs, and, 416t, 418t
energy needs, 400. 40 I
enteral feeding, 402-416, 409t, 412t, 414t;
see also Enteral feeding
formulas, 403-408, 404t, 405t, 406t,407t
immune-enhancing additives, 402
immunocompetence, and, 483
macronutrient needs, 40 I, 40 It
metabolic response of stress vs. starvation, 394t

Index
Nutrition support--eont'd
micronutrient needs, 402
nutrition assessment, 394
nutrition management, 399
parenteral nutrition, 416-420, 417t, 419t, 420t
patient history, 394
protein-energy malnutrition (PEM), 393
physical assessment, 395
starvation, 394
stress factors, 400t
vitamins, minerals, and trace elements, 402t
NYHA grading system, lSI

o
02ER, 244, 264
Observational scales, 553-556
Observational tools, 557, 559
Obstructive shock, 922
Obtundation, 346t
Occipital lobe, 328
Occipital sinus, 327
Occiput pressure ulcer, 518
Occult bacteremia, 449t
Octreotide, 791
Oculocephalic response, 349, 350
Oculomotor nerve, 327, 333, 335t
Oculovestibular response, 349, 350
ODC, 241, 242
OKT3, 490, 884t, 888, 889
Olfactory nerve, 333, 334t
Oliguria, 736-741
OLT,801
Omeprazole, 782, 790
Omphalocele, 793, 794
Oncologic critical care problems, 853-873
acute GYHD, 869-871
acute respiratory failure, 858-860
ATLS, 862-864
BMT, 868-871
ethical concerns, 872
hemorrhage, 860, 861
hyperleukocytosis, 866-868
increased ICP/hemiation syndromes, 860
infection/sepsis, 854-857
leukemic disease, 866-868
neurologic complications, 860
neutropenic patient, 853, 854
pericardial tamponade, 857, 858
platelet transfusion support, 861 t
SCC, 865, 866
seizures, 860
SMS, 864, 865
SYCS, 864, 865
typhlitis, 861, 862
YOD,871
Ondine's curse, 690
Open pneumothorax, 960
Opioid-induced side effects, 563
Opioid withdrawal, 572
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Opioids
ceiling dose, 562
equianalgesia, 562
fentanyl, 566
hydromorphone (Dilaudid), 566
key concepts, 562-563
methadone, 566
morphine, 566
oxycodone, 566
recommended dosages, 562
specific, 566
tolerance, 562-563
OPOs,878
Optic nerve, 327, 333, 334t
Optimal patient outcomes, 12-14
Oral cavity, 766, 767
Oral transmucosal fentanyl citrate (OTFC), 566
Organ procurement organizations (OPOs), 878
Organ transplantation, 875-919
abdominal viscera, 900-9l5
current challenges, 876, 877
evaluation process, 877-879
graft tolerance, 879
heartlheart-Iung/lung transplantation, 890-900;
see also Heart/lung transplantation
history, 876
intestinallmultivisceral transplantation, 907-910;
see also Intestinallmultivisceral transplantation
kidney transplantation, 910-915; see also Kidney
transplantation
liver transplantation, 900-907; see also Liver
transplantation
matching procedures, 878
pancreatic/islet cell transplantation, 915
pharmacologic immunosuppressive therapy, 879-889
quality of life/follow-up care issues, 916, 917
rejection of organ allograft, 889
thoracic viscera, 890-900
Organizational empowerment, 74
Orientation, 10 1-) 04
Oropharyngeal airway, 268, 269
Orotracheal intubation, 271
Orthoclone OKT3, 884t, 888
Orthopedic injury, 969-973
Orthopnea, 252t
Orthotopic liver transplantation (OLT), 80 I
Oscillometric blood pressure monitoring, lSI
Osmitrol, 700, 713
Osmolality, 371, 372
Osmosis, 371, 372
Osmotic agents, 700
Osmotic diuretics, 748
Ostium primum ASD, 592
Ostium secundum ASD, 592
Ostomy, 537
Ostomy care, 537, 542
OTFC,566
Oucher,553
Outcome evaluation, 101
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Outcome statements, 100, 101
Oversedation, 556
Oversensing, 212, 214t
Oxacillin, 534t, 759t
Oxazepam, 759t
Oxidative phosphorylation, 243
Oximetry catheter, 178
Oxycodone, 564t, 566
Oxygen consumption (Voz), 243, 244, 264
Oxygen delivery (Do z), 241, 243t
Oxygen delivery devices, 266-268
Oxygen extraction ratio (OzER), 244, 264
Oxygen-hemoglobin affinity, 241
Oxygen insufflation catheters, 277
Oxygen reserve, 264
Oxygen therapy, 266-268
Oxygen transport, 239-245
Oxygen transport in the blood, 263
Oxygenation and ventilation, 233-308
airway adjuncts, 268-276; see also Airway adjuncts
airway management, 276, 277
airways, 236-238
assessment of intubated child, 254
assessment of ventilated child, 254-256
blood gas analysis, 262, 263
bronchotherapy, 265, 266
chest physiotherapy, 277, 278
chest tubes, 281
control of respiration, 239
diagnostic studies, 264-266
ECMO, 298-306; see also ECMO
ETco z monitoring, 258-261
high-frequency ventilation (HFV), 293-298
inhaled medications, 283
invasive monitoring, 262-264
Iymphatic system, 239
mechanical support, 282-293; see also Mechanical
support for ventilation
medical history, 251
noninvasive monitoring, 256-262
oxygen therapy, 266-268
oxygen transport, 239-245
oxygenation profile monitoring, 263, 264
physical assessment, 25) -256
pulmonary circulation, 239
pulmonary development, 234-236
pulmonary metabolism, 239
pulmonary ventilation, 245-248
pulse oximetry, 256-258
radiologic procedures, 264, 265
respiratory support, 266-282; see also Respiratory
support
SBcoz monitoring, 262
Svo z monitoring, 264
thoracic cavity, 238
ventilation/perfusion ratio, 248-251
Oxygenation profile monitoring, 263, 264
Oxygenation profile values, 240t

Oxyhemoglobin dissociation curve (ODe), 241, 242
Oxyhood, 267
P
P-450 enzyme activity, 430, 430
P-QRS relationship, 159-162
P wave, 158
PA catheters, 178, 179
PA-IYS, 603t, 606-608
PA occlusion pressure (PAOP), 181
PA wedge (PAW) pressure, 181
Pacemaker therapy, 209-215
Packed red blood cells (PRBC), 829t
Pacoz, 289
Pain, 547-549
Pain and intrusive procedures, 22
Pain assessment
CRIES, 554, 555t
FLACC, 554, 555t
self-reported scales, 552-553
observational scales, 553-554, 553t-554t, 556
other considerations, 556
physiologic indicators, 556
Pain management, 116, 117,547-576
agitation, 556-559
alteration in consciousness, 702-703
barriers to effective, 548-549
cardiovascular disorders, 628-629
central nervous system, 550
cognitive behavioral techniques, 561
deep sedation, 571
discontinuation of medication, 571-574
environmental control, 560
epidural analgesia, 568-570
inhalational agents, 571
local analgesics, 568
nonopioids, 567, 568
nonpharmacologic management, 559-563
nurse's role, 573
observational scales, 553-556
opioids, 562-567
pain assessment, 552-556
peripheral nervous system, 550
pharmacologic management, 562-573
physical comfort measures, 561
physiologic effects of untreated pain, 551
responses to pain, 551
sedatives, 570-571
self-report scales, 552-553
spinal cord, 550
types of pain, 551- 552
Palivizumab, 666
Pall filters, 830
Palpable cardiac thrill, 153t
Palpation
lungs/pulmonary system, 253
tissue perfusion, 152, 153
PALS bradycardia algorithm, 1037
Pancreas, 766, 767

Index

Pancreatic injuries, 965
Pancreatic/islet cell transplantation, 915
Pancreatitis, 788, 789
Pancuronium, 747t
Pancuronium bromide, 271t
Pao 2,289
PA02' 240, 249
PAOP, 181
PAP monitoring, 625
Paradoxical splitting, 154
Parasympathetic system, 333
Parens patriae doctrine, 121
Parental
authority, 120, 121
coping, 19
daily bedside contact, 57-61
enabling strategies, 57-58
initial contact in PICU, 57
needs and coping strategies, identifying, 54-56
stress, 50-54
vigilance, factors influencing, SSt
Parent-controlled analgesia, 567
Parenteral fluid solutions, 377t
Parenteral nutrition (PN), 416-420, 417t, 419t, 420t
Parent-infant attachment, 22-23
Parent-professional partnerships, 48
Parent-professional trust, 55
Parents' Bill of Rights, 56
Parietal lobe, 328
Partial exchange transfusion, 842
Partial rebreathing mask, 267
Partial-thickness wounds, 537
Participation in decision making and in care, 8
Passive immunity, 474t
Patent ductus arteriosus (PDA), 589-591
clinical presentation and course, 591
coil occlusion, 591
management, 591
surgical correction, 591
Pathologic oxygen supply dependency, 245
Patient characteristics, 8, 9
Patient comfort, optimizing, 484
Patient-controlled analgesia (PCA), 567, 841
Patient level outcomes, 13
Patient-nurse level outcomes, 13, 14
Patient population, 5
Patient-system level outcomes, 14
Patient transfer, 63
Pavulon, 271t, 747t
PAW pressure, 181
PCA, 567, 841
PCCMeds,6
PCIRV, 286, 287
PCP, 498, 499
PCP poisoning, 1019, 1020
PCR,496
PCV, 285t, 286
PD,750-755
PDA, 589-591
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PDA embolization, 189
PE,686,687
PEA, 1038
Pectus carinatum, 251
Pedi-CAP, 261
Pediatric Bill of Rights, 56
Pediatric cervical spine immobilization collar, 948
Pediatric CCNS exam blueprint, 8t
Pediatric critical care Ii terature, 6
Pediatric dosage forms, 438, 439
Pediatric emergency medications reference guide, /029
Pediatric ICU admission criteria, 656
Pediatric intensive care unit (PICU), 5
Pediatric Trauma Score (PTS), 950, 951
PEEP, 183,184,676,677
PEG tube, 411
Pelvic fractures, 971
PEM,393
Pendelluft flow, 294
Penicillin, 759t
Penicillin G
antidote, as, 534t
renal failure, 747t
Pentamidine, 282t
Pentamidine isethionate, 486
Pentobarbital, 565t, 570
Pentothal, 270t, 702
Percocet, 566
Percussion, 153, 253
Percutaneous endoscopic gastrostomy (PEG) tubes, 411
Percutaneous transluminal coronary angioplasty
(PTCA),635
Perfloxacin, 759t
Perforati ve peritonitis, 783
Performance improvement (PI) program, 1051
Pericardial friction rub, 154
Pericardial tamponade, 857, 858
Perineal injuries, 969
Periosteum, 326
Peripheral chemoreceptors, 239
Peripheral cyanosis, 152
Peripheral intravenous needles (PIVs), 568
Peripheral nervous system (PNS), 332, 550
Peripheral temperature monitoring, 448
Peripherally inserted central catheter (PICC), 178, 416
Peristomal candidal infections, 541
Peristomal irritant dermatitis, 541
Peristomal skin compromise, 543
Peritoneal dialysis (PD), 750-755
Peritoneal dialysis worksheet, 754
Peritoneal inflammation, 783
Peritoneal lavage, 9661
Peritonitis, 783, 784
Persistent pulmonary hypertension of the newborn
(PPHN), 687-689
PET scans, 366
PGE 1,206
pH, 309, 310
Phagocytic disorders, 493

1118

Index

Phagocytosis, 471, 472
Phantom limb sensations, 552
Pharmacodynamic drug interactions, 441
Pharmacodynamics, 432-435
Pharmacokinetic drug-drug interactions, 441
Pharmacokinetics, 425-432
Pharmacologic immunosuppressive therapy, 879-889
Pharmacologic management of pain and agitation,
562, 564t-565t
Pharmacology; see Clinical pharmacology
Pharyngeal obstruction, 663
Pharynx, 766
Phencyclidine poisoning, 1019, 1020
Phenobarbital
hemofiltration, 759t
renal failure, 747t
Phentolamine, 535
Phenytoin
antidote, as, 534t
drug absorption, and, 428
hemofiltration, 759t
pain management, 568
renal failure, 747t
Philosophy statement, 99
Phlebostatic axis, 170
Phosphate buffer pair, 311
Phosphodiesterase (POE) inhibitors, 192
Phosphomycin, 759t
Phosphorus, 379t
Physical abuse, 974
Physical comfort measures, 561-562
Physical dependence, 548, 563, 566
Physical development; see Developmental stages
Physical neglect, 974, 975
Physiologic effects of untreated pain and anxiety, 551
Physiologic oxygen supply dependency, 244
PI agents, 502
PI program, 1051
Pia mater, 326
PICC, 178,416
PICU
care levels,S
environment, 20-21
first, 5, 6
parental stress related to, 50-61
stress unique to, 51-53
Pi nk tets, 602
Piperacillin
antidote, as, 534t
hemofiltration, 759t
renal failure, 747t
Piperacillin sodium and tazobactam, 784t
PIYs,568
Plasma thromboplastin antecedent, 827t
Plateau waves, 355
Platelet count, 828t
Platelet production, 826, 827
Platelets, 823, 829t
Play therapy, 561

Pleural effusions, 858
Pleural rubs, 254
PMI, 152
PN,416-420
Pneumatic YADs, 220
Pneumocystis carinii pneumonia (PCP), 498, 499, 499t
Pneumonia, 672
Pneumothorax, 671, 672, 960
PNS, 332, 550
Point of maximal impulse (PMl), 152
Poiseuille's law, 207, 237
Poisoning; see Toxic ingestions
Polycythemia, 588
Polymerase chain reaction (PCR), 496
Pons, 328, 330
Pores of Kohn, 238
Portosystemic shunts, 792
Positive Babinski reflex, 345
Positive coping in children, factors, 19
Positive end-expiratory pressure (PEEP), 183,184,
676,677
Positive self-communication, 76
Positron emission tomography (PET), 366
Postcoarctectomy syndrome, 599
Postconceptional age (PCA), 426t
Postnatal age (PNA), 426t
Postrenal failure, 741
Postural drainage, 280
Postural drainage positions, 278, 279
Postventricular atrial refractory period (PYARP), 211
Potassium, 378t, 383-385
Potassium salls, 534t
Potassium-sparing agents, 749
Potassium-sparing diuretics, 191
Pouching system, 538, 541
Povidone iodine, 994t
PPHN, 611, 687-689
PQRST,552
PR intervaL 158, 159
Practice differentiation program guidelines, 97t
PRBC,829t
Pre-B cells, 477
Prealbumin, 397, 587
Preceptor programs, 104
Precordial palpation, 152
Predictability, 8
Preload, 145, 146
Premature ventricular contractions (PYCs), 162, 648
Prerenal failure, 735-739
Preschoolers
development, 32t
developmental care, 33-34
developmental characteristics, 31, 32t
hospitalization, and, 31, 33
Pressure control ventilation (PCY), 285t, 286
Pressure-controlled inverse ratio ventilation (PCIRV),
286,287
Pressure support ventilation (PSV), 285t, 286
Pressure ulcer algorithm, 524
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Pressure ulcers, 518-529
algorithm, 524, 524
dressing, 524, 526t
management, 523-529
modified Braden Q pressure ulcer risk assessment
tool, 520t
prevention/risk modification, 5 I9, 523
risk assessment, 519
staging, 523
therapeutic support surfaces, 525-529, 528t, 529t
Primary adrenal insufficiency, 811
Primary brain injury, 716
Primary intention wounds, 537
Primary interventricular foramen, 132
Primary peritonitis, 783
Primary renal 01, 807
Primum ASDs, 592
PRISMA system, 757, 760
PRN program, 75
Proaccelerin, 827t
Procainamide
atrial fibrillation, 644
dosage/administration, 202
hemofiltration, 759t
Process evaluations, 101
Proconvertin, 827t
Professional development; see Clinical development,
Staff development
Professional organizations, 6, 7
Professional reimbursement for nurses (PRN), 75
Professional relationships, 62
Proficient nurse (RN III), 90t, 94, 97t, 98t
Prograf, 882t, 886, 887
Projection, 20
Projection fibers, 326
Prone positioning, 679
Propafenone, 202
Propofol
intubation medication, as, 270t
pain management, 565t
sedative, as, 57 I
Propranolol, 203
Prostaglandin E, 550
Protein buffer pair, 3 I I
Protein-calorie malnutrition, 393
Protein-energy malnutrition, 393
Prothrombin (PT), 772t, 827t, 828t
Proventil 5%, 282t
Providing comfort; see Pain management
Providing developmentally supportive care, 17-46
Proximal convoluted tubule, 733
Pseudocyst, 788
Pseudoglandular period, 234, 235
Pseudohyperkalemia, 385
PSV, 285t, 286
Psychological stresses, 18
Psychoneuroimmunology, 483
Psychosocial support staff, 62, 63
PT,828t
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PTCA,635
Pulmonary agenesis, 236
Pulmonary angiography, 265
Pulmonary arteries, 238
Pulmonary artery cannulation, 179
Pulmonary artery catheters, 178, 179
Pulmonary artery pressure (PAP) monitoring,
178-184,625
Pulmonary artery temperatures, 448
Pulmonary atresia with intact ventricular septum
(PA-IVS), 603t, 606-608
Pulmonary capillary membrane, 240
Pulmonary circulation, 239
Pulmonary congestion, 585
Pulmonary contusion, 961
Pulmonary critical care problems, 655-694
alterations in control of breathing, 689-69 I
alveolar hypoventilation syndromes, 690
apnea, 689, 690
ARDS, 672-681
asthma, 667-670
bacterial tracheitis, 662
botulism, 686
bronchiolitis, 664-667
bronchopulmonary dysplasia, 682-684
circulatory alterations, 686-689
congenital diaphragmatic hernia, 681, 682
croup, 659, 660
epiglottitis, 660-662
final common pathways, 656
foreign body aspiration, 662, 663
GuiIIain-Barre syndrome, 684-686
impairment of respiratory muscle function, 684-686
lower airways disease, 664-670
mechanisms of abnormal gas exchange, 656
mixed obstructive/restrictive disease, 682-684
PE, 686, 687
pharyngeal obstruction, 663
pneumonia, 672
pneumothorax, 671, 672
PPHN, 687-689
respiratory failure, 655, 656
restrictive disease, 670-682
tracheobronchomalacia, 663, 664
upper airway disease, 658-664
Pulmonary diseases in children with AIDS, 498t
Pulmonary embolism (PE), 686, 687
Pulmonary hypertension of the newborn (PPHN), 611
Pulmonary infiltrates, 858-860
Pulmonary metabolism, 239
Pulmonary stenosis (PS), 596t, 60 I, 602
Pulmonary system; see Oxygenation and ventilation
Pulmonary vascular resistance (PVR), 206-209, 587
Pulmonary vascular resistance index (PVRI), 187
Pulmonary ventilation, 245-248
Pulmonary volumes capacities, 247, 248
Pulmonic stenosis, 153t
Pulse oximetry, 256-268
Pulse/intensity/scale, 153t
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Pulseless electrical activity (PEA), 1038
Pulses, 153
Pulsus paradoxus, 153
Purpura fulminans, 94 J
PVARP, 211
PVCs, 162, 648
PVR, 206-209, 587
PVRI, 187
Pyridostigmine, 2711
Q
Qp/Qs, 208

QRS complexes, 162-164
QRS duration, 163
Qs/Qt, 249
QT interval, 165
Quadruple lumen catheter, 178
Quelicin, 702
Quinidine, 20 I
Quinine, 486
Quinlan, Karen Ann, 120

R
RAAS stimulation, 584
Racemic epinephrine, 282t
Radial artery, 172
Radiant warmers, 450, 457
Radiative heat loss, 446
Radicular cutaneous fields, 346
Radiocontrast dye, 534t
Raincoat negative pressure ventilator, 293
RALES, 587
Ramsey scale, 557
Randomized Aldactone evaluation study (RALES), 587
Ranitidine
acute gastritis, 790
GER,782
hemofiltration, 759t
IV infusion, 438t
renal failure, 747t
Rapacuronium, 271 t
Rapamune, 882t, 887
Rapid-sequence induction (RSI), 1031
Rapid-sequence intubation, 272
Rapidly adapting receptors (RARs), 239
Raplon, 271t
RARs, 239
Rationalization, 20
RBC studies, 824t, 825t
RBCs, 822, 823
RDS,7
Reaction formation, 20
Reactive airways disease, 667-670
Reactive oxygen species (ROS), 667
Recidivism, 14
Rectal temperature, 448
Red blood cell studies, 824t, 825t
Red blood cells (RECs), 822, 823
Red blood count (RBC), 824t

Red marrow, 821
Reduced-size liver transplantation (RSLT), 90 I
REE,4oo
Reentrant SVT, 643
Reentry circuit, 158
Reepithelialization, 514
Reflective blankets, 457
Reflex hypoxic vasoconstriction, 673
Reflexes, 345
Regional temperature, 448
Registered nurse statistics fact sheet, 14
Regression, 19,20
Renal artery, 733
Renal biopsy, 746
Renal clearance, 431
Renal critical care problems, 731-764
acid-base balance, 743
critical care management, 741-749
CVVH,755-761
dosing of medication, 434, 435
electrolyte balance, 742, 743
embryologic development, 731, 732
function of renal system, 732-735
HD,761-763
imaging techniques, 745, 746
infection, 744
intravascular volume, 741, 742
intrinsic renal failure, 739-741
laboratory studies, 744
maturational limitations of renal function, 733t
nutrition, 743
PD,750-755
pharmacology, 746-749
postrenal failure, 741
prerenal failure, 735-739
renal biopsy, 746
renal replacement therapy, 749-763
respiratory status, 743
structure of renal system, 732
Renal injuries, 967, 968
Renal replacement therapy, 749-763
Renin-angiotensin aldosterone cascade, 735
Reperfusion injury, 716, 717
Residual volume (RV), 247
Resiliency, 8
Resource availability, 9, 19
Respiratory acidosis, 314-317
Respiratory alkalosis, 317, 318
Respiratory assessment, 151
Respiratory distress and failure protocol, 1045
Respiratory failure, 655, 656; see also Pulmonary critical
care problems
Respiratory support, 266-282
aerosol therapy, 281, 282, 282t
airway adjuncts, 268-276; see also Airway adjuncts
airway management, 276, 277
chest physiotherapy, 277, 278
chest tubes, 281
oxygen therapy, 266-268

Index

Respiratory syncytial virus (RSV), 664-667
Respiratory syncytial virus immune globulin
(RSV-Ig), 488
Respiratory system; see Oxygenation and ventilation
Response to diversity, 12
Resting energy expenditure (REE), 400
Restrictive cardiomyopathy, 635, 637t
Restrictive disease, 670-682
Restructuri ng, 53
Resuscitation bags, 267, 268
Resuscitation efforts, 1025-1053
airway management, 1028-1032
cardiac compressions, 1032
cardiac dysrhythmia management, 1037, 1038
cardiopulmonary arrest, 1025-1028
circulation, 1032- 1038
collaborative management, 1028-1040
courses, 1025
diagnostic studies, 1042
documentation, 1042
evaluation of interventions, 1038
family care, 1042
fluid resuscitation, 1033
intrafacility transport, 1043-1051
intraosseous infusion, 1033
performance improvement, 1051-1052
physiologic approach to resuscitation, 1034t
postresuscitation management, 1042-1044
resuscitation medications, 1034-1036
routes of drug administration, 1036
vascular access, 1032, 1033
Resuscitation medications, 1034- 1036
Reticulocyte count, 825t
Retractions, 252
Rewarming shock, 457
Reye's syndrome (RS), 504
Rhonchi, 253
Rhythm disturbances; see Cardiac rhythm disturbances
Rib fractures, 959
Ribavirin
aerosol therapy, in, 282t
antifungal drug, as, 486
bronchiolitis, 666
Rifampin, 431, 534t
Right BBB, 163
Right shift, 480
Right ventricle, J32
Right ventricular assist device (RVAO), 221, 222
Right ventricular end-diastolic pressure (RVEOP), 625
Right ventricular outflow tract obstruction (RVOTO),
602-604
Right-sided heart catheterization, 188
Rigid bronchoscopy, 265
Rimantadine, 486
Risk of altered body temperature, 443
Rituxan, 889
Rituximab, 889
RLQ ileostomy, 536
RMSF, 503-504

RN 1, 87, 88t, 97t, 98t
RN II, 87, 89t, 94, 97t, 98t
RN 1Il, 90t, 94, 97t, 98t
RN IV, 92t, 95, 97t, 98t
Roberta Straessle Abruzzese (RSA) model, 101
Robertson, James, 47
Rocky Mountain spotted fever (RMSF), 503-504
Rocuronium,27lt
Rofecoxib, 567
Role delineation study (ROS), 7
ROS,667
Ross procedure, 600
Routine suctioning technique, 276
RSI, 1031
RSLT,901
RSV, 664-667
RSV-Ig, 488
RSV-IGIV, 857
RSV-IVIG, 666
rTPA,838t
Rule of 6'5,440
Rule of nines, 983, 985
Run chart, 77, 78
RV,247
RVAD, 221, 222
RVEOP, 174,625
RVOTO, 602-604

S
Saccular period, 235
Sacred Hoops (Jackson), 73
Safe passage, I0
Salter and Harris classification of epiphyseal plate
fractures, 970t
SAM,639
Sandimmune, 880, 88lt, 886
Santyl, 994t
SAP, 172
Sarcoplasmic reticulum (SR), 583
SARs, 239
SAS, 557, 559
SBS, 786-788
SBc0 2 monitoring, 262
SBT,792
Scalp lacerations, 951
SCC, 865, 866
SCCM,7
SCD, 840-844
Scheduling, 81
School-age children
development, 35t
developmental care, 36-37
developmental characteristics, 34, 35t
hospitalization, and, 34, 36
scm, 494
SCIWORA, 955, 956
Sclerotherapy, 792
Scoliosis, 251, 724, 725
Scoop, 267
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SCUF,761
SDC, 485, 486
Sebaceous glands, 512
Sebum, 469, 512
Second-degree heart block, 159, 647
Secondary adrenocortical disease, 811
Secondary cardiomyopathy, 629
Secondary cerebral injury, 716
Secondary drowning, 719
Secondary peritonitis, 783
Secondary renal 01, 807
Secretory IgA, 469, 470
Secretory piece, 470
Sedation-agitation scale (SAS), 559
Sedatives, 548, 570-571
Segmented neutrophils, 464
Seizure activity, 356, 357
Seizures, 703-705
Selective brain cooling, 719
Self-control, 22
Self-directed learning, 99
Self-esteem, 82
Self-inflating bags, 268
Self-report pain tools, 552, 553
Sellick maneuver, 1030
Semilunar valves, 134
Sengstaken-Blakemore tube (SBT), 792
Sensing threshold, 212
Separation, 21
SEPs, 362-364
Septation of heart, 133
Septic shock, 923-925, 930, 932t
Serologic testing, 481
Serum albumin, 397
Serum glutamincoxaloacetic transaminase (SGOT), 504
Serum glutamic-pyruvate transaminase (SGPT), 504
Serum immunoglobins, 477-478, 478t
Serum osmolality, 372, 376, 700
Serum sodium, 376, 382, 383
Setting-sun sign, 344
7 Habits of Highly Effective People, The (Covey), 72
Severe combined immunodeficiency disease (SCID), 494
Sexual abuse, 975
SGOT,504
SGPT,504
Shared decision making, 117-119
Shared governance, 74, 75
Shared visions, 72
Shear, 523
Sheepskin heel protectors, 523
Shift to the left, 480
Shifts, 480
Shivering, 449
Shivering thermogenesis, 455
Shock,921-945
anaerobic metabolism, 927, 928
causes of, 922
clinical assessment, 930-933
cold,926

Shock---cont'd
collaborative management, 933-940
definitive treatment, 934
enhance substrate delivery, 934-939
fluid shifts, 928
hemodynamic/oxygenation profiles, 931-933
low-flow, 922, 930, 931
maldistributive, 923, 931
mediator release, 928-930
minimize energy expenditure, 939, 940
MODS, 940-942
neuroendocrine activation, 926, 927
newborns, 940
optimize nutrition, 940
pharmacologic therapy, 937-939
physiologic responses to, 926-930
septic, 923-925, 932t
supportive treatment, 934
TSS, 925
unconventional therapies, 942, 943
warm, 926
Short bowel syndrome (SBS), 786-788
Shortening fraction, 167
Shovel,267
Shunt, 249
SI, 187
SIADH,809-811
Sick sinus syndrome, 641
Sickle cell disease (SCD), 840-844
Side effects, management, 563
Sidestream capnometer, 258
Siemens EEG cassette, 358
SICs, 7
SIGs, 6-7
Sigmoid sinus, 327
Sigmoidal model, 432
Silvadene, 994t
Silver sulfadiazine, 994t
Simple meconium ileus, 778, 779
Simulect, 885t, 889
SIMV, 285t, 286
Single-breath CO 2 monitoring, 262
Sinus bradycardia, 158, 641
Sinus node abnormalities, 641, 642
Sinus node action potential, 142
Sinus node disease (SND), 641, 642
Sinus tachycardia, 158, 641, 644t
Sinus venosus, 132, 133
Sinus venosus ASD, 592
Sirolimus, 882t, 887
SIRS, 471, 923, 924
Skill acquisition model, 86
Skin care algorithm, 519, 522
Skin compromise, 543
Skin integrity, 511-546
dressings, 524, 526t, 527t, 535, 536
enteral feeding tubes, 542-543
integumentary structure, 512
intravenous infiltrate injury, 531-535

Index
Skin integrity-cont'd
irritant contact diaper dermatitis, 529-531
leech therapy, 543-544
nursing practice guidelines, 515
ostomy care, 537-542, 504t
pressure reduction/relief devices, 528t
pressure ulcer algorithm, 524
pressure ulcers, 518-529, 523t; see also pressure ulcers
promoting, 515-518
skin care algorithm, 522
surgical wounds, 536, 537
topical agents for wound care, 528t
wound care, 528t, 535- 536
wound healing, 512-514, 513t
Skin temperature, 153, 448
Skull, 325
Skull and spine x-rays, 365
Skull examination, 343, 344
Skull fracture, 951-953
Sleep deprivation in PICU, 20
Slow continuous ultrafiltration (SCUF), 761
Slow rhythms, 1037, 1038
Slow-speed capnograms, 260
Slowly adapting receptors (SARs), 239
SLT,901
Small intestine, 766, 767
Small-particle aerosol generator (SPAG), 283
Small-volume nebulizer (SVN), 283
Smoke inhalation, 986, 987
SMS, 864, 865
SND, 641, 642
SNS stimulation, 580, 584
Society of critical care medicine (SCCM), 7
Sodium, 378t, 382, 383
Sodium bicarbonate
antidote, as, 534t
dosage/administration, 818
resuscitation drug, as, 1035, 1036
Sodium nitroprusside
cardiac arrest, 198
dosage/administration, 198
shock, 939
side effects, 198
toxicity, 198
Solid organ transplantation; see Organ transplantation
Somatosensory evoked potentials (SEPs), 362-364
Somatostatin, 791
Sotalol, 204
SPAG,283
Special interest counsultants (SICs), 7
Special interest groups (SIGs), 6-7
Specialty beds, 525-529
Specific gravity, 744
Specific immunity, 473-480
Specificity, 473
Spectral Doppler, 167
Sphenoparietal sinus, 327
Spinal accessory nerve, 327, 333, 337t
Spinal cord, 330-332, 550

Spinal cord compression (SCC), 865, 866
Spinal cord injury, 955-958
Spinal cord ischemia, 599
Spinal fusion, 725
Spinal nerves, 332
Spironolactone
diuretic therapy, in, 200, 378t
dosage/administration, 192
heart failure, 586t, 587
renal failure, 749t
Spinothalamic and spinoreticular tracts, 550
Spleen, 463
Spleen injury scale, 964t
Splenic injury, 963-965
Splenic sequestration, 843
Splenorenal shunts, 792
Split heart sounds, 154
Split-liver transplantation (SLT), 901
SPN,7
Sponging, 452
Spontaneous breathing, 248, 249
SR,583
SSSS, 988
ST segment, 164
Stability, 8
Staff development, 96-106
adult learning theory, 99
centralized vs. decentralized programs, 98
continuing education, 105
fostering professional advancement, 105
in-service education, 104
organizing framework, 99, 100
orientation, 101-104
philosophy statement, 99
preceptor programs, 104
steps in program development, 100, 101
Stages of separation, 21
Staging of intravenous (IV) infiltrates, 532t
Staging of pressure ulcers, 523t
Standard concentrations, 440
Standard orthotopic liver transplant, 90 I
Staphylococcal scalded skin syndrome (SSSS), 988
Starling's law, 936
Static compliance (Cst), 245
Static high-air-Ioss beds, 525
Static low-air-Ioss beds, 525
Status asthmaticus, 667
Status epilepticus, 703-705
Steady-state, 431, 432
Stevens-Johnson syndrome, 988
Stewardship delegation, 81, 82
Stimulus-response model, 549
Stockinette, 516
Stomach, 766, 767
Stomas, 538
Straight sinus, 327
Streptokinase, 838t
Streptomycin, 759t
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Stress
caring practice, and, 17, 18
hospitalization, and, 20-22
immune system, and, 483, 484
management of, 80, 81
parental, 50-54
PICU-related, 51-52
reduction, 483-484
Stress appraisal, 18
Stroke index (SI), 187
Stroke work index (SWI), 187
Stuart-Power factor, 827t
Stupor, 346t
Subaortic stenosis, 600
Subarachnoid space, 326
Subcutaneous emphysema, 253
Subdural hematoma, 954, 955
Subdural space, 326
Sublimation, 20
Substance P, 550
Subvalvular pulmonary stenosis, 602
Succinylcholine, 270t, 702
Sucralfate, 790
Suction catheters, 276
Suctioning, 276
Sulfamethoxazole, 759t
Sulfamylon, 994t
Summation gallop, 154
Superficial reflexes, 345
Superior mediastinal syndrome (SMS), 864, 865
Superior patrosal sinus, 327
Superior sagittal sinus, 326
Superior vena cava (SVC), 133
Superior vena cava syndrome (SVCS), 177, 864, 865
Supernumerary arteries, 238
Suppressor T cells, 466
Supraglottic airway, 236
Supratentorial astrocytomas, 708
Supratentorial herniation, 696
Supravalvular aortic stenosis, 601
Supravalvular pulmonary stenosis, 602
Supraventricular tachycardia (SVT), ISS, 163,
642-644
Surgical wounds, 536, 537
SVC,133
SVC syndrome, 616, 617
SVCS, 864, 865
SVN,281
S\'02' 243, 264
S\'02 monitoring, 264
SVRI, 187
SVT, ISS, 163, 642-644
Sweating, 447, 469
SWI, 187
Sympathetic nervous system, 333, 338
Sympathetic nervous system stimulation (SNS), 580, 584
Sympathomimetic agents, 192
Synchronized cardioversion, 644-646
Synchronized IMV (SIMV), 285t, 286

Syndrome of inappropriate antidiuretic hormone
(SIADH),809-811
Synergistic neurotoxins hypothesis, 799
Synergy, 8
Synergy model
care perspecti ve, 113
clinical development, 86
conceptual framework of CCRN blueprints, 8t
describing what nurses do, 8
ethical principles, 119
nurse competencies, 9-12
optimal patient outcomes, 12-14
patient characteristics, 8, 9
Systemic inflammatory response syndrome (SIRS),
471, 923-924
Systemic vascular resistance index (SVRI), 187
Systemic venous congestion, 585
System savvy parents, 57-58
Systems thinking, 12,76-78
Systolic anterior motion (SAM), 639
Systolic arterial pressure (SAP), 172
Systolic murmurs, 154
T

T cell disorders, 493
T cell independent activation, 473
T cells, 466
T tubules, 140
T wave, 164
Tachypnea, 252t
Tacrolimus, 882t, 886, 887
TA-GVHD, 830
Tamponade, 622, 960, 961
TAPVC, 609-611
Taussig-Bing malfonnation, 133
Taylor dispersion, 294
TBB,894
TBI, 714, 715, 951-955
TBW,370
TCAs,568
Teamwork, 72, 73
Tectum, 328
TEE, 168, 169
TEF,774-776
Tegmentum, 328
Tegretol, 568
Teicoplanin, 759t
Telencephalon, 326
Temperament, 19
Temporal lobe, 328
Temporary external cardiac pacing, 209-212
Temporary external demand, dual chamber
pacemaker, 211
Temporary pulse generator, 210
Temporary trans venous leads, 210
TEN, 988
Teniposide, 534t
TENS, 561
Tension pneumothorax, 960

Index

Tentorium cerebelli, 696, 697
Terbutaline, 282t, 668
Testicular trauma, 969
Tet spells, 604
Tetralogy of Fallot (TOF), 602-606
Tetralogy of Fallot with pulmonary atresia (TOF-PA),
603-606
Tetralogy of Fallot with pulmonary stenosis (TOF-PS),
602-606
TGA,617-620
Thalamus, 328, 329
Theophylline
apnea, 690
hemofiltration, 759t
overdose, 1011, 1012
Therapeutic drug monitoring, 435
Therapeutic index, 432
Therapeutic support surfaces, 525-529
Therapy
aerosol, 281, 282, 282t
antiretroviral, 502
diuretic therapy, 586
experimental, 504
immunosuppressant, 880, 881 t, 886
inotropic, 192-197
pacemaker, 209-215
thrombolytic, 635
Thermal injuries, 983
Thermal regulation, 443-459
assessment of temperature imbalance, 448, 449
behavioral control of body temperature, 445
cooling devices, 450
core temperature monitoring, 447, 448
drug fever, 452
fever, 451, 452
heat loss, 446
hyperthermia, 450-454
hypothermia, 454-457
ineffective thermoregulation, factors related to, 444t
maintenance of normal body temperature,
447-448
mechanisms of thermoregulation, 445-447
MH, 452, 453
nursing care of patients with decreased body
temperature, 455-457
nursing care of patients with elevated body
temperature, 454
peripheral temperature monitoring, 448
physiologic control of body temperature,
444,445
physiologic consequences, 445
sweating, 447
warming devices, 449, 450
Thermodilution, 185, 186t
Thermogenesis, 445, 455
Thermoregulation, 444
Thermoregulation devices, 449, 450
Thiazide diuretics, 586t
Thiazides, 191, 749
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Thiopental
increasing ICP, 702
intubation medication, as, 270t, 272
Third-degree heart block, 647
Thoracic airway, 237
Thoracic cavity, 238
Thoracic injury, 958-963
Thrill, 152
Thrombin time (IT), 828t
Thrombocytes, 823
Thrombocytopenia, 854, 861
Thrombolytic therapy, 635
Thrombosis, 174, 177
Thrombotic thrombocytopenic purpura (ITP), 848
Thymocytes, 477
Thymoglobulin, 884t, 888
Thymus gland, 463
Ticarcillin, 747t
Ticlopidine, 635
Tidal volume (VT ), 247
TILs, 491
Time constants, 246, 247
Time management, 80-82
Time-temperature cardiac output curve, 185
Tissue perfusion, 13 1-231
cardiac cycle, 142, 144
cardiac output, 144-148
cardiovascular system; see Cardiovascular system
circulatory changes at birth, 137, 138
congenital cardiac defects, 135, 136
development of heart, 132-135
ductal patency/pulmonary vascular resistance, 205-209
fetal circulation, 136, 137
heart, 139-141
heart's electrical activity, 141, 142
pacemaker therapy, 209-215
regulation of, 148-150
Tissue thromboplastin, 827t
TLC,247
TLI,889
TMP-SMX, 499, 857
TNA,417
TNF, 929, 930
TNF-a, 488, 490
Tobramycin
aerosol therapy, in, 282t
antidote, as, 534t
hemofiltration, 759t
IV infusion, 438t
renal failure, 747t
Tocainide, 202
Toddlers
development, 29t
developmental care, 30-31
developmental characteristics, 28-30
hospitalization, and, 28, 30
TOF, 602-606
TOF monitoring, 255
TOF-PA, 603-606
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TOF-PS, 602-606
TOF suppression, 255
Tolerance, 548
Tonicity, 372
Toradol, 564t, 567
Total anomalous pulmonary venous connection (TAPVC),
609-611
Total body clearance, 43 I
Total body water (TBW), 370
Total cardiac transplantation, 89 I
Total lung capacity (TLC), 247
Total lymphoid irradiation (TLI), 889
Total nutrient admixture (TNA), 417
Total protein, 376
Total WBC count, 464t, 480
Toxic epidermal necrolysis (TEN), 988
Toxic ingestions, 999-1024
activated charcoal, 1002, 1003
acetaminophen, 1004-1006
algorithm for management, 1001
alkaline diuresis, 1003
barbiturates, 1006, 1007
carbamazepine, 1007, 1008
caustics, 1020, 1021
c1onidine, 1008, 1009
cocaine, 1017, 1018
cyclic antidepressants, 10 12-10 I4
ethanol, 1016, 1017
ethylene glycol, 1015, 1016
extracorporeal drug removal, 1003
gastric emptying, 1002
gastrointestinal decontamination, 1002- I004
heroin, 1018, 1019
hydrocarbons, 1021, 1022
identification of toxin, 1000
iron, 1009-1011
isopropanol, 1016
methanol, 1014, 1015
methadone, 10 I9
most common vs. most toxic agents, lO00t
PCP, 1019, 1020
theophylline, 1011, 1012
toxidromes, 1000, 100 It
unknown toxins, 1002
whole bowel irrigation, 1003
Toxic megacolon, 780, 781
Toxic shock syndrome (TSS), 503, 925
Trabeculars, 326
Tracheobronchial injury, 962
Tracheobronchomalacia, 663, 664
Tracheoesophageal fistula (TEF), 236, 774-776
Tracheostomy tube (TT), 274-276
Tracking, 211
Train-of-four (TOF) monitoring, 255
Transbronchial biopsy (TBB), 894
Transcutaneous electrical nerve stimulation (TENS), 561
Transdermal patches, 439
Transesophageal echocardiography (TEE), 168, 169
Transesophageal leads, 210

Transferrin, 397
Transfusion-associated graft-versus-host disease
(TA-GVHD), 830
Transient immune dysfunction, 49 I-493
Transillumination, 344
Transplantation; see Organ transplantation
Transport equipment pack list, 1047, 1048
Transport intake form, 1049
Transport programs, 1043-1051
Transport team quality assurance form, 1050
Transposition of the great arteries (TGA), 617-620
Transthoracic intracardiac catheters, 625, 626
Transvenous leads, 210
Transverse fractures, 971
Transverse sinus, 327
Trauma, 947-979
abdominal injury, 963-967
child maltreatment, 974-977
gastric/intestinal injury, 966
genitourinary injuries, 967-969
head injury, 951-955
initial resuscitation, 948-950
liver, 965
multiple, 973
orthopedic injury, 969-973
pancreas, 965
primary survey, 948-950
scoring systems, 950, 951
secondary survey, 950
spinal cord injury, 955-958
spleen, 963-965
thoracic injury, 958-963
Trauma injury severity score (TRISS), 95 I
Trauma scores, 950, 951
Traumatic asphyxia, 960
Traumatic brain injury (TB1), 714, 715, 951-955
Treating infections
antifungal drugs, 486
antimalarial drugs, 486-487
antimicrobial-resistant microorganisms, 486
antimicrobial therapeutics, 485-486
antiprotozoal drugs, 486
antiviral drugs, 486
Triceps skinfold (TSF), 397
Tricuspid atresia, 603t, 608, 609
Tricyclic antidepressant ingestion, 164
Tricyclic antidepressant overdose, 1012-10 I4
Tricyclic antidepressants (TCAs), 568
Trigeminal nerve, 327, 333, 335t
Trigger points, 561
Trilisate, 564t
Trimethoprim-sulfamethoxazole, 747t
Triple acid-base disorders, 321
Triple-chamber chest drainage systems, 281, 282
Triple-lumen catheter, 178
Trisomy 21, 135
TRISS,951
Trochlear nerve, 327, 333, 335t
Tromethamine, 534t

Index

Trophamine, 417
Trousseau's sign, 375
Trucco, Massimo, 915
Truncus arteriosus, 609t, 611, 612
Trust, 82
Truth telling, 112
TSF, 397
TSS, 503, 925
TSST-I,503
TT, 274-276, 828t
TIP, 848
Tuberculosis, 500
Tumor necrosis factor (TNF), 929, 930
2: I AV block, 161
2,3-DPG, 241
Two-dimensional echocardiography, 167
Two-lead bipolar (pairs) systems, 358, 361
Tylenol, 565t
Type I diabetes, 815
Typhlitis, 861, 862
U
U waves, 165
UBT,447
Ultrasonic nebulizers, 283
Ultrasonography (US), 966
Umbilical arteries, 172
Umbilical vein, 132
Unasyn, 784t
Uncal herniation, 696
Undersedation, 556
Undersensing, 212-214
United Network for Organ Sharing (UNOS), 878
Upper airways disease, 658-664
Upper GI bleeding, 789t
Ureteral trauma, 968
Urea, 376, 701, 713
Urethral injuries, 969
Urinalysis, 744
Urinary alkalinization, 1003
Urinary bladder temperature (UBT), 447
Urinary pouches, 538
Urinary tract infection (UTI), 470, 483
Urine osmolality, 376
Urine sediment, 744
Urine sodium, 376
Urine specific gravity (US G), 376
Urostomy diversions, 537
US, 966
USG,376
UTI, 470, 483
V

VA ,248
V D ,247
V E ,247
'1/0.,248,249
V/0. mismatching, 656
'110. scanning, 265
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VA ECMO, 299, 300
VAC dressing, 537
VACTERL, 775
Vacuum-assisted closure system, 537
VAD,220-224
Vagus nerve, 327, 333, 337t
Valium, 570
Values, 72
Valvar aortic stenosis, 599
Valvular pulmonary stenosis, 602
Vancomycin
antidote, as, 534t
hemofiltration, 759t
intraabdominal sepsis, 784t
IV infusion, 438t
renal failure, 747t
Vaponefrin, 282t
Variable segment (Fab), 465, 479
Varicella zoster, 896
Vascular access thrombi, 837, 838
Vasodilating agents, 197-200
Vasogenic edema, 697
Vasopressin, 374, 791, 80S, 809
Vaughan-Williams classification of antiarrhythmic
drugs, 20lt
VBG analysis, 262
VC,247
Vd,428
Vecuronium, 273
Vecuronium bromide, 27lt
Veno-occlusive disease (VOD), 871
Venous admixture, 249
Venous blood gas (VBG) analysis, 262
Venous pressure waveform analysis, 175, 176
Venous sinuses, 327
Ventilation, 245; see also Oxygenation and ventilation
Ventilation-perfusion abnormalities, 249-251
Ventilation-to-perfusion ratio (VIQ), 248, 249
Ventilator-induced lung injury (VILI), 675
Ventilators; see Mechanical support for ventilation
Ventolin, 282t
Ventral respiratory group (VRG), 239
Ventricular arrhythmias, 648-651
Ventricular assist devices (VAD), 220-224
Ventricular diastole, 144
Ventricular fibrillation (VF), 649-651
Ventricular looping, 135
Ventricular septal defect (VSD), 153t, 590t, 592-594
Ventricular shunting, 701
Ventricular system, 329, 330, 331
Ventricular systole, 142, 144
Ventricular tachycardia (VT), 648, 649, 650, ISS, 163
Venturi effect, 639
VEPs,362
Veracity, 112
Verapamil, 204
Versed, 270t, 570
Vestal, Katherine W., 6
VF,649-651
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Index

Vicodin, 566
Vigilance, 10, II, 55
VIU,675
Vinblastine, 534t
Vincristine, 534t
Viral encephalitis, 711, 712
Viral hepatitis, 797, 798, 832
Viral meningitis, 709
Viscerocranium, 325
Vision, 72
Visitation, 55
Visual evoked potentials (VEPs), 362
Visual stimulation in PICD, 20
Visual survey, 53
Vital capacity (VC), 247
Vitelline vein, 132
VM-26,534t
Vo z, 243, 244, 264
VOD,871
Volume of distribution (Vd), 428
Volume/pressure curve, 341
Volutrauma, 675
VP-16,534t
VRG,239
VT (ventricular tachycardia), 155, 163,648,649,650

Whole blood, 829t
Whole bowel irrigation, 1003
Wide-complex tachycardia, 163
Williams' syndrome, 601
Wilson, James, 5
Wilson's disease, 797
Withdrawal, 53
Wong-Baker faces pain scale, 553
Wood alcohol, 1014, 1015
Work of breathing, 248
World Wide Web, 6
Wound,512
Wound care
enteral feeding tubes, 542-543
general principles, 535
ostomy care, 537-542, 540t
surgical wounds, 536-537
topical agents, 528t
Wound contraction, 514
Wound healing
inflammatory phase, 512-513
maturation phase, 514
proliferative phase, 513-514
WPW syndrome, 136, 159, 160, 190,643
Writing competency outcome statements, 10 I

VT> 247

Vulnerability, 8
VV ECMO, 299, 300

X
Xenograft transplantation, 877

W
Warfarin, 833t
Warm shock, 941
Warming devices, 449, 450
Water absorption, 770
Waterhouse-Friderichsen syndrome, 811
WBC count, 464t, 480
WBC differential, 480
WBCs, 464, 822
Weaning benzodiazepines and opioids, 574
Weeks-Webster, Holly, 6
Weight, 395
Welch, Jack, 78
Wheezes, 253, 254
White blood cell count
differential WBC count, 480
total WBC count, 480
White blood cells (WBCs), 464, 822

Y

Yellow marrow, 821

Z
Zaroxolyn, 378t
Zemuron, 27lt
Zenapax, 885t, 889
Zidovudine (AZT), 495, 501
Zipper injuries, 969
Zone I conditions, 249
Zone II conditions, 249
Zone III conditions, 249
Zone of coagulation, 982
Zone of hyperemia, 982
Zone of stasis, 982
Zosyn, 784t
Zovirax, 886t

PALS Medications for Cardiac Arrest and Symptomatic Arrhythmias
n.F.

~'1)rug

Dosage (Pediatric)

Remarks

t~denosine

0.1 mglkg
Repeat dose: 0.2 mglkg
Maximum single dose: 12 mg
5 mglkg IV110
Loading dose: 5 mglkg IV110
Maximum dose: 15 mglkg per day

Rapid (VIIO bolus
Rapid flush to central circulation
Monitor ECG during dose
Rapid IV bolus
IV over 20 to 60 minutes
Routine use in combination with drugs prolonging
QT interval is not recommended: hypotension is
most frequent side effect
May give IV, 10, or ET
Tachycardia and pupil dilation may occur but nor
fixed dilated pupils

~:

~{c
~i,Amiodarone

for pulseless VFNT
perfusing tachycardias

~'Amiodarone for

I ..
~

~tropine

~1
"'Z',

sulfate*

_ cium chloride 10% = 100 mg/mJ

0.02 mglkg
Minimum dose: 0.1 mg
Maximum single dose: 0.5 mg in
child, 1.0 mg in adolescents; may
repeat once
20 mglkg (0.2 mllkg) IVIJO

~: (=27.2 mglml elemental Cal

u:.

~ cium gluconate 10% = 100 mglml
'[(=9 mglml elemental Cal

60-100 mglkg (0.6- 1.0 mllkg)
IV/IO

(

inephrine for symptomatic
bradycardia*
inephrine for pulseless arrest*

'idocaine infusion (start after a bolus)
.~. agnesium sulfate (500 mglml)

IV110: 0.0 I mglkg (I: 10,000,
0.1 mllkg)
ET: O. I mglkg (J: 1000. 0.1 mllkg)
First dose:
IV/IO: 0.01 mglkg
(I: I0,000 0.1 mllkg)
ET: 0.1 mglkg (I: 1000, O. I mllkg)
Subsequent doses: Repeat initial
dose or may increase up to 10 times
(0. 1 mglkg, I: 1000, O. I mllkg)
Administer epinephrine every 3 to
5 min
rVIIOIET doses as high as 0,2
mglkg of I: 1000 may be effective
IVIIO: 0.5- 1.0 glkg
• 1-2 mJlkg 50%
• 2-4 mllkg 25%
• 5-10 mllkg 10%
IVIIO/ET: I mglkg
IV110: 20-50 fLglkg per minute
IVIIO: 25-50 mglkg: maximum
dose: 2 g per dose

:55 years or :520 kg: 0, I mglkg
>5 years or >20 kg: 2.0 mg
Loading dose: 15 mglkg IV/IO

.um bicarbonate (I mEq/ml and
0.5 mEq/ml)

!itT,

IV110: I mEqlkg per dose

Give slow IV push for hypocalcemia,
hypermagnesemia, calcium channel blocker
toxicity, preferably via central vein. Monitor
heart rate; bradycardia may occur
Give slow IV push for hypocalcemia,
hypermagnesemia, calcium channel blocker
toxicity, preferably via central vein
Tachyarrhythmias. hypertension may occur

For suspected hypoglycemia; avoid hyperglycemia

Rapid bolus
I to 25 mllkg per hour of 120 mgllOO ml solution
or use "Rule of 6" (see back cover)
Rapid IV infusion for torsades or suspected
hypomagnesemia; 10- to 20-min infusion for
asthma that responds poorly to a-adrenergic
agonists
For total reversal of narcotic effec!. Use small
repeated doses (0,0 I to 0.03 mglkg) titrated to
desired effect
Infusion over 30 to 60 min; routine use in
combination with drugs prolonging QT interval
is not recommended
Infuse slowly and only if ventilation is adequate

The American Heart Association in Collaboration with the Intemational Liaison Comminee on Resuscitation OLCOR): Guidelines 2000 for
iopulmonary Resuscitation and Emergency Cardiovascular Care: An International Consensus on Science, Circulation 102(Suppl 1):1-308,2000.
Endotracheal: 10, intraosseous; IV, intravenous.
endotracheal administration, use higher doses (2 to 10 times the IV dose): dilute medication with normal saline to a volume of 3 to 5 ml and follow

;:'l'or

'th several positive-pressure ventilations.

PALS Medications to Maintain Cardiac Output and for Postresuscitation Stabilization
Dose Range

Comment

Preparation*

IVIIO loading dose: 0.75- 1.0
mglkg IV over 5 min; may
repeat 2 times
IVIIO infusion: 5- 10 ILg/kg
per min
IVIIO infusion: 2-20 ILg/kg
per min

Inodilator

6 X body weight (in kg) = No. of mg
diluted to total 100 ml; then
I ml/hr delivers I ILglkg per min

Inotrope; vasodilator

IVIIO infusion 2-20 ILglkg
per min

Inotrope; chronotope;
renal and splanchnic
vasodilator in lower
doses; pressor in
higher doses
Inotrope; chronotrope;
vasodilator in lower
doses and pressor in
higher doses
Antiarrhythmic, mild
negative inotrope. Use
lower infusion rate if
poor cardiac output or
poor hepatic function.
Inodilator

6 x body weight (in kg) = No. of mg
diluted to total 100 ml; then I mlthr
deli vers I ILg/kg per min
6 x body weight (in kg) = No. of mg
diluted to total 100 ml; then I mlthr
delivers I ILglkg per min

IVIIO infusion: O. I-1.0 ILg/kg
per min

IVIIO loading dose: I mglkg
IVIIO infusion: 20-50 ILglkg
per min

IVIIO loading dose: 50-75 ILglkg
IVIIO infusion: 0.5-0.75 ILglkg
per min
IVIIO infusion: 0.1-2.0 ILglkg
per min
staglandin E,

IVIIO infusion: 0.05-0. I ILglkg
per min

ium nitroprusside

IVIIO infusion: 1-8 ILglkg per min

Vasopressor

Maintains patency of
ductus arteriosus in
cyanotic congenital heart
disease. Monitor for
apnea, hypotension,
and hypoglycemia
Vasodilator; prepare only
in dextrose in water

0.6 x body weight (in kg) = No. of
mg diluted to total J00 ml; then
I mllhr delivers 0.1 ILglkg per min
60 X body weight (in kg) = No. of mg
diluted to total 100 ml; then I mlthr
delivers 10 ILglkg per min or
alternative premix 120 mg/loo ml
at I to 2.5 ml/kg per hr
0.6 x body weight (in kg) = No. of
mg diluted to total 100 ml; then
I mlthr delivers 0.1 ILg/kg per min
0.6 X body weight (in kg) = No. of
mg diluted to total 100 ml; then
I mllhr delivers 0.1 ILglkg per min
0.3 X body weight (in kg) = No. of
mg diluted to total 50 mt; then
I mllhr delivers 0.1 ILg/kg per min

6 X body weight (in kg) = No. of mg
diluted to total 100 ml; then I mlthr
delivers I ILglkg per min

m The American Hean Association in Collaboration with the International Liaison Committee on Resuscitation (ILCOR): Guidelines 2000 for
·ardiopulmonary Resuscitation and Emergency Cardiovascular Care: An International Consensus on Science, Circulation I02(Suppl 1):1-328, 2000.
Intraosseous; IV, intravenous.
ost infusions may be calculated on the basis of "Rule of 6" as illustrated in the table. Alternatively, a standard concentration may be used to provide
re dilute or more concentrated drug solution, but then an individual dose must be calculated for each patient and each infusion rate as follows: Infusion
(ml/hr) = (weight (kg) X dose (lLg!kg per minute) X 60 minlhr]/concentration (lLglml). Diluent may be 5% dextrose in water, 5% dextrose in half. at saline, nonnal saline. or Ringer's lactate unless noted otherwise.
J

